The	O
Impact	O
of	O
Deployment	O
on	O
Parental	O
,	O
Family	O
and	O
Child	O
Adjustment	O
in	O
Military	O
Families	O

Since	O
9	O
/	O
11	O
,	O
military	B-T097
service	I-T097
in	O
the	O
United	B-T082
States	I-T082
has	O
been	O
characterized	O
by	O
wartime	O
deployments	O
and	O
reintegration	O
challenges	O
that	O
contribute	O
to	O
a	O
context	O
of	O
stress	B-T033
for	O
military	O
families	O
.	O

Research	B-T062
indicates	O
the	O
negative	B-T033
impact	I-T033
of	O
wartime	O
deployment	O
on	O
the	O
well	O
being	O
of	O
service	B-T097
members	B-T098
,	O
military	B-T097
spouses	O
,	O
and	O
children	O
.	O

Yet	O
,	O
few	O
studies	O
have	O
considered	O
how	O
parental	O
deployments	O
may	O
affect	O
adjustment	O
in	O
young	O
children	O
and	O
their	O
families	O
.	O

Using	O
deployment	B-T170
records	I-T170
and	O
parent	O
-	O
reported	B-T170
measures	O
from	O
primary	O
caregiving	O
(	O
N	O
=	O
680	O
)	O
and	O
military	B-T097
(	O
n	O
=	O
310	O
)	O
parents	O
,	O
we	O
examined	O
the	O
influence	O
of	O
deployment	O
on	O
adjustment	O
in	O
military	O
families	O
with	O
children	O
ages	O
0	O
-	O
10	O
years	O
.	O

Greater	O
deployment	O
exposure	O
was	O
related	O
to	O
impaired	O
family	O
functioning	O
and	O
marital	B-T033
instability	B-T033
.	O

Parental	O
depressive	B-T038
and	O
posttraumatic	B-T038
stress	I-T038
symptoms	I-T038
were	O
associated	O
with	O
impairments	O
in	O
social	O
emotional	B-T033
adjustment	O
in	O
young	O
children	O
,	O
increased	O
anxiety	B-T033
in	O
early	O
childhood	O
,	O
and	O
adjustment	O
problems	O
in	O
school	O
-	O
age	O
children	O
.	O

Conversely	O
,	O
parental	O
sensitivity	B-T038
was	O
associated	O
with	O
improved	O
social	O
and	O
emotional	B-T033
outcomes	I-T033
across	O
childhood	O
.	O

These	O
findings	B-T033
provide	O
guidance	O
to	O
developing	O
preventive	O
approaches	O
for	O
military	O
families	O
with	O
young	O
children	O
.	O

Beyond	O
neutral	O
and	O
forbidden	O
links	O
:	O
morphological	B-T082
matches	O
and	O
the	O
assembly	O
of	O
mutualistic	O
hawkmoth	B-T204
-	O
plant	B-T204
networks	O

A	O
major	O
challenge	O
in	O
evolutionary	O
ecology	O
is	O
to	O
understand	O
how	O
co	O
-	O
evolutionary	O
processes	O
shape	O
patterns	B-T082
of	O
interactions	O
between	O
species	B-T170
at	O
community	O
level	O
.	O

Pollination	B-T038
of	O
flowers	B-T204
with	O
long	B-T204
corolla	I-T204
tubes	I-T204
by	O
long	B-T204
-	I-T204
tongued	I-T204
hawkmoths	I-T204
has	O
been	O
invoked	O
as	O
a	O
showcase	O
model	O
of	O
co	B-T038
-	I-T038
evolution	I-T038
.	O

Recently	O
,	O
optimal	O
foraging	O
models	O
have	O
predicted	O
that	O
there	O
might	O
be	O
a	O
close	O
association	O
between	O
mouthparts	O
'	O
length	O
and	O
the	O
corolla	B-T204
depth	B-T082
of	O
the	O
visited	O
flowers	B-T204
,	O
thus	O
favouring	O
trait	O
convergence	O
and	O
specialization	O
at	O
community	O
level	O
.	O

Here	O
,	O
we	O
assessed	O
whether	O
hawkmoths	B-T204
more	O
frequently	O
pollinate	B-T204
plants	I-T204
with	O
floral	B-T170
tube	I-T170
lengths	O
similar	O
to	O
their	O
proboscis	B-T204
lengths	O
(	O
morphological	B-T082
match	O
hypothesis	O
)	O
against	O
abundance	O
-	O
based	O
processes	O
(	O
neutral	O
hypothesis	O
)	O
and	O
ecological	O
trait	O
mismatches	O
constraints	O
(	O
forbidden	O
links	O
hypothesis	O
)	O
,	O
and	O
how	O
these	O
processes	O
structure	B-T082
hawkmoth	B-T204
-	O
plant	B-T204
mutualistic	O
networks	O
from	O
five	O
communities	O
in	O
four	O
biogeographical	B-T082
regions	I-T082
of	O
South	B-T082
America	I-T082
.	O

We	O
found	O
convergence	O
in	O
morphological	B-T082
traits	O
across	O
the	O
five	O
communities	O
and	O
that	O
the	O
distribution	O
of	O
morphological	B-T082
differences	O
between	O
hawkmoths	B-T204
and	O
plants	B-T204
is	O
consistent	O
with	O
expectations	O
under	O
the	O
morphological	B-T082
match	O
hypothesis	O
in	O
three	O
of	O
the	O
five	O
communities	O
.	O

In	O
the	O
two	O
remaining	O
communities	O
,	O
which	O
are	O
ecotones	O
between	O
two	O
distinct	O
biogeographical	B-T082
areas	I-T082
,	O
interactions	O
are	O
better	O
predicted	O
by	O
the	O
neutral	O
hypothesis	O
.	O

Our	O
findings	O
are	O
consistent	O
with	O
the	O
idea	O
that	O
diffuse	O
co	B-T038
-	I-T038
evolution	I-T038
drives	O
the	O
evolution	B-T038
of	O
extremely	O
long	B-T204
proboscises	I-T204
and	O
flower	B-T204
tubes	I-T204
,	O
and	O
highlight	O
the	O
importance	O
of	O
morphological	B-T082
traits	O
,	O
beyond	O
the	O
forbidden	O
links	O
hypothesis	O
,	O
in	O
structuring	O
interactions	O
between	O
mutualistic	O
partners	O
,	O
revealing	O
that	O
the	O
role	O
of	O
niche	O
-	O
based	O
processes	O
can	O
be	O
much	O
more	O
complex	O
than	O
previously	O
known	O
.	O

Nosocomial	B-T038
pneumonia	I-T038
caused	O
by	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
treated	B-T058
with	I-T058
linezolid	B-T103
or	O
vancomycin	B-T103
:	O
A	O
secondary	O
economic	O
analysis	O
of	O
resource	O
use	O
from	O
a	O
Spanish	B-T082
perspective	O

Adopting	O
a	O
unique	O
Spanish	B-T082
perspective	O
,	O
this	O
study	B-T062
aims	O
to	O
assess	O
healthcare	O
resource	O
utilization	O
(	O
HCRU	O
)	O
and	O
the	O
costs	O
of	O
treating	O
nosocomial	B-T038
pneumonia	I-T038
(	O
NP	B-T038
)	O
produced	O
by	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
in	O
hospitalized	B-T033
adults	I-T033
using	O
linezolid	B-T103
or	O
vancomycin	B-T103
.	O

An	O
evaluation	O
is	O
also	O
made	O
of	O
the	O
renal	B-T038
failure	I-T038
rate	O
and	O
related	O
economic	O
outcomes	O
between	O
study	O
groups	O
.	O

An	O
economic	O
post	O
hoc	O
evaluation	O
of	O
a	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
multicenter	B-T062
phase	I-T062
4	I-T062
study	I-T062
was	O
carried	O
out	O
.	O

Nosocomial	B-T038
pneumonia	I-T038
due	O
to	O
MRSA	B-T007
in	O
hospitalized	B-T033
adults	I-T033
.	O

The	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
population	B-T098
comprised	O
224	O
linezolid	B-T103
-	O
and	O
224	O
vancomycin	B-T103
-	O
treated	B-T058
patients	O
.	O

Costs	O
and	O
HCRU	O
were	O
evaluated	O
between	O
patients	O
administered	O
either	O
linezolid	B-T103
or	O
vancomycin	B-T103
,	O
and	O
between	O
patients	O
who	O
developed	O
renal	B-T038
failure	I-T038
and	O
those	O
who	O
did	O
not	O
.	O

Analysis	O
of	O
HCRU	O
outcomes	O
and	O
costs	O
.	O

Total	O
costs	O
were	O
similar	O
between	O
the	O
linezolid	B-T103
-	O
(	O
€17	O
,	O
782±€9	O
,	O
615	O
)	O
and	O
vancomycin	B-T103
-	O
treated	B-T058
patients	O
(	O
€17	O
,	O
423±€9	O
,	O
460	O
)	O
(	O
P	O
=	O
.	O
69	O
)	O
.	O

The	O
renal	B-T038
failure	I-T038
rate	O
was	O
significantly	O
lower	O
in	O
the	O
linezolid	B-T103
-	O
treated	B-T058
patients	O
(	O
4	O
%	O
vs	O
.	O

15	O
%	O
;	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
total	O
costs	O
tended	O
to	O
be	O
higher	O
in	O
patients	O
who	O
developed	O
renal	B-T038
failure	I-T038
(	O
€19	O
,	O
626±€10	O
,	O
840	O
vs	O
.	O

€17	O
,	O
388±€9	O
,	O
369	O
;	O
P	O
=	O
.	O
14	O
)	O
.	O

Among	O
the	O
patients	O
who	O
developed	O
renal	B-T038
failure	I-T038
,	O
HCRU	O
(	O
days	O
on	O
mechanical	B-T058
ventilation	I-T058
:	O
13	O
.	O
2±10	O
.	O
7	O
vs	O
.	O

7	O
.	O
6±3	O
.	O
6	O
days	O
;	O
P	O
=	O
.	O
21	O
;	O
ICU	O
stay	O
:	O
14	O
.	O
4±10	O
.	O
5	O
vs	O
.	O

9	O
.	O
9±6	O
.	O
6	O
days	O
;	O
P	O
=	O
.	O
30	O
;	O
hospital	O
stay	O
:	O
19	O
.	O
5±9	O
.	O
5	O
vs	O
.	O

16	O
.	O
1±11	O
.	O
0	O
days	O
;	O
P	O
=	O
.	O
26	O
)	O
and	O
cost	O
(	O
€17	O
,	O
219±€8	O
,	O
792	O
vs	O
.	O

€20	O
,	O
263±€11	O
,	O
350	O
;	O
P	O
=	O
.	O
51	O
)	O
tended	O
to	O
be	O
lower	O
in	O
the	O
linezolid	B-T103
-	O
vs	O
.	O

vancomycin	B-T103
-	O
treated	B-T058
patients	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
costs	O
per	O
patient	O
-	O
day	O
between	O
cohorts	B-T098
after	O
correcting	O
for	O
mortality	O
(	O
€1000	O
vs	O
.	O

€1	O
,	O
010	O
;	O
P	O
=	O
.	O
98	O
)	O
.	O

From	O
a	O
Spanish	B-T082
perspective	O
,	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
total	O
costs	O
between	O
the	O
linezolid	B-T103
and	O
vancomycin	B-T103
pneumonia	B-T038
cohorts	B-T098
.	O

The	O
drug	O
cost	O
corresponding	O
to	O
linezolid	B-T103
was	O
partially	O
offset	O
by	O
fewer	O
renal	B-T038
failure	I-T038
adverse	B-T038
events	I-T038
.	O

HERG1	B-T103
potassium	B-T103
channel	I-T103
expression	B-T038
in	O
potentially	O
malignant	B-T038
disorders	I-T038
of	O
the	O
oral	B-T017
mucosa	I-T017
and	O
prognostic	B-T170
relevance	O
in	O
oral	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038

HERG1	B-T103
potassium	B-T103
channel	I-T103
plays	O
a	O
critical	O
role	O
in	O
the	O
cell	B-T038
proliferation	I-T038
.	O

HERG1	B-T103
protein	I-T103
expression	B-T038
was	O
analyzed	B-T062
by	O
immunohistochemistry	B-T058
(	O
IHC	B-T058
)	O
in	O
62	O
patients	O
with	O
oral	B-T038
leukoplakias	I-T038
and	O
100	O
patients	O
with	O
oral	B-T038
squamous	I-T038
cell	I-T038
carcinomas	I-T038
(	O
OSCC	B-T038
)	O
.	O

HERG1	B-T017
mRNA	B-T103
levels	O
were	O
assessed	O
by	O
real	B-T062
-	I-T062
time	I-T062
reverse	I-T062
transcriptase	I-T062
-	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
RT	B-T062
-	I-T062
PCR	I-T062
)	O
in	O
22	O
patients	O
with	O
primary	O
head	B-T038
and	I-T038
neck	I-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
HNSCC	B-T038
)	O
.	O

Statistically	O
significant	O
associations	O
were	O
found	O
between	O
HERG1	B-T103
expression	B-T038
and	O
tobacco	O
consumption	O
,	O
disease	O
stage	O
,	O
tumor	B-T038
differentiation	B-T038
,	O
tumor	B-T038
recurrence	I-T038
,	O
and	O
reduced	O
survival	O
.	O

There	O
was	O
no	O
association	O
between	O
HERG1	B-T103
expression	B-T038
and	O
the	O
risk	O
of	O
progression	B-T038
from	O
oral	B-T038
leukoplakia	I-T038
to	O
OSCC	B-T038
.	O

In	O
addition	O
,	O
a	O
high	O
proportion	O
of	O
tumors	B-T038
(	O
80	O
%	O
)	O
showed	O
increased	O
HERG1	B-T017
mRNA	B-T103
levels	O
compared	O
to	O
normal	B-T017
mucosa	I-T017
from	O
nononcologic	O
patients	O
.	O

Aberrant	O
HERG1	B-T103
expression	B-T038
increases	O
as	O
oral	O
tumorigenesis	B-T038
progresses	I-T038
from	O
oral	O
hyperplasia	O
to	O
OSCC	B-T038
.	O

Increased	O
HERG1	B-T017
mRNA	B-T103
levels	O
were	O
also	O
frequently	O
detected	B-T033
in	O
OSCC	B-T038
and	O
other	O
HNSCC	B-T038
subsites	B-T082
.	O

HERG1	B-T103
expression	B-T038
emerges	O
as	O
a	O
clinically	O
relevant	O
feature	O
during	O
tumor	B-T038
progression	I-T038
and	O
a	O
potential	O
poor	O
prognostic	B-T170
biomarker	B-T201
for	O
OSCC	B-T038
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Head	O
Neck	O
38	O
:	O
1708	O
-	O
1716	O
,	O
2016	O
.	O

Nationwide	O
reduction	O
in	O
the	O
number	O
of	O
corneal	B-T058
transplantations	I-T058
for	O
keratoconus	B-T038
following	O
the	O
implementation	O
of	O
cross	O
-	O
linking	O

Keratoconus	B-T038
is	O
characterized	O
by	O
corneal	B-T038
ectasia	I-T038
and	O
irregular	B-T038
astigmatism	I-T038
,	O
which	O
can	O
lead	O
to	O
diminished	B-T038
vision	I-T038
and	O
corneal	B-T033
scarring	I-T033
.	O

Approximately	O
10	O
-	O
20	O
%	O
of	O
patients	O
with	O
keratoconus	B-T038
eventually	O
require	O
a	O
corneal	B-T058
transplant	I-T058
.	O

Corneal	O
cross	O
-	O
linking	O
(	O
CXL	O
)	O
is	O
a	O
relatively	O
new	O
treatment	B-T058
that	O
may	O
help	O
prevent	O
the	O
need	O
for	O
corneal	B-T058
transplantation	I-T058
.	O

Here	O
,	O
we	O
investigated	O
whether	O
the	O
introduction	O
of	O
CXL	O
has	O
reduced	O
the	O
number	O
of	O
corneal	B-T058
transplants	I-T058
performed	O
annually	O
.	O

Data	O
regarding	O
the	O
transplantation	B-T058
procedures	I-T058
performed	O
in	O
patients	O
under	O
the	O
age	O
of	O
50	O
years	O
were	O
extracted	O
from	O
the	O
Dutch	B-T170
National	I-T170
Organ	I-T170
Transplant	I-T170
Registry	I-T170
.	O

The	O
number	O
of	O
corneal	B-T058
transplants	I-T058
performed	O
prior	O
to	O
(	O
i	O
.	O
e	O
.	O

in	O
2005	O
through	O
2007	O
)	O
and	O
following	O
the	O
introduction	O
of	O
CXL	O
(	O
i	O
.	O
e	O
.	O

in	O
2012	O
through	O
2014	O
)	O
were	O
compared	O
.	O

Furthermore	O
,	O
a	O
trend	O
analysis	O
on	O
annual	O
keratoplasties	B-T058
over	O
time	O
was	O
performed	O
.	O

Approximately	O
25	O
%	O
fewer	O
corneal	B-T058
transplants	I-T058
were	O
performed	O
in	O
the	O
3	O
-	O
year	O
period	O
following	O
the	O
introduction	O
of	O
CXL	O
compared	O
to	O
the	O
3	O
-	O
year	O
period	O
prior	O
to	O
the	O
introduction	O
of	O
CXL	O
(	O
201	O
versus	O
269	O
transplants	B-T058
,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

Age	O
,	O
gender	O
and	O
visual	B-T201
acuity	I-T201
were	O
similar	O
between	O
the	O
patient	O
groups	O
in	O
the	O
two	O
time	O
periods	O
.	O

Trend	O
analysis	O
also	O
demonstrated	O
a	O
significant	O
decrease	O
in	O
the	O
amount	O
of	O
corneal	B-T058
transplants	I-T058
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Significantly	O
fewer	O
corneal	B-T058
transplants	I-T058
were	O
performed	O
for	O
treating	O
keratoconus	B-T038
following	O
the	O
nationwide	O
introduction	O
of	O
CXL	O
.	O

This	O
reduction	O
suggests	O
that	O
corneal	O
cross	O
-	O
linking	O
can	O
significantly	O
reduce	O
the	O
need	O
for	O
corneal	B-T058
transplantation	I-T058
.	O

Basal	B-T038
and	O
maximal	O
metabolic	O
rates	O
differ	O
in	O
their	O
response	O
to	O
rapid	O
temperature	O
change	O
among	O
avian	B-T204
species	B-T170

In	O
birds	B-T204
,	O
acclimation	B-T038
and	O
acclimatization	B-T038
to	O
temperature	O
are	O
associated	O
with	O
changes	O
in	O
basal	B-T038
(	O
BMR	B-T038
)	O
,	O
summit	O
(	O
Msum	O
)	O
and	O
maximal	O
(	O
MMR	O
)	O
metabolic	O
rates	O
but	O
little	O
is	O
known	O
about	O
the	O
rate	O
at	O
which	O
species	B-T170
adjust	O
their	O
phenotype	O
to	O
short	O
-	O
term	O
temperature	O
variations	O
.	O

Our	O
aims	O
were	O
(	O
1	O
)	O
to	O
determine	O
the	O
pattern	B-T082
of	O
metabolic	O
adjustments	O
following	O
a	O
rapid	O
temperature	O
change	O
,	O
(	O
2	O
)	O
to	O
determine	O
whether	O
performance	O
varies	O
at	O
similar	O
rates	O
during	O
exposure	O
to	O
warm	O
or	O
cold	O
environments	O
,	O
and	O
(	O
3	O
)	O
to	O
determine	O
if	O
BMR	B-T038
,	O
Msum	O
and	O
MMR	O
change	O
at	O
comparable	O
rates	O
during	O
thermal	O
acclimation	B-T038
.	O

We	O
measured	O
these	O
parameters	O
in	O
white	B-T204
-	I-T204
throated	I-T204
sparrows	I-T204
(	O
Zonotrichia	B-T204
albicollis	I-T204
)	O
,	O
black	B-T204
-	I-T204
capped	I-T204
chickadees	I-T204
(	O
Poecile	B-T204
atricapillus	I-T204
)	O
,	O
and	O
snow	B-T204
buntings	I-T204
(	O
Plectrophenax	B-T204
nivalis	I-T204
)	O
after	O
acclimation	B-T038
to	O
10	O
°C	O
(	O
day	O
0	O
)	O
and	O
on	O
the	O
4th	O
and	O
8th	O
days	O
of	O
acclimation	B-T038
to	O
either	O
-	O
5	O
or	O
28	O
°C	O
.	O

Birds	B-T204
changed	O
their	O
metabolic	O
phenotype	O
within	O
8	O
days	O
with	O
patterns	B-T082
differing	O
among	O
species	B-T170
.	O

Sparrows	B-T204
expressed	O
the	O
expected	O
metabolic	O
increases	O
in	O
the	O
cold	O
and	O
decreases	O
at	O
thermoneutrality	O
while	O
performance	O
in	O
chickadees	B-T204
and	O
buntings	B-T204
was	O
not	O
influenced	O
by	O
temperature	O
but	O
changed	O
over	O
time	O
with	O
inverse	O
patterns	B-T082
.	O

Our	O
results	O
suggest	O
that	O
BMR	B-T038
varies	O
at	O
comparable	O
rates	O
in	O
warm	O
and	O
cold	O
environments	O
but	O
changes	O
faster	O
than	O
Msum	O
and	O
MMR	O
,	O
likely	O
due	O
to	O
limitations	O
in	O
the	O
rate	O
of	O
change	O
in	O
organ	O
size	O
and	O
function	O
.	O

They	O
also	O
suggest	O
that	O
maximal	O
metabolic	O
capacity	O
is	O
lost	O
faster	O
in	O
a	O
warm	O
environment	O
than	O
it	O
is	O
gained	O
in	O
a	O
cold	O
environment	O
.	O

With	O
the	O
expected	O
increase	O
in	O
temperature	O
stochasticity	O
at	O
northern	B-T082
latitudes	I-T082
,	O
a	O
loss	O
of	O
thermogenic	O
capacity	O
during	O
warm	O
winter	O
days	O
could	O
,	O
therefore	O
,	O
be	O
detrimental	O
if	O
birds	B-T204
are	O
slow	O
to	O
readjust	O
their	O
phenotype	O
with	O
the	O
return	O
of	O
cold	O
days	O
.	O

A	O
prime	O
a	O
day	O
keeps	O
calories	O
away	O
:	O
The	O
effects	O
of	O
supraliminal	O
priming	O
on	O
food	O
consumption	O
and	O
the	O
moderating	B-T170
role	I-T170
of	O
gender	O
and	O
eating	B-T170
restraint	I-T170

The	O
link	O
between	O
intentions	B-T038
and	O
action	O
in	O
weight	B-T058
control	I-T058
is	O
weaker	O
than	O
previously	O
thought	O
,	O
so	O
recent	O
research	B-T062
has	O
called	O
for	O
further	O
investigation	O
of	O
ways	O
to	O
improve	O
weight	B-T058
control	I-T058
that	O
bypass	O
conscious	B-T038
intentions	B-T038
.	O

Priming	O
has	O
been	O
shown	O
to	O
have	O
effects	O
on	O
individual	O
behavior	O
in	O
a	O
variety	O
of	O
contexts	O
by	O
influencing	O
subconscious	B-T038
cognition	B-T038
.	O

This	O
paper	O
investigates	O
the	O
effects	O
of	O
semantic	O
priming	O
using	O
healthy	O
body	B-T038
image	I-T038
,	O
goal	B-T170
-	I-T170
oriented	I-T170
words	I-T170
on	O
food	O
consumption	O
.	O

The	O
moderating	B-T170
role	I-T170
of	O
both	O
restrained	B-T170
eating	I-T170
and	O
gender	O
is	O
investigated	O
.	O

161	O
participants	B-T098
were	O
involved	O
in	O
an	O
experiment	B-T062
using	O
a	O
novel	O
version	O
of	O
a	O
scrambled	O
sentence	B-T170
priming	O
game	O
.	O

The	O
outcome	O
measure	O
was	O
the	O
number	O
of	O
kilocalories	O
consumed	O
,	O
examined	O
using	O
a	O
between	O
subjects	O
ANCOVA	O
with	O
priming	O
,	O
gender	O
,	O
restrained	B-T170
eating	I-T170
index	I-T170
,	O
self	B-T062
-	I-T062
reported	I-T062
BMI	B-T201
,	O
and	O
two	O
interaction	O
terms	O
(	O
priming	O
x	O
gender	O
,	O
and	O
priming	O
x	O
restrained	B-T170
eating	I-T170
index	I-T170
)	O
.	O

There	O
was	O
no	O
main	O
effect	O
of	O
priming	O
but	O
there	O
was	O
an	O
interaction	O
of	O
priming	O
with	O
gender	O
.	O

Females	O
consumed	O
significantly	O
fewer	O
kilocalories	O
after	O
being	O
exposed	O
to	O
priming	O
words	B-T170
related	O
to	O
a	O
healthy	O
body	B-T038
image	I-T038
(	O
i	O
.	O
e	O
.	O

"	O
slim	O
"	O
,	O
"	O
fit	O
,	O
"	O
)	O
compared	O
to	O
females	O
receiving	O
the	O
neutral	O
prime	O
,	O
with	O
a	O
medium	O
effect	O
size	O
(	O
d	O
=	O
0	O
.	O
58	O
)	O
.	O

The	O
body	B-T038
image	I-T038
prime	O
did	O
not	O
significantly	O
affect	O
food	B-T038
intake	I-T038
for	O
males	O
,	O
nor	O
did	O
it	O
have	O
a	O
differential	O
effect	O
on	O
restrained	B-T098
eaters	I-T098
.	O

This	O
study	O
shows	O
that	O
priming	O
can	O
be	O
an	O
effective	O
method	O
for	O
influencing	O
females	O
to	O
reduce	O
food	B-T038
intake	I-T038
,	O
regardless	O
of	O
whether	O
they	O
are	O
restrained	B-T098
or	O
unrestrained	B-T098
eaters	I-T098
.	O

Future	O
studies	O
could	O
investigate	O
whether	O
different	O
priming	O
words	B-T170
related	O
to	O
a	O
male	O
'	O
s	O
healthy	O
body	B-T038
image	I-T038
goal	O
(	O
i	O
.	O
e	O
.	O

"	O
buff	O
,	O
"	O
"	O
muscles	B-T017
,	O
"	O
etc	O
.	O
)	O
would	O
similarly	O
reduce	O
food	B-T038
intake	I-T038
for	O
males	O
.	O

Neurotrophins	B-T103
and	O
specific	B-T103
receptors	I-T103
in	O
the	O
oviduct	B-T017
tracts	I-T017
of	O
Japanese	B-T204
quail	I-T204
(	O
Coturnix	B-T204
coturnix	I-T204
japonica	I-T204
)	O

Neurotrophins	B-T103
(	O
NGF	B-T103
,	O
BDNF	B-T103
and	O
NT	B-T103
-	I-T103
3	I-T103
)	O
and	O
their	O
specific	B-T103
receptors	I-T103
(	O
TrkA	B-T103
,	O
TrkB	B-T103
and	O
TrkC	B-T103
)	O
were	O
studied	B-T062
in	O
the	O
oviduct	B-T017
of	O
egg	B-T038
laying	I-T038
quails	B-T204
.	O

Neurotrophins	B-T103
(	O
NTs	B-T103
)	O
are	O
mainly	O
involved	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
neuronal	B-T017
populations	I-T017
in	O
the	O
central	B-T022
and	O
peripheral	B-T022
nervous	I-T022
system	I-T022
,	O
but	O
also	O
in	O
reproductive	B-T022
system	I-T022
.	O

In	O
this	O
survey	O
,	O
we	O
first	O
studied	B-T062
the	O
morphological	O
organization	B-T038
of	O
the	O
quail	B-T204
oviduct	B-T017
,	O
distinguished	O
in	O
infundibulum	B-T017
,	O
magnum	B-T017
,	O
isthmus	B-T017
,	O
uterus	B-T017
and	O
vagina	B-T017
,	O
and	O
then	O
we	O
analyzed	B-T062
the	O
expression	B-T038
and	O
localization	B-T038
of	O
NTs	B-T103
and	O
Trks	B-T103
receptors	I-T103
in	O
the	O
whole	O
tracts	B-T017
.	O

By	O
western	B-T058
blotting	I-T058
we	O
detected	O
that	O
the	O
investigated	O
NTs	B-T103
and	O
Trks	B-T103
receptors	I-T103
are	O
expressed	B-T038
in	O
all	O
oviductal	B-T017
tracts	I-T017
.	O

By	O
immunohistochemistry	B-T058
we	O
were	O
able	O
to	O
define	O
the	O
distribution	O
of	O
NTs	B-T103
and	O
Trks	B-T103
.	O

Specifically	O
,	O
NGF	B-T103
,	O
BDNF	B-T103
and	O
NT3	B-T103
were	O
localized	O
in	O
lining	O
and	O
ductal	B-T017
epithelial	I-T017
cells	I-T017
,	O
and	O
NGF	B-T103
was	O
also	O
detected	O
in	O
secretory	B-T017
cells	I-T017
of	O
tubular	B-T017
glands	I-T017
and	O
in	O
nervous	B-T017
fibers	I-T017
of	O
vessel	B-T017
wall	I-T017
.	O

TrkA	B-T103
and	O
TrkB	B-T103
were	O
present	O
in	O
the	O
lining	O
and	O
ductal	B-T017
epithelium	I-T017
;	O
TrkA	B-T103
and	O
TrkC	B-T103
were	O
present	O
in	O
nervous	B-T017
fibers	I-T017
of	O
vessel	B-T017
wall	I-T017
in	O
all	O
oviductal	B-T017
tracts	I-T017
.	O

Furthermore	O
,	O
we	O
also	O
observed	O
NGF	B-T103
and	O
BDNF	B-T103
co	O
-	O
localized	O
with	O
TrkA	B-T103
and	O
TrkB	B-T103
in	O
cells	B-T017
of	O
the	O
lining	O
and	O
ductal	B-T017
epithelium	I-T017
,	O
suggesting	O
an	O
autocrine	O
mechanism	O
of	O
action	O
.	O

The	O
influence	O
of	O
liposomal	B-T103
formulation	O
on	O
the	O
incorporation	O
and	O
retention	O
of	O
PNA	B-T103
oligomers	I-T103

Liposomal	B-T103
formulations	O
composed	O
of	O
phospholipids	B-T103
with	O
different	O
unsaturation	O
degrees	O
,	O
head	O
groups	O
and	O
at	O
different	O
cholesterol	B-T058
content	I-T058
have	I-T058
been	I-T058
tested	I-T058
for	O
the	O
encapsulation	O
of	O
Peptide	B-T103
Nucleic	I-T103
Acid	I-T103
(	I-T103
PNA	I-T103
)	I-T103
oligomers	I-T103
.	O

The	O
best	O
loading	O
capability	O
(	O
177μg	O
,	O
ER	O
%	O
=	O
87	O
.	O
2	O
)	O
was	O
obtained	O
for	O
pure	O
liposomes	B-T103
of	O
phosphatidylglycerol	B-T103
(	O
DOPG	B-T103
)	O
with	O
negatively	B-T103
charged	I-T103
head	O
group	O
.	O

The	O
insertion	B-T058
of	O
a	O
10	O
-	O
20	O
%	O
of	O
cholesterol	B-T103
in	O
DOPG	B-T103
based	O
liposomes	B-T103
provides	O
a	O
slight	O
decrease	O
(	O
∼160μg	O
)	O
of	O
the	O
PNA	B-T103
loading	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
cholesterol	B-T103
addition	O
(	O
20	O
-	O
30	O
%	O
)	O
slows	O
down	O
the	O
PNA	B-T103
'	I-T103
s	I-T103
release	O
(	O
∼27	O
%	O
)	O
in	O
fetal	B-T103
bovine	I-T103
serum	I-T103
from	O
the	O
liposomal	B-T103
formulation	O
.	O

Based	O
on	O
the	O
encapsulation	O
and	O
the	O
release	O
properties	O
,	O
PEGylated	B-T103
DOPG	B-T103
liposomes	B-T103
with	O
a	O
percentage	O
of	O
cholesterol	B-T103
of	O
10	O
-	O
20	O
%	O
are	O
the	O
optimal	B-T062
formulation	I-T062
for	O
the	O
loading	O
of	O
PNA	B-T103
-	I-T103
a210	I-T103
.	O

Histopathology	B-T091
of	O
the	O
filum	B-T017
terminale	I-T017
in	O
children	O
with	O
and	O
without	O
tethered	B-T038
cord	I-T038
syndrome	I-T038
with	O
attention	O
to	O
the	O
elastic	B-T017
tissue	I-T017
within	O
the	O
filum	B-T017

To	O
compare	O
histologically	O
transected	O
fila	B-T017
from	O
pediatric	O
patients	O
with	O
tethered	B-T038
cord	I-T038
syndrome	I-T038
(	O
TCS	B-T038
)	O
,	O
with	O
and	O
without	O
a	O
low	B-T082
conus	B-T017
,	O
with	O
controls	O
,	O
focusing	O
on	O
collagenous	B-T017
and	O
elastic	B-T017
tissue	I-T017
.	O

Thirty	O
fila	B-T017
from	O
patients	O
with	O
TCS	B-T038
,	O
including	O
5	O
where	O
minimal	O
cautery	B-T058
was	O
used	O
prior	O
to	O
filum	B-T017
section	B-T058
,	O
were	O
compared	O
with	O
fila	B-T017
from	O
27	O
pediatric	O
cadavers	B-T017
without	O
TCS	B-T038
(	O
controls	O
)	O
.	O

Sections	O
of	O
fila	B-T017
were	O
stained	B-T058
with	O
H	B-T058
&	I-T058
E	I-T058
,	O
Masson	B-T058
trichrome	I-T058
and	O
Verhoeff	B-T058
von	I-T058
Gieson	I-T058
elastic	I-T058
stains	I-T058
,	O
and	O
7	O
with	O
Gordon	B-T058
and	I-T058
Sweet	I-T058
'	I-T058
s	I-T058
reticulin	I-T058
stain	I-T058
.	O

Fila	B-T017
from	O
controls	O
showed	O
loose	O
fibrous	B-T017
connective	I-T017
tissue	I-T017
(	O
FCT	B-T017
)	O
with	O
thin	O
and	O
evenly	O
dispersed	O
elastic	B-T017
fibers	I-T017
(	O
EFs	B-T017
)	O
.	O

Reticulin	B-T103
fibers	I-T103
(	O
RFs	B-T103
)	O
were	O
seen	O
in	O
blood	B-T017
vessel	I-T017
walls	I-T017
and	O
nerve	B-T017
twigs	O
.	O

Fat	B-T103
was	O
identified	O
microscopically	O
in	O
2	O
fila	B-T017
.	O

All	O
fila	B-T017
from	O
patients	O
with	O
TCS	B-T038
had	O
dense	B-T017
FCT	I-T017
.	O

The	O
EFs	B-T017
were	O
in	O
normal	O
numbers	O
in	O
17	O
,	O
and	O
focally	B-T082
or	O
diffusely	O
decreased	O
in	O
13	O
.	O

All	O
25	O
patients	O
where	O
the	O
fila	B-T017
were	O
cauterized	B-T058
during	O
resection	B-T058
had	O
thick	O
and	O
coiled	B-T082
EFs	B-T017
.	O

Coiling	B-T082
was	O
not	O
seen	O
when	O
minimal	O
cautery	B-T058
was	O
applied	O
.	O

RFs	B-T103
were	O
seen	O
in	O
blood	B-T017
vessel	I-T017
walls	I-T017
and	O
nerve	O
twigs	O
.	O

Fat	B-T103
was	O
identified	O
in	O
19	O
patients	O
.	O

Findings	B-T033
were	O
similar	O
,	O
whether	O
the	O
conus	B-T017
termination	O
was	O
normal	O
or	O
low	B-T082
.	O

The	O
fila	B-T017
of	O
all	O
patients	O
with	O
TCS	B-T038
,	O
whether	O
or	O
not	O
the	O
conus	B-T017
was	O
low	B-T082
,	O
showed	O
abnormal	B-T033
FCT	B-T017
.	O

EFs	B-T017
were	O
decreased	O
in	O
48	O
%	O
of	O
patients	O
;	O
however	O
,	O
there	O
were	O
thick	O
and	O
coiled	B-T082
EFs	B-T017
in	O
all	O
patients	O
.	O

Coiling	B-T082
of	O
EFs	B-T017
,	O
initially	O
thought	O
to	O
be	O
an	O
abnormality	B-T033
in	O
patients	O
,	O
is	O
considered	O
most	O
likely	O
to	O
be	O
a	O
result	O
of	O
cautery	B-T058
(	O
i	O
.	O
e	O
.	O
,	O
artifactual	O
/	O
iatrogenic	O
coiling	B-T082
)	O
.	O

Clinical	B-T033
value	I-T033
of	O
pathologic	B-T058
examination	I-T058
of	O
non	B-T017
-	I-T017
neoplastic	I-T017
kidney	I-T017
in	O
patients	O
with	O
upper	B-T022
urinary	I-T022
tract	I-T022
malignancies	B-T038

While	O
surgical	B-T058
resection	I-T058
remains	O
the	O
standard	O
of	O
care	O
in	O
the	O
treatment	B-T058
of	O
upper	B-T022
urinary	I-T022
tract	I-T022
malignancies	B-T038
,	O
nephrectomy	B-T058
is	O
a	O
risk	B-T033
factor	I-T033
for	O
the	O
development	O
of	O
chronic	B-T038
kidney	I-T038
disease	I-T038
(	O
CKD	B-T038
)	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
whether	O
histologic	O
evaluation	B-T058
of	O
non	B-T017
-	I-T017
neoplastic	I-T017
kidney	I-T017
could	O
enable	O
early	O
identification	O
of	O
unrecognized	O
kidney	B-T038
disease	I-T038
and	O
could	O
be	O
of	O
prognostic	B-T170
value	O
in	O
predicting	O
postoperative	O
renal	B-T017
outcomes	O
.	O

We	O
retrospectively	B-T062
analyzed	I-T062
51	O
patients	O
with	O
upper	B-T022
urinary	I-T022
tract	I-T022
malignancies	B-T038
who	O
received	O
uninephrectomy	B-T058
or	O
uninephroureterectomy	B-T058
.	O

A	O
thorough	O
pathologic	O
evaluation	B-T058
of	O
non	B-T017
-	I-T017
neoplastic	I-T017
kidney	I-T017
including	O
special	B-T058
stains	I-T058
,	O
immunofluorescence	B-T058
,	O
and	O
electron	B-T058
microscopic	I-T058
studies	I-T058
was	O
performed	O
.	O

The	O
degree	O
of	O
parenchymal	B-T017
changes	O
was	O
graded	O
from	O
0	O
to	O
15	O
.	O

Of	O
51	O
patients	O
,	O
only	O
13	O
showed	O
normal	O
kidney	B-T017
pathology	B-T091
.	O

Fifteen	O
patients	O
showed	O
glomerular	O
abnormalities	O
,	O
14	O
showed	O
diabetic	B-T038
nephropathy	I-T038
,	O
and	O
11	O
showed	O
vascular	B-T017
nephropathy	B-T058
.	O

There	O
was	O
one	O
case	O
each	O
of	O
reflux	B-T038
nephropathy	I-T038
and	O
chronic	B-T038
pyelonephritis	I-T038
.	O

The	O
median	O
histologic	O
score	O
was	O
5	O
points	O
.	O

Only	O
25	O
.	O
4	O
%	O
of	O
patients	O
had	O
≤	O
3	O
points	O
.	O

Score	O
more	O
than	O
5	O
was	O
observed	O
in	O
47	O
.	O
1	O
%	O
of	O
patients	O
.	O

Postoperative	O
estimated	B-T058
glomerular	I-T058
filtration	I-T058
rate	I-T058
(	O
eGFR	B-T058
)	O
at	O
3	O
to	O
36	O
months	O
were	O
obtained	O
from	O
90	O
.	O
2	O
%	O
of	O
patients	O
,	O
and	O
of	O
those	O
,	O
34	O
.	O
8	O
%	O
had	O
de	O
novo	O
CKD	B-T038
.	O

Since	O
no	O
one	O
had	O
CKD	B-T038
in	O
partial	O
nephrectomized	O
patients	O
,	O
we	O
determined	O
risk	B-T033
factors	I-T033
for	O
CKD	B-T038
in	O
radical	O
nephrectomized	O
patients	O
.	O

Cox	B-T170
regression	I-T170
analysis	I-T170
revealed	O
that	O
postoperative	O
AKI	B-T037
,	O
preoperative	O
eGFR	B-T058
,	O
and	O
histologic	O
score	O
of	O
non	B-T017
-	I-T017
neoplastic	I-T017
kidney	I-T017
were	O
the	O
independent	O
predictors	O
for	O
CKD	B-T038
.	O

We	O
conclude	O
that	O
routine	O
pathologic	O
evaluation	B-T058
of	O
non	B-T017
-	I-T017
neoplastic	I-T017
kidney	I-T017
provides	O
valuable	O
diagnostic	O
and	O
prognostic	B-T170
information	O
.	O

Concordant	O
but	O
Varied	O
Phenotypes	O
among	O
Duchenne	B-T038
Muscular	I-T038
Dystrophy	I-T038
Patient	O
-	O
Specific	O
Myoblasts	B-T017
Derived	O
using	O
a	O
Human	B-T204
iPSC	B-T017
-	O
Based	O
Model	B-T038

Duchenne	B-T038
muscular	I-T038
dystrophy	I-T038
(	O
DMD	B-T038
)	O
remains	O
an	O
intractable	O
genetic	B-T038
disease	I-T038
.	O

Althogh	O
there	O
are	O
several	O
animal	B-T038
models	I-T038
of	O
DMD	B-T038
,	O
there	O
is	O
no	O
human	B-T017
cell	I-T017
model	O
that	O
carries	O
patient	O
-	O
specific	O
DYSTROPHIN	B-T017
mutations	B-T038
.	O

Here	O
,	O
we	O
present	O
a	O
human	B-T204
DMD	B-T038
model	B-T038
using	O
human	B-T017
induced	I-T017
pluripotent	I-T017
stem	I-T017
cells	I-T017
(	O
hiPSCs	B-T017
)	O
.	O

Our	O
model	O
reveals	O
concordant	O
disease	B-T038
-	O
related	O
phenotypes	O
with	O
patient	O
-	O
dependent	O
variation	O
,	O
which	O
are	O
partially	O
reversed	O
by	O
genetic	O
and	O
pharmacological	O
approaches	O
.	O

Our	O
"	O
chemical	B-T103
-	I-T103
compound	I-T103
-	O
based	O
"	O
strategy	B-T062
successfully	O
directs	O
hiPSCs	B-T017
into	O
expandable	O
myoblasts	B-T017
,	O
which	O
exhibit	O
a	O
myogenic	B-T038
transcriptional	I-T038
program	O
,	O
forming	O
striated	O
contractile	B-T017
myofibers	B-T017
and	O
participating	O
in	O
muscle	B-T033
regeneration	I-T033
in	B-T082
vivo	I-T082
.	O

DMD	B-T038
-	O
hiPSC	B-T017
-	O
derived	O
myoblasts	B-T017
show	O
disease	B-T038
-	O
related	O
phenotypes	O
with	O
patient	O
-	O
to	O
-	O
patient	O
variability	O
,	O
including	O
aberrant	O
expression	O
of	O
inflammation	B-T038
or	O
immune	B-T017
-	I-T017
response	I-T017
genes	I-T017
and	O
collagens	B-T103
,	O
increased	O
BMP	B-T038
/	O
TGFβ	B-T038
signaling	I-T038
,	O
and	O
reduced	O
fusion	O
competence	O
.	O

Furthermore	O
,	O
by	O
genetic	O
correction	O
and	O
pharmacological	O
"	O
dual	O
-	O
SMAD	B-T103
"	O
inhibition	B-T038
,	O
the	O
DMD	B-T038
-	O
hiPSC	B-T017
-	O
derived	O
myoblasts	B-T017
and	O
genetically	O
corrected	O
isogenic	O
myoblasts	B-T017
form	O
"	O
rescued	O
"	O
multi	O
-	O
nucleated	O
myotubes	B-T017
.	O

In	O
conclusion	O
,	O
our	O
findings	O
demonstrate	O
the	O
feasibility	O
of	O
establishing	O
a	O
human	B-T204
"	O
DMD	B-T038
-	O
in	O
-	O
a	O
-	O
dish	O
"	O
model	B-T038
using	O
hiPSC	B-T017
-	O
based	O
disease	B-T038
modeling	I-T038
.	O

SNAI1	B-T103
promotes	O
the	O
development	O
of	O
HCC	B-T038
through	O
the	O
enhancement	O
of	O
proliferation	O
and	O
inhibition	B-T038
of	I-T038
apoptosis	I-T038

SNAI1	B-T103
,	O
a	O
zinc	B-T103
-	I-T103
finger	I-T103
transcription	I-T103
factor	I-T103
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
induction	O
of	O
epithelial	B-T038
-	I-T038
mesenchymal	I-T038
transition	I-T038
(	O
EMT	B-T038
)	O
in	O
various	O
cancers	B-T038
.	O

However	O
,	O
the	O
possible	O
functions	O
of	O
SNAI1	B-T103
in	O
the	O
proliferation	O
and	O
apoptosis	B-T038
of	O
hepatocellular	B-T038
carcinoma	I-T038
have	O
not	O
been	O
clearly	O
identified	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
investigated	O
the	O
effects	O
and	O
mechanisms	O
of	O
SNAI1	B-T103
in	O
the	O
proliferation	O
and	O
apoptosis	B-T038
of	O
hepatocellular	B-T038
carcinoma	I-T038
using	O
clinical	O
samples	O
and	O
cell	B-T017
lines	I-T017
.	O

We	O
found	O
that	O
SNAI1	B-T103
is	O
highly	O
expressed	B-T038
in	O
the	O
tissues	B-T017
of	O
liver	B-T038
cancer	I-T038
compared	O
with	O
adjacent	O
nontumor	B-T017
tissues	I-T017
.	O

SNAI1	B-T103
is	O
also	O
highly	O
expressed	B-T038
in	O
the	O
hepatoma	B-T017
cell	I-T017
lines	I-T017
HepG2	I-T017
,	O
SMMC	B-T017
-	I-T017
7721	I-T017
,	O
and	O
BEL	B-T017
-	I-T017
7402	I-T017
compared	O
with	O
the	O
human	B-T017
normal	I-T017
liver	I-T017
cell	I-T017
line	I-T017
L02	I-T017
.	O

We	O
also	O
observed	O
that	O
SNAI1	B-T103
expression	B-T038
was	O
correlated	O
with	O
distal	B-T038
metastasis	I-T038
,	O
incomplete	O
tumor	B-T038
capsule	I-T038
formation	I-T038
,	O
and	O
histological	B-T201
differentiation	I-T201
in	O
hepatocellular	B-T038
carcinoma	I-T038
(	O
HCC	B-T038
)	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
knockdown	B-T062
of	O
SNAI1	B-T017
via	O
lentiviral	B-T005
vectors	B-T103
of	O
RNAi	B-T038
against	O
SNAI	B-T103
inhibited	O
cell	O
proliferation	O
by	O
inducing	O
G1	B-T038
arrest	I-T038
,	O
which	O
was	O
accompanied	O
by	O
the	O
downregulation	B-T038
of	O
cyclin	B-T103
D1	I-T103
but	O
not	O
that	O
of	O
cyclin	B-T103
A	I-T103
.	O

In	O
addition	O
,	O
knockdown	B-T062
of	O
SNAI1	B-T017
promoted	O
apoptosis	B-T038
by	O
decreasing	O
the	O
expression	B-T038
of	O
Bcl	B-T103
-	I-T103
2	I-T103
.	O

In	O
conclusion	O
,	O
our	O
findings	O
revealed	O
that	O
SNAI1	B-T103
is	O
involved	O
in	O
the	O
development	O
of	O
hepatocellular	B-T038
carcinoma	I-T038
via	O
regulating	B-T038
the	I-T038
growth	I-T038
and	O
apoptosis	B-T038
of	O
tumor	B-T017
cells	I-T017
.	O

Quantitative	O
assessment	O
of	O
fluorescent	B-T103
proteins	I-T103

The	O
advent	O
of	O
fluorescent	B-T103
proteins	I-T103
(	O
FPs	B-T103
)	O
for	O
genetic	B-T062
labeling	I-T062
of	O
molecules	O
and	O
cells	B-T017
has	O
revolutionized	O
fluorescence	B-T058
microscopy	I-T058
.	O

Genetic	O
manipulations	O
have	O
created	O
a	O
vast	O
array	O
of	O
bright	O
and	O
stable	O
FPs	B-T103
spanning	O
blue	O
to	O
red	O
spectral	O
regions	O
.	O

Common	O
to	O
autofluorescent	B-T058
FPs	B-T103
is	O
their	O
tight	O
β	O
-	O
barrel	O
structure	O
,	O
which	O
provides	O
the	O
rigidity	O
and	O
chemical	B-T103
environment	B-T082
needed	O
for	O
effectual	O
fluorescence	O
.	O

Despite	O
the	O
common	O
structure	B-T082
,	O
each	O
FP	B-T103
has	O
unique	O
properties	O
.	O

Thus	O
,	O
there	O
is	O
no	O
single	O
'	O
best	O
'	O
FP	B-T103
for	O
every	O
circumstance	O
,	O
and	O
each	O
FP	B-T103
has	O
advantages	O
and	O
disadvantages	O
.	O

To	O
guide	O
decisions	O
about	O
which	O
FP	B-T103
is	O
right	O
for	O
a	O
given	O
application	O
,	O
we	O
have	O
quantitatively	O
characterized	O
the	O
brightness	O
,	O
photostability	B-T033
,	O
pH	O
stability	O
and	O
monomeric	B-T103
properties	O
of	O
more	O
than	O
40	O
FPs	B-T103
to	O
enable	O
straightforward	O
and	O
direct	O
comparison	O
between	O
them	O
.	O

We	O
focus	O
on	O
popular	O
and	O
/	O
or	O
top	O
-	O
performing	O
FPs	B-T103
in	O
each	O
spectral	O
region	O
.	O

Consumption	B-T038
of	I-T038
fruits	I-T038
and	I-T038
vegetables	I-T038
associated	O
with	O
other	O
risk	O
behaviors	O
among	O
adolescents	O
in	O
Northeast	B-T082
Brazil	I-T082

To	O
determine	O
the	O
prevalence	O
of	O
consumption	B-T038
of	I-T038
fruits	I-T038
and	I-T038
vegetables	I-T038
and	O
identify	O
the	O
association	O
with	O
low	O
level	O
of	O
physical	O
activity	O
,	O
exposure	O
to	O
sedentary	O
behavior	O
,	O
consumption	O
of	O
soft	B-T168
drinks	I-T168
and	O
overweight	B-T033
/	O
obesity	B-T038
in	O
adolescents	O
.	O

This	O
is	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
school	I-T062
-	I-T062
based	I-T062
study	I-T062
with	O
a	O
representative	O
sample	O
of	O
3992	O
students	B-T098
aged	O
14	O
-	O
19	O
years	O
from	O
the	O
state	B-T082
of	I-T082
Sergipe	I-T082
,	O
Brazil	B-T082
.	O

The	O
outcome	O
was	O
low	O
consumption	B-T038
of	I-T038
fruits	I-T038
and	I-T038
vegetables	I-T038
(	O
<	O
5	O
servings	O
/	O
day	O
)	O
.	O

Independent	O
variables	O
were	O
:	O
level	O
of	O
physical	O
activity	O
,	O
sedentary	O
behavior	O
,	O
consumption	O
of	O
soft	B-T168
drinks	I-T168
,	O
and	O
overweight	B-T033
/	O
obesity	B-T038
.	O

Global	B-T170
Student	I-T170
Health	I-T170
Survey	I-T170
questionnaire	I-T170
and	O
body	B-T058
mass	I-T058
and	O
height	O
measurements	O
were	O
used	O
,	O
as	O
well	O
as	O
chi	B-T170
-	I-T170
square	I-T170
test	I-T170
and	O
crude	B-T062
and	I-T062
adjusted	I-T062
binary	I-T062
logistic	I-T062
regression	I-T062
.	O

The	O
significance	B-T062
level	I-T062
adopted	O
was	O
5	O
%	O
.	O

The	O
prevalence	O
of	O
inadequate	O
consumption	B-T038
of	I-T038
fruits	I-T038
and	I-T038
vegetables	I-T038
was	O
high	O
-	O
88	O
.	O
6	O
%	O
(	O
95	O
%	O
CI	O
=	O
87	O
.	O
6	O
-	O
89	O
.	O
5	O
)	O
.	O

Higher	O
likelihood	O
of	O
low	O
consumption	B-T038
of	I-T038
fruits	I-T038
and	I-T038
vegetables	I-T038
was	O
verified	O
among	O
boys	O
who	O
were	O
exposed	O
to	O
sedentary	O
behavior	O
(	O
OR	O
=	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
18	O
-	O
2	O
.	O
24	O
)	O
,	O
who	O
consumed	O
soft	B-T168
drinks	I-T168
(	O
OR	O
=	O
3	O
.	O
04	O
;	O
95	O
%	O
CI	O
=	O
2	O
.	O
10	O
-	O
4	O
.	O
40	O
)	O
,	O
with	O
insufficiently	O
physical	O
activity	O
(	O
OR	O
=	O
1	O
.	O
98	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
43	O
-	O
2	O
.	O
73	O
)	O
and	O
girls	O
who	O
consumed	O
soft	B-T168
drinks	I-T168
(	O
OR	O
=	O
1	O
.	O
88	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
43	O
-	O
2	O
.	O
47	O
)	O
and	O
those	O
with	O
overweight	B-T033
/	O
obesity	B-T038
(	O
OR	O
=	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
19	O
-	O
2	O
.	O
23	O
)	O
.	O

There	O
is	O
a	O
need	O
of	O
public	O
policies	O
aimed	O
at	O
encouraging	O
the	O
consumption	O
of	O
healthy	O
foods	O
among	O
adolescents	O
.	O

Cobalamin	B-T103
Protection	O
against	O
Oxidative	B-T038
Stress	I-T038
in	O
the	O
Acidophilic	O
Iron	B-T007
-	I-T007
oxidizing	I-T007
Bacterium	I-T007
Leptospirillum	B-T007
Group	I-T007
II	I-T007
CF	I-T007
-	I-T007
1	I-T007

Members	O
of	O
the	O
genus	O
Leptospirillum	B-T007
are	O
aerobic	O
iron	B-T007
-	I-T007
oxidizing	I-T007
bacteria	I-T007
belonging	O
to	O
the	O
phylum	B-T007
Nitrospira	I-T007
.	O

They	O
are	O
important	O
members	O
of	O
microbial	O
communities	O
that	O
catalyze	O
the	O
biomining	O
of	O
sulfidic	B-T103
ores	I-T103
,	O
thereby	O
solubilizing	O
metal	B-T103
ions	I-T103
.	O

These	O
microorganisms	O
live	O
under	O
extremely	O
acidic	O
and	O
metal	B-T103
-	O
loaded	O
environments	B-T082
and	O
thus	O
must	O
tolerate	O
high	O
concentrations	O
of	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
.	O

Cobalamin	B-T103
(	O
vitamin	B-T103
B12	I-T103
)	O
is	O
a	O
cobalt	B-T103
-	O
containing	O
tetrapyrrole	B-T103
cofactor	B-T103
involved	O
in	O
intramolecular	O
rearrangement	O
reactions	O
and	O
has	O
recently	O
been	O
suggested	O
to	O
be	O
an	O
intracellular	B-T082
antioxidant	B-T103
.	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
exogenous	O
addition	O
of	O
cobalamin	B-T103
on	O
oxidative	B-T038
stress	I-T038
parameters	O
in	O
Leptospirillum	B-T007
group	I-T007
II	I-T007
strain	I-T007
CF	I-T007
-	I-T007
1	I-T007
.	O

Our	O
results	O
revealed	O
that	O
the	O
external	B-T168
supplementation	I-T168
of	O
cobalamin	B-T103
reduces	O
the	O
levels	O
of	O
intracellular	B-T082
ROSs	B-T103
and	O
the	O
damage	O
to	O
biomolecules	B-T103
,	O
and	O
also	O
stimulates	O
the	O
growth	B-T038
and	O
survival	B-T038
of	I-T038
cells	I-T038
exposed	O
to	O
oxidative	B-T038
stress	I-T038
exerted	O
by	O
ferric	B-T103
ion	I-T103
,	O
hydrogen	B-T103
peroxide	I-T103
,	O
chromate	B-T103
and	O
diamide	B-T103
.	O

Furthermore	O
,	O
exposure	O
of	O
strain	B-T007
CF	I-T007
-	I-T007
1	I-T007
to	O
oxidative	B-T038
stress	I-T038
elicitors	O
resulted	O
in	O
the	O
transcriptional	B-T038
activation	I-T038
of	O
the	O
cbiA	B-T017
gene	I-T017
encoding	O
CbiA	B-T103
of	O
the	O
cobalamin	B-T103
biosynthetic	B-T038
pathway	I-T038
.	O

Altogether	O
,	O
these	O
data	O
suggest	O
that	O
cobalamin	B-T103
plays	O
an	O
important	O
role	O
in	O
redox	B-T038
protection	O
of	O
Leptospirillum	B-T007
strain	I-T007
CF	I-T007
-	I-T007
1	I-T007
,	O
supporting	O
survival	O
of	O
this	O
microorganism	O
under	O
extremely	O
oxidative	O
environmental	O
conditions	O
.	O

Understanding	O
the	O
mechanisms	O
underlying	O
the	O
protective	O
effect	O
of	O
cobalamin	B-T103
against	O
oxidative	B-T038
stress	I-T038
may	O
help	O
to	O
develop	O
strategies	O
to	O
make	O
biomining	O
processes	O
more	O
effective	O
.	O

A	O
longitudinal	B-T062
study	I-T062
assessing	O
childcare	O
services	O
'	O
adoption	O
of	O
obesity	B-T038
prevention	O
policies	O
and	O
practices	O

Despite	O
ongoing	O
investments	O
to	O
improve	O
the	O
obesogenic	B-T038
environments	B-T082
of	O
childcare	O
settings	O
,	O
little	O
is	O
known	O
regarding	O
how	O
these	O
services	O
have	O
changed	O
their	O
physical	O
activity	O
and	O
nutrition	B-T062
-	I-T062
promoting	I-T062
practices	I-T062
.	O

This	O
study	O
aims	O
to	O
describe	O
changes	O
in	O
the	O
proportion	O
of	O
Australian	B-T098
childcare	O
services	O
that	O
have	O
adopted	O
best	O
-	O
practice	O
healthy	B-T058
eating	I-T058
and	O
physical	O
activity	O
practices	O
between	O
2006	O
and	O
2013	O
and	O
to	O
assess	O
whether	O
adoption	O
varied	O
by	O
socio	O
-	O
economic	O
status	O
and	O
locality	O
.	O

A	O
randomly	B-T062
selected	I-T062
sample	I-T062
of	O
nominated	O
supervisors	B-T097
(	O
n	O
=	O
358	O
)	O
from	O
childcare	O
services	O
located	O
in	O
New	B-T082
South	I-T082
Wales	I-T082
,	O
Australia	B-T082
,	O
participated	O
in	O
a	O
telephone	O
survey	O
in	O
2006	O
,	O
2009	O
,	O
2010	O
and	O
2013	O
.	O

Supervisors	B-T097
reported	O
on	O
their	O
service	O
'	O
s	O
adoption	O
of	O
six	O
practices	O
:	O
(	O
i	O
)	O
having	O
written	O
nutrition	B-T062
and	O
physical	O
activity	O
policies	B-T170
;	O
(	O
ii	O
)	O
staff	B-T097
trained	O
in	O
physical	O
activity	O
and	O
nutrition	B-T062
in	O
the	O
past	O
year	O
;	O
(	O
iii	O
)	O
scheduled	O
time	O
for	O
fundamental	O
movement	B-T038
skills	O
and	O
(	O
iv	O
)	O
outdoor	O
play	O
;	O
(	O
v	O
)	O
weekly	O
or	O
less	O
screen	B-T033
time	I-T033
opportunitie	I-T033
s	O
;	O
and	O
(	O
vi	O
)	O
serving	O
only	O
non	B-T168
-	I-T168
sweetened	I-T168
beverages	I-T168
.	O

A	O
significant	O
increase	O
in	O
the	O
prevalence	O
of	O
services	O
adopting	O
all	O
but	O
one	O
practice	O
,	O
between	O
2006	O
and	O
2013	O
was	O
identified	O
.	O

Ninety	O
one	O
percent	O
of	O
services	O
adopted	O
four	O
or	O
more	O
practices	O
,	O
a	O
significant	O
increase	O
from	O
38	O
%	O
in	O
2006	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
services	O
adopting	O
each	O
practice	O
by	O
locality	O
and	O
socio	O
-	O
economic	O
status	O
.	O

Government	B-T092
investment	O
in	O
obesity	B-T038
prevention	O
programmes	O
can	O
equitably	O
improve	O
childcare	O
service	O
'	O
s	O
adoption	O
of	O
healthy	B-T058
eating	I-T058
and	O
physical	O
activity	O
promoting	O
practices	O
on	O
a	O
jurisdiction	B-T170
-	O
wide	O
basis	O
.	O

The	O
establishment	O
of	O
a	O
routine	O
system	O
to	O
monitor	O
adoption	O
of	O
a	O
broader	O
range	O
of	O
practices	O
by	O
childcare	O
services	O
is	O
warranted	O
.	O

Isolation	O
and	O
characterization	O
of	O
Burkholderia	B-T007
sp	I-T007
.	I-T007
strain	I-T007
CCA53	I-T007
exhibiting	O
ligninolytic	B-T038
potential	O

Microbial	O
degradation	B-T038
of	O
lignin	B-T103
releases	O
fermentable	B-T103
sugars	I-T103
,	O
effective	O
utilization	O
of	O
which	O
could	O
support	O
biofuel	B-T103
production	O
from	O
lignocellulosic	B-T103
biomass	O
.	O

In	O
the	O
present	O
study	B-T062
,	O
a	O
lignin	B-T038
-	I-T038
degrading	I-T038
bacterium	B-T007
was	O
isolated	O
from	O
leaf	B-T204
soil	O
and	O
identified	O
as	O
Burkholderia	B-T007
sp	I-T007
.	I-T007

based	O
on	O
16S	B-T103
rRNA	I-T103
gene	B-T058
sequencing	I-T058
.	O

This	O
strain	O
was	O
named	O
CCA53	B-T007
,	O
and	O
its	O
lignin	B-T038
-	I-T038
degrading	I-T038
capability	O
was	O
assessed	O
by	O
observing	O
its	O
growth	B-T038
on	O
medium	B-T103
containing	O
alkali	B-T103
lignin	I-T103
or	O
lignin	B-T103
-	O
associated	O
aromatic	B-T103
monomers	I-T103
as	O
the	O
sole	O
carbon	B-T103
source	B-T033
.	O

Alkali	B-T103
lignin	I-T103
and	O
at	O
least	O
eight	O
lignin	B-T103
-	O
associated	O
aromatic	B-T103
monomers	I-T103
supported	O
growth	B-T038
of	O
this	O
strain	O
,	O
and	O
the	O
most	O
effective	O
utilization	O
was	O
observed	O
for	O
p	B-T103
-	I-T103
hydroxybenzene	I-T103
monomers	I-T103
.	O

These	O
findings	B-T033
indicate	O
that	O
Burkholderia	B-T007
sp	I-T007
.	I-T007

strain	I-T007
CCA53	I-T007
has	O
fragmentary	O
activity	O
for	O
lignin	B-T038
degradation	I-T038
.	O

Diagnostic	O
utility	O
of	O
additional	O
conventional	O
techniques	B-T058
after	O
endobronchial	B-T058
ultrasonography	I-T058
guidance	B-T058
during	O
transbronchial	B-T058
biopsy	I-T058

Endobronchial	B-T058
ultrasonography	I-T058
with	O
a	O
guide	B-T074
sheath	I-T074
transbronchial	B-T058
biopsy	I-T058
(	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
)	O
has	O
been	O
used	O
to	O
diagnose	B-T033
peripheral	B-T033
pulmonary	I-T033
lesions	I-T033
(	O
PPLs	B-T033
)	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
conventional	O
TBB	B-T058
after	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
.	O

A	O
retrospective	B-T062
analysis	I-T062
of	O
patients	O
who	O
underwent	O
conventional	O
TBB	B-T058
after	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
for	O
PPL	B-T033
between	O
August	O
1	O
,	O
2012	O
and	O
December	O
31	O
,	O
2014	O
.	O

We	O
performed	O
multivariate	O
analysis	O
to	O
examine	O
the	O
association	O
of	O
various	O
clinical	O
factors	O
,	O
including	O
EBUS	B-T058
probe	B-T074
distance	O
and	O
sample	O
size	O
area	B-T082
,	O
with	O
diagnostic	O
yield	O
.	O

Of	O
88	O
eligible	O
patients	O
,	O
57	O
(	O
65	O
%	O
)	O
were	O
successfully	O
diagnosed	B-T033
by	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
.	O

In	O
31	O
patients	O
not	O
diagnosed	B-T033
by	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
,	O
15	O
(	O
48	O
%	O
)	O
were	O
successfully	O
diagnosed	B-T033
by	O
additional	O
conventional	O
TBB	B-T058
.	O

Ground	B-T033
glass	I-T033
opacity	I-T033
(	O
GGO	B-T033
)	O
was	O
a	O
significant	O
factor	O
associated	O
with	O
the	O
diagnostic	O
yield	O
of	O
additional	O
conventional	O
TBB	B-T058
following	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
.	O

Multivariate	O
analysis	O
and	O
receiver	O
operator	O
curves	O
revealed	O
that	O
distance	O
between	O
the	O
PPL	B-T033
and	O
the	O
EBUS	B-T058
probe	B-T074
of	O
less	O
than	O
2	O
.	O
55	O
mm	O
favored	O
the	O
utility	O
of	O
conventional	O
TBB	B-T058
.	O

Additional	O
conventional	O
TBB	B-T058
after	O
EBUS	B-T058
-	O
GS	B-T074
TBB	B-T058
could	O
be	O
a	O
useful	O
procedure	B-T058
for	O
the	O
diagnosis	B-T033
of	O
ground	B-T033
glass	I-T033
opacity	I-T033
PPLs	B-T033
and	O
in	O
cases	O
of	O
a	O
distance	O
of	O
less	O
than	O
2	O
.	O
55	O
mm	O
between	O
the	O
EBUS	B-T058
probe	B-T074
and	O
the	O
lesion	B-T033
.	O

Active	O
diffusion	O
and	O
microtubule	B-T038
-	I-T038
based	I-T038
transport	I-T038
oppose	O
myosin	B-T103
forces	O
to	O
position	B-T082
organelles	B-T017
in	O
cells	B-T017

Even	O
distribution	O
of	O
peroxisomes	B-T017
(	O
POs	B-T017
)	O
and	O
lipid	B-T017
droplets	I-T017
(	O
LDs	B-T017
)	O
is	O
critical	O
to	O
their	O
role	O
in	O
lipid	B-T103
and	O
reactive	B-T103
oxygen	I-T103
species	I-T103
homeostasis	B-T038
.	O

How	O
even	O
distribution	O
is	O
achieved	O
remains	O
elusive	O
,	O
but	O
diffusive	O
motion	O
and	O
directed	O
motility	B-T038
may	O
play	O
a	O
role	O
.	O

Here	O
we	O
show	O
that	O
in	O
the	O
fungus	B-T204
Ustilago	B-T204
maydis	I-T204
~	O
95	O
%	O
of	O
POs	B-T017
and	O
LDs	B-T017
undergo	O
diffusive	O
motions	O
.	O

These	O
movements	B-T038
require	O
ATP	B-T103
and	O
involve	O
bidirectional	O
early	O
endosome	B-T017
motility	B-T038
,	O
indicating	O
that	O
microtubule	B-T017
-	O
associated	O
membrane	B-T017
trafficking	O
enhances	O
diffusion	O
of	O
organelles	B-T017
.	O

When	O
early	O
endosome	B-T038
transport	I-T038
is	O
abolished	O
,	O
POs	B-T017
and	O
LDs	B-T017
drift	O
slowly	O
towards	O
the	O
growing	B-T017
cell	I-T017
end	I-T017
.	O

This	O
pole	B-T038
-	I-T038
ward	I-T038
drift	I-T038
is	O
facilitated	O
by	O
anterograde	O
delivery	O
of	O
secretory	O
cargo	O
to	O
the	O
cell	B-T017
tip	I-T017
by	O
myosin	B-T103
-	I-T103
5	I-T103
.	O

Modelling	B-T062
reveals	O
that	O
microtubule	B-T038
-	I-T038
based	I-T038
directed	I-T038
transport	I-T038
and	O
active	O
diffusion	O
support	O
distribution	O
,	O
mobility	B-T038
and	O
mixing	O
of	O
POs	B-T017
.	O

In	O
mammalian	B-T204
COS	B-T017
-	I-T017
7	I-T017
cells	I-T017
,	O
microtubules	B-T017
and	O
F	B-T103
-	I-T103
actin	I-T103
also	O
counteract	O
each	O
other	O
to	O
distribute	O
POs	B-T017
.	O

This	O
highlights	O
the	O
importance	O
of	O
opposing	O
cytoskeletal	B-T017
forces	O
in	O
organelle	B-T017
positioning	B-T082
in	O
eukaryotes	B-T204
.	O

The	O
role	O
of	O
catheter	B-T058
ablation	I-T058
in	O
the	O
management	B-T058
of	O
atrial	B-T038
fibrillation	I-T038

Atrial	B-T038
fibrillation	I-T038
is	O
driven	O
by	O
spontaneous	O
electrical	B-T038
activation	I-T038
emerging	O
from	O
the	O
pulmonary	B-T017
veins	I-T017
.	O

Catheter	B-T058
ablation	I-T058
using	O
either	O
radiofrequency	B-T058
or	O
cryothermal	B-T058
energy	I-T058
electrically	O
isolates	O
these	O
veins	B-T017
from	O
the	O
left	B-T017
atrium	I-T017
,	O
both	O
reducing	O
the	O
burden	O
of	O
atrial	B-T038
fibrillation	I-T038
episodes	O
and	O
improving	O
the	O
patient	O
'	O
s	O
symptoms	B-T033
.	O

Catheter	B-T058
ablation	I-T058
is	O
superior	O
to	O
antiarryhthmic	B-T103
drugs	I-T103
when	O
patients	O
are	O
carefully	O
selected	O
.	O

Underlying	O
medical	B-T201
problems	I-T201
-	O
including	O
obesity	B-T038
,	O
hypertension	B-T038
and	O
obstructive	B-T038
sleep	I-T038
apnoea	I-T038
-	O
should	O
be	O
optimally	O
treated	O
before	O
considering	O
ablation	B-T058
.	O

Although	O
this	O
treatment	B-T058
has	O
the	O
potential	O
to	O
cure	O
patients	O
of	O
their	O
symptoms	B-T033
,	O
they	O
should	O
be	O
aware	O
of	O
the	O
important	O
associated	O
procedural	B-T033
complications	I-T033
.	O

The	O
Chinese	O
Herbal	O
Mixture	O
Tien	B-T103
-	I-T103
Hsien	I-T103
Liquid	I-T103
Augments	O
the	O
Anticancer	O
Immunity	B-T038
in	O
Tumor	B-T017
Cell	I-T017
-	O
Vaccinated	B-T033
Mice	B-T204

Background	O
The	O
Chinese	O
herbal	O
mixture	O
,	O
Tien	B-T103
-	I-T103
Hsien	I-T103
liquid	I-T103
(	O
THL	B-T103
)	O
,	O
has	O
been	O
used	O
as	O
an	O
anticancer	O
dietary	B-T168
supplement	I-T168
for	O
more	O
than	O
20	O
years	O
.	O

Our	O
previous	O
studies	B-T062
have	O
shown	O
that	O
THL	B-T103
can	O
modulate	B-T082
immune	B-T038
response	I-T038
and	O
inhibit	O
tumor	O
growth	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
further	O
evaluated	B-T058
the	O
effect	O
of	O
THL	B-T103
on	O
anticancer	O
immune	B-T038
response	I-T038
in	O
mice	B-T204
vaccinated	B-T033
with	O
γ	O
-	O
ray	O
-	O
irradiated	O
tumor	B-T017
cells	I-T017
.	O

Methods	O
The	O
antitumor	O
effect	O
of	O
THL	B-T103
was	O
determined	O
in	O
mice	B-T204
vaccinated	B-T033
with	O
low	B-T017
-	I-T017
tumorigenic	I-T017
CT	I-T017
-	I-T017
26	I-T017
-	I-T017
low	I-T017
colon	I-T017
cancer	I-T017
cells	I-T017
or	O
γ	B-T058
-	I-T058
ray	I-T058
-	I-T058
irradiated	I-T058
high	B-T017
-	I-T017
tumorigenic	I-T017
CT	I-T017
-	I-T017
26	I-T017
-	I-T017
high	I-T017
colon	I-T017
cancer	I-T017
cells	I-T017
.	O

The	O
number	O
of	O
natural	B-T017
killer	I-T017
(	I-T017
NK	I-T017
)	I-T017
cells	I-T017
and	O
T	B-T017
lymphocytes	I-T017
in	O
the	O
spleen	B-T017
was	O
analyzed	B-T062
by	O
flow	B-T058
cytometry	I-T058
.	O

The	O
tumor	B-T038
-	O
killing	B-T038
activities	O
of	O
NK	B-T017
cells	I-T017
and	O
cytotoxic	B-T017
T	I-T017
lymphocytes	I-T017
(	O
CTLs	B-T017
)	O
were	O
analyzed	B-T062
by	O
flow	B-T058
cytometry	I-T058
using	O
YAC	B-T017
-	I-T017
1	I-T017
and	O
CT	B-T017
-	I-T017
26	I-T017
-	I-T017
high	I-T017
cells	I-T017
,	O
respectively	O
,	O
as	O
target	O
cells	B-T017
.	O

The	O
levels	O
of	O
IFN	B-T103
-	I-T103
γ	I-T103
,	O
IL	B-T103
-	I-T103
2	I-T103
,	O
and	O
TNF	B-T103
-	I-T103
α	I-T103
were	O
determined	O
by	O
ELISA	B-T058
.	O

Results	O
THL	B-T103
suppressed	O
the	O
growth	B-T038
of	O
CT	B-T017
-	I-T017
26	I-T017
-	I-T017
high	I-T017
tumor	I-T017
in	O
mice	B-T204
previously	O
vaccinated	B-T033
with	O
low	B-T017
-	I-T017
tumorigenic	I-T017
CT	I-T017
-	I-T017
26	I-T017
-	I-T017
low	I-T017
cells	I-T017
or	O
γ	B-T058
-	I-T058
irradiated	I-T058
CT	B-T017
-	I-T017
26	I-T017
-	I-T017
high	I-T017
cells	I-T017
.	O

THL	B-T103
increased	O
the	O
populations	O
of	O
NK	B-T017
cells	I-T017
and	O
CD4	B-T017
+	I-T017
T	I-T017
lymphocytes	I-T017
in	O
the	O
spleen	B-T017
and	O
enhanced	O
the	O
tumor	B-T038
-	O
killing	B-T038
activities	O
of	O
NK	B-T017
cells	I-T017
and	O
CTL	B-T017
in	O
mice	B-T204
vaccinated	B-T033
with	O
γ	B-T058
-	I-T058
irradiated	I-T058
CT	B-T017
-	I-T017
26	I-T017
-	I-T017
high	I-T017
cells	I-T017
.	O

THL	B-T103
increased	O
the	O
production	O
of	O
IFN	B-T103
-	I-T103
γ	I-T103
,	O
IL	B-T103
-	I-T103
2	I-T103
,	O
and	O
TNF	B-T103
-	I-T103
α	I-T103
in	O
mice	B-T204
vaccinated	B-T033
with	O
γ	B-T058
-	I-T058
irradiated	I-T058
CT	B-T017
-	I-T017
26	I-T017
-	I-T017
high	I-T017
cells	I-T017
.	O

Conclusion	O
THL	B-T103
can	O
enhance	O
the	O
antitumor	O
immune	B-T038
responses	I-T038
in	O
mice	B-T204
vaccinated	B-T033
with	O
killed	O
tumor	B-T017
cells	I-T017
.	O

These	O
results	O
suggest	O
that	O
THL	B-T103
may	O
be	O
used	O
as	O
a	O
complementary	B-T091
medicine	I-T091
for	O
cancer	B-T038
patients	O
previously	O
treated	O
with	O
killed	B-T103
tumor	I-T103
cell	I-T103
vaccines	I-T103
,	O
radiotherapy	B-T058
,	O
or	O
chemotherapy	B-T058
.	O

Timing	O
of	O
False	O
Ring	B-T038
Formation	I-T038
in	O
Pinus	B-T204
halepensis	I-T204
and	O
Arbutus	B-T204
unedo	I-T204
in	O
Southern	B-T082
Italy	B-T082
:	O
Outlook	B-T201
from	O
an	O
Analysis	B-T062
of	O
Xylogenesis	B-T038
and	O
Tree	B-T204
-	I-T204
Ring	I-T204
Chronologies	B-T170

Mediterranean	B-T082
tree	B-T204
rings	I-T204
are	O
characterized	O
by	O
intra	O
-	O
annual	O
density	O
fluctuations	O
(	O
IADFs	O
)	O
due	O
to	O
partly	O
climate	O
-	O
driven	O
cambial	B-T038
activity	I-T038
.	O

IADFs	O
are	O
used	O
as	O
structural	B-T082
signals	O
to	O
gain	O
information	O
on	O
relations	O
between	B-T082
environmental	B-T082
conditions	O
and	O
eco	B-T038
-	I-T038
physiological	I-T038
processes	O
during	O
xylogenesis	B-T038
,	O
with	O
intra	O
-	O
annual	O
resolution	O
.	O

To	O
reach	O
an	O
unbiased	B-T062
synchronization	O
of	O
the	O
IADF	O
position	B-T082
within	O
tree	B-T204
rings	B-T082
and	O
seasonal	O
fluctuations	B-T033
in	O
environmental	B-T082
conditions	O
,	O
it	O
is	O
necessary	O
to	O
know	O
the	O
timing	O
of	O
cambial	B-T038
activity	I-T038
and	O
wood	O
formation	O
,	O
which	O
are	O
species	O
-	O
and	O
site	O
-	O
specific	O
processes	O
.	O

We	O
applied	O
the	O
microcoring	O
technique	O
to	O
analyze	B-T062
xylogenesis	B-T038
in	O
Pinus	B-T204
halepensis	I-T204
and	O
Arbutus	B-T204
unedo	I-T204
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
attempt	O
to	O
study	B-T062
xylogenesis	B-T038
in	O
a	O
hardwood	O
species	B-T170
forming	O
frequent	O
IADFs	O
.	O

Both	O
species	B-T170
co	O
-	O
occur	O
at	O
a	O
site	B-T082
in	O
southern	B-T082
Italy	B-T082
characterized	O
by	O
a	O
Mediterranean	B-T082
climate	O
.	O

To	O
facilitate	O
tree	B-T062
-	I-T062
ring	I-T062
dating	I-T062
and	O
identification	O
of	O
IADFs	O
,	O
we	O
performed	O
traditional	O
dendroecological	O
analysis	B-T062
.	O

We	O
analyzed	B-T062
xylogenesis	B-T038
during	O
summer	O
,	O
which	O
is	O
considered	O
a	O
constraint	O
for	O
xylogenesis	B-T038
and	O
a	O
trigger	O
for	O
IADF	O
formation	O
.	O

We	O
followed	O
the	O
different	O
phases	O
of	O
cell	B-T038
development	I-T038
in	O
the	O
current	O
wood	O
increment	O
with	O
the	O
aim	O
of	O
evaluating	O
whether	O
and	O
which	O
type	O
of	O
IADFs	O
were	O
formed	O
.	O

We	O
additionally	O
analyzed	B-T062
the	O
same	O
phases	O
again	O
in	O
September	O
and	O
in	O
winter	O
to	O
verify	O
the	O
possible	B-T033
formation	O
of	O
IADFs	O
in	O
fall	O
and	O
whether	O
cell	B-T017
production	B-T038
and	O
differentiation	B-T038
was	O
completed	O
by	O
the	O
end	O
of	O
the	O
calendar	O
year	O
.	O

Both	O
species	B-T170
formed	O
the	O
same	O
type	O
of	O
IADFs	O
(	O
earlywood	O
-	O
like	O
cells	B-T017
within	O
latewood	O
)	O
,	O
due	O
to	O
temporary	O
growth	O
restoration	B-T033
triggered	O
by	O
rain	O
events	O
during	O
the	O
period	O
of	O
summer	O
drought	O
.	O

At	O
the	O
end	O
of	O
the	O
calendar	O
year	O
,	O
no	O
cells	B-T017
in	O
the	O
phases	O
of	O
enlargement	O
and	O
secondary	B-T017
cell	I-T017
wall	I-T017
deposition	O
occurred	O
.	O

A	B-T204
.	I-T204

unedo	I-T204
was	O
more	O
sensitive	O
than	O
P	B-T204
.	I-T204

halepensis	I-T204
because	O
IADF	O
s	O
were	O
formed	O
earlier	O
in	O
the	O
season	O
and	O
were	O
more	O
frequent	O
in	O
the	O
tree	B-T204
-	I-T204
ring	I-T204
series	O
.	O

The	O
dendro	O
-	O
anatomical	O
approach	O
,	O
combining	O
analysis	B-T062
of	O
tree	B-T204
-	I-T204
ring	I-T204
series	O
and	O
of	O
xylogenesis	B-T038
,	O
helped	O
to	O
detect	B-T033
the	O
period	O
of	O
IADF	O
formation	O
in	O
the	O
two	O
species	B-T170
.	O

Results	O
are	O
discussed	O
in	O
functional	O
terms	O
,	O
highlighting	O
the	O
environmental	B-T082
conditions	O
triggering	O
IADFs	O
,	O
and	O
also	O
in	O
methodological	O
terms	O
,	O
evaluating	O
the	O
applicability	O
of	O
xylogenesis	B-T038
analysis	B-T062
in	O
Mediterranean	B-T082
woods	O
,	O
especially	O
when	O
the	O
formation	O
of	O
IADFs	O
is	O
not	O
uniform	O
around	O
the	O
stem	B-T204
.	O

Emergence	O
of	O
family	B-T091
medicine	I-T091
in	O
Ethiopia	B-T082
[	O
corrected	O
]	O
:	O
an	O
international	O
collaborative	O
education	B-T170
model	I-T170

Family	B-T091
Medicine	I-T091
(	O
FM	B-T091
)	O
is	O
a	O
new	O
specialty	B-T091
in	O
Ethiopia	B-T082
.	O

The	O
first	B-T097
seven	I-T097
family	I-T097
physicians	I-T097
graduated	B-T098
in	O
February	O
2016	O
from	O
the	O
inaugural	O
residency	O
programme	B-T170
at	O
Addis	B-T092
Ababa	I-T092
University	I-T092
.	O

Cooperation	O
amongst	O
Ethiopian	B-T098
and	O
expatriate	O
decision	B-T097
-	I-T097
makers	I-T097
and	O
physicians	B-T097
was	O
needed	O
to	O
begin	O
the	O
programme	B-T170
.	O

Intentional	O
replacement	O
of	O
expatriates	O
with	O
Ethiopian	B-T098
family	B-T097
physicians	I-T097
has	O
begun	O
.	O

Barriers	O
include	O
lack	O
of	O
understanding	B-T038
of	O
FM	B-T091
and	O
the	O
human	O
and	O
financial	O
resources	O
needed	O
for	O
scaling	O
up	O
the	O
programme	B-T170
.	O

Regular	O
programme	B-T170
review	O
with	O
resident	B-T097
physician	I-T097
involvement	O
has	O
allowed	O
the	O
FM	B-T091
training	O
programme	O
to	O
adapt	O
and	O
fit	O
the	O
Ethiopian	B-T098
context	O
.	O

Further	O
successes	O
will	O
result	O
from	O
ongoing	O
support	O
and	O
advocacy	O
from	O
the	O
Federal	O
Ministry	O
of	O
Health	O
and	O
other	O
Ethiopian	B-T098
,	O
African	B-T098
,	O
and	O
international	O
primary	O
care	O
organisations	O
.	O

The	O
Experience	B-T038
of	O
Women	B-T098
Veterans	B-T098
Coming	O
Back	O
from	O
War	O

Issues	O
surrounding	O
mental	O
health	O
are	O
common	O
for	O
women	B-T098
veterans	B-T098
who	O
have	O
served	O
in	O
Iraq	B-T082
and	O
Afghanistan	B-T082
wars	O
.	O

The	O
goal	O
of	O
this	O
phenomenological	O
study	B-T062
was	O
to	O
document	B-T170
themes	O
in	O
the	O
stories	B-T170
gathered	O
from	O
eight	O
women	B-T098
veterans	B-T098
who	O
had	O
come	O
back	O
from	O
war	O
.	O

Themes	O
in	O
the	O
stories	B-T170
were	O
:	O
arriving	O
with	O
mixed	O
sentiments	O
;	O
evolving	O
to	O
a	O
changed	O
view	B-T038
of	I-T038
self	I-T038
;	O
permeating	B-T033
aggravation	I-T033
;	O
confounding	O
broken	O
relationships	O
,	O
frequent	B-T033
deployments	I-T033
,	O
and	O
change	O
in	O
military	O
status	O
;	O
remembering	B-T038
war	O
experiences	B-T038
;	O
and	O
seeking	B-T033
opportunity	I-T033
for	I-T033
what	I-T033
is	I-T033
possible	I-T033
.	O

Mental	O
health	O
issues	O
can	O
be	O
observed	O
in	O
the	O
themes	O
.	O

Including	O
story	B-T170
as	O
part	O
of	O
the	O
mental	B-T038
health	I-T038
visit	O
with	O
veterans	B-T098
may	O
be	O
beneficial	O
to	O
veterans	B-T098
as	O
they	O
deal	O
with	O
the	O
transition	O
of	O
coming	O
back	O
.	O

Trajectories	B-T082
of	O
Health	O
and	O
Behavioral	B-T058
Health	I-T058
Services	I-T058
Use	O
among	O
Community	O
Corrections	O
-	O
Involved	O
Rural	B-T033
Adults	O

This	O
article	O
seeks	O
to	O
establish	O
time	O
-	O
based	O
trajectories	B-T082
of	O
health	O
and	O
behavioral	B-T058
health	I-T058
services	I-T058
utilization	O
for	O
community	O
corrections	O
-	O
involved	O
(	O
CCI	O
)	O
adults	O
and	O
to	O
examine	O
demographic	O
and	O
clinical	O
correlates	O
associated	O
with	O
these	O
trajectories	B-T082
.	O

To	O
accomplish	O
this	O
aim	O
,	O
the	O
authors	O
applied	O
a	O
latent	B-T062
class	I-T062
growth	I-T062
analysis	I-T062
(	O
LCGA	B-T062
)	O
to	O
services	B-T058
use	O
data	O
from	O
a	O
sample	O
of	O
rural	B-T033
CCI	O
adults	O
who	O
reported	O
their	O
medical	O
,	O
mental	B-T038
health	I-T038
,	O
and	O
substance	O
use	O
treatment	O
utilization	O
behavior	O
every	O
60	O
days	O
for	O
1	O
.	O
5	O
years	O
.	O

LCGA	B-T062
established	O
1	O
.	O
5	O
-	O
year	O
trajectories	B-T082
and	O
demographic	O
correlates	O
of	O
health	B-T058
services	I-T058
among	O
rural	B-T033
CCI	O
adults	O
.	O

For	O
medical	B-T058
services	I-T058
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
users	B-T098
,	O
13	O
%	O
;	O
stable	O
-	O
intermediate	O
users	B-T098
,	O
40	O
%	O
;	O
and	O
stable	O
-	O
high	O
users	B-T098
,	O
47	O
%	O
)	O
.	O

For	O
mental	B-T038
health	I-T038
and	O
substance	O
use	O
services	B-T058
,	O
three	O
classes	O
emerged	O
(	O
stable	O
-	O
low	O
,	O
69	O
%	O
and	O
61	O
%	O
,	O
respectively	O
;	O
low	O
-	O
baseline	O
-	O
increase	O
,	O
10	O
%	O
and	O
12	O
%	O
,	O
respectively	O
;	O
high	O
-	O
baseline	O
decline	O
,	O
21	O
%	O
and	O
28	O
%	O
,	O
respectively	O
)	O
.	O

Employment	O
,	O
gender	O
,	O
medication	O
usage	O
,	O
and	O
depression	B-T038
severity	O
predicted	O
membership	O
across	O
all	O
services	B-T058
.	O

Results	O
underscore	O
the	O
importance	O
of	O
social	B-T097
workers	I-T097
and	O
other	O
community	B-T058
services	I-T058
providers	B-T097
aligning	O
health	B-T058
services	I-T058
access	O
with	O
the	O
needs	O
of	O
the	O
CCI	O
population	O
,	O
and	O
highlight	O
CCI	O
adults	O
as	O
being	O
at	O
risk	O
of	O
underservice	O
in	O
critical	O
prevention	B-T058
and	O
intervention	B-T058
domains	I-T058
.	O

Data	B-T170
set	I-T170
of	O
interactomes	B-T038
and	O
metabolic	O
pathways	O
of	O
proteins	B-T103
differentially	O
expressed	B-T038
in	O
brains	B-T017
with	O
Alzheimer	B-T038
׳	I-T038
s	I-T038
disease	I-T038

Alzheimer	B-T038
׳	I-T038
s	I-T038
disease	I-T038
is	O
one	O
of	O
the	O
main	O
causes	O
of	O
dementia	B-T038
in	O
the	O
elderly	B-T098
and	O
its	O
frequency	O
is	O
on	O
the	O
rise	O
worldwide	B-T098
.	O

It	O
is	O
considered	O
the	O
result	O
of	O
complex	O
interactions	O
between	O
genetic	O
and	O
environmental	O
factors	O
,	O
being	O
many	O
of	O
them	O
unknown	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
dire	O
necessity	O
for	O
the	O
identification	O
of	O
novel	O
molecular	B-T103
players	I-T103
for	O
the	O
understanding	O
of	O
this	O
disease	B-T038
.	O

In	O
this	O
data	O
article	B-T170
we	O
determined	O
the	O
protein	B-T038
expression	I-T038
profiles	O
of	O
whole	O
protein	B-T103
extracts	O
from	O
cortex	B-T082
regions	I-T082
of	I-T082
brains	I-T082
from	O
patients	O
with	O
Alzheimer	B-T038
׳	I-T038
s	I-T038
disease	I-T038
in	O
comparison	O
to	O
a	O
normal	B-T017
brain	I-T017
.	O

We	O
identified	O
721	O
iTRAQ	B-T103
-	I-T103
labeled	I-T103
polypeptides	B-T103
with	O
more	O
than	O
95	O
%	O
in	O
confidence	O
.	O

We	O
analyzed	B-T062
all	O
proteins	B-T103
that	O
changed	O
in	O
their	O
expression	O
level	O
and	O
located	O
them	O
in	O
the	O
KEGG	O
metabolic	O
pathways	O
,	O
as	O
well	O
as	O
in	O
the	O
mitochondrial	B-T017
complexes	I-T017
of	I-T017
the	I-T017
electron	I-T017
transport	I-T017
chain	I-T017
and	O
ATP	B-T103
synthase	I-T103
.	O

In	O
addition	O
,	O
we	O
analyzed	B-T062
the	O
over	B-T103
-	I-T103
and	I-T103
sub	I-T103
-	I-T103
expressed	I-T103
polypeptides	I-T103
through	O
IPA	B-T170
software	I-T170
,	O
specifically	O
Core	B-T170
I	I-T170
and	I-T170
Biomarkers	I-T170
I	I-T170
modules	I-T170
.	O

Data	O
in	O
this	O
article	B-T170
is	O
related	O
to	O
the	O
research	B-T062
article	B-T170
"	O
Identification	O
of	O
proteins	B-T103
that	O
are	O
differentially	O
expressed	B-T038
in	O
brains	B-T017
with	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
using	O
iTRAQ	B-T058
labeling	I-T058
and	O
tandem	B-T062
mass	I-T062
spectrometry	I-T062
"	O
(	O
Minjarez	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O

Emergency	O
general	O
surgery	O
specific	B-T170
frailty	I-T170
index	I-T170
:	O
A	O
validation	B-T062
study	I-T062

Assessment	B-T058
of	O
operative	O
risk	O
in	O
geriatric	O
patients	O
undergoing	O
emergency	O
general	O
surgery	O
(	O
EGS	O
)	O
is	O
challenging	O
.	O

Frailty	B-T033
is	O
an	O
established	O
measure	O
for	O
risk	B-T058
assessment	I-T058
in	O
surgical	O
cases	O
.	O

The	O
aim	O
of	O
our	O
study	B-T062
was	O
to	O
validate	B-T062
a	O
modified	O
15	O
variable	O
emergency	B-T058
general	I-T058
surgery	I-T058
specific	I-T058
frailty	I-T058
index	I-T058
(	O
EGSFI	B-T058
)	O
.	O

We	O
prospectively	O
collected	O
geriatric	O
(	O
age	O
>	O
65	O
)	O
emergency	O
general	O
surgery	O
patients	O
for	O
1	O
-	O
year	O
.	O

Post	B-T038
-	I-T038
operative	I-T038
complications	I-T038
were	O
collected	O
.	O

Frailty	B-T170
Index	I-T170
was	O
calculated	B-T058
for	O
200	O
patients	O
based	O
on	O
their	O
pre	O
-	O
admission	O
condition	O
using	O
50	O
-	O
variable	O
modified	O
Rockwood	B-T170
Frailty	I-T170
Index	I-T170
(	O
FI	B-T170
)	O
.	O

EGSFI	B-T058
was	O
developed	O
based	O
on	O
the	O
regression	B-T170
model	I-T170
for	O
complications	B-T038
and	O
the	O
most	O
significant	O
factors	O
in	O
the	O
FI	B-T170
.	O

ROC	O
curve	O
analysis	O
was	O
performed	O
to	O
determine	O
cutoff	O
for	O
frail	B-T033
status	O
.	O

We	O
validated	B-T062
our	O
results	O
using	O
60	O
patients	O
for	O
predicting	O
complications	B-T038
.	O

A	O
total	O
of	O
260	O
patients	O
(	O
200	O
developing	O
,	O
60	O
Validation	B-T062
)	O
were	O
enrolled	B-T058
in	O
this	O
study	B-T062
.	O

Mean	O
age	O
was	O
71	O
±	O
11	O
years	O
,	O
and	O
33	O
%	O
developed	O
complications	B-T038
.	O

Most	O
common	O
complications	B-T038
were	O
pneumonia	B-T038
(	O
12	O
%	O
)	O
,	O
UTI	B-T038
(	O
9	O
%	O
)	O
,	O
and	O
wound	B-T038
infection	I-T038
(	O
7	O
%	O
)	O
.	O

Univariate	O
analysis	O
identified	O
15	O
variables	O
significantly	O
associated	O
with	O
complications	B-T038
that	O
were	O
used	O
to	O
develop	O
the	O
EGSFI	B-T058
.	O

A	O
cutoff	O
frailty	B-T033
score	I-T033
of	O
0	O
.	O
325	O
was	O
identified	O
using	O
ROC	O
curve	O
analysis	O
for	O
frail	B-T033
status	O
.	O
Sixty	O
-	O
patients	O
(	O
frail	B-T033
:	O
18	O
,	O
non	B-T033
-	I-T033
frail	I-T033
:	O
42	O
)	O
were	O
enrolled	B-T058
in	O
the	O
validation	B-T062
cohort	B-T098
.	O

Frail	B-T033
patients	O
were	O
more	O
likely	O
to	O
have	O
post	B-T038
-	I-T038
operative	I-T038
complications	I-T038
(	O
47	O
%	O
vs	O
.	O

20	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
compared	O
to	O
nonfrail	O
patients	O
.	O

Frail	B-T033
status	O
based	O
on	O
EGSFI	B-T058
was	O
a	O
significant	O
predictor	O
of	O
post	B-T038
-	I-T038
operative	I-T038
complications	I-T038
(	O
OR	O
=	O
7	O
.	O
3	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
7	O
-	O
19	O
.	O
8	O
;	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

Age	O
was	O
not	O
associated	O
with	O
postoperative	B-T038
complications	I-T038
(	O
OR	O
=	O
0	O
.	O
99	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
92	O
-	O
1	O
.	O
06	O
;	O
p	O
=	O
0	O
.	O
86	O
)	O
.	O

The	O
15	O
-	O
variable	O
validated	B-T062
EGSFI	B-T058
is	O
a	O
simple	O
and	O
reliable	O
bedside	O
tool	O
to	O
determine	O
the	O
frailty	B-T033
status	I-T033
of	O
patients	O
undergoing	O
emergency	O
general	O
surgery	O
.	O

Frail	B-T033
status	O
as	O
determined	O
by	O
Abstract	O
the	O
EGSFI	B-T058
is	O
an	O
independent	O
predictor	O
of	O
post	B-T038
-	I-T038
operative	I-T038
complications	I-T038
and	O
mortality	O
in	O
geriatric	O
emergency	O
general	O
surgery	O
patients	O
.	O

Level	O
II	O
,	O
Prognostic	B-T062
Studies	I-T062
-	O
Investigating	O
the	O
Effect	O
of	O
a	O
Patient	B-T201
Characteristic	I-T201
on	O
the	O
Outcome	B-T033
of	I-T033
Disease	I-T033
.	O

Comparative	O
Epidemiologic	O
Characteristics	O
of	O
Pertussis	B-T038
in	O
10	O
Central	B-T082
and	O
Eastern	B-T082
European	I-T082
Countries	I-T082
,	O
2000	O
-	O
2013	O

We	O
undertook	O
an	O
epidemiological	B-T062
survey	I-T062
of	O
the	O
annual	O
incidence	O
of	O
pertussis	B-T038
reported	B-T058
from	O
2000	O
to	O
2013	O
in	O
ten	O
Central	B-T082
and	O
Eastern	B-T082
European	I-T082
countries	I-T082
to	O
ascertain	O
whether	O
increased	O
pertussis	B-T038
reports	B-T170
in	O
some	O
countries	B-T082
share	O
common	O
underlying	O
drivers	O
or	O
whether	O
there	O
are	O
specific	O
features	O
in	O
each	O
country	B-T082
.	O

The	O
annual	O
incidence	O
of	O
pertussis	B-T038
in	O
the	O
participating	O
countries	B-T082
was	O
obtained	O
from	O
relevant	O
government	B-T092
institutions	I-T092
and	O
/	O
or	O
national	B-T092
surveillance	I-T092
systems	I-T092
.	O

We	O
reviewed	O
the	O
changes	O
in	O
the	O
pertussis	B-T038
incidence	O
rates	O
in	O
each	O
country	B-T082
to	O
explore	O
differences	O
and	O
/	O
or	O
similarities	O
between	O
countries	B-T082
in	O
relation	O
to	O
pertussis	B-T038
surveillance	O
;	O
case	O
definitions	O
for	O
detection	B-T033
and	O
confirmation	O
of	O
pertussis	B-T038
;	O
incidence	O
and	O
number	O
of	O
cases	O
of	O
pertussis	B-T038
by	O
year	O
,	O
overall	O
and	O
by	O
age	O
group	O
;	O
population	B-T098
by	O
year	O
,	O
overall	O
and	O
by	O
age	O
group	O
;	O
pertussis	B-T038
immunization	B-T058
schedule	I-T058
and	O
coverage	O
,	O
and	O
switch	O
from	O
whole	B-T103
-	I-T103
cell	I-T103
pertussis	I-T103
vaccines	I-T103
(	O
wP	B-T103
)	O
to	O
acellular	B-T103
pertussis	I-T103
vaccines	I-T103
(	O
aP	B-T103
)	O
.	O

There	O
was	O
heterogeneity	O
in	O
the	O
reported	B-T058
annual	O
incidence	O
rates	O
and	O
trends	O
observed	O
across	O
countries	B-T082
.	O

Reported	B-T058
pertussis	B-T038
incidence	O
rates	O
varied	O
considerably	O
,	O
ranging	O
from	O
0	O
.	O
01	O
to	O
96	O
per	O
100	O
,	O
000	O
population	B-T098
,	O
with	O
the	O
highest	O
rates	O
generally	O
reported	B-T058
in	O
Estonia	B-T082
and	O
the	O
lowest	O
in	O
Hungary	B-T082
and	O
Serbia	B-T082
.	O

The	O
greatest	O
burden	O
appears	O
for	O
the	O
most	O
part	O
in	O
infants	O
(	O
<	O
1	O
year	O
)	O
in	O
Bulgaria	B-T082
,	O
Hungary	B-T082
,	O
Latvia	B-T082
,	O
Romania	B-T082
,	O
and	O
Serbia	B-T082
,	O
but	O
not	O
in	O
the	O
other	O
participating	O
countries	B-T082
where	O
the	O
burden	O
may	O
have	O
shifted	O
to	O
older	O
children	O
,	O
though	O
surveillance	O
of	O
adults	O
may	O
be	O
inappropriate	O
.	O

There	O
was	O
no	O
consistent	O
pattern	O
associated	O
with	O
the	O
switch	O
from	O
wP	B-T103
to	O
aP	B-T103
vaccines	I-T103
on	O
reported	B-T058
pertussis	B-T038
incidence	O
rates	O
.	O

The	O
heterogeneity	O
in	O
reported	B-T058
data	O
may	O
be	O
related	O
to	O
a	O
number	O
of	O
factors	O
including	O
surveillance	O
system	O
characteristics	O
or	O
capabilities	O
,	O
different	O
case	O
definitions	O
,	O
type	O
of	O
pertussis	B-T038
confirmation	B-T058
tests	I-T058
used	O
,	O
public	B-T092
awareness	O
of	O
the	O
disease	B-T038
,	O
as	O
well	O
as	O
real	O
differences	O
in	O
the	O
magnitude	O
of	O
the	O
disease	B-T038
,	O
or	O
a	O
combination	O
of	O
these	O
factors	O
.	O

Our	O
study	O
highlights	O
the	O
need	O
to	O
standardize	O
pertussis	B-T038
detection	B-T033
and	O
confirmation	O
in	O
surveillance	B-T062
programs	I-T062
across	O
Europe	B-T082
,	O
complemented	O
with	O
carefully	O
-	O
designed	O
seroprevalence	B-T062
studies	I-T062
using	O
the	O
same	O
protocols	B-T170
and	O
methodologies	B-T062
.	O

Identification	O
and	O
characterization	O
of	O
Dichelobacter	B-T007
nodosus	I-T007
serogroup	B-T170
H	I-T170
from	O
ovine	B-T204
footrot	B-T038
in	O
India	B-T082

A	O
total	O
of	O
56	O
foot	O
swabs	O
were	O
collected	O
from	O
inter	B-T082
digital	I-T082
spaces	I-T082
of	O
sheep	B-T204
with	O
footrot	B-T038
lesions	B-T033
were	O
screened	B-T058
for	O
16	O
rRNA	B-T103
of	O
Dichelobacter	B-T007
nodosus	I-T007
by	O
PCR	B-T062
.	O

Out	O
of	O
the	O
56	O
samples	O
,	O
38	O
(	O
67	O
.	O
85	O
%	O
)	O
were	O
found	O
to	O
be	O
positive	B-T033
.	O

All	O
the	O
positive	B-T033
samples	O
were	O
subjected	O
to	O
multiplex	B-T062
PCR	I-T062
targeting	B-T062
fimA	I-T062
gene	I-T062
for	O
identification	O
of	O
serogroups	B-T170
of	O
D	B-T007
.	I-T007

nodosus	I-T007
.	O

Serogroup	B-T170
H	I-T170
was	O
found	O
along	O
with	O
serogroup	B-T170
B	I-T170
in	O
12	O
(	O
55	O
.	O
26	O
%	O
)	O
samples	O
and	O
with	O
serogroup	B-T170
I	I-T170
in	O
8	O
(	O
22	O
.	O
2	O
%	O
)	O
samples	O
.	O

The	O
serogroup	B-T170
H	I-T170
was	O
identified	O
for	O
the	O
first	O
time	O
from	O
the	O
Indian	B-T082
subcontinent	I-T082
.	O

The	O
phylogenetic	B-T062
analysis	I-T062
of	O
the	O
present	O
sequence	B-T082
with	O
the	O
available	O
serogroup	B-T170
H	I-T170
sequences	B-T082
of	O
GenBank	B-T170
revealed	O
to	O
be	O
in	O
close	O
association	O
with	O
the	O
serotype	B-T170
H1	I-T170
.	O

Conservation	O
education	O
and	O
habitat	B-T082
restoration	O
for	O
the	O
endangered	B-T098
Sagalla	B-T204
caecilian	I-T204
(	O
Boulengerula	B-T204
niedeni	I-T204
)	O
in	O
Sagalla	B-T082
Hill	I-T082
,	O
Kenya	B-T082

The	O
Sagalla	B-T204
caecilian	I-T204
(	O
Boulengerula	B-T204
niedeni	I-T204
)	O
is	O
an	O
endangered	B-T098
amphibian	B-T204
endemic	O
to	O
Sagalla	B-T082
Hill	I-T082
in	O
the	O
Taita	B-T082
Hills	I-T082
.	O

This	O
burrowing	B-T204
worm	I-T204
-	O
like	O
species	B-T170
prefers	O
soft	O
soil	O
with	O
high	O
moisture	O
and	O
organic	O
matter	O
.	O

The	O
major	O
threats	O
to	O
the	O
Sagalla	B-T204
caecilian	I-T204
are	O
soil	O
erosion	O
caused	O
by	O
steep	O
slopes	O
,	O
bare	O
ground	B-T082
and	O
water	O
siphoning	O
/	O
soil	O
hardening	O
from	O
exotic	B-T204
eucalyptus	I-T204
trees	I-T204
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
get	O
a	O
better	O
understanding	B-T038
of	O
the	O
local	B-T082
people	B-T098
'	I-T098
s	I-T098
attitude	B-T038
towards	O
this	O
species	B-T170
and	O
how	O
they	O
can	O
contribute	O
to	O
its	O
continued	O
conservation	O
through	O
restoration	O
of	O
its	O
remaining	O
habitat	B-T082
.	O

In	O
this	O
study	B-T062
,	O
it	O
was	O
found	B-T033
that	O
96	O
%	O
of	O
Sagalla	B-T082
people	B-T098
are	O
aware	B-T038
of	O
the	O
species	B-T170
,	O
its	O
habits	O
and	O
its	O
association	O
with	O
soils	O
high	O
in	O
organic	O
matter	O
.	O

It	O
was	O
also	O
found	B-T033
that	O
96	O
%	O
of	O
Sagalla	B-T082
people	B-T098
use	O
organic	O
manure	O
from	O
cow	B-T204
dung	B-T031
in	O
their	O
farms	B-T082
.	O

Habitat	B-T082
restoration	O
through	O
planting	O
of	O
indigenous	B-T082
plants	B-T204
was	O
found	B-T033
to	O
be	O
ongoing	O
,	O
especially	O
on	O
compounds	B-T103
of	O
public	B-T092
institutions	I-T092
as	O
well	O
as	O
on	O
private	O
lands	O
.	O

Although	O
drought	O
was	O
found	B-T033
to	O
be	O
a	O
challenge	O
for	O
seedlings	B-T204
development	O
especially	O
on	O
the	O
low	O
elevation	B-T082
sites	B-T082
,	O
destruction	O
by	O
livestock	B-T204
especially	O
during	O
the	O
dry	O
season	O
is	O
also	O
a	O
major	O
threat	O
.	O

In	O
this	O
study	B-T062
,	O
it	O
was	O
recommended	O
that	O
any	O
future	O
habitat	B-T082
restoration	O
initiative	B-T038
should	O
include	O
strong	O
chain	O
-	O
link	O
fencing	O
to	O
protect	O
the	O
seedlings	B-T204
from	O
livestock	B-T204
activity	O
.	O

Recognizing	O
that	O
the	O
preferred	O
habitats	B-T082
for	O
the	O
species	B-T170
are	O
in	O
the	O
valleys	B-T082
,	O
systematic	O
planting	O
of	O
keystone	B-T204
plant	I-T204
species	B-T170
such	O
as	O
fig	B-T204
trees	I-T204
(	O
Ficus	B-T204
)	O
creates	O
the	O
best	O
microhabitats	B-T082
.	O

These	O
are	O
better	O
than	O
general	B-T082
woodlots	O
of	O
indigenous	B-T082
trees	B-T204
.	O

The	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	B-T038
during	O
lung	B-T058
resection	I-T058
surgery	I-T058
:	O
A	O
retrospective	B-T062
matched	I-T062
cohort	I-T062
analysis	I-T062
of	O
real	O
-	O
world	B-T098
data	O

The	O
objective	O
of	O
this	O
retrospective	B-T062
study	I-T062
was	O
to	O
quantify	O
the	O
clinical	O
and	O
economic	O
burden	O
of	O
significant	O
bleeding	B-T038
in	O
lung	B-T058
resection	I-T058
surgery	I-T058
in	O
the	O
US	B-T082
.	O

This	O
study	B-T062
utilized	O
2009	O
-	O
2012	O
data	O
from	O
the	O
Premier	B-T170
Perspective	I-T170
Database	I-T170
(	I-T170
TM	I-T170
)	I-T170
.	O

Adult	O
patients	O
with	O
primary	B-T058
pulmonary	I-T058
lobectomy	I-T058
or	O
segmentectomy	B-T058
procedures	I-T058
were	O
categorized	O
by	O
the	O
surgical	O
approach	O
(	O
VATS	B-T058
vs	O
open	B-T058
)	O
and	O
primary	O
diagnosis	O
(	O
primary	B-T058
or	O
metastatic	B-T058
lung	I-T058
cancer	I-T058
vs	O
non	B-T058
-	I-T058
lung	I-T058
cancer	I-T058
)	O
.	O

Patients	O
requiring	O
≥3	O
units	O
of	O
blood	B-T103
products	I-T103
with	O
at	O
least	O
1	O
unit	O
of	O
PRBCs	B-T103
:	O
"	O
significant	O
bleeding	B-T038
"	O
cohort	B-T098
;	O
those	O
requiring	O
<	O
3	O
units	O
:	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	B-T038
"	O
cohort	B-T098
;	O
and	O
those	O
not	O
requiring	O
blood	B-T103
products	I-T103
:	O
"	O
no	O
bleeding	B-T038
"	O
cohort	B-T098
.	O

A	O
matched	O
cohort	B-T062
analysis	I-T062
was	O
performed	O
between	O
the	O
"	O
significant	O
bleeding	B-T038
"	O
and	O
the	O
"	O
no	O
bleeding	B-T038
cohort	B-T098
"	O
using	O
matching	O
variables	O
:	O
hospital	B-T092
,	O
lung	B-T058
cancer	I-T058
diagnosis	I-T058
,	O
year	O
of	O
surgery	O
,	O
APR	O
-	O
DRG	O
severity	O
score	O
,	O
procedure	B-T201
type	I-T201
and	O
approach	O
,	O
age	O
,	O
and	O
gender	O
.	O

The	O
"	O
All	O
-	O
patient	O
"	O
cohort	B-T098
comprised	O
21	O
,	O
429	O
patients	O
:	O
213	O
"	O
significant	O
bleeding	B-T038
"	O
;	O
2	O
,	O
780	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	B-T038
"	O
;	O
and	O
18	O
,	O
436	O
"	O
no	O
bleeding	B-T038
"	O
.	O

Overall	O
incidence	O
of	O
significant	O
chest	B-T082
bleeding	B-T038
was	O
0	O
.	O
99	O
%	O
.	O

Patients	O
from	O
"	O
significant	O
bleeding	B-T038
"	O
cohort	B-T098
and	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	B-T038
"	O
cohort	B-T098
had	O
2	O
.	O
5	O
days	O
and	O
2	O
days	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
longer	O
length	O
of	O
stay	O
in	O
the	O
hospital	B-T092
compared	O
to	O
those	O
in	O
the	O
"	O
no	O
bleeding	B-T038
"	O
cohort	B-T098
,	O
respectively	O
.	O

Overall	O
,	O
hospital	O
costs	O
for	O
"	O
significant	O
bleeding	B-T038
"	O
cohort	B-T098
were	O
higher	O
than	O
"	O
no	O
bleeding	B-T038
"	O
cohort	B-T098
for	O
those	O
who	O
were	O
covered	O
under	O
Medicare	O
(	O
$	O
59	O
,	O
871	O
vs	O
$	O
23	O
,	O
641	O
)	O
,	O
were	O
≥76	O
years	O
of	O
age	O
(	O
$	O
64	O
,	O
010	O
vs	O
$	O
24	O
,	O
243	O
)	O
,	O
had	O
greater	O
severity	O
of	O
illness	O
(	O
$	O
97	O
,	O
813	O
vs	O
$	O
51	O
,	O
871	O
)	O
and	O
underwent	O
open	O
segmentectomy	B-T058
(	O
$	O
74	O
,	O
220	O
vs	O
$	O
21	O
,	O
903	O
)	O
.	O

Hospital	O
costs	O
for	O
"	O
significant	O
bleeding	B-T038
"	O
cohort	B-T098
and	O
"	O
non	B-T033
-	I-T033
significant	I-T033
bleeding	B-T038
"	O
were	O
significantly	O
higher	O
(	O
$	O
11	O
,	O
589	O
and	O
$	O
5	O
,	O
280	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
than	O
no	O
bleeding	B-T038
cohort	B-T098
.	O

Although	O
significant	O
bleeding	B-T038
during	O
lung	B-T058
resection	I-T058
surgery	I-T058
is	O
rare	O
,	O
patients	O
with	O
such	O
complication	B-T038
could	O
stay	O
longer	O
at	O
the	O
hospital	B-T092
and	O
cost	O
an	O
average	O
of	O
$	O
13	O
,	O
103	O
more	O
than	O
those	O
without	O
.	O

Laceration	B-T037
of	O
a	O
branch	B-T082
of	I-T082
the	O
profunda	B-T017
femoris	I-T017
artery	I-T017
caused	O
by	O
a	O
spike	B-T033
of	O
the	O
displaced	B-T082
lesser	B-T017
trochanter	I-T017
in	O
an	O
inter	B-T082
-	I-T082
trochanteric	I-T082
femoral	B-T037
fracture	I-T037
.	O
A	O
case	B-T170
report	I-T170

Injury	B-T037
of	O
femoral	B-T017
vessels	I-T017
is	O
an	O
extremely	O
rare	O
complication	B-T038
in	O
intertrochanteric	B-T082
femoral	B-T037
fractures	I-T037
.	O

In	O
most	O
cases	O
reported	B-T058
,	O
the	O
vascular	B-T038
lesion	I-T038
involves	O
the	O
superficial	B-T017
femoral	I-T017
artery	I-T017
,	O
whereas	O
in	O
very	O
few	O
cases	O
does	O
it	O
involve	O
the	O
profunda	B-T017
femoris	I-T017
artery	I-T017
.	O

We	O
report	B-T170
a	O
case	O
of	O
acute	B-T038
bleeding	I-T038
due	O
to	O
laceration	B-T037
of	O
a	O
perforating	B-T033
branch	B-T082
of	I-T082
the	O
profunda	B-T017
femoris	I-T017
artery	I-T017
caused	O
by	O
a	O
sharp	B-T033
fragment	O
of	O
the	O
displaced	B-T082
lesser	B-T017
trochanter	I-T017
in	O
an	O
intertrochanteric	B-T082
femoral	B-T037
fracture	I-T037
;	O
the	O
lesion	B-T033
was	O
treated	O
by	O
transcatheter	B-T058
embolization	I-T058
.	O

The	O
arterial	B-T037
injury	I-T037
may	O
be	O
iatrogenic	O
,	O
occurring	O
during	O
intramedullary	B-T082
internal	B-T058
fixation	I-T058
,	O
or	O
less	O
frequently	O
,	O
the	O
injury	B-T037
may	O
be	O
due	O
to	O
the	O
fracture	B-T037
itself	O
,	O
caused	O
by	O
a	O
sharp	B-T033
bone	B-T037
fragment	I-T037
that	O
damages	O
the	O
profunda	B-T017
femoris	I-T017
artery	I-T017
or	O
one	O
of	O
its	O
perforating	B-T033
branches	B-T082
.	O

We	O
believe	O
that	O
intertrochanteric	B-T082
femoral	B-T037
fractures	I-T037
with	O
avulsed	B-T037
lesser	B-T017
trochanter	I-T017
are	O
at	O
risk	O
for	O
femoral	B-T017
vessel	I-T017
injuries	B-T037
caused	O
by	O
the	O
displaced	B-T082
bone	B-T017
spike	B-T033
,	O
and	O
we	O
advise	O
meticulous	O
clinical	O
and	O
laboratory	B-T058
monitoring	I-T058
pre	O
-	O
and	O
post	O
-	O
operatively	O
to	O
prevent	O
serious	O
complications	O
.	O

Direct	O
contact	O
with	O
perivascular	B-T017
tumor	B-T017
cells	I-T017
enhances	O
integrin	B-T103
αvβ3	I-T103
signaling	B-T038
and	O
migration	B-T038
of	O
endothelial	B-T017
cells	I-T017

The	O
secretion	B-T038
of	O
soluble	O
pro	B-T103
-	I-T103
angiogenic	I-T103
factors	I-T103
by	O
tumor	B-T017
cells	I-T017
and	O
stromal	B-T017
cells	I-T017
in	O
the	O
perivascular	B-T017
niche	O
promotes	O
the	O
aggressive	B-T038
angiogenesis	I-T038
that	O
is	O
typical	O
of	O
glioblastoma	B-T038
(	O
GBM	B-T038
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
angiogenesis	B-T038
also	O
can	O
be	O
promoted	O
by	O
a	O
direct	O
interaction	O
between	O
brain	B-T017
tumor	B-T017
cells	I-T017
,	O
including	O
tumor	B-T017
cells	I-T017
with	O
cancer	B-T017
stem	I-T017
-	O
like	O
properties	O
(	O
CSCs	B-T017
)	O
,	O
and	O
endothelial	B-T017
cells	I-T017
(	O
ECs	B-T017
)	O
.	O

As	O
shown	O
in	O
vitro	O
,	O
this	O
direct	O
interaction	O
is	O
mediated	O
by	O
binding	B-T038
of	O
integrin	B-T103
αvβ3	I-T103
expressed	O
on	O
ECs	B-T017
to	O
the	O
RGD	B-T103
-	I-T103
peptide	I-T103
in	O
L1CAM	B-T103
expressed	B-T038
on	O
CSCs	B-T017
.	O

It	O
promotes	O
both	O
EC	B-T017
network	B-T038
formation	I-T038
and	O
enhances	O
directed	O
migration	B-T038
toward	O
basic	O
fibroblast	B-T103
growth	I-T103
factor	I-T103
.	O

Activation	O
of	O
αvβ3	B-T103
and	O
bone	B-T103
marrow	I-T103
tyrosine	I-T103
kinase	I-T103
on	I-T103
chromosome	I-T103
X	I-T103
(	O
BMX	B-T103
)	O
is	O
required	O
for	O
migration	B-T038
stimulated	O
by	O
direct	O
binding	B-T038
but	O
not	O
for	O
migration	B-T038
stimulated	O
by	O
soluble	O
factors	O
.	O

RGD	B-T103
-	I-T103
peptide	I-T103
treatment	O
of	O
mice	B-T204
with	O
established	O
intracerebral	B-T082
GBM	B-T038
xenografts	B-T103
significantly	O
reduced	O
the	O
percentage	O
of	O
Sox2	B-T103
-	O
positive	O
tumor	B-T017
cells	I-T017
and	O
CSCs	B-T017
in	O
close	O
proximity	O
to	O
ECs	B-T017
,	O
decreased	O
integrin	B-T103
αvβ3	I-T103
and	O
BMX	B-T103
activation	O
and	O
p130CAS	B-T103
phosphorylation	B-T038
in	O
the	O
ECs	B-T017
,	O
and	O
reduced	O
the	O
vessel	B-T017
surface	B-T082
area	I-T082
.	O

These	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
aspect	O
of	O
the	O
regulation	B-T038
of	O
angiogenesis	B-T038
in	O
GBM	B-T038
that	O
can	O
impact	O
therapeutic	O
anti	B-T103
-	I-T103
angiogenic	I-T103
targeting	O
.	O

The	O
use	O
of	O
Ocimum	B-T204
americanum	I-T204
essential	B-T103
oil	I-T103
against	O
the	O
pathogens	O
Aeromonas	B-T007
hydrophila	I-T007
and	O
Gyrodactylus	B-T204
sp	I-T204
.	I-T204
in	O
silver	B-T204
catfish	I-T204
(	O
Rhamdia	B-T204
quelen	I-T204
)	O

The	O
bactericidal	B-T033
activity	I-T033
(	O
MIC	B-T058
-	I-T058
test	I-T058
)	O
of	O
Ocimum	B-T204
americanum	I-T204
(	O
inflorescences	B-T204
)	O
essential	B-T103
oil	I-T103
(	O
OAEO	B-T103
)	O
against	O
Aeromonas	B-T007
hydrophila	I-T007
was	O
determined	O
in	O
this	O
study	O
.	O

It	O
was	O
also	O
investigated	O
the	O
potential	O
of	O
OAEO	B-T103
and	O
the	O
main	O
compound	O
found	O
in	O
the	O
oil	B-T103
(	O
linalool	B-T103
)	O
at	O
subinhibitory	O
concentrations	O
to	O
be	O
inhibitors	B-T103
of	O
hemolysis	B-T038
caused	O
by	O
Aer	B-T007
.	I-T007

hydrophila	I-T007
in	O
fish	B-T204
erythrocytes	B-T017
.	O

An	O
in	O
vivo	O
experiment	O
was	O
conducted	O
to	O
evaluate	O
survival	O
of	O
fish	B-T204
(	O
Rhamdia	B-T204
quelen	I-T204
)	O
experimentally	B-T062
infected	B-T033
with	O
Aer	B-T007
.	I-T007

hydrophila	I-T007
and	O
exposed	O
to	O
OAEO	B-T103
.	O

A	O
second	O
experiment	B-T062
was	O
conducted	O
to	O
evaluate	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
activity	O
of	O
OAEO	B-T103
(	O
mix	O
from	O
inflorescences	B-T204
and	O
leaves	B-T204
)	O
against	O
the	O
parasite	B-T204
Gyrodactylus	I-T204
sp	I-T204
.	I-T204

The	O
OAEO	B-T103
showed	O
weak	O
in	O
vitro	O
activity	O
against	O
Aer	B-T007
.	I-T007

hydrophila	I-T007
(	O
6400	O
μg	O
ml	O
(	O
-	O
1	O
)	O
)	O
.	O

At	O
subinhibitory	O
concentrations	O
OAEO	B-T103
(	O
100	O
μg	O
ml	O
(	O
-	O
1	O
)	O
)	O
inhibited	O
hemolysis	B-T038
(	O
90	O
%	O
)	O
caused	O
by	O
Aer	B-T007
.	I-T007

hydrophila	I-T007
in	O
fish	B-T204
erythrocytes	B-T017
,	O
however	O
,	O
linalool	B-T103
did	O
not	O
present	O
hemolysis	B-T038
inhibition	O
activity	O
.	O

At	O
low	O
concentrations	O
(	O
10	O
and	O
20	O
mg	O
l	O
(	O
-	O
1	O
)	O
)	O
added	O
to	O
the	O
water	B-T103
OAEO	B-T103
promoted	O
survival	O
of	O
experimentally	O
infected	B-T033
fish	B-T204
with	O
Aer	B-T007
.	I-T007

hydrophila	I-T007
.	O

Lastly	O
,	O
OAEO	B-T103
-	O
mix	O
(	O
50	O
mg	O
l	O
(	O
-	O
1	O
)	O
)	O
was	O
effective	O
against	O
Gyrodactylus	B-T204
sp	I-T204
.	I-T204

significantly	O
reducing	O
(	O
60	O
%	O
)	O
the	O
number	O
of	O
parasites	B-T204
in	O
the	O
fish	B-T204
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Interleukin	B-T103
-	I-T103
1β	I-T103
induced	O
Stress	B-T017
Granules	I-T017
Sequester	O
COX	B-T103
-	I-T103
2	I-T103
mRNA	B-T103
and	O
Regulates	B-T038
its	O
Stability	O
and	O
Translation	O
in	O
Human	B-T204
OA	B-T038
Chondrocytes	B-T017

Enhanced	O
and	O
immediate	O
expression	B-T038
of	O
cyclooxygenase	B-T017
-	I-T017
2	I-T017
(	O
COX	B-T017
-	I-T017
2	I-T017
)	O
mRNA	B-T103
is	O
observed	O
in	O
IL	B-T103
-	I-T103
1β	I-T103
-	O
stimulated	B-T058
OA	B-T038
chondrocytes	B-T017
but	O
the	O
synthesis	B-T038
of	I-T038
protein	I-T038
found	O
significantly	O
delayed	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
stress	B-T017
granules	I-T017
(	O
SGs	B-T017
)	O
,	O
ribonucleoprotein	B-T017
complexes	I-T017
that	O
regulate	B-T038
mRNA	O
translation	O
,	O
in	O
the	O
delayed	O
translation	O
of	O
COX	B-T017
-	I-T017
2	I-T017
mRNAs	B-T103
in	O
IL	B-T103
-	I-T103
1β	I-T103
-	O
stimulated	B-T058
OA	B-T038
chondrocytes	B-T017
.	O

Stimulation	B-T058
of	O
human	B-T204
chondrocytes	B-T017
with	O
IL	B-T103
-	I-T103
1β	I-T103
activated	O
the	O
stress	B-T038
response	I-T038
genes	B-T017
and	O
the	O
phosphorylation	B-T038
of	O
eIF2α	B-T103
that	O
triggered	O
the	O
assembly	B-T038
of	I-T038
SGs	I-T038
.	O

Using	O
combined	O
immunofluorescence	B-T058
staining	I-T058
of	O
SGs	B-T017
markers	B-T201
and	O
COX	B-T103
-	I-T103
2	I-T103
protein	I-T103
,	O
RNA	B-T103
fluorescence	B-T062
in	I-T062
situ	I-T062
hybridization	I-T062
and	O
RNA	B-T103
immunoprecipitation	B-T058
,	O
the	O
COX	B-T017
-	I-T017
2	I-T017
mRNAs	B-T103
were	O
found	O
sequestered	O
in	O
SGs	B-T017
in	O
IL	B-T103
-	I-T103
1β	I-T103
-	O
stimulated	B-T058
OA	B-T038
chondrocytes	B-T017
.	O

No	B-T033
increase	O
in	O
COX	B-T103
-	I-T103
2	I-T103
protein	B-T038
expression	I-T038
was	O
observed	O
during	O
the	O
persistence	O
of	O
SGs	B-T017
but	O
enhanced	O
expression	B-T038
of	O
COX	B-T103
-	I-T103
2	I-T103
protein	I-T103
was	O
noted	O
upon	O
clearance	O
of	O
the	O
SGs	B-T017
.	O

Inhibition	O
of	O
SGs	B-T017
clearance	O
blocked	O
COX	B-T017
-	I-T017
2	I-T017
mRNA	B-T103
translation	O
whereas	O
blocking	O
the	O
assembly	B-T038
of	I-T038
SGs	I-T038
by	O
TIA	B-T103
-	I-T103
1	I-T103
depletion	O
resulted	O
in	O
rapid	O
and	O
increased	O
production	O
of	O
COX	B-T103
-	I-T103
2	I-T103
and	O
PGE2	B-T103
.	O

Our	O
findings	O
show	O
for	O
the	O
first	O
time	O
assembly	B-T038
of	I-T038
SGs	I-T038
and	O
sequestration	O
of	O
COX	B-T017
-	I-T017
2	I-T017
mRNAs	B-T103
in	O
human	B-T204
OA	B-T038
chondrocytes	B-T017
under	O
pathological	B-T033
conditions	I-T033
.	O

Post	B-T038
-	I-T038
transcriptional	I-T038
regulation	I-T038
of	O
COX	B-T017
-	I-T017
2	I-T017
mRNAs	O
translation	O
by	O
SGs	B-T017
indicates	O
a	O
role	O
in	O
IL	B-T103
-	I-T103
1β	I-T103
-	O
mediated	O
catabolic	O
response	O
that	O
could	O
be	O
therapeutically	B-T058
targeted	O
in	O
OA	B-T038
.	O

Spatio	O
-	O
Temporal	O
Distribution	O
of	O
Bark	B-T204
and	O
Ambrosia	B-T204
Beetles	B-T204
in	O
a	O
Brazilian	B-T082
Tropical	O
Dry	O
Forest	O

Bark	B-T204
and	O
the	O
ambrosia	B-T204
beetles	B-T204
dig	O
into	O
host	O
plants	O
and	O
live	O
most	O
of	O
their	O
lives	O
in	O
concealed	O
tunnels	B-T082
.	O

We	O
assessed	O
beetle	B-T204
community	O
dynamics	O
in	O
tropical	O
dry	O
forest	O
sites	B-T082
in	O
early	O
,	O
intermediate	O
,	O
and	O
late	O
successional	O
stages	O
,	O
evaluating	O
the	O
influence	O
of	O
resource	O
availability	O
and	O
seasonal	O
variations	O
in	O
guild	O
structure	O
.	O

We	O
collected	O
a	O
total	O
of	O
763	O
beetles	B-T204
from	O
23	O
species	B-T170
,	O
including	O
14	O
bark	B-T204
beetle	B-T204
species	B-T170
,	O
and	O
9	O
ambrosia	B-T204
beetle	B-T204
species	B-T170
.	O

Local	B-T082
richness	O
of	O
bark	B-T204
and	O
ambrosia	B-T204
beetles	B-T204
was	O
estimated	O
at	O
31	O
species	B-T170
.	O

Bark	B-T204
and	O
ambrosia	B-T204
composition	O
was	O
similar	O
over	O
the	O
successional	O
stages	O
gradient	O
,	O
and	O
beta	O
diversity	O
among	O
sites	B-T082
was	O
primarily	O
determined	O
by	O
species	B-T170
turnover	O
,	O
mainly	O
in	O
the	O
bark	B-T204
beetle	B-T204
community	O
.	O

Bark	B-T204
beetle	B-T204
richness	O
and	O
abundance	O
were	O
higher	O
at	O
intermediate	O
stages	O
;	O
availability	O
of	O
wood	O
was	O
the	O
main	O
spatial	O
mechanism	O
.	O

Climate	O
factors	O
were	O
effectively	O
non	O
-	O
seasonal	O
.	O

Ambrosia	B-T204
beetles	B-T204
were	O
not	O
influenced	O
by	O
successional	O
stages	O
,	O
however	O
the	O
increase	O
in	O
wood	O
resulted	O
in	O
increased	O
abundance	O
.	O

We	O
found	O
higher	O
richness	O
at	O
the	O
end	O
of	O
the	O
dry	O
and	O
wet	O
seasons	O
,	O
and	O
abundance	O
increased	O
with	O
air	O
moisture	O
and	O
decreased	O
with	O
higher	O
temperatures	O
and	O
greater	O
rainfall	O
.	O

In	O
summary	O
,	O
bark	B-T204
beetle	B-T204
species	B-T170
accumulation	O
was	O
higher	O
at	O
sites	B-T082
with	O
better	O
wood	O
production	O
,	O
while	O
the	O
needs	O
of	O
fungi	B-T204
(	O
host	O
and	O
air	O
moisture	O
)	O
,	O
resulted	O
in	O
a	O
favorable	O
conditions	O
for	O
species	B-T170
accumulation	O
of	O
ambrosia	B-T204
.	O

The	O
overall	O
biological	O
pattern	O
among	O
guilds	O
differed	O
from	O
tropical	O
rain	O
forests	O
,	O
showing	O
patterns	O
similar	O
to	O
dry	O
forest	O
areas	O
.	O

Detection	B-T058
and	O
Characterization	O
of	O
Flat	B-T038
Aberrant	I-T038
Crypt	I-T038
Foci	I-T038
(	I-T038
Flat	I-T038
ACF	I-T038
)	I-T038
in	O
the	O
Novel	O
A	B-T038
/	I-T038
J	I-T038
Min	I-T038
/	I-T038
+	I-T038
Mouse	I-T038

Flat	B-T038
aberrant	I-T038
crypt	I-T038
foci	I-T038
(	O
flat	B-T038
ACF	I-T038
)	O
and	O
mucin	B-T038
-	I-T038
depleted	I-T038
foci	I-T038
(	O
MDF	B-T038
)	O
have	O
previously	O
been	O
described	O
as	O
preneoplastic	B-T038
colonic	I-T038
lesions	I-T038
.	O

We	O
used	O
the	O
novel	O
A	B-T038
/	I-T038
J	I-T038
Min	I-T038
/	I-T038
+	I-T038
mouse	I-T038
model	I-T038
,	O
that	O
demonstrates	O
extensive	O
spontaneous	O
colon	B-T038
carcinogenesis	I-T038
to	O
refine	O
the	O
method	O
of	O
detection	B-T058
of	O
flat	B-T038
ACF	I-T038
and	O
further	O
characterize	O
and	O
define	O
them	O
as	O
early	O
lesions	B-T033
by	O
histological	B-T058
examination	I-T058
and	O
comparison	O
with	O
MDF	B-T038
.	O

Colons	B-T017
were	O
stained	B-T058
with	I-T058
methylene	I-T058
blue	I-T058
(	O
MB	B-T103
)	O
for	O
flat	B-T038
ACF	I-T038
detection	B-T058
and	O
restained	B-T058
with	O
high	B-T103
-	I-T103
iron	I-T103
diamine	I-T103
-	I-T103
alcian	I-T103
blue	I-T103
(	O
HID	B-T103
-	I-T103
AB	I-T103
)	O
for	O
MDF	B-T038
detection	B-T058
.	O

Optimal	O
flat	B-T038
ACF	I-T038
recognition	O
required	O
at	O
least	O
24	O
h	O
of	O
storage	O
post	O
-	O
MB	B-T058
staining	I-T058
and	O
adherence	O
to	O
a	O
set	O
of	O
characteristics	O
.	O

The	O
fraction	O
of	O
flat	B-T038
ACF	I-T038
corresponding	O
with	O
MDF	B-T038
was	O
93	O
%	O
.	O

Flat	B-T038
ACF	I-T038
/	O
MDF	B-T038
displayed	O
the	O
same	O
picture	O
of	O
severe	B-T038
dysplasia	I-T038
,	O
lack	O
of	O
mucus	B-T017
and	O
goblet	B-T017
cells	I-T017
and	O
accumulation	B-T033
of	O
cytoplasmic	B-T017
β	B-T103
-	I-T103
catenin	I-T103
.	O

The	O
easily	O
detectable	O
flat	B-T038
ACF	I-T038
are	O
reliable	O
surface	B-T017
biomarkers	B-T201
of	O
Apc	B-T017
-	O
driven	O
colon	B-T038
carcinogenesis	I-T038
.	O

Transcriptional	B-T038
enhancement	I-T038
of	O
Smn	B-T017
levels	B-T033
in	O
motoneurons	B-T017
is	O
crucial	O
for	O
proper	O
axon	B-T017
morphology	O
in	O
zebrafish	B-T204

An	O
unresolved	O
mystery	O
in	O
the	O
field	O
of	O
spinal	B-T038
muscular	I-T038
atrophy	I-T038
(	O
SMA	B-T038
)	O
is	O
why	O
a	O
reduction	O
of	O
the	O
ubiquitously	O
expressed	O
Smn	B-T103
protein	I-T103
causes	O
defects	O
mostly	O
in	O
motoneurons	B-T017
.	O

We	O
addressed	O
the	O
possibility	O
that	O
this	O
restricted	O
vulnerability	O
stems	O
from	O
elevated	O
Smn	B-T038
expression	I-T038
in	O
motoneurons	B-T017
.	O

To	O
explore	O
this	O
,	O
we	O
established	O
an	O
ex	B-T074
vivo	I-T074
zebrafish	B-T204
culture	I-T074
system	I-T074
of	O
GFP	B-T103
-	O
marked	O
motoneurons	B-T017
to	O
quantitatively	O
measure	O
Smn	B-T033
protein	I-T033
and	O
smn	B-T103
mRNA	I-T103
levels	O
as	O
well	O
as	O
promoter	O
activity	O
in	O
motoneurons	B-T017
versus	O
other	O
cell	B-T017
types	O
.	O

Importantly	O
,	O
we	O
uncovered	O
that	O
Smn	B-T033
levels	I-T033
are	O
elevated	O
in	O
motoneurons	B-T017
by	O
means	O
of	O
transcriptional	B-T038
activation	I-T038
.	O

In	O
addition	O
,	O
we	O
identified	O
the	O
ETS	B-T103
family	I-T103
transcription	I-T103
factor	I-T103
Etv5b	I-T103
to	O
be	O
responsible	O
for	O
increased	O
smn	B-T038
transcription	I-T038
in	O
motoneurons	B-T017
.	O

Moreover	O
,	O
we	O
established	O
that	O
the	O
additional	O
supply	O
of	O
Smn	B-T103
protein	I-T103
in	O
motoneurons	B-T017
is	O
necessary	O
for	O
proper	O
axonogenesis	B-T038
in	O
a	O
cell	B-T038
-	I-T038
autonomous	I-T038
manner	I-T038
.	O

These	O
findings	B-T033
demonstrate	O
the	O
reliance	O
of	O
motoneurons	B-T017
on	O
more	O
Smn	B-T103
,	O
thereby	O
adding	O
a	O
novel	O
piece	O
of	O
evidence	O
for	O
their	O
increased	O
vulnerability	B-T201
under	O
SMA	B-T038
conditions	I-T038
.	O

Evaluation	B-T058
of	O
response	O
from	O
axitinib	B-T103
per	O
Response	B-T170
Evaluation	I-T170
Criteria	I-T170
in	I-T170
Solid	I-T170
Tumors	I-T170
versus	O
Choi	O
criteria	O
in	O
previously	O
treated	B-T033
patients	O
with	O
metastatic	B-T038
renal	I-T038
cell	I-T038
carcinoma	I-T038

Axitinib	B-T103
,	O
a	O
selective	O
and	O
potent	O
tyrosine	B-T103
kinase	I-T103
inhibitor	I-T103
of	O
vascular	B-T103
endothelial	I-T103
growth	I-T103
factor	I-T103
receptors	I-T103
,	O
was	O
available	O
to	O
patients	O
from	O
Canada	B-T082
and	O
Australia	B-T082
,	O
prior	O
to	O
regulatory	O
approval	B-T170
of	O
axitinib	B-T103
in	O
these	O
countries	B-T082
,	O
for	O
treatment	B-T058
of	O
clear	B-T038
-	I-T038
cell	I-T038
metastatic	I-T038
renal	I-T038
cell	I-T038
carcinoma	I-T038
(	O
mRCC	B-T038
)	O
after	O
failure	O
of	O
one	O
prior	O
systemic	O
regimen	B-T058
.	O

This	O
single	B-T062
-	I-T062
arm	I-T062
,	O
open	B-T062
-	I-T062
label	I-T062
study	I-T062
of	O
axitinib	B-T103
evaluated	O
the	O
efficacy	B-T062
,	O
safety	B-T062
,	O
and	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
in	O
patients	O
with	O
mRCC	B-T038
whose	O
disease	B-T038
progressed	B-T038
after	O
one	O
prior	O
systemic	O
first	B-T058
-	I-T058
line	I-T058
regimen	I-T058
.	O

Primary	O
objective	O
was	O
objective	O
response	O
rate	O
evaluated	B-T058
per	O
Response	B-T170
Evaluation	I-T170
Criteria	I-T170
in	I-T170
Solid	I-T170
Tumors	I-T170
(	O
RECIST	B-T170
)	O
and	O
Choi	O
criteria	O
.	O

Progression	O
-	O
free	O
survival	O
,	O
overall	O
survival	O
,	O
safety	B-T062
,	O
and	O
QoL	O
were	O
secondary	O
end	O
points	O
.	O

Due	O
to	O
the	O
small	O
study	B-T062
size	O
,	O
analyses	O
comprised	O
of	O
descriptive	O
statistics	B-T062
.	O

Fifteen	O
patients	O
were	O
recruited	O
,	O
five	O
from	O
Canada	B-T082
and	O
ten	O
from	O
Australia	B-T082
,	O
over	O
a	O
limited	O
recruitment	O
period	O
.	O

Thirteen	O
patients	O
received	O
sunitinib	B-T103
as	O
prior	O
therapy	B-T058
.	O

All	O
patients	O
had	O
clear	B-T038
-	I-T038
cell	I-T038
carcinoma	I-T038
,	O
eleven	O
had	O
prior	O
nephrectomy	B-T058
.	O

Liver	B-T017
,	O
lung	B-T017
,	O
and	O
lymph	B-T017
nodes	I-T017
were	O
the	O
most	O
frequent	O
sites	O
of	O
metastases	B-T038
;	O
one	O
patient	O
had	O
brain	B-T038
metastasis	I-T038
.	O

Median	O
time	O
on	O
axitinib	B-T103
was	O
118	O
.	O
0	O
days	O
(	O
range	O
:	O
3	O
.	O
5	O
-	O
645	O
.	O
0	O
days	O
)	O
;	O
estimated	O
survival	O
probability	O
at	O
12	O
months	O
was	O
57	O
.	O
8	O
%	O
.	O

Two	O
(	O
13	O
.	O
3	O
%	O
)	O
patients	O
had	O
objective	O
responses	O
per	O
RECIST	B-T170
versus	O
nine	O
(	O
60	O
.	O
0	O
%	O
)	O
per	O
Choi	O
criteria	O
.	O

Six	O
patients	O
had	O
progressive	B-T038
disease	B-T038
based	O
on	O
RECIST	B-T170
versus	O
three	O
per	O
Choi	O
criteria	O
.	O

Nine	O
(	O
60	O
.	O
0	O
%	O
)	O
events	O
of	O
progression	B-T038
or	O
death	B-T038
occurred	O
by	O
the	O
end	O
of	O
study	B-T062
,	O
and	O
three	O
patients	O
continued	O
to	O
receive	O
the	O
study	B-T062
drug	B-T103
.	O

Fatigue	B-T033
(	O
33	O
%	O
)	O
and	O
diarrhea	B-T033
(	O
20	O
%	O
)	O
were	O
the	O
most	O
common	O
grade	O
≥3	O
all	O
-	O
causality	O
,	O
treatment	B-T058
-	O
emergent	O
adverse	B-T038
events	I-T038
.	O

The	O
mean	O
change	O
in	O
European	B-T082
Quality	O
of	O
Life	O
-	O
5	O
Dimensions	O
score	O
from	O
baseline	O
to	O
end	O
of	O
treatment	B-T058
was	O
-	O
0	O
.	O
0837	O
.	O

The	O
small	O
number	O
of	O
patients	O
and	O
lack	O
of	O
a	O
comparator	O
arm	O
limit	O
the	O
ability	O
to	O
draw	O
definitive	O
conclusions	O
;	O
however	O
,	O
safety	B-T062
and	O
efficacy	B-T062
profiles	O
of	O
axitinib	B-T103
were	O
consistent	O
with	O
reports	O
from	O
previous	O
studies	B-T062
in	O
patients	O
with	O
mRCC	B-T038
,	O
and	O
patients	O
generally	O
maintained	O
QoL	O
.	O

The	O
sizeable	O
difference	O
observed	O
in	O
objective	O
response	O
rate	O
by	O
RECIST	B-T170
versus	O
Choi	O
criteria	O
merits	O
further	O
research	B-T062
.	O

Biochemical	O
characteristics	O
of	O
AtFAR2	B-T103
,	O
a	O
fatty	B-T103
acid	I-T103
reductase	I-T103
from	O
Arabidopsis	B-T204
thaliana	I-T204
that	O
reduces	O
fatty	B-T103
acyl	I-T103
-	I-T103
CoA	I-T103
and	O
-	O
ACP	B-T103
substrates	I-T103
into	O
fatty	B-T103
alcohols	I-T103

Fatty	B-T103
alcohols	I-T103
and	O
derivatives	B-T103
are	O
important	O
for	O
proper	O
deposition	O
of	O
a	O
functional	O
pollen	B-T017
wall	I-T017
.	O

Mutations	B-T038
in	O
specific	O
genes	B-T017
encoding	O
fatty	B-T103
acid	I-T103
reductases	I-T103
(	O
FAR	B-T103
)	O
responsible	O
for	O
fatty	B-T103
alcohol	I-T103
production	O
cause	O
abnormal	B-T033
development	O
of	O
pollen	B-T204
.	O

A	O
disrupted	O
AtFAR2	B-T017
(	I-T017
MS2	I-T017
)	I-T017
gene	I-T017
in	O
Arabidopsis	B-T204
thaliana	I-T204
results	O
in	O
pollen	B-T204
developing	O
an	O
abnormal	B-T033
exine	B-T017
layer	I-T017
and	O
a	O
reduced	B-T033
fertility	I-T033
phenotype	O
.	O

AtFAR2	B-T103
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
chloroplasts	B-T017
and	O
in	O
a	O
purified	O
form	O
to	O
be	O
specific	O
for	O
acyl	B-T103
-	I-T103
ACP	I-T103
substrates	I-T103
.	O

Here	O
,	O
we	O
present	O
data	O
on	O
the	O
in	O
vitro	O
and	O
in	O
planta	B-T204
characterizations	O
of	O
AtFAR2	B-T103
from	O
A	B-T204
.	I-T204

thaliana	I-T204
and	O
show	O
that	O
this	O
enzyme	B-T103
has	O
the	O
ability	O
to	O
use	O
both	O
,	O
C16	B-T103
:	I-T103
0	I-T103
-	I-T103
ACP	I-T103
and	O
C16	B-T103
:	I-T103
0	I-T103
-	I-T103
CoA	I-T103
,	O
as	O
substrates	O
to	O
produce	O
C16	B-T103
:	I-T103
0	I-T103
-	I-T103
alcohol	I-T103
.	O

Our	O
results	O
further	O
show	O
that	O
AtFAR2	B-T103
is	O
highly	O
similar	O
in	O
properties	O
and	O
substrate	O
specificity	O
to	O
AtFAR6	B-T103
for	O
which	O
in	O
vitro	O
data	O
has	O
been	O
published	O
,	O
and	O
which	O
is	O
also	O
a	O
chloroplast	B-T017
localized	B-T082
enzyme	B-T103
.	O

This	O
suggests	O
that	O
although	O
AtFAR2	B-T103
is	O
the	O
major	O
enzyme	B-T103
responsible	O
for	O
exine	B-T017
layer	I-T017
functionality	O
,	O
AtFAR6	B-T103
might	O
provide	O
functional	O
redundancy	O
to	O
AtFAR2	B-T103
.	O

Comparing	O
Time	B-T038
Perception	I-T038
among	O
Morphine	B-T103
-	O
Derived	O
Drugs	B-T103
Addicts	O
and	O
Controls	O

The	O
aim	O
of	O
the	O
present	O
study	B-T062
is	O
to	O
compare	O
time	B-T038
perception	I-T038
among	O
drug	B-T033
addicts	I-T033
and	O
controls	O
.	O

30	O
drug	B-T033
addicts	I-T033
were	O
selected	O
,	O
and	O
30	O
non	B-T098
-	I-T098
addict	I-T098
individuals	I-T098
were	O
selected	O
as	O
the	O
control	O
group	O
.	O

The	O
two	O
groups	O
performed	O
three	O
tests	B-T170
of	O
time	O
reproduction	B-T038
,	O
time	O
estimation	O
,	O
and	O
time	O
discrimination	B-T038
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
the	O
addicts	O
group	O
and	O
the	O
control	O
group	O
regarding	O
the	O
error	O
of	O
time	O
reproduction	B-T038
and	O
time	O
estimation	O
.	O

The	O
addict	O
group	O
in	O
comparison	O
to	O
the	O
control	O
group	O
had	O
a	O
lower	O
under	O
-	O
reproduction	B-T038
and	O
a	O
higher	O
over	O
-	O
reproduction	B-T038
error	O
,	O
and	O
also	O
a	O
lower	O
under	O
-	O
estimation	B-T038
and	O
higher	O
over	O
-	O
estimation	B-T038
error	O
.	O

However	O
,	O
regarding	O
time	O
discrimination	B-T038
,	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
errors	O
committed	O
by	O
both	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
showing	O
images	B-T170
of	O
drug	O
consumption	O
tools	O
and	O
normal	O
images	B-T170
with	O
same	O
durations	O
,	O
the	O
normal	O
group	O
believed	O
that	O
the	O
images	B-T170
related	O
to	O
drug	O
consumption	O
tools	O
were	O
shown	O
for	O
a	O
shorter	O
period	O
of	O
time	O
.	O

Time	B-T038
perception	I-T038
is	O
different	O
between	O
morphine	B-T103
-	O
derived	O
drugs	B-T103
addicts	O
and	O
controls	O
.	O

Co	O
-	O
delivery	O
of	O
pemetrexed	B-T103
and	O
miR	B-T103
-	I-T103
21	I-T103
antisense	I-T103
oligonucleotide	I-T103
by	O
lipid	B-T103
-	O
polymer	B-T103
hybrid	O
nanoparticles	O
and	O
effects	O
on	O
glioblastoma	B-T038
cells	B-T017

Combination	B-T058
therapy	I-T058
using	O
anticancer	B-T103
drugs	I-T103
and	O
nucleic	B-T103
acid	I-T103
is	O
a	O
more	O
promising	O
strategy	O
to	O
overcome	O
multidrug	O
resistance	O
in	O
cancer	B-T038
and	O
to	O
enhance	O
apoptosis	B-T038
.	O

In	O
this	O
study	B-T062
,	O
lipid	B-T103
-	O
polymer	B-T103
hybrid	O
nanoparticles	O
(	O
LPNs	B-T103
)	O
,	O
which	O
contain	O
both	O
pemetrexed	B-T103
and	O
miR	B-T103
-	I-T103
21	I-T103
antisense	I-T103
oligonucleotide	I-T103
(	O
anti	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
)	O
,	O
have	O
been	O
developed	O
for	O
treatment	O
of	O
glioblastoma	B-T038
,	O
the	O
most	O
aggressive	O
type	O
of	O
brain	B-T038
tumor	I-T038
.	O

Prepared	O
LPNs	B-T103
have	O
been	O
well	O
characterized	O
by	O
particle	O
size	O
distribution	O
and	O
zeta	O
potential	O
measurements	O
,	O
determination	O
of	O
encapsulation	O
efficiency	O
,	O
and	O
in	O
vitro	O
release	B-T062
experiments	I-T062
.	O

Morphology	O
of	O
LPNs	B-T103
was	O
determined	O
by	O
transmission	B-T058
electron	I-T058
microscopy	I-T058
.	O

LPNs	B-T103
had	O
a	O
hydrodynamic	O
size	B-T082
below	O
100	O
nm	O
and	O
exhibited	O
sustained	O
release	O
of	O
pemetrexed	B-T103
up	O
to	O
10	O
h	O
.	O

Encapsulation	O
of	O
pemetrexed	B-T103
in	O
LPNs	B-T103
increased	O
cellular	B-T038
uptake	I-T038
from	O
6	O
%	O
to	O
78	O
%	O
.	O

Results	O
of	O
confocal	B-T058
microscopy	I-T058
analysis	I-T058
have	O
shown	O
that	O
co	O
-	O
delivery	O
of	O
anti	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
significantly	O
improved	O
accumulation	B-T033
of	O
LPNs	B-T103
in	O
the	O
nucleus	B-T017
of	O
U87MG	B-T017
cells	I-T017
.	O

Nevertheless	O
,	O
more	O
effective	O
cytotoxicity	B-T038
results	O
could	O
not	O
be	O
obtained	O
due	O
to	O
low	O
concentration	O
of	O
anti	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
,	O
loaded	O
in	O
LPNs	B-T103
.	O

We	O
expect	O
that	O
the	O
effective	O
drug	B-T074
delivery	I-T074
systems	I-T074
can	O
be	O
obtained	O
with	O
higher	O
concentration	O
of	O
anti	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
for	O
the	O
treatment	B-T058
of	O
glioblastoma	B-T038
.	O

Expert	B-T097
position	B-T170
paper	I-T170
on	O
prolonged	O
dual	B-T058
antiplatelet	I-T058
therapy	I-T058
in	O
secondary	B-T058
prevention	I-T058
following	O
myocardial	B-T038
infarction	I-T038

The	O
protective	O
effect	O
of	O
dual	B-T058
antiplatelet	I-T058
therapy	I-T058
(	O
DAPT	B-T058
)	O
following	O
acute	B-T038
coronary	I-T038
syndrome	I-T038
is	O
undisputed	O
,	O
but	O
its	O
duration	O
is	O
subject	O
of	O
debate	O
.	O

Several	O
studies	B-T062
show	O
that	O
prolonged	O
therapy	B-T058
provides	O
a	O
clinical	O
benefit	O
in	O
patients	O
following	O
acute	B-T038
coronary	I-T038
syndrome	I-T038
.	O

The	O
aim	O
of	O
this	O
position	B-T170
paper	I-T170
authored	O
by	O
Austrian	B-T098
experts	B-T097
is	O
to	O
outline	O
the	O
current	O
evidence	O
and	O
provide	O
an	O
overview	O
of	O
recent	O
studies	B-T062
.	O

It	O
is	O
also	O
intended	O
to	O
serve	O
as	O
a	O
practical	O
guide	O
to	O
identify	O
those	O
patients	O
who	O
may	O
benefit	O
from	O
prolonged	O
DAPT	B-T058
.	O

Medulloblastoma	B-T038
:	O
molecular	B-T038
pathways	I-T038
and	O
histopathological	O
classification	B-T170

Malignant	B-T038
brain	I-T038
tumors	I-T038
are	O
the	O
leading	O
cause	O
of	O
cancer	B-T038
death	B-T033
among	O
pediatric	O
patients	O
,	O
and	O
medulloblastoma	B-T038
constitutes	O
20	O
%	O
of	O
them	O
.	O

Currently	O
,	O
the	O
treatment	B-T058
is	O
risk	O
-	O
adapted	O
.	O

Maximum	O
surgical	B-T058
resection	I-T058
is	O
recommended	O
,	O
always	O
followed	O
by	O
chemotherapy	B-T058
and	O
neuroaxis	B-T022
radiotherapy	B-T058
.	O

In	O
spite	O
of	O
the	O
improving	O
survival	O
rate	O
,	O
survivors	O
succumb	O
to	O
treatment	B-T058
-	O
induced	O
side	B-T038
effects	I-T038
.	O

To	O
reduce	O
toxic	B-T037
effects	I-T037
,	O
molecular	B-T058
-	I-T058
targeted	I-T058
treatment	I-T058
is	O
proposed	O
.	O

Medulloblastoma	B-T038
research	B-T062
is	O
very	O
robust	O
,	O
and	O
new	O
articles	B-T170
on	O
the	O
subject	O
are	O
published	O
daily	O
.	O

In	O
the	O
current	O
review	B-T170
we	O
have	O
tried	O
to	O
bring	O
together	O
molecular	O
pathophysiology	O
of	O
the	O
neoplasm	B-T038
and	O
current	O
pathological	O
classification	B-T170
,	O
thus	O
making	O
an	O
effort	O
to	O
relate	O
tumor	B-T062
biology	I-T062
and	O
the	O
histological	B-T201
picture	I-T201
.	O

Spatio	B-T062
-	I-T062
Temporal	I-T062
History	I-T062
of	O
HIV	O
-	O
1	O
CRF35	O
_	O
AD	O
in	O
Afghanistan	B-T082
and	O
Iran	B-T082

HIV	B-T005
-	I-T005
1	I-T005
Circulating	I-T005
Recombinant	I-T005
Form	I-T005
35	I-T005
_	I-T005
AD	I-T005
(	O
CRF35	O
_	O
AD	O
)	O
has	O
an	O
important	O
position	O
in	O
the	O
epidemiological	B-T091
profile	O
of	O
Afghanistan	B-T082
and	O
Iran	B-T082
.	O

Despite	O
the	O
presence	O
of	O
this	O
clade	O
in	O
Afghanistan	B-T082
and	O
Iran	B-T082
for	O
over	O
a	O
decade	O
,	O
our	O
understanding	O
of	O
its	O
origin	O
and	O
dissemination	O
patterns	O
is	O
limited	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
Bayesian	O
phylogeographic	O
analysis	O
to	O
reconstruct	O
the	O
spatio	O
-	O
temporal	O
dispersion	O
pattern	O
of	O
this	O
clade	O
using	O
eligible	O
CRF35	O
_	O
AD	O
gag	B-T082
and	I-T082
pol	I-T082
sequences	I-T082
available	O
in	O
the	O
Los	B-T082
Alamos	I-T082
HIV	B-T170
database	I-T170
(	O
432	O
sequences	B-T082
available	O
from	O
Iran	B-T082
,	O
16	O
sequences	B-T082
available	O
from	O
Afghanistan	B-T082
,	O
and	O
a	O
single	O
CRF35	O
_	O
AD	O
-	O
like	O
pol	B-T082
sequence	I-T082
available	O
from	O
USA	B-T082
)	O
.	O

Bayesian	B-T170
Markov	I-T170
Chain	I-T170
Monte	I-T170
Carlo	I-T170
algorithm	I-T170
was	O
implemented	O
in	O
BEAST	B-T170
v1	I-T170
.	I-T170
8	I-T170
.	I-T170
1	I-T170
.	O

Between	O
-	O
country	O
dispersion	O
rates	O
were	O
tested	O
with	O
Bayesian	B-T170
stochastic	I-T170
search	I-T170
variable	I-T170
selection	I-T170
method	I-T170
and	O
were	O
considered	O
significant	O
where	O
Bayes	O
factor	O
values	O
were	O
greater	O
than	O
three	O
.	O

The	O
findings	O
suggested	O
that	O
CRF35	O
_	O
AD	O
sequences	B-T082
were	O
genetically	O
similar	O
to	O
parental	B-T082
sequences	I-T082
from	O
Kenya	B-T082
and	O
Uganda	B-T082
,	O
and	O
to	O
a	O
set	O
of	O
subtype	O
A1	O
sequences	B-T082
available	O
from	O
Afghan	B-T082
refugees	B-T098
living	O
in	O
Pakistan	B-T082
.	O

Our	O
results	O
also	O
showed	O
that	O
across	O
all	O
phylogenies	O
,	O
Afghan	B-T082
and	O
Iranian	B-T082
CRF35	O
_	O
AD	O
sequences	B-T082
formed	O
a	O
monophyletic	O
cluster	O
(	O
posterior	O
clade	O
credibility	O
>	O
0	O
.	O
7	O
)	O
.	O

The	O
divergence	O
date	O
of	O
this	O
cluster	O
was	O
estimated	O
to	O
be	O
between	O
1990	O
and	O
1992	O
.	O

Within	O
this	O
cluster	O
,	O
a	O
bidirectional	O
dispersion	O
of	O
the	O
virus	B-T005
was	O
observed	O
across	O
Afghanistan	B-T082
and	O
Iran	B-T082
.	O

We	O
could	O
not	O
clearly	O
identify	O
if	O
Afghanistan	B-T082
or	O
Iran	B-T082
first	O
established	O
or	O
received	O
this	O
epidemic	B-T038
,	O
as	O
the	O
root	O
location	O
of	O
this	O
cluster	O
could	O
not	O
be	O
robustly	O
estimated	O
.	O

Three	O
CRF35	O
_	O
AD	O
sequences	B-T082
from	O
Afghan	B-T082
refugees	B-T098
living	B-T082
in	I-T082
Pakistan	B-T082
nested	O
among	O
Afghan	B-T082
and	O
Iranian	B-T082
CRF35	O
_	O
AD	O
branches	O
.	O

However	O
,	O
the	O
CRF35	O
_	O
AD	O
-	O
like	O
sequence	B-T082
available	O
from	O
USA	B-T082
diverged	O
independently	O
from	O
Kenyan	B-T082
subtype	O
A1	O
sequences	B-T082
,	O
suggesting	O
it	O
not	O
to	O
be	O
a	O
true	O
CRF35	O
_	O
AD	O
lineage	O
.	O

Potential	O
factors	O
contributing	O
to	O
viral	B-T005
exchange	O
between	O
Afghanistan	B-T082
and	O
Iran	B-T082
could	O
be	O
injection	O
drug	O
networks	O
and	O
mass	O
migration	O
of	O
Afghan	B-T082
refugees	B-T098
and	O
labours	O
to	O
Iran	B-T082
,	O
which	O
calls	O
for	O
extensive	O
preventive	O
efforts	O
.	O

The	O
Benefits	O
of	O
Combination	B-T058
Therapy	I-T058
with	O
Esomeprazole	B-T103
and	O
Rebamipide	B-T103
in	O
Symptom	B-T033
Improvement	O
in	O
Reflux	B-T038
Esophagitis	I-T038
:	O
An	O
International	O
Multicenter	B-T062
Study	I-T062

To	O
investigate	O
the	O
effects	O
of	O
esomeprazole	B-T103
and	O
rebamipide	B-T103
combination	B-T058
therapy	I-T058
on	O
symptomatic	B-T033
improvement	O
in	O
patients	O
with	O
reflux	B-T038
esophagitis	I-T038
.	O

A	O
total	O
of	O
501	O
patients	O
with	O
reflux	B-T038
esophagitis	I-T038
were	O
randomized	B-T062
into	O
one	O
of	O
the	O
following	O
two	O
treatment	B-T058
regimens	I-T058
:	O
40	O
mg	O
esomeprazole	B-T103
plus	O
300	O
mg	O
rebamipide	B-T103
daily	O
(	O
combination	B-T058
therapy	I-T058
group	O
)	O
or	O
40	O
mg	O
esomeprazole	B-T103
daily	O
(	O
monotherapy	B-T058
group	O
)	O
.	O

We	O
used	O
a	O
symptom	B-T033
questionnaire	B-T170
that	O
evaluated	O
heartburn	B-T033
,	O
acid	O
regurgitation	O
,	O
and	O
four	O
upper	B-T038
gastrointestinal	I-T038
symptoms	I-T038
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	O
mean	O
decrease	O
in	O
the	O
total	O
symptom	O
score	O
.	O

The	O
mean	O
decreases	O
in	O
the	O
total	O
symptom	O
score	O
at	O
4	O
weeks	O
were	O
estimated	O
to	O
be	O
-	O
18	O
.	O
1±13	O
.	O
8	O
in	O
the	O
combination	B-T058
therapy	I-T058
group	O
and	O
-	O
15	O
.	O
1±11	O
.	O
9	O
in	O
the	O
monotherapy	B-T058
group	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

Changes	O
in	O
reflux	B-T038
symptom	B-T033
s	O
from	O
baseline	O
after	O
4	O
weeks	O
of	O
treatment	B-T058
were	O
-	O
8	O
.	O
4±6	O
.	O
6	O
in	O
the	O
combination	B-T058
therapy	I-T058
group	O
and	O
-	O
6	O
.	O
8±5	O
.	O
9	O
in	O
the	O
monotherapy	B-T058
group	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
.	O

Over	O
a	O
4	O
-	O
week	O
treatment	B-T058
course	O
,	O
esomeprazole	B-T103
and	O
rebamipide	B-T103
combination	B-T058
therapy	I-T058
was	O
more	O
effective	O
in	O
decreasing	B-T033
the	O
symptoms	B-T033
of	O
reflux	B-T038
esophagitis	I-T038
than	O
esomeprazole	B-T103
monotherapy	B-T058
.	O

Integrating	O
Palliative	B-T091
Care	I-T091
in	O
Pediatric	B-T091
Oncology	I-T091
:	O
Evidence	O
for	O
an	O
Evolving	O
Paradigm	O
for	O
Comprehensive	B-T058
Cancer	O
Care	O

The	O
demonstrated	O
benefit	O
of	O
integrating	O
palliative	B-T091
care	I-T091
(	O
PC	B-T091
)	O
into	O
cancer	B-T058
treatment	I-T058
has	O
triggered	O
an	O
increased	O
need	O
for	O
PC	B-T091
services	O
.	O

The	O
trajectory	O
of	O
integrating	O
PC	B-T091
in	O
comprehensive	B-T058
cancer	B-T092
centers	I-T092
,	I-T092
particularly	O
pediatric	B-T092
centers	I-T092
,	O
is	O
unknown	O
.	O

We	O
describe	O
our	O
8	O
-	O
year	O
experience	O
of	O
initiating	O
and	O
establishing	O
PC	B-T091
with	O
the	O
Quality	B-T058
of	I-T058
Life	I-T058
Service	I-T058
(	O
QoLS	B-T058
)	O
at	O
St	B-T092
.	I-T092

Jude	I-T092
Children	I-T092
'	I-T092
s	I-T092
Research	I-T092
Hospital	I-T092
.	O

We	O
retrospectively	O
reviewed	O
records	B-T170
of	I-T170
patients	I-T170
seen	O
by	O
the	O
QoLS	B-T058
(	O
n	O
=	O
615	O
)	O
from	O
March	O
2007	O
to	O
December	O
2014	O
.	O

Variables	O
analyzed	O
for	O
each	O
year	O
,	O
using	O
descriptive	O
statistics	O
,	O
included	O
diagnostic	B-T170
groups	I-T170
,	O
QoLS	B-T058
encounters	B-T058
,	O
goals	B-T058
of	I-T058
care	I-T058
,	O
duration	B-T201
of	I-T201
survival	I-T201
,	O
and	O
location	B-T082
of	I-T082
death	I-T082
.	O

Total	O
QoLS	B-T058
patient	O
encounters	B-T058
increased	O
from	O
58	O
(	O
2007	O
)	O
to	O
1	O
,	O
297	O
(	O
2014	O
)	O
,	O
new	O
consults	B-T058
increased	O
from	O
17	O
(	O
2007	O
)	O
to	O
115	O
(	O
2014	O
)	O
,	O
and	O
mean	O
encounters	B-T058
per	O
patient	O
increased	O
from	O
5	O
.	O
06	O
(	O
2007	O
)	O
to	O
16	O
.	O
11	O
(	O
2014	O
)	O
.	O

Goal	B-T058
of	I-T058
care	I-T058
at	O
initial	O
consultation	O
shifted	O
from	O
primarily	O
comfort	B-T038
to	O
an	O
increasing	O
goal	B-T170
of	I-T170
cure	I-T170
.	O

The	O
median	O
number	O
of	O
days	O
from	O
initial	O
consult	O
to	O
death	B-T033
increased	O
from	O
52	O
days	O
(	O
2008	O
)	O
to	O
223	O
days	O
(	O
2014	O
)	O
.	O

A	O
trend	O
toward	O
increased	O
outpatient	O
location	B-T082
of	I-T082
death	I-T082
was	O
noted	O
with	O
42	O
%	O
outpatient	O
deaths	B-T033
in	O
2007	O
,	O
increasing	O
to	O
a	O
majority	O
in	O
each	O
subsequent	O
year	O
(	O
range	O
,	O
51	O
%	O
-	O
74	O
%	O
)	O
.	O

Hospital	O
-	O
wide	O
,	O
patients	O
receiving	O
PC	B-T091
services	O
before	O
death	B-T033
increased	O
from	O
approximately	O
50	O
%	O
to	O
nearly	O
100	O
%	O
.	O

Since	O
its	O
inception	O
,	O
the	O
QoLS	B-T058
experienced	O
a	O
dramatic	O
increase	O
in	O
referrals	B-T058
and	O
encounters	B-T058
per	O
patient	O
,	O
increased	O
use	O
by	O
all	O
clinical	B-T058
services	I-T058
,	O
a	O
trend	O
toward	O
earlier	O
consultation	B-T058
and	O
longer	O
term	O
follow	B-T058
-	I-T058
up	I-T058
,	O
increasing	O
outpatient	O
location	B-T082
of	I-T082
death	I-T082
,	O
and	O
near	O
-	O
universal	O
PC	B-T091
involvement	O
at	O
the	O
end	B-T058
-	I-T058
of	I-T058
-	I-T058
life	I-T058
.	O

The	O
successful	O
integration	O
of	O
PC	B-T091
in	O
a	O
comprehensive	B-T058
cancer	B-T092
center	I-T092
,	O
and	O
the	O
resulting	O
potential	O
for	O
improved	O
care	O
provision	O
over	O
time	O
,	O
can	O
serve	O
as	O
a	O
model	B-T170
for	O
other	O
programs	O
on	O
a	O
broad	O
scale	O
.	O

PROTECTIVE	O
EFFECTS	O
OF	O
DIPEPTIDYL	B-T103
PEPTIDASE	I-T103
-	I-T103
4	I-T103
INHIBITORS	I-T103
ON	O
PROGRESSION	B-T038
OF	O
DIABETIC	B-T038
RETINOPATHY	I-T038
IN	O
PATIENTS	O
WITH	O
TYPE	B-T038
2	I-T038
DIABETES	I-T038

To	O
investigate	O
the	O
effects	O
of	O
dipeptidyl	B-T103
peptidase	I-T103
-	I-T103
4	I-T103
inhibitors	I-T103
(	O
DPP4	B-T103
)	O
on	O
the	O
progression	B-T038
of	O
diabetic	B-T038
retinopathy	I-T038
(	O
DR	B-T038
)	O
in	O
patients	O
with	O
Type	B-T038
2	I-T038
diabetes	I-T038
based	O
on	O
the	O
DR	B-T038
severity	O
scale	O
.	O

The	O
medical	B-T170
records	I-T170
of	O
82	O
patients	O
with	O
Type	B-T038
2	I-T038
diabetes	I-T038
enrolled	O
from	O
2005	O
to	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

Fundus	B-T058
photographs	I-T058
were	O
graded	B-T170
using	O
Early	B-T170
Treatment	I-T170
Diabetic	I-T170
Retinopathy	I-T170
Study	I-T170
methods	I-T170
.	O

The	O
associations	O
between	O
baseline	O
risk	B-T033
factors	I-T033
and	O
progression	B-T038
of	O
DR	B-T038
were	O
investigated	O
.	O

Seven	O
of	O
28	O
patients	O
treated	O
with	O
DPP4	B-T103
inhibitors	I-T103
and	O
26	O
of	O
54	O
treated	O
with	O
other	O
hypoglycemic	B-T103
agents	I-T103
showed	O
progression	B-T038
of	O
retinopathy	B-T038
,	O
defined	O
as	O
one	O
or	O
more	O
steps	O
on	O
the	O
Early	O
Treatment	O
Diabetic	O
Retinopathy	O
Study	O
scale	O
(	O
P	O
=	O
0	O
.	O
043	O
)	O
.	O

Only	O
treatment	O
with	O
DPP4	B-T103
inhibitors	I-T103
significantly	O
reduced	O
the	O
progression	B-T038
of	O
DR	B-T038
in	O
patients	O
after	O
propensity	O
score	O
matching	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O

Treatment	O
with	O
DPP4	B-T103
inhibitors	I-T103
was	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
DR	B-T038
progression	B-T038
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Treatment	O
with	O
DPP4	B-T103
inhibitors	I-T103
was	O
the	O
independent	O
protective	O
factor	O
against	O
the	O
progression	B-T038
of	O
DR	B-T038
,	O
aside	O
from	O
improving	B-T033
glycemic	I-T033
control	I-T033
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
the	O
benefits	O
of	O
DPP4	B-T103
inhibitors	I-T103
in	O
reducing	O
DR	B-T038
progression	B-T038
,	O
and	O
provides	O
encouraging	O
preliminary	O
data	O
for	O
further	O
evaluation	B-T058
of	O
DPP4	B-T103
inhibitors	I-T103
in	O
the	O
progression	B-T038
of	O
DR	B-T038
in	O
a	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

Production	O
of	O
Laccase	B-T103
by	O
Cochliobolus	B-T204
sp	I-T204
.	I-T204
Isolated	O
from	O
Plastic	O
Dumped	O
Soils	O
and	O
Their	O
Ability	O
to	O
Degrade	O
Low	B-T103
Molecular	I-T103
Weight	I-T103
PVC	I-T103

One	O
of	O
the	O
utmost	O
man	O
-	O
made	O
problems	O
faced	O
today	O
has	O
been	O
the	O
ever	O
-	O
increasing	O
plastic	O
waste	O
filling	O
the	O
world	O
.	O

It	O
accounts	O
for	O
an	O
estimated	O
20	O
-	O
30	O
%	O
(	O
by	O
volume	O
)	O
of	O
municipal	O
solid	O
waste	O
in	O
landfill	O
sites	O
worldwide	O
.	O

Research	O
on	O
plastic	O
biodegradation	O
has	O
been	O
steadily	O
growing	O
over	O
the	O
past	O
four	O
decades	O
.	O

Several	O
fungi	B-T204
have	O
been	O
identified	O
that	O
produce	O
enzymes	B-T103
capable	O
of	O
plastic	O
degradation	O
in	O
various	O
laboratory	O
conditions	O
.	O

This	O
paper	O
presents	O
a	O
study	O
that	O
determined	O
the	O
ability	O
of	O
fungi	B-T204
to	O
degrade	O
low	B-T103
molecular	I-T103
weight	I-T103
polyvinyl	I-T103
chloride	I-T103
(	O
PVC	B-T103
)	O
by	O
the	O
enzyme	B-T103
laccase	I-T103
.	O

We	O
have	O
isolated	O
a	O
fungal	B-T204
species	B-T170
,	O
Cochliobolus	B-T204
sp	I-T204
.	I-T204
,	O
from	O
plastic	O
dumped	O
soils	O
and	O
they	O
were	O
cultured	B-T058
on	O
Czapek	B-T103
Dox	I-T103
Agar	I-T103
slants	I-T103
at	O
30°C	O
.	O

The	O
effectiveness	O
of	O
this	O
fungal	B-T204
species	B-T170
on	O
the	O
degradation	O
of	O
commercial	O
low	B-T103
molecular	I-T103
weight	I-T103
polyvinyl	I-T103
chloride	I-T103
(	O
PVC	B-T103
)	O
was	O
studied	O
under	O
laboratory	O
conditions	O
.	O

Significant	O
differences	O
were	O
observed	O
from	O
the	O
FTIR	B-T062
,	O
GC	B-T058
-	I-T058
MS	I-T058
,	O
and	O
SEM	B-T058
results	O
in	O
between	O
control	O
and	O
Cochliobolus	B-T204
sp	I-T204
.	I-T204

treated	O
PVC	B-T103
.	O

Effects	O
of	O
Cerium	B-T103
and	O
Titanium	B-T103
Oxide	I-T103
Nanoparticles	O
in	O
Soil	O
on	O
the	O
Nutrient	B-T168
Composition	B-T201
of	O
Barley	B-T204
(	O
Hordeum	B-T204
vulgare	I-T204
L	I-T204
.	O
)	O
Kernels	B-T168

The	O
implications	O
of	O
metal	O
nanoparticles	O
(	O
MeNPs	O
)	O
are	O
still	O
unknown	O
for	O
many	O
food	B-T204
crops	I-T204
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
effects	O
of	O
cerium	B-T103
oxide	I-T103
(	O
nCeO₂	B-T103
)	O
and	O
titanium	B-T103
oxide	I-T103
(	O
nTiO₂	B-T103
)	O
nanoparticles	O
in	O
soil	O
at	O
0	O
,	O
500	O
and	O
1000	O
mg	O
·	O
kg	O
(	O
-	O
1	O
)	O
on	O
the	O
nutritional	O
parameters	O
of	O
barley	B-T204
(	O
Hordeum	B-T204
vulgare	I-T204
L	I-T204
.	I-T204
)	O
kernels	B-T168
.	O

Mineral	O
nutrients	O
,	O
amylose	B-T103
,	O
β	B-T103
-	I-T103
glucans	I-T103
,	O
amino	B-T103
acid	I-T103
and	O
crude	B-T103
protein	I-T103
(	O
CP	B-T103
)	O
concentrations	O
were	O
measured	O
in	O
kernels	B-T168
.	O

Whole	O
flour	B-T168
samples	O
were	O
analyzed	O
by	O
ICP	B-T058
-	I-T058
AES	I-T058
/	I-T058
MS	I-T058
,	O
HPLC	B-T058
and	O
Elemental	O
CHNS	O
Analyzer	O
.	O

Results	O
showed	O
that	O
Ce	B-T103
and	O
Ti	B-T103
accumulation	B-T033
under	O
MeNPs	O
treatments	O
did	O
not	O
differ	O
from	O
the	O
control	O
treatment	O
.	O

However	O
,	O
nCeO₂	B-T103
and	O
nTiO₂	B-T103
had	O
an	O
impact	O
on	O
composition	B-T201
and	O
nutritional	O
quality	O
of	O
barley	B-T204
kernels	B-T168
in	O
contrasting	O
ways	O
.	O

Both	O
MeNPs	O
left	O
β	B-T103
-	I-T103
glucans	I-T103
unaffected	O
but	O
reduced	O
amylose	B-T103
content	O
by	O
approximately	O
21	O
%	O
.	O

Most	O
amino	B-T103
acids	I-T103
and	O
CP	B-T103
increased	O
.	O

Among	O
amino	B-T103
acids	I-T103
,	O
lysine	B-T103
followed	O
by	O
proline	B-T103
saw	O
the	O
largest	O
increase	O
(	O
51	O
%	O
and	O
37	O
%	O
,	O
respectively	O
)	O
.	O

Potassium	B-T103
and	O
S	B-T103
were	O
both	O
negatively	O
impacted	O
by	O
MeNPs	O
,	O
while	O
B	O
was	O
only	O
affected	O
by	O
500	O
mg	O
nCeO₂	B-T103
·	O
kg	O
(	O
-	O
1	O
)	O
.	O

On	O
the	O
contrary	O
Zn	B-T058
and	O
Mn	B-T058
concentrations	I-T058
were	O
improved	O
by	O
500	O
mg	O
nTiO₂	B-T103
·	O
kg	O
(	O
-	O
1	O
)	O
,	O
and	O
Ca	O
by	O
both	O
nTiO₂	B-T103
treatments	O
.	O

Generally	O
,	O
our	O
findings	O
demonstrated	O
that	O
kernels	B-T168
are	O
negatively	B-T033
affected	I-T033
by	O
nCeO₂	B-T103
while	O
nTiO₂	B-T103
can	O
potentially	O
have	O
beneficial	O
effects	O
.	O

However	O
,	O
both	O
MeNPs	O
have	O
the	O
potential	O
to	O
negatively	O
impact	O
malt	B-T168
and	O
feed	O
production	O
.	O

Quantifying	O
Nonlinear	O
Contributions	O
to	O
Cortical	B-T058
Responses	I-T058
Evoked	I-T058
by	O
Continuous	B-T058
Wrist	I-T058
Manipulation	I-T058

Cortical	B-T058
responses	I-T058
to	O
continuous	B-T038
stimuli	I-T038
as	O
recorded	O
using	O
either	O
magneto	B-T058
-	I-T058
or	O
electroencephalography	B-T058
(	O
EEG	B-T058
)	O
have	O
shown	O
power	O
at	O
harmonics	O
of	O
the	O
stimulated	O
frequency	O
,	O
indicating	O
nonlinear	O
behavior	O
.	O

Even	O
though	O
the	O
selection	O
of	O
analysis	B-T062
techniques	O
depends	O
on	O
the	O
linearity	B-T082
of	O
the	O
system	O
under	O
study	O
,	O
the	O
importance	O
of	O
nonlinear	O
contributions	O
to	O
cortical	B-T058
responses	I-T058
has	O
not	O
been	O
formally	O
addressed	O
.	O

The	O
goal	B-T170
of	I-T170
this	I-T170
paper	I-T170
is	O
to	O
quantify	O
the	O
nonlinear	O
contributions	O
to	O
the	O
cortical	B-T058
response	I-T058
obtained	O
from	O
continuous	O
sensory	B-T058
stimulation	I-T058
.	O

EEG	B-T058
was	O
used	O
to	O
record	O
the	O
cortical	B-T058
response	I-T058
evoked	I-T058
by	O
continuous	B-T033
movement	I-T033
of	I-T033
the	I-T033
wrist	I-T033
joint	I-T033
of	O
healthy	O
subjects	O
applied	O
with	O
a	O
robotic	O
manipulator	O
.	O

Multisine	O
stimulus	O
signals	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
sum	O
of	O
several	O
sinusoids	B-T082
)	O
elicit	O
a	O
periodic	O
cortical	B-T058
response	I-T058
and	O
allow	O
to	O
assess	O
the	O
nonlinear	O
contributions	O
to	O
the	O
response	O
.	O

Wrist	B-T058
dynamics	I-T058
(	O
relation	O
between	O
joint	B-T082
angle	I-T082
and	O
torque	O
)	O
were	O
successfully	O
linearized	B-T082
,	O
explaining	O
99	O
%	O
of	O
the	O
response	O
.	O

In	O
contrast	O
,	O
the	O
cortical	B-T058
response	I-T058
revealed	O
a	O
highly	O
nonlinear	O
relation	O
;	O
where	O
most	O
power	O
(	O
∼	O
80	O
%	O
)	O
occurred	O
at	O
non	O
-	O
stimulated	O
frequencies	O
.	O

Moreover	O
,	O
only	O
10	O
%	O
of	O
the	O
response	O
could	O
be	O
explained	O
using	O
a	O
nonparametric	O
linear	O
model	O
.	O

These	O
results	O
indicate	O
that	O
the	O
recorded	O
evoked	B-T058
cortical	I-T058
responses	I-T058
are	O
governed	O
by	O
nonlinearities	O
and	O
that	O
linear	B-T082
methods	O
do	O
not	O
suffice	O
when	O
describing	O
the	O
relation	O
between	O
mechanical	O
stimulus	O
and	O
cortical	O
response	O
.	O

Using	O
melanopsin	B-T103
to	O
study	B-T062
G	B-T038
protein	I-T038
signaling	I-T038
in	O
cortical	B-T017
neurons	B-T017

Our	O
understanding	B-T038
of	O
G	B-T103
protein	I-T103
-	I-T103
coupled	I-T103
receptors	I-T103
(	O
GPCRs	B-T103
)	O
in	O
the	O
central	B-T022
nervous	I-T022
system	I-T022
(	O
CNS	B-T022
)	O
has	O
been	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
tools	O
allowing	O
for	O
the	O
study	B-T062
of	O
their	O
signaling	B-T038
with	O
precise	O
temporal	O
control	O
.	O

To	O
overcome	O
this	O
,	O
we	O
tested	O
the	O
utility	O
of	O
the	O
bistable	O
mammalian	B-T204
opsin	B-T103
melanopsin	B-T103
to	O
examine	O
G	B-T038
protein	I-T038
signaling	I-T038
in	O
CNS	B-T022
neurons	B-T017
.	O

Specifically	O
,	O
we	O
used	O
biolistic	B-T062
(	O
gene	O
gun	O
)	O
approaches	O
to	O
transfect	B-T103
melanopsin	I-T103
into	O
cortical	B-T017
pyramidal	B-T017
cells	I-T017
maintained	O
in	O
organotypic	B-T058
slice	I-T058
culture	I-T058
.	O

Whole	B-T062
cell	I-T062
recordings	I-T062
from	O
transfected	B-T017
neurons	I-T017
indicated	O
that	O
application	O
of	O
blue	O
light	O
effectively	O
activated	O
the	O
transfected	B-T103
melanopsin	I-T103
to	O
elicit	O
the	O
canonical	O
biphasic	O
modulation	O
of	O
membrane	B-T017
excitability	B-T033
previously	O
associated	O
with	O
the	O
activation	O
of	O
GPCRs	B-T103
coupling	O
to	O
Gαq	B-T103
-	I-T103
11	I-T103
Remarkably	O
,	O
full	O
mimicry	O
of	O
exogenous	O
agonist	B-T103
concentration	O
could	O
be	O
obtained	O
with	O
pulses	O
as	O
short	O
as	O
a	O
few	O
milliseconds	O
,	O
suggesting	O
that	O
their	O
triggering	O
required	O
a	O
single	O
melanopsin	B-T103
activation	O
-	O
deactivation	O
cycle	O
.	O

The	O
resulting	O
temporal	O
control	O
over	O
melanopsin	B-T103
activation	O
allowed	O
us	O
to	O
compare	O
the	O
activation	O
kinetics	O
of	O
different	O
components	O
of	O
the	O
electrophysiological	B-T038
response	O
.	O

We	O
also	O
replaced	O
the	O
intracellular	B-T082
loops	B-T082
of	O
melanopsin	B-T103
with	O
those	O
of	O
the	O
5	B-T103
-	I-T103
HT2A	I-T103
receptor	I-T103
to	O
create	O
a	O
light	O
-	O
activated	O
GPCR	B-T103
capable	O
of	O
interacting	O
with	O
the	O
5	B-T103
-	I-T103
HT2A	I-T103
receptor	I-T103
interacting	O
proteins	B-T103
.	O

The	O
resulting	O
chimera	B-T103
expressed	O
weak	O
activity	O
but	O
validated	B-T062
the	O
potential	O
usefulness	O
of	O
melanopsin	B-T103
as	O
a	O
tool	O
for	O
the	O
study	B-T062
of	O
G	B-T038
protein	I-T038
signaling	I-T038
in	O
CNS	B-T022
neurons	B-T017
.	O

Maternal	O
vitamin	B-T103
D	I-T103
levels	O
and	O
the	O
risk	O
of	O
perinatal	B-T038
death	I-T038

To	O
determine	O
the	O
association	O
between	O
maternal	O
vitamin	B-T103
D	I-T103
levels	O
and	O
perinatal	B-T038
death	I-T038
.	O

A	O
retrospective	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
of	O
all	O
non	O
-	O
anomalous	O
,	O
singleton	O
births	B-T038
(	O
≥24	O
weeks	O
)	O
with	O
perinatal	B-T038
death	I-T038
compared	O
to	O
a	O
matched	O
control	O
group	O
.	O

Only	O
pregnancies	B-T038
with	O
a	O
recorded	O
vitamin	B-T103
D	I-T103
level	O
at	O
booking	O
(	O
8	O
-	O
19	O
weeks	O
gestation	B-T038
)	O
were	O
included	O
for	O
analysis	B-T062
.	O

Maternal	O
vitamin	B-T103
D	I-T103
levels	O
were	O
categorized	O
into	O
normal	O
,	O
deficient	O
and	O
insufficient	O
cohorts	B-T098
and	O
variables	O
compared	O
between	O
the	O
three	O
groups	B-T098
.	O

There	O
were	O
31	O
perinatal	B-T038
deaths	I-T038
which	O
were	O
compared	O
to	O
111	O
controls	O
.	O

Median	O
vitamin	B-T103
D	I-T103
levels	O
were	O
lower	O
in	O
the	O
perinatal	B-T038
death	I-T038
cohort	B-T098
compared	O
to	O
the	O
control	O
group	O
(	O
55	O
nmol	O
/	O
L	O
versus	O
64	O
nmol	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
43	O
)	O
.	O

There	O
was	O
no	O
significant	O
increase	O
in	O
deaths	B-T038
between	O
the	O
normal	O
and	O
deficient	O
(	O
p	O
=	O
0	O
.	O
33	O
)	O
or	O
insufficient	O
(	O
p	O
=	O
0	O
.	O
09	O
)	O
groups	B-T098
.	O

Low	O
maternal	O
vitamin	B-T103
D	I-T103
levels	O
at	O
booking	O
were	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
perinatal	B-T038
demise	I-T038
.	O

Effect	O
of	O
constitutive	B-T038
inactivation	I-T038
of	O
the	O
myostatin	B-T017
gene	I-T017
on	O
the	O
gain	O
in	O
muscle	B-T038
strength	I-T038
during	O
postnatal	B-T038
growth	I-T038
in	O
two	O
murine	B-T204
models	B-T204

The	O
effect	O
of	O
constitutive	B-T038
inactivation	I-T038
of	O
the	O
gene	B-T017
encoding	I-T017
myostatin	I-T017
on	O
the	O
gain	O
in	O
muscle	B-T038
performance	I-T038
during	O
postnatal	B-T038
growth	I-T038
has	O
not	O
been	O
well	O
characterized	O
.	O

We	O
analyzed	O
2	O
murine	B-T204
myostatin	B-T017
knockout	O
(	O
KO	O
)	O
models	O
,	O
(	O
i	O
)	O
the	O
Lee	B-T204
model	I-T204
(	O
KO	B-T204
(	I-T204
Lee	I-T204
)	O
)	O
and	O
(	O
ii	O
)	O
the	O
Grobet	B-T204
model	I-T204
(	O
KO	B-T204
(	I-T204
Grobet	I-T204
)	I-T204
)	O
,	O
and	O
measured	O
the	O
contraction	B-T038
of	O
tibialis	B-T017
anterior	I-T017
muscle	I-T017
in	B-T082
situ	I-T082
.	O

Absolute	B-T038
maximal	I-T038
isometric	I-T038
force	I-T038
was	O
increased	O
in	O
6	O
-	O
month	O
-	O
old	O
KO	B-T204
(	I-T204
Lee	I-T204
)	I-T204
and	O
KO	B-T204
(	I-T204
Grobet	I-T204
)	I-T204
mice	I-T204
,	O
as	O
compared	O
to	O
wild	B-T204
-	I-T204
type	I-T204
mice	I-T204
.	O

Similarly	O
,	O
absolute	B-T038
maximal	I-T038
power	I-T038
was	O
increased	O
in	O
6	O
-	O
month	O
-	O
old	O
KO	B-T204
(	I-T204
Lee	I-T204
)	I-T204
mice	I-T204
.	O

In	O
contrast	O
,	O
specific	O
maximal	B-T038
force	I-T038
(	O
relative	O
maximal	B-T038
force	I-T038
per	O
unit	O
of	O
muscle	B-T017
mass	B-T033
was	O
decreased	O
in	O
all	O
6	O
-	O
month	O
-	O
old	O
male	O
and	O
female	O
KO	B-T204
mice	I-T204
,	O
except	O
in	O
6	O
-	O
month	O
-	O
old	O
female	O
KO	B-T204
(	I-T204
Grobet	I-T204
)	I-T204
mice	I-T204
,	O
whereas	O
specific	O
maximal	O
power	O
was	O
reduced	O
only	O
in	O
male	O
KO	B-T204
(	I-T204
Lee	I-T204
)	I-T204
mice	I-T204
.	O

Genetic	B-T038
inactivation	I-T038
of	O
myostatin	B-T017
increases	O
maximal	B-T038
force	I-T038
and	O
power	O
,	O
but	O
in	O
return	O
it	O
reduces	O
muscle	B-T017
quality	O
,	O
particularly	O
in	O
male	O
mice	B-T204
.	O

Muscle	O
Nerve	O
55	O
:	O
254	O
-	O
261	O
,	O
2017	O
.	O

Methylation	B-T038
status	O
of	O
the	O
promoter	B-T103
region	I-T103
of	O
the	O
human	B-T204
frizzled	B-T017
9	I-T017
gene	I-T017
in	O
acute	B-T038
myeloid	I-T038
leukemia	I-T038

The	O
FZD9	B-T017
gene	I-T017
is	O
located	O
at	O
chromosome	O
7q11	O
.	O
23	O
,	O
and	O
has	O
been	O
indicated	O
to	O
be	O
a	O
tumor	B-T017
suppressor	I-T017
gene	I-T017
.	O

The	O
present	O
study	B-T062
examined	B-T033
the	O
involvement	O
of	O
FZD9	B-T017
promoter	B-T103
methylation	B-T038
in	O
the	O
downregulation	B-T038
of	O
FZD9	B-T017
expression	B-T038
in	O
leukemia	B-T038
cells	B-T017
.	O

The	O
expression	B-T038
of	O
the	O
FZD9	B-T017
gene	I-T017
was	O
absent	O
in	O
various	O
leukemic	B-T038
cell	B-T017
lines	I-T017
,	O
while	O
it	O
was	O
restored	O
following	O
treatment	O
with	O
DNA	B-T103
demethylating	I-T103
agent	I-T103
5	B-T103
-	I-T103
aza	I-T103
-	I-T103
2	I-T103
'	I-T103
-	I-T103
deoxycytidine	I-T103
.	O

Bisulfite	B-T062
sequencing	I-T062
analysis	I-T062
of	O
the	O
FZD9	B-T017
promoter	B-T103
region	I-T103
showed	O
that	O
it	O
was	O
partially	O
methylated	B-T038
in	O
cell	B-T017
lines	I-T017
in	O
which	O
FZD9	B-T017
gene	I-T017
was	O
not	O
expressed	B-T038
.	O

Thus	O
,	O
DNA	B-T038
methylation	I-T038
in	O
the	O
promoter	B-T103
region	I-T103
may	O
lead	O
to	O
inactivation	O
of	O
the	O
FZD9	B-T017
gene	I-T017
,	O
which	O
may	O
represent	O
and	O
aberration	O
associated	O
with	O
leukemia	B-T038
,	O
since	O
DNA	B-T103
was	O
not	O
methylated	B-T038
in	O
normal	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
.	O

Methylation	B-T038
-	O
specific	O
polymerase	B-T062
chain	I-T062
reaction	I-T062
analysis	I-T062
revealed	O
that	O
the	O
promoter	B-T103
region	I-T103
of	O
the	O
FZD9	B-T017
gene	I-T017
was	O
frequently	O
methylated	B-T038
in	O
primary	O
or	O
relapse	O
acute	B-T038
myeloid	I-T038
leukemia	I-T038
(	O
52	O
.	O
9	O
%	O
;	O
excluding	O
acute	B-T038
promyelocytic	I-T038
leukemia	I-T038
)	O
;	O
however	O
,	O
methylation	B-T038
was	O
infrequent	O
in	O
B	B-T017
-	I-T017
cell	I-T017
acute	B-T038
lymphocytic	I-T038
leukemia	I-T038
(	O
5	O
.	O
6	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	B-T062
indicated	O
that	O
the	O
methylation	B-T038
profile	B-T058
of	O
the	O
FZD9	B-T017
gene	I-T017
corresponded	O
to	O
that	O
of	O
a	O
candidate	O
tumor	B-T017
-	I-T017
suppressor	I-T017
gene	I-T017
in	O
acute	B-T038
myeloid	I-T038
leukemia	I-T038
.	O

Identification	O
of	O
a	O
group	O
of	O
XTHs	B-T103
genes	B-T017
responding	O
to	O
heavy	B-T103
metal	I-T103
mercury	B-T103
,	O
salinity	O
and	O
drought	O
stresses	O
in	O
Medicago	B-T204
truncatula	I-T204

Xyloglucan	B-T103
endotransglucosylase	I-T103
/	I-T103
hydrolases	I-T103
(	O
XTH	B-T103
)	O
are	O
one	O
of	O
the	O
key	O
enzymes	B-T103
regulating	B-T038
cell	B-T038
wall	I-T038
construction	I-T038
,	O
extension	O
and	O
metabolism	O
.	O

In	O
the	O
study	B-T062
,	O
44	O
XTH	B-T103
protein	I-T103
genes	B-T017
from	O
Medicago	B-T204
truncatula	I-T204
genome	B-T017
were	O
identified	O
using	O
bioinformatics	B-T091
,	O
microarray	O
and	O
RT	B-T062
-	I-T062
PCR	I-T062
.	O

Each	O
XTH	B-T103
was	O
showed	O
to	O
possess	O
a	O
highly	B-T082
conserved	I-T082
domain	I-T082
(	O
(	O
D	O
/	O
N	O
)	O
-	O
E	O
-	O
(	O
I	O
/	O
L	O
/	O
F	O
/	O
V	O
)	O
-	O
D	O
-	O
(	O
F	O
/	O
I	O
/	O
L	O
)	O
-	O
E	O
-	O
(	O
F	O
/	O
L	O
)	O
-	O
L	O
-	O
G	O
)	O
,	O
and	O
most	O
of	O
XTHs	B-T103
possess	O
four	O
Cys	B-T103
in	O
the	O
C	B-T082
terminal	I-T082
region	I-T082
,	O
which	O
suggests	O
the	O
potential	O
for	O
generating	O
disulfide	B-T082
bonds	I-T082
.	O

Based	O
on	O
the	O
XTH	B-T103
protein	B-T082
sequences	I-T082
,	O
these	O
XTHs	B-T103
can	O
be	O
classified	O
into	O
three	O
major	O
families	B-T103
and	O
each	O
family	B-T103
can	O
be	O
subdivided	O
into	O
more	O
groups	O
.	O

Examination	O
of	O
the	O
genomic	B-T082
location	I-T082
of	O
XTH	B-T017
genes	I-T017
on	O
M	B-T204
.	I-T204

truncatula	I-T204
chromosomes	B-T017
showed	O
that	O
the	O
evolutional	B-T038
expansion	I-T038
of	O
the	O
genes	B-T017
was	O
possibly	O
attributed	O
to	O
localized	B-T082
gene	B-T038
duplications	I-T038
.	O

To	O
investigate	O
the	O
possible	O
involvement	O
of	O
the	O
XTHs	B-T103
responding	O
to	O
heavy	B-T103
metals	I-T103
and	O
other	O
abiotic	O
stresses	O
,	O
the	O
XTH	B-T017
genes	I-T017
were	O
exposed	O
to	O
heavy	B-T103
metal	I-T103
(	O
Hg	B-T103
or	O
Cu	B-T103
)	O
,	O
salt	O
and	O
drought	O
stresses	O
.	O

There	O
were	O
28	O
,	O
21	O
and	O
21	O
MtXTH	B-T017
genes	I-T017
found	O
to	O
respond	O
to	O
HgCl2	B-T103
,	O
salt	O
and	O
drought	O
stresses	O
,	O
respectively	O
,	O
but	O
their	O
expression	B-T038
were	O
different	O
under	O
the	O
stresses	O
.	O

Some	O
of	O
the	O
XTH	B-T017
genes	I-T017
were	O
well	O
confirmed	O
by	O
quantitative	O
RT	B-T062
-	I-T062
PCR	I-T062
(	O
qRT	B-T062
-	I-T062
PCR	I-T062
)	O
.	O

We	O
further	O
specified	O
expression	B-T038
of	O
a	O
XTH	B-T017
gene	I-T017
Medtr4g128580	B-T017
(	O
MtXTH3	B-T017
)	O
under	O
different	O
environmental	O
stresses	O
,	O
and	O
showed	O
that	O
MtXTH3	B-T017
was	O
induced	O
by	O
Hg	B-T103
exposure	O
.	O

These	O
results	O
indicated	O
that	O
a	O
group	O
of	O
MtXTHs	B-T017
could	O
be	O
differentially	O
expressed	B-T038
under	O
the	O
environmental	O
stresses	O
.	O

Vestibular	B-T038
disorders	I-T038
and	O
nausea	B-T033
during	O
head	B-T038
and	O
neck	B-T038
intensity	B-T058
-	I-T058
modulated	I-T058
radiation	I-T058
therapy	I-T058

We	O
studied	O
whether	O
there	O
is	O
a	O
relationship	O
between	O
nausea	B-T033
and	O
vestibular	B-T038
disorders	I-T038
in	O
patients	O
treated	B-T058
with	I-T058
intensity	B-T058
modulated	I-T058
radiation	I-T058
therapy	I-T058
(	O
IMRT	B-T058
)	O
for	O
head	B-T038
and	O
neck	B-T038
cancer	I-T038
.	O

We	O
performed	O
a	O
prospective	B-T062
single	I-T062
-	I-T062
centre	I-T062
study	I-T062
that	O
enrolled	B-T058
31	O
patients	O
.	O

A	O
videonystagmography	B-T058
was	O
carried	O
out	O
before	O
and	O
within	O
15	O
days	O
after	O
radiation	B-T058
therapy	I-T058
for	O
each	O
patient	O
.	O

Nausea	B-T033
was	O
assessed	O
at	O
baseline	O
,	O
every	O
week	O
,	O
and	O
at	O
the	O
post	B-T058
-	I-T058
radiotherapy	I-T058
videonystagmography	B-T058
visit	O
.	O

Twenty	O
-	O
six	O
patients	O
had	O
benefited	O
from	O
a	O
complete	O
interpretable	O
videonystagmography	B-T058
.	O

For	O
14	O
of	O
these	O
patients	O
vestibular	B-T033
damage	I-T033
was	O
diagnosed	B-T033
post	B-T058
-	I-T058
radiotherapy	I-T058
.	O

During	O
irradiation	O
,	O
six	O
patients	O
felt	O
nauseous	B-T033
,	O
but	O
without	O
dizziness	B-T033
.	O

In	O
univariate	O
analysis	O
,	O
we	O
found	O
a	O
relationship	O
statistically	O
significant	O
between	O
the	O
average	O
dose	O
received	O
by	O
the	O
vestibules	B-T082
and	O
vestibular	B-T038
disorder	I-T038
videonystagmography	B-T058
(	O
P	O
=	O
0	O
.	O
001	O
,	O
odds	O
ratio	O
[	O
OR	O
]	O
:	O
1	O
.	O
08	O
[	O
1	O
.	O
025	O
-	O
.	O
138	O
]	O
)	O
,	O
but	O
there	O
was	O
no	B-T033
relationship	O
between	O
vestibular	B-T038
disorder	I-T038
videonystagmography	B-T058
and	O
nausea	B-T033
(	O
P	O
=	O
0	O
.	O
701	O
)	O
.	O

Irradiation	O
of	O
the	O
vestibular	B-T022
system	I-T022
during	O
IMRT	B-T058
does	O
not	O
seem	O
to	O
explain	O
the	O
nausea	B-T033
.	O

Preventing	O
Youth	O
Internalizing	O
Symptoms	O
Through	O
the	O
Familias	O
Unidas	O
Intervention	O
:	O
Examining	O
Variation	O
in	O
Response	B-T201

Prevention	O
programs	O
that	O
strengthen	O
parenting	O
and	O
family	O
functioning	O
have	O
been	O
found	O
to	O
reduce	B-T058
poor	O
behavioral	O
outcomes	O
in	O
adolescents	O
,	O
including	O
substance	B-T038
use	I-T038
,	O
HIV	O
risk	O
,	O
externalizing	O
and	O
internalizing	O
problems	O
.	O

However	O
,	O
there	O
is	O
evidence	O
that	O
not	O
all	O
youth	O
benefit	O
similarly	O
from	O
these	O
programs	O
.	O

Familias	O
Unidas	O
is	O
a	O
family	O
-	O
focused	O
intervention	O
designed	O
to	O
prevent	O
substance	B-T038
use	I-T038
and	O
sexual	B-T033
risk	I-T033
among	O
Hispanic	B-T098
youth	O
and	O
has	O
recently	O
demonstrated	O
unanticipated	O
reductions	B-T058
in	O
internalizing	O
symptoms	O
for	O
some	O
youth	O
.	O

This	O
paper	O
examines	O
variation	O
in	O
intervention	O
response	O
for	O
internalizing	O
symptoms	O
using	O
individual	O
-	O
level	O
data	O
pooled	O
across	O
four	O
distinct	O
Familias	O
Unidas	O
trials	B-T062
:	O
(	O
1	O
)	O
266	O
eighth	B-T033
grade	I-T033
students	B-T098
recruited	O
from	O
the	O
general	O
school	B-T098
population	I-T098
;	O
(	O
2	O
)	O
160	O
ninth	B-T033
grade	I-T033
students	B-T098
from	O
the	O
general	O
school	B-T098
population	I-T098
;	O
(	O
3	O
)	O
213	O
adolescents	O
with	O
conduct	B-T038
,	O
aggression	O
,	O
and	O
/	O
or	O
attention	O
problems	O
;	O
and	O
(	O
4	O
)	O
242	O
adolescents	O
with	O
a	O
delinquency	B-T038
history	O
.	O

Causal	O
inference	O
growth	O
mixture	O
modeling	O
suggests	O
a	O
three	O
-	O
class	B-T170
model	B-T170
.	O

The	O
two	O
largest	O
classes	B-T170
represent	O
youth	O
with	O
low	O
(	O
60	O
%	O
)	O
and	O
medium	O
(	O
27	O
%	O
)	O
internalizing	O
symptoms	O
at	O
baseline	O
,	O
and	O
both	O
intervention	O
and	O
control	O
participants	B-T098
show	O
reductions	B-T058
in	O
internalizing	O
symptoms	O
.	O

The	O
third	O
class	B-T170
(	O
13	O
%	O
)	O
represents	O
youth	O
with	O
high	O
levels	O
of	O
baseline	O
internalizing	O
symptoms	O
who	O
remain	O
at	O
steady	O
levels	O
of	O
internalizing	O
symptoms	O
when	O
exposed	O
to	O
the	O
intervention	O
,	O
but	O
who	O
experience	O
an	O
increase	O
in	O
symptoms	O
under	O
the	O
control	O
condition	O
.	O

Female	O
gender	O
,	O
low	O
baseline	O
levels	O
of	O
parent	O
-	O
adolescent	O
communication	O
,	O
and	O
older	B-T098
age	I-T098
were	O
associated	O
with	O
membership	O
in	O
the	O
high	B-T033
-	I-T033
risk	I-T033
class	B-T170
.	O

These	O
synthesis	O
analyses	O
involving	O
a	O
large	O
sample	O
of	O
youth	O
with	O
varying	O
initial	O
risk	O
levels	O
represent	O
a	O
further	O
step	O
toward	O
strengthening	O
our	O
knowledge	O
of	O
preventive	O
intervention	O
response	B-T201
and	O
improving	O
preventive	O
interventions	O
.	O

Acute	B-T037
Kidney	I-T037
Injury	I-T037
Severity	O
and	O
Long	O
-	O
Term	O
Readmission	B-T058
and	O
Mortality	O
After	O
Cardiac	B-T058
Surgery	I-T058

Acute	B-T037
kidney	I-T037
injury	I-T037
(	O
AKI	B-T037
)	O
is	O
a	O
common	O
complication	B-T038
after	O
cardiac	B-T058
surgery	I-T058
.	O

While	O
AKI	B-T037
severity	O
is	O
known	O
to	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
short	O
-	O
term	O
outcomes	O
,	O
its	O
long	O
-	O
term	O
impact	O
is	O
less	O
well	O
understood	O
.	O

Adult	O
patients	O
undergoing	O
isolated	O
coronary	B-T058
artery	I-T058
bypass	I-T058
graft	I-T058
surgery	I-T058
at	O
eight	O
centers	O
were	O
enrolled	O
into	O
the	O
Northern	B-T170
New	I-T170
England	I-T170
biomarker	I-T170
registry	I-T170
(	O
n	O
=	O
1	O
,	O
610	O
)	O
.	O

Patients	O
were	O
excluded	O
if	O
they	O
had	O
renal	B-T038
failure	I-T038
(	O
n	O
=	O
15	O
)	O
or	O
died	B-T033
during	O
index	B-T058
admission	I-T058
(	O
n	O
=	O
38	O
)	O
.	O

Severity	O
of	O
AKI	B-T037
was	O
defined	O
using	O
the	O
Acute	B-T170
Kidney	I-T170
Injury	I-T170
Network	I-T170
(	O
AKIN	B-T170
)	O
.	O

We	O
linked	O
our	O
cohort	O
to	O
national	O
Medicare	O
and	O
state	B-T170
all	I-T170
-	I-T170
payer	I-T170
claims	I-T170
to	O
ascertain	O
readmissions	B-T058
and	O
to	O
the	O
National	B-T170
Death	I-T170
Index	I-T170
to	O
ascertain	O
survival	O
.	O

Kaplan	O
-	O
Meier	O
and	O
multivariate	B-T170
Cox	I-T170
proportional	I-T170
hazards	I-T170
modeling	I-T170
was	O
conducted	O
for	O
time	O
to	O
readmission	B-T058
and	O
death	B-T033
over	O
5	O
years	O
.	O

Within	O
5	O
years	O
,	O
513	O
patients	O
(	O
33	O
.	O
8	O
%	O
)	O
had	O
AKI	B-T037
with	O
AKIN	B-T170
stage	O
1	O
(	O
29	O
.	O
9	O
%	O
)	O
and	O
stage	O
2	O
to	O
3	O
(	O
3	O
.	O
9	O
%	O
)	O
.	O

There	O
were	O
620	O
readmissions	B-T058
(	O
39	O
.	O
9	O
%	O
)	O
and	O
370	O
deaths	B-T033
(	O
23	O
.	O
8	O
%	O
)	O
.	O

After	O
adjustment	O
,	O
stage	O
1	O
AKI	B-T037
patients	O
had	O
a	O
31	O
%	O
increased	O
risk	O
of	O
readmission	B-T058
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1	O
.	O
10	O
to	O
1	O
.	O
57	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	O
had	O
a	O
98	O
%	O
increased	O
risk	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
41	O
to	O
2	O
.	O
78	O
)	O
compared	O
with	O
patients	O
having	O
no	B-T033
AKI	B-T037
.	O

Relative	O
to	O
patients	O
without	O
AKI	B-T037
,	O
stage	O
1	O
patients	O
had	O
a	O
56	O
%	O
increased	O
risk	O
of	O
mortality	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
14	O
to	O
2	O
.	O
13	O
)	O
,	O
whereas	O
stage	O
2	O
or	O
3	O
patients	O
had	O
a	O
3	O
.	O
5	O
times	O
higher	O
risk	O
(	O
95	O
%	O
CI	O
:	O
2	O
.	O
16	O
to	O
5	O
.	O
60	O
)	O
.	O

Severity	O
of	O
AKI	B-T037
using	O
the	O
AKIN	B-T170
stage	O
criteria	O
is	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
5	O
-	O
year	O
readmission	B-T058
and	O
mortality	O
.	O

Our	O
findings	O
suggest	O
that	O
efforts	O
to	O
reduce	O
AKI	B-T037
in	O
the	O
perioperative	O
period	O
may	O
have	O
a	O
significant	O
long	O
-	O
term	O
impact	O
on	O
patients	O
and	O
payers	O
in	O
reducing	O
mortality	O
and	O
health	B-T058
care	I-T058
utilization	I-T058
.	O

Association	O
of	O
abdominal	B-T017
fat	I-T017
with	O
serum	B-T031
amylase	B-T103
in	O
an	O
older	B-T098
cohort	B-T098
:	O
The	O
Baltimore	B-T082
Longitudinal	B-T062
Study	I-T062
of	O
Aging	B-T038

Abdominal	B-T017
fat	I-T017
is	O
a	O
major	O
determinant	O
of	O
metabolic	B-T038
diseases	I-T038
in	O
older	B-T098
individuals	B-T098
.	O

Obesity	B-T038
and	O
diabetes	B-T038
are	O
associated	O
with	O
low	O
serum	B-T033
amylase	I-T033
(	I-T033
SA	I-T033
)	I-T033
levels	I-T033
,	O
but	O
the	O
association	O
between	O
SA	B-T033
and	O
metabolic	B-T038
disease	I-T038
is	O
poorly	O
understood	O
.	O

We	O
investigated	O
the	O
association	O
of	O
low	O
SA	B-T033
with	O
diabetes	B-T038
and	O
sex	O
-	O
specific	O
associations	O
of	O
serum	B-T031
amylase	B-T103
with	O
abdominal	B-T017
fat	I-T017
in	O
older	O
adults	O
.	O

In	O
community	O
-	O
dwelling	O
volunteers	B-T098
from	O
the	O
Baltimore	B-T082
Longitudinal	B-T062
Study	I-T062
of	O
Aging	B-T038
(	O
778	O
participants	B-T098
,	O
age	O
66	O
.	O
8±13	O
.	O
6	O
years	O
)	O
,	O
we	O
assessed	O
abdominal	B-T017
fat	I-T017
by	O
computed	B-T058
tomography	I-T058
and	O
diabetes	O
status	O
using	O
the	O
American	B-T092
Diabetes	I-T092
Association	I-T092
criteria	O
.	O

Linear	O
regression	O
analyses	O
assessed	O
the	O
cross	O
-	O
sectional	O
associations	O
between	O
abdominal	B-T017
fat	I-T017
and	O
SA	B-T033
,	O
and	O
logistic	B-T062
regression	I-T062
assessed	O
the	O
odds	O
of	O
diabetes	B-T038
,	O
given	O
low	O
SA	B-T033
.	O

In	O
unadjusted	B-T062
analyses	I-T062
,	O
individuals	B-T098
in	O
the	O
lowest	O
SA	B-T033
quartile	O
(	O
<	O
48μ	O
/	O
L	O
)	O
had	O
1	O
.	O
97	O
greater	O
odds	O
of	O
diabetes	B-T038
,	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
01	O
-	O
3	O
.	O
83	O
)	O
than	O
those	O
in	O
the	O
highest	O
quartile	O
(	O
⩾80μ	O
/	O
L	O
)	O
.	O

This	O
association	O
was	O
no	O
longer	O
significant	O
after	O
adjusting	O
for	O
visceral	B-T017
adipose	I-T017
tissue	I-T017
area	I-T017
(	O
VAT	B-T017
,	O
dm	O
(	O
2	O
)	O
)	O
,	O
abdominal	B-T017
subcutaneous	I-T017
adipose	I-T017
tissue	I-T017
(	O
SAT	B-T017
,	O
dm	O
(	O
2	O
)	O
)	O
or	O
BMI	B-T201
.	O

In	O
adjusted	B-T062
analyses	I-T062
,	O
VAT	B-T017
and	O
SAT	B-T017
were	O
significantly	O
associated	O
with	O
SA	B-T033
in	O
both	O
sexes	O
.	O

Among	O
women	B-T098
,	O
SA	B-T033
was	O
more	O
strongly	O
associated	O
with	O
VAT	B-T017
than	O
with	O
SAT	B-T017
or	O
BMI	B-T201
;	O
VAT	B-T017
(	O
β	O
=	O
-	O
0	O
.	O
117±0	O
.	O
048	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
SAT	B-T017
(	O
β	O
=	O
-	O
0	O
.	O
023±0	O
.	O
025	O
,	O
P	O
=	O
0	O
.	O
346	O
)	O
and	O
BMI	B-T201
(	O
β	O
=	O
-	O
0	O
.	O
0052±0	O
.	O
075	O
,	O
P	O
=	O
0	O
.	O
49	O
)	O
.	O

The	O
association	O
between	O
SA	B-T103
and	O
diabetes	B-T038
was	O
explained	O
mainly	O
by	O
abdominal	B-T017
visceral	I-T017
fat	I-T017
.	O

In	O
women	B-T098
,	O
SA	B-T103
was	O
more	O
strongly	O
associated	O
with	O
VAT	B-T017
than	O
with	O
BMI	B-T201
or	O
SAT	B-T017
.	O

These	O
findings	O
provide	O
motivation	O
for	O
future	O
mechanistic	B-T170
studies	I-T170
on	O
SA	B-T103
'	I-T103
s	I-T103
role	O
in	O
metabolic	B-T038
diseases	I-T038
.	O

Efficacy	O
of	O
Intravenous	B-T082
Chlorothiazide	B-T103
for	O
Refractory	O
Acute	B-T038
Decompensated	I-T038
Heart	I-T038
Failure	I-T038
Unresponsive	O
to	O
Adjunct	O
Metolazone	B-T103

To	O
assess	O
the	O
efficacy	O
of	O
intravenous	B-T082
chlorothiazide	B-T103
in	O
patients	O
with	O
acute	B-T038
decompensated	I-T038
heart	I-T038
failure	I-T038
(	O
ADHF	B-T038
)	O
who	O
were	O
determined	O
to	O
be	O
loop	B-T103
diuretic	I-T103
resistant	O
and	O
refractory	O
to	O
metolazone	B-T103
.	O

Retrospective	B-T062
cohort	I-T062
study	I-T062
with	O
patients	O
serving	O
as	O
their	O
own	O
controls	O
.	O

Large	O
,	O
academic	B-T092
,	O
tertiary	B-T092
care	I-T092
hospital	I-T092
.	O

Forty	O
-	O
five	O
patients	O
with	O
ADHF	B-T038
who	O
had	O
an	O
inadequate	O
response	O
to	O
high	O
-	O
dose	O
loop	B-T103
diuretics	I-T103
and	O
then	O
received	O
at	O
least	O
one	O
dose	O
of	O
oral	B-T082
metolazone	B-T103
5	O
mg	O
or	O
greater	O
(	O
metolazone	B-T103
index	O
dose	O
)	O
followed	O
by	O
at	O
least	O
one	O
dose	O
of	O
intravenous	B-T082
chlorothiazide	B-T103
500	O
mg	O
(	O
chlorothiazide	B-T103
index	O
dose	O
)	O
if	O
the	O
response	O
to	O
metolazone	B-T103
was	O
considered	O
inadequate	O
,	O
according	O
to	O
the	O
institutional	B-T170
protocol	I-T170
,	O
between	O
February	O
4	O
,	O
2013	O
,	O
and	O
February	O
28	O
,	O
2015	O
,	O
were	O
included	O
.	O

If	O
multiple	O
doses	O
of	O
metolazone	B-T103
were	O
administered	B-T058
,	O
the	O
last	O
dose	O
given	O
before	O
the	O
chlorothiazide	B-T103
index	O
dose	O
was	O
considered	O
the	O
index	O
dose	O
;	O
the	O
metolazone	B-T103
index	O
dose	O
had	O
to	O
have	O
been	O
administered	B-T058
more	O
than	O
2	O
hours	O
before	O
the	O
chlorothiazide	B-T103
index	O
dose	O
.	O

Data	O
for	O
a	O
total	O
of	O
90	O
diuretic	B-T103
doses	O
(	O
45	O
metolazone	B-T103
,	O
45	O
chlorothiazide	B-T103
)	O
were	O
included	O
in	O
the	O
analysis	B-T062
.	O

The	O
median	O
dose	O
of	O
loop	B-T103
diuretic	I-T103
in	O
intravenous	B-T082
furosemide	B-T103
equivalents	O
given	O
over	O
the	O
24	O
-	O
hour	O
period	O
before	O
the	O
metolazone	B-T103
index	O
dose	O
was	O
400	O
mg	O
.	O

The	O
average	O
length	O
of	O
stay	O
was	O
34	O
.	O
7	O
days	O
,	O
and	O
in	O
-	O
hospital	O
mortality	O
was	O
35	O
.	O
6	O
%	O
(	O
16	O
/	O
45	O
patients	O
)	O
.	O

The	O
primary	O
end	O
point	O
of	O
a	O
net	B-T033
-	I-T033
negative	I-T033
urine	B-T201
output	I-T201
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	O
after	O
the	O
index	O
dose	O
occurred	O
in	O
42	O
.	O
2	O
%	O
(	O
19	O
/	O
45	O
patients	O
)	O
and	O
35	O
.	O
5	O
%	O
(	O
16	O
/	O
45	O
patients	O
)	O
for	O
the	O
chlorothiazide	B-T103
and	O
metolazone	B-T103
doses	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
581	O
)	O
.	O

The	O
median	O
12	O
-	O
hour	O
urine	B-T201
output	I-T201
following	O
administration	O
of	O
metolazone	B-T103
was	O
810	O
ml	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
866	O
ml	O
)	O
versus	O
1075	O
ml	O
(	O
IQR	O
940	O
ml	O
)	O
following	O
administration	O
of	O
chlorothiazide	B-T103
(	O
p	O
=	O
0	O
.	O
363	O
)	O
.	O

Compared	O
with	O
metolazone	B-T103
,	O
the	O
chlorothiazide	B-T103
doses	O
did	O
not	O
result	O
in	O
an	O
increase	O
in	O
urine	B-T201
output	I-T201
of	O
at	O
least	O
500	O
ml	O
during	O
the	O
12	O
hours	O
following	O
the	O
dose	O
relative	O
to	O
the	O
12	O
hours	O
before	O
the	O
dose	O
(	O
31	O
.	O
1	O
%	O
vs	O
22	O
.	O
2	O
%	O
,	O
p	O
=	O
0	O
.	O
754	O
)	O
.	O

No	O
significant	O
difference	O
in	O
achievement	O
of	O
net	B-T033
-	I-T033
negative	I-T033
urine	B-T201
output	I-T201
of	O
500	O
ml	O
or	O
greater	O
during	O
the	O
12	O
hours	O
following	O
the	O
chlorothiazide	B-T103
or	O
metolazone	B-T103
dose	O
was	O
noted	O
(	O
42	O
.	O
2	O
%	O
for	O
chlorothiazide	B-T103
vs	O
35	O
.	O
5	O
%	O
for	O
metolazone	B-T103
,	O
p	O
=	O
0	O
.	O
581	O
)	O
.	O

The	O
addition	O
of	O
intravenous	B-T082
chlorothiazide	B-T103
did	O
not	O
result	O
in	O
improved	B-T033
diuresis	B-T038
in	O
patients	O
with	O
ADHF	B-T038
determined	O
to	O
be	O
refractory	O
to	O
loop	B-T103
diuretic	I-T103
s	O
and	O
adjunctive	O
oral	B-T082
metolazone	B-T103
.	O

Comparisons	O
of	O
Safety	O
and	O
Clinical	O
Outcomes	O
Between	O
Multiple	B-T058
-	I-T058
level	I-T058
and	O
Single	B-T058
-	I-T058
level	I-T058
Cervical	I-T058
Disk	I-T058
Replacement	I-T058
for	O
Cervical	B-T038
Spondylosis	I-T038
:	O
A	O
Systematic	B-T170
Review	I-T170
and	O
Meta	B-T170
-	I-T170
analysis	I-T170

This	O
is	O
a	O
systematic	B-T170
review	I-T170
and	O
meta	B-T170
-	I-T170
analysis	I-T170
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
multiple	B-T058
-	I-T058
level	I-T058
cervical	I-T058
disk	I-T058
replacement	I-T058
(	O
CDR	B-T058
)	O
over	O
single	B-T058
-	I-T058
level	I-T058
CDR	I-T058
for	O
the	O
treatment	B-T058
of	O
cervical	B-T038
spondylosis	I-T038
.	O

Some	O
authors	O
advocate	O
for	O
the	O
multiple	B-T058
-	I-T058
level	I-T058
CDR	I-T058
instead	O
of	O
anterior	B-T082
decompression	B-T058
and	O
fusion	B-T058
in	O
cervical	B-T038
multiple	I-T038
-	I-T038
level	I-T038
spondylosis	I-T038
.	O

However	O
,	O
whether	O
the	O
efficacy	O
and	O
safety	O
of	O
multi	B-T058
-	I-T058
level	I-T058
CDR	I-T058
are	O
as	O
favorable	O
as	O
that	O
of	O
single	B-T058
-	I-T058
level	I-T058
CDR	I-T058
remains	O
controversial	O
.	O

MEDLINE	B-T170
,	O
EMBASE	B-T170
,	O
and	O
Cochrane	B-T170
library	I-T170
databases	I-T170
were	O
searched	O
up	O
to	O
November	O
2015	O
for	O
controlled	B-T062
studies	I-T062
that	O
compared	O
the	O
clinical	O
outcomes	O
of	O
single	B-T058
-	I-T058
level	I-T058
and	O
multiple	B-T058
-	I-T058
level	I-T058
CDR	I-T058
for	O
the	O
treatment	B-T058
of	O
cervical	B-T038
spondylosis	I-T038
.	O

The	O
following	O
outcomes	O
were	O
extracted	O
and	O
analyzed	B-T062
:	O
prevalence	O
of	O
heterotopic	B-T038
ossification	I-T038
and	O
reoperation	B-T058
,	O
preoperative	O
and	O
postoperative	O
Neck	B-T033
Disability	I-T033
Index	I-T033
scores	I-T033
,	O
preoperative	O
and	O
postoperative	O
Visual	B-T201
Analog	I-T201
Scale	I-T201
scores	I-T201
,	O
and	O
success	O
rate	O
using	O
the	O
Odom	B-T170
grading	I-T170
system	I-T170
.	O

Ten	O
studies	B-T062
involving	O
1402	O
patients	O
were	O
included	O
:	O
including	O
3	O
randomized	B-T062
controlled	I-T062
trials	I-T062
,	O
5	O
prospective	B-T062
studies	I-T062
,	O
and	O
3	O
retrospective	B-T062
studies	I-T062
.	O

No	O
significant	O
differences	O
between	O
single	B-T058
-	I-T058
level	I-T058
and	O
multiple	B-T058
-	I-T058
level	I-T058
groups	O
were	O
found	O
in	O
terms	O
of	O
the	O
prevalence	O
of	O
heterotopic	B-T038
ossification	I-T038
and	O
reoperation	B-T058
rate	O
,	O
Neck	B-T033
Disability	I-T033
Index	I-T033
score	I-T033
,	O
Visual	B-T201
Analog	I-T201
Scale	I-T201
score	I-T201
,	O
and	O
success	O
rate	O
using	O
the	O
Odom	B-T170
grading	I-T170
system	I-T170
.	O

On	O
the	O
basis	O
of	O
this	O
meta	B-T170
-	I-T170
analysis	I-T170
,	O
clinical	O
outcomes	O
of	O
multiple	B-T058
-	I-T058
level	I-T058
CDR	I-T058
are	O
similar	O
to	O
those	O
of	O
single	B-T058
-	I-T058
level	I-T058
CDR	I-T058
for	O
cervical	B-T038
spondylosis	I-T038
,	O
which	O
suggests	O
the	O
multiple	B-T058
-	I-T058
level	I-T058
CDR	I-T058
is	O
as	O
effective	O
and	O
safe	O
as	O
the	O
single	B-T058
-	I-T058
level	I-T058
CDR	I-T058
.	O

Nonetheless	O
,	O
more	O
well	O
-	O
designed	O
studies	B-T062
are	O
needed	O
for	O
further	O
evaluation	B-T062
.	O

Evaluation	B-T058
of	O
the	O
Effects	O
of	O
Intravenous	B-T082
and	O
Percutaneous	B-T082
Low	B-T058
Level	I-T058
Laser	I-T058
Therapy	I-T058
in	O
the	O
Management	B-T058
of	O
Shoulder	B-T082
Myofascial	B-T038
Pain	I-T038
Syndrome	I-T038

Myofascial	B-T038
pain	I-T038
syndrome	I-T038
(	O
MPS	B-T038
)	O
treatment	B-T058
is	O
challenging	O
with	O
a	O
high	O
recurrence	O
rate	O
and	O
still	O
lacks	O
a	O
clear	O
treatment	B-T058
frame	I-T058
.	O

Therefore	O
research	O
on	O
new	O
,	O
more	O
efficient	O
and	O
long	O
lasting	O
effect	O
treatment	B-T058
modalities	O
is	O
necessary	O
.	O

This	O
study	O
looked	O
at	O
the	O
effects	O
of	O
intravenous	B-T082
laser	B-T058
therapy	I-T058
(	O
IVL	B-T058
)	O
and	O
percutaneous	B-T082
low	B-T058
level	I-T058
laser	I-T058
(	O
PLLL	B-T058
)	O
in	O
the	O
management	B-T058
of	O
shoulder	B-T082
MPS	B-T038
.	O

In	O
this	O
randomized	B-T062
controlled	I-T062
trial	I-T062
,	O
30	O
patients	O
fulfilling	O
inclusion	O
criteria	O
were	O
randomly	O
equally	O
allocated	O
to	O
3	O
groups	O
,	O
control	O
,	O
IVL	B-T098
and	O
PLLL	B-T098
.	O

Control	O
group	O
received	O
12	O
sessions	O
of	O
placebo	B-T062
low	B-T058
level	I-T058
laser	I-T058
,	O
IVL	B-T098
group	I-T098
received	O
12	O
sessions	O
of	O
IVL	B-T058
therapy	I-T058
,	O
and	O
PLLL	B-T098
group	I-T098
received	O
12	O
sessions	O
of	O
PLLL	B-T058
therapy	I-T058
.	O

All	O
patients	O
were	O
trained	O
for	O
better	O
body	O
posture	O
,	O
body	O
mechanics	O
,	O
gentle	B-T058
massage	I-T058
of	O
trigger	B-T082
points	I-T082
,	O
stretching	B-T058
exercises	I-T058
of	O
affected	O
muscle	B-T017
(	O
trapezius	B-T017
)	O
,	O
and	O
received	O
10	O
mg	O
of	O
oral	B-T082
nortriptyline	B-T103
regimen	B-T058
every	O
night	O
for	O
3	O
months	O
.	O

Outcomes	O
included	O
pain	O
severity	O
,	O
functional	O
disability	O
,	O
and	O
quality	O
of	O
life	O
.	O

Patients	O
were	O
assessed	O
using	O
Numeric	B-T170
Rating	I-T170
Scale	I-T170
(	O
NRS	B-T170
)	O
,	O
Pain	B-T170
Disability	I-T170
Index	I-T170
(	O
PDI	B-T170
)	O
,	O
and	O
Short	B-T170
Form	I-T170
Health	I-T170
Survey	I-T170
(	O
SF	B-T170
-	I-T170
12	I-T170
)	O
.	O

Data	B-T033
collected	I-T033
were	O
analyzed	B-T062
using	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
Mann	B-T170
-	I-T170
Whitney	I-T170
and	O
t	B-T170
tests	I-T170
.	O

The	O
mean	O
of	O
PDI	B-T170
and	O
maximum	O
pain	B-T201
intensity	I-T201
during	O
day	O
and	O
night	O
significantly	O
reduced	O
in	O
both	O
PLLL	B-T098
and	O
IVL	B-T098
groups	I-T098
compared	O
to	O
control	O
group	O
.	O

Although	O
pain	O
severity	O
and	O
PDI	B-T170
reduction	O
was	O
more	O
pronounced	O
in	O
IVL	B-T098
group	I-T098
compared	O
to	O
PLLL	B-T098
group	I-T098
,	O
the	O
differences	O
were	O
not	O
statistically	O
significant	O
.	O

Also	O
,	O
quality	O
of	O
life	O
statistically	O
significantly	O
improved	O
in	O
both	O
IVL	B-T098
and	O
PLLL	B-T098
groups	I-T098
compared	O
to	O
control	O
group	O
was	O
more	O
,	O
and	O
although	O
higher	O
in	O
IVL	B-T098
group	I-T098
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
when	O
compared	O
to	O
PLLL	B-T098
group	I-T098
.	O

No	B-T033
side	I-T033
effects	I-T033
were	O
observed	O
in	O
the	O
intervention	B-T098
groups	I-T098
.	O

Intravenous	B-T082
laser	B-T058
and	O
PLLL	B-T058
therapy	I-T058
had	O
a	O
positive	O
effect	O
on	O
pain	O
severity	O
and	O
PDI	B-T170
reduction	O
,	O
and	O
quality	O
of	O
life	O
in	O
this	O
study	O
.	O

Also	O
no	B-T033
adverse	I-T033
event	I-T033
was	O
recorded	O
.	O

Thus	O
,	O
intravenous	B-T082
lasers	B-T058
and	O
PLLL	B-T058
therapy	I-T058
seem	O
to	O
be	O
effective	O
complementary	O
modalities	O
in	O
managing	B-T058
patients	O
with	O
shoulder	B-T082
MPS	B-T038
.	O

Structural	B-T082
Insights	B-T038
into	O
5	B-T103
-	I-T103
HT1A	I-T103
/	O
D4	B-T103
Selectivity	O
of	O
WAY	B-T103
-	I-T103
100635	I-T103
Analogues	B-T103
:	O
Molecular	B-T062
Modeling	I-T062
,	O
Synthesis	O
,	O
and	O
in	O
Vitro	O
Binding	B-T038

The	O
resurgence	O
of	O
interest	O
in	O
5	B-T103
-	I-T103
HT1A	I-T103
receptors	I-T103
as	O
a	O
therapeutic	O
target	O
requires	O
the	O
existence	O
of	O
highly	O
selective	O
5	B-T103
-	I-T103
HT1A	I-T103
ligands	B-T103
.	O

To	O
date	O
,	O
WAY	B-T103
-	I-T103
100635	I-T103
has	O
been	O
the	O
prototypical	B-T103
antagonist	I-T103
of	O
these	O
receptors	B-T103
.	O

However	O
,	O
this	O
compound	O
also	O
has	O
significant	O
affinity	O
for	O
and	O
activity	O
at	O
D4	B-T103
dopamine	I-T103
receptors	I-T103
.	O

In	O
this	O
context	O
,	O
this	O
work	O
was	O
aimed	O
at	O
better	O
understanding	O
the	O
5	B-T103
-	I-T103
HT1A	I-T103
/	O
D4	B-T103
selectivity	O
of	O
WAY	B-T103
-	I-T103
100635	I-T103
and	O
analogues	B-T103
from	O
a	O
structural	B-T082
point	O
of	O
view	O
.	O

In	O
silico	O
investigations	O
revealed	O
two	O
key	O
interactions	O
for	O
the	O
5	B-T103
-	I-T103
HT1A	I-T103
/	O
D4	B-T103
selectivity	O
of	O
WAY	B-T103
-	I-T103
100635	I-T103
and	O
analogues	B-T103
.	O

First	O
,	O
a	O
hydrogen	O
bond	O
only	O
found	O
with	O
the	O
Ser	B-T103
7	I-T103
.	I-T103
36	I-T103
of	O
D4	B-T103
receptor	I-T103
appeared	O
to	O
be	O
the	O
key	O
for	O
a	O
higher	O
D4	B-T103
affinity	O
for	O
newly	O
synthesized	O
aza	B-T103
analogues	B-T103
.	O

The	O
role	O
of	O
Ser	B-T103
7	I-T103
.	I-T103
36	I-T103
was	O
confirmed	O
as	O
the	O
affinity	O
of	O
aza	B-T103
analogues	B-T103
for	O
the	O
mutant	B-T038
D4	B-T103
receptor	I-T103
S7	I-T103
.	I-T103
36A	I-T103
was	O
reduced	O
.	O

Then	O
,	O
the	O
formation	O
of	O
another	O
hydrogen	O
bond	O
with	O
the	O
conserved	O
Ser	B-T103
5	I-T103
.	I-T103
42	I-T103
residue	I-T103
appeared	O
to	O
be	O
also	O
critical	O
for	O
D4	B-T103
binding	B-T038
.	O

Genomic	B-T058
analysis	I-T058
of	O
nontypeable	B-T007
pneumococci	I-T007
causing	O
invasive	B-T038
pneumococcal	I-T038
disease	I-T038
in	O
South	B-T082
Africa	I-T082
,	O
2003	O
-	O
2013	O

The	O
capsular	O
polysaccharide	O
is	O
the	O
principal	O
virulence	B-T103
factor	I-T103
of	O
Streptococcus	B-T007
pneumoniae	I-T007
and	O
a	O
target	O
for	O
current	O
pneumococcal	B-T103
vaccines	I-T103
.	O

However	O
,	O
some	O
pathogenic	B-T033
pneumococci	B-T007
are	O
serologically	B-T170
nontypeable	I-T170
[	O
nontypeable	B-T007
pneumococci	I-T007
(	O
NTPn	B-T007
)	O
]	O
.	O

Due	O
to	O
their	O
relative	O
rarity	O
,	O
NTPn	B-T007
are	O
poorly	O
characterized	O
,	O
and	O
,	O
as	O
such	O
,	O
limited	O
data	O
exist	O
which	O
describe	O
these	O
organisms	O
.	O

We	O
aimed	O
to	O
describe	O
disease	B-T038
and	O
genotypically	O
characterize	O
NTPn	B-T007
causing	O
invasive	B-T038
pneumococcal	I-T038
disease	I-T038
in	O
South	B-T082
Africa	I-T082
.	O

Isolates	B-T103
were	O
detected	O
through	O
national	O
,	O
laboratory	B-T092
-	O
based	O
surveillance	O
for	O
invasive	B-T038
pneumococcal	I-T038
disease	I-T038
in	O
South	B-T082
Africa	I-T082
and	O
characterized	O
by	O
whole	O
genome	B-T058
analysis	I-T058
.	O

We	O
predicted	O
ancestral	O
serotypes	B-T170
(	O
serotypes	B-T170
from	O
which	O
NTPn	B-T007
may	O
have	O
originated	O
)	O
for	O
Group	O
I	O
NTPn	B-T007
using	O
multilocus	B-T062
sequence	I-T062
typing	I-T062
and	O
capsular	O
region	O
sequence	B-T058
analyses	I-T058
.	O

Antimicrobial	B-T201
resistance	I-T201
patterns	B-T082
and	O
mutations	B-T038
potentially	O
causing	O
nontypeability	B-T170
were	O
identified	O
.	O

From	O
2003	O
-	O
2013	O
,	O
39	O
(	O
0	O
.	O
1	O
%	O
,	O
39	O
/	O
32	O
,	O
824	O
)	O
NTPn	B-T007
were	O
reported	O
.	O

Twenty	O
-	O
two	O
(	O
56	O
%	O
)	O
had	O
partial	O
capsular	B-T017
genes	I-T017
(	O
Group	O
I	O
)	O
and	O
17	O
(	O
44	O
%	O
)	O
had	O
complete	O
capsular	B-T038
deletion	I-T038
of	O
which	O
15	O
had	O
replacement	O
by	O
other	O
genes	B-T017
(	O
Group	O
II	O
)	O
.	O

Seventy	O
-	O
nine	O
percent	O
(	O
31	O
/	O
39	O
)	O
of	O
our	O
NTPn	B-T007
isolates	B-T103
were	O
derived	O
from	O
encapsulated	O
S	B-T007
.	I-T007

pneumoniae	I-T007
.	O

Ancestral	O
serotypes	B-T170
1	O
(	O
27	O
%	O
,	O
6	O
/	O
22	O
)	O
and	O
8	O
(	O
14	O
%	O
,	O
3	O
/	O
22	O
)	O
were	O
most	O
prevalent	O
,	O
and	O
59	O
%	O
(	O
13	O
/	O
22	O
)	O
of	O
ancestral	O
serotypes	B-T170
were	O
serotypes	B-T170
included	O
in	O
the	O
13	B-T103
-	I-T103
valent	I-T103
pneumococcal	I-T103
conjugate	I-T103
vaccine	I-T103
.	O

We	O
identified	O
a	O
variety	O
of	O
mutations	B-T038
within	O
the	O
capsular	O
region	O
of	O
Group	O
I	O
NTPn	B-T007
,	O
some	O
of	O
which	O
may	O
be	O
responsible	O
for	O
the	O
nontypeable	B-T170
phenotype	O
.	O

Nonsusceptibility	B-T033
to	O
tetracycline	B-T103
and	O
erythromycin	B-T103
was	O
higher	O
in	O
NTPn	B-T007
than	O
encapsulated	O
S	B-T007
.	I-T007

pneumoniae	I-T007
.	O

NTPn	B-T007
are	O
currently	O
a	O
rare	O
cause	O
of	O
invasive	B-T038
pneumococcal	I-T038
disease	I-T038
in	O
South	B-T082
Africa	I-T082
and	O
represent	O
a	O
genetically	O
diverse	O
collection	O
of	O
isolates	O
.	O

Pre	B-T038
-	I-T038
hypertension	I-T038
,	O
pre	B-T038
-	I-T038
diabetes	I-T038
or	O
both	O
:	O
which	O
is	O
best	O
at	O
predicting	O
cardiovascular	B-T033
events	I-T033
in	O
the	O
long	O
term	O
?	O

The	O
present	O
study	B-T062
aimed	O
to	O
assess	O
the	O
value	O
of	O
pre	B-T038
-	I-T038
diabetes	I-T038
and	O
pre	B-T038
-	I-T038
hypertension	I-T038
in	O
predicting	O
cardiovascular	B-T033
events	I-T033
.	O

A	O
population	O
-	O
based	O
,	O
cross	B-T062
-	I-T062
sectional	I-T062
survey	I-T062
was	O
conducted	O
,	O
representing	O
a	O
large	O
sample	O
of	O
the	O
general	O
Iranian	B-T098
population	B-T098
aged	O
35	O
years	O
and	O
older	O
from	O
the	O
Isfahan	B-T082
Province	I-T082
and	O
determined	O
using	O
a	O
random	B-T062
,	I-T062
multistage	I-T062
cluster	I-T062
-	I-T062
sampling	I-T062
10	O
-	O
year	O
cohort	B-T098
.	O

The	O
five	O
end	O
points	O
considered	O
as	O
study	O
outcome	O
were	O
unstable	B-T038
angina	I-T038
(	O
UA	B-T038
)	O
,	O
acute	O
occurrence	O
of	O
myocardial	B-T038
infarction	I-T038
(	O
MI	B-T038
)	O
,	O
sudden	B-T038
cardiac	I-T038
death	I-T038
(	O
SCD	B-T038
)	O
,	O
brain	O
stroke	O
and	O
cardiovascular	B-T038
disease	I-T038
(	O
CVD	B-T038
)	O
.	O

Of	O
the	O
6323	O
subjects	O
scheduled	O
for	O
assessment	B-T058
of	O
diabetes	B-T038
state	I-T038
617	O
were	O
diabetics	B-T033
and	O
712	O
were	O
pre	B-T033
-	I-T033
diabetic	I-T033
.	O

In	O
addition	O
,	O
of	O
these	O
subjects	O
,	O
1754	O
had	O
hypertension	B-T038
and	O
2500	O
had	O
pre	B-T038
-	I-T038
hypertension	I-T038
.	O

Analysing	O
only	O
pre	B-T038
-	I-T038
hypertension	I-T038
,	O
pre	B-T038
-	I-T038
diabetes	I-T038
and	O
its	O
combination	O
and	O
adjusted	O
for	O
gender	O
and	O
age	O
variables	O
,	O
pre	B-T038
-	I-T038
hypertension	I-T038
and	O
pre	B-T038
-	I-T038
diabetes	I-T038
status	O
together	O
,	O
could	O
only	O
effectively	O
predict	O
occurrence	O
of	O
MI	B-T038
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
=	O
3	O
.	O
21	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1	O
.	O
06	O
-	O
9	O
.	O
76	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

In	O
the	O
same	O
COX	B-T170
regression	I-T170
models	I-T170
,	O
pre	B-T038
-	I-T038
hypertension	I-T038
status	O
could	O
predict	O
UA	B-T038
and	O
CVD	B-T038
occurrence	O
(	O
HR	O
=	O
2	O
.	O
94	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
68	O
-	O
5	O
.	O
14	O
,	O
P	O
<	O
0	O
.	O
001	O
and	O
HR	O
=	O
1	O
.	O
74	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
23	O
-	O
2	O
.	O
47	O
,	O
P	O
=	O
0	O
.	O
002	O
,	O
respectively	O
)	O
.	O

However	O
,	O
pre	B-T038
-	I-T038
diabetes	I-T038
status	O
could	O
not	O
predict	O
any	O
of	O
these	O
events	O
after	O
adjustment	O
for	O
gender	O
and	O
age	O
.	O

Our	O
data	O
provide	O
valuable	O
evidence	O
of	O
the	O
triggering	O
role	O
of	O
pre	B-T038
-	I-T038
hypertension	I-T038
and	O
pre	B-T038
-	I-T038
diabetes	I-T038
together	O
,	O
on	O
appearance	O
and	O
progression	B-T038
of	O
MI	B-T038
even	O
in	O
healthy	B-T098
individuals	I-T098
and	O
the	O
significant	O
predicting	O
value	O
of	O
pre	B-T038
-	I-T038
hypertension	I-T038
on	O
the	O
occurrence	O
of	O
UA	B-T038
and	O
CVD	B-T038
.	O

In	O
this	O
regard	O
,	O
the	O
value	O
of	O
pre	B-T038
-	I-T038
hypertension	I-T038
and	O
pre	B-T038
-	I-T038
diabetes	I-T038
together	O
,	O
and	O
the	O
pre	B-T038
-	I-T038
hypertension	I-T038
state	O
alone	O
,	O
are	O
clearly	O
superior	O
to	O
pre	B-T038
-	I-T038
diabetes	I-T038
state	O
alone	O
in	O
predicting	O
cardiovascular	B-T033
events	I-T033
.	O

Strategies	O
for	O
Successful	O
Clinical	O
Teaching	O

This	O
article	B-T170
is	O
one	O
in	O
a	O
series	O
on	O
the	O
roles	O
of	O
adjunct	B-T097
clinical	I-T097
faculty	I-T097
and	O
preceptors	B-T097
,	O
who	O
teach	O
nursing	B-T097
students	I-T097
and	O
new	O
graduates	B-T098
to	O
apply	O
knowledge	B-T170
in	O
clinical	O
settings	O
.	O

This	O
article	B-T170
describes	O
teaching	O
strategies	O
as	O
well	O
as	O
the	O
importance	O
of	O
the	O
learning	O
environment	O
.	O

Learned	B-T038
helplessness	I-T038
at	O
fifty	O
:	O
Insights	B-T038
from	O
neuroscience	B-T091

Learned	B-T038
helplessness	I-T038
,	O
the	O
failure	O
to	O
escape	B-T038
shock	B-T038
induced	O
by	O
uncontrollable	O
aversive	O
events	O
,	O
was	O
discovered	O
half	O
a	O
century	O
ago	O
.	O

Seligman	B-T204
and	I-T204
Maier	I-T204
(	O
1967	O
)	O
theorized	O
that	O
animals	B-T204
learned	B-T038
that	O
outcomes	O
were	O
independent	O
of	O
their	O
responses	O
-	O
that	O
nothing	O
they	O
did	O
mattered	O
-	O
and	O
that	O
this	O
learning	B-T038
undermined	O
trying	O
to	O
escape	B-T038
.	O

The	O
mechanism	O
of	O
learned	B-T038
helplessness	I-T038
is	O
now	O
very	O
well	O
-	O
charted	O
biologically	O
,	O
and	O
the	O
original	O
theory	O
got	O
it	O
backward	O
.	O

Passivity	O
in	O
response	O
to	O
shock	B-T038
is	O
not	O
learned	B-T038
.	O

It	O
is	O
the	O
default	O
,	O
unlearned	O
response	O
to	O
prolonged	O
aversive	O
events	O
and	O
it	O
is	O
mediated	O
by	O
the	O
serotonergic	B-T038
activity	I-T038
of	O
the	O
dorsal	B-T017
raphe	I-T017
nucleus	I-T017
,	O
which	O
in	O
turn	O
inhibits	O
escape	B-T038
.	O

This	O
passivity	O
can	O
be	O
overcome	O
by	O
learning	B-T038
control	O
,	O
with	O
the	O
activity	O
of	O
the	O
medial	B-T017
prefrontal	I-T017
cortex	I-T017
,	O
which	O
subserves	O
the	O
detection	B-T033
of	O
control	O
leading	O
to	O
the	O
automatic	O
inhibition	O
of	O
the	O
dorsal	B-T017
raphe	I-T017
nucleus	I-T017
.	O

So	O
animals	B-T204
learn	B-T038
that	O
they	O
can	O
control	O
aversive	O
events	O
,	O
but	O
the	O
passive	O
failure	O
to	O
learn	B-T038
to	O
escape	B-T038
is	O
an	O
unlearned	O
reaction	O
to	O
prolonged	O
aversive	O
stimulation	O
.	O

In	O
addition	O
,	O
alterations	O
of	O
the	O
ventromedial	B-T017
prefrontal	I-T017
cortex	I-T017
-	O
dorsal	B-T017
raphe	I-T017
pathway	O
can	O
come	O
to	O
subserve	O
the	O
expectation	O
of	O
control	O
.	O

We	O
speculate	O
that	O
default	O
passivity	O
and	O
the	O
compensating	O
detection	B-T033
and	O
expectation	O
of	O
control	O
may	O
have	O
substantial	O
implications	O
for	O
how	O
to	O
treat	O
depression	B-T038
.	O

(	O
PsycINFO	O
Database	O
Record	O

A	O
peptide	B-T103
from	O
human	B-T103
β	I-T103
thymosin	I-T103
as	O
a	O
platform	O
for	O
the	O
development	O
of	O
new	O
anti	B-T103
-	I-T103
biofilm	I-T103
agents	I-T103
for	O
Staphylococcus	B-T007
spp	I-T007
.	I-T007
and	O
Pseudomonas	B-T007
aeruginosa	I-T007

Conventional	O
antibiotics	B-T103
might	O
fail	O
in	O
the	O
treatment	O
of	O
biofilm	B-T007
-	O
associated	O
infections	B-T038
causing	O
infection	B-T038
recurrence	B-T038
and	O
chronicity	O
.	O

The	O
search	O
for	O
antimicrobial	B-T103
peptides	I-T103
has	O
been	O
performed	O
with	O
the	O
aim	O
to	O
discover	O
novel	O
anti	B-T103
-	I-T103
infective	I-T103
agents	I-T103
active	O
on	O
pathogens	O
in	O
both	O
planktonic	B-T007
and	O
biofilm	B-T007
associated	O
forms	O
.	O

The	O
fragment	B-T103
9	O
-	O
19	O
of	O
human	B-T103
thymosin	I-T103
β4	I-T103
was	O
studied	B-T062
through	O
1	O
μs	O
MD	O
simulation	O
.	O

Two	O
main	O
conformations	B-T082
of	I-T082
the	I-T082
peptide	I-T082
were	O
detected	O
,	O
both	O
constituted	O
by	O
a	O
central	B-T082
hydrophobic	I-T082
core	I-T082
and	O
by	O
the	O
presence	O
of	O
peripheral	B-T082
charged	O
residues	O
suggesting	O
a	O
possible	O
mechanism	O
of	O
interaction	O
with	O
two	O
models	B-T170
of	O
biological	O
membranes	O
,	O
related	O
to	O
eukaryotic	B-T204
or	O
bacterial	O
membrane	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
peptide	B-T103
was	O
chemically	O
synthesized	O
and	O
its	O
antimicrobial	B-T033
activity	I-T033
was	O
tested	O
in	O
vitro	O
against	O
planktonic	B-T007
and	O
biofilm	B-T007
form	O
of	O
a	O
group	O
of	O
reference	O
strains	O
of	O
Staphylococcus	B-T007
spp	I-T007
.	I-T007

and	O
one	O
P	B-T007
.	I-T007

aeruginosa	I-T007
strain	O
.	O

The	O
human	B-T103
thymosin	I-T103
β4	I-T103
fragment	B-T103
EIEKFDKSKLK	B-T082
showed	O
antibacterial	B-T038
activity	I-T038
against	O
staphylococcal	B-T007
strains	O
and	O
Pseudomonas	B-T007
aeruginosa	I-T007
ATCC	O
15442	O
at	O
concentrations	O
from	O
12	O
.	O
5	O
to	O
6	O
.	O
2	O
mg	O
/	O
ml	O
and	O
inhibited	O
biofilm	B-T038
formation	I-T038
at	O
sub	O
-	O
inhibitory	O
concentrations	O
(	O
3	O
.	O
1	O
-	O
0	O
.	O
75	O
mg	O
/	O
ml	O
)	O
.	O

The	O
activity	O
of	O
the	O
fragment	B-T103
in	O
inhibiting	O
biofilm	B-T038
formation	I-T038
,	O
could	O
be	O
due	O
to	O
the	O
conformations	B-T082
highlighted	O
by	O
the	O
MD	O
simulations	O
,	O
suggesting	O
its	O
interaction	O
with	O
the	O
bacterial	O
membrane	O
.	O

Human	B-T103
thymosin	I-T103
β4	I-T103
fragment	B-T103
can	O
be	O
considered	O
a	O
promising	O
lead	B-T103
compound	I-T103
to	O
develop	O
novel	O
synthetic	O
or	O
recombinant	B-T103
derivatives	I-T103
with	O
improved	O
pharmaceutical	B-T091
potential	O
.	O

Structural	B-T082
Basis	O
for	O
Simvastatin	B-T103
Competitive	B-T038
Antagonism	I-T038
of	O
Complement	B-T103
Receptor	I-T103
3	I-T103

The	O
complement	B-T103
system	I-T103
is	O
an	O
important	O
part	O
of	O
the	O
innate	O
immune	O
response	O
to	O
infection	B-T038
but	O
may	O
also	O
cause	O
severe	B-T033
complications	I-T033
during	O
inflammation	B-T038
.	O

Small	B-T103
molecule	I-T103
antagonists	B-T103
to	O
complement	B-T103
receptor	I-T103
3	I-T103
(	O
CR3	B-T103
)	O
have	O
been	O
widely	O
sought	O
,	O
but	O
a	O
structural	B-T082
basis	O
for	O
their	O
mode	O
of	O
action	O
is	O
not	O
available	O
.	O

We	O
report	B-T170
here	O
on	O
the	O
structure	B-T082
of	O
the	O
human	B-T204
CR3	B-T103
ligand	B-T082
-	I-T082
binding	I-T082
I	I-T082
domain	I-T082
in	O
complex	B-T103
with	O
simvastatin	B-T103
.	O

Simvastatin	B-T103
targets	O
the	O
metal	B-T103
ion	O
-	O
dependent	O
adhesion	O
site	O
of	O
the	O
open	O
,	O
ligand	B-T038
-	I-T038
binding	I-T038
conformation	B-T082
of	O
the	O
CR3	B-T103
I	B-T082
domain	I-T082
by	O
direct	O
contact	O
with	O
the	O
chelated	B-T103
Mg	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
ion	I-T103
.	O

Simvastatin	B-T103
antagonizes	B-T033
I	B-T082
domain	I-T082
binding	I-T082
to	O
the	O
complement	B-T103
fragments	I-T103
iC3b	B-T103
and	O
C3d	B-T103
but	O
not	O
to	O
intercellular	B-T103
adhesion	I-T103
molecule	I-T103
-	I-T103
1	I-T103
.	O

By	O
virtue	O
of	O
the	O
I	B-T082
domain	I-T082
'	I-T082
s	I-T082
wide	O
distribution	B-T082
in	O
binding	B-T038
kinetics	I-T038
to	O
ligands	B-T103
,	O
it	O
was	O
possible	B-T033
to	O
identify	O
ligand	B-T038
binding	I-T038
kinetics	B-T038
as	O
discriminator	O
for	O
simvastatin	B-T103
antagonism	B-T038
.	O

In	O
static	O
cellular	B-T058
experiments	B-T062
,	O
15	O
-	O
25	O
μm	O
simvastatin	B-T103
reduced	O
adhesion	O
by	O
K562	B-T017
cells	I-T017
expressing	O
recombinant	O
CR3	B-T103
and	O
by	O
primary	O
human	B-T204
monocytes	B-T017
,	O
with	O
an	O
endogenous	O
expression	O
of	O
this	O
receptor	B-T103
.	O

Application	B-T058
of	O
force	O
to	O
adhering	O
monocytes	B-T017
potentiated	O
the	O
effects	O
of	O
simvastatin	B-T103
where	O
only	O
a	O
50	O
-	O
100	O
nm	O
concentration	O
of	O
the	O
drug	B-T103
reduced	O
the	O
adhesion	O
by	O
20	O
-	O
40	O
%	O
compared	O
with	O
untreated	O
cells	B-T017
.	O

The	O
ability	O
of	O
simvastatin	B-T103
to	O
target	O
CR3	B-T103
in	O
its	O
ligand	B-T038
binding	I-T038
-	O
activated	O
conformation	B-T082
is	O
a	O
novel	O
mechanism	O
to	O
explain	O
the	O
known	O
anti	O
-	O
inflammatory	O
effects	O
of	O
this	O
compound	B-T103
,	O
in	O
particular	O
because	O
this	O
CR3	B-T103
conformation	B-T082
is	O
found	O
in	O
pro	O
-	O
inflammatory	O
environments	B-T082
.	O

Our	O
report	B-T170
points	O
to	O
new	O
designs	O
of	O
CR3	B-T103
antagonists	B-T103
and	O
opens	O
new	O
perspectives	O
and	O
identifies	B-T033
druggable	O
receptors	B-T103
from	O
characterization	O
of	O
the	O
ligand	B-T038
binding	I-T038
kinetics	B-T038
in	O
the	O
presence	O
of	O
antagonists	B-T103
.	O

Common	O
Laboratory	B-T092
Parameters	B-T033
for	O
Differentiating	O
Between	O
Community	B-T038
-	I-T038
Acquired	I-T038
and	O
Healthcare	B-T038
-	I-T038
Associated	I-T038
Pneumonia	I-T038

The	O
correct	O
diagnosis	B-T033
of	O
healthcare	B-T038
-	I-T038
associated	I-T038
pneumonia	I-T038
(	O
HCAP	B-T038
)	O
as	O
opposed	O
to	O
community	B-T038
-	I-T038
acquired	I-T038
pneumonia	I-T038
is	O
essential	O
for	O
the	O
selection	O
of	O
a	O
correct	O
empirical	O
antimicrobial	B-T103
approach	O
,	O
reserving	O
the	O
broad	O
-	O
spectrum	O
or	O
highly	O
potent	O
antimicrobial	B-T058
therapies	I-T058
for	O
resistant	O
strains	O
most	O
commonly	O
present	O
in	O
HCAP	B-T038
,	O
whereas	O
treating	O
the	O
less	O
resistant	O
strains	O
,	O
most	O
commonly	O
associated	O
with	O
community	O
and	O
long	B-T092
-	I-T092
term	I-T092
care	I-T092
facility	I-T092
-	O
acquired	B-T038
infections	I-T038
,	O
with	O
a	O
more	O
targeted	O
empirical	O
approach	O
.	O

The	O
standard	O
approach	O
today	O
is	O
to	O
differentiate	O
between	O
the	O
two	O
based	O
on	O
the	O
medical	B-T033
history	I-T033
of	O
the	O
past	O
90	O
days	O
prior	O
to	O
admission	B-T058
.	O

Measurable	O
,	O
quantitative	O
assessment	B-T058
may	O
be	O
able	O
to	O
assist	O
in	O
this	O
decision	B-T038
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
find	O
a	O
measurable	O
method	B-T170
of	O
differentiating	O
between	O
community	B-T038
-	I-T038
acquired	I-T038
and	O
healthcare	B-T038
-	I-T038
associated	I-T038
pneumonias	I-T038
.	O

The	O
records	B-T170
of	O
126	O
patients	O
admitted	B-T058
with	O
a	O
diagnosis	B-T033
of	O
pneumonia	B-T038
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
the	O
probable	O
cause	O
of	O
their	O
disease	O
,	O
in	O
accordance	O
with	O
common	B-T038
practice	I-T038
.	O

The	O
routine	O
laboratory	B-T058
work	I-T058
taken	O
upon	O
admittance	B-T058
was	O
analyzed	B-T062
using	O
logistical	B-T062
regression	I-T062
and	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

We	O
have	O
found	O
that	O
the	O
red	B-T058
blood	I-T058
cell	I-T058
distribution	I-T058
width	I-T058
and	O
the	O
neutrophil	B-T017
-	O
to	O
-	O
lymphocyte	B-T017
ratio	O
,	O
both	O
routine	B-T033
parameters	I-T033
obtained	O
in	O
a	O
simple	O
blood	B-T058
count	I-T058
,	O
can	O
each	O
assist	O
in	O
differentiating	O
between	O
community	B-T038
-	I-T038
acquired	I-T038
and	O
healthcare	B-T038
-	I-T038
associated	I-T038
pneumonias	I-T038
.	O

We	O
have	O
found	O
two	O
statistically	O
significant	O
parameters	O
that	O
may	O
be	O
used	O
as	O
adjuncts	O
to	O
the	O
medical	B-T033
history	I-T033
,	O
chest	B-T058
radiography	I-T058
and	O
other	B-T033
parameters	I-T033
in	O
forming	O
an	O
immediate	O
clinical	O
impression	O
of	O
a	O
patient	O
presenting	O
with	O
pneumonia	B-T038
.	O

A	O
quasi	B-T062
-	I-T062
experimental	I-T062
study	I-T062
of	O
a	O
reminiscence	B-T058
program	I-T058
focused	O
on	O
autobiographical	B-T038
memory	I-T038
in	O
institutionalized	O
older	B-T098
adults	I-T098
with	O
cognitive	B-T038
impairment	I-T038

Working	O
with	O
past	B-T038
memories	I-T038
through	O
reminiscence	B-T058
interventions	I-T058
has	O
been	O
practiced	O
for	O
several	O
decades	O
with	O
successful	O
outcomes	O
on	O
mental	B-T038
health	I-T038
in	O
older	B-T098
adults	I-T098
.	O

Few	O
studies	B-T062
however	O
have	O
focused	O
on	O
autobiographical	B-T038
memory	I-T038
recall	B-T038
in	O
older	O
individuals	O
with	O
cognitive	B-T038
impairment	I-T038
.	O

This	O
study	B-T062
aims	O
to	O
analyze	O
the	O
impact	O
of	O
an	O
individual	B-T098
reminiscence	B-T058
program	I-T058
in	O
a	O
group	O
of	O
older	O
persons	O
with	O
cognitive	B-T038
decline	I-T038
living	O
in	O
nursing	B-T092
homes	I-T092
on	O
the	O
dimensions	O
of	O
cognition	B-T038
,	O
autobiographical	B-T038
memory	I-T038
,	O
mood	B-T038
,	O
behavior	O
and	O
anxiety	B-T038
.	O

A	O
two	O
-	O
group	O
pre	B-T170
-	I-T170
test	I-T170
and	I-T170
post	I-T170
-	I-T170
test	I-T170
design	I-T170
with	O
single	B-T058
blinded	I-T058
assessment	I-T058
was	O
conducted	O
.	O

Forty	O
-	O
one	O
participants	B-T098
were	O
randomized	O
to	O
an	O
experimental	B-T098
group	I-T098
(	O
n	O
=	O
20	O
)	O
and	O
a	O
control	O
group	O
(	O
n	O
=	O
21	O
)	O
.	O

The	O
first	O
group	O
attended	O
five	O
weekly	O
individual	B-T098
reminiscence	O
sessions	O
.	O

Changes	O
in	O
the	O
outcome	O
measures	O
were	O
examined	B-T033
for	O
cognition	B-T038
(	O
Montreal	B-T170
Cognitive	I-T170
Assessment	I-T170
;	O
Autobiographical	B-T170
Memory	I-T170
Test	I-T170
)	O
,	O
behavior	O
(	O
Alzheimer	B-T170
Disease	I-T170
Assessment	I-T170
Subscale	I-T170
Non	I-T170
-	I-T170
Cog	I-T170
)	O
and	O
emotional	B-T033
status	I-T033
(	O
Cornell	B-T170
Scale	I-T170
for	I-T170
Depression	I-T170
in	O
Dementia	B-T038
;	O
Geriatric	B-T170
Depression	I-T170
Scale	I-T170
,	O
and	O
Geriatric	B-T170
Anxiety	I-T170
Inventory	I-T170
)	O
.	O

Participants	B-T098
attending	O
reminiscence	O
sessions	O
exhibited	O
better	O
outcomes	O
compared	O
to	O
the	O
control	O
group	O
in	O
cognition	B-T038
,	O
anxiety	B-T038
and	O
depression	B-T038
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
presented	O
a	O
higher	O
number	O
of	O
retrieved	B-T038
autobiographical	O
events	O
,	O
specificity	O
of	O
evoked	O
memories	B-T038
and	O
positive	O
valence	O
of	O
events	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
also	O
presented	O
lower	O
latency	O
time	O
for	O
recalling	B-T038
events	O
,	O
and	O
lower	O
negative	O
recalled	B-T038
events	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

This	O
study	O
supports	O
the	O
potential	O
value	O
of	O
reminiscence	B-T058
therapy	I-T058
in	O
improving	O
the	O
recall	B-T038
of	O
autobiographical	B-T038
memory	I-T038
.	O

Reminiscence	B-T058
therapy	I-T058
can	O
be	O
helpful	O
to	O
maintain	O
or	O
improve	O
cognitive	B-T038
function	I-T038
,	O
decrease	O
anxiety	B-T038
and	O
manage	O
depressive	B-T033
symptoms	I-T033
and	O
altered	O
behavior	O
,	O
but	O
further	O
investigation	O
is	O
needed	O
to	O
clarify	O
long	O
-	O
term	O
effects	O
.	O

Economic	O
Burden	O
of	O
Illness	B-T033
Among	O
Patients	O
with	O
Severe	B-T033
Asthma	I-T033
in	O
a	O
Managed	O
Care	O
Setting	O

Despite	O
intensive	O
pharmacotherapy	B-T058
,	O
a	O
considerable	O
number	O
of	O
patients	O
with	O
severe	B-T033
asthma	I-T033
have	O
inadequate	O
disease	B-T038
control	O
.	O

Patients	O
with	O
severe	B-T033
asthma	I-T033
who	O
experience	B-T038
exacerbations	B-T033
consume	O
significant	O
health	O
care	O
resources	O
.	O

To	O
assess	O
health	O
care	O
resource	O
utilization	O
and	O
associated	O
costs	O
among	O
patients	O
with	O
persistent	O
severe	B-T033
asthma	I-T033
who	O
experienced	B-T038
exacerbations	B-T033
compared	O
with	O
patients	O
with	O
persistent	O
but	O
nonsevere	O
asthma	B-T038
.	O

This	O
retrospective	O
analysis	B-T062
of	O
a	O
national	B-T170
administrative	I-T170
claims	I-T170
database	I-T170
identified	O
patients	O
aged	O
≥	O
12	O
years	O
who	O
had	O
at	O
least	O
1	O
medical	O
claim	O
with	O
an	O
asthma	B-T038
diagnosis	B-T033
in	O
2012	O
and	O
had	O
continuous	O
medical	O
and	O
pharmacy	O
coverage	O
under	O
a	O
commercial	B-T170
or	O
Medicare	O
Advantage	O
plan	O
from	O
January	O
1	O
,	O
2012	O
,	O
to	O
December	O
31	O
,	O
2013	O
.	O

Patients	O
were	O
assigned	O
to	O
1	O
of	O
2	O
mutually	O
exclusive	O
cohorts	B-T098
-	O
persistent	B-T038
asthma	I-T038
(	O
PA	B-T038
)	O
or	O
severe	B-T033
asthma	I-T033
(	O
SA	B-T033
)	O
-	O
according	O
to	O
an	O
established	O
algorithm	B-T170
based	O
on	O
asthma	B-T038
-	O
related	O
health	O
care	O
resource	O
use	O
and	O
pharmacy	O
claims	O
for	O
controller	B-T103
medication	I-T103
.	O

SA	B-T033
patients	O
were	O
required	O
to	O
meet	O
PA	B-T038
criteria	O
and	O
also	O
have	O
evidence	O
of	O
≥2	O
asthma	B-T033
exacerbations	I-T033
in	O
2012	O
.	O

Asthma	B-T038
-	O
related	O
health	O
care	O
resource	O
utilization	O
and	O
costs	O
were	O
computed	O
from	O
asthma	B-T038
medication	B-T058
use	O
(	O
rescue	O
and	O
controller	O
therapy	O
)	O
and	O
medical	O
claims	O
with	O
an	O
asthma	B-T038
diagnosis	B-T033
in	O
the	O
primary	B-T082
position	I-T082
in	O
2012	O
and	O
2013	O
.	O

Adherence	O
to	O
controller	O
therapy	O
was	O
assessed	O
over	O
365	O
days	O
by	O
using	O
the	O
proportion	O
of	O
days	O
covered	O
(	O
PDC	O
)	O
,	O
starting	O
with	O
the	O
first	O
claim	O
for	O
controller	O
therapy	O
in	O
2012	O
.	O

Differences	O
between	O
the	O
PA	B-T038
and	O
SA	B-T033
cohorts	B-T098
were	O
analyzed	B-T062
by	O
t	B-T170
-	I-T170
test	I-T170
for	O
continuous	O
variables	O
and	O
chi	B-T170
-	I-T170
square	I-T170
test	I-T170
for	O
categorical	O
variables	O
.	O

Asthma	B-T038
-	O
related	O
costs	O
in	O
2013	O
were	O
also	O
analyzed	B-T062
using	O
a	O
generalized	O
linear	O
model	O
with	O
a	O
gamma	O
distribution	O
and	O
log	B-T170
link	I-T170
,	O
adjusted	O
for	O
patient	O
demographics	O
(	O
age	O
,	O
gender	O
,	O
region	B-T082
,	O
and	O
insurance	O
type	O
)	O
and	O
Quan	O
-	O
Charlson	O
comorbidity	O
score	O
.	O

A	O
total	O
of	O
65	O
,	O
359	O
patients	O
were	O
included	O
:	O
63	O
,	O
597	O
(	O
97	O
.	O
3	O
%	O
)	O
PA	B-T038
patients	O
and	O
1	O
,	O
762	O
SA	B-T033
patients	O
(	O
2	O
.	O
7	O
%	O
)	O
.	O

Compared	O
with	O
the	O
PA	B-T038
cohort	B-T098
,	O
the	O
SA	B-T033
cohort	B-T098
was	O
older	O
(	O
mean	O
age	O
=	O
50	O
.	O
8	O
years	O
vs	O
.	O

46	O
.	O
5	O
years	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
had	O
higher	O
mean	O
comorbidity	O
score	O
(	O
1	O
.	O
47	O
vs	O
.	O

1	O
.	O
31	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
mean	O
count	O
of	O
all	O
asthma	B-T038
medications	B-T058
fills	O
was	O
2	O
.	O
2	O
-	O
fold	O
(	O
2012	O
)	O
and	O
2	O
.	O
1	O
-	O
fold	O
(	O
2013	O
)	O
higher	O
in	O
the	O
SA	B-T033
cohort	B-T098
,	I-T098
compared	O
with	O
the	O
PA	B-T038
cohort	B-T098
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Mean	O
PDC	O
for	O
all	O
oral	B-T103
and	O
inhaled	B-T038
controller	B-T058
therapy	I-T058
was	O
also	O
higher	O
in	O
the	O
SA	B-T033
cohort	B-T098
compared	O
with	O
the	O
PA	B-T038
cohort	B-T098
(	O
0	O
.	O
80	O
vs	O
.	O

0	O
.	O
65	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

SA	B-T033
patients	O
had	O
a	O
significantly	O
greater	O
mean	O
count	O
of	O
asthma	B-T038
-	O
related	O
hospitalizations	B-T058
,	O
emergency	B-T058
room	I-T058
visits	I-T058
,	O
and	O
ambulatory	O
visits	O
in	O
2012	O
and	O
2013	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Unadjusted	O
mean	O
annual	O
asthma	B-T038
-	O
related	O
costs	O
in	O
the	O
SA	B-T033
versus	O
PA	B-T038
cohorts	B-T098
were	O
$	O
6	O
,	O
496	O
versus	O
$	O
2	O
,	O
739	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
2012	O
and	O
$	O
5	O
,	O
174	O
versus	O
$	O
1	O
,	O
775	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
2013	O
.	O

Higher	O
asthma	B-T038
-	O
related	O
costs	O
were	O
driven	O
by	O
greater	O
mean	O
annual	O
asthma	B-T038
medication	B-T058
costs	O
in	O
2012	O
(	O
$	O
4	O
,	O
545	O
vs	O
.	O

$	O
1	O
,	O
738	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
2013	O
(	O
$	O
4	O
,	O
068	O
vs	O
.	O

$	O
1	O
,	O
348	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Adjusted	O
mean	O
annual	O
asthma	B-T038
-	O
related	O
costs	O
in	O
2013	O
were	O
$	O
3	O
,	O
336	O
greater	O
(	O
cost	O
ratio	O
=	O
2	O
.	O
878	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
SA	B-T033
cohort	B-T098
,	O
and	O
adjusted	O
mean	O
annual	O
asthma	B-T038
medication	B-T058
costs	O
were	O
$	O
2	O
,	O
672	O
higher	O
(	O
cost	O
ratio	O
=	O
2	O
.	O
982	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
SA	B-T033
cohort	B-T098
.	O

Patients	O
with	O
SA	B-T033
who	O
experienced	B-T038
2	O
or	O
more	O
exacerbations	B-T033
had	O
2	O
.	O
1	O
-	O
fold	O
greater	O
use	O
of	O
controller	B-T058
medications	I-T058
across	O
both	O
study	O
years	O
and	O
were	O
more	O
adherent	O
to	O
controller	O
therapy	O
than	O
patients	O
with	O
PA	B-T038
.	O

Despite	O
more	O
intensive	O
pharmacotherapy	B-T058
,	O
SA	B-T033
patients	O
incurred	O
2	O
.	O
9	O
-	O
fold	O
higher	O
adjusted	O
asthma	B-T038
-	O
related	O
costs	O
and	O
3	O
-	O
fold	O
higher	O
adjusted	O
asthma	B-T038
medication	B-T058
costs	O
than	O
PA	B-T038
patients	O
.	O

Patients	O
with	O
SA	B-T033
consistently	O
demonstrated	O
a	O
higher	O
rate	O
of	O
health	B-T058
care	I-T058
utilization	O
.	O

Funding	O
for	O
this	O
study	B-T062
(	O
HO	O
-	O
14	O
-	O
14443	O
)	O
was	O
provided	O
by	O
GlaxoSmithKline	B-T092
(	O
GSK	B-T092
)	O
.	O

All	O
listed	O
authors	B-T097
meet	O
the	O
criteria	O
for	O
authorship	O
set	O
forth	O
by	O
the	O
International	O
Committee	O
for	O
Medical	O
Journal	O
Editors	O
.	O

Albers	O
,	O
Forshag	O
,	O
and	O
Yancey	O
are	O
employees	B-T097
of	O
GSK	B-T092
and	O
hold	O
stock	O
in	O
GSK	B-T092
.	O

Dalal	O
,	O
Nagar	O
,	O
and	O
Ortega	O
were	O
employees	B-T097
of	O
GSK	B-T092
at	O
the	O
time	O
this	O
research	B-T062
was	O
conducted	O
.	O

Chastek	O
and	O
Korrer	O
are	O
employees	B-T097
of	O
Optum	O
,	O
which	O
received	O
consulting	O
fees	O
from	O
GSK	B-T092
for	O
research	B-T062
related	O
to	O
this	O
study	B-T062
.	O

Study	O
concept	O
and	O
design	O
were	O
contributed	O
by	O
Chastek	O
,	O
Nagar	O
,	O
and	O
Dalal	O
.	O

Korrer	O
took	O
the	O
lead	O
in	O
data	B-T062
collection	I-T062
,	O
along	O
with	O
Chastek	O
,	O
and	O
data	O
interpretation	O
was	O
performed	O
by	O
Chastek	O
,	O
Ortega	O
,	O
Forshag	O
,	O
and	O
Dalal	O
.	O

The	O
manuscript	B-T170
was	O
written	O
by	O
Chastek	O
and	O
Dalal	O
and	O
revised	O
by	O
Albers	O
and	O
Yancy	O
,	O
assisted	O
by	O
the	O
other	O
authors	B-T097
.	O

Differential	B-T038
regulation	I-T038
of	O
spontaneous	O
and	O
evoked	O
inhibitory	B-T038
synaptic	I-T038
transmission	I-T038
in	O
somatosensory	B-T017
cortex	I-T017
by	O
retinoic	B-T103
acid	I-T103

Retinoic	B-T103
acid	I-T103
(	O
RA	B-T103
)	O
,	O
a	O
developmental	O
morphogen	B-T103
,	O
has	O
emerged	O
in	O
recent	O
studies	O
as	O
a	O
novel	O
synaptic	B-T038
signaling	B-T103
molecule	I-T103
that	O
acts	O
in	O
mature	O
hippocampal	B-T017
neurons	B-T017
to	O
modulate	O
excitatory	B-T038
and	O
inhibitory	B-T038
synaptic	I-T038
transmission	I-T038
in	O
the	O
context	O
of	O
homeostatic	B-T038
synaptic	B-T038
plasticity	I-T038
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
RA	B-T103
is	O
capable	O
of	O
modulating	O
neural	O
circuits	O
outside	B-T082
of	O
the	O
hippocampus	B-T017
,	O
and	O
if	O
so	O
,	O
whether	O
the	O
mode	O
of	O
RA	O
'	O
s	O
action	O
at	O
synapses	B-T082
is	O
similar	O
to	O
that	O
within	B-T082
the	O
hippocampal	B-T017
network	O
.	O

Here	O
we	O
explore	O
for	O
the	O
first	O
time	O
RA	B-T103
'	O
s	O
synaptic	B-T038
function	I-T038
outside	B-T082
the	O
hippocampus	B-T017
and	O
uncover	O
a	O
novel	O
function	O
of	O
all	B-T103
-	I-T103
trans	I-T103
retinoic	I-T103
acid	I-T103
at	O
inhibitory	B-T017
synapses	I-T017
.	O

Acute	O
RA	B-T103
treatment	O
increases	O
spontaneous	O
inhibitory	B-T038
synaptic	I-T038
transmission	I-T038
in	O
L2	B-T017
/	I-T017
3	I-T017
pyramidal	I-T017
neurons	I-T017
of	O
the	O
somatosensory	B-T017
cortex	I-T017
,	O
and	O
this	O
effect	O
requires	O
expression	O
of	O
RA	B-T103
'	I-T103
s	I-T103
receptor	I-T103
RARα	B-T103
both	O
pre	B-T038
-	I-T038
and	I-T038
post	I-T038
-	I-T038
synaptically	I-T038
.	O

Intriguingly	O
,	O
RA	B-T103
does	O
not	O
seem	O
to	O
affect	O
evoked	O
inhibitory	B-T038
transmission	I-T038
assayed	O
with	O
either	O
extracellular	B-T017
stimulation	O
or	O
direct	O
activation	B-T038
of	I-T038
action	I-T038
potentials	I-T038
in	O
presynaptic	B-T017
interneurons	B-T017
at	O
connected	O
pairs	O
of	O
interneurons	B-T017
and	O
pyramidal	B-T017
neurons	I-T017
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
RA	B-T103
'	I-T103
s	I-T103
action	O
at	O
synapses	B-T082
is	O
not	O
monotonous	O
,	O
but	O
is	O
diverse	O
depending	O
on	O
the	O
type	O
of	O
synaptic	B-T038
connection	I-T038
(	O
excitatory	B-T038
versus	O
inhibitory	B-T038
)	O
and	O
circuit	O
(	O
hippocampal	B-T017
versus	O
cortical	B-T017
)	I-T017
.	O

Thus	O
,	O
synaptic	B-T038
signaling	I-T038
of	O
RA	B-T103
may	O
mediate	O
multi	O
-	O
faceted	O
regulation	B-T038
of	I-T038
synaptic	I-T038
plasticity	I-T038
.	O

In	O
addition	O
to	O
its	O
classic	O
roles	O
in	O
brain	B-T038
development	I-T038
,	O
retinoic	B-T103
acid	I-T103
(	O
RA	B-T103
)	O
has	O
recently	O
been	O
shown	O
to	O
regulate	B-T038
excitatory	B-T038
and	O
inhibitory	B-T038
transmission	I-T038
in	O
the	O
adult	O
brain	B-T017
.	O

Here	O
,	O
the	O
authors	B-T097
show	O
that	O
in	O
layer	B-T017
2	I-T017
/	I-T017
3	I-T017
(	O
L2	B-T017
/	I-T017
3	I-T017
)	O
of	O
the	O
somatosensory	B-T017
cortex	I-T017
(	O
S1	B-T017
)	O
,	O
acute	O
RA	B-T103
induces	O
increases	O
in	O
spontaneous	O
but	O
not	O
action	B-T038
-	I-T038
potential	I-T038
evoked	O
transmission	B-T038
,	O
and	O
that	O
this	O
requires	O
retinoic	B-T103
acid	I-T103
receptor	I-T103
(	O
RARα	B-T103
)	O
both	O
in	O
presynaptic	B-T017
PV	B-T103
-	O
positive	O
interneurons	B-T017
and	O
postsynaptic	O
pyramidal	B-T017
(	I-T017
PN	I-T017
)	I-T017
neurons	I-T017
.	O

Utilization	O
Pattern	B-T082
and	O
Drug	O
Use	O
of	O
Traditional	B-T091
Chinese	I-T091
Medicine	I-T091
,	O
Western	B-T091
Medicine	I-T091
,	O
and	O
Integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
Medicine	I-T091
Treatments	B-T058
for	O
Allergic	B-T038
Rhinitis	I-T038
Under	O
the	O
National	O
Health	O
Insurance	O
Program	O
in	O
Taiwan	B-T082

Patients	O
in	O
Taiwan	B-T082
with	O
allergic	B-T038
rhinitis	I-T038
seek	O
not	O
only	O
Western	B-T091
medicine	I-T091
treatment	B-T058
but	O
also	O
Traditional	B-T091
Chinese	I-T091
Medicine	I-T091
treatment	B-T058
or	O
integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
medicine	I-T091
treatment	B-T058
.	O

Various	O
studies	O
have	O
conducted	O
pairwise	O
comparison	O
on	O
Traditional	B-T091
Chinese	I-T091
Medicine	I-T091
,	O
Western	B-T091
medicine	I-T091
,	O
and	O
integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
medicine	I-T091
treatments	B-T058
.	O

However	O
,	O
none	O
conducted	O
simultaneous	O
analysis	B-T062
of	O
the	O
three	O
treatments	B-T058
.	O

This	O
study	O
analyzed	B-T062
patients	O
with	O
allergic	B-T038
rhinitis	I-T038
receiving	O
the	O
three	O
treatments	B-T058
to	O
identify	O
differences	O
in	O
demographic	O
characteristic	O
and	O
medical	O
use	O
and	O
thereby	O
to	O
determine	O
drug	O
use	O
patterns	O
of	O
different	O
treatments	B-T058
.	O

The	O
National	B-T170
Health	I-T170
Insurance	I-T170
Research	I-T170
Database	I-T170
was	O
the	O
data	O
source	O
,	O
and	O
included	O
patients	O
were	O
those	O
diagnosed	B-T033
with	O
allergic	B-T038
rhinitis	I-T038
(	O
International	B-T170
Classification	I-T170
of	I-T170
Diseases	I-T170
,	I-T170
Ninth	I-T170
Revision	I-T170
,	O
Clinical	B-T170
Modification	I-T170
codes	I-T170
470	I-T170
-	I-T170
478	I-T170
)	O
.	O

Chi	B-T170
-	I-T170
square	I-T170
test	I-T170
and	O
Tukey	B-T170
studentized	I-T170
range	I-T170
(	I-T170
honest	I-T170
significant	I-T170
difference	I-T170
)	I-T170
test	I-T170
were	O
conducted	O
to	O
investigate	O
the	O
differences	O
among	O
the	O
three	O
treatments	B-T058
.	O

Visit	O
frequency	O
for	O
allergic	B-T038
rhinitis	I-T038
treatment	B-T058
was	O
higher	O
in	O
female	B-T098
than	O
male	B-T098
patients	O
,	O
regardless	O
of	O
treatment	B-T058
with	O
Traditional	B-T091
Chinese	I-T091
Medicine	I-T091
,	O
Western	B-T091
medicine	I-T091
,	O
or	O
integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
medicine	I-T091
.	O

Persons	B-T098
aged	O
0	O
-	O
19	O
years	O
ranked	O
the	O
highest	O
in	O
proportion	O
of	O
visits	B-T058
for	O
allergic	B-T038
rhinitis	I-T038
.	O

Traditional	B-T091
Chinese	I-T091
Medicine	I-T091
treatment	B-T058
had	O
more	O
medical	O
items	O
per	O
person	B-T098
-	I-T098
time	I-T098
and	O
daily	O
drug	O
cost	O
per	O
person	B-T098
-	I-T098
time	I-T098
and	O
had	O
the	O
lowest	O
total	O
expenditure	O
per	O
person	B-T098
-	I-T098
time	I-T098
.	O

In	O
contrast	O
,	O
Western	B-T091
medicine	I-T091
had	O
the	O
lowest	O
daily	O
drug	O
cost	O
per	O
person	B-T098
-	I-T098
time	I-T098
and	O
the	O
highest	O
total	O
expenditure	O
per	O
person	B-T098
-	I-T098
time	I-T098
.	O

The	O
total	O
expenditure	O
per	O
person	B-T098
-	I-T098
time	I-T098
,	O
daily	O
drug	O
cost	O
per	O
person	B-T098
-	I-T098
time	I-T098
,	O
and	O
medical	O
items	O
per	O
person	B-T098
-	I-T098
time	I-T098
of	O
integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
medicine	I-T091
treatment	B-T058
lay	O
between	O
those	O
seen	O
with	O
Traditional	B-T091
Chinese	I-T091
Medicine	I-T091
and	O
Western	B-T091
medicine	I-T091
treatments	B-T058
.	O

Although	O
only	O
6	O
.	O
82	O
%	O
of	O
patients	O
with	O
allergic	B-T038
rhinitis	I-T038
chose	O
integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
medicine	I-T091
treatment	B-T058
,	O
the	O
visit	O
frequency	O
per	O
person	O
-	O
year	O
of	O
integrated	B-T091
Chinese	I-T091
-	I-T091
Western	I-T091
medicine	I-T091
ranked	O
highest	O
.	O

In	O
addition	O
,	O
multiple	O
-	O
composition	O
medicines	B-T103
were	O
used	O
more	O
frequently	O
than	O
single	O
-	O
composition	O
medicines	B-T103
,	O
and	O
mar	B-T103
huang	I-T103
(	O
Ephedra	B-T204
sinica	I-T204
Stapf	I-T204
)	O
was	O
seldom	O
used	O
to	O
decrease	O
the	O
risk	O
of	O
combining	O
medications	B-T103
.	O

TLR9	B-T017
Deficiency	O
Leads	O
to	O
Accelerated	O
Renal	B-T038
Disease	I-T038
and	O
Myeloid	B-T017
Lineage	I-T017
Abnormalities	B-T033
in	O
Pristane	B-T103
-	O
Induced	O
Murine	B-T204
Lupus	B-T038

Systemic	B-T038
lupus	I-T038
erythematosus	I-T038
(	O
SLE	B-T038
)	I-T038
is	O
a	O
chronic	O
,	O
life	B-T033
-	I-T033
threatening	I-T033
autoimmune	B-T038
disorder	I-T038
,	O
leading	O
to	O
multiple	O
organ	B-T017
pathologies	B-T091
and	O
kidney	B-T017
destruction	O
.	O

Analyses	O
of	O
numerous	O
murine	B-T204
models	B-T038
of	O
spontaneous	O
SLE	B-T038
have	O
revealed	O
a	O
critical	O
role	O
for	O
endosomal	B-T017
TLRs	B-T103
in	O
the	O
production	O
of	O
autoantibodies	B-T103
and	O
development	O
of	O
other	O
clinical	O
disease	B-T038
manifestations	O
.	O

Nevertheless	O
,	O
the	O
corresponding	O
TLR9	B-T017
-	O
deficient	O
autoimmune	B-T038
-	O
prone	O
strains	O
consistently	O
develop	O
more	O
severe	O
disease	B-T038
pathology	B-T091
.	O

Injection	B-T058
of	O
BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
with	O
2	B-T103
,	I-T103
6	I-T103
,	I-T103
10	I-T103
,	I-T103
14	I-T103
-	I-T103
tetramethylpentadecane	I-T103
(	O
TMPD	B-T103
)	O
,	O
commonly	O
known	O
as	O
pristane	B-T103
,	O
also	O
results	O
in	O
the	O
development	O
of	O
SLE	B-T038
-	I-T038
like	I-T038
disease	I-T038
.	O

We	O
now	O
show	O
that	O
Tlr9	B-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
injected	B-T058
i	I-T058
.	I-T058
p	I-T058
.	I-T058

with	O
TMPD	B-T103
develop	O
more	O
severe	O
autoimmunity	B-T038
than	O
do	O
their	O
TLR	B-T103
-	O
sufficient	O
cohorts	O
.	O

Early	O
indications	O
include	O
an	O
increased	O
accumulation	B-T033
of	O
TLR7	B-T017
-	O
expressing	B-T038
Ly6C	B-T103
(	I-T103
hi	I-T103
)	I-T103
inflammatory	O
monocytes	B-T017
at	O
the	O
site	B-T082
of	I-T082
injection	I-T082
,	O
upregulation	B-T038
of	O
IFN	B-T103
-	O
regulated	O
gene	B-T038
expression	I-T038
in	O
the	O
peritoneal	B-T082
cavity	I-T082
,	O
and	O
an	O
increased	O
production	O
of	O
myeloid	B-T017
lineage	I-T017
precursors	I-T017
(	O
common	B-T017
myeloid	I-T017
progenitors	I-T017
and	O
granulocyte	B-T017
myeloid	B-T017
precursors	I-T017
)	O
in	O
the	O
bone	B-T017
marrow	I-T017
.	O

TMPD	B-T103
-	O
injected	B-T058
Tlr9	B-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
develop	O
higher	O
autoantibody	B-T103
titers	O
against	O
RNA	B-T103
,	O
neutrophil	B-T017
cytoplasmic	B-T017
Ags	B-T103
,	O
and	O
myeloperoxidase	B-T103
than	O
do	O
TMPD	B-T103
-	O
injected	B-T058
wild	B-T204
-	I-T204
type	I-T204
BALB	I-T204
/	I-T204
c	I-T204
mice	I-T204
.	O

The	O
TMP	B-T103
-	O
injected	B-T058
Tlr9	B-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
mice	B-T204
,	O
and	O
not	O
the	O
wild	B-T204
-	I-T204
type	I-T204
mice	I-T204
,	O
also	O
develop	O
a	O
marked	O
increase	O
in	O
glomerular	B-T103
IgG	I-T103
deposition	O
and	O
infiltrating	O
granulocytes	B-T017
,	O
much	O
more	O
severe	O
glomerulonephritis	B-T038
,	O
and	O
a	O
reduced	O
lifespan	O
.	O

Collectively	O
,	O
the	O
data	O
point	O
to	O
a	O
major	O
role	O
for	O
TLR7	B-T017
in	O
the	O
response	O
to	O
self	B-T103
-	I-T103
antigens	I-T103
in	O
this	O
model	B-T038
of	O
experimental	O
autoimmunity	B-T038
.	O

Therefore	O
,	O
the	O
BALB	B-T204
/	I-T204
c	I-T204
pristane	B-T103
model	B-T038
recapitulates	O
other	O
TLR7	B-T017
-	O
driven	O
spontaneous	O
models	B-T038
of	O
SLE	B-T038
and	O
is	O
negatively	B-T033
regulated	O
by	O
TLR9	B-T017
.	O

Effect	O
of	O
Xenotransplantation	B-T058
Site	B-T082
on	O
MicroRNA	B-T103
Expression	B-T038
of	O
Human	B-T204
Colon	B-T038
Cancer	I-T038
Stem	B-T017
Cells	I-T017

Cancer	B-T017
stem	I-T017
cells	I-T017
(	O
CSCs	B-T017
)	O
have	O
a	O
high	O
tumorigenic	B-T038
ability	O
to	O
form	O
patient	B-T038
-	I-T038
derived	I-T038
tumor	I-T038
xenografts	I-T038
(	O
PDXs	B-T038
)	O
.	O

PDXs	B-T038
are	O
an	O
attractive	O
pre	B-T170
-	I-T170
clinical	I-T170
model	I-T170
,	O
but	O
gene	B-T038
expression	I-T038
and	O
biological	O
behavior	O
of	O
cancer	B-T017
cells	I-T017
in	O
the	O
tumor	B-T038
will	O
change	O
during	O
establishment	O
and	O
passage	O
of	O
PDXs	B-T038
.	O

Human	B-T204
colon	B-T038
cancer	I-T038
PDX	B-T038
was	O
established	O
and	O
passaged	B-T058
either	O
subcutaneously	B-T082
or	O
orthotopically	B-T082
into	O
the	O
murine	B-T204
intestine	B-T017
.	O

Histology	B-T091
and	O
flow	B-T058
cytometric	I-T058
profile	B-T058
of	O
the	O
surgical	B-T058
specimen	O
and	O
the	O
PDX	B-T038
were	O
analyzed	B-T062
.	O

CSCs	B-T017
were	O
then	O
isolated	O
from	O
the	O
tumors	B-T038
and	O
their	O
microRNA	B-T103
(	O
miRNA	B-T103
)	O
expression	B-T038
was	O
analyzed	B-T062
by	O
semi	B-T058
-	I-T058
quantitative	I-T058
polymerase	I-T058
chain	I-T058
reaction	I-T058
.	O

The	O
surgical	B-T058
specimens	O
and	O
PDXs	B-T038
were	O
histologically	B-T091
similar	O
.	O

The	O
size	B-T082
of	O
CSC	B-T017
population	B-T098
increased	O
and	O
expression	B-T038
of	O
miRNA	B-T103
s	O
in	O
CSCs	B-T017
changed	O
in	O
the	O
passaged	B-T058
PDXs	B-T038
.	O

Expression	B-T038
of	O
oncogenic	B-T103
miRNAs	B-T103
was	O
highly	O
up	B-T038
-	I-T038
regulated	I-T038
in	O
the	O
CSCs	B-T017
of	O
the	O
orthotopically	B-T082
passaged	B-T058
PDXs	B-T038
.	O

The	O
xenotransplantation	B-T058
site	B-T082
and	O
the	O
number	O
of	O
tumor	B-T038
passages	B-T058
affect	B-T038
the	O
miRNA	B-T103
expression	B-T038
of	O
human	B-T204
colon	B-T017
CSCs	B-T017
.	O

Chemosensitivity	B-T033
,	O
Cardiovascular	O
Risk	O
,	O
and	O
the	O
Ventilatory	B-T201
Response	I-T201
to	O
Exercise	O
in	O
COPD	B-T038

COPD	B-T038
is	O
associated	O
with	O
elevated	O
cardiovascular	O
risk	O
and	O
a	O
potentiated	O
ventilatory	B-T201
response	I-T201
to	O
exercise	O
.	O

Enhanced	O
carotid	O
chemoreceptor	B-T017
(	O
CC	B-T017
)	O
activity	B-T038
/	O
sensitivity	B-T038
is	O
present	O
in	O
other	O
clinical	O
conditions	O
,	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
sympathetic	B-T022
vasoconstrictor	B-T038
outflow	I-T038
,	O
and	O
is	O
predictive	O
of	O
mortality	B-T033
.	O

CC	B-T017
activity	B-T038
/	O
sensitivity	B-T038
,	O
and	O
the	O
resulting	O
functional	O
significance	O
,	O
has	O
not	O
been	O
well	O
examined	O
in	O
COPD	B-T038
.	O

We	O
hypothesized	O
that	O
CC	B-T017
activity	B-T038
/	O
sensitivity	B-T038
would	O
be	O
elevated	O
in	O
COPD	B-T038
,	O
and	O
related	O
to	O
increased	O
pulse	O
wave	O
velocity	O
(	O
a	O
marker	B-T201
of	O
CV	O
risk	O
)	O
and	O
the	O
ventilatory	B-T201
response	I-T201
to	O
exercise	O
.	O

30	O
COPD	B-T038
patients	O
and	O
10	O
healthy	O
age	O
-	O
matched	O
controls	O
were	O
examined	B-T033
.	O

Participants	B-T098
performed	O
baseline	O
cardiopulmonary	B-T058
exercise	I-T058
and	O
pulmonary	B-T058
function	I-T058
testing	I-T058
.	O

CC	B-T017
activity	B-T038
was	O
later	O
evaluated	B-T058
by	O
the	O
drop	B-T033
in	I-T033
ventilation	B-T038
with	O
breathing	B-T038
100	O
%	O
O2	B-T103
,	O
and	O
CC	B-T017
sensitivity	B-T038
was	O
then	O
assessed	O
by	O
the	O
ventilatory	B-T058
response	I-T058
to	I-T058
hypoxia	I-T058
(	O
ΔVE	O
/	O
ΔS	O
pO2	B-T058
)	O
.	O

Peripheral	B-T082
arterial	B-T038
stiffness	I-T038
was	O
subsequently	O
evaluated	B-T058
by	O
measurement	O
of	O
pulse	O
wave	O
velocity	O
(	O
PWV	O
)	O
using	O
applanation	B-T058
tonometry	I-T058
while	O
the	O
subjects	O
were	O
breathing	B-T038
room	O
air	O
,	O
and	O
then	O
following	O
chemoreceptor	B-T017
inhibition	O
by	O
breathing	B-T038
100	O
%	O
O2	B-T103
for	O
2	O
minutes	O
.	O

CC	B-T017
activity	B-T038
,	O
CC	B-T017
sensitivity	B-T038
,	O
PWV	O
and	O
the	O
ventilatory	B-T201
response	I-T201
to	O
exercise	O
were	O
all	O
increased	O
in	O
COPD	B-T038
relative	O
to	O
controls	O
.	O

CC	B-T017
sensitivity	B-T038
was	O
related	O
to	O
PWV	O
;	O
however	O
,	O
neither	O
CC	B-T017
activity	B-T038
nor	O
CC	B-T017
sensitivity	B-T038
was	O
related	O
to	O
the	O
ventilatory	B-T201
response	I-T201
to	O
exercise	O
in	O
COPD	B-T038
.	O

CC	B-T017
inhibition	O
by	O
breathing	B-T038
100	O
%	O
O2	B-T103
normalized	O
PWV	O
in	O
COPD	B-T038
,	O
while	O
no	O
effect	O
was	O
observed	O
in	O
controls	O
.	O

CC	B-T017
activity	B-T038
and	O
sensitivity	B-T038
are	O
elevated	O
in	O
COPD	B-T038
,	O
and	O
appear	O
related	O
to	O
cardiovascular	O
risk	O
;	O
however	O
,	O
CC	B-T017
activity	B-T038
/	O
sensitivity	B-T038
does	O
not	O
contribute	O
to	O
the	O
potentiated	O
ventilatory	B-T201
response	I-T201
to	O
exercise	O
.	O

Isolation	B-T058
of	I-T058
Cells	I-T058
Specialized	O
in	O
Anticancer	B-T103
Alkaloid	B-T038
Metabolism	I-T038
by	O
Fluorescence	B-T058
-	I-T058
Activated	I-T058
Cell	I-T058
Sorting	I-T058

Plant	B-T204
specialized	O
metabolism	B-T038
often	O
presents	O
a	O
complex	O
cell	B-T017
-	O
specific	O
compartmentation	B-T038
essential	O
to	O
accomplish	O
the	O
biosynthesis	O
of	O
valuable	O
plant	B-T204
natural	B-T103
products	I-T103
.	O

Hence	O
,	O
the	O
disclosure	O
and	O
potential	O
manipulation	O
of	O
such	O
pathways	O
may	O
depend	O
on	O
the	O
capacity	O
to	O
isolate	B-T058
and	O
characterize	O
specific	O
cell	B-T170
types	I-T170
.	O

Catharanthus	B-T204
roseus	I-T204
is	O
the	O
source	O
of	O
several	O
medicinal	B-T103
terpenoid	B-T103
indole	I-T103
alkaloids	I-T103
,	O
including	O
the	O
low	O
-	O
level	O
anticancer	B-T103
vinblastine	B-T103
and	O
vincristine	B-T103
,	O
for	O
which	O
the	O
late	O
biosynthetic	O
steps	O
occur	O
in	O
specialized	O
mesophyll	B-T017
cells	I-T017
called	O
idioblasts	B-T017
.	O

Here	O
,	O
the	O
optical	O
,	O
fluorescence	O
,	O
and	O
alkaloid	B-T103
-	O
accumulating	B-T033
properties	O
of	O
C	B-T204
.	I-T204

roseus	I-T204
leaf	B-T204
idioblasts	B-T017
are	O
characterized	O
,	O
and	O
a	O
methodology	O
for	O
the	O
isolation	B-T058
of	O
idioblast	B-T017
protoplasts	B-T017
by	O
fluorescence	B-T058
-	I-T058
activated	I-T058
cell	I-T058
sorting	I-T058
is	O
established	O
,	O
taking	O
advantage	O
of	O
the	O
distinctive	O
autofluorescence	B-T058
of	O
these	O
cells	B-T017
.	O

This	O
achievement	O
represents	O
a	O
crucial	O
step	O
for	O
the	O
development	O
of	O
differential	O
omic	B-T062
strategies	I-T062
leading	O
to	O
the	O
identification	O
of	O
candidate	B-T017
genes	I-T017
putatively	O
involved	O
in	O
the	O
biosynthesis	O
,	O
pathway	O
regulation	B-T038
,	O
and	O
transmembrane	B-T038
transport	I-T038
leading	O
to	O
the	O
anticancer	B-T033
alkaloids	B-T103
from	O
C	B-T204
.	I-T204

roseus	I-T204
.	O

Interaction	O
of	O
the	O
Antimicrobial	B-T103
Peptides	I-T103
Rhesus	B-T103
θ	I-T103
-	I-T103
Defensin	I-T103
and	O
Porcine	B-T204
Protegrin	B-T103
-	I-T103
1	I-T103
with	O
Anionic	B-T103
Phospholipid	I-T103
Monolayers	I-T103

A	O
combination	O
of	O
Langmuir	B-T170
isotherm	I-T170
,	O
Brewster	B-T058
angle	I-T058
microscopy	I-T058
(	O
BAM	B-T058
)	O
,	O
and	O
neutron	B-T062
reflectivity	I-T062
studies	I-T062
have	O
been	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
on	O
model	O
bacterial	B-T017
cell	I-T017
membranes	I-T017
of	O
the	O
antimicrobial	B-T103
peptides	I-T103
,	O
Rhesus	B-T103
θ	I-T103
-	I-T103
defensin	I-T103
1	I-T103
(	O
RTD	B-T103
-	I-T103
1	I-T103
)	O
,	O
and	O
porcine	B-T204
protegrin	B-T103
1	I-T103
(	O
PG	B-T103
-	I-T103
1	I-T103
)	O
.	O

The	O
peptides	B-T103
were	O
interacted	O
with	O
monolayers	B-T103
spread	O
at	O
the	O
air	O
-	O
water	B-T103
interface	O
and	O
prepared	O
from	O
a	O
3	O
:	O
1	O
molar	O
mixture	O
of	O
phosphatidylethanolamine	B-T103
and	O
phosphatidylglycerol	B-T103
used	O
to	O
approximate	O
the	O
cell	B-T017
membranes	I-T017
of	O
Gram	B-T007
positive	I-T007
bacteria	I-T007
.	O

The	O
Langmuir	O
film	O
balance	O
measurements	O
show	O
that	O
both	O
peptides	B-T103
perturb	O
the	O
lipid	B-T103
monolayers	I-T103
causing	O
an	O
increase	O
in	O
surface	O
pressure	O
,	O
and	O
the	O
BAM	B-T058
studies	O
show	O
that	O
each	O
results	O
in	O
the	O
formation	O
of	O
small	B-T082
domains	I-T082
within	O
the	O
lipid	O
films	O
,	O
around	O
5	O
μm	O
diameter	O
.	O

The	O
overall	O
change	O
in	O
monolayer	B-T103
surface	O
pressure	O
caused	O
by	O
PG	B-T103
-	I-T103
1	I-T103
,	O
however	O
,	O
is	O
a	O
little	O
more	O
pronounced	O
than	O
that	O
due	O
to	O
RTD	B-T103
-	I-T103
1	I-T103
(	O
+	O
8	O
.	O
5	O
mN	O
·	O
m	O
(	O
-	O
1	O
)	O
vs	O
+	O
5	O
.	O
5	O
mN	O
·	O
m	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
the	O
rate	O
of	O
its	O
initial	O
interaction	O
with	O
the	O
monolayer	B-T103
is	O
a	O
little	O
more	O
rapid	O
than	O
that	O
for	O
RTD	B-T103
-	I-T103
1	I-T103
.	O

The	O
neutron	O
reflectivity	O
studies	O
also	O
show	O
differences	O
for	O
PG	B-T103
-	I-T103
1	I-T103
and	O
RTD	B-T103
-	I-T103
1	I-T103
,	O
with	O
the	O
model	O
fits	O
to	O
these	O
data	O
showing	O
that	O
the	O
more	O
amphiphilic	B-T103
PG	B-T103
-	I-T103
1	I-T103
becomes	O
fully	O
embedded	B-T058
within	O
the	O
lipid	O
film	O
-	O
causing	O
an	O
extension	O
of	O
the	O
lipid	O
acyl	O
chains	O
but	O
leaving	O
the	O
thickness	O
of	O
the	O
lipid	O
headgroup	O
layer	O
unaffected	O
-	O
while	O
RTD	B-T103
-	I-T103
1	I-T103
is	O
seen	O
to	O
insert	O
less	O
deeply	O
-	O
causing	O
the	O
same	O
extension	O
of	O
the	O
lipid	O
acyl	O
chains	O
as	O
PG	B-T103
-	I-T103
1	I-T103
but	O
also	O
causing	O
a	O
significant	O
increase	O
in	O
thickness	O
of	O
the	O
lipid	O
headgroup	O
layer	O
.	O

The	O
various	O
differing	O
effects	O
of	O
the	O
two	O
peptides	B-T103
on	O
anionic	B-T103
lipid	I-T103
monolayers	I-T103
are	O
discussed	O
in	O
the	O
context	O
of	O
their	O
differing	O
hemolytic	B-T058
activities	I-T058
,	O
and	O
their	O
proposed	O
differing	O
propensities	O
to	O
form	O
transmembrane	B-T017
pores	B-T017
.	O

Development	B-T038
of	O
chrysin	B-T103
loaded	O
poloxamer	B-T103
micelles	O
and	O
toxicity	O
evaluation	B-T058
in	O
fish	B-T204
embryos	B-T017

Poloxamer	B-T103
micelles	B-T103
promise	O
safety	O
and	O
efficacy	O
for	O
many	O
water	B-T103
insoluble	O
drugs	B-T103
.	O

Chrysin	B-T103
has	O
been	O
reported	O
to	O
have	O
anticancer	O
,	O
anti	O
-	O
inflammatory	O
,	O
antioxidant	B-T038
,	O
and	O
anti	B-T038
-	I-T038
aromatase	I-T038
activities	I-T038
but	O
its	O
water	B-T103
insoluble	O
properties	O
limit	O
its	O
pharmaceutical	B-T091
application	I-T091
.	O

In	O
the	O
present	O
study	O
,	O
chrysin	B-T103
loaded	O
poloxamer	B-T103
micelles	B-T103
were	O
developed	O
.	O

Two	O
types	O
of	O
poloxamers	B-T103
,	O
Pluronic	B-T103
F	I-T103
-	I-T103
68	I-T103
and	O
Pluronic	B-T103
F	I-T103
-	I-T103
127	I-T103
were	O
compared	O
.	O

It	O
was	O
found	O
that	O
chrysin	B-T103
loaded	O
Pluronic	B-T103
F	I-T103
-	I-T103
68	I-T103
micelles	B-T103
(	O
CS	B-T103
-	I-T103
P68	I-T103
)	O
and	O
chrysin	B-T103
loaded	O
Pluronic	B-T103
F	I-T103
-	I-T103
127	I-T103
micelles	B-T103
(	O
CS	B-T103
-	I-T103
P127	I-T103
)	O
obviously	O
increase	O
the	O
aqueous	O
solubility	O
of	O
chrysin	B-T103
.	O

The	O
results	O
also	O
indicated	O
that	O
the	O
type	O
of	O
polymer	B-T103
and	O
ratio	O
of	O
drug	B-T103
to	O
polymer	B-T103
affected	O
size	B-T082
and	O
desirable	O
characteristics	O
of	O
the	O
micelles	B-T103
.	O

The	O
micelle	B-T103
system	I-T103
of	O
CS	B-T103
-	I-T103
P68	I-T103
and	O
CS	B-T103
-	I-T103
P127	I-T103
formed	O
at	O
drug	B-T103
to	O
polymer	B-T103
ratios	O
of	O
1	O
:	O
4	O
and	O
1	O
:	O
2	O
,	O
respectively	O
,	O
was	O
found	O
to	O
be	O
the	O
most	O
suitable	O
monodispersed	O
system	O
with	O
a	O
nanosize	O
-	O
range	O
diameter	O
.	O

The	O
in	O
vivo	O
study	O
in	O
zebrafish	B-T204
eggs	B-T017
indicates	O
that	O
the	O
toxicity	O
of	O
CS	B-T103
-	I-T103
P68	I-T103
and	O
CS	B-T103
-	I-T103
P127	I-T103
is	O
a	O
dose	O
response	O
.	O

CS	B-T103
-	I-T103
P68	I-T103
and	O
CS	B-T103
-	I-T103
P127	I-T103
at	O
a	O
drug	O
dose	O
of	O
10	O
ng	O
/	O
mL	O
or	O
less	O
is	O
safe	O
for	O
zebrafish	B-T204
embryo	B-T017
growth	B-T038
.	O

The	O
results	O
of	O
this	O
study	B-T062
indicate	O
enhanced	O
water	O
solubility	O
of	O
chrysin	B-T103
.	O

Chrysin	B-T103
loaded	O
poloxamer	B-T103
micelles	B-T103
are	O
promising	O
for	O
further	O
use	O
in	O
in	O
vivo	O
studies	O
in	O
mammalian	B-T204
animals	B-T204
and	O
humans	B-T204
.	O

Adenoviral	B-T005
Delivery	B-T058
of	O
Tumor	B-T103
Necrosis	I-T103
Factor	I-T103
-	I-T103
α	I-T103
and	O
Interleukin	B-T103
-	I-T103
2	I-T103
Enables	O
Successful	O
Adoptive	B-T058
Cell	I-T058
Therapy	I-T058
of	O
Immunosuppressive	B-T103
Melanoma	B-T038

Adoptive	B-T058
T	I-T058
-	I-T058
cell	I-T058
transfer	I-T058
is	O
a	O
promising	O
treatment	O
approach	O
for	O
metastatic	B-T038
cancer	I-T038
,	O
but	O
efficacy	O
in	O
solid	B-T038
tumors	I-T038
has	O
only	O
been	O
achieved	O
with	O
toxic	O
pre	O
-	O
and	O
postconditioning	O
regimens	O
.	O

Thus	O
,	O
adoptive	B-T058
T	I-T058
-	I-T058
cell	I-T058
therapies	I-T058
would	O
benefit	O
from	O
complementary	O
modalities	O
that	O
enable	O
their	O
full	O
potential	O
without	O
excessive	O
toxicity	O
.	O

We	O
aimed	O
to	O
improve	O
the	O
efficacy	O
and	O
safety	O
of	O
adoptive	B-T058
T	I-T058
-	I-T058
cell	I-T058
transfer	I-T058
by	O
using	O
adenoviral	B-T103
vectors	I-T103
for	O
direct	O
delivery	O
of	O
immunomodulatory	B-T058
murine	B-T204
cytokines	B-T103
into	O
B16	B-T017
.	I-T017
OVA	I-T017
melanoma	B-T038
tumors	B-T038
with	O
concomitant	O
T	B-T103
-	I-T103
cell	I-T103
receptor	I-T103
transgenic	B-T058
OT	I-T058
-	I-T058
I	I-T058
T	I-T058
-	I-T058
cell	I-T058
transfer	I-T058
.	O

Armed	O
adenoviruses	B-T005
expressed	O
high	O
local	O
and	O
low	O
systemic	O
levels	O
of	O
cytokine	B-T103
when	O
injected	O
into	O
B16	B-T017
.	I-T017
OVA	I-T017
tumors	B-T038
,	O
suggesting	O
safety	O
of	O
virus	B-T058
-	I-T058
mediated	I-T058
cytokine	B-T103
delivery	I-T058
.	O

Antitumor	O
efficacy	O
was	O
significantly	O
enhanced	O
with	O
adenoviruses	B-T005
coding	O
for	O
murine	B-T204
interleukin	B-T103
-	I-T103
2	I-T103
(	O
mIL	B-T103
-	I-T103
2	I-T103
)	O
and	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
-	I-T103
α	I-T103
(	O
mTNFα	B-T103
)	O
when	O
compared	O
with	O
T	B-T058
-	I-T058
cell	I-T058
transfer	I-T058
alone	O
or	O
viruses	B-T005
alone	O
.	O

Further	O
improvement	O
in	O
efficacy	O
was	O
achieved	O
with	O
a	O
triple	O
combination	O
of	O
mIL	B-T103
-	I-T103
2	I-T103
,	O
mTNFα	B-T103
,	O
and	O
OT	B-T017
-	I-T017
I	I-T017
T	I-T017
-	I-T017
cells	I-T017
.	O

Mechanistic	O
studies	O
suggest	O
that	O
mIL	B-T103
-	I-T103
2	I-T103
has	O
an	O
important	O
role	O
in	O
activating	O
T	B-T017
-	I-T017
cells	I-T017
at	O
the	O
tumor	B-T038
,	O
while	O
mTNFα	B-T103
induces	O
chemokine	B-T103
expression	B-T038
.	O

Furthermore	O
,	O
adenovirus	B-T005
treatments	B-T058
enhanced	O
tumor	B-T038
-	O
infiltration	O
of	O
OT	B-T017
-	I-T017
I	I-T017
T	I-T017
-	I-T017
cells	I-T017
as	O
demonstrated	O
by	O
SPECT	B-T058
/	I-T058
CT	I-T058
imaging	I-T058
of	O
(	B-T017
111	I-T017
)	I-T017
In	I-T017
-	I-T017
labeled	I-T017
cells	I-T017
.	O

Our	O
results	O
suggest	O
the	O
utility	O
of	O
cytokine	B-T103
-	I-T103
coding	I-T103
adenoviruses	B-T005
for	O
improving	O
the	O
efficacy	O
of	O
adoptive	B-T058
T	I-T058
-	I-T058
cell	I-T058
therapies	I-T058
.	O

The	O
Maternal	B-T033
Legacy	O
:	O
Female	O
Identity	O
Predicts	O
Offspring	O
Sex	O
Ratio	O
in	O
the	O
Loggerhead	B-T204
Sea	I-T204
Turtle	I-T204

In	O
organisms	O
with	O
temperature	O
-	O
dependent	O
sex	B-T038
determination	I-T038
,	O
the	O
incubation	B-T082
environment	I-T082
plays	O
a	O
key	O
role	O
in	O
determining	O
offspring	O
sex	O
ratios	O
.	O

Given	O
that	O
global	O
temperatures	O
have	O
warmed	O
approximately	O
0	O
.	O
6	O
°C	O
in	O
the	O
last	O
century	O
,	O
it	O
is	O
necessary	O
to	O
consider	O
how	O
organisms	O
will	O
adjust	B-T033
to	O
climate	O
change	O
.	O

To	O
better	O
understand	O
the	O
degree	O
to	O
which	O
mothers	O
influence	O
the	O
sex	O
ratios	O
of	O
their	O
offspring	O
,	O
we	O
use	O
24	O
years	O
of	O
nesting	O
data	O
for	O
individual	B-T098
female	O
loggerhead	B-T204
sea	I-T204
turtles	I-T204
(	O
Caretta	B-T204
caretta	I-T204
)	O
observed	O
on	O
Bald	B-T082
Head	I-T082
Island	I-T082
,	O
North	B-T082
Carolina	I-T082
.	O

We	O
find	O
that	O
maternal	B-T033
identity	O
is	O
the	O
best	O
predictor	O
of	O
nest	O
sex	O
ratio	O
in	O
univariate	O
and	O
multivariate	B-T062
predictive	I-T062
models	I-T062
.	O

We	O
find	O
significant	O
variability	O
in	O
estimated	O
nest	O
sex	O
ratios	O
among	O
mothers	O
,	O
but	O
a	O
high	O
degree	O
of	O
consistency	O
within	O
mothers	O
,	O
despite	O
substantial	O
spatial	O
and	O
temporal	O
thermal	O
variation	O
.	O

Our	O
results	O
suggest	O
that	O
individual	B-T098
differences	O
in	O
nesting	O
preferences	O
are	O
the	O
main	O
driver	O
behind	O
divergences	B-T082
in	O
nest	O
sex	O
ratios	O
.	O

As	O
such	O
,	O
a	O
female	O
'	O
s	O
ability	O
to	O
plastically	O
adjust	O
her	O
nest	O
sex	O
ratios	O
in	O
response	O
to	O
environmental	B-T082
conditions	O
is	O
constrained	O
,	O
potentially	O
limiting	O
how	O
individuals	B-T098
behaviorally	O
mitigate	O
the	O
effects	O
of	O
environmental	O
change	O
.	O

Given	O
that	O
many	O
loggerhead	B-T204
populations	B-T098
already	O
show	O
female	O
-	O
biased	O
offspring	O
sex	O
ratios	O
,	O
understanding	O
maternal	O
behavioral	O
responses	O
is	O
critical	O
for	O
predicting	O
the	O
future	O
of	O
long	O
-	O
lived	O
species	B-T170
vulnerable	O
to	O
extinction	O
.	O

Increased	O
RhoA	B-T103
Activity	O
Predicts	O
Worse	B-T033
Overall	O
Survival	O
in	O
Patients	O
Undergoing	O
Surgical	B-T058
Resection	I-T058
for	O
Lauren	B-T170
Diffuse	B-T038
-	I-T038
Type	I-T038
Gastric	I-T038
Adenocarcinoma	I-T038

Several	O
studies	O
have	O
reported	O
a	O
high	O
rate	O
of	O
RHOA	B-T017
mutations	B-T038
in	O
the	O
Lauren	B-T170
diffuse	B-T038
-	I-T038
type	I-T038
gastric	I-T038
adenocarcinoma	I-T038
(	O
GA	B-T038
)	O
but	O
not	O
in	O
intestinal	B-T038
-	I-T038
type	I-T038
GA	I-T038
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
RhoA	B-T103
activity	O
is	O
prognostic	B-T201
for	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	O
with	O
resectable	O
GA	B-T038
.	O

Retrospective	B-T062
review	I-T062
was	O
performed	O
on	O
a	O
prospective	O
database	O
of	O
GA	B-T038
patients	O
who	O
underwent	O
potentially	O
curative	B-T058
resection	I-T058
between	O
2003	O
and	O
2012	O
at	O
a	O
single	B-T092
institution	I-T092
.	O

Tissue	B-T017
microarrays	O
were	O
constructed	O
from	O
surgical	O
specimens	O
and	O
analyzed	O
for	O
phosphorylated	B-T103
RhoA	B-T103
,	O
a	O
marker	B-T201
of	O
inactive	O
RhoA	B-T103
signaling	B-T038
.	O

OS	O
was	O
estimated	O
by	O
the	O
Kaplan	B-T062
-	I-T062
Meier	I-T062
method	I-T062
,	O
and	O
multivariate	O
analysis	O
was	O
performed	O
by	O
Cox	B-T170
proportional	I-T170
hazards	I-T170
regression	I-T170
modeling	I-T170
.	O

One	O
hundred	O
thirty	O
-	O
six	O
patients	O
with	O
diffuse	B-T038
-	I-T038
type	I-T038
GA	I-T038
and	O
129	O
patients	O
with	O
intestinal	B-T038
-	I-T038
type	I-T038
GA	I-T038
were	O
examined	O
.	O

Compared	O
to	O
intestinal	B-T038
-	I-T038
type	I-T038
GA	I-T038
,	O
diffuse	B-T038
-	I-T038
type	I-T038
GA	I-T038
tumors	B-T038
were	O
significantly	O
associated	O
with	O
increased	O
tumor	B-T082
size	I-T082
and	O
advanced	B-T170
tumor	I-T170
,	I-T170
node	I-T170
,	I-T170
metastasis	I-T170
(	I-T170
TNM	I-T170
)	I-T170
classification	I-T170
system	I-T170
stage	I-T170
.	O

In	O
patients	O
with	O
diffuse	B-T038
-	I-T038
type	I-T038
GA	I-T038
,	O
high	O
RhoA	B-T103
activity	O
was	O
associated	O
with	O
significantly	O
worse	B-T033
OS	O
when	O
compared	O
to	O
low	O
RhoA	B-T103
activity	O
(	O
5	O
-	O
year	O
OS	O
52	O
.	O
5	O
vs	O
.	O

81	O
.	O
0	O
%	O
,	O
p	O
=	O
0	O
.	O
017	O
)	O
.	O

This	O
difference	O
in	O
OS	O
was	O
not	O
observed	O
in	O
patients	O
with	O
intestinal	B-T038
-	I-T038
type	I-T038
GA	I-T038
(	O
5	O
-	O
year	O
OS	O
83	O
.	O
9	O
vs	O
.	O

81	O
.	O
6	O
%	O
,	O
p	O
=	O
0	O
.	O
766	O
)	O
.	O

On	O
multivariate	O
analysis	O
of	O
diffuse	B-T038
-	I-T038
type	I-T038
GA	I-T038
patients	O
,	O
high	O
RhoA	B-T103
activity	O
was	O
an	O
independent	O
negative	O
prognostic	B-T201
factor	I-T201
for	O
OS	O
(	O
hazard	O
ratio	O
2	O
.	O
38	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
07	O
-	O
5	O
.	O
28	O
)	O
.	O

Increased	O
RhoA	B-T103
activity	O
is	O
predictive	O
of	O
worse	B-T033
OS	O
in	O
patients	O
with	O
diffuse	B-T038
-	I-T038
type	I-T038
GA	I-T038
who	O
undergo	O
potentially	O
curative	B-T058
surgical	I-T058
resection	I-T058
.	O

Along	O
with	O
findings	O
from	O
genomic	B-T091
studies	I-T091
,	O
these	O
results	O
suggest	O
RhoA	B-T103
may	O
be	O
a	O
novel	O
therapeutic	B-T058
target	O
in	O
diffuse	B-T038
-	I-T038
type	I-T038
GA	I-T038
.	O

Doxifluridine	B-T103
-	O
conjugated	B-T082
2	B-T103
-	I-T103
5A	I-T103
analog	B-T103
shows	O
strong	O
RNase	B-T103
L	I-T103
activation	O
ability	O
and	O
tumor	B-T038
suppressive	I-T038
effect	O

RNase	B-T103
L	I-T103
is	O
activated	O
by	O
2	B-T103
'	I-T103
,	I-T103
5	I-T103
'	I-T103
-	I-T103
oligoadenylates	I-T103
(	O
2	B-T103
-	I-T103
5A	I-T103
)	O
at	O
subnanomolar	O
levels	O
to	O
cleave	B-T082
single	B-T103
-	I-T103
stranded	I-T103
RNA	I-T103
.	O

We	O
previously	O
reported	B-T170
the	O
hypothesis	O
that	O
the	O
introduction	O
of	O
an	O
8	B-T103
-	I-T103
methyladenosine	I-T103
residue	O
at	O
the	O
2	O
'	O
-	O
terminus	B-T082
of	O
the	O
2	B-T103
-	I-T103
5A	I-T103
tetramer	I-T103
shifts	O
the	O
2	B-T103
-	I-T103
5A	I-T103
binding	B-T103
site	I-T103
of	O
RNase	B-T103
L	I-T103
.	O

In	O
this	O
study	B-T062
,	O
we	O
synthesized	O
various	O
5	O
'	O
-	O
modified	O
2	B-T103
-	I-T103
5A	I-T103
analog	B-T103
s	O
with	O
8	B-T103
-	I-T103
methyladenosine	I-T103
at	O
the	O
2	O
'	O
-	O
terminus	B-T082
.	O

The	O
doxifluridine	B-T103
-	O
conjugated	B-T082
8	B-T103
-	I-T103
methyladenosine	I-T103
-	O
substituted	O
2	B-T103
-	I-T103
5A	I-T103
analog	B-T103
was	O
significantly	O
more	O
effective	O
as	O
an	O
activator	O
of	O
RNase	B-T103
L	I-T103
than	O
the	O
parent	O
5	O
'	O
-	O
monophophorylated	B-T038
2	B-T103
-	I-T103
5A	I-T103
tetramer	I-T103
and	O
showed	O
a	O
tumor	B-T038
suppressive	I-T038
effect	O
against	O
human	B-T204
cervical	B-T038
cancer	I-T038
cells	B-T017
.	O

Does	O
Video	O
Laryngoscopy	O
Offer	O
Advantages	O
over	O
Direct	B-T058
Laryngoscopy	I-T058
during	O
Cardiopulmonary	B-T058
Resuscitation	I-T058
?	O

Interruption	O
of	O
chest	O
compressions	O
should	O
be	O
minimized	O
because	O
of	O
its	O
negative	B-T033
effects	O
on	O
survival	O
.	O

This	O
randomized	B-T062
,	O
controlled	O
,	O
cross	B-T062
-	I-T062
over	I-T062
study	I-T062
aimed	O
to	O
analyze	B-T062
the	O
effectiveness	O
of	O
Macintosh	B-T074
,	O
Miller	B-T074
,	O
McCoy	B-T074
and	O
McGrath	B-T074
laryngoscopes	I-T074
during	O
with	O
or	O
without	O
chest	O
compressions	O
in	O
the	O
scope	O
of	O
a	O
simulated	O
cardiopulmonary	B-T058
resuscitation	I-T058
scenario	O
.	O

The	O
time	O
required	O
for	O
successful	O
tracheal	B-T058
intubation	I-T058
,	O
number	B-T201
of	I-T201
attempts	I-T201
,	O
dental	B-T037
trauma	I-T037
severity	O
and	O
the	O
need	O
for	O
optimization	O
manoeuvres	O
were	O
recorded	B-T033
during	O
cardiopulmonary	B-T058
resuscitation	I-T058
with	O
and	O
without	O
chest	O
compressions	O
.	O

The	O
experience	B-T038
with	O
computer	O
games	O
during	O
the	O
last	O
10	O
years	O
were	O
asked	O
to	O
the	O
participants	B-T098
and	O
recorded	B-T033
.	O

McCoy	B-T074
laryngoscope	I-T074
yielded	O
the	O
shortest	O
time	O
for	O
successful	O
tracheal	B-T058
intubation	I-T058
both	O
in	O
the	O
presence	B-T033
of	O
and	O
without	O
chest	O
compressions	O
.	O

During	O
the	O
use	O
of	O
McCoy	B-T074
laryngoscopes	I-T074
,	O
fewer	O
tracheal	B-T058
intubation	I-T058
attempts	O
,	O
lower	O
incidence	O
of	O
dental	B-T037
trauma	I-T037
and	O
lower	O
visual	B-T201
analogue	I-T201
scale	I-T201
scores	I-T201
on	O
the	O
ease	O
of	O
intubation	B-T058
were	O
recorded	B-T033
.	O

Participants	B-T098
who	O
are	O
experienced	B-T038
computer	O
game	O
players	B-T098
using	O
Macintosh	B-T074
,	O
McCoy	B-T074
and	O
McGrath	B-T074
achieved	B-T033
successful	O
tracheal	B-T058
intubation	I-T058
in	O
a	O
significantly	O
shorter	O
time	O
during	O
resuscitation	B-T058
without	O
chest	O
compressions	O
.	O

Dental	B-T037
trauma	I-T037
incidence	O
and	O
number	O
of	O
tracheal	B-T058
intubation	I-T058
attempts	O
did	O
not	O
show	O
any	O
significant	O
difference	O
between	O
the	O
four	O
laryngoscopes	B-T074
being	O
related	O
to	O
the	O
rate	O
of	O
playing	O
computer	O
games	O
.	O

McGrath	O
video	O
laryngoscopes	O
do	O
not	O
appear	O
to	O
have	O
advantages	O
over	O
direct	B-T058
laryngoscopes	I-T058
for	O
securing	O
a	O
smooth	O
and	O
successful	O
tracheal	B-T058
intubation	I-T058
during	O
rhythmic	O
chest	O
compressions	O
.	O

We	O
believe	O
that	O
as	O
McCoy	B-T074
laryngoscope	I-T074
provided	O
tracheal	B-T058
intubation	I-T058
in	O
a	O
shorter	O
time	O
and	O
with	O
fewer	O
attempts	O
,	O
this	O
laryngoscope	B-T074
may	O
increase	O
the	O
success	O
rate	O
of	O
resuscitation	B-T058
.	O

The	O
nurse	O
-	O
patient	O
communication	O
:	O
voices	O
from	O
nursing	B-T097
students	I-T097

Effective	O
communication	O
skills	O
have	O
been	O
found	O
to	O
be	O
one	O
of	O
the	O
pivotal	O
factors	O
in	O
building	O
positive	O
interpersonal	O
relationships	O
.	O

Little	O
is	O
known	O
about	O
nursing	B-T097
undergraduates	I-T097
'	O
perspectives	O
on	O
communicating	O
with	O
patients	O
.	O

This	O
study	B-T062
aimed	O
to	O
explore	O
nursing	B-T097
students	I-T097
'	I-T097
perspectives	O
and	O
experiences	B-T038
of	O
nurse	O
-	O
patient	O
communication	O
in	O
their	O
clinical	O
placement	O
.	O

The	O
participants	B-T098
included	O
21	O
second	B-T098
-	I-T098
year	I-T098
undergraduates	I-T098
and	O
21	O
first	B-T098
-	I-T098
year	I-T098
master	I-T098
'	I-T098
s	I-T098
students	I-T098
.	O

Interviews	O
were	O
conducted	O
in	O
Cantonese	O
and	O
then	O
transcribed	O
in	O
Chinese	O
and	O
translated	O
into	O
English	O
.	O

A	O
content	O
analysis	O
approach	B-T082
was	O
adopted	O
to	O
analyze	O
the	O
data	O
.	O

Five	O
themes	O
emerged	O
from	O
the	O
interview	O
data	O
.	O

'	O
The	O
necessity	O
of	O
nurse	O
-	O
patient	O
communication	O
'	O
reveals	O
why	O
the	O
students	B-T098
valued	O
nurse	O
-	O
patient	O
communication	O
.	O

'	O
The	O
conversation	B-T033
contents	I-T033
'	O
describes	O
the	O
content	B-T033
of	I-T033
the	I-T033
conversations	I-T033
that	O
students	B-T098
typically	O
had	O
with	O
patients	O
.	O

The	O
third	O
theme	O
is	O
'	O
self	B-T033
-	I-T033
reflection	I-T033
on	O
the	O
nurse	O
-	O
patient	O
communication	O
'	O
.	O

The	O
last	O
two	O
themes	O
,	O
'	O
the	O
communication	O
pattern	O
in	O
different	O
hospital	B-T092
settings	I-T092
'	O
and	O
'	O
the	O
obstacles	O
impeding	O
nurse	O
-	O
patient	O
communication	O
'	O
,	O
are	O
about	O
the	O
students	B-T098
'	I-T098
communication	O
styles	O
in	O
different	O
hospitals	B-T092
and	O
the	O
barriers	O
they	O
encounter	O
.	O

To	O
improve	B-T033
students	B-T098
'	I-T098
communication	O
skills	O
,	O
educators	B-T097
and	O
clinical	B-T097
staff	I-T097
should	O
listen	O
to	O
students	B-T098
,	O
enhance	O
students	B-T098
'	I-T098
reflective	O
skills	O
and	O
strengthen	O
their	O
confidence	B-T038
.	O

Through	O
understanding	B-T038
students	B-T098
'	I-T098
difficulties	O
in	O
the	O
nurse	O
-	O
patient	O
communication	O
experience	B-T038
and	O
the	O
skills	O
that	O
they	O
lack	O
,	O
educators	B-T097
can	O
provide	O
them	O
with	O
helpful	O
recommendations	O
to	O
improve	B-T033
their	O
communication	O
skills	O
in	O
clinical	O
practice	O
.	O

The	O
results	O
of	O
this	O
study	B-T062
reveal	O
that	O
students	B-T098
'	I-T098
nurse	O
-	O
patient	O
communication	O
skills	O
need	O
to	O
be	O
improved	B-T033
.	O

Early	O
hippocampal	B-T017
volume	B-T033
loss	I-T033
as	O
a	O
marker	B-T201
of	O
eventual	O
memory	B-T038
deficits	I-T038
caused	O
by	O
repeated	B-T033
stress	I-T033

Exposure	O
to	O
severe	O
and	O
prolonged	O
stress	B-T033
has	O
detrimental	B-T033
effects	I-T033
on	O
the	O
hippocampus	B-T017
.	O

However	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
gradual	O
changes	O
in	O
hippocampal	B-T017
structure	I-T017
,	O
and	O
its	O
behavioral	O
consequences	O
,	O
over	O
the	O
course	O
of	O
repeated	B-T033
stress	I-T033
.	O

Behavioral	B-T058
analyses	I-T058
during	O
10	O
days	O
of	O
chronic	O
stress	O
pointed	O
to	O
a	O
delayed	O
decline	O
in	O
spatial	B-T038
memory	I-T038
,	O
the	O
full	O
impact	O
of	O
which	O
is	O
evident	O
only	O
after	O
the	O
end	O
of	O
stress	B-T033
.	O

In	O
contrast	O
,	O
concurrent	O
volumetric	O
measurements	O
in	O
the	O
same	O
animals	B-T204
revealed	O
significant	O
reduction	O
in	O
hippocampal	B-T017
volumes	O
in	O
stressed	B-T033
animals	B-T204
relative	O
to	O
their	O
unstressed	B-T033
counterparts	I-T033
,	O
as	O
early	O
as	O
the	O
third	O
day	O
of	O
stress	B-T033
.	O

Notably	O
,	O
animals	B-T204
that	O
were	O
behaviorally	O
the	O
worst	O
affected	O
at	O
the	O
end	O
of	O
chronic	O
stress	O
suffered	B-T038
the	O
most	O
pronounced	O
early	B-T033
loss	I-T033
in	I-T033
hippocampal	I-T033
volume	I-T033
.	O

Together	O
,	O
these	O
findings	O
support	O
the	O
view	O
that	O
not	O
only	O
is	O
smaller	O
hippocampal	B-T017
volume	O
linked	O
to	O
stress	B-T033
-	O
induced	O
memory	B-T038
deficits	I-T038
,	O
but	O
it	O
may	O
also	O
act	O
as	O
an	O
early	O
risk	B-T033
factor	I-T033
for	O
the	O
eventual	O
development	O
of	O
cognitive	B-T038
impairments	I-T038
seen	O
in	O
stress	O
-	O
related	O
psychiatric	O
disorders	O
.	O

The	O
Association	O
between	O
C9orf72	B-T017
Repeats	B-T082
and	O
Risk	O
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
Disease	I-T038
and	O
Amyotrophic	B-T038
Lateral	I-T038
Sclerosis	I-T038
:	O
A	O
Meta	B-T062
-	I-T062
Analysis	I-T062

C9orf72	B-T017
is	O
the	O
most	O
common	O
genetic	O
cause	O
of	O
amyotrophic	B-T038
lateral	I-T038
sclerosis	I-T038
(	O
ALS	B-T038
)	O
and	O
frontotemporal	B-T038
dementia	I-T038
(	O
FTD	B-T038
)	O
in	O
Caucasian	B-T098
populations	I-T098
.	O

However	O
,	O
the	O
relationship	O
between	O
C9orf72	B-T017
repeats	B-T082
and	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
was	O
not	O
clear	O
.	O

Additionally	O
,	O
there	O
were	O
few	O
articles	B-T170
assessing	O
C9orf72	B-T017
in	O
other	O
ethnicities	O
with	O
ALS	B-T038
.	O

In	O
this	O
meta	B-T062
-	I-T062
analysis	I-T062
,	O
we	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
C9orf72	B-T017
repeat	B-T038
expansions	I-T038
(	O
≥30	O
repeats	B-T082
)	O
and	O
intermediate	B-T082
repeat	B-T082
copies	I-T082
(	O
20	O
-	O
29	O
repeats	B-T082
)	O
and	O
AD	B-T038
or	O
ALS	B-T038
.	O

The	O
results	O
suggested	O
positive	B-T033
correlations	O
between	O
C9orf72	B-T017
repeat	B-T038
expansions	I-T038
and	O
the	O
risk	O
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
OR	O
=	O
6	O
.	O
36	O
,	O
95	O
%	O
CI	O
=	O
3	O
.	O
13	O
-	O
12	O
.	O
92	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
)	O
,	O
while	O
intermediate	B-T082
repeat	B-T082
copies	I-T082
of	O
C9orf72	B-T017
gene	I-T017
were	O
not	O
associated	O
with	O
the	O
risk	O
of	O
the	O
disease	B-T038
.	O

C9orf72	B-T017
repeat	B-T038
expansions	I-T038
were	O
positively	B-T033
correlated	O
with	O
the	O
risk	O
of	O
familial	B-T038
and	O
sporadic	B-T038
ALS	I-T038
(	O
OR	O
=	O
293	O
.	O
25	O
,	O
95	O
%	O
CI	O
=	O
148	O
.	O
17	O
-	O
580	O
.	O
38	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
;	O
OR	O
=	O
35	O
.	O
57	O
,	O
95	O
%	O
CI	O
=	O
19	O
.	O
61	O
-	O
64	O
.	O
51	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
)	O
.	O

There	O
was	O
a	O
positive	B-T033
correlation	O
between	O
the	O
gene	O
variations	O
and	O
ALS	B-T038
risk	O
among	O
Caucasians	B-T098
and	O
Asians	B-T098
(	O
OR	O
=	O
57	O
.	O
56	O
,	O
95	O
%	O
CI	O
=	O
36	O
.	O
73	O
-	O
90	O
.	O
22	O
,	O
and	O
p	O
<	O
0	O
.	O
00001	O
;	O
OR	O
=	O
6	O
.	O
35	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
39	O
-	O
29	O
.	O
02	O
,	O
and	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Demonstration	O
and	O
validation	B-T062
of	O
a	O
new	O
pressure	O
-	O
based	O
MRI	B-T074
-	O
safe	O
pain	B-T033
tolerance	I-T033
device	B-T074

One	O
of	O
the	O
barriers	O
to	O
studying	O
the	O
behavioral	O
and	O
emotional	B-T038
effects	O
of	O
pain	B-T033
using	O
functional	B-T058
Magnetic	I-T058
Resonance	I-T058
Imaging	I-T058
(	O
fMRI	B-T058
)	O
is	O
the	O
absence	O
of	O
a	O
commercially	O
available	O
,	O
MRI	B-T074
-	O
compatible	O
,	O
pressure	O
-	O
based	O
algometer	B-T074
to	O
elicit	O
pain	B-T033
.	O

The	O
present	O
study	O
sought	O
to	O
address	O
this	O
barrier	O
through	O
creation	O
and	O
validation	O
of	O
a	O
novel	O
MRI	B-T074
-	O
safe	O
apparatus	B-T074
capable	O
of	O
delivering	O
incremental	O
,	O
measurable	O
amounts	O
of	O
pressure	O
inside	O
a	O
scanning	B-T074
bore	I-T074
.	O

We	O
introduced	O
an	O
MR	O
-	O
safe	O
device	B-T074
used	O
to	O
administer	O
pressure	O
-	O
based	O
pain	B-T033
.	O

To	O
test	B-T058
against	O
a	O
commercially	O
available	O
,	O
MRI	B-T074
-	O
incompatible	O
algometer	B-T074
(	O
AlgoMed	B-T074
)	O
,	O
199	O
participants	O
reported	O
their	O
pain	B-T033
tolerance	I-T033
for	O
both	O
devices	O
.	O

A	O
second	O
experiment	O
tested	B-T058
the	O
validity	O
of	O
pressure	O
-	O
based	O
pain	B-T033
in	O
an	O
MRI	B-T074
environment	B-T082
by	O
comparing	O
brain	B-T017
activation	O
with	O
established	O
neural	B-T017
networks	I-T017
for	O
pain	B-T033
.	O

10	O
participants	O
performed	O
an	O
identical	O
procedure	O
to	O
test	B-T058
for	O
pain	B-T033
tolerance	O
while	O
being	O
scanned	B-T058
in	O
a	O
7T	O
MRI	B-T074
scanner	I-T074
.	O

Results	O
support	O
the	O
validity	O
and	O
reliability	O
of	O
our	O
novel	O
device	B-T074
.	O

In	O
Study	O
1	O
,	O
pain	B-T033
tolerance	I-T033
with	O
this	O
device	B-T074
was	O
strongly	O
correlated	O
with	O
pain	B-T033
tolerance	I-T033
as	O
measured	O
by	O
a	O
commercially	O
available	O
algometer	B-T074
(	O
r	O
=	O
0	O
.	O
78	O
)	O
.	O

In	O
Study	O
2	O
,	O
this	O
device	B-T074
yielded	O
BOLD	B-T038
activation	O
within	O
the	O
insula	B-T017
(	O
BA	B-T017
13	I-T017
)	O
and	O
anterior	B-T017
cingulate	I-T017
gyrus	I-T017
(	O
BA	B-T082
24	I-T082
)	O
;	O
as	O
pressure	O
increased	O
,	O
activation	O
in	O
these	O
areas	O
parametrically	O
increased	O
.	O

These	O
findings	O
correspond	O
to	O
other	O
studies	O
using	O
thermal	O
,	O
electrical	O
,	O
or	O
mechanical	B-T058
pain	B-T033
applications	I-T033
.	O

Behavioral	O
and	O
functional	O
data	O
demonstrate	O
that	O
this	O
new	O
device	B-T074
is	O
a	O
valid	O
method	O
of	O
administering	B-T058
pressure	O
-	O
related	O
pain	B-T033
in	O
MRI	B-T074
environments	B-T082
.	O

Our	O
novel	O
MRI	B-T074
-	O
safe	O
device	B-T074
is	O
a	O
valid	O
instrument	B-T074
to	O
measure	O
and	O
administer	O
pressure	O
-	O
based	O
pain	B-T033
.	O

Anti	O
-	O
Inflammatory	O
Properties	O
of	O
Menthol	B-T103
and	O
Menthone	B-T103
in	O
Schistosoma	B-T038
mansoni	I-T038
Infection	I-T038

Schistosomiasis	B-T038
is	O
a	O
parasitic	B-T038
disease	I-T038
caused	O
by	O
several	O
species	B-T170
of	O
trematode	B-T204
worms	I-T204
and	O
it	O
is	O
believed	O
that	O
more	O
than	O
261	O
million	O
people	B-T098
are	O
affected	O
worldwide	O
.	O

New	O
drug	B-T091
development	I-T091
has	O
become	O
essential	O
because	O
there	O
is	O
a	O
risk	O
of	O
the	O
parasite	B-T204
becoming	O
resistant	B-T038
to	O
Praziquantel	B-T103
,	O
the	O
only	O
drug	B-T103
available	O
for	O
this	O
infection	B-T038
.	O

This	O
study	B-T062
evaluated	B-T058
parasitological	O
,	O
immunological	O
and	O
histological	O
parameters	B-T033
in	O
mice	B-T204
infected	B-T033
with	O
Schistosoma	B-T204
mansoni	I-T204
and	O
treated	B-T058
with	I-T058
an	O
herbal	B-T103
commercial	I-T103
medicine	I-T103
.	O

This	O
drug	B-T103
consists	O
of	O
menthol	B-T103
(	O
30	O
-	O
55	O
%	O
)	O
and	O
menthone	B-T103
(	O
14	O
-	O
32	O
%	O
)	O
.	O

A	O
60	O
day	O
treatment	B-T058
regimen	I-T058
with	O
the	O
herbal	B-T103
medicine	I-T103
decreased	O
the	O
number	O
of	O
S	B-T204
.	I-T204

mansoni	I-T204
eggs	B-T204
in	O
the	O
feces	B-T031
,	O
liver	B-T017
,	O
and	O
intestine	B-T017
and	O
reduced	O
the	O
number	O
of	O
hepatic	B-T038
granulomas	I-T038
.	O

We	O
observed	O
a	O
reduction	B-T058
of	O
84	O
%	O
in	O
blood	B-T038
eosinophilia	I-T038
and	O
a	O
decrease	O
in	O
the	O
IL	B-T103
-	I-T103
4	I-T103
and	O
IL	B-T103
-	I-T103
10	I-T103
blood	B-T031
levels	I-T031
after	O
treatment	B-T058
.	O

Therefore	O
,	O
we	O
propose	O
that	O
schistosomiasis	B-T038
treatment	B-T058
with	O
this	O
herbal	B-T103
medicine	I-T103
for	O
60	O
days	O
has	O
an	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
action	O
in	O
this	O
animal	B-T204
model	I-T204
for	O
schistosomiasis	B-T038
thus	O
contributing	O
to	O
the	O
decrease	O
in	O
physio	O
pathological	O
effects	O
caused	O
by	O
S	B-T038
.	I-T038

mansoni	I-T038
infection	I-T038
.	O

Catastrophic	B-T038
health	O
expenditure	O
:	O
a	O
comparative	O
analysis	O
of	O
empty	O
-	O
nest	O
and	O
non	O
-	O
empty	O
-	O
nest	O
households	O
with	O
seniors	B-T098
in	O
Shandong	B-T082
,	I-T082
China	I-T082

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	O
the	O
catastrophic	B-T038
health	O
expenditure	O
(	O
CHE	O
)	O
prevalence	O
and	O
its	O
determinants	O
between	O
empty	O
-	O
nest	O
and	O
non	O
-	O
empty	O
-	O
nest	O
elderly	B-T098
households	O
.	O

Shandong	B-T082
province	I-T082
of	I-T082
China	I-T082
.	O

A	O
total	O
of	O
2761	O
elderly	B-T098
households	O
are	O
included	O
in	O
the	O
analysis	B-T062
.	O

CHE	O
incidence	O
among	O
elderly	B-T098
households	O
was	O
44	O
.	O
9	O
%	O
.	O

The	O
CHE	O
incidence	O
of	O
empty	O
-	O
nest	O
singles	B-T033
(	O
59	O
.	O
3	O
%	O
,	O
p	O
=	O
0	O
.	O
000	O
,	O
OR	O
=	O
3	O
.	O
19	O
)	O
and	O
empty	O
-	O
nest	O
couples	O
(	O
52	O
.	O
9	O
%	O
,	O
p	O
=	O
0	O
.	O
000	O
,	O
OR	O
=	O
2	O
.	O
45	O
)	O
are	O
both	O
statistically	O
higher	O
than	O
that	O
of	O
non	O
-	O
empty	O
-	O
nest	O
elderly	B-T098
households	O
(	O
31	O
.	O
4	O
%	O
)	O
.	O

An	O
inverse	O
association	O
was	O
observed	O
between	O
CHE	O
incidence	O
and	O
income	O
level	O
in	O
all	O
elderly	B-T098
household	O
types	O
.	O

Factors	O
including	O
1	O
or	O
more	O
household	O
elderly	B-T098
members	I-T098
with	O
non	B-T038
-	I-T038
communicable	I-T038
chronic	I-T038
diseases	I-T038
in	O
the	O
past	O
6	O
months	O
,	O
1	O
or	O
more	O
elderly	B-T098
household	O
members	O
being	O
hospitalised	B-T033
in	O
the	O
past	O
year	O
and	O
lower	O
household	O
income	O
,	O
are	O
significant	O
risk	B-T033
factors	I-T033
for	O
CHE	O
in	O
all	O
3	O
household	O
types	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Health	B-T058
insurance	I-T058
status	O
was	O
found	O
to	O
be	O
a	O
significant	O
determinant	O
of	O
CHE	O
among	O
empty	O
-	O
nest	O
singles	B-T033
and	O
non	O
-	O
empty	O
-	O
nest	O
households	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CHE	O
incidence	O
among	O
elderly	B-T098
households	O
is	O
high	O
in	O
China	B-T082
.	O

Empty	O
-	O
nest	O
households	O
are	O
at	O
higher	O
risk	O
for	O
CHE	O
than	O
non	O
-	O
empty	O
-	O
nest	O
households	O
.	O

Based	O
on	O
these	O
findings	B-T033
,	O
we	O
suggest	O
that	O
special	O
insurance	B-T058
be	O
developed	O
to	O
broaden	B-T082
the	O
coverage	O
of	O
health	B-T058
services	I-T058
and	O
heighten	O
the	O
reimbursement	B-T058
rate	I-T058
for	O
empty	O
-	O
nest	O
elderly	B-T098
in	O
the	O
existing	O
health	B-T058
insurance	I-T058
schemes	B-T170
.	O

Financial	O
and	O
social	O
protection	O
interventions	O
are	O
also	O
essential	O
for	O
identifie	O
d	O
at	O
-	O
risk	O
subgroups	B-T170
among	O
different	O
types	O
of	O
elderly	B-T098
households	O
.	O

Role	O
of	O
agonistic	B-T103
autoantibodies	I-T103
against	O
type	B-T103
-	I-T103
1	I-T103
angiotensin	I-T103
II	I-T103
receptor	I-T103
in	O
the	O
pathogenesis	B-T038
of	O
retinopathy	B-T038
in	O
preeclampsia	B-T038

To	O
investigate	O
the	O
mechanism	O
underlying	O
AT1	B-T103
-	I-T103
AA	I-T103
-	O
induced	O
retinopathy	B-T038
in	O
severe	O
preeclampsia	B-T038
by	O
measuring	O
the	O
positive	O
rate	O
and	O
titer	O
of	O
AT1	B-T103
-	I-T103
AA	I-T103
in	O
plasma	B-T031
from	O
women	B-T098
with	O
severe	B-T038
preeclampsia	I-T038
and	O
normal	O
pregnant	B-T098
women	I-T098
to	O
see	O
whether	O
AT1	B-T103
-	I-T103
AA	I-T103
titer	O
was	O
correlated	O
with	O
the	O
grade	O
of	O
retinopathy	B-T038
.	O

A	O
preeclampsia	B-T038
rat	B-T204
model	B-T204
was	O
also	O
established	O
by	O
intravenous	O
injection	O
of	O
AT1	B-T103
-	I-T103
AA	I-T103
extracted	O
from	O
the	O
plasma	B-T031
of	O
patient	O
suffering	O
from	O
severe	B-T038
preeclampsia	I-T038
.	O

The	O
results	O
showed	O
that	O
the	O
plasma	B-T031
titer	O
and	O
positive	O
rate	O
of	O
AT1	B-T103
-	I-T103
AA	I-T103
were	O
significantly	O
higher	O
in	O
women	B-T098
with	O
severe	B-T038
preeclampsia	I-T038
than	O
normal	O
pregnant	B-T098
women	I-T098
.	O

The	O
antibody	B-T103
titer	O
in	O
cases	O
of	O
severe	O
preeclampsia	B-T038
was	O
associated	O
with	O
the	O
grade	O
of	O
retinopathy	B-T038
,	O
and	O
positively	O
correlated	O
with	O
the	O
level	O
of	O
TNF	B-T103
-	I-T103
α	I-T103
and	O
VEGF	B-T103
.	O

The	O
animal	B-T062
experiment	I-T062
results	O
showed	O
that	O
the	O
modeled	B-T204
rats	I-T204
presented	O
symptoms	B-T033
very	O
similar	O
to	O
symptoms	B-T033
of	O
human	B-T204
preeclampsia	B-T038
,	O
including	O
retinopathy	B-T038
.	O

Ocular	O
fundus	O
examination	B-T058
showed	O
retinal	B-T033
microvascular	I-T033
abnormalities	I-T033
,	O
hemorrhaging	B-T038
and	O
leakage	B-T033
in	O
the	O
severe	B-T038
preeclampsia	I-T038
.	O

Morphological	O
changes	O
included	O
edema	B-T033
,	O
thickening	B-T033
of	O
the	O
INL	B-T017
and	O
ONL	B-T017
,	O
and	O
pigment	B-T033
atrophy	I-T033
.	O

TNF	B-T103
-	I-T103
α	I-T103
and	O
VEGF	B-T103
levels	O
were	O
increased	O
in	O
the	O
vitreous	B-T031
humor	I-T031
and	O
retina	B-T017
of	O
the	O
model	B-T204
rats	I-T204
.	O

Our	O
studies	B-T062
results	O
suggest	O
that	O
abnormal	B-T038
expression	I-T038
of	O
AT1	B-T103
-	I-T103
AA	I-T103
could	O
induce	O
damage	O
to	O
retinal	B-T017
capillary	I-T017
endothelial	I-T017
cells	I-T017
and	O
increase	O
vascular	B-T038
permeability	I-T038
,	O
resulting	O
in	O
retinopathy	B-T038
.	O

Characterizing	O
sexual	B-T038
function	I-T038
in	O
patients	O
with	O
generalized	B-T038
anxiety	I-T038
disorder	I-T038
:	O
a	O
pooled	B-T062
analysis	I-T062
of	O
three	O
vilazodone	B-T103
studies	B-T062

Vilazodone	B-T103
has	O
been	O
shown	O
to	O
reduce	O
core	B-T033
symptoms	I-T033
of	O
generalized	B-T038
anxiety	I-T038
disorder	I-T038
(	O
GAD	B-T038
)	O
in	O
three	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	O
-	O
controlled	O
trials	O
.	O

Since	O
sexual	B-T038
dysfunction	I-T038
(	O
SD	B-T038
)	O
is	O
not	O
well	O
characterized	O
in	O
GAD	B-T038
,	O
a	O
post	B-T062
hoc	I-T062
analysis	I-T062
of	O
these	O
trials	B-T062
was	O
conducted	O
to	O
evaluate	B-T058
the	O
effects	O
of	O
vilazodone	B-T103
on	O
sexual	B-T038
functioning	I-T038
in	O
GAD	B-T038
patients	O
.	O

Data	O
were	O
pooled	O
from	O
one	O
fixed	B-T062
-	I-T062
dose	I-T062
trial	I-T062
of	O
vilazodone	B-T103
20	O
and	O
40	O
mg	O
/	O
day	O
(	O
NCT01629966	B-T170
)	O
and	O
two	O
flexible	B-T062
-	I-T062
dose	I-T062
studies	I-T062
of	O
vilazodone	B-T103
20	O
-	O
40	O
mg	O
/	O
day	O
(	O
NCT01766401	B-T170
,	O
NCT01844115	B-T170
)	O
in	O
adults	O
with	O
GAD	B-T038
.	O

Sexual	B-T038
functioning	I-T038
was	O
assessed	O
using	O
the	O
Changes	B-T170
in	I-T170
Sexual	I-T170
Functioning	I-T170
Questionnaire	I-T170
(	O
CSFQ	B-T170
)	O
.	O

Outcomes	B-T062
included	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
of	O
treatment	O
(	O
EOT	O
)	O
in	O
CSFQ	B-T033
total	I-T033
score	I-T033
and	O
percentage	O
of	O
patients	O
shifting	O
from	O
SD	B-T038
at	O
baseline	O
(	O
CSFQ	B-T033
total	I-T033
score	I-T033
≤47	O
for	O
males	B-T098
,	O
≤41	O
for	O
females	B-T098
)	O
to	O
normal	O
functioning	O
at	O
EOT	O
.	O

Treatment	B-T038
-	I-T038
emergent	I-T038
adverse	I-T038
events	I-T038
related	O
to	O
sexual	B-T038
functioning	I-T038
were	O
also	O
analyzed	B-T062
.	O

A	O
total	O
of	O
1	O
,	O
373	O
patients	O
were	O
included	O
in	O
the	O
analyses	B-T062
.	O

SD	B-T038
at	O
baseline	O
was	O
more	O
common	O
in	O
females	B-T098
(	O
placebo	B-T103
,	O
46	O
.	O
4	O
%	O
;	O
vilazodone	B-T103
,	O
49	O
%	O
)	O
than	O
in	O
males	B-T098
(	O
placebo	B-T103
,	O
35	O
.	O
1	O
%	O
;	O
vilazodone	B-T103
,	O
40	O
.	O
9	O
%	O
)	O
.	O

CSFQ	B-T033
total	I-T033
score	I-T033
improvement	O
was	O
found	O
in	O
both	O
females	B-T098
(	O
placebo	B-T103
,	O
+	O
1	O
.	O
2	O
;	O
vilazodone	B-T103
,	O
+	O
1	O
.	O
6	O
)	O
and	O
males	B-T098
(	O
placebo	B-T103
,	O
+	O
2	O
.	O
1	O
;	O
vilazodone	B-T103
,	O
+	O
1	O
.	O
0	O
)	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
between	O
treatment	O
groups	O
.	O

The	O
percentage	O
of	O
patients	O
who	O
shifted	O
from	O
SD	B-T038
at	O
baseline	O
to	O
normal	O
sexual	B-T038
functioning	I-T038
at	O
EOT	O
was	O
higher	O
in	O
males	B-T098
(	O
placebo	B-T103
,	O
40	O
.	O
6	O
%	O
;	O
vilazodone	B-T103
,	O
35	O
.	O
7	O
%	O
)	O
than	O
in	O
females	B-T098
(	O
placebo	B-T103
,	O
24	O
.	O
9	O
%	O
;	O
vilazodone	B-T103
,	O
34	O
.	O
9	O
%	O
)	O
;	O
no	O
statistical	O
testing	O
was	O
performed	O
.	O

Except	O
for	O
erectile	B-T038
dysfunction	I-T038
and	O
delayed	B-T038
ejaculation	I-T038
in	O
vilazodone	B-T103
-	O
treated	O
males	B-T098
(	O
2	O
.	O
4	O
%	O
and	O
2	O
.	O
1	O
%	O
,	O
respectively	O
)	O
,	O
no	B-T033
treatment	I-T033
-	I-T033
emergent	I-T033
adverse	I-T033
events	I-T033
related	O
to	O
sexual	B-T038
functioning	I-T038
occurred	O
in	O
≥2	O
%	O
of	O
patients	O
in	O
either	O
treatment	O
group	O
.	O

Approximately	O
35	O
%	O
-	O
50	O
%	O
of	O
patients	O
in	O
the	O
vilazodone	B-T103
GAD	B-T038
studies	B-T062
had	O
SD	B-T038
at	O
baseline	O
.	O

Vilazodone	B-T103
and	O
placebo	B-T103
had	O
similar	O
effects	O
on	O
CSFQ	B-T170
outcomes	B-T062
in	O
both	O
females	B-T098
and	O
males	B-T098
,	O
indicating	O
a	O
limited	O
adverse	B-T038
impact	I-T038
on	O
sexual	B-T038
functioning	I-T038
with	O
vilazodone	B-T103
.	O

Biogeochemical	O
Controls	O
of	O
Uranium	B-T103
Bioavailability	O
from	O
the	O
Dissolved	O
Phase	O
in	O
Natural	O
Freshwaters	O

To	O
gain	O
insights	O
into	O
the	O
risks	O
associated	O
with	O
uranium	B-T103
(	O
U	B-T103
)	O
mining	O
and	O
processing	O
,	O
we	O
investigated	O
the	O
biogeochemical	O
controls	O
of	O
U	B-T103
bioavailability	O
in	O
the	O
model	O
freshwater	O
species	B-T170
Lymnaea	B-T204
stagnalis	I-T204
(	O
Gastropoda	B-T204
)	O
.	O

Bioavailability	O
of	O
dissolved	B-T103
U	I-T103
(	I-T103
VI	I-T103
)	I-T103
was	O
characterized	O
in	O
controlled	O
laboratory	B-T092
experiments	B-T062
over	O
a	O
range	O
of	O
water	B-T103
hardness	O
,	O
pH	O
,	O
and	O
in	O
the	O
presence	B-T033
of	O
complexing	B-T103
ligands	I-T103
in	O
the	O
form	O
of	O
dissolved	O
natural	O
organic	O
matter	O
(	O
DOM	O
)	O
.	O

Results	B-T033
show	O
that	O
dissolved	B-T103
U	I-T103
is	O
bioavailable	O
under	O
all	O
the	O
geochemical	O
conditions	O
tested	O
.	O

Uranium	B-T103
uptake	B-T038
rates	O
follow	O
first	O
order	O
kinetics	O
over	O
a	O
range	O
encompassing	O
most	O
environmental	B-T082
concentrations	O
.	O

Uranium	B-T103
uptake	B-T038
rates	O
in	O
L	B-T204
.	I-T204

stagnalis	I-T204
ultimately	O
demonstrate	O
saturation	O
uptake	B-T038
kinetics	O
when	O
exposure	O
concentrations	O
exceed	O
100	O
nM	O
,	O
suggesting	O
uptake	B-T038
via	O
a	O
finite	O
number	O
of	O
carriers	O
or	O
ion	B-T103
channels	I-T103
.	O

The	O
lack	O
of	O
a	O
relationship	O
between	O
U	B-T103
uptake	B-T038
rate	O
constants	O
and	O
Ca	B-T103
uptake	B-T038
rates	O
suggest	O
that	O
U	B-T103
does	O
not	O
exclusively	O
use	O
Ca	B-T103
membrane	B-T103
transporters	I-T103
.	O

In	O
general	O
,	O
U	B-T103
bioavailability	O
decreases	B-T033
with	O
increasing	O
pH	O
,	O
increasing	O
Ca	B-T103
and	O
Mg	B-T103
concentrations	O
,	O
and	O
when	O
DOM	O
is	O
present	B-T033
.	O

Competing	O
ions	B-T103
did	O
not	O
affect	O
U	B-T103
uptake	B-T038
rates	O
.	O

Speciation	B-T062
modeling	I-T062
that	O
includes	O
formation	O
constants	O
for	O
U	B-T103
ternary	O
complexes	O
reveals	O
that	O
the	O
aqueous	O
concentration	O
of	O
dicarbonato	B-T103
U	I-T103
species	B-T170
(	O
UO2	O
(	O
CO3	O
)	O
2	O
(	O
-	O
2	O
)	O
)	O
best	O
predicts	O
U	B-T103
bioavailability	O
to	O
L	B-T204
.	I-T204

stagnalis	I-T204
,	O
challenging	O
the	O
free	O
-	O
ion	O
activity	O
model	O
postulate	O
.	O

Interleukin	B-T103
-	I-T103
21	I-T103
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	B-T038
and	O
severity	O
of	O
type	B-T038
I	I-T038
autoimmune	I-T038
hepatitis	I-T038

Recently	O
,	O
the	O
number	O
of	O
follicular	B-T017
helper	B-T017
T	I-T017
(	I-T017
Tfh	I-T017
)	I-T017
cells	I-T017
expressing	O
interleukin	B-T103
(	I-T103
IL	I-T103
)	I-T103
-	I-T103
21	I-T103
was	O
found	O
to	O
increase	O
in	O
peripheral	B-T031
blood	I-T031
of	O
human	B-T204
and	O
murine	B-T204
models	B-T038
of	O
autoimmune	B-T038
hepatitis	I-T038
(	O
AIH	B-T038
)	O
.	O

IL	B-T103
-	I-T103
21	I-T103
,	O
the	O
most	O
recently	O
discovered	O
member	O
of	O
the	O
type	B-T103
-	I-T103
I	I-T103
cytokine	I-T103
family	I-T103
,	O
exerts	O
various	O
effects	O
on	O
the	O
immune	B-T022
system	I-T022
,	O
including	O
B	B-T038
cell	I-T038
activation	I-T038
,	O
plasma	B-T038
cell	I-T038
differentiation	I-T038
,	O
and	O
immunoglobulin	B-T038
production	I-T038
.	O

We	O
aimed	O
to	O
assess	O
the	O
relationship	O
of	O
serum	B-T031
IL	B-T103
-	I-T103
21	I-T103
levels	O
in	O
patients	O
with	O
type	B-T038
I	I-T038
AIH	I-T038
with	O
clinical	O
and	O
laboratory	B-T092
parameters	O
and	O
histology	B-T091
.	O

Ninety	O
-	O
two	O
Japanese	B-T098
patients	O
with	O
liver	B-T038
disease	I-T038
(	O
22	O
AIH	B-T038
,	O
20	O
primary	B-T038
biliary	I-T038
cholangitis	I-T038
,	O
19	O
drug	B-T038
-	I-T038
induced	I-T038
liver	I-T038
injury	I-T038
,	O
8	O
acute	B-T038
hepatitis	I-T038
B	I-T038
,	O
8	O
chronic	B-T038
hepatitis	I-T038
C	I-T038
,	O
10	O
non	B-T038
-	I-T038
alcoholic	I-T038
steatohepatitis	I-T038
,	O
5	O
viral	B-T038
hepatitis	I-T038
)	O
and	O
10	O
healthy	B-T098
volunteers	I-T098
were	O
recruited	O
.	O

Serum	B-T031
IL	B-T103
-	I-T103
21	I-T103
levels	O
were	O
detected	O
by	O
enzyme	B-T058
-	I-T058
linked	I-T058
immunosorbent	I-T058
assay	I-T058
.	O

Real	B-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
measured	O
mRNA	B-T103
levels	O
of	O
Bcl	B-T017
-	I-T017
6	I-T017
,	O
IL	B-T017
-	I-T017
21	I-T017
,	O
and	O
CXCR5	B-T017
(	O
Tfh	B-T103
-	I-T103
related	I-T103
factors	I-T103
)	O
in	O
peripheral	B-T082
mononuclear	O
cells	O
.	O

Mean	O
age	O
at	O
diagnosis	B-T033
of	O
AIH	B-T038
was	O
58	O
.	O
6	O
years	O
,	O
male	B-T033
-	I-T033
to	I-T033
-	I-T033
female	I-T033
ratio	I-T033
was	O
4	O
:	O
18	O
,	O
18	O
.	O
2	O
%	O
of	O
participants	O
had	O
cirrhosis	B-T038
,	O
and	O
22	O
.	O
7	O
%	O
had	O
severe	O
disease	B-T038
.	O

IL	B-T103
-	I-T103
21	I-T103
levels	O
were	O
significantly	O
increased	O
in	O
the	O
serum	B-T031
of	O
patients	O
with	O
AIH	B-T038
compared	O
to	O
those	O
with	O
other	O
liver	O
diseases	O
and	O
controls	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Particularly	O
,	O
serum	B-T031
IL	B-T103
-	I-T103
21	I-T103
levels	O
were	O
significantly	O
increased	O
in	O
severe	O
AIH	B-T038
cases	O
compared	O
to	O
non	O
-	O
severe	O
cases	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Serum	B-T031
IL	B-T103
-	I-T103
21	I-T103
levels	O
correlated	O
positively	O
with	O
total	O
serum	B-T031
bilirubin	B-T058
levels	I-T058
(	O
r	O
=	O
0	O
.	O
46	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
grading	B-T033
of	I-T033
necroinflammatory	I-T033
activity	I-T033
(	O
r	O
=	O
0	O
.	O
68	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
and	O
negatively	O
with	O
serum	B-T033
albumin	I-T033
levels	I-T033
in	O
patients	O
with	O
AIH	B-T038
(	O
r	O
=	O
-	O
0	O
.	O
49	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
patients	O
with	O
biochemical	O
remission	B-T033
of	O
AIH	B-T038
,	O
serum	B-T031
IL	B-T103
-	I-T103
21	I-T103
levels	O
remained	O
elevated	O
and	O
correlated	O
positively	B-T033
with	O
serum	B-T058
IgG	I-T058
levels	I-T058
(	O
r	O
=	O
0	O
.	O
84	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Expression	B-T038
of	O
Tfh	B-T103
-	I-T103
related	I-T103
factors	I-T103
,	O
such	O
as	O
Bcl	B-T103
-	I-T103
6	I-T103
and	O
IL	B-T103
-	I-T103
21	I-T103
,	O
in	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
of	O
patients	O
with	O
AIH	B-T038
was	O
significantly	O
higher	O
than	O
that	O
in	O
healthy	B-T098
volunteers	I-T098
.	O

IL	B-T103
-	I-T103
21	I-T103
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-T038
and	O
severity	O
of	O
AIH	B-T038
,	O
and	O
may	O
present	O
a	O
promising	O
target	O
for	O
AIH	B-T038
therapy	O
.	O

Resistance	O
Exercise	O
in	O
Pregnancy	B-T038
and	O
Outcome	B-T033

As	O
the	O
health	O
benefits	O
of	O
exercise	O
are	O
increasingly	O
recognized	O
,	O
the	O
traditional	B-T058
advice	I-T058
to	O
rest	O
during	O
pregnancy	B-T038
has	O
changed	O
toward	O
a	O
more	O
healthy	O
and	O
active	O
pregnancy	B-T038
,	O
therefore	O
different	O
forms	O
of	O
exercise	O
have	O
been	O
integrated	O
into	O
the	O
life	O
of	O
the	O
pregnant	B-T098
woman	I-T098
.	O

Although	O
the	O
benefits	O
of	O
using	O
a	O
combination	O
of	O
resistance	O
and	O
aerobic	B-T058
exercises	I-T058
are	O
not	O
yet	O
determined	O
,	O
studies	B-T062
about	O
resistance	O
and	O
strengthen	O
training	O
programs	O
are	O
few	O
although	O
no	B-T033
adverse	I-T033
outcomes	B-T033
were	O
reported	O
.	O

Custom	O
ocular	B-T074
prosthesis	I-T074
in	O
rehabilitation	B-T058
of	O
a	O
child	O
operated	O
for	O
retinoblastoma	B-T038

A	O
maxillofacial	O
prosthodontist	O
forms	O
an	O
important	O
link	O
in	O
the	O
interdisciplinary	O
management	B-T058
of	I-T058
a	I-T058
patient	I-T058
with	O
anopthalmosis	B-T017
.	O

Prosthetic	B-T058
management	I-T058
of	O
an	O
anopthalmic	B-T017
defect	I-T017
aims	O
to	O
deliver	O
a	O
well	O
-	O
fitting	O
ocular	B-T074
prosthesis	I-T074
that	O
can	O
mimic	O
the	O
original	O
eye	B-T017
as	O
closely	O
as	O
possible	O
,	O
and	O
thus	O
restoring	O
the	O
patient	O
'	O
s	O
self	B-T038
-	I-T038
confidence	I-T038
and	O
thereby	O
rehabilitating	O
them	O
in	O
the	O
society	B-T092
.	O

The	O
fabrication	B-T058
of	O
a	O
custom	O
ocular	B-T074
prosthesis	I-T074
is	O
a	O
demanding	O
art	O
.	O

This	O
case	B-T170
report	I-T170
presents	O
a	O
simplified	O
technique	O
for	O
the	O
fabrication	B-T058
of	O
a	O
custom	O
ocular	B-T074
prosthesis	I-T074
for	O
a	O
child	O
who	O
had	O
lost	O
his	O
eye	B-T017
to	O
enucleation	B-T058
following	O
retinoblastoma	B-T038
.	O

Early	O
and	O
effective	O
rehabilitation	B-T058
of	O
the	O
defect	O
goes	O
a	O
long	O
way	O
in	O
restoring	O
the	O
self	O
-	O
image	O
of	O
a	O
child	O
in	O
its	O
early	O
character	O
building	O
age	O
.	O

Pulmonary	B-T038
function	I-T038
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
1	O
-	O
year	O
follow	B-T058
up	I-T058
after	O
cardiac	B-T058
surgery	I-T058

Pulmonary	B-T038
function	I-T038
is	O
severely	O
reduced	O
in	O
the	O
early	O
period	O
after	O
cardiac	B-T058
surgery	I-T058
,	O
and	O
impairments	B-T038
have	O
been	O
described	O
up	O
to	O
4	O
-	O
6	O
months	O
after	O
surgery	O
.	O

Evaluation	B-T058
of	O
pulmonary	B-T038
function	I-T038
in	O
a	O
longer	O
perspective	O
is	O
lacking	O
.	O

In	O
this	O
prospective	B-T062
study	I-T062
pulmonary	B-T038
function	I-T038
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
were	O
investigated	O
1	O
year	O
after	O
cardiac	B-T058
surgery	I-T058
.	O

Pulmonary	B-T038
function	I-T038
measurements	O
,	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
SF	B-T170
-	I-T170
36	I-T170
)	O
,	O
dyspnoea	B-T033
,	O
subjective	O
breathing	B-T038
and	O
coughing	B-T033
ability	O
and	O
pain	B-T033
were	O
evaluated	B-T058
before	O
and	O
1	O
year	O
after	O
surgery	O
in	O
150	O
patients	O
undergoing	O
coronary	B-T058
artery	I-T058
bypass	I-T058
grafting	I-T058
,	O
valve	B-T058
surgery	I-T058
or	O
combined	O
surgery	B-T058
.	O

One	O
year	O
after	O
surgery	O
the	O
forced	B-T201
vital	I-T201
capacity	I-T201
and	O
forced	B-T038
expiratory	I-T038
volume	I-T038
in	O
1	O
s	O
were	O
significantly	O
decreased	O
(	O
by	O
4	O
-	O
5	O
%	O
)	O
compared	O
to	O
preoperative	O
values	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Saturation	B-T038
of	I-T038
peripheral	I-T038
oxygen	I-T038
was	O
unchanged	B-T033
1	O
year	O
postoperatively	O
compared	O
to	O
baseline	O
.	O

A	O
significantly	O
improved	B-T033
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
found	O
1	O
year	O
after	O
surgery	O
,	O
with	O
improvements	O
in	O
all	O
eight	O
aspects	O
of	O
SF	B-T170
-	I-T170
36	I-T170
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Sternotomy	B-T058
-	O
related	O
pain	B-T033
was	O
low	O
1	O
year	O
postoperatively	O
at	O
rest	O
(	O
median	O
0	O
[	O
min	O
-	O
max	O
;	O
0	O
-	O
7	O
]	O
)	O
,	O
while	O
taking	O
a	O
deep	B-T033
breath	I-T033
(	O
0	O
[	O
0	O
-	O
4	O
]	O
)	O
and	O
while	O
coughing	B-T033
(	O
0	O
[	O
0	O
-	O
8	O
]	O
)	O
.	O

A	O
more	O
pronounced	O
decrease	O
in	O
pulmonary	B-T038
function	I-T038
was	O
associated	O
with	O
dyspnoea	B-T033
limitations	O
and	O
impaired	B-T038
subjective	O
breathing	B-T038
and	O
coughing	B-T033
ability	O
.	O

One	O
year	O
after	O
cardiac	B-T058
surgery	I-T058
static	O
and	O
dynamic	O
lung	B-T058
function	I-T058
measurements	I-T058
were	O
slightly	O
decreased	O
,	O
while	O
health	O
-	O
related	O
quality	O
of	O
life	O
was	O
improved	B-T033
in	O
comparison	O
to	O
preoperative	O
values	O
.	O

Measured	O
levels	O
of	O
pain	B-T033
were	O
low	O
and	O
saturation	B-T038
of	I-T038
peripheral	I-T038
oxygen	I-T038
was	O
same	O
as	O
preoperatively	O
.	O

Impact	O
of	O
Soil	O
Salinity	O
on	O
the	O
Structure	B-T082
of	O
the	O
Bacterial	B-T007
Endophytic	B-T204
Community	O
Identified	O
from	O
the	O
Roots	B-T204
of	O
Caliph	B-T204
Medic	I-T204
(	O
Medicago	B-T204
truncatula	I-T204
)	O

In	O
addition	O
to	O
being	O
a	O
forage	B-T204
crop	I-T204
,	O
Caliph	B-T204
medic	I-T204
(	O
Medicago	B-T204
truncatula	I-T204
)	O
is	O
also	O
a	O
model	B-T062
legume	I-T062
plant	I-T062
and	O
is	O
used	O
for	O
research	O
focusing	O
on	O
the	O
molecular	O
characterization	O
of	O
the	O
interaction	O
between	O
rhizobia	B-T007
and	O
plants	B-T204
.	O

However	O
,	O
the	O
endophytic	O
microbiome	O
in	O
this	O
plant	B-T204
is	O
poorly	O
defined	O
.	O

Endophytic	B-T204
bacteria	B-T007
play	O
a	O
role	O
in	O
supplying	O
plants	B-T204
with	O
the	O
basic	O
requirements	O
necessary	O
for	O
growth	B-T038
and	O
development	B-T038
.	O

Moreover	O
,	O
these	O
bacteria	B-T007
also	O
play	O
a	O
role	O
in	O
the	O
mechanism	O
of	O
salinity	O
stress	O
adaptation	B-T038
in	O
plants	B-T204
.	O

As	O
a	O
prelude	O
to	O
the	O
isolation	B-T058
and	O
utilization	O
of	O
these	O
bacteria	B-T007
in	O
Caliph	B-T204
medic	I-T204
farming	B-T082
,	O
41	O
bacterial	B-T007
OTUs	B-T170
were	O
identified	O
in	O
this	O
project	O
from	O
within	O
the	O
interior	B-T082
of	O
the	O
roots	B-T204
of	O
this	O
plant	B-T204
by	O
pyrosequencing	B-T058
of	O
the	O
small	B-T017
ribosomal	I-T017
subunit	I-T017
gene	I-T017
(	O
16S	B-T017
rDNA	I-T017
)	O
using	O
a	O
cultivation	B-T058
-	I-T058
independent	I-T058
approach	I-T058
.	O

In	O
addition	O
,	O
the	O
differential	O
abundance	O
of	O
these	O
bacteria	B-T007
was	O
studied	O
following	O
exposure	O
of	O
the	O
plants	B-T204
to	O
salinity	O
stress	O
.	O

About	O
29	O
,	O
064	O
high	O
-	O
quality	O
reads	O
were	O
obtained	O
from	O
the	O
sequencing	B-T058
of	O
six	O
libraries	B-T017
prepared	O
from	O
control	B-T017
and	O
salinity	B-T017
-	I-T017
treated	I-T017
tissues	I-T017
.	O

Statistical	O
analysis	O
revealed	O
that	O
the	O
abundance	O
of	O
~	O
70	O
%	O
of	O
the	O
OTUs	B-T170
was	O
significantly	O
(	O
p	O
≤	O
0	O
.	O
05	O
)	O
altered	O
in	O
roots	B-T204
that	O
were	O
exposed	O
to	O
salinity	O
stress	O
.	O

Sequence	B-T058
analysis	I-T058
showed	O
a	O
similarity	O
between	O
some	O
of	O
the	O
identified	O
species	B-T170
and	O
other	O
,	O
known	O
,	O
growth	B-T007
-	I-T007
promoting	I-T007
bacteria	I-T007
,	O
marine	O
and	O
salt	B-T007
-	I-T007
stressed	I-T007
soil	I-T007
-	I-T007
borne	I-T007
bacteria	I-T007
,	O
and	O
nitrogen	B-T007
-	I-T007
fixing	I-T007
bacterial	I-T007
isolates	B-T103
.	O

Determination	O
of	O
the	O
amendments	O
to	O
the	O
bacteria	B-T007
l	O
community	O
due	O
to	O
salinity	O
stress	O
in	O
Caliph	B-T204
medic	I-T204
provides	O
a	O
crucial	O
step	O
toward	O
developing	O
an	O
understanding	O
of	O
the	O
association	O
of	O
these	O
endophytes	B-T204
,	O
under	O
salt	O
stress	O
conditions	O
,	O
in	O
this	O
model	B-T062
plant	I-T062
.	O

To	O
provide	O
direct	O
evidence	O
regarding	O
their	O
growth	O
promoting	O
activity	O
,	O
a	O
group	O
of	O
endophytic	B-T204
bacteria	B-T007
were	O
isolated	O
from	O
inside	O
of	O
plant	B-T204
roots	I-T204
using	O
a	O
cultivation	B-T058
-	I-T058
dependent	I-T058
approach	I-T058
.	O

Several	O
of	O
these	O
isolates	B-T103
were	O
able	O
to	O
produce	O
ACC	B-T103
-	I-T103
deaminase	I-T103
,	O
ammonia	B-T103
and	O
IAA	B-T103
;	O
and	O
to	O
solubilize	O
Zn	B-T103
+	I-T103
2	I-T103
and	O
PO4	B-T103
-	I-T103
3	I-T103
.	O

This	O
data	O
is	O
consistent	O
with	O
the	O
predicted	O
occurrence	O
(	O
based	O
on	O
cultivation	B-T058
-	I-T058
independent	I-T058
techniques	I-T058
)	O
of	O
these	O
bacteria	B-T007
and	O
provides	O
some	O
insight	O
into	O
the	O
importance	O
of	O
the	O
endophytic	B-T204
bacteria	B-T007
in	O
Caliph	B-T204
medic	I-T204
when	O
grown	O
under	O
normal	O
and	O
saline	O
conditions	O
.	O

Eliminating	O
Cancer	B-T017
Stem	I-T017
Cells	I-T017
in	O
CML	B-T038
with	O
Combination	O
Transcriptional	B-T038
Therapy	B-T058

Leukemia	B-T038
stem	B-T017
cells	I-T017
(	O
LSCs	B-T017
)	O
are	O
resistant	O
to	O
current	O
therapies	B-T058
used	O
to	O
treat	O
chronic	B-T038
myeloid	I-T038
leukemia	I-T038
(	O
CML	B-T038
)	O
.	O

Abraham	O
et	O
al	O
.	O

(	O
2016	O
)	O
have	O
identified	O
a	O
molecular	B-T038
network	I-T038
critical	O
for	O
CML	B-T038
LSC	B-T017
survival	B-T038
and	O
propose	O
that	O
simultaneously	O
targeting	O
two	O
of	O
their	O
major	O
transcriptional	B-T103
regulators	I-T103
,	O
p53	B-T017
and	O
c	B-T103
-	I-T103
Myc	I-T103
,	O
may	O
facilitate	O
their	O
eradication	B-T038
.	O

Crocetin	B-T103
improves	B-T033
the	O
quality	O
of	O
in	O
vitro	O
-	O
produced	O
bovine	B-T204
embryos	B-T017
:	O
Implications	O
for	O
blastocyst	B-T038
development	I-T038
,	O
cryotolerance	O
,	O
and	O
apoptosis	B-T038

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
effect	O
of	O
supplementation	B-T058
of	O
bovine	B-T204
culture	B-T103
medium	I-T103
with	O
the	O
natural	B-T103
antioxidant	I-T103
crocetin	B-T103
on	O
in	O
vitro	O
blastocyst	B-T038
development	I-T038
and	O
quality	O
.	O

This	O
was	O
evaluated	B-T058
as	O
cryotolerance	O
,	O
apoptosis	B-T170
index	I-T170
,	O
and	O
total	B-T058
cells	I-T058
number	I-T058
and	O
allocation	O
.	O

Abattoir	O
-	O
derived	O
oocytes	B-T017
were	O
matured	O
and	O
fertilized	O
in	O
vitro	O
according	O
to	O
standard	O
procedure	O
.	O

Twenty	O
hours	O
after	O
IVF	B-T058
,	O
presumptive	O
zygotes	B-T017
were	O
cultured	B-T058
in	O
synthetic	B-T017
oviduct	I-T017
fluid	O
medium	O
,	O
supplemented	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
crocetin	B-T103
(	O
experiment	O
1	O
)	O
at	O
39	O
°C	O
under	O
humidified	O
air	O
with	O
5	O
%	O
CO2	B-T103
,	O
7	O
%	O
O2	B-T103
,	O
and	O
88	O
%	O
N2	B-T103
.	O

On	O
Day	O
7	O
,	O
embryo	O
yields	O
were	O
assessed	O
and	O
the	O
blastocysts	B-T017
were	O
vitrified	O
by	O
Cryotop	B-T170
method	I-T170
in	O
16	O
.	O
5	O
%	O
ethylene	B-T103
glycol	I-T103
,	O
16	O
.	O
5	O
%	O
DMSO	B-T103
,	O
and	O
0	O
.	O
5	O
M	O
sucrose	B-T103
.	O

Finally	O
,	O
blastocysts	B-T017
produced	O
on	O
Day	O
8	O
in	O
the	O
absence	O
(	O
control	O
)	O
and	O
presence	B-T033
of	O
1	O
μM	O
crocetin	B-T103
were	O
used	O
for	O
terminal	B-T062
deoxynucleotidyl	I-T062
transferase	I-T062
-	I-T062
mediated	I-T062
dUTP	I-T062
nick	I-T062
end	I-T062
labelling	I-T062
and	O
differential	B-T058
staining	I-T058
to	O
evaluate	B-T058
,	O
respectively	O
,	O
the	O
apoptotic	O
rate	O
and	O
the	O
allocation	O
of	O
cells	B-T017
into	O
inner	B-T017
cell	I-T017
mass	I-T017
(	O
ICM	B-T017
)	O
and	O
trophectoderm	B-T017
(	O
TE	B-T017
)	O
lineages	O
(	O
experiment	O
2	O
)	O
.	O

Embryo	B-T038
development	I-T038
was	O
higher	O
in	O
the	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	O
,	O
both	O
in	O
terms	O
of	O
total	O
embryo	B-T017
output	O
(	O
37	O
.	O
7	O
±	O
4	O
.	O
2	O
%	O
,	O
52	O
.	O
9	O
±	O
6	O
.	O
3	O
%	O
,	O
40	O
.	O
9	O
±	O
7	O
.	O
6	O
%	O
,	O
and	O
42	O
.	O
4	O
±	O
8	O
.	O
7	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
grade	B-T170
1	I-T170
and	O
2	B-T170
blastocysts	B-T017
(	O
33	O
.	O
6	O
±	O
4	O
.	O
9	O
%	O
,	O
46	O
.	O
1	O
±	O
7	O
.	O
3	O
%	O
,	O
37	O
.	O
8	O
±	O
7	O
.	O
9	O
%	O
,	O
and	O
39	O
.	O
4	O
±	O
7	O
.	O
9	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Moreover	O
,	O
the	O
percentage	O
of	O
fast	B-T038
-	I-T038
developing	I-T038
embryos	I-T038
increased	O
in	O
1	O
μM	O
crocetin	O
group	O
compared	O
to	O
the	O
control	O
(	O
23	O
.	O
4	O
±	O
4	O
.	O
7	O
%	O
,	O
32	O
.	O
7	O
±	O
6	O
.	O
6	O
%	O
,	O
27	O
.	O
2	O
±	O
6	O
.	O
6	O
%	O
,	O
and	O
30	O
.	O
1	O
±	O
7	O
.	O
2	O
%	O
,	O
respectively	O
,	O
with	O
0	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
μM	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
the	O
enrichment	O
of	O
culture	O
medium	O
with	O
1	O
μM	O
crocetin	B-T103
improved	B-T033
embryo	B-T017
cryotolerance	O
compared	O
to	O
the	O
control	O
,	O
as	O
indicated	O
by	O
higher	O
hatching	B-T038
rates	O
recorded	O
after	O
48	O
hours	O
postwarming	B-T103
culture	I-T103
(	O
46	O
.	O
5	O
%	O
vs	O
.	O

60	O
.	O
4	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
1	O
μM	O
crocetin	B-T103
decreased	O
both	O
the	O
average	O
number	O
(	O
9	O
.	O
9	O
±	O
0	O
.	O
4	O
vs	O
.	O

7	O
.	O
1	O
±	O
0	O
.	O
3	O
)	O
and	O
the	O
percentage	O
of	O
apoptotic	O
cells	B-T017
(	O
7	O
.	O
1	O
±	O
0	O
.	O
4	O
vs	O
.	O

4	O
.	O
2	O
±	O
0	O
.	O
2	O
)	O
in	O
blastocysts	B-T017
compared	O
to	O
the	O
control	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
,	O
no	O
differences	O
were	O
recorded	O
in	O
the	O
average	O
number	O
of	O
ICM	B-T017
,	O
TE	B-T017
,	O
and	O
total	O
cells	B-T017
between	O
1	O
μM	O
crocetin	B-T103
and	O
control	O
groups	O
.	O

In	O
conclusion	O
,	O
the	O
enrichment	O
of	O
bovine	O
culture	O
medium	O
with	O
1	O
μM	O
crocetin	B-T103
increased	O
both	O
blastocyst	O
yield	O
and	O
quality	O
,	O
as	O
indicated	O
by	O
the	O
improved	B-T033
chronology	B-T170
of	O
embryo	B-T038
development	I-T038
,	O
increased	O
resistance	O
to	O
cryopreservation	B-T058
,	O
and	O
reduced	O
incidence	O
of	O
apoptosis	B-T038
.	O

Matrix	B-T058
solid	I-T058
-	I-T058
phase	I-T058
dispersion	I-T058
combined	O
to	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
for	O
the	O
determination	B-T058
of	O
paraben	B-T103
preservatives	B-T103
in	O
mollusks	B-T204

A	O
method	B-T170
for	I-T170
the	I-T170
extraction	I-T170
and	O
determination	B-T058
of	O
seven	O
parabens	B-T103
,	O
esters	B-T103
of	O
4	B-T103
-	I-T103
hydroxybenzoic	I-T103
acid	I-T103
,	O
widely	O
used	O
as	O
preservatives	B-T103
in	O
personal	O
care	O
products	O
,	O
pharmaceuticals	B-T103
,	O
etc	O
.	O
,	O
and	O
two	O
chlorinated	B-T103
derivatives	I-T103
(	O
mono	B-T103
-	I-T103
and	O
di	B-T103
-	I-T103
chloro	I-T103
methyl	I-T103
paraben	I-T103
)	O
from	O
mollusk	B-T204
samples	O
was	O
developed	O
by	O
combining	O
matrix	B-T058
solid	I-T058
-	I-T058
phase	I-T058
dispersion	I-T058
(	O
MSPD	B-T058
)	O
and	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
.	O

MSPD	B-T170
parameters	I-T170
,	O
such	O
as	O
solvent	B-T103
,	O
solid	O
support	O
and	O
clean	O
-	O
up	O
sorbent	O
,	O
were	O
optimized	O
.	O

Besides	O
,	O
since	O
blank	O
problems	O
were	O
observed	O
for	O
some	O
parabens	B-T103
,	O
these	O
were	O
investigated	O
and	O
blanks	O
were	O
tackled	O
by	O
precleaning	O
all	O
sorbents	O
prior	O
to	O
use	O
.	O

Under	O
final	O
conditions	O
,	O
0	O
.	O
5g	O
of	O
freeze	B-T058
-	I-T058
dried	I-T058
mollusk	B-T204
were	O
dispersed	B-T082
with	O
1	O
.	O
2g	O
of	O
silica	B-T103
and	O
packed	O
into	O
a	O
cartridge	B-T170
containing	O
3g	O
of	O
C18	B-T103
,	O
as	O
on	O
-	O
line	O
clean	O
-	O
up	O
sorbent	O
.	O

This	O
cartridge	B-T170
was	O
eluted	O
with	O
10mL	O
of	O
acetonitrile	B-T103
,	O
evaporated	O
and	O
reconstituted	O
in	O
methanol	B-T103
for	O
analysis	B-T062
.	O

In	O
the	O
validation	B-T062
stage	O
,	O
successful	O
linearity	O
(	O
R	O
(	O
2	O
)	O
>	O
0	O
.	O
999	O
)	O
,	O
recoveries	O
(	O
between	O
71	O
and	O
117	O
%	O
for	O
most	O
analytes	O
)	O
,	O
precision	O
(	O
RSD	O
lower	O
than	O
21	O
%	O
)	O
and	O
limits	O
of	O
detection	O
and	O
quantification	O
(	O
LOD	O
and	O
LOQ	B-T062
,	O
lower	O
than	O
0	O
.	O
4	O
and	O
1	O
.	O
4ngg	O
(	O
-	O
1	O
)	O
dry	O
weight	O
respectively	O
)	O
levels	O
were	O
achieved	O
.	O

Finally	O
,	O
the	O
new	O
methodology	B-T170
was	O
applied	O
to	O
mussel	B-T204
,	O
clam	B-T204
and	O
cockle	B-T204
samples	O
.	O

Methyl	B-T103
paraben	I-T103
was	O
above	O
the	O
LOQ	O
in	O
five	O
of	O
the	O
six	O
samples	O
(	O
not	O
found	O
in	O
one	O
clam	B-T204
sample	O
)	O
at	O
concentrations	O
up	O
to	O
7ngg	O
(	O
-	O
1	O
)	O
dry	O
weight	O
.	O

Ethyl	B-T103
paraben	I-T103
was	O
found	O
above	O
the	O
LOQ	O
in	O
mussel	B-T204
and	O
cockle	B-T204
samples	O
at	O
a	O
concentration	O
level	O
around	O
0	O
.	O
3ngg	O
(	O
-	O
1	O
)	O
.	O

n	B-T103
-	I-T103
Propyl	I-T103
paraben	I-T103
was	O
only	O
above	O
the	O
LOQ	O
in	O
one	O
mussel	B-T204
sample	O
.	O

Two	O
-	O
stage	O
reconstructive	B-T058
overlapping	B-T074
stent	I-T074
LEO	B-T074
+	I-T074
and	O
SILK	B-T074
for	O
treatment	B-T058
of	O
intracranial	B-T082
circumferential	B-T082
fusiform	B-T017
aneurysms	I-T017
in	O
the	O
posterior	O
circulation	B-T038

Intracranial	B-T082
circumferential	B-T082
fusiform	B-T017
aneurysms	I-T017
of	O
the	O
posterior	O
circulation	B-T038
involving	O
arterial	B-T017
branches	I-T017
or	O
perforating	B-T033
vessels	B-T017
are	O
difficult	O
to	O
treat	O
.	O

This	O
article	O
shows	O
an	O
endovascular	O
reconstruction	B-T058
technique	I-T058
not	O
yet	O
described	O
,	O
using	O
a	O
telescoping	B-T074
self	I-T074
-	I-T074
expandable	I-T074
stent	I-T074
(	O
LEO	B-T074
+	I-T074
)	O
and	O
flow	B-T074
-	I-T074
diverter	I-T074
device	I-T074
(	O
SILK	B-T074
)	O
at	O
different	O
surgical	O
times	O
.	O

Two	O
patients	O
with	O
circumferential	B-T082
fusiform	B-T017
aneurysm	I-T017
,	O
one	O
being	O
an	O
aneurysm	B-T038
of	O
the	O
segments	O
P2	O
and	O
P3	O
of	O
the	O
posterior	B-T017
cerebral	I-T017
artery	I-T017
,	O
diagnosed	B-T033
after	O
a	O
headache	B-T033
,	O
and	O
the	O
other	O
a	O
partially	O
thrombosed	B-T038
aneurysm	I-T038
of	O
the	O
lower	B-T082
basilar	B-T017
artery	I-T017
,	O
diagnosed	B-T033
following	O
ischemia	B-T038
of	O
the	O
brain	B-T017
stem	I-T017
.	O

Endovascular	O
treatment	B-T058
was	O
performed	O
by	O
means	O
of	O
a	O
vascular	B-T017
reconstruction	B-T058
technique	I-T058
that	O
used	O
at	O
different	O
surgical	O
times	O
:	O
overlapping	B-T058
;	I-T058
a	I-T058
telescoped	I-T058
self	I-T058
-	I-T058
expandable	I-T058
stent	I-T058
,	O
LEO	B-T074
+	I-T074
;	O
and	O
a	O
flow	B-T074
-	I-T074
diverter	I-T074
device	I-T074
,	O
SILK	B-T074
.	O

Angiographic	B-T058
control	O
was	O
carried	O
out	O
at	O
6	O
and	O
12	O
months	O
,	O
to	O
evaluate	O
arterial	O
patency	O
,	O
flow	O
maintenance	O
in	O
the	O
arterial	B-T017
branches	I-T017
and	O
perforating	B-T033
vessels	B-T017
,	O
and	O
thrombosis	B-T038
of	O
the	O
aneurysm	B-T038
.	O

The	O
combined	O
use	O
at	O
different	O
surgical	O
times	O
of	O
the	O
self	B-T074
-	I-T074
expandable	I-T074
stent	I-T074
and	O
flow	B-T074
-	I-T074
diverter	I-T074
device	I-T074
was	O
technically	O
successful	O
in	O
both	O
patients	O
.	O

There	O
were	O
no	O
complications	B-T038
during	O
the	O
procedure	O
,	O
nor	O
in	O
the	O
long	O
-	O
term	O
follow	B-T058
-	I-T058
up	I-T058
with	O
full	O
arterial	B-T017
vascular	B-T017
reconstruction	B-T058
,	O
maintenance	O
of	O
cerebral	O
perfusion	O
and	O
complete	O
aneurysm	B-T038
occlusion	O
at	O
the	O
6	O
-	O
and	O
12	O
-	O
month	O
angiographic	B-T058
follow	B-T058
-	I-T058
up	I-T058
.	O

There	O
was	O
no	O
aneurysm	B-T037
recanalization	I-T037
nor	O
intra	B-T038
-	I-T038
stent	I-T038
stenosis	I-T038
.	O

Circumferential	B-T082
fusiform	B-T017
aneurysm	I-T017
of	O
the	O
posterior	O
circulation	B-T038
involving	O
arterial	B-T017
branches	I-T017
or	O
perforating	B-T033
vessels	B-T017
to	O
the	O
brain	B-T017
stem	I-T017
may	O
be	O
treated	O
with	O
this	O
arterial	B-T017
reconstruction	B-T058
technique	I-T058
at	O
different	O
surgical	O
times	O
,	O
using	O
the	O
self	B-T074
-	I-T074
expandable	I-T074
stent	I-T074
called	O
LEO	B-T074
+	I-T074
and	O
the	O
flow	B-T074
-	I-T074
diverter	I-T074
device	I-T074
SILK	B-T074
,	O
minimizing	O
the	O
risk	O
of	O
complications	B-T038
and	O
failure	O
of	O
the	O
endovascular	O
technique	B-T058
,	O
with	O
the	O
potential	O
for	O
arterial	B-T058
reconstruction	I-T058
with	O
thrombosis	B-T038
of	O
the	O
aneurysmatic	B-T038
sac	I-T038
,	O
as	O
well	O
as	O
flow	O
maintenance	O
in	O
the	O
eloquent	B-T017
arteries	I-T017
,	O
in	O
this	O
type	O
of	O
cerebral	B-T038
aneurysm	I-T038
.	O

Polysaccharide	B-T103
-	O
Specific	O
Memory	B-T017
B	I-T017
Cells	I-T017
Predict	O
Protection	O
against	O
Experimental	O
Human	B-T204
Pneumococcal	B-T007
Carriage	B-T033

We	O
have	O
previously	O
demonstrated	O
that	O
experimental	O
pneumococcal	B-T007
carriage	B-T033
enhances	O
immunity	B-T038
and	O
protects	O
healthy	O
adults	O
against	O
carriage	B-T033
reacquisition	O
after	O
rechallenge	B-T058
with	O
a	O
homologous	O
strain	O
.	O

To	O
investigate	O
the	O
role	O
of	O
naturally	O
acquired	O
pneumococcal	B-T103
protein	I-T103
and	O
polysaccharide	B-T103
(	O
PS	B-T103
)	O
-	O
specific	O
immunity	B-T038
in	O
protection	O
against	O
carriage	B-T033
acquisition	O
using	O
a	O
heterologous	B-T038
challenge	I-T038
model	O
.	O

We	O
identified	O
healthy	B-T098
volunteers	I-T098
that	O
were	O
naturally	O
colonized	B-T017
with	O
pneumococcus	B-T007
and	O
,	O
after	O
clearance	O
of	O
their	O
natural	O
carriage	B-T033
episode	O
,	O
challenged	O
them	O
with	O
a	O
heterologous	O
6B	B-T007
strain	I-T007
.	O

In	O
another	O
cohort	B-T098
of	O
volunteers	B-T098
we	O
assessed	O
6BPS	B-T103
-	O
specific	O
,	O
PspA	B-T103
-	O
specific	O
,	O
and	O
PspC	B-T103
-	O
specific	O
IgG	B-T103
and	O
IgA	B-T103
plasma	B-T017
and	O
memory	B-T017
B	I-T017
-	I-T017
cell	I-T017
populations	I-T017
before	O
and	O
7	O
,	O
14	O
,	O
and	O
35	O
days	O
after	O
experimental	O
pneumococcal	B-T007
inoculation	B-T058
.	O

Heterologous	B-T038
challenge	I-T038
with	O
6B	B-T007
resulted	O
in	O
50	O
%	O
carriage	B-T033
among	O
volunteers	B-T098
with	O
previous	O
natural	O
pneumococcal	B-T007
carriage	B-T033
.	O

Protection	O
from	O
carriage	B-T033
was	O
associated	O
with	O
a	O
high	O
number	O
of	O
circulating	O
6BPS	B-T103
IgG	B-T103
-	O
secreting	B-T038
memory	B-T017
B	I-T017
cells	I-T017
at	O
baseline	O
.	O

There	O
were	O
no	O
associations	O
between	O
protection	O
from	O
carriage	B-T033
and	O
baseline	O
levels	O
of	O
6BPS	B-T103
IgG	B-T103
in	O
serum	B-T031
or	O
nasal	B-T031
wash	I-T031
,	O
PspA	B-T103
-	O
specific	O
,	O
or	O
PspC	B-T103
-	O
specific	O
memory	B-T017
B	I-T017
cells	I-T017
or	O
plasma	B-T017
cells	I-T017
.	O

In	O
volunteers	B-T098
who	O
did	O
not	B-T033
develop	I-T033
carriage	B-T033
,	O
the	O
number	O
of	O
circulating	O
6BPS	B-T103
memory	B-T017
B	I-T017
cells	I-T017
decreased	O
and	O
the	O
number	O
of	O
6BPS	B-T103
plasma	B-T017
cells	I-T017
increased	O
postinoculation	B-T033
.	O

Our	O
data	O
indicate	O
that	O
naturally	O
acquired	O
PS	B-T103
-	O
specific	O
memory	B-T017
B	I-T017
cells	I-T017
,	O
but	O
not	B-T033
levels	I-T033
of	O
circulating	O
IgG	B-T103
at	O
time	O
of	O
pneumococcal	B-T007
exposure	O
,	O
are	O
associated	O
with	O
protection	O
against	O
carriage	B-T033
acquisition	O
.	O

Hounsfield	O
unit	O
recovery	O
in	O
clinical	O
cone	B-T058
beam	I-T058
CT	I-T058
images	O
of	O
the	O
thorax	B-T082
acquired	O
for	O
image	B-T058
guided	I-T058
radiation	I-T058
therapy	I-T058

A	O
comprehensive	O
artefact	O
correction	O
method	B-T170
for	O
clinical	O
cone	B-T058
beam	I-T058
CT	I-T058
(	O
CBCT	B-T058
)	O
images	O
acquired	O
for	O
image	B-T058
guided	I-T058
radiation	I-T058
therapy	I-T058
(	O
IGRT	B-T058
)	O
on	O
a	O
commercial	O
system	O
is	O
presented	O
.	O

The	O
method	B-T170
is	O
demonstrated	O
to	O
reduce	O
artefacts	O
and	O
recover	O
CT	B-T058
-	O
like	O
Hounsfield	O
units	O
(	O
HU	O
)	O
in	O
reconstructed	O
CBCT	B-T058
images	O
of	O
five	O
lung	B-T038
cancer	I-T038
patients	O
.	O

Projection	O
image	O
based	O
artefact	O
corrections	O
of	O
image	O
lag	O
,	O
detector	O
scatter	O
,	O
body	O
scatter	O
and	O
beam	B-T033
hardening	I-T033
are	O
described	O
and	O
applied	O
to	O
CBCT	B-T058
images	O
of	O
five	O
lung	B-T038
cancer	I-T038
patients	O
.	O

Image	O
quality	O
is	O
evaluated	B-T058
through	O
visual	O
appearance	O
of	O
the	O
reconstructed	O
images	O
,	O
HU	O
-	O
correspondence	O
with	O
the	O
planning	O
CT	B-T058
images	O
,	O
and	O
total	O
volume	O
HU	O
error	O
.	O

Artefacts	O
are	O
reduced	O
and	O
CT	B-T058
-	O
like	O
HUs	O
are	O
recovered	O
in	O
the	O
artefact	O
corrected	O
CBCT	B-T058
images	O
.	O

Visual	B-T058
inspection	I-T058
confirms	B-T033
that	O
artefacts	O
are	O
indeed	O
suppressed	O
by	O
the	O
proposed	O
method	B-T170
,	O
and	O
the	O
HU	O
root	O
mean	O
square	O
difference	O
between	O
reconstructed	O
CBCTs	B-T058
and	O
the	O
reference	O
CT	B-T058
images	O
are	O
reduced	O
by	O
31	O
%	O
when	O
using	O
the	O
artefact	O
corrections	O
compared	O
to	O
the	O
standard	O
clinical	O
CBCT	B-T058
reconstruction	O
.	O

A	O
versatile	O
artefact	O
correction	O
method	B-T170
for	O
clinical	O
CBCT	B-T058
images	O
acquired	O
for	O
IGRT	B-T058
has	O
been	O
developed	O
.	O

HU	O
values	O
are	O
recovered	O
in	O
the	O
corrected	O
CBCT	B-T058
images	O
.	O

The	O
proposed	O
method	B-T170
relies	O
on	O
post	B-T170
processing	I-T170
of	O
clinical	O
projection	O
images	O
,	O
and	O
does	O
not	O
require	O
patient	O
specific	O
optimisation	O
.	O

It	O
is	O
thus	O
a	O
powerful	O
tool	B-T170
for	O
image	O
quality	O
improvement	O
of	O
large	O
numbers	O
of	O
CBCT	B-T058
images	O
.	O

Risk	B-T033
Factors	I-T033
for	O
Infection	B-T038
After	O
Knee	B-T058
Arthroscopy	I-T058
:	O
Analysis	B-T062
of	O
595	O
,	O
083	O
Cases	O
From	O
3	O
United	B-T082
States	I-T082
Databases	B-T170

To	O
identify	O
and	O
quantify	O
patient	B-T033
-	I-T033
and	O
procedure	B-T033
-	I-T033
related	I-T033
risk	I-T033
factors	I-T033
for	O
post	O
-	O
arthroscopic	O
knee	O
infections	O
using	O
a	O
large	O
dataset	B-T170
.	O

An	O
administrative	B-T170
health	I-T170
care	I-T170
database	I-T170
including	O
8	O
years	O
of	O
records	O
from	O
2	O
large	O
commercial	O
insurers	B-T092
and	O
Medicare	O
(	O
a	O
5	O
%	O
random	B-T062
sample	I-T062
)	O
was	O
queried	O
to	O
identify	O
all	O
knee	B-T058
arthroscopies	I-T058
performed	O
on	O
patients	O
aged	O
at	O
least	O
15	O
years	O
using	O
Current	B-T170
Procedural	I-T170
Terminology	I-T170
(	I-T170
CPT	I-T170
)	I-T170
codes	I-T170
.	O

Each	O
CPT	B-T170
code	I-T170
was	O
designated	O
as	O
a	O
high	B-T058
-	I-T058
or	O
low	B-T058
-	I-T058
complexity	I-T058
procedure	I-T058
,	O
with	O
the	O
former	O
typically	O
requiring	O
accessory	O
incisions	B-T058
or	O
increased	O
operative	O
time	O
.	O

Deep	O
infections	B-T038
were	O
identified	O
by	O
a	O
CPT	B-T170
code	I-T170
for	O
incision	B-T058
and	O
drainage	B-T058
within	O
90	O
days	O
of	O
surgery	O
.	O

Superficial	B-T038
infections	I-T038
were	O
identified	O
by	O
International	B-T170
Classification	I-T170
of	I-T170
Diseases	I-T170
,	I-T170
Ninth	I-T170
Revision	I-T170
infection	I-T170
codes	I-T170
without	O
any	O
record	B-T170
of	O
incision	B-T058
and	O
drainage	B-T058
.	O

Patients	O
were	O
compared	O
based	O
on	O
age	O
,	O
sex	O
,	O
body	B-T201
mass	I-T201
index	I-T201
,	O
tobacco	O
use	O
,	O
presence	O
of	O
diabetes	B-T038
,	O
and	O
Charlson	O
Comorbidity	O
Index	O
.	O

A	O
total	O
of	O
526	O
,	O
537	O
patients	O
underwent	O
595	O
,	O
083	O
arthroscopic	B-T058
knee	I-T058
procedures	I-T058
.	O

Deep	O
postoperative	B-T038
infections	I-T038
occurred	O
at	O
a	O
rate	O
of	O
0	O
.	O
22	O
%	O
.	O

Superficial	B-T038
infections	I-T038
occurred	O
at	O
a	O
rate	O
of	O
0	O
.	O
29	O
%	O
.	O

Tobacco	O
use	O
and	O
morbid	B-T038
obesity	I-T038
were	O
the	O
largest	O
risk	B-T033
factors	I-T033
for	O
deep	B-T038
and	O
superficial	B-T038
infections	I-T038
,	O
respectively	O
(	O
P	O
<	O
.	O
001	O
;	O
relative	O
risk	O
of	O
1	O
.	O
90	O
and	O
2	O
.	O
19	O
,	O
respectively	O
)	O
.	O

There	O
were	O
also	O
higher	O
infection	B-T038
rates	I-T038
among	O
patients	O
undergoing	O
relatively	O
high	B-T058
-	I-T058
complexity	I-T058
arthroscopies	I-T058
,	O
men	B-T098
,	O
obese	B-T038
patients	O
,	O
diabetic	B-T038
patients	O
,	O
and	O
younger	O
patients	O
(	O
in	O
order	O
of	O
decreasing	O
relative	O
risk	O
)	O
.	O

Increased	O
Charlson	O
Comorbidity	O
Index	O
was	O
associated	O
with	O
superficial	B-T038
and	O
total	B-T038
infections	I-T038
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Post	O
-	O
arthroscopic	O
knee	O
infections	O
were	O
more	O
frequent	O
among	O
morbidly	B-T038
obese	I-T038
patients	O
,	O
tobacco	B-T033
users	I-T033
,	O
patients	O
undergoing	O
relatively	O
complex	B-T058
procedures	I-T058
,	O
men	B-T098
,	O
obese	O
patients	O
,	O
diabetic	O
patients	O
,	O
relatively	O
young	O
patients	O
,	O
and	O
patients	O
with	O
increased	O
comorbidity	O
burdens	O
in	O
this	O
study	O
population	O
.	O

This	O
knowledge	O
may	O
allow	O
more	O
informed	O
preoperative	B-T058
counseling	I-T058
,	O
aid	B-T097
surgeons	I-T097
in	O
patient	B-T062
selection	I-T062
,	O
and	O
facilitate	O
infection	O
prevention	O
by	O
targeting	O
individuals	B-T098
with	O
higher	O
inherent	O
risk	O
.	O

Level	O
IV	O
,	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
.	O

Association	O
of	O
prenatal	O
and	O
early	O
life	O
exposure	O
to	O
tetrachloroethylene	B-T103
(	O
PCE	B-T103
)	O
with	O
polycystic	B-T038
ovary	I-T038
syndrome	I-T038
and	O
other	O
reproductive	O
disorders	O
in	O
the	O
cape	B-T082
cod	I-T082
health	B-T062
study	I-T062
:	O
A	O
retrospective	B-T062
cohort	I-T062
study	I-T062

Tetrachloroethylene	B-T103
(	O
PCE	B-T103
)	O
is	O
an	O
organic	O
lipophilic	O
solvent	B-T103
with	O
possible	O
neuroendocrine	B-T022
toxicity	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
association	O
of	O
prenatal	O
and	O
early	O
childhood	O
exposure	O
to	O
PCE	B-T103
-	O
contaminated	O
drinking	O
water	O
and	O
development	B-T038
of	O
adult	B-T033
-	I-T033
onset	I-T033
Polycystic	B-T038
Ovary	I-T038
Syndrome	I-T038
(	O
PCOS	B-T038
)	O
,	O
endometriosis	B-T038
,	O
difficulty	B-T033
conceiving	I-T033
and	O
miscarriage	B-T038
.	O

Five	O
-	O
hundred	O
exposed	O
and	O
331	O
unexposed	B-T098
female	O
participants	B-T098
born	O
between	O
1969	O
and	O
1983	O
completed	O
questionnaires	B-T170
on	O
demographic	O
and	O
lifestyle	O
characteristics	O
,	O
and	O
reproductive	O
disorders	O
.	O

Residential	B-T082
locations	I-T082
from	O
the	O
prenatal	O
period	O
through	O
five	O
years	O
of	O
age	O
were	O
used	O
to	O
estimate	O
early	O
life	O
PCE	B-T103
exposure	O
with	O
water	B-T170
modeling	I-T170
software	I-T170
.	O

For	O
any	O
early	O
life	O
exposure	O
to	O
PCE	B-T103
,	O
the	O
adjusted	O
risk	O
ratio	O
for	O
PCOS	B-T038
was	O
0	O
.	O
9	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
5	O
-	O
1	O
.	O
6	O
)	O
.	O

No	O
statistically	O
significan	O
t	O
associations	O
were	O
observed	O
for	O
increasing	O
levels	O
of	O
exposure	O
with	O
PCOS	B-T038
or	O
the	O
other	O
reproductive	O
disorders	O
.	O

No	O
meaningful	O
associations	O
were	O
found	B-T033
among	O
adult	O
women	B-T098
with	O
early	O
life	O
exposure	O
to	O
PCE	B-T103
-	O
contaminated	O
drinking	O
water	O
and	O
adult	B-T033
-	I-T033
onset	I-T033
reproductive	O
disorders	O
.	O

Host	B-T204
plant	I-T204
affects	O
the	O
sexual	O
attractiveness	O
of	O
the	O
female	O
white	B-T204
-	I-T204
spotted	I-T204
longicorn	I-T204
beetle	I-T204
,	O
Anoplophora	B-T204
malasiaca	I-T204

Anoplophora	B-T204
malasiaca	I-T204
(	O
Coleoptera	B-T204
:	O
Cerambycidae	B-T204
)	O
is	O
a	O
serious	O
pest	O
that	O
destroys	O
various	O
landscape	B-T082
and	O
crop	B-T204
trees	B-T204
in	O
Japan	B-T082
.	O

We	O
evaluated	O
the	O
precopulatory	O
responses	O
of	O
three	O
different	O
A	B-T204
.	I-T204

malasiaca	I-T204
populations	B-T098
collected	O
from	O
mandarin	B-T204
orange	I-T204
,	O
willow	B-T204
and	O
blueberry	B-T204
trees	I-T204
.	O

Most	O
of	O
the	O
males	O
accepted	O
mates	O
from	O
within	O
the	O
same	O
host	B-T204
plant	I-T204
population	B-T098
as	O
well	O
as	O
females	O
from	O
the	O
willow	B-T204
and	O
blueberry	B-T204
populations	O
.	O

However	O
,	O
significant	O
number	O
of	O
males	O
from	O
the	O
blueberry	B-T204
and	O
willow	B-T204
populations	B-T098
rejected	O
females	O
from	O
the	O
mandarin	B-T204
orange	I-T204
population	O
immediately	O
after	O
touching	O
them	O
with	O
their	O
antennae	B-T017
.	O

Because	O
all	O
three	O
of	O
the	O
female	O
populations	B-T098
produced	O
contact	O
sex	B-T103
pheromones	I-T103
on	O
their	O
elytra	B-T017
,	O
the	O
females	O
of	O
the	O
mandarin	B-T204
orange	I-T204
population	O
were	O
predicted	O
to	O
possess	O
extra	O
chemicals	B-T103
that	O
repelled	O
the	O
males	O
of	O
the	O
other	O
two	O
populations	O
.	O

β	B-T103
-	I-T103
Elemene	I-T103
was	O
identified	O
as	O
a	O
key	O
component	O
that	O
was	O
only	O
found	O
in	O
mandarin	B-T204
orange	I-T204
-	O
fed	O
females	O
and	O
induced	O
a	O
rejection	O
response	O
in	O
willow	B-T204
-	O
fed	O
males	O
.	O

Our	O
results	O
represent	O
the	O
first	O
example	O
of	O
a	O
female	O
-	O
acquired	O
repellent	O
against	O
conspecific	O
males	O
of	O
different	O
host	B-T204
plant	I-T204
populations	O
,	O
indicating	O
that	O
the	O
host	B-T204
plant	I-T204
greatly	O
affects	O
the	O
female	O
'	O
s	O
sexual	O
attractiveness	O
.	O

Molecular	O
detection	B-T058
of	O
infection	B-T038
homogeneity	O
and	O
impact	O
of	O
miltefosine	B-T103
treatment	O
in	O
a	O
Syrian	B-T204
golden	I-T204
hamster	I-T204
model	O
of	O
Leishmania	B-T204
donovani	I-T204
and	O
L	B-T204
.	I-T204
infantum	I-T204
visceral	B-T038
leishmaniasis	I-T038

Control	O
of	O
visceral	B-T038
leishmaniasis	I-T038
caused	O
by	O
Leishmania	B-T204
infantum	I-T204
and	O
Leishmania	B-T204
donovani	I-T204
primarily	O
relies	O
on	O
chemotherapy	B-T058
using	O
an	O
increasingly	O
compromised	O
repertoire	O
of	O
antileishmanial	B-T103
compounds	I-T103
.	O

For	O
evaluation	B-T058
of	O
novel	O
drugs	B-T103
,	O
the	O
Syrian	B-T204
golden	I-T204
hamster	I-T204
is	O
considered	O
as	O
a	O
clinically	O
relevant	O
laboratory	B-T170
model	I-T170
.	O

In	O
this	O
study	B-T062
,	O
two	O
molecular	B-T058
parasite	I-T058
detection	I-T058
assays	I-T058
were	O
developed	O
targeting	O
cathepsin	B-T103
-	I-T103
like	I-T103
cysteine	I-T103
protease	I-T103
B	I-T103
(	O
CPB	B-T103
)	O
DNA	B-T103
and	O
18S	O
rRNA	B-T103
to	O
achieve	O
absolute	O
amastigote	B-T204
quantification	O
in	O
the	O
major	O
target	O
organs	B-T017
liver	B-T017
and	O
spleen	B-T017
.	O

Both	O
quantitative	B-T062
PCR	I-T062
(	B-T062
qPCR	I-T062
)	I-T062
techniques	I-T062
showed	O
excellent	O
agreement	O
with	O
a	O
strong	O
correlation	O
with	O
the	O
conventional	O
microscopic	B-T058
reading	I-T058
of	O
Giemsa	B-T058
-	I-T058
stained	I-T058
tissue	B-T017
smears	B-T058
.	O

Using	O
multiple	O
single	O
tissue	B-T017
pieces	I-T017
and	O
all	O
three	O
detection	B-T033
methods	B-T170
,	O
we	O
confirmed	O
homogeneity	O
of	O
infection	B-T038
in	O
liver	B-T017
and	O
spleen	B-T017
and	O
the	O
robustness	O
of	O
extrapolating	O
whole	O
organ	O
burdens	O
from	O
a	O
small	O
single	O
tissue	B-T017
piece	I-T017
.	O

Comparison	O
of	O
pre	O
-	O
and	O
post	O
-	O
treatment	O
burdens	O
in	O
infected	B-T033
hamsters	B-T204
using	O
the	O
three	O
detection	B-T033
methods	B-T170
consistently	O
revealed	O
a	O
stronger	O
parasite	B-T204
reduction	O
in	O
the	O
spleen	B-T017
compared	O
to	O
the	O
liver	B-T017
,	O
indicating	O
an	O
organ	B-T017
-	O
dependent	O
clearance	O
efficacy	O
for	O
miltefosine	B-T103
.	O

In	O
conclusion	O
,	O
this	O
study	B-T062
in	O
the	O
hamster	B-T204
demonstrated	O
high	O
homogeneity	O
of	O
infection	B-T038
in	O
liver	B-T017
and	O
spleen	B-T017
and	O
advocates	O
the	O
use	O
of	O
molecular	O
detection	B-T058
methods	B-T170
for	O
assessment	B-T058
of	O
low	O
(	O
post	O
-	O
treatment	O
)	O
tissue	B-T017
burdens	O
.	O

Approximate	O
Bayesian	O
computation	O
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-T058
microscopy	I-T058

We	O
present	O
an	O
approximate	O
Bayesian	O
computation	O
scheme	B-T170
for	O
estimating	O
number	O
concentrations	O
of	O
monodisperse	O
diffusing	O
nanoparticles	O
in	O
suspension	O
by	O
optical	B-T058
particle	I-T058
tracking	I-T058
microscopy	I-T058
.	O

The	O
method	O
is	O
based	O
on	O
the	O
probability	O
distribution	O
of	O
the	O
time	O
spent	O
by	O
a	O
particle	B-T103
inside	B-T082
a	O
detection	B-T058
region	B-T082
.	O

We	O
validate	O
the	O
method	O
on	O
suspensions	O
of	O
well	O
-	O
controlled	O
reference	O
particles	B-T103
.	O

We	O
illustrate	O
its	O
usefulness	O
with	O
an	O
application	O
in	O
gene	B-T058
therapy	I-T058
,	O
applying	O
the	O
method	O
to	O
estimate	O
number	O
concentrations	O
of	O
plasmid	B-T103
DNA	B-T103
molecules	I-T103
and	O
the	O
average	O
number	O
of	O
DNA	B-T103
molecules	I-T103
complexed	B-T103
with	O
liposomal	B-T103
drug	B-T074
delivery	I-T074
particles	B-T103
.	O

Gestational	O
age	O
specific	O
stillbirth	B-T033
risk	O
among	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-T098
in	O
Queensland	B-T082
,	O
Australia	B-T082
:	O
a	O
population	B-T062
based	I-T062
study	I-T062

In	O
Australia	B-T082
,	O
significant	O
disparity	O
persists	O
in	O
stillbirth	B-T033
rates	O
between	O
Aboriginal	O
and	O
Torres	B-T098
Strait	I-T098
Islander	I-T098
(	O
Indigenous	O
Australian	O
)	O
and	O
non	O
-	O
Indigenous	O
women	B-T098
.	O

Diabetes	B-T038
,	O
hypertension	B-T038
,	O
antepartum	B-T038
haemorrhage	I-T038
and	O
small	B-T038
-	I-T038
for	I-T038
-	I-T038
gestational	I-T038
age	I-T038
(	O
SGA	B-T038
)	O
have	O
been	O
identified	O
as	O
important	O
contributors	O
to	O
higher	O
rates	O
among	O
Indigenous	O
women	B-T098
.	O

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
examine	O
gestational	O
age	O
specific	O
risk	O
of	O
stillbirth	B-T033
associated	O
with	O
these	O
conditions	O
among	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-T098
.	O

Retrospective	O
population	B-T062
-	I-T062
based	I-T062
study	I-T062
of	O
all	O
singleton	O
births	O
of	O
at	O
least	O
20	O
weeks	O
gestation	B-T038
or	O
at	O
least	O
400	O
grams	O
birthweight	O
in	O
Queensland	B-T082
between	O
July	O
2005	O
and	O
December	O
2011	O
using	O
data	O
from	O
the	O
Queensland	B-T082
Perinatal	O
Data	B-T062
Collection	I-T062
,	O
which	O
is	O
a	O
routinely	B-T170
-	I-T170
maintained	I-T170
database	I-T170
that	O
collects	O
data	O
on	O
all	O
births	O
in	O
Queensland	B-T082
.	O

Multivariate	B-T062
logistic	I-T062
regression	I-T062
was	O
used	O
to	O
calculate	O
adjusted	O
odds	O
ratios	O
(	O
aOR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
,	O
adjusting	O
for	O
maternal	B-T033
demographic	O
and	O
pregnancy	B-T033
factors	I-T033
.	O

Of	O
360987	O
births	O
analysed	B-T062
,	O
20273	O
(	O
5	O
.	O
6	O
%	O
)	O
were	O
to	O
Indigenous	O
women	B-T098
and	O
340714	O
(	O
94	O
.	O
4	O
%	O
)	O
were	O
to	O
non	O
-	O
Indigenous	O
women	B-T098
.	O

Stillbirth	B-T033
rates	O
were	O
7	O
.	O
9	O
(	O
95	O
%	O
CI	O
6	O
.	O
8	O
-	O
9	O
.	O
2	O
)	O
and	O
4	O
.	O
1	O
(	O
95	O
%	O
CI	O
3	O
.	O
9	O
-	O
4	O
.	O
3	O
)	O
per	O
1000	O
births	O
,	O
respectively	O
.	O

For	O
both	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-T098
across	O
most	O
gestational	O
age	O
groups	O
,	O
antepartum	B-T038
haemorrhage	I-T038
,	O
SGA	B-T038
,	O
pre	O
-	O
existing	O
diabetes	O
and	O
pre	O
-	O
existing	O
hypertension	O
were	O
associated	O
with	O
increased	O
risk	O
of	O
stillbirth	B-T033
.	O

There	O
were	O
mixed	O
results	O
for	O
pre	B-T038
-	I-T038
eclampsia	I-T038
and	O
eclampsia	B-T038
and	O
a	O
consistently	O
raised	O
risk	O
of	O
stillbirth	B-T033
was	O
not	O
seen	O
for	O
gestational	B-T038
diabetes	I-T038
.	O

This	O
study	B-T062
highlights	O
gestational	O
age	O
specific	O
stillbirth	B-T033
risk	O
for	O
Indigenous	O
and	O
non	O
-	O
Indigenous	O
women	B-T098
;	O
and	O
disparity	O
in	O
risk	O
at	O
term	B-T038
gestations	I-T038
.	O

Improving	O
access	O
to	O
and	O
utilisation	O
of	O
appropriate	O
and	O
responsive	O
healthcare	B-T058
may	O
help	O
to	O
address	O
disparities	O
in	O
stillbirth	B-T033
risk	O
for	O
Indigenous	O
women	B-T098
.	O

Defining	O
,	O
Describing	B-T170
,	O
and	O
Categorizing	O
Public	B-T058
Health	I-T058
Infrastructure	I-T058
Priorities	O
for	O
Tropical	O
Cyclone	O
,	O
Flood	O
,	O
Storm	O
,	O
Tornado	O
,	O
and	O
Tsunami	O
-	O
Related	O
Disasters	O

The	O
study	B-T062
aim	O
was	O
to	O
undertake	O
a	O
qualitative	O
research	O
literature	B-T170
review	I-T170
to	O
analyze	O
available	O
databases	B-T170
to	O
define	O
,	O
describe	B-T170
,	O
and	O
categorize	O
public	B-T058
health	I-T058
infrastructure	I-T058
(	O
PHI	B-T058
)	O
priorities	O
for	O
tropical	O
cyclone	O
,	O
flood	O
,	O
storm	O
,	O
tornado	O
,	O
and	O
tsunami	O
-	O
related	O
disasters	O
.	O

Five	O
electronic	O
publication	B-T170
databases	I-T170
were	O
searched	O
to	O
define	O
,	O
describe	B-T170
,	O
or	O
categorize	O
PHI	B-T058
and	O
discuss	O
tropical	O
cyclone	O
,	O
flood	O
,	O
storm	O
,	O
tornado	O
,	O
and	O
tsunami	O
-	O
related	O
disasters	O
and	O
their	O
impact	O
on	O
PHI	B-T058
.	O

The	O
data	O
were	O
analyzed	O
through	O
aggregation	O
of	O
individual	O
articles	B-T170
to	O
create	O
an	O
overall	O
data	O
description	O
.	O

The	O
data	O
were	O
grouped	O
into	O
PHI	B-T058
themes	O
,	O
which	O
were	O
then	O
prioritized	O
on	O
the	O
basis	O
of	O
degree	O
of	O
interdependency	O
.	O

Sixty	O
-	O
seven	O
relevant	O
articles	B-T170
were	O
identified	O
.	O

PHI	B-T058
was	O
categorized	O
into	O
13	O
themes	O
with	O
a	O
total	O
of	O
158	O
descriptors	B-T170
.	O

The	O
highest	O
priority	O
PHI	B-T058
identified	O
was	O
workforce	O
.	O

This	O
was	O
followed	O
by	O
water	O
,	O
sanitation	O
,	O
equipment	O
,	O
communication	O
,	O
physical	O
structure	O
,	O
power	O
,	O
governance	B-T170
,	O
prevention	O
,	O
supplies	O
,	O
service	O
,	O
transport	O
,	O
and	O
surveillance	O
.	O

This	O
review	B-T170
identified	O
workforce	O
as	O
the	O
most	O
important	O
of	O
the	O
13	O
thematic	O
areas	O
related	O
to	O
PHI	B-T058
and	O
disasters	O
.	O

If	O
its	O
functionality	O
fails	O
,	O
workforce	O
has	O
the	O
greatest	O
impact	O
on	O
the	O
performance	O
of	O
health	B-T058
services	I-T058
.	O

If	O
addressed	O
post	O
-	O
disaster	O
,	O
the	O
remaining	O
forms	O
of	O
PHI	B-T058
will	O
then	O
be	O
progressively	O
addressed	O
.	O

These	O
findings	O
are	O
a	O
step	O
toward	O
providing	O
an	O
evidence	O
base	O
to	O
inform	O
PHI	B-T058
priorities	O
in	O
the	O
disaster	O
setting	O
.	O

(	O
Disaster	O
Med	O
Public	O
Health	O
Preparedness	O
.	O

2016	O
;	O
10	O
:	O
598	O
-	O
610	O
)	O
.	O

Fragment	B-T103
-	O
Based	O
Discovery	O
of	O
5	B-T103
-	I-T103
Arylisatin	I-T103
-	O
Based	O
Inhibitors	B-T103
of	O
Matrix	B-T103
Metalloproteinases	I-T103
2	I-T103
and	O
13	B-T103

Matrix	B-T103
metalloproteinases	I-T103
(	O
MMPs	B-T103
)	O
are	O
well	O
-	O
established	O
targets	O
for	O
several	O
pathologies	B-T038
.	O

In	O
particular	O
,	O
MMP	B-T103
-	I-T103
2	I-T103
and	O
MMP	B-T103
-	I-T103
13	I-T103
play	O
a	O
prominent	O
role	O
in	O
cancer	B-T038
progression	I-T038
.	O

In	O
this	O
study	B-T062
,	O
a	O
structure	B-T058
-	I-T058
based	I-T058
screening	I-T058
campaign	O
was	O
applied	O
to	O
prioritize	O
metalloproteinase	B-T103
-	O
oriented	O
fragments	B-T103
.	O

This	O
computational	O
model	O
was	O
applied	O
to	O
a	O
representative	O
fragment	B-T103
set	O
from	O
the	O
publically	O
available	O
EDASA	B-T170
Scientific	I-T170
compound	I-T170
library	I-T170
.	O

These	O
fragments	B-T103
were	O
prioritized	O
,	O
and	O
the	O
top	O
-	O
ranking	O
hits	O
were	O
tested	O
in	O
a	O
biological	B-T058
assay	I-T058
to	O
validate	B-T062
the	O
model	O
.	O

Two	O
scaffolds	B-T103
showed	O
consistent	O
activity	O
in	O
the	O
assay	B-T058
,	O
and	O
the	O
isatin	B-T103
-	I-T103
based	I-T103
compounds	I-T103
were	O
the	O
most	O
interesting	O
.	O

These	O
latter	O
fragments	B-T103
have	O
significant	O
potential	O
as	O
tools	O
for	O
the	O
design	O
and	O
realization	O
of	O
novel	O
MMP	B-T103
inhibitors	I-T103
.	O

In	O
addition	O
to	O
their	O
micromolar	O
activity	O
,	O
the	O
chemical	O
synthesis	O
affords	O
flexible	O
and	O
creative	B-T082
access	I-T082
to	O
their	O
analogues	B-T103
.	O

Incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	B-T017
cataract	I-T017
in	O
Children	O
of	O
Lahore	O

To	O
check	O
the	O
incidence	O
of	O
environmental	O
and	O
genetic	O
factors	O
causing	O
congenital	B-T017
cataract	I-T017
in	O
infants	O
.	O

The	O
descriptive	B-T062
study	I-T062
was	O
conducted	O
at	O
Layton	B-T092
Rahmatullah	I-T092
Benevolent	I-T092
Trust	I-T092
,	O
Lahore	O
,	O
Pakistan	B-T082
,	O
from	O
October	O
2013	O
to	O
April	O
2014	O
,	O
and	O
comprised	O
children	O
under	O
15	O
years	O
of	O
age	O
who	O
had	O
rubella	O
syndrome	O
,	O
herpes	B-T038
simplex	I-T038
,	O
birth	B-T033
trauma	I-T033
,	O
trisomy	B-T038
21	I-T038
,	O
Nance	B-T038
-	I-T038
Horan	I-T038
syndrome	I-T038
or	O
Lowe	B-T038
'	I-T038
s	I-T038
syndrome	I-T038
.	O

Of	O
the	O
38	O
,	O
000	O
cases	O
examined	O
,	O
120	O
(	O
0	O
.	O
3	O
%	O
)	O
patients	O
were	O
diagnosed	B-T033
with	O
congenital	B-T017
cataract	I-T017
.	O

Of	O
them	O
,	O
52	O
(	O
43	O
.	O
33	O
%	O
)	O
were	O
aged	O
between	O
2	O
and	O
5	O
years	O
,	O
22	O
(	O
18	O
.	O
33	O
%	O
)	O
<	O
11	O
years	O
and	O
10	O
(	O
8	O
.	O
33	O
%	O
)	O
?	O
15	O
years	O
.	O

Bilateral	B-T038
congenital	I-T038
cataract	I-T038
was	O
observed	O
in	O
91	O
(	O
75	O
.	O
83	O
%	O
)	O
patients	O
and	O
unilateral	B-T038
congenital	I-T038
cataract	I-T038
in	O
29	O
(	O
24	O
.	O
17	O
%	O
)	O
.	O

Environmental	O
factors	O
caused	O
72	O
(	O
62	O
.	O
07	O
%	O
)	O
cases	O
and	O
genetic	O
factors	O
caused	O
44	O
(	O
37	O
.	O
93	O
%	O
)	O
.	O
.	O

Congenital	B-T017
cataract	I-T017
predominated	O
in	O
boys	O
compared	O
to	O
girls	O
.	O

Early	O
diagnosis	B-T033
and	O
adequate	O
therapy	B-T058
requires	O
specific	O
technology	O
,	O
as	O
well	O
as	O
long	O
-	O
term	O
and	O
permanent	O
care	O
.	O
.	O

Transcriptome	B-T082
and	O
Metabolome	O
Analyses	B-T062
of	O
Glucosinolates	B-T103
in	O
Two	O
Broccoli	B-T204
Cultivars	I-T204
Following	O
Jasmonate	B-T103
Treatment	O
for	O
the	O
Induction	O
of	O
Glucosinolate	B-T103
Defense	O
to	O
Trichoplusia	B-T204
ni	I-T204
(	O
Hübner	O
)	O

Lepidopteran	B-T204
larvae	B-T204
growth	B-T038
is	O
influenced	O
by	O
host	O
plant	B-T204
glucosinolate	B-T103
(	O
GS	B-T103
)	O
concentrations	O
,	O
which	O
are	O
,	O
in	O
turn	O
,	O
influenced	O
by	O
the	O
phytohormone	B-T103
jasmonate	B-T103
(	O
JA	B-T103
)	O
.	O

In	O
order	O
to	O
elucidate	O
insect	B-T204
resistance	O
biomarkers	B-T038
to	O
lepidopteran	B-T204
pests	O
,	O
transcriptome	B-T082
and	O
metabolome	O
analyses	B-T062
following	O
JA	B-T103
treatments	O
were	O
conducted	O
with	O
two	O
broccoli	B-T204
cultivars	I-T204
,	O
Green	B-T204
Magic	I-T204
and	O
VI	B-T204
-	I-T204
158	I-T204
,	O
which	O
have	O
differentially	O
induced	O
indole	B-T103
GSs	I-T103
,	O
neoglucobrassicin	B-T103
and	O
glucobrassicin	B-T103
,	O
respectively	O
.	O

To	O
test	O
these	O
two	O
inducible	O
GSs	B-T103
on	O
growth	B-T038
of	O
cabbage	B-T204
looper	I-T204
(	O
Trichoplusia	B-T204
ni	I-T204
)	O
,	O
eight	O
neonate	O
cabbage	B-T204
looper	I-T204
larvae	I-T204
were	O
placed	O
onto	O
each	O
of	O
three	O
plants	B-T204
per	O
JA	B-T103
treatments	O
(	O
0	O
,	O
100	O
,	O
200	O
,	O
400	O
µM	O
)	O
three	O
days	O
after	O
treatment	O
.	O

After	O
five	O
days	O
of	O
feeding	O
,	O
weight	O
of	O
larvae	B-T204
and	O
their	O
survival	O
rate	O
was	O
found	O
to	O
decrease	O
with	O
increasing	O
JA	B-T103
concentrations	O
in	O
both	O
broccoli	B-T204
cultivars	I-T204
.	O

JA	B-T103
-	O
inducible	O
GSs	B-T103
were	O
measured	O
by	O
high	B-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
.	O

Neoglucobrassicin	B-T103
in	O
Green	B-T204
Magic	I-T204
and	O
glucobrassicin	B-T103
in	O
VI	B-T204
-	I-T204
158	I-T204
leaves	B-T204
were	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

One	O
or	O
both	O
of	O
these	O
glucosinolates	B-T103
and	O
/	O
or	O
their	O
hydrolysis	O
products	O
showed	O
significant	O
inverse	O
correlations	O
with	O
larval	B-T204
weight	O
and	O
survival	O
(	O
five	O
days	O
after	O
treatment	O
)	O
while	O
being	O
positively	B-T033
correlated	O
with	O
the	O
number	O
of	O
days	O
to	O
pupation	B-T038
.	O

This	O
implies	O
that	O
these	O
two	O
JA	B-T103
-	O
inducible	O
glucosinolates	B-T103
can	O
influence	O
the	O
growth	B-T038
and	O
survival	O
of	O
cabbage	B-T204
looper	I-T204
larvae	I-T204
.	O

Transcriptome	B-T058
profiling	I-T058
supported	O
the	O
observed	O
changes	O
in	O
glucosinolate	B-T103
and	O
their	O
hydrolysis	O
product	O
concentrations	O
following	O
JA	B-T103
treatments	O
.	O

Several	O
genes	B-T017
related	O
to	O
GS	B-T103
metabolism	B-T038
differentiate	O
the	O
two	O
broccoli	B-T204
cultivars	I-T204
in	O
their	O
pattern	B-T082
of	O
transcriptional	B-T038
response	O
to	O
JA	B-T103
treatments	O
.	O

Indicative	O
of	O
the	O
corresponding	O
change	O
in	O
indole	B-T103
GS	I-T103
concentrations	O
,	O
transcripts	B-T103
of	O
the	O
transcription	B-T103
factor	I-T103
MYB122	B-T103
,	O
core	O
structure	O
biosynthesis	O
genes	B-T017
(	O
CYP79B2	B-T017
,	O
UGT74B1	B-T017
,	O
SUR1	B-T017
,	O
SOT16	B-T017
,	O
SOT17	B-T017
,	O
and	O
SOT18	B-T017
)	O
,	O
an	O
indole	O
glucosinolate	O
side	O
chain	O
modification	B-T033
gene	B-T017
(	O
IGMT1	B-T017
)	O
,	O
and	O
several	O
glucosinolate	B-T103
hydrolysis	O
genes	O
(	O
TGG1	B-T017
,	O
TGG2	B-T017
,	O
and	O
ESM1	B-T017
)	O
were	O
significantly	O
increased	O
in	O
Green	B-T204
Magic	I-T204
(	O
statistically	O
significant	O
in	O
most	O
cases	O
at	O
400	O
µM	O
)	O
while	O
UGT74B1	B-T017
and	O
MYB122	B-T017
were	O
significantly	O
increased	O
in	O
VI	B-T204
-	I-T204
158	I-T204
.	O

Therefore	O
,	O
these	O
metabolite	B-T103
and	O
transcript	B-T103
biomarker	B-T038
results	O
indicate	O
that	O
transcriptome	B-T058
profiling	I-T058
can	O
identify	O
genes	B-T017
associated	O
with	O
the	O
formation	O
of	O
two	O
different	O
indole	B-T103
GS	I-T103
and	O
their	O
hydrolysis	O
products	O
.	O

Therefore	O
,	O
these	O
metabolite	B-T103
and	O
transcript	B-T103
biomarkers	B-T038
could	O
be	O
useful	O
in	O
an	O
effective	O
marker	B-T038
-	O
assisted	O
breeding	B-T038
strategy	O
for	O
resistance	O
to	O
generalist	O
lepidopteran	B-T204
pests	O
in	O
broccoli	B-T204
and	O
potentially	O
other	O
Brassica	B-T168
vegetables	I-T168
.	O

The	O
clinical	O
prognosis	O
of	O
implants	B-T074
that	O
are	O
placed	O
against	O
super	B-T038
-	I-T038
erupted	I-T038
opposing	O
dentition	B-T017

If	O
teeth	B-T017
are	O
missing	B-T017
,	O
super	B-T038
-	I-T038
eruption	I-T038
of	I-T038
teeth	I-T038
in	O
the	O
opposing	O
arch	O
can	O
occur	O
in	O
the	O
area	B-T082
and	O
can	O
change	O
the	O
occlusal	B-T038
plane	I-T038
.	O

When	O
missing	B-T017
teeth	I-T017
are	O
replaced	O
with	O
implants	B-T074
,	O
the	O
oral	B-T097
surgeon	I-T097
must	O
determine	O
whether	O
or	O
not	O
the	O
super	B-T017
-	I-T017
erupted	I-T017
teeth	I-T017
need	O
to	O
be	O
treated	O
in	O
order	O
to	O
normalize	B-T062
the	O
occlusal	B-T038
plane	I-T038
.	O

In	O
this	O
study	B-T062
,	O
we	O
evaluated	B-T058
the	O
clinical	O
prognosis	O
of	O
dentition	B-T017
after	O
implant	B-T058
placement	I-T058
and	O
prosthetic	B-T058
treatment	I-T058
were	O
completed	O
in	O
an	O
occlusal	B-T038
plane	I-T038
altered	O
by	O
super	B-T017
-	I-T017
erupted	I-T017
teeth	I-T017
in	O
the	O
opposing	O
arch	O
without	O
additional	O
treatment	O
of	O
the	O
super	B-T017
-	I-T017
erupted	I-T017
teeth	I-T017
.	O

Twenty	O
-	O
two	O
patients	O
(	O
9	O
males	O
,	O
13	O
females	O
)	O
were	O
treated	O
with	O
implants	B-T074
and	O
prosthetics	B-T074
without	O
addressing	O
the	O
super	B-T038
-	I-T038
erupted	I-T038
opposing	O
dentition	B-T017
from	O
April	O
2004	O
to	O
August	O
2012	O
at	O
Seoul	B-T082
National	B-T092
University	I-T092
Bundang	I-T092
Hospital	I-T092
.	O

A	O
total	O
of	O
33	O
implants	B-T074
were	O
placed	O
.	O

Values	O
of	O
crestal	B-T038
bone	I-T038
loss	I-T038
,	O
survival	O
rates	O
,	O
and	O
surgical	B-T038
and	O
prosthetic	B-T038
complications	I-T038
for	O
an	O
average	O
of	O
29	O
.	O
6	O
months	O
after	O
prosthetic	B-T058
loading	I-T058
were	O
recorded	O
.	O

In	O
one	O
case	O
,	O
the	O
cover	B-T074
screw	I-T074
was	O
exposed	O
after	O
implant	B-T058
surgery	I-T058
.	O

The	O
mean	O
crestal	B-T038
bone	I-T038
loss	I-T038
was	O
0	O
.	O
09±0	O
.	O
30	O
mm	O
.	O

Of	O
the	O
33	O
implants	B-T074
,	O
31	O
survived	O
,	O
a	O
survival	O
rate	O
of	O
93	O
.	O
94	O
%	O
.	O

A	O
prosthetic	B-T038
complication	I-T038
occurred	O
in	O
one	O
case	O
but	O
functioned	O
well	O
after	O
correction	O
.	O

Favorable	O
clinical	B-T033
results	I-T033
from	O
prosthetic	B-T038
complications	I-T038
,	O
crestal	B-T038
bone	I-T038
loss	I-T038
,	O
and	O
implant	B-T074
survival	O
rates	O
were	O
exhibited	O
in	O
implants	B-T074
next	O
to	O
a	O
super	B-T017
-	I-T017
erupted	I-T017
opposing	I-T017
tooth	I-T017
.	O

Evaluation	O
of	O
Mathisen	O
'	O
s	O
technique	O
for	O
ureteral	B-T058
reimplantation	I-T058
in	O
children	O
with	O
primary	O
vesicoureteral	B-T038
reflux	I-T038

Although	O
cross	B-T058
-	I-T058
trigonal	I-T058
ureteral	I-T058
reimplantation	I-T058
(	I-T058
Cohen	I-T058
)	I-T058
is	O
a	O
commonly	O
used	O
technique	O
in	O
children	O
,	O
it	O
represents	O
a	O
non	B-T038
-	I-T038
physiological	I-T038
transfer	I-T038
of	O
the	O
ureteral	B-T082
orifices	I-T082
and	O
may	O
prove	O
challenging	O
with	O
regard	O
to	O
endoscopic	B-T058
ureteral	I-T058
operations	I-T058
in	O
later	O
life	O
.	O

In	O
1964	O
,	O
Mathisen	O
described	O
an	O
alternative	O
method	O
of	O
ureteral	B-T058
reimplantation	I-T058
with	O
lateralization	O
of	O
the	O
neohiatus	O
,	O
creating	O
an	O
orthotopic	B-T082
course	O
of	O
the	O
submucosal	B-T017
ureter	I-T017
.	O

We	O
have	O
evaluated	O
success	O
and	O
complication	O
rates	O
of	O
both	O
techniques	O
that	O
were	O
applied	O
sequentially	O
at	O
our	O
departments	B-T092
.	O

Forty	O
-	O
eight	O
consecutive	O
patients	O
(	O
83	O
ureters	B-T098
,	O
24	O
males	B-T098
/	O
24	O
females	B-T098
)	O
following	O
Mathisen	B-T058
reimplantation	I-T058
were	O
compared	O
with	O
53	O
consecutive	O
patients	O
(	O
98	O
ureters	B-T098
,	O
30	O
males	B-T098
/	O
23	O
females	B-T098
)	O
following	O
Cohen	B-T058
reimplantation	I-T058
.	O

Inclusion	O
criteria	O
were	O
primary	O
vesicoureteral	B-T038
reflux	I-T038
(	O
VUR	B-T038
)	O
and	O
no	O
previous	O
intervention	B-T058
.	O

Reflux	B-T038
grades	B-T170
(	O
Mathisen	O
58	O
ureters	B-T098
/	O
69	O
.	O
9	O
%	O
VUR	B-T033
≥	I-T033
III	I-T033
;	O
Cohen	O
66	O
ureters	B-T098
/	O
66	O
.	O
7	O
%	O
VUR	B-T033
≥	I-T033
III	I-T033
)	O
and	O
the	O
occurence	O
of	O
other	O
complicating	O
factors	O
(	O
ureteroceles	B-T017
,	O
megaureters	B-T017
,	O
posterior	B-T017
urethral	I-T017
valves	I-T017
)	O
in	O
both	O
groups	O
were	O
comparable	O
.	O

After	O
Cohen	B-T058
'	I-T058
s	I-T058
reimplantation	I-T058
there	O
were	O
no	O
immediate	O
complications	B-T038
requiring	O
intervention	B-T058
;	O
during	O
follow	B-T058
-	I-T058
up	I-T058
(	O
mean	O
28	O
.	O
2	O
months	O
)	O
three	O
patients	O
(	O
5	O
.	O
6	O
%	O
)	O
suffered	B-T038
febrile	B-T038
urinary	I-T038
tract	I-T038
infections	I-T038
(	O
UTIs	B-T038
)	O
,	O
of	O
which	O
one	O
(	O
1	O
.	O
8	O
%	O
)	O
was	O
diagnosed	B-T033
with	O
a	O
persisting	O
VUR	B-T038
.	O

Persistent	O
hydronephroses	B-T038
(	O
≥II	O
SFU	B-T038
)	O
were	O
recorded	O
in	O
six	O
patients	O
(	O
13	O
.	O
2	O
%	O
)	O
.	O

After	O
reimplantation	B-T058
using	O
Mathisen	O
'	O
s	O
technique	O
,	O
two	O
patients	O
(	O
4	O
.	O
1	O
%	O
)	O
suffered	B-T038
significant	O
intravesical	O
bleeding	O
;	O
during	O
follow	B-T058
-	I-T058
up	I-T058
(	O
mean	O
23	O
.	O
06	O
months	O
)	O
four	O
patients	O
(	O
8	O
.	O
3	O
%	O
)	O
suffered	B-T038
febrile	B-T038
UTIs	I-T038
,	O
and	O
seven	O
patients	O
(	O
14	O
.	O
5	O
%	O
)	O
were	O
diagnosed	B-T033
with	O
persisting	O
VUR	B-T038
after	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
10	O
.	O
8	O
months	O
.	O

The	O
patients	O
with	O
persistent	O
VUR	B-T038
had	O
more	O
commonly	O
high	O
-	O
grade	O
(	O
IV	O
and	O
V	O
)	O
VUR	B-T038
initially	O
,	O
compared	O
to	O
the	O
whole	O
group	O
.	O

Two	O
patients	O
(	O
4	O
.	O
1	O
%	O
)	O
had	O
persistent	O
hydronephroses	B-T038
(	O
≥II	O
SFU	B-T038
)	O
.	O

Mathisen	O
'	O
s	O
technique	O
for	O
ureteral	B-T058
reimplantation	I-T058
yielded	O
a	O
significantly	O
(	O
p	O
=	O
0	O
.	O
0256	O
patients	O
,	O
p	O
=	O
0	O
.	O
006	O
ureterorenal	O
units	O
)	O
lower	B-T082
success	O
rate	O
(	O
85	O
.	O
5	O
%	O
patients	O
,	O
89	O
.	O
2	O
%	O
ureterorenal	O
units	O
)	O
in	O
comparison	O
with	O
Cohen	O
'	O
s	O
technique	O
(	O
98	O
.	O
2	O
%	O
patients	O
,	O
99	O
%	O
ureterorenal	O
units	O
)	O
.	O

Although	O
there	O
was	O
no	O
intervention	B-T058
for	O
obstruction	B-T038
,	O
persistent	O
hydronephrosis	B-T038
was	O
more	O
common	O
in	O
the	O
Cohen	O
group	O
(	O
13	O
.	O
2	O
%	O
vs	O
.	O

4	O
.	O
1	O
%	O
,	O
n	O
.	O
s	O
.	O
)	O
.	O

Despite	O
the	O
advantages	O
of	O
an	O
orthotopic	B-T082
ureteral	B-T082
orifice	I-T082
close	O
to	O
the	O
bladder	B-T017
neck	I-T017
,	O
as	O
achieved	O
by	O
Mathisen	B-T058
'	I-T058
s	I-T058
reimplantation	I-T058
,	O
cross	B-T058
-	I-T058
trigonal	I-T058
ureteral	I-T058
reimplantation	I-T058
proved	O
more	O
reliable	O
for	O
VUR	B-T038
correction	O
.	O

As	O
regards	O
optimizing	O
the	O
results	O
,	O
patient	B-T062
selection	I-T062
for	O
either	O
technique	O
could	O
prove	O
essential	O
.	O

Nevertheless	O
,	O
as	O
regards	O
the	O
difficulties	O
with	O
ectopic	B-T082
ureteral	B-T082
orifices	I-T082
in	O
the	O
Cohen	O
technique	O
in	O
the	O
long	O
-	O
term	O
follow	B-T058
-	I-T058
up	I-T058
,	O
the	O
concept	O
of	O
anatomic	O
,	O
orthotopic	B-T082
ureteral	B-T058
reimplantation	I-T058
should	O
be	O
pursued	O
and	O
the	O
technique	O
should	O
be	O
further	O
refined	O
.	O

The	O
use	O
of	O
neonatal	O
extracorporeal	B-T058
life	I-T058
support	I-T058
in	O
pediatric	O
cardiac	B-T092
intensive	I-T092
care	I-T092
unit	I-T092

The	O
aim	O
of	O
the	O
study	O
is	O
to	O
evaluate	B-T058
extracorporeal	B-T058
life	I-T058
support	I-T058
system	I-T058
(	O
ECLS	B-T058
)	O
employed	O
in	O
neonates	O
in	O
pediatric	O
cardiac	B-T092
intensive	I-T092
care	I-T092
unit	I-T092
.	O

Twenty	O
-	O
five	O
neonates	O
that	O
required	O
ECLS	B-T058
in	O
between	O
November	O
2010	O
and	O
November	O
2015	O
were	O
evaluated	B-T058
.	O

The	O
median	O
age	O
was	O
12	O
days	O
(	O
range	O
3	O
-	O
28	O
days	O
)	O
and	O
the	O
median	O
body	O
weight	O
was	O
3	O
kg	O
(	O
range	O
2	O
.	O
5	O
-	O
5	O
kg	O
)	O
.	O

Venoarterial	B-T082
ECLS	B-T058
was	O
performed	O
in	O
all	O
of	O
the	O
cases	O
.	O

Ascendan	B-T017
aorta	I-T017
-	O
right	B-T017
atrial	I-T017
cannulation	B-T058
in	O
22	O
patients	O
and	O
neck	B-T082
cannulation	B-T058
in	O
three	O
patients	O
were	O
performed	O
.	O

The	O
reason	O
for	O
ECLS	B-T058
was	O
E	B-T058
-	I-T058
CPR	I-T058
in	O
two	O
patients	O
,	O
inability	B-T033
to	I-T033
wean	I-T033
from	O
cardiopulmonary	B-T058
bypass	I-T058
(	O
CPB	B-T058
)	O
in	O
seven	O
patients	O
,	O
respiratory	B-T038
insufficiency	I-T038
and	O
hypoxia	B-T038
in	O
nine	O
patients	O
,	O
low	B-T038
cardiac	I-T038
output	I-T038
(	O
LCOS	B-T038
)	O
in	O
seven	O
patients	O
.	O

Median	O
duration	O
of	O
ECLS	B-T058
was	O
four	O
days	O
(	O
range	O
1	O
-	O
15	O
)	O
.	O

Hemorrhagic	O
complications	B-T038
developed	O
in	O
15	O
,	O
renal	O
complications	O
in	O
13	O
,	O
pulmonary	B-T038
complications	I-T038
in	O
12	O
,	O
infectious	B-T038
complications	B-T038
in	O
11	O
,	O
neurologic	B-T038
complications	I-T038
in	O
three	O
and	O
mechanical	B-T038
complications	I-T038
in	O
two	O
of	O
the	O
patients	O
.	O

Weaning	B-T033
was	O
successful	O
in	O
15	O
of	O
the	O
patients	O
.	O

Eleven	O
patients	O
were	O
successfully	O
discharged	B-T058
.	O

ECLS	B-T058
is	O
an	O
important	O
treatment	B-T058
option	I-T058
that	O
is	O
performed	O
successfully	O
in	O
many	O
centers	B-T092
around	O
the	O
world	B-T098
to	O
maintain	O
life	B-T058
support	I-T058
in	O
patients	O
unresponsive	O
to	O
medical	O
treatment	O
.	O

The	O
utilization	O
of	O
this	O
modality	O
especially	O
in	O
newborns	O
with	O
congenital	B-T017
heart	I-T017
disease	I-T017
should	O
be	O
taken	O
into	O
consideration	O
.	O

Medicare	O
claims	O
indicators	O
of	O
healthcare	B-T058
utilization	O
differences	O
after	O
hospitalization	B-T058
for	O
ischemic	B-T038
stroke	I-T038
:	O
Race	B-T098
,	O
gender	O
,	O
and	O
caregiving	O
effects	O

Background	O
Differences	O
in	O
healthcare	B-T058
utilization	O
after	O
stroke	B-T038
may	O
partly	O
explain	O
race	B-T098
or	O
gender	O
differences	O
in	O
stroke	B-T038
outcomes	O
and	O
identify	O
factors	O
that	O
might	O
reduce	O
post	O
-	O
acute	B-T038
stroke	I-T038
care	O
costs	O
.	O

Aim	O
To	O
examine	O
systematic	O
differences	O
in	O
Medicare	O
claims	O
for	O
healthcare	B-T058
utilization	O
after	O
hospitalization	B-T058
for	O
ischemic	B-T038
stroke	I-T038
in	O
a	O
US	B-T082
population	B-T098
-	O
based	O
sample	O
.	O

Methods	O
Claims	O
were	O
examined	B-T033
over	O
a	O
six	O
-	O
month	O
period	O
after	O
hospitalization	B-T058
for	O
279	O
ischemic	B-T038
stroke	I-T038
survivors	O
65	O
years	O
or	O
older	B-T098
from	O
the	O
REasons	O
for	O
Geographic	O
And	O
Racial	O
Differences	O
in	O
Stroke	B-T038
(	O
REGARDS	B-T038
)	O
study	O
.	O

Statistical	O
analyses	O
examined	B-T033
differences	O
in	O
post	O
-	O
acute	B-T058
healthcare	I-T058
utilization	O
,	O
adjusted	O
for	O
pre	O
-	O
stroke	B-T038
utilization	O
,	O
as	O
a	O
function	O
of	O
race	B-T098
(	O
African	B-T098
-	I-T098
American	I-T098
vs	O
.	O

White	B-T098
)	O
,	O
gender	O
,	O
age	O
,	O
stroke	O
belt	O
residence	B-T082
,	O
income	O
,	O
Medicaid	O
dual	O
-	O
eligibility	O
,	O
Charlson	B-T170
comorbidity	I-T170
index	I-T170
,	O
and	O
whether	O
the	O
person	B-T098
lived	O
with	O
an	O
available	O
caregiver	B-T097
.	O

Results	O
After	O
adjusting	O
for	O
covariates	O
,	O
women	B-T098
were	O
more	O
likely	O
than	O
men	B-T098
to	O
receive	O
home	O
health	O
care	O
and	O
to	O
use	O
emergency	B-T058
department	I-T058
services	I-T058
during	O
the	O
post	O
-	O
acute	B-T058
care	I-T058
period	O
.	O

These	O
effects	O
were	O
maintained	O
even	O
after	O
further	B-T082
adjustment	O
for	O
acute	B-T038
stroke	I-T038
severity	O
.	O

African	B-T098
-	I-T098
Americans	I-T098
had	O
more	O
home	O
health	O
care	O
visits	B-T058
than	O
Whites	B-T098
among	O
patients	O
who	O
received	O
some	O
home	O
health	O
care	O
.	O

Having	O
a	O
co	O
-	O
residing	O
caregiver	B-T097
was	O
associated	O
with	O
reduced	O
acute	B-T058
hospitalization	I-T058
length	O
of	O
stay	O
and	O
fewer	O
post	O
-	O
acute	B-T058
emergency	I-T058
department	I-T058
and	O
primary	O
care	O
physician	O
visits	O
.	O

Conclusions	O
Underutilization	O
of	O
healthcare	O
after	O
stroke	B-T038
does	O
not	O
appear	O
to	O
explain	O
poorer	O
long	O
-	O
term	O
stroke	B-T038
outcomes	O
for	O
women	B-T098
and	O
African	B-T098
-	I-T098
Americans	I-T098
in	O
this	O
epidemiologically	O
-	O
derived	O
sample	O
.	O

Caregiver	B-T097
availability	O
may	O
contribute	O
to	O
reduced	O
formal	O
care	O
and	O
cost	O
during	O
the	O
post	O
-	O
acute	B-T058
period	O
.	O

Do	O
dynamic	B-T170
global	I-T170
vegetation	I-T170
models	I-T170
capture	O
the	O
seasonality	O
of	O
carbon	O
fluxes	O
in	O
the	O
Amazon	B-T082
basin	I-T082
?	O
A	O
data	O
-	O
model	B-T170
intercomparison	O

To	O
predict	O
forest	O
response	O
to	O
long	O
-	O
term	O
climate	O
change	O
with	O
high	O
confidence	O
requires	O
that	O
dynamic	B-T170
global	I-T170
vegetation	I-T170
models	I-T170
(	O
DGVMs	B-T170
)	O
be	O
successfully	O
tested	O
against	O
ecosystem	O
response	O
to	O
short	O
-	O
term	O
variations	O
in	O
environmental	B-T082
drivers	I-T082
,	O
including	O
regular	O
seasonal	O
patterns	O
.	O

Here	O
,	O
we	O
used	O
an	O
integrated	O
dataset	B-T170
from	O
four	O
forests	O
in	O
the	O
Brasil	B-T170
flux	I-T170
network	I-T170
,	O
spanning	O
a	O
range	O
of	O
dry	O
-	O
season	O
intensities	O
and	O
lengths	O
,	O
to	O
determine	O
how	O
well	O
four	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
models	B-T170
(	O
IBIS	B-T170
,	O
ED2	B-T170
,	O
JULES	B-T170
,	O
and	O
CLM3	B-T170
.	I-T170
5	I-T170
)	O
simulated	O
the	O
seasonality	O
of	O
carbon	O
exchanges	O
in	O
Amazonian	B-T082
tropical	O
forests	O
.	O

We	O
found	O
that	O
most	O
DGVMs	B-T170
poorly	O
represented	O
the	O
annual	O
cycle	O
of	O
gross	O
primary	O
productivity	O
(	O
GPP	O
)	O
,	O
of	O
photosynthetic	O
capacity	O
(	O
Pc	O
)	O
,	O
and	O
of	O
other	O
fluxes	O
and	O
pools	O
.	O

Models	B-T170
simulated	O
consistent	O
dry	O
-	O
season	O
declines	O
in	O
GPP	O
in	O
the	O
equatorial	B-T082
Amazon	I-T082
(	O
Manaus	B-T082
K34	I-T082
,	O
Santarem	B-T082
K67	I-T082
,	O
and	O
Caxiuanã	B-T082
CAX	I-T082
)	O
;	O
a	O
contrast	O
to	O
observed	O
GPP	O
increases	O
.	O

Model	B-T170
simulated	O
dry	O
-	O
season	O
GPP	O
reductions	O
were	O
driven	O
by	O
an	O
external	O
environmental	B-T082
factor	O
,	O
'	O
soil	B-T033
water	I-T033
stress	I-T033
'	O
and	O
consequently	O
by	O
a	O
constant	O
or	O
decreasing	O
photosynthetic	O
infrastructure	O
(	O
Pc	O
)	O
,	O
while	O
observed	O
dry	O
-	O
season	O
GPP	O
resulted	O
from	O
a	O
combination	O
of	O
internal	O
biological	O
(	O
leaf	B-T204
-	O
flush	O
and	O
abscission	B-T038
and	O
increased	O
Pc	O
)	O
and	O
environmental	B-T082
(	O
incoming	O
radiation	O
)	O
causes	O
.	O

Moreover	O
,	O
we	O
found	O
models	B-T170
generally	O
overestimated	O
observed	O
seasonal	O
net	O
ecosystem	O
exchange	O
(	O
NEE	O
)	O
and	O
respiration	B-T038
(	O
Re	B-T038
)	O
at	O
equatorial	O
locations	O
.	O

In	O
contrast	O
,	O
a	O
southern	B-T082
Amazon	I-T082
forest	O
(	O
Jarú	O
RJA	O
)	O
exhibited	O
dry	O
-	O
season	O
declines	O
in	O
GPP	O
and	O
Re	B-T038
consistent	O
with	O
most	O
DGVMs	B-T170
simulations	B-T062
.	O

While	O
water	O
limitation	O
was	O
represented	O
in	O
models	B-T170
and	O
the	O
primary	O
driver	O
of	O
seasonal	O
photosynthesis	O
in	O
southern	B-T082
Amazonia	I-T082
,	O
changes	O
in	O
internal	O
biophysical	B-T038
processes	I-T038
,	O
light	B-T038
-	I-T038
harvesting	I-T038
adaptations	O
(	O
e	O
.	O
g	O
.	O
,	O
variations	O
in	O
leaf	B-T170
area	I-T170
index	I-T170
(	O
LAI	B-T170
)	O
and	O
increasing	O
leaf	B-T204
-	O
level	O
assimilation	B-T038
rate	O
related	O
to	O
leaf	O
demography	O
)	O
,	O
and	O
allocation	O
lags	O
between	O
leaf	B-T204
and	O
wood	B-T204
,	O
dominated	O
equatorial	B-T082
Amazon	I-T082
carbon	O
flux	O
dynamics	O
and	O
were	O
deficient	O
or	O
absent	O
from	O
current	O
model	B-T170
formulations	O
.	O

Correctly	O
simulating	O
flux	O
seasonality	O
at	O
tropical	O
forests	O
requires	O
a	O
greater	O
understanding	O
and	O
the	O
incorporation	O
of	O
internal	O
biophysical	B-T038
mechanisms	I-T038
in	O
future	O
model	O
developments	O
.	O

Blood	B-T038
Pressure	I-T038
and	O
All	B-T033
-	I-T033
Cause	I-T033
Mortality	I-T033
by	O
Level	O
of	O
Cognitive	B-T038
Function	I-T038
in	O
the	O
Elderly	B-T098
:	O
Results	O
From	O
a	O
Population	B-T062
-	I-T062
Based	I-T062
Study	I-T062
in	O
Rural	B-T082
Greece	I-T082

This	O
study	B-T062
aimed	O
to	O
investigate	O
whether	O
the	O
effect	O
of	O
blood	B-T038
pressure	I-T038
(	O
BP	B-T038
)	O
on	O
mortality	B-T033
differs	O
by	O
levels	O
of	O
cognitive	B-T038
function	I-T038
.	O

The	O
associations	O
of	O
brachial	B-T082
systolic	B-T201
BP	I-T201
,	O
diastolic	B-T201
BP	I-T201
,	O
mean	B-T033
arterial	I-T033
pressure	I-T033
(	O
MAP	B-T033
)	O
,	O
and	O
pulse	B-T038
pressure	I-T038
with	O
all	B-T033
-	I-T033
cause	I-T033
mortality	I-T033
were	O
prospectively	B-T033
explored	I-T033
(	O
follow	B-T058
-	I-T058
up	I-T058
7	O
.	O
0±2	O
.	O
2	O
years	O
)	O
in	O
660	O
community	O
-	O
dwelling	O
individuals	B-T098
(	O
≥60	O
years	O
)	O
using	O
adjusted	B-T170
Cox	I-T170
models	I-T170
,	O
stratified	O
by	O
cognitive	B-T038
impairment	I-T038
(	O
Mini	B-T058
-	I-T058
Mental	I-T058
State	I-T058
Examination	I-T058
[	O
MMSE	B-T058
]	O
<	O
24	O
)	O
.	O

No	O
association	O
between	O
brachial	B-T082
BP	B-T038
variables	O
and	O
mortality	B-T033
was	O
shown	O
for	O
the	O
total	O
sample	O
in	O
quartiles	O
analysis	O
;	O
however	O
,	O
MAP	B-T033
in	O
the	O
highest	O
quartile	O
,	O
compared	O
with	O
the	O
second	O
,	O
was	O
associated	O
with	O
mortality	B-T033
(	O
hazard	O
ratio	O
,	O
1	O
.	O
85	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
1	O
.	O
09	O
-	O
3	O
.	O
12	O
)	O
among	O
cognitively	B-T038
impaired	I-T038
individuals	B-T098
.	O

The	O
fractional	B-T062
-	I-T062
polynomials	I-T062
approach	I-T062
for	O
BP	B-T038
confirmed	B-T033
this	O
finding	B-T033
and	O
further	B-T082
showed	O
,	O
solely	O
in	O
the	O
MMSE	B-T058
<	O
24	O
subcohort	O
,	O
U	O
-	O
shaped	O
trends	O
of	O
MAP	B-T033
and	O
systolic	B-T201
BP	I-T201
,	O
with	O
increased	O
mortality	O
risk	O
in	O
extremely	O
low	O
or	O
high	O
values	O
;	O
no	O
such	O
pattern	B-T082
was	O
evident	O
for	O
patients	O
with	O
MMSE	B-T058
≥24	O
.	O

Elderly	B-T098
individuals	B-T098
with	O
cognitive	B-T038
impairment	I-T038
might	O
be	O
more	O
susceptible	O
to	O
the	O
detrimental	B-T038
effects	I-T038
of	O
low	O
and	O
elevated	O
MAP	B-T033
and	O
systolic	B-T201
BP	I-T201
.	O

Hypovitaminosis	B-T038
D	I-T038
and	O
Associated	O
Cardiometabolic	O
Risk	O
in	O
Women	B-T098
with	O
PCOS	B-T038

Women	B-T098
with	O
Polycystic	B-T038
Ovary	I-T038
Syndrome	I-T038
(	O
PCOS	B-T038
)	O
frequently	O
suffer	O
from	O
metabolic	O
disturbances	O
like	O
insulin	B-T038
resistance	I-T038
,	O
hypertension	B-T038
and	O
atherogenic	B-T038
dyslipidemia	I-T038
.	O

Accumulating	B-T033
evidences	O
suggest	O
that	O
Vitamin	B-T038
D	I-T038
deficiency	I-T038
is	O
common	O
in	O
PCOS	B-T038
and	O
may	O
be	O
associated	O
with	O
metabolic	B-T038
and	O
endocrinal	O
dysfunctions	O
in	O
PCOS	B-T038
.	O

Thus	O
women	B-T098
with	O
PCOS	B-T038
may	O
be	O
at	O
elevated	O
risk	O
of	O
cardiovascular	B-T038
disease	I-T038
.	O

Present	O
study	B-T062
aims	O
to	O
evaluate	O
Vitamin	B-T103
D	I-T103
status	O
and	O
to	O
assess	O
its	O
association	O
with	O
metabolic	B-T038
and	O
endocrinal	O
dysregulations	O
in	O
women	B-T098
with	O
PCOS	B-T038
,	O
which	O
might	O
help	O
in	O
early	O
identification	O
and	O
prevention	O
of	O
future	O
symptomatic	O
cardiac	B-T038
disease	I-T038
.	O

A	O
total	O
of	O
44	O
women	B-T098
with	O
PCOS	B-T038
,	O
diagnosed	O
by	O
Rotterdam	B-T170
criteria	I-T170
and	O
45	O
healthy	O
control	O
without	O
PCOS	B-T038
,	O
were	O
evaluated	O
for	O
Vitamin	B-T103
D	I-T103
and	O
cardiometabolic	B-T033
risk	I-T033
factors	I-T033
,	O
including	O
fasting	B-T033
plasma	I-T033
glucose	I-T033
,	O
insulin	B-T038
resistance	I-T038
,	O
dyslipidemia	B-T038
,	O
hs	B-T033
-	I-T033
CRP	I-T033
.	O

That	O
apart	O
,	O
several	O
endocrinal	O
parameters	O
of	O
hyperandrogenism	B-T038
were	O
also	O
examined	O
.	O

Several	O
correlation	B-T062
studies	I-T062
were	O
determined	O
to	O
establish	O
the	O
role	O
of	O
Vitamin	B-T103
D	I-T103
as	O
a	O
cardiometabolic	B-T033
risk	I-T033
factor	I-T033
in	O
PCOS	B-T038
.	O

Results	O
were	O
expressed	O
as	O
mean±SD	O
and	O
were	O
statistically	O
analysed	O
using	O
SPSS	B-T170
software	I-T170
version	I-T170
16	I-T170
,	O
unpaired	B-T170
student	I-T170
'	I-T170
s	I-T170
t	I-T170
-	I-T170
test	I-T170
and	O
Pearson	O
'	O
s	O
correlation	O
coefficient	O
.	O

We	O
found	O
lower	O
levels	O
of	O
Vitamin	B-T103
D	I-T103
,	O
which	O
was	O
statistically	O
significant	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

Hyperinsulinemia	B-T038
,	O
rise	O
in	O
insulin	B-T038
resistance	I-T038
and	O
marked	O
dyslipidemia	B-T038
was	O
observed	O
in	O
the	O
present	O
study	B-T062
.	O

Another	O
relevant	O
finding	O
was	O
significant	O
correlation	O
of	O
Vitamin	B-T103
D	I-T103
with	O
insulin	B-T103
and	O
Homeostatic	B-T058
Model	I-T058
of	I-T058
Assessment	I-T058
-	I-T058
Insulin	I-T058
Resistance	I-T058
Index	I-T058
(	O
HOMA	B-T058
-	I-T058
IR	I-T058
)	O
.	O

Hypovitaminosis	B-T038
D	I-T038
was	O
prevalent	O
in	O
PCOS	B-T038
.	O

This	O
was	O
related	O
to	O
metabolic	B-T038
and	O
hormonal	B-T033
disorders	I-T033
in	O
PCOS	B-T038
.	O

Possibly	O
this	O
combined	O
with	O
impaired	B-T033
fasting	I-T033
glucose	I-T033
,	O
IR	B-T038
and	O
dyslipidemia	B-T038
,	O
could	O
account	O
for	O
Cardio	O
vascular	O
risks	O
in	O
PCOS	B-T038
.	O

Further	O
prospective	O
observational	B-T170
studies	I-T170
and	O
randomized	B-T062
control	I-T062
trials	I-T062
are	O
required	O
to	O
explore	O
the	O
above	O
hypothesis	O
.	O

Family	O
close	B-T033
but	O
friends	B-T098
closer	B-T033
:	O
exploring	O
social	O
support	O
and	O
resilience	O
in	O
older	B-T098
spousal	O
dementia	B-T038
carers	B-T097

Spousal	O
dementia	B-T038
carers	B-T097
have	O
unique	O
support	O
needs	O
;	O
they	O
are	O
likely	O
to	O
disengage	O
from	O
their	O
existing	O
social	B-T098
networks	I-T098
as	O
they	O
need	O
to	O
devote	O
more	O
time	O
to	O
caring	O
as	O
the	O
disease	B-T038
progresses	I-T038
.	O

Previously	O
we	O
showed	O
that	O
support	O
resources	O
can	O
facilitate	O
resilience	O
in	O
carers	B-T097
,	O
but	O
the	O
relationship	O
is	O
complex	O
and	O
varies	O
by	O
relationship	O
type	O
.	O

The	O
current	O
paper	O
aims	O
to	O
explore	O
social	O
support	O
as	O
a	O
key	O
component	O
of	O
resilience	O
to	O
identify	O
the	O
availability	O
,	O
function	O
and	O
perceived	O
functional	O
aspects	O
of	O
support	O
provided	O
to	O
older	B-T098
spousal	O
dementia	B-T038
carers	B-T097
.	O

We	O
conducted	O
23	O
in	O
-	O
depth	O
qualitative	O
interviews	O
with	O
spousal	O
carers	B-T097
from	O
two	O
carer	B-T097
support	B-T092
groups	I-T092
and	O
a	O
care	O
home	O
in	O
North	B-T082
West	I-T082
England	I-T082
.	O

Family	O
and	O
friends	B-T098
served	O
a	O
wide	O
range	O
of	O
functions	O
but	O
were	O
equally	O
available	O
to	O
resilient	B-T098
and	O
non	B-T098
-	I-T098
resilient	I-T098
participants	I-T098
.	O

Family	B-T058
support	I-T058
was	O
perceived	B-T038
as	O
unhelpful	O
if	O
it	O
created	O
feelings	B-T038
of	O
over	O
-	O
dependence	O
.	O

Participants	B-T098
were	O
less	O
likely	O
to	O
resist	O
involvement	O
of	O
grandchildren	O
due	O
to	O
their	O
relatively	O
narrow	O
and	O
low	O
-	O
level	O
support	O
functions	O
.	O

Friend	B-T098
support	O
was	O
perceived	B-T038
as	O
most	O
helpful	O
when	O
it	O
derived	O
from	O
those	O
in	O
similar	O
circumstances	O
.	O

Neighbours	B-T098
played	O
a	O
functionally	O
unique	O
role	O
of	O
crisis	O
management	O
.	O

These	O
perceptions	B-T038
may	O
moderate	O
the	O
effect	O
of	O
support	O
on	O
resilience	O
.	O

Family	B-T058
and	O
friend	B-T098
support	O
is	O
not	O
always	O
sufficient	O
to	O
facilitate	O
resilience	O
.	O

Support	O
functions	O
facilitate	O
resilience	O
only	O
if	O
they	O
are	O
perceived	B-T038
to	O
match	O
need	O
.	O

Implications	B-T033
of	O
these	O
findings	O
are	O
discussed	O
.	O

Measure	B-T058
Up	I-T058
Pressure	I-T058
Down	I-T058
:	I-T058
Provider	I-T058
Toolkit	I-T058
to	O
Improve	O
Hypertension	B-T038
Control	B-T038

Hypertension	B-T038
is	O
one	O
of	O
the	O
most	O
important	O
risk	B-T033
factors	I-T033
for	O
heart	B-T038
disease	I-T038
,	O
stroke	B-T038
,	O
kidney	B-T038
failure	I-T038
,	O
and	O
diabetes	B-T038
complications	I-T038
.	O

Nearly	O
one	O
in	O
three	O
Americans	B-T098
adults	O
has	O
high	B-T038
blood	I-T038
pressure	I-T038
,	O
and	O
the	O
cost	O
associated	O
with	O
treating	B-T058
this	O
condition	B-T038
is	O
staggering	O
.	O

The	O
Measure	B-T058
Up	I-T058
Pressure	I-T058
Down	I-T058
:	I-T058
Provider	I-T058
Toolkit	I-T058
to	O
Improve	O
Hypertension	B-T038
Control	B-T038
is	O
a	O
resource	O
developed	O
by	O
the	O
American	B-T092
Medical	I-T092
Group	I-T092
Foundation	I-T092
in	O
partnership	B-T092
with	O
the	O
American	B-T092
Medical	I-T092
Group	I-T092
Association	I-T092
.	O

The	O
goal	B-T170
of	O
this	O
toolkit	B-T170
is	O
to	O
mobilize	O
health	B-T097
care	I-T097
practitioners	I-T097
to	O
work	O
together	O
through	O
team	O
-	O
based	O
approaches	O
to	O
achieve	O
an	O
80	O
%	O
control	B-T038
rate	O
of	O
high	B-T038
blood	I-T038
pressure	I-T038
among	O
their	O
patient	O
population	O
.	O

The	O
toolkit	B-T170
can	O
be	O
used	O
by	O
health	B-T097
educators	I-T097
,	O
clinic	B-T097
administrators	I-T097
,	O
physicians	B-T097
,	O
students	B-T098
,	O
and	O
other	O
clinic	B-T097
staff	I-T097
as	O
a	O
step	O
-	O
by	O
-	O
step	O
resource	O
for	O
developing	O
the	O
infrastructure	B-T062
needed	O
to	O
better	O
identify	O
and	O
treat	B-T058
individuals	B-T098
with	O
high	B-T038
blood	I-T038
pressure	I-T038
or	O
other	O
chronic	B-T038
conditions	I-T038
.	I-T038

Potentiation	B-T058
of	O
LPS	B-T103
-	O
Induced	B-T038
Apoptotic	B-T038
Cell	I-T038
Death	I-T038
in	O
Human	B-T017
Hepatoma	I-T017
HepG2	I-T017
Cells	I-T017
by	O
Aspirin	B-T103
via	O
ROS	B-T103
and	O
Mitochondrial	B-T033
Dysfunction	I-T033
:	O
Protection	O
by	O
N	B-T103
-	I-T103
Acetyl	I-T103
Cysteine	I-T103

Cytotoxicity	B-T038
and	O
inflammation	B-T038
-	O
associated	B-T038
toxic	O
responses	O
have	O
been	O
observed	O
to	O
be	O
induced	O
by	O
bacterial	O
lipopolysaccharides	B-T103
(	O
LPS	B-T103
)	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
respectively	O
.	O

Use	O
of	O
nonsteroidal	B-T103
anti	I-T103
-	I-T103
inflammatory	I-T103
drugs	I-T103
(	O
NSAIDs	B-T103
)	O
,	O
such	O
as	O
aspirin	B-T103
,	O
has	O
been	O
reported	B-T058
to	O
be	O
beneficial	O
in	O
inflammation	B-T038
-	O
associated	B-T038
diseases	I-T038
like	O
cancer	B-T038
,	O
diabetes	B-T038
and	O
cardiovascular	B-T038
disorders	I-T038
.	O

Their	O
precise	O
molecular	O
mechanisms	O
,	O
however	O
,	O
are	O
not	O
clearly	O
understood	O
.	O

Our	O
previous	O
studies	B-T062
on	O
aspirin	B-T103
treated	B-T058
HepG2	B-T017
cells	I-T017
strongly	O
suggest	O
cell	B-T038
cycle	I-T038
arrest	I-T038
and	O
induction	O
of	O
apoptosis	B-T038
associated	O
with	O
mitochondrial	B-T033
dysfunction	I-T033
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
have	O
further	O
demonstrated	O
that	O
HepG2	B-T017
cells	I-T017
treated	B-T058
with	I-T058
LPS	B-T103
alone	O
or	O
in	O
combination	O
with	O
aspirin	B-T103
induces	O
subcellular	B-T017
toxic	B-T038
responses	I-T038
which	O
are	O
accompanied	O
by	O
increase	O
in	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
production	O
,	O
oxidative	B-T038
stress	I-T038
,	O
mitochondrial	B-T033
respiratory	I-T033
dysfunction	I-T033
and	O
apoptosis	B-T038
.	O

The	O
LPS	B-T103
/	O
Aspirin	B-T103
induced	O
toxicity	B-T037
was	O
attenuated	O
by	O
pre	O
-	O
treatment	O
of	O
cells	B-T017
with	O
N	B-T103
-	I-T103
acetyl	I-T103
cysteine	I-T103
(	O
NAC	B-T103
)	O
.	O

Alterations	O
in	O
oxidative	B-T038
stress	I-T038
and	O
glutathione	B-T103
-	O
dependent	O
redox	B-T038
-	I-T038
homeostasis	I-T038
were	O
more	O
pronounced	O
in	O
mitochondria	B-T017
compared	O
to	O
extra	O
-	O
mitochondrial	B-T017
cellular	B-T017
compartments	I-T017
.	O

Pre	O
-	O
treatment	O
of	O
HepG2	B-T017
cells	I-T017
with	O
NAC	B-T103
exhibited	O
a	O
selective	O
protection	O
in	O
redox	B-T038
homeostasis	I-T038
and	O
mitochondrial	B-T033
dysfunction	I-T033
.	O

Our	O
results	O
suggest	O
that	O
the	O
altered	O
redox	B-T038
metabolism	I-T038
,	O
oxidative	B-T038
stress	I-T038
and	O
mitochondrial	B-T017
function	O
in	O
HepG2	B-T017
cells	I-T017
play	O
a	O
critical	O
role	O
in	O
LPS	B-T103
/	O
aspirin	B-T103
-	O
induced	O
cytotoxicity	B-T038
.	O

These	O
results	O
may	O
help	O
in	O
better	O
understanding	O
the	O
pharmacological	O
,	O
toxicological	O
and	O
therapeutic	O
properties	O
of	O
NSAIDs	B-T103
in	O
cancer	B-T017
cells	I-T017
exposed	O
to	O
bacterial	B-T103
endotoxins	I-T103
.	O

Placental	B-T017
Pathologic	O
Associations	O
with	O
Morbidly	B-T038
Adherent	I-T038
Placenta	I-T038
:	O
Potential	O
insights	O
into	O
Pathogenesis	B-T038

The	O
pathology	O
that	O
underlies	O
morbidly	B-T038
adherent	I-T038
placenta	I-T038
(	O
MAP	B-T038
)	O
is	O
poorly	O
understood	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
placental	B-T017
pathology	O
,	O
especially	O
implantation	B-T082
site	I-T082
pathology	O
,	O
associated	O
with	O
MAP	B-T038
.	O

This	O
was	O
a	O
single	O
institution	B-T092
,	O
retrospective	B-T062
case	I-T062
-	I-T062
control	I-T062
study	I-T062
design	O
examining	O
placentas	B-T017
of	O
patients	O
who	O
delivered	B-T033
between	O
January	O
2008	O
and	O
September	O
2013	O
.	O

MAP	B-T038
cases	O
were	O
defined	O
by	O
the	O
need	O
for	O
clinical	O
intervention	B-T058
at	O
delivery	B-T058
beyond	O
spontaneous	O
placental	B-T058
delivery	I-T058
or	O
simple	O
manual	B-T058
extraction	I-T058
of	O
the	O
placenta	B-T017
.	O

Controls	O
consisted	O
of	O
patients	O
with	O
placentas	B-T017
sent	O
for	O
examination	B-T058
due	O
to	O
a	O
history	B-T033
of	O
maternal	O
malignancy	B-T038
with	O
no	B-T033
clinical	O
suspicion	O
of	O
accreta	B-T038
.	O

Placental	B-T017
pathologic	O
findings	O
of	O
maternal	B-T038
vascular	I-T038
underperfusion	I-T038
(	O
MVU	B-T038
)	O
,	O
acute	B-T033
inflammation	I-T033
,	O
chronic	B-T038
inflammation	I-T038
,	O
fetal	B-T017
vascular	B-T038
obstruction	I-T038
and	O
hemorrhage	B-T038
were	O
recorded	O
and	O
compared	O
using	O
bivariable	O
and	O
multivariable	O
analyses	O
.	O

Three	O
categories	B-T170
of	O
pathologic	O
changes	O
were	O
seen	O
more	O
commonly	O
in	O
MAP	B-T038
placentas	B-T017
(	O
N	O
=	O
101	O
)	O
than	O
control	O
placentas	B-T017
(	O
N	O
=	O
110	O
)	O
:	O
chronic	B-T038
basal	I-T038
inflammation	I-T038
,	O
villous	O
changes	O
of	O
MVU	B-T038
and	O
retromembranous	O
and	O
retromembranous	B-T038
/	O
intervillous	B-T038
hemorrhage	I-T038
.	O

In	O
multivariable	O
analyses	O
adjusted	O
for	O
confounders	O
,	O
chronic	B-T038
basal	I-T038
villitis	I-T038
(	O
aOR	O
5	O
.	O
6	O
,	O
1	O
.	O
73	O
-	O
18	O
.	O
18	O
)	O
,	O
plasma	B-T033
cell	I-T033
deciduitis	I-T033
(	O
aOR	O
2	O
.	O
63	O
,	O
1	O
.	O
08	O
-	O
6	O
.	O
39	O
)	O
,	O
increased	B-T033
syncytial	I-T033
knots	I-T033
(	O
aOR	O
3	O
.	O
92	O
,	O
1	O
.	O
57	O
-	O
9	O
.	O
75	O
)	O
,	O
villous	O
agglutination	O
(	O
aOR	O
24	O
.	O
85	O
,	O
2	O
.	O
78	O
-	O
221	O
.	O
75	O
)	O
,	O
increased	B-T033
perivillous	I-T033
fibrin	I-T033
(	O
aOR	O
5	O
.	O
08	O
,	O
1	O
.	O
49	O
-	O
17	O
.	O
34	O
)	O
,	O
and	O
the	O
presence	O
of	O
subchorionic	B-T038
/	O
intervillous	B-T033
thrombi	I-T033
(	O
aOR	O
4	O
.	O
01	O
,	O
1	O
.	O
63	O
-	O
9	O
.	O
86	O
)	O
remained	O
associated	O
with	O
MAP	B-T038
.	O

MAP	B-T038
is	O
highly	O
associated	O
with	O
evidence	O
of	O
intraparenchymal	B-T038
placental	I-T038
hemorrhage	I-T038
villous	O
changes	O
of	O
MVU	B-T038
,	O
and	O
a	O
lymphoplasmacytic	B-T033
infiltrate	I-T033
at	O
the	O
implantation	B-T082
site	I-T082
.	O

The	O
contribution	O
of	O
this	O
basal	B-T033
chronic	I-T033
inflammatory	I-T033
infiltrate	I-T033
to	O
MAP	B-T038
requires	O
further	O
investigation	O
.	O

An	O
ion	O
-	O
gating	O
multinanochannel	O
system	O
based	O
on	O
a	O
copper	B-T103
-	O
responsive	O
self	O
-	O
cleaving	B-T082
DNAzyme	B-T103

We	O
developed	O
an	O
ion	O
-	O
gating	O
nanochannel	O
composite	O
system	O
by	O
immobilizing	O
a	O
Cu	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
responsive	O
self	O
-	O
cleaving	B-T082
DNAzyme	B-T103
into	O
PET	B-T103
conical	B-T103
multinanochannels	I-T103
,	O
which	O
could	O
control	O
the	O
ion	B-T038
transport	I-T038
by	O
regulating	B-T038
the	O
surface	B-T082
charge	O
density	O
of	O
the	O
channels	B-T103
.	O

High	O
-	O
Intensity	O
Intermittent	O
Training	O
Positively	B-T033
Affects	O
Aerobic	B-T058
and	O
Anaerobic	O
Performance	O
in	O
Judo	O
Athletes	B-T097
Independently	O
of	O
Exercise	O
Mode	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
high	O
-	O
intensity	O
intermittent	O
training	O
(	O
HIIT	O
)	O
on	O
lower	B-T017
-	O
and	O
upper	B-T017
-	I-T017
body	I-T017
graded	O
exercise	O
and	O
high	O
-	O
intensity	O
intermittent	O
exercise	O
(	O
HIIE	O
,	O
four	O
Wingate	O
bouts	O
)	O
performance	O
,	O
and	O
on	O
physiological	O
and	O
muscle	B-T017
damage	I-T017
markers	B-T033
responses	I-T033
in	O
judo	O
athletes	B-T097
.	O

Thirty	O
-	O
five	O
subjects	B-T098
were	O
randomly	B-T062
allocated	I-T062
to	O
a	O
control	O
group	O
(	O
n	O
=	O
8	O
)	O
or	O
to	O
one	O
of	O
the	O
following	O
HIIT	O
groups	O
(	O
n	O
=	O
9	O
for	O
each	O
)	O
and	O
tested	B-T170
pre	I-T170
-	I-T170
and	I-T170
post	I-T170
-	O
four	O
weeks	O
(	O
2	O
training	O
d	O
·	O
wk	O
(	O
-	O
1	O
)	O
)	O
:	O
(	O
1	O
)	O
lower	B-T017
-	I-T017
body	I-T017
cycle	O
-	O
ergometer	O
;	O
(	O
2	O
)	O
upper	O
-	O
body	O
cycle	O
-	O
ergometer	O
;	O
(	O
3	O
)	O
uchi	O
-	O
komi	O
(	O
judo	O
technique	O
entrance	O
)	O
.	O

All	O
HIIT	O
were	O
constituted	O
by	O
two	O
blocks	O
of	O
10	O
sets	O
of	O
20	O
s	O
of	O
all	O
out	O
effort	O
interspersed	O
by	O
10	O
s	O
set	O
intervals	O
and	O
5	O
-	O
min	O
between	O
blocks	O
.	O

For	O
the	O
upper	B-T017
-	I-T017
body	I-T017
group	O
there	O
was	O
an	O
increase	O
in	O
maximal	O
aerobic	O
power	O
in	O
graded	O
upper	B-T017
-	I-T017
body	I-T017
exercise	B-T033
test	I-T033
(	O
12	O
.	O
3	O
%	O
)	O
.	O

The	O
lower	B-T017
-	I-T017
body	I-T017
group	O
increased	O
power	O
at	O
onset	O
blood	O
lactate	O
in	O
graded	O
upper	B-T017
-	I-T017
body	I-T017
exercise	B-T033
test	I-T033
(	O
22	O
.	O
1	O
%	O
)	O
.	O

The	O
uchi	O
-	O
komi	O
group	O
increased	O
peak	O
power	O
in	O
upper	B-T017
-	O
(	O
16	O
.	O
7	O
%	O
)	O
and	O
lower	B-T017
-	I-T017
body	I-T017
(	O
8	O
.	O
5	O
%	O
)	O
,	O
while	O
the	O
lower	B-T017
-	I-T017
body	I-T017
group	O
increased	O
lower	B-T017
-	I-T017
body	I-T017
mean	O
power	O
(	O
14	O
.	O
2	O
%	O
)	O
during	O
the	O
HIIE	O
.	O

There	O
was	O
a	O
decrease	O
in	O
the	O
delta	O
blood	O
lactate	O
for	O
the	O
uchi	O
-	O
komi	O
training	O
group	O
and	O
in	O
the	O
third	O
and	O
fourth	O
bouts	O
for	O
the	O
upper	B-T017
-	I-T017
body	I-T017
training	O
group	O
.	O

Training	O
induced	O
testosterone	O
-	O
cortisol	O
ratio	O
increased	O
in	O
the	O
lower	B-T017
-	I-T017
body	I-T017
HIIE	O
for	O
the	O
lower	B-T017
-	I-T017
body	I-T017
(	O
14	O
.	O
9	O
%	O
)	O
and	O
uchi	O
-	O
komi	O
(	O
61	O
.	O
4	O
%	O
)	O
training	O
groups	O
.	O

Thus	O
,	O
short	O
-	O
duration	O
low	O
-	O
volume	O
HIIT	O
added	O
to	O
regular	O
judo	O
training	O
was	O
able	O
to	O
increase	O
upper	B-T017
-	I-T017
body	I-T017
aerobic	O
power	O
,	O
lower	B-T017
-	O
and	O
upper	B-T017
-	I-T017
body	I-T017
HIIE	O
performance	O
.	O

Microbiomes	O
of	O
Muricea	B-T204
californica	I-T204
and	O
M	B-T204
.	I-T204
fruticosa	I-T204
:	O
Comparative	O
Analyses	O
of	O
Two	O
Co	O
-	O
occurring	O
Eastern	B-T082
Pacific	I-T082
Octocorals	B-T204

Octocorals	B-T204
are	O
sources	O
of	O
novel	O
but	O
understudied	B-T062
microbial	O
diversity	O
.	O

Conversely	O
,	O
scleractinian	B-T204
or	O
reef	O
-	O
building	O
coral	O
microbiomes	O
have	O
been	O
heavily	O
examined	B-T033
in	O
light	O
of	O
the	O
threats	O
of	O
climate	O
change	O
.	O

Muricea	B-T204
californica	I-T204
and	O
Muricea	B-T204
fruticosa	I-T204
are	O
two	O
co	B-T170
-	I-T170
occurring	I-T170
species	I-T170
of	O
gorgonian	B-T204
octocoral	I-T204
abundantly	B-T033
found	I-T033
in	O
the	O
kelp	B-T204
forests	O
of	O
southern	B-T082
California	I-T082
,	O
and	O
thus	O
provide	O
an	O
excellent	O
basis	O
to	O
determine	O
if	O
octocoral	B-T204
microbiomes	O
are	O
host	O
specific	O
.	O

Using	O
Illumina	B-T170
MiSeq	I-T170
amplicon	I-T170
sequencing	I-T170
and	O
replicate	O
samples	O
,	O
we	O
evaluated	O
the	O
microbiomes	O
collected	O
from	O
multiple	O
colonies	O
of	O
both	O
species	B-T170
of	O
Muricea	B-T204
to	O
measure	O
both	O
inter	B-T017
-	I-T017
and	O
intra	B-T017
-	I-T017
colony	I-T017
microbiome	O
variabilities	O
.	O

In	O
addition	O
,	O
microbiomes	O
from	O
overlying	O
sea	O
water	O
and	O
nearby	O
zoanthids	B-T204
(	O
another	O
benthic	B-T204
invertebrate	I-T204
)	O
were	O
also	O
included	O
in	O
the	O
analysis	B-T062
to	O
evaluate	O
whether	O
bacterial	O
taxa	O
specifically	O
associate	O
with	O
octocorals	B-T204
.	O

This	O
is	O
also	O
the	O
first	B-T170
report	I-T170
of	O
microbiomes	O
from	O
these	O
species	B-T170
of	O
Muricea	B-T204
.	O

We	O
show	O
that	O
microbiomes	O
isolated	O
from	O
each	O
sample	O
type	O
are	O
distinct	O
,	O
and	O
specifically	O
,	O
that	O
octocoral	B-T204
species	B-T170
type	O
had	O
the	O
greatest	O
effect	O
on	O
predicting	O
the	O
composition	B-T201
of	O
the	O
Muricea	B-T204
microbiome	O
.	O

Bacterial	O
taxa	O
contributing	O
to	O
compositional	O
differences	O
include	O
distinct	O
strains	O
of	O
Mycoplasma	B-T007
associated	O
with	O
either	O
M	B-T204
.	I-T204

californica	I-T204
or	O
M	B-T204
.	I-T204

fruticosa	I-T204
,	O
an	O
abundance	O
of	O
Spirochaetes	B-T007
observed	O
on	O
M	B-T204
.	I-T204

californica	I-T204
,	O
and	O
a	O
greater	O
diversity	O
of	O
γ	B-T007
-	I-T007
Proteobacteria	I-T007
associated	O
with	O
M	B-T204
.	I-T204

fruticosa	I-T204
.	O

Many	O
of	O
the	O
bacterial	O
taxa	O
contributing	O
to	O
these	O
differences	O
are	O
known	O
for	O
their	O
presence	B-T033
in	O
photosymbiont	B-T204
-	I-T204
containing	I-T204
invertebrate	I-T204
microbiomes	O
.	O

2	B-T103
,	I-T103
8	I-T103
-	I-T103
Dihydroxyadenine	I-T103
Nephropathy	B-T038
Identified	O
as	O
Cause	O
of	O
End	B-T038
-	I-T038
Stage	I-T038
Renal	I-T038
Disease	I-T038
After	O
Renal	B-T058
Transplant	I-T058

Adenine	B-T038
phosphoribosyltransferase	I-T038
deficiency	I-T038
is	O
a	O
rare	O
autosomal	B-T038
recessive	I-T038
disorder	I-T038
of	O
uric	B-T103
acid	I-T103
metabolism	B-T038
that	O
leads	O
to	O
formation	O
and	O
excretion	B-T038
of	O
2	B-T103
,	I-T103
8	I-T103
-	I-T103
dihydroxyadenine	I-T103
into	O
urine	B-T031
.	O

The	O
low	O
solubility	O
of	O
2	B-T103
,	I-T103
8	I-T103
-	I-T103
dihydroxyadenine	I-T103
results	O
in	O
precipitation	O
and	O
formation	O
of	O
urinary	B-T033
crystals	I-T033
and	O
renal	B-T038
stones	I-T038
.	O

Patients	O
with	O
this	O
disorder	B-T038
usually	O
have	O
recurrent	B-T038
nephrolithiasis	I-T038
and	O
can	O
develop	O
nephropathy	B-T038
secondary	I-T038
to	O
crystal	B-T031
precipitation	O
in	O
the	O
renal	B-T017
parenchyma	I-T017
.	O

The	O
disease	B-T038
is	O
most	O
often	O
underdiagnosed	B-T033
and	O
can	O
recur	O
in	O
renal	B-T058
transplant	I-T058
,	O
causing	O
graft	B-T038
failure	I-T038
.	O

Lack	O
of	O
specific	O
clinical	O
manifestations	O
,	O
chemical	O
and	O
radiologic	O
features	O
identical	O
to	O
those	O
shown	O
with	O
uric	B-T031
acid	I-T031
stones	I-T031
,	O
and	O
lack	B-T033
of	I-T033
awareness	I-T033
among	O
clinicians	B-T097
are	O
among	O
the	O
causes	O
for	O
the	O
underdiagnoses	B-T033
of	O
this	O
treatable	O
disease	B-T038
.	O

Allopurinol	B-T103
,	O
a	O
xanthine	B-T103
dehydrogenase	I-T103
inhibitor	B-T103
,	O
is	O
the	O
mainstay	O
of	O
treatment	O
,	O
supported	O
by	O
high	O
fluid	B-T201
intake	I-T201
and	O
dietary	B-T058
modifications	I-T058
.	O

The	O
possibility	O
of	O
adenine	B-T038
phosphoribosyl	I-T038
transferase	I-T038
deficiency	I-T038
should	O
be	O
considered	O
in	O
all	O
cases	O
of	O
urolithiasis	B-T038
in	O
children	O
,	O
patients	O
with	O
recurrent	O
urolithiasis	O
,	O
and	O
patients	O
with	O
urolithiasis	B-T038
associated	O
with	O
renal	B-T038
failure	I-T038
of	O
unknown	O
cause	O
,	O
including	O
patients	O
with	O
end	B-T038
-	I-T038
stage	I-T038
renal	I-T038
disease	I-T038
and	O
renal	O
transplant	O
recipients	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
a	O
41	O
-	O
year	O
-	O
old	O
female	O
patient	O
who	O
had	O
a	O
late	O
diagnosis	O
of	O
2	B-T103
,	I-T103
8	I-T103
-	I-T103
dihydroxyadenine	I-T103
nephropathy	B-T038
-	O
induced	O
end	B-T038
-	I-T038
stage	I-T038
renal	I-T038
disease	I-T038
,	O
made	O
on	O
the	O
native	O
nephrectomy	B-T058
that	O
accompanied	O
the	O
renal	B-T058
transplant	I-T058
,	O
and	O
who	O
had	O
a	O
timely	O
intervention	O
that	O
prevented	O
recurrence	B-T038
in	O
the	O
graft	B-T058
.	O

Social	O
capital	O
and	O
healthy	O
ageing	B-T038
in	O
Indonesia	B-T082

A	O
large	O
international	O
literature	B-T170
has	O
found	O
a	O
positive	B-T033
association	O
between	O
social	O
capital	O
and	O
measures	O
of	O
physical	B-T033
and	O
mental	B-T038
health	I-T038
.	O

However	O
,	O
there	O
is	O
a	O
paucity	O
of	O
research	B-T062
on	O
the	O
links	O
between	O
social	O
capital	O
and	O
healthy	O
ageing	B-T038
in	O
a	O
developing	O
country	O
environment	B-T082
,	O
where	O
universal	O
social	O
security	O
coverage	O
is	O
absent	O
and	O
health	O
infrastructure	O
is	O
poor	O
.	O

In	O
this	O
paper	O
,	O
we	O
develop	O
and	O
empirically	O
test	O
a	O
model	B-T170
of	O
the	O
linkages	B-T170
between	O
social	O
capital	O
and	O
the	O
health	O
outcomes	O
for	O
older	B-T098
adults	I-T098
in	O
Indonesia	B-T082
,	O
using	O
data	O
from	O
the	O
Indonesian	B-T170
Family	I-T170
Life	I-T170
Survey	I-T170
-	I-T170
East	I-T170
(	O
IFLS	B-T170
-	I-T170
East	I-T170
)	O
,	O
conducted	O
in	O
2012	O
.	O

Using	O
multivariate	B-T170
regression	I-T170
analysis	I-T170
,	O
we	O
examine	O
whether	O
social	O
capital	O
plays	O
a	O
role	O
in	O
mitigating	O
poor	O
health	O
among	O
older	B-T098
individuals	B-T098
aged	O
50	O
years	O
and	O
above	O
in	O
Indonesia	B-T082
'	O
s	O
most	O
vulnerable	B-T082
provinces	I-T082
.	O

We	O
test	O
the	O
robustness	O
of	O
these	O
social	O
capital	O
variables	O
across	O
different	O
health	O
measures	O
(	O
self	O
-	O
assessed	O
health	O
,	O
Activities	O
of	O
Daily	O
Living	O
(	O
ADL	O
)	O
,	O
measures	O
of	O
chronic	B-T038
illness	I-T038
and	O
mental	B-T038
health	I-T038
measures	O
)	O
,	O
as	O
well	O
as	O
across	O
different	O
demographic	O
groups	O
,	O
after	O
controlling	O
for	O
an	O
array	B-T082
of	O
socio	O
-	O
economic	O
,	O
demographic	O
and	O
geographic	B-T082
characteristics	O
.	O

Our	O
findings	B-T033
show	O
that	O
access	B-T082
to	O
better	O
social	O
capital	O
(	O
using	O
measures	O
of	O
neighbourhood	B-T098
trust	O
and	O
community	O
participation	O
)	O
is	O
associated	O
with	O
a	O
higher	O
degree	O
of	O
physical	O
mobility	O
,	O
independence	O
,	O
and	O
mental	B-T038
well	I-T038
-	I-T038
being	I-T038
among	O
older	B-T098
individuals	B-T098
but	O
has	O
no	O
influence	O
on	O
chronic	B-T038
illnesses	I-T038
.	O

These	O
results	O
are	O
consistent	O
when	O
we	O
estimate	O
samples	O
disaggregated	O
by	O
gender	O
,	O
rural	B-T033
/	O
urban	O
residence	B-T082
,	O
and	O
by	O
age	O
categories	B-T170
.	O

From	O
a	O
policy	B-T170
perspective	O
these	O
results	O
point	O
to	O
the	O
importance	O
of	O
social	O
capital	O
measures	O
in	O
moderating	O
the	O
influence	O
of	O
poor	O
health	O
,	O
particularly	O
in	O
the	O
Activities	O
of	O
Daily	O
Living	O
.	O

Modulation	B-T082
of	O
Interleukins	B-T103
in	O
Sepsis	B-T038
-	O
Associated	O
Clotting	B-T038
Disorders	I-T038
:	O
Interplay	O
With	O
Hemostatic	B-T038
Derangement	I-T038

Interleukins	B-T103
play	O
a	O
central	B-T082
role	O
in	O
the	O
immune	B-T022
system	I-T022
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
immunological	B-T038
,	O
inflammatory	B-T038
,	O
and	O
infectious	B-T038
disease	I-T038
states	O
including	O
sepsis	B-T038
syndrome	I-T038
.	O

Levels	O
of	O
interleukins	B-T103
may	O
correlate	O
with	O
overall	O
survival	O
and	O
may	O
directly	O
or	O
indirectly	O
affect	B-T038
some	O
of	O
the	O
regulators	B-T103
of	O
coagulation	B-T038
and	O
fibrinolysis	B-T038
,	O
thereby	O
disrupting	O
hemostasis	B-T038
and	O
thrombosis	B-T038
.	O

Our	O
hypothesis	O
is	O
that	O
in	O
sepsis	B-T038
-	I-T038
associated	I-T038
coagulopathies	I-T038
(	O
SACs	B-T038
)	O
,	O
interleukins	B-T103
may	O
be	O
upregulated	B-T038
,	O
leading	O
to	O
hemostatic	B-T038
imbalance	I-T038
by	O
generating	O
thrombogenic	B-T103
mediators	I-T103
.	O

We	O
profiled	O
the	O
levels	O
of	O
interleukins	B-T103
IL	B-T103
-	I-T103
1α	I-T103
,	O
IL	B-T103
-	I-T103
1β	I-T103
,	O
IL	B-T103
-	I-T103
2	I-T103
,	O
IL	B-T103
-	I-T103
4	I-T103
,	O
IL	B-T103
-	I-T103
6	I-T103
,	O
IL	B-T103
-	I-T103
8	I-T103
,	O
and	O
IL	B-T103
-	I-T103
10	I-T103
in	O
addition	O
to	O
d	B-T103
-	I-T103
dimer	I-T103
(	O
DD	B-T103
)	O
in	O
patients	O
with	O
SAC	B-T038
and	O
in	O
normal	O
donors	B-T098
.	O

We	O
observed	O
the	O
highest	O
increase	O
in	O
interleukins	B-T103
IL	B-T103
-	I-T103
6	I-T103
(	O
322	O
-	O
fold	O
)	O
,	O
IL	B-T103
-	I-T103
8	I-T103
(	O
48	O
-	O
fold	O
)	O
,	O
IL	B-T103
-	I-T103
10	I-T103
(	O
72	O
-	O
fold	O
)	O
,	O
and	O
DD	B-T103
(	O
18	O
-	O
fold	O
)	O
.	O

This	O
suggests	O
that	O
interleukins	B-T103
such	O
as	O
IL	B-T103
-	I-T103
6	I-T103
and	O
IL	B-T103
-	I-T103
10	I-T103
have	O
a	O
close	O
association	O
with	O
coagulopathy	B-T038
and	O
fibrinolytic	O
dysregulation	O
in	O
sepsis	B-T038
and	O
can	O
be	O
considered	O
as	O
candidates	B-T103
for	O
potential	O
therapeutic	O
targets	O
in	O
SAC	B-T038
.	O

Thymosin	B-T103
β4	I-T103
:	O
Roles	O
in	O
Development	O
,	O
Repair	B-T038
,	O
and	O
Engineering	O
of	O
the	O
Cardiovascular	B-T022
System	I-T022

The	O
burden	O
of	O
cardiovascular	B-T038
disease	I-T038
is	O
a	O
growing	O
worldwide	O
issue	O
that	O
demands	O
attention	O
.	O

While	O
many	O
clinical	B-T062
trials	I-T062
are	O
ongoing	O
to	O
test	O
therapies	B-T058
for	O
treating	O
the	O
heart	B-T017
after	O
myocardial	B-T038
infarction	I-T038
(	O
MI	B-T038
)	O
and	O
heart	B-T038
failure	I-T038
,	O
there	O
are	O
few	O
options	O
doctors	B-T097
able	O
to	O
currently	O
give	O
patients	O
to	O
repair	B-T058
the	I-T058
heart	I-T058
.	O

This	O
eventually	O
leads	O
to	O
decreased	O
ventricular	B-T038
contractility	I-T038
and	O
increased	O
systemic	B-T038
disease	I-T038
,	O
including	O
vascular	B-T038
disorders	I-T038
that	O
could	O
result	O
in	O
stroke	B-T038
.	O

Small	O
peptides	B-T103
such	O
as	O
thymosin	B-T103
β4	I-T103
(	O
Tβ4	B-T103
)	O
are	O
upregulated	O
in	O
the	O
cardiovascular	B-T082
niche	B-T082
during	O
fetal	B-T038
development	I-T038
and	O
after	O
injuries	B-T037
such	O
as	O
MI	B-T038
,	O
providing	O
increased	O
neovasculogenesis	B-T038
and	O
paracrine	B-T038
signals	I-T038
for	O
endogenous	B-T017
stem	I-T017
cell	I-T017
recruitment	O
to	O
aid	O
in	O
wound	B-T038
repair	I-T038
.	O

New	O
research	B-T062
is	O
looking	O
into	O
the	O
effects	O
of	O
in	B-T082
vivo	I-T082
administration	B-T058
of	O
Tβ4	B-T103
through	O
injections	B-T058
and	O
coatings	B-T103
on	O
implants	B-T074
,	O
as	O
well	O
as	O
its	O
effect	O
on	O
cell	B-T038
differentiation	I-T038
.	O

Results	O
so	O
far	O
demonstrate	O
Tβ4	B-T103
administration	B-T058
leads	O
to	O
robust	O
increases	O
in	O
angiogenesis	B-T038
and	O
wound	B-T038
healing	I-T038
in	O
the	O
heart	B-T017
after	O
MI	B-T038
and	O
the	O
brain	B-T017
after	O
stroke	B-T038
,	O
and	O
can	O
differentiate	O
adult	B-T017
stem	I-T017
cells	I-T017
toward	O
the	O
cardiac	B-T017
lineage	O
for	O
implantation	B-T058
to	O
the	O
heart	B-T017
to	O
increase	O
contractility	B-T038
and	O
survival	O
.	O

Future	O
work	O
,	O
some	O
of	O
which	O
is	O
currently	O
in	O
clinical	B-T062
trials	I-T062
,	O
will	O
demonstrate	O
the	O
in	B-T082
vivo	I-T082
effect	O
of	O
these	O
therapies	B-T058
on	O
human	B-T204
patients	O
,	O
with	O
the	O
goal	B-T170
of	O
helping	O
the	O
millions	O
of	O
people	B-T098
worldwide	O
affected	O
by	O
cardiovascular	B-T038
disease	I-T038
.	O

Yersinia	B-T007
ruckeri	I-T007
Isolates	B-T103
Recovered	O
from	O
Diseased	B-T038
Atlantic	B-T204
Salmon	I-T204
(	O
Salmo	B-T204
salar	I-T204
)	O
in	O
Scotland	B-T082
Are	O
More	O
Diverse	O
than	O
Those	O
from	O
Rainbow	B-T204
Trout	I-T204
(	O
Oncorhynchus	B-T204
mykiss	I-T204
)	O
and	O
Represent	O
Distinct	O
Subpopulations	B-T098

Yersinia	B-T007
ruckeri	I-T007
is	O
the	O
etiological	O
agent	O
of	O
enteric	B-T038
redmouth	I-T038
(	O
ERM	B-T038
)	O
disease	B-T038
of	O
farmed	O
salmonids	B-T204
.	O

Enteric	B-T038
redmouth	I-T038
disease	I-T038
is	O
traditionally	O
associated	O
with	O
rainbow	B-T204
trout	I-T204
(	O
Oncorhynchus	B-T204
mykiss	I-T204
,	O
Walbaum	B-T204
)	O
,	O
but	O
its	O
incidence	O
in	O
Atlantic	B-T204
salmon	I-T204
(	O
Salmo	B-T204
salar	I-T204
)	O
is	O
increasing	O
.	O

Yersinia	B-T007
ruckeri	I-T007
isolates	B-T103
recovered	O
from	O
diseased	B-T038
Atlantic	B-T204
salmon	I-T204
have	O
been	O
poorly	O
characterized	O
,	O
and	O
very	O
little	O
is	O
known	O
about	O
the	O
relationship	O
of	O
the	O
isolates	B-T103
associated	O
with	O
these	O
two	O
species	B-T170
.	O

Phenotypic	O
approaches	O
were	O
used	O
to	O
characterize	O
109	O
Y	B-T007
.	I-T007

ruckeri	I-T007
isolates	B-T103
recovered	O
over	O
a	O
14	O
-	O
year	O
period	O
from	O
infected	B-T033
Atlantic	B-T204
salmon	I-T204
in	O
Scotland	B-T082
;	O
26	O
isolates	B-T103
from	O
infected	B-T033
rainbow	B-T204
trout	I-T204
were	O
also	O
characterized	O
.	O

Biotyping	B-T058
,	O
serotyping	B-T058
,	O
and	O
comparison	O
of	O
outer	B-T017
membrane	I-T017
protein	B-T033
profiles	I-T033
identified	O
19	O
Y	B-T007
.	I-T007

ruckeri	I-T007
clones	B-T017
associated	O
with	O
Atlantic	B-T204
salmon	I-T204
but	O
only	O
five	O
associated	O
with	O
rainbow	B-T204
trout	I-T204
;	O
none	O
of	O
the	O
Atlantic	B-T204
salmon	I-T204
clones	B-T017
occurred	O
in	O
rainbow	B-T204
trout	I-T204
and	O
vice	O
versa	O
These	O
findings	B-T033
suggest	O
that	O
distinct	O
subpopulations	B-T098
of	O
Y	B-T007
.	I-T007

ruckeri	I-T007
are	O
associated	O
with	O
each	O
species	B-T170
.	O

A	O
new	O
O	B-T170
serotype	I-T170
(	O
designated	O
O8	O
)	O
was	O
identified	O
in	O
56	B-T170
biotype	I-T170
1	I-T170
Atlantic	B-T204
salmon	I-T204
isolates	B-T103
and	O
was	O
the	O
most	O
common	O
serotype	B-T170
identified	O
from	O
2006	O
to	O
2011	O
and	O
in	O
2014	O
,	O
suggesting	O
an	O
increased	O
prevalence	O
during	O
the	O
time	O
period	O
sampled	O
.	O

Rainbow	B-T204
trout	I-T204
isolates	B-T103
were	O
represented	O
almost	O
exclusively	O
by	O
the	O
same	O
biotype	B-T170
2	I-T170
,	O
serotype	B-T170
O1	I-T170
clone	O
that	O
has	O
been	O
responsible	O
for	O
the	O
majority	O
of	O
ERM	B-T038
outbreaks	O
in	O
this	O
species	B-T170
within	O
the	O
United	B-T082
Kingdom	I-T082
since	O
the	O
1980s	O
.	O

However	O
,	O
the	O
identification	O
of	O
two	O
biotype	B-T170
2	I-T170
,	O
serotype	B-T170
O8	I-T170
isolates	B-T103
in	O
rainbow	B-T204
trout	I-T204
suggests	O
that	O
vaccines	B-T103
containing	O
serotypes	B-T170
O1	I-T170
and	I-T170
O8	I-T170
should	O
be	O
evaluated	O
in	O
both	O
rainbow	B-T204
trout	I-T204
and	O
Atlantic	B-T204
salmon	I-T204
for	O
application	O
in	O
Scotland	B-T082
.	O

Vaccination	B-T058
plays	O
an	O
important	O
role	O
in	O
protecting	O
Atlantic	B-T204
salmon	I-T204
against	O
the	O
bacterial	B-T007
pathogen	O
Yersinia	B-T007
ruckeri	I-T007
,	O
but	O
,	O
in	O
recent	O
years	O
,	O
there	O
has	O
been	O
an	O
increasing	O
incidence	O
of	O
vaccine	B-T103
breakdown	O
in	O
salmon	B-T204
.	O

This	O
is	O
largely	O
because	O
current	O
vaccines	B-T103
are	O
aimed	O
at	O
rainbow	B-T204
trout	I-T204
and	O
are	O
based	O
on	O
serotypes	B-T170
specific	O
for	O
this	O
species	B-T170
.	O

A	O
wider	O
range	O
of	O
serotypes	B-T170
is	O
responsible	O
for	O
infection	B-T038
in	O
Atlantic	B-T204
salmon	I-T204
,	O
but	O
very	O
little	O
is	O
known	O
about	O
the	O
diversity	O
of	O
these	O
strains	B-T204
and	O
their	O
relationships	O
to	O
those	O
recovered	O
from	O
rainbow	B-T204
trout	I-T204
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Y	B-T007
.	I-T007

ruckeri	I-T007
isolates	B-T103
recovered	O
from	O
diseased	B-T038
Atlantic	B-T204
salmon	I-T204
in	O
Scotland	B-T082
are	O
more	O
diverse	O
than	O
those	O
from	O
rainbow	B-T204
trout	I-T204
;	O
furthermore	O
,	O
isolates	B-T103
from	O
the	O
two	O
species	B-T170
represent	O
distinct	O
subpopulations	B-T098
.	O

In	O
addition	O
,	O
a	O
new	O
O	B-T170
serotype	I-T170
was	O
identified	O
that	O
is	O
responsible	O
for	O
a	O
significant	O
proportion	O
of	O
the	O
disease	B-T038
in	O
Atlantic	B-T204
salmon	I-T204
.	O

Our	O
findings	B-T033
are	O
likely	O
to	O
have	O
important	O
implications	O
for	O
the	O
development	B-T062
of	I-T062
improved	I-T062
vaccines	I-T062
against	O
Y	B-T007
.	I-T007

ruckeri	I-T007
.	O

CD84	B-T103
mediates	O
CLL	B-T038
-	O
microenvironment	O
interactions	B-T038

Chronic	B-T038
lymphocytic	I-T038
leukemia	I-T038
(	O
CLL	B-T038
)	O
is	O
a	O
malignant	B-T038
disease	I-T038
of	O
small	O
mature	B-T017
lymphocytes	I-T017
.	O

Signals	O
from	O
the	O
CLL	B-T038
microenvironment	O
promote	O
progression	B-T038
of	I-T038
the	I-T038
disease	I-T038
and	O
induce	O
drug	B-T038
resistance	I-T038
.	O

This	O
phenomenon	O
is	O
largely	O
dependent	O
on	O
direct	O
contact	O
between	O
the	O
malignant	B-T038
B	I-T038
cells	I-T038
and	O
stromal	B-T017
cells	I-T017
.	O

CD84	B-T103
belongs	O
to	O
the	O
signaling	B-T103
lymphocyte	I-T103
activation	I-T103
molecule	I-T103
family	I-T103
of	O
immunoreceptors	B-T103
,	O
which	O
self	B-T038
-	I-T038
associates	I-T038
,	O
forming	O
an	O
orthogonal	O
homophilic	O
dimer	O
.	O

We	O
therefore	O
hypothesized	O
that	O
CD84	B-T103
may	O
bridge	O
between	O
CLL	B-T038
cells	B-T017
and	O
their	O
microenvironment	O
,	O
promoting	O
cell	B-T038
survival	I-T038
.	O

Our	O
in	O
vitro	O
results	O
show	O
that	O
CD84	B-T038
expressed	I-T038
on	O
CLL	B-T038
cells	B-T017
interact	O
with	O
CD84	B-T038
expressed	I-T038
on	O
cells	B-T017
in	O
their	O
microenvironment	O
,	O
inducing	O
cell	B-T038
survival	I-T038
in	O
both	O
sides	O
.	O

Blocking	O
CD84	B-T103
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
disrupt	O
the	O
interaction	O
of	O
CLL	B-T038
cells	B-T017
with	O
their	O
microenvironment	O
,	O
resulting	O
in	O
induced	O
cell	B-T038
death	I-T038
.	O

Thus	O
,	O
our	O
findings	B-T033
suggest	O
novel	O
therapeutic	O
strategies	O
based	O
on	O
the	O
blockade	B-T103
of	O
this	O
CD84	B-T103
-	O
dependent	O
survival	B-T038
pathway	B-T038
.	O

Aurantimonas	B-T007
endophytica	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	O
a	O
novel	O
endophytic	B-T204
bacterium	I-T204
isolated	O
from	O
roots	B-T204
of	O
Anabasis	B-T204
elatior	I-T204
(	I-T204
C	I-T204
.	I-T204
A	I-T204
.	I-T204
Mey	I-T204
.	I-T204
)	I-T204
Schischk	I-T204

An	O
orange	O
-	O
coloured	O
,	O
aerobic	O
,	O
motile	O
and	O
short	B-T007
-	I-T007
rods	I-T007
bacterial	I-T007
strain	I-T007
,	O
designated	O
EGI	B-T007
6500337T	I-T007
,	O
was	O
isolated	O
from	O
the	O
surface	O
-	O
sterilized	O
root	B-T204
of	O
a	O
halophyte	B-T204
Anabasis	B-T204
elatior	I-T204
(	I-T204
C	I-T204
.	I-T204

A	I-T204
.	I-T204

Mey	I-T204
.	I-T204
)	I-T204
Schischk	I-T204
collected	O
from	O
Urumqi	B-T082
,	O
Xinjiang	B-T082
province	I-T082
,	O
north	B-T082
-	I-T082
west	I-T082
China	I-T082
.	O

Growth	B-T038
occurred	O
at	O
5	O
-	O
35	O
°C	O
(	O
optimum	O
30	O
°C	O
)	O
,	O
at	O
pH	O
6	O
.	O
0	O
-	O
9	O
.	O
0	O
(	O
optimum	O
pH	O
7	O
.	O
0	O
)	O
,	O
and	O
in	O
the	O
presence	O
of	O
0	O
-	O
6	O
%	O
NaCl	B-T103
(	O
w	O
/	O
v	O
)	O
(	O
optimum	O
0	O
-	O
1	O
%	O
)	O
.	O

Phylogenetic	O
tree	O
based	O
on	O
16S	B-T103
rRNA	I-T103
gene	B-T082
sequences	I-T082
indicated	O
that	O
strain	B-T007
EGI	I-T007
6500337T	I-T007
formed	O
a	O
distinct	O
lineage	O
in	O
the	O
cluster	O
that	O
comprised	O
the	O
genera	B-T007
Aurantimonas	I-T007
and	O
Aureimonas	B-T007
in	O
the	O
family	B-T007
Aurantimonadaceae	I-T007
.	O

The	O
16S	B-T103
rRNA	I-T103
gene	B-T082
sequence	I-T082
of	O
strain	B-T007
EGI	I-T007
6500337T	I-T007
shared	O
the	O
highest	O
similarities	O
to	O
those	O
of	O
Aurantimonas	B-T007
coralicida	I-T007
DSM	I-T007
14790T	I-T007
(	O
97	O
.	O
15	O
%	O
)	O
and	O
Aurantimonas	B-T007
manganoxydans	I-T007
DSM	I-T007
21871T	I-T007
(	O
97	O
.	O
15	O
%	O
)	O
.	O

Strain	B-T007
EGI	I-T007
6500337T	I-T007
contained	O
Q	B-T103
-	I-T103
10	I-T103
as	O
the	O
dominant	O
isoprenoid	B-T103
quinone	I-T103
.	O

The	O
major	O
cellular	O
fatty	B-T103
acids	I-T103
were	O
C18	O
:	O
1	O
7c	O
(	O
66	O
.	O
4	O
%	O
)	O
and	O
C19	B-T103
:	I-T103
0	I-T103
8c	I-T103
cyclo	I-T103
(	O
23	O
.	O
3	O
%	O
)	O
.	O

The	O
polar	O
lipid	B-T103
profile	I-T103
of	O
strain	B-T007
EGI	I-T007
6500337T	I-T007
contained	O
diphosphatidylglycerol	B-T103
,	O
phosphatidylglycerol	B-T103
,	O
phosphatidylcholine	B-T103
,	O
phosphatidylethanolamine	B-T103
as	O
major	O
components	O
,	O
similarly	O
to	O
the	O
members	O
of	O
the	O
genus	B-T007
Aurantimonas	I-T007
.	O

The	O
DNA	B-T103
G	O
+	O
C	O
content	O
of	O
strain	B-T007
EGI	I-T007
6500337T	I-T007
was	O
66	O
.	O
8	O
mol	O
%	O
.	O

The	O
DNA	B-T103
-	O
DNA	B-T103
relatedness	O
between	O
strain	B-T007
EGI	I-T007
6500337T	I-T007
and	O
Aurantimonas	B-T007
coralicida	I-T007
DSM	I-T007
14790T	I-T007
was	O
24	O
.	O
7	O
±	O
2	O
.	O
9	O
%	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	B-T062
analysis	I-T062
,	O
chemotaxonomic	O
data	O
and	O
phenotypic	O
characteristics	O
,	O
strain	B-T007
EGI	I-T007
6500337T	I-T007
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	B-T007
Aurantimonas	I-T007
,	O
for	O
which	O
the	O
name	O
Aurantimonas	B-T007
endophytica	I-T007
sp	I-T007
.	I-T007

nov	I-T007
.	I-T007

is	O
proposed	O
.	O

The	O
type	O
strain	B-T007
is	O
EGI	B-T007
6500337T	I-T007
(	O
=	O
KCTC	B-T007
52296T	I-T007
=	O
CPCC	B-T007
100904T	I-T007
)	O
.	O

Assessment	B-T058
and	O
classification	B-T170
of	O
protocol	B-T033
deviations	I-T033

Deviations	B-T033
from	O
the	O
approved	O
trial	B-T170
protocol	I-T170
are	O
common	O
during	O
clinical	B-T062
trials	I-T062
.	O

They	O
have	O
been	O
conventionally	O
classified	B-T170
as	O
deviations	B-T033
or	O
violations	B-T062
,	O
depending	O
on	O
their	O
impact	O
on	O
the	O
trial	B-T062
.	O

A	O
new	O
method	O
has	O
been	O
proposed	O
by	O
which	O
deviations	B-T033
are	O
classified	B-T170
in	O
five	O
grades	B-T170
from	I-T170
1	I-T170
to	I-T170
5	I-T170
.	O

A	O
deviation	B-T033
of	O
Grade	B-T033
1	I-T033
has	O
no	B-T033
impact	O
on	O
the	O
subjects	B-T098
'	I-T098
well	B-T033
-	I-T033
being	I-T033
or	O
on	O
the	O
quality	O
of	O
data	O
.	O

At	O
the	O
maximum	O
,	O
a	O
deviation	B-T033
Grade	B-T170
5	I-T170
leads	O
to	O
the	O
death	B-T033
of	O
the	O
subject	B-T098
.	O

This	O
method	O
of	O
classification	B-T170
was	O
applied	O
to	O
deviations	B-T033
noted	O
in	O
the	O
center	O
over	O
the	O
last	O
3	O
years	O
.	O

It	O
was	O
observed	O
that	O
most	O
deviations	B-T033
were	O
of	O
Grades	B-T170
1	I-T170
and	I-T170
2	I-T170
,	O
with	O
fewer	O
falling	O
in	O
Grades	B-T170
3	I-T170
and	I-T170
4	I-T170
.	O

There	O
were	O
no	O
deviations	B-T033
that	O
led	O
to	O
the	O
death	B-T033
of	I-T033
the	I-T033
subject	I-T033
(	O
Grade	O
5	O
)	O
.	O

This	O
method	O
of	O
classification	B-T170
would	O
help	O
trial	B-T062
managers	B-T097
decide	O
on	O
the	O
action	O
to	O
be	O
taken	O
on	O
the	O
occurrence	O
of	O
deviations	B-T033
,	O
which	O
would	O
be	O
based	O
on	O
their	O
impact	O
.	O

Fabrication	O
and	O
modelling	B-T062
of	O
fractal	B-T082
,	O
biomimetic	B-T082
,	O
micro	B-T082
and	O
nano	B-T082
-	I-T082
topographical	I-T082
surfaces	I-T082

Natural	O
surface	O
topographies	O
are	O
often	O
self	O
-	O
similar	O
with	O
hierarchical	O
features	O
at	O
the	O
micro	O
and	O
nanoscale	O
,	O
which	O
may	O
be	O
mimicked	O
to	O
overcome	O
modern	O
tissue	B-T058
engineering	I-T058
and	O
biomaterial	B-T103
design	O
limitations	O
.	O

Specifically	O
,	O
a	O
cell	O
'	O
s	O
microenvironment	O
within	O
the	O
human	B-T204
body	I-T204
contains	O
highly	O
optimised	O
,	O
fractal	B-T082
topographical	I-T082
cues	I-T082
,	O
which	O
directs	O
precise	O
cell	B-T017
behaviour	O
.	O

However	O
,	O
recreating	O
biomimetic	B-T082
,	O
fractal	B-T082
topographies	I-T082
in	O
vitro	O
is	O
not	O
a	O
trivial	O
process	O
and	O
a	O
number	O
of	O
fabrication	O
methods	O
have	O
been	O
proposed	O
but	O
often	O
fail	O
to	O
precisely	O
control	O
the	O
spatial	O
resolution	O
of	O
features	O
at	O
different	O
lengths	O
scales	O
and	O
hence	O
,	O
to	O
provide	O
true	O
biomimetic	O
properties	O
.	O

Here	O
,	O
we	O
propose	O
a	O
method	B-T170
of	O
accurately	O
reproducing	O
the	O
self	O
-	O
similar	O
,	O
micro	B-T082
and	O
nanoscale	B-T082
topography	I-T082
of	O
a	O
human	B-T204
biological	B-T017
tissue	I-T017
into	O
a	O
synthetic	B-T103
polymer	I-T103
through	O
an	O
innovative	O
fabrication	O
process	O
.	O

The	O
biological	B-T017
tissue	I-T017
surface	B-T082
was	O
characterised	O
using	O
atomic	B-T058
force	I-T058
microscopy	I-T058
(	O
AFM	B-T058
)	O
to	O
obtain	O
spatial	O
data	O
in	O
X	O
,	O
Y	O
and	O
Z	O
,	O
which	O
was	O
converted	O
into	O
a	O
grayscale	O
'	O
digital	O
photomask	O
'	O
.	O

As	O
a	O
result	O
of	O
maskless	O
grayscale	O
optical	O
lithography	O
followed	O
by	O
modified	O
deep	O
reactive	O
ion	O
etching	O
and	O
replica	O
molding	O
,	O
we	O
were	O
able	O
to	O
accurately	O
reproduce	O
the	O
fractal	B-T082
topography	I-T082
of	O
acellular	B-T017
dermal	I-T017
matrix	I-T017
(	O
ADM	B-T017
)	O
into	O
polydimethylsiloxane	B-T103
(	O
PDMS	B-T103
)	O
.	O

Characterisation	O
using	O
AFM	B-T058
at	O
three	O
different	O
length	O
scales	O
revealed	O
that	O
the	O
nano	B-T082
and	O
micro	B-T082
-	I-T082
topographical	I-T082
features	O
,	O
in	O
addition	O
to	O
the	O
fractal	O
dimension	O
,	O
of	O
native	O
ADM	B-T017
were	O
reproduced	O
in	O
PDMS	B-T103
.	O

In	O
conclusion	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
fractal	B-T082
topography	I-T082
of	O
biological	B-T082
surfaces	I-T082
can	O
be	O
mimicked	O
in	O
synthetic	O
materials	O
using	O
the	O
novel	O
fabrication	O
process	O
outlined	O
,	O
which	O
may	O
be	O
applied	O
to	O
significantly	O
enhance	O
medical	B-T074
device	I-T074
biocompatibility	O
and	O
performance	O
.	O

Investigating	O
Effects	O
of	O
Acidic	O
pH	O
on	O
Proliferation	B-T038
,	O
Invasion	B-T038
and	O
Drug	B-T103
-	O
Induced	O
Apoptosis	B-T038
in	O
Lymphoblastic	B-T038
Leukemia	I-T038

Some	O
studies	O
have	O
shown	O
that	O
extracellular	B-T082
pH	O
in	O
tumors	B-T038
,	O
which	O
results	O
in	O
tumor	B-T038
progression	I-T038
,	O
is	O
less	O
than	O
that	O
in	O
normal	O
tissues	B-T017
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
the	O
effects	O
of	O
extracellular	B-T082
acidic	O
pH	O
on	O
proliferation	B-T038
,	O
invasion	B-T038
,	O
and	O
drug	B-T103
-	O
induced	O
apoptosis	B-T038
in	O
acute	B-T017
lymphoblastic	I-T017
cells	I-T017
.	O

The	O
cells	B-T017
were	O
cultured	O
in	O
different	O
pH	O
(	O
pH	O
6	O
.	O
6	O
and	O
pH	O
7	O
.	O
4	O
)	O
for	O
12	O
days	O
.	O

Cell	B-T038
proliferation	I-T038
was	O
assessed	O
by	O
MTT	B-T062
assay	I-T062
and	O
cell	B-T038
invasion	I-T038
was	O
assayed	O
by	O
invasion	B-T058
assay	I-T058
and	O
gene	B-T062
expression	I-T062
analysis	I-T062
of	O
MMP	B-T103
-	I-T103
9	I-T103
.	O

Drug	B-T103
-	O
induced	O
apoptosis	B-T038
was	O
evaluated	O
after	O
exposure	O
to	O
doxorubicin	B-T103
for	O
24	O
hours	O
by	O
annexin	B-T103
V	I-T103
/	O
PI	B-T103
staining	B-T058
and	O
gene	B-T062
expression	I-T062
analysis	I-T062
of	O
BAX	B-T103
pro	I-T103
-	I-T103
apoptotic	I-T103
protein	I-T103
.	O

The	O
results	O
indicated	O
the	O
enhanced	O
growth	B-T038
and	O
invasion	B-T038
of	O
leukemic	B-T038
cells	B-T017
at	O
pH	O
6	O
.	O
6	O
(	O
P	O
≤	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
the	O
cells	B-T017
at	O
pH	O
6	O
.	O
6	O
were	O
resistant	O
to	O
apoptosis	B-T038
by	O
doxorubicin	B-T103
(	O
P	O
≤	O
0	O
.	O
05	O
)	O
.	O

It	O
can	O
be	O
concluded	O
that	O
acidic	O
pH	O
increases	O
the	O
proliferation	B-T038
,	O
invasion	B-T038
and	O
reduces	O
the	O
drug	B-T103
-	O
induced	O
apoptosis	B-T038
in	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
.	O

Extracellular	B-T082
acidity	O
can	O
influence	O
the	O
behavior	O
of	O
leukemic	B-T038
cells	B-T017
and	O
therefore	O
,	O
the	O
manipulation	O
of	O
extracellular	B-T031
liquid	I-T031
can	O
be	O
selected	O
as	O
a	O
therapeutic	B-T058
strategy	I-T058
for	O
leukemia	B-T038
,	O
especially	O
for	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
.	O

Gold	B-T103
-	O
Nanosponge	B-T074
-	O
Based	O
Multistimuli	B-T103
-	I-T103
Responsive	I-T103
Drug	I-T103
Vehicles	I-T103
for	O
Targeted	O
Chemo	B-T058
-	I-T058
Photothermal	I-T058
Therapy	I-T058

Gold	B-T103
-	O
nanosponge	B-T074
-	O
based	O
multistimuli	B-T103
-	I-T103
responsive	I-T103
drug	I-T103
vehicles	I-T103
are	O
constructed	O
for	O
combined	O
chemo	B-T058
-	I-T058
photothermal	I-T058
therapy	I-T058
with	O
pinpointed	O
drug	B-T103
delivery	O
and	O
release	O
capabilities	O
and	O
minimized	O
nonspecific	O
systemic	O
spread	O
of	O
drugs	B-T103
,	O
remarkably	O
enhancing	O
the	O
therapeutic	O
efficiency	O
while	O
minimizing	O
acute	O
side	B-T038
effects	I-T038
.	O

Hemodynamic	B-T038
correlates	O
of	O
transient	B-T038
cognitive	I-T038
impairment	I-T038
after	O
transient	B-T038
ischemic	I-T038
attack	I-T038
and	O
minor	B-T038
stroke	I-T038
:	O
A	O
transcranial	B-T058
Doppler	I-T058
study	I-T058

Transient	B-T038
cognitive	I-T038
impairment	I-T038
(	O
TCI	B-T038
)	O
on	O
the	O
Mini	B-T058
Mental	I-T058
State	I-T058
Evaluation	I-T058
score	O
is	O
common	O
after	O
transient	B-T038
ischemic	I-T038
attack	I-T038
/	O
minor	B-T038
stroke	I-T038
and	O
might	O
identify	O
patients	O
at	O
increased	O
risk	O
of	O
dementia	B-T038
.	O

We	O
aimed	O
to	O
replicate	O
TCI	B-T038
using	O
the	O
Montreal	B-T170
Cognitive	I-T170
Assessment	I-T170
(	O
MoCA	B-T170
)	O
,	O
compare	O
it	O
with	O
persistent	B-T038
Mild	I-T038
Cognitive	I-T038
Impairment	I-T038
(	O
PMCI	B-T038
)	O
,	O
and	O
to	O
determine	O
whether	O
global	O
cerebral	B-T017
hemodynamic	B-T038
changes	O
could	O
explain	O
transient	O
impairment	O
.	O

Consecutive	O
patients	O
with	O
transient	B-T038
ischemic	I-T038
attack	I-T038
/	O
minor	B-T038
stroke	I-T038
(	O
NIHSS	O
≤	O
3	O
)	O
were	O
assessed	O
with	O
the	O
MoCA	B-T170
and	O
transcranial	B-T058
Doppler	I-T058
ultrasound	I-T058
acutely	O
and	O
at	O
1	O
month	O
.	O

We	O
compared	O
patients	O
with	O
TCI	B-T038
(	O
baseline	O
MoCA	B-T170
<	O
26	O
with	O
≥	O
2	O
points	O
increase	O
at	O
1	O
month	O
)	O
,	O
PMCI	B-T038
(	O
MoCA	B-T170
<	O
26	O
with	O
<	O
2	O
points	O
increase	O
)	O
,	O
and	O
no	B-T033
cognitive	I-T033
impairment	I-T033
(	O
NCI	B-T033
;	O
MoCA	B-T170
≥	O
26	O
)	O
.	O

Of	O
326	O
patients	O
,	O
46	O
(	O
14	O
.	O
1	O
%	O
)	O
had	O
PMCI	B-T038
,	O
98	O
(	O
30	O
.	O
1	O
%	O
)	O
TCI	B-T038
,	O
and	O
182	O
(	O
55	O
.	O
8	O
%	O
)	O
NCI	B-T033
.	O

At	O
baseline	O
,	O
TCI	B-T038
patients	O
had	O
higher	B-T033
systolic	I-T033
blood	I-T033
pressure	I-T033
(	O
150	O
.	O
95	O
±	O
21	O
.	O
52	O
vs	O
144	O
.	O
86	O
±	O
22	O
.	O
44	O
mmHg	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
lower	O
cerebral	O
blood	O
flow	O
velocities	O
,	O
particularly	O
end	O
-	O
diastolic	O
velocity	O
(	O
30	O
.	O
16	O
±	O
9	O
.	O
63	O
vs	O
35	O
.	O
02	O
±	O
9	O
.	O
01	O
cm	O
/	O
s	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
mean	B-T033
flow	I-T033
velocity	I-T033
(	O
48	O
.	O
95	O
±	O
12	O
.	O
72	O
vs	O
54	O
±	O
12	O
.	O
46	O
cm	O
/	O
s	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
than	O
those	O
with	O
NCI	B-T033
,	O
but	O
similar	O
clinical	O
and	O
hemodynamic	B-T038
profiles	B-T058
to	O
those	O
with	O
PMCI	B-T038
.	O

Systolic	B-T033
BP	I-T033
fell	I-T033
between	O
baseline	O
and	O
1	O
month	O
(	O
mean	O
reduction	B-T058
=	O
14	O
.	O
01	O
±	O
21	O
.	O
26	O
mmHg	O
)	O
and	O
end	O
-	O
diastolic	O
velocity	O
and	O
mean	B-T033
flow	I-T033
velocity	I-T033
increased	O
(	O
mean	O
increase	O
=	O
+	O
2	O
.	O
42	O
±	O
6	O
.	O
41	O
and	O
1	O
.	O
89	O
±	O
8	O
.	O
77	O
cm	O
/	O
s	O
,	O
respectively	O
)	O
,	O
but	O
these	O
changes	O
did	O
not	O
differ	O
between	O
patients	O
with	O
TCI	B-T038
,	O
PMCI	B-T038
,	O
and	O
NCI	B-T033
.	O

TCI	B-T038
is	O
detectable	B-T201
with	O
the	O
MoCA	B-T170
after	O
transient	B-T038
ischemic	I-T038
attack	I-T038
and	O
minor	B-T038
stroke	I-T038
and	O
has	O
similar	O
clinical	O
and	O
hemodynamic	B-T038
profile	B-T058
to	O
PMCI	B-T038
.	O

However	O
,	O
TCI	B-T038
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
exaggerated	O
acute	O
reversible	O
global	O
hemodynamic	B-T038
changes	O
.	O

Apixaban	B-T103
5	O
mg	O
Twice	O
Daily	O
and	O
Clinical	O
Outcomes	O
in	O
Patients	O
With	O
Atrial	B-T038
Fibrillation	I-T038
and	O
Advanced	O
Age	O
,	O
Low	O
Body	O
Weight	O
,	O
or	O
High	O
Creatinine	B-T103
:	O
A	O
Secondary	O
Analysis	O
of	O
a	O
Randomized	B-T062
Clinical	I-T062
Trial	I-T062

In	O
the	O
Apixaban	B-T103
for	O
Reduction	O
of	O
Stroke	B-T038
and	O
Other	O
Thromboembolic	B-T038
Complications	I-T038
in	O
Atrial	B-T038
Fibrillation	I-T038
(	O
ARISTOTLE	B-T062
)	O
trial	B-T062
,	O
the	O
standard	O
dose	O
of	O
apixaban	B-T103
was	O
5	O
mg	O
twice	O
daily	O
;	O
patients	O
with	O
at	O
least	O
2	O
dose	O
-	O
reduction	O
criteria	O
-	O
80	O
years	O
or	O
older	O
,	O
weight	O
60	O
kg	O
or	O
less	O
,	O
and	O
creatinine	B-T033
level	I-T033
1	O
.	O
5	O
mg	O
/	O
dL	O
or	O
higher	O
-	O
received	O
a	O
reduced	O
dose	O
of	O
apixaban	B-T103
of	O
2	O
.	O
5	O
mg	O
twice	O
daily	O
.	O

Little	O
is	O
known	O
about	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
who	O
received	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
.	O

To	O
determine	O
the	O
frequency	O
of	O
1	O
dose	O
-	O
reduction	O
criterion	O
and	O
whether	O
the	O
effects	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
on	O
stroke	B-T038
or	O
systemic	O
embolism	O
and	O
bleeding	B-T038
varied	O
among	O
patients	O
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
.	O

Among	O
18	O
201	O
patients	O
in	O
the	O
ARISTOTLE	B-T062
trial	I-T062
,	O
17	O
322	O
were	O
included	O
in	O
this	O
analysis	B-T062
.	O

Annualized	O
event	O
rates	O
of	O
stroke	B-T038
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	B-T038
and	O
hazard	O
ratios	O
(	O
HRs	O
)	O
and	O
95	O
%	O
CIs	O
were	O
evaluated	B-T058
.	O

Interactions	O
between	O
the	O
effects	O
of	O
apixaban	B-T103
vs	O
warfarin	B-T103
and	O
the	O
presence	O
of	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
were	O
assessed	O
.	O

The	O
first	O
patient	O
was	O
enrolled	O
in	O
the	O
ARISTOTLE	B-T062
trial	I-T062
on	O
December	O
19	O
,	O
2006	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
was	O
completed	O
on	O
January	O
30	O
,	O
2011	O
.	O

Data	O
were	O
analyzed	O
from	O
January	O
2015	O
to	O
May	O
30	O
,	O
2016	O
.	O

Analysis	B-T062
of	O
major	O
bleeding	B-T038
included	O
events	O
during	O
study	B-T062
drug	B-T058
treatment	I-T058
.	O

Analysis	B-T062
of	O
stroke	B-T038
or	O
systemic	O
embolism	O
was	O
based	O
on	O
intention	O
to	O
treat	O
.	O

Of	O
the	O
patients	O
with	O
1	O
or	O
no	O
dose	O
-	O
reduction	O
criteria	O
assigned	O
to	O
receive	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
or	O
warfarin	B-T103
,	O
3966	O
had	O
1	O
dose	O
-	O
reduction	O
criterion	O
;	O
these	O
patients	O
had	O
higher	O
rates	O
of	O
stroke	B-T038
or	O
systemic	O
embolism	O
(	O
HR	O
,	O
1	O
.	O
47	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
20	O
-	O
1	O
.	O
81	O
)	O
and	O
major	O
bleeding	B-T038
(	O
HR	O
,	O
1	O
.	O
89	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
62	O
-	O
2	O
.	O
20	O
)	O
compared	O
with	O
those	O
with	O
no	O
dose	O
-	O
reduction	O
criteria	O
(	O
n	O
=	O
13	O
356	O
)	O
.	O

The	O
benefit	O
of	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
(	O
n	O
=	O
8665	O
)	O
compared	O
with	O
warfarin	B-T103
(	O
n	O
=	O
8657	O
)	O
on	O
stroke	B-T038
or	O
systemic	O
embolism	O
in	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
94	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
66	O
-	O
1	O
.	O
32	O
)	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
77	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
62	O
-	O
0	O
.	O
97	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.	O
36	O
)	O
.	O

Similarly	O
,	O
the	O
benefit	O
of	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
compared	O
with	O
warfarin	B-T103
on	O
major	O
bleeding	B-T038
in	O
patients	O
with	O
1	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
68	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
53	O
-	O
0	O
.	O
87	O
)	O
and	O
no	O
dose	O
-	O
reduction	O
criterion	O
(	O
HR	O
,	O
0	O
.	O
72	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
60	O
-	O
0	O
.	O
86	O
)	O
were	O
similar	O
(	O
P	O
for	O
interaction	O
=	O
.	O
71	O
)	O
.	O

Similar	O
patterns	O
were	O
seen	O
for	O
each	O
dose	O
-	O
reduction	O
criterion	O
and	O
across	O
the	O
spectrum	O
of	O
age	O
,	O
body	O
weight	O
,	O
creatinine	B-T033
level	I-T033
,	O
and	O
creatinine	B-T103
clearance	B-T201
.	O

Patients	O
with	O
atrial	B-T038
fibrillation	I-T038
and	O
isolated	O
advanced	O
age	O
,	O
low	O
body	O
weight	O
,	O
or	O
renal	B-T033
dysfunction	I-T033
have	O
a	O
higher	O
risk	O
of	O
stroke	B-T038
or	O
systemic	O
embolism	O
and	O
major	O
bleeding	B-T038
but	O
show	O
consistent	O
benefits	O
with	O
the	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
vs	O
warfarin	B-T103
compared	O
with	O
patients	O
without	O
these	O
characteristics	O
.	O

The	O
5	O
mg	O
twice	O
daily	O
dose	O
of	O
apixaban	B-T103
is	O
safe	O
,	O
efficacious	O
,	O
and	O
appropriate	O
for	O
patients	O
with	O
only	O
1	O
dose	O
-	O
reduction	O
criterion	O
.	O

clinicaltrials	O
.	O
gov	O
Identifier	O
:	O
NCT00412984	O
.	O

Transition	O
From	O
Hospital	B-T092
to	O
Home	B-T082
in	O
Preterm	O
Infants	O
and	O
Their	O
Families	O

When	O
the	O
day	O
of	O
discharge	B-T058
from	O
a	O
neonatal	B-T092
intensive	I-T092
care	I-T092
unit	I-T092
(	O
NICU	B-T092
)	O
comes	O
for	O
the	O
parents	O
of	O
newborn	O
infants	O
,	O
they	O
are	O
filled	O
with	O
long	O
-	O
awaited	O
joy	B-T038
and	O
happiness	B-T038
.	O

They	O
go	O
home	B-T082
feeling	B-T038
as	O
parents	O
,	O
away	O
from	O
scheduled	O
routines	O
of	O
the	O
hospital	B-T092
,	O
monitor	O
alarms	O
,	O
clinical	O
rounds	O
,	O
numerous	O
tests	B-T058
,	O
and	O
so	O
on	O
.	O

What	O
do	O
we	O
know	O
about	O
what	O
happens	O
after	O
these	O
little	O
patients	O
and	O
their	O
families	O
leave	O
the	O
NICU	B-T092
?	O
What	O
happens	O
from	O
the	O
point	O
of	O
leaving	O
the	O
hospital	B-T092
until	O
when	O
things	O
get	O
settled	O
and	O
life	O
becomes	O
perceived	B-T038
as	O
normal	O
?	O
This	O
article	B-T170
presents	O
a	O
short	O
summary	B-T170
of	O
research	B-T062
conducted	O
with	O
the	O
vulnerable	B-T098
population	I-T098
of	O
high	B-T033
-	I-T033
risk	I-T033
and	O
preterm	O
infants	O
and	O
their	O
families	O
postdischarge	B-T058
.	O

Available	O
evidence	O
suggests	O
that	O
transition	O
to	O
home	B-T082
after	O
hospital	B-T058
discharge	I-T058
,	O
a	O
phenomenon	O
that	O
many	O
families	O
experience	B-T038
,	O
is	O
challenging	O
and	O
requires	O
attention	B-T058
from	O
clinicians	B-T097
and	O
researchers	O
if	O
we	O
are	O
to	O
provide	O
effective	O
,	O
efficient	O
,	O
and	O
high	B-T058
-	I-T058
quality	I-T058
care	I-T058
.	O

Visual	B-T058
Analytics	I-T058
for	O
Pattern	B-T038
Discovery	I-T038
in	O
Home	B-T058
Care	I-T058
.	O
Clinical	O
Relevance	O
for	O
Quality	O
Improvement	O

Visualization	B-T038
can	O
reduce	O
the	O
cognitive	O
load	O
of	O
information	O
,	O
allowing	O
users	O
to	O
easily	O
interpret	O
and	O
assess	O
large	O
amounts	O
of	O
data	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
examine	O
home	B-T170
health	I-T170
data	I-T170
using	O
visual	B-T058
analysis	I-T058
techniques	I-T058
to	O
discover	O
clinically	O
salient	O
associations	O
between	O
patient	O
characteristics	O
with	O
problem	O
-	O
oriented	O
health	O
outcomes	O
of	O
older	B-T058
adult	I-T058
home	I-T058
health	I-T058
patients	I-T058
during	O
the	O
home	B-T058
health	I-T058
service	I-T058
period	O
.	O

Knowledge	B-T170
,	O
Behavior	O
and	O
Status	O
ratings	O
at	O
discharge	B-T058
as	O
well	O
as	O
change	O
from	O
admission	B-T058
to	O
discharge	B-T058
that	O
was	O
coded	O
using	O
the	O
Omaha	B-T170
System	I-T170
was	O
collected	O
from	O
a	O
dataset	B-T170
on	O
988	O
de	O
-	O
identified	O
patient	O
data	O
from	O
15	O
home	B-T092
health	I-T092
agencies	I-T092
.	O

SPSS	B-T170
Visualization	I-T170
Designer	I-T170
v1	I-T170
.	I-T170
0	I-T170
was	O
used	O
to	O
visually	B-T058
analyze	I-T058
patterns	I-T058
between	O
independent	O
and	O
outcome	O
variables	O
using	O
heat	O
maps	O
and	O
histograms	O
.	O

Visualizations	B-T038
suggesting	O
clinical	B-T033
salience	I-T033
were	O
tested	O
for	O
significance	O
using	O
correlation	B-T062
analysis	I-T062
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
80	O
years	O
,	O
with	O
the	O
majority	O
female	O
(	O
66	O
%	O
)	O
.	O

Of	O
the	O
150	O
visualizations	B-T038
,	O
69	O
potentially	O
meaningful	O
patterns	O
were	O
statistically	O
evaluated	O
through	O
bivariate	O
associations	O
,	O
revealing	O
21	O
significant	O
associations	O
.	O

Further	O
,	O
14	O
associations	O
between	O
episode	O
length	O
and	O
Charlson	B-T170
co	I-T170
-	I-T170
morbidity	I-T170
index	I-T170
mainly	O
with	O
urinary	O
related	O
diagnoses	O
and	O
problems	O
remained	O
significant	O
after	O
adjustment	O
analyses	O
.	O

Through	O
visual	B-T058
analysis	I-T058
,	O
the	O
adverse	O
association	O
of	O
the	O
longer	O
home	B-T058
health	I-T058
episode	I-T058
length	O
and	O
higher	O
Charlson	B-T170
co	I-T170
-	I-T170
morbidity	I-T170
index	I-T170
with	O
behavior	B-T033
or	I-T033
status	I-T033
outcomes	I-T033
for	O
patients	O
with	O
impaired	O
urinary	O
function	O
was	O
revealed	O
.	O

We	O
have	O
demonstrated	O
the	O
use	O
of	O
visual	B-T058
analysis	I-T058
to	O
discover	O
novel	O
patterns	O
that	O
described	O
high	O
-	O
needs	O
subgroups	B-T170
among	O
the	O
older	O
home	O
health	O
patient	O
population	O
.	O

The	O
effective	O
presentation	O
of	O
these	O
data	O
patterns	O
can	O
allow	O
clinicians	B-T097
to	O
identify	O
areas	O
of	O
patient	O
improvement	O
,	O
and	O
time	O
periods	O
that	O
are	O
most	O
effective	O
for	O
implementing	O
home	B-T058
health	I-T058
interventions	I-T058
to	O
improve	O
patient	B-T058
outcomes	I-T058
.	O

Transforming	B-T103
Growth	I-T103
Factor	I-T103
Beta	I-T103
1	I-T103
(	O
TGF	B-T103
-	I-T103
β1	I-T103
)	O
in	O
Thyroid	B-T038
Cancer	I-T038
Patients	O
:	O
a	O
View	O
from	O
the	O
Peripheral	B-T031
Blood	I-T031

Transforming	B-T103
growth	I-T103
factor	I-T103
beta	I-T103
(	O
TGF	B-T103
-	I-T103
β	I-T103
)	O
plays	O
an	O
important	O
role	O
in	O
many	O
pathophysiological	O
conditions	O
,	O
including	O
cancer	B-T038
.	O

The	O
level	O
of	O
TGF	B-T103
-	I-T103
β	I-T103
in	O
patients	O
with	O
differentiated	B-T038
thyroid	I-T038
cancer	I-T038
(	O
DTC	B-T038
)	O
has	O
not	O
been	O
examined	B-T033
so	O
far	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
measure	O
TGF	B-T103
-	I-T103
β	I-T103
concentration	O
in	O
serum	B-T031
samples	I-T031
and	O
in	O
PHA	B-T103
-	O
stimulated	B-T038
whole	B-T031
blood	I-T031
culture	B-T058
in	O
vitro	O
and	O
to	O
analyze	B-T062
possible	O
associations	O
of	O
TGF	B-T103
-	I-T103
β1	I-T103
levels	O
with	O
leukocyte	B-T017
,	O
lymphocyte	B-T017
and	O
platelets	B-T017
counts	B-T058
,	O
the	O
histological	O
type	O
of	O
thyroid	B-T038
cancer	I-T038
,	O
and	O
stage	O
of	O
disease	O
.	O

TGF	B-T103
-	I-T103
β1	I-T103
was	O
measured	O
in	O
22	O
DTC	B-T038
patients	O
and	O
20	O
healthy	O
controls	O
using	O
the	O
duoSet	B-T074
ELISA	I-T074
Development	I-T074
kit	I-T074
for	O
human	B-T103
TGF	I-T103
-	I-T103
β1	I-T103
.	O

The	O
concentration	O
of	O
TGF	B-T103
-	I-T103
β1	I-T103
in	O
serum	B-T031
samples	I-T031
from	O
both	O
groups	B-T098
correlated	O
positively	O
with	O
the	O
platelet	B-T017
counts	B-T058
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
serum	O
concentrations	O
of	O
TGF	B-T103
-	I-T103
β1	I-T103
between	O
DTC	B-T038
patients	O
and	O
control	O
subjects	O
,	O
but	O
PHA	B-T103
stimulated	B-T038
whole	B-T031
blood	I-T031
cultures	B-T058
of	O
DTC	B-T038
patients	O
produced	O
less	O
TGF	B-T103
-	I-T103
β1	I-T103
than	O
those	O
from	O
controls	O
.	O

Additional	O
studies	B-T062
are	O
needed	O
to	O
determine	O
the	O
significance	O
of	O
these	O
in	O
vitro	O
findings	B-T033
.	O

P	B-T103
-	I-T103
glycoprotein	I-T103
traffics	O
from	O
the	O
nucleus	B-T017
to	O
the	O
plasma	B-T017
membrane	I-T017
in	O
rat	B-T017
brain	I-T017
endothelium	B-T017
during	O
inflammatory	B-T033
pain	I-T033

P	B-T103
-	I-T103
glycoprotein	I-T103
(	O
PgP	B-T103
)	O
,	O
a	O
drug	B-T103
efflux	B-T017
pump	I-T017
in	O
blood	B-T017
-	I-T017
brain	I-T017
barrier	I-T017
endothelial	B-T017
cells	I-T017
,	O
is	O
a	O
major	O
clinical	O
obstacle	O
for	O
effective	O
central	B-T022
nervous	I-T022
system	I-T022
drug	B-T058
delivery	I-T058
.	O

Identifying	O
PgP	B-T103
regulatory	O
pathways	O
that	O
can	O
be	O
exploited	O
clinically	O
is	O
critical	O
for	O
improving	O
central	B-T022
nervous	I-T022
system	I-T022
drug	B-T058
delivery	I-T058
.	O

We	O
previously	O
found	O
that	O
PgP	B-T038
activity	I-T038
increases	O
in	O
rat	B-T017
brain	I-T017
microvessels	B-T017
concomitant	O
with	O
decreased	O
central	B-T022
nervous	I-T022
system	I-T022
drug	B-T058
delivery	I-T058
in	O
response	O
to	O
acute	O
peripheral	B-T082
inflammatory	B-T033
pain	I-T033
.	O

In	O
the	O
current	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
PgP	B-T103
traffics	O
to	O
the	O
luminal	B-T082
plasma	B-T017
membrane	I-T017
of	O
the	O
microvessel	B-T017
endothelial	B-T017
cells	I-T017
from	O
intracellular	B-T082
stores	O
during	O
peripheral	B-T082
inflammatory	B-T033
pain	I-T033
.	O

Using	O
immunofluorescence	B-T058
microscopy	I-T058
,	O
we	O
detected	B-T033
PgP	B-T103
in	O
endothelial	B-T017
cell	I-T017
nuclei	B-T017
and	O
in	O
the	O
luminal	B-T082
plasma	B-T017
membrane	I-T017
in	O
control	B-T204
animals	I-T204
.	O

Following	O
peripheral	B-T082
inflammatory	B-T033
pain	I-T033
,	O
luminal	B-T082
PgP	B-T103
staining	B-T058
increased	O
while	O
staining	B-T058
in	O
the	O
nucleus	B-T017
decreased	O
.	O

Biochemical	B-T058
analysis	I-T058
of	O
nuclear	B-T017
PgP	B-T103
content	O
confirmed	O
our	O
visual	O
observations	O
.	O

Peripheral	B-T082
inflammatory	B-T033
pain	I-T033
also	O
increased	O
endothelial	B-T017
cell	I-T017
luminal	B-T082
staining	B-T058
of	O
polymerase	B-T017
1	I-T017
and	I-T017
transcript	I-T017
release	I-T017
factor	I-T017
/	O
cavin1	B-T017
and	O
serum	B-T017
deprivation	I-T017
response	I-T017
protein	I-T017
/	O
cavin2	B-T017
,	O
two	O
caveolar	B-T103
scaffold	I-T103
proteins	I-T103
,	O
without	O
changing	O
caveolin1	B-T103
or	O
protein	B-T017
kinase	I-T017
C	I-T017
delta	I-T017
binding	I-T017
protein	I-T017
/	O
cavin3	B-T017
location	B-T082
.	O

Our	O
data	O
(	O
a	O
)	O
indicate	O
that	O
PgP	B-T103
traffics	O
from	O
stores	O
in	O
the	O
nucleus	B-T017
to	O
the	O
endothelial	B-T017
cell	I-T017
luminal	O
membrane	O
in	O
response	O
to	O
peripheral	B-T082
inflammatory	B-T033
pain	I-T033
;	O
(	O
b	O
)	O
provide	O
an	O
explanation	O
for	O
our	O
previous	O
observation	B-T062
that	O
peripheral	B-T082
inflammatory	B-T033
pain	I-T033
inhibits	O
central	B-T022
nervous	I-T022
system	I-T022
drug	B-T103
uptake	B-T038
;	O
and	O
(	O
c	O
)	O
suggest	O
a	O
novel	O
regulatory	B-T033
mechanism	I-T033
for	O
PgP	B-T038
activity	I-T038
in	O
rat	B-T017
brain	I-T017
.	O

Functional	O
Impairment	O
in	O
Children	O
With	O
Externalizing	B-T038
Behavior	I-T038
Disorders	I-T038
:	O
Psychometric	B-T058
Properties	O
of	O
the	O
Weiss	B-T170
Functional	I-T170
Impairment	I-T170
Rating	I-T170
Scale	I-T170
-	I-T170
Parent	I-T170
Report	I-T170
in	O
a	O
German	B-T082
Clinical	O
Sample	O

To	O
examine	O
the	O
psychometric	B-T058
properties	O
of	O
a	O
German	B-T082
adaptation	O
of	O
the	O
Weiss	B-T170
Functional	I-T170
Impairment	I-T170
Rating	I-T170
Scale	I-T170
-	I-T170
Parent	I-T170
Report	I-T170
(	O
WFIRS	B-T170
-	I-T170
P	I-T170
)	O
in	O
a	O
clinical	O
sample	O
of	O
children	O
(	O
4	O
-	O
12	O
years	O
)	O
with	O
externalizing	B-T038
behavior	I-T038
disorders	I-T038
.	O

Data	O
were	O
collected	O
within	O
two	O
clinical	B-T062
trials	I-T062
(	O
N	O
=	O
264	O
)	O
.	O

Factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
from	O
symptoms	B-T033
of	O
ADHD	B-T038
and	O
oppositional	B-T038
defiant	I-T038
disorder	I-T038
(	O
ODD	B-T038
)	O
were	O
assessed	O
.	O

Confirmatory	O
factor	O
analyses	O
revealed	O
that	O
a	O
bifactor	B-T170
model	I-T170
consistent	O
with	O
the	O
theoretical	O
assumption	O
of	O
a	O
general	B-T170
construct	I-T170
of	O
impairment	O
(	O
total	O
scale	O
)	O
and	O
additional	O
specific	O
factors	O
(	O
subscales	O
)	O
provided	O
satisfactory	O
data	O
fit	O
.	O

Model	B-T170
-	O
based	O
reliability	O
estimates	O
showed	O
that	O
both	O
the	O
general	B-T170
construct	I-T170
and	O
specific	O
factors	O
accounted	O
for	O
item	O
variance	O
.	O

Internal	O
consistencies	O
were	O
>	O
.	O
70	O
,	O
part	O
-	O
whole	O
corrected	O
item	O
-	O
scale	O
correlations	O
mostly	O
>	O
.	O
30	O
.	O

Correlations	O
between	O
the	O
WFIRS	B-T170
-	I-T170
P	I-T170
Scales	I-T170
and	O
ADHD	B-T038
and	O
ODD	B-T038
symptoms	B-T033
were	O
low	O
to	O
moderate	O
.	O

The	O
results	O
support	O
the	O
factorial	O
validity	O
,	O
reliability	O
,	O
and	O
divergent	O
validity	O
of	O
the	O
WFIRS	B-T170
-	I-T170
P	I-T170
.	O

What	O
can	O
the	O
Canadians	B-T098
and	O
Americans	B-T098
learn	B-T038
from	O
each	O
other	O
'	O
s	O
health	B-T092
care	I-T092
systems	I-T092
?	O

Numerous	O
papers	B-T170
have	O
been	O
written	O
comparing	O
the	O
Canadian	B-T098
and	O
US	B-T082
healthcare	B-T092
systems	I-T092
,	O
and	O
a	O
number	O
of	O
health	B-T170
policy	I-T170
experts	B-T097
have	O
recommended	O
that	O
the	O
Americans	B-T098
implement	O
their	O
single	B-T058
-	I-T058
payer	I-T058
system	I-T058
to	O
save	O
12	O
-	O
20	O
%	O
of	O
its	O
healthcare	O
expenditures	O
.	O

This	O
paper	B-T170
is	O
different	O
in	O
that	O
it	O
assumes	O
that	O
neither	O
country	B-T082
will	O
undertake	O
a	O
significant	O
philosophic	O
or	O
structural	B-T082
change	O
in	O
their	O
healthcare	B-T092
system	I-T092
,	O
but	O
there	O
are	O
lessons	O
to	O
be	O
learned	B-T038
that	O
are	O
inherent	O
in	O
one	O
that	O
could	O
be	O
a	O
major	O
breakthrough	O
for	O
the	O
other	O
.	O

Following	O
the	O
model	B-T082
in	O
Canada	B-T082
and	O
in	O
Western	B-T082
Europe	I-T082
,	O
the	O
USA	B-T082
could	O
implement	O
universal	O
health	B-T058
insurance	I-T058
so	O
that	O
the	O
32	O
.	O
0	O
million	O
(	O
2015	O
)	O
Americans	B-T098
still	O
uninsured	B-T098
would	O
have	O
at	O
least	O
minimal	O
coverage	O
when	O
incurring	O
medical	O
expenditures	O
.	O

Also	O
,	O
the	O
USA	B-T082
could	O
use	O
smart	O
cards	O
to	O
evaluate	B-T058
eligibility	I-T058
and	O
to	O
process	O
health	O
insurance	O
claims	O
;	O
these	O
changes	O
resulting	O
in	O
an	O
estimated	O
15	O
%	O
reduction	O
in	O
US	B-T082
health	O
expenditures	O
without	O
adversely	O
effecting	O
access	O
or	O
quality	B-T058
of	I-T058
care	I-T058
.	O

Such	O
a	O
strategy	O
would	O
result	O
in	O
the	O
eventual	O
loss	O
of	O
2	O
.	O
5	O
million	O
white	O
-	O
collar	O
jobs	O
at	O
hospitals	B-T092
,	O
physician	B-T092
offices	I-T092
and	O
insurance	O
companies	O
,	O
a	O
long	O
-	O
term	O
economic	O
gain	O
.	O

Only	O
a	O
few	O
would	O
agree	O
with	O
the	O
statement	O
that	O
Canada	B-T082
already	O
functions	O
with	O
a	O
multi	B-T092
-	I-T092
payer	I-T092
reimbursement	B-T170
system	I-T170
as	O
evidenced	O
by	O
(	O
1	O
)	O
a	O
federal	B-T092
-	O
provincial	B-T082
,	O
tax	O
-	O
supported	O
plan	O
,	O
administered	O
by	O
each	O
of	O
the	O
provinces	B-T082
,	O
providing	O
universal	O
coverage	O
for	O
hospital	B-T092
and	O
physician	B-T058
services	I-T058
and	O
(	O
2	O
)	O
roughly	O
60	O
%	O
of	O
its	O
residents	B-T098
receiving	O
employer	O
-	O
paid	O
health	B-T058
insurance	I-T058
benefits	O
,	O
underwritten	O
primarily	O
by	O
investor	O
-	O
owned	O
plans	O
,	O
that	O
are	O
less	O
than	O
effective	O
to	O
reimburse	O
for	O
pharmaceuticals	B-T058
,	O
dental	B-T058
and	O
other	O
healthcare	B-T058
services	I-T058
.	O

What	O
could	O
be	O
learned	O
from	O
the	O
USA	B-T082
and	O
particularly	O
from	O
Western	B-T082
European	I-T082
countries	I-T082
is	O
possibly	O
implementing	O
an	O
approach	O
,	O
whereby	O
at	O
least	O
upper	O
-	O
income	O
Canadians	B-T098
could	O
opt	O
out	O
of	O
their	O
federal	B-T092
-	O
provincial	B-T082
plan	O
and	O
purchase	O
private	B-T092
insurance	O
coverage	O
-	O
being	O
eligible	O
for	O
far	O
more	O
comprehensive	O
"	O
private	O
"	O
benefits	O
for	O
hospital	B-T092
,	O
physician	B-T058
,	O
pharmaceutical	B-T058
,	O
dental	B-T058
and	O
other	O
healthcare	B-T058
services	I-T058
.	O

Aside	O
from	O
generating	O
billions	O
of	O
additional	O
needed	O
revenues	O
from	O
the	O
private	B-T098
sector	I-T098
,	O
it	O
could	O
(	O
1	O
)	O
help	O
eliminate	O
long	O
waits	O
for	O
non	O
-	O
emergent	O
physicians	O
'	O
care	O
by	O
appointing	O
newly	O
minted	O
specialists	B-T097
to	O
their	O
medical	B-T097
staffs	I-T097
;	O
(	O
2	O
)	O
offer	O
prompt	O
admissions	B-T058
for	O
elective	B-T033
cases	I-T033
to	O
"	O
private	B-T092
"	O
wings	B-T092
of	I-T092
hospitals	I-T092
;	O
(	O
3	O
)	O
increase	O
available	O
funding	O
for	O
what	O
is	O
currently	O
an	O
undercapitalized	B-T033
system	O
;	O
(	O
4	O
)	O
enhance	O
the	O
system	O
'	O
s	O
sluggish	B-T033
operations	O
;	O
and	O
(	O
5	O
)	O
encourage	O
more	O
competition	O
among	O
various	O
providers	O
.	O

Although	O
such	O
a	O
two	B-T170
-	I-T170
tier	I-T170
approach	I-T170
,	O
such	O
as	O
available	O
in	O
the	O
USA	B-T082
and	O
elsewhere	O
,	O
is	O
politically	O
dead	O
on	O
arrival	O
in	O
Canada	B-T082
today	O
,	O
private	O
insurance	O
being	O
already	O
legal	O
and	O
commonly	O
available	O
there	O
.	O

Interestingly	O
,	O
this	O
recommended	O
solution	O
is	O
utilized	O
in	O
most	O
western	B-T082
European	I-T082
countries	I-T082
where	O
there	O
is	O
a	O
higher	O
percentagea	O
than	O
in	O
Canada	B-T082
of	O
public	B-T092
(	O
versus	O
private	O
)	O
funding	O
of	O
their	O
total	O
health	O
expenditures	O
.	O

Because	O
of	O
various	O
vested	O
interests	O
,	O
attempts	O
to	O
implement	O
any	O
of	O
the	O
aforementioned	O
proposals	O
will	O
undoubtedly	O
result	O
in	O
considerable	O
political	O
rancor	B-T038
.	O

There	O
is	O
greater	O
likelihood	O
,	O
however	O
,	O
that	O
the	O
Canadians	B-T098
because	O
their	O
need	O
to	O
be	O
more	O
effective	O
and	O
efficient	O
in	O
their	O
delivery	B-T058
of	I-T058
care	I-T058
,	O
and	O
their	O
overall	O
long	O
-	O
term	O
fiscal	O
outlook	O
will	O
agree	B-T033
to	O
the	O
further	O
privatization	O
of	O
their	O
healthcare	B-T092
system	I-T092
before	O
the	O
Americans	B-T098
will	O
mandate	O
universal	O
access	O
,	O
use	O
the	O
smart	O
card	O
to	O
process	O
insurance	O
eligibility	O
and	O
claims	O
or	O
will	O
impose	O
price	O
controls	O
on	O
high	O
-	O
tech	O
services	O
and	O
on	O
pharmaceuticals	B-T103
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Optimal	O
Duration	O
of	O
Coronary	B-T058
Ligation	I-T058
and	O
Reperfusion	B-T058
for	O
Reperfusion	B-T037
Injury	I-T037
Study	B-T062
in	O
a	O
Rat	B-T204
Model	O

Reperfusion	B-T037
injury	I-T037
(	O
RI	B-T037
)	O
has	O
an	O
important	O
impact	O
on	O
the	O
clinical	O
prognosis	B-T201
for	O
patients	O
with	O
acute	O
myocardial	O
injury	O
who	O
had	O
their	O
coronary	B-T082
blood	B-T038
flow	I-T038
reestablished	O
.	O

However	O
,	O
no	O
studies	B-T062
to	O
date	O
have	O
investigated	O
the	O
timeframe	O
of	O
coronary	B-T038
occlusion	I-T038
and	O
reperfusion	B-T058
effects	O
on	O
RI	B-T037
.	O

A	O
total	O
of	O
100	O
rats	B-T204
were	O
divided	O
into	O
4	O
groups	O
based	O
on	O
the	O
coronary	B-T058
ligation	I-T058
period	O
:	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
,	O
and	O
each	O
group	O
was	O
further	O
divided	O
into	O
5	O
subgroups	O
with	O
different	O
reperfusion	B-T058
periods	O
:	O
0	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
180	O
min	O
.	O

R0	O
was	O
the	O
baseline	O
of	O
each	O
subgroup	O
.	O

All	O
animals	B-T204
received	O
the	O
same	O
protocols	B-T170
for	O
designed	O
ligation	B-T058
and	O
reperfusion	B-T058
periods	O
.	O

Evans	B-T103
blue	I-T103
and	O
2	B-T103
,	I-T103
3	I-T103
,	I-T103
5	I-T103
-	I-T103
triphenyltetrazolium	I-T103
chloride	I-T103
were	O
used	O
to	O
distinguish	O
different	O
myocardial	O
injury	O
areas	B-T082
:	O
area	B-T082
at	O
risk	O
(	O
AAR	B-T082
)	O
and	O
myocardial	B-T038
necrosis	I-T038
.	O

The	O
differences	O
of	O
the	O
ratios	O
of	O
the	O
necrotic	B-T038
area	B-T082
to	O
AAR	B-T082
between	O
each	O
subgroup	O
and	O
baseline	O
were	O
further	O
averaged	O
to	O
calculate	O
an	O
overall	O
value	O
of	O
each	O
heart	B-T017
.	O

The	O
relative	O
RI	B-T037
percentages	O
showed	O
significant	O
differences	O
(	O
0	O
.	O
8	O
±	O
2	O
.	O
3	O
%	O
,	O
4	O
.	O
9	O
±	O
3	O
.	O
3	O
%	O
,	O
10	O
.	O
8	O
±	O
3	O
.	O
1	O
%	O
,	O
and	O
20	O
.	O
3	O
±	O
3	O
.	O
6	O
%	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
at	O
different	O
time	O
points	O
of	O
reperfusion	B-T058
but	O
not	O
at	O
different	O
time	O
points	O
of	O
ligation	B-T058
(	O
p	O
=	O
0	O
.	O
593	O
)	O
.	O

The	O
effects	O
of	O
different	O
time	O
courses	O
in	O
RI	B-T037
showed	O
that	O
the	O
L120R180	O
group	O
(	O
43	O
.	O
4	O
±	O
2	O
.	O
3	O
%	O
)	O
had	O
the	O
highest	O
RI	B-T037
difference	O
with	O
the	O
baseline	O
group	O
.	O

Maximal	O
RI	B-T037
occurred	O
at	O
the	O
timeframe	O
of	O
L120R180	O
in	O
our	O
animal	O
model	O
.	O

This	O
result	O
may	O
be	O
utilized	O
to	O
assess	O
the	O
substantial	O
benefits	O
of	O
RI	B-T058
therapies	I-T058
in	O
an	O
experimental	B-T038
rat	I-T038
model	I-T038
setting	O
.	O

Derivation	O
of	O
a	O
Predictive	O
Score	O
for	O
Hemorrhagic	B-T038
Progression	O
of	O
Cerebral	B-T037
Contusions	I-T037
in	O
Moderate	O
and	O
Severe	O
Traumatic	O
Brain	O
Injury	O

After	O
traumatic	B-T037
brain	I-T037
injury	I-T037
(	O
TBI	B-T037
)	O
,	O
hemorrhagic	B-T038
progression	O
of	O
contusions	B-T037
(	O
HPCs	B-T037
)	O
occurs	O
frequently	O
.	O

However	O
,	O
there	O
is	O
no	O
established	O
predictive	O
score	O
to	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
for	O
HPC	B-T037
.	O

Consecutive	O
patients	O
who	O
were	O
hospitalized	B-T033
(	O
2008	O
-	O
2013	O
)	O
with	O
non	O
-	O
penetrating	O
moderate	O
or	O
severe	O
TBI	O
were	O
studied	O
.	O

The	O
primary	O
outcome	O
was	O
HPC	B-T037
,	O
defined	O
by	O
both	O
a	O
relative	O
increase	O
in	O
contusion	B-T037
volume	O
by	O
≥30	O
%	O
and	O
an	O
absolute	O
increase	O
by	O
≥10	O
mL	O
on	O
serial	O
imaging	O
.	O

Logistic	B-T170
regression	I-T170
models	I-T170
were	O
created	O
to	O
identify	O
independent	O
risk	B-T033
factors	I-T033
for	O
HPC	B-T037
.	O

The	O
HPC	B-T037
Score	O
was	O
then	O
derived	O
based	O
on	O
the	O
final	B-T170
model	I-T170
.	O

Among	O
a	O
total	O
of	O
286	O
eligible	O
patients	O
,	O
61	O
(	O
21	O
%	O
)	O
patients	O
developed	O
HPC	B-T037
.	O

On	O
univariate	O
analyses	O
,	O
HPC	B-T037
was	O
associated	O
with	O
older	O
age	O
,	O
higher	B-T033
initial	I-T033
blood	I-T033
pressure	I-T033
,	O
antiplatelet	B-T103
medications	I-T103
,	O
anticoagulants	B-T103
,	O
subarachnoid	B-T038
hemorrhage	I-T038
(	O
SAH	B-T038
)	O
subdural	B-T038
hematoma	I-T038
(	O
SDH	B-T038
)	O
,	O
skull	B-T037
fracture	I-T037
,	O
frontal	B-T017
contusion	B-T037
,	O
larger	O
contusion	B-T037
volume	O
,	O
and	O
shorter	O
interval	O
from	O
injury	B-T037
to	O
initial	B-T058
CT	I-T058
.	O

In	O
the	O
final	B-T170
model	I-T170
,	O
SAH	B-T038
(	O
OR	O
6	O
.	O
33	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
80	O
-	O
22	O
.	O
23	O
)	O
,	O
SDH	B-T038
(	O
OR	O
3	O
.	O
46	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
39	O
-	O
8	O
.	O
63	O
)	O
,	O
and	O
skull	B-T037
fracture	I-T037
(	O
OR	O
2	O
.	O
67	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
28	O
-	O
5	O
.	O
58	O
)	O
were	O
associated	O
with	O
HPC	B-T037
.	O

Based	O
on	O
these	O
factors	O
,	O
the	O
HPC	B-T037
Score	O
was	O
derived	O
(	O
SAH	B-T038
=	O
2	O
points	O
,	O
SDH	B-T038
=	O
1	O
point	O
,	O
and	O
skull	B-T037
fracture	I-T037
=	O
1	O
point	O
)	O
.	O

This	O
score	O
had	O
an	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
of	O
0	O
.	O
77	O
.	O

Patients	O
with	O
a	O
score	O
of	O
0	O
-	O
2	O
had	O
a	O
4	O
.	O
0	O
%	O
incidence	O
of	O
HPC	B-T037
,	O
while	O
patients	O
with	O
a	O
score	O
of	O
3	O
-	O
4	O
had	O
a	O
34	O
.	O
6	O
%	O
incidence	O
of	O
HPC	B-T037
.	O

A	O
simple	O
HPC	B-T037
Score	O
was	O
developed	O
for	O
early	O
risk	O
stratification	O
of	O
HPC	B-T037
in	O
patients	O
with	O
moderate	O
or	O
severe	O
TBI	O
.	O

Expressing	O
sexuality	O
in	O
nursing	B-T092
homes	I-T092
.	O
The	O
experience	O
of	O
older	B-T098
women	I-T098
:	O
A	O
qualitative	B-T062
study	I-T062

In	O
nursing	B-T092
homes	I-T092
,	O
a	O
number	O
of	O
barriers	O
to	O
the	O
expression	O
of	O
sexuality	O
exist	O
,	O
such	O
as	O
the	O
lack	B-T033
of	I-T033
privacy	I-T033
,	O
certain	O
attitudes	B-T038
on	O
behalf	O
of	O
the	O
staff	B-T097
and	O
the	O
family	O
,	O
the	O
lack	O
of	O
a	O
sexual	B-T098
partner	I-T098
,	O
and	O
physical	B-T033
limitations	I-T033
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
describe	O
the	O
lived	O
experience	O
of	O
sexuality	O
in	O
elderly	B-T098
Spanish	I-T098
women	I-T098
residing	O
in	O
nursing	B-T092
homes	I-T092
.	O

A	O
qualitative	B-T062
phenomenological	I-T062
approach	I-T062
was	O
followed	O
.	O

Data	O
were	O
collected	B-T062
over	O
an	O
18	O
-	O
month	O
period	O
between	O
2013	O
and	O
2015	O
.	O

Purposeful	O
sampling	O
was	O
conducted	O
with	O
Spanish	B-T098
residents	I-T098
in	O
nursing	B-T092
homes	I-T092
in	O
Madrid	B-T082
.	O

Data	O
were	O
collected	O
using	O
unstructured	O
and	O
semi	O
-	O
structured	O
interviews	O
.	O

The	O
data	O
were	O
analyzed	B-T062
using	O
thematic	B-T062
analysis	I-T062
.	O

Twenty	O
female	O
residents	B-T098
participated	O
.	O

Three	O
main	O
themes	O
emerged	O
from	O
the	O
data	O
:	O
a	O
)	O
expressing	O
sexuality	O
,	O
b	O
)	O
sexuality	O
as	O
a	O
duty	B-T058
and	O
c	O
)	O
respecting	O
vows	O
.	O

Female	O
residents	B-T098
reported	O
key	O
elements	O
influencing	O
how	O
they	O
manage	O
their	O
sexuality	O
in	O
Nursing	B-T092
Homes	I-T092
.	O

These	O
results	O
serve	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
expression	O
of	O
sexuality	O
in	O
older	O
female	O
nursing	B-T092
home	I-T092
residents	B-T098
.	O

Xylan	B-T103
-	I-T103
based	I-T103
temperature	O
/	O
pH	O
sensitive	O
hydrogels	B-T103
for	O
drug	B-T103
controlled	I-T103
release	I-T103

Xylan	B-T103
-	I-T103
based	I-T103
temperature	O
/	O
pH	O
sensitive	O
hydrogels	B-T103
were	O
prepared	O
by	O
the	O
crosslinking	B-T038
copolymerization	I-T038
of	O
xylan	B-T103
with	O
N	B-T103
-	I-T103
isopropylacrylamide	I-T103
(	O
NIPAm	B-T103
)	O
and	O
acrylic	B-T103
acid	I-T103
(	O
AA	B-T103
)	O
using	O
N	B-T103
,	I-T103
Ń	I-T103
-	I-T103
methylenebis	I-T103
-	I-T103
acrylamide	I-T103
(	O
MBA	B-T103
)	O
as	O
a	O
cross	B-T103
-	I-T103
linker	I-T103
and	O
2	B-T103
,	I-T103
2	I-T103
-	I-T103
dimethoxy	I-T103
-	I-T103
2	I-T103
-	I-T103
phenylacetophenone	I-T103
as	O
a	O
photoinitiator	B-T103
via	O
ultraviolet	O
irradiation	O
.	O

The	O
influence	O
of	O
the	O
NIPAm	B-T103
,	O
AA	B-T103
and	O
MBA	B-T103
amount	O
on	O
properties	O
of	O
xylan	B-T103
-	I-T103
based	I-T103
hydrogels	B-T103
was	O
discussed	O
.	O

The	O
morphology	O
and	O
interactions	O
of	O
hydrogels	B-T103
were	O
characterized	O
by	O
SEM	B-T058
and	O
FTIR	B-T062
.	O

The	O
lower	O
critical	O
solution	O
temperature	O
(	O
LCST	O
)	O
of	O
hydrogels	B-T103
was	O
investigated	O
by	O
DSC	B-T058
.	O

The	O
results	O
indicated	O
that	O
the	O
LCST	O
of	O
hydrogels	B-T103
emerged	O
at	O
around	O
34°C	O
and	O
increased	O
with	O
increasing	O
the	O
AA	B-T103
content	O
.	O

The	O
drug	B-T103
encapsulation	O
efficiency	O
of	O
as	O
-	O
prepared	O
hydrogels	B-T103
reached	O
to	O
97	O
.	O
60	O
%	O
and	O
the	O
cumulative	O
release	O
rate	O
of	O
acetylsalicylic	B-T103
acid	I-T103
was	O
90	O
.	O
12	O
%	O
and	O
26	O
.	O
35	O
%	O
in	O
the	O
intestinal	B-T017
and	O
gastric	B-T031
fluid	I-T031
,	O
respectively	O
.	O

Xylan	B-T103
-	I-T103
based	I-T103
hydrogels	B-T103
were	O
proved	O
to	O
be	O
biocompatible	O
with	O
NIH3T3	B-T017
cell	I-T017
by	O
MTT	B-T062
assay	I-T062
and	O
showed	O
the	O
promising	O
application	O
as	O
drug	B-T103
carriers	I-T103
for	O
the	O
intestinal	B-T017
-	O
targeted	O
oral	B-T058
drug	I-T058
delivery	I-T058
.	O

Isolation	B-T058
and	O
prebiotic	B-T103
activity	O
of	O
water	O
-	O
soluble	O
polysaccharides	B-T103
fractions	O
from	O
the	O
bamboo	B-T168
shoots	I-T168
(	O
Phyllostachys	B-T204
praecox	I-T204
)	O

The	O
water	O
-	O
soluble	O
polysaccharides	B-T103
from	O
bamboo	B-T168
shoots	I-T168
(	O
Phyllostachys	B-T204
praecox	I-T204
)	O
(	O
WBP	B-T103
)	O
were	O
isolated	O
,	O
and	O
the	O
characterizations	B-T170
as	O
well	O
as	O
prebiotic	B-T103
activities	O
were	O
investigated	O
.	O

The	O
yield	O
of	O
WBP	B-T103
was	O
7	O
.	O
58±0	O
.	O
31	O
%	O
under	O
optimal	O
hot	B-T103
-	I-T103
water	I-T103
extraction	B-T058
conditions	O
.	O

Two	O
fractions	O
,	O
i	O
.	O
e	O
.	O
,	O
WBP	B-T103
-	I-T103
1	I-T103
and	O
WBP	B-T103
-	I-T103
2	I-T103
with	O
molecular	O
weight	O
of	O
83	O
.	O
50kDa	O
and	O
80	O
.	O
08kDa	O
,	O
respectively	O
,	O
were	O
purified	O
by	O
chromatography	B-T058
.	O

Both	O
the	O
polysaccharides	B-T103
fractions	O
were	O
identified	O
as	O
heteropolysaccharides	B-T103
-	I-T103
protein	I-T103
complexes	I-T103
composed	O
of	O
15	O
kinds	O
of	O
common	O
amino	B-T103
acids	I-T103
in	O
protein	B-T103
part	O
and	O
rhamnose	B-T103
,	O
arabinose	B-T103
,	O
xylose	B-T103
,	O
mannose	B-T103
,	O
glucose	B-T103
and	O
galactose	B-T103
in	O
different	O
molar	O
ratios	O
in	O
polysaccharide	B-T103
part	O
.	O

The	O
existence	O
of	O
α	O
-	O
and	O
β	O
-	O
glycosidic	O
linkages	O
between	O
the	O
sugar	B-T103
units	O
was	O
confirmed	O
by	O
FTIR	B-T062
and	O
NMR	B-T058
spectra	I-T058
.	O

Compared	O
with	O
the	O
blank	O
control	O
and	O
the	O
reference	O
of	O
FOS	O
,	O
WBP	B-T103
-	I-T103
1	I-T103
and	O
WBP	B-T103
-	I-T103
2	I-T103
significantly	O
increased	O
the	O
numbers	O
of	O
Bifidobacterium	B-T007
adolescentis	I-T007
and	O
Bifidobacterium	B-T007
bifidum	I-T007
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
which	O
contributed	O
to	O
the	O
production	O
of	O
organic	B-T103
acids	I-T103
,	O
suggesting	O
that	O
the	O
polysaccharides	B-T103
have	O
potential	O
prebiotic	B-T103
properties	O
.	O

Evaluation	O
of	O
nutraceutical	B-T033
and	O
antinutritional	B-T033
properties	I-T033
in	O
barnyard	B-T204
and	O
finger	B-T168
millet	I-T168
varieties	O
grown	O
in	O
Himalayan	O
region	O

Five	O
elite	O
varieties	O
of	O
barnyard	B-T204
(	O
Echinochloa	B-T204
frumentacea	I-T204
)	O
and	O
finger	B-T204
(	O
Eleusine	B-T204
coracana	I-T204
)	O
growing	O
at	O
northwestern	O
Himalaya	O
were	O
investigated	O
for	O
nutraceutical	B-T033
and	O
antinutritional	B-T033
properties	I-T033
.	O

Barnyard	B-T168
millet	I-T168
contained	O
higher	O
amount	O
of	O
crude	B-T103
fiber	I-T103
,	O
total	B-T168
dietary	I-T168
fiber	I-T168
,	O
tryptophan	B-T103
content	O
,	O
total	B-T103
carotenoids	I-T103
,	O
α	B-T103
-	I-T103
tocopherol	I-T103
compared	O
to	O
the	O
finger	B-T168
millet	I-T168
whereas	O
the	O
finger	B-T168
millet	I-T168
contains	O
higher	O
amount	O
of	O
methionine	B-T103
and	O
ascorbic	B-T103
acid	I-T103
as	O
compared	O
to	O
the	O
barnyard	B-T168
millet	I-T168
.	O

The	O
secondary	B-T103
metabolites	I-T103
of	O
biological	B-T038
functions	I-T038
were	O
analyzed	O
and	O
found	O
that	O
barnyard	B-T168
millet	I-T168
contained	O
the	O
higher	O
amount	O
of	O
polyphenols	B-T103
,	O
tannins	B-T103
and	O
ortho	B-T103
-	I-T103
dihydroxy	I-T103
phenol	I-T103
content	O
compared	O
to	O
finger	B-T168
millet	I-T168
.	O

Among	O
antinutitional	B-T103
compounds	I-T103
barnyard	B-T168
millet	I-T168
contained	O
lower	O
phytic	B-T103
acid	I-T103
content	O
compare	O
to	O
finger	B-T168
millet	I-T168
whereas	O
no	O
significant	O
difference	O
in	O
trypsin	B-T038
inhibition	I-T038
activity	I-T038
of	O
barnyard	B-T168
millet	I-T168
and	O
finger	B-T168
millet	I-T168
varieties	O
were	O
found	O
.	O

Barnyard	B-T168
millet	I-T168
contained	O
higher	O
acid	B-T103
phosphatase	I-T103
,	O
α	B-T103
-	I-T103
galactosidase	I-T103
and	O
α	B-T038
-	I-T038
amylase	I-T038
inhibitor	I-T038
activity	I-T038
compared	O
to	O
finger	B-T168
millet	I-T168
.	O

Finger	B-T168
millet	I-T168
seeds	I-T168
contained	O
about	O
10	O
-	O
13	O
folds	O
higher	O
calcium	B-T103
content	O
and	O
double	O
amount	O
of	O
manganese	B-T103
content	O
in	O
comparison	O
to	O
barnyard	B-T168
millet	I-T168
seeds	I-T168
.	O

Present	O
study	O
suggests	O
that	O
barnyard	B-T168
millet	I-T168
varieties	O
studied	O
under	O
present	O
investigation	O
were	O
found	O
nutritionally	O
superior	O
compared	O
to	O
finger	B-T168
millet	I-T168
varieties	O
.	O

Polymorphisms	B-T082
in	O
Inflammatory	O
Mediator	B-T017
Genes	I-T017
and	O
Risk	O
of	O
Preeclampsia	B-T038
in	O
Taiyuan	O
,	O
China	B-T082

Excessive	O
maternal	B-T033
inflammatory	B-T038
response	I-T038
is	O
involved	O
in	O
the	O
pathogenesis	B-T038
of	O
preeclampsia	B-T038
.	O

Few	O
epidemiologic	B-T062
studies	I-T062
have	O
investigated	O
the	O
associations	O
between	O
genetic	O
variations	O
in	O
the	O
inflammatory	O
mediator	B-T017
genes	I-T017
and	O
preeclampsia	B-T038
risk	O
,	O
and	O
these	O
studies	B-T062
have	O
reached	O
inconsistent	O
results	O
.	O

We	O
examined	O
31	O
single	B-T082
-	I-T082
nucleotide	I-T082
polymorphisms	I-T082
in	O
IL	B-T017
-	I-T017
1A	I-T017
,	O
IL	B-T017
-	I-T017
1B	I-T017
,	O
IL	B-T103
-	I-T103
1R1	I-T103
,	O
IL	B-T103
-	I-T103
2RA	I-T103
,	O
IL	B-T103
-	I-T103
5RA	I-T103
,	O
IL	B-T017
-	I-T017
6	I-T017
,	O
IL	B-T103
-	I-T103
6R	I-T103
,	O
TNFSF11	B-T017
,	O
TNFRSF11A	B-T017
,	O
IL	B-T017
-	I-T017
28RA	I-T017
,	O
IRAK4	B-T017
,	O
and	O
KIT	B-T017
genes	I-T017
and	O
the	O
risk	O
of	O
preeclampsia	B-T038
and	O
its	O
clinical	O
subtypes	B-T170
in	O
a	O
nested	B-T062
case	I-T062
-	I-T062
control	I-T062
study	I-T062
including	O
203	O
preeclampsia	B-T038
cases	O
and	O
233	O
controls	O
.	O

We	O
found	O
that	O
IL	B-T103
-	I-T103
1R1	I-T103
,	O
IL	B-T103
-	I-T103
5RA	I-T103
,	O
IL	B-T103
-	I-T103
6R	I-T103
,	O
and	O
TNFSF11	B-T017
were	O
associated	O
with	O
the	O
risk	O
of	O
preeclampsia	B-T038
.	O

Although	O
the	O
significant	O
associations	O
observed	O
for	O
preeclampsia	B-T038
overall	O
were	O
mainly	O
seen	O
for	O
late	O
-	O
onset	O
preeclampsia	B-T038
and	O
severe	O
preeclampsia	B-T038
,	O
IL	B-T103
-	I-T103
6R	I-T103
(	O
rs2229238	B-T170
)	O
and	O
TNFSF11	B-T017
(	O
rs9525643	B-T170
)	O
polymorphisms	B-T082
were	O
associated	O
with	O
the	O
risk	O
of	O
early	O
-	O
onset	O
preeclampsia	B-T038
.	O

TNFSF11	B-T017
(	O
rs2200287	B-T170
and	O
rs2148072	B-T170
)	O
polymorphisms	B-T082
were	O
associated	O
with	O
risk	O
of	O
mild	O
preeclampsia	B-T038
.	O

Our	O
study	B-T062
provided	O
the	O
first	O
evidence	O
that	O
genetic	O
variations	O
in	O
inflammatory	O
mediator	B-T017
genes	I-T017
IL	B-T103
-	I-T103
1R1	I-T103
,	O
IL	B-T103
-	I-T103
6R	I-T103
,	O
TNFSF11	B-T017
,	O
and	O
IL	B-T103
-	I-T103
5RA	I-T103
were	O
associated	O
with	O
preeclampsia	B-T038
risk	O
,	O
and	O
the	O
risk	O
varied	O
by	O
preeclampsia	B-T038
subtypes	B-T170
.	O

A	O
closer	O
look	O
at	O
school	B-T092
bonding	B-T038
among	O
African	B-T098
American	I-T098
adolescents	O
in	O
low	B-T098
-	I-T098
income	I-T098
communities	I-T098
:	O
A	O
latent	B-T062
class	I-T062
analysis	I-T062

Positive	B-T033
school	B-T092
bonding	B-T038
is	O
a	O
significant	O
precursor	O
to	O
students	B-T098
'	O
school	B-T092
success	O
.	O

However	O
,	O
African	B-T098
American	I-T098
youth	O
report	O
lower	O
school	B-T092
success	O
compared	O
with	O
their	O
White	B-T098
counterparts	I-T098
.	O

This	O
study	B-T062
examined	O
correlates	O
of	O
school	B-T092
bonding	B-T038
among	O
633	O
African	B-T098
American	I-T098
youth	O
who	O
were	O
recruited	O
from	O
community	O
settings	O
in	O
Chicago	B-T082
.	O

Major	O
findings	B-T033
indicated	O
that	O
negative	B-T033
peer	I-T033
norms	I-T033
,	O
exposure	O
to	O
community	O
violence	O
,	O
and	O
poor	O
mental	B-T038
health	I-T038
were	O
negatively	B-T033
correlated	O
with	O
school	B-T092
bonding	B-T038
,	O
while	O
parental	O
monitoring	O
,	O
positive	O
self	O
-	O
regard	O
,	O
and	O
future	O
orientation	B-T038
were	O
correlated	O
with	O
higher	O
school	B-T092
motivation	B-T038
.	O

Students	B-T098
classified	B-T170
as	O
having	O
high	O
or	O
moderate	O
school	B-T092
bonding	B-T038
were	O
more	O
likely	O
to	O
live	O
with	O
both	O
parents	O
,	O
experience	B-T038
higher	O
levels	O
of	O
parental	O
monitoring	O
,	O
and	O
exhibit	O
positive	O
self	O
-	O
regard	O
.	O

Implications	O
are	O
discussed	O
in	O
view	O
of	O
these	O
findings	B-T033
.	O

DEPRESSION	B-T038
,	O
ANXIETY	B-T038
,	O
STRESS	B-T038
,	O
AND	O
THEIR	O
ASSOCIATED	O
FACTORS	O
AMONG	O
CORPS	B-T098
MEMBERS	I-T098
SERVING	O
IN	O
KEBBI	O
STATE	O

Depression	B-T038
,	O
anxiety	B-T038
and	O
stress	B-T038
,	O
are	O
not	O
only	O
health	B-T033
problems	I-T033
by	O
themselves	O
,	O
but	O
also	O
associated	O
with	O
other	O
negative	B-T033
health	O
consequences	O
.	O

The	O
national	B-T092
youth	I-T092
service	I-T092
is	O
usually	O
characterized	O
by	O
a	O
number	O
of	O
new	O
challenges	O
and	O
experiences	B-T038
which	O
may	O
require	O
life	O
style	O
adjustments	O
by	O
the	O
corps	B-T098
member	I-T098
.	O

However	O
,	O
no	O
previous	O
study	O
on	O
psychological	B-T038
factors	I-T038
has	O
been	O
conducted	O
among	O
corps	B-T098
members	I-T098
.	O

This	O
study	B-T062
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
depression	B-T038
,	O
anxiety	B-T038
and	O
,	O
stress	B-T038
and	O
their	O
associated	O
factors	O
among	O
corps	B-T098
members	I-T098
serving	O
in	O
Kebbi	O
state	O
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
was	O
conducted	O
among	O
264	O
corps	B-T098
members	I-T098
from	O
four	O
local	O
government	O
areas	O
of	O
the	O
state	B-T082
.	O

Selection	O
of	O
the	O
local	O
government	O
areas	O
and	O
the	O
individual	O
participants	B-T098
was	O
by	O
simple	B-T062
random	I-T062
sampling	I-T062
.	O

Data	O
was	O
collected	O
from	O
May	O
to	O
June	O
2014	O
using	O
a	O
self	B-T170
-	I-T170
administered	I-T170
questionnaire	I-T170
.	O

Data	O
analysis	O
used	O
chi	B-T170
-	I-T170
square	I-T170
test	I-T170
to	O
identify	O
the	O
relationship	O
between	O
categorical	O
variables	O
and	O
multivariate	B-T062
logistic	I-T062
regression	I-T062
to	O
identify	O
the	O
independent	O
factors	O
for	O
depression	B-T038
,	O
anxiety	B-T038
and	O
stress	B-T038
each	O
.	O

The	O
response	O
rate	O
was	O
97	O
%	O
.	O

Most	O
of	O
the	O
respondents	B-T098
were	O
males	O
(	O
63	O
.	O
6	O
%	O
)	O
,	O
single	B-T098
(	O
85	O
.	O
5	O
%	O
)	O
,	O
and	O
above	O
20	O
years	O
of	O
age	O
(	O
71	O
.	O
6	O
%	O
)	O
.	O

The	O
overall	O
prevalences	O
of	O
depression	B-T038
,	O
anxiety	B-T038
and	O
stress	B-T038
among	O
the	O
respondents	B-T098
were	O
36	O
.	O
4	O
%	O
,	O
54	O
.	O
5	O
%	O
and	O
18	O
.	O
2	O
%	O
respectively	O
.	O

The	O
independent	O
factors	O
for	O
depression	B-T038
were	O
;	O
being	O
from	O
the	O
North	B-T082
central	I-T082
(	O
OR	O
=	O
5	O
.	O
99	O
;	O
95	O
%	O
CI	O
:	O
2	O
.	O
194	O
-	O
16	O
.	O
354	O
)	O
or	O
South	B-T082
-	I-T082
south	I-T082
;	O
and	O
the	O
perception	B-T038
of	O
earning	O
enough	O
income	O
(	O
OR	O
=	O
2	O
.	O
987	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
062	O
-	O
8	O
.	O
400	O
)	O
.	O

For	O
anxiety	B-T038
,	O
male	O
gender	O
(	O
OR	O
=	O
0	O
.	O
411	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
169	O
-	O
0	O
.	O
999	O
)	O
;	O
and	O
being	O
from	O
the	O
North	B-T082
central	I-T082
were	O
significant	O
risk	B-T033
factors	I-T033
(	O
OR	O
=	O
3	O
.	O
731	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
450	O
-	O
9	O
.	O
599	O
)	O
.	O

Being	O
above	O
26	O
years	O
of	O
age	O
was	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
stress	B-T038
(	O
OR	O
=	O
0	O
.	O
083	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
018	O
-	O
0	O
.	O
381	O
)	O
.	O

Also	O
,	O
those	O
who	O
had	O
ever	O
schooled	B-T033
outside	O
their	O
towns	O
of	O
residence	B-T082
were	O
less	O
likely	O
to	O
be	O
stressed	B-T038
compared	O
to	O
those	O
who	O
had	O
never	O
(	O
OR	O
=	O
0	O
.	O
30	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
110	O
-	O
0	O
.	O
855	O
)	O
.	O

All	O
other	O
factors	O
did	O
not	O
show	O
any	O
significant	O
association	O
with	O
any	O
of	O
the	O
outcome	O
variables	O
in	O
multivariate	O
analysis	O
.	O

In	O
conclusion	O
,	O
the	O
prevalences	O
of	O
depression	B-T038
,	O
anxiety	B-T038
and	O
stress	B-T038
are	O
high	O
among	O
corps	B-T098
members	I-T098
serving	O
in	O
Kebbi	O
state	O
.	O

There	O
is	O
need	O
to	O
expand	O
the	O
scope	O
of	O
this	O
study	B-T062
to	O
a	O
national	O
level	O
so	O
as	O
to	O
get	O
a	O
bigger	O
picture	O
of	O
the	O
problem	B-T033
.	O

Trans	B-T082
-	I-T082
oral	I-T082
fine	O
needle	O
aspiration	O
cytology	O
in	O
cervical	B-T017
(	I-T017
C1	I-T017
and	I-T017
C2	I-T017
)	I-T017
vertebral	I-T017
lesions	B-T033
:	O
a	O
novel	O
diagnostic	B-T058
approach	I-T058

Fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
cytology	O
is	O
a	O
relatively	O
non	O
-	O
invasive	O
method	O
for	O
diagnosing	B-T033
both	O
superficial	B-T033
and	O
deep	B-T038
-	I-T038
seated	I-T038
neoplastic	I-T038
and	O
non	B-T033
-	I-T033
neoplastic	I-T033
lesions	I-T033
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
diagnostic	O
utility	O
of	O
trans	B-T082
-	I-T082
oral	I-T082
FNA	O
in	O
cervical	B-T017
(	I-T017
C1	I-T017
and	I-T017
C2	I-T017
)	I-T017
vertebral	I-T017
and	O
paravertebral	B-T082
lesions	B-T033
.	O

Eighteen	O
FNA	O
cases	O
of	O
cervical	B-T017
vertebral	I-T017
and	O
paravertebral	B-T082
lesions	B-T033
performed	O
by	O
a	O
trans	B-T082
-	I-T082
oral	I-T082
route	I-T082
without	O
any	O
image	O
-	O
guidance	O
between	O
1995	O
and	O
2014	O
were	O
retrieved	O
from	O
the	O
archives	O
of	O
the	O
cytology	B-T091
department	B-T092
at	O
PGIMER	B-T092
,	O
Chandigarh	O
and	O
reviewed	O
.	O

Out	O
of	O
18	O
cases	O
,	O
a	O
definite	O
diagnosis	B-T033
was	O
given	O
in	O
15	O
cases	O
(	O
83	O
.	O
3	O
%	O
)	O
.	O

The	O
commonest	O
diagnosis	B-T033
seen	O
was	O
granulomatous	B-T038
inflammation	I-T038
consistent	O
with	O
tuberculosis	B-T038
(	O
33	O
.	O
3	O
%	O
)	O
.	O

Trans	B-T082
-	I-T082
oral	I-T082
FNA	O
is	O
a	O
quick	O
,	O
inexpensive	O
and	O
relatively	O
safe	O
outpatient	B-T058
procedure	I-T058
for	O
sampling	O
C1	B-T017
and	I-T017
C2	I-T017
vertebral	I-T017
and	O
paravertebral	B-T082
lesions	B-T033
,	O
which	O
are	O
clinically	O
and	O
radiologically	B-T091
difficult	O
to	O
approach	O
.	O

It	O
helps	O
in	O
the	O
early	B-T058
diagnosis	I-T058
and	O
management	B-T058
of	I-T058
these	I-T058
patients	I-T058
.	O

Neonatal	B-T038
infections	I-T038
:	O
Case	B-T170
definition	I-T170
and	O
guidelines	B-T170
for	O
data	B-T062
collection	I-T062
,	O
analysis	B-T062
,	O
and	O
presentation	O
of	O
immunisation	B-T058
safety	O
data	O

Maternal	B-T033
vaccination	B-T058
is	O
an	O
important	O
area	O
of	O
research	B-T062
and	O
requires	O
appropriate	O
and	O
internationally	O
comparable	O
definitions	B-T170
and	O
safety	B-T170
standards	I-T170
.	O

The	O
GAIA	B-T097
group	I-T097
,	O
part	O
of	O
the	O
Brighton	B-T097
Collaboration	I-T097
was	O
created	O
with	O
the	O
mandate	O
of	O
proposing	O
standardised	O
definitions	B-T170
applicable	O
to	O
maternal	B-T033
vaccine	B-T103
research	B-T062
.	O

This	O
study	B-T062
proposes	O
international	O
definitions	B-T170
for	O
neonatal	B-T038
infections	I-T038
.	O

The	O
neonatal	B-T038
infections	I-T038
GAIA	B-T097
working	B-T098
group	I-T098
performed	O
a	O
literature	B-T170
review	O
using	O
Medline	B-T170
,	O
EMBASE	B-T170
and	O
the	O
Cochrane	O
collaboration	O
and	O
collected	O
definitions	B-T170
in	O
use	O
in	O
neonatal	O
and	O
public	O
health	O
networks	O
.	O

The	O
common	O
criteria	O
derived	O
from	O
the	O
extensive	O
search	O
formed	O
the	O
basis	O
for	O
a	O
consensus	O
process	O
that	O
resulted	O
in	O
three	O
separate	O
definitions	B-T170
for	O
neonatal	O
blood	B-T038
stream	I-T038
infections	I-T038
(	O
BSI	B-T038
)	O
,	O
meningitis	B-T038
and	O
lower	B-T038
respiratory	I-T038
tract	I-T038
infections	I-T038
(	O
LRTI	B-T038
)	O
.	O

For	O
each	O
definition	B-T170
three	O
levels	O
of	O
evidence	O
are	O
proposed	O
to	O
ensure	O
the	O
applicability	O
of	O
the	O
definitions	B-T170
to	O
different	O
settings	O
.	O

Recommendations	O
about	O
data	B-T062
collection	I-T062
,	O
analysis	B-T062
and	O
presentation	O
are	O
presented	O
and	O
harmonized	B-T062
with	O
the	O
Brighton	B-T097
Collaboration	I-T097
and	O
GAIA	B-T097
format	B-T170
and	O
other	O
existing	O
international	B-T170
standards	I-T170
for	O
study	B-T062
reporting	B-T062
.	O

Beneficial	O
effects	O
of	O
dark	B-T168
chocolate	I-T168
on	O
exercise	O
capacity	O
in	O
sedentary	O
subjects	B-T098
:	O
underlying	O
mechanisms	O
.	O
A	O
double	B-T062
blind	I-T062
,	O
randomized	B-T062
,	O
placebo	B-T062
controlled	I-T062
trial	B-T062

In	O
heart	B-T038
failure	I-T038
patients	O
the	O
consumption	B-T038
of	O
(	B-T103
-	I-T103
)	I-T103
-	I-T103
epicatechin	I-T103
(	O
(	B-T103
-	I-T103
)	I-T103
-	I-T103
Epi	I-T103
)	O
-	O
rich	O
cocoa	B-T168
can	O
restore	O
skeletal	B-T017
muscle	I-T017
(	O
SkM	B-T017
)	O
mitochondrial	B-T017
structure	B-T082
and	O
decrease	O
biomarkers	B-T201
of	O
oxidative	B-T038
stress	I-T038
.	O

However	O
,	O
nothing	O
is	O
known	O
about	O
its	O
effects	O
on	O
exercise	O
capacity	O
and	O
underlying	O
mechanisms	O
in	O
normal	O
,	O
sedentary	O
subjects	B-T098
.	O

Twenty	O
normal	O
,	O
sedentary	O
subjects	B-T098
(	O
∼50	O
years	O
old	O
)	O
were	O
randomized	B-T062
to	O
placebo	B-T058
or	O
dark	B-T168
chocolate	I-T168
(	O
DC	B-T168
)	O
groups	O
and	O
consumed	O
20	O
g	O
of	O
the	O
products	O
for	O
3	O
months	O
.	O

Subjects	B-T098
underwent	O
before	O
and	O
after	O
treatment	B-T058
,	O
bicycle	B-T058
ergometry	I-T058
to	O
assess	O
VO2	B-T033
max	I-T033
and	O
work	O
,	O
SkM	B-T058
biopsy	I-T058
to	O
assess	O
changes	O
in	O
mitochondrial	B-T017
density	O
,	O
function	O
and	O
oxidative	B-T038
stress	I-T038
and	O
blood	B-T058
sampling	I-T058
to	O
assess	O
metabolic	O
endpoints	O
.	O

Seventeen	O
subjects	B-T098
completed	O
the	O
trial	B-T062
.	O

In	O
the	O
DC	B-T168
group	O
(	O
n	O
=	O
9	O
)	O
,	O
VO2	B-T033
max	I-T033
increased	O
(	O
17	O
%	O
increase	O
,	O
p	O
=	O
0	O
.	O
056	O
)	O
as	O
well	O
as	O
maximum	O
work	O
(	O
watts	O
)	O
achieved	O
(	O
p	O
=	O
0	O
.	O
026	O
)	O
with	O
no	O
changes	O
with	O
placebo	B-T058
(	O
n	O
=	O
8	O
)	O
.	O

The	O
DC	B-T168
group	O
evidenced	O
increases	O
in	O
HDL	B-T103
levels	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
decreased	O
triglycerides	B-T103
(	O
p	O
=	O
0	O
.	O
07	O
)	O
.	O

With	O
DC	B-T168
,	O
SkM	B-T017
evidenced	O
significant	O
increases	O
in	O
protein	B-T103
levels	O
for	O
LKB1	B-T103
,	O
AMPK	B-T103
and	O
PGC1α	B-T103
and	O
in	O
their	O
active	O
forms	O
(	O
phosphorylated	B-T038
AMPK	B-T103
and	O
LKB1	B-T103
)	O
as	O
well	O
as	O
in	O
citrate	B-T038
synthase	I-T038
activity	I-T038
while	O
no	O
changes	O
were	O
observed	O
in	O
mitochondrial	B-T017
density	O
.	O

With	O
DC	B-T168
,	O
significant	O
increases	O
in	O
SkM	B-T017
reduced	O
glutathione	B-T103
levels	O
and	O
decreases	O
in	O
protein	B-T038
carbonylation	I-T038
were	O
observed	O
.	O

Improvements	O
in	O
maximum	O
work	O
achieved	O
and	O
VO2	B-T033
max	I-T033
may	O
be	O
due	O
to	O
DC	B-T168
activation	O
of	O
upstream	O
control	O
systems	O
and	O
enhancement	O
of	O
SkM	B-T017
mitochondria	B-T017
efficiency	O
.	O

Larger	O
clinical	B-T062
studies	I-T062
are	O
warranted	O
to	O
confirm	O
these	O
observations	B-T062
.	O

Reduction	O
in	O
Hospital	B-T092
-	I-T092
Wide	I-T092
Clinical	B-T058
Laboratory	I-T058
Specimen	I-T058
Identification	I-T058
Errors	O
following	O
Process	O
Interventions	O
:	O
A	O
10	O
-	O
Year	O
Retrospective	B-T062
Observational	I-T062
Study	I-T062

Accurate	O
patient	B-T058
identification	I-T058
and	O
specimen	O
labeling	O
at	O
the	O
time	O
of	O
collection	O
are	O
crucial	O
steps	O
in	O
the	O
prevention	B-T062
of	O
medical	O
errors	O
,	O
thereby	O
improving	O
patient	B-T058
safety	I-T058
.	O

All	O
patient	B-T031
specimen	I-T031
identification	O
errors	O
that	O
occurred	O
in	O
the	O
outpatient	B-T082
department	I-T082
(	O
OPD	B-T082
)	O
,	O
emergency	B-T092
department	I-T092
(	O
ED	B-T092
)	O
,	O
and	O
inpatient	B-T082
department	I-T082
(	O
IPD	B-T082
)	O
of	O
a	O
3	O
,	O
800	O
-	O
bed	O
academic	B-T092
medical	I-T092
center	I-T092
in	O
Taiwan	B-T082
were	O
documented	B-T058
and	O
analyzed	O
retrospectively	O
from	O
2005	O
to	O
2014	O
.	O

To	O
reduce	O
such	O
errors	O
,	O
the	O
following	O
series	O
of	O
strategies	O
were	O
implemented	O
:	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
for	O
the	O
ED	B-T092
and	O
IPD	B-T082
in	O
2006	O
;	O
a	O
computer	O
-	O
assisted	O
barcode	B-T170
positive	B-T170
patient	I-T170
identification	I-T170
system	I-T170
for	O
the	O
ED	B-T092
and	O
IPD	B-T082
in	O
2007	O
and	O
2010	O
,	O
and	O
automated	O
sample	O
labeling	O
combined	O
with	O
electronic	O
identification	O
systems	O
introduced	O
to	O
the	O
OPD	B-T082
in	O
2009	O
.	O

Of	O
the	O
2000345	O
specimens	B-T031
collected	O
in	O
2005	O
,	O
1023	O
(	O
0	O
.	O
0511	O
%	O
)	O
were	O
identified	B-T033
as	O
having	O
patient	B-T058
identification	I-T058
errors	O
,	O
compared	O
with	O
58	O
errors	O
(	O
0	O
.	O
0015	O
%	O
)	O
among	O
3761238	O
specimens	B-T031
collected	O
in	O
2014	O
,	O
after	O
serial	O
interventions	B-T058
;	O
this	O
represents	O
a	O
97	O
%	O
relative	O
reduction	O
.	O

The	O
total	O
number	O
(	O
rate	O
)	O
of	O
institutional	O
identification	O
errors	O
contributed	O
from	O
the	O
ED	B-T092
,	O
IPD	B-T082
,	O
and	O
OPD	B-T082
over	O
a	O
10	O
-	O
year	O
period	O
were	O
423	O
(	O
0	O
.	O
1058	O
%	O
)	O
,	O
556	O
(	O
0	O
.	O
0587	O
%	O
)	O
,	O
and	O
44	O
(	O
0	O
.	O
0067	O
%	O
)	O
errors	O
before	O
the	O
interventions	B-T058
,	O
and	O
3	O
(	O
0	O
.	O
0007	O
%	O
)	O
,	O
52	O
(	O
0	O
.	O
0045	O
%	O
)	O
and	O
3	O
(	O
0	O
.	O
0001	O
%	O
)	O
after	O
interventions	B-T058
,	O
representing	O
relative	O
99	O
%	O
,	O
92	O
%	O
and	O
98	O
%	O
reductions	O
,	O
respectively	O
.	O

Accurate	O
patient	B-T058
identification	I-T058
is	O
a	O
challenge	O
of	O
patient	B-T058
safety	I-T058
in	O
different	O
health	O
settings	O
.	O

The	O
data	B-T033
collected	I-T033
in	O
our	O
study	B-T062
indicate	O
that	O
a	O
restrictive	O
specimen	O
acceptance	O
policy	O
,	O
computer	B-T058
-	I-T058
generated	I-T058
positive	B-T170
identification	I-T170
systems	I-T170
,	O
and	O
interdisciplinary	O
cooperation	O
can	O
significantly	O
reduce	O
patient	B-T058
identification	I-T058
errors	O
.	O

Management	B-T058
of	O
skin	B-T038
and	I-T038
soft	I-T038
-	I-T038
tissue	I-T038
infections	I-T038
at	O
a	O
community	O
teaching	B-T092
hospital	I-T092
using	O
a	O
severity	O
-	O
of	O
-	O
illness	O
tool	O

Skin	B-T038
and	I-T038
soft	I-T038
-	I-T038
tissue	I-T038
infections	I-T038
(	O
SSTIs	B-T038
)	O
encompass	O
a	O
diverse	O
range	O
of	O
infections	B-T038
of	O
varying	O
severity	O
.	O

The	O
Clinical	B-T170
Resource	I-T170
Efficiency	I-T170
Support	I-T170
Team	I-T170
(	I-T170
CREST	I-T170
)	I-T170
scoring	I-T170
system	I-T170
stratifies	B-T170
patients	O
into	O
four	O
classes	B-T170
(	O
I	O
=	O
least	O
severe	O
to	O
IV	O
=	O
most	O
severe	O
)	O
based	O
on	O
the	O
Standardized	B-T170
Early	I-T170
Warning	I-T170
Score	I-T170
(	O
SEWS	B-T170
)	O
.	O

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
apply	O
CREST	B-T170
to	O
hospitalized	O
patients	O
with	O
SSTIs	B-T038
in	O
order	O
to	O
quantify	O
disease	O
severity	O
and	O
evaluate	B-T058
appropriateness	O
of	O
antibiotic	B-T103
management	O
.	O

This	O
was	O
a	O
retrospective	B-T062
,	O
hypothesis	O
-	O
generating	O
,	O
single	O
-	O
centre	O
evaluation	B-T058
of	O
hospitalized	O
patients	O
with	O
SSTIs	B-T038
admitted	B-T058
in	O
2011	O
.	O

Based	O
on	O
CREST	B-T170
classification	O
,	O
the	O
empirical	O
antimicrobial	B-T103
choices	O
were	O
categorized	O
as	O
appropriate	O
,	O
over	B-T058
-	I-T058
treatment	I-T058
or	O
under	B-T058
-	I-T058
treatment	I-T058
.	O

A	O
total	O
of	O
369	O
patients	O
were	O
screened	O
and	O
200	O
met	O
the	O
inclusion	O
criteria	O
.	O

The	O
majority	O
of	O
patients	O
were	O
classified	B-T170
as	O
either	O
CREST	B-T170
class	O
I	O
(	O
n	O
=	O
68	O
)	O
or	O
class	O
I	O
I	O
(	O
n	O
=	O
102	O
)	O
.	O

Over	B-T058
-	I-T058
treatment	I-T058
was	O
more	O
common	O
in	O
the	O
less	O
severe	O
classes	B-T170
(	O
88	O
%	O
and	O
32	O
%	O
in	O
class	O
I	O
and	O
class	O
II	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Sixty	O
-	O
three	O
percent	O
of	O
class	O
I	O
(	O
n	O
=	O
43	O
)	O
were	O
over	B-T058
-	I-T058
treated	I-T058
due	O
to	O
both	O
the	O
use	O
of	O
intravenous	O
antibiotic	B-T103
s	O
when	O
oral	B-T058
therapy	I-T058
was	O
sufficient	O
and	O
use	O
of	O
unnecessarily	O
broad	B-T103
-	I-T103
spectrum	I-T103
antibiotics	I-T103
.	O

In	O
contrast	O
,	O
25	O
%	O
(	O
n	O
=	O
26	O
)	O
of	O
class	O
II	O
were	O
over	B-T058
-	I-T058
treated	I-T058
due	O
to	O
use	O
of	O
unnecessarily	O
broad	B-T103
-	I-T103
spectrum	I-T103
antibiotics	I-T103
.	O

Overall	O
clinical	B-T033
failure	I-T033
rates	O
remained	O
low	O
with	O
only	O
1	O
%	O
,	O
4	O
%	O
and	O
17	O
%	O
of	O
patients	O
unable	O
to	O
achieve	O
initial	O
response	B-T201
in	O
class	O
II	O
,	O
class	O
III	O
and	O
class	O
IV	O
.	O

Retrospective	O
application	B-T058
of	O
CREST	B-T170
identified	O
opportunities	O
to	O
improve	O
the	O
management	B-T058
of	O
SSTIs	B-T038
.	O

CREST	B-T170
can	O
be	O
of	O
great	O
value	O
in	O
discriminating	O
less	O
-	O
severe	O
SSTIs	B-T038
,	O
which	O
can	O
be	O
treated	B-T058
on	O
an	O
outpatient	O
basis	O
.	O

Breakthrough	O
viridans	B-T038
streptococcal	I-T038
bacteremia	I-T038
in	O
allogeneic	B-T058
hematopoietic	I-T058
stem	I-T058
cell	I-T058
transplant	I-T058
recipients	O
receiving	O
levofloxacin	B-T103
prophylaxis	B-T058
in	O
a	O
Japanese	B-T082
hospital	B-T092

Breakthrough	O
viridans	B-T038
streptococcal	I-T038
bacteremia	I-T038
(	O
VSB	B-T038
)	O
in	O
patients	O
with	O
hematological	B-T038
malignancy	I-T038
receiving	O
levofloxacin	B-T103
prophylaxis	B-T058
is	O
a	O
major	O
blood	B-T038
stream	I-T038
infection	I-T038
(	O
BSI	B-T038
)	O
occurring	O
during	O
febrile	B-T038
neutropenia	I-T038
.	O

However	O
,	O
clinical	B-T170
data	I-T170
focused	O
on	O
VSB	B-T038
in	O
allogeneic	B-T058
hematopoietic	I-T058
stem	I-T058
cell	I-T058
transplant	I-T058
(	O
allo	B-T058
-	I-T058
HSCT	I-T058
)	O
recipients	O
are	O
lacking	O
.	O

The	O
medical	B-T170
records	I-T170
of	O
allo	B-T058
-	I-T058
HSCT	I-T058
recipients	O
who	O
received	O
oral	O
levofloxacin	B-T103
prophylaxis	B-T058
between	O
January	O
2011	O
and	O
August	O
2013	O
at	O
Toranomon	B-T092
Hospital	I-T092
were	O
reviewed	O
to	O
evaluate	B-T058
breakthrough	O
VSB	B-T038
.	O

Stored	O
viridans	B-T007
streptococcal	I-T007
(	O
VGS	B-T007
)	O
species	B-T170
were	O
identified	O
by	O
using	O
sodA	B-T017
gene	I-T017
sequencing	B-T058
,	O
and	O
were	O
assessed	O
for	O
drug	B-T038
susceptibility	I-T038
.	O

Among	O
the	O
184	O
allo	B-T058
-	I-T058
HSCT	I-T058
recipients	O
on	O
levofloxacin	B-T103
prophylaxis	B-T058
,	O
28	O
(	O
15	O
.	O
2	O
%	O
)	O
experienced	O
breakthrough	O
VSB	B-T038
.	O

All	O
of	O
the	O
28	O
recipients	O
with	O
VSB	B-T038
were	O
treated	O
with	O
a	O
cefepime	B-T103
-	O
based	O
or	O
piperacillin	B-T103
/	I-T103
tazobactam	I-T103
-	O
based	O
regimen	B-T058
.	O

The	O
susceptibility	B-T038
rates	O
of	O
the	O
VGS	B-T007
strains	O
for	O
levofloxacin	B-T103
,	O
cefepime	B-T103
,	O
piperacillin	B-T103
/	I-T103
tazobactam	I-T103
,	O
meropenem	B-T103
,	O
and	O
vancomycin	B-T103
were	O
0	O
%	O
,	O
95	O
%	O
,	O
100	O
%	O
,	O
100	O
%	O
,	O
and	O
100	O
%	O
,	O
respectively	O
.	O

Both	O
the	O
MIC50	B-T058
(	O
minimum	B-T058
inhibitory	I-T058
concentration	I-T058
)	O
and	O
the	O
MIC90	B-T058
of	O
ceftazidim	B-T103
(	O
0	O
.	O
5	O
μg	O
/	O
mL	O
and	O
2	O
μg	O
/	O
mL	O
,	O
respectively	O
)	O
were	O
higher	O
than	O
the	O
MIC90	B-T058
of	O
all	O
the	O
other	O
anti	B-T103
-	I-T103
pseudomonal	I-T103
beta	I-T103
-	I-T103
lactams	I-T103
(	O
APBLs	B-T103
)	O
.	O

Only	O
1	O
VGS	B-T007
strain	O
had	O
a	O
penicillin	B-T103
MIC	B-T058
≥	O
2	O
μg	O
/	O
mL	O
by	O
the	O
Etest	B-T058
(	O
3	O
.	O
6	O
%	O
)	O
.	O

There	O
were	O
no	O
cases	O
with	O
acute	B-T033
respiratory	I-T033
distress	I-T033
syndrome	I-T033
(	O
ARDS	B-T033
)	O
that	O
was	O
associated	O
with	O
VSB	B-T038
,	O
although	O
the	O
rate	O
of	O
viridans	B-T038
group	I-T038
streptococcal	I-T038
shock	I-T038
syndrome	I-T038
was	O
high	O
(	O
26	O
%	O
)	O
.	O

The	O
crude	O
30	O
-	O
day	O
mortality	O
rate	O
in	O
the	O
VSB	B-T038
group	O
(	O
10	O
.	O
7	O
%	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
in	O
the	O
BSI	B-T038
without	O
VSB	B-T038
group	O
(	O
9	O
.	O
3	O
%	O
)	O
or	O
non	O
-	O
BSI	B-T038
group	O
(	O
7	O
.	O
0	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
77	O
)	O
.	O

Also	O
,	O
VSB	B-T038
was	O
not	O
a	O
risk	B-T033
factor	I-T033
for	O
all	O
-	O
cause	O
mortality	O
up	O
to	O
60	O
days	O
following	O
allo	B-T058
-	I-T058
HSCT	I-T058
(	O
P	O
=	O
0	O
.	O
43	O
)	O
.	O

APBL	B-T103
with	O
increased	O
anti	B-T033
-	I-T033
VGS	I-T033
activity	I-T033
(	O
APBL	B-T033
-	I-T033
VA	I-T033
)	O
monotherapy	B-T058
would	O
typically	O
be	O
optimal	O
for	O
treating	O
the	O
VGS	B-T007
strains	O
in	O
this	O
setting	O
.	O

Indication	O
of	O
adding	O
an	O
empiric	O
anti	B-T103
-	I-T103
gram	I-T103
-	I-T103
positive	I-T103
agent	I-T103
to	O
APBL	B-T033
-	I-T033
VA	I-T033
for	O
treating	O
VSB	B-T038
should	O
depend	O
on	O
local	B-T082
factors	O
,	O
such	O
as	O
the	O
susceptibility	B-T038
results	O
.	O

In	O
addition	O
,	O
breakthrough	O
VSB	B-T038
is	O
probably	O
not	O
a	O
major	O
cause	B-T033
of	I-T033
death	I-T033
in	O
allo	B-T058
-	I-T058
HSCT	I-T058
settings	O
,	O
where	O
beta	B-T103
-	I-T103
lactam	I-T103
non	B-T007
-	I-T007
susceptible	I-T007
VGS	I-T007
and	O
the	O
ARDS	B-T033
are	O
rare	O
.	O

The	O
lost	O
art	O
of	O
the	O
splenorrhaphy	B-T058

In	O
the	O
case	O
of	O
the	O
hemodynamically	B-T038
unstable	I-T038
child	O
,	O
splenorrhaphy	B-T058
is	O
preferred	O
to	O
splenectomy	B-T058
to	O
avert	O
postsplenectomy	B-T038
sepsis	B-T038
.	O

However	O
,	O
successful	O
splenorrhaphy	B-T058
requires	O
familiarity	B-T038
with	O
the	O
procedure	B-T058
.	O

We	O
sought	O
to	O
determine	O
how	O
many	O
splenectomies	B-T058
or	O
splenorrhaphies	B-T058
for	O
trauma	B-T037
the	O
average	O
pediatric	B-T097
surgeon	I-T097
can	O
be	O
expected	O
to	O
perform	O
during	O
their	O
career	O
.	O

The	O
Pediatric	B-T170
Health	I-T170
Information	I-T170
System	I-T170
(	I-T170
PHIS	I-T170
)	I-T170
Database	I-T170
was	O
queried	O
for	O
patients	O
≤18	O
years	O
coded	O
with	O
an	O
International	B-T170
Classification	I-T170
of	I-T170
Diseases	I-T170
9th	I-T170
Edition	I-T170
diagnosis	O
code	O
of	O
a	O
splenic	B-T037
injury	I-T037
from	O
2004	O
to	O
2013	O
.	O

Age	O
,	O
gender	O
,	O
grade	B-T170
of	O
splenic	B-T037
injury	I-T037
,	O
and	O
operations	B-T058
performed	O
were	O
extracted	O
.	O

Numbers	O
of	O
pediatric	B-T097
surgeons	I-T097
per	O
hospital	B-T092
were	O
obtained	O
.	O

9567	O
children	O
were	O
identified	O
.	O

2	O
.	O
1	O
%	O
underwent	O
a	O
splenectomy	B-T058
and	O
0	O
.	O
8	O
%	O
underwent	O
a	O
splenorrhaphy	B-T058
.	O

The	O
average	O
surgeon	B-T097
performed	O
0	O
.	O
6	O
(	O
SD	O
=	O
0	O
.	O
6	O
)	O
splenectomies	B-T058
and	O
0	O
.	O
2	O
(	O
SD	O
=	O
0	O
.	O
4	O
)	O
splenorrhaphies	B-T058
for	O
trauma	B-T037
.	O

If	O
these	O
rates	O
remain	O
constant	O
over	O
time	O
,	O
the	O
average	O
surgeon	B-T097
would	O
perform	O
1	O
.	O
8	O
(	O
SD	O
=	O
1	O
.	O
7	O
)	O
splenectomies	B-T058
and	O
0	O
.	O
6	O
(	O
SD	O
=	O
1	O
.	O
1	O
)	O
splenorrhaphies	B-T058
for	O
trauma	B-T037
over	O
a	O
30	O
-	O
year	O
surgical	O
career	O
.	O

Nonoperative	B-T058
management	I-T058
is	O
associated	O
with	O
a	O
host	O
of	O
benefits	O
,	O
but	O
has	O
resulted	O
in	O
a	O
decrease	O
in	O
the	O
experience	O
level	O
of	O
the	O
pediatric	B-T097
surgeons	I-T097
expected	O
to	O
perform	O
an	O
emergency	O
splenectomy	B-T058
or	O
splenorrhaphy	B-T058
when	O
the	O
unusual	O
occasion	O
arises	O
.	O

Vestibular	B-T082
-	O
dependent	O
inter	O
-	O
stimulus	O
interval	O
effects	O
on	O
sound	B-T038
evoked	I-T038
potentials	I-T038
of	O
central	B-T082
origin	O

Todd	O
et	O
al	O
.	O

(	O
2014ab	O
)	O
have	O
recently	O
demonstrated	O
the	O
presence	B-T033
of	O
vestibular	B-T082
-	O
dependent	O
contributions	O
to	O
auditory	B-T038
evoked	I-T038
potentials	I-T038
(	O
AEPs	B-T038
)	O
when	O
passing	O
through	O
the	O
vestibular	B-T082
threshold	O
as	O
determined	O
by	O
vestibular	B-T033
evoked	I-T033
myogenic	I-T033
potentials	I-T033
(	O
VEMPs	B-T033
)	O
,	O
including	O
a	O
particular	O
deflection	B-T082
labeled	O
as	O
an	O
N42	O
/	O
P52	O
prior	O
to	O
the	O
long	O
-	O
latency	O
AEPs	B-T038
N1	O
and	O
P2	O
.	O

In	O
this	O
paper	O
we	O
report	B-T058
the	O
results	B-T033
of	O
an	O
experiment	B-T062
to	O
determine	O
the	O
effect	O
of	O
inter	O
-	O
stimulus	O
interval	O
(	O
ISI	O
)	O
and	O
regularity	O
on	O
potentials	B-T038
recorded	O
above	B-T082
and	O
below	B-T082
VEMP	B-T033
threshold	O
.	O

Five	O
healthy	O
,	O
right	O
-	O
handed	O
subjects	B-T098
were	O
recruited	O
and	O
evoked	B-T038
potentials	I-T038
were	O
recorded	O
to	O
binaurally	O
presented	O
sound	B-T058
stimulation	I-T058
,	O
above	B-T082
and	O
below	B-T082
vestibular	B-T082
threshold	O
,	O
at	O
seven	O
stimulus	O
rates	O
with	O
ISIs	O
of	O
212	O
,	O
300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
and	O
1696	O
ms	O
.	O

The	O
inner	O
five	O
intervals	O
,	O
i	O
.	O
e	O
.	O

300	O
,	O
424	O
,	O
600	O
,	O
848	O
,	O
1200	O
ms	O
,	O
were	O
presented	O
twice	O
in	O
both	O
regular	O
and	O
irregular	O
conditions	O
.	O

ANOVA	O
on	O
the	O
global	O
field	O
power	O
(	O
GFP	O
)	O
were	O
conducted	O
for	O
each	O
of	O
four	O
waves	O
,	O
N42	O
,	O
P52	O
,	O
N1	O
and	O
P2	O
with	O
factors	O
of	O
intensity	O
,	O
ISI	O
and	O
regularity	O
.	O

Both	O
N42	O
and	O
P52	O
waves	O
showed	O
significant	O
ANOVA	O
effects	O
of	O
intensity	O
but	O
no	O
other	O
main	O
effects	O
or	O
interactions	O
.	O

In	O
contrast	O
both	O
N1	O
and	O
P2	O
showed	O
additional	O
effects	O
of	O
ISI	O
,	O
as	O
well	O
as	O
intensity	O
,	O
and	O
evidence	O
of	O
non	O
-	O
linear	B-T082
interactions	O
between	O
ISI	O
and	O
intensity	O
.	O

A	O
source	B-T062
analysis	I-T062
was	O
carried	O
out	O
consistent	O
with	O
prior	O
work	O
suggesting	O
that	O
when	O
above	B-T082
vestibular	B-T082
threshold	O
,	O
in	O
addition	O
to	O
bilateral	B-T082
superior	B-T082
temporal	B-T017
cortex	I-T017
,	O
ocular	B-T017
,	O
cerebellar	B-T017
and	O
cingulate	B-T017
sources	B-T033
are	O
recruited	O
.	O

Further	O
statistical	O
analysis	O
of	O
the	O
source	B-T033
currents	O
indicated	O
that	O
the	O
origin	O
of	O
the	O
interactions	O
with	O
intensity	O
may	O
be	O
the	O
ISI	O
sensitivity	O
of	O
the	O
vestibular	B-T082
-	O
dependent	O
sources	B-T033
.	O

This	O
in	O
turn	O
may	O
reflect	O
a	O
specific	O
vestibular	B-T082
preference	O
for	O
stimulus	O
rates	O
associated	O
with	O
locomotion	B-T038
,	O
i	O
.	O
e	O
.	O

rates	O
close	O
to	O
2	O
Hz	O
,	O
or	O
ISIs	O
close	O
to	O
500	O
ms	O
,	O
where	O
saccular	B-T082
afferents	B-T082
show	O
increased	O
gain	O
and	O
the	O
corresponding	O
reflexes	B-T038
are	O
most	O
sensitive	O
.	O

A	O
Systematic	B-T170
Review	I-T170
of	O
the	O
Diagnostic	O
and	O
Prognostic	O
Value	O
of	O
Urinary	O
Protein	B-T103
Biomarkers	B-T201
in	O
Urothelial	B-T038
Bladder	I-T038
Cancer	I-T038

For	O
over	O
80	O
years	O
,	O
cystoscopy	B-T058
has	O
remained	O
the	O
gold	O
-	O
standard	O
for	O
detecting	B-T033
tumours	B-T038
of	O
the	O
urinary	B-T017
bladder	I-T017
.	O

Since	O
bladder	B-T038
tumours	I-T038
have	O
a	O
tendency	O
to	O
recur	O
and	O
progress	B-T038
,	O
many	O
patients	O
are	O
subjected	O
to	O
repeated	O
cystoscopies	B-T058
during	O
long	O
-	O
term	O
surveillance	B-T058
,	O
with	O
the	O
procedure	B-T058
being	O
both	O
unpleasant	O
for	O
the	O
patient	O
and	O
expensive	O
for	O
healthcare	B-T097
providers	I-T097
.	O

The	O
identification	O
and	O
validation	B-T062
of	O
bladder	B-T038
tumour	I-T038
specific	O
molecular	B-T201
markers	I-T201
in	O
urine	B-T031
could	O
enable	O
tumour	B-T038
detection	B-T033
and	O
reduce	O
reliance	O
on	O
cystoscopy	B-T058
,	O
and	O
numerous	O
classes	O
of	O
biomarkers	B-T201
have	O
been	O
studied	O
.	O

Proteins	B-T103
represent	O
the	O
most	O
intensively	O
studied	O
class	O
of	O
biomolecule	O
in	O
this	O
setting	O
.	O

As	O
an	O
aid	O
to	O
researchers	B-T097
searching	O
for	O
better	O
urinary	O
biomarkers	B-T201
,	O
we	O
report	O
a	O
comprehensive	B-T170
systematic	I-T170
review	I-T170
of	O
the	O
literature	B-T170
and	O
a	O
searchable	O
database	B-T170
of	O
proteins	B-T103
that	O
have	O
been	O
investigated	B-T058
to	O
date	O
.	O

Our	O
objective	O
was	O
to	O
classify	O
these	O
proteins	B-T103
as	O
:	O
1	O
)	O
those	O
with	O
robustly	O
characterised	O
sensitivity	O
and	O
specificity	O
for	O
bladder	B-T038
cancer	I-T038
detection	B-T033
;	O
2	O
)	O
those	O
that	O
show	O
potential	O
but	O
further	O
investigation	B-T058
is	O
required	O
;	O
3	O
)	O
those	O
unlikely	O
to	O
warrant	O
further	O
investigation	B-T058
;	O
and	O
4	O
)	O
those	O
investigated	B-T058
as	O
prognostic	O
markers	O
.	O

This	O
work	O
should	O
help	O
to	O
prioritise	O
certain	O
biomarkers	B-T201
for	O
rigorous	B-T062
validation	I-T062
,	O
whilst	O
preventing	O
wasted	O
effort	O
on	O
proteins	B-T103
that	O
have	O
shown	O
no	O
association	O
whatsoever	O
with	O
the	O
disease	B-T038
,	O
or	O
only	O
modest	O
biomarker	B-T201
performance	O
despite	O
large	O
-	O
scale	O
efforts	O
at	O
validation	B-T062
.	O

Well	O
,	O
I	O
Wouldn	O
'	O
t	O
be	O
Any	O
Worse	O
Off	O
,	O
Would	O
I	O
,	O
Than	O
I	O
am	O
Now	O
?	O
A	O
Qualitative	B-T062
Study	I-T062
of	O
Decision	B-T038
-	I-T038
Making	I-T038
,	O
Hopes	B-T038
,	O
and	O
Realities	O
of	O
Adults	O
With	O
Type	B-T038
1	I-T038
Diabetes	I-T038
Undergoing	O
Islet	B-T058
Cell	I-T058
Transplantation	I-T058

For	O
selected	O
individuals	B-T098
with	O
type	B-T038
1	I-T038
diabetes	I-T038
,	O
pancreatic	B-T058
islet	I-T058
transplantation	I-T058
(	O
IT	B-T058
)	O
prevents	O
recurrent	O
severe	O
hypoglycemia	B-T038
and	O
optimizes	B-T058
glycemia	I-T058
,	O
although	O
ongoing	O
systemic	B-T058
immunosuppression	I-T058
is	O
needed	O
.	O

Our	O
aim	O
was	O
to	O
explore	O
candidates	B-T098
and	O
recipients	O
'	O
expectations	O
of	O
transplantation	B-T058
,	O
their	O
experience	O
of	O
being	O
on	O
the	O
waiting	B-T033
list	I-T033
,	O
and	O
(	O
for	O
recipients	O
)	O
the	O
procedure	O
and	O
life	O
posttransplant	O
.	O

Cross	O
-	O
sectional	O
qualitative	O
research	B-T062
design	I-T062
using	O
semistructured	O
interviews	O
with	O
16	O
adults	O
(	O
8	O
pretransplant	O
,	O
8	O
posttransplant	O
;	O
from	O
4	O
UK	B-T082
centers	B-T092
(	O
n	O
=	O
13	O
)	O
and	O
1	O
Canadian	B-T082
center	B-T092
(	O
n	O
=	O
3	O
)	O
)	O
.	O

Interviews	O
were	O
audio	B-T058
-	I-T058
recorded	I-T058
,	O
transcribed	O
,	O
and	O
underwent	O
inductive	B-T062
thematic	I-T062
analysis	I-T062
.	O

Interviewees	B-T098
were	O
aged	O
(	O
mean	O
±	O
SD	O
)	O
52	O
±	O
10	O
years	O
(	O
range	O
,	O
30	O
-	O
64	O
)	O
;	O
duration	O
of	O
diabetes	B-T038
,	O
36	O
±	O
9	O
years	O
(	O
range	O
,	O
21	O
-	O
56	O
)	O
;	O
12	O
(	O
75	O
%	O
)	O
were	O
women	B-T098
.	O

Narrative	O
accounts	O
centered	O
on	O
expectations	O
,	O
hopes	B-T038
,	O
and	O
realities	O
;	O
decision	B-T038
-	I-T038
making	I-T038
;	O
waiting	O
and	O
uncertainty	O
;	O
the	O
procedure	O
,	O
hospital	O
stay	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Expected	O
benefits	O
included	O
fewer	O
severe	O
hypoglycemic	B-T038
episodes	I-T038
,	O
reduced	O
need	O
for	O
insulin	B-T103
,	O
preventing	O
onset	O
/	O
progression	O
of	O
complications	B-T038
and	O
improved	O
psychological	B-T033
well	I-T033
-	I-T033
being	I-T033
.	O

These	O
were	O
realized	O
for	O
most	O
,	O
at	O
least	O
in	O
the	O
short	O
term	O
.	O

Most	O
interviewees	B-T098
described	O
well	O
-	O
informed	O
,	O
shared	O
decision	B-T038
-	I-T038
making	I-T038
with	O
clinicians	B-T097
and	O
family	O
,	O
and	O
managing	O
their	O
expectations	O
.	O

Although	O
life	O
"	O
on	O
the	O
list	O
"	O
could	O
be	O
stressful	O
,	O
and	O
immunosuppressant	B-T103
side	B-T038
effects	I-T038
were	O
severe	O
,	O
interviewees	B-T098
reported	O
"	O
no	B-T033
regrets	B-T038
.	O
"	O
Posttransplant	O
,	O
interviewees	B-T098
experienced	O
increased	O
confidence	B-T038
,	O
through	O
freedom	B-T033
from	I-T033
hypoglycemia	I-T033
and	O
regained	O
glycemic	B-T058
control	I-T058
,	O
which	O
tempered	O
any	O
disappointment	O
about	O
continued	O
reliance	O
on	O
insulin	B-T103
.	O

Most	O
viewed	O
their	O
transplant	B-T058
as	O
a	O
success	O
,	O
though	O
several	O
reflected	O
upon	O
setbacks	O
and	O
hidden	O
hopes	B-T038
for	O
becoming	O
"	O
insulin	B-T033
-	I-T033
free	I-T033
.	O
"	O
Independently	O
undertaken	O
interviews	O
demonstrated	O
realistic	O
and	O
balanced	O
expectations	O
of	O
IT	B-T058
and	O
indicate	O
how	O
to	O
optimize	O
the	O
process	O
and	O
support	O
for	O
future	O
IT	B-T058
candidates	B-T098
.	O

The	O
nanocomposite	O
nature	O
of	O
bone	B-T017
drives	O
its	O
strength	O
and	O
damage	O
resistance	O

In	O
human	B-T017
bone	I-T017
,	O
an	O
amorphous	O
mineral	B-T103
serves	O
as	O
a	O
precursor	O
to	O
the	O
formation	O
of	O
a	O
highly	O
substituted	O
nanocrystalline	O
apatite	B-T103
.	O

However	O
,	O
the	O
precise	O
role	O
of	O
this	O
amorphous	O
mineral	B-T103
remains	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
by	O
using	O
transmission	B-T058
electron	I-T058
microscopy	I-T058
that	O
100	O
-	O
300	O
nm	O
amorphous	O
calcium	B-T103
phosphate	I-T103
regions	B-T082
are	O
present	O
in	O
the	O
disordered	O
phase	O
of	O
trabecular	B-T017
bone	I-T017
.	O

Nanomechanical	B-T062
experiments	I-T062
on	O
cylindrical	B-T082
samples	O
,	O
with	O
diameters	O
between	O
250	O
nm	O
and	O
3	O
,	O
000	O
nm	O
,	O
of	O
the	O
bone	B-T017
'	I-T017
s	I-T017
ordered	O
and	O
disordered	O
phases	O
revealed	O
a	O
transition	O
from	O
plastic	O
deformation	B-T033
to	O
brittle	B-T033
failure	B-T037
and	O
at	O
least	O
a	O
factor	O
-	O
of	O
-	O
2	O
higher	O
strength	O
in	O
the	O
smaller	O
samples	O
.	O

We	O
postulate	O
that	O
this	O
transition	O
in	O
failure	O
mechanism	O
is	O
caused	O
by	O
the	O
suppression	O
of	O
extrafibrillar	B-T017
shearing	B-T058
in	O
the	O
smaller	O
samples	O
,	O
and	O
that	O
the	O
emergent	O
smaller	O
-	O
is	O
-	O
stronger	O
size	O
effect	O
is	O
related	O
to	O
the	O
sample	O
-	O
size	O
scaling	O
of	O
the	O
distribution	O
of	O
flaws	O
.	O

Our	O
findings	B-T033
should	O
help	O
in	O
the	O
understanding	O
of	O
the	O
multi	O
-	O
scale	O
nature	O
of	O
bone	B-T017
and	O
provide	O
insights	O
into	O
the	O
biomineralization	B-T038
process	O
.	O

Assessing	O
the	O
physiological	O
relevance	O
of	O
alternate	O
architectures	B-T082
of	O
the	O
p7	B-T103
protein	I-T103
of	O
hepatitis	B-T005
C	I-T005
virus	I-T005
in	O
different	O
environments	B-T082

The	O
viroporin	B-T038
p7	B-T103
of	O
the	O
hepatitis	B-T005
C	I-T005
virus	I-T005
forms	O
multimeric	B-T103
channels	I-T103
eligible	O
for	O
ion	B-T038
transport	I-T038
across	O
the	O
endoplasmic	B-T017
reticulum	I-T017
membrane	I-T017
.	O

Currently	O
the	O
subject	O
of	O
many	O
studies	B-T062
and	O
discussion	O
,	O
the	O
molecular	O
assembly	O
of	O
the	O
ion	B-T103
channel	I-T103
and	O
the	O
structural	B-T082
characteristics	O
of	O
the	O
p7	B-T103
monomer	B-T103
are	O
not	O
yet	O
fully	O
understood	O
.	O

Structural	B-T082
investigation	O
of	O
p7	B-T103
has	O
been	O
carried	O
out	O
only	O
in	O
detergent	B-T103
environments	B-T082
,	O
making	O
the	O
interpretation	O
of	O
the	O
experimental	O
results	O
somewhat	O
questionable	O
.	O

Here	O
,	O
we	O
analyze	B-T062
by	O
means	O
of	O
molecular	O
dynamics	O
simulations	O
the	O
structure	B-T082
of	O
the	O
p7	B-T103
monomer	B-T103
as	O
a	O
function	O
of	O
its	O
sequence	B-T082
,	O
initial	O
conformation	B-T082
and	O
environment	B-T082
.	O

We	O
investigate	O
the	O
conductance	O
properties	O
of	O
three	O
models	O
of	O
a	O
hexameric	O
p7	B-T103
ion	B-T103
channel	I-T103
by	O
examining	O
ion	B-T038
translocation	I-T038
in	O
a	O
pure	O
lipid	B-T017
bilayer	I-T017
.	O

It	O
is	O
noteworthy	O
that	O
although	O
none	O
of	O
the	O
models	O
reflects	O
the	O
experimentally	O
observed	O
trend	O
to	O
conduct	O
preferentially	O
cations	B-T103
,	O
we	O
were	O
able	O
to	O
identify	O
the	O
position	B-T082
and	O
orientation	B-T082
of	O
titratable	O
acidic	O
or	O
basic	O
residues	O
playing	O
a	O
crucial	O
role	O
in	O
ion	B-T103
selectivity	O
and	O
in	O
the	O
overall	O
conductance	O
of	O
the	O
channel	B-T103
.	O

In	O
addition	O
,	O
too	O
compact	O
a	O
packing	B-T038
of	O
the	O
monomers	B-T103
leads	O
to	O
channel	B-T103
collapse	O
rather	O
than	O
formation	O
of	O
a	O
reasonable	O
pore	B-T017
,	O
amenable	O
to	O
ion	B-T038
translocation	I-T038
.	O

The	O
present	O
findings	O
are	O
envisioned	O
to	O
help	O
assess	O
the	O
physiological	O
relevance	O
of	O
p7	B-T103
ion	B-T103
channel	I-T103
models	O
consisting	O
of	O
multimeric	B-T082
structures	I-T082
obtained	O
in	O
non	O
-	O
native	O
environments	B-T082
.	O

The	O
genome	B-T017
-	O
scale	O
DNA	B-T038
-	I-T038
binding	I-T038
profile	B-T058
of	O
BarR	B-T103
,	O
a	O
β	B-T103
-	I-T103
alanine	I-T103
responsive	O
transcription	B-T103
factor	I-T103
in	O
the	O
archaeon	O
Sulfolobus	O
acidocaldarius	O

The	O
Leucine	B-T103
-	I-T103
responsive	I-T103
Regulatory	I-T103
Protein	I-T103
(	O
Lrp	B-T103
)	O
family	B-T103
is	O
a	O
widespread	O
family	B-T103
of	O
regulatory	B-T103
transcription	I-T103
factors	I-T103
in	O
prokaryotes	O
.	O

BarR	B-T103
is	O
an	O
Lrp	B-T103
-	O
like	O
transcription	B-T103
factor	I-T103
in	O
the	O
model	O
archaeon	O
Sulfolobus	O
acidocaldarius	O
that	O
activates	O
the	O
expression	B-T038
of	O
a	O
β	B-T017
-	I-T017
alanine	I-T017
aminotransferase	I-T017
gene	I-T017
,	O
which	O
is	O
involved	O
in	O
β	B-T038
-	I-T038
alanine	I-T038
degradation	I-T038
.	O

In	O
contrast	O
to	O
classical	O
Lrp	B-T103
-	O
like	O
transcription	B-T103
factors	I-T103
,	O
BarR	B-T103
is	O
not	B-T033
responsive	I-T033
to	O
any	O
of	O
the	O
α	B-T103
-	I-T103
amino	I-T103
acids	I-T103
but	O
interacts	O
specifically	O
with	O
β	B-T103
-	I-T103
alanine	I-T103
.	O

Besides	O
the	O
juxtaposed	O
β	B-T017
-	I-T017
alanine	I-T017
aminotransferase	I-T017
gene	I-T017
,	O
other	O
regulatory	O
targets	O
of	O
BarR	B-T103
have	O
not	O
yet	O
been	O
identified	O
although	O
β	B-T103
-	I-T103
alanine	I-T103
is	O
the	O
precursor	B-T103
of	O
coenzyme	B-T103
A	I-T103
and	O
thus	O
an	O
important	O
central	O
metabolite	B-T103
.	O

The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
extend	O
the	O
knowledge	O
of	O
the	O
DNA	B-T038
-	I-T038
binding	I-T038
characteristics	O
of	O
BarR	B-T103
and	O
of	O
its	O
corresponding	O
regulon	B-T017
from	O
a	O
local	B-T082
to	O
a	O
genome	B-T017
-	O
wide	O
perspective	O
.	O

We	O
characterized	O
the	O
genome	B-T058
-	I-T058
wide	I-T058
binding	I-T058
profile	I-T058
of	O
BarR	B-T103
using	O
chromatin	B-T058
immunoprecipation	I-T058
combined	O
with	O
high	B-T062
-	I-T062
throughput	I-T062
sequencing	I-T062
(	O
ChIP	B-T062
-	I-T062
seq	I-T062
)	O
.	O

This	O
revealed	O
21	O
genomic	B-T017
binding	B-T038
loci	B-T082
.	O

High	O
-	O
enrichment	O
binding	B-T038
regions	I-T038
were	O
validated	O
to	O
interact	O
with	O
purified	O
BarR	B-T103
protein	I-T103
in	O
vitro	O
using	O
electrophoretic	B-T058
mobility	I-T058
shift	I-T058
assays	I-T058
and	O
almost	O
all	O
targets	O
were	O
also	O
shown	O
to	O
harbour	O
a	O
conserved	B-T082
semi	B-T103
-	I-T103
palindromic	I-T103
binding	B-T082
motif	I-T082
.	O

Only	O
a	O
small	O
subset	O
of	O
enriched	O
genomic	B-T017
sites	I-T017
are	O
located	O
in	O
intergenic	B-T103
regions	I-T103
at	O
a	O
relative	O
short	O
distance	O
to	O
a	O
promoter	B-T103
,	O
and	O
qRT	B-T058
-	I-T058
PCR	I-T058
analysis	I-T058
demonstrated	O
that	O
only	O
one	O
additional	O
operon	B-T017
is	O
under	O
activation	O
of	O
BarR	B-T103
,	O
namely	O
the	O
glutamine	B-T017
synthase	I-T017
operon	I-T017
.	O

The	O
latter	O
is	O
also	O
a	O
target	O
of	O
other	O
Lrp	B-T103
-	O
like	O
transcription	B-T103
factors	I-T103
.	O

Detailed	O
inspection	O
of	O
the	O
BarR	B-T103
ChIP	B-T033
-	I-T033
seq	I-T033
profile	I-T033
at	O
the	O
β	B-T103
-	I-T103
alanine	I-T103
aminotransferase	I-T103
promoter	I-T103
region	I-T103
in	O
combination	O
with	O
binding	B-T082
motif	I-T082
predictions	O
indicate	O
that	O
the	O
operator	B-T103
structure	I-T103
is	O
more	O
complicated	O
than	O
previously	O
anticipated	O
,	O
consisting	O
of	O
multiple	B-T103
(	I-T103
major	I-T103
and	I-T103
auxiliary	I-T103
)	I-T103
operators	I-T103
.	O

BarR	B-T103
has	O
a	O
limited	O
regulon	B-T017
,	O
and	O
includes	O
also	O
glutamine	B-T017
synthase	I-T017
genes	I-T017
besides	O
the	O
previously	O
characterized	O
β	B-T017
-	I-T017
alanine	I-T017
aminotransferase	I-T017
.	O

Regulation	B-T038
of	O
glutamine	B-T103
synthase	I-T103
is	O
suggestive	O
of	O
a	O
link	O
between	O
β	B-T038
-	I-T038
alanine	I-T038
and	O
α	B-T038
-	I-T038
amino	I-T038
acid	I-T038
metabolism	I-T038
in	O
S	O
.	O

acidocaldarius	O
.	O

Furthermore	O
,	O
this	O
work	O
reveals	O
that	O
the	O
BarR	B-T103
regulon	B-T017
overlaps	O
with	O
that	O
of	O
other	O
Lrp	B-T103
-	O
like	O
regulators	O
.	O

GH32	B-T103
family	I-T103
activity	B-T038
:	O
a	O
topological	B-T082
approach	O
through	O
protein	O
contact	O
networks	O

The	O
application	O
of	O
Protein	O
Contact	O
Networks	O
methodology	O
allowed	O
to	O
highlight	O
a	O
novel	O
response	O
of	O
border	O
region	O
between	O
the	O
two	O
domains	B-T082
to	I-T082
substrate	I-T082
binding	I-T082
.	O

Glycoside	B-T103
hydrolases	I-T103
(	O
GH	B-T103
)	O
are	O
enzymes	B-T103
that	O
mainly	O
hydrolyze	O
the	O
glycosidic	O
bond	O
between	O
two	O
carbohydrates	B-T103
or	O
a	O
carbohydrate	B-T103
and	O
a	O
non	O
-	O
carbohydrate	O
moiety	O
.	O

These	O
enzymes	B-T103
are	O
involved	O
in	O
many	O
fundamental	O
and	O
diverse	O
biological	B-T038
processes	I-T038
in	O
plants	B-T204
.	O

We	O
have	O
focused	O
on	O
the	O
GH32	B-T103
family	I-T103
,	O
including	O
enzymes	B-T103
very	O
similar	O
in	O
both	O
sequence	B-T082
and	O
structure	O
,	O
each	O
having	O
however	O
clear	O
specificities	O
of	O
substrate	O
preferences	O
and	O
kinetic	O
properties	O
.	O

Structural	B-T103
and	O
topological	B-T082
differences	O
among	O
proteins	B-T103
of	O
the	O
GH32	B-T103
family	I-T103
have	O
been	O
here	O
identified	O
by	O
means	O
of	O
an	O
emerging	O
approach	O
(	O
Protein	O
Contact	O
network	O
,	O
PCN	O
)	O
based	O
on	O
the	O
formalization	O
of	O
3D	B-T082
structures	I-T082
as	O
contact	O
networks	O
among	O
amino	B-T082
-	I-T082
acid	I-T082
residues	I-T082
.	O

The	O
PCN	O
approach	O
proved	O
successful	O
in	O
both	O
reconstructing	O
the	O
already	O
known	O
functional	O
domains	B-T082
and	O
in	O
identifying	O
the	O
structural	B-T103
counterpart	O
of	O
the	O
properties	O
of	O
GH32	B-T103
enzymes	I-T103
,	O
which	O
remain	O
uncertain	O
,	O
like	O
their	O
allosteric	O
character	O
.	O

The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	O
discovery	O
of	O
the	O
activation	B-T038
upon	O
binding	B-T038
of	I-T038
the	I-T038
border	I-T038
(	I-T038
cleft	I-T038
)	I-T038
region	I-T038
between	O
the	O
two	O
domains	B-T082
.	O

This	O
reveals	O
the	O
allosteric	O
nature	O
of	O
the	O
enzymatic	B-T038
activity	I-T038
for	O
all	O
the	O
analyzed	O
forms	O
in	O
the	O
GH32	B-T103
family	I-T103
,	O
a	O
character	O
yet	O
to	O
be	O
highlighted	O
in	O
biochemical	B-T058
studies	I-T058
.	O

Furthermore	O
,	O
we	O
have	O
been	O
able	O
to	O
recognize	O
a	O
topological	B-T082
signature	I-T082
(	O
graph	O
energy	O
)	O
of	O
the	O
different	O
affinity	O
of	O
the	O
enzymes	B-T103
towards	O
small	O
and	O
large	O
substrates	O
.	O

Grasping	B-T038
At	O
The	O
Moon	B-T082
:	O
Enhancing	O
Access	B-T082
To	O
Careers	O
In	O
The	O
Health	B-T091
Professions	I-T091

A	O
former	O
HHS	B-T092
secretary	B-T097
reflects	B-T038
on	O
what	O
'	O
s	O
needed	O
to	O
enable	O
more	O
minorities	B-T098
to	O
become	O
doctors	B-T097
and	O
other	O
health	B-T097
professionals	I-T097
.	O

Multivariate	O
Imaging	B-T058
Genetics	B-T062
Study	I-T062
of	O
MRI	B-T058
Gray	B-T017
Matter	I-T017
Volume	O
and	O
SNPs	B-T082
Reveals	O
Biological	O
Pathways	O
Correlated	O
with	O
Brain	B-T017
Structural	B-T082
Differences	O
in	O
Attention	B-T038
Deficit	I-T038
Hyperactivity	I-T038
Disorder	I-T038

Attention	B-T038
deficit	I-T038
hyperactivity	I-T038
disorder	I-T038
(	O
ADHD	B-T038
)	O
is	O
a	O
prevalent	O
neurodevelopmental	B-T038
disorder	I-T038
affecting	O
children	O
,	O
adolescents	O
,	O
and	O
adults	O
.	O

Its	O
etiology	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
increasingly	O
believed	O
to	O
result	O
from	O
diverse	O
pathophysiologies	B-T038
that	O
affect	O
the	O
structure	B-T082
and	O
function	O
of	O
specific	O
brain	O
circuits	O
.	O

Although	O
one	O
of	O
the	O
best	O
-	O
studied	O
neurobiological	B-T038
abnormalities	I-T038
in	O
ADHD	B-T038
is	O
reduced	O
fronto	B-T017
-	I-T017
striatal	I-T017
-	I-T017
cerebellar	I-T017
gray	I-T017
matter	I-T017
(	O
GM	B-T017
)	O
volume	O
,	O
its	O
specific	O
genetic	O
correlates	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	B-T062
,	O
T1	O
-	O
weighted	O
MR	O
images	O
of	O
brain	O
structure	O
were	O
collected	O
from	O
198	O
adolescents	O
(	O
63	O
ADHD	B-T038
-	O
diagnosed	B-T033
)	O
.	O

A	O
multivariate	O
parallel	O
independent	O
component	O
analysis	O
(	O
Para	O
-	O
ICA	O
)	O
technique	O
-	O
identified	O
imaging	B-T058
genetic	O
relationships	O
between	O
regional	B-T082
GM	B-T017
volume	O
and	O
single	B-T082
nucleotide	I-T082
polymorphism	I-T082
data	O
.	O

Para	O
-	O
ICA	O
analyses	O
extracted	O
14	O
components	O
from	O
genetic	B-T170
data	I-T170
and	O
9	O
from	O
MR	B-T058
data	O
.	O

An	O
iterative	B-T062
cross	I-T062
-	I-T062
validation	I-T062
using	O
randomly	O
chosen	O
subsamples	O
indicated	O
acceptable	O
stability	O
of	O
these	O
ICA	O
solutions	O
.	O

A	O
series	O
of	O
partial	O
correlation	O
analyses	O
controlling	O
for	O
age	O
,	O
sex	O
,	O
and	O
ethnicity	O
revealed	O
two	O
genotype	O
-	O
phenotype	O
component	O
pairs	O
significantly	O
differed	O
between	O
ADHD	B-T038
and	O
non	B-T033
-	I-T033
ADHD	I-T033
groups	O
,	O
after	O
a	O
Bonferroni	O
correction	O
for	O
multiple	O
comparisons	O
.	O

The	O
brain	B-T017
phenotype	O
component	O
not	O
only	O
included	O
structures	B-T082
frequently	O
found	O
to	O
have	O
abnormally	O
low	O
volume	O
in	O
previous	O
ADHD	B-T038
studies	B-T062
but	O
was	O
also	O
significantly	O
associated	O
with	O
ADHD	B-T038
differences	O
in	O
symptom	B-T033
severity	I-T033
and	O
performance	O
on	O
cognitive	B-T170
tests	I-T170
frequently	O
found	O
to	O
be	O
impaired	O
in	O
patients	O
diagnosed	B-T033
with	O
the	O
disorder	B-T038
.	O

Pathway	B-T170
analysis	I-T170
of	O
the	O
genotype	O
component	O
identified	O
several	O
different	O
biological	O
pathways	O
linked	O
to	O
these	O
structural	B-T082
abnormalities	B-T033
in	O
ADHD	B-T038
.	O

Some	O
of	O
these	O
pathways	O
implicate	O
well	O
-	O
known	O
dopaminergic	B-T038
neurotransmission	I-T038
and	O
neurodevelopment	O
hypothesized	O
to	O
be	O
abnormal	B-T033
in	O
ADHD	B-T038
.	O

Other	O
more	O
recently	O
implicated	O
pathways	O
included	O
glutamatergic	B-T038
and	O
GABA	B-T038
-	I-T038
eric	I-T038
physiological	I-T038
systems	I-T038
;	O
others	O
might	O
reflect	O
sources	O
of	O
shared	O
liability	O
to	O
disturbances	O
commonly	O
found	O
in	O
ADHD	B-T038
,	O
such	O
as	O
sleep	B-T033
abnormalities	I-T033
.	O

Clinicopathological	B-T058
and	O
Immunohistochemical	O
Characteristics	O
of	O
Verruciform	B-T038
Xanthoma	I-T038
of	O
the	O
Lower	B-T017
Gingiva	I-T017
:	O
A	O
Case	B-T170
Report	I-T170

Verruciform	B-T038
xanthoma	I-T038
(	O
VX	B-T038
)	O
is	O
a	O
rare	O
benign	B-T038
lesion	I-T038
and	O
mainly	O
effects	O
the	O
oral	B-T017
mucosa	I-T017
.	O

This	O
slow	B-T033
-	I-T033
growing	I-T033
asymptomatic	B-T033
lesion	B-T038
typically	O
develops	O
along	O
the	O
gingival	B-T082
margin	I-T082
of	O
the	O
masticatory	O
mucosa	B-T017
,	O
followed	O
by	O
the	O
hard	B-T017
palate	I-T017
,	O
tongue	B-T017
,	O
buccal	B-T017
mucosa	I-T017
,	O
floor	B-T082
of	I-T082
the	I-T082
mouth	I-T082
,	O
alveolar	B-T082
mucosa	I-T082
,	O
soft	B-T017
palate	I-T017
and	O
junction	B-T082
between	O
the	O
hard	B-T017
and	O
soft	B-T017
palate	I-T017
.	O

Moreover	O
,	O
this	O
lesion	B-T038
can	O
also	O
affect	O
the	O
skin	B-T022
and	O
genital	B-T017
organs	I-T017
.	O

Clinically	O
,	O
VX	B-T038
generally	O
presents	O
a	O
sessile	B-T033
or	O
pedunculated	B-T033
appearance	I-T033
,	O
forming	O
a	O
papule	B-T033
or	O
single	O
plaque	O
with	O
verrucous	B-T038
or	O
papillomatous	B-T038
mucosal	B-T017
growth	B-T038
.	O

The	O
colour	O
(	O
white	O
,	O
pink	O
,	O
grey	O
,	O
or	O
yellow	O
)	O
depends	O
on	O
the	O
thickness	O
of	O
the	O
overlying	O
epidermis	B-T017
.	O

In	O
fact	O
,	O
the	O
clinical	O
findings	B-T033
of	O
VX	B-T038
are	O
similar	O
to	O
those	O
of	O
verrucous	B-T038
carcinoma	I-T038
and	O
other	O
benign	B-T038
tumours	I-T038
,	O
such	O
as	O
squamous	B-T038
papilloma	I-T038
,	O
verruca	B-T038
vulgaris	I-T038
and	O
mucosal	B-T038
fibroma	I-T038
.	O

For	O
this	O
reason	O
,	O
clinical	O
and	O
histopathological	O
examinations	B-T058
are	O
essential	O
for	O
accurate	B-T058
differential	I-T058
diagnosis	I-T058
.	O

Histologically	O
,	O
VX	B-T038
is	O
characterized	O
by	O
parakeratosis	B-T038
,	O
rete	B-T017
ridges	I-T017
of	O
uniform	O
depth	O
and	O
the	O
accumulation	B-T033
of	O
foam	B-T017
cells	I-T017
,	O
which	O
are	O
also	O
called	O
"	O
xanthoma	B-T017
cells	I-T017
"	O
.	O

Here	O
,	O
we	O
describe	O
the	O
clinicopathological	B-T058
and	O
immunohistochemical	O
findings	B-T033
of	O
a	O
VX	B-T038
located	O
on	O
the	O
lower	B-T017
gingiva	I-T017
of	O
a	O
64	O
-	O
year	O
-	O
old	O
male	O
patient	O
.	O

MicroRNA	B-T017
101b	I-T017
Is	O
Downregulated	B-T038
in	O
the	O
Prefrontal	B-T017
Cortex	I-T017
of	O
a	O
Genetic	B-T170
Model	I-T170
of	O
Depression	B-T038
and	O
Targets	O
the	O
Glutamate	B-T103
Transporter	I-T103
SLC1A1	B-T103
(	O
EAAT3	B-T103
)	O
in	O
Vitro	O

MicroRNAs	B-T103
(	O
miRNAs	B-T103
)	O
are	O
small	O
regulatory	O
molecules	O
that	O
cause	O
translational	B-T038
repression	I-T038
by	O
base	B-T038
pairing	I-T038
with	I-T038
target	I-T038
mRNAs	I-T038
.	O

Cumulative	O
evidence	O
suggests	O
that	O
changes	O
in	O
miRNA	B-T017
expression	B-T038
may	O
in	O
part	O
underlie	O
the	O
pathophysiology	O
and	O
treatment	B-T058
of	O
neuropsychiatric	O
disorders	O
,	O
including	O
major	B-T038
depressive	I-T038
disorder	I-T038
(	O
MDD	B-T038
)	O
.	O

A	O
miRNA	B-T017
expression	B-T038
assay	B-T058
that	O
can	O
simultaneously	O
detect	O
423	O
rat	O
miRNAs	B-T017
(	O
miRBase	O
v	O
.	O
17	O
)	O
was	O
used	O
to	O
profile	B-T058
the	O
prefrontal	B-T017
cortex	I-T017
(	O
PFC	B-T017
)	O
of	O
a	O
genetic	B-T170
rat	I-T170
model	I-T170
of	O
MDD	B-T038
(	O
the	O
Flinders	B-T170
Sensitive	I-T170
Line	I-T170
[	O
FSL	B-T170
]	O
)	O
and	O
the	O
controls	O
,	O
the	O
Flinders	B-T170
Resistant	I-T170
Line	I-T170
(	O
FRL	B-T170
)	O
.	O

Gene	B-T038
expression	I-T038
data	O
from	O
the	O
PFC	B-T017
of	O
FSL	B-T170
/	O
FRL	B-T170
animals	B-T204
(	O
GEO	O
accession	O
no	O
.	O

GSE20388	O
)	O
were	O
used	O
to	O
guide	O
mRNA	B-T103
target	O
selection	O
.	O

Luciferase	B-T058
reporter	I-T058
assays	I-T058
were	O
used	O
to	O
verify	O
miRNA	B-T017
targets	O
in	O
vitro	O
.	O

We	O
identified	O
23	O
miRNAs	B-T017
that	O
were	O
downregulated	B-T038
in	O
the	O
PFC	B-T017
of	O
the	O
FSL	B-T170
model	I-T170
compared	O
with	O
controls	O
.	O

Interestingly	O
,	O
one	O
of	O
the	O
identified	O
miRNAs	B-T017
(	O
miR	B-T017
-	I-T017
101b	I-T017
)	O
is	O
highly	O
conserved	O
between	O
rat	B-T204
and	O
human	B-T204
and	O
was	O
recently	O
found	O
to	O
be	O
downregulated	B-T038
in	O
the	O
PFC	B-T017
of	O
depressed	B-T033
suicide	B-T033
subjects	O
.	O

Using	O
a	O
combination	O
of	O
in	O
silico	O
and	O
in	O
vitro	O
analyses	B-T062
,	O
we	O
found	O
that	O
miR	B-T017
-	I-T017
101b	I-T017
targets	O
the	O
neuronal	B-T017
glutamate	B-T103
transporter	I-T103
SLC1A1	B-T103
(	O
also	O
known	O
as	O
EAAC1	B-T103
or	O
EAAT3	B-T103
)	O
.	O

Accordingly	O
,	O
both	O
mRNA	B-T103
and	O
protein	B-T033
levels	I-T033
of	O
SLC1A1	B-T103
were	O
found	O
to	O
be	O
upregulated	B-T038
in	O
the	O
PFC	B-T017
of	O
the	O
FSL	B-T170
model	I-T170
.	O

Besides	O
providing	O
a	O
list	O
of	O
novel	O
miRNAs	B-T017
associated	O
with	O
depression	B-T033
-	I-T033
like	I-T033
states	I-T033
,	O
this	O
preclinical	B-T062
study	I-T062
replicated	O
the	O
human	B-T204
association	O
of	O
miR	B-T017
-	I-T017
101	I-T017
with	O
depression	B-T038
.	O

In	O
addition	O
,	O
since	O
one	O
of	O
the	O
targets	O
of	O
miR	B-T017
-	I-T017
101b	I-T017
appears	O
to	O
be	O
a	O
glutamate	B-T103
transporter	I-T103
,	O
our	O
preclinical	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	B-T103
dysregulation	B-T033
being	O
implicated	O
in	O
the	O
etiology	O
of	O
depression	B-T038
.	O

A	O
Practical	B-T097
Guide	I-T097
to	O
Forensic	B-T091
Nursing	I-T091
:	O
Incorporating	O
forensic	B-T091
principles	O
into	O
nursing	B-T058
practice	I-T058
Amar	B-T204
Angela	I-T204
F	I-T204
and	O
Sekula	B-T204
L	I-T204
Kathleen	I-T204
A	O
Practical	B-T097
Guide	I-T097
to	O
Forensic	B-T091
Nursing	I-T091
:	O
Incorporating	O
forensic	B-T091
principles	O
into	O
nursing	B-T058
practice	I-T058
392pp	O
US	O
$	O
59	O
.	O
95	O
Sigma	O
Theta	O
Tau	O
International	O
Honor	O
Society	O
of	O
Nursing	O
9781940446349	O
1940446341	O
[	O
Formula	O
:	O
see	O
text	O

George	B-T204
Bernard	I-T204
Shaw	I-T204
described	O
Britons	B-T098
and	O
Americans	B-T098
as	O
'	O
divided	O
by	O
a	O
common	O
language	O
'	O
,	O
and	O
that	O
is	O
made	O
very	O
clear	O
in	O
this	O
fascinating	B-T170
publication	I-T170
that	O
describes	O
in	O
depth	O
the	O
roles	B-T170
and	I-T170
responsibilities	I-T170
of	O
forensic	B-T097
nurses	I-T097
in	O
the	O
US	B-T082
.	O

Incidence	O
of	O
Diabetes	B-T038
Mellitus	I-T038
and	O
Obesity	B-T038
and	O
the	O
Overlap	O
of	O
Comorbidities	O
in	O
HIV	B-T033
+	I-T033
Hispanics	B-T098
Initiating	O
Antiretroviral	B-T058
Therapy	I-T058

Cardiovascular	B-T038
disease	I-T038
(	O
CVD	B-T038
)	O
is	O
a	O
leading	O
health	O
threat	O
for	O
HIV	B-T033
+	I-T033
patients	O
on	O
antiretroviral	B-T058
therapy	I-T058
(	O
ART	B-T058
)	O
;	O
cardiometabolic	B-T038
comorbidities	O
are	O
key	O
predictors	B-T033
of	I-T033
risk	I-T033
.	O

Data	O
are	O
limited	O
on	O
incidence	O
of	O
metabolic	O
comorbidities	O
in	O
HIV	B-T033
+	I-T033
individuals	B-T098
initiating	O
ART	B-T058
in	O
low	O
and	O
middle	O
income	O
countries	B-T082
(	O
LMICs	B-T082
)	O
,	O
particularly	O
for	O
Hispanics	B-T098
.	O

We	O
examined	B-T033
incidence	O
of	O
diabetes	B-T038
and	O
obesity	B-T038
in	O
a	O
prospective	B-T098
cohort	I-T098
of	O
those	O
initiating	O
ART	B-T058
in	O
the	O
Dominican	B-T082
Republic	I-T082
.	O

Participants	B-T098
≥18	O
years	O
,	O
initiating	O
ART	B-T058
<	O
90	O
days	O
prior	O
to	O
study	B-T062
enrollment	B-T058
,	O
were	O
examined	B-T033
for	O
incidence	O
of	O
impaired	B-T033
fasting	I-T033
glucose	I-T033
(	O
IFG	B-T033
)	O
,	O
diabetes	B-T038
mellitus	I-T038
(	O
DM	B-T038
)	O
,	O
overweight	B-T038
,	I-T038
and	I-T038
obesity	I-T038
.	O

Fasting	B-T058
plasma	I-T058
glucose	I-T058
(	O
FPG	B-T058
)	O
100	O
-	O
125mg	O
/	O
dl	O
defined	O
IFG	B-T033
;	O
FPG	B-T058
≥126	O
mg	O
/	O
dl	O
,	O
diagnosis	B-T062
per	O
medical	B-T170
record	I-T170
,	O
or	O
use	O
of	O
hypoglycemic	B-T103
medication	I-T103
defined	O
DM	B-T038
.	O

Overweight	B-T038
and	I-T038
obesity	I-T038
were	O
BMI	B-T201
25	O
-	O
30	O
and	O
≥30kg	O
/	O
m2	O
,	O
respectively	O
.	O

Dyslipidemia	B-T038
was	O
total	B-T103
cholesterol	I-T103
≥240mg	O
/	O
dl	O
or	O
use	O
of	O
lipid	B-T103
-	I-T103
lowering	I-T103
medication	I-T103
.	O

Framingham	O
risk	O
equation	O
was	O
used	B-T033
to	O
determine	O
ten	O
-	O
year	O
CVD	B-T038
risk	B-T058
at	O
the	O
end	B-T062
of	I-T062
observation	I-T062
.	O

Of	O
153	O
initiating	O
ART	B-T058
,	O
8	O
(	O
6	O
%	O
)	O
had	O
DM	B-T038
and	O
23	O
(	O
16	O
%	O
)	O
had	O
IFG	B-T033
at	O
baseline	O
,	O
6	O
developed	O
DM	B-T038
(	O
28	O
/	O
1000	O
person	B-T098
-	O
years	O
follow	B-T058
up	I-T058
[	O
PYFU	B-T058
]	O
)	O
and	O
46	O
developed	O
IFG	B-T033
(	O
329	O
/	O
1000	O
PYFU	B-T058
)	O
.	O

At	O
baseline	O
,	O
24	O
(	O
18	O
%	O
)	O
were	O
obese	B-T038
and	O
36	O
(	O
27	O
%	O
)	O
were	O
overweight	B-T033
,	O
15	O
became	O
obese	B-T038
(	O
69	O
/	O
1000	O
PYFU	B-T058
)	O
and	O
22	O
became	O
overweight	B-T033
(	O
163	O
/	O
1000	O
PYFU	B-T058
)	O
.	O

Median	B-T082
observation	B-T058
periods	O
for	O
the	O
diabetes	B-T038
and	O
obesity	B-T038
analyses	B-T062
were	O
23	O
.	O
5	O
months	O
and	O
24	O
.	O
3	O
months	O
,	O
respectively	O
.	O

Increased	O
CVD	B-T038
risk	B-T058
(	O
≥10	O
%	O
10	B-T033
-	I-T033
year	I-T033
Framingham	I-T033
risk	I-T033
score	I-T033
)	O
was	O
present	B-T033
for	O
13	O
%	O
of	O
the	O
cohort	B-T098
;	O
79	O
%	O
of	O
the	O
cohort	B-T098
had	O
≥1	O
cardiometabolic	O
comorbidity	O
,	O
48	O
%	O
had	O
≥2	O
,	O
and	O
13	O
%	O
had	O
all	O
three	O
.	O

In	O
this	O
Hispanic	B-T098
cohort	B-T098
in	O
an	O
LMIC	B-T082
,	O
incidences	O
of	O
IFG	B-T033
/	O
DM	B-T038
and	O
overweight	B-T033
/	O
obesity	B-T038
were	O
similar	O
to	O
or	O
higher	O
than	O
that	O
found	B-T033
in	O
high	B-T033
income	I-T033
countries	B-T082
,	O
and	O
cardiometabolic	B-T038
disorders	I-T038
affected	O
three	O
-	O
quarters	O
of	O
those	O
initiating	O
ART	B-T058
.	O

Care	O
models	O
incorporating	O
cardiovascular	O
risk	O
reduction	B-T058
into	O
HIV	B-T038
treatment	O
programs	O
are	O
needed	O
to	O
prevent	O
CVD	B-T038
-	O
associated	O
mortality	O
in	O
this	O
vulnerable	B-T098
population	I-T098
.	O

Laparoscopic	B-T058
Approach	I-T058
for	O
Thermoablation	B-T058
Microwave	I-T058
in	O
the	O
Treatment	B-T058
of	O
Hepatocellular	B-T038
Carcinoma	I-T038
:	O
A	O
Single	O
Center	O
Experience	B-T038

The	O
surgical	B-T058
therapy	I-T058
of	O
choice	O
for	O
hepatocellular	B-T038
carcinoma	I-T038
(	O
HCC	B-T038
)	O
is	O
liver	B-T058
transplantation	I-T058
(	O
LT	B-T058
)	O
or	O
hepatic	B-T058
resection	I-T058
,	O
although	O
only	O
a	O
small	O
percentage	O
of	O
patients	O
can	O
undergo	O
these	O
procedures	O
.	O

Microwave	B-T058
thermal	I-T058
ablation	I-T058
(	O
MWTA	B-T058
)	O
can	O
be	O
an	O
effective	O
alternative	O
treatment	B-T058
for	O
HCC	B-T038
that	O
complicates	O
a	O
cirrhotic	B-T038
liver	I-T038
disease	I-T038
,	O
either	O
as	O
a	O
final	O
procedure	O
or	O
for	O
downstaging	B-T058
patients	O
on	O
the	O
waiting	O
list	O
for	O
LT	B-T058
,	O
or	O
in	O
combination	O
with	O
resective	B-T058
surgery	B-T058
to	O
achieve	O
oncological	B-T038
radicality	O
.	O

The	O
purpose	O
of	O
this	O
retrospective	B-T062
study	I-T062
was	O
to	O
evaluate	B-T058
experience	B-T038
with	O
the	O
laparoscopic	B-T058
approach	I-T058
of	O
MWTA	B-T058
at	O
our	O
center	O
.	O

In	O
a	O
cohort	B-T098
of	O
35	O
consecutive	O
patients	O
undergoing	O
MWTA	B-T058
with	O
laparoscopic	B-T058
approach	I-T058
between	O
January	O
,	O
2013	O
and	O
May	O
,	O
2016	O
,	O
we	O
reviewed	O
the	O
demographic	B-T062
data	I-T062
,	O
the	O
Barcelona	B-T170
clinic	I-T170
liver	I-T170
cancer	I-T170
stage	I-T170
,	O
the	O
severity	O
of	O
cirrhotic	B-T038
liver	I-T038
disease	I-T038
,	O
the	O
size	B-T082
of	O
the	O
ablated	B-T058
lesion	B-T033
,	O
the	O
duration	O
of	O
the	O
procedure	O
,	O
and	O
complications	O
occurring	O
within	O
90	O
days	O
of	O
surgery	B-T058
.	O

MWTA	B-T058
was	O
performed	O
by	O
applying	O
one	O
to	O
three	O
hepatic	B-T082
parenchymal	B-T017
insertions	B-T058
(	O
mean	O
1	O
.	O
8	O
)	O
per	O
patient	O
.	O

The	O
mean	O
duration	O
of	O
surgery	B-T058
was	O
163	O
±	O
18	O
minutes	O
.	O

There	O
was	O
no	O
blood	B-T033
loss	I-T033
in	O
any	O
of	O
the	O
procedures	O
.	O

Complete	O
necrosis	B-T038
on	O
CT	B-T058
scan	I-T058
was	O
achieved	O
in	O
26	O
/	O
35	O
patients	O
(	O
75	O
%	O
)	O
.	O

The	O
mean	O
hospital	O
stay	O
was	O
4	O
.	O
6	O
(	O
range	O
2	O
-	O
7	O
)	O
days	O
;	O
major	O
complications	O
were	O
postablation	O
syndrome	B-T038
in	O
2	O
/	O
35	O
(	O
5	O
.	O
7	O
%	O
)	O
,	O
peritoneal	B-T031
fluid	I-T031
in	O
4	O
/	O
35	O
(	O
11	O
.	O
4	O
%	O
)	O
,	O
and	O
transient	O
jaundice	B-T038
in	O
1	O
/	O
35	O
(	O
2	O
.	O
8	O
%	O
)	O
patients	O
.	O

There	O
was	O
no	B-T033
mortality	I-T033
.	O

Laparoscopic	B-T058
MWTA	B-T058
is	O
a	O
safe	O
and	O
effective	O
treatment	B-T058
for	O
unresectable	B-T201
HCC	B-T038
and	O
when	O
a	O
percutaneous	B-T082
procedure	O
is	O
not	O
feasible	O
.	O

Structured	B-T082
Instruction	B-T170
With	O
Modified	O
Storybooks	O
to	O
Teach	O
Morphosyntax	O
and	O
Vocabulary	B-T170
to	O
Preschoolers	O
Who	O
are	O
Deaf	O
/	O
Hard	O
of	O
Hearing	O

Children	O
who	O
are	O
deaf	O
/	O
hard	O
of	O
hearing	O
(	O
D	O
/	O
HH	O
)	O
are	O
at	O
risk	O
for	O
diminished	O
morphosyntactical	O
and	O
vocabulary	B-T170
development	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
repeated	O
reading	O
combined	O
with	O
structured	B-T082
instruction	B-T170
.	O

Targets	O
were	O
a	O
morphosyntactical	O
form	O
and	O
novel	O
vocabulary	B-T170
words	I-T170
.	O

Participants	B-T098
were	O
3	O
preschoolers	O
who	O
are	O
D	O
/	O
HH	O
who	O
were	O
receiving	O
instruction	B-T170
with	O
an	O
oral	B-T082
approach	O
.	O

Data	O
from	O
a	O
multiple	O
baseline	B-T062
design	I-T062
indicated	O
that	O
all	O
children	O
acquired	O
the	O
targeted	O
skills	O
and	O
demonstrated	O
high	O
levels	O
of	O
generalization	B-T038
of	O
these	O
skills	O
to	O
untrained	B-T033
context	O
.	O

Implications	O
for	O
teaching	O
young	O
children	O
who	O
are	O
D	O
/	O
HH	O
using	O
repeated	O
storybook	O
reading	O
are	O
discussed	O
.	O

Application	B-T058
of	O
BRAF	O
V600E	O
mutation	B-T038
-	O
specific	O
immunohistochemistry	B-T058
in	O
diagnosis	B-T033
of	O
gastrointestinal	B-T038
stromal	I-T038
tumors	I-T038

To	O
evaluate	B-T058
the	O
utility	O
of	O
BRAF	O
V600E	O
allele	B-T017
-	O
specific	O
antibody	B-T103
in	O
the	O
diagnosis	B-T033
of	O
gastrointestinal	B-T038
stromal	I-T038
tumors	I-T038
(	O
GISTs	B-T038
)	O
.	O

BRAF	O
V600E	O
mutation	B-T038
-	O
specific	O
immunohistochemistry	B-T058
and	O
BRAF	B-T017
sequencing	O
were	O
performed	O
in	O
24	O
consecutive	O
GISTs	B-T038
,	O
including	O
14	O
cases	O
of	O
KIT	B-T038
or	O
PDGFRA	B-T038
mutations	I-T038
and	O
10	O
cases	O
of	O
KIT	B-T017
/	O
PDGFRA	B-T017
wild	I-T017
GISTs	B-T038
.	O

GISTs	B-T038
of	O
11	O
men	B-T098
and	O
13	O
women	B-T098
with	O
a	O
mean	O
age	O
54	O
years	O
(	O
range	O
29	O
-	O
75	O
years	O
)	O
were	O
included	O
with	O
tumors	B-T038
arising	O
from	O
stomach	B-T017
(	O
16	O
cases	O
)	O
,	O
small	B-T017
bowel	I-T017
(	O
7	O
cases	O
)	O
,	O
and	O
peritoneal	B-T082
cavity	I-T082
(	O
1	O
case	O
)	O
.	O

Strong	O
and	O
diffuse	B-T082
cytoplasmic	B-T017
BRAF	B-T103
staining	B-T033
was	O
noted	O
in	O
4	O
of	O
24	O
cases	O
(	O
17	O
%	O
)	O
,	O
while	O
1	O
of	O
24	O
cases	O
(	O
4	O
%	O
)	O
showed	O
weak	O
staining	B-T033
,	O
and	O
19	O
of	O
24	O
cases	O
(	O
79	O
%	O
)	O
had	O
no	O
staining	B-T033
.	O

The	O
four	O
cases	O
with	O
strong	O
BRAF	B-T103
immunostain	B-T103
were	O
confirmed	O
to	O
have	O
BRAF	B-T038
mutations	I-T038
,	O
including	O
3	O
cases	O
in	O
the	O
stomach	B-T017
and	O
1	O
case	O
in	O
the	O
small	B-T017
intestine	I-T017
.	O

All	O
tumors	B-T038
showed	O
spindle	O
cell	O
morphology	O
.	O

Only	O
one	O
case	O
had	O
progressive	B-T038
disease	I-T038
.	O

No	O
BRAF	B-T038
mutations	I-T038
were	O
detected	B-T033
in	O
cases	O
with	O
weak	O
or	O
negative	B-T033
BRAF	B-T103
immunostain	B-T103
.	O

BRAF	O
V600E	O
mutation	B-T038
-	O
specific	O
immunohistochemistry	B-T058
is	O
a	O
highly	O
sensitive	O
and	O
specific	O
marker	B-T201
for	O
detecting	B-T033
BRAF	B-T038
-	I-T038
mutated	I-T038
GISTs	B-T038
.	O

Efficacy	O
of	O
pegylated	B-T103
liposomal	I-T103
etoposide	I-T103
nanoparticles	I-T103
on	O
breast	B-T017
cancer	I-T017
cell	I-T017
lines	I-T017

This	O
study	O
aimed	O
to	O
investigate	O
the	O
efficacy	O
of	O
pegylated	B-T103
liposomal	I-T103
etoposide	I-T103
nanoparticles	I-T103
(	O
NPs	O
)	O
against	O
T	B-T038
-	I-T038
47D	I-T038
and	O
MCF	B-T017
-	I-T017
7	I-T017
breast	I-T017
cancer	I-T017
cell	I-T017
lines	I-T017
.	O

Pegylated	B-T103
liposomal	I-T103
etoposide	I-T103
NPs	I-T103
were	O
prepared	O
by	O
reverse	O
phase	O
evaporation	O
method	O
.	O

The	O
size	B-T082
,	O
size	B-T082
distribution	I-T082
,	O
and	O
zeta	O
potential	O
of	O
the	O
NPs	B-T103
was	O
measured	O
by	O
a	O
Zetasizer	B-T074
instrument	I-T074
.	O

The	O
cytotoxicity	B-T038
of	O
NPs	B-T103
was	O
inspected	O
by	O
methyl	B-T062
thiazol	I-T062
tetrazolium	I-T062
assay	I-T062
.	O

The	O
release	O
pattern	O
of	O
the	O
drug	O
from	O
the	O
vesicles	O
was	O
studied	O
by	O
the	O
dialysis	O
method	O
.	O

Drug	O
loading	O
and	O
encapsulation	O
efficiency	O
(	O
EE	O
)	O
were	O
also	O
measured	O
.	O

The	O
mean	B-T082
size	I-T082
,	O
size	B-T082
distribution	I-T082
,	O
and	O
zeta	O
potential	O
of	O
pegylated	B-T103
liposomal	I-T103
etoposide	I-T103
NPs	I-T103
were	O
491	O
±	O
15	O
.	O
5	O
nm	O
,	O
0	O
.	O
504	O
±	O
0	O
.	O
14	O
,	O
and	O
-	O
35	O
.	O
8	O
±	O
2	O
.	O
5	O
mV	O
,	O
respectively	O
.	O

Drug	O
loading	O
and	O
EE	O
were	O
10	O
.	O
3	O
±	O
1	O
.	O
6	O
%	O
and	O
99	O
.	O
1	O
±	O
2	O
.	O
8	O
%	O
,	O
respectively	O
.	O

The	O
etoposide	O
release	O
in	O
the	O
formulation	O
was	O
estimated	O
at	O
about	O
3	O
.	O
48	O
%	O
after	O
48	O
h	O
.	O

The	O
cytotoxicity	B-T038
effect	I-T038
of	O
etoposide	B-T103
NPs	I-T103
on	O
T	B-T038
-	I-T038
47D	I-T038
and	O
MCF	B-T017
-	I-T017
7	I-T017
cell	I-T017
lines	I-T017
of	I-T017
breast	I-T017
cancer	I-T017
showed	O
higher	O
antitumor	O
activity	O
as	O
compared	O
with	O
those	O
of	O
the	O
free	O
drug	O
.	O

Liposome	B-T103
-	I-T103
based	I-T103
NPs	I-T103
may	O
hold	O
great	O
potential	O
as	O
a	O
drug	B-T074
delivery	I-T074
system	I-T074
.	O

The	O
Bindex	B-T074
(	I-T074
®	I-T074
)	I-T074
ultrasound	I-T074
device	I-T074
:	O
reliability	O
of	O
cortical	B-T017
bone	I-T017
thickness	O
measures	O
and	O
their	O
relationship	O
to	O
regional	B-T082
bone	B-T201
mineral	I-T201
density	I-T201

The	O
Bindex	B-T074
(	I-T074
®	I-T074
)	I-T074
quantitative	I-T074
ultrasound	I-T074
(	I-T074
QUS	I-T074
)	I-T074
device	I-T074
is	O
currently	O
available	O
and	O
this	O
study	B-T062
analyzed	B-T062
(	O
I	O
)	O
its	O
relative	O
and	O
absolute	O
intra	O
-	O
and	O
inter	O
-	O
session	O
reliability	O
and	O
(	O
II	O
)	O
the	O
relationship	O
between	O
the	O
data	O
provided	O
by	O
Bindex	B-T074
(	I-T074
®	I-T074
)	I-T074
-	I-T074
QUS	I-T074
and	O
the	O
bone	B-T201
mineral	I-T201
density	I-T201
(	O
BMD	B-T201
)	O
measured	O
by	O
dual	B-T058
-	I-T058
energy	I-T058
x	I-T058
-	I-T058
ray	I-T058
absorptiometry	I-T058
at	O
corresponding	O
skeletal	B-T082
sites	I-T082
in	O
young	B-T098
and	O
healthy	B-T098
subjects	I-T098
(	O
age	O
:	O
25	O
.	O
0	O
±	O
3	O
.	O
6	O
years	O
)	O
.	O

Bindex	B-T074
(	I-T074
®	I-T074
)	I-T074
-	I-T074
QUS	I-T074
calculates	O
a	O
density	B-T201
index	I-T201
on	O
the	O
basis	O
of	O
the	O
thickness	O
of	O
cortical	B-T017
bone	I-T017
measured	O
at	O
the	O
distal	B-T017
radius	I-T017
and	O
the	O
distal	B-T017
plus	O
proximal	B-T017
tibia	I-T017
.	O

The	O
data	O
show	O
a	O
very	O
good	O
relative	O
and	O
absolute	O
intra	O
-	O
(	O
ICC	O
=	O
0	O
.	O
977	O
,	O
CV	O
=	O
1	O
.	O
5	O
%	O
)	O
and	O
inter	O
-	O
session	O
reliability	O
(	O
ICC	O
=	O
0	O
.	O
978	O
,	O
CV	O
=	O
1	O
.	O
4	O
%	O
)	O
for	O
the	O
density	B-T201
index	I-T201
.	O

The	O
highest	O
positive	B-T033
correlations	O
were	O
found	O
between	O
cortical	B-T017
thickness	O
and	O
BMD	B-T201
for	O
the	O
distal	B-T017
radius	I-T017
and	O
distal	B-T017
tibia	I-T017
(	O
r	O
⩾	O
0	O
.	O
71	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
data	O
indicate	O
that	O
the	O
Bindex	B-T074
(	I-T074
®	I-T074
)	I-T074
-	I-T074
QUS	I-T074
parameters	B-T033
are	O
repeatable	O
within	O
and	O
between	O
measurement	O
sessions	O
.	O

Furthermore	O
,	O
the	O
measurements	O
reflect	O
the	O
BMD	B-T201
at	O
specific	O
skeletal	B-T082
sites	I-T082
.	O

Bindex	B-T074
(	I-T074
®	I-T074
)	I-T074
-	I-T074
QUS	I-T074
might	O
be	O
a	O
useful	O
tool	O
for	O
the	O
measurement	O
of	O
skeletal	B-T038
adaptations	I-T038
.	O

Botulinum	B-T103
Toxin	I-T103
Use	O
in	O
Refractory	B-T033
Pain	I-T033
and	O
Other	O
Symptoms	B-T033
in	O
Parkinsonism	B-T038

Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
and	O
other	O
parkinsonian	B-T038
syndromes	I-T038
are	O
chronic	O
,	O
progressive	O
neurodegenerative	B-T038
diseases	I-T038
.	O

With	O
advancing	O
disease	B-T038
,	O
both	O
motor	B-T033
and	O
non	B-T033
-	I-T033
motor	I-T033
symptoms	I-T033
represent	O
a	O
considerable	O
burden	O
and	O
symptom	B-T033
relief	B-T033
and	O
quality	O
of	O
life	O
improvement	O
become	O
the	O
main	O
goal	B-T170
of	O
treatment	B-T058
.	O

Botulinum	B-T103
toxins	I-T103
(	O
BTX	B-T103
)	O
are	O
an	O
effective	O
treatment	B-T058
modality	O
for	O
many	O
neurological	B-T038
conditions	I-T038
.	O

To	O
understand	O
the	O
potential	O
usefulness	O
of	O
BTX	B-T103
in	O
this	O
population	B-T098
,	O
we	O
performed	O
a	O
retrospective	O
chart	B-T058
review	I-T058
of	O
all	O
patients	O
with	O
a	O
clinical	B-T058
diagnosis	I-T058
of	O
idiopathic	B-T038
PD	I-T038
and	O
atypical	B-T038
parkinsonism	I-T038
who	O
received	O
treatment	O
with	O
BTX	B-T058
injections	I-T058
in	O
our	O
center	B-T092
from	O
1995	O
to	O
2014	O
for	O
a	O
variety	O
of	O
symptoms	B-T033
.	O

Response	O
to	O
BTX	B-T103
was	O
assessed	O
using	O
a	O
subjective	B-T170
Clinical	I-T170
Global	I-T170
Impression	I-T170
.	O

Records	B-T170
of	O
160	O
patients	O
were	O
reviewed	O
.	O

Probable	O
idiopathic	B-T038
PD	I-T038
was	O
the	O
diagnosis	B-T033
in	O
117	O
patients	O
(	O
73	O
.	O
1	O
%	O
)	O
.	O

The	O
main	O
indication	O
for	O
BTX	B-T103
treatment	B-T058
was	O
pain	B-T033
(	O
50	O
.	O
6	O
%	O
of	O
cases	O
)	O
.	O

Other	O
indications	O
were	O
the	O
treatment	B-T058
of	O
functional	O
impairment	O
resulting	O
from	O
dystonia	B-T033
(	O
26	O
.	O
25	O
%	O
)	O
,	O
sialorrhea	B-T038
(	O
18	O
.	O
75	O
%	O
)	O
,	O
freezing	B-T033
of	I-T033
gait	I-T033
,	O
and	O
camptocormia	B-T017
.	O

Considering	O
pain	B-T033
as	O
indication	O
,	O
81	O
%	O
of	O
all	O
patients	O
with	O
PD	B-T038
reported	B-T058
benefits	O
after	O
the	O
first	O
BTX	B-T058
injections	I-T058
.	O

This	O
benefit	O
was	O
maintained	O
after	O
the	O
last	B-T058
recorded	I-T058
visit	I-T058
without	O
significant	O
difference	O
in	O
outcome	O
compared	O
with	O
the	O
first	O
injection	B-T058
(	O
p	O
=	O
0	O
.	O
067	O
)	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
patients	O
with	O
atypical	B-T038
parkinsonism	I-T038
.	O

Our	O
results	O
confirm	O
the	O
safety	O
and	O
efficacy	O
of	O
different	O
uses	O
of	O
BTX	B-T103
in	O
the	O
symptomatic	O
treatment	O
of	O
patients	O
with	O
parkinsonism	B-T038
even	O
in	O
advanced	O
stages	O
of	O
the	O
disease	B-T038
,	O
and	O
suggest	O
BTX	B-T103
treatment	B-T058
could	O
have	O
a	O
safe	O
and	O
useful	O
role	O
in	O
the	O
treatment	O
of	O
pain	B-T033
in	O
this	O
population	B-T098
.	O

Chronic	B-T033
exposure	I-T033
to	I-T033
haloperidol	B-T103
and	O
olanzapine	B-T103
leads	O
to	O
common	O
and	O
divergent	O
shape	B-T033
changes	I-T033
in	O
the	O
rat	B-T204
hippocampus	B-T017
in	O
the	O
absence	O
of	O
grey	B-T017
-	I-T017
matter	I-T017
volume	O
loss	O

One	O
of	O
the	O
most	O
consistently	O
reported	O
brain	B-T017
abnormalities	I-T017
in	O
schizophrenia	B-T038
(	O
SCZ	B-T038
)	O
is	O
decreased	O
volume	B-T033
and	I-T033
shape	I-T033
deformation	I-T033
of	O
the	O
hippocampus	B-T017
.	O

However	O
,	O
the	O
potential	O
contribution	O
of	O
chronic	B-T103
antipsychotic	I-T103
medication	I-T103
exposure	B-T033
to	O
these	O
phenomena	O
remains	O
unclear	O
.	O

We	O
examined	O
the	O
effect	O
of	O
chronic	B-T033
exposure	I-T033
(	O
8	O
weeks	O
)	O
to	O
clinically	O
relevant	O
doses	O
of	O
either	O
haloperidol	B-T103
(	O
HAL	B-T103
)	O
or	O
olanzapine	B-T103
(	O
OLZ	B-T103
)	O
on	O
adult	O
rat	B-T204
hippocampal	B-T082
volume	B-T033
and	I-T033
shape	I-T033
using	O
ex	O
vivo	O
structural	B-T058
MRI	I-T058
with	O
the	O
brain	B-T017
retained	I-T017
inside	I-T017
the	I-T017
cranium	I-T017
to	O
prevent	O
distortions	B-T017
due	O
to	O
dissection	B-T058
,	O
followed	O
by	O
tensor	B-T058
-	I-T058
based	I-T058
morphometry	I-T058
(	O
TBM	B-T058
)	O
and	O
elastic	B-T062
surface	I-T062
-	I-T062
based	I-T062
shape	I-T062
deformation	I-T062
analysis	I-T062
.	O

The	O
volume	O
of	O
the	O
hippocampus	B-T017
was	O
also	O
measured	O
post	B-T058
-	I-T058
mortem	I-T058
from	O
brain	B-T017
tissue	I-T017
sections	O
in	O
each	O
group	O
.	O

Chronic	B-T033
exposure	I-T033
to	O
either	O
HAL	B-T103
or	O
OLZ	B-T103
had	O
no	O
effect	O
on	O
the	O
volume	O
of	O
the	O
hippocampus	B-T017
,	O
even	O
at	O
exploratory	B-T058
thresholds	I-T058
,	O
which	O
was	O
confirmed	O
post	B-T058
-	I-T058
mortem	I-T058
.	O

In	O
contrast	O
,	O
shape	B-T062
deformation	I-T062
analysis	I-T062
revealed	O
that	O
chronic	O
HAL	B-T103
and	O
OLZ	B-T103
exposure	B-T033
lead	O
to	O
both	O
common	O
and	O
divergent	B-T033
shape	I-T033
deformations	I-T033
(	O
q	O
=	O
0	O
.	O
05	O
,	O
FDR	O
-	O
corrected	O
)	O
in	O
the	O
rat	B-T204
hippocampus	B-T017
.	O

In	O
particular	O
,	O
in	O
the	O
dorsal	B-T017
hippocampus	I-T017
,	O
HAL	B-T103
exposure	B-T033
led	O
to	O
inward	B-T033
shape	I-T033
deformation	I-T033
,	O
whereas	O
OLZ	B-T103
exposure	B-T033
led	O
to	O
outward	B-T033
shape	I-T033
deformation	I-T033
.	O

Interestingly	O
,	O
outward	B-T033
shape	I-T033
deformations	I-T033
that	O
were	O
common	O
to	O
both	O
drugs	B-T103
occurred	O
in	O
the	O
ventral	B-T017
hippocampus	I-T017
.	O

These	O
effects	O
remained	O
significant	O
after	O
controlling	O
for	O
hippocampal	B-T017
volume	O
suggesting	O
true	O
shape	B-T033
changes	I-T033
.	O

Chronic	B-T033
exposure	I-T033
to	O
either	O
HAL	B-T103
or	O
OLZ	B-T103
leads	O
to	O
both	O
common	O
and	O
divergent	O
effects	O
on	O
rat	B-T204
hippocampal	B-T017
shape	I-T017
in	O
the	O
absence	O
of	O
volume	O
change	O
.	O

The	O
implications	O
of	O
these	O
findings	O
for	O
the	O
clinic	O
are	O
discussed	O
.	O

Shear	O
and	O
extensional	O
properties	O
of	O
kefiran	B-T103

Kefiran	B-T103
is	O
a	O
neutral	B-T103
polysaccharide	I-T103
constituted	O
by	O
glucose	B-T103
and	O
galactose	B-T103
produced	O
by	O
Lactobacillus	B-T007
kefiranofaciens	I-T007
.	O

It	O
is	O
included	O
into	O
kefir	B-T168
grains	I-T168
and	O
has	O
several	O
health	O
promoting	O
properties	O
.	O

In	O
the	O
present	O
work	O
,	O
shear	O
and	O
extensional	O
properties	O
of	O
different	O
kefiran	B-T103
aqueous	O
dispersions	O
(	O
0	O
.	O
5	O
,	O
1	O
and	O
2	O
%	O
wt	O
.	O
)	O
were	O
assessed	O
and	O
compared	O
to	O
other	O
neutral	B-T103
gums	I-T103
commonly	O
used	O
in	O
food	B-T168
,	O
cosmetic	O
and	O
pharmaceutics	B-T092
industries	I-T092
(	O
methylcellulose	B-T103
,	O
locust	O
bean	O
gum	O
and	O
guar	B-T103
gum	I-T103
)	O
.	O

Kefiran	B-T103
showed	O
shear	O
flow	O
characteristics	O
similar	O
to	O
that	O
displayed	O
by	O
other	O
representative	O
neutral	B-T103
gums	I-T103
,	O
although	O
it	O
always	O
yielded	O
lower	O
viscosities	O
at	O
a	O
given	O
concentration	O
.	O

For	O
each	O
gum	B-T103
system	O
it	O
was	O
possible	O
to	O
find	O
a	O
correlation	O
between	O
dynamic	O
and	O
steady	O
shear	O
properties	O
by	O
a	O
master	B-T082
curve	I-T082
including	O
both	O
the	O
apparent	O
and	O
complex	O
viscosities	O
.	O

When	O
studying	O
extensional	O
properties	O
of	O
selected	O
gums	B-T103
at	O
2	O
%	O
wt	O
.	O

by	O
means	O
of	O
a	O
capillary	O
break	O
-	O
up	O
rheometer	O
,	O
kefiran	B-T103
solutions	O
did	O
not	O
show	O
important	O
extensional	O
properties	O
,	O
displaying	O
a	O
behaviour	O
close	O
the	O
Newtonian	O
.	O

Air	O
tamponade	O
of	O
the	O
heart	B-T017

Pneumopericardium	B-T038
is	O
a	O
rare	B-T038
disease	I-T038
defined	O
as	O
the	O
presence	B-T033
of	O
air	O
or	O
gas	B-T103
in	O
the	O
pericardial	B-T017
sac	I-T017
.	O

Among	O
the	O
etiological	O
factors	O
,	O
the	O
following	O
stand	O
out	O
:	O
chest	B-T037
trauma	I-T037
,	O
barotrauma	B-T037
,	O
air	O
-	O
containing	O
fistulas	B-T017
between	O
the	O
pericardium	B-T017
and	O
the	O
surrounding	B-T082
structures	B-T082
,	O
secondary	O
gas	O
production	O
by	O
microorganisms	O
growing	O
in	O
the	O
pericardial	B-T017
sac	I-T017
,	O
and	O
iatrogenic	O
factors	O
.	O

Until	O
now	O
,	O
spontaneous	O
pneumopericardium	B-T038
has	O
been	O
considered	O
a	O
harmless	O
and	O
temporary	O
state	O
,	O
but	O
a	O
review	O
of	O
clinical	O
cases	O
indicates	O
that	O
the	O
presence	B-T033
of	O
air	O
in	O
the	O
pericardium	B-T017
can	O
lead	O
to	O
cardiac	B-T038
tamponade	I-T038
and	O
life	B-T033
-	I-T033
threatening	I-T033
hemodynamic	B-T038
disturbances	O
.	O

We	O
present	B-T033
the	O
case	O
of	O
an	O
80	O
-	O
year	O
-	O
old	O
patient	O
with	O
a	O
chronic	O
bronchopericardial	B-T017
fistula	B-T017
,	O
who	O
suffered	O
from	O
a	O
cardiac	B-T038
arrest	I-T038
due	O
to	O
air	O
tamponade	O
of	O
the	O
heart	B-T017
.	O

The	O
Complete	O
Chloroplast	B-T017
Genome	I-T017
Sequence	B-T082
of	O
the	O
Medicinal	B-T204
Plant	I-T204
Swertia	B-T204
mussotii	I-T204
Using	O
the	O
PacBio	O
RS	O
II	O
Platform	O

Swertia	B-T204
mussotii	I-T204
is	O
an	O
important	O
medicinal	B-T204
plant	I-T204
that	O
has	O
great	O
economic	O
and	O
medicinal	B-T103
value	I-T103
and	O
is	O
found	O
on	O
the	O
Qinghai	O
Tibetan	O
Plateau	O
.	O

The	O
complete	O
chloroplast	B-T017
(	I-T017
cp	I-T017
)	I-T017
genome	I-T017
of	O
S	B-T204
.	I-T204

mussotii	I-T204
is	O
153	O
,	O
431	O
bp	O
in	O
size	O
,	O
with	O
a	O
pair	O
of	O
inverted	B-T103
repeat	I-T103
(	I-T103
IR	I-T103
)	I-T103
regions	I-T103
of	O
25	O
,	O
761	O
bp	O
each	O
that	O
separate	O
an	O
large	B-T082
single	I-T082
-	I-T082
copy	I-T082
(	I-T082
LSC	I-T082
)	I-T082
region	I-T082
of	O
83	O
,	O
567	O
bp	O
and	O
an	O
a	O
small	B-T082
single	I-T082
-	I-T082
copy	I-T082
(	I-T082
SSC	I-T082
)	I-T082
region	I-T082
of	O
18	O
,	O
342	O
bp	O
.	O

The	O
S	B-T204
.	I-T204

mussotii	I-T204
cp	B-T017
genome	I-T017
encodes	O
84	O
protein	B-T017
-	I-T017
coding	I-T017
genes	I-T017
,	O
37	O
transfer	B-T103
RNA	I-T103
(	O
tRNA	B-T103
)	O
genes	B-T017
,	O
and	O
eight	O
ribosomal	B-T017
RNA	I-T017
(	I-T017
rRNA	I-T017
)	I-T017
genes	I-T017
.	O

The	O
identity	O
,	O
number	O
,	O
and	O
GC	O
content	O
of	O
S	B-T204
.	I-T204

mussotii	I-T204
cp	B-T017
genes	I-T017
were	O
similar	O
to	O
those	O
in	O
the	O
genomes	B-T017
of	O
other	O
Gentianales	B-T204
species	B-T170
.	O

Via	O
analysis	B-T062
of	O
the	O
repeat	B-T082
structure	I-T082
,	O
11	O
forward	O
repeats	B-T082
,	O
eight	O
palindromic	B-T103
repeats	I-T103
,	O
and	O
one	O
reverse	O
repeat	O
were	O
detected	B-T033
in	O
the	O
S	B-T204
.	I-T204

mussotii	I-T204
cp	B-T017
genome	I-T017
.	O

There	O
are	O
45	O
SSRs	B-T103
in	O
the	O
S	B-T204
.	I-T204

mussotii	I-T204
cp	B-T017
genome	I-T017
,	O
the	O
majority	O
of	O
which	O
are	O
mononucleotides	B-T103
found	O
in	O
all	O
other	O
Gentianales	B-T204
species	B-T170
.	O

An	O
entire	O
cp	B-T017
genome	I-T017
comparison	B-T062
study	I-T062
of	O
S	B-T204
.	I-T204

mussotii	I-T204
and	O
two	O
other	O
species	B-T170
in	O
Gentianaceae	B-T204
was	O
conducted	O
.	O

The	O
complete	O
cp	B-T017
genome	I-T017
sequence	B-T082
provides	O
intragenic	B-T017
information	O
for	O
the	O
cp	B-T017
genetic	B-T062
engineering	I-T062
of	O
this	O
medicinal	B-T204
plant	I-T204
.	O

Meta	B-T062
-	I-T062
Analysis	I-T062
of	O
29	O
Experiments	B-T062
Evaluating	B-T058
the	O
Effects	O
of	O
Rapamycin	B-T103
on	O
Life	O
Span	O
in	O
the	O
Laboratory	B-T204
Mouse	I-T204

Rapamycin	B-T103
has	O
favorable	O
effects	O
on	O
aging	B-T038
in	O
mice	B-T204
and	O
may	O
eventually	O
be	O
applied	O
to	O
encourage	O
"	O
healthy	O
aging	B-T038
"	O
in	O
humans	B-T204
.	O

This	O
study	B-T062
analyzed	B-T062
raw	O
data	O
from	O
29	O
survival	B-T062
studies	I-T062
of	O
rapamycin	B-T103
-	O
and	O
control	O
-	O
treated	O
mice	B-T204
,	O
with	O
the	O
goals	B-T170
of	O
estimating	O
summary	B-T170
statistics	B-T170
and	O
identifying	O
factors	O
associated	O
with	O
effect	O
size	O
heterogeneity	O
.	O

Meta	B-T062
-	I-T062
analysis	I-T062
demonstrated	O
significant	O
heterogeneity	O
across	O
studies	B-T058
,	O
with	O
hazard	O
ratio	O
(	O
HR	O
)	O
estimates	O
ranging	O
from	O
0	O
.	O
22	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
0	O
.	O
06	O
-	O
0	O
.	O
82	O
)	O
to	O
0	O
.	O
92	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
65	O
-	O
1	O
.	O
28	O
)	O
.	O

Sex	O
was	O
the	O
major	O
factor	O
accounting	O
for	O
effect	O
size	O
variation	O
,	O
and	O
mortality	O
was	O
decreased	O
more	O
in	O
females	O
(	O
HR	O
=	O
0	O
.	O
41	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
35	O
-	O
0	O
.	O
48	O
)	O
as	O
compared	O
with	O
males	O
(	O
HR	O
=	O
0	O
.	O
63	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
55	O
-	O
0	O
.	O
71	O
)	O
.	O

Rapamycin	B-T103
effects	O
were	O
also	O
genotype	O
dependent	O
,	O
however	O
,	O
with	O
stronger	O
survivorship	O
increases	O
in	O
hybrid	O
mice	B-T204
(	O
14	O
.	O
4	O
%	O
;	O
95	O
%	O
CI	O
:	O
12	O
.	O
5	O
-	O
16	O
.	O
3	O
%	O
)	O
relative	O
to	O
pure	O
inbred	B-T204
strains	I-T204
(	O
8	O
.	O
8	O
%	O
;	O
95	O
%	O
CI	O
:	O
6	O
.	O
2	O
-	O
11	O
.	O
6	O
%	O
)	O
.	O

Number	O
needed	O
to	O
treat	O
was	O
applied	O
as	O
an	O
effect	O
size	O
metric	O
,	O
which	O
consistently	O
identified	O
early	O
senescence	B-T033
as	O
the	O
age	O
of	O
peak	O
treatment	O
benefit	O
.	O

These	O
results	O
provide	O
synthesis	O
of	O
existing	O
data	O
to	O
support	O
the	O
potential	O
translation	B-T062
of	O
findings	B-T033
from	O
mouse	B-T204
to	O
primate	B-T204
species	I-T204
.	O

Because	O
rapamycin	B-T103
'	I-T103
s	I-T103
effect	O
on	O
survival	O
depends	O
on	O
sex	O
and	O
genotype	O
,	O
further	O
work	O
is	O
justified	O
to	O
understand	O
how	O
these	O
factors	O
shape	O
treatment	O
response	O
.	O

Transfusion	B-T091
medicine	I-T091
in	O
medical	O
education	O
:	O
an	O
analysis	B-T062
of	O
curricular	O
grids	O
in	O
Brazil	B-T082
and	O
a	O
review	O
of	O
the	O
current	B-T170
literature	I-T170

Blood	B-T058
transfusions	I-T058
are	O
one	O
of	O
the	O
most	O
performed	O
medical	B-T058
procedures	I-T058
in	O
the	O
world	B-T098
.	O

Thus	O
,	O
as	O
education	O
in	O
transfusion	B-T091
medicine	I-T091
is	O
vital	O
to	O
medical	B-T033
care	I-T033
,	O
it	O
should	O
aim	O
to	O
promote	O
a	O
responsible	O
practice	O
with	O
the	O
rational	O
use	O
of	O
blood	B-T031
by	O
doctors	B-T097
.	O

This	O
study	O
aims	O
to	O
investigate	O
the	O
situation	O
of	O
the	O
teaching	O
of	O
transfusion	B-T091
medicine	I-T091
in	O
medical	B-T092
schools	I-T092
in	O
Brazil	B-T082
.	O

The	O
websites	B-T170
of	O
the	O
249	O
Brazilian	B-T098
medical	B-T092
schools	I-T092
in	O
operation	O
in	O
June	O
2015	O
were	O
visited	O
and	O
the	O
curricula	B-T170
of	O
the	O
medical	O
courses	O
were	O
investigated	O
in	O
respect	O
to	O
the	O
presence	O
or	O
absence	O
of	O
a	O
transfusion	B-T091
medicine	I-T091
discipline	I-T091
.	O

When	O
available	O
,	O
the	O
subject	O
grids	O
were	O
analyzed	B-T062
to	O
verify	O
whether	O
a	O
description	B-T170
of	I-T170
content	I-T170
regarding	O
transfusion	B-T091
medicine	I-T091
was	O
given	O
within	O
other	O
disciplines	O
.	O

Of	O
the	O
249	O
medical	B-T092
school	I-T092
sites	O
visited	O
,	O
information	O
on	O
the	O
curriculum	B-T170
was	O
obtained	O
from	O
178	O
.	O

Of	O
the	O
medical	B-T092
schools	I-T092
that	O
published	O
their	O
curriculum	B-T170
,	O
132	O
(	O
74	O
.	O
1	O
%	O
)	O
did	O
not	O
have	O
disciplines	B-T091
of	I-T091
transfusion	I-T091
medicine	I-T091
or	O
hematology	B-T091
and	O
only	O
seven	O
(	O
3	O
.	O
9	O
%	O
)	O
had	O
a	O
discipline	B-T091
of	I-T091
transfusion	I-T091
medicine	I-T091
in	O
the	O
curricular	O
grid	O
.	O

Education	O
on	O
transfusion	B-T091
medicine	I-T091
is	O
of	O
fundamental	O
importance	O
for	O
safe	B-T058
and	I-T058
efficient	I-T058
transfusion	I-T058
practices	I-T058
.	O

Deficiencies	O
in	O
medical	O
knowledge	B-T170
of	O
this	O
subject	O
have	O
been	O
found	O
worldwide	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
a	O
possible	O
deficiency	O
in	O
teaching	O
the	O
basics	O
of	O
this	O
specialty	O
.	O

Thus	O
,	O
additional	O
prospective	B-T062
studies	I-T062
to	O
assess	O
the	O
knowledge	B-T170
and	O
practice	O
of	O
transfusion	B-T091
medicine	I-T091
in	O
Brazilian	B-T098
medical	B-T092
schools	I-T092
are	O
warranted	O
,	O
which	O
could	O
prompt	O
a	O
discussion	O
on	O
the	O
importance	O
of	O
offering	O
training	O
in	O
transfusion	B-T091
medicine	I-T091
to	O
medical	B-T097
students	I-T097
.	O

Advanced	O
interlocking	B-T074
systems	I-T074
to	O
improve	B-T033
heavy	O
-	O
load	O
-	O
bearing	O
characteristics	O
of	O
flexible	O
intramedullary	B-T058
nailing	I-T058

Flexible	O
intramedullary	B-T058
nailing	I-T058
(	O
FIN	B-T058
)	O
is	O
a	O
minimally	B-T058
invasive	I-T058
and	O
widespread	B-T082
standard	O
method	B-T058
for	O
osteosynthesis	B-T058
of	O
pediatric	O
long	B-T033
bone	I-T033
fractures	I-T033
.	O

In	O
the	O
case	O
of	O
unstable	B-T037
fractures	I-T037
of	O
the	O
lower	B-T017
extremity	I-T017
,	O
interlocking	B-T074
systems	I-T074
need	O
to	O
be	O
used	O
to	O
prevent	O
axial	B-T082
shortening	B-T058
and	O
subsequent	O
perforation	B-T038
of	O
the	O
nail	B-T074
at	O
its	O
insertion	B-T082
site	I-T082
.	O

In	O
the	O
present	O
study	B-T062
,	O
four	O
different	O
screw	B-T074
-	O
fixed	O
interlocking	B-T074
systems	I-T074
for	O
FINs	B-T058
(	O
Hofer	B-T074
TwinPlug	I-T074
with	O
two	O
3	O
-	O
mm	O
titanium	B-T103
interlocking	B-T074
screws	I-T074
,	O
Hofer	B-T074
FixPlug	I-T074
with	O
3	O
-	O
mm	O
titanium	B-T103
interlocking	B-T074
screw	I-T074
,	O
Hofer	B-T074
Plug	I-T074
with	O
3	O
.	O
5	O
-	O
mm	O
titanium	B-T103
interlocking	B-T074
screw	I-T074
,	O
and	O
Hofer	B-T074
Plug	I-T074
with	O
3	O
-	O
mm	O
titanium	B-T103
interlocking	B-T074
screw	I-T074
)	O
in	O
comparison	O
with	O
the	O
commonly	O
used	O
Ender	O
stainless	B-T103
steel	I-T103
nails	B-T074
(	O
locked	O
with	O
3	O
.	O
5	O
-	O
mm	O
screw	B-T074
)	O
were	O
experimentally	O
investigated	O
in	O
cadaveric	B-T017
lamb	B-T204
tibiae	B-T017
,	O
regarding	O
their	O
load	O
characteristics	O
and	O
failure	O
modes	O
in	O
the	O
case	O
of	O
heavy	O
loading	O
.	O

The	O
specimens	O
were	O
subjected	O
to	O
sequential	O
axial	B-T082
cyclic	O
loading	O
of	O
5000	O
cycles	O
with	O
stepwise	O
increase	O
of	O
the	O
load	O
amplitude	B-T082
until	O
failure	O
.	O

Migration	O
of	O
locking	B-T074
screws	I-T074
and	O
internal	B-T082
damage	B-T037
of	O
bone	B-T017
tissue	I-T017
was	O
quantified	O
by	O
micro	B-T058
-	I-T058
computed	I-T058
tomography	I-T058
(	I-T058
CT	I-T058
)	I-T058
imaging	I-T058
.	O

Ender	B-T074
nails	I-T074
failed	O
on	O
average	O
at	O
a	O
peak	O
load	O
of	O
800	O
N	O
,	O
TwinPlugs	B-T074
at	O
1367	O
N	O
,	O
FixPlugs	B-T074
at	O
1222	O
N	O
,	O
Plugs	B-T074
3	O
.	O
5mm	O
at	O
1225	O
N	O
and	O
Plugs	B-T074
3	O
.	O
0mm	O
at	O
971	O
N	O
.	O

TwinPlugs	B-T074
,	O
FixPlugs	B-T074
,	O
and	O
Plugs	B-T074
3	O
.	O
5mm	O
failed	O
in	O
a	O
slow	O
manner	O
over	O
several	O
hundred	O
loading	O
cycles	O
,	O
whereas	O
Ender	B-T074
nails	I-T074
and	O
Plugs	B-T074
3	O
.	O
0mm	O
exhibited	O
abrupt	O
failure	O
without	O
any	O
prior	O
indication	O
.	O

Our	O
results	O
confirm	O
that	O
axial	B-T082
stability	O
of	O
FIN	B-T058
can	O
be	O
further	O
improved	B-T033
by	O
screw	B-T074
-	O
fixed	O
plugs	B-T074
by	O
simultaneously	O
avoiding	O
shortcomings	O
of	O
an	O
eye	O
-	O
locked	O
system	O
,	O
which	O
the	O
Ender	B-T074
nails	I-T074
are	O
.	O

Considering	O
biomechanical	O
results	O
,	O
plug	B-T074
interlocking	B-T074
systems	I-T074
with	O
3	O
.	O
5	O
-	O
mm	O
screws	B-T074
should	O
be	O
favored	O
over	O
conventional	O
Ender	B-T074
nails	I-T074
and	O
plugs	B-T074
with	O
3	O
-	O
mm	O
screws	B-T074
.	O

Surgical	B-T058
Guidance	B-T058
via	O
Multiplexed	B-T058
Molecular	I-T058
Imaging	I-T058
of	O
Fresh	O
Tissues	B-T017
Labeled	B-T103
with	O
SERS	O
-	O
Coded	O
Nanoparticles	O

The	O
imaging	B-T058
of	O
dysregulated	O
cell	B-T103
-	I-T103
surface	I-T103
receptors	I-T103
(	O
or	O
biomarkers	B-T201
)	I-T201
is	O
a	O
potential	O
means	O
of	O
identifying	O
the	O
presence	B-T033
of	O
cancer	B-T038
with	O
high	O
sensitivity	O
and	O
specificity	O
.	O

However	O
,	O
due	O
to	O
heterogeneities	O
in	O
the	O
expression	B-T038
of	I-T038
protein	I-T038
biomarkers	B-T103
in	O
tumors	B-T038
,	O
molecular	B-T058
imaging	I-T058
technologies	B-T058
should	O
ideally	O
be	O
capable	O
of	O
visualizing	O
a	O
multiplexed	O
panel	O
of	O
cancer	B-T103
biomarkers	I-T103
.	O

Recently	O
,	O
surface	O
-	O
enhanced	O
Raman	O
-	O
scattering	O
(	O
SERS	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
have	O
attracted	O
wide	O
interest	O
due	O
to	O
their	O
potential	O
for	O
sensitive	O
and	O
multiplexed	O
biomarker	O
detection	B-T058
.	O

In	O
this	O
review	B-T170
,	O
we	O
focus	O
on	O
the	O
most	O
recent	O
advances	O
in	O
tumor	B-T038
imaging	B-T058
using	O
SERS	O
-	O
coded	O
NPs	O
.	O

A	O
brief	O
introduction	O
of	O
the	O
structure	B-T082
and	O
optical	O
properties	O
of	O
SERS	O
NPs	O
is	O
provided	O
,	O
followed	O
by	O
a	O
detailed	O
discussion	O
of	O
key	O
imaging	B-T058
issues	O
such	O
as	O
the	O
administration	O
of	O
NPs	O
in	O
tissue	B-T017
(	O
topical	B-T082
versus	O
systemic	O
)	O
,	O
the	O
optical	O
configuration	O
and	O
imaging	B-T058
approach	O
of	O
Raman	B-T058
imaging	I-T058
systems	I-T058
,	O
spectral	B-T058
demultiplexing	I-T058
methods	I-T058
for	O
quantifying	O
NP	O
concentrations	O
,	O
and	O
the	O
disambiguation	O
of	O
specific	O
vs	O
.	O

nonspecific	O
sources	O
of	O
contrast	O
through	O
ratiometric	B-T058
imaging	I-T058
of	O
targeted	O
and	O
untargeted	O
(	O
control	O
)	O
NP	O
pairs	O
.	O

Finally	O
,	O
future	O
challenges	O
and	O
directions	O
are	O
briefly	O
outlined	O
.	O

Expression	B-T038
and	O
methylation	B-T038
in	O
posttraumatic	B-T038
stress	I-T038
disorder	I-T038
and	O
resilience	O
;	O
evidence	O
of	O
a	O
role	O
for	O
odorant	B-T103
receptors	I-T103

Post	B-T038
-	I-T038
traumatic	I-T038
stress	I-T038
disorder	I-T038
(	O
PTSD	B-T038
)	O
is	O
a	O
common	O
and	O
potentially	O
disabling	O
disorder	O
that	O
develops	O
in	O
1	O
/	O
5	O
to	O
1	O
/	O
3	O
of	O
people	B-T098
exposed	O
to	O
severe	O
trauma	B-T037
.	O

Twin	B-T170
studies	I-T170
indicate	O
that	O
genetic	O
factors	O
account	O
for	O
at	O
least	O
one	O
third	O
of	O
the	O
variance	O
in	O
the	O
risk	O
for	O
developing	O
PTSD	B-T038
,	O
however	O
,	O
the	O
specific	O
role	O
for	O
genetic	O
factors	O
in	O
the	O
pathogenesis	B-T038
of	O
PTSD	B-T038
is	O
not	O
well	O
understood	O
.	O

We	O
studied	O
genome	B-T062
-	I-T062
wide	I-T062
gene	B-T038
expression	I-T038
and	O
DNA	B-T038
methylation	I-T038
profiles	O
in	O
12	O
participants	B-T098
with	O
PTSD	B-T038
and	O
12	O
participants	B-T098
who	O
were	O
resilient	O
to	O
similar	O
severity	O
trauma	B-T037
exposure	O
.	O

Close	O
to	O
4000	O
genes	B-T017
were	O
differentially	O
expressed	B-T038
with	O
adjusted	O
p	O
<	O
0	O
.	O
05	O
,	O
fold	O
-	O
change	O
>	O
2	O
,	O
with	O
all	O
but	O
3	O
upregulated	B-T038
with	O
PTSD	B-T038
.	O

Eight	O
odorant	B-T103
/	I-T103
olfactory	I-T103
receptor	I-T103
related	O
genes	B-T017
were	O
up	B-T038
-	I-T038
regulated	I-T038
with	O
PTSD	B-T038
as	O
well	O
as	O
genes	B-T017
related	O
to	O
immune	B-T038
activation	I-T038
,	O
the	O
Gamma	B-T103
-	I-T103
Aminobutyric	I-T103
Acid	I-T103
A	I-T103
(	I-T103
GABAA	I-T103
)	I-T103
receptor	I-T103
,	O
and	O
vitamin	B-T038
D	I-T038
synthesis	I-T038
.	O

No	O
differences	O
with	O
adjusted	O
significance	O
for	O
DNA	B-T038
methylation	I-T038
were	O
found	O
.	O

We	O
conclude	O
that	O
increased	O
gene	B-T038
expression	I-T038
may	O
play	O
an	O
important	O
role	O
in	O
PTSD	B-T038
and	O
this	O
expression	B-T038
may	O
not	O
be	O
a	O
consequence	O
of	O
DNA	B-T038
methylation	I-T038
.	O

The	O
role	O
of	O
odorant	B-T103
receptor	I-T103
expression	O
warrants	O
independent	O
replication	B-T038
.	O

Absorption	O
Characteristics	O
of	O
Vertebrate	B-T204
Non	O
-	O
Visual	O
Opsin	B-T103
,	I-T103
Opn3	I-T103

Most	O
animals	B-T204
possess	O
multiple	O
opsins	B-T103
which	O
sense	B-T038
light	O
for	O
visual	O
and	O
non	O
-	O
visual	B-T038
functions	I-T038
.	O

Here	O
,	O
we	O
show	O
spectral	O
characteristics	O
of	O
non	O
-	O
visual	O
opsins	B-T103
,	O
vertebrate	B-T204
Opn3s	B-T103
,	O
which	O
are	O
widely	O
distributed	O
among	O
vertebrates	B-T204
.	O

We	O
successfully	O
expressed	B-T038
zebrafish	B-T204
Opn3	B-T103
in	O
mammalian	B-T204
cultured	B-T017
cells	I-T017
and	O
measured	O
its	O
absorption	B-T058
spectrum	I-T058
spectroscopically	I-T058
.	O

When	O
incubated	B-T058
with	O
11	B-T103
-	I-T103
cis	I-T103
retinal	I-T103
,	O
zebrafish	B-T204
Opn3	B-T103
formed	O
a	O
blue	B-T103
-	I-T103
sensitive	I-T103
photopigment	I-T103
with	O
an	O
absorption	B-T038
maximum	O
around	O
465	O
nm	O
.	O

The	O
Opn3	B-T103
converts	O
to	O
an	O
all	B-T103
-	I-T103
trans	I-T103
retinal	I-T103
-	I-T103
bearing	I-T103
photoproduct	O
with	O
an	O
absorption	B-T058
spectrum	I-T058
similar	O
to	O
the	O
dark	B-T038
state	I-T038
following	O
brief	O
blue	O
-	O
light	O
irradiation	O
.	O

The	O
photoproduct	O
experienced	O
a	O
remarkable	O
blue	O
-	O
shift	O
,	O
with	O
changes	O
in	B-T082
position	I-T082
of	O
the	O
isosbestic	O
point	O
,	O
during	O
further	O
irradiation	O
.	O

We	O
then	O
used	O
a	O
cAMP	B-T103
-	O
dependent	O
luciferase	B-T103
reporter	B-T103
assay	B-T058
to	O
investigate	O
light	O
-	O
dependent	O
cAMP	B-T103
responses	B-T038
in	O
cultured	B-T017
cells	I-T017
expressing	B-T038
zebrafish	B-T204
,	O
pufferfish	B-T204
,	O
anole	B-T204
and	O
chicken	B-T204
Opn3	B-T103
.	O

The	O
wild	B-T017
type	I-T017
opsins	B-T103
did	O
not	O
produce	O
responses	B-T038
,	O
but	O
cells	B-T017
expressing	B-T038
chimera	O
mutants	B-T103
(	O
WT	B-T103
Opn3s	I-T103
in	O
which	O
the	O
third	B-T082
intracellular	I-T082
loops	B-T082
were	O
replaced	O
with	O
the	O
third	B-T082
intracellular	I-T082
loop	B-T082
of	O
a	O
Gs	B-T103
-	I-T103
coupled	I-T103
jellyfish	B-T204
opsin	B-T103
)	O
displayed	O
light	O
-	O
dependent	O
changes	O
in	O
cAMP	B-T103
.	O

The	O
results	O
suggest	O
that	O
Opn3	B-T103
is	O
capable	O
of	O
activating	O
G	B-T103
protein	I-T103
(	I-T103
s	I-T103
)	I-T103
in	O
a	O
light	O
-	O
dependent	O
manner	O
.	O

Finally	O
,	O
we	O
used	O
this	O
assay	B-T058
to	O
measure	O
the	O
relative	O
wavelength	O
-	O
dependent	O
response	O
of	O
cells	B-T017
expressing	B-T038
Opn3	B-T103
chimeras	O
to	O
multiple	O
quantally	B-T170
-	O
matched	O
stimuli	O
.	O

The	O
inferred	O
spectral	O
sensitivity	O
curve	B-T082
of	O
zebrafish	B-T204
Opn3	B-T103
accurately	O
matched	O
the	O
measured	O
absorption	B-T058
spectrum	I-T058
.	O

We	O
were	O
unable	O
to	O
estimate	O
the	O
spectral	O
sensitivity	O
curve	B-T082
of	O
mouse	B-T204
or	O
anole	B-T204
Opn3	B-T103
,	O
but	O
,	O
like	O
zebrafish	B-T204
Opn3	B-T103
,	O
the	O
chicken	B-T204
and	O
pufferfish	B-T204
Opn3	B-T103
-	I-T103
JiL3	I-T103
chimeras	O
also	O
formed	O
blue	B-T103
-	I-T103
sensitive	I-T103
pigments	I-T103
.	O

These	O
findings	O
suggest	O
that	O
vertebrate	B-T204
Opn3s	B-T103
may	O
form	O
blue	B-T103
-	I-T103
sensitive	I-T103
G	I-T103
protein	I-T103
-	I-T103
coupled	I-T103
pigments	I-T103
.	O

Further	O
,	O
we	O
suggest	O
that	O
the	O
method	O
described	O
here	O
,	O
combining	O
a	O
cAMP	B-T103
-	O
dependent	O
luciferase	B-T103
reporter	B-T103
assay	B-T058
with	O
chimeric	O
opsins	B-T103
possessing	O
the	O
third	B-T082
intracellular	I-T082
loop	B-T082
of	O
jellyfish	B-T204
opsin	B-T103
,	O
is	O
a	O
versatile	O
approach	O
for	O
estimating	O
absorption	B-T058
spectra	I-T058
of	O
opsins	B-T103
with	O
unknown	O
signaling	B-T038
cascades	I-T038
or	O
for	O
which	O
absorption	B-T058
spectra	I-T058
are	O
difficult	O
to	O
obtain	O
.	O

Effectiveness	O
of	O
offloading	O
methods	B-T058
in	O
preventing	O
primary	O
diabetic	B-T038
foot	I-T038
ulcers	I-T038
in	O
adults	O
with	O
diabetes	B-T038
:	O
a	O
systematic	B-T170
review	I-T170

The	O
incidence	O
of	O
foot	B-T038
ulceration	I-T038
related	O
to	O
diabetes	B-T038
is	O
increasing	O
.	O

Many	O
foot	B-T058
care	I-T058
professionals	B-T097
recommend	O
offloading	O
measures	O
as	O
part	O
of	O
management	O
strategies	O
for	O
modulating	O
excess	O
pressure	O
to	O
prevent	O
development	O
of	O
diabetic	B-T038
foot	I-T038
ulcers	I-T038
(	O
DFUs	B-T038
)	O
.	O

These	O
measures	O
may	O
include	O
padding	B-T058
,	O
insoles	O
/	O
orthotic	B-T074
devices	I-T074
and	O
footwear	O
.	O

There	O
is	O
a	O
lack	O
of	O
evidence	O
-	O
based	O
guidance	O
on	O
the	O
effectiveness	O
of	O
the	O
different	O
offloading	O
options	O
for	O
preventing	O
primary	O
ulceration	B-T038
in	O
those	O
with	O
diabetes	B-T038
.	O

To	O
identify	O
,	O
critically	O
appraise	O
and	O
synthesize	O
the	O
best	O
available	O
evidence	O
on	O
methods	B-T058
of	O
offloading	O
to	O
prevent	O
the	O
development	O
,	O
and	O
reduce	O
the	O
risk	O
,	O
of	O
primary	O
foot	B-T038
ulceration	I-T038
in	O
adults	O
with	O
diabetes	B-T038
.	O
The	O
question	O
addressed	B-T170
by	O
the	O
review	B-T170
was	O
:	O
what	O
is	O
the	O
effectiveness	O
of	O
methods	B-T058
of	O
offloading	O
in	O
preventing	O
primary	O
DFUs	B-T038
in	O
adults	O
with	O
diabetes	B-T038
?	O
Adults	O
18	O
years	O
and	O
older	O
with	O
diabetes	B-T038
mellitus	I-T038
,	O
regardless	O
of	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
duration	O
or	O
type	O
of	O
diabetes	B-T038
,	O
with	O
no	O
history	B-T033
of	O
DFUs	B-T038
and	O
in	O
any	O
clinical	O
setting	O
will	O
be	O
included	O
.	O

Interventions	B-T058
will	O
include	O
all	O
external	O
methods	B-T058
of	O
offloading	O
.	O

All	O
comparators	O
will	O
be	O
considered	O
.	O

Studies	B-T062
that	O
utilize	O
interventions	B-T058
not	O
considered	O
usual	O
practice	B-T058
in	O
the	O
prevention	O
of	O
DFUs	B-T038
will	O
be	O
excluded	O
.	O

The	O
primary	O
outcome	O
will	O
be	O
primary	O
foot	B-T038
ulceration	I-T038
.	O

The	O
secondary	O
outcome	O
will	O
be	O
indications	O
of	O
changes	O
in	O
plantar	B-T082
pressure	O
.	O

This	O
review	B-T170
will	O
consider	O
all	O
quantitative	O
study	B-T062
designs	I-T062
.	O

A	O
three	O
-	O
step	O
strategy	O
for	O
published	O
and	O
unpublished	O
literature	B-T170
will	O
be	O
used	O
.	O

Fourteen	O
databases	B-T170
will	O
be	O
searched	O
for	O
studies	B-T062
in	O
English	O
up	O
to	O
November	O
2013	O
.	O

The	O
JBI	B-T170
-	I-T170
MAStARI	I-T170
extraction	I-T170
tool	I-T170
was	O
used	O
to	O
extract	O
relevant	O
data	O
.	O

Results	O
were	O
summarized	O
using	O
narrative	O
and	O
tables	B-T170
.	O

Three	O
studies	B-T062
which	O
examined	O
the	O
effectiveness	O
of	O
four	O
different	O
offloading	O
interventions	B-T058
met	O
the	O
inclusion	O
criteria	O
.	O

There	O
is	O
limited	O
evidence	O
that	O
use	O
of	O
a	O
footwear	O
system	O
(	O
prototype	O
shoe	O
plus	O
polyurethane	O
or	O
cork	O
insole	O
)	O
may	O
prevent	O
a	O
break	O
in	O
the	O
skin	B-T022
;	O
use	O
of	O
customized	O
rigid	O
orthotic	B-T074
devices	I-T074
may	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
grade	O
and	O
number	O
of	O
calluses	B-T017
;	O
and	O
a	O
manufactured	O
shoe	O
plus	O
customized	O
insole	O
may	O
reduce	O
plantar	B-T082
pressure	O
and	O
therefore	O
reduce	O
the	O
potential	O
risk	O
of	O
skin	B-T038
ulceration	I-T038
.	O

There	O
is	O
limited	O
and	O
low	O
-	O
quality	O
evidence	O
that	O
in	O
a	O
population	B-T098
of	O
adults	O
with	O
diabetes	B-T038
with	O
no	O
history	B-T033
of	O
DFU	B-T038
,	O
the	O
use	O
of	O
footwear	O
with	O
customized	O
or	O
prefabricated	O
orthotic	B-T074
devices	I-T074
may	O
provide	O
some	O
reduction	O
in	O
plantar	B-T082
pressure	O
and	O
therefore	O
help	O
to	O
prevent	O
a	O
primary	O
DFU	B-T038
.	O

There	O
is	O
a	O
lack	O
of	O
evidence	O
on	O
the	O
relative	O
effectiveness	O
of	O
different	O
offloading	O
options	O
.	O

Punch	B-T038
injury	B-T037
self	B-T037
-	I-T037
harm	I-T037
in	O
young	O
people	O

Punch	B-T038
injuries	B-T037
are	O
a	O
form	O
of	O
self	B-T037
-	I-T037
harm	I-T037
characterised	O
by	O
the	O
intentional	O
act	O
of	O
striking	O
an	O
object	O
with	O
a	O
closed	O
fist	O
.	O

We	O
aimed	O
to	O
describe	O
the	O
characteristics	O
and	O
trends	O
in	O
young	O
people	O
presenting	O
with	O
injuries	B-T037
sustained	O
via	O
the	O
punch	B-T038
mechanism	O
.	O

A	O
comprehensive	O
retrospective	B-T062
review	I-T062
of	O
medical	B-T170
records	I-T170
was	O
completed	O
of	O
all	O
young	O
people	O
aged	O
10	O
-	O
18	O
years	O
presenting	O
to	O
our	O
Central	B-T092
London	I-T092
Emergency	I-T092
Department	I-T092
over	O
a	O
12	O
-	O
month	O
period	O
.	O

A	O
subset	B-T170
of	I-T170
the	I-T170
total	I-T170
group	I-T170
was	O
identified	O
as	O
the	O
punch	B-T038
injury	B-T037
subgroup	B-T170
.	O

A	O
total	O
of	O
78	O
punch	B-T038
injury	B-T037
presentations	O
were	O
identified	O
.	O

In	O
this	O
subgroup	B-T170
,	O
the	O
male	O
:	O
female	O
ratio	O
is	O
4	O
.	O
57	O
:	O
1	O
;	O
37	O
.	O
18	O
%	O
of	O
presentations	O
were	O
associated	O
with	O
a	O
fracture	B-T037
(	O
n	O
=	O
29	O
)	O
and	O
35	O
.	O
90	O
%	O
(	O
n	O
=	O
28	O
)	O
of	O
patients	O
re	O
-	O
presented	O
following	O
another	O
punch	B-T038
injury	B-T037
,	O
as	O
a	O
victim	B-T033
of	I-T033
violence	I-T033
,	O
or	O
by	O
other	O
psychiatric	O
presentation	O
.	O

In	O
conclusion	O
,	O
a	O
male	B-T033
preponderance	I-T033
was	O
observed	O
,	O
with	O
frequent	O
re	O
-	O
presentations	O
,	O
often	O
in	O
high	B-T033
-	I-T033
risk	I-T033
circumstances	O
.	O

An	O
opportunity	O
for	O
screening	B-T058
,	O
including	O
mental	B-T038
health	I-T038
,	O
social	O
and	O
substance	O
misuse	O
,	O
was	O
identified	O
.	O

Further	O
research	B-T062
is	O
needed	O
to	O
enable	O
targeted	O
effective	O
interventions	B-T058
in	O
this	O
group	O
.	O

Delayed	O
Recognition	B-T038
of	O
Deterioration	B-T033
of	O
Patients	O
in	O
General	O
Wards	O
Is	O
Mostly	O
Caused	O
by	O
Human	B-T204
Related	O
Monitoring	B-T058
Failures	O
:	O
A	O
Root	O
Cause	O
Analysis	O
of	O
Unplanned	O
ICU	B-T058
Admissions	I-T058

An	O
unplanned	O
ICU	B-T058
admission	I-T058
of	O
an	O
inpatient	O
is	O
a	O
serious	B-T033
adverse	I-T033
event	I-T033
(	O
SAE	B-T033
)	O
.	O

So	O
far	O
,	O
no	O
in	O
depth	O
-	O
study	O
has	O
been	O
performed	O
to	O
systematically	O
analyse	O
the	O
root	O
causes	O
of	O
unplanned	O
ICU	B-T058
-	I-T058
admissions	I-T058
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
healthcare	B-T097
worker	I-T097
-	O
,	O
organisational	O
-	O
,	O
technical	B-T097
,	O
-	O
disease	B-T038
-	O
and	O
patient	O
-	O
related	O
causes	O
that	O
contribute	O
to	O
acute	O
unplanned	O
ICU	B-T058
admissions	I-T058
from	O
general	O
wards	O
using	O
a	O
Root	O
-	O
Cause	O
Analysis	O
Tool	O
called	O
PRISMA	B-T058
-	I-T058
medical	I-T058
.	O

Although	O
a	O
Track	O
and	O
Trigger	O
System	O
(	O
MEWS	O
)	O
was	O
introduced	O
in	O
our	O
hospital	B-T092
a	O
few	O
years	O
ago	O
,	O
it	O
was	O
implemented	O
without	O
a	O
clear	O
protocol	B-T058
.	O

Therefore	O
,	O
the	O
secondary	O
aim	O
was	O
to	O
assess	O
the	O
adherence	O
to	O
a	O
Track	O
and	O
Trigger	O
system	O
to	O
identify	O
deterioration	B-T033
on	O
general	O
hospital	O
wards	O
in	O
patients	O
eventually	O
transferred	O
to	O
the	O
ICU	B-T092
.	O

Retrospective	B-T062
observational	I-T062
study	I-T062
in	O
49	O
consecutive	O
adult	O
patients	O
acutely	O
admitted	B-T058
to	O
the	O
Intensive	B-T092
Care	I-T092
Unit	I-T092
from	O
a	O
general	B-T058
nursing	I-T058
ward	I-T058
.	O

1	O
.	O

PRISMA	B-T062
-	I-T062
analysis	I-T062
on	O
root	O
causes	O
of	O
unplanned	O
ICU	B-T058
admissions	I-T058
2	O
.	O

Assessment	O
of	O
protocol	B-T058
adherence	O
to	O
the	O
early	B-T033
warning	I-T033
score	I-T033
system	I-T033
.	O

Out	O
of	O
49	O
cases	O
,	O
156	O
root	O
causes	O
were	O
identified	O
.	O

The	O
most	O
frequent	O
root	O
causes	O
were	O
healthcare	B-T097
worker	I-T097
related	O
(	O
46	O
%	O
)	O
,	O
which	O
were	O
mainly	O
failures	O
in	O
monitoring	B-T058
the	O
patient	O
.	O

They	O
were	O
followed	O
by	O
disease	B-T038
-	O
related	O
(	O
45	O
%	O
)	O
,	O
patient	O
-	O
related	O
causes	O
(	O
7	O
,	O
5	O
%	O
)	O
,	O
and	O
organisational	O
root	O
causes	O
(	O
3	O
%	O
)	O
.	O

In	O
only	O
40	O
%	O
of	O
the	O
patients	O
vital	O
parameters	O
were	O
monitored	O
as	O
was	O
instructed	O
by	O
the	O
doctor	B-T097
.	O

477	O
vital	O
parameter	O
sets	O
were	O
found	O
in	O
the	O
48	O
hours	O
before	O
ICU	B-T058
admission	I-T058
,	O
in	O
only	O
1	O
%	O
a	O
correct	O
MEWS	O
was	O
explicitly	O
documented	B-T058
in	O
the	O
record	O
.	O

This	O
in	B-T062
-	I-T062
depth	I-T062
analysis	I-T062
demonstrates	O
that	O
almost	O
half	O
of	O
the	O
unplanned	O
ICU	B-T058
admissions	I-T058
from	O
the	O
general	O
ward	O
had	O
healthcare	B-T097
worker	I-T097
related	O
root	O
causes	O
,	O
mostly	O
due	O
to	O
monitoring	B-T058
failures	O
in	O
clinically	B-T033
deteriorating	I-T033
patients	O
.	O

In	O
order	O
to	O
reduce	O
unplanned	O
ICU	B-T058
admissions	I-T058
,	O
improving	O
the	O
monitoring	B-T058
of	O
patients	O
is	O
therefore	O
warranted	O
.	O

Effects	O
of	O
a	O
novel	O
phosphodiesterase	B-T103
10A	I-T103
inhibitor	I-T103
in	O
non	B-T204
-	I-T204
human	I-T204
primates	I-T204
:	O
A	O
therapeutic	O
approach	O
for	O
schizophrenia	B-T038
with	O
improved	O
side	B-T038
effect	I-T038
profile	I-T038

Schizophrenia	B-T038
symptoms	B-T033
are	O
associated	O
with	O
alterations	B-T038
in	I-T038
basal	I-T038
ganglia	I-T038
-	I-T038
cortical	I-T038
networks	I-T038
that	O
include	O
the	O
cyclic	B-T103
nucleotides	I-T103
(	O
cAMP	B-T103
/	O
cGMP	B-T103
)	O
signaling	B-T038
pathways	I-T038
.	O

Phosphodiesterase	B-T103
10A	I-T103
(	I-T103
PDE10A	I-T103
)	I-T103
inhibitors	I-T103
have	O
been	O
considered	O
as	O
therapeutic	B-T103
agents	I-T103
for	O
schizophrenia	B-T038
because	O
the	O
regulation	B-T038
of	I-T038
cAMP	I-T038
and	O
cGMP	B-T038
in	O
the	O
striatum	B-T017
by	O
PDE10A	B-T103
plays	O
an	O
important	O
role	O
in	O
the	O
signaling	B-T038
mechanisms	I-T038
of	O
the	O
striatal	O
-	O
cortical	O
network	O
,	O
and	O
thereby	O
in	O
cognitive	B-T038
function	I-T038
.	O

In	O
the	O
present	O
study	O
we	O
assessed	O
in	O
non	B-T204
-	I-T204
human	I-T204
primates	I-T204
(	O
NHPs	B-T204
)	O
the	O
effects	O
of	O
a	O
novel	O
PDE10A	B-T103
inhibitor	I-T103
(	O
FRM	B-T103
-	I-T103
6308	I-T103
)	O
that	O
has	O
demonstrated	O
high	O
potency	O
and	O
selectivity	O
for	O
human	B-T103
recombinant	I-T103
PDE10A	I-T103
in	O
vitro	O
.	O

The	O
behavioral	B-T033
effects	I-T033
of	O
FRM	B-T103
-	I-T103
6308	I-T103
in	O
a	O
dose	O
range	O
were	O
determined	O
in	O
rhesus	B-T204
monkeys	I-T204
using	O
a	O
standardized	B-T033
motor	I-T033
disability	I-T033
scale	I-T033
for	O
primates	B-T204
,	O
motor	B-T058
tasks	I-T058
,	O
and	O
the	O
"	O
drug	O
effects	O
on	O
the	O
nervous	O
system	O
"	O
(	O
DENS	O
)	O
scale	O
.	O

The	O
neuronal	O
metabolic	O
effects	O
of	O
FRM	B-T103
-	I-T103
6308	I-T103
were	O
determined	O
with	O
[	B-T058
(	I-T058
18	I-T058
)	I-T058
F	I-T058
]	I-T058
-	I-T058
fluorodeoxyglucose	I-T058
PET	I-T058
imaging	I-T058
.	O

Results	O
showed	O
that	O
FRM	B-T103
-	I-T103
6308	I-T103
did	O
not	O
have	O
any	O
specific	O
effects	O
on	O
the	O
motor	O
system	O
at	O
s	O
.	O
c	O
.	O

doses	O
up	O
to	O
0	O
.	O
32	O
mg	O
/	O
kg	O
in	O
NHPs	B-T204
,	O
which	O
induced	O
a	O
significant	O
increase	O
in	O
the	O
FDG	B-T103
-	O
SUV	O
in	O
striatum	B-T017
(	O
F	O
16	O
.	O
069	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
cortical	B-T082
(	O
F	O
15	O
.	O
181	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
regions	O
.	O

Higher	O
doses	O
induced	O
sedation	B-T033
and	O
occasional	B-T033
involuntary	I-T033
movements	I-T033
with	O
clear	O
development	O
of	O
tolerance	B-T033
after	I-T033
repeated	I-T033
exposures	I-T033
.	O

These	O
findings	O
suggest	O
that	O
FRM	B-T103
-	I-T103
6308	I-T103
has	O
the	O
adequate	B-T058
pharmacological	I-T058
profile	I-T058
to	O
advance	O
testing	O
in	O
clinical	B-T062
trials	I-T062
and	O
demonstrate	O
antipsychotic	B-T038
efficacy	I-T038
of	O
PDE10A	B-T103
inhibition	O
for	O
the	O
treatment	O
of	O
schizophrenia	B-T038
patients	O
.	O

Agglomeration	O
of	O
Luminescent	O
Porous	B-T082
Silicon	B-T103
Nanoparticles	O
in	O
Colloidal	B-T103
Solutions	I-T103

We	O
have	O
prepared	B-T033
colloidal	B-T103
solutions	I-T103
of	O
clusters	O
composed	O
from	O
porous	B-T082
silicon	B-T103
nanoparticles	O
in	O
methanol	B-T103
,	O
water	B-T103
and	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
.	O

Even	O
if	O
the	O
size	B-T082
of	O
the	O
nanoclusters	O
is	O
between	O
60	O
and	O
500	O
nm	O
,	O
due	O
to	O
their	O
highly	O
porous	B-T082
"	B-T082
cauliflower	I-T082
"	I-T082
-	I-T082
like	I-T082
structure	I-T082
,	O
the	O
porous	B-T082
silicon	B-T103
nanoparticles	O
are	O
composed	O
of	O
interconnected	B-T082
nanocrystals	O
having	O
around	O
2	O
.	O
5	O
nm	O
in	O
size	B-T082
and	O
showing	O
strong	O
visible	O
luminescence	O
in	O
the	O
orange	O
-	O
red	O
spectral	O
region	B-T082
(	O
centred	O
at	O
600	O
-	O
700	O
nm	O
)	O
.	O

Hydrophilic	O
behaviour	O
and	O
good	O
solubility	O
of	O
the	O
nanoclusters	O
in	O
water	B-T103
and	O
water	B-T103
-	O
based	O
solutions	O
were	O
obtained	O
by	O
adding	O
hydrogen	B-T103
peroxide	I-T103
into	O
the	O
etching	O
solution	O
during	O
preparation	O
and	O
16	O
min	O
long	O
after	O
-	O
bath	O
in	O
hydrogen	B-T103
peroxide	I-T103
.	O

By	O
simple	O
filtration	O
of	O
the	O
solutions	O
with	O
syringe	B-T074
filters	I-T074
,	O
we	O
have	O
extracted	O
smaller	O
nanoclusters	O
with	O
sizes	B-T082
of	O
approx	O
.	O

60	O
-	O
70	O
nm	O
;	O
however	O
,	O
these	O
nanoclusters	O
in	O
water	B-T103
and	O
PBS	O
solution	O
(	O
pH	O
neutral	O
)	O
are	O
prone	O
to	O
agglomeration	O
,	O
as	O
was	O
confirmed	B-T033
by	O
zeta	O
potential	O
measurements	O
.	O

When	O
the	O
samples	O
were	O
left	O
at	O
ambient	O
conditions	O
for	O
several	O
weeks	O
,	O
the	O
typical	O
nanocluster	O
size	B-T082
increased	O
to	O
approx	O
.	O

330	O
-	O
400	O
nm	O
and	O
then	O
remained	O
stable	O
.	O

However	O
,	O
both	O
freshly	O
filtered	O
and	O
aged	O
samples	O
(	O
with	O
agglomerated	O
porous	B-T082
silicon	B-T103
nanoparticles	O
)	O
of	O
porous	B-T082
silicon	B-T103
in	O
water	B-T103
and	O
PBS	O
solutions	O
can	O
be	O
further	O
used	O
for	O
biological	O
studies	B-T062
or	O
as	O
luminescent	O
markers	B-T201
in	O
living	B-T017
cells	I-T017
.	O

Development	O
of	O
a	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
method	O
for	O
quantitative	O
analysis	O
of	O
trace	O
d	B-T103
-	I-T103
amino	I-T103
acids	I-T103

d	B-T103
-	I-T103
Amino	I-T103
acids	I-T103
have	O
recently	O
attracted	O
much	O
attention	B-T038
in	O
various	O
research	B-T062
fields	I-T062
including	O
medical	O
,	O
clinical	O
and	O
food	O
industry	O
due	O
to	O
their	O
important	O
biological	B-T038
functions	I-T038
that	O
differ	O
from	O
l	B-T103
-	I-T103
amino	I-T103
acid	I-T103
.	O

Most	O
chiral	O
amino	B-T103
acid	I-T103
separation	O
techniques	O
require	O
complicated	O
derivatization	O
procedures	O
in	O
order	O
to	O
achieve	O
the	O
desirable	O
chromatographic	O
behavior	O
and	O
detectability	B-T033
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
research	B-T062
is	O
to	O
develop	O
a	O
highly	O
sensitive	O
analytical	O
method	O
for	O
the	O
enantioseparation	O
of	O
chiral	O
amino	B-T103
acids	I-T103
without	O
any	O
derivatization	O
process	O
using	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
(	O
LC	B-T058
-	I-T058
MS	I-T058
/	I-T058
MS	I-T058
)	O
.	O

By	O
optimizing	O
MS	O
/	O
MS	O
parameters	O
,	O
we	O
established	O
a	O
quantification	O
method	O
that	O
allowed	O
the	O
simultaneous	O
analysis	B-T062
of	O
18	O
d	B-T103
-	I-T103
amino	I-T103
acids	I-T103
with	O
high	O
sensitivity	O
and	O
reproducibility	O
.	O

Additionally	O
,	O
we	O
applied	O
the	O
method	O
to	O
food	O
sample	O
(	O
vinegar	B-T103
)	O
for	O
the	O
validation	B-T062
,	O
and	O
successfully	O
quantified	O
trace	O
levels	O
of	O
d	B-T103
-	I-T103
amino	I-T103
acids	I-T103
in	O
samples	O
.	O

These	O
results	B-T033
demonstrated	O
the	O
applicability	O
and	O
feasibility	O
of	O
the	O
LC	B-T058
-	I-T058
MS	I-T058
/	I-T058
MS	I-T058
method	O
as	O
a	O
novel	O
,	O
effective	O
tool	O
for	O
d	B-T103
-	I-T103
amino	I-T103
acid	I-T103
measurement	O
in	O
various	O
biological	O
samples	O
.	O

The	O
Multi	B-T170
-	I-T170
center	I-T170
Evaluation	I-T170
of	I-T170
the	I-T170
Accuracy	I-T170
of	I-T170
the	I-T170
Contrast	I-T170
MEdium	I-T170
INduced	I-T170
Pd	I-T170
/	I-T170
Pa	I-T170
RaTiO	I-T170
in	O
Predicting	O
FFR	B-T201
(	O
MEMENTO	B-T170
-	O
FFR	B-T201
)	O
Study	B-T062

Adenosine	B-T103
administration	B-T058
is	O
needed	O
for	O
the	O
achievement	O
of	O
maximal	O
hyperaemia	B-T038
fractional	B-T201
flow	I-T201
reserve	I-T201
(	O
FFR	B-T201
)	O
assessment	B-T058
.	O

The	O
objective	O
was	O
to	O
test	O
the	O
accuracy	O
of	O
Pd	O
/	O
Pa	B-T033
ratio	O
registered	O
during	O
submaximal	O
hyperaemia	B-T038
induced	O
by	O
non	B-T103
-	I-T103
ionic	I-T103
contrast	I-T103
medium	I-T103
(	O
contrast	B-T201
FFR	I-T201
[	O
cFFR	B-T201
]	O
)	O
in	O
predicting	O
FFR	B-T201
and	O
comparing	O
it	O
to	O
the	O
performance	O
of	O
resting	B-T033
Pd	O
/	O
Pa	B-T033
in	O
a	O
collaborative	O
registry	O
of	O
926	O
patients	O
enrolled	O
in	O
10	O
hospitals	B-T092
from	O
four	O
European	O
countries	O
(	O
Italy	B-T082
,	O
Spain	B-T082
,	O
France	B-T082
and	O
Portugal	B-T082
)	O
.	O

Resting	B-T033
Pd	O
/	O
Pa	B-T033
,	O
cFFR	B-T201
and	O
FFR	B-T201
were	O
measured	O
in	O
1	O
,	O
026	O
coronary	B-T038
stenoses	I-T038
functionally	O
evaluated	O
using	O
commercially	O
available	O
pressure	B-T074
wires	I-T074
.	O

cFFR	B-T201
was	O
obtained	O
after	O
intracoronary	O
injection	O
of	O
contrast	B-T103
medium	I-T103
,	O
while	O
FFR	B-T201
was	O
measured	O
after	O
administration	B-T058
of	O
adenosine	B-T103
.	O

Resting	B-T033
Pd	O
/	O
Pa	B-T033
and	O
cFFR	B-T201
were	O
significantly	O
higher	O
than	O
FFR	B-T201
(	O
0	O
.	O
93±0	O
.	O
05	O
vs	O
.	O

0	O
.	O
87±0	O
.	O
08	O
vs	O
.	O

0	O
.	O
84±0	O
.	O
08	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
strong	O
correlation	O
and	O
a	O
close	O
agreement	O
at	O
Bland	B-T170
-	I-T170
Altman	I-T170
analysis	I-T170
between	O
cFFR	B-T201
and	O
FFR	B-T201
were	O
observed	O
(	O
r	O
=	O
0	O
.	O
90	O
,	O
p	O
<	O
0	O
.	O
001	O
and	O
95	O
%	O
CI	O
of	O
disagreement	O
:	O
from	O
-	O
0	O
.	O
042	O
to	O
0	O
.	O
11	O
)	O
.	O

ROC	O
curve	O
analysis	B-T062
showed	O
an	O
excellent	O
accuracy	O
(	O
89	O
%	O
)	O
of	O
the	O
cFFR	B-T201
cut	O
-	O
off	O
of	O
≤0	O
.	O
85	O
in	O
predicting	O
an	O
FFR	B-T201
value	O
≤0	O
.	O
80	O
(	O
AUC	O
0	O
.	O
95	O
[	O
95	O
%	O
CI	O
:	O
0	O
.	O
94	O
-	O
0	O
.	O
96	O
]	O
)	O
,	O
significantly	O
better	O
than	O
that	O
observed	O
using	O
resting	B-T033
Pd	O
/	O
Pa	B-T033
(	O
AUC	O
:	O
0	O
.	O
90	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
88	O
-	O
0	O
.	O
91	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
cFFR	B-T201
/	O
FFR	B-T201
hybrid	B-T170
approach	I-T170
showed	O
a	O
significantly	O
lower	O
number	O
of	O
lesions	B-T033
requiring	O
adenosine	B-T103
than	O
a	O
resting	B-T033
Pd	O
/	O
Pa	B-T033
/	O
FFR	B-T201
hybrid	B-T170
approach	I-T170
(	O
22	O
%	O
vs	O
.	O

44	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

cFFR	B-T201
is	O
accurate	O
in	O
predicting	O
the	O
functional	O
significance	O
of	O
coronary	B-T038
stenosis	I-T038
.	O

This	O
could	O
allow	O
limiting	O
the	O
use	O
of	O
adenosine	B-T103
to	O
obtain	O
FFR	B-T201
to	O
a	O
minority	O
of	O
stenoses	B-T038
with	O
considerable	O
savings	O
of	O
time	O
and	O
costs	O
.	O

Transfemoral	B-T058
aortic	I-T058
valve	I-T058
implantation	I-T058
with	O
the	O
repositionable	B-T074
Lotus	I-T074
valve	I-T074
for	O
treatment	B-T058
of	O
patients	O
with	O
symptomatic	O
severe	O
aortic	B-T038
stenosis	I-T038
:	O
results	O
from	O
a	O
single	B-T038
-	I-T038
centre	I-T038
experience	I-T038

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
procedural	O
and	O
30	O
-	O
day	O
results	O
for	O
the	O
repositionable	B-T074
Lotus	I-T074
valve	I-T074
in	O
patients	O
undergoing	O
transfemoral	B-T058
aortic	I-T058
valve	I-T058
implantation	I-T058
in	O
a	O
single	B-T038
-	I-T038
centre	I-T038
experience	I-T038
.	O

We	O
prospectively	O
enrolled	O
110	O
patients	O
with	O
severe	O
symptomatic	O
aortic	B-T038
stenosis	I-T038
(	O
NCT02162069	B-T170
)	O
.	O

All	O
procedures	O
were	O
performed	O
without	O
general	B-T058
anaesthesia	I-T058
by	O
the	O
transfemoral	B-T058
approach	I-T058
.	O

Patients	O
were	O
followed	O
for	O
30	O
days	O
.	O

Patients	O
received	O
the	O
23	O
mm	O
(	O
n	O
=	O
20	O
)	O
,	O
25	O
mm	O
(	O
n	O
=	O
43	O
)	O
or	O
27	O
mm	O
(	O
n	O
=	O
47	O
)	O
Lotus	B-T074
device	I-T074
.	O

Mean	O
oversizing	O
in	O
relation	O
to	O
annulus	B-T017
or	O
left	B-T017
ventricular	I-T017
outflow	I-T017
tract	I-T017
(	O
LVOT	B-T017
)	O
did	O
not	O
differ	O
among	O
groups	O
.	O

There	O
was	O
no	O
residual	O
moderate	O
or	O
severe	O
aortic	B-T038
regurgitation	I-T038
.	O

The	O
rate	O
of	O
mild	O
aortic	B-T038
regurgitation	I-T038
was	O
low	O
at	O
9	O
.	O
1	O
%	O
.	O

There	O
was	O
no	O
valve	B-T017
embolisation	B-T058
,	O
no	O
need	O
for	O
a	O
second	O
valve	B-T017
and	O
no	B-T033
conversion	I-T033
to	O
surgery	B-T058
.	O

The	O
need	O
for	O
a	O
new	O
pacemaker	B-T058
implantation	I-T058
due	O
to	O
complete	B-T038
(	O
third	B-T038
degree	I-T038
)	O
or	O
type	B-T038
II	I-T038
(	I-T038
Mobitz	I-T038
)	I-T038
second	I-T038
degree	I-T038
atrioventricular	I-T038
block	I-T038
was	O
24	O
.	O
1	O
%	O
,	O
excluding	O
patients	O
with	O
previously	O
implanted	B-T058
devices	I-T058
.	O

Within	O
30	O
days	O
the	O
rates	O
of	O
all	O
-	O
cause	O
mortalit	O
y	O
and	O
stroke	B-T038
were	O
low	O
.	O

In	O
patients	O
with	O
severe	O
aortic	B-T038
stenosis	I-T038
,	O
transfemoral	B-T058
TAVI	I-T058
with	O
the	O
repositionable	B-T074
Lotus	I-T074
valve	I-T074
was	O
associated	O
with	O
a	O
high	O
rate	O
of	O
device	B-T074
success	O
,	O
no	O
moderate	O
or	O
severe	O
residual	O
aortic	B-T038
regurgitation	I-T038
,	O
low	O
rates	O
of	O
major	O
vascular	O
complications	O
and	O
mortality	O
within	O
30	O
days	O
.	O

A	O
Comparison	O
Between	O
Measured	O
Concentration	O
of	O
3H	B-T103
in	O
Kalpakkam	O
Environment	O
with	O
Predicted	O
Atmospheric	O
Dispersion	O
Model	O

The	O
field	B-T082
measurements	O
of	O
3H	B-T103
in	O
the	O
form	O
of	O
HTO	B-T103
present	O
in	O
air	O
moisture	O
carried	O
out	O
around	O
Madras	O
Atomic	O
Power	O
Station	O
were	O
compared	O
with	O
predicted	O
values	O
using	O
atmospheric	O
dispersion	O
modeling	O
.	O

Air	O
3H	O
samples	O
were	O
collected	O
from	O
different	O
sectors	B-T082
at	O
the	O
site	B-T082
boundary	B-T170
of	O
the	O
operating	O
reactors	O
for	O
the	O
period	O
of	O
2	O
y	O
and	O
compared	O
with	O
Gaussian	O
Plume	O
model	O
.	O

The	O
predictions	O
were	O
comparable	O
with	O
the	O
measured	O
value	O
.	O

The	O
slight	O
variation	O
observed	O
between	O
the	O
two	O
methods	B-T170
is	O
attributed	O
to	O
the	O
uncertainty	B-T033
involved	O
in	O
the	O
measurement	O
of	O
air	O
3H	B-T103
concentration	O
and	O
in	O
the	O
measurement	O
of	O
site	B-T082
-	I-T082
specific	I-T082
meteorological	O
parameters	O
.	O

The	O
radiation	O
dose	O
imparted	O
to	O
members	B-T092
of	I-T092
public	I-T092
due	O
to	O
the	O
levels	O
observed	O
is	O
well	O
within	O
station	O
technical	O
specification	O
limit	O
for	O
3H	B-T103
.	O

The	O
four	O
-	O
component	O
aureocin	B-T103
A70	I-T103
as	O
a	O
promising	B-T103
agent	I-T103
for	O
food	O
biopreservation	O

Aureocin	B-T103
A70	I-T103
is	O
the	O
only	O
four	O
-	O
component	O
bacteriocin	B-T103
described	O
to	O
date	O
.	O

As	O
it	O
inhibits	B-T038
the	I-T038
growth	I-T038
of	O
a	O
wide	O
range	O
of	O
Gram	B-T007
-	I-T007
positive	I-T007
bacteria	I-T007
,	O
including	O
Listeria	B-T007
monocytogenes	I-T007
strains	O
isolated	O
from	O
food	B-T168
,	O
its	O
potential	O
for	O
improving	O
food	O
safety	O
was	O
investigated	O
in	O
this	O
study	O
.	O

Aureocin	B-T103
A70	I-T103
(	O
10	O
,	O
240AU	O
/	O
mL	O
)	O
proved	O
to	O
be	O
bactericidal	B-T103
,	O
but	O
not	O
extensively	O
lytic	O
,	O
against	O
listerial	B-T007
strains	O
.	O

The	O
antibacterial	O
activity	O
of	O
aureocin	B-T103
A70	I-T103
(	O
16AU	O
/	O
mL	O
)	O
was	O
then	O
tested	O
in	O
UHT	B-T058
-	I-T058
treated	I-T058
skimmed	B-T168
milk	I-T168
inoculated	B-T058
with	O
the	O
food	B-T168
-	O
associated	O
L	B-T007
.	I-T007

monocytogenes	I-T007
L12	I-T007
strain	I-T007
(	O
4	O
-	O
log	O
CFU	O
/	O
mL	O
)	O
during	O
storage	O
at	O
4°C	O
for	O
one	O
week	O
.	O

Aureocin	B-T103
A70	I-T103
caused	O
a	O
time	O
-	O
dependent	O
reduction	O
in	O
the	O
listerial	B-T007
viable	B-T058
cell	I-T058
counts	I-T058
(	O
5	O
.	O
51	O
-	O
log	O
units	O
)	O
up	O
to	O
7days	O
of	O
incubation	B-T058
.	O

Aureocin	B-T103
A70	I-T103
was	O
neither	O
toxic	O
to	O
the	O
Vero	B-T017
and	O
the	O
L	B-T017
-	I-T017
929	I-T017
cell	I-T017
lines	I-T017
nor	O
exhibited	O
a	O
hemolytic	B-T038
activity	I-T038
against	O
sheep	B-T204
red	B-T017
blood	I-T017
cells	I-T017
.	O

Aureocin	B-T103
A70	I-T103
proved	O
to	O
be	O
completely	O
stable	O
for	O
one	O
month	O
at	O
25°C	O
,	O
16weeks	O
at	O
4°C	O
and	O
20weeks	O
at	O
-	O
20°C	O
.	O

Aureocin	B-T103
A70	I-T103
exhibited	O
a	O
time	O
-	O
dependent	O
susceptibility	O
to	O
simulated	O
gastric	B-T031
juice	I-T031
and	O
bile	B-T103
salts	I-T103
mimicking	O
gastrointestinal	O
conditions	O
.	O

The	O
entrapment	B-T038
of	O
aureocin	B-T103
A70	I-T103
in	O
an	O
alginate	B-T103
/	O
gelatin	B-T103
matrix	I-T103
revealed	O
that	O
this	O
bacteriocin	B-T103
can	O
be	O
released	O
from	O
this	O
matrix	O
.	O

Moreover	O
,	O
it	O
remained	O
adsorbed	O
to	O
and	O
active	O
on	O
a	O
low	B-T103
-	I-T103
density	I-T103
polyethylene	I-T103
plastic	I-T103
surface	O
suggesting	O
that	O
aureocin	B-T103
A70	I-T103
may	O
be	O
employed	O
in	O
bioactive	O
packaging	O
to	O
control	B-T038
the	I-T038
growth	I-T038
of	O
undesirable	O
bacteria	B-T007
.	O

Taken	O
together	O
these	O
results	O
suggest	O
that	O
aureocin	B-T103
A70	I-T103
is	O
a	O
promising	B-T103
alternative	I-T103
to	O
be	O
used	O
in	O
food	O
applications	O
.	O

Folate	B-T103
-	O
conjugated	B-T082
gene	B-T017
-	O
carrying	B-T038
microbubbles	B-T074
with	O
focused	B-T058
ultrasound	I-T058
for	O
concurrent	O
blood	B-T017
-	I-T017
brain	I-T017
barrier	I-T017
opening	O
and	O
local	B-T082
gene	B-T038
delivery	I-T038

Previous	O
studies	B-T062
have	O
demonstrated	O
that	O
circulating	O
DNA	B-T103
-	O
encapsulated	O
microbubbles	B-T074
(	O
MBs	B-T074
)	O
combined	O
with	O
focused	B-T058
ultrasound	I-T058
(	O
FUS	B-T058
)	O
can	O
be	O
used	O
for	O
local	B-T082
blood	B-T017
-	I-T017
brain	I-T017
barrier	I-T017
(	O
BBB	B-T017
)	O
opening	O
and	O
gene	B-T038
delivery	I-T038
.	O

However	O
,	O
few	O
studies	B-T062
focused	O
on	O
how	O
to	O
increase	O
the	O
efficiency	O
of	O
gene	B-T038
delivery	I-T038
to	O
brain	B-T038
tumors	I-T038
after	O
the	O
released	O
gene	B-T017
penetrating	O
the	O
BBB	B-T017
.	O

Here	O
,	O
we	O
proposed	O
the	O
use	O
of	O
folate	B-T103
-	O
conjugated	O
DNA	O
-	O
loaded	O
cationic	B-T074
MBs	I-T074
(	O
FCMBs	B-T074
)	O
.	O

When	O
combined	O
with	O
FUS	B-T058
as	O
a	O
trigger	O
for	O
BBB	B-T017
opening	O
,	O
FCMBs	B-T074
were	O
converted	O
into	O
nanometer	O
-	O
sized	B-T082
vesicles	B-T017
that	O
were	O
transported	B-T038
to	O
the	O
brain	B-T017
parenchyma	B-T017
.	O

The	O
FCMBs	B-T074
can	O
selectively	O
aggregate	O
around	O
tumor	B-T017
cells	I-T017
that	O
overexpressed	B-T038
the	O
folate	B-T103
receptor	I-T103
,	O
thus	O
enhancing	O
gene	B-T038
delivery	I-T038
via	O
folate	B-T103
-	O
stimulated	O
endocytosis	B-T038
.	O

Our	O
results	O
confirmed	O
that	O
FCMBs	B-T074
can	O
carry	B-T038
DNA	B-T103
on	O
the	O
surface	B-T082
of	O
the	O
MB	B-T074
shell	O
and	O
have	O
good	O
targeting	O
ability	O
on	O
C6	B-T017
glioma	I-T017
cells	I-T017
.	O

In	O
addition	O
,	O
the	O
optimized	O
FUS	B-T058
parameters	O
for	O
FCMBs	B-T074
-	O
enhanced	O
gene	B-T038
delivery	I-T038
were	O
confirmed	O
by	O
cell	B-T017
experiments	B-T062
(	O
center	O
frequency	O
=	O
1	O
MHz	O
;	O
acoustic	O
pressure	O
=	O
700	O
kPa	O
;	O
pulse	O
repetition	O
frequency	O
=	O
5	O
Hz	O
;	O
cycle	O
number	O
=	O
10000	O
;	O
exposure	O
time	O
=	O
1	O
min	O
;	O
FCMBs	B-T074
concentration	O
=	O
4	O
×	O
10	O
(	O
7	O
)	O
MB	O
/	O
mL	O
)	O
.	O

In	B-T082
vivo	I-T082
data	O
also	O
indicated	B-T033
that	O
FCMBs	B-T074
show	O
better	O
gene	B-T017
transfection	B-T038
efficiency	O
than	O
MBs	B-T074
without	O
folate	B-T103
conjugation	B-T038
and	O
the	O
traditional	O
approach	B-T082
of	O
directly	O
injecting	B-T058
the	O
gene	B-T017
.	O

This	O
study	B-T062
described	O
our	O
novel	O
development	O
of	O
multifunctional	O
MBs	B-T074
for	O
FUS	B-T058
-	O
triggered	O
gene	B-T038
delivery	I-T038
/	O
therapy	B-T058
.	O

Modulation	B-T082
of	O
IL	B-T103
-	I-T103
6	I-T103
induced	O
RANKL	B-T103
expression	B-T038
in	O
arthritic	B-T038
synovium	B-T017
by	O
a	O
transcription	B-T103
factor	I-T103
SOX5	I-T103

Receptor	B-T103
activator	I-T103
of	I-T103
nuclear	I-T103
factor	I-T103
κB	I-T103
ligand	I-T103
(	O
RANKL	B-T103
)	O
is	O
critically	O
involved	O
in	O
bone	B-T038
erosion	I-T038
of	O
rheumatoid	B-T038
arthritis	I-T038
(	O
RA	B-T038
)	O
.	O

We	O
previously	O
reported	O
association	O
between	O
younger	O
age	O
at	O
onset	O
of	O
RA	B-T038
and	O
a	O
RANKL	B-T103
promoter	O
SNP	B-T082
that	O
conferred	O
an	O
elevated	O
promoter	O
activity	O
via	O
binding	O
to	O
a	O
transcription	B-T103
factor	I-T103
SOX5	I-T103
.	O

Here	O
we	O
study	B-T062
the	O
regulation	B-T038
of	O
SOX5	B-T103
levels	O
in	O
relation	O
to	O
RANKL	B-T103
expression	B-T038
in	O
RA	B-T038
synovial	B-T017
fibroblasts	B-T017
(	O
SF	B-T017
)	O
and	O
the	O
development	O
of	O
bone	B-T038
erosion	I-T038
in	O
the	O
collagen	B-T038
-	I-T038
induced	I-T038
arthritis	I-T038
(	O
CIA	B-T038
)	O
mouse	B-T204
.	O

Our	O
data	B-T170
indicated	B-T033
SOX5	B-T103
levels	O
were	O
higher	O
in	O
synovium	B-T017
and	O
synovial	B-T031
fluid	I-T031
from	O
RA	B-T038
compared	O
to	O
osteoarthritis	B-T038
patients	O
.	O

Pro	O
-	O
inflammatory	O
cytokines	B-T103
upregulated	B-T038
SOX5	B-T103
and	O
RANKL	B-T103
expression	B-T038
in	O
both	O
primary	O
RA	B-T038
SF	B-T017
and	O
the	O
rheumatoid	O
synovial	O
fibroblast	O
cell	O
line	O
,	O
MH7A	B-T017
.	O

Overexpression	B-T038
of	O
SOX5	B-T103
resulted	O
in	O
significantly	O
increased	O
RANKL	B-T103
levels	O
,	O
while	O
knockdown	B-T062
of	O
SOX5	B-T017
resulted	O
in	O
diminished	O
IL	B-T103
-	I-T103
6	I-T103
mediated	O
RANKL	B-T103
upregulation	B-T038
in	O
MH7A	B-T017
cells	I-T017
.	O

Chromatin	B-T058
immunoprecipitation	I-T058
(	O
ChIP	B-T058
)	O
showed	O
approximately	O
3	O
-	O
fold	O
enrichment	O
of	O
RANKL	B-T103
-	I-T103
specific	I-T103
DNA	I-T103
in	O
anti	B-T103
-	I-T103
SOX5	I-T103
immunoprecipitate	I-T103
in	O
IL	B-T103
-	I-T103
6	I-T103
treated	O
MH7A	B-T017
cells	I-T017
as	O
compared	O
to	O
untreated	B-T033
cells	I-T033
.	O

Locally	O
silencing	B-T038
SOX5	B-T017
gene	I-T017
significantly	O
diminished	O
RANKL	B-T103
positive	B-T033
cells	B-T017
and	O
bone	B-T038
erosion	I-T038
in	O
CIA	B-T038
mice	B-T204
.	O

These	O
findings	B-T033
suggest	O
SOX5	B-T103
is	O
an	O
important	O
regulator	O
of	O
IL	B-T103
-	I-T103
6	I-T103
-	O
induced	O
RANKL	B-T103
expression	B-T038
in	O
RA	B-T038
SF	B-T017
.	O

Intracameral	B-T082
cefuroxime	B-T103
in	O
the	O
prevention	O
of	O
postoperative	B-T038
endophthalmitis	I-T038
:	O
an	O
experience	B-T038
from	O
Hong	B-T082
Kong	I-T082

The	O
purpose	O
was	O
to	O
study	B-T062
the	O
effect	O
of	O
introducing	O
intracameral	B-T082
cefuroxime	B-T103
,	O
which	O
was	O
compounded	B-T058
by	O
a	O
hospital	O
pharmacy	O
,	O
on	O
postoperative	B-T038
endophthalmitis	I-T038
in	O
a	O
tertiary	O
eye	O
centre	O
in	O
Hong	B-T082
Kong	I-T082
.	O

All	O
cases	O
that	O
underwent	O
cataract	B-T058
surgeries	I-T058
over	O
a	O
12	O
-	O
year	O
period	O
(	O
January	O
2004	O
to	O
December	O
2015	O
)	O
were	O
included	O
.	O

The	O
routine	O
use	O
of	O
intracameral	B-T082
cefuroxime	B-T103
at	O
the	O
end	O
of	O
cataract	B-T058
surgery	I-T058
was	O
introduced	O
at	O
our	O
centre	O
after	O
April	O
2010	O
.	O

All	O
cefuroxime	B-T103
aliquots	O
were	O
prepared	O
by	O
the	O
hospital	O
pharmacy	O
using	O
an	O
aseptic	B-T058
compounding	I-T058
technique	O
.	O

The	O
rates	O
of	O
postoperative	B-T038
endophthalmitis	I-T038
before	O
April	O
2010	O
(	O
Group	O
1	O
,	O
no	O
intracameral	B-T082
cefuroxime	B-T103
)	O
and	O
after	O
April	O
2010	O
(	O
Group	O
2	O
,	O
routine	O
use	O
of	O
intracameral	B-T082
cefuroxime	B-T103
)	O
were	O
compared	O
.	O

A	O
total	O
of	O
30	O
,	O
428	O
eyes	B-T017
(	O
7	O
,	O
332	O
in	O
Group	O
1	O
and	O
23	O
,	O
096	O
in	O
Group	O
2	O
)	O
were	O
studied	O
.	O

Eight	O
cases	O
developed	O
postoperative	B-T038
endophthalmitis	I-T038
(	O
1	O
.	O
09	O
in	O
1000	O
;	O
0	O
.	O
11	O
%	O
)	O
in	O
Group	O
1	O
whereas	O
no	O
cases	O
developed	O
endophthalmitis	B-T038
(	O
0	O
%	O
)	O
in	O
Group	O
2	O
.	O

The	O
rate	O
of	O
reduction	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Seven	O
out	O
of	O
eight	O
cases	O
of	O
endophthalmitis	B-T038
were	O
confirmed	O
by	O
positive	B-T033
culture	I-T033
.	O

Organisms	O
identified	O
were	O
Group	B-T007
G	I-T007
Streptococcus	I-T007
(	O
two	O
cases	O
)	O
,	O
Group	B-T007
B	I-T007
Streptococcus	I-T007
,	O
Staphylococcus	B-T007
aureus	I-T007
,	O
Serratia	B-T007
marcescens	I-T007
,	O
and	O
coagulase	B-T007
-	I-T007
negative	I-T007
Staphylococcus	I-T007
(	O
two	O
cases	O
)	O
.	O

Antibiotic	B-T033
susceptibility	I-T033
testing	B-T033
results	I-T033
were	O
available	O
in	O
six	O
cases	O
.	O

Four	O
out	O
of	O
six	O
organisms	O
were	O
susceptible	O
to	O
the	O
penicillin	B-T103
group	I-T103
.	O

No	B-T033
adverse	I-T033
events	I-T033
related	O
to	O
the	O
use	O
of	O
intracameral	B-T082
cefuroxime	B-T103
were	O
encountered	O
.	O

The	O
use	O
of	O
intracameral	B-T082
cefuroxime	B-T103
could	O
significantly	O
reduce	O
the	O
rate	O
of	O
postoperative	B-T038
endophthalmitis	I-T038
in	O
a	O
tertiary	O
centre	O
in	O
Hong	B-T082
Kong	I-T082
.	O

The	O
use	O
of	O
aseptic	B-T058
compounding	I-T058
to	O
prepare	O
cefuroxime	B-T103
aliquots	O
by	O
hospital	O
pharmacy	O
appeared	O
to	O
be	O
safe	O
and	O
efficacious	O
.	O

A	O
standardized	O
approach	O
for	O
the	O
assessment	B-T058
and	O
treatment	B-T058
of	O
internationally	O
adopted	O
children	O
with	O
a	O
previously	O
repaired	O
anorectal	B-T017
malformation	I-T017
(	O
ARM	B-T017
)	O

A	O
significant	O
number	O
of	O
internationally	O
adopted	O
children	O
have	O
congenital	B-T017
birth	I-T017
defects	I-T017
.	O

As	O
a	O
specialist	O
center	O
for	O
colorectal	B-T082
diagnoses	B-T058
,	O
we	O
evaluate	O
such	O
children	O
with	O
an	O
anorectal	B-T017
malformation	I-T017
(	O
ARM	B-T017
)	O
and	O
have	O
found	O
that	O
a	O
significant	O
number	O
need	O
a	O
reoperation	B-T058
.	O

Knowledge	O
of	O
the	O
common	O
complications	B-T038
following	O
ARM	B-T017
surgery	B-T058
has	O
led	O
us	O
to	O
develop	O
treatment	B-T058
algorithms	B-T170
for	O
patients	O
with	O
unknown	O
past	B-T033
medical	I-T033
and	O
surgical	O
history	O
,	O
a	O
situation	O
typically	O
encountered	O
in	O
the	O
adopted	B-T033
population	B-T098
.	O

The	O
results	O
of	O
investigations	B-T058
,	O
indications	O
,	O
and	O
rate	O
of	O
reoperation	B-T058
were	O
assessed	O
for	O
adopted	O
children	O
with	O
an	O
ARM	B-T017
evaluated	O
between	O
2014	O
and	O
2016	O
.	O

56	O
patients	O
(	O
28	O
males	O
)	O
were	O
identified	O
.	O

76	O
.	O
8	O
%	O
required	O
reoperative	B-T058
surgery	I-T058
.	O

Mislocation	O
of	O
the	O
anus	B-T017
outside	B-T082
the	O
sphincter	B-T017
complex	O
was	O
seen	O
in	O
50	O
%	O
of	O
males	O
and	O
39	O
.	O
3	O
%	O
of	O
females	O
.	O

Anal	B-T017
stricture	I-T017
,	O
rectal	B-T038
prolapse	I-T038
,	O
retained	O
vaginal	B-T017
septum	I-T017
,	O
and	O
a	O
strictured	B-T038
vaginal	B-T082
introitus	I-T082
were	O
also	O
common	O
.	O

The	O
reoperative	B-T058
surgery	I-T058
rate	O
in	O
the	O
internationally	O
adopted	O
child	O
with	O
an	O
ARM	B-T017
is	O
high	O
.	O

Complete	O
,	O
systematic	O
evaluation	O
of	O
these	O
children	O
is	O
required	O
to	O
identify	O
complications	B-T038
following	O
initial	O
repair	B-T058
.	O

Development	O
of	O
mechanisms	O
to	O
improve	O
the	O
primary	O
surgical	B-T058
care	I-T058
these	O
children	O
receive	O
is	O
needed	O
.	O

Highly	O
fluorescent	O
gold	B-T103
nanoclusters	O
stabilized	O
by	O
food	B-T103
proteins	I-T103
:	O
From	O
preparation	O
to	O
application	O
in	O
detection	B-T058
of	O
food	B-T168
contaminants	O
and	O
bioactive	O
nutrients	O

Applications	O
of	O
nanotechnology	O
in	O
food	B-T168
have	O
rapidly	O
increased	O
in	O
the	O
past	O
decades	O
.	O

Ultra	O
-	O
small	O
gold	O
nanoclusters	O
(	O
Au	O
NCs	O
)	O
,	O
composed	O
of	O
several	O
to	O
roughly	O
a	O
hundred	O
atoms	O
,	O
represent	O
a	O
kind	O
of	O
novel	O
nanomaterials	O
.	O

The	O
Au	O
NCs	O
directed	O
by	O
food	B-T103
proteins	I-T103
have	O
drawn	O
considerable	O
research	O
attention	O
due	O
to	O
their	O
environmentally	O
friendly	O
preparation	O
,	O
strong	O
fluorescence	O
,	O
excellent	O
photo	O
-	O
stability	O
and	O
favorable	O
biocompatibility	O
.	O

These	O
interesting	O
protein	O
-	O
Au	O
hybrids	O
have	O
opened	O
up	O
a	O
new	O
area	O
at	O
the	O
nano	B-T092
-	I-T092
bio	I-T092
-	I-T092
food	I-T092
interface	I-T092
,	O
not	O
only	O
did	O
they	O
provide	O
the	O
missing	O
link	O
between	O
single	B-T103
metal	I-T103
atoms	I-T103
and	O
plasmonic	B-T062
metal	O
nanoparticles	O
,	O
but	O
also	O
developed	O
the	O
hybrid	B-T103
system	I-T103
between	O
biomacromolecule	O
and	O
inorganic	O
ions	B-T103
.	O

In	O
this	O
review	O
,	O
we	O
highlighted	O
the	O
synthesis	O
strategies	O
and	O
optical	O
properties	O
of	O
the	O
Au	O
NCs	O
stabilized	O
by	O
typical	O
food	B-T103
proteins	I-T103
as	O
well	O
as	O
their	O
applications	O
in	O
detection	B-T058
of	O
food	B-T168
contaminants	O
or	O
bioactive	O
nutrients	O
.	O

In	O
addition	O
,	O
we	O
discussed	O
current	O
challenges	O
and	O
future	O
development	O
in	O
food	B-T103
proteins	I-T103
directed	O
gold	O
nanoclusters	O
for	O
size	O
-	O
controlled	O
synthesis	O
and	O
multifunctional	O
applications	O
.	O

Sub	B-T033
-	I-T033
lethal	I-T033
effects	I-T033
of	O
dietary	B-T168
neonicotinoid	B-T103
insecticide	I-T103
exposure	O
on	O
honey	B-T204
bee	I-T204
queen	I-T204
fecundity	B-T038
and	O
colony	B-T017
development	B-T038

Many	O
factors	O
can	O
negatively	B-T033
affect	O
honey	B-T204
bee	I-T204
(	O
Apis	B-T204
mellifera	I-T204
L	I-T204
.	I-T204
)	O
health	O
including	O
the	O
pervasive	B-T082
use	O
of	O
systemic	O
neonicotinoid	B-T103
insecticides	I-T103
.	O

Through	O
direct	O
consumption	B-T038
of	O
contaminated	O
nectar	B-T103
and	O
pollen	B-T204
from	O
treated	O
plants	B-T204
,	O
neonicotinoids	B-T103
can	O
affect	O
foraging	O
,	O
learning	B-T038
,	O
and	O
memory	B-T038
in	O
worker	B-T204
bees	I-T204
.	O

Less	O
well	O
studied	O
are	O
the	O
potential	O
effects	O
of	O
neonicotinoids	B-T103
on	O
queen	B-T204
bees	I-T204
,	O
which	O
may	O
be	O
exposed	O
indirectly	O
through	O
trophallaxis	O
,	O
or	O
food	B-T168
-	O
sharing	O
.	O

To	O
assess	O
effects	O
on	O
queen	B-T204
productivity	O
,	O
small	O
colonies	B-T017
of	O
different	O
sizes	B-T082
(	O
1500	O
,	O
3000	O
,	O
and	O
7000	O
bees	B-T204
)	O
were	O
fed	O
imidacloprid	B-T103
(	O
0	O
,	O
10	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ppb	O
)	O
in	O
syrup	B-T168
for	O
three	O
weeks	O
.	O

We	O
found	O
adverse	B-T038
effects	I-T038
of	O
imidacloprid	B-T103
on	O
queens	B-T204
(	O
egg	B-T038
-	I-T038
laying	I-T038
and	O
locomotor	B-T038
activity	I-T038
)	O
,	O
worker	B-T204
bees	I-T204
(	O
foraging	O
and	O
hygienic	B-T091
activities	O
)	O
,	O
and	O
colony	B-T017
development	B-T038
(	O
brood	B-T204
production	O
and	O
pollen	B-T204
stores	O
)	O
in	O
all	O
treated	O
colonies	B-T017
.	O

Some	O
effects	O
were	O
less	O
evident	O
as	O
colony	B-T017
size	B-T082
increased	O
,	O
suggesting	O
that	O
larger	O
colony	B-T017
populations	B-T098
may	O
act	O
as	O
a	O
buffer	O
to	O
pesticide	O
exposure	O
.	O

This	O
study	B-T062
is	O
the	O
first	O
to	O
show	O
adverse	B-T038
effects	I-T038
of	O
imidacloprid	B-T103
on	O
queen	B-T204
bee	I-T204
fecundity	B-T038
and	O
behavior	O
and	O
improves	O
our	O
understanding	B-T038
of	O
how	O
neonicotinoids	B-T103
may	O
impair	O
short	O
-	O
term	O
colony	B-T017
functioning	O
.	O

These	O
data	O
indicate	O
that	O
risk	O
-	O
mitigation	O
efforts	O
should	O
focus	O
on	O
reducing	O
neonicotinoid	B-T103
exposure	O
in	O
the	O
early	O
spring	O
when	O
colonies	B-T017
are	O
smallest	O
and	O
queens	B-T204
are	O
most	O
vulnerable	O
to	O
exposure	O
.	O

Therapeutic	O
applications	O
of	O
CRISPR	B-T103
RNA	B-T103
-	I-T103
guided	I-T103
genome	B-T062
editing	I-T062

The	O
rapid	O
development	O
of	O
programmable	B-T103
nuclease	I-T103
-	O
based	O
genome	B-T062
editing	I-T062
technologies	O
has	O
enabled	O
targeted	O
gene	B-T017
disruption	O
and	O
correction	B-T058
both	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
This	O
revolution	O
opens	O
up	O
the	O
possibility	O
of	O
precise	O
genome	B-T062
editing	I-T062
at	O
target	O
genomic	B-T082
sites	I-T082
to	O
modulate	O
gene	B-T038
function	I-T038
in	O
animals	B-T204
and	O
plants	B-T204
.	O

Among	O
several	O
programmable	B-T103
nucleases	I-T103
,	O
the	O
type	B-T103
II	I-T103
clustered	I-T103
regularly	I-T103
interspaced	I-T103
short	I-T103
palindromic	I-T103
repeats	I-T103
(	O
CRISPR	B-T103
)	O
-	O
CRISPR	B-T038
-	I-T038
associated	I-T038
nuclease	I-T038
9	I-T038
(	I-T038
Cas9	I-T038
)	I-T038
system	I-T038
has	O
progressed	O
remarkably	O
in	O
recent	O
years	O
,	O
leading	O
to	O
its	O
widespread	O
use	O
in	O
research	B-T062
,	O
medicine	B-T091
and	O
biotechnology	B-T091
.	O

In	O
particular	O
,	O
CRISPR	B-T038
-	I-T038
Cas9	I-T038
shows	O
highly	O
efficient	O
gene	B-T062
editing	I-T062
activity	O
for	O
therapeutic	O
purposes	O
in	O
systems	O
ranging	O
from	O
patient	O
stem	B-T017
cells	I-T017
to	O
animal	B-T204
models	I-T204
.	O

However	O
,	O
the	O
development	O
of	O
therapeutic	O
approaches	O
and	O
delivery	B-T058
methods	I-T058
remains	O
a	O
great	O
challenge	O
for	O
biomedical	B-T091
applications	O
.	O

Herein	O
,	O
we	O
review	O
therapeutic	O
applications	O
that	O
use	O
the	O
CRISPR	B-T038
-	I-T038
Cas9	I-T038
system	I-T038
and	O
discuss	O
the	O
possibilities	O
and	O
challenges	O
ahead	O
.	O

Design	O
and	O
characteristics	O
of	O
cytotoxic	O
fibroblast	B-T103
growth	I-T103
factor	I-T103
1	I-T103
conjugate	B-T103
for	O
fibroblast	B-T103
growth	I-T103
factor	I-T103
receptor	I-T103
-	O
targeted	B-T058
cancer	I-T058
therapy	I-T058

Fibroblast	B-T103
growth	I-T103
factor	I-T103
receptors	I-T103
(	O
FGFRs	B-T103
)	O
are	O
attractive	O
candidate	O
cancer	B-T058
therapy	I-T058
targets	O
as	O
they	O
are	O
overexpressed	B-T038
in	O
multiple	O
types	O
of	O
tumors	B-T038
,	O
such	O
as	O
breast	B-T038
,	O
prostate	B-T038
,	O
bladder	B-T038
,	O
and	O
lung	B-T038
cancer	I-T038
.	O

In	O
this	O
study	O
,	O
a	O
natural	B-T038
ligand	I-T038
of	O
FGFR	B-T103
,	O
an	O
engineered	B-T103
variant	I-T103
of	O
fibroblast	B-T103
growth	I-T103
factor	I-T103
1	I-T103
(	O
FGF1V	B-T103
)	O
,	O
was	O
conjugated	B-T082
to	O
a	O
potent	B-T103
cytotoxic	I-T103
drug	I-T103
,	O
monomethyl	B-T103
auristatin	I-T103
E	I-T103
(	O
MMAE	B-T103
)	O
,	O
and	O
used	O
as	O
a	O
targeting	B-T038
agent	I-T038
for	O
cancer	B-T017
cells	I-T017
overexpressing	B-T038
FGFRs	B-T103
,	O
similar	O
to	O
antibodies	B-T103
in	O
antibody	B-T058
-	I-T058
drug	I-T058
conjugates	I-T058
.	O

The	O
FGF1V	B-T103
-	I-T103
valine	I-T103
-	I-T103
citrulline	I-T103
-	I-T103
MMAE	I-T103
conjugate	I-T103
showed	O
a	O
favorable	O
stability	B-T038
profile	I-T038
,	O
bound	B-T038
FGFRs	B-T103
on	O
the	O
cell	B-T017
surface	I-T017
specifically	O
,	O
and	O
efficiently	O
released	O
the	O
drug	B-T103
(	I-T103
MMAE	I-T103
)	I-T103
upon	O
cleavage	B-T038
by	O
the	O
lysosomal	B-T103
protease	I-T103
cathepsin	I-T103
B	I-T103
.	O

Importantly	O
,	O
the	O
conjugate	B-T103
showed	O
a	O
prominent	O
cytotoxic	B-T038
effect	I-T038
toward	O
cell	B-T017
lines	I-T017
expressing	O
FGFR	B-T103
.	O

FGF1V	B-T103
-	I-T103
vcMMAE	I-T103
was	O
highly	O
cytotoxic	O
at	O
concentrations	O
even	O
an	O
order	O
of	O
magnitude	O
lower	O
than	O
those	O
found	O
for	O
free	O
MMAE	B-T103
.	O

This	O
effect	O
was	O
FGFR	B-T103
-	O
specific	O
as	O
cells	B-T017
lacking	O
FGFR	B-T103
did	B-T033
not	I-T033
show	I-T033
any	O
increased	O
mortality	B-T038
.	O

Effects	O
of	O
morphology	O
and	O
surface	B-T103
hydroxyl	I-T103
on	O
the	O
toxicity	B-T037
of	O
BiOCl	B-T103
in	O
human	B-T204
HaCaT	B-T017
cells	I-T017

Recently	O
,	O
bismuth	B-T103
oxychloride	I-T103
nanomaterials	B-T170
(	O
BiOCls	B-T103
)	O
are	O
showing	O
great	O
promise	O
in	O
pollutant	B-T103
removal	O
.	O

Residues	B-T103
from	O
these	O
environmental	O
remediations	O
are	O
potential	O
hazardous	B-T103
materials	I-T103
.	O

Unfortunately	O
,	O
human	B-T204
health	B-T058
risks	I-T058
of	O
BiOCls	B-T103
are	O
still	O
unexplored	O
widely	O
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
focused	O
on	O
the	O
influence	O
of	O
physicochemical	O
properties	O
on	O
the	O
cytotoxicity	B-T038
of	O
BiOCls	B-T103
toward	O
a	O
human	B-T204
skin	B-T022
derived	O
cell	B-T017
line	I-T017
(	O
HaCaT	B-T017
)	O
.	O

Results	O
showed	O
that	O
morphology	O
and	O
surface	B-T103
hydroxyl	I-T103
both	O
had	O
a	O
profound	O
effect	O
on	O
the	O
toxicity	B-T037
of	O
BiOCls	B-T103
.	O

Microsphere	B-T082
-	I-T082
shaped	I-T082
BiOCl	B-T103
caused	O
less	O
toxicity	B-T037
than	O
nanosheet	B-T082
-	I-T082
shaped	I-T082
BiOCl	B-T103
because	O
of	O
weaker	B-T038
particle	I-T038
-	I-T038
membrane	I-T038
interactions	I-T038
,	O
while	O
the	O
presence	O
of	O
surface	B-T103
hydroxyl	I-T103
on	O
microsphere	B-T082
-	I-T082
shaped	I-T082
BiOCl	B-T103
significantly	O
raised	O
the	O
toxicity	B-T037
owing	O
to	O
the	O
increased	O
interaction	B-T038
with	O
cell	B-T017
membrane	I-T017
.	O

Both	O
microsphere	B-T082
-	I-T082
shaped	I-T082
BiOCl	B-T103
with	O
surface	B-T103
hydroxyl	I-T103
and	O
nanosheet	B-T082
-	I-T082
shaped	I-T082
BiOCl	B-T103
caused	O
significant	O
cell	B-T017
membrane	I-T017
damage	O
(	O
PI	B-T058
uptake	I-T058
and	O
LDH	B-T058
release	I-T058
)	O
,	O
however	O
,	O
based	O
on	O
the	O
different	O
mechanism	B-T038
.	O

The	O
former	O
may	O
be	O
a	O
predominant	O
"	B-T038
chemical	I-T038
"	I-T038
mechanism	I-T038
involved	O
an	O
oxidative	O
stress	O
paradigm	O
,	O
as	O
manifested	O
by	O
elevated	O
ROS	B-T103
and	O
depleted	O
GSH	B-T103
,	O
while	O
the	O
latter	O
is	O
mainly	O
due	O
to	O
a	O
direct	O
"	O
physical	O
"	O
damage	O
to	O
cell	B-T017
membrane	I-T017
.	O

Both	O
"	O
physical	B-T038
"	O
and	O
"	B-T038
chemical	I-T038
"	I-T038
response	I-T038
led	O
to	O
cell	B-T038
death	I-T038
.	O

Furthermore	O
,	O
a	O
set	O
of	O
experiments	B-T062
including	O
MMP	B-T038
collapse	O
,	O
cell	B-T038
cycle	I-T038
arrest	I-T038
,	O
and	O
apoptosis	B-T038
/	O
necrosis	B-T038
were	O
conducted	O
to	O
propose	O
a	O
scenario	O
for	O
toxicological	O
aspects	O
of	O
BiOCls	B-T103
.	O

Data	O
presented	O
here	O
would	O
help	O
to	O
enable	O
the	O
rational	O
design	O
of	O
BiOCls	B-T103
for	O
either	O
reducing	O
their	O
unintended	O
consequences	O
or	O
increasing	O
their	O
application	O
potentials	O
.	O

Reduced	O
haemodynamic	B-T038
coupling	I-T038
and	O
exercise	O
are	O
associated	O
with	O
vascular	B-T038
stiffening	I-T038
in	O
pulmonary	B-T038
arterial	I-T038
hypertension	I-T038

Inadequate	O
right	B-T017
ventricular	I-T017
(	O
RV	B-T017
)	O
and	O
pulmonary	B-T017
arterial	I-T017
(	O
PA	B-T017
)	O
functional	O
responses	O
to	O
exercise	O
are	O
important	O
yet	O
poorly	O
understood	O
features	O
of	O
pulmonary	B-T038
arterial	I-T038
hypertension	I-T038
(	O
PAH	B-T038
)	O
.	O

This	O
study	B-T062
combined	O
invasive	O
catheterisation	B-T058
with	O
echocardiography	B-T058
to	O
assess	O
RV	B-T017
afterload	O
,	O
RV	B-T038
function	I-T038
and	O
ventricular	B-T017
-	O
vascular	B-T017
coupling	O
in	O
subjects	B-T098
with	O
PAH	B-T038
.	O

Twenty	O
-	O
six	O
subjects	B-T098
with	O
PAH	B-T038
were	O
prospectively	O
recruited	O
to	O
undergo	O
right	B-T082
heart	I-T082
catheterisation	B-T058
and	O
Doppler	B-T058
echocardiography	I-T058
at	O
rest	O
and	O
during	O
incremental	O
exercise	O
,	O
and	O
cardiac	B-T058
MRI	I-T058
at	O
rest	O
.	O

Measurements	O
at	O
rest	O
included	O
basic	O
haemodynamics	B-T038
,	O
RV	B-T038
function	I-T038
and	O
coupling	O
efficiency	O
(	O
η	O
)	O
.	O

Measurements	O
during	O
incremental	O
exercise	O
included	O
pulmonary	B-T033
vascular	I-T033
resistance	I-T033
(	O
Z0	B-T033
)	O
,	O
characteristic	B-T058
impedance	I-T058
(	O
ZC	B-T058
,	O
a	O
measure	O
of	O
proximal	B-T082
PA	B-T017
stiffness	B-T038
)	O
and	O
proximal	B-T082
and	O
distal	B-T082
PA	O
compliance	O
(	O
CPA	O
)	O
.	O

In	O
patients	O
with	O
PAH	B-T038
,	O
the	O
proximal	B-T082
PAs	B-T017
were	O
significantly	O
stiffer	B-T033
at	O
maximum	O
exercise	O
(	O
ZC	B-T058
=	O
2	O
.	O
31±0	O
.	O
38	O
vs	O
1	O
.	O
33±0	O
.	O
15	O
WU×m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
PA	O
compliance	O
was	O
decreased	O
(	O
CPA	O
=	O
0	O
.	O
88±0	O
.	O
10	O
vs	O
1	O
.	O
32±0	O
.	O
17	O
mL	O
/	O
mm	O
Hg	O
/	O
m	O
(	O
2	O
)	O
at	O
rest	O
;	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

Z0	B-T033
did	O
not	O
change	O
with	O
exercise	O
.	O

As	O
a	O
result	O
,	O
the	O
resistance	O
-	O
compliance	O
(	O
RC	O
)	O
time	O
decreased	O
with	O
exercise	O
(	O
0	O
.	O
67±0	O
.	O
05	O
vs	O
1	O
.	O
00±0	O
.	O
07	O
s	O
at	O
rest	O
;	O
p	O
<	O
10	O
(	O
-	O
6	O
)	O
)	O
.	O

When	O
patients	O
were	O
grouped	O
according	O
to	O
resting	O
coupling	O
efficiency	O
,	O
those	O
with	O
poorer	O
η	O
exhibited	O
stiffer	B-T033
proximal	B-T082
PAs	B-T017
at	O
rest	O
,	O
a	O
lower	O
maximum	O
exercise	O
level	O
,	O
and	O
more	O
limited	O
CPA	O
reduction	O
at	O
maximum	O
exercise	O
.	O

In	O
PAH	B-T038
,	O
exercise	O
causes	O
proximal	B-T082
and	O
distal	B-T082
PA	B-T017
stiffening	B-T038
,	O
which	O
combined	O
with	O
preserved	O
Z0	B-T033
results	O
in	O
decreased	O
RC	O
time	O
with	O
exercise	O
.	O

Stiff	B-T017
PAs	I-T017
at	O
rest	O
may	O
also	O
contribute	O
to	O
poor	O
haemodynamic	B-T038
coupling	I-T038
,	O
reflecting	O
reduced	O
pulmonary	B-T017
vascular	I-T017
reserve	O
that	O
contributes	O
to	O
limit	O
the	O
maximum	O
exercise	O
level	O
tolerated	O
.	O

Altered	O
pH	O
gradient	O
at	O
the	O
plasma	B-T017
membrane	I-T017
of	O
osteosarcoma	B-T038
cells	B-T017
is	O
a	O
key	O
mechanism	O
of	O
drug	B-T038
resistance	I-T038

Current	O
therapy	B-T058
of	O
osteosarcoma	B-T038
(	O
OS	B-T038
)	O
,	O
the	O
most	O
common	O
primary	B-T038
bone	I-T038
malignancy	I-T038
,	O
is	O
based	O
on	O
a	O
combination	O
of	O
surgery	O
and	O
chemotherapy	O
.	O

Multidrug	O
resistance	O
mediated	O
by	O
P	B-T103
-	I-T103
glycoprotein	I-T103
(	O
P	B-T103
-	I-T103
gp	I-T103
)	O
overexpression	B-T038
has	O
been	O
previously	O
associated	O
with	O
treatment	B-T033
failure	I-T033
and	O
progression	B-T038
of	O
OS	B-T038
,	O
although	O
other	O
mechanisms	O
may	O
also	O
play	O
a	O
role	O
.	O

We	O
considered	O
the	O
typical	O
acidic	O
extracellular	O
pH	O
(	O
pHe	O
)	O
of	O
sarcomas	B-T038
,	O
and	O
found	O
that	O
doxorubicin	B-T103
(	O
DXR	B-T103
)	O
cytotoxicity	B-T038
is	O
reduced	O
in	O
P	B-T017
-	I-T017
gp	I-T017
negative	O
OS	B-T038
cells	B-T017
cultured	I-T017
at	O
pHe	O
6	O
.	O
5	O
compared	O
to	O
standard	O
7	O
.	O
4	O
.	O

Short	O
-	O
time	O
(	O
24	O
-	O
48	O
hours	O
)	O
exposure	O
to	O
low	O
pHe	O
significantly	O
increased	O
the	O
number	O
and	O
acidity	B-T033
of	O
lysosomes	B-T017
,	O
and	O
the	O
combination	O
of	O
DXR	B-T103
with	O
omeprazole	B-T103
,	O
a	O
proton	B-T103
pump	I-T103
inhibitor	I-T103
targeting	O
lysosomal	B-T038
acidity	I-T038
,	O
significantly	O
enhanced	O
DXR	B-T103
cytotoxicity	B-T038
.	O

In	O
OS	B-T038
xenografts	B-T103
,	O
the	O
combination	B-T058
treatment	I-T058
of	O
DXR	B-T103
and	O
omeprazole	B-T103
significantly	B-T038
reduced	I-T038
tumor	O
volume	O
and	O
body	B-T033
weight	I-T033
loss	I-T033
.	O

The	O
impaired	B-T037
toxicity	I-T037
of	O
DXR	B-T103
at	O
low	O
pHe	O
was	O
not	O
associated	O
with	O
increased	O
autophagy	B-T038
or	O
lysosomal	B-T038
acidification	I-T038
,	O
but	O
rather	O
,	O
as	O
shown	O
by	O
SNARF	B-T103
staining	B-T058
,	O
with	O
a	O
reversal	O
of	O
the	O
pH	O
gradient	O
at	O
the	O
plasma	B-T017
membrane	I-T017
(	O
ΔpHcm	O
)	O
,	O
eventually	O
leading	O
to	O
a	O
reduced	O
DXR	B-T103
intracellular	B-T082
accumulation	B-T033
.	O

Finally	O
,	O
the	O
reversal	O
of	O
ΔpHcm	O
in	O
OS	B-T038
cells	B-T017
promoted	O
resistance	O
not	O
only	O
to	O
DXR	B-T103
,	O
but	O
also	O
to	O
cisplatin	B-T103
and	O
methotrexate	B-T103
,	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
vincristine	B-T103
.	O

Altogether	O
,	O
our	O
findings	O
show	O
that	O
,	O
in	O
OS	B-T038
cells	B-T017
,	O
short	O
-	O
term	O
acidosis	B-T038
induces	O
resistance	O
to	O
different	O
chemotherapeutic	B-T103
drugs	I-T103
by	O
a	O
reversal	O
of	O
ΔpHcm	O
,	O
suggesting	O
that	O
buffer	B-T103
therapies	B-T058
or	O
regimens	B-T170
including	O
proton	B-T103
pump	I-T103
inhibitors	I-T103
in	O
combination	O
to	O
low	O
concentrations	O
of	O
conventional	O
anticancer	B-T103
agents	I-T103
may	O
offer	O
novel	O
solutions	O
to	O
overcome	O
drug	B-T038
resistance	I-T038
.	O

Boston	B-T074
Keratoprosthesis	I-T074
Type	I-T074
1	I-T074
:	O
A	O
Randomized	B-T062
Controlled	I-T062
Trial	I-T062
of	O
Fresh	O
versus	O
Frozen	O
Corneal	O
Donor	O
Carriers	O
with	O
Long	O
-	O
Term	O
Follow	B-T058
-	I-T058
up	I-T058

To	O
compare	O
the	O
long	O
-	O
term	O
clinical	O
outcomes	O
of	O
fresh	O
versus	O
frozen	O
corneal	O
graft	O
carriers	O
for	O
the	O
Boston	B-T074
Keratoprosthesis	I-T074
type	I-T074
1	I-T074
(	O
B	B-T074
-	I-T074
KPro	I-T074
)	O
.	O

Prospective	O
,	O
single	O
-	O
center	O
,	O
nonblinded	O
,	O
randomized	B-T062
controlled	I-T062
trial	I-T062
.	I-T062

All	O
participants	B-T098
were	O
followed	O
through	O
the	O
initial	O
study	B-T170
protocol	I-T170
of	O
24	O
months	O
and	O
were	O
approached	O
to	O
enter	O
an	O
extension	O
phase	O
,	O
with	O
continuing	O
follow	B-T058
-	I-T058
up	I-T058
visits	I-T058
to	O
60	O
months	O
.	O

All	O
patients	O
undergoing	O
B	B-T058
-	I-T058
KPro	I-T058
surgery	I-T058
between	O
October	O
2008	O
and	O
December	O
2009	O
by	O
a	O
single	O
experienced	B-T097
surgeon	I-T097
at	O
the	O
Centre	O
Hospitalier	B-T092
de	I-T092
l	I-T092
'	I-T092
Université	I-T092
de	I-T092
Montréal	I-T092
using	O
an	O
allograft	B-T017
carrier	I-T017
were	O
considered	O
.	O

Patients	O
were	O
excluded	O
if	O
they	O
had	O
previously	O
undergone	O
B	B-T074
-	I-T074
KPro	I-T074
implantation	B-T058
.	O

Participants	B-T098
were	O
randomized	B-T033
individually	O
to	O
receive	O
a	O
B	B-T074
-	I-T074
KPro	I-T074
using	O
a	O
frozen	O
or	O
a	O
fresh	O
corneal	B-T017
graft	I-T017
carrier	I-T017
on	O
the	O
basis	O
of	O
tissue	B-T017
availability	O
on	O
the	O
day	O
of	O
surgery	B-T058
,	O
as	O
determined	O
by	O
the	O
local	O
eye	B-T092
bank	I-T092
.	O

The	O
primary	O
outcome	O
measure	O
was	O
device	B-T033
retention	I-T033
at	O
24	O
and	O
60	O
months	O
.	O

Secondary	O
outcome	O
measures	O
included	O
surgical	B-T033
feasibility	I-T033
,	O
visual	B-T201
acuity	I-T201
(	O
VA	B-T201
)	O
,	O
and	O
complications	B-T038
.	O

Thirty	O
-	O
seven	O
eyes	B-T017
of	O
37	O
patients	O
were	O
enrolled	O
in	O
the	O
initial	O
study	B-T170
protocol	I-T170
,	O
with	O
19	O
eyes	B-T017
randomized	B-T062
to	O
fresh	O
and	O
18	O
to	O
frozen	O
carrier	B-T017
grafts	I-T017
.	O

Thirty	O
-	O
six	O
eyes	B-T017
were	O
followed	O
through	O
to	O
24	O
months	O
,	O
with	O
1	O
lost	O
to	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Of	O
these	O
,	O
26	O
were	O
enrolled	O
in	O
the	O
extension	O
(	O
11	O
eyes	B-T017
with	O
a	O
frozen	O
and	O
15	O
eyes	B-T017
with	O
a	O
fresh	O
carrier	B-T017
graft	I-T017
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
baseline	O
characteristics	O
of	O
patients	O
enrolled	O
in	O
the	O
extension	O
phase	O
versus	O
those	O
who	O
were	O
not	O
.	O

At	O
60	O
months	O
,	O
median	O
corrected	O
distance	O
VA	B-T201
)	O
in	O
the	O
fresh	O
group	O
had	O
improved	B-T033
to	O
20	O
/	O
150	O
from	O
a	O
baseline	O
of	O
counting	O
fingers	O
,	O
whereas	O
the	O
frozen	O
group	O
improved	B-T033
to	O
20	O
/	O
400	O
from	O
a	O
baseline	O
of	O
hand	O
motions	O
.	O

Device	B-T033
retention	I-T033
was	O
100	O
%	O
at	O
24	O
months	O
and	O
96	O
%	O
at	O
60	O
months	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
rate	O
of	O
complications	B-T038
between	O
groups	O
.	O

Fresh	O
and	O
frozen	O
corneal	B-T098
donors	I-T098
offer	O
similar	O
clinical	O
outcomes	O
when	O
used	O
as	O
carriers	B-T017
for	O
the	O
B	B-T074
-	I-T074
KPro	I-T074
,	O
with	O
no	O
significant	O
differences	O
in	O
device	B-T033
retention	I-T033
,	O
visual	B-T033
rehabilitation	I-T033
,	O
or	O
rates	O
of	O
complications	B-T038
at	O
24	O
or	O
60	O
months	O
.	O

Impact	O
of	O
an	O
Educational	B-T058
Intervention	I-T058
to	O
Improve	B-T033
Antibiotic	B-T103
Prescribing	B-T058
for	O
Nurse	B-T097
Practitioners	I-T097
in	O
a	O
Pediatric	O
Urgent	B-T092
Care	I-T092
Center	I-T092

Up	O
to	O
21	O
%	O
of	O
pediatric	B-T058
visits	I-T058
result	O
in	O
an	O
antibiotic	B-T103
prescription	B-T058
,	O
and	O
a	O
large	O
portion	O
of	O
these	O
are	O
unnecessary	O
.	O

To	O
determine	O
if	O
educational	O
sessions	O
would	O
reduce	O
inappropriate	O
antibiotic	B-T103
use	O
.	O

Intervention	B-T170
study	I-T170
evaluating	B-T058
antibiotic	B-T103
prescribing	B-T058
following	O
educational	O
sessions	O
for	O
urinary	B-T038
tract	I-T038
infection	I-T038
,	O
skin	B-T038
and	O
soft	B-T038
tissue	I-T038
infection	I-T038
,	O
pharyngitis	B-T038
,	O
upper	B-T038
respiratory	I-T038
tract	I-T038
infection	I-T038
,	O
acute	B-T038
otitis	I-T038
media	I-T038
,	O
and	O
acute	B-T038
bacterial	I-T038
sinusitis	I-T038
.	O

A	O
total	O
of	O
26	O
out	O
of	O
43	O
(	O
60	O
%	O
)	O
nurse	B-T097
practitioners	I-T097
in	O
4	O
urgent	B-T092
care	I-T092
centers	I-T092
were	O
enrolled	B-T058
in	O
the	O
study	B-T062
.	O

The	O
rate	O
of	O
inappropriate	O
antibiotic	B-T103
use	O
among	O
all	O
conditions	O
was	O
10	O
%	O
before	O
and	O
8	O
%	O
after	O
the	O
intervention	B-T058
(	O
p	O
=	O
.	O
02	O
)	O
.	O

A	O
decrease	O
in	O
inappropriate	O
antibiotic	B-T103
prescribing	B-T058
was	O
seen	O
after	O
the	O
educational	O
session	O
(	O
p	O
<	O
.	O
01	O
)	O
.	O

The	O
most	O
common	O
reasons	O
for	O
inappropriate	O
antibiotic	B-T103
prescribing	B-T058
were	O
too	O
broad	O
(	O
41	O
%	O
)	O
,	O
wrong	O
dosage	O
(	O
22	O
%	O
)	O
,	O
and	O
not	B-T033
indicated	I-T033
(	O
17	O
%	O
)	O
.	O

Educational	O
sessions	O
led	O
to	O
improvement	O
in	O
overall	O
inappropriate	O
antibiotic	B-T103
use	O
.	O

Additional	O
stewardship	O
interventions	B-T058
are	O
needed	O
to	O
further	O
reduce	O
unnecessary	O
antibiotic	B-T103
use	O
.	O

Zika	B-T005
Virus	I-T005
Disrupts	O
Phospho	B-T103
-	I-T103
TBK1	I-T103
Localization	B-T038
and	O
Mitosis	B-T038
in	O
Human	B-T204
Neuroepithelial	O
Stem	B-T017
Cells	I-T017
and	O
Radial	B-T017
Glia	I-T017

The	O
mechanisms	O
underlying	O
Zika	B-T005
virus	I-T005
(	O
ZIKV	B-T005
)	O
-	O
related	O
microcephaly	B-T017
and	O
other	O
neurodevelopment	O
defects	O
remain	O
poorly	O
understood	B-T038
.	O

Here	O
,	O
we	O
describe	O
the	O
derivation	O
and	O
characterization	O
,	O
including	O
single	B-T082
-	I-T082
cell	I-T082
RNA	I-T082
-	I-T082
seq	I-T082
,	O
of	O
neocortical	B-T017
and	O
spinal	B-T017
cord	I-T017
neuroepithelial	O
stem	B-T017
(	I-T017
NES	I-T017
)	I-T017
cells	I-T017
to	O
model	O
early	O
human	B-T204
neurodevelopment	O
and	O
ZIKV	B-T005
-	O
related	O
neuropathogenesis	B-T038
.	O

By	O
analyzing	O
human	B-T204
NES	B-T017
cells	I-T017
,	O
organotypic	O
fetal	B-T017
brain	B-T017
slices	O
,	O
and	O
a	O
ZIKV	B-T005
-	O
infected	B-T033
micrencephalic	B-T017
brain	B-T017
,	O
we	O
show	O
that	O
ZIKV	B-T005
infects	B-T033
both	O
neocortical	B-T017
and	O
spinal	B-T017
NES	B-T017
cells	I-T017
as	O
well	O
as	O
their	O
fetal	B-T017
homolog	O
,	O
radial	B-T017
glial	I-T017
cells	I-T017
(	O
RGCs	B-T017
)	O
,	O
causing	O
disrupted	O
mitoses	B-T038
,	O
supernumerary	O
centrosomes	B-T017
,	O
structural	B-T082
disorganization	O
,	O
and	O
cell	B-T038
death	I-T038
.	O

ZIKV	B-T038
infection	I-T038
of	O
NES	B-T017
cells	I-T017
and	O
RGCs	B-T017
causes	O
centrosomal	B-T017
depletion	O
and	O
mitochondrial	B-T017
sequestration	O
of	O
phospho	B-T103
-	I-T103
TBK1	I-T103
during	O
mitosis	B-T038
.	O

We	O
also	O
found	O
that	O
nucleoside	B-T103
analogs	I-T103
inhibit	O
ZIKV	B-T005
replication	B-T038
in	O
NES	B-T017
cells	I-T017
,	O
protecting	O
them	O
from	O
ZIKV	B-T005
-	O
induced	O
pTBK1	B-T103
relocalization	B-T038
and	O
cell	B-T038
death	I-T038
.	O

We	O
established	O
a	O
model	B-T170
system	I-T170
of	O
human	B-T204
neural	B-T017
stem	I-T017
cells	I-T017
to	O
reveal	O
cellular	B-T017
and	O
molecular	O
mechanisms	O
underlying	O
neurodevelopmental	O
defects	O
associated	O
with	O
ZIKV	B-T038
infection	I-T038
and	O
its	O
potential	O
treatment	B-T058
.	O

Prevalence	O
of	O
HPV	B-T005
genotypes	O
in	O
cervical	B-T038
adenocarcinoma	I-T038
:	O
a	O
study	B-T062
in	O
Greek	B-T098
women	B-T098

To	O
study	B-T062
the	O
prevalence	O
of	O
human	B-T005
papillomavirus	I-T005
(	O
HPV	B-T005
)	O
genotypes	O
among	O
cervical	B-T038
adenocarcinomas	I-T038
in	O
Greek	B-T098
women	B-T098
.	O

The	O
study	O
group	O
comprised	O
78	O
adenocarcinoma	B-T038
cases	O
(	O
20	O
in	B-T038
situ	I-T038
and	O
58	O
invasive	B-T038
)	O
.	O

HPV	B-T103
DNA	I-T103
was	O
amplified	B-T038
using	O
polymerase	B-T062
chain	I-T062
reaction	I-T062
(	O
PCR	B-T062
)	O
and	O
HPV	B-T005
genotypes	O
were	O
identified	O
by	O
reverse	B-T062
hybridization	I-T062
.	O

There	O
was	O
a	O
high	O
prevalence	O
of	O
HPV	B-T038
infection	I-T038
both	O
for	O
in	B-T038
situ	I-T038
(	O
95	O
%	O
)	O
or	O
invasive	B-T038
(	I-T038
94	I-T038
.	I-T038
83	I-T038
%	I-T038
)	I-T038
adenocarcinomas	I-T038
,	O
comprising	O
also	O
cancers	B-T038
of	O
unusual	O
morphology	O
.	O

HPV	B-T005
16	I-T005
was	O
the	O
commonest	O
strain	O
(	O
N	O
=	O
57	O
,	O
73	O
.	O
08	O
%	O
)	O
followed	O
by	O
HPV	B-T005
18	I-T005
(	O
N	O
=	O
28	O
,	O
35	O
.	O
90	O
%	O
)	O
.	O

Interestingly	O
,	O
13	O
cases	O
(	O
16	O
.	O
67	O
%	O
)	O
were	O
also	O
HPV	B-T005
52	I-T005
positive	I-T005
(	O
as	O
co	B-T038
-	I-T038
infection	I-T038
with	O
HPV	B-T005
16	I-T005
or	O
18	B-T005
)	O
.	O

All	O
other	O
strains	O
with	O
the	O
exception	O
of	O
HPV	B-T005
66	I-T005
were	O
found	O
only	O
as	O
co	B-T038
-	I-T038
infections	I-T038
.	O

No	O
significant	O
age	O
difference	O
was	O
noted	O
in	O
terms	O
of	O
any	O
HPV	B-T005
strain	O
positivity	B-T033
.	O

HPV	B-T103
DNA	I-T103
was	O
found	O
in	O
the	O
large	O
majority	O
of	O
cervical	B-T038
adenocarcinomas	I-T038
.	O

As	O
opposed	O
to	O
other	O
studies	B-T062
,	O
HPV	B-T005
52	I-T005
was	O
the	O
third	O
most	O
commonly	O
encountered	B-T058
strain	O
after	O
HPV	B-T005
16	I-T005
and	O
HPV	B-T005
18	I-T005
.	O

The	O
above	O
findings	O
would	O
probably	O
be	O
of	O
help	O
in	O
decision	B-T038
making	I-T038
concerning	O
vaccination	B-T058
policy	B-T170
for	O
the	O
prevention	O
of	O
HPV	B-T038
infection	I-T038
in	O
Greece	B-T082
.	O

Glucose	B-T038
metabolism	I-T038
-	O
weighted	B-T058
imaging	I-T058
with	O
chemical	B-T058
exchange	I-T058
-	I-T058
sensitive	I-T058
MRI	I-T058
of	O
2	B-T103
-	I-T103
deoxyglucose	I-T103
(	O
2DG	B-T103
)	O
in	O
brain	B-T017
:	O
Sensitivity	O
and	O
biological	O
sources	B-T033

Recent	B-T062
proof	I-T062
-	I-T062
of	I-T062
-	I-T062
principle	I-T062
studies	I-T062
have	O
demonstrated	O
the	O
feasibility	O
of	O
measuring	O
the	O
uptake	B-T038
and	O
metabolism	B-T038
of	O
non	O
-	O
labeled	O
2	B-T103
-	I-T103
deoxy	I-T103
-	I-T103
D	I-T103
-	I-T103
glucose	I-T103
(	O
2DG	B-T103
)	O
by	O
a	O
chemical	B-T058
exchange	I-T058
-	I-T058
sensitive	I-T058
spin	I-T058
-	I-T058
lock	I-T058
(	I-T058
CESL	I-T058
)	I-T058
MRI	I-T058
approach	I-T058
.	O

In	O
order	O
to	O
gain	O
better	O
understanding	O
of	O
this	O
new	O
approach	O
,	O
we	O
performed	O
dynamic	O
in	B-T082
vivo	I-T082
CESL	B-T058
MRI	I-T058
on	O
healthy	O
rat	B-T204
brains	B-T017
with	O
an	O
intravenous	O
injection	O
of	O
2DG	B-T103
under	O
various	O
conditions	O
at	O
9	O
.	O
4T	O
.	O

For	O
three	O
2DG	B-T103
doses	O
of	O
0	O
.	O
25	O
,	O
0	O
.	O
5	O
and	O
1g	O
/	O
kg	O
,	O
we	O
found	O
that	O
2DG	B-T103
-	O
CESL	B-T058
signals	O
increased	O
linearly	O
with	O
injection	B-T058
dose	O
at	O
the	O
initial	O
(	O
<	O
20min	O
)	O
but	O
not	O
the	O
later	O
period	O
(	O
>	O
40min	O
)	O
suggesting	O
time	O
-	O
dependent	O
differential	O
weightings	O
of	O
2DG	B-T103
transport	B-T038
and	O
metabolism	B-T038
.	O

Remaining	O
2DG	B-T103
-	O
CESL	B-T058
studies	O
were	O
performed	O
with	O
0	O
.	O
25g	O
/	O
kg	O
2DG	B-T103
.	O

Since	O
a	O
higher	O
isoflurane	B-T103
level	O
reduces	O
glucose	B-T038
metabolism	I-T038
and	O
increases	O
blood	B-T038
flow	I-T038
,	O
2DG	B-T103
-	O
CESL	B-T058
was	O
measured	O
under	O
0	O
.	O
5	O
%	O
,	O
1	O
.	O
5	O
%	O
and	O
2	O
.	O
2	O
%	O
isoflurane	B-T103
.	O

The	O
2DG	B-T103
-	O
CESL	B-T058
signal	O
was	O
reduced	O
at	O
higher	O
isoflurane	B-T103
levels	O
correlating	O
well	O
with	O
the	O
2DG	B-T103
phosphorylation	B-T038
in	O
the	O
intracellular	B-T082
space	I-T082
.	O

To	O
detect	O
regional	O
heterogeneities	O
of	O
glucose	B-T038
metabolism	I-T038
,	O
2DG	B-T103
-	O
CESL	B-T058
with	O
0	O
.	O
33×0	O
.	O
33×1	O
.	O
50mm	O
(	O
3	O
)	O
resolution	O
was	O
obtained	O
,	O
which	O
indeed	O
showed	O
a	O
higher	O
response	O
in	O
the	O
cortex	B-T017
compared	O
to	O
the	O
corpus	B-T017
callosum	I-T017
.	O

Lastly	O
,	O
unlike	O
CESL	B-T058
MRI	I-T058
with	O
the	O
injection	B-T058
of	O
non	B-T103
-	I-T103
transportable	I-T103
mannitol	I-T103
,	O
the	O
2DG	B-T103
-	O
CESL	B-T058
response	O
decreased	O
with	O
an	O
increased	O
spin	O
-	O
lock	O
pulse	O
power	O
confirming	O
that	O
2DG	B-T103
-	O
CESL	B-T058
is	O
dominated	O
by	O
chemical	B-T103
exchange	B-T201
processes	O
in	O
the	O
extravascular	O
space	O
.	O

Taken	O
together	O
,	O
our	O
results	O
showed	O
that	O
2DG	B-T103
-	O
CESL	B-T058
MRI	I-T058
signals	O
mainly	O
indicate	O
glucose	B-T038
transport	I-T038
and	O
metabolism	B-T038
and	O
may	O
be	O
a	O
useful	O
biomarker	B-T201
for	O
metabolic	O
studies	B-T062
of	O
normal	B-T017
and	O
diseased	B-T038
brains	B-T017
.	O

Parental	O
perceptions	B-T038
of	O
children´s	B-T092
agency	I-T092
:	O
Parental	O
warmth	O
,	O
school	O
achievement	O
and	O
adjustment	O

The	O
present	O
study	B-T062
examined	O
Swedish	B-T098
mothers	O
'	O
and	O
fathers	O
'	O
warmth	O
towards	O
their	O
children	O
in	O
relation	O
to	O
their	O
children´s	B-T092
agency	I-T092
.	O

It	O
also	O
examined	O
the	O
longitudinal	O
relation	O
between	O
agency	B-T092
and	O
children	O
'	O
s	O
externalizing	O
,	O
internalizing	O
,	O
and	O
school	O
achievement	O
.	O

Swedish	B-T098
children	O
'	O
s	O
mothers	O
and	O
fathers	O
(	O
N	O
=	O
103	O
)	O
were	O
interviewed	O
at	O
three	O
time	O
points	O
(	O
when	O
children	O
were	O
8	O
,	O
9	O
,	O
and	O
10	O
years	O
old	O
)	O
about	O
their	O
warmth	O
towards	O
their	O
children	O
,	O
children	B-T092
'	I-T092
s	I-T092
agency	I-T092
,	O
and	O
children	O
'	O
s	O
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
school	O
achievement	O
.	O

Parental	O
warmth	O
at	O
Time	O
1	O
was	O
significantly	O
correlated	O
with	O
child	B-T092
agency	I-T092
at	O
Time	O
2	O
,	O
which	O
was	O
significantly	O
correlated	O
with	O
child	O
externalizing	O
and	O
internalizing	O
behaviors	O
and	O
academic	O
achievement	O
at	O
Time	O
3	O
.	O

There	O
were	O
no	O
differences	O
between	O
girls	O
and	O
boys	O
.	O

Results	O
from	O
this	O
study	B-T062
indicate	O
that	O
Swedish	B-T098
parents	O
'	O
warmth	O
is	O
directly	O
related	O
to	O
subsequent	O
perceptions	B-T038
of	O
children	B-T092
'	I-T092
s	I-T092
agency	I-T092
,	O
which	O
in	O
turn	O
are	O
related	O
to	O
subsequently	O
lower	O
child	O
externalizing	O
and	O
internalizing	O
problems	B-T033
and	O
higher	O
academic	O
achievement	O
.	O

These	O
findings	B-T033
held	O
in	O
the	O
context	O
of	O
a	O
three	O
-	O
year	O
longitudinal	B-T062
study	I-T062
and	O
for	O
both	O
boys	O
and	O
girls	O
,	O
suggesting	O
the	O
importance	O
of	O
child	B-T092
agency	I-T092
in	O
the	O
link	O
between	O
parental	O
warmth	O
and	O
children	O
'	O
s	O
adjustment	O
.	O

Vasopressin	B-T103
regulates	B-T038
the	I-T038
growth	I-T038
of	O
the	O
biliary	O
epithelium	O
in	O
polycystic	B-T017
liver	I-T017
disease	I-T017

The	O
neurohypophysial	B-T103
hormone	I-T103
arginine	B-T103
vasopressin	I-T103
(	O
AVP	B-T103
)	O
acts	O
by	O
three	O
distinct	O
receptor	B-T103
subtypes	O
:	O
V1a	B-T103
,	O
V1b	B-T103
,	O
and	O
V2	B-T103
.	O

In	O
the	O
liver	B-T017
,	O
AVP	B-T103
is	O
involved	O
in	O
ureogenesis	B-T038
,	O
glycogenolysis	B-T038
,	O
neoglucogenesis	O
and	O
regeneration	B-T038
.	O

No	O
data	O
exist	O
about	O
the	O
presence	B-T033
of	O
AVP	B-T103
in	O
the	O
biliary	O
epithelium	O
.	O

Cholangiocytes	O
are	O
the	O
target	B-T017
cells	I-T017
in	O
a	O
number	O
of	O
animal	B-T038
models	I-T038
of	O
cholestasis	B-T038
,	O
including	O
bile	B-T017
duct	I-T017
ligation	B-T058
(	O
BDL	B-T058
)	O
,	O
and	O
in	O
several	O
human	B-T204
pathologies	B-T091
,	O
such	O
as	O
polycystic	B-T017
liver	I-T017
disease	I-T017
characterized	O
by	O
the	O
presence	B-T033
of	O
cysts	B-T038
that	O
bud	O
from	O
the	O
biliary	O
epithelium	O
.	O

In	B-T082
vivo	I-T082
,	O
liver	B-T017
fragments	B-T031
from	O
normal	O
and	O
BDL	B-T058
mice	B-T204
and	O
rats	B-T204
as	O
well	O
as	O
liver	B-T017
samples	I-T017
from	O
normal	O
and	O
ADPKD	B-T017
patients	O
were	O
collected	O
to	O
evaluate	O
:	O
(	O
i	O
)	O
intrahepatic	B-T082
bile	B-T017
duct	I-T017
mass	B-T033
by	O
immunohistochemistry	B-T058
for	O
cytokeratin	B-T103
-	I-T103
19	I-T103
;	O
and	O
(	O
ii	O
)	O
expression	O
of	O
V1a	B-T103
,	O
V1b	B-T103
and	O
V2	B-T103
by	O
immunohistochemistry	B-T058
,	O
immunofluorescence	B-T058
and	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
.	O

In	O
vitro	O
,	O
small	O
and	O
large	O
mouse	B-T204
cholangiocytes	O
,	O
H69	B-T017
(	O
non	O
-	O
malignant	O
human	B-T204
cholangiocytes	O
)	O
and	O
LCDE	B-T017
(	O
human	B-T204
cholangiocytes	O
from	O
the	O
cystic	B-T017
epithelium	I-T017
)	O
were	O
stimulated	B-T038
with	O
vasopressin	B-T103
in	O
the	O
absence	O
/	O
presence	B-T033
of	O
AVP	B-T103
antagonists	I-T103
such	O
as	O
OPC	B-T103
-	I-T103
31260	I-T103
and	O
Tolvaptan	B-T103
,	O
before	O
assessing	O
cellular	B-T038
growth	I-T038
by	O
MTT	B-T058
assay	I-T058
and	O
cAMP	B-T103
levels	O
.	O

Cholangiocytes	O
express	O
V2	B-T103
receptor	I-T103
that	O
was	O
upregulated	B-T038
following	O
BDL	B-T058
and	O
in	O
ADPKD	B-T017
liver	B-T017
samples	I-T017
.	O

Administration	B-T058
of	O
AVP	B-T103
increased	O
proliferation	B-T038
and	O
cAMP	B-T103
levels	O
of	O
small	O
cholangiocytes	O
and	O
LCDE	B-T017
cells	I-T017
.	O

We	O
found	O
no	O
effect	O
in	O
the	O
proliferation	B-T038
of	O
large	O
mouse	B-T204
cholangiocytes	O
and	O
H69	B-T017
cells	I-T017
.	O

Increases	O
were	O
blocked	O
by	O
preincubation	O
with	O
the	O
AVP	B-T103
antagonists	I-T103
.	O

These	O
results	O
showed	O
that	O
AVP	B-T103
and	O
its	O
receptors	B-T103
may	O
be	O
important	O
in	O
the	O
modulation	O
of	O
the	O
proliferation	B-T033
rate	I-T033
of	O
the	O
biliary	O
epithelium	O
.	O

Central	B-T201
Corneal	I-T201
Thickness	I-T201
Reproducibility	O
among	O
Ten	O
Different	O
Instruments	O

To	O
assess	O
agreement	O
between	O
one	O
ultrasonic	B-T074
(	O
US	B-T074
)	O
and	O
nine	O
optical	O
instruments	O
for	O
the	O
measurement	O
of	O
central	B-T201
corneal	I-T201
thickness	I-T201
(	O
CCT	B-T201
)	O
,	O
and	O
to	O
evaluate	B-T058
intra	O
-	O
and	O
inter	O
-	O
operator	O
reproducibility	O
.	O

In	O
this	O
observational	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
,	O
two	O
masked	O
operators	O
measured	O
CCT	B-T201
thickness	O
twice	O
in	O
28	O
healthy	O
eyes	B-T017
.	O

We	O
used	O
seven	O
spectral	B-T074
-	I-T074
domain	I-T074
optical	I-T074
coherence	I-T074
tomography	I-T074
(	I-T074
SD	I-T074
-	I-T074
OCT	I-T074
)	I-T074
devices	I-T074
,	O
one	O
time	O
-	O
domain	O
OCT	O
,	O
one	O
Scheimpflug	B-T074
camera	I-T074
,	O
and	O
one	O
US	B-T074
-	I-T074
based	I-T074
instrument	I-T074
.	O

Inter	O
-	O
and	O
intra	O
-	O
operator	O
reproducibility	O
was	O
evaluated	B-T058
by	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
,	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
,	O
and	O
Bland	O
-	O
Altman	O
test	O
analysis	B-T062
.	O

Instrument	B-T074
-	O
to	O
-	O
instrument	B-T074
reproducibility	O
was	O
determined	O
by	O
ANOVA	O
for	O
repeated	O
measurements	O
.	O

We	O
also	O
tested	O
how	O
the	O
devices	B-T074
disagreed	O
regarding	O
systemic	O
bias	O
and	O
random	O
error	O
using	O
a	O
structural	O
equation	O
model	O
.	O

Mean	O
CCT	B-T201
of	O
all	O
instruments	B-T074
ranged	O
from	O
536	O
±	O
42	O
μm	O
to	O
577	O
±	O
40	O
μm	O
.	O

An	O
instrument	B-T074
-	O
to	O
-	O
instrument	B-T074
correlation	B-T170
test	I-T170
showed	O
high	O
values	O
among	O
the	O
10	O
investigated	O
devices	B-T074
(	O
correlation	O
coefficient	O
range	O
0	O
.	O
852	O
-	O
0	O
.	O
995	O
;	O
p	O
values	O
<	O
0	O
.	O
0001	O
in	O
all	O
cases	O
)	O
.	O

The	O
highest	O
correlation	O
coefficient	O
values	O
were	O
registered	O
between	O
3D	O
OCT	O
-	O
2000	O
Topcon	O
-	O
Spectral	O
OCT	O
/	O
SLO	O
Opko	O
(	O
0	O
.	O
995	O
)	O
and	O
Cirrus	O
HD	O
-	O
OCT	O
Zeiss	O
-	O
RS	O
-	O
3000	O
Nidek	O
(	O
0	O
.	O
995	O
)	O
,	O
whereas	O
the	O
lowest	O
were	O
seen	O
between	O
SS	O
-	O
1000	O
CASIA	O
and	O
Spectral	O
OCT	O
/	O
SLO	O
Opko	O
(	O
0	O
.	O
852	O
)	O
.	O

ICC	O
and	O
CV	O
showed	O
excellent	O
inter	O
-	O
and	O
intra	O
-	O
operator	O
reproducibility	O
for	O
all	O
optic	O
-	O
based	O
devices	B-T074
,	O
except	O
for	O
the	O
US	B-T074
-	O
based	O
device	B-T074
.	O

Bland	O
-	O
Altman	O
analysis	B-T062
demonstrated	O
low	O
mean	O
biases	O
between	O
operators	O
.	O

Despite	O
highlighting	O
good	O
intra	O
-	O
and	O
inter	O
-	O
operator	O
reproducibility	O
,	O
we	O
found	O
that	O
a	O
scale	B-T170
bias	O
between	O
instruments	B-T074
might	O
interfere	O
with	O
thorough	O
CCT	B-T201
monitoring	B-T058
.	O

We	O
suggest	O
that	O
optimal	O
monitoring	B-T058
is	O
achieved	O
with	O
the	O
same	O
operator	O
and	O
the	O
same	O
device	B-T074
.	O

Predictors	O
of	O
neurologic	B-T038
and	O
nonneurologic	B-T033
death	I-T033
in	O
patients	O
with	O
brain	B-T038
metastasis	I-T038
initially	O
treated	O
with	O
upfront	B-T058
stereotactic	I-T058
radiosurgery	I-T058
without	O
whole	B-T058
-	I-T058
brain	I-T058
radiation	I-T058
therapy	I-T058

In	O
this	O
study	B-T062
we	O
attempted	O
to	O
discern	O
the	O
factors	O
predictive	O
of	O
neurologic	B-T038
death	I-T038
in	O
patients	O
with	O
brain	B-T038
metastasis	I-T038
treated	O
with	O
upfront	B-T058
stereotactic	I-T058
radiosurgery	I-T058
(	O
SRS	B-T058
)	O
without	O
whole	B-T058
brain	I-T058
radiation	I-T058
therapy	I-T058
(	O
WBRT	B-T058
)	O
while	O
accounting	O
for	O
the	O
competing	O
risk	O
of	O
nonneurologic	B-T033
death	I-T033
.	O

We	O
performed	O
a	O
retrospective	O
single	B-T092
-	I-T092
institution	I-T092
analysis	B-T062
of	O
patients	O
with	O
brain	B-T038
metastasis	I-T038
treated	O
with	O
upfront	O
SRS	B-T058
without	O
WBRT	B-T058
.	O

Competing	O
risks	O
analysis	O
was	O
performed	O
to	O
estimate	O
the	O
subdistribution	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
neurologic	B-T038
and	O
nonneurologic	B-T033
death	I-T033
for	O
predictor	O
variables	O
of	O
interest	O
.	O

Of	O
738	O
patients	O
treated	O
with	O
upfront	B-T058
SRS	I-T058
alone	O
,	O
neurologic	B-T038
death	I-T038
occurred	O
in	O
226	O
(	O
30	O
.	O
6	O
%	O
)	O
,	O
while	O
nonneurologic	B-T033
death	I-T033
occurred	O
in	O
309	O
(	O
41	O
.	O
9	O
%	O
)	O
.	O

Multivariate	O
competing	O
risks	O
analysis	O
identified	O
an	O
increased	O
hazard	O
of	O
neurologic	B-T038
death	I-T038
associated	O
with	O
diagnosis	B-T170
-	I-T170
specific	I-T170
graded	I-T170
prognostic	I-T170
assessment	I-T170
(	O
DS	B-T170
-	I-T170
GPA	I-T170
)	O
≤	O
2	O
(	O
P	O
=	O
.	O
005	O
)	O
,	O
melanoma	B-T038
histology	B-T058
(	O
P	O
=	O
.	O
009	O
)	O
,	O
and	O
increased	O
number	O
of	O
brain	B-T038
metastases	I-T038
(	O
P	O
<	O
.	O
001	O
)	O
,	O
while	O
there	O
was	O
a	O
decreased	O
hazard	O
associated	O
with	O
higher	O
SRS	B-T058
dose	O
(	O
P	O
=	O
.	O
004	O
)	O
.	O

Targeted	B-T103
agents	I-T103
were	O
associated	O
with	O
a	O
decreased	O
HR	O
of	O
neurologic	B-T038
death	I-T038
in	O
the	O
first	O
1	O
.	O
5	O
years	O
(	O
P	O
=	O
.	O
04	O
)	O
but	O
not	O
afterwards	O
.	O

An	O
increased	O
hazard	O
of	O
nonneurologic	B-T033
death	I-T033
was	O
seen	O
with	O
increasing	O
age	O
(	O
P	O
=	O
.	O
03	O
)	O
,	O
nonmelanoma	B-T058
histology	I-T058
(	O
P	O
<	O
.	O
001	O
)	O
,	O
presence	O
of	O
extracranial	B-T038
disease	I-T038
(	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
progressive	O
systemic	B-T038
disease	I-T038
(	O
P	O
=	O
.	O
004	O
)	O
.	O

Melanoma	B-T038
,	O
DS	B-T170
-	I-T170
GPA	I-T170
,	O
number	O
of	O
brain	B-T038
metastases	I-T038
,	O
and	O
SRS	B-T058
dose	O
are	O
predictive	O
of	O
neurologic	B-T038
death	I-T038
,	O
while	O
age	O
,	O
nonmelanoma	B-T058
histology	I-T058
,	O
and	O
more	O
advanced	O
systemic	B-T038
disease	I-T038
are	O
predictive	O
of	O
nonneurologic	B-T033
death	I-T033
.	O

Targeted	B-T103
agents	I-T103
appear	O
to	O
delay	O
neurologic	B-T038
death	I-T038
.	O

Pharmacological	B-T038
Actions	I-T038
of	O
Glucagon	B-T103
-	I-T103
Like	I-T103
Peptide	I-T103
-	I-T103
1	I-T103
,	O
Gastric	B-T103
Inhibitory	I-T103
Polypeptide	I-T103
,	O
and	O
Glucagon	B-T103

Glucagon	B-T103
family	I-T103
of	O
peptide	B-T103
hormones	I-T103
is	O
a	O
group	O
of	O
structurally	O
related	O
brain	B-T103
-	I-T103
gut	I-T103
peptides	I-T103
that	O
exert	O
their	O
pleiotropic	B-T038
actions	I-T038
through	O
interactions	O
with	O
unique	B-T170
members	I-T170
of	I-T170
class	I-T170
B1	I-T170
G	B-T103
protein	I-T103
-	I-T103
coupled	I-T103
receptors	I-T103
(	O
GPCRs	B-T103
)	O
.	O

They	O
are	O
key	O
regulators	O
of	O
hormonal	O
homeostasis	B-T038
and	O
are	O
important	O
drug	B-T074
targets	I-T074
for	O
metabolic	B-T038
disorders	I-T038
such	O
as	O
type	B-T038
-	I-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
(	O
T2DM	B-T038
)	O
,	O
obesity	B-T038
,	O
and	O
dysregulations	B-T038
of	I-T038
the	I-T038
nervous	I-T038
systems	I-T038
such	O
as	O
migraine	B-T038
,	O
anxiety	B-T038
,	O
depression	B-T038
,	O
neurodegeneration	B-T038
,	O
psychiatric	B-T038
disorders	I-T038
,	O
and	O
cardiovascular	B-T038
diseases	I-T038
.	O

The	O
current	O
review	O
aims	O
to	O
provide	O
a	O
detailed	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
pharmacological	B-T038
actions	I-T038
and	O
therapeutic	B-T058
advances	I-T058
of	O
three	O
members	O
within	O
this	O
family	O
including	O
glucagon	B-T103
-	I-T103
like	I-T103
peptide	I-T103
-	I-T103
1	I-T103
(	O
GLP	B-T103
-	I-T103
1	I-T103
)	O
,	O
gastric	B-T103
inhibitory	I-T103
polypeptide	I-T103
(	O
GIP	B-T103
)	O
,	O
and	O
glucagon	B-T103
.	O

Endemic	O
hydrothermal	O
vent	O
species	B-T170
identified	O
in	O
the	O
open	O
ocean	O
seed	B-T204
bank	I-T204

Hydrothermal	O
vent	O
systems	O
host	O
microbial	O
communities	O
among	O
which	O
several	O
microorganisms	O
have	O
been	O
considered	O
endemic	O
to	O
this	O
type	O
of	O
habitat	B-T082
.	O

It	O
is	O
still	O
unclear	O
how	O
these	O
organisms	O
colonize	B-T033
geographically	B-T082
distant	B-T082
hydrothermal	O
environments	B-T082
.	O

Based	O
on	O
16S	B-T103
rRNA	I-T103
gene	B-T082
sequences	I-T082
,	O
we	O
compare	O
the	O
bacterial	O
communities	O
of	O
sixteen	O
Atlantic	B-T082
hydrothermal	O
vent	O
samples	O
with	O
our	O
own	O
and	O
publicly	O
available	O
global	O
open	O
ocean	O
samples	O
.	O

Analysing	B-T062
sequences	B-T082
obtained	O
from	O
63	O
million	O
16S	B-T103
rRNA	I-T103
genes	B-T017
,	O
the	O
genera	B-T170
we	O
could	O
identify	O
in	O
the	O
open	O
ocean	O
waters	O
contained	O
99	O
.	O
9	O
%	O
of	O
the	O
vent	O
reads	O
.	O

This	O
suggests	O
that	O
previously	O
observed	O
vent	O
exclusiveness	B-T033
is	O
,	O
in	O
most	O
cases	O
,	O
probably	O
an	O
artefact	B-T033
of	O
lower	O
sequencing	B-T058
depth	O
.	O

These	O
findings	B-T033
are	O
a	O
further	O
step	O
towards	O
elucidating	O
the	O
role	B-T170
of	O
the	O
open	O
ocean	O
as	O
a	O
seed	B-T204
bank	I-T204
.	O

They	O
can	O
explain	O
the	O
predicament	B-T033
of	O
how	O
species	B-T170
expected	B-T170
to	O
be	O
endemic	O
to	O
vent	O
systems	O
are	O
able	B-T033
to	O
colonize	B-T033
geographically	B-T082
distant	B-T082
hydrothermal	O
habitats	B-T082
and	O
contribute	O
to	O
our	O
understanding	B-T038
of	O
whether	O
'	O
everything	O
is	O
really	O
everywhere	O
'	O
.	O

Cerebral	B-T038
toxoplasmosis	I-T038
in	O
patients	O
with	O
acquired	B-T038
immune	I-T038
deficiency	I-T038
syndrome	I-T038
in	O
the	O
neurological	B-T092
emergency	I-T092
department	I-T092
of	O
a	O
tertiary	B-T092
hospital	I-T092

Cerebral	B-T038
toxoplasmosis	I-T038
is	O
the	O
most	O
common	O
cause	O
of	O
space	B-T082
occupying	O
brain	B-T038
lesion	I-T038
in	O
patients	O
with	O
HIV	O
/	O
AIDS	O
in	O
Brazil	B-T082
.	O

In	O
the	O
post	O
-	O
HAART	O
era	O
,	O
it	O
is	O
responsible	O
for	O
high	O
rates	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

This	O
study	B-T062
consists	O
of	O
a	O
case	B-T062
series	I-T062
of	O
56	O
patients	O
diagnosed	B-T033
with	O
cerebral	B-T038
toxoplasmosis	I-T038
whose	O
clinical	O
features	O
,	O
brain	B-T058
imaging	I-T058
and	O
cerebrospinal	B-T031
fluid	I-T031
aspects	O
were	O
analyzed	B-T062
.	O

Cerebral	B-T038
toxoplasmosis	I-T038
led	O
to	O
the	O
diagnosis	B-T033
of	O
infection	B-T038
by	O
the	O
human	B-T005
immunodeficiency	I-T005
virus	I-T005
(	O
HIV	B-T005
)	O
in	O
27	O
(	O
48	O
.	O
2	O
%	O
)	O
of	O
the	O
patients	O
,	O
while	O
29	O
(	O
51	O
.	O
2	O
%	O
)	O
others	O
already	O
knew	O
to	O
be	O
HIV	B-T033
seropositive	I-T033
.	O

However	O
,	O
at	O
the	O
time	O
of	O
diagnosis	B-T033
of	O
cerebral	B-T038
toxoplasmosis	I-T038
,	O
only	O
9	O
(	O
16	O
.	O
6	O
%	O
)	O
reported	B-T058
being	O
under	O
antiretroviral	B-T058
therapy	I-T058
and	O
5	O
(	O
8	O
.	O
9	O
%	O
)	O
were	O
receiving	O
primary	O
prophylaxis	B-T058
for	O
toxoplasmosis	B-T038
.	O

Headache	B-T033
,	O
strength	B-T033
deficit	I-T033
and	O
fever	B-T033
were	O
the	O
most	O
frequent	O
signs	B-T033
and	I-T033
symptoms	I-T033
throughout	O
the	O
study	B-T062
.	O

Fifty	O
-	O
three	O
patients	O
showed	O
changes	O
consistent	O
with	O
toxoplasmosis	B-T038
in	O
CT	B-T058
or	O
MRI	B-T058
.	O

Thirty	O
-	O
four	O
(	O
60	O
.	O
7	O
%	O
)	O
CSF	B-T031
samples	I-T031
were	O
positive	B-T033
in	O
the	O
indirect	B-T058
haemagglutination	I-T058
test	I-T058
and	O
for	O
the	O
reaction	O
of	O
Toxoplasma	B-T103
gondii	I-T103
IgG	I-T103
ELISA	B-T058
,	O
while	O
31	O
(	O
55	O
.	O
4	O
%	O
)	O
were	O
positive	B-T033
in	O
the	O
direct	B-T058
haemagglutination	I-T058
test	I-T058
.	O

Fifty	O
(	O
89	O
.	O
3	O
%	O
)	O
patients	O
underwent	O
first	B-T058
-	I-T058
line	I-T058
treatment	I-T058
for	O
toxoplasmosis	B-T038
.	O

Cerebral	B-T038
toxoplasmosis	I-T038
is	O
still	O
a	O
very	O
relevant	O
neurological	B-T038
disease	I-T038
in	O
individuals	B-T098
with	O
AIDS	B-T038
admitted	B-T058
to	O
neurology	B-T091
emergency	B-T092
departments	I-T092
.	O

Early	B-T058
diagnosis	I-T058
and	O
initiation	O
of	O
empiric	B-T033
treatment	I-T033
and	O
antiretroviral	B-T058
therapy	I-T058
are	O
important	O
for	O
good	O
prognosis	B-T058
.	O

Maf1	B-T017
-	O
mediated	O
regulation	B-T038
of	O
yeast	B-T204
RNA	B-T103
polymerase	I-T103
III	I-T103
is	O
correlated	O
with	O
CCA	B-T038
addition	I-T038
at	I-T038
the	I-T038
3	I-T038
'	I-T038
end	I-T038
of	I-T038
tRNA	B-T103
precursors	I-T103

In	O
eukaryotic	B-T017
cells	I-T017
tRNA	B-T038
synthesis	I-T038
is	O
negatively	B-T033
regulated	B-T038
by	O
the	O
protein	B-T103
Maf1	I-T103
,	O
conserved	O
from	O
yeast	B-T204
to	O
humans	B-T204
.	O

Maf1	B-T017
from	O
yeast	B-T204
Saccharomyces	B-T204
cerevisiae	I-T204
mediates	O
repression	B-T038
of	O
trna	B-T038
transcription	I-T038
when	O
cells	B-T017
are	O
transferred	O
from	O
medium	B-T103
with	O
glucose	B-T103
to	O
medium	B-T103
with	O
glycerol	B-T103
,	O
a	O
non	B-T038
-	I-T038
fermentable	I-T038
carbon	B-T103
source	B-T033
.	O

The	O
strain	O
with	O
deleted	O
gene	B-T017
encoding	O
Maf1	B-T017
(	O
maf1Δ	B-T017
)	O
is	O
viable	O
but	O
accumulates	O
tRNA	B-T103
precursors	I-T103
.	O

In	O
this	O
study	B-T062
tRNA	B-T103
precursors	I-T103
were	O
analysed	B-T062
by	O
RNA	B-T058
-	I-T058
Seq	I-T058
and	O
Northern	O
hybridization	O
in	O
wild	B-T017
type	I-T017
strain	O
and	O
maf1Δ	B-T017
mutant	B-T017
grown	O
in	O
glucose	B-T103
medium	B-T103
or	O
upon	O
shift	O
to	O
repressive	O
conditions	O
.	O

A	O
negative	B-T033
effect	O
of	O
maf1Δ	B-T017
mutant	B-T017
on	O
the	O
addition	B-T038
of	I-T038
the	I-T038
auxiliary	I-T038
CCA	I-T038
nucleotides	I-T038
to	I-T038
the	I-T038
3	I-T038
'	I-T038
end	I-T038
of	I-T038
pre	I-T038
-	I-T038
tRNAs	I-T038
was	O
observed	O
in	O
cells	B-T017
shifted	O
to	O
unfavourable	O
growth	B-T038
conditions	O
.	O

This	O
effect	O
was	O
reduced	O
by	O
overexpression	B-T038
of	O
the	O
yeast	B-T204
CCA1	B-T017
gene	I-T017
encoding	O
ATP	B-T103
(	I-T103
CTP	I-T103
)	I-T103
:	I-T103
tRNA	I-T103
nucleotidyltransferase	I-T103
.	O

The	O
CCA	B-T082
sequence	I-T082
at	O
the	O
3	O
'	O
end	O
is	O
important	O
for	O
export	O
of	O
tRNA	B-T103
precursors	I-T103
from	O
the	O
nucleus	B-T017
and	O
essential	O
for	O
tRNA	B-T038
charging	I-T038
with	O
amino	B-T103
acids	I-T103
.	O

Data	O
presented	O
here	O
indicate	O
that	O
CCA	B-T038
-	I-T038
addition	I-T038
to	I-T038
intron	B-T103
-	I-T038
containing	I-T038
end	I-T038
-	I-T038
processed	I-T038
tRNA	I-T038
precursors	I-T038
is	O
a	O
limiting	O
step	O
in	O
tRNA	B-T038
maturation	I-T038
when	O
there	O
is	O
no	O
Maf1	B-T017
mediated	O
RNA	B-T103
polymerase	I-T103
III	I-T103
(	O
Pol	B-T103
III	I-T103
)	O
repression	B-T038
.	O

The	O
correlation	O
between	O
CCA	B-T082
synthesis	B-T038
and	O
Pol	B-T103
III	I-T103
regulation	B-T038
by	O
Maf1	B-T017
could	O
be	O
important	O
in	O
coordination	O
of	O
tRNA	B-T038
transcription	I-T038
,	O
processing	B-T038
and	O
regulation	B-T038
of	I-T038
translation	I-T038
.	O

Pre	O
-	O
existing	O
renal	B-T017
lesions	B-T033
revealed	O
after	O
renal	B-T017
trauma	B-T037
,	O
Difficulties	O
in	O
diagnosis	B-T062
and	O
accountability	O
:	O
About	O
14	O
cases	O

Pre	O
-	O
existing	O
renal	B-T017
lesions	B-T033
(	O
PERL	B-T033
)	O
may	O
interfere	O
with	O
the	O
patho	O
-	O
physiology	O
of	O
trauma	B-T037
,	O
alter	O
the	O
radiographic	B-T058
imaging	I-T058
and	O
influence	O
the	O
therapeutic	B-T058
approach	O
.	O

The	O
aims	O
of	O
this	O
study	B-T062
were	O
to	O
record	O
the	O
PERL	B-T033
found	O
incidentally	O
during	O
blunt	O
renal	B-T017
trauma	B-T037
,	O
to	O
specify	O
the	O
place	O
for	O
effective	O
conservative	B-T058
management	I-T058
and	O
to	O
determin	O
the	O
estimated	O
partial	O
permanent	O
disability	O
(	O
PPD	O
)	O
.	O

The	O
medical	B-T170
records	I-T170
of	O
14	O
patients	O
with	O
PERL	B-T033
and	O
blunt	O
renal	B-T017
trauma	B-T037
were	O
reviewed	O
.	O

In	O
each	O
patient	O
,	O
pre	O
-	O
existing	O
renal	B-T017
abnormalities	O
,	O
clinical	O
symptoms	B-T033
,	O
CT	B-T058
scan	I-T058
study	B-T062
findings	B-T033
,	O
associated	O
injuries	B-T037
,	O
therapeutic	B-T058
approach	O
,	O
the	O
accountability	O
criteria	O
and	O
the	O
estimated	O
PPD	O
were	O
recorded	O
.	O

There	O
were	O
11	O
men	B-T098
and	O
3	O
women	B-T098
with	O
a	O
mean	O
age	O
of	O
35	O
,	O
6	O
years	O
(	O
range	O
19	O
-	O
66	O
years	O
)	O
.	O

Renal	B-T017
trauma	B-T037
was	O
due	O
to	O
a	O
traffic	B-T037
accident	I-T037
in	O
8	O
patients	O
.	O

Renal	B-T017
damage	O
appeared	O
to	O
be	O
disproportionate	O
to	O
the	O
severity	O
of	O
the	O
trauma	B-T037
(	O
minor	O
trauma	B-T037
)	O
.	O

They	O
had	O
a	O
lower	O
rate	O
of	O
associated	O
trauma	B-T037
to	O
other	O
abdominal	B-T017
organs	I-T017
(	O
four	O
patients	O
only	O
)	O
.	O

Urinary	B-T031
stones	I-T031
were	O
present	O
in	O
5	O
patients	O
,	O
pelvi	B-T038
-	I-T038
ureteric	I-T038
junction	I-T038
obstruction	I-T038
in	O
3	O
,	O
horseshoe	B-T017
kidny	I-T017
in	O
3	O
,	O
ectopic	B-T017
kidney	I-T017
in	O
2	O
and	O
upper	O
urinary	O
tract	O
carcinoma	O
in	O
one	O
case	O
.	O

Early	O
nephrectomy	B-T058
was	O
required	O
in	O
three	O
cases	O
for	O
hemodynamic	B-T038
instability	I-T038
.	O

Ureteral	B-T074
stenting	I-T074
was	O
indicated	O
in	O
3	O
cases	O
.	O

Six	O
patients	O
were	O
operated	B-T058
later	O
because	O
of	O
their	O
underlying	O
renal	B-T017
pathology	B-T058
.	O

A	O
conservative	B-T058
treatment	I-T058
was	O
possible	O
only	O
in	O
7	O
of	O
cases	O
.	O

The	O
PPD	O
related	O
to	O
renal	B-T017
trauma	B-T037
varide	O
from	O
0	O
to	O
13	O
%	O
in	O
all	O
cases	O
.	O

PERL	B-T033
may	O
complicate	O
a	O
negligible	O
renal	B-T017
trauma	B-T037
while	O
in	O
some	O
cases	O
they	O
may	O
be	O
of	O
vital	O
importance	O
for	O
the	O
patient	O
'	O
s	O
final	O
outcome	O
.	O

The	O
imaging	O
findings	B-T033
are	O
crucial	O
but	O
may	O
be	O
confusing	O
.	O

The	O
therapeutic	B-T058
approach	O
is	O
,	O
to	O
a	O
large	O
extent	O
,	O
dependent	O
on	O
the	O
type	O
of	O
PERL	B-T033
and	O
the	O
severity	O
of	O
damage	O
,	O
and	O
is	O
often	O
conservative	O
in	O
the	O
hemo	B-T033
-	I-T033
dynamically	I-T033
stable	I-T033
patient	O
.	O

Accountability	O
link	O
may	O
be	O
difficult	O
to	O
establish	O
and	O
the	O
PPD	O
depends	O
on	O
the	O
PERL	B-T033
and	O
the	O
renal	B-T037
injuries	I-T037
severity	O
.	O

We	O
have	O
no	O
involvement	O
with	O
funding	O
in	O
this	O
case	O
.	O

Ethical	O
approval	O
:	O
Not	O
required	O
Conflicts	O
of	O
interest	O
:	O
None	O
.	O

Polymeric	B-T103
Nanostructure	O
Compiled	O
with	O
Multifunctional	O
Components	O
To	O
Exert	O
Tumor	B-T038
-	O
Targeted	B-T062
Delivery	I-T062
of	O
Antiangiogenic	B-T038
Gene	B-T017
for	O
Tumor	O
Growth	O
Suppression	O

Nucleic	B-T103
acid	I-T103
-	I-T103
based	I-T103
therapy	B-T058
has	O
emerged	O
as	O
a	O
revolutionary	O
methodology	O
for	O
treatment	O
of	O
the	O
diseases	B-T038
related	O
to	O
protein	B-T103
dysfunction	O
;	O
however	O
,	O
lack	O
of	O
systemically	O
applicable	O
synthetic	B-T062
delivery	I-T062
systems	I-T062
limits	O
its	O
current	O
usage	O
in	O
local	O
applications	O
,	O
particularly	O
for	O
DNA	B-T103
-	I-T103
based	I-T103
therapy	B-T058
with	O
regard	O
to	O
the	O
poor	O
bioavailability	O
in	O
the	O
systemic	O
administrations	O
.	O

To	O
overcome	O
this	O
obstacle	O
,	O
we	O
compiled	O
multiple	O
chemistry	B-T058
-	I-T058
based	I-T058
strategies	I-T058
into	O
the	O
manufacture	O
of	O
the	O
gene	B-T062
delivery	I-T062
formulations	I-T062
to	O
pursue	O
improved	B-T033
tolerability	O
of	O
DNA	B-T103
to	O
the	O
enzymatic	B-T038
degradation	B-T038
in	O
the	O
biological	O
milieu	B-T082
and	O
prolonged	B-T038
retention	I-T038
in	O
the	O
systemic	O
circulation	O
.	O

Here	O
,	O
we	O
constructed	O
a	O
distinctive	O
multilayered	O
functional	O
architecture	O
:	O
plasmid	B-T103
DNA	I-T103
(	O
pDNA	B-T103
)	O
was	O
electrostatically	O
complexed	O
with	O
cationic	B-T103
poly	B-T103
(	I-T103
lysine	I-T103
)	I-T103
(	O
polyplex	B-T103
)	O
as	O
the	O
interior	B-T082
pDNA	B-T103
reservoir	O
,	O
which	O
was	O
further	O
cross	O
-	O
linked	O
by	O
redox	B-T038
-	O
responsive	O
disulfide	B-T103
cross	O
-	O
linking	O
to	O
minimize	O
the	O
occurrence	O
of	O
polyplex	B-T103
disassembly	O
through	O
exchange	B-T038
reaction	I-T038
with	O
the	O
biological	O
charged	B-T103
components	I-T103
.	O

Still	O
,	O
the	O
pDNA	B-T103
reservoir	O
was	O
spatially	O
protected	O
by	O
a	O
sequential	O
thermoresponsive	O
poly	B-T103
(	I-T103
N	I-T103
-	I-T103
isopropylacrylamide	I-T103
)	I-T103
palisade	O
as	O
the	O
intermediate	O
barrier	O
and	O
a	O
biocompatible	B-T103
hydrophilic	O
poly	B-T103
(	I-T103
ethylene	I-T103
glycol	I-T103
)	I-T103
(	O
PEG	B-T103
)	O
shell	O
with	O
the	O
aim	O
of	O
preventing	O
the	O
accessibility	O
of	O
the	O
biological	O
species	B-T170
,	O
particularly	O
the	O
nuclease	B-T103
degradation	O
to	O
the	O
pDNA	B-T103
payload	O
.	O

Subsequent	O
investigations	B-T058
validated	O
the	O
utilities	O
of	O
these	O
strategies	O
in	O
accomplishing	O
prolonged	O
blood	B-T031
retention	B-T038
.	O

In	O
an	O
attempt	O
to	O
apply	O
this	O
method	B-T170
for	O
tumor	O
therapy	B-T058
,	O
ligand	B-T103
cyclic	I-T103
(	I-T103
Arg	I-T103
-	I-T103
Gly	I-T103
-	I-T103
Asp	I-T103
)	I-T103
peptide	I-T103
was	O
attached	O
at	O
the	O
distal	O
end	O
of	O
PEG	B-T103
,	O
validating	O
prompted	O
tumor	B-T038
-	O
targeted	O
delivery	O
and	O
gene	B-T038
expression	I-T038
of	O
the	O
loaded	O
antiangiogenic	B-T038
gene	B-T017
at	O
the	O
targeted	O
tumor	B-T017
cells	I-T017
and	O
accordingly	O
exerting	B-T038
antiangiogenesis	B-T038
of	O
the	O
tumors	B-T038
for	O
abrogation	O
of	O
tumor	O
growth	O
.	O

Together	O
with	O
its	O
excellent	O
safe	O
profile	O
,	O
the	O
proposed	O
formulation	O
suggests	O
potential	O
utility	O
as	O
a	O
practical	O
gene	B-T062
delivery	I-T062
system	I-T062
for	O
treatment	O
of	O
intractable	O
diseases	B-T038
.	O

Evaluation	B-T058
of	O
the	O
VIDAS	B-T058
Anti	I-T058
-	I-T058
HCV	I-T058
Assay	I-T058
for	O
Detection	B-T058
of	O
Hepatitis	B-T038
C	I-T038
Virus	I-T038
Infection	I-T038

Anti	B-T103
-	I-T103
hepatitis	I-T103
C	I-T103
virus	I-T103
antibody	I-T103
(	O
anti	B-T103
-	I-T103
HCV	I-T103
)	O
assays	B-T058
are	O
recommended	O
for	O
screening	B-T058
HCV	B-T098
-	I-T098
infected	I-T098
persons	I-T098
.	O

The	O
VIDAS	B-T058
Anti	I-T058
-	I-T058
HCV	I-T058
Assay	I-T058
(	O
bioMérieux	O
,	O
France	B-T082
)	O
,	O
based	O
on	O
the	O
enzyme	B-T058
-	I-T058
linked	I-T058
fluorescence	I-T058
test	I-T058
principle	O
,	O
was	O
recently	O
introduced	O
in	O
Korea	B-T082
.	O

We	O
evaluated	O
the	O
clinical	O
performance	O
of	O
the	O
VIDAS	B-T058
assay	I-T058
.	O

One	O
hundred	O
HCV	B-T033
-	I-T033
positive	I-T033
and	O
1	O
,	O
002	O
HCV	B-T033
-	I-T033
negative	I-T033
blood	B-T031
samples	I-T031
confirmed	O
by	O
Architect	B-T058
anti	I-T058
-	I-T058
HCV	I-T058
(	O
Abbott	O
Laboratories	O
,	O
USA	B-T082
)	O
and	O
COBAS	B-T062
TaqMan	I-T062
HCV	I-T062
real	I-T062
-	I-T062
time	I-T062
PCR	I-T062
(	O
Roche	B-T092
Diagnostics	I-T092
,	O
USA	B-T082
)	O
or	O
the	O
Procleix	B-T058
Ultrio	I-T058
Plus	I-T058
Assay	I-T058
(	O
Gen	O
-	O
Probe	O
Incorporated	O
,	O
USA	B-T082
)	O
were	O
obtained	O
from	O
the	O
Human	O
Serum	O
Bank	O
(	O
HSB	O
)	O
and	O
tested	O
by	O
VIDAS	O
.	O

In	O
case	O
of	O
discrepant	B-T033
results	I-T033
,	O
we	O
conducted	O
a	O
recombinant	B-T058
immunoblot	I-T058
assay	I-T058
(	O
RIBA	B-T058
)	O
.	O

The	O
agreement	O
rates	O
for	O
known	O
HCV	B-T033
-	I-T033
positive	I-T033
and	O
HCV	B-T033
-	I-T033
negative	I-T033
samples	B-T031
between	O
the	O
VIDAS	B-T058
assay	I-T058
and	O
the	O
HSB	O
testing	O
were	O
100	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
96	O
.	O
4	O
-	O
100	O
%	O
)	O
and	O
99	O
.	O
5	O
%	O
(	O
95	O
%	O
CI	O
:	O
98	O
.	O
8	O
-	O
99	O
.	O
8	O
%	O
)	O
,	O
respectively	O
.	O

One	O
of	O
the	O
five	O
discrepant	B-T033
samples	B-T031
was	O
positive	B-T033
for	O
Core	B-T103
2	I-T103
+	I-T103
and	O
NS3	B-T103
-	I-T103
2	I-T103
2	I-T103
+	I-T103
reactivity	O
,	O
two	O
samples	B-T031
were	O
negative	B-T033
,	O
and	O
the	O
other	O
two	O
were	O
indeterminate	O
regarding	O
NS4	B-T103
2	I-T103
+	I-T103
reactivity	O
in	O
RIBA	B-T058
.	O

We	O
observed	O
a	O
significant	O
but	O
weak	O
positive	O
correlation	O
between	O
the	O
titers	O
of	O
VIDAS	O
and	O
Architect	B-T058
assays	I-T058
(	O
r	O
=	O
0	O
.	O
315	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
VIDAS	B-T058
anti	I-T058
-	I-T058
HCV	I-T058
assay	I-T058
,	O
developed	O
on	O
the	O
VIDAS	O
automated	B-T058
immunoassay	I-T058
platform	I-T058
based	O
on	O
the	O
ready	O
-	O
to	O
-	O
use	O
,	O
single	O
-	O
sample	O
test	O
concept	O
may	O
be	O
useful	O
in	O
small	O
-	O
to	O
-	O
medium	O
-	O
sized	O
laboratories	B-T092
.	O

It	O
showed	O
good	O
agreement	O
with	O
Architect	B-T058
anti	I-T058
-	I-T058
HCV	I-T058
and	O
COBAS	B-T062
PCR	I-T062
assays	I-T062
and	O
is	O
therefore	O
useful	O
for	O
detection	O
of	O
HCV	B-T038
infection	I-T038
.	O

Weakly	B-T033
test	I-T033
-	I-T033
positive	I-T033
(	I-T033
ambiguous	I-T033
)	I-T033
samples	B-T031
require	O
additional	O
testing	O
by	O
another	O
anti	B-T103
-	I-T103
HCV	I-T103
,	O
RIBA	B-T058
,	O
or	O
HCV	B-T058
RNA	I-T058
assay	I-T058
.	O

Reassembly	O
of	O
Excitable	O
Domains	O
after	O
CNS	B-T022
Axon	B-T038
Regeneration	I-T038

Action	B-T038
potential	I-T038
initiation	I-T038
and	O
propagation	B-T038
in	O
myelinated	O
axons	O
require	O
ion	B-T038
channel	I-T038
clustering	I-T038
at	O
axon	B-T017
initial	I-T017
segments	I-T017
(	B-T017
AIS	I-T017
)	O
and	O
nodes	B-T082
of	I-T082
Ranvier	I-T082
.	O

Disruption	O
of	O
these	O
domains	O
after	O
injury	B-T037
impairs	O
nervous	B-T038
system	I-T038
function	I-T038
.	O

Traditionally	O
,	O
injured	O
CNS	B-T022
axons	B-T017
are	O
considered	O
refractory	B-T038
to	O
regeneration	B-T038
,	O
but	O
some	O
recent	O
approaches	O
challenge	O
this	O
view	O
by	O
showing	O
robust	O
long	O
-	O
distance	O
regeneration	B-T038
.	O

However	O
,	O
whether	O
these	O
approaches	O
allow	O
remyelination	B-T038
and	O
promote	O
the	O
reestablishment	O
of	O
AIS	B-T017
and	O
nodes	B-T082
of	I-T082
Ranvier	I-T082
is	O
unknown	O
.	O

Using	O
mouse	B-T204
optic	B-T017
nerve	I-T017
crush	B-T037
as	O
a	O
model	B-T038
for	O
CNS	B-T022
traumatic	B-T037
injury	I-T037
,	O
we	O
performed	O
a	O
detailed	O
analysis	B-T062
of	O
AIS	B-T017
and	O
node	B-T082
disruption	O
after	O
nerve	B-T037
crush	I-T037
.	O

We	O
found	O
significant	O
disruption	O
of	O
AIS	B-T017
and	O
loss	O
of	O
nodes	B-T082
within	O
days	O
of	O
the	O
crush	B-T037
,	O
and	O
complete	O
loss	O
of	O
nodes	B-T082
1	O
week	O
after	O
injury	B-T037
.	O

Genetic	B-T038
deletion	I-T038
of	O
the	O
tumor	B-T017
suppressor	I-T017
phosphatase	I-T017
and	I-T017
tensin	I-T017
homolog	I-T017
(	O
Pten	B-T017
)	O
in	O
retinal	B-T017
ganglion	I-T017
cells	I-T017
(	O
RGCs	B-T017
)	O
,	O
coupled	O
with	O
stimulation	B-T038
of	O
RGCs	B-T017
by	O
inflammation	B-T038
and	O
cAMP	B-T103
,	O
dramatically	O
enhanced	O
regeneration	B-T038
.	O

With	O
this	O
treatmen	B-T062
t	O
,	O
we	O
found	O
significant	O
reestablishment	O
of	O
RGC	B-T017
AIS	B-T017
,	O
remyelination	B-T038
,	O
and	O
even	O
reassembly	O
of	O
nodes	B-T082
in	O
regions	B-T082
proximal	I-T082
,	O
within	B-T082
,	O
and	O
distal	B-T082
to	O
the	O
crush	B-T037
site	B-T082
.	O

Remyelination	B-T038
began	O
near	B-T082
the	I-T082
retina	I-T082
,	O
progressed	O
distally	B-T082
,	O
and	O
was	O
confirmed	O
by	O
electron	B-T058
microscopy	I-T058
.	O

Although	O
axons	B-T017
grew	B-T038
rapidly	O
,	O
remyelination	B-T038
and	O
nodal	B-T038
ion	I-T038
channel	I-T038
clustering	I-T038
was	O
much	O
slower	O
.	O

Finally	O
,	O
genetic	B-T038
deletion	I-T038
of	O
ankyrinG	B-T103
from	O
RGCs	B-T017
to	O
block	O
AIS	B-T017
reassembly	O
did	O
not	O
affect	O
axon	B-T038
regeneration	I-T038
,	O
indicating	O
that	O
preservation	O
of	O
neuronal	B-T082
polarity	I-T082
is	O
not	B-T033
required	I-T033
for	O
axon	B-T038
regeneration	I-T038
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerating	B-T038
CNS	B-T022
axons	B-T017
can	O
be	O
remyelinated	B-T038
and	O
reassemble	O
new	O
AIS	B-T017
and	O
nodes	B-T082
of	I-T082
Ranvier	I-T082
.	O

We	O
show	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
regenerated	B-T038
CNS	B-T022
axons	B-T017
have	O
the	O
capacity	O
to	O
both	O
remyelinate	B-T038
and	O
reassemble	O
the	O
axon	B-T017
initial	I-T017
segments	I-T017
and	O
nodes	B-T082
of	I-T082
Ranvier	I-T082
necessary	O
for	O
rapid	O
and	O
efficient	O
action	B-T038
potential	I-T038
propagation	I-T038
.	O

Clinicopathological	B-T091
relevance	O
of	O
kinesin	B-T103
family	I-T103
member	I-T103
18A	I-T103
expression	B-T038
in	O
invasive	B-T038
breast	I-T038
cancer	I-T038

Recently	O
,	O
kinesin	B-T103
motor	B-T103
proteins	I-T103
have	O
been	O
focused	O
on	O
as	O
targets	O
for	O
cancer	B-T058
therapy	I-T058
.	O

Kinesins	B-T103
are	O
microtubule	B-T103
-	O
based	O
motor	B-T103
proteins	I-T103
that	O
mediate	O
diverse	O
functions	O
within	O
the	O
cell	B-T017
,	O
including	O
the	O
transport	B-T038
of	O
vesicles	B-T017
,	O
organelles	B-T017
,	O
chromosomes	B-T017
and	O
protein	B-T103
complexes	I-T103
,	O
as	O
well	O
as	O
the	O
movement	B-T038
of	I-T038
microtubules	I-T038
.	O

In	O
the	O
current	O
study	O
,	O
the	O
expression	B-T038
of	O
kinesin	B-T103
family	I-T103
member	I-T103
18A	I-T103
(	O
KIF18A	B-T103
)	O
,	O
a	O
member	B-T103
of	I-T103
kinesin	I-T103
superfamily	I-T103
,	O
was	O
investigated	O
in	O
breast	B-T038
cancer	I-T038
using	O
immunohistochemistry	B-T058
,	O
and	O
its	O
effect	O
on	O
breast	B-T038
cancer	I-T038
prognosis	O
was	O
examined	O
.	O

KIF18A	B-T103
expression	O
level	O
was	O
significantly	O
associated	O
with	O
lymph	B-T038
node	I-T038
metastasis	I-T038
(	O
P	O
=	O
0	O
.	O
047	O
)	O
.	O

In	O
patients	O
with	O
high	O
levels	O
of	O
KIF18A	B-T103
expression	B-T038
,	O
survival	O
was	O
significantly	O
poorer	O
compared	O
to	O
patients	O
with	O
low	O
levels	O
of	O
KIF18A	B-T103
expression	B-T038
(	O
disease	O
-	O
free	O
survival	O
,	O
P	O
=	O
0	O
.	O
030	O
)	O
.	O

Multivariate	O
analysis	O
revealed	O
that	O
venous	B-T033
invasion	I-T033
(	O
hazard	O
ratio	O
,	O
9	O
.	O
22	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
3	O
.	O
90	O
-	O
23	O
.	O
66	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
KIF18A	B-T103
expression	B-T038
(	O
hazard	O
ratio	O
,	O
3	O
.	O
20	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
34	O
-	O
6	O
.	O
09	O
;	O
P	O
=	O
0	O
.	O
010	O
)	O
were	O
independent	O
predictive	B-T170
factors	I-T170
for	O
lymph	B-T038
node	I-T038
metastasis	I-T038
.	O

KIF18A	B-T103
may	O
be	O
a	O
useful	O
predictive	B-T170
marker	B-T201
for	O
lymph	B-T038
node	I-T038
metastasis	I-T038
in	O
breast	B-T038
cancer	I-T038
,	O
which	O
could	O
facilitate	O
curative	O
adjuvant	O
treatment	B-T058
.	O

The	O
underlying	O
inflammatory	B-T038
chronic	I-T038
disease	I-T038
influences	O
infliximab	B-T103
pharmacokinetics	O

Infliximab	B-T103
is	O
an	O
anti	B-T103
-	I-T103
tumor	I-T103
necrosis	I-T103
factor	I-T103
monoclonal	B-T103
antibody	I-T103
approved	O
in	O
chronic	B-T038
inflammatory	I-T038
diseases	I-T038
such	O
as	O
rheumatoid	B-T038
arthritis	I-T038
(	O
RA	B-T038
)	O
,	O
psoriatic	B-T038
arthritis	I-T038
(	O
PsA	B-T038
)	O
,	O
ankylosing	B-T038
spondylitis	I-T038
(	O
AS	B-T038
)	O
,	O
Crohn	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
CD	B-T038
)	O
and	O
ulcerative	B-T038
colitis	I-T038
(	O
UC	B-T038
)	O
.	O

Infliximab	B-T103
pharmacokinetics	O
is	O
variable	O
between	O
patients	O
,	O
but	O
influence	O
of	O
the	O
underlying	B-T038
disease	I-T038
was	O
never	O
assessed	O
.	O

This	O
study	O
aimed	O
at	O
assessing	O
this	O
influence	O
using	O
a	O
cohort	B-T098
of	O
patients	B-T058
monitored	I-T058
in	O
a	O
single	O
center	O
and	O
with	O
the	O
same	O
assay	B-T058
.	O

Infliximab	B-T103
trough	O
concentrations	O
were	O
determined	O
on	O
samples	B-T058
collected	I-T058
between	O
weeks	O
0	O
and	O
22	O
after	O
treatment	O
initiation	O
in	O
218	O
patients	O
treated	O
for	O
RA	B-T038
,	O
PsA	B-T038
,	O
AS	B-T038
,	O
CD	B-T038
or	O
UC	B-T038
.	O

Infliximab	B-T103
pharmacokinetics	O
was	O
analyzed	B-T062
by	O
a	O
one	O
-	O
compartment	O
population	B-T098
model	O
with	O
first	O
-	O
order	O
elimination	B-T033
rate	O
constant	O
.	O

In	O
AS	B-T038
patients	O
,	O
volume	O
of	O
distribution	O
(	O
V	O
)	O
and	O
elimination	B-T033
clearance	O
(	O
CL	O
)	O
were	O
5	O
.	O
4	O
L	O
and	O
0	O
.	O
24	O
L	O
/	O
day	O
,	O
respectively	O
.	O

In	O
CD	B-T038
and	O
UC	B-T038
patients	O
,	O
V	O
was	O
49	O
%	O
and	O
52	O
%	O
higher	O
than	O
in	O
AS	B-T038
,	O
respectively	O
,	O
and	O
CL	O
was	O
47	O
%	O
and	O
60	O
%	O
higher	O
than	O
in	O
AS	B-T038
,	O
respectively	O
.	O

In	O
RA	B-T038
patients	O
,	O
CL	O
was	O
49	O
%	O
higher	O
than	O
in	O
AS	B-T038
patients	O
.	O

Simulations	B-T062
showed	O
that	O
without	O
methotrexate	B-T103
,	O
a	O
3	O
mg	O
/	O
kg	O
dosing	O
regimen	B-T058
would	O
lead	O
only	O
16	O
%	O
of	O
RA	B-T038
patients	O
to	O
reach	O
the	O
target	O
concentration	O
(	O
2	O
.	O
5	O
mg	O
/	O
L	O
)	O
at	O
week	O
22	O
,	O
whereas	O
target	O
concentrations	O
would	O
be	O
reached	O
in	O
approximately	O
half	O
of	O
RA	B-T038
patients	O
cotreated	O
with	O
methotrexate	B-T103
,	O
as	O
well	O
as	O
half	O
of	O
CD	B-T038
(	O
3	O
.	O
5	O
mg	O
/	O
L	O
)	O
and	O
UC	B-T038
(	O
3	O
.	O
7	O
mg	O
/	O
L	O
)	O
patients	O
.	O

The	O
suboptimality	O
of	O
approved	O
dosing	O
regimens	B-T058
supports	O
the	O
development	O
of	O
dosing	O
optimization	O
based	O
on	O
concentration	O
measurements	O
.	O

International	O
validation	B-T062
of	O
a	O
urinary	B-T031
biomarker	B-T201
panel	B-T058
for	O
identification	O
of	O
active	O
lupus	B-T038
nephritis	I-T038
in	O
children	O

Conventional	O
markers	B-T201
of	O
juvenile	B-T038
-	I-T038
onset	I-T038
systemic	I-T038
lupus	I-T038
erythematosus	I-T038
(	O
JSLE	B-T038
)	O
disease	O
activity	O
fail	O
to	O
adequately	O
identify	O
lupus	B-T038
nephritis	I-T038
(	O
LN	B-T038
)	O
.	O

While	O
individual	O
novel	O
urine	B-T031
biomarkers	B-T201
are	O
good	O
at	O
detecting	B-T058
LN	B-T038
flares	B-T033
,	O
biomarker	B-T201
panels	B-T058
may	O
improve	O
diagnostic	O
accuracy	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
assess	O
the	O
performance	O
of	O
a	O
biomarker	B-T201
panel	B-T058
to	O
identify	O
active	O
LN	B-T038
in	O
two	O
international	O
JSLE	B-T038
cohorts	B-T098
.	O

Novel	O
urinary	B-T031
biomarkers	B-T201
,	O
namely	O
vascular	B-T103
cell	I-T103
adhesion	I-T103
molecule	I-T103
-	I-T103
1	I-T103
(	O
VCAM	B-T103
-	I-T103
1	I-T103
)	O
,	O
monocyte	B-T103
chemoattractant	I-T103
protein	I-T103
1	I-T103
(	O
MCP	B-T103
-	I-T103
1	I-T103
)	O
,	O
lipocalin	B-T103
-	I-T103
like	I-T103
prostaglandin	I-T103
D	I-T103
synthase	I-T103
(	O
LPGDS	B-T103
)	O
,	O
transferrin	B-T103
(	O
TF	B-T103
)	O
,	O
ceruloplasmin	B-T103
,	O
alpha	B-T103
-	I-T103
1	I-T103
-	I-T103
acid	I-T103
glycoprotein	I-T103
(	O
AGP	B-T103
)	O
and	O
neutrophil	B-T103
gelatinase	I-T103
-	I-T103
associated	I-T103
lipocalin	I-T103
(	O
NGAL	B-T103
)	O
,	O
were	O
quantified	O
in	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
that	O
included	O
participants	B-T098
of	O
the	O
UK	B-T082
JSLE	B-T038
Cohort	O
Study	O
(	O
Cohort	B-T098
1	I-T098
)	O
and	O
validated	O
within	O
the	O
Einstein	B-T092
Lupus	I-T092
Cohort	B-T098
(	O
Cohort	B-T098
2	I-T098
)	O
.	O

Binary	O
logistic	B-T062
regression	I-T062
modelling	I-T062
and	O
receiver	O
operating	O
characteristic	O
curve	O
analysis	O
[	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
]	O
were	O
used	O
to	O
identify	O
and	O
assess	O
combinations	O
of	O
biomarkers	B-T201
for	O
diagnostic	O
accuracy	O
.	O

A	O
total	O
of	O
91	O
JSLE	B-T038
patients	O
were	O
recruited	O
across	O
both	O
cohorts	B-T098
,	O
of	O
whom	O
31	O
(	O
34	O
%	O
)	O
had	O
active	O
LN	B-T038
and	O
60	O
(	O
66	O
%	O
)	O
had	O
no	O
LN	B-T038
.	O

Urinary	B-T031
AGP	B-T103
,	O
ceruloplasmin	B-T103
,	O
VCAM	B-T103
-	I-T103
1	I-T103
,	O
MCP	B-T103
-	I-T103
1	I-T103
and	O
LPGDS	B-T103
levels	O
were	O
significantly	O
higher	O
in	O
those	O
patients	O
with	O
active	O
LN	B-T038
than	O
in	O
non	O
-	O
LN	B-T038
patients	O
[	O
all	O
corrected	O
p	O
values	O
(	O
p	O
c	O
)	O
<	O
0	O
.	O
05	O
]	O
across	O
both	O
cohorts	B-T098
.	O

Urinary	B-T031
TF	B-T103
also	O
differed	O
between	O
patient	O
groups	O
in	O
Cohort	B-T098
2	I-T098
(	O
p	O
c	O
=	O
0	O
.	O
001	O
)	O
.	O

Within	O
Cohort	B-T098
1	I-T098
,	O
the	O
optimal	O
biomarker	B-T201
panel	B-T058
included	O
AGP	B-T103
,	O
ceruloplasmin	B-T103
,	O
LPGDS	B-T103
and	O
TF	B-T103
(	O
AUC	O
0	O
.	O
920	O
for	O
active	O
LN	B-T038
identification	O
)	O
.	O

These	O
results	O
were	O
validated	O
in	O
Cohort	B-T098
2	I-T098
,	O
with	O
the	O
same	O
markers	B-T201
resulting	O
in	O
the	O
optimal	O
urine	B-T031
biomarker	B-T201
panel	B-T058
(	O
AUC	O
0	O
.	O
991	O
)	O
.	O

In	O
two	O
international	O
JSLE	B-T038
cohorts	B-T098
,	O
urinary	B-T031
AGP	B-T103
,	O
ceruloplasmin	B-T103
,	O
LPGDS	B-T103
and	O
TF	B-T103
demonstrate	O
an	O
'	O
excellent	O
'	O
ability	O
for	O
accurately	O
identifying	O
active	O
LN	B-T038
in	O
children	O
.	O

Fine	O
structure	O
of	O
interleukin	B-T103
18	I-T103
(	I-T103
IL	I-T103
-	I-T103
18	I-T103
)	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
in	O
the	O
retrosplenial	B-T017
cortex	I-T017
and	O
its	O
changes	O
in	O
IL18	B-T017
knockout	B-T204
mice	I-T204

Interleukin	B-T103
18	I-T103
(	O
IL	B-T103
-	I-T103
18	I-T103
)	O
participates	O
in	O
the	O
inflammatory	O
immune	B-T038
response	I-T038
of	O
lymphocytes	B-T017
.	O

Delay	O
in	O
learning	O
or	O
memory	O
are	O
common	O
in	O
the	O
IL	B-T017
-	I-T017
18	I-T017
knockout	B-T204
mouse	I-T204
.	O

Many	O
IL	B-T103
-	I-T103
18	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
are	O
found	O
in	O
the	O
retrosplenial	B-T017
cortex	I-T017
(	O
RSC	B-T017
)	O
and	O
the	O
subiculum	B-T017
.	O

These	O
neurons	B-T017
also	O
contain	O
the	O
IL	B-T103
-	I-T103
18	I-T103
receptor	I-T103
.	O

We	O
determined	O
the	O
location	O
and	O
the	O
ultrastructure	O
of	O
the	O
IL	B-T103
-	I-T103
18	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
in	O
the	O
RSC	B-T017
and	O
observed	O
changes	O
in	O
the	O
IL	B-T103
-	I-T103
18	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
of	O
the	O
IL	B-T017
-	I-T017
18	I-T017
knockout	B-T204
mouse	I-T204
.	O

The	O
IL	B-T103
-	I-T103
18	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
were	O
found	O
specifically	O
in	O
layer	O
V	O
of	O
the	O
granular	O
RSC	O
.	O

They	O
were	O
medium	O
-	O
sized	O
neurons	B-T017
with	O
a	O
light	O
oval	B-T017
nucleus	I-T017
and	O
had	O
little	O
cytoplasm	B-T017
with	O
many	O
free	B-T017
ribosomes	I-T017
,	O
rough	O
endoplasmic	B-T017
reticulum	I-T017
and	O
many	O
mitochondria	B-T017
,	O
but	O
no	O
Nissl	B-T017
bodies	I-T017
.	O

The	O
number	O
of	O
axosomatic	B-T082
terminals	I-T082
was	O
about	O
six	O
per	O
section	O
.	O

The	O
IL	B-T103
-	I-T103
18	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
were	O
not	O
found	O
in	O
the	O
RSC	B-T017
in	O
the	O
IL	B-T017
-	I-T017
18	I-T017
knockout	B-T204
mouse	I-T204
at	O
5	O
or	O
9	O
weeks	O
of	O
age	O
.	O

However	O
,	O
many	O
small	O
electron	O
-	O
dense	O
neurons	B-T017
were	O
found	O
in	O
layer	O
V	O
.	O

Both	O
the	O
nucleus	B-T017
and	O
cytoplasm	B-T017
were	O
electron	O
-	O
dense	O
,	O
but	O
not	O
necrotic	O
.	O

The	O
mitochondria	B-T017
and	O
rough	B-T017
endoplasmic	I-T017
reticulum	I-T017
were	O
swollen	B-T033
.	O

The	O
IL	B-T103
-	I-T103
18	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
were	O
presumed	O
to	O
be	O
degenerating	B-T033
.	O

The	O
degeneration	B-T038
of	O
the	O
IL18	B-T103
-	I-T103
receptor	I-T103
-	O
immunoreactive	B-T022
neurons	B-T017
in	O
the	O
RSC	B-T017
may	O
cause	O
the	O
abnormal	B-T038
behaviors	I-T038
of	O
the	O
IL	B-T017
-	I-T017
18	I-T017
knockout	B-T204
mice	I-T204
.	O

Exploring	O
the	O
genetic	O
variability	O
in	O
water	B-T103
use	O
efficiency	O
:	O
Evaluation	O
of	O
inter	O
and	O
intra	B-T204
cultivar	I-T204
genetic	O
diversity	O
in	O
grapevines	B-T204

Genetic	O
improvement	O
of	O
crop	B-T204
Water	B-T103
Use	O
Efficiency	O
(	O
WUE	O
)	O
is	O
a	O
general	O
goal	O
because	O
the	O
increasing	O
water	B-T103
scarcity	O
and	O
the	O
trend	O
to	O
a	O
more	O
sustainable	O
agriculture	O
.	O

For	O
grapevines	B-T204
,	O
this	O
subject	O
is	O
relevant	O
and	O
need	O
an	O
urgent	O
response	O
because	O
their	O
wide	O
distribution	O
in	O
semi	O
-	O
arid	O
areas	B-T082
.	O

New	O
cultivars	B-T204
are	O
difficult	O
to	O
introduce	O
in	O
viticulture	O
due	O
to	O
the	O
narrow	O
dependency	O
of	O
consumer	B-T098
appreciation	O
often	O
linked	O
to	O
a	O
certain	O
particular	O
wine	B-T168
taste	O
.	O

Clones	B-T017
of	O
reputed	O
cultivars	B-T204
would	O
presumably	O
be	O
more	O
accepted	O
but	O
little	O
is	O
known	O
on	O
the	O
intra	B-T204
-	I-T204
cultivar	I-T204
genetic	O
variability	O
of	O
the	O
WUE	O
.	O

The	O
present	O
work	O
compares	O
,	O
on	O
the	O
basis	O
of	O
two	O
field	O
assays	O
,	O
the	O
variability	O
of	O
intrinsic	O
water	B-T103
use	O
efficiency	O
(	O
WUEi	O
)	O
in	O
a	O
large	O
collection	O
of	O
cultivars	B-T204
in	O
contrast	O
with	O
a	O
collection	O
of	O
clones	B-T017
of	O
Tempranillo	B-T204
cultivar	I-T204
.	O

The	O
results	O
show	O
that	O
clonal	O
variability	O
of	O
WUEi	O
was	O
around	O
80	O
%	O
of	O
the	O
inter	B-T204
-	I-T204
cultivar	I-T204
,	O
thus	O
providing	O
a	O
first	O
assessment	O
on	O
the	O
opportunity	O
for	O
clonal	O
selection	O
by	O
WUE	O
.	O

Plotting	O
the	O
WUEi	O
data	O
against	O
stem	B-T204
water	B-T103
potential	O
or	O
stomatal	B-T038
conductance	I-T038
it	O
was	O
possible	B-T033
to	O
identify	O
cultivars	B-T204
and	O
clones	B-T017
out	O
of	O
the	O
confidence	O
intervals	O
of	O
this	O
linear	O
regression	O
thus	O
with	O
significantly	O
higher	O
and	O
lower	O
WUEi	O
values	O
.	O

The	O
present	O
results	O
contribute	O
to	O
open	O
the	O
expectative	O
for	O
a	O
genetic	O
improvement	O
of	O
grapevine	B-T204
WUE	O
.	O

Comparison	O
of	O
methods	O
for	O
isolating	B-T058
primary	O
hepatocytes	B-T017
from	O
mini	B-T204
pigs	I-T204

Successful	O
porcine	B-T204
hepatocyte	B-T017
isolation	B-T058
is	O
crucial	O
for	O
the	O
development	O
of	O
bioartificial	B-T074
liver	I-T074
devices	I-T074
and	O
hepatocyte	B-T058
transplantation	I-T058
.	O

Serva	B-T103
collagenase	I-T103
NB	I-T103
grades	I-T103
are	O
formulated	O
collagenases	B-T103
that	O
are	O
suitable	O
for	O
various	O
tissue	B-T017
isolation	B-T058
applications	O
.	O

N	B-T103
-	I-T103
acetylcysteine	I-T103
(	O
NAC	B-T103
)	O
can	O
improve	O
the	O
viability	O
of	O
human	B-T204
hepatocytes	B-T017
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
two	O
collagenases	B-T103
and	O
effect	O
of	O
NAC	B-T103
on	O
hepatocyte	B-T017
isolation	B-T058
from	O
porcine	B-T204
liver	B-T017
tissue	I-T017
.	O

Porcine	B-T204
hepatocytes	B-T017
were	O
isolated	B-T058
using	O
the	O
perfusion	B-T058
method	I-T058
from	O
Bama	O
mini	B-T204
pigs	I-T204
assigned	O
to	O
the	O
Serva	B-T103
NB	I-T103
4	I-T103
group	O
(	O
n	O
=	O
6	O
)	O
,	O
the	O
Serva	B-T103
NB	I-T103
8	I-T103
group	O
(	O
n	O
=	O
6	O
)	O
,	O
or	O
the	O
NB	B-T103
8	I-T103
+	O
NAC	B-T103
group	O
(	O
n	O
=	O
6	O
)	O
.	O

Viability	O
and	O
yield	O
were	O
defined	O
as	O
fresh	O
hepatocytes	B-T017
and	O
their	O
spheroids	B-T033
formation	I-T033
after	O
24	O
-	O
hour	O
rocker	B-T058
culture	I-T058
in	O
serum	B-T103
-	I-T103
free	I-T103
medium	I-T103
.	O

Metabolic	B-T038
function	I-T038
was	O
assessed	O
by	O
gene	B-T038
expression	I-T038
,	O
albumin	B-T103
,	O
and	O
urea	B-T103
synthesis	B-T038
.	O

All	O
procedures	O
resulted	O
in	O
successful	O
hepatocyte	B-T017
isolation	B-T058
.	O

Cells	B-T017
from	O
the	O
NB	B-T103
8	I-T103
+	O
NAC	B-T103
group	O
had	O
(	O
97	O
.	O
8±1	O
.	O
9	O
)	O
%	O
viability	O
,	O
which	O
was	O
higher	O
than	O
the	O
NB	B-T103
8	I-T103
group	O
with	O
(	O
94	O
.	O
4±2	O
.	O
4	O
)	O
%	O
and	O
the	O
NB	B-T103
4	I-T103
group	O
with	O
(	O
94	O
.	O
5±3	O
.	O
2	O
)	O
%	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
final	O
cell	B-T017
yield	O
reached	O
(	O
11	O
.	O
8±1	O
.	O
0	O
)	O
×10	O
(	O
9	O
)	O
cells	B-T017
in	O
the	O
NB	B-T103
8	I-T103
+	O
NAC	B-T103
group	O
,	O
compared	O
to	O
(	O
9	O
.	O
5±2	O
.	O
1	O
)	O
×10	O
(	O
9	O
)	O
cells	B-T017
in	O
the	O
NB	B-T103
8	I-T103
group	O
(	O
P	O
<	O
.	O
01	O
)	O
and	O
(	O
9	O
.	O
1±1	O
.	O
1	O
)	O
×10	O
(	O
9	O
)	O
cells	B-T017
in	O
the	O
NB	B-T103
4	I-T103
group	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
secretion	B-T038
of	O
albumin	B-T103
was	O
superior	O
in	O
the	O
NB	B-T103
8	I-T103
+	O
NAC	B-T103
group	O
at	O
a	O
concentration	O
of	O
(	O
425	O
.	O
8±35	O
.	O
3	O
)	O
ng	O
/	O
mL	O
compared	O
to	O
the	O
NB	B-T103
8	I-T103
group	O
(	O
339	O
.	O
1±32	O
.	O
6	O
)	O
ng	O
/	O
mL	O
(	O
P	O
<	O
.	O
001	O
)	O
and	O
NB	B-T103
4	I-T103
group	O
(	O
293	O
.	O
6±43	O
.	O
3	O
)	O
ng	O
/	O
mL	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

The	O
injury	B-T037
of	O
hepatocytes	B-T017
also	O
decreased	O
in	O
the	O
NB	B-T103
8	I-T103
+	O
NAC	B-T103
group	O
(	O
P	O
<	O
.	O
01	O
)	O
.	O

The	O
data	O
are	O
presented	O
as	O
means	O
±	O
SD	O
.	O

Formulated	O
collagenase	B-T103
Serva	I-T103
NB	I-T103
8	I-T103
and	O
NAC	B-T103
could	O
improve	O
the	O
porcine	B-T204
hepatocyte	B-T017
isolation	B-T058
,	O
resulting	O
in	O
higher	O
yields	O
of	O
viable	O
cells	O
.	O

Endothermal	B-T058
venous	I-T058
ablation	I-T058
of	O
the	O
saphenous	B-T017
vein	I-T017
on	O
patients	O
who	O
are	O
on	O
anticoagulation	B-T058
therapy	I-T058

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
risks	O
of	O
bleeding	B-T038
,	O
deep	B-T038
venous	I-T038
thrombosis	I-T038
(	O
DVT	B-T038
)	O
,	O
endovenous	B-T038
heat	I-T038
induced	I-T038
thrombosis	I-T038
(	O
EHIT	B-T038
)	O
and	O
failure	O
of	O
ablation	B-T058
on	O
patients	O
who	O
undergo	O
ablation	B-T058
while	O
on	O
oral	B-T058
anticoagulation	I-T058
.	O

We	O
compared	O
378	O
(	O
3	O
.	O
4	O
%	O
)	O
out	O
of	O
11252	O
patients	O
(	O
group	B-T170
A	I-T170
)	O
who	O
had	O
undergone	O
724	O
endovenous	B-T058
ablation	I-T058
of	O
the	O
saphenous	B-T017
veins	I-T017
from	O
January	O
1	O
,	O
2011	O
to	O
September	O
30	O
,	O
2014	O
while	O
on	O
oral	B-T058
anticoagulation	I-T058
to	O
a	O
randomly	O
selected	O
375	O
patients	O
(	O
group	B-T170
B	I-T170
)	O
who	O
underwent	O
641	O
endovenous	B-T058
ablation	I-T058
in	O
the	O
same	O
time	O
period	O
but	O
were	O
not	O
on	O
anticoagulation	B-T058
.	O

The	O
demographic	O
data	O
,	O
history	B-T033
of	I-T033
DVT	B-T038
,	O
the	O
Clinical	O
,	O
Etiologic	O
,	O
Anatomic	O
,	O
Pathologic	O
(	O
CEAP	O
)	O
classification	B-T170
and	O
the	O
VCSS	O
(	O
Venous	O
Clinical	O
Severity	O
Score	O
)	O
scores	O
were	O
analyzed	O
.	O

The	O
indications	O
for	O
anticoagulation	B-T058
,	O
the	O
anticoagulants	B-T103
used	O
were	O
recorded	O
.	O

The	O
primary	O
endpoints	O
were	O
bleeding	B-T038
,	O
development	O
of	O
DVT	B-T038
or	O
EHIT	B-T038
,	O
and	O
failure	O
of	O
ablation	B-T058
.	O

Patients	O
in	O
group	B-T170
A	I-T170
were	O
older	O
,	O
had	O
more	O
men	B-T098
,	O
more	O
history	O
of	O
DVT	B-T038
and	O
PE	B-T038
,	O
had	O
higher	O
CEAP	O
and	O
VCSS	O
scores	O
compared	O
to	O
group	B-T170
B	I-T170
.	O

The	O
type	O
of	O
anticoagulation	B-T058
used	O
was	O
warfarin	B-T103
in	O
77	O
.	O
2	O
%	O
direct	B-T103
oral	I-T103
inhibitors	I-T103
(	O
DOIs	B-T103
)	O
in	O
22	O
.	O
8	O
%	O
.	O

The	O
rate	O
of	O
failure	O
of	O
ablation	B-T058
at	O
3	O
days	O
was	O
39	O
(	O
5	O
.	O
6	O
%	O
)	O
for	O
Group	B-T170
A	I-T170
and	O
3	O
(	O
0	O
.	O
5	O
%	O
)	O
for	O
Group	B-T170
B	I-T170
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
at	O
one	O
month	O
it	O
was	O
46	O
(	O
10	O
.	O
1	O
%	O
)	O
vs	O
.	O

27	O
(	O
6	O
.	O
7	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
086	O
)	O
.	O

The	O
number	O
of	O
EHIT	B-T038
cases	O
in	O
group	B-T170
A	I-T170
at	O
3	O
days	O
was	O
2	O
(	O
0	O
.	O
3	O
%	O
)	O
,	O
compared	O
to	O
6	O
(	O
0	O
.	O
9	O
%	O
)	O
in	O
group	B-T170
B	I-T170
(	O
P	O
=	O
0	O
.	O
016	O
)	O
and	O
at	O
1	O
month	O
it	O
was	O
0	O
compared	O
to	O
4	O
(	O
1	O
.	O
0	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
0483	O
)	O
.	O

The	O
DVT	B-T038
,	O
SVT	B-T038
,	O
hematoma	B-T038
and	O
wound	B-T038
infection	I-T038
rates	O
were	O
similar	O
in	O
the	O
two	O
groups	O
.	O

Ablation	B-T058
of	O
the	O
saphenous	B-T017
veins	I-T017
in	O
patients	O
who	O
are	O
on	O
oral	B-T058
anticoagulation	I-T058
is	O
safe	O
and	O
does	O
not	O
increase	O
the	O
risk	O
of	O
bleeding	B-T038
or	O
hematoma	B-T038
,	O
but	O
it	O
may	O
slightly	O
lower	O
the	O
incidence	O
of	O
EHIT	B-T038
and	O
increase	O
the	O
incidence	O
of	O
failure	O
of	O
ablation	B-T058
.	O

Variation	B-T062
analysis	I-T062
of	O
PRIM1	B-T017
gene	I-T017
in	O
Chinese	B-T098
patients	O
with	O
primary	B-T038
ovarian	I-T038
insufficiency	I-T038

Insights	O
into	O
common	O
genetic	O
susceptibility	O
between	O
primary	B-T038
ovarian	I-T038
insufficiency	I-T038
(	O
POI	B-T038
)	O
and	O
natural	B-T038
or	O
early	B-T038
menopause	I-T038
have	O
delivered	O
an	O
innovative	O
way	O
of	O
assessing	O
the	O
genetic	O
mechanisms	O
involved	O
in	O
POI	B-T038
.	O

PRIM1	B-T017
plays	O
a	O
crucial	O
role	O
in	O
DNA	B-T038
replication	I-T038
by	O
synthesizing	O
RNA	B-T103
primers	I-T103
for	O
Okazaki	B-T103
fragments	I-T103
.	O

It	O
is	O
closely	O
associated	O
with	O
age	O
at	O
natural	B-T038
menopause	I-T038
,	O
early	B-T038
menopause	I-T038
and	O
POI	B-T038
in	O
European	B-T098
women	B-T098
.	O

In	O
this	O
study	B-T062
,	O
we	O
aimed	O
to	O
investigate	O
whether	O
mutations	B-T038
in	O
PRIM1	B-T017
contribute	O
to	O
POI	B-T038
in	O
Chinese	B-T098
women	B-T098
.	O

All	O
exons	B-T103
and	O
exon	B-T103
-	I-T103
intron	I-T103
boundaries	I-T103
of	O
PRIM1	B-T017
gene	I-T017
were	O
sequenced	B-T058
in	O
192	O
Han	O
Chinese	O
women	B-T098
with	O
non	O
-	O
syndromic	O
POI	B-T038
.	O

No	O
plausible	O
mutations	B-T038
were	O
identified	O
.	O

The	O
results	O
suggest	O
that	O
the	O
perturbations	O
in	O
PRIM1	B-T017
gene	I-T017
are	O
not	O
a	O
common	O
explanation	O
for	O
POI	B-T038
in	O
Chinese	B-T098
women	B-T098
.	O

Selection	O
of	O
a	O
marker	B-T017
gene	I-T017
to	O
construct	O
a	O
reference	B-T092
library	I-T092
for	O
wetland	O
plants	B-T204
,	O
and	O
the	O
application	O
of	O
metabarcoding	B-T062
to	O
analyze	B-T062
the	O
diet	B-T168
of	O
wintering	O
herbivorous	B-T204
waterbirds	B-T204

Food	B-T168
availability	O
and	O
diet	B-T168
selection	O
are	O
important	O
factors	O
influencing	O
the	O
abundance	O
and	O
distribution	O
of	O
wild	B-T170
waterbirds	B-T204
.	O

In	O
order	O
to	O
better	O
understand	O
changes	O
in	O
waterbird	B-T204
population	O
,	O
it	O
is	O
essential	O
to	O
figure	O
out	O
what	O
they	O
feed	O
on	O
.	O

However	O
,	O
analyzing	B-T062
their	O
diet	B-T168
could	O
be	O
difficult	O
and	O
inefficient	O
using	O
traditional	O
methods	O
such	O
as	O
microhistologic	B-T058
observation	I-T058
.	O

Here	O
,	O
we	O
addressed	O
this	O
gap	O
of	O
knowledge	O
by	O
investigating	O
the	O
diet	B-T168
of	O
greater	B-T204
white	I-T204
-	I-T204
fronted	I-T204
goose	I-T204
Anser	I-T204
albifrons	I-T204
and	O
bean	B-T204
goose	I-T204
Anser	I-T204
fabalis	I-T204
,	O
which	O
are	O
obligate	B-T204
herbivores	I-T204
wintering	O
in	O
China	B-T082
,	O
mostly	O
in	O
the	O
Middle	B-T082
and	O
Lower	B-T082
Yangtze	I-T082
River	I-T082
floodplain	I-T082
.	O

First	O
,	O
we	O
selected	O
a	O
suitable	O
and	O
high	O
-	O
resolution	O
marker	B-T017
gene	I-T017
for	O
wetland	O
plants	B-T204
that	O
these	O
geese	B-T204
would	O
consume	O
during	O
the	O
wintering	O
period	O
.	O

Eight	O
candidate	B-T017
genes	I-T017
were	O
included	O
:	O
rbcL	B-T017
,	O
rpoC1	B-T017
,	O
rpoB	B-T017
,	O
matK	B-T017
,	O
trnH	B-T082
-	I-T082
psbA	I-T082
,	O
trnL	B-T017
(	O
UAA	B-T082
)	O
,	O
atpF	B-T082
-	I-T082
atpH	I-T082
,	O
and	O
psbK	B-T082
-	I-T082
psbI	I-T082
.	O

The	O
selection	O
was	O
performed	O
via	O
analysis	B-T062
of	O
representative	O
sequences	B-T082
from	O
NCBI	B-T092
and	O
comparison	O
of	O
amplification	B-T038
efficiency	O
and	O
resolution	O
power	O
of	O
plant	B-T204
samples	O
collected	O
from	O
the	O
wintering	B-T082
area	I-T082
.	O

The	O
trnL	B-T017
gene	I-T017
was	O
chosen	O
at	O
last	O
with	O
c	B-T103
/	I-T103
h	I-T103
primers	I-T103
,	O
and	O
a	O
local	B-T082
plant	B-T204
reference	B-T092
library	I-T092
was	O
constructed	B-T170
with	O
this	O
gene	B-T017
.	O

Then	O
,	O
utilizing	O
DNA	B-T062
metabarcoding	I-T062
,	O
we	O
discovered	O
15	O
food	B-T168
items	I-T168
in	O
total	O
from	O
the	O
feces	B-T031
of	O
these	O
birds	B-T204
.	O

Of	O
the	O
15	O
unique	O
dietary	B-T168
sequences	B-T082
,	O
10	O
could	O
be	O
identified	O
at	O
specie	B-T170
level	O
.	O

As	O
for	O
greater	B-T204
white	I-T204
-	I-T204
fronted	I-T204
goose	I-T204
,	O
73	O
%	O
of	O
sequences	B-T082
belonged	O
to	O
Poaceae	B-T204
spp	I-T204
.	I-T204
,	O
and	O
26	O
%	O
belonged	O
to	O
Carex	B-T204
spp	I-T204
.	O

In	O
contrast	O
,	O
almost	O
all	O
sequences	B-T082
of	O
bean	B-T204
goose	I-T204
belonged	O
to	O
Carex	B-T204
spp	I-T204
.	O

(	O
99	O
%	O
)	O
.	O

Using	O
the	O
same	O
samples	O
,	O
microhistology	B-T058
provided	O
consistent	O
food	B-T168
composition	I-T168
with	O
metabarcoding	B-T062
results	O
for	O
greater	B-T204
white	I-T204
-	I-T204
fronted	I-T204
goose	I-T204
,	O
while	O
13	O
%	O
of	O
Poaceae	B-T204
was	O
recovered	O
for	O
bean	B-T204
goose	I-T204
.	O

In	O
addition	O
,	O
two	O
other	O
taxa	O
were	O
discovered	O
only	O
through	O
microhistologic	B-T058
analysis	I-T058
.	O

Although	O
most	O
of	O
the	O
identified	O
taxa	O
matched	O
relatively	O
well	O
between	O
the	O
two	O
methods	O
,	O
DNA	B-T062
metabarcoding	I-T062
gave	O
taxonomically	O
more	O
detailed	O
information	O
.	O

Discrepancies	B-T033
were	O
likely	O
due	O
to	O
biased	O
PCR	B-T062
amplification	B-T038
in	O
metabarcoding	B-T062
,	O
low	O
discriminating	O
power	O
of	O
current	O
marker	B-T017
genes	I-T017
for	O
monocots	B-T204
,	O
and	O
biases	O
in	O
microhistologic	B-T058
analysis	I-T058
.	O

The	O
diet	B-T168
differences	O
between	O
two	O
geese	B-T204
species	B-T170
might	O
indicate	O
deeper	O
ecological	O
significance	O
beyond	O
the	O
scope	O
of	O
this	O
study	B-T062
.	O

We	O
concluded	O
that	O
DNA	B-T062
metabarcoding	I-T062
provides	O
new	O
perspectives	O
for	O
studies	B-T062
of	O
herbivorous	B-T204
waterbird	B-T204
diets	B-T168
and	O
inter	O
-	O
specific	O
interactions	O
,	O
as	O
well	O
as	O
new	O
possibilities	O
to	O
investigate	O
interactions	O
between	O
herbivores	B-T204
and	O
plants	B-T204
.	O

In	O
addition	O
,	O
microhistologic	B-T058
analysis	I-T058
should	O
be	O
used	O
together	O
with	O
metabarcoding	B-T062
methods	I-T062
to	O
integrate	O
this	O
information	O
.	O

Expressions	B-T038
of	O
CD8	B-T103
+	O
TILs	B-T017
,	O
PD	B-T103
-	I-T103
L1	I-T103
and	O
Foxp3	B-T103
+	O
TILs	B-T017
in	O
stage	B-T038
I	I-T038
NSCLC	I-T038
guiding	O
adjuvant	B-T058
chemotherapy	I-T058
decisions	B-T038

Currently	O
,	O
adjuvant	B-T058
chemotherapy	I-T058
is	O
recommended	O
for	O
patients	O
with	O
high	B-T033
risk	I-T033
stage	B-T038
I	I-T038
non	I-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
(	O
NSCLC	B-T038
)	O
.	O

However	O
,	O
identifying	O
high	B-T033
risk	I-T033
patients	O
remains	O
a	O
challenge	O
.	O

This	O
study	B-T062
aims	O
to	O
identify	O
the	O
patient	O
cohorts	B-T098
more	O
likely	O
to	O
benefit	O
from	O
adjuvant	B-T058
chemotherapy	I-T058
based	O
on	O
the	O
tumor	B-T038
micro	O
-	O
immune	O
environment	B-T082
.	O

CD8	B-T103
+	O
TILs	B-T017
significantly	O
associated	O
with	O
disease	O
-	O
free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survial	O
(	O
OS	O
)	O
(	O
p	O
=	O
0	O
.	O
002	O
;	O
0	O
.	O
040	O
)	O
.	O

Patients	O
with	O
high	O
risk	O
factors	O
may	O
also	O
predict	O
shorter	O
DFS	O
(	O
P	O
=	O
0	O
.	O
056	O
)	O
.	O

When	O
compared	O
together	O
,	O
patients	O
with	O
high	O
-	O
CD8	B-T103
+	O
TILs	B-T017
showed	O
better	O
DFS	O
than	O
patients	O
with	O
low	O
-	O
CD8	B-T103
+	O
TILs	B-T017
,	O
no	O
matter	O
their	O
risk	O
factors	O
status	O
.	O

There	O
'	O
s	O
no	B-T033
correlation	I-T033
between	O
PD	B-T103
-	I-T103
L1	I-T103
expressions	B-T038
and	O
survival	O
.	O

PD	B-T103
-	I-T103
L1	I-T103
was	O
highly	O
expressed	B-T038
in	O
men	B-T098
,	O
squamous	O
and	O
well	O
differentiated	O
carcinoma	B-T038
.	O

In	O
addition	O
,	O
Foxp3	B-T103
+	O
TILs	B-T017
alone	O
didn	O
'	O
t	O
show	O
any	O
prognostic	O
effects	O
,	O
but	O
low	O
-	O
Foxp3	B-T103
/	O
high	O
-	O
CD8	B-T103
+	O
TILs	B-T017
were	O
associated	O
with	O
prolonged	O
DFS	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
.	O

A	O
total	O
of	O
126	O
patients	O
with	O
surgically	O
resected	O
stage	B-T038
I	I-T038
NSCLC	I-T038
were	O
included	O
to	O
perform	O
immunohistochemistry	B-T058
of	O
CD8	B-T103
+	O
tumor	B-T017
infiltrating	I-T017
lymphocytes	I-T017
(	O
TILs	B-T017
)	O
,	O
programmed	B-T103
death	I-T103
ligand	I-T103
-	I-T103
1	I-T103
(	O
PD	B-T103
-	I-T103
L1	I-T103
)	O
and	O
forkhead	B-T103
box	I-T103
P3	I-T103
(	O
Foxp3	B-T103
)	O
+	O
TILs	B-T017
.	O

CD8	B-T103
+	O
TILs	B-T017
are	O
effective	O
prognostic	O
predictors	O
.	O

Patients	O
with	O
surgically	O
resected	O
stage	B-T038
I	I-T038
NSCLC	I-T038
showing	O
low	O
CD8	B-T103
+	O
TILs	B-T017
could	O
be	O
considered	O
for	O
adjuvant	B-T058
chemotherapy	I-T058
,	O
even	O
if	O
they	O
have	O
no	O
high	B-T033
risk	I-T033
features	O
.	O

Unaffected	O
twins	B-T038
discordant	I-T038
for	O
affective	B-T038
disorders	I-T038
show	O
changes	O
in	O
anterior	B-T017
callosal	I-T017
white	B-T017
matter	I-T017
microstructure	B-T082

The	O
neurobiological	B-T091
mechanisms	O
mediating	O
an	O
increased	O
risk	O
to	O
develop	O
affective	B-T038
disorders	I-T038
remain	O
poorly	O
understood	O
.	O

In	O
a	O
group	B-T098
of	I-T098
individuals	I-T098
with	O
a	O
family	B-T033
history	I-T033
of	O
major	B-T038
depressive	I-T038
(	O
MDD	B-T038
)	O
or	O
bipolar	B-T038
disorder	I-T038
(	O
BD	B-T038
)	O
,	O
we	O
investigated	O
the	O
microstructural	O
properties	O
of	O
white	B-T017
matter	I-T017
fiber	O
tracts	O
,	O
that	O
is	O
,	O
cingulum	B-T017
bundle	I-T017
,	O
uncinate	B-T017
fasciculus	I-T017
,	O
anterior	B-T017
limb	I-T017
of	I-T017
the	I-T017
internal	I-T017
capsule	I-T017
,	O
and	O
corpus	B-T017
callosum	I-T017
,	O
that	O
facilitate	O
the	O
communication	O
between	O
brain	B-T082
regions	I-T082
implicated	O
in	O
affective	B-T038
disorders	I-T038
.	O

Eighty	O
-	O
nine	O
healthy	O
mono	O
-	O
or	O
dizygotic	O
twins	O
with	O
a	O
co	O
-	O
twin	O
diagnosed	B-T033
with	O
MDD	B-T038
or	O
BD	B-T038
(	O
high	B-T098
-	I-T098
risk	I-T098
)	O
and	O
57	O
healthy	O
twins	O
with	O
a	O
co	O
-	O
twin	O
with	O
no	B-T033
familial	I-T033
history	I-T033
of	I-T033
affective	B-T038
disorders	I-T038
(	O
low	O
-	O
risk	O
)	O
were	O
included	O
in	O
a	O
diffusion	B-T058
tensor	I-T058
imaging	I-T058
study	I-T058
.	O

The	O
high	B-T098
-	I-T098
risk	I-T098
group	I-T098
showed	O
decreased	O
fractional	B-T058
anisotropy	I-T058
(	O
FA	B-T058
)	O
,	O
a	O
measure	O
of	O
water	B-T103
diffusion	O
directionality	O
,	O
and	O
increased	O
radial	O
diffusivity	O
in	O
the	O
anterior	B-T017
region	I-T017
of	I-T017
corpus	I-T017
callosum	I-T017
compared	O
to	O
the	O
low	B-T098
-	I-T098
risk	I-T098
group	I-T098
.	O

This	O
abnormality	B-T033
was	O
not	O
associated	O
with	O
zygosity	O
or	O
type	O
of	O
depressive	B-T038
disorder	I-T038
of	O
co	O
-	O
twin	O
.	O

The	O
observed	O
decreased	O
anterior	B-T017
callosal	I-T017
fiber	I-T017
FA	B-T058
in	O
the	O
high	B-T098
-	I-T098
risk	I-T098
group	I-T098
may	O
be	O
indicative	O
of	O
a	O
compromised	O
interhemispheric	O
communication	O
between	O
left	B-T017
and	O
right	B-T017
frontal	I-T017
regions	I-T017
critically	O
involved	O
in	O
mood	O
regulation	O
.	O

Reduced	O
anterior	B-T017
callosal	I-T017
FA	B-T058
may	O
act	O
as	O
a	O
vulnerability	O
marker	B-T201
for	O
affective	B-T038
disorders	I-T038
in	O
individuals	B-T098
at	O
familial	O
risk	O
.	O

A	O
Window	O
on	O
the	O
Study	B-T058
of	I-T058
Aversive	I-T058
Instrumental	B-T038
Learning	I-T038
:	O
Strains	O
,	O
Performance	O
,	O
Neuroendocrine	B-T022
,	O
and	O
Immunologic	B-T022
Systems	I-T022

The	O
avoidance	B-T038
response	O
is	O
present	O
in	O
pathological	O
anxiety	B-T033
and	O
interferes	O
with	O
normal	O
daily	O
functions	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
shed	O
light	O
on	O
performance	O
markers	O
of	O
active	O
avoidance	O
(	O
AA	O
)	O
using	O
two	O
different	O
rat	B-T204
strains	I-T204
,	O
Sprague	B-T204
-	I-T204
Dawley	I-T204
(	O
SD	B-T204
)	O
and	O
Wistar	B-T204
.	O

Specifically	O
,	O
good	O
and	O
poor	O
performers	O
were	O
evaluated	B-T058
regarding	O
anxiety	B-T033
traits	O
exhibited	O
in	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
corticosterone	B-T058
levels	I-T058
and	O
motor	B-T038
activity	I-T038
in	O
the	O
open	B-T058
field	I-T058
test	I-T058
.	O

In	O
addition	O
,	O
the	O
plasma	B-T058
levels	I-T058
of	O
Interleukin	B-T103
-	I-T103
6	I-T103
(	O
IL	B-T103
-	I-T103
6	I-T103
)	O
,	O
Interleukin	B-T103
-	I-T103
1Beta	I-T103
(	O
IL	B-T103
-	I-T103
1beta	I-T103
)	O
,	O
Nerve	B-T103
Growth	I-T103
Factor	I-T103
Beta	I-T103
(	O
NGF	B-T103
-	I-T103
beta	I-T103
)	O
,	O
Tumor	B-T103
Necrosis	I-T103
Factor	I-T103
-	I-T103
Alpha	I-T103
(	O
TNF	B-T103
-	I-T103
alpha	I-T103
)	O
and	O
cytokine	B-T103
-	I-T103
induced	I-T103
neutrophil	I-T103
chemoattractant	I-T103
1	I-T103
(	O
CINC	B-T103
-	I-T103
1	I-T103
)	O
were	O
compared	O
in	O
the	O
good	O
and	O
poor	O
performers	O
to	O
better	O
understand	O
the	O
role	O
of	O
the	O
immunologic	B-T022
system	I-T022
in	O
aversive	B-T058
learning	I-T058
.	O

Behavioral	B-T170
criteria	I-T170
were	O
employed	O
to	O
identify	O
subpopulations	B-T098
of	O
SD	B-T204
and	O
Wistar	B-T204
rats	I-T204
based	O
on	O
their	O
behavioral	B-T170
scores	I-T170
during	O
a	O
two	O
-	O
way	O
AA	O
test	B-T170
.	O

The	O
animals	B-T204
were	O
tested	B-T170
for	O
anxiety	B-T033
-	O
like	O
behavior	O
in	O
the	O
EPM	O
and	O
motor	B-T038
activity	I-T038
in	O
the	O
open	B-T058
-	I-T058
field	I-T058
test	I-T058
.	O

Plasma	B-T058
corticosterone	I-T058
levels	I-T058
were	O
measured	O
at	O
the	O
end	O
of	O
the	O
avoidance	B-T038
test	B-T170
.	O

Cytokine	B-T058
levels	I-T058
of	O
IL	B-T103
-	I-T103
6	I-T103
,	O
IL	B-T103
-	I-T103
1beta	I-T103
,	O
NGF	B-T103
-	I-T103
beta	I-T103
,	O
TNF	B-T103
-	I-T103
alpha	I-T103
,	O
and	O
CINC	B-T103
-	I-T103
1	I-T103
were	O
measured	O
in	O
the	O
plasma	B-T031
of	O
the	O
Wistar	B-T204
rats	I-T204
.	O

Sixty	O
-	O
six	O
percent	O
of	O
the	O
Wistar	B-T204
rats	I-T204
and	O
35	O
%	O
of	O
the	O
SD	B-T204
rats	I-T204
exhibited	O
a	O
poor	O
performance	O
.	O

This	O
feature	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
anxiety	B-T033
-	O
like	O
behavior	O
in	O
the	O
EPM	O
.	O

The	O
poor	O
and	O
good	O
performers	O
exhibited	O
lower	O
levels	B-T058
of	I-T058
corticosterone	I-T058
compared	O
with	O
the	O
control	B-T204
animals	I-T204
,	O
which	O
suggests	O
that	O
training	O
alters	O
corticosterone	B-T058
levels	I-T058
,	O
thereby	O
leading	O
to	O
hypocortisolism	B-T038
,	O
independent	O
of	O
the	O
performance	O
.	O

The	O
CINC	B-T103
-	I-T103
1	I-T103
levels	O
were	O
increased	O
in	O
the	O
poor	O
performers	O
,	O
which	O
reinforces	O
the	O
role	O
of	O
immunologic	B-T022
system	I-T022
activation	O
in	O
learning	B-T038
deficits	I-T038
.	O

Our	O
study	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
complex	O
interactions	O
that	O
underlie	O
neuroimmune	O
consequences	O
and	O
their	O
implications	O
for	O
performance	O
.	O

Costing	O
'	O
healthy	B-T168
'	I-T168
food	I-T168
baskets	I-T168
in	O
Australia	B-T082
-	O
a	O
systematic	B-T170
review	I-T170
of	O
food	B-T168
price	O
and	O
affordability	O
monitoring	B-T170
tools	I-T170
,	O
protocols	B-T170
and	O
methods	B-T170

To	O
undertake	O
a	O
systematic	B-T170
review	I-T170
to	O
determine	O
similarities	O
and	O
differences	O
in	O
metrics	O
and	O
results	O
between	O
recently	O
and	O
/	O
or	O
currently	O
used	O
tools	B-T170
,	O
protocols	B-T170
and	O
methods	B-T170
for	O
monitoring	B-T058
Australian	B-T082
healthy	B-T168
food	I-T168
prices	O
and	O
affordability	O
.	O

Electronic	B-T170
databases	I-T170
of	O
peer	B-T170
-	I-T170
reviewed	I-T170
literature	I-T170
and	O
online	B-T170
grey	I-T170
literature	I-T170
were	O
systematically	O
searched	O
using	O
the	O
PRISMA	B-T062
approach	O
for	O
articles	B-T170
and	O
reports	B-T170
relating	O
to	O
healthy	B-T168
food	I-T168
and	O
diet	B-T170
price	I-T170
assessment	I-T170
tools	I-T170
,	O
protocols	B-T170
,	O
methods	B-T170
and	O
results	O
that	O
utilised	O
retail	O
pricing	O
.	O

National	O
,	O
state	B-T082
,	O
regional	B-T082
and	O
local	B-T082
areas	I-T082
of	O
Australia	B-T082
from	O
1995	O
to	O
2015	O
.	O

Assessment	B-T170
tools	I-T170
,	O
protocols	B-T170
and	O
methods	B-T170
to	O
measure	O
the	O
price	O
of	O
'	B-T168
healthy	I-T168
'	I-T168
foods	I-T168
and	O
diets	B-T168
.	O

The	O
search	O
identified	O
fifty	O
-	O
nine	O
discrete	O
surveys	B-T170
of	O
'	O
healthy	B-T168
'	I-T168
food	I-T168
pricing	O
incorporating	O
six	O
major	O
food	B-T170
pricing	I-T170
tools	I-T170
(	O
those	O
used	O
in	O
multiple	O
areas	O
and	O
time	O
periods	O
)	O
and	O
five	O
minor	O
food	B-T170
pricing	I-T170
tools	I-T170
(	O
those	O
used	O
in	O
a	O
single	B-T082
survey	I-T082
area	I-T082
or	O
time	O
period	O
)	O
.	O

Analysis	B-T062
demonstrated	O
methodological	O
differences	O
regarding	O
:	O
included	O
foods	B-T168
;	O
reference	O
households	O
;	O
use	O
of	O
availability	O
and	O
/	O
or	O
quality	O
measures	O
;	O
household	B-T033
income	I-T033
sources	B-T033
;	O
store	O
sampling	B-T170
methods	I-T170
;	O
data	B-T062
collection	I-T062
protocols	B-T170
;	O
analysis	B-T062
methods	I-T062
;	O
and	O
results	O
.	O

'	O
Healthy	B-T168
'	I-T168
food	I-T168
price	O
assessment	O
methods	B-T170
used	O
in	O
Australia	B-T082
lack	O
comparability	O
across	O
all	O
metrics	O
and	O
most	O
do	O
not	O
fully	O
align	O
with	O
a	O
'	O
healthy	B-T168
'	I-T168
diet	I-T168
as	O
recommended	O
by	O
the	O
current	O
Australian	B-T170
Dietary	I-T170
Guidelines	I-T170
.	O

None	O
have	O
been	O
applied	O
nationally	O
.	O

Assessment	O
of	O
the	O
price	O
,	O
price	O
differential	O
and	O
affordability	O
of	O
healthy	B-T058
(	O
recommended	O
)	O
and	O
current	O
(	O
unhealthy	O
)	O
diets	O
would	O
provide	O
more	O
robust	O
and	O
meaningful	O
data	O
to	O
inform	O
health	O
and	O
fiscal	O
policy	O
in	O
Australia	B-T082
.	O

The	O
INFORMAS	B-T170
'	O
optimal	O
'	O
approach	O
provides	O
a	O
potential	O
framework	O
for	O
development	O
of	O
these	O
methods	B-T170
.	O

Consecutive	O
Endovascular	B-T058
Treatment	I-T058
of	O
20	O
Ruptured	O
Very	O
Small	O
(	O
<	O
3	O
mm	O
)	O
Anterior	B-T038
Communicating	I-T038
Artery	I-T038
Aneurysms	I-T038

Small	O
aneurysms	B-T038
located	O
at	O
the	O
anterior	B-T017
communicating	I-T017
artery	I-T017
carry	O
significant	O
procedural	O
challenges	O
due	O
to	O
a	O
complex	O
anatomy	B-T017
.	O

Recent	O
advances	O
in	O
endovascular	B-T058
technologies	I-T058
have	O
expanded	O
the	O
use	O
of	O
coil	B-T058
embolization	I-T058
for	O
small	O
aneurysm	B-T038
treatment	O
.	O

However	O
,	O
limited	O
reports	O
describe	O
their	O
safety	O
and	O
efficacy	O
profiles	O
in	O
very	O
small	O
anterior	B-T038
communicating	I-T038
artery	I-T038
aneurysms	I-T038
.	O

We	O
sought	O
to	O
review	O
and	O
report	O
the	O
immediate	O
and	O
long	O
-	O
term	O
clinical	O
as	O
well	O
as	O
radiographic	O
outcomes	O
of	O
consecutive	O
patients	O
with	O
ruptured	O
very	O
small	O
anterior	B-T038
communicating	I-T038
artery	I-T038
aneurysms	I-T038
treated	O
with	O
current	O
endovascular	B-T058
coil	I-T058
embolization	I-T058
techniques	I-T058
.	O

A	O
prospectively	O
maintained	O
single	O
-	O
institution	O
neuroendovascular	B-T170
database	I-T170
was	O
accessed	O
to	O
identify	O
consecutive	O
cases	O
of	O
very	O
small	O
(	O
<	O
3	O
mm	O
)	O
ruptured	O
anterior	B-T038
communicating	I-T038
artery	I-T038
aneurysms	I-T038
treated	O
endovascularly	O
between	O
2006	O
and	O
2013	O
.	O

A	O
total	O
of	O
20	O
patients	O
with	O
ruptured	O
very	O
small	O
(	O
<	O
3	O
mm	O
)	O
anterior	B-T038
communicating	I-T038
artery	I-T038
aneurysms	I-T038
were	O
consecutively	O
treated	O
with	O
coil	B-T058
embolization	I-T058
.	O

The	O
average	O
maximum	O
diameter	O
was	O
2	O
.	O
66	O
±	O
0	O
.	O
41	O
mm	O
.	O

Complete	O
aneurysm	B-T058
occlusion	I-T058
was	O
achieved	O
for	O
17	O
(	O
85	O
%	O
)	O
aneurysms	B-T038
and	O
near	O
-	O
complete	O
aneurysm	B-T058
occlusion	I-T058
for	O
3	O
(	O
15	O
%	O
)	O
aneurysms	B-T038
.	O

Intraoperative	O
perforation	B-T033
was	O
seen	O
in	O
2	O
(	O
10	O
%	O
)	O
patients	O
without	O
any	O
clinical	O
worsening	O
or	O
need	O
for	O
an	O
external	O
ventricular	O
drain	O
.	O

A	O
thromboembolic	B-T038
event	I-T038
occurred	O
in	O
1	O
(	O
5	O
%	O
)	O
patient	O
without	O
clinical	O
worsening	O
or	O
radiologic	B-T038
infarct	I-T038
.	O

Median	O
clinical	O
follow	B-T058
-	I-T058
up	I-T058
was	O
12	O
(	O
±14	O
.	O
1	O
)	O
months	O
and	O
median	O
imaging	O
follow	B-T058
-	I-T058
up	I-T058
was	O
12	O
(	O
±18	O
.	O
4	O
)	O
months	O
.	O

This	O
report	O
describes	O
the	O
largest	O
series	O
of	O
consecutive	O
endovascular	B-T058
treatments	I-T058
of	O
ruptured	O
very	O
small	O
anterior	B-T038
communicating	I-T038
artery	I-T038
aneurysms	I-T038
.	O

These	O
findings	O
suggest	O
that	O
coil	B-T058
embolization	I-T058
of	O
very	O
small	O
aneurysms	B-T038
in	O
this	O
location	B-T082
can	O
be	O
performed	O
with	O
acceptable	O
rates	O
of	O
complications	B-T038
and	O
recanalization	B-T058
.	O

Factors	O
affecting	O
the	O
formation	O
of	O
nitrogenous	B-T058
disinfection	I-T058
by	B-T103
-	I-T103
products	I-T103
during	O
chlorination	O
of	O
aspartic	B-T103
acid	I-T103
in	O
drinking	O
water	O

The	O
formation	O
of	O
emerging	O
nitrogenous	B-T058
disinfection	I-T058
by	B-T103
-	I-T103
products	I-T103
(	O
N	B-T103
-	I-T103
DBPs	I-T103
)	O
from	O
the	O
chlorination	O
of	O
aspartic	B-T103
acid	I-T103
(	O
Asp	B-T103
)	O
was	O
investigated	O
.	O

The	O
yield	O
of	O
dichloroacetonitrile	B-T103
(	O
DCAN	B-T103
)	O
was	O
higher	O
than	O
other	O
N	B-T103
-	I-T103
DBPs	I-T103
,	O
such	O
as	O
dichloroacetamide	B-T103
(	O
DCAcAm	B-T103
)	O
and	O
chloropicrin	B-T103
(	O
TCNM	B-T103
)	O
during	O
the	O
chlorination	O
of	O
Asp	B-T103
.	O

The	O
formation	O
of	O
DCAN	B-T103
,	O
DCAcAm	B-T103
,	O
and	O
TCNM	B-T103
all	O
showed	O
a	O
trend	O
of	O
first	O
increasing	O
and	O
then	O
decreasing	B-T033
during	O
the	O
chlorination	O
of	O
Asp	B-T103
with	O
increasing	O
contact	O
time	O
.	O

The	O
dosage	O
of	O
chlorine	B-T103
had	O
an	O
impact	O
on	O
the	O
formation	O
of	O
DCAN	B-T103
,	O
DCAcAm	B-T103
,	O
and	O
TCNM	B-T103
.	O

The	O
highest	O
yields	O
of	O
DCAN	B-T103
and	O
DCAcAm	B-T103
appeared	O
when	O
the	O
Cl2	B-T103
/	O
Asp	B-T103
molar	O
ratio	O
was	O
about	O
20	O
,	O
the	O
yield	O
of	O
TCNM	B-T103
increased	O
with	O
increasing	O
the	O
Cl2	B-T103
/	O
Asp	B-T103
molar	O
ratio	O
from	O
5	O
to	O
30	O
and	O
TCNM	B-T103
was	O
not	O
produced	O
when	O
the	O
ratio	O
was	O
less	O
than	O
5	O
.	O

Cyanogen	B-T103
chloride	I-T103
(	O
CNCl	B-T103
)	O
was	O
detected	O
when	O
the	O
Cl2	B-T103
/	O
Asp	B-T103
molar	O
ratio	O
was	O
lower	O
than	O
5	O
.	O

N	B-T103
-	I-T103
DBPs	I-T103
formation	O
was	O
influenced	O
by	O
pH	O
.	O

DCAN	B-T103
formation	O
increased	O
with	O
increasing	O
pH	O
from	O
5	O
to	O
6	O
and	O
then	O
decreased	O
with	O
increasing	O
pH	O
from	O
6	O
to	O
9	O
,	O
but	O
DCAcAm	B-T103
and	O
TCNM	B-T103
increased	O
with	O
increasing	O
pH	O
from	O
5	O
to	O
8	O
and	O
then	O
decreased	O
.	O

Higher	O
temperatures	O
reduced	O
the	O
formation	O
of	O
DCAN	B-T103
and	O
DCAcAm	B-T103
,	O
but	O
increased	O
TCNM	B-T103
formation	O
.	O

DCAN	B-T103
and	O
DCAcAm	B-T103
formation	O
decreased	O
,	O
and	O
relatively	O
stable	O
TCNM	B-T103
formation	O
increased	O
,	O
with	O
increasing	O
free	O
chlorine	B-T103
contact	O
time	O
during	O
chloramination	O
.	O

N	B-T103
-	I-T103
nitrosodimethylamine	I-T103
(	O
NDMA	B-T103
)	O
was	O
produced	O
during	O
chloramination	O
of	O
Asp	B-T103
and	O
increased	O
with	O
prolonged	O
chloramination	O
contact	O
time	O
.	O

The	O
presence	O
of	O
bromide	B-T103
ions	I-T103
enhanced	O
the	O
yields	O
of	O
haloacetonitriles	B-T103
and	O
shifted	O
N	B-T103
-	I-T103
DBPs	I-T103
to	O
more	O
brominated	B-T103
species	I-T103
.	O

Midodrine	B-T103
and	O
tolvaptan	B-T103
in	O
patients	O
with	O
cirrhosis	B-T038
and	O
refractory	B-T033
or	O
recurrent	O
ascites	O
:	O
a	O
randomised	B-T062
pilot	B-T062
study	I-T062

Splanchnic	B-T038
arterial	I-T038
vasodilatation	I-T038
and	O
subsequent	O
sodium	B-T038
and	O
water	B-T033
retention	I-T033
play	O
an	O
important	O
role	O
in	O
cirrhotic	B-T038
ascites	I-T038
.	O

Midodrine	B-T103
and	O
tolvaptan	B-T103
have	O
been	O
used	O
separately	O
in	O
these	O
patients	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
on	O
the	O
use	O
of	O
combination	B-T058
of	O
midodrine	B-T103
and	O
tolvaptan	B-T103
in	O
the	O
control	O
of	O
ascites	B-T038
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	B-T058
the	O
safety	O
and	O
efficacy	O
of	O
midodrine	B-T103
,	O
tolvaptan	B-T103
and	O
their	O
combination	B-T058
in	O
control	O
of	O
refractory	B-T033
or	O
recurrent	O
ascites	O
in	O
cirrhotics	B-T038
.	O

Fifty	O
cirrhotic	O
patients	O
with	O
refractory	B-T033
or	O
recurrent	O
ascites	O
were	O
randomised	B-T062
to	O
receive	O
midodrine	B-T103
(	O
n	O
=	O
13	O
)	O
,	O
tolvaptan	B-T103
(	O
n	O
=	O
12	O
)	O
or	O
both	O
(	O
n	O
=	O
13	O
)	O
plus	O
standard	O
medical	B-T058
therapy	I-T058
(	O
SMT	B-T058
)	O
or	O
SMT	B-T058
alone	O
(	O
n	O
=	O
12	O
)	O
.	O

A	O
significant	B-T033
increase	I-T033
in	I-T033
urinary	I-T033
volume	I-T033
and	O
urinary	B-T038
sodium	I-T038
at	O
1	O
and	O
3	O
months	O
(	O
P	O
<	O
.	O
05	O
)	O
was	O
observed	O
in	O
all	O
groups	B-T098
except	O
SMT	B-T058
.	O

There	O
was	O
no	O
worsening	O
of	O
renal	B-T033
or	O
hepatic	B-T038
function	I-T038
in	O
any	O
group	B-T098
.	O

There	O
was	O
deterioration	O
of	O
model	B-T170
for	I-T170
end	I-T170
-	I-T170
stage	I-T170
liver	I-T170
disease	I-T170
(	O
MELD	B-T170
)	O
in	O
SMT	O
.	O

Midodrine	B-T103
as	O
well	O
as	O
combination	B-T058
of	O
midodrine	B-T103
and	O
tolvaptan	B-T103
but	O
not	O
tolvaptan	B-T103
alone	O
was	O
superior	O
to	O
SMT	B-T058
in	O
control	O
of	O
ascites	B-T038
at	O
3	O
months	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

The	O
combination	B-T058
therapy	I-T058
was	O
also	O
superior	O
to	O
midodrine	B-T103
in	O
the	O
control	O
of	O
ascites	B-T038
at	O
1	O
month	O
.	O

The	O
morbidity	O
and	O
mortality	O
were	O
similar	O
in	O
all	O
the	O
groups	B-T098
except	O
SMT	B-T058
.	O

The	O
results	O
of	O
this	O
pilot	B-T062
study	I-T062
suggest	O
that	O
midodrine	B-T103
and	O
combination	B-T058
with	O
tolvaptan	B-T103
better	O
controls	O
ascites	B-T038
without	O
any	O
renal	B-T038
or	O
hepatic	B-T038
dysfunction	I-T038
.	O

The	O
combination	B-T058
therapy	I-T058
rapidly	O
controls	O
ascites	B-T038
as	O
compared	O
to	O
midodrine	B-T103
or	O
tolvaptan	B-T103
alone	O
.	O

Acute	B-T038
Complicated	I-T038
Sinusitis	I-T038
:	O
Ten	O
Years	O
Experience	B-T038
from	O
the	O
University	B-T092
Hospital	I-T092
of	O
the	O
West	B-T082
Indies	I-T082

Complicated	B-T038
sinusitis	I-T038
is	O
rare	B-T038
.	O

It	O
might	O
not	O
be	O
identified	O
early	O
and	O
might	O
expose	O
the	O
patient	O
to	O
an	O
unfavourable	O
outcome	O
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
this	O
condition	B-T038
in	O
the	O
Caribbean	B-T082
.	O

This	O
study	B-T062
was	O
undertaken	O
to	O
describe	O
the	O
clinical	O
characteristics	O
and	O
treatment	O
outcomes	O
of	O
patients	O
admitted	B-T058
with	O
this	O
condition	B-T038
.	O

A	O
retrospective	O
chart	O
review	O
was	O
performed	O
on	O
patients	O
admitted	B-T058
to	O
the	O
University	B-T092
Hospital	I-T092
of	I-T092
the	I-T092
West	I-T092
Indies	I-T092
(	O
UHWI	B-T092
)	O
with	O
complicated	B-T038
sinusitis	I-T038
between	O
1999	O
to	O
2011	O
.	O

The	O
data	O
was	O
analysed	B-T062
using	O
SPSS	B-T170
statistics	I-T170
22	I-T170
software	I-T170
.	O

There	O
were	O
30	O
patients	O
(	O
23	O
males	O
and	O
7	O
females	O
)	O
.	O

The	O
mean	O
(	O
SD	O
)	O
age	O
was	O
19	O
(	O
13	O
.	O
96	O
)	O
years	O
.	O

Twenty	O
-	O
two	O
had	O
orbital	B-T082
complications	B-T038
,	O
two	O
had	O
intracranial	B-T082
complications	B-T038
and	O
one	O
had	O
both	O
.	O

The	O
most	O
common	O
organisms	O
isolated	O
were	O
streptococcus	B-T007
and	O
the	O
most	O
common	O
sensitivity	O
was	O
to	O
amoxicillin	B-T103
and	O
clavulinic	B-T103
acid	I-T103
.	O

Sixteen	O
patients	O
who	O
had	O
an	O
external	B-T082
surgical	O
approach	O
had	O
a	O
mean	O
(	O
SD	O
)	O
hospital	O
stay	O
of	O
8	O
.	O
8	O
(	O
3	O
.	O
71	O
)	O
days	O
compared	O
to	O
three	O
patients	O
who	O
had	O
a	O
purely	O
endoscopic	B-T082
approach	I-T082
who	O
had	O
a	O
mean	O
(	O
SD	O
)	O
hospital	O
stay	O
of	O
7	O
.	O
67	O
(	O
0	O
.	O
577	O
)	O
days	O
.	O

There	O
was	O
no	B-T033
statistical	O
difference	O
in	O
mean	O
hospital	O
stay	O
between	O
these	O
two	O
groups	O
(	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
49	O
-	O
5	O
.	O
78	O
;	O
p	O
=	O
0	O
.	O
609	O
)	O
.	O

The	O
mean	O
duration	O
of	O
hospital	O
stay	O
for	O
those	O
treated	B-T058
medically	I-T058
was	O
six	O
days	O
versus	O
ten	O
days	O
for	O
the	O
surgical	O
group	O
.	O

The	O
mean	O
difference	O
was	O
three	O
days	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
193	O
-	O
6	O
.	O
595	O
;	O
p	O
=	O
0	O
.	O
039	O
)	O
.	O

Acute	B-T038
complicated	I-T038
sinusitis	I-T038
is	O
seen	O
more	O
commonly	O
in	O
adolescent	O
males	O
.	O

The	O
most	O
common	O
complication	B-T038
was	O
orbital	B-T082
.	O

Surgical	B-T058
treatment	I-T058
is	O
indicated	O
for	O
those	O
patients	O
who	O
fail	O
medical	O
management	O
and	O
should	O
consist	O
of	O
an	O
endoscopic	B-T082
approach	I-T082
which	O
may	O
be	O
combined	O
with	O
open	O
approaches	O
if	O
indicated	O
.	O

Comparative	O
proteomic	B-T058
analysis	I-T058
reveals	O
alterations	O
in	O
development	B-T038
and	O
photosynthesis	O
-	O
related	O
proteins	B-T103
in	O
diploid	O
and	O
triploid	B-T038
rice	B-T204

Polyploidy	B-T038
has	O
pivotal	O
influences	O
on	O
rice	B-T204
(	O
Oryza	B-T204
sativa	I-T204
L	I-T204
.	I-T204
)	O
morphology	O
and	O
physiology	B-T038
,	O
and	O
is	O
very	O
important	O
for	O
understanding	O
rice	B-T204
domestication	O
and	O
improving	O
agricultural	O
traits	O
.	O

Diploid	O
(	O
DP	O
)	O
and	O
triploid	B-T038
(	O
TP	B-T038
)	O
rice	B-T204
shows	O
differences	O
in	O
morphological	O
parameters	B-T033
,	O
such	O
as	O
plant	B-T204
height	O
,	O
leaf	B-T204
length	O
,	O
leaf	B-T204
width	O
and	O
the	O
physiological	O
index	B-T170
of	O
chlorophyll	B-T103
content	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
determining	O
these	O
morphological	O
differences	O
are	O
remain	O
to	O
be	O
defined	O
.	O

To	O
better	O
understand	O
the	O
proteomic	B-T103
changes	O
between	O
DP	O
and	O
TP	B-T038
,	O
tandem	O
mass	O
tags	O
(	O
TMT	O
)	O
mass	O
spectrometry	O
(	O
MS	O
)	O
/	O
MS	B-T058
was	O
used	O
to	O
detect	O
the	O
significant	O
changes	O
to	O
protein	B-T038
expression	I-T038
between	O
DP	O
and	O
TP	B-T038
.	O

Results	O
indicated	O
that	O
both	O
photosynthesis	O
and	O
metabolic	O
pathways	O
were	O
highly	O
significantly	O
associated	O
with	O
proteomic	B-T038
alteration	I-T038
between	O
DP	O
and	O
TP	B-T038
based	O
on	O
biological	B-T038
process	I-T038
and	O
pathway	B-T058
enrichment	I-T058
analysis	I-T058
,	O
and	O
13	O
higher	O
abundance	O
chloroplast	B-T103
proteins	I-T103
involving	O
in	O
these	O
two	O
pathways	B-T038
were	O
identified	O
in	O
TP	B-T038
.	O

Quantitative	B-T062
real	I-T062
-	I-T062
time	I-T062
PCR	I-T062
analysis	I-T062
demonstrated	O
that	O
5	O
of	O
the	O
13	O
chloroplast	B-T103
proteins	I-T103
ATPF	B-T103
,	O
PSAA	B-T103
,	O
PSAB	B-T103
,	O
PSBB	B-T103
and	O
RBL	B-T103
in	O
TP	B-T038
were	O
higher	O
abundance	O
compared	O
with	O
those	O
in	O
DP	O
.	O

This	O
study	B-T062
integrates	O
morphology	O
,	O
physiology	B-T038
and	O
proteomic	B-T058
profiling	I-T058
alteration	O
of	O
DP	O
and	O
TP	B-T038
to	O
address	O
their	O
underlying	O
different	O
molecular	B-T038
mechanisms	I-T038
.	O

Our	O
finding	O
revealed	O
that	O
ATPF	B-T103
,	O
PSAA	B-T103
,	O
PSAB	B-T103
,	O
PSBB	B-T103
and	O
RBL	B-T103
can	O
induce	O
considerable	O
expression	B-T038
changes	O
in	O
TP	B-T038
and	O
may	O
affect	O
the	O
development	B-T038
and	O
growth	B-T038
of	O
rice	B-T204
through	O
photosynthesis	O
and	O
metabolic	O
pathways	O
.	O

Correlation	O
of	O
cardiopulmonary	B-T058
exercise	I-T058
testing	I-T058
parameters	O
with	O
quality	O
of	O
life	O
in	O
stable	B-T033
COPD	B-T038
patients	O

The	O
precise	O
head	O
to	O
head	O
relationships	O
between	O
Cardio	B-T058
-	I-T058
pulmonary	I-T058
exercise	I-T058
testing	I-T058
(	O
CPET	B-T058
)	O
parameters	O
and	O
patients	O
'	O
daily	B-T033
symptoms	I-T033
/	O
activities	O
and	O
the	O
disease	B-T038
social	O
/	O
emotional	B-T201
impact	I-T201
are	O
less	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
the	O
correlation	O
of	O
COPD	B-T038
daily	B-T033
symptoms	I-T033
and	O
quality	O
of	O
life	O
[	O
assessed	O
by	O
St	B-T170
.	I-T170

George	I-T170
'	I-T170
s	I-T170
Respiratory	I-T170
Questionnaire	I-T170
(	O
SGRQ	B-T170
)	O
]	O
and	O
COPD	B-T038
severity	B-T170
index	I-T170
(	O
BODE	B-T170
-	I-T170
index	I-T170
)	O
with	O
CPET	B-T058
parameters	O
were	O
investigated	O
.	O

Symptom	B-T033
-	O
limited	O
CPET	B-T058
was	O
performed	O
in	O
37	O
consecutive	O
COPD	B-T038
(	O
GOLD	O
I	O
-	O
III	O
)	O
subjects	O
during	O
non	O
-	O
exacerbation	B-T038
phase	O
.	O

The	O
SGRQ	B-T170
was	O
also	O
completed	O
by	O
each	O
patient	O
.	O

SGRQ	B-T201
-	I-T201
score	I-T201
correlated	O
negatively	B-T033
with	O
FEV1	B-T058
(	O
r	O
=	O
-	O
0	O
.	O
49	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
predicted	O
maximal	B-T033
work	I-T033
-	I-T033
rate	I-T033
(	O
%	B-T033
WR	I-T033
-	I-T033
max	I-T033
)	O
(	O
r	O
=	O
-	O
0	O
.	O
44	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
V	B-T033
'	I-T033
O2	I-T033
/	O
WR	B-T201
(	O
r	O
=	O
-	O
0	O
.	O
52	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
breathing	O
reserve	O
(	O
r	O
=	O
-	O
0	O
.	O
50	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

However	O
it	O
did	B-T033
not	I-T033
correlate	I-T033
with	O
Peak	B-T033
-	I-T033
V	I-T033
'	I-T033
O2	I-T033
%	O
predicted	O
(	O
r	O
=	O
-	O
0	O
.	O
27	O
,	O
P	O
=	O
0	O
.	O
10	O
)	O
.	O

In	O
20	O
(	O
54	O
.	O
1	O
%	O
)	O
subjects	O
in	O
which	O
leg	O
fatigue	O
was	O
the	O
main	O
cause	O
for	O
stopping	O
the	O
test	O
,	O
Peak	B-T033
-	I-T033
V	I-T033
'	I-T033
O2	I-T033
,	O
%	B-T033
WR	I-T033
-	I-T033
max	I-T033
,	O
HR	O
-	O
Reserve	O
and	O
Breathing	O
reserve	O
were	O
higher	O
(	O
P	O
=	O
0	O
.	O
04	O
,	O
<	O
0	O
.	O
01	O
,	O
0	O
.	O
04	O
and	O
<	O
0	O
.	O
01	O
respectively	O
)	O
than	O
the	O
others	O
.	O

There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
BODE	B-T170
-	I-T170
index	I-T170
and	O
∆VO2	B-T033
/	O
∆WR	B-T201
(	O
r	O
=	O
-	O
0	O
.	O
64	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
breathing	O
-	O
reserve	O
(	O
r	O
=	O
-	O
0	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
018	O
)	O
.	O

The	O
observed	O
relationships	O
between	O
CPET	B-T058
parameter	O
and	O
daily	O
subjective	B-T038
complaints	I-T038
in	O
COPD	B-T038
were	O
not	O
strong	O
.	O

Those	O
who	O
discontinued	O
the	O
CPET	B-T058
because	O
of	O
leg	O
fatigue	O
were	O
in	O
the	O
earlier	O
stages	O
of	O
COPD	B-T038
.	O

Significant	O
negative	B-T033
correlation	O
between	O
∆VO2	B-T033
/	O
∆WR	B-T201
and	O
BODE	B-T170
-	I-T170
index	I-T170
suggests	O
that	O
along	O
with	O
COPD	B-T038
progression	B-T038
,	O
regardless	O
of	O
negative	O
past	O
history	O
,	O
other	O
comorbidities	O
such	O
as	O
cardiac	O
/	O
musculoskeletal	B-T033
problems	I-T033
should	O
be	O
sought	O
.	O

Intrapartum	O
Cervical	B-T037
Laceration	I-T037
and	O
Subsequent	O
Pregnancy	B-T033
Outcomes	I-T033

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
describe	O
pregnancy	B-T033
outcomes	I-T033
,	O
including	O
cervical	O
insufficiency	O
and	O
preterm	B-T033
birth	I-T033
,	O
in	O
the	O
subsequent	O
pregnancy	B-T038
following	O
an	O
intrapartum	O
cervical	B-T037
laceration	I-T037
.	O

Retrospective	O
cohort	B-T098
of	O
women	B-T098
with	O
their	O
first	O
two	O
consecutive	O
singleton	B-T038
pregnancies	I-T038
carried	O
to	O
≥	O
20	O
(	O
0	O
/	O
7	O
)	O
weeks	O
'	O
gestation	B-T038
within	O
a	O
tertiary	B-T092
health	I-T092
care	I-T092
system	I-T092
from	O
2002	O
to	O
2012	O
.	O

Cervical	B-T037
laceration	I-T037
cases	O
were	O
identified	O
by	O
ICD9	B-T170
codes	I-T170
and	O
included	O
if	O
suture	B-T058
repair	I-T058
was	O
required	O
.	O

In	O
this	O
study	B-T062
,	O
55	O
women	B-T098
were	O
confirmed	B-T033
to	O
have	O
a	O
cervical	B-T037
laceration	I-T037
in	O
the	O
first	O
delivery	B-T038
;	O
43	O
lacerations	B-T037
after	O
vaginal	B-T058
delivery	I-T058
(	B-T058
VD	I-T058
)	I-T058
and	O
12	O
after	O
cesarean	B-T058
delivery	I-T058
(	B-T058
CD	I-T058
)	I-T058
.	O

The	O
median	O
gestational	O
age	O
of	O
the	O
first	O
delivery	B-T038
was	O
40	O
(	O
0	O
/	O
7	O
)	O
weeks	O
and	O
the	O
median	O
birth	O
weight	O
3	O
,	O
545	O
g	O
;	O
these	O
did	O
not	O
differ	O
between	O
VD	B-T058
and	O
CD	B-T058
.	O

In	O
the	O
second	O
pregnancy	B-T038
,	O
2	O
of	O
55	O
women	B-T098
(	O
4	O
.	O
6	O
%	O
)	O
had	O
a	O
prophylactic	O
cerclage	B-T058
placed	O
;	O
1	O
carried	O
to	O
term	B-T038
and	O
the	O
other	O
delivered	B-T033
at	O
35	O
(	O
6	O
/	O
7	O
)	O
weeks	O
.	O

In	O
total	O
,	O
four	O
women	B-T098
(	O
9	O
.	O
3	O
%	O
)	O
delivered	B-T033
the	O
second	O
pregnancy	B-T038
<	O
37	O
weeks	O
:	O
three	O
had	O
a	O
prior	O
term	B-T038
VD	B-T058
and	O
one	O
had	O
a	O
prior	O
34	O
weeks	O
VD	B-T058
.	O

There	O
was	O
only	O
one	O
case	O
of	O
recurrent	O
cervical	B-T037
laceration	I-T037
,	O
occurring	O
in	O
the	O
setting	O
of	O
vaginal	B-T058
deliveries	I-T058
.	O

Obstetric	O
cervical	B-T037
lacerations	I-T037
are	O
uncommon	O
.	O

Complications	B-T038
in	O
the	O
following	O
pregnancy	B-T038
were	O
low	O
,	O
despite	O
lack	O
of	O
additional	O
prophylactic	O
cerclage	B-T058
use	O
.	O

A	O
Wnt	B-T038
Pathway	I-T038
Activator	B-T103
Induces	B-T038
Apoptosis	I-T038
and	O
Cell	B-T038
Death	I-T038
in	O
Mouse	B-T038
Monocytic	I-T038
Leukemia	I-T038
Cells	B-T017

A	O
Wnt	B-T103
agonist	I-T103
,	I-T103
2	B-T103
-	I-T103
amino	I-T103
-	I-T103
4	I-T103
-	I-T103
[	I-T103
3	I-T103
,	I-T103
4	I-T103
-	I-T103
(	I-T103
methylenedioxy	I-T103
)	I-T103
benzylamino	I-T103
]	I-T103
-	I-T103
6	I-T103
-	I-T103
(	I-T103
3	I-T103
-	I-T103
methoxyphenyl	I-T103
)	I-T103
pyrimidine	I-T103
,	O
is	O
a	O
cell	B-T038
-	I-T038
permeable	I-T038
pyrimidine	B-T103
compound	I-T103
that	O
has	O
been	O
shown	O
to	O
mimic	O
the	O
effect	O
of	O
Wnt	B-T103
.	O

In	O
this	O
study	O
,	O
leukemic	B-T017
mouse	I-T017
cell	I-T017
lines	I-T017
,	O
RAW	B-T017
264	I-T017
.	I-T017
7	I-T017
and	O
J774	B-T017
.	I-T017
1	I-T017
,	O
were	O
incubated	O
with	O
the	O
Wnt	B-T103
agonist	I-T103
.	O

The	O
Wnt	B-T103
agonist	I-T103
showed	O
cell	B-T038
death	I-T038
in	O
the	O
concentration	O
of	O
1	O
-	O
10	O
μM	O
.	O

The	O
Wnt	B-T103
agonist	I-T103
did	O
not	O
show	O
inhibition	O
of	O
GSK	B-T103
-	I-T103
3β	I-T103
activity	B-T038
but	O
induced	O
β	B-T038
-	I-T038
catenin	I-T038
accumulation	I-T038
in	O
the	O
nucleus	B-T017
.	O

The	O
Wnt	B-T103
agonist	I-T103
showed	O
caspase	B-T038
-	I-T038
independent	I-T038
cell	I-T038
death	I-T038
,	O
but	O
no	O
further	O
involvement	O
in	O
cell	B-T038
death	I-T038
ER	I-T038
stress	I-T038
signaling	I-T038
.	O

Here	O
we	O
discuss	O
the	O
possible	O
mechanism	O
of	O
Wnt	B-T103
agonist	I-T103
-	O
induced	B-T038
apoptotic	I-T038
cell	I-T038
death	I-T038
in	O
RAW	B-T017
264	I-T017
.	I-T017
7	I-T017
cells	I-T017
.	O

Extracorporeal	B-T058
membrane	I-T058
oxygenation	I-T058
outcomes	O
in	O
children	O
with	O
hemophagocytic	B-T038
lymphohistiocytosis	I-T038

Pediatric	O
patients	O
with	O
hemophagocytic	B-T038
lymphohistiocytosis	I-T038
(	O
HLH	B-T038
)	O
may	O
develop	O
refractory	O
respiratory	B-T038
or	O
cardiac	B-T038
failure	I-T038
that	O
warrants	O
consideration	B-T033
for	O
extracorporeal	B-T058
membrane	I-T058
oxygenation	I-T058
(	O
ECMO	B-T058
)	O
support	B-T074
.	O

The	O
purposes	O
of	O
this	O
study	B-T062
were	O
to	O
describe	O
the	O
use	O
and	O
outcomes	O
of	O
ECMO	B-T058
in	O
pediatric	O
HLH	B-T038
patients	O
,	O
to	O
identify	O
risk	B-T033
factors	I-T033
for	O
hospital	O
mortality	O
and	O
to	O
compare	O
their	O
ECMO	B-T058
use	O
and	O
outcomes	O
to	O
the	O
ECMO	B-T058
population	B-T098
as	O
a	O
whole	O
.	O

Pediatric	O
patients	O
(	O
⩽	O
18	O
years	O
)	O
with	O
a	O
diagnosis	B-T033
of	O
HLH	B-T038
in	O
the	O
Extracorporeal	O
Life	O
Support	O
Organization	O
(	O
ELSO	O
)	O
Registry	B-T170
were	O
included	O
.	O

Between	O
1983	O
and	O
2014	O
,	O
data	O
for	O
30	O
children	O
with	O
HLH	B-T038
were	O
available	O
in	O
the	O
ELSO	O
registry	B-T170
and	O
all	O
were	O
included	O
in	O
this	O
study	B-T062
.	O

All	O
cases	O
occurred	O
in	O
the	O
last	O
decade	O
.	O

Of	O
the	O
30	O
HLH	B-T038
patients	O
,	O
24	O
(	O
80	O
%	O
)	O
had	O
a	O
respiratory	B-T038
indication	O
for	O
ECMO	B-T058
and	O
six	O
(	O
20	O
%	O
)	O
had	O
a	O
cardiac	B-T038
indication	O
(	O
of	O
which	O
4	O
were	O
E	B-T082
-	O
CPR	B-T058
and	O
2	O
cardiac	B-T038
failure	I-T038
)	O
.	O

Of	O
the	O
24	O
respiratory	B-T038
ECMO	B-T058
patients	O
,	O
63	O
%	O
were	O
placed	O
on	O
VA	O
ECMO	O
.	O

Compared	O
with	O
all	O
pediatric	O
patients	O
in	O
the	O
ELSO	O
registry	B-T170
during	O
the	O
study	O
period	O
(	O
n	O
=	O
17	O
,	O
007	O
)	O
,	O
HLH	B-T038
patients	O
had	O
worse	O
hospital	O
survival	O
(	O
non	O
-	O
HLH	O
59	O
%	O
vs	O
HLH	B-T038
30	O
%	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
pediatric	O
HLH	B-T038
patients	O
,	O
no	O
pre	O
-	O
ECMO	B-T058
risk	B-T033
factors	I-T033
for	O
mortality	O
were	O
identified	O
.	O

The	O
development	O
of	O
a	O
hemorrhagic	O
complication	B-T038
on	O
ECMO	B-T058
was	O
associated	O
with	O
decreased	O
mortality	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Comparing	O
HLH	B-T038
patients	O
with	O
respiratory	B-T038
failure	I-T038
to	O
patients	O
with	O
other	O
immune	B-T201
compromised	I-T201
conditions	I-T201
,	O
the	O
overall	O
survival	O
rate	O
is	O
similar	O
(	O
HLH	B-T038
38	O
%	O
vs	O
.	O

non	O
-	O
HLH	O
immune	B-T201
compromised	I-T201
31	O
%	O
,	O
p	O
=	O
0	O
.	O
64	O
)	O
.	O

HLH	B-T038
is	O
an	O
uncommon	O
indication	O
for	O
ECMO	B-T058
and	O
these	O
patients	O
have	O
increased	O
mortality	O
compared	O
to	O
the	O
overall	O
pediatric	O
ECMO	B-T058
population	B-T098
.	O

These	O
data	O
should	O
be	O
factored	O
into	O
decision	B-T038
-	I-T038
making	I-T038
when	O
considering	O
ECMO	B-T058
for	O
pediatric	O
HLH	B-T038
patients	O
.	O

Gut	O
microbiome	O
alterations	O
in	O
patients	O
with	O
stage	O
4	O
hepatitis	B-T038
C	I-T038

Hepatitis	B-T005
C	I-T005
virus	I-T005
(	O
HCV	B-T005
)	O
causes	O
debilitating	O
liver	B-T038
diseases	I-T038
,	O
which	O
may	O
progress	O
to	O
cirrhosis	B-T038
and	O
cancer	B-T038
,	O
and	O
claims	O
500	O
,	O
000	O
annual	O
lives	O
worldwide	O
.	O

While	O
HCV	B-T005
epidemiology	B-T062
,	O
pathophysiology	B-T038
,	O
and	O
therapy	O
are	O
being	O
deeply	O
studied	O
,	O
rare	O
attention	O
is	O
given	O
to	O
reciprocal	B-T038
interactions	I-T038
between	O
HCV	B-T038
infection	I-T038
,	O
HCV	B-T005
-	O
induced	O
chronic	B-T038
liver	I-T038
diseases	I-T038
,	O
and	O
the	O
human	B-T204
gut	O
microbiome	O
.	O

As	O
Egypt	B-T082
has	O
the	O
world	B-T098
'	I-T098
s	I-T098
highest	O
prevalence	O
of	O
HCV	B-T038
infections	I-T038
,	O
we	O
launched	O
this	O
study	B-T062
to	O
monitor	O
differences	O
in	O
the	O
gut	O
microbial	O
community	O
composition	B-T201
of	O
Egyptian	B-T098
HCV	B-T005
patients	O
that	O
may	O
affect	O
,	O
or	O
result	O
from	O
,	O
the	O
patients	O
'	O
liver	B-T017
state	O
.	O

To	O
this	O
end	O
,	O
we	O
analyzed	O
stool	B-T031
samples	I-T031
from	O
six	O
stage	O
4	O
-	O
HCV	B-T005
patients	O
and	O
eight	O
healthy	B-T098
individuals	I-T098
by	O
high	O
-	O
throughput	O
16S	B-T058
rRNA	I-T058
gene	I-T058
sequencing	I-T058
using	O
Illumina	B-T074
MiSeq	I-T074
.	O

Overall	O
,	O
the	O
alpha	O
-	O
diversity	O
of	O
the	O
healthy	B-T098
persons	I-T098
'	I-T098
gut	O
microbiomes	O
was	O
higher	O
than	O
those	O
of	O
the	O
HCV	B-T005
patients	O
.	O

Whereas	O
members	O
of	O
phylum	B-T007
Bacteroidetes	I-T007
were	O
more	O
abundant	O
in	O
HCV	B-T005
patients	O
,	O
healthy	B-T098
individuals	I-T098
had	O
higher	O
abundance	O
of	O
Firmicutes	B-T007
,	O
Proteobacteria	B-T007
,	O
and	O
Actinobacteria	B-T007
.	O

Genus	B-T170
-	O
level	O
analysis	B-T062
showed	O
differential	O
abundance	O
of	O
Prevotella	B-T007
and	O
Faecalibacterium	B-T007
(	O
higher	O
in	O
HCV	B-T005
patients	O
)	O
vs	O
.	O

Ruminococcus	B-T007
and	O
Clostridium	B-T007
(	O
healthy	O
group	O
)	O
,	O
indicating	O
that	O
the	O
higher	O
abundance	O
of	O
Bacteroidetes	B-T007
in	O
HCV	B-T005
patients	O
is	O
most	O
likely	O
due	O
to	O
Prevotella	B-T007
overabundance	O
.	O

The	O
probiotic	B-T007
genus	I-T007
,	O
Bifidobacterium	B-T007
,	O
was	O
only	O
observed	O
in	O
the	O
microbiotas	O
of	O
healthy	B-T098
individuals	I-T098
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	B-T062
provides	O
a	O
first	O
overview	O
of	O
major	O
phyla	B-T170
and	O
genera	B-T170
differentiating	O
stage	O
4	O
-	O
HCV	B-T005
patients	O
from	O
healthy	B-T098
individuals	I-T098
and	O
suggests	O
possible	O
microbiome	O
remodeling	O
in	O
chronic	B-T038
hepatitis	I-T038
C	I-T038
,	O
possibly	O
shaped	O
by	O
bacterial	B-T038
translocation	I-T038
as	O
well	O
as	O
the	O
liver	B-T017
'	I-T017
s	I-T017
impaired	B-T033
role	I-T033
in	O
digestion	B-T038
and	O
protein	B-T038
synthesis	I-T038
.	O

Future	O
studies	O
will	O
investigate	O
the	O
microbiome	O
composition	B-T201
and	O
functional	O
capabilities	O
in	O
more	O
patients	O
while	O
tracing	O
some	O
potential	O
biomarker	B-T201
taxa	O
(	O
e	O
.	O
g	O
.	O
,	O
Prevotella	B-T007
,	O
Faecalibacterium	B-T007
vs	O
.	O

Bifidobacterium	B-T007
)	O
.	O

Peptide	B-T103
-	O
Mediated	O
Interference	O
of	O
PB2	B-T103
-	O
eIF4G1	B-T103
Interaction	B-T038
Inhibits	O
Influenza	B-T005
A	I-T005
Viruses	I-T005
'	O
Replication	B-T038
in	O
Vitro	O
and	O
in	O
Vivo	O

Influenza	B-T005
viruses	I-T005
are	O
obligate	B-T204
parasites	I-T204
that	O
hijack	B-T038
the	I-T038
host	I-T038
cellular	I-T038
system	I-T038
.	O

Previous	O
results	O
have	O
shown	O
that	O
the	O
influenza	B-T103
virus	I-T103
PB2	I-T103
subunit	O
confers	O
a	O
dependence	O
of	O
host	B-T103
eukaryotic	I-T103
translation	I-T103
initiation	I-T103
factor	I-T103
4	I-T103
-	I-T103
γ	I-T103
1	I-T103
(	O
eIF4G1	B-T103
)	O
for	O
viral	B-T038
mRNA	I-T038
translation	I-T038
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
peptide	B-T103
-	O
mediated	O
interference	O
of	O
the	O
PB2	B-T103
-	O
eIF4G1	B-T103
interaction	B-T038
inhibited	O
virus	B-T038
replication	I-T038
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Remarkably	O
,	O
intranasal	B-T058
administration	I-T058
of	O
the	O
peptide	B-T103
provided	O
100	O
%	O
protection	O
against	O
lethal	B-T033
challenges	B-T058
of	O
influenza	B-T005
A	I-T005
viruses	I-T005
in	O
BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
,	O
including	O
H1N1	B-T005
,	O
H5N1	B-T005
,	O
and	O
H7N9	B-T005
influenza	I-T005
virus	I-T005
subtypes	I-T005
.	O

Mapping	B-T062
of	O
the	O
PB2	B-T103
protein	I-T103
indicated	O
that	O
the	O
eIF4G1	B-T103
binding	B-T103
sites	I-T103
resided	O
within	O
the	O
PB2	B-T103
cap	I-T103
-	O
binding	B-T038
domain	I-T038
.	O

Virtual	B-T170
docking	I-T170
analysis	I-T170
suggested	O
that	O
the	O
inhibitory	O
peptide	B-T103
associated	O
with	O
the	O
conserved	O
amino	B-T103
acid	I-T103
residues	I-T103
that	O
were	O
essential	O
to	O
PB2	B-T103
cap	B-T058
-	I-T058
binding	I-T058
activity	I-T058
.	O

Overall	O
,	O
our	O
results	O
identified	O
the	O
PB2	B-T103
-	O
eIF4G1	B-T103
interactive	B-T103
site	I-T103
as	O
a	O
druggable	B-T103
target	O
for	O
influenza	B-T038
therapeutics	B-T058
.	O

DRG1	B-T017
is	O
a	O
potential	O
oncogene	B-T017
in	O
lung	B-T038
adenocarcinoma	I-T038
and	O
promotes	O
tumor	B-T038
progression	I-T038
via	O
spindle	B-T038
checkpoint	I-T038
signaling	I-T038
regulation	B-T038

Developmentally	O
regulated	O
GTP	B-T103
binding	I-T103
protein	I-T103
1	I-T103
(	O
DRG1	B-T103
)	O
,	O
a	O
member	O
of	O
the	O
DRG	B-T103
family	I-T103
,	O
plays	O
important	O
roles	O
in	O
regulating	B-T038
cell	I-T038
growth	I-T038
.	O

However	O
,	O
the	O
molecular	O
basis	O
of	O
DRG1	B-T103
in	O
cell	B-T038
proliferation	I-T038
regulation	I-T038
and	O
the	O
relationship	O
between	O
DRG1	B-T103
and	O
tumor	B-T038
progression	I-T038
remain	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
DRG1	B-T103
is	O
elevated	O
in	O
lung	B-T038
adenocarcinomas	I-T038
while	O
weakly	O
expressed	B-T038
in	O
adjacent	O
lung	B-T017
tissues	B-T017
.	O

DRG1	B-T017
knockdown	B-T062
causes	O
growth	B-T038
inhibition	I-T038
of	O
tumor	B-T017
cells	I-T017
by	O
significantly	O
increasing	O
the	O
proportion	O
of	O
cells	B-T017
in	O
M	B-T038
phase	I-T038
.	O

Overexpression	B-T038
of	O
DRG1	B-T103
leads	O
to	O
chromosome	B-T017
missegregation	B-T038
which	O
is	O
an	O
important	O
index	O
for	O
tumorigenesis	B-T038
.	O

Interestingly	O
,	O
ectopic	B-T038
of	O
DRG1	B-T017
reduces	O
taxol	B-T103
induced	O
apoptosis	B-T038
of	O
lung	B-T038
adenocarcinoma	I-T038
cells	B-T017
.	O

Mechanistic	O
analyses	B-T062
confirm	O
that	O
DRG1	B-T103
localizes	B-T082
at	O
mitotic	B-T017
spindles	I-T017
in	O
dividing	B-T017
cells	I-T017
and	O
binds	B-T038
to	O
spindle	B-T038
checkpoint	I-T038
signaling	I-T038
proteins	B-T103
in	B-T082
vivo	I-T082
.	O

These	O
studies	B-T062
highlight	O
the	O
expanding	O
role	O
of	O
DRG1	B-T017
in	O
tumorigenesis	B-T038
and	O
reveal	O
a	O
mechanism	O
of	O
DRG1	B-T017
in	O
taxol	B-T103
resistance	O
.	O

Gelsolin	B-T103
in	O
Onychophora	B-T204
and	O
Tardigrada	B-T204
with	O
notes	O
on	O
its	O
variability	O
in	O
the	O
Ecdysozoa	B-T204

Rearrangements	O
of	O
the	O
filamentous	B-T103
actin	I-T103
network	I-T103
involve	O
a	O
broad	O
range	O
of	O
actin	B-T103
binding	I-T103
proteins	I-T103
.	O

Among	O
these	O
,	O
the	O
gelsolin	B-T103
proteins	I-T103
sever	O
actin	B-T017
filaments	I-T017
,	O
cap	O
their	O
fast	B-T033
growing	I-T033
end	O
and	O
nucleate	B-T038
actin	B-T038
assembly	I-T038
in	O
a	O
calcium	B-T103
-	O
dependent	O
manner	O
.	O

Here	O
,	O
we	O
focus	O
on	O
the	O
gelsolin	B-T103
of	O
the	O
onychophoran	B-T204
Peripatoides	B-T204
novaezealandiae	I-T204
and	O
the	O
eutardigrade	B-T204
Hypsibius	B-T204
dujardini	I-T204
.	O

From	O
the	O
cDNA	B-T103
of	O
P	B-T204
.	I-T204

novaezealandiae	I-T204
we	O
obtained	O
the	O
complete	O
coding	B-T017
sequence	I-T017
with	O
an	O
open	B-T017
reading	I-T017
frame	I-T017
of	O
2178	O
bp	B-T038
.	O

It	O
encodes	O
a	O
protein	B-T103
of	O
726	O
amino	B-T103
acids	I-T103
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
82	O
,	O
610	O
.	O
9Da	O
and	O
a	O
pI	O
of	O
5	O
.	O
57	O
.	O

This	O
sequence	B-T082
is	O
comprised	O
of	O
six	O
segments	B-T082
(	O
S1	O
-	O
S6	O
)	O
.	O

However	O
,	O
analysis	B-T062
of	O
data	O
from	O
TardiBase	B-T170
reveals	O
that	O
the	O
gelsolin	B-T103
of	O
the	O
eutardigrade	B-T204
Hypsibius	B-T204
dujardini	I-T204
has	O
only	O
three	O
segments	B-T082
(	O
S1	O
-	O
S3	O
)	O
.	O

The	O
coding	B-T017
sequence	I-T017
consist	O
of	O
1119	O
bp	B-T038
for	O
373	O
amino	B-T103
acids	I-T103
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
42	O
,	O
440	O
.	O
95Da	O
and	O
a	O
pI	O
of	O
6	O
.	O
17	O
.	O

The	O
Peripatoides	B-T204
and	O
Hypsibius	B-T204
gelsolin	B-T103
revealed	O
both	O
conserved	B-T082
binding	B-T103
motifs	I-T103
for	O
G	B-T103
-	I-T103
actin	I-T103
,	O
F	B-T103
-	I-T103
actin	I-T103
and	O
phosphatidylinositol	B-T103
4	I-T103
,	I-T103
5	I-T103
-	I-T103
bisphosphate	I-T103
(	O
PIP2	B-T103
)	O
,	O
along	O
with	O
a	O
full	O
set	O
of	O
type	B-T103
-	I-T103
1	I-T103
and	O
type	B-T103
-	I-T103
2	I-T103
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
binding	B-T103
sites	I-T103
which	O
could	O
result	O
in	O
the	O
binding	B-T038
of	O
eight	O
and	O
four	O
calcium	B-T103
ions	I-T103
,	O
respectively	O
.	O

Both	O
gelsolin	B-T103
proteins	I-T103
lack	O
a	O
C	B-T082
-	I-T082
terminal	I-T082
latch	B-T082
-	I-T082
helix	I-T082
indicating	O
a	O
more	O
rapid	O
activation	O
in	O
the	O
submicromolar	O
Ca	B-T058
(	I-T058
2	I-T058
+	I-T058
)	I-T058
range	I-T058
.	O

We	O
suggest	O
that	O
a	O
gelsolin	B-T103
with	O
three	O
segments	B-T082
was	O
present	B-T033
in	O
the	O
last	O
common	O
ancestor	O
of	O
the	O
ecdysozoan	B-T204
clade	O
Panarthropoda	B-T204
(	O
Onychophora	B-T204
,	O
Tardigrada	B-T204
,	O
Arthropoda	B-T204
)	O
,	O
primarily	O
because	O
the	O
gelsolin	B-T103
of	O
all	O
non	O
-	O
Ecdysozoa	O
studied	B-T062
so	O
far	O
(	O
except	O
Chordata	B-T204
)	O
reveals	O
this	O
number	O
of	O
segments	B-T082
.	O

Mapping	B-T058
of	O
our	O
molecular	B-T170
data	I-T170
onto	O
a	O
well	O
-	O
established	O
phylogeny	O
revealed	O
that	O
the	O
number	O
of	O
gelsolin	B-T103
segments	B-T082
does	O
not	O
correlate	O
with	O
the	O
phylogenetic	O
lineage	O
but	O
rather	O
with	O
particular	O
functional	O
demands	O
to	O
alter	O
the	O
kinetics	O
of	O
actin	B-T038
polymerization	I-T038
.	O

MiR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
participates	O
in	O
esophageal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
invasion	B-T038
and	O
metastasis	B-T038
via	O
SMAD7	B-T017
pathway	B-T038
mediated	O
EMT	B-T038

ESCC	B-T038
is	O
a	O
life	B-T033
-	I-T033
threatening	I-T033
disease	B-T038
due	O
to	O
invasion	B-T038
and	O
metastasis	B-T038
in	O
the	O
early	O
stage	O
.	O

Great	O
efforts	O
had	O
been	O
made	O
to	O
detect	B-T033
the	O
molecular	O
mechanisms	O
which	O
led	O
to	O
the	O
invasion	B-T038
and	O
metastasis	B-T038
in	O
ESCC	B-T038
.	O

Recent	O
evidence	O
had	O
suggested	O
that	O
deregulation	O
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
took	O
an	O
important	O
role	O
in	O
cancers	B-T038
.	O

However	O
,	O
its	O
role	O
and	O
functional	O
mechanism	O
in	O
ESCC	B-T038
had	O
seldom	O
been	O
elucidated	O
.	O

The	O
expression	O
levels	O
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
were	O
detected	B-T033
in	O
ESCC	B-T038
tissues	B-T017
and	O
cell	B-T017
lines	I-T017
by	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
methods	I-T062
.	O

Then	O
,	O
the	O
invasion	B-T038
,	O
metastasis	B-T038
and	O
proliferation	B-T038
ability	O
of	O
ESCC	B-T038
cell	B-T017
lines	I-T017
transfected	B-T038
with	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
mimics	O
were	O
analyzed	B-T062
separately	O
by	O
transwell	B-T058
invasion	I-T058
assay	I-T058
,	O
wound	B-T058
healing	I-T058
assay	I-T058
and	O
cell	B-T062
proliferation	I-T062
assay	I-T062
.	O

Finally	O
,	O
the	O
target	B-T017
gene	I-T017
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
was	O
studied	O
and	O
verified	O
by	O
luciferase	B-T058
activity	I-T058
assay	I-T058
.	O

And	O
the	O
role	O
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
in	O
EMT	B-T038
was	O
also	O
investigated	O
by	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
and	O
western	B-T058
blot	I-T058
assay	I-T058
.	O

We	O
showed	O
that	O
the	O
expression	O
levels	O
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
were	O
decreased	O
both	O
in	O
ESCC	B-T038
tissues	B-T017
and	O
cell	B-T017
lines	I-T017
.	O

Furthermore	O
,	O
the	O
expression	O
levels	O
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
were	O
negatively	O
linked	O
to	O
lymph	B-T017
node	I-T017
metastasis	B-T038
in	O
ESCC	B-T038
tissues	B-T017
.	O

Restoration	O
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
in	O
EC	B-T017
-	I-T017
1	I-T017
cells	I-T017
by	O
using	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
mimics	O
could	O
decrease	O
the	O
invasion	B-T038
,	O
metastasis	B-T038
and	O
proliferation	B-T038
of	O
EC	B-T017
-	I-T017
1	I-T017
cells	I-T017
,	O
indicating	O
its	O
role	O
in	O
inhibition	O
on	O
the	O
invasion	B-T038
and	O
metastasis	B-T038
ability	O
of	O
ESCC	B-T038
cells	B-T017
and	O
tissues	B-T017
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
SMAD7	B-T017
was	O
a	O
specific	O
target	B-T017
gene	I-T017
for	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
by	O
luciferase	B-T058
activity	I-T058
assay	I-T058
and	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
could	O
not	O
only	O
negatively	B-T033
regulate	B-T038
SMAD7	B-T017
expression	B-T038
but	O
also	O
participate	O
in	O
EMT	B-T038
via	O
SMAD7	B-T017
,	O
because	O
overexpression	B-T038
of	O
SMAD7	B-T017
could	O
partly	O
enhance	O
the	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
anti	B-T033
-	I-T033
EMT	I-T033
function	O
.	O

Our	O
results	O
described	O
that	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
-	O
SMAD7	B-T017
pathway	B-T038
contributed	O
to	O
ESCC	B-T038
invasion	B-T038
and	O
metastasis	B-T038
and	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
miR	B-T017
-	I-T017
424	I-T017
-	I-T017
5p	I-T017
perhaps	O
provided	O
a	O
strategy	O
for	O
preventing	O
tumor	B-T033
invasion	I-T033
,	O
metastasis	B-T038
.	O

Double	B-T103
-	I-T103
Network	I-T103
Hydrogel	I-T103
with	O
Tunable	O
Mechanical	O
Performance	O
and	O
Biocompatibility	O
for	O
the	O
Fabrication	B-T170
of	O
Stem	B-T017
Cells	I-T017
-	O
Encapsulated	B-T103
Fibers	I-T103
and	O
3D	O
Assemble	O

Fabrication	B-T170
of	O
cell	B-T017
-	O
encapsulated	B-T103
fibers	I-T103
could	O
greatly	O
contribute	O
to	O
tissue	B-T058
engineering	I-T058
and	O
regenerative	B-T091
medicine	I-T091
.	O

However	O
,	O
existing	O
methods	O
suffered	O
from	O
not	O
only	O
unavoidability	O
of	O
cell	O
damaging	O
conditions	O
and	O
/	O
or	O
sophisticated	O
equipment	O
,	O
but	O
also	O
unavailability	O
of	O
proper	O
materials	O
to	O
satisfy	O
both	O
mechanical	O
and	O
biological	O
expectations	O
.	O

In	O
this	O
work	O
,	O
a	O
simple	O
method	O
is	O
proposed	O
to	O
prepare	O
cell	B-T017
-	O
encapsulated	B-T103
fibers	I-T103
with	O
tunable	O
mechanical	O
strength	O
and	O
stretching	O
behavior	O
as	O
well	O
as	O
diameter	O
and	O
microstructure	O
.	O

The	O
hydrogel	B-T103
fibers	B-T103
are	O
made	O
from	O
optimal	O
combination	O
of	O
alginate	B-T103
and	O
poly	B-T103
(	I-T103
N	I-T103
-	I-T103
iso	I-T103
-	I-T103
propylacrylamide	I-T103
)	I-T103
-	I-T103
poly	I-T103
(	I-T103
ethylene	I-T103
glycol	I-T103
)	I-T103
,	O
characteristics	O
of	O
double	B-T103
-	I-T103
network	I-T103
hydrogel	I-T103
,	O
with	O
enough	O
stiffness	B-T033
and	O
flexibility	O
to	O
create	O
a	O
variety	O
of	O
three	B-T082
dimensional	I-T082
structures	I-T082
like	O
parallel	O
helical	O
and	O
different	O
knots	O
without	O
crack	O
.	O

Furthermore	O
,	O
such	O
hydrogel	B-T103
fibers	B-T103
exhibit	O
better	O
compatibility	O
as	O
indicated	B-T033
by	O
the	O
viability	O
,	O
proliferation	O
and	O
expression	O
of	O
pluripotency	O
markers	B-T201
of	O
embryonic	B-T017
stem	I-T017
cells	I-T017
encapsulated	O
after	O
4	O
-	O
day	O
culture	B-T058
.	O

The	O
double	B-T103
-	I-T103
network	I-T103
hydrogel	I-T103
possesses	B-T038
specific	O
quick	O
responses	O
to	O
either	O
of	O
alginate	B-T103
lyase	I-T103
,	O
EDTA	B-T103
or	O
lower	O
environmental	O
temperature	O
which	O
facilitate	O
the	O
optional	O
degradation	O
of	O
fibers	B-T103
or	O
fibrous	O
assemblies	O
to	O
release	O
the	O
cells	B-T017
encapsulated	O
for	O
subsequent	O
assay	B-T058
or	O
treatment	B-T058
.	O

Synchronous	O
vitellogenin	B-T103
expression	B-T038
and	O
sexual	B-T038
maturation	I-T038
during	O
migration	B-T038
are	O
negatively	B-T033
correlated	O
with	O
juvenile	B-T103
hormone	I-T103
levels	O
in	O
Mythimna	B-T204
separata	I-T204

Annual	O
migration	B-T038
of	O
pests	O
between	O
different	O
seasonal	O
habitats	B-T082
can	O
lead	O
to	O
serious	O
crop	B-T204
damage	O
.	O

Reproductive	B-T038
immaturity	O
is	O
generally	O
associated	O
with	O
the	O
migratory	B-T038
process	I-T038
(	O
oogenesis	B-T038
-	O
flight	B-T038
syndrome	I-T038
)	O
,	O
but	O
the	O
mechanism	O
of	O
reproductive	O
development	O
during	O
migration	B-T038
varies	O
unpredictably	B-T033
.	O

Here	O
,	O
the	O
vitellogenin	B-T017
gene	I-T017
(	O
MsVg	B-T017
)	O
and	O
three	O
key	O
regulatory	B-T017
enzyme	I-T017
genes	I-T017
(	O
MsJhamt	B-T017
,	O
MsJheh	B-T017
and	O
MsJhe	B-T017
)	O
related	O
to	O
juvenile	B-T103
hormone	I-T103
(	O
JH	B-T103
)	O
synthesis	O
and	O
degradation	B-T038
were	O
identified	O
and	O
characterized	O
in	O
Mythimna	B-T204
separata	I-T204
.	O

The	O
relative	B-T038
expression	I-T038
of	O
MsVg	B-T017
varied	O
significantly	O
in	O
response	O
to	O
seasonal	O
changes	O
and	O
was	O
significantly	O
correlated	O
with	O
stages	O
of	O
ovarian	B-T038
development	I-T038
.	O

The	O
relatively	O
low	O
levels	O
of	O
JH	B-T103
titer	O
did	O
not	O
differ	O
significantly	O
in	O
male	O
moths	B-T204
but	O
slightly	O
increased	O
in	O
female	B-T098
adults	I-T098
during	O
the	O
migratory	B-T038
season	I-T038
,	O
which	O
was	O
consistent	O
with	O
changes	O
in	O
mRNA	B-T103
levels	O
for	O
MsJhamt	B-T017
,	O
MsJheh	B-T017
and	O
MsJhe	B-T017
.	O

JH	B-T103
titer	O
was	O
negatively	B-T033
associated	O
with	O
relative	O
seasonal	O
levels	O
of	O
vitellogenin	B-T103
mRNA	B-T103
transcripts	B-T103
and	O
with	O
ovarian	B-T038
development	I-T038
in	O
migrating	B-T038
M	B-T204
.	I-T204

separata	I-T204
.	O

The	O
synchrony	O
of	O
MsVg	B-T038
expression	I-T038
with	O
sexual	B-T038
maturation	I-T038
highlighted	O
the	O
potential	O
of	O
MsVg	B-T017
transcript	B-T103
levels	O
to	O
serve	O
as	O
an	O
index	B-T170
to	O
monitor	O
the	O
adult	O
reproductive	B-T038
status	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
JH	B-T103
and	O
sexual	B-T038
maturity	I-T038
were	O
correlated	O
with	O
the	O
extent	O
of	O
JH	B-T103
in	O
regulating	B-T038
the	O
MsVg	B-T038
expression	I-T038
and	O
reproduction	B-T038
during	O
seasonal	O
northern	B-T038
and	I-T038
southern	I-T038
migration	B-T038
.	O

Functional	O
Result	O
After	O
Cochlear	B-T058
Implantation	I-T058
in	O
Children	O
and	O
Adults	O
With	O
Single	B-T038
-	I-T038
sided	I-T038
Deafness	I-T038

Patients	O
with	O
single	B-T038
-	I-T038
sided	I-T038
deafness	I-T038
(	O
SSD	B-T038
)	O
suffer	O
from	O
reduced	O
binaural	O
hearing	O
(	O
i	O
.	O
e	O
.	O
,	O
sound	B-T038
localization	I-T038
and	O
speech	B-T038
in	O
noise	B-T038
discrimination	I-T038
)	O
.	O

Cochlear	B-T058
implantation	I-T058
has	O
recently	O
been	O
introduced	O
for	O
patients	O
with	O
SSD	B-T038
,	O
as	O
an	O
alternative	O
to	O
hearing	B-T074
devices	I-T074
that	O
employ	O
contralateral	B-T082
routing	O
of	O
the	O
signal	O
.	O

Application	B-T058
to	O
children	O
has	O
also	O
been	O
started	O
.	O

We	O
retrospectively	B-T062
analyze	O
a	O
case	O
series	O
of	O
4	O
children	O
and	O
17	O
adults	O
with	O
SSD	B-T038
,	O
treated	B-T058
with	I-T058
cochlear	B-T058
implantation	I-T058
.	O

The	O
outcome	O
of	O
adult	O
patients	O
was	O
compared	O
with	O
a	O
control	O
group	O
of	O
27	O
patients	O
with	O
bilateral	B-T038
profound	I-T038
hearing	I-T038
loss	I-T038
using	O
a	O
cochlear	B-T074
implant	I-T074
.	O

During	O
12	O
months	O
,	O
the	O
mean	O
speech	O
recognition	O
score	O
increased	O
from	O
30	O
to	O
41	O
%	O
for	O
monosyllabic	B-T170
words	I-T170
in	O
adults	O
,	O
and	O
from	O
58	O
to	O
89	O
%	O
for	O
multisyllabic	B-T170
numbers	O
.	O

The	O
cochlear	B-T074
implant	I-T074
(	O
CI	B-T074
)	O
improved	B-T033
hearing	I-T033
in	O
noise	O
in	O
all	O
SSD	B-T038
patients	O
,	O
as	O
was	O
demonstrated	O
by	O
a	O
significant	O
improvement	O
of	O
the	O
speech	B-T201
reception	I-T201
threshold	I-T201
in	O
different	O
speech	O
and	O
noise	O
configurations	O
.	O

Sound	B-T038
localization	I-T038
-	O
correlated	O
angle	B-T170
detection	I-T170
error	I-T170
improved	O
with	O
CI	B-T074
use	O
at	O
every	O
time	O
point	O
.	O

The	O
maximum	O
word	B-T038
recognition	I-T038
score	O
for	O
monosyllabic	B-T170
words	I-T170
in	O
quiet	O
correlated	O
with	O
the	O
logarithm	O
of	O
the	O
duration	O
of	O
deafness	B-T033
;	O
improvement	O
of	O
the	O
speech	B-T201
reception	I-T201
threshold	I-T201
and	O
RMS	B-T170
angle	I-T170
detection	I-T170
error	I-T170
by	O
the	O
CI	B-T074
did	O
not	O
.	O

All	O
SSD	B-T038
patients	O
benefitted	O
from	O
the	O
CI	B-T074
in	O
different	O
hearing	B-T038
situations	O
.	O

Patients	O
with	O
SSD	B-T038
for	O
a	O
long	O
period	O
can	O
improve	O
after	O
cochlear	B-T058
implantation	I-T058
.	O

CHOROIDAL	O
VASCULARITY	O
INDEX	O
:	O
A	O
Novel	O
Optical	B-T058
Coherence	I-T058
Tomography	I-T058
Based	O
Parameter	O
in	O
Patients	O
With	O
Exudative	B-T038
Age	I-T038
-	I-T038
Related	I-T038
Macular	I-T038
Degeneration	I-T038

To	O
evaluate	O
choroidal	B-T017
structural	B-T082
changes	O
in	O
exudative	B-T038
age	I-T038
-	I-T038
related	I-T038
macular	I-T038
degeneration	I-T038
(	O
AMD	B-T038
)	O
using	O
choroidal	O
vascularity	O
index	O
computed	O
from	O
image	O
binarization	O
on	O
spectral	B-T058
domain	I-T058
optical	I-T058
coherence	I-T058
tomography	I-T058
with	O
enhanced	O
depth	B-T058
imaging	I-T058
.	O

This	O
prospective	O
case	B-T062
series	I-T062
included	O
42	O
consecutive	O
patients	O
with	O
unilateral	B-T082
exudative	B-T038
AMD	I-T038
.	O

Choroidal	B-T017
images	B-T058
were	O
segmented	O
into	O
luminal	B-T082
area	B-T082
and	O
stromal	O
area	O
.	O

Choroidal	O
vascularity	O
index	O
was	O
defined	O
as	O
the	O
ratio	O
of	O
luminal	B-T082
area	B-T082
to	O
total	O
choroid	O
area	B-T082
.	O

Mean	O
choroidal	O
vascularity	O
index	O
and	O
mean	O
choroidal	O
thickness	O
between	O
study	B-T062
and	O
fellow	O
eyes	B-T017
of	O
the	O
same	O
patient	O
with	O
dry	O
AMD	B-T038
were	O
compared	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

There	O
was	O
a	O
significantly	O
lower	O
choroidal	O
vascularity	O
index	O
in	O
eyes	B-T017
with	O
exudative	B-T038
AMD	I-T038
(	O
60	O
.	O
14	O
±	O
4	O
.	O
55	O
vs	O
.	O

62	O
.	O
75	O
±	O
4	O
.	O
82	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Luminal	B-T082
area	I-T082
(	O
P	O
<	O
0	O
.	O
01	O
)	O
was	O
decreased	O
in	O
eyes	B-T017
with	O
exudative	B-T038
AMD	I-T038
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
total	O
choroid	O
area	B-T082
(	O
P	O
=	O
0	O
.	O
05	O
)	O
and	O
choroidal	O
thickness	O
(	O
P	O
=	O
0	O
.	O
93	O
)	O
between	O
study	B-T062
and	O
fellow	O
eyes	B-T017
.	O

Eyes	B-T017
with	O
exudative	B-T038
AMD	I-T038
demonstrated	O
reduced	O
choroidal	O
vascularity	O
index	O
but	O
insignificant	O
differences	O
in	O
choroidal	O
thickness	O
compared	O
with	O
their	O
fellow	O
eyes	B-T017
.	O

Choroidal	O
vascularity	O
index	O
may	O
be	O
a	O
potential	O
noninvasive	B-T033
tool	I-T033
for	O
studying	B-T062
structural	B-T082
changes	O
in	O
choroid	B-T017
and	O
monitoring	O
choroidal	B-T038
disease	I-T038
in	O
exudative	B-T038
AMD	I-T038
.	O

Comparison	O
of	O
Esophageal	B-T201
,	O
Rectal	B-T033
,	O
and	O
Gastrointestinal	O
Temperatures	O
During	O
Passive	O
Rest	O
After	O
Exercise	O
in	O
The	O
Heat	O
:	O
The	O
Influence	O
of	O
Hydration	B-T033

It	O
is	O
unknown	O
how	O
valid	O
esophageal	B-T201
,	O
rectal	B-T033
,	O
and	O
gastrointestinal	O
temperatures	O
(	O
TES	B-T201
,	O
TRE	B-T033
,	O
and	O
TGI	O
)	O
compare	O
after	O
exercise	O
-	O
induced	O
hyperthermia	B-T033
in	O
various	O
hydration	B-T033
states	I-T033
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
examine	O
the	O
differences	O
between	O
TES	B-T201
,	O
TRE	B-T033
,	O
and	O
TGI	O
during	O
passive	O
rest	O
following	O
exercise	O
-	O
induced	O
hyperthermia	B-T033
under	O
two	O
different	O
hydration	B-T033
states	I-T033
:	O
euhydrated	B-T033
(	O
EU	B-T033
)	O
and	O
hypohydrated	B-T038
(	O
HY	B-T038
)	O
.	O

Randomized	B-T062
-	I-T062
crossover	I-T062
design	I-T062
.	O

Controlled	O
laboratory	B-T092
setting	I-T092
.	O

Nine	O
recreationally	O
active	O
male	O
participants	B-T098
(	O
mean±	O
SD	O
;	O
age	O
,	O
24±4	O
;	O
height	O
,	O
177	O
.	O
3±9	O
.	O
9cm	O
;	O
body	O
mass	O
,	O
76	O
.	O
7±11	O
.	O
6kg	O
;	O
body	B-T201
fat	I-T201
,	O
14	O
.	O
7±5	O
.	O
8	O
%	O
)	O
.	O

Participants	B-T098
completed	O
two	O
trials	B-T062
(	O
EU	B-T033
and	O
HY	B-T038
)	O
consisting	O
of	O
a	O
bout	O
of	O
treadmill	O
exercise	O
(	O
a	O
10	O
minute	O
walk	O
ranging	O
4	O
.	O
8	O
-	O
7	O
.	O
2km	O
·	O
hr	O
(	O
-	O
1	O
)	O
at	O
a	O
5	O
%	O
grade	B-T170
followed	O
by	O
a	O
20	O
minute	O
jog	O
ranging	O
8	O
.	O
0	O
-	O
12	O
.	O
1km	O
·	O
hr	O
(	O
-	O
1	O
)	O
at	O
a	O
1	O
%	O
grade	O
)	O
in	O
a	O
hot	O
environment	O
(	O
ambient	O
temperature	O
,	O
39	O
.	O
3±1	O
.	O
0°C	O
;	O
relative	O
humidity	O
,	O
37	O
.	O
6±6	O
.	O
0	O
%	O
;	O
wet	O
bulb	O
globe	O
temperature	O
,	O
31	O
.	O
3±1	O
.	O
5°C	O
)	O
followed	O
by	O
passive	O
rest	O
.	O

Root	O
mean	O
squared	O
difference	O
(	O
RMSD	O
)	O
was	O
used	O
to	O
compare	O
the	O
variance	O
of	O
temperature	O
readings	O
at	O
corresponding	O
time	O
points	O
for	O
TRE	B-T033
vs	O
TGI	O
,	O
TRE	B-T033
vs	O
TES	B-T201
,	O
and	O
TGI	O
vs	O
TES	B-T201
in	O
EU	B-T033
and	O
HY	B-T038
.	O

RMSD	O
values	O
were	O
compared	O
using	O
three	O
-	O
way	O
repeated	O
measures	O
ANOVA	O
.	O

Post	O
hoc	O
analysis	B-T062
of	O
significant	O
main	O
effects	O
was	O
done	O
using	O
Tukey	B-T170
'	I-T170
s	I-T170
HSD	I-T170
with	O
significance	O
set	O
at	O
p	O
<	O
0	O
.	O
05	O
.	O

RMSD	O
values	O
(	O
°C	O
)	O
for	O
all	O
device	B-T074
comparisons	O
were	O
significantly	O
different	O
in	O
EU	B-T033
(	O
TRE	B-T033
-	O
TGI	O
,	O
0	O
.	O
11±0	O
.	O
12	O
;	O
TRE	B-T033
-	O
TES	B-T201
,	O
1	O
.	O
58±1	O
.	O
01	O
;	O
TGI	O
-	O
TES	B-T201
,	O
2	O
.	O
04±1	O
.	O
19	O
)	O
than	O
HY	B-T038
(	O
TRE	B-T033
-	O
TGI	O
,	O
0	O
.	O
22±0	O
.	O
28	O
;	O
TRE	B-T033
-	O
TES	B-T201
,	O
1	O
.	O
27±0	O
.	O
61	O
;	O
TGI	O
-	O
TES	B-T201
,	O
1	O
.	O
16±0	O
.	O
76	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Across	O
the	O
45	O
-	O
minute	O
bout	O
of	O
passive	O
rest	O
,	O
there	O
were	O
no	O
differences	O
in	O
TRE	B-T033
,	O
TGI	O
and	O
TES	B-T201
between	O
EU	B-T033
and	O
HY	B-T038
trials	B-T062
(	O
p	O
=	O
0	O
.	O
468	O
)	O
.	O

During	O
passive	O
rest	O
after	O
exercise	O
in	O
the	O
heat	O
,	O
TRE	B-T033
and	O
TGI	O
were	O
in	O
good	O
agreement	O
when	O
tracking	O
body	O
temperature	O
,	O
with	O
a	O
better	O
agreement	O
appearing	O
in	O
those	O
maintaining	O
a	O
state	O
of	O
euhydration	B-T033
versus	O
those	O
who	O
became	O
hypohydrated	B-T038
during	O
exercise	O
;	O
however	O
,	O
this	O
small	O
difference	O
does	O
not	O
appear	O
to	O
be	O
of	O
clinical	B-T033
significance	I-T033
.	O

Annexin	B-T103
A1	I-T103
restores	O
Aβ1	B-T103
-	I-T103
42	I-T103
-	O
induced	O
blood	B-T058
-	I-T058
brain	I-T058
barrier	I-T058
disruption	I-T058
through	O
the	O
inhibition	B-T038
of	O
RhoA	B-T038
-	I-T038
ROCK	I-T038
signaling	I-T038
pathway	I-T038

The	O
blood	B-T017
-	I-T017
brain	I-T017
barrier	I-T017
(	O
BBB	B-T017
)	O
is	O
composed	O
of	O
brain	B-T017
capillary	I-T017
endothelial	B-T017
cells	I-T017
and	O
has	O
an	O
important	O
role	O
in	O
maintaining	O
homeostasis	B-T038
of	O
the	O
brain	B-T017
separating	O
the	O
blood	B-T031
from	O
the	O
parenchyma	B-T017
of	O
the	O
central	B-T022
nervous	I-T022
system	I-T022
(	O
CNS	B-T022
)	O
.	O

It	O
is	O
widely	O
known	O
that	O
disruption	B-T058
of	I-T058
the	I-T058
BBB	I-T058
occurs	O
in	O
various	O
neurodegenerative	B-T038
diseases	I-T038
,	O
including	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
.	O

Annexin	B-T103
A1	I-T103
(	O
ANXA1	B-T103
)	O
,	O
an	O
anti	B-T103
-	I-T103
inflammatory	I-T103
messenger	I-T103
,	O
is	O
expressed	B-T038
in	O
brain	B-T017
endothelial	I-T017
cells	I-T017
and	O
regulates	O
the	O
BBB	B-T017
integrity	O
.	O

However	O
,	O
its	O
role	O
and	O
mechanism	O
for	O
protecting	O
BBB	B-T017
in	O
AD	B-T038
have	O
not	O
been	O
identified	O
.	O

We	O
found	O
that	O
β	B-T103
-	I-T103
Amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
(	O
Aβ42	B-T103
)	O
-	O
induced	O
BBB	B-T058
disruption	I-T058
was	O
rescued	O
by	O
human	B-T103
recombinant	I-T103
ANXA1	I-T103
(	O
hrANXA1	B-T103
)	O
in	O
the	O
murine	B-T103
brain	B-T017
endothelial	I-T017
cell	I-T017
line	I-T017
bEnd	I-T017
.	I-T017
3	I-T017
.	I-T017

Also	O
,	O
ANXA1	B-T103
was	O
decreased	O
in	O
the	O
bEnd	B-T017
.	I-T017
3	I-T017
cells	I-T017
,	O
the	O
capillaries	B-T017
of	O
5XFAD	O
mice	O
,	O
and	O
the	O
human	B-T031
serum	I-T031
of	O
patients	O
with	O
AD	B-T038
.	O

To	O
find	O
out	O
the	O
mechanism	O
by	O
which	O
ANXA1	B-T103
recovers	O
the	O
BBB	B-T017
integrity	O
in	O
AD	B-T038
,	O
the	O
RhoA	B-T038
-	I-T038
ROCK	I-T038
signaling	I-T038
pathway	I-T038
was	O
examined	O
in	O
both	O
Aβ42	B-T103
-	O
treated	O
bEnd	B-T017
.	I-T017
3	I-T017
cells	I-T017
and	O
the	O
capillaries	B-T017
of	O
5XFAD	O
mice	O
as	O
RhoA	B-T103
was	O
activated	O
in	O
both	O
cases	O
.	O

RhoA	O
inhibitors	O
alleviated	O
Aβ42	B-T103
-	O
induced	O
BBB	B-T058
disruption	I-T058
and	O
constitutively	O
overexpressed	B-T038
RhoA	B-T103
-	I-T103
GTP	I-T103
(	O
active	O
form	O
of	O
RhoA	B-T103
)	O
attenuated	O
the	O
protective	O
effect	O
of	O
ANXA1	B-T103
.	O

When	O
pericytes	B-T017
were	O
cocultured	B-T058
with	O
bEnd	B-T017
.	I-T017
3	I-T017
cells	I-T017
,	O
Aβ42	B-T103
-	O
induced	O
RhoA	O
activation	O
of	O
bEnd	B-T017
.	I-T017
3	I-T017
cells	I-T017
was	O
inhibited	O
by	O
the	O
secretion	B-T038
of	O
ANXA1	B-T103
from	O
pericytes	B-T017
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
ANXA1	B-T103
restores	O
Aβ42	B-T103
-	O
induced	O
BBB	B-T058
disruption	I-T058
through	O
inhibition	B-T038
of	O
RhoA	B-T038
-	I-T038
ROCK	I-T038
signaling	I-T038
pathway	I-T038
and	O
we	O
propose	O
ANXA1	B-T103
as	O
a	O
therapeutic	B-T103
reagent	I-T103
,	O
protecting	O
against	O
the	O
breakdown	B-T058
of	I-T058
the	I-T058
BBB	I-T058
in	O
AD	B-T038
.	O

Association	O
of	O
kidney	B-T038
disease	I-T038
with	O
obstructive	B-T038
sleep	I-T038
apnea	I-T038
in	O
a	O
population	B-T062
study	I-T062
of	O
men	B-T098

To	O
determine	B-T058
the	O
relationship	O
between	O
obstructive	B-T038
sleep	I-T038
apnea	I-T038
(	O
OSA	B-T038
)	O
and	O
chronic	B-T038
kidney	I-T038
disease	I-T038
(	O
CKD	B-T038
)	O
.	O

Previous	O
population	B-T062
studies	I-T062
of	O
the	O
association	O
are	O
sparse	O
,	O
conflicting	B-T033
and	O
confined	O
largely	O
to	O
studies	B-T062
of	O
administrative	B-T033
data	O
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
analysis	I-T062
in	O
unselected	O
participants	B-T098
of	O
the	O
Men	O
Androgens	O
Inflammation	O
Lifestyle	O
Environment	O
and	O
Stress	O
(	O
MAILES	O
)	O
study	O
,	O
aged	O
>	O
40	O
y	O
.	O

Renal	B-T017
data	O
were	O
available	O
on	O
812	O
men	B-T098
without	O
a	O
prior	O
OSA	B-T038
diagnosis	B-T033
who	O
underwent	O
full	O
in	B-T082
-	I-T082
home	I-T082
polysomnography	B-T058
(	O
Embletta	B-T074
X100	I-T074
)	O
in	O
2010	O
-	O
2011	O
.	O

CKD	B-T038
was	O
defined	O
as	O
an	O
estimated	B-T058
glomerular	I-T058
filtration	I-T058
rate	I-T058
(	O
eGFR	B-T058
)	O
<	O
60	O
mL	O
/	O
min	O
/	O
1	O
.	O
73m2	O
or	O
eGFR	B-T058
≥60	O
and	O
albuminuria	B-T033
(	O
albumin	O
creatinine	O
ratio	O
≥3	O
.	O
0	O
mg	O
/	O
mmol	O
)	O
.	O

CKD	B-T038
[	O
10	O
.	O
5	O
%	O
,	O
n	O
=	O
85	O
(	O
Stage	O
1	O
-	O
3	O
,	O
9	O
.	O
7	O
%	O
;	O
Stage	O
4	O
-	O
5	O
,	O
0	O
.	O
7	O
%	O
)	O
]	O
of	O
predominantly	O
mild	B-T033
severity	I-T033
showed	O
significant	O
association	O
s	O
with	O
OSA	B-T038
(	O
AHI≥10	O
)	O
:	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
1	O
.	O
9	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1	O
.	O
02	O
-	O
3	O
.	O
5	O
,	O
severe	O
OSA	B-T038
(	O
AHI	O
≥30	O
/	O
h	O
)	O
:	O
OR	O
=	O
2	O
.	O
6	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
6	O
.	O
2	O
,	O
and	O
respiratory	O
related	O
arousal	B-T038
index	B-T170
:	O
≥7	O
.	O
6	O
/	O
h	O
OR	O
=	O
2	O
.	O
3	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
1	O
-	O
4	O
.	O
7	O
,	O
but	O
not	O
measures	O
of	O
hypoxemia	B-T033
after	O
adjustment	O
for	O
age	O
,	O
hypertension	B-T038
,	O
diabetes	B-T038
,	O
smoking	O
,	O
obesity	B-T038
,	O
and	O
NSAID	B-T103
use	O
.	O

There	O
was	O
no	O
association	O
of	O
CKD	B-T038
with	O
daytime	B-T033
sleepiness	I-T033
.	O

In	O
men	B-T098
with	O
CKD	B-T038
,	O
those	O
with	O
OSA	B-T038
were	O
not	B-T033
significantly	I-T033
more	O
likely	O
to	O
report	B-T058
symptoms	B-T033
(	O
sleepiness	B-T033
,	O
snoring	B-T033
,	O
apneas	B-T038
)	O
or	O
be	O
identified	O
with	O
the	O
STOP	B-T062
OSA	I-T062
screening	I-T062
questionnaire	I-T062
,	O
compared	O
to	O
men	B-T098
without	O
OSA	B-T038
.	O

Predominantly	O
mild	O
CKD	B-T038
is	O
associated	O
with	O
severe	O
OSA	B-T038
and	O
arousals	B-T038
.	O

Further	O
population	B-T062
studies	I-T062
examining	B-T033
the	O
longitudinal	B-T082
relationship	O
between	O
CKD	B-T038
and	O
OSA	B-T038
are	O
warranted	O
.	O

Better	O
methods	B-T170
are	O
needed	O
to	O
identify	B-T038
OSA	B-T038
in	O
CKD	B-T038
which	O
may	O
have	O
few	O
symptoms	B-T033
.	O

Evidence	O
that	O
vitronectin	B-T103
is	O
a	O
potent	O
migration	B-T103
-	I-T103
enhancing	I-T103
factor	I-T103
for	O
cancer	B-T017
cells	I-T017
chaperoned	B-T103
by	O
fibrinogen	B-T103
:	O
a	O
novel	O
view	O
of	O
the	O
metastasis	B-T038
of	O
cancer	B-T017
cells	I-T017
to	O
low	O
-	O
fibrinogen	B-T103
lymphatics	B-T022
and	O
body	B-T082
cavities	I-T082

Diluted	O
(	O
1	O
%	O
)	O
plasma	B-T031
induces	O
migration	B-T038
of	O
malignant	B-T017
cell	I-T017
lines	I-T017
much	O
more	O
strongly	O
than	O
potent	O
pro	O
-	O
metastatic	O
factors	O
.	O

To	O
characterize	O
the	O
factor	O
(	O
s	O
)	O
present	O
in	O
diluted	O
plasma	B-T031
responsible	O
for	O
this	O
phenomenon	O
we	O
performed	O
i	O
)	O
heat	O
inactivation	O
,	O
ii	O
)	O
dialysis	O
,	O
iii	O
)	O
proteinase	B-T103
K	I-T103
treatment	O
,	O
and	O
iv	O
)	O
molecular	O
size	O
filtration	O
studies	O
.	O

We	O
found	O
that	O
this	O
remarkable	O
pro	O
-	O
migratory	O
activity	O
of	O
diluted	O
normal	O
plasma	B-T031
is	O
associated	O
with	O
a	O
~	O
50	O
-	O
100	O
-	O
kD	O
protein	B-T103
that	O
interacts	O
with	O
GαI	B-T103
protein	I-T103
-	I-T103
coupled	I-T103
receptors	I-T103
and	O
activates	O
p42	B-T103
/	I-T103
44	I-T103
MAPK	I-T103
and	O
AKT	B-T038
signaling	I-T038
in	O
target	O
cells	B-T017
.	O

Since	O
this	O
pro	O
-	O
migratory	O
activity	O
of	O
1	O
%	O
plasma	B-T031
decreases	O
at	O
higher	O
plasma	O
concentrations	O
(	O
>	O
20	O
%	O
)	O
,	O
but	O
is	O
retained	O
in	O
serum	B-T031
,	O
we	O
hypothesized	O
that	O
fibrinogen	B-T103
may	O
be	O
involved	O
as	O
a	O
chaperone	B-T103
of	O
the	O
protein	B-T103
(	I-T103
s	I-T103
)	I-T103
.	O

To	O
identify	O
the	O
pro	B-T103
-	I-T103
migratory	I-T103
protein	I-T103
(	I-T103
s	I-T103
)	I-T103
present	O
in	O
diluted	O
plasma	B-T031
and	O
fibrinogen	B-T103
-	O
depleted	O
serum	B-T031
,	O
we	O
performed	O
gel	B-T058
filtration	I-T058
and	O
hydrophobic	B-T058
interaction	I-T058
chromatography	I-T058
followed	O
by	O
mass	B-T058
spectrometry	I-T058
analysis	I-T058
.	O

We	O
identified	O
several	O
putative	O
protein	B-T103
candidates	O
that	O
were	O
further	O
tested	O
in	O
in	O
vitro	O
experiments	B-T062
.	O

We	O
found	O
that	O
this	O
pro	B-T103
-	I-T103
migratory	I-T103
factor	I-T103
chaperoned	B-T103
by	O
fibrinogen	B-T103
is	O
vitronectin	B-T103
,	O
which	O
activates	O
uPAR	O
,	O
and	O
that	O
this	O
effect	O
can	O
be	O
inhibited	O
by	O
fibrinogen	B-T103
.	O

These	O
results	O
provide	O
a	O
novel	O
mechanism	O
for	O
the	O
metastasis	B-T038
of	O
cancer	B-T017
cells	I-T017
to	O
lymphatics	B-T022
and	O
body	B-T082
cavities	I-T082
,	O
in	O
which	O
the	O
concentration	O
of	O
fibrinogen	B-T103
is	O
low	O
,	O
and	O
thus	O
suggests	O
that	O
free	O
vitronectin	B-T103
stimulates	O
migration	B-T038
of	O
tumor	B-T017
cells	I-T017
.	O

Development	O
and	O
initial	O
validation	B-T062
of	O
the	O
Respirator	O
Comfort	B-T038
,	O
Wearing	B-T038
Experience	I-T038
,	O
and	O
Function	O
Instrument	B-T074
[	O
R	B-T074
-	I-T074
COMFI	I-T074

Filtering	O
face	O
-	O
piece	O
respirators	O
(	O
FFRs	O
)	O
are	O
worn	O
to	O
protect	O
health	B-T097
care	I-T097
personnel	I-T097
from	O
airborne	B-T103
particles	I-T103
;	O
however	O
,	O
clinical	B-T062
studies	I-T062
have	O
demonstrated	O
that	O
FFR	O
adherence	O
is	O
relatively	O
low	O
in	O
some	O
settings	O
,	O
in	O
part	B-T082
,	O
due	O
to	O
discomfort	B-T033
and	O
intolerance	B-T038
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
develop	O
and	O
initially	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
an	O
instrument	B-T074
designed	O
to	O
measure	O
the	O
comfort	B-T038
and	O
tolerability	O
of	O
FFRs	O
.	O

Instrument	B-T074
items	O
were	O
developed	O
through	O
literature	B-T170
reviews	I-T170
,	O
focus	O
groups	O
,	O
and	O
several	O
iterations	B-T033
of	O
ranking	B-T170
and	O
refining	O
by	O
experts	B-T097
.	O

Psychometric	B-T058
evaluation	I-T058
of	O
the	O
instrument	B-T074
was	O
conducted	O
using	O
Rasch	B-T170
partial	I-T170
credit	I-T170
model	I-T170
(	O
PCM	B-T170
)	O
analysis	B-T062
.	O

Pivot	B-T170
anchoring	I-T170
was	O
used	O
to	O
specify	O
the	O
threshold	O
defining	O
item	O
difficulty	O
;	O
in	O
our	O
analyses	B-T062
,	O
this	O
was	O
the	O
point	O
that	O
participants	B-T098
moved	O
from	O
possessing	O
none	O
of	O
the	O
trait	O
to	O
some	O
of	O
the	O
trait	O
.	O

The	O
final	O
instrument	B-T074
was	O
completed	O
by	O
165	O
health	B-T097
care	I-T097
personnel	I-T097
from	O
3	O
Veterans	B-T098
Health	B-T058
Administration	I-T058
facilities	I-T058
,	O
and	O
data	O
were	O
analyzed	B-T062
using	O
Rasch	B-T170
PCM	I-T170
.	O

Seven	O
items	O
were	O
removed	O
because	O
they	O
:	O
(	O
1	O
)	O
violated	O
the	O
assumption	O
of	O
independence	O
;	O
(	O
2	O
)	O
were	O
mis	O
-	O
fitting	O
;	O
and	O
/	O
or	O
(	O
3	O
)	O
were	O
deemed	O
not	O
relevant	O
.	O

Category	B-T170
function	O
analysis	B-T062
demonstrated	O
that	O
all	O
categories	B-T170
progressed	O
monotonically	O
.	O

Principal	O
components	O
analysis	O
demonstrated	O
the	O
existence	O
of	O
three	O
subscales	O
(	O
Discomfort	B-T033
,	O
General	O
Wearing	B-T038
Experience	I-T038
,	O
and	O
Function	O
)	O
.	O

Final	O
reliability	O
analyses	B-T062
showed	O
that	O
the	O
scale	O
had	O
moderate	O
to	O
high	O
person	O
reliability	O
and	O
high	O
item	O
reliability	O
.	O

The	O
final	O
instrument	B-T074
contained	O
21	O
items	O
.	O

Until	O
now	O
,	O
to	O
our	O
knowledge	B-T038
no	O
instrument	B-T074
with	O
evidence	O
supporting	O
its	O
reliability	O
and	O
validity	O
to	O
assess	O
discomfort	B-T033
and	O
tolerance	O
of	O
FFRs	O
among	O
health	B-T097
care	I-T097
personnel	I-T097
has	O
been	O
published	O
.	O

A	O
21	O
-	O
item	O
psychometrically	O
sound	O
measure	O
of	O
comfort	B-T038
and	O
tolerability	O
of	O
FFRs	O
,	O
Respirator	O
Comfort	B-T038
,	O
Wearing	B-T038
Experience	I-T038
,	O
and	O
Function	O
Instrument	B-T074
(	O
R	B-T074
-	I-T074
COMFI	I-T074
)	O
,	O
was	O
developed	O
.	O

The	O
significance	O
of	O
developing	O
such	O
an	O
instrument	B-T074
is	O
that	O
it	O
will	O
help	O
identify	O
respirators	O
that	O
are	O
likely	O
to	O
have	O
better	O
adherence	O
in	O
practice	B-T038
settings	O
.	O

The	O
R	B-T074
-	I-T074
COMFI	I-T074
may	O
be	O
used	O
within	B-T082
and	O
beyond	O
the	O
VA	B-T092
healthcare	I-T092
system	I-T092
as	O
a	O
psychometrically	B-T074
sound	I-T074
instrument	I-T074
to	O
evaluate	O
the	O
comfort	B-T038
and	O
tolerability	O
of	O
respirators	O
,	O
including	O
developmental	O
prototypes	O
.	O

Kidney	B-T033
transplant	I-T033
recipients	I-T033
after	O
nonrenal	B-T058
solid	I-T058
organ	I-T058
transplantation	I-T058
show	O
low	O
alloreactivity	B-T038
but	O
an	O
increased	O
risk	O
of	O
infection	B-T038

The	O
number	O
of	O
kidney	B-T033
transplant	I-T033
recipients	I-T033
(	O
KTRs	B-T033
)	O
after	O
nonrenal	B-T058
solid	I-T058
organ	I-T058
transplantation	I-T058
(	O
SOT	B-T058
)	O
has	O
increased	O
to	O
almost	O
5	O
%	O
.	O

Knowledge	O
on	O
patient	O
and	O
allograft	B-T058
outcomes	O
,	O
infections	B-T038
,	O
and	O
alloreactivity	B-T038
,	O
however	O
,	O
remains	O
scarce	O
.	O

We	O
studied	B-T062
40	O
KTRs	B-T033
after	O
nonrenal	B-T058
SOT	I-T058
.	O

Seven	O
hundred	O
and	O
twenty	O
primary	O
KTRs	B-T033
and	O
119	O
repeat	O
KTRs	B-T033
were	O
used	O
for	O
comparison	O
.	O

Samples	B-T031
were	O
collected	O
pretransplantation	O
,	O
at	O
+	O
1	O
,	O
+	O
2	O
,	O
and	O
+	O
3	O
months	O
post	O
-	O
transplantation	O
.	O

Alloreactive	B-T038
and	O
CMV	B-T005
-	I-T005
specific	I-T005
T	B-T017
cells	I-T017
were	O
measured	O
by	O
interferon	B-T058
-	I-T058
γ	I-T058
ELISPOT	I-T058
assay	I-T058
.	O

Patient	O
survival	O
in	O
KTRs	B-T033
after	O
SOT	B-T058
,	O
primary	O
and	O
repeat	O
KTRs	B-T033
was	O
comparable	O
.	O

While	O
death	B-T038
-	O
censored	O
allograft	B-T058
survival	O
was	O
comparable	O
between	O
KTRs	B-T033
after	O
SOT	B-T058
and	O
primary	O
KTRs	B-T033
,	O
KTRs	B-T033
after	O
SOT	B-T058
showed	O
superior	O
5	O
-	O
year	O
death	B-T038
-	O
censored	O
allograft	B-T058
survival	O
of	O
92	O
.	O
5	O
%	O
compared	O
to	O
81	O
.	O
2	O
%	O
in	O
repeat	O
KTRs	B-T033
.	O

Interestingly	O
,	O
KTRs	B-T033
after	O
SOT	B-T058
show	O
less	O
preformed	O
panel	B-T058
-	I-T058
reactive	I-T058
antibodies	I-T058
,	O
frequencies	O
of	O
alloreactive	B-T038
T	B-T017
cells	I-T017
,	O
and	O
acute	B-T033
rejections	I-T033
compared	O
to	O
repeat	O
KTRs	B-T033
.	O

KTRs	B-T033
after	O
SOT	B-T058
,	O
however	O
,	O
show	O
higher	O
incidences	O
of	O
EBV	B-T038
viremia	I-T038
and	O
PTLD	B-T038
,	O
sepsis	B-T038
,	O
and	O
death	B-T038
from	O
sepsis	B-T038
.	O

Impaired	O
CMV	B-T005
-	I-T005
specific	I-T005
cellular	B-T038
immunity	I-T038
was	O
associated	O
with	O
more	O
CMV	B-T005
replication	B-T038
compared	O
to	O
repeat	O
KTRs	B-T033
.	O

Our	O
results	O
suggest	O
comparable	O
patient	O
and	O
allograft	B-T058
outcomes	O
in	O
KTRs	B-T033
after	O
SOT	B-T058
and	O
primary	O
KTRs	B-T033
.	O

The	O
observed	O
low	O
alloreactivity	B-T038
may	O
contribute	O
to	O
excellent	O
allograft	B-T058
outcomes	O
.	O

Caution	O
should	O
be	O
taken	O
in	O
KTRs	B-T033
after	O
SOT	B-T058
regarding	O
infectious	O
complications	O
due	O
to	O
overimmunosuppression	B-T038
.	O

Improved	B-T033
protocol	B-T170
for	O
the	O
isolation	B-T058
of	O
naïve	O
follicular	B-T017
dendritic	I-T017
cells	I-T017

Follicular	B-T017
dendritic	I-T017
cells	I-T017
(	O
FDCs	B-T017
)	O
in	O
lymphoid	B-T017
organs	I-T017
play	O
an	O
important	O
role	O
in	O
the	O
humoral	B-T038
immune	I-T038
response	I-T038
.	O

However	O
,	O
because	O
the	O
isolation	B-T058
of	O
FDCs	B-T017
is	O
difficult	O
due	O
to	O
their	O
very	O
small	O
population	O
size	O
and	O
fragility	B-T038
under	O
mechanical	O
and	O
chemical	O
stresses	O
,	O
the	O
genetic	O
and	O
biochemical	O
characteristics	O
of	O
FDCs	B-T017
remain	O
unclear	O
.	O

Previously	O
,	O
we	O
identified	O
FDCs	B-T017
as	O
ICAM	B-T103
-	I-T103
1	I-T103
(	I-T103
+	I-T103
)	I-T103
cells	B-T017
in	O
the	O
CD45	B-T103
(	B-T033
-	I-T033
)	I-T033
non	B-T017
-	I-T017
hematopoietic	I-T017
cell	I-T017
fraction	I-T017
from	O
naïve	O
mouse	B-T017
spleen	I-T017
after	O
cell	B-T058
separation	I-T058
by	O
means	O
of	O
digestion	O
with	O
a	O
combination	O
of	O
enzymes	B-T103
.	O

In	O
the	O
present	O
study	O
,	O
using	O
a	O
new	O
combination	O
of	O
enzymes	B-T103
,	O
we	O
found	O
that	O
FDCs	B-T017
are	O
highly	O
enriched	O
in	O
the	O
CD45	B-T103
(	B-T033
-	I-T033
)	I-T033
ICAM	B-T103
-	I-T103
1	I-T103
(	I-T103
+	I-T103
)	I-T103
CD21	B-T103
/	O
35	B-T103
(	I-T103
+	I-T103
)	I-T103
cell	B-T017
fraction	I-T017
.	O

CD45	B-T103
(	B-T033
-	I-T033
)	I-T033
ICAM	B-T103
-	I-T103
1	I-T103
(	I-T103
+	I-T103
)	I-T103
CD21	B-T103
/	O
35	B-T103
(	I-T103
+	I-T103
)	I-T103
cells	B-T017
in	O
the	O
mouse	B-T017
spleen	I-T017
retained	O
an	O
antigen	B-T103
administered	O
in	B-T082
vivo	I-T082
for	O
more	O
than	O
7	O
days	O
.	O

Moreover	O
,	O
CD45	B-T103
(	B-T033
-	I-T033
)	I-T033
ICAM	B-T103
-	I-T103
1	I-T103
(	I-T103
+	I-T103
)	I-T103
CD21	B-T103
/	O
35	B-T103
(	I-T103
+	I-T103
)	I-T103
cells	B-T017
isolated	O
from	O
the	O
spleen	B-T017
of	I-T017
mice	I-T017
administered	O
with	O
a	O
cognate	B-T103
antigen	I-T103
enhanced	O
the	O
survival	B-T038
and	O
proliferation	O
of	O
antigen	B-T017
-	I-T017
specific	I-T017
B	I-T017
cells	I-T017
in	O
vitro	O
.	O

Our	O
improved	B-T033
protocol	B-T170
for	O
the	O
isolation	B-T058
of	O
naïve	O
FDCs	B-T017
will	O
be	O
useful	O
for	O
the	O
analysis	B-T062
of	O
FDCs	B-T017
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

Dental	O
enamel	B-T033
defects	I-T033
in	O
German	B-T098
medieval	O
and	O
early	O
-	O
modern	O
-	O
age	O
populations	B-T098

Aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
the	O
frequency	O
and	O
type	O
of	O
developmental	B-T033
defects	I-T033
of	I-T033
enamel	I-T033
(	O
DDE	B-T033
)	O
in	O
a	O
medieval	O
and	O
an	O
early	O
-	O
modern	O
-	O
age	O
population	B-T098
from	O
Thuringia	B-T082
,	I-T082
Germany	I-T082
.	O

Sixty	O
-	O
six	O
skeletons	B-T022
subdivided	O
into	O
31	O
single	O
burials	O
(	O
12	O
(	O
th	O
)	O
/	O
13	O
(	O
th	O
)	O
c	O
.	O
)	O
and	O
35	O
individuals	B-T098
buried	O
in	O
groups	O
(	O
15	O
(	O
th	O
)	O
/	O
16	O
(	O
th	O
)	O
c	O
.	O
)	O
were	O
examined	B-T033
.	O

DDE	B-T033
were	O
classified	B-T170
on	O
1	O
,	O
246	O
teeth	B-T017
according	O
to	O
the	O
DDE	B-T033
index	B-T170
.	O

Molar	B-T038
-	I-T038
incisor	I-T038
-	I-T038
hypomineralisation	I-T038
(	O
MIH	B-T038
)	O
,	O
a	O
special	O
type	O
of	O
DDE	B-T033
,	O
was	O
recorded	B-T170
according	O
to	O
the	O
European	B-T092
Academy	I-T092
of	I-T092
Paediatric	I-T092
Dentistry	I-T092
(	O
EAPD	B-T092
)	O
criteria	O
.	O

DDE	B-T033
was	O
found	O
in	O
89	O
.	O
4	O
%	O
of	O
the	O
individuals	B-T098
(	O
single	O
burials	O
90	O
.	O
3	O
%	O
and	O
group	O
burials	O
88	O
.	O
6	O
%	O
)	O
.	O

Hypoplastic	O
pits	B-T033
were	O
the	O
most	O
frequent	O
defect	O
in	O
primary	B-T017
teeth	I-T017
and	O
linear	B-T038
enamel	I-T038
hypoplasia	I-T038
(	O
LEH	B-T038
)	O
in	O
permanent	B-T017
teeth	I-T017
.	O

13	O
individuals	B-T098
(	O
24	O
.	O
1	O
%	O
)	O
showed	O
at	O
least	O
one	O
hypomineralised	B-T038
permanent	B-T017
tooth	I-T017
,	O
12	O
.	O
2	O
%	O
had	O
MIH	B-T038
on	O
at	O
least	O
one	O
first	O
permanent	B-T017
molar	I-T017
and	O
10	O
.	O
0	O
%	O
in	O
permanent	B-T017
incisors	I-T017
.	O

Second	B-T017
primary	I-T017
molars	I-T017
were	O
affected	O
in	O
8	O
.	O
0	O
%	O
of	O
the	O
children	O
and	O
juveniles	O
.	O

No	O
individual	B-T098
suffered	O
from	O
affected	O
molars	B-T017
and	O
incisors	B-T017
in	O
combination	O
.	O

Endogenous	O
factors	O
like	O
nutritional	B-T038
deficiencies	I-T038
and	O
health	O
problems	O
in	O
early	O
childhood	O
could	O
have	O
been	O
aetiological	O
reasons	O
of	O
DDE	B-T033
and	O
MIH	B-T038
.	O

The	O
frequency	O
of	O
DDE	B-T033
and	O
MIH	B-T038
might	O
have	O
been	O
masked	B-T062
by	O
extended	B-T082
carious	B-T038
lesions	I-T038
,	O
dental	B-T037
wear	I-T037
and	O
ante	B-T033
-	I-T033
mortem	I-T033
tooth	B-T017
loss	I-T017
.	O

Breast	B-T038
Cancer	I-T038
Detection	O
Rate	O
,	O
Incidence	O
,	O
Prevalence	O
and	O
Interval	O
Cancer	B-T038
-	O
related	O
Mammography	B-T058
Screening	I-T058
Times	O
among	O
Thai	B-T098
Women	B-T098

A	O
recent	O
guideline	B-T170
by	O
the	O
American	B-T092
Cancer	I-T092
Society	I-T092
recommended	O
that	O
mammography	B-T058
(	O
MMG	B-T058
)	O
should	O
be	O
done	O
for	O
women	B-T098
starting	O
in	O
their	O
mid	O
-	O
40s	O
.	O

In	O
Thailand	B-T082
,	O
information	O
on	O
opportunistic	B-T058
mammography	I-T058
screening	I-T058
is	O
limited	O
and	O
data	O
on	O
the	O
total	O
incidence	O
of	O
breast	B-T038
cancer	I-T038
are	O
also	O
lacking	O
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
estimate	O
the	O
breast	B-T038
cancer	I-T038
detection	B-T058
,	O
incident	O
and	O
prevalence	O
rates	O
among	O
Thai	B-T098
women	B-T098
.	O

We	O
retrospectively	O
reviewed	O
the	O
opportunistic	B-T058
mammography	I-T058
screening	I-T058
of	O
normal	O
women	B-T098
between	O
30	O
and	O
80	O
years	O
who	O
underwent	O
the	O
procedure	B-T058
between	O
2001	O
and	O
2010	O
.	O

All	O
cases	O
were	O
followed	O
until	O
2012	O
.	O

The	O
detection	O
rate	O
was	O
calculated	O
for	O
the	O
whole	O
period	O
of	O
observation	B-T062
using	O
'	O
number	O
of	O
women	B-T098
with	O
positive	B-T033
findings	I-T033
'	O
divided	O
by	O
'	O
total	O
number	O
of	O
women	B-T098
screened	B-T058
'	O
.	O

The	O
incidence	O
rate	O
was	O
calculated	O
only	O
at	O
the	O
first	O
MMG	B-T058
while	O
the	O
subsequence	O
rate	O
was	O
calculated	O
based	O
on	O
all	O
new	O
cases	O
detected	B-T033
at	O
each	O
subsequent	O
MMG	B-T058
.	O

Among	O
the	O
47	O
,	O
430	O
women	B-T098
,	O
there	O
were	O
152	O
,	O
091	O
MMGs	B-T058
or	O
approximately	O
3	O
.	O
2	O
occasions	O
per	O
person	B-T098
(	O
range	O
,	O
1	O
-	O
10	O
)	O
.	O

The	O
average	O
duration	O
of	O
the	O
interval	O
between	O
each	O
subsequence	O
visit	O
was	O
1	O
.	O
8	O
years	O
.	O

Overall	O
,	O
breast	B-T038
cancer	I-T038
was	O
detected	B-T033
in	O
543	O
women	B-T098
,	O
with	O
a	O
detection	O
rate	O
of	O
10	O
.	O
3	O
per	O
1	O
,	O
000	O
persons	B-T098
.	O

The	O
prevalence	O
rate	O
of	O
breast	B-T038
cancer	I-T038
at	O
the	O
first	O
visit	O
was	O
5	O
.	O
78	O
per	O
1	O
,	O
000	O
person	B-T098
s	O
.	O

The	O
incidence	O
or	O
new	O
cases	O
detected	B-T033
at	O
any	O
follow	O
-	O
up	O
visit	O
was	O
10	O
.	O
4	O
per	O
1	O
,	O
000	O
person	B-T098
s	O
.	O

The	O
overall	O
interval	O
cancer	O
was	O
0	O
.	O
91	O
per	O
1	O
,	O
000	O
women	B-T098
,	O
mainly	O
detected	B-T033
before	O
their	O
second	O
and	O
third	O
MMG	B-T058
,	O
with	O
a	O
rate	O
of	O
0	O
.	O
0	O
.	O
47	O
and	O
0	O
.	O
76	O
per	O
1	O
,	O
000	O
women	B-T098
.	O

Opportunistic	B-T058
mammography	I-T058
screening	I-T058
in	O
Thailand	B-T082
detected	B-T033
10	O
cases	O
of	O
breast	B-T038
cancer	I-T038
from	O
each	O
1	O
,	O
000	O
women	B-T098
.	O

This	O
paper	O
indicated	O
a	O
high	O
rate	O
of	O
cancer	B-T058
detection	I-T058
during	O
a	O
two	O
year	O
interval	O
,	O
hence	O
,	O
a	O
screening	B-T058
mammogram	I-T058
should	O
be	O
performed	O
more	O
often	O
.	O

Assessment	O
of	O
groundwater	B-T082
vulnerability	O
in	O
the	O
Daule	O
aquifer	O
,	O
Ecuador	B-T082
,	O
using	O
the	O
susceptibility	B-T058
index	I-T058
method	I-T058

The	O
Guayas	B-T082
region	I-T082
in	O
Ecuador	B-T082
is	O
economically	O
very	O
important	O
,	O
producing	O
68	O
%	O
of	O
the	O
national	B-T204
crops	I-T204
.	O

The	O
main	O
agricultural	O
activities	O
threaten	O
the	O
groundwater	B-T082
therein	O
with	O
nitrate	B-T103
contamination	O
given	O
the	O
large	O
fertiliser	B-T103
and	O
water	B-T103
needs	O
.	O

The	O
present	O
work	O
tests	O
the	O
applicability	O
of	O
the	O
susceptibility	B-T058
index	I-T058
assessment	I-T058
method	I-T058
in	O
evaluating	O
the	O
impact	O
of	O
agricultural	O
activities	O
on	O
groundwater	B-T082
quality	O
,	O
using	O
as	O
a	O
case	O
study	O
an	O
aquifer	O
of	O
the	O
Guayas	B-T082
river	B-T082
basin	I-T082
in	O
Ecuador	B-T082
.	O

The	O
index	O
adapts	O
four	O
parameters	O
of	O
the	O
DRASTIC	B-T058
method	I-T058
and	O
incorporated	O
a	O
new	O
land	O
use	O
parameter	O
.	O

Results	O
show	O
that	O
the	O
areas	B-T082
highly	O
vulnerable	O
to	O
contamination	O
are	O
located	O
in	O
irrigation	O
perimeters	B-T082
of	O
dominant	O
paddy	B-T082
fields	I-T082
associated	O
with	O
the	O
high	O
recharge	O
rates	O
in	O
the	O
alluvial	B-T103
deposits	I-T103
.	O

Respectively	O
,	O
moderately	O
vulnerable	O
and	O
low	O
-	O
vulnerability	O
areas	B-T082
correspond	O
to	O
aquatic	O
environments	O
and	O
forests	O
,	O
semi	B-T082
-	I-T082
natural	I-T082
zones	I-T082
and	O
water	O
bodies	O
.	O

One	O
of	O
the	O
main	O
contributions	O
of	O
the	O
Daule	O
aquifer	O
vulnerability	O
is	O
likely	O
its	O
wide	B-T082
,	O
flat	B-T082
topography	I-T082
.	O

A	O
great	O
part	O
of	O
the	O
aquifer	O
is	O
at	O
high	O
risk	O
of	O
contamination	O
by	O
nitrates	B-T103
if	O
a	O
code	O
of	O
good	O
agricultural	O
practices	O
is	O
not	O
applied	O
.	O

Therefore	O
the	O
implementation	O
of	O
a	O
monitoring	B-T033
network	I-T033
to	I-T033
control	I-T033
the	O
nitrates	B-T103
concentrations	O
is	O
the	O
first	O
step	O
to	O
assure	O
groundwater	B-T082
quality	O
for	O
drinking	O
purposes	O
.	O

Heterogeneous	O
depression	B-T038
trajectories	O
in	O
multiple	B-T038
sclerosis	I-T038
patients	O

Trajectories	O
of	O
depression	B-T038
over	O
time	O
may	O
be	O
heterogeneous	O
in	O
Multiple	B-T038
Sclerosis	I-T038
(	O
MS	B-T038
)	O
patients	O
.	O

Describing	O
these	O
trajectories	O
will	O
help	O
clinicians	B-T097
understand	O
better	O
the	O
progression	O
of	O
depression	B-T038
in	O
MS	B-T038
patients	O
to	O
aid	O
in	O
patient	O
care	O
decisions	O
.	O

Latent	O
class	O
growth	O
analysis	O
(	O
LCGA	O
)	O
was	O
applied	O
to	O
3507	O
MS	B-T038
patients	O
using	O
an	O
electronic	B-T170
health	I-T170
records	I-T170
(	I-T170
EHR	I-T170
)	I-T170
data	I-T170
base	I-T170
to	O
identify	O
subgroups	B-T098
of	O
MS	B-T038
patients	O
based	O
on	O
self	O
-	O
reported	O
depression	B-T058
screening	I-T058
(	O
PHQ	O
-	O
9	O
)	O
.	O

Latent	O
trajectory	O
classes	O
were	O
used	O
for	O
group	B-T098
comparisons	O
based	O
on	O
baseline	O
clinical	O
characteristics	O
.	O

Three	O
subgroups	B-T098
were	O
found	O
characterized	O
by	O
high	O
(	O
10	O
.	O
0	O
%	O
[	O
of	O
participants	B-T098
]	O
)	O
,	O
wavering	O
above	O
and	O
below	O
moderate	O
(	O
26	O
.	O
2	O
%	O
)	O
and	O
low	O
and	O
variable	O
(	O
63	O
.	O
8	O
%	O
)	O
depression	B-T033
level	I-T033
trajectories	O
.	O

The	O
subpopulation	B-T098
trajectories	O
,	O
respectively	O
,	O
were	O
also	O
characterized	O
by	O
high	O
,	O
moderate	O
and	O
low	O
MS	B-T038
disability	B-T033
at	O
baseline	O
.	O

In	O
contrast	O
,	O
the	O
overall	O
average	O
trajectory	O
was	O
slightly	O
declining	O
and	O
below	O
the	O
moderate	O
depression	B-T038
threshold	O
.	O

The	O
LCGA	O
approach	O
described	O
in	O
this	O
paper	O
and	O
applied	O
to	O
MS	B-T038
patients	O
provides	O
a	O
template	O
for	O
improved	O
use	O
of	O
an	O
EHR	B-T170
data	I-T170
base	I-T170
for	O
understanding	O
heterogeneous	O
depression	B-T058
screening	I-T058
trajectories	O
.	O

Clinicians	B-T097
may	O
use	O
such	O
information	O
to	O
more	O
closely	O
monitor	B-T058
patients	I-T058
that	O
are	O
expected	O
to	O
maintain	O
high	O
or	O
unstable	B-T033
depression	B-T033
levels	I-T033
.	O

The	O
PLA2	B-T017
gene	I-T017
mediates	O
the	O
humoral	B-T038
immune	I-T038
responses	I-T038
in	O
Bactrocera	B-T204
dorsalis	I-T204
(	I-T204
Hendel	I-T204
)	I-T204

The	O
phospholipase	B-T017
A2	I-T017
(	I-T017
PLA2	I-T017
)	I-T017
gene	I-T017
encodes	O
the	O
enzyme	B-T103
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
phospholipids	B-T103
(	O
PLs	B-T103
)	O
from	O
the	O
sn	B-T082
-	I-T082
2	I-T082
position	I-T082
.	O

However	O
,	O
little	O
is	O
known	O
about	O
its	O
role	B-T170
in	O
humoral	B-T038
immune	I-T038
responses	I-T038
.	O

In	O
this	O
study	B-T062
,	O
we	O
investigated	O
the	O
expression	O
profile	O
of	O
PLA2	B-T017
in	O
different	O
tissues	B-T017
and	O
developmental	O
stages	O
in	O
Bactrocera	B-T204
dorsalis	I-T204
(	I-T204
Hendel	I-T204
)	I-T204
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
transcriptional	B-T038
level	O
of	O
PLA2	B-T017
was	O
high	O
in	O
the	O
egg	O
and	O
mature	B-T038
stage	I-T038
and	O
in	O
the	O
testis	B-T017
tissue	B-T017
.	O

Bacterial	B-T038
infection	I-T038
increased	O
the	O
expression	B-T038
of	O
PLA2	B-T017
,	O
and	O
the	O
highest	O
degree	O
of	O
up	B-T038
-	I-T038
regulation	I-T038
appeared	O
in	O
the	O
fat	B-T017
body	I-T017
.	O

Silencing	B-T038
PLA2	B-T017
influenced	O
the	O
expression	B-T038
of	O
immune	B-T017
-	I-T017
related	I-T017
genes	I-T017
,	O
including	O
MyD88	B-T017
and	O
defensin	B-T103
in	O
the	O
Toll	B-T038
pathway	I-T038
and	O
relish	B-T103
and	O
diptericin	B-T103
in	O
the	O
Imd	O
pathway	O
.	O

Moreover	O
,	O
the	O
expression	B-T038
of	O
MyD88	B-T017
and	O
defensin	B-T103
was	O
down	B-T038
-	I-T038
regulated	I-T038
significantly	O
in	O
the	O
ds	B-T017
-	I-T017
PLA2	I-T017
group	O
compared	O
with	O
those	O
in	O
the	O
ds	B-T103
-	I-T103
egfp	I-T103
group	O
when	O
B	B-T204
.	I-T204

dorsalis	I-T204
was	O
infected	B-T033
with	O
L	B-T007
.	I-T007

monocytogenes	I-T007
and	O
S	B-T007
.	I-T007

aureus	I-T007
,	O
indicating	O
that	O
PLA2	B-T017
was	O
involved	O
in	O
the	O
activation	B-T038
of	O
the	O
Toll	B-T038
pathway	I-T038
.	O

Meanwhile	O
,	O
infection	B-T038
with	O
L	B-T007
.	I-T007

monocytogenes	I-T007
and	O
E	B-T007
.	I-T007

coli	I-T007
,	O
which	O
activate	O
the	O
Imd	O
pathway	O
,	O
does	O
not	O
increase	O
the	O
mRNA	B-T103
levels	O
of	O
relish	B-T103
and	O
diptericin	B-T103
in	O
the	O
ds	B-T017
-	I-T017
PLA2	I-T017
group	O
as	O
severely	O
as	O
it	O
increases	O
those	O
in	O
the	O
ds	B-T103
-	I-T103
egfp	I-T103
group	O
,	O
indicating	O
that	O
the	O
Imd	O
pathway	O
was	O
also	O
repressed	O
after	O
silencing	B-T038
PLA2	B-T017
.	O

Notably	O
,	O
the	O
development	O
of	O
lipid	B-T017
droplets	I-T017
in	O
fat	B-T017
body	I-T017
cells	B-T017
was	O
influenced	O
by	O
silencing	B-T038
PLA2	B-T017
,	O
implying	O
that	O
PLA2	B-T017
affects	O
the	O
function	O
of	O
fat	B-T017
body	I-T017
tissue	B-T017
.	O

These	O
results	O
suggest	O
that	O
the	O
PLA2	B-T017
gene	I-T017
may	O
mediate	O
humoral	B-T038
immune	I-T038
responses	I-T038
by	O
reducing	O
lipid	B-T038
storage	I-T038
in	O
fat	B-T017
body	I-T017
cells	B-T017
in	O
B	B-T204
.	I-T204

dorsalis	I-T204
.	O

Gambling	B-T038
disorders	I-T038
,	O
gambling	O
type	O
preferences	O
,	O
and	O
psychiatric	O
comorbidity	O
among	O
the	O
Thai	B-T098
general	I-T098
population	I-T098
:	O
Results	O
of	O
the	O
2013	O
National	O
Mental	O
Health	O
Survey	O

Background	O
and	O
aims	O
To	O
estimate	O
the	O
prevalence	O
of	O
problem	O
and	O
pathological	B-T038
gambling	I-T038
,	O
gender	O
and	O
age	O
-	O
group	O
differences	O
in	O
gambling	O
types	O
,	O
and	O
comorbidities	O
with	O
other	O
psychiatric	B-T038
disorders	I-T038
among	O
the	O
Thai	B-T098
general	I-T098
population	I-T098
.	O

Methods	O
Analysis	O
was	O
conducted	O
on	O
4	O
,	O
727	O
participants	B-T098
of	O
Thailand	B-T082
'	I-T082
s	I-T082
2013	O
National	O
Mental	O
Health	O
Survey	O
,	O
a	O
multistage	B-T170
stratified	I-T170
cluster	I-T170
survey	I-T170
,	O
using	O
the	O
Composite	B-T170
International	I-T170
Diagnostic	I-T170
Interview	I-T170
.	O

Diagnoses	B-T033
of	O
problem	O
and	O
pathological	B-T038
gambling	I-T038
and	O
other	O
psychiatric	B-T038
disorders	I-T038
were	O
based	O
on	O
the	O
DSM	B-T170
-	I-T170
IV	I-T170
-	I-T170
TR	I-T170
criteria	I-T170
with	O
the	O
following	O
additional	O
criteria	O
for	O
gamblers	O
:	O
more	O
than	O
10	O
lifetime	O
gambling	O
episodes	O
and	O
a	O
single	O
year	O
loss	O
of	O
at	O
least	O
365	O
USD	O
from	O
gambling	O
.	O

Results	O
The	O
estimated	O
lifetime	O
prevalence	O
rates	O
of	O
pathological	B-T038
and	O
problem	O
gambling	O
were	O
0	O
.	O
90	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0	O
.	O
51	O
-	O
1	O
.	O
29	O
]	O
and	O
1	O
.	O
14	O
%	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
58	O
-	O
1	O
.	O
70	O
)	O
,	O
respectively	O
.	O

The	O
most	O
popular	O
type	O
of	O
gambling	O
was	O
playing	O
lotteries	O
[	O
69	O
.	O
5	O
%	O
,	O
standard	O
error	O
(	O
SE	O
)	O
=	O
1	O
.	O
9	O
]	O
,	O
the	O
prevalence	O
of	O
which	O
was	O
significantly	O
higher	O
among	O
females	O
and	O
older	B-T098
age	I-T098
groups	I-T098
.	O

The	O
most	O
common	O
psychiatric	B-T038
disorders	I-T038
seen	O
among	O
pathological	B-T038
gamblers	I-T038
were	O
alcohol	B-T038
abuse	I-T038
(	O
57	O
.	O
4	O
%	O
)	O
,	O
nicotine	B-T038
dependence	I-T038
(	O
49	O
.	O
5	O
%	O
)	O
,	O
and	O
any	O
drug	B-T038
use	I-T038
disorder	I-T038
(	O
16	O
.	O
2	O
%	O
)	O
.	O

Pathological	B-T038
gambling	I-T038
was	O
highly	O
prevalent	O
among	O
those	O
who	O
ever	O
experienced	O
major	B-T038
depressive	I-T038
episodes	I-T038
(	O
5	O
.	O
5	O
%	O
)	O
,	O
any	O
drug	B-T038
dependence	I-T038
(	O
5	O
.	O
1	O
%	O
)	O
,	O
and	O
intermittent	B-T038
explosive	I-T038
disorder	I-T038
(	O
4	O
.	O
8	O
%	O
)	O
.	O

The	O
association	O
between	O
pathological	B-T038
gambling	I-T038
was	O
strongest	O
with	O
a	O
history	O
of	O
major	B-T038
depressive	I-T038
episode	I-T038
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
)	O
=	O
10	O
.	O
4	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
80	O
-	O
38	O
.	O
4	O
]	O
.	O

Conclusion	O
The	O
study	O
confirms	O
the	O
recognition	B-T038
of	O
gambling	B-T038
disorders	I-T038
as	O
a	O
public	B-T170
health	I-T170
concern	O
in	O
Thailand	B-T082
and	O
suggests	O
a	O
need	O
for	O
culturally	O
specific	O
preventive	O
measures	O
for	O
pathological	B-T038
gamblers	I-T038
and	O
those	O
with	O
a	O
history	O
of	O
substance	B-T038
use	I-T038
disorders	I-T038
or	O
major	B-T038
depression	I-T038
.	O

Synovial	B-T038
sarcoma	I-T038
of	O
the	O
hypopharynx	B-T082
in	O
a	O
pediatric	O
patient	O
:	O
Case	B-T170
report	I-T170

Synovial	B-T038
sarcoma	I-T038
(	O
SS	B-T038
)	O
is	O
uncommon	O
high	O
grade	O
soft	B-T017
tissue	I-T017
sarcoma	B-T038
,	O
accounting	O
for	O
less	O
than	O
10	O
%	O
of	O
all	O
head	B-T038
and	I-T038
neck	I-T038
sarcomas	I-T038
.	O

Also	O
,	O
about	O
10	O
%	O
of	O
SS	B-T038
occur	O
within	O
the	O
Head	B-T082
&	O
Neck	B-T082
.	O

In	O
the	O
pediatric	O
population	B-T098
,	O
SS	B-T038
is	O
an	O
extremely	O
rare	O
head	B-T038
&	I-T038
neck	I-T038
malignancy	I-T038
.	O

We	O
present	O
a	O
case	O
of	O
sixteen	O
years	O
old	O
boy	O
diagnosed	B-T033
with	O
SS	B-T038
situated	O
of	O
the	O
hypopharynx	B-T082
treated	B-T058
by	I-T058
surgical	B-T058
excision	I-T058
and	O
post	B-T033
operative	I-T033
radio	B-T058
-	O
chemotherapy	B-T058
.	O

This	O
anatomical	B-T082
location	I-T082
brings	O
additional	O
functional	O
challenges	B-T058
(	O
swallowing	B-T038
,	O
phonation	B-T038
,	O
respiration	B-T038
)	O
,	O
especially	O
in	O
the	O
pediatric	O
population	B-T098
.	O

Pre	O
-	O
operative	O
and	O
even	O
post	B-T033
-	I-T033
operative	I-T033
histopathological	O
diagnosis	B-T033
of	O
SS	B-T038
remains	O
difficult	O
.	O

Optimal	O
treatment	B-T058
of	O
Head	B-T082
&	O
Neck	B-T082
SS	B-T038
has	O
to	O
balance	O
functional	O
and	O
oncologic	B-T091
aspects	O
.	O

SS	B-T038
is	O
an	O
extremely	O
rare	O
head	B-T038
&	I-T038
neck	I-T038
malignancy	I-T038
in	O
pediatric	O
population	B-T098
.	O

It	O
has	O
multifaceted	B-T082
challenges	B-T058
including	O
pre	O
and	O
post	B-T033
-	I-T033
operative	I-T033
histopathological	O
diagnosis	B-T033
and	O
optimal	O
modality	O
of	O
treatment	B-T058
.	O

Clinical	B-T170
judgment	I-T170
,	O
especially	O
in	O
the	O
pediatric	O
population	B-T098
,	O
needs	O
to	O
balance	O
tumor	B-T033
free	I-T033
margins	I-T033
and	O
organ	B-T058
preservation	I-T058
in	O
head	B-T082
and	O
neck	B-T082
region	B-T082
.	O

Ocular	B-T038
hypotensive	I-T038
effect	O
of	O
the	O
novel	O
EP3	B-T103
/	O
FP	B-T103
agonist	B-T103
ONO	B-T103
-	I-T103
9054	I-T103
versus	O
Xalatan	B-T103
:	O
results	O
of	O
a	O
28	O
-	O
day	O
,	O
double	B-T062
-	I-T062
masked	I-T062
,	O
randomised	O
study	B-T062

ONO	B-T103
-	I-T103
9054	I-T103
is	O
being	O
developed	O
for	O
the	O
reduction	O
of	O
intraocular	B-T038
pressure	I-T038
(	O
IOP	B-T038
)	O
in	O
patients	O
with	O
ocular	B-T038
hypertension	I-T038
(	O
OHT	B-T038
)	O
and	O
open	B-T038
-	I-T038
angle	I-T038
glaucoma	I-T038
(	O
OAG	B-T038
)	O
.	O

This	O
study	B-T062
compared	O
the	O
novel	O
dual	O
EP3	B-T103
/	O
FP	B-T103
agonist	B-T103
ONO	B-T103
-	I-T103
9054	I-T103
with	O
the	O
FP	B-T103
agonist	B-T103
Xalatan	B-T103
.	O

Adults	O
(	O
n	O
=	O
123	O
)	O
with	O
bilateral	O
mild	O
/	O
moderate	O
OAG	B-T038
or	O
OHT	B-T038
,	O
with	O
unmedicated	O
IOP	B-T038
of	O
≥24	O
mm	O
Hg	O
at	O
8	O
:	O
00	O
hours	O
,	O
≥21	O
mm	O
Hg	O
at	O
10	O
:	O
00	O
hours	O
and	O
≤36	O
mm	O
Hg	O
,	O
were	O
randomised	O
1	O
:	O
1	O
to	O
receive	O
ONO	B-T103
-	I-T103
9054	I-T103
(	O
0	O
.	O
003	O
%	O
,	O
30	O
μg	O
/	O
mL	O
)	O
or	O
Xalatan	B-T103
(	O
0	O
.	O
005	O
%	O
,	O
50	O
μg	O
/	O
mL	O
)	O
once	O
daily	O
for	O
28	O
days	O
.	O

Day	O
29	O
mean	O
diurnal	O
IOP	B-T038
was	O
-	O
7	O
.	O
2	O
mm	O
Hg	O
for	O
ONO	B-T103
-	I-T103
9054	I-T103
vs	O
-	O
6	O
.	O
6	O
mm	O
Hg	O
for	O
Xalatan	B-T103
.	O

At	O
08	O
:	O
00	O
hours	O
,	O
the	O
IOPs	B-T038
were	O
comparable	O
,	O
and	O
at	O
all	O
later	O
time	O
points	O
the	O
decrease	O
in	O
IOP	B-T038
was	O
greater	O
for	O
ONO	B-T103
-	I-T103
9054	I-T103
.	O

On	O
day	O
29	O
,	O
the	O
odds	O
of	O
a	O
mean	O
IOP	B-T038
reduction	O
of	O
≤	O
-	O
25	O
%	O
,	O
≤	O
-	O
30	O
%	O
and	O
≤	O
-	O
35	O
%	O
for	O
ONO	B-T103
-	I-T103
9054	I-T103
were	O
2	O
.	O
39	O
,	O
2	O
.	O
37	O
and	O
4	O
.	O
85	O
times	O
more	O
,	O
respectively	O
,	O
than	O
the	O
odds	O
for	O
Xalatan	B-T103
(	O
p	O
<	O
0	O
.	O
05	O
,	O
post	B-T062
hoc	I-T062
analyses	I-T062
)	O
.	O

The	O
percentage	O
of	O
subjects	O
achieving	O
target	O
IOPs	B-T038
on	O
day	O
29	O
(	O
≤17	O
,	O
≤16	O
and	O
≤15	O
mm	O
Hg	O
)	O
was	O
greater	O
for	O
ONO	B-T103
-	I-T103
9054	I-T103
than	O
for	O
Xalatan	B-T103
;	O
the	O
odds	O
of	O
achieving	O
an	O
IOP	B-T038
≤15	O
mm	O
Hg	O
for	O
ONO	B-T103
-	I-T103
9054	I-T103
were	O
2	O
.	O
4	O
times	O
more	O
than	O
the	O
odds	O
for	O
Xalatan	B-T103
(	O
p	O
<	O
0	O
.	O
01	O
,	O
post	B-T062
hoc	I-T062
analysis	I-T062
)	O
.	O

Subjects	O
randomised	O
to	O
receive	O
ONO	B-T103
-	I-T103
9054	I-T103
were	O
more	O
likely	O
to	O
achieve	O
a	O
greater	O
per	O
cent	O
reduction	O
in	O
IOP	B-T038
and	O
were	O
more	O
likely	O
to	O
achieve	O
target	O
IOPs	B-T038
than	O
those	O
receiving	O
Xalatan	B-T103
.	O

The	O
effects	O
of	O
ONO	B-T103
-	I-T103
9054	I-T103
in	O
reducing	O
IOP	B-T038
appear	O
to	O
persist	O
longer	O
than	O
those	O
of	O
Xalatan	B-T103
.	O

NCT02083289	O
,	O
Results	O
.	O

Whole	B-T058
-	I-T058
body	I-T058
strength	I-T058
training	I-T058
with	O
Huber	O
Motion	O
Lab	O
and	O
traditional	B-T058
strength	I-T058
training	I-T058
in	O
cardiac	B-T058
rehabilitation	I-T058
:	O
A	O
randomized	B-T062
controlled	I-T062
study	I-T062

Isometric	B-T058
strengthening	I-T058
has	O
been	O
rarely	O
studied	O
in	O
patients	O
with	O
coronary	B-T038
heart	I-T038
disease	I-T038
(	O
CHD	B-T038
)	O
,	O
mainly	O
because	O
of	O
possible	O
potential	B-T038
side	I-T038
effects	I-T038
and	O
lack	O
of	O
appropriate	O
and	O
reliable	O
devices	O
.	O

We	O
aimed	O
to	O
compare	O
2	O
different	O
modes	O
of	O
resistance	B-T058
training	I-T058
,	O
an	O
isometric	O
mode	O
with	O
the	O
Huber	O
Motion	O
Lab	O
(	O
HML	O
)	O
and	O
traditional	B-T058
strength	I-T058
training	I-T058
(	O
TST	B-T058
)	O
,	O
in	O
CHD	B-T038
patients	O
undergoing	O
a	O
cardiac	B-T058
rehabilitation	I-T058
program	O
.	O

We	O
randomly	O
assigned	O
50	O
patients	O
to	O
HML	O
or	O
TST	B-T058
.	O

Patients	O
underwent	O
complete	O
blinded	B-T062
evaluation	B-T058
before	O
and	O
after	O
the	O
rehabilitation	B-T058
program	I-T058
,	O
including	O
testing	B-T058
for	I-T058
cardiopulmonary	I-T058
exercise	I-T058
,	O
maximal	B-T058
isometric	I-T058
voluntary	I-T058
contraction	I-T058
,	O
endothelial	B-T017
function	O
and	O
body	O
composition	O
.	O

After	O
4	O
weeks	O
of	O
training	O
(	O
16	O
sessions	O
)	O
,	O
the	O
groups	O
did	O
not	O
differ	O
in	O
body	O
composition	O
,	O
anthropometric	B-T062
characteristics	O
,	O
or	O
endothelial	B-T017
function	O
.	O

With	O
HML	O
,	O
peak	O
power	O
output	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
maximal	O
heart	B-T201
rate	I-T201
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
gain	O
of	O
force	O
measured	O
in	O
the	O
chest	O
press	O
position	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
were	O
greater	O
after	O
versus	O
before	O
training	O
.	O

Both	O
protocols	B-T170
appeared	O
to	O
be	O
well	O
tolerated	O
,	O
safe	O
and	O
feasible	O
for	O
these	O
CHD	B-T038
patients	O
.	O

A	O
training	B-T170
protocol	I-T170
involving	O
6s	O
phases	O
of	O
isometric	B-T038
contractions	I-T038
with	O
10s	O
of	O
passive	O
recovery	B-T038
on	O
an	O
HML	O
device	O
could	O
be	O
safely	O
implemented	O
in	O
rehabilitation	B-T058
programs	I-T058
for	O
patients	O
with	O
CHD	B-T038
and	O
improve	O
functional	O
outcomes	O
.	O

Percutaneous	B-T058
coronary	I-T058
intervention	I-T058
and	O
heart	B-T058
surgery	I-T058
learning	B-T038
needs	O
of	O
patients	O
in	O
Jordan	B-T082

This	O
study	O
aimed	O
to	O
identify	O
and	O
prioritize	O
the	O
perceived	B-T038
learning	B-T038
needs	O
of	O
patients	O
who	O
underwent	O
percutaneous	B-T058
coronary	I-T058
intervention	I-T058
or	O
open	B-T058
-	I-T058
heart	I-T058
surgery	I-T058
.	O

Identifying	O
learning	B-T038
needs	O
for	O
post	B-T058
-	I-T058
cardiac	I-T058
intervention	I-T058
patients	O
is	O
essential	O
to	O
establish	O
successful	O
health	O
education	O
programmes	O
based	O
on	O
patient	O
central	B-T058
care	I-T058
.	O

A	O
descriptive	O
comparative	O
design	O
was	O
employed	O
on	O
a	O
convenience	O
sample	B-T098
of	O
260	O
patients	O
who	O
underwent	O
a	O
percutaneous	B-T058
coronary	I-T058
intervention	I-T058
and	O
105	O
patients	O
who	O
underwent	O
open	B-T058
-	I-T058
heart	I-T058
surgery	I-T058
patients	O
.	O

Participants	B-T098
had	O
completed	O
the	O
Patient	O
Learning	B-T170
Needs	I-T170
Scale	I-T170
.	O

Data	O
were	O
collected	O
between	O
1	O
October	O
2014	O
and	O
31	O
June	O
2015	O
.	O

Patients	O
from	O
the	O
two	O
groups	O
highly	O
requesting	O
health	O
and	O
recovery	O
related	O
information	O
.	O

They	O
scored	O
all	O
learning	B-T038
need	I-T038
topics	B-T170
as	O
important	O
or	O
highly	O
important	O
for	O
them	O
.	O

The	O
top	O
priority	O
learning	B-T038
need	O
for	O
both	O
patient	O
groups	O
was	O
'	O
information	O
about	O
wound	B-T058
care	I-T058
'	O
,	O
and	O
the	O
lowest	O
priority	O
learning	B-T038
need	O
topic	B-T170
was	O
'	O
physical	O
activity	O
'	O
.	O

The	O
learning	B-T038
needs	O
of	O
both	O
groups	O
were	O
very	O
close	O
,	O
which	O
indicated	O
that	O
educational	O
secondary	O
prevention	O
programmes	O
'	O
content	O
can	O
be	O
prepared	O
in	O
a	O
unified	O
structure	O
for	O
those	O
patients	O
.	O

Although	O
,	O
specific	O
headings	B-T170
can	O
be	O
used	O
to	O
address	O
the	O
unique	O
needs	O
that	O
emerge	O
from	O
having	O
a	O
specific	O
cardiac	B-T017
interventional	B-T058
procedure	I-T058
.	O

The	O
fact	O
that	O
wound	B-T058
care	I-T058
and	O
medications	B-T058
are	O
areas	O
of	O
highest	O
learning	B-T038
needs	O
for	O
patients	O
requires	O
health	B-T170
policy	I-T170
decision	B-T097
makers	I-T097
to	O
address	O
these	O
topics	B-T170
at	O
the	O
time	O
of	O
hospital	B-T058
discharge	I-T058
.	O

In	O
addition	O
,	O
a	O
policy	B-T170
focus	O
on	O
considering	O
patients	O
'	O
actual	O
learning	B-T038
needs	O
requires	O
establishment	O
and	O
managerial	O
support	O
.	O

As	O
patients	O
'	O
learning	B-T038
needs	O
might	O
change	O
later	O
after	O
discharge	B-T058
,	O
the	O
health	B-T058
services	I-T058
should	O
be	O
proactive	O
and	O
focus	O
on	O
continuous	O
support	O
for	O
patients	O
after	O
hospital	B-T058
discharge	I-T058
.	O

Secondary	O
prevention	O
programmes	O
should	O
incorporate	O
health	O
education	O
topics	B-T170
based	O
on	O
patients	O
'	O
own	O
views	O
.	O

This	O
can	O
be	O
done	O
by	O
giving	O
higher	O
priority	O
to	O
understand	O
patients	O
'	O
needs	O
,	O
put	O
much	O
more	O
effort	O
into	O
how	O
to	O
meet	O
patients	O
'	O
information	O
needs	O
and	O
to	O
create	O
a	O
more	O
engaging	O
learning	B-T038
environment	B-T082
for	O
patients	O
and	O
their	O
families	O
.	O

Complications	B-T038
and	O
Near	O
-	O
Miss	O
Events	O
After	O
Hepatectomy	B-T058
for	O
Living	B-T058
-	I-T058
Related	I-T058
Liver	I-T058
Donation	I-T058
:	O
An	O
Italian	B-T082
Single	B-T092
Center	I-T092
Report	B-T170
of	O
One	O
Hundred	O
Cases	O

BACKGROUND	O
In	O
healthy	O
individuals	B-T098
,	O
such	O
as	O
liver	B-T098
living	I-T098
donors	I-T098
,	O
potential	O
complications	B-T038
may	O
occur	O
during	O
surgery	B-T058
.	O

Reporting	O
such	O
complications	B-T038
and	O
near	O
-	O
miss	O
events	O
is	O
mandatory	O
to	O
improve	O
living	B-T098
donor	I-T098
management	O
and	O
safety	O
.	O

MATERIAL	O
AND	O
METHODS	O
This	O
retrospective	B-T062
study	I-T062
was	O
performed	O
on	O
a	O
prospective	O
database	B-T170
with	O
the	O
aim	O
of	O
providing	O
a	O
brief	O
analysis	B-T062
of	O
the	O
perioperative	O
,	O
medium	O
-	O
term	O
,	O
and	O
long	O
-	O
term	O
complications	B-T038
,	O
and	O
the	O
near	O
-	O
miss	O
events	O
in	O
a	O
single	B-T092
center	I-T092
series	O
of	O
100	O
consecutive	O
liver	B-T058
resections	I-T058
for	O
adult	O
-	O
to	O
-	O
adult	O
living	B-T098
-	I-T098
donor	I-T098
liver	B-T058
transplantation	I-T058
.	O

RESULTS	O
Only	O
23	O
.	O
3	O
%	O
of	O
potential	O
living	B-T098
donors	I-T098
underwent	O
surgery	B-T058
.	O

No	B-T033
living	B-T098
donor	I-T098
mortality	O
was	O
reported	O
;	O
29	O
patients	O
(	O
29	O
%	O
)	O
experienced	O
at	O
least	O
one	O
complication	B-T038
.	O

Five	O
patients	O
developed	O
mild	O
long	O
-	O
term	O
dysfunction	O
;	O
two	O
aborted	O
hepatectomies	B-T058
,	O
and	O
there	O
were	O
two	O
near	O
-	O
miss	O
events	O
reported	O
.	O

CONCLUSIONS	O
A	O
strategy	O
for	O
an	O
accurate	O
assessment	B-T058
of	O
living	B-T098
donor	I-T098
complications	B-T038
and	O
strict	O
selection	O
criterion	O
cannot	O
be	O
overemphasized	O
,	O
as	O
well	O
as	O
the	O
need	O
to	O
continuously	O
update	O
center	B-T092
patient	O
outcome	O
reports	B-T170
.	O

Tooth	B-T037
wear	I-T037
as	O
a	O
means	O
to	O
quantify	O
intra	O
-	O
specific	O
variations	O
in	O
diet	B-T168
and	O
chewing	B-T038
movements	B-T038

In	O
mammals	B-T204
,	O
tooth	B-T017
function	O
,	O
and	O
its	O
efficiency	O
,	O
depends	O
both	O
on	O
the	O
mechanical	O
properties	O
of	O
the	O
food	B-T168
and	O
on	O
chewing	B-T038
dynamics	O
.	O

These	O
aspects	O
have	O
rarely	O
been	O
studied	B-T062
in	O
combination	O
and	O
/	O
or	O
at	O
the	O
intra	O
-	O
specific	O
level	O
.	O

Here	O
we	O
applied	O
3D	B-T082
dental	B-T017
surface	B-T082
texture	O
analysis	B-T062
to	O
a	O
sample	O
of	O
field	B-T204
voles	I-T204
(	O
Microtus	B-T204
agrestis	I-T204
)	O
trapped	O
from	O
Finnish	B-T082
Lapland	I-T082
at	O
different	O
seasons	O
and	O
localities	B-T082
to	O
test	O
for	O
inter	B-T098
-	I-T098
population	I-T098
variations	O
.	O

We	O
also	O
explored	O
intra	B-T098
-	I-T098
individual	I-T098
variation	O
in	O
chewing	B-T038
dynamics	O
by	O
analysing	B-T062
two	O
facets	B-T082
on	O
the	O
second	B-T017
upper	I-T017
molars	I-T017
.	O

Our	O
results	O
confirm	O
that	O
the	O
two	O
localities	B-T082
have	O
similar	O
environments	B-T082
and	O
that	O
the	O
voles	B-T204
feed	O
on	O
the	O
same	O
items	O
there	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
texture	O
data	O
suggest	O
that	O
diets	B-T168
are	O
seasonally	O
variable	O
,	O
probably	O
due	O
to	O
varying	O
concentrations	O
of	O
abrasives	B-T103
.	O

Lastly	O
,	O
the	O
textures	O
on	O
the	O
buccal	B-T082
facets	I-T082
are	O
more	O
isotropic	O
and	O
their	O
direction	B-T082
deviates	B-T082
more	O
from	O
the	O
mesial	B-T082
chewing	B-T038
direction	B-T082
than	O
the	O
lingual	B-T017
facets	B-T082
.	O

We	O
interpret	O
these	O
results	O
as	O
reflecting	O
food	B-T168
,	O
rather	O
than	O
chewing	B-T038
,	O
movements	B-T038
,	O
where	O
food	B-T168
particles	I-T168
are	O
more	O
guided	O
on	O
the	O
lingual	B-T017
side	O
of	O
the	O
molars	B-T017
.	O

This	O
has	O
implications	O
for	O
the	O
application	O
of	O
dental	B-T037
microwear	I-T037
analysis	B-T062
to	O
fossils	O
:	O
only	O
homologous	O
facets	B-T082
can	O
be	O
compared	O
,	O
even	O
when	O
the	O
molar	B-T017
row	O
seems	O
to	O
constitute	O
a	O
functional	O
unit	O
.	O

Human	B-T103
cathelicidin	I-T103
LL	I-T103
-	I-T103
37	I-T103
enhance	O
the	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T103
on	O
Streptococcus	B-T007
mutans	I-T007

Streptococcus	B-T007
mutans	I-T007
forms	O
biofilms	B-T007
as	O
a	O
resistance	O
mechanism	O
against	O
antimicrobial	B-T103
agents	I-T103
in	O
the	O
human	B-T204
oral	B-T082
cavity	I-T082
.	O

We	O
recently	O
showed	O
that	O
human	B-T103
cathelicidin	I-T103
LL	I-T103
-	I-T103
37	I-T103
exhibits	O
inhibitory	O
effects	O
on	O
biofilm	B-T038
formation	I-T038
of	O
S	B-T007
.	I-T007

mutans	I-T007
through	O
interaction	O
with	O
lipoteichoic	B-T103
acid	I-T103
(	O
LTA	B-T103
)	O
,	O
but	O
without	O
antibacterial	B-T033
or	O
biofilm	B-T007
dispersal	B-T082
abilities	I-T082
.	O

(	B-T103
-	I-T103
)	I-T103
-	I-T103
Epigallocatechin	I-T103
gallate	I-T103
(	O
EGCG	B-T103
)	O
is	O
the	O
most	O
abundant	O
constituent	O
of	O
tea	B-T168
catechins	B-T103
that	O
has	O
the	O
greatest	O
anti	B-T033
-	I-T033
infective	I-T033
potential	I-T033
to	O
inhibit	B-T038
the	I-T038
growth	I-T038
of	O
various	O
microorganisms	O
and	O
biofilm	B-T038
formation	I-T038
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	B-T058
whether	O
LL	B-T103
-	I-T103
37	I-T103
interacts	O
with	O
EGCG	B-T103
to	O
enhance	O
the	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T103
on	O
S	B-T007
.	I-T007

mutans	I-T007
biofilm	B-T038
formation	I-T038
.	O

Clinical	O
S	B-T007
.	I-T007

mutans	I-T007
strains	O
(	O
n	O
=	O
10	O
)	O
isolated	O
from	O
children	O
'	O
s	O
saliva	B-T031
were	O
tested	O
in	O
a	O
biofilm	B-T038
formation	I-T038
assay	B-T058
.	O

The	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T103
with	O
and	O
without	O
LL	B-T103
-	I-T103
37	I-T103
was	O
analyzed	B-T062
by	O
the	O
minimum	O
biofilm	B-T007
eradication	O
concentration	O
assay	B-T058
and	O
confirmed	O
using	O
field	O
emission	B-T058
-	I-T058
scanning	I-T058
electron	I-T058
microscopy	I-T058
.	O

In	O
addition	O
,	O
the	O
interaction	O
among	O
EGCG	B-T103
,	O
LL	B-T103
-	I-T103
37	I-T103
,	O
and	O
LTA	B-T103
of	O
S	B-T007
.	I-T007

mutans	I-T007
was	O
determined	O
using	O
quartz	B-T062
crystal	I-T062
microbalance	I-T062
analysis	I-T062
.	O

EGCG	B-T103
killed	O
100	O
%	O
of	O
planktonic	B-T007
S	B-T007
.	I-T007

mutans	I-T007
within	O
5	O
h	O
,	O
inhibited	O
biofilm	B-T038
formation	I-T038
within	O
24	O
h	O
,	O
and	O
reduced	O
bacteria	B-T007
cells	I-T007
in	O
preformed	O
biofilms	B-T007
within	O
3	O
h	O
at	O
a	O
concentration	O
of	O
0	O
.	O
2	O
mg	O
/	O
mL	O
.	O

However	O
,	O
EGCG	B-T103
did	O
not	O
appear	O
to	O
interact	O
with	O
LTA	B-T103
.	O

LL	B-T103
-	I-T103
37	I-T103
effectively	O
enhanced	O
the	O
bactericidal	B-T038
activity	I-T038
of	O
EGCG	B-T103
against	O
biofilm	B-T038
formation	I-T038
and	O
preformed	O
biofilms	B-T007
as	O
determined	O
by	O
quantitative	O
crystal	B-T103
violet	I-T103
staining	B-T058
and	O
field	O
emission	B-T058
-	I-T058
scanning	I-T058
electron	I-T058
microscopy	I-T058
.	O

In	O
addition	O
,	O
quartz	B-T062
crystal	I-T062
microbalance	I-T062
analysis	I-T062
revealed	O
that	O
LL	B-T103
-	I-T103
37	I-T103
interacted	O
with	O
EGCG	B-T103
and	O
promoted	O
binding	B-T038
between	O
EGCG	B-T103
and	O
LTA	B-T103
of	O
S	B-T007
.	I-T007

mutans	I-T007
.	O

We	O
show	O
that	O
LL	B-T103
-	I-T103
37	I-T103
enhances	O
the	O
antibiofilm	B-T033
effect	I-T033
of	O
EGCG	B-T103
on	O
S	B-T007
.	I-T007

mutans	I-T007
.	O

This	O
finding	O
provides	O
new	O
knowledge	O
for	O
dental	B-T058
treatment	I-T058
by	O
using	O
LL	B-T103
-	I-T103
37	I-T103
as	O
a	O
potential	O
antibiofilm	B-T103
compound	I-T103
.	O

Discovery	O
of	O
Orally	B-T082
Efficacious	O
Phosphoinositide	B-T103
-	I-T103
3	I-T103
-	I-T103
Kinase	I-T103
delta	I-T103
Inhibitors	B-T103
with	O
Improved	B-T033
Metabolic	O
Stability	O

Aberrant	B-T038
signaling	I-T038
of	O
phosphoinositide	B-T103
-	I-T103
3	I-T103
-	I-T103
kinase	I-T103
delta	I-T103
(	O
PI3K	B-T103
-	I-T103
delta	I-T103
)	O
has	O
been	O
implicated	O
in	O
numerous	O
pathologies	B-T038
including	O
hematological	B-T038
malignancies	I-T038
and	O
rheumatoid	B-T038
arthritis	I-T038
.	O

Described	O
in	O
this	O
manuscript	O
is	O
the	O
discovery	O
,	O
optimization	O
and	O
in	B-T082
vivo	I-T082
evaluation	B-T058
of	O
a	O
novel	O
series	O
of	O
pyridine	B-T103
-	I-T103
containing	I-T103
PI3K	B-T103
-	I-T103
delta	I-T103
inhibitors	B-T103
.	O

This	O
work	O
led	O
to	O
the	O
discovery	O
of	O
35	B-T103
,	O
a	O
highly	O
selective	O
inhibitor	B-T103
of	O
PI3K	B-T103
-	I-T103
delta	I-T103
which	O
displays	O
an	O
excellent	O
pharmacokinetic	O
profile	O
and	O
is	O
efficacious	O
in	O
a	O
rodent	B-T038
model	I-T038
of	O
rheumatoid	B-T038
arthritis	I-T038
.	O

Mobile	O
phone	O
use	O
,	O
behavioural	B-T038
problems	I-T038
and	O
concentration	B-T038
capacity	O
in	O
adolescents	O
:	O
A	O
prospective	B-T062
study	I-T062

The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
prospectively	O
investigate	O
whether	O
exposure	O
to	O
radiofrequency	O
electromagnetic	O
fields	O
(	O
RF	O
-	O
EMF	O
)	O
emitted	O
by	O
mobile	O
phones	O
and	O
other	O
wireless	O
communication	O
devices	O
is	O
related	O
to	O
behavioural	B-T038
problems	I-T038
or	O
concentration	B-T038
capacity	O
in	O
adolescents	O
.	O

The	O
HERMES	B-T062
(	O
Health	O
Effects	O
Related	O
to	O
Mobile	O
phonE	O
use	O
in	O
adolescentS	O
)	O
study	O
sample	O
consisted	O
of	O
439	O
Swiss	B-T098
adolescents	O
aged	O
12	O
-	O
17	O
years	O
.	O

Behavioural	B-T038
problems	I-T038
were	O
assessed	O
using	O
the	O
Strengths	B-T170
and	I-T170
Difficulties	I-T170
Questionnaire	I-T170
(	O
SDQ	B-T170
)	O
,	O
concentration	B-T038
capacity	O
of	O
the	O
adolescents	O
was	O
measured	O
by	O
means	O
of	O
a	O
standardized	O
computerized	O
cognitive	O
test	O
named	O
FAKT	B-T170
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
and	O
longitudinal	B-T062
(	O
1year	O
of	O
follow	B-T033
-	I-T033
up	I-T033
)	O
analyses	B-T062
were	O
performed	O
to	O
investigate	O
possible	O
associations	O
between	O
behavioural	B-T038
problems	I-T038
and	O
concentration	B-T038
capacity	O
and	O
different	O
exposure	O
measures	O
:	O
self	B-T062
-	I-T062
reported	I-T062
and	O
operator	B-T097
-	O
recorded	O
wireless	O
communication	O
device	O
use	O
,	O
cumulative	O
RF	O
-	O
EMF	O
brain	B-T017
and	O
whole	B-T017
body	I-T017
dose	O
and	O
measured	O
personal	O
RF	O
-	O
EMF	O
exposure	O
.	O

In	O
the	O
cross	B-T062
-	I-T062
sectional	I-T062
analyses	I-T062
behavioural	B-T038
problems	I-T038
were	O
associated	O
with	O
several	O
self	B-T170
-	I-T170
reported	I-T170
wireless	O
device	O
use	O
measures	O
but	O
not	O
operator	B-T097
-	O
recorded	O
mobile	O
phone	O
use	O
measures	O
,	O
concentration	B-T038
capacity	O
was	O
associated	O
with	O
several	O
self	B-T062
-	I-T062
reported	I-T062
and	O
operator	B-T097
-	O
recorded	O
exposures	O
.	O

The	O
longitudinal	B-T062
analyses	I-T062
point	O
towards	O
absence	O
of	O
associations	O
.	O

The	O
lack	O
of	O
consistent	O
exposure	O
-	O
response	O
patterns	B-T082
in	O
the	O
longitudinal	B-T062
analyses	I-T062
suggests	O
that	O
behavioural	B-T038
problems	I-T038
and	O
concentration	B-T038
capacity	O
are	O
not	O
affected	O
by	O
the	O
use	O
of	O
wireless	O
communication	O
devices	O
or	O
RF	O
-	O
EMF	O
exposure	O
.	O

Information	O
bias	O
and	O
reverse	O
causality	O
are	O
likely	O
explanations	B-T170
for	O
the	O
observed	O
cross	B-T062
-	I-T062
sectional	I-T062
findings	I-T062
.	O

Twisting	O
method	O
for	O
reducing	O
friction	O
during	O
insertion	B-T058
of	O
a	O
sheath	B-T074
introducer	B-T074
and	O
a	O
sheathless	B-T074
guiding	I-T074
catheter	I-T074

A	O
sheathless	O
system	O
that	O
inserts	B-T058
a	O
catheter	B-T074
directly	O
into	O
the	O
artery	B-T017
can	O
reduce	O
puncture	O
site	B-T082
-	O
related	O
complications	B-T038
through	O
a	O
2	O
-	O
Fr	O
reduction	O
of	O
the	O
outer	B-T082
diameter	I-T082
.	O

However	O
,	O
the	O
gap	B-T082
between	O
the	O
dilator	B-T074
and	O
the	O
guiding	B-T074
catheter	I-T074
of	O
the	O
sheathless	O
system	O
is	O
larger	O
than	O
the	O
gap	B-T082
between	O
the	O
dilator	B-T074
and	O
sheath	B-T074
of	O
the	O
introducer	B-T074
system	I-T074
,	O
resulting	O
in	O
stronger	O
insertion	B-T058
resistance	O
.	O

A	O
twisting	O
method	O
with	O
rapid	O
alternating	O
rotation	O
of	O
a	O
device	B-T074
to	O
the	O
left	O
and	O
right	O
during	O
insertion	B-T058
can	O
reduce	O
the	O
insertion	B-T058
resistance	O
.	O

This	O
method	O
can	O
be	O
effective	O
with	O
the	O
sheathless	O
system	O
which	O
has	O
a	O
larger	O
gap	B-T082
.	O

To	O
examine	O
the	O
effect	O
of	O
size	B-T082
reduction	O
on	O
the	O
sheathless	O
system	O
and	O
the	O
effect	O
of	O
insertion	B-T058
resistance	O
reduction	O
using	O
the	O
twisting	O
method	O
,	O
we	O
developed	O
an	O
insertion	B-T058
simulator	B-T074
and	O
compared	O
insertion	B-T058
resistance	O
to	O
a	O
5	B-T074
-	I-T074
Fr	I-T074
sheath	I-T074
introducer	B-T074
and	O
a	O
5	O
-	O
Fr	O
sheathless	O
system	O
,	O
with	O
and	O
without	O
the	O
twisting	O
method	O
.	O

The	O
insertion	B-T058
simulator	B-T074
pushed	O
a	O
sheath	B-T074
introducer	B-T074
or	O
a	O
sheathless	O
system	O
toward	O
a	O
mock	B-T033
artery	B-T017
consisted	O
with	O
a	O
5	O
-	O
mm	O
urethane	O
and	O
a	O
1	O
-	O
mm	O
rubber	O
sheet	O
by	O
an	O
electrical	O
motor	O
with	O
or	O
without	O
twisting	O
motion	O
generated	O
by	O
a	O
crank	O
shaft	O
.	O

Insertion	B-T058
resistance	O
during	O
the	O
penetration	O
was	O
measured	O
by	O
a	O
tension	B-T074
meter	I-T074
.	O

The	O
insertion	B-T058
resistance	O
was	O
less	O
with	O
the	O
5	O
-	O
Fr	O
sheathless	O
system	O
than	O
with	O
the	O
5	B-T074
-	I-T074
Fr	I-T074
sheath	I-T074
introducer	B-T074
.	O

The	O
resistance	O
reduced	O
further	O
with	O
use	O
of	O
twisting	O
for	O
both	O
the	O
sheathed	B-T074
and	O
sheathless	B-T074
catheters	I-T074
.	O

In	O
conclusion	O
,	O
the	O
experiment	O
suggests	O
the	O
benefits	O
of	O
twisting	O
insertion	B-T058
of	O
a	O
sheathless	B-T074
guiding	I-T074
catheter	I-T074
for	O
reduction	O
of	O
puncture	O
site	B-T082
-	O
related	O
complications	B-T038
.	O

Unconventional	O
Protein	B-T038
Secretion	I-T038
in	O
Plants	B-T204

Unconventional	O
protein	B-T038
secretion	I-T038
(	O
UPS	B-T038
)	O
describes	O
secretion	B-T038
pathways	I-T038
that	O
bypass	O
one	O
or	O
several	O
of	O
the	O
canonical	O
secretion	B-T038
pit	O
-	O
stops	O
on	O
the	O
way	O
to	O
the	O
plasma	B-T017
membrane	I-T017
,	O
and	O
/	O
or	O
involve	O
the	O
secretion	B-T038
of	O
leaderless	O
proteins	B-T103
.	O

So	O
far	O
,	O
alternatives	O
to	O
conventional	O
secretion	B-T038
were	O
primarily	O
observed	O
and	O
studied	B-T062
in	O
yeast	B-T204
and	O
animal	B-T017
cells	I-T017
.	O

The	O
sessile	O
lifestyle	O
of	O
plants	B-T204
brings	O
with	O
it	O
unique	O
restraints	O
on	O
how	O
they	O
adapt	B-T038
to	I-T038
adverse	I-T038
conditions	I-T038
and	O
environmental	B-T082
challenges	I-T082
.	O

Recently	O
,	O
attention	B-T038
towards	O
unconventional	O
secretion	B-T038
pathways	I-T038
in	O
plant	B-T017
cells	I-T017
has	O
substantially	O
increased	O
,	O
with	O
the	O
large	O
number	O
of	O
leaderless	O
proteins	B-T103
identified	O
through	O
proteomic	B-T091
studies	I-T091
.	O

While	O
UPS	B-T038
pathways	O
in	O
plants	B-T204
are	O
certainly	O
not	O
yet	O
exhaustively	O
researched	O
,	O
an	O
emerging	O
notion	O
is	O
that	O
induction	O
of	O
UPS	B-T038
pathways	O
is	O
correlated	O
with	O
pathogenesis	B-T038
and	O
stress	B-T038
responses	I-T038
.	O

Given	O
the	O
multitude	O
UPS	B-T038
events	O
observed	O
,	O
comprehensively	O
organizing	O
the	O
routes	O
proteins	B-T103
take	O
to	O
the	O
apoplast	B-T017
in	O
defined	O
UPS	B-T038
categories	O
is	O
challenging	O
.	O

With	O
the	O
establishment	O
of	O
a	O
larger	O
collection	O
of	O
studied	O
plant	B-T103
proteins	I-T103
taking	O
these	O
UPS	B-T038
pathways	O
,	O
a	O
clearer	O
picture	O
of	O
endomembrane	B-T017
trafficking	O
as	O
a	O
whole	O
will	O
emerge	O
.	O

There	O
are	O
several	O
novel	O
enabling	B-T038
technologies	O
,	O
such	O
as	O
vesicle	B-T017
proteomics	B-T091
and	O
chemical	B-T103
genomics	B-T091
,	O
with	O
great	O
potential	O
for	O
dissecting	O
secretion	B-T038
pathways	I-T038
,	O
providing	O
information	O
about	O
the	O
cargo	O
that	O
travels	O
along	O
them	O
and	O
the	O
conditions	O
that	O
induce	O
them	O
.	O

Neospora	B-T204
caninum	I-T204
in	O
Axis	B-T204
Deer	I-T204
(	O
Axis	B-T204
axis	I-T204
)	O
and	O
Fallow	B-T204
Deer	I-T204
(	O
Dama	B-T204
dama	I-T204
)	O
in	O
Northern	B-T082
Mexico	B-T082

Serum	B-T031
samples	I-T031
from	O
18	O
axis	B-T204
deer	I-T204
(	O
Axis	B-T204
axis	I-T204
)	O
and	O
19	O
fallow	B-T204
deer	I-T204
(	O
Dama	B-T204
dama	I-T204
)	O
were	O
analyzed	O
with	O
an	O
enzyme	B-T058
-	I-T058
linked	I-T058
immunosorbent	I-T058
assay	I-T058
for	O
Neospora	B-T103
caninum	I-T103
antibodies	I-T103
.	O

Two	O
axis	B-T204
(	O
11	O
%	O
)	O
and	O
two	O
fallow	B-T204
deer	I-T204
(	O
11	O
%	O
)	O
were	O
positive	B-T033
for	O
N	B-T103
.	I-T103

caninum	I-T103
antibodies	I-T103
.	O

The	O
ABBA	B-T062
study	I-T062
-	O
approach	O
bias	O
modification	O
in	O
bulimia	B-T038
nervosa	I-T038
and	O
binge	B-T038
eating	I-T038
disorder	I-T038
:	O
study	O
protocol	O
for	O
a	O
randomised	B-T062
controlled	I-T062
trial	I-T062

The	O
core	O
symptoms	B-T033
of	O
bulimia	B-T038
nervosa	I-T038
(	O
BN	B-T038
)	O
and	O
binge	B-T038
eating	I-T038
disorder	I-T038
(	O
BED	B-T038
)	O
are	O
recurrent	B-T033
episodes	I-T033
of	I-T033
binge	I-T033
eating	I-T033
.	O

Despite	O
negative	B-T038
psychological	I-T038
and	O
physical	B-T033
consequences	I-T033
,	O
BN	B-T038
/	I-T038
BED	I-T038
patients	O
show	O
uncontrollable	O
approach	O
tendencies	B-T038
towards	I-T038
food	I-T038
.	O

This	O
cognitive	O
bias	O
occurs	O
at	O
an	O
early	O
stage	O
of	O
information	B-T038
processing	I-T038
.	O

Cognitive	O
bias	O
modification	O
(	O
CBM	O
)	O
directly	O
targets	O
such	O
biases	O
and	O
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
treating	B-T058
several	O
mental	B-T038
disorders	I-T038
.	O

In	O
alcohol	B-T038
addiction	I-T038
,	O
automatic	O
action	O
tendencies	O
towards	O
alcohol	O
cues	O
and	O
relapse	O
rates	O
were	O
successfully	O
reduced	O
by	O
a	O
specific	O
form	O
of	O
CBM	O
,	O
termed	O
approach	O
bias	O
modification	O
.	O

Based	O
on	O
these	O
findings	O
and	O
data	O
from	O
a	O
proof	B-T062
-	I-T062
of	I-T062
-	I-T062
concept	I-T062
study	I-T062
in	O
people	B-T098
with	O
high	O
levels	O
of	O
food	O
craving	O
,	O
CBM	O
is	O
considered	O
a	O
promising	O
new	O
treatment	O
approach	O
for	O
BN	B-T038
/	I-T038
BED	I-T038
.	O

Given	O
the	O
similarities	O
between	O
BN	B-T038
/	I-T038
BED	I-T038
and	O
addictive	B-T038
disorders	I-T038
,	O
the	O
rationale	O
for	O
using	O
approach	O
bias	O
modification	O
appears	O
to	O
be	O
particularly	O
strong	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
examine	O
whether	O
,	O
compared	O
to	O
a	O
sham	B-T062
training	I-T062
,	O
computerised	O
approach	O
bias	O
modification	O
(	O
10	O
sessions	O
)	O
can	O
reduce	O
binge	B-T033
-	I-T033
eating	I-T033
episodes	I-T033
in	O
BN	B-T038
/	I-T038
BED	I-T038
patients	O
from	O
pre	O
-	O
treatment	O
to	O
follow	O
-	O
up	O
.	O

Additionally	O
,	O
we	O
will	O
investigate	O
whether	O
this	O
CBM	O
programme	O
also	O
reduces	O
global	O
eating	B-T038
disorder	I-T038
psychopathology	I-T038
,	O
trait	O
and	O
cue	O
-	O
elicited	O
food	O
craving	O
,	O
food	B-T038
intake	I-T038
as	O
well	O
as	O
approach	O
and	O
attentional	B-T038
bias	I-T038
towards	O
visual	O
food	O
cues	O
.	O

Treatment	O
acceptance	O
will	O
be	O
determined	O
by	O
attrition	O
rates	O
and	O
responses	B-T170
on	O
a	O
feedback	O
form	O
.	O

This	O
is	O
a	O
double	B-T062
-	I-T062
blind	I-T062
,	O
randomised	B-T062
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
superiority	O
trial	O
with	O
two	O
parallel	O
arms	O
.	O

A	O
total	O
of	O
54	O
BN	B-T038
/	I-T038
BED	I-T038
patients	O
will	O
be	O
recruited	O
.	O

Approach	O
bias	O
towards	O
food	O
will	O
be	O
retrained	O
by	O
a	O
computer	O
task	O
adopting	O
an	O
implicit	O
learning	O
paradigm	O
.	O

Patients	O
in	O
the	O
control	O
condition	O
(	O
sham	B-T062
)	O
will	O
conduct	O
a	O
similar	O
task	O
but	O
will	O
not	O
be	O
trained	O
to	O
avoid	O
food	O
cues	O
.	O

Methods	O
against	O
bias	O
include	O
public	B-T170
registration	I-T170
,	O
randomisation	B-T062
by	O
a	O
central	B-T097
study	I-T097
office	I-T097
,	O
standardisation	B-T062
of	I-T062
the	I-T062
treatments	I-T062
and	O
blinding	B-T062
of	I-T062
assessors	I-T062
.	O

Furthermore	O
,	O
the	O
session	O
number	O
and	O
duration	O
will	O
be	O
equivalent	O
in	O
the	O
two	O
conditions	O
.	O

This	O
is	O
the	O
first	O
registered	O
randomised	B-T062
controlled	I-T062
trial	I-T062
of	O
approach	O
bias	O
modification	O
in	O
a	O
clinical	B-T062
BN	I-T062
/	I-T062
BED	I-T062
sample	I-T062
.	O

Results	O
from	O
this	O
study	O
will	O
provide	O
an	O
indication	O
of	O
the	O
efficacy	O
of	O
approach	O
bias	O
modification	O
training	O
for	O
BN	B-T038
/	I-T038
BED	I-T038
and	O
the	O
potential	O
mechanisms	O
of	O
action	O
underlying	O
this	O
treatment	B-T058
.	O

DRKS00010231	O
(	O
retrospectively	O
registered	O
on	O
24	O
March	O
2016	O
;	O
first	O
version	O
)	O
.	O

Protein	B-T103
Design	O
for	O
Nanostructural	B-T058
Engineering	I-T058
:	O
Concluding	O
Remarks	B-T170
and	O
Future	O
Directions	O

This	O
final	O
chapter	B-T170
aims	O
to	O
summarize	O
the	O
main	O
conclusions	O
of	O
the	O
book	B-T170
and	O
to	O
point	O
to	O
possible	O
directions	O
for	O
further	O
research	B-T062
in	O
the	O
field	O
of	O
protein	B-T103
design	O
for	O
nanostructural	B-T058
engineering	I-T058
.	O

Even	O
though	O
this	O
research	O
field	O
is	O
still	O
at	O
its	O
infancy	O
,	O
multidisciplinary	O
research	B-T062
efforts	I-T062
in	O
the	O
design	O
of	O
synthetic	O
protein	O
-	O
based	O
nanostructures	O
and	O
functional	O
materials	O
have	O
resulted	O
in	O
significant	O
progress	O
.	O

The	O
chapters	B-T170
in	O
this	O
book	B-T170
cover	O
several	O
selected	O
examples	O
of	O
the	O
most	O
recent	O
advances	O
concerning	O
the	O
use	O
of	O
proteins	B-T103
and	O
peptides	B-T103
as	O
building	O
blocks	O
for	O
the	O
fabrication	O
of	O
architectures	O
and	O
functional	O
nanostructures	O
,	O
assemblies	O
,	O
and	O
materials	O
.	O

Here	O
,	O
we	O
provide	O
a	O
general	O
overview	O
of	O
the	O
strategies	O
that	O
can	O
be	O
employed	O
to	O
prepare	O
functional	O
protein	B-T103
-	O
based	O
nanostructures	O
,	O
and	O
nanostructured	O
materials	O
and	O
devices	O
.	O

Finally	O
,	O
we	O
highlight	O
some	O
of	O
the	O
main	O
aspects	O
to	O
be	O
considered	O
by	O
the	O
research	B-T062
community	O
to	O
set	O
the	O
path	O
for	O
the	O
near	O
future	O
developments	B-T062
.	O

Synthesis	O
,	O
characterization	O
and	O
drug	B-T103
loading	O
property	O
of	O
Monomethoxy	B-T103
-	I-T103
Poly	I-T103
(	I-T103
ethylene	I-T103
glycol	I-T103
)	I-T103
-	I-T103
Poly	I-T103
(	I-T103
ε	I-T103
-	I-T103
caprolactone	I-T103
)	I-T103
-	I-T103
Poly	I-T103
(	I-T103
D	I-T103
,	I-T103
L	I-T103
-	I-T103
lactide	I-T103
)	I-T103
(	I-T103
MPEG	I-T103
-	I-T103
PCLA	I-T103
)	I-T103
copolymers	I-T103

Amphiphilic	B-T103
block	I-T103
copolymers	I-T103
have	O
attracted	O
a	O
great	O
deal	O
of	O
attention	O
in	O
drug	B-T074
delivery	I-T074
systems	I-T074
.	O

In	O
this	O
work	O
,	O
a	O
series	O
of	O
monomethoxy	B-T103
-	I-T103
poly	I-T103
(	I-T103
ethylene	I-T103
glycol	I-T103
)	I-T103
-	I-T103
poly	I-T103
(	I-T103
ε	I-T103
-	I-T103
caprolactone	I-T103
-	I-T103
co	I-T103
-	I-T103
D	I-T103
,	I-T103
L	I-T103
-	I-T103
lactide	I-T103
)	I-T103
(	I-T103
MPEG	I-T103
-	I-T103
PCLA	I-T103
)	I-T103
copolymers	I-T103
with	O
variable	O
composition	O
of	O
poly	B-T103
(	I-T103
ε	I-T103
-	I-T103
caprolactone	I-T103
)	I-T103
(	O
PCL	B-T103
)	O
and	O
poly	B-T103
(	I-T103
D	I-T103
,	I-T103
L	I-T103
-	I-T103
lactide	I-T103
)	I-T103
(	O
PDLLA	B-T103
)	O
were	O
prepared	O
via	O
ring	B-T038
-	I-T038
opening	I-T038
copolymerization	I-T038
of	O
ε	B-T103
-	I-T103
CL	I-T103
and	O
D	B-T103
,	I-T103
L	I-T103
-	I-T103
LA	I-T103
in	O
the	O
presence	O
of	O
MPEG	B-T103
and	O
stannous	B-T103
octoate	I-T103
.	O

The	O
structure	B-T082
and	O
molecular	O
weight	O
were	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
and	O
gel	B-T058
permeation	I-T058
chromatography	I-T058
(	O
GPC	B-T058
)	O
.	O

The	O
crystallinity	B-T103
,	O
hydrophilicity	O
,	O
thermal	O
stability	O
and	O
hydrolytic	O
degradation	O
behavior	O
were	O
investigated	O
in	O
detail	O
,	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
the	O
prepared	O
amphiphilic	B-T103
MPEG	I-T103
-	I-T103
PCLA	I-T103
copolymers	I-T103
have	O
adjustable	O
properties	O
by	O
altering	O
the	O
composition	O
of	O
PCLA	B-T103
,	O
which	O
make	O
it	O
convenient	O
for	O
clinical	O
applications	O
.	O

Besides	O
,	O
the	O
drug	B-T103
loading	O
properties	O
were	O
also	O
studied	O
.	O

Docetaxel	B-T103
(	O
DTX	B-T103
)	O
could	O
be	O
entrapped	O
in	O
MPEG	B-T103
-	I-T103
PCLA	I-T103
micelles	B-T103
with	O
high	O
loading	O
capacity	O
and	O
encapsulation	O
efficiency	O
.	O

And	O
all	O
lyophilized	O
DTX	B-T103
-	O
loaded	O
MPEG	B-T103
-	I-T103
PCLA	I-T103
micelles	B-T103
except	O
MPEG	B-T103
-	I-T103
PCL	I-T103
micelles	B-T103
were	O
readily	O
re	O
-	O
dissolved	O
in	O
normal	B-T103
saline	I-T103
at	O
25	O
°C	O
.	O

In	O
addition	O
,	O
DTX	B-T103
-	O
loaded	O
MPEG	B-T103
-	I-T103
PCLA	I-T103
micelles	B-T103
showed	O
a	O
slightly	O
enhanced	O
antitumor	O
activity	O
compared	O
with	O
free	O
DTX	B-T103
.	O

Furthermore	O
,	O
DTX	B-T103
micelles	B-T103
exhibited	O
a	O
slower	O
and	O
sustained	O
release	O
behavior	O
in	O
vitro	O
,	O
and	O
higher	O
DTX	B-T103
concentration	O
and	O
longer	O
retention	O
time	O
in	B-T082
vivo	I-T082
.	O

The	O
results	O
suggested	O
that	O
the	O
MPEG	B-T103
-	I-T103
PCLA	I-T103
copolymer	I-T103
with	O
the	O
adjustable	O
ratio	O
of	O
PCL	B-T103
to	O
PDLLA	B-T103
may	O
be	O
a	O
promising	O
drug	B-T103
delivery	I-T103
carrier	I-T103
for	O
DTX	B-T103
.	O

Thyroid	B-T038
cancer	I-T038
burden	O
in	O
Central	B-T082
and	O
South	B-T082
America	I-T082

Incidence	O
of	O
thyroid	B-T038
cancer	I-T038
(	O
TC	B-T038
)	O
is	O
rapidly	O
increasing	O
worldwide	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
TC	B-T038
burden	O
in	O
Central	B-T082
and	O
South	B-T082
America	I-T082
(	O
CSA	B-T082
)	O
.	O

We	O
describe	O
the	O
geographic	B-T082
patterns	I-T082
and	O
trends	O
of	O
TC	B-T038
by	O
sex	O
in	O
CSA	B-T082
.	O

We	O
obtained	O
regional	O
-	O
and	O
national	O
-	O
level	O
incidence	O
data	O
from	O
48	O
population	B-T170
-	I-T170
based	I-T170
cancer	I-T170
registries	I-T170
in	O
13	O
countries	B-T082
and	O
nationwide	O
cancer	O
deaths	O
from	O
the	O
WHO	B-T092
mortality	O
database	B-T170
for	O
18	O
countries	B-T082
.	O

We	O
estimated	O
world	B-T098
population	O
age	O
-	O
standardized	O
incidence	O
rates	O
(	O
ASRs	O
)	O
and	O
age	O
-	O
standardized	O
mortality	O
rates	O
(	O
ASMRs	O
)	O
per	O
100	O
,	O
000	O
person	B-T098
-	O
years	O
.	O

We	O
calculated	O
ASRs	O
by	O
histological	B-T201
subtype	I-T201
.	O

We	O
estimated	O
the	O
annual	O
percentage	O
change	O
(	O
EAPC	O
)	O
to	O
describe	O
time	O
trends	O
.	O

Between	O
CSA	B-T082
countries	B-T082
,	O
TC	B-T038
incidence	O
and	O
mortality	O
rates	O
varied	O
from	O
8	O
-	O
fold	O
to	O
12	O
-	O
fold	O
and	O
from	O
2	O
-	O
fold	O
to	O
5	O
-	O
fold	O
,	O
respectively	O
.	O

In	O
2003	O
-	O
2007	O
,	O
the	O
highest	O
TC	B-T038
ASRs	O
in	O
females	O
and	O
males	O
were	O
in	O
Ecuador	B-T082
(	O
16	O
.	O
0	O
and	O
3	O
.	O
5	O
,	O
respectively	O
)	O
,	O
Brazil	B-T082
(	O
14	O
.	O
4	O
and	O
3	O
.	O
4	O
)	O
,	O
Costa	B-T082
Rica	I-T082
(	O
12	O
.	O
6	O
and	O
2	O
.	O
1	O
)	O
and	O
Colombia	B-T082
(	O
10	O
.	O
7	O
and	O
2	O
.	O
5	O
)	O
.	O

The	O
highest	O
ASMRs	O
were	O
in	O
Ecuador	B-T082
,	O
Colombia	B-T082
,	O
Mexico	B-T082
,	O
Peru	B-T082
and	O
Panama	B-T082
(	O
0	O
.	O
68	O
-	O
0	O
.	O
91	O
in	O
females	O
and	O
0	O
.	O
41	O
-	O
0	O
.	O
48	O
in	O
males	O
)	O
.	O

Papillary	B-T038
TC	I-T038
was	O
the	O
most	O
commonly	O
diagnosed	B-T033
histological	B-T201
subtype	I-T201
,	O
following	O
the	O
same	O
incidence	O
pattern	O
as	O
overall	O
TC	B-T038
.	O

In	O
Argentinean	O
,	O
Brazilian	O
,	O
Chilean	O
and	O
Costa	O
Rican	O
females	O
TC	B-T038
incidence	O
increased	O
by	O
2	O
.	O
2	O
-	O
17	O
.	O
9	O
%	O
annually	O
,	O
and	O
papillary	B-T038
TC	I-T038
increased	O
by	O
9	O
.	O
1	O
-	O
15	O
.	O
0	O
%	O
annually	O
,	O
while	O
mortality	O
remained	O
stable	O
between	O
1997	O
and	O
2008	O
.	O

In	O
males	O
,	O
trends	O
in	O
TC	B-T038
were	O
stable	O
.	O

TC	B-T038
occurred	O
more	O
frequently	O
in	O
females	O
than	O
in	O
males	O
.	O

The	O
overall	O
high	O
incidence	O
and	O
low	O
mortality	O
of	O
TC	B-T038
suggest	O
identification	O
of	O
subclinical	B-T038
disease	I-T038
due	O
to	O
improved	O
detection	B-T170
methods	I-T170
.	O

Histopathological	O
Evaluation	B-T058
of	O
the	O
Effectiveness	O
of	O
Glycyrrhizic	B-T103
Acid	I-T103
as	O
a	O
Radioprotector	B-T058
Against	O
the	O
Development	O
of	O
Radiation	B-T038
-	I-T038
Induced	I-T038
Lung	I-T038
Fibrosis	I-T038

Radiotherapy	B-T058
of	O
the	O
thorax	B-T082
often	O
causes	O
lung	B-T038
inflammation	I-T038
leading	O
to	O
fibrosis	B-T038
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
whether	O
the	O
use	O
of	O
glycyrrhizic	B-T103
acid	I-T103
(	O
GLA	B-T103
)	O
could	O
improve	O
the	O
development	O
of	O
lung	B-T038
fibrosis	I-T038
in	O
irradiated	B-T058
animals	B-T204
.	O

Wistar	B-T204
rats	I-T204
were	O
divided	O
into	O
four	O
groups	O
.	O

Group	O
A	O
rats	B-T204
received	O
thoracic	O
irradiation	O
.	O

Rats	B-T204
in	O
group	O
B	O
received	O
GLA	B-T103
and	O
irradiation	B-T058
.	O

Group	O
C	O
received	O
GLA	B-T103
and	O
no	O
irradiation	B-T058
.	O

Group	O
D	O
received	O
no	O
GLA	B-T103
and	O
irradiation	B-T058
.	O

GLA	B-T103
was	O
administered	O
at	O
a	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
using	O
an	O
intraperitoneal	B-T058
injection	I-T058
one	O
hour	O
before	O
thoracic	O
irradiation	O
.	O

Radiation	B-T058
therapy	I-T058
was	O
delivered	O
on	O
a	O
Cobalt	B-T103
-	I-T103
60	I-T103
unit	O
using	O
a	O
single	O
fraction	O
of	O
16	O
Gy	O
.	O

The	O
animals	B-T204
were	O
sacrificed	O
at	O
32	O
weeks	O
following	O
thoracic	O
irradiation	O
.	O

The	O
lungs	B-T017
were	O
dissected	O
and	O
blind	O
histopathological	O
evaluation	B-T058
was	O
performed	O
.	O

Histopathologically	O
,	O
a	O
decrease	O
(	O
statistically	O
not	O
significant	O
)	O
in	O
the	O
thickening	B-T033
of	O
alveolar	B-T017
or	O
bronchial	B-T017
wall	I-T017
,	O
formation	O
of	O
fibrous	B-T017
bands	I-T017
,	O
and	O
superimposed	O
collagen	B-T103
were	O
noted	O
in	O
the	O
animals	B-T204
in	O
group	O
B	O
as	O
compared	O
to	O
the	O
animals	B-T204
in	O
group	O
A	O
.	O

In	O
this	O
experimental	B-T062
study	I-T062
,	O
administration	O
of	O
GLA	B-T103
one	O
hour	O
before	O
thoracic	O
irradiation	O
may	O
be	O
a	O
protective	B-T103
agent	I-T103
against	O
radiation	B-T038
-	I-T038
induced	I-T038
fibrosis	I-T038
in	O
animals	B-T204
and	O
this	O
model	B-T038
could	O
be	O
used	O
in	O
future	O
studies	O
.	O

Avulsions	B-T037
of	O
Triceps	B-T017
Brachii	I-T017
:	O
associated	O
injuries	B-T037
and	O
surgical	B-T058
treatment	I-T058
;	O
a	O
case	O
series	O

This	O
study	B-T062
reports	O
the	O
clinical	O
presentations	O
,	O
intra	O
-	O
operative	O
findings	B-T033
,	O
type	O
of	O
the	O
treatments	B-T058
,	O
outcome	O
of	O
the	O
treatment	B-T058
and	O
specially	O
associated	O
injuries	B-T037
in	O
patients	O
with	O
the	O
avulsion	B-T037
of	O
the	O
distal	B-T082
end	I-T082
of	O
the	O
triceps	B-T017
brachii	I-T017
(	I-T017
TB	I-T017
)	I-T017
tendon	I-T017
.	O

We	O
studied	O
6	O
patients	O
with	O
rupture	B-T037
or	O
avulsion	B-T037
of	O
the	O
distal	B-T082
end	I-T082
of	O
the	O
TB	B-T017
tendon	I-T017
.	O

The	O
medical	B-T170
records	I-T170
,	O
imaging	B-T170
files	I-T170
,	O
clinical	O
outcomes	O
at	O
the	O
final	O
follow	B-T058
up	I-T058
visit	I-T058
were	O
reviewed	O
.	O

The	O
clinical	O
outcomes	O
were	O
assessed	O
by	O
Mayo	B-T170
Elbow	I-T170
Score	I-T170
at	O
the	O
final	O
follow	B-T058
-	I-T058
up	I-T058
visit	I-T058
.	O

All	O
patients	O
were	O
male	O
,	O
4	O
of	O
them	O
having	O
injury	B-T037
in	O
the	O
left	B-T017
hand	I-T017
as	O
the	O
non	O
-	O
dominant	O
hand	B-T017
.	O

Mean	O
age	O
of	O
them	O
was	O
34	O
.	O
5	O
years	O
.	O

All	O
cases	O
had	O
small	O
bony	O
fleck	B-T037
in	O
the	O
posterior	O
of	O
elbow	B-T082
in	O
lateral	B-T058
radiograph	I-T058
.	O

Three	O
patients	O
had	O
associated	O
injuries	B-T037
-	O
including	O
intra	B-T082
-	I-T082
articular	I-T082
fractures	B-T037
and	O
medial	O
collateral	O
ligament	O
rupture	O
.	O

In	O
one	O
case	O
V	B-T058
-	I-T058
Y	I-T058
plasty	I-T058
of	O
the	O
distal	B-T082
TB	B-T017
was	O
done	O
.	O

In	O
4	O
patients	O
the	O
results	O
of	O
surgery	B-T058
were	O
excellent	O
,	O
one	O
was	O
good	O
and	O
one	O
was	O
fair	O
.	O

Although	O
TB	B-T017
tendon	I-T017
rupture	B-T037
is	O
rare	O
,	O
it	O
should	O
be	O
-	O
considered	O
in	O
differential	O
diagnosis	B-T062
of	O
the	O
upper	O
-	O
extremity	O
trauma	O
and	O
its	O
associated	O
injuries	B-T037
should	O
be	O
addressed	O
properly	O
.	O

Prolyl	B-T103
-	I-T103
4	I-T103
-	I-T103
hydroxylase	I-T103
2	I-T103
and	O
3	B-T103
coregulate	O
murine	B-T103
erythropoietin	B-T103
in	O
brain	B-T017
pericytes	B-T017

A	O
classic	O
response	B-T033
to	O
systemic	O
hypoxia	B-T038
is	O
the	O
increased	O
production	B-T038
of	I-T038
red	I-T038
blood	I-T038
cells	I-T038
due	O
to	O
hypoxia	B-T103
-	I-T103
inducible	I-T103
factor	I-T103
(	O
HIF	B-T103
)	O
-	O
mediated	O
induction	O
of	O
erythropoietin	B-T103
(	O
EPO	B-T103
)	O
.	O

EPO	B-T103
is	O
a	O
glycoprotein	B-T103
hormone	I-T103
that	O
is	O
essential	O
for	O
normal	B-T038
erythropoiesis	I-T038
and	O
is	O
predominantly	O
synthesized	O
by	O
peritubular	B-T082
renal	B-T017
interstitial	I-T017
fibroblast	I-T017
-	I-T017
like	I-T017
cells	I-T017
,	O
which	O
express	O
cellular	B-T201
markers	I-T201
characteristic	O
of	O
neuronal	B-T017
cells	I-T017
and	O
pericytes	B-T017
.	O

To	O
investigate	O
whether	O
the	O
ability	O
to	O
synthesize	O
EPO	B-T103
is	O
a	O
general	O
functional	O
feature	O
of	O
pericytes	B-T017
,	O
we	O
used	O
conditional	O
gene	B-T062
targeting	I-T062
to	O
examine	O
the	O
von	B-T038
Hippel	I-T038
-	I-T038
Lindau	I-T038
/	O
prolyl	B-T103
-	I-T103
4	I-T103
-	I-T103
hydroxylase	I-T103
domain	I-T103
(	I-T103
PHD	I-T103
)	I-T103
/	I-T103
HIF	I-T103
axis	O
in	O
cell	B-T017
-	O
expressing	B-T038
neural	B-T103
glial	I-T103
antigen	I-T103
2	I-T103
,	O
a	O
known	O
molecular	B-T201
marker	I-T201
of	O
pericytes	B-T017
in	O
multiple	B-T017
organs	I-T017
.	O

We	O
found	O
that	O
pericytes	B-T017
in	O
the	O
brain	B-T017
synthesized	O
EPO	B-T103
in	O
mice	B-T204
with	O
genetic	O
HIF	B-T103
activation	O
and	O
were	O
capable	O
of	O
responding	O
to	O
systemic	O
hypoxia	B-T038
with	O
the	O
induction	O
of	O
Epo	B-T103
.	O

Using	O
high	O
-	O
resolution	O
multiplex	O
in	B-T062
situ	I-T062
hybridization	I-T062
,	O
we	O
determined	O
that	O
brain	B-T017
pericytes	B-T017
represent	O
an	O
important	O
cellular	B-T017
source	I-T017
of	O
Epo	B-T103
in	O
the	O
hypoxic	B-T038
brain	B-T017
(	O
up	O
to	O
70	O
%	O
of	O
all	O
Epo	B-T103
-	O
expressing	B-T038
cells	B-T017
)	O
.	O

We	O
furthermore	O
determined	O
that	O
Epo	B-T103
transcription	B-T038
in	O
brain	B-T017
pericytes	B-T017
was	O
HIF	B-T103
-	I-T103
2	I-T103
dependent	O
and	O
cocontrolled	O
by	O
PHD2	B-T103
and	O
PHD3	B-T103
,	O
oxygen	B-T103
-	O
and	O
2	B-T103
-	I-T103
oxoglutarate	I-T103
-	O
dependent	O
prolyl	B-T103
-	I-T103
4	I-T103
-	I-T103
hydroxylases	I-T103
that	O
regulate	O
HIF	B-T103
activity	B-T038
.	O

In	O
summary	O
,	O
our	O
studies	O
provide	O
experimental	O
evidence	O
that	O
pericytes	B-T017
in	O
the	O
brain	B-T017
have	O
the	O
ability	O
to	O
function	O
as	O
oxygen	B-T074
sensors	I-T074
and	O
respond	O
to	O
hypoxia	B-T038
with	O
EPO	B-T103
synthesis	O
.	O

Our	O
findings	O
furthermore	O
suggest	O
that	O
the	O
ability	O
to	O
synthesize	O
EPO	B-T103
may	O
represent	O
a	O
functional	O
feature	O
of	O
pericytes	B-T017
in	O
the	O
brain	B-T017
and	O
kidney	B-T017
.	O

Patient	O
Satisfaction	O
with	O
Pharmacist	B-T097
-	O
Led	O
Collaborative	O
Follow	B-T058
-	I-T058
Up	I-T058
Care	I-T058
in	O
an	O
Ambulatory	O
Rheumatology	B-T092
Clinic	I-T092

Patient	O
satisfaction	O
is	O
known	O
to	O
increase	O
with	O
pharmacist	B-T097
intervention	B-T058
in	O
general	B-T092
outpatient	I-T092
clinics	I-T092
and	O
with	O
nurse	B-T058
-	I-T058
led	I-T058
care	I-T058
in	O
rheumatology	B-T092
clinics	I-T092
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
describe	O
and	O
compare	O
patient	O
satisfaction	O
with	O
two	O
different	O
types	O
of	O
care	B-T058
:	O
a	O
pharmacist	B-T097
physician	B-T097
collaborative	O
model	O
and	O
a	O
traditional	O
physician	O
model	O
in	O
a	O
rheumatology	B-T092
clinic	I-T092
setting	O
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
survey	I-T062
of	O
inflammatory	B-T038
arthritis	I-T038
patients	O
seen	O
during	O
a	O
follow	B-T058
-	I-T058
up	I-T058
visit	I-T058
in	O
Edmonton	O
,	O
Alberta	O
,	O
Canada	B-T082
,	O
was	O
conducted	O
over	O
a	O
ten	B-T062
-	I-T062
week	I-T062
period	I-T062
.	O

Patient	O
satisfaction	O
was	O
measured	O
using	O
a	O
modified	O
version	O
of	O
the	O
validated	O
Leeds	B-T058
Satisfaction	I-T058
Questionnaire	I-T058
,	O
which	O
uses	O
a	O
five	O
-	O
point	O
Likert	B-T170
scale	I-T170
to	O
measure	O
six	B-T082
dimensions	I-T082
of	O
satisfaction	O
,	O
and	O
compared	O
between	O
the	O
collaborative	B-T058
care	I-T058
and	O
traditional	O
physician	O
models	O
.	O

A	O
total	O
of	O
62	O
patients	O
completed	O
the	O
questionnaire	B-T170
(	O
21	O
collaborative	B-T058
care	I-T058
and	O
41	O
traditional	O
physician	O
model	O
)	O
.	O

The	O
average	O
age	O
of	O
respondents	B-T098
was	O
52	O
years	O
and	O
the	O
majority	O
were	O
female	O
.	O

The	O
mean	B-T170
score	I-T170
for	I-T170
satisfaction	I-T170
across	O
the	O
six	B-T082
dimensions	I-T082
was	O
4	O
.	O
56	O
in	O
the	O
collaborative	B-T092
care	I-T092
group	I-T092
and	O
4	O
.	O
30	O
in	O
the	O
traditional	B-T097
physician	I-T097
group	I-T097
(	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Patient	O
satisfaction	O
in	O
the	O
collaborative	B-T092
care	I-T092
group	I-T092
was	O
consistently	O
higher	O
across	O
all	O
dimensions	O
.	O

No	O
difference	O
was	O
noted	O
between	O
participants	B-T098
seen	O
for	O
the	O
first	O
time	O
compared	O
with	O
those	O
seen	O
two	O
or	O
more	O
times	O
by	O
the	O
pharmacist	B-T097
.	O

A	O
collaborative	O
care	O
model	O
can	O
exceed	O
the	O
already	O
high	O
expectations	O
for	O
care	B-T058
of	I-T058
patients	I-T058
with	O
inflammatory	B-T038
arthritis	I-T038
.	O

Our	O
findings	O
support	O
the	O
role	O
of	O
pharmacists	B-T097
using	O
a	O
collaborative	B-T058
care	I-T058
approach	O
to	O
care	B-T058
for	I-T058
patients	I-T058
in	O
rheumatology	B-T092
clinics	I-T092
.	O

Ontology	O
-	O
Based	O
High	O
-	O
Level	O
Context	O
Inference	B-T038
for	O
Human	O
Behavior	O
Identification	O

Recent	O
years	O
have	O
witnessed	O
a	O
huge	O
progress	O
in	O
the	O
automatic	O
identification	O
of	O
individual	B-T098
primitives	B-T170
of	O
human	O
behavior	O
,	O
such	O
as	O
activities	O
or	O
locations	B-T082
.	O

However	O
,	O
the	O
complex	O
nature	O
of	O
human	O
behavior	O
demands	O
more	O
abstract	O
contextual	O
information	O
for	O
its	O
analysis	O
.	O

This	O
work	O
presents	O
an	O
ontology	O
-	O
based	O
method	B-T170
that	O
combines	O
low	O
-	O
level	O
primitives	B-T170
of	O
behavior	O
,	O
namely	O
activity	O
,	O
locations	B-T082
and	O
emotions	B-T038
,	O
unprecedented	O
to	O
date	O
,	O
to	O
intelligently	O
derive	O
more	O
meaningful	O
high	O
-	O
level	O
context	O
information	O
.	O

The	O
paper	O
contributes	O
with	O
a	O
new	O
open	O
ontology	O
describing	O
both	O
low	O
-	O
level	O
and	O
high	O
-	O
level	O
context	O
information	O
,	O
as	O
well	O
as	O
their	O
relationships	O
.	O

Furthermore	O
,	O
a	O
framework	O
building	O
on	O
the	O
developed	O
ontology	O
and	O
reasoning	O
models	B-T170
is	O
presented	O
and	O
evaluated	O
.	O

The	O
proposed	O
method	O
proves	O
to	O
be	O
robust	O
while	O
identifying	O
high	O
-	O
level	O
contexts	O
even	O
in	O
the	O
event	O
of	O
erroneously	O
-	O
detected	B-T033
low	O
-	O
l	O
evel	O
context	O
s	O
.	O

Despite	O
reasonable	O
inference	B-T038
times	O
being	O
obtained	O
for	O
a	O
relevant	O
set	B-T038
of	O
users	B-T098
and	O
instances	O
,	O
additional	O
work	O
is	O
required	O
to	O
scale	O
to	O
long	O
-	O
term	O
scenarios	O
with	O
a	O
large	O
number	O
of	O
users	B-T098
.	O

Characterization	O
of	O
exposure	B-T037
in	O
epidemiological	B-T062
studies	I-T062
on	O
air	O
pollution	O
from	O
biodegradable	O
wastes	O
:	O
Misclassification	B-T170
and	O
comparison	O
of	O
exposure	B-T037
assessment	B-T058
strategies	B-T062

The	O
assignment	O
of	O
exposure	B-T037
is	O
one	O
of	O
the	O
main	O
challenges	O
faced	O
by	O
environmental	B-T082
epidemiologists	B-T097
.	O

However	O
,	O
misclassification	B-T170
of	O
exposures	B-T037
has	O
not	O
been	O
explored	O
in	O
population	B-T098
epidemiological	B-T062
studies	I-T062
on	O
air	O
pollution	O
from	O
biodegradable	O
wastes	O
.	O

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
the	O
use	O
of	O
different	O
approaches	O
for	O
assessing	O
exposure	B-T037
to	O
air	O
pollution	O
from	O
biodegradable	O
wastes	O
by	O
analyzing	B-T062
(	O
1	O
)	O
the	O
misclassification	B-T170
of	O
exposure	B-T037
that	O
is	O
committed	O
by	O
using	O
these	O
surrogates	O
,	O
(	O
2	O
)	O
the	O
existence	O
of	O
differentia	O
l	O
misclassification	B-T170
(	O
3	O
)	O
the	O
effects	O
that	O
misclassification	B-T170
may	O
have	O
on	O
health	O
effect	O
estimates	O
and	O
the	O
interpretation	O
of	O
epidemiological	B-T062
results	O
,	O
and	O
(	O
4	O
)	O
the	O
ability	O
of	O
the	O
exposure	B-T037
measures	O
to	O
predict	O
health	O
outcomes	O
using	O
10	O
-	O
fold	O
cross	B-T062
validation	I-T062
.	O

Four	O
different	O
exposure	B-T037
assessment	B-T058
approaches	O
were	O
studied	B-T062
:	O
ammonia	B-T103
concentrations	O
at	O
the	O
residence	B-T082
(	O
Metric	O
I	O
)	O
,	O
distance	O
to	O
the	O
closest	O
source	B-T033
(	O
Metric	O
II	O
)	O
,	O
number	O
of	O
sources	B-T033
within	O
certain	O
distances	O
from	O
the	O
residence	B-T082
(	O
Metric	O
IIIa	O
,	O
b	O
)	O
and	O
location	B-T082
in	O
a	O
specific	O
region	B-T082
(	O
Metric	O
IV	O
)	O
.	O

Exposure	B-T170
-	I-T170
response	I-T170
models	I-T170
based	O
on	O
Metric	O
I	O
provided	O
the	O
highest	O
predictive	O
ability	O
(	O
72	O
.	O
3	O
%	O
)	O
and	O
goodness	O
-	O
of	O
-	O
fit	O
,	O
followed	O
by	O
IV	O
,	O
III	O
and	O
II	O
.	O

When	O
compared	O
to	O
Metric	O
I	O
,	O
Metric	O
IV	O
yielded	O
the	O
best	O
results	O
for	O
exposure	B-T037
misclassification	B-T170
analysis	B-T062
and	O
interpretation	O
of	O
health	O
effect	O
estimates	O
,	O
followed	O
by	O
Metric	O
IIIb	O
,	O
IIIa	O
and	O
II	O
.	O

The	O
study	B-T062
showed	O
that	O
modelled	O
NH3	B-T103
concentrations	O
provide	O
more	O
accurate	O
estimations	O
of	O
true	O
exposure	B-T037
than	O
distances	O
-	O
based	O
surrogates	O
,	O
and	O
that	O
distance	O
-	O
based	O
surrogates	O
(	O
especially	O
those	O
based	O
on	O
distance	O
to	O
the	O
closest	O
point	O
source	B-T033
)	O
are	O
imprecise	O
methods	O
to	O
identify	O
exposed	O
populations	B-T098
,	O
although	O
they	O
may	O
be	O
useful	O
for	O
initial	O
studies	B-T062
.	O

De	O
Ritis	O
Ratio	O
(	O
AST	O
/	O
ALT	O
)	O
as	O
a	O
Significant	B-T201
Prognostic	I-T201
Factor	I-T201
in	O
Patients	O
With	O
Upper	B-T038
Tract	I-T038
Urothelial	I-T038
Cancer	I-T038
Treated	O
With	O
Surgery	O

We	O
investigated	O
the	O
clinical	B-T170
prognostic	I-T170
value	I-T170
of	O
preoperative	O
De	O
Ritis	O
ratio	O
(	O
aspartate	O
aminotransferase	O
[	O
AST	O
]	O
/	O
alanine	O
aminotransferase	O
[	O
ALT	O
]	O
)	O
on	O
postsurgical	B-T033
survival	O
outcomes	O
in	O
patients	O
with	O
upper	B-T038
tract	I-T038
urothelial	I-T038
cancer	I-T038
(	O
UTUC	B-T038
)	O
.	O

We	O
retrospectively	B-T062
analyzed	I-T062
the	O
data	O
of	O
623	O
patients	O
who	O
underwent	O
radical	B-T058
nephrouretectomy	I-T058
for	O
UTUC	B-T038
.	O

Multivariate	O
regression	O
tests	B-T170
were	O
performed	O
to	O
identify	O
possible	O
associations	O
between	O
adverse	B-T038
pathologic	I-T038
events	I-T038
and	O
AST	O
/	O
ALT	O
.	O

The	O
risk	O
of	O
postoperative	O
progression	O
and	O
survival	O
were	O
tested	O
using	O
Kaplan	O
-	O
Meier	O
analyses	O
and	O
Cox	B-T170
proportional	I-T170
hazards	I-T170
models	I-T170
.	O

According	O
to	O
the	O
receiver	O
operator	O
characteristic	O
curve	O
of	O
AST	O
/	O
ALT	O
for	O
cancer	O
-	O
specific	O
mortality	O
,	O
patients	O
with	O
AST	O
/	O
ALT	O
value	O
≥1	O
.	O
5	O
were	O
regarded	O
as	O
the	O
high	O
AST	O
/	O
ALT	O
group	O
,	O
and	O
the	O
remaining	O
patients	O
formed	O
the	O
low	O
AST	O
/	O
ALT	O
group	O
.	O

In	O
Kaplan	O
-	O
Meier	O
analyses	O
,	O
the	O
high	O
AST	O
/	O
ALT	O
group	O
showed	O
worse	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
,	O
cancer	O
-	O
specific	O
survival	O
(	O
CSS	O
)	O
,	O
and	O
overall	O
survival	O
(	O
all	O
P	O
<	O
.	O
001	O
)	O
.	O

Elevated	O
AST	O
/	O
ALT	O
was	O
associated	O
with	O
higher	O
T	B-T170
stage	I-T170
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
1	O
.	O
577	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
077	O
-	O
2	O
.	O
311	O
;	O
P	O
=	O
.	O
033	O
)	O
and	O
higher	B-T170
cellular	I-T170
grade	I-T170
(	O
HR	O
,	O
1	O
.	O
538	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
034	O
-	O
2	O
.	O
287	O
;	O
P	O
=	O
.	O
041	O
)	O
in	O
multivariate	O
regression	O
tests	B-T170
.	O

In	O
multivariate	O
Cox	O
analyses	O
,	O
high	O
AST	O
/	O
ALT	O
was	O
revealed	O
as	O
an	O
independent	O
predictor	O
of	O
PFS	O
(	O
HR	O
,	O
2	O
.	O
335	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
633	O
-	O
3	O
.	O
340	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
CSS	O
(	O
HR	O
,	O
2	O
.	O
550	O
;	O
1	O
.	O
689	O
-	O
3	O
.	O
851	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
overall	O
survival	O
(	O
HR	O
,	O
2	O
.	O
069	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
409	O
-	O
3	O
.	O
038	O
;	O
P	O
<	O
.	O
001	O
)	O
.	O

Elevated	O
preoperative	O
AST	O
/	O
ALT	O
was	O
a	O
significant	O
predictor	O
of	O
worse	B-T033
postoperative	O
survival	O
in	O
patients	O
surgically	B-T058
treated	I-T058
for	O
UTUC	B-T038
.	O

Further	O
large	O
prospective	B-T062
studies	I-T062
are	O
needed	O
for	O
better	O
understanding	O
of	O
the	O
prognostic	B-T170
value	I-T170
of	O
preoperative	O
AST	O
/	O
ALT	O
.	O

Molecular	O
simulation	O
study	B-T062
on	O
concentration	O
effects	O
of	O
rofecoxib	B-T103
with	O
POPC	B-T103
bilayer	B-T017

The	O
interactions	B-T038
between	O
rofecoxib	B-T103
and	O
POPC	B-T103
(	B-T103
1	I-T103
-	I-T103
palmitoyl	I-T103
-	I-T103
2	I-T103
-	I-T103
oleoyl	I-T103
-	I-T103
sn	I-T103
-	I-T103
glycero	I-T103
-	I-T103
3	I-T103
-	I-T103
phosphocholine	I-T103
)	I-T103
bilayer	B-T017
were	O
studied	B-T062
using	O
all	O
-	O
atom	O
molecular	O
dynamics	O
simulation	O
method	B-T170
.	O

Four	O
POPC	B-T103
bilayer	B-T017
systems	O
with	O
different	O
number	O
of	O
rofecoxib	B-T103
molecules	O
were	O
constructed	O
to	O
simulate	O
different	O
drug	B-T103
concentration	O
.	O

The	O
free	O
energy	O
of	O
rofecoxib	B-T103
passing	O
across	O
pure	O
POPC	B-T103
bilayer	B-T017
has	O
two	O
minima	O
(	O
at	O
z	O
∼1	O
.	O
2nm	O
or	O
1	O
.	O
6nm	O
)	O
.	O

As	O
for	O
the	O
high	O
concentration	O
model	B-T170
,	O
the	O
minimum	O
of	O
the	O
free	O
energy	O
profile	O
slightly	O
shifts	O
to	O
the	O
bilayer	B-T017
center	B-T082
.	O

Moreover	O
,	O
the	O
energy	O
change	O
from	O
bulk	O
water	O
to	O
POPC	B-T103
bilayer	B-T017
increases	O
while	O
the	O
central	B-T082
barrier	B-T038
to	O
cross	O
the	O
hydrophobic	O
core	O
of	O
bilayer	B-T017
slightly	O
decreases	O
,	O
suggesting	O
that	O
increasing	O
drug	B-T103
concentration	O
makes	O
it	O
favorable	B-T033
for	O
rofecoxib	B-T103
to	O
partition	O
into	O
the	O
bilayer	B-T017
and	O
easier	O
to	O
pass	O
across	O
bialyer	B-T017
center	B-T082
.	O

Energy	O
analysis	B-T062
show	O
that	O
the	O
stabilization	O
between	O
the	O
selected	O
rofecoxib	B-T103
and	O
other	O
pre	O
-	O
inserted	O
rofecoxib	B-T103
molecule	O
is	O
mainly	O
due	O
to	O
van	O
der	O
Waals	O
interaction	O
energy	O
.	O

The	O
predicted	O
permeability	O
of	O
rofecoxib	B-T103
in	O
high	O
concentration	O
model	B-T170
slightly	O
weakens	O
as	O
compared	O
with	O
low	O
concentration	O
model	B-T170
.	O

Short	O
-	O
term	O
Variability	O
of	O
Vitamin	B-T103
D	I-T103
-	O
Related	O
Biomarkers	B-T201

Quantifying	O
the	O
variability	O
of	O
biomarkers	B-T201
is	O
important	O
,	O
as	O
high	O
within	O
-	O
person	O
variability	O
can	O
lead	O
to	O
misclassification	B-T170
of	O
individuals	B-T098
.	O

Short	O
-	O
term	O
variability	O
of	O
important	O
markers	B-T201
of	O
vitamin	B-T038
D	I-T038
metabolism	I-T038
is	O
relatively	O
unknown	O
.	O

A	O
repeatability	B-T062
study	I-T062
was	O
conducted	O
in	O
160	O
Atherosclerosis	B-T038
Risk	O
in	O
Communities	B-T098
study	I-T098
participants	I-T098
(	O
60	O
%	O
female	O
,	O
28	O
%	O
black	B-T098
,	O
mean	O
age	O
76	O
years	O
)	O
.	O

Fasting	B-T033
serum	B-T031
was	O
drawn	O
at	O
2	O
time	O
points	O
,	O
a	O
median	O
of	O
6	O
(	O
range	O
3	O
-	O
13	O
)	O
weeks	O
apart	O
.	O

Vitamin	B-T103
D	I-T103
binding	I-T103
protein	I-T103
(	O
VDBP	B-T103
)	O
and	O
25	B-T103
-	I-T103
hydroxyvitamin	I-T103
D	I-T103
[	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
]	O
were	O
measured	O
by	O
LC	B-T058
-	I-T058
MS	I-T058
,	O
fibroblast	B-T103
growth	I-T103
factor	I-T103
(	O
FGF23	B-T103
)	O
and	O
parathyroid	B-T103
hormone	I-T103
(	O
PTH	B-T103
)	O
by	O
enzyme	B-T058
-	I-T058
linked	I-T058
immunoassay	I-T058
,	O
and	O
calcium	B-T103
and	O
phosphorus	B-T103
by	O
Roche	B-T058
Cobas	I-T058
6000	I-T058
.	O

Free	O
and	O
bioavailable	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
were	O
calculated	O
.	O

We	O
calculated	O
the	O
within	O
-	O
person	O
CV	O
(	O
CVW	O
)	O
,	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
,	O
Spearman	O
rank	O
correlation	O
coefficient	O
(	O
r	O
)	O
,	O
and	O
percent	O
reclassified	O
.	O

The	O
CVW	O
was	O
lowest	O
for	O
calcium	B-T103
(	O
2	O
.	O
0	O
%	O
)	O
,	O
albumin	B-T103
(	O
3	O
.	O
6	O
%	O
)	O
,	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
(	O
6	O
.	O
9	O
%	O
)	O
,	O
VDBP	B-T103
(	O
7	O
.	O
0	O
%	O
)	O
and	O
phosphorus	B-T103
(	O
7	O
.	O
6	O
%	O
)	O
;	O
intermediate	B-T033
for	O
free	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
(	O
9	O
.	O
0	O
%	O
)	O
and	O
bioavailable	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
(	O
9	O
.	O
9	O
%	O
)	O
;	O
and	O
highest	O
for	O
PTH	B-T103
(	O
16	O
.	O
7	O
%	O
)	O
and	O
FGF23	B-T103
(	O
17	O
.	O
8	O
%	O
)	O
.	O

Reclassification	B-T170
was	O
highest	O
for	O
PTH	B-T103
,	O
VDBP	B-T103
,	O
and	O
phosphorus	B-T103
(	O
all	O
7	O
.	O
5	O
%	O
)	O
.	O

The	O
ICC	O
and	O
r	O
were	O
highest	O
(	O
≥0	O
.	O
80	O
)	O
for	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
,	O
free	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
,	O
bioavailable	O
25	B-T103
(	I-T103
OH	I-T103
)	I-T103
D	I-T103
and	O
PTH	B-T103
,	O
but	O
somewhat	O
lower	O
(	O
approximately	O
0	O
.	O
60	O
-	O
0	O
.	O
75	O
)	O
for	O
the	O
other	O
biomarkers	B-T201
.	O

Six	O
-	O
week	O
short	O
-	O
term	O
variability	O
,	O
as	O
assessed	O
by	O
CVW	O
,	O
was	O
quite	O
low	O
for	O
VDBP	B-T103
,	O
calcium	B-T103
and	O
phosphorus	B-T103
,	O
but	O
fairly	O
high	O
for	O
FGF23	B-T103
and	O
PTH	B-T103
.	O

As	O
such	O
,	O
multiple	O
measurements	O
of	O
FGF23	B-T103
and	O
PTH	B-T103
may	O
be	O
needed	O
to	O
minimize	O
misclassification	B-T170
.	O

These	O
results	O
provide	O
insight	B-T038
into	O
the	O
extent	O
of	O
potential	O
misclassification	B-T170
of	O
vitamin	B-T103
D	I-T103
markers	B-T201
in	O
research	B-T062
and	O
clinical	O
settings	O
.	O

Fabrication	O
of	O
gelatin	B-T103
methacrylate	I-T103
/	O
nanohydroxyapatite	B-T103
microgel	B-T103
arrays	B-T082
for	O
periodontal	B-T058
tissue	I-T058
regeneration	I-T058

Periodontitis	B-T038
is	O
a	O
chronic	B-T038
infectious	I-T038
disease	I-T038
and	O
is	O
the	O
major	B-T033
cause	I-T033
of	O
tooth	B-T017
loss	I-T017
and	O
other	O
oral	B-T058
health	I-T058
issues	B-T033
around	O
the	O
world	B-T098
.	O

Periodontal	B-T058
tissue	I-T058
regeneration	I-T058
has	O
therefore	O
always	O
been	O
the	O
ultimate	B-T170
goal	I-T170
of	O
dentists	B-T097
and	O
researchers	B-T097
.	O

Existing	O
fabrication	O
methods	B-T170
mainly	O
focused	O
on	O
a	O
top	B-T058
-	I-T058
down	I-T058
tissue	I-T058
engineering	I-T058
strategy	O
in	O
which	O
several	O
drawbacks	O
remain	B-T033
,	O
including	O
low	O
throughput	O
and	O
limited	O
diffusion	O
properties	O
resulting	O
from	O
a	O
large	O
sample	O
size	O
.	O

Gelatin	B-T103
methacrylate	I-T103
(	O
GelMA	B-T103
)	O
is	O
a	O
kind	O
of	O
photocrosslinkable	O
and	O
biocompatible	B-T103
hydrogel	B-T103
,	O
with	O
the	O
capacities	O
of	O
enabling	B-T038
cell	B-T058
encapsulation	I-T058
and	O
regeneration	B-T038
of	I-T038
functional	I-T038
tissues	I-T038
.	O

Here	O
,	O
we	O
developed	O
a	O
novel	O
method	O
to	O
fabricate	O
GelMA	B-T103
/	O
nanohydroxylapatite	B-T103
(	O
nHA	B-T103
)	O
microgel	B-T103
arrays	B-T082
using	O
a	O
photocrosslinkable	O
strategy	O
.	O

The	O
viability	B-T038
,	O
proliferation	B-T038
,	O
and	O
osteogenic	B-T038
differentiation	I-T038
and	O
in	B-T082
vivo	I-T082
osteogenesis	B-T038
of	O
human	B-T204
periodontal	B-T017
ligament	I-T017
stem	B-T017
cells	I-T017
(	O
hPDLSCs	B-T017
)	O
encapsulated	O
in	O
microgels	B-T103
were	O
evaluated	B-T058
.	O

The	O
results	O
suggested	O
that	O
such	O
microgels	B-T103
provide	O
great	O
potential	O
for	O
periodontal	B-T058
tissue	I-T058
repair	I-T058
and	I-T058
regeneration	I-T058
.	O

Microgel	B-T103
arrays	B-T082
were	O
fabricated	O
by	O
blending	O
different	O
weight	O
ratios	O
of	O
GelMA	B-T103
and	O
nHA	B-T103
.	O

hPDLSCs	B-T017
were	O
encapsulated	O
in	O
GelMA	B-T103
/	O
nHA	B-T103
microgels	B-T103
of	O
various	O
ratios	O
for	O
a	O
systematic	O
evaluation	B-T058
of	O
cell	B-T038
viability	I-T038
,	O
proliferation	B-T038
,	O
and	O
osteogenic	B-T038
differentiation	I-T038
.	O

In	B-T082
vivo	I-T082
osteogenesis	B-T038
in	O
nude	B-T204
mice	I-T204
was	O
also	O
studied	O
.	O

The	O
GelMA	B-T103
/	O
nHA	B-T103
microgels	B-T103
exhibited	O
appropriate	O
microarchitecture	O
,	O
mechanical	O
strength	O
,	O
and	O
surface	B-T082
roughness	O
,	O
thus	O
enabling	O
cell	B-T038
adhesion	I-T038
and	O
proliferation	B-T038
.	O

Additionally	O
,	O
the	O
GelMA	B-T103
/	O
nHA	B-T103
microgels	B-T103
(	O
10	O
%	O
/	O
2	O
%	O
w	O
/	O
v	O
)	O
enhanced	O
the	O
osteogenic	B-T038
differentiation	I-T038
of	O
hPDLSCs	B-T017
by	O
elevating	O
the	O
expression	O
levels	O
of	O
osteogenic	B-T201
biomarker	I-T201
genes	B-T017
,	O
such	O
as	O
ALP	B-T017
,	O
BSP	B-T017
,	O
OCN	B-T017
,	O
and	O
RUNX2	B-T017
.	O

In	B-T082
vivo	I-T082
ectopic	B-T082
transplantation	B-T058
results	O
showed	O
that	O
GelMA	B-T103
/	O
nHA	B-T103
microgels	B-T103
(	O
10	O
%	O
/	O
2	O
%	O
w	O
/	O
v	O
)	O
increased	O
mineralized	B-T017
tissue	I-T017
formation	O
with	O
abundant	O
vascularization	O
,	O
compared	O
with	O
the	O
1	O
%	O
,	O
3	O
%	O
,	O
and	O
the	O
pure	O
GelMA	B-T103
group	I-T103
.	O

The	O
GelMA	B-T103
/	O
nHA	B-T103
microgels	B-T103
(	O
10	O
%	O
/	O
2	O
%	O
w	O
/	O
v	O
)	O
facilitated	O
hPDLSCs	B-T017
viability	B-T038
,	O
proliferation	B-T038
,	O
and	O
osteogenic	B-T038
differentiation	I-T038
in	O
vitro	O
and	O
further	B-T082
promoted	O
new	O
bone	B-T038
formation	I-T038
in	B-T082
vivo	I-T082
,	O
suggesting	O
that	O
the	O
GelMA	B-T103
/	O
nHA	B-T103
microgels	B-T103
(	O
10	O
%	O
/	O
2	O
%	O
w	O
/	O
v	O
)	O
provide	O
great	O
potential	O
for	O
periodontal	B-T058
tissue	I-T058
regeneration	I-T058
.	O

Esomeprazole	B-T103
-	O
or	O
rabeprazole	B-T103
-	O
based	O
triple	O
therapy	B-T058
eradicated	O
Helicobacter	B-T007
pylori	I-T007
comparably	O
regardless	O
of	O
clarithromycin	B-T103
susceptibility	O
and	O
CYP2C19	B-T017
genotypes	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
assess	O
the	O
efficacy	O
of	O
esomeprazole	B-T103
-	O
based	O
triple	O
therapy	B-T058
compared	O
with	O
rabeprazole	B-T103
-	O
based	O
triple	O
therapy	B-T058
according	O
to	O
CYP2C19	B-T017
genotype	O
and	O
clarithromycin	B-T103
susceptibility	O
status	O
for	O
first	O
-	O
line	O
eradication	B-T058
therapy	I-T058
of	I-T058
Helicobacter	I-T058
pylori	I-T058
(	O
H	B-T007
.	I-T007

pylori	I-T007
)	O
in	O
Japan	B-T082
.	O

We	O
enrolled	O
219	O
H	B-T007
.	I-T007

pylori	I-T007
-	O
infected	O
patients	O
,	O
and	O
randomly	O
allocated	O
patients	O
to	O
the	O
EAC	O
group	O
(	O
esomeprazole	B-T103
20	O
mg	O
,	O
clarithromycin	B-T103
200	O
mg	O
,	O
amoxicillin	B-T103
750	O
mg	O
for	O
one	O
week	O
,	O
with	O
all	O
drugs	B-T103
given	O
twice	O
daily	O
)	O
or	O
RAC	O
group	O
(	O
rabeprazole	B-T103
10	O
mg	O
,	O
clarithromycin	B-T103
200	O
mg	O
,	O
amoxicillin	B-T103
750	O
mg	O
for	O
one	O
week	O
,	O
with	O
all	O
drugs	B-T103
given	O
twice	O
daily	O
)	O
.	O

The	O
H	B-T007
.	I-T007

pylori	I-T007
eradication	O
rate	O
according	O
to	O
the	O
PP	B-T062
analyses	I-T062
was	O
75	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
:	O
65	O
.	O
2	O
-	O
82	O
.	O
8	O
%	O
)	O
in	O
the	O
EAC	O
group	O
and	O
71	O
.	O
4	O
%	O
(	O
95	O
%	O
CI	O
:	O
61	O
.	O
4	O
-	O
79	O
.	O
1	O
%	O
)	O
in	O
the	O
RAC	O
group	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
.	O

The	O
eradication	O
rates	O
of	O
the	O
clarithromycin	B-T038
-	I-T038
resistant	I-T038
/	O
-	O
sensitive	O
strains	B-T007
were	O
,	O
respectively	O
,	O
45	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
:	O
30	O
.	O
7	O
-	O
60	O
.	O
2	O
%	O
)	O
/	O
98	O
.	O
0	O
%	O
(	O
95	O
%	O
CI	O
:	O
88	O
.	O
7	O
-	O
100	O
%	O
)	O
in	O
the	O
EAC	O
group	O
and	O
39	O
.	O
5	O
%	O
(	O
95	O
%	O
CI	O
:	O
25	O
.	O
6	O
-	O
55	O
.	O
3	O
%	O
)	O
/	O
93	O
.	O
5	O
%	O
(	O
95	O
%	O
CI	O
:	O
81	O
.	O
9	O
-	O
98	O
.	O
4	O
%	O
)	O
in	O
the	O
RAC	O
group	O
.	O

The	O
eradication	O
rate	O
of	O
the	O
clarithromycin	B-T103
-	O
sensitive	O
strains	B-T007
was	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
resistant	B-T038
strains	I-T038
in	O
both	O
groups	O
.	O

In	O
conclusion	O
,	O
EAC	O
and	O
RAC	O
therapies	B-T058
show	O
a	O
comparable	O
efficacy	O
regardless	O
of	O
the	O
CYP2C19	B-T017
genotype	O
and	O
clarithromycin	B-T103
susceptibility	O
status	O
in	O
Japan	B-T082
.	O

Optimization	O
of	O
Early	O
Response	B-T058
Monitoring	I-T058
and	O
Prediction	O
of	O
Cancer	B-T038
Antiangiogenesis	B-T058
Therapy	I-T058
via	O
Noninvasive	B-T170
PET	B-T058
Molecular	I-T058
Imaging	I-T058
Strategies	O
of	O
Multifactorial	B-T033
Bioparameters	O

Objective	O
:	O
Antiangiogenesis	B-T058
therapy	I-T058
(	O
AAT	B-T058
)	O
has	O
provided	O
substantial	O
benefits	O
regarding	O
improved	O
outcomes	O
and	O
survival	O
for	O
suitable	O
patients	O
in	O
clinical	O
settings	O
.	O

Therefore	O
,	O
the	O
early	O
definition	O
of	O
therapeutic	B-T201
effects	I-T201
is	O
urgently	O
needed	O
to	O
guide	O
cancer	B-T038
AAT	B-T058
.	O

We	O
aimed	O
to	O
optimize	O
the	O
early	O
response	B-T058
monitoring	I-T058
and	O
prediction	O
of	O
AAT	B-T058
efficacy	O
,	O
as	O
indicated	O
by	O
the	O
multi	O
-	O
targeted	O
anti	B-T103
-	I-T103
angiogenic	I-T103
drug	I-T103
sunitinib	B-T103
in	O
U87MG	B-T038
tumors	I-T038
,	O
using	O
noninvasive	B-T170
positron	B-T058
emission	I-T058
computed	I-T058
tomography	I-T058
(	I-T058
PET	I-T058
)	I-T058
molecular	I-T058
imaging	I-T058
strategies	O
of	O
multifactorial	B-T033
bioparameters	O
.	O

Methods	O
:	O
U87MG	B-T038
tumor	I-T038
mice	B-T204
were	O
treated	O
via	O
intragastric	B-T082
injections	B-T058
of	O
sunitinib	B-T103
(	O
80	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	B-T103
for	O
7	O
consecutive	O
days	O
.	O

Longitudinal	B-T082
MicroPET	B-T058
/	I-T058
CT	I-T058
scans	I-T058
with	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
FDG	I-T103
,	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
FMISO	I-T103
,	I-T103
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
ML	I-T103
-	I-T103
10	I-T103
and	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
Alfatide	I-T103
II	I-T103
were	O
acquired	O
to	O
quantitatively	O
measure	O
metabolism	B-T038
,	O
hypoxia	B-T038
,	O
apoptosis	B-T038
and	O
angiogenesis	B-T038
on	O
days	O
0	O
,	O
1	O
,	O
3	O
,	O
7	O
and	O
13	O
following	O
therapy	B-T058
initiation	O
.	O

Tumor	B-T017
tissues	I-T017
from	O
a	O
dedicated	O
group	O
of	O
mice	B-T204
were	O
collected	O
for	O
immunohistochemical	O
(	O
IHC	O
)	O
analysis	O
of	O
key	O
biomarkers	B-T103
(	O
Glut	B-T103
-	I-T103
1	I-T103
,	O
CA	B-T103
-	I-T103
IX	I-T103
,	O
TUNEL	O
,	O
ανβ3	B-T103
and	O
CD31	B-T103
)	O
at	O
the	O
time	O
points	O
of	O
PET	B-T058
imaging	I-T058
.	O

The	O
tumor	B-T082
sizes	I-T082
and	O
mouse	B-T204
weights	O
were	O
measured	O
throughout	O
the	O
study	O
.	O

The	O
tumor	B-T038
uptake	B-T038
(	O
ID	O
%	O
/	O
gmax	O
)	O
,	O
the	O
ratios	O
of	O
the	O
tumor	B-T038
/	O
muscle	B-T017
(	O
T	B-T038
/	O
M	B-T017
)	O
for	O
each	O
probe	O
,	O
and	O
the	O
tumor	O
growth	O
ratios	O
(	O
TGR	O
)	O
were	O
calculated	O
and	O
used	O
for	O
statistical	O
analyses	O
of	O
the	O
differences	O
and	O
correlations	O
.	O

Results	O
:	O
Sunitinib	B-T103
successfully	O
inhibited	O
U87MG	O
tumor	O
growth	O
with	O
significant	O
differences	O
in	O
the	O
tumor	B-T082
size	I-T082
from	O
day	O
9	O
after	O
sunitinib	B-T103
treatment	B-T058
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
uptakes	B-T038
of	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
FMISO	I-T103
(	O
reduced	O
hypoxia	B-T038
)	O
,	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
ML	I-T103
-	I-T103
10	I-T103
(	O
increased	O
apoptosis	B-T038
)	O
and	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
Alfatide	I-T103
II	I-T103
(	O
decreased	O
angiogenesis	B-T038
)	O
in	O
the	O
tumor	B-T038
lesions	B-T033
significantly	O
changed	O
during	O
the	O
early	O
stage	O
(	O
days	O
1	O
to	O
3	O
)	O
of	O
sunitinib	B-T103
treatment	B-T058
;	O
however	O
,	O
the	O
uptake	B-T038
of	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
FDG	I-T103
(	O
increased	O
glucose	B-T038
metabolism	I-T038
)	O
was	O
significantly	O
different	O
during	O
the	O
late	O
stage	O
.	O

The	O
PET	B-T058
imaging	I-T058
data	O
of	O
each	O
probe	O
were	O
all	O
confirmed	O
via	O
ex	O
vivo	O
IHC	O
of	O
the	O
relevant	O
biomarkers	B-T103
.	O

Notably	O
,	O
the	O
PET	B-T058
imaging	I-T058
of	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
Alfatide	I-T103
II	I-T103
and	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
FMISO	I-T103
was	O
significantly	O
correlated	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
TGR	O
,	O
whereas	O
the	O
imaging	O
of	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
FDG	I-T103
and	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
ML	I-T103
-	I-T103
10	I-T103
was	O
not	O
significantly	O
correlated	O
with	O
TGR	O
.	O

Conclusion	O
:	O
Based	O
on	O
the	O
tumor	B-T038
uptake	B-T038
of	O
the	O
PET	B-T058
probes	O
and	O
their	O
correlations	O
with	O
MVD	O
and	O
TGR	O
,	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
Alfatide	I-T103
II	I-T103
PET	B-T058
may	O
not	O
only	O
monitor	O
the	O
early	O
response	B-T058
but	O
also	O
precisely	O
predict	O
the	O
therapeutic	O
efficacy	O
of	O
the	O
multi	O
-	O
targeted	O
,	O
anti	B-T103
-	I-T103
angiogenic	I-T103
drug	I-T103
sunitinib	B-T103
in	O
U87MG	B-T038
tumors	I-T038
.	O

In	O
conclusion	O
,	O
it	O
is	O
feasible	O
to	O
optimize	O
the	O
early	O
response	B-T058
monitoring	I-T058
and	O
efficacy	O
prediction	O
of	O
cancer	B-T038
AAT	B-T058
using	O
noninvasive	B-T170
PET	B-T058
molecular	I-T058
imaging	I-T058
strategies	O
of	O
multifactorial	B-T033
bioparameters	O
,	O
such	O
as	O
angiogenesis	B-T038
imaging	B-T058
with	O
(	B-T103
18	I-T103
)	I-T103
F	I-T103
-	I-T103
Alfatide	I-T103
II	I-T103
,	O
which	O
represents	O
an	O
RGD	B-T103
-	O
based	O
probe	O
.	O

Identifying	O
research	B-T062
priorities	I-T062
with	O
nurses	B-T097
at	O
a	O
tertiary	O
children	O
'	O
s	O
hospital	B-T092
in	O
the	O
United	B-T082
Kingdom	I-T082

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
undertake	O
a	O
research	B-T062
priority	I-T062
setting	O
exercise	O
with	O
the	O
aim	O
of	O
maximizing	O
efficiency	O
and	O
impact	O
in	O
research	B-T062
activity	I-T062
undertaken	O
by	O
nurses	B-T097
at	O
one	O
children	O
'	O
s	O
tertiary	O
healthcare	B-T092
institution	I-T092
by	O
ensuring	O
the	O
clinical	B-T097
staff	I-T097
directly	O
shaped	O
a	O
coherent	O
,	O
transparent	O
and	O
consensus	O
driven	O
nurse	O
-	O
led	O
research	O
agenda	O
.	O

In	O
Round	O
1	O
,	O
the	O
research	O
topics	O
of	O
147	O
nurses	B-T097
were	O
elicited	O
using	O
a	O
modified	B-T062
nominal	I-T062
group	I-T062
technique	I-T062
as	O
the	O
consensus	B-T170
method	I-T170
.	O

The	O
number	O
of	O
participants	B-T098
in	O
the	O
24	O
separate	O
discussions	O
ranged	O
from	O
3	O
to	O
21	O
,	O
generating	O
lists	O
of	O
between	O
6	O
and	O
23	O
topics	O
.	O

In	O
Round	O
2	O
,	O
nurses	B-T097
from	O
the	O
clinical	O
areas	O
ranked	B-T170
topics	O
of	O
importance	O
resulting	O
in	O
a	O
set	O
of	O
four	O
to	O
five	O
priorities	B-T062
.	O

In	O
Round	O
3	O
,	O
the	O
divisional	B-T097
heads	I-T097
of	O
nursing	B-T091
consulted	O
with	O
staff	B-T097
in	O
all	O
of	O
their	O
clinical	O
areas	O
to	O
each	O
finalize	O
their	O
five	O
divisional	B-T062
priorities	I-T062
.	O

The	O
Nursing	B-T097
Research	I-T097
Working	I-T097
Group	I-T097
discussed	O
and	O
refined	O
the	O
divisions	B-T062
'	I-T062
priorities	I-T062
and	O
voted	O
on	O
the	O
final	O
list	O
to	O
agree	O
the	O
top	O
five	O
research	B-T062
priorities	I-T062
for	O
the	O
organization	B-T092
.	O

A	O
total	O
of	O
269	O
research	O
topics	O
were	O
initially	O
generated	O
.	O

Following	O
three	O
rounds	O
of	O
ranking	B-T170
and	O
prioritizing	O
,	O
five	O
priorities	B-T062
were	O
agreed	O
at	O
Divisional	B-T092
level	I-T092
,	O
and	O
from	O
these	O
,	O
the	O
five	O
top	O
organizational	B-T062
priorities	I-T062
were	O
selected	O
.	O

These	O
were	O
(	O
i	O
)	O
understanding	O
and	O
improving	O
all	O
aspects	O
of	O
the	O
patient	O
journey	O
through	O
the	O
hospital	B-T092
system	I-T092
;	O
(	O
ii	O
)	O
play	O
;	O
(	O
iii	O
)	O
staff	O
wellbeing	O
,	O
patient	B-T058
care	I-T058
and	O
productivity	O
;	O
(	O
iv	O
)	O
team	O
work	O
-	O
linking	O
to	O
a	O
more	O
efficient	O
service	O
;	O
and	O
(	O
v	O
)	O
supporting	O
parents	O
/	O
parent	O
pathway	O
.	O

Divisional	O
priorities	B-T062
have	O
been	O
disseminated	O
widely	O
to	O
clinical	B-T058
teams	I-T058
to	O
inform	O
a	O
patient	O
-	O
specific	O
nurse	O
-	O
led	O
research	O
agenda	O
.	O

Organizational	B-T062
priorities	I-T062
agreed	O
upon	O
have	O
been	O
disseminated	O
through	O
management	O
structures	O
and	O
processes	O
to	O
ensure	O
engagement	O
at	O
all	O
levels	O
.	O

A	O
subgroup	B-T097
of	O
the	O
Nursing	B-T097
Research	I-T097
Working	I-T097
Group	I-T097
has	O
been	O
delegated	O
to	O
take	O
this	O
work	O
forward	O
so	O
that	O
the	O
agreed	O
priorities	B-T062
continue	O
to	O
contribute	O
towards	O
shaping	O
nurse	B-T062
-	I-T062
led	I-T062
research	I-T062
activity	I-T062
,	O
thereby	O
going	O
some	O
way	O
to	O
inform	O
and	O
embed	O
an	O
evidence	O
-	O
based	O
culture	O
of	O
inquiry	O
.	O

Accurate	O
Lungs	B-T017
Segmentation	B-T058
on	O
CT	B-T058
Chest	B-T082
Images	B-T170
by	O
Adaptive	B-T062
Appearance	I-T062
-	I-T062
Guided	I-T062
Shape	I-T062
Modeling	I-T062

To	O
accurately	O
segment	B-T058
pathological	O
and	O
healthy	O
lungs	B-T017
for	O
reliable	O
computer	B-T058
-	I-T058
aided	I-T058
disease	I-T058
diagnostics	I-T058
,	O
a	O
stack	B-T082
of	O
chest	B-T082
CT	B-T058
scans	B-T058
is	O
modeled	B-T062
as	O
a	O
sample	O
of	O
a	O
spatially	O
inhomogeneous	O
joint	O
3D	O
Markov	O
-	O
Gibbs	O
random	O
field	O
(	O
MGRF	O
)	O
of	O
voxel	O
-	O
wise	O
lung	B-T017
and	O
chest	B-T082
CT	B-T058
image	B-T170
signals	O
(	O
intensities	O
)	O
.	O

The	O
proposed	O
learnable	O
MGRF	O
integrates	O
two	O
visual	O
appearance	O
sub	O
-	O
models	O
with	O
an	O
adaptive	O
lung	B-T017
shape	O
submodel	O
.	O

The	O
first	O
-	O
order	O
appearance	O
submodel	O
accounts	O
for	O
both	O
the	O
original	O
CT	B-T058
image	B-T170
and	O
its	O
Gaussian	O
scale	O
space	O
(	O
GSS	O
)	O
filtered	O
version	O
to	O
specify	O
local	O
and	O
global	O
signal	O
properties	O
,	O
respectively	O
.	O

Each	O
empirical	O
marginal	O
probability	O
distribution	O
of	O
signals	O
is	O
closely	O
approximated	O
with	O
a	O
linear	O
combination	O
of	O
discrete	O
Gaussians	O
(	O
LCDG	O
)	O
,	O
containing	O
two	O
positive	O
dominant	O
and	O
multiple	O
sign	O
-	O
alternate	O
subordinate	O
DGs	O
.	O

The	O
approximation	O
is	O
separated	O
into	O
two	O
LCDGs	O
to	O
describe	O
individually	O
the	O
lungs	B-T017
and	O
their	O
background	O
,	O
i	O
.	O
e	O
.	O
,	O
all	O
other	O
chest	B-T082
tissues	B-T017
.	O

The	O
second	O
-	O
order	O
appearance	O
submodel	O
quantifies	O
conditional	O
pairwise	O
intensity	O
dependencies	B-T170
in	O
the	O
nearest	O
voxel	O
26	O
-	O
neighborhood	O
in	O
both	O
the	O
original	O
and	O
GSS	O
-	O
filtered	O
images	B-T170
.	O

The	O
shape	O
submodel	O
is	O
built	O
for	O
a	O
set	O
of	O
training	O
data	O
and	O
is	O
adapted	O
during	O
segmentation	B-T058
using	O
both	O
the	O
lung	B-T017
and	O
chest	B-T082
appearances	O
.	O

The	O
accuracy	O
of	O
the	O
proposed	O
segmentation	B-T058
framework	O
is	O
quantitatively	O
assessed	O
using	O
two	O
public	O
databases	B-T170
(	O
ISBI	B-T170
VESSEL12	I-T170
challenge	I-T170
and	O
MICCAI	B-T170
LOLA11	I-T170
challenge	I-T170
)	O
and	O
our	O
own	O
database	B-T170
with	O
,	O
respectively	O
,	O
20	O
,	O
55	O
,	O
and	O
30	O
CT	B-T058
images	B-T170
of	O
various	O
lung	B-T017
pathologies	O
acquired	O
with	O
different	O
scanners	B-T074
and	O
protocols	B-T058
.	O

Quantitative	O
assessment	O
of	O
our	O
framework	O
in	O
terms	O
of	O
Dice	O
similarity	O
coefficients	O
,	O
95	O
-	O
percentile	O
bidirectional	O
Hausdorff	O
distances	O
,	O
and	O
percentage	O
volume	O
differences	O
confirms	O
the	O
high	O
accuracy	O
of	O
our	O
model	O
on	O
both	O
our	O
database	B-T170
(	O
98	O
.	O
4±1	O
.	O
0	O
%	O
,	O
2	O
.	O
2±1	O
.	O
0	O
mm	O
,	O
0	O
.	O
42±0	O
.	O
10	O
%	O
)	O
and	O
the	O
VESSEL12	B-T170
database	I-T170
(	O
99	O
.	O
0±0	O
.	O
5	O
%	O
,	O
2	O
.	O
1±1	O
.	O
6	O
mm	O
,	O
0	O
.	O
39±0	O
.	O
20	O
%	O
)	O
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
accuracy	O
of	O
our	O
approach	O
is	O
further	O
verified	O
via	O
a	O
blind	B-T170
evaluation	B-T170
by	O
the	O
organizers	O
of	O
the	O
LOLA11	B-T170
competition	O
,	O
where	O
an	O
average	O
overlap	O
of	O
98	O
.	O
0	O
%	O
with	O
the	O
expert	O
'	O
s	O
segmentation	B-T058
is	O
yielded	O
on	O
all	O
55	O
subjects	O
with	O
our	O
framework	O
being	O
ranked	O
first	O
among	O
all	O
the	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
techniques	O
compared	O
.	O

Influence	O
of	O
Different	O
Levels	O
of	O
Lipoic	B-T017
Acid	I-T017
Synthase	I-T017
Gene	B-T038
Expression	I-T038
on	O
Diabetic	B-T038
Nephropathy	I-T038

Oxidative	B-T038
stress	I-T038
is	O
implicated	O
in	O
the	O
pathogenesis	B-T038
of	O
diabetic	B-T038
nephropathy	I-T038
(	O
DN	B-T038
)	O
but	O
outcomes	O
of	O
many	O
clinical	B-T062
trials	I-T062
are	O
controversial	O
.	O

To	O
define	O
the	O
role	O
of	O
antioxidants	B-T103
in	O
kidney	B-T017
protection	O
during	O
the	O
development	O
of	O
diabetic	B-T038
nephropathy	I-T038
,	O
we	O
have	O
generated	O
a	O
novel	O
genetic	B-T038
antioxidant	I-T038
mouse	I-T038
model	I-T038
with	O
over	B-T038
-	I-T038
or	I-T038
under	I-T038
-	I-T038
expression	I-T038
of	O
lipoic	B-T017
acid	I-T017
synthase	I-T017
gene	I-T017
(	O
Lias	B-T017
)	O
.	O

These	O
models	B-T038
have	O
been	O
mated	B-T038
with	O
Ins2Akita	B-T204
/	I-T204
+	I-T204
mice	I-T204
,	O
a	O
type	B-T038
I	I-T038
diabetic	I-T038
mouse	B-T038
model	I-T038
.	O

We	O
compare	O
the	O
major	O
pathologic	B-T033
changes	I-T033
and	O
oxidative	B-T038
stress	I-T038
status	O
in	O
two	O
new	O
strains	O
of	O
the	O
mice	B-T204
with	O
controls	O
.	O

Our	O
results	O
show	O
that	O
Ins2Akita	B-T204
/	I-T204
+	I-T204
mice	I-T204
with	O
under	B-T038
-	I-T038
expressed	I-T038
Lias	B-T017
gene	I-T017
,	O
exhibit	O
higher	O
oxidative	B-T038
stress	I-T038
and	O
more	O
severe	O
DN	B-T038
features	O
(	O
albuminuria	B-T033
,	O
glomerular	B-T033
basement	I-T033
membrane	I-T033
thickening	I-T033
and	O
mesangial	B-T033
matrix	I-T033
expansion	I-T033
)	O
.	O

In	O
contrast	O
,	O
Ins2Akita	B-T204
/	I-T204
+	I-T204
mice	I-T204
with	O
highly	O
-	O
expressed	B-T038
Lias	B-T017
gene	I-T017
display	O
lower	O
oxidative	B-T038
stress	I-T038
and	O
less	O
DN	B-T038
pathologic	B-T033
changes	I-T033
.	O

Our	O
study	B-T062
demonstrates	O
that	O
strengthening	O
endogenous	O
antioxidant	B-T103
capacity	O
could	O
be	O
an	O
effective	O
strategy	O
for	O
prevention	O
and	O
treatment	O
of	O
DN	B-T038
.	O

Assessment	O
of	O
genetic	O
relationship	O
among	O
Rhododendron	B-T204
cultivars	O
using	O
amplified	B-T062
fragment	I-T062
length	I-T062
polymorphism	I-T062
and	O
inter	O
-	O
simple	O
sequence	O
repeat	O
markers	B-T082

Genetic	O
relationships	O
of	O
17	O
Rhododendron	B-T204
cultivars	O
,	O
China	B-T082
,	O
were	O
assessed	O
using	O
inter	O
-	O
simple	O
sequence	O
repeat	O
(	O
ISSR	O
)	O
and	O
amplified	B-T062
fragment	I-T062
length	I-T062
polymorphism	I-T062
(	O
AFLP	B-T062
)	O
markers	B-T082
.	O

A	O
total	O
of	O
133	O
bands	O
were	O
obtained	O
using	O
nine	O
selected	O
ISSR	O
primers	B-T103
,	O
129	O
(	O
96	O
.	O
99	O
%	O
)	O
of	O
which	O
were	O
polymorphic	O
;	O
267	O
bands	O
were	O
amplified	O
by	O
four	O
AFLP	B-T062
primer	B-T103
pairs	I-T103
,	O
251	O
(	O
94	O
.	O
01	O
%	O
)	O
of	O
which	O
exhibited	O
polymorphism	O
.	O

Based	O
on	O
these	O
polymorphic	O
products	O
,	O
a	O
cluster	B-T062
analysis	I-T062
revealed	O
similarities	O
between	O
the	O
results	O
of	O
the	O
ISSR	O
and	O
AFLP	B-T062
.	O

All	O
of	O
the	O
cultivars	O
were	O
clustered	O
into	O
two	O
major	O
branches	O
;	O
one	O
branch	O
contained	O
the	O
same	O
four	O
cultivars	O
,	O
and	O
the	O
other	O
cultivars	O
were	O
separated	O
into	O
different	O
groups	O
in	O
the	O
other	O
branch	O
.	O

The	O
cluster	O
results	O
showed	O
that	O
the	O
genetic	O
relationships	O
of	O
the	O
17	O
cultivars	O
were	O
partly	O
related	O
to	O
their	O
morphological	B-T082
characteristics	O
,	O
particularly	O
the	O
flowering	B-T038
phase	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
this	O
study	B-T062
support	O
the	O
classification	B-T170
of	O
Rhododendron	B-T204
cultivars	O
according	O
to	O
flowering	B-T038
phase	O
.	O

In	O
addition	O
,	O
the	O
cluster	O
results	O
can	O
be	O
used	O
to	O
select	O
suitable	O
parents	O
for	O
breeding	B-T038
.	O

Spontaneous	B-T038
activity	I-T038
is	O
correlated	O
with	O
coding	O
density	O
in	O
primary	B-T082
auditory	I-T082
cortex	I-T082

Sensory	B-T017
neurons	I-T017
across	O
sensory	O
modalities	O
and	O
specific	O
processing	O
areas	O
have	O
diverse	O
levels	O
of	O
spontaneous	O
firing	O
rates	O
(	O
SFRs	O
)	O
in	O
the	O
absence	O
of	O
sensory	O
stimuli	O
.	O

However	O
,	O
the	O
functional	O
significance	O
of	O
this	O
spontaneous	B-T038
activity	I-T038
is	O
not	O
well	O
-	O
understood	O
.	O

Previous	O
studies	B-T062
in	O
the	O
auditory	B-T022
system	I-T022
have	O
demonstrated	O
that	O
different	O
levels	O
of	O
spontaneous	B-T038
activity	I-T038
are	O
correlated	O
with	O
a	O
variety	O
of	O
physiological	O
and	O
anatomic	O
properties	O
,	O
suggesting	O
that	O
neurons	B-T017
with	O
differing	O
SFRs	O
make	O
unique	O
contributions	O
to	O
the	O
encoding	O
of	O
auditory	B-T038
stimuli	I-T038
.	O

Additionally	O
,	O
altered	O
SFRs	O
are	O
a	O
correlate	O
of	O
tinnitus	B-T033
,	O
arising	O
in	O
several	O
auditory	B-T017
areas	I-T017
after	O
exposure	O
to	O
ototoxic	O
substances	O
and	O
noise	O
trauma	B-T037
.	O

In	O
this	O
study	B-T062
,	O
we	O
recorded	O
single	O
-	O
unit	O
activity	O
from	O
primary	B-T082
auditory	I-T082
cortex	I-T082
of	O
awake	O
marmoset	B-T204
monkeys	B-T204
while	O
delivering	O
wide	O
-	O
band	O
random	O
-	O
spectrum	O
stimuli	O
and	O
white	B-T170
Gaussian	I-T170
noise	I-T170
(	O
WGN	B-T170
)	O
to	O
examine	O
any	O
divergences	B-T082
in	O
stimulus	O
encoding	O
properties	O
across	O
SFR	O
classes	O
.	O

We	O
found	O
that	O
higher	O
levels	O
of	O
spontaneous	B-T038
activity	I-T038
were	O
associated	O
with	O
both	O
higher	O
levels	O
of	O
activation	O
relative	O
to	O
suppression	O
across	O
a	O
variety	O
of	O
wide	O
-	O
band	O
stimuli	O
and	O
higher	O
driven	O
rates	O
in	O
response	O
to	O
WGN	B-T170
.	O

Moreover	O
,	O
response	O
latencies	O
to	O
WGN	B-T170
were	O
negatively	O
correlated	O
with	O
the	O
level	O
of	O
activation	O
in	O
response	O
to	O
both	O
stimulus	O
types	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
novel	O
view	O
of	O
the	O
role	O
spontaneous	B-T038
spiking	I-T038
may	O
play	O
during	O
normal	O
stimulus	O
processing	O
in	O
primary	B-T082
auditory	I-T082
cortex	I-T082
and	O
how	O
it	O
may	O
malfunction	O
in	O
cases	O
of	O
tinnitus	B-T033
.	O

Systematic	B-T062
mapping	I-T062
of	O
functional	O
enhancer	B-T103
-	O
promoter	B-T103
connections	O
with	O
CRISPR	B-T058
interference	I-T058

Gene	B-T038
expression	I-T038
in	O
mammals	B-T204
is	O
regulated	B-T038
by	O
noncoding	B-T103
elements	I-T103
that	O
can	O
affect	O
physiology	B-T038
and	O
disease	B-T038
,	O
yet	O
the	O
functions	O
and	O
target	B-T017
genes	I-T017
of	O
most	O
noncoding	B-T103
elements	I-T103
remain	O
unknown	O
.	O

We	O
present	O
a	O
high	O
-	O
throughput	O
approach	O
that	O
uses	O
clustered	B-T058
regularly	I-T058
interspaced	I-T058
short	I-T058
palindromic	I-T058
repeats	I-T058
(	I-T058
CRISPR	B-T103
)	I-T058
interference	I-T058
(	O
CRISPRi	B-T058
)	O
to	O
discover	O
regulatory	B-T103
elements	I-T103
and	O
identify	O
their	O
target	B-T017
genes	I-T017
.	O

We	O
assess	O
>	O
1	O
megabase	O
of	O
sequence	B-T082
in	O
the	O
vicinity	O
of	O
two	O
essential	O
transcription	B-T103
factors	I-T103
,	O
MYC	B-T103
and	O
GATA1	B-T103
,	O
and	O
identify	O
nine	O
distal	B-T082
enhancers	B-T103
that	O
control	O
gene	B-T038
expression	I-T038
and	O
cellular	B-T038
proliferation	I-T038
.	O

Quantitative	O
features	O
of	O
chromatin	B-T103
state	O
and	O
chromosome	B-T017
conformation	B-T033
distinguish	O
the	O
seven	O
enhancers	B-T103
that	O
regulate	O
MYC	B-T103
from	O
other	O
elements	B-T082
that	O
do	O
not	O
,	O
suggesting	O
a	O
strategy	O
for	O
predicting	O
enhancer	B-T103
-	O
promoter	B-T103
connectivity	O
.	O

This	O
CRISPRi	B-T058
-	O
based	O
approach	O
can	O
be	O
applied	O
to	O
dissect	O
transcriptional	B-T038
networks	I-T038
and	O
interpret	O
the	O
contributions	O
of	O
noncoding	O
genetic	O
variation	O
to	O
human	B-T204
disease	B-T038
.	O

Proliferation	B-T038
-	O
enhancing	O
effects	O
of	O
gastrodin	B-T103
on	O
RSC96	B-T017
Schwann	I-T017
cells	I-T017
by	O
regulating	B-T038
ERK1	B-T103
/	O
2	B-T103
and	O
PI3K	B-T103
signaling	B-T038
pathways	I-T038

The	O
proliferation	B-T038
and	O
migration	B-T038
of	O
Schwann	B-T017
cells	I-T017
(	O
SCs	B-T017
)	O
are	O
essential	O
in	O
the	O
process	O
of	O
peripheral	B-T058
nerve	I-T058
repair	I-T058
.	O

A	O
large	O
amount	O
of	O
studies	O
focused	O
on	O
the	O
promotion	O
of	O
the	O
growth	B-T038
of	O
SCs	B-T017
for	O
cell	B-T058
based	I-T058
therapy	I-T058
.	O

Gastrodin	B-T103
(	O
GAS	B-T103
)	O
,	O
the	O
main	O
constituent	O
of	O
a	O
Chinese	B-T091
traditional	I-T091
herbal	B-T103
medicine	I-T103
named	O
Gastrodia	B-T204
elata	I-T204
Blume	I-T204
,	O
has	O
been	O
reported	B-T058
to	O
be	O
associated	O
with	O
neuroprotective	B-T038
properties	I-T038
.	O

Besides	O
,	O
GAS	B-T103
activated	O
MAPK	B-T103
and	O
PI3K	B-T103
signaling	B-T038
pathways	I-T038
which	O
are	O
often	O
involved	O
in	O
growth	B-T038
of	O
nerve	B-T017
cells	I-T017
were	O
also	O
reported	B-T058
.	O

Based	O
on	O
the	O
hypothesis	O
that	O
GAS	B-T103
may	O
have	O
an	O
effect	O
on	O
SCs	B-T017
growth	B-T038
,	O
we	O
studied	O
the	O
effect	O
of	O
GAS	B-T103
on	O
rat	B-T204
RSC96	B-T017
Schwann	I-T017
cells	I-T017
(	O
SCs	B-T017
)	O
and	O
further	O
explored	O
the	O
underlying	O
mechanism	O
.	O

Various	O
concentration	O
of	O
GAS	B-T103
(	O
0μM	O
,	O
50μM	O
,	O
100μM	O
,	O
and	O
200μM	O
)	O
was	O
used	O
for	O
treatment	B-T058
of	O
RSC96	B-T017
SCs	I-T017
,	O
with	O
the	O
cell	B-T038
proliferation	I-T038
and	O
gene	B-T038
expression	I-T038
of	O
several	O
neurotrophic	B-T103
factors	I-T103
to	O
be	O
detected	O
.	O

Regulation	B-T038
of	I-T038
MAPK	B-T103
and	O
PI3K	B-T103
signaling	B-T038
pathways	I-T038
were	O
assayed	O
by	O
detecting	O
phosphorylation	B-T038
of	O
ERK1	B-T103
/	O
2	B-T103
and	O
Akt	B-T103
.	O

The	O
results	O
showed	O
that	O
GAS	B-T103
could	O
effectively	O
promote	O
proliferation	B-T038
of	O
RSC96	B-T017
SCs	I-T017
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

The	O
best	O
performance	O
was	O
obtained	O
at	O
the	O
concentration	O
of	O
200μM	O
.	O

Exploration	B-T058
of	O
the	O
underlying	O
mechanism	O
showed	O
that	O
GAS	B-T103
probably	O
affects	O
SCs	B-T017
metabolism	B-T038
through	O
inhibiting	O
ERK1	B-T103
/	O
2	B-T103
phosphorylation	B-T038
and	O
activating	O
Akt	B-T103
phosphorylation	B-T038
in	O
RSC96	B-T017
SCs	I-T017
.	O

This	O
study	O
may	O
provide	O
reference	O
for	O
its	O
application	O
in	O
treatment	B-T058
of	O
peripheral	B-T037
nerve	I-T037
injuries	I-T037
.	O

An	O
influenza	B-T005
A	I-T005
virus	I-T005
(	I-T005
H7N9	I-T005
)	I-T005
anti	B-T033
-	I-T033
neuraminidase	I-T033
monoclonal	B-T103
antibody	I-T103
with	O
prophylactic	B-T058
and	I-T058
therapeutic	I-T058
activity	I-T058
in	B-T082
vivo	I-T082

Zoonotic	B-T038
A	B-T005
(	I-T005
H7N9	I-T005
)	I-T005
avian	I-T005
influenza	I-T005
viruses	I-T005
emerged	O
in	O
China	B-T082
in	O
2013	O
and	O
continue	O
to	O
be	O
a	O
threat	O
to	O
human	B-T204
public	B-T058
health	I-T058
,	O
having	O
infected	B-T033
over	O
800	O
individuals	B-T098
with	O
a	O
mortality	O
rate	O
approaching	O
40	O
%	O
.	O

Treatment	B-T058
options	I-T058
for	O
people	O
infected	B-T033
with	O
A	B-T005
(	I-T005
H7N9	I-T005
)	I-T005
include	O
the	O
use	O
of	O
neuraminidase	B-T103
(	I-T103
NA	I-T103
)	I-T103
inhibitors	I-T103
.	O

However	O
,	O
like	O
other	O
influenza	B-T005
viruses	I-T005
,	O
A	B-T005
(	I-T005
H7N9	I-T005
)	I-T005
can	O
become	O
resistant	O
to	O
these	O
drugs	B-T103
.	O

The	O
use	O
of	O
monoclonal	B-T103
antibodies	I-T103
is	O
a	O
rapidly	O
developing	O
strategy	O
for	O
controlling	O
influenza	B-T005
virus	I-T005
infection	B-T038
.	O

Here	O
we	O
generated	O
a	O
murine	B-T204
monoclonal	B-T103
antibody	I-T103
(	O
3c10	B-T103
-	I-T103
3	I-T103
)	O
directed	O
against	O
the	O
NA	O
of	O
A	B-T005
(	I-T005
H7N9	I-T005
)	I-T005
and	O
show	O
that	O
prophylactic	O
systemic	O
administration	O
of	O
3c10	B-T103
-	I-T103
3	I-T103
fully	O
protected	O
mice	O
from	O
lethal	O
challenge	O
with	O
wild	B-T017
-	I-T017
type	I-T017
A	B-T005
/	I-T005
Anhui	I-T005
/	I-T005
1	I-T005
/	I-T005
2013	I-T005
(	O
H7N9	B-T005
)	O
.	O

Further	O
,	O
post	O
-	O
infection	B-T038
treatment	B-T058
with	O
a	O
single	O
systemic	O
dose	O
of	O
3c10	B-T103
-	I-T103
3	I-T103
at	O
either	O
24	O
,	O
48	O
or	O
72	O
h	O
post	O
A	B-T005
(	I-T005
H7N9	I-T005
)	I-T005
challenge	O
resulted	O
in	O
both	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
protection	O
of	O
up	O
to	O
100	O
%	O
of	O
mice	B-T204
,	O
demonstrating	O
therapeutic	O
potential	O
for	O
3c10	B-T103
-	I-T103
3	I-T103
.	O

Epitope	B-T058
mapping	I-T058
revealed	O
that	O
3c10	B-T103
-	I-T103
3	I-T103
binds	B-T038
near	O
the	O
enzyme	B-T103
active	O
site	O
of	O
NA	O
,	O
and	O
functional	O
characterization	O
showed	O
that	O
3c10	B-T103
-	I-T103
3	I-T103
inhibits	O
the	O
enzyme	B-T038
activity	I-T038
of	O
NA	O
and	O
restricts	O
the	O
cell	O
-	O
to	O
-	O
cell	O
spread	O
of	O
the	O
virus	B-T005
in	O
cultured	B-T017
cells	I-T017
.	O

Affinity	O
analysis	B-T062
also	O
revealed	O
that	O
3c10	B-T103
-	I-T103
3	I-T103
binds	B-T038
equally	O
well	O
to	O
recombinant	B-T103
NA	O
of	O
wild	B-T017
-	I-T017
type	I-T017
A	B-T005
/	I-T005
Anhui	I-T005
/	I-T005
1	I-T005
/	I-T005
2013	I-T005
and	O
to	O
a	O
variant	O
NA	O
carrying	O
a	O
R289K	O
mutation	B-T038
known	O
to	O
infer	O
NAI	B-T103
resistance	O
.	O

These	O
results	O
suggest	O
that	O
3c10	B-T103
-	I-T103
3	I-T103
has	O
the	O
potential	O
to	O
be	O
used	O
as	O
a	O
therapeutic	O
to	O
treat	O
A	B-T005
(	I-T005
H7N9	I-T005
)	I-T005
infections	B-T038
either	O
as	O
an	O
alternative	O
to	O
,	O
or	O
in	O
combination	O
with	O
,	O
current	O
NA	O
antiviral	B-T103
inhibitors	I-T103
.	O

Mechanisms	O
of	O
ear	B-T017
trauma	B-T037
and	O
reconstructive	B-T058
techniques	O
in	O
105	O
consecutive	O
patients	O

Acquired	O
auricular	B-T017
deformities	B-T017
may	O
diminish	O
facial	O
esthetics	O
and	O
cause	O
psychological	O
distress	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
type	O
of	O
injuries	B-T037
and	O
applied	B-T058
reconstructive	I-T058
techniques	O
in	O
a	O
large	O
academic	B-T092
hospital	I-T092
in	O
The	O
Netherlands	B-T082
.	O

A	O
retrospective	O
chart	O
review	O
was	O
conducted	O
for	O
the	O
last	O
105	O
patients	O
who	O
underwent	O
auricular	B-T017
reconstruction	B-T058
for	O
an	O
acquired	B-T017
deformity	I-T017
.	O

Data	O
concerning	O
gender	O
,	O
affected	O
side	O
,	O
cause	B-T033
of	I-T033
injury	I-T033
,	O
anatomical	B-T082
region	I-T082
,	O
the	O
previous	O
and	O
further	O
surgeries	B-T058
,	O
type	O
of	O
cartilage	B-T017
,	O
and	O
skin	B-T074
cover	I-T074
used	I-T074
were	O
collected	O
and	O
analyzed	B-T062
.	O

105	O
patients	O
were	O
included	O
.	O

Acquired	O
auricular	B-T017
deformities	B-T017
were	O
mainly	O
caused	O
by	O
bite	B-T037
injuries	I-T037
(	O
22	O
%	O
)	O
,	O
traffic	B-T037
accidents	I-T037
(	O
17	O
%	O
)	O
,	O
burns	B-T037
(	O
9	O
.	O
5	O
%	O
)	O
,	O
and	O
post	B-T058
-	I-T058
otoplasty	I-T058
complications	B-T038
(	O
9	O
.	O
5	O
%	O
)	O
.	O

The	O
upper	B-T017
third	I-T017
of	I-T017
the	I-T017
auricle	I-T017
was	O
most	O
often	O
injured	O
(	O
41	O
%	O
)	O
,	O
followed	O
by	O
the	O
entire	B-T017
auricle	I-T017
(	O
19	O
%	O
)	O
.	O

70	O
%	O
of	O
cases	O
required	O
reconstruction	B-T058
with	O
costal	B-T017
cartilage	I-T017
.	O

The	O
most	O
common	O
form	O
of	O
cutaneous	B-T082
cover	I-T082
was	O
a	O
postauricular	B-T058
skin	I-T058
flap	I-T058
(	O
40	O
%	O
of	O
cases	O
)	O
.	O

This	O
study	B-T062
gives	O
a	O
complete	O
overview	O
of	O
causes	O
and	O
treatment	O
of	O
acquired	O
auricular	B-T017
deformities	B-T017
.	O

The	O
results	O
are	O
comparable	O
with	O
the	O
results	O
of	O
similar	O
studies	B-T062
found	O
in	O
literature	B-T170
.	O

Bite	B-T037
wounds	I-T037
are	O
the	O
leading	O
cause	O
of	O
acquired	O
auricular	B-T017
injuries	B-T037
.	O

The	O
upper	B-T017
third	I-T017
is	O
most	O
commonly	O
affected	O
.	O

In	O
the	O
largest	O
percentage	O
of	O
reconstructions	B-T058
,	O
costal	B-T017
cartilage	I-T017
and	O
a	O
postauricular	B-T017
flap	I-T017
were	O
used	O
to	O
correct	O
the	O
deformity	B-T017
.	O

Anatomic	O
assessment	B-T058
of	O
the	O
left	O
main	O
bifurcation	O
and	O
dynamic	O
bifurcation	O
angles	O
using	O
computed	B-T058
tomography	I-T058
angiography	I-T058

An	O
understanding	O
of	O
the	O
left	B-T017
main	I-T017
coronary	I-T017
artery	I-T017
(	O
LMCA	B-T017
)	O
anatomy	B-T017
is	O
important	O
for	O
accurate	O
diagnosis	O
and	O
therapeutic	B-T058
.	O

We	O
aimed	O
to	O
investigate	O
LMCA	B-T017
anatomy	B-T017
via	O
128	B-T058
-	I-T058
multisliced	I-T058
coronary	I-T058
computed	I-T058
-	I-T058
tomography	I-T058
-	I-T058
angiography	I-T058
(	O
CCTA	B-T058
)	O
in	O
patients	O
with	O
normal	O
LMCA	B-T017
.	O

A	O
total	O
of	O
201	O
CCTA	B-T058
studies	B-T062
were	O
included	O
in	O
this	O
study	B-T062
.	O

Anatomical	B-T017
features	I-T017
of	O
LMCA	B-T017
including	O
cross	B-T082
-	I-T082
sectional	I-T082
areas	I-T082
of	O
the	O
LMCA	B-T017
ostial	B-T082
,	O
LMCA	B-T017
distal	B-T082
,	O
LAD	B-T017
ostial	I-T017
and	O
LCX	B-T017
ostial	B-T082
,	O
and	O
degree	O
of	O
tapering	O
and	O
LMCA	B-T017
bifurcation	O
angles	O
(	O
BA	O
)	O
in	O
the	O
form	O
of	O
LMCA	B-T017
-	O
LCX	B-T017
BA	O
,	O
LMCA	B-T017
-	O
LAD	B-T017
BA	O
,	O
LAD	B-T017
-	O
LCX	B-T017
BA	O
at	O
end	O
-	O
diastole	O
and	O
end	O
-	O
systole	O
.	O

The	O
mean	O
age	O
was	O
55	O
±	O
11	O
with	O
55	O
.	O
7	O
%	O
males	O
.	O

RCA	B-T017
was	O
dominant	O
in	O
173	O
(	O
86	O
.	O
1	O
%	O
)	O
patients	O
.	O

Mean	O
LMCA	B-T017
length	O
was	O
10	O
.	O
0±4	O
.	O
5	O
mm	O
.	O

The	O
mean	O
values	O
of	O
LMCA	B-T017
ostial	B-T082
,	O
LMCA	B-T017
distal	B-T082
,	O
LAD	B-T017
ostial	I-T017
and	O
LCX	B-T017
ostial	B-T082
areas	B-T082
were	O
18	O
.	O
2±5	O
.	O
1	O
mm²	O
,	O
13	O
.	O
2±4	O
.	O
0	O
,	O
9	O
.	O
0±3	O
.	O
2	O
mm²	O
and	O
7	O
.	O
6±2	O
.	O
8	O
mm²	O
,	O
respectively	O
.	O

LMCA	B-T017
ostial	B-T082
-	O
distal	B-T082
area	B-T082
,	O
LMCA	B-T017
distal	B-T082
-	O
LAD	B-T017
ostial	I-T017
area	B-T082
and	O
LMCA	B-T017
distal	B-T082
-	O
LCX	B-T017
ostial	B-T082
area	O
ratios	O
were	O
≥1	O
.	O
44	O
-	O
<	O
1	O
.	O
69	O
in	O
47	O
(	O
23	O
.	O
4	O
%	O
)	O
,	O
53	O
(	O
26	O
.	O
4	O
%	O
)	O
,	O
47	O
(	O
23	O
.	O
4	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
and	O
were	O
≥1	O
.	O
69	O
-	O
<	O
1	O
.	O
96	O
in	O
19	O
(	O
9	O
.	O
5	O
%	O
)	O
,	O
24	O
(	O
11	O
.	O
9	O
%	O
)	O
,	O
40	O
(	O
19	O
.	O
9	O
%	O
)	O
patients	O
respectively	O
.	O

Systolic	O
motion	O
modifies	O
LMCA	B-T017
BAs	O
;	O
systolic	O
motion	O
begets	O
an	O
increment	O
of	O
LMCA	B-T017
-	O
LAD	B-T017
angle	O
in	O
72	O
.	O
6	O
%	O
of	O
patients	O
and	O
decrement	O
of	O
LAD	B-T017
-	O
LCX	B-T017
angle	O
in	O
75	O
.	O
6	O
%	O
of	O
the	O
patients	O
.	O

Patients	O
with	O
T	O
-	O
shaped	O
LAD	B-T017
-	O
LCX	B-T017
BA	O
was	O
shown	O
to	O
have	O
significantly	O
longer	O
LMCA	B-T017
,	O
larger	O
LAD	B-T017
ostial	I-T017
area	B-T082
,	O
larger	O
LCX	B-T017
ostial	B-T082
area	B-T082
and	O
higher	O
diastolic	O
-	O
to	O
-	O
systolic	O
range	O
(	O
DSR	O
)	O
of	O
LAD	B-T017
-	O
LCX	B-T017
BA	O
compared	O
to	O
patients	O
with	O
Y	O
-	O
shaped	O
LAD	B-T017
-	O
LCX	B-T017
BA	O
.	O

LMCA	B-T017
with	O
T	B-T082
-	I-T082
shaped	I-T082
distal	I-T082
BA	O
was	O
found	O
to	O
have	O
significantly	O
longer	O
LMCA	B-T017
,	O
larger	O
LAD	B-T017
ostial	I-T017
area	B-T082
,	O
larger	O
LCX	B-T017
ostial	B-T082
area	B-T082
and	O
higher	O
DSR	O
of	O
distal	B-T082
BA	O
compared	O
to	O
patients	O
with	O
Y	B-T082
-	I-T082
shaped	I-T082
distal	I-T082
BA	O
.	O

These	O
findings	B-T033
may	O
provide	O
useful	O
information	O
for	O
LMCA	B-T017
bifurcation	B-T058
stenting	I-T058
or	O
designing	O
dedicated	O
stents	B-T074
for	O
LMCA	B-T017
.	O

A	O
three	O
perspective	B-T062
study	I-T062
of	O
the	O
sense	O
of	O
home	B-T082
of	O
nursing	O
home	O
residents	O
:	O
the	O
views	O
of	O
residents	O
,	O
care	B-T097
professionals	I-T097
and	O
relatives	O

The	O
sense	O
of	O
home	B-T082
of	O
nursing	O
home	O
residents	O
is	O
a	O
multifactorial	B-T033
phenomenon	O
which	O
is	O
important	O
for	O
the	O
quality	O
of	O
living	O
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
is	O
to	O
investigate	O
the	O
factors	O
influencing	O
the	O
sense	O
of	O
home	B-T082
of	O
older	O
adults	O
residing	O
in	O
the	O
nursing	B-T092
home	I-T092
from	O
the	O
perspective	O
of	O
residents	O
,	O
relatives	O
and	O
care	B-T097
professionals	I-T097
.	O

A	O
total	O
of	O
78	O
participants	B-T098
(	O
n	O
=	O
24	O
residents	O
,	O
n	O
=	O
18	O
relatives	O
and	O
n	O
=	O
26	O
care	B-T097
professionals	I-T097
)	O
from	O
4	O
nursing	B-T092
homes	I-T092
in	O
the	O
Netherlands	B-T082
engaged	O
in	O
a	O
qualitative	B-T062
study	I-T062
,	O
in	O
which	O
photography	O
was	O
as	O
a	O
supportive	O
tool	O
for	O
subsequent	O
interviews	O
and	O
focus	O
groups	O
.	O

The	O
data	O
were	O
analyzed	O
based	O
on	O
open	O
ended	O
coding	O
,	O
axial	O
coding	O
and	O
selective	O
coding	O
.	O

The	O
sense	O
of	O
home	B-T082
of	O
nursing	O
home	O
residents	O
is	O
influenced	O
by	O
a	O
number	O
of	O
jointly	O
identified	O
factors	O
,	O
including	O
the	O
building	O
and	O
interior	O
design	O
;	O
eating	O
and	O
drinking	O
;	O
autonomy	O
and	O
control	O
;	O
involvement	O
of	O
relatives	O
;	O
engagement	O
with	O
others	O
and	O
activities	O
;	O
quality	B-T058
of	I-T058
care	I-T058
are	O
shared	O
themes	O
.	O

Residents	O
and	O
relatives	O
stressed	O
the	O
importance	O
of	O
having	O
a	O
connection	O
with	O
nature	O
and	O
the	O
outdoors	B-T082
,	O
as	O
well	O
as	O
coping	O
strategies	O
.	O

Relatives	O
and	O
care	B-T097
professionals	I-T097
emphasized	O
the	O
role	O
the	O
organization	B-T092
of	O
facilitation	O
of	O
care	O
played	O
,	O
as	O
well	O
as	O
making	O
residents	O
feel	O
like	O
they	O
still	O
matter	O
.	O

The	O
sense	O
of	O
home	B-T082
of	O
nursing	O
home	O
residents	O
is	O
influenced	O
by	O
a	O
multitude	O
of	O
factors	O
related	O
to	O
the	O
psychology	O
of	O
the	O
residents	O
,	O
and	O
the	O
social	O
and	O
built	O
environmental	O
contexts	O
.	O

A	O
holistic	O
understanding	O
of	O
which	O
factors	O
influence	O
the	O
sense	O
of	O
home	B-T082
of	O
residents	O
can	O
lead	O
to	O
strategies	O
to	O
optimize	O
this	O
sense	O
of	O
home	B-T082
.	O

This	O
study	B-T062
also	O
indicated	O
that	O
the	O
nursing	B-T092
home	I-T092
has	O
a	O
dual	O
nature	O
as	O
a	O
place	O
of	O
residence	B-T082
and	O
a	O
place	B-T082
where	O
people	B-T098
are	O
supported	O
through	O
numerous	O
care	O
strategies	O
.	O

Integrating	O
one	B-T091
health	I-T091
in	O
national	B-T170
health	I-T170
policies	I-T170
of	O
developing	O
countries	O
:	O
India	B-T082
'	I-T082
s	I-T082
lost	O
opportunities	O

Globally	O
,	O
the	O
threat	O
of	O
infectious	B-T038
diseases	I-T038
,	O
particularly	O
emerging	B-T038
infectious	I-T038
diseases	I-T038
,	O
originating	O
at	O
the	O
human	B-T204
-	O
animal	B-T204
-	O
environment	B-T082
interface	O
,	O
has	O
caught	O
health	O
systems	O
off	O
guard	O
.	O

With	O
forecasts	O
that	O
future	O
pathogen	O
emergence	B-T038
will	O
be	O
centred	O
in	O
hotspots	O
in	O
Asia	B-T082
,	O
Africa	B-T082
,	O
and	O
Latin	B-T082
America	I-T082
,	O
the	O
need	O
to	O
prepare	O
policy	B-T170
frameworks	I-T170
that	O
can	O
combat	O
this	O
threat	O
is	O
urgent	O
.	O

Emergence	B-T038
of	I-T038
diseases	I-T038
such	O
as	O
avian	B-T038
influenza	I-T038
and	O
Ebola	B-T038
virus	I-T038
disease	I-T038
,	O
which	O
threatened	O
social	O
disruption	O
,	O
have	O
established	O
the	O
need	O
for	O
intersectoral	B-T058
coordination	I-T058
/	I-T058
collaboration	I-T058
.	O

These	O
events	O
led	O
to	O
the	O
initiation	O
of	O
establishing	O
institutionalised	B-T033
collaborative	O
frameworks	O
in	O
India	B-T082
to	O
adopt	O
a	O
One	B-T091
Health	I-T091
approach	I-T091
to	O
disease	B-T058
prevention	I-T058
and	I-T058
control	I-T058
.	O

However	O
,	O
the	O
gains	O
made	O
in	O
influenza	B-T038
control	O
could	O
not	O
be	O
adapted	O
to	O
other	O
infectious	B-T038
diseases	I-T038
.	O

Intersectoral	B-T058
coordination	I-T058
was	O
briefly	O
carried	O
out	O
,	O
more	O
as	O
a	O
reactive	O
response	O
to	O
threats	O
.	O

The	O
systemic	O
failure	O
to	O
sustain	O
such	O
efforts	O
have	O
therefore	O
,	O
only	O
undermined	O
a	O
coordinated	O
response	O
.	O

The	O
recent	O
draft	B-T170
National	B-T170
Health	I-T170
Policy	I-T170
,	O
2015	O
,	O
has	O
also	O
failed	O
to	O
establish	O
the	O
need	O
for	O
intersectoral	B-T058
coordination	I-T058
in	O
disease	B-T058
control	I-T058
approaches	I-T058
.	O

Neglecting	O
the	O
need	O
to	O
endorse	O
linkages	B-T170
between	O
human	B-T204
health	O
,	O
animal	B-T204
health	O
and	O
husbandry	O
,	O
agriculture	O
,	O
and	O
environmental	B-T082
sectors	B-T082
,	O
has	O
led	O
to	O
duplicative	O
and	O
weak	B-T033
response	I-T033
systems	I-T033
.	O

The	O
absence	O
of	O
health	B-T058
impact	I-T058
assessment	I-T058
with	O
respect	O
to	O
the	O
development	O
agenda	O
in	O
policies	B-T170
,	O
has	O
cast	O
negative	B-T033
effects	O
on	O
the	O
health	O
and	O
wellbeing	B-T170
of	I-T170
man	I-T170
,	O
animal	B-T204
,	O
and	O
the	O
environment	B-T082
.	O

Lack	O
of	O
attention	O
to	O
building	O
core	O
capacity	O
in	O
these	O
critical	O
sectors	B-T082
has	O
further	O
raised	O
challenges	B-T058
in	O
designing	O
and	O
deploying	O
mitigation	O
strategies	O
.	O

With	O
developing	O
countries	O
like	O
India	B-T082
being	O
home	O
to	O
a	O
major	O
portion	B-T082
of	O
the	O
world	B-T098
'	I-T098
s	I-T098
poorest	O
livestock	B-T097
farmers	I-T097
,	O
the	O
absence	O
of	O
a	O
policy	B-T170
discourse	O
that	O
endorses	O
the	O
One	B-T091
Health	I-T091
approach	I-T091
in	O
development	O
and	O
health	B-T170
policies	I-T170
is	O
a	O
major	O
hurdle	B-T038
in	O
eliminating	O
poverty	O
and	O
poverty	O
-	O
related	O
diseases	B-T038
.	O

The	O
adoption	O
of	O
One	B-T091
Health	I-T091
approaches	I-T091
in	O
health	O
and	O
related	O
sectoral	B-T082
policies	B-T170
is	O
a	O
critical	O
policy	B-T170
requirement	O
for	O
India	B-T082
and	O
other	O
developing	O
countries	O
.	O

The	O
goal	O
should	O
be	O
to	O
not	O
just	O
establish	O
preparedness	B-T033
plans	B-T038
,	O
but	O
also	O
to	O
encourage	O
a	O
policy	O
environment	O
where	O
assessment	B-T058
and	O
mitigation	O
of	O
downstream	B-T082
impacts	O
of	O
different	O
agenda	O
are	O
incorporated	O
.	O

Assessment	B-T058
of	O
demographic	O
and	O
pathoanatomic	B-T033
risk	I-T033
factors	I-T033
in	O
recurrent	O
patellofemoral	B-T082
instability	B-T033

The	O
WARPS	B-T170
/	I-T170
STAID	I-T170
classification	I-T170
employs	O
clinical	O
assessment	B-T058
of	O
presenting	O
features	O
and	O
anatomic	O
characteristics	O
to	O
identify	O
two	O
distinct	O
subsets	B-T170
of	O
patients	O
within	O
the	O
patellofemoral	B-T033
instability	I-T033
population	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
further	O
define	O
the	O
specific	O
demographics	O
and	O
the	O
prevalence	O
of	O
risky	O
pathoanatomies	O
in	O
patients	O
classified	O
as	O
either	O
WARPS	B-T170
or	O
STAID	B-T170
presenting	O
with	O
recurrent	O
patellofemoral	B-T082
instability	B-T033
.	O

A	O
secondary	O
purpose	O
was	O
to	O
further	O
validate	O
the	O
WARPS	B-T170
/	I-T170
STAID	I-T170
classification	I-T170
with	O
the	O
Banff	B-T170
Patella	I-T170
Instability	I-T170
Instrument	I-T170
(	O
BPII	B-T170
)	O
,	O
the	O
Marx	B-T170
activity	I-T170
scale	I-T170
and	O
the	O
Patellar	B-T017
Instability	B-T170
Severity	I-T170
Score	I-T170
(	O
ISS	B-T170
)	O
.	O

A	O
convenience	O
sample	O
of	O
50	O
patients	O
with	O
recurrent	O
patellofemoral	B-T082
instability	B-T033
,	O
including	O
25	O
WARPS	B-T170
and	O
25	O
STAID	B-T170
subtype	I-T170
patients	O
,	O
were	O
assessed	O
.	O

Clinical	B-T170
data	I-T170
were	O
collected	O
including	O
assessment	B-T058
of	O
demographic	O
risk	B-T033
factors	I-T033
(	O
sex	O
,	O
BMI	B-T201
,	O
bilaterality	B-T082
of	O
symptoms	B-T033
,	O
affected	B-T082
limb	B-T017
side	I-T017
and	O
age	O
at	O
first	O
dislocation	B-T037
)	O
and	O
pathoanatomic	B-T033
risk	I-T033
factors	I-T033
(	O
TT	O
-	O
TG	O
distance	O
,	O
patella	B-T017
height	O
,	O
patellar	O
tilt	O
,	O
grade	B-T170
of	O
trochlear	B-T038
dysplasia	I-T038
,	O
Beighton	O
score	O
and	O
rotational	B-T033
abnormalities	I-T033
of	O
the	O
tibia	B-T017
or	O
femur	B-T017
)	O
.	O

Patients	O
completed	O
the	O
BPII	B-T170
and	O
the	O
Marx	B-T170
activity	I-T170
scale	I-T170
.	O

The	O
ISS	B-T170
was	O
calculated	B-T058
from	O
the	O
clinical	B-T170
assessment	I-T170
data	I-T170
.	O

Patients	O
were	O
stratified	O
into	O
the	O
WARPS	B-T170
or	O
STAID	B-T170
subtypes	I-T170
for	O
comparative	O
analysis	O
.	O

An	O
independent	O
t	B-T170
test	I-T170
was	O
used	O
to	O
compare	O
demographics	O
,	O
the	O
pathoanatomic	B-T033
risk	I-T033
factors	I-T033
and	O
subjective	O
measures	O
between	O
the	O
groups	O
.	O

Convergent	O
validity	O
was	O
tested	O
with	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
between	O
the	O
WARPS	O
/	O
STAID	O
and	O
ISS	B-T170
scores	I-T170
.	O

Demographic	O
risk	O
factors	O
statistically	O
associated	O
with	O
a	O
WARPS	B-T170
subtype	I-T170
included	O
female	O
sex	O
,	O
age	O
at	O
first	O
dislocation	B-T037
and	O
bilaterality	B-T082
.	O

Pathoanatomic	B-T033
risk	I-T033
factors	I-T033
statistically	O
associated	O
with	O
a	O
WARPS	B-T170
subtype	I-T170
included	O
trochlear	B-T038
dysplasia	I-T038
,	O
TT	O
-	O
TG	O
distance	O
,	O
generalized	O
ligamentous	B-T038
laxity	I-T038
,	O
patellar	O
tilt	O
and	O
rotational	B-T033
abnormalities	I-T033
.	O

The	O
independent	O
t	B-T170
test	I-T170
revealed	O
a	O
significant	O
difference	O
between	O
the	O
ISS	B-T170
scores	O
:	O
WARPS	B-T170
subtype	I-T170
(	O
M	O
=	O
4	O
.	O
4	O
,	O
SD	O
=	O
1	O
.	O
1	O
)	O
and	O
STAID	B-T170
subtype	I-T170
(	O
M	O
=	O
2	O
.	O
5	O
,	O
SD	O
=	O
1	O
.	O
5	O
)	O
;	O
t	O
(	O
48	O
)	O
=	O
5	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
001	O
.	O

The	O
relationship	O
between	O
the	O
WARPS	O
/	O
STAID	O
and	O
the	O
ISS	B-T170
scores	I-T170
,	O
measured	O
using	O
a	O
Pearson	O
r	O
correlation	O
coefficient	O
,	O
demonstrated	O
a	O
strong	O
relationship	O
:	O
r	O
=	O
-	O
0	O
.	O
61	O
,	O
n	O
=	O
50	O
,	O
p	O
<	O
0	O
.	O
001	O
.	O

This	O
study	B-T062
has	O
demonstrated	O
statistically	O
significant	O
evidence	O
that	O
certain	O
demographics	O
and	O
pathoanatomies	O
are	O
more	O
prevalent	O
in	O
each	O
of	O
the	O
WARPS	B-T170
and	O
STAID	B-T170
patellofemoral	B-T082
instability	B-T033
subtypes	B-T170
.	O

There	O
was	O
no	O
difference	O
in	O
quality	O
-	O
of	O
-	O
life	O
or	O
activity	O
level	O
between	O
the	O
subtypes	B-T170
.	O

The	O
WARPS	O
/	O
STAID	O
score	O
demonstrated	O
convergent	O
validity	O
to	O
the	O
ISS	B-T170
and	O
divergent	O
validity	O
to	O
the	O
BPII	B-T170
score	I-T170
and	O
the	O
Marx	B-T170
activity	I-T170
scale	I-T170
.	O

This	O
study	B-T062
has	O
further	O
validated	O
both	O
the	O
WARPS	B-T170
/	I-T170
STAID	I-T170
classification	I-T170
and	O
the	O
ISS	B-T170
of	O
patients	O
that	O
present	O
with	O
recurrent	O
patellofemoral	B-T082
instability	B-T033
.	O

III	O
.	O

Expression	B-T038
of	O
caspase	B-T103
3	I-T103
in	O
ovarian	B-T017
follicle	I-T017
cells	B-T017
of	O
the	O
lizard	B-T204
Podarcis	B-T204
sicula	I-T204

In	O
this	O
study	O
,	O
our	O
aim	O
was	O
to	O
determine	O
whether	O
caspase	B-T103
3	I-T103
plays	O
a	O
role	O
,	O
during	O
previtellogenesis	B-T038
,	O
in	O
the	O
ovarian	B-T017
follicular	B-T017
epithelium	I-T017
of	O
the	O
lizard	B-T204
Podarcis	B-T204
sicula	I-T204
.	O

We	O
investigated	O
the	O
presence	O
and	O
localization	O
of	O
proform	O
and	O
active	O
caspase	B-T103
3	I-T103
by	O
enzyme	B-T058
assay	I-T058
,	O
Western	B-T058
blotting	I-T058
and	O
immunocytochemistry	B-T058
.	O

In	O
parallel	O
,	O
a	O
fragment	O
of	O
caspase	B-T017
3	I-T017
was	O
cloned	B-T058
for	O
the	O
first	O
time	O
in	O
this	O
species	B-T170
,	O
sequenced	O
and	O
used	O
for	O
in	B-T062
situ	I-T062
hybridization	I-T062
to	O
localize	B-T082
messengers	O
and	O
analysed	O
by	O
a	O
phylogenetic	B-T062
survey	I-T062
to	O
shed	O
light	O
on	O
its	O
homology	O
with	O
reptilian	B-T204
caspases	B-T103
.	O

Results	O
demonstrated	O
that	O
:	O
(	O
1	O
)	O
the	O
follicle	B-T017
cells	B-T017
expressed	B-T038
a	O
caspase	B-T103
of	O
the	O
3	O
/	O
7	O
group	O
and	O
the	O
mRNA	B-T103
for	O
caspase	B-T103
3	I-T103
was	O
transcribed	B-T038
in	O
the	O
stem	O
phase	O
and	O
was	O
completely	O
translated	B-T038
during	O
cell	B-T038
differentiation	I-T038
;	O
(	O
2	O
)	O
the	O
proform	B-T103
protein	I-T103
was	O
stored	O
during	O
the	O
differentiated	O
(	O
nurse	O
)	O
stage	O
and	O
activated	O
at	O
the	O
end	O
of	O
previtellogenesis	B-T038
provoking	O
the	O
degeneration	B-T038
of	I-T038
cells	I-T038
;	O
(	O
3	O
)	O
the	O
predicted	O
protein	B-T082
sequence	I-T082
,	O
although	O
partial	O
,	O
had	O
a	O
strong	O
similarity	O
with	O
the	O
known	O
reptilian	B-T204
caspases	B-T103
3	I-T103
.	O

The	O
epithelial	B-T017
cells	I-T017
of	O
the	O
ovarian	B-T017
follicle	I-T017
,	O
therefore	O
,	O
do	O
not	O
employ	O
caspase	B-T103
3	I-T103
during	O
the	O
nurse	O
stage	O
but	O
,	O
instead	O
,	O
prepare	O
for	O
apoptosis	B-T038
long	O
before	O
the	O
process	O
actually	O
begins	O
.	O

The	O
relevance	O
of	O
this	O
strategy	O
is	O
discussed	O
.	O

Increased	O
acute	O
mortality	O
with	O
chemoradiotherapy	B-T058
for	O
locally	B-T038
advanced	I-T038
head	I-T038
and	I-T038
neck	I-T038
cancer	I-T038
in	O
patients	O
≥70	O
years	O

Concurrent	B-T058
chemoradiotherapy	I-T058
(	O
CRT	B-T058
)	O
is	O
the	O
standard	B-T058
of	I-T058
care	I-T058
for	O
many	O
sites	B-T082
of	O
locally	B-T038
advanced	I-T038
head	I-T038
and	I-T038
neck	I-T038
squamous	I-T038
cell	I-T038
carcinomas	I-T038
(	O
LAHNC	B-T038
)	O
.	O

However	O
,	O
on	O
meta	B-T062
-	I-T062
analysis	I-T062
,	O
the	O
addition	O
of	O
chemotherapy	B-T058
did	O
not	O
improve	O
survival	O
for	O
patients	O
>	O
70	O
years	O
.	O

We	O
hypothesized	O
that	O
elderly	B-T098
patients	O
treated	O
with	O
CRT	B-T058
would	O
have	O
increased	O
toxicity	B-T037
without	O
similar	O
improvements	O
in	O
survival	O
.	O

A	O
single	B-T092
-	I-T092
institution	I-T092
,	O
IRB	B-T170
-	I-T170
approved	I-T170
retrospective	B-T062
study	I-T062
took	O
place	O
from	O
2005	O
to	O
2012	O
including	O
369	O
patients	O
treated	O
with	O
CRT	B-T058
for	O
LAHNC	B-T038
.	O

Multivariate	B-T170
models	I-T170
for	O
death	B-T033
at	O
3	O
months	O
and	O
death	B-T033
over	O
time	O
were	O
developed	O
using	O
logistic	B-T062
regression	I-T062
and	O
Cox	B-T062
modeling	I-T062
,	O
respectively	O
.	O

Patients	O
≥70	O
years	O
were	O
treated	O
less	O
often	O
with	O
concurrent	O
cisplatin	B-T103
dosed	O
every	O
3	O
weeks	O
(	O
25	O
.	O
5	O
%	O
vs	O
.	O

71	O
.	O
4	O
%	O
,	O
respectively	O
)	O
and	O
more	O
often	O
with	O
weekly	O
carboplatin	B-T103
(	O
31	O
.	O
9	O
%	O
vs	O
.	O

3	O
.	O
4	O
%	O
)	O
than	O
patients	O
<	O
70	O
years	O
(	O
n	O
=	O
322	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Patients	O
≥70	O
years	O
experienced	O
increased	O
toxicity	B-T037
during	O
treatment	B-T058
with	O
more	O
frequently	O
hospitalizations	B-T058
(	O
36	O
.	O
2	O
%	O
vs	O
.	O

21	O
.	O
1	O
%	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
a	O
lower	O
rate	O
of	O
PEG	B-T058
removal	I-T058
at	O
last	O
follow	B-T058
-	I-T058
up	I-T058
or	O
death	B-T033
(	O
77	O
.	O
1	O
%	O
vs	O
.	O

92	O
.	O
9	O
%	O
;	O
p	O
=	O
0	O
.	O
004	O
)	O
.	O

A	O
higher	O
proportion	O
of	O
patients	O
≥70	O
years	O
died	O
within	O
3	O
months	O
(	O
12	O
.	O
8	O
%	O
vs	O
.	O

2	O
.	O
8	O
%	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
following	O
CRT	B-T058
.	O

Patients	O
≥70	O
had	O
an	O
increased	O
risk	O
of	O
death	B-T033
at	O
3	O
months	O
following	O
CRT	B-T058
(	O
odds	O
ratio	O
5	O
.	O
19	O
,	O
95	O
%	O
CI	O
1	O
.	O
64	O
-	O
16	O
.	O
41	O
;	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
worse	O
survival	O
over	O
time	O
(	O
hazard	O
ratio	O
2	O
.	O
30	O
,	O
95	O
%	O
CI	O
1	O
.	O
34	O
-	O
3	O
.	O
93	O
;	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

Patients	O
≥70	O
years	O
were	O
more	O
often	O
treated	O
with	O
less	O
toxic	O
chemotherapy	B-T058
,	O
yet	O
experienced	O
higher	O
rates	O
of	O
hospitalization	B-T058
during	O
treatment	B-T058
and	O
increased	O
rates	O
of	O
acute	O
mortality	O
following	O
CRT	B-T058
.	O

The	O
efficacy	O
of	O
chemoradiotherapy	B-T058
for	O
elderly	B-T098
patients	O
should	O
be	O
evaluated	O
in	O
a	O
prospective	O
setting	O
.	O

Food	O
security	O
and	O
the	O
nutritional	B-T033
status	I-T033
of	O
children	O
in	O
foster	O
care	O
:	O
new	O
horizons	O
in	O
the	O
protection	O
of	O
a	O
fragile	O
population	O

The	O
nutritional	B-T033
status	I-T033
of	O
foster	O
children	O
,	O
the	O
quality	O
of	O
daily	B-T168
menus	I-T168
in	O
group	B-T092
homes	I-T092
and	O
the	O
Food	O
Security	O
inside	O
these	O
organizations	B-T092
have	O
been	O
poorly	O
studied	O
and	O
this	O
study	B-T062
means	O
to	O
investigate	O
them	O
.	O

A	O
sample	O
of	O
125	O
children	O
,	O
ranging	O
in	O
age	O
from	O
0	O
-	O
17	O
years	O
,	O
among	O
seven	O
group	B-T092
homes	I-T092
(	O
group	O
A	O
)	O
was	O
compared	O
with	O
121	O
children	O
of	O
the	O
general	B-T098
population	I-T098
we	O
(	O
group	O
B	O
)	O
.	O

To	O
evaluate	O
nutritional	B-T033
status	I-T033
,	O
BMI	O
percentiles	O
were	O
used	O
.	O

Mean	O
percentiles	O
of	O
both	O
groups	O
were	O
compared	O
through	O
statistical	O
analysis	O
.	O

Both	O
nutritional	B-T033
and	O
caloric	O
daily	O
distributions	O
in	O
each	O
organization	B-T092
were	O
obtained	O
using	O
the	O
24	O
-	O
hour	O
recall	B-T170
method	I-T170
.	O

A	O
specific	O
questionnaire	B-T170
was	O
administered	O
to	O
evaluate	O
Food	O
Security	O
.	O

From	O
the	O
analysis	B-T062
of	O
mean	O
BMI	B-T201
-	O
for	O
-	O
age	O
(	O
or	O
height	O
-	O
for	O
-	O
length	O
)	O
percentiles	O
,	O
did	O
not	O
observe	O
statistically	O
significant	O
differences	O
between	O
group	O
A	O
and	O
group	O
B	O
.	O

The	O
average	O
daily	O
nutrient	B-T033
and	O
calorie	B-T033
distribution	I-T033
in	O
group	B-T092
homes	I-T092
proves	O
to	O
be	O
nearly	B-T033
optimal	I-T033
with	O
the	O
exception	O
of	O
a	O
slight	O
excess	O
in	O
proteins	B-T168
and	O
a	O
slight	O
deficiency	O
in	O
PUFAs	B-T103
.	O

Moreover	O
,	O
a	O
low	B-T033
intake	I-T033
of	O
iron	B-T033
and	O
calcium	B-T201
was	O
revealed	O
.	O

All	O
organizations	B-T092
obtained	O
a	O
"	O
High	O
Food	O
Security	O
"	O
profile	O
.	O

Nutritional	B-T033
conditions	I-T033
of	O
foster	O
children	O
are	O
no	O
worse	O
than	O
that	O
of	O
children	O
of	O
the	O
general	B-T098
population	I-T098
.	O

Foster	O
care	O
provides	O
the	O
necessary	O
conditions	O
to	O
support	O
their	O
growth	B-T038
.	O

Incontinence	B-T038
-	O
associated	O
dermatitis	B-T038
:	O
reducing	O
adverse	B-T038
events	I-T038

Incontinence	B-T038
-	O
associated	O
dermatitis	B-T038
(	O
IAD	B-T038
)	O
is	O
a	O
common	O
problem	B-T033
in	O
patients	O
with	O
faecal	B-T038
and	O
/	O
or	O
urinary	B-T038
incontinence	I-T038
.	O

Urine	B-T031
alters	O
the	O
normal	O
skin	B-T022
flora	B-T033
and	O
increases	O
permeability	O
of	O
the	O
stratum	B-T017
corneum	I-T017
and	O
faecal	B-T031
enzymes	B-T103
on	O
the	O
skin	B-T022
contribute	O
to	O
skin	O
damage	O
.	O

Faecal	B-T031
bacteria	B-T007
can	O
then	O
penetrate	O
the	O
skin	B-T022
,	O
increasing	O
the	O
risk	O
of	O
secondary	B-T038
infection	I-T038
.	O

However	O
,	O
IAD	B-T038
can	O
be	O
prevented	B-T058
and	O
healed	O
with	O
timely	O
and	O
appropriate	O
skin	B-T058
cleansing	I-T058
and	O
skin	O
protection	O
.	O

This	O
includes	O
appropriate	O
use	O
of	O
containment	O
devices	O
.	O

This	O
article	O
also	O
looks	O
at	O
HARTMANN	B-T074
incontinence	I-T074
pads	I-T074
that	O
have	O
been	O
developed	O
to	O
absorb	O
the	O
fluids	O
that	O
cause	O
IAD	B-T038
and	O
maintain	O
the	O
skin	B-T022
'	I-T022
s	I-T022
acidic	O
pH	O
.	O

The	O
acidic	O
pH	O
of	O
the	O
skin	B-T022
contributes	O
to	O
its	O
barrier	B-T038
function	I-T038
and	O
defence	O
against	O
infection	B-T038
.	O

Therefore	O
,	O
maintaining	O
an	O
acidic	O
pH	O
will	O
help	O
protect	O
the	O
skin	B-T022
from	O
damage	O
.	O

Feasibility	B-T062
of	O
a	O
transition	O
intervention	B-T058
aimed	O
at	O
adolescents	O
with	O
chronic	B-T038
illness	I-T038

International	O
guidelines	B-T170
recommend	O
planned	O
and	O
structured	O
transition	O
programmes	B-T058
for	O
adolescents	O
with	O
chronic	B-T038
illness	I-T038
because	O
inadequate	O
transition	O
may	O
lead	O
to	O
poor	B-T033
disease	I-T033
control	I-T033
and	O
risk	O
of	O
lacking	O
outpatient	B-T058
follow	I-T058
-	I-T058
up	I-T058
.	O

To	O
investigate	O
the	O
feasibility	B-T062
of	O
a	O
transition	O
intervention	B-T058
aimed	O
at	O
adolescents	O
with	O
chronic	B-T038
illness	I-T038
focusing	B-T038
on	O
declines	O
,	O
drop	B-T098
-	I-T098
outs	I-T098
,	O
no	O
-	O
shows	O
and	O
advantages	O
and	O
disadvantages	O
of	O
participating	O
.	O

We	O
invited	O
236	O
adolescents	O
(	O
12	O
-	O
20	O
years	O
)	O
with	O
juvenile	B-T038
idiopathic	I-T038
arthritis	I-T038
(	O
JIA	B-T038
)	O
to	O
participate	O
in	O
a	O
randomised	B-T062
controlled	I-T062
trial	I-T062
(	O
RCT	B-T062
)	O
transition	O
intervention	B-T058
.	O

Reasons	O
for	O
decline	O
and	O
drop	B-T098
-	I-T098
outs	I-T098
were	O
calculated	O
.	O

Adolescents	O
'	O
experiences	B-T038
of	O
advantages	O
and	O
disadvantages	O
of	O
participating	O
and	O
reasons	O
for	O
no	O
-	O
shows	O
were	O
investigated	O
through	O
focus	O
groups	O
and	O
telephone	B-T062
interviews	I-T062
,	O
which	O
were	O
analysed	B-T062
using	O
thematic	B-T062
analysis	B-T062
.	O

One	O
hundred	O
and	O
twenty	O
of	O
the	O
236	O
eligible	O
patients	O
declined	O
to	O
participate	O
in	O
the	O
intervention	B-T058
and	O
20	O
%	O
dropped	B-T098
out	I-T098
during	O
the	O
intervention	B-T058
.	O

Unspecified	O
declines	O
and	O
practical	B-T033
issues	I-T033
were	O
the	O
most	O
common	O
reason	O
to	O
decline	O
,	O
and	O
'	O
do	O
not	O
wish	O
to	O
continue	O
'	O
was	O
the	O
most	O
common	O
reason	O
to	O
drop	B-T098
-	I-T098
out	I-T098
.	O

Reasons	O
for	O
no	O
-	O
shows	O
were	O
forgetting	O
and	O
being	O
too	O
busy	O
.	O

Advantages	O
of	O
participating	O
were	O
stated	O
as	O
'	O
participating	O
without	O
parents	O
'	O
,	O
'	O
trust	O
and	O
confidentiality	O
'	O
,	O
'	O
being	O
able	O
to	O
set	O
the	O
agenda	O
'	O
and	O
'	O
responsiveness	O
'	O
.	O

Disadvantages	O
were	O
'	O
unclear	O
aim	O
of	O
the	O
study	B-T062
'	O
,	O
'	O
meeting	O
others	O
with	O
JIA	B-T038
'	O
,	O
'	O
too	O
few	O
conversations	O
'	O
and	O
'	O
transport	O
issues	B-T033
'	O
.	O

Many	O
adolescents	O
had	O
difficulties	B-T033
understanding	B-T038
the	O
aim	O
of	O
the	O
intervention	B-T058
.	O

However	O
,	O
most	O
participants	O
appreciated	O
the	O
conversations	O
about	O
identity	O
as	O
well	O
as	O
the	O
trust	O
and	O
confidentiality	O
in	O
the	O
communication	O
.	O

In	O
the	O
future	O
,	O
adolescents	O
should	O
be	O
offered	O
more	O
individually	O
organised	O
programmes	B-T058
according	O
to	O
their	O
preferences	O
and	O
needs	O
in	O
cooperation	O
with	O
parents	O
and	O
health	B-T097
care	I-T097
providers	I-T097
.	O

High	O
-	O
Throughput	O
Analysis	O
of	O
the	O
IgG	B-T103
N	I-T103
-	I-T103
Glycome	I-T103
by	O
UPLC	B-T058
-	O
FLR	O

As	O
biological	O
and	O
clinical	O
relevance	O
of	O
glycosylation	O
is	O
becoming	O
more	O
apparent	O
,	O
interest	O
in	O
large	B-T062
scale	I-T062
studies	I-T062
of	O
the	O
glycome	B-T103
is	O
growing	O
.	O

Glycans	B-T103
attached	O
to	O
immunoglobulin	B-T103
G	I-T103
(	O
IgG	B-T103
)	O
were	O
shown	O
to	O
be	O
essential	O
for	O
its	O
function	B-T038
and	O
IgG	B-T103
glycosylation	O
was	O
shown	O
to	O
change	O
with	O
various	O
processes	O
,	O
making	O
IgG	B-T103
one	O
of	O
the	O
most	O
studied	O
glycoproteins	B-T103
.	O

Many	O
approaches	B-T082
including	O
liquid	B-T058
chromatography	I-T058
,	O
capillary	B-T058
gel	I-T058
electrophoresis	I-T058
,	O
and	O
mass	B-T058
spectrometry	I-T058
were	O
developed	O
to	O
study	B-T062
IgG	B-T103
glycosylation	O
.	O

Generation	O
of	O
high	O
-	O
quality	O
glycomics	O
data	O
in	O
a	O
high	O
-	O
throughput	O
fashion	O
requires	O
reproducible	O
and	O
robust	O
sample	O
preparation	O
and	O
accurate	O
and	O
reliable	O
quantitative	O
analysis	O
.	O

This	O
chapter	O
presents	O
a	O
protocol	B-T170
for	O
an	O
optimized	O
and	O
high	O
-	O
throughput	O
IgG	B-T103
N	I-T103
-	I-T103
glycan	I-T103
release	O
,	O
fluorescent	B-T058
labeling	I-T058
and	O
cleanup	O
,	O
and	O
analysis	B-T062
of	O
fluorescently	O
labeled	O
IgG	B-T103
N	I-T103
-	I-T103
glycans	I-T103
by	O
hydrophilic	B-T058
interaction	I-T058
liquid	I-T058
chromatography	I-T058
(	O
HILIC	B-T058
)	O
on	O
an	O
ultra	B-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
(	O
UPLC	B-T058
)	O
system	O
with	O
fluorescence	O
(	O
FLR	O
)	O
detection	B-T058
.	O

Biomimetic	O
whitlockite	B-T103
inorganic	O
nanoparticles	O
-	O
mediated	O
in	B-T082
situ	I-T082
remodeling	B-T038
and	O
rapid	O
bone	B-T038
regeneration	I-T038

Bone	B-T038
remodeling	I-T038
process	O
relies	O
on	O
complex	O
signaling	B-T038
pathway	I-T038
between	O
osteoblasts	B-T017
and	O
osteoclasts	B-T017
and	O
control	O
mechanisms	O
to	O
achieve	O
homeostasis	B-T038
of	O
their	O
growth	B-T038
and	O
differentiation	B-T038
.	O

Despite	O
previous	O
achievements	O
in	O
understanding	O
complicated	O
signaling	B-T038
pathways	I-T038
between	O
cells	B-T017
and	O
bone	B-T017
extracellular	B-T017
matrices	I-T017
during	O
bone	B-T038
remodeling	I-T038
process	O
,	O
a	O
role	O
of	O
local	O
ionic	B-T103
concentration	O
remains	O
to	O
be	O
elucidated	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
synthetic	O
whitlockite	B-T103
(	O
WH	B-T103
:	I-T103
Ca18Mg2	I-T103
(	I-T103
HPO4	I-T103
)	I-T103
2	I-T103
(	I-T103
PO4	I-T103
)	I-T103
12	I-T103
)	I-T103
nanoparticles	O
can	O
recapitulate	O
early	O
-	O
stage	O
of	O
bone	B-T038
regeneration	I-T038
through	O
stimulating	O
osteogenic	B-T038
differentiation	I-T038
,	O
prohibiting	O
osteoclastic	B-T017
activity	O
,	O
and	O
transforming	B-T038
into	O
mechanically	O
enhanced	O
hydroxyapatite	B-T103
(	O
HAP	B-T103
)	O
-	O
neo	B-T017
bone	I-T017
tissues	I-T017
by	O
continuous	O
supply	O
of	O
PO4	B-T103
(	I-T103
3	I-T103
-	I-T103
)	I-T103
and	O
Mg	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
under	O
physiological	O
conditions	O
.	O

In	O
addition	O
,	O
based	O
on	O
their	O
structural	B-T062
analysis	I-T062
,	O
the	O
dynamic	O
phase	O
transformation	B-T038
from	O
WH	B-T103
into	O
HAP	B-T103
contributed	O
as	O
a	O
key	O
factor	O
for	O
rapid	O
bone	B-T038
regeneration	I-T038
with	O
denser	O
hierarchical	O
neo	B-T017
-	I-T017
bone	I-T017
structure	B-T082
.	O

Our	O
findings	B-T033
suggest	O
a	O
groundbreaking	O
concept	O
of	O
'	O
living	O
bone	B-T017
minerals	B-T103
'	O
that	O
actively	O
communicate	B-T038
with	O
the	O
surrounding	O
system	O
to	O
induce	O
self	O
-	O
healing	O
,	O
while	O
previous	O
notions	O
about	O
bone	B-T017
minerals	B-T103
have	O
been	O
limited	O
to	O
passive	O
products	O
of	O
cellular	B-T017
mineralization	O
.	O

Is	O
the	O
inactivation	O
of	O
dentin	B-T031
proteases	B-T103
by	O
crosslinkers	B-T103
reversible	O
?	O

Inactivation	O
of	O
dentin	B-T031
proteases	B-T103
by	O
crosslinkers	B-T103
has	O
been	O
suggested	O
as	O
a	O
way	O
to	O
prevent	O
the	O
degradation	B-T038
of	O
dentin	B-T031
collagen	B-T103
in	O
the	O
hybrid	O
layer	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
if	O
the	O
inhibition	O
is	O
reversible	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
inactivation	O
effect	O
of	O
various	O
crosslinkers	B-T103
on	O
dentin	B-T031
protease	B-T103
activity	B-T038
over	O
a	O
period	O
of	O
6	O
months	O
.	O

Demineralized	B-T103
dentin	I-T103
beams	I-T103
(	O
1×2×6mm	O
,	O
n	O
=	O
10	O
/	O
group	O
)	O
were	O
treated	O
with	O
(	O
1	O
)	O
1	O
%	O
glutaraldehyde	B-T103
(	O
GA1	B-T103
)	O
,	O
(	O
2	O
)	O
5	O
%	O
glutaraldehyde	B-T103
(	O
GA5	B-T103
)	O
,	O
(	O
3	O
)	O
1	O
%	O
grape	B-T103
seed	I-T103
extract	I-T103
(	O
GS1	B-T103
)	O
,	O
(	O
4	O
)	O
5	O
%	O
grape	B-T103
seed	I-T103
extract	I-T103
(	O
GS5	B-T103
)	O
,	O
(	O
5	O
)	O
10	O
%	O
sumac	B-T204
berry	I-T204
extract	I-T204
(	O
S	B-T204
)	O
,	O
(	O
6	O
)	O
20μM	B-T103
curcumin	I-T103
(	O
CR20	B-T103
)	O
,	O
and	O
(	O
7	O
)	O
200μM	O
curcumin	B-T103
(	O
CR200	B-T103
)	O
for	O
5min	O
.	O

Untreated	B-T033
beams	B-T103
served	O
as	O
control	O
.	O

The	O
beams	B-T103
were	O
incubated	B-T058
up	O
to	O
6	O
months	O
and	O
incubation	B-T103
media	I-T103
were	O
used	O
to	O
analyze	B-T062
solubilized	O
telopeptide	B-T103
(	O
ICTP	B-T103
and	O
CTX	B-T103
)	O
fragments	B-T103
as	O
indicators	O
of	O
MMP	B-T103
-	O
and	O
cathepsin	B-T103
K	I-T103
-	O
mediated	O
degradation	B-T038
after	O
1	O
,	O
3	O
and	O
6	O
months	O
of	O
incubation	B-T058
.	O

The	O
relative	O
MMP	B-T103
activity	B-T038
of	O
dentin	B-T103
beams	I-T103
was	O
tested	O
using	O
a	O
generic	O
MMP	B-T103
assay	B-T058
.	O

Data	O
were	O
analyzed	B-T062
using	O
repeated	O
-	O
measures	O
ANOVA	O
,	O
α	O
=	O
0	O
.	O
05	O
.	O

All	O
treated	O
groups	O
showed	O
significant	O
decrease	O
in	O
CTX	B-T103
release	O
(	O
32	O
.	O
2	O
-	O
469	O
.	O
5pg	O
/	O
mg	O
dentin	B-T031
)	O
and	O
ICTP	B-T103
(	O
1	O
.	O
8	O
-	O
47	O
.	O
6ng	O
/	O
mg	O
dentin	B-T031
)	O
fragments	B-T103
during	O
the	O
first	O
month	O
of	O
incubation	B-T058
compared	O
to	O
control	O
(	O
1159pg	O
/	O
mg	O
and	O
72	O
.	O
9ng	O
/	O
mg	O
dentin	B-T031
,	O
respectively	O
)	O
.	O

GA5	B-T103
,	O
GS5	B-T103
and	O
CR200	B-T103
maintained	O
their	O
inhibitory	O
effect	O
during	O
6	O
-	O
month	O
incubation	B-T058
.	O

The	O
results	O
were	O
confirmed	O
by	O
dry	O
mass	O
loss	O
and	O
relative	O
MMP	B-T103
activity	B-T038
following	O
6	O
months	O
.	O

The	O
results	O
of	O
this	O
study	B-T062
indicate	O
that	O
the	O
long	O
-	O
term	O
effect	O
is	O
both	O
crosslinker	B-T103
and	O
dose	O
dependent	O
.	O

Inhibition	B-T038
of	O
STEP61	B-T103
ameliorates	O
deficits	O
in	O
mouse	B-T204
and	O
hiPSC	B-T017
-	O
based	O
schizophrenia	B-T038
models	B-T038

The	O
brain	B-T017
-	O
specific	O
tyrosine	B-T103
phosphatase	I-T103
,	O
STEP	B-T103
(	O
STriatal	B-T103
-	I-T103
Enriched	I-T103
protein	I-T103
tyrosine	I-T103
Phosphatase	I-T103
)	O
is	O
an	O
important	O
regulator	O
of	O
synaptic	B-T038
function	I-T038
.	O

STEP	B-T103
normally	O
opposes	O
synaptic	B-T082
strengthening	O
by	O
increasing	O
N	B-T103
-	I-T103
methyl	I-T103
D	I-T103
-	I-T103
aspartate	I-T103
glutamate	I-T103
receptor	I-T103
(	O
NMDAR	B-T103
)	O
internalization	O
through	O
dephosphorylation	B-T038
of	O
GluN2B	B-T103
and	O
inactivation	B-T038
of	O
the	O
kinases	B-T103
extracellular	B-T103
signal	I-T103
-	I-T103
regulated	I-T103
kinase	I-T103
1	I-T103
/	O
2	B-T103
and	O
Fyn	B-T103
.	O

Here	O
we	O
show	O
that	O
STEP61	B-T103
is	O
elevated	O
in	O
the	O
cortex	B-T017
in	O
the	O
Nrg1	B-T017
(	I-T017
+	I-T017
/	I-T017
-	I-T017
)	I-T017
knockout	B-T038
mouse	B-T038
model	I-T038
of	O
schizophrenia	B-T038
(	O
SZ	B-T038
)	O
.	O

Genetic	O
reduction	B-T058
or	O
pharmacological	O
inhibition	O
of	O
STEP	B-T103
prevents	O
the	O
loss	O
of	O
NMDARs	B-T103
from	O
synaptic	B-T017
membranes	I-T017
and	O
reverses	O
behavioral	B-T038
deficits	I-T038
in	O
Nrg1	B-T017
(	I-T017
+	I-T017
/	I-T017
-	I-T017
)	I-T017
mice	B-T204
.	O

STEP61	B-T103
protein	I-T103
is	O
also	O
increased	O
in	O
cortical	B-T017
lysates	O
from	O
the	O
central	B-T022
nervous	I-T022
system	I-T022
-	O
specific	O
ErbB2	B-T103
/	O
4	B-T103
mouse	B-T038
model	I-T038
of	O
SZ	B-T038
,	O
as	O
well	O
as	O
in	O
human	B-T017
induced	I-T017
pluripotent	I-T017
stem	I-T017
cell	I-T017
(	O
hiPSC	B-T017
)	O
-	O
derived	O
forebrain	B-T017
neurons	B-T017
and	O
Ngn2	B-T017
-	O
induced	O
excitatory	B-T017
neurons	I-T017
,	O
from	O
two	O
independent	O
SZ	B-T038
patient	O
cohorts	B-T098
.	O

In	O
these	O
selected	O
SZ	B-T038
models	B-T038
,	O
increased	O
STEP61	B-T103
protein	B-T058
levels	I-T058
likely	O
reflect	O
reduced	O
ubiquitination	B-T038
and	O
degradation	B-T038
.	O

These	O
convergent	O
findings	B-T033
from	O
mouse	B-T204
and	O
hiPSC	B-T017
SZ	B-T038
models	B-T038
provide	O
evidence	O
for	O
STEP61	B-T103
dysfunction	O
in	O
SZ	B-T038
.	O
Molecular	O
Psychiatry	O
advance	O
online	O
publication	O
,	O
18	O
October	O
2016	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
mp	O
.	O
2016	O
.	O
163	O
.	O

Incident	O
fracture	B-T037
associated	O
with	O
increased	O
risk	O
of	O
mortality	O
even	O
after	O
adjusting	O
for	O
frailty	B-T033
status	O
in	O
elderly	B-T098
Japanese	B-T098
men	B-T098
:	O
the	O
Fujiwara	O
-	O
kyo	O
Osteoporosis	O
Risk	O
in	O
Men	O
(	O
FORMEN	O
)	O
Cohort	O
Study	O

Frail	B-T033
elderly	B-T098
individuals	B-T098
have	O
elevated	O
risks	O
of	O
both	O
fracture	B-T037
and	O
mortality	O
.	O

We	O
found	O
that	O
incident	O
fractures	B-T037
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-T033
even	O
after	O
adjusting	O
for	O
pre	B-T037
-	I-T037
fracture	I-T037
frailty	B-T033
status	O
as	O
represented	O
by	O
physical	B-T058
performance	I-T058
tests	I-T058
and	O
laboratory	B-T058
tests	I-T058
for	O
common	O
geriatric	O
diseases	B-T038
in	O
community	O
-	O
dwelling	O
elderly	B-T098
Japanese	B-T098
men	B-T098
.	O

While	O
fractures	B-T037
reportedly	O
increase	O
the	O
risk	O
of	O
mortality	O
,	O
frailty	B-T033
may	O
complicate	O
this	O
association	O
,	O
generating	O
a	O
false	B-T033
-	I-T033
positive	I-T033
result	I-T033
.	O

We	O
evaluated	B-T058
this	O
association	O
after	O
adjusting	O
for	O
pre	B-T037
-	I-T037
fracture	I-T037
levels	O
of	O
frailty	B-T033
.	O

We	O
examined	B-T033
1998	O
community	O
-	O
dwelling	O
ambulatory	O
men	B-T098
aged	O
≥65	O
years	O
at	O
baseline	O
in	O
the	O
Fujiwara	O
-	O
kyo	O
Osteoporosis	O
Risk	O
in	O
Men	O
Study	O
for	O
frailty	B-T033
status	O
as	O
represented	O
by	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
,	O
physical	B-T058
performance	I-T058
tests	I-T058
(	O
grip	O
strength	O
,	O
one	O
-	O
foot	O
standing	O
balance	O
with	O
eyes	O
open	O
,	O
timed	B-T058
10	I-T058
-	I-T058
m	I-T058
walk	I-T058
)	O
,	O
and	O
laboratory	B-T058
sera	B-T031
tests	I-T058
.	O

Participants	B-T098
were	O
then	O
followed	O
for	O
5	O
years	O
for	O
incident	O
clinical	O
fractures	B-T037
and	O
death	B-T033
.	O

Effects	O
of	O
incident	O
fracture	B-T037
on	O
death	B-T033
were	O
determined	O
by	O
Cox	B-T170
proportional	I-T170
hazards	I-T170
model	I-T170
with	O
the	O
first	O
fracture	B-T037
during	O
follow	B-T058
-	I-T058
up	I-T058
as	O
a	O
time	O
-	O
dependent	O
predictor	O
and	O
with	O
frailty	B-T170
status	I-T170
indices	I-T170
as	O
covariates	O
.	O

We	O
identified	O
111	O
fractures	B-T037
in	O
99	O
men	B-T098
and	O
138	O
deaths	B-T033
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
period	O
(	O
median	B-T082
follow	B-T058
-	I-T058
up	I-T058
,	O
4	O
.	O
5	O
years	O
)	O
.	O

Participants	B-T098
with	O
incident	O
fractures	B-T037
did	O
not	B-T033
have	I-T033
significantly	I-T033
worse	I-T033
frailty	B-T033
statuses	O
,	O
but	O
did	O
show	O
a	O
significantly	O
higher	O
cumulative	O
mortality	O
rate	O
than	O
those	O
without	O
fractures	B-T037
(	O
p	O
=	O
0	O
.	O
0047	O
)	O
.	O

Age	O
-	O
adjusted	O
hazard	O
ratio	O
(	O
HR	O
)	O
of	O
death	B-T033
for	O
incident	O
fracture	B-T037
was	O
3	O
.	O
57	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
2	O
.	O
05	O
,	O
6	O
.	O
24	O
)	O
.	O

When	O
adjusted	O
for	O
physical	O
performance	O
,	O
this	O
decreased	O
to	O
2	O
.	O
77	O
(	O
1	O
.	O
51	O
,	O
5	O
.	O
06	O
)	O
,	O
but	O
remained	O
significant	O
.	O

The	O
HR	O
showed	O
no	B-T033
significant	I-T033
change	I-T033
when	O
adjusted	O
for	O
laboratory	O
test	O
results	O
(	O
3	O
.	O
96	O
(	O
2	O
.	O
26	O
,	O
6	O
.	O
94	O
)	O
)	O
.	O

Exclusion	O
of	O
deaths	B-T033
within	O
the	O
first	O
24	O
months	O
of	O
follow	B-T058
-	I-T058
up	I-T058
did	O
not	B-T033
alter	I-T033
these	O
results	B-T033
.	O

Incident	O
clinical	O
fracture	B-T037
was	O
associated	O
with	O
an	O
elevated	O
risk	O
of	O
death	B-T033
independently	B-T033
of	O
pre	B-T037
-	I-T037
fracture	I-T037
levels	O
of	O
frailty	B-T033
in	O
community	O
-	O
dwelling	O
elderly	B-T098
men	B-T098
.	O

Total	B-T033
Energy	I-T033
Expenditure	I-T033
in	O
Obese	B-T038
Kuwaiti	B-T092
Primary	I-T092
School	I-T092
Children	O
Assessed	O
by	O
the	O
Doubly	O
-	O
Labeled	O
Water	O
Technique	O

The	O
aim	O
of	O
this	O
pilot	B-T062
study	I-T062
was	O
to	O
assess	O
body	O
composition	O
and	O
total	B-T033
energy	I-T033
expenditure	I-T033
(	O
TEE	B-T033
)	O
in	O
35	O
obese	B-T038
7	O
-	O
9	O
years	O
old	O
Kuwaiti	B-T098
children	O
(	O
18	O
girls	O
and	O
17	O
boys	O
)	O
.	O

Total	B-T033
body	I-T033
water	I-T033
(	O
TBW	B-T033
)	O
and	O
TEE	B-T033
were	O
assessed	O
by	O
doubly	O
-	O
labeled	O
water	O
technique	O
.	O

TBW	B-T033
was	O
derived	O
from	O
the	O
intercept	O
of	O
the	O
elimination	B-T033
rate	I-T033
of	O
deuterium	B-T103
and	O
TEE	B-T033
from	O
the	O
difference	O
in	O
elimination	B-T033
rates	I-T033
of	O
(	B-T103
18	I-T103
)	I-T103
O	I-T103
and	O
deuterium	B-T103
.	O

TBW	B-T033
was	O
used	O
to	O
estimate	O
fat	B-T033
-	I-T033
free	I-T033
mass	I-T033
(	O
FFM	B-T033
)	O
,	O
using	O
hydration	O
factors	O
for	O
different	O
ages	O
and	O
gender	O
.	O

Fat	O
mass	O
(	O
FM	O
)	O
was	O
calculated	O
as	O
the	O
difference	O
between	O
body	O
weight	O
and	O
FFM	B-T033
.	O

Body	O
weight	O
was	O
not	O
statistically	O
different	O
but	O
TBW	B-T033
was	O
significantly	O
higher	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
in	O
boys	O
(	O
44	O
.	O
9	O
%	O
±	O
3	O
.	O
3	O
%	O
)	O
than	O
girls	O
(	O
42	O
.	O
4	O
%	O
±	O
3	O
.	O
0	O
%	O
)	O
,	O
while	O
girls	O
had	O
significantly	O
higher	O
estimated	O
FM	O
(	O
45	O
.	O
2	O
±	O
3	O
.	O
9	O
weight	O
%	O
versus	O
41	O
.	O
6	O
%	O
±	O
4	O
.	O
3	O
%	O
;	O
p	O
=	O
0	O
.	O
014	O
)	O
.	O

TEE	B-T033
was	O
significantly	O
higher	O
in	O
boys	O
(	O
2395	O
±	O
349	O
kcal	O
/	O
day	O
)	O
compared	O
with	O
girls	O
(	O
1978	O
±	O
169	O
kcal	O
/	O
day	O
)	O
;	O
p	O
=	O
0	O
.	O
001	O
.	O

Estimated	O
physical	O
activity	O
level	O
(	O
PAL	O
)	O
was	O
significantly	O
higher	O
in	O
boys	O
;	O
1	O
.	O
61	O
±	O
0	O
.	O
167	O
versus	O
1	O
.	O
51	O
±	O
0	O
.	O
870	O
;	O
p	O
=	O
0	O
.	O
034	O
.	O

Our	O
results	O
provide	O
the	O
first	O
dataset	B-T170
of	O
TEE	B-T033
in	O
7	O
-	O
9	O
years	O
old	O
obese	B-T038
Kuwaiti	B-T098
children	O
and	O
highlight	O
important	O
gender	O
differences	O
to	O
be	O
considered	O
during	O
the	O
development	O
of	O
school	O
based	O
interventions	O
targeted	O
to	O
combat	O
childhood	B-T038
obesity	I-T038
.	O

Mesenchymal	B-T017
stromal	I-T017
cells	I-T017
in	O
clinical	O
kidney	B-T058
transplantation	I-T058
:	O
how	O
tolerant	O
can	O
it	O
be	O
?	O

Progress	O
in	O
the	O
improvement	O
of	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
outcomes	O
of	O
kidney	B-T058
transplantation	I-T058
seems	O
to	O
have	O
reached	O
a	O
plateau	O
,	O
partially	O
due	O
to	O
consequences	O
of	O
very	O
efficient	O
,	O
but	O
nonspecific	O
immunosuppressive	B-T103
drugs	I-T103
.	O

In	O
recent	O
years	O
,	O
various	O
forms	O
of	O
cell	B-T058
therapy	I-T058
,	O
including	O
the	O
use	O
of	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
,	O
have	O
been	O
put	O
forward	O
as	O
an	O
alternative	O
strategy	O
for	O
more	O
defined	O
therapy	B-T058
.	O

It	O
is	O
thought	O
that	O
these	O
therapies	B-T058
will	O
not	O
only	O
allow	O
controlled	O
tapering	B-T058
of	O
immunosuppressive	B-T103
medication	I-T103
,	O
but	O
might	O
bring	O
us	O
also	O
closer	O
to	O
the	O
ambition	O
of	O
generating	O
donor	B-T098
-	O
specific	O
immune	B-T038
regulation	I-T038
and	O
tolerance	B-T038
.	O

Different	O
forms	O
of	O
alloimmunity	O
,	O
including	O
direct	O
,	O
indirect	O
and	O
semi	O
-	O
direct	O
alloantigen	B-T103
presentation	O
have	O
to	O
be	O
controlled	O
before	O
donor	B-T098
-	O
specific	O
immune	B-T038
regulation	I-T038
can	O
be	O
reached	O
.	O

Several	O
mechanisms	O
have	O
been	O
described	O
how	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
can	O
affect	O
alloimmunity	O
.	O

Especially	O
,	O
the	O
interaction	B-T038
with	O
professional	O
antigen	B-T017
presenting	I-T017
cells	I-T017
,	O
like	O
dendritic	B-T017
cells	I-T017
,	O
is	O
of	O
critical	O
importance	O
.	O

This	O
review	O
will	O
discuss	O
the	O
current	O
status	O
of	O
ongoing	O
clinical	B-T062
trials	I-T062
with	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
in	O
kidney	B-T058
transplantation	I-T058
and	O
specifically	O
concentrate	O
on	O
the	O
possibilities	O
and	O
impossibilities	O
of	O
how	O
these	O
therapeutic	B-T058
strategies	I-T058
can	O
contribute	O
to	O
control	O
of	O
the	O
different	O
forms	O
of	O
alloreactivity	O
operation	O
in	O
organ	B-T058
transplantation	I-T058
.	O

Facilitating	O
factors	O
and	O
barriers	O
to	O
malaria	B-T038
research	B-T062
utilization	O
for	O
policy	O
development	O
in	O
Malawi	B-T082

Research	B-T062
on	O
various	O
determinants	O
of	O
health	O
is	O
key	O
in	O
providing	O
evidence	O
for	O
policy	O
development	O
,	O
thereby	O
leading	O
to	O
successful	O
interventions	O
.	O

Utilization	O
of	O
research	B-T062
is	O
an	O
intricate	O
process	O
requiring	O
an	O
understanding	O
of	O
contextual	O
factors	O
.	O

The	O
study	O
was	O
conducted	O
to	O
assess	O
enhancing	O
factors	O
and	O
barriers	O
of	O
research	B-T062
utilization	O
for	O
malaria	B-T038
policy	O
development	O
in	O
Malawi	B-T082
.	O

Qualitative	O
research	B-T062
approach	O
was	O
used	O
through	O
in	O
-	O
depth	O
interviews	O
with	O
39	O
key	O
informants	O
that	O
included	O
malaria	B-T038
researchers	B-T097
,	O
policy	B-T097
makers	I-T097
,	O
programme	O
managers	B-T097
,	O
and	O
key	B-T098
stakeholders	I-T098
.	O

Purposive	B-T062
sampling	I-T062
and	O
snowballing	B-T062
techniques	I-T062
were	O
used	O
in	O
identifying	O
key	O
informants	O
.	O

Interview	O
transcripts	B-T170
were	O
entered	O
in	O
QSR	B-T170
Nvivo	I-T170
11	I-T170
software	I-T170
for	O
coding	O
and	O
analysis	B-T062
.	O

Respondents	B-T098
identified	O
global	O
efforts	O
as	O
key	O
in	O
advancing	O
knowledge	B-T062
translation	I-T062
,	O
while	O
local	B-T082
political	O
will	O
has	O
been	O
conducive	O
for	O
research	B-T062
utilization	O
.	O

Other	O
factors	O
were	O
availability	O
of	O
research	B-T062
,	O
availability	O
of	O
diverse	O
local	B-T082
researchers	B-T097
and	O
stakeholders	B-T098
supporting	O
knowledge	B-T062
translation	I-T062
.	O

While	O
barriers	O
included	O
:	O
lack	O
of	O
platforms	O
for	O
researcher	B-T097
-	O
public	B-T092
engagement	B-T033
,	O
politics	O
,	O
researchers	B-T097
'	I-T097
lack	O
of	O
communication	O
skills	O
,	O
lack	O
of	O
research	B-T062
collaborations	O
,	O
funder	O
driven	O
research	O
,	O
unknown	O
World	B-T092
Health	I-T092
Organization	I-T092
policy	B-T170
position	O
,	O
and	O
the	O
lack	O
of	O
a	O
malaria	B-T038
research	B-T062
repository	O
.	O

Overall	O
,	O
the	O
study	O
identified	O
facilitating	O
factors	O
to	O
malaria	B-T038
research	B-T062
utilization	O
for	O
policy	O
development	O
in	O
Malawi	B-T082
.	O

These	O
factors	O
need	O
to	O
be	O
systematically	O
coordinated	O
to	O
address	O
the	O
identified	O
barriers	O
and	O
improve	B-T033
on	O
malaria	B-T038
research	B-T062
utilization	O
in	O
policy	O
development	O
.	O

Malaria	B-T038
research	B-T062
can	O
be	O
key	O
in	O
the	O
implementation	O
of	O
evidence	O
-	O
based	O
interventions	O
to	O
reduce	O
the	O
malaria	B-T038
burden	O
and	O
assist	O
in	O
the	O
paradigm	O
shift	O
from	O
malaria	B-T038
control	O
to	O
elimination	O
in	O
Malawi	B-T082
.	O

Altered	O
interregional	B-T082
correlations	O
between	O
serotonin	B-T103
transporter	I-T103
availability	O
and	O
cerebral	O
glucose	B-T038
metabolism	I-T038
in	O
schizophrenia	B-T038
:	O
A	O
high	B-T058
-	I-T058
resolution	I-T058
PET	I-T058
study	O
using	O
[	B-T103
(	I-T103
11	I-T103
)	I-T103
C	I-T103
]	I-T103
DASB	I-T103
and	O
[	B-T103
(	I-T103
18	I-T103
)	I-T103
F	I-T103
]	I-T103
FDG	I-T103

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
patterns	O
of	O
interregional	B-T082
correlations	O
of	O
serotonin	B-T103
transporter	I-T103
(	O
SERT	B-T103
)	O
availability	O
with	O
glucose	B-T038
metabolism	I-T038
using	O
7	B-T058
-	I-T058
Tesla	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
(	O
MRI	B-T058
)	O
and	O
high	B-T058
-	I-T058
resolution	I-T058
positron	I-T058
emission	I-T058
tomography	I-T058
(	O
PET	B-T058
)	O
with	O
(	B-T103
11	I-T103
)	I-T103
C	I-T103
-	I-T103
3	I-T103
-	I-T103
amino	I-T103
-	I-T103
4	I-T103
-	I-T103
(	I-T103
2	I-T103
-	I-T103
dimethylaminomethylphenylthio	I-T103
)	I-T103
benzonitrile	I-T103
(	O
[	B-T103
(	I-T103
11	I-T103
)	I-T103
C	I-T103
]	I-T103
DASB	I-T103
)	O
and	O
[	B-T103
(	I-T103
18	I-T103
)	I-T103
F	I-T103
]	I-T103
fluorodeoxyglucose	I-T103
(	O
[	B-T103
(	I-T103
18	I-T103
)	I-T103
F	I-T103
]	I-T103
FDG	I-T103
)	O
in	O
antipsychotic	O
-	O
free	O
patients	O
with	O
schizophrenia	B-T038
in	O
order	O
to	O
shed	O
new	O
light	O
on	O
the	O
disrupted	O
functional	O
connectivity	O
in	O
schizophrenia	B-T038
.	O

Nineteen	O
patients	O
with	O
schizophrenia	B-T038
and	O
18	O
healthy	O
controls	O
underwent	O
high	B-T058
-	I-T058
resolution	I-T058
PET	I-T058
and	O
MRI	B-T058
.	O

The	O
binding	O
potential	O
(	O
BPND	O
)	O
of	O
[	B-T103
(	I-T103
11	I-T103
)	I-T103
C	I-T103
]	I-T103
DASB	I-T103
and	O
standardized	O
uptake	O
value	O
ratio	O
(	O
SUVR	O
)	O
of	O
[	B-T103
(	I-T103
18	I-T103
)	I-T103
F	I-T103
]	I-T103
FDG	I-T103
were	O
obtained	O
.	O

In	O
SERT	B-T103
availability	O
,	O
the	O
region	B-T082
of	I-T082
interest	I-T082
(	O
ROI	B-T082
)	O
-	O
based	O
analyses	B-T062
showed	O
no	O
significant	O
group	O
differences	O
in	O
any	O
region	B-T082
,	O
except	O
for	O
the	O
anterior	B-T082
hippocampus	B-T017
where	O
the	O
SERT	B-T103
availability	O
was	O
lower	O
in	O
patients	O
with	O
schizophrenia	B-T038
than	O
in	O
controls	O
.	O

The	O
ROI	B-T082
-	O
and	O
voxel	O
-	O
based	O
analyses	B-T062
revealed	O
that	O
the	O
[	B-T103
(	I-T103
18	I-T103
)	I-T103
F	I-T103
]	I-T103
FDG	I-T103
SUVR	O
values	O
were	O
significantly	O
lower	O
in	O
patients	O
than	O
in	O
controls	O
in	O
the	O
right	B-T017
superior	I-T017
frontal	I-T017
gyrus	I-T017
and	O
medial	B-T082
part	I-T082
of	O
the	O
left	B-T017
superior	I-T017
frontal	I-T017
gyrus	I-T017
.	O

Regarding	O
the	O
interregional	B-T082
correlations	O
of	O
[	B-T103
(	I-T103
11	I-T103
)	I-T103
C	I-T103
]	I-T103
DASB	I-T103
BPND	O
with	O
[	B-T103
(	I-T103
18	I-T103
)	I-T103
F	I-T103
]	I-T103
FDG	I-T103
SUVR	O
,	O
more	O
widespread	O
positive	B-T033
correlations	O
across	O
the	O
brain	B-T082
regions	I-T082
were	O
observed	O
in	O
control	O
subjects	O
than	O
in	O
patients	O
with	O
schizophrenia	B-T038
.	O

Notably	O
,	O
the	O
patients	O
and	O
control	O
subjects	O
showed	O
statistically	O
significant	O
differences	O
in	O
correlations	O
between	O
the	O
SERT	B-T103
availability	O
in	O
the	O
parietal	B-T017
and	O
temporal	B-T017
cortices	I-T017
and	O
the	O
glucose	B-T038
metabolism	I-T038
in	O
the	O
posterior	B-T017
cingulate	I-T017
cortex	I-T017
.	O

These	O
results	O
suggest	O
abnormal	B-T033
functional	O
connectivity	O
between	O
the	O
higher	B-T082
-	I-T082
order	I-T082
cortical	I-T082
regions	I-T082
in	O
schizophrenia	B-T038
and	O
a	O
possible	O
important	O
role	O
of	O
the	O
posterior	B-T017
cingulate	I-T017
gyrus	I-T017
and	O
its	O
related	O
circuitry	O
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-T038
.	O

Urticarial	B-T038
exanthema	B-T033
due	O
to	O
hepatitis	B-T038
B	I-T038
in	O
a	O
pregnant	B-T098
woman	I-T098
,	O
mimicking	O
a	O
polymorphic	B-T038
eruption	I-T038
of	O
pregnancy	B-T038

Hepatitis	B-T038
B	I-T038
virus	I-T038
(	I-T038
HBV	I-T038
)	I-T038
infection	I-T038
in	I-T038
pregnant	I-T038
women	I-T038
is	O
very	O
rare	O
in	O
western	B-T082
countries	I-T082
,	O
thus	O
,	O
cutaneous	B-T082
manifestation	O
of	O
HBV	B-T038
infection	I-T038
may	O
be	O
confused	O
with	O
a	O
dermatosis	B-T038
specific	O
of	O
pregnancy	B-T038
.	O

We	O
report	O
a	O
39	O
-	O
year	O
-	O
old	O
woman	B-T098
who	O
presented	O
in	O
her	O
20th	O
week	O
of	O
pregnancy	B-T038
with	O
a	O
pruritic	B-T038
rash	I-T038
,	O
which	O
consisted	O
of	O
generalized	O
erythematous	B-T033
plaques	I-T033
,	O
some	O
of	O
them	O
with	O
a	O
purple	B-T033
centre	I-T033
.	O

Serology	B-T058
testing	I-T058
showed	O
acute	B-T038
HBV	I-T038
infection	I-T038
,	O
and	O
a	O
biopsy	B-T058
revealed	O
a	O
superficial	B-T082
and	O
interstitial	B-T033
perivascular	I-T033
inflammatory	I-T033
infiltrate	I-T033
of	O
lymphocytes	B-T017
and	O
eosinophils	B-T017
.	O

A	O
diagnosis	B-T033
of	O
exanthema	B-T033
due	O
to	O
acute	B-T038
hepatitis	I-T038
B	I-T038
infection	I-T038
was	O
established	O
.	O

The	O
patient	O
delivered	B-T033
a	O
clinically	B-T033
healthy	I-T033
boy	I-T033
,	O
who	O
was	O
given	O
the	O
first	O
dose	O
of	O
the	O
HBV	B-T058
vaccine	I-T058
and	O
intravenous	B-T103
specific	I-T103
immunoglobulin	I-T103
,	O
followed	O
by	O
the	O
second	O
dose	O
2	O
months	O
later	O
,	O
and	O
did	O
not	O
get	O
infected	B-T033
with	O
HBV	B-T005
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
describing	O
HBV	B-T038
exanthema	B-T033
in	O
a	O
pregnant	B-T098
woman	I-T098
,	O
which	O
led	O
to	O
early	O
action	O
for	O
the	O
newborn	O
,	O
avoiding	O
vertical	B-T038
transmission	I-T038
and	O
its	O
high	O
prevalence	O
of	O
cirrhosis	B-T038
and	O
hepatocellular	B-T038
carcinoma	I-T038
.	O

Determination	O
of	O
the	O
Mutant	B-T058
Prevention	I-T058
Concentration	I-T058
and	O
the	O
Mutant	O
Selection	O
Window	O
of	O
Topical	B-T103
Antimicrobial	I-T103
Agents	I-T103
against	O
Propionibacterium	B-T007
acnes	I-T007

Determination	O
of	O
the	O
mutant	B-T058
prevention	I-T058
concentration	I-T058
(	O
MPC	B-T058
)	O
and	O
the	O
mutant	O
selection	O
window	O
(	O
MSW	O
)	O
of	O
antimicrobial	B-T103
agents	I-T103
used	O
to	O
treat	O
pathogenic	O
bacteria	B-T007
is	O
important	O
in	O
order	O
to	O
apply	O
effective	O
antimicrobial	B-T103
therapies	B-T058
.	O

Here	O
,	O
we	O
determined	O
the	O
MPCs	B-T058
of	O
the	O
major	O
topical	B-T103
antimicrobial	I-T103
agents	I-T103
against	O
Propionibacterium	B-T007
acnes	I-T007
and	O
Staphylococcus	B-T007
aureus	I-T007
which	O
cause	O
skin	B-T038
infections	I-T038
and	O
compared	O
their	O
MSWs	O
.	O

Among	O
the	O
MPCs	B-T058
of	O
nadifloxacin	B-T103
and	O
clindamycin	B-T103
,	O
the	O
clindamycin	B-T103
MPC	B-T058
was	O
determined	O
to	O
be	O
the	O
lowest	O
against	O
P	B-T007
.	I-T007

acnes	I-T007
.	O

In	O
contrast	O
,	O
the	O
nadifloxacin	B-T103
MPC	B-T058
was	O
the	O
lowest	O
against	O
S	B-T007
.	I-T007

aureus	I-T007
.	O

Calculations	O
based	O
on	O
the	O
minimum	B-T033
inhibitory	I-T033
concentrations	I-T033
and	O
MPCs	B-T058
showed	O
that	O
clindamycin	B-T103
has	O
the	O
lowest	O
MSW	O
against	O
both	O
P	B-T007
.	I-T007

acnes	I-T007
and	O
S	B-T007
.	I-T007

aureus	I-T007
.	O

Nadifloxacin	B-T103
MSWs	O
were	O
4	O
-	O
fold	O
higher	O
against	O
P	B-T007
.	I-T007

acnes	I-T007
than	O
against	O
S	B-T007
.	I-T007

aureus	I-T007
.	O

It	O
is	O
more	O
likely	O
for	O
P	B-T007
.	I-T007

acnes	I-T007
to	O
acquire	O
resistance	B-T038
to	O
fluoroquinolones	B-T103
than	O
S	B-T007
.	I-T007

aureus	I-T007
.	O

Therefore	O
,	O
topical	O
application	O
of	O
clindamycin	B-T103
contributes	O
very	O
little	O
to	O
the	O
emergence	O
of	O
resistant	B-T038
P	B-T007
.	I-T007

acnes	I-T007
and	O
S	B-T007
.	I-T007

aureus	I-T007
strains	O
.	O

Total	O
colectomy	B-T058
for	O
colon	B-T037
perforation	I-T037
after	O
kayexalate	B-T103
administration	B-T058
:	O
a	O
case	O
report	O
and	O
literature	B-T170
review	I-T170
of	O
a	O
rare	O
complication	B-T038

Kayexalate	B-T103
is	O
an	O
ion	B-T103
exchange	I-T103
resin	I-T103
that	O
is	O
commonly	O
used	O
to	O
acutely	O
treat	B-T058
patients	O
with	O
hyperkalemia	B-T033
.	O

Bowel	B-T038
ulceration	I-T038
and	O
necrosis	B-T038
is	O
a	O
rare	O
and	O
uncommonly	O
recognized	O
complication	B-T038
of	O
kayexalate	B-T103
administration	B-T058
.	O

More	O
often	O
,	O
concomitant	O
administration	B-T058
with	O
sorbitol	B-T103
is	O
reported	O
to	O
damage	O
the	O
bowel	B-T017
;	O
however	O
,	O
there	O
are	O
reports	O
of	O
kayexalate	B-T103
administration	B-T058
causing	O
bowel	B-T038
necrosis	I-T038
without	O
sorbitol	B-T103
.	O

We	O
present	O
a	O
case	O
of	O
a	O
critically	B-T038
ill	I-T038
patient	O
who	O
underwent	O
total	O
colectomy	B-T058
for	O
colonic	O
necrosis	O
secondary	O
to	O
oral	B-T082
kayexalate	B-T103
administration	B-T058
that	O
was	O
not	O
recognized	O
until	O
late	O
in	O
the	O
pathologic	B-T038
process	I-T038
.	O

We	O
also	O
review	B-T170
the	I-T170
literature	I-T170
to	O
further	O
investigate	O
this	O
progression	B-T038
.	O

Total	O
Arsenic	B-T103
,	O
Cadmium	B-T103
,	O
and	O
Lead	B-T103
Determination	B-T058
in	O
Brazilian	B-T168
Rice	I-T168
Samples	O
Using	O
ICP	B-T058
-	I-T058
MS	I-T058

This	O
study	B-T062
is	O
aimed	O
at	O
investigating	O
a	O
suitable	O
method	B-T170
for	O
rice	B-T168
sample	O
preparation	O
as	O
well	O
as	O
validating	B-T062
and	O
applying	O
the	O
method	B-T170
for	O
monitoring	O
the	O
concentration	O
of	O
total	O
arsenic	B-T103
,	O
cadmium	B-T103
,	O
and	O
lead	B-T103
in	O
rice	B-T168
by	O
using	O
Inductively	B-T058
Coupled	I-T058
Plasma	I-T058
Mass	I-T058
Spectrometry	I-T058
(	O
ICP	B-T058
-	I-T058
MS	I-T058
)	O
.	O

Various	O
rice	B-T168
sample	O
preparation	O
procedures	O
were	O
evaluated	O
.	O

The	O
analytical	O
method	O
was	O
validated	B-T062
by	O
measuring	O
several	O
parameters	B-T033
including	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
,	O
limit	O
of	O
quantification	O
(	O
LOQ	O
)	O
,	O
linearity	O
,	O
relative	O
bias	O
,	O
and	O
repeatability	O
.	O

Regarding	O
the	O
sample	O
preparation	O
,	O
recoveries	O
of	O
spiked	O
samples	O
were	O
within	O
the	O
acceptable	O
range	O
from	O
89	O
.	O
3	O
to	O
98	O
.	O
2	O
%	O
for	O
muffle	O
furnace	O
,	O
94	O
.	O
2	O
to	O
103	O
.	O
3	O
%	O
for	O
heating	O
block	O
,	O
81	O
.	O
0	O
to	O
115	O
.	O
0	O
%	O
for	O
hot	O
plate	O
,	O
and	O
92	O
.	O
8	O
to	O
108	O
.	O
2	O
%	O
for	O
microwave	O
.	O

Validation	B-T062
parameters	B-T033
showed	O
that	O
the	O
method	B-T170
fits	O
for	O
its	O
purpose	O
,	O
being	O
the	O
total	O
arsenic	B-T103
,	O
cadmium	B-T103
,	O
and	O
lead	B-T103
within	O
the	O
Brazilian	O
Legislation	O
limits	O
.	O

The	O
method	B-T170
was	O
applied	O
for	O
analyzing	B-T062
37	O
rice	B-T168
samples	O
(	O
including	O
polished	B-T168
,	O
brown	B-T168
,	O
and	O
parboiled	B-T168
)	O
,	O
consumed	O
by	O
the	O
Brazilian	O
population	O
.	O

The	O
total	O
arsenic	B-T103
,	O
cadmium	B-T103
,	O
and	O
lead	B-T103
contents	O
were	O
lower	O
than	O
the	O
established	O
legislative	O
values	O
,	O
except	O
for	O
total	O
arsenic	B-T103
in	O
one	O
brown	B-T168
rice	I-T168
sample	O
.	O

This	O
study	B-T062
indicated	O
the	O
need	O
to	O
establish	O
monitoring	O
programs	O
for	O
emphasizing	O
the	O
study	B-T062
on	O
this	O
type	O
of	O
cereal	B-T168
,	O
aiming	O
at	O
promoting	O
the	O
Public	B-T170
Health	I-T170
.	O

Safety	B-T058
Precautions	I-T058
and	O
Operating	B-T170
Procedures	I-T170
in	O
an	O
(	O
A	O
)	O
BSL	B-T170
-	I-T170
4	I-T170
Laboratory	B-T092
:	O
1	O
.	O
Biosafety	B-T170
Level	I-T170
4	I-T170
Suit	B-T092
Laboratory	I-T092
Suite	B-T170
Entry	I-T170
and	I-T170
Exit	I-T170
Procedures	I-T170

Biosafety	B-T170
level	I-T170
4	I-T170
(	O
BSL	B-T170
-	I-T170
4	I-T170
)	O
suit	B-T092
laboratories	I-T092
are	O
specifically	O
designed	O
to	O
study	B-T062
high	O
-	O
consequence	O
pathogens	O
for	O
which	O
neither	O
infection	B-T038
prophylaxes	B-T058
nor	O
treatment	B-T058
options	O
exist	O
.	O

The	O
hallmarks	O
of	O
these	O
laboratories	B-T092
are	O
:	O
custom	O
-	O
designed	O
airtight	O
doors	O
,	O
dedicated	O
supply	O
and	O
exhaust	O
airflow	O
systems	O
,	O
a	O
negative	O
-	O
pressure	O
environment	O
,	O
and	O
mandatory	O
use	O
of	O
positive	O
-	O
pressure	O
(	O
"	O
space	O
"	O
)	O
suits	O
.	O

The	O
risk	O
for	O
laboratory	B-T092
specialists	B-T097
working	O
with	O
highly	O
pathogenic	O
agents	O
is	O
minimized	O
through	O
rigorous	O
training	O
and	O
adherence	O
to	O
stringent	O
safety	B-T170
protocols	I-T170
and	O
standard	B-T170
operating	I-T170
procedures	I-T170
.	O

Researchers	B-T097
perform	O
the	O
majority	O
of	O
their	O
work	O
in	O
BSL	B-T170
-	I-T170
2	I-T170
laboratories	B-T092
and	O
switch	O
to	O
BSL	B-T170
-	I-T170
4	I-T170
suit	B-T092
laboratories	I-T092
when	O
work	O
with	O
a	O
high	O
-	O
consequence	O
pathogen	O
is	O
required	O
.	O

Collaborators	B-T092
and	O
scientists	B-T097
considering	O
BSL	B-T170
-	I-T170
4	I-T170
projects	O
should	O
be	O
aware	O
of	O
the	O
challenges	B-T033
associated	O
with	O
BSL	B-T170
-	I-T170
4	I-T170
research	B-T062
both	O
in	O
terms	O
of	O
experimental	O
technical	O
limitations	O
in	O
BSL	B-T170
-	I-T170
4	I-T170
laboratory	B-T092
space	B-T082
and	O
the	O
increased	O
duration	O
of	O
such	O
experiments	B-T062
.	O

Tasks	O
such	O
as	O
entering	O
and	O
exiting	O
the	O
BSL	B-T170
-	I-T170
4	I-T170
suit	B-T092
laboratories	I-T092
are	O
considerably	O
more	O
complex	O
and	O
time	O
-	O
consuming	O
compared	O
to	O
BSL	B-T170
-	I-T170
2	I-T170
and	O
BSL	B-T170
-	I-T170
3	I-T170
laboratories	B-T092
.	O

The	O
focus	O
of	O
this	O
particular	O
article	B-T170
is	O
to	O
address	B-T170
basic	O
biosafety	O
concerns	O
and	O
describe	O
the	O
entrance	B-T170
and	I-T170
exit	I-T170
procedures	I-T170
for	O
the	O
BSL	B-T170
-	I-T170
4	I-T170
laboratory	B-T092
at	O
the	O
NIH	B-T092
/	O
NIAID	B-T092
Integrated	O
Research	O
Facility	O
at	O
Fort	O
Detrick	O
.	O

Such	O
procedures	B-T170
include	O
checking	O
external	O
systems	O
that	O
support	O
the	O
BSL	B-T170
-	I-T170
4	I-T170
laboratory	B-T092
,	O
and	O
inspecting	O
and	O
donning	O
positive	O
-	O
pressure	O
suits	O
,	O
entering	O
the	O
laboratory	B-T092
,	O
moving	O
through	O
air	O
pressure	O
-	O
resistant	O
doors	O
,	O
and	O
connecting	O
to	O
air	B-T074
-	I-T074
supply	I-T074
hoses	I-T074
.	O

We	O
will	O
also	O
discuss	O
moving	B-T038
within	O
and	O
exiting	O
the	O
BSL	B-T170
-	I-T170
4	I-T170
suit	B-T092
laboratories	I-T092
,	O
including	O
using	O
the	O
chemical	B-T103
shower	O
and	O
removing	O
and	O
storing	O
positive	O
-	O
pressure	O
suits	O
.	O

Masters	O
Athletes	O
:	O
Exemplars	O
of	O
Successful	B-T038
Aging	I-T038
?	O

Global	B-T098
population	I-T098
aging	B-T038
has	O
raised	B-T033
academic	I-T033
interest	I-T033
in	O
successful	B-T038
aging	I-T038
to	O
a	O
public	O
policy	O
priority	O
.	O

Currently	O
there	O
is	O
no	O
consensus	O
regarding	O
the	O
definition	O
of	O
successful	B-T038
aging	I-T038
.	O

However	O
,	O
a	O
synthesis	O
of	O
research	O
shows	O
successful	B-T038
aging	I-T038
can	O
be	O
defined	O
as	O
a	O
late	B-T038
-	I-T038
life	I-T038
process	I-T038
of	I-T038
change	I-T038
characterized	O
by	O
high	B-T033
physical	I-T033
,	O
psychological	B-T038
,	O
cognitive	B-T038
,	O
and	O
social	O
functioning	O
.	O

Masters	O
athletes	O
systematically	O
train	O
for	O
,	O
and	O
compete	O
in	O
,	O
organized	O
forms	O
of	O
team	O
and	O
individual	O
sport	O
specifically	O
designed	O
for	O
older	B-T098
adults	I-T098
.	O

Masters	O
athletes	O
are	O
often	O
proposed	O
as	O
exemplars	O
of	O
successful	B-T038
aging	I-T038
.	O

However	O
,	O
their	O
aging	B-T033
status	I-T033
has	O
never	O
been	O
examined	O
using	O
a	O
comprehensive	O
multidimensional	B-T082
successful	B-T038
aging	I-T038
definition	O
.	O

Here	O
,	O
we	O
examine	O
the	O
successful	B-T170
aging	I-T170
literature	I-T170
,	O
propose	O
a	O
successful	B-T038
aging	I-T038
definition	O
based	O
on	O
this	O
literature	B-T170
,	O
present	O
evidence	O
which	O
suggests	O
masters	O
athletes	O
could	O
be	O
considered	O
exemplars	O
of	O
successful	B-T038
aging	I-T038
according	O
to	O
the	O
proposed	O
definition	O
,	O
and	O
list	O
future	O
experimental	B-T062
research	I-T062
directions	O
.	O

Non	O
-	O
specific	O
transient	O
mutualism	O
between	O
the	O
plant	B-T204
parasitic	I-T204
nematode	I-T204
,	O
Bursaphelenchus	B-T204
xylophilus	I-T204
,	O
and	O
the	O
opportunistic	O
bacterium	B-T007
Serratia	B-T007
quinivorans	I-T007
BXF1	I-T007
,	O
a	O
plant	B-T038
-	I-T038
growth	I-T038
promoting	O
pine	B-T204
endophyte	B-T204
with	O
antagonistic	B-T103
effects	O

The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
understand	O
the	O
biological	O
role	O
of	O
Serratia	B-T007
quinivorans	I-T007
BXF1	I-T007
,	O
a	O
bacterium	B-T007
commonly	O
found	O
associated	O
with	O
Bursaphelenchus	B-T204
xylophilus	I-T204
,	O
the	O
plant	B-T204
parasitic	I-T204
nematode	I-T204
responsible	O
for	O
pine	B-T204
wilt	B-T038
disease	I-T038
.	O

Therefore	O
,	O
we	O
studied	O
strain	B-T007
BXF1	I-T007
effect	O
in	O
pine	B-T204
wilt	B-T038
disease	I-T038
.	O

We	O
found	O
that	O
strain	B-T007
BXF1	I-T007
promoted	O
in	O
vitro	O
nematode	B-T204
reproduction	B-T038
.	O

Moreover	O
,	O
the	O
presence	O
of	O
bacteria	B-T007
led	O
to	O
the	O
absence	O
of	O
nematode	B-T204
chitinase	B-T017
gene	I-T017
(	I-T017
Bxcht	I-T017
-	I-T017
1	I-T017
)	I-T017
expression	B-T038
,	O
suggesting	O
an	O
effect	O
for	O
bacterial	B-T007
chitinase	B-T103
in	O
nematode	B-T204
reproduction	B-T038
.	O

Nevertheless	O
,	O
strain	B-T007
BXF1	I-T007
was	O
unable	O
to	O
colonize	B-T033
the	O
nematode	B-T204
interior	O
,	O
bind	O
to	O
its	O
cuticle	O
with	O
high	O
affinity	O
or	O
protect	O
the	O
nematode	B-T204
from	O
xenobiotic	B-T103
stress	B-T038
.	O

Interestingly	O
,	O
strain	B-T007
BXF1	I-T007
was	O
able	O
to	O
promote	O
tomato	B-T204
and	O
pine	B-T204
plant	B-T038
-	I-T038
growth	I-T038
,	O
as	O
well	O
as	O
to	O
colonize	B-T033
its	O
interior	O
,	O
thus	O
,	O
acting	O
like	O
a	O
plant	B-T038
-	I-T038
growth	I-T038
promoting	O
endophyte	B-T204
.	O

Consequently	O
,	O
strain	B-T007
BXF1	I-T007
failed	O
to	O
induce	O
wilting	B-T033
symptoms	I-T033
when	O
inoculated	O
in	O
pine	B-T204
shoot	B-T204
artificial	O
incisions	O
.	O

This	O
bacterium	B-T007
also	O
presented	O
strong	O
antagonistic	B-T103
activities	O
against	O
fungi	B-T204
and	O
bacteria	B-T007
isolated	O
from	O
Pinus	B-T204
pinaster	I-T204
.	O

Our	O
results	O
suggest	O
that	O
B	B-T204
.	I-T204

xylophilus	I-T204
does	O
not	O
possess	O
a	O
strict	O
symbiotic	O
community	O
capable	O
of	O
inducing	O
pine	B-T204
wilt	B-T038
disease	I-T038
symptoms	B-T033
as	O
previously	O
hypothesized	O
.	O

We	O
show	O
that	O
bacteria	B-T007
like	O
BXF1	B-T007
,	O
which	O
possess	O
plant	B-T038
-	I-T038
growth	I-T038
promoting	O
and	O
antagonistic	B-T103
effects	O
,	O
may	O
be	O
opportunistically	O
associated	O
with	O
B	B-T204
.	I-T204

xylophilus	I-T204
,	O
possibly	O
acquired	O
from	O
the	O
bacterial	B-T007
endophytic	B-T204
community	I-T204
of	O
the	O
host	O
pine	B-T204
.	O

Habitual	O
physical	O
activity	O
is	O
associated	O
with	O
improved	O
anthropometric	O
and	O
androgenic	B-T103
profile	B-T058
in	O
PCOS	B-T038
:	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062

To	O
examine	O
the	O
effect	O
of	O
habitual	O
physical	O
activity	O
(	O
PA	O
)	O
on	O
the	O
metabolic	B-T038
and	O
hormonal	B-T058
profiles	I-T058
of	O
women	B-T098
with	O
polycystic	B-T038
ovary	I-T038
syndrome	I-T038
.	O

Anthropometric	O
,	O
metabolic	O
and	O
hormonal	B-T058
assessment	I-T058
and	O
determination	O
of	O
habitual	O
PA	O
levels	O
with	O
a	O
digital	B-T074
pedometer	I-T074
were	O
evaluated	O
in	O
84	O
women	B-T098
with	O
PCOS	B-T038
and	O
67	O
age	O
-	O
and	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
-	O
matched	O
controls	O
.	O

PA	O
status	O
was	O
defined	O
according	O
to	O
number	O
of	O
steps	O
(	O
≥7500	O
steps	O
,	O
active	O
,	O
or	O
<	O
7500	O
steps	O
,	O
sedentary	O
)	O
.	O

BMI	B-T201
was	O
lower	O
in	O
active	O
women	B-T098
from	O
both	O
groups	O
.	O

Active	O
PCOS	B-T038
women	B-T098
presented	O
lower	O
waist	B-T201
circumference	I-T201
(	O
WC	B-T201
)	O
and	O
lipid	O
accumulation	O
product	O
(	O
LAP	O
)	O
values	O
versus	O
sedentary	O
PCOS	B-T038
women	B-T098
.	O

In	O
the	O
control	O
group	O
,	O
active	O
women	B-T098
also	O
had	O
lower	O
WC	B-T201
,	O
lower	O
values	O
for	O
fasting	O
and	O
120	O
-	O
min	O
insulin	B-T103
,	O
and	O
lower	O
LAP	O
than	O
sedentary	O
controls	O
.	O

In	O
the	O
PCOS	B-T038
group	O
,	O
androgen	B-T103
levels	O
were	O
lower	O
in	O
active	O
versus	O
sedentary	B-T098
women	I-T098
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

In	O
the	O
control	O
group	O
,	O
free	B-T033
androgen	I-T033
index	I-T033
(	O
FAI	B-T033
)	O
was	O
also	O
lower	O
in	O
active	O
versus	O
sedentary	B-T098
women	I-T098
(	O
p	O
=	O
0	O
.	O
018	O
)	O
.	O

Homeostasis	B-T058
model	I-T058
assessment	I-T058
of	O
insulin	B-T038
resistance	I-T038
and	O
2000	O
daily	O
step	O
increments	O
were	O
independent	O
predictors	O
of	O
FAI	B-T033
.	O

Each	O
2000	O
daily	O
step	O
increment	O
was	O
associated	O
with	O
a	O
decrease	O
of	O
1	O
.	O
07	O
in	O
FAI	B-T033
.	O

Habitual	O
PA	O
was	O
associated	O
with	O
a	O
better	O
anthropometric	O
and	O
androgenic	B-T103
profile	B-T058
in	O
PCOS	B-T038
.	O

Geolocalization	B-T082
of	O
Influenza	B-T038
Outbreak	O
Within	O
an	O
Acute	B-T058
Care	I-T058
Population	B-T098
:	O
A	O
Layered	O
-	O
Surveillance	O
Approach	B-T082

We	O
seek	O
to	O
use	O
a	O
novel	O
layered	O
-	O
surveillance	O
approach	B-T082
to	O
localize	B-T082
influenza	B-T038
clusters	O
within	O
an	O
acute	B-T058
care	I-T058
population	B-T098
.	O

The	O
first	O
layer	O
of	O
this	O
system	O
is	O
a	O
syndromic	B-T038
surveillance	B-T058
screen	I-T058
to	O
guide	O
rapid	O
polymerase	O
chain	O
reaction	O
testing	O
.	O

The	O
second	O
layer	O
is	O
geolocalization	B-T082
and	O
cluster	B-T062
analysis	I-T062
of	O
these	O
patients	O
.	O

We	O
posit	O
that	O
any	O
identified	O
clusters	O
could	O
represent	O
at	B-T098
-	I-T098
risk	I-T098
populations	I-T098
who	O
could	O
serve	O
as	O
high	O
-	O
yield	O
targets	O
for	O
preventive	O
medical	O
interventions	O
.	O

This	O
was	O
a	O
prospective	B-T062
observational	I-T062
surveillance	I-T062
study	I-T062
.	O

Patients	O
were	O
screened	B-T058
with	O
a	O
previously	O
derived	O
clinical	B-T170
decision	I-T170
guideline	I-T170
that	O
has	O
a	O
90	O
%	O
sensitivity	O
and	O
30	O
%	O
specificity	O
for	O
influenza	B-T038
.	O

Patients	O
received	O
points	O
for	O
the	O
following	O
signs	B-T033
and	I-T033
symptoms	I-T033
within	O
the	O
past	O
7	O
days	O
:	O
cough	B-T033
(	O
2	O
points	O
)	O
,	O
headache	B-T033
(	O
1	O
point	O
)	O
,	O
subjective	O
fever	O
(	O
1	O
point	O
)	O
,	O
and	O
documented	B-T033
fever	I-T033
at	O
triage	B-T058
(	O
temperature	O
>	O
38°C	O
[	O
100	O
.	O
4°F	O
]	O
)	O
(	O
1	O
point	O
)	O
.	O

Patients	O
scoring	O
3	O
points	O
or	O
higher	O
were	O
indicated	B-T033
for	O
influenza	B-T038
testing	O
.	O

Patients	O
were	O
tested	O
with	O
Xpert	B-T058
Flu	I-T058
(	O
Cepheid	B-T092
,	O
Sunnyvale	B-T082
,	O
CA	B-T082
)	O
,	O
a	O
rapid	O
polymerase	O
chain	O
reaction	O
test	O
.	O

Positive	B-T033
results	O
were	O
mapped	O
with	O
ArcGIS	B-T170
(	O
ESRI	B-T092
,	O
Redlands	B-T082
,	O
CA	B-T082
)	O
and	O
analyzed	B-T062
with	O
kernel	B-T062
density	I-T062
estimation	I-T062
to	O
create	O
heat	O
maps	O
.	O

There	O
were	O
1	O
,	O
360	O
patients	O
tested	O
with	O
Xpert	B-T058
Flu	I-T058
with	O
retrievable	O
addresses	B-T170
within	O
the	O
greater	O
Phoenix	O
metro	O
area	O
.	O

One	O
hundred	O
sixty	O
-	O
seven	O
(	O
12	O
%	O
)	O
of	O
them	O
tested	O
positive	B-T033
for	I-T033
influenza	I-T033
A	I-T033
and	O
23	O
(	O
2	O
%	O
)	O
tested	O
positive	B-T033
for	I-T033
influenza	I-T033
B	I-T033
.	O

The	O
influenza	B-T005
A	I-T005
virus	I-T005
exhibited	O
a	O
clear	O
cluster	O
pattern	B-T082
within	O
this	O
patient	O
population	B-T098
.	O

The	O
densest	O
cluster	O
was	O
located	B-T082
in	O
an	O
approximately	O
1	O
-	O
square	O
-	O
mile	O
region	B-T082
southeast	B-T082
of	O
our	O
hospital	B-T092
.	O

Our	O
layered	O
-	O
surveillance	O
approach	B-T082
was	O
effective	O
in	O
localizing	B-T082
a	O
cluster	O
of	O
influenza	O
A	O
outbreak	O
.	O

This	O
region	B-T082
may	O
house	O
a	O
high	O
-	O
yield	O
target	O
population	B-T098
for	O
public	B-T058
health	I-T058
intervention	I-T058
.	O

Further	O
collaborative	O
efforts	O
will	O
be	O
made	O
between	O
our	O
hospital	B-T092
and	O
the	O
Maricopa	B-T082
County	I-T082
Department	B-T092
of	I-T092
Public	I-T092
Health	I-T092
to	O
perform	O
a	O
series	O
of	O
community	O
vaccination	B-T058
events	O
before	O
the	O
next	O
influenza	B-T038
season	O
.	O

We	O
hope	O
these	O
efforts	O
will	O
ultimately	O
serve	O
to	O
reduce	O
the	O
burden	O
of	O
this	O
disease	B-T038
on	O
our	O
patient	O
population	B-T098
,	O
and	O
that	O
this	O
system	O
will	O
serve	O
as	O
a	O
framework	O
for	O
future	O
investigations	B-T058
locating	O
at	B-T098
-	I-T098
risk	I-T098
populations	I-T098
.	O

Heart	B-T201
rate	I-T201
variability	O
:	O
Pre	O
-	O
deployment	O
predictor	O
of	O
post	O
-	O
deployment	O
PTSD	B-T038
symptoms	B-T033

Heart	B-T201
rate	I-T201
variability	O
is	O
a	O
physiological	O
measure	O
associated	O
with	O
autonomic	B-T022
nervous	I-T022
system	I-T022
activity	O
.	O

This	O
study	B-T062
hypothesized	O
that	O
lower	O
pre	O
-	O
deployment	O
HRV	B-T038
would	O
be	O
associated	O
with	O
higher	O
post	O
-	O
deployment	O
post	B-T038
-	I-T038
traumatic	I-T038
stress	I-T038
disorder	I-T038
(	O
PTSD	B-T038
)	O
symptoms	B-T033
.	O

Three	O
-	O
hundred	O
-	O
forty	O
-	O
three	O
Army	B-T097
National	I-T097
Guard	I-T097
soldiers	I-T097
enrolled	O
in	O
the	O
Warriors	B-T062
Achieving	I-T062
Resilience	I-T062
(	I-T062
WAR	I-T062
)	I-T062
study	I-T062
were	O
analyzed	O
.	O

The	O
primary	O
outcome	O
was	O
PTSD	B-T038
symptom	B-T033
severity	O
using	O
the	O
PTSD	B-T038
Checklist	B-T170
-	O
Military	B-T097
version	B-T170
(	O
PCL	B-T170
)	O
measured	O
at	O
baseline	O
,	O
3	O
-	O
and	O
12	O
-	O
month	O
post	O
-	O
deployment	O
.	O

Heart	B-T201
rate	I-T201
variability	O
predictor	O
variables	O
included	O
:	O
high	O
frequency	O
power	O
(	O
HF	O
)	O
and	O
standard	O
deviation	O
of	O
the	O
normal	O
cardiac	B-T038
inter	I-T038
-	I-T038
beat	I-T038
interval	O
(	O
SDNN	O
)	O
.	O

Generalized	O
linear	B-T170
mixed	I-T170
models	I-T170
revealed	O
that	O
the	O
pre	O
-	O
deployment	O
PCL	B-T170
*	O
ln	O
(	O
HF	O
)	O
interaction	O
term	O
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Pre	O
-	O
deployment	O
SDNN	O
was	O
not	O
a	O
significant	O
predictor	O
of	O
post	O
-	O
deployment	O
PCL	B-T170
.	O

Covariates	O
included	O
age	O
,	O
pre	O
-	O
deployment	O
PCL	B-T170
,	O
race	B-T098
/	O
ethnicity	B-T098
,	O
marital	O
status	O
,	O
tobacco	O
use	O
,	O
childhood	B-T038
abuse	I-T038
,	O
pre	O
-	O
deployment	O
traumatic	B-T037
brain	I-T037
injury	I-T037
,	O
and	O
previous	O
combat	B-T082
zone	I-T082
deployment	O
.	O

Pre	O
-	O
deployment	O
heart	B-T201
rate	I-T201
variability	O
predicts	O
post	O
-	O
deployment	O
PTSD	B-T038
symptoms	B-T033
in	O
the	O
context	O
of	O
higher	O
pre	O
-	O
deployment	O
PCL	B-T170
scores	O
.	O

A	O
neuronal	B-T017
PI	B-T103
(	I-T103
3	I-T103
,	I-T103
4	I-T103
,	I-T103
5	I-T103
)	I-T103
P3	I-T103
-	O
dependent	O
program	O
of	O
oligodendrocyte	B-T017
precursor	O
recruitment	O
and	O
myelination	B-T038

The	O
molecular	B-T038
trigger	I-T038
of	O
CNS	B-T022
myelination	B-T038
is	O
unknown	O
.	O

By	O
targeting	O
Pten	B-T103
in	O
cerebellar	B-T017
granule	I-T017
cells	I-T017
and	O
activating	O
the	O
AKT1	B-T103
-	O
mTOR	B-T103
pathway	B-T038
,	O
we	O
increased	O
the	O
caliber	O
of	O
normally	O
unmyelinated	B-T017
axons	I-T017
and	O
the	O
expression	B-T038
of	O
numerous	O
genes	B-T017
encoding	O
regulatory	B-T103
proteins	I-T103
.	O

This	O
led	O
to	O
the	O
expansion	B-T038
of	O
genetically	B-T017
wild	I-T017
-	I-T017
type	I-T017
oligodendrocyte	B-T017
progenitor	B-T017
cells	I-T017
,	O
oligodendrocyte	B-T017
differentiation	B-T038
and	O
de	O
novo	O
myelination	B-T038
of	O
parallel	B-T017
fibers	I-T017
.	O

Thus	O
,	O
a	O
neuronal	B-T017
program	O
dependent	O
on	O
the	O
phosphoinositide	B-T103
PI	B-T103
(	I-T103
3	I-T103
,	I-T103
4	I-T103
,	I-T103
5	I-T103
)	I-T103
P3	I-T103
is	O
sufficient	O
to	O
trigger	B-T038
all	O
steps	O
of	O
myelination	B-T038
.	O

Atypical	O
microglial	B-T017
response	O
to	O
biodiesel	B-T103
exhaust	I-T103
in	O
healthy	O
and	O
hypertensive	B-T038
rats	B-T204

Accumulating	O
evidence	O
suggests	O
a	O
deleterious	O
role	O
for	O
urban	B-T082
air	O
pollution	O
in	O
central	B-T038
nervous	I-T038
system	I-T038
(	I-T038
CNS	I-T038
)	I-T038
diseases	I-T038
and	O
neurodevelopmental	B-T038
disorders	I-T038
.	O

Microglia	B-T017
,	O
the	O
resident	O
innate	O
immune	B-T017
cells	I-T017
and	O
sentinels	B-T103
in	O
the	O
brain	B-T017
,	O
are	O
a	O
common	O
source	B-T033
of	O
neuroinflammation	O
and	O
are	O
implicated	O
in	O
air	O
pollution	O
-	O
induced	O
CNS	B-T038
effects	I-T038
.	O

While	O
renewable	O
energy	O
,	O
such	O
as	O
soy	B-T103
-	I-T103
based	I-T103
biofuel	I-T103
,	O
is	O
of	O
increasing	O
public	B-T098
interest	B-T038
,	O
there	O
is	O
little	O
information	O
on	O
how	O
soy	B-T103
biofuel	I-T103
may	O
affect	O
the	O
brain	B-T017
,	O
especially	O
in	O
people	B-T098
with	O
preexisting	B-T033
disease	I-T033
conditions	I-T033
.	O

To	O
address	O
this	O
,	O
male	O
spontaneously	B-T204
hypertensive	I-T204
rats	I-T204
(	O
SHR	B-T204
)	O
and	O
normotensive	B-T033
Wistar	B-T204
Kyoto	I-T204
(	I-T204
WKY	I-T204
)	I-T204
rats	I-T204
were	O
exposed	O
to	O
100	B-T103
%	I-T103
Soy	I-T103
-	I-T103
based	I-T103
Biodiesel	I-T103
Exhaust	I-T103
(	O
100SBDE	B-T103
;	O
0	O
,	O
50	O
,	O
150	O
and	O
500μg	O
/	O
m	O
(	O
3	O
)	O
)	O
by	O
inhalation	B-T038
,	O
4h	O
/	O
day	O
for	O
4	O
weeks	O
(	O
5	O
days	O
/	O
week	O
)	O
.	O

Ionized	B-T103
calcium	I-T103
-	I-T103
binding	I-T103
adapter	I-T103
molecule	I-T103
-	I-T103
1	I-T103
(	O
IBA	B-T103
-	I-T103
1	I-T103
)	O
staining	B-T058
of	O
microglia	B-T017
in	O
the	O
substantia	B-T017
nigra	I-T017
revealed	O
significant	O
changes	O
in	O
morphology	O
with	O
100SBDE	B-T103
exposure	O
in	O
rats	B-T204
from	O
both	O
genotypes	O
,	O
where	O
SHR	B-T204
were	O
less	O
sensitive	O
.	O

Aconitase	B-T038
activity	I-T038
was	O
inhibited	O
in	O
the	O
frontal	B-T017
cortex	I-T017
and	O
cerebellum	B-T017
of	O
WKY	B-T204
rats	I-T204
exposed	O
to	O
100SBDE	B-T103
.	O

No	O
consistent	O
changes	O
occurred	O
in	O
pro	O
-	O
inflammatory	O
cytokine	B-T103
expression	B-T038
,	O
nitrated	B-T103
protein	I-T103
,	O
or	O
arginase1	B-T103
expression	B-T038
in	O
brain	B-T082
regions	I-T082
from	O
either	O
rat	B-T204
strain	I-T204
exposed	O
to	O
100SBDE	B-T103
.	O

However	O
,	O
while	O
IBA	B-T103
-	I-T103
1	I-T103
mRNA	B-T038
expression	I-T038
was	O
not	O
modified	O
,	O
CX3CR1	B-T103
mRNA	B-T038
expression	I-T038
was	O
lower	O
in	O
the	O
striatum	B-T017
of	O
100SBDE	B-T103
exposed	B-T204
rats	I-T204
regardless	O
of	O
genotype	O
,	O
suggesting	O
a	O
downregulation	B-T038
of	O
the	O
fractalkine	B-T103
receptor	I-T103
on	O
microglia	B-T017
in	O
this	O
brain	B-T082
region	I-T082
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
while	O
microglia	B-T017
are	O
detecting	B-T033
and	O
responding	O
to	O
100SBDE	B-T103
exposure	O
with	O
changes	O
in	O
morphology	O
,	O
there	O
is	O
reduced	O
expression	B-T038
of	O
CX3CR1	B-T103
regardless	O
of	O
genetic	O
background	O
and	O
the	O
activation	O
response	O
is	O
atypical	O
without	O
traditional	O
inflammatory	B-T201
markers	I-T201
of	O
M1	B-T017
or	O
M2	B-T017
activation	O
in	O
the	O
brain	B-T017
.	O

Pre	B-T033
-	I-T033
Activation	I-T033
Negativity	I-T033
(	O
PrAN	B-T033
)	O
in	O
Brain	B-T017
Potentials	O
to	O
Unfolding	B-T038
Words	I-T038

We	O
describe	O
an	O
event	B-T038
-	I-T038
related	I-T038
potential	I-T038
(	O
ERP	B-T038
)	O
effect	O
termed	O
the	O
"	O
pre	B-T033
-	I-T033
activation	I-T033
negativity	I-T033
"	O
(	O
PrAN	B-T033
)	O
,	O
which	O
is	O
proposed	O
to	O
index	B-T170
the	O
degree	O
of	O
pre	O
-	O
activation	O
of	O
upcoming	O
word	O
-	O
internal	B-T082
morphemes	O
in	O
speech	B-T038
processing	O
.	O

Using	O
lexical	O
competition	O
measures	O
based	O
on	O
word	O
-	O
initial	O
speech	O
fragments	O
(	O
WIFs	O
)	O
,	O
as	O
well	O
as	O
statistical	O
analyses	O
of	O
ERP	B-T038
data	O
from	O
three	O
experiments	B-T062
,	O
it	O
is	O
shown	O
that	O
the	O
PrAN	B-T033
is	O
sensitive	O
to	O
lexical	O
competition	O
and	O
that	O
it	O
reflects	O
the	O
degree	O
of	O
predictive	O
certainty	O
:	O
the	O
negativity	B-T033
is	O
larger	O
when	O
there	O
are	O
fewer	O
upcoming	O
lexical	O
competitors	B-T098
.	O

Angiotensin	B-T033
-	I-T033
converting	I-T033
enzyme	I-T033
insertion	I-T033
/	I-T033
deletion	I-T033
polymorphism	I-T033
association	O
with	O
obesity	B-T038
and	O
some	O
related	O
disorders	B-T038
in	O
Egyptian	B-T098
females	O
:	O
a	O
case	B-T062
-	I-T062
control	I-T062
observational	I-T062
study	I-T062

According	O
to	O
the	O
WHO	B-T092
report	B-T170
in	O
2015	O
,	O
obesity	B-T038
is	O
the	O
fifth	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
worldwide	O
,	O
and	O
the	O
prevalence	O
of	O
Egyptian	B-T098
female	B-T098
obesity	B-T038
is	O
37	O
.	O
5	O
%	O
.	O

Since	O
obesity	B-T038
is	O
highly	O
influenced	O
by	O
genetics	O
,	O
and	O
adipose	B-T017
tissue	I-T017
renin	B-T022
-	I-T022
angiotensin	I-T022
system	I-T022
is	O
over	O
-	O
activated	O
in	O
obesity	B-T038
,	O
the	O
effect	O
of	O
angiotensin	B-T033
-	I-T033
converting	I-T033
enzyme	I-T033
(	I-T033
ACE	I-T033
)	I-T033
insertion	I-T033
/	I-T033
deletion	I-T033
(	I-T033
I	I-T033
/	I-T033
D	I-T033
)	I-T033
polymorphism	I-T033
on	O
obesity	B-T038
and	O
related	O
disorders	B-T038
was	O
studied	O
in	O
several	O
populations	B-T098
,	O
because	O
of	O
its	O
effect	O
on	O
ACE	B-T038
activity	I-T038
.	O

Our	O
objective	B-T170
was	O
to	O
study	B-T062
the	O
association	O
of	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
polymorphism	I-T033
with	O
obesity	B-T038
and	O
certain	O
related	O
disorders	B-T038
,	O
namely	O
hypertension	B-T038
,	O
insulin	B-T038
resistance	I-T038
and	O
metabolic	B-T038
syndrome	I-T038
,	O
in	O
Egyptian	B-T098
females	O
.	O

Eighty	O
female	B-T098
volunteers	B-T098
were	O
recruited	O
,	O
blood	B-T058
pressure	I-T058
and	O
body	B-T058
measurements	I-T058
were	O
recorded	O
and	O
a	O
fasting	B-T033
blood	B-T031
sample	I-T031
was	O
obtained	O
for	O
the	O
quantitation	O
of	O
glucose	B-T103
,	O
lipid	B-T058
profile	I-T058
,	O
insulin	B-T103
,	I-T103
leptin	B-T103
and	O
identification	O
of	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
polymorphs	I-T033
.	O

Subjects	B-T098
were	O
grouped	O
based	O
on	O
hypertension	B-T038
and	O
obesity	O
states	O
.	O

Comparisons	O
of	O
continuous	O
parameters	B-T033
were	O
made	O
with	O
independent	O
sample	B-T170
t	I-T170
-	I-T170
test	I-T170
between	O
two	O
groups	O
.	O

The	O
frequencies	O
of	O
ACE	B-T103
genotypes	O
and	O
alleles	B-T017
,	O
and	O
the	O
association	O
between	O
gene	O
polymorphism	O
and	O
metabolic	O
parameters	B-T033
were	O
assessed	O
using	O
chi	B-T170
-	I-T170
square	I-T170
or	O
Fisher	B-T170
'	I-T170
s	I-T170
exact	I-T170
test	I-T170
.	O

Genotype	O
frequencies	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
for	O
all	O
groups	O
.	O

Genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
controls	O
and	O
cases	O
of	O
all	O
the	O
studied	O
disorders	B-T038
.	O

Although	O
DD	B-T033
carriers	I-T033
had	O
apparently	O
higher	O
parameters	B-T033
of	O
blood	B-T038
pressure	I-T038
,	O
lipid	B-T058
profile	I-T058
and	O
insulin	B-T038
resistance	I-T038
,	O
only	O
diastolic	B-T201
blood	I-T201
pressure	I-T201
was	O
almost	O
significant	O
(	O
p	O
=	O
0	O
.	O
057	O
)	O
.	O

I	B-T033
-	I-T033
carriers	I-T033
were	O
significantly	O
less	O
susceptible	O
to	O
hypertension	B-T038
than	O
DD	B-T033
carriers	I-T033
having	O
normal	O
waist	O
/	O
hip	O
ratio	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
OR	O
=	O
17	O
.	O
29	O
,	O
CI	O
=	O
1	O
.	O
81	O
-	O
164	O
.	O
96	O
)	O
and	O
normal	O
conicity	O
index	O
(	O
p	O
=	O
0	O
.	O
024	O
,	O
OR	O
=	O
7	O
.	O
00	O
,	O
CI	O
=	O
1	O
.	O
36	O
-	O
35	O
.	O
93	O
)	O
.	O

In	O
DD	B-T033
genotype	I-T033
carriers	I-T033
,	O
a	O
significant	O
association	O
was	O
found	O
between	O
insulin	B-T038
resistance	I-T038
and	O
high	B-T033
body	I-T033
mass	I-T033
index	I-T033
(	O
p	O
=	O
0	O
.	O
004	O
,	O
OR	O
=	O
8	O
.	O
89	O
,	O
CI	O
=	O
1	O
.	O
94	O
-	O
40	O
.	O
71	O
)	O
,	O
waist	B-T201
circumference	I-T201
(	O
p	O
=	O
0	O
.	O
003	O
,	O
OR	O
=	O
9	O
.	O
63	O
,	O
CI	O
=	O
2	O
.	O
14	O
-	O
43	O
.	O
36	O
)	O
and	O
waist	B-T033
/	I-T033
height	I-T033
ratio	I-T033
(	O
p	O
=	O
0	O
.	O
034	O
,	O
OR	O
=	O
6	O
.	O
86	O
,	O
CI	O
=	O
1	O
.	O
25	O
-	O
37	O
.	O
61	O
)	O
,	O
although	O
the	O
variations	O
in	O
percentages	O
between	O
DD	B-T033
and	O
I	B-T033
-	I-T033
carriers	I-T033
were	O
not	O
high	O
enough	O
to	O
conclude	O
an	O
effect	O
of	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
on	O
such	O
an	O
association	O
.	O

In	O
this	O
sample	O
of	O
Egyptian	B-T098
females	O
,	O
ACE	B-T033
I	I-T033
/	I-T033
D	I-T033
polymorphism	I-T033
was	O
not	B-T033
significantly	I-T033
associated	O
with	O
obesity	B-T038
nor	O
with	O
any	O
of	O
its	O
related	O
disorders	B-T038
studied	O
.	O

The	O
I	B-T017
allele	I-T017
seemed	O
protective	O
against	O
hypertension	B-T038
in	O
subjects	B-T098
with	O
normal	O
,	O
not	O
high	O
,	O
waist	O
/	O
hip	O
ratio	O
and	O
conicity	O
index	O
compared	O
to	O
DD	B-T033
genotype	I-T033
carriers	I-T033
.	O

Expressed	B-T038
microRNA	B-T103
associated	O
with	O
high	O
rate	O
of	O
egg	B-T038
production	I-T038
in	O
chicken	B-T204
ovarian	B-T017
follicles	I-T017

MicroRNA	B-T103
(	O
miRNA	B-T103
)	O
is	O
a	O
highly	O
conserved	O
class	O
of	O
small	O
noncoding	B-T103
RNA	I-T103
about	O
19	O
-	O
24	O
nucleotides	B-T103
in	O
length	O
that	O
function	O
in	O
a	O
specific	O
manner	O
to	O
post	B-T038
-	I-T038
transcriptionally	I-T038
regulate	I-T038
gene	B-T038
expression	I-T038
in	O
organisms	O
.	O

Tissue	B-T017
miRNA	B-T103
expression	B-T038
studies	B-T062
have	O
discovered	O
a	O
myriad	O
of	O
functions	O
for	O
miRNAs	B-T103
in	O
various	O
aspects	O
,	O
but	O
a	O
role	O
for	O
miRNAs	B-T103
in	O
chicken	B-T204
ovarian	B-T017
tissue	I-T017
at	O
300	O
days	O
of	O
age	O
has	O
not	O
hitherto	O
been	O
reported	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
the	O
first	O
miRNA	B-T103
analysis	B-T062
of	O
ovarian	B-T017
tissues	I-T017
in	O
chickens	B-T204
with	O
low	O
and	O
high	O
rates	O
of	O
egg	B-T038
production	I-T038
using	O
high	B-T062
-	I-T062
throughput	I-T062
sequencing	I-T062
.	O

By	O
comparing	O
low	O
rate	O
of	O
egg	B-T038
production	I-T038
chickens	B-T204
with	O
high	O
rate	O
of	O
egg	B-T038
production	I-T038
chickens	B-T204
,	O
17	O
significantly	O
differentially	O
expressed	B-T038
miRNAs	B-T103
were	O
found	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
including	O
11	O
known	O
and	O
six	O
novel	O
miRNAs	B-T103
.	O

We	O
found	O
that	O
all	O
11	O
known	O
miRNAs	B-T103
were	O
involved	O
mainly	O
in	O
pathways	B-T038
of	O
reproduction	B-T038
regulation	B-T038
,	O
such	O
as	O
steroid	B-T038
hormone	I-T038
biosynthesis	I-T038
and	O
dopaminergic	B-T082
synapse	I-T082
.	O

Additionally	O
,	O
expression	B-T038
profiling	O
of	O
six	O
randomly	O
selected	O
differentially	O
regulated	B-T038
miRNAs	B-T103
were	O
validated	O
by	O
quantitative	B-T062
real	I-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
RT	B-T062
-	I-T062
qPCR	I-T062
)	O
.	O

Some	O
miRNAs	B-T103
,	O
such	O
as	O
gga	B-T017
-	I-T017
miR	I-T017
-	I-T017
34b	I-T017
,	O
gga	B-T017
-	I-T017
miR	I-T017
-	I-T017
34c	I-T017
and	O
gga	B-T017
-	I-T017
miR	I-T017
-	I-T017
216b	I-T017
,	O
were	O
reported	O
to	O
regulate	B-T038
processes	O
such	O
as	O
proliferation	B-T038
,	O
cell	B-T038
cycle	I-T038
,	O
apoptosis	B-T038
and	O
metastasis	B-T038
and	O
were	O
expressed	B-T038
differentially	O
in	O
ovaries	B-T017
of	O
chickens	B-T204
with	O
high	O
rates	O
of	O
egg	B-T038
production	I-T038
,	O
suggesting	O
that	O
these	O
miRNAs	B-T103
have	O
an	O
important	O
role	O
in	O
ovary	B-T017
development	B-T038
and	O
reproductive	B-T038
management	I-T038
of	O
chicken	B-T204
.	O

Furthermore	O
,	O
we	O
uncovered	O
that	O
a	O
significantly	O
up	B-T038
-	I-T038
regulated	I-T038
miRNA	B-T103
-	O
gga	B-T017
-	I-T017
miR	I-T017
-	I-T017
200a	I-T017
-	I-T017
3p	I-T017
-	O
is	O
ubiquitous	O
in	O
reproduction	B-T038
-	O
regulation	B-T038
-	O
related	O
pathways	B-T038
.	O

This	O
miRNA	B-T103
may	O
play	O
a	O
special	O
central	O
role	O
in	O
the	O
reproductive	B-T038
management	I-T038
of	O
chicken	B-T204
,	O
and	O
needs	O
to	O
be	O
further	O
studied	O
for	O
confirmation	O
.	O

Air	O
pollution	O
,	O
neighbourhood	O
and	O
maternal	B-T033
-	O
level	O
factors	O
modify	O
the	O
effect	O
of	O
smoking	O
on	O
birth	O
weight	O
:	O
a	O
multilevel	B-T062
analysis	I-T062
in	O
British	B-T082
Columbia	I-T082
,	O
Canada	B-T082

Maternal	B-T033
smoking	O
during	O
pregnancy	B-T038
negatively	B-T033
impacts	O
fetal	B-T038
growth	I-T038
,	O
but	O
the	O
effect	O
is	O
not	O
homogenous	B-T082
across	O
the	O
population	O
.	O

We	O
sought	O
to	O
determine	O
how	O
the	O
relationship	O
between	O
cigarette	O
use	O
and	O
fetal	B-T038
growth	I-T038
is	O
modified	B-T033
by	O
the	O
social	O
and	O
physical	B-T082
environment	I-T082
.	O

Birth	O
records	O
with	O
covariates	O
were	O
obtained	O
from	O
the	O
BC	B-T170
Perinatal	I-T170
Database	I-T170
Registry	I-T170
(	O
N	O
=	O
232	O
,	O
291	O
)	O
.	O

Maternal	B-T033
smoking	B-T201
status	I-T201
was	O
self	B-T062
-	I-T062
reported	I-T062
as	O
the	O
number	O
of	O
cigarettes	O
smoked	O
per	O
day	O
usually	O
at	O
the	O
first	B-T058
prenatal	I-T058
care	I-T058
visit	I-T058
.	O

Census	O
dissemination	B-T082
areas	B-T082
(	O
DAs	B-T082
)	O
were	O
used	O
as	O
neighbourhood	O
-	O
level	O
units	O
and	O
linked	O
to	O
individual	B-T098
births	B-T038
using	O
residential	O
postal	O
codes	O
to	O
assign	O
exposure	O
to	O
particulate	B-T103
air	O
pollution	O
(	O
PM2	O
.	O
5	O
)	O
and	O
neighbourhood	O
-	O
level	O
attributes	O
such	O
as	O
socioeconomic	O
status	O
(	O
SES	O
)	O
,	O
proportion	O
of	O
post	O
-	O
secondary	O
education	O
,	O
immigrant	B-T098
density	O
and	O
living	O
in	O
a	O
rural	O
place	O
.	O

Random	O
coefficient	O
models	B-T170
were	O
used	O
with	O
cigarettes	O
/	O
day	O
modeled	B-T170
with	O
a	O
random	O
slope	O
to	O
estimate	O
its	O
between	O
-	O
DA	B-T082
variability	O
and	O
test	O
cross	O
-	O
level	O
interactions	O
with	O
the	O
neighbourhood	O
-	O
level	O
variables	O
on	O
continuous	O
birth	O
weight	O
.	O

A	O
significant	O
negative	B-T033
and	O
non	O
-	O
linear	O
association	O
was	O
found	O
between	O
maternal	B-T033
smoking	O
and	O
birth	O
weight	O
.	O

There	O
was	O
significant	O
between	O
-	O
DA	B-T082
intercept	O
variability	O
in	O
birth	O
weight	O
as	O
well	O
as	O
between	O
-	O
DA	B-T082
slope	O
variability	O
of	O
maternal	B-T033
smoking	O
on	O
birth	O
weight	O
of	O
which	O
68	O
and	O
30	O
%	O
respectively	O
was	O
explained	O
with	O
the	O
inclusion	O
of	O
DA	B-T082
-	O
level	O
variables	O
and	O
their	O
cross	O
-	O
level	O
interactions	O
.	O

High	O
DA	B-T082
-	O
level	O
SES	O
had	O
a	O
strong	O
positive	B-T033
association	O
with	O
birth	O
weight	O
but	O
the	O
effect	O
was	O
moderated	O
with	O
increased	O
cigarettes	O
/	O
day	O
.	O

Conversely	O
,	O
heavy	B-T033
smokers	I-T033
showed	O
the	O
largest	O
increases	O
in	O
birth	O
weight	O
with	O
rising	O
neighbourhood	O
education	B-T033
levels	I-T033
.	O

Increased	O
levels	O
of	O
PM2	B-T103
.	I-T103
5	I-T103
and	O
immigrant	B-T098
density	O
were	O
negatively	B-T033
associated	O
with	O
birth	O
weight	O
,	O
but	O
showed	O
positive	B-T033
interactions	O
with	O
increased	O
levels	O
of	O
smoking	O
.	O

Older	O
maternal	O
age	O
and	O
suspected	O
drug	B-T038
or	O
alcohol	O
use	O
both	O
had	O
negative	B-T033
interactions	O
with	O
increased	O
levels	O
of	O
maternal	B-T033
smoking	O
.	O

Maternal	B-T033
smoking	O
had	O
a	O
negative	B-T033
and	O
non	O
-	O
linear	O
dose	O
-	O
response	O
association	O
with	O
birth	O
weight	O
which	O
was	O
highly	O
variable	O
between	O
neighbourhood	O
s	O
and	O
evidence	O
of	O
effect	O
modification	B-T033
with	O
neighbourhood	O
-	O
level	O
factors	O
.	O

These	O
results	O
suggest	O
that	O
focusing	O
exclusively	O
on	O
individual	B-T098
behaviours	O
may	O
have	O
limited	O
success	O
in	O
improving	O
outcomes	O
without	O
addressing	O
the	O
contextual	B-T038
influences	O
at	O
the	O
neighbourhood	O
-	O
level	O
.	O

Further	O
studies	B-T062
are	O
needed	O
to	O
corroborate	O
our	O
findings	B-T033
and	O
to	O
understand	B-T038
how	O
neighbourhood	O
-	O
level	O
attributes	O
interact	O
with	O
smoking	O
to	O
affect	B-T038
birth	B-T201
outcomes	I-T201
.	O

Individual	B-T098
Leg	B-T017
Muscle	I-T017
Contributions	O
to	O
the	O
Cost	O
of	O
Walking	O
:	O
Effects	O
of	O
Age	O
and	O
Walking	O
Speed	O

This	O
study	B-T062
examined	B-T033
the	O
contributions	O
of	O
individual	B-T098
muscles	B-T017
to	O
changes	O
in	O
energetic	O
cost	O
of	O
transport	O
(	O
COT	O
)	O
over	O
seven	O
walking	O
speeds	O
,	O
and	O
compared	O
results	O
between	O
healthy	O
young	O
and	O
elderly	B-T098
subjects	I-T098
.	O

Twenty	O
six	O
participants	B-T098
(	O
13	O
young	O
aged	O
18	O
-	O
30	O
;	O
13	O
old	B-T098
aged	I-T098
70	O
-	O
80	O
)	O
were	O
recruited	O
.	O

COT	O
(	O
O2	O
/	O
kg	O
body	O
mass	O
/	O
km	O
)	O
was	O
calculated	O
by	O
standardizing	O
the	O
mean	B-T201
oxygen	I-T201
consumption	I-T201
recorded	O
during	O
steady	O
state	O
walking	O
.	O

Electromyography	B-T058
signals	O
from	O
10	O
leg	B-T017
muscles	I-T017
were	O
used	O
to	O
calculate	O
the	O
cumulative	O
activity	O
required	O
to	O
traverse	O
a	O
unit	O
of	O
distance	O
(	O
CMAPD	O
)	O
for	O
each	O
muscle	B-T017
at	O
each	O
speed	O
.	O

In	O
the	O
old	B-T098
group	I-T098
CMAPD	O
was	O
correlated	O
with	O
COT	O
,	O
presented	O
higher	O
and	O
more	O
variable	O
values	O
,	O
and	O
showed	O
greater	O
increases	O
around	O
optimal	O
speed	O
for	O
all	O
studied	O
muscles	B-T017
.	O

Soleus	B-T017
CMAPD	O
was	O
independent	O
of	O
speed	O
in	O
the	O
young	O
group	O
,	O
but	O
this	O
was	O
not	O
evident	O
with	O
aging	B-T038
.	O

Greater	O
energy	O
cost	O
of	O
walking	O
in	O
older	B-T098
individuals	B-T098
seems	O
to	O
be	O
attributable	O
to	O
increased	O
energy	O
cost	O
of	O
all	O
lower	B-T017
limb	I-T017
muscles	I-T017
.	O

Glycated	B-T103
Hemoglobin	I-T103
(	O
HbA1c	B-T103
)	O
Correlation	O
with	O
Severity	O
of	O
Coronary	B-T038
Artery	I-T038
Disease	I-T038
in	O
Non	B-T033
-	I-T033
diabetic	I-T033
Patients	O
-	O
A	O
Hospital	B-T092
based	I-T092
Study	B-T062
from	O
North	B-T082
-	I-T082
Eastern	I-T082
India	I-T082

Glycated	B-T033
Hemoglobin	I-T033
(	I-T033
HbA1c	I-T033
)	I-T033
levels	I-T033
are	O
predictive	O
of	O
cardiovascular	B-T038
disease	I-T038
and	O
mortality	O
in	O
patients	O
with	O
diabetes	B-T038
mellitus	I-T038
,	O
however	O
,	O
association	O
of	O
HbA1c	B-T103
with	O
Coronary	B-T038
Artery	I-T038
Disease	I-T038
(	O
CAD	B-T038
)	O
in	O
non	B-T033
-	I-T033
diabetics	I-T033
is	O
inconsistent	O
.	O

To	O
evaluate	B-T058
the	O
correlation	O
between	O
HbA1c	B-T033
level	I-T033
and	O
severity	O
of	O
CAD	B-T038
in	O
non	O
-	O
diabetic	O
patients	O
using	O
SYNTAX	O
score	O
in	O
a	O
cohort	B-T098
of	O
proven	O
CAD	B-T038
on	O
angiography	B-T058
at	O
Gauhati	B-T092
Medical	I-T092
College	I-T092
,	O
Guwahati	B-T082
,	I-T082
Assam	I-T082
,	O
India	B-T082
,	O
which	O
is	O
a	O
major	O
tertiary	B-T092
care	I-T092
hospital	I-T092
of	O
North	B-T082
-	I-T082
Eastern	I-T082
India	I-T082
.	O

We	O
prospectively	O
collected	O
data	O
of	O
non	O
-	O
diabetic	O
patients	O
with	O
proven	O
CAD	B-T038
on	O
angiography	B-T058
from	O
June	O
2014	O
to	O
June	O
2015	O
.	O

Patients	O
were	O
divided	O
into	O
four	O
groups	O
(	O
interquartiles	O
)	O
according	O
to	O
HbA1c	B-T033
levels	I-T033
,	O
less	O
than	O
4	O
.	O
8	O
%	O
,	O
4	O
.	O
8	O
%	O
to	O
5	O
.	O
1	O
%	O
,	O
5	O
.	O
1	O
%	O
to	O
5	O
.	O
6	O
%	O
,	O
and	O
5	O
.	O
6	O
%	O
to	O
6	O
.	O
5	O
%	O
.	O

Severity	O
of	O
CAD	B-T038
was	O
assessed	O
using	O
SYNTAX	O
score	O
and	O
the	O
number	O
of	O
coronary	O
vessels	O
diseased	O
.	O

We	O
compared	O
different	O
quartiles	O
of	O
HbA1c	B-T103
with	O
regard	O
to	O
SYNTAX	O
score	O
and	O
number	O
of	O
diseased	O
vessels	O
.	O

A	O
total	O
of	O
346	O
patients	O
were	O
included	O
in	O
the	O
study	B-T062
.	O

Mean	O
age	O
was	O
58	O
.	O
1±10	O
.	O
4	O
years	O
.	O

Of	O
the	O
total	O
91	O
.	O
9	O
%	O
(	O
318	O
)	O
were	O
males	O
,	O
44	O
.	O
8	O
%	O
(	O
155	O
)	O
were	O
hypertensives	B-T033
,	O
29	O
.	O
2	O
%	O
(	O
101	O
)	O
were	O
smokers	B-T033
and	O
34	O
.	O
7	O
%	O
(	O
120	O
)	O
were	O
dyslipidemic	B-T033
.	O

We	O
found	O
that	O
CAD	B-T038
severity	O
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	B-T017
involved	O
was	O
significantly	O
different	O
among	O
quartiles	O
(	O
p	O
-	O
values	O
<	O
0	O
.	O
001	O
and	O
<	O
0	O
.	O
001	O
respectively	O
)	O
.	O

Increase	O
in	O
HbA1c	B-T033
level	I-T033
was	O
strongly	O
correlated	O
with	O
disease	O
severity	O
and	O
higher	O
SYNTAX	O
score	O
.	O

A	O
significant	O
increase	O
was	O
noted	O
in	O
the	O
mean	O
number	O
of	O
diseased	O
vessels	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
001	O
)	O
as	O
HbA1c	B-T033
level	I-T033
increases	O
.	O

Age	O
,	O
gender	O
,	O
hypertension	B-T038
and	O
dyslipidemia	B-T038
did	O
not	O
show	O
significant	O
difference	O
among	O
quartiles	O
however	O
smoking	O
was	O
found	O
to	O
be	O
an	O
independent	O
predictor	O
of	O
severity	O
of	O
CAD	B-T038
by	O
SYNTAX	O
score	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

From	O
this	O
clinical	B-T062
study	I-T062
,	O
we	O
can	O
conclude	O
that	O
a	O
significant	O
correlation	O
exists	O
between	O
HbA1c	B-T103
and	O
severity	O
of	O
CAD	B-T038
by	O
SYNTAX	O
score	O
as	O
well	O
as	O
number	O
of	O
vessels	B-T017
involved	O
in	O
non	B-T033
-	I-T033
diabetes	I-T033
.	O

On	O
the	O
Relation	O
between	O
Face	O
and	O
Object	O
Recognition	O
in	O
Developmental	B-T038
Prosopagnosia	I-T038
:	O
No	O
Dissociation	B-T038
but	O
a	O
Systematic	O
Association	O

There	O
is	O
an	O
ongoing	O
debate	O
about	O
whether	O
face	O
recognition	O
and	O
object	O
recognition	O
constitute	O
separate	O
domains	O
.	O

Clarification	O
of	O
this	O
issue	B-T033
can	O
have	O
important	O
theoretical	O
implications	O
as	O
face	O
recognition	O
is	O
often	O
used	O
as	O
a	O
prime	O
example	O
of	O
domain	O
-	O
specificity	O
in	O
mind	O
and	O
brain	B-T017
.	O

An	O
important	O
source	B-T033
of	O
input	O
to	O
this	O
debate	O
comes	O
from	O
studies	O
of	O
individuals	B-T098
with	O
developmental	B-T038
prosopagnosia	I-T038
,	O
suggesting	O
that	O
face	O
recognition	O
can	O
be	O
selectively	O
impaired	O
.	O

We	O
put	O
the	O
selectivity	O
hypothesis	O
to	O
test	O
by	O
assessing	O
the	O
performance	O
of	O
10	O
individuals	B-T098
with	O
developmental	B-T038
prosopagnosia	I-T038
on	O
demanding	O
tests	O
of	O
visual	B-T038
object	I-T038
processing	I-T038
involving	O
both	O
regular	O
and	O
degraded	B-T033
drawings	B-T170
.	O

None	O
of	O
the	O
individuals	B-T098
exhibited	O
a	O
clear	O
dissociation	B-T038
between	O
face	O
and	O
object	O
recognition	O
,	O
and	O
as	O
a	O
group	O
they	O
were	O
significantly	O
more	O
affected	O
by	O
degradation	B-T033
of	O
objects	O
than	O
control	O
participants	B-T098
.	O

Importantly	O
,	O
we	O
also	O
find	O
positive	B-T033
correlations	O
between	O
the	O
severity	O
of	O
the	O
face	O
recognition	O
impairment	O
and	O
the	O
degree	O
of	O
impaired	O
performance	O
with	O
degraded	B-T033
objects	O
.	O

This	O
suggests	O
that	O
the	O
face	O
and	O
object	O
deficits	O
are	O
systematically	O
related	O
rather	O
than	O
coincidental	O
.	O

We	O
conclude	O
that	O
at	O
present	O
,	O
there	O
is	O
no	O
strong	O
evidence	O
in	O
the	O
literature	B-T170
on	O
developmental	B-T038
prosopagnosia	I-T038
supporting	O
domain	O
-	O
specific	O
accounts	O
of	O
face	O
recognition	O
.	O

Reduced	B-T033
Chest	I-T033
and	O
Abdominal	B-T017
Wall	I-T017
Mobility	O
and	O
Their	O
Relationship	O
to	O
Lung	B-T038
Function	I-T038
,	O
Respiratory	O
Muscle	B-T038
Strength	I-T038
,	O
and	O
Exercise	B-T201
Tolerance	I-T201
in	O
Subjects	O
With	O
COPD	B-T038

Advanced	O
air	B-T038
-	I-T038
flow	I-T038
limitation	O
in	O
patients	O
with	O
COPD	B-T038
leads	O
to	O
a	O
reduction	O
in	O
vital	B-T201
capacity	I-T201
,	O
respiratory	O
muscle	B-T038
strength	I-T038
,	O
and	O
exercise	B-T201
capacity	I-T201
.	O

However	O
,	O
its	O
impact	O
on	O
chest	B-T082
and	O
abdominal	B-T017
wall	I-T017
mobility	O
is	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
ascertain	O
the	O
prevalence	O
of	O
patients	O
with	O
COPD	B-T038
with	O
reduced	B-T033
chest	I-T033
and	O
abdominal	B-T017
wall	I-T017
mobility	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
reduced	B-T033
chest	I-T033
and	O
abdominal	B-T017
wall	I-T017
mobility	O
on	O
pulmonary	B-T038
function	I-T038
,	O
respiratory	O
muscle	B-T038
strength	I-T038
,	O
and	O
exercise	B-T201
capacity	I-T201
.	O

In	O
51	O
elderly	B-T098
male	O
subjects	O
with	O
COPD	B-T038
,	O
chest	B-T082
and	O
abdominal	B-T017
wall	I-T017
mobility	O
,	O
FVC	B-T033
,	O
FEV1	B-T058
,	O
FEV1	B-T058
/	I-T058
FVC	I-T058
,	O
maximal	B-T058
inspiratory	I-T058
pressure	I-T058
(	O
PImax	B-T058
)	O
,	O
maximal	B-T058
expiratory	I-T058
pressure	I-T058
(	O
PEmax	B-T058
)	O
,	O
and	O
the	O
6	B-T058
-	I-T058
min	I-T058
walk	I-T058
distance	I-T058
(	O
6MWD	B-T058
)	O
were	O
assessed	O
.	O

Chest	B-T017
and	O
abdominal	B-T017
wall	I-T017
mobility	O
were	O
measured	O
using	O
the	O
breathing	B-T038
movement	B-T058
scale	I-T058
(	O
0	O
-	O
8	O
)	O
at	O
the	O
3	O
regions	B-T082
(	O
upper	B-T082
chest	I-T082
,	O
lower	B-T082
chest	I-T082
,	O
and	O
abdomen	B-T082
)	O
.	O

Reduced	B-T033
mobility	I-T033
was	O
defined	O
as	O
a	O
value	O
lower	O
than	O
the	O
lower	O
limit	O
of	O
the	O
normal	O
scale	O
.	O

The	O
unpaired	B-T170
t	I-T170
test	I-T170
,	O
Mann	B-T170
-	I-T170
Whitney	I-T170
test	I-T170
,	O
and	O
multiple	O
regression	O
analysis	O
were	O
performed	O
.	O

The	O
percentages	O
of	O
subjects	O
with	O
reduced	B-T033
mobility	I-T033
were	O
78	O
%	O
for	O
the	O
upper	B-T082
chest	I-T082
,	O
76	O
%	O
for	O
the	O
lower	B-T082
chest	I-T082
,	O
and	O
53	O
%	O
for	O
the	O
abdomen	B-T082
.	O

The	O
subjects	O
with	O
reduced	B-T033
mobility	I-T033
had	O
significantly	O
low	O
FVC	B-T033
,	O
FEV1	B-T058
,	O
and	O
6MWD	B-T058
in	O
each	O
region	B-T082
and	O
significantly	O
low	O
FEV1	B-T058
/	I-T058
FVC	I-T058
,	O
PImax	B-T058
,	O
and	O
PEmax	B-T058
in	O
the	O
abdominal	B-T082
region	I-T082
compared	O
with	O
those	O
with	O
nonreduced	O
mobility	O
.	O

FVC	B-T033
and	O
6MWD	B-T058
were	O
independently	O
associated	O
with	O
the	O
scale	O
values	O
in	O
each	O
region	B-T082
and	O
with	O
the	O
abdominal	B-T082
scale	O
value	O
,	O
respectively	O
.	O

The	O
majority	O
of	O
subjects	O
with	O
COPD	B-T038
had	O
reduced	B-T033
chest	I-T033
and	O
abdominal	B-T017
wall	I-T017
mobility	O
,	O
which	O
was	O
independently	O
associated	O
with	O
FVC	B-T033
.	O

Even	O
though	O
abdominal	B-T017
wall	I-T017
mobility	O
was	O
relatively	O
preserved	O
compared	O
with	O
chest	B-T017
wall	I-T017
mobility	O
,	O
it	O
was	O
also	O
independently	O
associated	O
with	O
6MWD	B-T058
.	O

FGF21	B-T103
is	O
a	O
biomarker	B-T201
for	O
mitochondrial	B-T038
translation	I-T038
and	O
mtDNA	B-T103
maintenance	O
disorders	B-T038

To	O
validate	O
new	O
mitochondrial	B-T017
myopathy	I-T017
serum	B-T031
biomarkers	B-T201
for	O
diagnostic	B-T058
use	I-T058
.	O

We	O
analyzed	B-T062
serum	B-T031
FGF21	B-T103
(	O
S	B-T103
-	I-T103
FGF21	I-T103
)	O
and	O
GDF15	B-T103
from	O
patients	O
with	O
(	O
1	O
)	O
mitochondrial	B-T038
diseases	I-T038
and	O
(	O
2	O
)	O
nonmitochondrial	B-T038
disorders	I-T038
partially	O
overlapping	O
with	O
mitochondrial	B-T038
disorder	I-T038
phenotypes	O
.	O

We	O
(	O
3	O
)	O
did	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
S	B-T103
-	I-T103
FGF21	I-T103
in	O
mitochondrial	B-T038
disease	I-T038
and	O
(	O
4	O
)	O
analyzed	B-T062
S	B-T103
-	I-T103
Fgf21	I-T103
and	O
skeletal	B-T017
muscle	I-T017
Fgf21	B-T103
expression	B-T038
in	O
6	O
mouse	B-T204
models	B-T204
with	O
different	O
muscle	B-T017
-	O
manifesting	O
mitochondrial	B-T033
dysfunctions	I-T033
.	O

We	O
report	O
that	O
S	B-T103
-	I-T103
FGF21	I-T103
consistently	O
increases	O
in	O
primary	O
mitochondrial	B-T017
myopathy	I-T017
,	O
especially	O
in	O
patients	O
with	O
mitochondrial	B-T038
translation	I-T038
defects	B-T017
or	O
mitochondrial	B-T033
DNA	I-T033
(	I-T033
mtDNA	I-T033
)	I-T033
deletions	I-T033
(	O
675	O
and	O
347	O
pg	O
/	O
mL	O
,	O
respectively	O
;	O
controls	O
:	O
66	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0	O
.	O
0001	O
for	O
both	O
)	O
.	O

This	O
is	O
corroborated	O
in	O
mice	B-T204
(	O
mtDNA	B-T033
deletions	I-T033
1	O
,	O
163	O
vs	O
379	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

However	O
,	O
patients	O
and	O
mice	B-T204
with	O
structural	B-T017
respiratory	I-T017
chain	I-T017
subunit	I-T017
or	I-T017
assembly	I-T017
factor	I-T017
defects	I-T017
showed	O
low	O
induction	O
(	O
human	B-T204
335	O
pg	O
/	O
mL	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
mice	B-T204
335	O
pg	O
/	O
mL	O
,	O
not	B-T033
significant	I-T033
)	O
.	O

Overall	O
specificities	O
of	O
FGF21	B-T103
and	O
GDF15	B-T103
to	O
find	O
patients	O
with	O
mitochondrial	B-T017
myopathy	I-T017
were	O
89	O
.	O
3	O
%	O
vs	O
86	O
.	O
4	O
%	O
,	O
and	O
sensitivities	O
67	O
.	O
3	O
%	O
and	O
76	O
.	O
0	O
%	O
,	O
respectively	O
.	O

However	O
,	O
GDF15	B-T103
was	O
increased	O
also	O
in	O
a	O
wide	O
range	O
of	O
nonmitochondrial	O
conditions	O
.	O

S	B-T103
-	I-T103
FGF21	I-T103
is	O
a	O
specific	O
biomarker	B-T201
for	O
muscle	B-T017
-	O
manifesting	O
defects	B-T017
of	O
mitochondrial	B-T038
translation	I-T038
,	O
including	O
mitochondrial	B-T017
transfer	B-T103
-	I-T103
RNA	I-T103
mutations	B-T038
and	O
primary	O
and	O
secondary	O
mtDNA	B-T033
deletions	I-T033
,	O
the	O
most	O
common	O
causes	O
of	O
mitochondrial	B-T038
disease	I-T038
.	O

However	O
,	O
normal	O
S	B-T103
-	I-T103
FGF21	I-T103
does	O
not	B-T033
exclude	O
structural	B-T017
respiratory	I-T017
chain	I-T017
complex	I-T017
or	I-T017
assembly	I-T017
factor	I-T017
defects	I-T017
,	O
important	O
to	O
acknowledge	O
in	O
diagnostics	B-T058
.	O

This	O
study	B-T062
provides	O
Class	B-T170
III	I-T170
evidence	O
that	O
elevated	O
S	B-T103
-	I-T103
FGF21	I-T103
accurately	O
distinguishes	O
patients	O
with	O
mitochondrial	B-T017
myopathies	I-T017
from	O
patients	O
with	O
other	O
conditions	O
,	O
and	O
FGF21	B-T103
and	O
GDF15	B-T103
mitochondrial	B-T017
myopathy	I-T017
from	O
other	O
myopathies	B-T038
.	O

The	O
effects	O
of	O
captopril	B-T103
on	O
lipopolysaccharide	B-T103
induced	O
learning	B-T038
and	O
memory	B-T038
impairments	I-T038
and	O
the	O
brain	B-T017
cytokine	B-T103
levels	O
and	O
oxidative	O
damage	B-T037
in	O
rats	B-T204

Renin	B-T022
-	I-T022
angiotensin	I-T022
system	I-T022
has	O
a	O
role	O
in	O
inflammation	B-T038
and	O
also	O
involves	O
in	O
learning	B-T038
and	O
memory	B-T038
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
captopril	B-T103
on	O
lipopolysaccharide	B-T103
(	O
LPS	B-T103
)	O
induced	O
learning	B-T038
and	O
memory	B-T038
impairments	I-T038
,	O
hippocampal	B-T017
cytokine	B-T103
levels	O
and	O
brain	B-T017
tissues	I-T017
oxidative	O
damage	B-T037
was	O
investigated	O
.	O

The	O
rats	B-T204
were	O
divided	O
and	O
treated	O
:	O
[	O
1	O
]	O
saline	O
(	O
Control	O
)	O
,	O
[	O
2	O
]	O
LPS	B-T103
(	O
1mg	O
/	O
kg	O
)	O
,	O
[	O
3	O
-	O
5	O
]	O
10	O
,	O
50	O
or	O
100mg	O
/	O
kg	O
captopril	B-T103
30min	O
before	O
LPS	B-T103
.	O

The	O
treatment	B-T058
was	O
started	O
since	O
six	O
days	O
before	O
the	O
behavioral	B-T058
experiments	I-T058
and	O
continued	O
during	O
the	O
behavioral	B-T058
tests	I-T058
(	O
LPS	B-T103
injection	B-T058
two	O
h	O
before	O
each	O
behavioral	B-T058
experiment	I-T058
)	O
.	O

Administration	B-T058
of	O
LPS	B-T103
prolonged	O
the	O
escape	O
latency	O
and	O
traveled	O
path	O
to	O
find	O
the	O
platform	O
in	O
Morris	B-T058
water	I-T058
maze	I-T058
(	I-T058
MWM	I-T058
)	I-T058
test	I-T058
(	O
P	O
<	O
0	O
.	O
01	O
-	O
P	O
<	O
0	O
.	O
001	O
)	O
while	O
,	O
shortened	O
the	O
latency	O
to	O
enter	O
the	O
dark	O
compartment	O
in	O
passive	O
avoidance	O
(	O
PA	O
)	O
test	B-T058
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Pretreatment	O
by	O
all	O
doses	O
of	O
captopril	B-T103
improved	O
performances	O
of	O
the	O
rats	B-T204
in	O
MWM	B-T058
(	O
P	O
<	O
0	O
.	O
05	O
-	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
also	O
prolonged	O
the	O
latency	O
to	O
enter	O
the	O
dark	O
in	O
PA	O
test	B-T058
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

LPS	B-T103
also	O
increased	O
IL	B-T103
-	I-T103
6	I-T103
,	O
TNF	B-T103
-	I-T103
α	I-T103
,	O
malondialdehyde	B-T103
(	O
MDA	B-T103
)	O
and	O
nitric	B-T103
oxide	I-T103
(	O
NO	B-T103
)	O
metabolites	B-T103
in	O
the	O
hippocampal	B-T017
tissues	B-T017
(	O
P	O
<	O
0	O
.	O
05	O
-	O
P	O
<	O
0	O
.	O
001	O
)	O
which	O
were	O
prevented	B-T058
by	O
captopril	B-T103
(	O
P	O
<	O
0	O
.	O
05	O
-	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
thiol	B-T103
,	O
superoxide	B-T103
dismutase	I-T103
(	O
SOD	B-T103
)	O
and	O
catalase	B-T103
(	O
CAT	B-T103
)	O
in	O
the	O
hippocampus	B-T017
of	O
LPS	B-T103
group	O
were	O
lower	O
than	O
the	O
control	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
while	O
,	O
they	O
were	O
enhanced	O
when	O
the	O
aniamls	B-T204
were	O
pretreated	O
by	O
captopril	B-T103
(	O
P	O
<	O
0	O
.	O
01	O
-	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
results	O
of	O
present	O
study	O
showed	O
that	O
captopril	B-T103
improved	O
the	O
LPS	B-T103
-	O
induced	O
learning	B-T038
and	O
memory	B-T038
impairments	I-T038
in	O
rats	B-T204
which	O
were	O
accompanied	O
with	O
attenuating	O
hippocampal	B-T017
cytokine	B-T103
levels	O
and	O
improving	O
the	O
brain	B-T017
tissues	I-T017
oxidative	O
damage	B-T037
criteria	O
.	O

Targeted	B-T058
therapy	I-T058
in	O
gastric	B-T038
cancer	I-T038

Gastric	B-T038
cancer	I-T038
is	O
the	O
fourth	O
most	O
common	O
cancer	B-T038
worldwide	O
.	O

Surgery	B-T058
in	O
combination	O
with	O
multimodal	B-T058
therapy	I-T058
provides	O
the	O
only	O
curative	B-T033
therapy	I-T033
until	O
now	O
.	O

The	O
importance	O
of	O
targeted	B-T058
therapy	I-T058
became	O
clear	O
over	O
the	O
last	O
few	O
years	O
.	O

Due	O
to	O
the	O
implication	O
of	O
HER2	B-T017
and	O
angiogenesis	B-T038
-	O
directed	O
targeted	B-T058
therapies	I-T058
major	O
advances	O
in	O
the	O
treatment	B-T058
of	O
gastric	B-T038
cancer	I-T038
could	O
be	O
reached	O
.	O

Nevertheless	O
,	O
benefits	O
in	O
survival	O
remain	O
unsatisfactory	O
and	O
the	O
development	O
of	O
resistance	O
to	O
monoclonal	B-T103
antibodies	I-T103
is	O
arising	O
.	O

A	O
comprehensive	O
and	O
comparative	B-T062
literature	B-T170
research	B-T062
was	O
performed	O
to	O
evaluate	B-T058
the	O
status	O
of	O
HER2	B-T017
and	O
angiogenesis	B-T038
-	O
directed	O
targeted	B-T058
therapy	I-T058
in	O
gastric	B-T038
cancer	I-T038
.	O

Up	O
to	O
now	O
,	O
trastuzumab	B-T103
and	O
ramucirumab	B-T103
are	O
the	O
only	O
agents	B-T103
showing	O
remarkable	O
benefits	O
in	O
the	O
therapy	B-T058
for	O
the	O
patients	O
suffering	O
from	O
gastric	B-T038
cancer	I-T038
.	O

The	O
limitations	O
of	O
targeted	B-T058
therapies	I-T058
in	O
gastric	B-T038
cancer	I-T038
are	O
mainly	O
associated	O
with	O
the	O
development	O
of	O
secondary	O
resistance	O
.	O

Addition	O
of	O
targeted	B-T058
therapy	I-T058
in	O
second	B-T058
-	I-T058
line	I-T058
treatment	I-T058
is	O
beneficial	O
when	O
compared	O
with	O
chemotherapy	B-T058
alone	O
.	O

Nevertheless	O
,	O
results	O
in	O
first	B-T058
-	I-T058
line	I-T058
treatment	I-T058
remain	O
modest	O
.	O

Therefore	O
,	O
new	O
therapeutic	B-T103
agents	I-T103
and	O
combinations	B-T103
in	O
the	O
first	B-T058
-	I-T058
line	I-T058
treatment	I-T058
of	O
gastric	B-T038
cancer	I-T038
are	O
urgently	O
needed	O
and	O
remain	O
to	O
be	O
validated	O
in	O
clinical	B-T062
trials	I-T062
.	O

Serum	B-T058
C	I-T058
-	I-T058
Reactive	I-T058
Protein	I-T058
in	O
Children	O
with	O
Liver	B-T038
Disease	I-T038
and	O
Ascites	B-T033

The	O
diagnosis	B-T062
of	O
peritonitis	B-T038
as	O
a	O
complication	B-T038
of	O
cirrhosis	B-T038
is	O
an	O
important	O
clinical	O
problem	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
serum	B-T058
C	I-T058
-	I-T058
reactive	I-T058
protein	I-T058
levels	I-T058
as	O
a	O
diagnostic	B-T201
factor	I-T201
for	O
spontaneous	B-T038
bacterial	I-T038
peritonitis	I-T038
(	O
SBP	B-T038
)	O
in	O
child	O
patients	O
with	O
liver	B-T038
disease	I-T038
.	O

In	O
this	O
study	B-T062
,	O
150	O
children	O
diagnosed	B-T062
with	O
liver	B-T038
disease	I-T038
and	O
ascites	B-T033
upon	O
admission	B-T058
to	O
Nemazee	B-T092
Teaching	I-T092
Hospital	I-T092
(	O
Shiraz	B-T082
,	O
Iran	B-T082
)	O
were	O
examined	B-T033
.	O

Patients	O
were	O
divided	O
into	O
spontaneous	B-T038
bacterial	I-T038
peritonitis	I-T038
and	O
sterile	B-T031
ascetic	I-T031
fluid	I-T031
groups	I-T031
according	O
to	O
the	O
PMN	B-T058
count	I-T058
≥	O
250	O
/	O
mm	O
(	O
3	O
)	O
in	O
the	O
ascetic	B-T031
fluids	I-T031
.	O

Routine	B-T058
laboratory	I-T058
tests	I-T058
were	O
conducted	O
and	O
quantitative	O
C	B-T058
-	I-T058
reactive	I-T058
protein	I-T058
(	I-T058
CRP	I-T058
)	I-T058
levels	I-T058
were	O
measured	O
for	O
all	O
of	O
the	O
patients	O
.	O

Accuracy	O
,	O
sensitivity	O
,	O
and	O
specificity	O
of	O
CRP	B-T058
was	O
evaluated	O
for	O
diagnosis	B-T062
of	O
SBP	B-T038
.	O

Of	O
150	O
cirrhotic	B-T038
patients	O
,	O
109	O
patients	O
presented	O
without	O
SBP	B-T038
(	O
52	O
.	O
29	O
%	O
male	B-T098
,	O
mean	O
age	O
:	O
5	O
.	O
02	O
±	O
4	O
.	O
49	O
years	O
)	O
and	O
41	O
patients	O
presented	O
with	O
SBP	B-T038
(	O
51	O
.	O
21	O
%	O
male	B-T098
,	O
mean	O
age	O
:	O
4	O
.	O
71	O
years	O
)	O
.	O

Cell	B-T058
counts	I-T058
,	O
protein	B-T033
levels	I-T033
,	O
albumin	B-T033
levels	I-T033
,	O
and	O
lactate	B-T058
dehydrogenize	I-T058
(	I-T058
LDH	I-T058
)	I-T058
levels	I-T058
of	O
the	O
ascetic	B-T031
fluid	I-T031
and	O
serum	B-T031
samples	I-T031
in	O
the	O
SBP	B-T038
group	O
were	O
higher	O
than	O
the	O
rates	O
for	O
those	O
without	O
SBP	B-T038
(	O
P	O
<	O
0	O
.	O
05	O
(	O
.	O

The	O
mean	O
±	O
SD	O
of	O
CRP	B-T058
in	O
the	O
SBP	B-T038
group	O
(	O
36	O
.	O
89	O
±	O
23	O
.	O
43	O
)	O
increased	O
significantly	O
compared	O
to	O
the	O
rate	O
among	O
those	O
without	O
SBP	B-T038
(	O
21	O
.	O
59	O
±	O
15	O
.	O
43	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

The	O
percentages	O
for	O
sensitivity	O
and	O
specificity	O
of	O
CRP	B-T058
,	O
the	O
diagnosis	B-T062
of	O
SBP	B-T038
based	O
on	O
the	O
PMN	B-T058
count	I-T058
≥	O
250	O
/	O
mm	O
(	O
3	O
)	O
,	O
and	O
cultured	B-T033
ascites	I-T033
were	O
69	O
.	O
23	O
%	O
,	O
90	O
.	O
25	O
%	O
,	O
88	O
.	O
43	O
%	O
,	O
and	O
84	O
.	O
32	O
%	O
,	O
respectively	O
.	O

The	O
areas	O
under	O
the	O
curve	O
of	O
CRP	B-T058
for	O
SBP	B-T038
based	O
on	O
the	O
PMN	B-T058
count	I-T058
≥	O
250	O
/	O
mm	O
(	O
3	O
)	O
and	O
cultured	B-T033
ascites	I-T033
was	O
0	O
.	O
94	O
(	O
CI	O
95	O
%	O
:	O
0	O
.	O
90	O
to	O
0	O
.	O
96	O
)	O
and	O
0	O
.	O
85	O
(	O
CI	O
95	O
%	O
:	O
0	O
.	O
84	O
to	O
0	O
.	O
92	O
)	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Our	O
study	B-T062
showed	O
that	O
CRP	B-T058
is	O
a	O
marker	O
with	O
high	O
sensitivity	O
and	O
specificity	O
for	O
the	O
diagnosis	B-T062
of	O
SBP	B-T038
in	O
cirrhotic	B-T038
children	O
.	O

Structure	O
of	O
the	O
bacterial	O
plant	B-T204
-	O
ferredoxin	B-T103
receptor	B-T103
FusA	B-T103

Iron	B-T103
is	O
a	O
limiting	O
nutrient	B-T168
in	O
bacterial	B-T038
infection	I-T038
putting	O
it	O
at	O
the	O
centre	O
of	O
an	O
evolutionary	O
arms	O
race	O
between	O
host	O
and	O
pathogen	O
.	O

Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
utilize	O
TonB	B-T103
-	O
dependent	O
outer	B-T017
membrane	I-T017
receptors	B-T103
to	O
obtain	O
iron	B-T103
during	O
infection	B-T038
.	O

These	O
receptors	B-T103
acquire	O
iron	B-T103
either	O
in	O
concert	O
with	O
soluble	O
iron	B-T103
-	I-T103
scavenging	I-T103
siderophores	I-T103
or	O
through	O
direct	O
interaction	O
and	O
extraction	B-T058
from	O
host	O
proteins	B-T103
.	O

Characterization	O
of	O
these	O
receptors	B-T103
provides	O
invaluable	O
insight	O
into	O
pathogenesis	B-T038
.	O

However	O
,	O
only	O
a	O
subset	O
of	O
virulence	B-T038
-	O
related	O
TonB	B-T103
-	O
dependent	O
receptors	B-T103
have	O
been	O
currently	O
described	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
of	O
FusA	B-T103
,	O
a	O
new	O
class	O
of	O
TonB	B-T103
-	O
dependent	O
receptor	B-T103
,	O
which	O
is	O
utilized	O
by	O
phytopathogenic	B-T007
Pectobacterium	I-T007
spp	I-T007
.	I-T007

to	O
obtain	O
iron	B-T103
from	O
plant	B-T204
ferredoxin	B-T103
.	O

Through	O
the	O
crystal	B-T103
structure	I-T103
of	O
FusA	B-T103
we	O
show	O
that	O
binding	B-T038
of	O
ferredoxin	B-T103
occurs	O
through	O
specialized	O
extracellular	B-T017
loops	I-T017
that	O
form	O
extensive	O
interactions	O
with	O
ferredoxin	B-T103
.	O

The	O
function	O
of	O
FusA	B-T103
and	O
the	O
presence	O
of	O
homologues	B-T082
in	O
clinically	O
important	O
pathogens	O
suggests	O
that	O
small	O
iron	B-T103
-	I-T103
containing	I-T103
proteins	I-T103
represent	O
an	O
iron	B-T103
source	B-T033
for	O
bacterial	O
pathogens	O
.	O

Antigen	B-T103
Masking	O
During	O
Fixation	B-T058
and	O
Embedding	B-T058
,	O
Dissected	O

Antigen	B-T103
masking	O
in	O
routinely	O
processed	O
tissue	B-T017
is	O
a	O
poorly	O
understood	O
process	O
caused	O
by	O
multiple	O
factors	O
.	O

We	O
sought	O
to	O
dissect	O
the	O
effect	O
on	O
antigenicity	B-T038
of	O
each	O
step	O
of	O
processing	O
by	O
using	O
frozen	B-T017
sections	I-T017
as	O
proxies	O
of	O
the	O
whole	B-T017
tissue	I-T017
.	O

An	O
equivalent	O
extent	O
of	O
antigen	B-T103
masking	O
occurs	O
across	O
variable	O
fixation	B-T058
times	O
at	O
room	O
temperature	O
.	O

Most	O
antigens	B-T103
benefit	O
from	O
longer	O
fixation	B-T058
times	O
(	O
>	O
24	O
hr	O
)	O
for	O
optimal	O
detection	B-T033
after	O
antigen	B-T103
retrieval	B-T058
(	O
AR	B-T058
;	O
for	O
example	O
,	O
Ki	B-T103
-	I-T103
67	I-T103
,	O
bcl	O
-	O
2	O
,	O
ER	O
)	O
.	O

The	O
transfer	O
to	O
a	O
graded	B-T103
alcohol	I-T103
series	O
results	O
in	O
an	O
enhanced	O
staining	B-T033
effect	I-T033
,	O
reproduced	O
by	O
treating	O
the	O
sections	B-T017
with	O
detergents	B-T103
,	O
possibly	O
because	O
of	O
a	O
better	O
access	O
of	O
the	O
polymeric	B-T103
immunohistochemical	O
detection	B-T033
system	O
to	O
tissue	B-T017
structures	B-T082
.	O

A	O
second	O
round	O
of	O
masking	O
occurs	O
upon	O
entering	O
the	O
clearing	B-T103
agent	I-T103
,	O
mostly	O
at	O
the	O
paraffin	B-T103
embedding	B-T058
step	O
.	O

This	O
may	O
depend	O
on	O
the	O
non	O
-	O
freezable	O
water	B-T103
removal	O
.	O

AR	B-T058
fully	O
reverses	O
the	O
masking	O
due	O
both	O
to	O
the	O
fixation	B-T058
time	O
and	O
the	O
paraffin	B-T103
embedding	B-T058
.	O

AR	B-T058
itself	O
destroys	O
some	O
epitopes	B-T103
which	O
do	O
not	O
survive	O
routine	O
processing	O
.	O

Processed	O
frozen	B-T017
sections	I-T017
are	O
a	O
tool	O
to	O
investigate	O
fixation	B-T058
and	O
processing	O
requirements	O
for	O
antigens	B-T103
in	O
routine	O
specimens	O
.	O

Synthesis	O
of	O
1	B-T103
,	I-T103
2	I-T103
-	I-T103
Dioxetanes	I-T103
as	O
Thermochemiluminescent	B-T103
Labels	I-T103
for	O
Ultrasensitive	B-T058
Bioassays	I-T058
:	O
Rational	O
Prediction	O
of	O
Olefin	B-T103
Photooxygenation	O
Outcome	O
by	O
Using	O
a	O
Chemometric	B-T058
Approach	I-T058

Great	O
interest	O
in	O
new	O
thermochemiluminescent	O
(	O
TCL	O
)	O
molecules	O
,	O
for	O
example	O
,	O
in	O
bioanalytical	B-T058
assays	I-T058
,	O
has	O
prompted	O
the	O
design	O
and	O
synthesis	O
of	O
a	O
small	O
library	B-T092
of	O
more	O
than	O
30	O
olefins	B-T103
to	O
be	O
subjected	O
to	O
photooxygenation	O
,	O
with	O
the	O
aim	O
of	O
obtaining	O
new	O
1	B-T103
,	I-T103
2	I-T103
-	I-T103
dioxetane	I-T103
-	I-T103
based	I-T103
TCL	B-T103
labels	I-T103
with	O
optimized	O
properties	O
.	O

Fluorine	B-T103
atoms	O
on	O
the	O
acridan	B-T103
system	O
remarkably	O
stabilize	O
1	B-T103
,	I-T103
2	I-T103
-	I-T103
dioxetanes	I-T103
when	O
they	O
are	O
located	O
in	O
the	O
3	O
-	O
and	O
/	O
or	O
6	O
-	O
position	O
(	O
4	O
h	O
and	O
4	O
i	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
2	B-T103
,	I-T103
7	I-T103
-	I-T103
difluorinated	I-T103
acridan	I-T103
dioxetane	I-T103
(	O
4	O
j	O
)	O
showed	O
a	O
significantly	O
enhanced	O
fluorescence	O
quantum	O
yield	O
with	O
respect	O
to	O
the	O
unsubstituted	B-T103
dioxetane	I-T103
(	O
4	O
a	O
)	O
.	O

Some	O
of	O
the	O
synthesized	O
olefins	B-T103
did	O
not	O
undergo	O
singlet	O
oxygen	O
addition	O
and	O
a	O
rationale	O
was	O
sought	O
to	O
ease	O
the	O
photooxygenation	O
step	O
,	O
leading	O
to	O
the	O
TCL	B-T103
dioxetanes	I-T103
.	O

A	O
chemometric	B-T058
approach	I-T058
has	O
been	O
adopted	O
to	O
exploit	O
principal	B-T062
component	I-T062
analysis	I-T062
and	O
linear	B-T062
discriminant	I-T062
analysis	I-T062
of	O
the	O
structural	B-T082
and	O
electronic	B-T170
molecular	I-T170
descriptors	I-T170
obtained	O
by	O
DFT	O
optimizations	O
of	O
olefins	B-T103
3	O
.	O

This	O
approach	B-T082
allows	O
the	O
steric	O
and	O
electronic	O
parameters	O
that	O
govern	O
dioxetane	B-T103
formation	O
to	O
be	O
revealed	O
.	O

Prostate	O
external	O
beam	O
radiotherapy	O
combined	O
with	O
high	B-T058
-	I-T058
dose	I-T058
-	I-T058
rate	I-T058
brachytherapy	I-T058
:	O
dose	O
-	O
volume	O
parameters	B-T033
from	O
deformably	B-T170
-	I-T170
registered	I-T170
plans	I-T170
correlate	O
with	O
late	O
gastrointestinal	B-T038
complications	I-T038

Derivation	O
of	O
dose	O
-	O
volume	O
correlated	O
with	O
toxicity	O
for	O
multi	B-T058
-	I-T058
modal	I-T058
treatments	I-T058
can	O
be	O
difficult	O
due	O
to	O
the	O
perceived	O
need	O
for	O
voxel	B-T058
-	I-T058
by	I-T058
-	I-T058
voxel	I-T058
dose	I-T058
accumulation	I-T058
.	O

With	O
data	O
available	O
for	O
a	O
single	O
-	O
institution	B-T092
cohort	B-T098
with	O
long	O
follow	B-T058
-	I-T058
up	I-T058
,	O
an	O
investigation	O
was	O
undertaken	O
into	O
rectal	B-T082
dose	O
-	O
volume	O
effects	O
for	O
gastrointestinal	B-T033
toxicities	I-T033
after	O
deformably	O
-	O
registering	O
each	O
phase	O
of	O
a	O
combined	O
external	O
beam	O
radiotherapy	O
(	O
EBRT	O
)	O
/	O
high	B-T058
-	I-T058
dose	I-T058
-	I-T058
rate	I-T058
(	I-T058
HDR	I-T058
)	I-T058
brachytherapy	I-T058
prostate	B-T058
treatment	I-T058
.	O

One	O
hundred	O
and	O
eighteen	O
patients	O
received	O
EBRT	O
in	O
23	O
fractions	O
of	O
2	O
Gy	O
and	O
HDR	B-T058
(	O
TG43	B-T170
algorithm	I-T170
)	O
in	O
3	O
fractions	O
of	O
6	O
.	O
5	O
Gy	O
.	O

Results	O
for	O
the	O
Late	B-T170
Effects	I-T170
of	I-T170
Normal	I-T170
Tissues	I-T170
-	I-T170
Subjective	I-T170
,	I-T170
Objective	I-T170
,	I-T170
Management	I-T170
and	I-T170
Analytic	I-T170
toxicity	I-T170
assessments	I-T170
were	O
available	O
with	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
72	O
months	O
.	O

The	O
HDR	B-T058
CT	B-T058
was	O
deformably	O
-	O
registered	O
to	O
the	O
EBRT	O
CT	B-T058
.	O

Doses	O
were	O
corrected	O
for	O
dose	B-T058
fractionation	I-T058
.	O

Rectum	B-T017
dose	B-T170
-	I-T170
volume	I-T170
histogram	I-T170
(	O
DVH	B-T170
)	O
parameters	B-T033
were	O
calculated	O
in	O
two	O
ways	O
.	O

(	O
1	O
)	O
Distribution	B-T170
-	I-T170
adding	I-T170
:	O
parameters	B-T033
were	O
calculated	O
after	O
the	O
EBRT	O
dose	O
distribution	O
was	O
3D	O
-	O
summed	O
with	O
the	O
registered	O
HDR	B-T058
dose	O
distribution	O
.	O

(	O
2	O
)	O
Parameter	B-T170
-	I-T170
adding	I-T170
:	O
the	O
EBRT	O
DVH	B-T170
parameters	B-T033
were	O
added	O
to	O
HDR	B-T058
DVH	B-T170
parameters	B-T033
.	O

Logistic	B-T062
regressions	I-T062
and	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
were	O
used	O
to	O
correlate	O
parameters	B-T033
with	O
late	O
peak	O
toxicity	O
(	O
dichotomised	O
at	O
grade	B-T170
1	O
or	O
2	O
)	O
.	O

The	O
48	O
-	O
80	O
,	O
40	O
-	O
63	O
and	O
49	O
-	O
55	O
Gy	O
dose	O
regions	B-T082
from	O
distribution	B-T170
-	I-T170
adding	I-T170
were	O
significantly	O
correlated	O
with	O
rectal	B-T038
bleeding	I-T038
,	O
urgency	B-T038
/	O
tenesmus	B-T033
and	O
stool	B-T033
frequency	I-T033
respectively	O
.	O

Additionally	O
,	O
urgency	B-T038
/	O
tenesmus	B-T033
and	O
anorectal	B-T033
pain	I-T033
were	O
associated	O
with	O
the	O
25	O
-	O
26	O
Gy	O
and	O
44	O
-	O
48	O
Gy	O
dose	O
regions	B-T082
from	O
distribution	B-T170
-	I-T170
adding	I-T170
respectively	O
.	O

Parameter	B-T170
-	I-T170
adding	I-T170
also	O
indicated	O
the	O
low	O
-	O
mid	B-T082
dose	O
region	B-T082
was	O
significantly	O
correlated	O
with	O
stool	B-T033
frequency	I-T033
and	O
proctitis	B-T038
.	O

This	O
study	B-T062
confirms	B-T033
significant	O
dose	B-T170
-	I-T170
histogram	I-T170
effects	O
for	O
gastrointestinal	B-T033
toxicities	I-T033
after	O
including	O
deformable	B-T170
registration	I-T170
to	O
combine	O
phases	O
of	O
EBRT	O
/	O
HDR	B-T058
prostate	B-T038
cancer	I-T038
treatment	B-T058
.	O

The	O
findings	B-T033
from	O
distribution	B-T170
-	I-T170
adding	I-T170
were	O
in	O
most	O
cases	O
consistent	O
with	O
those	O
from	O
parameter	B-T170
-	I-T170
adding	I-T170
.	O

The	O
mid	B-T082
-	O
high	O
dose	O
range	O
and	O
near	O
maximum	O
doses	O
were	O
important	O
for	O
rectal	B-T038
bleeding	I-T038
.	O

The	O
distribution	B-T170
-	I-T170
adding	I-T170
mid	B-T082
-	O
high	O
dose	O
range	O
was	O
also	O
important	O
for	O
stool	B-T033
frequency	I-T033
and	O
urgency	B-T038
/	O
tenesmus	B-T033
.	O

We	O
encourage	O
additional	O
studies	B-T062
in	O
a	O
variety	O
of	O
institutions	O
using	O
a	O
variety	O
of	O
dose	B-T058
accumulation	I-T058
methods	I-T058
with	O
appropriate	O
inter	O
-	O
fraction	O
motion	O
management	O
.	O

NCT	O
NCT00193856	O
.	O

Retrospectively	O
registered	O
12	O
September	O
2005	O
.	O

Prescription	B-T170
of	O
opioids	B-T103
for	O
breathlessness	B-T033
in	O
end	O
-	O
stage	O
COPD	B-T038
:	O
a	O
national	O
population	B-T062
-	I-T062
based	I-T062
study	I-T062

Low	O
-	O
dose	O
opioids	B-T103
can	O
relieve	O
breathlessness	B-T033
but	O
may	O
be	O
underused	O
in	O
late	O
-	O
stage	O
COPD	B-T038
due	O
to	O
fear	B-T038
of	O
complications	B-T038
,	O
contributing	O
to	O
poor	O
symptom	B-T058
control	I-T058
.	O

We	O
aimed	O
to	O
study	B-T062
the	O
period	O
prevalence	O
and	O
indications	O
of	O
opioids	B-T103
actually	O
prescribed	O
in	O
people	B-T098
with	O
end	O
-	O
stage	O
COPD	B-T038
.	O

The	O
study	B-T062
was	O
a	O
longitudinal	B-T062
,	O
population	B-T062
-	I-T062
based	I-T062
study	I-T062
of	O
patients	O
starting	O
long	B-T058
-	I-T058
term	I-T058
oxygen	I-T058
therapy	I-T058
(	O
LTOT	B-T058
)	O
for	O
COPD	B-T038
between	O
October	O
1	O
,	O
2005	O
and	O
June	O
30	O
,	O
2009	O
in	O
Sweden	B-T082
.	O

A	O
random	O
sample	O
(	O
n	O
=	O
2	O
,	O
000	O
)	O
of	O
their	O
dispensed	B-T058
opioid	B-T103
prescriptions	B-T170
was	O
obtained	O
from	O
the	O
national	B-T170
Prescribed	I-T170
Drugs	I-T170
Register	I-T170
from	O
91	O
days	O
before	O
starting	O
LTOT	B-T058
until	O
the	O
first	O
of	O
LTOT	B-T058
withdrawal	O
,	O
death	B-T038
,	O
or	O
study	O
end	O
(	O
December	O
31	O
,	O
2009	O
)	O
.	O

We	O
analyzed	O
medication	O
type	O
,	O
dispensed	O
quantity	O
,	O
date	B-T033
of	I-T033
dispensing	I-T033
,	O
and	O
indications	O
categorized	O
as	O
pain	B-T033
,	O
breathlessness	B-T033
,	O
other	O
,	O
or	O
unknown	O
.	O

In	O
total	O
,	O
2	O
,	O
249	O
COPD	B-T038
patients	O
(	O
59	O
%	O
women	B-T098
)	O
were	O
included	O
.	O

During	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
1	O
.	O
1	O
(	O
interquartile	O
range	O
0	O
.	O
6	O
-	O
2	O
.	O
0	O
)	O
years	O
,	O
1	O
,	O
034	O
patients	O
(	O
46	O
%	O
)	O
were	O
dispensed	B-T058
≥1	O
opioid	B-T103
prescription	B-T058
(	O
N	O
=	O
13	O
,	O
722	O
prescriptions	B-T058
)	O
.	O

The	O
most	O
frequently	O
prescribed	O
opioids	B-T103
were	O
tramadol	B-T103
(	O
23	O
%	O
)	O
,	O
oxycodone	B-T103
(	O
23	O
%	O
)	O
,	O
morphine	B-T103
(	O
16	O
%	O
)	O
,	O
and	O
codeine	B-T103
(	O
16	O
%	O
)	O
.	O

Average	O
dispensed	O
quantity	O
was	O
9	O
.	O
3	O
(	O
interquartile	O
range	O
3	O
.	O
7	O
-	O
16	O
.	O
7	O
)	O
defined	O
daily	O
doses	O
per	O
prescription	B-T058
.	O

In	O
the	O
random	O
sample	O
,	O
the	O
most	O
commonly	O
stated	O
indication	O
was	O
pain	B-T033
(	O
97	O
%	O
)	O
,	O
with	O
only	O
2	O
%	O
for	O
breathlessness	B-T033
and	O
1	O
%	O
for	O
other	O
reasons	O
.	O

Despite	O
evidence	O
that	O
supported	O
the	O
use	O
of	O
opioids	B-T103
for	O
the	O
relief	O
of	O
breathlessness	B-T033
predating	O
this	O
study	B-T062
,	O
opioids	B-T103
are	O
rarely	O
prescribed	O
to	O
relieve	O
breathlessness	B-T033
in	O
oxygen	B-T038
-	I-T038
dependent	I-T038
COPD	B-T038
,	O
potentially	O
contributing	O
to	O
less	O
-	O
than	O
-	O
optimal	O
symptom	B-T058
control	I-T058
.	O

This	O
study	B-T062
creates	O
a	O
baseline	O
against	O
which	O
to	O
compare	O
future	O
changes	O
in	O
morphine	B-T103
prescribing	O
in	O
this	O
setting	O
.	O

In	B-T082
Vivo	I-T082
3	B-T082
-	I-T082
Dimensional	I-T082
Strain	O
Mapping	O
Confirms	O
Large	O
Optic	B-T017
Nerve	I-T017
Head	I-T017
Deformations	B-T017
Following	O
Horizontal	B-T038
Eye	I-T038
Movements	I-T038

To	O
measure	O
lamina	B-T017
cribrosa	I-T017
(	O
LC	B-T017
)	O
strains	B-T017
(	O
deformations	B-T017
)	O
following	O
abduction	B-T038
and	O
adduction	O
in	O
healthy	B-T098
subjects	I-T098
and	O
to	O
compare	O
them	O
with	O
those	O
resulting	O
from	O
a	O
relatively	O
high	O
acute	O
intraocular	B-T038
pressure	I-T038
(	O
IOP	B-T038
)	O
elevation	B-T082
.	O

A	O
total	O
of	O
16	O
eyes	B-T017
from	O
8	O
healthy	B-T098
subjects	I-T098
were	O
included	O
.	O

Among	O
the	O
16	O
eyes	B-T017
,	O
11	O
had	O
peripapillary	B-T033
atrophy	I-T033
(	O
PPA	B-T033
)	O
.	O

For	O
each	O
subject	O
,	O
both	O
optic	B-T017
nerve	I-T017
heads	I-T017
(	O
ONHs	B-T017
)	O
were	O
imaged	B-T170
using	O
optical	B-T058
coherence	I-T058
tomography	I-T058
(	O
OCT	B-T058
)	O
at	O
baseline	O
(	O
twice	O
)	O
,	O
in	O
different	O
gaze	B-T074
positions	B-T082
(	O
adduction	O
and	O
abduction	B-T038
of	O
20°	O
)	O
and	O
following	O
an	O
acute	O
IOP	B-T038
elevation	B-T082
of	O
approximately	O
20	O
mm	O
Hg	B-T103
from	O
baseline	O
(	O
via	O
ophthalmodynamometry	B-T058
)	O
.	O

Strains	B-T017
of	O
LC	B-T017
for	O
all	O
loading	O
scenarios	O
were	O
mapped	O
using	O
a	O
three	B-T082
-	I-T082
dimensional	I-T082
tracking	B-T082
algorithm	B-T170
.	O

In	O
all	O
16	O
eyes	B-T017
,	O
LC	B-T017
strains	B-T017
induced	O
by	O
adduction	O
and	O
abduction	B-T038
were	O
5	O
.	O
83	O
%	O
±	O
3	O
.	O
78	O
%	O
and	O
3	O
.	O
93	O
%	O
±	O
2	O
.	O
57	O
%	O
,	O
respectively	O
,	O
and	O
both	O
significantly	O
higher	O
than	O
the	O
control	O
strains	B-T017
measured	O
from	O
the	O
repeated	O
baseline	O
acquisitions	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Strains	B-T017
of	O
LC	B-T017
in	O
adduction	O
were	O
on	O
average	O
higher	O
than	O
those	O
in	O
abduction	B-T038
,	O
but	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Strains	B-T017
of	O
LC	B-T017
induced	O
by	O
IOP	B-T038
elevations	B-T082
(	O
on	O
average	O
21	O
.	O
13	O
±	O
7	O
.	O
61	O
mm	O
Hg	B-T103
)	O
were	O
6	O
.	O
41	O
%	O
±	O
3	O
.	O
21	O
%	O
and	O
significantly	O
higher	O
than	O
the	O
control	O
strains	B-T017
(	O
P	O
<	O
0	O
.	O
0005	O
)	O
.	O

Gaze	B-T074
-	O
induced	O
LC	B-T017
strains	B-T017
in	O
the	O
PPA	B-T033
group	O
were	O
on	O
average	O
larger	O
than	O
those	O
in	O
the	O
non	O
-	O
PPA	O
group	O
;	O
however	O
,	O
the	O
relationship	O
was	O
not	O
statistically	O
significant	O
.	O

Our	O
results	O
confirm	O
that	O
horizontal	B-T038
eye	I-T038
movements	I-T038
generate	O
significant	O
ONH	B-T017
strains	B-T017
,	O
which	O
is	O
consistent	O
with	O
our	O
previous	O
estimations	B-T038
using	O
finite	B-T170
element	I-T170
analysis	I-T170
.	O

Further	B-T062
studies	I-T062
are	O
needed	O
to	O
explore	O
a	O
possible	B-T033
link	O
between	O
ONH	B-T017
strains	B-T017
induced	O
by	O
eye	B-T038
movements	I-T038
and	O
axonal	B-T033
loss	I-T033
in	O
optic	B-T038
neuropathies	I-T038
.	O

Simultaneously	O
Targeting	O
Myofibroblast	B-T038
Contractility	I-T038
and	O
Extracellular	B-T017
Matrix	I-T017
Cross	O
-	O
Linking	O
as	O
a	O
Therapeutic	O
Concept	O
in	O
Airway	B-T017
Fibrosis	B-T038

Fibrosis	B-T038
after	O
solid	B-T058
organ	I-T058
transplantation	I-T058
is	O
considered	O
an	O
irreversible	O
process	O
and	O
remains	O
the	O
major	O
cause	O
of	O
graft	B-T038
dysfunction	I-T038
and	O
death	B-T038
with	O
limited	O
therapies	B-T058
.	O

This	O
remodeling	O
is	O
characterized	O
by	O
aberrant	O
accumulation	B-T033
of	O
contractile	B-T017
myofibroblasts	I-T017
that	O
deposit	O
excessive	O
extracellular	B-T017
matrix	I-T017
(	O
ECM	B-T017
)	O
and	O
increase	O
tissue	O
stiffness	O
.	O

Studies	B-T062
demonstrate	O
,	O
however	O
,	O
that	O
a	O
stiff	B-T033
ECM	B-T017
itself	O
promotes	O
fibroblast	B-T017
-	O
to	O
-	O
myofibroblast	B-T017
differentiation	B-T038
,	O
stimulating	O
further	O
ECM	B-T017
production	O
.	O

This	O
creates	O
a	O
positive	O
feedback	O
loop	O
that	O
perpetuates	O
fibrosis	B-T038
.	O

We	O
hypothesized	O
that	O
simultaneously	O
targeting	O
myofibroblast	B-T038
contractility	I-T038
with	O
relaxin	B-T103
and	O
ECM	B-T017
stiffness	B-T033
with	O
lysyl	B-T103
oxidase	I-T103
inhibitors	B-T103
could	O
break	O
the	O
feedback	B-T038
loop	I-T038
,	O
reversing	O
established	O
fibrosis	B-T038
.	O

To	O
test	O
this	O
,	O
we	O
used	O
the	O
orthotopic	B-T058
tracheal	I-T058
transplantation	I-T058
(	O
OTT	B-T058
)	O
mouse	B-T038
model	I-T038
,	O
which	O
develops	O
robust	O
fibrotic	O
airway	B-T017
remodeling	O
.	O

Mice	B-T204
with	O
established	O
fibrosis	B-T038
were	O
treated	O
with	O
saline	O
,	O
mono	B-T058
-	I-T058
,	O
or	O
combination	B-T058
therapies	I-T058
.	O

Although	O
monotherapies	B-T058
had	O
no	O
effect	O
,	O
combining	B-T103
these	I-T103
agents	I-T103
decreased	O
collagen	B-T103
deposition	O
and	O
promoted	O
re	B-T038
-	I-T038
epithelialization	I-T038
of	O
remodeled	B-T033
airways	I-T033
.	O

Relaxin	B-T103
inhibited	O
myofibroblast	B-T017
differentiation	B-T038
and	O
contraction	B-T038
in	O
a	O
matrix	B-T017
-	O
stiffness	B-T033
-	O
dependent	O
manner	O
through	O
prostaglandin	B-T103
E2	I-T103
(	O
PGE2	B-T103
)	O
.	O

Furthermore	O
,	O
the	O
effect	O
of	O
combination	B-T058
therapy	I-T058
was	O
lost	O
in	O
PGE2	B-T103
receptor	I-T103
knockout	B-T204
and	O
PGE2	B-T103
-	O
inhibited	O
OTT	B-T058
mice	B-T204
.	O

This	O
study	B-T062
revealed	O
the	O
important	O
synergistic	O
roles	O
of	O
cellular	B-T038
contractility	I-T038
and	O
tissue	O
stiffness	O
in	O
the	O
maintenance	O
of	O
fibrotic	O
tissue	B-T017
and	O
suggests	O
a	O
new	O
therapeutic	O
principle	O
for	O
fibrosis	B-T038
.	O

Systemic	B-T103
matrix	I-T103
metalloproteinase	I-T103
-	I-T103
8	I-T103
response	B-T038
in	O
chronic	B-T038
tonsillitis	I-T038

The	O
development	O
of	O
several	O
life	O
-	O
long	O
diseases	B-T038
,	O
such	O
as	O
coronary	B-T038
heart	I-T038
disease	I-T038
,	O
is	O
affected	O
by	O
low	O
-	O
grade	O
systemic	O
inflammation	B-T038
.	O

Data	O
on	O
the	O
potential	O
long	O
-	O
term	O
health	O
effects	O
of	O
chronic	B-T038
tonsillitis	I-T038
are	O
limited	O
.	O

Many	O
inflammatory	B-T038
conditions	O
present	O
with	O
enhanced	O
systemic	B-T103
matrix	I-T103
metalloproteinase	I-T103
(	B-T103
MMP	I-T103
)	I-T103
-	I-T103
8	I-T103
response	B-T038
.	O

In	O
head	B-T038
and	I-T038
neck	I-T038
cancer	I-T038
,	O
high	O
plasma	B-T031
level	O
of	O
tissue	B-T103
inhibitor	I-T103
of	I-T103
metalloproteinase	I-T103
(	B-T103
TIMP	I-T103
)	I-T103
-	I-T103
1	I-T103
predicts	O
poor	B-T033
prognosis	I-T033
.	O

We	O
analyzed	O
S	B-T103
-	I-T103
MMP	I-T103
-	I-T103
8	I-T103
with	O
immunofluorometric	B-T058
assay	I-T058
and	O
S	B-T103
-	I-T103
TIMP	I-T103
-	I-T103
1	I-T103
with	O
an	O
immunosorbent	B-T058
assay	I-T058
in	O
175	O
consecutive	O
patients	O
undergoing	O
tonsillectomy	B-T058
for	O
benign	B-T038
tonsillar	I-T038
disease	I-T038
,	O
and	O
in	O
33	O
control	O
patients	O
with	O
tonsillar	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
.	O

Tonsillar	B-T017
human	B-T005
papillomavirus	I-T005
(	O
HPV	B-T005
)	O
status	O
was	O
determined	O
by	O
PCR	B-T062
.	O

In	O
patients	O
with	O
benign	B-T038
tonsillar	I-T038
disease	I-T038
,	O
chronic	B-T038
tonsillitis	I-T038
without	O
hypertrophy	B-T038
was	O
associated	O
with	O
enhanced	O
systemic	B-T103
MMP	I-T103
-	I-T103
8	I-T103
response	B-T038
.	O

Compared	O
to	O
patients	O
with	O
benign	B-T038
tonsillar	I-T038
disease	I-T038
,	O
patients	O
with	O
tonsillar	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
had	O
significantly	O
higher	O
concentrations	O
of	O
S	B-T103
-	I-T103
MMP	I-T103
-	I-T103
8	I-T103
and	O
S	B-T103
-	I-T103
TIMP	I-T103
-	I-T103
1	I-T103
.	O

Neither	O
S	B-T103
-	I-T103
MMP	I-T103
-	I-T103
8	I-T103
nor	O
S	B-T103
-	I-T103
TIMP	I-T103
-	I-T103
1	I-T103
correlated	O
with	O
tonsillar	B-T017
HPV	B-T005
positivity	B-T033
.	O

Addressing	B-T170
holistic	O
health	O
and	O
work	O
empowerment	O
through	O
a	O
body	O
-	O
mind	O
-	O
spirit	O
intervention	O
program	O
among	O
helping	O
professionals	B-T097
in	O
continuous	O
education	O
:	O
A	O
pilot	B-T062
study	I-T062

To	O
examine	O
the	O
effectiveness	O
of	O
a	O
body	O
-	O
mind	O
-	O
spirit	O
(	O
BMS	O
)	O
intervention	O
program	O
in	O
improving	O
the	O
holistic	O
well	O
-	O
being	O
and	O
work	O
empowerment	O
among	O
helping	O
professionals	B-T097
in	O
continuous	O
education	O
.	O

Forty	O
-	O
four	O
helping	O
professionals	B-T097
,	O
who	O
were	O
in	O
their	O
first	O
-	O
year	O
part	O
-	O
time	O
postgraduate	O
study	O
,	O
participated	O
in	O
the	O
present	O
study	O
.	O

All	O
participants	B-T098
attended	O
a	O
3	O
-	O
day	O
BMS	O
intervention	O
program	O
which	O
emphasized	O
a	O
holistic	O
approach	O
to	O
health	O
and	O
well	O
-	O
being	O
.	O

Ratings	O
on	O
their	O
levels	O
of	O
physical	B-T033
distress	I-T033
,	O
daily	O
functioning	O
,	O
affect	B-T038
,	O
spirituality	O
,	O
and	O
psychologica	O
l	O
empowerment	O
at	O
work	O
were	O
compared	O
before	O
and	O
immediately	O
after	O
the	O
intervention	B-T058
.	O

Participants	B-T098
reported	O
significantly	O
lower	O
levels	O
of	O
negative	B-T033
affect	I-T033
and	O
physical	B-T033
distress	I-T033
,	O
and	O
were	O
less	O
spiritually	B-T033
disoriented	I-T033
after	O
the	O
intervention	B-T058
.	O

Enhanced	O
levels	O
of	O
daily	O
functioning	O
,	O
positive	B-T038
affect	I-T038
,	O
spiritual	O
resilience	O
,	O
and	O
tranquility	B-T038
were	O
also	O
reported	O
.	O

Results	O
also	O
suggested	O
that	O
participants	B-T098
were	O
empowered	B-T038
at	O
work	O
,	O
and	O
specifically	O
felt	O
more	O
able	O
to	O
make	O
an	O
impact	O
on	O
work	O
outcomes	O
.	O

The	O
3	O
-	O
day	O
BMS	O
intervention	O
program	O
produced	O
a	O
positive	B-T033
and	O
measurable	O
effec	O
t	O
on	O
participants	B-T098
'	O
holistic	O
well	O
-	O
being	O
and	O
empowerment	O
at	O
work	O
.	O

Educators	B-T097
in	O
related	O
fields	O
could	O
incorporate	O
holistic	O
practices	B-T038
into	O
the	O
curriculum	B-T170
to	O
better	O
prepare	O
the	O
future	O
practitioners	B-T097
,	O
leading	O
to	O
better	O
outcomes	O
both	O
to	O
the	O
professionals	B-T097
themselves	O
and	O
their	O
clients	O
or	O
patients	O
.	O

Successful	B-T058
Restoration	I-T058
of	O
Severely	O
Mutilated	O
Primary	B-T017
Incisors	I-T017
Using	O
a	O
Novel	O
Method	O
to	O
Retain	O
Zirconia	O
Crowns	B-T074
-	O
Two	O
Year	O
Results	O

This	O
manuscript	B-T170
describes	O
a	O
simple	O
reliable	O
technique	O
for	O
restoring	B-T058
severely	O
mutilated	O
primary	B-T017
anterior	I-T017
teeth	I-T017
.	O

A	O
rigid	O
glass	B-T103
ionomer	I-T103
post	I-T103
is	O
created	O
over	O
which	O
zirconia	O
crowns	B-T074
can	O
be	O
fitted	O
to	O
achieve	O
a	O
long	O
-	O
term	O
stable	O
esthetic	B-T058
restoration	B-T058
for	O
primary	B-T017
anterior	I-T017
teeth	I-T017
.	O

Children	O
aged	O
2	O
-	O
5	O
years	O
with	O
two	O
up	O
to	O
six	O
extensively	O
decayed	B-T038
upper	B-T017
primary	I-T017
incisors	I-T017
were	O
included	O
.	O

Fuji	B-T103
IX	I-T103
was	O
condensed	O
into	O
an	O
intracanal	B-T058
space	I-T058
created	O
to	O
a	O
depth	B-T082
of	O
3mm	O
,	O
to	O
provide	O
a	O
core	B-T082
which	O
also	O
extended	O
3mm	O
supragingivally	B-T058
.	O

Crown	B-T058
preparations	I-T058
were	O
completed	O
upon	O
these	O
cores	B-T082
.	O

Zirconia	O
crowns	B-T074
(	O
Nusmile	B-T170
,	O
Houston	B-T082
Texas	I-T082
USA	B-T082
)	O
were	O
fitted	O
and	O
cemented	B-T031
over	O
the	O
prepared	O
cores	B-T082
.	O

All	O
patients	O
were	O
recalled	B-T058
at	O
regular	O
intervals	O
.	O

Twenty	O
-	O
three	O
healthy	O
children	O
with	O
86	O
restorations	B-T058
participated	O
in	O
the	O
study	B-T062
.	O

The	O
overall	O
survival	O
of	O
the	O
restorations	B-T058
was	O
95	O
.	O
3	O
%	O
after	O
12	O
months	O
and	O
80	O
.	O
2	O
%	O
after	O
24	O
months	O
.	O

According	O
to	O
Kaplan	B-T062
-	I-T062
Meier	I-T062
survival	I-T062
analysis	I-T062
,	O
the	O
median	O
survival	O
time	O
was	O
not	O
reached	O
while	O
the	O
estimated	O
mean	O
survival	O
time	O
was	O
22	O
.	O
9	O
months	O
.	O

This	O
newly	O
described	O
clinical	B-T058
technique	I-T058
is	O
simple	O
and	O
reliable	O
to	O
use	O
for	O
restoration	B-T058
of	O
extensively	O
decayed	B-T038
primary	B-T017
incisors	I-T017
.	O

Use	O
of	O
zirconia	O
crowns	B-T074
retained	O
using	O
this	O
technique	O
offers	O
superior	O
esthetic	O
,	O
durable	O
restorations	B-T058
with	O
remarkable	O
gingival	B-T033
response	I-T033
up	O
to	O
24	O
months	O
.	O

Reimbursement	O
Based	O
on	O
Value	O
in	O
Knee	B-T058
Surgery	I-T058
:	O
What	O
You	O
Need	O
to	O
Know	O
about	O
the	O
Medicare	B-T170
Access	I-T170
and	I-T170
Children	I-T170
'	I-T170
s	I-T170
Health	I-T170
Insurance	I-T170
Program	I-T170
Reauthorization	I-T170
Act	I-T170
of	I-T170
2015	I-T170

Health	O
care	O
cost	O
is	O
consuming	O
a	O
large	O
portion	O
of	O
the	O
nation	O
'	O
s	O
gross	O
domestic	O
product	O
while	O
placing	O
added	O
economic	O
burdens	O
on	O
physicians	B-T097
and	O
their	O
patients	O
.	O

With	O
total	B-T058
joint	I-T058
replacement	I-T058
being	O
one	O
of	O
the	O
early	O
-	O
targeted	O
procedures	B-T058
in	O
the	O
evolving	O
health	B-T092
care	I-T092
environment	I-T092
,	O
knee	B-T097
surgeons	I-T097
will	O
benefit	O
from	O
developing	O
a	O
critical	O
knowledge	O
on	O
health	O
care	O
reforms	O
and	O
their	O
financial	O
implications	O
.	O

The	O
Medicare	B-T170
Access	I-T170
and	I-T170
Children	I-T170
'	I-T170
s	I-T170
Health	I-T170
Insurance	I-T170
Program	I-T170
Reauthorization	I-T170
Act	I-T170
represents	O
a	O
cohesive	O
movement	O
toward	O
value	O
-	O
based	O
payment	O
reform	O
and	O
contains	O
several	O
unchartered	O
rulings	O
that	O
require	O
detailed	O
attention	O
by	O
knee	B-T097
surgeons	I-T097
.	O

In	O
this	O
article	O
,	O
we	O
provide	O
a	O
contextual	O
framework	O
of	O
health	B-T170
care	I-T170
legislation	I-T170
that	O
has	O
led	O
to	O
the	O
formation	O
of	O
the	O
current	O
health	B-T170
policy	I-T170
,	O
and	O
present	O
a	O
comprehensive	O
summary	B-T170
and	O
update	O
on	O
the	O
Merit	B-T170
-	I-T170
Based	I-T170
Incentive	I-T170
Payment	I-T170
Systems	I-T170
and	O
Alternative	B-T170
Payment	I-T170
Models	I-T170
reimbursement	I-T170
models	I-T170
.	O

Empty	O
Capsids	B-T017
and	O
Macrophage	B-T017
Inhibition	O
/	O
Depletion	O
Increase	O
rAAV	B-T103
Transgene	B-T017
Expression	B-T038
in	O
Joints	B-T082
of	O
Both	O
Healthy	O
and	O
Arthritic	B-T038
Mice	B-T204

Gene	B-T058
therapy	I-T058
has	O
potential	O
to	O
treat	B-T058
rheumatic	B-T038
diseases	I-T038
;	O
however	O
,	O
the	O
presence	B-T033
of	O
macrophages	B-T017
in	O
the	O
joint	B-T082
might	O
hamper	O
adeno	B-T005
-	I-T005
associated	I-T005
viral	I-T005
vector	B-T103
-	O
mediated	O
gene	O
delivery	O
.	O

Here	O
we	O
demonstrate	O
that	O
in	O
arthritic	B-T038
,	O
but	O
also	O
in	O
healthy	O
,	O
mice	B-T204
administration	B-T058
of	I-T058
agents	I-T058
that	O
influence	O
macrophage	B-T017
activity	O
/	O
number	O
and	O
/	O
or	O
addition	O
of	O
empty	O
decoy	B-T017
capsids	I-T017
substantially	O
improve	B-T033
the	O
efficacy	O
of	O
recombinant	O
adeno	B-T005
-	I-T005
associated	I-T005
viral	I-T005
vector	B-T103
5	O
transgene	B-T017
expression	B-T038
in	O
the	O
joint	B-T082
.	O

Pretreatment	O
with	O
triamcinolone	B-T103
or	O
clodronate	B-T103
liposomes	B-T103
improved	B-T033
luciferase	B-T103
expression	B-T038
over	O
a	O
period	O
of	O
4	O
weeks	O
.	O

Similar	O
results	O
were	O
seen	O
when	O
empty	O
decoy	B-T017
capsids	I-T017
were	O
added	O
to	O
full	O
genome	B-T017
containing	O
capsids	B-T017
in	O
a	O
5	O
:	O
1	O
ratio	O
.	O

In	O
a	O
study	B-T062
to	O
assess	O
the	O
duration	O
of	O
expression	B-T038
as	O
well	O
as	O
to	O
investigate	O
the	O
combination	O
of	O
these	O
two	O
approaches	O
,	O
we	O
observed	O
a	O
synergistic	O
enhancement	O
of	O
gene	B-T038
expression	I-T038
,	O
sustained	O
for	O
at	O
least	O
12	O
weeks	O
.	O

The	O
enhancement	O
of	O
gene	B-T038
expression	I-T038
was	O
independent	O
of	O
the	O
route	O
of	O
administration	O
of	O
triamcinolone	B-T103
(	O
intra	B-T082
-	I-T082
articular	I-T082
or	O
intramuscular	B-T082
)	O
.	O

In	O
healthy	O
mice	B-T204
it	O
was	O
demonstrated	O
that	O
the	O
combination	O
improved	B-T033
expression	B-T038
of	O
the	O
transgene	B-T017
significantly	O
,	O
in	O
a	O
serotype	B-T170
independent	O
manner	O
.	O

These	O
data	O
have	O
implications	O
for	O
future	O
applications	O
of	O
gene	B-T058
therapy	I-T058
to	O
the	O
joint	B-T082
and	O
for	O
other	O
tissues	B-T017
with	O
an	O
abundance	O
of	O
macrophages	B-T017
.	O

An	O
Inhibitory	O
Septum	O
to	O
Lateral	B-T082
Hypothalamus	I-T082
Circuit	O
That	O
Suppresses	O
Feeding	O

Feeding	O
behavior	O
is	O
orchestrated	O
by	O
neural	O
circuits	O
primarily	O
residing	O
in	O
the	O
hypothalamus	B-T017
and	O
hindbrain	B-T017
.	O

However	O
,	O
the	O
relative	O
influence	O
of	O
cognitive	O
and	O
emotional	B-T038
brain	O
circuits	O
to	O
the	O
feeding	O
circuitry	O
in	O
the	O
hypothalamus	B-T017
and	O
hindbrain	B-T017
remains	O
unclear	O
.	O

Here	O
,	O
using	O
the	O
cell	B-T170
-	I-T170
type	I-T170
selectivity	O
of	O
genetic	B-T062
methods	I-T062
,	O
circuit	B-T058
mapping	I-T058
,	O
and	O
behavior	O
assays	B-T058
,	O
we	O
sought	O
to	O
decipher	O
neural	O
circuits	O
emanating	O
from	O
the	O
septal	B-T017
nucleus	I-T017
to	O
the	O
lateral	B-T082
hypothalamus	I-T082
(	O
LH	B-T082
)	O
that	O
contribute	O
to	O
neural	O
regulation	O
of	O
food	B-T038
intake	I-T038
in	O
mice	B-T204
.	O

We	O
found	O
that	O
chemogenetic	O
and	O
optogenetic	O
activation	O
of	O
septal	B-T082
vesicular	B-T103
GABA	I-T103
transporter	I-T103
(	O
vGAT	B-T103
)	O
-	O
containing	O
neurons	B-T017
or	O
their	O
projections	O
in	O
the	O
LH	B-T082
reduced	O
food	B-T038
intake	I-T038
in	O
mice	B-T204
.	O

Consistently	O
,	O
chemogenetic	O
inhibition	O
of	O
septal	B-T082
vGAT	B-T103
neurons	B-T017
increased	O
food	B-T038
intake	I-T038
.	O

Furthermore	O
,	O
we	O
investigated	O
a	O
previously	O
unknown	O
neural	O
circuit	O
originating	O
from	O
septal	B-T082
vGAT	B-T103
neurons	B-T017
to	O
a	O
subset	B-T170
of	O
vGAT	B-T103
neurons	B-T017
in	O
the	O
LH	B-T082
,	O
an	O
area	B-T082
involved	O
in	O
homeostatic	B-T038
and	O
hedonic	B-T038
control	O
of	O
energy	O
states	O
.	O

Collectively	O
,	O
our	O
data	O
reveal	O
an	O
inhibitory	O
septohypothalamic	B-T082
feeding	O
circuit	O
that	O
might	O
serve	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
eating	B-T038
disorders	I-T038
such	O
as	O
anorexia	B-T038
nervosa	I-T038
.	O

Our	O
results	O
demonstrate	O
that	O
top	O
-	O
down	O
projections	O
from	O
the	O
septum	O
to	O
the	O
hypothalamus	B-T017
control	O
food	B-T038
intake	I-T038
negatively	B-T033
.	O

Given	O
the	O
known	O
role	O
for	O
both	O
of	O
these	O
brain	B-T082
regions	I-T082
in	O
the	O
control	O
of	O
feeding	O
and	O
emotion	B-T038
-	O
related	O
behaviors	O
,	O
these	O
findings	B-T033
reveal	O
previously	O
unknown	O
neural	O
circuitry	O
that	O
is	O
likely	O
implicated	O
in	O
emotional	O
aspects	O
of	O
food	B-T038
intake	I-T038
and	O
provide	O
new	O
insights	B-T038
into	O
the	O
development	O
of	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
eating	B-T038
disorders	I-T038
.	O

Human	B-T204
Umbilical	B-T031
Cord	I-T031
Blood	I-T031
-	O
Derived	O
Neural	B-T017
Stem	I-T017
Cell	I-T017
Line	I-T017
as	O
a	O
Screening	B-T058
Model	O
for	O
Toxicity	B-T037

The	O
aim	O
was	O
to	O
investigate	O
whether	O
a	O
human	B-T204
neural	B-T017
stem	I-T017
cell	I-T017
(	O
NSC	B-T017
)	O
line	B-T017
derived	O
from	O
human	B-T204
umbilical	B-T031
cord	I-T031
blood	I-T031
(	O
hUCB	B-T031
)	O
can	O
be	O
used	O
for	O
toxicity	B-T037
study	B-T062
.	O

Toxicity	B-T037
of	O
both	O
neurotoxic	O
environmental	B-T082
xenobiotics	B-T103
,	O
methyl	B-T103
mercury	I-T103
chloride	I-T103
(	O
CH3HgCl	B-T103
)	O
,	O
lead	B-T103
acetate	I-T103
(	O
CH3COOPb	B-T103
)	O
,	O
and	O
chlorpyrifos	B-T103
(	O
CP	B-T103
)	O
,	O
and	O
non	B-T033
-	I-T033
neurotoxic	I-T033
insecticide	B-T103
,	O
dichlorvos	B-T103
,	O
as	O
well	O
as	O
non	B-T033
-	I-T033
neurotoxic	I-T033
drugs	B-T103
,	O
theophylline	B-T103
and	O
acetaminophen	B-T103
were	O
assessed	O
.	O

Additionally	O
,	O
differentiation	O
of	O
neuronal	O
and	O
glial	B-T017
cell	I-T017
lines	I-T017
derived	O
from	O
hUCB	B-T031
was	O
elucidated	O
.	O

It	O
was	O
observed	O
that	O
CH3HgCl	B-T103
was	O
more	O
toxic	O
to	O
human	B-T204
NSCs	B-T017
in	O
comparison	O
to	O
CH3COOPb	B-T103
and	O
CP	B-T103
.	O

The	O
minimum	B-T033
inhibitory	I-T033
concentration	I-T033
(	I-T033
MIC	I-T033
)	I-T033
value	I-T033
against	O
NSCs	B-T017
was	O
3	O
,	O
10	O
,	O
and	O
300	O
mg	O
/	O
L	O
,	O
in	O
each	O
staining	B-T058
process	I-T058
,	O
acridine	B-T103
orange	I-T103
/	O
ethidium	B-T103
bromide	I-T103
(	O
AO	B-T103
/	O
EB	B-T103
)	O
staining	B-T058
,	O
3	B-T103
-	I-T103
(	I-T103
4	I-T103
,	I-T103
5	I-T103
-	I-T103
dimethylthiazol	I-T103
-	I-T103
2	I-T103
-	I-T103
yl	I-T103
)	I-T103
2	I-T103
,	I-T103
5	I-T103
-	I-T103
diphenyl	I-T103
tetrazolium	I-T103
bromide	I-T103
(	O
MTT	B-T103
)	O
assay	B-T058
,	O
and	O
Hoechst	O
staining	O
,	O
for	O
CH3HgCl	B-T103
,	O
CP	B-T103
,	O
and	O
CH3COOPb	B-T103
,	O
respectively	O
.	O

CH3HgCl	B-T103
had	O
the	O
LC25	O
value	O
as	O
10	O
.	O
0	O
,	O
14	O
.	O
4	O
,	O
and	O
12	O
.	O
7	O
mg	O
/	O
L	O
,	O
by	O
staining	B-T058
method	I-T058
mentioned	O
in	O
succession	O
.	O

CP	B-T103
had	O
the	O
LC25	O
value	O
as	O
21	O
.	O
9	O
,	O
23	O
.	O
7	O
,	O
and	O
18	O
.	O
4	O
mg	O
/	O
L	O
;	O
similarly	O
,	O
CH3COOPb	B-T103
had	O
LC25	O
values	O
,	O
successively	O
as	O
616	O
.	O
9	O
,	O
719	O
.	O
2	O
,	O
and	O
890	O
.	O
3	O
mg	O
/	O
L	O
.	O

LC50	O
values	O
ranged	O
from	O
18	O
.	O
2	O
to	O
21	O
.	O
7	O
mg	O
/	O
L	O
for	O
CH3HgCl	B-T103
,	O
56	O
.	O
4	O
to	O
60	O
.	O
2	O
mg	O
/	O
L	O
for	O
CP	B-T103
,	O
and	O
1000	O
to	O
1460	O
.	O
1	O
for	O
CH3COOPb	B-T103
.	O

Theophylline	B-T103
,	O
acetaminophen	B-T103
,	O
and	O
dichlorvos	B-T103
had	O
no	O
impact	O
on	O
the	O
viability	O
of	O
NSCs	B-T017
.	O

This	O
work	O
justified	O
that	O
hUCB	B-T031
-	O
NSC	B-T017
model	O
can	O
be	O
used	O
for	O
toxicity	B-T037
study	B-T062
.	O

MiR	B-T017
221	I-T017
/	O
222	B-T017
as	O
new	O
players	O
in	O
tamoxifen	B-T103
resistance	B-T038

Breast	B-T038
cancer	I-T038
is	O
the	O
most	O
frequent	O
cancer	B-T038
in	O
women	B-T098
.	O

Despite	O
advances	O
in	O
early	B-T058
detection	I-T058
and	O
treatment	B-T058
,	O
it	O
has	O
the	O
second	O
highest	O
mortality	O
rate	O
after	O
lung	B-T038
cancer	I-T038
.	O

Around	O
85	O
%	O
of	O
breast	B-T038
carcinomas	I-T038
are	O
ER	B-T033
+	I-T033
;	O
thus	O
,	O
antiestrogens	B-T103
like	O
tamoxifen	B-T103
are	O
beneficial	O
.	O

Although	O
,	O
tamoxifen	B-T103
is	O
useful	O
for	O
many	O
patients	O
,	O
plenty	O
of	O
patients	O
respond	B-T033
poorly	I-T033
to	O
initial	O
therapy	B-T058
or	O
recurrence	O
occurs	O
in	O
about	O
30	O
%	O
of	O
cases	O
,	O
because	O
tamoxifen	B-T103
resistance	B-T038
happens	O
.	O

Drug	B-T038
resistance	I-T038
remains	O
a	O
major	O
clinical	O
obstacle	O
to	O
successful	B-T201
treatment	I-T201
of	O
breast	B-T038
cancer	I-T038
and	O
more	O
than	O
90	O
%	O
of	O
unsuccessful	B-T033
treatments	I-T033
are	O
because	O
of	O
acquired	O
resistance	B-T038
and	O
MultiDrug	O
Resistance	O
(	O
MDR	O
)	O
is	O
a	O
major	O
contributor	O
.	O

MicroRNAs	B-T103
are	O
members	O
of	O
a	O
novel	O
class	O
of	O
short	O
noncoding	B-T103
RNAs	I-T103
.	O

Besides	O
to	O
their	O
various	O
roles	O
in	O
gene	B-T038
expression	I-T038
,	O
miRNAs	B-T103
are	O
considered	O
as	O
important	O
cancer	B-T038
therapeutic	B-T103
targets	I-T103
and	O
biomarkers	B-T201
.	O

Since	O
2005	O
,	O
when	O
miRNA	B-T103
deregulation	O
was	O
first	O
reported	O
in	O
breast	B-T038
cancer	I-T038
,	O
more	O
than	O
1000	O
reports	B-T170
have	O
been	O
published	O
about	O
miRNAs	B-T103
.	O

Increasing	O
number	O
of	O
studies	B-T062
showed	O
the	O
importance	O
of	O
miRNAs	B-T103
in	O
antiestrogen	B-T058
therapy	I-T058
,	O
especially	O
on	O
tamoxifen	B-T103
;	O
thus	O
,	O
it	O
is	O
not	O
surprising	O
that	O
these	O
tiny	O
molecules	O
are	O
involved	O
in	O
drug	B-T038
resistance	I-T038
.	O

Due	O
to	O
the	O
pivotal	O
role	O
of	O
these	O
known	O
RNA	B-T103
molecules	I-T103
,	O
in	O
this	O
review	O
,	O
we	O
tried	O
to	O
illustrate	O
the	O
importance	O
of	O
the	O
miRNAs	B-T103
as	O
a	O
new	O
player	O
in	O
breast	B-T038
cancer	I-T038
pathogenesis	B-T038
.	O

We	O
have	O
also	O
focused	O
on	O
cancer	B-T038
drug	B-T038
resistance	I-T038
mechanisms	O
highlighting	O
the	O
role	O
of	O
important	O
oncomirs	B-T103
,	O
miR	B-T017
221	I-T017
/	O
222	B-T017
,	O
involved	O
in	O
cell	B-T038
cycle	I-T038
deregulation	I-T038
in	O
breast	B-T038
cancer	I-T038
.	O

The	O
relationship	O
between	O
these	O
oncomiRs	B-T103
with	O
resistance	B-T038
to	O
tamoxifen	B-T103
is	O
also	O
emphasized	O
.	O

Ultra	O
-	O
low	O
activities	O
of	O
a	O
common	O
radioisotope	B-T103
for	O
permission	O
-	O
free	O
tracking	B-T082
of	O
a	O
drosophilid	B-T204
fly	I-T204
in	O
its	O
natural	B-T082
habitat	I-T082

Knowledge	O
of	O
a	O
species	B-T170
'	O
ecology	O
,	O
including	O
its	O
movement	B-T038
in	O
time	O
and	O
space	B-T082
,	O
is	O
key	O
for	O
many	O
questions	O
in	O
biology	B-T091
and	O
conservation	O
.	O

While	O
numerous	O
tools	O
for	O
tracking	B-T082
larger	O
animals	B-T204
are	O
available	O
,	O
millimetre	B-T204
-	I-T204
sized	I-T204
insects	I-T204
are	O
averse	O
to	O
standard	O
tracking	B-T082
and	O
labelling	B-T062
procedures	I-T062
.	O

Here	O
,	O
we	O
evaluated	O
the	O
applicability	O
of	O
ultra	O
-	O
low	O
,	O
permission	O
-	O
exempt	O
activities	O
of	O
the	O
metastable	O
isomer	O
of	O
the	O
radionuclide	B-T103
Technetium	B-T103
-	I-T103
99	I-T103
for	O
labelling	B-T062
and	O
field	B-T033
detection	I-T033
of	O
the	O
mountain	B-T082
fly	B-T204
Drosophila	B-T204
nigrosparsa	I-T204
.	O

We	O
demonstrate	O
that	O
an	O
activity	O
of	O
less	O
than	O
10	O
MBq	O
is	O
sufficient	O
to	O
label	B-T062
dozens	O
of	O
flies	B-T204
and	O
detect	B-T033
single	I-T033
individuals	I-T033
using	O
standard	O
radiation	B-T058
protection	I-T058
monitors	B-T058
.	O

The	O
methodology	O
presented	O
here	O
is	O
applicable	O
to	O
many	O
small	O
-	O
sized	O
,	O
low	B-T033
-	I-T033
mobility	I-T033
animals	B-T204
as	O
well	O
as	O
independent	O
from	O
light	O
and	O
weather	O
conditions	O
and	O
visual	B-T033
contact	I-T033
with	O
the	O
target	O
organism	O
.	O

Injury	O
surveillance	O
of	O
female	O
adult	O
Zumba	O
®	O
dancers	B-T097

We	O
sought	O
to	O
describe	O
the	O
patterns	B-T082
of	O
injury	B-T037
and	O
to	O
establish	O
the	O
injury	B-T037
incidence	O
rates	O
associated	O
with	O
Zumba	O
®	O
.	O

Zumba	O
®	O
dancers	B-T097
were	O
invited	O
to	O
complete	O
an	O
anonymous	O
web	O
-	O
based	O
survey	B-T170
containing	O
13	O
demographic	O
background	O
and	O
14	O
(	O
1	O
yr	O
retrospective	O
)	O
injury	B-T037
history	O
questions	B-T170
.	O

Inclusion	O
criteria	O
stated	O
that	O
the	O
respondents	B-T098
had	O
to	O
be	O
aged	O
18	O
-	O
64	O
yr	O
and	O
currently	O
involved	O
in	O
group	B-T098
-	O
based	O
classes	B-T170
of	O
Zumba	O
®	O
,	O
either	O
as	O
a	O
registered	B-T097
instructor	I-T097
or	O
class	B-T170
participant	B-T098
.	O

Binomial	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
predict	O
the	O
odds	O
of	O
injury	B-T037
during	O
Zumba	O
®	O
and	O
Mann	B-T170
-	I-T170
Whitney	I-T170
tests	I-T170
were	O
employed	O
to	O
ascertain	O
differences	O
between	O
groups	B-T098
.	O

The	O
survey	B-T170
response	O
rate	O
was	O
74	O
%	O
.	O

The	O
final	O
sample	O
of	O
respondents	B-T098
(	O
N	O
=	O
138	O
;	O
female	O
=	O
100	O
%	O
)	O
included	O
19	O
registered	B-T097
instructors	I-T097
and	O
119	O
class	B-T170
participants	B-T098
,	O
of	O
which	O
58	O
%	O
and	O
16	O
%	O
,	O
respectively	O
,	O
sustained	O
≥	O
1	O
injury	B-T037
during	O
Zumba	O
®	O
in	O
the	O
past	O
year	O
.	O

The	O
odds	O
of	O
injury	B-T037
was	O
7	O
(	O
95	O
%	O
CI	O
2	O
-	O
19	O
)	O
times	O
greater	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
for	O
registered	B-T097
instructors	I-T097
than	O
for	O
class	B-T170
participants	B-T098
.	O

Zumba	O
®	O
dancers	B-T097
had	O
a	O
17	O
(	O
95	O
%	O
CI	O
7	O
-	O
28	O
)	O
%	O
greater	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
odds	O
of	O
injury	B-T037
for	O
every	O
1	O
h	O
of	O
non	O
-	O
Zumba	O
®	O
-	O
related	O
moderate	O
to	O
vigorous	O
physical	O
activity	O
(	O
MVPA	O
)	O
engagement	O
per	O
week	O
.	O

The	O
injury	B-T037
incidence	O
rate	O
for	O
registered	B-T097
instructors	I-T097
and	O
class	B-T170
participants	B-T098
was	O
5	O
.	O
7	O
(	O
95	O
%	O
CI	O
3	O
.	O
1	O
-	O
8	O
.	O
2	O
)	O
and	O
3	O
.	O
9	O
(	O
95	O
%	O
CI	O
2	O
.	O
5	O
-	O
5	O
.	O
3	O
)	O
injuries	B-T037
per	O
1000	O
h	O
of	O
exposure	O
,	O
respectively	O
.	O

Zumba	O
®	O
presents	O
a	O
low	O
risk	O
of	O
injury	B-T037
;	O
for	O
registered	B-T097
instructors	I-T097
,	O
the	O
increased	O
risk	O
of	O
injury	B-T037
is	O
likely	O
due	O
to	O
the	O
high	O
total	O
volume	O
of	O
MVPA	O
participated	O
in	O
weekly	O
.	O

Clinical	O
Features	O
of	O
Smokers	B-T033
With	O
Radiological	B-T058
Emphysema	B-T038
But	O
Without	O
Airway	B-T017
Limitation	O

The	O
clinical	O
characteristics	O
of	O
patients	O
with	O
emphysema	B-T038
but	O
without	O
airway	B-T017
limitations	O
remain	O
unknown	O
.	O

The	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
compare	O
the	O
clinical	O
features	O
of	O
current	B-T033
and	O
former	B-T033
smokers	I-T033
without	O
airflow	B-T038
limitation	O
who	O
have	O
radiologic	B-T058
emphysema	B-T038
on	O
chest	B-T058
CT	I-T058
scans	I-T058
vs	O
a	O
control	O
group	O
of	O
current	B-T033
and	O
ex	B-T033
-	I-T033
smokers	I-T033
without	O
emphysema	B-T038
.	O

Subjects	O
enrolled	O
had	O
anthropometric	O
characteristics	O
recorded	O
,	O
provided	O
a	O
medical	B-T033
history	I-T033
,	O
and	O
underwent	O
low	O
-	O
dose	O
chest	B-T058
CT	I-T058
scanning	I-T058
.	O

The	O
following	O
parameters	B-T033
were	O
also	O
evaluated	O
:	O
pulmonary	B-T058
function	I-T058
tests	I-T058
including	O
diffusion	B-T058
capacity	I-T058
for	I-T058
carbon	I-T058
monoxide	I-T058
(	O
Dlco	B-T058
)	O
,	O
the	O
modified	O
Medical	B-T170
Research	I-T170
Council	I-T170
dyspnea	I-T170
score	I-T170
,	O
COPD	B-T170
assessment	I-T170
test	I-T170
(	O
CAT	B-T170
)	O
,	O
and	O
6	B-T058
-	I-T058
min	I-T058
walk	I-T058
test	I-T058
(	O
6MWT	B-T058
)	O
.	O

A	O
comparison	O
was	O
conducted	O
between	O
those	O
with	O
and	O
without	O
CT	B-T058
-	O
confirmed	B-T033
emphysema	B-T038
.	O

Of	O
the	O
203	O
subjects	O
,	O
154	O
had	O
emphysema	B-T038
,	O
and	O
49	O
did	O
not	O
.	O

Adjusted	O
group	B-T098
comparisons	O
revealed	O
that	O
a	O
higher	O
proportion	O
of	O
patients	O
with	O
emphysema	B-T038
according	O
to	O
low	O
-	O
dose	O
chest	B-T058
CT	I-T058
scanning	I-T058
had	O
an	O
abnormal	B-T033
Dlco	I-T033
value	O
(	O
<	O
80	O
%	O
)	O
(	O
46	O
%	O
vs	O
19	O
%	O
;	O
P	O
=	O
.	O
02	O
)	O
,	O
a	O
decrease	O
in	O
percentage	O
of	O
oxygen	B-T038
saturation	I-T038
>	O
4	O
%	O
during	O
the	O
6MWT	B-T058
(	O
8	O
.	O
5	O
%	O
vs	O
0	O
;	O
P	O
=	O
.	O
04	O
)	O
,	O
and	O
an	O
altered	O
quality	O
of	O
life	O
(	O
CAT	B-T170
score	O
≥	O
10	O
)	O
(	O
32	O
%	O
vs	O
14	O
%	O
;	O
P	O
=	O
.	O
01	O
)	O
.	O

A	O
detailed	O
analysis	B-T062
of	O
the	O
CAT	B-T170
questionnaire	I-T170
items	O
revealed	O
that	O
more	O
patients	O
with	O
emphysema	B-T038
had	O
a	O
score	O
≥	O
1	O
in	O
the	O
"	O
chest	B-T033
tightness	I-T033
"	O
(	O
P	O
=	O
.	O
05	O
)	O
and	O
"	O
limitation	O
when	O
doing	O
activities	O
at	O
home	B-T082
"	O
(	O
P	O
<	O
.	O
01	O
)	O
items	O
compared	O
with	O
those	O
with	O
no	B-T033
emphysema	I-T033
.	O

They	O
also	O
experienced	O
significantly	O
more	O
exacerbations	B-T033
in	O
the	O
previous	O
year	O
(	O
0	O
.	O
19	O
vs	O
0	O
.	O
04	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

A	O
significant	O
proportion	O
of	O
smokers	B-T033
with	O
emphysema	B-T038
according	O
to	O
low	O
-	O
dose	O
chest	B-T058
CT	I-T058
scanning	I-T058
but	O
without	O
airway	B-T017
limitation	O
had	O
alterations	O
in	O
their	O
quality	O
of	O
life	O
,	O
number	O
of	O
exacerbations	B-T033
,	O
Dlco	B-T058
values	O
,	O
and	O
oxygen	B-T038
saturation	I-T038
during	O
the	O
6MWT	B-T058
test	I-T058
.	O

Anti	B-T038
-	I-T038
tumor	I-T038
activity	I-T038
of	O
SL4	B-T103
against	O
breast	B-T017
cancer	I-T017
cells	I-T017
:	O
induction	O
of	O
G2	B-T038
/	I-T038
M	I-T038
arrest	I-T038
through	O
modulation	O
of	O
the	O
MAPK	B-T103
-	O
dependent	O
p21	B-T103
signaling	B-T038
pathway	I-T038

SL4	B-T103
,	O
a	O
chalcone	B-T103
-	O
based	O
compound	B-T103
,	O
has	O
been	O
shown	O
to	O
retard	O
tumor	B-T033
invasion	I-T033
and	O
angiogenesis	B-T038
by	O
suppressing	O
HIF1	B-T103
activity	O
and	O
to	O
induce	O
apoptosis	B-T038
by	O
promoting	O
ROS	B-T103
release	O
.	O

Here	O
,	O
we	O
report	B-T170
that	O
SL4	B-T103
is	O
able	O
to	O
inhibit	O
the	O
proliferation	B-T038
of	O
different	O
types	O
of	O
breast	B-T017
cancer	I-T017
cell	I-T017
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
by	O
inducing	O
G2	B-T038
/	I-T038
M	I-T038
cell	I-T038
cycle	I-T038
arrest	I-T038
.	O

Our	O
results	O
showed	O
that	O
SL4	B-T103
exhibited	O
strong	O
anti	B-T103
-	I-T103
proliferative	I-T103
activity	O
in	O
several	O
human	B-T204
breast	B-T038
cancer	I-T038
cell	B-T017
lines	I-T017
,	O
with	O
IC50	O
values	O
lower	O
than	O
1	O
.	O
3	O
μM	O
.	O

Further	O
studies	B-T062
indicated	B-T033
that	O
SL4	B-T103
induced	O
G2	B-T038
/	I-T038
M	I-T038
arrest	I-T038
in	O
these	O
cell	B-T017
lines	I-T017
.	O

Mechanistically	O
,	O
SL4	B-T103
reduces	O
the	O
expression	B-T038
of	O
cyclin	B-T103
A2	I-T103
and	O
cdc25C	B-T103
and	O
decreases	O
the	O
activity	O
of	O
the	O
cdc2	B-T103
/	O
cyclin	B-T103
B1	I-T103
complex	B-T103
.	O

Notably	O
,	O
SL4	B-T103
treatment	B-T058
resulted	O
in	O
an	O
obvious	O
increase	O
in	O
p21	B-T017
mRNA	B-T103
and	O
protein	B-T103
levels	O
through	O
activation	B-T038
of	O
MAPK	B-T038
signaling	I-T038
pathways	I-T038
,	O
but	O
not	O
the	O
TGF	B-T038
-	I-T038
β	I-T038
pathway	I-T038
.	O

SP600125	B-T103
and	O
PD98059	B-T103
,	O
specific	O
inhibitors	B-T103
of	O
JNK	B-T103
kinase	I-T103
and	O
ERK	B-T103
kinase	I-T103
,	O
significantly	O
blocked	O
the	O
SL4	B-T103
-	O
induced	O
G2	B-T038
/	I-T038
M	I-T038
phase	I-T038
arrest	I-T038
and	O
upregulation	B-T038
of	O
p21	B-T103
.	O

Furthermore	O
,	O
SL4	B-T103
suppressed	O
the	O
growth	B-T038
of	O
established	O
breast	B-T038
tumors	I-T038
in	O
nude	B-T204
mice	I-T204
through	O
upregulation	B-T038
of	O
p21	B-T103
and	O
downregulation	B-T038
of	O
cdc25C	B-T103
,	O
and	O
displayed	O
a	O
good	O
safety	O
profile	O
.	O

Taken	O
together	O
,	O
these	O
findings	B-T033
demonstrate	O
the	O
potential	O
value	O
of	O
SL4	B-T103
as	O
a	O
novel	O
multi	B-T103
-	I-T103
target	I-T103
anti	I-T103
-	I-T103
tumor	I-T103
drug	I-T103
candidate	I-T103
.	O

Identification	O
of	O
In	B-T103
-	I-T103
Chain	I-T103
-	I-T103
Functionalized	I-T103
Compounds	I-T103
and	O
Methyl	B-T103
-	I-T103
Branched	I-T103
Alkanes	I-T103
in	O
Cuticular	B-T204
Waxes	B-T103
of	O
Triticum	B-T204
aestivum	I-T204
cv	I-T204
.	I-T204
Bethlehem	I-T204

In	O
this	O
work	O
,	O
cuticular	B-T204
waxes	B-T103
from	O
flag	B-T204
leaf	I-T204
blades	B-T204
and	O
peduncles	B-T204
of	O
Triticum	B-T204
aestivum	I-T204
cv	I-T204
.	I-T204

Bethlehem	I-T204
were	O
investigated	O
in	O
search	O
for	O
novel	O
wax	B-T103
compounds	I-T103
.	O

Seven	O
wax	B-T103
compound	I-T103
classes	B-T170
were	O
detected	B-T033
that	O
had	O
previously	O
not	O
been	O
reported	O
,	O
and	O
their	O
structures	B-T170
were	O
elucidated	O
using	O
gas	B-T058
chromatography	I-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
of	O
various	O
derivatives	B-T103
.	O

Six	O
of	O
the	O
classes	O
were	O
identified	O
as	O
series	O
of	O
homologs	O
differing	O
by	O
two	O
methylene	O
units	O
,	O
while	O
the	O
seventh	O
was	O
a	O
homologous	O
series	O
with	O
homologs	O
with	O
single	O
methylene	O
unit	O
differences	O
.	O

In	O
the	O
waxes	B-T103
of	O
flag	B-T204
leaf	I-T204
blades	B-T204
,	O
secondary	O
alcohols	O
(	O
predominantly	O
C27	O
and	O
C33	O
)	O
,	O
primary	B-T103
/	O
secondary	B-T103
diols	I-T103
(	O
predominantly	O
C28	B-T103
)	O
and	O
esters	B-T103
of	I-T103
primary	I-T103
/	O
secondary	B-T103
diols	I-T103
(	O
predominantly	O
C50	B-T103
,	O
combining	O
C28	B-T103
diol	I-T103
with	O
C22	B-T103
acid	I-T103
)	O
were	O
found	O
,	O
all	O
sharing	O
similar	O
secondary	O
hydroxyl	O
group	O
positions	O
at	O
and	O
around	O
C	O
-	O
12	O
or	O
ω	O
-	O
12	O
.	O

7	B-T103
-	I-T103
and	O
8	B-T103
-	I-T103
hydroxy	I-T103
-	I-T103
2	I-T103
-	I-T103
alkanol	I-T103
esters	I-T103
(	O
predominantly	O
C35	B-T103
)	O
,	O
7	B-T103
-	I-T103
and	O
8	B-T103
-	I-T103
oxo	I-T103
-	I-T103
2	I-T103
-	I-T103
alkanol	I-T103
esters	I-T103
(	O
predominantly	O
C35	B-T103
)	O
,	O
and	O
4	B-T103
-	I-T103
alkylbutan	I-T103
-	I-T103
4	I-T103
-	I-T103
olides	I-T103
(	O
predominantly	O
C28	B-T103
)	O
were	O
found	O
both	O
in	O
flag	B-T204
leaf	I-T204
and	O
peduncle	B-T204
wax	B-T103
mixtures	O
.	O

Finally	O
,	O
a	O
series	O
of	O
even	O
-	O
and	O
odd	O
-	O
numbered	O
alkane	O
homologs	O
was	O
identified	O
in	O
both	O
leaf	B-T204
and	O
peduncle	B-T204
waxes	B-T103
,	O
with	O
an	O
internal	O
methyl	O
branch	O
preferentially	O
on	O
C	B-T103
-	I-T103
11	I-T103
and	O
C	B-T103
-	I-T103
13	I-T103
of	I-T103
homologs	I-T103
with	I-T103
even	I-T103
total	I-T103
carbon	I-T103
number	I-T103
and	O
on	O
C	B-T103
-	I-T103
12	I-T103
of	I-T103
odd	I-T103
-	I-T103
numbered	I-T103
homologs	I-T103
.	O

Biosynthetic	B-T038
pathways	I-T038
are	O
suggested	O
for	O
all	O
compounds	O
,	O
based	O
on	O
common	O
structural	B-T170
features	O
and	O
matching	O
chain	O
length	O
profiles	O
with	O
other	O
wheat	B-T204
wax	B-T103
compound	I-T103
classes	O
.	O

Pupillary	O
response	O
abnormalities	B-T033
in	O
depressive	B-T038
disorders	I-T038

Depressive	B-T038
disorders	I-T038
lack	O
objective	O
physiological	O
measurements	O
to	O
characterize	O
the	O
affected	O
population	O
and	O
facilitate	O
study	B-T062
of	O
relevant	O
mechanisms	O
.	O

The	O
melanopsin	B-T103
-	O
mediated	O
light	B-T038
signaling	I-T038
pathway	I-T038
may	O
contribute	O
to	O
seasonal	O
variation	O
and	O
can	O
be	O
measured	O
non	O
-	O
invasively	O
by	O
pupillometry	B-T058
.	O

We	O
prospectively	B-T062
studied	I-T062
changes	O
in	O
melanopsin	B-T103
-	O
mediated	O
pupillary	B-T038
constriction	I-T038
in	O
19	O
participants	O
with	O
major	B-T038
depressive	I-T038
disorder	I-T038
(	O
MDD	B-T038
)	O
and	O
10	O
control	O
across	O
the	O
summer	O
and	O
winter	O
solstices	O
.	O

The	O
melanopsin	B-T103
-	O
mediated	O
response	O
,	O
as	O
measured	O
by	O
the	O
pupil	B-T033
'	I-T033
s	I-T033
sustained	I-T033
constriction	I-T033
six	O
s	O
after	O
a	O
high	O
intensity	O
blue	O
light	O
stimulus	O
,	O
was	O
marginally	O
attenuated	O
in	O
those	O
with	O
MDD	B-T038
relative	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
071	O
)	O
.	O

The	O
participants	O
with	O
MDD	B-T038
unexpectedly	O
showed	O
a	O
significantly	O
reduced	O
transient	O
pupillary	O
response	O
to	O
low	O
intensity	O
red	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
and	O
blue	O
light	O
(	O
p	O
=	O
0	O
.	O
013	O
)	O
,	O
but	O
not	O
high	O
intensity	O
red	O
and	O
blue	O
light	O
.	O

Sustained	O
pupillary	B-T038
constriction	I-T038
in	O
response	O
to	O
high	O
intensity	O
blue	O
light	O
was	O
more	O
pronounced	O
with	O
increasing	O
daylight	O
hours	O
(	O
p	O
=	O
0	O
.	O
037	O
)	O
and	O
was	O
more	O
strongly	O
related	O
to	O
objectively	O
measured	O
versus	O
estimated	O
light	O
exposure	O
.	O

Melanopsin	B-T103
-	O
mediated	O
impairments	O
in	O
pupil	O
response	O
may	O
serve	O
as	O
a	O
biological	B-T201
marker	I-T201
for	O
vulnerability	O
to	O
depression	B-T038
in	O
low	O
light	O
conditions	O
.	O

Assessment	B-T058
of	O
these	O
and	O
other	O
responses	O
to	O
light	O
stimuli	O
,	O
such	O
as	O
response	O
to	O
low	O
intensity	O
light	O
,	O
may	O
be	O
useful	O
for	O
the	O
study	B-T062
of	O
the	O
neurobiology	B-T091
of	O
MDD	B-T038
and	O
related	O
mood	B-T038
disorders	I-T038
.	O

Long	B-T103
Noncoding	I-T103
RNAs	I-T103
in	O
Cardiovascular	B-T038
Pathology	I-T038
,	O
Diagnosis	B-T062
,	O
and	O
Therapy	B-T058

Vast	O
parts	O
of	O
mammalian	B-T204
genomes	B-T017
encode	O
for	O
transcripts	B-T103
that	O
are	O
not	O
further	O
translated	B-T038
into	I-T038
proteins	I-T038
.	O

The	O
purpose	O
of	O
the	O
majority	O
of	O
such	O
noncoding	B-T103
ribonucleic	I-T103
acids	I-T103
(	B-T103
RNAs	I-T103
)	I-T103
remained	O
paradoxical	O
for	O
a	O
long	O
time	O
.	O

However	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
demonstrates	O
that	O
long	B-T103
noncoding	I-T103
RNAs	I-T103
are	O
dynamically	O
expressed	B-T038
in	O
different	O
cell	B-T017
types	I-T017
,	O
diseases	B-T038
,	O
or	O
developmental	O
stages	O
to	O
execute	O
a	O
wide	O
variety	O
of	O
regulatory	O
roles	O
at	O
virtually	O
every	O
step	O
of	O
gene	B-T038
expression	I-T038
and	O
translation	B-T038
.	O

Indeed	O
,	O
long	B-T103
noncoding	I-T103
RNAs	I-T103
influence	O
gene	B-T038
expression	I-T038
via	O
epigenetic	B-T038
modulations	I-T038
,	O
through	O
regulating	B-T038
alternative	B-T038
splicing	I-T038
,	O
or	O
by	O
acting	O
as	O
molecular	O
sponges	O
.	O

The	O
abundance	O
of	O
long	B-T103
noncoding	I-T103
RNAs	I-T103
in	O
the	O
cardiovascular	B-T022
system	I-T022
indicates	O
that	O
they	O
may	O
be	O
part	O
of	O
a	O
complex	O
regulatory	B-T038
network	I-T038
governing	O
physiology	O
and	O
pathology	B-T038
of	O
the	O
heart	B-T017
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
multifaceted	B-T082
functions	O
of	O
long	B-T103
noncoding	I-T103
RNAs	I-T103
and	O
highlight	O
the	O
current	B-T170
literature	I-T170
with	O
an	O
emphasis	O
on	O
cardiac	B-T038
development	I-T038
and	O
disease	B-T038
.	O

Furthermore	B-T082
,	O
as	O
the	O
enormous	O
spectrum	O
of	O
long	B-T103
noncoding	I-T103
RNAs	I-T103
potentially	O
opens	O
up	O
new	O
avenues	O
for	O
diagnosis	B-T062
and	O
prevention	B-T058
of	O
heart	B-T038
failure	I-T038
,	O
we	O
ultimately	O
evaluate	O
the	O
futuristic	O
prospects	O
of	O
long	B-T103
noncoding	I-T103
RNAs	I-T103
as	O
biomarkers	B-T201
,	O
and	O
therapeutic	O
targets	B-T103
for	O
the	O
treatment	B-T058
of	O
cardiovascular	B-T038
disorders	I-T038
,	O
as	O
well	O
.	O

Flexible	O
Coordination	O
of	O
Stationary	O
and	O
Mobile	O
Conversations	O
with	O
Gaze	B-T033
:	O
Resource	O
Allocation	O
among	O
Multiple	O
Joint	O
Activities	O

Gaze	B-T033
is	O
instrumental	O
in	O
coordinating	O
face	O
-	O
to	O
-	O
face	O
social	B-T033
interactions	I-T033
.	O

But	O
little	O
is	O
known	O
about	O
gaze	B-T033
use	O
when	O
social	B-T033
interactions	I-T033
co	O
-	O
occur	O
with	O
other	O
joint	O
activities	O
.	O

We	O
investigated	O
the	O
case	O
of	O
walking	O
while	O
talking	O
.	O

We	O
assessed	O
how	O
gaze	B-T033
gets	O
allocated	O
among	O
various	O
targets	B-T098
in	O
mobile	O
conversations	O
,	O
whether	O
allocation	O
of	O
gaze	B-T033
to	O
other	O
targets	B-T098
affects	B-T038
conversational	O
coordination	O
,	O
and	O
whether	O
reduced	O
availability	O
of	O
gaze	B-T033
for	O
conversational	O
coordination	O
affects	B-T038
conversational	O
performance	O
and	O
content	O
.	O

In	O
an	O
experimental	B-T062
study	I-T062
,	O
pairs	O
were	O
videotaped	O
in	O
four	O
conditions	O
of	O
mobility	B-T033
(	O
standing	B-T082
still	I-T082
,	O
talking	O
while	O
walking	B-T058
along	I-T058
a	I-T058
straight	I-T058
-	I-T058
line	I-T058
itinerary	I-T058
,	O
talking	O
while	O
walking	O
along	O
a	O
complex	O
itinerary	O
,	O
or	O
walking	O
along	O
a	O
complex	O
itinerary	O
with	O
no	B-T033
conversational	I-T033
task	O
)	O
.	O

Gaze	B-T033
to	O
partners	B-T098
was	O
substantially	O
reduced	O
in	O
mobile	O
conversations	O
,	O
but	O
gaze	B-T033
was	O
still	O
used	O
to	O
coordinate	O
conversation	O
via	O
displays	O
of	O
mutual	O
orientation	B-T082
,	O
and	O
conversational	O
performance	O
and	O
content	O
was	O
not	O
different	O
between	O
stationary	O
and	O
mobile	O
conditions	O
.	O

Results	B-T033
expand	O
the	O
phenomena	O
of	O
multitasking	O
to	O
joint	O
activities	O
.	O

Sepsis	B-T038
Clinical	O
Criteria	O
in	O
Emergency	B-T092
Department	I-T092
Patients	O
Admitted	B-T058
to	O
an	O
Intensive	B-T092
Care	I-T092
Unit	I-T092
:	O
An	O
External	B-T062
Validation	I-T062
Study	I-T062
of	O
Quick	B-T033
Sequential	I-T033
Organ	I-T033
Failure	I-T033
Assessment	I-T033

Quick	B-T033
Sequential	I-T033
Organ	I-T033
Failure	I-T033
Assessment	I-T033
(	O
qSOFA	B-T033
)	O
is	O
a	O
prognostic	O
score	O
for	O
patients	O
with	O
sepsis	B-T038
.	O

Our	O
aim	O
was	O
to	O
compare	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
(	O
AUROC	O
)	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
of	O
qSOFA	B-T033
vs	O
.	O

systemic	B-T038
inflammation	I-T038
response	I-T038
syndrome	I-T038
(	O
SIRS	B-T038
)	O
in	O
predicting	O
in	O
-	O
hospital	O
mortality	O
among	O
emergency	B-T092
department	I-T092
(	O
ED	B-T092
)	O
patients	O
with	O
suspected	B-T038
infection	I-T038
admitted	B-T058
to	O
intensive	B-T092
care	I-T092
units	I-T092
(	O
ICUs	B-T092
)	O
.	O

We	O
conducted	O
a	O
retrospective	B-T062
cohort	I-T062
chart	I-T062
review	I-T062
study	I-T062
of	O
ED	B-T092
patients	O
admitted	B-T058
to	O
an	O
ICU	B-T092
with	O
suspected	B-T038
infection	I-T038
from	O
August	O
1	O
,	O
2012	O
to	O
February	O
28	O
,	O
2015	O
.	O

We	O
included	O
all	O
patients	O
with	O
body	B-T031
fluid	I-T031
cultures	I-T031
sampled	I-T031
either	O
during	O
their	O
ED	B-T092
stay	O
without	O
antibiotic	B-T058
administration	I-T058
or	O
within	O
24	O
h	O
of	O
antibiotics	B-T058
administered	I-T058
in	O
the	O
ED	B-T092
.	O

Trained	B-T097
chart	I-T097
abstractors	I-T097
blinded	O
to	O
the	O
study	B-T062
hypothesis	O
double	O
-	O
entered	O
data	O
from	O
each	O
patient	O
'	O
s	O
electronic	B-T170
medical	I-T170
record	I-T170
including	O
demographic	O
characteristics	O
,	O
vital	B-T201
signs	I-T201
,	O
laboratory	B-T058
study	I-T058
results	I-T058
,	O
physical	B-T058
examination	I-T058
findings	B-T033
,	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

We	O
then	O
calculated	O
the	O
AUROC	O
,	O
sensitivity	O
,	O
specificity	O
,	O
and	O
likelihood	O
ratios	O
for	O
qSOFA	B-T033
and	O
SIRS	B-T038
for	O
predicting	O
in	O
-	O
hospital	O
mortality	O
.	O

Of	O
214	O
patients	O
admitted	B-T058
to	O
an	O
ICU	B-T092
with	O
presumed	B-T038
sepsis	I-T038
,	O
39	O
(	O
18	O
.	O
2	O
%	O
)	O
died	O
during	O
hospitalization	O
.	O

The	O
AUROC	O
value	O
was	O
0	O
.	O
65	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
0	O
.	O
56	O
-	O
0	O
.	O
74	O
)	O
for	O
SIRS	B-T038
vs	O
.	O

0	O
.	O
66	O
(	O
95	O
%	O
CI	O
0	O
.	O
57	O
-	O
0	O
.	O
76	O
)	O
for	O
qSOFA	B-T033
;	O
2	O
+	O
qSOFA	B-T033
criteria	O
predicted	O
in	O
-	O
hospital	O
mortality	O
with	O
89	O
.	O
7	O
%	O
sensitivity	O
,	O
27	O
.	O
4	O
%	O
specificity	O
,	O
1	O
.	O
2	O
positive	O
likelihood	O
ratio	O
,	O
and	O
0	O
.	O
4	O
negative	O
likelihood	O
ratio	O
.	O

Among	O
ED	B-T092
patients	O
admitted	B-T058
to	O
an	O
ICU	B-T092
,	O
the	O
SIRS	B-T038
and	O
qSOFA	B-T033
criteria	O
had	O
comparable	O
prognostic	O
value	O
for	O
predicting	O
in	O
-	O
hospital	O
mortality	O
.	O

These	O
prognostic	O
values	O
are	O
similar	O
to	O
those	O
reported	O
by	O
the	O
Sepsis	B-T170
-	I-T170
3	I-T170
guidelines	I-T170
for	O
ICU	B-T092
encounters	B-T170
.	O

Repetitive	B-T058
transcranial	I-T058
magnetic	I-T058
stimulation	I-T058
improves	O
cognitive	B-T038
function	I-T038
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
patients	O

Repetitive	B-T058
transcranial	I-T058
magnetic	I-T058
stimulation	I-T058
(	O
rTMS	B-T058
)	O
acts	O
as	O
a	O
kind	O
of	O
widely	O
-	O
applied	O
and	O
non	O
-	O
invasive	O
method	O
in	O
the	O
intervention	B-T058
of	O
some	O
neurological	B-T038
disorders	I-T038
.	O

This	O
prospective	B-T062
,	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	B-T062
-	I-T062
controlled	I-T062
trial	I-T062
investigates	O
the	O
effect	O
of	O
rTMS	B-T058
on	O
30	O
cases	O
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
participants	B-T098
,	O
who	O
were	O
classified	O
into	O
mild	O
and	O
moderate	O
groups	B-T098
.	O

Neuropsychological	B-T058
tests	I-T058
were	O
carried	O
out	O
using	O
the	O
AD	B-T170
Assessment	I-T170
Scale	I-T170
-	O
cognitive	B-T170
subscale	I-T170
(	O
ADAS	B-T170
-	O
cog	B-T170
)	O
,	O
Mini	B-T058
-	I-T058
Mental	I-T058
State	I-T058
Examination	I-T058
(	O
MMSE	B-T058
)	O
,	O
Montreal	B-T170
Cognitive	I-T170
Assessment	I-T170
(	O
MoCA	B-T170
)	O
,	O
and	O
World	B-T170
Health	I-T170
Organization	I-T170
University	I-T170
of	I-T170
California	I-T170
-	I-T170
Los	I-T170
Angeles	I-T170
,	I-T170
Auditory	I-T170
Verbal	I-T170
Learning	I-T170
Test	I-T170
(	O
WHO	B-T170
-	I-T170
UCLA	I-T170
AVLT	I-T170
)	O
before	O
,	O
immediately	O
after	O
,	O
and	O
6	O
weeks	O
after	O
the	O
intervention	B-T058
.	O

In	O
this	O
work	O
,	O
data	O
from	O
30	O
AD	B-T038
patients	O
revealed	O
that	O
there	O
was	O
no	O
obvious	O
interaction	O
effect	O
of	O
time	O
-	O
by	O
-	O
group	O
.	O

The	O
ADAS	B-T170
-	O
cog	B-T170
,	O
MMSE	B-T058
and	O
WHO	B-T170
-	I-T170
UCLA	I-T170
AVLT	I-T170
score	O
in	O
the	O
rTMS	B-T058
group	B-T098
was	O
significantly	O
improved	O
compared	O
with	O
baselines	O
at	O
6	O
weeks	O
after	O
treatment	B-T058
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Meanwhile	O
,	O
MoCA	B-T170
scores	O
were	O
also	O
obviously	O
ameliorated	B-T033
in	O
the	O
mild	O
AD	B-T038
patients	O
with	O
rTMS	B-T058
.	O

Besides	O
,	O
subgroup	B-T062
analysis	I-T062
showed	O
that	O
the	O
effect	O
of	O
rTMS	B-T058
on	O
the	O
memory	B-T038
and	O
language	O
of	O
mild	O
AD	B-T038
patients	O
was	O
superior	O
to	O
those	O
of	O
moderate	O
AD	B-T038
patients	O
.	O

In	O
conclusion	O
,	O
our	O
findings	B-T033
suggested	O
that	O
repetitive	B-T058
transcranial	I-T058
magnetic	I-T058
stimulation	I-T058
improves	O
cognitive	B-T038
function	I-T038
,	O
memory	B-T038
and	O
language	O
level	O
of	O
AD	B-T038
patients	O
,	O
especially	O
in	O
the	O
mild	O
stage	O
of	O
AD	B-T038
.	O

Thus	O
,	O
rTMS	B-T058
can	O
be	O
recommended	O
as	O
a	O
promising	O
adjuvant	B-T058
therapy	I-T058
combined	O
with	O
cholinesterase	B-T103
inhibitors	I-T103
at	O
the	O
mild	O
stage	O
of	O
AD	B-T038
patients	O
.	O

A	O
Novel	O
Insulin	O
/	O
Glucose	O
Model	B-T170
after	O
a	O
Mixed	B-T058
-	I-T058
Meal	I-T058
Test	I-T058
in	O
Patients	O
with	O
Type	B-T038
1	I-T038
Diabetes	I-T038
on	O
Insulin	B-T074
Pump	I-T074
Therapy	B-T058

Current	O
closed	B-T074
-	I-T074
loop	I-T074
insulin	I-T074
delivery	I-T074
methods	I-T074
stem	O
from	O
sophisticated	O
models	O
of	O
the	O
glucose	O
-	O
insulin	O
(	O
G	O
/	O
I	O
)	O
system	O
,	O
mostly	O
based	O
on	O
complex	O
studies	B-T062
employing	B-T033
glucose	O
tracer	O
technology	O
.	O

We	O
tested	O
the	O
performance	O
of	O
a	O
new	O
minimal	B-T170
model	I-T170
(	O
GLUKINSLOOP	B-T170
2	I-T170
.	I-T170
0	I-T170
)	O
of	O
the	O
G	O
/	O
I	O
system	O
to	O
characterize	O
the	O
glucose	O
and	O
insulin	O
dynamics	O
during	O
multiple	O
mixed	B-T058
meal	I-T058
tests	I-T058
(	O
MMT	B-T058
)	O
of	O
different	O
sizes	B-T082
in	O
patients	O
with	O
type	B-T038
1	I-T038
diabetes	I-T038
(	O
T1D	B-T038
)	O
on	O
insulin	B-T074
pump	I-T074
therapy	B-T058
(	O
continuous	B-T058
subcutaneous	I-T058
insulin	I-T058
infusion	I-T058
,	O
CSII	B-T058
)	O
.	O

The	O
GLUKINSLOOP	B-T170
2	I-T170
.	I-T170
0	I-T170
identified	O
the	O
G	O
/	O
I	O
system	O
,	O
provided	O
a	O
close	O
fit	O
of	O
the	O
G	O
/	O
I	O
time	O
-	O
courses	O
and	O
showed	O
acceptable	O
reproducibility	O
of	O
the	O
G	O
/	O
I	O
system	O
parameters	B-T033
in	O
repeated	O
studies	B-T062
of	O
identical	O
and	O
double	O
-	O
sized	O
MMTs	B-T058
.	O

This	O
model	B-T170
can	O
provide	O
a	O
fairly	O
good	O
and	O
reproducible	O
description	B-T170
of	O
the	O
G	O
/	O
I	O
system	O
in	O
T1D	B-T038
patients	O
on	O
CSII	B-T058
,	O
and	O
it	O
may	O
be	O
applied	O
to	O
create	O
a	O
bank	O
of	O
"	B-T058
virtual	I-T058
"	I-T058
patients	I-T058
.	O

Our	O
results	B-T033
might	O
be	O
relevant	O
at	O
improving	O
the	O
architecture	O
of	O
upcoming	O
closed	O
-	O
loop	O
CSII	B-T058
systems	O
.	O

Impact	O
of	O
Strategically	O
Located	O
White	B-T038
Matter	I-T038
Hyperintensities	I-T038
on	O
Cognition	B-T038
in	O
Memory	B-T092
Clinic	I-T092
Patients	O
with	O
Small	B-T038
Vessel	I-T038
Disease	I-T038

Studies	O
on	O
the	O
impact	O
of	O
small	B-T038
vessel	I-T038
disease	I-T038
(	O
SVD	B-T038
)	O
on	O
cognition	B-T038
generally	O
focus	B-T082
on	O
white	B-T038
matter	I-T038
hyperintensity	I-T038
(	O
WMH	B-T038
)	O
volume	O
.	O

The	O
extent	B-T082
to	O
which	O
WMH	B-T038
location	B-T082
relates	O
to	O
cognitive	B-T038
performance	I-T038
has	O
received	O
less	O
attention	B-T038
,	O
but	O
is	O
likely	O
to	O
be	O
functionally	O
important	O
.	O

We	O
examined	O
the	O
relation	O
between	O
WMH	B-T038
location	B-T082
and	O
cognition	B-T038
in	O
a	O
memory	B-T092
clinic	I-T092
cohort	B-T098
of	O
patients	O
with	O
sporadic	O
SVD	B-T038
.	O

A	O
total	O
of	O
167	O
patients	O
with	O
SVD	B-T038
were	O
recruited	O
from	O
memory	B-T092
clinics	I-T092
.	O

Assumption	B-T062
-	I-T062
free	I-T062
region	I-T062
of	I-T062
interest	I-T062
-	I-T062
based	I-T062
analyses	I-T062
based	O
on	O
major	O
white	B-T017
matter	I-T017
tracts	B-T017
and	O
voxel	O
-	O
wise	O
analyses	B-T062
were	O
used	O
to	O
determine	O
the	O
association	O
between	O
WMH	B-T038
location	B-T082
and	O
executive	B-T038
functioning	I-T038
,	O
visuomotor	B-T038
speed	I-T038
and	O
memory	B-T038
.	O

Region	B-T062
of	I-T062
interest	I-T062
-	I-T062
based	I-T062
analyses	I-T062
showed	O
that	O
WMHs	B-T038
located	B-T082
particularly	O
within	B-T082
the	O
anterior	B-T017
thalamic	I-T017
radiation	I-T017
and	O
forceps	B-T017
minor	I-T017
were	O
inversely	O
associated	O
with	O
both	O
executive	B-T038
functioning	I-T038
and	O
visuomotor	B-T038
speed	I-T038
,	O
independent	O
of	O
total	O
WMH	B-T038
volume	O
.	O

Memory	B-T038
was	O
significantly	O
associated	O
with	O
WMH	B-T038
volume	O
in	O
the	O
forceps	B-T017
minor	I-T017
,	O
independent	O
of	O
total	O
WMH	B-T038
volume	O
.	O

An	O
independent	B-T062
assumption	I-T062
-	I-T062
free	I-T062
voxel	I-T062
-	I-T062
wise	I-T062
analysis	I-T062
identified	O
strategic	O
voxels	O
in	O
these	O
same	O
tracts	B-T017
.	O

Region	B-T062
of	I-T062
interest	I-T062
-	I-T062
based	I-T062
analyses	I-T062
showed	O
that	O
WMH	B-T038
volume	O
within	B-T082
the	O
anterior	B-T017
thalamic	I-T017
radiation	I-T017
explained	O
6	O
.	O
8	O
%	O
of	O
variance	O
in	O
executive	B-T038
functioning	I-T038
,	O
compared	O
to	O
3	O
.	O
9	O
%	O
for	O
total	O
WMH	B-T038
volume	O
;	O
WMH	B-T038
volume	O
within	B-T082
the	O
forceps	B-T017
minor	I-T017
explained	O
4	O
.	O
6	O
%	O
of	O
variance	O
in	O
visuomotor	B-T038
speed	I-T038
and	O
4	O
.	O
2	O
%	O
of	O
variance	O
in	O
memory	B-T038
,	O
compared	O
to	O
1	O
.	O
8	O
%	O
and	O
1	O
.	O
3	O
%	O
respectively	O
for	O
total	O
WMH	B-T038
volume	O
.	O

Our	O
findings	B-T033
identify	O
the	O
anterior	B-T017
thalamic	I-T017
radiation	I-T017
and	O
forceps	B-T017
minor	I-T017
as	O
strategic	O
white	B-T017
matter	I-T017
tracts	B-T017
in	O
which	O
WMHs	B-T038
are	O
most	O
strongly	O
associated	O
with	O
cognitive	B-T038
impairment	I-T038
in	O
memory	B-T092
clinic	I-T092
patients	O
with	O
SVD	B-T038
.	O

WMH	B-T038
volumes	O
in	O
individual	O
tracts	B-T017
explained	O
more	O
variance	O
in	O
cognition	B-T038
than	O
total	O
WMH	B-T038
burden	O
,	O
emphasizing	O
the	O
importance	O
of	O
lesion	O
location	O
when	O
addressing	O
the	O
functional	O
consequences	O
of	O
WMHs	B-T038
.	O

Natural	O
competence	O
for	O
transformation	B-T038

While	O
most	O
molecular	O
biologists	O
are	O
familiar	O
with	O
the	O
artificial	O
transformation	B-T038
of	I-T038
bacteria	I-T038
in	O
the	O
context	O
of	O
laboratory	B-T092
cloning	B-T062
experiments	B-T062
,	O
natural	O
competence	O
for	O
transformation	B-T038
refers	O
to	O
a	O
specific	O
physiological	O
state	O
in	O
which	O
prokaryotes	O
are	O
able	O
to	O
take	O
up	O
genetic	B-T017
material	I-T017
from	O
their	O
surroundings	B-T082
.	O

Occasionally	O
,	O
such	O
absorbed	O
DNA	B-T103
is	O
recombined	O
into	O
the	O
organism	O
'	O
s	O
own	O
genome	B-T017
,	O
resulting	O
in	O
natural	O
transformation	B-T038
(	O
Figure	O
1	O
)	O
.	O

As	O
a	O
consequence	O
,	O
natural	O
competence	O
for	O
transformation	B-T038
is	O
considered	O
a	O
primary	O
mode	O
of	O
horizontal	B-T038
gene	I-T038
transfer	I-T038
(	O
HGT	B-T038
)	O
in	O
prokaryotes	O
,	O
together	O
with	O
conjugation	B-T038
(	O
direct	O
cell	B-T017
to	O
cell	B-T017
transfer	O
of	O
DNA	B-T103
via	O
a	O
specialized	O
conjugal	B-T017
pilus	I-T017
)	O
and	O
phage	B-T005
transduction	B-T038
(	O
DNA	B-T103
transfer	O
mediated	O
by	O
viruses	B-T005
)	O
.	O

HGT	B-T038
plays	O
a	O
major	O
role	O
in	O
bacterial	O
evolution	B-T038
,	O
and	O
past	O
research	B-T062
has	O
demonstrated	O
that	O
HGT	B-T038
,	O
including	O
natural	O
competence	O
for	O
transformation	B-T038
,	O
contributes	O
to	O
the	O
emergence	O
of	O
pathogens	O
and	O
the	O
spread	O
of	O
virulence	B-T103
factors	I-T103
.	O

Indeed	O
,	O
Frederick	O
Griffith	O
discovered	O
natural	O
competence	O
for	O
transformation	B-T038
in	O
1928	O
while	O
he	O
was	O
investigating	O
the	O
exchange	B-T038
of	O
pathogenic	B-T033
traits	O
in	O
pneumococci	B-T007
.	O

Due	O
to	O
the	O
increase	O
in	O
the	O
abundance	O
and	O
spread	O
of	O
multidrug	B-T007
-	I-T007
resistant	I-T007
microbes	I-T007
,	O
research	B-T062
on	O
HGT	B-T038
is	O
even	O
more	O
important	O
today	O
than	O
ever	O
before	O
.	O

Three	O
-	O
dimensional	O
constructive	O
interference	O
in	O
steady	O
-	O
state	O
(	O
3D	O
-	O
CISS	O
)	O
sequences	O
and	O
Phase	B-T058
-	I-T058
contrast	I-T058
MRI	I-T058
of	O
arrested	B-T038
hydrocephalus	I-T038

to	O
evaluate	O
role	O
of	O
three	O
-	O
dimensional	O
constructive	O
interference	O
in	O
steady	O
-	O
state	O
(	O
3D	O
-	O
CISS	O
)	O
sequences	O
and	O
phase	B-T058
-	I-T058
contrast	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
(	O
PC	B-T058
-	I-T058
MRI	I-T058
)	O
in	O
patients	O
with	O
arrested	B-T038
hydrocephalus	I-T038
.	O

Prospective	B-T062
study	I-T062
was	O
conducted	O
on	O
20	O
patients	O
with	O
arrested	B-T038
hydrocephalus	I-T038
.	O

All	O
patients	O
underwent	O
PC	B-T058
-	I-T058
MRI	I-T058
and	O
3D	O
-	O
CISS	O
for	O
assessment	B-T058
of	O
the	O
aqueduct	B-T082
.	O

Axial	B-T082
(	O
through	O
-	O
plane	O
)	O
,	O
sagittal	B-T082
(	O
in	O
-	O
plane	O
)	O
PC	B-T058
-	I-T058
MRI	I-T058
and	O
sagittal	B-T082
3D	O
-	O
CISS	O
were	O
applied	O
to	O
assess	O
the	O
cerebral	B-T082
aqueduct	I-T082
and	O
the	O
spontaneous	O
third	O
ventriculostomy	O
if	O
present	O
.	O

Aqueductal	B-T082
patency	B-T082
was	O
graded	B-T170
using	O
3D	O
-	O
CISS	O
and	O
PC	B-T058
-	I-T058
MRI	I-T058
.	O

Quantitative	B-T058
analysis	I-T058
of	O
flow	O
through	O
the	O
aqueduct	B-T082
was	O
done	O
using	O
PC	B-T058
-	I-T058
MRI	I-T058
.	O

The	O
causes	O
of	O
obstruction	B-T038
were	O
aqueductal	B-T082
obstruction	B-T038
in	O
75	O
%	O
(	O
n	O
=	O
15	O
)	O
,	O
3rd	O
ventricular	B-T038
obstruction	I-T038
in	O
5	O
%	O
(	O
n	O
=	O
1	O
)	O
and	O
4th	O
ventricular	B-T038
obstruction	I-T038
in	O
20	O
%	O
(	O
n	O
=	O
4	O
)	O
.	O

The	O
cause	O
of	O
arrest	O
of	O
hydrocephalus	B-T038
was	O
spontaneous	O
third	O
ventriculostomy	O
in	O
65	O
%	O
(	O
n	O
=	O
13	O
)	O
,	O
endoscopic	B-T058
third	I-T058
ventriculostomy	I-T058
in	O
10	O
%	O
(	O
n	O
=	O
2	O
)	O
,	O
ventriculo	B-T074
-	I-T074
peritoneal	I-T074
shunt	I-T074
in	O
5	O
%	O
(	O
n	O
=	O
1	O
)	O
and	O
no	O
cause	O
could	O
be	O
detected	B-T033
in	O
20	O
%	O
of	O
patients	O
(	O
n	O
=	O
4	O
)	O
.	O

There	O
is	O
a	O
positive	B-T033
correlation	O
(	O
r	O
=	O
0	O
.	O
80	O
)	O
and	O
moderate	O
agreement	O
(	O
κ	O
=	O
0	O
.	O
509	O
)	O
of	O
grading	B-T170
with	O
PC	B-T058
-	I-T058
MRI	I-T058
and	O
3D	O
-	O
CISS	O
sequences	O
.	O

The	O
mean	O
peak	O
systolic	O
velocity	O
of	O
CSF	B-T031
was	O
1	O
.	O
86	O
±	O
2	O
.	O
48	O
cm	O
/	O
sec	O
,	O
the	O
stroke	B-T201
volume	I-T201
was	O
6	O
.	O
43	O
±	O
13	O
.	O
81μl	O
/	O
cycle	O
,	O
and	O
the	O
mean	O
flow	O
was	O
0	O
.	O
21	O
±	O
0	O
.	O
32	O
ml	O
/	O
min	O
.	O

We	O
concluded	O
that	O
3D	O
-	O
CISS	O
and	O
PC	B-T058
-	I-T058
MRI	I-T058
are	O
non	O
-	O
invasive	O
sequences	O
for	O
diagnosis	B-T033
of	O
the	O
level	O
and	O
cause	O
of	O
arrested	B-T038
hydrocephalus	I-T038
.	O

Historical	O
Environment	B-T082
Is	O
Reflected	O
in	O
Modern	O
Population	O
Genetics	O
and	O
Biogeography	O
of	O
an	O
Island	B-T082
Endemic	O
Lizard	B-T204
(	O
Xantusia	B-T204
riversiana	I-T204
reticulata	I-T204
)	O

The	O
restricted	O
distribution	O
and	O
isolation	O
of	O
island	B-T082
endemics	O
often	O
produces	O
unique	O
genetic	O
and	O
phenotypic	O
diversity	O
of	O
conservation	O
interest	O
to	O
management	O
agencies	B-T092
.	O

However	O
,	O
these	O
isolated	O
species	B-T170
,	O
especially	O
those	O
with	O
sensitive	O
life	O
history	O
traits	O
,	O
are	O
at	O
high	B-T033
risk	I-T033
for	O
the	O
adverse	B-T038
effects	I-T038
of	O
genetic	B-T038
drift	I-T038
and	O
habitat	B-T082
degradation	O
by	O
non	B-T204
-	I-T204
native	I-T204
wildlife	I-T204
.	O

Here	O
,	O
we	O
study	B-T062
the	O
population	B-T098
genetic	O
diversity	O
,	O
structure	B-T082
,	O
and	O
stability	O
of	O
a	O
classic	O
"	O
island	B-T204
giant	I-T204
"	O
(	O
Xantusia	B-T204
riversiana	I-T204
,	O
the	O
Island	B-T204
Night	I-T204
Lizard	I-T204
)	O
on	O
San	B-T082
Clemente	I-T082
Island	I-T082
,	O
California	B-T082
following	O
the	O
removal	O
of	O
feral	B-T204
goats	I-T204
.	O

Using	O
DNA	B-T103
microsatellites	B-T103
,	O
we	O
found	O
that	O
this	O
population	B-T098
is	O
reasonably	O
genetically	O
robust	O
despite	O
historical	O
grazing	B-T038
,	O
with	O
similar	O
effective	O
population	O
sizes	O
and	O
genetic	O
diversity	O
metrics	O
across	O
all	O
sampling	O
locations	B-T082
irrespective	O
of	O
habitat	B-T082
type	O
and	O
degree	O
of	O
degradation	O
.	O

However	O
,	O
we	O
also	O
found	O
strong	O
site	B-T082
-	I-T082
specific	I-T082
patterns	B-T082
of	O
genetic	O
variation	O
and	O
low	O
genetic	O
diversity	O
compared	O
to	O
mainland	B-T204
congeners	I-T204
,	O
warranting	O
continued	O
special	O
management	O
as	O
an	O
island	B-T082
endemic	O
.	O

We	O
identify	O
both	O
high	O
and	O
low	O
elevation	B-T082
areas	I-T082
that	O
remain	O
valuable	O
repositories	O
of	O
genetic	O
diversity	O
and	O
provide	O
a	O
case	B-T170
study	I-T170
for	O
other	O
low	O
-	O
dispersal	O
coastal	B-T082
organisms	O
in	O
the	O
face	O
of	O
future	O
climate	O
change	O
.	O

Cross	O
-	O
Species	O
Rhesus	B-T204
Cytomegalovirus	B-T038
Infection	I-T038
of	O
Cynomolgus	B-T204
Macaques	I-T204

Cytomegaloviruses	B-T005
(	O
CMV	B-T005
)	O
are	O
highly	O
species	O
-	O
specific	O
due	O
to	O
millennia	O
of	O
co	B-T038
-	I-T038
evolution	I-T038
and	O
adaptation	B-T038
to	O
their	O
host	O
,	O
with	O
no	O
successful	O
experimental	O
cross	O
-	O
species	B-T170
infection	B-T038
in	O
primates	B-T204
reported	O
to	O
date	O
.	O

Accordingly	O
,	O
full	O
genome	B-T017
phylogenetic	B-T062
analysis	I-T062
of	O
multiple	O
new	O
CMV	B-T005
field	O
isolates	B-T103
derived	O
from	O
two	O
closely	O
related	O
nonhuman	B-T204
primate	I-T204
species	B-T170
,	O
Indian	B-T033
-	I-T033
origin	I-T033
rhesus	B-T204
macaques	I-T204
(	O
RM	B-T204
)	O
and	O
Mauritian	B-T082
-	O
origin	O
cynomolgus	B-T204
macaques	I-T204
(	O
MCM	B-T204
)	O
,	O
revealed	O
distinct	O
and	O
tight	O
lineage	O
clustering	O
according	O
to	O
the	O
species	B-T033
of	I-T033
origin	I-T033
,	O
with	O
MCM	B-T204
CMV	B-T005
isolates	B-T103
mirroring	O
the	O
limited	O
genetic	O
diversity	O
of	O
their	O
primate	B-T204
host	O
that	O
underwent	O
a	O
population	O
bottleneck	O
400	O
years	O
ago	O
.	O

Despite	O
the	O
ability	O
of	O
Rhesus	B-T204
CMV	B-T005
(	O
RhCMV	B-T005
)	O
laboratory	B-T017
strain	I-T017
68	O
-	O
1	O
to	O
replicate	O
efficiently	O
in	O
MCM	B-T204
fibroblasts	B-T017
and	O
potently	O
inhibit	B-T038
antigen	I-T038
presentation	I-T038
to	O
MCM	B-T204
T	B-T017
cells	I-T017
in	O
vitro	O
,	O
RhCMV	B-T005
68	O
-	O
1	O
failed	O
to	O
productively	O
infect	B-T038
MCM	B-T204
in	B-T082
vivo	I-T082
,	O
even	O
in	O
the	O
absence	O
of	O
host	O
CD8	B-T017
+	I-T017
T	I-T017
and	O
NK	B-T017
cells	I-T017
.	O

In	O
contrast	O
,	O
RhCMV	B-T005
clone	B-T017
68	O
-	O
1	O
.	O
2	O
,	O
genetically	O
repaired	B-T058
to	O
express	B-T038
the	O
homologues	B-T017
of	O
the	O
HCMV	B-T005
anti	B-T038
-	I-T038
apoptosis	I-T038
gene	B-T103
UL36	I-T103
and	O
epithelial	B-T038
cell	I-T038
tropism	I-T038
genes	B-T103
UL128	I-T103
and	O
UL130	B-T103
absent	O
in	O
68	O
-	O
1	O
,	O
efficiently	O
infected	B-T038
MCM	B-T098
as	O
evidenced	O
by	O
the	O
induction	B-T038
of	O
transgene	B-T017
-	O
specific	O
T	B-T017
cells	I-T017
and	O
virus	B-T038
shedding	I-T038
.	O

Recombinant	B-T103
variants	I-T103
of	O
RhCMV	B-T005
68	O
-	O
1	O
and	O
68	O
-	O
1	O
.	O
2	O
revealed	O
that	O
expression	B-T038
of	O
either	O
UL36	B-T103
or	O
UL128	B-T103
together	O
with	O
UL130	B-T103
enabled	O
productive	O
MCM	B-T098
infection	B-T038
,	O
indicating	O
that	O
multiple	O
layers	O
of	O
cross	O
-	O
species	B-T170
restriction	O
operate	O
even	O
between	O
closely	O
related	O
hosts	O
.	O

Cumulatively	O
,	O
these	O
results	O
implicate	O
cell	B-T038
tropism	I-T038
and	O
evasion	O
of	O
apoptosis	B-T038
as	O
critical	O
determinants	O
of	O
CMV	B-T005
transmission	B-T038
across	O
primate	B-T204
species	B-T170
barriers	O
,	O
and	O
extend	O
the	O
macaque	B-T204
model	B-T170
of	O
human	B-T204
CMV	B-T005
infection	B-T038
and	O
immunology	B-T091
to	O
MCM	B-T098
,	O
a	O
nonhuman	B-T204
primate	I-T204
species	B-T170
with	O
uniquely	O
simplified	O
host	O
immunogenetics	B-T091
.	O

Mildly	O
raised	O
tricuspid	O
regurgitant	O
velocity	O
2	O
.	O
5	O
-	O
3	O
.	O
0	O
m	O
/	O
s	O
in	O
pregnant	B-T098
women	I-T098
with	O
sickle	B-T038
cell	I-T038
disease	I-T038
is	O
not	O
associated	O
with	O
poor	O
obstetric	O
outcome	O
-	O
An	O
observational	B-T062
cross	I-T062
-	I-T062
sectional	I-T062
study	I-T062

Pulmonary	B-T038
hypertension	I-T038
is	O
associated	O
with	O
36	O
%	O
mortality	O
in	O
pregnancy	B-T038
,	O
and	O
6	O
-	O
10	O
%	O
of	O
patients	O
with	O
sickle	B-T038
cell	I-T038
disease	I-T038
have	O
pulmonary	B-T038
hypertension	I-T038
.	O

Tricuspid	O
regurgitant	O
velocity	O
≥2	O
.	O
5	O
m	O
/	O
s	O
on	O
echocardiography	B-T058
is	O
a	O
well	O
validated	O
means	O
of	O
screening	B-T058
for	O
pulmonary	B-T038
hypertension	I-T038
in	O
the	O
non	B-T033
-	I-T033
pregnant	I-T033
population	B-T098
.	O

This	O
is	O
a	O
pilot	B-T062
study	I-T062
to	O
determine	O
if	O
this	O
is	O
a	O
useful	O
non	O
-	O
invasive	O
screening	B-T058
test	I-T058
for	O
pulmonary	B-T038
hypertension	I-T038
in	O
pregnancy	B-T038
,	O
and	O
whether	O
raised	O
tricuspid	O
regurgitant	O
velocity	O
≥2	O
.	O
5	O
m	O
/	O
s	O
was	O
associated	O
with	O
poor	O
outcomes	O
.	O

This	O
is	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
over	O
a	O
five	O
-	O
year	O
period	O
in	O
a	O
tertiary	B-T092
referral	I-T092
centre	I-T092
with	O
a	O
specialised	O
multidisciplinary	B-T092
clinic	I-T092
for	O
pregnant	B-T098
women	I-T098
with	O
sickle	B-T038
cell	I-T038
disease	I-T038
.	O

Women	B-T098
with	O
sickle	B-T038
cell	I-T038
disease	I-T038
,	O
no	O
prior	O
pulmonary	B-T038
hypertension	I-T038
and	O
singleton	O
pregnancies	B-T038
who	O
had	O
echocardiography	B-T058
with	O
a	O
measurable	O
tricuspid	O
regurgitant	O
velocity	O
in	O
pregnancy	B-T038
were	O
included	O
.	O

There	O
were	O
34	O
pregnancies	B-T038
,	O
of	O
which	O
eight	O
had	O
tricuspid	O
regurgitant	O
velocity	O
≥2	O
.	O
5	O
m	O
/	O
s	O
.	O

There	O
were	O
no	B-T033
significant	I-T033
differences	O
in	O
their	O
characteristics	O
,	O
sickle	B-T017
cell	I-T017
-	O
related	O
complications	B-T038
or	O
medical	O
co	O
-	O
morbidities	O
.	O

The	O
women	B-T098
with	O
tricuspid	O
regurgitant	O
velocity	O
≥2	O
.	O
5	O
m	O
/	O
s	O
had	O
similar	O
obstetric	O
and	O
perinatal	O
outcomes	O
as	O
those	O
with	O
a	O
tricuspid	O
regurgitant	O
velocity	O
<	O
2	O
.	O
5	O
m	O
/	O
s	O
.	O

A	O
randomized	B-T062
trial	I-T062
of	O
TLR	B-T103
-	I-T103
2	I-T103
agonist	B-T103
CADI	B-T103
-	I-T103
05	I-T103
targeting	O
desmocollin	B-T103
-	I-T103
3	I-T103
for	O
advanced	O
non	B-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038

Randomized	B-T062
controlled	I-T062
trial	I-T062
to	O
evaluate	B-T058
synergy	B-T038
between	O
taxane	B-T103
plus	O
platinum	B-T103
chemotherapy	B-T058
and	O
CADI	B-T103
-	I-T103
05	I-T103
,	O
a	O
Toll	B-T103
like	I-T103
receptor	I-T103
-	I-T103
2	I-T103
agonist	B-T103
targeting	O
desmocollin	B-T103
-	I-T103
3	I-T103
as	O
a	O
first	B-T058
-	I-T058
line	I-T058
therapy	I-T058
in	O
advanced	O
non	B-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
(	O
NSCLC	B-T038
)	O
.	O

Patients	O
with	O
advanced	O
NSCLC	B-T038
(	O
stage	O
IIIB	O
or	O
IV	O
)	O
were	O
randomized	B-T033
to	O
cisplatin	B-T058
-	I-T058
paclitaxel	I-T058
(	O
chemotherapy	B-T058
group	O
,	O
N	O
=	O
112	O
)	O
or	O
cisplatin	B-T058
-	I-T058
paclitaxel	I-T058
plus	O
CADI	B-T103
-	I-T103
05	I-T103
(	O
chemoimmunotherapy	B-T058
group	O
,	O
N	O
=	O
109	O
)	O
.	O

CADI	B-T103
-	I-T103
05	I-T103
was	O
administered	O
a	O
week	O
before	O
chemotherapy	B-T058
and	O
on	O
days	O
8	O
and	O
15	O
of	O
each	O
cycle	B-T058
and	O
every	O
month	O
subsequently	O
for	O
12	O
months	O
or	O
disease	B-T038
progression	I-T038
.	O

Overall	O
survival	O
was	O
compared	O
using	O
a	O
log	B-T170
-	I-T170
rank	I-T170
test	I-T170
.	O

Computed	B-T058
tomography	I-T058
was	O
carried	O
out	O
at	O
baseline	O
,	O
end	O
of	O
two	O
cycles	B-T058
and	O
four	O
cycles	B-T058
.	O

Response	O
rate	O
was	O
evaluated	B-T058
using	O
Response	B-T170
Evaluation	I-T170
Criteria	I-T170
in	I-T170
Solid	I-T170
Tumors	I-T170
criteria	O
by	O
an	O
independent	B-T097
radiologist	I-T097
.	O

As	O
per	O
intention	B-T062
-	I-T062
to	I-T062
-	I-T062
treat	I-T062
analysis	I-T062
,	O
no	O
survival	O
benefit	O
was	O
observed	O
between	O
two	O
groups	O
[	O
208	O
versus	O
196	O
days	O
;	O
hazard	O
ratio	O
,	O
0	O
.	O
86	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
63	O
-	O
1	O
.	O
19	O
;	O
P	O
=	O
0	O
.	O
3804	O
]	O
.	O

In	O
a	O
subgroup	B-T062
analysis	I-T062
,	O
improvement	O
in	O
median	O
survival	O
by	O
127	O
days	O
was	O
observed	O
in	O
squamous	B-T038
NSCC	I-T038
with	O
chemoimmunotherapy	B-T058
(	O
hazard	O
ratio	O
,	O
0	O
.	O
55	O
;	O
95	O
%	O
CI	O
0	O
.	O
32	O
-	O
0	O
.	O
95	O
;	O
P	O
=	O
0	O
.	O
046	O
)	O
.	O

In	O
patients	O
receiving	O
planned	O
four	O
cycles	B-T058
of	O
chemotherapy	B-T058
,	O
there	O
was	O
improved	O
median	O
overall	O
survival	O
by	O
66	O
days	O
(	O
299	O
versus	O
233	O
days	O
;	O
hazard	O
ratio	O
,	O
0	O
.	O
64	O
;	O
95	O
%	O
CI	O
0	O
.	O
41	O
to	O
0	O
.	O
98	O
;	O
P	O
=	O
0	O
.	O
04	O
)	O
in	O
the	O
chemoimmunotherapy	B-T058
group	O
compared	O
with	O
the	O
chemotherapy	B-T058
group	O
.	O

This	O
was	O
associated	O
with	O
the	O
improved	O
survival	O
by	O
17	O
.	O
48	O
%	O
at	O
the	O
end	O
of	O
1	O
year	O
,	O
in	O
the	O
chemoimmunotherapy	B-T058
group	O
.	O

Systemic	B-T038
adverse	I-T038
events	I-T038
were	O
identical	O
in	O
both	O
the	O
group	O
s	O
.	O

There	O
was	O
no	O
survival	O
benefit	O
with	O
the	O
addition	O
of	O
CADI	B-T103
-	I-T103
05	I-T103
to	O
the	O
combination	O
of	O
cisplatin	B-T058
-	I-T058
paclitaxel	I-T058
in	O
patients	O
with	O
advanced	O
NSCLC	B-T038
;	O
however	O
,	O
the	O
squamous	B-T017
cell	I-T017
subset	I-T017
did	O
demonstrate	O
a	O
survival	O
advantage	O
.	O

Sex	O
Life	O
and	O
Impact	O
of	O
Operative	O
Intervention	B-T058
on	O
Sex	B-T033
Life	I-T033
-	I-T033
related	I-T033
Pain	I-T033
in	O
Degenerative	B-T038
Spinal	B-T017
Conditions	O
:	O
An	O
Analysis	B-T062
of	O
the	O
SPORT	B-T062
Study	I-T062

This	O
study	B-T062
is	O
a	O
therapeutic	B-T062
retrospective	I-T062
cohort	I-T062
study	I-T062
OBJECTIVES	O
.	O
:	O
This	O
study	B-T062
aims	O
to	O
determine	O
whether	O
sexual	B-T038
function	I-T038
is	O
relevant	O
for	O
patients	O
with	O
spinal	B-T017
stenosis	I-T017
(	O
SPS	B-T017
)	O
and	O
degenerative	B-T038
spondylolisthesis	I-T038
(	O
DS	B-T038
)	O
and	O
to	O
determine	O
the	O
impact	O
of	O
operative	O
inter	O
vqAvention	O
on	O
sexual	B-T038
function	I-T038
for	O
these	O
patients	O
.	O

The	O
benefits	O
of	O
nonoperative	O
versus	O
operative	O
treatment	O
for	O
patients	O
with	O
SPS	B-T017
and	O
DS	B-T038
with	O
regards	O
to	O
sexual	B-T038
function	I-T038
are	O
unknown	O
.	O

Demographic	O
,	O
treatment	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
data	O
,	O
including	O
the	O
Oswestry	O
Disability	O
Index	O
(	O
ODI	O
)	O
,	O
were	O
obtained	O
on	O
patients	O
enrolled	O
in	O
the	O
SPORT	B-T062
study	I-T062
.	O

Based	O
on	O
the	O
response	O
to	O
question	O
#	O
9	O
in	O
the	O
ODI	O
,	O
patients	O
were	O
classified	O
into	O
a	O
sexual	O
life	O
relevant	O
(	O
SLR	O
)	O
or	O
sexual	O
life	O
not	O
relevant	O
(	O
NR	O
)	O
group	O
.	O

Univariate	O
and	O
multivariate	O
analysis	O
of	O
patient	O
characteristics	O
comparing	O
the	O
NR	O
and	O
SLR	O
group	O
were	O
performed	O
.	O

Operative	O
treatment	O
groups	O
were	O
compared	O
to	O
the	O
nonoperative	O
group	O
with	O
regards	O
to	O
response	O
to	O
ODI	O
question	O
#	O
9	O
to	O
determine	O
the	O
impact	O
of	O
surgery	B-T058
on	O
sexual	B-T038
function	I-T038
.	O

A	O
total	O
of	O
1235	O
patients	O
were	O
included	O
to	O
determine	O
relevance	O
of	O
sex	O
life	O
.	O

Three	O
hundred	O
sixty	O
-	O
six	O
patients	O
(	O
29	O
%	O
)	O
were	O
included	O
in	O
the	O
NR	O
group	O
.	O

Eight	O
hundred	O
sixty	O
-	O
nine	O
patients	O
(	O
71	O
%	O
)	O
were	O
included	O
in	O
the	O
SLR	O
group	O
.	O

Patients	O
that	O
were	O
older	B-T098
,	O
female	O
,	O
unmarried	B-T098
,	O
had	O
three	O
or	O
more	O
stenotic	O
levels	O
,	O
and	O
had	O
central	O
stenosis	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
NR	O
group	O
.	O

Eight	O
hundred	O
twenty	O
-	O
five	O
patients	O
were	O
included	O
in	O
the	O
analysis	B-T062
comparing	O
operative	O
versus	O
nonoperative	O
treatment	O
.	O

At	O
all	O
follow	B-T058
-	I-T058
up	I-T058
time	O
points	O
,	O
the	O
operative	O
groups	O
had	O
a	O
lower	O
percentage	O
of	O
patients	O
reporting	O
pain	B-T033
with	O
their	O
sex	O
life	O
compared	O
to	O
the	O
nonoperative	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
at	O
all	O
time	O
points	O
except	O
between	O
more	O
than	O
one	O
level	O
fusion	O
and	O
nonoperative	O
at	O
4	O
years	O
'	O
follow	B-T058
-	I-T058
up	I-T058
)	O
.	O

Sex	O
life	O
is	O
a	O
relevant	O
consideration	O
for	O
the	O
majority	O
of	O
patients	O
with	O
DS	B-T038
and	O
SPS	B-T017
;	O
operative	O
treatment	O
leads	O
to	O
improved	B-T033
sex	B-T033
life	I-T033
-	I-T033
related	I-T033
pain	I-T033
.	O

3	O
.	O

Functional	B-T062
analyses	I-T062
of	O
OcRhS1	B-T103
and	O
OcUER1	B-T103
involved	O
in	O
UDP	B-T103
-	I-T103
L	I-T103
-	I-T103
rhamnose	I-T103
biosynthesis	O
in	O
Ornithogalum	B-T204
caudatum	I-T204

UDP	B-T103
-	I-T103
L	I-T103
-	I-T103
rhamnose	I-T103
(	O
UDP	B-T103
-	I-T103
Rha	I-T103
)	O
is	O
an	O
important	O
sugar	B-T103
donor	I-T103
for	O
the	O
synthesis	O
of	O
rhamnose	B-T103
-	O
containing	O
compounds	B-T103
in	O
plants	B-T204
.	O

However	O
,	O
only	O
a	O
few	O
enzymes	B-T103
and	O
their	O
encoding	O
genes	B-T017
involved	O
in	O
UDP	B-T103
-	I-T103
Rha	I-T103
biosynthesis	O
are	O
available	O
in	O
plants	B-T204
.	O

Here	O
,	O
two	O
genes	B-T017
encoding	O
rhamnose	B-T103
synthase	I-T103
(	O
RhS	B-T103
)	O
and	O
bi	B-T103
-	I-T103
functional	I-T103
UDP	B-T103
-	I-T103
4	I-T103
-	I-T103
keto	I-T103
-	I-T103
6	I-T103
-	I-T103
deoxy	I-T103
-	I-T103
D	I-T103
-	I-T103
glucose	I-T103
(	O
UDP	B-T103
-	I-T103
4K6DG	I-T103
)	O
3	B-T103
,	I-T103
5	I-T103
-	I-T103
epimerase	I-T103
/	I-T103
UDP	I-T103
-	I-T103
4	I-T103
-	I-T103
keto	I-T103
-	I-T103
L	I-T103
-	I-T103
rhamnose	I-T103
(	O
UDP	B-T103
-	I-T103
4KR	I-T103
)	O
4	B-T103
-	I-T103
keto	I-T103
-	I-T103
reductase	I-T103
(	O
UER	B-T103
)	O
were	O
isolated	O
from	O
Ornithogalum	B-T204
caudatum	I-T204
based	O
on	O
the	O
RNA	B-T103
-	O
Seq	B-T170
data	I-T170
.	O

The	O
OcRhS1	B-T017
gene	I-T017
has	O
an	O
ORF	B-T017
(	O
open	B-T017
reading	I-T017
frame	I-T017
)	O
of	O
2019	O
bp	O
encoding	O
a	O
tri	B-T017
-	I-T017
functional	I-T017
RhS	I-T017
enzyme	I-T017
.	O

In	O
vitro	O
enzymatic	B-T058
assays	I-T058
revealed	O
OcRhS1	B-T103
can	O
really	O
convert	O
UDP	B-T103
-	I-T103
D	I-T103
-	I-T103
glucose	I-T103
(	O
UDP	B-T103
-	I-T103
Glc	I-T103
)	O
into	O
UDP	B-T103
-	I-T103
Rha	I-T103
via	O
three	O
consecutive	O
reactions	O
.	O

Biochemical	O
evidences	O
indicated	O
that	O
the	O
recombinant	B-T103
OcRhS1	I-T103
was	O
active	O
in	O
the	O
pH	O
range	O
of	O
5	O
-	O
11	O
and	O
over	O
the	O
temperature	O
range	O
of	O
0	O
-	O
60	O
°C	O
.	O

The	O
Km	O
value	O
of	O
OcRhS1	B-T103
for	O
UDP	B-T103
-	I-T103
Glc	I-T103
was	O
determined	O
to	O
be	O
1	O
.	O
52	O
×	O
10	O
(	O
-	O
4	O
)	O
M	O
.	O

OcRhS1	B-T103
is	O
a	O
multi	B-T103
-	I-T103
domain	I-T103
protein	I-T103
with	O
two	O
sets	O
of	O
cofactor	B-T038
-	I-T038
binding	I-T038
motifs	I-T038
.	O

The	O
cofactors	B-T038
dependent	O
properties	O
of	O
OcRhS1	B-T103
were	O
thus	O
characterized	O
in	O
this	O
research	B-T062
.	O

Moreover	O
,	O
the	O
N	B-T103
-	I-T103
terminal	I-T103
portion	I-T103
of	I-T103
OcRhS1	I-T103
(	O
OcRhS1	B-T103
-	I-T103
N	I-T103
)	O
was	O
observed	O
to	O
metabolize	O
UDP	B-T103
-	I-T103
Glc	I-T103
to	O
form	O
intermediate	O
UDP	O
-	O
4K6DG	O
.	O

OcUER1	B-T017
contains	O
an	O
ORF	B-T017
of	O
906	O
bp	O
encoding	O
a	O
polypeptide	B-T103
of	O
301	O
aa	B-T103
.	O

OcUER1	B-T103
shared	O
high	O
similarity	O
with	O
the	O
carboxy	B-T103
-	I-T103
terminal	I-T103
domain	I-T103
of	I-T103
OcRhS1	I-T103
(	O
OcRhS1	B-T103
-	I-T103
C	I-T103
)	O
,	O
suggesting	O
its	O
intrinsic	O
ability	O
of	O
converting	O
UDP	O
-	O
4K6DG	O
into	O
UDP	B-T103
-	I-T103
Rha	I-T103
.	O

It	O
was	O
thus	O
reasonably	O
inferred	O
that	O
UDP	B-T103
-	I-T103
Glc	I-T103
could	O
be	O
bio	O
-	O
transformed	O
into	O
UDP	B-T103
-	I-T103
Rha	I-T103
under	O
the	O
collaborating	O
action	O
of	O
OcRhS1	B-T103
-	I-T103
N	I-T103
and	O
OcUER1	B-T103
.	O

The	O
subsequently	O
biochemical	B-T058
assay	I-T058
verified	O
this	O
notion	O
.	O

Importantly	O
,	O
expression	B-T033
profiles	I-T033
of	O
OcRhS1	B-T103
and	O
OcUER1	B-T103
revealed	O
their	O
possible	O
involvement	O
in	O
the	O
biosynthesis	O
of	O
rhamnose	B-T103
-	O
containing	O
polysaccharides	B-T103
in	O
O	B-T204
.	I-T204

caudatum	I-T204
.	O

Differing	O
rates	O
of	O
antibody	B-T103
acquisition	O
to	O
merozoite	B-T204
antigens	B-T103
in	O
malaria	B-T038
:	O
implications	O
for	O
immunity	B-T038
and	O
surveillance	B-T058

Antibodies	B-T103
play	O
a	O
key	O
role	O
in	O
acquired	B-T038
human	I-T038
immunity	I-T038
to	O
Plasmodium	B-T038
falciparum	I-T038
(	I-T038
Pf	I-T038
)	I-T038
malaria	I-T038
and	O
target	O
merozoites	B-T204
to	O
reduce	O
or	O
prevent	O
blood	B-T031
-	O
stage	O
replication	B-T038
and	O
the	O
development	O
of	O
disease	B-T038
.	O

Merozoites	B-T204
present	O
a	O
complex	O
array	O
of	O
antigens	B-T103
to	O
the	O
immune	B-T022
system	I-T022
,	O
and	O
currently	O
,	O
there	O
is	O
only	O
a	O
partial	O
understanding	O
of	O
the	O
targets	O
of	O
protective	O
antibodies	B-T103
and	O
how	O
responses	B-T038
to	O
different	O
antigens	B-T103
are	O
acquired	O
and	O
boosted	O
.	O

We	O
hypothesized	O
that	O
there	O
would	O
be	O
differences	O
in	O
the	O
rate	O
of	O
acquisition	O
of	O
antibodies	B-T103
to	O
different	O
antigens	B-T103
and	O
how	O
well	O
they	O
are	O
boosted	O
by	O
infection	B-T038
,	O
which	O
impacts	O
the	O
acquisition	O
of	O
immunity	B-T038
.	O

We	O
examined	O
responses	B-T038
to	O
a	O
range	O
of	O
merozoite	B-T204
antigens	B-T103
in	O
2	O
different	O
cohorts	O
of	O
children	O
and	O
adults	O
with	O
different	O
age	O
structures	O
and	O
levels	O
of	O
malaria	B-T038
exposure	O
.	O

Overall	O
,	O
antibodies	B-T103
were	O
associated	O
with	O
age	O
,	O
exposure	O
,	O
and	O
active	O
infection	B-T038
,	O
and	O
the	O
repertoire	O
of	O
responses	B-T038
increased	O
with	O
age	O
and	O
active	O
infection	B-T038
.	O

However	O
,	O
rates	O
of	O
antibody	B-T103
acquisition	O
varied	O
between	O
antigens	B-T103
and	O
different	O
regions	O
within	O
an	O
antigen	B-T103
following	O
exposure	O
to	O
malaria	B-T038
,	O
supporting	O
our	O
hypothesis	O
.	O

Antigen	B-T103
-	O
specific	O
responses	B-T038
could	O
be	O
broadly	O
classified	O
into	O
early	O
response	B-T038
types	O
in	O
which	O
antibodies	B-T103
were	O
acquired	O
early	O
in	O
childhood	O
exposure	O
and	O
late	O
response	B-T038
types	O
that	O
appear	O
to	O
require	O
substantially	O
more	O
exposure	O
for	O
the	O
development	O
of	O
substantial	O
levels	O
.	O

We	O
identified	O
antigen	B-T103
-	O
specific	O
responses	B-T038
that	O
were	O
effectively	O
boosted	O
after	O
recent	O
infection	B-T038
,	O
whereas	O
other	O
responses	B-T038
were	O
not	O
.	O

These	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
acquisition	O
of	O
human	B-T204
immunity	B-T038
to	O
malaria	B-T038
and	O
are	O
relevant	O
to	O
the	O
development	O
of	O
malaria	B-T103
vaccines	I-T103
targeting	O
merozoite	B-T204
antigens	B-T103
and	O
the	O
selection	O
of	O
antigens	B-T103
for	O
use	O
in	O
malaria	B-T038
surveillance	B-T058
.	O

Variety	O
of	O
DNA	B-T038
Replication	I-T038
Activity	I-T038
Among	O
Cyanobacteria	B-T007
Correlates	O
with	O
Distinct	O
Respiration	B-T038
Activity	I-T038
in	O
the	O
Dark	O

Cyanobacteria	B-T007
exhibit	O
light	O
-	O
dependent	O
cell	B-T038
growth	I-T038
since	O
most	O
of	O
their	O
cellular	B-T017
energy	O
is	O
obtained	O
by	O
photosynthesis	O
.	O

In	O
Synechococcus	B-T007
elongatus	I-T007
PCC	I-T007
7942	I-T007
,	O
one	O
of	O
the	O
model	O
cyanobacteria	B-T007
,	O
DNA	B-T038
replication	I-T038
depends	O
on	O
photosynthetic	B-T038
electron	I-T038
transport	I-T038
.	O

However	O
,	O
the	O
critical	O
signal	O
for	O
the	O
regulatory	B-T038
mechanism	O
of	O
DNA	B-T038
replication	I-T038
has	O
not	O
been	O
identified	O
.	O

In	O
addition	O
,	O
conservation	O
of	O
this	O
regulatory	O
mechanism	O
has	O
not	O
been	O
investigated	O
among	O
cyanobacteria	B-T007
.	O

To	O
understand	O
this	O
regulatory	B-T038
signal	O
and	O
its	O
dependence	O
on	O
light	O
,	O
we	O
examined	O
the	O
regulation	B-T038
of	O
DNA	B-T038
replication	I-T038
under	O
both	O
light	O
and	O
dark	O
conditions	O
among	O
three	O
model	O
cyanobacteria	B-T007
,	O
S	B-T007
.	I-T007

elongatus	I-T007
PCC	I-T007
7942	I-T007
,	O
Synechocystis	B-T007
sp	I-T007
.	I-T007

PCC	I-T007
6803	I-T007
and	O
Anabaena	B-T007
sp	I-T007
.	I-T007

PCC	I-T007
7120	I-T007
.	O

Interestingly	O
,	O
DNA	B-T038
replication	I-T038
activity	I-T038
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
was	O
retained	O
when	O
cells	B-T017
were	O
transferred	B-T033
to	I-T033
the	O
dark	O
,	O
although	O
it	O
was	O
drastically	O
decreased	O
in	O
S	B-T007
.	I-T007

elongatus	I-T007
.	O

Glycogen	B-T038
metabolism	I-T038
and	O
respiration	B-T038
were	O
higher	O
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
than	O
in	O
S	B-T007
.	I-T007

elongatus	I-T007
in	O
the	O
dark	O
.	O

Moreover	O
,	O
DNA	B-T038
replication	I-T038
activity	I-T038
in	O
Synechocystis	B-T007
and	O
Anabaena	B-T007
was	O
reduced	O
to	O
the	O
same	O
level	O
as	O
that	O
in	O
S	B-T007
.	I-T007

elongatus	I-T007
by	O
inhibition	O
of	O
respiratory	O
electron	B-T038
transport	I-T038
after	O
transfer	O
to	O
the	O
dark	O
.	O

These	O
results	O
demonstrate	O
that	O
there	O
is	O
disparity	B-T033
in	O
DNA	B-T038
replication	I-T038
occurring	O
in	O
the	O
dark	O
among	O
cyanobacteria	B-T007
,	O
which	O
is	O
caused	O
by	O
the	O
difference	O
in	O
activity	O
of	O
respiratory	O
electron	B-T038
transport	I-T038
.	O

Radiosensitization	B-T058
of	O
non	B-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
cells	B-T017
and	O
xenografts	B-T058
by	O
the	O
interactive	O
effects	O
of	O
pemetrexed	B-T103
and	O
methoxyamine	B-T103

The	O
anti	B-T103
-	I-T103
folate	I-T103
pemetrexed	B-T103
is	O
a	O
radiosensitizer	B-T103
.	O

In	O
pre	B-T170
-	I-T170
clinical	I-T170
models	I-T170
,	O
pemetrexed	B-T103
is	O
more	O
effective	O
along	O
with	O
the	O
base	B-T038
-	I-T038
excision	I-T038
-	I-T038
repair	I-T038
inhibitor	O
methoxyamine	B-T103
.	O

We	O
tested	O
whether	O
methoxyamine	B-T103
enhances	O
pemetrexed	B-T103
-	O
mediated	O
radiosensitization	B-T058
of	O
lung	B-T038
adenocarcinoma	I-T038
cells	O
and	O
xenografts	B-T058
.	O

A549	B-T017
and	O
H1299	B-T017
cells	I-T017
were	O
evaluated	O
for	O
cell	B-T038
cycle	I-T038
distribution	O
by	O
flow	B-T058
cytometry	I-T058
,	O
radiosensitization	B-T058
by	O
clonogenic	B-T058
assay	I-T058
,	O
and	O
DNA	B-T038
repair	I-T038
by	O
neutral	B-T062
comet	I-T062
assay	I-T062
and	O
repair	B-T038
protein	I-T038
activation	O
.	O

H460	B-T017
cells	I-T017
were	O
included	O
in	O
some	O
studies	O
.	O

Xenografts	B-T058
in	O
nude	B-T204
mice	I-T204
received	B-T033
drug	I-T033
(	O
s	O
)	O
and	O
/	O
or	O
radiation	O
,	O
and	O
tumor	O
growth	O
was	O
monitored	O
by	O
caliper	B-T074
and	O
in	O
vivo	O
toxicity	B-T037
by	O
animal	O
weight	O
.	O

Exposure	O
to	O
pemetrexed	B-T103
/	O
methoxyamine	B-T103
for	O
24	O
(	O
H1299	B-T017
,	O
H460	B-T017
)	O
or	O
48	O
(	O
A549	B-T017
)	O
hours	O
before	O
irradiation	O
resulted	O
in	O
accumulation	B-T033
of	O
cells	B-T017
near	O
the	O
radiosensitive	O
G1	O
/	O
S	O
border	O
;	O
dose	O
-	O
enhancement	O
factors	O
of	O
1	O
.	O
62±0	O
.	O
19	O
,	O
1	O
.	O
97±0	O
.	O
25	O
,	O
and	O
1	O
.	O
67±0	O
.	O
30	O
,	O
respectively	O
;	O
reduction	O
of	O
mean	O
inactivation	O
dose	O
by	O
32	O
%	O
,	O
30	O
%	O
,	O
and	O
46	O
%	O
,	O
respectively	O
;	O
and	O
significant	O
reductions	O
of	O
SF2	O
and	O
SF4	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Radiosensitization	B-T058
was	O
associated	O
with	O
rapid	O
DNA	B-T038
double	I-T038
-	I-T038
strand	I-T038
-	I-T038
break	I-T038
rejoining	I-T038
and	O
increased	O
levels	O
of	O
DNA	B-T103
-	I-T103
PKcs	I-T103
.	O

Both	O
tumor	O
-	O
growth	O
rate	O
and	O
tumor	O
-	O
growth	O
delay	O
were	O
significantly	O
improved	O
by	O
adding	O
methoxyamine	B-T103
to	O
pemetrexed	B-T103
pre	O
-	O
irradiation	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
;	O
no	O
mice	B-T204
lost	O
weight	O
during	O
treatment	O
.	O

Addition	O
of	O
methoxyamine	B-T103
to	O
pemetrexed	B-T103
and	O
fractionated	O
radiotherapy	O
may	O
improve	O
outcome	O
for	O
patients	O
with	O
locally	O
advanced	O
non	B-T038
-	I-T038
squamous	I-T038
non	I-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
.	O

Using	O
language	O
for	O
social	B-T033
interaction	I-T033
:	O
Communication	O
mechanisms	O
promote	O
recovery	O
from	O
chronic	O
non	B-T038
-	I-T038
fluent	I-T038
aphasia	I-T038

Clinical	B-T062
research	I-T062
highlights	O
the	O
importance	O
of	O
massed	O
practice	O
in	O
the	O
rehabilitation	B-T058
of	O
chronic	O
post	O
-	O
stroke	O
aphasia	B-T038
.	O

However	O
,	O
while	O
necessary	O
,	O
massed	O
practice	O
may	O
not	O
be	O
sufficient	O
for	O
ensuring	O
progress	O
in	O
speech	B-T058
-	I-T058
language	I-T058
therapy	I-T058
.	O

Motivated	O
by	O
recent	O
advances	O
in	O
neuroscience	B-T091
,	O
it	O
has	O
been	O
claimed	O
that	O
using	O
language	O
as	O
a	O
tool	O
for	O
communication	O
and	O
social	B-T033
interaction	I-T033
leads	O
to	O
synergistic	O
effects	O
in	O
left	B-T082
perisylvian	I-T082
eloquent	I-T082
areas	I-T082
.	O

Here	O
,	O
we	O
conducted	O
a	O
crossover	O
randomized	O
controlled	O
trial	O
to	O
determine	O
the	O
influence	O
of	O
communicative	O
language	B-T038
function	I-T038
on	O
the	O
outcome	O
of	O
intensive	B-T058
aphasia	I-T058
therapy	I-T058
.	O

Eighteen	O
individuals	B-T098
with	O
left	O
-	O
hemisphere	O
lesions	O
and	O
chronic	O
non	B-T038
-	I-T038
fluent	I-T038
aphasia	I-T038
each	O
received	O
two	O
types	O
of	O
training	O
in	O
counterbalanced	O
order	O
:	O
(	O
i	O
)	O
Intensive	B-T058
Language	I-T058
-	I-T058
Action	I-T058
Therapy	I-T058
(	O
ILAT	B-T058
,	O
an	O
extended	O
form	O
of	O
Constraint	B-T058
-	I-T058
Induced	I-T058
Aphasia	I-T058
Therapy	I-T058
)	O
embedding	O
verbal	B-T058
utterances	I-T058
in	O
the	O
context	O
of	O
communication	O
and	O
social	B-T033
interaction	I-T033
,	O
and	O
(	O
ii	O
)	O
Naming	B-T170
Therapy	I-T170
focusing	O
on	O
speech	B-T058
production	I-T058
per	I-T058
se	I-T058
.	O

Both	O
types	O
of	O
training	O
were	O
delivered	O
with	O
the	O
same	O
high	O
intensity	O
(	O
3	O
.	O
5	O
h	O
per	O
session	O
)	O
and	O
duration	O
(	O
six	O
consecutive	O
working	O
days	O
)	O
,	O
with	O
therapy	B-T058
materials	O
and	O
number	B-T033
of	I-T033
utterances	I-T033
matched	O
between	O
treatment	B-T058
groups	I-T058
.	O

A	O
standardized	O
aphasia	B-T038
test	B-T058
battery	I-T058
revealed	O
significantly	O
improved	O
language	O
performance	O
with	O
ILAT	B-T058
,	O
independent	O
of	O
when	O
this	O
method	B-T170
was	O
administered	O
.	O

In	O
contrast	O
,	O
Naming	B-T170
Therapy	I-T170
tended	O
to	O
benefit	O
language	O
performance	O
only	O
when	O
given	O
at	O
the	O
onset	O
of	O
the	O
treatment	B-T058
,	O
but	O
not	O
when	O
applied	O
after	O
previous	O
intensive	O
training	O
.	O

The	O
current	O
results	O
challenge	O
the	O
notion	O
that	O
massed	O
practice	O
alone	O
promotes	O
recovery	O
from	O
chronic	O
post	O
-	O
stroke	O
aphasia	B-T038
.	O

Instead	O
,	O
our	O
results	O
demonstrate	O
that	O
using	O
language	O
for	O
communication	O
and	O
social	B-T033
interaction	I-T033
increases	O
the	O
efficacy	O
of	O
intensive	B-T058
aphasia	I-T058
therapy	I-T058
.	O

miR	B-T017
-	I-T017
27b	I-T017
inhibits	O
gastric	B-T038
cancer	I-T038
metastasis	B-T038
by	O
targeting	O
NR2F2	B-T103

Increasing	O
attention	B-T038
is	O
focused	O
on	O
the	O
down	B-T038
-	I-T038
regulation	I-T038
of	O
miRNAs	B-T103
in	O
cancer	B-T038
process	I-T038
.	O

Nuclear	B-T103
receptor	I-T103
subfamily	I-T103
2	I-T103
(	O
NR2F2	B-T103
,	O
also	O
known	O
as	O
COUP	B-T103
-	I-T103
TFII	I-T103
)	O
is	O
involved	O
in	O
the	O
development	O
of	O
many	O
types	O
of	O
cancers	B-T038
,	O
but	O
its	O
role	O
in	O
gastric	B-T038
cancer	I-T038
remains	O
elusive	O
.	O

In	O
this	O
experiment	B-T062
,	O
oncomine	B-T170
and	O
Kaplan	B-T170
-	I-T170
meier	I-T170
database	I-T170
revealed	O
that	O
NR2F2	B-T103
was	O
up	B-T038
-	I-T038
regulated	I-T038
in	O
gastric	B-T038
cancer	I-T038
and	O
that	O
the	O
high	O
NR2F2	B-T103
expression	B-T038
contributed	O
to	O
poor	O
survival	O
.	O

MicroRNA	B-T017
-	I-T017
27b	I-T017
was	O
targeted	O
and	O
down	B-T038
-	I-T038
regulated	I-T038
by	O
NR2F2	B-T103
in	O
human	B-T204
gastric	B-T038
cancer	I-T038
tissues	B-T017
and	O
cells	B-T017
.	O

The	O
ectopic	B-T038
expression	I-T038
of	O
miR	B-T017
-	I-T017
27b	I-T017
inhibited	O
gastric	B-T038
cancer	I-T038
cell	B-T038
proliferation	I-T038
and	O
tumor	O
growth	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

Assays	B-T058
suggested	O
that	O
the	O
overexpression	B-T038
of	O
miR	B-T017
-	I-T017
27b	I-T017
could	O
promote	O
MGC	B-T017
-	I-T017
803	I-T017
cells	I-T017
'	O
migration	B-T038
and	O
invasion	B-T038
and	O
retard	O
their	O
metastasis	B-T038
to	O
the	O
liver	B-T017
.	O

In	O
addition	O
,	O
down	B-T038
-	I-T038
regulation	I-T038
of	O
miR	B-T017
-	I-T017
27b	I-T017
enhanced	O
GES	B-T017
-	I-T017
1	I-T017
cells	I-T017
'	O
proliferation	B-T038
and	O
metastasis	B-T038
in	O
vitro	O
.	O

These	O
findings	B-T033
reveal	O
that	O
miR	B-T017
-	I-T017
27b	I-T017
is	O
a	O
tumor	B-T017
suppressor	I-T017
in	O
gastric	B-T038
cancer	I-T038
and	O
a	O
biomarker	B-T201
for	O
improving	O
patients	O
'	O
survival	O
.	O

Promoting	O
Healthy	O
Growth	B-T038
or	O
Feeding	O
Obesity	B-T038
?	O
The	O
Need	O
for	O
Evidence	O
-	O
Based	O
Oversight	O
of	O
Infant	O
Nutritional	B-T168
Supplement	I-T168
Claims	O

The	O
Developmental	B-T170
Origins	I-T170
of	I-T170
Health	I-T170
and	I-T170
Disease	I-T170
(	O
DOHaD	B-T170
)	O
model	O
recognizes	O
growth	B-T038
in	O
infancy	O
and	O
childhood	O
as	O
a	O
fundamental	O
determinant	O
of	O
lifespan	O
health	O
.	O

Evidence	O
of	O
long	O
-	O
term	O
health	O
risks	O
among	O
small	O
neonates	O
who	O
subsequently	O
grow	O
rapidly	O
poses	O
a	O
challenge	O
for	O
interventions	B-T058
aiming	O
to	O
support	O
healthy	O
growth	B-T038
,	O
not	O
merely	O
drive	O
weight	B-T033
gain	I-T033
.	O

Defining	O
healthy	O
growth	B-T038
beyond	O
"	O
getting	O
bigger	O
"	O
is	O
essential	O
as	O
infant	O
and	O
young	O
child	O
feeding	O
industries	O
expand	O
.	O

Liquid	O
-	O
based	O
nutritional	B-T168
supplements	I-T168
,	O
originally	O
formulated	B-T168
for	O
undernourished	B-T038
children	O
,	O
are	O
increasingly	O
marketed	O
for	O
and	O
consumed	O
by	O
children	O
generally	O
.	O

Clarifying	O
the	O
nature	O
of	O
the	O
evidentiary	O
base	O
on	O
which	O
structure	O
/	O
function	O
claims	O
promoting	O
"	O
healthy	O
growth	B-T038
"	O
are	O
constructed	O
is	O
important	O
to	O
curb	O
invalid	O
generalizations	O
.	O

Evidence	O
points	O
to	O
changing	O
social	O
beliefs	O
and	O
cultural	O
practices	B-T038
surrounding	O
supplementary	B-T058
feeding	I-T058
,	O
raising	O
specific	O
concerns	O
about	O
the	O
long	O
-	O
term	O
health	O
consequences	O
of	O
an	O
associated	O
altered	O
feeding	O
culture	O
,	O
including	O
reduced	O
dietary	B-T168
variety	O
and	O
weight	B-T033
gain	I-T033
.	O

Reassessing	O
the	O
evidence	O
for	O
and	O
relevance	O
of	O
dietary	B-T168
supplements	I-T168
'	I-T168
"	O
promoting	O
healthy	O
growth	B-T038
"	O
claims	O
for	O
otherwise	O
healthy	O
children	O
is	O
both	O
needed	O
in	O
a	O
time	O
of	O
global	O
obesity	B-T038
and	O
an	O
opportunity	O
to	O
refine	O
intervention	B-T058
approaches	I-T058
among	O
small	O
children	O
for	O
whom	O
rapid	O
subsequent	O
growth	B-T038
in	O
early	O
life	O
augments	O
risk	O
for	O
chronic	B-T038
disease	I-T038
.	O

Scientific	O
and	O
health	B-T058
care	I-T058
partnerships	B-T092
are	O
needed	O
to	O
consider	O
current	O
governmental	O
oversight	O
shortfalls	O
in	O
protecting	O
vulnerable	O
populations	B-T098
from	O
overconsumption	O
.	O

This	O
is	O
important	O
because	O
we	O
may	O
be	O
doing	O
more	O
harm	O
than	O
good	O
.	O

On	B-T082
-	I-T082
Site	I-T082
Fertility	B-T058
Preservation	I-T058
Services	I-T058
for	O
Adolescents	O
and	O
Young	O
Adults	O
in	O
a	O
Comprehensive	B-T092
Cancer	I-T092
Center	I-T092

Adolescents	O
and	O
young	O
adults	O
(	O
AYAs	O
)	O
receiving	O
cancer	B-T058
treatments	I-T058
that	O
may	O
impair	B-T038
fertility	I-T038
should	O
receive	O
counseling	B-T058
about	O
risk	B-T033
of	I-T033
infertility	I-T033
and	O
options	O
for	O
fertility	B-T058
preservation	I-T058
(	O
FP	B-T058
)	O
before	O
treatment	B-T058
and	O
/	O
or	O
during	O
survivorship	O
.	O

Our	O
objective	B-T170
was	O
to	O
define	O
the	O
AYA	O
patient	O
population	B-T098
referred	O
to	O
an	O
on	B-T058
-	I-T058
site	I-T058
fertility	I-T058
consultation	I-T058
service	I-T058
within	O
a	O
comprehensive	B-T092
cancer	I-T092
center	I-T092
and	O
determine	O
factors	O
associated	O
with	O
patients	O
proceeding	O
with	O
FP	B-T058
treatment	I-T058
.	O

We	O
conducted	O
a	O
retrospective	B-T062
chart	I-T062
review	I-T062
of	O
AYA	O
women	B-T098
who	O
completed	O
a	O
consultation	B-T058
at	O
the	O
MD	B-T058
Anderson	I-T058
Fertility	I-T058
Preservation	I-T058
and	I-T058
Family	I-T058
Building	I-T058
Service	I-T058
during	O
the	O
first	O
year	O
of	O
service	O
.	O

Records	B-T170
of	O
154	O
referred	O
AYA	O
patients	O
were	O
reviewed	O
for	O
age	O
,	O
ethnicity	B-T098
,	O
cancer	O
type	O
gravidity	B-T033
and	O
parity	B-T033
,	O
survivorship	O
status	O
,	O
and	O
decision	O
to	O
pursue	O
FP	B-T058
treatment	I-T058
.	O

Patients	O
(	O
mean	O
age	O
29	O
.	O
7	O
)	O
were	O
Caucasian	B-T098
(	O
55	O
%	O
)	O
,	O
Hispanic	B-T098
(	O
23	O
%	O
)	O
,	O
and	O
African	B-T098
American	I-T098
(	O
10	O
%	O
)	O
.	O

The	O
majority	O
of	O
women	B-T098
(	O
67	O
%	O
)	O
were	O
seen	O
for	O
FP	B-T058
before	O
cancer	B-T058
treatment	I-T058
and	O
the	O
remaining	O
sought	O
options	O
for	O
family	B-T058
building	I-T058
while	O
in	O
survivorship	O
.	O

The	O
most	O
common	O
cancer	O
types	O
were	O
hematologic	B-T038
(	O
29	O
%	O
)	O
,	O
breast	B-T038
(	O
25	O
%	O
)	O
,	O
and	O
gynecologic	B-T038
(	O
23	O
%	O
)	O
.	O

Patients	O
referred	O
to	O
an	O
on	B-T058
-	I-T058
site	I-T058
fertility	I-T058
consultation	I-T058
service	I-T058
were	O
medically	O
and	O
ethnically	O
diverse	O
.	O

Interest	O
in	O
fertility	O
counseling	O
and	O
treatment	B-T058
was	O
apparent	O
in	O
both	O
survivorship	O
pre	B-T058
-	I-T058
and	I-T058
postcancer	I-T058
treatment	I-T058
.	O

Although	O
the	O
referral	B-T058
group	O
was	O
ethnically	O
diverse	O
,	O
Caucasian	B-T098
women	B-T098
were	O
most	O
likely	O
to	O
pursue	O
FP	B-T058
treatment	I-T058
compared	O
to	O
women	B-T098
of	O
other	O
ethnicities	O
.	O

Results	O
of	O
a	O
Multicenter	B-T062
,	O
Randomized	B-T062
,	O
Controlled	B-T170
Trial	I-T170
of	O
a	O
Hydrogen	B-T103
Peroxide	I-T103
-	O
based	O
Kit	B-T074
versus	O
a	O
Benzoyl	B-T103
Peroxide	I-T103
-	O
based	O
Kit	B-T074
in	O
Mild	O
-	O
to	O
-	O
moderate	O
Acne	B-T038

Objective	O
:	O
To	O
evaluate	B-T058
the	O
efficacy	O
and	O
tolerability	B-T062
of	O
a	O
novel	O
hydrogen	B-T103
peroxide	I-T103
-	O
based	O
regimen	B-T058
versus	O
a	O
benzoyl	B-T103
peroxide	I-T103
-	O
based	O
regimen	B-T058
in	O
mild	O
-	O
to	O
-	O
moderate	O
acne	B-T038
.	O

Methods	B-T170
:	O
In	O
this	O
eight	O
-	O
week	O
multicenter	B-T062
study	I-T062
,	O
patients	O
were	O
randomized	B-T062
to	O
either	O
a	O
hydrogen	B-T103
peroxide	I-T103
-	O
based	O
or	O
a	O
benzoyl	B-T103
peroxide	I-T103
-	O
based	O
regimen	B-T058
.	O
The	O
primary	O
outcome	O
measure	O
of	O
clinical	B-T033
response	I-T033
was	O
assessed	O
using	O
the	O
Global	B-T058
Acne	I-T058
Grading	I-T058
System	I-T058
(	O
GAGS	B-T058
)	O
at	O
baseline	O
,	O
four	O
weeks	O
,	O
and	O
eight	O
weeks	O
.	O

At	O
Week	O
8	O
,	O
a	O
patient	O
self	B-T170
-	I-T170
satisfaction	I-T170
questionnaire	I-T170
was	O
administered	O
.	O

Investigators	B-T097
were	O
also	O
queried	B-T170
at	O
that	O
time	O
regarding	O
assessment	B-T058
of	O
tolerability	B-T062
and	O
cosmetic	O
acceptability	O
.	O

Tolerability	B-T062
was	O
also	O
measured	O
at	O
each	O
visit	B-T058
.	O

Results	O
:	O
Both	O
treatment	B-T058
regimens	I-T058
were	O
associated	O
with	O
improvement	O
of	O
GAGS	O
score	O
at	O
Week	O
8	O
compared	O
to	O
baseline	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

GAGS	O
score	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
regimens	B-T058
over	O
the	O
same	O
period	O
(	O
p	O
=	O
0	O
.	O
7765	O
)	O
.	O

No	B-T033
significant	I-T033
adverse	I-T033
events	I-T033
were	O
reported	B-T058
or	O
observed	O
in	O
either	O
treatment	B-T062
arm	I-T062
.	O

Both	O
patients	O
and	O
investigators	B-T097
found	O
both	O
regimens	B-T058
to	O
be	O
similarly	O
effective	O
and	O
cosmetically	O
acceptable	O
.	O

Conclusion	O
:	O
A	O
novel	O
hydrogen	B-T103
peroxide	I-T103
-	O
based	O
regimen	B-T058
was	O
shown	O
to	O
be	O
comparable	O
in	O
efficacy	O
,	O
safety	O
,	O
and	O
cosmetic	O
acceptability	O
to	O
a	O
benzoyl	B-T103
peroxide	I-T103
-	O
based	O
regimen	B-T058
in	O
the	O
treatment	B-T058
of	O
mild	O
-	O
to	O
-	O
moderate	O
acne	B-T038
.	O

Multisensory	B-T038
Integration	I-T038
in	O
the	O
Virtual	B-T038
Hand	I-T038
Illusion	I-T038
with	O
Active	B-T038
Movement	I-T038

Improving	O
the	O
sense	B-T033
of	I-T033
immersion	I-T033
is	O
one	O
of	O
the	O
core	O
issues	O
in	O
virtual	O
reality	O
.	O

Perceptual	O
illusions	O
of	O
ownership	O
can	O
be	O
perceived	B-T038
over	O
a	O
virtual	O
body	O
in	O
a	O
multisensory	B-T058
virtual	O
reality	O
environment	O
.	O

Rubber	B-T074
Hand	I-T074
and	O
Virtual	B-T038
Hand	I-T038
Illusions	I-T038
showed	O
that	O
body	O
ownership	O
can	O
be	O
manipulated	O
by	O
applying	O
suitable	O
visual	B-T058
and	O
tactile	B-T058
stimulation	I-T058
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
effects	O
of	O
multisensory	B-T038
integration	I-T038
in	O
the	O
Virtual	B-T038
Hand	I-T038
Illusion	I-T038
with	O
active	B-T038
movement	I-T038
.	O

A	O
virtual	O
xylophone	O
playing	O
system	O
which	O
can	O
interactively	O
provide	O
synchronous	O
visual	B-T058
,	O
tactile	B-T058
,	O
and	O
auditory	B-T058
stimulation	I-T058
was	O
constructed	O
.	O

We	O
conducted	O
two	O
experiments	O
regarding	O
different	O
movement	O
conditions	O
and	O
different	O
sensory	B-T058
stimulations	I-T058
.	O

Our	O
results	O
demonstrate	O
that	O
multisensory	B-T038
integration	I-T038
with	O
free	O
active	B-T038
movement	I-T038
can	O
improve	O
the	O
sense	B-T038
of	I-T038
immersion	O
in	O
virtual	O
reality	O
.	O

Obstructive	O
Acute	B-T038
Pancreatitis	I-T038
Secondary	O
to	O
PEG	B-T074
Tube	I-T074
Migration	B-T033

Percutaneous	B-T058
gastrostomy	I-T058
is	O
a	O
well	O
-	O
established	O
method	O
of	O
providing	O
enteral	B-T058
nutrition	I-T058
to	O
patients	O
incapable	O
of	O
oral	O
intake	O
,	O
or	O
for	O
whom	O
oral	O
intake	O
is	O
insufficient	O
to	O
meet	O
metabolic	O
needs	O
.	O

In	O
comparison	O
to	O
total	B-T058
parenteral	I-T058
nutrition	I-T058
,	O
enteral	B-T058
feeding	I-T058
is	O
advantageous	O
in	O
that	O
it	O
helps	O
maintain	O
gut	B-T017
mucosal	B-T017
integrity	O
,	O
which	O
decreases	O
the	O
risk	O
of	O
bacterial	B-T038
translocation	I-T038
through	O
the	O
gastrointestinal	B-T022
tract	I-T022
.	O

Complications	B-T038
include	O
bleeding	B-T038
,	O
aspiration	B-T038
,	O
internal	B-T037
organ	I-T037
injury	I-T037
,	O
perforation	B-T038
,	O
periostomal	B-T038
leaks	I-T038
,	O
tube	B-T037
dislodgement	I-T037
,	O
and	O
occlusion	B-T038
.	O

Acute	B-T038
pancreatitis	I-T038
secondary	O
to	O
percutaneous	B-T074
gastrostomy	I-T074
tube	I-T074
migration	B-T033
is	O
rare	O
.	O

We	O
present	O
a	O
patient	O
with	O
acute	O
obstructive	O
pancreatitis	B-T038
secondary	O
to	O
percutaneous	B-T074
gastrostomy	I-T074
tube	I-T074
migration	B-T033
.	O

A	O
Tractable	O
Method	B-T170
for	O
Measuring	O
Nanomaterial	O
Risk	O
Using	O
Bayesian	B-T170
Networks	I-T170

While	O
control	O
banding	B-T058
has	O
been	O
identified	O
as	O
a	O
suitable	O
framework	O
for	O
the	O
evaluation	O
and	O
the	O
determination	O
of	O
potential	O
human	B-T204
health	O
risks	O
associated	O
with	O
exposure	O
to	O
nanomaterials	O
(	O
NMs	O
)	O
,	O
the	O
approach	O
currently	O
lacks	O
any	O
implementation	O
that	O
enjoys	O
widespread	O
support	O
.	O

Large	O
inconsistencies	O
in	O
characterisation	O
data	O
,	O
toxicological	B-T038
measurements	O
and	O
exposure	O
scenarios	O
make	O
it	O
difficult	O
to	O
map	O
and	O
compare	O
the	O
risk	O
associated	O
with	O
NMs	O
based	O
on	O
physicochemical	O
data	O
,	O
concentration	O
and	O
exposure	O
route	O
.	O

Here	O
we	O
demonstrate	O
the	O
use	O
of	O
Bayesian	B-T170
networks	I-T170
as	O
a	O
reliable	O
tool	O
for	O
NM	O
risk	O
estimation	O
.	O

This	O
tool	O
is	O
tractable	O
,	O
accessible	O
and	O
scalable	O
.	O

Most	O
importantly	O
,	O
it	O
captures	O
a	O
broad	O
span	O
of	O
data	O
types	O
,	O
from	O
complete	O
,	O
high	O
quality	O
data	B-T170
sets	I-T170
through	O
to	O
data	B-T170
sets	I-T170
with	O
missing	O
data	O
and	O
/	O
or	O
values	O
with	O
a	O
relatively	O
high	O
spread	O
of	O
probability	O
distribution	O
.	O

The	O
tool	O
is	O
able	O
to	O
learn	O
iteratively	O
in	O
order	O
to	O
further	O
refine	O
forecasts	O
as	O
the	O
quality	O
of	O
data	O
available	O
improves	O
.	O

We	O
demonstrate	O
how	O
this	O
risk	O
measurement	O
approach	O
works	O
on	O
NMs	O
with	O
varying	O
degrees	O
of	O
risk	O
potential	O
,	O
namely	O
,	O
carbon	B-T103
nanotubes	I-T103
,	O
silver	B-T103
and	O
titanium	B-T103
dioxide	I-T103
.	O

The	O
results	O
afford	O
even	O
non	B-T098
-	I-T098
experts	I-T098
an	O
accurate	O
picture	O
of	O
the	O
occupational	O
risk	O
probabilities	O
associated	O
with	O
these	O
NMs	O
and	O
,	O
in	O
doing	O
so	O
,	O
demonstrated	O
how	O
NM	O
risk	O
can	O
be	O
evaluated	O
into	O
a	O
tractable	O
,	O
quantitative	O
risk	O
comparator	O
.	O

Gender	O
and	O
Direction	B-T082
of	O
Effect	O
of	O
Alcohol	B-T038
Problems	I-T038
and	O
Internalizing	O
Symptoms	O
in	O
a	O
Longitudinal	B-T062
Sample	I-T062
of	O
College	B-T098
Students	I-T098

Alcohol	B-T038
problems	I-T038
and	O
internalizing	O
symptoms	O
are	O
consistently	O
found	O
to	O
be	O
associated	O
but	O
how	O
they	O
relate	O
to	O
each	O
other	O
is	O
unclear	O
.	O

The	O
present	O
study	B-T062
aimed	O
to	O
address	O
limitations	O
in	O
the	O
literature	B-T170
of	O
comorbidity	O
of	O
alcohol	B-T038
problems	I-T038
and	O
internalizing	O
symptoms	O
by	O
investigating	O
the	O
direction	B-T082
of	O
effect	O
between	O
the	O
phenotypes	O
and	O
possible	O
gender	O
differences	O
in	O
college	B-T098
students	I-T098
.	O

We	O
utilized	O
data	O
from	O
a	O
large	O
longitudinal	B-T062
study	I-T062
of	O
college	B-T098
students	I-T098
from	O
the	O
United	B-T082
States	I-T082
(	O
N	O
=	O
2607	O
)	O
.	O

Three	O
waves	O
of	O
questionnaire	B-T170
-	I-T170
based	I-T170
data	O
were	O
collected	O
over	O
the	O
first	O
two	O
years	O
of	O
college	O
(	O
in	O
2011	O
-	O
2013	O
)	O
.	O

Cross	O
-	O
lagged	O
models	O
were	O
applied	O
to	O
examine	O
the	O
possible	O
direction	B-T082
of	O
effect	O
of	O
internalizing	O
symptoms	O
and	O
alcohol	B-T038
problems	I-T038
.	O

Possible	O
effects	O
of	O
gender	O
were	O
investigated	O
using	O
multigroup	O
modeling	O
.	O

There	O
were	O
significant	O
correlations	O
between	O
alcohol	B-T038
problems	I-T038
and	O
internalizing	O
symptoms	O
.	O

A	O
direction	B-T082
of	O
effect	O
was	O
found	O
between	O
alcohol	B-T038
problems	I-T038
and	O
internalizing	O
symptoms	O
but	O
differed	O
between	O
genders	O
.	O

A	O
unidirectional	O
relationship	O
varying	O
with	O
age	O
was	O
identified	O
for	O
males	O
where	O
alcohol	B-T038
problems	I-T038
initially	O
predicted	O
internalizing	O
symptoms	O
followed	O
by	O
internalizing	O
symptoms	O
predicting	O
alcohol	B-T038
problems	I-T038
.	O

For	O
females	O
,	O
a	O
unidirectional	O
relationship	O
existed	O
wherein	O
alcohol	B-T038
problems	I-T038
predicted	O
internalizing	O
symptoms	O
.	O

Conclusions	O
/	O
Importance	O
:	O
We	O
conclude	O
that	O
the	O
relationship	O
between	O
alcohol	B-T038
problems	I-T038
and	O
internalizing	O
symptoms	O
is	O
complex	O
and	O
differ	O
between	O
genders	O
.	O

In	O
males	O
,	O
both	O
phenotypes	O
are	O
predictive	O
of	O
each	O
other	O
,	O
while	O
in	O
females	O
the	O
relationship	O
is	O
driven	O
by	O
alcohol	B-T038
problems	I-T038
.	O

Importantly	O
,	O
our	O
study	B-T062
examines	O
a	O
population	O
-	O
based	O
sample	O
,	O
revealing	O
that	O
the	O
observed	O
relationships	O
between	O
alcohol	B-T038
problems	I-T038
and	O
internalizing	O
symptoms	O
are	O
not	O
limited	O
to	O
individuals	B-T098
with	O
clinically	B-T058
diagnosed	I-T058
mental	B-T038
health	I-T038
or	O
substance	B-T038
use	I-T038
problems	I-T038
.	O

Real	O
-	O
time	O
monitoring	B-T058
of	O
vesicle	B-T017
pH	O
in	O
an	O
endocytic	B-T038
pathway	B-T038
using	O
an	O
EGF	B-T103
-	O
conjugated	B-T103
two	I-T103
-	I-T103
photon	I-T103
probe	I-T103

Herein	O
,	O
we	O
developed	O
a	O
ratiometric	B-T103
two	I-T103
-	I-T103
photon	I-T103
probe	I-T103
(	O
BHS3	B-T103
-	O
EGF	B-T103
)	O
,	O
derived	O
from	O
a	O
pH	O
sensitive	O
dye	O
and	O
epidermal	B-T103
growth	I-T103
factor	I-T103
(	O
EGF	B-T103
)	O
,	O
for	O
real	O
-	O
time	O
monitoring	B-T058
and	O
quantitative	O
analysis	B-T062
of	O
acidic	B-T082
luminal	I-T082
pH	O
values	O
during	O
endocytic	B-T038
pathway	B-T038
activity	I-T038
.	O

Two	O
-	O
photon	O
microscopy	O
imaging	O
with	O
BHS3	B-T103
-	O
EGF	B-T103
allows	O
the	O
quantitative	O
analysis	B-T062
of	O
pH	O
distributions	O
of	O
single	O
vesicles	B-T017
and	O
their	O
dynamics	O
in	O
receptor	B-T038
-	I-T038
mediated	I-T038
endocytosis	I-T038
in	O
real	O
-	O
time	O
.	O

Body	O
burden	O
of	O
heavy	B-T103
metals	I-T103
among	O
HIV	O
high	B-T098
risk	I-T098
population	I-T098
in	O
USA	B-T082

HIV	O
high	B-T098
risk	I-T098
population	I-T098
may	O
face	O
not	O
only	O
the	O
threat	O
of	O
HIV	B-T038
infection	I-T038
but	O
also	O
a	O
higher	O
chance	O
of	O
exposure	B-T037
to	I-T037
environmental	I-T037
contaminants	I-T037
.	O

However	O
,	O
no	O
previous	O
studies	B-T062
have	O
examined	O
the	O
body	O
burden	O
of	O
environmental	B-T103
pollutants	I-T103
including	O
heavy	B-T103
metals	I-T103
among	O
HIV	O
high	B-T098
risk	I-T098
populations	I-T098
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
whether	O
adults	O
aged	O
20	O
-	O
59	O
years	O
old	O
at	O
high	B-T033
risk	I-T033
of	I-T033
HIV	B-T038
infection	I-T038
have	O
higher	O
blood	B-T033
levels	I-T033
of	I-T033
heavy	I-T033
metals	I-T033
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	B-T038
infection	I-T038
in	O
United	B-T082
States	I-T082
.	O

We	O
used	O
the	O
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
(	O
NHANES	B-T062
)	O
1999	O
-	O
2010	O
to	O
compare	O
exposures	O
to	O
heavy	B-T103
metals	I-T103
including	O
cadmium	B-T103
,	O
lead	B-T103
,	O
and	O
total	O
mercury	B-T103
by	O
HIV	O
risk	B-T033
status	I-T033
.	O

The	O
results	O
showed	O
that	O
people	B-T098
at	O
high	B-T033
risk	I-T033
of	I-T033
HIV	O
had	O
higher	O
blood	B-T033
concentrations	I-T033
of	O
all	O
heavy	B-T103
metals	I-T103
compared	O
to	O
their	O
counterparts	O
with	O
lower	O
HIV	O
risks	O
.	O

In	O
multivariate	O
linear	O
regression	O
models	O
,	O
HIV	O
risk	O
status	O
was	O
significantly	O
associated	O
with	O
increased	O
blood	B-T058
cadmium	I-T058
,	O
lead	B-T058
,	O
and	O
total	B-T058
mercury	I-T058
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
race	B-T098
,	O
education	O
,	O
and	O
poverty	O
income	O
ratio	O
.	O

Our	O
study	B-T062
suggests	O
that	O
people	B-T098
at	O
high	B-T033
risk	I-T033
of	I-T033
HIV	O
have	O
significantly	O
higher	O
body	O
burden	O
of	O
heavy	B-T103
metals	I-T103
including	O
cadmium	B-T103
,	O
lead	B-T103
,	O
and	O
mercury	B-T103
compared	O
to	O
those	O
with	O
low	O
risk	O
of	O
HIV	O
.	O

Further	O
longitudinal	B-T062
study	I-T062
collecting	O
more	O
pollutants	B-T103
are	O
warranted	O
to	O
determine	O
the	O
potential	O
health	O
effects	O
of	O
these	O
elevated	O
pollutants	B-T103
on	O
both	O
HIV	B-T038
-	I-T038
infected	I-T038
and	O
HIV	O
high	B-T098
-	I-T098
risk	I-T098
populations	I-T098
.	O

Fluorescence	B-T058
-	I-T058
and	O
magnetic	B-T058
-	I-T058
activated	I-T058
cell	I-T058
sorting	I-T058
strategies	O
to	O
separate	O
spermatozoa	B-T017
involving	O
plural	O
contributors	B-T098
from	O
biological	O
mixtures	O
for	O
human	B-T058
identification	I-T058

No	O
effective	O
method	O
has	O
been	O
developed	O
to	O
distinguish	O
sperm	B-T017
cells	I-T017
originating	O
from	O
different	O
men	B-T098
in	O
multi	O
-	O
suspect	O
sexual	B-T038
assault	I-T038
cases	O
.	O

Here	O
we	O
combined	O
MACS	B-T058
and	O
FACS	B-T058
to	O
isolate	B-T058
single	O
donor	B-T098
sperm	B-T017
cells	I-T017
from	O
forensic	O
mixture	O
samples	O
including	O
female	B-T098
vaginal	B-T017
epithelial	B-T017
cells	I-T017
and	O
sperm	B-T017
cells	I-T017
from	O
multiple	O
contributors	B-T098
.	O

Sperms	B-T017
from	O
vaginal	O
swab	O
were	O
isolated	O
by	O
MACS	B-T058
using	O
FITC	B-T103
-	O
conjugated	O
A	B-T103
kinase	I-T103
anchor	I-T103
protein	I-T103
3	I-T103
(	O
AKAP3	B-T103
)	O
antibody	B-T103
;	O
target	B-T098
individual	I-T098
sperm	B-T017
cells	I-T017
involving	O
two	O
or	O
three	O
donors	B-T098
were	O
separated	O
by	O
FACS	B-T058
using	O
FITC	B-T103
-	O
labeled	O
blood	B-T103
group	I-T103
A	I-T103
/	I-T103
B	I-T103
antigen	I-T103
antibody	B-T103
.	O

This	O
procedure	O
was	O
further	O
tested	O
in	O
two	O
mock	B-T033
multi	O
-	O
suspect	O
sexual	B-T038
assault	I-T038
samples	O
and	O
one	O
practical	B-T074
casework	I-T074
sample	O
.	O

Our	O
results	O
showed	O
that	O
complete	O
single	O
donor	B-T098
STR	B-T103
profiles	I-T103
could	O
be	O
successfully	O
obtained	O
from	O
sperm	B-T017
/	O
epithelial	B-T017
cell	I-T017
and	O
sperm	B-T017
mixtures	O
from	O
two	O
contributors	B-T098
.	O

For	O
unbalanced	O
sperm	B-T017
/	O
epithelial	B-T017
cells	I-T017
and	O
sperm	B-T017
cells	I-T017
mixtures	O
,	O
sensitivity	O
results	O
revealed	O
that	O
target	B-T033
cells	I-T033
could	O
be	O
detected	B-T033
at	O
as	O
low	O
as	O
1	O
:	O
32	O
and	O
1	O
:	O
8	O
mixed	O
ratios	O
,	O
respectively	O
.	O

Although	O
highly	O
relies	O
on	O
cell	B-T058
number	I-T058
and	O
blood	B-T201
types	I-T201
or	O
secretor	O
status	O
of	O
the	O
individuals	B-T098
,	O
this	O
procedure	O
would	O
still	O
be	O
useful	O
tools	O
for	O
forensic	B-T058
DNA	I-T058
analysis	I-T058
of	O
multi	O
-	O
suspect	O
sexual	B-T038
assault	I-T038
cases	O
by	O
the	O
combined	O
use	O
of	O
FACS	B-T058
and	O
MACS	B-T058
based	O
on	O
sperm	B-T017
-	O
specific	O
AKAP3	B-T103
antigen	B-T103
and	O
human	B-T204
blood	B-T033
type	I-T033
antigen	I-T033
.	O

The	O
Role	O
of	O
the	O
Iron	B-T058
Stain	I-T058
in	O
Assessing	O
Intracranial	B-T038
Hemorrhage	I-T038

The	O
timing	O
of	O
the	O
breakdown	O
of	O
red	B-T017
blood	I-T017
cells	I-T017
and	O
organization	O
of	O
hemorrhage	B-T038
has	O
significance	O
in	O
the	O
catabolism	B-T038
of	O
heme	B-T103
and	O
the	O
processing	O
of	O
iron	B-T103
,	O
but	O
also	O
has	O
a	O
practical	O
application	O
in	O
terms	O
of	O
assigning	O
,	O
or	O
attempting	O
to	O
assign	O
,	O
a	O
time	O
course	O
with	O
respect	O
to	O
traumatic	B-T037
events	O
(	O
e	O
.	O
g	O
.	O

contusions	B-T037
and	O
hemorrhages	B-T038
)	O
.	O

Attempts	O
to	O
date	B-T037
contusions	I-T037
,	O
however	O
,	O
have	O
generally	O
been	O
unsuccessful	O
by	O
macroscopic	O
observation	O
,	O
whereas	O
the	O
microscopic	B-T058
observations	I-T058
provide	O
broad	O
data	O
but	O
are	O
also	O
anatomically	O
imprecise	O
as	O
a	O
function	O
of	O
time	O
.	O

Intracranial	B-T033
lesions	I-T033
are	O
of	O
particular	O
significance	O
with	O
respect	O
to	O
the	O
timing	O
of	O
organizing	O
hemorrhage	B-T038
given	O
the	O
acute	O
,	O
and	O
often	O
life	B-T033
-	I-T033
threatening	I-T033
nature	O
of	O
the	O
hemorrhages	B-T038
,	O
and	O
the	O
medicolegal	B-T058
investigation	I-T058
into	O
potential	O
crimes	O
.	O

Of	O
concern	O
is	O
that	O
the	O
Prussian	B-T058
Blue	I-T058
reaction	I-T058
for	O
iron	B-T103
,	O
a	O
relatively	O
straightforward	O
histochemical	B-T058
reaction	O
that	O
has	O
been	O
in	O
use	O
for	O
over	O
150	O
years	O
,	O
is	O
sometimes	O
suggested	O
as	O
a	O
diagnostic	B-T058
test	I-T058
for	O
chronicity	O
.	O

Therefore	O
,	O
this	O
study	B-T062
examined	B-T033
the	O
utility	O
of	O
the	O
Prussian	B-T103
Blue	I-T103
iron	I-T103
stain	I-T103
in	O
living	O
patients	O
with	O
intracranial	B-T038
hemorrhages	I-T038
and	O
well	O
-	O
defined	O
symptom	O
onset	O
,	O
to	O
test	O
whether	O
the	O
presence	B-T033
of	O
Prussian	B-T103
Blue	I-T103
reactivity	O
could	O
be	O
correlated	O
with	O
chronicity	O
.	O

It	O
was	O
found	B-T033
that	O
out	O
of	O
12	O
cases	O
with	O
intracranial	B-T038
hemorrhage	I-T038
,	O
eight	O
cases	O
showed	O
at	O
least	O
focal	B-T103
iron	I-T103
reactivity	O
.	O

The	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	B-T058
in	O
those	O
eight	O
cases	O
ranged	O
from	O
<	O
24	O
hours	O
to	O
more	O
than	O
3	O
days	O
.	O

Of	O
those	O
cases	O
with	O
no	B-T033
iron	I-T033
reactivity	I-T033
,	O
the	O
duration	O
from	O
symptom	O
onset	O
to	O
surgery	B-T058
ranged	O
from	O
<	O
24	O
hours	O
to	O
six	O
days	O
.	O

In	O
conclusion	O
,	O
the	O
Prussian	B-T058
Blue	I-T058
reaction	I-T058
was	O
unreliable	O
as	O
an	O
indicator	B-T103
of	O
timing	O
in	O
intracranial	B-T038
hemorrhage	I-T038
.	O

The	O
use	O
of	O
the	O
Prussian	B-T058
blue	I-T058
reaction	I-T058
as	O
an	O
independent	B-T103
indicator	I-T103
of	O
chronicity	O
is	O
therefore	O
not	O
valid	O
and	O
can	O
be	O
misleading	O
.	O

Caution	O
is	O
indicated	B-T033
when	O
employing	O
iron	B-T058
staining	I-T058
for	O
timing	O
purposes	O
,	O
as	O
its	O
only	O
use	O
is	O
to	O
highlight	O
,	O
as	O
opposed	O
to	O
identify	O
,	O
pre	O
-	O
existing	O
lesions	B-T033
.	O

With	O
respect	O
to	O
brain	B-T038
lesions	I-T038
,	O
the	O
Prussian	B-T058
blue	I-T058
reaction	I-T058
should	O
not	O
be	O
used	O
in	O
place	O
of	O
the	O
clinical	O
timing	O
of	O
the	O
neurologic	B-T033
decline	I-T033
,	O
or	O
clinical	B-T170
data	I-T170
that	O
is	O
otherwise	O
more	O
accurate	O
and	O
less	O
susceptible	O
to	O
false	B-T033
positive	I-T033
results	I-T033
.	O

Successful	O
Fetal	B-T058
Tele	I-T058
-	I-T058
Echo	I-T058
at	O
a	O
Small	B-T092
Regional	I-T092
Hospital	I-T092

Prenatal	B-T058
diagnosis	I-T058
of	O
complex	O
congenital	B-T017
heart	I-T017
disease	I-T017
(	O
CHD	B-T017
)	O
has	O
been	O
shown	O
to	O
improve	B-T033
newborn	B-T033
outcomes	O
.	O

The	O
rate	O
of	O
prenatal	B-T058
diagnosis	I-T058
and	O
access	B-T082
to	O
fetal	B-T058
echocardiography	I-T058
vary	O
widely	O
across	O
the	O
United	B-T082
States	I-T082
.	O

A	O
clinical	B-T058
fetal	I-T058
tele	I-T058
-	I-T058
echo	I-T058
service	O
was	O
established	O
at	O
King	B-T092
'	I-T092
s	I-T092
Daughters	I-T092
Medical	I-T092
Center	I-T092
(	O
KDMC	B-T092
)	O
in	O
Ashland	B-T082
,	O
KY	B-T082
,	O
a	O
region	O
in	O
eastern	B-T082
Kentucky	I-T082
that	O
is	O
3	O
h	O
from	O
the	O
nearest	O
congenital	B-T097
heart	I-T097
surgeon	I-T097
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
if	O
fetal	B-T058
tele	I-T058
-	I-T058
echo	I-T058
utilizing	O
local	B-T097
sonographers	I-T097
at	O
a	O
small	B-T092
regional	I-T092
hospital	I-T092
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	B-T017
with	O
complex	O
CHD	B-T017
.	O

Medical	B-T170
records	I-T170
were	O
reviewed	O
for	O
all	O
mother	O
-	O
infant	O
pairs	O
who	O
had	O
fetal	B-T058
tele	I-T058
-	I-T058
echoes	I-T058
performed	O
at	O
KDMC	B-T092
and	O
interpreted	O
by	O
University	B-T092
of	I-T092
Louisville	I-T092
pediatric	I-T092
cardiology	I-T092
between	O
March	O
2011	O
and	O
December	O
2013	O
.	O

Findings	B-T033
on	O
fetal	B-T058
tele	I-T058
-	I-T058
echo	I-T058
were	O
compared	O
to	O
newborn	O
echo	B-T058
and	O
clinical	O
course	O
,	O
and	O
divided	O
into	O
four	O
groups	O
:	O
(	O
1	O
)	O
Correct	O
-	O
no	O
difference	O
between	O
fetal	B-T058
tele	I-T058
-	I-T058
echo	I-T058
and	O
newborn	O
echo	B-T058
,	O
(	O
2	O
)	O
Likely	O
Correct	O
-	O
normal	O
fetal	B-T058
tele	I-T058
-	I-T058
echo	I-T058
and	O
benign	O
newborn	O
course	O
,	O
(	O
3	O
)	O
Major	O
Difference	O
-	O
one	O
that	O
affected	O
newborn	B-T033
clinical	O
course	O
,	O
and	O
(	O
4	O
)	O
Minor	O
Difference	O
-	O
did	O
not	O
affect	O
clinical	O
course	O
.	O

Seventy	O
-	O
five	O
mother	O
-	O
infant	O
pairs	O
were	O
analyzed	B-T062
.	O

Fetal	B-T058
tele	I-T058
-	I-T058
echoes	I-T058
were	O
Correct	O
in	O
21	O
%	O
,	O
Likely	O
Correct	O
in	O
56	O
%	O
,	O
showed	O
Major	O
Differences	O
in	O
0	O
%	O
,	O
and	O
showed	O
Minor	O
Differences	O
in	O
23	O
%	O
.	O

For	O
identifying	O
complex	O
CHD	B-T017
,	O
fetal	B-T058
tele	I-T058
-	I-T058
echo	I-T058
had	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
.	O

The	O
average	O
number	O
of	O
fetal	B-T058
echocardiograms	I-T058
per	O
mother	O
-	O
infant	O
pair	O
was	O
1	O
.	O
1	O
.	O

Fetal	B-T058
tele	I-T058
-	I-T058
echocardiography	I-T058
performed	O
by	O
local	B-T097
sonographers	I-T097
at	O
a	O
small	B-T092
regional	I-T092
hospital	I-T092
can	O
accurately	O
and	O
efficiently	O
identify	O
fetuses	B-T017
with	O
complex	O
CHD	B-T017
.	O

Identification	O
of	O
mineral	B-T103
-	O
binding	O
peptides	B-T103
that	O
discriminate	O
between	O
chalcopyrite	B-T103
and	O
enargite	B-T103

Innovative	O
approaches	O
to	O
the	O
separation	O
of	O
minerals	B-T103
and	O
subsequent	O
extraction	B-T058
of	O
metals	B-T103
are	O
imperative	O
owing	O
to	O
the	O
increasing	O
mineralogical	B-T103
complexity	O
of	O
ore	B-T103
deposits	I-T103
that	O
are	O
difficult	O
or	O
even	O
impossible	B-T033
to	O
separate	O
into	O
slurries	O
or	O
solutions	O
containing	O
only	O
the	O
minerals	B-T103
or	O
metals	B-T103
of	O
interest	O
.	O

Low	O
recovery	O
of	O
metal	B-T103
is	O
typical	O
for	O
these	O
complex	O
deposits	B-T103
leading	O
to	O
significant	O
losses	O
to	O
tailings	B-T103
.	O

In	O
addition	O
,	O
the	O
minerals	B-T103
often	O
contain	O
impurities	O
,	O
some	O
toxic	O
,	O
which	O
are	O
difficult	O
and	O
costly	O
to	O
control	O
or	O
manage	O
during	O
the	O
processing	O
of	O
a	O
concentrate	O
or	O
other	O
mineral	B-T103
product	O
.	O

One	O
example	O
of	O
this	O
complex	O
situation	O
is	O
the	O
significant	O
economic	O
and	O
environmental	B-T082
costs	O
associated	O
with	O
diluting	O
and	O
processing	O
copper	B-T103
concentrates	O
containing	O
arsenic	B-T103
(	O
in	O
the	O
form	O
of	O
the	O
mineral	B-T103
enargite	I-T103
,	O
Cu3	B-T103
AsS4	I-T103
)	O
in	O
the	O
production	O
of	O
pure	O
copper	B-T103
.	O

To	O
overcome	O
these	O
separation	O
problems	B-T033
,	O
we	O
have	O
utilized	O
phage	B-T062
display	I-T062
to	O
identify	O
peptides	B-T103
that	O
demonstrate	O
selective	O
recognition	O
of	O
enargite	B-T103
and	O
the	O
arsenic	B-T103
-	O
free	O
copper	B-T103
sulfide	I-T103
,	O
chalcopyrite	B-T103
.	O

Screening	O
of	O
two	O
random	O
peptide	B-T103
phage	I-T103
display	I-T103
libraries	I-T103
resulted	O
in	O
the	O
identification	O
of	O
an	O
enargite	B-T103
-	O
selective	O
peptide	B-T103
with	O
the	O
sequence	B-T082
MHKPTVHIKGPT	I-T082
and	O
a	O
chalcopyrite	B-T103
-	O
selective	O
peptide	B-T103
with	O
the	O
sequence	B-T082
RKKKCKGNCCYTPQ	I-T082
.	O

Mineral	B-T103
-	O
binding	O
selectivity	O
was	O
demonstrated	O
by	O
binding	O
studies	B-T062
,	O
zeta	O
potential	O
determination	B-T058
and	O
immunochemistry	B-T091
.	O

Peptides	B-T103
that	O
have	O
the	O
ability	B-T033
to	O
discriminate	O
between	O
enargite	B-T103
and	O
chalcopyrite	B-T103
provide	O
a	O
greener	O
option	O
for	O
the	O
separation	O
of	O
arsenic	B-T103
containing	O
contaminants	O
from	O
copper	B-T103
concentrates	O
.	O

This	O
represents	O
the	O
first	O
step	O
towards	O
a	O
major	O
advance	O
in	O
the	O
replacement	O
or	O
reduction	O
of	O
toxic	O
collectors	O
as	O
well	O
as	O
reducing	O
the	O
level	O
of	O
arsenic	B-T103
-	O
bearing	O
minerals	B-T103
in	O
the	O
early	O
stages	O
of	O
mineral	B-T103
processing	O
.	O

Biotechnol	O
.	O

Bioeng	O
.	O

2016	O
;	O
9999	O
:	O
1	O
-	O
8	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

High	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
-	O
associated	O
sphingosine	B-T103
-	I-T103
1	I-T103
-	I-T103
phosphate	I-T103
activity	O
in	O
heterozygous	B-T038
familial	I-T038
hypercholesterolaemia	I-T038

Patients	O
with	O
heterozygous	B-T038
familial	I-T038
hypercholesterolaemia	I-T038
(	O
FH	B-T038
)	O
suffer	B-T033
from	O
high	B-T033
plasma	I-T033
cholesterol	I-T033
and	O
an	O
environment	B-T082
of	O
increased	O
oxidative	B-T038
stress	I-T038
.	O

We	O
examined	O
its	O
potential	O
effects	O
on	O
high	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
(	O
HDL	B-T103
)	O
-	O
associated	O
sphingosine	B-T103
-	I-T103
1	I-T103
-	I-T103
phosphate	I-T103
(	O
S1P	B-T103
)	O
content	O
(	O
HDL	B-T103
-	O
S1P	B-T103
)	O
and	O
HDL	B-T103
-	O
mediated	O
protection	B-T038
against	I-T038
oxidative	I-T038
stress	I-T038
,	O
both	O
with	O
and	O
without	O
statin	O
treatment	O
.	O

In	O
a	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
,	O
HDL	B-T103
was	O
isolated	O
from	O
12	O
FH	B-T038
patients	O
with	O
and	O
without	O
statin	O
treatment	O
and	O
from	O
12	O
healthy	O
controls	O
.	O

The	O
HDL	B-T103
-	O
S1P	B-T103
content	O
and	O
the	O
capacity	O
of	O
HDL	B-T103
to	O
protect	O
cardiomyocytes	B-T017
against	O
oxidative	B-T038
stress	I-T038
in	O
vitro	O
were	O
measured	O
.	O

HDL	B-T103
-	O
associated	O
S1P	B-T103
was	O
significantly	O
correlated	O
with	O
cell	B-T038
protection	I-T038
,	O
but	O
not	O
with	O
HDL	B-T103
-	I-T103
cholesterol	I-T103
or	O
apolipoprotein	B-T103
AI	I-T103
.	O

The	O
latter	O
did	O
not	O
correlate	O
with	O
HDL	B-T103
-	O
mediated	O
cell	B-T038
protection	I-T038
.	O

Neither	O
the	O
HDL	B-T103
-	O
S1P	B-T103
content	O
nor	O
HDL	B-T103
protective	O
capacity	O
differed	O
between	O
nontreated	O
FH	B-T038
patients	O
and	O
controls	O
.	O

The	O
relative	O
amounts	O
of	O
apolipoprotein	B-T103
AI	I-T103
and	O
apolipoprotein	B-T103
M	I-T103
were	O
similar	O
between	O
controls	O
and	O
FH	B-T038
patients	O
.	O

Statin	O
treatment	O
had	O
no	O
effect	O
on	O
any	O
of	O
these	O
measures	O
.	O

The	O
FH	B-T038
environment	B-T082
is	O
not	O
detrimental	O
to	O
HDL	B-T103
-	O
S1P	B-T103
content	O
or	O
HDL	B-T103
-	O
S1P	B-T103
-	O
mediated	O
cell	B-T038
protection	I-T038
.	O

Statin	O
treatment	O
does	O
not	O
modulate	O
HDL	B-T103
function	O
in	O
this	O
regard	O
.	O

Moberg	B-T058
Picking	I-T058
-	I-T058
Up	I-T058
Test	I-T058
in	O
patients	O
with	O
hand	B-T038
osteoarthritis	I-T038

Clinical	O
measurement	O
.	O

The	O
Moberg	B-T058
Pick	I-T058
-	I-T058
up	I-T058
Test	I-T058
(	O
MPUT	B-T058
)	O
was	O
previously	O
used	O
to	O
evaluate	O
functional	B-T033
performance	I-T033
in	O
patients	O
with	O
hand	B-T017
inflammatory	B-T038
disease	I-T038
.	O

This	O
is	O
the	O
first	O
study	O
using	O
the	O
MPUT	B-T058
in	O
hand	B-T038
osteoarthritis	I-T038
(	O
OA	B-T038
)	O
.	O

Compare	O
the	O
functional	B-T033
performance	I-T033
(	O
MPUT	B-T058
)	O
in	O
hand	B-T038
OA	I-T038
patients	O
and	O
healthy	O
controls	O
.	O

Fifty	O
hand	B-T038
OA	I-T038
patients	O
and	O
50	O
controls	O
were	O
assessed	O
using	O
the	O
MPUT	B-T058
,	O
AUSCAN	B-T170
and	O
Cochin	B-T170
questionnaires	I-T170
,	O
grip	O
and	O
pinch	B-T058
strength	I-T058
,	O
pain	B-T033
using	O
a	O
visual	B-T058
analog	I-T058
scale	I-T058
and	O
a	O
Likert	B-T170
scale	I-T170
regarding	O
difficulty	O
to	O
perform	O
MPUT	B-T058
.	O

In	O
the	O
MPUT	B-T058
evaluation	B-T058
,	O
the	O
OA	B-T038
group	O
presented	O
a	O
statistically	O
significant	O
difference	O
from	O
the	O
control	O
group	O
.	O

The	O
OA	B-T038
group	O
spent	O
more	O
time	O
executing	O
test	B-T170
.	O

The	O
grip	O
and	O
pinch	B-T058
strength	I-T058
measurements	I-T058
showed	O
higher	O
values	O
for	O
the	O
control	O
group	O
.	O

The	O
OA	B-T038
group	O
reported	O
a	O
greater	O
difficulty	O
than	O
the	O
control	O
group	O
in	O
performing	O
the	O
test	B-T170
.	O

The	O
MPUT	B-T058
is	O
a	O
short	O
and	O
easy	O
to	O
apply	O
test	B-T170
,	O
which	O
can	O
be	O
safely	O
used	O
to	O
assess	O
the	O
functional	B-T033
performance	I-T033
of	O
the	O
hand	B-T038
OA	I-T038
.	O

II	O
.	O

Soymilk	O
residue	O
(	O
okara	B-T103
)	O
as	O
a	O
natural	O
immobilization	O
carrier	O
for	O
Lactobacillus	B-T007
plantarum	I-T007
cells	B-T017
enhances	O
soymilk	O
fermentation	B-T038
,	O
glucosidic	B-T103
isoflavone	I-T103
bioconversion	O
,	O
and	O
cell	B-T038
survival	I-T038
under	O
simulated	O
gastric	O
and	O
intestinal	B-T017
conditions	O

Cell	B-T017
immobilization	I-T017
is	O
an	O
alternative	O
to	O
microencapsulation	B-T058
for	O
the	O
maintenance	O
of	O
cells	B-T017
in	O
a	O
liquid	O
medium	O
.	O

However	O
,	O
artificial	O
immobilization	O
carriers	O
are	O
expensive	O
and	O
pose	O
a	O
high	O
safety	O
risk	O
.	O

Okara	B-T103
,	O
a	O
food	B-T168
-	I-T168
grade	I-T168
byproduct	O
from	O
soymilk	O
production	O
,	O
is	O
rich	O
in	O
prebiotics	B-T103
.	O

Lactobacilli	B-T007
could	O
provide	O
health	O
enhancing	O
effects	O
to	O
the	O
host	O
.	O

This	O
study	B-T062
aimed	O
to	O
evaluate	O
the	O
potential	O
of	O
okara	B-T103
as	O
a	O
natural	O
immobilizer	O
for	O
L	B-T017
.	I-T017

plantarum	I-T017
70810	I-T017
cells	I-T017
.	O

The	O
study	O
also	O
aimed	O
to	O
evaluate	O
the	O
effects	O
of	O
okara	B-T103
-	I-T103
immobilized	I-T103
L	B-T017
.	I-T017

plantarum	I-T017
70810	I-T017
cells	I-T017
(	O
IL	B-T017
)	O
on	O
soymilk	O
fermentation	B-T038
,	O
glucosidic	B-T103
isoflavone	I-T103
bioconversion	O
,	O
and	O
cell	B-T017
resistance	O
to	O
simulated	O
gastric	O
and	O
intestinal	B-T017
stresses	B-T038
.	O

Scanning	B-T058
electron	I-T058
microscopy	I-T058
(	O
SEM	B-T058
)	O
was	O
used	O
to	O
show	O
cells	B-T017
adherence	O
to	O
the	O
surface	B-T082
of	O
okara	B-T103
.	O

Lactic	B-T103
acid	I-T103
,	O
acetic	B-T103
acid	I-T103
and	O
isoflavone	B-T103
analyses	B-T062
in	O
unfermented	O
and	O
fermented	B-T168
soymilk	O
were	O
performed	O
by	O
HPLC	B-T058
with	I-T058
UV	I-T058
detection	I-T058
.	O

Viability	O
and	O
growth	O
kinetics	O
of	O
immobilized	B-T017
and	O
free	B-T017
L	I-T017
.	I-T017

plantarum	I-T017
70810	I-T017
cells	I-T017
(	O
FL	B-T017
)	O
were	O
followed	O
during	O
soymilk	O
fermentation	B-T038
.	O

Moreover	O
,	O
changes	O
in	O
pH	B-T033
,	O
titrable	B-T033
acidity	I-T033
and	O
viscosity	O
were	O
measured	O
by	O
conventional	B-T170
methods	I-T170
.	O

For	O
in	O
vitro	O
testing	O
of	O
simulated	O
gastrointestinal	B-T082
resistance	O
,	O
fermented	B-T168
soymilk	O
was	O
inoculated	B-T058
with	O
FL	B-T017
or	O
IL	B-T017
and	O
an	O
aliquot	O
incubated	B-T058
into	O
acidic	O
MRS	O
broth	O
which	O
was	O
conveniently	O
prepared	O
to	O
simulate	O
gastric	O
,	O
pancreatic	B-T031
juices	I-T031
and	O
bile	B-T103
salts	I-T103
.	O

Survival	O
to	O
simulated	O
gastric	O
and	O
intestinal	B-T017
stresses	B-T038
was	O
evaluated	O
by	O
plate	B-T058
count	I-T058
of	I-T058
colony	I-T058
forming	I-T058
units	I-T058
on	O
MRS	B-T103
agar	I-T103
.	O

SEM	B-T058
revealed	O
that	O
the	O
lactobacilli	B-T007
cells	B-T017
attached	O
and	O
bound	O
to	O
the	O
surface	B-T082
of	O
okara	B-T103
.	O

Compared	O
with	O
FL	B-T017
,	O
IL	B-T017
exhibited	O
a	O
significantly	O
higher	O
specific	O
growth	O
rate	O
,	O
shorter	O
lag	O
phase	O
of	O
growth	B-T038
,	O
higher	O
productions	O
of	O
lactic	B-T103
and	O
acetic	B-T103
acids	I-T103
,	O
a	O
faster	O
decrease	O
in	O
pH	B-T033
and	O
increase	O
in	O
titrable	B-T033
acidity	I-T033
,	O
and	O
a	O
higher	O
soymilk	O
viscosity	O
.	O

Similarly	O
,	O
IL	B-T017
in	O
soymilk	O
showed	O
higher	O
productions	O
of	O
daizein	B-T103
and	O
genistein	B-T103
compared	O
with	O
the	O
control	O
.	O

Compared	O
with	O
FL	B-T017
,	O
IL	B-T017
showed	O
reinforced	O
resistance	O
to	O
simulatedgastric	O
and	O
intestinal	B-T017
stresses	B-T038
in	O
vitro	O
that	O
included	O
low	B-T033
pH	I-T033
,	O
low	B-T033
pH	I-T033
plus	I-T033
pepsin	B-T103
,	O
pancreatin	B-T103
,	O
and	O
bile	B-T103
salt	I-T103
.	O

Our	O
results	O
indicate	O
that	O
okara	B-T103
is	O
a	O
new	O
potential	O
immobilization	O
carrier	O
to	O
enhance	O
the	O
growth	B-T038
and	O
glucosidic	B-T103
isoflavone	I-T103
bioconversion	O
activities	O
of	O
L	B-T007
.	I-T007

plantarum	I-T007
in	O
soymilk	O
and	O
improve	B-T033
cell	B-T038
survivability	I-T038
following	O
simulated	O
gastric	O
and	O
intestinal	B-T017
conditions	O
.	O

Comparison	O
of	O
a	O
new	O
visual	B-T058
stylet	I-T058
(	I-T058
Discopo	I-T058
)	I-T058
-	I-T058
guided	I-T058
laryngeal	B-T058
mask	I-T058
airway	I-T058
placement	I-T058
vs	O
conventional	B-T058
blind	I-T058
technique	I-T058
:	O
a	O
prospective	O
randomized	B-T062
study	O

To	O
compare	O
the	O
ease	O
of	O
laryngeal	B-T058
mask	I-T058
airway	I-T058
(	I-T058
LMA	I-T058
)	I-T058
insertion	I-T058
and	O
fiberoptic	B-T082
view	I-T082
of	O
LMA	B-T074
after	O
placement	O
using	O
the	O
Discopo	B-T058
visual	I-T058
stylet	I-T058
-	I-T058
guided	I-T058
insertion	I-T058
and	O
conventional	B-T058
blind	I-T058
technique	I-T058
.	O

Prospective	O
,	O
randomized	B-T062
controlled	B-T062
study	I-T062
.	O

Operating	B-T092
room	I-T092
in	O
a	O
university	B-T092
hospital	I-T092
.	O

One	O
hundred	O
adult	O
patients	O
scheduled	O
for	O
elective	B-T058
surgery	I-T058
under	O
LMA	B-T074
general	B-T058
anesthesia	I-T058
were	O
enrolled	O
.	O

Patients	O
were	O
randomly	B-T062
allocated	O
to	O
2	O
groups	O
:	O
GLMA	O
group	O
using	O
a	O
visual	B-T058
stylet	I-T058
-	I-T058
guided	I-T058
technique	I-T058
(	O
n	O
=	O
50	O
)	O
and	O
BLMA	O
group	O
using	O
standard	O
blind	B-T058
technique	I-T058
(	O
n	O
=	O
50	O
)	O
.	O

Correct	O
placement	O
of	O
the	O
LMA	B-T074
was	O
confirmed	O
using	O
clinical	O
test	O
along	O
with	O
fiberoptic	O
assessment	B-T058
.	O

Unblinded	O
data	O
were	O
collected	O
about	O
the	O
insertion	B-T058
time	O
,	O
the	O
first	O
attempt	O
success	O
rate	O
,	O
the	O
LMA	B-T074
position	B-T082
adjustment	O
rate	O
,	O
fiberoptic	B-T082
view	I-T082
of	O
LMA	B-T074
anatomical	B-T082
position	I-T082
,	O
hemodynamic	B-T038
responses	I-T038
,	O
and	O
the	O
adverse	O
insertion	B-T058
responses	O
(	O
bucking	B-T037
,	O
breathholding	B-T033
,	O
and	O
laryngospasm	B-T037
)	O
.	O

Blinded	O
data	O
were	O
recorded	O
about	O
postoperative	O
airway	B-T038
morbidity	I-T038
(	O
visible	O
blood	B-T031
staining	I-T031
on	O
LMA	B-T074
at	O
removal	O
,	O
sore	B-T033
throat	I-T033
,	O
and	O
hoarseness	B-T033
)	O
.	O

Insertion	B-T058
was	O
more	O
frequently	O
successful	O
at	O
the	O
first	O
attempt	O
in	O
GLMA	O
than	O
that	O
in	O
BLMA	O
group	O
(	O
100	O
%	O
vs	O
92	O
%	O
;	O
P	O
=	O
.	O
041	O
)	O
.	O

The	O
time	O
taken	O
for	O
establishing	O
effective	O
airway	O
was	O
shorter	O
in	O
GLMA	O
than	O
that	O
in	O
BLMA	O
(	O
54	O
.	O
8	O
vs	O
62	O
.	O
9	O
seconds	O
;	O
P	O
=	O
.	O
001	O
)	O
.	O

The	O
patients	O
in	O
BLMA	O
group	O
required	O
more	O
readjustment	O
and	O
reinsertion	B-T058
than	O
those	O
in	O
GLMA	O
group	O
(	O
38	O
%	O
vs	O
0	O
%	O
;	O
P	O
=	O
.	O
000	O
)	O
.	O

The	O
fiberoptic	B-T082
view	I-T082
was	O
significantly	O
better	O
in	O
GLMA	O
group	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

No	O
difference	O
between	O
the	O
2	O
groups	O
existed	O
regarding	O
hemodynamic	B-T038
stress	I-T038
responses	I-T038
,	O
incidences	O
of	O
adverse	O
insertion	B-T058
responses	O
,	O
and	O
postoperative	O
airway	B-T038
morbidity	I-T038
.	O

By	O
direct	O
visualizing	O
the	O
whole	O
process	O
of	O
LMA	B-T074
insertion	B-T058
,	O
the	O
Discopo	B-T058
visual	I-T058
stylet	I-T058
increases	O
the	O
success	O
rate	O
and	O
accuracy	O
rate	O
of	O
LMA	B-T074
placement	O
without	O
increasing	O
hemodynamic	B-T038
stress	I-T038
response	I-T038
or	O
incidences	O
of	O
adverse	B-T038
events	I-T038
.	O

Targeting	O
brain	B-T017
and	O
peripheral	B-T038
plasticity	I-T038
of	O
the	O
lipidome	B-T103
in	O
acute	O
kainic	B-T103
acid	I-T103
-	O
induced	O
epileptic	B-T038
seizures	I-T038
in	O
mice	B-T204
via	O
quantitative	B-T058
mass	I-T058
spectrometry	I-T058

Epilepsy	B-T038
is	O
a	O
highly	O
common	O
chronic	B-T038
neurological	I-T038
disorder	I-T038
,	O
manifested	O
in	O
many	O
different	O
types	O
,	O
affecting	O
~	O
1	O
%	O
of	O
the	O
worldwide	O
human	B-T204
population	B-T098
.	O

The	O
molecular	B-T038
mechanisms	I-T038
of	O
epileptogenesis	B-T038
have	O
not	O
yet	O
been	O
clarified	O
,	O
and	O
pharmacoresistance	O
exhibited	O
by	O
30	O
-	O
40	O
%	O
of	O
epilepsy	B-T038
patients	O
remains	O
a	O
major	O
obstacle	O
in	O
medical	O
care	B-T058
.	O

Growing	O
evidence	O
indicates	O
a	O
role	O
of	O
lipid	B-T103
signalling	B-T038
pathways	I-T038
in	O
epileptogenesis	B-T038
,	O
thus	O
lipid	B-T103
signals	B-T038
emerge	O
as	O
potential	O
biomarkers	B-T201
for	O
the	O
onset	O
and	O
evolving	O
course	O
of	O
the	O
epileptic	B-T038
disorder	I-T038
,	O
as	O
well	O
as	O
potential	O
therapeutic	B-T103
agents	I-T103
and	O
targets	O
.	O

For	O
this	O
purpose	O
,	O
we	O
applied	O
a	O
lipidomic	B-T103
strategy	B-T062
to	O
unravel	O
lipid	B-T103
alterations	O
in	O
brain	B-T082
regions	I-T082
,	O
periphery	B-T017
tissues	I-T017
and	O
plasma	B-T031
that	O
are	O
specific	O
for	O
acute	O
epileptic	B-T038
seizures	I-T038
in	O
mice	B-T204
at	O
1h	O
after	O
seizure	B-T038
induction	O
by	O
systemic	B-T062
kainic	B-T103
acid	I-T103
injection	B-T062
as	O
compared	O
to	O
vehicle	O
controls	O
.	O

Specifically	O
,	O
levels	O
of	O
(	O
i	O
)	O
selected	O
phospholipids	B-T103
and	O
sphingomyelins	B-T103
,	O
(	O
ii	O
)	O
the	O
endocannabinoids	B-T103
anandamide	B-T103
(	O
AEA	B-T103
)	O
and	O
2	B-T103
-	I-T103
arachidonoyl	I-T103
glycerol	I-T103
(	O
2	B-T103
-	I-T103
AG	I-T103
)	O
,	O
and	O
the	O
endocannabinoid	B-T103
-	O
related	O
compounds	B-T103
oleoylethanolamide	B-T103
(	O
OEA	B-T103
)	O
and	O
palmitoylethanolamide	B-T103
(	O
PEA	B-T103
)	O
,	O
(	O
iii	O
)	O
arachidonic	B-T103
acid	I-T103
(	O
AA	B-T103
)	O
,	O
(	O
iv	O
)	O
selected	O
eicosanoids	B-T103
,	O
and	O
(	O
v	O
)	O
fatty	B-T103
acyl	I-T103
content	O
of	O
lipidome	B-T103
were	O
determined	O
in	O
pulverized	B-T062
tissues	B-T017
from	O
six	O
brain	B-T082
regions	I-T082
of	O
kainic	B-T103
acid	I-T103
induced	O
epileptic	B-T038
seizure	I-T038
models	O
and	O
vehicle	O
controls	O
:	O
hypothalamus	B-T017
,	O
hippocampus	B-T017
,	O
thalamus	B-T017
,	O
striatum	B-T017
,	O
cerebellum	B-T017
and	O
cerebral	B-T017
cortex	I-T017
,	O
and	O
from	O
peripheral	B-T082
organs	B-T017
,	O
such	O
as	O
heart	B-T017
and	O
lungs	B-T017
,	O
and	O
in	O
plasma	B-T031
.	O

Alterations	O
in	O
lipid	B-T103
levels	O
after	O
acute	O
epileptic	B-T038
seizures	I-T038
as	O
compared	O
to	O
non	O
-	O
seizure	O
controls	O
were	O
found	O
to	O
be	O
brain	B-T082
region	I-T082
-	O
and	O
periphery	B-T017
tissue	I-T017
-	O
specific	O
,	O
including	O
specific	O
plasma	B-T031
lipid	B-T103
correlates	O
,	O
highlighting	O
their	O
value	O
as	O
marker	B-T201
candidates	I-T201
in	O
translational	O
research	B-T062
studies	I-T062
,	O
and	O
/	O
or	O
drug	B-T062
discovery	I-T062
and	O
response	B-T058
monitoring	I-T058
.	O

Panitumumab	B-T103
-	O
Associated	O
Encephalopathy	B-T038
after	O
Accidental	O
Intra	O
-	O
arterial	O
Application	B-T058
through	O
Dislocated	B-T074
Central	I-T074
Venous	I-T074
Access	I-T074
Device	I-T074

Acute	O
central	B-T022
nervous	I-T022
system	I-T022
(	O
CNS	B-T022
)	O
toxicity	B-T037
and	O
immune	O
-	O
related	O
side	B-T038
effects	I-T038
are	O
increasingly	O
recognized	O
with	O
the	O
use	O
of	O
monoclonal	B-T103
antibodies	I-T103
for	O
cancer	B-T058
therapy	I-T058
.	O

Here	O
,	O
we	O
report	O
a	O
patient	O
who	O
developed	O
of	O
acute	B-T033
-	I-T033
onset	I-T033
encephalopathy	I-T033
and	O
coma	B-T038
,	O
which	O
began	O
shortly	O
after	O
administration	O
of	O
panitumumab	B-T103
for	O
the	O
treatment	B-T058
of	O
metastatic	B-T038
colorectal	I-T038
cancer	I-T038
.	O

Echocardiography	B-T058
revealed	O
that	O
the	O
drug	B-T103
had	O
been	O
infused	O
into	O
the	O
left	B-T017
cardiac	I-T017
ventricle	I-T017
via	O
a	O
dislocated	B-T074
central	I-T074
venous	I-T074
line	I-T074
.	O

Diffusion	B-T058
-	I-T058
weighted	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
disclosed	O
multiple	O
cortical	B-T033
hyperintensities	I-T033
,	O
which	O
were	O
preferentially	O
located	O
in	O
the	O
frontal	B-T017
lobes	I-T017
.	O

While	O
the	O
neurological	B-T038
condition	I-T038
improved	O
within	O
a	O
few	O
days	O
,	O
the	O
patient	O
died	B-T038
4	O
weeks	O
later	O
.	O

It	O
seems	O
likely	O
that	O
the	O
administration	O
of	O
the	O
antibody	B-T103
via	O
the	O
intra	O
-	O
arterial	O
route	O
contributed	O
to	O
the	O
development	O
of	O
this	O
condition	B-T038
.	O

Toxic	B-T037
encephalopathy	I-T037
may	O
be	O
a	O
hitherto	O
unrecognized	O
complication	B-T038
of	O
panitumumab	B-T103
treatment	B-T058
and	O
should	O
be	O
taken	O
into	O
consideration	O
in	O
patients	O
developing	O
CNS	B-T022
symptoms	B-T033
undergoing	O
this	O
therapy	B-T058
.	O

Abundance	O
and	O
Characterization	O
of	O
Perfect	O
Microsatellites	B-T103
on	O
the	O
Cattle	B-T204
Y	B-T017
Chromosome	I-T017

Microsatellites	B-T103
or	O
simple	B-T103
sequence	I-T103
repeats	I-T103
(	O
SSRs	B-T103
)	O
are	O
found	O
in	O
most	O
organisms	O
and	O
play	O
an	O
important	O
role	O
in	O
genomic	B-T017
organization	I-T017
and	O
function	B-T038
.	O

To	O
characterize	O
the	O
abundance	O
of	O
SSRs	B-T103
(	O
1	O
-	O
6	O
base	B-T038
-	I-T038
pairs	I-T038
[	O
bp	B-T038
]	O
)	O
on	O
the	O
cattle	B-T204
Y	B-T017
chromsome	I-T017
,	O
the	O
relative	O
frequency	O
and	O
density	O
of	O
perfect	O
or	O
uninterrupted	O
SSRs	B-T103
based	O
on	O
the	O
published	O
Y	B-T017
chromosome	I-T017
sequence	B-T082
were	O
examined	B-T033
.	O

A	O
total	O
of	O
17	O
,	O
273	O
perfect	O
SSRs	B-T103
were	O
found	O
,	O
with	O
total	O
length	O
of	O
324	O
.	O
78	O
kb	O
,	O
indicating	O
that	O
approximately	O
0	O
.	O
75	O
%	O
of	O
the	O
cattle	B-T204
Y	B-T017
chromosome	I-T017
sequence	B-T082
(	O
43	O
.	O
30	O
Mb	O
)	O
comprises	O
perfect	O
SSRs	B-T103
,	O
with	O
an	O
average	O
length	B-T082
of	O
18	O
.	O
80	O
bp	B-T038
.	O

The	O
relative	O
frequency	O
and	O
density	O
were	O
398	O
.	O
92	O
loci	O
/	O
Mb	O
and	O
7500	O
.	O
62	O
bp	B-T038
/	O
Mb	O
,	O
respectively	O
.	O

The	O
proportions	O
of	O
the	O
six	O
classes	O
of	O
perfect	O
SSRs	B-T103
were	O
highly	O
variable	O
on	O
the	O
cattle	B-T204
Y	B-T017
chromosome	I-T017
.	O

Mononucleotide	B-T103
repeats	I-T103
had	O
a	O
total	O
number	O
of	O
8073	O
(	O
46	O
.	O
74	O
%	O
)	O
and	O
an	O
average	O
length	B-T082
of	O
15	O
.	O
45	O
bp	B-T038
,	O
and	O
were	O
the	O
most	O
abundant	O
SSRs	B-T103
class	O
,	O
while	O
the	O
percentages	O
of	O
di	B-T103
-	I-T103
,	O
tetra	B-T103
-	I-T103
,	O
tri	B-T103
-	I-T103
,	O
penta	B-T103
-	I-T103
,	O
and	O
hexa	B-T103
-	I-T103
nucleotide	I-T103
repeats	I-T103
were	O
22	O
.	O
86	O
%	O
,	O
11	O
.	O
98	O
%	O
,	O
11	O
.	O
58	O
%	O
,	O
6	O
.	O
65	O
%	O
,	O
and	O
0	O
.	O
19	O
%	O
,	O
respectively	O
.	O

Different	O
classes	O
of	O
SSRs	B-T103
varied	O
in	O
their	O
repeat	O
number	O
,	O
with	O
the	O
highest	O
being	O
42	O
for	O
dinucleotides	B-T103
.	O

Results	O
reveal	O
that	O
repeat	O
categories	O
A	B-T103
,	O
AC	B-T082
,	O
AT	B-T082
,	O
AAC	B-T082
,	O
AGC	B-T082
,	O
GTTT	B-T082
,	O
CTTT	B-T082
,	O
ATTT	B-T082
,	O
and	O
AACTG	B-T082
predominate	O
on	O
the	O
Y	B-T017
chromosome	I-T017
.	O

This	O
study	B-T062
provides	O
insight	O
into	O
the	O
organization	O
of	O
cattle	B-T204
Y	B-T017
chromosome	I-T017
repetitive	O
DNA	B-T103
,	O
as	O
well	O
as	O
information	O
useful	O
for	O
developing	O
more	O
polymorphic	O
cattle	B-T204
Y	B-T017
-	I-T017
chromosome	I-T017
-	O
specific	O
SSRs	B-T103
.	O

Antenatal	O
Stressful	O
Life	O
Events	O
and	O
Postpartum	O
Depressive	B-T033
Symptoms	I-T033
in	O
the	O
United	B-T082
States	I-T082
:	O
The	O
Role	O
of	O
Women	B-T098
'	I-T098
s	I-T098
Socioeconomic	O
Status	O
Indices	B-T170
at	O
the	O
State	O
Level	O

Approximately	O
10	O
%	O
-	O
20	O
%	O
of	O
women	B-T098
suffer	B-T038
from	O
postpartum	B-T038
depression	I-T038
(	O
PPD	B-T038
)	O
,	O
important	O
predictors	O
of	O
which	O
are	O
antenatal	O
stressful	O
life	O
event	O
(	O
SLE	O
)	O
experiences	O
.	O

The	O
association	O
between	O
women	B-T098
'	I-T098
s	I-T098
state	O
-	O
level	O
socioeconomic	O
status	O
(	O
SES	O
)	O
and	O
PPD	B-T038
has	O
not	O
been	O
explored	O
.	O

This	O
study	B-T062
aimed	O
to	O
examine	O
whether	O
the	O
association	O
between	O
antenatal	O
SLE	O
and	O
PPD	B-T038
symptoms	B-T033
was	O
moderated	O
by	O
women	B-T098
'	I-T098
s	I-T098
state	O
-	O
level	O
SES	O
.	O

Data	O
from	O
the	O
2009	O
-	O
2011	O
Pregnancy	B-T170
Risk	I-T170
Assessment	I-T170
Monitoring	I-T170
System	I-T170
(	O
PRAMS	B-T170
)	O
were	O
used	O
.	O

State	O
-	O
level	O
women	B-T098
'	I-T098
s	I-T098
employment	O
/	O
earnings	O
and	O
social	O
/	O
economic	O
autonomy	O
indices	B-T170
were	O
computed	O
from	O
indicators	B-T103
published	O
by	O
the	O
Institute	B-T092
of	I-T092
Women	I-T092
'	I-T092
s	I-T092
Policy	I-T092
Research	I-T092
(	O
IWPR	B-T092
)	O
.	O

Multilevel	O
multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
.	O

Among	O
91	O
,	O
253	O
women	B-T098
with	O
valid	O
responses	O
,	O
11	O
.	O
3	O
%	O
had	O
PPD	B-T038
symptoms	B-T033
,	O
prevalence	O
ranging	O
from	O
7	O
.	O
1	O
%	O
in	O
Illinois	B-T082
to	O
17	O
.	O
1	O
%	O
in	O
Arkansas	B-T082
.	O

Women	B-T098
who	O
experienced	O
all	O
four	O
stressor	O
categories	B-T170
,	O
including	O
partner	B-T098
related	B-T033
,	O
traumatic	O
,	O
emotional	B-T033
,	O
and	O
financial	O
,	O
had	O
the	O
highest	O
odds	O
(	O
adjusted	O
odds	O
ratio	O
[	O
aOR	O
]	O
:	O
5	O
.	O
43	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
5	O
.	O
36	O
-	O
5	O
.	O
51	O
)	O
of	O
PPD	B-T038
symptoms	B-T033
.	O

The	O
odds	O
of	O
experiencing	O
PPD	B-T038
symptoms	B-T033
decreased	O
with	O
an	O
increase	O
in	O
the	O
state	O
-	O
level	O
social	O
/	O
economic	O
autonomy	O
index	B-T170
(	O
aOR	O
:	O
0	O
.	O
75	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
64	O
-	O
0	O
.	O
88	O
)	O
.	O

There	O
was	O
significant	O
cross	O
-	O
level	O
interaction	O
between	O
number	O
of	O
stressor	O
categories	B-T170
experienced	O
and	O
state	O
-	O
level	O
index	B-T170
.	O

Screening	O
for	O
antenatal	O
SLEs	O
can	O
help	O
identify	O
women	B-T098
at	O
risk	O
for	O
PPD	B-T038
symptoms	B-T033
.	O

That	O
the	O
odds	O
of	O
having	O
PPD	B-T038
symptoms	B-T033
decreased	O
with	O
increasing	O
state	O
-	O
level	O
social	O
/	O
economic	O
autonomy	O
and	O
women	B-T098
residing	O
in	O
states	B-T082
with	O
lower	O
indices	B-T170
were	O
more	O
vulnerable	O
to	O
the	O
impacts	O
of	O
antenatal	O
stressors	O
,	O
could	O
have	O
policy	O
implications	O
related	O
to	O
improving	O
the	O
SES	O
of	O
women	B-T098
in	O
these	O
states	B-T082
.	O

Multi	O
-	O
component	O
model	O
of	O
intramural	B-T038
hematoma	I-T038

A	O
novel	O
multi	O
-	O
component	O
model	O
is	O
introduced	O
for	O
studying	B-T062
interaction	O
between	O
blood	B-T038
flow	I-T038
and	O
deforming	B-T033
aortic	B-T017
wall	I-T017
with	O
intramural	B-T038
hematoma	I-T038
(	O
IMH	B-T038
)	O
.	O

The	O
aortic	B-T017
wall	I-T017
is	O
simulated	B-T062
by	O
a	O
composite	O
structure	O
submodel	O
representing	O
material	O
properties	O
of	O
the	O
three	O
main	O
wall	B-T017
layers	I-T017
.	O

The	O
IMH	B-T038
is	O
described	O
by	O
a	O
poroelasticity	O
submodel	O
which	O
takes	O
into	O
account	O
both	O
the	O
pressure	O
inside	O
hematoma	B-T038
and	O
its	O
deformation	B-T033
.	O

The	O
submodel	O
of	O
the	O
hematoma	B-T038
is	O
fully	O
coupled	O
with	O
the	O
aortic	O
submodel	O
as	O
well	O
as	O
with	O
the	O
submodel	O
of	O
the	O
pulsatile	O
blood	O
flow	O
.	O

Model	B-T062
simulations	I-T062
are	O
used	O
to	O
investigate	O
the	O
relation	O
between	O
the	O
peak	O
wall	O
stress	O
,	O
hematoma	B-T038
thickness	O
and	O
permeability	O
in	O
patients	O
of	O
different	O
age	O
.	O

The	O
results	O
indicate	O
that	O
an	O
increase	O
in	O
hematoma	B-T038
thickness	O
leads	O
to	O
larger	O
wall	B-T033
stress	I-T033
,	O
which	O
is	O
in	O
agreement	O
with	O
clinical	B-T170
data	I-T170
.	O

Further	O
simulations	B-T062
demonstrate	O
that	O
a	O
hematoma	B-T038
with	O
smaller	O
permeability	O
results	O
in	O
larger	O
wall	B-T033
stress	I-T033
,	O
suggesting	O
that	O
blood	B-T038
coagulation	I-T038
in	O
hematoma	B-T038
might	O
increase	O
its	O
mechanical	B-T033
stability	I-T033
.	O

This	O
is	O
in	O
agreement	O
with	O
previous	O
experimental	O
observations	B-T062
of	O
coagulation	B-T038
having	O
a	O
beneficial	O
effect	O
on	O
the	O
condition	O
of	O
a	O
patient	O
with	O
the	O
IMH	B-T038
.	O

The	O
Impact	O
of	O
Diabetes	B-T038
on	O
the	O
Risk	O
of	O
Prostate	B-T038
Cancer	I-T038
Development	O
according	O
to	O
Body	B-T201
Mass	I-T201
Index	I-T201
:	O
A	O
10	O
-	O
year	O
Nationwide	O
Cohort	O
Study	O

Purpose	O
:	O
We	O
examined	O
the	O
association	O
between	O
obesity	B-T038
and	O
prostate	B-T038
cancer	I-T038
both	O
with	O
and	O
without	O
diabetic	B-T038
patients	O
included	O
in	O
the	O
analysis	O
using	O
nationally	O
representative	O
data	O
of	O
the	O
Korean	B-T098
population	I-T098
from	O
the	O
National	B-T058
Health	I-T058
Insurance	I-T058
System	I-T058
(	O
NHIS	B-T058
)	O
.	O

Materials	O
and	O
Methods	O
:	O
Of	O
the	O
424	O
,	O
712	O
participants	B-T098
who	O
underwent	O
health	B-T058
examinations	I-T058
in	O
2002	O
-	O
2008	O
,	O
139	O
,	O
519	O
men	B-T098
≥40	I-T098
years	I-T098
old	I-T098
and	O
without	O
prostate	B-T038
cancer	I-T038
were	O
followed	O
from	O
the	O
beginning	O
of	O
2002	O
to	O
the	O
end	O
of	O
2012	O
.	O

Multivariate	O
adjusted	O
Cox	B-T170
regression	I-T170
analysis	I-T170
was	O
conducted	O
to	O
examine	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
the	O
association	O
between	O
prostate	B-T038
cancer	I-T038
and	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
both	O
with	O
and	O
without	O
diabetes	B-T038
.	O

Results	O
:	O
The	O
HR	O
for	O
prostate	B-T038
cancer	I-T038
according	O
to	O
the	O
existence	O
of	O
diabetes	B-T038
was	O
stratified	O
by	O
BMI	B-T201
in	O
both	O
age	O
-	O
and	O
multivariable	O
-	O
adjusted	O
models	O
.	O

In	O
the	O
population	B-T098
without	O
diabetes	B-T038
,	O
the	O
HR	O
for	O
prostate	B-T038
cancer	I-T038
significantly	O
increased	O
as	O
BMI	B-T201
increased	O
beyond	O
the	O
reference	O
range	O
in	O
a	O
model	O
adjusted	O
for	O
age	O
and	O
multiple	O
variables	O
;	O
however	O
,	O
the	O
increase	O
in	O
the	O
HR	O
was	O
small	O
.	O

In	O
the	O
population	B-T098
with	O
diabetes	B-T038
,	O
the	O
HR	O
for	O
prostate	B-T038
cancer	I-T038
significantly	O
increased	O
as	O
BMI	B-T201
increased	O
from	O
<	O
18	O
.	O
5	O
kg	O
/	O
m	O
(	O
2	O
)	O
to	O
within	O
the	O
reference	O
range	O
(	O
18	O
.	O
5	O
to	O
22	O
.	O
9	O
)	O
in	O
the	O
multivariable	O
-	O
adjusted	O
model	O
.	O

In	O
addition	O
,	O
a	O
marked	O
decrease	O
in	O
HR	O
in	O
the	O
population	B-T098
with	O
BMI	B-T201
of	O
<	O
18	O
.	O
5	O
kg	O
/	O
m	O
(	O
2	O
)	O
was	O
seen	O
compared	O
to	O
the	O
reference	O
or	O
higher	O
BMI	B-T201
population	B-T098
.	O

Conclusion	O
:	O
This	O
population	B-T098
-	O
based	O
study	O
shows	O
the	O
evidence	O
of	O
association	O
between	O
obesity	B-T038
and	O
development	O
of	O
prostate	B-T038
cancer	I-T038
,	O
and	O
the	O
risk	B-T033
increases	I-T033
vary	O
according	O
to	O
the	O
change	O
of	O
BMI	B-T201
category	O
and	O
the	O
existence	O
of	O
diabetes	B-T038
.	O

Bioinformatic	B-T091
Analysis	B-T062
of	O
Codon	B-T082
Usage	O
and	O
Phylogenetic	O
Relationships	O
in	O
Different	O
Genotypes	O
of	O
the	O
Hepatitis	B-T005
C	I-T005
Virus	I-T005

The	O
hepatitis	B-T005
C	I-T005
virus	I-T005
(	O
HCV	B-T005
)	O
has	O
six	O
major	O
genotypes	O
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
phylogenetically	B-T062
investigate	I-T062
the	O
differences	O
between	O
the	O
genotypes	O
of	O
HCV	B-T005
,	O
and	O
to	O
determine	O
the	O
types	O
of	O
amino	B-T103
acid	I-T103
codon	B-T082
usage	O
in	O
the	O
structure	B-T017
of	I-T017
the	I-T017
virus	I-T017
in	O
order	O
to	O
discover	O
new	O
methods	O
for	O
treatment	B-T058
regimes	I-T058
.	O

The	O
codon	B-T082
usage	O
of	O
the	O
six	O
genotypes	O
of	O
the	O
HCV	B-T005
nucleotide	B-T082
sequence	I-T082
was	O
investigated	O
through	O
the	O
online	O
application	O
available	O
on	O
the	O
website	B-T170
Gene	I-T170
Infinity	I-T170
.	O

Also	O
,	O
phylogenetic	B-T062
analysis	I-T062
and	O
the	O
evolutionary	O
relationship	O
of	O
HCV	B-T005
genotypes	O
were	O
analyzed	B-T062
with	O
MEGA	B-T170
7	I-T170
software	I-T170
.	O

The	O
six	O
genotypes	O
of	O
HCV	B-T005
were	O
divided	O
into	O
two	O
groups	O
based	O
on	O
their	O
codon	B-T082
usage	O
properties	O
.	O

In	O
the	O
first	O
group	O
,	O
genotypes	O
1	O
and	O
5	O
(	O
74	O
.	O
02	O
%	O
)	O
,	O
and	O
in	O
the	O
second	O
group	O
,	O
genotypes	O
2	O
and	O
6	O
(	O
72	O
.	O
43	O
%	O
)	O
were	O
shown	O
to	O
have	O
the	O
most	O
similarity	O
in	O
terms	O
of	O
codon	B-T082
usage	O
.	O

Unlike	O
the	O
results	O
with	O
respect	O
to	O
determining	O
the	O
similarity	O
of	O
codon	B-T082
usage	O
,	O
the	O
phylogenetic	B-T062
analysis	I-T062
showed	O
the	O
closest	O
resemblance	O
and	O
correlation	O
between	O
genotypes	O
1	O
and	O
4	O
.	O

The	O
results	O
also	O
showed	O
that	O
HCV	B-T005
has	O
a	O
GC	B-T103
(	O
guanine	B-T103
-	I-T103
cytosine	B-T103
)	O
abundant	O
genome	B-T017
structure	I-T017
and	O
prefers	O
codons	B-T082
with	O
GC	O
for	O
translation	O
.	O

Genotypes	O
1	O
and	O
4	O
demonstrated	O
remarkable	O
similarity	O
in	O
terms	O
of	O
genome	O
sequences	O
and	O
proteins	B-T103
,	O
but	O
surprisingly	O
,	O
in	O
terms	O
of	O
the	O
preferred	O
codons	B-T082
for	O
gene	B-T038
expression	I-T038
,	O
they	O
showed	O
the	O
greatest	O
difference	O
.	O

More	O
studies	B-T062
are	O
therefore	O
needed	O
to	O
confirm	O
the	O
results	O
and	O
select	O
the	O
best	O
approach	B-T082
for	O
treatment	O
of	O
these	O
genotypes	O
based	O
on	O
their	O
codon	B-T082
usage	O
properties	O
.	O

Chronic	O
adiponectin	B-T038
deficiency	I-T038
leads	O
to	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
-	O
like	O
cognitive	B-T038
impairments	I-T038
and	O
pathologies	B-T091
through	O
AMPK	B-T103
inactivation	O
and	O
cerebral	B-T017
insulin	B-T038
resistance	I-T038
in	O
aged	O
mice	B-T204

Insulin	B-T038
resistance	I-T038
is	O
the	O
major	O
pathogenesis	B-T038
underlying	O
type	B-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
(	O
T2DM	B-T038
)	O
and	O
these	O
patients	O
have	O
doubled	O
risk	O
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
insulin	B-T038
resistance	I-T038
plays	O
an	O
important	O
role	O
in	O
AD	O
pathogenesis	B-T038
,	O
possibly	O
due	O
to	O
abnormal	O
GSK3β	B-T103
activation	B-T038
,	O
causing	O
intra	B-T017
-	I-T017
and	O
extracellular	B-T017
amyloid	O
-	O
beta	O
(	O
Aβ	O
)	O
accumulation	O
.	O

Adiponectin	B-T103
(	O
APN	B-T103
)	O
is	O
an	O
adipokine	B-T103
with	O
insulin	O
-	O
sensitizing	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

Reduced	O
circulatory	O
APN	B-T103
level	O
is	O
associated	O
with	O
insulin	B-T038
resistance	I-T038
and	O
T2DM	B-T038
.	O

The	O
role	O
of	O
APN	B-T103
in	O
AD	B-T038
has	O
not	O
been	O
elucidated	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
aim	O
to	O
examine	O
if	O
adiponectin	B-T038
deficiency	I-T038
would	O
lead	O
to	O
cerebral	B-T017
insulin	B-T038
resistance	I-T038
,	O
cognitive	B-T038
decline	I-T038
and	O
Alzheimer	B-T038
'	I-T038
s	I-T038
-	I-T038
like	I-T038
pathology	I-T038
in	O
mice	B-T204
.	O

To	O
study	B-T062
the	O
role	O
of	O
adiponectin	B-T103
in	O
cognitive	B-T038
functions	I-T038
,	O
we	O
employed	O
adiponectin	B-T038
-	I-T038
knockout	I-T038
(	B-T204
APN	I-T204
-	I-T204
KO	I-T204
)	I-T204
mice	I-T204
and	O
demonstrated	O
chronic	O
APN	B-T038
deficiency	I-T038
in	O
their	O
CNS	B-T022
.	O

Behavioral	B-T058
tests	I-T058
were	O
performed	O
to	O
study	B-T062
the	O
cognitions	B-T038
of	O
male	O
APN	B-T204
-	I-T204
KO	I-T204
mice	I-T204
.	O

Brains	B-T017
and	O
tissue	B-T017
lysates	O
were	O
collected	O
to	O
study	B-T062
the	O
pathophysiological	O
and	O
molecular	B-T038
changes	I-T038
in	O
the	O
brain	B-T017
of	O
APN	B-T204
-	I-T204
KO	I-T204
mice	I-T204
.	O

SH	B-T017
-	I-T017
SY5Y	I-T017
neuroblastoma	I-T017
cell	I-T017
line	I-T017
was	O
used	O
to	O
study	B-T062
the	O
molecular	B-T038
mechanism	I-T038
upon	O
APN	B-T103
and	O
insulin	O
treatment	O
.	O

Aged	O
APN	B-T103
-	O
deficient	O
mice	B-T204
displayed	O
spatial	B-T038
memory	I-T038
and	O
learning	B-T038
impairments	B-T038
,	O
fear	O
-	O
conditioned	O
memory	B-T038
deficit	I-T038
as	O
well	O
as	O
anxiety	B-T033
.	O

These	O
mice	B-T204
also	O
developed	O
AD	B-T038
pathologies	B-T038
including	O
increased	O
cerebral	B-T017
Aβ42	B-T103
level	O
,	O
Aβ	O
deposition	O
,	O
hyperphosphorylated	B-T103
Tau	I-T103
proteins	I-T103
,	O
microgliosis	B-T038
and	O
astrogliosis	B-T038
with	O
increased	O
cerebral	B-T017
IL	B-T103
-	I-T103
1β	I-T103
and	O
TNFα	B-T103
levels	O
that	O
associated	O
with	O
increased	O
neuronal	B-T038
apoptosis	I-T038
and	O
reduced	O
synaptic	B-T082
proteins	B-T033
levels	I-T033
,	O
suggesting	O
APN	B-T038
deficiency	I-T038
may	O
lead	O
to	O
neuronal	O
and	O
synaptic	O
loss	O
in	O
the	O
brain	B-T017
.	O

AD	B-T038
pathologies	O
-	O
associated	O
APN	B-T103
-	O
KO	B-T204
mice	I-T204
displayed	O
attenuated	O
AMPK	B-T103
phosphorylation	B-T038
and	O
impaired	O
insulin	B-T038
signaling	I-T038
including	O
decreased	O
Akt	B-T103
induction	O
and	O
increased	O
GSK3β	B-T103
activation	B-T038
in	O
the	O
hippocampus	B-T017
and	O
frontal	B-T017
cortex	I-T017
.	O

Aged	O
APN	B-T103
-	O
KO	O
mice	B-T204
developed	O
hippocampal	B-T017
insulin	B-T038
resistance	I-T038
with	O
reduced	O
pAkt	B-T103
induction	O
upon	O
intracerebral	O
insulin	B-T058
injection	I-T058
.	O

Consistently	O
,	O
APN	B-T103
treatment	B-T058
in	O
SH	O
-	O
SY5Y	O
cells	O
with	O
insulin	B-T038
resistance	I-T038
and	O
overexpressing	B-T038
Aβ	O
induce	O
higher	O
pAkt	B-T103
levels	O
through	O
AdipoR1	B-T103
upon	O
insulin	O
treatment	O
whereas	O
the	O
induction	O
was	O
blocked	B-T038
by	O
compound	B-T103
C	I-T103
,	O
indicating	O
APN	B-T103
can	O
enhance	O
neuronal	O
insulin	B-T038
sensitivity	I-T038
through	O
AMPK	B-T103
activation	O
.	O

Our	O
results	O
indicated	O
that	O
chronic	O
APN	B-T038
deficiency	I-T038
inactivated	O
AMPK	B-T103
causing	O
insulin	O
desensitization	O
and	O
elicited	O
AD	B-T038
-	I-T038
like	I-T038
pathogenesis	I-T038
in	O
aged	O
mice	B-T204
which	O
also	O
developed	O
significant	O
cognitive	B-T038
impairments	I-T038
and	O
psychiatric	B-T033
symptoms	I-T033
.	O

Can	O
inorganic	B-T103
phosphate	I-T103
explain	O
sag	O
during	O
unfused	O
tetanic	B-T038
contractions	I-T038
of	O
skeletal	B-T017
muscle	I-T017
?	O

We	O
test	O
the	O
hypothesis	O
that	O
cytosolic	B-T017
inorganic	B-T103
phosphate	I-T103
(	O
Pi	B-T103
)	O
can	O
account	O
for	O
the	O
contraction	B-T038
-	O
induced	O
reductions	O
in	O
twitch	B-T033
duration	O
which	O
impair	O
summation	O
and	O
cause	O
force	O
to	O
decline	O
(	O
sag	O
)	O
during	O
unfused	O
tetanic	B-T038
contractions	I-T038
of	O
fast	B-T017
-	I-T017
twitch	I-T017
muscle	I-T017
.	O

A	O
five	O
-	O
state	O
model	O
of	O
crossbridge	B-T038
cycling	I-T038
was	O
used	O
to	O
simulate	O
twitch	B-T033
and	O
unfused	O
tetanic	B-T038
contractions	I-T038
.	O

As	O
Pi	B-T103
concentration	O
(	O
[	O
Pi	B-T103
]	O
)	O
was	O
increased	O
from	O
0	O
to	O
30	O
mmol	O
·	O
L	O
(	O
-	O
1	O
)	O
,	O
twitch	B-T033
duration	O
decreased	O
,	O
with	O
progressive	O
reductions	B-T058
in	O
sensitivity	O
to	O
Pi	B-T103
as	O
[	O
Pi	B-T103
]	O
was	O
increased	O
.	O

When	O
unfused	O
tetani	O
were	O
simulated	B-T062
with	O
rising	O
[	O
Pi	B-T103
]	O
,	O
sag	O
was	O
most	O
pronounced	O
when	O
initial	O
[	O
Pi	B-T103
]	O
was	O
low	O
,	O
and	O
when	O
the	O
magnitude	O
of	O
[	O
Pi	B-T103
]	O
increase	O
was	O
large	O
.	O

Fast	B-T033
-	I-T033
twitch	I-T033
extensor	B-T017
digitorum	I-T017
longus	I-T017
(	I-T017
EDL	I-T017
)	I-T017
muscles	I-T017
(	O
sag	O
-	O
prone	O
,	O
typically	O
low	O
basal	O
[	O
Pi	B-T103
]	O
)	O
and	O
slow	B-T033
-	I-T033
twitch	I-T033
soleus	B-T017
muscles	I-T017
(	O
sag	O
-	O
resistant	B-T038
,	O
typically	O
high	O
basal	O
[	O
Pi	B-T103
]	O
)	O
were	O
isolated	O
from	O
14	O
female	O
C57BL	B-T204
/	I-T204
6	I-T204
mice	I-T204
.	O

Muscles	B-T017
were	O
sequentially	O
incubated	B-T058
in	O
solutions	O
containing	O
either	O
glucose	B-T103
or	O
pyruvate	B-T103
to	O
create	O
typical	O
and	O
low	O
Pi	B-T103
environments	B-T082
,	O
respectively	O
.	O

Twitch	B-T033
duration	O
was	O
greater	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
pyruvate	B-T103
than	O
glucose	B-T103
in	O
both	O
muscles	B-T017
.	O

Stimuli	O
applied	O
at	O
intervals	O
approximately	O
three	O
times	O
the	O
time	O
to	O
peak	O
twitch	B-T033
tension	O
resulted	O
in	O
sag	O
of	O
35	O
.	O
0	O
±	O
3	O
.	O
7	O
%	O
in	O
glucose	B-T103
and	O
50	O
.	O
5	O
±	O
1	O
.	O
4	O
%	O
in	O
pyruvate	B-T103
in	O
the	O
EDL	B-T017
(	O
pyruvate	B-T103
>	O
glucose	B-T103
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
3	O
.	O
9	O
±	O
0	O
.	O
3	O
%	O
in	O
glucose	B-T103
and	O
37	O
.	O
8	O
±	O
2	O
.	O
7	O
%	O
in	O
pyruvate	B-T103
in	O
the	O
soleus	B-T017
(	O
pyruvate	B-T103
>	O
glucose	B-T103
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
influence	O
of	O
Pi	B-T103
on	O
crossbridge	B-T038
cycling	I-T038
provides	O
a	O
tenable	O
mechanism	O
for	O
sag	O
.	O

Moreover	O
,	O
the	O
low	O
basal	O
[	O
Pi	B-T103
]	O
in	O
fast	B-T033
-	I-T033
twitch	I-T033
relative	O
to	O
slow	B-T033
-	I-T033
twitch	I-T033
muscle	I-T033
has	O
promise	O
as	O
an	O
explanation	B-T170
for	O
the	O
fiber	B-T017
-	I-T017
type	I-T017
dependency	O
of	O
sag	O
.	O

Pancreatic	B-T038
Cancer	I-T038
:	O
A	O
Survival	B-T062
Analysis	I-T062
Study	B-T062
in	O
Oklahoma	B-T082

Pancreatic	B-T038
cancer	I-T038
is	O
among	O
the	O
most	O
deadly	B-T038
cancers	I-T038
.	O

Risk	B-T033
factors	I-T033
associated	O
with	O
the	O
disease	B-T038
include	O
age	O
,	O
race	B-T098
,	O
sex	O
,	O
smoking	B-T201
status	I-T201
,	O
and	O
diabetes	O
status	O
.	O

We	O
conducted	O
a	O
prospective	B-T062
analysis	I-T062
of	O
risk	B-T033
factors	I-T033
and	O
length	O
of	O
survival	O
among	O
pancreatic	O
cancer	O
patients	O
living	O
in	O
Oklahoma	B-T082
between	O
1997	O
and	O
2012	O
(	O
n	O
=	O
6	O
,	O
291	O
)	O
.	O

Kaplan	O
-	O
Meier	O
survival	O
curves	O
were	O
created	O
followed	O
by	O
the	O
log	O
-	O
rank	O
test	O
to	O
compare	O
difference	O
in	O
the	O
survival	B-T201
time	I-T201
.	O

Cox	B-T170
proportional	I-T170
hazard	I-T170
regression	I-T170
models	I-T170
were	O
used	O
to	O
examine	O
the	O
strength	O
of	O
association	O
through	O
the	O
estimated	O
hazard	O
ratios	O
.	O

The	O
median	O
survival	O
time	O
of	O
the	O
cohort	B-T098
was	O
three	O
months	O
.	O

Significant	O
risk	B-T033
factors	I-T033
for	O
reduced	O
survival	B-T201
times	I-T201
included	O
age	O
,	O
stage	B-T170
at	I-T170
diagnosis	I-T170
,	O
and	O
year	O
of	O
diagnosis	O
.	O

Results	B-T033
are	O
in	O
agreement	O
with	O
previous	O
research	B-T033
findings	I-T033
.	O

There	O
have	O
been	O
small	O
but	O
noteworthy	O
improvements	O
in	O
survival	B-T201
times	I-T201
for	O
pancreatic	O
cancer	O
patients	O
in	O
Oklahoma	B-T082
.	O

Length	O
of	O
survival	O
during	O
the	O
study	B-T062
period	I-T062
was	O
significantly	O
associated	O
with	O
known	O
risk	B-T033
factors	I-T033
such	O
as	O
age	O
and	O
stage	B-T170
of	I-T170
diagnosis	I-T170
.	O

Biochemical	O
and	O
proteomic	B-T091
analyses	B-T062
of	O
the	O
physiological	B-T038
response	I-T038
induced	O
by	O
individual	O
housing	O
in	O
gilts	B-T204
provide	O
new	O
potential	O
stress	B-T038
markers	B-T201

The	O
objective	O
assessment	B-T058
of	O
animal	B-T204
stress	B-T038
and	O
welfare	O
requires	O
proper	O
laboratory	B-T092
biomarkers	B-T201
.	O

In	O
this	O
work	O
,	O
we	O
have	O
analyzed	O
the	O
changes	O
in	O
serum	B-T031
composition	B-T201
in	O
gilts	B-T204
after	O
switching	O
their	O
housing	O
,	O
from	O
pen	O
to	O
individual	O
stalls	O
,	O
which	O
is	O
generally	O
accepted	O
to	O
cause	O
animal	B-T204
discomfort	B-T033
.	O

Blood	B-T031
and	O
saliva	B-T031
samples	I-T031
were	O
collected	O
a	O
day	O
before	O
and	O
up	O
to	O
four	O
days	O
after	O
changing	O
the	O
housing	O
system	O
.	O

Biochemical	O
analyses	B-T062
showed	O
adaptive	O
changes	O
in	O
lipid	B-T103
and	O
protein	B-T038
metabolism	I-T038
after	O
the	O
housing	O
switch	O
,	O
whereas	O
cortisol	B-T103
and	O
muscular	B-T017
markers	B-T201
showed	O
a	O
large	O
variability	O
between	O
animals	B-T204
.	O

2D	B-T058
-	I-T058
DIGE	I-T058
and	O
iTRAQ	B-T170
proteomic	B-T091
approaches	O
revealed	O
variations	O
in	O
serum	B-T103
protein	I-T103
composition	B-T201
after	O
changing	O
housing	O
and	O
diet	O
of	O
gilts	B-T204
.	O

Both	O
techniques	O
showed	O
alterations	O
in	O
two	O
main	O
homeostatic	B-T038
mechanisms	I-T038
:	O
the	O
innate	O
immune	O
and	O
redox	B-T038
systems	O
.	O

The	O
acute	B-T103
phase	I-T103
proteins	I-T103
haptoglobin	B-T103
,	O
apolipoprotein	B-T103
A	I-T103
-	I-T103
I	I-T103
and	O
α1	O
-	O
antichymotrypsin	O
3	O
,	O
and	O
the	O
antioxidant	B-T103
enzyme	O
peroxiredoxin	B-T103
2	I-T103
were	O
found	O
differentially	O
expressed	O
by	O
2D	B-T058
-	I-T058
DIGE	I-T058
.	O

Other	O
proteins	B-T103
related	O
to	O
the	O
innate	O
immune	O
system	O
,	O
including	O
lactotransferrin	B-T103
,	O
protegrin	B-T103
3	I-T103
and	O
galectin	B-T103
1	I-T103
were	O
also	O
identified	O
by	O
iTRAQ	B-T170
,	O
as	O
well	O
as	O
oxidative	B-T038
stress	I-T038
enzymes	B-T103
such	O
as	O
peroxiredoxin	B-T103
2	I-T103
and	O
glutathione	B-T103
peroxidase	I-T103
3	I-T103
.	O

Proteomics	B-T091
also	O
revealed	O
the	O
decrease	O
of	O
apolipoproteins	B-T103
,	O
and	O
the	O
presence	O
of	O
intracellular	B-T082
proteins	B-T103
in	O
serum	B-T031
,	O
which	O
may	O
indicate	O
physical	O
injury	O
to	O
tissues	B-T017
.	O

Housing	O
of	O
gilts	B-T204
in	O
individual	O
stalls	O
and	O
diet	O
change	O
increase	O
lipid	B-T103
and	O
protein	B-T038
catabolism	I-T038
,	O
oxidative	B-T038
stress	I-T038
,	O
activate	O
the	O
innate	O
immune	O
system	O
and	O
cause	O
a	O
certain	O
degree	O
of	O
tissue	B-T037
damage	I-T037
.	O

We	O
propose	O
that	O
valuable	O
assays	O
for	O
stress	B-T058
assessment	I-T058
in	O
gilts	B-T204
may	O
be	O
based	O
on	O
a	O
score	O
composed	O
by	O
a	O
combination	O
of	O
salivary	O
cortisol	O
,	O
lipid	B-T103
metabolites	B-T103
,	O
innate	O
immunity	O
and	O
oxidative	B-T038
stress	I-T038
markers	B-T201
and	O
intracellular	B-T082
proteins	B-T103
.	O

Cultivation	B-T058
of	O
four	O
microalgae	B-T204
species	B-T170
in	O
the	O
effluent	O
of	O
anaerobic	O
digester	O
for	O
biodiesel	B-T103
production	O

This	O
study	B-T062
investigated	O
if	O
an	O
effluent	O
from	O
anaerobic	O
digestion	O
(	O
AD	O
)	O
system	O
can	O
be	O
used	O
as	O
a	O
nutrients	B-T168
source	B-T033
for	O
the	O
microalgae	B-T204
cultivation	B-T058
,	O
and	O
in	O
so	O
doing	O
,	O
if	O
the	O
effluent	O
can	O
be	O
properly	O
treated	O
.	O

Nitrogen	B-T103
and	O
phosphorus	B-T103
in	O
the	O
AD	O
effluent	O
well	O
supported	O
microalgal	B-T204
growth	B-T038
,	O
and	O
their	O
removal	O
efficiency	O
reached	O
>	O
97	O
.	O
9	O
%	O
and	O
99	O
.	O
2	O
%	O
,	O
respectively	O
.	O

Among	O
four	O
different	O
algal	B-T204
species	B-T170
tested	O
,	O
Micractinium	B-T204
inermum	I-T204
particularly	O
stood	O
out	O
,	O
showing	O
the	O
highest	O
biomass	O
and	O
FAME	B-T103
productivity	O
:	O
0	O
.	O
16gL	O
(	O
-	O
1	O
)	O
d	O
(	O
-	O
1	O
)	O
with	O
3	O
.	O
23gL	O
(	O
-	O
1	O
)	O
of	O
dry	O
cell	B-T017
weight	O
,	O
and	O
0	O
.	O
04gL	O
(	O
-	O
1	O
)	O
d	O
(	O
-	O
1	O
)	O
with	O
27	O
.	O
54	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
FAME	B-T103
contents	O
,	O
respectively	O
.	O

As	O
the	O
concentrations	O
of	O
the	O
nutrients	B-T168
decreased	O
over	O
time	O
,	O
the	O
FAME	B-T103
contents	O
were	O
increased	O
and	O
its	O
quality	O
as	O
well	O
,	O
satisfying	O
several	O
biodiesel	B-T103
quality	O
standards	O
.	O

This	O
study	B-T062
supports	O
that	O
the	O
AD	O
effluent	O
can	O
indeed	O
serve	O
as	O
a	O
cheap	O
and	O
nutrient	B-T168
-	O
rich	O
medium	O
for	O
microalgae	B-T204
cultivation	B-T058
,	O
and	O
equally	O
importantly	O
,	O
microalgae	B-T204
can	O
be	O
a	O
workable	O
treatment	O
option	O
for	O
it	O
.	O

Antiviral	B-T033
activities	I-T033
of	O
selected	O
antimalarials	B-T103
against	O
dengue	B-T005
virus	I-T005
type	I-T005
2	I-T005
and	O
Zika	B-T005
virus	I-T005

In	O
a	O
previous	O
study	B-T062
,	I-T062
twelve	O
antimalarial	B-T103
compounds	I-T103
,	O
amodiaquine	B-T103
(	O
AQ	B-T103
)	O
and	O
derivatives	B-T103
,	O
were	O
shown	O
to	O
have	O
potent	O
anti	B-T033
-	I-T033
dengue	I-T033
viral	I-T033
(	I-T033
DENV	I-T033
)	I-T033
activity	I-T033
by	O
using	O
the	O
stable	O
DENV2	B-T005
Renilla	B-T103
luciferase	I-T103
reporter	B-T017
replicon	B-T103
expressing	B-T038
BHK	B-T017
-	I-T017
21	I-T017
cells	I-T017
,	O
infectivity	O
(	O
plaque	O
)	O
,	O
and	O
the	O
qRT	B-T062
-	I-T062
PCR	I-T062
assays	I-T062
.	O

In	O
this	O
study	B-T062
,	O
we	O
performed	O
molecular	B-T062
modeling	I-T062
on	O
these	O
compounds	B-T103
to	O
determine	O
their	O
stereo	O
-	O
electronic	O
properties	O
required	O
for	O
optimal	O
antiviral	B-T033
activity	I-T033
.	O

Based	O
on	O
the	O
similarity	O
of	O
calculated	O
stereo	O
-	O
electronic	O
profiles	O
,	O
specifically	O
the	O
electrostatic	O
potential	O
profiles	O
of	O
the	O
compounds	B-T103
,	O
and	O
in	O
silico	O
screening	O
of	O
related	O
compounds	B-T103
from	O
literature	B-T170
,	O
we	O
identified	O
three	O
additional	O
compounds	B-T103
,	O
Quinacrine	B-T103
(	O
QC	B-T103
)	O
,	O
Mefloquine	B-T103
(	O
MQ	B-T103
)	O
,	O
and	O
GSK369796	B-T103
.	O

Analysis	O
of	O
their	O
antiviral	B-T033
activities	I-T033
indicated	O
that	O
all	O
three	B-T103
compounds	I-T103
have	O
high	O
anti	B-T033
-	I-T033
DENV	I-T033
activity	I-T033
in	O
the	O
DENV2	B-T005
replicon	B-T103
expressing	B-T038
cells	B-T017
with	O
EC50	O
values	O
of	O
5	O
.	O
30	O
±	O
1	O
.	O
31	O
μM	O
(	O
QC	B-T103
)	O
,	O
3	O
.	O
22	O
±	O
0	O
.	O
37	O
μM	O
(	O
MQ	B-T103
)	O
,	O
and	O
5	O
.	O
06	O
±	O
0	O
.	O
86	O
μM	O
(	O
GSK369796	B-T103
)	O
.	O

The	O
infectivity	O
assays	O
revealed	O
the	O
EC50	O
values	O
of	O
7	O
.	O
09	O
±	O
1	O
.	O
67	O
μM	O
(	O
QC	B-T103
)	O
,	O
4	O
.	O
36	O
±	O
0	O
.	O
31	O
μM	O
(	O
MQ	B-T103
)	O
and	O
3	O
.	O
03	O
±	O
0	O
.	O
35	O
μM	O
(	O
GSK369796	B-T103
)	O
.	O

The	O
mode	O
of	O
action	O
of	O
these	O
compounds	B-T103
is	O
through	O
inhibition	O
of	O
autophagy	B-T038
,	O
thereby	O
affecting	O
DENV2	B-T005
replication	B-T038
.	O

Moreover	O
,	O
these	O
compounds	B-T103
also	O
showed	O
antiviral	B-T033
activity	I-T033
against	O
the	O
rapidly	O
emerging	O
Zika	B-T005
virus	I-T005
(	O
ZIKV	B-T005
)	O
with	O
EC50	O
values	O
of	O
2	O
.	O
27	O
±	O
0	O
.	O
14	O
μM	O
(	O
QC	B-T103
)	O
,	O
3	O
.	O
95	O
±	O
0	O
.	O
21	O
μM	O
(	O
MQ	B-T103
)	O
,	O
and	O
2	O
.	O
57	O
±	O
0	O
.	O
09	O
μM	O
(	O
GSK369796	B-T103
)	O
.	O

1	O
in	O
100	O
babies	O
:	O
the	O
fetal	B-T017
alcohol	I-T017
spectrum	I-T017
disorder	I-T017
pathway	O

Alcohol	B-T168
consumed	O
during	O
pregnancy	B-T038
is	O
the	O
nation	O
'	O
s	O
leading	O
preventable	O
cause	O
of	O
developmental	B-T038
disabilities	I-T038
and	O
birth	B-T017
defects	I-T017
.	O

One	O
in	O
100	O
babies	O
is	O
estimated	O
to	O
be	O
born	B-T038
with	O
alcohol	B-T038
-	I-T038
related	I-T038
damage	I-T038
,	O
according	O
to	O
the	O
World	B-T092
Health	I-T092
Organization	I-T092
.	O

Fetal	B-T017
alcohol	I-T017
spectrum	I-T017
disorders	I-T017
(	O
FASDs	B-T017
)	O
are	O
more	O
common	O
than	O
autism	B-T038
but	O
are	O
under	O
-	O
diagnosed	B-T033
.	O

Genotyping	B-T058
of	O
German	B-T098
and	O
Austrian	B-T098
Taylorella	B-T007
equigenitalis	I-T007
isolates	B-T103
using	O
repetitive	B-T062
extragenic	I-T062
palindromic	I-T062
(	I-T062
REP	I-T062
)	I-T062
PCR	I-T062
and	O
pulsed	B-T058
-	I-T058
field	I-T058
gel	I-T058
electrophoresis	I-T058
(	O
PFGE	B-T058
)	O

A	O
total	O
of	O
124	O
Taylorella	B-T007
(	I-T007
T	I-T007
.	I-T007
)	I-T007
equigenitalis	I-T007
and	O
five	O
T	B-T007
.	I-T007

asinigenitalis	I-T007
field	O
isolates	B-T103
collected	O
between	O
2002	O
and	O
2014	O
were	O
available	O
for	O
genotyping	B-T058
using	O
REP	B-T062
-	I-T062
(	I-T062
repetitive	I-T062
extragenic	I-T062
palindromic	I-T062
)	I-T062
PCR	I-T062
and	O
PFGE	B-T058
(	O
pulsed	B-T058
-	I-T058
field	I-T058
gel	I-T058
electrophoresis	I-T058
)	O
.	O

The	O
study	B-T062
comprised	O
79	O
T	B-T007
.	I-T007

equigenitalis	I-T007
field	O
isolates	B-T103
originating	O
from	O
ten	O
defined	O
breeds	B-T038
of	O
German	B-T204
horses	I-T204
and	O
revealed	O
a	O
spectrum	O
of	O
five	O
REP	B-T082
(	O
rep	O
-	O
E1	O
-	O
E4	O
,	O
rep	O
-	O
E3a	O
)	O
and	O
15	O
PFGE	B-T058
(	O
TE	O
-	O
A1	O
-	O
A9	O
,	O
TE	O
-	O
B1	O
-	O
B3	O
,	O
TE	O
-	O
C	O
,	O
TE	O
-	O
E1	O
,	O
and	O
TE	O
-	O
E2	O
)	O
genotypes	O
.	O

T	B-T007
.	I-T007

equigenitalis	I-T007
field	O
isolates	B-T103
(	O
n	O
=	O
40	O
)	O
obtained	O
from	O
Austrian	B-T204
Lipizzaner	I-T204
horses	I-T204
were	O
differentiated	O
into	O
three	O
REP	B-T082
(	O
rep	O
-	O
E1	O
,	O
rep	O
-	O
E3a	O
,	O
and	O
rep	O
-	O
E4	O
)	O
and	O
three	O
PFGE	B-T058
genotypes	O
(	O
TE	O
-	O
A2	O
,	O
TE	O
-	O
A5	O
,	O
and	O
TE	O
-	O
D	O
)	O
;	O
those	O
isolated	O
from	O
four	O
Austrian	B-T204
Trotters	I-T204
belonged	O
to	O
the	O
REP	B-T082
/	O
PFGE	B-T058
genotype	O
rep	O
-	O
E2	O
/	O
TE	O
-	O
A1	O
.	O

Interestingly	O
,	O
a	O
T	B-T007
.	I-T007

equigenitalis	I-T007
isolate	B-T103
recovered	O
from	O
a	O
Holsteiner	B-T204
stallion	I-T204
living	O
in	O
South	B-T082
Africa	I-T082
revealed	O
the	O
REP	B-T082
/	O
PFGE	B-T058
genotype	O
rep	O
-	O
E1	O
/	O
TE	O
-	O
A5	O
which	O
was	O
otherwise	O
exclusively	O
present	B-T033
in	O
the	O
majority	O
of	O
Austrian	B-T204
Lipizzaner	I-T204
horses	I-T204
in	O
our	O
study	B-T062
.	O

The	O
type	O
strain	O
included	O
in	O
this	O
study	B-T062
revealed	O
the	O
genotype	O
REP	B-T082
/	O
PFGE	B-T058
rep	O
-	O
E1	O
/	O
TE	O
-	O
F	O
.	O

Six	O
strains	O
of	O
T	B-T007
.	I-T007

asinigenitalis	I-T007
including	O
the	O
type	O
strain	O
were	O
separated	O
into	O
three	O
REP	B-T082
(	O
rep	O
-	O
A1	O
-	O
A3	O
)	O
and	O
six	O
PFGE	B-T058
genotypes	O
(	O
TA	O
-	O
A1	O
,	O
TA	O
-	O
A2	O
,	O
TA	O
-	O
A3	O
,	O
TA	O
-	O
B	O
,	O
TA	O
-	O
C	O
,	O
TA	O
-	O
D	O
)	O
.	O

Overall	O
,	O
the	O
generated	O
REP	B-T082
and	O
PFGE	B-T058
genotypes	O
showed	O
a	O
good	O
correlation	O
,	O
whereas	O
REP	B-T062
-	I-T062
PCR	I-T062
proved	O
to	O
be	O
a	O
suitable	B-T058
method	I-T058
for	O
molecular	B-T058
epidemiological	I-T058
screening	I-T058
of	O
T	B-T007
.	I-T007

equigenitalis	I-T007
and	O
T	B-T007
.	I-T007

asinigenitalis	I-T007
isolates	B-T103
that	O
should	O
be	O
differentiated	O
in	O
detail	O
by	O
genotyping	B-T058
using	O
PFGE	B-T058
.	O

The	O
Urokinase	B-T103
/	O
Urokinase	B-T103
Receptor	I-T103
System	O
in	O
Mast	B-T017
Cells	I-T017
:	O
Effects	O
of	O
its	O
Functional	O
Interaction	O
with	O
fMLF	B-T103
Receptors	I-T103

Mast	B-T017
cell	I-T017
and	O
basophils	B-T017
express	O
the	O
high	B-T103
affinity	I-T103
receptor	I-T103
for	O
IgE	B-T103
(	O
FcɛRI	B-T103
)	O
and	O
are	O
primary	B-T017
effector	I-T017
cells	I-T017
of	O
allergic	B-T038
disorders	I-T038
.	O

The	O
urokinase	B-T103
(	O
uPA	B-T103
)	O
-	O
mediated	O
plasminogen	B-T038
activation	I-T038
system	I-T038
is	O
involved	O
in	O
physiological	B-T038
and	O
pathological	B-T038
events	I-T038
based	O
on	O
cell	B-T038
migration	I-T038
and	O
tissue	O
remodelling	O
,	O
such	O
as	O
inflammation	B-T038
,	O
wound	B-T038
healing	I-T038
,	O
angiogenesis	B-T038
and	O
metastasis	B-T038
.	O

uPA	B-T103
is	O
a	O
serine	B-T103
protease	I-T103
that	O
binds	O
uPAR	B-T103
,	O
a	O
high	B-T103
affinity	I-T103
glycosyl	I-T103
-	I-T103
phosphatidyl	I-T103
-	I-T103
inositol	I-T103
(	I-T103
GPI	I-T103
)	I-T103
-	I-T103
anchored	I-T103
receptor	B-T103
.	O

uPAR	B-T103
focuses	O
uPA	B-T103
activity	B-T038
at	O
the	O
cell	B-T017
surface	I-T017
and	O
activates	B-T038
intracellular	I-T038
signaling	I-T038
through	O
lateral	O
interactions	O
with	O
integrins	B-T103
,	O
receptor	B-T103
tyrosine	I-T103
kinases	I-T103
and	O
the	O
G	B-T103
-	I-T103
protein	I-T103
-	I-T103
coupled	I-T103
family	I-T103
of	O
fMLF	B-T103
chemotaxis	I-T103
receptors	I-T103
(	O
FPRs	B-T103
)	O
.	O

We	O
investigated	O
the	O
expression	B-T038
of	O
the	O
uPA	B-T103
-	O
uPAR	B-T103
system	O
and	O
its	O
functional	O
interaction	O
with	O
FPRs	B-T103
in	O
human	B-T204
mast	B-T017
cells	I-T017
(	O
MCs	B-T017
)	O
.	O

Differently	O
from	O
basophils	B-T017
,	O
MCs	B-T017
produced	O
uPA	B-T103
that	O
was	O
able	O
to	O
induce	O
their	O
chemotaxis	B-T038
.	O

Indeed	O
,	O
MCs	B-T017
also	O
expressed	O
uPAR	B-T103
,	O
both	O
in	O
the	O
intact	O
and	O
in	O
a	O
cleaved	O
form	O
(	O
DII	B-T103
-	I-T103
DIII	I-T103
-	I-T103
uPAR	I-T103
)	O
that	O
can	O
expose	O
,	O
at	O
the	O
N	O
-	O
terminus	O
,	O
the	O
SRSRY	B-T082
sequence	I-T082
,	O
able	O
to	O
interact	O
with	O
FPRs	B-T103
and	O
to	O
mediate	O
cell	B-T038
chemotaxis	I-T038
.	O

MCs	B-T017
also	O
expressed	O
mRNAs	B-T103
for	O
FPRs	B-T103
that	O
were	O
functionally	O
active	O
;	O
indeed	O
,	O
uPA	B-T103
and	O
a	O
soluble	B-T103
peptide	I-T103
(	O
uPAR84	B-T103
-	I-T103
95	I-T103
)	O
,	O
containing	O
the	O
SRSRY	B-T082
chemotactic	I-T082
sequence	I-T082
of	O
uPAR	B-T103
and	O
able	O
to	O
interact	O
with	O
FPRs	B-T103
,	O
were	O
able	O
to	O
induce	O
MCs	B-T017
chemotaxis	B-T038
.	O

Thus	O
,	O
uPA	B-T103
is	O
a	O
potent	O
chemoattractant	B-T103
for	O
MCs	B-T017
acting	O
through	O
the	O
exposure	O
of	O
the	O
chemotactic	B-T038
epitope	B-T103
of	O
uPAR	B-T103
,	O
that	O
is	O
an	O
endogenous	O
ligand	B-T103
for	O
FPRs	B-T103
.	O

The	O
same	O
mechanism	O
could	O
be	O
involved	O
in	O
VEGF	B-T103
-	I-T103
A	I-T103
secretion	B-T038
by	O
human	B-T204
MCs	B-T017
,	O
also	O
induced	O
by	O
uPA	B-T103
and	O
uPAR84	B-T103
-	I-T103
95	I-T103
stimulation	B-T038
.	I-T038

Psychogenic	B-T038
non	I-T038
-	I-T038
epileptic	I-T038
seizure	I-T038
in	O
patients	O
with	O
intellectual	B-T038
disability	I-T038
with	O
special	O
focus	O
on	O
choice	O
of	O
therapeutic	B-T058
intervention	I-T058

There	O
have	O
been	O
a	O
number	O
of	O
studies	B-T062
exploring	O
treatments	B-T058
for	O
psychogenic	B-T038
non	I-T038
-	I-T038
epileptic	I-T038
seizure	I-T038
(	O
PNES	B-T038
)	O
but	O
largely	O
neglecting	B-T033
the	O
sizable	O
subgroup	B-T170
of	O
patients	O
with	O
intellectual	B-T038
disability	I-T038
(	O
ID	B-T038
)	O
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
attempted	O
to	O
demonstrate	O
effects	O
and	O
preferred	O
modes	O
of	O
therapeutic	B-T058
intervention	I-T058
in	O
PNES	B-T038
patients	O
with	O
ID	B-T038
being	O
treated	O
at	O
a	O
Japanese	B-T092
municipal	I-T092
center	I-T092
with	O
a	O
short	O
referral	B-T058
chain	I-T058
.	O

We	O
examined	B-T033
46	O
PNES	B-T038
patients	O
with	O
ID	B-T038
(	O
ID	B-T038
group	O
)	O
and	O
106	O
PNES	B-T038
patients	O
without	O
ID	B-T038
(	O
non	B-T033
-	I-T033
ID	I-T033
group	O
)	O
retrospectively	O
in	O
case	O
charts	O
.	O

In	O
addition	O
to	O
examining	B-T033
basic	O
demographic	O
and	O
clinical	B-T170
data	I-T170
,	O
effects	O
of	O
different	O
therapeutic	B-T058
intervention	I-T058
were	O
examined	B-T033
as	O
a	O
function	O
of	O
decrease	O
or	O
disappearance	O
of	O
PNES	B-T038
attacks	O
in	O
the	O
ID	B-T038
group	O
.	O

Age	O
at	O
the	O
first	O
visit	B-T058
as	O
well	O
as	O
PNES	B-T038
onset	O
was	O
younger	O
in	O
the	O
ID	B-T038
than	O
in	O
the	O
non	B-T033
-	I-T033
ID	I-T033
group	O
(	O
t	O
=	O
2	O
.	O
651	O
,	O
p	O
=	O
0	O
.	O
009	O
;	O
t	O
=	O
3	O
.	O
528	O
,	O
p	O
=	O
0	O
.	O
001	O
,	O
respectively	O
)	O
.	O

PNES	B-T038
-	O
free	O
ratio	O
at	O
the	O
last	O
visit	B-T058
tended	O
to	O
be	O
higher	O
in	O
the	O
non	B-T033
-	I-T033
ID	I-T033
group	O
(	O
chi	O
square	O
=	O
3	O
.	O
455	O
;	O
p	O
=	O
0	O
.	O
063	O
)	O
.	O

Psychosis	B-T038
was	O
more	O
often	O
encountered	O
in	O
the	O
ID	B-T038
group	O
(	O
chi	O
square	O
=	O
13	O
.	O
443	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Although	O
cognitive	B-T058
therapy	I-T058
and	O
pharmaco	B-T058
-	I-T058
therapeutic	I-T058
approaches	O
were	O
quite	O
similarly	O
distributed	O
in	O
both	O
groups	O
,	O
environmental	B-T082
adjustment	O
was	O
often	O
introduced	O
in	O
the	O
ID	B-T038
group	O
(	O
44	O
%	O
)	O
as	O
compared	O
to	O
the	O
non	B-T033
-	I-T033
ID	I-T033
group	O
(	O
15	O
%	O
)	O
(	O
chi	O
square	O
=	O
14	O
.	O
299	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Brief	O
weekly	O
visit	B-T058
service	I-T058
is	O
also	O
more	O
often	O
utilized	O
by	O
the	O
patients	O
with	O
ID	B-T038
(	O
54	O
%	O
)	O
than	O
by	O
those	O
without	O
ID	B-T038
(	O
35	O
%	O
)	O
(	O
chi	O
square	O
=	O
5	O
.	O
021	O
,	O
p	O
=	O
0	O
.	O
025	O
)	O
.	O

Optimal	O
treatment	B-T058
approaches	O
in	O
this	O
sizable	O
patient	O
subgroup	B-T170
should	O
be	O
the	O
subject	O
of	O
future	O
prospective	B-T062
studies	I-T062
.	O

Effect	O
of	O
an	O
immunomodulatory	B-T058
regimen	I-T058
for	O
cancer	B-T058
prevention	I-T058
:	O
A	O
case	B-T170
report	I-T170

In	O
the	O
present	B-T033
case	B-T170
study	I-T170
,	O
an	O
immunomodulatory	B-T058
regimen	I-T058
for	O
cancer	B-T058
prevention	I-T058
is	O
reported	B-T058
.	O

A	O
patient	O
with	O
an	O
abnormally	O
high	O
level	O
of	O
the	O
tumor	B-T103
markers	I-T103
,	O
carbohydrate	B-T103
antigen	I-T103
-	I-T103
724	I-T103
(	O
CA724	B-T103
)	O
,	O
CA19	B-T103
-	I-T103
9	I-T103
and	O
carcinoembryonic	B-T103
antigen	I-T103
(	O
CEA	B-T103
)	O
,	O
although	O
without	O
any	O
detectable	B-T201
tumor	B-T038
,	O
was	O
treated	B-T058
with	I-T058
an	O
immunomodulatory	B-T058
therapy	I-T058
featuring	O
an	O
infusion	B-T058
of	O
cytokine	B-T017
-	I-T017
induced	I-T017
autologous	I-T017
killer	I-T017
cells	I-T017
(	O
CIKs	B-T017
)	O
at	O
the	O
request	O
of	O
the	O
patient	O
.	O

Following	O
the	O
therapy	B-T058
,	O
the	O
three	O
tumor	B-T103
markers	I-T103
rapidly	O
decreased	O
to	O
below	O
the	O
normal	O
reference	O
level	O
,	O
although	O
there	O
still	O
were	O
slight	O
fluctuations	O
within	O
a	O
narrow	O
range	O
frequently	O
.	O

The	O
patient	O
was	O
monitored	B-T058
for	O
21	O
months	O
to	O
the	O
present	B-T033
day	O
and	O
no	B-T033
abnormality	I-T033
was	O
observed	O
.	O

The	O
results	O
indicated	O
that	O
this	O
therapy	B-T058
may	O
be	O
applied	O
as	O
a	O
novel	O
strategy	O
that	O
is	O
effective	O
and	O
reliable	O
for	O
cancer	B-T058
prevention	I-T058
.	O

As	O
there	O
is	O
no	O
promising	O
regimen	B-T058
for	O
the	O
prevention	B-T058
of	I-T058
malignancies	I-T058
to	O
date	O
,	O
such	O
a	O
treatment	B-T058
may	O
become	O
a	O
major	O
cancer	B-T038
prophylactic	B-T058
regimen	I-T058
,	O
particularly	O
for	O
patients	O
who	O
are	O
at	O
a	O
high	B-T033
risk	I-T033
of	I-T033
cancer	B-T038
.	O

The	O
relationships	O
between	O
rugby	O
players	B-T098
'	I-T098
tackle	O
training	O
attitudes	B-T038
and	O
behaviour	O
and	O
their	O
match	B-T038
tackle	I-T038
attitudes	I-T038
and	O
behaviour	O

The	O
tackle	O
event	O
in	O
rugby	O
is	O
a	O
technical	O
and	O
physical	O
contest	O
between	O
opposing	O
players	B-T098
.	O

A	O
player	B-T098
'	I-T098
s	I-T098
ability	O
to	O
tolerate	O
and	O
contest	O
during	O
a	O
tackle	O
is	O
a	O
prerequisite	O
for	O
safe	O
participation	O
and	O
success	O
in	O
rugby	O
.	O

Little	O
is	O
known	O
about	O
the	O
relationship	O
between	O
tackle	O
training	O
and	O
tackling	O
in	O
matches	O
in	O
rugby	O
union	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
relationships	O
between	O
players	B-T098
'	I-T098
training	B-T038
attitudes	I-T038
and	O
behaviour	O
and	O
their	O
match	B-T038
attitudes	I-T038
and	O
behaviour	O
for	O
tackling	O
in	O
rugby	O
union	O
.	O

A	O
questionnaire	B-T170
was	O
designed	O
to	O
assess	O
attitude	B-T038
(	O
importance	O
)	O
and	O
behaviours	O
(	O
frequency	O
and	O
quantity	O
)	O
among	O
junior	O
(	O
under	O
19	O
)	O
players	B-T098
on	O
a	O
5	B-T170
-	I-T170
point	I-T170
Likert	I-T170
Scale	I-T170
.	O

Questionnaires	B-T170
were	O
handed	O
out	O
to	O
220	O
players	B-T098
(	O
10	O
schools	B-T092
)	O
at	O
a	O
tournament	O
and	O
75	O
%	O
(	O
9	O
schools	B-T092
,	O
n	O
=	O
164	O
)	O
were	O
returned	O
for	O
analysis	B-T062
.	O

Associations	B-T038
between	O
training	B-T038
attitudes	I-T038
and	O
behaviours	O
were	O
tested	O
using	O
the	O
χ	B-T170
(	I-T170
2	I-T170
)	I-T170
test	I-T170
,	I-T170
Cramer	I-T170
'	I-T170
s	I-T170
V	I-T170
and	I-T170
τ	I-T170
-	I-T170
b	I-T170
.	O

The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	O
to	O
prevent	O
injuries	B-T037
in	O
training	O
,	O
the	O
more	O
important	O
players	B-T098
rated	O
'	O
own	O
safety	O
'	O
(	O
τ	O
-	O
b	O
=	O
0	O
.	O
21	O
,	O
moderate	O
,	O
z	O
=	O
3	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
'	O
going	O
for	O
the	O
ball	O
only	O
'	O
(	O
τ	O
-	O
b	O
=	O
0	O
.	O
27	O
,	O
moderate	O
,	O
z	O
=	O
4	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
'	O
staying	O
on	O
feet	O
'	O
(	O
τ	O
-	O
b	O
=	O
0	O
.	O
23	O
,	O
moderate	O
,	O
z	O
=	O
3	O
.	O
6	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
match	O
play	O
.	O

The	O
more	O
time	O
spent	O
on	O
emphasising	O
proper	O
technique	O
to	O
improve	B-T033
performance	O
in	O
training	O
,	O
the	O
more	O
important	O
players	B-T098
rated	O
actions	O
'	O
going	O
for	O
ball	O
only	O
'	O
(	O
τ	O
-	O
b	O
=	O
0	O
.	O
23	O
,	O
moderate	O
,	O
z	O
=	O
3	O
.	O
7	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
'	O
preventing	O
the	O
ball	O
carrier	O
from	O
retaining	O
position	B-T082
'	O
(	O
τ	O
-	O
b	O
=	O
0	O
.	O
20	O
,	O
moderate	O
,	O
z	O
=	O
3	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
match	O
play	O
.	O

This	O
is	O
the	O
first	O
study	B-T062
to	O
report	O
on	O
the	O
relationships	O
between	O
players	B-T098
'	O
training	B-T038
attitudes	I-T038
and	O
behaviour	O
and	O
their	O
match	B-T038
attitudes	I-T038
and	O
behaviour	O
s	O
for	O
tackling	O
in	O
rugby	O
union	O
.	O

The	O
importance	O
of	O
tackle	O
training	O
to	O
prevent	O
injury	B-T037
,	O
and	O
the	O
amount	O
of	O
time	O
spent	O
on	O
technique	O
to	O
prevent	O
injuries	B-T037
,	O
was	O
associated	O
with	O
behaviours	O
that	O
reduce	O
the	O
risk	B-T033
of	I-T033
injury	I-T033
in	O
matches	O
.	O

Role	O
of	O
Oxidative	B-T038
Stress	I-T038
and	O
Inflammatory	O
Factors	O
in	O
Diabetic	B-T038
Kidney	I-T038
Disease	I-T038

Diabetic	B-T038
nephropathy	I-T038
(	O
DN	B-T038
)	O
is	O
a	O
serious	O
complication	B-T038
of	O
diabetes	B-T038
mellitus	I-T038
,	O
and	O
its	O
prevalence	O
has	O
been	O
increasing	O
in	O
developed	O
countries	O
.	O

Diabetic	B-T038
nephropathy	I-T038
has	O
become	O
the	O
most	O
common	O
single	O
cause	O
of	O
end	B-T038
-	I-T038
stage	I-T038
renal	I-T038
disease	I-T038
worldwide	B-T098
.	O

Oxidative	B-T038
stress	I-T038
and	O
inflammation	B-T038
factors	O
are	O
hypothesized	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
late	O
diabetes	B-T038
complications	I-T038
.	O

Chronic	B-T038
hyperglycemia	I-T038
increases	O
oxidative	B-T038
stress	I-T038
,	O
significantly	O
modifies	O
the	O
structure	B-T082
and	O
function	B-T038
of	O
proteins	B-T103
and	O
lipids	B-T103
,	O
and	O
induces	O
glycoxidation	O
and	O
peroxidation	O
.	O

Therefore	O
,	O
hyperglycemia	B-T038
causes	O
auto	O
-	O
oxidation	O
of	O
glucose	B-T103
,	O
glycation	O
of	O
proteins	B-T103
,	O
and	O
activation	O
of	O
polyol	O
mechanism	O
.	O

Overproduction	O
of	O
intracellular	B-T082
reactive	B-T103
oxygen	I-T103
species	I-T103
contributes	O
to	O
several	O
microvascular	O
and	O
macrovascular	O
complications	B-T038
of	O
DN	B-T038
.	O

On	O
the	O
other	O
hand	O
,	O
reactive	B-T103
oxygen	I-T103
species	I-T103
modulates	B-T082
signaling	B-T038
cascade	I-T038
of	O
immune	B-T103
factors	I-T103
.	O

An	O
increase	O
in	O
reactive	B-T103
oxygen	I-T103
species	I-T103
can	O
increase	O
the	O
production	O
of	O
inflammatory	O
cytokines	B-T103
,	O
and	O
likewise	O
,	O
an	O
increase	O
in	O
inflammatory	O
cytokines	B-T103
can	O
stimulate	O
the	O
production	O
of	O
free	B-T103
radicals	I-T103
.	O

Some	O
studies	B-T062
have	O
shown	O
that	O
kidney	B-T038
inflammation	I-T038
is	O
serious	O
in	O
promoting	O
the	O
development	O
and	O
progression	O
of	O
DN	B-T038
.	O

Inflammatory	O
factors	O
which	O
are	O
activated	O
by	O
the	O
metabolic	O
,	O
biochemical	O
,	O
and	O
hemodynamic	B-T038
derangements	O
are	O
known	O
to	O
exist	O
in	O
the	O
diabetic	B-T038
kidney	I-T038
.	O

This	O
review	B-T170
discusses	O
facts	O
for	O
oxidative	B-T038
stress	I-T038
and	O
inflammatory	O
factors	O
in	O
DN	B-T038
and	O
encompasses	O
the	O
role	O
of	O
immune	B-T017
and	O
inflammatory	B-T017
cells	I-T017
,	O
inflammatory	O
cytokines	B-T103
,	O
and	O
stress	B-T038
oxidative	I-T038
factors	O
.	O

Cobalt	B-T074
-	I-T074
60	I-T074
Machines	I-T074
and	O
Medical	B-T074
Linear	I-T074
Accelerators	I-T074
:	O
Competing	O
Technologies	O
for	O
External	B-T058
Beam	I-T058
Radiotherapy	I-T058

Medical	B-T074
linear	I-T074
accelerators	I-T074
(	O
linacs	B-T074
)	O
and	O
cobalt	B-T074
-	I-T074
60	I-T074
machines	I-T074
are	O
both	O
mature	O
technologies	O
for	O
external	B-T058
beam	I-T058
radiotherapy	I-T058
.	O

A	O
comparison	O
is	O
made	O
between	O
these	O
two	O
technologies	O
in	O
terms	O
of	O
infrastructure	B-T170
and	O
maintenance	O
,	O
dosimetry	B-T058
,	O
shielding	B-T033
requirements	O
,	O
staffing	O
,	O
costs	O
,	O
security	O
,	O
patient	O
throughput	O
and	O
clinical	O
use	O
.	O

Infrastructure	B-T170
and	O
maintenance	O
are	O
more	O
demanding	O
for	O
linacs	B-T074
due	O
to	O
the	O
complex	O
electric	O
componentry	O
.	O

In	O
dosimetry	B-T058
,	O
a	O
higher	O
beam	O
energy	O
,	O
modulated	B-T082
dose	O
rate	O
and	O
smaller	O
focal	O
spot	O
size	O
mean	O
that	O
it	O
is	O
easier	B-T033
to	O
create	O
an	O
optimised	O
treatment	B-T058
with	O
a	O
linac	B-T074
for	O
conformal	O
dose	O
coverage	O
of	O
the	O
tumour	B-T038
while	O
sparing	O
healthy	B-T017
organs	I-T017
at	O
risk	O
.	O

In	O
shielding	B-T033
,	O
the	O
requirements	O
for	O
a	O
concrete	O
bunker	O
are	O
similar	O
for	O
cobalt	B-T074
-	I-T074
60	I-T074
machines	I-T074
and	O
linacs	B-T074
but	O
extra	O
shielding	B-T033
and	O
protection	O
from	O
neutrons	O
are	O
required	O
for	O
linacs	B-T074
.	O

Staffing	O
levels	O
can	O
be	O
higher	O
for	O
linacs	B-T074
and	O
more	O
staff	O
training	O
is	O
required	O
for	O
linacs	B-T074
.	O

Life	O
cycle	O
costs	O
are	O
higher	O
for	O
linacs	B-T074
,	O
especially	O
multi	B-T074
-	I-T074
energy	I-T074
linacs	I-T074
.	O

Security	O
is	O
more	O
complex	O
for	O
cobalt	B-T074
-	I-T074
60	I-T074
machines	I-T074
because	O
of	O
the	O
high	O
activity	O
radioactive	B-T103
source	I-T103
.	O

Patient	O
throughput	O
can	O
be	O
affected	O
by	O
source	B-T033
decay	O
for	O
cobalt	B-T074
-	I-T074
60	I-T074
machines	I-T074
but	O
poor	O
maintenance	O
and	O
breakdowns	O
can	O
severely	O
affect	O
patient	O
throughput	O
for	O
linacs	B-T074
.	O

In	O
clinical	O
use	O
,	O
more	O
complex	O
treatment	B-T058
techniques	O
are	O
easier	B-T033
to	O
achieve	O
with	O
linacs	B-T074
,	O
and	O
the	O
availability	O
of	O
electron	O
beams	O
on	O
high	O
-	O
energy	O
linacs	B-T074
can	O
be	O
useful	O
for	O
certain	O
treatments	B-T058
.	O

In	O
summary	O
,	O
there	O
is	O
no	O
simple	O
answer	O
to	O
the	O
question	O
of	O
the	O
choice	O
of	O
either	O
cobalt	B-T074
-	I-T074
60	I-T074
machines	I-T074
or	O
linacs	B-T074
for	O
radiotherapy	B-T058
in	O
low	B-T033
-	I-T033
and	O
middle	O
-	O
income	O
countries	B-T082
.	O

In	O
fact	O
a	O
radiotherapy	B-T092
department	I-T092
with	O
a	O
combination	O
of	O
technologies	O
,	O
including	O
orthovoltage	B-T092
X	I-T092
-	I-T092
ray	I-T092
units	I-T092
,	O
may	O
be	O
an	O
option	O
.	O

Local	B-T082
needs	O
,	O
conditions	O
and	O
resources	O
will	O
have	O
to	O
be	O
factored	O
into	O
any	O
decision	B-T038
on	O
technology	O
taking	O
into	O
account	O
the	O
characteristics	O
of	O
both	O
forms	O
of	O
teletherapy	B-T058
,	O
with	O
the	O
primary	O
goal	B-T170
being	O
the	O
sustainability	O
of	O
the	O
radiotherapy	B-T092
service	I-T092
over	O
the	O
useful	O
lifetime	O
of	O
the	O
equipment	O
.	O

Design	O
,	O
synthesis	O
,	O
molecular	B-T170
docking	I-T170
,	O
anti	B-T103
-	I-T103
Proteus	I-T103
mirabilis	I-T103
and	O
urease	B-T103
inhibition	B-T038
of	O
new	O
fluoroquinolone	B-T103
carboxylic	I-T103
acid	I-T103
derivatives	I-T103

New	O
hydroxamic	B-T103
acid	I-T103
,	O
hydrazide	B-T103
and	O
amide	B-T103
derivatives	I-T103
of	O
ciprofloxacin	B-T103
in	O
addition	O
to	O
their	O
analogues	B-T103
of	O
levofloxacin	B-T103
were	O
prepared	O
and	O
identified	O
by	O
different	O
spectroscopic	O
techniques	O
.	O

Some	O
of	O
the	O
prepared	O
compounds	B-T103
revealed	O
good	O
activity	B-T038
against	O
the	O
urease	B-T103
splitting	O
bacteria	B-T007
,	O
Proteus	B-T007
mirabilis	I-T007
.	O

The	O
urease	B-T103
inhibitory	B-T038
activity	I-T038
was	O
investigated	O
using	O
indophenol	B-T058
method	I-T058
.	O

Most	O
of	O
the	O
tested	B-T170
compounds	B-T103
showed	O
better	O
activity	B-T038
than	O
the	O
reference	O
acetohydroxamic	B-T103
acid	I-T103
(	O
AHA	B-T103
)	O
.	O

The	O
ciprofloxacin	B-T103
hydrazide	I-T103
derivative	I-T103
3a	I-T103
and	O
levofloxacin	B-T103
hydroxamic	I-T103
acid	I-T103
7	I-T103
experienced	O
the	O
highest	O
activity	B-T038
(	O
IC50	O
=	O
1	O
.	O
22μM	O
and	O
2	O
.	O
20μM	O
,	O
respectively	O
)	O
.	O

Molecular	B-T170
docking	I-T170
study	I-T170
revealed	O
high	O
spontaneous	O
binding	B-T038
ability	I-T038
of	O
the	O
tested	B-T170
compounds	B-T103
to	O
the	O
active	O
site	O
of	O
urease	B-T103
.	O

Interobserver	O
and	O
Intraobserver	O
Reliability	O
of	O
Clinical	O
Assessments	O
in	O
Knee	B-T038
Osteoarthritis	I-T038

Clinical	O
examination	O
of	O
the	O
knee	B-T017
is	O
subject	O
to	O
measurement	O
error	O
.	O

The	O
aim	O
of	O
this	O
analysis	O
was	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
reliability	O
of	O
commonly	O
used	O
clinical	O
tests	O
in	O
patients	O
with	O
knee	B-T038
osteoarthritis	I-T038
(	O
OA	B-T038
)	O
.	O

We	O
studied	O
subjects	O
with	O
symptomatic	O
knee	B-T038
OA	I-T038
who	O
were	O
participants	B-T098
in	O
an	O
open	B-T062
-	I-T062
label	I-T062
clinical	I-T062
trial	I-T062
of	O
intraarticular	B-T058
steroid	I-T058
therapy	I-T058
.	O

Following	O
standardization	B-T062
of	O
the	O
clinical	B-T058
test	I-T058
procedures	I-T058
,	O
2	O
clinicians	B-T097
assessed	B-T058
25	O
subjects	O
independently	O
at	O
the	O
same	O
visit	B-T058
,	O
and	O
the	O
same	O
clinician	B-T097
assessed	B-T058
88	O
subjects	O
over	O
an	O
interval	O
period	O
of	O
2	O
-	O
10	O
weeks	O
;	O
in	O
both	O
cases	O
prior	O
to	O
the	O
steroid	B-T058
intervention	B-T058
.	O

Clinical	O
examination	O
included	O
assessment	B-T058
of	O
bony	O
enlargement	O
,	O
crepitus	B-T038
,	O
quadriceps	B-T033
wasting	I-T033
,	O
knee	B-T033
effusion	I-T033
,	O
joint	B-T082
-	I-T082
line	I-T082
and	O
anserine	B-T017
tenderness	B-T033
,	O
and	O
knee	B-T033
range	I-T033
of	I-T033
movement	I-T033
(	O
ROM	B-T033
)	O
.	O

Intraclass	O
correlation	O
coefficients	O
(	O
ICC	O
)	O
,	O
estimated	O
kappa	O
(	O
κ	O
)	O
,	O
weighted	O
kappa	O
(	O
κω	O
)	O
,	O
and	O
Bland	O
-	O
Altman	O
plots	O
were	O
used	O
to	O
determine	O
interobserver	O
and	O
intraobserver	O
levels	O
of	O
agreement	O
.	O

Using	O
Landis	O
and	O
Koch	O
criteria	O
,	O
interobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
patellofemoral	B-T082
joint	I-T082
(	O
κ	O
=	O
0	O
.	O
53	O
)	O
and	O
anserine	B-T017
tenderness	B-T033
(	O
κ	O
=	O
0	O
.	O
48	O
)	O
;	O
good	O
for	O
bony	O
enlargement	O
(	O
κ	O
=	O
0	O
.	O
66	O
)	O
,	O
quadriceps	B-T033
wasting	I-T033
(	O
κ	O
=	O
0	O
.	O
78	O
)	O
,	O
crepitus	B-T038
(	O
κ	O
=	O
0	O
.	O
78	O
)	O
,	O
medial	B-T082
tibiofemoral	B-T082
joint	I-T082
tenderness	B-T033
(	O
κ	O
=	O
0	O
.	O
76	O
)	O
,	O
and	O
effusion	B-T033
assessed	O
by	O
ballottement	B-T033
(	O
κ	O
=	O
0	O
.	O
73	O
)	O
and	O
bulge	B-T058
sign	I-T058
(	O
κω	O
=	O
0	O
.	O
78	O
)	O
;	O
and	O
excellent	O
for	O
lateral	B-T082
tibiofemoral	B-T082
joint	I-T082
tenderness	B-T033
(	O
κ	O
=	O
1	O
.	O
00	O
)	O
,	O
flexion	B-T038
(	O
ICC	O
=	O
0	O
.	O
97	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0	O
.	O
87	O
)	O
ROM	B-T033
.	O

Intraobserver	O
κ	O
scores	O
were	O
moderate	O
for	O
lateral	B-T082
tibiofemoral	B-T082
joint	I-T082
tenderness	B-T033
(	O
κ	O
=	O
0	O
.	O
60	O
)	O
;	O
good	O
for	O
crepitus	O
(	O
κ	O
=	O
0	O
.	O
78	O
)	O
,	O
effusion	B-T033
assessed	O
by	O
ballottement	B-T033
test	I-T033
(	O
κ	O
=	O
0	O
.	O
77	O
)	O
,	O
patellofemoral	B-T082
joint	I-T082
(	O
κ	O
=	O
0	O
.	O
66	O
)	O
,	O
medial	B-T082
tibiofemoral	B-T082
joint	I-T082
(	O
κ	O
=	O
0	O
.	O
64	O
)	O
,	O
and	O
anserine	B-T017
tenderness	B-T033
(	O
κ	O
=	O
0	O
.	O
73	O
)	O
;	O
and	O
excellent	O
for	O
effusion	B-T033
assessed	O
by	O
bulge	B-T058
sign	I-T058
(	O
κω	O
=	O
0	O
.	O
83	O
)	O
,	O
bony	O
enlargement	O
(	O
κ	O
=	O
0	O
.	O
98	O
)	O
,	O
quadriceps	B-T033
wasting	I-T033
(	O
κ	O
=	O
0	O
.	O
83	O
)	O
,	O
flexion	B-T038
(	O
ICC	O
=	O
0	O
.	O
99	O
)	O
,	O
and	O
extension	O
(	O
ICC	O
=	O
0	O
.	O
96	O
)	O
ROM	B-T033
.	O

Among	O
individuals	B-T098
with	O
symptomatic	O
knee	B-T038
OA	I-T038
,	O
the	O
reliability	O
of	O
clinical	O
examination	O
of	O
the	O
knee	B-T017
was	O
at	O
least	O
good	O
for	O
the	O
majority	O
of	O
clinical	B-T033
signs	I-T033
of	O
knee	B-T038
OA	I-T038
.	O

Assessing	O
the	O
benefits	O
of	O
targeted	O
drug	B-T074
delivery	I-T074
by	O
nanocarriers	O
:	O
A	O
partico	O
/	O
pharmacokinetic	O
framework	O

An	O
in	B-T082
vivo	I-T082
kinetic	O
framework	O
is	O
introduced	O
to	O
analyze	B-T062
and	O
predict	O
the	O
quantitative	O
advantage	O
of	O
using	O
nanocarriers	O
to	O
deliver	B-T074
drugs	I-T074
,	O
especially	O
anticancer	B-T103
agents	I-T103
,	O
compared	O
to	O
administering	B-T058
the	O
same	O
drugs	B-T103
in	O
their	O
free	O
form	O
.	O

This	O
framework	O
recognizes	O
three	O
levels	O
of	O
kinetics	B-T038
.	O

First	O
is	O
the	O
particokinetics	O
associated	O
with	O
deposition	O
of	O
nanocarriers	O
into	O
tissues	B-T017
associated	O
with	O
drug	O
effect	O
and	O
toxicity	B-T037
,	O
their	O
residence	B-T082
inside	O
those	O
tissues	B-T017
,	O
and	O
elimination	O
of	O
the	O
nanocarriers	O
from	O
the	O
body	B-T204
.	O

Second	O
is	O
the	O
release	B-T033
pattern	I-T033
in	O
time	O
of	O
free	O
drug	O
from	O
the	O
nanocarriers	O
.	O

Third	O
is	O
the	O
pharmacokinetics	B-T038
of	O
free	O
drug	O
,	O
as	O
it	O
relates	O
to	O
deposition	O
and	O
elimination	O
processes	O
in	O
the	O
target	O
and	O
toxicity	B-T037
associated	O
tissues	B-T017
,	O
and	O
total	B-T033
body	I-T033
clearance	I-T033
.	O

A	O
figure	O
of	O
merit	O
,	O
the	O
drug	O
targeting	O
index	O
(	O
DTI	O
)	O
,	O
is	O
used	O
to	O
quantitate	O
the	O
benefit	O
of	O
nanocarrier	O
based	O
drug	B-T074
delivery	I-T074
by	O
considering	O
the	O
effects	O
of	O
preferential	O
deposition	O
of	O
nanoparticles	O
into	O
target	O
tissues	B-T017
and	O
relative	O
avoidance	O
of	O
tissues	B-T017
associated	O
with	O
drug	B-T037
toxicity	I-T037
,	O
compared	O
to	O
drug	B-T103
that	O
is	O
administered	B-T058
in	O
its	O
free	O
form	O
.	O

General	O
methods	B-T170
are	O
derived	O
for	O
calculating	O
DTI	O
when	O
appropriate	O
particokinetic	O
,	O
pharmacokinetic	O
,	O
and	O
drug	O
release	O
rate	O
information	O
is	O
available	O
,	O
and	O
it	O
is	O
shown	O
that	O
relatively	O
simple	O
algebraic	O
forms	O
result	O
when	O
some	O
common	O
assumptions	O
are	O
made	O
.	O

This	O
approach	O
may	O
find	O
use	O
in	O
developing	B-T091
and	O
selecting	O
nanocarrier	O
formulations	O
,	O
either	O
for	O
populations	B-T098
or	O
for	O
individuals	B-T098
.	O

Recombinant	O
MHC	B-T017
Tetramers	I-T017
for	O
Isolation	B-T058
of	O
Virus	B-T005
-	O
Specific	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
Cells	I-T017
from	O
Healthy	O
Donors	O
:	O
Potential	O
Approach	O
for	O
Cell	B-T058
Therapy	I-T058
of	O
Posttransplant	B-T038
Cytomegalovirus	I-T038
Infection	I-T038

Patients	O
undergoing	O
allogeneic	O
hematopoietic	B-T058
stem	I-T058
cell	I-T058
transplantation	I-T058
have	O
a	O
high	O
risk	O
of	O
cytomegalovirus	B-T038
reactivation	I-T038
,	O
which	O
in	O
the	O
absence	O
of	O
T	B-T038
-	I-T038
cell	I-T038
immunity	I-T038
can	O
result	O
in	O
the	O
development	O
of	O
an	O
acute	B-T033
inflammatory	I-T033
reaction	I-T033
and	O
damage	B-T037
of	I-T037
internal	I-T037
organs	I-T037
.	O

Transfusion	B-T058
of	O
the	O
virus	O
-	O
specific	O
donor	B-T017
T	I-T017
-	I-T017
lymphocytes	I-T017
represents	O
an	O
alternative	O
to	O
a	O
highly	O
toxic	O
and	O
often	O
ineffective	O
antiviral	B-T058
therapy	I-T058
.	O

Potentially	O
promising	O
cell	B-T058
therapy	I-T058
approach	O
comprises	O
transfusion	B-T058
of	O
cytotoxic	B-T017
T	I-T017
-	I-T017
lymphocytes	I-T017
,	O
specific	O
to	O
the	O
viral	B-T103
antigens	I-T103
,	O
immediately	O
after	O
their	O
isolation	B-T058
from	O
the	O
donor	B-T038
'	I-T038
s	I-T038
blood	I-T038
circulation	I-T038
without	O
any	O
in	O
vitro	O
expansion	O
.	O

Specific	O
T	B-T017
-	I-T017
cells	I-T017
could	O
be	O
separated	O
from	O
potentially	O
alloreactive	B-T017
lymphocytes	I-T017
using	O
recombinant	O
major	B-T017
histocompatibility	I-T017
complex	I-T017
(	O
MHC	B-T017
)	O
multimers	O
,	O
carrying	O
synthetic	O
viral	O
peptides	O
.	O

Rapid	O
transfusion	B-T058
of	O
virus	B-T005
-	O
specific	O
T	B-T017
-	I-T017
cells	I-T017
to	O
patients	O
has	O
several	O
crucial	O
advantages	O
in	O
comparison	O
with	O
methods	O
based	O
on	O
the	O
in	O
vitro	O
expansion	O
of	O
the	O
cells	B-T017
.	O

About	O
30	O
%	O
of	O
hematopoietic	O
stem	O
cell	O
donors	O
and	O
46	O
%	O
of	O
transplant	O
recipients	O
at	O
the	O
National	B-T092
Research	I-T092
Center	I-T092
for	I-T092
Hematology	I-T092
were	O
carriers	O
of	O
the	O
HLA	B-T017
-	I-T017
A	I-T017
*	I-T017
02	I-T017
allele	I-T017
.	O

Moreover	O
,	O
94	O
%	O
of	O
Russian	B-T098
donors	O
have	O
an	O
immune	B-T038
response	I-T038
against	O
the	O
cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
.	O

Using	O
recombinant	O
HLA	B-T017
-	I-T017
A	I-T017
*	I-T017
02	I-T017
multimers	O
carrying	O
an	O
immunodominant	O
cytomegalovirus	B-T103
peptide	I-T103
(	O
NLV	B-T103
)	O
,	O
we	O
have	O
shown	O
that	O
the	O
majority	O
of	O
healthy	O
donors	O
have	O
pronounced	O
T	B-T038
-	I-T038
cell	I-T038
immunity	I-T038
against	O
this	O
antigen	B-T103
,	O
whereas	O
shortly	O
after	O
the	O
transplantation	B-T058
the	O
patients	O
do	O
not	O
have	O
specific	O
T	B-T017
-	I-T017
lymphocytes	I-T017
.	O

The	O
donor	B-T017
cells	I-T017
have	O
the	O
immune	O
phenotype	O
of	O
memory	B-T017
cells	I-T017
and	O
can	O
be	O
activated	B-T038
and	O
proliferate	B-T038
after	O
stimulation	O
with	O
the	O
specific	O
antigen	B-T103
.	O

Donor	B-T033
lymphocytes	I-T033
can	O
be	O
substantially	O
enriched	O
to	O
significant	O
purity	O
by	O
magnetic	B-T058
separation	I-T058
with	O
recombinant	O
MHC	B-T017
multimers	O
and	O
are	O
not	O
activated	O
upon	O
cocultivation	B-T058
with	O
the	O
antigen	B-T103
-	O
presenting	O
cells	B-T017
from	O
HLA	B-T103
-	O
incompatible	B-T098
donors	I-T098
without	O
addition	O
of	O
the	O
specific	O
antigen	B-T103
.	O

This	O
study	B-T062
demonstrated	O
that	O
strong	O
immune	B-T038
response	I-T038
to	O
CMV	B-T005
of	O
healthy	O
donors	O
and	O
prevalence	O
of	O
HLA	B-T017
-	I-T017
A	I-T017
*	I-T017
02	I-T017
allele	I-T017
in	O
the	O
Russian	B-T098
population	I-T098
make	O
it	O
possible	O
to	O
isolate	O
a	O
significant	O
number	O
of	O
virus	O
-	O
specific	O
cells	B-T017
using	O
HLA	B-T017
-	I-T017
A	I-T017
*	I-T017
02	I-T017
-	I-T017
NLV	I-T017
multimers	O
.	O

After	O
the	O
transfusion	B-T058
,	O
these	O
cells	B-T017
should	O
protect	O
patients	O
from	O
CMV	B-T005
without	O
development	O
of	O
allogeneic	O
immune	B-T038
response	I-T038
.	O

Outcomes	O
of	O
chest	B-T058
wall	I-T058
resections	I-T058
in	O
pediatric	O
sarcoma	B-T038
patients	O

Chest	B-T038
wall	I-T038
tumors	I-T038
in	O
pediatric	O
patients	O
are	O
rare	O
.	O

This	O
study	B-T062
evaluates	O
outcomes	O
in	O
pediatric	O
patients	O
who	O
have	O
undergone	O
chest	B-T058
wall	I-T058
resections	I-T058
secondary	O
to	O
sarcomas	B-T038
.	O

A	O
retrospective	B-T062
review	I-T062
was	O
performed	O
for	O
patients	O
<	O
19years	O
old	O
who	O
underwent	O
chest	B-T058
wall	I-T058
resections	I-T058
for	O
sarcoma	B-T038
1999	O
-	O
2014	O
at	O
the	O
University	B-T092
of	I-T092
Texas	I-T092
MD	I-T092
Anderson	I-T092
Cancer	I-T092
Center	I-T092
.	O

Of	O
44	O
patients	O
,	O
Ewing	B-T038
'	I-T038
s	I-T038
sarcoma	I-T038
(	O
n	O
=	O
18	O
)	O
and	O
osteosarcoma	B-T038
(	O
n	O
=	O
16	O
)	O
were	O
most	O
common	O
.	O

Other	O
sarcomas	B-T038
included	O
synovial	B-T038
sarcoma	I-T038
,	O
chondrosarcoma	B-T038
,	O
and	O
rhabdomyosarcoma	B-T038
.	O

Gore	B-T103
-	I-T103
Tex	I-T103
®	O
or	O
a	O
Marlex™	B-T103
mesh	I-T103
and	O
methyl	B-T103
methacrylate	I-T103
sandwich	I-T103
was	O
used	O
in	O
22	O
patients	O
,	O
and	O
9	O
children	O
did	O
not	O
require	O
reconstruction	O
.	O

Twenty	O
-	O
four	O
(	O
54	O
.	O
5	O
%	O
)	O
patients	O
had	O
normal	O
activity	O
,	O
3	O
(	O
6	O
.	O
8	O
%	O
)	O
had	O
occasional	B-T033
discomfort	I-T033
,	O
2	O
(	O
4	O
.	O
5	O
%	O
)	O
had	O
pain	B-T038
impairing	I-T038
function	I-T038
,	O
7	O
(	O
15	O
.	O
9	O
%	O
)	O
required	O
medication	B-T103
or	O
physical	B-T058
therapy	I-T058
for	O
impairment	B-T038
,	O
and	O
8	O
(	O
18	O
.	O
2	O
%	O
)	O
needed	O
additional	O
surgery	B-T091
.	O

Five	O
children	O
(	O
11	O
.	O
4	O
%	O
)	O
developed	O
scoliosis	B-T017
,	O
and	O
all	O
of	O
these	O
patients	O
had	O
posterior	B-T082
rib	B-T038
tumors	I-T038
.	O

Median	O
overall	O
survival	O
for	O
the	O
entire	B-T098
cohort	I-T098
was	O
41	O
.	O
9±11	O
.	O
82	O
months	O
.	O

Histology	B-T091
(	O
p	O
=	O
0	O
.	O
003	O
)	O
,	O
location	B-T082
of	O
tumor	B-T038
on	O
the	O
ribs	B-T017
(	O
p	O
=	O
0	O
.	O
007	O
)	O
,	O
and	O
surgical	B-T017
margins	I-T017
(	O
p	O
=	O
0	O
.	O
011	O
)	O
were	O
significantly	O
associated	O
with	O
overall	O
survival	O
.	O

Tumors	B-T038
on	O
the	O
middle	O
and	O
posterior	B-T082
(	O
p	O
=	O
0	O
.	O
003	O
)	O
portions	O
of	O
the	O
ribs	B-T017
had	O
a	O
lower	O
chance	O
of	O
death	B-T038
.	O

Scoliosis	B-T017
is	O
more	O
common	O
in	O
posterior	B-T082
rib	B-T058
resections	I-T058
.	O

Histology	B-T091
,	O
location	B-T082
of	O
the	O
tumor	B-T038
,	O
and	O
surgical	B-T017
margins	I-T017
impact	O
survival	O
,	O
but	O
,	O
type	O
of	O
reconstruction	O
does	O
not	O
.	O

III	O
.	O

Treatment	B-T062
Study	I-T062
.	O

Tetrabromobisphenol	B-T103
A	I-T103
activates	O
the	O
hepatic	B-T017
interferon	B-T038
pathway	I-T038
in	O
rats	B-T204

Tetrabromobisphenol	B-T103
A	I-T103
(	O
TBBPA	B-T103
)	O
is	O
a	O
widely	O
used	O
flame	B-T103
retardant	I-T103
in	O
printed	O
circuit	O
boards	O
,	O
paper	O
,	O
and	O
textiles	O
.	O

In	O
a	O
two	O
-	O
year	O
study	B-T062
,	O
TBBPA	B-T103
showed	O
evidence	O
of	O
uterine	B-T038
tumors	I-T038
in	O
female	O
Wistar	B-T204
-	I-T204
Han	I-T204
rats	I-T204
and	O
liver	B-T038
and	O
colon	B-T038
tumors	I-T038
in	O
B6C3F1	B-T204
mice	I-T204
.	O

In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
early	O
gene	B-T017
and	O
pathway	B-T038
changes	O
leading	O
to	O
cancer	B-T038
,	O
we	O
exposed	O
female	O
Wistar	B-T204
Han	I-T204
rats	I-T204
to	O
TBBPA	B-T103
at	O
0	O
,	O
25	O
,	O
250	O
,	O
or	O
1000mg	O
/	O
kg	O
(	O
oral	O
gavage	O
in	O
corn	B-T103
oil	I-T103
,	O
5×	O
/	O
week	O
)	O
for	O
13	O
weeks	O
.	O

Because	O
at	O
the	O
end	O
of	O
the	O
TBBPA	B-T103
exposure	O
period	O
,	O
there	O
were	O
no	O
treatment	O
-	O
related	O
effects	O
on	O
body	O
weights	O
,	O
liver	B-T033
or	O
uterus	B-T033
lesions	I-T033
,	O
and	O
liver	O
and	O
uterine	O
organ	O
weights	O
were	O
within	O
10	O
%	O
of	O
controls	O
,	O
only	O
the	O
high	O
dose	O
animals	B-T204
were	O
analyzed	B-T062
.	O

Analysis	B-T062
of	O
the	O
hepatic	B-T017
and	O
uterine	B-T017
transcriptomes	B-T082
showed	O
TBBPA	B-T103
-	O
induced	O
changes	O
primarily	O
in	O
the	O
liver	B-T017
(	O
1000mg	O
/	O
kg	O
)	O
,	O
with	O
159	O
transcripts	B-T103
corresponding	O
to	O
132	O
genes	B-T017
differentially	O
expressed	B-T038
compared	O
to	O
controls	O
(	O
FDR	O
=	O
0	O
.	O
05	O
)	O
.	O

Pathway	B-T170
analysis	I-T170
showed	O
activation	O
of	O
interferon	B-T103
(	O
IFN	B-T103
)	O
and	O
metabolic	B-T038
networks	I-T038
.	O

TBBPA	B-T103
induced	O
few	O
molecular	O
changes	O
in	O
the	O
uterus	B-T017
.	O

Activation	O
of	O
the	O
interferon	B-T038
pathway	I-T038
in	O
the	O
liver	B-T017
occurred	O
after	O
13	O
-	O
weeks	O
of	O
TBBPA	B-T103
exposure	O
,	O
and	O
with	O
longer	O
term	O
TBBPA	B-T103
exposure	O
this	O
may	O
lead	O
to	O
immunomodulatory	B-T058
changes	O
that	O
contribute	O
to	O
carcinogenic	B-T038
processes	I-T038
.	O

Famous	O
faces	O
and	O
voices	O
:	O
Differential	O
profiles	B-T082
in	O
early	O
right	B-T017
and	O
left	B-T017
semantic	B-T038
dementia	I-T038
and	O
in	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038

Famous	O
face	O
and	O
voice	O
recognition	O
is	O
reported	O
to	O
be	O
impaired	O
both	O
in	O
semantic	B-T038
dementia	I-T038
(	O
SD	B-T038
)	O
and	O
in	O
Alzheimer	B-T038
'	I-T038
s	I-T038
Disease	I-T038
(	O
AD	B-T038
)	O
,	O
although	O
more	O
severely	O
in	O
the	O
former	O
.	O

In	O
AD	B-T038
a	O
coexistence	O
of	O
perceptual	B-T038
impairment	O
in	O
face	O
and	O
voice	O
processing	B-T038
has	O
also	O
been	O
reported	O
and	O
this	O
could	O
contribute	O
to	O
the	O
altered	O
performance	O
in	O
complex	O
semantic	O
tasks	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
SD	B-T038
both	O
face	O
and	O
voice	O
recognition	O
disorders	B-T038
could	O
be	O
related	O
to	O
the	O
prevalence	O
of	O
atrophy	B-T038
in	O
the	O
right	B-T017
temporal	I-T017
lobe	I-T017
(	O
RTL	B-T017
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
twofold	O
:	O
(	O
1	O
)	O
to	O
investigate	O
famous	O
faces	O
and	O
voices	O
recognition	O
in	O
SD	B-T038
and	O
AD	B-T038
to	O
verify	O
if	O
the	O
two	O
diseases	B-T038
show	O
a	O
differential	O
pattern	B-T082
of	O
impairment	O
,	O
resulting	O
from	O
disruption	O
of	O
different	O
cognitive	B-T038
mechanisms	O
;	O
(	O
2	O
)	O
to	O
check	O
if	O
face	O
and	O
voice	O
recognition	O
disorders	B-T038
prevail	O
in	O
patients	O
with	O
atrophy	B-T038
mainly	O
affecting	O
the	O
RTL	B-T017
.	O

To	O
avoid	O
the	O
potential	O
influence	O
of	O
primary	O
perceptual	B-T038
problems	B-T033
in	O
face	O
and	O
voice	O
recognition	O
,	O
a	O
pool	O
of	O
patients	O
suffering	O
from	O
early	O
SD	B-T038
and	O
AD	B-T038
were	O
administered	O
a	O
detailed	O
set	O
of	O
tests	B-T058
exploring	O
face	O
and	O
voice	O
perception	B-T038
.	O

Thirteen	O
SD	B-T038
(	O
8	O
with	O
prevalence	O
of	O
right	B-T017
and	O
5	O
with	O
prevalence	O
of	O
left	B-T017
temporal	I-T017
atrophy	B-T038
)	O
and	O
25	O
CE	O
patients	O
,	O
who	O
did	O
not	O
show	O
visual	O
and	O
auditory	O
perceptual	B-T038
impairment	O
,	O
were	O
finally	O
selected	O
and	O
were	O
administered	O
an	O
experimental	O
battery	B-T170
exploring	O
famous	O
face	O
and	O
voice	O
recognition	O
and	O
naming	B-T170
.	O

Twelve	O
SD	B-T038
patients	O
underwent	O
cerebral	B-T017
PET	B-T058
imaging	I-T058
and	O
were	O
classified	O
in	O
right	B-T017
and	O
left	B-T017
SD	B-T038
according	O
to	O
the	O
onset	O
modality	O
and	O
to	O
the	O
prevalent	O
decrease	O
in	O
FDG	B-T103
uptake	I-T103
in	O
right	B-T017
or	O
left	B-T017
temporal	I-T017
lobe	I-T017
respectively	O
.	O

Correlation	O
of	O
PET	B-T058
imaging	I-T058
and	O
famous	O
face	O
and	O
voice	O
recognition	O
was	O
performed	O
.	O

Results	O
showed	O
a	O
differential	O
performance	O
profile	B-T082
in	O
the	O
two	O
diseases	B-T038
,	O
because	O
AD	B-T038
patients	O
were	O
significantly	O
impaired	O
in	O
the	O
naming	B-T170
tests	I-T170
,	O
but	O
showed	O
preserved	O
recognition	B-T038
,	O
whereas	O
SD	B-T038
patients	O
were	O
profoundly	O
impaired	O
both	O
in	O
naming	B-T170
and	O
in	O
recognition	O
of	O
famous	O
faces	O
and	O
voices	O
.	O

Furthermore	O
,	O
face	O
and	O
voice	O
recognition	O
disorders	B-T038
prevailed	O
in	O
SD	B-T038
patients	O
with	O
RTL	B-T017
atrophy	B-T038
,	O
who	O
also	O
showed	O
a	O
conceptual	O
impairment	O
on	O
the	O
Pyramids	B-T170
and	I-T170
Palm	I-T170
Trees	I-T170
test	I-T170
more	O
important	O
in	O
the	O
pictorial	O
than	O
in	O
the	O
verbal	O
modality	O
.	O

Finally	O
,	O
in	O
12	O
SD	B-T038
patients	O
in	O
whom	O
PET	B-T058
was	O
available	O
,	O
a	O
strong	O
correlation	O
between	O
FDG	B-T103
uptake	I-T103
and	O
face	O
-	O
to	O
-	O
name	O
and	O
voice	O
-	O
to	O
-	O
name	O
matching	O
data	O
was	O
found	O
in	O
the	O
right	B-T017
but	O
not	O
in	O
the	O
left	B-T017
temporal	I-T017
lobe	I-T017
.	O

The	O
data	O
support	O
the	O
hypothesis	O
of	O
a	O
different	O
cognitive	B-T038
basis	O
for	O
impairment	O
of	O
face	O
and	O
voice	O
recognition	O
in	O
the	O
two	O
dementias	B-T038
and	O
suggest	O
that	O
the	O
pattern	B-T082
of	O
impairment	O
in	O
SD	B-T038
may	O
be	O
due	O
to	O
a	O
loss	O
of	O
semantic	O
representations	O
,	O
while	O
a	O
defect	O
of	O
semantic	O
control	O
,	O
with	O
impaired	O
naming	B-T170
and	O
preserved	B-T038
recognition	I-T038
might	O
be	O
hypothesized	O
in	O
AD	B-T038
.	O

Furthermore	O
,	O
the	O
correlation	O
between	O
face	O
and	O
voice	O
recognition	O
disorders	B-T038
and	O
RTL	B-T017
damage	B-T037
are	O
consistent	O
with	O
the	O
hypothesis	O
assuming	O
that	O
in	O
the	O
RTL	B-T017
person	B-T098
-	O
specific	O
knowledge	B-T170
may	O
be	O
mainly	O
based	O
upon	O
non	B-T038
-	I-T038
verbal	I-T038
representations	I-T038
.	O

Dry	B-T033
skin	I-T033
conditions	O
are	O
related	O
to	O
the	O
recovery	O
rate	O
of	O
skin	O
temperature	O
after	O
cold	O
stress	B-T038
rather	O
than	O
to	O
blood	B-T038
flow	I-T038

Cutaneous	B-T082
blood	B-T038
flow	I-T038
plays	O
an	O
important	O
role	O
in	O
the	O
thermoregulation	B-T038
,	O
oxygen	B-T201
supply	I-T201
,	O
and	O
nutritional	B-T058
support	I-T058
necessary	O
to	O
maintain	O
the	O
skin	B-T022
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
for	O
a	O
link	O
between	O
blood	B-T038
flow	I-T038
and	O
skin	B-T038
physiology	I-T038
.	O

Therefore	O
,	O
we	O
conducted	O
surveys	B-T170
of	O
healthy	B-T098
volunteers	I-T098
to	O
determine	O
the	O
relationship	O
(	O
s	O
)	O
between	O
dry	B-T033
skin	I-T033
properties	O
and	O
cutaneous	B-T082
vascular	B-T201
function	I-T201
.	O

Water	O
content	O
of	O
the	O
stratum	B-T017
corneum	I-T017
,	O
transepidermal	B-T033
water	I-T033
loss	I-T033
,	O
and	O
visual	O
dryness	O
score	O
were	O
investigated	O
as	O
dry	B-T033
skin	I-T033
parameters	B-T033
.	O

Cutaneous	B-T082
blood	B-T038
flow	I-T038
in	O
the	O
resting	B-T033
state	I-T033
,	O
the	O
recovery	O
rate	O
(	O
RR	O
)	O
of	O
skin	O
temperature	O
on	O
the	O
hand	B-T017
after	O
a	O
cold	B-T058
-	I-T058
stress	I-T058
test	I-T058
,	O
and	O
the	O
responsiveness	O
of	O
facial	B-T017
skin	I-T017
blood	B-T038
flow	I-T038
to	O
local	B-T058
cooling	I-T058
were	O
examined	B-T033
as	O
indices	B-T170
of	O
cutaneous	B-T082
vascular	B-T201
functions	I-T201
.	O

The	O
relationships	O
between	O
dry	B-T033
skin	I-T033
parameters	B-T033
and	O
cutaneous	B-T082
vascular	B-T201
functions	I-T201
were	O
assessed	O
.	O

The	O
RR	O
correlated	O
negatively	O
with	O
the	O
visual	O
dryness	O
score	O
of	O
skin	B-T022
on	O
the	O
leg	B-T017
but	O
correlated	O
positively	O
with	O
water	O
content	O
of	O
the	O
stratum	B-T017
corneum	I-T017
on	O
the	O
arm	O
.	O

No	O
significant	O
correlation	O
between	O
the	O
resting	B-T033
state	I-T033
of	O
blood	B-T038
flow	I-T038
and	O
dry	B-T033
skin	I-T033
parameters	B-T033
was	O
observed	O
.	O

In	O
both	O
the	O
face	B-T082
and	O
the	O
body	B-T204
,	O
deterioration	O
in	O
skin	B-T033
dryness	I-T033
from	O
summer	O
to	O
winter	O
was	O
significant	O
in	O
subjects	O
with	O
low	O
RR	O
.	O

The	O
RR	O
correlated	O
well	O
with	O
the	O
responsiveness	O
of	O
facial	B-T017
skin	I-T017
blood	B-T038
flow	I-T038
to	O
local	B-T058
cooling	I-T058
,	O
indicating	B-T033
that	O
the	O
RR	O
affects	O
systemic	O
dry	B-T033
skin	I-T033
conditions	O
.	O

These	O
results	O
suggest	O
that	O
the	O
RR	O
but	O
not	O
blood	B-T038
flow	I-T038
at	O
the	O
resting	B-T033
state	I-T033
is	O
associated	O
with	O
dry	B-T033
skin	I-T033
conditions	O
and	O
is	O
involved	O
in	O
skin	O
homeostasis	B-T038
during	O
seasonal	O
environmental	O
changes	O
.	O

Molar	B-T017
loss	I-T017
and	O
powder	B-T058
diet	I-T058
leads	O
to	O
memory	B-T038
deficit	I-T038
and	O
modifies	O
the	O
mRNA	B-T038
expression	I-T038
of	O
brain	B-T103
-	I-T103
derived	I-T103
neurotrophic	I-T103
factor	I-T103
in	O
the	O
hippocampus	B-T017
of	O
adult	O
mice	B-T204

It	O
is	O
known	O
that	O
tooth	B-T017
loss	I-T017
is	O
known	O
to	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
and	O
soft	B-T058
diet	I-T058
feeding	O
induces	O
memory	B-T038
impairment	I-T038
.	O

Recent	O
studies	O
have	O
shown	O
that	O
brain	B-T103
-	I-T103
derived	I-T103
neurotrophic	I-T103
factor	I-T103
(	O
BDNF	B-T103
)	O
is	O
associated	O
with	O
tooth	B-T017
loss	I-T017
or	O
soft	B-T058
diet	I-T058
in	O
young	O
animal	B-T204
model	I-T204
,	O
and	O
that	O
BDNF	B-T017
expression	B-T038
is	O
decreased	O
in	O
patients	O
with	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
.	O

However	O
,	O
single	O
or	O
combined	O
effect	O
of	O
tooth	B-T017
loss	I-T017
and	O
/	O
or	O
soft	B-T058
diet	I-T058
on	O
brain	O
function	O
has	O
not	O
fully	O
understood	O
.	O

Here	O
we	O
examined	O
the	O
effect	O
of	O
molar	B-T017
loss	I-T017
and	O
powder	B-T058
diet	I-T058
on	O
memory	B-T038
ability	I-T038
and	O
the	O
expression	B-T038
of	O
BDNF	B-T017
mRNA	I-T017
in	O
the	O
hippocampus	B-T017
of	O
adult	O
C57BL	B-T204
/	I-T204
6J	I-T204
mice	I-T204
.	O

Twenty	O
eight	O
-	O
weeks	O
-	O
old	O
C57BL	B-T204
/	I-T204
6J	I-T204
mice	I-T204
were	O
divided	O
into	O
intact	O
molar	O
group	O
and	O
extracted	O
molar	O
group	O
.	O

They	O
were	O
randomly	B-T062
divided	O
into	O
the	O
I	O
/	O
S	O
group	O
(	O
Intact	O
upper	B-T017
molar	I-T017
teeth	I-T017
/	O
Solid	B-T168
diet	I-T168
feeding	O
)	O
,	O
the	O
E	O
/	O
S	O
group	O
(	O
Extracted	B-T058
upper	B-T017
molar	I-T017
teeth	I-T017
/	O
Solid	B-T168
diet	I-T168
feeding	O
)	O
,	O
the	O
I	O
/	O
P	O
group	O
(	O
Intact	O
upper	B-T017
molar	I-T017
teeth	I-T017
/	O
Powder	B-T058
diet	I-T058
feeding	O
)	O
,	O
and	O
the	O
E	O
/	O
P	O
group	O
(	O
Extracted	O
upper	B-T017
molar	I-T017
teeth	I-T017
/	O
Powder	B-T058
diet	I-T058
feeding	O
)	O
.	O

The	O
observation	O
periods	O
were	O
4	O
and	O
16	O
-	O
week	O
.	O

To	O
analyze	B-T062
the	O
memory	B-T038
ability	I-T038
,	O
the	O
step	O
-	O
through	O
passive	O
avoidance	O
test	O
was	O
conducted	O
.	O

BDNF	B-T017
-	I-T017
related	I-T017
mRNA	I-T017
in	O
the	O
hippocampus	B-T017
was	O
analyzed	B-T062
by	O
real	B-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
RT	B-T062
-	I-T062
PCR	I-T062
)	O
.	O

At	O
4	O
weeks	O
later	O
,	O
we	O
performed	O
memory	B-T058
test	I-T058
and	O
isolated	O
brains	B-T017
to	O
analyze	B-T062
.	O

There	O
were	O
no	O
differences	O
in	O
memory	B-T038
function	I-T038
and	O
BDNF	B-T017
mRNA	I-T017
level	O
between	O
these	O
four	O
groups	O
.	O

However	O
,	O
at	O
16	O
weeks	O
later	O
,	O
E	O
/	O
S	O
and	O
E	O
/	O
P	O
group	O
showed	O
memory	B-T038
impairment	I-T038
,	O
and	O
decreased	O
level	O
of	O
BDNF	B-T017
mRNA	I-T017
.	O

Whereas	O
,	O
the	O
powder	B-T058
diet	I-T058
had	O
no	O
effect	O
on	O
memory	B-T038
function	I-T038
and	O
BDNF	B-T017
mRNA	I-T017
level	O
even	O
at	O
16	O
weeks	O
later	O
.	O

These	O
results	O
suggest	O
that	O
the	O
effect	O
of	O
molar	B-T017
loss	I-T017
and	O
powder	B-T058
diet	I-T058
on	O
memory	B-T038
function	I-T038
and	O
BDNF	B-T017
mRNA	I-T017
levels	O
were	O
different	O
,	O
molar	B-T017
loss	I-T017
may	O
have	O
a	O
greater	O
long	O
-	O
term	O
effect	O
on	O
memory	B-T038
ability	I-T038
than	O
powder	B-T058
diet	I-T058
does	O
.	O

Description	O
of	O
the	O
first	O
species	B-T170
of	O
Fiorianteon	B-T204
Olmi	I-T204
(	O
Hymenoptera	B-T204
,	O
Dryinidae	B-T204
)	O
from	O
the	O
Afrotropical	B-T082
region	I-T082

Fiorianteon	B-T204
sulcatumsp	I-T204
.	O

n	O
.	O

is	O
described	O
from	O
Fianarantsoa	B-T082
Province	I-T082
(	O
Madagascar	B-T082
)	O
.	O

It	O
is	O
the	O
first	O
species	B-T170
of	O
Fiorianteon	B-T204
found	O
in	O
the	O
Afrotropical	B-T082
region	I-T082
.	O

The	O
genus	B-T170
Fiorianteon	B-T204
can	O
be	O
distinguished	O
from	O
the	O
closely	O
related	O
genus	B-T170
Conganteon	B-T204
by	O
the	O
distal	B-T082
part	O
of	O
the	O
stigmal	B-T017
vein	I-T017
,	O
which	O
is	O
as	O
long	O
as	O
,	O
or	O
shorter	B-T033
than	O
the	O
proximal	B-T082
part	O
of	O
the	O
stigmal	B-T017
vein	I-T017
(	O
longer	O
than	O
the	O
proximal	B-T082
part	O
of	O
the	O
vein	B-T017
in	O
Conganteon	B-T204
)	O
.	O

The	B-T170
Daniel	I-T170
K	I-T170
.	I-T170
Inouye	I-T170
College	I-T170
of	I-T170
Pharmacy	I-T170
Scripts	I-T170
:	O
Poha	B-T168
Berry	I-T168
(	O
Physalis	B-T204
peruviana	I-T204
)	O
with	O
Potential	O
Anti	O
-	O
inflammatory	O
and	O
Cancer	B-T058
Prevention	I-T058
Activities	O

The	B-T092
Daniel	I-T092
K	I-T092
.	I-T092

Inouye	I-T092
College	I-T092
of	I-T092
Pharmacy	I-T092
,	O
during	O
a	O
historic	O
event	O
in	O
Spring	O
2016	O
,	O
graduated	B-T098
the	O
first	O
two	O
students	B-T098
in	O
the	O
Pacific	B-T082
region	I-T082
to	O
earn	O
a	O
PhD	B-T170
in	O
pharmaceutical	B-T091
sciences	I-T091
at	O
the	O
University	B-T092
of	I-T092
Hawai	I-T092
'	I-T092
i	I-T092
at	O
Hilo	B-T082
.	O

The	O
college	B-T092
offers	O
PhD	B-T170
programs	O
in	O
these	O
five	O
disciplines	O
:	O
Cancer	B-T091
Biology	I-T091
,	O
Medicinal	B-T091
Chemistry	I-T091
,	O
Pharmaceutics	B-T062
,	O
Pharmacognosy	B-T091
,	O
and	O
Pharmacology	B-T091
.	O

One	O
of	O
the	O
Pharmacognosy	B-T091
dissertations	B-T170
focused	O
on	O
plant	B-T204
-	I-T204
derived	I-T204
natural	B-T103
products	I-T103
with	O
potential	O
anti	O
-	O
inflammatory	O
and	O
cancer	B-T038
chemopreventive	O
activities	O
.	O

Physalis	B-T204
peruviana	I-T204
(	O
Pp	B-T204
)	O
L	O
.	O

originated	O
in	O
tropical	O
South	B-T082
America	I-T082
.	O

It	O
has	O
become	O
naturalized	O
and	O
is	O
found	O
readily	O
on	O
the	O
Island	B-T082
of	I-T082
Hawai	I-T082
'	I-T082
i	I-T082
.	O

The	O
edible	B-T168
fruits	B-T168
are	O
commonly	O
known	O
as	O
cape	B-T204
gooseberry	I-T204
or	O
poha	B-T204
in	O
Hawai	B-T082
'	I-T082
i	I-T082
.	O

In	O
part	O
of	O
our	O
study	O
,	O
three	O
new	O
withanolides	B-T103
,	O
physaperuvin	B-T103
G	I-T103
(	O
1	O
)	O
,	O
physaperuvins	B-T103
I	I-T103
-	I-T103
J	I-T103
(	O
2	O
-	O
3	O
)	O
,	O
along	O
with	O
four	O
known	O
withanolides	B-T103
,	O
namely	O
,	O
4β	B-T103
-	I-T103
hydroxywithanolide	I-T103
E	I-T103
(	O
4	O
)	O
,	O
withaperuvin	B-T103
C	I-T103
(	O
5	O
)	O
,	O
and	O
physalactone	B-T103
(	O
6	O
)	O
,	O
coagulin	B-T103
(	O
7	O
)	O
were	O
isolated	O
from	O
the	O
aerial	B-T204
parts	I-T204
of	O
P	B-T204
.	I-T204

peruviana	I-T204
.	O

In	O
addition	O
,	O
two	O
known	O
compounds	B-T103
,	O
phyperunolide	B-T103
F	I-T103
(	O
8	O
)	O
,	O
and	O
withanolide	B-T103
S	I-T103
(	O
9	O
)	O
,	O
were	O
isolated	O
and	O
identified	O
from	O
the	O
poha	B-T168
berry	I-T168
fruits	I-T168
.	O

The	O
structures	B-T082
and	O
absolute	B-T082
stereochemistry	I-T082
of	O
new	O
compounds	O
from	O
poha	B-T204
were	O
elucidated	O
by	O
several	O
spectroscopy	O
methods	O
:	O
Nuclear	B-T058
Magnetic	I-T058
Resonance	I-T058
(	I-T058
NMR	I-T058
)	I-T058
spectroscopy	I-T058
,	O
X	B-T058
-	I-T058
ray	I-T058
diffraction	I-T058
,	O
and	O
mass	B-T058
spectrometry	I-T058
analyses	B-T062
.	O

All	O
isolated	O
poha	B-T204
compounds	B-T103
(	O
aerial	B-T204
parts	I-T204
and	O
fruits	B-T168
)	O
were	O
evaluated	O
for	O
their	O
anti	O
-	O
inflammatory	O
activity	O
with	O
lipopolysaccharide	B-T103
(	O
LPS	B-T103
)	O
-	O
activated	O
murine	B-T204
macrophage	B-T017
RAW	I-T017
264	I-T017
.	I-T017
7	I-T017
cells	I-T017
,	O
and	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
alpha	I-T103
(	O
TNF	B-T103
-	I-T103
α	I-T103
)	O
-	O
activated	O
nuclear	B-T103
factor	I-T103
-	I-T103
kappa	I-T103
B	I-T103
(	O
NF	B-T103
-	I-T103
κB	I-T103
)	O
with	O
transfected	O
human	B-T017
embryonic	I-T017
kidney	I-T017
cells	I-T017
293	I-T017
.	O

Most	O
of	O
the	O
isolated	O
natural	B-T103
compounds	I-T103
showed	O
activity	O
with	O
these	O
assays	B-T058
.	O

Additional	O
studies	O
were	O
performed	O
with	O
models	B-T170
of	O
colon	B-T038
cancer	I-T038
.	O

Specifically	O
,	O
4β	B-T103
-	I-T103
hydroxywithanolide	I-T103
E	I-T103
(	O
4HWE	B-T103
)	O
inhibited	O
the	O
growth	B-T038
of	O
colon	B-T038
cancer	I-T038
monolayer	B-T058
and	O
spheroid	B-T017
cultures	B-T058
.	O

The	O
compound	B-T103
induced	O
cell	B-T038
cycle	I-T038
arrest	I-T038
at	O
low	O
concentrations	O
and	O
apoptosis	B-T038
at	O
higher	O
concentrations	O
.	O

These	O
data	O
suggest	O
the	O
ingestion	B-T038
of	O
poha	B-T168
berries	I-T168
may	O
have	O
some	O
effect	O
on	O
the	O
prevalence	O
of	O
colon	B-T038
cancer	I-T038
.	O

Additionally	O
,	O
poha	B-T168
isolates	B-T103
compounds	I-T103
were	O
evaluated	O
for	O
their	O
growth	B-T038
inhibitory	I-T038
effects	I-T038
with	O
U251MG	B-T038
glioblastoma	I-T038
and	O
MDA	B-T038
-	I-T038
MB	I-T038
-	I-T038
231	I-T038
breast	I-T038
cancer	I-T038
cells	I-T038
that	O
harbor	O
aberrantly	O
-	O
active	O
signal	B-T103
transducer	I-T103
and	I-T103
activation	I-T103
of	I-T103
transcription	I-T103
3	I-T103
(	I-T103
STAT3	I-T103
)	I-T103
,	O
compared	O
to	O
normal	O
NIH	B-T017
-	I-T017
3T3	I-T017
mouse	I-T017
fibroblasts	I-T017
.	O

This	O
work	O
has	O
led	O
to	O
the	O
filing	O
of	O
three	O
provisional	B-T170
patents	I-T170
with	O
the	O
University	B-T092
of	I-T092
Hawai	I-T092
'	I-T092
i	I-T092
Office	I-T092
of	I-T092
Technology	I-T092
Transfer	I-T092
and	I-T092
Economic	I-T092
Development	I-T092
.	O

Air	B-T103
Pollutant	I-T103
Exposure	O
Within	O
a	O
Few	O
Days	O
of	O
Delivery	B-T058
and	O
Placental	B-T038
Abruption	I-T038
in	O
Japan	B-T082

Placental	B-T038
abruption	I-T038
is	O
an	O
emergency	B-T038
obstetric	I-T038
complication	I-T038
.	O

Although	O
the	O
etiology	O
of	O
abruption	B-T038
is	O
not	O
fully	O
understood	O
,	O
acute	O
stimuli	O
,	O
such	O
as	O
ischemia	B-T038
and	O
/	O
or	O
inflammation	B-T038
,	O
are	O
associated	O
with	O
rupture	B-T038
of	I-T038
the	I-T038
decidual	I-T038
artery	I-T038
,	O
resulting	O
in	O
placental	B-T038
separation	I-T038
.	O

Ischemia	B-T038
and	O
inflammation	B-T038
are	O
acute	O
biologic	O
effects	O
of	O
air	O
pollution	O
.	O

Using	O
a	O
case	B-T062
-	I-T062
crossover	I-T062
design	I-T062
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
a	O
short	O
-	O
term	O
increase	O
in	O
exposure	O
to	O
air	B-T103
pollutants	I-T103
is	O
a	O
potential	O
trigger	B-T201
of	O
placental	B-T038
abruption	I-T038
.	O

We	O
received	O
data	O
for	O
western	B-T082
Japan	I-T082
(	O
Kyushu	B-T082
-	I-T082
Okinawa	I-T082
Districts	I-T082
)	O
from	O
the	O
Japan	B-T170
Perinatal	I-T170
Registry	I-T170
Network	I-T170
database	I-T170
.	O

From	O
2005	O
to	O
2010	O
,	O
821	O
singleton	O
pregnant	B-T098
women	I-T098
with	O
placental	B-T038
abruption	I-T038
were	O
identified	O
.	O

We	O
assigned	O
daily	O
concentrations	O
of	O
air	B-T103
pollutants	I-T103
,	O
including	O
nitrogen	B-T103
dioxide	I-T103
(	O
NO2	B-T103
)	O
,	O
suspended	B-T103
particulate	I-T103
matter	I-T103
,	O
ozone	B-T103
,	O
and	O
sulfur	B-T103
dioxide	I-T103
(	O
SO2	B-T103
)	O
,	O
from	O
the	O
nearest	O
monitoring	O
station	O
to	O
the	O
respective	O
delivery	B-T058
hospital	B-T092
of	O
each	O
woman	B-T098
.	O

Because	O
information	O
on	O
the	O
onset	O
day	O
of	O
abruption	B-T038
was	O
not	O
obtained	O
,	O
we	O
assumed	O
the	O
case	O
day	O
to	O
be	O
1	O
day	O
before	O
the	O
day	O
of	O
delivery	B-T058
.	O

Exposure	O
to	O
NO2	B-T103
at	O
2	O
days	O
'	O
lag	O
was	O
associated	O
with	O
placental	B-T038
abruption	I-T038
(	O
temperature	O
adjusted	O
odds	O
ratio	O
per	O
10	O
ppb	O
increase	O
=	O
1	O
.	O
4	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
1	O
.	O
1	O
,	O
1	O
.	O
8	O
)	O
.	O

The	O
association	O
patterns	O
were	O
similar	O
,	O
when	O
we	O
restricted	O
to	O
participants	B-T098
who	O
delivered	B-T058
by	O
emergency	B-T058
cesarean	I-T058
(	O
1	O
.	O
4	O
,	O
1	O
.	O
1	O
,	O
1	O
.	O
9	O
)	O
,	O
or	O
who	O
delivered	B-T058
after	O
35	O
weeks	O
of	O
gestation	O
(	O
1	O
.	O
4	O
,	O
1	O
.	O
0	O
,	O
2	O
.	O
0	O
)	O
.	O

There	O
was	O
no	B-T033
association	I-T033
with	O
suspended	B-T103
particulate	I-T103
matter	I-T103
,	O
ozone	B-T103
,	O
or	O
SO2	B-T103
.	O

We	O
observed	O
an	O
association	O
between	O
NO2	B-T103
exposure	O
at	O
2	O
days	O
before	O
the	O
day	O
of	O
delivery	B-T058
and	O
placental	B-T038
abruption	I-T038
in	O
pregnant	B-T098
Japanese	I-T098
women	I-T098
.	O

The	O
2016	O
Infusion	O
Therapy	O
Standards	O
of	O
Practice	B-T038

Approximately	O
every	O
5	O
years	O
,	O
the	O
Infusion	B-T092
Nurses	I-T092
Society	I-T092
publishes	O
evidence	O
-	O
based	O
practice	O
standards	O
.	O

This	O
article	B-T170
provides	O
an	O
overview	O
of	O
the	O
process	O
used	O
in	O
standards	O
development	O
,	O
describes	O
the	O
format	B-T170
of	O
the	O
standards	O
,	O
and	O
provides	O
a	O
short	O
summary	B-T170
of	O
selected	O
standards	O
as	O
applied	O
to	O
home	B-T058
care	I-T058
.	O

The	O
Standards	O
are	O
an	O
important	O
document	B-T170
that	O
should	O
be	O
available	O
to	O
every	O
home	B-T058
care	I-T058
organization	B-T092
that	O
provides	O
home	B-T058
infusion	I-T058
therapy	I-T058
.	O

Datasets	B-T170
for	O
the	O
validation	B-T062
of	O
the	O
"	O
in	B-T082
vivo	I-T082
"	O
siRNA	B-T103
-	O
silencing	B-T038
of	O
CD40	B-T017
and	O
for	O
the	O
detection	B-T058
of	O
new	O
markers	B-T038
of	O
atherosclerosis	B-T038
progression	B-T038
in	O
ApoE	B-T017
-	O
deficient	O
mice	B-T204

Data	O
presented	O
in	O
this	O
Data	O
in	O
Brief	O
article	O
correspond	O
to	O
the	O
article	O
"	O
in	B-T082
vivo	I-T082
"	O
silencing	B-T038
of	O
CD40	B-T017
reduces	O
progression	B-T038
of	O
experimental	B-T062
atherogenesis	B-T038
through	O
a	O
NFκB	B-T103
/	O
miR	B-T103
-	I-T103
125b	I-T103
axis	O
and	O
reveals	O
new	O
potential	O
mediators	B-T103
in	O
the	O
pathogenesis	B-T038
of	O
atherosclerosis	B-T038
"	O
(	O
M	B-T170
.	I-T170

Hueso	I-T170
,	O
L	B-T170
.	I-T170

De	I-T170
Ramon	I-T170
,	O
E	B-T170
.	I-T170

Navarro	I-T170
,	O
E	B-T170
.	I-T170

Ripoll	I-T170
,	O
J	B-T170
.	I-T170
M	I-T170
.	I-T170

Cruzado	I-T170
,	O
J	B-T170
.	I-T170
M	I-T170
.	I-T170

Grinyo	I-T170
,	O
J	B-T170
.	I-T170

Torras	I-T170
,	O
2016	O
)	O
[	O
1	O
]	O
.	O

Here	O
,	O
we	O
describe	O
the	O
validation	B-T062
of	O
the	O
silencing	B-T038
of	O
CD40	B-T017
expression	B-T038
with	O
a	O
specific	O
siRNA	B-T103
in	O
ApoE	B-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
mouse	B-T204
aortas	B-T017
,	O
and	O
its	O
systemic	O
effects	O
on	O
splenic	B-T017
lymphocytic	B-T170
subpopulations	I-T170
as	O
well	O
as	O
on	O
the	O
infiltration	B-T038
of	O
aortic	B-T017
intima	I-T017
by	O
F4	B-T017
/	I-T017
80	I-T017
(	I-T017
+	I-T017
)	I-T017
,	O
galectin	B-T017
-	I-T017
3	I-T017
(	I-T017
+	I-T017
)	I-T017
macrophages	I-T017
or	O
by	O
NF	B-T017
-	I-T017
κB	I-T017
(	I-T017
+	I-T017
)	I-T017
cells	I-T017
.	O

We	O
also	O
show	O
the	O
output	O
of	O
a	O
Gene	B-T170
Ontology	I-T170
and	O
TLDA	B-T062
analysis	I-T062
which	O
allowed	O
the	O
detection	B-T058
of	O
potential	O
mediators	B-T103
of	O
atherosclerosis	B-T038
progression	B-T038
.	O

We	O
provide	O
the	O
scientific	O
community	O
with	O
a	O
set	O
of	O
genes	B-T017
whose	O
expression	B-T038
is	O
increased	O
during	O
atherosclerosis	B-T038
progression	B-T038
but	O
downregulated	B-T038
upon	O
CD40	B-T017
silencing	B-T038
.	O

Investigation	B-T170
on	O
evaluation	B-T058
criteria	O
of	O
backwashing	O
effects	O
for	O
a	O
pilot	B-T062
-	I-T062
scale	I-T062
BAF	O
treating	O
petrochemical	B-T103
wastewater	O

Parameters	O
for	O
evaluation	B-T058
criteria	O
of	O
air	O
-	O
water	B-T103
backwashing	O
effect	O
s	O
of	O
a	O
pilot	B-T062
-	I-T062
scale	I-T062
biological	O
aerated	O
filter	O
(	O
BAF	O
)	O
treating	O
petrochemical	B-T103
wastewater	O
were	O
investigated	O
.	O

The	O
parameters	O
included	O
the	O
suspended	O
solids	O
(	O
SS	O
)	O
and	O
specific	B-T033
oxygen	I-T033
uptake	I-T033
rate	I-T033
(	O
SOUR	B-T033
)	O
of	O
the	O
backwashing	O
effluent	O
,	O
recovery	O
of	O
the	O
BAF	O
after	O
backwashing	O
,	O
and	O
the	O
removal	O
of	O
the	O
biomass	O
/	O
bioactivity	O
attached	O
on	O
the	O
filter	O
media	O
after	O
backwashing	O
.	O

Results	O
showed	O
that	O
the	O
weight	O
of	O
the	O
total	O
sludge	O
produced	O
in	O
the	O
backwashing	O
effluent	O
increased	O
with	O
the	O
increase	O
in	O
water	B-T103
-	O
backwashing	O
intensity	O
,	O
while	O
the	O
total	O
SOUR	B-T033
of	O
backwashing	O
effluent	O
rose	O
notably	O
with	O
the	O
increase	O
of	O
air	O
-	O
backwashing	O
intensity	O
.	O

The	O
optimal	O
backwashing	O
intensity	O
of	O
14	O
L	O
/	O
(	O
m	O
(	O
2	O
)	O
·	O
s	O
)	O
for	O
air	O
and	O
4	O
L	O
/	O
(	O
m	O
(	O
2	O
)	O
·	O
s	O
)	O
for	O
water	B-T103
were	O
obtained	O
.	O

When	O
the	O
BAF	O
was	O
backwashed	O
on	O
this	O
condition	O
,	O
the	O
BAF	O
recovered	O
with	O
high	O
average	O
removal	O
of	O
chemical	B-T038
oxygen	I-T038
demand	I-T038
(	O
COD	B-T038
)	O
and	O
ammonia	B-T103
nitrogen	I-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
14	O
.	O
3	O
%	O
and	O
50	O
.	O
3	O
%	O
,	O
respectively	O
.	O

High	O
amount	O
of	O
biomass	O
removal	O
at	O
15	O
.	O
8	O
%	O
and	O
low	O
level	O
of	O
bioactivity	O
removal	O
at	O
8	O
.	O
8	O
%	O
attached	O
on	O
the	O
filter	O
media	O
were	O
also	O
found	O
.	O

Concentrations	O
of	O
the	O
benzene	B-T103
,	O
toluene	B-T103
,	O
ethylbenzene	B-T103
and	O
(	B-T103
o	I-T103
-	I-T103
,	I-T103
m	I-T103
-	I-T103
,	I-T103
p	I-T103
-	I-T103
)	I-T103
xylenes	I-T103
(	O
BTEX	B-T103
)	O
and	O
phenol	B-T103
in	O
the	O
backwashed	O
sludge	O
were	O
analyzed	B-T062
,	O
showing	O
that	O
the	O
backwashing	O
was	O
essential	O
to	O
remove	O
some	O
aromatic	B-T103
compounds	I-T103
adsorbed	B-T058
in	O
the	O
microorganisms	O
.	O

Implementation	O
of	O
infrared	B-T058
and	O
Raman	B-T058
modalities	O
for	O
glycosaminoglycan	B-T103
characterization	B-T170
in	O
complex	O
systems	O

Glycosaminoglycans	B-T103
(	O
GAGs	B-T103
)	O
are	O
natural	O
,	O
linear	B-T082
and	O
negatively	B-T103
charged	I-T103
heteropolysaccharides	B-T103
which	O
are	O
incident	O
in	O
every	O
mammalian	B-T204
tissue	B-T017
.	O

They	O
consist	O
of	O
repeating	O
disaccharide	B-T103
units	O
,	O
which	O
are	O
composed	O
of	O
either	O
sulfated	B-T103
or	O
non	B-T103
-	I-T103
sulfated	I-T103
monosaccharides	I-T103
.	O

Depending	O
on	O
tissue	B-T017
types	O
,	O
GAGs	B-T103
exhibit	O
structural	B-T082
heterogeneity	O
such	O
as	O
the	O
position	B-T082
and	O
degree	O
of	O
sulfation	O
or	O
within	O
their	O
disaccharide	B-T103
units	O
composition	O
being	O
heparin	B-T103
,	O
heparan	B-T103
sulfate	I-T103
,	O
chondroitine	B-T103
sulfate	I-T103
,	O
dermatan	B-T103
sulfate	I-T103
,	O
keratan	B-T103
sulfate	I-T103
,	O
and	O
hyaluronic	B-T103
acid	I-T103
.	O

They	O
are	O
covalently	B-T038
linked	I-T038
to	O
a	O
core	B-T082
protein	B-T103
(	O
proteoglycans	B-T103
)	O
or	O
as	O
free	O
chains	O
(	O
hyaluronan	B-T103
)	O
.	O

GAGs	B-T103
affect	O
cell	B-T017
properties	O
and	O
functions	B-T038
either	O
by	O
direct	O
interaction	O
with	O
cell	B-T103
receptors	I-T103
or	O
by	O
sequestration	O
of	O
growth	B-T103
factors	I-T103
.	O

These	O
evidences	O
of	O
divert	O
biological	O
roles	O
of	O
GAGs	B-T103
make	O
their	O
characterization	B-T170
at	O
cell	B-T017
and	O
tissue	B-T017
levels	O
of	O
importance	O
.	O

Thus	O
,	O
non	O
-	O
invasive	O
techniques	O
are	O
interesting	O
to	O
investigate	O
,	O
to	O
qualitatively	O
and	O
quantitatively	O
characterize	O
GAGs	B-T103
in	O
vitro	O
in	O
order	O
to	O
use	O
them	O
as	O
diagnostic	O
biomarkers	B-T201
and	O
/	O
or	O
as	O
therapeutic	O
targets	B-T074
in	O
several	O
human	B-T204
diseases	B-T038
including	O
cancer	B-T038
.	O

Infrared	B-T058
and	O
Raman	B-T058
microspectroscopies	I-T058
and	O
imaging	B-T058
are	O
sensitive	O
enough	O
to	O
differentiate	O
and	O
classify	B-T170
GAG	B-T103
types	O
and	O
subtypes	B-T170
in	O
spite	O
of	O
their	O
close	O
molecular	B-T082
structures	I-T082
.	O

Spectroscopic	B-T058
markers	O
characteristic	O
of	O
reference	O
GAG	B-T103
molecules	O
were	O
identified	O
.	O

Beyond	O
these	O
investigations	B-T058
of	O
the	O
standard	O
GAG	B-T103
spectral	O
signature	O
,	O
infrared	B-T058
and	O
Raman	B-T058
spectral	O
signatures	O
of	O
GAG	B-T103
were	O
searched	O
in	O
complex	O
biological	O
systems	O
like	O
cells	B-T017
.	O

The	O
aim	O
of	O
the	O
present	O
review	O
is	O
to	O
describe	O
the	O
implementation	O
of	O
these	O
complementary	O
vibrational	B-T058
spectroscopy	I-T058
techniques	I-T058
,	O
and	O
to	O
discuss	O
their	O
potentials	O
,	O
advantages	O
and	O
disadvantages	O
for	O
GAG	B-T103
analysis	B-T058
.	O

In	O
addition	O
,	O
this	O
review	O
presents	O
new	O
data	O
as	O
we	O
show	O
for	O
the	O
first	O
time	O
GAG	B-T103
infrared	B-T058
and	O
Raman	B-T058
spectral	O
signatures	O
from	O
conditioned	B-T103
media	I-T103
and	O
live	B-T017
cells	I-T017
,	O
respectively	O
.	O

Targeting	O
HIF2	B-T103
in	O
Clear	B-T038
Cell	I-T038
Renal	I-T038
Cell	I-T038
Carcinoma	I-T038

Inactivation	O
of	O
the	O
von	B-T103
Hippel	I-T103
-	I-T103
Lindau	I-T103
tumor	I-T103
-	I-T103
suppressor	I-T103
protein	I-T103
(	O
pVHL	B-T103
)	O
is	O
the	O
signature	B-T033
"	I-T033
truncal	I-T033
"	I-T033
event	I-T033
in	O
clear	B-T038
cell	I-T038
renal	I-T038
cell	I-T038
carcinoma	I-T038
,	O
which	O
is	O
the	O
most	O
common	O
form	O
of	O
kidney	B-T038
cancer	I-T038
.	O

pVHL	B-T103
is	O
part	O
of	O
a	O
ubiquitin	B-T103
ligase	I-T103
the	O
targets	O
the	O
α	B-T103
subunit	I-T103
of	O
the	O
hypoxia	B-T103
-	I-T103
inducible	I-T103
factor	I-T103
(	I-T103
HIF	I-T103
)	I-T103
transcription	I-T103
factor	I-T103
for	O
destruction	O
when	O
oxygen	O
is	O
available	O
.	O

Preclinical	O
studies	B-T062
strongly	O
suggest	O
that	O
deregulation	B-T038
of	O
HIF	B-T103
,	O
and	O
particularly	O
HIF2	B-T103
,	O
drives	O
pVHL	B-T103
-	O
defective	O
renal	B-T038
carcinogenesis	I-T038
.	O

Although	O
HIF2α	B-T103
was	O
classically	O
considered	O
undruggable	O
,	O
structural	O
and	O
chemical	O
work	O
by	O
Rick	O
Bruick	O
and	O
Kevin	O
Gardner	O
at	O
University	B-T092
of	I-T092
Texas	I-T092
Southwestern	I-T092
laid	O
the	O
foundation	O
for	O
the	O
development	O
of	O
small	B-T103
molecule	I-T103
direct	O
HIF2α	B-T103
antagonists	I-T103
(	O
PT2385	B-T103
and	O
the	O
related	O
tool	O
compound	O
PT2399	B-T103
)	O
by	O
Peloton	B-T092
Therapeutics	I-T092
that	O
block	O
the	O
dimerization	B-T038
of	O
HIF2α	B-T103
with	O
its	O
partner	O
protein	B-T103
ARNT1	I-T103
.	O

These	O
compounds	O
inhibit	B-T038
clear	I-T038
cell	I-T038
renal	I-T038
cell	I-T038
carcinoma	I-T038
growth	I-T038
in	O
preclinical	B-T170
models	I-T170
,	O
and	O
PT2385	B-T103
has	O
now	O
entered	O
the	O
clinic	B-T092
.	O

Nonetheless	O
,	O
the	O
availability	O
of	O
such	B-T103
compounds	I-T103
,	O
together	O
with	O
clustered	B-T103
regularly	I-T103
interspaced	I-T103
short	I-T103
palindromic	I-T103
repeat	I-T103
(	O
CRISPR	B-T103
)	O
-	O
based	O
gene	B-T062
editing	I-T062
approaches	I-T062
,	O
has	O
revealed	O
a	O
previously	O
unappreciated	O
heterogeneity	O
among	O
clear	B-T038
cell	I-T038
renal	I-T038
carcinomas	I-T038
and	O
patient	O
-	O
derived	O
xenografts	B-T058
with	O
respect	O
to	O
HIF2	B-T103
dependence	O
,	O
suggesting	O
that	O
predictive	B-T103
biomarkers	I-T103
will	O
be	O
needed	O
to	O
optimize	O
the	O
use	O
of	O
such	B-T103
agents	I-T103
in	O
the	O
clinic	B-T092
.	O

Prevalence	O
of	O
high	B-T033
-	I-T033
risk	I-T033
human	B-T038
papillomavirus	I-T038
infection	I-T038
among	O
women	O
in	O
Shaanxi	B-T082
province	B-T082
of	O
China	B-T082
:	O
A	O
hospital	B-T092
-	O
based	O
investigation	B-T058

This	O
study	O
aimed	O
to	O
investigate	O
the	O
characteristics	O
of	O
female	O
high	B-T038
-	I-T038
risk	I-T038
human	I-T038
papillomavirus	I-T038
(	I-T038
HR	I-T038
-	I-T038
HPV	I-T038
)	I-T038
infection	I-T038
in	O
Shaanxi	B-T082
province	B-T082
of	O
China	B-T082
.	O

A	O
total	O
of	O
14	O
111	O
women	O
were	O
enrolled	O
for	O
HPV	B-T005
genotyping	O
test	O
,	O
and	O
a	O
cytology	B-T058
,	O
and	O
/	O
or	O
cervix	B-T058
biopsy	I-T058
were	O
performed	O
in	O
partial	O
women	O
.	O

Of	O
these	O
women	O
,	O
the	O
HPV	B-T038
infection	I-T038
rate	O
was	O
30	O
.	O
21	O
%	O
,	O
and	O
26	O
.	O
73	O
%	O
were	O
caused	O
by	O
HR	B-T005
-	I-T005
HPV	I-T005
.	O

The	O
most	O
common	O
HR	B-T005
-	I-T005
HPV	I-T005
genotypes	O
were	O
HPV	B-T005
-	I-T005
16	I-T005
,	O
HPV	B-T005
-	I-T005
58	I-T005
,	O
HPV	B-T005
-	I-T005
52	I-T005
,	O
HPV	B-T005
-	I-T005
18	I-T005
,	O
and	O
HPV	B-T005
-	I-T005
31	I-T005
.	O

The	O
prevalence	O
of	O
HR	B-T005
-	I-T005
HPV	I-T005
among	O
women	O
older	O
than	O
50	O
years	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
main	O
carcinogenic	B-T103
genotypes	O
were	O
HPV	B-T005
-	I-T005
16	I-T005
,	O
HPV	B-T005
-	I-T005
18	I-T005
,	O
HPV	B-T005
-	I-T005
58	I-T005
,	O
HPV	B-T005
-	I-T005
52	I-T005
,	O
and	O
HPV	B-T005
-	I-T005
31	I-T005
.	O

HPV	B-T005
-	I-T005
16	I-T005
and	O
HPV	B-T005
-	I-T005
18	I-T005
combined	O
caused	O
80	O
.	O
79	O
%	O
of	O
cervical	B-T038
cancer	I-T038
cases	O
.	O

The	O
infection	B-T038
with	O
multiple	O
HR	B-T005
-	I-T005
HPVs	I-T005
was	O
not	B-T033
a	O
risk	B-T033
factor	I-T033
for	O
cervical	B-T038
lesions	I-T038
.	O

In	O
conclusion	O
,	O
HPV	B-T038
infection	I-T038
was	O
common	O
among	O
women	O
in	O
Shaanxi	B-T082
province	B-T082
.	O

Women	O
older	O
than	O
50	O
years	O
were	O
a	O
high	O
-	O
risk	O
group	O
for	O
HR	B-T038
-	I-T038
HPV	I-T038
infection	I-T038
and	O
cervical	B-T038
cancer	I-T038
.	O

HPV	B-T005
-	I-T005
16	I-T005
and	O
HPV	B-T005
-	I-T005
18	I-T005
were	O
the	O
main	O
carcinogenic	B-T103
genotypes	O
in	O
this	O
region	B-T082
.	O

Novel	O
and	O
Lost	O
Forests	O
in	O
the	O
Upper	B-T082
Midwestern	I-T082
United	I-T082
States	I-T082
,	O
from	O
New	O
Estimates	O
of	O
Settlement	O
-	O
Era	O
Composition	O
,	O
Stem	B-T204
Density	O
,	O
and	O
Biomass	O

EuroAmerican	O
land	O
-	O
use	O
and	O
its	O
legacies	O
have	O
transformed	O
forest	O
structure	O
and	O
composition	O
across	O
the	O
United	B-T082
States	I-T082
(	O
US	B-T082
)	O
.	O

More	O
accurate	O
reconstructions	O
of	O
historical	B-T082
states	I-T082
are	O
critical	O
to	O
understanding	O
the	O
processes	O
governing	O
past	O
,	O
current	O
,	O
and	O
future	O
forest	O
dynamics	O
.	O

Here	O
we	O
present	O
new	O
gridded	O
(	O
8x8km	O
)	O
reconstructions	O
of	O
pre	O
-	O
settlement	O
(	O
1800s	O
)	O
forest	O
composition	O
and	O
structure	O
from	O
the	O
upper	B-T082
Midwestern	I-T082
US	I-T082
(	O
Minnesota	B-T082
,	O
Wisconsin	B-T082
,	O
and	O
most	O
of	O
Michigan	O
)	O
,	O
using	O
19th	O
Century	B-T170
Public	I-T170
Land	I-T170
Survey	I-T170
System	I-T170
(	O
PLSS	B-T170
)	O
,	O
with	O
estimates	O
of	O
relative	O
composition	O
,	O
above	B-T082
-	I-T082
ground	I-T082
biomass	O
,	O
stem	B-T204
density	O
,	O
and	O
basal	B-T082
area	I-T082
for	O
28	O
tree	B-T204
types	O
.	O

This	O
mapping	O
is	O
more	O
robust	O
than	O
past	O
efforts	O
,	O
using	O
spatially	O
varying	O
correction	O
factors	O
to	O
accommodate	O
sampling	B-T170
design	I-T170
,	O
azimuthal	O
censoring	O
,	O
and	O
biases	O
in	O
tree	B-T204
selection	O
.	O

We	O
compare	O
pre	O
-	O
settlement	O
to	O
modern	O
forests	O
using	O
US	B-T082
Forest	O
Service	O
Forest	B-T170
Inventory	I-T170
and	I-T170
Analysis	I-T170
(	I-T170
FIA	I-T170
)	I-T170
data	I-T170
to	O
show	O
the	O
prevalence	O
of	O
lost	O
forests	O
(	O
pre	O
-	O
settlement	O
forests	O
with	O
no	O
current	O
analog	O
)	O
,	O
and	O
novel	O
forests	O
(	O
modern	O
forests	O
with	O
no	O
past	O
analogs	O
)	O
.	O

Differences	O
between	O
pre	O
-	O
settlement	O
and	O
modern	O
forests	O
are	O
spatially	O
structured	O
owing	O
to	O
differences	O
in	O
land	O
-	O
use	O
impacts	O
and	O
accompanying	O
ecological	O
responses	O
.	O

Modern	O
forests	O
are	O
more	O
homogeneous	O
,	O
and	O
ecotonal	O
gradients	O
are	O
more	O
diffuse	B-T082
today	O
than	O
in	O
the	O
past	O
.	O

Novel	O
forest	O
assemblages	O
represent	O
28	O
%	O
of	O
all	O
FIA	B-T170
cells	O
,	O
and	O
28	O
%	O
of	O
pre	O
-	O
settlement	O
forests	O
no	B-T033
longer	I-T033
exist	O
in	O
a	O
modern	O
context	O
.	O

Lost	O
forests	O
include	O
tamarack	B-T204
forests	O
in	O
northeastern	B-T082
Minnesota	B-T082
,	O
hemlock	B-T204
and	O
cedar	B-T204
dominated	O
forests	O
in	O
north	B-T082
-	I-T082
central	I-T082
Wisconsin	I-T082
and	O
along	O
the	O
Upper	B-T082
Peninsula	I-T082
of	I-T082
Michigan	I-T082
,	O
and	O
elm	B-T204
,	O
oak	B-T204
,	O
basswood	B-T204
and	O
ironwood	B-T204
forests	O
along	O
the	O
forest	O
-	O
prairie	B-T082
boundary	I-T082
in	O
south	B-T082
central	I-T082
Minnesota	I-T082
and	O
eastern	B-T082
Wisconsin	B-T082
.	O

Novel	O
FIA	B-T170
forest	O
assemblages	O
are	O
distributed	O
evenly	O
across	O
the	O
region	B-T082
,	O
but	O
novelty	O
shows	O
a	O
strong	O
relationship	O
to	O
spatial	O
distance	O
from	O
remnant	O
forests	O
in	O
the	O
upper	B-T082
Midwest	I-T082
,	O
with	O
novelty	O
predicted	O
at	O
between	O
20	O
to	O
60km	O
from	O
remnants	O
,	O
depending	O
on	O
historical	O
forest	O
type	O
.	O

The	O
spatial	B-T082
relationships	O
between	O
remnant	O
and	O
novel	O
forests	O
,	O
shifts	O
in	O
ecotone	O
structure	O
and	O
the	O
loss	O
of	O
historic	O
forest	O
types	O
point	O
to	O
significant	O
challenges	O
for	O
land	O
managers	B-T097
if	O
landscape	B-T082
restoration	O
is	O
a	O
priority	O
.	O

The	O
spatial	O
signals	O
of	O
novelty	O
and	O
ecological	O
change	O
also	O
point	O
to	O
potential	O
challenges	O
in	O
using	O
modern	O
spatial	B-T082
distributions	I-T082
of	O
species	B-T204
and	O
communities	O
and	O
their	O
relationship	O
to	O
underlying	O
geophysical	O
and	O
climatic	O
attributes	O
in	O
understanding	O
potential	O
responses	O
to	O
changing	O
climate	O
.	O

The	O
signal	O
of	O
human	B-T204
settlement	O
on	O
modern	O
forests	O
is	O
broad	B-T082
,	O
spatially	O
varying	O
and	O
acts	O
to	O
homogenize	O
modern	O
forests	O
relative	O
to	O
their	O
historic	O
counterparts	O
,	O
with	O
significant	O
implications	O
for	O
future	O
management	O
.	O

Prevalence	O
of	O
Self	B-T062
-	I-T062
Reported	I-T062
Prescription	B-T103
Drug	I-T103
Use	O
in	O
a	O
National	O
Sample	O
of	O
U	B-T082
.	I-T082
S	I-T082
.	O
Drivers	B-T098

Drug	B-T103
-	O
involved	O
driving	O
has	O
become	O
an	O
increasing	O
concern	O
.	O

Although	O
the	O
focus	O
has	O
been	O
on	O
illegal	B-T103
drugs	I-T103
,	O
there	O
is	O
evidence	O
that	O
prescribed	B-T103
medications	I-T103
can	O
impair	B-T033
driving	I-T033
ability	I-T033
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	B-T058
the	O
self	B-T062
-	I-T062
reported	I-T062
prevalence	O
of	O
prescription	B-T103
drug	I-T103
use	O
,	O
including	O
medical	O
and	O
nonmedical	B-T033
use	O
,	O
among	O
a	O
nationally	O
representative	O
sample	O
of	O
drivers	B-T098
and	O
to	O
report	O
related	O
driver	B-T098
characteristics	O
.	O

As	O
part	O
of	O
the	O
2013	O
-	O
2014	O
National	B-T062
Roadside	I-T062
Survey	I-T062
,	O
drivers	B-T098
from	O
60	O
sites	O
were	O
randomly	O
recruited	O
and	O
asked	O
to	O
complete	O
a	O
survey	O
on	O
prescription	B-T103
drug	I-T103
use	O
.	O

Almost	O
20	O
%	O
of	O
drivers	B-T098
reported	O
using	O
a	O
prescription	B-T103
drug	I-T103
within	O
the	O
past	O
2	O
days	O
,	O
with	O
the	O
most	O
common	B-T103
drug	I-T103
class	I-T103
being	O
sedatives	B-T103
(	O
8	O
.	O
0	O
%	O
)	O
,	O
followed	O
by	O
antidepressants	B-T103
(	O
7	O
.	O
7	O
%	O
)	O
,	O
narcotics	B-T103
(	O
7	O
.	O
5	O
%	O
)	O
,	O
and	O
stimulants	B-T103
(	O
3	O
.	O
9	O
%	O
)	O
.	O

Drivers	B-T098
who	O
reported	O
prescription	B-T103
drug	I-T103
use	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
female	O
,	O
older	B-T098
,	O
non	O
-	O
Hispanic	O
White	O
,	O
and	O
report	O
disability	B-T033
.	O

Three	O
of	O
four	O
drivers	B-T098
who	O
reported	O
medication	B-T103
use	O
(	O
78	O
.	O
2	O
%	O
)	O
said	O
the	O
drug	B-T103
was	O
prescribed	O
for	O
their	O
use	O
;	O
the	O
odds	O
of	O
using	O
without	O
a	O
prescription	B-T170
were	O
significantly	O
higher	O
for	O
males	O
,	O
Black	B-T098
/	I-T098
African	I-T098
American	I-T098
,	O
and	O
Hispanic	B-T098
drivers	B-T098
,	O
and	O
lower	O
for	O
older	B-T098
drivers	B-T098
.	O

Among	O
those	O
with	O
a	O
prescription	B-T170
,	O
taking	O
more	O
than	O
prescribed	O
was	O
most	O
common	O
for	O
narcotics	B-T103
(	O
6	O
.	O
8	O
%	O
)	O
,	O
followed	O
by	O
sedatives	B-T103
(	O
4	O
.	O
8	O
%	O
)	O
,	O
stimulants	B-T103
(	O
3	O
.	O
8	O
%	O
)	O
,	O
and	O
antidepressants	B-T103
(	O
1	O
.	O
5	O
%	O
)	O
.	O

These	O
findings	O
help	O
to	O
identify	O
drivers	B-T098
using	O
potentially	O
impairing	O
prescription	B-T103
drugs	I-T103
,	O
both	O
medically	O
and	O
nonmedically	B-T033
,	O
and	O
may	O
inform	O
the	O
targeting	O
of	O
interventions	B-T058
to	O
reduce	O
impaired	B-T033
driving	I-T033
related	O
to	O
medications	B-T170
.	O

Repetitive	O
and	O
Prolonged	O
Omega	B-T103
-	I-T103
3	I-T103
Fatty	I-T103
Acid	I-T103
Treatment	B-T058
After	O
Traumatic	B-T037
Brain	I-T037
Injury	I-T037
Enhances	O
Long	O
-	O
Term	O
Tissue	B-T017
Restoration	B-T058
and	O
Cognitive	B-T058
Recovery	I-T058

Traumatic	B-T037
brain	I-T037
injury	I-T037
(	O
TBI	B-T037
)	O
is	O
one	O
of	O
the	O
most	O
disabling	O
clinical	O
conditions	O
that	O
could	O
lead	O
to	O
neurocognitive	B-T038
disorders	I-T038
in	O
survivors	O
.	O

Our	O
group	B-T098
and	O
others	B-T098
previously	O
reported	B-T170
that	O
prophylactic	B-T058
enrichment	I-T058
of	O
dietary	O
omega	B-T103
-	I-T103
3	I-T103
polyunsaturated	I-T103
fatty	I-T103
acids	I-T103
(	O
n	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
)	O
markedly	O
ameliorate	O
cognitive	B-T038
deficits	I-T038
after	O
TBI	B-T037
.	O

However	O
,	O
it	O
remains	O
unclear	O
whether	O
a	O
clinically	O
relevant	O
therapeutic	B-T058
regimen	I-T058
with	O
n	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
administered	O
after	O
TBI	B-T037
would	O
still	O
offer	O
significant	O
improvement	O
of	O
long	O
-	O
term	O
cognitive	B-T058
recovery	I-T058
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
employed	O
the	O
decline	O
of	O
spatial	O
cognitive	B-T038
function	I-T038
as	O
a	O
main	O
outcome	O
after	O
TBI	B-T037
to	O
investigate	O
the	O
therapeutic	O
efficacy	O
of	O
post	O
-	O
TBI	B-T037
n	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
treatment	B-T058
and	O
the	O
underlying	O
mechanisms	O
.	O

Mice	B-T204
were	O
subjected	O
to	O
sham	B-T058
operation	I-T058
or	O
controlled	O
cortical	B-T017
impact	O
,	O
followed	O
by	O
random	O
assignment	O
to	O
receive	O
the	O
following	O
four	O
treatments	B-T058
:	O
(	O
1	O
)	O
vehicle	B-T103
control	O
;	O
(	O
2	O
)	O
daily	O
intraperitoneal	B-T058
injections	I-T058
of	O
n	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
for	O
2	O
weeks	O
,	O
beginning	O
2	O
h	O
after	O
TBI	B-T037
;	O
(	O
3	O
)	O
fish	B-T168
oil	I-T168
dietary	I-T168
supplementation	B-T058
throughout	O
the	O
study	B-T062
,	O
beginning	O
1	O
day	O
after	O
TBI	B-T037
;	O
or	O
(	O
4	O
)	O
combination	O
of	O
treatments	B-T058
(	O
2	O
)	O
and	O
(	O
3	O
)	O
.	O

Spatial	O
cognitive	O
deficits	O
and	O
chronic	O
brain	B-T017
tissue	I-T017
loss	O
,	O
as	O
well	O
as	O
endogenous	O
brain	B-T058
repair	I-T058
processes	I-T058
such	O
as	O
neurogenesis	B-T038
,	O
angiogenesis	B-T038
,	O
and	O
oligodendrogenesis	B-T038
,	O
were	O
evaluated	O
up	O
to	O
35	O
days	O
after	O
TBI	B-T037
.	O

The	O
results	O
revealed	O
prominent	O
spatial	O
cognitive	B-T038
deficits	I-T038
and	O
massive	O
tissue	B-T017
loss	O
caused	O
by	O
TBI	B-T037
.	O

Among	O
all	O
mice	B-T204
receiving	O
post	B-T037
-	I-T037
TBI	I-T037
n	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
treatments	B-T058
,	O
the	O
combined	O
treatment	B-T058
of	O
fish	B-T168
oil	I-T168
dietary	I-T168
supplement	B-T168
and	O
n	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
injections	B-T103
demonstrated	O
a	O
reproducible	O
beneficial	O
effect	O
in	O
attenuating	O
cognitive	B-T038
deficits	I-T038
although	O
without	O
reducing	O
gross	O
tissue	B-T017
loss	O
.	O

Mechanistically	O
,	O
the	O
combined	O
treatment	B-T058
promoted	O
post	B-T037
-	I-T037
TBI	I-T037
restorative	O
processes	O
in	O
the	O
brain	B-T017
,	O
including	O
generation	O
of	O
immature	B-T017
neurons	I-T017
,	O
microvessels	B-T017
,	O
and	O
oligodendrocytes	B-T017
,	O
each	O
of	O
which	O
was	O
significantly	O
correlated	O
with	O
the	O
improved	B-T033
cognitive	O
recovery	O
.	O

These	O
results	O
indicated	B-T033
that	O
repetitive	O
and	O
prolonged	O
n	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
treatments	B-T058
after	O
TBI	B-T037
are	O
capable	O
of	O
enhancing	O
brain	B-T017
remodeling	O
and	O
could	O
be	O
developed	O
as	O
a	O
potential	O
therapy	B-T058
to	O
treat	O
TBI	B-T037
victims	O
in	O
the	O
clinic	B-T092
.	O

Influence	O
of	O
yeast	B-T204
and	O
lactic	B-T007
acid	I-T007
bacterium	I-T007
on	O
the	O
constituent	O
profile	B-T058
of	O
soy	B-T168
sauce	I-T168
during	O
fermentation	B-T038

Soy	B-T168
sauce	I-T168
is	O
a	O
Japanese	B-T082
traditional	O
seasoning	B-T168
composed	O
of	O
various	O
constituents	O
that	O
are	O
produced	O
by	O
various	O
microbes	O
during	O
a	O
long	O
-	O
term	O
fermentation	B-T038
process	I-T038
.	O

Due	O
to	O
the	O
complexity	O
of	O
the	O
process	O
,	O
the	O
investigation	B-T062
of	O
the	O
constituent	O
profile	B-T058
during	O
fermentation	B-T038
is	O
difficult	B-T033
.	O

Metabolomics	B-T091
,	O
the	O
comprehensive	O
study	B-T062
of	O
low	O
molecular	O
weight	O
compounds	O
in	O
biological	O
samples	O
,	O
is	O
thought	O
to	O
be	O
a	O
promising	O
strategy	O
for	O
deep	O
understanding	B-T038
of	O
the	O
constituent	O
contribution	O
to	O
food	O
flavor	O
characteristics	O
.	O

Therefore	O
,	O
metabolomics	B-T091
is	O
suitable	O
for	O
the	O
analysis	B-T062
of	O
soy	B-T168
sauce	I-T168
fermentation	B-T038
.	O

Unfortunately	O
,	O
only	O
few	O
and	O
unrefined	O
studies	B-T062
of	O
soy	B-T168
sauce	I-T168
fermentation	B-T038
using	O
metabolomics	B-T091
approach	B-T082
have	O
been	O
reported	B-T170
.	O

Therefore	O
,	O
we	O
investigated	O
changes	O
in	O
low	O
molecular	O
weight	O
hydrophilic	O
and	O
volatile	B-T103
compounds	I-T103
of	O
soy	B-T168
sauce	I-T168
using	O
gas	B-T058
chromatography	I-T058
/	I-T058
mass	I-T058
spectrometry	I-T058
(	O
GC	B-T058
/	I-T058
MS	I-T058
)	O
-	O
based	O
non	O
-	O
targeted	O
metabolic	B-T091
profiling	I-T091
.	O

The	O
data	O
were	O
analyzed	B-T062
by	O
statistical	O
analysis	O
to	O
evaluate	O
influences	O
of	O
yeast	B-T204
and	O
lactic	B-T007
acid	I-T007
bacterium	I-T007
on	O
the	O
constituent	O
profile	B-T058
.	O

Consequently	O
,	O
our	O
results	O
suggested	O
a	O
novel	O
finding	B-T033
that	O
lactic	B-T007
acid	I-T007
bacterium	I-T007
affected	O
the	O
production	O
of	O
several	O
constituents	O
such	O
as	O
cyclotene	B-T103
,	O
furfural	B-T103
,	O
furfuryl	B-T103
alcohol	I-T103
and	O
methional	B-T103
in	O
the	O
soy	B-T168
sauce	I-T168
fermentation	B-T038
process	I-T038
.	O

Low	O
intensity	O
sprint	B-T058
training	I-T058
with	O
blood	O
flow	O
restriction	O
improves	O
100	O
m	O
dash	O

We	O
investigated	O
the	O
effects	O
of	O
practical	O
blood	O
flow	O
restriction	O
(	O
pBFR	O
)	O
of	O
leg	B-T017
muscles	I-T017
during	O
sprint	B-T058
training	I-T058
on	O
the	O
100	O
m	O
dash	O
time	O
in	O
well	B-T098
-	I-T098
trained	I-T098
sport	I-T098
students	I-T098
.	O

Participants	B-T098
performed	O
6x100	O
m	O
sprints	O
at	O
60	O
-	O
70	O
%	O
of	O
their	O
maximal	O
100	O
m	O
sprinting	O
speed	O
twice	O
a	O
week	O
for	O
6	O
weeks	O
,	O
either	O
with	O
(	O
IG	B-T098
;	O
n	O
=	O
12	O
)	O
or	O
without	O
pBFR	O
(	O
CG	O
;	O
n	O
=	O
12	O
)	O
.	O

The	O
100	O
m	O
dash	O
time	O
significantly	O
decreased	O
more	O
in	O
the	O
IG	B-T098
(	O
-	O
0	O
.	O
38±0	O
.	O
24	O
s	O
)	O
than	O
in	O
the	O
CG	O
(	O
-	O
0	O
.	O
16±0	O
.	O
17	O
s	O
)	O
.	O

The	O
muscle	B-T017
thickness	O
of	O
the	O
rectus	B-T017
femoris	I-T017
increased	O
only	O
in	O
the	O
IG	B-T098
,	O
while	O
no	O
group	O
by	O
time	O
interactions	O
were	O
found	O
for	O
the	O
muscle	B-T017
thickness	O
of	O
the	O
biceps	B-T017
femoris	I-T017
and	O
the	O
biceps	B-T017
brachii	I-T017
.	O

The	O
maximal	O
isometric	O
force	O
,	O
measured	O
using	O
a	O
leg	O
press	O
,	O
did	O
not	B-T033
change	I-T033
in	O
either	O
group	O
.	O

However	O
,	O
the	O
rate	O
of	O
force	O
development	O
improved	O
in	O
the	O
IG	B-T098
.	O

Growth	B-T103
hormone	I-T103
,	O
testosterone	B-T103
,	O
insulin	B-T103
-	I-T103
like	I-T103
growth	I-T103
factor	I-T103
1	I-T103
,	O
and	O
cortisol	B-T103
concentrations	O
did	O
not	B-T033
significantly	I-T033
differ	I-T033
between	O
both	O
groups	O
at	O
any	O
measurement	O
time	O
point	O
(	O
pre	O
,	O
1	O
min	O
,	O
20	O
min	O
,	O
120	O
min	O
,	O
and	O
24	O
h	O
after	O
the	O
six	O
all	O
-	O
out	O
sprints	O
of	O
the	O
first	O
training	O
session	O
)	O
.	O

The	O
muscle	B-T017
damage	I-T017
marker	B-T201
h	B-T103
-	I-T103
FABP	I-T103
increased	O
significantly	O
more	O
in	O
the	O
CG	O
than	O
in	O
the	O
IG	B-T098
.	O

The	O
pBFR	O
improved	O
the	O
100	O
m	O
dash	O
time	O
significantly	O
more	O
than	O
low	O
-	O
intensity	O
sprint	B-T058
interval	I-T058
training	I-T058
alone	O
.	O

Other	O
noted	O
benefits	O
of	O
training	O
with	O
pBFR	O
were	O
a	O
decreased	O
level	O
of	O
muscle	B-T017
damage	I-T017
,	O
a	O
greater	O
increase	O
of	O
the	O
rectus	B-T017
femoris	I-T017
muscle	I-T017
thickness	O
,	O
and	O
a	O
higher	O
rate	O
of	O
force	O
development	O
.	O

However	O
,	O
the	O
tested	O
hormones	B-T103
were	O
unable	O
to	O
explain	O
the	O
additional	O
beneficial	O
effects	O
.	O

Sedation	B-T058
of	O
Patients	O
With	O
Disorders	B-T038
of	I-T038
Consciousness	I-T038
During	O
Neuroimaging	B-T058
:	O
Effects	O
on	O
Resting	B-T058
State	I-T058
Functional	I-T058
Brain	I-T058
Connectivity	I-T058

To	O
reduce	O
head	B-T038
movement	I-T038
during	O
resting	B-T058
state	I-T058
functional	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
,	O
post	O
-	O
coma	O
patients	O
with	O
disorders	B-T038
of	I-T038
consciousness	I-T038
(	O
DOC	B-T038
)	O
are	O
frequently	O
sedated	B-T058
with	O
propofol	B-T103
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
this	O
sedation	B-T058
on	O
the	O
brain	B-T082
connectivity	I-T082
patterns	I-T082
in	O
the	O
damaged	B-T037
brain	I-T037
essential	O
for	O
differential	B-T058
diagnosis	I-T058
.	O

In	O
this	O
study	B-T062
,	O
we	O
aimed	O
to	O
assess	O
these	O
effects	O
.	O

Using	O
resting	B-T058
state	I-T058
functional	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
3T	O
data	O
obtained	O
over	O
several	O
years	O
of	O
scanning	B-T058
patients	O
for	O
diagnostic	O
and	O
research	B-T062
purposes	O
,	O
we	O
employed	O
a	O
seed	O
-	O
based	O
approach	O
to	O
examine	O
resting	O
state	O
connectivity	O
in	O
higher	O
-	O
order	O
(	O
default	O
mode	O
,	O
bilateral	B-T082
external	O
control	O
,	O
and	O
salience	O
)	O
and	O
lower	O
-	O
order	O
(	O
auditory	O
,	O
sensorimotor	O
,	O
and	O
visual	O
)	O
resting	O
state	O
networks	O
and	O
connectivity	O
with	O
the	O
thalamus	B-T017
,	O
in	O
20	O
healthy	O
unsedated	B-T033
controls	O
,	O
8	O
unsedated	B-T033
patients	O
with	O
DOC	B-T038
,	O
and	O
8	O
patients	O
with	O
DOC	B-T038
sedated	B-T058
with	O
propofol	B-T103
.	O

The	O
DOC	B-T038
groups	O
were	O
matched	O
for	O
age	O
at	O
onset	O
,	O
etiology	O
,	O
time	B-T033
spent	I-T033
in	O
DOC	B-T038
,	O
diagnosis	B-T033
,	O
standardized	O
behavioral	O
assessment	O
scores	O
,	O
movement	B-T038
intensities	O
,	O
and	O
pattern	O
of	O
structural	B-T037
brain	I-T037
injury	I-T037
(	O
as	O
assessed	O
with	O
T1	B-T058
-	I-T058
based	I-T058
voxel	I-T058
-	I-T058
based	I-T058
morphometry	I-T058
)	O
.	O

DOC	B-T038
were	O
associated	O
with	O
severely	O
impaired	O
resting	O
state	O
network	O
connectivity	O
in	O
all	O
but	O
the	O
visual	O
network	O
.	O

Thalamic	B-T017
connectivity	O
to	O
higher	O
-	O
order	O
network	O
regions	O
was	O
also	O
reduced	O
.	O

Propofol	B-T103
administration	B-T058
to	O
patients	O
was	O
associated	O
with	O
minor	O
further	O
decreases	O
in	O
thalamic	B-T017
and	O
insular	B-T017
connectivity	O
.	O

Our	O
findings	O
indicate	O
that	O
connectivity	O
decreases	O
associated	O
with	O
propofol	B-T103
sedation	B-T058
,	O
involving	O
the	O
thalamus	B-T017
and	O
insula	B-T017
,	O
are	O
relatively	O
small	O
compared	O
with	O
those	O
already	O
caused	O
by	O
DOC	B-T038
-	O
associated	O
structural	B-T037
brain	I-T037
injury	I-T037
.	O

Nonetheless	O
,	O
given	O
the	O
known	O
importance	O
of	O
the	O
thalamus	B-T017
in	O
brain	B-T038
arousal	I-T038
,	O
its	O
disruption	O
could	O
well	O
reflect	O
the	O
diminished	O
movement	B-T038
obtained	O
in	O
these	O
patients	O
.	O

However	O
,	O
more	O
research	B-T062
is	O
needed	O
on	O
this	O
topic	O
to	O
fully	O
address	O
the	O
research	O
question	O
.	O

Potassium	B-T038
depletion	I-T038
stimulates	O
Na	B-T103
-	I-T103
Cl	I-T103
cotransporter	I-T103
via	O
phosphorylation	B-T038
and	O
inactivation	O
of	O
the	O
ubiquitin	B-T103
ligase	I-T103
Kelch	B-T103
-	I-T103
like	I-T103
3	I-T103

Kelch	B-T103
-	I-T103
like	I-T103
3	I-T103
(	O
KLHL3	B-T103
)	O
is	O
a	O
component	B-T103
of	O
an	O
E3	B-T103
ubiquitin	I-T103
ligase	I-T103
complex	I-T103
that	O
regulates	B-T038
blood	B-T038
pressure	I-T038
by	O
targeting	O
With	B-T103
-	I-T103
No	I-T103
-	I-T103
Lysine	I-T103
(	I-T103
WNK	I-T103
)	I-T103
kinases	I-T103
for	O
degradation	O
.	O

Mutations	B-T038
in	O
KLHL3	B-T103
cause	O
constitutively	O
increased	B-T033
renal	I-T033
salt	I-T033
reabsorption	I-T033
and	O
impaired	O
K	B-T103
(	I-T103
+	I-T103
)	I-T103
secretion	B-T038
,	O
resulting	O
in	O
hypertension	B-T038
and	O
hyperkalemia	B-T033
.	O

Although	O
clinical	B-T062
studies	I-T062
have	O
shown	O
that	O
dietary	B-T168
K	I-T168
(	I-T168
+	I-T168
)	I-T168
intake	O
affects	O
blood	B-T038
pressure	I-T038
,	O
the	O
mechanisms	O
have	O
been	O
obscure	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
KLHL3	B-T103
ubiquitin	B-T103
ligase	I-T103
complex	B-T103
is	O
involved	O
in	O
the	O
low	O
-	O
K	B-T103
(	I-T103
+	I-T103
)	I-T103
-	O
mediated	O
activation	O
of	O
Na	B-T103
-	I-T103
Cl	I-T103
cotransporter	I-T103
(	O
NCC	B-T103
)	O
in	O
the	O
kidney	B-T017
.	O

In	O
the	O
distal	B-T017
convoluted	I-T017
tubules	I-T017
of	O
mice	B-T204
eating	B-T038
a	O
low	B-T058
-	I-T058
K	I-T058
(	I-T058
+	I-T058
)	I-T058
diet	I-T058
,	O
we	O
found	O
increased	O
KLHL3	B-T103
phosphorylation	B-T038
at	O
S433	O
(	B-T103
KLHL3	I-T103
(	I-T103
S433	I-T103
-	I-T103
P	I-T103
)	I-T103
)	I-T103
,	O
a	O
modification	B-T033
that	O
impairs	O
WNK	B-T103
binding	O
,	O
and	O
also	O
reduced	O
total	O
KLHL3	B-T103
levels	O
.	O

These	O
changes	O
are	O
accompanied	O
by	O
the	O
accumulation	B-T033
of	O
the	O
target	O
substrate	O
WNK4	B-T103
,	O
and	O
activation	O
of	O
the	O
downstream	B-T082
kinases	B-T103
SPAK	I-T103
(	O
STE20	B-T103
/	O
SPS1	B-T103
-	O
related	O
proline	B-T103
-	I-T103
alanine	I-T103
-	I-T103
rich	I-T103
protein	I-T103
kinase	I-T103
)	O
and	O
OSR1	B-T103
(	O
oxidative	B-T103
stress	I-T103
-	I-T103
responsive	I-T103
1	I-T103
)	O
,	O
resulting	O
in	O
NCC	B-T103
phosphorylation	B-T038
and	O
its	O
accumulation	B-T033
at	O
the	O
plasma	B-T017
membrane	I-T017
.	O

Increased	O
phosphorylation	B-T038
of	O
S433	O
was	O
explained	O
by	O
increased	O
levels	O
of	O
active	O
,	O
phosphorylated	O
protein	B-T103
kinase	I-T103
C	I-T103
(	O
but	O
not	O
protein	B-T103
kinase	I-T103
A	I-T103
)	O
,	O
which	O
directly	O
phosphorylates	B-T038
S433	O
.	O

Moreover	O
,	O
in	O
HEK	B-T017
cells	I-T017
expressing	B-T038
KLHL3	B-T103
and	O
WNK4	B-T103
,	O
we	O
showed	O
that	O
the	O
activation	O
of	O
protein	B-T103
kinase	I-T103
C	I-T103
by	O
phorbol	B-T103
12	I-T103
-	I-T103
myristate	I-T103
13	I-T103
-	I-T103
acetate	I-T103
induces	O
KLHL3	B-T103
(	I-T103
S433	I-T103
-	I-T103
P	I-T103
)	I-T103
and	O
increases	O
WNK4	B-T103
levels	O
by	O
abrogating	O
its	O
ubiquitination	B-T038
.	O

These	O
data	O
demonstrate	O
the	O
role	O
of	O
KLHL3	B-T103
in	O
low	O
-	O
K	B-T103
(	I-T103
+	I-T103
)	I-T103
-	O
mediated	O
induction	O
of	O
NCC	B-T103
;	O
this	O
physiologic	B-T038
adaptation	I-T038
reduces	O
distal	B-T082
electrogenic	B-T038
Na	B-T038
(	I-T038
+	I-T038
)	I-T038
reabsorption	I-T038
,	O
preventing	O
further	O
renal	B-T017
K	B-T103
(	I-T103
+	I-T103
)	I-T103
loss	O
but	O
promoting	O
increased	O
blood	B-T038
pressure	I-T038
.	O

The	O
relationship	O
between	O
thoracic	B-T082
configuration	B-T082
and	O
changes	O
in	O
volumes	O
of	O
hemithoraces	B-T082
in	O
upright	B-T033
sitting	I-T033

[	O
Purpose	O
]	O
Some	O
patients	O
with	O
respiratory	B-T038
disease	I-T038
exhibit	O
asymmetrical	O
movement	O
of	O
the	O
thorax	O
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
the	O
relationship	O
of	O
thoracic	B-T082
configuration	B-T082
with	O
changes	O
in	O
thoracic	B-T201
volume	I-T201
in	O
13	O
sedentary	O
healthy	O
men	B-T098
.	O

[	O
Subjects	O
and	O
Methods	O
]	O
In	O
upright	B-T033
sitting	I-T033
,	O
84	O
reflective	O
markers	O
were	O
placed	O
on	O
the	O
anterior	B-T082
and	O
posterior	B-T082
aspects	O
of	O
the	O
trunk	B-T082
to	O
record	O
thoracic	B-T201
volume	I-T201
during	O
quiet	O
and	O
volitional	B-T038
deep	B-T033
breathing	I-T033
.	O

Using	O
a	O
three	B-T074
-	I-T074
dimensional	I-T074
motion	I-T074
analyzer	I-T074
,	O
the	O
difference	O
in	O
volume	O
within	O
the	O
upper	B-T082
and	O
lower	B-T082
hemithoraces	B-T082
was	O
measured	O
.	O

For	O
calculation	O
of	O
the	O
thoracic	B-T201
volume	I-T201
six	O
imaginary	B-T082
hexahedra	I-T082
were	O
visualized	O
for	O
the	O
upper	B-T082
and	O
lower	B-T082
thorax	B-T082
using	O
four	O
reflective	O
markers	O
for	O
each	O
on	O
the	O
anterior	B-T082
and	O
posterior	B-T082
aspects	O
of	O
the	O
thorax	B-T082
.	O

Each	O
hexahedron	B-T082
was	O
then	O
divided	O
into	O
three	O
imaginary	O
triangular	O
pyramids	O
to	O
calculate	O
positional	O
vectors	B-T082
.	O

Finally	O
,	O
the	O
volume	O
for	O
both	O
the	O
hexahedra	B-T082
and	O
triangular	O
pyramids	O
was	O
calculated	O
.	O

Four	O
thoracic	B-T201
volumes	I-T201
were	O
obtained	O
.	O

[	O
Results	O
]	O
The	O
findings	O
showed	O
that	O
the	O
left	B-T082
upper	B-T082
and	O
right	B-T082
lower	B-T082
hemithorax	B-T082
yielded	O
significantly	O
larger	O
thoracic	B-T201
volumes	I-T201
.	O

[	O
Conclusion	O
]	O
In	O
conclusion	O
the	O
left	B-T082
upper	B-T082
and	O
right	B-T082
lower	B-T082
hemithoraces	B-T082
were	O
found	O
to	O
expand	B-T082
more	O
than	O
their	O
corresponding	O
sides	B-T082
.	O

Understanding	O
the	O
characteristics	O
of	O
thoracic	B-T082
excursion	B-T033
during	O
quiet	O
and	O
volitional	B-T038
deep	B-T033
breathing	I-T033
could	O
be	O
of	O
value	O
in	O
assessment	B-T058
and	O
instruction	B-T170
of	O
breathing	O
techniques	O
to	O
patients	O
.	O

Development	O
of	O
the	O
four	O
-	O
item	O
Letter	O
and	O
Shape	O
Drawing	O
test	O
(	O
LSD	O
-	O
4	O
)	O
:	O
A	O
brief	O
bedside	B-T058
test	I-T058
of	O
visuospatial	O
function	O

Conventional	O
bedside	B-T058
tests	I-T058
of	O
visuospatial	O
function	O
such	O
as	O
the	O
Clock	O
Drawing	O
(	O
CDT	O
)	O
and	O
Intersecting	O
Pentagons	O
(	O
IPT	O
)	O
lack	O
consistency	O
in	O
delivery	O
and	O
interpretation	B-T033
.	O

We	O
compared	O
performance	O
on	O
a	O
novel	O
test	O
of	O
visuospatial	O
ability	O
-	O
the	O
LSD	O
-	O
with	O
the	O
IPT	O
,	O
CDT	O
and	O
MMSE	B-T058
in	O
180	O
acute	O
elderly	B-T098
medical	O
inpatients	O
[	O
mean	O
age	O
79	O
.	O
7±7	O
.	O
1	O
(	O
range	O
62	O
-	O
96	O
)	O
;	O
91	O
females	O
(	O
50	O
.	O
6	O
%	O
)	O
]	O
.	O

124	O
(	O
69	O
%	O
)	O
scored	O
≤23	O
on	O
the	O
MMSE	B-T058
;	O
60	O
with	O
mild	O
(	O
score	O
18	O
-	O
23	O
)	O
and	O
64	O
with	O
severe	O
(	O
score	O
≤17	O
)	O
impairment	O
.	O

78	O
(	O
43	O
%	O
)	O
scored	O
≥6	O
on	O
the	O
CDT	O
,	O
while	O
for	O
the	O
IPT	O
,	O
87	O
(	O
47	O
%	O
)	O
scored	O
≥4	O
.	O

The	O
CDT	O
and	O
IPT	O
agreed	B-T033
on	O
the	O
classification	B-T170
of	O
138	O
patients	O
(	O
77	O
%	O
)	O
with	O
modest	O
-	O
strong	O
agreement	O
with	O
the	O
MMSE	B-T058
categories	B-T170
.	O

Correlation	O
between	O
the	O
LSD	O
and	O
visuospatial	O
tests	O
was	O
high	O
.	O

A	O
four	B-T170
-	I-T170
item	I-T170
version	I-T170
of	O
the	O
LSD	O
incorporating	O
items	O
1	O
,	O
10	O
,	O
12	O
,	O
15	O
had	O
high	O
correlation	O
with	O
the	O
LSD	O
-	O
15	O
and	O
strong	O
association	O
with	O
MMSE	B-T058
categories	B-T170
.	O

The	O
LSD	O
-	O
4	O
provides	O
a	O
brief	O
and	O
easily	B-T033
interpreted	O
bedside	B-T058
test	I-T058
of	O
visuospatial	O
function	O
that	O
has	O
high	O
coverage	O
of	O
elderly	B-T098
patients	O
with	O
neurocognitive	B-T038
impairment	I-T038
,	O
good	O
agreement	O
with	O
conventional	O
tests	O
of	O
visuospatial	O
ability	O
and	O
favourable	O
ability	O
to	O
identify	O
significant	O
cognitive	B-T038
impairment	I-T038
.	O

[	O
181	O
words	O
]	O
.	O

Salvage	B-T058
Therapy	I-T058
with	O
Ceftolozane	B-T103
-	I-T103
Tazobactam	I-T103
for	O
Multidrug	B-T007
-	I-T007
Resistant	I-T007
Pseudomonas	I-T007
aeruginosa	I-T007
Infections	B-T038

Infections	B-T038
caused	O
by	O
multidrug	B-T007
-	I-T007
resistant	I-T007
Pseudomonas	I-T007
aeruginosa	I-T007
(	O
MDRPA	B-T007
)	O
present	O
a	O
major	O
problem	O
for	O
therapeutic	B-T058
management	I-T058
.	O

We	O
report	O
here	O
our	O
experience	O
with	O
12	O
patients	O
with	O
a	O
severe	O
MDRPA	B-T007
infection	B-T038
(	O
6	O
of	O
which	O
were	O
pneumonia	B-T038
)	O
who	O
received	O
salvage	B-T058
therapy	I-T058
with	O
ceftolozane	B-T103
-	I-T103
tazobactam	I-T103
after	O
inappropriate	O
empirical	B-T058
treatment	I-T058
and	O
/	O
or	O
suboptimal	O
targeted	O
treatment	B-T058
.	O

Although	O
10	O
of	O
the	O
12	O
patients	O
(	O
83	O
.	O
3	O
%	O
)	O
experienced	O
septic	B-T038
shock	I-T038
,	O
only	O
3	O
patients	O
(	O
25	O
%	O
)	O
died	B-T038
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O

Microbiological	B-T058
cure	O
in	O
7	O
patients	O
(	O
58	O
.	O
3	O
%	O
)	O
was	O
observed	O
.	O

Ankaflavin	B-T103
and	O
Monascin	B-T103
Induce	O
Apoptosis	B-T038
in	O
Activated	O
Hepatic	B-T017
Stellate	I-T017
Cells	I-T017
through	O
Suppression	O
of	O
the	O
Akt	B-T103
/	O
NF	B-T103
-	I-T103
κB	I-T103
/	O
p38	B-T103
Signaling	B-T038
Pathway	I-T038

The	O
increased	O
proliferation	B-T038
of	O
activated	O
hepatic	B-T017
stellate	I-T017
cells	I-T017
(	O
HSCs	B-T017
)	O
is	O
associated	O
with	O
hepatic	B-T038
fibrosis	I-T038
and	O
excessive	O
extracellular	B-T017
matrix	I-T017
(	O
ECM	B-T017
)	O
-	O
protein	B-T103
production	O
.	O

We	O
examined	O
the	O
inhibitory	O
effects	O
of	O
the	O
Monascus	B-T204
purpureus	I-T204
-	O
fermented	O
metabolites	B-T103
,	O
ankaflavin	B-T103
and	O
monascin	B-T103
(	O
15	O
and	O
30	O
μM	O
)	O
,	O
on	O
the	O
Akt	B-T103
/	O
nuclear	B-T103
factor	I-T103
(	I-T103
NF	I-T103
)	I-T103
-	I-T103
κB	I-T103
and	O
p38	B-T103
mitogen	I-T103
-	I-T103
activated	I-T103
protein	I-T103
kinase	I-T103
(	O
MAPK	B-T103
)	O
signaling	B-T038
pathways	I-T038
in	O
HSC	B-T017
-	I-T017
T6	I-T017
(	O
activated	B-T017
hepatic	I-T017
stellate	I-T017
cell	I-T017
line	I-T017
)	O
.	O

Ankaflavin	B-T103
and	O
monascin	B-T103
(	O
30	O
μM	O
)	O
induced	O
apoptosis	B-T038
and	O
significantly	O
inhibited	O
cell	B-T038
growth	I-T038
(	O
cell	B-T038
viabilities	I-T038
:	O
80	O
.	O
2	O
±	O
5	O
.	O
43	O
%	O
and	O
62	O
.	O
8	O
±	O
8	O
.	O
20	O
%	O
,	O
respectively	O
,	O
versus	O
control	B-T017
cells	I-T017
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Apoptosis	B-T038
and	O
G1	B-T038
phase	I-T038
arrest	I-T038
(	O
G1	O
phase	O
percentages	O
:	O
76	O
.	O
1	O
±	O
2	O
.	O
85	O
%	O
and	O
79	O
.	O
9	O
±	O
1	O
.	O
80	O
%	O
,	O
respectively	O
,	O
versus	O
control	B-T017
cells	I-T017
65	O
.	O
9	O
±	O
4	O
.	O
94	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
correlated	O
with	O
increased	O
p53	B-T103
and	O
p21	B-T103
levels	B-T033
and	O
caspase	B-T038
3	I-T038
activity	I-T038
and	O
decreased	O
cyclin	B-T103
D1	I-T103
and	O
Bcl	B-T017
-	I-T017
2	I-T017
-	I-T017
family	I-T017
protein	I-T017
levels	B-T033
(	O
P	O
<	O
0	O
.	O
05	O
,	O
all	O
cases	O
)	O
.	O

The	O
apoptotic	O
effects	O
of	O
ankaflavin	B-T103
and	O
monascin	B-T103
were	O
HSC	B-T017
-	I-T017
T6	I-T017
-	O
specific	O
,	O
suggesting	O
their	O
potential	O
in	O
treating	O
liver	B-T038
fibrosis	I-T038
.	O

Low	B-T092
-	I-T092
Volume	I-T092
vs	O
High	B-T092
-	I-T092
Volume	I-T092
Centers	I-T092
and	O
Management	B-T058
of	I-T058
Fournier	B-T038
'	I-T038
s	I-T038
Gangrene	I-T038
in	O
Washington	B-T082
State	I-T082

Fournier	B-T038
'	I-T038
s	I-T038
gangrene	I-T038
(	O
FG	B-T038
)	O
is	O
a	O
life	B-T033
-	I-T033
threatening	I-T033
infection	I-T033
affecting	O
the	O
perineum	B-T082
and	O
genitals	B-T017
.	O

Complex	O
patient	B-T058
management	I-T058
often	O
necessitates	O
transfer	O
to	O
tertiary	B-T092
centers	I-T092
.	O

We	O
aimed	O
to	O
characterize	O
hospital	O
transfer	O
patterns	B-T082
and	O
assess	O
morbidity	O
among	O
patients	O
with	O
FG	B-T038
in	O
Washington	B-T082
State	I-T082
.	O

The	O
Washington	B-T082
State	I-T082
Comprehensive	O
Hospital	O
Abstract	O
Reporting	O
System	O
includes	O
claims	O
from	O
all	O
hospital	O
discharges	O
in	O
Washington	B-T082
.	O

We	O
identified	O
patients	O
with	O
FG	B-T038
between	O
2007	O
and	O
2013	O
,	O
based	O
on	O
diagnosis	B-T170
and	I-T170
treatment	I-T170
codes	I-T170
.	O

Analyses	O
were	O
stratified	O
by	O
center	O
volume	O
(	O
low	B-T092
-	I-T092
volume	I-T092
centers	I-T092
[	O
LVCs	B-T092
]	O
or	O
high	B-T092
-	I-T092
volume	I-T092
centers	I-T092
[	O
HVCs	B-T092
]	O
)	O
,	O
and	O
transfer	B-T033
status	I-T033
.	O

Variables	O
of	O
interest	O
included	O
number	O
of	O
debridements	B-T058
,	O
septic	B-T038
shock	I-T038
,	O
acute	B-T038
renal	I-T038
failure	I-T038
,	O
acute	B-T038
respiratory	I-T038
failure	I-T038
,	O
length	O
of	O
hospitalization	O
,	O
and	O
death	B-T033
.	O

We	O
identified	O
165	O
FG	B-T038
patients	O
.	O

Only	O
1	O
HVC	B-T092
treated	O
more	O
than	O
2	O
FG	B-T038
patients	O
per	O
year	O
.	O

Overall	O
mortality	O
was	O
6	O
.	O
7	O
%	O
.	O

Most	O
patients	O
(	O
57	O
%	O
)	O
were	O
treated	O
entirely	O
at	O
LVCs	B-T092
;	O
87	O
%	O
of	O
patients	O
treated	O
at	O
the	O
HVC	B-T092
were	O
transferred	O
from	O
an	O
LVC	B-T092
.	O

High	B-T092
-	I-T092
volume	I-T092
center	I-T092
-	O
treated	O
patients	O
had	O
similar	O
baseline	O
comorbidities	O
(	O
p	O
=	O
0	O
.	O
77	O
)	O
and	O
similar	O
mortality	O
(	O
p	O
=	O
0	O
.	O
87	O
)	O
,	O
despite	O
higher	O
rates	O
of	O
septic	B-T038
shock	I-T038
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
respiratory	B-T038
failure	I-T038
(	O
p	O
=	O
0	O
.	O
01	O
)	O
compared	O
with	O
LVC	B-T092
patients	O
.	O

Among	O
HVC	B-T092
-	O
transferred	B-T058
patients	I-T058
,	O
immediate	O
compared	O
with	O
delayed	O
transfer	O
was	O
associated	O
with	O
fewer	O
debridements	B-T058
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
lower	O
rates	O
of	O
septic	B-T038
shock	I-T038
(	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
and	O
acute	B-T038
renal	I-T038
failure	I-T038
(	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O

Patients	O
treated	O
at	O
the	O
HVC	B-T092
were	O
more	O
acutely	O
ill	O
,	O
yet	O
mortality	O
was	O
similar	O
compared	O
with	O
patients	O
treated	O
solely	O
at	O
LVCs	B-T092
,	O
suggesting	O
a	O
benefit	O
to	O
transfer	O
of	O
high	O
acuity	O
patients	O
.	O

Immediate	O
vs	O
delayed	O
transfer	O
may	O
benefit	O
FG	B-T038
health	O
outcomes	O
;	O
however	O
,	O
this	O
may	O
also	O
reflect	O
greater	O
disease	B-T038
acuity	O
of	O
patients	O
with	O
delayed	O
transfer	B-T033
status	I-T033
.	O

Functional	O
Characterization	O
of	O
Pneumocystis	B-T204
carinii	I-T204
Inositol	B-T103
Transporter	I-T103
1	I-T103

Fungi	B-T204
in	O
the	O
genus	B-T204
Pneumocystis	I-T204
live	O
in	O
the	O
lungs	B-T017
of	O
mammals	B-T204
,	O
where	O
they	O
can	O
cause	O
a	O
fatal	O
pneumonia	B-T038
(	O
PCP	B-T038
[	O
Pneumocystis	B-T038
pneumonia	I-T038
]	O
)	O
in	O
hosts	O
with	O
compromised	O
immune	B-T022
systems	I-T022
.	O

The	O
absence	O
of	O
a	O
continuous	O
in	O
vitro	O
culture	B-T058
system	I-T058
for	O
any	O
species	B-T170
of	O
Pneumocystis	B-T204
has	O
led	O
to	O
limited	O
understanding	O
of	O
these	O
fungi	B-T204
,	O
especially	O
for	O
the	O
discovery	O
of	O
new	O
therapies	B-T058
.	O

We	O
recently	O
reported	O
that	O
Pneumocystis	B-T204
carinii	I-T204
,	O
Pneumocystis	B-T204
murina	I-T204
,	O
and	O
most	O
significantly	O
,	O
Pneumocystis	B-T204
jirovecii	I-T204
lack	O
both	O
enzymes	B-T103
necessary	O
for	O
myo	B-T038
-	I-T038
inositol	I-T038
biosynthesis	I-T038
but	O
contain	O
genes	B-T017
with	I-T017
homologies	I-T017
to	O
fungal	B-T204
myo	B-T103
-	I-T103
inositol	I-T103
transporters	B-T103
.	O

Since	O
myo	B-T103
-	I-T103
inositol	I-T103
is	O
essential	O
for	O
eukaryotic	B-T017
viability	B-T038
,	O
the	O
primary	O
transporter	B-T103
,	O
ITR1	B-T103
,	O
was	O
functionally	O
and	O
structurally	B-T082
characterized	O
in	O
P	B-T204
.	I-T204

carinii	I-T204
The	O
predicted	O
structure	B-T103
of	O
P	B-T204
.	I-T204

carinii	I-T204
ITR1	B-T103
(	O
PcITR1	B-T103
)	O
contained	O
12	O
transmembrane	B-T017
alpha	B-T082
-	I-T082
helices	I-T082
with	O
intracellular	B-T082
C	B-T082
and	O
N	B-T082
termini	I-T082
,	O
consistent	O
with	O
other	O
inositol	B-T103
transporters	B-T103
.	O

The	O
apparent	O
Km	O
was	O
0	O
.	O
94	O
±	O
0	O
.	O
08	O
(	O
mean	O
±	O
standard	O
deviation	O
)	O
,	O
suggesting	O
that	O
myo	B-T038
-	I-T038
inositol	I-T038
transport	I-T038
in	O
P	B-T204
.	I-T204

carinii	I-T204
is	O
likely	O
through	O
a	O
low	O
-	O
affinity	O
,	O
highly	O
selective	O
transport	B-T038
system	I-T038
,	O
as	O
no	O
other	O
sugars	B-T103
or	O
inositol	B-T103
stereoisomers	B-T103
were	O
significant	O
competitive	B-T038
inhibitors	B-T103
.	O

Glucose	B-T038
transport	I-T038
was	O
shown	O
to	O
use	O
a	O
different	O
transport	B-T038
system	O
.	O

The	O
myo	B-T038
-	I-T038
inositol	I-T038
transport	I-T038
was	O
distinct	O
from	O
mammalian	B-T204
transporters	B-T103
,	O
as	O
it	O
was	O
not	O
sodium	B-T038
dependent	I-T038
and	O
was	O
cytochalasin	B-T103
B	I-T103
resistant	O
.	O

Inositol	B-T038
transport	I-T038
in	O
these	O
fungi	B-T204
offers	O
an	O
attractive	O
new	O
drug	B-T103
target	O
because	O
of	O
the	O
reliance	O
of	O
the	O
fungi	B-T204
on	O
its	O
transport	B-T038
,	O
clear	O
differences	O
between	O
the	O
mammalian	B-T204
and	O
fungal	B-T204
transporters	B-T103
,	O
and	O
the	O
ability	O
of	O
the	O
host	O
to	O
both	O
synthesize	O
and	O
transport	B-T038
this	O
critical	O
nutrient	B-T168
,	O
predicting	O
low	O
toxicity	B-T037
of	O
potential	O
inhibitors	B-T103
to	O
the	O
fungal	B-T204
transporter	B-T103
.	O

myo	B-T103
-	I-T103
Inositol	I-T103
is	O
a	O
sugarlike	B-T103
nutrient	B-T168
that	O
is	O
essential	O
for	O
life	O
in	O
most	O
organisms	O
.	O

Humans	B-T204
and	O
microbes	O
alike	O
can	O
obtain	O
it	O
by	O
making	O
it	O
,	O
which	O
involves	O
only	O
2	O
enzymes	B-T103
,	O
by	O
taking	O
it	O
from	O
the	O
environment	B-T082
by	O
a	O
transport	B-T038
process	I-T038
,	O
or	O
by	O
recycling	O
it	O
from	O
other	O
cellular	B-T017
constituents	O
.	O

Inspection	O
of	O
the	O
genomes	B-T017
of	O
the	O
pathogenic	O
fungi	O
of	O
the	O
genus	B-T204
Pneumocystis	I-T204
showed	O
that	O
these	O
pneumonia	B-T038
-	O
causing	O
parasites	B-T204
could	O
not	O
make	O
myo	B-T103
-	I-T103
inositol	I-T103
,	O
as	O
they	O
lacked	O
the	O
2	O
enzymes	B-T103
.	O

Instead	O
,	O
we	O
found	O
evidence	O
of	O
inositol	B-T103
transporters	B-T103
,	O
which	O
would	O
import	O
the	O
sugar	B-T103
from	O
the	O
lungs	B-T017
where	O
the	O
fungi	B-T204
reside	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
characterized	O
the	O
transport	B-T038
of	O
myo	B-T103
-	I-T103
inositol	I-T103
in	O
the	O
fungus	B-T204
and	O
found	O
that	O
the	O
transporter	B-T103
was	O
highly	O
selective	O
for	O
myo	B-T103
-	I-T103
inositol	I-T103
and	O
did	O
not	O
transport	B-T038
any	O
other	O
molecules	O
.	O

The	O
transport	B-T038
was	O
distinct	O
from	O
that	O
in	O
mammalian	B-T017
cells	I-T017
,	O
and	O
since	O
mammals	B-T204
can	O
both	O
make	O
and	O
transport	B-T038
myo	B-T103
-	I-T103
inositol	I-T103
,	O
while	O
Pneumocystis	B-T204
fungi	I-T204
must	O
transport	B-T038
it	O
,	O
this	O
process	O
offers	O
a	O
potential	O
new	O
drug	B-T103
target	O
.	O

Worldwide	B-T082
Occurrence	O
of	O
Mycotoxins	B-T103
in	O
Cereals	B-T168
and	O
Cereal	B-T168
-	O
Derived	O
Food	B-T168
Products	I-T168
:	O
Public	B-T092
Health	O
Perspectives	O
of	O
Their	O
Co	O
-	O
occurrence	O

Cereal	B-T168
grains	I-T168
and	O
their	O
processed	O
food	B-T168
products	I-T168
are	O
frequently	O
contaminated	O
with	O
mycotoxins	B-T103
.	O

Among	O
many	O
,	O
five	O
major	O
mycotoxins	B-T103
of	O
aflatoxins	B-T103
,	O
ochratoxins	B-T103
,	O
fumonisins	B-T103
,	O
deoxynivalenol	B-T103
,	O
and	O
zearalenone	B-T103
are	O
of	O
significant	O
public	B-T092
health	O
concern	O
as	O
they	O
can	O
cause	O
adverse	B-T038
effects	I-T038
in	O
humans	B-T204
.	O

Being	O
airborne	O
or	O
soilborne	O
,	O
the	O
cosmopolitan	O
nature	O
of	O
mycotoxigenic	B-T204
fungi	I-T204
contribute	O
to	O
the	O
worldwide	B-T082
occurrence	O
of	O
mycotoxins	B-T103
.	O

On	O
the	O
basis	O
of	O
the	O
global	O
occurrence	O
data	O
reported	B-T058
during	O
the	O
past	O
10	O
years	O
,	O
the	O
incidences	O
and	O
maximum	O
levels	O
in	O
raw	O
cereal	B-T168
grains	I-T168
were	O
55	O
%	O
and	O
1642	O
μg	O
/	O
kg	O
for	O
aflatoxins	B-T103
,	O
29	O
%	O
and	O
1164	O
μg	O
/	O
kg	O
for	O
ochratoxin	B-T103
A	I-T103
,	O
61	O
%	O
and	O
71	O
,	O
121	O
μg	O
/	O
kg	O
for	O
fumonisins	B-T103
,	O
58	O
%	O
and	O
41	O
,	O
157	O
μg	O
/	O
kg	O
,	O
for	O
deoxynivalenol	B-T103
,	O
and	O
46	O
%	O
and	O
3049	O
μg	O
/	O
kg	O
for	O
zearalenone	B-T103
.	O

The	O
concentrations	O
of	O
mycotoxins	B-T103
tend	O
to	O
be	O
lower	O
in	O
processed	O
food	B-T168
products	I-T168
;	O
the	O
incidences	O
varied	O
depending	O
on	O
the	O
individual	O
mycotoxins	B-T103
,	O
possibly	O
due	O
to	O
the	O
varying	O
stability	O
during	O
processing	O
and	O
distribution	O
of	O
mycotoxins	B-T103
.	O

It	O
should	O
be	O
noted	O
that	O
more	O
than	O
one	O
mycotoxin	B-T103
,	O
produced	O
by	O
a	O
single	O
or	O
several	O
fungal	B-T204
species	B-T170
,	O
may	O
occur	O
in	O
various	O
combinations	O
in	O
a	O
given	O
sample	O
or	O
food	B-T168
.	O

Most	O
studies	B-T062
reported	B-T058
additive	O
or	O
synergistic	O
effects	O
,	O
suggesting	O
that	O
these	O
mixtures	O
may	O
pose	O
a	O
significant	O
threat	O
to	O
public	B-T092
health	O
,	O
particularly	O
to	O
infants	O
and	O
young	O
children	O
.	O

Therefore	O
,	O
information	O
on	O
the	O
co	O
-	O
occurrence	O
of	O
mycotoxins	B-T103
and	O
their	O
interactive	O
toxicity	B-T037
is	O
summarized	B-T170
in	O
this	O
paper	O
.	O

Locating	O
the	O
Seventh	B-T017
Cervical	I-T017
Spinous	I-T017
Process	I-T017
:	O
Development	O
and	O
Validation	O
of	O
a	O
Multivariate	B-T170
Model	I-T170
Using	O
Palpation	B-T058
and	O
Personal	O
Information	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
validate	O
a	O
multivariate	B-T170
prediction	I-T170
model	I-T170
,	O
guided	O
by	O
palpation	B-T058
and	O
personal	O
information	O
,	O
for	O
locating	O
the	O
seventh	B-T017
cervical	I-T017
spinous	I-T017
process	I-T017
(	O
C7SP	B-T017
)	O
.	O

A	O
single	B-T062
-	I-T062
blinded	I-T062
,	I-T062
cross	I-T062
-	I-T062
sectional	I-T062
study	I-T062
at	O
a	O
primary	B-T092
to	I-T092
tertiary	I-T092
health	I-T092
care	I-T092
center	I-T092
was	O
conducted	O
for	O
model	O
development	O
and	O
temporal	B-T062
validation	I-T062
.	O

One	O
-	O
hundred	O
sixty	O
participants	B-T098
were	O
prospectively	O
included	O
for	O
model	O
development	O
(	O
n	O
=	O
80	O
)	O
and	O
time	O
-	O
split	O
validation	O
stages	O
(	O
n	O
=	O
80	O
)	O
.	O

The	O
C7SP	B-T017
was	O
located	O
using	O
the	O
thorax	B-T058
-	I-T058
rib	I-T058
static	I-T058
method	I-T058
(	O
TRSM	B-T058
)	O
.	O

Participants	B-T098
underwent	O
chest	B-T058
radiography	I-T058
for	O
assessment	O
of	O
the	O
inner	B-T082
body	B-T017
structure	I-T017
located	O
with	O
TRSM	B-T058
and	O
using	O
radio	B-T074
-	I-T074
opaque	I-T074
markers	I-T074
placed	O
over	O
the	O
skin	B-T022
.	O

Age	O
,	O
sex	O
,	O
height	O
,	O
body	O
mass	O
,	O
body	B-T201
mass	I-T201
index	I-T201
,	O
and	O
vertex	O
-	O
marker	O
distanc	O
e	O
(	O
DV	O
-	O
M	O
)	O
were	O
used	O
to	O
predict	O
the	O
distance	O
from	O
the	O
C7SP	B-T017
to	O
the	O
vertex	B-T082
(	O
DV	O
-	O
C7	O
)	O
.	O

Multivariate	B-T170
linear	I-T170
regression	I-T170
modeling	I-T170
,	O
limits	O
of	O
agreement	O
plot	O
,	O
histogram	O
of	O
residues	O
,	O
receiver	O
operating	O
characteristic	O
curves	O
,	O
and	O
confusion	B-T170
tables	I-T170
were	O
analyzed	O
.	O

The	O
multivariate	B-T170
linear	I-T170
prediction	I-T170
model	I-T170
for	O
DV	O
-	O
C7	O
(	O
in	O
centimeters	O
)	O
was	O
DV	O
-	O
C7	O
=	O
0	O
.	O
986DV	O
-	O
M	O
+	O
0	O
.	O
018	O
(	O
mass	O
)	O
+	O
0	O
.	O
014	O
(	O
age	O
)	O
-	O
1	O
.	O
008	O
.	O

Receiver	O
operating	O
characteristic	O
curves	O
had	O
better	O
discrimination	O
of	O
DV	O
-	O
C7	O
(	O
area	O
under	O
the	O
curve	O
=	O
0	O
.	O
661	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0	O
.	O
541	O
-	O
0	O
.	O
782	O
;	O
P	O
=	O
.	O
015	O
)	O
than	O
DV	O
-	O
M	O
(	O
area	O
under	O
the	O
curve	O
=	O
0	O
.	O
480	O
;	O
95	O
%	O
confidence	O
interval	O
=	O
0	O
.	O
345	O
-	O
0	O
.	O
614	O
;	O
P	O
=	O
.	O
761	O
)	O
,	O
with	O
respective	O
cutoff	O
points	O
at	O
23	O
.	O
40	O
cm	O
(	O
sensitivity	O
=	O
41	O
%	O
,	O
specificity	O
=	O
63	O
%	O
)	O
and	O
24	O
.	O
75	O
cm	O
(	O
sensitivity	O
=	O
69	O
%	O
,	O
specificity	O
=	O
52	O
%	O
)	O
.	O

The	O
C7SP	B-T017
was	O
correctly	O
located	O
more	O
often	O
when	O
using	O
predicted	O
DV	O
-	O
C7	O
in	O
the	O
validation	O
sample	O
than	O
when	O
using	O
the	O
TRSM	B-T058
in	O
the	O
development	O
sample	O
:	O
n	O
=	O
53	O
(	O
66	O
%	O
)	O
vs	O
n	O
=	O
32	O
(	O
40	O
%	O
)	O
,	O
P	O
<	O
.	O
001	O
.	O

Better	O
accuracy	O
was	O
obtained	O
when	O
locating	O
the	O
C7SP	B-T017
by	O
use	O
of	O
a	O
multivariate	B-T170
model	I-T170
that	O
incorporates	O
palpation	B-T058
and	O
personal	O
information	O
.	O

Comparison	O
of	O
Leishmania	B-T204
typing	B-T058
results	B-T033
obtained	O
from	O
16	O
European	B-T082
clinical	B-T092
laboratories	I-T092
in	O
2014	O

Leishmaniasis	B-T038
is	O
endemic	O
in	O
southern	B-T082
Europe	I-T082
,	O
and	O
in	O
other	O
European	B-T082
countries	B-T082
cases	O
are	O
diagnosed	B-T033
in	O
travellers	B-T097
who	O
have	O
visited	O
affected	B-T033
areas	I-T033
both	O
within	B-T082
the	O
continent	B-T082
and	O
beyond	O
.	O

Prompt	O
and	O
accurate	O
diagnosis	B-T033
poses	O
a	O
challenge	O
in	O
clinical	B-T170
practice	I-T170
in	O
Europe	B-T082
.	O

Different	O
methods	B-T170
exist	O
for	O
identification	O
of	O
the	O
infecting	B-T033
Leishmania	B-T204
species	B-T170
.	O

Sixteen	O
clinical	B-T092
laboratories	I-T092
in	O
10	O
European	B-T082
countries	B-T082
,	O
plus	O
Israel	B-T082
and	O
Turkey	B-T082
,	O
conducted	O
a	O
study	B-T062
to	O
assess	O
their	O
genotyping	B-T058
performance	O
.	O

DNA	B-T103
from	O
21	O
promastigote	B-T204
cultures	I-T204
of	O
13	O
species	B-T170
was	O
analysed	B-T062
blindly	O
by	O
the	O
routinely	O
used	O
typing	B-T058
method	B-T170
.	O

Five	O
different	O
molecular	B-T103
targets	I-T103
were	O
used	O
,	O
which	O
were	O
analysed	B-T062
with	O
PCR	B-T062
-	I-T062
based	I-T062
methods	B-T170
.	O

Different	O
levels	O
of	O
identification	O
were	O
achieved	B-T033
,	O
and	O
either	O
the	O
Leishmania	B-T204
subgenus	O
,	O
species	B-T170
complex	O
,	O
or	O
actual	O
species	B-T170
were	O
reported	B-T170
.	O

The	O
overall	O
error	O
rate	O
of	O
strains	O
placed	O
in	O
the	O
wrong	O
complex	O
or	O
species	B-T170
was	O
8	O
.	O
5	O
%	O
.	O

Various	O
reasons	O
for	O
incorrect	O
typing	B-T058
were	O
identified	O
.	O

The	O
study	B-T062
shows	O
there	O
is	O
considerable	O
room	O
for	O
improvement	O
and	O
standardisation	B-T062
of	O
Leishmania	B-T204
typing	B-T058
.	O

The	O
use	O
of	O
well	O
validated	B-T062
standard	O
operating	O
procedures	O
is	O
recommended	O
,	O
covering	O
testing	O
,	O
interpretation	B-T170
,	O
and	O
reporting	B-T058
guidelines	B-T170
.	O

Application	O
of	O
the	O
internal	B-T082
transcribed	O
spacer	B-T103
1	I-T103
of	O
the	O
rDNA	B-T103
array	O
should	O
be	O
restricted	O
to	O
Old	O
World	O
samples	O
,	O
while	O
the	O
heat	B-T017
-	I-T017
shock	I-T017
protein	I-T017
70	I-T017
gene	I-T017
and	O
the	O
mini	B-T103
-	I-T103
exon	I-T103
can	O
be	O
applied	O
globally	O
.	O

Scoparone	B-T103
Inhibits	O
LPS	B-T103
-	O
Simulated	O
Inflammatory	B-T038
Response	I-T038
by	O
Suppressing	O
IRF3	B-T103
and	O
ERK	B-T103
in	O
BV	B-T017
-	I-T017
2	I-T017
Microglial	I-T017
Cells	I-T017

Microglia	B-T017
activation	B-T038
and	O
the	O
release	O
of	O
various	O
inflammatory	O
cytokines	B-T103
are	O
largely	O
related	O
to	O
neurological	O
diseases	O
,	O
including	O
Parkinson	B-T038
'	I-T038
s	I-T038
,	O
Alzheimer	B-T038
'	I-T038
s	I-T038
,	O
and	O
other	O
brain	B-T038
diseases	I-T038
.	O

The	O
suppression	O
of	O
microglial	B-T017
cells	I-T017
using	O
natural	O
bioactive	B-T103
compounds	I-T103
has	O
become	O
increasingly	O
important	O
for	O
brain	O
therapy	O
owing	O
to	O
the	O
expected	O
beneficial	O
effect	O
of	O
lower	O
toxicity	O
.	O

Scoparone	B-T103
(	O
6	B-T103
,	I-T103
7	I-T103
-	I-T103
dimethoxycoumarin	I-T103
)	O
,	O
a	O
major	O
bioactive	B-T103
compound	I-T103
found	B-T033
in	O
various	O
plant	B-T170
parts	I-T170
,	O
including	O
the	O
inner	O
shell	O
of	O
chestnut	B-T168
(	O
Castanea	B-T204
crenata	I-T204
)	O
,	O
was	O
evaluated	O
on	O
lipopolysaccharide	B-T103
(	O
LPS	B-T103
)	O
-	O
activated	O
BV	B-T017
-	I-T017
2	I-T017
microglia	I-T017
cells	I-T017
.	O

The	O
results	O
indicated	B-T033
that	O
scoparone	B-T103
suppresses	O
the	O
LPS	B-T103
-	O
stimulated	O
increase	O
of	O
neuroinflammatory	B-T038
responses	I-T038
and	O
inhibited	O
the	O
pro	O
-	O
inflammatory	O
cytokine	B-T103
production	O
in	O
the	O
BV	B-T017
-	I-T017
2	I-T017
microglial	I-T017
cells	I-T017
.	O

A	O
mechanistic	O
study	O
showed	O
that	O
scoparone	B-T103
specifically	O
inhibited	O
the	O
LPS	B-T103
-	O
stimulated	O
activation	B-T038
via	O
a	O
major	O
regulation	B-T038
of	O
IRF	B-T103
-	I-T103
3	I-T103
and	O
a	O
regulation	B-T038
of	O
ERK	B-T103
,	O
whereby	O
the	O
phosphorylation	B-T038
in	O
the	O
BV	B-T017
-	I-T017
2	I-T017
microglial	I-T017
cells	I-T017
is	O
blocked	O
.	O

These	O
data	O
suggest	O
that	O
scoparone	B-T103
has	O
anti	O
-	O
neuroinflammatory	O
effects	O
in	O
LPS	B-T103
-	O
activated	O
BV	B-T017
-	I-T017
2	I-T017
microglial	I-T017
cells	I-T017
,	O
and	O
could	O
possibly	O
be	O
used	O
in	O
the	O
development	O
of	O
novel	O
drugs	B-T103
for	O
the	O
prevention	O
and	O
treatment	O
of	O
neuroinflammatory	O
diseases	O
.	O

Efficient	O
genome	B-T062
editing	I-T062
of	O
differentiated	O
renal	B-T017
epithelial	B-T017
cells	I-T017

Recent	O
advances	O
in	O
genome	B-T062
editing	I-T062
technologies	I-T062
have	O
enabled	O
the	O
rapid	O
and	O
precise	O
manipulation	O
of	O
genomes	O
,	O
including	O
the	O
targeted	B-T062
introduction	I-T062
,	O
alteration	B-T062
,	O
and	O
removal	B-T062
of	I-T062
genomic	I-T062
sequences	I-T062
.	O

However	O
,	O
respective	O
methods	B-T170
have	O
been	O
described	O
mainly	O
in	O
non	B-T170
-	I-T170
differentiated	I-T170
or	O
haploid	B-T017
cell	B-T170
types	I-T170
.	O

Genome	B-T062
editing	I-T062
of	O
well	O
-	O
differentiated	O
renal	B-T017
epithelial	B-T017
cells	I-T017
has	O
been	O
hampered	O
by	O
a	O
range	O
of	O
technological	B-T033
issues	I-T033
,	O
including	O
optimal	O
design	O
,	O
efficient	O
expression	B-T062
of	I-T062
multiple	I-T062
genome	I-T062
editing	I-T062
constructs	I-T062
,	O
attainable	O
mutation	O
rates	O
,	O
and	O
best	O
screening	B-T170
strategies	I-T170
.	O

Here	O
,	O
we	O
present	O
an	O
easily	O
implementable	O
workflow	O
for	O
the	O
rapid	O
generation	B-T062
of	I-T062
targeted	I-T062
heterozygous	I-T062
and	I-T062
homozygous	I-T062
genomic	I-T062
sequence	I-T062
alterations	I-T062
in	O
renal	B-T017
cells	B-T017
using	O
transcription	B-T103
activator	I-T103
-	I-T103
like	I-T103
effector	I-T103
nucleases	I-T103
(	O
TALENs	B-T103
)	O
and	O
the	O
clustered	B-T103
regularly	I-T103
interspaced	I-T103
short	I-T103
palindromic	I-T103
repeat	I-T103
(	I-T103
CRISPR	I-T103
)	I-T103
system	I-T103
.	O

We	O
demonstrate	O
the	O
versatility	O
of	O
established	O
protocols	B-T170
by	O
generating	O
novel	O
cellular	O
models	O
for	O
studying	B-T062
autosomal	B-T017
dominant	I-T017
polycystic	I-T017
kidney	I-T017
disease	I-T017
(	O
ADPKD	B-T017
)	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
cell	B-T062
culture	I-T062
-	I-T062
validated	I-T062
genetic	I-T062
modifications	I-T062
can	O
be	O
readily	O
applied	O
to	O
mouse	B-T017
embryonic	I-T017
stem	I-T017
cells	I-T017
(	O
mESCs	B-T017
)	O
for	O
the	O
generation	O
of	O
corresponding	O
mouse	B-T204
models	B-T204
.	O

The	O
described	O
procedure	O
for	O
efficient	O
genome	B-T062
editing	I-T062
can	O
be	O
applied	O
to	O
any	O
cell	B-T170
type	I-T170
to	O
study	B-T062
physiological	B-T038
and	O
pathophysiological	B-T038
functions	I-T038
in	O
the	O
context	O
of	O
precisely	O
engineered	B-T017
genotypes	I-T017
.	O

Right	B-T017
Ventricular	I-T017
Response	O
During	O
Exercise	O
in	O
Patients	O
with	O
Chronic	B-T038
Obstructive	I-T038
Pulmonary	I-T038
Disease	I-T038

Right	B-T017
ventricular	I-T017
(	O
RV	B-T017
)	O
pump	B-T038
function	I-T038
is	O
of	O
essential	O
clinical	O
and	O
prognostic	B-T170
importance	O
in	O
a	O
variety	O
of	O
heart	B-T038
and	O
lung	B-T038
diseases	I-T038
.	O

While	O
the	O
evaluation	B-T058
of	O
RV	B-T017
performance	O
at	O
rest	O
has	O
been	O
implemented	O
in	O
the	O
clinical	O
setting	O
,	O
it	O
is	O
unknown	O
whether	O
this	O
assessment	B-T058
during	O
exercise	O
may	O
provide	O
additional	O
benefit	O
.	O

With	O
this	O
aim	O
,	O
we	O
evaluated	B-T058
the	O
exercise	O
-	O
induced	O
pulmonary	B-T058
arterial	I-T058
systolic	I-T058
pressure	I-T058
(	O
PASP	B-T058
)	O
increase	O
during	O
exercise	O
in	O
patients	O
with	O
severe	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
(	O
COPD	B-T038
)	O
as	O
an	O
expression	O
of	O
RV	B-T017
contractile	O
reserve	O
.	O

Cardiopulmonary	B-T058
exercise	I-T058
testing	I-T058
(	O
CPET	B-T058
)	O
with	O
synchronic	B-T058
echocardiography	I-T058
was	O
performed	O
in	O
81	O
patients	O
.	O

Patients	O
were	O
classified	B-T170
into	O
two	O
groups	O
according	O
to	O
an	O
exercise	O
-	O
induced	O
PASP	B-T058
increase	O
above	O
30mmHg	O
(	O
High	O
PSAP	B-T058
)	O
or	O
below	O
30mmHg	O
(	O
Low	O
PSAP	B-T058
)	O
during	O
maximal	O
exercise	O
.	O

Patients	O
were	O
then	O
followed	O
for	O
three	O
years	O
.	O

Sixteen	O
patients	O
(	O
20	O
%	O
)	O
had	O
low	O
PSAP	B-T058
and	O
65	O
(	O
80	O
%	O
)	O
showed	O
high	O
PSAP	B-T058
.	O

These	O
were	O
not	B-T033
significant	I-T033
clinical	O
and	O
functional	O
differences	O
.	O

Low	O
PSAP	B-T058
was	O
associated	O
with	O
a	O
significantly	O
lower	O
peak	O
VO2	B-T033
(	O
mean	O
(	O
SD	O
)	O
,	O
35	O
(	O
2	O
)	O
%	O
predicted	O
)	O
compared	O
to	O
high	O
PSAP	B-T058
response	O
(	O
peak	O
VO2	B-T033
45	O
(	O
3	O
)	O
%	O
predicted	O
)	O
,	O
p	O
=	O
0	O
.	O
045	O
.	O

Factors	O
associated	O
with	O
mortality	O
were	O
age	O
and	O
exercise	O
-	O
induced	O
PASP	B-T058
.	O

Seventeen	O
patients	O
died	O
during	O
the	O
three	O
years	O
of	O
follow	B-T058
-	I-T058
up	I-T058
(	O
7	O
(	O
39	O
%	O
)	O
in	O
the	O
low	O
PSAP	B-T058
group	O
and	O
only	O
10	O
(	O
1	O
%	O
)	O
in	O
the	O
high	O
PSAP	B-T058
group	O
,	O
p	O
=	O
0	O
.	O
041	O
)	O
.	O

Cardiopulmonary	B-T058
exercise	I-T058
testing	I-T058
with	O
a	O
synchronic	B-T058
echocardiography	I-T058
may	O
be	O
a	O
useful	O
tool	O
for	O
the	O
assessment	B-T058
of	O
RV	B-T017
contractile	O
reserve	O
in	O
severe	O
COPD	B-T038
patients	O
.	O

Exercise	O
-	O
induced	O
PSAP	B-T058
emerges	O
as	O
a	O
possible	O
prognostic	B-T201
factor	I-T201
in	O
these	O
patients	O
.	O

Adverse	O
outcomes	O
in	O
older	B-T098
adults	I-T098
attending	O
emergency	B-T092
departments	I-T092
:	O
a	O
systematic	B-T170
review	I-T170
and	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
the	O
Identification	B-T170
of	I-T170
Seniors	I-T170
At	I-T170
Risk	I-T170
(	I-T170
ISAR	I-T170
)	I-T170
screening	I-T170
tool	I-T170

older	B-T098
adults	I-T098
are	O
frequent	O
users	O
of	O
emergency	B-T058
services	I-T058
and	O
demonstrate	O
high	O
rates	O
of	O
adverse	O
outcomes	O
following	O
emergency	B-T058
care	I-T058
.	O

to	O
perform	O
a	O
systematic	B-T170
review	I-T170
and	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
the	O
Identification	B-T170
of	I-T170
Seniors	I-T170
At	I-T170
Risk	I-T170
(	I-T170
ISAR	I-T170
)	I-T170
screening	I-T170
tool	I-T170
,	O
to	O
determine	O
its	O
predictive	O
value	O
in	O
identifying	O
adults	O
≥65	O
years	O
at	O
risk	O
of	O
functional	B-T033
decline	I-T033
,	O
unplanned	O
emergency	B-T058
department	I-T058
(	I-T058
ED	I-T058
)	I-T058
readmission	I-T058
,	O
emergency	O
hospitalisation	B-T058
or	O
death	B-T033
within	O
180	O
days	O
after	O
index	O
ED	B-T058
visit	I-T058
/	O
hospitalisation	B-T058
.	O

a	O
systematic	O
literature	B-T170
search	O
was	O
conducted	O
in	O
PubMed	B-T170
,	O
EMBASE	B-T170
,	O
CINAHL	B-T170
,	O
EBSCO	B-T170
and	O
the	O
Cochrane	B-T170
Library	I-T170
to	O
identify	O
validation	B-T062
and	O
impact	O
analysis	B-T062
studies	O
of	O
the	O
ISAR	B-T170
tool	I-T170
.	O

A	O
pre	O
-	O
specified	O
ISAR	B-T170
score	O
of	O
≥2	O
(	O
maximum	O
score	O
6	O
points	O
)	O
was	O
used	O
to	O
identify	O
patients	O
at	O
high	B-T033
risk	I-T033
of	I-T033
adverse	O
outcomes	O
.	O

A	O
bivariate	B-T170
random	I-T170
effects	I-T170
model	I-T170
generated	O
pooled	O
estimates	O
of	O
sensitivity	O
and	O
specificity	O
.	O

Statistical	O
heterogeneity	O
was	O
explored	O
and	O
methodological	O
quality	O
was	O
assessed	O
using	O
validated	O
criteria	O
.	O

thirty	O
-	O
two	O
validation	B-T062
studies	I-T062
(	O
n	O
=	O
12	O
,	O
939	O
)	O
are	O
included	O
.	O

At	O
≥2	O
,	O
the	O
pooled	O
sensitivity	O
of	O
the	O
ISAR	B-T170
for	O
predicting	O
ED	B-T092
return	O
,	O
emergency	O
hospitalisation	B-T058
and	O
mortality	O
at	O
6	O
months	O
is	O
0	O
.	O
80	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
70	O
-	O
0	O
.	O
87	O
)	O
,	O
0	O
.	O
82	O
(	O
95	O
%	O
CI	O
0	O
.	O
74	O
-	O
0	O
.	O
88	O
)	O
and	O
0	O
.	O
87	O
(	O
95	O
%	O
CI	O
0	O
.	O
75	O
-	O
0	O
.	O
94	O
)	O
,	O
respectively	O
,	O
with	O
a	O
pooled	O
specificity	O
of	O
0	O
.	O
31	O
(	O
95	O
%	O
CI	O
0	O
.	O
24	O
-	O
0	O
.	O
38	O
)	O
,	O
0	O
.	O
32	O
(	O
95	O
%	O
CI	O
0	O
.	O
24	O
-	O
0	O
.	O
41	O
)	O
and	O
0	O
.	O
35	O
(	O
95	O
%	O
CI	O
0	O
.	O
26	O
-	O
0	O
.	O
44	O
)	O
.	O

Similar	O
values	O
are	O
demonstrated	O
at	O
30	O
and	O
90	O
days	O
.	O

Three	O
heterogeneous	O
impact	O
analysis	B-T062
studies	O
examined	B-T033
the	O
clinical	O
implementation	O
of	O
the	O
ISAR	B-T170
and	O
reported	O
mixed	O
findings	O
across	O
patient	O
and	O
process	O
outcomes	O
.	O

the	O
ISAR	B-T170
has	O
modest	O
predictive	O
accuracy	O
and	O
may	O
serve	O
as	O
a	O
decision	B-T038
-	I-T038
making	I-T038
adjunct	O
when	O
determining	O
which	O
older	B-T098
adults	I-T098
can	O
be	O
safely	O
discharged	B-T058
.	O

Ecohydrological	B-T062
modeling	I-T062
and	O
environmental	B-T082
flow	O
regime	O
in	O
the	O
Formoso	O
River	O
,	O
Minas	B-T082
Gerais	I-T082
State	I-T082
,	O
Brazil	B-T082

This	O
paper	B-T170
aimed	O
at	O
determining	O
the	O
environmental	B-T082
flow	O
regime	O
in	O
a	O
1	O
km	O
stretch	O
of	O
the	O
Formoso	O
River	O
,	O
MG	B-T082
,	O
using	O
River2D	B-T062
model	I-T062
.	O

To	O
carry	O
out	O
the	O
ecohydrological	B-T062
modeling	I-T062
,	O
the	O
following	O
information	O
was	O
used	O
:	O
bathymetry	O
,	O
physical	O
and	O
hydraulic	O
features	O
,	O
and	O
the	O
Habitat	B-T082
Suitability	O
Index	O
for	O
species	B-T170
of	O
the	O
Hypostomus	B-T204
auroguttatus	I-T204
.	O

In	O
the	O
River2D	B-T062
,	O
the	O
Weighted	O
Usable	O
Areas	B-T082
were	O
determined	O
from	O
the	O
average	O
long	O
-	O
term	O
streamflows	O
with	O
percentage	O
from	O
10	O
%	O
to	O
100	O
%	O
.	O

Those	O
streamflows	O
were	O
simulated	O
for	O
the	O
later	O
construction	O
of	O
optimization	O
matrices	B-T082
that	O
maximize	O
the	O
habitat	B-T082
area	B-T082
throughout	O
the	O
year	O
.	O

For	O
H	B-T204
.	I-T204

auroguttatus	I-T204
Juvenile	O
,	O
higher	O
values	O
of	O
Weighted	O
Usable	O
Area	B-T082
were	O
associated	O
with	O
the	O
percentage	O
of	O
60	O
%	O
and	O
70	O
%	O
of	O
the	O
average	O
long	O
-	O
term	O
streamflows	O
in	O
October	O
and	O
September	O
,	O
respectively	O
.	O

For	O
H	B-T204
.	I-T204

auroguttatus	I-T204
Adult	O
,	O
the	O
highest	O
value	O
of	O
Weighted	O
Usable	O
Area	B-T082
was	O
associated	O
with	O
the	O
percentage	O
of	O
100	O
%	O
of	O
the	O
average	O
long	O
-	O
term	O
streamflow	O
in	O
September	O
.	O

The	O
environmental	B-T082
flows	O
found	B-T033
for	O
this	O
stretch	O
of	O
the	O
Formoso	O
River	O
varied	O
over	O
the	O
year	O
.	O

The	O
lowest	O
environmental	B-T082
flow	O
was	O
observed	O
in	O
December	O
(	O
2	O
.	O
85	O
m3	O
s	O
-	O
1	O
)	O
,	O
while	O
the	O
highest	O
was	O
observed	O
in	O
May	O
(	O
4	O
.	O
13	O
m3	O
s	O
-	O
1	O
)	O
.	O

This	O
paper	B-T170
shows	O
the	O
importance	O
of	O
ecohydrological	B-T062
studies	I-T062
in	O
forming	O
a	O
basis	O
for	O
water	O
resources	O
management	O
actions	O
.	O

Risk	B-T033
factors	I-T033
for	O
hepatitis	B-T038
C	I-T038
virus	I-T038
infection	I-T038
in	O
the	O
Colombian	O
Caribbean	B-T082
coast	I-T082
:	O
A	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062

An	O
estimated	O
6	O
.	O
8	O
-	O
8	O
.	O
9	O
million	O
people	B-T098
are	O
infected	B-T033
with	O
hepatitis	B-T005
C	I-T005
virus	I-T005
in	O
Latin	B-T082
America	I-T082
,	O
of	O
which	O
less	O
than	O
1	O
%	O
receives	O
antiviral	B-T058
treatment	I-T058
.	O

Studies	B-T062
so	O
far	O
in	O
Colombia	B-T082
have	O
attempted	O
to	O
determine	O
the	O
prevalence	O
of	O
the	O
disease	B-T038
in	O
some	O
risk	O
groups	B-T098
,	O
thus	O
preventing	O
the	O
identification	O
of	O
other	O
factors	O
potentially	O
involved	O
in	O
the	O
spread	O
of	O
the	O
infection	B-T038
.	O

To	O
identify	O
traditional	O
and	O
non	O
-	O
traditional	O
risk	B-T033
factors	I-T033
for	O
chronic	B-T038
hepatitis	I-T038
C	I-T038
in	O
the	O
Colombian	O
Caribbean	B-T082
coast	I-T082
.	O

This	O
was	O
a	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
(	O
1	O
:	O
3	O
)	O
matched	O
by	O
health	B-T097
care	I-T097
provider	I-T097
and	O
age	O
(	O
±	O
10	O
years	O
)	O
conducted	O
at	O
the	O
primary	B-T058
care	I-T058
level	I-T058
of	O
gastroenterology	B-T091
and	O
hepatology	B-T091
outpatient	B-T058
services	I-T058
.	O

All	O
patients	O
with	O
a	O
positive	B-T033
ELISA	B-T058
underwent	O
a	O
confirmatory	O
viral	O
load	O
test	O
.	O

A	O
multivariate	O
logistic	O
regression	O
analysis	O
identified	O
the	O
independent	O
predictors	O
of	O
infection	B-T038
.	O

Blood	B-T058
transfusion	I-T058
(	O
OR	O
=	O
159	O
.	O
2	O
;	O
95	O
%	O
CI	O
:	O
35	O
.	O
4	O
-	O
715	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
history	B-T201
of	I-T201
hospitalization	I-T201
before	O
1994	O
(	O
OR	O
=	O
4	O
.	O
7	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
3	O
-	O
17	O
.	O
1	O
;	O
p	O
=	O
0	O
.	O
018	O
)	O
were	O
identified	O
as	O
the	O
only	O
two	O
independent	O
predictors	O
of	O
infection	B-T038
.	O

It	O
is	O
necessary	O
to	O
check	O
the	O
reproducibility	O
of	O
these	O
results	O
and	O
to	O
conduct	O
cost	O
-	O
effectiveness	O
studies	B-T062
before	O
recommending	O
their	O
use	O
in	O
the	O
design	O
of	O
new	B-T062
screening	I-T062
strategies	I-T062
.	O

Quo	O
vadis	O
G	B-T038
protein	I-T038
-	I-T038
coupled	I-T038
receptor	I-T038
ligands	I-T038
?	O
A	O
tool	O
for	O
analysis	B-T062
of	O
the	O
emergence	O
of	O
new	O
groups	O
of	O
compounds	B-T103
over	O
time	O

Exponential	O
growth	O
in	O
the	O
number	O
of	O
compounds	B-T103
with	O
experimentally	O
verified	O
activity	O
towards	O
particular	O
target	O
has	O
led	O
to	O
the	O
emergence	O
of	O
various	O
databases	B-T170
gathering	O
data	O
on	O
biological	O
activity	O
.	O

In	O
this	O
study	B-T062
,	O
the	O
ligands	B-T103
of	O
family	B-T103
A	I-T103
of	I-T103
the	I-T103
G	I-T103
Protein	I-T103
-	I-T103
Coupled	I-T103
Receptors	I-T103
that	O
are	O
collected	O
in	O
the	O
ChEMBL	B-T170
database	I-T170
were	O
examined	B-T033
,	O
and	O
special	O
attention	O
was	O
given	O
to	O
serotonin	B-T103
receptors	I-T103
.	O

Sets	O
of	O
compounds	B-T103
were	O
examined	B-T033
in	O
terms	O
of	O
their	O
appearance	O
over	O
time	O
,	O
they	O
were	O
mapped	O
to	O
the	O
chemical	O
space	O
of	O
drugs	B-T103
deposited	O
in	O
DrugBank	O
,	O
and	O
the	O
emergence	O
of	O
structurally	O
new	O
clusters	O
of	O
compounds	O
was	O
indicated	B-T033
.	O

In	O
addition	O
,	O
a	O
tool	O
for	O
detailed	O
analysis	B-T062
of	O
the	O
obtained	O
visualizations	B-T170
was	O
prepared	B-T033
and	O
made	O
available	O
online	O
at	O
http	B-T170
:	I-T170
/	I-T170
/	I-T170
chem	I-T170
.	I-T170
gmum	I-T170
.	I-T170
net	I-T170
/	I-T170
vischem	I-T170
,	O
which	O
enables	O
the	O
investigation	O
of	O
chemical	B-T170
structures	I-T170
while	O
referring	O
to	O
particular	O
data	O
points	O
depicted	O
in	O
the	O
figures	O
and	O
changes	O
in	O
compounds	B-T103
datasets	B-T170
over	O
time	O
.	O

Diabetes	B-T038
and	O
breast	B-T038
cancer	I-T038
mortality	O
in	O
Black	B-T098
women	I-T098

Breast	B-T038
cancer	I-T038
mortality	O
is	O
higher	O
in	O
Black	B-T098
women	I-T098
than	O
in	O
White	B-T098
women	I-T098
.	O

The	O
prevalence	O
of	O
type	B-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
is	O
also	O
higher	O
,	O
yet	O
data	O
on	O
whether	O
diabetes	B-T038
affects	O
breast	B-T038
cancer	I-T038
mortality	O
in	O
this	O
population	B-T098
are	O
lacking	O
.	O

We	O
investigated	O
the	O
relation	O
of	O
diabetes	B-T038
at	O
the	O
time	O
of	O
breast	B-T038
cancer	I-T038
diagnosis	B-T033
to	O
breast	B-T038
cancer	I-T038
mortality	O
in	O
the	O
Black	B-T098
Women	I-T098
'	I-T098
s	I-T098
Health	B-T058
Study	B-T062
,	O
a	O
prospective	B-T062
cohort	I-T062
study	I-T062
.	O

1	O
,	O
621	O
Black	B-T098
women	I-T098
with	O
invasive	O
breast	B-T038
cancer	I-T038
diagnosed	B-T033
in	O
1995	O
-	O
2013	O
were	O
followed	O
by	O
mailed	O
questionnaires	B-T170
and	O
searches	O
of	O
the	O
National	B-T170
Death	I-T170
Index	I-T170
.	O

Multivariable	B-T170
Cox	I-T170
regression	I-T170
analysis	I-T170
was	O
used	O
to	O
compute	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
diabetes	B-T038
in	O
relation	O
to	O
breast	B-T038
cancer	I-T038
mortality	O
and	O
all	O
-	O
cause	O
mortality	O
,	O
with	O
adjustment	O
for	O
age	O
,	O
stage	B-T201
,	O
treatment	B-T058
modality	I-T058
,	O
estrogen	B-T103
receptor	I-T103
(	O
ER	B-T103
)	O
status	O
,	O
and	O
body	B-T201
mass	I-T201
index	I-T201
.	O

There	O
were	O
368	O
deaths	B-T033
during	O
follow	B-T058
-	I-T058
up	I-T058
,	O
of	O
which	O
273	O
were	O
due	O
to	O
breast	B-T038
cancer	I-T038
.	O

Breast	B-T038
cancer	I-T038
mortality	O
was	O
significantly	O
increased	O
in	O
women	B-T098
who	O
had	O
been	O
diagnosed	B-T033
with	O
diabetes	B-T038
at	O
least	O
5	O
years	O
before	O
breast	B-T038
cancer	I-T038
occurrence	O
,	O
HR	O
1	O
.	O
86	O
(	O
95	O
%	O
CI	O
1	O
.	O
20	O
-	O
2	O
.	O
89	O
)	O
,	O
with	O
elevations	B-T082
observed	O
for	O
both	O
ER	B-T033
+	I-T033
and	O
ER	B-T033
-	I-T033
breast	B-T038
cancer	I-T038
.	O

All	O
-	O
cause	O
mortality	O
was	O
also	O
higher	O
in	O
diabetics	B-T033
,	O
with	O
HRs	O
of	O
1	O
.	O
54	O
(	O
95	O
%	O
CI	O
1	O
.	O
12	O
-	O
2	O
.	O
07	O
)	O
overall	O
and	O
2	O
.	O
26	O
(	O
95	O
%	O
CI	O
1	O
.	O
62	O
-	O
3	O
.	O
15	O
)	O
for	O
≥5	O
-	O
year	O
duration	O
of	O
diabetes	B-T038
relative	O
to	O
non	B-T033
-	I-T033
diabetics	I-T033
.	O

Our	O
results	B-T033
present	B-T033
the	O
first	O
solid	O
evidence	O
of	O
a	O
positive	B-T033
association	O
of	O
type	B-T038
2	I-T038
diabetes	I-T038
with	O
breast	B-T038
cancer	I-T038
mortality	O
in	O
Black	B-T098
women	I-T098
.	O

Given	O
the	O
higher	O
prevalence	O
and	O
earlier	B-T033
onset	I-T033
of	O
type	B-T038
2	I-T038
diabetes	I-T038
in	O
Black	B-T098
women	I-T098
,	O
it	O
is	O
likely	O
that	O
diabetes	B-T038
contributes	O
to	O
racial	B-T098
disparities	B-T033
in	O
breast	B-T038
cancer	I-T038
mortality	O
.	O

Neuro	B-T038
-	I-T038
Behcet	I-T038
disease	I-T038
presenting	O
as	O
a	O
solitary	O
cerebellar	B-T038
hemorrhagic	I-T038
lesion	B-T033
:	O
a	O
case	B-T170
report	I-T170
and	O
review	B-T170
of	I-T170
the	I-T170
literature	I-T170

Behcet	B-T038
'	I-T038
s	I-T038
disease	I-T038
is	O
a	O
heterogeneous	B-T033
,	O
multisystem	B-T038
,	O
inflammatory	B-T038
disorder	I-T038
of	O
unknown	O
etiology	O
.	O

The	O
classic	O
triad	O
of	O
oral	B-T038
and	O
genital	B-T038
ulcerations	I-T038
in	O
conjunction	O
with	O
uveitis	B-T038
was	O
originally	O
described	O
by	O
the	O
Turkish	B-T098
dermatologist	B-T097
Hulusi	O
Behcet	O
in	O
1937	O
,	O
but	O
associated	B-T033
symptoms	I-T033
of	O
the	O
cardiovascular	B-T022
,	O
central	B-T022
nervous	I-T022
,	O
pulmonary	O
,	O
and	O
gastrointestinal	B-T022
systems	I-T022
were	O
later	O
identified	O
.	O

In	O
fact	O
,	O
Behcet	B-T038
'	I-T038
s	I-T038
disease	I-T038
with	O
neurological	B-T038
involvement	I-T038
(	O
neuro	B-T038
-	I-T038
Behcet	I-T038
'	I-T038
s	I-T038
disease	I-T038
)	O
is	O
not	O
uncommon	O
.	O

Patients	O
with	O
neuro	B-T038
-	I-T038
Behcet	I-T038
'	I-T038
s	I-T038
disease	I-T038
typically	O
exhibit	O
a	O
diverse	O
array	O
of	O
symptoms	B-T033
,	O
most	O
commonly	O
in	O
the	O
brainstem	B-T017
and	O
diencephalic	B-T017
regions	B-T082
.	O

Herein	O
,	O
we	O
report	B-T170
an	O
unusual	O
case	O
of	O
neuro	B-T038
-	I-T038
Behcet	I-T038
'	I-T038
s	I-T038
disease	I-T038
in	O
a	O
patient	O
who	O
presented	O
with	O
a	O
solitary	O
cerebellar	B-T038
hemorrhage	I-T038
.	O

A	O
39	O
-	O
year	O
-	O
old	O
Asian	B-T098
woman	B-T098
was	O
admitted	B-T058
to	O
our	O
hospital	B-T092
with	O
complaints	B-T033
of	O
a	O
sudden	O
speech	B-T033
difficulty	I-T033
that	O
had	O
manifested	O
the	O
same	O
morning	O
,	O
and	O
dizziness	B-T033
and	O
mild	O
vomiting	B-T033
experienced	O
over	O
the	O
previous	O
3	O
days	O
.	O

Magnetic	B-T170
resonance	I-T170
images	I-T170
revealed	O
target	O
-	O
like	O
hemorrhagic	B-T038
lesions	B-T033
in	O
the	O
right	B-T017
hemisphere	I-T017
of	I-T017
the	I-T017
cerebellum	I-T017
.	O

Risk	B-T033
factors	I-T033
that	O
may	O
result	O
in	O
cerebellar	B-T038
hemorrhage	I-T038
,	O
such	O
as	O
high	B-T038
blood	I-T038
pressure	I-T038
or	O
bleeding	B-T038
diathesis	I-T038
,	O
were	O
ruled	O
out	O
,	O
and	O
subsequent	O
brain	B-T017
angiograms	B-T058
were	O
normal	O
.	O

These	O
findings	B-T033
suggest	O
that	O
the	O
patient	O
'	O
s	O
cerebellar	B-T038
hemorrhage	I-T038
could	O
have	O
been	O
due	O
to	O
intracranial	B-T082
vasculitis	B-T038
in	O
a	O
rare	O
,	O
if	O
not	O
unique	O
,	O
complication	B-T038
of	O
neuro	B-T038
-	I-T038
Behcet	I-T038
'	I-T038
s	I-T038
disease	I-T038
.	O

Intrinsic	B-T082
rifamycin	B-T103
resistance	O
of	O
Mycobacterium	B-T007
abscessus	I-T007
is	O
mediated	O
by	O
ADP	B-T103
-	I-T103
ribosyltransferase	I-T103
MAB	B-T017
_	I-T017
0591	I-T017

Rifampicin	B-T103
,	O
a	O
potent	O
first	O
-	O
line	O
TB	B-T103
drug	I-T103
of	O
the	O
rifamycin	B-T103
group	I-T103
,	O
shows	O
only	O
little	O
activity	O
against	O
the	O
emerging	O
pathogen	O
Mycobacterium	B-T007
abscessus	I-T007
.	O

Reportedly	O
,	O
bacterial	B-T038
resistance	I-T038
to	O
rifampicin	B-T103
is	O
associated	O
with	O
polymorphisms	B-T038
in	O
the	O
target	O
gene	B-T017
rpoB	I-T017
or	O
the	O
presence	O
of	O
enzymes	B-T103
that	O
modify	O
and	O
thereby	O
inactivate	O
rifampicin	B-T103
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
MAB	B-T017
_	I-T017
0591	I-T017
(	O
arrMab	B-T017
)	O
-	O
encoded	O
rifampicin	B-T103
ADP	B-T103
-	I-T103
ribosyltransferase	I-T103
(	O
Arr	B-T103
_	I-T103
Mab	I-T103
)	O
in	O
innate	O
high	O
-	O
level	O
rifampicin	B-T103
resistance	O
in	O
M	B-T007
.	I-T007

abscessus	I-T007
.	O

Recombinant	O
Escherichia	B-T007
coli	I-T007
and	O
Mycobacterium	B-T007
tuberculosis	I-T007
strains	O
expressing	B-T038
MAB	B-T017
_	I-T017
0591	I-T017
were	O
generated	O
,	O
as	O
was	O
an	O
M	B-T007
.	I-T007

abscessus	I-T007
deletion	B-T038
mutant	I-T038
deficient	O
for	O
MAB	B-T017
_	I-T017
0591	I-T017
.	O

MIC	B-T058
assays	I-T058
were	O
used	O
to	O
study	O
susceptibility	O
to	O
rifampicin	B-T103
and	O
C25	B-T103
carbamate	I-T103
-	O
modified	O
rifamycin	B-T103
derivatives	I-T103
.	O

Heterologous	O
expression	B-T038
of	O
MAB	B-T017
_	I-T017
0591	I-T017
conferred	O
rifampicin	B-T103
resistance	O
to	O
E	B-T007
.	I-T007

coli	I-T007
and	O
M	B-T007
.	I-T007

tuberculosis	I-T007
Rifamycin	B-T103
MIC	B-T033
values	I-T033
were	O
consistently	O
lower	O
for	O
the	O
M	B-T007
.	I-T007

abscessus	I-T007
ΔarrMab	B-T017
mutant	I-T017
as	O
compared	O
with	O
the	O
M	B-T007
.	I-T007

abscessus	I-T007
ATCC	I-T007
19977	I-T007
parental	O
type	O
strain	O
.	O

The	O
rifamycin	B-T103
WT	B-T017
phenotype	O
was	O
restored	O
after	O
complementation	O
of	O
the	O
M	B-T007
.	I-T007

abscessus	I-T007
ΔarrMab	B-T017
mutant	I-T017
with	O
arrMab	B-T103
Further	O
MIC	B-T033
data	I-T033
demonstrated	O
that	O
a	O
C25	B-T103
modification	B-T033
increases	O
rifamycin	B-T103
activity	O
in	O
WT	B-T017
M	B-T007
.	I-T007

abscessus	I-T007
However	O
,	O
MIC	B-T062
studies	I-T062
in	O
the	O
M	B-T007
.	I-T007

abscessus	I-T007
ΔarrMab	B-T017
mutant	I-T017
suggest	O
that	O
C25	B-T103
modified	O
rifamycins	B-T103
are	O
still	O
subject	O
to	O
modification	B-T033
by	O
Arr	B-T103
_	I-T103
Mab	I-T103
CONCLUSIONS	O
:	O
Our	O
findings	O
identify	O
Arr	B-T103
_	I-T103
Mab	I-T103
as	O
the	O
major	O
innate	O
rifamycin	B-T103
resistance	O
determinant	O
of	O
M	B-T007
.	I-T007

abscessus	I-T007
.	O

Our	O
data	O
also	O
indicate	O
that	O
Arr	B-T103
_	I-T103
Mab	I-T103
-	O
mediated	O
rifamycin	B-T103
resistance	O
in	O
M	B-T007
.	I-T007

abscessus	I-T007
can	O
only	O
in	O
part	O
be	O
overcome	O
by	O
C25	B-T103
carbamate	I-T103
modification	B-T033
.	O

The	O
Silorane	B-T103
-	I-T103
based	I-T103
Resin	I-T103
Composites	I-T103
:	O
A	O
Review	B-T170

This	O
article	B-T170
aims	O
to	O
review	B-T170
the	O
research	B-T062
done	O
on	O
the	O
silorane	B-T103
-	I-T103
based	I-T103
resin	I-T103
composites	I-T103
(	O
SBRC	B-T103
)	O
regarding	O
polymerization	O
shrinkage	O
and	O
contraction	O
stresses	O
and	O
their	O
ability	O
to	O
improve	O
the	O
shortcomings	O
of	O
the	O
methacrylate	B-T103
-	I-T103
based	I-T103
resin	I-T103
composites	I-T103
(	O
MRBC	B-T103
)	O
.	O

Special	O
attention	O
is	O
given	O
to	O
their	O
physical	O
and	O
mechanical	O
properties	O
,	O
bond	O
strength	O
,	O
marginal	B-T058
adaptation	I-T058
,	O
and	O
cusp	O
deflection	O
.	O

The	O
clinical	B-T033
significance	I-T033
of	O
this	O
material	O
is	O
critically	O
appraised	O
with	O
a	O
focus	O
on	O
the	O
ability	O
of	O
SBRC	B-T103
to	O
strengthen	O
the	O
tooth	B-T017
structure	I-T017
as	O
a	O
direct	O
restorative	O
material	O
.	O

A	O
search	O
of	O
English	O
peer	B-T170
-	I-T170
reviewed	I-T170
dental	I-T170
literature	I-T170
(	O
2003	O
-	O
2015	O
)	O
from	O
PubMed	B-T170
and	O
MEDLINE	B-T170
databases	B-T170
was	O
conducted	O
with	O
the	O
terms	O
"	O
low	O
shrinkage	O
"	O
and	O
"	O
silorane	B-T103
composites	I-T103
.	O
"	O
The	O
list	O
was	O
screened	O
,	O
and	O
70	O
articles	B-T170
that	O
were	O
relevant	O
to	O
the	O
objectives	B-T170
of	O
this	O
work	O
were	O
included	O
.	O

Endoscopic	B-T058
endonasal	B-T082
surgery	B-T058
for	O
remission	B-T033
of	O
Cushing	B-T038
'	I-T038
s	I-T038
Disease	I-T038
caused	O
by	O
ectopic	B-T082
intracavernous	O
macroadenoma	B-T038
:	O
case	B-T170
report	I-T170
and	O
literature	B-T170
review	I-T170

Complete	O
surgical	B-T058
resection	I-T058
of	O
an	O
ACTH	B-T038
-	I-T038
secreting	I-T038
pituitary	I-T038
adenoma	I-T038
is	O
the	O
gold	O
standard	O
of	O
treatment	B-T058
of	O
Cushing	B-T038
'	I-T038
s	I-T038
Disease	I-T038
.	O

Ectopic	B-T082
location	B-T082
of	O
these	O
adenomas	B-T038
is	O
an	O
extremely	O
rare	O
condition	O
that	O
may	O
compromise	O
the	O
diagnosis	B-T033
and	O
surgical	B-T058
success	O
.	O

We	O
present	O
the	O
first	O
case	O
of	O
an	O
ectopic	B-T082
intracavernous	O
ACTH	B-T038
-	I-T038
secreting	I-T038
macroadenoma	I-T038
totally	O
resected	O
with	O
endoscopic	B-T058
endonasal	B-T082
surgery	B-T058
(	O
EES	B-T058
)	O
.	O

A	O
36	O
year	O
old	O
female	O
presented	O
with	O
Cushing	B-T038
syndrome	I-T038
.	O

Increased	O
ACTH	B-T103
,	O
serum	B-T103
cortisol	I-T103
and	O
free	O
urine	O
cortisol	O
levels	O
were	O
identified	O
,	O
however	O
the	O
pituitary	B-T058
MRI	I-T058
failed	O
to	O
reveal	O
a	O
pituitary	B-T038
tumor	I-T038
;	O
instead	O
,	O
a	O
parasellar	B-T033
lesion	I-T033
in	O
the	O
left	O
cavernous	B-T082
sinus	I-T082
(	O
CS	B-T082
)	O
was	O
noticed	O
.	O

Inferior	B-T058
petrosal	I-T058
sinus	I-T058
sampling	I-T058
demonstrated	O
a	O
significant	O
central	B-T082
-	O
to	O
-	O
peripheral	B-T082
and	O
lateralized	O
left	O
-	O
sided	O
ACTH	B-T103
gradient	O
.	O

The	O
patient	O
underwent	O
EES	B-T058
.	O

No	B-T033
tumor	I-T033
was	O
found	O
in	O
the	O
sella	B-T017
,	O
however	O
,	O
the	O
left	O
CS	B-T082
was	O
widely	O
explored	O
and	O
a	O
tumor	B-T038
was	O
found	O
lateral	B-T082
to	O
the	O
paraclival	O
segment	O
of	O
the	O
carotid	B-T017
artery	I-T017
.	O

There	O
were	O
no	B-T033
complications	B-T038
following	O
EES	B-T058
.	O

Pathology	B-T091
confirmed	O
the	O
diagnosis	B-T033
of	O
an	O
ACTH	B-T038
-	I-T038
secreting	I-T038
adenoma	I-T038
.	O

During	O
the	O
immediately	O
postoperative	O
course	O
serum	B-T103
cortisol	I-T103
levels	O
dropped	O
below	O
5	O
mcg	O
/	O
dl	O
.	O

Postoperative	O
MRI	B-T058
demonstrated	O
complete	O
tumor	B-T058
resection	I-T058
.	O

At	O
20	O
months	O
follow	B-T058
-	I-T058
up	I-T058
,	O
the	O
patient	O
remains	O
in	O
clinical	O
and	O
biochemical	O
remission	B-T033
of	O
Cushing	B-T038
'	I-T038
s	I-T038
Disease	I-T038
.	O

Only	O
12	O
cases	O
of	O
ectopic	B-T082
intracavernous	O
ACTH	B-T038
-	I-T038
secreting	I-T038
adenomas	I-T038
have	O
been	O
reported	O
to	O
date	O
and	O
all	O
were	O
microadenomas	B-T038
.	O

The	O
presence	O
of	O
an	O
ectopic	B-T082
ACTH	B-T038
-	I-T038
secreting	I-T038
macroadenoma	I-T038
in	O
the	O
CS	B-T082
represents	O
a	O
surgical	B-T058
challenge	O
.	O

EES	B-T058
is	O
the	O
ideal	O
approach	O
for	O
complete	O
resection	B-T058
of	O
ectopic	B-T082
intracavernous	O
adenomas	B-T038
allowing	O
for	O
a	O
wide	O
exploration	B-T058
of	O
the	O
CS	B-T082
with	O
no	B-T033
surgical	B-T058
complications	B-T038
.	O

Preliminary	O
Randomized	B-T062
Controlled	I-T062
Trial	I-T062
of	O
Habit	B-T058
Reversal	I-T058
Training	I-T058
for	O
Treatment	B-T058
of	O
Hair	B-T038
Pulling	I-T038
in	O
Youth	O

This	O
study	B-T062
evaluated	B-T058
the	O
treatment	B-T058
efficacy	O
of	O
habit	B-T058
reversal	I-T058
training	I-T058
(	O
HRT	B-T058
)	O
relative	O
to	O
treatment	O
as	O
usual	O
(	O
TAU	O
)	O
for	O
children	O
and	O
adolescents	O
aged	O
7	O
-	O
17	O
years	O
with	O
a	O
primary	O
diagnosis	B-T062
of	O
trichotillomania	B-T038
(	O
TTM	B-T038
)	O
.	O

An	O
initial	O
assessment	B-T058
consisting	O
of	O
semistructured	O
interviews	O
and	O
rating	O
scales	O
was	O
conducted	O
.	O

Participants	B-T098
(	O
N	O
=	O
40	O
,	O
85	O
%	O
female	O
)	O
meeting	O
diagnostic	B-T170
criteria	I-T170
for	O
TTM	B-T038
were	O
randomized	B-T062
to	O
either	O
8	O
weekly	O
sessions	O
of	O
HRT	B-T058
by	O
trained	O
therapists	O
or	O
8	O
weeks	O
of	O
TAU	O
.	O

One	O
week	O
after	O
the	O
final	O
HRT	B-T058
session	O
or	O
final	O
TAU	O
week	O
,	O
patients	O
completed	O
a	O
posttreatment	B-T058
assessment	I-T058
,	O
followed	O
by	O
1	O
-	O
and	O
3	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
assessments	B-T058
.	O

All	O
assessments	B-T058
were	O
conducted	O
by	O
a	O
trained	O
rater	B-T097
who	O
was	O
blinded	B-T062
to	O
treatment	B-T058
condition	O
.	O

The	O
group	O
by	O
time	O
analysis	O
of	O
variance	O
yielded	O
a	O
significant	O
interaction	O
on	O
the	O
National	B-T092
Institute	I-T092
of	I-T092
Mental	I-T092
Health	I-T092
-	O
Trichotillomania	O
Severity	O
Scale	O
Total	O
Score	O
(	O
F1	O
,	O
38	O
=	O
16	O
.	O
47	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
η	O
(	O
2	O
)	O
p	O
=	O
0	O
.	O
30	O
)	O
.	O

The	O
mean	O
score	O
decreased	O
from	O
12	O
.	O
67	O
±	O
4	O
.	O
60	O
at	O
baseline	O
to	O
5	O
.	O
62	O
±	O
4	O
.	O
38	O
at	O
posttreatment	B-T058
in	O
the	O
HRT	B-T058
group	B-T098
(	O
t20	O
=	O
5	O
.	O
99	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
d	O
=	O
1	O
.	O
31	O
)	O
,	O
whereas	O
the	O
TAU	O
group	B-T098
changed	O
from	O
10	O
.	O
42	O
±	O
4	O
.	O
35	O
to	O
9	O
.	O
32	O
±	O
4	O
.	O
11	O
(	O
t18	O
=	O
1	O
.	O
34	O
,	O
p	O
=	O
0	O
.	O
20	O
,	O
d	O
=	O
0	O
.	O
31	O
)	O
.	O

The	O
Massachusetts	O
General	O
Hospital	O
-	O
Hair	O
Pulling	O
Scale	O
Total	O
Score	O
decreased	O
from	O
15	O
.	O
14	O
±	O
3	O
.	O
86	O
at	O
baseline	O
to	O
7	O
.	O
14	O
±	O
5	O
.	O
54	O
at	O
posttreatment	B-T058
in	O
the	O
HRT	B-T058
group	B-T098
(	O
t20	O
=	O
6	O
.	O
16	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
d	O
=	O
1	O
.	O
34	O
)	O
;	O
the	O
TAU	O
group	B-T098
changed	O
from	O
14	O
.	O
16	O
±	O
4	O
.	O
51	O
to	O
12	O
.	O
26	O
±	O
4	O
.	O
34	O
(	O
t18	O
=	O
1	O
.	O
50	O
,	O
p	O
=	O
0	O
.	O
15	O
,	O
d	O
=	O
0	O
.	O
34	O
)	O
.	O

On	O
the	O
Clinical	B-T170
Global	I-T170
Impressions	I-T170
-	I-T170
Improvement	I-T170
,	O
16	O
/	O
21	O
participants	B-T098
(	O
76	O
%	O
)	O
were	O
rated	O
as	O
treatment	B-T058
responders	B-T098
in	O
the	O
HRT	B-T058
group	B-T098
versus	O
4	O
/	O
19	O
(	O
21	O
%	O
)	O
in	O
the	O
TAU	O
group	B-T098
(	O
χ	O
(	O
2	O
)	O
=	O
12	O
.	O
13	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
V	O
=	O
0	O
.	O
55	O
)	O
.	O

At	O
1	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
,	O
10	O
-	O
12	O
treatment	B-T058
responders	B-T098
who	O
completed	O
the	O
assessment	B-T058
maintained	O
improvement	O
.	O

At	O
3	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
,	O
six	O
of	O
eight	O
maintained	O
improvement	O
.	O

HRT	B-T058
can	O
be	O
an	O
effective	O
treatment	B-T058
for	O
TTM	B-T038
in	O
youth	O
.	O

Fully	O
Endoscope	B-T074
-	O
Controlled	O
Clipping	B-T058
Bilateral	B-T038
Middle	I-T038
Cerebral	I-T038
Artery	I-T038
Aneurysm	I-T038
Via	O
Unilateral	B-T058
Supraorbital	I-T058
Keyhole	I-T058
Approach	I-T058

Clipping	B-T058
bilateral	B-T038
middle	I-T038
cerebral	I-T038
artery	I-T038
(	I-T038
bMCA	I-T038
)	I-T038
aneurysms	I-T038
via	O
unilateral	B-T058
approach	I-T058
in	O
a	O
single	B-T058
-	I-T058
stage	I-T058
operation	I-T058
is	O
considered	O
as	O
a	O
challenge	O
procedure	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
study	O
in	O
surgical	B-T058
management	I-T058
of	O
patients	O
with	O
bMCA	B-T038
aneurysms	I-T038
by	O
fully	O
endoscope	B-T074
-	O
controlled	O
techniques	O
.	O

The	O
author	O
reported	O
a	O
patient	O
with	O
bMCA	B-T038
aneurysms	I-T038
who	O
underwent	O
aneurysms	B-T058
clipping	I-T058
via	O
a	O
unilateral	B-T058
supraorbital	I-T058
keyhole	I-T058
approach	I-T058
by	O
endoscope	B-T074
-	O
controlled	O
microneurosurgery	B-T058
,	O
and	O
the	O
patient	O
had	O
an	O
uneventful	O
postoperative	O
course	O
without	O
neurologic	O
impairment	B-T038
and	O
complication	B-T038
.	O

Furthermore	O
,	O
the	O
author	O
discussed	O
the	O
advantages	O
and	O
adaptation	B-T170
of	O
endoscope	B-T074
-	O
controlled	O
clipping	B-T058
bMCA	B-T038
aneurysms	I-T038
via	O
unilateral	B-T058
supraorbital	I-T058
keyhole	I-T058
approach	I-T058
.	O

Novel	O
Observations	B-T062
in	O
11	O
Heteroresistant	B-T038
Vancomycin	B-T103
-	I-T103
Intermediate	I-T103
Methicillin	B-T007
-	I-T007
Resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
Strains	I-T007
from	O
South	B-T082
India	I-T082

We	O
report	O
here	O
the	O
draft	O
genome	B-T082
sequences	I-T082
of	O
11	O
heteroresistant	B-T038
vancomycin	B-T007
-	I-T007
intermediate	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	I-T007
hVISA	I-T007
)	I-T007
strains	I-T007
from	O
bloodstream	B-T038
infection	I-T038
.	O

All	O
strains	O
harbor	O
mutations	B-T038
in	O
vraSR	B-T017
,	O
graSR	B-T017
,	O
walKR	B-T017
,	O
and	O
/	O
or	O
tcaRAB	B-T017
and	O
are	O
often	O
implicated	O
as	O
the	O
frequently	O
mutated	B-T038
candidate	O
genes	B-T017
in	O
hVISA	B-T007
phenotypes	O
.	O

Endpoints	O
for	O
screening	B-T058
thyroid	B-T038
cancer	I-T038
in	O
the	O
Republic	B-T082
of	I-T082
Korea	I-T082
:	O
thyroid	B-T017
specialists	B-T097
'	O
perspectives	B-T038

Cancer	B-T058
screening	I-T058
is	O
aimed	O
primarily	O
at	O
reducing	O
deaths	B-T033
from	O
the	O
specific	O
cancer	B-T038
.	O

Thyroid	B-T038
-	I-T038
specific	I-T038
cancer	I-T038
mortality	O
may	O
be	O
the	O
most	O
ambitious	O
endpoint	O
for	O
obtaining	O
estimates	O
of	O
screening	B-T058
effect	O
.	O

Numerous	O
observations	B-T058
have	O
accumulated	B-T033
over	O
the	O
years	O
,	O
indicating	O
that	O
thyroid	B-T038
cancer	I-T038
mortality	O
endpoint	O
has	O
been	O
difficult	O
to	O
study	O
and	O
is	O
confounded	O
by	O
population	O
heterogeneity	O
,	O
provision	B-T058
of	O
randomization	B-T062
,	O
and	O
requirement	O
of	O
large	O
cohorts	B-T098
with	O
sufficiently	O
long	B-T058
follow	I-T058
-	I-T058
up	I-T058
due	O
to	O
the	O
excellent	O
prognosis	B-T201
of	I-T201
the	I-T201
cancer	I-T201
.	O

Accordingly	O
,	O
it	O
may	O
be	O
important	O
to	O
reconsider	O
how	O
to	O
best	O
measure	O
thyroid	B-T038
cancer	I-T038
screening	B-T058
efficacy	O
.	O

Recommendations	O
against	O
thyroid	B-T038
cancer	I-T038
screening	B-T058
should	O
be	O
based	O
upon	O
trials	O
designed	O
to	O
evaluate	O
its	O
effectiveness	O
not	O
only	O
in	O
significant	O
reduction	O
in	O
cancer	B-T038
mortality	O
,	O
but	O
also	O
of	O
other	O
distinct	O
endpoint	O
s	O
.	O

It	O
is	O
desirable	O
to	O
evaluate	O
derivative	O
endpoints	O
that	O
can	O
reliably	O
predict	O
reductions	O
in	O
mortality	O
.	O

The	O
term	O
"	O
derivative	O
"	O
means	O
a	O
variable	O
that	O
is	O
related	O
to	O
the	O
true	O
endpoint	O
and	O
is	O
likely	O
to	O
be	O
observable	O
before	O
the	O
primary	O
endpoint	O
.	O

Derivative	O
endpoints	O
may	O
include	O
thyroid	B-T038
cancer	I-T038
incidence	O
,	O
the	O
proportion	O
of	O
early	O
-	O
stage	O
tumors	B-T038
detected	B-T033
,	O
more	O
treatable	B-T201
stage	I-T201
,	O
the	O
identification	O
of	O
small	O
tumors	O
(	O
to	O
maintain	O
in	O
observation	O
)	O
,	O
decrease	O
in	O
the	O
number	O
of	O
people	O
who	O
develop	O
metastatic	B-T038
disease	I-T038
,	O
the	O
increased	O
chance	O
of	O
lesser	O
extent	O
surgery	B-T058
,	O
and	O
the	O
application	O
of	O
minimally	O
invasive	O
approaches	O
,	O
as	O
well	O
as	O
no	O
need	O
for	O
lifelong	O
thyroid	B-T058
replacement	I-T058
therapy	I-T058
,	O
a	O
consistent	O
follow	B-T058
-	I-T058
up	I-T058
,	O
low	O
-	O
dose	O
or	O
no	O
RAI	B-T058
administration	I-T058
and	O
risk	B-T170
factor	I-T170
assessments	I-T170
where	O
case	B-T058
findings	I-T058
should	O
be	O
continuous	O
.	O

The	O
Korean	B-T170
guidelines	I-T170
for	O
thyroid	B-T038
cancer	I-T038
national	O
-	O
level	O
screening	B-T058
were	O
published	O
by	O
a	O
relevant	O
group	O
of	O
multidisciplinary	B-T058
thyroid	I-T058
experts	I-T058
.	O

It	O
was	O
concluded	O
that	O
the	O
evidence	O
is	O
insufficient	O
to	O
balance	O
the	O
benefits	O
and	O
harms	O
of	O
thyroid	B-T038
cancer	I-T038
screening	B-T058
.	O

However	O
,	O
the	O
paper	O
seems	O
to	O
raise	O
the	O
necessary	O
investments	O
in	O
future	O
research	B-T062
and	O
demand	O
a	O
complete	O
analysis	B-T062
for	O
derivative	O
endpoints	O
,	O
and	O
offer	O
screening	B-T058
participants	B-T098
with	O
complete	O
information	O
necessary	O
to	B-T038
make	I-T038
decisions	I-T038
that	O
will	O
provide	O
them	O
with	O
the	O
most	O
value	O
when	O
a	O
small	O
thyroid	B-T038
cancer	I-T038
is	O
screen	O
-	O
identified	O
.	O

Zebrafish	B-T204
adult	B-T017
pigment	I-T017
stem	I-T017
cells	I-T017
are	O
multipotent	B-T017
and	O
form	B-T017
pigment	I-T017
cells	I-T017
by	O
a	O
progressive	O
fate	B-T038
restriction	I-T038
process	I-T038
:	O
Clonal	B-T058
analysis	I-T058
identifies	O
shared	O
origin	O
of	O
all	O
pigment	B-T017
cell	I-T017
types	I-T017

Skin	B-T033
pigment	I-T033
pattern	B-T038
formation	I-T038
is	O
a	O
paradigmatic	O
example	O
of	O
pattern	B-T038
formation	I-T038
.	O

In	O
zebrafish	B-T204
,	O
the	O
adult	O
body	B-T017
stripes	I-T017
are	O
generated	O
by	O
coordinated	O
rearrangement	B-T038
of	O
three	O
distinct	O
pigment	B-T017
cell	I-T017
-	I-T017
types	I-T017
,	O
black	O
melanocytes	B-T017
,	O
shiny	O
iridophores	B-T017
and	O
yellow	O
xanthophores	B-T017
.	O

A	O
stem	B-T017
cell	I-T017
origin	I-T017
of	O
melanocytes	B-T017
and	O
iridophores	B-T017
has	O
been	O
proposed	O
although	O
the	O
potency	O
of	O
those	O
stem	B-T017
cells	I-T017
has	O
remained	O
unclear	O
.	O

Xanthophores	B-T017
,	O
however	O
,	O
seemed	O
to	O
originate	O
predominantly	O
from	O
proliferation	B-T038
of	O
embryonic	B-T017
xanthophores	B-T017
.	O

Now	O
,	O
data	O
from	O
Singh	O
et	O
al	O
.	O

shows	O
that	O
all	O
three	O
cell	B-T017
-	I-T017
types	I-T017
derive	O
from	O
shared	O
stem	B-T017
cells	I-T017
,	O
and	O
that	O
these	O
cells	B-T017
generate	O
peripheral	B-T082
neural	B-T017
cell	I-T017
-	I-T017
types	I-T017
too	O
.	O

Furthermore	O
,	O
clonal	B-T017
compositions	O
are	O
best	O
explained	O
by	O
a	O
progressive	O
fate	B-T038
restriction	I-T038
model	I-T038
generating	O
the	O
individual	O
cell	B-T017
-	I-T017
types	I-T017
.	O

The	O
numbers	O
of	O
adult	B-T017
pigment	I-T017
stem	I-T017
cells	I-T017
associated	O
with	O
the	O
dorsal	B-T017
root	I-T017
ganglia	I-T017
remain	B-T033
low	O
,	O
but	O
progenitor	B-T017
numbers	O
increase	O
significantly	O
during	O
larval	B-T038
development	I-T038
up	O
to	O
metamorphosis	B-T038
,	O
likely	O
via	O
production	O
of	O
partially	O
restricted	O
progenitors	B-T017
on	O
the	O
spinal	B-T017
nerves	I-T017
.	O

Covalent	B-T103
Modulators	I-T103
of	O
the	O
Vacuolar	B-T103
ATPase	I-T103

The	O
vacuolar	B-T103
H	I-T103
(	I-T103
+	I-T103
)	I-T103
ATPase	I-T103
(	O
V	B-T103
-	I-T103
ATPase	I-T103
)	O
is	O
a	O
complex	B-T103
multisubunit	O
machine	O
that	O
regulates	B-T038
important	O
cellular	B-T038
processes	I-T038
through	O
controlling	O
acidity	O
of	O
intracellular	B-T082
compartments	B-T017
in	O
eukaryotes	B-T204
.	O

Existing	O
small	B-T103
-	I-T103
molecule	I-T103
modulators	B-T103
of	O
V	B-T103
-	I-T103
ATPase	I-T103
either	O
are	O
restricted	O
to	O
targeting	B-T038
one	O
membranous	O
subunit	O
of	O
V	B-T103
-	I-T103
ATPase	I-T103
or	O
have	O
poorly	O
understood	B-T038
mechanisms	O
of	O
action	O
.	O

Small	B-T103
molecules	I-T103
with	O
novel	O
and	O
defined	O
mechanisms	O
of	O
inhibition	B-T038
are	O
thus	O
needed	O
to	O
functionally	O
characterize	O
V	B-T103
-	I-T103
ATPase	I-T103
and	O
to	O
fully	O
evaluate	O
the	O
therapeutic	O
relevance	O
of	O
V	B-T103
-	I-T103
ATPase	I-T103
in	O
human	B-T204
diseases	B-T038
.	O

We	O
have	O
discovered	O
electrophilic	O
quinazolines	B-T103
that	O
covalently	B-T038
modify	I-T038
a	O
soluble	O
catalytic	B-T082
subunit	I-T082
of	O
V	B-T103
-	I-T103
ATPase	I-T103
with	O
high	O
potency	O
and	O
exquisite	O
proteomic	O
selectivity	O
as	O
revealed	O
by	O
fluorescence	B-T058
imaging	I-T058
and	O
chemical	B-T058
proteomic	I-T058
activity	I-T058
-	I-T058
based	I-T058
profiling	I-T058
.	O

The	O
site	B-T082
of	O
covalent	O
modification	O
was	O
mapped	O
to	O
a	O
cysteine	B-T103
residue	O
located	B-T082
in	I-T082
a	O
region	B-T082
of	O
V	B-T103
-	I-T103
ATPase	I-T103
subunit	B-T103
A	I-T103
that	O
is	O
thought	B-T038
to	O
regulate	B-T038
the	O
dissociation	B-T038
of	O
V	B-T103
-	I-T103
ATPase	I-T103
.	O

We	O
further	O
demonstrate	O
that	O
a	O
previously	O
reported	O
V	B-T103
-	I-T103
ATPase	I-T103
inhibitor	I-T103
,	O
3	B-T103
-	I-T103
bromopyruvate	I-T103
,	O
also	O
targets	O
the	O
same	O
cysteine	B-T103
residue	O
and	O
that	O
our	O
electrophilic	O
quinazolines	B-T103
modulate	B-T082
the	O
function	O
of	O
V	B-T103
-	I-T103
ATPase	I-T103
in	O
cells	B-T017
.	O

With	O
their	O
well	O
-	O
defined	O
mechanism	O
of	O
action	O
and	O
high	O
proteomic	O
specificity	O
,	O
the	O
described	O
quinazolines	B-T103
offer	O
a	O
powerful	O
set	O
of	O
chemical	B-T103
probes	I-T103
to	O
investigate	O
the	O
physiological	O
and	O
pathological	O
roles	O
of	O
V	B-T103
-	I-T103
ATPase	I-T103
.	O

Association	O
of	O
Radiomics	O
and	O
Metabolic	O
Tumor	O
Volumes	O
in	O
Radiation	O
Treatment	O
of	O
Glioblastoma	B-T038
Multiforme	I-T038

To	O
build	O
a	O
framework	O
for	O
investigation	B-T058
of	O
the	O
associations	O
between	O
imaging	B-T058
,	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
,	O
and	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
features	O
for	O
better	O
understanding	O
of	O
the	O
underlying	O
information	O
in	O
the	O
CTVs	O
and	O
dependencies	O
between	O
these	O
volumes	O
.	O

High	O
-	O
throughput	O
extraction	O
of	O
imaging	B-T058
and	O
metabolomic	B-T091
quantitative	O
features	O
from	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
(	O
MRI	B-T058
)	O
and	O
magnetic	B-T058
resonance	I-T058
spectroscopic	I-T058
imaging	I-T058
of	O
glioblastoma	B-T038
multiforme	I-T038
(	O
GBM	B-T038
)	O
results	O
in	O
tens	O
of	O
variables	O
per	O
patient	O
.	O

In	O
radiation	O
therapy	O
of	O
GBM	B-T038
the	O
relevant	O
metabolic	O
tumor	O
volumes	O
(	O
MTVs	O
)	O
are	O
related	O
to	O
aberrant	O
levels	O
of	O
N	B-T103
-	I-T103
acetyl	I-T103
aspartate	I-T103
(	O
NAA	B-T103
)	O
and	O
choline	B-T103
(	O
Cho	B-T103
)	O
.	O

The	O
corresponding	O
clinical	O
target	O
volumes	O
(	O
CTVs	O
)	O
for	O
radiation	O
therapy	O
are	O
based	O
on	O
contrast	B-T058
-	I-T058
enhanced	I-T058
T1	I-T058
-	I-T058
weighted	I-T058
(	O
CE	B-T058
-	I-T058
T1w	I-T058
)	O
and	O
T2	B-T058
-	I-T058
weighted	I-T058
(	I-T058
T2w	I-T058
)	I-T058
/	I-T058
fluid	I-T058
-	I-T058
attenuated	I-T058
inversion	I-T058
recovery	I-T058
MRI	I-T058
.	O

Necrotic	B-T033
portions	I-T033
,	O
enhancing	B-T033
lesion	I-T033
,	O
and	O
edema	B-T033
were	O
manually	O
contoured	O
on	O
CE	B-T170
-	I-T170
T1w	I-T170
/	O
T2w	B-T170
images	I-T170
for	O
17	O
GBM	B-T038
patients	O
.	O

Clinical	O
target	O
volumes	O
and	O
MTVs	O
for	O
NAA	B-T103
(	O
MTVNAA	O
)	O
and	O
Cho	B-T103
(	O
MTVCho	O
)	O
were	O
constructed	O
.	O

Imaging	B-T058
and	O
metabolic	B-T201
features	I-T201
related	O
to	O
size	B-T082
,	O
shape	B-T082
,	O
and	O
signal	O
intensities	O
of	O
the	O
volumes	O
were	O
extracted	O
.	O

Tumors	B-T038
were	O
also	O
scored	O
categorically	O
for	O
10	O
semantic	O
imaging	O
traits	O
by	O
a	O
neuroradiologist	B-T097
.	O

All	O
features	O
were	O
investigated	O
for	O
redundancy	O
.	O

Two	O
-	O
way	O
correlations	O
between	O
imaging	B-T170
and	O
CTVs	O
/	O
MTVs	O
features	O
were	O
visualized	O
as	O
heatmaps	O
.	O

Associations	O
between	O
MTVNAA	O
and	O
MTVCho	O
and	O
imaging	O
features	O
were	O
studied	O
using	O
Spearman	B-T170
correlation	I-T170
.	O

Forty	O
-	O
eight	O
imaging	O
features	O
were	O
extracted	O
per	O
patient	O
.	O

Half	O
of	O
the	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O

Twenty	O
features	O
were	O
extracted	O
from	O
CTVs	O
and	O
MTVs	O
.	O

A	O
series	O
of	O
semantic	O
imaging	O
traits	O
were	O
replaced	O
with	O
automatically	O
extracted	O
continuous	O
variables	O
.	O

There	O
were	O
multiple	O
(	O
22	O
)	O
significant	O
correlations	O
of	O
imaging	O
measures	O
with	O
CTVs	O
/	O
MTVNAA	O
,	O
whereas	O
there	O
were	O
only	O
6	O
with	O
CTVs	O
/	O
MTVCho	O
.	O

A	O
framework	O
for	O
investigation	O
of	O
codependencies	O
between	O
MRI	B-T058
and	O
magnetic	B-T058
resonance	I-T058
spectroscopic	I-T058
imaging	I-T058
radiomic	O
features	O
and	O
CTVs	O
/	O
MTVs	O
has	O
been	O
established	O
.	O

The	O
MTV	O
for	O
NAA	B-T103
was	O
found	O
to	O
be	O
closely	O
associated	O
with	O
MRI	B-T058
volumes	O
,	O
whereas	O
very	O
few	O
imaging	O
features	O
were	O
related	O
to	O
MTVCho	O
,	O
indicating	O
that	O
Cho	B-T103
provides	O
additional	O
information	O
to	O
imaging	B-T058
.	O

Measurement	O
of	O
fidgeting	B-T033
in	O
patients	O
with	O
anorexia	B-T038
nervosa	I-T038
using	O
a	O
novel	O
shoe	O
-	O
based	O
monitor	B-T074

To	O
objectively	O
assess	O
seated	B-T033
non	O
-	O
exercise	O
physical	O
activity	O
in	O
patients	O
with	O
anorexia	B-T038
nervosa	I-T038
(	O
AN	B-T038
)	O
relative	O
to	O
healthy	O
controls	O
(	O
HCs	O
)	O
and	O
examine	O
the	O
associations	O
between	O
this	O
physical	O
activity	O
,	O
eating	B-T038
disorder	I-T038
pathology	B-T038
,	O
and	O
levels	O
of	O
anxiety	B-T033
and	O
depression	B-T038
.	O

Eleven	O
inpatients	O
with	O
AN	B-T038
and	O
10	O
HCs	O
wore	O
a	O
shoe	O
-	O
based	O
accelerometer	B-T074
(	O
SmartShoe	B-T074
)	O
at	O
three	O
time	O
points	O
:	O
a	O
)	O
while	O
eating	O
lunch	O
,	O
b	O
)	O
filling	O
out	O
questionnaires	O
,	O
and	O
c	O
)	O
watching	O
television	O
for	O
1h	O
.	O

Across	O
all	O
three	O
tasks	O
,	O
patients	O
with	O
AN	B-T038
were	O
significantly	O
more	O
active	O
than	O
HCs	O
,	O
thereby	O
engaging	O
in	O
a	O
greater	O
degree	O
of	O
restless	B-T033
or	O
fidgeting	B-T033
behavior	O
.	O

Degree	O
of	O
physical	O
activity	O
was	O
positively	B-T033
correlated	I-T033
with	O
eating	B-T038
disorder	I-T038
psychopathology	B-T091
in	O
the	O
sample	O
with	O
AN	B-T038
,	O
and	O
a	O
trend	O
towards	O
a	O
positive	B-T033
association	I-T033
between	O
physical	O
activity	O
and	O
levels	O
of	O
depression	B-T038
and	O
anxiety	B-T033
was	O
also	O
found	O
in	O
this	O
sample	O
.	O

Among	O
individuals	B-T098
with	O
AN	B-T038
,	O
physical	O
activity	O
was	O
not	B-T033
significantly	O
correlated	O
with	O
BMI	B-T201
,	O
duration	O
of	O
illness	O
,	O
or	O
number	O
of	O
days	O
since	O
hospital	B-T058
admission	I-T058
.	O

Use	O
of	O
a	O
minimally	O
invasive	O
,	O
shoe	O
-	O
based	O
monitor	B-T074
revealed	O
patients	O
with	O
AN	B-T038
engaged	O
in	O
a	O
greater	O
degree	O
of	O
fidgeting	B-T033
relative	O
to	O
HCs	O
during	O
quiet	O
,	O
seated	B-T033
tasks	O
and	O
this	O
heightened	O
activity	O
was	O
related	O
to	O
measures	O
of	O
pathology	B-T038
.	O

Non	O
-	O
exercise	O
physical	O
activity	O
,	O
including	O
fidgeting	B-T033
,	O
may	O
warrant	O
further	O
clinical	O
attention	O
in	O
this	O
patient	O
population	O
.	O

Hospital	B-T092
clowning	I-T092
:	O
a	O
paediatrician	B-T097
'	I-T097
s	I-T097
view	B-T038

This	O
study	B-T062
investigates	O
the	O
current	O
position	O
of	O
hospital	B-T097
clowns	I-T097
from	O
the	O
perspective	B-T038
of	O
paediatricians	B-T097
and	O
paediatric	O
residents	O
.	O

A	O
total	O
of	O
14	O
attending	B-T097
paediatricians	I-T097
and	O
paediatric	O
residents	O
participated	O
in	O
two	O
focus	O
group	O
sessions	O
.	O

Data	O
were	O
analysed	B-T062
using	O
Atlas	B-T170
.	I-T170
ti	I-T170
5	I-T170
.	I-T170
0	I-T170
.	O

In	O
general	B-T082
,	O
physicians	B-T097
reported	B-T170
positive	B-T033
experiences	B-T038
regarding	O
the	O
interaction	B-T033
between	O
hospital	B-T097
clowns	I-T097
and	O
paediatric	O
patients	O
on	O
the	O
ward	B-T092
.	O

Physicians	B-T097
were	O
more	O
interested	B-T038
in	O
research	B-T062
on	O
children	O
'	O
s	O
perception	O
of	O
hospital	B-T097
clowns	I-T097
than	O
in	O
research	B-T062
on	O
the	O
clinical	O
efficacy	O
of	O
hospital	B-T092
clowning	I-T092
.	O

No	O
direct	O
collaboration	O
between	O
physicians	B-T097
and	O
hospital	B-T097
clowns	I-T097
was	O
reported	B-T170
.	O

However	O
,	O
physicians	B-T097
proposed	O
conditions	O
which	O
may	O
streamline	O
their	O
encounters	O
with	O
hospital	B-T097
clowns	I-T097
such	O
as	O
clear	O
communication	O
prior	O
to	O
hospital	B-T097
clown	I-T097
visits	B-T058
,	O
and	O
the	O
condition	O
that	O
visits	O
do	O
not	O
impede	O
medical	B-T058
interventions	I-T058
.	O

Overall	O
,	O
paediatricians	B-T097
and	O
paediatric	O
residents	O
view	B-T038
the	O
positive	B-T033
impact	O
on	O
paediatric	O
patients	O
as	O
the	O
most	O
important	O
aspect	O
of	O
hospital	B-T097
clown	I-T097
visits	B-T058
,	O
rather	O
than	O
the	O
clinical	O
efficacy	O
of	O
hospital	B-T092
clowning	I-T092
.	O

In	O
light	O
of	O
the	O
growing	O
number	O
of	O
hospital	B-T097
clowns	I-T097
worldwide	B-T098
,	O
this	O
article	B-T170
provides	O
recommendations	O
for	O
arranging	O
their	O
encounters	O
with	O
paediatricians	B-T097
and	O
paediatric	O
residents	O
to	O
maintain	O
optimal	O
health	B-T058
care	I-T058
.	O

What	O
is	O
known	O
:	O
•	O
Previous	O
studies	B-T062
show	O
a	O
clinically	O
significant	O
pain	B-T033
-	O
and	O
anxiety	B-T033
-	O
reducing	O
effect	O
of	O
hospital	B-T092
clowning	I-T092
in	O
paediatric	O
patients	O
admitted	B-T058
to	I-T058
hospitals	I-T058
or	O
undergoing	O
(	O
invasive	O
)	O
medical	B-T058
procedures	I-T058
.	O

•	O
In	O
general	O
,	O
paediatricians	B-T097
have	O
positive	B-T033
ideas	O
about	O
hospital	B-T097
clowns	I-T097
,	O
aside	O
from	O
personal	O
prejudices	O
.	O

What	O
is	O
new	O
:	O
•	O
This	O
novel	O
study	B-T062
gives	O
deeper	O
insight	B-T038
into	O
day	O
-	O
to	O
-	O
day	O
interaction	B-T033
between	O
paediatricians	B-T097
and	O
hospital	B-T097
clowns	I-T097
on	O
the	O
ward	B-T092
.	O

•	O
This	O
study	B-T062
provides	O
recommendations	O
for	O
clinical	B-T170
practice	I-T170
to	O
arrange	O
encounters	O
between	O
physicians	B-T097
and	O
hospital	B-T097
clowns	I-T097
during	O
hospital	B-T097
clown	I-T097
visits	B-T058
.	O

Multiparametric	B-T062
estimation	I-T062
of	O
brain	B-T038
hemodynamics	I-T038
with	O
MR	B-T058
fingerprinting	I-T058
ASL	I-T058

Assessment	B-T058
of	O
brain	B-T038
hemodynamics	I-T038
without	O
exogenous	O
contrast	B-T103
agents	I-T103
is	O
of	O
increasing	O
importance	O
in	O
clinical	O
applications	O
.	O

This	O
study	O
aims	O
to	O
develop	O
an	O
MR	B-T058
perfusion	I-T058
technique	I-T058
that	O
can	O
provide	O
noncontrast	B-T033
and	O
multiparametric	B-T062
estimation	I-T062
of	O
hemodynamic	B-T038
markers	B-T074
.	O

We	O
devised	O
an	O
arterial	B-T058
spin	I-T058
labeling	I-T058
(	O
ASL	B-T058
)	O
method	O
based	O
on	O
the	O
principle	O
of	O
MR	B-T058
fingerprinting	I-T058
(	O
MRF	B-T058
)	O
,	O
referred	O
to	O
as	O
MRF	B-T058
-	I-T058
ASL	I-T058
.	O

By	O
taking	O
advantage	O
of	O
the	O
rich	O
information	O
contained	O
in	O
MRF	B-T058
sequence	I-T058
,	O
up	O
to	O
seven	O
hemodynamic	B-T038
parameters	B-T033
can	O
be	O
estimated	O
concomitantly	O
.	O

Feasibility	B-T062
demonstration	I-T062
,	O
flip	O
angle	O
optimization	O
,	O
comparison	O
with	O
Look	B-T058
-	I-T058
Locker	I-T058
ASL	I-T058
,	O
reproducibility	O
test	O
,	O
sensitivity	O
to	O
hypercapnia	B-T033
challenge	I-T033
,	O
and	O
initial	O
clinical	O
application	O
in	O
an	O
intracranial	B-T058
steno	I-T058
-	I-T058
occlusive	I-T058
process	I-T058
,	O
Moyamoya	B-T038
disease	I-T038
,	O
were	O
performed	O
to	O
evaluate	O
this	O
technique	O
.	O

Magnetic	B-T058
resonance	I-T058
fingerprinting	I-T058
ASL	I-T058
provided	O
estimation	O
of	O
up	O
to	O
seven	O
parameters	B-T033
,	O
including	O
B1	O
+	O
,	O
tissue	B-T017
T1	O
,	O
cerebral	B-T033
blood	I-T033
flow	I-T033
(	O
CBF	B-T033
)	O
,	O
tissue	B-T017
bolus	B-T033
arrival	I-T033
time	I-T033
(	O
BAT	B-T033
)	O
,	O
pass	O
-	O
through	O
arterial	B-T017
BAT	B-T033
,	O
pass	O
-	O
through	O
blood	B-T201
volume	I-T201
,	O
and	O
pass	O
-	O
through	O
blood	B-T058
travel	I-T058
time	I-T058
.	O

Coefficients	O
of	O
variation	O
of	O
the	O
estimated	O
parameters	B-T033
ranged	O
from	O
0	O
.	O
2	O
to	O
9	O
.	O
6	O
%	O
.	O

Hypercapnia	B-T033
resulted	O
in	O
an	O
increase	O
in	O
CBF	B-T033
by	O
57	O
.	O
7	O
%	O
,	O
and	O
a	O
decrease	O
in	O
BAT	B-T033
by	O
13	O
.	O
7	O
and	O
24	O
.	O
8	O
%	O
in	O
tissue	B-T017
and	O
vessels	B-T017
,	O
respectively	O
.	O

Patients	O
with	O
Moyamoya	B-T038
disease	I-T038
showed	O
diminished	O
CBF	B-T033
and	O
lengthened	O
BAT	B-T033
that	O
could	B-T033
not	I-T033
be	I-T033
detected	I-T033
with	O
regular	O
ASL	B-T058
.	O

Magnetic	B-T058
resonance	I-T058
fingerprinting	I-T058
ASL	I-T058
is	O
a	O
promising	O
technique	O
for	O
noncontrast	B-T033
,	O
multiparametric	B-T062
perfusion	B-T058
assessment	I-T058
.	O

Magn	O
Reson	O
Med	O
,	O
2016	O
.	O

©	O
2016	O
International	B-T092
Society	I-T092
for	I-T092
Magnetic	I-T092
Resonance	I-T092
in	I-T092
Medicine	I-T092
.	O

Acute	O
sensitivity	O
of	O
the	O
vernal	B-T204
pool	I-T204
fairy	I-T204
shrimp	I-T204
,	O
Branchinecta	B-T204
lynchi	I-T204
(	O
Anostraca	B-T204
;	O
Branchinectidae	B-T204
)	O
,	O
and	O
surrogate	O
species	B-T170
to	O
10	O
chemicals	B-T103

Vernal	B-T204
pool	I-T204
fairy	I-T204
shrimp	I-T204
,	O
Branchinecta	B-T204
lynchi	I-T204
,	O
(	O
Branchiopoda	B-T204
;	O
Anostraca	B-T204
)	O
and	O
other	O
fairy	B-T204
shrimp	I-T204
species	B-T170
have	O
been	O
listed	O
as	O
threatened	B-T098
or	O
endangered	B-T098
under	O
the	O
US	O
Endangered	O
Species	O
Act	O
.	O

Because	O
few	O
data	O
exist	O
about	O
the	O
sensitivity	O
of	O
Branchinecta	B-T204
spp	B-T170
.	I-T170

to	O
toxic	B-T037
effects	I-T037
of	O
contaminants	O
,	O
it	O
is	O
difficult	O
to	O
determine	O
whether	O
they	O
are	O
adequately	B-T204
protected	I-T204
by	O
water	O
quality	O
criteria	O
.	O

A	O
series	O
of	O
acute	B-T058
(	I-T058
24	I-T058
-	I-T058
h	I-T058
)	I-T058
lethality	I-T058
/	I-T058
immobilization	I-T058
tests	I-T058
was	O
conducted	O
with	O
3	O
species	B-T170
of	O
fairy	B-T204
shrimp	I-T204
(	O
B	B-T204
.	I-T204

lynchi	I-T204
,	O
Branchinecta	B-T204
lindahli	I-T204
,	O
and	O
Thamnocephalus	B-T204
platyurus	I-T204
)	O
and	O
10	O
chemicals	B-T103
with	O
varying	O
modes	O
of	O
toxic	B-T103
action	I-T103
:	O
ammonia	B-T103
,	O
potassium	B-T103
,	O
chloride	B-T103
,	O
sulfate	B-T103
,	O
chromium	B-T103
(	I-T103
VI	I-T103
)	I-T103
,	O
copper	B-T103
,	O
nickel	B-T103
,	O
zinc	B-T103
,	O
alachlor	B-T103
,	O
and	O
metolachlor	B-T103
.	O

The	O
same	O
chemicals	B-T103
were	O
tested	O
in	O
48	O
-	O
h	O
tests	B-T058
with	O
other	O
branchiopods	B-T204
(	O
the	O
cladocerans	B-T204
Daphnia	B-T204
magna	I-T204
and	O
Ceriodaphnia	B-T204
dubia	I-T204
)	O
and	O
an	O
amphipod	B-T204
(	O
Hyalella	B-T204
azteca	I-T204
)	O
,	O
and	O
in	O
96	O
-	O
h	O
tests	B-T058
with	O
snails	B-T204
(	O
Physa	B-T204
gyrina	I-T204
and	O
Lymnaea	B-T204
stagnalis	I-T204
)	O
.	O

Median	O
effect	O
concentrations	O
(	O
EC50s	O
)	O
for	O
B	B-T204
.	I-T204

lynchi	I-T204
were	O
strongly	O
correlated	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
975	O
)	O
with	O
EC50s	O
for	O
the	O
commercially	O
available	O
fairy	B-T204
shrimp	I-T204
species	B-T170
T	B-T204
.	I-T204

platyurus	I-T204
for	O
most	O
chemicals	B-T103
tested	O
.	O

Comparison	O
of	O
EC50s	O
for	O
fairy	B-T204
shrimp	I-T204
and	O
EC50s	O
for	O
invertebrate	B-T204
taxa	I-T204
tested	O
concurrently	O
and	O
with	O
other	O
published	O
toxicity	B-T037
data	O
indicated	O
that	O
fairy	B-T204
shrimp	I-T204
were	O
relatively	O
sensitive	O
to	O
potassium	B-T103
and	O
several	O
trace	B-T103
metals	I-T103
compared	O
with	O
other	O
invertebrate	B-T204
taxa	I-T204
,	O
although	O
cladocerans	B-T204
,	O
amphipods	B-T204
,	O
and	O
mussels	B-T204
had	O
similar	O
broad	O
toxicant	O
sensitivity	O
.	O

Interspecies	B-T170
correlation	I-T170
estimation	I-T170
models	I-T170
for	O
predicting	O
toxicity	B-T037
to	O
fairy	B-T204
shrimp	I-T204
from	O
surrogate	O
species	B-T170
indicated	O
that	O
models	B-T170
with	O
cladocerans	B-T204
and	O
freshwater	B-T204
mussels	I-T204
as	O
surrogates	O
produced	O
the	O
best	O
predictions	O
of	O
the	O
sensitivity	O
of	O
fairy	B-T204
shrimp	I-T204
to	O
contaminants	O
.	O

The	O
results	O
of	O
these	O
studies	B-T062
indicate	O
that	O
fairy	B-T204
shrimp	I-T204
are	O
relatively	O
sensitive	O
to	O
a	O
range	O
of	O
toxicants	O
,	O
but	O
Endangered	O
Species	O
Act	O
-	O
listed	O
fairy	B-T204
shrimp	I-T204
of	O
the	O
genus	B-T204
Branchinecta	I-T204
were	O
not	O
consistently	O
more	O
sensitive	O
than	O
other	O
fairy	B-T204
shrimp	I-T204
taxa	I-T204
.	O

Environ	O
Toxicol	O
Chem	O
2016	O
;	O
9999	O
:	O
1	O
-	O
10	O
.	O

Published	O
2016	O
Wiley	O
Periodicals	O
Inc	O
.	O

on	O
behalf	O
of	O
SETAC	O
.	O

This	O
article	O
is	O
a	O
US	O
government	O
work	O
and	O
,	O
as	O
such	O
,	O
is	O
in	O
the	O
public	O
domain	O
in	O
the	O
United	O
States	O
of	O
America	O
.	O

Bi	B-T103
-	I-T103
layered	I-T103
constructs	I-T103
of	O
poly	B-T103
(	I-T103
glycerol	I-T103
-	I-T103
sebacate	I-T103
)	I-T103
-	O
β	B-T103
-	I-T103
tricalcium	I-T103
phosphate	I-T103
for	O
bone	O
-	O
soft	O
tissue	O
interface	O
applications	O

This	O
study	B-T062
aims	O
to	O
establish	O
a	O
facile	O
protocol	B-T170
for	O
the	O
preparation	O
of	O
a	O
bi	O
-	O
layered	O
poly	B-T103
(	I-T103
glycerol	I-T103
-	I-T103
sebacate	I-T103
)	I-T103
(	O
PGS	B-T103
)	O
/	O
β	B-T103
-	I-T103
tricalcium	I-T103
phosphate	I-T103
(	O
β	B-T103
-	I-T103
TCP	I-T103
)	O
construct	B-T103
and	O
to	O
investigate	O
its	O
potential	O
for	O
bone	O
-	O
soft	O
tissue	O
engineering	B-T058
applications	O
.	O

The	O
layered	B-T082
structure	I-T082
was	O
prepared	O
by	O
distributing	O
the	O
ceramic	O
particles	B-T103
within	O
a	O
prepolymer	B-T103
synthesized	O
in	O
a	O
microwave	O
reactor	O
followed	O
by	O
a	O
cross	O
-	O
linking	O
of	O
the	O
final	O
construct	B-T103
in	O
vacuum	O
(	O
<	O
10mbar	O
)	O
.	O

The	O
vacuum	O
stage	O
led	O
to	O
the	O
separation	O
of	O
cross	O
-	O
linked	O
elastomer	B-T103
(	O
top	B-T082
)	O
and	O
ceramic	O
(	O
bottom	B-T082
)	O
phases	O
.	O

Results	O
showed	O
that	O
addition	O
of	O
β	B-T103
-	I-T103
TCP	I-T103
particles	B-T103
to	O
the	O
elastomer	B-T103
matrix	I-T103
after	O
the	O
polymerization	O
led	O
to	O
an	O
increase	O
in	O
compression	O
strength	O
(	O
up	O
to	O
14±2	O
.	O
3MPa	O
)	O
.	O

Tensile	O
strength	O
(	O
σ	O
)	O
,	O
Young	O
'	O
s	O
modulus	O
(	O
E	O
)	O
,	O
and	O
elongation	O
at	O
break	O
(	O
%	O
)	O
values	O
were	O
calculated	O
as	O
0	O
.	O
29±0	O
.	O
03MPa	O
and	O
0	O
.	O
21±0	O
.	O
03	O
;	O
0	O
.	O
38±0	O
.	O
02	O
and	O
1	O
.	O
95±0	O
.	O
4	O
;	O
and	O
240±50	O
%	O
and	O
24±2	O
%	O
for	O
PGS	B-T103
and	O
PGS	B-T103
/	O
β	B-T103
-	I-T103
TCP	I-T103
bi	B-T103
-	I-T103
layered	I-T103
constructs	I-T103
,	O
respectively	O
.	O

Morphology	B-T082
was	O
characterized	O
by	O
using	O
Scanning	B-T058
Electron	I-T058
Microscopy	I-T058
(	O
SEM	B-T058
)	O
and	O
micro	B-T058
-	I-T058
computed	I-T058
tomography	I-T058
(	O
μ	B-T058
-	I-T058
CT	I-T058
)	O
.	O

Tomography	B-T058
data	O
revealed	O
an	O
open	O
porosity	O
of	O
35	O
%	O
for	O
the	O
construct	B-T103
,	O
mostly	O
contributed	O
from	O
the	O
ceramic	O
phase	O
since	O
the	O
elastomer	B-T103
side	B-T082
has	O
no	O
pore	O
.	O

Homogeneous	O
β	B-T103
-	I-T103
TCP	I-T103
distribution	O
within	O
the	O
elastomeric	B-T082
structure	I-T082
was	O
observed	O
.	O

Cell	O
culture	O
studies	O
confirmed	O
biocompatibility	O
with	O
poor	O
elastomer	B-T103
-	O
side	B-T082
and	O
good	O
bone	B-T017
-	O
side	B-T082
cell	B-T017
attachment	I-T017
.	O

In	O
a	O
further	O
study	O
to	O
investigate	O
the	O
osteogenic	B-T017
properties	O
,	O
the	O
construct	B-T103
were	O
loaded	O
with	O
BMP	B-T103
-	I-T103
2	I-T103
and	O
/	O
or	O
TGF	B-T103
-	I-T103
β1	I-T103
.	O

The	O
PGS	B-T103
/	O
β	B-T103
-	I-T103
TCP	I-T103
bi	B-T103
-	I-T103
layered	I-T103
constructs	I-T103
with	O
improved	O
mechanical	O
and	O
biological	O
properties	O
have	O
the	O
potential	O
to	O
be	O
used	O
in	O
bone	O
-	O
soft	O
tissue	O
interface	O
applications	O
where	O
soft	B-T017
tissue	I-T017
penetration	O
is	O
a	O
problem	B-T033
.	O

Effects	O
of	O
high	O
-	O
intensity	O
training	O
on	O
cardiovascular	O
risk	O
factors	O
in	O
premenopausal	B-T033
and	O
postmenopausal	B-T033
women	B-T098

Menopause	B-T038
is	O
associated	O
with	O
increased	O
risk	O
of	O
cardiovascular	B-T038
disease	I-T038
and	O
the	O
causal	O
factors	O
have	O
been	O
proposed	O
to	O
be	O
the	O
loss	O
of	O
estrogen	B-T103
and	O
the	O
subsequent	O
alterations	O
of	O
the	O
hormonal	B-T103
milieu	I-T103
.	O

However	O
,	O
which	O
factors	O
contribute	O
to	O
the	O
deterioration	O
of	O
cardiometabolic	O
health	O
in	O
postmenopausal	B-T033
women	B-T098
is	O
debated	O
as	O
the	O
menopausal	B-T038
transition	O
is	O
also	O
associated	O
with	O
increased	O
age	O
and	O
fat	O
mass	O
.	O

Furthermore	O
,	O
indications	O
of	O
reduced	O
cardiometabolic	O
adaptations	B-T038
to	O
exercise	O
in	O
postmenopausal	B-T033
women	B-T098
add	O
to	O
the	O
adverse	B-T038
health	O
profile	O
.	O

We	O
sought	O
to	O
evaluate	B-T058
risk	B-T033
factors	I-T033
for	O
type	B-T038
2	I-T038
diabetes	I-T038
and	O
cardiovascular	B-T038
disease	I-T038
in	O
late	O
premenopausal	B-T033
and	O
early	O
postmenopausal	B-T033
women	B-T098
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
high	O
-	O
intensity	O
training	O
.	O

A	O
3	O
-	O
month	O
high	O
-	O
intensity	O
aerobic	O
training	O
intervention	B-T058
,	O
involving	O
healthy	O
,	O
nonobese	B-T033
,	O
late	O
premenopausal	B-T033
(	O
n	O
=	O
40	O
)	O
and	O
early	O
postmenopausal	B-T033
(	O
n	O
=	O
39	O
)	O
women	B-T098
was	O
conducted	O
and	O
anthropometrics	B-T201
,	O
body	O
composition	O
,	O
blood	B-T038
pressure	I-T038
,	O
lipid	O
profile	O
,	O
glucose	O
tolerance	O
,	O
and	O
maximal	B-T201
oxygen	I-T201
consumption	I-T201
were	O
determined	O
at	O
baseline	O
and	O
after	O
the	O
intervention	B-T058
.	O

At	O
baseline	O
,	O
the	O
groups	B-T098
matched	O
in	O
anthropometrics	B-T201
and	O
body	O
composition	O
,	O
and	O
only	O
differed	O
by	O
4	O
.	O
2	O
years	O
in	O
age	O
(	O
mean	O
[	O
95	O
%	O
confidence	O
limits	O
]	O
49	O
.	O
2	O
[	O
48	O
.	O
5	O
-	O
49	O
.	O
9	O
]	O
vs	O
53	O
.	O
4	O
[	O
52	O
.	O
4	O
-	O
54	O
.	O
4	O
]	O
years	O
)	O
.	O

Time	O
since	O
last	O
menstrual	B-T038
period	I-T038
for	O
the	O
postmenopausal	B-T033
women	B-T098
was	O
(	O
mean	O
[	O
95	O
%	O
confidecnce	O
limits	O
]	O
3	O
.	O
1	O
[	O
2	O
.	O
6	O
-	O
3	O
.	O
7	O
]	O
years	O
)	O
.	O

Hormonal	B-T033
levels	I-T033
(	O
estrogen	B-T103
,	O
follicle	B-T103
stimulation	I-T103
hormone	I-T103
,	O
luteinizing	B-T103
hormone	I-T103
)	O
confirmed	O
menopausal	B-T201
status	I-T201
.	O

At	O
baseline	O
the	O
postmenopausal	B-T033
women	B-T098
had	O
higher	O
total	B-T103
cholesterol	I-T103
(	O
P	O
<	O
.	O
001	O
)	O
,	O
low	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
-	I-T103
cholesterol	I-T103
(	O
P	O
<	O
.	O
05	O
)	O
,	O
and	O
high	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
-	I-T103
cholesterol	I-T103
(	O
P	O
<	O
.	O
001	O
)	O
than	O
the	O
premenopausal	B-T033
women	B-T098
.	O

The	O
training	O
intervention	B-T058
reduced	O
body	O
weight	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
waist	B-T201
circumference	I-T201
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
improved	B-T033
body	O
composition	O
by	O
increasing	O
lean	B-T201
body	I-T201
mass	I-T201
(	O
P	O
<	O
.	O
001	O
)	O
and	O
decreasing	B-T033
fat	O
mass	O
(	O
P	O
<	O
.	O
001	O
)	O
similarly	O
in	O
both	O
groups	B-T098
.	O

Moreover	O
,	O
training	O
resulted	O
in	O
lower	B-T033
diastolic	I-T033
blood	I-T033
pressure	I-T033
(	O
P	O
<	O
.	O
05	O
)	O
,	O
resting	B-T033
heart	I-T033
rate	I-T033
(	O
P	O
<	O
.	O
001	O
)	O
,	O
total	B-T103
cholesterol	I-T103
(	O
P	O
<	O
.	O
01	O
)	O
,	O
low	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
-	I-T103
cholesterol	I-T103
(	O
P	O
<	O
.	O
01	O
)	O
,	O
total	B-T103
cholesterol	I-T103
/	O
high	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
-	I-T103
cholesterol	I-T103
index	O
(	O
P	O
<	O
.	O
01	O
)	O
,	O
and	O
improved	B-T033
plasma	B-T058
insulin	I-T058
concentration	I-T058
during	O
the	O
oral	B-T058
glucose	I-T058
tolerance	I-T058
test	I-T058
(	O
P	O
<	O
.	O
05	O
)	O
in	O
both	O
groups	B-T098
.	O

Cardiovascular	O
risk	O
factors	O
are	O
similar	O
in	O
late	O
premenopausal	B-T033
and	O
early	O
postmenopausal	B-T033
women	B-T098
,	O
matched	O
by	O
age	O
and	O
body	O
composition	O
,	O
with	O
the	O
exception	O
that	O
postmenopausal	B-T033
women	B-T098
have	O
higher	O
high	B-T058
-	I-T058
and	O
low	B-T058
-	I-T058
density	I-T058
lipoprotein	I-T058
-	I-T058
cholesterol	I-T058
levels	I-T058
.	O

A	O
3	O
-	O
month	O
intervention	B-T058
of	O
high	O
-	O
intensity	O
aerobic	O
training	O
reduces	O
risk	B-T033
factors	I-T033
for	O
type	B-T038
2	I-T038
.	I-T038
diabetes	I-T038
and	O
cardiovascular	B-T038
disease	I-T038
to	O
a	O
similar	O
extent	O
in	O
late	O
premenopausal	B-T033
and	O
early	O
postmenopausal	B-T033
women	B-T098
.	O

Correlation	O
between	O
preoperative	O
physical	B-T033
signs	I-T033
and	O
functional	O
outcomes	O
after	O
laminoplasty	B-T058
for	O
ossification	B-T038
of	I-T038
the	I-T038
posterior	I-T038
longitudinal	I-T038
ligament	I-T038

Ossification	B-T038
of	I-T038
the	I-T038
posterior	I-T038
longitudinal	I-T038
ligament	I-T038
(	O
OPLL	B-T038
)	O
can	O
cause	O
myelopathy	B-T038
that	O
is	O
often	O
managed	O
surgically	B-T058
.	O

Knowledge	B-T038
of	O
predictors	O
of	O
surgical	B-T058
outcomes	O
can	O
provide	O
decision	O
support	O
to	O
surgeons	B-T097
.	O

The	O
aims	O
of	O
this	O
study	B-T062
were	O
to	O
investigate	O
the	O
relationships	O
between	O
preoperative	O
physical	B-T033
signs	I-T033
and	O
postoperative	O
functional	O
outcomes	O
in	O
patients	O
with	O
OPLL	B-T038
and	O
to	O
clarify	O
whether	O
physical	B-T033
signs	I-T033
could	O
predict	O
functional	O
outcomes	O
.	O

Fifty	O
-	O
five	O
patients	O
with	O
OPLL	B-T038
who	O
had	O
undergone	O
cervical	B-T058
laminoplasty	I-T058
were	O
included	O
in	O
this	O
study	B-T062
.	O

Six	O
physical	B-T033
signs	I-T033
including	O
hyperreflexia	B-T033
,	O
Babinski	B-T033
sign	I-T033
,	O
sensory	B-T038
disturbance	I-T038
,	O
grip	O
strength	O
,	O
10	O
-	O
s	O
grip	O
and	O
release	O
test	O
,	O
and	O
bladder	B-T038
dysfunction	I-T038
,	O
and	O
four	O
other	O
factors	O
including	O
age	O
,	O
duration	O
of	O
symptoms	O
,	O
history	O
of	O
minor	B-T037
trauma	I-T037
and	O
preoperative	O
Japanese	O
Orthopaedic	O
Association	O
(	O
JOA	O
)	O
score	O
were	O
investigated	O
as	O
potential	O
predictive	O
prognostic	B-T201
factors	I-T201
using	O
both	O
univariate	O
and	O
multivariate	O
analyses	O
.	O

The	O
mean	O
recovery	O
rate	O
of	O
JOA	O
score	O
was	O
62	O
.	O
5	O
±	O
32	O
.	O
5	O
%	O
.	O

The	O
neurological	O
recovery	O
rate	O
was	O
negatively	B-T033
associated	O
with	O
age	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
the	O
duration	O
of	O
symptoms	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
and	O
Babinski	B-T033
sign	I-T033
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
whereas	O
it	O
was	O
positively	B-T033
correlated	O
with	O
grip	O
strength	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Multiple	B-T170
logistic	I-T170
regression	I-T170
analyses	I-T170
revealed	O
that	O
age	O
(	O
Odds	O
ratio	O
:	O
0	O
.	O
89	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
81	O
-	O
0	O
.	O
99	O
)	O
and	O
Babinski	B-T033
sign	I-T033
(	O
Odds	O
ratio	O
:	O
0	O
.	O
18	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
04	O
-	O
0	O
.	O
89	O
)	O
were	O
factors	O
associated	O
with	O
functional	O
outcomes	O
.	O

Satisfactory	O
functional	O
outcomes	O
could	O
be	O
expected	B-T170
for	O
patients	O
who	O
are	O
young	O
and	O
do	O
not	O
exhibit	O
the	O
Babinski	B-T033
sign	I-T033
,	O
showing	O
that	O
the	O
Babinski	B-T033
sign	I-T033
could	O
be	O
useful	O
as	O
an	O
indicator	O
of	O
the	O
window	O
of	O
opportunity	O
for	O
achieving	O
satisfactory	O
functional	O
outcomes	O
.	O

Bacteria	B-T007
and	O
Hoverflies	B-T204
(	O
Diptera	B-T204
:	O
Syrphidae	B-T204
)	O
in	O
Tree	B-T017
Hollows	I-T017
From	O
the	O
Iberian	O
Mediterranean	O
Forest	O

Saproxylic	B-T204
insect	I-T204
communities	I-T204
inhabiting	B-T082
tree	B-T017
hollows	I-T017
in	O
Mediterranean	O
forests	O
depend	O
on	O
a	O
combination	O
of	O
physical	O
characteristics	O
and	O
interactions	O
occurring	O
between	O
community	B-T170
member	I-T170
species	I-T170
.	O

Despite	O
the	O
need	O
to	O
preserve	O
these	O
organisms	O
,	O
little	O
is	O
known	O
about	O
their	O
interrelationships	O
,	O
in	O
particular	O
those	O
relationships	O
between	O
saproxylic	B-T204
insects	I-T204
and	O
microbiota	O
occurring	O
in	O
these	O
microhabitats	B-T082
.	O

In	O
tree	B-T017
hollows	I-T017
of	O
Quercus	B-T204
rotundifolia	I-T204
Lamark	I-T204
that	O
hold	O
water	O
and	O
contain	O
dead	B-T204
leaves	I-T204
,	O
abundant	O
microbial	O
populations	O
can	O
be	O
found	O
.	O

Developing	O
on	O
them	O
are	O
the	O
larvae	B-T204
of	O
Mallota	B-T204
dusmeti	I-T204
Andréu	O
,	O
1926	O
(	O
Diptera	B-T204
:	O
Syrphidae	B-T204
)	O
,	O
a	O
vulnerable	B-T170
species	I-T170
(	O
IUCN	B-T170
category	I-T170
:	O
Marcos	B-T098
-	I-T098
García	I-T098
and	O
Quinto	B-T098
2011	O
)	O
.	O

This	O
study	O
provides	O
the	O
first	O
data	O
on	O
the	O
microbiota	O
living	B-T082
inside	I-T082
the	O
gut	B-T017
of	O
the	O
larvae	B-T204
of	O
M	B-T204
.	I-T204

dusmeti	I-T204
,	O
as	O
well	O
as	O
the	O
microbiota	O
in	O
the	O
hollow	B-T082
where	O
these	O
larvae	B-T204
develop	B-T038
.	O

Bacteria	B-T007
were	O
identified	O
by	O
amplification	O
and	O
partial	O
sequencing	O
of	O
the	O
V1	O
-	O
V3	O
regions	O
and	O
the	O
complete	O
nucleotide	B-T082
sequence	I-T082
of	O
16S	B-T103
rRNA	I-T103
genes	I-T103
.	O

We	O
found	O
eight	O
species	B-T007
of	I-T007
bacteria	I-T007
living	B-T082
in	I-T082
tree	B-T017
hollows	I-T017
and	O
three	O
species	B-T170
in	B-T017
the	I-T017
gut	I-T017
of	O
M	B-T204
.	I-T204

dusmeti	I-T204
larvae	B-T204
:	O
Bacillus	B-T007
cereus	I-T007
,	O
Bacillus	B-T007
toyonensis	I-T007
,	O
and	O
Lysinibacillus	B-T007
sphaericus	I-T007
The	O
filter	B-T033
-	I-T033
feeding	I-T033
mechanism	I-T033
characteristic	I-T033
of	O
M	B-T204
.	I-T204

dusmeti	I-T204
larvae	B-T204
is	O
selective	O
in	O
enabling	O
ingestion	B-T038
of	O
bacteria	B-T007
only	O
above	O
2	O
.	O
1	O
µm	O
in	O
diameter	O
.	O

Impact	O
sports	O
and	O
bone	B-T037
fractures	I-T037
among	O
adolescents	O

The	O
objective	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
investigate	O
the	O
effects	O
of	O
different	O
sports	O
on	O
stress	B-T037
fractures	I-T037
among	O
adolescents	O
during	O
a	O
9	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O

The	O
sample	B-T098
was	O
composed	O
of	O
184	O
adolescents	O
divided	O
into	O
three	O
groups	B-T098
(	O
impact	O
sports	O
[	O
n	O
=	O
102	O
]	O
;	O
swimming	O
[	O
n	O
=	O
35	O
]	O
;	O
non	O
-	O
sports	O
[	O
n	O
=	O
47	O
]	O
)	O
.	O

The	O
occurrence	O
of	O
stress	B-T037
fracture	I-T037
was	O
reported	O
by	O
participants	B-T098
and	O
coaches	B-T097
.	O

As	O
potential	O
confounders	O
we	O
considered	O
age	O
,	O
sex	O
,	O
resistance	B-T058
training	I-T058
,	O
body	O
composition	O
variables	O
and	O
age	O
at	O
peak	O
of	O
height	O
velocity	O
.	O

There	O
were	O
13	O
adolescents	O
who	O
reported	O
fractures	B-T037
during	O
the	O
9	O
-	O
month	O
period	O
.	O

Bone	B-T201
mineral	I-T201
density	I-T201
values	O
were	O
higher	O
in	O
adolescents	O
engaged	O
in	O
impact	O
sports	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
002	O
)	O
.	O

Independently	O
of	O
confounders	O
,	O
the	O
risk	O
of	O
stress	B-T037
fracture	I-T037
was	O
lower	O
in	O
adolescents	O
engaged	O
in	O
impact	O
sports	O
than	O
in	O
non	O
-	O
active	O
adolescents	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0	O
.	O
23	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0	O
.	O
05	O
to	O
0	O
.	O
98	O
]	O
)	O
,	O
while	O
swimming	O
practice	B-T038
was	O
not	O
associated	O
to	O
lower	O
risk	O
of	O
fracture	B-T037
(	O
HR	O
=	O
0	O
.	O
49	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
09	O
to	O
2	O
.	O
55	O
]	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
findings	B-T033
from	O
this	O
study	B-T062
indicate	O
the	O
importance	O
of	O
sports	O
participation	O
among	O
adolescents	O
in	O
the	O
reduction	O
of	O
stress	B-T037
fracture	I-T037
risk	O
,	O
especially	O
with	O
impact	O
sports	O
.	O

More	O
importantly	O
,	O
these	O
results	O
could	O
be	O
relevant	O
for	O
recognising	O
adolescents	O
in	O
danger	O
of	O
not	O
reaching	O
their	O
potential	O
for	O
peak	O
bone	B-T201
mass	I-T201
and	O
later	O
an	O
increased	O
risk	O
of	O
fractures	B-T037
.	O

The	O
Business	O
of	O
Health	B-T091
Physics	I-T091
-	O
Jobs	O
In	O
A	O
Changing	O
Market	O

The	O
health	B-T091
physics	I-T091
profession	O
was	O
born	O
abruptly	O
when	O
once	O
rare	O
and	O
precious	O
radioactive	B-T103
materials	I-T103
became	O
commonplace	O
.	O

The	O
technological	O
advancements	O
that	O
triggered	O
an	O
industrial	O
complex	O
and	O
ended	O
World	O
War	O
II	O
demanded	O
radiation	O
safety	O
on	O
an	O
unprecedented	B-T170
scale	I-T170
.	O

Until	O
then	O
,	O
protective	O
measures	O
against	O
radiation	O
were	O
largely	O
absent	O
in	O
laboratories	B-T092
.	O

Over	O
the	O
subsequent	O
decades	O
,	O
health	B-T097
physicists	I-T097
began	O
protecting	B-T058
people	I-T058
and	O
the	O
environment	O
in	O
a	O
wide	O
range	O
of	O
settings	O
including	O
medical	B-T058
,	O
research	B-T062
,	O
and	O
industrial	O
.	O

The	O
use	O
of	O
radioactive	O
materials	O
and	O
radiation	O
-	O
generating	O
devices	O
is	O
prevalent	B-T082
today	I-T082
.	O

Radiation	O
doses	O
occur	O
continuously	O
including	O
during	O
airline	O
flights	O
,	O
in	O
our	O
homes	O
,	O
during	O
medical	B-T058
procedures	I-T058
,	O
and	O
in	O
energy	O
production	O
.	O

Radiation	O
is	O
integral	O
to	O
numerous	O
applications	O
including	O
those	O
in	O
medicine	B-T091
,	O
dentistry	B-T091
,	O
manufacturing	O
,	O
construction	O
,	O
scientific	O
research	O
,	O
nuclear	O
electric	O
power	O
generation	O
,	O
and	O
oil	O
and	O
gas	O
exploration	O
.	O

Activities	O
that	O
were	O
once	O
groundbreaking	O
have	O
now	O
become	O
routine	O
and	O
scripted	B-T170
.	O

At	O
higher	O
doses	O
,	O
health	O
effects	O
are	O
understood	O
and	O
avoided	O
.	O

Instruments	B-T074
for	I-T074
the	I-T074
detection	I-T074
and	I-T074
measurement	I-T074
of	I-T074
radiation	I-T074
are	O
at	O
times	O
smarter	O
than	O
their	O
users	O
.	O

Ironically	O
,	O
the	O
same	O
health	B-T091
physics	I-T091
community	O
that	O
has	O
been	O
successful	O
in	O
demonstrating	O
that	O
exposures	B-T037
to	I-T037
radiation	I-T037
and	O
to	O
radioactive	B-T103
materials	I-T103
can	O
be	O
effectively	B-T058
managed	I-T058
is	O
shrinking	O
at	O
an	O
increasingly	O
rapid	O
rate	O
.	O

This	O
paper	O
highlights	O
the	O
creation	O
of	O
past	O
and	O
current	O
jobs	O
,	O
predicts	O
the	O
future	O
opportunities	O
in	O
the	O
profession	O
,	O
and	O
makes	O
recommendations	O
necessary	O
to	O
protect	O
the	O
disappearing	B-T091
specialties	I-T091
.	O

Permanence	O
can	O
be	O
Defended	O

In	O
donation	O
after	O
the	O
circulatory	B-T058
-	I-T058
respiratory	I-T058
determination	I-T058
of	I-T058
death	I-T058
(	O
DCDD	B-T058
)	O
,	O
the	O
dead	B-T038
donor	B-T098
rule	B-T170
requires	O
that	O
the	O
donor	B-T098
be	O
dead	B-T038
before	O
organ	B-T058
procurement	I-T058
can	O
proceed	O
.	O

Under	O
the	O
relevant	O
limb	O
of	O
the	O
Uniform	B-T170
Determination	I-T170
of	I-T170
Death	I-T170
Act	I-T170
1981	I-T170
(	I-T170
USA	I-T170
)	I-T170
,	O
a	O
person	B-T098
is	O
dead	B-T038
when	O
the	O
cessation	O
of	O
circulatory	O
-	O
respiratory	O
function	O
is	O
'	O
irreversible	B-T033
'	O
.	O

Critics	B-T097
of	O
current	O
practice	B-T038
in	O
DCDD	B-T058
have	O
argued	O
that	O
the	O
donor	B-T098
is	O
not	O
dead	B-T038
at	O
the	O
time	O
organs	B-T017
are	O
procured	B-T058
,	O
and	O
so	O
the	O
procurement	B-T058
of	I-T058
organs	I-T058
from	O
these	O
donors	B-T098
violates	O
the	O
dead	B-T038
donor	B-T098
rule	B-T170
.	O

We	O
offer	B-T033
a	O
new	O
argument	O
here	O
in	O
defence	O
of	O
current	O
DCDD	B-T058
practice	B-T038
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
the	O
interpretation	B-T170
of	O
the	O
requirement	O
of	O
'	O
irreversibility	B-T033
'	O
as	O
permanence	O
.	O

Untypeable	O
hepatitis	B-T005
C	I-T005
virus	I-T005
subtypes	B-T170
in	O
Pakistan	B-T082
:	O
A	O
neglected	O
section	O

Diagnostically	O
untypeable	O
subtypes	B-T170
contribute	O
a	O
considerable	O
percent	O
of	O
hepatitis	B-T005
C	I-T005
virus	I-T005
(	O
HCV	B-T005
)	O
subtypes	B-T170
in	O
Pakistan	B-T082
.	O

In	O
the	O
present	O
study	B-T062
,	O
chronically	B-T038
infected	I-T038
HCV	B-T005
patients	O
with	O
known	O
viremia	B-T038
were	O
subjected	O
to	O
HCV	B-T005
genotyping	O
.	O

Among	O
the	O
total	O
retrieved	O
samples	O
,	O
92	O
.	O
7	O
%	O
(	O
64	O
/	O
69	O
)	O
were	O
found	O
typeable	O
while	O
7	O
.	O
24	O
%	O
(	O
5	O
/	O
69	O
)	O
were	O
diagnostically	O
untypeable	O
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
large	O
number	O
of	O
untypeable	O
HCV	B-T005
subtypes	B-T170
emphasizes	O
the	O
need	O
of	O
an	O
updated	O
type	O
-	O
specific	O
genotyping	O
assay	B-T058
and	O
consideration	O
of	O
primers	B-T103
for	O
proportionally	O
rare	O
subtypes	B-T170
to	O
minimize	O
the	O
number	O
of	O
untypeable	O
HCV	B-T005
subtypes	B-T170
.	O

ITPR3	B-T017
gene	I-T017
haplotype	O
is	O
associated	O
with	O
cervical	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
risk	O
in	O
Taiwanese	B-T098
women	B-T098

Host	B-T091
immunogenetic	I-T091
background	O
plays	O
an	O
important	O
role	O
in	O
human	B-T038
papillomavirus	I-T038
(	I-T038
HPV	I-T038
)	I-T038
infection	I-T038
and	O
cervical	B-T038
cancer	I-T038
development	I-T038
.	O

Inositol	B-T017
1	I-T017
,	I-T017
4	I-T017
,	I-T017
5	I-T017
-	I-T017
triphosphate	I-T017
receptor	I-T017
type	I-T017
3	I-T017
(	O
ITPR3	B-T017
)	O
is	O
essential	O
for	O
both	O
immune	B-T038
activation	I-T038
and	O
cancer	B-T038
pathogenesis	B-T038
.	O

We	O
aim	O
to	O
investigate	O
if	O
ITPR3	B-T017
genetic	B-T038
polymorphisms	I-T038
are	O
associated	O
with	O
the	O
risk	O
of	O
cervical	O
cancer	O
in	O
Taiwanese	B-T098
women	B-T098
.	O

ITPR3	B-T017
rs3748079	B-T082
A	I-T082
/	I-T082
G	I-T082
and	O
rs2229634	B-T082
C	I-T082
/	I-T082
T	I-T082
polymorphisms	I-T082
were	O
genotyped	O
in	O
a	O
hospital	B-T062
-	I-T062
based	I-T062
study	I-T062
of	O
462	O
women	B-T098
with	O
cervical	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
CSCC	B-T038
)	O
and	O
921	O
age	O
-	O
matched	O
healthy	O
control	O
women	B-T098
.	O

The	O
presence	O
and	O
genotypes	O
of	O
HPV	B-T005
in	O
CSCC	B-T038
was	O
determined	O
.	O

No	O
significant	O
association	O
of	O
individual	O
ITPR3	B-T017
variants	B-T017
were	O
found	O
among	O
controls	O
,	O
CSCC	B-T038
,	O
and	O
HPV	B-T033
-	I-T033
16	I-T033
positive	I-T033
CSCC	B-T038
.	O

However	O
,	O
we	O
found	O
a	O
significant	O
association	O
of	O
haplotype	O
AT	O
between	O
CSCC	B-T038
and	O
controls	O
(	O
OR	O
=	O
2	O
.	O
28	O
,	O
95	O
%	O
CI	O
1	O
.	O
31	O
-	O
3	O
.	O
97	O
,	O
P	O
=	O
2	O
.	O
83	O
×	O
10	O
-	O
3	O
)	O
and	O
the	O
OR	O
increased	O
further	O
in	O
CSCC	B-T038
patients	O
infected	O
with	O
HPV	B-T005
-	I-T005
16	I-T005
(	O
OR	O
=	O
2	O
.	O
89	O
,	O
95	O
%	O
CI	O
1	O
.	O
55	O
-	O
5	O
.	O
37	O
,	O
P	O
=	O
4	O
.	O
54	O
×	O
10	O
-	O
4	O
)	O
.	O

The	O
linkage	B-T062
disequilibrium	I-T062
analysis	I-T062
demonstrated	O
that	O
ITPR3	B-T017
association	B-T062
with	O
CSCC	B-T038
was	O
independent	O
of	O
HLA	B-T017
-	I-T017
DRB1	I-T017
alleles	B-T017
.	O

In	O
conclusion	O
,	O
these	O
findings	O
suggest	O
that	O
AT	O
haplotype	O
in	O
the	O
ITPR3	B-T017
gene	I-T017
may	O
serve	O
as	O
a	O
potential	B-T038
marker	I-T038
for	O
genetic	O
susceptibility	O
to	O
CSCC	B-T038
.	O

Defining	O
categories	B-T170
of	O
actionability	O
for	O
secondary	O
findings	B-T033
in	O
next	B-T058
-	I-T058
generation	I-T058
sequencing	I-T058

Next	B-T058
-	I-T058
generation	I-T058
sequencing	I-T058
is	O
increasingly	O
used	O
in	O
clinical	O
practice	O
for	O
the	O
diagnosis	B-T033
of	O
Mendelian	B-T038
diseases	I-T038
.	O

Because	O
of	O
the	O
high	O
likelihood	O
of	O
secondary	O
findings	B-T033
associated	O
with	O
this	O
technique	O
,	O
the	O
process	O
of	O
informing	B-T058
patients	I-T058
is	O
beset	O
with	O
new	O
challenges	O
.	O

One	O
of	O
them	O
is	O
regarding	O
the	O
type	O
of	O
secondary	O
findings	B-T033
that	O
ought	O
to	O
be	O
disclosed	O
to	O
patients	O
.	O

The	O
aim	O
of	O
this	O
research	B-T062
is	O
to	O
propose	O
a	O
practical	O
implementation	O
of	O
the	O
notion	O
of	O
actionability	O
,	O
a	O
common	O
criteria	O
justifying	O
the	O
disclosure	O
of	O
secondary	O
findings	B-T033
but	O
whose	O
interpretation	B-T170
varies	O
greatly	O
among	O
professionals	B-T097
.	O

We	O
distinguish	O
three	O
types	O
of	O
actionability	O
corresponding	O
to	O
(	O
1	O
)	O
well	O
-	O
established	O
medical	O
actions	O
,	O
(	O
2	O
)	O
patient	O
-	O
initiated	O
health	O
-	O
related	O
actions	O
and	O
(	O
3	O
)	O
life	B-T038
-	I-T038
plan	I-T038
decisions	I-T038
.	O

We	O
argue	O
that	O
actionability	O
depends	O
on	O
the	O
characteristics	O
of	O
the	O
mutation	B-T038
or	O
gene	B-T017
and	O
on	O
the	O
values	O
of	O
patients	O
.	O

In	O
discussing	O
the	O
return	O
of	O
secondary	O
findings	B-T033
,	O
it	O
is	O
important	O
that	O
the	O
physician	B-T097
tries	O
to	O
get	O
an	O
impression	O
of	O
the	O
specific	O
situation	O
and	O
values	O
of	O
patients	O
.	O

Regarding	O
variants	B-T017
of	O
uncertain	O
clinical	B-T033
significance	I-T033
in	O
actionable	O
genes	B-T017
,	O
we	O
found	O
that	O
different	O
understandings	O
of	O
autonomy	O
lead	O
to	O
different	O
conclusions	O
and	O
that	O
,	O
for	O
some	O
of	O
them	O
,	O
it	O
may	O
be	O
legitimate	O
to	O
refrain	O
from	O
returning	O
uncertain	O
information	O
.	O

Allergen	B-T103
Valency	O
,	O
Dose	O
,	O
and	O
FcεRI	B-T103
Occupancy	O
Set	O
Thresholds	O
for	O
Secretory	B-T038
Responses	I-T038
to	O
Pen	B-T103
a	I-T103
1	I-T103
and	O
Motivate	O
Design	O
of	O
Hypoallergens	B-T103

Ag	B-T103
-	O
mediated	O
crosslinking	O
of	O
IgE	B-T103
-	O
FcεRI	B-T103
complexes	B-T103
activates	O
mast	B-T017
cells	I-T017
and	O
basophils	B-T017
,	O
initiating	O
the	O
allergic	B-T038
response	I-T038
.	O

Of	O
34	O
donors	O
recruited	O
having	O
self	B-T062
-	I-T062
reported	I-T062
shrimp	B-T038
allergy	I-T038
,	O
only	O
35	O
%	O
had	O
significant	O
levels	O
of	O
shrimp	B-T103
-	I-T103
specific	I-T103
IgE	I-T103
in	O
serum	B-T031
and	O
measurable	O
basophil	B-T017
secretory	B-T038
responses	B-T038
to	O
rPen	O
a	O
1	O
(	O
shrimp	B-T204
tropomyosin	B-T103
)	O
.	O

We	O
report	O
that	O
degranulation	O
is	O
linked	O
to	O
the	O
number	O
of	O
FcεRI	B-T103
occupied	O
with	O
allergen	B-T103
-	I-T103
specific	I-T103
IgE	I-T103
,	O
as	O
well	O
as	O
the	O
dose	O
and	O
valency	O
of	O
Pen	B-T103
a	I-T103
1	I-T103
.	O

Using	O
clustered	B-T062
regularly	I-T062
interspaced	I-T062
palindromic	I-T062
repeat	I-T062
-	I-T062
based	I-T062
gene	I-T062
editing	I-T062
,	O
human	O
RBL	O
(	O
rαKO	O
)	O
cells	O
were	O
created	O
that	O
exclusively	O
express	O
the	O
human	O
FcεRIα	B-T103
subunit	O
.	O

Pen	B-T103
a	I-T103
1	I-T103
-	O
specific	B-T103
IgE	I-T103
was	O
affinity	O
purified	O
from	O
shrimp	B-T204
-	O
positive	B-T033
plasma	B-T031
.	O

Cells	O
primed	O
with	O
a	O
range	O
of	O
Pen	B-T103
a	I-T103
1	I-T103
-	O
specific	B-T103
IgE	I-T103
and	O
challenged	O
with	O
Pen	B-T103
a	I-T103
1	I-T103
showed	O
a	O
bell	O
-	O
shaped	O
dose	O
response	B-T038
for	I-T038
secretion	I-T038
,	O
with	O
optimal	O
Pen	B-T103
a	I-T103
1	I-T103
doses	O
of	O
0	O
.	O
1	O
-	O
10	O
ng	O
/	O
ml	O
.	O

Mathematical	B-T170
modeling	I-T170
provided	O
estimates	O
of	O
receptor	B-T038
aggregation	I-T038
kinetics	O
based	O
on	O
FcεRI	B-T103
occupancy	O
with	O
IgE	B-T103
and	O
allergen	B-T103
dose	O
.	O

Maximal	O
degranulation	O
was	O
elicited	O
when	O
∼2700	O
I	O
gE	B-T103
-	O
FcεRI	B-T103
complexes	B-T103
were	O
occupied	O
with	O
specific	B-T103
IgE	I-T103
and	O
challenged	O
with	O
Pen	B-T103
a	I-T103
1	I-T103
(	O
IgE	B-T103
epitope	B-T103
valency	O
of	O
≥8	O
)	O
,	O
although	O
measurable	O
responses	O
were	O
achieved	O
when	O
only	O
a	O
few	O
hundred	O
FcεRI	B-T103
were	O
occupied	O
.	O

Prolonged	O
periods	O
of	O
pepsin	B-T103
-	O
mediated	O
Pen	B-T103
a	I-T103
1	I-T103
proteolysis	B-T038
,	O
which	O
simulates	O
gastric	O
digestion	B-T038
,	O
were	O
required	O
to	O
diminish	O
secretory	B-T038
responses	I-T038
.	O

Recombinant	O
fragments	O
(	O
60	O
-	O
79	O
aa	O
)	O
,	O
which	O
together	O
span	O
the	O
entire	O
length	O
of	O
tropomyosin	B-T103
,	O
were	O
weak	O
secretagogues	O
.	O

These	O
fragments	O
have	O
reduced	O
dimerization	B-T038
capacity	O
,	O
compete	O
with	O
intact	O
Pen	B-T103
a	I-T103
1	I-T103
for	O
binding	O
to	O
IgE	B-T103
-	O
FcεRI	B-T103
complexes	B-T103
,	O
and	O
represent	O
a	O
starting	O
point	O
for	O
the	O
design	O
of	O
promising	O
hypoallergens	B-T103
for	O
immunotherapy	B-T058
.	O

Selected	O
flavonoid	B-T103
compounds	I-T103
as	O
promising	O
inhibitors	B-T103
of	O
protein	B-T103
kinase	I-T103
CK2α	B-T103
and	O
CK2α	B-T103
'	I-T103
,	O
the	O
catalytic	B-T082
subunits	I-T082
of	O
CK2	B-T103

CK2	B-T103
is	O
a	O
ubiquitous	O
protein	B-T103
kinase	I-T103
involved	O
in	O
many	O
cell	B-T038
functions	I-T038
.	O

During	O
the	O
last	O
years	O
it	O
became	O
an	O
interesting	O
target	O
in	O
cancer	B-T062
research	I-T062
.	O

A	O
series	O
of	O
flavonoid	B-T103
compounds	I-T103
was	O
tested	O
as	O
inhibitors	B-T103
of	O
protein	B-T103
kinase	I-T103
CK2	B-T103
.	O

Several	O
substances	O
were	O
found	O
to	O
be	O
highly	O
active	O
against	O
both	O
catalytic	B-T082
subunits	I-T082
with	O
IC50	O
values	O
below	O
1	O
μM	O
in	O
case	O
of	O
CK2α	B-T103
'	I-T103
.	O

The	O
most	O
promising	O
inhibitor	B-T103
we	O
identified	O
is	O
chrysoeriol	B-T103
with	O
IC50	O
values	O
of	O
250	O
and	O
34	O
nM	O
for	O
CK2α	B-T103
and	O
CK2α	B-T103
'	I-T103
,	O
respectively	O
.	O

Fibrinogen	B-T103
:	O
A	O
Marker	B-T201
in	O
Predicting	O
Diabetic	B-T038
Foot	I-T038
Ulcer	I-T038
Severity	O

Aims	O
.	O

To	O
examine	B-T058
whether	O
fibrinogen	B-T033
levels	I-T033
are	O
a	O
valuable	O
biomarker	B-T201
for	O
assessing	B-T058
disease	O
severity	O
and	O
monitoring	B-T058
disease	B-T038
progression	I-T038
in	O
patients	O
with	O
diabetic	B-T038
foot	I-T038
ulcer	I-T038
(	O
DFU	B-T038
)	O
.	O

Methods	O
.	O

A	O
retrospective	B-T062
study	I-T062
was	O
designed	O
to	O
examine	O
the	O
utility	O
of	O
fibrinogen	B-T103
in	O
estimating	O
disease	O
severity	O
in	O
patients	O
with	O
DFU	B-T038
admitted	B-T058
to	O
our	O
hospital	B-T092
between	O
January	O
2015	O
and	O
January	O
2016	O
.	O

In	O
total	O
,	O
152	O
patients	O
with	O
DFU	B-T038
were	O
enrolled	O
in	O
the	O
study	O
group	O
,	O
and	O
52	O
age	O
and	O
gender	O
matched	O
people	O
with	O
diabetes	B-T038
but	O
no	O
DFU	B-T038
were	O
included	O
as	O
the	O
control	O
group	O
.	O

DFU	B-T038
severity	O
was	O
assessed	O
using	O
Wagner	O
criteria	O
.	O

Results	O
.	O

Patients	O
with	O
DFU	B-T038
were	O
divided	O
into	O
2	O
subgroups	B-T170
based	O
on	O
the	O
Wagner	O
criteria	O
.	O

Mean	O
fibrinogen	B-T033
values	I-T033
were	O
significantly	O
higher	O
in	O
patients	O
with	O
DFU	B-T038
grade	B-T170
≧	O
3	O
compared	O
to	O
those	O
with	O
DFU	B-T038
grades	B-T170
1	O
-	O
2	O
(	O
5	O
.	O
23	O
±	O
1	O
.	O
37	O
g	O
/	O
L	O
versus	O
3	O
.	O
61	O
±	O
1	O
.	O
04	O
g	O
/	O
L	O
)	O
.	O

Using	O
ROC	O
statistic	O
,	O
a	O
cut	O
-	O
off	O
value	O
of	O
5	O
.	O
13	O
g	O
/	O
L	O
indicated	O
the	O
possible	O
amputation	B-T058
with	O
a	O
sensitivity	O
of	O
81	O
.	O
8	O
%	O
and	O
a	O
specificity	O
of	O
78	O
.	O
9	O
%	O
(	O
positive	O
predictive	O
value	O
[	O
PPV	O
]	O
78	O
.	O
6	O
%	O
,	O
negative	O
predictive	O
value	O
[	O
89	O
.	O
0	O
%	O
]	O
)	O
.	O

Fibrinogen	B-T033
values	I-T033
were	O
found	O
to	O
be	O
correlated	O
with	O
CRP	B-T033
levels	I-T033
,	O
neutrophil	B-T058
,	O
and	O
WBC	B-T058
count	I-T058
.	O

Conclusions	O
.	O

Fibrinogen	B-T033
levels	I-T033
might	O
be	O
a	O
valuable	O
tool	O
for	O
assessing	B-T058
the	O
disease	O
severity	O
and	O
monitoring	B-T058
the	O
disease	B-T038
progression	I-T038
in	O
patients	O
with	O
DFU	B-T038
.	O

Nitrogen	B-T038
utilization	I-T038
efficiency	O
and	O
prediction	O
of	O
nitrogen	B-T103
excretion	B-T038
in	O
sheep	B-T204
offered	B-T033
fresh	B-T204
perennial	I-T204
ryegrass	I-T204
(	O
)	O

Nitrogen	B-T103
excretion	B-T038
from	O
sheep	B-T204
production	B-T082
systems	I-T082
is	O
an	O
important	O
source	O
of	O
nitrate	B-T103
,	O
ammonia	B-T103
,	O
and	O
nitrous	B-T103
oxide	I-T103
responsible	O
for	O
groundwater	B-T082
pollution	O
and	O
global	O
warming	O
.	O

The	O
present	O
study	B-T062
aimed	O
to	O
identify	O
key	O
parameters	O
influencing	O
N	B-T038
utilization	I-T038
efficiency	O
and	O
develop	O
prediction	O
equations	O
for	O
manure	O
N	B-T103
,	O
feces	B-T031
N	B-T103
,	O
and	O
urine	B-T031
N	B-T103
outputs	O
in	O
sheep	B-T204
.	O

Data	O
used	O
were	O
collected	O
from	O
82	O
sheep	B-T204
offered	B-T033
fresh	B-T204
perennial	I-T204
ryegrass	I-T204
(	O
)	O
as	O
the	O
sole	B-T168
diet	I-T168
in	O
6	O
metabolism	B-T038
experiments	B-T062
(	O
data	O
from	O
non	B-T168
-	I-T168
grass	I-T168
-	I-T168
only	I-T168
diets	I-T168
were	O
not	O
used	O
)	O
.	O

Sheep	B-T204
were	O
from	O
breeds	B-T170
of	O
Highlander	B-T098
,	O
Texel	B-T204
,	O
Scottish	B-T204
Blackface	I-T204
,	O
and	O
Swaledale	B-T204
at	O
the	O
age	O
of	O
5	O
to	O
18	O
mo	O
and	O
weighing	O
from	O
24	O
.	O
5	O
to	O
62	O
.	O
7	O
kg	O
.	O

Herbage	B-T204
was	O
harvested	O
daily	O
from	O
6	O
swards	B-T204
of	O
contrasting	O
harvest	O
dates	O
(	O
May	O
to	O
December	O
)	O
,	O
offering	B-T033
wide	O
variation	O
in	O
feed	O
value	O
to	O
cover	O
the	O
range	O
that	O
would	O
be	O
offered	B-T033
in	O
most	O
practical	O
farm	B-T082
situations	I-T082
.	O

Before	O
the	O
commencement	O
of	O
each	O
study	B-T062
,	O
the	O
experimental	O
sward	B-T204
was	O
harvested	O
at	O
a	O
residual	O
height	O
of	O
4	O
cm	O
and	O
allowed	O
to	O
grow	B-T038
for	O
2	O
to	O
4	O
wk	O
to	O
target	O
an	O
average	O
pregrazing	O
sward	B-T204
height	O
in	O
a	O
range	O
of	O
8	O
to	O
15	O
cm	O
depending	O
on	O
the	O
time	O
of	O
year	O
.	O

Sheep	B-T204
were	O
housed	B-T082
in	O
individual	O
pens	O
for	O
14	O
d	O
and	O
then	O
transferred	B-T033
to	I-T033
individual	O
metabolism	B-T038
crates	O
for	O
4	O
d	O
with	O
feed	O
intake	O
and	O
feces	B-T031
and	O
urine	B-T031
outputs	O
measured	O
.	O

Data	O
were	O
analyzed	B-T062
using	O
the	O
linear	O
mixed	O
model	O
procedure	O
to	O
develop	O
prediction	O
equations	O
for	O
feces	B-T031
N	O
,	O
urine	B-T031
N	O
,	O
and	O
manure	O
N	B-T103
outputs	O
using	O
N	B-T033
intake	I-T033
,	O
herbage	B-T204
chemical	O
composition	O
,	O
and	O
digestibility	O
with	O
effects	O
of	O
sex	O
,	O
breed	B-T170
,	O
and	O
experimental	O
periods	O
removed	O
.	O

Nitrogen	B-T103
intake	O
was	O
the	O
best	O
single	O
predictor	O
for	O
N	B-T103
output	O
in	O
feces	B-T031
,	O
urine	B-T031
,	O
and	O
manure	O
,	O
and	O
the	O
value	O
for	O
prediction	O
of	O
manure	O
N	B-T103
output	O
was	O
greater	O
than	O
those	O
for	O
feces	B-T031
N	B-T103
and	O
urine	B-T031
N	B-T103
(	O
0	O
.	O
86	O
vs	O
.	O

0	O
.	O
70	O
and	O
0	O
.	O
77	O
,	O
respectively	O
;	O
<	O
0	O
.	O
001	O
)	O
.	O

Animal	B-T204
BW	O
and	O
herbage	B-T204
DM	O
,	O
ether	O
extract	O
,	O
NDF	B-T168
,	O
ADF	B-T168
,	O
water	B-T058
soluble	I-T058
carbohydrate	I-T058
,	O
and	O
DE	O
concentrations	O
and	O
N	B-T103
digestibility	O
were	O
also	O
used	O
to	O
predict	O
N	B-T103
outputs	O
because	O
N	B-T103
intake	O
may	O
not	O
be	O
available	O
in	O
commercial	O
practice	O
.	O

The	O
prediction	O
equations	O
for	O
N	B-T038
utilizatio	I-T038
n	O
efficiency	O
indicated	O
that	O
increasing	O
feeding	O
level	O
and	O
ME	O
concentration	O
and	O
reducing	O
N	B-T033
concentration	I-T033
could	O
improve	B-T033
N	B-T038
utilization	I-T038
efficiency	O
and	O
shift	O
N	B-T103
excretion	B-T038
into	O
feces	B-T031
rather	B-T033
than	I-T033
urine	B-T031
(	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
equations	O
developed	O
in	O
the	O
current	O
study	B-T062
provide	O
an	O
approach	B-T082
for	O
sheep	B-T204
producers	B-T098
to	O
quantify	O
N	B-T103
excretion	B-T038
against	O
production	O
and	O
,	O
consequently	O
,	O
to	O
develop	O
their	O
own	O
mitigation	B-T062
strategies	I-T062
to	O
reduce	O
the	O
environmental	O
impact	O
of	O
sheep	B-T204
production	B-T082
systems	I-T082
.	O

Improving	O
protein	B-T103
complex	I-T103
prediction	O
by	O
reconstructing	B-T170
a	O
high	O
-	O
confidence	O
protein	O
-	O
protein	O
interaction	O
network	O
of	O
Escherichia	B-T007
coli	I-T007
from	O
different	O
physical	O
interaction	O
data	O
sources	O

Although	O
different	O
protein	B-T038
-	I-T038
protein	I-T038
physical	I-T038
interaction	I-T038
(	O
PPI	B-T038
)	O
datasets	B-T170
exist	O
for	O
Escherichia	B-T007
coli	I-T007
,	O
no	O
common	O
methodology	O
exists	O
to	O
integrate	O
these	O
datasets	B-T170
and	O
extract	O
reliable	O
modules	O
reflecting	O
the	O
existing	O
biological	B-T038
process	I-T038
and	O
protein	B-T103
complexes	I-T103
.	O

Naïve	B-T170
Bayesian	I-T170
formula	I-T170
is	O
the	O
highly	O
accepted	O
method	O
to	O
integrate	O
different	O
PPI	B-T038
datasets	B-T170
into	O
a	O
single	O
weighted	O
PPI	O
network	O
,	O
but	O
detecting	O
proper	O
weights	O
in	O
such	O
network	O
is	O
still	O
a	O
major	O
problem	O
.	O

In	O
this	O
paper	O
,	O
we	O
proposed	O
a	O
new	O
methodology	O
to	O
integrate	O
various	O
physical	B-T038
PPI	I-T038
datasets	B-T170
into	O
a	O
single	O
weighted	O
PPI	O
network	O
in	O
a	O
way	O
that	O
the	O
detected	B-T033
modules	O
in	O
PPI	O
network	O
exhibit	O
the	O
highest	O
similarity	O
to	O
available	O
functional	O
modules	O
.	O

We	O
used	O
the	O
co	B-T058
-	I-T058
expression	I-T058
modules	O
as	O
functional	O
modules	O
,	O
and	O
we	O
shown	O
that	O
direct	O
functional	O
modules	O
detected	B-T033
from	O
Gene	B-T170
Ontology	I-T170
terms	O
could	O
be	O
used	O
as	O
an	O
alternative	O
dataset	B-T170
.	O

After	O
running	O
this	O
integrating	O
methodology	O
over	O
six	O
different	O
physical	B-T038
PPI	I-T038
datasets	B-T170
,	O
orthologous	O
high	O
-	O
confidence	O
interactions	O
from	O
a	O
related	O
organism	O
and	O
two	O
AP	B-T058
-	I-T058
MS	I-T058
PPI	B-T038
datasets	B-T170
gained	B-T033
high	I-T033
weights	I-T033
in	O
the	O
integrated	O
networks	O
,	O
while	O
the	O
weights	O
for	O
one	O
AP	B-T058
-	I-T058
MS	I-T058
PPI	B-T038
dataset	B-T170
and	O
two	O
other	O
datasets	B-T170
derived	O
from	O
public	B-T170
databases	I-T170
have	O
converged	O
to	O
zero	O
.	O

The	O
majority	O
of	O
detected	B-T033
modules	O
shaped	O
around	O
one	O
or	O
few	O
hub	B-T103
protein	I-T103
(	I-T103
s	I-T103
)	I-T103
.	O

Still	O
,	O
a	O
large	O
number	O
of	O
highly	O
interacting	O
protein	B-T103
modules	O
were	O
detected	B-T033
which	O
are	O
functionally	O
relevant	O
and	O
are	O
likely	O
to	O
construct	B-T170
protein	B-T103
complexes	I-T103
.	O

We	O
provided	O
a	O
new	O
high	O
confidence	O
protein	B-T103
complex	I-T103
prediction	O
method	O
supported	O
by	O
functional	O
studies	O
and	O
literature	B-T170
mining	O
.	O

AAV9	B-T005
-	O
NPC1	B-T017
significantly	O
ameliorates	B-T033
Purkinje	B-T017
cell	I-T017
death	B-T038
and	O
behavioral	B-T038
abnormalities	I-T038
in	O
mouse	B-T204
NPC	B-T038
disease	I-T038

Niemann	B-T038
-	I-T038
Pick	I-T038
type	I-T038
C	I-T038
(	I-T038
NPC	I-T038
)	I-T038
disease	I-T038
is	O
a	O
fatal	O
inherited	O
neurodegenerative	B-T038
disorder	I-T038
caused	O
by	O
loss	B-T033
-	I-T033
of	I-T033
-	I-T033
function	I-T033
mutations	B-T038
in	O
the	O
NPC1	B-T017
or	O
NPC2	B-T017
gene	I-T017
.	O

There	O
is	O
no	O
effective	O
way	O
to	O
treat	O
NPC	B-T038
disease	I-T038
.	O

In	O
this	O
study	O
,	O
we	O
used	O
adeno	B-T005
-	I-T005
associated	I-T005
virus	I-T005
(	O
AAV	B-T005
)	O
serotype	B-T170
9	I-T170
(	O
AAV9	B-T005
)	O
to	O
deliver	O
a	O
functional	O
NPC1	B-T017
gene	I-T017
systemically	O
into	O
NPC1	B-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
mice	B-T204
at	O
postnatal	B-T058
day	I-T058
4	I-T058
.	O

One	O
single	O
AAV9	B-T058
-	I-T058
NPC1	I-T058
injection	I-T058
resulted	O
in	O
robust	O
NPC1	B-T017
expression	B-T038
in	O
various	O
tissues	B-T017
,	O
including	O
brain	B-T017
,	O
heart	B-T017
,	O
and	O
lung	B-T017
.	O

Strikingly	O
,	O
AAV9	O
-	O
mediated	O
NPC1	O
delivery	O
significantly	O
promoted	O
Purkinje	B-T017
cell	I-T017
survival	O
,	O
restored	O
locomotor	B-T038
activity	I-T038
and	O
coordination	B-T038
,	O
and	O
increased	O
the	O
lifespan	O
of	O
NPC1	B-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
mice	B-T204
.	O

Our	O
work	O
suggests	O
that	O
AAV	B-T058
-	I-T058
based	I-T058
gene	I-T058
therapy	I-T058
is	O
a	O
promising	O
means	O
to	O
treat	O
NPC	B-T038
disease	I-T038
.	O

Executive	B-T038
functions	I-T038
deficits	O
impair	O
extinction	B-T038
of	O
generalization	B-T038
of	O
fear	B-T038
of	O
movement	O
-	O
related	O
pain	O

Generalization	B-T038
of	O
fear	B-T038
of	O
movement	O
-	O
related	O
pain	O
across	O
novel	O
but	O
similar	O
movements	B-T038
can	O
lead	O
to	O
fear	B-T038
responses	I-T038
to	O
movements	B-T038
that	O
are	O
actually	O
not	O
associated	O
with	O
pain	B-T033
.	O

The	O
peak	O
-	O
shift	O
effect	O
describes	O
a	O
phenomenon	O
whereby	O
particular	O
novel	O
movements	B-T038
elicit	O
even	O
greater	O
fear	B-T038
responses	I-T038
than	O
the	O
original	O
pain	B-T033
-	I-T033
provoking	I-T033
movement	B-T038
(	O
CS	B-T038
+	I-T038
)	O
,	O
because	O
they	O
represent	O
a	O
more	O
extreme	O
version	O
of	O
the	O
CS	B-T038
+	I-T038
.	O

There	O
is	O
great	O
variance	O
in	O
the	O
propensity	O
to	O
generalize	B-T038
as	O
well	O
as	O
the	O
speed	O
of	O
extinction	B-T038
learning	I-T038
when	O
these	O
novel	O
movements	B-T038
are	O
not	O
followed	O
by	O
pain	B-T033
.	O

It	O
can	O
be	O
argued	O
that	O
this	O
variance	O
may	O
be	O
associated	O
with	O
executive	B-T038
function	I-T038
capacity	I-T038
,	O
as	O
individuals	B-T098
may	O
be	O
unable	O
to	O
intentionally	O
inhibit	B-T038
fear	I-T038
responses	I-T038
.	O

This	O
study	O
examined	B-T033
whether	O
executive	B-T038
function	I-T038
capacity	I-T038
contributes	O
to	O
generalization	B-T038
and	O
extinction	B-T038
of	O
generalization	B-T038
as	O
well	O
as	O
peak	O
-	O
shift	O
of	O
conditioned	O
fear	O
of	O
movement	O
-	O
related	O
pain	O
and	O
expectancy	O
.	O

Healthy	B-T098
participants	I-T098
performed	O
a	O
proprioceptive	O
fear	B-T038
conditioning	I-T038
task	I-T038
.	O

Executive	B-T038
function	I-T038
tests	I-T038
assessing	O
updating	O
,	O
switching	O
,	O
and	O
inhibition	B-T038
were	O
used	O
to	O
predict	O
changes	O
in	O
(	O
extinction	B-T038
of	O
)	O
fear	B-T038
of	O
movement	O
-	O
related	O
pain	O
and	O
pain	B-T033
expectancy	O
generalization	B-T038
.	O

Low	B-T038
inhibitory	I-T038
capacity	I-T038
was	O
associated	O
with	O
slower	O
extinction	B-T038
of	O
generalized	B-T038
fear	I-T038
of	O
movement	O
-	O
related	O
pain	O
and	O
pain	B-T033
expectancy	O
.	O

Evidence	O
was	O
found	O
in	O
favor	O
of	O
an	O
area	O
-	O
shift	O
,	O
rather	O
than	O
a	O
peak	O
-	O
shift	O
effect	O
,	O
which	O
implies	O
that	O
the	O
peak	O
conditioned	B-T038
fear	I-T038
response	I-T038
extended	O
to	O
,	O
but	O
did	O
not	O
shift	O
to	O
a	O
novel	O
stimulus	O
.	O

Participants	B-T098
with	O
low	O
inhibitory	B-T038
capacity	I-T038
may	O
have	O
difficulties	O
withholding	O
fear	B-T038
responses	I-T038
,	O
leading	O
to	O
a	O
slower	O
decrease	O
of	O
generalized	B-T038
fear	I-T038
over	O
time	O
.	O

The	O
findings	B-T033
may	O
be	O
relevant	O
to	O
inform	O
treatments	O
.	O

Low	B-T038
inhibitory	I-T038
capacity	I-T038
is	O
not	O
associated	O
with	O
slower	O
generalization	B-T038
,	O
but	O
extinction	B-T038
of	O
fear	B-T038
generalization	B-T038
.	O

Fear	B-T038
elicited	O
by	O
a	O
novel	O
safe	O
movement	B-T038
,	O
situated	O
outside	O
the	O
CS	B-T038
+	I-T038
/	I-T038
-	I-T038
continuum	O
on	O
the	O
CS	B-T038
+	I-T038
side	O
,	O
can	O
be	O
as	O
strong	O
as	O
to	O
the	O
original	O
stimulus	O
predicting	O
the	O
pain	O
-	O
onset	O
.	O

Robust	O
DLPP	O
With	O
Nongreedy	O
ℓ₁	O
$	O
-	O
Norm	O
Minimization	O
and	O
Maximization	O

Recently	O
,	O
discriminant	O
locality	O
preserving	O
projection	O
based	O
on	O
L1	O
-	O
norm	O
(	O
DLPP	O
-	O
L1	O
)	O
was	O
developed	O
for	O
robust	O
subspace	B-T038
learning	I-T038
and	O
image	B-T170
classification	B-T170
.	O

It	O
obtains	O
projection	B-T082
vectors	B-T082
by	O
greedy	B-T062
strategy	I-T062
,	O
i	O
.	O
e	O
.	O
,	O
all	O
projection	B-T082
vectors	B-T082
are	O
optimized	O
individually	O
through	O
maximizing	O
the	O
objective	O
function	O
.	O

Thus	O
,	O
the	O
obtained	O
solution	B-T170
does	O
not	O
necessarily	O
best	O
optimize	O
the	O
corresponding	O
trace	B-T170
ratio	I-T170
optimization	I-T170
algorithm	I-T170
,	O
which	O
is	O
the	O
essential	O
objective	O
function	O
for	O
general	O
dimensionality	B-T170
reduction	I-T170
.	O

It	O
results	O
in	O
insufficient	O
recognition	B-T038
accuracy	O
.	O

To	O
tackle	O
this	O
problem	O
,	O
we	O
propose	O
a	O
nongreedy	B-T170
algorithm	I-T170
to	O
solve	O
the	O
trace	B-T170
ratio	I-T170
formula	I-T170
of	O
DLPP	O
-	O
L1	O
,	O
and	O
analyze	O
its	O
convergence	O
.	O

Experimental	O
results	O
on	O
three	O
databases	B-T170
illustrate	O
the	O
effectiveness	O
of	O
our	O
proposed	O
algorithm	B-T170
.	O

A	O
Double	B-T062
-	I-T062
Blind	I-T062
Randomized	B-T062
Controlled	I-T062
Trial	I-T062
of	O
Maternal	B-T038
Postpartum	I-T038
Deworming	B-T058
to	O
Improve	O
Infant	O
Weight	B-T033
Gain	I-T033
in	O
the	O
Peruvian	O
Amazon	O

Nutritional	B-T058
interventions	I-T058
targeting	O
the	O
critical	O
growth	O
and	O
development	O
period	O
before	O
two	O
years	O
of	O
age	O
can	O
have	O
the	O
greatest	O
impact	O
on	O
health	O
trajectories	O
over	O
the	O
life	O
course	O
.	O

Compelling	O
evidence	O
has	O
demonstrated	O
that	O
interventions	B-T058
investing	O
in	O
maternal	O
health	O
in	O
the	O
first	O
1000	O
days	O
of	O
life	O
are	O
beneficial	O
for	O
both	O
mothers	O
and	O
their	O
children	O
.	O

One	O
such	O
potential	O
intervention	B-T058
is	O
deworming	B-T058
integrated	O
into	O
maternal	O
postpartum	O
care	O
in	O
areas	B-T082
where	O
soil	O
-	O
transmitted	O
helminth	B-T204
(	O
STH	B-T204
)	O
infections	B-T038
are	O
endemic	B-T038
.	O

From	O
February	O
to	O
August	O
2014	O
,	O
1010	O
mother	O
-	O
infant	O
pairs	O
were	O
recruited	O
into	O
a	O
trial	B-T062
aimed	O
at	O
assessing	B-T058
the	O
effectiveness	O
of	O
maternal	B-T038
postpartum	I-T038
deworming	B-T058
on	O
infant	O
and	O
maternal	O
health	O
outcomes	O
.	O

Following	O
delivery	B-T038
,	O
mothers	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
single	O
-	O
dose	O
400	O
mg	O
albendazole	B-T103
or	O
placebo	B-T103
.	O

Participants	B-T098
were	O
followed	B-T058
-	I-T058
up	I-T058
at	O
1	O
and	O
6	O
months	O
postpartum	O
.	O

There	O
was	O
no	B-T033
statistically	I-T033
significant	I-T033
difference	O
in	O
mean	O
weight	B-T033
gain	I-T033
between	O
infants	O
in	O
the	O
experimental	O
and	O
control	O
groups	O
(	O
mean	O
difference	O
:	O
-	O
0	O
.	O
02	O
;	O
95	O
%	O
CI	O
:	O
-	O
0	O
.	O
1	O
,	O
0	O
.	O
08	O
)	O
at	O
6	O
months	O
of	O
age	O
.	O

Further	O
,	O
deworming	B-T058
had	O
no	O
effect	O
on	O
measured	O
infant	O
morbidity	O
indicators	B-T170
.	O

However	O
,	O
ad	B-T170
hoc	I-T170
analyses	I-T170
restricted	O
to	O
mothers	O
who	O
tested	O
positive	B-T033
for	O
STHs	B-T204
at	O
baseline	O
suggest	O
that	O
infants	O
of	O
mothers	O
in	O
the	O
experimental	O
group	O
had	O
greater	O
mean	O
length	O
gain	O
in	O
cm	O
(	O
mean	O
difference	O
:	O
0	O
.	O
8	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
1	O
,	O
1	O
.	O
4	O
)	O
and	O
length	O
-	O
for	O
-	O
age	O
z	O
-	O
score	O
(	O
mean	O
difference	O
:	O
0	O
.	O
5	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
2	O
,	O
0	O
.	O
8	O
)	O
at	O
6	O
months	O
of	O
age	O
.	O

In	O
a	O
study	B-T098
population	I-T098
composed	O
of	O
both	O
STH	B-T038
-	I-T038
infected	I-T038
and	O
uninfected	O
mothers	O
,	O
maternal	B-T038
postpartum	I-T038
deworming	B-T058
was	O
insufficient	O
to	O
impact	O
infant	O
growth	B-T038
and	O
morbidity	O
indicators	B-T170
up	O
to	O
6	O
months	O
postpartum	O
.	O

Among	O
STH	B-T038
-	I-T038
infected	I-T038
mothers	O
,	O
however	O
,	O
important	O
improvements	O
in	O
infant	O
length	O
gain	O
and	O
length	O
-	O
for	O
-	O
age	O
were	O
observed	O
.	O

The	O
benefits	O
of	O
maternal	B-T038
postpartum	I-T038
deworming	B-T058
should	O
be	O
further	O
investigated	O
in	O
study	B-T098
populations	I-T098
having	O
higher	O
overall	O
prevalences	O
and	O
intensities	B-T170
of	O
STH	B-T038
infections	I-T038
and	O
,	O
in	O
particular	O
,	O
where	O
whipworm	B-T038
and	O
hookworm	B-T038
infections	I-T038
are	O
of	O
public	B-T058
health	I-T058
concern	I-T058
.	O

ClinicalTrials	O
.	O
gov	O
(	O
NCT01748929	O
)	O
.	O

Technical	O
note	O
:	O
A	O
preliminary	O
comparative	B-T062
study	I-T062
between	O
classical	O
and	O
interventional	B-T091
radiological	I-T091
approaches	I-T091
for	O
multi	O
-	O
phase	O
post	B-T058
-	I-T058
mortem	I-T058
CT	I-T058
angiography	B-T058

Multi	O
-	O
phase	O
post	B-T058
-	I-T058
mortem	I-T058
computed	I-T058
tomography	I-T058
angiography	I-T058
(	O
MPMCTA	B-T058
)	O
is	O
a	O
new	O
diagnostic	B-T058
tool	I-T058
,	O
used	O
in	O
forensic	B-T091
pathology	I-T091
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
technique	O
allows	O
a	O
better	O
and	O
direct	O
visualization	O
of	O
vascular	B-T038
and	O
solid	B-T017
organ	I-T017
lesions	B-T033
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
invasiveness	O
of	O
the	O
procedure	O
-	O
which	O
requires	O
surgical	B-T033
denudation	I-T033
(	O
inguinal	B-T082
and	O
/	O
or	O
cervical	B-T082
)	O
and	O
the	O
insertion	B-T058
of	O
surgical	B-T074
cannulas	I-T074
-	O
leads	O
to	O
many	O
relatives	O
refusing	O
scientific	B-T058
autopsies	I-T058
.	O

Our	O
hypothesis	O
states	O
that	O
a	O
minimally	O
-	O
invasive	O
procedure	O
combining	O
interventional	B-T058
radiological	I-T058
techniques	I-T058
with	O
MPMCTA	B-T058
(	O
replacement	O
of	O
surgical	B-T074
cannulas	I-T074
by	O
radiological	B-T074
catheters	I-T074
)	O
will	O
improve	B-T033
the	O
approval	O
rate	O
of	O
scientific	B-T058
autopsies	I-T058
by	O
families	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
feasibility	B-T062
of	O
the	O
minimally	O
-	O
invasive	O
MPMCTA	B-T058
approach	O
and	O
to	O
compare	O
its	O
performance	O
to	O
the	O
current	O
reference	O
-	O
standard	O
(	O
the	O
conventional	O
approach	O
)	O
.	O

We	O
included	O
consecutively	O
16	O
corpses	B-T017
divided	O
in	O
two	O
groups	O
according	O
to	O
the	O
contrast	O
enhancement	O
approach	O
:	O
radiological	B-T074
catheters	I-T074
(	O
n	O
=	O
8	O
)	O
,	O
and	O
surgical	B-T074
cannulas	I-T074
(	O
n	O
=	O
8	O
)	O
.	O

Corpses	B-T017
were	O
chosen	O
and	O
assigned	O
randomly	O
from	O
our	O
local	O
data	O
.	O

The	O
quality	O
of	O
the	O
imaging	B-T058
procedure	I-T058
was	O
compared	O
according	O
to	O
four	O
items	O
:	O
global	B-T017
vascular	I-T017
opacification	O
,	O
cerebral	O
venous	O
opacification	O
,	O
and	O
lower	B-T017
limbs	I-T017
opacification	O
(	O
arterial	B-T082
and	O
venous	B-T082
)	O
.	O

A	O
minimally	O
-	O
invasive	O
approach	O
for	O
scientific	B-T058
autopsies	I-T058
is	O
feasible	O
through	O
a	O
radiological	B-T074
catheter	I-T074
.	O

Vascular	B-T017
opacification	O
was	O
optimal	O
in	O
8	O
out	O
of	O
8	O
cases	O
and	O
was	O
no	O
less	O
effective	O
than	O
the	O
control	O
reference	O
group	O
using	O
surgical	B-T074
cannula	I-T074
incision	B-T058
associated	O
with	O
their	O
non	O
-	O
occlusive	O
aspects	O
.	O

Correlations	O
between	O
physical	O
activity	O
and	O
neurocognitive	B-T038
domain	I-T038
functions	I-T038
in	O
patients	O
with	O
schizophrenia	B-T038
:	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062

Neurocognitive	B-T038
dysfunction	I-T038
is	O
a	O
critical	O
target	O
symptom	B-T033
of	O
schizophrenia	B-T038
treatment	B-T058
.	O

A	O
positive	O
correlation	O
between	O
physical	O
activity	O
level	O
and	O
neurocognitive	B-T038
function	I-T038
has	O
been	O
reported	O
in	O
healthy	B-T098
individuals	I-T098
,	O
but	O
it	O
is	O
unclear	O
whether	O
such	O
a	O
correlation	O
exists	O
in	O
patients	O
with	O
schizophrenia	B-T038
and	O
whether	O
the	O
relationship	O
is	O
different	O
according	O
to	O
inpatients	O
or	O
outpatients	O
.	O

This	O
study	B-T062
aimed	O
to	O
examine	B-T058
the	O
differences	O
in	O
the	O
correlations	O
between	O
physical	O
activity	O
and	O
multiple	O
neurocognitive	B-T038
domains	I-T038
in	O
inpatients	O
and	O
outpatients	O
with	O
schizophrenia	B-T038
and	O
obtain	O
suggestions	O
for	O
further	O
study	B-T062
to	O
facilitate	O
this	O
field	O
.	O

Twenty	O
-	O
nine	O
patients	O
with	O
schizophrenia	B-T038
were	O
examined	B-T058
(	O
16	O
inpatients	O
and	O
13	O
outpatients	O
,	O
56	O
.	O
0	O
±	O
11	O
.	O
4	O
years	O
of	O
age	O
)	O
.	O

Current	O
symptoms	B-T033
were	O
assessed	O
using	O
the	O
Positive	B-T033
and	O
Negative	B-T033
Symptom	B-T170
Scale	I-T170
and	O
neurocognitive	B-T038
functions	I-T038
using	O
Cognitrax	O
,	O
which	O
yields	O
a	O
composite	O
neurocognitive	O
index	O
(	O
NCI	O
)	O
and	O
11	O
domain	O
scores	O
.	O

After	O
testing	O
,	O
participants	B-T098
wore	O
an	O
HJA	B-T074
-	I-T074
750C	I-T074
accelerometer	I-T074
for	O
one	O
week	O
to	O
measure	O
physical	O
activity	O
levels	O
and	O
durations	O
.	O

Partial	B-T062
correlation	I-T062
analyses	I-T062
were	O
performed	O
between	O
exercise	O
and	O
cognitive	B-T038
parameters	B-T033
.	O

In	O
the	O
outpatient	O
group	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
faster	O
Motor	O
and	O
Psychomotor	B-T038
Speeds	O
in	O
outpatients	O
.	O

However	O
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
lower	O
overall	O
NCI	O
,	O
Attention	B-T038
score	O
,	O
and	O
Memory	B-T038
scores	O
in	O
inpatients	O
.	O

Although	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
better	O
neurocognitive	B-T038
functions	I-T038
of	O
outpatients	O
,	O
in	O
inpatients	O
with	O
non	O
-	O
remitted	O
schizophrenia	B-T038
,	O
higher	O
physical	O
activity	O
was	O
associated	O
with	O
worsening	O
of	O
several	O
cognitive	B-T038
domains	I-T038
.	O

In	O
a	O
future	O
study	B-T062
examining	B-T058
the	O
relationship	O
between	O
physical	O
activity	O
and	O
neurocognitive	B-T038
function	I-T038
for	O
facilitating	O
this	O
research	O
field	O
,	O
separation	O
between	O
inpatients	O
and	O
outpatients	O
are	O
needed	O
because	O
the	O
relationship	O
is	O
different	O
between	O
inpatients	O
and	O
outpatients	O
.	O

A	O
completely	O
calcified	O
prostate	B-T017

Prostatic	B-T038
calcification	I-T038
and	O
prostatic	B-T038
calculus	I-T038
formation	O
is	O
commonly	O
seen	O
in	O
adult	O
population	B-T098
with	O
chronic	B-T038
prostatitis	I-T038
,	O
however	O
,	O
gross	O
prostatic	B-T038
calcification	I-T038
which	O
involves	O
more	O
than	O
3	O
cm	O
(	O
2	O
)	O
of	O
the	O
gland	B-T017
is	O
quite	O
rare	O
.	O

We	O
are	O
presenting	O
here	O
one	O
such	O
case	O
in	O
which	O
almost	O
whole	O
glandular	B-T017
prostate	I-T017
was	O
converted	O
into	O
stone	B-T031
which	O
is	O
never	O
reported	O
so	O
far	O
.	O

A	O
rare	O
cause	O
of	O
gastric	B-T038
obstruction	I-T038
:	O
Lighters	O
swallowing	B-T038

The	O
majority	O
of	O
swallowed	B-T033
foreign	I-T033
bodies	I-T033
are	O
thrown	O
spontaneously	O
without	O
causing	O
complications	B-T038
in	O
the	O
digestive	B-T022
system	I-T022
.	O

Multiple	O
number	O
of	O
foreign	B-T037
bodies	I-T037
may	O
be	O
swallowed	B-T038
by	O
psychiatric	O
patients	O
which	O
delay	O
diagnosis	O
and	O
increase	O
the	O
complication	B-T038
rate	O
.	O

Long	O
and	O
hard	O
objects	B-T037
cannot	O
pass	O
through	O
the	O
pylorus	B-T017
,	O
and	O
may	O
cause	O
obstruction	B-T038
,	O
ulceration	B-T038
,	O
bleeding	B-T038
and	O
perforation	B-T033
.	O

Endoscopy	B-T058
is	O
used	O
as	O
an	O
effective	O
method	O
in	O
such	O
cases	O
.	O

An	O
exploratory	B-T058
laparatomy	I-T058
was	O
performed	O
after	O
unsuccessful	O
endoscopic	B-T082
foreign	B-T037
object	I-T037
removal	B-T058
in	O
a	O
28	O
-	O
year	O
-	O
old	O
schizophrenic	B-T038
patient	O
with	O
gastric	B-T038
outlet	I-T038
obstruction	I-T038
due	O
to	O
multiple	O
cigarette	O
lighter	O
swallowing	B-T038
.	O

Ten	O
lighters	O
were	O
removed	O
from	O
the	O
stomach	B-T017
through	O
gastrotomy	B-T058
and	O
one	O
more	O
lighter	O
was	O
removed	O
from	O
the	O
descending	B-T017
colon	I-T017
by	O
milking	B-T058
through	O
the	O
anus	B-T017
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
discuss	O
encountered	O
difficulties	B-T033
in	O
psychiatric	O
patients	O
who	O
underwent	O
surgery	B-T058
due	O
to	O
intake	O
of	O
foreign	B-T037
bodies	I-T037
.	O

Ceftaroline	B-T103
fosamil	I-T103
for	O
community	B-T038
-	I-T038
acquired	I-T038
pneumonia	I-T038
and	O
skin	B-T022
and	O
skin	B-T038
structure	I-T038
infections	I-T038
:	O
a	O
systematic	B-T170
review	I-T170

Background	O
Ceftaroline	B-T103
is	O
a	O
parentally	O
administered	O
cephalosporin	B-T103
that	O
has	O
an	O
in	O
vitro	O
expanded	B-T082
spectrum	O
of	O
activity	B-T038
compared	O
with	O
other	O
cephalosporins	B-T103
yet	O
data	O
is	O
conflicting	O
regarding	O
its	O
place	O
in	O
therapy	B-T058
.	O

Aim	O
of	O
the	O
Review	B-T170
To	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
ceftaroline	B-T103
against	O
standard	O
antibiotic	B-T103
regimens	B-T058
for	O
community	B-T038
-	I-T038
acquired	I-T038
pneumonia	I-T038
(	O
CAP	B-T038
)	O
and	O
complicated	B-T038
skin	I-T038
and	I-T038
skin	I-T038
structure	I-T038
infections	I-T038
(	O
cSSSIs	B-T038
)	O
.	O

Method	O
The	O
databases	B-T170
of	O
MEDLINE	B-T170
,	O
EBSCO	B-T170
,	O
and	O
Embase	B-T170
were	O
searched	O
up	O
to	O
June	O
2016	O
.	O

Manual	O
review	O
of	O
references	O
was	O
completed	O
and	O
experts	B-T097
in	O
the	O
field	O
were	O
contacted	O
for	O
unpublished	B-T170
data	I-T170
.	O

Randomized	B-T062
controlled	I-T062
trials	I-T062
of	O
ceftaroline	B-T103
in	O
CAP	B-T038
or	O
cSSSI	B-T038
populations	B-T098
were	O
included	O
.	O

Outcomes	O
included	O
clinical	B-T033
cure	I-T033
,	O
mortality	O
,	O
adverse	B-T038
events	I-T038
,	O
serious	B-T033
adverse	I-T033
events	I-T033
,	O
and	O
discontinuation	B-T058
due	O
to	O
adverse	B-T038
events	I-T038
.	O

Meta	B-T170
-	I-T170
analysis	I-T170
was	O
used	O
to	O
pool	O
results	O
for	O
these	O
outcomes	O
.	O

We	O
performed	O
subgroup	B-T170
analyses	B-T062
for	O
gram	B-T038
positive	I-T038
infections	I-T038
in	O
CAP	B-T038
and	O
infections	B-T038
caused	O
by	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
in	O
cSSSIs	B-T038
.	O

Risk	O
of	O
bias	O
was	O
assessed	O
for	O
all	O
studies	B-T062
.	O

Results	O
Six	O
trials	O
(	O
three	O
for	O
each	O
indication	O
)	O
were	O
included	O
,	O
each	O
of	O
which	O
had	O
an	O
unclear	O
or	O
high	O
risk	O
of	O
bias	O
in	O
at	O
least	O
one	O
domain	O
.	O

For	O
CAP	B-T038
,	O
ceftaroline	B-T103
was	O
significantly	O
more	O
efficacious	O
in	O
achieving	O
clinical	B-T033
cure	I-T033
than	O
ceftriaxone	B-T103
[	O
risk	O
ratio	O
(	O
RR	O
)	O
1	O
.	O
11	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
04	O
-	O
1	O
.	O
19	O
;	O
I	O
(	O
2	O
)	O
=	O
47	O
%	O
]	O
.	O

For	O
cSSSIs	B-T038
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
clinical	B-T033
cure	I-T033
between	O
ceftaroline	B-T103
and	O
vancomycin	B-T103
plus	O
aztreonam	B-T103
(	O
RR	O
1	O
.	O
01	O
,	O
95	O
%	O
CI	O
0	O
.	O
97	O
-	O
1	O
.	O
05	O
;	O
I	O
(	O
2	O
)	O
=	O
0	O
%	O
)	O
.	O

No	O
differences	O
were	O
found	O
for	O
overall	O
mortality	O
,	O
serious	B-T033
adverse	I-T033
events	I-T033
,	O
discontinuation	B-T058
due	O
to	O
adverse	B-T038
events	I-T038
,	O
and	O
overall	O
adverse	B-T038
events	I-T038
.	O

Conclusion	O
Ceftaroline	B-T103
is	O
a	O
viable	O
therapeutic	B-T058
alternative	I-T058
for	O
patients	O
with	O
CAP	B-T038
and	O
cSSSIs	B-T038
,	O
yet	O
identified	O
risks	O
of	O
bias	O
and	O
poor	B-T033
external	I-T033
validity	I-T033
preclude	O
it	O
from	O
being	O
recommended	O
as	O
a	O
first	B-T103
-	I-T103
line	I-T103
agent	I-T103
.	O

Direct	O
effects	O
of	O
glucose	B-T103
,	O
insulin	B-T103
,	O
GLP	B-T103
-	I-T103
1	I-T103
,	O
and	O
GIP	B-T103
on	O
bulbospinal	B-T082
neurons	B-T017
in	O
the	O
rostral	B-T017
ventrolateral	I-T017
medulla	I-T017
in	O
neonatal	O
wistar	B-T204
rats	I-T204

Although	O
patients	O
with	O
diabetes	B-T038
mellitus	I-T038
(	O
DM	B-T038
)	O
often	O
exhibit	O
hypertension	B-T038
,	O
the	O
mechanisms	O
responsible	O
for	O
this	O
correlation	O
are	O
not	O
well	O
known	O
.	O

We	O
hypothesized	O
that	O
the	O
bulbospinal	B-T082
neurons	B-T017
in	O
the	O
rostral	B-T017
ventrolateral	I-T017
medulla	I-T017
(	O
RVLM	B-T017
)	O
are	O
affected	O
by	O
the	O
levels	O
of	O
glucose	B-T103
,	O
insulin	B-T103
,	O
or	O
incretins	B-T103
(	O
glucagon	B-T103
like	I-T103
peptide	I-T103
-	I-T103
1	I-T103
[	O
GLP	B-T103
-	I-T103
1	I-T103
]	O
or	O
glucose	B-T103
-	I-T103
dependent	I-T103
insulinotropic	I-T103
peptide	I-T103
[	O
GIP	B-T103
]	O
)	O
in	O
patients	O
with	O
DM	B-T038
.	O

To	O
investigate	O
whether	O
RVLM	B-T017
neurons	B-T017
are	O
activated	O
by	O
glucose	B-T103
,	O
insulin	B-T103
,	O
GLP	B-T103
-	I-T103
1	I-T103
,	O
or	O
GIP	B-T103
,	O
we	O
examined	O
changes	O
in	O
the	O
membrane	B-T038
potentials	I-T038
of	O
bulbospinal	B-T082
RVLM	B-T017
neurons	B-T017
using	O
whole	B-T017
-	I-T017
cell	I-T017
patch	B-T062
-	I-T062
clamp	I-T062
technique	I-T062
during	O
superfusion	O
with	O
various	O
levels	O
of	O
glucose	B-T103
or	O
these	O
hormones	B-T103
in	O
neonatal	O
Wistar	B-T204
rats	I-T204
.	O

A	O
brainstem	B-T017
-	O
spinal	B-T017
cord	I-T017
preparation	O
was	O
used	O
for	O
the	O
experiments	B-T062
.	O

A	O
low	O
level	O
of	O
glucose	B-T103
stimulated	O
bulbospinal	B-T082
RVLM	B-T017
neurons	B-T017
.	O

During	O
insulin	B-T103
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	B-T017
neurons	B-T017
were	O
depolarized	B-T038
,	O
while	O
during	O
GLP	B-T103
-	I-T103
1	I-T103
or	O
GIP	B-T103
superfusion	O
,	O
almost	O
all	O
the	O
RVLM	B-T017
neurons	B-T017
were	O
hyperpolarized	B-T038
.	O

Next	O
,	O
histological	B-T058
examinations	I-T058
were	O
performed	O
to	O
examine	O
transporters	B-T103
for	I-T103
glucose	I-T103
and	O
receptors	B-T103
for	O
insulin	B-T103
,	O
GLP	B-T103
-	I-T103
1	I-T103
,	O
and	O
GIP	B-T103
on	O
RVLM	B-T017
neurons	B-T017
.	O

Low	O
-	O
level	O
glucose	B-T103
-	O
depolarized	B-T038
RVLM	B-T017
neurons	B-T017
exhibited	O
the	O
presence	O
of	O
glucose	B-T103
transporter	I-T103
3	I-T103
(	O
GLUT3	B-T103
)	O
.	O

Meanwhile	O
,	O
insulin	B-T103
-	O
depolarized	B-T038
,	O
GLP	B-T103
-	I-T103
1	I-T103
-	O
hyperpolarized	B-T038
,	O
and	O
GIP	B-T103
-	O
hyperpolarized	B-T038
RVLM	B-T017
neurons	B-T017
showed	O
each	O
of	O
the	O
respective	O
specific	O
receptor	B-T103
.	O

These	O
results	O
indicate	O
that	O
a	O
low	O
level	O
of	O
glucose	B-T103
stimulates	O
bulbospinal	B-T082
RVLM	B-T017
neurons	B-T017
via	O
specific	O
transporters	B-T103
on	O
these	O
neurons	B-T017
,	O
inducing	O
hypertension	B-T038
.	O

Furthermore	O
,	O
an	O
increase	O
in	O
insulin	B-T103
or	O
a	O
reduction	O
in	O
incretins	B-T103
may	O
also	O
activate	O
the	O
sympathetic	B-T022
nervous	I-T022
system	I-T022
and	O
induce	O
hypertension	B-T038
by	O
activating	O
RVLM	B-T017
neurons	B-T017
via	O
their	O
own	O
receptors	B-T103
.	O

Mechanisms	O
of	O
compensation	B-T058
in	O
the	O
gait	B-T033
of	O
patients	O
with	O
drop	B-T038
foot	I-T038

Drop	B-T038
foot	I-T038
is	O
a	O
complex	O
syndrome	B-T038
,	O
with	O
multiple	O
interactions	O
between	O
joints	B-T082
and	O
muscles	B-T017
.	O

Abnormalities	B-T033
in	O
movement	B-T033
patterns	I-T033
can	O
be	O
measured	O
using	O
motion	B-T058
capture	I-T058
techniques	I-T058
,	O
but	O
identifying	O
compensation	B-T058
mechanisms	O
remains	O
challenging	O
.	O

In	O
order	O
to	O
identify	O
compensatory	O
mechanisms	O
in	O
patients	O
with	O
drop	B-T038
foot	I-T038
,	O
this	O
study	B-T062
evaluated	O
a	O
sample	O
of	O
15	O
such	O
patients	O
using	O
a	O
computerized	O
gait	B-T074
analysis	I-T074
system	I-T074
,	O
as	O
compared	O
to	O
a	O
group	O
of	O
15	O
healthy	B-T098
subjects	I-T098
.	O

Four	O
classes	O
of	O
parameters	O
were	O
distinguished	O
,	O
falling	B-T033
in	O
differing	O
intervals	O
of	O
percentage	O
differences	O
between	O
the	O
groups	B-T098
in	O
the	O
study	B-T062
.	O

The	O
first	O
class	O
comprised	O
two	O
kinematic	B-T091
parameters	I-T091
for	O
which	O
the	O
values	O
of	O
percentage	O
differences	O
in	O
the	O
control	O
group	O
were	O
more	O
than	O
100	O
%	O
greater	O
than	O
for	O
the	O
patient	O
group	O
.	O

The	O
second	O
class	O
comprised	O
two	O
kinetic	O
parameters	O
falling	B-T033
in	O
the	O
interval	O
of	O
100	O
-	O
49	O
%	O
.	O

In	O
the	O
third	O
class	O
,	O
in	O
the	O
49	O
-	O
20	O
%	O
interval	O
the	O
main	O
differences	O
were	O
observed	O
for	O
spatiotemporal	B-T062
parameters	I-T062
,	O
whereas	O
in	O
the	O
20	O
-	O
4	O
%	O
interval	O
the	O
differences	O
were	O
distributed	O
similarly	O
for	O
kinematic	B-T091
,	O
kinetic	O
and	O
spatiotemporal	B-T062
parameters	I-T062
.	O

These	O
differences	O
in	O
gait	B-T033
pattern	I-T033
between	O
the	O
groups	B-T098
may	O
be	O
related	O
to	O
both	O
primary	O
motor	B-T033
deficits	I-T033
and	O
secondary	O
compensatory	O
mechanisms	O
.	O

Generally	O
,	O
we	O
conclude	O
that	O
drop	B-T038
foot	I-T038
affects	O
the	O
patients	O
'	O
overall	O
kinematic	B-T091
and	O
kinetic	O
gait	B-T033
parameters	O
,	O
with	O
compensation	B-T058
seen	O
as	O
a	O
chain	O
originating	O
from	O
a	O
change	O
of	O
movement	B-T038
within	O
the	O
ankle	B-T082
joint	I-T082
.	O

Inhibitory	O
effects	O
of	O
Lactobacillus	B-T007
rhamnosus	I-T007
and	O
Lactobacillus	B-T007
casei	I-T007
on	O
Candida	B-T204
biofilm	B-T007
of	O
denture	B-T033
surface	I-T033

Candida	B-T204
albicans	I-T204
biofilm	B-T007
is	O
associated	O
with	O
denture	B-T038
-	I-T038
related	I-T038
stomatitis	I-T038
and	O
oral	B-T038
candidiasis	I-T038
of	O
elderly	B-T098
.	O

Probiotics	B-T007
are	O
beneficial	O
bacteria	B-T007
and	O
have	O
antibacterial	B-T033
activity	I-T033
against	O
pathogenic	B-T007
bacteria	I-T007
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
antifungal	B-T033
activity	I-T033
of	O
various	O
probiotics	B-T007
against	O
C	B-T204
.	I-T204

albicans	I-T204
and	O
the	O
inhibitory	O
effects	O
of	O
probiotics	B-T007
on	O
Candida	B-T204
biofilm	B-T007
on	O
the	O
denture	B-T033
surface	I-T033
.	O

The	O
spent	B-T103
culture	I-T103
media	I-T103
of	O
various	O
probiotics	B-T007
were	O
investigated	O
the	O
antifungal	O
efficacy	O
against	O
C	B-T204
.	I-T204

albicans	I-T204
.	O

Candida	B-T204
biofilm	B-T007
was	O
formed	O
on	O
a	O
denture	O
base	O
resin	O
and	O
was	O
then	O
treated	O
with	O
Lactobacillus	B-T007
rhamnosus	I-T007
and	O
Lactobacillus	B-T007
casei	I-T007
.	O

Also	O
,	O
the	O
biofilm	B-T007
s	O
of	O
L	B-T007
.	I-T007

rhamnosus	I-T007
and	O
L	B-T007
.	I-T007

casei	I-T007
were	O
formed	O
and	O
were	O
sequentially	O
treated	O
with	O
C	B-T204
.	I-T204

albicans	I-T204
.	O

Colony	O
-	O
forming	O
units	O
of	O
C	B-T204
.	I-T204

albicans	I-T204
on	O
the	O
denture	B-T033
surface	I-T033
were	O
counted	O
after	O
spreading	O
on	O
agar	B-T103
plate	B-T074
.	O

The	O
denture	O
base	O
resin	O
was	O
treated	O
with	O
the	O
spent	B-T103
culture	I-T103
media	I-T103
for	O
30	O
days	O
,	O
after	O
which	O
the	O
denture	B-T033
surface	I-T033
roughness	B-T033
was	O
analyzed	O
with	O
an	O
atomic	B-T058
force	I-T058
microscope	I-T058
.	O

L	B-T007
.	I-T007

rhamnosus	I-T007
and	O
L	B-T007
.	I-T007

casei	I-T007
exhibited	O
stronger	O
antifungal	B-T033
activity	I-T033
than	O
other	O
probiotics	B-T007
.	O

The	O
spent	B-T103
culture	I-T103
medium	I-T103
of	O
L	B-T007
.	I-T007

rhamnosus	I-T007
and	O
L	B-T007
.	I-T007

casei	I-T007
exhibited	O
the	O
antifungal	B-T033
activity	I-T033
against	O
blastoconidia	B-T204
and	O
biofilm	B-T007
of	O
C	B-T204
.	I-T204

albicans	I-T204
.	O

L	B-T007
.	I-T007

rhamnosus	I-T007
and	O
L	B-T007
.	I-T007

casei	I-T007
showed	O
the	O
antifungal	B-T033
activity	I-T033
against	O
Candida	B-T204
biofilm	B-T007
,	O
and	O
the	O
biofilm	B-T007
of	O
L	B-T007
.	I-T007

rhamnosus	I-T007
and	O
L	B-T007
.	I-T007

casei	I-T007
inhibited	O
formation	O
of	O
Candida	B-T204
biofilm	B-T007
on	O
denture	B-T033
surface	I-T033
.	O

Neither	O
of	O
the	O
probiotics	B-T007
affected	O
the	O
surface	B-T033
roughness	I-T033
of	O
the	O
denture	O
base	O
resin	O
.	O

L	B-T007
.	I-T007

rhamnosus	I-T007
and	O
L	B-T007
.	I-T007

casei	I-T007
may	O
be	O
the	O
ideal	O
probiotics	B-T007
for	O
the	O
prevention	O
and	O
treatment	O
of	O
denture	B-T038
-	I-T038
related	I-T038
stomatitis	I-T038
.	O

Persistent	B-T103
Organic	I-T103
Pollutants	I-T103
(	O
POPs	B-T103
)	O
in	O
the	O
atmosphere	O
of	O
three	O
Chilean	O
cities	B-T082
using	O
passive	O
air	O
samplers	O

In	O
this	O
study	B-T062
passive	O
air	O
samplers	O
containing	O
polyurethane	B-T103
foam	I-T103
(	O
PUF	B-T103
)	O
disks	B-T074
were	O
deployed	O
in	O
three	O
cities	B-T082
across	O
Chile	B-T082
;	O
Santiago	B-T082
(	O
STG	B-T082
)	O
(	O
n	O
=	O
5	O
,	O
sampling	B-T082
sites	I-T082
)	O
,	O
Concepciόn	B-T082
(	O
CON	B-T082
)	O
(	O
n	O
=	O
6	O
)	O
and	O
Temuco	B-T082
(	O
TEM	B-T082
)	O
(	O
n	O
=	O
6	O
)	O
from	O
2008	O
to	O
2009	O
.	O

Polychlorinated	B-T103
biphenyls	I-T103
(	O
PCBs	B-T103
)	O
(	O
7	O
indicator	O
congeners	O
)	O
,	O
chlorinated	B-T103
pesticides	I-T103
hexachlorocyclohexanes	B-T103
(	O
HCHs	B-T103
)	O
,	O
dichlorodiphenyl	B-T103
trichloroethanes	I-T103
(	O
DDTs	B-T103
)	O
and	O
flame	B-T103
retardants	I-T103
such	O
as	O
polybrominated	B-T103
diphenyl	I-T103
ethers	I-T103
(	O
PBDEs	B-T103
)	O
were	O
determined	O
by	O
gas	B-T058
chromatography	I-T058
coupled	I-T058
mass	I-T058
spectrometry	I-T058
(	O
GC	B-T058
/	I-T058
MS	I-T058
)	O
.	O

A	O
sampling	O
rate	O
(	O
R	O
)	O
typical	O
of	O
urban	O
sites	O
(	O
4m	O
(	O
3	O
)	O
/	O
day	O
)	O
was	O
used	O
to	O
estimate	O
the	O
atmospheric	O
concentrations	O
of	O
individual	O
compounds	O
.	O

PCB	B-T103
concentrations	O
in	O
the	O
air	O
(	O
pg	O
/	O
m	O
(	O
3	O
)	O
)	O
ranged	O
from	O
~	O
1	O
-	O
10	O
(	O
TEM	B-T082
)	O
,	O
~	O
1	O
-	O
40	O
(	O
STG	B-T082
)	O
and	O
4	O
-	O
30	O
(	O
CON	B-T082
)	O
.	O

Higher	O
molecular	O
weight	O
PCBs	B-T103
(	O
PCB	B-T103
-	O
153	O
,	O
-	O
180	O
)	O
were	O
detected	B-T033
at	O
industrial	B-T082
sites	I-T082
(	O
in	O
Concepción	B-T082
)	O
.	O

The	O
HCHs	B-T103
showed	O
a	O
prevalence	O
of	O
γ	B-T103
-	I-T103
HCH	I-T103
across	O
all	O
sites	B-T082
,	O
indicative	O
of	O
inputs	O
from	O
the	O
use	O
of	O
lindane	B-T103
but	O
a	O
limited	O
use	O
of	O
technical	O
HCHs	B-T103
in	O
Chile	B-T082
.	O

DDTs	B-T103
were	O
detected	B-T033
with	O
a	O
prevalence	O
of	O
p	B-T103
,	I-T103
p	I-T103
'	I-T103
-	I-T103
DDE	I-T103
accounting	O
for	O
~	O
50	O
%	O
of	O
the	O
total	O
DDTs	B-T103
.	O

PBDE	B-T103
concentrations	O
in	O
air	O
(	O
pg	O
/	O
m	O
(	O
3	O
)	O
)	O
ranged	O
from	O
1	O
to	O
55	O
(	O
STG	B-T082
)	O
,	O
0	O
.	O
5	O
to	O
20	O
(	O
CON	B-T082
)	O
and	O
from	O
0	O
.	O
4	O
to	O
10	O
(	O
TEM	B-T082
)	O
,	O
and	O
were	O
generally	O
similar	O
to	O
those	O
reported	B-T170
for	O
many	O
other	O
urban	O
areas	O
globally	O
.	O

The	O
pattern	B-T082
of	O
PBDEs	B-T103
was	O
different	O
among	O
the	O
three	O
cities	B-T082
;	O
however	O
,	O
PBDE	B-T103
-	O
209	O
was	O
dominant	O
at	O
most	O
of	O
the	O
sites	B-T082
.	O

These	O
results	O
represent	O
one	O
of	O
the	O
few	O
assessments	B-T058
of	O
air	O
concentrations	O
of	O
POPs	B-T103
across	O
different	O
urban	O
areas	O
within	O
the	O
same	O
country	B-T082
.	O

These	O
data	O
will	O
support	O
Chilean	O
commitments	O
as	O
a	O
signatory	O
to	O
the	O
Stockholm	O
Convention	O
on	O
POPs	B-T103
and	O
for	O
reporting	B-T062
as	O
a	O
member	B-T097
country	B-T082
of	O
the	O
Group	B-T082
of	I-T082
Latin	I-T082
America	I-T082
and	I-T082
Caribbean	I-T082
Countries	I-T082
(	I-T082
GRULAC	I-T082
)	I-T082
region	I-T082
.	O

Intraoperative	O
ketamine	B-T103
reduces	O
immediate	O
postoperative	O
opioid	B-T103
consumption	O
after	O
spinal	B-T058
fusion	I-T058
surgery	I-T058
in	O
chronic	B-T033
pain	I-T033
patients	O
with	O
opioid	B-T103
dependency	O
:	O
a	O
randomized	B-T062
,	O
blinded	B-T062
trial	I-T062

Perioperative	O
handling	B-T033
of	O
surgical	O
patients	O
with	O
opioid	B-T103
dependency	O
represents	O
an	O
important	O
clinical	O
problem	B-T033
.	O

Animal	B-T204
studies	I-T204
suggest	O
that	O
ketamine	B-T103
attenuates	O
central	B-T038
sensitization	I-T038
and	O
hyperalgesia	B-T033
and	O
thereby	O
reduces	O
postoperative	O
opioid	B-T103
tolerance	O
.	O

We	O
hypothesized	O
that	O
intraoperative	O
ketamine	B-T103
would	O
reduce	O
immediate	O
postoperative	O
opioid	B-T103
consumption	O
compared	O
with	O
placebo	B-T103
in	O
chronic	B-T033
pain	I-T033
patients	O
with	O
opioid	B-T103
dependency	O
undergoing	O
lumbar	B-T058
spinal	I-T058
fusion	I-T058
surgery	I-T058
.	O

Primary	O
outcome	O
was	O
morphine	B-T103
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
.	O

Secondary	O
outcomes	O
were	O
acute	B-T033
pain	I-T033
at	I-T033
rest	I-T033
and	O
during	O
mobilization	B-T058
2	O
to	O
24	O
hours	O
postoperatively	O
(	O
visual	B-T058
analogue	I-T058
scale	I-T058
)	O
,	O
adverse	B-T038
events	I-T038
,	O
and	O
persistent	O
pain	B-T033
6	O
months	O
postoperatively	O
.	O

One	O
hundred	O
fifty	O
patients	O
were	O
randomly	B-T062
assigned	I-T062
to	O
intraoperative	O
S	B-T103
-	I-T103
ketamine	I-T103
bolus	B-T058
0	I-T058
.	I-T058
5	I-T058
mg	I-T058
/	I-T058
kg	I-T058
and	I-T058
infusion	I-T058
0	O
.	O
25	O
mg	O
·	O
kg	O
·	O
h	O
or	O
placebo	B-T103
.	O

Postoperatively	O
,	O
patients	O
received	O
their	O
usual	O
opioids	B-T103
,	O
paracetamol	B-T103
and	O
IV	O
patient	B-T058
-	I-T058
controlled	I-T058
analgesia	I-T058
with	O
morphine	B-T103
.	O

In	O
the	O
final	B-T170
analyses	I-T170
,	O
147	O
patients	O
were	O
included	O
.	O

Patient	B-T058
-	I-T058
controlled	I-T058
analgesia	I-T058
IV	O
morphine	B-T103
consumption	O
0	O
to	O
24	O
hours	O
postoperatively	O
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	B-T103
group	O
compared	O
with	O
the	O
placebo	B-T103
group	O
:	O
79	O
(	O
47	O
)	O
vs	O
121	O
(	O
53	O
)	O
mg	O
IV	O
,	O
mean	O
difference	O
42	O
mg	O
(	O
95	O
%	O
confidence	O
interval	O
-	O
59	O
to	O
-	O
25	O
)	O
,	O
P	O
<	O
0	O
.	O
001	O
.	O

Sedation	B-T033
was	O
significantly	O
reduced	O
in	O
the	O
ketamine	B-T103
group	O
6	O
and	O
24	O
hours	O
postoperatively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
regarding	O
acute	B-T033
pain	I-T033
,	O
nausea	B-T033
,	O
vomiting	B-T033
,	O
hallucinations	B-T038
,	O
or	O
nightmares	B-T033
.	O

Back	B-T033
pain	I-T033
at	O
6	O
months	O
postoperatively	O
compared	O
with	O
preoperative	O
pain	B-T033
was	O
significantly	O
more	O
improved	B-T033
in	O
the	O
ketamine	B-T103
group	O
compared	O
with	O
the	O
placebo	B-T103
group	O
,	O
P	O
=	O
0	O
.	O
005	O
.	O

In	O
conclusion	O
,	O
intraoperative	O
ketamine	B-T103
significantly	O
reduced	O
morphine	B-T103
consumption	O
0	O
to	O
24	O
hours	O
after	O
lumbar	B-T058
fusion	I-T058
surgery	I-T058
in	O
opioid	B-T103
-	O
dependent	O
patients	O
.	O

The	O
trend	O
regarding	O
less	O
persistent	O
pain	B-T033
6	O
months	O
postoperatively	O
needs	O
further	B-T082
investigation	O
.	O

Effects	O
of	O
argan	B-T103
oil	I-T103
on	O
the	O
mitochondrial	B-T038
function	I-T038
,	O
antioxidant	B-T022
system	I-T022
and	O
the	O
activity	B-T038
of	O
NADPH	B-T103
-	O
generating	O
enzymes	B-T103
in	O
acrylamide	B-T103
treated	B-T058
rat	B-T204
brain	B-T017

Argan	B-T103
oil	I-T103
(	O
AO	B-T103
)	O
is	O
rich	O
in	O
minor	O
compounds	B-T103
such	O
as	O
polyphenols	B-T103
and	O
tocopherols	B-T103
which	O
are	O
powerful	O
antioxidants	B-T103
.	O

Acrylamide	B-T103
(	O
ACR	B-T103
)	O
has	O
been	O
classified	B-T170
as	O
a	O
neurotoxic	O
agent	O
in	O
animals	B-T204
and	O
humans	B-T204
.	O

Mitochondrial	B-T017
oxidative	B-T038
stress	I-T038
and	O
dysfunction	B-T033
is	O
one	O
of	O
the	O
most	O
probable	O
molecular	O
mechanisms	O
of	O
neurodegenerative	B-T038
diseases	I-T038
.	O

Female	O
Sprague	B-T204
Dawley	I-T204
rats	I-T204
were	O
exposed	O
to	O
ACR	B-T103
(	O
50mg	O
/	O
kg	O
i	O
.	O
p	O
.	O

three	O
times	O
a	O
week	O
)	O
,	O
AO	B-T103
(	O
6ml	O
/	O
kg	O
,	O
o	O
.	O
p	O
,	O
per	O
day	O
)	O
or	O
together	O
for	O
30days	O
.	O

The	O
activities	O
of	O
cytosolic	B-T017
enzymes	B-T103
such	O
as	O
xanthine	B-T103
oxidase	I-T103
(	O
XO	B-T103
)	O
,	O
glucose	B-T103
6	I-T103
-	I-T103
phosphate	I-T103
dehydrogenase	I-T103
(	O
G6PDH	B-T103
)	O
,	O
glutathione	B-T103
-	I-T103
S	I-T103
-	I-T103
transferase	I-T103
(	O
GST	B-T103
)	O
,	O
mitochondrial	B-T017
oxidative	B-T038
stress	I-T038
,	O
oxidative	B-T038
phosphorylation	I-T038
(	O
OXPHOS	B-T038
)	O
and	O
tricarboxylic	B-T038
acid	I-T038
cycle	I-T038
(	O
TCA	B-T038
)	O
enzymes	B-T103
,	O
mitochondrial	B-T017
metabolic	B-T038
function	I-T038
,	O
adenosine	B-T103
triphosphate	I-T103
(	O
ATP	B-T103
)	O
level	O
and	O
acetylcholinesterase	B-T038
(	I-T038
AChE	I-T038
)	I-T038
activity	I-T038
were	O
assessed	O
in	O
rat	B-T204
brain	B-T017
.	O

Cytosolic	B-T017
and	O
mitochondrial	B-T017
antioxidant	B-T103
enzymes	I-T103
were	O
significantly	O
diminished	O
in	O
the	O
brains	B-T017
of	O
rats	B-T204
treated	B-T058
with	I-T058
ACR	B-T103
compared	O
to	O
those	O
in	O
control	O
.	O

Besides	O
,	O
ACR	B-T103
treatment	B-T058
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
brain	B-T017
ATP	B-T103
level	O
,	O
mitochondrial	B-T017
metabolic	B-T038
function	I-T038
,	O
OXPHOS	B-T038
and	O
TCA	B-T038
enzymes	B-T103
.	O

Administration	B-T058
of	O
AO	B-T103
restored	O
both	O
the	O
cytosolic	B-T017
and	O
mitochondrial	B-T017
oxidative	B-T038
stress	I-T038
by	O
normalizing	B-T062
nicotinamide	B-T103
adenine	I-T103
dinucleotide	I-T103
phosphate	I-T103
(	O
NADPH	B-T103
)	O
generating	O
enzymes	B-T103
.	O

In	O
addition	O
,	O
improved	B-T033
mitochondrial	B-T038
function	I-T038
primarily	O
enhancing	O
nicotinamide	B-T103
adenine	I-T103
dinucleotide	I-T103
(	O
NADH	B-T103
)	O
generated	O
enzymes	B-T038
activities	I-T038
and	O
ATP	B-T103
level	O
in	O
the	O
mitochondria	B-T017
.	O

The	O
reason	O
for	O
AO	B-T103
'	I-T103
s	I-T103
obvious	O
beneficial	O
effects	O
in	O
this	O
study	B-T062
may	O
be	O
due	O
to	O
synergistic	O
effects	O
of	O
its	O
different	O
bioactive	O
compounds	O
which	O
is	O
especially	O
effective	O
on	O
mitochondria	B-T017
.	O

Modulation	B-T082
of	O
the	O
brain	B-T017
mitochondrial	B-T038
functions	I-T038
and	O
antioxidant	B-T022
systems	I-T022
by	O
AO	B-T103
may	O
lead	O
to	O
the	O
development	O
of	O
new	O
mitochondria	B-T017
-	O
targeted	B-T038
antioxidants	B-T103
in	O
the	O
future	O
.	O

Encaged	O
Chironomus	B-T204
riparius	I-T204
larvae	B-T204
in	O
assessment	O
of	O
trace	B-T103
metal	I-T103
bioavailability	O
and	O
transfer	O
in	O
a	O
landfill	B-T103
leachate	I-T103
collection	O
pond	B-T082

Household	O
wastes	B-T103
may	O
constitute	O
a	O
vector	O
of	O
environmental	O
contamination	O
when	O
buried	O
,	O
in	O
particular	O
through	O
degradation	O
and	O
production	O
of	O
leachates	B-T103
containing	O
significant	O
trace	B-T103
metal	I-T103
(	O
TM	B-T103
)	O
concentrations	O
that	O
may	O
constitute	O
a	O
serious	O
risk	O
to	O
biota	O
.	O

The	O
objectives	B-T170
of	O
this	O
study	B-T062
were	O
to	O
assess	O
the	O
bioavailability	O
and	O
transfer	O
potential	O
of	O
various	O
TMs	B-T103
present	B-T033
in	O
water	B-T103
and	O
sediments	O
in	O
a	O
reservoir	B-T082
receiving	O
landfill	B-T103
leachates	I-T103
.	O

An	O
active	O
biomonitoring	O
approach	O
was	O
adopted	O
consisting	O
of	O
exposing	O
naive	O
laboratory	O
organisms	O
in	O
cages	O
deployed	O
in	B-T082
the	I-T082
field	I-T082
.	O

Aquatic	O
insects	O
such	O
as	O
Chironomus	B-T204
riparius	I-T204
larvae	B-T204
are	O
good	O
candidates	O
since	O
they	O
represent	O
key	O
organisms	O
in	O
the	O
trophic	O
functioning	O
of	O
aquatic	O
ecosystems	O
.	O

The	O
results	O
show	O
that	O
water	B-T103
,	O
suspended	O
particles	B-T103
,	O
and	O
sediments	O
were	O
significant	O
ly	O
contaminated	O
by	O
various	O
TMs	B-T103
(	O
As	B-T103
,	O
Cd	B-T103
,	O
Cu	B-T103
,	O
Ni	B-T103
,	O
Pb	B-T103
,	O
and	O
Zn	B-T103
)	O
.	O

Their	O
contribution	O
to	O
the	O
transfer	O
of	O
TMs	B-T103
depends	O
,	O
however	O
,	O
on	O
the	O
specific	O
element	B-T103
considered	O
,	O
e	O
.	O
g	O
.	O
,	O
Cd	B-T103
in	O
sediments	O
or	O
Pb	B-T103
in	O
both	O
suspended	O
particles	B-T103
and	O
sediments	O
.	O

The	O
internal	O
fate	O
of	O
TMs	B-T103
was	O
investigated	O
according	O
to	O
their	O
fractionation	B-T058
between	O
an	O
insoluble	O
and	O
a	O
cytosolic	B-T017
fraction	O
.	O

This	O
approach	O
revealed	O
different	O
detoxification	B-T058
strategies	O
capable	O
of	O
preventing	O
the	O
induction	O
of	O
deleterious	B-T038
effects	I-T038
at	O
the	O
individual	B-T098
scale	O
.	O

However	O
,	O
the	O
accumulation	B-T033
of	O
several	O
TMs	B-T103
in	O
C	B-T204
.	I-T204

riparius	I-T204
larvae	B-T204
tissues	B-T017
may	O
also	O
represent	O
a	O
significant	O
load	O
potentially	O
transferable	O
to	O
higher	O
trophic	O
levels	O
.	O

Effects	O
of	O
Binge	O
-	O
Like	O
Ethanol	O
Exposure	O
During	O
Adolescence	O
on	O
the	O
Febrile	B-T033
Response	O
in	O
Rats	B-T204

Ethanol	O
(	O
EtOH	O
)	O
exposure	O
during	O
different	O
phases	O
of	O
life	O
may	O
increase	O
the	O
risk	B-T033
of	I-T033
infections	I-T033
and	O
cause	O
alterations	O
in	O
the	O
central	B-T022
nervous	I-T022
system	I-T022
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
binge	O
-	O
like	O
EtOH	O
exposure	O
in	O
adolescent	O
rats	B-T204
on	O
the	O
febrile	B-T033
response	O
that	O
was	O
induced	O
by	O
lipopolysaccharide	B-T103
(	O
LPS	B-T103
)	O
and	O
interleukin	B-T103
-	I-T103
1β	I-T103
(	O
IL	B-T103
-	I-T103
1β	I-T103
)	O
.	O

Male	O
rats	B-T204
were	O
exposed	O
to	O
EtOH	O
from	O
postnatal	O
days	O
25	O
to	O
38	O
in	O
a	O
binge	O
-	O
like	O
pattern	O
.	O

Fever	B-T033
was	O
induced	O
by	O
LPS	B-T103
(	O
5	O
and	O
50	O
μg	O
/	O
kg	O
,	O
intraperitoneally	B-T082
)	O
and	O
evaluated	O
on	O
postnatal	O
days	O
51	O
and	O
63	O
,	O
or	O
by	O
IL	B-T103
-	I-T103
β	I-T103
(	O
3	O
ng	O
)	O
and	O
evaluated	O
on	O
postnatal	O
day	O
51	O
.	O

Hematological	B-T091
parameters	O
,	O
the	O
status	O
of	O
peritoneal	B-T017
macrophages	I-T017
,	O
and	O
plasma	B-T031
and	O
cerebrospinal	O
IL	B-T103
-	I-T103
1β	I-T103
levels	O
were	O
also	O
evaluated	O
on	O
postnatal	O
day	O
51	O
.	O

EtOH	O
exposure	O
during	O
adolescence	O
did	O
not	O
alter	O
normal	B-T033
body	I-T033
temperature	I-T033
.	O

However	O
,	O
a	O
significant	O
reduction	O
in	O
the	O
febrile	B-T033
response	O
that	O
was	O
induced	O
by	O
LPS	B-T103
at	O
both	O
doses	O
was	O
observed	O
on	O
postnatal	O
day	O
51	O
.	O

However	O
,	O
no	O
changes	O
in	O
the	O
febrile	B-T033
response	O
were	O
observed	O
on	O
postnatal	O
day	O
63	O
in	O
EtOH	O
-	O
exposed	O
animals	B-T204
.	O

The	O
febrile	B-T033
response	O
that	O
was	O
induced	O
by	O
intracerebroventricular	B-T082
IL	B-T103
-	I-T103
1β	I-T103
also	O
significantly	O
decreased	O
in	O
animals	B-T204
that	O
received	O
binge	O
-	O
like	O
EtOH	O
exposure	O
during	O
adolescence	O
.	O

Acute	O
oral	O
treatment	O
with	O
EtOH	B-T103
24	O
h	O
prior	O
to	O
LPS	B-T103
administration	B-T058
did	O
not	O
alter	O
the	O
febrile	B-T033
response	O
that	O
was	O
induced	O
by	O
LPS	B-T103
.	O

Binge	O
-	O
like	O
EtOH	O
exposure	O
during	O
adolescence	O
did	O
not	O
alter	O
hematological	B-T091
parameters	O
or	O
the	O
number	O
or	O
viability	B-T038
of	O
peritoneal	B-T017
macrophages	I-T017
.	O

Binge	O
-	O
like	O
EtOH	O
exposure	O
did	O
not	O
alter	O
plasma	B-T031
IL	B-T103
-	I-T103
1β	I-T103
levels	O
but	O
reduced	O
the	O
cerebrospinal	B-T031
fluid	I-T031
levels	O
of	O
this	O
cytokine	B-T103
.	O

These	O
results	O
suggest	O
that	O
binge	O
-	O
like	O
EtOH	O
exposure	O
during	O
adolescence	O
causes	O
changes	O
in	O
the	O
central	B-T022
nervous	I-T022
system	I-T022
that	O
can	O
impair	O
the	O
febrile	B-T033
response	O
that	O
can	O
be	O
observed	O
after	O
the	O
cessation	O
of	O
EtOH	O
exposure	O
.	O

These	O
changes	O
were	O
reversible	O
and	O
appeared	O
to	O
involve	O
the	O
LPS	B-T103
/	O
IL	B-T103
-	I-T103
1β	I-T103
system	O
.	O

Genital	B-T038
and	O
Extragenital	B-T038
Gonorrhea	I-T038
and	O
Chlamydia	B-T038
in	O
Children	O
and	O
Adolescents	O
Evaluated	B-T058
for	O
Sexual	B-T037
Abuse	I-T037

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
describe	O
the	O
use	O
of	O
a	O
nucleic	B-T058
acid	I-T058
amplification	I-T058
test	I-T058
in	O
detecting	B-T058
genital	B-T007
and	O
extragenital	B-T007
Neisseria	I-T007
gonorrhoeae	I-T007
(	O
NG	B-T007
)	O
and	O
Chlamydia	B-T007
trachomatis	I-T007
(	O
CT	B-T007
)	O
in	O
children	O
and	O
adolescents	O
assessed	O
for	O
sexual	B-T037
abuse	I-T037
/	O
assault	B-T038
.	O

The	O
charts	O
of	O
children	O
aged	O
0	O
to	O
17	O
years	O
,	O
consecutively	O
evaluated	B-T058
for	O
sexual	O
victimization	O
,	O
in	O
emergency	B-T092
department	I-T092
and	O
outpatient	B-T092
settings	I-T092
were	O
reviewed	O
.	O

Data	O
extracted	O
included	O
age	O
,	O
sex	O
,	O
type	O
of	O
sexual	O
contact	O
,	O
anogenital	O
findings	B-T033
,	O
previous	O
sexual	O
contact	O
,	O
toxicology	B-T033
results	I-T033
,	O
and	O
sites	B-T082
tested	B-T058
for	O
NG	B-T007
and	O
CT	B-T007
.	O

Of	O
the	O
1319	O
patients	O
who	O
were	O
tested	B-T058
,	O
579	O
were	O
tested	B-T058
at	O
more	O
than	O
1	O
site	B-T082
,	O
and	O
120	O
had	O
at	O
least	O
1	O
infected	B-T033
site	B-T082
.	O

Chlamydia	B-T007
trachomatis	I-T007
was	O
identified	O
in	O
104	O
patients	O
,	O
and	O
NG	B-T007
was	O
found	O
in	O
33	O
.	O

In	O
bivariate	O
analysis	O
,	O
a	O
positive	O
test	O
was	O
associated	O
with	O
female	O
sex	O
,	O
age	O
older	O
than	O
11	O
years	O
,	O
previous	O
sexual	O
contact	O
,	O
acute	O
or	O
healed	O
genital	B-T037
injury	I-T037
,	O
drug	O
/	O
alcohol	O
intoxication	O
,	O
and	O
examination	B-T058
within	O
72	O
hours	O
of	O
sexual	O
contact	O
.	O

Fifty	O
-	O
one	O
patients	O
had	O
positive	B-T033
anal	B-T017
tests	B-T058
,	O
and	O
24	O
had	O
positive	B-T033
oral	B-T082
tests	B-T058
.	O

More	O
than	O
75	O
%	O
of	O
patients	O
with	O
positive	B-T033
extragenital	B-T058
tests	I-T058
had	O
additional	O
positive	B-T033
tests	B-T058
or	O
anogenital	O
injury	B-T037
.	O

Most	O
with	O
a	O
positive	B-T033
anal	B-T017
(	O
59	O
%	O
)	O
or	O
oral	B-T082
(	O
77	O
%	O
)	O
test	B-T058
did	O
not	O
report	O
that	O
the	O
assailant	O
'	O
s	O
genitals	B-T017
came	O
into	O
contact	O
with	O
that	O
site	B-T082
.	O

Positive	B-T033
tests	B-T058
for	O
NG	B-T007
and	O
CT	B-T007
in	O
patients	O
evaluated	B-T058
for	O
sexual	O
victimization	O
may	O
represent	O
infection	B-T038
from	O
sexual	O
contact	O
,	O
contiguous	O
spread	O
of	O
infection	B-T038
,	O
or	O
the	O
presence	O
of	O
infected	B-T031
assailant	I-T031
secretions	I-T031
.	O

Relying	O
on	O
patient	O
reports	O
of	O
symptoms	B-T033
,	O
or	O
types	O
of	O
sexual	O
contact	O
,	O
to	O
determine	O
need	O
for	O
testing	O
may	O
miss	O
NG	B-T038
and	O
CT	B-T038
infections	I-T038
in	O
patients	O
evaluated	B-T058
for	O
sexual	O
victimization	O
.	O

The	O
Longitudinal	B-T082
Effects	O
of	O
Parenting	O
on	O
Adaptive	O
Behavior	O
in	O
Children	O
with	O
Fragile	B-T038
X	I-T038
Syndrome	I-T038

Several	O
studies	B-T062
have	O
reported	O
declines	O
in	O
adaptive	O
behavior	O
amongst	O
children	O
with	O
fragile	B-T038
X	I-T038
syndrome	I-T038
(	O
FXS	B-T038
)	O
starting	O
in	O
middle	O
childhood	O
.	O

We	O
examined	B-T033
the	O
effects	O
of	O
maternal	O
responsivity	O
on	O
adaptive	O
behavior	O
in	O
55	O
children	O
with	O
FXS	B-T038
visited	O
5	O
-	O
6	O
times	O
in	O
their	O
homes	B-T092
from	O
early	O
through	O
middle	O
childhood	O
.	O

Our	O
analyses	B-T062
indicated	O
that	O
sustained	O
maternal	O
responsivity	O
had	O
a	O
significant	O
positive	O
impact	O
on	O
the	O
trajectories	O
of	O
communication	O
and	O
to	O
a	O
lesser	O
extent	O
other	O
adaptive	O
behavior	O
domains	O
through	O
middle	O
childhood	O
with	O
many	O
effects	O
remaining	O
significant	O
after	O
controlling	O
for	O
autism	B-T033
symptoms	I-T033
and	O
developmental	B-T038
level	I-T038
.	O

For	O
children	O
who	O
showed	O
declines	O
in	O
adaptive	O
behavior	O
during	O
middle	O
childhood	O
,	O
sustained	O
high	O
levels	O
of	O
maternal	O
responsivity	O
minimized	O
the	O
amount	O
of	O
decline	O
observed	O
in	O
the	O
communication	O
,	O
socialization	O
,	O
and	O
daily	O
living	O
domains	O
.	O

Development	O
and	O
Validation	B-T062
of	O
a	O
New	O
Reliable	O
Method	B-T058
for	O
the	O
Diagnosis	B-T033
of	O
Avian	B-T204
Botulism	B-T037

Liver	B-T017
is	O
a	O
reliable	O
matrix	B-T031
for	O
laboratory	B-T058
confirmation	O
of	O
avian	B-T204
botulism	B-T037
using	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
.	O

Here	O
,	O
we	O
developed	O
,	O
optimized	O
,	O
and	O
validated	B-T062
the	O
analytical	B-T062
steps	O
preceding	O
PCR	B-T062
to	O
maximize	O
the	O
detection	B-T033
of	O
Clostridium	B-T007
botulinum	I-T007
group	I-T007
III	I-T007
in	O
avian	B-T204
liver	B-T017
.	O

These	O
pre	O
-	O
PCR	B-T062
steps	O
included	O
enrichment	B-T103
incubation	B-T058
of	O
the	O
whole	O
liver	B-T017
(	O
maximum	O
25	O
g	O
)	O
at	O
37°C	O
for	O
at	O
least	O
24	O
h	O
in	O
an	O
anaerobic	B-T074
chamber	I-T074
and	O
DNA	B-T062
extraction	I-T062
using	O
an	O
enzymatic	B-T058
digestion	I-T058
step	O
followed	O
by	O
a	O
DNA	O
purification	O
step	O
.	O

Conditions	O
of	O
sample	O
storage	O
before	O
analysis	B-T062
appear	O
to	O
have	O
a	O
strong	O
effect	O
on	O
the	O
detection	B-T033
of	O
group	B-T007
III	I-T007
C	I-T007
.	I-T007

botulinum	I-T007
strains	I-T007
and	O
our	O
results	O
recommend	O
storage	O
at	O
temperatures	O
below	O
-	O
18°C	O
.	O

Short	O
-	O
term	O
storage	O
at	O
5°C	O
is	O
possible	O
for	O
up	O
to	O
24	O
h	O
,	O
but	O
a	O
decrease	O
in	O
sensitivity	O
was	O
observed	O
at	O
48	O
h	O
of	O
storage	O
at	O
this	O
temperature	O
.	O

Analysis	B-T062
of	O
whole	O
livers	B-T017
(	O
maximum	O
25	O
g	O
)	O
is	O
required	O
and	O
pooling	O
samples	O
before	O
enrichment	B-T058
culturing	I-T058
must	O
be	O
avoided	O
.	O

Pooling	O
is	O
however	O
possible	O
before	O
or	O
after	O
DNA	B-T062
extraction	I-T062
under	O
certain	O
conditions	O
.	O

Whole	O
livers	B-T017
should	O
be	O
10	O
-	O
fold	O
diluted	O
in	O
enrichment	B-T103
medium	I-T103
and	O
homogenized	O
using	O
a	O
Pulsifier®	O
blender	O
(	O
Microgen	O
,	O
Surrey	B-T082
,	O
UK	B-T082
)	O
instead	O
of	O
a	O
conventional	O
paddle	O
blender	O
.	O

Spiked	B-T017
liver	I-T017
samples	O
showed	O
a	O
limit	O
of	O
detection	B-T033
of	O
5	O
spores	B-T007
/	O
g	O
liver	B-T017
for	O
types	B-T007
C	I-T007
and	O
D	B-T007
and	O
250	O
spores	B-T007
/	O
g	O
for	O
type	B-T007
E	I-T007
.	O

Using	O
the	O
method	B-T058
developed	O
here	O
,	O
the	O
analysis	B-T062
of	O
268	O
samples	O
from	O
73	O
suspected	O
outbreaks	O
showed	O
100	O
%	O
specificity	O
and	O
95	O
.	O
35	O
%	O
sensitivity	O
compared	O
with	O
other	O
PCR	B-T062
-	O
based	O
methods	B-T058
considered	O
as	O
reference	O
.	O

The	O
mosaic	B-T007
type	I-T007
C	I-T007
/	O
D	B-T007
was	O
the	O
most	O
common	O
neurotoxin	B-T103
type	O
found	O
in	O
examined	O
samples	O
,	O
which	O
included	O
both	O
wild	B-T204
and	O
domestic	B-T204
birds	I-T204
.	O

Quality	O
Improvement	O
of	O
Liver	B-T017
Ultrasound	B-T058
Images	B-T170
Using	O
Fuzzy	B-T170
Techniques	B-T170

Liver	B-T017
ultrasound	B-T058
images	B-T170
are	O
so	O
common	O
and	O
are	O
applied	O
so	O
often	O
to	O
diagnose	B-T033
diffuse	B-T038
liver	I-T038
diseases	I-T038
like	O
fatty	B-T038
liver	I-T038
.	O

However	O
,	O
the	O
low	O
quality	O
of	O
such	O
images	B-T170
makes	O
it	O
difficult	O
to	O
analyze	B-T062
them	O
and	O
diagnose	B-T033
diseases	B-T038
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
,	O
therefore	O
,	O
is	O
to	O
improve	O
the	O
contrast	O
and	O
quality	O
of	O
liver	B-T017
ultrasound	B-T058
images	B-T170
.	O

In	O
this	O
study	B-T062
,	O
a	O
number	O
of	O
image	B-T170
contrast	O
enhancement	B-T170
algorithms	I-T170
which	O
are	O
based	O
on	O
fuzzy	B-T170
logic	I-T170
were	O
applied	O
to	O
liver	B-T017
ultrasound	B-T058
images	B-T170
-	O
in	O
which	O
the	O
view	O
of	O
kidney	B-T017
is	O
observable	O
-	O
using	O
Matlab2013b	B-T170
to	O
improve	O
the	O
image	B-T170
contrast	O
and	O
quality	O
which	O
has	O
a	O
fuzzy	B-T170
definition	B-T170
;	O
just	O
like	O
image	B-T170
contrast	O
improvement	O
algorithms	B-T170
using	O
a	O
fuzzy	B-T170
intensification	O
operator	O
,	O
contrast	O
improvement	O
algorithms	B-T170
applying	O
fuzzy	B-T170
image	B-T170
histogram	B-T170
hyperbolization	I-T170
,	O
and	O
contrast	O
improvement	O
algorithms	B-T170
by	O
fuzzy	B-T170
IF	B-T170
-	I-T170
THEN	I-T170
rules	I-T170
.	O

With	O
the	O
measurement	O
of	O
Mean	O
Squared	O
Error	O
and	O
Peak	O
Signal	O
to	O
Noise	O
Ratio	O
obtained	O
from	O
different	O
images	B-T170
,	O
fuzzy	B-T170
methods	B-T170
provided	O
better	O
results	O
,	O
and	O
their	O
implementation	O
-	O
compared	O
with	O
histogram	B-T170
equalization	I-T170
method	I-T170
-	O
led	O
both	O
to	O
the	O
improvement	O
of	O
contrast	O
and	O
visual	B-T033
quality	I-T033
of	O
images	B-T170
and	O
to	O
the	O
improvement	O
of	O
liver	B-T017
segmentation	B-T170
algorithms	I-T170
results	O
in	O
images	B-T170
.	O

Comparison	O
of	O
the	O
four	O
algorithms	B-T170
revealed	O
the	O
power	O
of	O
fuzzy	B-T170
logic	I-T170
in	O
improving	O
image	B-T170
contrast	O
compared	O
with	O
traditional	O
image	O
processing	O
algorithms	B-T170
.	O

Moreover	O
,	O
contrast	O
improvement	O
algorithm	O
based	O
on	O
a	O
fuzzy	B-T170
intensification	O
operator	O
was	O
selected	O
as	O
the	O
strongest	O
algorithm	B-T170
considering	O
the	O
measured	O
indicators	O
.	O

This	O
method	B-T170
can	O
also	O
be	O
used	O
in	O
future	O
studies	B-T062
on	O
other	O
ultrasound	B-T058
images	B-T170
for	O
quality	O
improvement	O
and	O
other	O
image	O
processing	O
and	O
analysis	B-T062
applications	O
.	O

Development	O
of	O
the	O
pediatric	B-T170
quality	I-T170
of	I-T170
life	I-T170
inventory	I-T170
neurofibromatosis	B-T038
type	I-T038
1	I-T038
module	B-T170
items	O
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
:	O
qualitative	O
methods	O

Health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
is	O
arguably	O
one	O
of	O
the	O
most	O
important	O
measures	O
in	O
evaluating	B-T058
effectiveness	O
of	O
clinical	B-T058
treatments	I-T058
.	O

At	O
present	O
,	O
there	O
is	O
no	O
disease	B-T038
-	O
specific	O
outcome	O
measure	O
to	O
assess	O
the	O
HRQOL	O
of	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
with	O
Neurofibromatosis	B-T038
Type	I-T038
1	I-T038
(	O
NF1	B-T038
)	O
.	O

This	O
study	B-T062
aimed	O
to	O
develop	O
the	O
items	O
and	O
support	O
the	O
content	O
validity	O
for	O
the	O
Pediatric	B-T170
Quality	I-T170
of	I-T170
Life	I-T170
Inventory™	I-T170
(	O
PedsQL™	B-T170
)	O
NF1	B-T038
Module	B-T170
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

The	O
iterative	B-T033
process	O
included	O
multiphase	O
qualitative	O
methods	O
including	O
a	O
literature	B-T170
review	I-T170
,	O
survey	B-T170
of	O
expert	O
opinions	O
,	O
semi	O
-	O
structured	O
interviews	O
,	O
cognitive	O
interviews	O
and	O
pilot	B-T062
testing	I-T062
.	O

Fifteen	O
domains	O
were	O
derived	O
from	O
the	O
qualitative	O
methods	O
,	O
with	O
content	O
saturation	O
achieved	O
,	O
resulting	O
in	O
115	O
items	O
.	O

The	O
domains	O
include	O
skin	B-T022
,	O
pain	B-T033
,	O
pain	B-T033
impact	O
,	O
pain	B-T058
management	I-T058
,	O
cognitive	B-T038
functioning	I-T038
,	O
speech	B-T038
,	O
fine	O
motor	O
,	O
balance	O
,	O
vision	B-T038
,	O
perceived	B-T038
physical	B-T033
appearance	I-T033
,	O
communication	O
,	O
worry	B-T033
,	O
treatment	B-T058
,	O
medicines	B-T103
and	O
gastrointestinal	B-T033
symptoms	I-T033
.	O

This	O
study	O
is	O
limited	O
because	O
all	O
participants	B-T098
are	O
recruited	O
from	O
a	O
single	O
-	O
site	B-T082
.	O

Qualitative	O
methods	O
support	O
the	O
content	O
validity	O
for	O
the	O
PedsQL™	B-T170
NF1	B-T038
Module	B-T170
for	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
.	O

The	O
PedsQL™	B-T170
NF1	B-T038
Module	B-T170
is	O
now	O
undergoing	O
national	O
multisite	O
field	O
testing	O
for	O
the	O
psychometric	B-T058
validation	B-T062
of	O
the	O
instrument	B-T170
development	O
.	O

Mimiviruses	B-T005
and	O
the	O
Human	B-T204
Interferon	B-T103
System	B-T022
:	O
Viral	B-T038
Evasion	I-T038
of	O
Classical	O
Antiviral	B-T038
Activities	I-T038
,	O
But	O
Inhibition	O
By	O
a	O
Novel	O
Interferon	B-T103
-	I-T103
β	I-T103
Regulated	B-T038
Immunomodulatory	B-T058
Pathway	O

In	O
this	O
review	B-T170
we	O
discuss	O
the	O
role	O
of	O
mimiviruses	B-T005
as	O
potential	O
human	B-T204
pathogens	O
focusing	O
on	O
clinical	O
and	O
evolutionary	B-T038
evidence	O
.	O

We	O
also	O
propose	O
a	O
novel	O
antiviral	B-T038
immunomodulatory	B-T103
pathway	O
controlled	O
by	O
interferon	B-T103
-	I-T103
β	I-T103
(	O
IFN	B-T103
-	I-T103
β	I-T103
)	O
and	O
mediated	O
by	O
immune	B-T103
-	I-T103
responsive	I-T103
gene	I-T103
1	I-T103
(	O
IRG1	B-T103
)	O
and	O
itaconic	B-T103
acid	I-T103
,	O
its	O
product	O
.	O

Acanthamoeba	B-T005
polyphaga	I-T005
Mimivirus	I-T005
(	O
APMV	B-T005
)	O
was	O
isolated	O
from	O
amoebae	B-T204
in	O
a	O
hospital	B-T092
while	O
investigating	O
a	O
pneumonia	B-T038
outbreak	O
.	O

Mimivirus	B-T005
ubiquity	O
and	O
role	O
as	O
protist	O
pathogens	O
are	O
well	O
understood	O
,	O
and	O
its	O
putative	B-T082
status	O
as	O
a	O
human	B-T204
pathogen	O
has	O
been	O
gaining	O
strength	O
as	O
more	O
evidence	O
is	O
being	O
found	O
.	O

The	O
study	B-T062
of	O
APMV	B-T005
and	O
human	B-T204
cells	B-T017
interaction	B-T038
revealed	O
that	O
the	O
virus	B-T005
is	O
able	O
to	O
evade	B-T038
the	O
IFN	B-T103
system	B-T022
by	O
inhibiting	O
the	O
regulation	B-T038
of	O
interferon	B-T103
-	O
stimulated	O
genes	B-T017
,	O
suggesting	O
that	O
the	O
virus	B-T005
and	O
humans	B-T204
have	O
had	O
host	B-T038
-	I-T038
pathogen	I-T038
interactions	I-T038
.	O

It	O
also	O
has	O
shown	O
that	O
the	O
virus	B-T005
is	O
capable	O
of	O
growing	O
on	O
IFN	B-T103
-	I-T103
α2	I-T103
,	O
but	O
not	O
on	O
IFN	B-T103
-	I-T103
β	I-T103
-	O
treated	O
cells	B-T017
,	O
hinting	O
at	O
an	O
exclusive	O
IFN	B-T103
-	I-T103
β	I-T103
antiviral	B-T038
pathway	O
.	O

Our	O
hypothesis	O
based	O
on	O
preliminary	O
data	O
and	O
published	B-T170
articles	I-T170
is	O
that	O
IFN	B-T103
-	I-T103
β	I-T103
preferentially	O
upregulates	B-T038
IRG1	B-T103
in	I-T103
human	I-T103
macrophagic	B-T017
cells	I-T017
,	O
which	O
in	O
turn	O
produces	O
itaconic	B-T103
acid	I-T103
.	O

This	O
metabolite	B-T103
links	O
metabolism	B-T038
to	O
antiviral	B-T038
activity	I-T038
by	O
inactivating	O
the	O
virus	B-T005
,	O
in	O
a	O
novel	O
immunomodulatory	B-T058
pathway	O
relevant	O
for	O
APMV	B-T005
infections	B-T038
and	O
probably	O
to	O
other	O
infectious	B-T038
diseases	I-T038
as	O
well	O
.	O

Heteroprotein	B-T103
Complex	B-T103
Formation	O
of	O
Bovine	B-T103
Lactoferrin	I-T103
and	O
Pea	O
Protein	O
Isolate	B-T103
:	O
A	O
Multiscale	O
Structural	O
Analysis	O

Associative	O
electrostatic	O
interactions	O
between	O
two	O
oppositely	O
charged	O
globular	O
proteins	O
,	O
lactoferrin	B-T103
(	O
LF	B-T103
)	O
and	O
pea	O
protein	O
isolate	B-T103
(	O
PPI	O
)	O
,	O
the	O
latter	O
being	O
a	O
mixture	O
of	O
vicilin	B-T103
,	O
legumin	B-T103
,	O
and	O
convicilin	B-T103
,	O
was	O
studied	B-T062
with	O
a	O
specific	O
PPI	O
/	O
LF	B-T103
molar	O
ratio	O
at	O
room	B-T033
temperature	I-T033
.	O

Structural	B-T082
aspects	O
of	O
the	O
electrostatic	O
complexes	B-T103
probed	O
at	O
different	O
length	O
scales	O
were	O
investigated	O
as	O
a	O
function	O
of	O
pH	O
by	O
means	O
of	O
different	O
complementary	O
techniques	O
,	O
namely	O
,	O
with	O
dynamic	B-T058
light	I-T058
scattering	I-T058
,	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
(	O
SAXS	O
)	O
,	O
turbidity	B-T058
measurements	I-T058
,	O
and	O
atomic	B-T058
force	I-T058
microscopy	I-T058
(	O
AFM	B-T058
)	O
.	O

Irrespective	O
of	O
the	O
applied	O
techniques	O
,	O
the	O
results	B-T033
consistently	O
displayed	O
that	O
complexation	B-T103
between	O
LF	B-T103
and	O
PPI	O
did	O
occur	O
.	O

In	O
an	O
optimum	O
narrow	O
range	O
of	O
pH	O
5	O
.	O
0	O
-	O
5	O
.	O
8	O
,	O
a	O
viscous	O
liquid	B-T033
phase	O
of	O
complex	B-T103
coacervate	O
was	O
obtained	O
upon	O
mild	O
centrifugation	B-T058
of	O
the	O
turbid	O
LF	B-T103
-	O
PPI	O
mixture	O
with	O
a	O
maximum	O
Rh	O
,	O
turbidity	O
and	O
the	O
ζ	O
-	O
potential	O
being	O
close	O
to	O
zero	O
observed	O
at	O
pH	O
5	O
.	O
4	O
.	O

In	O
particular	O
,	O
the	O
SAXS	O
data	O
demonstrated	O
that	O
the	O
coacervates	O
were	O
densely	O
assembled	O
with	O
a	O
roughly	O
spherical	B-T082
size	B-T082
distribution	B-T082
exhibiting	O
a	O
maximum	O
extension	O
of	O
∼80	O
nm	O
at	O
pH	O
5	O
.	O
4	O
.	O

Equally	O
,	O
AFM	B-T058
image	B-T058
analysis	I-T058
showed	O
size	B-T082
distributions	B-T082
containing	O
most	O
frequent	O
cluster	O
sizes	B-T082
around	O
40	O
-	O
80	O
nm	O
with	O
spherical	B-T082
to	O
elliptical	B-T082
shapes	I-T082
(	O
axis	O
aspect	O
ratio	O
≤	O
2	O
)	O
as	O
well	O
as	O
less	O
frequent	O
elongated	O
to	O
chainlike	O
structures	B-T082
.	O

The	O
most	O
frequently	O
observed	O
compact	O
complexes	B-T103
,	O
we	O
identify	O
as	O
mainly	O
leading	O
to	O
LF	B-T103
-	O
PPI	O
coacervation	O
,	O
whereas	O
for	O
the	O
less	O
frequent	O
chain	O
-	O
like	O
aggregates	O
,	O
we	O
hypothesize	O
that	O
additionally	O
PPI	O
-	O
PPI	O
facilitated	O
complexes	B-T103
exist	O
.	O

Visual	O
outcome	O
,	O
endocrine	B-T038
function	I-T038
and	O
tumor	B-T038
control	O
after	O
fractionated	B-T058
stereotactic	I-T058
radiation	I-T058
therapy	I-T058
of	O
craniopharyngiomas	B-T038
in	I-T038
adults	I-T038
:	O
findings	O
in	O
a	O
prospective	B-T062
cohort	I-T062

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
examine	B-T058
visual	O
outcome	O
,	O
endocrine	B-T038
function	I-T038
and	O
tumor	B-T038
control	O
in	O
a	O
prospective	B-T062
cohort	I-T062
of	O
craniopharyngioma	B-T038
patients	O
,	O
treated	B-T058
with	I-T058
fractionated	B-T058
stereotactic	I-T058
radiation	I-T058
therapy	I-T058
(	O
FSRT	B-T058
)	O
.	O

Sixteen	O
adult	O
patients	O
with	O
craniopharyngiomas	B-T038
were	O
eligible	O
for	O
analysis	B-T062
.	O

They	O
were	O
treated	B-T058
with	I-T058
linear	B-T074
accelerator	I-T074
-	I-T074
based	I-T074
FSRT	B-T058
during	O
1999	O
-	O
2015	O
.	O

In	O
all	O
cases	O
,	O
diagnosis	B-T062
was	O
confirmed	O
by	O
histological	O
analysis	B-T062
.	O

The	O
prescription	B-T058
dose	O
to	O
the	O
tumor	B-T038
was	O
54	O
Gy	O
(	O
median	O
,	O
range	O
48	O
-	O
54	O
)	O
in	O
1	O
.	O
8	O
or	O
2	O
.	O
0	O
Gy	O
per	O
fraction	O
,	O
and	O
the	O
maximum	O
radiation	O
dose	O
to	O
the	O
optic	B-T017
nerves	I-T017
and	O
chiasm	B-T017
was	O
54	O
.	O
2	O
Gy	O
(	O
median	O
,	O
range	O
48	O
.	O
6	O
-	O
60	O
.	O
0	O
)	O
for	O
the	O
cohort	B-T098
.	O

Serial	O
ophthalmological	B-T058
and	O
endocrine	B-T058
evaluations	I-T058
and	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
(	O
MRI	B-T058
)	O
scans	B-T058
were	O
performed	O
at	O
regular	O
intervals	O
.	O

Median	O
follow	B-T058
-	I-T058
up	I-T058
was	O
3	O
.	O
3	O
years	O
(	O
range	O
1	O
.	O
1	O
-	O
14	O
.	O
1	O
)	O
,	O
3	O
.	O
7	O
years	O
(	O
range	O
0	O
.	O
8	O
-	O
15	O
.	O
2	O
)	O
,	O
and	O
3	O
.	O
6	O
years	O
(	O
range	O
0	O
.	O
7	O
-	O
13	O
.	O
1	O
)	O
for	O
visual	O
outcome	O
,	O
endocrine	B-T038
function	I-T038
,	O
and	O
tumor	B-T038
control	O
,	O
respectively	O
.	O

Visual	B-T201
acuity	I-T201
impairment	O
was	O
present	O
in	O
10	O
patients	O
(	O
62	O
.	O
5	O
%	O
)	O
and	O
visual	B-T033
field	I-T033
defects	I-T033
were	O
present	O
in	O
12	O
patients	O
(	O
75	O
%	O
)	O
before	O
FSRT	B-T058
.	O

One	O
patient	O
developed	O
radiation	B-T038
-	I-T038
induced	I-T038
optic	I-T038
neuropathy	I-T038
at	O
seven	O
years	O
after	O
FSRT	B-T058
.	O

Thirteen	O
of	O
16	O
patients	O
(	O
81	O
.	O
3	O
%	O
)	O
had	O
pituitary	B-T038
deficiency	I-T038
before	O
FSRT	B-T058
,	O
and	O
did	O
not	O
develop	O
further	O
pituitary	B-T038
deficiency	I-T038
after	O
FSRT	B-T058
.	O

Mean	O
tumor	O
volume	O
pre	O
-	O
FSRT	B-T058
was	O
2	O
.	O
72	O
cm	O
(	O
3	O
)	O
(	O
range	O
0	O
.	O
20	O
-	O
9	O
.	O
90	O
)	O
and	O
post	O
-	O
FSRT	B-T058
1	O
.	O
2	O
cm	O
(	O
3	O
)	O
(	O
range	O
0	O
.	O
00	O
-	O
13	O
.	O
10	O
)	O
.	O

Tumor	B-T038
control	O
rate	O
was	O
81	O
.	O
3	O
%	O
at	O
two	O
,	O
five	O
,	O
and	O
10	O
years	O
after	O
FSRT	B-T058
.	O

FSRT	B-T058
was	O
relatively	O
safe	O
in	O
this	O
prospective	O
cohort	B-T098
of	O
craniopharyngiomas	B-T038
,	O
with	O
only	O
one	O
case	O
of	O
radiation	B-T038
-	I-T038
induced	I-T038
optic	I-T038
neuropathy	I-T038
and	O
no	O
case	O
of	O
new	O
endocrinopathy	B-T038
.	O

Tumor	B-T038
control	O
rate	O
was	O
acceptable	O
.	O

Scutellaria	B-T103
barbata	I-T103
D	I-T103
.	I-T103
Don	I-T103
extract	I-T103
inhibits	O
the	O
tumor	O
growth	O
through	O
down	B-T038
-	I-T038
regulating	I-T038
of	O
Treg	B-T017
cells	I-T017
and	O
manipulating	B-T038
Th1	B-T038
/	O
Th17	B-T038
immune	I-T038
response	I-T038
in	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204

Previous	O
studies	O
showed	O
Scutellaria	B-T103
barbata	I-T103
D	I-T103
.	I-T103

Don	I-T103
extract	I-T103
(	O
SBE	B-T103
)	O
is	O
a	O
potent	O
inhibitor	B-T103
in	O
hepatoma	B-T038
and	O
could	O
improve	O
immune	B-T038
function	I-T038
of	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
.	O

However	O
,	O
the	O
immunomodulatory	B-T038
function	I-T038
of	O
SBE	B-T103
on	O
the	O
tumor	O
growth	O
of	O
hepatoma	B-T038
remains	O
unclear	O
.	O

This	O
study	B-T062
aimed	O
to	O
investigate	O
the	O
anti	O
-	O
tumor	O
effects	O
of	O
SBE	B-T103
on	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
and	O
explore	O
the	O
underlying	O
immunomodulatory	B-T038
function	I-T038
.	O

The	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
were	O
treated	O
by	O
SBE	B-T103
for	O
30	O
days	O
.	O

The	O
effect	O
of	O
SBE	B-T103
on	O
the	O
proliferation	B-T038
of	O
HepG2	B-T017
cells	I-T017
in	O
vitro	O
,	O
the	O
growth	O
of	O
transplanted	O
tumor	O
,	O
the	O
cytotoxicity	B-T038
of	I-T038
natural	I-T038
killer	I-T038
(	I-T038
NK	I-T038
)	I-T038
cells	I-T038
in	O
spleen	B-T017
,	O
the	O
amount	O
of	O
CD4	B-T103
(	I-T103
+	I-T103
)	I-T103
CD25	I-T103
(	I-T103
+	I-T103
)	I-T103
Foxp3	I-T103
(	I-T103
+	I-T103
)	I-T103
Treg	I-T103
cells	I-T103
and	O
Th17	B-T017
cells	I-T017
in	O
tumor	B-T017
tissue	I-T017
,	O
and	O
the	O
levels	O
of	O
IL	B-T103
-	I-T103
10	I-T103
,	O
TGF	B-T103
-	I-T103
β	I-T103
,	O
IL	B-T103
-	I-T103
17A	I-T103
,	O
IL	B-T103
-	I-T103
2	I-T103
,	O
and	O
IFN	B-T103
-	I-T103
γ	I-T103
in	O
serum	B-T031
of	O
the	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
was	O
observered	O
.	O

IL	B-T103
-	I-T103
17A	I-T103
was	O
injected	O
to	O
the	O
SBE	B-T103
treated	O
mice	B-T204
from	O
day	O
9	O
post	O
H22	O
inoculation	B-T058
to	O
examine	O
its	O
effect	O
on	O
tumor	O
growth	O
.	O

SBE	B-T103
treatment	O
inhibited	O
the	O
proliferation	B-T038
of	O
HepG2	B-T017
cells	I-T017
in	O
vitro	O
with	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
significantly	O
suppressed	O
the	O
tumor	O
growth	O
of	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
.	O

Meanwhile	O
,	O
it	O
increased	O
NK	B-T038
cells	I-T038
'	I-T038
cytotoxicity	I-T038
in	O
spleen	B-T017
,	O
down	B-T038
-	I-T038
regulated	I-T038
the	O
amount	O
of	O
CD4	B-T103
(	I-T103
+	I-T103
)	I-T103
CD25	I-T103
(	I-T103
+	I-T103
)	I-T103
Foxp3	I-T103
(	I-T103
+	I-T103
)	I-T103
Treg	I-T103
cells	I-T103
and	O
Th17	B-T017
cells	I-T017
in	O
tumor	B-T017
tissue	I-T017
,	O
and	O
decreased	O
IL	B-T103
-	I-T103
10	I-T103
,	O
TGF	B-T103
-	I-T103
β	I-T103
,	O
and	O
IL	B-T103
-	I-T103
17A	I-T103
levels	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
whereas	O
increased	O
IL	B-T103
-	I-T103
2	I-T103
and	O
IFN	B-T103
-	I-T103
γ	I-T103
levels	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
the	O
serum	B-T031
of	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
.	O

Moreover	O
,	O
administration	O
of	O
recombinant	B-T204
mouse	I-T204
IL	B-T103
-	I-T103
17A	I-T103
reversed	O
the	O
anti	O
-	O
tumor	O
effects	O
of	O
SBE	B-T103
.	O

SBE	B-T103
could	O
inhibit	O
the	O
proliferation	B-T038
of	O
HepG2	B-T017
cells	I-T017
in	O
vitro	O
.	O

Meanwhile	O
,	O
SBE	B-T103
also	O
could	O
inhibit	O
the	O
growth	B-T038
of	O
H22	O
implanted	B-T038
tumor	I-T038
in	O
hepatoma	O
H22	O
-	O
bearing	O
mice	B-T204
,	O
and	O
this	O
function	O
might	O
be	O
associated	O
with	O
immunomodulatory	B-T038
activity	I-T038
through	O
down	B-T038
-	I-T038
regulating	I-T038
of	O
Treg	B-T017
cells	I-T017
and	O
manipulating	B-T038
Th1	B-T038
/	O
Th17	B-T038
immune	I-T038
response	I-T038
.	O

Clinical	O
characteristics	O
of	O
genital	O
chlamydia	O
infection	O
in	O
pelvic	B-T038
inflammatory	I-T038
disease	I-T038

Chlamydia	B-T038
infection	I-T038
in	O
acute	B-T038
pelvic	I-T038
inflammatory	I-T038
disease	I-T038
(	O
PID	B-T038
)	O
is	O
associated	O
with	O
serious	O
complications	B-T038
including	O
ectopic	B-T038
pregnancy	I-T038
,	O
tubal	B-T038
infertility	I-T038
,	O
Fitz	B-T038
-	I-T038
Hugh	I-T038
-	I-T038
Curtis	I-T038
syndrome	I-T038
and	O
tubo	B-T038
-	I-T038
ovarian	I-T038
abscess	I-T038
(	O
TOA	B-T038
)	O
.	O

This	O
study	B-T062
compared	O
clinical	B-T170
and	O
laboratory	B-T170
data	I-T170
between	O
PID	B-T038
with	O
and	O
without	O
chlamydia	B-T038
infection	I-T038
.	O

The	O
medical	B-T170
records	I-T170
of	O
497	O
women	B-T098
who	O
were	O
admitted	O
with	O
PID	B-T038
between	O
2002	O
and	O
2011	O
were	O
reviewed	O
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	B-T098
(	O
PID	B-T038
with	O
and	O
without	O
chlamydia	B-T038
infection	I-T038
)	O
,	O
which	O
were	O
compared	O
in	O
terms	O
of	O
the	O
patients	O
'	O
characteristics	O
,	O
clinical	O
presentation	O
,	O
and	O
laboratory	B-T033
findings	I-T033
,	O
including	O
inflammatory	O
markers	B-T201
.	O

The	O
chlamydia	B-T098
and	O
non	B-T098
-	I-T098
chlamydia	I-T098
groups	I-T098
comprised	O
175	O
and	O
322	O
women	B-T098
,	O
respectively	O
.	O

The	O
patients	O
in	O
the	O
chlamydia	B-T098
group	I-T098
were	O
younger	O
and	O
had	O
a	O
higher	O
rate	O
of	O
TOA	B-T038
,	O
a	O
longer	O
mean	O
hospital	O
stay	O
,	O
and	O
had	O
undergone	O
more	O
surgeries	B-T058
than	O
the	O
patients	O
in	O
the	O
non	B-T098
-	I-T098
chlamydia	I-T098
group	I-T098
.	O

The	O
erythrocyte	B-T033
sedimentation	I-T033
rate	I-T033
(	O
ESR	B-T033
)	O
,	O
C	B-T103
-	I-T103
reactive	I-T103
protein	I-T103
(	O
CRP	B-T103
)	O
,	O
and	O
CA	B-T103
-	I-T103
125	I-T103
level	O
were	O
higher	O
in	O
the	O
chlamydia	B-T098
group	I-T098
than	O
in	O
the	O
non	B-T098
-	I-T098
chlamydia	I-T098
group	I-T098
,	O
but	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
white	O
blood	O
cell	O
count	O
between	O
the	O
two	O
groups	B-T098
.	O

The	O
CA	B-T103
-	I-T103
125	I-T103
level	O
was	O
the	O
strongest	O
predictor	O
of	O
chlamydia	B-T038
infection	I-T038
,	O
followed	O
by	O
the	O
ESR	B-T033
and	O
CRP	B-T103
level	O
.	O

The	O
area	B-T082
under	O
the	O
receiving	O
operating	O
curve	O
for	O
CA	B-T103
-	I-T103
125	I-T103
,	O
ESR	B-T033
,	O
and	O
CRP	B-T103
was	O
0	O
.	O
804	O
,	O
0	O
.	O
755	O
,	O
and	O
0	O
.	O
663	O
,	O
respectively	O
.	O

Chlamydia	B-T038
infection	I-T038
in	O
acute	B-T038
PID	I-T038
is	O
associated	O
with	O
increased	O
level	O
of	O
inflammatory	O
markers	B-T201
,	O
such	O
as	O
CA	B-T103
-	I-T103
125	I-T103
,	O
ESR	B-T033
and	O
CRP	B-T103
,	O
incidence	O
of	O
TOA	B-T038
,	O
operation	B-T058
risk	O
,	O
and	O
longer	O
hospitalization	B-T058
.	O

Incidence	O
and	O
effect	O
of	O
variant	O
histology	B-T091
on	O
oncological	O
outcomes	O
in	O
patients	O
with	O
bladder	B-T038
cancer	I-T038
treated	O
with	O
radical	B-T058
cystectomy	I-T058

We	O
sought	O
to	O
describe	O
incidence	O
of	O
histological	O
variants	O
after	O
radical	B-T058
cystectomy	I-T058
(	O
RC	B-T058
)	O
due	O
to	O
bladder	B-T038
cancer	I-T038
(	O
BCa	B-T038
)	O
.	O

Moreover	O
,	O
we	O
investigated	O
survival	O
outcomes	O
accounting	O
for	O
this	O
parameter	O
.	O

We	O
retrospectively	O
evaluated	B-T058
data	O
from	O
1	O
,	O
067	O
patients	O
with	O
BCa	B-T038
treated	O
with	O
RC	B-T058
between	O
1990	O
and	O
2013	O
at	O
a	O
single	B-T092
tertiary	I-T092
care	I-T092
referral	I-T092
center	I-T092
.	O

All	O
specimen	O
were	O
evaluated	B-T058
by	O
dedicated	O
uropathologists	B-T097
.	O

Univariable	B-T170
and	I-T170
multivariable	I-T170
Cox	I-T170
regression	I-T170
analyses	I-T170
tested	O
the	O
effect	O
of	O
different	O
histopathological	O
variant	O
on	O
recurrence	O
,	O
cancer	O
-	O
specific	O
mortality	O
(	O
CSM	O
)	O
,	O
and	O
overall	O
mortality	O
(	O
OM	O
)	O
after	O
accounting	O
for	O
all	O
available	O
confounders	O
.	O

Of	O
1	O
,	O
067	O
patients	O
,	O
729	O
(	O
68	O
.	O
3	O
%	O
)	O
harbored	O
pure	B-T038
urothelial	I-T038
BCa	I-T038
while	O
338	O
(	O
31	O
.	O
7	O
%	O
)	O
were	O
found	O
to	O
have	O
a	O
variant	O
.	O

Considering	O
uncommon	O
variants	O
,	O
21	O
(	O
2	O
.	O
0	O
%	O
)	O
were	O
sarcomatoid	B-T038
,	O
10	O
(	O
0	O
.	O
9	O
%	O
)	O
lymphoepitelial	B-T038
,	O
19	O
(	O
1	O
.	O
8	O
%	O
)	O
small	B-T038
cell	I-T038
,	O
109	O
(	O
10	O
.	O
2	O
%	O
)	O
squamous	B-T038
,	O
89	O
(	O
8	O
.	O
3	O
%	O
)	O
micropapillary	B-T038
,	O
23	O
(	O
2	O
.	O
2	O
%	O
)	O
glandular	B-T038
,	O
34	O
(	O
3	O
.	O
2	O
%	O
)	O
mixed	O
variants	O
,	O
and	O
33	O
(	O
3	O
.	O
1	O
%	O
)	O
were	O
found	O
with	O
other	O
types	O
of	O
variants	O
.	O

With	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
6	O
.	O
2	O
years	O
,	O
343	O
recurrence	O
,	O
365	O
CSM	O
,	O
and	O
451	O
OM	O
were	O
recorded	O
,	O
respectively	O
.	O

At	O
multivariable	B-T170
Cox	I-T170
regression	I-T170
analyses	I-T170
,	O
the	O
presence	O
of	O
small	B-T038
cell	I-T038
variant	I-T038
was	O
associated	O
with	O
higher	O
recurrence	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
3	O
.	O
47	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
CSM	O
(	O
HR	O
=	O
3	O
.	O
30	O
,	O
P	O
<	O
0	O
.	O
04	O
)	O
,	O
and	O
OM	O
(	O
HR	O
=	O
2	O
.	O
97	O
,	O
P	O
<	O
0	O
.	O
003	O
)	O
as	O
compared	O
with	O
pure	O
urothelial	B-T038
cancer	I-T038
.	O

Conversely	O
,	O
no	O
survival	O
differences	O
were	O
recorded	O
considering	O
other	O
histological	O
variants	O
(	O
all	O
P	O
>	O
0	O
.	O
1	O
)	O
.	O

Our	O
study	O
confirms	O
that	O
histological	O
variant	O
is	O
not	O
an	O
infrequent	O
event	O
at	O
RC	B-T058
specimen	O
.	O

However	O
,	O
in	O
our	O
single	B-T092
-	I-T092
center	I-T092
series	I-T092
,	O
only	O
patients	O
found	O
with	O
small	B-T038
cell	I-T038
variant	I-T038
were	O
associated	O
with	O
a	O
negative	B-T033
effect	O
on	O
survival	O
after	O
RC	B-T058
.	O

Psychometric	B-T058
properties	O
of	O
the	O
Japanese	O
version	B-T170
of	O
short	O
forms	O
of	O
the	O
Pain	B-T170
Catastrophizing	I-T170
Scale	I-T170
in	O
participants	B-T098
with	O
musculoskeletal	B-T033
pain	I-T033
:	O
A	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062

The	O
Pain	B-T170
Catastrophizing	I-T170
Scale	I-T170
(	O
PCS	B-T170
)	O
is	O
a	O
commonly	O
used	O
as	O
measure	O
of	O
pain	B-T038
catastrophizing	I-T038
.	O

The	O
scale	B-T170
comprises	O
13	O
items	O
related	O
to	O
magnification	B-T058
,	O
rumination	B-T038
,	O
and	O
helplessness	B-T038
.	O

To	O
facilitate	O
quick	O
screening	B-T058
and	O
to	O
reduce	O
participant	B-T098
'	I-T098
s	I-T098
burden	O
,	O
the	O
four	O
-	O
item	O
and	O
six	O
-	O
item	O
short	O
forms	O
of	O
the	O
English	O
version	B-T170
of	O
the	O
PCS	B-T170
were	O
developed	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
psychometric	B-T058
properties	O
of	O
a	O
Japanese	O
version	B-T170
of	O
the	O
short	O
forms	O
of	O
PCS	B-T170
using	O
a	O
contemporary	O
approach	O
called	O
Rasch	B-T062
analysis	I-T062
.	O

A	O
total	O
of	O
216	O
patients	O
with	O
musculoskeletal	B-T038
disorders	I-T038
were	O
recruited	O
in	O
this	O
study	B-T062
.	O

Participants	B-T098
completed	O
study	B-T062
measures	O
,	O
which	O
included	O
the	O
pain	B-T201
intensity	I-T201
,	O
the	O
Pain	B-T170
Catastrophizing	I-T170
Scale	I-T170
(	O
PCS	B-T170
)	O
,	O
and	O
the	O
Tampa	B-T170
Scale	I-T170
of	I-T170
Kinesiophobia	I-T170
(	O
TSK	B-T170
)	O
.	O

Furthermore	O
,	O
the	O
four	O
-	O
item	O
(	O
items	O
3	O
,	O
6	O
,	O
8	O
,	O
and	O
11	O
)	O
and	O
six	O
-	O
item	O
(	O
items	O
4	O
,	O
5	O
,	O
6	O
,	O
10	O
,	O
11	O
,	O
and	O
13	O
)	O
short	O
forms	O
of	O
the	O
Japanese	O
version	B-T170
of	O
PCS	B-T170
were	O
measured	O
.	O

We	O
used	O
Rasch	B-T062
analysis	I-T062
to	O
analyze	O
the	O
psychometric	B-T058
properties	O
of	O
the	O
original	O
,	O
four	O
-	O
item	O
,	O
and	O
six	O
-	O
item	O
short	O
forms	O
of	O
PCS	B-T170
.	O

Rasch	B-T062
analysis	I-T062
showed	O
that	O
both	O
short	O
forms	O
of	O
PCS	B-T170
had	O
acceptable	O
internal	O
consistency	O
,	O
unidimensionality	B-T082
,	O
and	O
no	O
notable	O
DIF	O
and	O
were	O
functional	O
on	O
the	O
category	B-T170
rating	I-T170
scale	I-T170
.	O

However	O
,	O
four	O
-	O
item	O
short	O
form	O
of	O
PCS	B-T170
had	O
two	O
misfit	O
items	O
.	O

Six	O
-	O
item	O
short	O
form	O
of	O
PCS	B-T170
has	O
acceptable	O
psychometric	B-T058
properties	O
and	O
is	O
suitable	O
for	O
use	O
in	O
participants	B-T098
with	O
musculoskeletal	B-T033
pain	I-T033
.	O

Thus	O
,	O
six	O
-	O
item	O
can	O
be	O
used	O
as	O
brief	O
instruments	B-T074
to	O
evaluate	B-T058
pain	B-T038
catastrophizing	I-T038
.	O

A	O
novel	O
quantitative	B-T062
PCR	I-T062
detects	O
Babesia	B-T204
infection	B-T038
in	O
patients	O
not	O
identified	O
by	O
currently	O
available	O
non	O
-	O
nucleic	O
acid	O
amplification	O
tests	O

Ticks	B-T204
transmit	O
Babesia	B-T204
microti	I-T204
,	O
the	O
causative	B-T033
agents	I-T033
of	O
babesiosis	B-T038
in	O
North	B-T082
America	I-T082
and	O
Europe	B-T082
.	O

Babesiosis	B-T038
is	O
now	O
endemic	B-T038
in	O
Northeastern	B-T082
USA	B-T082
and	O
affects	O
people	B-T098
of	O
all	O
ages	O
.	O

Babesia	B-T204
species	I-T204
infect	O
erythrocytes	B-T017
and	O
can	O
be	O
transmitted	B-T038
through	O
blood	B-T058
transfusion	I-T058
.	O

Whole	B-T031
blood	I-T031
and	O
blood	B-T103
products	I-T103
,	O
which	O
are	O
not	O
tested	O
for	O
Babesia	B-T204
,	O
can	O
cause	O
transfusion	B-T058
-	O
transmitted	B-T038
babesiosis	B-T038
(	O
TTB	B-T038
)	O
resulting	O
in	O
severe	O
consequences	O
in	O
the	O
immuno	B-T033
-	I-T033
compromised	I-T033
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
epidemiological	B-T062
evaluation	I-T062
of	O
babesiosis	B-T038
in	O
a	O
tick	B-T038
-	I-T038
infested	I-T038
state	I-T038
.	O

We	O
examined	B-T033
blood	B-T031
samples	I-T031
from	O
192	O
patients	O
who	O
visited	O
clinics	B-T092
during	O
the	O
active	O
tick	B-T038
-	I-T038
borne	I-T038
diseases	I-T038
season	O
,	O
using	O
a	O
newly	O
developed	O
qPCR	B-T062
assay	I-T062
that	O
uses	O
the	O
specific	O
molecular	B-T103
beacon	I-T103
probe	I-T103
.	O

Due	O
to	O
the	O
absence	O
of	O
clear	O
symptomology	B-T033
,	O
clinical	O
laboratories	O
did	O
not	O
test	O
131	O
samples	B-T031
by	O
IFA	B-T058
,	O
FISH	B-T062
or	O
microscopic	B-T058
examination	I-T058
of	O
Giemsa	B-T103
-	I-T103
stained	I-T103
blood	B-T058
smears	I-T058
.	O

Babesia	B-T204
infection	B-T038
was	O
detected	O
in	O
all	O
age	O
groups	O
by	O
FISH	B-T062
and	O
microscopy	B-T058
;	O
notably	O
patients	O
>	O
40	O
years	O
of	O
age	O
represented	O
64	O
%	O
of	O
tested	O
samples	B-T031
and	O
13	O
%	O
were	O
younger	O
patients	O
.	O

We	O
tested	O
all	O
samples	B-T031
using	O
qPCR	B-T062
and	O
found	O
that	O
38	O
%	O
were	O
positive	B-T033
for	O
Babesia	B-T204
.	O

Of	O
28	O
samples	B-T031
that	O
were	O
positive	B-T033
by	O
FISH	B-T062
,	O
27	O
(	O
96	O
%	O
)	O
were	O
also	O
positive	B-T033
by	O
qPCR	B-T062
indicating	O
high	O
congruency	O
between	O
nucleic	B-T058
acid	I-T058
based	I-T058
tests	I-T058
.	O

Interestingly	O
,	O
of	O
78	O
asymptomatic	B-T033
samples	B-T031
not	O
tested	O
by	O
FISH	B-T062
,	O
22	O
were	O
positive	B-T033
by	O
our	O
qPCR	B-T062
.	O

Direct	O
detection	B-T058
of	O
Babesia	B-T204
relies	O
upon	O
microscopic	B-T058
examination	I-T058
of	O
patient	O
blood	B-T058
smears	I-T058
,	O
which	O
is	O
labor	O
intensive	O
,	O
difficult	O
to	O
scale	O
up	O
,	O
requires	O
specific	O
expertise	O
and	O
is	O
hence	O
,	O
often	O
not	O
performed	O
.	O

In	O
fact	O
,	O
a	O
clinical	O
laboratory	O
examined	B-T033
only	O
23	O
of	O
86	O
blood	B-T031
samples	I-T031
obtained	O
from	O
two	O
different	O
counties	B-T082
by	O
microscopy	B-T058
.	O

By	O
considering	O
individuals	B-T098
positive	B-T033
for	O
Babesia	B-T204
infection	B-T038
when	O
results	O
from	O
currently	O
available	O
microscopy	B-T058
,	O
FISH	B-T062
or	O
serological	B-T058
tests	I-T058
were	O
positive	B-T033
,	O
we	O
found	O
that	O
our	O
qPCR	B-T062
is	O
highly	O
sensitive	O
(	O
96	O
.	O
2	O
%	O
)	O
and	O
showed	O
a	O
specificity	O
of	O
70	O
.	O
5	O
%	O
for	O
Babesia	B-T204
.	O

Robust	O
qPCR	B-T062
using	O
specific	O
probes	B-T103
can	O
be	O
highly	O
useful	O
for	O
efficient	O
and	O
appropriate	O
diagnosis	B-T062
of	O
babesiosis	B-T038
in	O
patients	O
in	O
conjunction	O
with	O
conventional	O
diagnostics	B-T062
,	O
or	O
as	O
a	O
stand	O
-	O
alone	O
test	O
,	O
especially	O
for	O
donated	O
blood	B-T058
screening	I-T058
.	O

The	O
use	O
of	O
a	O
nucleic	B-T058
acid	I-T058
amplification	I-T058
test	I-T058
based	O
screening	B-T058
of	I-T058
blood	I-T058
and	O
blood	B-T103
products	I-T103
could	O
prevent	O
TTB	B-T038
.	O

Historical	O
relationships	O
of	O
three	O
enigmatic	O
phasianid	B-T204
genera	I-T204
(	O
Aves	B-T204
:	O
Galliformes	B-T204
)	O
inferred	O
using	O
phylogenomic	B-T170
and	I-T170
mitogenomic	I-T170
data	I-T170

The	O
phylogeny	O
of	O
the	O
Phasianidae	B-T204
(	O
pheasants	B-T204
,	O
partridges	B-T204
,	O
and	O
allies	B-T204
)	O
has	O
been	O
studied	O
extensively	O
.	O

However	O
,	O
these	O
studies	O
have	O
largely	O
ignored	O
three	O
enigmatic	O
genera	O
because	O
of	O
scarce	O
DNA	B-T103
source	B-T033
material	I-T033
and	O
limited	O
overlapping	O
phylogenetic	B-T170
data	I-T170
:	O
blood	B-T204
pheasants	I-T204
(	O
Ithaginis	B-T204
)	O
,	O
snow	B-T204
partridges	I-T204
(	O
Lerwa	B-T204
)	O
,	O
and	O
long	B-T204
-	I-T204
billed	I-T204
partridges	I-T204
(	O
Rhizothera	B-T204
)	O
.	O

Thus	O
,	O
phylogenetic	O
positions	O
of	O
these	O
three	O
genera	O
remain	O
uncertain	O
in	O
what	O
is	O
otherwise	O
a	O
well	O
-	O
resolved	O
phylogeny	O
.	O

Previous	O
studies	O
using	O
different	O
data	O
types	O
place	O
Lerwa	B-T204
and	O
Ithaginis	B-T204
in	O
similar	O
positions	O
,	O
but	O
the	O
absence	O
of	O
overlapping	O
data	O
means	O
the	O
relationship	O
between	O
them	O
could	O
not	O
be	O
inferred	O
.	O

Rhizothera	B-T204
was	O
originally	O
described	O
in	O
the	O
genus	O
Perdix	B-T204
(	O
true	B-T204
partridges	I-T204
)	O
,	O
although	O
a	O
partial	O
cytochrome	B-T103
b	I-T103
(	O
CYB	B-T103
)	O
sequence	O
suggests	O
it	O
is	O
sister	O
to	O
Pucrasia	B-T204
(	O
koklass	B-T204
pheasant	I-T204
)	O
.	O

To	O
identify	O
robust	O
relationships	O
among	O
Ithaginis	B-T204
,	O
Lerwa	B-T204
,	O
Rhizothera	B-T204
,	O
and	O
their	O
phasianid	B-T204
relatives	I-T204
,	O
we	O
used	O
3692	O
ultra	B-T017
-	I-T017
conserved	I-T017
element	I-T017
(	I-T017
UCE	I-T017
)	I-T017
loci	I-T017
and	O
complete	O
mitogenomes	B-T017
from	O
19	O
species	B-T170
including	O
previously	O
hypothesized	O
relatives	O
of	O
the	O
three	O
focal	O
genera	O
and	O
representatives	O
from	O
all	O
major	O
phasianid	B-T204
clades	I-T204
.	O

We	O
used	O
DNA	B-T103
extracted	I-T103
from	O
historical	O
specimen	B-T033
toepads	I-T033
for	O
species	O
that	O
lacked	B-T017
fresh	I-T017
tissue	I-T017
in	O
museum	B-T058
collections	I-T058
.	O

Maximum	O
likelihood	O
and	O
multispecies	O
coalescent	O
UCE	O
analyses	O
strongly	O
supported	O
Lerwa	B-T204
sister	O
to	O
a	O
large	B-T204
clade	I-T204
which	O
included	O
Ithaginis	B-T204
at	O
its	O
base	O
,	O
and	O
also	O
including	O
turkey	B-T204
,	O
grouse	B-T204
,	O
typical	O
pheasants	B-T204
,	O
tragopans	B-T204
,	O
Pucrasia	B-T204
,	O
and	O
Perdix	B-T204
.	O

Rhizothera	B-T204
was	O
also	O
in	O
this	O
clade	B-T204
,	O
sister	O
to	O
a	O
diverse	O
group	O
comprising	O
Perdix	B-T204
,	O
typical	O
pheasants	B-T204
,	O
Pucrasia	B-T204
,	O
turkey	B-T204
and	O
grouse	B-T204
.	O

Mitogenomic	B-T170
genealogies	I-T170
differed	O
from	O
UCEs	O
topologies	O
,	O
supporting	O
a	O
sister	O
relationship	O
between	O
Ithaginis	B-T204
and	O
Lerwa	B-T204
rather	O
than	O
a	O
grade	O
.	O

The	O
position	O
of	O
Rhizothera	B-T204
using	O
mitogenomes	B-T017
depended	O
on	O
analytical	B-T062
choices	I-T062
.	O

Unpartitioned	O
and	O
codon	B-T058
-	I-T058
based	I-T058
analyses	I-T058
placed	O
Rhizothera	B-T204
sister	O
to	O
a	O
tragopan	B-T204
clade	I-T204
,	O
whereas	O
a	O
partitioned	O
DNA	B-T170
model	I-T170
of	O
the	O
mitogenome	B-T017
was	O
congruent	O
with	O
UCE	B-T033
results	I-T033
.	O

In	O
all	O
mitogenome	B-T058
analyses	I-T058
,	O
Pucrasia	B-T204
was	O
sister	O
to	O
a	O
clade	B-T204
including	O
Perdix	B-T204
and	O
the	O
typical	O
pheasants	B-T204
with	O
high	O
support	O
,	O
in	O
contrast	O
to	O
UCEs	O
and	O
published	B-T170
nuclear	I-T170
intron	I-T170
data	I-T170
.	O

Due	O
to	O
the	O
strong	O
support	O
and	O
consistent	O
topology	O
provided	O
by	O
all	O
UCE	O
analyses	O
,	O
we	O
have	O
identified	O
phylogenetic	O
relationships	O
of	O
these	O
three	O
enigmatic	O
,	O
poorly	O
-	O
studied	O
,	O
phasianid	B-T204
taxa	I-T204
.	O

A	O
novel	O
combination	O
treatment	O
to	O
stimulate	B-T058
bone	B-T033
healing	I-T033
and	O
regeneration	B-T038
under	O
hypoxic	B-T038
conditions	I-T038
:	O
photobiomodulation	B-T058
and	O
melatonin	B-T103

Melatonin	B-T103
has	O
anabolic	B-T038
effects	I-T038
on	O
the	O
bone	B-T017
,	O
even	O
under	O
hypoxia	B-T038
,	O
and	O
laser	O
irradiation	O
has	O
been	O
shown	O
to	O
improve	O
osteoblastic	B-T038
differentiation	I-T038
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
whether	O
laser	O
irradiation	O
and	O
melatonin	B-T103
would	O
have	O
synergistic	O
effects	O
on	O
osteoblastic	B-T038
differentiation	I-T038
and	O
mineralization	B-T038
under	O
hypoxic	B-T038
conditions	I-T038
.	O

MC3T3	B-T017
-	I-T017
E1	I-T017
cells	I-T017
were	O
exposed	O
to	O
1	O
%	O
oxygen	B-T033
tension	I-T033
for	O
the	O
hypoxia	B-T038
condition	I-T038
.	O

The	O
cells	B-T017
were	O
divided	O
into	O
four	O
groups	O
:	O
G1	O
-	O
osteoblast	B-T038
differentiation	I-T038
medium	B-T103
only	O
(	O
as	O
the	O
hypoxic	B-T038
condition	I-T038
)	O
,	O
G2	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	B-T103
only	O
,	O
G3	O
-	O
laser	O
irradiation	O
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
only	O
,	O
and	O
G4	O
-	O
treatment	O
with	O
50	O
μM	O
melatonin	B-T103
and	O
laser	O
irradiation	O
(	O
808	O
nm	O
,	O
80	O
mW	O
,	O
GaAlAs	O
diode	O
)	O
.	O

Immunoblotting	B-T058
showed	O
that	O
osterix	B-T103
expression	B-T038
was	O
markedly	O
increased	O
in	O
the	O
melatonin	B-T103
-	O
treated	O
and	O
laser	O
-	O
irradiated	O
cells	B-T017
at	O
48	O
and	O
72	O
h	O
.	O

In	O
addition	O
,	O
alkaline	B-T103
phosphatase	I-T103
activity	O
significantly	O
increased	O
and	O
continued	O
to	O
rise	O
throughout	O
the	O
experiment	B-T062
.	O

Alizarin	B-T058
Red	I-T058
staining	I-T058
showed	O
markedly	O
increased	O
mineralized	B-T038
nodules	B-T038
as	O
compared	O
with	O
only	O
melatonin	B-T103
-	O
treated	O
or	O
laser	O
-	O
irradiated	O
cells	B-T017
at	O
day	O
7	O
,	O
which	O
significantly	O
increased	O
by	O
day	O
14	O
.	O

Moreover	O
,	O
when	O
melatonin	B-T103
-	O
treated	O
cells	B-T017
were	O
laser	O
-	O
irradiated	O
,	O
the	O
differentiation	B-T038
and	O
mineralization	B-T038
of	O
cells	B-T017
were	O
found	O
to	O
involve	O
p38	B-T103
MAPK	I-T103
and	O
PRKD1	B-T103
signaling	B-T038
mechanisms	I-T038
.	O

However	O
,	O
the	O
enhanced	O
effects	O
of	O
laser	O
irradiation	O
with	O
melatonin	B-T103
were	O
markedly	O
inhibited	O
when	O
the	O
cells	B-T017
were	O
treated	O
with	O
luzindole	B-T103
,	O
a	O
selective	O
melatonin	B-T103
receptor	I-T103
antagonist	I-T103
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
laser	O
irradiation	O
could	O
promote	O
the	O
effect	O
of	O
melatonin	B-T103
on	O
the	O
differentiation	B-T038
and	O
mineralization	B-T038
of	O
MC3T3	B-T017
-	I-T017
E1	I-T017
cells	I-T017
under	O
hypoxic	B-T038
conditions	I-T038
,	O
and	O
that	O
this	O
process	O
is	O
mediated	O
through	O
melatonin	B-T103
1	I-T103
/	I-T103
2	I-T103
receptors	I-T103
and	O
PKRD	B-T103
/	O
p38	B-T103
signaling	B-T038
pathways	I-T038
.	O

Aquaporin	B-T103
-	I-T103
2	I-T103
excretion	B-T038
in	O
hospitalized	O
patients	O
with	O
cirrhosis	B-T038
:	O
Relation	O
to	O
development	O
of	O
renal	B-T038
insufficiency	I-T038
and	O
mortality	O

Urinary	O
aquaporin	B-T103
-	I-T103
2	I-T103
(	O
AQP2	B-T103
)	O
is	O
a	O
parameter	O
of	O
water	B-T038
transport	I-T038
in	O
the	O
principal	B-T017
cells	I-T017
in	O
the	O
distal	B-T082
part	I-T082
of	O
the	O
nephron	B-T017
and	O
involved	O
in	O
water	B-T038
retention	I-T038
in	O
cirrhosis	B-T038
and	O
may	O
be	O
a	O
marker	B-T201
of	O
renal	B-T038
function	I-T038
.	O

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
evaluate	O
AQP2	B-T103
as	O
a	O
predictor	B-T170
of	O
renal	B-T038
insufficiency	I-T038
and	O
death	B-T038
in	O
patients	O
with	O
cirrhosis	B-T038
.	O

Urine	B-T031
samples	I-T031
from	O
199	O
patients	O
(	O
90	O
patients	O
without	O
organ	B-T033
failure	I-T033
[	O
Group	O
1	O
]	O
,	O
58	O
patients	O
with	O
organ	B-T033
failure	I-T033
excluding	O
renal	B-T038
failure	I-T038
[	O
Group	O
2	O
]	O
,	O
and	O
51	O
patients	O
with	O
organ	B-T033
failure	I-T033
including	O
renal	B-T038
failure	I-T038
[	O
Group	O
3	O
]	O
)	O
from	O
the	O
CANONIC	B-T062
study	I-T062
were	O
analyzed	O
for	O
urine	B-T031
AQP2	B-T103
and	O
urine	B-T201
osmolality	I-T201
.	O

There	O
was	O
no	O
difference	O
in	O
AQP2	B-T103
between	O
the	O
three	O
groups	O
.	O

Urine	B-T201
osmolality	I-T201
was	O
significantly	O
lower	O
in	O
patients	O
in	O
Group	O
3	O
versus	O
Group	O
1	O
and	O
Group	O
2	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
.	O

No	B-T033
relation	I-T033
was	O
found	O
between	O
AQP2	B-T103
and	O
glomerular	B-T058
filtration	I-T058
rate	I-T058
or	O
creatinine	B-T103
;	O
however	O
,	O
AQP2	B-T103
was	O
a	O
significant	O
predictor	B-T170
of	O
the	O
development	O
of	O
renal	B-T038
insufficiency	I-T038
(	O
P	O
=	O
0	O
.	O
0485	O
)	O
.	O

In	O
a	O
univariate	O
analysis	O
,	O
AQP2	B-T103
was	O
a	O
significant	O
predictor	B-T170
of	O
14	O
and	O
28	O
-	O
day	O
survival	O
,	O
but	O
this	O
was	O
not	O
confirmed	O
in	O
multivariate	O
analysis	O
.	O

Aquaporin	B-T103
-	I-T103
2	I-T103
was	O
not	O
associated	O
with	O
disease	O
severity	O
or	O
markers	O
of	O
renal	B-T038
function	I-T038
but	O
was	O
a	O
predictor	B-T170
for	O
the	O
development	O
of	O
renal	B-T038
insufficiency	I-T038
and	O
death	B-T038
.	O

Therefore	O
,	O
its	O
future	O
use	O
as	O
marker	B-T201
of	O
renal	B-T038
insufficiency	I-T038
could	O
be	O
promising	O
,	O
but	O
further	O
research	B-T062
is	O
needed	O
before	O
it	O
can	O
be	O
considered	O
a	O
clinical	O
useful	O
tool	O
.	O

Decompression	B-T058
Surgery	I-T058
Alone	O
Versus	O
Decompression	B-T058
Plus	O
Fusion	B-T058
in	O
Symptomatic	O
Lumbar	B-T038
Spinal	I-T038
Stenosis	I-T038
:	O
A	O
Swiss	B-T098
Prospective	B-T062
Multi	I-T062
-	I-T062
center	I-T062
Cohort	I-T062
Study	I-T062
with	O
3	O
Years	O
of	O
Follow	B-T062
-	I-T062
up	I-T062

Retrospective	B-T062
analysis	I-T062
of	O
a	O
prospective	B-T062
,	I-T062
multicenter	I-T062
cohort	I-T062
study	I-T062
.	O

To	O
estimate	O
the	O
added	O
effect	O
of	O
surgical	B-T058
fusion	I-T058
as	O
compared	O
to	O
decompression	B-T058
surgery	I-T058
alone	O
in	O
symptomatic	O
lumbar	B-T038
spinal	I-T038
stenosis	I-T038
patients	O
with	O
spondylolisthesis	B-T038
.	O

The	O
optimal	B-T058
surgical	I-T058
management	I-T058
of	O
lumbar	B-T038
spinal	I-T038
stenosis	I-T038
patients	O
with	O
spondylolisthesis	B-T038
remains	O
controversial	O
.	O

Patients	O
of	O
the	O
LSOS	B-T062
with	O
confirmed	O
DLSS	B-T038
and	O
spondylolisthesis	B-T038
were	O
enrolled	O
in	O
this	O
study	O
.	O

The	O
outcomes	B-T062
of	O
this	O
study	O
were	O
Spinal	B-T017
Stenosis	I-T017
Measure	O
(	O
SSM	O
)	O
symptoms	B-T033
(	O
score	O
range	O
1	O
-	O
5	O
,	O
best	O
-	O
worst	O
)	O
and	O
function	O
(	O
1	O
-	O
4	O
)	O
over	O
time	O
,	O
measured	O
at	O
baseline	O
,	O
6	O
,	O
12	O
,	O
24	O
and	O
36	O
months	O
follow	B-T062
-	I-T062
up	I-T062
.	O

In	O
order	O
to	O
quantify	O
the	O
effect	O
of	O
fusion	B-T058
surgery	I-T058
as	O
compared	O
to	O
decompression	B-T058
alone	O
and	O
number	B-T033
of	I-T033
decompressed	I-T033
levels	I-T033
,	O
we	O
used	O
mixed	O
effects	O
models	O
and	O
accounted	O
for	O
the	O
repeated	B-T062
observations	I-T062
in	O
main	O
outcomes	B-T062
(	O
SSM	O
symptoms	B-T033
and	O
SSM	O
function	O
)	O
over	O
time	O
.	O

In	O
addition	O
to	O
individual	O
patients	O
'	O
random	O
effects	O
,	O
we	O
also	O
fitted	O
random	O
slopes	O
for	O
follow	B-T033
-	I-T033
up	I-T033
time	O
points	O
and	O
compared	O
these	O
two	O
approaches	O
with	O
Akaike	B-T170
'	I-T170
s	I-T170
Information	I-T170
Criterion	I-T170
(	O
AIC	B-T170
)	O
and	O
the	O
chi	B-T170
-	I-T170
squared	I-T170
test	I-T170
.	O

Confounders	O
were	O
adjusted	O
with	O
fixed	O
effects	O
for	O
age	O
,	O
gender	O
,	O
BMI	B-T201
,	O
diabetes	B-T038
,	O
CIRS	O
musculoskeletal	B-T038
disorders	I-T038
and	O
duration	B-T103
of	O
symptoms	B-T033
.	O

One	O
hundred	O
and	O
thirty	O
-	O
one	O
patients	O
undergoing	O
decompression	B-T058
surgery	I-T058
alone	O
(	O
n	O
=	O
85	O
)	O
or	O
decompression	B-T058
plus	O
fusion	B-T058
surgery	I-T058
(	O
n	O
=	O
46	O
)	O
were	O
included	O
in	O
this	O
study	O
.	O

In	O
the	O
multiple	O
mixed	O
effects	O
model	O
the	O
adjusted	O
effect	O
of	O
fusion	B-T058
versus	O
decompression	B-T058
alone	I-T058
surgery	I-T058
on	O
SSM	O
symptoms	B-T033
was	O
0	O
.	O
06	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
CI	O
:	O
-	O
0	O
.	O
16	O
to	O
0	O
.	O
27	O
)	O
and	O
-	O
0	O
.	O
07	O
(	O
95	O
%	O
CI	O
:	O
-	O
0	O
.	O
25	O
to	O
0	O
.	O
10	O
)	O
on	O
SSM	O
function	O
,	O
respectively	O
.	O

Among	O
the	O
patients	O
with	O
degenerative	B-T038
lumbar	I-T038
spinal	I-T038
stenosis	I-T038
and	O
spondylolisthesis	B-T038
our	O
study	O
confirms	O
that	O
in	O
the	O
two	O
groups	O
,	O
decompression	B-T058
alone	O
and	O
decompression	B-T058
plus	O
fusion	B-T058
,	O
patients	O
distinctively	O
benefited	O
from	O
surgical	B-T058
treatment	I-T058
.	O

When	O
adjusted	O
for	O
confounders	O
,	O
fusion	B-T058
surgery	I-T058
was	O
not	O
associated	O
with	O
a	O
more	O
favorable	O
outcome	B-T062
in	O
both	O
SSM	O
scores	O
as	O
compared	O
to	O
decompression	B-T058
alone	I-T058
surgery	I-T058
.	O

3	O
.	O

Muscle	B-T017
synergies	O
after	O
stroke	B-T038
are	O
correlated	O
with	O
perilesional	O
high	O
gamma	O

Movements	O
can	O
be	O
factored	O
into	O
modules	O
termed	O
"	O
muscle	B-T017
synergies	O
"	O
.	O

After	O
stroke	B-T038
,	O
abnormal	B-T033
synergies	O
are	O
linked	O
to	O
impaired	O
movements	O
;	O
however	O
,	O
their	O
neural	B-T017
basis	O
is	O
not	O
understood	O
.	O

In	O
a	O
single	O
subject	O
,	O
we	O
examined	O
how	O
electrocorticography	B-T058
signals	I-T058
from	O
the	O
perilesional	O
cortex	B-T017
were	O
associated	O
with	O
synergies	O
.	O

The	O
measured	O
synergies	O
contained	O
a	O
mix	O
of	O
both	O
normal	O
and	O
abnormal	B-T033
patterns	B-T082
and	O
were	O
remarkably	O
similar	O
to	O
those	O
described	O
in	O
past	O
work	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
both	O
normal	O
and	O
abnormal	B-T033
synergies	O
were	O
correlated	O
with	O
perilesional	O
high	O
gamma	O
.	O

Given	O
the	O
link	O
between	O
high	O
gamma	O
and	O
cortical	B-T033
spiking	I-T033
,	O
our	O
results	O
suggest	O
that	O
perilesional	B-T033
spiking	I-T033
may	O
organize	O
synergies	O
after	O
stroke	B-T038
.	O

Assessing	O
nitrous	B-T103
oxide	I-T103
effect	O
using	O
electroencephalographically	B-T058
-	O
based	O
depth	B-T033
of	I-T033
anesthesia	I-T033
measures	O
cortical	B-T017
state	B-T170
and	O
cortical	B-T017
input	B-T170

Existing	O
electroencephalography	B-T058
(	O
EEG	B-T058
)	O
based	O
depth	B-T033
of	I-T033
anesthesia	I-T033
monitors	O
cannot	O
reliably	O
track	O
sedative	B-T103
or	O
anesthetic	B-T103
states	O
during	O
n	B-T103
-	I-T103
methyl	I-T103
-	I-T103
D	I-T103
-	I-T103
aspartate	I-T103
(	I-T103
NMDA	I-T103
)	I-T103
receptor	I-T103
antagonist	I-T103
based	O
anesthesia	B-T058
with	O
ketamine	B-T103
or	O
nitrous	B-T103
oxide	I-T103
(	O
N2O	B-T103
)	O
.	O

Here	O
,	O
a	O
physiologically	O
-	O
motivated	O
depth	B-T033
of	I-T033
anesthesia	I-T033
monitoring	B-T058
algorithm	B-T170
based	O
on	O
autoregressive	B-T170
-	I-T170
moving	I-T170
-	I-T170
average	I-T170
(	I-T170
ARMA	I-T170
)	I-T170
modeling	I-T170
and	O
derivative	O
measures	O
of	O
interest	O
,	O
Cortical	B-T017
State	B-T170
(	O
CS	B-T170
)	O
and	O
Cortical	B-T017
Input	B-T170
(	O
CI	B-T170
)	O
,	O
is	O
retrospectively	B-T062
applied	O
in	O
an	O
exploratory	O
manner	O
to	O
the	O
NMDA	B-T103
receptor	I-T103
antagonist	I-T103
N2O	B-T103
,	O
an	O
adjuvant	B-T103
anesthetic	I-T103
gas	I-T103
used	O
in	O
clinical	O
practice	O
.	O

Composite	B-T170
Cortical	I-T170
State	I-T170
(	O
CCS	B-T170
)	O
and	O
Composite	B-T170
Cortical	I-T170
State	I-T170
distance	I-T170
(	O
CCSd	B-T170
)	O
,	O
two	O
new	O
modifications	B-T033
of	O
CS	B-T170
,	O
along	O
with	O
CS	B-T170
and	O
CI	B-T170
were	O
evaluated	B-T058
on	O
electroencephalographic	B-T058
(	O
EEG	B-T058
)	O
data	O
of	O
healthy	O
control	O
individuals	O
undergoing	O
N2O	B-T103
inhalation	B-T038
up	O
to	O
equilibrated	O
peak	O
gas	O
concentrations	O
of	O
20	O
,	O
40	O
or	O
60	O
%	O
N2O	B-T103
/	O
O2	B-T103
.	O

In	O
particular	O
,	O
CCSd	B-T170
has	O
been	O
devised	O
to	O
vary	O
consistently	O
for	O
increasing	O
levels	O
of	O
anesthetic	B-T033
concentration	I-T033
independent	O
of	O
the	O
anesthetic	B-T103
'	I-T103
s	I-T103
microscopic	O
mode	O
of	O
action	O
for	O
both	O
N2O	B-T103
and	O
propofol	B-T103
.	O

The	O
strongest	O
effects	O
were	O
observed	O
for	O
the	O
60	O
%	O
peak	O
gas	O
concentration	O
group	B-T098
.	O

For	O
the	O
50	O
-	O
60	O
%	O
peak	O
gas	O
levels	O
,	O
individuals	B-T098
showed	O
statistically	O
significant	O
reductions	B-T058
in	O
responsiveness	O
compared	O
to	O
rest	O
,	O
and	O
across	O
the	O
group	B-T098
CS	B-T170
and	O
CCS	B-T170
increased	O
by	O
39	O
and	O
42	O
%	O
,	O
respectively	O
,	O
while	O
CCSd	B-T170
was	O
found	O
to	O
decrease	O
by	O
398	O
%	O
.	O

On	O
the	O
other	O
hand	O
a	O
clear	O
conclusion	O
regarding	O
the	O
changes	O
in	O
CI	B-T170
could	O
not	O
be	O
reached	O
.	O

These	O
results	O
indicate	O
that	O
,	O
contrary	B-T082
to	O
previous	O
depth	B-T033
of	I-T033
anesthesia	I-T033
monitoring	B-T058
measures	O
,	O
the	O
CS	B-T170
,	O
CCS	B-T170
,	O
and	O
especially	O
CCSd	B-T170
measures	O
derived	O
from	O
frontal	B-T082
EEG	B-T058
are	O
potentially	O
useful	O
for	O
differentiating	O
gas	O
concentration	O
and	O
responsiveness	O
levels	O
in	O
people	B-T098
under	O
N2O	B-T103
.	O

On	O
the	O
other	O
hand	O
,	O
determining	O
the	O
utility	O
of	O
CI	B-T170
in	O
this	O
regard	O
will	O
require	O
larger	O
sample	O
sizes	O
and	O
potentially	O
higher	O
gas	O
concentrations	O
.	O

Future	O
work	O
will	O
assess	O
the	O
sensitivity	O
of	O
CS	B-T170
-	O
based	O
and	O
CI	B-T170
measures	O
to	O
other	O
anesthetics	B-T103
and	O
their	O
utility	O
in	O
a	O
clinical	B-T092
environment	B-T082
.	O

DT	B-T058
MRI	I-T058
microstructural	O
cortical	B-T017
lesion	B-T038
damage	O
does	O
not	O
explain	O
cognitive	B-T038
impairment	I-T038
in	O
MS	B-T038

We	O
combined	O
double	B-T058
inversion	I-T058
recovery	I-T058
(	O
DIR	B-T058
)	O
and	O
diffusion	B-T058
tensor	I-T058
(	I-T058
DT	I-T058
)	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
(	I-T058
MRI	I-T058
)	I-T058
to	O
quantify	O
the	O
severity	O
of	O
cortical	B-T017
lesion	B-T038
(	O
CL	B-T038
)	O
microstructural	O
tissue	B-T017
abnormalities	B-T017
in	O
a	O
large	O
cohort	B-T098
of	O
relapse	O
-	O
onset	O
multiple	B-T038
sclerosis	I-T038
(	O
MS	B-T038
)	O
patients	O
and	O
its	O
contribution	O
to	O
cognitive	B-T038
dysfunction	I-T038
.	O

DIR	B-T058
,	O
DT	B-T058
,	O
dual	B-T058
-	I-T058
echo	I-T058
,	O
and	O
three	B-T082
-	I-T082
dimensional	I-T082
(	O
3D	B-T082
)	O
T1	B-T058
-	I-T058
weighted	I-T058
scans	I-T058
were	O
acquired	O
from	O
149	O
MS	B-T038
patients	O
and	O
40	O
controls	O
.	O

Cognitively	B-T038
impaired	I-T038
(	O
CI	B-T038
)	O
patients	O
had	O
⩾2	O
abnormal	B-T033
neuropsychological	B-T058
tests	I-T058
.	O

Diffusivity	O
values	O
in	O
CLs	B-T038
,	O
cortex	B-T017
,	O
white	B-T033
matter	I-T033
(	I-T033
WM	I-T033
)	I-T033
lesions	I-T033
,	O
and	O
normal	B-T017
-	I-T017
appearing	I-T017
(	I-T017
NA	I-T017
)	I-T017
WM	I-T017
were	O
assessed	O
.	O

Predictors	O
of	O
cognitive	B-T038
impairment	I-T038
were	O
identified	O
using	O
a	O
random	B-T062
forest	I-T062
analysis	I-T062
.	O

Compared	O
to	O
controls	O
,	O
MS	B-T038
patients	O
had	O
lower	O
normalized	O
brain	O
volume	O
(	O
NBV	O
)	O
,	O
gray	O
matter	O
volume	O
(	O
GMV	O
)	O
,	O
WM	B-T033
volume	I-T033
,	O
lower	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
,	O
and	O
higher	O
mean	O
diffusivity	O
in	O
cortex	B-T017
and	O
normal	B-T017
-	I-T017
appearing	I-T017
white	I-T017
matter	I-T017
(	O
NAWM	B-T017
)	O
.	O

A	O
total	O
of	O
44	O
(	O
29	O
.	O
5	O
%	O
)	O
patients	O
were	O
CI	B-T038
.	O

Compared	O
to	O
cognitively	O
preserved	O
(	O
CP	O
)	O
,	O
CI	B-T038
patients	O
had	O
higher	O
T2	O
WM	O
lesion	O
volume	O
(	O
LV	O
)	O
,	O
lower	O
NBV	O
and	O
GMV	O
,	O
and	O
more	O
severe	O
diffusivity	O
abnormalities	B-T017
in	O
WM	B-T033
lesions	I-T033
,	O
cortex	B-T017
,	O
and	O
NAWM	B-T017
.	O

CL	B-T038
measures	O
did	O
not	B-T033
differ	I-T033
between	O
CI	O
and	O
CP	O
patients	O
.	O

Cortex	B-T017
FA	O
,	O
age	O
,	O
disease	O
duration	O
,	O
T2	O
WM	O
LV	O
,	O
and	O
GMV	O
best	O
predicted	O
MS	B-T038
-	O
related	O
cognitive	B-T038
impairment	I-T038
(	O
C	O
-	O
statistic	O
=	O
0	O
.	O
88	O
)	O
.	O

"	O
Diffuse	B-T082
"	O
GM	B-T017
and	O
NAWM	B-T017
damage	O
and	O
WM	B-T033
lesions	I-T033
,	O
rather	O
than	O
intrinsic	B-T082
CL	B-T038
damage	O
,	O
contribute	O
to	O
cognitive	B-T038
impairment	I-T038
in	O
MS	B-T038
.	O

Correlation	O
between	O
the	O
histopathology	O
of	O
chronic	B-T038
urticaria	I-T038
and	O
its	O
clinical	O
picture	O

Chronic	B-T038
urticaria	I-T038
is	O
characterized	O
by	O
transient	O
,	O
pruritic	O
lesions	O
of	O
varying	O
sizes	B-T082
,	O
with	O
central	B-T082
pallor	B-T033
and	O
well	O
-	O
defined	O
edges	O
,	O
with	O
disease	B-T038
duration	O
longer	O
than	O
six	O
weeks	O
.	O

Its	O
cellular	B-T038
infiltrate	I-T038
consists	O
of	O
neutrophils	B-T017
,	O
lymphocytes	B-T017
and	O
eosinophils	B-T017
.	O

There	O
is	O
a	O
subgroup	O
of	O
patients	O
with	O
eosinophilic	B-T017
or	O
neutrophilic	B-T038
urticaria	I-T038
,	O
resistant	O
to	O
the	O
treatment	B-T058
with	O
antihistamines	B-T103
,	O
but	O
that	O
respond	O
to	O
a	O
combination	O
of	O
antihistamine	B-T103
with	O
other	O
drugs	B-T103
.	O

To	O
evaluate	O
the	O
present	O
infiltration	B-T038
in	O
chronic	B-T038
urticaria	I-T038
biopsies	B-T058
and	O
correlate	O
it	O
with	O
the	O
clinical	O
disease	O
activity	O
and	O
response	B-T201
to	I-T201
treatment	I-T201
.	O

Forty	O
-	O
one	O
patients	O
with	O
chronic	B-T038
urticaria	I-T038
were	O
classified	O
according	O
to	O
the	O
score	O
of	O
severity	O
of	O
the	O
disease	B-T038
,	O
response	B-T201
to	I-T201
treatment	I-T201
and	O
type	O
of	O
perivascular	B-T038
infiltrate	I-T038
.	O

Inflammatory	B-T031
infiltrates	I-T031
were	O
divided	O
in	O
eosinophilic	B-T017
(	O
46	O
.	O
30	O
%	O
)	O
,	O
neutrophilic	B-T017
and	O
mixed	O
.	O

An	O
association	O
was	O
found	O
between	O
the	O
eosinophilic	B-T031
infiltrate	I-T031
and	O
clinical	O
scores	O
of	O
greater	O
severity	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

This	O
association	O
shows	O
that	O
the	O
eosinophilic	B-T031
inflammatory	I-T031
infiltrates	I-T031
denote	O
high	O
clinical	B-T033
activity	I-T033
,	O
which	O
means	O
more	O
severe	O
and	O
exuberant	O
clinical	O
pictures	O
of	O
the	O
disease	B-T038
.	O

Barriers	O
to	O
access	O
and	O
uptake	O
of	O
antiretroviral	B-T058
therapy	I-T058
among	O
HIV	B-T033
-	I-T033
positive	I-T033
men	B-T098
who	I-T098
have	I-T098
sex	I-T098
with	I-T098
men	I-T098
in	O
Hanoi	O
,	O
Vietnam	B-T082
:	O
from	O
HIV	B-T058
testing	I-T058
to	O
treatment	B-T058

Little	O
is	O
known	O
about	O
the	O
experiences	B-T038
of	O
Vietnamese	B-T098
men	B-T098
who	I-T098
have	I-T098
sex	I-T098
with	I-T098
men	I-T098
in	O
accessing	B-T082
HIV	B-T058
testing	I-T058
and	O
treatment	B-T058
.	O

We	O
aimed	O
to	O
explore	O
barriers	O
to	O
access	O
and	O
uptake	O
of	O
antiretroviral	B-T058
therapy	I-T058
(	O
ART	B-T058
)	O
among	O
HIV	B-T033
-	I-T033
positive	I-T033
men	B-T098
who	I-T098
have	I-T098
sex	I-T098
with	I-T098
men	I-T098
in	O
Hanoi	O
.	O

During	O
2015	O
,	O
we	O
conducted	O
qualitative	O
interviews	O
with	O
35	O
participants	B-T098
recruited	O
using	O
snowball	B-T062
sampling	I-T062
based	O
on	O
previous	O
research	B-T062
and	O
social	B-T098
networks	I-T098
.	O

Key	O
individual	O
impediments	O
to	O
ART	B-T058
uptake	O
included	O
inadequate	O
preparation	O
for	O
a	O
positive	B-T033
diagnosis	B-T033
and	O
the	O
dual	O
stigmatisation	O
of	O
homosexuality	O
and	O
HIV	B-T005
and	O
its	O
consequences	B-T062
,	O
leading	O
to	O
fear	B-T038
of	O
disclosure	O
of	O
HIV	B-T033
status	I-T033
.	O

Health	B-T092
system	I-T092
barriers	O
included	O
lack	O
of	O
clarity	O
and	O
consistency	O
about	O
how	O
to	O
register	O
for	O
and	O
access	O
ART	B-T058
,	O
failure	O
to	O
protect	O
patient	O
confidentiality	O
and	O
a	O
reticence	O
by	O
providers	O
to	O
discuss	O
sexual	B-T038
identity	I-T038
and	O
same	O
-	O
sex	O
issues	O
.	O

Results	O
suggest	O
fundamental	O
problems	O
in	O
the	O
way	O
HIV	B-T058
testing	I-T058
is	O
currently	O
delivered	O
in	O
Hanoi	O
,	O
including	O
a	O
lack	O
of	O
client	O
-	O
centred	O
counselling	B-T058
,	O
peer	O
support	O
and	O
clear	B-T058
referral	I-T058
pathways	O
.	O

Overcoming	O
these	O
barriers	O
will	O
require	O
educating	O
men	B-T098
who	I-T098
have	I-T098
sex	I-T098
with	I-T098
men	I-T098
about	O
the	O
benefits	O
of	O
routine	O
testing	O
,	O
improving	O
access	O
to	O
quality	O
diagnostic	B-T058
services	I-T058
and	O
building	O
a	O
safe	O
,	O
confidential	O
treatment	B-T058
environment	B-T082
for	O
HIV	B-T033
-	I-T033
positive	I-T033
men	B-T098
to	O
access	O
,	O
receive	O
and	O
remain	O
in	O
care	O
.	O

Cdc45	B-T103
-	O
induced	O
loading	O
of	O
human	B-T103
RPA	I-T103
onto	O
single	B-T103
-	I-T103
stranded	I-T103
DNA	I-T103

Cell	B-T103
division	I-T103
cycle	I-T103
protein	I-T103
45	I-T103
(	O
Cdc45	B-T103
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
eukaryotic	B-T204
replicative	O
DNA	B-T103
helicase	I-T103
.	O

We	O
found	O
that	O
human	B-T103
Cdc45	I-T103
forms	O
a	O
complex	B-T103
with	O
the	O
single	B-T103
-	I-T103
stranded	I-T103
DNA	I-T103
(	I-T103
ssDNA	I-T103
)	I-T103
binding	I-T103
protein	I-T103
RPA	I-T103
.	O

Moreover	O
,	O
it	O
actively	O
loads	O
RPA	B-T103
onto	O
nascent	O
ssDNA	B-T103
.	O

Pull	B-T058
-	I-T058
down	I-T058
assays	I-T058
and	O
surface	B-T062
plasmon	I-T062
resonance	I-T062
studies	I-T062
revealed	O
that	O
Cdc45	B-T103
-	O
bound	B-T038
RPA	B-T103
complexed	B-T103
with	O
ssDNA	B-T103
in	O
the	O
8	O
-	O
10	O
nucleotide	B-T038
binding	I-T038
mode	O
,	O
but	O
dissociated	B-T038
when	O
RPA	B-T103
covered	O
a	O
30	B-T082
-	I-T082
mer	I-T082
.	O

Real	B-T058
-	I-T058
time	I-T058
analysis	I-T058
of	O
RPA	B-T103
-	O
ssDNA	B-T103
binding	B-T038
demonstrated	O
that	O
Cdc45	B-T103
catalytically	O
loaded	O
RPA	B-T103
onto	O
ssDNA	B-T103
.	O

This	O
placement	O
reaction	O
required	O
physical	O
contacts	O
of	O
Cdc45	B-T103
with	O
the	O
RPA70A	B-T082
subdomain	I-T082
.	O

Our	O
results	O
imply	O
that	O
Cdc45	B-T103
controlled	O
stabilization	B-T058
of	O
the	O
8	O
-	O
nt	B-T103
RPA	B-T103
binding	B-T038
mode	O
,	O
the	O
subsequent	O
RPA	B-T103
transition	O
into	O
30	B-T082
-	I-T082
mer	I-T082
mode	O
and	O
facilitated	O
an	O
ordered	O
binding	B-T038
to	O
ssDNA	B-T103
.	O

We	O
propose	O
that	O
a	O
Cdc45	B-T103
-	O
mediated	O
loading	O
guarantees	O
a	O
seamless	O
deposition	O
of	O
RPA	B-T103
on	O
newly	O
emerging	O
ssDNA	B-T103
at	O
the	O
nascent	O
replication	B-T017
fork	I-T017
.	O

The	O
antineoplastic	B-T103
drug	I-T103
,	O
trastuzumab	B-T103
,	O
dysregulates	B-T033
metabolism	B-T038
in	O
iPSC	B-T017
-	O
derived	O
cardiomyocytes	B-T017

The	O
targeted	B-T058
ERBB2	I-T058
therapy	I-T058
,	O
trastuzumab	B-T103
,	O
has	O
had	O
a	O
tremendous	O
impact	O
on	O
management	B-T058
of	O
patients	O
with	O
HER2	B-T038
+	I-T038
breast	I-T038
cancer	I-T038
,	O
leading	O
to	O
development	O
and	O
increased	O
use	O
of	O
further	O
HER2	B-T103
targeted	B-T058
therapies	I-T058
.	O

The	O
major	O
clinical	O
side	B-T038
effect	I-T038
is	O
cardiotoxicity	B-T037
but	O
the	O
mechanism	O
is	O
largely	O
unknown	O
.	O

On	O
the	O
basis	O
that	O
gene	B-T038
expression	I-T038
is	O
known	O
to	O
be	O
altered	O
in	O
multiple	O
models	B-T170
of	O
heart	B-T038
failure	I-T038
,	O
we	O
examined	O
differential	B-T038
gene	I-T038
expression	I-T038
of	O
iPSC	B-T017
-	O
derived	O
cardiomyocytes	B-T017
treated	O
at	O
day	O
11	O
with	O
the	O
ERBB2	B-T103
targeted	O
monoclonal	B-T103
antibody	I-T103
,	O
trastuzumab	B-T103
for	O
48	O
h	O
and	O
the	O
small	B-T103
molecule	I-T103
tyrosine	I-T103
kinase	I-T103
inhibitor	I-T103
of	O
EGFR	B-T103
and	O
ERBB2	B-T103
.	O

Transcriptome	B-T058
sequencing	I-T058
was	O
performed	O
on	O
four	O
replicates	O
from	O
each	O
group	O
(	O
48	O
h	O
untreated	O
,	O
48	O
h	O
trastuzumab	B-T103
and	O
48	O
h	O
lapatinib	B-T103
)	O
and	O
differential	B-T038
gene	I-T038
expression	I-T038
analyses	B-T062
were	O
performed	O
on	O
each	O
treatment	O
group	O
relative	O
to	O
untreated	O
cardiomyocytes	B-T017
.	O

517	O
and	O
1358	O
genes	B-T017
were	O
differentially	B-T038
expressed	I-T038
,	O
p	O
<	O
0	O
.	O
05	O
,	O
respectively	O
in	O
cardiomyocytes	B-T017
treated	O
with	O
trastuzumab	B-T103
and	O
lapatinib	B-T103
.	O

Gene	B-T170
ontology	I-T170
analyses	B-T062
revealed	O
in	O
cardiomyocytes	B-T017
treated	O
with	O
trastuzumab	B-T103
,	O
significant	O
down	B-T038
-	I-T038
regulation	I-T038
of	O
genes	B-T017
involved	O
in	O
small	B-T038
molecule	I-T038
metabolism	I-T038
(	O
p	O
=	O
3	O
.	O
22	O
—	O
10	O
(	O
-	O
9	O
)	O
)	O
and	O
cholesterol	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
sterol	O
sterol	B-T103
p	O
=	O
0	O
.	O
03	O
)	O
processing	O
.	O

We	O
next	O
measured	O
glucose	O
uptake	O
and	O
lactate	O
production	O
in	O
iPSC	O
-	O
derived	O
cardiomyocytes	O
13	O
days	O
post	O
-	O
plating	O
,	O
treated	O
with	O
trastuzumab	O
up	O
to	O
96	O
h	O
.	O

We	O
observed	O
significantly	O
decreased	O
glucose	O
uptake	O
from	O
the	O
media	O
of	O
iPSC	O
-	O
derived	O
cardiomyocytes	O
treated	O
with	O
trastuzumab	O
as	O
early	O
as	O
24	O
h	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
consistently	O
up	O
to	O
96	O
h	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Our	O
study	O
suggests	O
dysregulation	O
of	O
cardiac	O
gene	O
expression	O
and	O
metabolism	O
as	O
key	O
elements	O
of	O
ERBB2	O
signaling	O
signaling	B-T038
could	O
potentially	O
be	O
early	O
biomarkers	O
of	O
cardiotoxicity	O
.	O

Simvastatin	B-T103
Promotes	O
Hematoma	B-T038
Absorption	O
and	O
Reduces	O
Hydrocephalus	B-T038
Following	O
Intraventricular	B-T038
Hemorrhage	I-T038
in	O
Part	O
by	O
Upregulating	B-T038
CD36	B-T017

We	O
previously	O
found	O
that	O
hematoma	B-T038
worsens	B-T033
hydrocephalus	B-T038
after	O
intraventricular	B-T038
hemorrhage	I-T038
(	O
IVH	B-T038
)	O
via	O
increasing	O
iron	B-T038
deposition	I-T038
and	O
aggravating	O
ependymal	B-T017
cilia	B-T017
injury	B-T037
;	O
therefore	O
,	O
promoting	O
hematoma	B-T038
absorption	O
may	O
be	O
a	O
promising	O
strategy	O
for	O
IVH	B-T038
.	O

Recently	O
,	O
some	O
investigations	O
imply	O
that	O
simvastatin	B-T103
has	O
the	O
ability	O
of	O
accelerating	O
hematoma	B-T038
absorption	O
.	O

Thus	O
,	O
this	O
study	O
was	O
designed	O
to	O
examine	O
the	O
efficacy	O
of	O
simvastatin	B-T103
for	O
IVH	B-T038
in	O
rats	B-T204
.	O

Intracerebral	B-T038
hemorrhage	I-T038
with	O
ventricular	O
extension	O
was	O
induced	O
in	O
adult	O
male	O
Sprague	B-T204
-	I-T204
Dawley	I-T204
rats	I-T204
after	O
autologous	O
blood	O
injection	O
.	O

Simvastatin	B-T103
or	O
vehicle	B-T103
was	O
administered	B-T058
orally	I-T058
at	O
1	O
day	O
after	O
IVH	B-T038
and	O
then	O
daily	O
for	O
1	O
week	O
.	O

MRI	B-T058
studies	I-T058
were	O
performed	O
to	O
measure	O
the	O
volumes	B-T058
of	O
intracranial	B-T082
hematoma	B-T038
and	O
lateral	B-T082
ventricle	I-T082
at	O
days	O
1	O
,	O
3	O
,	O
7	O
,	O
14	O
,	O
and	O
28	O
after	O
IVH	B-T038
.	O

Motor	B-T038
and	O
neurocognitive	B-T038
functions	I-T038
were	O
assessed	O
at	O
days	O
1	O
to	O
7	O
and	O
23	O
to	O
28	O
,	O
respectively	O
.	O

Iron	B-T038
deposition	I-T038
,	O
iron	B-T103
-	O
related	O
protein	B-T038
expression	I-T038
,	O
ependymal	O
damage	O
,	O
and	O
histology	O
were	O
detected	B-T033
at	O
day	O
28	O
.	O

Expression	B-T038
of	O
CD36	B-T017
scavenger	B-T103
receptor	I-T103
(	O
facilitating	O
phagocytosis	B-T038
)	O
was	O
examined	B-T033
at	O
day	O
3	O
after	O
IVH	B-T038
using	O
western	B-T058
blotting	I-T058
and	O
immunofluorescence	B-T058
.	O

Simvastatin	B-T103
significantly	O
increased	O
hematoma	B-T038
absorption	O
ratio	O
,	O
reduced	O
ventricular	O
volume	O
,	O
and	O
attenuated	B-T033
neurological	I-T033
dysfunction	I-T033
post	O
-	O
IVH	B-T038
.	O

In	O
addition	O
,	O
less	B-T033
iron	I-T033
accumulation	I-T033
and	O
more	O
cilia	B-T017
survival	O
was	O
observed	O
in	O
the	O
simvastatin	B-T103
group	O
when	O
compared	O
with	O
the	O
control	O
.	O

What	O
'	O
s	O
more	O
,	O
higher	O
expression	B-T038
of	O
CD36	B-T017
was	O
detected	B-T033
around	O
the	O
hematoma	B-T038
after	O
simvastatin	B-T103
administration	B-T058
.	O

Simvastatin	B-T103
significantly	O
enhanced	O
brain	B-T017
hematoma	B-T038
absorption	O
,	O
alleviated	B-T038
hydrocephalus	I-T038
,	O
and	O
improved	B-T033
neurological	O
recovery	B-T038
after	O
experimental	O
IVH	B-T038
,	O
which	O
may	O
in	O
part	O
by	O
upregulating	B-T038
CD36	B-T017
expression	B-T038
.	O

Our	O
data	O
suggest	O
that	O
early	O
simvastatin	B-T103
use	O
may	O
be	O
a	O
novel	O
therapy	B-T058
for	O
IVH	B-T038
patients	O
.	O

AMPK	B-T103
-	O
autophagy	B-T038
inhibition	O
sensitizes	O
icaritin	B-T103
-	O
induced	O
anti	B-T033
-	I-T033
colorectal	I-T033
cancer	I-T033
cell	B-T038
activity	I-T038

The	O
current	O
research	B-T062
studied	O
the	O
potential	O
effect	O
of	O
autophagy	B-T038
on	O
icaritin	B-T103
-	O
induced	O
anti	B-T033
-	I-T033
colorectal	I-T033
cancer	I-T033
(	O
CRC	B-T038
)	O
cell	B-T038
activity	I-T038
.	O

Treatment	O
of	O
icaritin	B-T103
in	O
both	O
primary	O
and	O
established	O
(	O
HT	B-T017
-	I-T017
29	I-T017
)	O
CRC	B-T038
cells	B-T017
induced	O
feedback	O
activation	O
of	O
autophagy	B-T038
,	O
evidenced	O
by	O
p62	B-T017
degradation	B-T038
,	O
Beclin	B-T017
-	I-T017
1	I-T017
and	O
autophagy	B-T017
-	I-T017
related	I-T017
gene	I-T017
-	I-T017
5	I-T017
(	O
ATG	B-T017
-	I-T017
5	I-T017
)	O
upregulation	B-T038
,	O
as	O
well	O
as	O
light	B-T103
chain	I-T103
3B	I-T103
(	O
LC3B	B-T103
)	O
-	O
GFP	B-T103
puncta	O
formation	O
.	O

Pharmacological	O
inhibiting	O
of	O
autophagy	B-T038
dramatically	O
potentiated	O
icaritin	B-T103
-	O
induced	O
CRC	B-T038
cell	B-T038
death	I-T038
and	O
apoptosis	B-T038
.	O

Meanwhile	O
,	O
shRNA	B-T103
-	O
mediated	O
knockdown	B-T062
of	O
Beclin	B-T017
-	I-T017
1	I-T017
or	O
ATG	B-T017
-	I-T017
5	I-T017
also	O
sensitized	O
icaritin	B-T103
-	O
induced	O
CRC	B-T038
cell	B-T038
death	I-T038
and	O
apoptosis	B-T038
.	O

Icaritin	B-T103
activated	O
AMP	B-T103
-	I-T103
activated	I-T103
protein	I-T103
kinase	I-T103
(	O
AMPK	B-T103
)	O
signaling	B-T038
in	O
CRC	B-T038
cells	B-T017
,	O
functioning	O
as	O
the	O
upstream	O
signaling	B-T038
for	O
autophagy	B-T038
activation	O
.	O

shRNA	B-T103
/	O
siRNA	B-T103
-	O
mediated	O
knockdown	B-T062
of	O
AMPKα1	B-T017
inhibited	O
icaritin	B-T103
-	O
induced	O
autophagy	B-T038
activation	O
,	O
but	O
exacerbated	O
CRC	B-T038
cell	B-T038
death	I-T038
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
AMPK	B-T103
activator	O
compound	B-T103
13	I-T103
(	O
C13	B-T103
)	O
or	O
the	O
autophagy	B-T038
activator	O
MHY1485	B-T103
attenuated	O
icaritin	B-T103
-	O
induced	O
cytotoxicity	B-T038
.	O

In	O
nude	B-T204
mice	I-T204
,	O
icaritin	B-T103
(	O
oral	B-T058
administration	I-T058
)	O
-	O
induced	O
HT	B-T017
-	I-T017
29	I-T017
tumor	O
growth	O
inhibition	O
was	O
potentiated	O
when	O
combined	O
with	O
AMPKα1	B-T017
shRNA	B-T103
knockdown	B-T062
in	O
tumors	B-T038
.	O

We	O
conclude	O
that	O
feedback	O
activation	O
of	O
AMPK	B-T103
-	O
autophagy	B-T038
pathway	B-T038
could	O
be	O
a	O
primary	O
resistance	O
factor	O
of	O
icaritin	B-T103
.	O

Classification	B-T170
of	O
Edible	B-T168
Oils	I-T168
Based	O
on	O
ATR	B-T062
-	I-T062
FTIR	I-T062
Spectral	O
Information	O
During	O
a	O
Long	O
Heating	O
Treatment	O

Identification	O
of	O
oil	B-T168
type	O
and	O
its	O
QC	O
are	O
important	O
concerns	O
in	O
food	B-T092
control	I-T092
laboratories	I-T092
.	O

Classifying	B-T170
edible	B-T168
oils	I-T168
that	O
have	O
not	O
been	O
used	O
(	O
i	O
.	O
e	O
.	O
,	O
unheated	O
)	O
with	O
the	O
aid	O
of	O
vibrational	B-T058
spectroscopy	I-T058
has	O
previously	O
been	O
reported	O
.	O

However	O
,	O
the	O
classification	B-T170
of	O
used	O
(	O
i	O
.	O
e	O
.	O
,	O
heat	O
-	O
treated	O
)	O
oils	B-T168
needs	O
special	O
attention	O
.	O

The	O
effect	O
of	O
long	O
heating	O
times	O
on	O
the	O
classification	B-T170
of	O
four	O
kinds	O
of	O
edible	B-T168
oils	I-T168
(	O
canola	B-T103
,	O
corn	B-T103
,	O
frying	B-T168
,	O
and	O
sunflower	B-T103
)	O
based	O
on	O
attenuated	B-T062
total	I-T062
reflectance	I-T062
(	I-T062
ATR	I-T062
)	I-T062
-	I-T062
FTIR	I-T062
spectra	I-T062
was	O
surveyed	O
.	O

The	O
sampling	O
was	O
done	O
on	O
the	O
oils	B-T168
during	O
a	O
36	O
h	O
heating	O
process	O
(	O
at	O
170°C	O
)	O
.	O

The	O
ATR	B-T062
-	I-T062
FTIR	I-T062
spectra	I-T062
of	O
the	O
samples	O
were	O
collected	O
in	O
the	O
range	O
of	O
4000	O
-	O
550	O
cm	O
-	O
1	O
.	O

Interval	O
extended	O
canonical	O
variates	O
analysis	O
(	O
ECVA	O
)	O
,	O
as	O
a	O
variable	O
selection	O
and	O
classification	B-T170
tool	O
,	O
was	O
used	O
to	O
determine	O
the	O
best	O
intervals	O
during	O
the	O
heating	O
procedure	O
for	O
classification	B-T170
.	O

Principal	O
component	O
analysis	O
discriminate	O
analysis	O
,	O
partial	O
least	O
-	O
squares	O
discriminate	O
analysis	O
,	O
and	O
ECVA	O
were	O
performed	O
on	O
the	O
selected	O
intervals	O
and	O
on	O
the	O
total	O
heating	O
time	O
.	O

The	O
effect	O
of	O
autoscaling	B-T033
and	O
mean	B-T033
-	I-T033
centering	I-T033
,	O
as	O
data	B-T170
preprocessing	I-T170
methods	I-T170
,	O
was	O
also	O
investigated	O
.	O

The	O
ECVA	O
method	O
resulted	O
in	O
the	O
best	O
performances	O
for	O
classification	B-T170
,	O
with	O
a	O
94	O
%	O
cross	O
-	O
validated	O
nonerror	O
rate	O
(	O
one	O
misclassification	O
)	O
for	O
the	O
heating	O
process	O
times	O
of	O
24	O
-	O
27	O
and	O
33	O
-	O
36	O
h	O
.	O

Intravitreal	O
chemotherapy	B-T058
in	O
the	O
management	B-T058
of	O
vitreous	B-T038
disease	I-T038
in	O
retinoblastoma	B-T038

To	O
evaluate	O
the	O
therapeutic	O
outcome	O
of	O
intravitreal	O
melphalan	B-T103
injection	B-T103
in	O
the	O
management	B-T058
of	O
vitreous	B-T038
disease	I-T038
in	O
patients	O
with	O
retinoblastoma	B-T038
.	O

We	O
particularly	O
aimed	O
to	O
assess	O
whether	O
higher	O
melphalan	B-T103
dose	O
with	O
lower	O
number	O
of	O
injections	B-T103
was	O
more	O
effective	O
and	O
associated	O
with	O
fewer	O
side	B-T038
effects	I-T038
.	O

This	O
retrospective	B-T062
,	O
interventional	B-T062
,	O
noncomparative	B-T062
,	O
and	O
nonrandomized	B-T062
study	I-T062
included	O
39	O
eyes	B-T017
of	O
37	O
patients	O
.	O

Vitreous	B-T033
seeds	I-T033
were	O
classified	B-T170
as	O
dust	B-T038
,	O
sphere	B-T038
,	O
and	O
cloud	B-T038
types	I-T038
.	O

Intravitreal	O
injections	B-T103
were	O
performed	O
through	O
pars	B-T017
plana	I-T017
free	O
of	O
any	O
visible	O
tumor	B-T038
using	O
30	B-T074
-	I-T074
G	I-T074
needle	I-T074
.	O

Response	B-T038
of	I-T038
the	I-T038
seeds	I-T038
(	O
disappearance	B-T033
,	O
conversion	O
into	O
inactive	B-T033
debris	I-T033
,	O
or	O
progression	B-T038
)	O
and	O
enucleation	B-T058
rate	O
were	O
determined	O
as	O
outcome	O
measures	O
.	O

All	O
patients	O
previously	O
received	O
systemic	B-T058
or	O
intra	B-T058
-	I-T058
arterial	I-T058
chemotherapy	I-T058
.	O

Vitreous	B-T033
seeding	I-T033
was	O
primary	O
in	O
54	O
%	O
of	O
eyes	B-T017
and	O
secondary	O
in	O
46	O
%	O
of	O
eyes	B-T017
.	O

Vitreous	B-T033
seeds	I-T033
were	O
classified	B-T170
as	O
dust	B-T038
in	O
9	O
(	O
23	O
.	O
1	O
%	O
)	O
eyes	B-T017
,	O
sphere	B-T038
in	O
24	O
(	O
61	O
.	O
5	O
%	O
)	O
eyes	B-T017
,	O
and	O
cloud	B-T038
in	O
6	O
(	O
15	O
.	O
4	O
%	O
)	O
eyes	B-T017
.	O

Melphalan	B-T103
dose	O
varied	O
between	O
20	O
and	O
40	O
µg	O
and	O
20	O
(	O
51	O
.	O
3	O
%	O
)	O
eyes	B-T017
received	O
>	O
30	O
µg	O
.	O

The	O
total	O
number	O
of	O
injections	B-T103
was	O
70	O
(	O
range	O
1	O
-	O
5	O
,	O
mean	O
1	O
.	O
8	O
per	O
eye	B-T017
)	O
.	O

Various	O
types	O
of	O
regression	B-T038
were	O
obtained	O
in	O
27	O
(	O
69	O
.	O
2	O
%	O
)	O
eyes	B-T017
.	O

Sphere	B-T038
-	I-T038
type	I-T038
seeds	I-T038
were	O
the	O
most	O
responsive	O
to	O
melphalan	B-T103
.	O

Nonresponse	O
and	O
disease	B-T038
progression	I-T038
were	O
noted	O
in	O
12	O
(	O
30	O
.	O
8	O
%	O
)	O
eyes	B-T017
.	O

After	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
11	O
.	O
8	O
months	O
,	O
17	O
(	O
44	O
%	O
)	O
eyes	B-T017
were	O
enucleated	O
.	O

Vitreous	B-T038
hemorrhage	I-T038
(	O
18	O
%	O
)	O
and	O
retinal	B-T017
pigment	I-T017
epithelial	I-T017
alterations	O
(	O
8	O
%	O
)	O
were	O
the	O
most	O
common	O
side	B-T038
effects	I-T038
.	O

Intravitreal	O
melphalan	B-T103
at	O
30	O
-	O
40	O
µg	O
in	O
1	O
or	O
2	O
injections	B-T103
proved	O
effective	O
in	O
69	O
.	O
2	O
%	O
of	O
eyes	B-T017
with	O
vitreous	B-T038
disease	I-T038
.	O

Fine	B-T082
structure	I-T082
of	O
the	O
anterior	B-T017
median	I-T017
eyes	I-T017
of	O
the	O
funnel	B-T082
-	O
web	B-T204
spider	I-T204
Agelena	B-T204
labyrinthica	I-T204
(	O
Araneae	B-T204
:	O
Agelenidae	B-T204
)	O

Only	O
few	O
electron	B-T058
microscopic	I-T058
studies	I-T058
exist	O
on	O
the	O
structure	B-T082
of	O
the	O
main	O
eyes	B-T017
(	O
anterior	B-T017
median	I-T017
eyes	I-T017
,	O
AME	B-T017
)	O
of	O
web	B-T204
spiders	I-T204
.	O

The	O
present	O
paper	O
provides	O
details	O
on	O
the	O
anatomy	B-T017
of	O
the	O
AME	B-T017
in	O
the	O
funnel	O
-	O
web	O
spider	B-T204
Agelena	B-T204
labyrinthica	I-T204
.	O

The	O
retina	B-T017
consists	O
of	O
two	O
separate	O
regions	B-T082
with	O
differently	O
arranged	O
photoreceptor	B-T017
cells	I-T017
.	O

Its	O
central	B-T082
part	I-T082
has	O
sensory	B-T017
cells	I-T017
with	O
rhabdomeres	B-T017
on	O
2	O
,	O
3	O
,	O
or	O
4	O
sides	O
,	O
whereas	O
those	O
of	O
the	O
ventral	B-T082
retina	B-T017
have	O
only	O
two	O
rhabdomeres	B-T017
on	O
opposite	O
sides	O
.	O

In	O
addition	O
,	O
the	O
rhabdomeres	B-T017
of	O
the	O
ventral	B-T082
retina	B-T017
are	O
arranged	O
in	O
a	O
specific	O
way	O
:	O
Whereas	O
in	O
the	O
most	O
ventral	B-T082
part	O
they	O
form	O
long	B-T082
tangential	I-T082
rows	I-T082
,	O
those	O
towards	O
the	O
center	B-T082
are	O
detached	O
and	O
are	O
arranged	O
radially	O
.	O

All	O
sensory	B-T017
cells	I-T017
are	O
wrapped	O
by	O
unpigmented	B-T033
pigment	B-T017
cell	I-T017
processes	B-T038
.	O

In	O
agelenid	B-T204
spiders	B-T204
the	O
axons	B-T017
of	O
the	O
sensory	B-T017
cells	I-T017
exit	O
from	O
the	O
middle	O
of	O
the	O
cell	B-T017
body	I-T017
;	O
their	O
fine	B-T082
structure	I-T082
and	O
course	O
through	O
the	O
eye	B-T074
cup	I-T074
is	O
described	O
in	O
detail	O
.	O

In	O
the	O
central	B-T082
part	I-T082
of	O
the	O
retina	B-T017
efferent	O
nerve	B-T017
fibres	I-T017
were	O
found	O
forming	O
synapses	B-T082
along	O
the	O
distal	B-T082
region	I-T082
of	O
the	O
receptor	B-T017
cells	I-T017
.	O

A	O
muscle	B-T017
is	O
attached	O
laterally	O
to	O
each	O
eye	B-T074
cup	I-T074
that	O
allows	O
mainly	O
rotational	B-T082
movements	B-T038
of	O
the	O
eyes	B-T017
.	O

The	O
optical	O
performance	O
(	O
image	O
resolution	O
)	O
of	O
these	O
main	O
eyes	B-T017
with	O
relatively	O
few	O
visual	B-T017
cells	I-T017
is	O
discussed	O
.	O

Knocking	B-T062
down	I-T062
TCF8	B-T017
inhibits	O
high	B-T033
glucose	I-T033
-	O
and	O
angiotensin	B-T103
II	I-T103
-	O
induced	O
epithelial	B-T038
to	I-T038
mesenchymal	I-T038
transition	I-T038
in	O
podocytes	B-T017

Epithelial	B-T038
to	I-T038
mesenchymal	I-T038
transition	I-T038
(	O
EMT	B-T038
)	O
is	O
a	O
physiological	B-T038
phenomenon	I-T038
in	O
mammalian	B-T204
embryogenesis	B-T038
by	O
which	O
epithelial	B-T017
cells	I-T017
become	O
mesenchymal	B-T017
stem	I-T017
cells	I-T017
.	O

Studies	O
have	O
indicated	O
that	O
an	O
inappropriate	O
EMT	B-T038
plays	O
a	O
key	O
role	O
in	O
a	O
variety	O
of	O
pathogenic	B-T033
processes	O
such	O
as	O
embryonic	B-T038
development	I-T038
and	O
tumor	B-T038
metastasis	I-T038
.	O

Moreover	O
,	O
recent	O
studies	O
have	O
indicated	O
EMT	B-T038
also	O
plays	O
an	O
important	O
role	O
in	O
renal	B-T038
fibrosis	I-T038
.	O

In	O
the	O
current	O
study	O
,	O
glucose	B-T103
and	O
angiotensin	B-T103
II	I-T103
promoted	O
EMT	B-T038
in	O
podocytes	B-T017
as	O
well	O
as	O
changes	O
in	O
the	O
cellular	B-T201
morphology	I-T201
of	O
podocytes	B-T017
.	O

A	O
high	O
concentration	O
of	O
glucose	B-T103
and	O
angiotensin	B-T103
II	I-T103
also	O
promoted	O
podocyte	B-T017
movement	B-T038
and	O
migration	B-T038
.	O

Moreover	O
,	O
a	O
high	O
concentration	O
of	O
glucose	B-T103
and	O
angiotensin	B-T103
II	I-T103
promoted	O
TCF8	B-T017
expression	B-T038
.	O

Inhibiting	O
TCF8	B-T017
expression	B-T038
with	O
siRNA	B-T103
reversed	O
EMT	B-T038
in	O
podocytes	B-T017
in	O
the	O
presence	O
of	O
a	O
high	O
concentration	O
of	O
glucose	B-T103
and	O
angiotensin	B-T103
.	O

Inhibiting	O
TCF8	B-T017
expression	B-T038
also	O
reversed	O
changes	O
in	O
cellular	B-T201
morphology	I-T201
and	O
podocyte	B-T017
movement	B-T038
and	O
migration	B-T038
.	O

Therefore	O
,	O
glucose	B-T103
and	O
angiotensin	B-T103
II	I-T103
may	O
promote	O
EMT	B-T038
in	O
podocytes	B-T017
via	O
TCF8	B-T017
.	O

Temporal	O
upregulation	B-T038
of	O
host	B-T103
surface	I-T103
receptors	I-T103
provides	O
a	O
window	O
of	O
opportunity	O
for	O
bacterial	B-T038
adhesion	I-T038
and	O
disease	B-T038

Host	B-T103
surface	I-T103
receptors	I-T103
provide	O
bacteria	B-T007
with	O
a	O
foothold	O
from	O
which	O
to	O
attach	O
,	O
colonize	O
and	O
,	O
in	O
some	O
cases	O
,	O
invade	O
tissue	B-T017
and	O
elicit	O
human	B-T204
disease	B-T038
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
several	O
key	O
host	B-T103
receptors	I-T103
and	O
cognate	B-T017
adhesins	I-T017
that	O
function	O
in	O
bacterial	B-T007
pathogenesis	B-T038
.	O

In	O
particular	O
,	O
we	O
examine	O
the	O
elevated	O
expression	O
of	O
host	B-T103
surface	I-T103
receptors	I-T103
such	O
as	O
CEACAM	B-T103
-	I-T103
1	I-T103
,	O
CEACAM	B-T103
-	I-T103
6	I-T103
,	O
ICAM	B-T103
-	I-T103
1	I-T103
and	O
PAFR	B-T103
in	O
response	B-T038
to	I-T038
specific	I-T038
stimuli	I-T038
.	O

We	O
explore	O
how	O
upregulated	B-T038
receptors	I-T038
,	O
in	O
turn	O
,	O
expose	O
the	O
host	O
to	O
a	O
range	O
of	O
bacterial	B-T038
infections	I-T038
in	O
the	O
respiratory	B-T022
tract	I-T022
.	O

It	O
is	O
apparent	O
that	O
exploitation	O
of	O
receptor	B-T103
induction	O
for	O
bacterial	B-T038
adherence	I-T038
is	O
not	O
unique	O
to	O
one	O
body	B-T022
system	I-T022
,	O
but	O
is	O
also	O
observed	O
in	O
the	O
central	B-T022
nervous	I-T022
,	O
gastrointestinal	B-T022
and	O
urogenital	B-T022
systems	I-T022
.	O

Prokaryotic	O
pathogens	B-T038
which	O
utilize	O
this	O
mechanism	O
for	O
their	O
infectivity	B-T038
include	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
Haemophilus	B-T007
influenzae	I-T007
,	O
Neisseria	B-T007
meningitidis	I-T007
and	O
Escherichia	B-T007
coli	I-T007
.	O

A	O
number	O
of	O
approaches	O
have	O
been	O
used	O
,	O
in	O
both	O
in	B-T062
vitro	I-T062
and	O
in	B-T062
vivo	I-T062
experimental	I-T062
models	I-T062
,	O
to	O
inhibit	O
bacterial	B-T038
attachment	I-T038
to	O
temporally	O
expressed	O
host	B-T103
receptors	I-T103
.	O

Some	O
of	O
these	O
novel	O
strategies	O
may	O
advance	O
future	O
targeted	O
interventions	B-T058
for	O
the	O
prevention	B-T058
and	O
treatment	B-T058
of	O
bacterial	B-T038
disease	I-T038
.	O

Optogenetic	B-T062
Demonstration	O
of	O
Functional	O
Innervation	B-T038
of	O
Mouse	B-T204
Colon	B-T017
by	O
Neurons	B-T017
Derived	O
From	O
Transplanted	O
Neural	B-T017
Cells	I-T017

Cell	B-T058
therapy	I-T058
offers	O
the	O
potential	O
to	O
treat	O
gastrointestinal	B-T038
motility	I-T038
disorders	I-T038
caused	O
by	O
diseased	B-T017
or	O
absent	O
enteric	B-T082
neurons	B-T017
.	O

We	O
examined	O
whether	O
neurons	B-T017
generated	O
from	O
transplanted	O
enteric	B-T082
neural	B-T017
cells	I-T017
provide	O
a	O
functional	O
innervation	B-T038
of	O
bowel	B-T017
smooth	B-T017
muscle	I-T017
in	O
mice	B-T204
.	O

Enteric	B-T082
neural	B-T017
cells	I-T017
expressing	O
the	O
light	B-T103
-	I-T103
sensitive	I-T103
ion	I-T103
channel	I-T103
,	O
channelrhodopsin	B-T103
,	O
were	O
isolated	O
from	O
the	O
fetal	O
or	O
postnatal	O
mouse	B-T204
bowel	B-T017
and	O
transplanted	O
into	O
the	O
distal	B-T017
colon	I-T017
of	O
3	O
-	O
to	O
4	O
-	O
week	O
-	O
old	O
wild	B-T017
-	I-T017
type	I-T017
recipient	B-T204
mice	I-T204
.	O

Intracellular	B-T082
electrophysiological	B-T058
recordings	I-T058
of	O
responses	O
to	O
light	O
stimulation	O
of	O
the	O
transplanted	O
cells	B-T017
were	O
made	O
from	O
colonic	B-T017
smooth	B-T017
muscle	I-T017
cells	I-T017
in	O
recipient	B-T204
mice	I-T204
.	O

Electrical	O
stimulation	O
of	O
endogenous	O
enteric	B-T082
neurons	B-T017
was	O
used	O
as	O
a	O
control	O
.	O

The	O
axons	B-T017
of	O
graft	B-T017
-	O
derived	O
neurons	B-T017
formed	O
a	O
plexus	B-T017
in	O
the	O
circular	B-T017
muscle	I-T017
layer	I-T017
.	O

Selective	O
stimulation	O
of	O
graft	B-T017
-	O
derived	O
cells	B-T017
by	O
light	O
resulted	O
in	O
excitatory	B-T038
and	O
inhibitory	B-T038
junction	I-T038
potentials	I-T038
,	O
the	O
electrical	O
events	O
underlying	O
contraction	B-T038
and	O
relaxation	B-T038
,	O
respectively	O
,	O
in	O
colonic	B-T017
muscle	B-T017
cells	I-T017
.	O

Graft	B-T017
-	O
derived	O
excitatory	B-T017
and	O
inhibitory	B-T017
motor	I-T017
neurons	I-T017
released	O
the	O
same	O
neurotransmitters	B-T103
as	O
endogenous	O
motor	B-T017
neurons	I-T017
-	O
acetylcholine	B-T103
and	O
a	O
combination	O
of	O
adenosine	B-T103
triphosphate	I-T103
and	O
nitric	B-T103
oxide	I-T103
,	O
respectively	O
.	O

Graft	B-T017
-	O
derived	O
neurons	B-T017
also	O
included	O
interneurons	B-T017
that	O
provided	O
synaptic	O
inputs	O
to	O
motor	O
neurons	B-T017
,	O
but	O
the	O
pharmacologic	O
properties	O
of	O
interneurons	B-T017
varied	O
with	O
the	O
age	O
of	O
the	O
donors	B-T098
from	O
which	O
enteric	B-T082
neural	B-T017
cells	I-T017
were	O
obtained	O
.	O

Enteric	B-T082
neural	B-T017
cells	I-T017
transplanted	O
into	O
the	O
bowel	B-T017
give	O
rise	O
to	O
multiple	O
functional	O
types	O
of	O
neurons	B-T017
that	O
integrate	O
and	O
provide	O
a	O
functional	O
innervation	B-T038
of	O
the	O
smooth	B-T017
muscle	I-T017
of	O
the	O
bowel	B-T017
wall	I-T017
.	O

Circuits	O
composed	O
of	O
both	O
motor	B-T017
neurons	I-T017
and	O
interneurons	B-T017
were	O
established	O
,	O
but	O
the	O
age	O
at	O
which	O
cells	B-T017
are	O
isolated	O
influences	O
the	O
neurotransmitter	B-T103
phenotype	O
of	O
interneurons	B-T017
that	O
are	O
generated	O
.	O

Assessment	B-T058
of	O
Vascular	B-T074
Stent	I-T074
Heating	O
with	O
Repetitive	B-T058
Transcranial	I-T058
Magnetic	I-T058
Stimulation	I-T058

A	O
high	O
proportion	O
of	O
patients	O
with	O
stroke	B-T038
do	O
not	O
qualify	O
for	O
repetitive	B-T058
transcranial	I-T058
magnetic	I-T058
stimulation	I-T058
(	O
rTMS	B-T058
)	O
clinical	B-T062
studies	I-T062
due	O
to	O
the	O
presence	O
of	O
metallic	B-T074
stents	I-T074
.	O

The	O
ultimate	O
concern	O
is	O
that	O
any	O
metal	B-T103
could	O
become	O
heated	O
due	O
to	O
eddy	O
currents	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
clinical	B-T170
safety	I-T170
data	I-T170
are	O
available	O
regarding	O
the	O
risk	O
of	O
metallic	B-T074
stents	I-T074
heating	O
with	O
rTMS	B-T058
.	O

We	O
tested	O
the	O
safety	B-T062
of	O
common	O
rTMS	B-T058
protocols	B-T170
(	O
1	O
Hz	O
and	O
10	O
Hz	O
)	O
with	O
stents	B-T074
used	O
commonly	O
in	O
stroke	B-T038
,	O
nitinol	B-T103
and	O
elgiloy	B-T103
.	O

In	O
our	O
method	O
,	O
stents	B-T074
were	O
tested	B-T170
in	O
gelled	O
saline	O
at	O
2	O
different	O
locations	B-T082
:	O
at	B-T082
the	I-T082
center	I-T082
and	O
at	O
the	O
lobe	B-T017
of	O
the	O
coil	B-T074
.	O

In	O
addition	O
,	O
at	O
each	O
location	B-T082
,	O
stent	B-T074
heating	O
was	O
evaluated	B-T058
in	O
3	O
different	O
orientations	B-T082
:	O
parallel	O
to	O
the	O
long	B-T082
axis	I-T082
of	O
coil	B-T074
,	O
parallel	O
to	O
the	O
short	B-T082
axis	I-T082
of	O
the	O
coil	B-T074
,	O
and	O
perpendicular	B-T082
to	O
the	O
plane	O
of	O
the	O
coil	B-T074
.	O

We	O
found	O
that	O
stents	B-T074
did	O
not	O
heat	O
to	O
more	O
than	O
1°C	O
with	O
either	O
1	O
Hz	O
rTMS	B-T058
or	O
10	O
Hz	O
rTMS	B-T058
in	O
any	O
configuration	O
or	O
orientation	B-T082
.	O

Heating	O
in	O
general	O
was	O
greater	O
at	O
the	O
lobe	B-T017
when	O
the	O
stent	B-T074
was	O
oriented	B-T082
perpendicularly	B-T082
.	O

Our	O
study	O
represents	O
a	O
new	O
method	O
for	O
ex	O
vivo	O
quantification	O
of	O
stent	B-T074
heating	O
.	O

We	O
have	O
found	O
that	O
heating	O
of	O
stents	B-T074
was	O
well	O
below	O
the	O
Food	B-T092
and	I-T092
Drug	I-T092
Administration	I-T092
standards	B-T170
of	O
2°C	O
.	O

Thus	O
,	O
our	O
study	O
paves	O
the	O
way	O
for	O
in	B-T082
vivo	I-T082
testing	O
of	O
rTMS	B-T058
(	O
≤10	O
Hz	O
)	O
in	O
the	O
presence	O
of	O
implanted	B-T074
magnetic	B-T058
resonance	I-T058
imaging	I-T058
-	O
compatible	O
stents	B-T074
in	O
animal	B-T204
studies	I-T204
.	O

When	O
planning	O
human	B-T204
safety	B-T062
studies	I-T062
though	O
,	O
geometry	O
,	O
orientation	B-T082
,	O
and	O
location	B-T082
relative	O
to	O
the	O
coil	B-T074
would	O
be	O
important	O
to	O
consider	O
as	O
well	O
.	O

Clinical	B-T058
Observation	I-T058
of	O
Treatment	O
of	O
Chronic	B-T038
Subdural	I-T038
Hematoma	I-T038
With	O
Novel	B-T074
Double	I-T074
Needle	I-T074
Minimally	I-T074
Invasive	I-T074
Aspiration	I-T074
Technology	I-T074

The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
explore	O
the	O
clinical	O
effects	O
,	O
including	O
the	O
prevention	O
of	O
complications	B-T038
,	O
of	O
the	O
treatment	O
of	O
chronic	B-T038
subdural	I-T038
hematoma	I-T038
with	O
double	B-T074
needle	I-T074
aspiration	I-T074
.	O

The	O
clinical	B-T170
data	I-T170
of	O
31	O
patients	O
with	O
chronic	B-T038
subdural	I-T038
hematoma	I-T038
treated	O
by	O
double	B-T074
YL	I-T074
-	I-T074
1	I-T074
needle	I-T074
double	O
skull	B-T058
drilling	I-T058
and	O
31	O
controls	O
treated	O
by	O
traditional	O
drilling	B-T058
and	O
drainage	B-T058
were	O
analyzed	O
retrospectively	O
.	O

In	O
the	O
YL	B-T074
-	I-T074
1	I-T074
needle	I-T074
group	O
,	O
only	O
1	O
patient	O
was	O
with	O
hematoma	B-T038
recurrence	B-T038
,	O
1	O
patient	O
was	O
with	O
intracranial	B-T038
pneumocephalus	I-T038
,	O
and	O
the	O
remaining	O
patients	O
who	O
were	O
followed	O
up	O
for	O
3	O
months	O
achieved	O
a	O
clinical	B-T033
cure	I-T033
.	O

In	O
the	O
traditional	B-T058
drilling	I-T058
and	O
drainage	B-T058
group	O
,	O
13	O
patients	O
were	O
with	O
hematoma	B-T038
recurrence	B-T038
within	O
3	O
months	O
after	O
the	O
operation	B-T058
and	O
7	O
patients	O
were	O
with	O
postoperative	O
intracranial	B-T038
pneumocephalus	I-T038
.	O

The	O
method	B-T170
of	O
double	B-T074
YL	I-T074
-	I-T074
1	I-T074
needle	I-T074
is	O
better	O
than	O
the	O
traditional	B-T058
drilling	I-T058
and	O
drainage	B-T058
method	I-T058
for	O
the	O
treatment	O
of	O
chronic	B-T038
subdural	I-T038
hematoma	I-T038
because	O
it	O
reduces	O
the	O
postoperative	O
recurrence	B-T038
rate	O
and	O
complications	B-T038
.	O

The	O
impact	O
of	O
adjunctive	B-T058
guanfacine	B-T103
extended	B-T103
release	I-T103
on	O
stimulant	B-T103
adherence	O
in	O
children	O
/	O
adolescents	O
with	O
attention	B-T038
-	I-T038
deficit	I-T038
/	O
hyperactivity	B-T038
disorder	I-T038

To	O
assess	O
stimulant	B-T103
adherence	O
among	O
children	O
/	O
adolescents	O
with	O
attention	B-T038
-	I-T038
deficit	I-T038
/	O
hyperactivity	B-T038
disorder	I-T038
(	O
ADHD	B-T038
)	O
augmenting	B-T103
stimulants	B-T103
with	O
guanfacine	B-T103
extended	I-T103
-	I-T103
release	I-T103
(	O
GXR	B-T103
)	O
.	O

Inclusion	O
criteria	O
:	O
6	O
-	O
17	O
years	O
,	O
≥1	O
ADHD	B-T038
diagnosis	B-T033
,	O
≥1	O
long	B-T103
-	I-T103
acting	I-T103
and	O
/	O
or	O
short	B-T103
-	I-T103
acting	I-T103
stimulant	I-T103
with	O
GXR	B-T103
augmentation	B-T058
.	O

Modified	O
medication	O
possession	O
ratio	O
(	O
mMPR	O
;	O
days	O
medication	B-T058
available	O
/	O
days	O
in	O
period	O
,	O
excluding	O
medication	B-T058
holidays	O
)	O
was	O
assessed	O
;	O
mMPR	O
<	O
0	O
.	O
80	O
nonadherent	O
.	O

Regression	B-T170
models	B-T170
assessed	O
change	O
in	O
mMPR	O
adjusting	O
for	O
demographic	O
and	O
clinical	O
characteristics	O
.	O

Among	O
patients	O
nonadherent	O
to	O
stimulants	B-T103
pre	O
-	O
augmentation	B-T058
(	O
n	O
=	O
165	O
)	O
,	O
unadjusted	O
mean	O
(	O
SD	O
)	O
pre	O
-	O
and	O
post	O
-	O
stimulant	B-T103
mMPRs	O
were	O
0	O
.	O
68	O
(	O
0	O
.	O
11	O
)	O
and	O
0	O
.	O
87	O
(	O
0	O
.	O
16	O
)	O
.	O

Adjusted	O
mean	O
change	O
in	O
mMPR	O
was	O
0	O
.	O
20	O
for	O
long	B-T103
-	I-T103
acting	I-T103
versus	O
0	O
.	O
18	O
for	O
short	B-T103
-	I-T103
acting	I-T103
stimulants	I-T103
(	O
p	O
=	O
0	O
.	O
34	O
)	O
.	O

Among	O
patients	O
nonadherent	O
to	O
stimulants	B-T103
,	O
GXR	B-T103
augmentation	B-T058
was	O
associated	O
with	O
increased	O
stimulant	B-T103
adherence	O
.	O

Bxb1	B-T005
phage	I-T005
recombinase	B-T103
assists	O
genome	B-T062
engineering	I-T062
in	O
Drosophila	B-T204
melanogaster	I-T204

Rapid	O
and	O
reliable	O
genome	B-T062
modifications	I-T062
provide	O
the	O
basis	O
for	O
detailed	O
in	B-T082
vivo	I-T082
functional	B-T058
analysis	I-T058
of	O
any	O
genomic	O
entity	O
(	O
gene	B-T017
,	O
regulatory	B-T082
DNA	I-T082
,	O
non	B-T103
-	I-T103
coding	I-T103
RNA	I-T103
,	O
etc	O
)	O
.	O

With	O
the	O
advent	O
of	O
CRISPR	B-T103
/	O
Cas9	B-T062
genome	I-T062
editing	I-T062
technology	I-T062
,	O
manipulation	O
of	O
a	O
particular	O
genomic	B-T017
locus	I-T017
has	O
become	O
a	O
routine	O
undertaking	O
in	O
variety	O
of	O
model	O
organisms	O
,	O
including	O
the	O
fruit	B-T204
fly	I-T204
Drosophila	I-T204
melanogaster	I-T204
.	O

To	O
further	O
diversify	O
the	O
available	O
tools	O
for	O
genome	B-T062
engineering	I-T062
,	O
we	O
successfully	O
harnessed	O
the	O
phage	B-T005
recombinase	B-T103
Bxb1	I-T103
to	O
perform	O
recombinase	O
-	O
mediated	O
cassette	O
exchange	O
(	O
RMCE	O
)	O
in	O
D	B-T204
.	I-T204

melanogaster	I-T204
.	O

We	O
demonstrate	O
that	O
Bxb1	B-T005
possesses	O
highly	O
efficient	O
recombinase	B-T038
activity	I-T038
and	O
could	O
be	O
used	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
currently	O
available	O
recombinases	B-T103
for	O
creating	O
platforms	O
for	O
cassette	O
exchange	O
of	O
targeted	B-T017
loci	I-T017
.	O

Tailor	B-T103
-	I-T103
made	I-T103
drug	I-T103
carrier	I-T103
:	O
Comparison	O
of	O
formation	O
-	O
dependent	O
physicochemical	O
properties	O
within	O
self	O
-	O
assembled	O
aggregates	O
for	O
an	O
optimal	O
drug	B-T103
carrier	I-T103

Self	O
-	O
assembled	O
surfactant	B-T103
aggregates	O
,	O
such	O
as	O
micelles	B-T103
and	O
vesicles	O
,	O
have	O
been	O
investigated	O
for	O
their	O
application	O
as	O
drug	B-T103
carriers	I-T103
in	O
the	O
treatment	B-T058
of	O
various	O
diseases	B-T038
.	O

However	O
,	O
the	O
characteristics	O
that	O
decide	O
which	O
aggregate	O
is	O
the	O
best	O
drug	B-T103
carrier	I-T103
for	O
each	O
disease	B-T038
have	O
not	O
yet	O
been	O
clarified	O
.	O

In	O
order	O
to	O
design	O
an	O
optimal	O
drug	B-T103
carrier	I-T103
for	O
each	O
disease	B-T038
,	O
various	O
kinds	O
of	O
self	O
-	O
assembled	O
aggregates	O
,	O
such	O
as	O
spherical	B-T103
micelles	I-T103
,	O
lens	O
-	O
like	O
vesicles	O
,	O
and	O
tube	O
-	O
like	O
vesicles	O
,	O
were	O
evaluated	O
by	O
"	O
multiple	O
techniques	O
"	O
including	O
dynamic	B-T058
light	I-T058
scattering	I-T058
,	O
differential	B-T058
scanning	I-T058
calorimetry	I-T058
,	O
nuclear	B-T058
magnetic	I-T058
resonance	I-T058
spectroscopy	I-T058
,	O
and	O
fluorescence	B-T058
measurement	I-T058
using	O
the	O
Laurdan	B-T103
probe	B-T074
.	O

These	O
studies	B-T062
led	O
to	O
the	O
compilation	O
of	O
a	O
database	B-T170
on	O
the	O
formation	O
-	O
dependent	O
properties	O
of	O
self	O
-	O
assembled	O
aggregates	O
.	O

As	O
the	O
relationship	O
between	O
physicochemical	O
properties	O
of	O
self	O
-	O
assembled	O
aggregates	O
and	O
their	O
functions	O
as	O
drug	B-T103
carriers	I-T103
have	O
been	O
extensively	O
reported	O
,	O
this	O
database	B-T170
can	O
be	O
utilized	O
for	O
designing	O
an	O
optimal	O
drug	B-T103
carrier	I-T103
,	O
i	O
.	O
e	O
.	O
,	O
a	O
tailor	B-T103
-	I-T103
made	I-T103
drug	I-T103
carrier	I-T103
.	O

Uridine	B-T103
stimulate	O
laxative	B-T103
effect	O
in	O
the	O
loperamide	B-T103
-	O
induced	O
constipation	B-T033
of	O
SD	B-T204
rats	I-T204
through	O
regulation	B-T038
of	O
the	O
mAChRs	B-T103
signaling	B-T038
pathway	I-T038
and	O
mucin	B-T103
secretion	B-T038

Uridine	B-T103
(	O
Urd	B-T103
)	O
,	O
which	O
has	O
been	O
reported	B-T058
as	O
a	O
major	O
component	O
of	O
RNA	B-T103
,	O
plays	O
an	O
important	O
role	O
in	O
various	O
biological	B-T038
process	I-T038
including	O
neuroprotection	B-T038
,	O
biochemical	O
modulation	O
and	O
glycolysis	B-T038
,	O
although	O
its	O
role	O
in	O
constipation	B-T033
has	O
yet	O
to	O
be	O
established	O
.	O

Therefore	O
,	O
in	O
this	O
study	B-T062
,	O
we	O
investigated	O
the	O
laxative	B-T103
effects	O
of	O
Urd	B-T103
on	O
chronic	O
constipation	B-T033
.	O

The	O
constipation	B-T033
phenotypes	O
and	O
their	O
related	O
mechanisms	O
were	O
investigated	O
in	O
the	O
transverse	B-T017
colons	I-T017
of	O
SD	B-T204
rats	I-T204
with	O
loperamide	B-T103
(	O
Lop	B-T103
)	O
-	O
induced	O
constipation	B-T033
after	O
treatment	B-T058
with	O
100	O
mg	O
/	O
kg	O
of	O
Urd	B-T103
.	O

The	O
number	O
,	O
weight	O
and	O
water	B-T103
contents	O
of	O
stools	B-T031
were	O
significantly	O
higher	O
in	O
the	O
Lop	B-T103
+	O
Urd	B-T103
treated	B-T033
group	O
than	O
the	O
Lop	B-T103
+	O
Vehicle	B-T103
treated	B-T033
group	O
,	O
while	O
food	B-T038
intake	I-T038
and	O
water	B-T038
consumption	I-T038
of	O
the	O
same	O
group	O
were	O
maintained	O
at	O
a	O
constant	O
level	O
.	O

The	O
thickness	O
of	O
the	O
mucosa	B-T017
layer	I-T017
,	O
muscle	B-T017
and	O
flat	B-T082
luminal	I-T082
surface	I-T082
,	O
as	O
well	O
as	O
the	O
number	O
of	O
goblet	B-T017
cells	I-T017
,	O
paneth	B-T017
cells	I-T017
and	O
lipid	B-T017
droplets	I-T017
were	O
enhanced	O
in	O
the	O
Lop	B-T103
+	O
Urd	B-T103
treated	B-T033
group	O
.	O

Furthermore	O
,	O
the	O
expression	B-T038
of	O
the	O
muscarinic	B-T103
acetylcholine	I-T103
receptors	I-T103
M2	I-T103
and	O
M3	B-T103
(	O
mAChR	B-T103
M2	I-T103
and	O
M3	B-T103
)	O
at	O
the	O
transcriptional	B-T038
and	O
translational	B-T038
level	O
was	O
recovered	O
in	O
the	O
Lop	B-T103
+	O
Urd	B-T103
treated	B-T033
group	O
,	O
while	O
some	O
markers	B-T201
such	O
as	O
Gα	B-T103
and	O
inositol	O
triphosphate	O
(	O
IP3	O
)	O
in	O
their	O
downstream	B-T082
signaling	B-T038
pathway	I-T038
were	O
completely	O
recovered	O
by	O
Urd	B-T103
treatment	B-T058
.	O

Moreover	O
,	O
the	O
ability	O
for	O
mucin	B-T103
secretion	B-T038
and	O
the	O
expression	B-T038
of	O
membrane	B-T103
water	I-T103
channel	I-T103
(	O
aquaporine	B-T103
8	I-T103
,	O
AQP8	B-T103
)	O
were	O
increased	O
significantly	O
in	O
the	O
Lop	B-T103
+	O
Urd	B-T103
treated	B-T033
group	O
compared	O
with	O
Lop	B-T103
+	O
Vehicle	B-T103
treated	B-T033
group	O
.	O

Finally	O
,	O
the	O
activity	O
of	O
Urd	B-T103
was	O
confirmed	O
in	O
primary	B-T017
smooth	I-T017
muscle	I-T017
of	O
rat	B-T204
intestine	B-T017
cells	I-T017
(	O
pRISMC	B-T017
)	O
based	O
on	O
Gα	B-T103
expression	B-T038
and	O
IP3	O
concentration	O
.	O

The	O
results	O
of	O
the	O
present	O
study	B-T062
provide	O
the	O
first	O
strong	O
evidence	O
that	O
Urd	B-T103
can	O
be	O
considered	O
an	O
important	O
candidate	O
for	O
improving	O
chronic	O
constipation	B-T033
induced	O
by	O
Lop	B-T103
treatment	B-T058
in	O
animal	B-T204
models	I-T204
.	O

Characterization	O
of	O
Phytochrome	B-T103
Interacting	I-T103
Factors	I-T103
from	O
the	O
Moss	B-T204
Physcomitrella	B-T204
patens	I-T204
Illustrates	O
Conservation	O
of	O
Phytochrome	B-T103
Signaling	I-T103
Modules	I-T103
in	O
Land	B-T204
Plants	I-T204

Across	O
the	O
plant	B-T204
kingdom	I-T204
,	O
phytochrome	B-T103
(	O
PHY	B-T103
)	O
photoreceptors	B-T017
play	O
an	O
important	O
role	O
during	O
adaptive	O
and	O
developmental	O
responses	O
to	O
light	O
.	O

In	O
Arabidopsis	B-T204
thaliana	I-T204
,	O
light	O
-	O
activated	O
PHYs	B-T103
accumulate	O
in	O
the	O
nucleus	B-T017
,	O
where	O
they	O
regulate	O
downstream	B-T103
signaling	I-T103
components	I-T103
,	O
such	O
as	O
phytochrome	B-T103
interacting	I-T103
factors	I-T103
(	O
PIFs	B-T103
)	O
.	O

PIFs	B-T103
are	O
transcription	B-T103
factors	I-T103
that	O
act	O
as	O
repressors	B-T103
of	O
photomorphogenesis	B-T038
;	O
their	O
inhibition	B-T038
by	O
PHYs	B-T103
leads	O
to	O
substantial	O
changes	O
in	O
gene	B-T038
expression	I-T038
.	O

The	O
nuclear	B-T038
function	I-T038
of	O
PHYs	B-T103
,	O
however	O
,	O
has	O
so	O
far	O
been	O
investigated	O
in	O
only	O
a	O
few	O
non	B-T204
-	I-T204
seed	I-T204
plants	I-T204
.	O

Here	O
,	O
we	O
identified	O
putative	O
target	O
genes	B-T017
of	O
PHY	B-T103
signaling	B-T038
in	O
the	O
moss	B-T204
Physcomitrella	B-T204
patens	I-T204
and	O
found	O
light	B-T017
-	I-T017
regulated	I-T017
genes	I-T017
that	O
are	O
putative	O
orthologs	B-T017
of	O
PIF	B-T017
-	I-T017
controlled	I-T017
genes	I-T017
in	O
Arabidopsis	B-T204
.	O

Phylogenetic	B-T062
analyses	I-T062
revealed	O
that	O
an	O
ancestral	O
PIF	B-T017
-	I-T017
like	I-T017
gene	I-T017
was	O
already	O
present	O
in	O
streptophyte	B-T204
algae	I-T204
,	O
i	O
.	O
e	O
.	O
,	O
before	O
the	O
water	O
-	O
to	O
-	O
land	O
transition	O
of	O
plants	B-T204
.	O

The	O
PIF	B-T103
homologs	I-T103
in	O
the	O
genome	B-T017
of	O
P	B-T204
.	I-T204

patens	I-T204
resemble	O
Arabidopsis	B-T204
PIFs	B-T103
in	O
their	O
protein	B-T103
domain	I-T103
structure	I-T103
,	O
molecular	O
properties	O
,	O
and	O
physiological	O
effects	O
,	O
albeit	O
with	O
notable	O
differences	O
in	O
the	O
motif	O
-	O
dependent	O
PHY	B-T103
interaction	O
.	O

Our	O
results	O
suggest	O
that	O
P	B-T204
.	I-T204

patens	I-T204
PIFs	B-T103
are	O
involved	O
in	O
PHY	B-T103
signaling	B-T038
.	O

The	O
PHY	B-T038
-	I-T038
PIF	I-T038
signaling	I-T038
node	I-T038
that	O
relays	O
light	O
signals	O
to	O
target	O
genes	B-T017
has	O
been	O
largely	O
conserved	O
during	O
land	B-T204
plant	I-T204
evolution	B-T038
,	O
with	O
evidence	O
of	O
lineage	O
-	O
specific	O
diversification	O
.	O

Conditional	B-T058
reprogramming	I-T058
and	O
long	O
-	O
term	O
expansion	B-T038
of	O
normal	B-T017
and	O
tumor	B-T017
cells	I-T017
from	O
human	B-T204
biospecimens	O

Historically	O
,	O
it	O
has	O
been	O
difficult	O
to	O
propagate	O
cells	B-T017
in	O
vitro	O
that	O
are	O
derived	O
directly	O
from	O
human	B-T204
tumors	B-T038
or	O
healthy	B-T017
tissue	I-T017
.	O

However	O
,	O
in	O
vitro	O
preclinical	B-T170
models	I-T170
are	O
essential	O
tools	O
for	O
both	O
the	O
study	B-T091
of	I-T091
basic	I-T091
cancer	I-T091
biology	I-T091
and	O
the	O
promotion	O
of	O
translational	B-T062
research	I-T062
,	O
including	O
drug	B-T062
discovery	I-T062
and	O
drug	B-T074
target	I-T074
identification	I-T074
.	O

This	O
protocol	B-T058
describes	O
conditional	B-T038
reprogramming	I-T038
(	O
CR	B-T038
)	O
,	O
which	O
involves	O
coculture	B-T058
of	O
irradiated	O
mouse	B-T204
fibroblast	B-T017
feeder	I-T017
cells	I-T017
with	O
normal	B-T017
and	O
tumor	B-T038
human	B-T204
epithelial	B-T017
cells	I-T017
in	O
the	O
presence	O
of	O
a	O
Rho	B-T103
kinase	I-T103
inhibitor	B-T103
(	O
Y	B-T103
-	I-T103
27632	I-T103
)	O
.	O

CR	B-T058
cells	B-T017
can	O
be	O
used	O
for	O
various	O
applications	O
,	O
including	O
regenerative	B-T091
medicine	I-T091
,	O
drug	B-T058
sensitivity	I-T058
testing	I-T058
,	O
gene	B-T058
expression	I-T058
profiling	I-T058
and	O
xenograft	B-T058
studies	I-T058
.	O

The	O
method	B-T058
requires	O
a	O
pathologist	B-T097
to	O
differentiate	O
healthy	B-T017
tissue	I-T017
from	O
tumor	B-T017
tissue	I-T017
,	O
and	O
basic	B-T058
tissue	I-T058
culture	I-T058
skills	O
.	O

The	O
protocol	B-T058
can	O
be	O
used	O
with	O
cells	B-T017
derived	O
from	O
both	O
fresh	B-T017
and	O
cryopreserved	B-T017
tissue	I-T017
samples	I-T017
.	O

As	O
approximately	O
1	O
million	O
cells	B-T017
can	O
be	O
generated	O
in	O
7	O
d	O
,	O
the	O
technique	B-T058
is	O
directly	O
applicable	O
to	O
diagnostic	B-T103
and	O
predictive	O
medicine	B-T103
.	O

Moreover	O
,	O
the	O
epithelial	B-T017
cells	I-T017
can	O
be	O
propagated	O
indefinitely	O
in	O
vitro	O
,	O
yet	O
retain	O
the	O
capacity	O
to	O
become	O
fully	O
differentiated	B-T038
when	O
placed	O
into	O
conditions	B-T082
that	O
mimic	O
their	O
natural	B-T082
environment	I-T082
.	O

Types	O
of	O
internal	B-T092
facilitation	I-T092
activities	O
in	O
hospitals	B-T092
implementing	B-T058
evidence	I-T058
-	I-T058
based	I-T058
interventions	I-T058

Implementation	O
models	B-T170
,	O
frameworks	O
,	O
and	O
theories	O
recognize	O
the	O
importance	O
of	O
activities	O
that	O
facilitate	O
implementation	O
success	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
internal	B-T092
facilitation	I-T092
activities	O
that	O
hospital	B-T097
personnel	I-T097
engage	O
in	O
during	O
implementation	O
efforts	O
.	O

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
examine	O
internal	B-T092
facilitation	I-T092
activities	O
at	O
10	O
critical	B-T092
access	I-T092
hospitals	I-T092
in	O
rural	B-T082
Iowa	I-T082
during	O
their	O
implementation	O
of	O
TeamSTEPPS	B-T092
,	O
a	O
patient	B-T058
safety	I-T058
intervention	B-T058
,	O
and	O
to	O
identify	O
characteristics	O
that	O
distinguish	O
different	O
types	O
of	O
facilitation	B-T092
activities	O
.	O

We	O
followed	O
10	O
critical	B-T092
access	I-T092
hospitals	I-T092
for	O
2	O
years	O
after	O
the	O
onset	O
of	O
implementation	O
,	O
conducting	O
quarterly	O
interviews	O
with	O
key	O
informants	O
.	O

On	O
the	O
basis	O
of	O
the	O
transcripts	B-T170
from	O
the	O
first	O
two	O
quarters	O
,	O
a	O
coding	O
template	O
was	O
developed	O
using	O
inductive	B-T062
analyses	I-T062
.	O

The	O
template	O
was	O
then	O
applied	O
deductively	O
to	O
code	O
all	O
interview	O
transcripts	B-T170
.	O

Using	O
comparative	O
analysis	O
,	O
we	O
examined	O
the	O
characteristics	O
that	O
distinguish	O
between	O
the	O
facilitation	B-T092
types	O
.	O

We	O
identified	O
four	O
types	O
of	O
facilitation	B-T092
activities	O
-	O
Leadership	O
,	O
Buy	O
-	O
in	O
,	O
Customization	O
,	O
and	O
Accountability	O
.	O

Individuals	B-T098
and	O
teams	O
engaged	O
in	O
different	O
types	O
of	O
facilitation	B-T092
activities	O
,	O
both	O
in	O
a	O
planned	O
and	O
an	O
ad	B-T033
hoc	I-T033
manner	I-T033
.	O

These	O
activities	O
targeted	O
at	O
both	O
people	B-T098
and	O
practices	B-T038
and	O
exhibited	O
varying	O
temporal	O
patterns	O
(	O
start	O
and	O
peak	O
time	O
)	O
.	O

There	O
are	O
four	O
types	O
of	O
facilitation	B-T092
activities	O
that	O
hospitals	B-T092
engage	O
in	O
while	O
implementing	O
evidence	B-T091
-	I-T091
based	I-T091
practices	I-T091
,	O
offering	O
a	O
parsimonious	O
way	O
to	O
characterize	O
facilitation	B-T092
activities	O
.	O

New	O
theoretical	O
and	O
empirical	B-T062
research	O
opportunities	O
are	O
discussed	O
.	O

Understanding	O
the	O
types	O
of	O
facilitation	B-T092
activities	O
and	O
their	O
distinguishing	O
characteristics	O
can	O
assist	O
managers	B-T097
in	O
planning	O
and	O
executing	O
implementations	O
of	O
evidence	B-T091
-	I-T091
based	I-T091
interventions	I-T091
.	O

Directing	B-T038
traffic	I-T038
on	I-T038
DNA	I-T038
-	O
How	O
transcription	B-T103
factors	I-T103
relieve	O
or	O
induce	O
transcriptional	B-T038
interference	I-T038

Transcriptional	B-T038
interference	I-T038
(	O
TI	B-T038
)	O
is	O
increasingly	O
recognized	O
as	O
a	O
widespread	B-T082
mechanism	O
of	O
gene	B-T038
control	I-T038
,	O
particularly	O
given	O
the	O
pervasive	O
nature	O
of	O
transcription	B-T038
,	O
both	O
sense	O
and	O
antisense	B-T103
,	O
across	O
all	O
kingdoms	B-T170
of	O
life	O
.	O

Here	O
,	O
we	O
discuss	O
how	O
transcription	B-T103
factor	I-T103
binding	O
kinetics	O
strongly	O
influence	O
the	O
ability	O
of	O
a	O
transcription	B-T103
factor	I-T103
to	O
relieve	O
or	O
induce	O
TI	B-T038
.	O

Acoustic	B-T038
startle	I-T038
response	I-T038
in	O
rats	B-T204
predicts	O
inter	B-T098
-	I-T098
individual	I-T098
variation	O
in	O
fear	B-T038
extinction	B-T038

Although	O
a	O
large	O
portion	O
of	O
the	O
population	B-T098
is	O
exposed	O
to	O
a	O
traumatic	O
event	O
at	O
some	O
point	O
,	O
only	O
a	O
small	O
percentage	O
of	O
the	O
population	B-T098
develops	O
post	B-T038
-	I-T038
traumatic	I-T038
stress	I-T038
disorder	I-T038
(	O
PTSD	B-T038
)	O
,	O
suggesting	O
the	O
presence	O
of	O
predisposing	O
factors	O
.	O

Abnormal	B-T033
acoustic	B-T038
startle	I-T038
response	I-T038
(	O
ASR	B-T038
)	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
PTSD	B-T038
,	O
implicating	O
it	O
as	O
a	O
potential	O
predictor	O
of	O
the	O
development	B-T038
of	O
PTSD	B-T038
-	O
like	O
behavior	O
.	O

Since	O
poor	O
extinction	B-T038
and	O
retention	O
of	O
extinction	B-T038
learning	I-T038
are	O
characteristic	O
of	O
PTSD	B-T038
patients	O
,	O
it	O
is	O
of	O
interest	O
to	O
determine	O
if	O
abnormal	B-T033
ASR	B-T038
is	O
predictive	O
of	O
development	B-T038
of	O
such	O
deficits	O
.	O

To	O
determine	O
whether	O
baseline	O
ASR	B-T038
has	O
utility	O
in	O
predicting	O
the	O
development	B-T038
of	O
PTSD	B-T038
-	O
like	O
behavior	O
,	O
the	O
relationship	O
between	O
baseline	O
ASR	B-T038
and	O
freezing	O
behavior	O
following	O
Pavlovian	O
fear	O
conditioning	O
was	O
examined	O
in	O
a	O
group	O
of	O
adult	O
,	O
male	O
Sprague	B-T204
-	I-T204
Dawley	I-T204
rats	I-T204
.	O

Baseline	O
acoustic	B-T038
startle	I-T038
response	I-T038
(	O
ASR	B-T038
)	O
was	O
assessed	O
preceding	O
exposure	O
to	O
a	O
Pavlovian	O
fear	O
conditioning	O
paradigm	O
where	O
freezing	O
behavior	O
was	O
measured	O
during	O
fear	O
conditioning	O
,	O
extinction	B-T038
training	O
,	O
and	O
extinction	B-T038
testing	O
.	O

Although	O
there	O
was	O
no	O
relationship	O
between	O
baseline	O
ASR	B-T038
and	O
fear	B-T038
memory	B-T038
following	O
conditioning	O
,	O
rats	B-T204
with	O
low	O
baseline	O
ASR	B-T038
had	O
significantly	O
lower	O
magnitude	O
of	O
retention	B-T038
of	O
the	O
extinction	B-T038
memory	B-T038
than	O
rats	B-T204
with	O
high	O
baseline	O
ASR	B-T038
.	O

The	O
results	O
suggest	O
that	O
baseline	O
ASR	B-T038
has	O
value	O
as	O
a	O
predictive	O
index	B-T170
of	O
the	O
development	B-T038
of	O
a	O
PTSD	B-T038
-	O
like	O
phenotype	O
.	O

High	O
tacrolimus	B-T103
blood	O
concentrations	O
early	O
after	O
lung	B-T058
transplantation	I-T058
and	O
the	O
risk	O
of	O
kidney	B-T037
injury	I-T037

Lung	B-T017
transplant	O
recipients	O
often	O
develop	O
acute	B-T037
kidney	I-T037
injury	I-T037
(	O
AKI	B-T037
)	O
evolving	O
into	O
chronic	B-T038
kidney	I-T038
disease	I-T038
(	O
CKD	B-T038
)	O
.	O

The	O
immunosuppressant	B-T103
tacrolimus	B-T103
might	O
be	O
associated	O
with	O
the	O
emergence	O
of	O
AKI	B-T037
.	O

We	O
analyzed	O
the	O
development	O
and	O
recovery	B-T038
of	O
kidney	B-T037
injury	I-T037
after	O
lung	B-T058
transplantation	I-T058
and	O
related	O
AKI	B-T037
to	O
whole	B-T031
-	I-T031
blood	I-T031
tacrolimus	B-T103
trough	O
concentrations	O
and	O
other	O
factors	O
causing	O
kidney	B-T037
injury	I-T037
.	O

We	O
retrospectively	B-T062
studied	I-T062
kidney	B-T037
injury	I-T037
in	O
186	O
lung	B-T058
-	I-T058
transplantation	I-T058
patients	O
at	O
the	O
UMC	B-T092
Utrecht	I-T092
between	O
2001	O
and	O
2011	O
.	O

Kidney	B-T038
function	I-T038
and	O
whole	B-T031
-	I-T031
blood	I-T031
tacrolimus	B-T103
trough	O
concentrations	O
were	O
determined	O
from	O
day	O
1	O
to	O
14	O
and	O
at	O
1	O
,	O
3	O
,	O
6	O
,	O
and	O
12	O
months	O
postoperative	O
.	O

Systemic	B-T038
inflammatory	I-T038
response	I-T038
syndrome	I-T038
(	O
SIRS	B-T038
)	O
,	O
septic	B-T038
shock	I-T038
,	O
and	O
nephrotoxic	O
medications	B-T170
were	O
evaluated	O
as	O
covariates	O
for	O
AKI	B-T037
.	O

We	O
analyzed	O
liver	B-T037
injury	I-T037
and	O
drug	B-T038
-	I-T038
drug	I-T038
interactions	I-T038
.	O

AKI	B-T037
was	O
present	B-T033
in	O
85	O
(	O
46	O
%	O
)	O
patients	O
.	O

Tacrolimus	B-T103
concentrations	O
were	O
supra	B-T033
-	I-T033
therapeutic	I-T033
in	O
135	O
of	O
186	O
patients	O
(	O
73	O
%	O
)	O
.	O

AKI	B-T037
in	O
the	O
first	O
week	O
after	O
transplantation	B-T058
was	O
related	O
to	O
supra	B-T033
-	I-T033
therapeutic	I-T033
tacrolimus	B-T103
concentrations	O
(	O
OR	O
1	O
.	O
55	O
;	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
2	O
.	O
27	O
)	O
,	O
≥3	O
other	O
nephrotoxic	B-T058
drugs	I-T058
(	O
OR	O
1	O
.	O
96	O
;	O
95	O
%	O
CI	O
1	O
.	O
02	O
-	O
3	O
.	O
77	O
)	O
,	O
infection	B-T038
(	O
OR	O
2	O
.	O
48	O
;	O
95	O
%	O
CI	O
1	O
.	O
31	O
-	O
4	O
.	O
70	O
)	O
,	O
and	O
cystic	B-T038
fibrosis	I-T038
(	O
OR	O
2	O
.	O
17	O
;	O
95	O
%	O
CI	O
1	O
.	O
16	O
-	O
4	O
.	O
06	O
)	O
.	O

Recovery	O
rate	O
of	O
AKI	B-T037
was	O
lower	O
than	O
expected	O
(	O
19	O
%	O
)	O
,	O
and	O
the	O
cumulative	O
incidence	O
of	O
severe	O
CKD	B-T038
at	O
1	O
year	O
was	O
15	O
%	O
.	O

After	O
lung	B-T058
transplantation	I-T058
,	O
AKI	B-T037
is	O
common	O
and	O
often	O
evolves	O
into	O
severe	O
CKD	B-T038
,	O
which	O
is	O
a	O
known	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Supra	B-T033
-	I-T033
therapeutic	I-T033
whole	B-T031
-	I-T031
blood	I-T031
tacrolimus	B-T103
trough	O
concentrations	O
are	O
related	O
to	O
the	O
early	O
onset	O
of	O
AKI	B-T037
.	O

Conscientious	B-T033
targeting	O
tacrolimus	B-T103
blood	O
concentrations	O
might	O
be	O
vital	O
in	O
the	O
early	O
phase	O
after	O
lung	B-T058
transplantation	I-T058
.	O

What	O
is	O
known	O
about	O
this	O
subject	O
?	O
•	O
Lung	B-T017
transplant	O
recipients	O
often	O
develop	O
acute	B-T037
kidney	I-T037
injury	I-T037
evolving	O
into	O
chronic	B-T038
kidney	I-T038
disease	I-T038
increasing	O
both	O
morbidity	O
and	O
mortality	O
.	O

•	O
To	O
date	O
,	O
the	O
pathophysiology	O
of	O
kidney	B-T037
injury	I-T037
after	O
lung	B-T058
transplantation	I-T058
has	O
not	O
been	O
fully	O
elucidated	O
.	O

•	O
The	O
immunosuppressant	B-T103
tacrolimus	B-T103
is	O
difficult	O
to	O
dose	O
,	O
especially	O
in	O
the	O
unstable	B-T033
clinical	O
setting	O
,	O
and	O
is	O
nephrotoxic	O
.	O

•	O
For	O
the	O
first	O
time	O
,	O
supra	B-T033
-	I-T033
therapeutic	I-T033
whole	B-T031
-	I-T031
blood	I-T031
tacrolimus	B-T103
trough	O
concentrations	O
are	O
related	O
to	O
the	O
emergence	O
of	O
acute	B-T037
kidney	I-T037
injury	I-T037
in	O
the	O
first	O
days	O
after	O
lung	B-T058
transplantation	I-T058
.	O

•	O
Supra	B-T033
-	I-T033
therapeutic	I-T033
whole	B-T031
-	I-T031
blood	I-T031
tacrolimus	B-T103
trough	O
concentrations	O
often	O
occur	O
early	O
after	O
lung	B-T058
transplantation	I-T058
.	O

•	O
AKI	B-T037
after	O
lung	B-T058
transplantation	I-T058
shows	O
low	O
recovery	B-T038
rates	O
.	O

Zebrafish	B-T204
akt2	B-T017
is	O
essential	O
for	O
survival	O
,	O
growth	B-T038
,	O
bone	B-T038
development	I-T038
,	O
and	O
glucose	B-T038
homeostasis	I-T038

As	O
one	O
of	O
three	O
akt	B-T103
isoforms	B-T103
,	O
akt2	B-T103
plays	O
a	O
key	O
role	O
in	O
the	O
regulation	B-T038
of	O
widely	O
divergent	O
cellular	B-T038
processes	I-T038
in	O
mammals	B-T204
.	O

However	O
,	O
its	O
role	O
and	O
underlying	O
mechanisms	O
in	O
zebrafish	B-T204
remain	O
largely	O
unknown	O
.	O

To	O
elucidate	O
the	O
function	O
of	O
akt2	B-T017
in	O
zebrafish	B-T204
,	O
we	O
generated	O
zebrafish	B-T204
lacking	O
akt2	B-T017
gene	I-T017
via	O
CRISPR	B-T038
/	I-T038
Cas9	I-T038
technology	O
.	O

Akt2	B-T017
-	O
null	O
zebrafish	B-T204
exhibit	O
partial	O
lethality	B-T033
and	O
severe	O
growth	B-T038
deficiency	O
,	O
which	O
is	O
different	O
from	O
those	O
observed	O
in	O
akt2	B-T017
-	O
null	O
mice	B-T204
.	O

Furthermore	O
,	O
akt2	B-T017
-	O
null	O
zebrafish	B-T204
display	O
deficiency	O
in	O
fin	B-T038
ray	I-T038
development	I-T038
,	O
but	O
their	O
cartilage	B-T017
is	O
not	O
affected	O
.	O

Similar	O
to	O
observations	B-T062
in	O
akt2	B-T017
-	O
null	O
mice	B-T204
,	O
akt2	B-T017
-	O
null	O
zebrafish	B-T204
display	O
impaired	O
glucose	B-T038
homeostasis	I-T038
.	O

However	O
,	O
in	O
contrast	O
to	O
that	O
in	O
akt2	B-T017
-	O
null	O
mice	B-T204
,	O
insulin	B-T058
level	I-T058
is	O
lower	O
in	O
akt2	B-T017
-	O
null	O
zebrafish	B-T204
,	O
implicating	O
the	O
symptoms	B-T033
of	O
type	B-T038
I	I-T038
diabetes	I-T038
exhibited	O
in	O
akt2	B-T017
-	O
null	O
zebrafish	B-T204
.	O

In	O
addition	O
,	O
transcriptome	B-T058
analysis	I-T058
reveals	O
that	O
the	O
genes	B-T017
involved	O
in	O
metabolism	B-T038
and	O
osteogenesis	B-T038
are	O
disturbed	O
in	O
akt2	B-T017
-	O
null	O
zebrafish	B-T204
.	O

Taken	O
together	O
,	O
these	O
data	O
not	O
only	O
support	O
an	O
important	O
role	O
of	O
akt2	B-T017
in	O
zebrafish	B-T204
survival	O
,	O
growth	B-T038
,	O
bone	B-T038
development	I-T038
and	O
glucose	B-T038
homeostasis	I-T038
,	O
but	O
also	O
suggest	O
that	O
akt2	B-T017
has	O
divergent	O
functions	O
between	O
mice	B-T204
and	O
zebrafish	B-T204
,	O
even	O
though	O
they	O
are	O
evolutionarily	B-T038
conserved	B-T038
.	O

Physiological	O
Properties	O
and	O
Behavioral	O
Correlates	O
of	O
Hippocampal	B-T017
Granule	B-T017
Cells	I-T017
and	O
Mossy	B-T017
Cells	I-T017

The	O
hippocampal	B-T017
dentate	B-T017
gyrus	I-T017
is	O
often	O
viewed	O
as	O
a	O
segregator	O
of	O
upstream	O
information	O
.	O

Physiological	B-T038
support	I-T038
for	O
such	O
function	O
has	O
been	O
hampered	O
by	O
a	O
lack	O
of	O
well	O
-	O
defined	O
characteristics	O
that	O
can	O
identify	O
granule	B-T017
cells	I-T017
and	O
mossy	B-T017
cells	I-T017
.	O

We	O
developed	O
an	O
electrophysiology	O
-	O
based	O
classification	B-T170
of	O
dentate	B-T017
granule	B-T017
cells	I-T017
and	O
mossy	B-T017
cells	I-T017
in	O
mice	B-T204
that	O
we	O
validated	O
by	O
optogenetic	B-T062
tagging	I-T062
of	O
mossy	B-T017
cells	I-T017
.	O

Granule	B-T017
cells	I-T017
exhibited	O
sparse	O
firing	B-T038
,	O
had	O
a	O
single	O
place	O
field	O
,	O
and	O
showed	O
only	O
modest	O
changes	O
when	O
the	O
mouse	B-T204
was	O
tested	O
in	O
different	O
mazes	O
in	O
the	O
same	O
room	B-T082
.	O

In	O
contrast	O
,	O
mossy	B-T017
cells	I-T017
were	O
more	O
active	O
,	O
had	O
multiple	O
place	O
fields	O
and	O
showed	O
stronger	O
remapping	O
of	O
place	O
fields	O
under	O
the	O
same	O
conditions	O
.	O

Although	O
the	O
granule	B-T017
cell	I-T017
-	O
mossy	B-T017
cell	I-T017
synapse	B-T082
was	O
strong	O
and	O
facilitating	O
,	O
mossy	B-T017
cells	I-T017
rarely	O
"	O
inherited	O
"	O
place	O
fields	O
from	O
single	O
granule	B-T017
cells	I-T017
.	O

Our	O
findings	O
suggest	O
that	O
the	O
granule	B-T017
cells	I-T017
and	O
mossy	B-T017
cells	I-T017
could	O
be	O
modulated	B-T082
separately	O
and	O
their	O
joint	O
action	O
may	O
be	O
critical	O
for	O
pattern	O
separation	O
.	O

A	O
primer	O
on	O
intraosseous	O
access	O
:	O
History	B-T033
,	O
clinical	B-T033
considerations	I-T033
,	O
and	O
current	B-T074
devices	I-T074

Intraosseous	O
(	O
IO	O
)	O
access	O
is	O
a	O
method	B-T170
recommended	O
by	O
the	O
American	B-T092
Heart	I-T092
Association	I-T092
and	O
the	O
European	B-T092
Resuscitation	I-T092
Council	I-T092
to	O
administer	O
resuscitative	B-T103
drugs	I-T103
and	O
fluids	O
when	O
intravenous	B-T082
(	I-T082
IV	I-T082
)	I-T082
access	I-T082
cannot	O
be	O
rapidly	O
or	O
easily	O
obtained	O
.	O

Many	O
clinicians	B-T097
have	O
limited	B-T170
knowledge	I-T170
or	O
experience	B-T038
with	O
the	O
IO	O
route	O
.	O

The	O
purpose	O
of	O
this	O
review	B-T170
was	O
to	O
provide	O
the	O
reader	O
with	O
a	O
succinct	B-T170
review	I-T170
of	O
the	O
history	B-T033
,	O
clinical	B-T033
considerations	I-T033
,	O
and	O
devices	B-T074
associated	O
with	O
IO	O
access	O
.	O

Narrative	O
review	O
.	O

University	O
-	O
based	O
academic	O
research	O
cell	O
.	O

Not	O
applicable	O
.	O

Not	O
applicable	O
.	O

IO	O
access	O
is	O
a	O
lifesaving	O
bridge	O
to	O
definitive	O
vascular	O
access	O
that	O
may	O
be	O
considered	O
when	O
an	O
IV	B-T082
cannot	O
be	O
rapidly	O
attained	O
and	O
the	O
patient	O
'	O
s	O
outcome	O
may	O
be	O
negatively	B-T033
affected	I-T033
without	O
prompt	B-T082
circulatory	I-T082
access	I-T082
.	O

The	O
IO	O
route	O
has	O
few	O
contraindications	O
for	O
use	O
and	O
a	O
low	O
rate	O
of	O
serious	B-T038
complications	I-T038
.	O

Multiple	O
manual	O
and	O
powered	B-T074
devices	I-T074
that	O
may	O
be	O
placed	O
in	O
several	B-T082
anatomic	I-T082
sites	I-T082
are	O
commercially	O
available	O
.	O

All	O
clinicians	B-T097
who	O
provide	O
acute	B-T058
care	I-T058
or	O
respond	O
to	O
cardiovascular	B-T082
emergencies	B-T038
should	O
obtain	O
training	O
and	O
maintain	O
proficiency	O
in	O
placing	O
and	O
using	O
IO	O
devices	B-T074
as	O
the	O
IO	O
route	O
is	O
recommended	O
by	O
the	O
major	O
resuscitation	B-T092
organizations	I-T092
as	O
the	O
preferred	O
route	O
of	O
infusion	O
when	O
rapid	O
,	O
reliable	O
IV	B-T082
access	I-T082
is	O
unavailable	O
.	O

C	B-T103
-	I-T103
5a	I-T103
-	I-T103
substituted	I-T103
validamine	I-T103
type	I-T103
glycosidase	B-T103
inhibitors	I-T103

A	O
series	O
of	O
N	B-T103
-	I-T103
alkyl	I-T103
derivatives	I-T103
of	O
the	O
D	B-T103
-	I-T103
galactosidase	I-T103
inhibitor	B-T103
1	B-T103
,	I-T103
4	I-T103
-	I-T103
di	I-T103
-	I-T103
epi	I-T103
-	I-T103
validamine	I-T103
featuring	O
lipophilic	O
substituents	O
at	O
position	O
C	O
-	O
5a	O
was	O
prepared	O
and	O
screened	B-T058
for	O
their	O
glycosidase	B-T103
inhibitory	B-T038
properties	I-T038
.	O

Products	O
turned	O
out	O
selective	O
for	O
β	B-T103
-	I-T103
galactosidases	I-T103
as	O
well	O
as	O
β	B-T103
-	I-T103
glucosidases	I-T103
.	O

Exposure	B-T033
to	I-T033
suicidal	I-T033
behaviors	I-T033
:	O
A	O
common	O
suicide	B-T033
risk	B-T033
factor	I-T033
or	O
a	O
personal	O
negative	O
life	O
event	O
?	O

Numerous	O
suicide	B-T033
risk	B-T033
factors	I-T033
have	O
been	O
proposed	O
but	O
not	O
adequately	O
validated	O
for	O
epidemiology	O
,	O
treatment	B-T058
and	O
prevention	O
efforts	O
.	O

Exposures	B-T033
to	I-T033
suicidal	I-T033
behaviors	I-T033
(	O
ESB	B-T033
)	O
,	O
from	O
family	O
and	O
friend	B-T098
suicide	B-T033
attempts	I-T033
and	O
completions	B-T033
,	O
were	O
tested	O
for	O
validity	O
as	O
a	O
suicidal	B-T033
risk	B-T033
factor	I-T033
and	O
also	O
for	O
measurement	O
and	O
construct	O
adequacy	O
.	O

An	O
anonymous	O
online	B-T170
survey	B-T170
yielded	O
713	O
participants	B-T098
(	O
aged	O
18	O
-	O
71	O
)	O
,	O
who	O
reported	O
ESB	B-T033
,	O
completed	O
the	O
Suicidal	B-T170
Affect	I-T170
-	I-T170
Behavior	I-T170
-	I-T170
Cognition	I-T170
Scale	I-T170
(	O
SABCS	B-T170
)	O
,	O
and	O
comprised	O
a	O
broad	O
spectrum	O
on	O
those	O
variables	O
.	O

Tests	B-T170
of	O
dimensionality	B-T082
and	O
internal	O
consistency	O
showed	O
the	O
four	O
ESB	B-T033
variables	O
(	O
attempts	B-T033
/	O
completions	B-T033
through	O
family	O
/	O
friends	B-T098
)	O
were	O
independent	O
and	O
did	O
not	O
form	O
a	O
common	O
factor	O
or	O
an	O
identifiable	O
ESB	B-T033
latent	O
trait	O
.	O

ESB	B-T033
variables	O
were	O
,	O
however	O
,	O
associated	O
with	O
demographic	B-T033
and	O
psychiatric	O
histories	O
.	O

A	O
battery	O
of	O
tests	B-T170
revealed	O
no	O
meaningful	O
associations	O
between	O
ESB	B-T033
and	O
total	O
suicidality	O
or	O
suicide	B-T033
risk	B-T033
factors	I-T033
(	O
social	O
support	O
,	O
depression	B-T038
,	O
anxiety	B-T033
,	O
stress	B-T033
,	O
satisfaction	O
with	O
life	O
and	O
emotional	B-T038
stability	I-T038
)	O
.	O

In	O
addition	O
,	O
in	O
contrast	O
to	O
previous	O
reports	B-T170
,	O
young	O
adults	O
(	O
n	O
=	O
200	O
;	O
aged	O
18	O
-	O
20	O
)	O
showed	O
no	O
increased	O
suicidality	O
due	O
to	O
ESB	B-T033
.	O

Results	O
showed	O
no	O
validity	O
for	O
ESB	B-T033
as	O
a	O
common	O
risk	B-T033
factor	I-T033
for	O
suicidality	O
or	O
other	O
psychopathology	O
,	O
or	O
as	O
a	O
latent	O
trait	O
.	O

ESB	B-T033
showed	O
evidence	O
as	O
a	O
personal	O
negative	O
life	O
event	O
with	O
individual	B-T098
effects	O
and	O
interpretations	B-T170
.	O

Direct	B-T082
anterior	I-T082
approach	I-T082
for	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
with	O
a	O
novel	O
mobile	B-T074
traction	I-T074
table	I-T074
-	O
a	O
prospective	B-T062
cohort	I-T062
study	I-T062

The	O
purpose	O
of	O
this	O
prospective	B-T062
cohort	I-T062
study	I-T062
was	O
to	O
clarify	O
the	O
safety	O
and	O
efficacy	O
of	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
via	O
the	O
direct	B-T082
anterior	I-T082
approach	I-T082
in	O
the	O
supine	B-T082
position	I-T082
with	O
a	O
novel	O
mobile	B-T074
traction	I-T074
table	I-T074
.	O

The	O
first	O
experience	O
of	O
consecutive	B-T058
surgeries	I-T058
by	O
a	O
single	B-T097
surgeon	I-T097
using	O
the	O
direct	B-T082
anterior	I-T082
approach	I-T082
with	O
a	O
traction	B-T074
table	I-T074
is	O
described	O
with	O
a	O
two	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O

Of	O
121	O
patients	O
,	O
100	O
patients	O
without	O
previous	B-T033
hip	I-T033
surgeries	I-T033
,	O
severe	B-T017
deformity	I-T017
,	O
or	O
cemented	B-T058
implants	I-T058
were	O
divided	O
into	O
two	O
groups	O
comprising	O
the	O
first	O
50	O
patients	O
and	O
the	O
second	O
50	O
patients	O
.	O

The	O
implant	O
survival	O
rate	O
was	O
99	O
%	O
at	O
the	O
two	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Revision	B-T058
surgery	I-T058
was	O
required	O
for	O
periprosthetic	B-T037
femoral	B-T037
fracture	I-T037
in	O
one	O
patient	O
.	O

The	O
complication	B-T038
rate	O
possibly	O
related	O
to	O
the	O
traction	B-T074
table	I-T074
was	O
5	O
%	O
(	O
5	O
patients	O
)	O
:	O
three	O
anterior	B-T037
dislocations	I-T037
,	O
one	O
periprosthetic	B-T037
femoral	B-T037
fracture	I-T037
,	O
and	O
one	O
intraoperative	B-T058
perforation	I-T058
caused	O
by	O
femoral	B-T037
rasping	I-T037
.	O

The	O
complication	B-T038
rate	O
tended	O
to	O
decrease	O
in	O
the	O
second	O
group	O
compared	O
to	O
the	O
first	O
group	O
(	O
4	O
%	O
versus	O
6	O
%	O
)	O
.	O

Mean	O
surgical	O
time	O
(	O
72	O
.	O
0	O
minutes	O
versus	O
82	O
.	O
5	O
min	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
,	O
rate	O
of	O
allogeneic	B-T058
blood	I-T058
transfusion	I-T058
(	O
2	O
%	O
versus	O
24	O
%	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
cup	O
alignment	O
in	O
the	O
safe	O
zone	O
(	O
100	O
%	O
versus	O
88	O
%	O
,	O
p	O
=	O
0	O
.	O
027	O
)	O
were	O
significantly	O
improved	O
in	O
the	O
second	O
group	O
compared	O
to	O
the	O
first	O
group	O
.	O

The	O
direct	B-T082
anterior	I-T082
approach	I-T082
with	O
a	O
novel	O
mobile	B-T074
traction	I-T074
table	I-T074
showed	O
a	O
positive	B-T033
learning	I-T033
curve	I-T033
for	O
surgical	O
time	O
,	O
rate	O
of	O
allogeneic	B-T058
blood	I-T058
transfusion	I-T058
,	O
and	O
cup	O
alignment	O
in	O
the	O
safe	O
zone	O
.	O

The	O
binding	B-T038
orientations	B-T082
of	O
structurally	B-T082
-	O
related	O
ligands	B-T103
can	O
differ	O
;	O
A	O
cautionary	O
note	O

Crystal	B-T103
structures	I-T103
can	O
identify	O
ligand	B-T038
-	I-T038
receptor	I-T038
interactions	I-T038
and	O
assist	O
the	O
development	O
of	O
novel	O
therapeutics	B-T058
,	O
but	O
experimental	O
challenges	O
sometimes	O
necessitate	O
the	O
use	O
of	O
homologous	B-T103
proteins	I-T103
.	O

Tropisetron	B-T103
is	O
an	O
orthosteric	B-T103
ligand	I-T103
at	O
both	O
5	B-T103
-	I-T103
HT3	I-T103
and	O
α7	B-T103
nACh	I-T103
receptors	I-T103
and	O
its	O
binding	B-T038
orientation	B-T082
has	O
been	O
determined	O
in	O
the	O
structural	B-T082
homologue	I-T082
AChBP	B-T103
(	O
pdbid	O
:	O
2WNC	O
)	O
.	O

Co	O
-	O
crystallisation	O
with	O
a	O
structurally	B-T082
-	O
related	O
ligand	B-T103
,	O
granisetron	B-T103
,	O
reveals	O
an	O
almost	O
identical	O
orientation	B-T082
(	O
pdbid	O
;	O
2YME	O
)	O
.	O

However	O
,	O
there	O
is	O
a	O
>	O
1000	O
-	O
fold	O
difference	O
in	O
the	O
affinity	O
of	O
tropisetron	B-T103
at	O
5	B-T103
-	I-T103
HT3	I-T103
versus	O
α7	B-T103
nACh	I-T103
receptors	I-T103
,	O
and	O
α7	B-T103
nACh	I-T103
receptors	I-T103
do	O
not	O
bind	B-T038
granisetron	B-T103
.	O

These	O
striking	O
pharmacological	O
differences	O
prompt	O
questions	O
about	O
which	O
receptor	B-T103
the	O
crystal	B-T103
structures	I-T103
most	O
closely	O
represent	O
and	O
whether	O
the	O
ligand	B-T103
orientations	B-T082
are	O
correct	O
.	O

Here	O
we	O
probe	O
the	O
binding	B-T038
orientation	B-T082
of	O
tropisetron	B-T103
and	O
granisetron	B-T103
at	O
5	B-T103
-	I-T103
HT3	I-T103
receptors	I-T103
by	O
in	O
silico	O
modelling	O
and	O
docking	B-T038
,	O
radioligand	B-T038
binding	I-T038
on	O
cysteine	B-T103
-	O
substituted	B-T038
5	B-T103
-	I-T103
HT3	I-T103
receptor	I-T103
mutants	B-T038
transiently	O
expressed	B-T038
in	O
HEK	B-T017
293	I-T017
cells	I-T017
,	O
and	O
synthetic	O
modification	O
of	O
the	O
ligands	B-T103
.	O

For	O
15	O
of	O
the	O
23	O
cysteine	B-T103
substitutions	B-T038
,	O
the	O
effects	O
on	O
tropisetron	B-T103
and	O
granisetron	B-T103
were	O
different	O
.	O

Structure	O
-	O
activity	O
relationships	O
on	O
synthesised	O
derivatives	O
of	O
both	O
ligands	B-T103
were	O
also	O
consistent	O
with	O
different	O
orientations	B-T082
,	O
revealing	O
that	O
contrary	O
to	O
the	O
crystallographic	B-T058
evidence	O
from	O
AChBP	B-T103
,	O
the	O
two	O
ligands	B-T103
adopt	O
different	O
orientations	B-T082
in	O
the	O
5	B-T103
-	I-T103
HT3	I-T103
receptor	I-T103
binding	B-T103
site	I-T103
.	O

Our	O
results	O
show	O
that	O
even	O
quite	O
structurally	B-T082
similar	O
molecules	O
can	O
adopt	O
different	O
orientations	B-T082
in	O
the	O
same	O
binding	B-T103
site	I-T103
,	O
and	O
that	O
caution	O
may	O
be	O
needed	O
when	O
using	O
homologous	B-T103
proteins	I-T103
to	O
predict	O
ligand	B-T038
binding	I-T038
.	O

Pancreatic	B-T017
neuroendocrine	O
cancer	O
with	O
liver	B-T038
metastases	I-T038
and	O
multiple	B-T038
peritoneal	I-T038
metastases	I-T038
:	O
report	O
of	O
one	O
case	O

Pancreatic	B-T017
neuroendocrine	O
tumor	O
(	O
pNET	O
)	O
is	O
a	O
rare	O
pancreatic	B-T038
tumor	I-T038
,	O
with	O
its	O
incidence	O
showing	O
a	O
rising	O
trend	O
in	O
recent	O
years	O
.	O

Most	O
of	O
its	O
distant	O
metastases	O
are	O
found	B-T033
in	O
the	O
liver	B-T017
.	O

This	O
article	O
describes	O
a	O
59	O
-	O
year	O
-	O
old	O
male	O
patient	O
with	O
pNET	O
with	O
liver	B-T038
metastasis	I-T038
and	O
multiple	B-T038
abdominal	I-T038
metastases	I-T038
,	O
focusing	O
on	O
the	O
management	B-T058
of	O
this	O
tumor	B-T038
in	O
its	O
advanced	O
stage	O
.	O

Lignans	B-T103
from	O
the	O
fruits	B-T168
of	O
Schisandra	B-T204
chinensis	I-T204
(	I-T204
Turcz	I-T204
.	I-T204
)	I-T204
Baill	I-T204
inhibit	O
proprotein	B-T017
convertase	I-T017
subtilisin	I-T017
/	I-T017
kexin	I-T017
type	I-T017
9	I-T017
expression	B-T038

Bioactivity	B-T058
-	I-T058
guided	I-T058
fractionation	I-T058
of	O
the	O
fruits	B-T168
of	O
Schisandra	B-T204
chinensis	I-T204
,	O
using	O
the	O
proprotein	B-T017
convertase	I-T017
subtilisin	I-T017
-	I-T017
kexin	I-T017
type	I-T017
9	I-T017
(	O
PCSK9	B-T017
)	O
mRNA	B-T038
expression	I-T038
screening	B-T058
assay	I-T058
,	O
led	O
to	O
isolation	O
of	O
two	O
previously	O
unknown	O
lignans	B-T103
,	O
14	B-T103
-	I-T103
tigloylschinlignan	I-T103
D	I-T103
and	O
rel	B-T103
-	I-T103
(	I-T103
7R	I-T103
,	I-T103
8R	I-T103
,	I-T103
7	I-T103
'	I-T103
R	I-T103
,	I-T103
8	I-T103
'	I-T103
R	I-T103
)	I-T103
-	I-T103
manglisin	I-T103
E	I-T103
,	O
along	O
with	O
28	O
known	O
compounds	O
.	O

All	O
structures	B-T170
were	O
established	O
by	O
NMR	B-T058
spectroscopic	I-T058
data	O
as	O
well	O
as	O
CD	B-T058
and	O
MS	B-T058
analysis	B-T062
.	O

All	O
isolates	O
were	O
tested	O
for	O
their	O
inhibitory	O
activities	O
on	O
the	O
mRNA	B-T038
expression	I-T038
of	O
PCSK9	B-T017
.	O

Of	O
the	O
tested	O
compounds	O
,	O
four	O
of	O
the	O
compounds	O
rel	B-T103
-	I-T103
(	I-T103
7R	I-T103
,	I-T103
8R	I-T103
,	I-T103
7	I-T103
'	I-T103
R	I-T103
,	I-T103
8	I-T103
'	I-T103
R	I-T103
)	I-T103
-	I-T103
manglisin	I-T103
E	I-T103
,	O
(	B-T103
-	I-T103
)	I-T103
-	I-T103
schisandrin	I-T103
C	I-T103
,	O
schinlignan	B-T103
D	I-T103
,	O
and	O
(	B-T103
+	I-T103
)	I-T103
-	I-T103
schisandrol	I-T103
B	I-T103
potently	O
inhibited	O
PCSK9	B-T017
mRNA	B-T038
expression	I-T038
with	O
IC50	O
values	O
of	O
3	O
.	O
15	O
,	O
3	O
.	O
85	O
,	O
0	O
.	O
36	O
,	O
and	O
1	O
.	O
10	O
μM	O
,	O
respectively	O
.	O

Furthermore	O
,	O
schinlignan	O
D	O
and	O
(	B-T103
+	I-T103
)	I-T103
-	I-T103
schisandrol	I-T103
B	I-T103
were	O
found	O
to	O
suppress	O
PCSK9	B-T103
protein	B-T038
expressions	I-T038
and	O
schinlignan	B-T103
D	I-T103
deemed	O
to	O
increase	O
low	B-T103
density	I-T103
lipoprotein	I-T103
receptor	I-T103
expression	O
.	O

A	O
comparison	O
of	O
outcomes	O
in	O
morbidly	B-T038
obese	I-T038
,	O
obese	B-T038
and	O
non	O
-	O
obese	O
patients	O
undergoing	O
primary	B-T058
total	I-T058
knee	I-T058
and	O
total	B-T058
hip	I-T058
arthroplasty	I-T058

Obesity	B-T038
is	O
a	O
growing	O
public	B-T092
health	O
issue	O
with	O
the	O
prevalence	O
of	O
morbid	B-T033
obesity	I-T033
,	I-T033
(	I-T033
Body	I-T033
Mass	I-T033
Index	I-T033
(	I-T033
BMI	I-T033
)	I-T033
≥	I-T033
40	I-T033
kg	I-T033
/	I-T033
m	I-T033
(	I-T033
2	I-T033
)	I-T033
)	I-T033
increasing	O
.	O

There	O
is	O
some	O
evidence	O
these	O
patients	O
have	O
more	O
peri	B-T038
-	I-T038
and	I-T038
post	I-T038
-	I-T038
operative	I-T038
complications	I-T038
and	O
poorer	O
outcomes	O
when	O
undergoing	O
arthroplasty	B-T058
procedures	I-T058
.	O

This	O
audit	O
aimed	O
to	O
determine	O
and	O
compare	O
the	O
outcomes	O
of	O
non	O
-	O
obese	O
,	O
obese	B-T038
and	O
morbidly	B-T038
obese	I-T038
patients	O
undergoing	O
arthroplasty	B-T058
at	O
our	O
institution	B-T092
.	O

This	O
was	O
a	O
retrospective	B-T058
audit	I-T058
of	O
patients	O
from	O
our	O
institution	B-T092
who	O
had	O
undergone	O
total	B-T058
knee	I-T058
(	O
TKA	B-T058
)	O
or	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
(	O
THA	B-T058
)	O
in	O
2009	O
.	O

Data	O
collected	O
were	O
:	O
age	O
,	O
gender	O
,	O
BMI	B-T201
,	O
length	O
of	O
stay	O
(	O
LOS	O
)	O
,	O
Oxford	B-T201
knee	I-T201
or	O
hip	B-T201
score	I-T201
(	O
OKS	B-T201
/	O
OHS	B-T201
)	O
,	O
satisfaction	O
and	O
complications	B-T038
up	O
to	O
two	O
years	O
post	B-T058
operation	I-T058
.	O

Patients	O
were	O
divided	O
into	O
three	O
groups	O
:	O
BMI	O
<	O
30	O
,	O
BMI	B-T201
30	I-T201
-	I-T201
40	I-T201
and	O
BMI	B-T033
>	I-T033
40	I-T033
.	O

Outcomes	O
for	O
each	O
BMI	B-T201
group	O
were	O
compared	O
.	O

1014	O
TKA	B-T058
and	O
906	O
THA	B-T058
operations	B-T058
were	O
included	O
.	O

When	O
compared	O
to	O
obese	B-T038
and	O
non	O
-	O
obese	O
patients	O
,	O
morbidly	B-T038
obese	I-T038
patients	O
undergoing	O
TKA	B-T058
had	O
a	O
mean	O
LOS	O
one	O
day	O
longer	O
,	O
a	O
mean	B-T201
OKS	I-T201
four	O
points	O
lower	O
and	O
higher	O
rates	O
of	O
postoperative	B-T038
problems	I-T038
,	O
37	O
%	O
vs	O
.	O

21	O
%	O
.	O

For	O
THA	B-T058
patients	O
there	O
was	O
no	O
difference	O
in	O
LOS	O
,	O
OHS	B-T201
score	I-T201
was	O
two	O
points	O
lower	O
for	O
each	O
increasing	O
BMI	B-T201
category	B-T170
and	O
postoperative	B-T038
problems	I-T038
increase	O
from	O
25	O
%	O
for	O
non	O
-	O
obese	O
to	O
31	O
%	O
for	O
obese	B-T038
and	O
38	O
%	O
for	O
morbidly	B-T038
obese	I-T038
patients	O
.	O

These	O
results	O
will	O
be	O
useful	O
in	O
informing	O
obese	B-T038
patients	O
of	O
their	O
potential	O
outcomes	O
following	O
TKA	B-T058
or	O
THA	B-T058
.	O

These	O
patients	O
can	O
then	O
make	O
a	O
more	O
informed	O
choice	O
before	O
proceeding	O
with	O
arthroplasty	B-T058
.	O

Vitamin	B-T103
D	I-T103
Receptor	I-T103
Activator	I-T103
Use	O
and	O
Cause	O
-	O
specific	O
Death	O
among	O
dialysis	B-T058
Patients	O
:	O
a	O
Nationwide	O
Cohort	O
Study	O
using	O
Coarsened	B-T170
Exact	I-T170
Matching	I-T170

Vitamin	B-T103
D	I-T103
receptor	I-T103
activators	I-T103
(	O
VDRA	B-T103
)	O
may	O
exert	O
pleiotropic	B-T038
effects	I-T038
on	O
cardiovascular	B-T038
disease	I-T038
,	O
malignancy	B-T038
,	O
and	O
infections	B-T038
among	O
dialysis	B-T058
patients	O
,	O
but	O
recent	O
studies	O
have	O
mainly	O
focused	O
on	O
cardiovascular	B-T033
outcomes	I-T033
.	O

Among	O
8	O
,	O
675	O
patients	O
who	O
started	O
dialysis	B-T058
in	O
2007	O
and	O
who	O
survived	O
until	O
January	O
1	O
,	O
2010	O
,	O
listed	O
in	O
the	O
Renal	B-T062
Data	I-T062
Registry	I-T062
of	O
the	O
Japanese	B-T092
Society	I-T092
for	O
Dialysis	B-T058
Therapy	I-T058
,	O
5	O
,	O
365	O
VDRA	B-T103
users	O
were	O
matched	O
to	O
3	O
,	O
203	O
non	O
-	O
users	O
based	O
on	O
clinically	O
relevant	O
variables	O
at	O
the	O
end	O
of	O
2009	O
using	O
the	O
coarsened	B-T170
exact	I-T170
matching	I-T170
procedure	I-T170
.	O

Until	O
December	O
31	O
,	O
2011	O
,	O
a	O
total	O
of	O
1	O
,	O
128	O
deaths	O
occurred	O
,	O
of	O
which	O
468	O
(	O
42	O
%	O
)	O
were	O
cardiovascular	B-T038
deaths	I-T038
,	O
229	O
(	O
20	O
%	O
)	O
were	O
infection	B-T033
-	I-T033
related	I-T033
deaths	I-T033
,	O
and	O
141	O
(	O
12	O
%	O
)	O
were	O
malignancy	O
-	O
related	O
deaths	O
.	O

Multivariable	B-T062
survival	I-T062
analyses	I-T062
accounting	O
for	O
intra	O
-	O
region	O
correlation	O
revealed	O
that	O
VDRA	B-T103
use	O
was	O
significantly	O
associated	O
with	O
lower	O
rates	O
of	O
infection	B-T038
-	O
and	O
malignancy	B-T038
-	O
related	O
deaths	O
[	O
subhazard	O
ratio	O
0	O
.	O
62	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
52	O
-	O
0	O
.	O
73	O
)	O
and	O
0	O
.	O
70	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
50	O
-	O
0	O
.	O
97	O
)	O
,	O
respectively	O
]	O
but	O
not	O
with	O
cardiovascular	B-T038
death	I-T038
[	O
subhazard	O
ratio	O
0	O
.	O
86	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
72	O
-	O
1	O
.	O
04	O
)	O
]	O
.	O

Future	O
randomized	B-T062
clinical	I-T062
trials	I-T062
with	O
a	O
sufficient	O
sample	O
size	O
and	O
an	O
adequate	O
follow	B-T058
-	I-T058
up	I-T058
period	O
are	O
warranted	O
to	O
test	O
the	O
clinical	O
effectiveness	O
of	O
VDRA	B-T103
on	O
infection	B-T038
and	O
malignancy	B-T038
,	O
rather	O
than	O
cardiovascular	B-T038
disease	I-T038
,	O
among	O
dialysis	B-T058
patients	O
.	O

Burden	O
of	O
cervical	B-T038
cancer	I-T038
and	O
role	O
of	O
screening	B-T058
in	O
India	B-T082

Cervical	B-T038
cancer	I-T038
is	O
a	O
major	O
cause	O
of	O
cancer	O
mortality	O
in	O
women	B-T098
and	O
more	O
than	O
a	O
quarter	O
of	O
its	O
global	O
burden	O
is	O
contributed	O
by	O
developing	O
countries	O
.	O

In	O
India	B-T082
,	O
in	O
spite	O
of	O
alarmingly	O
high	O
figures	O
,	O
there	O
is	O
no	O
nationwide	O
government	O
-	O
sponsored	O
screening	O
program	O
.	O

This	O
study	B-T062
was	O
conducted	O
to	O
assess	O
the	O
burden	O
of	O
cervical	B-T038
cancer	I-T038
in	O
India	B-T082
and	O
review	O
the	O
performance	O
characteristics	O
of	O
available	O
cervical	B-T038
cancer	I-T038
screening	B-T058
tools	O
,	O
so	O
as	O
to	O
provide	O
evidence	O
-	O
based	O
recommendations	O
for	O
application	O
of	O
most	O
practically	O
suited	O
screening	B-T058
test	I-T058
to	O
be	O
used	O
in	O
resource	O
-	O
poor	O
field	O
settings	O
.	O

MEDLINE	B-T170
and	O
Web	O
of	O
Science	O
electronic	O
database	O
were	O
searched	O
from	O
January	O
1990	O
to	O
December	O
2015	O
,	O
using	O
the	O
keywords	B-T170
such	O
as	O
"	O
cervical	B-T038
cancer	I-T038
"	O
,	O
"	O
screening	B-T058
"	O
,	O
"	O
early	B-T058
detection	I-T058
"	O
,	O
"	O
cervical	B-T058
cytology	I-T058
"	O
and	O
"	O
visual	B-T058
inspection	I-T058
"	O
,	O
and	O
their	O
corresponding	O
MeSH	B-T170
terms	I-T170
in	O
combination	O
with	O
Boolean	O
operators	O
"	O
OR	O
,	O
AND	O
.	O
"	O
Two	O
authors	B-T097
independently	O
selected	O
studies	B-T062
that	O
are	O
published	B-T170
in	O
English	O
and	O
conducted	O
in	O
India	B-T082
.	O

A	O
total	O
of	O
11	O
studies	B-T062
were	O
found	B-T033
to	O
be	O
relevant	O
and	O
eligible	O
to	O
be	O
included	O
in	O
the	O
present	B-T033
study	B-T062
.	O

In	O
India	B-T082
,	O
cervical	B-T038
cancer	I-T038
contributes	O
to	O
approximately	O
6	O
-	O
29	O
%	O
of	O
all	O
cancers	B-T038
in	O
women	B-T098
.	O

The	O
age	O
-	O
adjusted	O
incidence	O
rate	O
of	O
cervical	B-T038
cancer	I-T038
varies	O
widely	O
among	O
registries	B-T170
;	O
highest	O
is	O
23	O
.	O
07	O
/	O
100	O
,	O
000	O
in	O
Mizoram	O
state	O
and	O
the	O
lowest	O
is	O
4	O
.	O
91	O
/	O
100	O
,	O
000	O
in	O
Dibrugarh	O
district	O
.	O

The	O
pooled	O
estimates	O
of	O
sensitivity	O
and	O
specificity	O
of	O
visual	B-T058
inspection	I-T058
with	I-T058
acetic	I-T058
acid	I-T058
(	O
VIA	B-T058
)	O
,	O
magnified	B-T058
VIA	I-T058
,	O
visual	B-T058
inspection	I-T058
with	I-T058
Lugol	I-T058
'	I-T058
s	I-T058
iodine	I-T058
(	O
VILI	B-T058
)	O
,	O
cytology	B-T058
(	O
Pap	B-T058
smear	I-T058
)	O
,	O
and	O
human	B-T058
papillomavirus	I-T058
DNA	I-T058
were	O
found	O
to	O
be	O
67	O
.	O
65	O
%	O
and	O
84	O
.	O
32	O
%	O
,	O
65	O
.	O
36	O
%	O
and	O
85	O
.	O
76	O
%	O
,	O
78	O
.	O
27	O
%	O
and	O
87	O
.	O
10	O
%	O
,	O
62	O
.	O
11	O
%	O
and	O
93	O
.	O
51	O
%	O
,	O
and	O
77	O
.	O
81	O
%	O
and	O
91	O
.	O
54	O
%	O
,	O
respectively	O
.	O

In	O
developing	O
countries	O
because	O
of	O
lack	O
of	O
necessary	O
infrastructure	B-T170
and	O
quality	O
control	O
,	O
high	O
-	O
quality	O
cytology	B-T058
screening	I-T058
may	O
not	O
be	O
feasible	O
for	O
wide	O
-	O
scale	O
implementation	O
.	O

Hence	O
,	O
cervical	B-T038
cancer	I-T038
screening	B-T058
program	O
based	O
on	O
visual	B-T058
screening	I-T058
test	I-T058
such	O
as	O
VIA	B-T058
/	O
VILI	B-T058
should	O
be	O
adopted	O
as	O
an	O
integral	O
part	O
of	O
primary	O
health	B-T058
-	I-T058
care	I-T058
setup	I-T058
in	O
resource	O
-	O
poor	O
countries	B-T082
like	O
India	B-T082
.	O

Structural	O
and	O
tribometric	O
characterization	O
of	O
biomimetically	O
inspired	O
synthetic	O
"	O
insect	B-T204
adhesives	O
"	O

Background	O
:	O
Based	O
on	O
previous	O
chemical	B-T058
analyses	I-T058
of	O
insect	B-T204
tarsal	O
adhesives	O
,	O
we	O
prepared	O
12	O
heterogeneous	O
synthetic	O
emulsions	B-T103
mimicking	O
the	O
polar	B-T033
/	I-T033
non	I-T033
-	I-T033
polar	I-T033
principle	I-T033
,	O
analysed	O
their	O
microscopical	B-T082
structure	I-T082
and	O
tested	O
their	O
adhesive	O
,	O
frictional	O
,	O
and	O
rheological	O
properties	O
.	O

Results	O
:	O
The	O
prepared	B-T033
emulsions	B-T103
varied	O
in	O
their	O
consistency	O
from	O
solid	O
rubber	B-T103
-	I-T103
like	I-T103
,	O
over	O
soft	O
elastic	O
,	O
to	O
fluid	O
(	O
watery	O
or	O
oily	O
)	O
.	O

With	O
droplet	B-T082
sizes	I-T082
>	O
100	O
nm	O
,	O
all	O
the	O
emulsions	B-T103
belonged	O
to	O
the	O
common	O
type	O
of	O
macroemulsions	B-T103
.	O

The	O
emulsions	B-T103
of	O
the	O
first	O
generation	O
generally	O
showed	O
broader	O
droplet	B-T082
-	I-T082
size	I-T082
ranges	O
compared	O
with	O
the	O
second	O
generation	O
,	O
especially	O
when	O
less	O
defined	O
components	O
such	O
as	O
petrolatum	B-T103
or	O
waxes	B-T103
were	O
present	O
in	O
the	O
lipophilic	O
fraction	O
of	O
the	O
first	O
generation	O
of	O
emulsions	B-T103
.	O

Some	O
of	O
the	O
prepared	B-T033
emulsions	B-T103
showed	O
a	O
yield	B-T033
point	I-T033
and	O
were	O
Bingham	O
fluids	O
.	O

Tribometric	B-T058
adhesion	I-T058
was	O
tested	O
via	O
probe	B-T058
tack	I-T058
tests	I-T058
.	O

Compared	O
with	O
the	O
"	O
second	O
generation	O
"	O
(	O
containing	O
less	O
viscous	O
components	O
)	O
,	O
the	O
"	O
first	O
generation	O
"	O
emulsions	B-T103
were	O
much	O
more	B-T033
adhesive	I-T033
(	O
31	O
-	O
93	O
mN	O
)	O
,	O
a	O
finding	O
attributable	O
to	O
their	O
highly	O
viscous	O
components	O
,	O
i	O
.	O
e	O
.	O
,	O
wax	B-T103
,	O
petrolatum	B-T103
,	O
gelatin	B-T103
and	O
poly	B-T103
(	I-T103
vinyl	I-T103
alcohol	I-T103
)	I-T103
.	O

In	O
the	O
second	O
generation	O
emulsions	B-T103
,	O
we	O
attained	O
much	O
lower	O
adhesivenesses	O
,	O
ranging	O
between	O
1	O
-	O
18	O
mN	O
.	O

The	O
adhesive	O
performance	O
was	O
drastically	O
reduced	O
in	O
the	O
emulsions	B-T103
that	O
contained	O
albumin	B-T103
as	O
the	O
protein	B-T103
component	I-T103
or	O
that	O
lacked	O
protein	B-T103
.	O

Tribometric	B-T058
shear	I-T058
tests	I-T058
were	O
performed	O
at	O
moderate	O
normal	O
loads	O
.	O

Our	O
measured	O
friction	O
forces	O
(	O
4	O
-	O
93	O
mN	O
in	O
the	O
first	O
and	O
0	O
.	O
1	O
-	O
5	O
.	O
8	O
mN	O
in	O
the	O
second	O
generation	O
emulsions	B-T103
)	O
were	O
comparatively	O
low	O
.	O

Differences	O
in	O
shear	O
performance	O
were	O
related	O
to	O
the	O
chemical	O
composition	O
and	O
emulsion	B-T103
structure	B-T082
.	O

Conclusion	O
:	O
By	O
varying	O
their	O
chemical	O
composition	O
,	O
synthetic	O
heterogeneous	O
adhesive	O
emulsions	B-T103
can	O
be	O
adjusted	O
to	O
have	O
diverse	O
consistencies	O
and	O
are	O
able	O
to	O
mimic	O
certain	O
rheological	O
and	O
tribological	O
properties	O
of	O
natural	O
tarsal	O
insect	B-T204
adhesives	O
.	O

Opioids	B-T103
for	O
chronic	B-T033
pain	I-T033
:	O
The	O
CDC	B-T092
'	I-T092
s	I-T092
12	O
recommendations	O

The	O
Centers	B-T092
for	I-T092
Disease	I-T092
Control	I-T092
and	I-T092
Prevention	I-T092
has	O
issued	O
12	O
recommendations	O
to	O
help	O
clinicians	B-T097
prescribe	B-T058
an	O
optimal	O
and	O
safe	O
course	O
of	O
treatment	B-T058
for	O
patients	O
.	O

Three	B-T082
-	I-T082
Dimensional	I-T082
HyCoSy	B-T058
With	O
Perfluoropropane	B-T103
-	I-T103
Albumin	I-T103
Microspheres	I-T103
as	O
Contrast	B-T103
Agents	I-T103
and	O
Normal	O
Saline	O
Injections	B-T058
Into	O
the	O
Pelvic	B-T082
Cavity	I-T082
for	O
Morphological	O
Assessment	B-T058
of	O
the	O
Fallopian	B-T017
Tube	I-T017
in	O
Infertile	B-T038
Women	B-T098

To	O
apply	O
the	O
three	B-T082
-	I-T082
dimensional	I-T082
(	O
3D	B-T082
)	O
hysterosalpingo	B-T058
-	I-T058
contrast	I-T058
sonography	I-T058
(	O
HyCoSy	B-T058
)	O
with	O
perfluoropropane	B-T103
-	I-T103
albumin	I-T103
microspheres	I-T103
as	O
contrast	B-T103
agents	I-T103
and	O
normal	O
saline	O
injections	B-T058
into	O
the	O
pelvic	B-T082
cavity	I-T082
for	O
assessment	B-T058
of	I-T058
the	I-T058
tubal	I-T058
patency	I-T058
and	O
adhesions	B-T038
of	I-T038
fimbrial	I-T038
parts	I-T038
.	O

Fifty	O
-	O
five	O
infertile	B-T038
female	O
patients	O
were	O
recruited	O
to	O
undergo	O
3D	B-T082
HyCoSy	B-T058
with	O
normal	O
saline	O
injected	B-T058
into	O
the	O
pelvic	B-T082
cavity	I-T082
,	O
in	O
which	O
the	O
tubal	O
patency	O
was	O
observed	O
by	O
visualizing	O
the	O
spillage	O
of	O
contrast	B-T103
agents	I-T103
from	O
the	O
fimbriae	B-T017
,	O
and	O
the	O
fimbrial	B-T038
adhesion	I-T038
was	O
confirmed	O
by	O
the	O
finger	B-T082
-	I-T082
like	I-T082
projections	I-T082
of	O
the	O
fimbriae	B-T017
and	O
their	O
floating	O
and	O
moving	O
status	O
.	O

Of	O
the	O
55	O
patients	O
,	O
bilateral	B-T033
tubal	I-T033
patency	I-T033
was	O
observed	O
in	O
44	O
(	O
80	O
.	O
0	O
%	O
)	O
,	O
unilateral	B-T033
tubal	I-T033
patency	I-T033
and	O
the	O
other	O
partial	B-T038
occlusion	I-T038
in	O
7	O
(	O
12	O
.	O
7	O
%	O
)	O
,	O
unilateral	B-T082
partial	B-T038
occlusion	I-T038
and	O
the	O
other	O
complete	B-T038
occlusion	I-T038
in	O
3	O
(	O
5	O
.	O
4	O
%	O
)	O
,	O
and	O
bilateral	B-T082
complete	B-T038
occlusion	I-T038
in	O
1	O
(	O
1	O
.	O
8	O
%	O
)	O
.	O

The	O
fimbrial	B-T017
parts	I-T017
were	O
observed	O
in	O
105	O
fallopian	B-T017
tubes	I-T017
,	O
among	O
which	O
101	O
were	O
seen	O
with	O
the	O
finger	O
-	O
like	O
fimbriae	B-T017
floated	O
and	O
moved	O
in	O
the	O
pelvic	B-T082
cavity	I-T082
,	O
whereas	O
4	O
tubes	O
were	O
not	O
because	O
of	O
adhesion	B-T038
to	O
the	O
pelvic	B-T082
cavity	I-T082
(	O
n	O
=	O
3	O
)	O
or	O
the	O
ovary	B-T017
and	O
intestine	B-T017
(	O
n	O
=	O
1	O
)	O
.	O

More	O
than	O
three	O
visible	O
,	O
quite	O
long	O
,	O
and	O
distributed	O
evenly	O
finger	B-T082
-	I-T082
like	I-T082
projection	I-T082
s	O
were	O
present	O
for	O
the	O
patent	B-T082
fimbrial	B-T017
parts	I-T017
;	O
however	O
,	O
fewer	O
,	O
flat	B-T082
,	O
and	O
not	O
evenly	O
distributed	O
finger	B-T082
-	I-T082
like	I-T082
projection	I-T082
s	O
were	O
present	O
for	O
the	O
adhesive	B-T038
tubes	I-T038
.	O

No	O
serious	O
complications	B-T038
occurred	O
during	O
or	O
after	O
this	O
procedure	B-T058
.	O

Combination	O
of	O
3D	B-T082
HyCoSy	B-T058
with	O
normal	O
saline	O
injected	B-T058
into	O
the	O
pelvic	B-T082
cavity	I-T082
may	O
be	O
a	O
feasible	O
and	O
safe	O
procedure	B-T058
to	O
assess	O
tubal	O
patency	O
and	O
adhesions	B-T038
of	I-T038
the	I-T038
fimbrial	I-T038
parts	I-T038
.	O

Challenging	B-T058
some	O
assumptions	O
about	O
empathy	O

In	O
New	B-T082
Zealand	I-T082
little	O
nursing	O
or	O
medical	O
curricula	O
time	O
,	O
if	O
any	O
,	O
is	O
specifically	O
devoted	O
to	O
the	O
enhancement	O
of	O
empathy	O
.	O

If	O
being	O
empathic	B-T033
is	O
important	O
in	O
the	O
context	O
of	O
patient	B-T058
care	I-T058
,	O
it	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	O
in	O
students	B-T098
or	O
is	O
learned	O
by	O
students	B-T098
during	O
their	O
practicum	O
in	O
the	O
company	O
of	O
experienced	B-T038
clinicians	B-T097
.	O

This	O
study	B-T062
aimed	O
to	O
compare	O
self	B-T062
-	I-T062
reported	I-T062
empathy	O
ratings	O
between	O
different	O
groups	B-T098
of	O
medical	B-T097
students	I-T097
and	O
one	O
cohort	B-T098
of	O
nursing	B-T097
students	I-T097
who	O
were	O
either	O
exposed	O
or	O
not	O
exposed	O
to	O
explicit	O
empathy	O
training	O
or	O
learning	B-T038
in	O
clinical	O
settings	O
in	O
the	O
presence	O
of	O
patients	O
.	O

The	O
Jefferson	O
Scale	O
of	O
Physician	O
Empathy	O
(	O
JSPE	O
)	O
was	O
completed	O
before	O
and	O
after	O
groups	O
of	O
medical	B-T097
and	O
nursing	B-T097
students	I-T097
had	O
been	O
exposed	O
to	O
various	O
extended	O
periods	O
of	O
practicum	O
.	O

Some	O
medical	B-T097
student	I-T097
cohorts	B-T098
undertook	O
brief	O
empathy	O
training	O
,	O
whereas	O
others	O
had	O
no	O
exposure	O
.	O

The	O
nursing	B-T097
student	I-T097
cohort	B-T098
had	O
no	B-T033
formal	I-T033
,	O
explicit	O
empathy	O
training	O
.	O

Irrespective	O
of	O
profession	O
,	O
length	O
of	O
practicum	O
or	O
exposure	O
to	O
specific	O
empathy	O
training	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
self	B-T062
-	I-T062
reported	I-T062
JSPE	O
scores	O
across	O
the	O
seven	O
different	O
cohorts	B-T098
of	O
students	B-T098
.	O

Empathy	O
is	O
a	O
quality	O
that	O
is	O
already	O
present	B-T033
in	O
students	B-T098
or	O
is	O
learned	B-T038
by	I-T038
students	B-T098
during	O
their	O
practicum	O
DISCUSSION	O
:	O
If	O
empathy	O
is	O
caught	O
rather	O
than	O
taught	O
,	O
then	O
brief	O
efforts	O
to	O
enhance	O
empathy	O
may	O
be	O
futile	O
.	O

To	O
optimise	O
the	O
inherent	B-T033
empathic	I-T033
qualities	I-T033
of	O
aspirant	O
health	B-T097
professionals	I-T097
,	O
explicit	O
consideration	B-T033
should	O
be	O
given	O
to	O
how	O
empathy	O
is	O
influenced	O
by	O
the	O
practicum	O
experience	B-T038
.	O

Surface	B-T082
mediated	O
cooperative	O
interactions	B-T038
of	I-T038
drugs	I-T038
enhance	O
mechanical	O
forces	O
for	O
antibiotic	B-T103
action	O

The	O
alarming	O
increase	O
of	O
pathogenic	O
bacteria	O
that	O
are	O
resistant	B-T038
to	I-T038
multiple	I-T038
antibiotics	I-T038
is	O
now	O
recognized	O
as	O
a	O
major	O
health	O
issue	O
fuelling	O
demand	B-T058
for	O
new	O
drugs	B-T103
.	O

Bacterial	B-T038
resistance	I-T038
is	O
often	O
caused	O
by	O
molecular	B-T033
changes	I-T033
at	O
the	O
bacterial	B-T033
surface	I-T033
,	O
which	O
alter	O
the	O
nature	O
of	O
specific	O
drug	B-T038
-	I-T038
target	I-T038
interactions	I-T038
.	O

Here	O
,	O
we	O
identify	O
a	O
novel	O
mechanism	O
by	O
which	O
drug	B-T038
-	I-T038
target	I-T038
interactions	I-T038
in	O
resistant	B-T007
bacteria	I-T007
can	O
be	O
enhanced	O
.	O

We	O
examined	O
the	O
surface	B-T082
forces	O
generated	O
by	O
four	O
antibiotics	B-T103
;	O
vancomycin	B-T103
,	O
ristomycin	B-T103
,	O
chloroeremomycin	B-T103
and	O
oritavancin	B-T103
against	O
drug	O
-	O
susceptible	O
and	O
drug	B-T007
-	I-T007
resistant	I-T007
targets	I-T007
on	O
a	O
cantilever	O
and	O
demonstrated	O
significant	O
differences	O
in	O
mechanical	O
response	O
when	O
drug	B-T007
-	I-T007
resistant	I-T007
targets	I-T007
are	O
challenged	O
with	O
different	O
antibiotics	B-T103
although	O
no	O
significant	O
differences	O
were	O
observed	O
when	O
using	O
susceptible	O
targets	O
.	O

Remarkably	O
,	O
the	O
binding	B-T038
affinity	I-T038
for	O
oritavancin	B-T103
against	O
drug	B-T007
-	I-T007
resistant	I-T007
targets	I-T007
(	O
70	O
nM	O
)	O
was	O
found	O
to	O
be	O
11	O
,	O
000	O
times	O
stronger	O
than	O
for	O
vancomycin	B-T103
(	O
800	O
μM	O
)	O
,	O
a	O
powerful	O
antibiotic	B-T103
used	O
as	O
the	O
last	O
resort	B-T058
treatment	I-T058
for	O
streptococcal	B-T007
and	O
staphylococcal	B-T007
bacteria	I-T007
including	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
.	O

Using	O
an	O
exactly	B-T170
solvable	I-T170
model	I-T170
,	O
which	O
takes	O
into	O
account	O
the	O
solvent	B-T103
and	O
membrane	B-T017
effects	O
,	O
we	O
demonstrate	O
that	O
drug	B-T038
-	I-T038
target	I-T038
interactions	I-T038
are	O
strengthened	O
by	O
pronounced	B-T038
polyvalent	I-T038
interactions	I-T038
catalyzed	O
by	O
the	O
surface	B-T082
itself	O
.	O

These	O
findings	O
further	O
enhance	O
our	O
understanding	B-T038
of	O
antibiotic	O
mode	O
of	O
action	O
and	O
will	O
enable	O
development	O
of	O
more	O
effective	O
therapies	B-T058
.	O

Intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
versus	O
intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
plus	O
methotrexate	B-T103
in	O
oligoarticular	B-T038
juvenile	I-T038
idiopathic	I-T038
arthritis	I-T038
:	O
a	O
multicentre	B-T062
,	O
prospective	B-T062
,	O
randomised	B-T062
,	O
open	B-T062
-	I-T062
label	I-T062
trial	I-T062

Little	O
evidence	O
-	O
based	O
information	O
is	O
available	O
to	O
guide	B-T170
the	O
treatment	B-T058
of	O
oligoarticular	B-T038
juvenile	I-T038
idiopathic	I-T038
arthritis	I-T038
.	O

We	O
aimed	O
to	O
investigate	O
whether	O
oral	O
methotrexate	O
increases	O
the	O
efficacy	O
of	O
intra	B-T058
-	I-T058
articular	I-T058
corticosteroid	I-T058
therapy	I-T058
.	O

We	O
did	O
this	O
prospective	B-T062
,	O
open	B-T062
-	I-T062
label	I-T062
,	O
randomised	B-T062
trial	I-T062
at	O
ten	O
hospitals	B-T092
in	O
Italy	B-T082
.	O

Using	O
a	O
concealed	O
computer	B-T170
-	I-T170
generated	I-T170
list	I-T170
,	O
children	O
younger	O
than	O
18	O
years	O
with	O
oligoarticular	B-T082
-	O
onset	O
disease	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
alone	O
or	O
in	O
combination	O
with	O
oral	O
methotrexate	O
(	O
15	O
mg	O
/	O
m	O
(	O
2	O
)	O
;	O
maximum	O
20	O
mg	O
)	O
.	O

Corticosteroids	B-T103
used	O
were	O
triamcinolone	B-T103
hexacetonide	I-T103
(	O
shoulder	B-T082
,	O
elbow	B-T082
,	O
wrist	B-T082
,	O
knee	B-T082
,	O
and	O
tibiotalar	B-T082
joints	I-T082
)	O
or	O
methylprednisolone	B-T103
acetate	I-T103
(	O
ie	O
,	O
subtalar	B-T082
and	O
tarsal	B-T082
joints	I-T082
)	O
.	O

We	O
did	O
not	O
mask	O
patients	O
or	O
investigators	B-T097
to	O
treatment	B-T058
assignments	O
.	O

Our	O
primary	O
outcome	O
was	O
the	O
proportion	O
of	O
patients	O
in	O
the	O
intention	B-T062
-	I-T062
to	I-T062
-	I-T062
treat	I-T062
population	B-T098
who	O
had	O
remission	B-T033
of	O
arthritis	B-T038
in	O
all	O
injected	B-T058
joints	B-T082
at	O
12	O
months	O
.	O

This	O
trial	B-T062
is	O
registered	B-T058
with	O
European	O
Union	O
Clinical	O
Trials	O
Register	O
,	O
EudraCT	B-T170
number	I-T170
2008	O
-	O
006741	O
-	O
70	O
.	O

Between	O
July	O
7	O
,	O
2009	O
,	O
and	O
March	O
31	O
,	O
2013	O
,	O
we	O
screened	O
226	O
participants	B-T098
and	O
randomly	O
assigned	O
102	O
to	O
intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
alone	O
and	O
105	O
to	O
intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
plus	O
methotrexate	B-T103
.	O

33	O
(	O
32	O
%	O
)	O
patients	O
assigned	O
to	O
intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
alone	O
and	O
39	O
(	O
37	O
%	O
)	O
assigned	O
to	O
intra	B-T082
-	I-T082
articular	I-T082
corticosteroids	B-T103
and	O
methotrexate	B-T103
therapy	B-T058
had	O
remission	B-T033
of	O
arthritis	B-T038
in	O
all	O
injected	B-T058
joints	B-T082
(	O
p	O
=	O
0	O
·	O
48	O
)	O
.	O

Adverse	B-T038
events	I-T038
were	O
recorded	O
for	O
20	O
(	O
17	O
%	O
)	O
patients	O
who	O
received	O
methotrexate	B-T103
,	O
which	O
led	O
to	O
permanent	O
treatment	B-T058
discontinuation	B-T033
in	O
two	O
patients	O
(	O
one	O
due	O
to	O
increased	B-T033
liver	I-T033
transaminases	I-T033
and	O
one	O
due	O
to	O
gastrointestinal	B-T033
discomfort	I-T033
)	O
.	O

No	B-T033
patient	O
had	O
a	O
serious	O
adverse	B-T038
event	I-T038
.	O

Concomitant	O
administration	O
of	O
methotrexate	B-T103
did	O
not	O
augment	O
the	O
effectiveness	O
of	O
intra	B-T058
-	I-T058
articular	I-T058
corticosteroid	I-T058
therapy	I-T058
.	O

Future	B-T062
studies	I-T062
are	O
needed	O
to	O
define	O
the	O
optimal	O
therapeutic	B-T058
strategies	I-T058
for	O
oligoarticular	B-T038
juvenile	I-T038
idiopathic	I-T038
arthritis	I-T038
.	O

Italian	B-T092
Agency	I-T092
of	I-T092
Drug	I-T092
Evaluation	I-T092
.	O

Methylation	B-T062
Analysis	I-T062
of	O
BRCA1	B-T017
and	O
APC	B-T017
in	O
Breast	B-T038
Cancer	I-T038
and	O
It	O
'	O
s	O
Relationship	O
to	O
Clinicopathological	O
Features	O

Promoter	B-T038
methylation	I-T038
of	O
tumor	B-T017
suppressor	I-T017
genes	I-T017
is	O
an	O
important	O
epigenetic	B-T038
alteration	I-T038
that	O
occurs	O
in	O
the	O
primary	O
stages	O
of	O
human	B-T204
tumors	B-T038
,	O
including	O
breast	B-T038
cancer	I-T038
.	O

Identification	O
of	O
methylated	B-T017
genes	I-T017
and	O
their	O
relationship	O
to	O
clinical	O
features	O
can	O
contribute	O
to	O
the	O
prognosis	B-T058
and	O
early	B-T058
detection	I-T058
of	O
tumors	B-T038
.	O

In	O
this	O
study	B-T062
,	O
we	O
explored	O
the	O
methylation	B-T038
status	O
of	O
APC	B-T017
and	O
BRCA1	B-T017
genes	I-T017
and	O
their	O
relationship	O
to	O
clinical	O
factors	O
in	O
breast	B-T038
cancer	I-T038
patients	O
.	O

BRCA1	B-T017
and	O
APC	B-T017
promoter	B-T038
methylation	I-T038
was	O
examined	O
by	O
methylation	B-T038
-	O
specific	B-T062
multiplex	I-T062
ligation	I-T062
-	I-T062
dependent	I-T062
probe	I-T062
amplification	I-T062
(	O
MS	B-T062
-	I-T062
MLPA	I-T062
)	O
assay	B-T058
in	O
formalin	B-T017
-	I-T017
fixed	I-T017
paraffin	I-T017
embedded	I-T017
(	I-T017
FFPE	I-T017
)	I-T017
breast	I-T017
tissue	I-T017
from	O
75	O
patients	O
.	O

APC	B-T017
promoter	B-T038
methylation	I-T038
was	O
detected	B-T033
in	O
30	O
.	O
67	O
%	O
breast	B-T038
cancer	I-T038
tissues	B-T017
and	O
BRCA1	B-T017
was	O
methylated	B-T038
in	O
9	O
.	O
33	O
%	O
of	O
breast	B-T038
tumors	I-T038
.	O

Methylation	B-T038
of	O
APC	B-T017
was	O
associated	O
with	O
low	O
histological	B-T170
grade	I-T170
(	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
methylation	B-T038
of	O
BRCA1	B-T017
was	O
related	O
with	O
lymph	B-T017
node	I-T017
metastasis	B-T038
(	O
p	O
=	O
0	O
.	O
017	O
)	O
.	O

These	O
findings	B-T033
suggest	O
that	O
the	O
methylation	B-T038
status	O
of	O
APC	B-T017
and	O
BRCA1	B-T017
can	O
be	O
a	O
predictive	B-T201
marker	I-T201
for	O
early	B-T058
detection	I-T058
and	O
better	O
management	B-T058
of	O
breast	B-T038
cancer	I-T038
patients	O
.	O

Recombinant	B-T103
fibrinogen	B-T103
reveals	O
the	O
differential	O
roles	O
of	O
α	B-T103
-	I-T103
and	O
γ	B-T103
-	I-T103
chain	I-T103
cross	B-T038
-	I-T038
linking	I-T038
and	O
molecular	O
heterogeneity	O
in	O
fibrin	B-T038
clot	I-T038
strain	O
-	O
stiffening	O

Essentials	O
Fibrinogen	B-T103
circulates	O
in	O
human	B-T204
plasma	B-T031
as	O
a	O
complex	B-T103
mixture	O
of	O
heterogeneous	O
molecular	O
variants	O
.	O

We	O
measured	O
strain	O
-	O
stiffening	O
of	O
recombinantly	B-T038
produced	O
fibrinogen	B-T103
upon	O
clotting	B-T038
.	O

Factor	B-T103
XIII	I-T103
and	O
molecular	O
heterogeneity	O
alter	O
clot	B-T038
elasticity	O
at	O
the	O
protofibril	B-T103
and	O
fiber	B-T017
level	O
.	O

This	O
highlights	O
the	O
hitherto	O
unknown	O
role	O
of	O
molecular	O
composition	O
in	O
fibrin	B-T038
clot	I-T038
mechanics	O
.	O

Background	O
Fibrin	B-T103
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	B-T038
and	O
wound	B-T038
healing	I-T038
by	O
forming	O
strain	O
-	O
stiffening	O
fibrous	B-T017
networks	I-T017
that	O
reinforce	O
blood	B-T038
clots	I-T038
.	O

The	O
molecular	O
origin	O
of	O
fibrin	B-T103
'	I-T103
s	I-T103
strain	O
-	O
stiffening	O
behavior	O
remains	O
poorly	O
understood	O
,	O
primarily	O
because	O
plasma	B-T031
fibrinogen	B-T103
is	O
a	O
complex	B-T103
mixture	O
of	O
heterogeneous	O
molecular	O
variants	O
and	O
is	O
often	O
contaminated	O
by	O
plasma	B-T103
factors	I-T103
that	O
affect	O
clot	B-T038
properties	O
.	O

Objectives	O
and	O
methods	O
To	O
facilitate	O
mechanistic	O
dissection	O
of	O
fibrin	B-T103
nonlinear	O
elasticity	O
,	O
we	O
produced	O
a	O
homogeneous	O
recombinant	B-T103
fibrinogen	B-T103
corresponding	O
to	O
the	O
main	O
variant	O
in	O
human	B-T204
plasma	B-T031
,	O
termed	O
rFib610	B-T103
.	O

We	O
characterized	O
the	O
structure	B-T082
of	O
rFib610	B-T103
clots	B-T038
using	O
turbidimetry	B-T058
,	O
microscopy	B-T058
and	O
X	B-T058
-	I-T058
ray	I-T058
scattering	I-T058
.	O

We	O
used	O
rheology	O
to	O
measure	O
the	O
strain	O
-	O
stiffening	O
behavior	O
of	O
the	O
clots	B-T038
and	O
determined	O
the	O
fiber	B-T017
properties	O
by	O
modeling	B-T062
the	O
clots	B-T038
as	O
semi	O
-	O
flexible	O
polymer	O
networks	O
.	O

Results	O
We	O
show	O
that	O
addition	O
of	O
FXIII	B-T103
to	O
rFib610	B-T103
clots	B-T038
causes	O
a	O
dose	O
-	O
dependent	O
stiffness	O
increase	O
at	O
small	O
deformations	O
and	O
renders	O
the	O
strain	O
-	O
stiffening	O
response	O
reversible	O
.	O

We	O
find	O
that	O
γ	B-T103
-	I-T103
chain	I-T103
cross	B-T038
-	I-T038
linking	I-T038
contributes	O
to	O
clot	B-T038
elasticity	O
by	O
changing	O
the	O
force	O
-	O
extension	O
behavior	O
of	O
the	O
protofibrils	B-T103
,	O
whereas	O
α	B-T103
-	I-T103
chain	I-T103
cross	B-T038
-	I-T038
linking	I-T038
stiffens	O
the	O
fibers	B-T017
,	O
as	O
a	O
consequence	O
of	O
tighter	O
coupling	O
between	O
the	O
constituent	O
protofibrils	B-T103
.	O

Interestingly	O
,	O
rFib610	B-T103
protofibrils	B-T103
have	O
a	O
25	O
%	O
larger	O
bending	O
rigidity	O
than	O
plasma	B-T031
-	O
purified	O
fibrin	B-T103
protofibrils	B-T103
and	O
a	O
delayed	O
strain	O
-	O
stiffening	O
,	O
indicating	O
that	O
molecular	O
heterogeneity	O
influences	O
clot	B-T038
mechanics	O
at	O
the	O
protofibril	B-T103
scale	I-T103
.	O

Conclusions	O
Fibrinogen	B-T103
molecular	O
heterogeneity	O
and	O
FXIII	B-T103
affect	O
the	O
mechanical	O
function	O
of	O
fibrin	B-T038
clots	I-T038
by	O
altering	O
the	O
nonlinear	O
viscoelastic	O
properties	O
at	O
the	O
protofibril	B-T017
and	O
fiber	B-T017
scale	I-T017
.	O

This	O
work	O
provides	O
a	O
starting	O
point	O
to	O
investigate	O
the	O
role	O
of	O
molecular	O
heterogeneity	O
of	O
plasma	B-T031
fibrinogen	B-T103
in	O
fibrin	B-T038
clot	I-T038
mechanics	O
and	O
haemostasis	B-T038
.	O

Effects	O
of	O
display	O
curvature	B-T082
,	O
display	O
zone	B-T082
,	O
and	O
task	O
duration	O
on	O
legibility	O
and	O
visual	B-T038
fatigue	I-T038
during	O
visual	O
search	O
task	O

This	O
study	O
examined	O
the	O
effects	O
of	O
display	O
curvature	B-T082
(	O
400	O
,	O
600	O
,	O
1200	O
mm	O
,	O
and	O
flat	B-T082
)	O
,	O
display	O
zone	B-T082
(	O
5	O
zones	B-T082
)	O
,	O
and	O
task	O
duration	O
(	O
15	O
and	O
30	O
min	O
)	O
on	O
legibility	O
and	O
visual	B-T038
fatigue	I-T038
.	O

Each	O
participant	B-T098
completed	O
two	O
15	O
-	O
min	O
visual	O
search	O
task	O
sets	O
at	O
each	O
curvature	B-T082
setting	B-T082
.	O

The	O
600	O
-	O
mm	O
and	O
1200	O
-	O
mm	O
settings	B-T082
yielded	O
better	O
results	O
than	O
the	O
flat	B-T082
setting	B-T082
in	O
terms	O
of	O
legibility	O
and	O
perceived	O
visual	B-T038
fatigue	I-T038
.	O

Relative	O
to	O
the	O
corresponding	O
centre	B-T082
zone	B-T082
,	O
the	O
outermost	O
zones	B-T082
of	O
the	O
1200	O
-	O
mm	O
and	O
flat	B-T082
settings	B-T082
showed	O
a	O
decrease	O
of	O
8	O
%	O
-	O
37	O
%	O
in	O
legibility	O
,	O
whereas	O
those	O
of	O
the	O
flat	B-T082
setting	B-T082
showed	O
an	O
increase	O
of	O
26	O
%	O
-	O
45	O
%	O
in	O
perceived	B-T038
visual	B-T038
fatigue	I-T038
.	O

Across	O
curvature	B-T082
s	O
,	O
legibility	O
decreased	O
by	O
2	O
%	O
-	O
8	O
%	O
,	O
whereas	O
perceived	B-T038
visual	B-T038
fatigue	I-T038
increased	O
by	O
22	O
%	O
during	O
the	O
second	O
task	O
set	O
.	O

The	O
two	O
task	O
sets	O
induced	O
an	O
increase	O
of	O
102	O
%	O
in	O
the	O
eye	O
complaint	O
score	O
and	O
a	O
decrease	O
of	O
0	O
.	O
3	O
Hz	O
in	O
the	O
critical	B-T033
fusion	I-T033
frequency	I-T033
,	O
both	O
of	O
which	O
indicated	O
an	O
increase	O
in	O
visual	B-T038
fatigue	I-T038
.	O

In	O
summary	O
,	O
a	O
curvature	B-T082
of	O
around	O
600	O
mm	O
,	O
central	B-T082
display	O
zones	B-T082
,	O
and	O
frequent	O
breaks	B-T082
are	O
recommended	O
to	O
improve	B-T033
legibility	O
and	O
reduce	O
visual	B-T038
fatigue	I-T038
.	O

Predicting	O
changes	O
in	O
adaptive	O
functioning	O
and	O
behavioral	O
adjustment	O
following	O
treatment	B-T058
for	O
a	O
pediatric	B-T038
brain	I-T038
tumor	I-T038
:	O
A	O
report	B-T201
from	O
the	O
Brain	B-T017
Radiation	B-T097
Investigative	I-T097
Study	I-T097
Consortium	I-T097

Children	O
are	O
at	O
risk	O
for	O
behavioral	O
and	O
adaptive	O
difficulties	O
following	O
pediatric	B-T038
brain	I-T038
tumor	I-T038
.	O

This	O
study	B-T062
explored	O
whether	O
familial	O
/	O
demographic	O
,	O
developmental	O
,	O
diagnostic	O
,	O
or	O
treatment	B-T058
-	O
related	O
variables	O
best	O
predict	O
posttreatment	O
behavioral	O
and	O
adaptive	O
functioning	O
.	O

Participants	B-T098
included	O
40	O
children	O
(	O
mean	O
age	O
=	O
12	O
.	O
76	O
years	O
,	O
SD	O
=	O
4	O
.	O
01	O
)	O
posttreatment	O
(	O
mean	O
time	O
since	O
diagnosis	B-T033
=	O
1	O
.	O
99	O
years	O
,	O
SD	O
=	O
0	O
.	O
21	O
)	O
for	O
pediatric	B-T038
brain	I-T038
tumor	I-T038
.	O

Parents	O
rated	O
children	O
'	O
s	O
behavioral	O
adjustment	O
and	O
adaptive	O
functioning	O
and	O
provided	O
demographic	O
and	O
developmental	O
histories	B-T033
.	O

Diagnostic	B-T033
and	O
treatment	B-T058
-	O
related	O
information	O
was	O
abstracted	O
from	O
medical	B-T170
records	I-T170
.	O

Ratings	O
of	O
adaptive	O
and	O
behavioral	O
functioning	O
approximately	O
2	O
years	O
postdiagnosis	B-T033
were	O
within	O
the	O
average	O
range	O
,	O
although	O
the	O
percentage	O
of	O
children	O
exceeding	O
clinical	O
cutoffs	O
for	O
impairment	O
in	O
adaptive	O
skills	O
exceeded	O
expectation	O
,	O
particularly	O
practical	O
skills	O
.	O

Premorbid	O
behavior	O
problems	O
and	O
tumor	B-T082
size	I-T082
predicted	O
posttreatment	O
adaptive	O
functioning	O
.	O

After	O
accounting	O
for	O
adaptive	O
functioning	O
near	O
diagnosis	B-T033
,	O
premorbid	O
behavior	O
problems	O
predicted	O
declines	O
in	O
adaptive	O
functioning	O
2	O
years	O
postdiagnosis	B-T033
.	O

After	O
accounting	O
for	O
adjustment	O
near	O
diagnosis	B-T033
,	O
no	O
variables	O
predicted	O
declines	O
in	O
behavioral	O
adjustment	O
.	O

Children	O
may	O
be	O
vulnerable	O
to	O
reduced	O
adaptive	O
functioning	O
following	O
pediatric	B-T038
brain	I-T038
tumor	I-T038
treatment	B-T058
,	O
especially	O
in	O
practical	O
skills	O
.	O

Assessing	O
prediagnosis	B-T033
functioning	O
and	O
diagnostic	B-T033
and	O
treatment	B-T058
-	O
related	O
variables	O
may	O
improve	B-T033
our	O
ability	O
to	O
predict	O
those	O
at	O
greatest	O
risk	O
,	O
although	O
those	O
factors	O
may	O
be	O
less	O
helpful	O
in	O
identifying	O
children	O
likely	O
to	O
develop	O
behavioral	O
difficulties	O
.	O

Screening	B-T058
of	O
these	O
factors	O
in	O
tertiary	B-T058
care	I-T058
and	O
long	O
-	O
term	O
follow	B-T058
-	I-T058
up	I-T058
settings	O
may	O
improve	B-T033
identification	O
of	O
those	O
at	O
greatest	O
need	O
for	O
support	O
services	O
.	O

Spine	B-T037
fracture	I-T037
prevalence	O
in	O
a	O
nationally	O
representative	O
sample	O
of	O
US	B-T082
women	B-T098
and	O
men	B-T098
aged	O
≥40	O
years	O
:	O
results	O
from	O
the	O
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
(	O
NHANES	B-T062
)	O
2013	O
-	O
2014	O

Spine	B-T037
fracture	I-T037
prevalence	O
is	O
similar	O
in	O
men	B-T098
and	O
women	B-T098
,	O
increasing	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70	O
-	O
79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Prevalence	O
was	O
higher	O
with	O
age	O
,	O
lower	O
bone	B-T201
mineral	I-T201
density	I-T201
(	O
BMD	B-T201
)	O
,	O
and	O
in	O
those	O
meeting	O
criteria	O
for	O
spine	B-T058
imaging	I-T058
.	O

Most	O
subjects	B-T062
with	O
spine	B-T037
fractures	I-T037
were	O
unaware	B-T033
of	O
them	O
.	O

Spine	B-T037
fractures	I-T037
have	O
substantial	O
medical	O
significance	O
but	O
are	O
seldom	O
recognized	O
.	O

This	O
study	O
collected	O
contemporary	O
nationally	O
representative	O
spine	B-T037
fracture	I-T037
prevalence	O
data	O
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
analysis	I-T062
of	O
3330	O
US	B-T082
adults	O
aged	O
≥40	O
years	O
participating	O
in	O
NHANES	B-T062
2013	O
-	O
2014	O
with	O
evaluable	O
Vertebral	B-T037
Fracture	I-T037
Assessment	O
(	O
VFA	B-T058
)	O
.	O

VFA	B-T058
was	O
graded	O
by	O
semiquantitative	O
measurement	O
.	O

BMD	B-T201
and	O
an	O
osteoporosis	B-T038
questionnaire	B-T170
were	O
collected	O
.	O

Overall	O
spine	B-T037
fracture	I-T037
prevalence	O
was	O
5	O
.	O
4	O
%	O
and	O
similar	O
in	O
men	B-T098
and	O
women	B-T098
.	O

Prevalence	O
increased	O
with	O
age	O
from	O
<	O
5	O
%	O
in	O
those	O
<	O
60	O
to	O
11	O
%	O
in	O
those	O
70	O
-	O
79	O
and	O
18	O
%	O
in	O
those	O
≥80	O
years	O
.	O

Fractures	B-T037
were	O
more	O
common	O
in	O
non	B-T098
-	I-T098
Hispanic	I-T098
whites	I-T098
and	O
in	O
people	O
with	O
lower	O
body	B-T201
mass	I-T201
index	I-T201
and	O
BMD	B-T201
.	O

Among	O
subjects	B-T062
with	O
spine	B-T037
fracture	I-T037
,	O
26	O
%	O
met	O
BMD	B-T201
criteria	O
for	O
osteoporosis	B-T038
.	O

Prevalence	O
was	O
higher	O
in	O
subjects	B-T062
who	O
met	O
National	O
Osteoporosis	O
Foundation	O
(	O
NOF	O
)	O
criteria	O
for	O
spine	B-T058
imaging	I-T058
(	O
14	O
vs	O
4	O
.	O
7	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Only	O
8	O
%	O
of	O
people	O
with	O
a	O
spine	B-T037
fracture	I-T037
diagnosed	B-T033
by	O
VFA	B-T058
had	O
a	O
self	B-T062
-	I-T062
reported	I-T062
fracture	B-T037
,	O
and	O
among	O
those	O
who	O
self	B-T062
-	I-T062
reported	I-T062
a	O
spine	B-T037
fracture	I-T037
,	O
only	O
21	O
%	O
were	O
diagnosed	B-T033
with	O
fracture	B-T037
by	O
VFA	B-T058
.	O

Spine	B-T037
fracture	I-T037
prevalence	O
is	O
similar	O
in	O
women	B-T098
and	O
men	B-T098
and	O
increases	O
with	O
age	O
and	O
lower	O
BMD	B-T201
,	O
although	O
most	O
subjects	B-T062
with	O
spine	B-T037
fracture	I-T037
do	O
not	O
meet	O
BMD	B-T201
criteria	O
for	O
osteoporosis	B-T038
.	O

Since	O
most	O
(	O
>	O
90	O
%	O
)	O
individuals	B-T098
were	O
unaware	B-T033
of	O
their	O
spine	B-T037
fractures	I-T037
,	O
lateral	B-T082
spine	B-T058
imaging	I-T058
is	O
needed	O
to	O
identify	O
these	O
women	B-T098
and	O
men	B-T098
.	O

Spine	B-T037
fracture	I-T037
prevalence	O
was	O
threefold	O
higher	O
in	O
individuals	B-T098
meeting	O
NOF	O
criteria	O
for	O
spine	B-T058
imaging	I-T058
(	O
∼1	O
in	O
7	O
undergoing	O
VFA	B-T058
)	O
.	O

Identifying	O
spine	B-T037
fractures	I-T037
as	O
part	O
of	O
comprehensive	O
risk	B-T058
assessment	I-T058
may	O
improve	B-T033
clinical	B-T058
decision	I-T058
making	I-T058
.	O

Renieramycin	B-T103
M	I-T103
Attenuates	O
Cancer	B-T017
Stem	I-T017
Cell	I-T017
-	O
like	O
Phenotypes	O
in	O
H460	B-T017
Lung	B-T017
Cancer	B-T017
Cells	I-T017

Cancer	B-T017
stem	I-T017
cells	I-T017
(	O
CSCs	B-T017
)	O
are	O
a	O
subpopulation	O
of	O
cancer	B-T017
cells	I-T017
that	O
possess	O
self	B-T038
-	I-T038
renewal	I-T038
and	O
differentiation	B-T038
capacities	O
.	O

CSCs	B-T017
contribute	O
to	O
drug	B-T038
-	I-T038
resistance	I-T038
,	O
cancer	O
recurrence	O
and	O
metastasis	B-T038
,	O
thus	O
development	O
of	O
CSC	B-T017
-	O
targeted	O
therapeutic	B-T058
strategies	I-T058
has	O
recently	O
received	O
significant	O
attention	O
in	O
cancer	B-T062
research	I-T062
.	O

In	O
this	O
study	B-T062
,	O
the	O
potential	O
efficacy	O
of	O
renieramycin	B-T103
M	I-T103
(	O
RM	B-T103
)	O
isolated	O
from	O
the	O
sponge	B-T204
Xestospongia	B-T204
species	I-T204
,	O
was	O
examined	B-T033
against	O
lung	B-T017
CSCs	B-T017
.	O

Colony	B-T058
and	I-T058
spheroid	I-T058
formation	I-T058
assays	I-T058
,	O
as	O
well	O
as	O
western	B-T058
blotting	I-T058
analysis	I-T058
of	O
lung	B-T017
CSC	B-T017
protein	B-T103
markers	B-T103
were	O
employed	O
to	O
determine	O
the	O
CSC	B-T017
-	O
like	O
phenotypes	O
of	O
H460	B-T017
lung	B-T017
cancer	B-T017
cells	I-T017
after	O
treatment	B-T058
with	O
RM	B-T103
at	O
non	O
-	O
toxic	O
concentrations	O
.	O

RM	B-T103
treatment	B-T058
reduced	O
significantly	O
colony	B-T058
and	I-T058
spheroid	I-T058
formation	I-T058
of	O
H460	B-T017
cells	I-T017
.	O

Moreover	O
,	O
the	O
CSC	B-T017
markers	B-T103
CD133	B-T103
,	O
CD44	B-T103
and	O
ALDH1A1	B-T103
of	O
CSC	B-T017
-	O
enriched	O
H460	B-T017
cells	I-T017
were	O
reduced	O
significantly	O
following	O
RM	B-T103
treatment	B-T058
.	O

RM	B-T103
could	O
be	O
a	O
potent	O
anti	B-T103
-	I-T103
metastatic	I-T103
agent	I-T103
by	O
suppressing	O
lung	B-T017
CSC	B-T017
-	O
like	O
phenotypes	O
in	O
H460	B-T017
cells	I-T017
.	O

Physicochemical	O
characterization	O
of	O
chitosan	B-T103
-	O
hyaluronan	B-T103
-	O
coated	O
solid	O
lipid	B-T074
nanoparticles	I-T074
for	O
the	O
targeted	O
delivery	B-T058
of	O
paclitaxel	B-T103
:	O
a	O
proof	B-T062
-	I-T062
of	I-T062
-	I-T062
concept	I-T062
study	I-T062
in	O
breast	B-T017
cancer	I-T017
cells	I-T017

To	O
investigate	O
the	O
potential	O
of	O
modified	O
solid	B-T074
lipid	I-T074
nanoparticles	I-T074
(	O
SLN	B-T074
)	O
for	O
the	O
delivery	O
of	O
paclitaxel	B-T103
(	O
PAX	B-T103
)	O
.	O

SLN	B-T103
loaded	I-T103
with	I-T103
PAX	I-T103
were	O
prepared	O
via	O
modified	O
high	B-T058
-	I-T058
pressure	I-T058
hot	I-T058
homogenization	I-T058
.	O

Formulation	B-T062
parameters	I-T062
were	O
optimized	O
to	O
obtain	O
a	O
high	B-T074
-	I-T074
quality	I-T074
delivery	I-T074
system	I-T074
.	O

SLN	B-T074
cores	O
were	O
coated	O
,	O
layer	O
-	O
by	O
-	O
layer	O
,	O
with	O
a	O
chitosan	B-T103
and	O
hyaluronan	B-T103
(	O
HA	B-T103
)	O
shell	O
.	O

Selectivity	O
toward	O
HA	B-T103
receptors	B-T103
was	O
tested	O
in	O
a	O
breast	B-T017
cancer	I-T017
cell	I-T017
line	I-T017
,	O
MCF	B-T017
-	I-T017
7	I-T017
.	O

Stable	O
and	O
reproducible	O
nano	O
-	O
sized	O
and	O
negatively	O
charged	O
nanoparticles	O
resulted	O
.	O

Findings	O
reveal	O
that	O
chitosan	B-T103
-	O
HA	B-T103
-	O
coated	O
SLN	B-T074
facilitated	O
the	O
targeting	O
,	O
cellular	B-T038
uptake	I-T038
and	O
the	O
time	O
-	O
/	O
dose	O
-	O
controlled	O
delivery	O
and	O
release	O
of	O
PAX	B-T103
,	O
enhancing	O
intrinsic	O
chemotherapeutic	O
activities	O
.	O

SLN	B-T074
are	O
suitable	O
carrier	B-T074
candidates	I-T074
for	O
nano	B-T091
-	I-T091
oncology	I-T091
given	O
their	O
localized	O
,	O
and	O
potent	O
cytotoxic	B-T103
potential	I-T103
overcoming	B-T033
multidrug	B-T038
-	I-T038
resistant	I-T038
cancer	I-T038
cells	I-T038
.	O

Epigenetic	B-T062
Editing	I-T062
of	O
Ascl1	B-T017
Gene	I-T017
in	O
Neural	B-T017
Stem	I-T017
Cells	I-T017
by	O
Optogenetics	B-T062

Enzymes	B-T103
involved	O
in	O
epigenetic	B-T038
processes	I-T038
such	O
as	O
methyltransferases	B-T103
or	O
demethylases	B-T103
are	O
becoming	O
highly	O
utilized	O
for	O
their	O
persistent	B-T103
DNA	I-T103
or	O
histone	B-T038
modifying	I-T038
efficacy	O
.	O

Herein	O
,	O
we	O
have	O
developed	O
an	O
optogenetic	B-T062
toolbox	B-T170
fused	O
to	O
the	O
catalytic	B-T082
domain	I-T082
(	O
CD	B-T082
)	O
of	O
DNA	B-T103
-	I-T103
methyltransferase3A	I-T103
(	O
DNMT3A	B-T103
-	O
CD	B-T082
)	O
or	O
Ten	B-T103
-	I-T103
Eleven	I-T103
Dioxygenase	I-T103
-	I-T103
1	I-T103
(	O
TET1	B-T103
-	O
CD	B-T082
)	O
for	O
loci	B-T082
-	O
specific	O
alteration	B-T038
of	O
the	O
methylation	B-T038
state	O
at	O
the	O
promoter	B-T103
of	O
Ascl1	B-T017
(	O
Mash1	B-T017
)	O
,	O
a	O
candidate	B-T017
proneuron	I-T017
gene	I-T017
.	O

Optogenetical	B-T103
protein	I-T103
pairs	I-T103
,	O
CRY2	B-T103
linked	O
to	O
DNMT3A	B-T103
-	O
CD	B-T082
or	O
TET1	B-T103
-	O
CD	B-T082
and	O
CIB1	B-T103
fused	O
to	O
a	O
Transcription	B-T103
Activator	I-T103
-	I-T103
Like	I-T103
Element	I-T103
(	O
TALE	B-T103
)	O
locating	O
an	O
Ascl1	B-T017
promoter	B-T103
region	I-T103
,	O
were	O
designed	O
for	O
site	B-T082
specific	I-T082
epigenetic	B-T062
editing	I-T062
.	O

A	O
differentially	O
methylated	O
region	O
at	O
the	O
Ascl1	B-T017
promoter	B-T103
,	O
isolated	O
from	O
murine	B-T204
dorsal	B-T017
root	I-T017
ganglion	I-T017
(	O
hypermethylated	B-T038
)	O
and	O
striated	O
cells	B-T017
(	O
hypomethylated	B-T038
)	O
,	O
was	O
targeted	O
with	O
these	O
optogenetic	B-T103
-	I-T103
epigenetic	I-T103
constructs	I-T103
.	O

Optimized	O
blue	O
-	O
light	O
illumination	B-T058
triggered	O
the	O
co	O
-	O
localization	O
of	O
TALE	B-T103
constructs	I-T103
with	O
DNMT3A	B-T103
-	O
CD	B-T082
or	O
TET1	B-T103
-	O
CD	B-T082
fusion	B-T103
proteins	I-T103
at	O
the	O
targeted	O
site	O
of	O
the	O
Ascl1	B-T017
promoter	B-T103
.	O

We	O
found	O
that	O
this	O
spatiotemporal	O
association	O
of	O
the	O
fusion	B-T103
proteins	I-T103
selectively	O
alters	O
the	O
methylation	B-T038
state	O
and	O
also	O
regulates	B-T038
gene	B-T038
activity	I-T038
.	O

This	O
proof	O
of	O
concept	O
developed	O
herein	O
holds	O
immense	O
promise	O
for	O
the	O
ability	O
to	O
regulate	B-T038
gene	B-T038
activity	I-T038
via	O
epigenetic	B-T062
modulation	I-T062
with	O
spatiotemporal	O
precision	O
.	O

Vaginal	B-T038
Infections	I-T038
of	O
Albanian	B-T082
women	B-T098
Infected	B-T038
with	O
HPV	B-T005
and	O
their	O
impact	O
in	O
intraepithelial	B-T038
cervical	I-T038
lesions	I-T038
evidenced	O
by	O
Pap	B-T058
test	I-T058

Cervical	B-T058
cytology	I-T058
is	O
the	O
best	O
single	O
method	O
for	O
large	O
screening	B-T058
of	O
the	O
population	O
in	O
identifying	O
precancerous	O
lesions	O
of	O
the	O
uterine	B-T017
cervix	I-T017
.	O

To	O
estimate	O
the	O
frequency	O
of	O
human	B-T033
papillomavirus	I-T033
(	I-T033
HPV	I-T033
)	I-T033
positivity	I-T033
in	O
a	O
group	O
of	O
Albanian	B-T082
women	B-T098
,	O
the	O
prevalence	O
of	O
vaginal	B-T038
coinfections	I-T038
,	O
and	O
the	O
relationship	O
of	O
coinfections	B-T038
with	O
HPV	B-T005
,	O
as	O
well	O
as	O
their	O
role	O
in	O
metaplasia	B-T038
or	O
cervical	B-T038
intraepithelial	I-T038
lesions	I-T038
(	O
CIN	B-T038
)	O
.	O

In	O
this	O
retrospective	B-T062
study	I-T062
,	O
2075	O
vaginal	B-T058
smears	I-T058
were	O
examined	O
.	O

The	O
Papanicolaou	B-T058
stain	I-T058
was	O
used	O
for	O
all	O
slides	O
.	O

The	O
New	O
Bethesda	O
System	O
2001	O
was	O
used	O
for	O
the	O
interpretations	B-T058
of	I-T058
the	I-T058
smears	I-T058
.	O

Data	O
analysis	O
was	O
completed	O
using	O
the	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
version	O
19	O
.	O
0	O
.	O

Prevalence	O
of	O
HPV	B-T033
positivity	I-T033
was	O
43	O
.	O
9	O
%	O
with	O
an	O
average	O
age	O
of	O
35	O
.	O
48	O
±	O
9	O
.	O
27	O
years	O
.	O

Candida	B-T038
coinfection	I-T038
resulted	O
in	O
57	O
.	O
8	O
%	O
of	O
HPV	B-T033
positive	I-T033
women	B-T098
with	O
a	O
significant	O
relationship	O
between	O
them	O
.	O

Gardnerella	B-T038
coinfection	I-T038
resulted	O
in	O
36	O
(	O
23	O
%	O
)	O
,	O
mixed	O
flora	O
in	O
34	O
(	O
8	O
%	O
)	O
,	O
and	O
Trichomonas	B-T038
vaginalis	I-T038
in	O
50	O
%	O
of	O
HPV	B-T033
positive	I-T033
woman	B-T098
.	O

Among	O
the	O
women	B-T098
with	O
positive	B-T033
HPV	I-T033
,	O
19	O
%	O
had	O
CIN	B-T038
,	O
8	O
%	O
had	O
metaplasia	B-T038
,	O
and	O
1	O
%	O
had	O
metaplasia	B-T038
and	O
CIN	B-T038
;	O
9	O
%	O
of	O
the	O
women	B-T098
with	O
HPV	B-T005
had	O
CIN1	B-T038
and	O
one	O
of	O
the	O
coinfections	B-T038
.	O

There	O
is	O
a	O
strong	O
relationship	O
between	O
CIN1	B-T038
and	O
HPV	B-T033
positivity	I-T033
as	O
well	O
as	O
between	O
CIN1	B-T038
and	O
coinfections	B-T038
.	O

HPV	B-T038
infection	I-T038
is	O
a	O
major	O
factor	O
contributing	O
to	O
metaplasia	B-T038
,	O
and	O
bacterial	B-T038
coinfections	I-T038
in	O
HPV	B-T033
positive	I-T033
women	B-T098
have	O
a	O
statistically	O
significant	O
impact	O
in	O
the	O
development	O
of	O
metaplasia	B-T038
.	O

A	O
Case	O
of	O
Acute	O
Hepatitis	B-T038
E	I-T038
Infection	I-T038
in	O
a	O
Patient	O
with	O
Non	B-T038
-	I-T038
Hodgkin	I-T038
Lymphoma	I-T038
Treated	B-T058
Successfully	O
with	O
Ribavirin	B-T103

We	O
present	O
the	O
case	O
of	O
a	O
man	B-T098
who	O
,	O
following	O
immunosuppressive	B-T058
treatment	I-T058
for	O
non	B-T038
-	I-T038
Hodgkin	I-T038
lymphoma	I-T038
,	O
became	O
infected	B-T033
with	O
viral	B-T038
hepatitis	I-T038
E	I-T038
.	O

Acute	O
hepatitis	B-T038
E	I-T038
virus	I-T038
infection	I-T038
should	O
be	O
considered	O
in	O
patients	O
with	O
deranged	O
liver	B-T038
function	I-T038
on	O
a	O
background	O
of	O
haematological	B-T038
malignancies	I-T038
or	O
immunosuppression	B-T038
,	O
even	O
without	O
travel	O
to	O
endemic	B-T082
regions	I-T082
.	O

Whilst	O
clearance	O
is	O
usually	O
spontaneous	O
in	O
immune	O
-	O
competent	O
individuals	B-T098
,	O
these	O
at	O
-	O
risk	O
groups	O
may	O
develop	O
a	O
more	O
complicated	O
and	O
protracted	B-T033
disease	I-T033
course	I-T033
.	O

Thus	O
awareness	O
is	O
important	O
as	O
additional	O
treatment	B-T058
with	O
ribavirin	B-T103
or	O
pegylated	B-T103
interferon	I-T103
may	O
be	O
required	O
,	O
as	O
in	O
this	O
case	O
,	O
in	O
order	O
to	O
help	O
achieve	O
eradication	B-T058
.	O

Commissioning	B-T097
through	O
competition	O
and	O
cooperation	O
in	O
the	O
English	B-T098
NHS	B-T058
under	O
the	O
Health	O
and	O
Social	O
Care	O
Act	O
2012	O
:	O
evidence	O
from	O
a	O
qualitative	B-T062
study	I-T062
of	O
four	O
clinical	B-T097
commissioning	I-T097
groups	I-T097

The	O
Health	O
and	O
Social	O
Care	O
Act	O
2012	O
(	O
'	O
HSCA	O
2012	O
'	O
)	O
introduced	O
a	O
new	O
,	O
statutory	O
,	O
form	O
of	O
regulation	O
of	O
competition	O
into	O
the	O
National	B-T058
Health	I-T058
Service	I-T058
(	O
NHS	B-T058
)	O
,	O
while	O
at	O
the	O
same	O
time	O
recognising	O
that	O
cooperation	O
was	O
necessary	O
.	O

NHS	B-T058
England	B-T170
'	I-T170
s	I-T170
policy	I-T170
document	I-T170
,	O
The	O
Five	B-T170
Year	I-T170
Forward	I-T170
View	I-T170
(	O
'	O
5YFV	B-T170
'	O
)	O
of	O
2014	O
placed	O
less	O
emphasis	O
on	O
competition	O
without	O
altering	O
the	O
legislation	B-T170
.	O

We	O
explored	O
how	O
commissioners	B-T062
and	O
providers	O
understand	O
the	O
complex	O
regulatory	B-T170
framework	I-T170
,	O
and	O
how	O
they	O
behave	O
in	O
relation	O
to	O
competition	O
and	O
cooperation	O
.	O

We	O
carried	O
out	O
detailed	O
case	B-T170
studies	I-T170
in	O
four	O
clinical	B-T097
commissioning	I-T097
groups	I-T097
,	O
using	O
interviews	O
and	O
documentary	B-T062
analysis	I-T062
to	O
explore	O
the	O
commissioners	B-T062
'	O
and	O
providers	O
'	O
understanding	O
and	O
experience	O
of	O
competition	O
and	O
cooperation	O
.	O

We	O
conducted	O
42	O
interviews	O
with	O
senior	B-T097
managers	I-T097
in	O
commissioning	B-T097
organisations	B-T092
and	O
senior	B-T097
managers	I-T097
in	O
NHS	B-T058
and	O
independent	B-T092
provider	I-T092
organisations	I-T092
(	O
acute	B-T092
and	I-T092
community	I-T092
services	I-T092
)	O
.	O

Neither	O
commissioners	B-T062
nor	O
providers	O
fully	O
understand	O
the	O
regulatory	B-T170
regime	I-T170
in	O
respect	O
of	O
competition	O
in	O
the	O
NHS	B-T058
,	O
and	O
have	O
not	O
found	O
that	O
the	O
regulatory	B-T170
authorities	I-T170
have	O
provided	O
adequate	O
guidance	O
.	O

Despite	O
the	O
HSCA	O
2012	O
promoting	O
competition	O
,	O
commissioners	B-T062
chose	O
mainly	O
to	O
use	O
collaborative	O
strategies	O
to	O
effect	O
major	O
service	O
reconfigurations	O
,	O
which	O
is	O
endorsed	O
as	O
a	O
suitable	O
approach	O
by	O
providers	O
.	O

Nevertheless	O
,	O
commissioners	B-T062
are	O
using	O
competitive	O
tendering	O
in	O
respect	O
of	O
more	O
peripheral	O
services	O
in	O
order	O
to	O
improve	O
quality	B-T058
of	I-T058
care	I-T058
and	O
value	O
for	O
money	O
.	O

Commissioners	B-T062
regard	O
the	O
use	O
of	O
competition	O
and	O
cooperation	O
as	O
appropriate	O
in	O
the	O
NHS	B-T058
currently	O
,	O
although	O
collaborative	O
strategies	O
appear	O
more	O
helpful	O
in	O
respect	O
of	O
large	O
-	O
scale	O
changes	O
.	O

However	O
,	O
the	O
current	O
regulatory	B-T170
framework	I-T170
contained	O
in	O
the	O
HSCA	O
2012	O
,	O
particularly	O
since	O
the	O
publication	B-T170
of	O
the	O
5YFV	B-T170
,	O
is	O
not	O
clear	O
.	O

Better	O
guidance	O
should	O
be	O
issued	O
by	O
the	O
regulatory	B-T170
authorities	I-T170
.	O

Prevalence	O
and	O
correlates	O
of	O
antibiotic	B-T103
sharing	O
in	O
the	O
Philippines	B-T082
:	O
antibiotic	B-T103
misconceptions	B-T038
and	O
community	O
-	O
level	O
access	O
to	O
non	O
-	O
medical	O
sources	B-T033
of	O
antibiotics	B-T103

To	O
identify	O
sociodemographic	O
,	O
knowledge	B-T170
and	O
attitudinal	B-T038
correlates	O
to	O
antibiotic	B-T103
sharing	O
among	O
a	O
community	O
-	O
based	O
sample	O
of	O
adults	O
(	O
age	O
18	O
and	O
older	O
)	O
in	O
a	O
low	B-T033
-	I-T033
income	I-T033
setting	I-T033
of	O
the	O
Philippines	B-T082
and	O
to	O
explore	O
community	O
-	O
level	O
data	O
on	O
informal	B-T033
antibiotic	B-T103
distribution	O
in	O
roadside	O
stands	O
(	O
i	O
.	O
e	O
.	O
,	O
sari	O
-	O
sari	O
stands	O
)	O
.	O

Participants	B-T098
(	O
n	O
=	O
307	O
)	O
completed	O
self	O
-	O
administered	O
surveys	B-T170
.	O

Correlates	O
to	O
antibiotic	B-T103
sharing	O
were	O
assessed	O
using	O
logistic	B-T062
regression	I-T062
with	O
Firth	B-T170
'	I-T170
s	I-T170
bias	I-T170
-	I-T170
adjusted	I-T170
estimate	I-T170
s	O
.	O

Study	O
staff	B-T097
also	O
visited	O
106	O
roadside	O
stands	O
and	O
collected	B-T033
data	I-T033
on	O
availability	O
and	O
characteristics	O
of	O
antibiotics	B-T103
in	O
the	O
stands	O
.	O

78	O
%	O
had	O
shared	O
antibiotics	B-T103
in	O
their	O
lifetime	O
,	O
most	O
often	O
with	O
family	O
members	O
.	O

In	O
multivariable	O
analysis	O
,	O
agreement	O
with	O
the	O
belief	O
that	O
it	O
is	O
safe	O
to	O
prematurely	O
stop	O
an	O
antibiotic	B-T103
course	O
(	O
OR	O
:	O
2	O
.	O
8	O
,	O
CI	O
:	O
1	O
.	O
3	O
-	O
5	O
.	O
8	O
)	O
and	O
concerns	O
about	O
antibiotic	O
side	O
effects	O
(	O
OR	O
:	O
2	O
.	O
1	O
,	O
CI	O
:	O
1	O
.	O
1	O
-	O
4	O
.	O
4	O
)	O
were	O
significantly	O
associated	O
with	O
increased	O
odds	O
of	O
reported	O
antibiotic	B-T103
sharing	O
.	O

Antibiotic	B-T103
sharing	O
was	O
not	O
associated	O
with	O
sociodemographic	O
characteristics	O
or	O
antibiotic	B-T103
knowledge	B-T170
.	O

Antibiotics	B-T103
were	O
widely	O
available	O
in	O
60	O
%	O
of	O
sampled	O
sari	O
-	O
sari	O
stands	O
,	O
in	O
which	O
59	O
%	O
of	O
antibiotics	B-T103
were	O
missing	B-T033
expiration	I-T033
dates	I-T033
.	O

Amoxicillin	B-T103
and	O
cephalexin	B-T103
were	O
the	O
most	O
commonly	O
available	O
antibiotics	B-T103
for	O
sale	O
at	O
the	O
stands	O
(	O
60	O
%	O
and	O
21	O
%	O
,	O
respectively	O
)	O
.	O

Antibiotic	B-T103
sharing	O
was	O
common	O
and	O
was	O
associated	O
with	O
misconceptions	B-T038
about	O
proper	O
antibiotic	B-T103
use	O
.	O

Antibiotics	B-T103
were	O
widely	O
available	O
in	O
sari	O
-	O
sari	O
stands	O
,	O
and	O
usually	O
without	O
expiration	B-T170
information	I-T170
.	O

This	O
study	O
suggests	O
that	O
multipronged	O
and	O
locally	O
tailored	O
approaches	O
to	O
curbing	O
informal	B-T033
antibiotic	B-T103
access	O
are	O
needed	O
in	O
the	O
Philippines	B-T082
and	O
similar	O
Southeast	B-T082
-	I-T082
Asian	I-T082
countries	I-T082
.	O

Automated	O
characterization	O
and	O
counting	O
of	O
Ki	B-T103
-	I-T103
67	I-T103
protein	I-T103
for	O
breast	B-T038
cancer	I-T038
prognosis	B-T058
:	O
A	O
quantitative	O
immunohistochemistry	B-T058
approach	B-T082

Ki	B-T103
-	I-T103
67	I-T103
protein	I-T103
expression	B-T038
plays	O
an	O
important	O
role	O
in	O
predicting	O
the	O
proliferative	O
status	O
of	O
tumour	B-T017
cell	I-T017
s	O
and	O
deciding	O
the	O
future	O
course	O
of	O
therapy	B-T058
in	O
breast	B-T038
cancer	I-T038
.	O

Immunohistochemical	B-T058
(	I-T058
IHC	I-T058
)	I-T058
determination	I-T058
of	O
Ki	B-T058
-	I-T058
67	I-T058
score	I-T058
or	O
labelling	B-T058
index	I-T058
,	O
by	O
estimating	O
the	O
fraction	O
of	O
Ki67	B-T103
positively	B-T033
stained	O
tumour	B-T017
cells	I-T017
,	O
is	O
the	O
most	O
widely	O
practiced	O
method	B-T058
to	O
assess	O
tumour	B-T038
proliferation	O
(	O
Dowsett	O
et	O
al	O
.	O

2011	O
)	O
.	O

Accurate	O
manual	B-T058
counting	I-T058
of	O
these	O
cells	B-T017
(	O
specifically	O
nuclei	B-T017
)	O
due	O
to	O
complex	O
and	O
dense	O
distribution	O
of	O
cells	B-T017
,	O
therefore	O
,	O
becomes	O
critical	O
and	O
presents	O
a	O
major	O
challenge	O
to	O
pathologists	B-T097
.	O

In	O
this	O
paper	O
,	O
we	O
suggest	O
a	O
hybrid	B-T170
clustering	I-T170
algorithm	I-T170
to	O
quantify	O
the	O
proliferative	O
index	O
of	O
breast	B-T017
cancer	I-T017
cells	I-T017
based	O
on	O
automated	B-T058
counting	I-T058
of	O
Ki	B-T103
-	I-T103
67	I-T103
nuclei	B-T017
.	O

The	O
proposed	O
methodology	B-T058
initially	O
pre	O
-	O
processes	O
the	O
IHC	B-T058
images	B-T170
of	O
Ki	B-T103
-	I-T103
67	I-T103
stained	O
slides	O
of	O
breast	B-T038
cancer	I-T038
.	O

The	O
RGB	O
images	O
are	O
converted	O
to	O
grey	O
,	O
L	O
*	O
a	O
*	O
b	O
*	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	B-T170
space	I-T170
.	O

All	O
the	O
stained	O
cells	B-T017
are	O
then	O
characterized	O
by	O
two	B-T058
stage	I-T058
segmentation	I-T058
process	I-T058
.	O

Fuzzy	B-T170
C	I-T170
-	I-T170
means	I-T170
quantifies	O
all	O
the	O
stained	O
cells	B-T017
as	O
one	O
cluster	O
.	O

The	O
blue	O
channel	O
of	O
the	O
first	B-T170
stage	I-T170
output	O
is	O
given	O
as	O
input	O
to	O
k	B-T062
-	I-T062
means	I-T062
algorithm	I-T062
,	O
which	O
provides	O
separate	O
cluster	O
for	O
Ki	B-T103
-	I-T103
67	I-T103
positive	O
and	O
negative	O
cells	B-T017
.	O

The	O
count	O
of	O
positive	O
and	O
negative	O
nuclei	B-T017
is	O
used	O
to	O
calculate	B-T058
the	O
F	O
-	O
measure	O
for	O
each	O
colour	B-T170
space	I-T170
.	O

A	O
comparative	B-T062
study	I-T062
of	O
our	O
work	O
with	O
the	O
expert	O
opinion	O
is	O
studied	O
to	O
evaluate	O
the	O
error	O
rate	O
.	O

The	O
positive	O
and	O
negative	O
nuclei	B-T017
detection	B-T033
results	O
for	O
all	O
colour	B-T170
space	I-T170
s	O
are	O
compared	O
with	O
the	O
ground	O
truth	O
for	O
validation	O
and	O
F	O
-	O
measure	O
is	O
calculated	B-T058
.	O

The	O
F	O
-	O
measure	O
for	O
L	O
*	O
a	O
*	O
b	O
*	O
colour	B-T170
space	I-T170
(	O
0	O
.	O
8847	O
)	O
provides	O
the	O
best	O
statistical	O
result	O
as	O
compared	O
to	O
grey	O
,	O
HSI	O
,	O
YCbCr	O
,	O
YIQ	O
and	O
XYZ	O
colour	B-T170
space	I-T170
.	O

Further	O
,	O
a	O
study	B-T062
is	O
carried	O
out	O
to	O
count	O
nuclei	B-T017
manually	B-T058
and	O
automatically	B-T058
from	O
the	O
proposed	O
algorithm	B-T170
with	O
an	O
average	O
error	O
rate	O
of	O
6	O
.	O
84	O
%	O
which	O
is	O
significant	O
.	O

The	O
study	B-T062
provides	O
an	O
automated	O
count	O
of	O
positive	O
and	O
negative	O
nuclei	B-T017
using	O
L	O
*	O
a	O
*	O
b	O
*	O
colour	B-T170
space	I-T170
and	O
hybrid	O
segmentation	O
technique	O
.	O

Computerized	B-T058
evaluation	I-T058
of	O
proliferation	O
index	O
can	O
aid	O
pathologist	B-T097
in	O
assessing	O
breast	B-T038
cancer	I-T038
severity	O
.	O

The	O
proposed	O
methodology	B-T058
,	O
further	O
,	O
has	O
the	O
potential	O
advantage	O
of	O
saving	O
time	O
and	O
assisting	B-T058
in	O
decision	O
making	O
over	O
the	O
present	O
manual	B-T058
procedure	I-T058
and	O
could	O
evolve	O
as	O
an	O
assistive	O
pathological	O
decision	O
support	O
system	O
.	O

Multitarget	O
sensing	B-T058
of	I-T058
glucose	I-T058
and	O
cholesterol	B-T058
based	O
on	O
Janus	B-T103
hydrogel	I-T103
microparticles	I-T103

A	O
visualized	O
sensing	B-T058
method	I-T058
for	I-T058
glucose	I-T058
and	O
cholesterol	B-T058
was	O
developed	O
based	O
on	O
the	O
hemispheres	O
of	O
the	O
same	O
Janus	B-T103
hydrogel	I-T103
microparticles	I-T103
.	O

Single	O
-	O
phase	O
and	O
Janus	B-T103
hydrogel	I-T103
microparticles	I-T103
were	O
both	O
generated	O
using	O
a	O
centrifugal	O
microfluidic	O
chip	O
.	O

For	O
glucose	B-T058
sensing	I-T058
,	O
concanavalin	B-T103
A	I-T103
and	O
fluorescein	B-T103
labeled	I-T103
dextran	I-T103
used	O
for	O
competitive	B-T058
binding	I-T058
assay	I-T058
were	O
encapsulated	O
in	O
alginate	B-T103
microparticles	B-T103
,	O
and	O
the	O
fluorescence	O
of	O
the	O
microparticles	B-T103
was	O
positively	B-T033
correlated	O
with	O
glucose	B-T103
concentration	O
.	O

For	O
cholesterol	B-T058
sensing	I-T058
,	O
the	O
microparticles	B-T103
embedded	O
with	O
γ	O
-	O
Fe2O3	O
nanoparticles	O
were	O
used	O
as	O
catalyst	O
for	O
the	O
oxidation	B-T038
of	O
3	B-T103
,	I-T103
3	I-T103
'	I-T103
,	I-T103
5	I-T103
,	I-T103
5	I-T103
'	I-T103
-	I-T103
Tetramethylbenzidine	I-T103
by	O
H2O2	B-T103
,	O
an	O
enzymatic	B-T103
hydrolysis	O
product	O
of	O
cholesterol	B-T103
.	O

And	O
the	O
color	O
transition	O
was	O
more	O
sensitive	O
in	O
the	O
microparticles	B-T103
than	O
in	O
solutions	O
,	O
indicating	O
the	O
microparticles	B-T103
are	O
more	O
applicable	O
for	O
visualized	O
determination	B-T058
.	O

Furthermore	O
,	O
Janus	B-T103
microparticles	I-T103
were	O
employed	B-T033
for	O
multitarget	O
sensing	O
in	O
the	O
two	O
hemespheres	O
,	O
and	O
glucose	B-T103
and	O
cholesterol	B-T103
were	O
detected	B-T033
within	O
the	O
same	O
microparticles	B-T103
without	O
obvious	O
interference	O
.	O

Besides	O
,	O
the	O
particles	B-T103
could	O
be	O
manipulated	O
by	O
an	O
external	B-T082
magnetic	O
field	O
.	O

The	O
glucose	B-T033
and	O
cholesterol	B-T033
levels	I-T033
were	O
measured	O
in	O
human	B-T204
serum	B-T031
utilizing	O
the	O
microparticles	B-T103
,	O
which	O
confirmed	B-T033
the	O
potential	O
application	O
of	O
the	O
microparticles	B-T103
in	O
real	O
sample	O
detection	B-T058
.	O

PI3K	B-T103
/	O
Akt	B-T103
pathway	B-T038
:	O
a	O
potential	O
therapeutic	O
target	O
for	O
chronic	B-T033
pain	I-T033

Chronic	B-T033
pain	I-T033
is	O
among	O
the	O
most	O
disabling	O
and	O
costly	O
disorders	B-T038
,	O
with	O
prevalence	O
ranging	O
from	O
10	O
%	O
to	O
55	O
%	O
.	O

However	O
,	O
current	O
therapeutic	O
strategies	O
for	O
chronic	B-T033
pain	I-T033
are	O
unsatisfactory	O
due	O
to	O
our	O
poor	O
understanding	B-T038
of	O
its	O
mechanisms	O
.	O

Thus	O
,	O
novel	O
therapeutic	O
targets	O
need	O
to	O
be	O
found	O
in	O
order	O
to	O
improve	B-T033
these	O
patients	O
'	O
quality	O
of	O
life	O
.	O

PI3K	B-T103
and	O
its	O
downstream	B-T082
Akt	B-T103
are	O
widely	O
expressed	B-T038
in	O
the	O
spinal	B-T017
cord	I-T017
,	O
particularly	O
in	O
the	O
laminae	B-T017
I	I-T017
-	I-T017
IV	I-T017
of	O
the	O
dorsal	B-T017
horn	I-T017
,	O
where	O
nociceptive	B-T017
C	I-T017
and	O
Aδ	B-T017
fibers	I-T017
of	O
primary	O
afferents	B-T017
principally	O
terminate	O
.	O

Recent	O
studies	B-T062
have	O
demonstrated	O
their	O
critical	O
roles	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
chronic	B-T033
pain	I-T033
.	O

In	O
this	O
review	B-T170
,	O
we	O
summarized	O
the	O
roles	O
and	O
mechanisms	O
of	O
PI3K	B-T103
/	O
Akt	B-T103
pathway	B-T038
in	O
the	O
progression	B-T038
of	O
chronic	B-T033
pain	I-T033
through	O
sciatic	B-T037
nerve	I-T037
injury	I-T037
,	O
diabetic	B-T038
neuropathy	I-T038
,	O
spinal	B-T037
cord	I-T037
injury	I-T037
,	O
bone	B-T038
cancer	I-T038
,	O
opioid	O
tolerance	O
,	O
or	O
opioid	B-T103
-	O
induced	O
hyperalgesia	B-T033
.	O

No	O
free	O
bed	O
with	O
ventilator	B-T074
:	O
experience	O
of	O
a	O
public	B-T097
health	I-T097
specialist	I-T097

While	O
the	O
author	B-T097
was	O
dealing	O
with	O
a	O
poor	O
elderly	O
father	O
struggling	O
to	O
shift	O
his	O
gravely	O
injured	O
young	O
son	O
to	O
a	O
government	B-T092
hospital	I-T092
due	O
to	O
the	O
high	O
cost	O
of	O
intensive	B-T058
care	I-T058
,	O
her	O
friends	B-T098
across	O
the	O
globe	O
were	O
discussing	O
euthanasia	B-T058
in	O
the	O
social	B-T170
media	I-T170
.	O

While	O
marginalised	O
groups	B-T098
of	I-T098
people	I-T098
are	O
struggling	O
to	O
access	O
care	O
in	O
India	B-T082
,	O
friends	B-T098
who	O
have	O
moved	O
to	O
developed	O
parts	O
of	O
the	O
world	O
were	O
discussing	O
one	O
'	O
s	O
choice	O
to	O
live	O
or	O
die	B-T038
!	O
The	O
poor	O
father	O
,	O
after	O
battling	O
to	O
save	O
his	O
son	O
and	O
reaching	O
out	O
to	O
many	O
people	B-T098
for	O
help	O
,	O
could	O
not	O
save	O
him	O
.	O

Early	O
treatment	O
might	O
have	O
helped	O
the	O
young	O
boy	O
.	O

The	O
incident	O
left	O
the	O
author	B-T097
thinking	O
about	O
how	O
the	O
poor	O
are	O
denied	O
care	O
simply	O
because	O
they	O
cannot	O
afford	O
it	O
.	O

Others	O
debate	O
when	O
to	O
pull	O
the	O
plug	O
on	O
the	O
patient	O
.	O

…	O
How	O
many	O
families	O
can	O
afford	O
such	O
care	O
in	O
India	B-T082
?	O
When	O
nearly	O
71	O
%	O
of	O
the	O
people	B-T098
are	O
paying	O
out	O
of	O
pocket	O
for	O
healthcare	B-T058
and	O
16	O
%	O
are	O
pushed	O
below	O
the	O
poverty	O
line	O
every	O
year	O
,	O
can	O
we	O
even	O
think	B-T038
of	O
universal	O
health	O
coverage	O
?	O
It	O
just	O
sounds	O
like	O
a	O
fancy	O
term	O
to	O
be	O
used	O
at	O
conferences	B-T058
and	I-T058
meetings	I-T058
because	O
the	O
ground	O
reality	O
is	O
completely	O
different	O
.	O

Quantitative	O
determination	B-T058
of	O
five	O
metabolites	B-T103
of	O
aspirin	B-T103
by	O
UHPLC	B-T058
-	I-T058
MS	I-T058
/	O
MS	B-T058
coupled	O
with	O
enzymatic	B-T038
reaction	I-T038
and	O
its	O
application	O
to	O
evaluate	O
the	O
effects	O
of	O
aspirin	B-T103
dosage	O
on	O
the	O
metabolic	B-T038
profile	I-T038

Acetylsalicylic	B-T103
acid	I-T103
(	O
Aspirin	B-T103
,	O
ASA	B-T103
)	O
is	O
a	O
famous	O
drug	B-T103
for	O
cardiovascular	B-T038
diseases	I-T038
in	O
recent	O
years	O
.	O

Effects	O
of	O
ASA	B-T103
dosage	O
on	O
the	O
metabolic	B-T038
profile	I-T038
have	O
not	O
been	O
fully	O
understood	O
.	O

The	O
purpose	O
of	O
our	O
study	B-T062
is	O
to	O
establish	O
a	O
rapid	O
and	O
reliable	O
method	B-T058
to	O
quantify	O
ASA	B-T103
metabolites	B-T103
in	O
biological	B-T031
matrices	I-T031
,	O
especially	O
for	O
glucuronide	B-T103
metabolites	B-T103
whose	O
standards	O
are	O
not	O
commercially	O
available	O
.	O

Then	O
we	O
applied	O
this	O
method	B-T058
to	O
evaluate	O
the	O
effects	O
of	O
ASA	B-T103
dosage	O
on	O
the	O
metabolic	B-T038
and	O
excretion	B-T038
profile	O
of	O
ASA	B-T103
metabolites	B-T103
in	O
rat	B-T204
urine	B-T031
.	O

Salicylic	B-T103
acid	I-T103
(	O
SA	B-T103
)	O
,	O
gentisic	B-T103
acid	I-T103
(	O
GA	B-T103
)	O
and	O
salicyluric	B-T103
acid	I-T103
(	O
SUA	B-T103
)	O
were	O
determined	O
directly	O
by	O
UHPLC	B-T058
-	I-T058
MS	I-T058
/	O
MS	B-T058
,	O
while	O
salicyl	B-T103
phenolic	I-T103
glucuronide	I-T103
(	O
SAPG	B-T103
)	O
and	O
salicyluric	B-T103
acid	I-T103
phenolic	I-T103
glucuronide	I-T103
(	O
SUAPG	B-T103
)	O
were	O
quantified	O
indirectly	O
by	O
measuring	O
the	O
released	O
SA	B-T103
and	O
SUA	B-T103
from	O
SAPG	B-T103
and	O
SUAPG	B-T103
after	O
β	B-T103
-	I-T103
glucuronidase	I-T103
digestion	B-T038
.	O

SUA	B-T103
and	O
SUAPG	B-T103
were	O
the	O
major	O
metabolites	B-T103
of	O
ASA	B-T103
in	O
rat	B-T204
urine	B-T031
24	O
h	O
after	O
ASA	B-T103
administration	O
,	O
which	O
accounted	O
for	O
50	O
%	O
(	O
SUA	B-T103
)	O
and	O
26	O
%	O
(	O
SUAPG	B-T103
)	O
.	O

When	O
ASA	B-T103
dosage	O
was	O
increased	O
,	O
the	O
contributions	O
dropped	O
to	O
32	O
%	O
and	O
18	O
%	O
,	O
respectively	O
.	O

The	O
excretion	B-T038
of	O
other	O
three	O
metabolites	B-T103
(	O
GA	B-T103
,	O
SA	B-T103
and	O
SAPG	B-T103
)	O
however	O
showed	O
remarkable	O
increases	O
by	O
16	O
%	O
,	O
6	O
%	O
and	O
4	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
SUA	B-T103
and	O
SUAPG	B-T103
were	O
mainly	O
excreted	B-T038
in	O
the	O
time	O
period	O
of	O
12	O
-	O
24	O
h	O
,	O
while	O
GA	B-T103
was	O
excreted	B-T038
in	O
the	O
earlier	O
time	O
periods	O
(	O
0	O
-	O
4	O
h	O
and	O
4	O
-	O
8	O
h	O
)	O
.	O

SA	B-T103
was	O
mainly	O
excreted	B-T038
in	O
the	O
time	O
period	O
of	O
0	O
-	O
4	O
h	O
and	O
12	O
-	O
24	O
h	O
.	O

And	O
the	O
excretion	B-T038
of	O
SAPG	B-T103
was	O
equally	O
distributed	O
in	O
the	O
four	O
time	O
periods	O
.	O

We	O
went	O
further	O
to	O
show	O
that	O
the	O
excretion	B-T038
of	O
five	O
metabolites	B-T103
in	O
rat	B-T204
urine	B-T031
was	O
delayed	O
when	O
ASA	B-T103
dosage	O
was	O
increased	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
rapid	O
and	O
sensitive	O
method	B-T058
to	O
determine	O
the	O
five	O
ASA	B-T103
metabolites	B-T103
(	O
SA	B-T103
,	O
GA	B-T103
,	O
SUA	B-T103
,	O
SAPG	B-T103
and	O
SUAPG	B-T103
)	O
in	O
rat	B-T204
urine	B-T031
.	O

We	O
showed	O
that	O
ASA	B-T103
dosage	O
could	O
significantly	O
influence	O
the	O
metabolic	B-T038
and	O
excretion	B-T038
profile	O
of	O
ASA	B-T103
metabolites	B-T103
in	O
rat	B-T204
urine	B-T031
.	O

Mismatch	B-T038
Repair	I-T038
Incompatibilities	O
in	O
Diverse	O
Yeast	B-T204
Populations	O

An	O
elevated	O
mutation	O
rate	O
can	O
provide	O
cells	B-T017
with	O
a	O
source	B-T033
of	O
mutations	B-T038
to	O
adapt	O
to	O
changing	O
environments	B-T082
.	O

We	O
identified	O
a	O
negative	B-T033
epistatic	B-T038
interaction	I-T038
involving	O
naturally	O
occurring	O
variants	O
in	O
the	O
MLH1	B-T017
and	O
PMS1	B-T017
mismatch	B-T038
repair	I-T038
(	O
MMR	B-T038
)	O
genes	B-T017
of	O
Saccharomyces	B-T204
cerevisiae	I-T204
We	O
hypothesized	O
that	O
this	O
MMR	B-T038
incompatibility	O
,	O
created	O
through	O
mating	B-T038
between	O
divergent	O
S	B-T204
.	I-T204

cerevisiae	I-T204
,	O
yields	O
mutator	O
progeny	O
that	O
can	O
rapidly	O
but	O
transiently	O
adapt	O
to	O
an	O
environmental	O
stress	O
.	O

Here	O
we	O
analyzed	B-T062
the	O
MLH1	B-T017
and	O
PMS1	B-T017
genes	I-T017
across	O
1010	O
S	B-T204
.	I-T204

cerevisiae	I-T204
natural	O
isolates	B-T103
spanning	O
a	O
wide	O
range	O
of	O
ecological	O
sources	B-T033
(	O
tree	B-T204
exudates	B-T031
,	O
Drosophila	B-T204
,	O
fruits	B-T168
,	O
and	O
various	O
fermentation	B-T038
and	O
clinical	O
isolates	B-T103
)	O
and	O
geographical	B-T082
sources	B-T033
(	O
Europe	B-T082
,	O
America	B-T082
,	O
Africa	B-T082
,	O
and	O
Asia	B-T082
)	O
.	O

We	O
identified	O
one	O
homozygous	O
clinical	O
isolate	B-T103
and	O
18	O
heterozygous	O
isolates	B-T103
containing	O
the	O
incompatible	O
MMR	B-T038
genotype	O
.	O

The	O
MLH1	B-T017
-	O
PMS1	B-T017
gene	I-T017
combination	O
isolated	O
from	O
the	O
homozygous	O
clinical	O
isolate	B-T103
conferred	O
a	O
mutator	O
phenotype	O
when	O
expressed	B-T038
in	O
the	O
S288c	O
laboratory	B-T092
background	O
.	O

Using	O
a	O
novel	O
reporter	B-T103
to	O
measure	O
mutation	O
rates	O
,	O
we	O
showed	O
that	O
the	O
overall	O
mutation	O
rate	O
in	O
the	O
homozygous	O
incompatible	O
background	O
was	O
similar	O
to	O
that	O
seen	O
in	O
compatible	O
strains	O
,	O
indicating	O
the	O
presence	O
of	O
suppressor	B-T038
mutations	I-T038
in	O
the	O
clinical	O
isolate	B-T103
that	O
lowered	O
its	O
mutation	O
rate	O
.	O

This	O
observation	B-T062
and	O
the	O
identification	O
of	O
18	O
heterozygous	O
isolates	B-T103
,	O
which	O
can	O
lead	O
to	O
MMR	B-T038
incompatible	O
genotypes	O
in	O
the	O
offspring	O
,	O
are	O
consistent	O
with	O
an	O
elevated	O
mutation	O
rate	O
rapidly	O
but	O
transiently	O
facilitating	O
adaptation	B-T038
.	O

To	O
avoid	O
long	O
-	O
term	O
fitness	B-T038
costs	O
,	O
the	O
incompatibility	O
is	O
apparently	O
buffered	B-T103
by	O
mating	B-T038
or	O
by	O
acquiring	O
suppressors	B-T038
.	O

These	O
observations	B-T062
highlight	O
effective	O
strategies	O
in	O
eukaryotes	B-T204
to	O
avoid	O
long	O
-	O
term	O
fitness	B-T038
costs	O
associated	O
with	O
elevated	O
mutation	O
rates	O
.	O

Mapping	O
circulating	O
serum	B-T031
miRNAs	B-T103
to	O
their	O
immune	O
-	O
related	O
target	O
mRNAs	B-T103

Evidence	O
suggests	O
that	O
circulating	O
serum	B-T031
microRNAs	B-T103
(	O
miRNAs	B-T103
)	O
might	O
preferentially	O
target	O
immune	O
-	O
related	O
mRNAs	B-T103
.	O

If	O
this	O
were	O
the	O
case	O
,	O
we	O
hypothesized	O
that	O
immune	O
-	O
related	O
mRNAs	B-T103
would	O
have	O
more	O
predicted	O
serum	B-T031
miRNA	B-T038
binding	I-T038
sites	B-T082
than	O
other	O
mRNAs	B-T103
and	O
,	O
reciprocally	O
,	O
that	O
serum	B-T031
miRNAs	B-T103
would	O
have	O
more	O
immune	O
-	O
related	O
mRNA	B-T103
targets	O
than	O
non	O
-	O
serum	B-T031
miRNAs	B-T103
.	O

We	O
developed	O
a	O
consensus	O
target	O
predictor	O
using	O
the	O
random	O
forest	O
framework	O
and	O
calculated	O
the	O
number	O
of	O
predicted	O
miRNA	B-T103
-	O
mRNA	B-T103
interactions	B-T038
in	O
various	O
subsets	B-T170
of	O
miRNAs	B-T103
(	O
serum	B-T031
,	O
non	O
-	O
serum	B-T031
)	O
and	O
mRNAs	B-T103
(	O
immune	O
related	O
,	O
nonimmune	O
related	O
)	O
.	O

Immune	O
-	O
related	O
mRNAs	B-T103
were	O
predicted	O
to	O
be	O
targeted	O
by	O
serum	B-T031
miRNA	B-T103
more	O
than	O
other	O
mRNAs	B-T103
.	O

Moreover	O
,	O
serum	B-T031
miRNAs	B-T103
were	O
predicted	O
to	O
target	O
many	O
more	O
immune	O
-	O
related	O
mRNA	B-T103
targets	O
than	O
non	O
-	O
serum	B-T031
miRNAs	B-T103
;	O
however	O
,	O
these	O
two	O
biases	O
in	O
immune	O
-	O
related	O
mRNAs	B-T103
and	O
serum	B-T031
miRNAs	B-T103
appear	O
to	O
be	O
completely	O
independent	O
.	O

Immune	O
-	O
related	O
mRNAs	B-T103
have	O
more	O
miRNA	B-T038
binding	I-T038
sites	B-T082
in	O
general	O
,	O
not	O
just	O
for	O
serum	B-T031
miRNAs	B-T103
;	O
likewise	O
,	O
serum	B-T031
miRNAs	B-T103
target	O
many	O
more	O
mRNAs	B-T103
than	O
non	O
-	O
serum	B-T031
miRNAs	B-T103
overall	O
,	O
regardless	O
of	O
whether	O
they	O
are	O
immune	O
related	O
or	O
not	O
.	O

Nevertheless	O
,	O
these	O
two	O
independent	O
phenomena	O
result	O
in	O
a	O
significantly	O
larger	O
number	O
of	O
predicted	O
serum	B-T031
miRNA	B-T103
-	O
immune	O
mRNA	B-T103
interactions	B-T038
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O

Oxidative	B-T038
stress	I-T038
and	O
immunosenescence	B-T038
in	O
spleen	B-T017
of	O
obese	B-T204
mice	I-T204
can	O
be	O
reversed	O
by	O
2	B-T103
-	I-T103
hydroxyoleic	I-T103
acid	I-T103

We	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
obesity	B-T038
on	O
oxidative	B-T038
stress	I-T038
and	O
leukocyte	B-T017
function	B-T038
in	O
spleen	B-T017
of	O
mice	B-T204
,	O
and	O
to	O
assess	O
whether	O
supplementation	B-T058
with	O
2	B-T103
-	I-T103
hydroxyoleic	I-T103
acid	I-T103
(	O
2	B-T103
-	I-T103
OHOA	I-T103
)	O
or	O
n	B-T103
-	I-T103
3	I-T103
polyunsaturated	I-T103
fatty	I-T103
acids	I-T103
(	O
PUFA	B-T103
)	O
could	O
reverse	O
those	O
effects	O
.	O

Female	O
ICR	B-T204
/	I-T204
CD1	I-T204
mice	I-T204
(	O
8	O
weeks	O
old	O
,	O
n	O
=	O
24	O
)	O
received	O
an	O
obesogenic	B-T168
diet	I-T168
(	O
22	O
%	O
fat	B-T103
for	O
4	O
weeks	O
and	O
60	O
%	O
fat	B-T103
for	O
14	O
weeks	O
)	O
.	O

After	O
6	O
weeks	O
,	O
mice	B-T204
were	O
split	O
in	O
three	O
groups	O
(	O
n	O
=	O
8	O
/	O
group	O
)	O
:	O
no	O
supplementation	O
,	O
2	O
-	O
OHOA	O
supplementation	O
(	O
1500	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
n	O
-	O
3	O
PUFA	O
supplementation	O
(	O
EPA	B-T103
+	O
DHA	B-T103
,	O
3000	O
mg	O
kg	O
(	O
-	O
1	O
)	O
diet	O
)	O
.	O

Eight	O
mice	B-T204
were	O
fed	O
standard	O
diet	B-T168
for	O
the	O
whole	O
duration	O
of	O
the	O
study	B-T062
(	O
control	O
group	O
)	O
.	O

At	O
the	O
end	O
of	O
the	O
experiment	B-T062
,	O
the	O
following	O
variables	O
were	O
assessed	O
in	O
spleens	B-T017
:	O
levels	O
of	O
reduced	B-T103
(	O
GSH	B-T103
)	O
and	O
oxidized	B-T103
(	I-T103
GSSG	I-T103
)	I-T103
glutathione	I-T103
,	O
GSH	B-T103
/	O
GSSG	B-T103
,	O
xanthine	B-T038
oxidase	I-T038
(	I-T038
XO	I-T038
)	I-T038
activity	I-T038
,	O
lipid	B-T038
peroxidation	I-T038
,	O
lymphocyte	B-T038
chemotaxis	I-T038
,	O
natural	B-T038
killer	I-T038
(	I-T038
NK	I-T038
)	I-T038
activity	I-T038
and	O
mitogen	B-T103
(	O
ConA	B-T103
and	O
LPS	B-T103
)	O
-	O
induced	O
lymphocyte	B-T038
proliferation	I-T038
.	O

Obese	O
animals	B-T204
presented	O
higher	O
GSSG	B-T103
levels	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
GSSG	B-T103
/	O
GSH	B-T103
ratio	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
,	O
lipid	B-T038
peroxidation	I-T038
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
XO	B-T038
activity	I-T038
(	O
P	O
=	O
0	O
.	O
015	O
)	O
and	O
lymphocyte	B-T038
chemotaxis	I-T038
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
lower	O
NK	B-T038
activity	I-T038
(	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
proliferation	O
in	O
response	O
to	O
ConA	B-T103
(	O
P	O
<	O
0	O
.	O
001	O
)	O
than	O
controls	O
.	O

2	B-T103
-	I-T103
OHOA	I-T103
reversed	O
totally	O
or	O
partially	O
most	O
of	O
the	O
changes	O
(	O
body	O
weight	O
,	O
fat	O
content	O
,	O
GSSG	B-T103
levels	O
,	O
GSH	B-T103
/	O
GSSG	B-T103
,	O
lipid	B-T038
peroxidation	I-T038
,	O
chemotaxis	B-T038
and	O
proliferation	B-T038
,	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
n	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
reversed	O
the	O
increase	O
in	O
XO	B-T038
activity	I-T038
(	O
P	O
=	O
0	O
.	O
032	O
)	O
.	O

In	O
conclusion	O
,	O
2	B-T103
-	I-T103
OHOA	I-T103
,	O
and	O
to	O
a	O
lesser	O
extent	O
n	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
,	O
could	O
ameliorate	O
the	O
oxidative	B-T038
stress	I-T038
and	O
alteration	O
of	O
leukocyte	B-T017
function	B-T038
in	O
spleen	B-T017
of	O
obese	B-T204
mice	I-T204
.	O

Our	O
findings	B-T033
support	O
a	O
link	O
between	O
obesity	B-T038
and	O
immunosenescence	B-T038
and	O
suggest	O
a	O
potential	O
therapeutic	O
tool	O
for	O
obesity	B-T038
-	O
related	O
immune	B-T038
dysfunction	I-T038
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Assembly	B-T038
of	I-T038
the	I-T038
outermost	I-T038
spore	I-T038
layer	I-T038
:	O
pieces	O
of	O
the	O
puzzle	O
are	O
coming	O
together	O

Certain	O
endospore	B-T007
-	I-T007
forming	I-T007
soil	I-T007
dwelling	I-T007
bacteria	I-T007
are	O
important	O
human	B-T204
,	O
animal	B-T204
or	O
insect	B-T204
pathogens	O
.	O

These	O
organisms	O
produce	O
spores	O
containing	O
an	O
outer	B-T017
layer	I-T017
,	O
the	O
exosporium	B-T017
.	O

The	O
exosporium	B-T017
is	O
the	O
site	O
of	O
interactions	O
between	O
the	O
spore	O
and	O
the	O
soil	O
environment	B-T082
and	O
between	O
the	O
spore	O
and	O
the	O
infected	B-T033
host	O
during	O
the	O
initial	O
stages	O
of	O
infection	B-T038
.	O

The	O
composition	B-T201
and	O
assembly	B-T038
process	I-T038
of	I-T038
the	I-T038
exosporium	I-T038
are	O
poorly	O
understood	O
.	O

This	O
is	O
partly	O
due	O
to	O
the	O
extreme	O
stability	O
of	O
the	O
exosporium	B-T017
that	O
has	O
proven	O
to	O
be	O
refractive	O
to	O
existing	O
methods	O
to	O
deconstruct	O
the	O
intact	O
structure	B-T082
into	O
its	O
component	O
parts	B-T082
.	O

Although	O
more	O
than	O
20	O
proteins	B-T103
have	O
been	O
identified	O
as	O
exosporium	B-T017
-	O
associated	O
,	O
their	O
abundance	O
,	O
relationship	O
to	O
other	O
proteins	B-T103
and	O
the	O
processes	O
by	O
which	O
they	O
are	O
assembled	B-T038
to	I-T038
create	I-T038
the	I-T038
exosporium	I-T038
are	O
largely	O
unknown	O
.	O

In	O
this	O
issue	O
of	O
Molecular	B-T091
Microbiology	I-T091
,	O
Terry	O
,	O
Jiang	O
,	O
and	O
colleagues	O
in	O
Per	O
Bullough	O
'	O
s	O
laboratory	B-T092
show	O
that	O
the	O
ExsY	B-T103
protein	I-T103
is	O
a	O
major	O
structural	B-T103
protein	I-T103
of	O
the	O
exosporium	B-T017
basal	I-T017
layer	I-T017
of	O
B	B-T007
.	I-T007

cereus	I-T007
family	I-T007
spores	O
and	O
that	O
it	O
can	O
self	O
-	O
assemble	O
into	O
complex	O
structures	B-T082
that	O
possess	O
many	O
of	O
the	O
structural	B-T082
features	O
characteristic	O
of	O
the	O
exosporium	B-T017
basal	I-T017
layer	I-T017
.	O

The	O
authors	B-T097
refined	O
a	O
model	B-T170
for	O
exosporium	B-T038
assembly	I-T038
.	O

Their	O
findings	B-T033
may	O
have	O
implications	O
for	O
exosporium	B-T017
formation	O
in	O
other	O
spore	B-T007
forming	I-T007
bacteria	I-T007
,	O
including	O
Clostridium	B-T007
species	I-T007
.	O

Skeletal	B-T017
muscle	I-T017
metabolic	O
adaptations	B-T038
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
in	O
mice	B-T204
with	O
simvastatin	B-T103
treatment	B-T058

We	O
tested	O
the	O
hypothesis	O
that	O
a	O
6	O
-	O
week	O
regimen	B-T058
of	O
simvastatin	B-T103
would	O
attenuate	O
skeletal	B-T017
muscle	I-T017
adaptation	B-T038
to	O
low	O
-	O
intensity	O
exercise	O
.	O

Male	O
C57BL	B-T204
/	I-T204
6J	I-T204
wildtype	I-T204
mice	I-T204
were	O
subjected	O
to	O
6	O
-	O
weeks	O
of	O
voluntary	O
wheel	O
running	O
or	O
normal	O
cage	O
activities	O
with	O
or	O
without	O
simvastatin	B-T103
treatment	B-T058
(	O
20	O
mg	O
/	O
kg	O
/	O
d	O
,	O
n	O
=	O
7	O
-	O
8	O
per	O
group	O
)	O
.	O

Adaptations	B-T038
in	O
in	O
vivo	O
fatigue	B-T033
resistance	O
were	O
determined	O
by	O
a	O
treadmill	B-T058
running	I-T058
test	I-T058
,	O
and	O
by	O
ankle	B-T017
plantarflexor	I-T017
contractile	B-T038
assessment	O
.	O

The	O
tibialis	B-T017
anterior	I-T017
,	O
gastrocnemius	B-T017
,	O
and	O
plantaris	B-T017
muscles	I-T017
were	O
evaluated	B-T058
for	O
exercised	O
-	O
induced	O
mitochondrial	B-T017
adaptations	B-T038
(	O
i	O
.	O
e	O
.	O
,	O
biogenesis	O
,	O
function	O
,	O
autophagy	B-T038
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
weekly	O
wheel	O
running	O
distance	O
between	O
control	O
and	O
simvastatin	B-T103
-	O
treated	O
mice	B-T204
(	O
P	O
=	O
0	O
.	O
51	O
)	O
.	O

Trained	O
mice	B-T204
had	O
greater	O
treadmill	O
running	O
distance	O
(	O
296	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
ankle	B-T017
plantarflexor	I-T017
contractile	B-T038
fatigue	B-T033
resistance	O
(	O
9	O
%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
sedentary	O
mice	B-T204
,	O
independent	O
of	O
simvastatin	B-T103
treatment	B-T058
.	O

At	O
the	O
cellular	B-T017
level	I-T017
,	O
trained	O
mice	B-T204
had	O
greater	O
mitochondrial	B-T038
biogenesis	I-T038
(	O
e	O
.	O
g	O
.	O
,	O
~	O
2	O
-	O
fold	O
greater	O
PGC1α	B-T103
expression	B-T038
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
mitochondrial	B-T017
content	O
(	O
e	O
.	O
g	O
.	O
,	O
25	O
%	O
greater	O
citrate	B-T103
synthase	I-T103
activity	B-T038
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
independent	O
of	O
simvastatin	B-T103
treatment	B-T058
.	O

Mitochondrial	B-T017
autophagy	B-T038
-	O
related	O
protein	B-T103
contents	O
were	O
greater	O
in	O
trained	O
mice	B-T204
(	O
e	O
.	O
g	O
.	O
,	O
40	O
%	O
greater	O
Bnip3	B-T103
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
independent	O
of	O
simvastatin	B-T103
treatment	B-T058
.	O

However	O
,	O
Drp1	B-T103
,	O
a	O
marker	B-T201
of	O
mitochondrial	B-T038
fission	I-T038
,	O
was	O
less	O
in	O
simvastatin	B-T103
treated	O
mice	B-T204
,	O
independent	O
of	O
exercise	O
training	O
,	O
and	O
there	O
was	O
a	O
significant	O
interaction	O
between	O
training	O
and	O
statin	O
treatment	B-T058
(	O
P	O
<	O
0	O
.	O
022	O
)	O
for	O
LC3	B-T103
-	I-T103
II	I-T103
protein	I-T103
content	O
,	O
a	O
marker	B-T201
of	O
autophagy	B-T038
flux	O
.	O

These	O
data	O
indicate	O
that	O
whole	B-T017
body	I-T017
and	O
skeletal	B-T017
muscle	I-T017
adaptations	B-T038
to	O
endurance	O
exercise	O
training	O
are	O
attainable	O
with	O
simvastatin	B-T103
treatment	B-T058
,	O
but	O
simvastatin	B-T103
may	O
have	O
side	B-T038
effects	I-T038
on	O
muscle	B-T017
mitochondrial	B-T017
maintenance	O
via	O
autophagy	B-T038
,	O
which	O
could	O
have	O
long	O
-	O
term	O
implications	O
on	O
muscle	B-T017
health	O
.	O

Evaluation	B-T058
and	O
Treatment	O
of	O
Anemia	B-T038
in	O
Premature	B-T038
Infants	I-T038

Anemia	B-T038
in	O
preterm	O
infants	O
is	O
the	O
pathophysiological	O
process	O
with	O
greater	O
and	O
more	O
rapid	O
decline	O
in	O
hemoglobin	B-T103
compared	O
to	O
the	O
physiological	O
anemia	B-T038
in	O
infants	O
.	O

There	O
is	O
a	O
need	O
for	O
transfusions	B-T058
and	O
administration	B-T058
of	O
human	B-T103
recombinant	I-T103
erythropoietin	I-T103
.	O

To	O
determine	O
the	O
frequency	O
of	O
anemia	B-T038
in	O
premature	B-T038
infants	I-T038
at	O
the	O
Pediatric	B-T092
Clinic	I-T092
,	I-T092
University	I-T092
Clinical	I-T092
Center	I-T092
Sarajevo	I-T092
,	O
as	O
well	O
as	O
parameter	O
values	O
in	O
the	O
blood	B-T058
count	I-T058
of	O
premature	B-T038
infants	I-T038
and	O
to	O
explore	O
a	O
relationship	O
between	O
blood	B-T058
transfusions	I-T058
with	O
the	O
advent	O
of	O
intraventricular	B-T038
hemorrhage	I-T038
(	O
determine	O
treatment	O
outcome	O
in	O
preterm	O
infants	O
)	O
.	O

Research	B-T062
is	O
retrospective	B-T062
study	I-T062
and	O
it	O
included	O
the	O
period	O
of	O
six	O
months	O
in	O
year	O
2014	O
.	O

Research	B-T062
included	O
100	O
patients	O
,	O
gestational	O
age	O
<	O
37	O
weeks	O
(	O
premature	B-T038
infants	I-T038
)	O
.	O

Data	O
were	O
collected	O
by	O
examining	B-T033
the	O
medical	B-T170
records	I-T170
of	O
patients	O
at	O
the	O
Pediatric	B-T092
Clinic	I-T092
,	I-T092
UCCS	I-T092
.	O

The	O
first	O
group	O
of	O
patients	O
were	O
premature	B-T038
infants	I-T038
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
(	O
62	O
/	O
100	O
)	O
and	O
the	O
second	O
group	O
were	O
premature	B-T038
infants	I-T038
of	O
gestational	O
age	O
33	O
-	O
37	O
weeks	O
(	O
38	O
/	O
100	O
)	O
.	O

Among	O
the	O
patients	O
,	O
5	O
%	O
were	O
boys	O
and	O
46	O
%	O
girls	O
.	O

There	O
was	O
significant	O
difference	O
in	O
birth	O
weight	O
and	O
APGAR	O
score	O
among	O
the	O
groups	O
.	O

In	O
the	O
first	O
group	O
,	O
there	O
were	O
27	O
.	O
42	O
%	O
of	O
deaths	B-T033
,	O
while	O
in	O
the	O
second	O
group	O
,	O
there	O
were	O
only	O
10	O
.	O
53	O
%	O
of	O
deaths	B-T033
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
the	O
length	O
of	O
treatment	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
the	O
need	O
for	O
transfusion	B-T058
among	O
the	O
groups	O
.	O

18	O
patients	O
in	O
the	O
first	O
group	O
required	O
a	O
transfusion	B-T058
,	O
while	O
in	O
the	O
second	O
group	O
only	O
3	O
patients	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
are	O
likely	O
candidates	O
for	O
blood	B-T058
transfusion	I-T058
during	O
treatment	O
.	O

Preterm	O
infants	O
of	O
gestational	O
age	O
≤	O
32	O
weeks	O
have	O
the	O
risk	O
of	O
intracranial	B-T038
bleeding	I-T038
associated	O
with	O
the	O
application	B-T058
of	O
blood	B-T058
transfusion	I-T058
in	O
the	O
first	O
week	O
of	O
life	O
.	O

Medial	B-T017
Patellofemoral	I-T017
Ligament	I-T017
Reconstruction	B-T058
Femoral	B-T017
Tunnel	O
Accuracy	O
:	O
Relationship	O
to	O
Disease	B-T038
-	O
Specific	O
Quality	O
of	O
Life	O

Medial	B-T017
patellofemoral	I-T017
ligament	I-T017
(	O
MPFL	B-T017
)	O
reconstruction	B-T058
is	O
a	O
procedure	O
aimed	O
to	O
reestablish	O
the	O
checkrein	O
to	O
lateral	B-T037
patellar	I-T037
translation	I-T037
in	O
patients	O
with	O
symptomatic	B-T037
patellofemoral	I-T037
instability	I-T037
.	O

Correct	O
femoral	B-T017
tunnel	O
position	B-T082
is	O
thought	O
to	O
be	O
crucial	O
to	O
successful	O
MPFL	B-T017
reconstruction	B-T058
,	O
but	O
the	O
accuracy	O
of	O
this	O
statement	O
in	O
terms	O
of	O
patient	B-T058
outcomes	I-T058
has	O
not	O
been	O
tested	O
.	O

To	O
assess	O
the	O
accuracy	O
of	O
femoral	B-T017
tunnel	O
placement	B-T058
in	O
an	O
MPFL	B-T017
reconstruction	B-T058
cohort	B-T098
and	O
to	O
determine	O
the	O
correlation	O
between	O
tunnel	O
accuracy	O
and	O
a	O
validated	B-T062
disease	B-T038
-	O
specific	O
,	O
patient	O
-	O
reported	O
quality	O
-	O
of	O
-	O
life	O
outcome	O
measure	O
.	O

Case	O
series	O
;	O
Level	O
of	O
evidence	O
,	O
4	O
.	O

Between	O
June	O
2008	O
and	O
February	O
2014	O
,	O
a	O
total	O
of	O
206	O
subjects	B-T098
underwent	O
an	O
MPFL	B-T017
reconstruction	B-T058
.	O

Lateral	B-T082
radiographs	B-T058
were	O
measured	O
to	O
determine	O
the	O
accuracy	O
of	O
the	O
femoral	B-T017
tunnel	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
center	O
of	O
the	O
femoral	B-T017
tunnel	O
to	O
the	O
Schöttle	O
point	O
.	O

Banff	O
Patella	O
Instability	O
Instrument	O
(	O
BPII	O
)	O
scores	O
were	O
collected	O
a	O
mean	O
24	O
months	O
postoperatively	O
.	O

A	O
total	O
of	O
155	O
(	O
79	O
.	O
5	O
%	O
)	O
subjects	O
had	O
adequate	O
postoperative	O
lateral	B-T082
radiographs	B-T058
and	O
complete	O
BPII	O
scores	O
.	O

The	O
mean	O
duration	O
of	O
follow	B-T058
-	I-T058
up	I-T058
(	O
±	O
SD	O
)	O
was	O
24	O
.	O
4	O
±	O
8	O
.	O
2	O
months	O
(	O
range	O
,	O
12	O
-	O
74	O
months	O
)	O
.	O

Measurement	O
from	O
the	O
center	B-T082
of	O
the	O
femoral	B-T017
tunnel	O
to	O
the	O
Schöttle	O
point	O
resulted	O
in	O
143	O
(	O
92	O
.	O
3	O
%	O
)	O
tunnel	O
s	O
being	O
categorized	O
as	O
"	O
good	O
"	O
or	O
"	O
ideal	O
.	O
"	O
There	O
were	O
8	O
failures	B-T038
in	O
the	O
cohort	B-T098
,	O
none	O
of	O
which	O
occurred	O
in	O
malpositioned	B-T082
tunnels	O
.	O

The	O
mean	O
distance	O
from	O
the	O
center	B-T082
of	O
the	O
MPFL	B-T017
tunnel	O
to	O
the	O
center	B-T082
of	O
the	O
Schöttle	O
point	O
was	O
5	O
.	O
9	O
±	O
4	O
.	O
2	O
mm	O
(	O
range	O
,	O
0	O
.	O
5	O
-	O
25	O
.	O
9	O
mm	O
)	O
.	O

The	O
mean	O
postoperative	O
BPII	O
score	O
was	O
65	O
.	O
2	O
±	O
22	O
.	O
5	O
(	O
range	O
,	O
9	O
.	O
2	O
-	O
100	O
)	O
.	O

Pearson	B-T170
r	I-T170
correlation	I-T170
demonstrated	O
no	B-T033
statistically	I-T033
significant	I-T033
relationship	O
between	O
accuracy	O
of	O
femoral	B-T017
tunnel	O
position	B-T082
and	O
BPII	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
24	O
to	O
0	O
.	O
08	O
)	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
correlation	O
between	O
the	O
accuracy	O
of	O
MPFL	B-T017
reconstruction	B-T058
femoral	B-T017
tunnel	O
in	O
relation	O
to	O
the	O
Schöttle	O
point	O
and	O
disease	B-T038
-	O
specific	O
quality	O
-	O
of	O
-	O
life	O
scores	O
.	O

Graft	B-T038
failure	I-T038
was	O
not	O
related	O
to	O
femoral	B-T017
tunnel	O
placement	B-T058
.	O

The	O
patellofemoral	B-T037
instability	I-T037
population	O
is	O
complex	O
,	O
and	O
patients	O
present	O
with	O
multiple	O
risk	B-T033
factors	I-T033
that	O
,	O
in	O
addition	O
to	O
the	O
accuracy	O
of	O
femoral	O
tunnel	O
position	B-T082
,	O
contribute	O
to	O
quality	O
of	O
life	O
and	O
warrant	O
further	O
investigation	B-T058
.	O

Evidence	O
for	O
instructions	O
-	O
based	O
updating	O
of	O
task	B-T058
-	I-T058
set	I-T058
representations	I-T058
:	O
the	O
informed	O
fadeout	B-T038
effect	I-T038

The	O
cognitive	B-T038
system	I-T038
can	O
be	O
updated	O
rapidly	O
and	O
efficiently	O
to	O
maximize	O
performance	B-T058
in	O
cognitive	B-T038
tasks	I-T038
.	O

This	O
paper	O
used	O
a	O
task	O
-	O
switching	O
task	O
to	O
explore	O
updating	O
at	O
the	O
level	O
of	O
the	O
plausible	O
task	O
-	O
sets	O
held	O
for	O
future	O
performance	B-T058
.	O

Previous	O
research	B-T062
suggested	O
a	O
"	O
fadeout	B-T038
effect	I-T038
"	O
,	O
performance	B-T058
improvement	B-T058
when	O
moving	O
from	O
task	O
-	O
switching	O
context	O
to	O
single	O
-	O
task	O
context	O
,	O
yet	O
this	O
effect	O
could	O
reflect	O
passive	O
learning	B-T038
rather	O
than	O
intentional	O
control	O
.	O

In	O
a	O
novel	O
"	O
informed	O
fadeout	O
paradigm	O
"	O
,	O
one	O
of	O
two	O
tasks	O
was	O
canceled	O
for	O
a	O
certain	O
number	O
of	O
trials	O
and	O
participants	B-T098
were	O
informed	O
or	O
uninformed	B-T033
regarding	O
task	O
cancelation	O
.	O

The	O
"	O
informed	O
fadeout	B-T038
effect	I-T038
"	O
indicates	O
better	O
performance	B-T058
in	O
the	O
informed	O
than	O
uninformed	B-T033
fadeout	B-T038
after	O
one	O
informed	O
trial	O
had	O
been	O
executed	O
.	O

However	O
,	O
the	O
results	O
regarding	O
the	O
first	O
trial	O
were	O
inconclusive	O
.	O

Possible	O
underlying	O
mechanisms	O
are	O
discussed	O
.	O

Metacarpophalangeal	B-T058
Joint	I-T058
Arthrodesis	I-T058
of	O
the	O
Thumb	B-T017
-	O
Minimum	O
of	O
Eight	O
Months	O
Follow	B-T058
-	I-T058
up	I-T058

Disorders	B-T038
of	O
the	O
thumb	B-T082
metacarpophalangeal	I-T082
(	I-T082
MCP	I-T082
)	I-T082
joint	I-T082
can	O
lead	O
to	O
significant	O
loss	O
of	O
function	O
and	O
pain	B-T033
.	O

Thumb	B-T082
MCP	I-T082
arthrodesis	B-T058
following	O
traumatic	B-T037
injuries	I-T037
is	O
inadequately	O
described	O
and	O
recent	O
studies	B-T062
have	O
questioned	O
the	O
outcome	O
of	O
this	O
treatment	B-T058
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
report	B-T058
outcome	O
and	O
disability	B-T033
following	O
thumb	B-T082
MCP	I-T082
joint	I-T082
arthrodesis	B-T058
in	O
the	O
treatment	B-T058
of	O
chronic	B-T038
instability	I-T038
after	O
traumatic	B-T037
injuries	I-T037
.	O

A	O
retrospective	O
review	B-T058
of	O
26	O
patients	O
operated	B-T058
on	O
with	O
MCP	B-T082
joint	I-T082
arthrodesis	B-T058
,	O
median	O
follow	B-T058
-	I-T058
up	I-T058
42	O
months	O
(	O
8	O
-	O
104	O
months	O
)	O
.	O

Subjective	O
outcome	O
was	O
assessed	O
using	O
the	O
disabilities	O
of	O
the	O
Arm	O
,	O
Shoulder	O
,	O
and	O
Hand	O
-	O
questionnaire	O
(	O
DASH	O
)	O
.	O

In	O
addition	O
,	O
patient	O
satisfaction	O
,	O
pain	B-T033
,	O
stiffness	B-T033
,	O
and	O
impairment	O
of	O
activities	O
of	O
daily	O
living	O
were	O
assessed	O
on	O
a	O
Visual	B-T058
Analogue	I-T058
Scale	I-T058
(	O
VAS	B-T058
)	O
followed	O
by	O
a	O
question	O
stating	O
whether	O
they	O
would	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Two	O
patients	O
(	O
7	O
.	O
7	O
%	O
)	O
needed	O
re	B-T058
-	I-T058
operation	I-T058
due	O
to	O
nonunion	B-T033
.	O

Four	O
patients	O
(	O
15	O
.	O
4	O
%	O
)	O
needed	O
hardware	B-T058
removal	I-T058
.	O

Median	O
DASH	O
-	O
score	O
was	O
18	O
(	O
25	O
-	O
75	O
%	O
range	O
6	O
-	O
47	O
)	O
,	O
with	O
lower	O
DASH	O
score	O
s	O
being	O
better	O
.	O

Score	O
s	O
were	O
significantly	O
worse	O
in	O
gender	O
and	O
age	O
matched	O
individuals	B-T098
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Median	O
VAS	B-T058
for	O
pain	B-T033
was	O
3	O
.	O
7	O
(	O
range	O
0	O
-	O
8	O
)	O
.	O

More	O
than	O
50	O
%	O
of	O
patients	O
reported	O
mild	B-T033
,	O
moderate	B-T033
or	O
severe	B-T033
pain	I-T033
,	O
but	O
all	O
patients	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

Our	O
data	O
suggest	O
,	O
that	O
patients	O
with	O
post	O
-	O
traumatic	O
thumb	B-T037
injuries	I-T037
managed	O
with	O
thumb	B-T082
MCP	I-T082
joint	I-T082
arthrodesis	B-T058
perform	O
worse	O
than	O
gender	O
and	O
age	O
matched	O
individuals	B-T098
.	O

Many	O
lived	O
with	O
pain	B-T033
,	O
but	O
all	O
reported	O
that	O
they	O
were	O
willing	O
to	O
undergo	O
the	O
same	O
procedure	O
again	O
.	O

We	O
suggest	O
that	O
the	O
disability	B-T170
scale	I-T170
by	O
the	O
National	B-T092
Board	I-T092
of	I-T092
Industrial	I-T092
Injuries	I-T092
should	O
be	O
reconsidered	O
for	O
patients	O
operated	B-T058
on	O
with	O
thumb	B-T082
MCP	I-T082
arthrodesis	B-T058
.	O

Pyoderma	B-T038
gangrenosum	I-T038
:	O
A	O
clinician	B-T097
'	I-T097
s	I-T097
nightmare	B-T033

Pyoderma	B-T038
gangrenosum	I-T038
(	O
PG	B-T038
)	O
is	O
a	O
rare	B-T038
disease	I-T038
and	O
that	O
affecting	O
specifically	O
the	O
sole	B-T082
of	I-T082
the	I-T082
foot	I-T082
,	O
is	O
even	O
rarer	O
.	O

Here	O
,	O
we	O
report	B-T170
the	O
case	O
of	O
a	O
54	O
-	O
year	O
-	O
old	O
female	O
admitted	B-T058
with	O
a	O
painful	B-T033
ulcer	B-T038
on	O
the	O
sole	B-T082
of	I-T082
the	I-T082
right	I-T082
foot	I-T082
which	O
was	O
initially	O
treated	B-T058
with	I-T058
empirical	O
antibiotics	B-T103
and	O
debridement	B-T058
.	O

The	O
disease	B-T038
was	O
found	O
to	O
spread	O
rapidly	O
after	O
each	O
debridement	B-T058
.	O

The	O
culture	O
reports	O
were	O
negative	B-T033
;	O
rheumatology	B-T091
workup	B-T058
and	O
Doppler	B-T058
study	I-T058
were	O
within	O
normal	B-T033
limits	I-T033
.	O

A	O
clinical	O
suspicion	O
of	O
PG	B-T038
was	O
made	O
and	O
was	O
confirmed	O
with	O
tissue	O
biopsy	O
.	O

She	O
was	O
started	B-T058
on	I-T058
oral	I-T058
steroids	I-T058
following	O
which	O
she	O
dramatically	O
improved	B-T033
.	O

Thus	O
,	O
when	O
a	O
patient	O
presents	O
with	O
a	O
rapidly	O
expanding	O
painful	B-T033
ulcer	B-T038
in	O
a	O
vascular	B-T017
limb	I-T017
that	O
is	O
refractory	O
to	O
antibiotic	B-T058
treatment	I-T058
and	O
exacerbating	O
on	O
debridement	B-T058
,	O
it	O
is	O
imperative	O
to	O
consider	O
the	O
possibility	O
of	O
PG	B-T038
.	O

Visualization	O
for	O
Understanding	O
Uncertainty	B-T033
in	O
Activation	O
Volumes	O
for	O
Deep	B-T058
Brain	I-T058
Stimulation	I-T058

We	O
have	O
created	O
the	O
Neurostimulation	B-T170
Uncertainty	I-T170
Viewer	I-T170
(	I-T170
nuView	I-T170
or	I-T170
νView	I-T170
)	I-T170
tool	I-T170
for	O
exploring	O
data	O
arising	O
from	O
deep	B-T058
brain	I-T058
stimulation	I-T058
(	O
DBS	B-T058
)	O
.	O

Simulated	B-T062
volume	O
of	O
tissue	O
activated	O
(	O
VTA	O
)	O
,	O
using	O
clinical	B-T058
electrode	I-T058
placements	I-T058
,	O
are	O
recorded	O
along	O
with	O
patient	O
outcomes	O
in	O
the	O
Unified	B-T170
Parkinson	I-T170
'	I-T170
s	I-T170
disease	I-T170
rating	I-T170
scale	I-T170
(	O
UPDRS	B-T170
)	O
.	O

The	O
data	O
is	O
volumetric	O
and	O
sparse	O
,	O
with	O
multi	O
-	O
value	O
patient	O
results	O
for	O
each	O
activated	O
voxel	O
in	O
the	O
simulation	B-T062
.	O

νView	O
provides	O
a	O
collection	O
of	O
visual	B-T170
methods	I-T170
to	O
explore	O
the	O
activated	O
tissue	B-T017
to	O
enhance	O
understanding	O
of	O
electrode	B-T074
usage	O
for	O
improved	O
therapy	B-T058
with	O
DBS	B-T058
.	O

Post	O
-	O
synthetic	O
conversion	O
of	O
5	B-T103
-	I-T103
pivaloyloxymethyluridine	I-T103
present	B-T033
in	O
a	O
support	O
-	O
bound	O
RNA	B-T103
oligomer	O
into	O
biologically	O
relevant	O
derivatives	B-T103
of	O
5	B-T103
-	I-T103
methyluridine	I-T103

A	O
post	O
-	O
synthetic	O
reaction	O
of	O
5	B-T103
-	I-T103
pivaloyloxymethyluridine	I-T103
(	O
present	B-T033
in	O
a	O
support	O
-	O
bound	O
RNA	B-T103
oligomer	O
)	O
with	O
various	O
nucleophilic	B-T103
reagents	I-T103
furnished	O
efficiently	O
the	O
corresponding	O
products	O
bearing	O
one	O
aof	O
the	O
tRNA	B-T038
wobble	I-T038
5	B-T103
-	I-T103
methyluridines	I-T103
(	O
mnm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
,	O
cmnm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
,	O
τm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
,	O
nm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
,	O
inm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
or	O
cnm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
)	O
.	O

The	O
syntheses	O
of	O
oligoribonucleotides	B-T103
modified	O
with	O
inm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
and	O
cnm	B-T103
(	I-T103
5	I-T103
)	I-T103
U	I-T103
are	O
reported	O
for	O
the	O
first	O
time	O
.	O

Non	O
-	O
pharmacological	O
treatments	B-T058
for	O
pain	B-T058
relief	I-T058
:	O
TENS	B-T058
and	O
acupuncture	B-T058

Acupuncture	B-T058
and	O
transcutaneous	B-T058
electrical	I-T058
nerve	I-T058
stimulation	I-T058
(	O
TENS	B-T058
)	O
are	O
non	O
-	O
pharmacological	O
methods	O
that	O
have	O
been	O
used	O
for	O
millennia	O
to	O
relieve	B-T058
pain	I-T058
.	O

As	O
with	O
all	O
complementary	B-T058
treatments	I-T058
,	O
efficacy	O
evaluations	B-T058
face	O
two	O
hurdles	O
:	O
the	O
non	O
-	O
feasibility	O
of	O
double	B-T062
-	I-T062
blinding	I-T062
and	O
the	O
difficulty	O
in	O
identifying	O
the	O
optimal	O
control	O
population	O
or	O
treatment	B-T058
.	O

Nevertheless	O
,	O
recent	O
studies	O
of	O
good	O
methodological	O
quality	O
have	O
demonstrated	O
benefits	O
in	O
many	O
types	O
of	O
pain	B-T033
compared	O
to	O
conventional	O
treatment	B-T058
.	O

The	O
mechanisms	O
of	O
action	O
of	O
acupuncture	B-T058
and	O
TENS	B-T058
,	O
which	O
are	O
increasingly	O
well	O
understood	O
,	O
involve	O
endogenous	O
pain	B-T058
control	I-T058
systems	I-T058
,	O
cerebral	B-T038
plasticity	I-T038
,	O
and	O
nonspecific	O
effects	O
(	O
e	O
.	O
g	O
.	O
,	O
expectations	O
and	O
placebo	O
effect	O
)	O
.	O

No	O
serious	O
adverse	B-T038
effects	I-T038
have	O
been	O
reported	O
.	O

These	O
data	O
support	O
the	O
more	O
widespread	O
use	O
of	O
non	O
-	O
pharmacological	O
pain	B-T058
management	I-T058
,	O
most	O
notably	O
in	O
patients	O
with	O
chronic	B-T033
pain	I-T033
inadequately	O
relieved	O
by	O
medications	B-T103
alone	O
.	O

Synaptic	B-T082
and	O
Neuronal	B-T017
Autoantibody	B-T103
-	O
Associated	O
Psychiatric	B-T038
Syndromes	I-T038
:	O
Controversies	O
and	O
Hypotheses	O

Autoimmune	B-T038
encephalitis	I-T038
(	O
AE	B-T038
)	O
mediated	O
by	O
antibodies	B-T103
against	O
synaptic	B-T082
and	O
neuronal	B-T017
surface	B-T082
targets	O
frequently	O
presents	B-T033
with	O
a	O
psychiatric	B-T038
syndrome	I-T038
.	O

In	O
these	O
patients	O
,	O
removal	B-T058
of	I-T058
autoantibodies	B-T103
treats	O
the	O
disease	B-T038
and	O
outcomes	O
are	O
closely	O
linked	O
to	O
early	O
intervention	B-T058
.	O

The	O
discovery	O
of	O
these	O
autoantibodies	B-T103
in	O
isolated	O
psychiatric	B-T038
syndromes	I-T038
has	O
raised	O
the	O
possibility	O
that	O
these	O
patients	O
may	O
derive	O
similar	O
benefits	O
from	O
immunotherapy	B-T058
,	O
a	O
potentially	O
transformational	O
approach	B-T082
to	O
the	O
treatment	O
of	O
mental	B-T038
illness	I-T038
.	O

Although	O
open	B-T062
-	I-T062
label	I-T062
case	I-T062
series	I-T062
suggest	O
impressive	O
therapeutic	O
outcomes	O
,	O
the	O
pathological	O
relevance	O
of	O
these	O
autoantibodies	B-T103
outside	O
of	O
canonical	O
presentations	O
is	O
debated	O
.	O

The	O
advent	O
of	O
diagnostic	B-T170
criteria	I-T170
for	O
AE	B-T038
attempts	O
to	O
facilitate	O
its	O
prompt	O
identification	O
but	O
risks	O
prematurely	O
neglecting	O
the	O
potential	O
scientific	O
and	O
clinical	B-T033
significance	I-T033
of	O
isolated	O
syndromes	B-T038
that	O
do	O
not	O
satisfy	O
these	O
criteria	O
.	O

Here	O
,	O
we	O
propose	O
using	O
a	O
syndrome	B-T038
-	O
level	O
taxonomy	O
that	O
has	O
occasional	O
,	O
but	O
not	O
necessary	O
,	O
overlap	O
with	O
AE	B-T038
:	O
synaptic	B-T082
and	O
neuronal	B-T017
autoantibody	B-T103
-	O
associated	O
psychiatric	B-T038
syndromes	I-T038
or	O
"	O
SNAps	B-T038
"	O
.	O

This	O
will	O
prevent	O
confusion	O
with	O
AE	B-T038
and	O
act	B-T170
heuristically	I-T170
to	O
promote	O
active	O
investigation	B-T058
into	O
this	O
rare	O
example	O
of	O
psychopathology	B-T091
defined	B-T170
on	O
a	O
molecular	O
level	O
.	O

We	O
suggest	O
that	O
this	O
concept	O
would	O
have	O
application	O
in	O
other	O
autoantibody	B-T103
-	O
associated	O
syndromes	B-T038
including	O
seizure	B-T033
,	O
cognitive	O
,	O
and	O
movement	B-T038
disorders	I-T038
,	O
in	O
which	O
similar	O
issues	B-T033
arise	O
.	O

We	O
review	O
putative	O
direct	O
and	O
indirect	O
mechanisms	O
and	O
outline	O
experimentally	O
testable	O
hypotheses	O
that	O
would	O
help	O
to	O
determine	O
prospectively	B-T062
in	O
whom	O
autoantibody	B-T103
detection	B-T058
is	O
relevant	O
,	O
and	O
as	O
important	O
,	O
in	O
whom	O
it	O
is	O
not	O
.	O

We	O
summarize	O
a	O
pragmatic	O
approach	O
to	O
autoantibody	B-T103
testing	O
and	O
management	B-T058
in	O
severe	O
mental	B-T038
illness	I-T038
in	O
order	O
to	O
promptly	O
diagnose	B-T033
AE	B-T038
and	O
advocate	O
a	O
research	B-T062
-	O
orientated	B-T033
experimental	O
medicine	B-T103
paradigm	O
for	O
SNAps	B-T038
,	O
where	O
there	O
is	O
greater	O
equipoise	B-T103
.	O

We	O
conclude	O
that	O
SNAps	B-T038
remains	O
a	O
nascent	O
area	O
of	O
clinical	O
neuroscience	B-T091
with	O
great	O
potential	O
and	O
in	O
ongoing	O
need	O
of	O
psychiatry	B-T091
-	O
led	O
basic	O
and	O
clinical	B-T062
research	I-T062
.	O

NF	B-T103
-	I-T103
κB	I-T103
Links	O
TLR2	B-T103
and	O
PAR1	B-T103
to	O
Soluble	O
Immunomodulator	B-T103
Factor	I-T103
Secretion	B-T038
in	O
Human	B-T204
Platelets	B-T017

The	O
primary	O
toll	B-T103
-	I-T103
like	I-T103
receptor	I-T103
(	O
TLR	B-T103
)	O
-	O
mediated	O
immune	B-T038
cell	I-T038
response	I-T038
pathway	I-T038
common	O
for	O
all	O
TLRs	B-T103
is	O
MyD88	B-T103
-	O
dependent	O
activation	O
of	O
NF	B-T103
-	I-T103
κB	I-T103
,	O
a	O
seminal	B-T017
transcription	B-T103
factor	I-T103
for	O
many	O
chemokines	B-T103
and	O
cytokines	B-T103
.	O

Remarkably	O
,	O
anucleate	B-T017
platelets	I-T017
express	O
the	O
NF	B-T103
-	I-T103
κB	I-T103
machinery	O
,	O
whose	O
role	O
in	O
platelets	B-T017
remains	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
contribution	O
of	O
NF	B-T103
-	I-T103
κB	I-T103
in	O
the	O
release	O
of	O
cytokines	B-T103
and	O
serotonin	B-T103
by	O
human	B-T204
platelets	B-T017
,	O
following	O
selective	O
stimulation	O
of	O
TLR2	B-T103
and	O
protease	B-T103
activated	I-T103
receptor	I-T103
1	I-T103
(	O
PAR1	B-T103
)	O
,	O
a	O
classical	O
and	O
non	O
-	O
classical	O
pattern	B-T103
-	I-T103
recognition	I-T103
receptor	I-T103
,	O
respectively	O
,	O
able	O
to	O
participate	O
to	O
the	O
innate	O
immune	O
system	O
.	O

We	O
discovered	O
that	O
platelet	B-T017
PAR1	B-T103
activation	O
drives	O
the	O
process	O
of	O
NF	B-T103
-	I-T103
κB	I-T103
phosphorylation	B-T038
,	O
in	O
contrast	O
to	O
TLR2	B-T103
activation	B-T038
,	O
which	O
induces	O
a	O
slower	O
phosphorylation	B-T038
process	I-T038
.	O

Conversely	O
,	O
platelet	B-T017
PAR1	B-T103
and	O
TLR2	B-T103
activation	O
induces	O
similar	O
ERK1	B-T038
/	I-T038
2	I-T038
,	O
p38	B-T103
,	O
and	O
AKT	B-T103
phosphorylation	B-T038
.	O

Moreover	O
,	O
we	O
found	O
that	O
engagement	O
of	O
platelet	B-T017
TLR2	B-T103
with	O
its	O
ligand	B-T103
,	O
Pam3CSK4	B-T103
,	O
significantly	O
increases	O
the	O
release	O
of	O
sCD62P	B-T103
,	O
RANTES	B-T103
,	O
and	O
sCD40L	B-T103
;	O
this	O
effect	O
was	O
attenuated	O
by	O
incubating	B-T058
platelets	B-T017
with	O
a	O
blocking	O
anti	B-T103
-	I-T103
TLR2	I-T103
antibody	I-T103
.	O

This	O
effect	O
appeared	O
selective	O
since	O
no	O
modulation	B-T082
of	O
serotonin	B-T038
secretion	I-T038
was	O
observed	O
following	O
platelet	B-T017
TLR2	B-T103
activation	B-T038
.	O

Platelet	B-T017
release	O
of	O
sCD62P	B-T103
,	O
RANTES	B-T103
,	O
and	O
sCD40L	B-T103
following	O
TLR2	B-T103
or	O
PAR1	B-T103
triggering	O
was	O
abolished	O
in	O
the	O
presence	B-T033
of	O
the	O
NF	B-T103
-	I-T103
κB	I-T103
inhibitor	B-T103
Bay11	B-T103
-	I-T103
7082	I-T103
,	O
while	O
serotonin	B-T038
release	I-T038
following	O
PAR1	B-T103
activation	B-T038
was	O
significantly	O
decreased	O
.	O

These	O
new	O
findings	O
support	O
the	O
concept	O
that	O
NF	B-T103
-	I-T103
κB	I-T103
is	O
an	O
important	O
player	O
in	O
platelet	B-T017
immunoregulations	B-T038
and	O
functions	B-T038
.	O

Optical	B-T062
tweezers	I-T062
studies	B-T062
of	O
transcription	B-T038
by	O
eukaryotic	B-T017
RNA	B-T103
polymerases	I-T103

Transcription	B-T038
is	O
the	O
first	O
step	O
in	O
the	O
expression	B-T038
of	O
genetic	O
information	O
and	O
it	O
is	O
carried	O
out	O
by	O
large	O
macromolecular	B-T103
enzymes	B-T103
called	O
RNA	B-T103
polymerases	I-T103
.	O

Transcription	B-T038
has	O
been	O
studied	B-T062
for	O
many	O
years	O
and	O
with	O
a	O
myriad	B-T170
of	O
experimental	O
techniques	O
,	O
ranging	O
from	O
bulk	O
studies	B-T062
to	O
high	B-T058
-	I-T058
resolution	I-T058
transcript	I-T058
sequencing	I-T058
.	O

In	O
this	O
review	B-T170
,	O
we	O
emphasise	O
the	O
advantages	O
of	O
using	O
single	O
-	O
molecule	O
techniques	O
,	O
particularly	O
optical	B-T062
tweezers	I-T062
,	O
to	O
study	B-T062
transcription	B-T038
dynamics	O
.	O

We	O
give	O
an	O
overview	O
of	O
the	O
latest	O
results	O
in	O
the	O
single	O
-	O
molecule	O
transcription	B-T038
field	O
,	O
focusing	O
on	O
transcription	B-T038
by	O
eukaryotic	B-T017
RNA	B-T103
polymerases	I-T103
.	O

Finally	O
,	O
we	O
evaluate	O
recent	O
quantitative	O
models	O
that	O
describe	O
the	O
biophysics	B-T091
of	O
RNA	B-T103
polymerase	I-T103
translocation	B-T038
and	O
backtracking	O
dynamics	O
.	O

Decreased	O
Frequencies	O
of	O
Peripheral	B-T031
Blood	I-T031
CD4	B-T017
+	I-T017
CD25	I-T017
+	I-T017
CD127	I-T017
-	I-T017
Foxp3	I-T017
+	I-T017
in	O
Patients	O
with	O
Graves	B-T038
'	I-T038
Disease	I-T038
and	O
Graves	B-T038
'	I-T038
Orbitopathy	I-T038
:	O
Enhancing	O
Effect	O
of	O
Insulin	B-T103
Growth	I-T103
Factor	I-T103
-	I-T103
1	I-T103
on	O
Treg	B-T017
Cells	I-T017

Graves	B-T038
'	I-T038
orbitopathy	I-T038
(	O
GO	B-T038
)	O
is	O
characterized	O
by	O
orbital	B-T017
T	I-T017
cell	I-T017
infiltration	B-T038
.	O

We	O
evaluated	B-T058
the	O
regulatory	B-T017
T	I-T017
(	I-T017
Treg	I-T017
)	I-T017
cell	I-T017
fractions	O
induced	O
with	O
IGF	B-T103
-	I-T103
1	I-T103
in	O
Graves	B-T038
'	I-T038
disease	I-T038
(	O
GD	B-T038
)	O
with	O
and	O
without	O
GO	B-T038
.	O

Peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
(	O
PBMCs	B-T017
)	O
were	O
obtained	O
from	O
13	O
patients	O
with	O
GD	B-T038
without	O
eye	B-T033
manifestations	I-T033
;	O
10	O
patients	O
with	O
active	O
GO	B-T038
;	O
and	O
12	O
patients	O
with	O
nodular	B-T038
goiter	I-T038
(	O
NG	B-T038
)	O
.	O

All	O
the	O
patients	O
from	O
GD	B-T038
,	O
GO	B-T038
,	O
and	O
NG	B-T038
were	O
subclinical	O
hyperthyroid	O
.	O

We	O
analyzed	B-T062
the	O
expression	B-T058
of	I-T058
Treg	I-T058
cell	I-T058
markers	I-T058
(	O
CD4	B-T103
,	O
CD25	B-T103
,	O
CD127	B-T103
(	I-T103
-	I-T103
)	I-T103
,	O
Foxp3	B-T103
)	O
on	O
T	B-T017
cells	I-T017
and	O
their	O
ability	O
to	O
respond	B-T170
to	I-T170
IGF	B-T103
-	I-T103
1	I-T103
stimulation	O
.	O

In	O
patients	O
with	O
GD	B-T038
without	O
GO	B-T038
,	O
we	O
found	O
lowered	O
percentages	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
Foxp3	I-T017
(	I-T017
+	I-T017
)	I-T017
cells	I-T017
,	O
as	O
compared	O
to	O
nodular	B-T038
goiter	I-T038
1	O
.	O
77	O
vs	O
.	O

5	O
.	O
42	O
%	O
(	O
p	O
=	O
0	O
.	O
0276	O
)	O
.	O

Similarly	O
,	O
significantly	O
reduced	O
frequencies	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
CD25	I-T017
(	I-T017
+	I-T017
)	I-T017
CD127	I-T017
(	I-T017
-	I-T017
)	I-T017
Foxp3	I-T017
(	I-T017
+	I-T017
)	I-T017
and	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
CD25	I-T017
(	I-T017
+	I-T017
)	I-T017
CD127	I-T017
(	I-T017
-	I-T017
)	I-T017
cells	I-T017
were	O
observed	O
in	O
GD	B-T038
patients	O
as	O
compared	O
to	O
nodular	B-T038
goiter	I-T038
patients	O
with	O
hyperthyreosis	B-T038
,	O
(	O
0	O
.	O
7	O
vs	O
.	O

1	O
.	O
48	O
%	O
)	O
(	O
p	O
=	O
0	O
.	O
0071	O
)	O
and	O
(	O
14	O
.	O
5	O
vs	O
.	O

37	O
.	O
2	O
%	O
)	O
(	O
p	O
=	O
0	O
.	O
0051	O
)	O
,	O
respectively	O
.	O

In	O
GO	B-T038
with	O
active	O
GO	B-T038
,	O
only	O
the	O
percentage	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
CD25	I-T017
(	I-T017
+	I-T017
)	I-T017
CD127	I-T017
(	I-T017
-	I-T017
)	I-T017
cells	I-T017
was	O
found	O
to	O
be	O
decreased	O
versus	O
nodular	B-T038
goiter	I-T038
(	O
9	O
.	O
35	O
vs	O
.	O

37	O
.	O
2	O
)	O
(	O
p	O
=	O
0	O
.	O
0275	O
)	O
.	O

Stimulation	O
of	O
PBMC	B-T017
derived	O
from	O
GO	B-T038
patients	O
with	O
IGF	B-T103
-	I-T103
1	I-T103
resulted	O
in	O
significant	O
increase	O
of	O
frequency	O
of	O
both	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
Foxp3	I-T017
(	I-T017
+	I-T017
)	I-T017
and	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
CD25	I-T017
(	I-T017
+	I-T017
)	I-T017
CD127	I-T017
(	I-T017
-	I-T017
)	I-T017
Foxp3	I-T017
cells	I-T017
.	O

Decreased	O
frequencies	O
of	O
peripheral	B-T031
blood	I-T031
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
CD25	I-T017
(	I-T017
+	I-T017
)	I-T017
CD127	I-T017
(	I-T017
-	I-T017
)	I-T017
Foxp3	I-T017
(	I-T017
+	I-T017
)	I-T017
in	O
patients	O
with	O
GD	B-T038
and	O
GO	B-T038
could	O
be	O
an	O
useful	B-T201
marker	I-T201
of	O
autoimmune	B-T038
process	I-T038
and	O
perhaps	O
a	O
possible	O
target	O
for	O
future	O
therapies	O
.	O

This	O
is	O
the	O
first	O
study	B-T062
demonstrating	O
Treg	B-T017
-	O
enhancing	O
effects	O
of	O
IGF	B-T103
-	I-T103
1	I-T103
.	O

Thus	O
IGF	B-T103
-	I-T103
1	I-T103
can	O
be	O
accounted	O
for	O
modulating	B-T082
Treg	B-T017
cell	I-T017
-	O
related	O
action	O
in	O
GO	B-T038
.	O

γ	B-T103
-	I-T103
Butenolide	I-T103
and	O
furanone	B-T103
derivatives	I-T103
from	O
the	O
soil	O
-	O
derived	O
fungus	B-T204
Aspergillus	B-T204
sclerotiorum	I-T204
PSU	B-T204
-	I-T204
RSPG178	I-T204

Chromatographic	B-T058
separation	I-T058
of	O
the	O
broth	B-T103
extract	O
of	O
the	O
soil	O
-	O
derived	O
fungus	B-T204
Aspergillus	B-T204
sclerotiorum	I-T204
PSU	B-T204
-	I-T204
RSPG178	I-T204
resulted	O
in	O
isolation	O
of	O
four	O
γ	B-T103
-	I-T103
butenolide	I-T103
-	I-T103
furanone	I-T103
dimers	I-T103
,	O
aspersclerotiorones	B-T103
A	I-T103
-	I-T103
D	I-T103
,	O
a	O
furanone	B-T103
derivative	I-T103
,	O
aspersclerotiorone	B-T103
E	I-T103
,	O
and	O
two	O
γ	B-T103
-	I-T103
butenolide	I-T103
derivatives	I-T103
,	O
aspersclerotiorones	B-T103
F	I-T103
and	O
G	B-T103
,	O
together	O
with	O
six	O
known	O
compounds	O
,	O
penicillic	B-T103
acid	I-T103
,	O
dihydropenicillic	B-T103
acid	I-T103
,	O
5	B-T103
,	I-T103
6	I-T103
-	I-T103
dihydro	I-T103
-	I-T103
6	I-T103
-	I-T103
hydroxypenicillic	I-T103
acid	I-T103
,	O
6	B-T103
-	I-T103
methoxy	I-T103
-	I-T103
5	I-T103
,	I-T103
6	I-T103
-	I-T103
dihydropenicillic	I-T103
acid	I-T103
,	O
coculnol	B-T103
and	O
(	B-T103
4R	I-T103
,	I-T103
5R	I-T103
)	I-T103
-	I-T103
4	I-T103
,	I-T103
5	I-T103
-	I-T103
dihydroxy	I-T103
-	I-T103
3	I-T103
-	I-T103
methoxy	I-T103
-	I-T103
5	I-T103
-	I-T103
methylcyclohex	I-T103
-	I-T103
2	I-T103
-	I-T103
en	I-T103
-	I-T103
1	I-T103
-	I-T103
one	I-T103
.	O

Their	O
structures	B-T170
were	O
determined	O
by	O
spectroscopic	B-T058
evidence	I-T058
.	O

For	O
aspersclerotiorones	B-T103
A	I-T103
and	O
B	B-T103
,	O
the	O
structures	B-T170
were	O
confirmed	O
by	O
single	B-T058
-	I-T058
crystal	I-T058
X	I-T058
-	I-T058
ray	I-T058
diffraction	I-T058
crystallography	I-T058
.	O

Penicillic	O
acid	O
displayed	O
weak	O
antibacterial	B-T033
activity	I-T033
against	O
Staphylococcus	B-T007
aureus	I-T007
and	O
Escherichia	B-T007
coli	I-T007
with	O
equal	O
MIC	B-T033
values	I-T033
of	O
128	O
μg	O
/	O
mL	O
,	O
and	O
it	O
was	O
noncytotoxic	O
towards	O
African	B-T204
green	I-T204
monkey	I-T204
kidney	B-T017
fibroblast	B-T017
cells	I-T017
.	O

E3	B-T103
Ligase	I-T103
RNF126	B-T103
Directly	O
Ubiquitinates	B-T038
Frataxin	B-T103
,	O
Promoting	O
Its	O
Degradation	O
:	O
Identification	O
of	O
a	O
Potential	O
Therapeutic	O
Target	O
for	O
Friedreich	B-T038
Ataxia	I-T038

Friedreich	B-T038
ataxia	I-T038
(	O
FRDA	B-T038
)	O
is	O
a	O
severe	O
genetic	O
neurodegenerative	B-T038
disease	I-T038
caused	O
by	O
reduced	O
expression	B-T038
of	O
the	O
mitochondrial	B-T103
protein	I-T103
frataxin	B-T103
.	O

To	O
date	O
,	O
there	O
is	O
no	O
therapy	O
to	O
treat	B-T058
this	O
condition	O
.	O

The	O
amount	O
of	O
residual	O
frataxin	B-T103
critically	O
affects	O
the	O
severity	O
of	O
the	O
disease	B-T038
;	O
thus	O
,	O
attempts	O
to	O
restore	O
physiological	O
frataxin	B-T103
levels	O
are	O
considered	O
therapeutically	O
relevant	O
.	O

Frataxin	B-T103
levels	O
are	O
controlled	O
by	O
the	O
ubiquitin	B-T038
-	I-T038
proteasome	I-T038
system	I-T038
;	O
therefore	O
,	O
inhibition	O
of	O
the	O
frataxin	B-T103
E3	B-T103
ligase	I-T103
may	O
represent	O
a	O
strategy	B-T062
to	O
achieve	O
an	O
increase	O
in	O
frataxin	B-T103
levels	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
the	O
RING	B-T103
E3	I-T103
ligase	I-T103
RNF126	B-T103
as	O
the	O
enzyme	B-T103
that	O
specifically	O
mediates	O
frataxin	B-T103
ubiquitination	B-T038
and	O
targets	O
it	O
for	O
degradation	O
.	O

RNF126	B-T103
interacts	O
with	O
frataxin	B-T103
and	O
promotes	O
its	O
ubiquitination	B-T038
in	O
a	O
catalytic	O
activity	O
-	O
dependent	O
manner	O
,	O
both	O
in	B-T082
vivo	I-T082
and	O
in	O
vitro	O
.	O

Most	O
importantly	O
,	O
RNF126	B-T103
depletion	O
results	O
in	O
frataxin	B-T103
accumulation	B-T033
in	O
cells	B-T017
derived	O
from	O
FRDA	B-T038
patients	O
,	O
highlighting	O
the	O
relevance	O
of	O
RNF126	B-T103
as	O
a	O
new	O
therapeutic	O
target	O
for	O
Friedreich	B-T038
ataxia	I-T038
.	O

Enhancing	O
Doctors	B-T097
'	I-T097
Competencies	O
in	O
Communication	O
With	O
and	O
Activation	O
of	O
Older	B-T098
Patients	O
:	O
The	O
Promoting	O
Active	O
Aging	B-T038
(	O
PRACTA	B-T058
)	O
Computer	B-T058
-	I-T058
Based	I-T058
Intervention	I-T058
Study	I-T058

Demographic	O
changes	O
over	O
the	O
past	O
decades	O
call	O
for	O
the	O
promotion	O
of	O
health	O
and	O
disease	O
prevention	O
for	O
older	B-T098
patients	O
,	O
as	O
well	O
as	O
strategies	O
to	O
enhance	O
their	O
independence	O
,	O
productivity	O
,	O
and	O
quality	O
of	O
life	O
.	O

Our	O
objective	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
computer	B-T058
-	I-T058
based	I-T058
educational	I-T058
intervention	I-T058
designed	O
for	O
general	B-T097
practitioners	I-T097
(	O
GPs	B-T097
)	O
to	O
promote	O
active	O
aging	B-T038
.	O

The	O
Promoting	O
Active	O
Aging	B-T038
(	O
PRACTA	B-T058
)	O
study	O
consisted	O
of	O
a	O
baseline	B-T170
questionnaire	I-T170
,	O
implementation	O
of	O
an	O
intervention	B-T058
,	O
and	O
a	O
follow	B-T170
-	I-T170
up	I-T170
questionnaire	I-T170
that	O
was	O
administered	O
1	O
month	O
after	O
the	O
intervention	B-T058
.	O

A	O
total	O
of	O
151	O
primary	B-T092
care	I-T092
facilities	I-T092
(	O
response	O
rate	O
151	O
/	O
767	O
,	O
19	O
.	O
7	O
%	O
)	O
and	O
503	O
GPs	B-T097
(	O
response	O
rate	O
503	O
/	O
996	O
,	O
50	O
.	O
5	O
%	O
)	O
agreed	O
to	O
participate	O
in	O
the	O
baseline	B-T062
assessment	I-T062
.	O

At	O
the	O
follow	B-T062
-	I-T062
up	I-T062
,	O
393	O
GPs	B-T097
filled	O
in	O
the	O
questionnaires	B-T170
(	O
response	O
rate	O
,	O
393	O
/	O
503	O
,	O
78	O
.	O
1	O
%	O
)	O
,	O
but	O
not	O
all	O
of	O
them	O
took	O
part	O
in	O
the	O
intervention	B-T058
.	O

The	O
final	O
study	O
group	O
of	O
225	O
GPs	B-T097
participated	O
in	O
3	O
study	O
conditions	O
:	O
e	O
-	O
learning	O
(	O
knowledge	B-T038
plus	O
skills	O
modelling	B-T170
,	O
n	O
=	O
42	O
)	O
,	O
a	O
pdf	B-T170
article	I-T170
(	O
knowledge	B-T038
only	O
,	O
n	O
=	O
89	O
)	O
,	O
and	O
control	O
(	O
no	O
intervention	B-T058
,	O
n	O
=	O
94	O
)	O
.	O

We	O
measured	O
the	O
outcome	O
as	O
scores	O
on	O
the	O
Patients	O
Expectations	B-T170
Scale	I-T170
,	O
Communication	B-T170
Scale	I-T170
,	O
Attitude	B-T170
Toward	I-T170
Treatment	I-T170
and	I-T170
Health	I-T170
Scale	I-T170
,	O
and	O
Self	B-T170
-	I-T170
Efficacy	I-T170
Scale	I-T170
.	O

GPs	B-T097
participating	O
in	O
e	O
-	O
learning	O
demonstrated	O
a	O
significant	O
rise	O
in	O
their	O
perception	B-T038
of	O
older	B-T098
patients	O
'	O
expectations	O
for	O
disease	B-T170
explanation	I-T170
(	O
Wald	O
χ	O
(	O
2	O
)	O
=	O
19	O
.	O
7	O
,	O
P	O
<	O
.	O
001	O
)	O
and	O
in	O
perception	B-T038
of	O
motivational	B-T038
aspect	O
of	O
older	B-T098
patients	O
'	O
attitude	O
toward	O
treatment	O
and	O
health	O
(	O
Wald	O
χ	O
(	O
2	O
)	O
=	O
8	O
.	O
9	O
,	O
P	O
=	O
.	O
03	O
)	O
in	O
comparison	O
with	O
both	O
the	O
control	O
and	O
pdf	O
article	O
groups	O
.	O

We	O
observed	O
additional	O
between	O
-	O
group	O
differences	O
at	O
the	O
level	O
of	O
statistical	O
trend	O
.	O

GPs	B-T097
participating	O
in	O
the	O
pdf	B-T170
article	I-T170
intervention	B-T058
demonstrated	O
a	O
decline	O
in	O
self	O
-	O
assessed	O
communication	O
,	O
both	O
at	O
the	O
level	O
of	O
global	O
scoring	O
(	O
Wald	O
χ	O
(	O
2	O
)	O
=	O
34	O
.	O
5	O
,	O
P	O
<	O
.	O
001	O
)	O
and	O
at	O
the	O
level	O
of	O
20	O
of	O
26	O
specific	O
behaviors	O
(	O
all	O
P	O
<	O
.	O
05	O
)	O
.	O

Factors	O
moderating	O
the	O
effects	O
of	O
the	O
intervention	B-T058
were	O
the	O
number	O
of	O
patients	O
per	O
GP	B-T097
and	O
the	O
facility	O
'	O
s	O
organizational	B-T170
structure	I-T170
.	O

Both	O
methods	O
were	O
suitable	O
,	O
but	O
in	O
different	O
areas	B-T082
and	O
under	O
different	O
conditions	O
.	O

The	O
key	O
benefit	O
of	O
the	O
pdf	B-T170
article	I-T170
intervention	B-T058
was	O
raising	O
doctors	B-T097
'	O
reflection	O
on	O
limitations	O
in	O
their	O
communication	O
skills	O
,	O
whereas	O
e	O
-	O
learning	O
was	O
more	O
effective	O
in	O
changing	O
their	O
perception	O
of	O
older	B-T098
patients	O
'	O
proactive	O
attitude	O
,	O
especially	O
among	O
GPs	B-T097
working	O
in	O
privately	B-T092
owned	I-T092
facilities	I-T092
and	O
having	O
a	O
greater	O
number	O
of	O
assigned	O
patients	O
.	O

Although	O
we	O
did	O
not	O
achieve	O
all	O
expected	O
effects	O
of	O
the	O
PRACTA	B-T058
intervention	I-T058
,	O
both	O
its	O
forms	O
seem	O
promising	O
in	O
terms	O
of	O
enhancing	O
the	O
competencies	O
of	O
doctors	B-T097
in	O
communication	O
with	O
and	O
activation	O
of	O
older	B-T098
patients	O
.	O

The	O
consummatory	O
and	O
motivational	B-T038
behaviors	O
for	O
natural	O
rewards	B-T038
following	O
long	O
-	O
term	O
withdrawal	B-T058
from	O
morphine	B-T103
:	O
no	O
anhedonia	B-T038
but	O
persistent	O
maladaptive	B-T033
behaviors	I-T033
for	O
high	O
-	O
value	O
rewards	B-T038

The	O
negative	O
affective	O
state	O
,	O
e	O
.	O
g	O
.	O
,	O
anhedonia	B-T038
,	O
emerges	O
after	O
abstinence	O
from	O
abused	B-T103
drugs	I-T103
may	O
be	O
linked	O
to	O
the	O
motivational	B-T038
processes	O
of	O
drug	B-T033
craving	I-T033
and	O
relapse	O
.	O

Although	O
anhedonia	B-T038
diminishes	O
over	O
time	O
with	O
drug	O
abstinence	O
,	O
it	O
is	O
not	O
yet	O
rather	O
explicit	O
whether	O
anhedonia	B-T038
exists	O
or	O
not	O
following	O
protracted	O
withdrawal	B-T058
.	O

The	O
behavioral	O
responses	O
to	O
natural	O
rewards	B-T038
were	O
examined	O
after	O
2	O
to	O
3	O
weeks	O
withdrawal	B-T058
from	O
morphine	B-T103
.	O

Male	O
rats	B-T204
were	O
pretreated	O
with	O
either	O
a	O
binge	O
-	O
like	O
morphine	B-T103
paradigm	O
or	O
daily	O
saline	B-T058
injection	I-T058
for	O
5	O
days	O
.	O

The	O
consummatory	O
and	O
motivational	B-T038
behaviors	O
for	O
three	O
natural	O
rewards	B-T038
(	O
sucrose	B-T103
solutions	I-T103
4	O
,	O
15	O
,	O
and	O
60	O
%	O
,	O
social	O
stimulus	O
:	O
male	O
rat	B-T204
,	O
and	O
sexual	O
stimulus	O
:	O
estrous	B-T038
female	O
rat	B-T204
)	O
were	O
examined	O
under	O
varied	O
testing	O
conditions	O
.	O

The	O
morphine	B-T103
-	O
withdrawn	B-T058
rats	B-T204
significantly	O
increased	O
their	O
intake	O
of	O
15	O
%	O
sucrose	B-T103
solution	I-T103
during	O
the	O
1	O
-	O
h	O
consumption	O
test	O
and	O
their	O
operant	B-T038
responding	I-T038
for	O
15	O
%	O
sucrose	B-T103
solution	I-T103
under	O
a	O
progressive	O
ratio	O
(	O
PR	O
)	O
schedule	O
of	O
reinforcement	O
.	O

When	O
obtaining	O
a	O
reinforcer	O
was	O
associated	O
with	O
a	O
0	O
.	O
5	O
mA	O
foot	B-T017
shock	B-T058
under	O
a	O
PR	B-T062
-	I-T062
punishment	I-T062
schedule	I-T062
,	O
the	O
morphine	B-T103
-	O
withdrawn	B-T058
rats	B-T204
showed	O
a	O
higher	O
performance	O
for	O
60	O
%	O
sucrose	B-T103
solution	I-T103
.	O

Meanwhile	O
,	O
the	O
morphine	B-T103
-	O
withdrawn	B-T058
rats	B-T204
displayed	O
a	O
higher	O
motivation	B-T038
to	O
sexual	O
stimulus	O
during	O
the	O
free	O
-	O
approach	O
test	O
and	O
more	O
approaching	O
behaviors	O
towards	O
sexual	O
stimulus	O
in	O
a	O
conflict	B-T058
-	I-T058
based	I-T058
approach	I-T058
test	I-T058
(	O
concurrent	O
presence	O
of	O
reward	B-T038
and	O
aversive	O
stimulus	O
)	O
.	O

No	B-T033
anhedonia	B-T038
-	O
like	O
behavior	O
but	O
sensitized	O
behaviors	O
for	O
natural	O
rewards	B-T038
were	O
found	O
after	O
long	O
-	O
term	O
morphine	B-T103
withdrawal	B-T058
.	O

Notably	O
,	O
the	O
morphine	B-T103
-	O
withdrawn	B-T058
rats	B-T204
displayed	O
persistent	O
motivated	B-T038
behaviors	O
for	O
high	O
-	O
value	O
rewards	B-T038
(	O
60	O
%	O
sucrose	B-T103
and	O
sexual	O
stimulus	O
)	O
in	O
the	O
conflict	O
tests	O
suggesting	O
impairments	O
in	O
inhibitory	O
control	O
in	O
morphine	B-T103
-	O
treated	O
rats	B-T204
.	O

Extracellular	B-T017
Self	O
-	O
Assembly	O
of	O
Functional	O
and	O
Tunable	B-T103
Protein	I-T103
Conjugates	I-T103
from	O
Bacillus	B-T007
subtilis	I-T007

The	O
ability	O
to	O
stably	O
and	O
specifically	O
conjugate	B-T038
recombinant	B-T103
proteins	I-T103
to	O
one	O
another	O
is	O
a	O
powerful	O
approach	O
for	O
engineering	B-T062
multifunctional	O
enzymes	B-T103
,	O
protein	O
therapeutics	O
,	O
and	O
novel	O
biological	B-T103
materials	I-T103
.	O

While	O
many	O
of	O
these	O
applications	O
have	O
been	O
illustrated	O
through	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
intracellular	B-T082
protein	B-T038
conjugation	I-T038
methods	O
,	O
extracellular	B-T017
self	O
-	O
assembly	O
of	O
protein	B-T103
conjugates	I-T103
offers	O
unique	O
advantages	O
:	O
simplifying	O
purification	B-T058
,	O
reducing	O
toxicity	B-T037
and	O
burden	O
,	O
and	O
enabling	O
tunability	O
.	O

Exploiting	O
the	O
recently	O
described	O
SpyTag	B-T058
-	I-T058
SpyCatcher	I-T058
system	I-T058
,	O
we	O
describe	O
here	O
how	O
enzymes	B-T103
and	O
structural	B-T103
proteins	I-T103
can	O
be	O
genetically	B-T038
encoded	I-T038
to	O
covalently	B-T038
conjugate	B-T038
in	O
culture	B-T103
media	I-T103
following	O
programmable	B-T038
secretion	I-T038
from	O
Bacillus	B-T007
subtilis	I-T007
.	O

Using	O
this	O
approach	O
,	O
we	O
demonstrate	O
how	O
self	B-T038
-	I-T038
conjugation	I-T038
of	O
a	O
secreted	B-T038
industrial	O
enzyme	B-T103
,	O
XynA	B-T103
,	O
dramatically	O
increases	O
its	O
resilience	O
to	O
boiling	O
,	O
and	O
we	O
show	O
that	O
cellular	B-T017
consortia	I-T017
can	O
be	O
engineered	B-T062
to	O
self	O
-	O
assemble	O
functional	O
protein	B-T103
-	I-T103
protein	I-T103
conjugates	I-T103
with	O
tunable	O
composition	O
.	O

This	O
novel	O
genetically	B-T038
encoded	I-T038
modular	O
system	O
provides	O
a	O
flexible	O
strategy	O
for	O
protein	B-T038
conjugation	I-T038
harnessing	O
the	O
substantial	O
advantages	O
of	O
extracellular	B-T017
self	O
-	O
assembly	O
.	O

Vascular	B-T017
smooth	I-T017
muscle	I-T017
cell	I-T017
peroxisome	B-T103
proliferator	I-T103
-	I-T103
activated	I-T103
receptor	I-T103
γ	I-T103
protects	O
against	O
endothelin	B-T103
-	I-T103
1	I-T103
-	O
induced	O
oxidative	B-T038
stress	I-T038
and	O
inflammation	B-T038

Peroxisome	B-T103
proliferator	I-T103
-	I-T103
activated	I-T103
receptor	I-T103
γ	I-T103
(	O
PPARγ	B-T103
)	O
agonists	B-T103
reduce	O
blood	B-T038
pressure	I-T038
and	O
vascular	B-T037
injury	I-T037
in	O
hypertensive	B-T033
rodents	B-T204
.	O

Pparγ	B-T103
inactivation	B-T038
in	O
vascular	B-T017
smooth	I-T017
muscle	I-T017
cells	I-T017
(	O
VSMC	B-T017
)	O
enhances	O
vascular	B-T037
injury	I-T037
.	O

Transgenic	B-T204
mice	I-T204
overexpressing	B-T038
endothelin	B-T103
(	I-T103
ET	I-T103
)	I-T103
-	I-T103
1	I-T103
selectively	O
in	O
the	O
endothelium	B-T017
(	B-T103
eET	I-T103
-	I-T103
1	I-T103
)	I-T103
exhibit	O
endothelial	B-T038
dysfunction	I-T038
,	O
increased	O
oxidative	B-T038
stress	I-T038
and	O
inflammation	B-T038
.	O

We	O
hypothesized	O
that	O
inactivation	B-T038
of	O
the	O
Pparγ	B-T017
gene	I-T017
in	O
VSMC	B-T017
(	O
smPparγ	B-T017
)	O
would	O
exaggerate	O
ET	B-T103
-	I-T103
1	I-T103
-	O
induced	O
vascular	B-T037
injury	I-T037
.	O

eET	B-T103
-	I-T103
1	I-T103
,	O
smPparγ	B-T103
and	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
mice	B-T204
were	O
treated	B-T033
with	O
tamoxifen	B-T103
for	O
5	O
days	O
and	O
studied	B-T062
4	O
weeks	O
later	O
.	O

SBP	B-T201
was	O
higher	O
in	O
eET	B-T103
-	I-T103
1	I-T103
and	O
unaffected	O
by	O
smPparγ	B-T103
inactivation	B-T038
.	O

Mesenteric	B-T017
artery	I-T017
vasodilatory	B-T038
responses	O
to	O
acetylcholine	B-T103
were	O
impaired	O
only	O
in	O
smPparγ	B-T103
.	O

N	B-T103
-	I-T103
Nitro	I-T103
-	I-T103
L	I-T103
-	I-T103
arginine	I-T103
methyl	I-T103
ester	I-T103
abrogated	O
relaxation	O
responses	O
,	O
and	O
the	O
Ednra	B-T017
/	O
Ednrb	B-T017
mRNA	B-T103
ratio	O
was	O
decreased	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
,	O
which	O
could	O
indicate	O
that	O
nitric	B-T103
oxide	I-T103
production	O
was	O
enhanced	O
by	O
ET	B-T103
-	I-T103
1	I-T103
stimulation	O
of	O
endothelin	B-T103
type	I-T103
B	I-T103
receptors	I-T103
.	O

Mesenteric	B-T017
artery	I-T017
media	O
/	O
lumen	O
was	O
greater	O
only	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
.	O

Mesenteric	B-T017
artery	I-T017
reactive	B-T103
oxygen	I-T103
species	I-T103
increased	O
in	O
smPparγ	B-T103
and	O
were	O
further	O
enhanced	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
.	O

Perivascular	B-T082
fat	B-T017
monocyte	I-T017
/	O
macrophage	B-T017
infiltration	B-T038
was	O
higher	O
in	O
eET	B-T103
-	I-T103
1	I-T103
and	O
smPparγ	B-T103
and	O
increased	O
further	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
.	O

Spleen	B-T017
CD11b	O
cells	O
were	O
increased	O
in	O
smPparγ	B-T103
and	O
further	O
enhance	O
d	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
,	O
whereas	O
Ly	B-T017
-	I-T017
6C	I-T017
monocytes	I-T017
increased	O
in	O
eET	B-T103
-	I-T103
1	I-T103
and	O
smPparγ	B-T103
but	O
not	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
.	O

Spleen	B-T017
T	B-T017
regulatory	I-T017
lymphocytes	I-T017
increased	O
in	O
smPparγ	B-T103
and	O
decreased	O
in	O
eET	B-T103
-	I-T103
1	I-T103
,	O
and	O
decreased	O
further	O
in	O
eET	B-T103
-	I-T103
1	I-T103
/	O
smPparγ	B-T103
.	O

VSMC	B-T017
Pparγ	B-T103
inactivation	B-T038
exaggerates	O
ET	B-T103
-	I-T103
1	I-T103
-	O
induced	O
vascular	B-T037
injury	I-T037
,	O
supporting	O
a	O
protective	O
role	O
for	O
PPARγ	B-T103
in	O
hypertension	B-T038
through	O
modulation	B-T082
of	O
pro	B-T103
-	I-T103
oxidant	I-T103
and	O
proinflammatory	O
pathways	B-T038
.	O

Paradoxically	O
,	O
ET	B-T103
-	I-T103
1	I-T103
overexpression	B-T038
preserved	O
endothelial	B-T017
function	O
in	O
smPparγ	B-T103
mice	B-T204
,	O
presumably	O
by	O
enhancing	O
nitric	B-T103
oxide	I-T103
through	O
stimulation	O
of	O
endothelin	B-T103
type	I-T103
B	I-T103
receptors	I-T103
.	O

Prospective	O
Evaluation	B-T058
of	O
Opioid	O
Consumption	O
After	O
Distal	B-T037
Radius	I-T037
Fracture	I-T037
Repair	B-T058
Surgery	I-T058

Pain	B-T058
management	I-T058
and	O
opioid	O
consumption	O
after	O
distal	B-T037
radius	I-T037
fracture	I-T037
(	O
DRF	B-T037
)	O
open	O
reduction	O
and	O
internal	O
fixation	O
(	O
ORIF	O
)	O
are	O
highly	O
variable	O
and	O
poorly	O
understood	O
.	O

To	O
optimize	B-T058
postoperative	O
opioid	B-T103
dosage	O
and	O
better	O
understand	O
opioid	O
consumption	O
patterns	O
after	O
DRF	B-T037
-	O
ORIF	O
,	O
we	O
conducted	O
a	O
prospective	B-T062
study	I-T062
with	O
the	O
hypothesis	O
that	O
opioid	O
consumption	O
would	O
increase	O
with	O
worsening	O
fracture	B-T037
classification	B-T170
and	O
various	O
patient	O
demographics	O
.	O

All	O
patients	O
who	O
underwent	O
DRF	B-T037
-	O
ORIF	O
were	O
consecutively	O
enrolled	O
over	O
a	O
6	O
-	O
month	O
period	O
.	O

Information	O
collected	O
included	O
patient	O
demographics	O
,	O
fracture	O
type	O
,	O
anesthesia	B-T170
type	I-T170
,	O
amount	O
and	O
type	O
of	O
opioid	B-T103
prescribed	O
,	O
number	O
of	O
pills	B-T103
taken	O
,	O
reason	O
for	O
stopping	O
,	O
and	O
adverse	B-T038
events	I-T038
.	O

Statistical	O
analysis	O
was	O
performed	O
.	O

Ninety	O
-	O
eight	O
patients	O
(	O
79	O
female	B-T098
,	O
19	O
male	B-T098
)	O
were	O
eligible	O
for	O
the	O
study	O
.	O

Mean	O
age	O
was	O
58	O
years	O
.	O

Of	O
the	O
98	O
patients	O
,	O
45	O
received	O
general	B-T058
anesthesia	I-T058
,	O
and	O
53	O
received	O
regional	O
anesthesia	O
with	O
a	O
single	O
-	O
shot	O
peripheral	B-T058
nerve	I-T058
block	I-T058
.	O

Mean	O
opioid	O
consumption	O
(	O
morphine	B-T103
equivalence	O
)	O
over	O
a	O
mean	O
of	O
4	O
.	O
8	O
postoperative	O
days	O
(	O
range	O
,	O
0	O
-	O
16	O
days	O
)	O
was	O
58	O
.	O
5	O
mg	O
(	O
range	O
,	O
0	O
-	O
280	O
mg	O
)	O
.	O

There	O
were	O
no	B-T033
significant	I-T033
differences	O
in	O
opioid	O
consumption	O
between	O
the	O
general	B-T058
and	O
regional	O
anesthesia	O
groups	O
.	O

Mean	O
opioid	O
consumption	O
for	O
the	O
3	O
fracture	O
-	O
type	O
groups	O
(	O
AO	B-T170
/	I-T170
OTA	I-T170
[	I-T170
Arbeitsgemeinschaft	I-T170
für	I-T170
Osteosynthesefragen	I-T170
/	I-T170
Orthopaedic	I-T170
Trauma	I-T170
Association	I-T170
]	I-T170
classification	I-T170
)	O
was	O
57	O
.	O
7	O
mg	O
(	O
class	B-T170
A	I-T170
)	O
,	O
60	O
.	O
3	O
mg	O
(	O
class	B-T170
B	I-T170
)	O
,	O
and	O
62	O
.	O
0	O
mg	O
(	O
class	B-T170
C	I-T170
)	O
.	O

Demographic	B-T062
analysis	I-T062
revealed	O
an	O
inverse	O
relationship	O
between	O
age	O
and	O
opioid	O
use	O
.	O

Similarly	O
,	O
there	O
was	O
a	O
trend	O
toward	O
more	O
opioid	O
consumption	O
among	O
self	O
-	O
pay	O
and	O
Medicaid	O
patients	O
.	O

Opioid	O
consumption	O
after	O
DRF	B-T037
-	O
ORIF	O
was	O
equivalent	O
for	O
general	B-T058
and	O
regional	O
anesthesia	O
.	O

A	O
significant	O
relationship	O
was	O
found	O
between	O
increasing	B-T033
age	I-T033
and	O
decreasing	B-T033
opioid	O
consumption	O
.	O

Worsening	O
fracture	B-T170
classification	I-T170
and	O
self	O
-	O
payment	O
/	O
Medicaid	O
payment	O
trended	O
toward	O
increasing	O
opioid	O
consumption	O
.	O

Mean	O
overall	O
opioid	O
consumption	O
(	O
morphine	B-T103
equivalence	O
)	O
was	O
58	O
.	O
5	O
mg	O
,	O
or	O
14	O
.	O
6	O
pills	B-T103
of	O
oxycodone	B-T103
/	I-T103
acetaminophen	I-T103
5	O
/	O
325	O
mg	O
.	O

Surgeons	B-T097
should	O
take	O
these	O
findings	O
into	O
account	O
when	O
optimizing	B-T058
opioid	B-T103
prescribing	O
after	O
DRF	B-T037
repair	B-T058
.	O

Entrapment	B-T038
of	O
the	O
posterior	B-T017
femoral	I-T017
cutaneous	I-T017
nerve	I-T017
and	O
its	O
inferior	B-T017
cluneal	I-T017
branches	I-T017
:	O
anatomical	B-T082
basis	I-T082
of	O
surgery	B-T091
for	O
inferior	B-T033
cluneal	I-T033
neuralgia	I-T033

The	O
apparent	O
failure	O
of	O
pudendal	B-T017
nerve	I-T017
surgery	B-T091
in	O
some	O
patients	O
has	O
led	O
us	O
to	O
suggest	O
the	O
possibility	O
of	O
entrapment	B-T038
of	O
other	O
adjacent	B-T017
nerve	I-T017
structures	I-T017
,	O
leading	O
to	O
the	O
concept	O
of	O
inferior	B-T033
cluneal	I-T033
neuralgia	I-T033
.	O

Via	O
its	O
numerous	O
collateral	B-T017
branches	I-T017
,	O
the	O
posterior	B-T017
femoral	I-T017
cutaneous	I-T017
nerve	I-T017
innervates	O
a	O
very	O
extensive	O
territory	O
including	O
the	O
posterior	B-T082
surface	I-T082
of	I-T082
the	I-T082
thigh	I-T082
,	O
the	O
infragluteal	B-T017
fold	I-T017
,	O
the	O
skin	B-T022
over	O
the	O
ischial	B-T017
tuberosity	I-T017
,	O
but	O
also	O
the	O
lateral	B-T082
anal	I-T082
region	I-T082
,	O
scrotum	B-T017
or	O
labium	B-T017
majus	I-T017
via	O
its	O
perineal	B-T017
branch	I-T017
.	O

We	O
described	O
the	O
pathophysiological	O
features	O
of	O
cluneal	B-T033
neuralgia	I-T033
,	O
the	O
surgical	B-T058
technique	I-T058
and	O
our	O
preliminary	O
results	O
.	O

We	O
performed	O
a	O
transmuscular	B-T058
approach	I-T058
leading	O
to	O
the	O
fat	B-T017
of	O
the	O
deep	O
gluteal	B-T082
region	I-T082
.	O

Exploration	B-T058
was	O
continued	O
cranially	O
underneath	O
the	O
piriformis	B-T017
,	O
looking	O
for	O
potential	O
entrapments	B-T038
affecting	O
the	O
posterior	B-T017
femoral	I-T017
cutaneous	I-T017
nerve	I-T017
and	O
the	O
sciatic	B-T017
nerve	I-T017
.	O

Nerve	B-T058
decompression	I-T058
on	O
the	O
lateral	B-T082
surface	I-T082
of	O
the	O
ischial	B-T017
tuberosity	I-T017
was	O
then	O
performed	O
.	O

A	O
constant	O
anatomical	B-T082
finding	I-T082
must	O
be	O
highlighted	O
:	O
the	O
presence	O
of	O
a	O
lateral	B-T017
fibrous	I-T017
expansion	B-T058
from	O
the	O
ischium	B-T017
passing	O
behind	O
the	O
nerves	B-T017
and	O
vessels	B-T017
,	O
especially	O
the	O
posterior	B-T017
femoral	I-T017
cutaneous	I-T017
nerve	I-T017
and	O
its	O
perineal	B-T017
branches	I-T017
.	O

In	O
our	O
patients	O
,	O
release	O
of	O
this	O
expansion	B-T058
allowed	O
decompression	B-T058
of	O
the	O
nerve	B-T038
trapped	I-T038
by	O
this	O
expansion	B-T058
.	O

Cluneal	B-T033
neuralgia	I-T033
constitutes	O
a	O
distinct	O
entity	O
of	O
perineal	B-T033
pain	I-T033
,	O
which	O
must	O
be	O
identified	O
and	O
distinguished	O
from	O
pudendal	B-T038
neuralgia	I-T038
.	O

Surgery	B-T091
should	O
be	O
performed	O
via	O
a	O
transgluteal	B-T082
approach	I-T082
.	O

A	O
lateral	B-T017
ischial	I-T017
obstacle	O
must	O
be	O
investigated	O
,	O
in	O
the	O
form	O
of	O
a	O
constant	O
fibrous	B-T017
expansion	B-T058
,	O
which	O
,	O
like	O
a	O
retinaculum	B-T017
,	O
can	O
cause	O
nerve	B-T038
entrapment	I-T038
.	O

Methods	B-T170
to	O
Study	B-T062
Autophagy	B-T038
in	O
Zebrafish	B-T204

Autophagy	B-T038
(	O
cellular	B-T038
self	I-T038
-	I-T038
eating	I-T038
)	O
is	O
a	O
highly	O
regulated	O
degradation	B-T038
process	I-T038
of	O
the	O
eukaryotic	B-T017
cell	I-T017
during	O
which	O
parts	O
of	O
the	O
cytoplasm	B-T017
are	O
delivered	O
into	O
,	O
and	O
broken	O
down	O
within	O
,	O
the	O
lysosomal	O
compartment	O
.	O

The	O
process	O
serves	O
as	O
a	O
main	O
route	O
for	O
the	O
elimination	B-T038
of	O
superfluous	O
and	O
damaged	O
cellular	B-T017
constituents	I-T017
,	O
thereby	O
mediating	O
macromolecular	B-T038
and	O
organellar	O
turnover	O
.	O

In	O
addition	O
to	O
maintaining	O
cellular	B-T038
homeostasis	I-T038
,	O
autophagy	B-T038
is	O
involved	O
in	O
various	O
other	O
cellular	B-T038
and	O
developmental	B-T038
processes	I-T038
by	O
degrading	B-T038
specific	O
regulatory	B-T103
proteins	I-T103
,	O
and	O
contributing	O
to	O
the	O
clearance	O
of	O
intracellular	B-T082
pathogens	O
.	O

The	O
physiological	O
roles	O
and	O
pathological	O
involvement	O
of	O
autophagy	B-T038
can	O
be	O
effectively	O
studied	O
in	O
divergent	O
eukaryotic	B-T204
model	O
systems	O
ranging	O
from	O
yeast	B-T204
to	O
mice	B-T204
.	O

Such	O
a	O
tractable	O
animal	B-T204
model	I-T204
applied	O
only	O
recently	O
for	O
autophagy	B-T038
researchis	O
the	O
zebrafish	B-T204
Danio	B-T204
rerio	I-T204
,	O
which	O
also	O
facilitates	O
the	O
analysis	B-T062
of	O
more	O
specific	O
biological	B-T038
processes	I-T038
such	O
as	O
tissue	B-T038
regeneration	I-T038
.	O

In	O
this	O
chapter	O
,	O
we	O
overview	O
the	O
main	O
methods	O
and	O
tools	O
that	O
are	O
used	O
to	O
monitor	O
autophagic	B-T017
structures	I-T017
and	O
to	O
assay	B-T058
autophagic	B-T038
responses	I-T038
in	O
this	O
vertebrate	B-T204
organism	I-T204
.	O

We	O
place	O
emphasis	O
on	O
genetic	B-T062
(	I-T062
functional	I-T062
)	I-T062
approaches	I-T062
applied	O
for	O
exploring	O
novel	O
cellular	B-T038
and	O
developmental	B-T038
roles	I-T038
of	O
the	O
autophagic	B-T038
process	I-T038
.	O

Healthcare	B-T058
usage	O
and	O
economic	O
impact	O
of	O
non	B-T033
-	I-T033
treated	I-T033
obesity	B-T038
in	O
Italy	B-T082
:	O
findings	O
from	O
a	O
retrospective	O
administrative	B-T033
and	O
clinical	B-T170
database	I-T170
analysis	B-T062

Investigate	O
the	O
prevalence	O
of	O
obesity	B-T038
in	O
Italy	B-T082
and	O
examine	O
its	O
resource	O
consumption	B-T033
and	O
economic	O
impact	O
on	O
the	O
Italian	B-T082
national	B-T170
healthcare	I-T170
system	I-T170
(	O
NHS	B-T170
)	O
.	O

Retrospective	O
,	O
observational	B-T062
and	O
real	B-T062
-	I-T062
life	I-T062
study	I-T062
.	O

Data	O
from	O
three	O
health	B-T092
units	I-T092
from	O
Northern	B-T082
(	O
Bergamo	B-T082
,	O
Lombardy	B-T082
)	O
,	O
Central	B-T082
(	O
Grosseto	B-T082
,	O
Tuscany	B-T082
)	O
and	O
Southern	B-T082
(	O
Naples	B-T082
,	O
Campania	B-T082
)	O
Italy	B-T082
.	O

All	O
patients	O
aged	O
≥18	O
years	O
with	O
at	O
least	O
one	O
recorded	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
measurement	O
between	O
1	O
January	O
2009	O
and	O
31	O
December	O
2012	O
were	O
included	O
.	O

Information	O
retrieved	O
from	O
the	O
databases	B-T170
included	O
primary	O
care	O
data	O
,	O
medical	B-T170
prescriptions	I-T170
,	O
specialist	B-T058
consultations	I-T058
and	O
hospital	B-T170
discharge	I-T170
records	I-T170
from	O
2009	O
-	O
2013	O
.	O

Costs	O
associated	O
with	O
these	O
data	O
were	O
also	O
calculated	O
.	O

Data	O
are	O
presented	O
for	O
two	O
time	O
periods	O
(	O
1	O
year	O
after	O
BMI	B-T201
measurement	O
and	O
study	O
end	O
)	O
.	O

Primary	O
-	O
to	O
estimate	O
health	O
resources	O
consumption	B-T033
and	O
the	O
associated	O
economic	O
impact	O
on	O
the	O
Italian	B-T082
NHS	B-T170
.	O

Secondary	O
-	O
the	O
prevalence	O
and	O
characteristics	O
of	O
subjects	B-T098
by	O
BMI	B-T201
category	B-T170
.	O

20	O
159	O
adult	O
subjects	B-T098
with	O
at	O
least	O
one	O
documented	B-T033
BMI	I-T033
measurement	O
.	O

Subjects	B-T098
with	O
BMI	B-T201
≥30	O
kg	O
/	O
m	O
(	O
2	O
)	O
were	O
defined	O
as	O
obese	B-T038
.	O

The	O
prevalence	O
of	O
obesity	B-T038
was	O
22	O
.	O
2	O
%	O
(	O
N	O
=	O
4471	O
)	O
and	O
increased	O
with	O
age	O
.	O

At	O
the	O
1	O
-	O
year	O
observation	B-T062
period	O
,	O
obese	B-T038
subjects	B-T098
who	O
did	O
not	O
receive	O
treatment	B-T058
for	O
their	O
obesity	B-T038
experienced	O
longer	O
durations	O
of	O
hospitalisation	B-T058
(	O
median	O
length	O
:	O
5	O
days	O
vs	O
3	O
days	O
)	O
,	O
used	O
more	O
prescription	B-T103
drugs	I-T103
(	O
75	O
.	O
0	O
%	O
vs	O
57	O
.	O
7	O
%	O
)	O
,	O
required	O
more	O
specialised	O
outpatient	O
healthcare	B-T058
(	O
mean	O
number	O
:	O
5	O
.	O
3	O
vs	O
4	O
.	O
4	O
)	O
and	O
were	O
associated	O
with	O
greater	O
costs	O
,	O
primarily	O
owing	O
to	O
prescription	B-T103
drugs	I-T103
and	O
hospital	B-T058
admissions	I-T058
(	O
mean	O
annual	O
cost	O
per	O
year	O
per	O
patient	O
:	O
€460	O
.	O
6	O
vs	O
€288	O
.	O
0	O
for	O
drug	B-T170
prescriptions	I-T170
,	O
€422	O
.	O
7	O
vs	O
€	O
279	O
.	O
2	O
for	O
hospitalisations	B-T058
and	O
€283	O
.	O
2	O
vs	O
€251	O
.	O
7	O
for	O
outpatient	B-T058
care	I-T058
)	O
,	O
compared	O
with	O
normal	B-T033
weight	I-T033
subjects	B-T098
.	O

Similar	O
findings	O
were	O
observed	O
for	O
the	O
period	O
up	O
to	O
data	O
cut	O
-	O
off	O
(	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
2	O
.	O
7	O
years	O
)	O
.	O

Untreated	B-T033
obesity	B-T038
has	O
a	O
significant	O
economic	O
impact	O
on	O
the	O
Italian	B-T082
healthcare	B-T170
system	I-T170
,	O
highlighting	O
the	O
need	O
to	O
raise	O
awareness	B-T038
and	O
proactively	O
treat	B-T058
obese	O
subjects	B-T098
.	O

Effects	O
of	O
heat	O
treatment	O
on	O
conformation	B-T082
and	O
cell	B-T038
growth	I-T038
activity	O
of	O
alpha	B-T103
-	I-T103
lactalbumin	I-T103
and	O
beta	B-T103
-	I-T103
lactoglobulin	I-T103
from	O
market	B-T082
milk	B-T168

Heat	O
processes	O
,	O
low	O
temperature	O
for	O
long	O
time	O
(	O
LTLT	O
)	O
pasteurization	O
and	O
ultra	B-T058
-	I-T058
heat	I-T058
treatment	I-T058
(	I-T058
UHT	I-T058
)	I-T058
sterilization	I-T058
,	O
are	O
essential	O
for	O
commercial	O
market	B-T082
milk	B-T168
to	O
improve	O
the	O
shelf	O
life	O
of	O
raw	O
milk	B-T168
and	O
ensure	O
microbial	O
safety	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
heat	O
experience	O
on	O
the	O
molecular	O
properties	O
of	O
α	B-T103
-	I-T103
lactalbumin	I-T103
(	O
α	B-T103
-	I-T103
LA	I-T103
)	O
and	O
β	B-T103
-	I-T103
lactoglobulin	I-T103
(	O
β	B-T103
-	I-T103
LG	I-T103
)	O
isolated	O
from	O
four	O
types	O
of	O
market	B-T082
milk	B-T168
such	O
as	O
LTLT	O
-	O
A	O
(	O
66°C	O
for	O
30	O
min	O
)	O
,	O
LTLT	O
-	O
B	O
(	O
65°C	O
for	O
30	O
min	O
)	O
,	O
UHT	B-T058
-	I-T058
I	I-T058
(	O
130°C	O
for	O
2	O
s	O
,	O
indirect	O
heating	O
)	O
and	O
UHT	B-T058
-	I-T058
D	I-T058
(	O
135°C	O
for	O
2	O
s	O
,	O
direct	O
heating	O
)	O
samples	O
.	O

We	O
examined	O
molecular	B-T082
conformations	I-T082
using	O
circular	B-T058
dichroism	I-T058
spectrum	I-T058
measurement	I-T058
and	O
cell	B-T038
growth	I-T038
activity	O
using	O
the	O
WST	B-T062
-	I-T062
1	I-T062
method	I-T062
for	O
the	O
proteins	B-T103
.	O

α	B-T103
-	I-T103
LA	I-T103
isolated	O
from	O
each	O
of	O
these	O
four	O
types	O
of	O
market	B-T082
milk	B-T168
displayed	O
no	B-T033
significant	I-T033
structural	B-T103
difference	O
as	O
compared	O
to	O
raw	O
milk	O
α	B-T103
-	I-T103
LA	I-T103
,	O
while	O
α	B-T103
-	I-T103
LA	I-T103
of	O
UHT	B-T058
-	I-T058
I	I-T058
only	O
inhibited	O
cell	B-T038
growth	I-T038
of	O
an	O
intestinal	B-T017
epithelial	B-T017
cell	I-T017
line	I-T017
more	O
potently	O
than	O
raw	O
milk	O
α	B-T103
-	I-T103
LA	I-T103
.	O

In	O
the	O
case	O
of	O
β	B-T103
-	I-T103
LG	I-T103
,	O
only	O
the	O
UHT	B-T058
-	I-T058
I	I-T058
sample	O
demonstrated	O
a	O
drastic	O
change	O
in	O
structure	B-T103
,	O
while	O
it	O
did	B-T033
not	I-T033
exhibit	I-T033
any	O
cytotoxicity	B-T038
.	O

We	O
found	O
that	O
cell	B-T038
viability	I-T038
effects	O
of	O
α	B-T103
-	I-T103
LA	I-T103
and	O
β	B-T103
-	I-T103
LG	I-T103
are	O
attributable	O
to	O
the	O
type	O
of	O
UHT	B-T058
;	O
indirect	O
and	O
direct	O
.	O

These	O
findings	B-T033
indicate	O
that	O
the	O
effect	O
of	O
heat	O
treatment	O
on	O
whey	B-T168
proteins	I-T168
should	O
carefully	O
be	O
investigated	O
further	O
.	O

Comparison	O
of	O
270	O
Versus	O
320	O
mg	O
I	O
/	O
mL	O
of	O
Iodixanol	O
in	O
1	O
Image	B-T058
Assessment	I-T058
of	O
Both	O
Renal	B-T017
Arteries	I-T017
and	O
Veins	B-T017
With	O
Dual	B-T058
-	I-T058
Energy	I-T058
Spectral	I-T058
CT	I-T058
Imaging	I-T058
in	O
Late	O
Arterial	O
Phase	O
and	O
Their	O
Influence	O
on	O
Renal	B-T038
Function	I-T038

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
compare	O
the	O
image	O
quality	O
of	O
renal	B-T017
arteries	I-T017
and	O
veins	B-T017
with	O
dual	B-T058
-	I-T058
energy	I-T058
spectral	I-T058
computed	I-T058
tomography	I-T058
(	I-T058
CT	I-T058
)	I-T058
imaging	I-T058
in	O
late	O
arterial	O
phase	O
using	O
270	O
and	O
320	O
mg	O
I	O
/	O
mL	O
of	O
iodixanol	O
and	O
their	O
influence	O
on	O
renal	B-T038
function	I-T038
.	O

A	O
total	O
of	O
1062	O
patients	O
underwent	O
renal	B-T058
CT	I-T058
angiography	I-T058
with	O
270	O
or	O
320	O
mg	O
I	O
/	O
mL	O
of	O
iodixanol	O
with	O
dual	B-T058
-	I-T058
energy	I-T058
spectral	I-T058
CT	I-T058
imaging	I-T058
in	O
late	O
arterial	O
phase	O
.	O

Image	O
quality	O
and	O
their	O
influence	O
on	O
renal	B-T038
function	I-T038
were	O
compared	O
.	O

There	O
were	O
no	O
significant	O
differences	O
of	O
CT	O
value	O
,	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
contrast	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
and	O
subjective	O
score	O
of	O
renal	B-T017
vessels	I-T017
between	O
2	O
groups	O
(	O
all	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
incidence	O
of	O
contrast	B-T038
-	I-T038
induced	I-T038
nephropathy	I-T038
in	O
patients	O
with	O
abnormal	B-T038
renal	I-T038
function	I-T038
using	O
320	O
mg	O
I	O
/	O
mL	O
of	O
iodixanol	O
was	O
significantly	O
higher	O
than	O
using	O
270	O
mg	O
I	O
/	O
mL	O
of	O
iodixanol	O
(	O
P	O
=	O
0	O
.	O
043	O
)	O
.	O

The	O
renal	B-T017
arteries	I-T017
and	O
veins	B-T017
can	O
be	O
fully	O
assessed	O
in	O
late	O
arterial	O
phase	O
with	O
270	O
mg	O
I	O
/	O
mL	O
of	O
iodixanol	O
using	O
dual	B-T058
-	I-T058
energy	I-T058
spectral	I-T058
CT	I-T058
scan	I-T058
with	O
better	O
preserved	O
renal	B-T038
function	I-T038
.	O

Effect	O
of	O
magnesium	B-T058
supplementation	I-T058
on	O
depression	B-T038
status	B-T033
in	O
depressed	B-T038
patients	O
with	O
magnesium	B-T038
deficiency	I-T038
:	O
A	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	B-T062
-	I-T062
controlled	I-T062
trial	I-T062

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
magnesium	B-T058
supplementation	I-T058
on	O
the	O
depression	B-T038
status	B-T033
of	O
depressed	B-T038
patients	O
suffering	B-T033
from	O
magnesium	B-T038
deficiency	I-T038
.	O

Sixty	B-T033
depressed	I-T033
people	I-T033
suffering	B-T033
from	O
hypomagnesemia	B-T033
participated	O
in	O
this	B-T062
trial	I-T062
.	O

The	O
individuals	B-T098
were	O
randomly	B-T062
categorized	I-T062
into	O
two	O
groups	O
of	O
30	O
members	O
;	O
one	O
receiving	O
two	O
250	O
-	O
mg	O
tablets	B-T103
of	I-T103
magnesium	I-T103
oxide	I-T103
(	O
MG	B-T103
)	O
daily	O
and	O
the	O
other	O
receiving	O
placebo	B-T103
(	O
PG	B-T103
)	O
for	O
8	O
wk	O
.	O

The	O
Beck	B-T058
Depression	I-T058
Inventory	I-T058
-	I-T058
II	I-T058
was	O
conducted	O
and	O
the	O
concentration	O
of	O
serum	B-T058
magnesium	I-T058
was	I-T058
measured	I-T058
.	O

At	O
the	O
end	O
of	O
intervention	O
,	O
88	O
.	O
5	O
%	O
of	O
the	O
MG	B-T103
and	O
48	O
.	O
1	O
%	O
of	O
the	O
PG	B-T103
(	O
P	O
=	O
0	O
.	O
002	O
)	O
had	O
a	O
normal	B-T033
level	I-T033
of	I-T033
magnesium	I-T033
.	O

The	O
mean	O
changes	B-T033
of	I-T033
serum	I-T033
magnesium	I-T033
were	O
significantly	O
different	O
across	O
the	O
two	O
groups	O
.	O

After	O
the	O
intervention	O
,	O
the	O
mean	B-T201
Beck	I-T201
score	I-T201
significantly	O
declined	O
.	O

However	O
,	O
in	O
the	O
MG	B-T103
,	O
this	O
reduction	O
was	O
more	O
significant	O
than	O
in	O
the	O
PG	B-T103
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
so	O
that	O
the	O
mean	O
changes	O
in	O
this	O
group	O
experienced	O
15	O
.	O
65	O
±	O
8	O
.	O
9	O
reduction	O
,	O
but	O
in	O
the	O
PG	B-T103
,	O
it	O
declined	O
by	O
10	O
.	O
40	O
±	O
7	O
.	O
9	O
.	O

Daily	O
consumption	O
of	O
500	O
mg	O
magnesium	B-T103
oxide	I-T103
tablets	I-T103
for	O
≥8	O
wk	O
by	O
depressed	B-T038
patients	O
suffering	B-T033
from	O
magnesium	B-T038
deficiency	I-T038
leads	O
to	O
improvements	O
in	O
depression	B-T038
status	B-T033
and	O
magnesium	B-T033
levels	I-T033
.	O

Therefore	O
,	O
assessment	B-T058
of	I-T058
the	I-T058
magnesium	I-T058
serum	I-T058
and	O
resolving	O
this	O
deficiency	B-T038
positively	O
influence	O
the	O
treatment	B-T058
of	O
depressed	B-T038
patients	O
.	O

The	O
influence	O
of	O
cognitive	O
load	O
on	O
metabolic	B-T038
cost	O
of	O
transport	O
during	O
overground	O
walking	O
in	O
healthy	O
,	O
young	O
adults	O

Our	O
aim	O
was	O
to	O
examine	O
whether	O
cognitive	B-T038
processing	I-T038
during	O
walking	O
increases	O
the	O
metabolic	B-T038
cost	O
of	O
transport	O
in	O
healthy	O
young	O
adults	O
.	O

Twenty	O
healthy	O
,	O
young	O
adults	O
completed	O
five	O
conditions	O
:	O
(	O
1	O
)	O
walking	O
at	O
a	O
self	O
-	O
selected	O
speed	O
(	O
spontaneous	O
single	O
-	O
task	O
)	O
,	O
(	O
2	O
)	O
seated	B-T033
resting	O
(	O
baseline	O
)	O
,	O
(	O
3	O
)	O
performing	O
cognitive	B-T038
task	O
while	O
seated	B-T033
(	O
cognitive	B-T038
single	O
-	O
task	O
)	O
,	O
(	O
4	O
)	O
walking	O
while	O
simultaneously	O
performing	O
the	O
cognitive	B-T038
task	O
(	O
dual	O
-	O
task	O
)	O
,	O
and	O
(	O
5	O
)	O
single	O
-	O
task	O
walking	O
at	O
a	O
speed	O
that	O
matched	O
the	O
participant	B-T098
'	I-T098
s	I-T098
dual	O
-	O
task	O
gait	O
speed	O
(	O
matched	O
single	O
-	O
task	O
)	O
.	O

Rate	O
of	O
oxygen	O
consumption	O
(	O
V̇O2	O
)	O
was	O
recorded	O
during	O
all	O
conditions	O
.	O

Gait	O
speed	O
and	O
cost	O
of	O
walking	O
(	O
Cw	O
;	O
oxygen	B-T201
consumed	I-T201
per	I-T201
distance	I-T201
traveled	I-T201
)	O
were	O
recorded	O
during	O
all	O
walking	O
conditions	O
.	O

Reaction	O
time	O
and	O
accuracy	O
of	O
responses	O
in	O
the	O
cognitive	B-T038
task	O
were	O
recorded	O
during	O
all	O
cognitive	B-T038
task	O
conditions	O
.	O

Data	O
from	O
the	O
fifth	O
minute	O
of	O
each	O
5	O
-	O
min	O
condition	O
were	O
analyzed	B-T062
.	O

There	O
was	O
no	O
difference	O
in	O
V̇O2	O
between	O
the	O
dual	O
-	O
task	O
and	O
matched	O
single	O
-	O
task	O
walking	O
conditions	O
.	O

V̇O2	O
in	O
the	O
seated	B-T033
cognitive	B-T038
condition	O
was	O
significantly	O
smaller	O
than	O
both	O
walking	O
conditions	O
,	O
but	O
was	O
not	O
significantly	O
different	O
than	O
zero	O
.	O

Cw	O
was	O
significantly	O
greater	O
during	O
the	O
matched	O
single	O
-	O
task	O
walking	O
condition	O
than	O
during	O
the	O
dual	O
-	O
task	O
walking	O
condition	O
.	O

However	O
,	O
the	O
difference	O
in	O
Cw	O
was	O
so	O
small	O
that	O
it	O
is	O
unlikely	O
to	O
be	O
clinically	O
significant	O
(	O
0	O
.	O
008	O
mLO2	O
/	O
kg	O
/	O
m	O
,	O
95	O
%	O
CI	O
0	O
.	O
002	O
-	O
0	O
.	O
014	O
)	O
.	O

Cognitive	B-T038
processing	I-T038
while	O
walking	O
may	O
not	O
increase	O
energy	O
demands	O
of	O
walking	O
in	O
healthy	O
young	O
adults	O
.	O

Maintaining	O
non	O
-	O
preferred	O
gait	O
speed	O
(	O
matched	O
speed	O
)	O
overground	O
continuously	O
for	O
5	O
min	O
may	O
require	O
attentional	B-T038
resources	O
,	O
and	O
thereby	O
increase	O
metabolic	B-T038
costs	O
relative	O
to	O
walking	O
at	O
habitual	O
speed	O
.	O

Problem	O
-	O
based	O
learning	O
using	O
patient	B-T170
-	I-T170
simulated	I-T170
videos	I-T170
showing	O
daily	O
life	O
for	O
a	O
comprehensive	O
clinical	O
approach	O

We	O
examined	O
whether	O
problem	O
-	O
based	O
learning	O
tutorials	B-T170
using	O
patient	B-T170
-	I-T170
simulated	I-T170
videos	I-T170
showing	O
daily	O
life	O
are	O
more	O
practical	O
for	O
clinical	O
learning	B-T038
,	O
compared	O
with	O
traditional	O
paper	O
-	O
based	O
problem	O
-	O
based	O
learning	O
,	O
for	O
the	O
consideration	O
rate	B-T033
of	I-T033
psychosocial	I-T033
issues	I-T033
and	O
the	O
recall	B-T033
rate	I-T033
for	O
experienced	B-T038
learning	I-T038
.	O

Twenty	O
-	O
two	O
groups	O
with	O
120	O
fifth	O
-	O
year	O
students	B-T098
were	O
each	O
assigned	O
paper	O
-	O
based	O
problem	O
-	O
based	O
learning	O
and	O
video	B-T170
-	O
based	O
problem	O
-	O
based	O
learning	O
using	O
patient	B-T170
-	I-T170
simulated	I-T170
videos	I-T170
.	O

We	O
compared	O
target	O
achievement	B-T033
rates	I-T033
in	O
questionnaires	B-T170
using	O
the	O
Wilcoxon	B-T170
signed	I-T170
-	I-T170
rank	I-T170
test	I-T170
and	O
discussion	O
contents	O
diversity	O
using	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

A	O
follow	B-T062
-	I-T062
up	I-T062
survey	B-T170
used	O
a	O
chi	B-T170
-	I-T170
square	I-T170
test	I-T170
to	O
measure	O
students	B-T098
'	O
recall	O
of	O
cases	O
in	O
three	O
categories	B-T170
:	O
video	B-T170
,	O
paper	O
,	O
and	O
non	O
-	O
experienced	O
.	O

Video	B-T170
-	O
based	O
problem	O
-	O
based	O
learning	O
displayed	O
significantly	O
higher	O
achievement	B-T033
rates	I-T033
for	O
imagining	O
authentic	O
patients	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
incorporating	O
a	O
comprehensive	O
approach	O
including	O
psychosocial	O
aspects	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
satisfaction	O
with	O
sessions	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

No	O
significant	O
differences	O
existed	O
in	O
the	O
discussion	O
contents	O
diversity	O
regarding	O
the	O
International	O
Classification	O
of	O
Primary	O
Care	O
Second	O
Edition	O
codes	O
and	O
chapter	O
types	O
or	O
in	O
the	O
rate	B-T033
of	I-T033
psychological	I-T033
codes	I-T033
.	O

In	O
a	O
follow	B-T062
-	I-T062
up	I-T062
survey	B-T170
comparing	O
video	B-T170
and	O
paper	O
groups	O
to	O
non	O
-	O
experienced	O
groups	O
,	O
the	O
rates	O
were	O
higher	O
for	O
video	B-T170
(	O
χ	O
(	O
2	O
)	O
=	O
24	O
.	O
319	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
paper	O
(	O
χ	O
(	O
2	O
)	O
=	O
11	O
.	O
134	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Although	O
the	O
video	B-T170
rate	O
tended	O
to	O
be	O
higher	O
than	O
the	O
paper	O
rate	O
,	O
no	O
significant	O
difference	O
was	O
found	O
between	O
the	O
two	O
.	O

Patient	B-T170
-	I-T170
simulated	I-T170
videos	I-T170
showing	O
daily	O
life	O
facilitate	O
imagining	O
true	O
patients	O
and	O
support	O
a	O
comprehensive	O
approach	O
that	O
fosters	O
better	O
memory	B-T038
.	O

The	O
clinical	O
patient	B-T170
-	I-T170
simulated	I-T170
video	I-T170
method	O
is	O
more	O
practical	O
and	O
clinical	O
problem	B-T170
-	I-T170
based	I-T170
tutorials	I-T170
can	O
be	O
implemented	O
if	O
we	O
create	O
patient	B-T170
-	I-T170
simulated	I-T170
videos	I-T170
for	O
each	O
symptom	B-T033
as	O
teaching	O
materials	O
.	O

Forensic	O
characteristics	O
and	O
phylogenetic	B-T062
analyses	I-T062
of	O
the	O
Chinese	B-T098
Yi	B-T098
population	I-T098
via	O
19	O
X	B-T017
-	I-T017
chromosomal	I-T017
STR	B-T082
loci	B-T017

The	O
demographic	O
characteristics	O
and	O
genetic	B-T038
polymorphism	I-T038
data	O
of	O
56	O
Chinese	B-T098
nationalities	O
or	O
31	O
administrative	B-T092
divisions	I-T092
in	O
Chinese	B-T082
mainland	I-T082
have	O
repeatedly	O
been	O
the	O
genetic	B-T062
research	I-T062
hotspots	B-T082
.	O

While	O
most	O
genetic	B-T062
studies	I-T062
focused	O
on	O
some	O
particular	O
Chinese	B-T098
populations	B-T098
based	O
on	O
autosomal	B-T017
or	O
Y	B-T017
-	I-T017
chromosomal	I-T017
genetic	B-T038
markers	I-T038
,	O
the	O
forensic	O
characteristics	O
and	O
phylogenetic	B-T062
analyses	I-T062
of	O
the	O
seventh	O
largest	O
Chinese	B-T098
population	B-T098
(	O
Yi	B-T098
ethnicity	I-T098
)	O
on	O
the	O
X	B-T017
-	I-T017
chromosomal	I-T017
genetic	B-T038
markers	I-T038
are	O
scarce	O
.	O

Here	O
,	O
allele	O
frequencies	O
and	O
forensic	B-T033
statistical	I-T033
parameters	I-T033
for	O
19	O
X	B-T017
-	I-T017
chromosomal	I-T017
short	B-T082
tandem	I-T082
repeat	I-T082
loci	B-T017
(	O
DXS7424	B-T017
-	I-T017
DXS101	I-T017
,	O
DXS6789	B-T017
-	I-T017
DXS6809	I-T017
,	O
DXS7423	B-T017
-	I-T017
DXS10134	I-T017
,	O
DXS10103	B-T017
-	I-T017
HPRTB	I-T017
-	I-T017
DXS10101	I-T017
,	O
DXS10159	B-T017
-	I-T017
DXS10162	I-T017
-	I-T017
DXS10164	I-T017
,	O
DXS10148	B-T017
-	I-T017
DXS10135	I-T017
-	I-T017
DXS8378	I-T017
,	O
and	O
DXS7132	B-T017
-	I-T017
DXS10079	I-T017
-	I-T017
DXS10074	I-T017
-	I-T017
DXS10075	I-T017
)	O
of	O
331	O
Chinese	B-T098
Yi	B-T098
individuals	I-T098
were	O
obtained	O
.	O

All	O
19	O
X	B-T017
-	I-T017
chromosomal	I-T017
short	B-T082
tandem	I-T082
repeat	I-T082
(	O
STR	B-T082
)	O
loci	B-T017
in	O
females	B-T098
were	O
consistent	O
with	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
test	O
.	O

A	O
total	O
of	O
214	O
alleles	B-T017
were	O
identified	O
with	O
the	O
corresponding	O
allele	O
frequencies	O
spanned	O
from	O
0	O
.	O
0019	O
to	O
0	O
.	O
6106	O
.	O

The	O
combined	O
PE	O
,	O
PDF	O
,	O
and	O
PDM	O
were	O
0	O
.	O
9999999214	O
,	O
0	O
.	O
9999999999999999999993	O
,	O
and	O
0	O
.	O
9999999999998	O
,	O
respectively	O
.	O

The	O
high	O
combined	O
MECKrüger	O
,	O
MECKishida	O
,	O
MECDesmarais	O
,	O
and	O
MECDesmarais	O
Duo	O
were	O
achieved	O
as	O
0	O
.	O
9999999617638	O
,	O
0	O
.	O
9999999999971	O
,	O
0	O
.	O
9999999999971	O
,	O
and	O
0	O
.	O
9999999931538	O
,	O
respectively	O
.	O

The	O
findings	B-T033
suggested	O
that	O
the	O
panel	O
of	O
19	O
X	B-T082
-	I-T082
STR	I-T082
loci	B-T017
is	O
highly	O
polymorphic	O
and	O
informative	O
in	O
the	O
Yi	B-T098
ethnic	I-T098
population	I-T098
and	O
can	O
be	O
considered	O
to	O
be	O
a	O
powerful	O
tool	O
in	O
forensic	O
complex	O
kinship	O
identification	O
.	O

Population	B-T062
differentiation	I-T062
analyses	I-T062
among	O
12	O
populations	B-T098
indicated	O
that	O
significant	O
differences	O
in	O
genetic	B-T017
structure	I-T017
were	O
observed	O
in	O
between	O
the	O
Yi	B-T098
ethnicity	I-T098
and	O
the	O
Chinese	B-T098
Uyghur	B-T098
as	O
well	O
as	O
Kazakh	B-T098
,	O
and	O
genetic	O
homogeneity	O
existed	O
in	O
similar	O
ethno	B-T098
-	I-T098
origin	I-T098
or	O
geographic	O
origin	O
populations	O
.	O

Loss	O
of	O
Snf5	B-T017
Induces	O
Formation	O
of	O
an	O
Aberrant	O
SWI	B-T017
/	I-T017
SNF	I-T017
Complex	I-T017

The	O
SWI	B-T017
/	I-T017
SNF	I-T017
chromatin	B-T017
remodeling	I-T017
complex	I-T017
is	O
highly	O
conserved	O
from	O
yeast	B-T204
to	O
human	B-T204
,	O
and	O
aberrant	O
SWI	B-T017
/	I-T017
SNF	I-T017
complexes	I-T017
contribute	O
to	O
human	B-T204
disease	B-T038
.	O

The	O
Snf5	B-T017
/	I-T017
SMARCB1	I-T017
/	I-T017
INI1	I-T017
subunit	O
of	O
SWI	B-T017
/	I-T017
SNF	I-T017
is	O
a	O
tumor	B-T017
suppressor	I-T017
frequently	O
lost	O
in	O
pediatric	O
rhabdoid	B-T038
cancers	I-T038
.	O

We	O
examined	O
the	O
effects	O
of	O
Snf5	B-T017
loss	O
on	O
the	O
composition	B-T033
,	O
nucleosome	B-T038
binding	I-T038
,	O
recruitment	O
,	O
and	O
remodeling	O
activities	O
of	O
yeast	B-T204
SWI	B-T017
/	I-T017
SNF	I-T017
.	O

The	O
Snf5	B-T017
subunit	O
is	O
shown	O
by	O
crosslinking	B-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
(	O
CX	B-T058
-	I-T058
MS	I-T058
)	O
and	O
subunit	O
deletion	B-T058
analysis	I-T058
to	O
interact	O
with	O
the	O
ATPase	B-T082
domain	I-T082
of	O
Snf2	B-T103
and	O
to	O
form	O
a	O
submodule	B-T038
consisting	O
of	O
Snf5	B-T017
,	O
Swp82	B-T017
,	O
and	O
Taf14	B-T017
.	O

Snf5	B-T017
promotes	O
binding	B-T038
of	O
the	O
Snf2	B-T103
ATPase	B-T082
domain	I-T082
to	O
nucleosomal	B-T038
DNA	I-T038
and	O
enhances	O
the	O
catalytic	O
and	O
nucleosome	O
remodeling	O
activities	O
of	O
SWI	B-T017
/	I-T017
SNF	I-T017
.	O

Snf5	B-T017
is	O
also	O
required	O
for	O
SWI	B-T017
/	I-T017
SNF	I-T017
recruitment	O
by	O
acidic	B-T103
transcription	I-T103
factors	I-T103
.	O

RNA	B-T058
-	I-T058
seq	I-T058
analysis	I-T058
suggests	O
that	O
both	O
the	O
recruitment	O
and	O
remodeling	O
functions	O
of	O
Snf5	B-T017
are	O
required	O
in	B-T082
vivo	I-T082
for	O
SWI	B-T017
/	I-T017
SNF	I-T017
regulation	B-T038
of	I-T038
gene	I-T038
expression	I-T038
.	O

Thus	O
,	O
loss	O
of	O
SNF5	B-T017
alters	O
the	O
structure	B-T082
and	O
function	O
of	O
SWI	B-T017
/	I-T017
SNF	I-T017
.	O

Identifying	O
the	O
presence	B-T033
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
using	O
low	O
-	O
frequency	O
fluctuations	B-T033
in	O
BOLD	B-T058
signals	I-T058

Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
is	O
a	O
chronic	O
,	O
progressive	O
,	O
and	O
degenerative	O
neurological	B-T038
disorder	I-T038
that	O
is	O
characterized	O
by	O
the	O
degeneration	O
of	O
dopamine	B-T017
neurons	I-T017
in	O
the	O
substantia	B-T017
nigra	I-T017
and	O
the	O
formation	O
of	O
intracellular	B-T082
Lewy	B-T017
inclusion	I-T017
bodies	I-T017
.	O

Resting	B-T058
-	I-T058
state	I-T058
functional	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
(	O
RS	B-T058
-	I-T058
fMRI	I-T058
)	O
has	O
demonstrated	O
evidence	O
of	O
changes	O
in	O
metabolic	O
patterns	B-T082
in	O
individuals	B-T098
with	O
PD	B-T038
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
whether	O
the	O
presence	B-T033
of	O
PD	B-T038
could	O
be	O
"	O
predicted	O
"	O
based	O
on	O
resting	O
fluctuations	B-T033
in	O
the	O
blood	B-T038
oxygenation	I-T038
level	I-T038
dependent	I-T038
signal	I-T038
.	O

We	O
utilized	O
RS	B-T058
-	I-T058
fMRI	I-T058
to	O
measure	O
the	O
amplitude	B-T082
of	O
low	O
-	O
frequency	O
fluctuation	B-T033
(	O
ALFF	B-T033
)	O
and	O
the	O
fractional	O
ALFF	B-T033
(	O
fALFF	B-T033
)	O
in	O
51	O
patients	O
with	O
PD	B-T038
and	O
50	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
the	O
individuals	B-T098
with	O
PD	B-T038
exhibited	O
altered	O
ALFFs	B-T033
in	O
the	O
bilateral	B-T082
lingual	B-T017
gyrus	I-T017
and	O
left	B-T017
putamen	I-T017
and	O
an	O
altered	O
fALFF	B-T033
in	O
the	O
right	B-T082
cerebellum	I-T082
posterior	I-T082
lobe	I-T082
.	O

Support	O
vector	O
machines	O
(	O
SVMs	O
)	O
,	O
which	O
comprise	O
a	O
supervised	O
pattern	B-T038
recognition	I-T038
method	B-T170
that	O
enables	O
predictions	O
at	O
the	O
individual	B-T098
level	O
,	O
were	O
trained	O
to	O
separate	O
individuals	B-T098
with	O
PD	B-T038
from	O
healthy	O
controls	O
based	O
on	O
the	O
ALFF	B-T033
and	O
fALFF	B-T033
.	O

Using	O
the	O
leave	O
-	O
one	O
-	O
out	O
cross	B-T062
-	I-T062
validation	I-T062
method	I-T062
to	O
analyze	B-T062
our	O
sample	O
,	O
we	O
reliably	O
distinguished	O
the	O
participants	B-T098
with	O
PD	B-T038
from	O
the	O
controls	O
with	O
92	O
%	O
sensitivity	O
and	O
87	O
%	O
specificity	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
SVM	O
-	O
neuroimaging	B-T058
approach	O
may	O
be	O
of	O
particular	O
clinical	O
value	O
because	O
it	O
enables	O
the	O
accurate	O
identification	O
of	O
PD	B-T038
at	O
the	O
individual	B-T098
level	O
.	O

RS	B-T058
-	I-T058
fMRI	I-T058
should	O
be	O
considered	O
for	O
development	O
as	O
a	O
biomarker	B-T201
and	O
an	O
analytical	O
tool	O
for	O
the	O
evaluation	B-T058
of	O
PD	B-T038
.	O

Methylation	B-T038
dynamics	O
during	O
folliculogenesis	B-T038
and	O
early	O
embryo	B-T038
development	I-T038
in	O
sheep	B-T204

Genome	B-T017
-	O
wide	O
DNA	B-T038
methylation	I-T038
reprogramming	O
occurs	O
during	O
mammalian	B-T204
gametogenesis	B-T038
and	O
early	O
embryogenesis	B-T038
.	O

Post	O
-	O
fertilization	B-T038
demethylation	B-T038
of	O
paternal	O
and	O
maternal	B-T033
genomes	B-T017
is	O
considered	O
to	O
occur	O
by	O
an	O
active	O
and	O
passive	O
mechanism	O
respectively	O
,	O
in	O
most	O
mammals	B-T204
but	O
sheep	B-T204
;	O
in	O
this	O
species	O
no	O
loss	O
of	O
methylation	B-T038
was	O
observed	O
in	O
either	O
pronucleus	B-T017
.	O

Post	O
-	O
fertilization	B-T038
reprogramming	O
relies	O
on	O
methylating	B-T103
and	O
demethylating	B-T103
enzymes	I-T103
and	O
co	O
-	O
factors	O
that	O
are	O
stored	O
during	O
oocyte	B-T038
growth	I-T038
,	O
concurrently	O
with	O
the	O
re	B-T038
-	I-T038
methylation	I-T038
of	O
the	O
oocyte	B-T017
itself	O
.	O

The	O
crucial	O
remodelling	O
of	O
the	O
oocyte	B-T017
epigenetic	O
baggage	O
often	O
overlaps	O
with	O
potential	O
interfering	O
events	O
such	O
as	O
exposure	O
to	O
assisted	O
reproduction	B-T058
technologies	I-T058
or	O
environmental	O
changes	O
.	O

Here	O
,	O
we	O
report	O
a	O
temporal	O
analysis	O
of	O
methylation	B-T038
dynamics	O
during	O
folliculogenesis	B-T038
and	O
early	O
embryo	B-T038
development	I-T038
in	O
sheep	B-T204
.	O

We	O
characterized	O
global	O
DNA	B-T038
methylation	I-T038
and	O
hydroxymethylation	B-T038
by	O
immunofluorescence	B-T058
and	O
relatively	O
quantified	O
the	O
expression	B-T038
of	O
the	O
enzymes	B-T103
and	O
co	O
-	O
factors	O
mainly	O
responsible	O
for	O
their	O
remodelling	O
(	O
DNA	B-T103
methyltransferases	I-T103
(	O
DNMTs	B-T103
)	O
,	O
ten	B-T103
-	I-T103
eleven	I-T103
translocation	I-T103
(	I-T103
TET	I-T103
)	I-T103
proteins	I-T103
and	O
methyl	B-T082
-	I-T082
CpG	I-T082
-	I-T082
binding	I-T082
domain	I-T082
(	O
MBD	B-T082
)	O
proteins	B-T103
)	O
.	O

Our	O
results	O
illustrate	O
for	O
the	O
first	O
time	O
the	O
patterns	O
of	O
hydroxymethylation	B-T038
during	O
oocyte	B-T038
growth	I-T038
.	O

We	O
observed	O
different	O
patterns	O
of	O
methylation	B-T038
and	O
hydroxymethylation	B-T038
between	O
the	O
two	O
parental	B-T017
pronuclei	I-T017
,	O
suggesting	O
that	O
male	B-T017
pronucleus	I-T017
undergoes	O
active	O
demethylation	B-T038
also	O
in	O
sheep	B-T204
.	O

Finally	O
,	O
we	O
describe	O
gene	B-T017
-	O
specific	O
accumulation	O
dynamics	O
for	O
methylating	B-T103
and	O
demethylating	B-T103
enzymes	I-T103
during	O
oocyte	B-T038
growth	I-T038
and	O
observe	O
patterns	O
of	O
expression	B-T038
associated	O
with	O
developmental	O
competence	O
in	O
a	O
differential	O
model	O
of	O
oocyte	B-T017
potential	O
.	O

Our	O
work	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
methylation	B-T038
dynamics	O
during	O
folliculogenesis	B-T038
and	O
early	O
embryo	B-T038
development	I-T038
and	O
improves	O
the	O
overall	O
picture	O
of	O
early	O
rearrangements	O
that	O
will	O
originate	O
the	O
embryo	B-T017
epigenome	B-T017
.	O

Network	O
analysis	B-T062
reveals	O
why	O
Xylella	B-T007
fastidiosa	I-T007
will	O
persist	O
in	O
Europe	B-T082

The	O
insect	B-T204
vector	I-T204
borne	O
bacterium	B-T007
Xylella	B-T007
fastidiosa	I-T007
was	O
first	O
detected	O
in	O
olive	B-T204
trees	I-T204
in	O
Southern	B-T082
Italy	I-T082
in	O
2013	O
,	O
and	O
identified	O
as	O
the	O
main	O
culprit	O
behind	O
the	O
'	O
olive	B-T038
quick	I-T038
decline	I-T038
syndrome	I-T038
'	O
.	O

Since	O
then	O
,	O
the	O
disease	B-T038
has	O
spread	O
rapidly	O
through	O
Italy	B-T082
'	I-T082
s	I-T082
main	O
olive	B-T103
oil	I-T103
producing	O
region	B-T082
.	O

The	O
epidemiology	B-T062
of	O
the	O
outbreak	O
is	O
largely	O
unstudied	O
,	O
with	O
the	O
list	O
of	O
X	B-T007
.	I-T007

fastidiosa	I-T007
hosts	O
and	O
vectors	B-T204
in	O
Europe	B-T082
likely	O
incomplete	O
,	O
and	O
the	O
role	O
humans	B-T204
play	O
in	O
dispersal	O
unknown	O
.	O

These	O
knowledge	B-T170
gaps	B-T082
have	O
led	O
to	O
management	O
strategies	O
based	O
on	O
general	O
assumptions	O
that	O
require	O
,	O
among	O
others	O
,	O
local	O
vector	O
control	O
and	O
,	O
in	O
certain	O
areas	O
,	O
the	O
destruction	O
of	O
infected	B-T204
plants	I-T204
and	O
healthy	O
ones	O
around	O
them	O
in	O
an	O
attempt	O
to	O
eradicate	O
or	O
halt	O
the	O
spreading	O
pest	B-T038
.	O

Here	O
we	O
show	O
that	O
,	O
regardless	O
of	O
epidemiological	O
uncertainties	B-T033
,	O
the	O
mere	O
distribution	O
of	O
olive	B-T204
orchards	O
in	O
Southern	B-T082
Italy	I-T082
makes	O
the	O
chances	O
of	O
eradicating	O
X	B-T007
.	I-T007

fastidiosa	I-T007
from	O
the	O
region	B-T082
extremely	O
slim	O
.	O

Our	O
results	O
imply	O
that	O
Southern	B-T082
Italy	I-T082
is	O
becoming	O
a	O
reservoir	B-T082
for	O
X	B-T007
.	I-T007

fastidiosa	I-T007
.	O

As	O
a	O
consequence	O
,	O
management	O
strategies	O
should	O
keep	O
the	O
prevalence	O
of	O
X	B-T007
.	I-T007

fastidiosa	I-T007
in	O
the	O
region	B-T082
as	O
low	O
as	O
possible	O
,	O
primarily	O
through	O
vector	O
control	O
,	O
lest	O
the	O
pathogen	O
,	O
that	O
has	O
also	O
been	O
detected	O
in	O
southern	B-T082
France	I-T082
and	O
the	O
island	B-T082
of	I-T082
Mallorca	I-T082
(	O
Spain	B-T082
)	O
,	O
continues	O
spreading	O
through	O
Italy	B-T082
and	O
Europe	B-T082
.	O

Novel	O
biomarkers	B-T201
for	O
patients	O
with	O
idiopathic	O
acute	B-T038
anterior	I-T038
uveitis	I-T038
:	O
neutrophil	B-T017
to	O
lymphocyte	B-T017
ratio	O
and	O
platelet	B-T017
to	O
lymphocyte	B-T017
ratio	O

To	O
assess	O
the	O
levels	O
of	O
the	O
neutrophil	B-T017
to	O
lymphocyte	B-T017
ratio	O
(	O
N	B-T017
/	O
L	B-T017
)	O
and	O
the	O
platelet	B-T017
to	O
lymphocyte	B-T017
ratio	O
(	O
P	B-T017
/	O
L	B-T017
)	O
in	O
patients	O
with	O
idiopathic	O
acute	B-T038
anterior	I-T038
uveitis	I-T038
(	O
AAU	B-T038
)	O
and	O
to	O
compare	O
with	O
healthy	O
controls	O
.	O

Thirty	O
-	O
six	O
male	B-T098
patients	O
with	O
idiopathic	O
AAU	B-T038
and	O
36	O
male	B-T098
healthy	O
subjects	B-T098
were	O
enrolled	O
in	O
this	O
retrospective	B-T062
study	I-T062
.	O

Complete	O
ophthalmological	B-T058
examination	I-T058
and	O
complete	O
blood	B-T058
count	I-T058
measurements	I-T058
results	O
of	O
all	O
subjects	B-T098
were	O
evaluated	B-T058
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
N	B-T017
/	O
L	B-T017
and	O
P	B-T017
/	O
L	B-T017
between	O
idiopathic	O
AAU	B-T038
and	O
control	O
groups	O
(	O
P	O
=	O
0	O
.	O
006	O
,	O
P	O
=	O
0	O
.	O
022	O
)	O
.	O

Also	O
,	O
correlation	B-T062
analysis	I-T062
revealed	O
a	O
significant	O
correlation	O
between	O
C	B-T103
-	I-T103
reactive	I-T103
protein	I-T103
(	O
CRP	B-T103
)	O
and	O
N	B-T017
/	O
L	B-T017
(	O
P	O
=	O
0	O
.	O
002	O
;	O
r	O
=	O
0	O
.	O
461	O
)	O
.	O

Our	O
study	B-T062
for	O
the	O
first	O
time	O
provides	O
evidence	O
of	O
N	B-T017
/	O
L	B-T017
and	O
P	B-T017
/	O
L	B-T017
may	O
be	O
useful	O
biomarkers	B-T201
in	O
patients	O
with	O
idiopathic	O
AAU	B-T038
.	O

N	B-T017
/	O
L	B-T017
is	O
correlated	O
with	O
CRP	B-T103
,	O
so	O
it	O
can	O
be	O
a	O
useful	O
biomarker	B-T201
to	O
predict	O
the	O
prognosis	B-T058
in	O
idiopathic	O
AAU	B-T038
.	O

Comparison	O
between	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
and	O
B	B-T058
-	I-T058
mode	I-T058
ultrasound	I-T058
in	O
detecting	B-T033
and	O
estimating	O
the	O
extent	B-T082
of	O
human	B-T204
carotid	B-T038
atherosclerosis	I-T038

In	O
MRI	B-T058
studies	I-T058
of	O
carotid	B-T017
plaques	I-T017
,	O
ultrasound	B-T058
is	O
used	O
to	O
find	B-T033
plaques	B-T033
,	O
which	O
are	O
later	O
imaged	B-T170
using	O
MRI	B-T058
.	O

The	O
performance	O
in	O
plaque	B-T033
detection	B-T033
has	O
not	O
been	O
compared	O
between	O
the	O
modalities	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	B-T062
was	O
to	O
compare	O
the	O
performance	O
of	O
MRI	B-T058
and	O
ultrasound	B-T058
in	O
detecting	B-T033
carotid	B-T017
artery	I-T017
plaques	I-T017
and	O
measuring	O
extent	B-T082
of	O
atherosclerosis	B-T038
.	O

Subjects	O
with	O
at	O
least	O
one	O
plaque	B-T033
(	O
height	O
≥2	O
·	O
5	O
mm	O
)	O
on	O
ultrasound	B-T058
were	O
imaged	B-T170
using	O
MRI	B-T058
.	O

The	O
number	O
of	O
plaques	B-T033
and	O
their	O
height	O
was	O
measured	O
in	O
both	O
modalities	O
;	O
plaque	B-T033
area	B-T082
and	O
volume	O
were	O
analysed	B-T062
on	O
ultrasound	B-T058
and	O
MRI	B-T058
,	O
respectively	O
.	O

Thirty	O
-	O
eight	O
subjects	O
were	O
included	O
.	O

MRI	B-T058
detected	B-T033
plaques	B-T033
in	O
95	O
%	O
of	O
carotid	B-T017
arteries	I-T017
with	O
a	O
plaque	B-T033
height	O
of	O
≥2	O
·	O
5	O
mm	O
on	O
ultrasound	B-T058
and	O
in	O
all	O
carotid	B-T017
arteries	I-T017
with	O
a	O
plaque	B-T033
exceeding	O
2	O
·	O
5	O
mm	O
.	O

MRI	B-T058
detected	B-T033
53	O
%	O
of	O
the	O
plaques	B-T033
with	O
a	O
height	O
below	O
2	O
·	O
5	O
mm	O
.	O

The	O
plaque	B-T033
height	O
measured	O
with	O
both	O
techniques	O
correlated	O
significantly	O
,	O
0	O
·	O
59	O
,	O
P	O
<	O
0	O
·	O
0001	O
.	O

Ultrasound	B-T058
-	O
derived	O
plaque	B-T033
height	O
and	O
plaque	B-T033
area	B-T082
correlated	O
similarly	O
to	O
MRI	B-T058
-	O
derived	O
plaque	B-T033
volume	O
,	O
r	O
=	O
0	O
·	O
52	O
;	O
P	O
<	O
0	O
·	O
0001	O
and	O
r	O
=	O
0	O
·	O
47	O
;	O
P	O
=	O
0	O
·	O
001	O
,	O
respectively	O
.	O

We	O
conclude	O
that	O
MRI	B-T058
has	O
a	O
similar	O
sensitivity	O
to	O
ultrasound	B-T058
in	O
finding	B-T033
carotid	B-T017
artery	I-T017
plaques	I-T017
that	O
are	O
2	O
·	O
5	O
mm	O
or	O
higher	O
.	O

In	O
smaller	O
plaques	B-T033
,	O
MRI	B-T058
detects	B-T033
fewer	O
plaques	B-T033
.	O

Multiple	B-T017
carotid	I-T017
plaques	I-T017
seen	O
on	O
ultrasound	B-T058
most	O
often	O
are	O
a	O
misinterpretation	O
of	O
the	O
anatomy	O
and	O
correspond	O
to	O
a	O
single	B-T033
plaque	I-T033
.	O

Plaque	B-T033
height	O
on	O
ultrasound	B-T058
is	O
comparable	O
to	O
plaque	B-T033
height	O
on	O
MRI	B-T058
and	O
correlates	O
fairly	O
well	O
with	O
plaque	B-T033
volume	O
on	O
MRI	B-T058
making	O
it	O
an	O
interesting	O
proxy	O
for	O
plaque	B-T033
burden	O
.	O

Lightweight	O
Open	B-T017
-	I-T017
Cell	I-T017
Scaffolds	I-T017
from	O
Sea	B-T204
Urchin	I-T204
Spines	B-T103
with	O
Superior	O
Material	O
Properties	O
for	O
Bone	B-T058
Defect	I-T058
Repair	I-T058

Sea	B-T204
urchin	I-T204
spines	B-T103
(	O
Heterocentrotus	B-T204
mammillatus	I-T204
)	O
,	O
with	O
a	O
hierarchical	O
open	B-T017
-	I-T017
cell	I-T017
structure	I-T017
similar	O
to	O
that	O
of	O
human	B-T204
trabecular	B-T017
bone	I-T017
and	O
superior	O
mechanical	O
property	O
(	O
compressive	O
strength	O
∼43	O
.	O
4	O
MPa	O
)	O
suitable	O
for	O
machining	O
to	O
shape	O
,	O
were	O
explored	O
for	O
potential	O
applications	O
of	O
bone	B-T058
defect	I-T058
repair	I-T058
.	O

Finite	B-T170
element	I-T170
analyses	I-T170
reveal	O
that	O
the	O
compressive	O
stress	B-T033
concentrates	O
along	O
the	O
dense	O
growth	B-T038
rings	I-T038
and	O
dissipates	B-T082
through	O
strut	O
structures	B-T017
of	I-T017
the	I-T017
stereoms	I-T017
,	O
indicating	O
that	O
the	O
exquisite	O
mesostructures	B-T082
play	O
an	O
important	O
role	O
in	O
high	O
strength	O
-	O
to	O
-	O
weight	O
ratios	O
.	O

The	O
fracture	B-T037
strength	O
of	O
magnesium	B-T103
-	O
substituted	B-T103
tricalcium	I-T103
phosphate	I-T103
(	B-T103
β	I-T103
-	I-T103
TCMP	I-T103
)	I-T103
scaffolds	I-T103
produced	O
by	O
hydrothermal	O
conversion	O
of	O
urchin	B-T204
spines	B-T103
is	O
about	O
9	O
.	O
3	O
MPa	O
,	O
comparable	O
to	O
that	O
of	O
human	B-T204
trabecular	B-T017
bone	I-T017
.	O

New	O
bone	B-T017
forms	O
along	O
outer	O
surfaces	B-T082
of	O
β	B-T103
-	I-T103
TCMP	I-T103
scaffolds	I-T103
after	O
implantation	B-T058
in	O
rabbit	B-T204
femoral	B-T037
defects	I-T037
for	O
one	O
month	O
and	O
grows	B-T038
into	O
the	O
majority	O
of	O
the	O
inner	O
open	B-T082
-	I-T082
cell	I-T082
spaces	I-T082
postoperation	O
in	O
three	O
month	O
s	O
,	O
showing	O
tight	O
interface	O
between	O
the	O
scaffold	B-T103
and	O
regenerative	B-T038
bone	I-T038
tissue	I-T038
.	O

Fusion	B-T058
of	O
beagle	B-T204
lumbar	B-T082
facet	I-T082
joints	I-T082
using	O
a	O
Ti	B-T103
-	I-T103
6Al	I-T103
-	I-T103
4V	I-T103
cage	I-T103
and	O
β	B-T103
-	I-T103
TCMP	I-T103
scaffold	I-T103
can	O
be	O
completed	O
within	O
seven	O
months	O
with	O
obvious	O
biodegradation	O
of	O
the	O
β	B-T103
-	I-T103
TCMP	I-T103
scaffold	I-T103
,	O
which	O
is	O
nearly	O
completely	O
degraded	O
and	O
replaced	O
by	O
newly	O
formed	O
bone	B-T017
ten	O
months	O
after	O
implantation	B-T058
.	O

Thus	O
,	O
sea	B-T204
urchin	I-T204
spines	B-T103
suitable	O
for	O
machining	O
to	O
shape	O
have	O
advantages	O
for	O
production	O
of	O
biodegradable	O
artificial	B-T103
grafts	I-T103
for	O
bone	B-T058
defect	I-T058
repair	I-T058
.	O

Melatonin	B-T103
and	O
nitric	B-T103
oxide	I-T103
regulate	B-T038
sunflower	B-T204
seedling	B-T038
growth	I-T038
under	O
salt	B-T038
stress	I-T038
accompanying	O
differential	O
expression	B-T038
of	O
Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
and	O
Mn	B-T103
SOD	I-T103

Salinity	B-T038
results	I-T038
in	O
significant	O
reduction	O
in	O
sunflower	B-T204
(	O
Helianthus	B-T204
annuus	I-T204
L	I-T204
.	I-T204
)	O
seedling	B-T038
growth	I-T038
and	O
excessive	O
generation	O
of	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
.	O

Present	O
work	O
highlights	O
the	O
possible	O
role	O
of	O
melatonin	B-T103
as	O
an	O
antioxidant	B-T103
through	O
its	O
interaction	O
with	O
nitric	B-T103
oxide	I-T103
(	O
NO	B-T103
)	O
,	O
and	O
as	O
an	O
early	O
and	O
long	O
distance	O
NaCl	B-T038
-	I-T038
stress	I-T038
sensing	O
signaling	B-T103
molecule	I-T103
in	O
seedling	B-T204
cotyledons	B-T204
.	O

Exogenous	O
melatonin	B-T103
(	O
15µM	O
)	O
±	O
NaCl	B-T103
(	O
120mM	O
)	O
inhibit	O
seedling	B-T038
growth	I-T038
,	O
which	O
is	O
also	O
correlated	O
with	O
NO	B-T103
availability	O
,	O
accumulation	O
of	O
potential	B-T103
superoxide	I-T103
anion	I-T103
(	O
O2	B-T103
(	I-T103
•	I-T103
-	I-T103
)	I-T103
)	O
and	O
peroxynitrite	B-T103
anion	I-T103
(	O
ONOO	B-T103
(	I-T103
-	I-T103
)	I-T103
)	O
,	O
extent	O
of	O
tyrosine	B-T038
-	I-T038
nitration	I-T038
of	O
proteins	B-T103
,	O
spatial	O
localization	O
and	O
activity	B-T038
of	I-T038
superoxide	I-T038
dismutase	I-T038
(	O
SOD	B-T103
)	O
isoforms	B-T103
.	O

NO	B-T103
acts	O
as	O
a	O
positive	O
modulator	O
of	O
melatonin	B-T103
accumulation	O
in	O
seedling	B-T204
cotyledons	B-T204
as	O
a	O
long	B-T038
-	I-T038
distance	I-T038
signaling	I-T038
response	I-T038
.	O

Modulation	B-T038
of	I-T038
superoxide	I-T038
anion	I-T038
and	O
peroxynitrite	B-T103
anion	I-T103
content	O
by	O
melatonin	B-T103
highlights	O
its	O
crucial	O
role	O
in	O
combating	O
deleterious	O
effects	O
of	O
ROS	B-T103
and	O
reactive	B-T103
nitrogen	I-T103
species	I-T103
(	O
RNS	O
)	O
.	O

Present	O
findings	O
provide	O
evidence	O
for	O
an	O
interaction	O
between	O
melatonin	B-T103
and	O
NO	B-T103
in	O
their	O
effect	O
on	O
seedling	B-T038
growth	I-T038
under	O
salt	B-T038
stress	I-T038
accompanying	I-T038
differential	O
modulation	O
of	O
two	O
SOD	B-T103
isoforms	B-T103
,	O
i	O
.	O
e	O
.	O

Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
and	O
Mn	B-T103
SOD	I-T103
.	O

The	O
Physiological	O
Role	O
and	O
Regulation	B-T038
of	O
Aquaporins	B-T103
in	O
Teleost	O
Germ	B-T017
Cells	I-T017

The	O
unicellular	O
germ	B-T017
cells	I-T017
and	O
gametes	B-T017
of	O
oviparous	B-T038
teleosts	O
lack	O
the	O
osmoregulatory	B-T038
organs	B-T017
present	O
in	O
juveniles	O
and	O
adults	O
,	O
yet	O
during	O
development	B-T038
and	O
particularly	O
at	O
spawning	O
,	O
they	O
face	O
tremendous	O
osmotic	O
challenges	B-T033
when	O
released	O
into	O
the	O
external	B-T082
aquatic	O
environment	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
transmembrane	B-T103
water	I-T103
channels	I-T103
(	O
aquaporins	B-T103
)	O
evolved	O
to	O
play	O
vital	O
adaptive	O
roles	O
that	O
mitigate	O
the	O
osmotic	O
and	O
oxidative	B-T038
stress	I-T038
problems	B-T033
of	O
the	O
developing	B-T038
oocytes	B-T017
,	O
embryos	B-T017
and	O
spermatozoa	B-T017
.	O

In	O
this	O
chapter	O
,	O
we	O
provide	O
a	O
short	O
overview	O
of	O
the	O
diversity	O
of	O
the	O
aquaporin	B-T103
superfamily	O
in	O
teleosts	O
,	O
and	O
summarize	O
the	O
findings	O
that	O
uncovered	O
a	O
highly	O
specific	O
molecular	B-T038
regulation	I-T038
of	O
aquaporins	B-T103
during	O
oogenesis	B-T038
and	O
spermatogenesis	B-T038
.	O

We	O
further	O
review	O
the	O
multiple	O
functions	O
that	O
these	O
channels	B-T103
play	O
during	O
the	O
establishment	O
of	O
egg	B-T017
buoyancy	B-T038
and	O
the	O
activation	O
and	O
detoxification	B-T058
of	O
spermatozoa	B-T017
in	O
the	O
marine	B-T082
environment	B-T082
.	O

Caribbean	B-T082
massive	B-T204
corals	I-T204
not	O
recovering	O
from	O
repeated	O
thermal	O
stress	O
events	O
during	O
2005	O
-	O
2013	O

Massive	B-T204
coral	I-T204
bleaching	O
events	O
associated	O
with	O
high	O
sea	B-T082
surface	B-T082
temperatures	O
are	O
forecast	O
to	O
become	O
more	O
frequent	O
and	O
severe	O
in	O
the	O
future	O
due	O
to	O
climate	O
change	O
.	O

Monitoring	B-T062
colony	O
recovery	O
from	O
bleaching	O
disturbances	O
over	O
multiyear	O
time	O
frames	O
is	O
important	O
for	O
improving	O
predictions	O
of	O
future	O
coral	B-T204
community	O
changes	O
.	O

However	O
,	O
there	O
are	O
currently	O
few	O
multiyear	B-T062
studies	I-T062
describing	O
long	O
-	O
term	O
outcomes	O
for	O
coral	B-T204
colonies	O
following	O
acute	O
bleaching	O
events	O
.	O

We	O
recorded	O
colony	O
pigmentation	O
and	O
size	B-T082
for	O
bleached	O
and	O
unbleached	O
groups	O
of	O
co	O
-	O
located	O
conspecifics	O
of	O
three	O
major	O
reef	B-T204
-	I-T204
building	I-T204
scleractinian	I-T204
corals	B-T204
(	O
Orbicella	B-T204
franksi	I-T204
,	O
Siderastrea	B-T204
siderea	I-T204
,	O
and	O
Stephanocoenia	B-T204
michelini	I-T204
;	O
n	O
=	O
198	O
total	O
)	O
in	O
Bocas	O
del	O
Toro	O
,	O
Panama	B-T082
,	O
during	O
the	O
major	O
2005	O
bleaching	O
event	O
and	O
then	O
monitored	B-T062
pigmentation	O
status	O
and	O
changes	O
live	B-T017
tissue	I-T017
colony	O
size	B-T082
for	O
8	O
years	O
(	O
2005	O
-	O
2013	O
)	O
.	O

Corals	B-T204
that	O
were	O
bleached	O
in	O
2005	O
demonstrated	O
markedly	O
different	O
response	O
trajectories	O
compared	O
to	O
unbleached	O
colony	O
groups	O
,	O
with	O
extensive	O
live	B-T017
tissue	I-T017
loss	O
for	O
bleached	O
corals	B-T204
of	O
all	O
species	B-T170
following	O
bleaching	O
,	O
with	O
mean	O
live	B-T017
tissue	I-T017
losses	O
per	O
colony	O
9	O
months	O
postbleaching	O
of	O
26	O
.	O
2	O
%	O
(	O
±5	O
.	O
4	O
SE	O
)	O
for	O
O	B-T204
.	I-T204

franksi	I-T204
,	O
35	O
.	O
7	O
%	O
(	O
±4	O
.	O
7	O
SE	O
)	O
for	O
S	B-T204
.	I-T204

michelini	I-T204
,	O
and	O
11	O
.	O
2	O
%	O
(	O
±3	O
.	O
9	O
SE	O
)	O
for	O
S	B-T204
.	I-T204

siderea	I-T204
.	O

Two	O
species	B-T170
,	O
O	B-T204
.	I-T204

franksi	I-T204
and	O
S	B-T204
.	I-T204

michelini	I-T204
,	O
later	O
recovered	O
to	O
net	O
positive	B-T033
growth	B-T038
,	O
which	O
continued	O
until	O
a	O
second	O
thermal	O
stress	O
event	O
in	O
2010	O
.	O

Following	O
this	O
event	O
,	O
all	O
species	B-T170
again	O
lost	O
tissue	B-T017
,	O
with	O
previously	O
unbleached	O
colony	O
species	B-T170
groups	O
experiencing	O
greater	O
declines	O
than	O
conspecific	O
sample	O
groups	O
,	O
which	O
were	O
previously	O
bleached	O
,	O
indicating	O
a	O
possible	O
positive	O
acclimative	B-T038
response	I-T038
.	O

However	O
,	O
despite	O
this	O
beneficial	O
effect	O
for	O
previously	O
bleached	O
corals	B-T204
,	O
all	O
groups	O
experienced	O
substantial	O
net	O
tissue	B-T017
loss	O
between	O
2005	O
and	O
2013	O
,	O
indicating	O
that	O
many	O
important	O
Caribbean	B-T082
reef	B-T204
-	I-T204
building	I-T204
corals	I-T204
will	O
likely	O
suffer	O
continued	O
tissue	B-T017
loss	O
and	O
may	O
be	O
unable	O
to	O
maintain	O
current	O
benthic	O
coverage	O
when	O
faced	O
with	O
future	O
thermal	O
stress	O
forecast	O
for	O
the	O
region	B-T082
,	O
even	O
with	O
potential	O
benefits	O
from	O
bleaching	O
-	O
related	O
acclimation	B-T038
.	O

Preparation	O
and	O
characterization	O
of	O
gastrointestinal	B-T082
wafer	B-T103
formulations	O

Many	O
active	B-T103
pharmaceutical	I-T103
ingredients	I-T103
(	O
API	B-T103
)	O
have	O
a	O
very	O
poor	O
or	O
highly	O
variable	O
bioavailability	O
after	O
oral	B-T058
administration	I-T058
.	O

One	O
possibility	O
to	O
overcome	O
this	O
problem	O
might	O
be	O
found	O
in	O
the	O
application	O
of	O
mucoadhesive	B-T103
dosage	I-T103
forms	I-T103
like	O
gastrointestinal	B-T082
wafers	B-T103
.	O

However	O
,	O
a	O
currently	O
unsolved	O
challenge	O
is	O
the	O
control	O
of	O
the	O
adhesion	O
of	O
the	O
wafer	B-T103
to	O
the	O
intestinal	B-T031
mucus	I-T031
.	O

One	O
suggested	O
solution	O
might	O
be	O
the	O
combination	O
of	O
gastrointestinal	B-T082
wafers	B-T103
and	O
expanding	O
systems	O
.	O

Such	O
a	O
combination	O
requires	O
thin	B-T103
and	I-T103
elastic	I-T103
wafers	I-T103
which	O
are	O
further	O
characterized	O
by	O
an	O
unidirectional	O
drug	O
release	O
.	O

In	O
this	O
study	B-T062
gastrointestinal	B-T082
,	O
twolayered	B-T103
wafers	I-T103
containing	O
a	O
water	O
-	O
insoluble	O
backing	O
layer	O
and	O
a	O
drug	O
-	O
loaded	O
,	O
mucoadhesive	O
layer	O
were	O
fabricated	O
by	O
casting	O
solvent	O
technique	O
.	O

The	O
backing	O
layer	O
consists	O
of	O
Ethocel™	B-T103
Standard	I-T103
10	I-T103
Premium	I-T103
and	O
the	O
mucoadhesive	O
layer	O
was	O
prepared	O
using	O
a	O
mixture	O
of	O
Methocel™	B-T103
E15	I-T103
Premium	I-T103
LV	I-T103
,	O
polyvinyl	B-T103
alcohol	I-T103
and	O
Macrogol	B-T103
400	I-T103
.	O

The	O
wafers	B-T103
were	O
characterized	O
regarding	O
their	O
appearance	O
,	O
mechanical	O
properties	O
and	O
dissolution	O
profiles	O
as	O
well	O
as	O
the	O
influence	O
of	O
backing	O
layer	O
thickness	O
on	O
drug	O
transfer	O
and	O
their	O
ability	O
of	O
unidirectional	O
drug	O
release	O
.	O

The	O
wafers	B-T103
with	O
backing	O
layer	O
thickness	O
of	O
500μg	B-T103
Ethocel	I-T103
™	O
/	O
cm	O
(	O
2	O
)	O
presented	O
adequate	O
mechanical	O
properties	O
,	O
a	O
drug	O
transfer	O
about	O
73	O
%	O
and	O
unidirectional	O
drug	O
release	O
.	O

Discovery	O
of	O
<	B-T204
i	I-T204
>	I-T204
Neopanorpa	I-T204
chillcotti	I-T204
<	I-T204
/	I-T204
i	I-T204
>	I-T204
Byers	I-T204
(	O
Mecoptera	B-T204
:	O
Panorpidae	B-T204
)	O
from	O
Tibet	B-T082
,	O
China	B-T082
,	O
with	O
discussion	O
of	O
its	O
generic	O
status	O

Neopanorpa	B-T204
chillcotti	I-T204
Byers	I-T204
,	O
1971	O
was	O
originally	O
described	O
from	O
Kathmandu	O
in	O
Nepal	B-T082
and	O
is	O
now	O
found	O
to	O
be	O
distributed	O
in	O
Gyirong	O
,	O
Tibet	B-T082
in	O
China	B-T082
.	O

The	O
species	O
is	O
redescribed	O
and	O
illustrated	O
based	O
on	O
new	O
material	O
from	O
China	B-T082
and	O
Nepal	B-T082
.	O

The	O
generic	O
status	O
of	O
this	O
species	B-T170
is	O
briefly	O
discussed	O
.	O

Passive	B-T062
case	I-T062
detection	I-T062
of	O
malaria	B-T038
in	O
Ratanakiri	O
Province	O
(	O
Cambodia	O
)	O
to	O
detect	B-T033
villages	B-T082
at	O
higher	O
risk	O
for	O
malaria	B-T038

Cambodia	O
reduced	O
malaria	B-T038
incidence	O
by	O
more	O
than	O
75	O
%	O
between	O
2000	O
and	O
2015	O
,	O
a	O
target	O
of	O
the	O
Millennium	B-T170
Development	I-T170
Goal	I-T170
6	I-T170
.	O

The	O
Cambodian	O
Government	B-T092
aims	O
to	O
eliminate	O
all	O
forms	O
of	O
malaria	B-T038
by	O
2025	O
.	O

The	O
country	B-T082
'	I-T082
s	I-T082
malaria	B-T038
incidence	O
is	O
highly	O
variable	O
at	O
provincial	O
level	O
,	O
but	O
less	O
is	O
known	O
at	O
village	B-T082
level	O
.	O

This	O
study	B-T062
used	O
passive	B-T062
case	I-T062
detection	I-T062
(	O
PCD	B-T062
)	O
data	O
at	O
village	B-T082
level	O
in	O
Ratanakiri	O
Province	O
from	O
2010	O
to	O
2014	O
to	O
describe	O
incidence	O
trends	O
and	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
areas	I-T033
of	I-T033
malaria	B-T038
to	O
be	O
primarily	O
targeted	O
towards	O
malaria	B-T038
elimination	O
.	O

In	O
2010	O
,	O
the	O
Cambodian	O
malaria	B-T038
programme	B-T170
created	O
a	O
Malaria	B-T170
Information	I-T170
System	I-T170
(	O
MIS	B-T170
)	O
to	O
capture	O
malaria	B-T038
information	O
at	O
village	B-T082
level	O
through	O
PCD	B-T062
by	O
village	B-T082
malaria	B-T097
workers	I-T097
and	O
health	B-T092
facilities	I-T092
.	O

The	O
MIS	B-T170
data	O
of	O
Ratanakiri	O
Province	O
2010	O
-	O
2014	O
were	O
used	O
to	O
calculate	O
annual	O
incidence	O
rates	O
by	O
Plasmodium	B-T204
species	I-T204
at	O
province	O
and	O
commune	O
levels	O
.	O

For	O
estimating	O
the	O
trend	O
at	O
provincial	O
level	O
only	O
villages	B-T082
reporting	B-T058
each	O
year	O
were	O
selected	O
.	O

The	O
communal	O
incidences	O
and	O
the	O
number	O
of	O
cases	O
per	O
village	B-T082
were	O
visualized	O
on	O
a	O
map	O
per	O
Plasmodium	B-T204
species	I-T204
and	O
per	O
year	O
.	O

Analysis	O
of	O
spatial	O
clustering	O
of	O
village	B-T082
malaria	B-T038
cases	O
by	O
Plasmodium	B-T204
species	I-T204
was	O
performed	O
by	O
year	O
.	O

Overall	O
,	O
malaria	B-T038
annual	O
incidence	O
rates	O
per	O
1000	O
inhabitants	O
decreased	O
from	O
86	O
(	O
2010	O
)	O
to	O
30	O
(	O
2014	O
)	O
.	O

Falciparum	B-T204
incidence	O
decreased	O
(	O
by	O
79	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
76	O
-	O
82	O
%	O
)	O
more	O
rapidly	O
than	O
vivax	B-T204
incidence	O
(	O
by	O
19	O
%	O
in	O
2014	O
compared	O
to	O
2010	O
;	O
CI	O
95	O
%	O
5	O
-	O
32	O
%	O
)	O
.	O

There	O
were	O
ten	O
to	O
16	O
significant	O
spatial	O
clusters	O
each	O
year	O
.	O

Big	O
clusters	O
tended	O
to	O
extend	B-T082
along	O
the	O
Cambodian	O
-	O
Vietnamese	O
border	O
and	O
along	O
the	O
Sesan	O
River	O
.	O

Three	O
clusters	O
appeared	O
throughout	O
all	O
years	O
(	O
2010	O
-	O
2014	O
)	O
:	O
one	O
with	O
21	O
villages	B-T082
appeared	O
each	O
year	O
,	O
the	O
second	O
shrunk	O
progressively	O
from	O
2012	O
to	O
2014	O
and	O
the	O
third	O
was	O
split	O
into	O
two	O
smaller	O
clusters	O
in	O
2013	O
and	O
2014	O
.	O

The	O
decline	O
of	O
malaria	B-T038
burden	O
can	O
be	O
attributed	O
to	O
intensive	O
malaria	O
control	O
activities	O
implemented	O
in	O
the	O
areas	B-T082
:	O
distribution	O
of	O
a	O
long	O
-	O
lasting	O
insecticidal	B-T074
net	I-T074
per	O
person	B-T098
and	O
early	B-T058
diagnosis	I-T058
and	O
prompt	O
treatment	O
.	O

Dihydro	B-T103
-	I-T103
artemisinin	I-T103
piperaquine	B-T103
was	O
the	O
only	O
first	B-T058
-	I-T058
line	I-T058
treatment	I-T058
for	O
all	O
malaria	B-T038
cases	O
.	O

No	O
radical	O
treatment	O
with	O
primaquine	B-T103
was	O
provided	O
for	O
Plasmodium	B-T204
vivax	I-T204
cases	O
,	O
which	O
could	O
explain	O
the	O
slow	O
decrease	O
of	O
P	B-T204
.	I-T204

vivax	I-T204
due	O
to	O
relapses	O
.	O

To	O
achieve	O
malaria	B-T038
elimination	O
by	O
2025	O
,	O
priority	O
should	O
be	O
given	O
to	O
the	O
control	O
of	O
stable	O
malaria	O
clusters	O
appearing	O
over	O
time	O
.	O

Interaction	O
of	O
lifestyle	O
,	O
behaviour	O
or	O
systemic	B-T038
diseases	I-T038
with	O
dental	B-T038
caries	I-T038
and	O
periodontal	B-T038
diseases	I-T038
:	O
consensus	B-T097
report	I-T097
of	I-T097
group	I-T097
2	I-T097
of	I-T097
the	I-T097
joint	I-T097
EFP	I-T097
/	I-T097
ORCA	I-T097
workshop	I-T097
on	O
the	O
boundaries	O
between	O
caries	B-T038
and	O
periodontal	B-T038
diseases	I-T038

Periodontal	B-T038
diseases	I-T038
and	O
dental	B-T038
caries	I-T038
are	O
the	O
most	O
common	B-T038
diseases	I-T038
of	O
humans	O
and	O
the	O
main	O
cause	O
of	O
tooth	B-T017
loss	I-T017
.	O

Both	O
diseases	B-T038
can	O
lead	O
to	O
nutritional	O
compromise	O
and	O
negative	O
impacts	O
upon	O
self	B-T038
-	I-T038
esteem	I-T038
and	O
quality	O
of	O
life	O
.	O

As	O
complex	B-T038
chronic	I-T038
diseases	I-T038
,	O
they	O
share	O
common	B-T033
risk	I-T033
factors	I-T033
,	O
such	O
as	O
a	O
requirement	O
for	O
a	O
pathogenic	O
plaque	O
biofilm	O
,	O
yet	O
they	O
exhibit	O
distinct	B-T038
pathophysiologies	I-T038
.	O

Multiple	O
exposures	O
contribute	O
to	O
their	O
causal	O
pathways	O
,	O
and	O
susceptibility	B-T201
involves	I-T201
risk	B-T033
factors	I-T033
that	O
are	O
inherited	O
(	O
e	O
.	O
g	O
.	O

genetic	O
variants	O
)	O
,	O
and	O
those	O
that	O
are	O
acquired	O
(	O
e	O
.	O
g	O
.	O

socio	O
-	O
economic	O
factors	O
,	O
biofilm	B-T007
load	O
or	O
composition	O
,	O
smoking	O
,	O
carbohydrate	B-T201
intake	I-T201
)	O
.	O

Identification	O
of	O
these	O
factors	O
is	O
crucial	O
in	O
the	O
prevention	O
of	O
both	O
diseases	O
as	O
well	O
as	O
in	O
their	B-T058
management	I-T058
.	O

To	O
systematically	O
appraise	O
the	O
scientific	B-T170
literature	I-T170
to	O
identify	O
potential	B-T033
risk	I-T033
factors	I-T033
for	O
caries	B-T038
and	O
periodontal	B-T038
diseases	I-T038
.	O

One	O
systematic	B-T170
review	I-T170
(	O
genetic	O
risk	O
factors	O
)	O
,	O
one	O
narrative	O
review	O
(	O
role	B-T062
of	I-T062
diet	I-T062
and	I-T062
nutrition	I-T062
)	O
and	O
reference	B-T170
documentation	I-T170
for	O
modifiable	B-T033
acquired	I-T033
risk	I-T033
factors	I-T033
common	O
to	O
both	O
disease	O
groups	O
,	O
formed	O
the	O
basis	O
of	O
the	O
report	O
.	O

There	O
is	O
moderately	O
strong	O
evidence	O
for	O
a	O
genetic	B-T033
contribution	I-T033
to	O
periodontal	B-T038
diseases	I-T038
and	O
caries	O
susceptibility	O
,	O
with	O
an	O
attributable	O
risk	O
estimated	O
to	O
be	O
up	O
to	O
50	O
%	O
.	O

The	O
genetics	O
literature	O
for	O
periodontal	B-T038
disease	I-T038
is	O
more	O
substantial	O
than	O
for	O
caries	B-T038
and	O
genes	B-T017
associated	O
with	O
chronic	B-T038
periodontitis	I-T038
are	O
the	O
vitamin	B-T017
D	I-T017
receptor	I-T017
(	O
VDR	B-T017
)	O
,	O
Fc	B-T017
gamma	I-T017
receptor	I-T017
IIA	I-T017
(	O
Fc	B-T017
-	I-T017
γRIIA	I-T017
)	O
and	O
Interleukin	B-T017
10	I-T017
(	I-T017
IL10	B-T017
)	I-T017
genes	I-T017
.	O

For	O
caries	B-T038
,	O
genes	B-T017
involved	O
in	O
enamel	B-T033
formation	I-T033
(	O
AMELX	B-T017
,	O
AMBN	B-T017
,	O
ENAM	B-T017
,	O
TUFT	B-T103
,	O
MMP20	B-T017
,	O
and	O
KLK4	B-T017
)	O
,	O
salivary	O
characteristics	O
(	O
AQP5	B-T017
)	O
,	O
immune	B-T038
regulation	I-T038
and	O
dietary	O
preferences	O
had	O
the	O
largest	O
impact	O
.	O

No	O
common	O
genetic	O
variants	O
were	O
found	O
.	O

Fermentable	B-T103
carbohydrates	I-T103
(	O
sugars	O
and	O
starches	O
)	O
were	O
the	O
most	O
relevant	O
common	O
dietary	O
risk	O
factor	O
for	O
both	O
diseases	O
,	O
but	O
associated	O
mechanisms	O
differed	O
.	O

In	O
caries	B-T038
,	O
the	O
fermentation	B-T038
process	I-T038
leads	O
to	O
acid	O
production	O
and	O
the	O
generation	B-T038
of	I-T038
biofilm	I-T038
components	O
such	O
as	O
Glucans	B-T103
.	O

In	O
periodontitis	B-T038
,	O
glycaemia	B-T033
drives	I-T033
oxidative	B-T038
stress	I-T038
and	O
advanced	O
glycation	O
end	O
-	O
products	O
may	O
also	O
trigger	O
a	O
hyper	B-T038
inflammatory	I-T038
state	O
.	O

Micronutrient	B-T038
deficiencies	I-T038
,	O
such	O
as	O
for	O
vitamin	B-T103
C	I-T103
,	O
vitamin	B-T103
D	I-T103
or	O
vitamin	B-T103
B12	I-T103
,	O
may	O
be	O
related	O
to	O
the	O
onset	O
and	O
progression	B-T038
of	I-T038
both	I-T038
diseases	I-T038
.	O

Functional	B-T168
foods	I-T168
or	O
probiotics	B-T007
could	O
be	O
helpful	O
in	O
caries	B-T058
prevention	I-T058
and	O
periodontal	B-T038
disease	I-T038
management	B-T058
,	O
although	O
evidence	O
is	O
limited	O
and	O
biological	O
mechanisms	O
not	O
fully	O
elucidated	O
.	O

Hyposalivation	B-T033
,	O
rheumatoid	B-T038
arthritis	I-T038
,	O
smoking	B-T033
/	I-T033
tobacco	I-T033
use	I-T033
,	O
undiagnosed	B-T033
or	O
sub	B-T033
-	I-T033
optimally	I-T033
controlled	I-T033
diabetes	B-T038
and	O
obesity	B-T038
are	O
common	O
acquired	O
risk	B-T033
factors	I-T033
for	O
both	O
caries	B-T038
and	O
periodontal	B-T038
diseases	I-T038
.	O

Intestinal	B-T017
micropatches	B-T074
for	O
oral	B-T082
insulin	O
delivery	O

Diabetes	B-T038
mellitus	I-T038
has	O
become	O
a	O
major	O
public	O
health	O
issue	O
that	O
has	O
almost	O
reached	O
epidemic	O
proportions	O
worldwide	O
.	O

Injectable	O
insulin	O
has	O
been	O
typically	O
utilized	O
for	O
the	O
management	B-T058
of	O
this	O
chronic	B-T038
disease	I-T038
.	O

However	O
,	O
lack	B-T033
of	I-T033
patient	I-T033
compliance	I-T033
with	O
injectable	B-T103
formulations	O
has	O
spurred	O
the	O
development	O
of	O
oral	B-T082
insulin	B-T103
formulations	O
,	O
which	O
although	O
appealing	O
,	O
face	O
several	O
delivery	B-T058
challenges	B-T058
.	O

We	O
have	O
developed	O
novel	O
mucoadhesive	O
intestinal	B-T017
patches	B-T074
,	O
several	O
hundred	O
micrometers	O
in	O
dimension	O
(	O
micropatches	B-T074
)	O
that	O
address	O
the	O
challenges	B-T058
of	O
oral	B-T082
insulin	O
delivery	O
.	O

The	O
micropatches	B-T074
adhere	O
to	O
the	O
intestinal	B-T017
mucosa	I-T017
,	O
release	O
their	O
drug	B-T103
load	O
rapidly	O
within	O
30	O
min	O
and	O
are	O
effective	O
in	O
lowering	B-T033
blood	I-T033
glucose	I-T033
levels	I-T033
in	B-T082
vivo	I-T082
.	O

When	O
insulin	B-T103
-	O
loaded	O
micropatches	B-T074
were	O
administered	B-T058
with	O
a	O
permeation	B-T103
enhancer	I-T103
and	O
protease	B-T103
inhibitor	I-T103
,	O
a	O
peak	O
efficacy	O
of	O
34	O
%	O
drop	B-T033
in	I-T033
blood	I-T033
glucose	I-T033
levels	I-T033
was	O
observed	O
within	O
3	O
h	O
.	O

Efficacy	O
further	O
improved	O
to	O
41	O
%	O
when	O
micropatches	B-T074
were	O
administered	B-T058
in	O
multiple	B-T201
doses	I-T201
.	O

Here	O
,	O
we	O
describe	O
the	O
design	O
of	O
micropatches	B-T074
as	O
an	O
oral	B-T082
insulin	B-T103
formulation	O
and	O
report	O
their	O
in	B-T082
vivo	I-T082
efficacy	O
.	O

Hybrid	O
automata	O
models	O
of	O
cardiac	B-T017
ventricular	I-T017
electrophysiology	B-T058
for	O
real	O
-	O
time	O
computational	O
applications	O

Virtual	O
heart	O
models	O
have	O
been	O
proposed	O
for	O
closed	O
loop	O
validation	B-T062
of	O
safety	O
-	O
critical	O
embedded	O
medical	B-T074
devices	I-T074
,	O
such	O
as	O
pacemakers	B-T074
.	O

These	O
models	O
must	O
react	O
in	O
real	O
-	O
time	O
to	O
off	O
-	O
the	O
-	O
shelf	O
medical	B-T074
devices	I-T074
.	O

Real	O
-	O
time	O
performance	O
can	O
be	O
obtained	O
by	O
implementing	O
models	O
in	O
computer	O
hardware	O
,	O
and	O
methods	O
of	O
compiling	O
classes	O
of	O
Hybrid	O
Automata	O
(	O
HA	O
)	O
onto	O
FPGA	B-T074
have	O
been	O
developed	O
.	O

Models	O
of	O
ventricular	B-T017
cardiac	I-T017
cell	I-T017
electrophysiology	B-T058
have	O
been	O
described	O
using	O
HA	O
which	O
capture	O
the	O
complex	O
nonlinear	O
behavior	O
of	O
biological	O
systems	O
.	O

However	O
,	O
many	O
models	O
that	O
have	O
been	O
used	O
for	O
closed	O
-	O
loop	O
validation	B-T062
of	O
pacemakers	B-T074
are	O
highly	O
abstract	O
and	O
do	O
not	O
capture	O
important	O
characteristics	O
of	O
the	O
dynamic	O
rate	O
response	O
.	O

We	O
developed	O
a	O
new	O
HA	O
model	O
of	O
cardiac	B-T017
cells	I-T017
which	O
captures	O
dynamic	O
behavior	O
and	O
we	O
implemented	O
the	O
model	O
in	O
hardware	O
.	O

This	O
potentially	O
enables	O
modeling	B-T062
the	O
heart	B-T017
with	O
over	O
1	O
million	O
dynamic	O
cells	B-T017
,	O
making	O
the	O
approach	O
ideal	O
for	O
closed	O
loop	O
testing	O
of	O
medical	B-T074
devices	I-T074
.	O

Comparison	O
of	O
pulse	O
wave	O
velocity	O
derived	O
from	O
accelerometer	B-T074
and	O
reflective	B-T058
photo	I-T058
-	I-T058
plethysmography	I-T058
signals	I-T058
placed	O
at	O
the	O
carotid	B-T017
and	O
femoral	B-T017
artery	I-T017

Carotid	B-T017
-	O
femoral	B-T017
pulse	O
wave	O
velocity	O
is	O
an	O
established	O
measure	O
to	O
assess	O
cardiovascular	O
risk	O
and	O
an	O
interesting	O
surrogate	O
parameter	O
towards	O
non	B-T201
-	I-T201
invasive	I-T201
continuous	I-T201
blood	I-T201
pressure	I-T201
inference	I-T201
.	O

Due	O
to	O
progress	O
in	O
sensing	O
technologies	O
for	O
wearable	O
wrist	O
worn	O
sensors	O
,	O
there	O
are	O
low	O
cost	O
sensor	O
combinations	O
of	O
photo	B-T058
-	I-T058
plethysmography	I-T058
and	O
high	B-T074
fidelity	I-T074
accelerometer	I-T074
s	I-T074
available	O
offering	O
access	O
to	O
pulse	B-T058
information	I-T058
from	O
larger	B-T017
arteries	I-T017
complemented	O
by	O
blood	B-T201
volume	I-T201
changes	O
in	O
the	O
superficial	B-T017
tissue	I-T017
.	O

In	O
this	O
work	O
we	O
compare	O
pulse	O
wave	O
velocities	O
derived	O
from	O
accelerometer	B-T074
and	O
reflective	B-T058
photo	I-T058
-	I-T058
plethysmography	I-T058
signals	I-T058
placed	O
at	O
the	O
carotid	B-T017
and	O
femoral	B-T017
artery	I-T017
.	O

We	O
discuss	O
the	O
different	O
underlying	O
physiological	B-T038
processes	I-T038
for	O
the	O
two	O
sensing	O
principles	O
and	O
present	O
experimental	B-T033
results	I-T033
obtained	O
in	O
a	O
study	B-T062
with	O
healthy	B-T098
subjects	I-T098
.	O

Constructive	B-T033
and	I-T033
Unproductive	I-T033
Processing	I-T033
of	O
Traumatic	B-T038
Experiences	I-T038
in	O
Trauma	B-T058
-	I-T058
Focused	I-T058
Cognitive	I-T058
-	I-T058
Behavioral	I-T058
Therapy	I-T058
for	O
Youth	O

Although	O
there	O
is	O
substantial	O
evidence	O
to	O
support	O
the	O
efficacy	O
of	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
treatments	I-T058
(	O
CBT	B-T058
)	O
for	O
posttraumatic	B-T038
stress	I-T038
disorder	I-T038
(	O
PTSD	B-T038
)	O
,	O
there	O
is	O
some	O
debate	O
about	O
how	O
these	O
treatments	B-T058
have	O
their	O
effects	O
.	O

Modern	O
learning	O
theory	O
and	O
cognitive	B-T170
and	I-T170
emotional	I-T170
processing	I-T170
theories	I-T170
highlight	O
the	O
importance	O
of	O
reducing	O
avoidance	B-T038
,	O
facilitating	O
the	O
constructive	O
processing	O
of	O
feared	O
experiences	O
,	O
and	O
strengthening	O
new	O
inhibitory	B-T038
learning	I-T038
.	O

We	O
examined	O
variables	O
thought	O
to	O
be	O
associated	O
with	O
unproductive	B-T033
and	I-T033
constructive	I-T033
processing	I-T033
of	O
traumatic	B-T038
experiences	I-T038
in	O
a	O
sample	O
of	O
81	O
youth	O
with	O
elevated	O
PTSD	B-T038
symptoms	B-T033
,	O
who	O
received	O
Trauma	B-T058
-	I-T058
Focused	I-T058
Cognitive	I-T058
Behavioral	I-T058
Therapy	I-T058
(	O
TF	B-T058
-	I-T058
CBT	I-T058
)	O
for	O
abuse	B-T033
or	O
traumatic	B-T038
interpersonal	O
loss	O
.	O

Sessions	O
during	O
the	O
trauma	B-T058
narrative	I-T058
phase	I-T058
of	O
TF	B-T058
-	I-T058
CBT	I-T058
were	O
coded	O
for	O
indicators	O
of	O
unproductive	B-T033
processing	I-T033
(	O
overgeneralization	B-T033
,	O
rumination	B-T038
,	O
avoidance	B-T038
)	O
and	O
constructive	B-T033
processing	I-T033
(	O
decentering	B-T033
,	O
accommodation	B-T033
of	I-T033
corrective	I-T033
information	I-T033
)	O
,	O
as	O
well	O
as	O
levels	O
of	O
negative	O
emotion	O
.	O

In	O
previous	O
analyses	O
of	O
this	O
trial	O
(	O
Ready	O
et	O
al	O
.	O
,	O
2015	O
)	O
,	O
more	O
overgeneralization	B-T033
during	O
the	O
narrative	B-T058
phase	I-T058
predicted	O
less	O
improvement	O
in	O
internalizing	B-T033
symptoms	I-T033
at	O
posttreatment	O
and	O
a	O
worsening	O
of	O
externalizing	B-T033
symptoms	I-T033
over	O
the	O
12	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
.	O

In	O
contrast	O
,	O
more	O
accommodation	B-T033
predicted	I-T033
improvement	I-T033
in	O
internalizing	B-T033
symptoms	I-T033
and	O
also	O
moderated	O
the	O
negative	B-T033
effects	O
of	O
overgeneralization	B-T033
on	O
internalizing	B-T033
and	I-T033
externalizing	I-T033
symptoms	I-T033
.	O

The	O
current	O
study	O
examined	O
correlates	O
of	O
overgeneralization	B-T033
and	O
accommodation	B-T033
.	O

Overgeneralization	B-T033
was	O
associated	O
with	O
more	O
rumination	B-T038
,	O
less	O
decentering	O
,	O
and	O
more	O
negative	O
emotion	O
,	O
suggesting	O
immersion	B-T058
in	O
trauma	B-T038
-	O
related	O
material	O
.	O

Accommodation	B-T033
was	O
associated	O
with	O
less	O
avoidance	B-T038
and	O
more	O
decentering	B-T033
,	O
suggesting	O
a	O
healthy	O
distance	O
from	O
trauma	B-T038
-	O
related	O
material	O
that	O
might	O
allow	O
for	O
processing	O
and	O
cognitive	B-T038
change	I-T038
.	O

Decentering	O
also	O
predicted	O
improvement	O
in	O
externalizing	B-T033
symptoms	I-T033
at	O
posttreatment	O
.	O

Rumination	B-T038
and	O
avoidance	B-T038
showed	O
important	O
associations	O
with	O
overgeneralization	B-T033
and	O
accommodation	B-T033
,	O
respectively	O
,	O
but	O
did	O
not	O
predict	O
treatment	O
outcomes	O
.	O

This	O
study	O
identifies	O
correlates	O
of	O
overgeneralization	B-T033
and	O
accommodation	B-T033
that	O
might	O
shed	O
light	O
on	O
how	O
these	O
variables	O
relate	O
to	O
unproductive	B-T033
and	I-T033
constructive	I-T033
processing	I-T033
of	O
traumatic	B-T038
experiences	I-T038
.	O

Giant	B-T017
Antrochoanal	B-T038
Polyp	I-T038
-	O
A	O
Rare	O
Presentation	O

Antrochoanal	B-T038
polyp	I-T038
(	O
ACP	B-T038
)	O
,	O
also	O
called	O
as	O
Killian	B-T038
polyp	I-T038
,	O
is	O
an	O
infrequent	O
,	O
benign	B-T033
lesion	I-T033
of	O
maxillary	B-T017
origin	O
in	O
non	O
-	O
atopic	O
patients	O
.	O

The	O
antrochoanal	B-T038
polyp	I-T038
is	O
shaped	O
according	O
to	O
the	O
anatomical	O
constraints	O
of	O
the	O
lateral	B-T082
nasal	I-T082
wall	I-T082
,	O
particularly	O
the	O
middle	B-T017
meatus	I-T017
and	O
antrum	B-T017
,	O
resembling	O
typically	O
a	O
dumbbell	B-T082
.	O

Here	O
presenting	O
a	O
common	O
problem	B-T033
with	O
unusual	O
presentation	O
.	O

Effects	O
of	O
obesity	B-T038
on	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
system	O
in	O
heart	B-T017
,	O
adipose	B-T017
tissue	I-T017
and	O
liver	B-T017
:	O
study	B-T062
in	O
the	O
experimental	B-T170
model	I-T170
of	O
Zucker	B-T204
rats	I-T204

Suppression	B-T103
of	I-T103
tumorigenicity	I-T103
2	I-T103
(	O
ST2	B-T103
)	O
mediates	O
the	O
effect	O
of	O
Interleukin	B-T103
-	I-T103
33	I-T103
(	O
IL	B-T103
-	I-T103
33	I-T103
)	O
.	O

Few	O
data	O
are	O
reported	O
on	O
the	O
relationship	O
between	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
and	O
obesity	B-T038
.	O

We	O
aimed	O
to	O
investigate	O
effects	O
of	O
obesity	B-T038
on	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
system	O
in	O
heart	B-T017
,	O
adipose	B-T017
tissue	I-T017
and	O
liver	B-T017
in	O
a	O
rodent	B-T038
model	I-T038
of	O
obesity	B-T038
.	O

The	O
relationship	O
of	O
cardiac	B-T017
expression	B-T038
of	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
system	O
with	O
natriuretic	B-T103
peptides	I-T103
(	O
NPs	B-T103
)	O
system	O
and	O
inflammatory	B-T038
mediators	I-T038
was	O
also	O
studied	O
.	O

mRNA	B-T038
expression	I-T038
of	O
IL	B-T017
-	I-T017
33	I-T017
/	O
ST2	B-T017
system	O
was	O
evaluated	O
in	O
cardiac	B-T058
,	O
adipose	B-T017
and	O
hepatic	B-T058
biopsies	I-T058
from	O
obese	B-T204
Zucker	I-T204
rats	I-T204
(	O
O	B-T204
)	O
and	O
controls	O
(	O
CO	O
)	O
.	O

Expression	B-T038
levels	O
of	O
sST2	B-T103
was	O
significantly	O
lower	O
in	O
O	B-T204
rats	I-T204
compared	O
with	O
CO	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
all	O
tissues	B-T017
.	O

Besides	O
,	O
the	O
mRNA	B-T103
levels	O
of	O
IL	B-T017
-	I-T017
33	I-T017
decreased	O
significant	O
in	O
fat	O
of	O
O	B-T204
respect	O
to	O
CO	O
,	O
while	O
,	O
expression	B-T038
levels	O
of	O
ST2L	B-T017
was	O
significantly	O
higher	O
in	O
liver	B-T017
of	O
CO	O
than	O
in	O
O	B-T204
.	O

A	O
strong	O
relationship	O
of	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
with	O
NPs	B-T103
and	O
classical	O
inflammatory	B-T038
mediators	I-T038
was	O
observed	O
in	O
cardiac	B-T017
tissue	I-T017
.	O

Expression	B-T038
of	O
sST2	B-T103
in	O
cardiac	B-T017
,	O
adipose	B-T017
and	O
liver	B-T017
tissue	I-T017
decreased	O
in	O
O	B-T204
compared	O
with	O
controls	O
,	O
suggesting	O
an	O
involvement	O
for	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
system	O
in	O
molecular	B-T038
mechanisms	I-T038
of	O
obesity	B-T038
.	O

The	O
strong	O
relationships	O
with	O
NP	B-T103
systems	O
and	O
inflammatory	B-T038
mediators	I-T038
could	O
suggest	O
an	O
involvement	O
for	O
IL	B-T103
-	I-T103
33	I-T103
/	O
ST2	B-T103
in	O
molecular	B-T038
pathways	I-T038
leading	O
to	O
cardiac	B-T033
dysfunction	I-T033
and	O
inflammation	B-T038
associated	O
with	O
obesity	B-T038
.	O

CXCL14	B-T103
-	O
CXCR4	B-T103
and	O
CXCL12	B-T103
-	O
CXCR4	B-T103
Axes	O
May	O
Play	O
Important	O
Roles	O
in	O
the	O
Unique	O
Invasion	B-T033
Process	O
of	O
Endometrioid	B-T038
Carcinoma	I-T038
With	O
MELF	B-T082
-	I-T082
Pattern	I-T082
Myoinvasion	B-T033

The	O
term	O
"	O
MELF	B-T082
-	I-T082
pattern	I-T082
myometrial	B-T082
invasion	B-T033
"	O
(	O
MELF	B-T082
pattern	I-T082
)	O
denotes	O
an	O
unusual	O
morphology	O
of	O
myometrial	B-T082
invasion	B-T033
in	O
endometrioid	B-T038
carcinomas	I-T038
,	O
and	O
is	O
associated	O
with	O
frequent	O
lymphovascular	B-T033
invasion	I-T033
and	O
lymph	B-T038
node	I-T038
metastasis	I-T038
.	O

In	O
this	O
study	O
,	O
tumor	B-T017
cells	I-T017
were	O
directly	O
collected	O
from	O
a	O
MELF	B-T082
pattern	I-T082
site	O
,	O
using	O
laser	B-T058
microdissection	I-T058
.	O

Comprehensive	O
microarray	B-T058
analysis	I-T058
of	O
the	O
genes	B-T017
was	O
conducted	O
,	O
and	O
based	O
on	O
the	O
results	O
,	O
expression	B-T038
of	O
a	O
metastasis	B-T103
progression	I-T103
gene	I-T103
,	I-T103
CXCR4	I-T103
,	O
and	O
its	O
ligands	B-T038
CXCL14	B-T103
and	O
CXCL12	B-T103
,	O
was	O
further	O
investigated	O
.	O

In	O
vitro	O
studies	O
of	O
endometrioid	B-T038
carcinoma	I-T038
cell	B-T017
lines	I-T017
revealed	O
elevated	O
invasion	B-T033
activity	O
in	O
a	O
manner	O
dependent	O
on	O
the	O
CXCL14	B-T103
-	O
CXCR4	B-T103
or	O
CXCL12	B-T103
-	O
CXCR4	B-T103
axis	O
.	O

Immunohistochemical	O
analysis	O
of	O
93	O
(	O
MELF	O
group	O
,	O
46	O
;	O
non	O
-	O
MELF	O
group	O
,	O
47	O
)	O
cases	O
illustrated	O
CXCR4	B-T103
was	O
expressed	B-T038
in	O
all	O
endometrioid	B-T038
carcinomas	I-T038
,	O
while	O
based	O
on	O
CXCL14	B-T103
and	O
CXCL12	B-T103
expression	B-T038
score	O
,	O
high	O
proportions	O
of	O
cells	B-T017
were	O
positive	B-T033
at	O
the	O
sites	B-T082
of	O
the	O
MELF	B-T082
pattern	I-T082
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
no	B-T033
significant	I-T033
difference	I-T033
in	O
progression	O
-	O
free	O
survival	O
or	O
overall	O
survival	O
between	O
MELF	O
group	O
and	O
non	O
-	O
MELF	O
group	O
by	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O

These	O
findings	O
suggest	O
a	O
possibility	O
that	O
cells	B-T017
at	O
the	O
sites	B-T082
of	O
MELF	B-T082
pattern	I-T082
had	O
acquired	O
increased	O
invasiveness	B-T038
through	O
the	O
function	B-T038
of	O
the	O
CXCL14	B-T103
-	O
CXCR4	B-T103
and	O
CXCL12	B-T103
-	O
CXCR4	B-T103
axes	O
.	O

Crude	O
4	B-T103
-	I-T103
methylcyclohexanemethanol	I-T103
(	O
MCHM	B-T103
)	O
did	O
not	O
cause	O
skin	B-T033
irritation	I-T033
in	O
humans	B-T204
in	O
48	O
-	O
h	O
patch	B-T058
test	I-T058

Crude	O
4	B-T103
-	I-T103
methylcyclohexanemethanol	I-T103
(	O
MCHM	B-T103
)	O
is	O
an	O
industrial	O
chemical	B-T103
used	O
to	O
wash	O
and	O
clean	O
coal	B-T103
.	O

On	O
January	O
9th	O
,	O
2014	O
approximately	O
10	O
,	O
000	O
gallons	O
of	O
a	O
mixture	O
containing	O
crude	O
MCHM	B-T103
were	O
released	O
into	O
the	O
Elk	O
River	O
near	O
Charleston	B-T082
,	O
West	B-T082
Virginia	I-T082
,	O
contaminating	O
the	O
local	B-T082
water	O
supply	O
.	O

Following	O
the	O
spill	O
,	O
residents	B-T098
reported	B-T058
numerous	O
health	O
complaints	O
,	O
and	O
sought	O
medical	B-T033
attention	I-T033
for	O
ailments	B-T033
including	O
rashes	B-T033
and	O
itching	B-T033
.	O

The	O
relationship	O
between	O
the	O
complaints	O
and	O
the	O
spill	O
were	O
unknown	O
,	O
as	O
such	O
symptoms	B-T033
are	O
reported	B-T058
frequently	O
in	O
the	O
background	O
.	O

In	O
this	O
study	B-T062
,	O
the	O
primary	O
irritation	B-T033
potential	O
of	O
crude	O
MCHM	B-T103
was	O
evaluated	O
in	O
206	O
individuals	B-T098
who	O
underwent	O
48	O
hour	O
semi	O
-	O
occluded	O
patch	B-T058
testing	I-T058
.	O

MCHM	B-T103
concentrations	O
assessed	O
in	O
this	O
study	B-T062
were	O
1	O
,	O
5	O
,	O
15	O
,	O
and	O
100	O
ppm	O
.	O

No	O
appreciable	O
skin	B-T201
reactions	I-T201
were	O
observed	O
in	O
individuals	B-T098
at	O
any	O
concentration	O
.	O

Three	O
of	O
the	O
five	O
concentrations	O
evaluated	O
were	O
above	O
the	O
highest	O
measured	O
concentration	O
of	O
MCHM	B-T103
in	O
the	O
tap	B-T103
water	I-T103
of	O
residents	B-T098
in	O
West	B-T082
Virginia	I-T082
(	O
3	O
.	O
7	O
ppm	O
)	O
.	O

The	O
results	O
of	O
this	O
study	B-T062
suggest	O
that	O
crude	O
MCHM	B-T103
would	O
not	O
be	O
a	O
dermal	O
irritant	B-T103
for	O
the	O
vast	O
majority	O
,	O
if	O
not	O
all	O
,	O
potentially	O
exposed	O
persons	B-T098
at	O
the	O
concentrations	O
in	O
the	O
water	B-T103
reported	B-T058
after	O
the	O
spill	O
.	O

New	O
metabolites	B-T103
from	O
the	O
sponge	B-T204
-	O
derived	O
fungus	B-T204
Aspergillus	B-T204
sydowii	I-T204
J05B	I-T204
-	I-T204
7F	I-T204
-	I-T204
4	I-T204

Two	O
new	O
metabolites	B-T103
,	O
diorcinolic	B-T103
acid	I-T103
(	O
1	O
)	O
and	O
β	B-T103
-	I-T103
d	I-T103
-	I-T103
glucopyranosyl	I-T103
aspergillusene	I-T103
A	I-T103
(	O
8	O
)	O
,	O
together	O
with	O
six	O
diphenylethers	B-T103
(	O
2	O
-	O
7	O
)	O
,	O
a	O
diketopiperazine	B-T103
(	O
9	O
)	O
,	O
a	O
chromone	B-T103
(	O
10	O
)	O
and	O
a	O
xanthone	B-T103
(	O
11	O
)	O
were	O
isolated	O
from	O
the	O
fungus	B-T204
Aspergillus	B-T204
sydowii	I-T204
derived	O
from	O
the	O
marine	B-T204
sponge	I-T204
Stelletta	B-T204
sp	I-T204
.	O

The	O
planar	O
structures	O
and	O
their	O
relative	O
configurations	B-T082
were	O
elucidated	O
by	O
analysing	O
1D	O
,	O
2D	O
NMR	O
and	O
HRESIMS	B-T058
data	O
.	O

Compound	B-T103
8	O
is	O
the	O
first	O
glycoside	B-T103
of	O
phenolic	B-T103
bisabolane	B-T103
sesquiterpenes	I-T103
.	O

Compounds	B-T103
1	I-T103
and	I-T103
8	I-T103
exhibited	O
mild	O
cytotoxicity	B-T038
against	O
KB	B-T017
(	O
human	B-T017
nasopharyngeal	I-T017
carcinoma	I-T017
cells	I-T017
)	O
,	O
HepG2	B-T017
(	O
human	B-T017
liver	I-T017
cancer	I-T017
cells	I-T017
)	O
and	O
HCT	B-T017
116	I-T017
(	O
human	B-T017
colon	I-T017
cancer	I-T017
cells	I-T017
)	O
.	O

All	O
compounds	B-T103
were	O
evaluated	B-T058
for	O
antibacterial	O
activity	O
and	O
their	O
abilities	O
to	O
suppress	O
LPS	B-T103
-	O
induced	O
nitric	B-T103
oxide	I-T103
(	O
NO	B-T103
)	O
production	O
.	O

Compounds	B-T103
2	I-T103
and	I-T103
4	I-T103
-	I-T103
7	I-T103
showed	O
mild	O
antibacterial	B-T033
activity	I-T033
against	O
human	B-T204
pathogen	O
Staphylococcus	B-T007
aureus	I-T007
and	O
fish	B-T204
pathogens	O
Streptococcus	B-T007
iniae	I-T007
and	O
Vibrio	B-T007
ichthyoenteri	I-T007
,	O
and	O
compounds	B-T103
4	I-T103
and	I-T103
7	I-T103
weakly	O
suppressed	O
NO	B-T103
production	O
.	O

The	O
neural	O
legacy	O
of	O
a	O
single	O
concussion	B-T037

It	O
has	O
been	O
hypothesized	O
that	O
concussions	B-T037
impart	O
lasting	O
brain	B-T037
damage	I-T037
,	O
even	O
after	O
a	O
patient	O
has	O
ostensibly	O
recovered	O
.	O

This	O
hypothesis	O
is	O
based	O
largely	O
upon	O
neuropathological	O
studies	B-T062
in	O
deceased	B-T038
athletes	B-T097
,	O
however	O
,	O
leaving	O
open	O
the	O
question	O
of	O
whether	O
it	O
can	O
be	O
detected	B-T058
in	O
vivo	O
.	O

We	O
measured	O
neural	O
responses	O
to	O
speech	B-T038
in	O
collegiate	B-T098
student	I-T098
-	O
athletes	B-T097
with	O
a	O
history	O
of	O
a	O
single	O
concussion	B-T037
from	O
which	O
they	O
had	O
recovered	O
.	O

These	O
student	B-T098
-	O
athletes	B-T097
had	O
weaker	O
responses	O
to	O
speech	B-T038
than	O
age	O
-	O
and	O
position	B-T082
-	O
matched	O
peers	B-T098
.	O

This	O
group	O
difference	O
suggests	O
that	O
concussions	B-T037
engender	O
small	O
,	O
but	O
detectable	B-T201
,	O
changes	O
in	O
brain	O
function	O
prior	O
to	O
the	O
emergence	O
of	O
frank	O
behavioral	O
indications	O
.	O

Enhanced	O
Performance	O
of	O
Colorimetric	B-T058
Biosensing	B-T058
on	O
Paper	O
Microfluidic	B-T058
Platforms	I-T058
Through	O
Chemical	O
Modification	O
and	O
Incorporation	O
of	O
Nanoparticles	O

This	O
chapter	O
describes	O
two	O
different	O
methodologies	B-T062
used	O
to	O
improve	O
the	O
analytical	O
performance	O
of	O
colorimetric	B-T058
paper	O
-	O
based	O
biosensors	O
.	O

Microfluidic	O
paper	O
-	O
based	O
analytical	O
devices	O
(	O
μPADs	O
)	O
have	O
been	O
produced	O
by	O
a	O
stamping	O
process	O
and	O
CO2	B-T103
laser	B-T058
ablation	I-T058
and	O
modified	O
,	O
respectively	O
,	O
through	O
an	O
oxidation	O
step	O
and	O
incorporation	O
of	O
silica	B-T103
nanoparticles	O
on	O
the	O
paper	O
structure	O
.	O

Both	O
methods	B-T170
are	O
employed	O
in	O
order	O
to	O
overcome	O
the	O
largest	O
problem	B-T033
associated	O
with	O
colorimetric	B-T058
detection	I-T058
,	O
the	O
heterogeneity	O
of	O
the	O
color	O
distribution	O
in	O
the	O
detection	B-T082
zones	I-T082
.	O

The	O
modification	O
steps	O
are	O
necessary	O
to	O
improve	O
the	O
interaction	O
between	O
the	O
paper	O
surface	B-T082
and	O
the	O
selected	O
enzymes	B-T103
.	O

The	O
enhanced	O
performance	O
has	O
ensured	O
reliability	O
for	O
quantitative	O
analysis	B-T062
of	O
clinically	O
relevant	O
compounds	B-T103
.	O

CXCR4	B-T103
(	O
CD184	B-T103
)	O
expression	B-T038
on	O
stem	B-T058
cell	I-T058
harvest	I-T058
and	O
CD34	B-T103
(	I-T103
+	I-T103
)	I-T103
cells	B-T017
post	O
-	O
transplant	O

CXCR4	B-T103
is	O
a	O
receptor	B-T103
for	O
stromal	B-T103
-	I-T103
derived	I-T103
factor	I-T103
-	I-T103
1	I-T103
(	O
SDF	B-T103
-	I-T103
1	I-T103
)	O
,	O
a	O
molecule	O
that	O
has	O
a	O
chemotactic	B-T038
activity	O
for	O
lymphocytes	B-T017
and	O
is	O
important	O
in	O
homing	B-T038
of	O
hematopoietic	B-T017
stem	I-T017
cells	I-T017
to	O
their	O
adult	B-T017
marrow	I-T017
.	O

We	O
evaluated	B-T058
the	O
CXCR4	B-T103
(	O
CD184	B-T103
)	O
expression	B-T038
in	O
the	O
harvest	B-T017
cells	I-T017
and	O
in	O
the	O
post	O
-	O
transplant	O
bone	B-T017
marrow	I-T017
(	O
BM	B-T017
)	O
and	O
its	O
relation	O
to	O
engraftment	B-T038
,	O
as	O
determined	O
by	O
the	O
consensus	O
criteria	O
and	O
chimerism	O
.	O

This	O
is	O
a	O
prospective	B-T062
study	I-T062
which	O
included	O
30	O
patients	O
undergoing	O
hematopoietic	B-T058
stem	I-T058
cell	I-T058
transplantation	I-T058
;	O
15	O
patients	O
received	O
autograft	B-T058
and	O
15	O
patients	O
received	O
allograft	B-T058
on	O
dates	O
between	O
January	O
2012	O
and	O
May	O
2014	O
.	O

We	O
assessed	O
CD184	B-T103
(	O
CXCR4	B-T103
)	O
using	O
flow	B-T058
cytometry	I-T058
in	O
the	O
harvest	B-T017
cells	I-T017
together	O
with	O
post	O
-	O
transplant	O
BM	B-T017
assessment	B-T058
on	O
Day	O
28	O
and	O
Day	O
90	O
for	O
complete	O
morphologic	B-T082
,	O
molecular	O
studies	O
,	O
and	O
detection	B-T058
of	O
CD184	B-T103
expression	B-T038
on	O
CD34	B-T103
(	I-T103
+	I-T103
)	I-T103
cells	B-T017
with	O
chimerism	O
studies	O
on	O
total	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
.	O

Diagnoses	B-T033
of	O
the	O
enrolled	O
patients	O
were	O
as	O
follows	O
:	O
seven	O
(	O
24	O
.	O
1	O
%	O
)	O
with	O
acute	B-T038
myeloid	I-T038
leukemia	I-T038
,	O
eight	O
(	O
27	O
.	O
6	O
%	O
)	O
with	O
multiple	B-T038
myeloma	I-T038
,	O
four	O
(	O
13	O
.	O
8	O
%	O
)	O
with	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
,	O
three	O
(	O
10	O
.	O
3	O
%	O
)	O
with	O
non	B-T038
-	I-T038
Hodgkin	I-T038
lymphoma	I-T038
,	O
two	O
(	O
6	O
.	O
9	O
%	O
)	O
with	O
myelodysplastic	B-T038
syndromes	I-T038
,	O
two	O
(	O
6	O
.	O
9	O
%	O
)	O
with	O
aplastic	B-T038
anemia	I-T038
,	O
two	O
(	O
6	O
.	O
9	O
%	O
)	O
with	O
chronic	B-T038
myeloid	I-T038
leukemia	I-T038
,	O
one	O
(	O
3	O
.	O
4	O
%	O
)	O
with	O
Hodgkin	B-T038
lymphoma	I-T038
,	O
and	O
one	O
(	O
3	O
.	O
4	O
%	O
)	O
with	O
plasmacytomas	B-T038
.	O

One	O
patient	O
died	B-T033
and	O
was	O
excluded	O
from	O
the	O
study	B-T062
because	O
there	O
were	O
not	O
enough	O
data	O
about	O
engraftment	B-T038
.	O

There	O
was	O
no	B-T033
statistical	O
significance	O
between	O
the	O
level	B-T033
of	O
CD184	B-T103
in	O
stem	B-T058
cell	I-T058
harvest	I-T058
and	O
the	O
prediction	O
of	O
successful	O
engraftment	B-T038
(	O
p	O
>	O
0	O
.	O
05	O
)	O
as	O
well	O
as	O
in	O
Day	O
28	O
BM	B-T031
sample	I-T031
(	O
p	O
>	O
0	O
.	O
05	O
)	O
,	O
whereas	O
there	O
was	O
a	O
statistical	O
significance	O
between	O
the	O
level	B-T033
of	O
CD184	B-T103
in	O
Day	O
90	O
BM	B-T031
sample	I-T031
and	O
the	O
occurrence	O
of	O
successful	O
engraftment	B-T038
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

SDF	B-T103
-	I-T103
1	I-T103
/	O
CXCR4	B-T103
axis	O
plays	O
a	O
crucial	O
role	O
in	O
engraftment	B-T038
;	O
however	O
,	O
more	O
studies	O
are	O
warranted	O
to	O
assess	O
their	O
expression	B-T038
post	O
-	O
transplant	O
.	O

Evaluating	O
the	O
ligand	O
(	O
chemokine	B-T103
,	O
SDF	B-T103
-	I-T103
1	I-T103
)	O
or	O
its	O
receptor	B-T103
(	O
CXCR4	B-T103
)	O
may	O
serve	O
as	O
potential	O
surrogate	O
markers	O
for	O
assessment	B-T058
of	O
engraftment	B-T038
.	O

Genetic	O
diversity	O
of	O
Taenia	B-T204
saginata	I-T204
(	O
Cestoda	B-T204
:	O
Cyclophyllidea	B-T204
)	O
from	O
Lao	B-T082
People	I-T082
'	I-T082
s	I-T082
Democratic	I-T082
Republic	I-T082
and	O
northeastern	B-T082
Thailand	B-T082
based	O
on	O
mitochondrial	B-T103
DNA	I-T103

Taenia	B-T204
saginata	I-T204
is	O
a	O
tapeworm	B-T204
found	O
in	O
cattle	B-T204
worldwide	O
.	O

Analysis	B-T062
of	O
genetic	O
diversity	O
in	O
different	O
geographical	O
populations	O
of	O
T	B-T204
.	I-T204

saginata	I-T204
not	O
only	O
helps	O
to	O
understand	O
the	O
origin	O
,	O
transmission	O
and	O
spread	O
of	O
this	O
organism	O
,	O
but	O
also	O
to	O
evaluate	O
the	O
selection	O
pressures	O
acting	O
on	O
T	B-T204
.	I-T204

saginata	I-T204
and	O
how	O
it	O
is	O
responding	O
to	O
them	O
.	O

However	O
,	O
there	O
are	O
few	O
reports	O
of	O
the	O
genetic	O
variability	O
of	O
T	B-T204
.	I-T204

saginata	I-T204
populations	I-T204
in	O
different	O
regions	B-T082
of	O
the	O
world	B-T098
,	O
including	O
Lao	B-T082
PDR	I-T082
and	O
Thailand	B-T082
.	O

We	O
report	O
the	O
genetic	B-T103
diversity	I-T103
of	O
T	B-T204
.	I-T204

saginata	I-T204
populations	I-T204
in	O
Lao	B-T082
PDR	I-T082
and	O
northeastern	B-T082
Thailand	B-T082
together	O
with	O
sequences	B-T082
of	O
T	B-T204
.	I-T204

saginata	I-T204
from	O
other	O
countries	B-T082
deposited	O
in	O
GenBank	B-T170
.	O

Mitochondrial	B-T017
cox1	I-T017
sequence	B-T058
analysis	I-T058
revealed	O
that	O
15	O
and	O
8	O
haplotypes	O
were	O
identified	O
in	O
30	O
and	O
21	O
T	B-T204
.	I-T204

saginata	I-T204
isolates	O
from	O
Lao	B-T082
PDR	I-T082
and	O
northeastern	B-T082
Thailand	B-T082
,	O
respectively	O
.	O

Fifty	O
-	O
three	O
haplotypes	O
were	O
identified	O
from	O
98	O
sequences	B-T082
.	O

Phylogenetic	B-T062
tree	I-T062
and	O
haplotype	B-T062
network	I-T062
analyses	I-T062
revealed	O
that	O
global	O
isolates	O
of	O
T	B-T204
.	I-T204

saginata	I-T204
were	O
genetically	O
divided	O
into	O
five	O
groups	O
(	O
A	O
,	O
B	O
,	O
C1	O
,	O
C2	O
and	O
D	O
)	O
.	O

Taenia	B-T204
saginata	I-T204
isolates	O
from	O
Lao	B-T082
PDR	I-T082
and	O
northeastern	B-T082
Thailand	B-T082
belonged	O
to	O
either	O
Group	O
A	O
or	O
B	O
.	O

Taenia	B-T204
saginata	I-T204
from	O
western	B-T082
Thailand	B-T082
clustered	O
in	O
groups	O
C1	O
,	O
C2	O
and	O
D	O
,	O
and	O
populations	B-T204
from	O
the	O
northeast	B-T082
and	O
western	B-T082
Thailand	B-T082
were	O
found	O
to	O
be	O
genetically	O
distinct	O
.	O

Taenia	B-T204
saginata	I-T204
isolates	O
in	O
Lao	B-T082
PDR	I-T082
and	O
Thailand	B-T082
were	O
also	O
found	O
to	O
be	O
genetically	O
diverse	O
but	O
the	O
degree	O
of	O
genetic	B-T038
differentiation	I-T038
was	O
low	O
.	O

Taenia	B-T204
saginata	I-T204
populations	I-T204
from	O
Lao	B-T082
PDR	I-T082
and	O
northeastern	B-T082
Thailand	B-T082
are	O
genetically	O
distinct	O
from	O
the	O
population	B-T204
in	O
western	B-T082
Thailand	B-T082
and	O
it	O
is	O
proposed	O
that	O
T	B-T204
.	I-T204

saginata	I-T204
has	O
been	O
dispersed	O
by	O
different	O
transmission	O
routes	O
in	O
Southeast	B-T082
Asia	I-T082
.	O

Development	O
of	O
a	O
novel	O
near	O
-	O
infrared	O
fluorescent	O
theranostic	B-T091
combretastain	B-T103
A	I-T103
-	I-T103
4	I-T103
analogue	B-T103
,	O
YK	B-T103
-	I-T103
5	I-T103
-	I-T103
252	I-T103
,	O
to	O
target	O
triple	B-T038
negative	I-T038
breast	I-T038
cancer	I-T038

The	O
treatment	B-T058
of	O
triple	B-T038
negative	I-T038
breast	I-T038
cancer	I-T038
(	O
TNBC	B-T038
)	O
is	O
a	O
significant	O
challenge	O
to	O
cancer	B-T062
research	I-T062
.	O

The	O
lack	O
of	O
hormone	B-T103
receptors	I-T103
limits	O
the	O
treatment	B-T058
options	O
available	O
to	O
patients	O
with	O
this	O
diagnosis	B-T033
,	O
forcing	O
them	O
to	O
endure	O
prolonged	O
radiation	B-T058
and	O
chemotherapy	B-T058
.	O

Anti	B-T058
-	I-T058
angiogenesis	I-T058
is	O
a	O
chemotherapeutic	O
strategy	O
that	O
targets	O
the	O
vasculature	B-T017
of	O
tumors	B-T038
.	O

Combretastatin	B-T103
A	I-T103
-	I-T103
4	I-T103
(	O
CA	B-T103
-	I-T103
4	I-T103
)	O
is	O
a	O
well	O
-	O
known	O
vasculature	B-T017
-	O
disrupting	O
agent	O
,	O
which	O
has	O
been	O
shown	O
to	O
effectively	O
kill	O
a	O
variety	O
of	O
cancers	B-T038
through	O
inhibition	O
of	O
tubulin	B-T103
polymerization	O
.	O

Due	O
to	O
its	O
toxicity	B-T037
,	O
small	O
molecule	O
analogues	B-T103
of	O
CA	B-T103
-	I-T103
4	I-T103
have	O
been	O
sought	O
out	O
.	O

We	O
have	O
designed	O
a	O
novel	O
dual	O
action	O
CA	B-T103
-	I-T103
4	I-T103
prodrug	B-T103
,	O
YK	B-T103
-	I-T103
5	I-T103
-	I-T103
252	I-T103
,	O
which	O
releases	O
the	O
drug	B-T103
through	O
a	O
disulfide	O
bond	O
cleavage	O
mechanism	O
and	O
contains	O
a	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
fluorophore	O
,	O
which	O
allows	O
fluorescence	O
monitoring	O
of	O
cleavage	O
.	O

This	O
disulfide	O
linkage	O
causes	O
CA	B-T103
-	I-T103
4	I-T103
to	O
become	O
effective	O
only	O
when	O
released	O
by	O
glutathione	B-T103
(	O
GSH	B-T103
)	O
reducing	O
the	O
toxicity	B-T037
of	O
the	O
drug	B-T103
while	O
simultaneously	O
releasing	O
the	O
NIR	O
fluorophore	O
.	O

Therefore	O
the	O
prodrug	B-T103
,	O
YK	B-T103
-	I-T103
5	I-T103
-	I-T103
252	I-T103
,	O
represents	O
a	O
novel	O
CA	B-T103
-	I-T103
4	I-T103
analogue	B-T103
which	O
has	O
reduced	O
toxicity	B-T037
and	O
can	O
be	O
used	O
for	O
theranostics	B-T091
imaging	B-T058
.	O

Epidemiological	O
patterns	B-T082
of	O
bovine	B-T204
besnoitiosis	B-T038
in	O
an	O
endemic	O
beef	B-T204
cattle	I-T204
herd	O
reared	O
under	O
extensive	O
conditions	O

Bovine	B-T204
besnoitiosis	B-T038
is	O
a	O
parasitic	B-T038
disease	I-T038
caused	O
by	O
the	O
protozoan	B-T204
Besnoitia	B-T204
besnoiti	I-T204
.	O

Described	O
many	O
decades	O
ago	O
,	O
recent	O
epidemiological	B-T062
studies	I-T062
reveal	O
its	O
important	O
spread	O
within	O
Europe	B-T082
in	O
the	O
last	O
years	O
.	O

To	O
date	O
,	O
many	O
epidemiological	O
aspects	O
related	O
to	O
life	O
cycle	O
,	O
routes	O
of	O
transmission	B-T038
,	O
incidence	O
rates	O
and	O
associated	O
risk	B-T033
factors	I-T033
are	O
lacking	O
;	O
hence	O
,	O
the	O
establishment	O
of	O
appropriate	B-T058
disease	I-T058
control	I-T058
programmes	B-T170
poses	O
an	O
important	O
challenge	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
determine	O
the	O
epidemiological	O
pattern	B-T082
of	O
the	O
disease	B-T038
in	O
an	O
endemic	O
herd	O
reared	O
under	O
extensive	O
conditions	O
(	O
Spanish	B-T082
Pyrenees	B-T082
)	O
by	O
identifying	O
main	O
factors	O
associated	O
with	O
infection	B-T038
and	O
clinical	B-T038
disease	I-T038
dynamics	O
.	O

The	O
study	B-T062
population	I-T062
consisted	O
of	O
276	O
Brown	B-T204
Swiss	I-T204
and	O
Pirenaica	B-T204
adult	O
animals	O
and	O
145	O
calves	B-T204
born	B-T038
and	O
weaned	B-T033
at	O
the	O
farm	B-T082
during	O
the	O
study	B-T062
.	O

Three	O
sampling	O
time	O
frames	O
were	O
used	O
:	O
January	O
2010	O
,	O
September	O
2010	O
and	O
February	O
2011	O
,	O
which	O
allowed	O
us	O
to	O
differentiate	O
two	O
periods	O
designated	O
as	O
mountain	B-T082
and	O
valley	B-T082
periods	O
.	O

The	O
data	O
related	O
to	O
animals	B-T204
(	O
breed	B-T170
,	O
sex	O
and	O
age	O
)	O
and	O
herd	O
management	O
(	O
animal	O
grouping	O
and	O
time	O
in	O
housing	O
)	O
were	O
recorded	O
.	O

The	O
data	B-T062
collection	I-T062
methodology	O
was	O
mainly	O
based	O
on	O
clinical	O
examinations	O
and	O
defining	O
the	O
serological	O
status	O
against	O
bovine	B-T204
besnoitiosis	B-T038
by	O
the	O
immunofluorescent	B-T058
antibody	I-T058
testing	I-T058
of	O
blood	B-T031
samples	I-T031
.	O

The	O
total	O
prevalence	O
among	O
adult	O
animals	O
was	O
38	O
.	O
34	O
%	O
(	O
CI	O
95	O
%	O
:	O
34	O
.	O
53	O
-	O
42	O
.	O
07	O
)	O
,	O
with	O
18	O
.	O
54	O
%	O
of	O
seropositive	O
animals	B-T204
showing	O
clinical	O
signs	O
.	O

In	O
regard	O
to	O
the	O
cumulative	O
incidence	O
,	O
34	O
.	O
57	O
%	O
of	O
new	O
infections	B-T038
were	O
detected	B-T033
during	O
the	O
mountain	B-T082
period	O
,	O
in	O
contrast	O
to	O
the	O
24	O
.	O
59	O
%	O
observed	O
in	O
the	O
valley	B-T082
period	O
.	O

The	O
incidence	O
density	O
was	O
0	O
.	O
058	O
and	O
0	O
.	O
061	O
new	O
infections	B-T038
per	O
animal	B-T204
-	O
month	O
for	O
the	O
mountain	B-T082
and	O
valley	B-T082
periods	O
,	O
respectively	O
.	O

According	O
to	O
the	O
seroepidemiological	B-T062
study	I-T062
,	O
the	O
seroconversion	O
probability	O
of	O
B	B-T204
.	I-T204

besnoiti	I-T204
infection	B-T038
was	O
directly	O
associated	O
with	O
the	O
number	O
of	O
seropositive	O
cows	B-T204
with	O
whom	O
an	O
animal	B-T204
had	O
been	O
stabled	O
as	O
well	O
as	O
the	O
housing	O
period	O
duration	O
,	O
supporting	O
horizontal	B-T038
transmission	I-T038
by	O
close	O
contact	O
as	O
one	O
of	O
the	O
most	O
important	O
methods	O
of	O
disease	B-T038
spread	O
.	O

In	O
addition	O
,	O
the	O
risk	O
of	O
developing	O
the	O
clinical	O
course	O
increased	O
with	O
age	O
,	O
and	O
the	O
presence	B-T033
of	O
clinical	B-T033
signs	I-T033
was	O
related	O
to	O
higher	O
antibody	B-T038
responses	I-T038
.	O

Among	O
calves	B-T204
(	O
from	O
3	O
.	O
1	O
to	O
7	O
.	O
1	O
months	O
old	O
)	O
sampled	O
once	O
at	O
weaning	B-T033
,	O
the	O
total	O
seroprevalence	B-T062
was	O
15	O
.	O
17	O
%	O
(	O
CI	O
95	O
%	O
:	O
9	O
.	O
36	O
-	O
21	O
.	O
04	O
)	O
,	O
and	O
the	O
chronic	O
stage	O
was	O
observed	O
in	O
three	O
animals	B-T204
,	O
supporting	O
the	O
ability	O
of	O
B	B-T204
.	I-T204

besnoiti	I-T204
to	O
infect	B-T038
and	O
even	O
cause	O
disease	B-T038
in	O
animals	B-T204
less	O
than	O
6	O
months	O
old	O
.	O

Finally	O
,	O
the	O
risk	O
of	O
calf	B-T204
seroconversion	O
was	O
positively	O
related	O
to	O
the	O
serological	O
status	O
of	O
the	O
cows	B-T204
,	O
suggesting	O
postnatal	O
transmission	B-T038
between	O
dams	B-T204
and	O
offspring	B-T204
by	O
contact	O
during	O
the	O
suckling	B-T204
period	O
.	O

A	O
fast	B-T170
small	I-T170
-	I-T170
sample	I-T170
kernel	I-T170
independence	I-T170
test	I-T170
for	O
microbiome	O
community	O
-	O
level	B-T062
association	I-T062
analysis	I-T062

To	O
fully	O
understand	O
the	O
role	O
of	O
microbiome	O
in	O
human	B-T204
health	O
and	O
diseases	B-T038
,	O
researchers	B-T097
are	O
increasingly	O
interested	O
in	O
assessing	O
the	O
relationship	O
between	O
microbiome	O
composition	O
and	O
host	O
genomic	B-T017
data	O
.	O

The	O
dimensionality	B-T082
of	O
the	O
data	O
as	O
well	O
as	O
complex	O
relationships	O
between	O
microbiota	O
and	O
host	O
genomics	B-T017
pose	O
considerable	O
challenges	B-T058
for	O
analysis	B-T062
.	O

In	O
this	O
article	O
,	O
we	O
apply	O
a	O
kernel	B-T170
RV	I-T170
coefficient	I-T170
(	I-T170
KRV	I-T170
)	I-T170
test	I-T170
to	O
evaluate	O
the	O
overall	O
association	O
between	O
host	O
gene	B-T038
expression	I-T038
and	O
microbiome	O
composition	O
.	O

The	O
KRV	B-T170
statistic	I-T170
can	O
capture	O
nonlinear	O
correlations	O
and	O
complex	O
relationships	O
among	O
the	O
individual	O
data	O
types	O
and	O
between	O
gene	B-T038
expression	I-T038
and	O
microbiome	O
composition	O
through	O
measuring	O
general	O
dependency	O
.	O

Testing	O
proceeds	O
via	O
a	O
similar	O
route	O
as	O
existing	O
tests	B-T170
of	O
the	O
generalized	O
RV	O
coefficients	O
and	O
allows	O
for	O
rapid	O
p	O
-	O
value	O
calculation	O
.	O

Strategies	O
to	O
allow	O
adjustment	O
for	O
confounding	O
effects	O
,	O
which	O
is	O
crucial	O
for	O
avoiding	O
misleading	O
results	O
,	O
and	O
to	O
alleviate	O
the	O
problem	B-T033
of	O
selecting	O
the	O
most	O
favorable	O
kernel	B-T170
are	O
considered	O
.	O

Simulation	B-T062
studies	I-T062
show	O
that	O
KRV	O
is	O
useful	O
in	O
testing	O
statistical	O
independence	O
with	O
finite	O
samples	O
given	O
the	O
kernels	B-T170
are	O
appropriately	O
chosen	O
,	O
and	O
can	O
powerfully	O
identify	O
existing	O
associations	O
between	O
microbiome	O
composition	O
and	O
host	O
genomic	B-T017
data	O
while	O
protecting	O
type	B-T170
I	I-T170
error	O
.	O

We	O
apply	O
the	O
KRV	O
to	O
a	O
microbiome	O
study	B-T062
examining	O
the	O
relationship	O
between	O
host	O
transcriptome	B-T082
and	O
microbiome	O
composition	O
within	O
the	O
context	O
of	O
inflammatory	B-T038
bowel	I-T038
disease	I-T038
and	O
are	O
able	O
to	O
derive	O
new	O
biological	O
insights	O
and	O
provide	O
formal	O
inference	O
on	O
prior	O
qualitative	O
observations	O
.	O

An	O
Analysis	B-T062
of	O
Systematic	O
Elemental	B-T103
Changes	O
in	O
Decomposing	B-T017
Bone	I-T017

The	O
aim	O
of	O
this	O
pilot	B-T062
study	I-T062
was	O
to	O
investigate	O
compositional	B-T201
changes	O
in	O
bone	B-T017
during	O
decomposition	O
.	O

Elemental	B-T103
concentrations	O
of	O
barium	B-T103
,	O
calcium	B-T103
,	O
iron	B-T103
,	O
potassium	B-T103
,	O
magnesium	B-T103
,	O
zinc	B-T103
and	O
phosphorus	B-T103
in	O
porcine	B-T204
bone	B-T017
(	O
as	O
an	O
experimental	O
analog	B-T103
for	O
human	B-T204
bone	B-T017
)	O
were	O
analyzed	B-T062
by	O
inductively	O
coupled	O
plasma	O
optical	O
emission	O
spectroscopy	O
(	O
ICP	O
-	O
OES	O
)	O
.	O

The	O
samples	O
were	O
taken	O
from	O
porcine	B-T204
bone	B-T017
subjected	O
to	O
shallow	O
burial	O
and	O
surface	B-T082
depositions	O
at	O
28	O
-	O
day	O
intervals	O
for	O
a	O
period	O
of	O
140	O
days	O
.	O

Results	O
indicated	B-T033
that	O
ICP	O
-	O
OES	O
elemental	B-T103
profiling	O
has	O
potential	O
to	O
be	O
developed	O
as	O
a	O
forensic	B-T058
test	I-T058
for	O
determining	O
whether	O
a	O
bone	O
sample	O
originates	O
from	O
the	O
early	O
stages	O
of	O
soft	B-T017
tissue	I-T017
putrefaction	B-T038
.	O

Significant	O
changes	O
in	O
iron	B-T103
,	O
sodium	B-T103
and	O
potassium	B-T103
concentrations	O
were	O
found	B-T033
over	O
140	O
days	O
.	O

These	O
elements	B-T103
are	O
known	O
to	O
be	O
primarily	O
associated	O
with	O
proteins	B-T103
and	O
/	O
or	O
tissue	B-T031
fluids	I-T031
within	O
the	O
bone	B-T017
.	O

Changes	O
in	O
their	O
respective	O
concentrations	O
may	O
therefore	O
be	O
linked	O
to	O
dehydration	B-T033
over	O
time	O
and	O
in	O
turn	O
may	O
be	O
indicative	O
of	O
time	O
since	O
deposition	O
.	O

Chasing	O
ghosts	O
:	O
allopolyploid	O
origin	O
of	O
Oxyria	B-T204
sinensis	I-T204
(	O
Polygonaceae	B-T204
)	O
from	O
its	O
only	O
diploid	O
congener	O
and	O
an	O
unknown	O
ancestor	O

Reconstructing	O
the	O
origin	O
of	O
a	O
polyploid	B-T038
species	B-T170
is	O
particularly	O
challenging	O
when	O
an	O
ancestor	O
has	O
become	O
extinct	O
.	O

Under	O
such	O
circumstances	O
,	O
the	O
extinct	O
donor	O
of	O
a	O
genome	B-T017
found	O
in	O
the	O
polyploid	B-T038
may	O
be	O
treated	O
as	O
a	O
'	O
ghost	O
'	O
species	B-T170
in	O
that	O
its	O
prior	O
existence	O
is	O
recognized	O
through	O
the	O
presence	O
of	O
its	O
genome	B-T017
in	O
the	O
polyploid	B-T038
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
polyploid	B-T038
origin	O
of	O
Oxyria	B-T204
sinensis	I-T204
(	O
2n	O
=	O
40	O
)	O
for	O
which	O
only	O
one	O
congeneric	O
species	B-T170
is	O
known	O
,	O
that	O
is	O
diploid	O
O	B-T204
.	I-T204

digyna	I-T204
(	O
2n	O
=	O
14	O
)	O
.	O

Genomic	B-T062
in	I-T062
situ	I-T062
hybridization	I-T062
(	O
GISH	B-T062
)	O
,	O
transcriptome	B-T058
,	O
phylogenetic	B-T062
and	O
demographic	B-T062
analyses	I-T062
,	O
and	O
ecological	B-T170
niche	I-T170
modelling	I-T170
were	O
conducted	O
for	O
this	O
purpose	O
.	O

GISH	B-T062
revealed	O
that	O
O	B-T204
.	I-T204

sinensis	I-T204
comprised	O
14	O
chromosomes	B-T017
from	O
O	B-T204
.	I-T204

digyna	I-T204
and	O
26	O
chromosomes	B-T017
from	O
an	O
unknown	O
ancestor	O
.	O

Transcriptome	B-T058
analysis	I-T058
indicated	O
that	O
following	O
divergence	B-T082
from	O
O	B-T204
.	I-T204

digyna	I-T204
,	O
involving	O
genome	B-T038
duplication	I-T038
around	O
12	O
million	O
years	O
ago	O
(	O
Ma	O
)	O
,	O
a	O
second	O
genome	B-T038
duplication	I-T038
occurred	O
approximately	O
6	O
Ma	O
to	O
give	O
rise	O
to	O
O	B-T204
.	I-T204

sinensis	I-T204
.	O

Oxyria	B-T204
sinensis	I-T204
was	O
shown	O
to	O
contain	O
homologous	B-T082
gene	I-T082
sequences	I-T082
divergent	B-T082
from	O
those	O
present	O
in	O
O	B-T204
.	I-T204

digyna	I-T204
in	O
addition	O
to	O
a	O
set	O
that	O
clustered	B-T017
with	O
those	O
in	O
O	B-T204
.	I-T204

digyna	I-T204
.	O

Coalescent	B-T170
simulations	I-T170
indicated	O
that	O
O	B-T204
.	I-T204

sinensis	I-T204
expanded	O
its	O
distribution	O
approximately	O
6	O
-	O
7	O
Ma	O
,	O
possibly	O
following	O
the	O
second	O
polyploidization	B-T038
event	I-T038
,	O
whereas	O
O	B-T204
.	I-T204

digyna	I-T204
expanded	O
its	O
range	O
much	O
later	O
.	O

It	O
was	O
also	O
indicated	O
that	O
the	O
distributions	O
of	O
both	O
species	B-T170
contracted	O
and	O
re	O
-	O
expanded	O
during	O
the	O
Pleistocene	O
climatic	O
oscillations	O
.	O

Ecological	B-T170
niche	I-T170
modelling	I-T170
similarly	O
suggested	O
that	O
both	O
species	B-T170
experienced	O
changes	O
in	O
their	O
distributional	O
ranges	O
in	O
response	O
to	O
Quaternary	O
climatic	O
changes	O
.	O

The	O
extinction	O
of	O
the	O
unknown	O
'	O
ghost	O
'	O
tetraploid	B-T038
species	B-T170
implicated	O
in	O
the	O
origin	O
of	O
O	B-T204
.	I-T204

sinensis	I-T204
could	O
have	O
resulted	O
from	O
superior	O
adaptation	B-T038
of	O
O	B-T204
.	I-T204

sinensis	I-T204
to	O
repeated	O
climatic	O
changes	O
in	O
the	O
region	O
where	O
it	O
now	O
occurs	O
.	O

Primitive	B-T038
Neuroectodermal	I-T038
Tumors	I-T038
of	O
the	O
Female	B-T017
Genital	I-T017
Tract	I-T017
:	O
A	O
Morphologic	O
,	O
Immunohistochemical	O
,	O
and	O
Molecular	O
Study	B-T062
of	O
19	O
Cases	O

Primary	B-T038
primitive	I-T038
neuroectodermal	I-T038
tumor	I-T038
(	O
PNET	B-T038
)	O
of	O
the	O
female	B-T017
genital	I-T017
tract	I-T017
is	O
rare	O
,	O
and	O
its	O
proper	O
classification	B-T170
remains	O
unclear	O
.	O

The	O
clinical	O
,	O
histologic	O
,	O
and	O
immunophenotypic	B-T058
features	O
as	O
well	O
as	O
EWSR1	B-T017
rearrangement	B-T038
status	O
of	O
19	O
gynecologic	B-T082
PNETs	B-T038
,	O
including	O
10	O
ovarian	B-T017
,	O
8	O
uterine	B-T017
,	O
and	O
1	O
vulvar	B-T017
tumors	B-T038
,	O
are	O
herein	O
reported	B-T170
.	O

Patient	O
age	O
ranged	O
from	O
12	O
to	O
68	O
years	O
,	O
with	O
a	O
median	O
age	O
of	O
20	O
and	O
51	O
years	O
among	O
those	O
with	O
ovarian	B-T017
and	O
uterine	B-T017
PNETs	B-T038
,	O
respectively	O
.	O

Morphologic	O
features	O
of	O
central	B-T022
nervous	I-T022
system	I-T022
(	O
CNS	B-T022
)	O
tumors	B-T038
were	O
seen	O
in	O
15	O
PNETs	B-T038
,	O
including	O
9	O
medulloblastomas	B-T038
,	O
3	O
ependymomas	B-T038
,	O
2	O
medulloepitheliomas	B-T038
,	O
and	O
1	O
glioblastoma	B-T038
,	O
consistent	O
with	O
central	B-T038
PNET	I-T038
.	O

The	O
remaining	O
4	O
PNETs	B-T038
were	O
composed	O
entirely	O
of	O
undifferentiated	O
small	B-T017
round	I-T017
blue	I-T017
cells	I-T017
and	O
were	O
classified	O
as	O
Ewing	B-T038
sarcoma	I-T038
/	I-T038
peripheral	I-T038
PNET	I-T038
.	O

Eight	O
PNETs	B-T038
were	O
associated	O
with	O
another	O
tumor	B-T038
type	O
,	O
including	O
5	O
ovarian	B-T017
mature	B-T038
cystic	I-T038
teratomas	I-T038
,	O
2	O
endometrial	O
low	O
-	O
grade	O
endometrioid	B-T038
carcinomas	I-T038
,	O
and	O
a	O
uterine	B-T038
carcinosarcoma	I-T038
.	O

By	O
immunohistochemistry	B-T058
,	O
17	O
PNETs	B-T038
expressed	O
at	O
least	O
1	O
marker	B-T103
of	O
neuronal	B-T033
differentiation	I-T033
,	O
including	O
synaptophysin	B-T103
,	O
NSE	B-T103
,	O
CD56	B-T103
,	O
S100	B-T103
,	O
and	O
chromogranin	B-T103
in	O
10	O
,	O
8	O
,	O
14	O
,	O
8	O
,	O
and	O
1	O
tumors	B-T038
,	O
respectively	O
.	O

GFAP	B-T103
was	O
positive	O
in	O
4	O
PNETs	B-T038
,	O
all	O
of	O
which	O
were	O
of	O
central	O
type	O
.	O

Membranous	B-T017
CD99	B-T103
and	O
nuclear	B-T082
Fli	B-T103
-	I-T103
1	I-T103
staining	B-T058
was	O
seen	O
in	O
10	O
and	O
16	O
tumors	B-T038
,	O
respectively	O
,	O
and	O
concurrent	O
expression	B-T038
of	O
both	O
markers	B-T103
was	O
seen	O
in	O
both	O
central	B-T038
and	O
Ewing	B-T038
sarcoma	I-T038
/	I-T038
peripheral	I-T038
PNET	I-T038
s	O
.	O

All	O
tumors	B-T038
expressed	B-T038
vimentin	B-T103
,	O
whereas	O
keratin	B-T103
cocktail	O
(	O
CAM5	B-T103
.	I-T103
2	I-T103
,	O
AE1	O
/	O
AE3	O
)	O
staining	B-T058
was	O
only	O
focally	O
present	O
in	O
4	O
PNETs	B-T038
.	O

Fluorescence	B-T062
in	I-T062
situ	I-T062
hybridization	I-T062
was	O
successful	O
in	O
all	O
cases	O
and	O
confirmed	O
EWSR1	B-T017
rearrangement	B-T038
in	O
2	O
of	O
4	O
tumors	B-T038
demonstrating	O
morphologic	O
features	O
of	O
Ewing	B-T038
sarcoma	I-T038
/	I-T038
peripheral	I-T038
PNET	I-T038
and	O
concurrent	O
CD99	B-T103
and	O
Fli	B-T103
-	I-T103
1	I-T103
expression	B-T038
.	O

In	O
conclusion	O
,	O
central	B-T038
and	O
Ewing	B-T038
sarcoma	I-T038
/	I-T038
peripheral	I-T038
PNETs	I-T038
may	O
be	O
encountered	O
in	O
the	O
female	B-T017
genital	I-T017
tract	I-T017
with	O
central	B-T038
PNETs	I-T038
being	O
more	O
common	O
.	O

Central	B-T038
PNETs	I-T038
show	O
a	O
spectrum	O
of	O
morphologic	O
features	O
that	O
overlaps	O
with	O
CNS	B-T022
tumors	B-T038
but	O
lack	O
EWSR1	B-T017
rearrangement	B-T038
s	O
.	O

GFAP	B-T103
expression	B-T038
supports	O
a	O
morphologic	O
impression	O
of	O
central	B-T038
PNET	I-T038
and	O
is	O
absent	O
in	O
Ewing	O
sarcoma	B-T038
/	I-T038
peripheral	I-T038
PNET	I-T038
.	O

Ewing	B-T038
sarcoma	I-T038
/	I-T038
peripheral	I-T038
PNETs	I-T038
lack	O
morphologic	O
features	O
of	O
CNS	B-T022
tumors	B-T038
.	O

Surgical	B-T058
Excision	I-T058
of	O
Heterotopic	B-T038
Ossification	I-T038
Leads	O
to	O
Re	O
-	O
Emergence	O
of	O
Mesenchymal	B-T017
Stem	I-T017
Cell	I-T017
Populations	I-T017
Responsible	O
for	O
Recurrence	O

Trauma	O
-	O
induced	O
heterotopic	B-T038
ossification	I-T038
(	O
HO	B-T038
)	O
occurs	O
after	O
severe	O
musculoskeletal	B-T037
injuries	I-T037
and	O
burns	B-T037
,	O
and	O
presents	O
a	O
significant	O
barrier	O
to	O
patient	O
rehabilitation	B-T058
.	O

Interestingly	O
,	O
the	O
incidence	O
of	O
HO	B-T038
significantly	O
increases	O
with	O
repeated	B-T058
operations	I-T058
and	O
after	O
resection	B-T058
of	O
previous	O
HO	B-T038
.	O

Treatment	B-T058
of	O
established	O
heterotopic	B-T038
ossification	I-T038
is	O
challenging	O
because	O
surgical	B-T058
excision	I-T058
is	O
often	O
incomplete	O
,	O
with	O
evidence	O
of	O
persistent	O
heterotopic	O
bone	O
.	O

As	O
a	O
result	O
,	O
patients	O
may	O
continue	O
to	O
report	O
the	O
signs	B-T033
or	I-T033
symptoms	I-T033
of	O
HO	B-T038
,	O
including	O
chronic	B-T033
pain	I-T033
,	O
nonhealing	O
wounds	B-T037
,	O
and	O
joint	B-T033
restriction	I-T033
.	O

In	O
this	O
study	B-T062
,	O
we	O
designed	O
a	O
model	B-T038
of	O
recurrent	O
HO	B-T038
that	O
occurs	O
after	O
surgical	B-T058
excision	I-T058
of	O
mature	O
HO	B-T038
in	O
a	O
mouse	B-T038
model	I-T038
of	O
hind	B-T017
-	I-T017
limb	I-T017
Achilles	I-T017
'	I-T017
tendon	I-T017
transection	B-T058
with	O
dorsal	B-T082
burn	B-T037
injury	I-T037
.	O

We	O
first	O
demonstrated	O
that	O
key	O
signaling	B-T038
mediators	B-T103
of	O
HO	B-T038
,	O
including	O
bone	B-T038
morphogenetic	I-T038
protein	I-T038
signaling	I-T038
,	O
are	O
diminished	O
in	O
mature	B-T017
bone	I-T017
.	O

However	O
,	O
upon	O
surgical	B-T058
excision	I-T058
,	O
we	O
have	O
noted	O
upregulation	B-T038
of	O
downstream	B-T082
mediators	B-T103
of	O
osteogenic	O
differentiation	O
,	O
including	O
pSMAD	B-T103
1	I-T103
/	O
5	B-T103
.	O

Additionally	O
,	O
surgical	B-T058
excision	I-T058
resulted	O
in	O
re	O
-	O
emergence	O
of	O
a	O
mesenchymal	B-T017
cell	I-T017
population	I-T017
marked	O
by	O
expression	O
of	O
platelet	B-T103
-	I-T103
derived	I-T103
growth	I-T103
factor	I-T103
receptor	I-T103
-	I-T103
α	I-T103
(	O
PDGFRα	B-T103
)	O
and	O
present	B-T033
in	O
the	O
initial	O
developing	O
HO	B-T038
lesion	B-T033
but	O
absent	O
in	O
mature	O
HO	B-T038
.	O

In	O
the	O
recurrent	O
lesion	B-T033
,	O
these	O
PDGFRα	B-T103
+	O
mesenchymal	B-T017
cells	I-T017
are	O
also	O
highly	O
proliferative	B-T038
,	O
similar	O
to	O
the	O
initial	O
developing	O
HO	B-T038
lesion	B-T033
.	O

These	O
findings	O
indicate	O
that	O
surgical	B-T058
excision	I-T058
of	O
HO	B-T038
results	O
in	O
recurrence	O
through	O
similar	O
mesenchymal	B-T017
cell	I-T017
populations	I-T017
and	O
signaling	B-T038
mechanisms	O
that	O
are	O
present	B-T033
in	O
the	O
initial	O
developing	O
HO	B-T038
lesion	B-T033
.	O

These	O
results	O
are	O
consistent	O
with	O
findings	B-T033
in	O
patients	O
that	O
new	O
foci	B-T082
of	O
ectopic	B-T017
bone	I-T017
can	O
develop	O
in	O
excision	B-T058
sites	B-T082
and	O
are	O
likely	O
related	O
to	O
de	O
novo	O
formation	O
rather	O
than	O
extension	O
of	O
unresected	B-T170
bone	B-T017
.	O

Stem	O
Cells	O
Translational	O
Medicine	O
2017	O
;	O
6	O
:	O
799	O
-	O
806	O
.	O

Extended	O
release	O
of	O
flurbiprofen	B-T103
from	O
tromethamine	B-T103
-	O
buffered	B-T103
HPMC	B-T103
hydrophilic	O
matrix	B-T103
tablets	I-T103

The	O
pH	O
-	O
dependent	O
solubility	O
of	O
a	O
drug	B-T103
can	O
lead	O
to	O
pH	O
-	O
dependent	O
drug	O
release	O
from	O
hydrophilic	O
matrix	B-T103
tablets	I-T103
.	O

Adding	O
buffer	O
salts	O
to	O
the	O
formulation	B-T103
to	O
attempt	O
to	O
mitigate	O
this	O
can	O
impair	O
matrix	O
hydration	O
and	O
negatively	B-T033
impact	O
drug	O
release	O
.	O

An	O
evaluation	B-T058
of	O
the	O
buffering	B-T103
of	O
hydrophilic	O
matrix	B-T103
tablets	I-T103
containing	O
a	O
pH	O
-	O
dependent	O
solubility	O
weak	B-T103
acid	I-T103
drug	I-T103
(	O
flurbiprofen	B-T103
)	O
,	O
identified	O
as	O
possessing	O
a	O
deleterious	O
effect	O
on	O
hydroxypropyl	B-T103
methylcellulose	I-T103
(	O
HPMC	B-T103
)	O
solubility	O
,	O
swelling	O
and	O
gelation	O
,	O
with	O
respect	O
to	O
drug	O
dissolution	O
and	O
the	O
characteristics	O
of	O
the	O
hydrophilic	O
matrix	B-T103
gel	I-T103
layer	I-T103
in	O
the	O
presence	O
of	O
tromethamine	B-T103
as	O
a	O
buffer	B-T103
was	O
undertaken	O
.	O

The	O
inclusion	O
of	O
tromethamine	B-T103
as	O
an	O
alkalizing	B-T103
agent	I-T103
afforded	O
pH	O
-	O
independent	O
flurbiprofen	B-T103
release	O
from	O
matrices	O
based	O
on	O
both	O
HPMC	B-T103
2910	I-T103
(	I-T103
E	I-T103
series	I-T103
)	I-T103
and	O
2208	B-T103
(	I-T103
K	I-T103
series	I-T103
)	I-T103
,	O
while	O
concomitantly	O
decreasing	B-T033
the	O
apparent	O
critical	O
effect	O
on	O
dissolution	O
mediated	O
by	O
this	O
drug	B-T103
with	O
respect	O
to	O
the	O
early	O
pseudo	O
-	O
gel	O
layer	O
formation	O
and	O
functionality	O
.	O

Drug	O
release	O
profiles	O
were	O
unaffected	O
by	O
matrix	O
pH	B-T033
-	I-T033
changes	I-T033
resulting	O
from	O
loss	O
of	O
tromethamine	B-T103
over	O
time	O
,	O
suggesting	O
that	O
HPMC	B-T103
inhibited	O
precipitation	O
of	O
drug	B-T103
from	O
supersaturated	O
solution	O
in	O
the	O
hydrated	O
matrix	O
.	O

We	O
propose	O
that	O
facilitation	B-T038
of	O
diffusion	O
-	O
based	O
release	O
of	O
potentially	O
deleterious	B-T103
drugs	I-T103
in	O
hydrophilic	O
matrices	O
may	O
be	O
achieved	O
through	O
judicious	O
selection	O
of	O
a	O
buffering	B-T103
species	I-T103
.	O

The	O
influence	O
of	O
slope	O
on	O
Spartium	B-T204
junceum	I-T204
root	B-T204
system	I-T204
:	O
morphological	O
,	O
anatomical	O
and	O
biomechanical	O
adaptation	B-T038

Root	B-T204
systems	I-T204
have	O
a	O
pivotal	O
role	O
in	O
plant	B-T204
anchorage	O
and	O
their	O
mechanical	O
interactions	O
with	O
the	O
soil	O
may	O
contribute	O
to	O
soil	O
reinforcement	O
and	O
stabilization	O
of	O
slide	O
-	O
prone	O
slopes	O
.	O

In	O
order	O
to	O
understand	O
the	O
responses	O
of	O
root	B-T204
system	I-T204
to	O
mechanical	O
stress	O
induced	O
by	O
slope	O
,	O
samples	O
of	O
Spartium	B-T204
junceum	I-T204
L	I-T204
.	I-T204
,	O
growing	O
in	O
slope	O
and	O
in	O
plane	O
natural	O
conditions	O
,	O
were	O
compared	O
in	O
their	O
morphology	O
,	O
biomechanical	O
properties	O
and	O
anatomical	B-T082
features	I-T082
.	O

Soils	O
sampled	O
in	O
slope	O
and	O
plane	O
revealed	O
similar	O
characteristics	O
,	O
with	O
the	O
exception	O
of	O
organic	O
matter	O
content	O
and	O
penetrometer	O
resistance	O
,	O
both	O
higher	O
in	O
slope	O
.	O

Slope	O
significantly	O
influenced	O
root	B-T204
morphology	O
and	O
in	O
particular	O
the	O
distribution	O
of	O
lateral	B-T082
roots	B-T204
along	O
the	O
soil	O
depth	B-T082
.	O

Indeed	O
,	O
first	O
-	O
order	O
lateral	B-T082
roots	B-T204
of	O
plants	B-T204
growing	O
on	O
slope	O
condition	O
showed	O
an	O
asymmetric	B-T082
distribution	O
between	O
up	O
-	O
and	O
down	O
-	O
slope	O
.	O

Contrarily	O
,	O
this	O
asymmetric	B-T082
distribution	O
was	O
not	O
observed	O
in	O
plants	B-T204
growing	O
in	O
plane	O
.	O

The	O
tensile	O
strength	O
was	O
higher	O
in	O
lateral	B-T082
roots	B-T204
growing	O
up	O
-	O
slope	O
and	O
in	O
plane	O
conditions	O
than	O
in	O
those	O
growing	O
down	O
-	O
slope	O
.	O

Anatomical	B-T062
investigations	I-T062
revealed	O
that	O
,	O
while	O
roots	B-T204
grown	O
up	O
-	O
slope	O
had	O
higher	O
area	B-T082
covered	O
by	O
xylem	B-T204
fibers	I-T204
,	O
the	O
ratio	O
of	O
xylem	B-T204
and	O
phloem	B-T204
fibers	I-T204
to	O
root	B-T204
diameter	O
did	O
not	O
differ	O
among	O
the	O
three	O
conditions	O
,	O
as	O
also	O
,	O
no	O
differences	O
were	O
found	O
for	O
xylem	B-T204
fiber	I-T204
cell	B-T017
wall	I-T017
thickness	O
.	O

Roots	B-T204
growing	O
up	O
-	O
slope	O
were	O
the	O
main	O
contributors	O
to	O
anchorage	O
properties	O
,	O
which	O
included	O
higher	O
strength	O
and	O
higher	O
number	O
of	O
fibers	B-T204
in	O
the	O
xylematic	B-T204
tissues	B-T017
.	O

Results	O
suggested	O
that	O
a	O
combination	O
of	O
root	B-T204
-	O
specific	O
morphological	O
,	O
anatomical	O
and	O
biomechanical	O
traits	O
,	O
determines	O
anchorage	O
functions	O
in	O
slope	O
conditions	O
.	O

Altered	O
expression	B-T038
of	O
the	O
Olr59	B-T017
,	O
Ethe1	B-T017
,	O
and	O
Slc10a2	B-T017
genes	I-T017
in	O
the	O
liver	B-T017
of	O
F344	B-T204
rats	I-T204
by	O
neonatal	O
thyroid	B-T037
hormone	I-T037
disruption	I-T037

Many	O
concerns	O
have	O
been	O
expressed	O
regarding	O
the	O
possible	O
adverse	O
effects	O
of	O
thyroid	B-T037
hormone	I-T037
-	I-T037
disrupting	I-T037
chemicals	B-T103
in	O
the	O
environment	B-T082
.	O

The	O
disruption	B-T037
of	I-T037
thyroid	I-T037
hormones	I-T037
in	O
the	O
neonatal	O
period	O
may	O
lead	O
to	O
permanent	O
effects	O
on	O
thyroid	B-T103
hormone	I-T103
homeostasis	B-T038
as	O
well	O
as	O
related	O
developmental	B-T038
disorders	I-T038
,	O
as	O
thyroid	B-T103
hormones	I-T103
are	O
essential	O
for	O
regulating	B-T038
the	I-T038
growth	I-T038
and	O
differentiation	B-T033
of	I-T033
many	I-T033
tissues	I-T033
.	O

To	O
understand	O
the	O
long	O
-	O
term	O
alteration	O
in	O
gene	B-T038
expressions	I-T038
by	O
neonatal	O
administration	B-T058
of	I-T058
thyroid	I-T058
hormone	I-T058
-	O
like	O
chemicals	O
in	O
general	O
,	O
we	O
identified	O
genes	B-T038
whose	I-T038
expression	I-T038
was	O
altered	O
in	O
the	O
liver	B-T017
,	O
an	O
important	O
component	O
of	O
the	O
thyroid	B-T103
hormone	I-T103
axis	O
,	O
by	O
neonatal	O
exposure	O
to	O
triiodothyronine	B-T103
(	O
T3	B-T103
)	O
.	O

T3	B-T103
was	O
administered	B-T058
to	O
male	B-T204
F344	I-T204
rats	I-T204
on	O
postnatal	O
days	O
1	O
,	O
3	O
,	O
and	O
5	O
(	O
week	O
0	O
)	O
.	O

At	O
8	O
weeks	O
of	O
age	O
,	O
cDNA	B-T062
microarray	I-T062
analysis	I-T062
was	O
used	O
to	O
identify	O
hepatic	B-T082
genes	B-T017
whose	O
expression	B-T038
was	O
altered	O
by	O
neonatal	O
exposure	O
to	O
T3	B-T103
.	O

Among	O
the	O
up	B-T038
-	I-T038
regulated	I-T038
genes	I-T038
that	O
were	O
identified	O
,	O
the	O
expression	B-T038
of	O
Olr59	B-T017
,	O
Ethe1	B-T017
,	O
and	O
Slc10a2	B-T017
increased	O
specifically	O
in	O
rats	B-T204
neonatally	O
exposed	O
to	O
T3	B-T103
.	O

Interestingly	O
,	O
altered	O
hepatic	B-T082
expression	B-T038
of	I-T038
these	I-T038
genes	I-T038
indeed	O
increased	O
when	O
a	O
hydroxylated	B-T103
polybrominated	I-T103
diphenyl	I-T103
ether	I-T103
(	O
PBDE	B-T103
)	O
,	O
OH	B-T103
-	I-T103
BDE42	I-T103
,	O
which	O
is	O
capable	O
of	O
binding	B-T038
to	I-T038
the	I-T038
TR	I-T038
,	O
was	O
given	O
neonatally	O
.	O

Our	O
data	O
demonstrated	O
that	O
neonatal	O
exposure	O
to	O
thyroid	B-T103
hormones	I-T103
could	O
affect	O
the	O
long	O
-	O
term	O
expression	B-T038
of	I-T038
the	I-T038
genes	I-T038
,	O
which	O
could	O
be	O
useful	O
markers	O
for	O
neonatal	B-T038
effects	I-T038
by	O
thyroid	B-T103
hormone	I-T103
-	O
disrupting	B-T103
chemicals	I-T103
.	O

Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

The	O
Psychometric	B-T058
Costs	I-T058
of	O
Applicants	B-T098
'	O
Faking	O
:	O
Examining	O
Measurement	O
Invariance	O
and	O
Retest	B-T062
Correlations	I-T062
Across	O
Response	B-T038
Conditions	I-T038

This	O
study	O
examines	O
the	O
stability	O
of	O
the	O
response	B-T038
process	I-T038
and	O
the	O
rank	O
-	O
order	O
of	O
respondents	B-T098
responding	B-T038
to	O
3	O
personality	B-T170
scales	I-T170
in	O
4	O
different	O
response	B-T038
conditions	I-T038
.	O

Applicants	B-T098
to	O
the	O
University	B-T092
College	I-T092
of	I-T092
Teacher	I-T092
Education	I-T092
Styria	B-T082
(	O
N	O
=	O
243	O
)	O
completed	O
personality	B-T170
scales	I-T170
as	O
part	O
of	O
their	O
college	B-T170
admission	I-T170
process	I-T170
.	O

Half	O
a	O
year	O
later	O
,	O
they	O
retook	O
the	O
same	O
personality	B-T170
scales	I-T170
in	O
1	O
of	O
3	O
randomly	O
assigned	O
experimental	O
response	B-T038
conditions	I-T038
:	O
honest	O
,	O
faking	O
-	O
good	O
,	O
or	O
reproduce	O
.	O

Longitudinal	B-T062
means	I-T062
and	O
covariance	O
structure	O
analyses	O
showed	O
that	O
applicants	B-T098
'	O
response	B-T038
processes	I-T038
could	O
be	O
partially	O
reproduced	O
after	O
half	O
a	O
year	O
,	O
and	O
respondents	B-T098
seemed	O
to	O
rely	O
on	O
an	O
honest	O
response	B-T038
behavior	I-T038
as	O
a	O
frame	O
of	O
reference	O
.	O

Additionally	O
,	O
applicants	B-T098
'	O
faking	O
behavior	O
and	O
instructed	O
faking	O
(	O
faking	O
-	O
good	O
)	O
caused	O
differences	O
in	O
the	O
latent	O
retest	B-T062
correlations	I-T062
and	O
consistently	O
affected	O
measurement	O
properties	O
.	O

The	O
varying	O
latent	O
retest	B-T062
correlations	I-T062
indicated	B-T033
that	O
faking	O
can	O
distort	O
respondents	B-T098
'	O
rank	O
-	O
order	O
and	O
thus	O
the	O
fairness	O
of	O
subsequent	O
selection	B-T038
decisions	I-T038
,	O
depending	O
on	O
the	O
kind	O
of	O
faking	O
behavior	O
.	O

Instructed	O
faking	O
(	O
faking	O
-	O
good	O
)	O
even	O
affected	O
weak	O
measurement	O
invariance	O
,	O
whereas	O
applicants	B-T098
'	O
faking	O
behavior	O
did	O
not	O
.	O

Consequently	O
,	O
correlations	O
with	O
personality	B-T170
scales	I-T170
-	O
which	O
can	O
be	O
utilized	O
for	O
predictive	O
validity	O
-	O
may	O
be	O
readily	O
interpreted	O
for	O
applicants	B-T098
.	O

Faking	O
behavior	O
also	O
introduced	O
a	O
uniform	O
bias	O
,	O
implying	O
that	O
the	O
classically	O
observed	O
mean	O
raw	O
score	O
differences	O
may	O
not	O
be	O
readily	O
interpreted	O
.	O

Intraspinal	B-T038
meningioma	I-T038
with	O
malignant	B-T038
transformation	I-T038
and	O
distant	B-T170
metastasis	I-T170

Meningioma	B-T038
is	O
typically	O
considered	O
to	O
be	O
a	O
benign	B-T038
tumor	I-T038
.	O

Malignant	B-T038
transformation	I-T038
and	O
metastasis	B-T038
of	O
meningiomas	B-T038
are	O
rare	O
.	O

Moreover	O
,	O
most	O
meningiomas	B-T038
are	O
intracranial	B-T082
,	O
and	O
there	O
are	O
few	O
reports	B-T170
on	O
intraspinal	B-T038
meningiomas	I-T038
.	O

This	O
report	B-T170
aimed	O
to	O
describe	O
the	O
clinical	O
features	O
and	O
pathological	O
findings	B-T033
of	O
a	O
case	O
of	O
malignant	B-T038
transformation	I-T038
and	O
distant	B-T170
metastasis	I-T170
of	O
intraspinal	B-T038
meningioma	I-T038
,	O
with	O
a	O
review	O
of	O
the	O
literature	B-T170
.	O

A	O
44	O
-	O
year	O
-	O
old	O
man	B-T098
with	O
a	O
bilateral	B-T082
lower	B-T033
limb	I-T033
paresis	I-T033
was	O
diagnosed	B-T033
with	O
an	O
intradural	B-T038
extramedullary	I-T038
tumor	I-T038
of	I-T038
the	I-T038
thoracic	I-T038
spine	I-T038
.	O

Primary	O
tumor	B-T058
resection	I-T058
was	O
performed	O
,	O
and	O
the	O
histological	B-T033
findings	I-T033
revealed	O
atypical	B-T038
meningioma	I-T038
.	O

The	O
meningioma	B-T038
recurred	O
2	O
years	O
after	O
the	O
primary	O
surgery	B-T058
,	O
and	O
a	O
second	O
resection	B-T058
was	O
performed	O
,	O
but	O
only	O
partial	O
resection	B-T058
was	O
possible	O
because	O
of	O
decreased	O
motor	B-T038
evoked	I-T038
potential	I-T038
.	O

At	O
age	O
48	O
,	O
the	O
patient	O
'	O
s	O
lower	B-T033
limb	I-T033
weakness	I-T033
returned	O
,	O
and	O
a	O
third	O
resection	B-T058
was	O
performed	O
,	O
and	O
the	O
histological	B-T033
finding	I-T033
remained	O
atypical	B-T038
meningioma	I-T038
.	O

At	O
age	O
54	O
,	O
the	O
tumor	B-T038
increased	O
and	O
stereotactic	B-T058
irradiation	I-T058
was	O
performed	O
.	O

At	O
age	O
60	O
,	O
the	O
patient	O
was	O
diagnosed	B-T033
with	O
metastatic	B-T038
tumors	I-T038
of	O
the	O
rib	B-T017
,	O
lumbar	B-T017
vertebra	I-T017
,	O
cervical	B-T017
spine	I-T017
,	O
and	O
sacrum	B-T017
.	O

Biopsy	B-T058
of	O
the	O
rib	B-T017
metastatic	B-T038
tumor	I-T038
was	O
performed	O
,	O
and	O
the	O
histological	B-T033
findings	I-T033
revealed	O
anaplastic	B-T038
meningioma	I-T038
.	O

This	O
case	O
is	O
the	O
first	O
report	B-T170
of	O
an	O
intraspinal	B-T038
meningioma	I-T038
that	O
transformed	B-T038
from	O
atypical	B-T038
to	O
anaplastic	B-T038
meningioma	I-T038
with	O
distant	B-T170
hematogenous	B-T033
metastasis	I-T170
.	O

Epidemiology	B-T091
and	O
risk	B-T033
factors	I-T033
associated	O
with	O
surgical	B-T038
site	I-T038
infection	I-T038
after	O
different	O
types	O
of	O
hepatobiliary	B-T091
and	I-T091
pancreatic	I-T091
surgery	I-T091

Surgical	B-T038
site	I-T038
infection	I-T038
(	O
SSI	B-T038
)	O
is	O
one	O
of	O
the	O
most	O
common	O
healthcare	B-T038
-	I-T038
associated	I-T038
infections	I-T038
(	O
HAIs	B-T038
)	O
;	O
however	O
,	O
SSI	B-T038
after	O
hepatobiliary	B-T091
and	I-T091
pancreatic	I-T091
surgery	I-T091
(	O
HBPS	B-T091
)	O
has	O
not	O
been	O
well	O
investigated	O
in	O
a	O
large	O
cohort	B-T098
of	O
patients	O
.	O

This	O
study	O
analyzed	O
the	O
factors	O
associated	O
with	O
SSI	B-T038
following	O
HBPS	B-T091
in	O
Japan	B-T082
,	O
using	O
a	O
Japanese	B-T170
national	I-T170
database	I-T170
.	O

Data	O
on	O
HBPS	B-T091
performed	O
between	O
2012	O
and	O
2014	O
were	O
extracted	B-T062
from	O
a	O
national	B-T170
monitoring	I-T170
system	I-T170
for	O
HAI	B-T038
:	O
The	O
Japan	B-T058
Nosocomial	I-T058
Infections	I-T058
Surveillance	I-T058
.	O

Using	O
multivariate	B-T062
logistic	I-T062
regression	I-T062
,	O
I	O
assessed	O
the	O
factors	O
associated	O
with	O
SSI	B-T038
.	O

The	O
cumulative	O
incidence	O
of	O
SSI	B-T038
following	O
HBPS	B-T091
was	O
15	O
.	O
6	O
%	O
(	O
2873	O
/	O
18	O
,	O
398	O
)	O
.	O

The	O
incidence	O
of	O
SSI	B-T038
after	O
pancreatoduodenectomy	B-T058
was	O
28	O
.	O
0	O
%	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
that	O
after	O
liver	B-T058
resection	I-T058
and	O
other	O
types	O
of	O
HBPS	B-T091
(	O
8	O
.	O
8	O
and	O
15	O
.	O
5	O
%	O
,	O
respectively	O
)	O
.	O

Among	O
the	O
four	O
traditional	O
risk	B-T033
factors	I-T033
,	O
the	O
American	B-T092
Society	I-T092
of	I-T092
Anesthesiologists	I-T092
score	O
was	O
ineffective	O
for	O
predicting	O
SSI	B-T038
in	O
the	O
final	O
model	B-T170
of	O
all	O
three	O
types	O
of	O
surgery	B-T058
.	O

Additional	O
risk	B-T033
factors	I-T033
were	O
identified	O
,	O
including	O
age	O
and	O
male	O
gender	O
.	O

The	O
incidence	O
of	O
and	O
factors	O
associated	O
with	O
SSI	B-T038
after	O
the	O
three	O
types	O
of	O
HBPS	B-T091
analyzed	O
differed	O
significantly	O
.	O

To	O
accurately	O
compare	O
hospital	B-T092
performance	O
in	O
relation	O
to	O
SSI	B-T038
following	O
HBPS	B-T091
,	O
the	O
operative	B-T058
procedure	I-T058
category	B-T170
in	O
the	O
surveillance	O
system	O
must	O
be	O
divided	O
into	O
three	O
types	O
.	O

Signature	B-T082
of	O
an	O
aggregation	O
-	O
prone	B-T082
conformation	O
of	O
tau	B-T103

The	O
self	O
-	O
assembly	O
of	O
the	O
microtubule	B-T017
associated	O
tau	B-T103
protein	I-T103
into	O
fibrillar	B-T017
cell	I-T017
inclusions	I-T017
is	O
linked	B-T082
to	O
a	O
number	O
of	O
devastating	O
neurodegenerative	B-T038
disorders	I-T038
collectively	O
known	O
as	O
tauopathies	B-T038
.	O

The	O
mechanism	O
by	O
which	O
tau	B-T103
self	O
-	O
assembles	O
into	O
pathological	O
entities	O
is	O
a	O
matter	O
of	O
much	O
debate	O
,	O
largely	O
due	O
to	O
the	O
lack	O
of	O
direct	O
experimental	O
insights	B-T038
into	O
the	O
earliest	O
stages	O
of	O
aggregation	O
.	O

We	O
present	O
pulsed	B-T058
double	I-T058
electron	I-T058
-	I-T058
electron	I-T058
resonance	I-T058
measurements	O
of	O
two	O
key	O
fibril	B-T017
-	O
forming	O
regions	B-T082
of	O
tau	B-T103
,	O
PHF6	B-T103
and	O
PHF6	B-T103
*	I-T103
,	O
in	O
transient	O
as	O
aggregation	O
happens	O
.	O

By	O
monitoring	O
the	O
end	O
-	O
to	O
-	O
end	O
distance	O
distribution	O
of	O
these	O
segments	O
as	O
a	O
function	O
of	O
aggregation	O
time	O
,	O
we	O
show	O
that	O
the	O
PHF6	B-T103
(	I-T103
(	I-T103
*	I-T103
)	I-T103
)	I-T103
regions	B-T082
dramatically	O
extend	O
to	O
distances	O
commensurate	O
with	O
extended	B-T082
β	B-T082
-	I-T082
strand	I-T082
structures	I-T082
within	O
the	O
earliest	O
stages	O
of	O
aggregation	O
,	O
well	O
before	O
fibril	B-T017
formation	O
.	O

Combined	O
with	O
simulations	B-T062
,	O
our	O
experiments	B-T062
show	O
that	O
the	O
extended	B-T082
β	B-T082
-	I-T082
strand	I-T082
conformational	I-T082
state	O
of	O
PHF6	B-T103
(	I-T103
(	I-T103
*	I-T103
)	I-T103
)	I-T103
is	O
readily	O
populated	O
under	O
aggregating	O
conditions	O
,	O
constituting	O
a	O
defining	O
signature	B-T082
of	O
aggregation	O
-	O
prone	B-T082
tau	B-T103
,	O
and	O
as	O
such	O
,	O
a	O
possible	O
target	O
for	O
therapeutic	B-T058
interventions	I-T058
.	O

Design	O
,	O
Synthesis	O
,	O
and	O
Cytotoxic	B-T038
Evaluation	B-T058
of	O
Certain	O
7	B-T103
-	I-T103
Chloro	I-T103
-	I-T103
4	I-T103
-	I-T103
(	I-T103
piperazin	I-T103
-	I-T103
1	I-T103
-	I-T103
yl	I-T103
)	I-T103
quinoline	I-T103
Derivatives	B-T103
as	O
VEGFR	B-T103
-	I-T103
II	I-T103
Inhibitors	B-T103

Signaling	B-T038
pathway	I-T038
inhibition	O
of	O
VEGFR	B-T103
-	I-T103
II	I-T103
is	O
visualized	O
as	O
valuable	O
tool	O
in	O
cancer	B-T038
management	B-T058
.	O

In	O
the	O
current	B-T062
study	I-T062
,	O
the	O
synthesis	O
of	O
novel	O
1	B-T103
-	I-T103
4	I-T103
-	I-T103
(	I-T103
7	I-T103
-	I-T103
chloroquinolin	I-T103
-	I-T103
4	I-T103
-	I-T103
yl	I-T103
)	I-T103
piperazin	I-T103
-	I-T103
1	I-T103
-	I-T103
yl	I-T103
)	I-T103
-	I-T103
2	I-T103
-	I-T103
(	I-T103
N	I-T103
-	I-T103
substituted	I-T103
-	I-T103
amino	I-T103
)	I-T103
-	I-T103
ethanone	I-T103
derivatives	B-T103
(	O
4a	B-T103
-	I-T103
t	I-T103
)	O
was	O
achieved	O
through	O
the	O
amination	O
of	O
2	B-T103
-	I-T103
chloro	I-T103
-	I-T103
1	I-T103
-	I-T103
(	I-T103
4	I-T103
-	I-T103
(	I-T103
7	I-T103
-	I-T103
chloroquinolin	I-T103
-	I-T103
4	I-T103
-	I-T103
yl	I-T103
)	I-T103
piperazin	I-T103
-	I-T103
1	I-T103
-	I-T103
yl	I-T103
)	I-T103
ethanone	I-T103
(	I-T103
3	I-T103
)	I-T103
with	O
different	O
secondary	B-T103
amines	I-T103
.	I-T103

The	O
structures	B-T082
of	O
the	O
target	O
compounds	B-T103
were	O
confirmed	O
by	O
IR	B-T058
,	O
(	B-T058
1	I-T058
)	I-T058
H	I-T058
-	I-T058
NMR	I-T058
,	O
(	B-T058
13	I-T058
)	I-T058
C	I-T058
-	I-T058
NMR	I-T058
,	O
HRMS	B-T058
,	O
and	O
microanalysis	B-T058
.	O

Compounds	B-T103
4a	B-T103
-	I-T103
t	I-T103
were	O
subjected	O
to	O
in	O
vitro	O
anticancer	B-T058
screening	B-T058
against	O
human	B-T038
breast	I-T038
cancer	I-T038
(	O
MCF	B-T017
-	I-T017
7	I-T017
)	O
and	O
prostate	B-T038
cancer	I-T038
(	O
PC3	B-T017
)	O
cell	B-T017
lines	I-T017
.	O

The	O
highest	O
cytotoxicty	B-T038
against	O
both	O
cell	B-T017
lines	I-T017
was	O
displayed	O
by	O
2	B-T103
-	I-T103
(	I-T103
4	I-T103
-	I-T103
(	I-T103
4	I-T103
-	I-T103
bromobenzyl	I-T103
)	I-T103
piperazin	I-T103
-	I-T103
1	I-T103
-	I-T103
yl	I-T103
)	I-T103
-	I-T103
1	I-T103
-	I-T103
(	I-T103
4	I-T103
-	I-T103
(	I-T103
7	I-T103
-	I-T103
chloroquinolin	I-T103
-	I-T103
4	I-T103
-	I-T103
yl	I-T103
)	I-T103
piperazin	I-T103
-	I-T103
1	I-T103
-	I-T103
yl	I-T103
)	I-T103
ethanone	I-T103
(	I-T103
4q	I-T103
)	I-T103
,	O
with	O
IC50	O
values	O
of	O
6	O
.	O
502	O
and	O
11	O
.	O
751	O
μM	O
against	O
MCF	B-T017
-	I-T017
7	I-T017
and	O
PC3	B-T017
cells	I-T017
,	O
respectively	O
,	O
compared	O
with	O
the	O
standard	O
drug	O
doxorubicin	B-T103
(	O
MCF	B-T017
-	I-T017
7	I-T017
:	O
6	O
.	O
774	O
μM	O
,	O
PC3	B-T017
:	O
7	O
.	O
7316	O
μM	O
)	O
.	O

Due	O
to	O
its	O
notable	O
activity	O
toward	O
MCF	B-T017
-	I-T017
7	I-T017
cells	I-T017
,	O
4q	B-T103
was	O
further	O
evaluated	O
as	O
VEGFR	B-T103
-	I-T103
II	I-T103
inhibitor	B-T103
,	O
showing	O
an	O
IC50	O
of	O
1	O
.	O
38	O
μM	O
compared	O
to	O
sorafenib	B-T103
(	O
0	O
.	O
33	O
μM	O
)	O
.	O

The	O
docking	B-T038
study	O
proved	O
that	O
4q	B-T103
has	O
a	O
binding	B-T038
mode	I-T038
akin	O
to	O
that	O
of	O
VEGFR	B-T103
-	I-T103
II	I-T103
inhibitors	B-T103
.	O

The	O
ErbB3	B-T103
receptor	I-T103
tyrosine	I-T103
kinase	I-T103
negatively	O
regulates	B-T038
Paneth	B-T017
cells	I-T017
by	O
PI3K	B-T103
-	O
dependent	O
suppression	B-T038
of	O
Atoh1	B-T017

Paneth	B-T017
cells	I-T017
(	O
PCs	B-T017
)	O
,	O
a	O
secretory	B-T017
population	I-T017
located	O
at	O
the	O
base	O
of	O
the	O
intestinal	O
crypt	O
,	O
support	O
the	O
intestinal	B-T017
stem	B-T017
cells	I-T017
(	O
ISC	B-T017
)	O
with	O
growth	B-T103
factors	I-T103
and	O
participate	O
in	O
innate	O
immunity	O
by	O
releasing	O
antimicrobial	B-T103
peptides	I-T103
,	O
including	O
lysozyme	B-T103
and	O
defensins	B-T103
.	O

PC	B-T017
dysfunction	O
is	O
associated	O
with	O
disorders	B-T038
such	O
as	O
Crohn	B-T038
'	I-T038
s	I-T038
disease	I-T038
and	O
necrotizing	B-T038
enterocolitis	I-T038
,	O
but	O
the	O
specific	O
pathways	B-T038
regulating	B-T038
PC	B-T017
development	B-T038
and	O
function	B-T038
are	O
not	O
fully	O
understood	O
.	O

Here	O
we	O
tested	O
the	O
role	O
of	O
the	O
neuregulin	B-T103
receptor	I-T103
ErbB3	I-T103
in	O
control	O
of	O
PC	B-T017
differentiation	B-T038
and	O
the	O
ISC	B-T022
niche	I-T022
.	O

Intestinal	B-T017
epithelial	O
ErbB3	B-T017
knockout	B-T062
caused	O
precocious	O
appearance	O
of	O
PCs	B-T017
as	O
early	O
as	O
postnatal	O
day	O
7	O
,	O
and	O
substantially	O
increased	O
the	O
number	O
of	O
mature	O
PCs	B-T017
in	O
adult	B-T204
mouse	I-T204
ileum	B-T017
.	O

ErbB3	B-T103
loss	O
had	O
no	O
effect	O
on	O
other	O
secretory	O
lineages	O
,	O
but	O
increased	O
expression	B-T038
of	O
the	O
ISC	B-T017
marker	O
Lgr5	B-T103
.	O

ErbB3	B-T103
-	O
null	O
intestines	B-T017
had	O
elevated	O
levels	O
of	O
the	O
Atoh1	B-T017
transcription	B-T103
factor	I-T103
,	O
which	O
is	O
required	O
for	O
secretory	O
fate	O
determination	O
,	O
while	O
Atoh1	B-T103
(	I-T103
+	I-T103
)	I-T103
cells	B-T017
had	O
reduced	O
ErbB3	B-T017
,	O
suggesting	O
reciprocal	O
negative	B-T033
regulation	B-T038
.	O

ErbB3	B-T103
-	O
null	O
intestinal	B-T017
progenitor	I-T017
cells	I-T017
showed	O
reduced	O
activation	O
of	O
the	O
PI3K	O
-	O
Akt	O
and	O
ERK	B-T038
MAPK	I-T038
pathways	I-T038
.	O

Inhibiting	O
these	O
pathways	B-T038
in	O
HT29	B-T017
cells	I-T017
increased	O
levels	O
of	O
ATOH1	B-T017
and	O
the	O
PC	B-T017
marker	O
LYZ	B-T017
.	O

Conversely	O
,	O
ErbB3	B-T103
activation	O
suppressed	B-T038
LYZ	B-T017
and	O
ATOH1	B-T017
in	O
a	O
PI3K	B-T103
-	O
dependent	O
manner	O
.	O

Expansion	O
of	O
the	O
PC	B-T017
compartment	O
in	O
ErbB3	B-T103
-	O
null	O
intestines	B-T017
was	O
accompanied	O
with	O
elevated	O
ER	B-T038
stress	I-T038
and	O
inflammation	B-T038
markers	B-T201
,	O
raising	O
the	O
possibility	O
that	O
negative	B-T033
regulation	B-T038
of	O
PCs	B-T017
by	O
ErbB3	B-T103
is	O
necessary	O
to	O
maintain	O
homeostasis	B-T038
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
ErbB3	B-T103
restricts	O
PC	B-T017
numbers	O
through	O
PI3K	B-T103
-	O
mediated	O
suppression	B-T038
of	O
Atoh1	B-T017
levels	O
leading	O
to	O
inhibition	O
of	O
PC	B-T017
differentiation	B-T038
,	O
with	O
important	O
implications	O
for	O
regulation	B-T038
of	O
the	O
ISC	B-T022
niche	I-T022
.	O

CDF	O
-	O
quantile	O
distributions	O
for	O
modelling	B-T170
random	O
variables	O
on	O
the	O
unit	B-T170
interval	I-T170

This	O
paper	O
introduces	O
a	O
two	O
-	O
parameter	O
family	O
of	O
distributions	O
for	O
modelling	B-T170
random	O
variables	O
on	O
the	O
(	O
0	O
,	O
1	O
)	O
interval	B-T170
by	O
applying	O
the	O
cumulative	O
distribution	O
function	O
of	O
one	O
'	O
parent	O
'	O
distribution	O
to	O
the	O
quantile	O
function	B-T170
of	O
another	O
.	O

Family	O
members	O
have	O
explicit	O
probability	O
density	O
functions	B-T170
,	O
cumulative	O
distribution	O
functions	O
and	O
quantile	O
s	O
in	O
a	O
location	B-T082
parameter	O
and	O
a	O
dispersion	B-T082
parameter	O
.	O

They	O
capture	O
a	O
wide	O
variety	O
of	O
shapes	B-T082
that	O
the	O
beta	O
and	O
Kumaraswamy	O
distributions	O
cannot	B-T033
.	O

They	O
are	O
amenable	O
to	O
likelihood	B-T170
inference	I-T170
,	O
and	O
enable	O
a	O
wide	O
variety	O
of	O
quantile	O
regression	B-T170
models	I-T170
,	O
with	O
predictors	O
for	O
both	O
the	O
location	B-T082
and	O
dispersion	B-T082
parameters	O
.	O

We	O
demonstrate	O
their	O
applicability	O
to	O
psychological	B-T091
research	B-T062
problems	I-T062
and	O
their	O
utility	O
in	O
modelling	B-T170
real	B-T170
data	I-T170
.	O

First	O
and	O
second	O
generation	O
DESs	B-T074
reduce	O
diabetes	B-T038
adverse	B-T038
effect	I-T038
on	O
mortality	O
and	O
re	B-T058
-	I-T058
intervention	I-T058
in	O
multivessel	B-T017
coronary	B-T038
disease	I-T038
:	O
9	O
-	O
Year	O
analysis	B-T062

Diabetes	B-T038
portends	O
an	O
increased	O
risk	O
of	O
adverse	B-T038
early	O
and	O
late	O
outcomes	O
in	O
patients	O
undergoing	O
PCI	B-T058
.	O

In	O
this	O
study	B-T062
,	O
we	O
aimed	O
to	O
investigate	O
if	O
the	O
adverse	B-T038
effect	I-T038
of	O
diabetes	B-T038
mellitus	I-T038
(	O
DM	B-T038
)	O
on	O
early	O
and	O
late	O
PCI	B-T058
outcomes	O
is	O
reduced	O
with	O
drug	B-T074
-	I-T074
eluting	I-T074
(	O
DES	B-T074
)	O
compared	O
to	O
bare	B-T074
-	I-T074
metal	I-T074
(	I-T074
BMS	I-T074
)	I-T074
stents	I-T074
.	O

We	O
reviewed	O
the	O
Mount	B-T092
Sinai	I-T092
Beth	I-T092
Israel	I-T092
Hospital	I-T092
first	O
PCI	B-T058
experience	O
for	O
multivessel	B-T017
coronary	B-T038
artery	I-T038
disease	I-T038
(	O
CAD	B-T038
,	O
1998	O
-	O
2009	O
)	O
.	O

Patients	O
were	O
excluded	O
if	O
they	O
had	O
single	B-T038
-	I-T038
vessel	I-T038
CAD	I-T038
,	O
emergency	O
,	O
no	B-T033
stent	B-T074
,	O
prior	O
bypass	B-T058
graft	I-T058
or	O
myocardial	B-T038
infarction	I-T038
<	O
24h	O
.	O

Diabetes	B-T038
-	O
effect	O
was	O
derived	O
from	O
9	O
-	O
year	O
all	O
-	O
cause	O
mortality	O
and	O
re	B-T058
-	I-T058
intervention	I-T058
risk	O
-	O
adjusted	O
hazard	O
ratios	O
[	O
AHR	O
(	O
95	O
%	O
confidence	O
intervals	O
)	O
]	O
for	O
DES	B-T074
(	O
N	O
=	O
2679	O
;	O
48	O
%	O
three	B-T038
-	I-T038
vessel	I-T038
;	O
39	O
%	O
DM	B-T038
)	O
and	O
BMS	B-T074
(	O
N	O
=	O
2651	O
;	O
40	O
%	O
three	B-T038
-	I-T038
vessel	I-T038
;	O
33	O
%	O
DM	B-T038
)	O
and	O
then	O
stratified	O
based	O
on	O
stent	B-T074
(	O
DES	B-T074
/	O
BMS	B-T074
)	O
and	O
vessel	B-T038
disease	I-T038
(	O
two	B-T038
/	O
three	B-T038
)	O
.	O

Diabetes	B-T038
-	O
effect	O
on	O
mortality	O
was	O
lower	O
for	O
DES	B-T074
(	O
AHRDM	O
/	O
NoDM	O
=	O
1	O
.	O
41	O
[	O
1	O
.	O
14	O
-	O
1	O
.	O
74	O
]	O
)	O
versus	O
BMS	B-T074
(	O
AHRDM	O
/	O
NoDM	O
=	O
1	O
.	O
71	O
[	O
1	O
.	O
50	O
-	O
2	O
.	O
01	O
]	O
)	O
,	O
but	O
this	O
was	O
predominantly	O
driven	O
by	O
two	B-T038
-	I-T038
vessel	I-T038
patients	O
.	O

This	O
diabetes	B-T038
effect	O
was	O
similar	O
for	O
first	O
(	O
DES1	B-T074
:	O
AHRDM	O
/	O
NoDM	O
=	O
1	O
.	O
43	O
[	O
1	O
.	O
14	O
-	O
1	O
.	O
79	O
]	O
)	O
and	O
second	O
(	O
DES2	B-T074
:	O
AHRDM	O
/	O
NoDM	O
=	O
1	O
.	O
53	O
[	O
0	O
.	O
77	O
-	O
3	O
.	O
07	O
]	O
)	O
generation	O
DES	B-T074
.	O

Re	B-T058
-	I-T058
intervention	I-T058
comparisons	O
were	O
similarly	O
increased	O
by	O
diabetes	B-T038
in	O
all	O
sub	B-T098
-	I-T098
cohorts	I-T098
.	O

Our	O
analysis	B-T062
of	O
a	O
large	O
real	O
-	O
world	O
PCI	B-T058
series	O
indicates	O
that	O
diabetes	B-T038
is	O
associated	O
with	O
worse	B-T033
9	O
-	O
year	O
mortality	O
irrespective	O
of	O
stent	B-T074
type	O
,	O
albeit	O
this	O
is	O
mitigated	O
to	O
varying	O
degrees	O
with	O
DES	B-T074
,	O
particularly	O
in	O
DES2	B-T074
and	O
in	O
case	O
of	O
2	B-T038
-	I-T038
vessel	I-T038
disease	I-T038
.	O

A	O
complementary	O
stent	B-T074
-	O
effect	O
analysis	B-T062
confirmed	B-T033
DES	B-T074
-	O
to	O
-	O
BMS	B-T074
and	O
DES2	B-T074
-	O
to	O
-	O
DES1	B-T074
superiority	O
in	O
both	O
diabetics	B-T033
and	O
non	B-T033
-	I-T033
diabetics	I-T033
.	O

Lycopene	B-T103
and	O
risk	O
of	O
cardiovascular	B-T038
diseases	I-T038
:	O
A	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
observational	O
studies	O

The	O
aim	O
of	O
current	O
meta	B-T062
-	I-T062
analysis	I-T062
was	O
to	O
investigate	O
the	O
relation	O
between	O
lycopene	B-T103
and	O
risk	O
of	O
cardiovascular	B-T038
diseases	I-T038
(	O
CVD	B-T038
)	O
.	O

Studies	B-T062
concerning	O
about	O
the	O
association	O
between	O
lycopene	B-T103
and	O
risk	O
of	O
CVD	B-T038
were	O
searched	O
on	O
Pubmed	B-T170
,	O
Embase	B-T170
,	O
and	O
Web	B-T170
of	I-T170
Science	I-T170
from	O
inception	O
to	O
October	O
2016	O
.	O

A	O
total	O
of	O
14	O
eligible	B-T062
studies	I-T062
were	O
identified	O
.	O

A	O
significantly	O
inverse	O
association	O
with	O
a	O
pooled	O
risk	O
ratio	O
(	O
RR	O
)	O
of	O
0	O
.	O
83	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
76	O
-	O
0	O
.	O
90	O
)	O
was	O
shown	O
between	O
lycopene	B-T103
exposure	O
and	O
risk	O
of	O
CVD	B-T038
.	O

Findings	B-T033
were	O
similar	O
restricting	O
to	O
dietary	B-T168
studies	B-T062
(	O
RR	O
=	O
0	O
.	O
87	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
79	O
-	O
0	O
.	O
96	O
)	O
and	O
biomarker	B-T201
studies	B-T062
(	O
RR	O
=	O
0	O
.	O
74	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O

62	O
-	O
0	O
.	O
87	O
)	O
.	O

Dietary	B-T168
lycopene	B-T103
intake	O
was	O
statistically	O
significant	O
for	O
coronary	B-T038
heart	I-T038
disease	I-T038
(	O
CHD	B-T038
)	O
(	O
RR	O
:	O
0	O
.	O
87	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
76	O
-	O
0	O
.	O
98	O
)	O
and	O
stroke	B-T038
(	O
RR	O
:	O
0	O
.	O
83	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
69	O
-	O
0	O
.	O
96	O
)	O
.	O
The	O
pooled	O
risk	O
estimate	O
was	O
generally	O
similar	O
for	O
lycopene	B-T103
biomarker	B-T201
concentrations	O
,	O
but	O
the	O
association	O
was	O
only	O
statistically	O
significant	O
for	O
stroke	B-T038
(	O
RR	O
:	O
0	O
.	O
65	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
42	O
-	O
0	O
.	O
87	O
)	O
.	O

Subgroup	B-T170
analyses	B-T062
showed	O
that	O
retrospective	B-T062
and	O
low	O
quality	O
studies	B-T062
were	O
statistically	O
significant	O
sources	O
of	O
heterogeneity	O
.	O

Higher	O
lycopene	B-T103
exposure	O
is	O
inversely	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
CVD	B-T038
.	O

Further	O
well	O
-	O
designed	O
randomized	B-T062
clinical	I-T062
trials	I-T062
are	O
required	O
to	O
assess	O
the	O
role	O
of	O
lycopene	B-T103
on	O
CVD	B-T038
.	O

Bacteria	B-T007
from	O
Wheat	B-T204
and	O
Cucurbit	B-T204
Plant	B-T204
Roots	I-T204
Metabolize	B-T038
PAHs	B-T103
and	O
Aromatic	B-T103
Root	B-T204
Exudates	O
:	O
Implications	O
for	O
Rhizodegradation	O

The	O
chemical	O
interaction	O
between	O
plants	B-T204
and	O
bacteria	B-T007
in	O
the	O
root	B-T204
zone	B-T082
can	O
lead	O
to	O
soil	O
decontamination	O
.	O

Bacteria	B-T007
which	O
degrade	O
PAHs	B-T103
have	O
been	O
isolated	O
from	O
the	O
rhizospheres	O
of	O
plant	B-T204
species	B-T170
with	O
varied	O
biological	O
traits	O
,	O
however	O
,	O
it	O
is	O
not	O
known	O
what	O
phytochemicals	B-T103
promote	O
contaminant	O
degradation	O
.	O

One	O
monocot	B-T204
and	O
two	O
dicotyledon	B-T204
plants	I-T204
were	O
grown	B-T038
in	O
PAH	B-T103
-	O
contaminated	O
soil	O
from	O
a	O
manufactured	O
gas	O
plant	O
(	O
MGP	O
)	O
site	B-T082
.	O

A	O
phytotoxicity	B-T058
assay	I-T058
confirmed	O
greater	O
soil	O
decontamination	O
in	O
rhizospheres	O
when	O
compared	O
to	O
bulk	O
soil	O
controls	O
.	O

Bacteria	B-T007
were	O
isolated	O
from	O
plant	B-T204
roots	I-T204
(	O
rhizobacteria	B-T007
)	O
and	O
selected	O
for	O
growth	B-T038
on	O
anthracene	B-T103
and	O
chrysene	B-T103
on	O
PAH	B-T103
-	O
amended	O
plates	O
.	O

Rhizosphere	O
isolates	B-T103
metabolized	B-T038
3	O
-	O
and	O
4	O
-	O
ring	O
PAHs	B-T103
and	O
PAH	B-T103
catabolic	O
intermediates	O
in	O
liquid	B-T058
incubations	I-T058
.	O

Aromatic	B-T103
root	B-T204
exudate	O
compounds	O
,	O
namely	O
flavonoids	B-T103
and	O
simple	B-T103
phenols	I-T103
,	O
were	O
also	O
substrates	O
for	O
isolated	O
rhizobacteria	B-T007
.	O

In	O
particular	O
,	O
the	O
phenolic	B-T103
compounds	I-T103
-	O
morin	B-T103
,	O
caffeic	B-T103
acid	I-T103
,	O
and	O
protocatechuic	B-T103
acid	I-T103
-	O
appear	O
to	O
be	O
linked	O
to	O
bacterial	B-T007
degradation	O
of	O
3	O
-	O
and	O
4	O
-	O
ring	O
PAHs	B-T103
in	O
the	O
rhizosphere	O
.	O

Joint	O
model	O
imputation	O
to	O
estimate	O
the	O
treatment	B-T033
effect	I-T033
on	O
long	O
-	O
term	O
survival	O
using	O
auxiliary	O
events	O

Clinical	B-T062
trial	I-T062
duration	O
may	O
be	O
a	O
concern	O
in	O
clinical	B-T062
research	I-T062
,	O
especially	O
in	O
cancer	B-T062
trials	I-T062
where	O
the	O
endpoint	B-T201
is	O
overall	O
survival	O
.	O

A	O
surrogate	O
endpoint	O
can	O
be	O
used	O
as	O
an	O
auxiliary	O
variable	O
to	O
analyze	B-T062
the	O
treatment	B-T033
effect	I-T033
earlier	O
.	O

At	O
an	O
early	O
time	O
point	O
,	O
the	O
high	O
number	O
of	O
censored	O
observations	B-T062
can	O
be	O
compensated	O
by	O
the	O
imputation	O
of	O
the	O
unobserved	B-T033
deaths	B-T033
times	O
.	O

We	O
propose	O
to	O
use	O
predictions	O
of	O
the	O
risk	O
of	O
death	B-T038
from	O
a	O
joint	O
model	O
for	O
a	O
recurrent	O
event	O
and	O
a	O
terminal	O
event	O
,	O
which	O
account	O
for	O
disease	B-T038
relapse	I-T038
information	O
.	O

Two	O
imputation	O
methods	O
were	O
compared	O
:	O
sampling	B-T062
from	O
the	O
estimated	O
parametric	O
distribution	O
of	O
the	O
survival	B-T201
time	I-T201
and	O
sampling	B-T062
using	O
its	O
nonparametric	O
estimation	O
.	O

The	O
treatment	B-T033
effect	I-T033
and	O
its	O
standard	O
error	O
were	O
estimated	O
via	O
multiple	O
imputations	O
.	O

The	O
performances	O
of	O
the	O
two	O
methods	B-T170
were	O
compared	O
in	O
terms	O
of	O
bias	O
in	O
the	O
estimates	O
,	O
standard	O
errors	O
,	O
and	O
coverage	O
probability	O
.	O

Both	O
methods	B-T170
were	O
then	O
retrospectively	O
applied	O
to	O
two	O
randomized	B-T062
clinical	I-T062
trials	I-T062
studying	O
the	O
effect	O
of	O
adjuvant	O
chemotherapy	B-T058
in	O
breast	B-T038
cancer	I-T038
patients	O
.	O

The	O
Corneal	B-T017
Epithelial	I-T017
Barrier	O
and	O
Its	O
Developmental	O
Role	O
in	O
Isolating	O
Corneal	B-T017
Epithelial	I-T017
and	O
Conjunctival	B-T017
Cells	I-T017
From	O
One	O
Another	O

During	O
development	O
,	O
the	O
corneal	B-T017
epithelium	I-T017
(	O
CE	B-T017
)	O
and	O
the	O
conjunctiva	B-T017
are	O
derived	O
from	O
the	O
surface	B-T017
ectoderm	I-T017
.	O

Here	O
we	O
have	O
examined	B-T033
how	O
,	O
during	O
development	O
,	O
the	O
cells	B-T017
of	O
these	O
two	O
issues	O
become	O
isolated	O
from	O
each	O
other	O
.	O

Epithelia	B-T017
from	O
the	O
anterior	B-T017
eyes	I-T017
of	O
chicken	B-T017
embryos	I-T017
were	O
labeled	B-T103
with	O
the	O
fluorescent	B-T103
,	O
lipophilic	B-T103
dye	I-T103
,	O
1	B-T103
,	I-T103
1	I-T103
'	I-T103
-	I-T103
dioctadecyl	I-T103
-	I-T103
3	I-T103
,	I-T103
3	I-T103
,	I-T103
3	I-T103
'	I-T103
,	I-T103
3	I-T103
'	I-T103
-	I-T103
tetramethylindocarbocyanine	I-T103
perchlorate	I-T103
(	O
DiI	B-T103
)	O
.	O

DiI	B-T103
was	O
placed	O
on	O
the	O
epithelial	B-T017
surface	I-T017
of	O
the	O
developing	O
anterior	B-T017
eye	I-T017
and	O
its	O
diffusion	O
was	O
monitored	O
by	O
fluorescence	B-T058
microscopy	I-T058
.	O

Concomitant	O
morphologic	O
changes	O
in	O
the	O
surface	B-T017
cells	I-T017
of	I-T017
these	I-T017
epithelial	I-T017
were	O
examined	B-T033
by	O
scanning	B-T058
electron	I-T058
microscopy	I-T058
.	O

Immunofluorescence	B-T058
was	O
used	O
to	O
analyze	O
the	O
expression	B-T038
of	O
cytokeratin	B-T103
K3	I-T103
,	O
ZO	B-T103
-	I-T103
1	I-T103
,	O
N	B-T103
-	I-T103
cadherin	I-T103
and	O
Connexin	B-T103
-	I-T103
43	I-T103
and	O
the	O
function	B-T038
of	O
gap	B-T082
junctions	I-T082
was	O
analyzed	B-T062
using	O
a	O
cut	O
-	O
loading	O
with	O
the	O
fluorescent	B-T103
dye	I-T103
rhodamine	B-T103
-	I-T103
dextran	I-T103
.	O

Prior	O
to	O
embryonic	B-T038
day	O
8	O
(	O
E	B-T038
8	O
)	O
,	O
DiI	B-T103
placed	O
on	O
the	O
surface	B-T082
of	O
the	O
CE	B-T017
spreads	O
throughout	O
all	O
the	O
epithelial	B-T017
cells	I-T017
of	O
the	O
anterior	B-T017
eye	I-T017
.	O

When	O
older	B-T017
eyes	I-T017
were	O
similarly	O
labeled	B-T103
,	O
dye	B-T103
diffusion	O
was	O
restricted	O
to	O
the	O
CE	B-T017
.	O

Similarly	O
,	O
diffusion	O
of	O
DiI	B-T103
placed	O
on	O
the	O
conjunctival	B-T017
surface	B-T082
after	O
E	B-T038
8	O
was	O
restricted	O
to	O
the	O
conjunctiva	B-T017
.	O

Scanning	B-T058
electron	I-T058
microscopy	I-T058
showed	O
that	O
developmentally	O
(	O
1	O
)	O
physical	O
separations	O
progressively	O
form	O
between	O
the	O
cells	B-T017
of	O
the	O
CE	B-T017
and	O
those	O
of	O
the	O
conjunctiva	B-T017
,	O
and	O
(	O
2	O
)	O
by	O
E	B-T038
8	O
these	O
separations	O
form	O
a	O
ring	B-T017
that	O
completely	O
encompasses	O
the	O
cornea	B-T017
.	O

The	O
functional	O
restriction	O
of	O
gap	B-T082
junctions	I-T082
between	O
these	O
tissues	B-T017
did	O
not	O
occur	O
until	O
E	B-T038
14	O
.	O

During	O
ocular	B-T038
development	I-T038
,	O
a	O
barrier	O
to	O
the	O
diffusion	O
of	O
DiI	B-T103
forms	O
between	O
the	O
contiguous	B-T082
CE	B-T017
and	O
conjunctiva	B-T017
prior	O
to	O
the	O
differential	O
expression	B-T038
of	O
gap	B-T082
junctions	I-T082
within	O
these	O
tissues	B-T017
.	O

Longitudinal	B-T062
study	I-T062
of	O
bovine	B-T204
rotavirus	B-T005
group	I-T005
A	I-T005
in	O
newborn	B-T204
calves	B-T204
from	O
vaccinated	B-T033
and	O
unvaccinated	B-T033
dairy	O
herds	O

Reports	O
of	O
rotavirus	B-T005
excretion	B-T031
in	O
calves	B-T204
usually	O
result	O
from	O
cross	B-T062
-	I-T062
sectional	I-T062
studies	I-T062
,	O
and	O
in	O
face	O
of	O
the	O
conflicting	O
results	O
regarding	O
protection	B-T058
of	O
calves	B-T204
born	B-T038
to	O
vaccinated	B-T033
dams	B-T204
against	O
diarrhea	B-T033
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
rotavirus	B-T005
excretion	B-T031
in	O
dairy	B-T204
calves	I-T204
born	O
to	O
vaccinated	B-T033
or	O
unvaccinated	B-T033
dams	B-T204
,	O
to	O
identify	O
the	O
genotypes	O
of	O
bovine	B-T204
rotavirus	B-T005
group	I-T005
A	I-T005
(	O
RVA	B-T005
)	O
strains	O
isolated	O
from	O
these	O
animals	B-T204
as	O
well	O
as	O
to	O
investigate	O
characteristics	O
of	O
the	O
disease	B-T038
in	O
naturally	O
occurring	O
circumstances	O
throughout	O
the	O
first	B-T033
month	I-T033
of	I-T033
life	I-T033
.	O

Five	O
hundred	O
fifty	O
-	O
two	O
fecal	B-T031
samples	I-T031
were	O
taken	O
from	O
56	O
calves	B-T204
,	O
28	O
from	O
each	O
farm	B-T082
and	O
,	O
in	O
the	O
vaccinated	B-T033
herd	O
,	O
11	O
/	O
281	O
samples	B-T031
(	O
3	O
.	O
91	O
%	O
)	O
taken	O
from	O
six	O
different	O
calves	B-T204
tested	B-T033
positive	I-T033
for	O
RVA	B-T005
while	O
in	O
the	O
unvaccinated	B-T033
herd	O
,	O
3	O
/	O
271	O
samples	B-T031
(	O
1	O
.	O
11	O
%	O
)	O
taken	O
from	O
3	O
different	O
calves	B-T204
tested	B-T033
positive	I-T033
.	O

The	O
genotyping	O
of	O
the	O
VP7	B-T017
genes	I-T017
showed	O
91	O
.	O
2	O
%	O
nucleotide	B-T082
sequence	I-T082
identity	O
to	O
G6	O
genotype	O
(	O
NCDV	O
strain	O
)	O
,	O
and	O
for	O
the	O
VP4	B-T017
gene	I-T017
,	O
strains	O
from	O
the	O
vaccinated	B-T033
herd	O
were	O
96	O
.	O
6	O
%	O
related	O
to	O
B223	O
strain	O
,	O
while	O
strains	O
from	O
the	O
unvaccinated	B-T033
herd	O
were	O
88	O
%	O
related	O
to	O
P	O
[	O
5	O
]	O
genotype	O
(	O
UK	O
strain	O
)	O
.	O

Genotypes	O
found	O
in	O
this	O
study	O
were	O
G6P	O
[	O
11	O
]	O
in	O
the	O
vaccinated	B-T033
herd	O
and	O
G6P	O
[	O
5	O
]	O
in	O
the	O
unvaccinated	B-T033
herd	O
.	O

All	O
calves	B-T204
infected	B-T033
with	O
rotavirus	B-T005
presented	O
an	O
episode	O
of	O
diarrhea	B-T033
in	O
the	O
first	O
month	O
of	O
life	O
,	O
and	O
the	O
discrepancy	O
between	O
the	O
genotypes	O
found	O
in	O
the	O
commercial	B-T103
vaccine	I-T103
(	O
G6P	O
[	O
1	O
]	O
and	O
G10P	O
[	O
11	O
]	O
)	O
and	O
the	O
rotavirus	B-T005
strains	O
circulating	O
in	O
both	O
vaccinated	B-T033
and	O
unvaccinated	B-T033
herds	O
show	O
the	O
importance	O
of	O
keeping	O
constant	O
surveillance	B-T058
in	O
order	O
to	O
avoid	O
potential	O
causes	O
of	O
vaccination	B-T058
failure	B-T033
.	O

Gene	B-T017
-	O
based	O
genome	B-T062
-	I-T062
wide	I-T062
association	I-T062
study	I-T062
identified	O
19p13	B-T017
.	I-T017
3	I-T017
for	O
lean	B-T201
body	I-T201
mass	I-T201

Lean	B-T201
body	I-T201
mass	I-T201
(	O
LBM	B-T201
)	O
is	O
a	O
complex	O
trait	O
for	O
human	B-T204
health	O
.	O

To	O
identify	O
genomic	B-T017
loci	I-T017
underlying	O
LBM	B-T201
,	O
we	O
performed	O
a	O
gene	B-T017
-	O
based	O
genome	B-T062
-	I-T062
wide	I-T062
association	I-T062
study	I-T062
of	O
lean	O
mass	O
index	O
(	O
LMI	O
)	O
in	O
1000	O
unrelated	B-T033
Caucasian	B-T098
subjects	B-T098
,	O
and	O
replicated	O
in	O
2283	O
unrelated	B-T033
Caucasians	B-T098
subjects	B-T098
.	O

Gene	B-T017
-	O
based	O
association	B-T062
analyses	I-T062
highlighted	O
the	O
significant	O
associations	O
of	O
three	O
genes	B-T017
UQCR	B-T017
,	O
TCF3	B-T017
and	O
MBD3	B-T017
in	O
one	O
single	O
locus	B-T017
19p13	B-T017
.	I-T017
3	I-T017
(	O
discovery	O
p	O
=	O
6	O
.	O
10	O
×	O
10	O
(	O
-	O
5	O
)	O
,	O
1	O
.	O
65	O
×	O
10	O
(	O
-	O
4	O
)	O
and	O
1	O
.	O
10	O
×	O
10	O
(	O
-	O
4	O
)	O
;	O
replication	O
p	O
=	O
2	O
.	O
21	O
×	O
10	O
(	O
-	O
3	O
)	O
,	O
1	O
.	O
84	O
×	O
10	O
(	O
-	O
3	O
)	O
and	O
6	O
.	O
95	O
×	O
10	O
(	O
-	O
3	O
)	O
;	O
combined	O
p	O
=	O
2	O
.	O
26	O
×	O
10	O
(	O
-	O
6	O
)	O
,	O
4	O
.	O
86	O
×	O
10	O
(	O
-	O
6	O
)	O
and	O
1	O
.	O
15	O
×	O
10	O
(	O
-	O
5	O
)	O
,	O
respectively	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
the	O
known	O
functional	O
relevance	O
of	O
the	O
three	O
genes	B-T017
to	O
LMI	O
,	O
suggested	O
that	O
the	O
19p13	B-T017
.	I-T017
3	I-T017
region	B-T082
containing	O
UQCR	B-T017
,	O
TCF3	B-T017
and	O
MBD3	B-T017
genes	I-T017
was	O
a	O
novel	O
locus	B-T017
underlying	O
lean	B-T201
mass	I-T201
variation	O
.	O

Basal	B-T082
ryanodine	B-T038
receptor	I-T038
activity	I-T038
suppresses	O
autophagic	B-T017
flux	O

The	O
inositol	B-T103
1	I-T103
,	I-T103
4	I-T103
,	I-T103
5	I-T103
-	I-T103
trisphosphate	I-T103
receptors	I-T103
(	O
IP3Rs	B-T103
)	O
and	O
intracellular	B-T038
Ca	I-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
signaling	I-T038
are	O
critically	O
involved	O
in	O
regulating	B-T038
different	O
steps	O
of	O
autophagy	B-T038
,	O
a	O
lysosomal	B-T017
degradation	O
pathway	O
.	O

The	O
ryanodine	B-T103
receptors	I-T103
(	O
RyR	B-T103
)	O
,	O
intracellular	B-T038
Ca	I-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
-	I-T038
release	I-T038
channels	I-T038
mainly	O
expressed	B-T038
in	O
excitable	B-T033
cell	B-T170
types	I-T170
including	O
muscle	B-T017
and	O
neurons	B-T017
,	O
have	O
however	O
not	O
yet	O
been	O
extensively	O
studied	B-T062
in	O
relation	O
to	O
autophagy	B-T038
.	O

Yet	O
,	O
aberrant	O
expression	B-T038
and	O
excessive	O
activity	O
of	O
RyRs	B-T103
in	O
these	O
tissues	B-T017
has	O
been	O
implicated	O
in	O
the	O
onset	O
of	O
several	O
diseases	B-T038
including	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
,	O
where	O
impaired	O
autophagy	B-T038
regulation	B-T038
contributes	O
to	O
the	O
pathology	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
determined	B-T058
whether	O
pharmacological	B-T038
RyR	B-T103
inhibition	O
could	O
modulate	B-T082
autophagic	B-T017
flux	O
in	O
ectopic	B-T082
RyR	B-T103
-	O
expressing	B-T038
models	B-T170
,	O
like	O
HEK293	B-T017
cells	I-T017
and	O
in	O
cell	B-T170
types	I-T170
that	O
endogenously	O
express	B-T038
RyR	B-T103
s	O
,	O
like	O
C2C12	B-T017
myoblasts	I-T017
and	O
primary	O
hippocampal	B-T017
neurons	B-T017
.	O

Importantly	O
,	O
RyR3	B-T103
overexpression	B-T038
in	O
HEK293	B-T017
cells	I-T017
impaired	O
the	O
autophagic	B-T017
flux	O
.	O

Conversely	O
,	O
in	O
all	O
cell	B-T017
models	B-T170
tested	O
,	O
pharmacological	B-T038
inhibition	O
of	O
endogenous	O
or	O
ectopically	B-T082
expressed	B-T038
RyRs	B-T103
,	O
using	O
dantrolene	B-T103
or	O
ryanodine	B-T103
,	O
augmented	O
autophagic	B-T017
flux	O
by	O
increasing	O
lysosomal	B-T017
turn	B-T038
-	I-T038
over	I-T038
(	O
number	O
of	O
autophagosomes	B-T017
and	O
autolysosomes	B-T017
measured	O
as	O
mCherry	B-T103
-	O
LC3	B-T103
punctae	I-T103
/	O
cell	B-T017
increased	O
from	O
70	O
.	O
37±7	O
.	O
81	O
in	O
control	O
HEK	B-T017
RyR3	I-T017
cells	I-T017
to	O
111	O
.	O
18±7	O
.	O
72	O
and	O
98	O
.	O
14±7	O
.	O
31	O
after	O
dantrolene	B-T103
and	O
ryanodine	B-T103
treatments	B-T058
,	O
respectively	O
)	O
.	O

Moreover	O
,	O
in	O
differentiated	B-T038
C2C12	B-T017
cells	I-T017
,	O
transmission	B-T058
electron	I-T058
microscopy	I-T058
demonstrated	O
that	O
dantrolene	B-T103
treatment	B-T058
decreased	O
the	O
number	O
of	O
early	O
autophagic	B-T017
vacuoles	B-T017
from	O
5	O
.	O
9±2	O
.	O
97	O
to	O
1	O
.	O
8±1	O
.	O
03	O
per	O
cellular	B-T017
cross	B-T082
section	I-T082
.	O

The	O
modulation	O
of	O
the	O
autophagic	B-T017
flux	O
could	O
be	O
linked	O
to	O
the	O
functional	O
inhibition	O
of	O
RyR	B-T103
channels	I-T103
as	O
both	O
RyR	B-T103
inhibitors	B-T103
efficiently	O
diminished	O
the	O
number	O
of	O
cells	B-T017
showing	O
spontaneous	O
RyR3	B-T103
activity	O
in	O
the	O
HEK293	B-T017
cell	I-T017
model	B-T170
(	O
from	O
41	O
.	O
14	O
%	O
±2	O
.	O
12	O
in	O
control	O
cells	B-T017
to	O
18	O
.	O
70	O
%	O
±2	O
.	O
25	O
and	O
9	O
.	O
74	O
%	O
±2	O
.	O
67	O
after	O
dantrolene	B-T103
and	O
ryanodine	B-T103
treatments	B-T058
,	O
respectively	O
)	O
.	O

In	O
conclusion	O
,	O
basal	B-T082
RyR	B-T103
-	O
mediated	O
Ca	B-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
-	I-T038
release	I-T038
events	I-T038
suppress	O
autophagic	B-T017
flux	O
at	O
the	O
level	O
of	O
the	O
lysosomes	B-T017
.	O

Fluoride	B-T103
concentration	O
in	O
saliva	B-T031
and	O
biofilm	B-T007
fluid	I-T007
following	O
the	O
application	B-T058
of	O
three	O
fluoride	B-T103
varnishes	I-T103

Most	O
of	O
the	O
commercially	O
available	O
fluoride	B-T103
varnishes	I-T103
(	O
FV	B-T103
)	O
have	O
not	O
been	O
evaluated	B-T058
for	O
their	O
cariostatic	B-T038
properties	I-T038
.	O

Consequently	O
,	O
the	O
aim	O
of	O
this	O
in	B-T082
vivo	I-T082
study	B-T062
was	O
to	O
investigate	B-T058
intra	B-T082
-	O
oral	B-T082
fluoride	B-T103
retention	O
and	O
clearance	B-T033
patterns	I-T033
from	O
three	O
different	O
FV	B-T103
.	O

Eighteen	O
subjects	B-T098
(	O
7	O
-	O
11	O
years	O
)	O
participated	O
in	O
a	O
laboratory	B-T092
analyst	O
-	O
blinded	B-T062
,	O
randomized	B-T062
,	O
crossover	B-T062
study	I-T062
comparing	O
the	O
ability	O
of	O
5	O
%	O
sodium	B-T103
fluoride	I-T103
varnishes	I-T103
(	O
CavityShield	B-T103
-	I-T103
CS	I-T103
,	O
Enamel	B-T103
Pro	I-T103
-	I-T103
EP	I-T103
,	O
Vanish	B-T103
-	I-T103
V	I-T103
)	O
to	O
enhance	O
fluoride	B-T103
concentrations	O
in	O
biofilm	B-T007
fluid	I-T007
,	O
centrifuged	B-T031
and	O
whole	O
saliva	B-T031
over	O
a	O
period	O
of	O
48h	O
after	O
a	O
single	O
FV	B-T103
application	O
.	O

Similar	O
fluoride	B-T103
concentration	O
×	O
time	O
patterns	O
were	O
noted	B-T170
for	O
all	O
investigated	O
FV	B-T103
and	O
studied	B-T062
variables	O
,	O
with	O
the	O
highest	O
fluoride	B-T103
concentrations	O
observed	O
for	O
the	O
first	O
biological	O
sample	O
collected	O
after	O
FV	B-T103
application	O
(	O
30min	O
)	O
.	O

Mean±SE	O
(	O
area	O
under	O
fluoride	O
clearance	O
curve	O
)	O
values	O
were	O
(	O
μg	O
F	O
/	O
g	O
or	O
ml×min	O
)	O
:	O
biofilm	B-T007
fluid	I-T007
-	O
CS	B-T103
(	O
472±191	O
)	O
,	O
EP	B-T103
(	O
423±75	O
)	O
,	O
V	B-T103
(	O
1264±279	O
)	O
;	O
centrifuged	B-T031
saliva	B-T031
-	O
CS	B-T103
(	O
42±7	O
)	O
,	O
EP	B-T103
(	O
19±3	O
)	O
,	O
V	B-T103
(	O
41±8	O
)	O
;	O
whole	O
saliva	B-T031
-	O
CS	B-T103
(	O
68±11	O
)	O
,	O
EP	B-T103
(	O
64±10	O
)	O
,	O
V	B-T103
(	O
60±7	O
)	O
.	O

V	B-T103
delivered	O
more	O
fluoride	B-T103
to	O
biofilm	B-T007
fluid	I-T007
than	O
CS	B-T103
(	O
p	O
=	O
0	O
.	O
0116	O
)	O
and	O
EP	B-T103
(	O
p	O
=	O
0	O
.	O
0065	O
)	O
,	O
which	O
did	O
not	O
differ	O
(	O
p	O
=	O
0	O
.	O
27	O
)	O
.	O

For	O
centrifuged	B-T031
saliva	B-T031
,	O
CS	B-T103
and	O
V	B-T103
were	O
not	O
significantly	O
different	O
(	O
p	O
=	O
0	O
.	O
86	O
)	O
,	O
but	O
resulted	O
in	O
higher	O
fluoride	B-T103
retention	O
than	O
EP	B-T103
(	O
p	O
<	O
0	O
.	O
0008	O
)	O
.	O

No	O
significant	O
differences	O
among	O
FV	B-T103
were	O
observed	O
for	O
whole	O
saliva	B-T031
(	O
p	O
=	O
0	O
.	O
79	O
)	O
.	O

The	O
present	B-T033
study	B-T062
has	O
shown	O
that	O
FV	B-T103
vary	O
in	O
their	O
ability	O
to	O
deliver	O
fluoride	B-T103
intra	B-T082
-	O
orally	B-T082
potentially	O
related	O
to	O
formulation	O
differences	O
.	O

To	O
what	O
extent	B-T082
the	O
present	B-T033
findings	B-T033
relate	O
to	O
clinical	O
efficacy	O
remains	O
,	O
however	O
,	O
to	O
be	O
determined	B-T058
.	O

Clinical	B-T062
research	I-T062
that	O
investigates	B-T058
fluoride	B-T103
release	O
patterns	B-T082
into	O
saliva	B-T031
and	O
biofilm	B-T007
fluid	I-T007
from	O
different	O
FV	B-T103
products	I-T103
is	O
insufficient	O
.	O

More	O
research	B-T062
is	O
needed	O
to	O
investigate	B-T058
different	O
FV	B-T103
formulations	I-T103
for	O
their	O
efficacy	O
in	O
order	O
to	O
help	O
clinicians	B-T097
make	O
better	O
evidence	O
based	O
treatment	O
choices	O
.	O

The	O
prognostic	B-T201
value	I-T201
of	O
extranodal	B-T033
extension	I-T033
in	O
human	B-T005
papillomavirus	I-T005
-	O
associated	O
oropharyngeal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038

Extranodal	B-T033
(	I-T033
or	I-T033
extracapsular	I-T033
)	I-T033
extension	I-T033
(	O
ENE	B-T033
)	O
is	O
an	O
adverse	B-T201
prognostic	I-T201
factor	I-T201
in	O
patients	O
with	O
head	B-T038
and	I-T038
neck	I-T038
cancers	I-T038
who	O
undergo	O
primary	B-T058
surgery	I-T058
.	O

However	O
,	O
the	O
significance	O
of	O
ENE	B-T033
in	O
human	B-T038
papillomavirus	I-T038
(	I-T038
HPV	I-T038
)	I-T038
-	I-T038
positive	I-T038
oropharyngeal	I-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	I-T038
OPSCC	I-T038
)	I-T038
is	O
not	O
well	O
established	O
,	O
and	O
single	B-T092
-	I-T092
institution	I-T092
studies	B-T062
have	O
not	O
established	O
that	O
ENE	B-T033
predicts	O
inferior	B-T082
outcome	O
.	O

The	O
authors	O
investigated	O
the	O
prognostic	B-T201
value	I-T201
of	O
ENE	B-T033
in	O
HPV	B-T005
-	O
positive	B-T033
patients	O
who	O
underwent	O
primary	B-T058
surgery	I-T058
and	O
whether	O
adjuvant	B-T058
chemoradiation	I-T058
improved	O
overall	O
survival	O
(	O
OS	O
)	O
compared	O
with	O
radiation	O
alone	O
in	O
ENE	B-T033
-	O
positive	B-T033
patients	O
.	O

Patients	O
who	O
underwent	O
primary	B-T058
surgery	I-T058
for	O
pathologic	O
T1	O
(	O
pT1	O
)	O
through	O
pT4	B-T038
tumors	I-T038
,	O
pathologic	O
N1	O
(	O
pN1	O
)	O
through	O
pN3	B-T017
lymph	I-T017
node	I-T017
status	O
,	O
HPV	B-T038
-	I-T038
positive	I-T038
OPSCC	I-T038
were	O
identified	O
in	O
the	O
National	O
Cancer	O
Data	O
Base	O
from	O
2010	O
through	O
2012	O
.	O

Features	O
associated	O
with	O
ENE	B-T033
were	O
analyzed	B-T062
.	O

Univariable	B-T170
and	I-T170
multivariable	I-T170
Cox	I-T170
regression	I-T170
analyses	I-T170
identified	O
predictors	O
of	O
OS	O
.	O

The	O
effect	O
of	O
adjuvant	O
treatment	O
on	O
OS	O
in	O
ENE	B-T033
-	O
positive	B-T033
cohort	O
was	O
also	O
evaluated	B-T058
.	O

In	O
total	O
,	O
1043	O
patients	O
met	O
inclusion	O
criteria	O
,	O
among	O
whom	O
43	O
.	O
5	O
%	O
were	O
ENE	B-T033
-	O
positive	B-T033
.	O

Of	O
the	O
ENE	B-T033
-	O
positive	B-T033
patients	O
who	O
had	O
treatment	B-T058
details	O
available	O
,	O
72	O
%	O
received	O
concurrent	B-T058
chemoradiotherapy	I-T058
,	O
16	O
%	O
received	O
radiotherapy	B-T058
,	O
and	O
12	O
%	O
received	O
no	O
adjuvant	O
treatment	O
.	O

After	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
28	O
.	O
4	O
months	O
,	O
ENE	B-T033
was	O
associated	O
with	O
worse	B-T033
3	O
-	O
year	O
OS	O
(	O
89	O
.	O
3	O
%	O
vs	O
93	O
.	O
6	O
%	O
;	O
P	O
=	O
.	O
01	O
)	O
.	O

On	O
multivariable	B-T170
analysis	I-T170
that	O
included	O
involved	O
lymph	B-T017
nodes	I-T017
,	O
only	O
ENE	B-T033
,	O
lymphovascular	B-T033
invasion	I-T033
,	O
pT3	B-T038
/	I-T038
pT4	I-T038
tumors	I-T038
,	O
and	O
Charlson	O
-	O
Deyo	O
score	O
were	O
associated	O
with	O
worse	B-T033
OS	O
.	O

Among	O
ENE	B-T033
-	O
positive	B-T033
patients	O
,	O
there	O
was	O
no	O
difference	O
in	O
3	O
-	O
year	O
OS	O
between	O
those	O
who	O
received	O
adjuvant	B-T058
concurrent	I-T058
chemoradiotherapy	I-T058
versus	O
radiotherapy	B-T058
alone	I-T058
(	O
89	O
.	O
6	O
%	O
vs	O
89	O
.	O
3	O
%	O
,	O
respectively	O
;	O
P	O
=	O
.	O
55	O
)	O
.	O

Propensity	O
score	O
-	O
matched	O
comparison	O
revealed	O
similar	O
results	O
.	O

ENE	B-T033
is	O
associated	O
with	O
inferior	B-T082
OS	O
in	O
patients	O
with	O
HPV	B-T038
-	I-T038
positive	I-T038
OPSCC	I-T038
.	O

However	O
,	O
OS	O
was	O
not	B-T033
better	I-T033
with	O
adjuvant	B-T058
chemoradiotherapy	I-T058
compared	O
with	O
radiotherapy	B-T058
alone	I-T058
in	O
ENE	B-T033
-	O
positive	B-T033
patients	O
.	O

The	O
current	O
findings	O
support	O
the	O
need	O
for	O
prospective	B-T062
studies	I-T062
of	O
adjuvant	B-T058
chemoradiation	I-T058
in	O
HPV	B-T005
-	O
positive	B-T033
patients	O
with	O
ENE	B-T033
.	O

Cancer	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

Psychological	O
Distress	O
Is	O
More	O
Prevalent	O
in	O
Fertile	B-T038
Age	O
and	O
Premenopausal	B-T038
Women	B-T098
with	O
PCOS	B-T038
Symptoms	B-T033
-	O
15	O
-	O
yr	O
Follow	B-T058
-	I-T058
up	I-T058

Polycystic	B-T038
ovary	I-T038
syndrome	I-T038
(	O
PCOS	B-T038
)	O
is	O
associated	O
with	O
increased	O
psychological	O
distress	O
;	O
obesity	B-T038
and	O
hyperandrogenism	B-T038
being	O
suggested	O
as	O
key	O
promoters	O
.	O

To	O
investigate	O
the	O
prevalence	O
of	O
anxiety	B-T038
/	O
depression	B-T038
and	O
their	O
coexistence	O
in	O
women	B-T098
with	O
PCOS	B-T038
/	O
PCOS	B-T038
symptoms	B-T033
at	O
age	O
s	O
31	O
and	O
46	O
.	O

The	O
roles	O
of	O
obesity	B-T038
,	O
hyperandrogenism	B-T038
and	O
awareness	B-T038
of	O
PCOS	B-T038
on	O
psychological	O
distress	O
were	O
also	O
assessed	O
.	O

Population	B-T062
based	I-T062
follow	I-T062
-	I-T062
up	I-T062
.	O

Northern	B-T082
Finland	I-T082
Birth	O
Cohort	O
1966	O
with	O
15	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
.	O

At	O
age	O
31	O
a	O
questionnaire	B-T062
-	I-T062
based	I-T062
screening	I-T062
for	O
oligoamenorrhea	B-T038
(	O
OA	B-T038
)	O
and	O
hirsutism	B-T038
(	O
H	B-T038
)	O
:	O
2188	O
asymptomatic	B-T033
(	O
controls	O
)	O
,	O
331	O
OA	B-T038
,	O
323	O
H	B-T038
,	O
125	O
OA	B-T038
+	O
H	B-T038
(	O
PCOS	B-T038
)	O
.	O

46	O
year	O
old	O
follow	B-T058
-	I-T058
up	I-T058
:	O
1576	O
controls	O
,	O
239	O
OA	B-T038
,	O
231	O
H	B-T038
and	O
85	O
PCOS	B-T038
.	O

Questionnaire	B-T062
-	I-T062
based	I-T062
screening	I-T062
for	O
anxiety	B-T038
and	O
depression	B-T033
symptoms	I-T033
(	O
Hopkins	B-T170
Symptom	I-T170
Checklist	I-T170
-	I-T170
25	I-T170
)	O
and	O
previously	O
diagnosed	B-T033
/	O
treated	B-T033
depression	B-T038
at	O
age	O
31	O
and	O
46	O
.	O

BMI	B-T201
,	O
serum	O
testosterone	O
/	O
free	B-T058
androgen	I-T058
index	I-T058
(	O
FAI	B-T058
)	O
and	O
awareness	B-T038
of	O
polycystic	B-T038
ovaries	I-T038
/	O
PCOS	B-T038
on	O
psychological	O
distress	O
were	O
also	O
assessed	O
.	O

Population	O
-	O
based	O
prevalence	O
of	O
anxiety	B-T038
and	O
/	O
or	O
depression	B-T038
in	O
women	B-T098
with	O
PCOS	B-T038
/	O
PCOS	B-T038
symptoms	B-T033
at	O
age	O
s	O
31	O
and	O
46	O
.	O

Anxiety	B-T038
and	O
/	O
or	O
depression	B-T033
symptoms	I-T033
,	O
their	O
coexistence	O
and	O
rate	O
of	O
depression	B-T038
were	O
increased	O
at	O
age	O
31	O
and	O
46	O
in	O
women	B-T098
with	O
PCOS	B-T038
or	O
isolated	O
H	B-T038
compared	O
with	O
controls	O
.	O

High	O
BMI	B-T201
or	O
hyperandrogenism	B-T038
did	O
not	O
associate	O
with	O
increased	O
anxiety	B-T038
or	O
depression	B-T033
symptoms	I-T033
.	O

The	O
awareness	B-T038
of	O
PCOS	B-T038
was	O
associated	O
with	O
increased	O
anxiety	B-T038
.	O

Women	B-T098
with	O
PCOS	B-T038
or	O
isolated	O
H	B-T038
present	O
more	O
often	O
with	O
anxiety	B-T038
and	O
/	O
or	O
depression	B-T033
symptoms	I-T033
and	O
their	O
coexistence	O
compared	O
with	O
controls	O
.	O

High	O
BMI	B-T201
or	O
hyperandrogenism	B-T038
did	O
not	O
provoke	O
psychological	O
distress	O
in	O
PCOS	B-T038
.	O

The	O
awareness	B-T038
of	O
PCOS	B-T038
increased	O
anxiety	B-T038
but	O
did	O
not	O
associate	O
with	O
severe	O
anxiety	B-T038
or	O
depression	B-T038
.	O

The	O
use	O
of	O
Oxford	B-T092
Nanopore	I-T092
native	O
barcoding	B-T062
for	O
complete	O
genome	B-T082
assembly	I-T082

The	O
Oxford	B-T092
Nanopore	I-T092
Technologies	I-T092
MinION	B-T074
(	I-T074
TM	I-T074
)	I-T074
is	O
a	O
mobile	O
DNA	O
sequencer	O
that	O
can	O
produce	O
long	B-T082
read	I-T082
sequences	I-T082
with	O
a	O
short	O
turn	O
-	O
around	O
time	O
.	O

Here	O
we	O
report	B-T170
the	O
first	O
demonstration	O
of	O
single	B-T082
contig	I-T082
genome	I-T082
assembly	I-T082
using	O
Oxford	B-T092
Nanopore	I-T092
native	O
barcoding	B-T062
when	O
applied	O
to	O
a	O
multiplexed	B-T017
library	I-T017
of	O
12	O
samples	O
and	O
combined	O
with	O
existing	O
Illumina	O
short	B-T170
-	I-T170
read	I-T170
data	I-T170
.	O

This	O
paves	O
the	O
way	O
for	O
the	O
closure	B-T062
of	O
multiple	O
bacterial	B-T017
genomes	I-T017
from	O
a	O
single	O
MinION	B-T074
(	I-T074
TM	I-T074
)	I-T074
sequencing	O
run	O
,	O
given	O
the	O
availability	O
of	O
existing	O
short	B-T170
-	I-T170
read	I-T170
data	I-T170
.	O

The	O
strain	O
we	O
used	O
,	O
MHO	O
_	O
001	O
,	O
represents	O
the	O
important	O
community	O
-	O
acquired	O
methicillin	O
resistant	O
Staphylococcus	B-T007
aureus	I-T007
lineage	O
USA300	O
.	O

Using	O
a	O
hybrid	O
assembly	B-T082
of	O
existing	O
short	O
read	O
and	O
barcoded	B-T082
long	I-T082
read	I-T082
sequences	I-T082
from	O
multiplexed	O
data	O
,	O
we	O
completed	O
a	O
genome	B-T017
of	O
the	O
S	B-T007
.	I-T007

aureus	I-T007
USA300	O
strain	O
MHO	O
_	O
001	O
.	O

The	O
long	B-T170
-	I-T170
read	I-T170
data	I-T170
represented	O
only	O
~	O
5	O
-	O
10	O
%	O
of	O
an	O
average	O
MinION	B-T074
(	I-T074
TM	I-T074
)	I-T074
run	O
(	O
~	O
7x	O
genomic	B-T017
coverage	O
)	O
,	O
but	O
,	O
using	O
standard	O
tools	B-T170
,	O
this	O
was	O
sufficient	O
to	O
complete	O
the	O
circular	B-T017
chromosome	I-T017
of	O
S	B-T007
.	I-T007

aureus	I-T007
strain	O
MHO	O
_	O
001	O
(	O
2	O
.	O
86	O
Mb	O
)	O
and	O
two	O
complete	O
plasmids	B-T103
(	O
27	O
Kb	O
and	O
3	O
Kb	O
)	O
.	O

Minor	O
differences	O
were	O
noted	O
when	O
compared	O
to	O
USA300	O
reference	O
genome	B-T017
,	O
USA300	B-T017
_	I-T017
FPR3757	I-T017
,	O
including	O
the	O
translocation	B-T038
,	O
loss	O
and	O
gain	O
of	O
mobile	B-T103
genetic	I-T103
elements	I-T103
.	O

Here	O
we	O
demonstrate	O
that	O
MinION	B-T074
(	I-T074
TM	I-T074
)	I-T074
reads	O
,	O
multiplexed	O
using	O
native	O
barcoding	B-T062
,	O
can	O
be	O
used	O
in	O
combination	O
with	O
short	B-T170
-	I-T170
read	I-T170
data	I-T170
,	O
to	O
fully	O
complete	O
a	O
bacterial	B-T017
genome	I-T017
.	O

The	O
ability	O
to	O
complete	O
multiple	O
genomes	B-T017
,	O
for	O
which	O
short	B-T170
-	I-T170
read	I-T170
data	I-T170
is	O
already	O
available	B-T033
,	O
from	O
a	O
single	O
MinION	B-T074
(	I-T074
TM	I-T074
)	I-T074
run	O
is	O
set	O
to	O
impact	O
on	O
our	O
understanding	B-T038
of	O
accessory	O
genome	B-T017
content	I-T017
,	O
plasmid	B-T103
diversity	O
and	O
genome	B-T017
rearrangements	B-T038
.	O

Doxorubicin	B-T103
Has	O
Dose	O
-	O
Dependent	O
Toxicity	B-T037
on	O
Mouse	B-T204
Ovarian	B-T017
Follicle	I-T017
Development	B-T038
,	O
Hormone	B-T038
Secretion	I-T038
,	O
and	O
Oocyte	B-T038
Maturation	I-T038

Doxorubicin	B-T103
(	O
DOX	B-T103
)	O
,	O
one	O
of	O
the	O
most	O
commonly	O
used	O
anticancer	B-T103
medications	I-T103
,	O
has	O
been	O
reported	O
to	O
affect	O
fertility	B-T038
by	O
damaging	O
ovarian	B-T017
follicles	I-T017
;	O
however	O
,	O
the	O
dose	O
-	O
dependent	O
toxicity	B-T037
of	O
DOX	B-T103
on	O
the	O
dynamic	O
follicle	B-T017
development	B-T038
and	O
oocyte	B-T038
maturation	I-T038
has	O
not	O
been	O
well	O
-	O
defined	O
.	O

Our	O
objective	B-T170
is	O
to	O
determine	O
the	O
effects	O
of	O
human	B-T204
-	O
relevant	O
exposure	O
levels	O
of	O
DOX	B-T103
on	O
follicular	B-T017
functions	O
across	O
developmental	B-T038
time	O
.	O

In	O
vitro	O
cultured	B-T058
multilayered	B-T017
secondary	I-T017
mouse	I-T017
follicles	I-T017
were	O
treated	O
with	O
DOX	B-T103
at	O
0	O
,	O
2	O
,	O
20	O
,	O
100	O
,	O
and	O
200	O
nM	O
for	O
24	O
h	O
,	O
and	O
follicle	B-T017
development	B-T038
,	O
hormone	B-T038
secretion	I-T038
,	O
and	O
oocyte	B-T038
maturation	I-T038
were	O
analyzed	O
.	O

DOX	B-T103
caused	O
dose	O
-	O
dependent	O
toxicity	B-T037
on	O
follicle	B-T038
growth	I-T038
,	O
survival	O
,	O
and	O
secretion	B-T038
of	O
17β	B-T103
-	I-T103
estradiol	I-T103
(	O
E2	B-T103
)	O
.	O

At	O
200	O
nM	O
,	O
DOX	B-T103
induced	O
DNA	B-T038
damage	I-T038
and	O
apoptosis	B-T038
in	O
follicle	B-T017
somatic	B-T017
cells	I-T017
first	O
and	O
then	O
in	O
oocytes	B-T017
,	O
which	O
was	O
correlated	O
with	O
the	O
uptake	B-T038
of	O
DOX	B-T103
first	O
to	O
the	O
somatic	B-T017
cells	I-T017
followed	O
by	O
germ	B-T017
cells	I-T017
.	O

Follicles	B-T017
treated	O
with	O
DOX	B-T103
at	O
0	O
,	O
2	O
,	O
and	O
20	O
nM	O
showed	O
similar	O
oocyte	B-T017
metaphase	B-T038
II	I-T038
(	O
MII	B-T038
)	O
percentages	O
after	O
in	O
vitro	O
oocyte	B-T038
maturation	I-T038
;	O
however	O
,	O
20	O
nM	O
DOX	B-T103
significantly	O
increased	O
the	O
number	O
of	O
MII	B-T038
oocytes	B-T017
with	O
abnormal	B-T033
spindle	B-T017
morphology	O
and	O
chromosome	B-T017
misalignment	O
.	O

In	O
an	O
effort	O
to	O
harmonize	O
the	O
in	O
vitro	O
study	O
to	O
in	B-T082
vivo	I-T082
treatment	O
,	O
dose	O
-	O
dependent	O
toxicity	B-T037
on	O
oocyte	B-T038
meiotic	I-T038
maturation	I-T038
was	O
found	O
in	O
16	O
-	O
day	O
-	O
old	O
CD	B-T204
-	I-T204
1	I-T204
mice	I-T204
treated	O
with	O
DOX	B-T103
at	O
0	O
,	O
0	O
.	O
4	O
,	O
2	O
,	O
and	O
10	O
mg	O
/	O
kg	O
,	O
consistent	O
with	O
the	O
in	O
vitro	O
oocyte	B-T038
maturation	I-T038
outcomes	O
.	O

Our	O
study	B-T062
demonstrates	O
that	O
DOX	B-T103
has	O
dose	O
-	O
dependent	O
toxicity	B-T037
on	O
ovarian	B-T017
follicle	I-T017
development	B-T038
,	O
hormone	B-T038
secretion	I-T038
,	O
and	O
oocyte	B-T038
maturation	I-T038
,	O
which	O
are	O
three	O
key	O
factors	O
to	O
support	O
the	O
female	B-T038
reproductive	I-T038
and	O
endocrine	B-T038
functions	I-T038
.	O

Involvement	O
of	O
apoptotic	B-T038
pathways	I-T038
in	O
docosahexaenoic	B-T103
acid	I-T103
-	O
induced	O
benefit	O
in	O
prostate	B-T038
cancer	I-T038
:	O
Pathway	O
-	O
focused	O
gene	B-T062
expression	I-T062
analysis	I-T062
using	O
RT	B-T062
(	I-T062
2	I-T062
)	I-T062
Profile	I-T062
PCR	I-T062
Array	I-T062
System	I-T062

Present	O
study	O
aimed	O
to	O
better	O
understand	O
the	O
potential	O
apoptotic	B-T038
pathways	I-T038
that	O
involved	O
in	O
docosahexaenoic	B-T103
acid	I-T103
(	O
DHA	B-T103
)	O
-	O
induced	O
apoptosis	B-T038
of	O
prostate	B-T038
cancer	I-T038
cells	B-T017
.	O

Human	B-T204
prostate	B-T038
cancer	I-T038
DU145	B-T017
cells	I-T017
were	O
treated	O
with	O
different	O
concentrations	O
of	O
fish	B-T103
oil	I-T103
,	O
omega	B-T103
-	I-T103
3	I-T103
PUFA	I-T103
(	O
DHA	B-T103
,	O
and	O
Eicosapentaenoic	B-T103
acid	I-T103
,	O
EPA	B-T103
)	O
,	O
or	O
omega	B-T103
-	I-T103
6	I-T103
PUFA	I-T103
(	O
Arachidonic	B-T103
acid	I-T103
,	O
AA	B-T103
)	O
.	O

Cell	B-T038
viability	I-T038
and	O
apoptosis	B-T038
were	O
evaluated	O
by	O
MTT	B-T062
assay	I-T062
and	O
Hoechst	O
staining	O
.	O

Pathway	O
-	O
focused	O
gene	B-T058
expression	I-T058
profiling	I-T058
of	O
DU145	B-T017
cells	I-T017
was	O
analyzed	O
with	O
the	O
RT	O
(	O
2	O
)	O
Profile	O
PCR	O
Array	O
System	O
.	O

The	O
results	O
were	O
verified	O
by	O
real	B-T062
time	I-T062
quantitative	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
RT	B-T062
-	I-T062
qPCR	I-T062
)	O
.	O

AA	B-T103
exposure	O
showed	O
no	O
obvious	O
effect	O
on	O
viability	B-T038
of	O
DU145	B-T017
cells	I-T017
.	O

However	O
,	O
exposure	O
with	O
fish	B-T103
oil	I-T103
,	O
EPA	B-T103
,	O
or	O
DHA	B-T103
for	O
24	O
h	O
significantly	O
affected	O
cell	B-T038
viability	I-T038
.	O

The	O
growth	B-T038
inhibition	I-T038
of	O
DHA	B-T103
was	O
more	O
pronounced	O
than	O
that	O
of	O
EPA	B-T103
and	O
showed	O
a	O
time	O
-	O
dependent	O
increase	O
.	O

DHA	B-T103
exposure	O
caused	O
typical	O
apoptotic	O
characteristics	O
.	O

Ten	O
genes	B-T017
were	O
more	O
expressed	O
,	O
while	O
5	O
genes	B-T017
were	O
less	O
expressed	O
following	O
DHA	B-T103
exposure	O
.	O

RT	B-T062
-	I-T062
qPCR	I-T062
confirmed	O
the	O
time	O
dependent	O
effect	O
of	O
DHA	B-T103
on	O
the	O
expression	O
of	O
these	O
differentially	O
expressed	O
genes	B-T017
.	O

KEGG	O
pathway	O
analysis	O
showed	O
that	O
DHA	B-T103
may	O
induce	O
the	O
apoptosis	B-T038
of	O
cancer	B-T017
cells	I-T017
preferentially	O
through	O
mediating	O
P53	B-T038
,	O
MAPK	B-T038
,	O
TNF	B-T038
,	O
PI3K	O
/	O
AKT	O
,	O
and	O
NF	B-T038
-	I-T038
κB	I-T038
signaling	I-T038
pathways	I-T038
.	O

Our	O
study	O
demonstrated	O
the	O
beneficial	O
action	O
of	O
DHA	B-T103
on	O
human	B-T204
prostate	B-T038
carcinoma	I-T038
cell	B-T017
line	I-T017
DU145	I-T017
.	O

The	O
pro	O
-	O
apoptotic	O
effect	O
of	O
DHA	B-T103
on	O
DU145	B-T017
cells	I-T017
may	O
involve	O
mediation	O
various	O
pathways	B-T038
,	O
especially	O
P53	B-T038
,	O
MAPK	B-T038
,	O
TNF	B-T038
,	O
PI3K	O
/	O
AKT	O
,	O
and	O
NF	B-T038
-	I-T038
κB	I-T038
signaling	I-T038
pathways	I-T038
.	O

Molecular	B-T038
mechanisms	I-T038
of	O
DHA	B-T103
on	O
apoptosis	B-T038
of	O
cancer	B-T017
cells	I-T017
still	O
need	O
to	O
be	O
further	O
clarified	O
.	O

Medication	B-T058
Reconciliation	I-T058
During	O
Hospitalization	B-T058
and	O
in	O
Hospital	O
-	O
Home	O
Interface	O
:	O
An	O
Observational	B-T062
Retrospective	I-T062
Study	I-T062

Medication	O
errors	O
are	O
one	O
of	O
the	O
leading	O
causes	O
of	O
patient	O
harms	O
.	O

Medication	B-T058
reconciliation	I-T058
is	O
a	O
fundamental	O
process	O
that	O
to	O
be	O
effective	O
,	O
it	O
should	O
be	O
embraced	O
during	O
each	O
single	O
care	B-T058
transition	I-T058
.	O

Our	O
objectives	O
were	O
to	O
investigate	O
current	O
medication	B-T058
reconciliation	I-T058
practices	O
in	O
the	O
2	O
Fondazione	B-T092
Toscana	I-T092
Gabriele	I-T092
Monasterio	I-T092
hospitals	I-T092
and	O
comprehensively	O
assess	O
the	O
quality	O
of	O
medication	B-T058
reconciliation	I-T058
practices	O
between	O
inpatient	O
and	O
outpatient	O
care	O
by	O
analyzing	B-T062
the	O
medication	O
patterns	O
6	O
months	O
before	O
admission	B-T058
,	O
during	O
hospitalization	B-T058
,	O
and	O
9	O
months	O
after	O
discharge	B-T058
for	O
a	O
selected	O
group	O
of	O
patients	O
with	O
cardiovascular	B-T038
diseases	I-T038
.	O

A	O
retrospective	B-T062
observational	I-T062
study	I-T062
was	O
conducted	O
in	O
the	O
Cardiothoracic	B-T092
Department	I-T092
of	O
the	O
Fondazione	B-T092
Toscana	I-T092
Gabriele	I-T092
Monasterio	I-T092
hospitals	I-T092
.	O

Medication	B-T170
history	I-T170
was	O
reviewed	O
for	O
all	O
the	O
patients	O
admitted	B-T058
from	O
and	O
discharged	B-T058
to	O
the	O
community	O
,	O
from	O
January	O
to	O
March	O
2013	O
.	O

Patients	O
were	O
excluded	O
if	O
they	O
had	O
less	O
than	O
4	O
drugs	B-T058
or	O
less	O
than	O
2	O
drugs	B-T058
for	O
cardiovascular	B-T022
system	I-T022
in	O
their	O
prescription	B-T170
list	I-T170
at	O
admission	B-T058
or	O
if	O
they	O
died	O
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O

We	O
selected	O
714	O
patients	O
,	O
and	O
we	O
obtained	O
the	O
clinical	B-T170
charts	I-T170
and	O
all	O
drug	B-T170
prescriptions	I-T170
collected	O
during	O
patients	O
'	O
hospitalization	B-T058
by	O
the	O
electronic	O
clinical	O
recording	O
system	O
.	O

We	O
also	O
analyzed	B-T062
the	O
list	B-T170
of	I-T170
prescriptions	I-T170
of	O
this	O
sample	O
of	O
patients	O
,	O
from	O
6	O
months	O
before	O
admission	B-T058
to	O
9	O
months	O
after	O
discharge	B-T058
,	O
extracted	O
from	O
the	O
regional	B-T170
prescription	I-T170
registry	I-T170
.	O

In	O
the	O
resulting	O
sample	O
,	O
prescriptions	B-T170
were	O
analyzed	B-T062
to	O
assess	O
unintentional	O
discrepancies	B-T033
.	O

The	O
study	B-T062
included	O
298	O
patients	O
(	O
mean	O
age	O
,	O
71	O
.	O
2	O
years	O
)	O
,	O
according	O
to	O
the	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

Among	O
14	O
,	O
573	O
prescriptions	B-T170
analyzed	B-T062
,	O
we	O
found	O
4363	O
discrepancies	B-T033
(	O
14	O
.	O
6	O
discrepancies	B-T033
per	O
patient	O
)	O
.	O

Among	O
these	O
discrepancies	B-T033
,	O
1310	O
were	O
classified	O
as	O
unintentional	O
(	O
4	O
.	O
4	O
discrepancies	B-T033
per	O
patient	O
)	O
.	O

Among	O
unintentional	O
discrepancies	B-T033
,	O
only	O
63	O
(	O
4	O
.	O
8	O
%	O
)	O
took	O
place	O
during	O
hospitalization	B-T058
.	O

Although	O
at	O
the	O
hospital	O
-	O
home	O
interface	O
,	O
33	O
.	O
1	O
%	O
of	O
unintentional	O
discrepancies	B-T033
were	O
detected	O
through	O
the	O
comparison	O
between	O
the	O
patients	O
'	O
declared	O
therapy	O
and	O
the	O
previous	O
medication	O
consumption	O
and	O
62	O
.	O
1	O
%	O
were	O
identified	O
in	O
the	O
comparison	O
between	O
the	O
prescription	B-T170
at	O
the	O
discharge	B-T058
and	O
the	O
following	O
medication	O
pattern	O
at	O
home	B-T082
.	O

Medication	O
errors	O
have	O
important	O
implications	O
for	O
patient	B-T058
safety	I-T058
,	O
and	O
their	O
identification	O
is	O
a	O
main	O
target	O
for	O
improving	O
clinical	O
practice	O
.	O

The	O
comparison	O
between	O
the	O
medication	O
patterns	O
acquired	O
through	O
the	O
regional	B-T170
prescription	I-T170
registry	I-T170
before	O
and	O
after	O
hospitalization	B-T058
outlined	O
critical	O
touchpoint	O
in	O
the	O
current	O
medication	B-T058
reconciliation	I-T058
process	O
,	O
calling	O
for	O
the	O
definition	O
of	O
shared	O
medication	B-T058
reconciliation	I-T058
standards	O
between	O
hospitals	B-T092
and	O
primary	B-T058
care	I-T058
services	I-T058
to	O
minimize	O
medication	O
discrepancies	O
and	O
enhance	O
patient	B-T058
safety	I-T058
.	O

Autologous	B-T103
vs	O
Irradiated	B-T103
Homologous	I-T103
Costal	I-T103
Cartilage	I-T103
as	O
Graft	B-T103
Material	I-T103
in	O
Rhinoplasty	B-T058

Studies	O
comparing	O
surgical	O
results	O
of	O
rhinoplasty	B-T058
using	O
autologous	B-T103
costal	I-T103
cartilage	I-T103
(	O
ACC	B-T103
)	O
and	O
irradiated	B-T103
homologous	I-T103
costal	I-T103
cartilage	I-T103
(	O
IHCC	B-T103
)	O
are	O
rare	O
.	O

To	O
compare	O
the	O
clinical	B-T033
results	I-T033
of	O
major	O
augmentation	B-T058
rhinoplasty	I-T058
using	O
ACC	B-T103
vs	O
IHCC	B-T103
and	O
analyze	O
the	O
histologic	O
properties	O
of	O
both	O
types	O
of	O
cartilage	B-T017
.	O

A	O
retrospective	B-T062
clinical	I-T062
study	I-T062
was	O
conducted	O
among	O
patients	O
who	O
had	O
undergone	O
rhinoseptoplasty	B-T058
using	O
ACC	B-T103
or	O
IHCC	B-T103
from	O
January	O
1	O
,	O
2009	O
,	O
to	O
December	O
31	O
,	O
2014	O
.	O

Patients	O
were	O
followed	B-T058
up	I-T058
for	O
more	O
than	O
1	O
year	O
after	O
surgery	B-T058
and	O
the	O
histologic	O
characteristics	O
of	O
ACC	B-T103
and	O
IHCC	B-T103
were	O
compared	O
.	O

The	O
details	O
of	O
the	O
surgical	B-T058
procedures	I-T058
and	O
complications	O
,	O
including	O
warping	O
,	O
infection	B-T038
,	O
resorption	B-T038
,	O
and	O
/	O
or	O
donor	B-T082
-	I-T082
site	I-T082
morbidity	O
,	O
were	O
evaluated	B-T058
by	O
reviewing	O
medical	B-T170
records	I-T170
and	O
facial	O
photographs	O
.	O

Patients	O
'	O
subjective	O
satisfaction	B-T038
with	O
aesthetic	O
and	O
functional	O
results	O
was	O
evaluated	B-T058
using	O
a	O
questionnaire	B-T170
.	O

The	O
details	O
of	O
the	O
surgical	B-T058
procedures	I-T058
and	O
complications	O
,	O
including	O
warping	O
,	O
infection	B-T038
,	O
resorption	B-T038
,	O
and	O
/	O
or	O
donor	B-T082
-	I-T082
site	I-T082
morbidity	O
;	O
patients	O
'	O
subjective	O
satisfaction	B-T038
with	O
aesthetic	O
and	O
functional	O
results	O
'	O
objective	O
evaluation	B-T058
of	O
surgical	B-T058
outcomes	O
,	O
including	O
symmetry	O
,	O
dorsal	B-T082
height	O
,	O
dorsal	B-T082
length	O
,	O
dorsal	B-T082
width	O
,	O
tip	B-T033
projection	I-T033
,	O
tip	B-T033
rotation	I-T033
,	O
tip	B-T033
width	I-T033
,	O
and	O
overall	O
result	O
;	O
and	O
histologic	O
structures	B-T082
.	O

Objective	O
evaluation	B-T058
of	O
surgical	B-T058
outcomes	O
was	O
graded	O
using	O
the	O
Objective	O
Rhinoplasty	B-T058
Outcome	B-T033
Score	I-T033
,	O
which	O
assessed	O
symmetry	O
,	O
dorsal	B-T082
height	O
,	O
dorsal	B-T082
length	O
,	O
dorsal	B-T082
width	O
,	O
tip	B-T033
projection	I-T033
,	O
tip	B-T033
rotation	I-T033
,	O
tip	B-T033
width	I-T033
,	O
and	O
overall	O
result	O
.	O

Histologic	O
structures	O
were	O
evaluated	B-T058
using	O
hematoxylin	B-T058
and	I-T058
eosin	I-T058
,	O
Masson	B-T058
trichrome	I-T058
,	O
Alcian	B-T058
blue	I-T058
,	O
and	O
Verhoeff	B-T058
elastic	I-T058
stains	I-T058
.	O

A	O
total	O
of	O
63	O
patients	O
(	O
27	O
males	O
and	O
36	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
30	O
.	O
6	O
[	O
9	O
.	O
5	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	B-T058
using	O
ACC	B-T103
and	O
20	O
(	O
9	O
males	O
and	O
11	O
females	O
;	O
mean	O
[	O
SD	O
]	O
age	O
,	O
35	O
.	O
4	O
[	O
15	O
.	O
4	O
]	O
years	O
)	O
had	O
rhinoseptoplasty	B-T058
using	O
IHCC	B-T103
.	O

Among	O
observed	O
complications	O
,	O
only	O
notable	O
resorption	B-T038
occurred	O
more	O
frequently	O
in	O
patients	O
using	O
IHCC	B-T103
(	O
6	O
[	O
30	O
%	O
]	O
)	O
than	O
with	O
ACC	B-T103
(	O
2	O
[	O
3	O
%	O
]	O
)	O
(	O
P	O
=	O
.	O
002	O
)	O
.	O

In	O
subjective	O
evaluations	B-T058
of	O
aesthetic	O
satisfaction	B-T038
,	O
patients	O
who	O
received	O
ACC	B-T103
showed	O
significantly	O
greater	O
satisfaction	B-T038
(	O
37	O
of	O
51	O
patients	O
[	O
73	O
%	O
]	O
were	O
very	O
satisfied	O
)	O
than	O
did	O
those	O
who	O
received	O
IHCC	B-T103
(	O
6	O
of	O
20	O
[	O
30	O
%	O
]	O
)	O
(	O
P	O
=	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
between	O
-	O
group	O
difference	O
in	O
subjective	O
functional	O
outcomes	O
:	O
4	O
of	O
51	O
patients	O
receiving	O
ACC	B-T103
(	O
8	O
%	O
)	O
and	O
5	O
of	O
20	O
receiving	O
IHCC	B-T103
(	O
25	O
%	O
)	O
were	O
satisfied	B-T038
(	O
P	O
=	O
.	O
50	O
)	O
and	O
45	O
of	O
51	O
receiving	O
ACC	B-T103
(	O
88	O
%	O
)	O
and	O
15	O
of	O
20	O
receiving	O
IHCC	B-T103
(	O
75	O
%	O
)	O
were	O
very	O
satisfied	O
(	O
P	O
=	O
.	O
15	O
)	O
.	O

Regarding	O
objective	O
aesthetic	O
outcomes	O
,	O
all	O
scores	O
for	O
both	O
ACC	B-T103
and	O
IHCC	B-T103
were	O
more	O
than	O
3	O
.	O
1	O
(	O
between	O
good	O
and	O
excellent	O
)	O
.	O

Histologic	B-T058
analyses	I-T058
showed	O
larger	O
,	O
more	O
evenly	O
distributed	O
,	O
uniform	O
chondrocytes	B-T017
and	O
more	O
collagens	B-T103
and	O
proteoglycan	B-T103
contents	O
in	O
ACC	B-T103
than	O
in	O
IHCC	B-T103
.	O

Compared	O
with	O
patients	O
receiving	O
IHCC	B-T103
,	O
those	O
receiving	O
ACC	B-T103
for	O
rhinoseptoplasty	B-T058
showed	O
superior	O
aesthetic	O
satisfaction	B-T038
;	O
ACC	B-T103
also	O
had	O
less	O
frequent	O
notable	O
resorption	B-T038
.	O

Autologous	B-T103
costal	I-T103
cartilage	I-T103
also	O
had	O
better	O
histologic	O
properties	O
than	O
IHCC	B-T103
did	O
,	O
suggesting	O
it	O
as	O
an	O
ideal	O
graft	B-T103
material	I-T103
with	O
less	O
chance	O
of	O
long	O
-	O
term	O
resorption	B-T038
.	O

3	O
.	O

Testing	O
the	O
Ret	B-T017
and	O
Sema3d	B-T017
genetic	O
interaction	O
in	O
mouse	B-T204
enteric	B-T038
nervous	I-T038
system	I-T038
development	I-T038

For	O
most	O
multigenic	B-T038
disorders	I-T038
,	O
clinical	O
manifestation	O
(	O
penetrance	O
)	O
and	O
presentation	O
(	O
expressivity	O
)	O
are	O
likely	O
to	O
be	O
an	O
outcome	O
of	O
genetic	O
interaction	O
between	O
multiple	O
susceptibility	B-T017
genes	I-T017
.	O

Here	O
,	O
using	O
gene	O
knockouts	O
in	O
mice	B-T204
we	O
evaluated	O
genetic	O
interaction	O
between	O
loss	O
of	O
Ret	B-T017
and	O
loss	O
of	O
Sema3d	B-T017
,	O
two	O
Hirschsprung	B-T017
disease	I-T017
susceptibility	B-T017
genes	I-T017
.	O

We	O
intercrossed	O
Ret	B-T017
and	O
Sema3d	B-T017
double	O
null	O
heterozygotes	O
to	O
generate	O
mice	O
with	O
the	O
nine	O
possible	O
genotypes	O
and	O
assessed	O
survival	O
by	O
counting	B-T058
various	I-T058
genotypes	I-T058
,	O
myenteric	B-T017
plexus	I-T017
presence	O
by	O
acetylcholinesterase	B-T058
staining	I-T058
and	O
embryonic	O
day	O
12	O
.	O
5	O
(	O
E12	O
.	O
5	O
)	O
intestine	B-T082
transcriptome	I-T082
by	O
RNA	B-T082
-	I-T082
sequencing	I-T082
.	O

Survival	O
rates	O
of	O
Ret	B-T017
wildtype	B-T017
,	O
null	O
heterozygote	O
and	O
null	O
homozygote	O
mice	B-T204
at	O
E12	O
.	O
5	O
,	O
birth	B-T038
and	O
weaning	B-T033
were	O
not	O
influenced	O
by	O
the	O
genotypes	O
at	O
Sema3d	B-T017
locus	B-T082
and	O
vice	O
-	O
versa	O
.	O

Loss	O
of	O
myenteric	B-T017
plexus	I-T017
was	O
observed	O
only	O
in	O
all	O
Ret	B-T017
null	O
homozygotes	O
,	O
irrespective	O
of	O
the	O
genotypes	O
at	O
Sema3d	B-T017
locus	B-T082
,	O
and	O
Sema3d	B-T017
null	O
heterozygote	O
and	O
homozygote	O
mice	O
had	O
normal	O
intestinal	O
innervation	O
.	O

As	O
compared	O
to	O
wildtype	B-T017
mice	I-T017
intestinal	I-T017
gene	B-T038
expression	I-T038
,	O
loss	O
of	O
Ret	B-T017
in	O
null	O
homozygotes	O
led	O
to	O
differential	O
expression	B-T038
of	I-T038
∼300	I-T038
genes	I-T038
,	I-T038
whereas	O
loss	O
of	O
Sema3d	B-T017
in	O
null	O
homozygotes	O
had	O
no	O
major	O
consequence	O
and	O
there	O
was	O
no	O
evidence	O
supporting	O
major	O
interaction	O
between	O
the	O
two	O
genes	O
influencing	O
intestine	B-T082
transcriptome	I-T082
.	O

Overall	O
,	O
given	O
the	O
null	B-T038
alleles	I-T038
and	O
phenotypic	B-T058
assays	I-T058
used	O
,	O
we	O
did	O
not	O
find	O
evidence	O
for	O
genetic	O
interaction	O
between	O
Ret	B-T017
and	O
Sema3d	B-T017
affecting	O
survival	O
,	O
presence	O
of	O
myenteric	B-T017
plexus	I-T017
or	O
intestine	B-T082
transcriptome	I-T082
.	O

Pembrolizumab	B-T103
for	O
the	O
treatment	B-T058
of	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038

In	O
the	O
last	O
years	O
,	O
a	O
spectacular	O
development	O
of	O
immunotherapeutic	B-T103
agents	I-T103
aimed	O
at	O
the	O
PD	B-T103
-	I-T103
1	I-T103
/	O
PD	O
-	O
L1	O
axis	O
has	O
taken	O
place	O
.	O

This	O
development	O
of	O
these	O
checkpoint	B-T103
inhibitors	I-T103
has	O
greatly	O
influenced	O
our	O
approach	O
to	O
the	O
treatment	B-T058
of	O
lung	B-T038
cancer	I-T038
in	O
first	B-T058
and	O
second	B-T058
line	I-T058
.	O

The	O
limited	O
toxicity	B-T037
profile	O
and	O
the	O
ability	O
to	O
treat	B-T058
for	O
prolonged	O
periods	O
,	O
even	O
in	O
smokers	B-T033
,	O
is	O
a	O
welcome	O
expansion	O
of	O
the	O
therapeutic	O
arsenal	O
of	O
the	O
oncologist	B-T097
.	O

Areas	O
covered	O
:	O
This	O
review	B-T170
highlights	O
the	O
results	O
of	O
recent	O
clinical	B-T062
trials	I-T062
on	O
pembrolizumab	B-T103
for	O
the	O
treatment	B-T058
of	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
.	O

The	O
authors	B-T097
discuss	O
both	O
first	B-T058
and	O
second	B-T058
line	I-T058
treatment	I-T058
with	O
pembrolizumab	B-T103
as	O
monotherapy	B-T058
and	O
in	O
combination	B-T058
therapies	I-T058
.	O

Additionally	O
,	O
implications	O
of	O
the	O
PD	O
-	O
L1	O
immunohistochemistry	B-T058
assay	I-T058
with	O
the	O
22C3	B-T103
antibody	I-T103
and	O
its	O
use	O
in	O
clinical	B-T062
practice	I-T062
and	O
trials	B-T062
is	O
discussed	O
.	O

Expert	O
commentary	O
:	O
A	O
higher	O
overall	B-T033
response	I-T033
,	O
overall	O
survival	O
and	O
a	O
moderate	O
toxicity	B-T037
profile	O
is	O
observed	O
with	O
the	O
use	O
of	O
pembrolizumab	B-T103
,	O
compared	O
to	O
chemotherapy	B-T058
,	O
in	O
both	O
first	B-T058
and	O
second	B-T058
line	I-T058
.	O

These	O
promising	O
results	O
have	O
already	O
translated	O
into	O
the	O
registration	B-T058
of	O
pembrolizumab	B-T103
in	O
first	B-T058
and	O
second	B-T058
line	I-T058
in	O
patients	O
with	O
a	O
high	O
expression	B-T038
of	O
PD	O
-	O
L1	O
.	O

However	O
,	O
as	O
PD	O
-	O
L1	O
staining	B-T058
does	O
not	O
sufficiently	O
discriminate	O
responders	B-T033
from	O
non	B-T033
-	I-T033
responders	I-T033
for	O
all	O
checkpoint	B-T103
inhibitors	I-T103
,	O
there	O
still	O
is	O
a	O
need	O
for	O
a	O
better	O
predictive	O
biomarker	B-T201
.	O

Synchronisms	O
between	O
bud	B-T204
and	O
cambium	B-T017
phenology	O
in	O
black	B-T204
spruce	I-T204
:	O
early	O
-	O
flushing	O
provenances	O
exhibit	O
early	O
xylem	B-T204
formation	O

Bud	B-T204
and	O
cambial	B-T017
phenology	O
represent	O
the	O
adaptation	B-T038
of	O
species	B-T170
to	O
the	O
local	B-T082
environment	B-T082
that	O
allows	O
the	O
growing	O
season	O
to	O
be	O
maximized	O
while	O
minimizing	O
the	O
risk	O
of	O
frost	B-T103
for	O
the	O
developing	O
tissues	B-T017
.	O

The	O
temporal	O
relationship	O
between	O
the	O
apical	B-T082
and	O
radial	O
meristems	B-T204
can	O
help	O
in	O
the	O
understanding	O
of	O
tree	B-T204
growth	B-T038
as	O
a	O
whole	O
process	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	O
cambial	B-T017
phenology	O
in	O
black	B-T204
spruce	I-T204
(	O
Picea	B-T204
mariana	I-T204
(	O
Mill	O
.	O
)	O
B	O
.	O
S	O
.	O
P	O
.	O
)	O
provenances	O
classified	B-T170
as	O
early	O
and	O
late	O
bud	B-T204
flushing	O
.	O

The	O
different	O
phases	O
of	O
cambial	B-T017
phenology	O
were	O
assessed	O
on	O
wood	O
microcores	B-T082
sampled	O
weekly	O
from	O
April	O
to	O
October	O
in	O
2014	O
and	O
2015	O
from	O
61	O
trees	B-T204
growing	B-T038
in	O
a	O
provenance	O
trial	O
in	O
Quebec	B-T082
,	O
Canada	B-T082
.	O

Trees	B-T204
showing	O
an	O
early	O
bud	B-T204
flush	O
also	O
exhibited	O
early	O
reactivation	O
of	O
xylem	B-T204
differentiation	B-T038
,	O
although	O
an	O
average	O
difference	O
of	O
12	O
days	O
for	O
buds	B-T204
corresponded	O
to	O
small	O
although	O
significant	O
differences	O
of	O
4	O
days	O
for	O
xylem	B-T204
.	O

Provenances	O
with	O
early	O
bud	B-T204
flush	O
had	O
an	O
early	O
bud	B-T204
set	O
and	O
completed	O
xylem	B-T204
formation	O
earlier	O
than	O
late	O
bud	B-T204
flush	O
provenances	O
.	O

No	B-T033
significant	I-T033
difference	O
in	O
the	O
period	O
of	O
xylem	B-T204
formation	O
and	O
total	O
growth	B-T038
was	O
observed	O
between	O
the	O
flushing	O
classes	O
.	O

Our	O
results	B-T033
demonstrate	O
that	O
the	O
ecotype	O
differentiation	B-T038
of	O
black	B-T204
spruce	I-T204
provenances	O
represented	O
by	O
the	O
phenological	O
adaptation	B-T038
of	O
buds	B-T204
to	O
the	O
local	B-T082
climate	O
corresponds	O
to	O
specific	O
growth	B-T038
dynamics	O
of	O
the	O
xylem	B-T204
.	O

An	O
approach	O
for	O
liposome	B-T103
immobilization	B-T058
using	O
sterically	O
stabilized	O
micelles	B-T103
(	O
SSMs	B-T103
)	O
as	O
a	O
precursor	O
for	O
bio	B-T058
-	I-T058
layer	I-T058
interferometry	I-T058
-	O
based	O
interaction	O
studies	B-T062

Non	O
-	O
fluidic	O
bio	B-T058
-	I-T058
layer	I-T058
interferometry	I-T058
(	O
BLI	B-T058
)	O
has	O
rapidly	O
become	O
a	O
standard	O
tool	O
for	O
monitoring	O
almost	O
all	O
biomolecular	O
interactions	O
in	O
a	O
label	O
-	O
free	O
,	O
real	O
-	O
time	O
and	O
high	O
-	O
throughput	O
manner	O
.	O

High	O
-	O
efficiency	O
screening	B-T058
methods	I-T058
which	O
measure	O
the	O
kinetics	O
of	O
liposomes	B-T103
with	O
a	O
variety	O
of	O
compounds	B-T103
require	O
the	O
immobilization	B-T058
of	O
liposomes	B-T103
.	O

In	O
this	O
work	O
,	O
a	O
method	O
is	O
described	O
for	O
immobilizing	B-T058
liposomes	B-T103
for	O
interaction	O
studies	B-T062
,	O
based	O
on	O
the	O
biophysical	O
principles	O
of	O
this	O
biosensor	O
platform	O
.	O

The	O
immobilization	B-T058
approach	O
includes	O
the	O
loading	O
of	O
DSPE	B-T103
-	I-T103
PEG	I-T103
(	I-T103
2000	I-T103
)	I-T103
-	O
biotin	B-T103
containing	O
sterically	O
stabilized	O
micelles	B-T103
(	O
SSMs	B-T103
)	O
which	O
are	O
restructured	O
in	O
a	O
buffer	O
change	O
step	O
,	O
resulting	O
in	O
an	O
accessible	O
substrate	O
for	O
liposome	B-T103
immobilization	B-T058
.	O

Liposomes	B-T103
in	O
a	O
concentration	O
of	O
5mM	O
of	O
varying	O
composition	B-T201
and	O
fluidity	O
were	O
immobilized	B-T058
on	O
the	O
sensor	O
surface	B-T082
by	O
inserting	O
the	O
hydrophobic	O
residues	O
of	O
the	O
former	O
loaded	O
SSMs	B-T103
.	O

This	O
proof	O
of	O
principle	O
was	O
carried	O
out	O
using	O
Cytochrome	B-T103
C	I-T103
as	O
a	O
membrane	O
-	O
interacting	O
model	O
protein	B-T103
.	O

The	O
binding	B-T038
of	O
Cytochrome	B-T103
C	I-T103
to	O
the	O
immobilized	B-T058
liposomes	B-T103
was	O
demonstrated	O
,	O
and	O
the	O
derived	O
kinetic	O
and	O
affinity	O
constants	O
were	O
similar	O
to	O
values	O
given	O
in	O
the	O
literature	B-T170
.	O

In	O
order	O
to	O
obtain	O
a	O
detailed	O
understanding	B-T038
of	O
this	O
surface	B-T082
,	O
and	O
to	O
show	O
the	O
integrity	O
of	O
the	O
liposomes	B-T103
,	O
confocal	B-T058
fluorescence	I-T058
microscopy	I-T058
was	O
used	O
.	O

Images	O
of	O
immobilized	B-T058
liposomes	B-T103
containing	O
calcein	B-T103
in	O
the	O
aqueous	O
core	B-T082
indicated	B-T033
intact	O
vesicles	B-T017
.	O

A	O
combination	O
of	O
this	O
simple	O
liposome	B-T103
immobilization	B-T058
approach	O
,	O
the	O
possibility	O
of	O
automation	O
on	O
BLI	B-T058
systems	O
with	O
high	O
throughput	O
within	O
an	O
acceptable	O
timescale	O
and	O
excellent	O
reproducibility	O
makes	O
this	O
assay	B-T058
suitable	O
for	O
basic	O
research	B-T062
as	O
well	O
as	O
for	O
industrial	O
and	O
regulatory	B-T170
applications	I-T170
.	O

Exercise	O
increases	O
lactoferrin	B-T103
,	O
but	O
decreases	O
lysozyme	B-T103
in	O
salivary	B-T082
granulocytes	B-T017

Intracellular	B-T103
lactoferrin	I-T103
(	O
Lac	B-T103
)	O
and	O
lysozyme	B-T103
(	O
Lys	B-T103
)	O
content	O
play	O
an	O
important	O
role	O
in	O
regulating	O
inflammation	B-T038
and	O
promoting	O
host	B-T038
protection	I-T038
.	O

While	O
exercise	O
has	O
demonstrated	O
an	O
increase	O
in	O
Lac	B-T103
and	O
Lys	B-T103
concentration	O
in	O
exocrine	B-T031
solutions	I-T031
,	O
little	O
is	O
known	O
regarding	O
intracellular	O
concentration	O
changes	O
in	O
response	O
to	O
exercise	O
.	O

To	O
quantify	O
intracellular	O
Lac	B-T103
and	O
Lys	B-T103
concentration	O
before	O
and	O
after	O
exercise	O
in	O
salivary	B-T082
CD45	B-T017
(	I-T017
+	I-T017
)	I-T017
CD15	I-T017
(	I-T017
+	I-T017
)	I-T017
cells	I-T017
.	O

11	O
males	O
(	O
20	O
.	O
3	O
±	O
0	O
.	O
8	O
years	O
,	O
57	O
.	O
2	O
±	O
7	O
.	O
6	O
mL	O
/	O
kg	O
/	O
min	O
V̇O2pk	O
,	O
11	O
.	O
1	O
±	O
3	O
.	O
9	O
%	O
body	B-T201
fat	I-T201
)	O
ran	O
for	O
45	O
min	O
at	O
75	O
%	O
of	O
VO2pk	O
.	O

12	O
mL	O
of	O
stimulated	B-T031
saliva	I-T031
were	O
collected	O
pre	O
and	O
immediately	O
post	O
exercise	O
.	O

Saliva	B-T031
was	O
filtered	O
through	O
a	O
30	O
-	O
µm	O
filter	O
before	O
analysis	O
of	O
leukocytes	B-T017
(	O
CD45	B-T017
(	I-T017
+	I-T017
)	I-T017
)	O
and	O
granulocytes	B-T017
(	O
CD45	B-T017
(	I-T017
+	I-T017
)	I-T017
CD15	I-T017
(	I-T017
+	I-T017
)	I-T017
)	O
using	O
flow	B-T058
cytometry	I-T058
.	O

Median	O
fluorescent	O
intensity	O
(	O
MFI	O
)	O
of	O
Lac	B-T103
increased	O
from	O
pre	O
(	O
64	O
,	O
268	O
±	O
46	O
,	O
036	O
MFI	O
)	O
to	O
post	O
(	O
117	O
,	O
134	O
±	O
88	O
,	O
115	O
MFI	O
)	O
exercise	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Lys	B-T103
MFI	O
decreased	O
with	O
exercise	O
(	O
pre	O
:	O
16	O
,	O
933	O
±	O
8249	O
;	O
post	O
:	O
11	O
,	O
616	O
±	O
6875	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Acute	O
running	O
resulted	O
in	O
an	O
increased	O
Lac	B-T103
concentration	O
which	O
could	O
lead	O
to	O
a	O
decrease	O
in	O
inflammation	B-T038
,	O
adding	O
further	O
evidence	O
of	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
exercise	O
.	O

Conversely	O
,	O
the	O
exercise	O
-	O
associated	O
decrease	O
of	O
intracellular	B-T103
Lys	I-T103
content	O
could	O
be	O
the	O
cause	O
of	O
increased	O
Lys	B-T103
in	O
exocrine	B-T031
solutions	I-T031
.	O

Chronic	B-T058
Enzyme	I-T058
Replacement	I-T058
to	O
the	O
Brain	B-T017
of	O
a	O
Late	B-T038
Infantile	I-T038
Neuronal	I-T038
Ceroid	I-T038
Lipofuscinosis	I-T038
Mouse	B-T204
Has	O
Differential	O
Effects	O
on	O
Phenotypes	O
of	O
Disease	B-T038

Late	B-T038
infantile	I-T038
neuronal	I-T038
ceroid	I-T038
lipofuscinosis	I-T038
(	O
LINCL	B-T038
)	O
is	O
a	O
fatal	O
inherited	O
neurodegenerative	B-T038
disease	I-T038
caused	O
by	O
loss	O
of	O
lysosomal	B-T103
protease	I-T103
tripeptidyl	I-T103
peptidase	I-T103
1	I-T103
(	O
TPP1	B-T103
)	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
chronic	O
intrathecal	O
(	O
IT	O
)	O
administration	O
using	O
enzyme	B-T058
replacement	I-T058
therapy	I-T058
(	O
ERT	B-T058
)	O
to	O
the	O
brain	B-T017
of	O
an	O
LINCL	B-T038
mouse	B-T038
model	I-T038
,	O
in	O
which	O
locomotor	B-T038
function	I-T038
declines	O
dramatically	O
prior	O
to	O
early	B-T033
death	I-T033
.	O

Median	O
lifespan	O
was	O
significantly	O
extended	O
from	O
126	O
days	O
to	O
>	O
259	O
days	O
when	O
chronic	O
IT	O
treatment	O
was	O
initiated	O
before	O
the	O
onset	O
of	O
disease	B-T038
.	O

While	O
treated	O
animals	B-T204
lived	O
longer	O
and	O
showed	O
little	O
sign	O
of	O
locomotor	B-T033
dysfunction	I-T033
as	O
measured	O
by	O
stride	O
length	O
,	O
some	O
or	O
all	O
(	O
depending	O
on	O
regimen	O
)	O
still	O
died	B-T038
prematurely	O
.	O

One	O
explanation	O
is	O
that	O
cerebrospinal	B-T031
fluid	I-T031
(	O
CSF	B-T031
)	O
-	O
mediated	O
delivery	O
may	O
not	O
deliver	O
TPP1	B-T103
to	O
all	O
brain	B-T082
regions	I-T082
.	O

Morphological	B-T082
studies	B-T062
support	O
this	O
,	O
showing	O
delivery	O
of	O
TPP1	B-T103
to	O
ventral	B-T082
,	O
but	O
not	O
deeper	O
and	O
dorsal	B-T082
regions	I-T082
.	O

When	O
IT	O
treatment	O
is	O
initiated	O
in	O
severely	O
affected	O
LINCL	B-T038
mice	B-T204
,	O
lifespan	O
was	O
extended	O
modestly	O
in	O
most	O
but	O
dramatically	O
extended	O
in	O
approximately	O
one	O
-	O
third	O
of	O
the	O
cohort	B-T098
.	O

Treatment	O
improved	O
locomotor	B-T038
function	I-T038
in	O
these	O
severely	O
compromised	O
animals	B-T204
after	O
it	O
had	O
declined	O
to	O
the	O
point	O
at	O
which	O
animals	B-T204
normally	O
die	B-T038
.	O

This	O
indicates	O
that	O
some	O
pathology	B-T038
in	O
LINCL	B-T038
is	O
reversible	O
and	O
does	O
not	O
simply	O
reflect	O
neuronal	B-T038
death	I-T038
.	O

5	B-T103
-	I-T103
Bromo	I-T103
-	I-T103
2	I-T103
-	I-T103
aryl	I-T103
benzimidazole	I-T103
derivatives	I-T103
as	O
non	B-T103
-	I-T103
cytotoxic	I-T103
potential	O
dual	O
inhibitors	B-T103
of	O
α	B-T103
-	I-T103
glucosidase	I-T103
and	O
urease	B-T103
enzymes	I-T103

On	O
the	O
basis	O
of	O
previous	O
report	B-T170
on	O
promising	O
α	B-T103
-	I-T103
glucosidase	I-T103
inhibitory	B-T038
activity	I-T038
of	O
5	B-T103
-	I-T103
bromo	I-T103
-	I-T103
2	I-T103
-	I-T103
aryl	I-T103
benzimidazole	I-T103
derivatives	I-T103
,	O
these	O
derivatives	O
were	O
further	O
screened	B-T058
for	O
urease	B-T103
inhibitory	B-T038
and	O
cytotoxicity	B-T058
activity	I-T058
in	O
order	O
to	O
get	O
more	O
potent	O
and	O
non	B-T103
-	I-T103
cytotoxic	I-T103
potential	O
dual	O
inhibitor	B-T103
for	O
the	O
patients	O
suffering	O
from	O
diabetes	B-T038
as	O
well	O
as	O
peptic	B-T038
ulcer	I-T038
.	O

In	O
this	O
study	B-T062
,	O
all	O
compounds	B-T103
showed	O
varying	O
degree	O
of	O
potency	O
in	O
the	O
range	O
of	O
(	O
IC50	O
=	O
8	O
.	O
15±0	O
.	O
03	O
-	O
354	O
.	O
67±0	O
.	O
19μM	O
)	O
as	O
compared	O
to	O
standard	O
thiourea	B-T103
(	O
IC50	O
=	O
21	O
.	O
25±0	O
.	O
15μM	O
)	O
.	O

It	O
is	O
worth	O
mentioning	O
that	O
derivatives	B-T103
7	I-T103
(	O
IC50	O
=	O
12	O
.	O
07±0	O
.	O
05μM	O
)	O
,	O
8	B-T103
(	O
IC50	O
=	O
10	O
.	O
57±0	O
.	O
12μM	O
)	O
,	O
11	B-T103
(	O
IC50	O
=	O
13	O
.	O
76±0	O
.	O
02μM	O
)	O
,	O
14	B-T103
(	O
IC50	O
=	O
15	O
.	O
70±0	O
.	O
12μM	O
)	O
and	O
22	B-T103
(	O
IC50	O
=	O
8	O
.	O
15±0	O
.	O
03μM	O
)	O
were	O
found	O
to	O
be	O
more	O
potent	B-T103
inhibitors	I-T103
than	O
standard	O
.	O

All	O
compounds	B-T103
were	O
also	O
evaluated	O
for	O
cytotoxicity	B-T058
towards	O
3T3	B-T017
mouse	B-T017
fibroblast	I-T017
cell	I-T017
line	I-T017
and	O
found	O
to	O
be	O
completely	O
non	B-T033
-	I-T033
toxic	I-T033
.	O

Previously	O
benzimidazole	B-T103
1	I-T103
-	I-T103
25	I-T103
were	O
also	O
showed	O
α	B-T103
-	I-T103
glucosidase	I-T103
inhibitory	B-T038
potential	I-T038
.	O

In	O
silico	O
studies	B-T062
were	O
performed	O
on	O
the	O
lead	B-T103
molecules	I-T103
i	O
.	O
e	O
.	O

2	B-T103
,	O
7	B-T103
,	O
8	B-T103
,	O
11	B-T103
,	O
14	B-T103
,	O
and	O
22	B-T103
,	O
in	O
order	O
to	O
rationalize	O
the	O
binding	B-T038
interaction	I-T038
of	O
compounds	B-T103
with	O
the	O
active	O
site	O
of	O
urease	B-T103
enzyme	I-T103
.	O

Intra	B-T082
-	I-T082
articular	I-T082
implantation	B-T058
of	O
collagen	B-T103
scaffold	O
carriers	B-T074
is	O
safe	B-T082
in	O
both	O
native	O
and	O
arthrofibrotic	B-T038
rabbit	B-T204
knee	B-T082
joints	I-T082

Sustained	O
intra	B-T082
-	I-T082
articular	I-T082
delivery	O
of	O
pharmacological	O
agents	O
is	O
an	O
attractive	O
modality	O
but	O
requires	O
use	O
of	O
a	O
safe	B-T082
carrier	B-T074
that	O
would	O
not	O
induce	O
cartilage	B-T037
damage	I-T037
or	O
fibrosis	B-T038
.	O

Collagen	B-T103
scaffolds	O
are	O
widely	O
available	O
and	O
could	O
be	O
used	O
intra	B-T082
-	I-T082
articularly	I-T082
,	O
but	O
no	O
investigation	B-T058
has	O
looked	O
at	O
the	O
safety	O
of	O
collagen	B-T103
scaffolds	O
within	O
synovial	B-T082
joints	I-T082
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
safety	O
of	O
collagen	B-T103
scaffold	O
implantation	B-T058
in	O
a	O
validated	B-T062
in	B-T082
vivo	I-T082
animal	B-T204
model	O
of	O
knee	B-T038
arthrofibrosis	I-T038
.	O

A	O
total	O
of	O
96	O
rabbits	B-T204
were	O
randomly	O
and	O
equally	O
assigned	O
to	O
four	O
different	O
groups	O
:	O
arthrotomy	B-T058
alone	O
;	O
arthrotomy	B-T058
and	O
collagen	B-T103
scaffold	O
placement	B-T058
;	O
contracture	B-T017
surgery	B-T058
;	O
and	O
contracture	B-T017
surgery	B-T058
and	O
collagen	B-T103
scaffold	O
placement	B-T058
.	O

Animals	B-T204
were	O
killed	O
in	O
equal	O
numbers	O
at	O
72	O
hours	O
,	O
two	O
weeks	O
,	O
eight	O
weeks	O
,	O
and	O
24	O
weeks	O
.	O

Joint	B-T017
contracture	I-T017
was	O
measured	O
,	O
and	O
cartilage	B-T017
and	O
synovial	O
samples	O
underwent	O
histological	B-T058
analysis	I-T058
.	O

Animals	B-T204
that	O
underwent	O
arthrotomy	B-T058
had	O
equivalent	O
joint	B-T017
contractures	I-T017
regardless	O
of	O
scaffold	O
implantation	B-T058
(	O
-	O
13	O
.	O
9°	O
versus	O
-	O
10	O
.	O
9°	O
,	O
equivalence	O
limit	O
15°	O
)	O
.	O

Animals	B-T204
that	O
underwent	O
surgery	B-T058
to	O
induce	O
contracture	B-T017
did	O
not	O
demonstrate	O
equivalent	O
joint	B-T017
contracture	I-T017
s	I-T017
with	O
(	O
41	O
.	O
8°	O
)	O
or	O
without	O
(	O
53	O
.	O
9°	O
)	O
collagen	B-T103
scaffold	O
implantation	B-T058
.	O

Chondral	B-T082
damage	O
occurred	O
in	O
similar	O
rates	O
with	O
(	O
11	O
of	O
48	O
)	O
and	O
without	O
(	O
nine	O
of	O
48	O
)	O
scaffold	O
implantation	B-T058
.	O

No	O
significant	O
difference	O
in	O
synovitis	B-T038
was	O
noted	O
between	O
groups	O
.	O

Absorption	O
of	O
the	O
collagen	B-T103
scaffold	O
occurred	O
within	O
eight	O
weeks	O
in	O
all	O
animals	B-T204
CONCLUSION	O
:	O
Our	O
data	O
suggest	O
that	O
intra	B-T082
-	I-T082
articular	I-T082
implantation	B-T058
of	O
a	O
collagen	B-T103
sponge	O
does	O
not	O
induce	O
synovitis	B-T038
or	O
cartilage	B-T037
damage	I-T037
.	O

Implantation	B-T058
in	O
a	O
native	O
joint	B-T082
does	O
not	O
seem	O
to	O
induce	O
contracture	B-T017
.	O

Implantation	B-T058
of	O
the	O
collagen	B-T103
sponge	O
in	O
a	O
rabbit	B-T204
knee	O
model	O
of	O
contracture	B-T017
may	O
decrease	O
the	O
severity	O
of	O
the	O
contracture	B-T017
.	O
Cite	O
this	O
article	O
:	O
J	O
.	O

A	O
.	O

Walker	O
,	O
T	O
.	O

J	O
.	O

Ewald	O
,	O
E	O
.	O

Lewallen	O
,	O
A	O
.	O

Van	O
Wijnen	O
,	O
A	O
.	O

D	O
.	O

Hanssen	O
,	O
B	O
.	O

F	O
.	O

Morrey	O
,	O
M	O
.	O

E	O
.	O

Morrey	O
,	O
M	O
.	O

P	O
.	O

Abdel	O
,	O
J	O
.	O

Sanchez	O
-	O
Sotelo	O
.	O

Intra	O
-	O
articular	O
implantation	O
of	O
collagen	O
scaffold	O
carriers	O
is	O
safe	O
in	O
both	O
native	O
and	O
arthrofibrotic	O
rabbit	O
knee	O
joints	O
.	O

Bone	O
Joint	O
Res	O
2016	O
;	O
6	O
:	O
162	O
-	O
171	O
.	O

DOI	O
:	O
10	O
.	O
1302	O
/	O
2046	O
-	O
3758	O
.	O
63	O
.	O
BJR	O
-	O
2016	O
-	O
0193	O
.	O

HOST	O
IMMUNE	B-T038
RECOGNITION	I-T038
OF	O
THE	O
EPIDEMIC	O
CYSTIC	B-T038
FIBROSIS	I-T038
PATHOGEN	O
BURKHOLDERIA	B-T007
DOLOSA	I-T007

Burkholderia	B-T007
dolosa	I-T007
caused	O
an	O
outbreak	O
in	O
the	O
cystic	B-T038
fibrosis	I-T038
(	O
CF	B-T038
)	O
clinic	O
at	O
Boston	B-T092
Children	I-T092
'	I-T092
s	I-T092
Hospital	I-T092
from	O
1998	O
to	O
2005	O
and	O
led	O
to	O
the	O
infection	B-T038
of	O
over	O
40	O
patients	O
,	O
many	O
of	O
whom	O
died	B-T038
due	O
to	O
complications	B-T038
from	O
infection	B-T038
by	O
this	O
organism	B-T007
.	O

To	O
assess	O
whether	O
B	B-T007
.	I-T007

dolosa	I-T007
significantly	O
contributes	O
to	O
disease	B-T038
or	O
is	O
recognized	O
by	O
the	O
host	O
immune	B-T038
response	I-T038
,	O
mice	B-T204
were	O
infected	B-T033
with	O
a	O
sequenced	O
outbreak	O
B	B-T007
.	I-T007

dolosa	I-T007
strain	I-T007
,	O
AU0158	B-T007
,	O
and	O
responses	O
compared	O
to	O
the	O
well	O
-	O
studied	O
CF	B-T038
pathogen	O
,	O
Pseudomonas	B-T007
aeruginosa	I-T007
In	O
parallel	O
,	O
mice	B-T204
were	O
also	O
infected	B-T033
with	O
a	O
polar	O
flagellin	B-T017
mutant	B-T038
of	O
B	B-T007
.	I-T007

dolosa	I-T007
to	O
examine	O
the	O
role	O
of	O
flagella	B-T017
in	O
B	B-T007
.	I-T007

dolosa	I-T007
lung	B-T017
colonization	B-T033
.	O

The	O
results	O
showed	O
a	O
higher	O
persistence	B-T038
in	O
the	O
host	O
by	O
B	B-T007
.	I-T007

dolosa	I-T007
strains	I-T007
and	O
yet	O
neutrophil	B-T017
recruitment	O
and	O
cytokine	B-T103
production	O
were	O
lower	O
compared	O
to	O
P	B-T007
.	I-T007

aeruginosa	I-T007
The	O
ability	O
of	O
host	O
immune	B-T017
cells	I-T017
to	O
recognize	O
B	B-T007
.	I-T007

dolosa	I-T007
was	O
then	O
assessed	O
and	O
B	B-T007
.	I-T007

dolosa	I-T007
induced	O
a	O
robust	O
cytokine	B-T103
response	O
in	O
cultured	B-T017
cells	I-T017
and	O
this	O
effect	O
was	O
dependent	O
on	O
the	O
flagella	B-T017
only	O
when	O
bacteria	B-T007
were	O
dead	B-T038
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
B	B-T007
.	I-T007

dolosa	I-T007
can	O
be	O
recognized	O
by	O
host	B-T017
cells	I-T017
in	O
vitro	O
but	O
may	O
avoid	O
or	O
suppress	O
the	O
host	O
immune	B-T038
response	I-T038
in	B-T082
vivo	I-T082
through	O
unknown	O
mechanisms	O
.	O

B	B-T007
.	I-T007

dolosa	I-T007
was	O
then	O
compared	O
to	O
other	O
Burkholderia	B-T007
species	I-T007
and	O
found	O
to	O
induce	O
similar	O
levels	O
of	O
cytokine	B-T103
production	O
despite	O
being	O
internalized	O
by	O
macrophages	B-T017
more	O
than	O
B	B-T007
.	I-T007

cenocepacia	I-T007
strains	I-T007
.	O

These	O
data	O
suggest	O
that	O
B	B-T007
.	I-T007

dolosa	I-T007
AU0158	I-T007
may	O
act	O
differently	O
with	O
host	B-T017
cells	I-T017
and	O
is	O
it	O
recognized	O
differently	O
by	O
immune	B-T022
systems	I-T022
compared	O
other	O
Burkholderia	B-T007
strains	I-T007
or	O
species	B-T170
.	O

Visualization	B-T033
and	O
targeting	O
of	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
human	B-T204
colon	B-T017
cancer	B-T017
stem	I-T017
cells	I-T017

The	O
cancer	B-T017
stem	I-T017
cell	I-T017
(	O
CSC	B-T017
)	O
theory	O
highlights	O
a	O
self	B-T038
-	I-T038
renewing	I-T038
subpopulation	B-T170
of	O
cancer	B-T017
cells	I-T017
that	O
fuels	O
tumour	O
growth	O
.	O

The	O
existence	O
of	O
human	B-T204
CSCs	B-T017
is	O
mainly	O
supported	O
by	O
xenotransplantation	B-T058
of	O
prospectively	O
isolated	B-T033
cells	I-T033
,	O
but	O
their	O
clonal	B-T017
dynamics	O
and	O
plasticity	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	B-T204
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
colorectal	B-T017
cancer	I-T017
cells	I-T017
serve	O
as	O
CSCs	B-T017
in	O
growing	O
cancer	B-T038
tissues	B-T017
.	O

Lineage	O
-	O
tracing	B-T058
experiments	I-T058
with	O
a	O
tamoxifen	B-T103
-	O
inducible	O
Cre	B-T103
knock	B-T062
-	I-T062
in	I-T062
allele	B-T017
of	O
LGR5	B-T103
reveal	O
the	O
self	B-T038
-	I-T038
renewal	I-T038
and	O
differentiation	B-T038
capacity	O
of	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
tumour	B-T017
cells	I-T017
.	O

Selective	O
ablation	B-T058
of	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
CSCs	B-T017
in	O
LGR5	B-T017
-	O
i	O
Caspase9	B-T017
knock	B-T062
-	I-T062
in	I-T062
organoids	B-T017
leads	O
to	O
tumour	O
regression	O
,	O
followed	O
by	O
tumour	O
regrowth	O
driven	O
by	O
re	O
-	O
emerging	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
CSCs	B-T017
.	O

KRT20	B-T017
knock	B-T062
-	I-T062
in	I-T062
reporter	B-T017
marks	O
differentiated	B-T038
cancer	B-T017
cells	I-T017
that	O
constantly	O
diminish	O
in	O
tumour	B-T017
tissues	I-T017
,	O
while	O
reverting	O
to	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
CSCs	B-T017
and	O
contributing	O
to	O
tumour	O
regrowth	O
after	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
CSC	B-T017
ablation	B-T058
.	O

We	O
also	O
show	O
that	O
combined	O
chemotherapy	B-T058
potentiates	O
targeting	O
of	O
LGR5	B-T017
(	I-T017
+	I-T017
)	I-T017
CSCs	B-T017
.	O

These	O
data	O
provide	O
insights	O
into	O
the	O
plasticity	O
of	O
CSCs	B-T017
and	O
their	O
potential	O
as	O
a	O
therapeutic	O
target	O
in	O
human	B-T204
colorectal	B-T038
cancer	I-T038
.	O

The	O
Use	O
of	O
a	O
Software	B-T170
-	O
Assisted	O
Method	B-T170
to	O
Estimate	O
Fetal	O
Weight	O
at	O
and	O
Near	O
Term	B-T038
Using	O
Magnetic	B-T058
Resonance	I-T058
Imaging	I-T058

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
apply	O
a	O
semi	O
-	O
automated	O
calculation	O
method	B-T170
of	O
fetal	B-T017
body	O
volume	O
and	O
,	O
thus	O
,	O
of	O
magnetic	O
resonance	O
-	O
estimated	O
fetal	O
weight	O
(	O
MR	O
-	O
EFW	O
)	O
prior	O
to	O
planned	O
delivery	B-T038
and	O
to	O
evaluate	B-T058
whether	O
the	O
technique	O
of	O
measurement	O
could	O
be	O
simplified	O
while	O
remaining	O
accurate	O
.	O

MR	O
-	O
EFW	O
was	O
calculated	O
using	O
a	O
semi	O
-	O
automated	O
method	B-T170
at	O
38	O
.	O
6	O
weeks	O
of	O
gestation	B-T038
in	O
36	O
patients	O
and	O
compared	O
to	O
the	O
picture	B-T074
archiving	I-T074
and	I-T074
communication	I-T074
system	I-T074
(	O
PACS	B-T074
)	O
.	O

Per	O
patient	O
,	O
8	O
sequences	O
were	O
acquired	O
with	O
a	O
slice	O
thickness	O
of	O
4	O
-	O
8	O
mm	O
and	O
an	O
intersection	B-T082
gap	I-T082
of	O
0	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
,	O
or	O
20	O
mm	O
.	O

The	O
median	B-T082
absolute	O
relative	O
errors	O
for	O
MR	O
-	O
EFW	O
and	O
the	O
time	O
of	O
planimetric	O
measurements	O
were	O
calculated	O
for	O
all	O
8	O
sequences	O
and	O
for	O
each	O
method	B-T170
(	O
assisted	O
vs	O
.	O

PACS	B-T074
)	O
,	O
and	O
the	O
difference	O
between	O
the	O
methods	B-T170
was	O
calculated	O
.	O

The	O
median	B-T082
delivery	O
weight	O
was	O
3	O
,	O
280	O
g	O
.	O

The	O
overall	O
median	B-T082
relative	O
error	O
for	O
all	O
288	O
MR	O
-	O
EFW	O
calculations	O
was	O
2	O
.	O
4	O
%	O
using	O
the	O
semi	O
-	O
automated	O
method	B-T170
and	O
2	O
.	O
2	O
%	O
for	O
the	O
PACS	B-T074
method	B-T170
.	O

Measurements	O
did	O
not	O
differ	O
between	O
the	O
8	O
sequences	O
using	O
the	O
assisted	O
method	B-T170
(	O
p	O
=	O
0	O
.	O
313	O
)	O
or	O
the	O
PACS	B-T074
(	O
p	O
=	O
0	O
.	O
118	O
)	O
,	O
while	O
the	O
time	O
of	O
planimetric	O
measurement	O
decreased	O
significantly	O
with	O
a	O
larger	O
gap	B-T082
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
the	O
assisted	O
method	B-T170
compared	O
to	O
the	O
PACS	B-T074
method	B-T170
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Our	O
simplified	O
MR	O
-	O
EFW	O
measurement	O
showed	O
a	O
dramatic	O
decrease	O
in	O
time	O
of	O
planimetric	O
measurement	O
without	O
a	O
decrease	O
in	O
the	O
accuracy	O
of	O
weight	O
estimates	O
.	O

Abiraterone	B-T103
-	O
induced	O
rhabdomyolysis	B-T038
resulting	O
in	O
acute	B-T037
kidney	I-T037
injury	I-T037
:	O
A	O
case	B-T170
report	I-T170
and	O
review	B-T170
of	I-T170
the	I-T170
literature	I-T170

Abiraterone	B-T103
,	O
a	O
CYP17	B-T103
inhibitor	I-T103
,	O
blocks	O
androgen	B-T038
biosynthesis	I-T038
in	O
multiple	O
tissue	B-T017
types	O
.	O

In	O
combination	O
with	O
prednisone	B-T103
,	O
it	O
is	O
approved	O
as	O
a	O
first	B-T058
-	I-T058
line	I-T058
treatment	I-T058
for	O
metastatic	B-T038
castration	B-T038
-	I-T038
resistant	I-T038
prostate	I-T038
cancer	I-T038
.	O

We	O
present	O
a	O
case	O
of	O
rhabdomyolysis	B-T038
associated	O
with	O
abiraterone	B-T103
therapy	B-T058
resulting	O
in	O
acute	B-T037
on	O
chronic	O
kidney	B-T037
injury	I-T037
in	O
a	O
patient	O
with	O
metastatic	B-T038
castration	B-T038
-	I-T038
resistant	I-T038
prostate	I-T038
cancer	I-T038
.	O

Strict	O
monitoring	B-T062
should	O
be	O
employed	O
in	O
patients	O
started	O
on	O
abiraterone	B-T103
who	O
have	O
additional	O
risk	B-T033
factors	I-T033
for	O
developing	O
rhabdomyolysis	B-T038
.	O

Association	O
between	O
XRCC1	B-T017
and	O
ERCC1	B-T017
single	B-T082
-	I-T082
nucleotide	I-T082
polymorphisms	I-T082
and	O
the	O
efficacy	O
of	O
concurrent	B-T058
radiochemotherapy	I-T058
in	O
patients	O
with	O
esophageal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
single	B-T082
-	I-T082
nucleotide	I-T082
polymorphisms	I-T082
(	O
SNPs	B-T082
)	O
in	O
X	B-T017
-	I-T017
ray	I-T017
repair	I-T017
cross	I-T017
-	I-T017
complementing	I-T017
1	I-T017
-	I-T017
399	I-T017
(	O
XRCC1	B-T017
-	I-T017
399	I-T017
)	O
or	O
excision	B-T017
repair	I-T017
cross	I-T017
-	I-T017
complementation	I-T017
group	I-T017
1	I-T017
-	I-T017
118	I-T017
(	O
ERCC1	B-T017
-	I-T017
118	I-T017
)	O
and	O
the	O
short	O
-	O
term	O
efficacy	O
of	O
radiochemotherapy	B-T058
,	O
tumor	B-T038
metastasis	I-T038
and	O
relapse	O
,	O
as	O
well	O
as	O
the	O
survival	B-T201
time	I-T201
in	O
patients	O
with	O
esophageal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
ESCC	B-T038
)	O
.	O

TaqMan	B-T062
probe	I-T062
-	I-T062
based	I-T062
quantitative	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
qPCR	B-T062
)	O
was	O
conducted	O
to	O
examine	B-T033
the	O
levels	O
of	O
XRCC1	B-T017
-	I-T017
399	I-T017
and	O
ERCC1	B-T017
-	I-T017
118	I-T017
SNPs	B-T082
in	O
the	O
peripheral	B-T031
blood	I-T031
of	O
50	O
patients	O
with	O
pathologically	O
confirmed	B-T033
ESCC	B-T038
.	O

In	O
addition	O
,	O
the	O
associations	O
between	O
different	O
genotypes	O
and	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
[	O
the	O
complete	B-T033
remission	I-T033
(	O
CR	B-T033
)	O
rate	O
]	O
,	O
tumor	B-T038
metastasis	I-T038
and	O
relapse	O
,	O
as	O
well	O
as	O
the	O
survival	B-T201
time	I-T201
following	O
concurrent	B-T058
radiochemotherapy	I-T058
,	O
were	O
determined	O
.	O

A	O
total	O
of	O
50	O
ESCC	B-T038
patients	O
who	O
received	O
concurrent	B-T058
radiochemotherapy	I-T058
were	O
enrolled	O
.	O

It	O
was	O
found	O
that	O
the	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
(	O
CR	B-T033
rate	O
)	O
was	O
higher	O
in	O
the	O
group	O
of	O
patients	O
carrying	O
the	O
homozygous	B-T038
mutation	I-T038
of	O
XRCC1	B-T017
-	I-T017
399	I-T017
(	O
A	B-T103
/	O
A	B-T103
genotype	O
)	O
than	O
in	O
the	O
group	O
of	O
patients	O
without	O
the	O
XRCC1	B-T017
-	I-T017
399	I-T017
mutation	B-T038
(	O
G	B-T103
/	O
G	B-T103
genotype	O
)	O
.	O

In	O
addition	O
,	O
the	O
CR	B-T033
rate	O
was	O
significantly	O
increased	O
in	O
patients	O
carrying	O
one	O
or	O
two	O
ERCC1	B-T017
-	I-T017
118	I-T017
C	O
alleles	B-T017
(	O
C	B-T103
/	O
C	B-T103
or	O
C	B-T103
/	O
T	B-T103
genotype	O
)	O
compared	O
with	O
patients	O
lacking	O
the	O
C	B-T103
allele	B-T017
(	O
T	B-T103
/	O
T	B-T103
genotype	O
)	O
.	O

The	O
differences	O
were	O
statistically	O
significant	O
(	O
A	B-T103
/	O
A	B-T103
vs	O
.	O

G	B-T103
/	O
G	B-T103
,	O
P	O
=	O
0	O
.	O
014	O
;	O
T	B-T103
T	B-T103
vs	O
.	O

C	B-T103
/	O
T	B-T103
+	O
C	B-T103
/	O
C	B-T103
,	O
P	O
=	O
0	O
.	O
040	O
)	O
.	O

During	O
the	O
follow	B-T033
-	I-T033
up	I-T033
period	I-T033
,	O
the	O
group	O
of	O
patients	O
carrying	O
the	O
homozygous	B-T038
mutation	I-T038
of	O
XRCC1	B-T017
-	I-T017
399	I-T017
(	O
A	B-T103
/	O
A	B-T103
genotype	O
)	O
exhibited	O
a	O
markedly	O
reduced	O
risk	O
of	O
metastasis	B-T038
and	O
relapse	O
compared	O
with	O
the	O
group	O
of	O
patients	O
carrying	O
non	O
-	O
mutated	O
XRCC1	B-T017
-	I-T017
399	I-T017
(	O
G	B-T103
/	O
G	B-T103
genotype	O
;	O
P	O
=	O
0	O
.	O
031	O
)	O
.	O

By	O
contrast	O
,	O
ERCC1	B-T017
-	I-T017
118	I-T017
SNP	B-T082
was	O
not	O
associated	O
with	O
the	O
risk	O
of	O
metastasis	B-T038
and	O
recurrence	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
combined	O
results	O
of	O
univariate	O
and	O
multivariate	B-T170
Cox	I-T170
regression	I-T170
analysis	I-T170
showed	O
that	O
the	O
SNP	B-T082
in	O
ERCC1	B-T017
-	I-T017
118	I-T017
was	O
closely	O
associated	O
with	O
survival	B-T201
time	I-T201
.	O

The	O
mean	O
survival	O
time	O
was	O
significantly	O
prolonged	O
in	O
patients	O
carrying	O
1	O
or	O
2	O
C	B-T103
alleles	B-T017
(	O
C	B-T103
/	O
C	B-T103
or	O
C	B-T103
/	O
T	B-T103
genotype	O
)	O
compared	O
with	O
patients	O
lacking	O
the	O
C	B-T103
allele	B-T017
(	O
T	B-T103
/	O
T	B-T103
genotype	O
)	O
[	O
T	B-T103
/	O
T	B-T103
vs	O
.	O

C	B-T103
/	O
C	B-T103
,	O
HR	O
=	O
12	O
.	O
96	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
3	O
.	O
08	O
-	O
54	O
.	O
61	O
,	O
P	O
<	O
0	O
.	O
001	O
;	O
T	B-T103
T	B-T103
vs	O
.	O

C	B-T103
/	O
T	B-T103
+	O
C	B-T103
/	O
C	B-T103
,	O
HR	O
=	O
11	O
.	O
71	O
,	O
95	O
%	O
CI	O
=	O
3	O
.	O
06	O
-	O
44	O
.	O
83	O
,	O
P	O
<	O
0	O
.	O
001	O
]	O
.	O

However	O
,	O
XRCC1	B-T017
-	I-T017
399	I-T017
SNP	B-T082
had	O
no	O
effect	O
on	O
survival	B-T201
time	I-T201
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

XRCCl	B-T017
-	I-T017
399	I-T017
SNP	B-T082
was	O
associated	O
with	O
the	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
(	O
the	O
CR	B-T033
rate	O
)	O
and	O
tumor	B-T038
metastasis	I-T038
/	O
relapse	O
in	O
ESCC	B-T038
patients	O
who	O
received	O
the	O
docetaxel	B-T058
plus	I-T058
cisplatin	I-T058
(	I-T058
TP	I-T058
)	I-T058
regimen	I-T058
-	O
based	O
concurrent	B-T058
radiochemotherapy	I-T058
.	O

By	O
contrast	O
,	O
ERCC1	B-T017
-	I-T017
118	I-T017
SNP	B-T082
was	O
significantly	O
associated	O
with	O
the	O
short	O
-	O
term	O
therapeutic	O
efficacy	O
(	O
the	O
CR	B-T033
rate	O
)	O
and	O
survival	B-T201
time	I-T201
in	O
ESCC	B-T038
patients	O
who	O
received	O
TP	B-T058
regimen	I-T058
-	O
based	O
concurrent	B-T058
radiochemotherapy	I-T058
.	O

Ventricular	B-T058
pacing	I-T058
site	O
separation	O
by	O
cardiac	B-T082
computed	B-T058
tomography	I-T058
:	O
validation	B-T062
for	O
the	O
prediction	O
of	O
clinical	B-T033
response	I-T033
to	O
cardiac	B-T058
resynchronization	I-T058
therapy	I-T058

Cardiac	B-T058
Resynchronization	I-T058
Therapy	I-T058
(	O
CRT	B-T058
)	O
fails	O
to	O
provide	O
benefit	O
in	O
up	O
to	O
one	O
-	O
third	O
of	O
patients	O
.	O

Maximizing	O
the	O
geographic	O
separation	O
of	O
right	O
and	O
left	O
ventricular	B-T058
pacing	I-T058
lead	B-T082
sites	I-T082
has	O
been	O
suggested	O
as	O
one	O
way	O
to	O
improve	B-T033
response	O
.	O

Cardiac	B-T058
CT	I-T058
provides	O
an	O
opportunity	O
to	O
explore	O
3	B-T082
-	I-T082
dimensional	I-T082
inter	O
-	O
lead	O
distance	O
(	O
ILD	O
)	O
measures	O
for	O
the	O
prediction	O
of	O
CRT	B-T058
response	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
associations	O
between	O
standardized	O
measures	O
of	O
ILD	O
by	O
cardiac	B-T058
CT	I-T058
and	O
echocardiographic	B-T058
response	O
to	O
CRT	B-T058
.	O

Forty	O
-	O
two	O
consecutive	O
patients	O
undergoing	O
CRT	B-T058
had	O
serial	O
clinical	B-T058
and	O
echocardiographic	B-T058
evaluations	B-T058
performed	O
in	O
addition	O
to	O
a	O
post	O
-	O
procedural	O
cardiac	B-T082
-	O
gated	O
CT	B-T058
with	O
blinded	B-T062
measurement	O
of	O
direct	O
and	O
circumferential	B-T082
(	O
via	O
the	O
myocardium	B-T017
)	O
ILD	O
measures	O
.	O

Clinical	B-T033
response	I-T033
to	O
CRT	B-T058
,	O
the	O
primary	B-T033
clinical	I-T033
outcome	I-T033
,	O
was	O
defined	O
as	O
a	O
≥15	O
%	O
reduction	O
in	O
LVESV	B-T033
using	O
echocardiography	B-T058
at	O
6	O
-	O
months	O
.	O

The	O
mean	O
age	O
and	O
ejection	B-T033
fraction	I-T033
was	O
63	O
.	O
6	O
±	O
8	O
.	O
9	O
years	O
and	O
25	O
.	O
2	O
±	O
7	O
.	O
8	O
%	O
,	O
respectively	O
.	O

The	O
primary	O
outcome	O
occurred	O
in	O
35	O
of	O
42	O
patients	O
(	O
83	O
%	O
)	O
.	O

Both	O
direct	O
and	O
circumferential	B-T082
CT	B-T058
-	O
based	O
ILD	O
measures	O
were	O
associated	O
with	O
the	O
primary	O
outcome	O
by	O
univariate	O
analysis	O
.	O

Receiver	O
Operator	O
Characteristic	O
analysis	B-T062
identified	O
Circumferential	B-T082
ILD	O
to	O
have	O
the	O
strongest	O
predictive	O
accuracy	O
(	O
AUC	O
0	O
.	O
78	O
)	O
.	O

Inter	O
-	O
and	O
intra	O
-	O
observer	O
reproducibility	O
of	O
CT	B-T058
-	O
derived	O
ILD	O
measures	O
was	O
excellent	O
.	O

Circumferential	B-T082
ILD	O
measures	O
on	O
cardiac	B-T058
CT	I-T058
are	O
predictive	O
of	O
clinical	B-T033
response	I-T033
to	O
CRT	B-T058
.	O

Incorporation	O
of	O
these	O
measures	O
into	O
the	O
selection	O
of	O
optimal	O
pacing	B-T058
targets	O
,	O
particularly	O
from	O
pre	O
-	O
procedural	O
CT	B-T058
coronary	B-T017
vein	I-T017
imaging	B-T058
may	O
be	O
of	O
therapeutic	O
benefit	O
and	O
warrants	O
further	O
investigation	B-T058
.	O

Iodine	B-T103
Storage	I-T103
and	O
Metabolism	B-T038
of	O
Mild	O
to	O
Moderate	O
Iodine	B-T038
-	I-T038
Deficient	I-T038
Pregnant	B-T038
Rats	B-T204

Severe	B-T038
iodine	I-T038
deficiency	I-T038
during	O
pregnancy	O
results	O
in	O
neurodevelopmental	B-T038
disorders	I-T038
in	O
children	O
,	O
while	O
the	O
consequences	O
of	O
mild	B-T038
to	I-T038
moderate	I-T038
iodine	I-T038
deficiency	I-T038
(	O
MMID	B-T038
)	O
are	O
uncertain	B-T033
.	O

The	O
concentration	B-T058
of	I-T058
iodine	I-T058
in	O
the	O
thyroid	B-T017
is	O
the	O
most	O
accurate	O
indicator	O
of	O
iodine	B-T103
nutrition	I-T103
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
the	O
iodine	B-T103
stores	I-T103
in	O
the	O
thyroid	B-T017
cover	I-T017
the	O
needs	O
of	O
the	O
mother	O
and	O
the	O
fetus	O
in	O
iodine	B-T103
-	O
sufficient	O
and	O
MMID	B-T038
conditions	O
by	O
inductively	B-T058
coupled	I-T058
plasma	I-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
.	O

One	O
hundred	O
four	O
-	O
week	O
-	O
old	O
female	B-T204
Wistar	I-T204
rats	I-T204
were	O
randomly	O
divided	O
into	O
MMID	B-T038
(	O
low	B-T033
iodine	I-T033
intake	I-T033
[	O
L	O
]	O
)	O
and	O
normal	B-T033
(	O
normal	B-T033
iodine	I-T033
intake	I-T033
[	O
N	O
]	O
)	O
groups	O
.	O

The	O
rats	B-T204
were	O
fed	O
for	O
the	O
next	O
three	O
months	O
,	O
and	O
after	O
pregnancy	O
they	O
were	O
further	O
divided	B-T170
into	I-T170
two	I-T170
subgroups	I-T170
,	O
respectively	O
:	O
low	B-T033
iodine	I-T033
pregnancy	B-T038
(	O
LP	B-T033
)	O
and	O
low	B-T033
iodine	I-T033
pregnancy	B-T038
with	O
iodine	B-T168
supplement	I-T168
(	O
LP	B-T168
+	I-T168
)	O
,	O
and	O
normal	B-T033
iodine	I-T033
intake	I-T033
pregnancy	B-T038
(	O
NP	B-T038
)	O
and	O
normal	B-T033
iodine	I-T033
intake	I-T033
pregnancy	B-T038
with	O
iodine	B-T168
supplement	I-T168
(	O
NP	B-T168
+	I-T168
)	O
.	O

The	O
iodine	O
intake	O
of	O
pregnant	B-T038
rats	B-T204
in	O
the	O
NP	B-T168
+	I-T168
and	O
LP	B-T168
+	I-T168
groups	I-T168
was	O
twice	O
as	O
much	O
as	O
in	O
the	O
NP	B-T033
and	O
LP	B-T033
groups	I-T033
.	O

The	O
rats	B-T204
were	O
sacrificed	O
on	O
gestational	O
day	O
15	O
and	O
postnatal	O
day	O
7	O
.	O

The	O
iodine	B-T058
concentration	I-T058
in	O
the	O
thyroid	B-T017
of	O
the	O
maternal	B-T033
and	O
newborn	B-T033
rats	B-T204
,	O
maternal	O
serum	O
,	O
placenta	B-T017
,	O
and	O
amniotic	B-T031
fluid	I-T031
were	O
determined	O
by	O
inductively	B-T058
coupled	I-T058
plasma	I-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
.	O

The	O
concentration	B-T058
of	I-T058
iodine	I-T058
in	O
the	O
thyroid	B-T017
of	O
the	O
N	B-T033
group	I-T033
was	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
L	B-T033
group	I-T033
before	O
pregnancy	O
.	O

The	O
concentration	B-T058
of	I-T058
iodine	I-T058
in	O
the	O
maternal	B-T058
thyroids	I-T058
of	O
the	O
LP	B-T033
group	I-T033
decreased	O
during	O
pregnancy	O
,	O
whereas	O
that	O
of	O
the	O
NP	B-T033
group	I-T033
did	O
not	O
change	O
significantly	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
iodine	B-T058
concentration	I-T058
in	O
the	O
thyroid	B-T017
of	O
mothers	O
and	O
offspring	O
between	O
the	O
NP	B-T033
and	O
NP	B-T168
+	I-T168
groups	I-T168
,	O
but	O
it	O
was	O
significant	O
between	O
LP	B-T038
and	O
LP	B-T168
+	I-T168
groups	I-T168
.	O

The	O
concentration	B-T058
of	I-T058
iodine	I-T058
in	O
amniotic	B-T031
fluid	I-T031
was	O
significantly	O
different	O
between	O
the	O
four	O
groups	O
.	O

There	O
is	O
sufficient	O
iodine	B-T103
storage	I-T103
in	O
the	O
thyroid	B-T017
of	O
maternal	B-T033
rats	B-T204
with	O
normal	O
iodine	O
intake	O
during	O
pregnancy	O
,	O
and	O
there	O
is	O
no	O
need	O
for	O
iodine	B-T058
supplementation	I-T058
.	O

However	O
,	O
iodine	B-T103
stores	I-T103
are	O
insufficient	O
in	O
rats	B-T204
with	O
MMID	B-T038
.	O

Iodine	B-T058
supplementation	I-T058
can	O
increase	O
the	O
iodine	B-T058
concentration	I-T058
in	O
the	O
thyroid	B-T017
of	O
maternal	B-T033
rats	B-T204
with	O
MMID	B-T038
and	O
their	O
offspring	O
,	O
as	O
well	O
as	O
in	O
the	O
amniotic	B-T031
fluid	I-T031
during	O
pregnancy	O
.	O

Omega	B-T103
3	I-T103
Fatty	I-T103
Acids	I-T103
Reduce	O
Bone	B-T038
Resorption	I-T038
While	O
Promoting	B-T038
Bone	I-T038
Generation	I-T038
in	O
Rat	B-T204
Apical	B-T038
Periodontitis	I-T038

This	O
study	O
evaluated	B-T058
the	O
effects	O
of	O
the	O
dietary	B-T168
supplement	I-T168
omega	B-T103
3	I-T103
polyunsaturated	I-T103
fatty	I-T103
acids	I-T103
(	O
ω	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
)	O
on	O
pulp	B-T038
exposure	I-T038
-	O
induced	O
apical	B-T038
periodontitis	I-T038
(	O
AP	B-T038
)	O
in	O
rats	B-T204
.	O

Twenty	O
-	O
eight	O
male	O
rats	B-T204
were	O
divided	O
into	O
groups	B-T098
:	O
control	O
untreated	B-T033
rats	B-T204
(	O
C	O
)	O
,	O
control	O
rats	B-T204
treated	O
with	O
ω	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
alone	O
(	O
C	O
-	O
O	O
)	O
,	O
rats	B-T204
with	O
pulp	B-T038
exposure	I-T038
-	O
induced	O
AP	B-T038
,	O
and	O
rats	B-T204
with	O
pulp	B-T038
exposure	I-T038
-	O
induced	O
AP	B-T038
treated	O
with	O
ω	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
(	O
AP	B-T038
-	O
O	O
)	O
.	O

The	O
ω	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
were	O
administered	B-T058
orally	I-T058
,	O
once	O
a	O
day	O
,	O
for	O
15	O
days	O
before	O
pulp	B-T038
exposure	I-T038
and	O
,	O
subsequently	O
,	O
30	O
days	O
after	O
pulp	B-T038
exposure	I-T038
.	O

Rats	B-T204
were	O
killed	O
30	O
days	O
after	O
pulp	B-T038
exposure	I-T038
,	O
and	O
jaws	B-T017
were	O
subjected	O
to	O
histologic	O
and	O
immunohistochemical	O
analyses	B-T062
.	O

Immunohistochemical	O
analyses	B-T062
were	O
performed	O
to	O
detect	O
tartrate	B-T103
-	I-T103
resistant	I-T103
acid	I-T103
phosphatase	I-T103
-	O
positive	B-T033
osteoclasts	B-T017
and	O
osteocalcin	B-T103
-	O
positive	B-T033
osteoblasts	B-T017
on	O
the	O
bone	B-T082
surface	I-T082
of	O
periapical	B-T082
area	I-T082
.	O

Results	O
were	O
statistically	O
evaluated	B-T058
by	O
using	O
analysis	O
of	O
variance	O
and	O
Tukey	O
honestly	O
significant	O
difference	O
,	O
and	O
P	O
<	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

The	O
bone	B-T038
resorption	I-T038
lesion	B-T033
was	O
significantly	O
larger	O
in	O
the	O
AP	B-T038
group	O
compared	O
with	O
AP	B-T038
-	O
O	O
,	O
C	O
,	O
and	O
C	O
-	O
O	O
groups	B-T098
(	O
P	O
<	O
.	O
05	O
)	O
.	O

The	O
level	O
of	O
inflammatory	B-T038
cell	I-T038
infiltration	I-T038
was	O
significantly	O
elevated	O
,	O
and	O
the	O
number	O
of	O
tartrate	B-T103
-	I-T103
resistant	I-T103
acid	I-T103
phosphatase	I-T103
-	O
positive	B-T033
osteoclasts	B-T017
was	O
significantly	O
higher	O
in	O
the	O
periapical	B-T082
lesions	B-T033
of	O
the	O
AP	B-T038
group	O
compared	O
with	O
AP	B-T038
-	O
O	O
,	O
C	O
,	O
and	O
C	O
-	O
O	O
groups	B-T098
(	O
P	O
<	O
.	O
05	O
)	O
.	O

The	O
number	O
of	O
osteocalcin	B-T103
-	O
positive	B-T033
osteoblasts	B-T017
was	O
significantly	O
increased	O
in	O
the	O
AP	B-T038
-	O
O	O
group	O
compared	O
with	O
the	O
AP	B-T038
group	O
(	O
P	O
>	O
.	O
05	O
)	O
.	O

Supplementation	B-T058
with	O
ω	B-T103
-	I-T103
3	I-T103
PUFAs	I-T103
not	O
only	O
suppresses	O
bone	B-T038
resorption	I-T038
but	O
also	O
promotes	B-T038
new	I-T038
bone	I-T038
formation	I-T038
in	O
the	O
periapical	B-T082
area	I-T082
of	O
rats	B-T204
with	O
AP	B-T038
in	O
conjunction	O
with	O
downregulation	B-T038
of	O
inflammatory	B-T038
cell	I-T038
infiltration	I-T038
into	O
the	O
lesion	B-T033
.	O

MagR	B-T103
Alone	O
Is	O
Insufficient	O
to	O
Confer	O
Cellular	B-T038
Calcium	I-T038
Responses	I-T038
to	O
Magnetic	O
Stimulation	B-T058

Magnetic	O
manipulation	B-T058
of	O
cell	B-T038
activity	I-T038
offers	O
advantages	O
over	O
optical	B-T058
manipulation	I-T058
but	O
an	O
ideal	O
tool	O
remains	O
elusive	O
.	O

The	O
MagR	B-T103
protein	I-T103
was	O
found	O
through	O
its	O
interaction	B-T038
with	O
cryptochrome	B-T103
(	O
Cry	B-T103
)	O
and	O
the	O
protein	B-T103
in	O
solution	O
appeared	O
to	O
respond	O
to	O
magnetic	O
stimulation	B-T058
(	O
MS	B-T058
)	O
.	O

After	O
we	O
initiated	O
an	O
investigation	B-T058
on	O
the	O
specific	O
role	O
of	O
MagR	B-T103
in	O
cellular	B-T038
response	I-T038
to	O
MS	B-T058
,	O
a	O
subsequent	O
study	B-T062
claimed	O
that	O
MagR	B-T103
expression	B-T038
alone	O
could	O
achieve	O
cellular	B-T038
activation	I-T038
by	O
MS	B-T058
.	O

Here	O
we	O
report	O
that	O
despite	O
systematically	O
testing	O
different	O
ways	O
of	O
measuring	O
intracellular	B-T082
calcium	B-T103
and	O
different	O
MS	B-T058
protocols	B-T170
,	O
it	O
was	O
not	O
possible	O
to	O
detect	B-T033
any	O
cellular	B-T017
or	O
neuronal	B-T017
responses	O
to	O
MS	B-T058
in	O
MagR	B-T103
-	O
expressing	B-T038
HEK	B-T017
cells	I-T017
or	O
primary	O
neurons	B-T017
from	O
the	O
dorsal	B-T082
root	B-T017
ganglion	I-T017
and	O
the	O
hippocampus	B-T017
.	O

By	O
contrast	O
,	O
in	O
neurons	B-T017
co	B-T038
-	I-T038
expressing	I-T038
MagR	B-T103
and	O
channelrhodopin	B-T103
,	O
optical	B-T058
but	O
not	O
MS	B-T058
increased	O
calcium	B-T038
influx	I-T038
in	O
hippocampal	B-T017
neurons	B-T017
.	O

Our	O
results	O
indicate	O
that	O
MagR	B-T103
alone	O
is	O
not	O
sufficient	O
to	O
confer	O
cellular	B-T017
magnetic	B-T038
responses	I-T038
.	O

Acute	B-T037
kidney	I-T037
injury	I-T037
and	O
fluid	B-T038
overload	I-T038
in	O
infants	O
and	O
children	O
after	O
cardiac	B-T058
surgery	I-T058

Acute	B-T037
kidney	I-T037
injury	I-T037
is	O
a	O
common	O
and	O
serious	O
complication	B-T038
after	O
congenital	O
heart	O
surgery	O
,	O
particularly	O
among	O
infants	O
.	O

This	O
comorbidity	O
has	O
been	O
independently	O
associated	O
with	O
adverse	B-T038
outcomes	I-T038
including	O
an	O
increase	O
in	O
mortality	O
.	O

Postoperative	O
acute	B-T037
kidney	I-T037
injury	I-T037
has	O
a	O
complex	O
pathophysiology	O
with	O
many	O
risk	B-T033
factors	I-T033
,	O
and	O
therefore	O
no	B-T033
single	I-T033
medication	I-T033
or	O
therapy	B-T033
has	O
been	O
demonstrated	O
to	O
be	O
effective	O
for	O
treatment	B-T058
or	O
prevention	O
.	O

However	O
,	O
it	O
has	O
been	O
established	O
that	O
the	O
associated	O
fluid	B-T038
overload	I-T038
is	O
one	O
of	O
the	O
major	O
determinants	O
of	O
morbidity	O
,	O
particularly	O
in	O
infants	O
after	O
cardiac	B-T058
surgery	I-T058
.	O

Therefore	O
,	O
in	O
the	O
absence	O
of	O
an	O
intervention	B-T058
to	O
prevent	O
acute	B-T037
kidney	I-T037
injury	I-T037
,	O
much	O
of	O
the	O
effort	O
to	O
improve	O
outcomes	O
has	O
focused	O
on	O
treating	O
and	O
preventing	O
fluid	B-T038
overload	I-T038
.	O

Early	O
renal	B-T058
replacement	I-T058
therapy	I-T058
,	O
often	O
in	O
the	O
form	O
of	O
peritoneal	B-T058
dialysis	I-T058
,	O
has	O
been	O
shown	O
to	O
be	O
safe	O
and	O
beneficial	O
in	O
infants	O
with	O
oliguria	B-T038
after	O
heart	B-T058
surgery	I-T058
.	O

As	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
acute	B-T037
kidney	I-T037
injury	I-T037
and	O
the	O
ability	O
to	O
confidently	O
diagnose	B-T033
it	O
earlier	O
continues	O
to	O
evolve	O
,	O
it	O
is	O
likely	O
that	O
novel	O
preventative	O
and	O
therapeutic	B-T058
interventions	I-T058
will	O
be	O
available	O
in	O
the	O
future	O
.	O

Systems	O
Toxicology	B-T091
:	O
Real	O
World	B-T098
Applications	O
and	O
Opportunities	O

Systems	O
Toxicology	B-T091
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	B-T103
are	O
characterized	O
from	O
empirical	O
end	O
points	O
to	O
describing	O
modes	O
of	O
action	O
as	O
adverse	O
outcome	O
pathways	O
and	O
perturbed	O
networks	O
.	O

Toward	O
this	O
aim	O
,	O
Systems	O
Toxicology	B-T091
entails	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
toxicity	B-T037
data	O
with	O
computational	O
modeling	O
.	O

This	O
evolving	O
approach	O
depends	O
critically	O
on	O
data	O
reliability	O
and	O
relevance	O
,	O
which	O
in	O
turn	O
depends	O
on	O
the	O
quality	O
of	O
experimental	B-T170
models	I-T170
and	O
bioanalysis	B-T062
techniques	I-T062
used	O
to	O
generate	O
toxicological	O
data	O
.	O

Systems	O
Toxicology	B-T091
involves	O
the	O
use	O
of	O
large	O
-	O
scale	O
data	B-T170
streams	I-T170
(	O
"	O
big	O
data	O
"	O
)	O
,	O
such	O
as	O
those	O
derived	O
from	O
omics	B-T062
measurements	I-T062
that	O
require	O
computational	O
means	O
for	O
obtaining	O
informative	O
results	O
.	O

Thus	O
,	O
integrative	B-T062
analysis	I-T062
of	O
multiple	O
molecular	O
measurements	O
,	O
particularly	O
acquired	O
by	O
omics	B-T058
strategies	I-T058
,	O
is	O
a	O
key	O
approach	O
in	O
Systems	O
Toxicology	B-T091
.	O

In	O
recent	O
years	O
,	O
there	O
have	O
been	O
significant	O
advances	O
centered	O
on	O
in	O
vitro	O
test	O
systems	O
and	O
bioanalytical	B-T058
strategies	I-T058
,	O
yet	O
a	O
frontier	O
challenge	O
concerns	O
linking	O
observed	O
network	O
perturbations	O
to	O
phenotypes	O
,	O
which	O
will	O
require	O
understanding	O
pathways	O
and	O
networks	O
that	O
give	O
rise	O
to	O
adverse	O
responses	O
.	O

This	O
summary	B-T170
perspective	O
from	O
a	O
2016	O
Systems	O
Toxicology	B-T091
meeting	O
,	O
an	O
international	O
conference	O
held	O
in	O
the	O
Alps	B-T082
of	O
Switzerland	B-T082
,	O
describes	O
the	O
limitations	O
and	O
opportunities	O
of	O
selected	O
emerging	O
applications	O
in	O
this	O
rapidly	O
advancing	O
field	O
.	O

Systems	O
Toxicology	B-T091
aims	O
to	O
change	O
the	O
basis	O
of	O
how	O
adverse	O
biological	O
effects	O
of	O
xenobiotics	B-T103
are	O
characterized	O
,	O
from	O
empirical	O
end	O
points	O
to	O
pathways	O
of	O
toxicity	B-T037
.	O

This	O
requires	O
the	O
integration	O
of	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
data	O
with	O
computational	O
modeling	O
.	O

Test	O
systems	O
and	O
bioanalytical	B-T058
technologies	I-T058
have	O
made	O
significant	O
advances	O
,	O
but	O
ensuring	O
data	O
reliability	O
and	O
relevance	O
is	O
an	O
ongoing	O
concern	O
.	O

The	O
major	O
challenge	O
facing	O
the	O
new	O
pathway	O
approach	O
is	O
determining	O
how	O
to	O
link	O
observed	O
network	O
perturbations	O
to	O
phenotypic	O
toxicity	B-T037
.	O

Validating	B-T062
Signs	B-T033
and	I-T033
Symptoms	I-T033
From	O
An	O
Actual	O
Mass	O
Casualty	O
Incident	O
to	O
Characterize	O
An	O
Irritant	O
Gas	O
Syndrome	O
Agent	O
(	O
IGSA	O
)	O
Exposure	O
:	O
A	O
First	O
Step	O
in	O
The	O
Development	O
of	O
a	O
Novel	O
IGSA	O
Triage	B-T058
Algorithm	B-T170

Chemical	B-T033
exposures	I-T033
can	O
pose	O
a	O
significant	O
threat	O
to	O
life	O
.	O

Rapid	O
assessment	B-T058
by	O
first	O
responders	O
/	O
emergency	B-T097
nurses	I-T097
is	O
required	O
to	O
reduce	O
death	B-T038
and	O
disability	B-T033
.	O

Currently	O
,	O
no	O
informatics	B-T170
tools	I-T170
for	O
irritant	O
gas	O
syndrome	O
agent	O
s	O
(	O
IGSA	O
)	O
exposures	O
exist	O
to	O
process	O
victims	O
efficiently	O
,	O
continuously	O
monitor	B-T058
for	O
latent	O
signs	B-T033
/	I-T033
symptoms	I-T033
,	O
or	O
make	O
triage	B-T058
recommendations	O
.	O

This	O
study	B-T062
describes	O
the	O
first	O
step	O
in	O
developing	O
ED	B-T092
informatics	B-T170
tools	I-T170
for	O
chemical	O
incidents	O
:	O
validation	B-T062
of	O
signs	B-T033
/	I-T033
symptoms	I-T033
that	O
characterize	O
an	O
IGSA	O
syndrome	B-T038
.	O

Data	O
abstracted	O
from	O
146	O
patients	O
treated	B-T058
for	O
chlorine	O
exposure	O
in	O
one	O
emergency	B-T092
department	I-T092
during	O
a	O
2005	O
train	O
derailment	O
and	O
152	O
patients	O
not	O
exposed	O
to	O
chlorine	O
(	O
a	O
comparison	O
group	O
)	O
were	O
mapped	O
to	O
93	O
possible	O
signs	B-T033
/	I-T033
symptoms	I-T033
within	O
2	O
tools	B-T170
(	O
WISER	B-T170
and	O
CHEMM	B-T170
-	I-T170
IST	I-T170
)	O
designed	O
to	O
assist	O
emergency	B-T097
responders	I-T097
/	O
emergency	B-T097
nurses	I-T097
with	O
managing	O
hazardous	B-T103
material	I-T103
exposures	O
.	O

Inferential	O
statistics	O
(	O
χ	O
(	O
2	O
)	O
/	O
Fisher	B-T170
'	I-T170
s	I-T170
exact	I-T170
test	I-T170
)	O
and	O
diagnostics	B-T058
tests	I-T058
were	O
used	O
to	O
examine	O
mapped	O
signs	B-T033
/	I-T033
symptoms	I-T033
of	O
persons	B-T098
who	O
were	O
and	O
were	O
not	O
exposed	O
to	O
chlorine	O
.	O

Three	O
clusters	O
of	O
signs	B-T033
/	I-T033
symptoms	I-T033
are	O
statistically	O
associated	O
with	O
an	O
IGSA	O
syndrome	B-T038
(	O
P	O
<	O
.	O
01	O
)	O
:	O
respiratory	O
(	O
shortness	B-T033
of	I-T033
breath	I-T033
,	O
wheezing	B-T033
,	O
coughing	B-T033
,	O
and	O
choking	B-T038
)	O
;	O
chest	B-T033
discomfort	I-T033
(	O
tightness	B-T033
,	O
pain	B-T033
,	O
and	O
burning	B-T033
)	O
,	O
and	O
eye	B-T017
,	O
nose	B-T017
and	O
/	O
or	O
throat	B-T017
(	O
pain	B-T033
,	O
irritation	O
,	O
and	O
burning	B-T033
)	O
.	O

The	O
syndrome	B-T038
requires	O
the	O
presence	B-T033
of	O
signs	B-T033
/	I-T033
symptoms	I-T033
from	O
at	O
least	O
2	O
of	O
these	O
clusters	O
.	O

The	O
latency	O
period	O
must	O
also	O
be	O
considered	O
for	O
exposed	B-T098
/	O
potentially	O
exposed	B-T098
persons	I-T098
.	O

This	O
study	B-T062
uses	O
actual	O
patient	O
data	O
from	O
a	O
chemical	O
incident	O
to	O
characterize	O
and	O
validate	B-T062
signs	B-T033
/	I-T033
symptoms	I-T033
of	O
an	O
IGSA	O
syndrome	B-T038
.	O

Validating	B-T062
signs	B-T033
/	I-T033
symptoms	I-T033
is	O
the	O
first	O
step	O
in	O
developing	O
new	O
ED	B-T092
informatics	B-T170
tools	I-T170
with	O
the	O
potential	O
to	O
revolutionize	O
the	O
process	O
by	O
which	O
emergency	B-T097
nurses	I-T097
manage	O
triage	B-T058
victims	O
of	O
chemical	O
incidents	O
.	O

Fyn	B-T103
regulates	O
multipolar	O
-	O
bipolar	B-T082
transition	O
and	O
neurite	B-T038
morphogenesis	I-T038
of	O
migrating	B-T038
neurons	I-T038
in	O
the	O
developing	B-T038
neocortex	I-T038

Fyn	B-T103
is	O
a	O
non	B-T033
-	I-T033
receptor	I-T033
protein	B-T103
tyrosine	I-T103
kinase	I-T103
that	O
belongs	O
to	O
Src	B-T103
family	I-T103
kinases	I-T103
.	O

Fyn	B-T103
plays	O
a	O
critical	O
role	O
in	O
neuronal	B-T038
migration	I-T038
,	O
but	O
the	O
mechanism	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
reported	O
that	O
suppression	B-T038
of	O
Fyn	B-T103
expression	B-T038
in	O
mouse	B-T017
cerebral	I-T017
cortex	I-T017
led	O
to	O
migration	B-T033
defects	I-T033
of	O
both	O
early	O
-	O
born	O
and	O
late	O
-	O
born	O
neurons	B-T017
.	O

Morphological	B-T082
analysis	B-T062
showed	O
that	O
loss	O
of	O
Fyn	B-T103
function	O
impaired	O
multipolar	O
-	O
bipolar	B-T082
transition	O
of	O
newly	O
generated	O
neurons	B-T017
and	O
neurite	B-T038
formation	I-T038
in	O
the	O
early	O
phase	O
of	O
migration	B-T038
.	O

Moreover	O
,	O
Fyn	B-T103
inhibition	B-T038
increased	O
the	O
length	O
of	O
leading	B-T038
process	I-T038
and	O
decreased	O
the	O
branching	B-T082
number	O
of	O
the	O
migrating	B-T038
cortical	I-T038
neurons	I-T038
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
Fyn	B-T103
controls	O
neuronal	B-T038
migration	I-T038
by	O
regulating	B-T038
the	O
cytoskeletal	B-T017
dynamics	O
and	O
multipolar	O
-	O
bipolar	B-T082
transition	O
of	O
newly	O
generated	O
neurons	B-T017
during	O
cortical	B-T038
development	I-T038
.	O

Closing	O
the	O
Loop	O
in	O
Adults	O
,	O
Children	O
and	O
Adolescents	O
With	O
Suboptimally	B-T033
Controlled	I-T033
Type	I-T033
1	I-T033
Diabetes	I-T033
Under	O
Free	O
Living	O
Conditions	O
:	O
A	O
Psychosocial	O
Substudy	B-T062

The	O
objective	O
was	O
to	O
explore	O
psychosocial	B-T033
experiences	I-T033
of	O
closed	B-T074
loop	I-T074
technology	I-T074
for	O
adults	O
,	O
children	O
,	O
and	O
adolescents	O
with	O
type	B-T038
1	I-T038
diabetes	I-T038
and	O
their	O
parents	O
taking	O
part	O
in	O
two	O
multicenter	B-T062
,	O
free	O
-	O
living	O
,	O
randomized	B-T062
crossover	B-T062
home	I-T062
studies	I-T062
.	O

Participants	B-T098
using	O
insulin	B-T074
pump	I-T074
therapy	B-T058
were	O
randomized	B-T062
to	O
either	O
12	O
weeks	O
of	O
automated	O
closed	O
-	O
loop	O
glucose	B-T103
control	I-T103
,	O
then	O
12	O
weeks	O
of	O
sensor	O
augmented	O
insulin	B-T074
pump	I-T074
therapy	B-T058
(	O
open	O
loop	O
)	O
,	O
or	O
vice	O
versa	O
.	O

Closed	O
loop	O
was	O
used	O
for	O
24	O
hours	O
by	O
adults	O
and	O
overnight	O
only	O
by	O
children	O
and	O
adolescents	O
.	O

Participants	B-T098
completed	O
the	O
Diabetes	B-T170
Technology	I-T170
Questionnaire	I-T170
(	O
DTQ	B-T170
)	O
periodically	O
and	O
shared	O
their	O
views	B-T082
in	O
semistructured	O
interviews	O
.	O

This	O
analysis	B-T062
characterizes	O
the	O
impact	O
of	O
the	O
technology	O
,	O
positive	B-T033
and	O
negative	O
aspects	O
of	O
living	O
with	O
the	O
device	B-T074
,	O
alongside	O
participants	B-T098
'	O
expectations	O
,	O
hopes	B-T038
,	O
and	O
anxieties	B-T033
.	O

Participants	B-T098
were	O
32	O
adults	O
,	O
age	O
38	O
.	O
6	O
±	O
9	O
.	O
6	O
years	O
,	O
55	O
%	O
male	O
,	O
and	O
26	O
children	O
,	O
mean	O
age	O
12	O
years	O
(	O
range	O
6	O
-	O
18	O
years	O
)	O
,	O
54	O
%	O
male	O
.	O

DTQ	B-T170
results	O
indicated	O
moderately	O
favorable	O
impact	O
of	O
,	O
and	O
satisfaction	O
with	O
,	O
both	O
open	O
and	O
closed	O
loop	O
interventions	B-T058
,	O
but	O
little	O
evidence	O
of	O
a	O
comparative	O
advantage	O
of	O
either	O
.	O

Key	O
positive	B-T033
themes	I-T033
included	O
perceived	O
improved	B-T103
blood	I-T103
glucose	I-T103
control	I-T103
,	O
improved	B-T033
general	I-T033
well	I-T033
-	I-T033
being	I-T033
,	O
particularly	O
on	O
waking	B-T038
,	O
improved	B-T038
sleep	I-T038
,	O
reduced	O
burden	O
of	O
diabetes	B-T038
,	O
and	O
visibility	O
of	O
data	O
.	O

Key	O
negative	O
themes	O
included	O
having	O
to	O
carry	O
around	O
the	O
equipment	O
and	O
dislike	O
of	O
the	O
pump	B-T074
and	O
second	O
cannula	B-T074
(	O
ie	O
,	O
sensor	O
)	O
inserted	O
.	O

Overall	O
,	O
participants	B-T098
reported	O
a	O
positive	B-T033
experience	O
of	O
the	O
closed	B-T074
loop	I-T074
technology	I-T074
.	O

Results	O
are	O
consistent	O
with	O
previous	O
research	O
with	O
size	B-T082
of	O
equipment	O
continuing	O
to	O
be	O
a	O
problem	B-T033
.	O

Progress	O
is	O
being	O
made	O
in	O
the	O
usability	O
of	O
the	O
closed	B-T074
-	I-T074
loop	I-T074
system	I-T074
.	O

Serum	B-T031
levels	O
of	O
genomic	B-T103
DNA	I-T103
of	O
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
are	O
elevated	O
in	O
scleroderma	B-T038
patients	O

Recent	O
studies	O
have	O
indicated	O
that	O
various	O
nucleic	B-T103
acids	I-T103
are	O
present	O
in	O
human	B-T204
sera	B-T031
,	O
and	O
attracted	O
attention	O
for	O
their	O
potential	O
as	O
novel	O
disease	O
markers	O
in	O
many	O
human	B-T204
diseases	B-T038
.	O

In	O
this	O
study	O
,	O
we	O
tried	O
to	O
evaluate	O
the	O
possibility	O
that	O
DNA	B-T103
and	O
RNA	B-T103
of	O
collagens	B-T017
exist	O
in	O
human	B-T204
sera	B-T031
,	O
and	O
determined	O
whether	O
their	O
serum	B-T031
levels	O
can	O
be	O
useful	O
biomarkers	B-T201
in	O
scleroderma	B-T038
patients	O
.	O

The	O
RNA	B-T103
or	O
DNA	B-T103
of	O
collagens	B-T017
were	O
purified	O
from	O
sera	B-T031
,	O
and	O
detected	B-T033
by	O
polymerase	B-T062
chain	I-T062
reaction	I-T062
or	O
quantitated	O
by	O
real	B-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
.	O

Among	O
approximately	O
18	O
360	B-T017
bases	I-T017
of	I-T017
full	I-T017
-	I-T017
length	I-T017
α1	I-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
,	O
various	O
regions	B-T017
were	O
detected	B-T033
by	O
polymerase	B-T062
chain	I-T062
reaction	I-T062
in	O
human	B-T204
sera	B-T031
.	O

However	O
,	O
α2	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
,	O
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
RNA	B-T103
or	O
α2	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
RNA	B-T103
were	O
not	B-T033
detectable	I-T033
.	O

α1	B-T017
(	I-T017
I	I-T017
)	I-T017
Collagen	I-T017
DNA	B-T103
in	O
sera	B-T031
was	O
quantitative	O
using	O
our	O
method	O
.	O

The	O
levels	O
of	O
serum	B-T031
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
were	O
significantly	O
increased	O
in	O
scleroderma	B-T038
patients	O
compared	O
with	O
healthy	O
control	O
subjects	B-T098
or	O
systemic	B-T038
lupus	I-T038
erythematosus	I-T038
patients	O
.	O

According	O
to	O
the	O
receiver	O
-	O
operator	O
curve	O
analysis	O
,	O
serum	B-T031
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
levels	O
were	O
shown	O
to	O
be	O
effective	O
as	O
a	O
diagnostic	B-T201
marker	I-T201
of	O
scleroderma	B-T038
.	O

Furthermore	O
,	O
when	O
we	O
determined	O
the	O
association	O
of	O
serum	B-T031
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
levels	O
with	O
clinical	O
/	O
laboratory	B-T092
features	O
in	O
scleroderma	B-T038
patients	O
,	O
those	O
with	O
elevated	O
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
levels	O
showed	O
significantly	O
higher	O
prevalence	O
of	O
pitting	B-T038
scars	I-T038
/	O
ulcers	B-T038
.	O

In	O
summary	O
,	O
elevation	O
of	O
serum	B-T031
α1	B-T017
(	I-T017
I	I-T017
)	I-T017
collagen	I-T017
DNA	B-T103
levels	O
in	O
scleroderma	B-T038
patients	O
may	O
be	O
useful	O
as	O
the	O
diagnostic	B-T201
marker	I-T201
,	O
reflecting	O
the	O
presence	O
of	O
vasculopathy	B-T038
.	O

Jou	O
rna	B-T103

Metabolite	B-T103
mapping	O
by	O
consecutive	O
nanostructure	O
and	O
silver	B-T058
-	I-T058
assisted	I-T058
mass	I-T058
spectrometry	I-T058
imaging	I-T058
on	O
tissue	B-T017
sections	I-T017

Nanostructure	B-T058
-	I-T058
based	I-T058
mass	I-T058
spectrometry	I-T058
imaging	I-T058
(	O
MSI	B-T058
)	O
is	O
a	O
promising	O
technology	O
for	O
molecular	B-T058
imaging	I-T058
of	O
small	B-T103
molecules	I-T103
,	O
without	O
the	O
complex	O
chemical	O
background	O
typically	O
encountered	O
in	O
matrix	B-T058
-	I-T058
assisted	I-T058
molecular	I-T058
imaging	I-T058
approaches	O
.	O

Here	O
,	O
we	O
have	O
enhanced	O
these	O
surfaces	B-T082
with	O
silver	B-T103
(	O
Ag	B-T103
)	O
to	O
provide	O
a	O
second	O
tier	O
of	O
MSI	B-T170
data	I-T170
from	O
a	O
single	O
sample	O
.	O

MSI	B-T170
data	I-T170
was	O
acquired	O
through	O
the	O
application	O
of	O
laser	B-T058
desorption	I-T058
/	I-T058
ionization	I-T058
mass	I-T058
spectrometry	I-T058
to	O
biological	O
samples	O
imprinted	O
onto	O
desorption	O
/	O
ionization	O
on	O
silicon	O
(	O
DIOS	O
)	O
substrates	O
.	O

Following	O
initial	O
analysis	B-T062
,	O
ultra	O
-	O
thin	O
Ag	O
layers	O
were	O
overlaid	O
onto	O
the	O
followed	O
by	O
MSI	B-T058
analysis	I-T058
(	O
Ag	B-T058
-	I-T058
DIOS	I-T058
MSI	I-T058
)	O
.	O

This	O
approach	O
was	O
first	O
demonstrated	O
for	O
fingermark	O
small	B-T103
molecules	I-T103
including	O
environmental	B-T082
contaminants	O
and	O
sebum	B-T031
components	O
.	O

Subsequently	O
,	O
this	O
bimodal	O
method	O
was	O
translated	O
to	O
lipids	B-T103
and	O
metabolites	B-T103
in	O
fore	B-T017
-	I-T017
stomach	I-T017
sections	I-T017
from	O
a	O
6	B-T103
-	I-T103
bromoisatin	I-T103
chemopreventative	O
murine	B-T038
mouse	I-T038
model	I-T038
.	O

DIOS	B-T058
MSI	I-T058
allowed	O
mapping	O
of	O
common	O
ions	B-T103
in	O
fingermarks	O
as	O
well	O
as	O
6	B-T103
-	I-T103
bromoisatin	I-T103
metabolites	B-T103
and	O
lipids	B-T103
in	O
murine	B-T017
fore	I-T017
-	I-T017
stomach	I-T017
.	O

Furthermore	O
,	O
DIOS	B-T058
MSI	I-T058
was	O
complemented	O
by	O
the	O
Ag	B-T058
-	I-T058
DIOS	I-T058
MSI	I-T058
of	O
Ag	B-T103
-	I-T103
adductable	I-T103
lipids	I-T103
such	O
as	O
wax	B-T103
esters	I-T103
in	O
fingermarks	O
and	O
cholesterol	B-T103
in	O
murine	B-T017
fore	I-T017
-	I-T017
stomach	I-T017
.	O

Gastrointestinal	B-T031
acid	I-T031
condensation	O
products	B-T103
of	O
6	B-T103
-	I-T103
bromoisatin	I-T103
,	O
such	O
as	O
the	O
6	B-T103
,	I-T103
6	I-T103
'	I-T103
-	I-T103
dibromoindirubin	I-T103
mapped	O
herein	O
,	O
are	O
very	O
challenging	O
to	O
isolate	B-T058
and	O
characterize	O
.	O

By	O
re	O
-	O
analyzing	O
the	O
same	O
tissue	B-T017
imprints	O
,	O
this	O
metabolite	B-T103
was	O
readily	O
detected	O
by	O
DIOS	O
,	O
placed	O
in	O
a	O
tissue	O
-	O
specific	O
spatial	O
context	O
,	O
and	O
subsequently	O
overlaid	O
with	O
additional	O
lipid	B-T038
distributions	I-T038
acquired	O
using	O
Ag	B-T058
-	I-T058
DIOS	I-T058
MSI	I-T058
.	O

The	O
ability	O
to	O
place	O
metabolite	B-T103
and	O
lipid	B-T103
classes	O
in	O
a	O
tissue	O
-	O
specific	O
context	O
makes	O
this	O
novel	O
method	O
suited	O
to	O
MSI	B-T058
analyses	I-T058
where	O
the	O
collection	O
of	O
additional	O
information	O
from	O
the	O
same	O
sample	O
maximises	O
resource	O
use	O
,	O
and	O
also	O
maximises	O
the	O
number	O
of	O
annotated	O
small	B-T103
molecules	I-T103
,	O
in	O
particular	O
for	O
metabolites	B-T103
that	O
are	O
typically	O
undetectable	B-T201
with	O
traditional	O
platforms	O
.	O

Copyright	O
©	O
2017	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Towards	O
culturally	B-T058
competent	I-T058
paediatric	I-T058
oncology	I-T058
care	I-T058
.	O
A	O
qualitative	B-T062
study	I-T062
from	O
the	O
perspective	O
of	O
care	B-T097
providers	I-T097

In	O
order	O
to	O
gain	O
more	O
insight	O
on	O
the	O
influence	O
of	O
ethnic	B-T033
diversity	O
in	O
paediatric	B-T091
cancer	O
care	O
,	O
the	O
perspectives	O
of	O
care	B-T097
providers	I-T097
were	O
explored	O
.	O

Semi	O
-	O
structured	O
interviews	O
were	O
conducted	O
among	O
12	O
paediatric	B-T097
oncologists	I-T097
and	O
13	O
nurses	B-T097
of	O
two	O
different	O
paediatric	B-T092
oncology	I-T092
wards	I-T092
and	O
were	O
analysed	B-T062
using	O
a	O
framework	B-T170
method	I-T170
.	O

We	O
found	O
that	O
care	B-T097
providers	I-T097
described	O
the	O
contact	O
with	O
Turkish	B-T098
and	O
Moroccan	B-T098
parents	O
as	O
more	O
difficult	O
.	O

They	O
offered	O
two	O
reasons	O
for	O
this	O
:	O
(	O
1	O
)	O
language	B-T033
barriers	I-T033
between	O
care	B-T097
provider	I-T097
and	O
parents	O
hindered	O
the	O
exchange	O
of	O
information	O
;	O
(	O
2	O
)	O
cultural	O
barriers	O
between	O
care	B-T097
provider	I-T097
and	O
parents	O
about	O
sharing	O
the	O
diagnosis	B-T033
and	O
palliative	O
perspective	O
hindered	O
communication	O
.	O

Care	B-T097
providers	I-T097
reported	O
different	O
solutions	O
to	O
deal	O
with	O
these	O
barriers	O
,	O
such	O
as	O
using	O
an	O
interpreter	B-T097
and	O
improving	O
their	O
cultural	B-T170
knowledge	I-T170
about	O
their	O
patients	O
.	O

They	O
,	O
however	O
,	O
were	O
not	O
using	O
interpreters	B-T097
sufficiently	O
and	O
were	O
unaware	O
of	O
the	O
importance	O
of	O
eliciting	B-T038
parents	O
'	O
perspectives	O
.	O

Communication	O
techniques	O
to	O
overcome	O
dilemmas	O
between	O
parents	O
and	O
care	B-T097
providers	I-T097
were	O
not	O
used	O
and	O
care	B-T097
providers	I-T097
were	O
unaware	O
of	O
stereotypes	O
and	O
prejudice	O
.	O

Care	B-T097
providers	I-T097
should	O
be	O
offered	O
insight	O
in	O
cultural	O
barriers	O
they	O
are	O
unaware	O
of	O
.	O

Training	O
in	O
cultural	O
competence	O
might	O
be	O
a	O
possibility	O
to	O
overcome	O
manifest	O
barriers	O
.	O

Obesogenic	B-T038
eating	O
behaviors	O
mediate	O
the	O
relationships	O
between	O
psychological	B-T033
problems	I-T033
and	O
BMI	B-T201
in	O
children	O

To	O
examine	O
the	O
association	O
between	O
psychological	B-T033
problems	I-T033
and	O
weight	O
status	O
in	O
children	O
aged	O
3	O
.	O
5	O
to	O
4	O
years	O
and	O
test	O
whether	O
obesogenic	B-T038
eating	O
behaviors	O
mediate	O
this	O
relationship	O
.	O

This	O
study	O
is	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
secondary	I-T062
analysis	I-T062
of	O
data	O
from	O
first	O
-	O
time	O
mothers	O
(	O
N	O
=	O
194	O
)	O
in	O
the	O
control	O
arm	O
of	O
the	O
NOURISH	B-T062
randomized	I-T062
controlled	I-T062
trial	I-T062
.	O

At	O
child	O
age	O
3	O
.	O
5	O
to	O
4	O
years	O
,	O
maternal	O
-	O
reported	O
child	O
eating	O
behaviors	O
and	O
psychological	B-T033
problems	I-T033
were	O
collected	O
via	O
valid	O
tools	O
,	O
and	O
child	O
weight	O
and	O
height	O
data	B-T062
were	I-T062
collected	I-T062
by	O
trained	O
study	O
staff	O
.	O

Pearson	B-T170
'	I-T170
s	I-T170
correlations	I-T170
and	O
linear	O
regressions	O
examined	O
associations	O
between	O
eating	O
behaviors	O
,	O
psychological	B-T033
problems	I-T033
,	O
and	O
BMI	B-T201
z	O
score	O
.	O

Multiple	O
mediation	O
models	O
were	O
tested	O
by	O
assessing	O
indirect	O
effects	O
of	O
psychological	B-T033
problems	I-T033
on	O
BMI	B-T201
z	O
score	O
via	O
obesogenic	B-T038
eating	O
behaviors	O
.	O

Peer	B-T098
problems	B-T033
were	O
associated	O
with	O
both	O
higher	O
food	B-T168
responsiveness	O
and	O
emotional	B-T038
overeating	I-T038
and	O
directly	O
with	O
higher	O
BMI	B-T201
z	O
score	O
.	O

This	O
relationship	O
was	O
partially	O
mediated	O
by	O
emotional	B-T038
overeating	I-T038
.	O

Both	O
emotional	B-T038
overeating	I-T038
and	O
food	B-T168
responsiveness	O
fully	O
mediated	O
the	O
association	O
between	O
emotional	B-T038
problems	I-T038
and	O
BMI	B-T201
z	O
score	O
,	O
and	O
food	B-T168
responsiveness	O
fully	O
mediated	O
the	O
association	O
between	O
conduct	B-T038
problems	I-T038
and	O
BMI	B-T201
z	O
score	O
.	O

The	O
findings	O
suggest	O
that	O
children	O
with	O
psychological	B-T033
problems	I-T033
may	O
also	O
display	O
obesogenic	B-T038
eating	O
behaviors	O
,	O
which	O
may	O
result	O
in	O
higher	O
BMI	B-T201
.	O

This	O
needs	O
to	O
be	O
considered	O
in	O
the	O
clinical	B-T058
management	I-T058
of	O
both	O
pediatric	O
overweight	B-T033
/	O
obesity	B-T038
and	O
psychological	B-T033
problems	I-T033
.	O

Homocysteine	B-T103
as	O
a	O
peripheral	B-T082
biomarker	B-T201
in	O
bipolar	B-T038
disorder	I-T038
:	O
A	O
meta	B-T062
-	I-T062
analysis	I-T062

Bipolar	B-T038
disorder	I-T038
(	O
BD	B-T038
)	O
is	O
a	O
psychiatric	B-T038
disorder	I-T038
with	O
an	O
uncertain	B-T033
aetiology	O
.	O

Recently	O
,	O
special	O
attention	O
has	O
been	O
given	O
to	O
homocysteine	B-T103
(	O
Hcy	B-T103
)	O
,	O
as	O
it	O
has	O
been	O
suggested	O
that	O
alterations	O
in	O
1	B-T038
-	I-T038
carbon	I-T038
metabolism	I-T038
might	O
be	O
implicated	O
in	O
diverse	O
psychiatric	B-T038
disorders	I-T038
.	O

However	O
,	O
there	O
is	O
uncertainty	B-T033
regarding	O
possible	O
alterations	O
in	O
peripheral	B-T082
Hcy	B-T103
levels	O
in	O
BD	B-T038
.	O

This	O
study	O
comprises	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
comparing	O
serum	B-T058
and	O
plasma	B-T058
Hcy	I-T058
levels	I-T058
in	O
persons	B-T098
with	O
BD	B-T038
and	O
healthy	O
controls	O
.	O

We	O
conducted	O
a	O
systematic	O
search	O
for	O
all	O
eligible	O
English	O
and	O
non	O
-	O
English	O
peer	B-T170
-	I-T170
reviewed	I-T170
articles	I-T170
.	O

Nine	O
cross	B-T062
-	I-T062
sectional	I-T062
studies	I-T062
were	O
included	O
in	O
the	O
meta	B-T062
-	I-T062
analyses	I-T062
,	O
providing	O
data	O
on	O
1547	O
participants	B-T098
.	O

Random	O
-	O
effects	O
meta	B-T062
-	I-T062
analysis	I-T062
showed	O
that	O
serum	B-T058
and	O
plasma	B-T058
levels	I-T058
of	I-T058
Hcy	I-T058
were	O
increased	O
in	O
subjects	O
with	O
BD	B-T038
in	O
either	O
mania	B-T038
or	O
euthymia	B-T038
when	O
compared	O
to	O
healthy	O
controls	O
,	O
with	O
a	O
large	O
effect	O
size	O
in	O
the	O
mania	B-T038
group	B-T098
(	O
g	O
=	O
0	O
.	O
98	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
8	O
-	O
1	O
.	O
17	O
,	O
P	O
<	O
0	O
.	O
001	O
,	O
n	O
=	O
495	O
)	O
and	O
a	O
small	O
effect	O
in	O
the	O
euthymia	B-T038
group	B-T098
(	O
g	O
=	O
0	O
.	O
3	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
11	O
-	O
0	O
.	O
48	O
,	O
P	O
=	O
0	O
.	O
002	O
,	O
n	O
=	O
1052	O
)	O
.	O

Our	O
meta	B-T062
-	I-T062
analysis	I-T062
provides	O
evidence	O
that	O
Hcy	B-T033
levels	I-T033
are	I-T033
elevated	I-T033
in	O
persons	B-T098
with	O
BD	B-T038
during	O
mania	B-T038
and	O
euthymia	B-T038
.	O

Peripheral	B-T082
Hcy	B-T103
could	O
be	O
considered	O
as	O
a	O
potential	O
biomarker	B-T201
in	O
BD	B-T038
,	O
both	O
of	O
trait	O
(	O
since	O
it	O
is	O
increased	O
in	O
euthymia	B-T038
)	O
,	O
and	O
also	O
of	O
state	O
(	O
since	O
its	O
increase	O
is	O
more	O
accentuated	O
in	O
mania	B-T038
)	O
.	O

Longitudinal	B-T062
studies	I-T062
are	O
needed	O
to	O
clarify	O
the	O
relationship	O
between	O
bipolar	B-T038
disorder	I-T038
and	O
Hcy	B-T103
,	O
as	O
well	O
as	O
the	O
usefulness	O
of	O
peripheral	B-T082
Hcy	B-T103
as	O
both	O
a	O
trait	O
and	O
state	O
biomarker	B-T201
in	O
BD	B-T038
.	O

Structural	B-T058
Modification	I-T058
of	O
Lipopolysaccharide	B-T103
Conferred	O
by	O
mcr	B-T017
-	I-T017
1	I-T017
in	O
Gram	B-T007
-	I-T007
Negative	I-T007
ESKAPE	I-T007
Pathogens	O

mcr	B-T017
-	I-T017
1	I-T017
was	O
initially	O
reported	O
as	O
the	O
first	O
plasmid	B-T103
-	O
mediated	O
colistin	B-T103
resistance	O
gene	O
in	O
clinical	B-T103
isolates	I-T103
of	O
Escherichia	B-T007
coli	I-T007
and	O
Klebsiella	B-T007
pneumoniae	I-T007
in	O
China	B-T082
and	O
has	O
subsequently	O
been	O
identified	O
worldwide	O
in	O
various	O
species	B-T170
of	O
the	O
family	B-T007
Enterobacteriaceae	I-T007
mcr	B-T017
-	I-T017
1	I-T017
encodes	O
a	O
phosphoethanolamine	B-T038
transferase	I-T038
,	O
and	O
its	O
expression	B-T038
has	O
been	O
shown	O
to	O
generate	O
phosphoethanolamine	B-T103
-	O
modified	O
bis	B-T103
-	I-T103
phosphorylated	I-T103
hexa	I-T103
-	I-T103
acylated	I-T103
lipid	I-T103
A	I-T103
in	O
E	B-T007
.	I-T007

coli	I-T007
Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
mcr	B-T017
-	I-T017
1	I-T017
on	O
colistin	B-T103
susceptibility	B-T033
and	O
on	O
lipopolysaccharide	B-T103
structures	B-T082
in	O
laboratory	B-T092
and	O
clinical	O
strains	O
of	O
the	O
Gram	B-T007
-	I-T007
negative	I-T007
ESKAPE	I-T007
(	O
Enterococcus	B-T007
faecium	I-T007
,	O
Staphylococcus	B-T007
aureus	I-T007
,	O
K	B-T007
.	I-T007

pneumoniae	I-T007
,	O
Acinetobacter	B-T007
baumannii	I-T007
,	O
Pseudomonas	B-T007
aeruginosa	I-T007
,	O
and	O
Enterobacter	B-T007
species	I-T007
)	O
pathogens	O
,	O
which	O
are	O
often	O
treated	O
clinically	O
by	O
colistin	B-T103
.	O

The	O
effects	O
of	O
mcr	B-T017
-	I-T017
1	I-T017
on	O
colistin	B-T103
resistance	O
were	O
determined	O
using	O
MIC	B-T058
assays	I-T058
of	O
laboratory	B-T092
and	O
clinical	O
strains	O
of	O
E	B-T007
.	I-T007

coli	I-T007
,	O
K	B-T007
.	I-T007

pneumoniae	I-T007
,	O
A	B-T007
.	I-T007

baumannii	I-T007
,	O
and	O
P	B-T007
.	I-T007

aeruginosa	I-T007
Lipid	B-T103
A	I-T103
structural	B-T082
changes	O
resulting	O
from	O
MCR	B-T103
-	I-T103
1	I-T103
were	O
analyzed	O
by	O
mass	B-T058
spectrometry	I-T058
.	O

The	O
introduction	O
of	O
mcr	B-T017
-	I-T017
1	I-T017
led	O
to	O
colistin	B-T103
resistance	O
in	O
E	B-T007
.	I-T007

coli	I-T007
,	O
K	B-T007
.	I-T007

pneumoniae	I-T007
,	O
and	O
A	B-T007
.	I-T007

baumannii	I-T007
but	O
only	O
moderately	O
reduced	O
susceptibility	B-T033
in	O
P	B-T007
.	I-T007

aeruginosa	I-T007
Phosphoethanolamine	B-T103
modification	B-T033
of	O
lipid	B-T103
A	I-T103
was	O
observed	O
consistently	O
for	O
all	O
four	O
species	B-T170
.	O

These	O
findings	O
highlight	O
the	O
risk	O
of	O
colistin	B-T103
resistance	O
as	O
a	O
consequence	O
of	O
mcr	B-T017
-	I-T017
1	I-T017
expression	B-T038
among	O
ESKAPE	B-T007
pathogens	O
,	O
especially	O
in	O
K	B-T007
.	I-T007

pneumoniae	I-T007
and	O
A	B-T007
.	I-T007

baumannii	I-T007
Furthermore	O
,	O
the	O
observation	O
that	O
lipid	B-T103
A	I-T103
structures	B-T082
were	O
modified	O
despite	O
only	O
modest	O
increases	O
in	O
colistin	B-T103
MICs	B-T058
in	O
some	O
instances	O
suggests	O
more	O
sophisticated	O
surveillance	B-T062
methods	I-T062
may	O
need	O
to	O
be	O
developed	O
to	O
track	O
the	O
dissemination	B-T082
of	O
mcr	B-T017
-	I-T017
1	I-T017
or	O
plasmid	B-T103
-	O
mediated	O
phosphoethanolamine	B-T038
transferases	I-T038
in	O
general	O
.	O

Effects	O
of	O
Transplanted	B-T058
Human	B-T204
Cord	B-T031
Blood	I-T031
-	O
Mononuclear	O
Cells	O
on	O
Pulmonary	B-T038
Hypertension	I-T038
in	O
Immunodeficient	O
Mice	O
and	O
Their	O
Distribution	O

To	O
investigate	B-T058
the	O
effects	O
of	O
human	B-T204
umbilical	B-T031
cord	I-T031
blood	I-T031
-	O
derived	O
mononuclear	O
cell	O
(	O
hUCB	B-T031
-	O
MNC	O
)	O
transplantation	B-T058
on	O
pulmonary	B-T038
hypertension	I-T038
(	O
PH	B-T038
)	O
induced	O
by	O
monocrotaline	B-T103
(	O
MCT	B-T103
)	O
in	O
immunodeficient	O
mice	O
and	O
their	O
distribution	O
.	O

MCT	B-T103
was	O
administered	O
to	O
BALB	B-T204
/	I-T204
c	I-T204
Slc	I-T204
-	I-T204
nu	I-T204
/	I-T204
nu	I-T204
mice	I-T204
,	O
and	O
PH	B-T038
was	O
induced	O
in	O
mice	B-T204
4	O
weeks	O
later	O
.	O

Fresh	O
hUCB	B-T031
-	O
MNCs	O
harvested	B-T058
from	O
a	O
human	B-T204
donor	B-T098
after	O
her	O
delivery	O
were	O
injected	O
intravenously	O
into	O
those	O
PH	B-T038
mice	B-T204
.	O

The	O
medial	B-T082
thickness	O
of	O
pulmonary	B-T017
arterioles	I-T017
,	O
ratio	O
of	O
right	B-T017
ventricular	I-T017
to	O
septum	B-T017
plus	O
left	B-T017
ventricular	I-T017
weight	O
(	O
RV	B-T017
/	O
S	B-T017
+	O
LV	B-T017
)	O
,	O
and	O
ratio	O
of	O
acceleration	O
time	O
to	O
ejection	B-T201
time	I-T201
of	O
pulmonary	O
blood	O
flow	O
waveform	O
(	O
AT	O
/	O
ET	B-T201
)	O
were	O
determined	O
4	O
weeks	O
after	O
hUCB	B-T031
-	O
MNC	O
transplantation	B-T058
.	O

To	O
reveal	O
the	O
incorporation	O
into	O
the	O
lung	B-T017
,	O
CMTMR	B-T103
-	O
labeled	B-T103
hUCB	B-T031
-	O
MNCs	O
were	O
observed	O
in	O
the	O
lung	B-T017
by	O
fluorescent	B-T058
microscopy	I-T058
.	O

DiR	B-T103
-	I-T103
labeled	I-T103
hUCB	B-T031
-	O
MNCs	O
were	O
detected	B-T033
in	O
the	O
lung	B-T017
and	O
other	O
organs	B-T017
by	O
bioluminescence	O
images	O
.	O

Medial	B-T082
thickness	O
,	O
RV	B-T017
/	O
S	B-T017
+	O
LV	B-T017
and	O
AT	O
/	O
ET	B-T201
were	O
significantly	O
improved	B-T033
4	O
weeks	O
after	O
hUCB	B-T031
-	O
MNC	O
transplantation	B-T058
compared	O
with	O
those	O
in	O
mice	B-T204
without	O
hUCB	B-T031
-	O
MNC	O
transplantation	B-T058
.	O

CMTMR	B-T103
-	O
positive	B-T033
hUCB	B-T031
-	O
MNCs	O
were	O
observed	O
in	O
the	O
lung	B-T017
3	O
hours	O
after	O
transplantation	B-T058
.	O

Bioluminescence	B-T038
signals	O
were	O
detected	B-T033
more	O
strongly	O
in	O
the	O
lung	B-T017
than	O
in	O
other	O
organs	B-T017
for	O
24	O
hours	O
after	O
transplantation	B-T058
.	O

The	O
results	O
indicate	B-T033
that	O
hUCB	B-T031
-	O
MNCs	O
are	O
incorporated	O
into	O
the	O
lung	B-T017
early	O
after	O
hUCB	B-T031
-	O
MNC	O
transplantation	B-T058
and	O
improve	B-T033
MCT	B-T103
-	O
induced	O
PH	B-T038
.	O

J	O
.	O

Med	O
.	O

Invest	O
.	O

64	O
:	O
43	O
-	O
49	O
,	O
February	O
,	O
2017	O
.	O

Interprofessional	B-T033
Barriers	I-T033
:	O
A	O
Study	O
of	O
Quality	O
Improvement	O
Work	O
Among	O
Nurses	B-T097
and	O
Physicians	B-T097

This	O
article	O
studies	O
interprofessional	B-T033
barriers	I-T033
between	O
nurses	B-T097
and	O
physicians	B-T097
in	O
the	O
context	O
of	O
quality	O
improvement	O
work	O
.	O

A	O
total	O
of	O
17	O
nurses	B-T097
and	O
10	O
physicians	B-T097
were	O
interviewed	B-T062
at	O
2	O
hospitals	B-T092
in	O
Sweden	B-T082
.	O

The	O
study	O
uncovered	O
a	O
number	O
of	O
barriers	O
relating	O
to	O
both	O
the	O
relative	O
status	O
of	O
each	O
group	O
and	O
their	O
defined	O
areas	O
of	O
responsibility	O
.	O

Recovery	O
from	O
alcohol	B-T038
dependence	I-T038
:	O
Do	O
smoking	O
indicators	O
predict	O
abstinence	O
?	O

There	O
is	O
inconsistent	O
evidence	O
about	O
the	O
potential	O
influence	O
of	O
smoking	O
on	O
recovery	O
from	O
alcohol	B-T038
dependence	I-T038
.	O

Our	O
study	B-T058
aimed	O
at	O
assessing	O
the	O
impact	O
of	O
smoking	O
-	O
behavior	O
on	O
relapse	O
during	O
a	O
12	O
months	O
follow	B-T058
-	I-T058
up	I-T058
period	O
following	O
a	O
detoxification	B-T058
in	O
patients	O
with	O
Alcohol	O
Use	O
Disorder	O
(	O
AUD	O
)	O
.	O

Three	O
hundred	O
Patients	O
with	O
AUD	O
(	O
74	O
.	O
9	O
%	O
smoking	O
)	O
were	O
recruited	O
from	O
two	O
inpatient	O
detoxification	B-T092
units	I-T092
in	O
psychiatric	B-T092
hospitals	I-T092
in	O
Germany	B-T082
and	O
their	O
alcohol	O
consumption	O
was	O
prospectively	O
followed	O
for	O
1	O
year	O
.	O

Data	O
on	O
different	O
indicators	O
of	O
smoking	O
behavior	O
was	O
gathered	O
.	O

Cox	B-T170
regression	I-T170
model	I-T170
was	O
used	O
to	O
evaluate	B-T058
potential	O
risk	B-T033
factors	I-T033
on	O
time	O
to	O
relapse	O
of	O
alcohol	O
consumption	O
.	O

Two	O
hundred	O
seventy	O
-	O
nine	O
participants	B-T098
(	O
n	O
=	O
279	O
)	O
were	O
included	O
in	O
the	O
final	O
analysis	B-T062
.	O

Smoking	O
increased	O
the	O
risk	O
for	O
alcohol	O
relapse	O
(	O
hazard	O
ratio	O
=	O
3	O
.	O
962	O
,	O
95	O
%	O
CI	O
1	O
.	O
582	O
-	O
9	O
.	O
921	O
)	O
.	O

However	O
,	O
this	O
increased	O
risk	O
is	O
slightly	O
reduced	O
with	O
higher	O
numbers	O
of	O
daily	O
consumed	B-T033
cigarettes	I-T033
(	O
hazard	O
ratio	O
per	O
cigarette	B-T033
=	O
.	O
986	O
,	O
95	O
%	O
CI	O
.	O
976	O
-	O
.	O
995	O
)	O
.	O

Smoking	B-T033
reduced	I-T033
the	O
probability	O
of	O
maintaining	O
alcohol	O
abstinence	O
significantly	O
,	O
whereas	O
higher	O
number	O
of	O
cigarettes	B-T033
smoked	I-T033
daily	O
diminished	O
the	O
increased	O
risk	O
of	O
alcohol	O
relapse	O
in	O
alcohol	B-T038
-	I-T038
dependent	I-T038
patients	O
.	O

Coordinated	O
psychiatric	O
and	O
substance	B-T038
abuse	I-T038
interventions	B-T058
for	O
different	O
subgroups	B-T170
of	O
patients	O
with	O
AUD	O
in	O
the	O
post	O
-	O
acute	O
treatment	O
phase	O
are	O
necessary	O
.	O

Individualized	O
treatment	O
planning	O
is	O
especially	O
important	O
in	O
smoking	O
patients	O
with	O
AUD	O
who	O
are	O
vulnerable	O
for	O
a	O
relapse	O
to	O
alcohol	O
drinking	O
and	O
for	O
somatic	O
complications	B-T038
.	O

Our	O
findings	B-T033
might	O
support	O
individualized	O
treatment	B-T170
plans	I-T170
.	O
(	O
Am	O
J	O
Addict	O
2017	O
;	O
XX	O
:	O
1	O
-	O
8	O
)	O
.	O

Similar	O
patterns	B-T082
of	O
neural	O
activity	O
predict	O
memory	B-T038
function	I-T038
during	O
encoding	B-T038
and	O
retrieval	O

Neural	B-T017
networks	I-T017
that	O
span	O
the	O
medial	B-T017
temporal	I-T017
lobe	I-T017
(	O
MTL	B-T017
)	O
,	O
prefrontal	B-T017
cortex	I-T017
,	O
and	O
posterior	B-T017
cortical	I-T017
regions	I-T017
are	O
essential	O
to	O
episodic	B-T038
memory	I-T038
function	I-T038
in	O
humans	B-T204
.	O

Encoding	B-T038
and	O
retrieval	O
are	O
supported	O
by	O
the	O
engagement	O
of	O
both	O
distinct	O
neural	B-T017
pathways	I-T017
across	O
the	O
cortex	B-T017
and	O
common	O
structures	B-T082
within	O
the	O
medial	B-T017
temporal	I-T017
lobes	I-T017
.	O

However	O
,	O
the	O
degree	O
to	O
which	O
memory	B-T038
performance	I-T038
can	O
be	O
determined	O
by	O
neural	O
processing	O
that	O
is	O
common	O
to	O
encoding	B-T038
and	O
retrieval	O
remains	O
to	O
be	O
determined	O
.	O

To	O
identify	O
neural	O
signatures	O
of	O
successful	O
memory	B-T038
function	I-T038
,	O
we	O
administered	O
a	O
delayed	O
free	O
-	O
recall	O
task	O
to	O
187	O
neurosurgical	B-T058
patients	O
implanted	B-T058
with	O
subdural	B-T082
or	O
intraparenchymal	B-T017
depth	B-T074
electrodes	I-T074
.	O

We	O
developed	O
multivariate	B-T170
classifiers	I-T170
to	O
identify	O
patterns	B-T082
of	O
spectral	O
power	O
across	O
the	O
brain	B-T017
that	O
independently	O
predicted	O
successful	O
episodic	B-T038
encoding	I-T038
and	O
retrieval	O
.	O

During	O
encoding	B-T038
and	O
retrieval	O
,	O
patterns	B-T082
of	O
increased	O
high	O
frequency	O
activity	O
in	O
prefrontal	B-T017
,	O
MTL	B-T017
,	O
and	O
inferior	B-T017
parietal	I-T017
cortices	I-T017
,	O
accompanied	O
by	O
widespread	O
decreases	O
in	O
low	O
frequency	O
power	O
across	O
the	O
brain	B-T017
predicted	O
successful	O
memory	B-T038
function	I-T038
.	O

Using	O
a	O
cross	O
-	O
decoding	O
approach	O
,	O
we	O
demonstrate	O
the	O
ability	O
to	O
predict	O
memory	B-T038
function	I-T038
across	O
distinct	O
phases	O
of	O
the	O
free	O
-	O
recall	O
task	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
classifiers	B-T170
that	O
combine	O
information	O
from	O
both	O
encoding	B-T038
and	O
retrieval	O
states	O
can	O
outperform	O
task	B-T170
-	I-T170
independent	I-T170
models	I-T170
.	O

These	O
findings	O
suggest	O
that	O
the	O
engagement	O
of	O
a	O
core	O
memory	B-T038
network	I-T038
during	O
either	O
encoding	B-T038
or	O
retrieval	O
shapes	B-T082
the	O
ability	B-T033
to	I-T033
remember	I-T033
the	I-T033
past	I-T033
,	O
despite	O
distinct	O
neural	O
interactions	O
that	O
facilitate	O
encoding	B-T038
and	O
retrieval	O
.	O

Trump	B-T204
'	I-T204
s	I-T204
got	O
the	O
right	O
idea	O

I	O
am	O
a	O
US	B-T082
nursing	B-T097
student	I-T097
and	O
feel	B-T038
that	O
Obamacare	B-T170
is	O
a	O
bad	O
idea	O
.	O

I	O
'	O
m	O
disappointed	O
that	O
President	O
Trump	B-T204
was	O
not	B-T033
able	I-T033
to	I-T033
get	I-T033
rid	I-T033
of	I-T033
it	O
last	O
month	O
.	O

Bilirubin	B-T103
and	O
atherosclerotic	B-T038
diseases	B-T038

Bilirubin	B-T103
is	O
the	O
final	O
product	O
of	O
heme	B-T038
catabolism	I-T038
in	O
the	O
systemic	O
circulation	O
.	O

For	O
decades	O
,	O
increased	O
serum	B-T031
/	O
plasma	B-T031
bilirubin	B-T103
levels	O
were	O
considered	O
an	O
ominous	O
sign	B-T033
of	O
an	O
underlying	O
liver	B-T038
disease	I-T038
.	O

However	O
,	O
data	O
from	O
recent	O
years	O
convincingly	O
suggest	O
that	O
mildly	O
elevated	O
bilirubin	B-T103
concentrations	O
are	O
associated	O
with	O
protection	O
against	O
various	O
oxidative	B-T038
stress	I-T038
-	O
mediated	O
diseases	B-T038
,	O
atherosclerotic	B-T038
conditions	O
being	O
the	O
most	O
clinically	O
relevant	O
.	O

Although	O
scarce	O
data	O
on	O
beneficial	O
effects	O
of	O
bilirubin	B-T103
had	O
been	O
published	O
also	O
in	O
the	O
past	O
,	O
it	O
took	O
until	O
1994	O
when	O
the	O
first	O
clinical	B-T062
study	I-T062
demonstrated	O
an	O
increased	O
risk	O
of	O
coronary	B-T038
heart	I-T038
disease	I-T038
in	O
subjects	O
with	O
low	O
serum	B-T031
bilirubin	B-T103
levels	O
,	O
and	O
bilirubin	B-T103
was	O
found	O
to	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
atherosclerotic	B-T038
diseases	B-T038
independent	O
of	O
standard	O
risk	B-T033
factors	I-T033
.	O

Consistent	O
with	O
these	O
results	O
,	O
we	O
proved	O
in	O
our	O
own	O
studies	B-T062
,	O
that	O
subjects	O
with	O
mild	O
elevation	O
of	O
serum	O
levels	O
of	O
unconjugated	O
bilirubin	O
(	O
benign	O
hyperbilirubinemia	B-T038
,	O
Gilbert	B-T038
syndrome	I-T038
)	O
have	O
much	O
lower	O
prevalence	O
/	O
incidence	O
of	O
coronary	B-T038
heart	I-T038
as	O
well	O
as	O
peripheral	B-T038
vascular	I-T038
disease	I-T038
.	O

We	O
have	O
also	O
demonstrated	O
that	O
this	O
association	O
is	O
even	O
more	O
general	O
,	O
with	O
serum	B-T031
bilirubin	B-T103
being	O
a	O
biomarker	B-T201
of	O
numerous	O
other	O
diseases	B-T038
,	O
often	O
associated	O
with	O
increased	O
risk	O
of	O
atherosclerosis	B-T038
.	O

In	O
addition	O
,	O
very	O
recent	O
data	O
have	O
demonstrated	O
biological	B-T038
pathways	I-T038
modulated	O
by	O
bilirubin	B-T103
,	O
which	O
are	O
responsible	O
for	O
observed	O
strong	O
clinical	O
associations	O
.	O

An	O
Automated	O
,	O
Pharmacist	B-T097
-	O
Driven	O
Initiative	B-T038
Improves	B-T033
Quality	B-T058
of	I-T058
Care	I-T058
for	O
Staphylococcus	B-T038
aureus	I-T038
Bacteremia	I-T038

Infectious	B-T038
diseases	I-T038
(	O
ID	B-T038
)	O
consultation	B-T058
and	O
antimicrobial	B-T058
stewardship	I-T058
intervention	I-T058
have	O
been	O
shown	O
to	O
improve	B-T033
the	O
management	B-T058
of	O
Staphylococcus	B-T038
aureus	I-T038
bacteremia	I-T038
(	O
SAB	B-T038
)	O
.	O

As	O
the	O
workload	O
of	O
antimicrobial	B-T058
stewardship	I-T058
programs	I-T058
(	O
ASPs	B-T058
)	O
continues	O
to	O
increase	O
,	O
ASPs	B-T058
must	O
find	O
a	O
way	O
to	O
maximize	O
the	O
efficiency	O
of	O
the	O
program	O
while	O
optimizing	O
patient	O
outcomes	O
.	O

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
impact	O
of	O
incorporating	O
health	B-T091
informatics	I-T091
into	O
the	O
management	B-T058
of	O
SAB	B-T038
via	O
a	O
pharmacist	B-T097
-	O
driven	O
initiative	B-T038
.	O

Retrospective	O
,	O
single	O
-	O
center	O
quasi	O
-	O
experimental	O
study	B-T062
of	O
hospitalized	O
patients	O
with	O
SAB	B-T038
.	O

During	O
the	O
intervention	B-T058
period	O
,	O
pharmacists	B-T097
were	O
alerted	O
to	O
patients	O
with	O
SAB	B-T038
via	O
a	O
patient	O
scoring	B-T074
tool	I-T074
integrated	O
into	O
the	O
electronic	B-T170
medical	I-T170
record	I-T170
.	O

Pharmacists	B-T097
utilized	O
the	O
scoring	B-T074
tool	I-T074
and	O
the	O
institution	B-T092
'	I-T092
s	I-T092
evidence	O
-	O
based	O
practice	O
guideline	B-T170
to	O
make	O
standardized	O
recommendations	O
to	O
promote	O
adherence	O
to	O
SAB	B-T038
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
measures	O
and	O
encourage	O
ID	B-T038
consultation	B-T058
.	O

The	O
primary	O
outcome	O
was	O
overall	O
compliance	B-T033
along	O
with	O
adherence	O
to	O
individual	B-T098
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
components	O
.	O

Secondary	O
clinical	O
outcomes	O
were	O
also	O
analyzed	B-T062
.	O

84	O
patients	O
were	O
identified	O
for	O
study	B-T062
inclusion	O
,	O
45	O
in	O
the	O
pre	O
-	O
intervention	B-T058
and	O
39	O
in	O
the	O
intervention	B-T058
group	O
.	O

As	O
a	O
whole	O
,	O
all	O
four	O
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
components	O
for	O
the	O
management	B-T058
of	O
SAB	B-T038
were	O
significantly	O
more	O
frequently	O
adhered	O
to	O
in	O
the	O
intervention	B-T058
group	O
(	O
68	O
.	O
9	O
%	O
vs	O
.	O

92	O
.	O
3	O
%	O
;	O
P	O
=	O
0	O
.	O
008	O
)	O
.	O

The	O
incidence	O
of	O
ID	B-T038
consult	B-T058
improved	B-T033
significantly	O
by	O
almost	O
20	O
%	O
in	O
the	O
intervention	B-T058
group	O
(	O
75	O
.	O
6	O
%	O
vs	O
.	O

94	O
.	O
9	O
%	O
,	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
in	O
duration	O
of	O
bacteremia	B-T038
,	O
length	O
-	O
of	O
-	O
stay	O
,	O
infection	B-T038
-	O
related	O
length	O
-	O
of	O
-	O
stay	O
,	O
or	O
readmission	B-T058
were	O
observed	O
between	O
the	O
groups	O
.	O

The	O
incidence	O
of	O
all	O
-	O
cause	O
mortality	O
was	O
6	O
-	O
fold	O
higher	O
in	O
the	O
pre	O
-	O
intervention	B-T058
group	O
compared	O
to	O
the	O
intervention	B-T058
group	O
(	O
15	O
.	O
6	O
%	O
vs	O
.	O

2	O
.	O
6	O
%	O
,	O
P	O
=	O
0	O
.	O
063	O
)	O
.	O

An	O
automated	O
,	O
pharmacist	B-T097
-	O
driven	O
intervention	B-T058
for	O
the	O
management	B-T058
of	O
patients	O
with	O
SAB	B-T038
demonstrated	O
a	O
significant	O
improvement	O
in	O
patients	O
receiving	O
an	O
ID	B-T038
consult	B-T058
,	O
targeted	O
antimicrobial	B-T103
therapy	I-T103
,	O
and	O
adherence	O
to	O
all	O
SAB	B-T038
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
care	I-T058
measures	O
.	O

As	O
antimicrobial	B-T058
stewardship	I-T058
becomes	O
a	O
mandatory	O
aspect	O
of	O
healthcare	B-T058
in	O
all	O
hospitals	B-T092
in	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	I-T082
,	O
ASPs	B-T058
will	O
be	O
forced	O
to	O
find	B-T033
ways	O
to	O
provide	O
more	O
efficient	O
,	O
impactful	O
,	O
disease	B-T038
state	O
-	O
based	O
patient	B-T058
care	I-T058
.	O

Our	O
study	B-T062
provides	O
the	O
framework	O
for	O
and	O
data	O
to	O
support	O
this	O
intervention	B-T058
in	O
one	O
of	O
the	O
most	O
clinically	O
important	O
infectious	B-T038
diseases	I-T038
.	O

Involvement	O
of	O
intracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
signaling	B-T038
in	O
LTP	B-T038
at	O
perforant	B-T017
pathway	I-T017
-	O
CA1	B-T017
pyramidal	I-T017
cell	I-T017
synapse	I-T017

Physiological	O
significance	O
of	O
synaptic	B-T038
Zn	I-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
signaling	I-T038
was	O
examined	O
at	O
perforant	B-T017
pathway	I-T017
-	O
CA1	B-T017
pyramidal	I-T017
cell	I-T017
synapses	I-T017
.	O

In	B-T082
vivo	I-T082
long	B-T038
-	I-T038
term	I-T038
potentiation	I-T038
(	O
LTP	B-T038
)	O
at	O
perforant	B-T017
pathway	I-T017
-	O
CA1	B-T017
pyramidal	I-T017
cell	I-T017
synapses	I-T017
was	O
induced	O
using	O
a	O
recording	O
electrode	B-T074
attached	O
to	O
a	O
microdialysis	B-T058
probe	B-T074
and	O
the	O
recording	O
region	O
was	O
locally	O
perfused	B-T058
with	O
artificial	B-T103
cerebrospinal	I-T103
fluid	I-T103
(	O
ACSF	B-T103
)	O
via	O
the	O
microdialysis	B-T058
probe	B-T074
.	O

Perforant	B-T017
pathway	I-T017
LTP	B-T038
was	O
not	O
attenuated	O
under	O
perfusion	B-T058
with	O
CaEDTA	B-T103
(	O
10	O
mM	O
)	O
,	O
an	O
extracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
chelator	O
,	O
but	O
attenuated	O
under	O
perfusion	B-T058
with	O
ZnAF	B-T103
-	I-T103
2DA	I-T103
(	O
50	O
μM	O
)	O
,	O
an	O
intracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
chelator	O
,	O
suggesting	O
that	O
intracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
signaling	B-T038
is	O
required	O
for	O
perforant	B-T017
pathway	I-T017
LTP	B-T038
.	O

Even	O
in	O
rat	B-T017
brain	I-T017
slices	I-T017
bathed	O
in	O
CaEDTA	B-T103
in	O
ACSF	B-T103
,	O
intracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
level	O
,	O
which	O
was	O
measured	O
with	O
intracellular	B-T017
ZnAF	B-T103
-	I-T103
2	I-T103
,	O
was	O
increased	O
in	O
the	O
stratum	O
lacunosum	O
-	O
moleculare	O
where	O
perforant	B-T017
pathway	I-T017
-	O
CA1	B-T017
pyramidal	I-T017
cell	I-T017
synapses	I-T017
were	O
contained	O
after	O
tetanic	B-T058
stimulation	I-T058
.	O

These	O
results	O
suggest	O
that	O
intracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
signaling	B-T038
,	O
which	O
originates	O
in	O
internal	O
stores	O
/	O
proteins	B-T103
,	O
is	O
involved	O
in	O
LTP	B-T038
at	O
perforant	B-T017
pathway	I-T017
-	O
CA1	B-T017
pyramidal	I-T017
cell	I-T017
synapses	I-T017
.	O

Because	O
the	O
influx	B-T038
of	O
extracellular	B-T017
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
,	O
which	O
originates	O
in	O
presynaptic	B-T038
Zn	I-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
release	I-T038
,	O
is	O
involved	O
in	O
LTP	B-T038
at	O
Schaffer	B-T017
collateral	I-T017
-	O
CA1	B-T017
pyramidal	I-T017
cell	I-T017
synapses	I-T017
,	O
synapse	B-T082
-	O
dependent	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
dynamics	O
may	O
be	O
involved	O
in	O
plasticity	B-T038
of	O
postsynaptic	O
CA1	B-T017
pyramidal	I-T017
cells	I-T017
.	O

20S	B-T103
immunoproteasomes	I-T103
remove	O
formaldehyde	B-T103
-	O
damaged	O
cytoplasmic	B-T103
proteins	I-T103
suppressing	O
caspase	B-T038
-	I-T038
independent	I-T038
cell	I-T038
death	I-T038

Immunoproteasomes	B-T103
are	O
known	O
for	O
their	O
involvement	O
in	O
antigen	B-T038
presentation	I-T038
.	O

However	O
,	O
their	O
broad	B-T082
tissue	B-T017
presence	B-T033
and	O
other	O
evidence	O
are	O
indicative	O
of	O
nonimmune	B-T038
functions	I-T038
.	O

We	O
examined	O
a	O
role	O
for	O
immunoproteasomes	B-T103
in	O
cellular	B-T038
responses	I-T038
to	O
the	O
endogenous	O
and	O
environmental	B-T103
carcinogen	I-T103
formaldehyde	B-T103
(	O
FA	B-T103
)	O
that	O
binds	O
to	O
cytosolic	B-T017
and	O
nuclear	B-T103
proteins	I-T103
producing	O
proteotoxic	B-T038
stress	I-T038
and	O
genotoxic	O
DNA	B-T103
-	O
histone	B-T103
crosslinks	O
.	O

We	O
found	O
that	O
immunoproteasomes	B-T103
were	O
important	O
for	O
suppression	O
of	O
a	O
caspase	B-T038
-	I-T038
independent	I-T038
cell	I-T038
death	I-T038
and	O
the	O
long	O
-	O
term	O
survival	O
of	O
FA	B-T017
-	I-T017
treated	I-T017
cells	I-T017
.	O

All	O
major	O
genotoxic	O
responses	O
to	O
FA	B-T103
,	O
including	O
replication	B-T038
inhibition	I-T038
and	O
activation	O
of	O
the	O
transcription	B-T103
factor	I-T103
p53	I-T103
and	O
the	O
apical	B-T082
ATM	B-T103
and	O
ATR	B-T103
kinases	I-T103
,	O
were	O
unaffected	O
by	O
immunoproteasome	B-T103
inactivity	O
.	O

Immunoproteasome	O
inhibition	O
enhanced	O
activation	O
of	O
the	O
cytosolic	B-T017
protein	B-T103
damage	O
sensor	B-T103
HSF1	I-T103
,	O
elevated	O
levels	O
of	O
K48	B-T038
-	I-T038
polyubiquitinated	I-T038
cytoplasmic	B-T103
proteins	I-T103
and	O
increased	O
depletion	O
of	O
unconjugated	O
ubiquitin	B-T103
.	O

We	O
further	O
found	O
that	O
FA	B-T103
induced	O
the	O
disassembly	O
of	O
26S	B-T103
immunoproteasomes	I-T103
,	O
but	O
not	O
standard	O
26S	B-T103
proteasomes	I-T103
,	O
releasing	O
the	O
20S	B-T103
catalytic	I-T103
immunoproteasome	I-T103
.	O

FA	B-T017
-	I-T017
treated	I-T017
cells	I-T017
also	O
had	O
higher	O
amounts	O
of	O
small	O
activators	B-T103
PA28αβ	I-T103
and	O
PA28γ	B-T103
bound	O
to	O
20S	B-T103
particles	I-T103
.	O

Our	O
findings	O
highlight	O
the	O
significance	O
of	O
nonnuclear	O
damage	O
in	O
FA	B-T103
injury	O
and	O
reveal	O
a	O
major	O
role	O
for	O
immunoproteasomes	B-T103
in	O
elimination	O
of	O
FA	O
-	O
damaged	O
cytoplasmic	B-T103
proteins	I-T103
through	O
ubiquitin	B-T103
-	O
independent	O
proteolysis	B-T038
.	O

Musculoskeletal	B-T033
pain	I-T033
profile	B-T170
of	O
obese	B-T038
individuals	B-T098
attending	O
a	O
multidisciplinary	O
weight	O
management	O
service	O

Obesity	B-T038
is	O
associated	O
with	O
numerous	O
chronic	B-T038
diseases	I-T038
,	O
including	O
musculoskeletal	B-T033
(	I-T033
MSK	I-T033
)	I-T033
pain	I-T033
,	O
which	O
impacts	O
on	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
.	O

There	O
is	O
,	O
however	O
,	O
limited	O
research	O
providing	O
a	O
comprehensive	O
MSK	B-T033
pain	I-T033
profile	B-T170
of	O
an	O
obese	B-T038
cohort	B-T098
.	O

This	O
retrospective	B-T062
study	I-T062
utilized	O
a	O
patient	O
database	B-T170
at	O
a	O
national	O
weight	O
management	O
service	O
(	O
WMS	O
)	O
.	O

Following	O
ethical	O
approval	B-T170
,	O
anonymized	O
patient	O
data	O
were	O
statistically	O
analyzed	O
to	O
develop	O
a	O
pain	B-T033
profile	B-T170
,	O
investigate	O
relationships	O
between	O
pain	B-T033
,	O
sleep	B-T038
,	O
and	O
function	B-T033
,	O
and	O
explore	O
variables	O
associated	O
with	O
having	O
low	B-T033
back	I-T033
pain	I-T033
(	O
LBP	B-T033
)	O
and	O
knee	B-T033
pain	I-T033
.	O

Overall	O
,	O
915	O
individuals	B-T098
attended	O
the	O
WMS	O
from	O
January	O
2011	O
to	O
September	O
2015	O
[	O
male	B-T098
,	O
35	O
%	O
(	O
n	O
=	O
318	O
;	O
CI	O
=	O
32	O
-	O
38	O
)	O
;	O
female	B-T098
,	O
65	O
%	O
(	O
n	O
=	O
597	O
;	O
CI	O
=	O
62	O
-	O
68	O
)	O
;	O
mean	O
age	O
44	O
.	O
6	O
]	O
.	O

Mean	O
BMI	B-T201
was	O
50	O
.	O
7	O
kg	O
/	O
m2	O
[	O
Class	O
III	O
obese	B-T038
(	O
BMI	B-T201
≥40	O
kg	O
/	O
m2	O
)	O
,	O
92	O
%	O
(	O
n	O
=	O
835	O
;	O
CI	O
=	O
91	O
-	O
94	O
)	O
]	O
.	O

Approximately	O
91	O
%	O
reported	O
MSK	B-T033
pain	I-T033
:	O
LBP	B-T033
,	O
69	O
%	O
(	O
n	O
=	O
539	O
;	O
CI	O
=	O
65	O
-	O
72	O
)	O
[	O
mean	O
NRS	O
7	O
.	O
4	O
]	O
;	O
knee	B-T033
pain	I-T033
,	O
58	O
%	O
(	O
n	O
=	O
447	O
;	O
CI	O
=	O
55	O
-	O
61	O
)	O
[	O
mean	O
NRS	O
6	O
.	O
8	O
]	O
.	O

Class	O
III	O
obese	B-T038
and	O
multi	O
-	O
site	O
pain	B-T033
patients	O
had	O
lower	O
QoL	O
and	O
physical	O
activity	O
levels	O
,	O
reduced	O
sleep	B-T038
,	O
and	O
poorer	O
physical	B-T033
function	I-T033
than	O
less	O
obese	B-T038
patients	O
and	O
those	O
without	O
pain	B-T033
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Relationships	O
were	O
found	O
between	O
demographic	O
,	O
pain	B-T033
,	O
self	B-T062
-	I-T062
report	I-T062
,	O
psychological	O
,	O
and	O
functional	O
measures	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Patients	O
who	O
slept	B-T033
fewer	I-T033
hours	I-T033
and	O
had	O
poorer	O
functional	B-T033
outcomes	I-T033
were	O
more	O
likely	O
to	O
have	O
LBP	B-T033
;	O
patients	O
who	O
were	O
divorced	B-T033
,	O
had	O
lower	O
QoL	O
,	O
and	O
more	O
frequent	O
nocturia	B-T038
were	O
more	O
likely	O
to	O
have	O
knee	B-T033
pain	I-T033
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Multi	O
-	O
site	O
MSK	B-T033
pain	I-T033
is	O
prevalent	O
and	O
severe	O
in	O
obese	B-T038
patients	O
and	O
is	O
negatively	B-T033
associated	O
with	O
most	O
self	O
-	O
report	O
and	O
functional	B-T033
outcomes	I-T033
.	O

This	O
high	O
prevalence	O
suggests	O
pain	B-T058
management	I-T058
strategies	O
must	O
be	O
considered	O
when	O
treating	B-T058
obesity	B-T038
.	O

Primary	O
Management	B-T058
and	O
Outcome	O
-	O
Open	B-T037
Laryngotracheal	I-T037
Trauma	I-T037

Acute	O
external	O
injury	O
to	O
the	O
larynx	B-T017
is	O
both	O
life	B-T033
threatening	I-T033
and	O
a	O
potential	O
long	O
term	O
management	O
challenge	O
.	O

As	O
Otorhinolaryngologist	B-T097
we	O
must	O
be	O
prepared	O
and	O
well	O
versed	O
to	O
manage	O
these	O
patients	O
.	O

In	O
our	O
study	O
seven	O
patients	O
of	O
open	B-T037
laryngeal	I-T037
traumas	I-T037
were	O
managed	O
by	O
primary	B-T058
closure	I-T058
.	O

In	O
five	O
patients	O
nature	B-T037
of	I-T037
injury	I-T037
was	O
known	O
in	O
other	O
two	O
patients	O
exact	O
nature	B-T037
of	I-T037
injury	I-T037
was	O
not	O
known	O
.	O

After	O
primary	B-T058
closure	I-T058
five	O
patients	O
with	O
known	O
injury	B-T037
survived	O
and	O
two	O
patients	O
with	O
unknown	O
injury	B-T037
died	B-T038
.	O

As	O
per	O
our	O
experience	B-T033
,	O
we	O
recommend	O
primary	B-T058
closure	I-T058
,	O
if	O
the	O
exact	O
nature	B-T037
of	I-T037
injury	I-T037
is	O
known	O
as	O
the	O
outcome	O
is	O
definitely	O
favourable	B-T033
.	O

Comparative	O
kinematic	B-T058
gait	I-T058
analysis	I-T058
in	O
young	O
and	O
old	O
Beagle	B-T204
dogs	I-T204

Age	O
-	O
related	O
involution	B-T038
in	O
dogs	B-T204
involves	O
loss	B-T033
of	I-T033
muscle	I-T033
mass	I-T033
and	O
changes	O
in	O
connective	B-T017
tissue	I-T017
and	O
articular	B-T017
cartilage	I-T017
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-T033
whether	O
an	O
age	O
-	O
related	O
influence	O
on	O
joint	O
mobility	O
can	O
be	O
detected	B-T033
in	O
the	O
absence	O
of	O
diseases	B-T038
.	O

Five	O
young	O
(	O
Ø	O
2	O
.	O
0	O
years	O
)	O
and	O
five	O
old	O
(	O
Ø	O
10	O
.	O
4	O
years	O
)	O
healthy	O
and	O
sound	B-T204
Beagle	I-T204
dogs	I-T204
were	O
measured	O
during	O
locomotion	B-T038
on	O
a	O
treadmill	O
by	O
computer	O
-	O
assisted	O
gait	B-T058
analysis	I-T058
.	O

Angles	B-T082
of	O
the	O
shoulder	B-T082
,	O
elbow	B-T082
,	O
carpal	B-T082
,	O
hip	B-T082
,	O
stifle	B-T082
and	O
tarsal	B-T082
joints	I-T082
were	O
analyzed	B-T062
,	O
including	O
joint	O
angle	O
progression	O
curves	O
,	O
minimum	O
and	O
maximum	O
joint	B-T082
angles	B-T082
and	O
range	B-T201
of	I-T201
motion	I-T201
(	O
ROM	B-T201
)	O
.	O

The	O
old	O
group	O
showed	O
a	O
smaller	O
maximum	O
joint	B-T082
angle	B-T082
(	O
p	O
=	O
0	O
.	O
037	O
)	O
and	O
ROM	B-T201
(	O
p	O
=	O
0	O
.	O
037	O
)	O
of	O
the	O
carpal	B-T082
joint	I-T082
and	O
similar	O
tendencies	O
in	O
the	O
shoulder	B-T082
,	O
elbow	B-T082
and	O
carpal	B-T082
joint	I-T082
.	O

The	O
descriptive	B-T170
analysis	I-T170
of	O
the	O
progression	O
curves	O
revealed	O
less	B-T033
flexion	I-T033
and	O
extension	O
of	O
the	O
joints	B-T082
of	O
the	O
forelimb	B-T082
.	O

This	O
indicates	O
restricted	O
joint	O
mobility	O
of	O
the	O
forelimb	B-T082
but	O
primarily	O
of	O
the	O
carpal	B-T082
joint	I-T082
.	O

Findings	O
in	O
the	O
joints	B-T082
of	O
the	O
hindlimb	B-T017
were	O
not	O
consistent	O
;	O
contrasting	O
alterations	O
may	O
be	O
due	O
to	O
a	O
compensatory	O
mechanism	O
.	O

As	O
most	O
alterations	O
were	O
found	B-T033
in	O
the	O
distal	B-T082
joints	I-T082
,	O
these	O
should	O
receive	O
particular	B-T038
attention	I-T038
when	O
examining	O
elderly	B-T204
dogs	I-T204
.	O

Propensity	O
Score	O
Matched	O
Comparison	O
of	O
Partial	O
to	O
Whole	O
Gland	B-T017
Cryotherapy	B-T058
for	O
Intermediate	B-T033
-	I-T033
Risk	I-T033
Prostate	B-T038
Cancer	I-T038
:	O
An	O
analysis	B-T062
of	O
the	O
COLD	B-T170
registry	I-T170
data	I-T170

To	O
compare	O
the	O
oncological	B-T038
and	O
functional	O
outcomes	O
of	O
partial	O
versus	O
whole	O
-	O
gland	B-T017
cryotherapy	B-T058
for	O
men	B-T098
with	O
intermediate	B-T033
-	I-T033
risk	I-T033
prostate	B-T038
cancer	I-T038
.	O

Men	B-T098
with	O
intermediate	B-T033
-	I-T033
risk	I-T033
prostate	B-T038
cancer	I-T038
treated	B-T058
with	I-T058
primary	O
prostate	B-T058
cryotherapy	I-T058
from	O
1993	O
-	O
2013	O
were	O
selected	O
from	O
the	O
Cryo	B-T170
On	I-T170
-	I-T170
Line	I-T170
Data	I-T170
Registry	I-T170
for	O
a	O
1	O
:	O
1	O
matched	B-T062
comparison	O
between	O
those	O
undergoing	O
whole	O
-	O
gland	B-T017
and	O
partial	O
prostate	B-T058
cryotherapy	I-T058
(	O
targeted	B-T058
-	I-T058
ablation	I-T058
,	O
unilateral	B-T058
/	I-T058
bilateral	I-T058
nerve	I-T058
-	I-T058
sparing	I-T058
ablations	I-T058
)	O
.	O

A	O
propensity	O
score	O
was	O
developed	O
based	O
on	O
age	O
,	O
pre	B-T031
-	I-T031
biopsy	I-T031
serum	I-T031
PSA	B-T103
,	O
biopsy	O
Gleason	O
score	O
,	O
clinical	O
stage	O
,	O
prostate	O
volume	O
,	O
neoadjuvant	B-T058
androgen	I-T058
deprivation	I-T058
status	O
,	O
year	O
of	O
surgery	B-T058
and	O
pre	O
-	O
treatment	O
potency	O
.	O

Outcomes	O
were	O
biochemical	B-T170
progression	O
-	O
free	O
survival	O
(	O
BPFS	O
)	O
using	O
ASTRO	O
and	O
Phoenix	O
criteria	O
,	O
12	O
-	O
month	O
continence	B-T038
(	O
strictly	O
pad	O
-	O
free	O
)	O
and	O
sexual	B-T038
function	I-T038
(	O
potency	O
sufficient	O
for	O
sexual	B-T038
intercourse	I-T038
)	O
.	O

After	O
propensity	O
score	O
-	O
matching	B-T062
,	O
BPFS	O
was	O
compared	O
using	O
Kaplan	O
-	O
Meier	O
analysis	O
and	O
functional	O
outcomes	O
using	O
chi	B-T170
-	I-T170
square	I-T170
tests	I-T170
.	O

In	O
all	O
,	O
897	O
men	B-T098
were	O
identified	O
(	O
731	O
whole	O
-	O
gland	B-T017
and	O
166	O
partial	O
)	O
.	O

Post	O
-	O
matching	O
,	O
166	O
pairs	O
of	O
men	B-T098
were	O
analysed	B-T062
(	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
31	O
months	O
)	O
.	O

The	O
2	O
/	O
5	O
year	O
BPFS	O
rate	O
was	O
87	O
.	O
2	O
%	O
/	O
76	O
.	O
4	O
%	O
for	O
whole	O
-	O
gland	B-T017
vs	O
.	O

80	O
.	O
7	O
%	O
/	O
70	O
.	O
0	O
%	O
for	O
partial	O
ablation	B-T058
using	O
Phoenix	O
(	O
p	O
=	O
0	O
.	O
26	O
)	O
and	O
72	O
.	O
3	O
%	O
/	O
69	O
.	O
6	O
%	O
for	O
whole	O
gland	B-T017
vs	O
.	O

82	O
.	O
1	O
%	O
/	O
75	O
.	O
0	O
%	O
for	O
partial	O
ablation	B-T058
using	O
ASTRO	O
criteria	O
(	O
p	O
=	O
0	O
.	O
10	O
)	O
.	O

Of	O
164	O
pairs	O
,	O
the	O
12	O
-	O
month	O
continence	B-T038
rate	O
was	O
similar	O
94	O
.	O
1	O
%	O
vs	O
.	O

95	O
.	O
1	O
%	O
(	O
p	O
=	O
0	O
.	O
803	O
)	O
.	O

Of	O
139	O
pairs	O
,	O
the	O
12	O
-	O
month	O
rate	O
of	O
successful	O
intercourse	B-T038
was	O
29	O
.	O
5	O
%	O
for	O
whole	O
-	O
gland	B-T017
and	O
46	O
.	O
8	O
%	O
for	O
partial	O
ablation	B-T058
(	O
OR	O
2	O
.	O
1	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O

The	O
incidence	O
of	O
post	O
-	O
treatment	O
urinary	B-T033
retention	I-T033
was	O
6	O
.	O
0	O
%	O
and	O
6	O
.	O
6	O
%	O
(	O
p	O
=	O
0	O
.	O
88	O
)	O
following	O
whole	O
-	O
gland	B-T017
and	O
partial	O
ablation	B-T058
respectively	O
and	O
that	O
of	O
rectourethral	B-T038
fistula	I-T038
was	O
1	O
.	O
2	O
%	O
and	O
0	O
%	O
(	O
p	O
=	O
0	O
.	O
50	O
)	O
Conclusion	O
:	O
Partial	O
ablation	B-T058
results	O
in	O
better	O
post	O
-	O
treatment	O
sexual	B-T038
function	I-T038
compared	O
to	O
whole	O
-	O
gland	B-T017
ablation	B-T058
in	O
men	B-T098
with	O
intermediate	B-T033
-	I-T033
risk	I-T033
prostate	B-T038
cancer	I-T038
.	O

We	O
did	O
not	O
observe	O
a	O
difference	O
in	O
early	O
BPFS	O
between	O
the	O
two	O
groups	O
.	O

Abnormal	B-T033
metabolic	O
brain	B-T017
network	B-T038
associated	O
with	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
:	O
replication	O
on	O
a	O
new	O
European	B-T098
sample	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
identify	O
the	O
specific	O
metabolic	O
brain	B-T017
pattern	B-T082
characteristic	O
for	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
:	O
Parkinson	O
'	O
s	O
disease	O
-	O
related	O
pattern	O
(	O
PDRP	O
)	O
,	O
using	O
network	B-T038
analysis	O
of	O
[	O
18F	O
]	O
-	O
fluorodeoxyglucose	O
positron	O
emission	O
tomography	O
(	O
FDG	O
-	O
PET	O
)	O
brain	B-T017
images	B-T170
in	O
a	O
cohort	B-T098
of	O
Slovenian	B-T082
PD	B-T038
patients	O
.	O

Twenty	O
PD	B-T038
patients	O
(	O
age	O
70	O
.	O
1	O
±	O
7	O
.	O
8	O
years	O
,	O
Movement	B-T170
Disorder	I-T170
Society	I-T170
Unified	I-T170
Parkinson	I-T170
'	I-T170
s	I-T170
Disease	I-T170
Motor	I-T170
Rating	I-T170
Scale	I-T170
(	O
MDS	B-T170
-	I-T170
UPDRS	I-T170
-	I-T170
III	I-T170
)	O
38	O
.	O
3	O
±	O
12	O
.	O
2	O
;	O
disease	O
duration	O
4	O
.	O
3	O
±	O
4	O
.	O
1	O
years	O
)	O
and	O
20	O
age	O
-	O
matched	O
normal	O
controls	O
(	O
NCs	O
)	O
underwent	O
FDG	O
-	O
PET	O
brain	B-T058
imaging	I-T058
.	O

An	O
automatic	O
voxel	O
-	O
based	O
scaled	O
subprofile	O
model	O
/	O
principal	O
component	O
analysis	O
(	O
SSM	O
/	O
PCA	O
)	O
was	O
applied	O
to	O
these	O
scans	B-T058
for	O
PDRP	O
-	O
Slovenia	B-T082
identification	O
.	O

The	O
pattern	O
was	O
characterized	O
by	O
relative	O
hypermetabolism	B-T033
in	O
pallidum	B-T017
,	O
putamen	B-T017
,	O
thalamus	B-T017
,	O
brain	B-T017
stem	I-T017
,	O
and	O
cerebellum	B-T017
associated	O
with	O
hypometabolism	B-T033
in	O
sensorimotor	B-T017
cortex	I-T017
,	O
posterior	B-T017
parietal	I-T017
,	O
occipital	B-T082
,	O
and	O
frontal	B-T017
cortices	I-T017
.	O

The	O
expression	O
of	O
PDRP	O
-	O
Slovenia	B-T082
discriminated	O
PD	B-T038
patients	O
from	O
NCs	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
correlated	O
positively	O
with	O
patients	O
'	O
clinical	O
score	O
(	O
MDS	B-T170
-	I-T170
UPDRS	I-T170
-	I-T170
III	I-T170
,	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Additionally	O
,	O
its	O
topography	B-T170
agrees	O
well	O
with	O
the	O
original	O
PDRP	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
identified	O
in	O
American	B-T098
cohort	B-T098
of	O
PD	B-T038
patients	O
.	O

We	O
validated	O
the	O
PDRP	O
-	O
Slovenia	B-T082
expression	O
on	O
additional	O
FDG	O
-	O
PET	O
scans	B-T058
of	O
20	O
PD	B-T038
patients	O
,	O
20	O
NCs	O
,	O
and	O
25	O
patients	O
with	O
atypical	B-T038
parkinsonism	I-T038
(	O
AP	B-T038
)	O
.	O

We	O
confirmed	O
that	O
the	O
expression	O
of	O
PDRP	O
-	O
Slovenia	B-T082
manifests	O
good	O
diagnostic	O
accuracy	O
with	O
specificity	O
and	O
sensitivity	O
of	O
85	O
-	O
90	O
%	O
at	O
optimal	O
pattern	O
expression	O
cutoff	O
for	O
discrimination	O
of	O
PD	B-T038
patients	O
and	O
NCs	O
and	O
is	O
not	O
expressed	O
in	O
AP	B-T038
.	O

PDRP	O
-	O
Slovenia	B-T082
proves	O
to	O
be	O
a	O
robust	O
and	O
reproducible	O
functional	B-T058
imaging	I-T058
biomarker	B-T201
independent	O
of	O
patient	O
population	B-T098
.	O

It	O
accurately	O
differentiates	O
PD	B-T038
patients	O
from	O
NCs	O
and	O
AP	B-T038
and	O
correlates	O
well	O
with	O
the	O
clinical	O
measure	O
of	O
PD	B-T038
progression	B-T038
.	O

The	O
effects	O
of	O
gestational	O
use	O
of	O
antidepressants	B-T103
and	O
antipsychotics	B-T103
on	O
neonatal	O
outcomes	O
for	O
women	B-T098
with	O
severe	O
mental	B-T038
illness	I-T038

Psychotropic	B-T103
medication	I-T103
use	O
occurs	O
in	O
8	O
%	O
of	O
pregnancies	B-T038
,	O
with	O
rates	O
increasing	O
,	O
and	O
often	O
multiple	O
medications	B-T103
prescribed	O
.	O

This	O
study	B-T062
aims	O
to	O
determine	O
if	O
the	O
use	O
of	O
psychotropic	B-T103
medication	I-T103
,	O
in	O
a	O
cohort	B-T098
of	O
women	B-T098
with	O
severe	O
mental	B-T038
illness	I-T038
,	O
increases	O
rates	O
of	O
special	B-T058
care	I-T058
nursery	I-T058
admission	B-T058
and	O
reports	B-T170
differences	O
between	O
antidepressant	B-T103
and	O
antipsychotic	B-T103
medication	I-T103
use	O
either	O
alone	O
or	O
in	O
combination	B-T103
.	O

A	O
retrospective	B-T062
database	I-T062
analysis	I-T062
from	I-T062
a	I-T062
cohort	I-T062
with	O
severe	O
mental	B-T038
illness	I-T038
in	O
pregnancy	B-T038
identified	O
268	O
pregnant	B-T098
women	I-T098
who	O
were	O
grouped	B-T170
according	O
to	O
medication	B-T103
type	O
.	O

Demographic	O
,	O
obstetric	O
and	O
neonatal	O
variables	O
were	O
analysed	B-T062
using	O
t	B-T170
-	I-T170
tests	I-T170
,	O
χ	O
(	O
2	O
)	O
,	O
analysis	B-T062
of	O
variance	O
and	O
logistic	O
regression	O
analysis	O
for	O
special	B-T058
care	I-T058
nursery	I-T058
admission	B-T058
.	O

The	O
medication	O
groups	O
consisted	O
of	O
:	O
women	B-T098
taking	O
no	O
psychotropic	O
medications	O
(	O
n	O
=	O
67	O
)	O
;	O
those	O
taking	O
antipsychotics	O
(	O
n	O
=	O
87	O
)	O
;	O
those	O
taking	O
antidepressants	O
(	O
n	O
=	O
55	O
)	O
;	O
those	O
taking	O
and	O
a	O
combination	O
of	O
antidepressants	O
/	O
antipsychotics	O
(	O
n	O
=	O
59	O
)	O
.	O

Rates	O
of	O
special	B-T058
care	I-T058
nursery	I-T058
admission	B-T058
in	O
women	B-T098
who	O
took	O
psychotropic	B-T103
medication	I-T103
(	O
41	O
.	O
3	O
%	O
)	O
were	O
elevated	O
compared	O
to	O
those	O
who	O
did	O
not	O
(	O
26	O
.	O
9	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
and	O
were	O
significantly	O
raised	O
when	O
compared	O
to	O
the	O
general	B-T098
population	I-T098
(	O
P	O
<	O
0	O
.	O
000	O
)	O
.	O

No	O
significant	O
difference	O
occurred	O
between	O
the	O
medication	O
groups	O
.	O

A	O
significant	O
adjusted	O
odds	O
ratio	O
of	O
2	O
.	O
79	O
(	O
95	O
%	O
CI	O
1	O
.	O
286	O
-	O
6	O
.	O
049	O
)	O
was	O
found	B-T033
for	O
special	B-T058
care	I-T058
nursery	I-T058
and	O
psychiatric	B-T058
admission	I-T058
during	O
pregnancy	B-T038
but	O
not	O
for	O
psychotropic	B-T103
medication	I-T103
.	O

Rates	O
of	O
special	B-T058
care	I-T058
nursery	I-T058
admission	B-T058
are	O
elevated	O
in	O
neonates	O
of	O
women	B-T098
with	O
severe	O
mental	B-T038
illness	I-T038
taking	O
psychotropic	B-T103
medication	I-T103
,	O
but	O
were	O
not	O
different	O
for	O
monotherapy	O
or	O
polytherapy	B-T058
when	O
prescribing	O
antidepressants	B-T103
or	O
antipsychotic	B-T103
medication	I-T103
.	O

Additional	O
vulnerability	O
occurs	O
in	O
the	O
neonates	O
of	O
women	B-T098
with	O
a	O
mental	B-T038
illness	I-T038
and	O
paediatric	B-T097
presence	O
at	O
delivery	B-T038
is	O
recommended	O
.	O

Does	O
Intrawound	B-T103
Vancomycin	I-T103
Application	O
During	O
Spine	B-T058
Surgery	I-T058
Create	O
Vancomycin	O
-	O
Resistant	O
Organism	O
?	O

Surgical	B-T038
site	I-T038
infection	I-T038
(	O
SSI	B-T038
)	O
following	O
spine	B-T058
surgery	I-T058
is	O
a	O
morbid	O
and	O
expensive	O
complication	O
.	O

The	O
use	O
of	O
intrawound	B-T103
vancomycin	I-T103
is	O
emerging	O
as	O
a	O
solution	O
to	O
reduce	O
SSI	B-T038
.	O

The	O
development	O
of	O
vancomycin	O
-	O
resistant	O
pathogens	O
is	O
an	O
understandable	O
concern	O
.	O

To	O
determine	O
the	O
occurrence	O
of	O
vancomycin	O
-	O
resistant	O
SSI	B-T038
in	O
patients	O
with	O
and	O
without	O
use	O
of	O
intrawound	B-T103
vancomycin	I-T103
.	O

Patients	O
undergoing	O
elective	O
spine	B-T058
surgery	I-T058
were	O
dichotomized	O
based	O
on	O
whether	O
intrawound	B-T103
vancomycin	I-T103
was	O
applied	O
.	O

Outcome	O
was	O
occurrence	O
of	O
SSI	B-T038
requiring	O
return	O
to	O
the	O
operating	B-T092
room	I-T092
within	O
postoperative	O
90	O
days	O
.	O

The	O
intrawound	O
culture	O
and	O
vancomycin	B-T103
minimal	B-T058
inhibitory	I-T058
concentrations	I-T058
(	O
MIC	B-T058
)	O
were	O
reviewed	O
.	O

Analyses	O
were	O
conducted	O
to	O
compare	O
the	O
pathogen	O
profile	O
and	O
MIC	B-T058
for	O
vancomycin	B-T103
in	O
patients	O
who	O
received	O
vancomycin	B-T103
and	O
those	O
who	O
did	O
not	O
.	O

Of	O
the	O
total	O
2802	O
patients	O
,	O
43	O
%	O
(	O
n	O
=	O
1215	O
)	O
had	O
intrawound	B-T103
vancomycin	I-T103
application	O
during	O
the	O
index	O
surgery	O
.	O

The	O
use	O
of	O
vancomycin	B-T103
was	O
associated	O
with	O
significantly	O
lower	O
deep	O
SSI	B-T038
rates	B-T017
(	O
1	O
.	O
6	O
%	O
[	O
n	O
=	O
20	O
]	O
vs	O
2	O
.	O
5	O
%	O
[	O
n	O
=	O
40	O
]	O
,	O
P	O
=	O
.	O
02	O
)	O
.	O

The	O
occurrence	O
of	O
Staphylococcus	B-T007
aureus	I-T007
SSI	B-T038
was	O
significantly	O
lower	O
in	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	B-T103
vancomycin	I-T103
(	O
32	O
%	O
vs	O
65	O
%	O
,	O
P	O
=	O
.	O
003	O
)	O
.	O

None	O
of	O
the	O
patients	O
who	O
had	O
application	O
of	O
intrawound	B-T103
vancomycin	I-T103
powder	I-T103
,	O
and	O
subsequently	O
developed	O
an	O
S	B-T007
aureus	I-T007
SSI	B-T038
,	O
demonstrated	O
pathogens	O
with	O
resistance	B-T033
to	I-T033
vancomycin	I-T033
.	O

All	O
patients	O
had	O
MIC	B-T058
<	O
2	O
μg	O
/	O
mL	O
,	O
the	O
vancomycin	B-T103
susceptibility	O
threshold	O
.	O

The	O
occurrence	O
of	O
gram	B-T038
-	I-T038
negative	I-T038
SSI	B-T038
(	O
28	O
%	O
vs	O
7	O
%	O
)	O
and	O
culture	B-T033
negative	I-T033
fluid	I-T033
collection	I-T033
(	O
16	O
%	O
vs	O
5	O
%	O
)	O
was	O
higher	O
in	O
the	O
vancomycin	B-T103
cohort	B-T098
.	O

The	O
use	O
of	O
intrawound	B-T103
vancomycin	I-T103
during	O
the	O
index	O
spine	B-T058
surgery	I-T058
was	O
protective	O
against	O
SSI	B-T038
following	O
spine	B-T058
surgery	I-T058
.	O

The	O
application	O
of	O
intrawound	B-T103
vancomycin	I-T103
during	O
index	O
surgery	O
does	O
not	O
appear	O
to	O
create	O
vancomycin	O
-	O
resistant	O
organisms	O
in	O
the	O
event	O
of	O
an	O
SSI	B-T038
.	O

Adequacy	O
criteria	O
for	O
thyroid	B-T058
FNA	I-T058
evaluated	B-T058
by	O
ThinPrep	B-T058
slides	I-T058
only	O

Adequacy	O
criteria	O
for	O
thyroid	B-T058
fine	I-T058
-	I-T058
needle	I-T058
aspiration	I-T058
(	O
FNA	B-T058
)	O
recommended	O
by	O
The	O
Bethesda	B-T058
System	I-T058
for	I-T058
Reporting	I-T058
Thyroid	I-T058
Cytopathology	I-T058
(	O
TBS	B-T058
)	O
were	O
developed	O
with	O
smears	B-T058
,	O
but	O
they	O
are	O
commonly	O
applied	O
to	O
ThinPreps	B-T058
(	O
TPs	B-T058
)	O
.	O

This	O
study	O
evaluated	B-T058
adequacy	O
in	O
TPs	B-T058
at	O
different	O
diagnostic	O
thresholds	O
.	O

All	O
FNA	B-T058
procedures	I-T058
performed	O
between	O
2010	O
and	O
2015	O
with	O
matched	O
surgical	O
specimens	O
were	O
analyzed	B-T062
.	O

Cell	B-T058
counts	I-T058
and	O
cytological	O
features	O
were	O
evaluated	B-T058
in	O
all	O
initially	O
nondiagnostic	B-T033
(	O
ND	B-T033
)	O
cases	O
.	O

ND	B-T033
cases	O
were	O
reclassified	O
into	O
TBS	B-T058
categories	B-T170
by	O
2	O
pathologists	B-T097
,	O
and	O
the	O
results	O
were	O
compared	O
with	O
surgical	O
outcomes	O
.	O

One	O
hundred	O
forty	O
-	O
six	O
of	O
the	O
151	O
cases	O
initially	O
classified	B-T170
as	O
ND	B-T033
were	O
available	O
for	O
review	O
,	O
and	O
they	O
had	O
a	O
mean	O
cell	B-T058
count	I-T058
of	O
60	O
.	O
5	O
(	O
standard	O
deviation	O
,	O
71	O
.	O
4	O
)	O
.	O

Interobserver	O
agreement	O
on	O
the	O
reclassification	B-T170
of	O
ND	B-T033
cases	O
was	O
moderate	O
(	O
k	O
=	O
0	O
.	O
57	O
)	O
,	O
and	O
consensus	O
yielded	O
48	O
ND	B-T033
cases	O
(	O
33	O
%	O
)	O
,	O
72	O
benign	O
cases	O
(	O
49	O
%	O
)	O
,	O
24	O
cases	O
of	O
atypia	B-T033
of	O
undetermined	B-T033
significance	I-T033
(	O
16	O
%	O
)	O
,	O
and	O
2	O
cases	O
suspicious	B-T033
for	I-T033
malignancy	I-T033
(	O
1	O
%	O
)	O
.	O

Lowering	O
the	O
diagnostic	O
threshold	O
to	O
any	O
follicular	B-T017
cells	B-T017
yielded	O
a	O
sensitivity	O
of	O
92	O
%	O
,	O
a	O
specificity	O
of	O
60	O
%	O
,	O
a	O
positive	O
predictive	O
value	O
of	O
59	O
%	O
,	O
a	O
negative	O
predictive	O
value	O
of	O
92	O
%	O
,	O
and	O
a	O
false	B-T033
-	I-T033
negative	I-T033
rate	O
of	O
7	O
.	O
7	O
%	O
,	O
whereas	O
the	O
values	O
for	O
the	O
initially	O
diagnostic	O
cases	O
were	O
93	O
%	O
,	O
58	O
%	O
,	O
59	O
%	O
,	O
93	O
%	O
,	O
and	O
7	O
.	O
7	O
%	O
,	O
respectively	O
.	O

Including	O
cases	O
with	O
>	O
60	O
cells	B-T017
but	O
lacking	O
6	O
groups	O
containing	O
at	O
least	O
10	O
cells	B-T017
did	O
not	O
affect	O
test	O
performance	O
.	O

Nuclear	B-T038
enlargement	I-T038
,	O
pallor	B-T033
,	O
grooves	B-T082
,	O
and	O
the	O
presence	B-T033
of	O
histiocytoid	B-T017
cells	I-T017
in	O
initially	O
ND	B-T033
FNA	B-T058
correlated	O
with	O
malignancy	B-T038
.	O

In	O
thyroid	B-T058
FNA	I-T058
examined	B-T033
with	O
TP	B-T058
only	O
,	O
lowering	O
the	O
adequacy	O
threshold	O
and	O
eliminating	O
the	O
requirement	O
of	O
6	O
groups	O
of	O
at	O
least	O
10	O
cells	B-T017
did	O
not	O
significantly	O
affect	O
test	O
performance	O
if	O
cytological	O
features	O
associated	O
with	O
malignancy	B-T038
were	O
absent	O
.	O

Cancer	O
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	O
Cancer	O
Society	O
.	O

Silk	B-T103
I	I-T103
and	O
Silk	B-T103
II	I-T103
studied	B-T062
by	O
fast	B-T058
scanning	I-T058
calorimetry	I-T058

Using	O
fast	B-T058
scanning	I-T058
calorimetry	I-T058
(	O
FSC	B-T058
)	O
,	O
we	O
investigated	O
the	O
glass	O
transition	O
and	O
crystal	B-T103
melting	O
of	O
samples	O
of	O
B	B-T204
.	I-T204

mori	I-T204
silk	B-T103
fibroin	I-T103
containing	O
Silk	B-T103
I	I-T103
and	O
/	O
or	O
Silk	B-T103
II	I-T103
crystal	B-T103
s	O
.	O

Due	O
to	O
the	O
very	O
short	O
residence	B-T082
times	O
at	O
high	O
temperatures	O
during	O
such	O
measurements	O
,	O
thermal	O
decomposition	O
of	O
silk	B-T103
protein	I-T103
can	O
be	O
significantly	O
suppressed	O
.	O

FSC	B-T058
was	O
performed	O
at	O
2000K	O
/	O
s	O
using	O
the	O
Mettler	B-T058
Flash	I-T058
DSC1	I-T058
on	O
fibroin	B-T103
films	O
with	O
masses	O
around	O
130	O
-	O
270ng	O
.	O

Films	O
were	O
prepared	O
with	O
different	O
crystalline	B-T103
fractions	O
(	O
ranging	O
from	O
0	O
.	O
26	O
to	O
0	O
.	O
50	O
)	O
and	O
with	O
different	O
crystal	B-T103
structures	I-T103
(	O
Silk	B-T103
I	I-T103
,	O
Silk	B-T103
II	I-T103
,	O
or	O
mixed	O
)	O
by	O
varying	O
the	O
processing	O
conditions	O
.	O

These	O
included	O
water	B-T103
annealing	B-T058
at	O
different	O
temperatures	O
,	O
exposure	O
to	O
50	O
%	O
MeOH	B-T103
in	O
water	B-T103
,	O
or	O
autoclaving	B-T074
.	O

The	O
resulting	O
crystal	B-T103
structure	I-T103
was	O
examined	O
using	O
wide	B-T082
angle	I-T082
X	B-T058
-	I-T058
ray	I-T058
scattering	I-T058
.	O

Degree	O
of	O
crystallinity	B-T103
was	O
evaluated	B-T033
from	O
Fourier	B-T062
transform	I-T062
infrared	I-T062
(	I-T062
FTIR	I-T062
)	I-T062
spectroscopy	I-T062
and	O
from	O
analysis	B-T062
of	O
the	O
heat	O
capacity	O
increment	O
at	O
the	O
glass	O
transition	O
temperature	O
.	O

Silk	B-T103
fibroin	I-T103
films	O
prepared	O
by	O
water	B-T103
annealing	B-T058
at	O
25°C	O
were	O
the	O
least	O
crystalline	B-T103
and	O
had	O
Silk	B-T103
I	I-T103
structure	B-T103
.	O

FTIR	B-T062
and	O
FSC	B-T058
studies	B-T062
showed	O
that	O
films	O
prepared	O
by	O
autoclaving	B-T074
or	O
50	O
%	O
MeOH	B-T103
exposure	O
were	O
the	O
most	O
crystalline	B-T103
and	O
had	O
Silk	B-T103
II	I-T103
structure	B-T103
.	O

Intermediate	B-T082
crystalline	B-T103
fraction	O
and	O
mixed	O
Silk	B-T103
I	I-T103
/	O
Silk	B-T103
II	I-T103
structure	B-T103
s	O
were	O
found	O
in	O
films	O
prepared	O
by	O
water	B-T103
annealing	B-T058
at	O
37°C	O
.	O

FSC	B-T058
results	O
indicate	O
that	O
Silk	B-T103
I	I-T103
I	I-T103
crystals	B-T103
exhibit	O
endotherms	O
of	O
narrower	O
width	O
and	O
have	O
higher	O
mean	O
melting	O
temperature	O
Tm	O
(	O
II	O
)	O
=	O
351±2	O
.	O
6°C	O
,	O
compared	O
to	O
Silk	B-T103
I	I-T103
crystals	B-T103
which	O
melt	O
at	O
Tm	O
(	O
I	O
)	O
=	O
292±3	O
.	O
8°C	O
.	O

Films	O
containing	O
mixed	O
Silk	B-T103
I	I-T103
/	O
Silk	B-T103
II	I-T103
structure	B-T103
showed	O
two	O
clearly	O
separated	O
endothermic	O
peaks	O
.	O

Evidence	O
suggests	O
that	O
the	O
two	O
types	O
of	O
crystal	B-T103
s	O
melt	O
separately	O
and	O
do	O
not	O
thermal	O
ly	O
interconvert	O
on	O
the	O
extremely	O
short	O
time	O
scale	O
(	O
0	O
.	O
065s	O
between	O
onset	O
and	O
end	O
of	O
melting	O
)	O
of	O
the	O
FSC	B-T058
experiment	I-T058
.	O

Silkworm	B-T204
silk	B-T103
is	O
a	O
naturally	O
occurring	O
biomaterial	O
.	O

The	O
fibroin	B-T103
component	I-T103
of	O
silk	B-T103
forms	I-T103
two	O
types	O
of	O
crystals	B-T103
.	O

Silk	B-T103
properties	O
depend	O
upon	O
the	O
amount	O
and	O
type	O
of	O
crystals	B-T103
,	O
and	O
their	O
stability	O
.	O

One	O
measure	O
of	O
stability	O
is	O
crystal	B-T103
melting	O
temperature	O
.	O

Crystal	B-T103
s	O
which	O
are	O
more	O
stable	O
have	O
a	O
higher	O
melting	O
temperature	O
.	O

Until	O
now	O
,	O
it	O
has	O
been	O
challenging	O
to	O
study	B-T062
thermal	O
behavior	O
of	O
silk	B-T103
crystal	B-T103
s	O
because	O
they	O
degrade	O
at	O
high	O
temperature	O
.	O

To	O
avoid	O
degradation	O
,	O
and	O
study	B-T062
the	O
melting	O
properties	O
of	O
silk	B-T103
biomaterial	O
,	O
we	O
heated	O
silk	B-T103
at	O
a	O
very	O
fast	O
rate	O
of	O
2000K	O
/	O
s	O
using	O
a	O
special	O
calorimeter	O
.	O

We	O
have	O
shown	O
that	O
the	O
two	O
crystal	B-T103
types	O
have	O
very	O
different	O
melting	O
temperature	O
s	O
,	O
indicating	O
that	O
one	O
crystal	B-T103
type	O
is	O
much	O
more	O
stable	O
than	O
the	O
other	O
.	O

Leonurine	B-T103
Attenuates	O
Hyperalgesia	B-T033
in	O
Mice	B-T204
with	O
Induced	O
Adenomyosis	B-T038

BACKGROUND	O
Adenomyosis	B-T038
,	O
defined	O
as	O
the	O
invasion	B-T038
of	O
endometrial	B-T017
glands	I-T017
and	O
stroma	B-T017
into	O
the	O
myometrium	B-T017
,	O
is	O
a	O
common	O
gynecological	B-T038
disorder	I-T038
.	O

In	O
the	O
present	O
study	O
we	O
report	B-T170
on	O
the	O
effect	O
of	O
leonurine	B-T103
on	O
ICR	B-T204
mice	I-T204
with	O
adenomyosis	B-T038
induced	O
by	O
neonatal	O
tamoxifen	B-T103
.	O

MATERIAL	O
AND	O
METHODS	O
After	O
being	O
treated	O
with	O
tamoxifen	B-T103
for	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
,	O
we	O
assessed	O
body	O
weight	O
and	O
pain	B-T033
modulation	O
in	O
mice	B-T204
in	O
hotplate	O
tests	B-T058
.	O

The	O
mice	B-T204
were	O
divided	O
into	O
5	O
groups	O
:	O
a	O
low	O
-	O
dose	O
leonurine	B-T103
treatment	B-T058
group	O
,	O
a	O
high	O
-	O
dose	O
leonurine	B-T103
treatment	B-T058
group	O
,	O
a	O
valproic	B-T103
acid	I-T103
(	O
VPA	B-T103
)	O
treatment	B-T058
group	O
,	O
a	O
vehicle	B-T103
only	O
treatment	B-T058
group	O
,	O
and	O
a	O
blank	O
control	O
group	O
.	O

We	O
evaluated	B-T058
body	O
weight	O
,	O
pain	O
modulation	O
in	O
hotplate	O
tests	B-T058
,	O
and	O
the	O
depth	B-T082
of	O
myometrial	B-T082
infiltration	B-T038
.	O

Immunoreactivity	O
staining	B-T058
of	O
progesterone	B-T103
receptor	I-T103
(	O
PR	B-T103
)	O
,	O
nuclear	B-T103
factor	I-T103
-	I-T103
κB	I-T103
phosphorylated	I-T103
-	I-T103
p65	I-T103
(	O
p	B-T103
-	I-T103
p65	I-T103
)	O
,	O
cyclooxygenase	B-T103
-	I-T103
2	I-T103
(	O
COX	B-T103
-	I-T103
2	I-T103
)	O
,	O
and	O
oxytocin	B-T103
receptor	I-T103
(	O
OTR	B-T103
)	O
was	O
evaluated	B-T058
by	O
immunohistochemistry	B-T058
.	O

RESULTS	O
The	O
measurement	O
of	O
the	O
body	O
weight	O
,	O
myometrial	B-T082
infiltration	B-T038
,	O
and	O
pain	O
modulation	O
showed	O
that	O
neonatal	O
tamoxifen	B-T103
treatment	B-T058
led	O
to	O
adenomyosis	B-T038
.	O

Leonurine	B-T103
treatment	B-T058
appeared	O
to	O
decrease	O
hyperalgesia	B-T033
and	O
myometrial	B-T082
infiltration	B-T038
.	O

Immunoreactivity	O
staining	B-T058
showed	O
decreased	O
p	B-T103
-	I-T103
p65	I-T103
,	O
COX	B-T103
-	I-T103
2	I-T103
,	O
and	O
OTR	B-T103
protein	B-T038
expressions	I-T038
.	O

CONCLUSIONS	O
Our	O
results	O
indicate	O
that	O
leonurine	B-T103
attenuates	O
hyperalgesia	B-T033
in	O
mice	B-T204
with	O
induced	O
adenomyosis	B-T038
via	O
down	B-T038
-	I-T038
regulating	I-T038
expressions	B-T038
of	O
p	B-T103
-	I-T103
P65	I-T103
,	O
COX	B-T103
-	I-T103
2	I-T103
,	O
and	O
OTR	B-T103
,	O
and	O
could	O
be	O
beneficial	O
for	O
treating	O
adenomyosis	B-T038
.	O

A	O
Randomized	B-T062
,	O
Head	O
-	O
to	O
-	O
Head	O
Study	B-T062
of	O
Virtual	B-T058
Reality	I-T058
Exposure	I-T058
Therapy	I-T058
for	O
Posttraumatic	B-T038
Stress	I-T038
Disorder	I-T038

Virtual	B-T058
reality	I-T058
exposure	I-T058
therapy	I-T058
(	O
VRET	B-T058
)	O
is	O
one	O
of	O
the	O
few	O
interventions	B-T058
supported	O
by	O
randomized	B-T062
controlled	I-T062
trials	I-T062
for	O
the	O
treatment	B-T058
of	O
combat	B-T038
-	I-T038
related	I-T038
posttraumatic	I-T038
stress	I-T038
disorder	I-T038
(	O
PTSD	B-T038
)	O
in	O
active	O
duty	O
service	O
members	B-T098
.	O

A	O
comparative	B-T062
effectiveness	I-T062
study	I-T062
was	O
conducted	O
to	O
determine	O
if	O
virtual	O
reality	O
technology	O
itself	O
improved	B-T033
outcomes	O
,	O
or	O
if	O
similar	O
results	O
could	O
be	O
achieved	O
with	O
a	O
control	B-T058
exposure	I-T058
therapy	I-T058
(	O
CET	B-T058
)	O
condition	O
.	O

Service	O
members	B-T098
with	O
combat	B-T038
-	I-T038
related	I-T038
PTSD	I-T038
were	O
randomly	O
selected	O
to	O
receive	O
nine	O
weeks	O
of	O
VRET	B-T058
or	O
CET	B-T058
.	O

Assessors	B-T097
,	O
but	O
not	O
therapists	O
,	O
were	O
blinded	B-T062
.	O

PTSD	B-T038
symptom	B-T033
improvement	O
was	O
assessed	O
one	O
week	O
and	O
3	O
months	O
after	O
the	O
conclusion	O
of	O
treatment	B-T058
using	O
the	O
clinician	B-T170
-	I-T170
administered	I-T170
PTSD	I-T170
scale	I-T170
(	O
CAPS	B-T170
)	O
.	O

A	O
small	O
crossover	O
component	O
was	O
included	O
.	O

Results	O
demonstrated	O
that	O
PTSD	B-T038
symptoms	B-T033
improved	B-T033
with	O
both	O
treatments	B-T058
,	O
but	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
groups	O
.	O

Dropout	B-T098
rates	O
were	O
higher	O
in	O
VRET	B-T058
.	O

Of	O
those	O
who	O
received	O
VRET	B-T058
,	O
13	O
/	O
42	O
(	O
31	O
%	O
)	O
showed	O
>	O
30	O
%	O
improvement	O
on	O
the	O
CAPS	B-T170
,	O
versus	O
16	O
/	O
43	O
(	O
37	O
%	O
)	O
who	O
received	O
CET	B-T058
.	O

Three	O
months	O
after	O
treatment	B-T058
,	O
>	O
30	O
%	O
improvement	O
was	O
seen	O
in	O
10	O
/	O
33	O
(	O
30	O
%	O
)	O
of	O
VRET	B-T058
participants	B-T098
and	O
12	O
/	O
33	O
(	O
36	O
%	O
)	O
in	O
CET	B-T058
.	O

Participants	B-T098
who	O
crossed	B-T033
over	I-T033
(	O
n	O
=	O
11	O
)	O
showed	O
no	O
statistically	O
significant	O
improvements	O
in	O
a	O
second	O
round	O
of	O
treatment	B-T058
,	O
regardless	O
of	O
condition	O
.	O

This	O
study	B-T062
supported	O
the	O
utility	O
of	O
exposure	B-T058
therapy	I-T058
for	O
PTSD	B-T038
,	O
but	O
did	O
not	O
support	O
additional	O
benefit	O
by	O
the	O
inclusion	O
of	O
virtual	O
reality	O
.	O

Accounting	O
for	O
linkage	O
disequilibrium	O
in	O
genome	O
scans	O
for	O
selection	B-T038
without	O
individual	O
genotypes	O
:	O
The	O
local	B-T062
score	I-T062
approach	I-T062

Detecting	B-T062
genomic	I-T062
footprints	I-T062
of	O
selection	B-T038
is	O
an	O
important	O
step	O
in	O
the	O
understanding	O
of	O
evolution	B-T038
.	O

Accounting	O
for	O
linkage	O
disequilibrium	O
in	O
genome	O
scans	O
increases	O
detection	B-T058
power	O
,	O
but	O
haplotype	O
-	O
based	O
methods	O
require	O
individual	O
genotypes	O
and	O
are	O
not	O
applicable	O
on	O
pool	B-T201
-	I-T201
sequenced	I-T201
samples	I-T201
.	O

We	O
propose	O
to	O
take	O
advantage	O
of	O
the	O
local	B-T062
score	I-T062
approach	I-T062
to	O
account	O
for	O
linkage	O
disequilibrium	O
in	O
genome	O
scans	O
for	O
selection	B-T038
,	O
cumulating	O
(	O
possibly	O
small	O
)	O
signals	B-T038
from	O
single	O
markers	B-T038
over	O
a	O
genomic	O
segment	O
,	O
to	O
clearly	O
pinpoint	O
a	O
selection	B-T038
signal	B-T038
.	O

Using	O
computer	O
simulations	O
,	O
we	O
demonstrate	O
that	O
this	O
approach	O
detects	B-T033
selection	B-T038
with	O
higher	O
power	O
than	O
several	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
single	B-T038
-	I-T038
marker	I-T038
,	O
windowing	O
or	O
haplotype	O
-	O
based	O
approaches	O
.	O

We	O
illustrate	O
this	O
on	O
two	O
benchmark	O
data	B-T170
sets	I-T170
including	O
individual	O
genotypes	O
,	O
for	O
which	O
we	O
obtain	O
similar	O
results	O
with	O
the	O
local	B-T062
score	I-T062
and	O
one	O
haplotype	O
-	O
based	O
approach	O
.	O

Finally	O
,	O
we	O
apply	O
the	O
local	B-T062
score	I-T062
approach	I-T062
to	O
Pool	B-T170
-	I-T170
Seq	I-T170
data	I-T170
obtained	O
from	O
a	O
divergent	O
selection	B-T038
experiment	B-T062
on	O
behaviour	O
in	O
quail	B-T204
and	O
obtain	O
precise	O
and	O
biologically	O
coherent	O
selection	B-T038
signals	B-T038
:	O
while	O
competing	O
methods	O
fail	O
to	O
highlight	O
any	O
clear	O
selection	B-T038
signature	O
,	O
our	O
method	O
detects	B-T033
several	O
regions	O
involving	O
genes	B-T017
known	O
to	O
act	O
on	O
social	O
responsiveness	O
or	O
autistic	B-T033
traits	I-T033
.	O

Although	O
we	O
focus	O
here	O
on	O
the	O
detection	B-T033
of	O
positive	B-T033
selection	B-T038
from	O
multiple	B-T170
population	I-T170
data	I-T170
,	O
the	O
local	B-T062
score	I-T062
approach	I-T062
is	O
general	O
and	O
can	O
be	O
applied	O
to	O
other	O
genome	O
scans	O
for	O
selection	B-T038
or	O
other	O
genomewide	B-T062
analyses	I-T062
such	O
as	O
GWAS	B-T062
.	O

Is	O
UV	O
-	O
Induced	O
Electron	O
-	O
Driven	O
Proton	O
Transfer	O
Active	O
in	O
a	O
Chemically	O
Modified	O
A	B-T103
·	O
T	B-T103
DNA	B-T103
Base	B-T038
Pair	I-T038
?	O

Transient	B-T058
electronic	I-T058
and	I-T058
vibrational	I-T058
absorption	I-T058
spectroscopies	I-T058
have	O
been	O
used	O
to	O
investigate	O
whether	O
UV	O
-	O
induced	O
electron	O
-	O
driven	O
proton	O
transfer	O
(	O
EDPT	O
)	O
mechanisms	O
are	O
active	O
in	O
a	O
chemically	O
modified	O
adenine	B-T103
-	O
thymine	B-T103
(	O
A	B-T103
·	O
T	B-T103
)	O
DNA	B-T103
base	B-T038
pair	I-T038
.	O

To	O
enhance	O
the	O
fraction	O
of	O
biologically	O
relevant	O
Watson	O
-	O
Crick	O
(	O
WC	O
)	O
hydrogen	O
-	O
bonding	O
motifs	B-T082
and	O
eliminate	O
undesired	O
Hoogsteen	O
structures	O
,	O
a	O
chemically	O
modified	O
derivative	O
of	O
A	B-T103
was	O
synthesized	O
,	O
8	B-T103
-	I-T103
(	I-T103
tert	I-T103
-	I-T103
butyl	I-T103
)	I-T103
-	I-T103
9	I-T103
-	I-T103
ethyladenine	I-T103
(	O
8tBA	B-T103
)	O
.	O

Equimolar	O
solutions	O
of	O
8tBA	B-T103
and	O
silyl	B-T103
-	I-T103
protected	I-T103
T	I-T103
nucleosides	B-T103
in	O
chloroform	B-T103
yield	O
a	O
mixture	O
of	O
WC	B-T038
pairs	I-T038
,	O
reverse	B-T038
WC	I-T038
pairs	I-T038
,	O
and	O
residual	B-T103
monomers	I-T103
.	O

Unlike	O
previous	O
transient	B-T058
absorption	I-T058
studies	I-T058
of	O
WC	O
guanine	B-T103
-	O
cytosin	B-T103
e	O
(	O
G	B-T103
·	O
C	B-T103
)	O
pairs	B-T038
,	O
no	O
clear	O
spectroscopic	O
or	O
kinetic	O
evidence	O
was	O
identified	O
for	O
the	O
participation	O
of	O
EDPT	O
in	O
the	O
excited	O
-	O
state	O
relaxation	O
dynamics	O
of	O
8tBA	B-T103
·	O
T	B-T103
pairs	B-T038
,	O
although	O
ultrafast	O
(	O
sub	O
-	O
100	O
fs	O
)	O
EDPT	O
cannot	O
be	O
discounted	O
.	O

Monomer	O
-	O
like	O
dynamics	O
are	O
proposed	O
to	O
dominate	O
in	O
8tBA	B-T103
·	O
T	B-T103
.	O

Monitoring	B-T058
proteolytic	B-T038
processing	I-T038
events	O
by	O
quantitative	B-T058
mass	I-T058
spectrometry	I-T058

Protease	B-T038
activity	I-T038
plays	O
a	O
key	O
role	O
in	O
a	O
wide	O
variety	O
of	O
biological	B-T038
processes	I-T038
including	O
gene	B-T038
expression	I-T038
,	O
protein	B-T038
turnover	I-T038
and	O
development	B-T038
.	O

misregulation	B-T033
of	O
these	O
proteins	B-T103
has	O
been	O
associated	O
with	O
many	O
cancer	O
types	O
such	O
as	O
prostate	B-T038
,	O
breast	B-T038
,	O
and	O
skin	B-T038
cancer	I-T038
.	O

thus	O
,	O
the	O
identification	O
of	O
protease	B-T103
substrates	O
will	O
provide	O
key	O
information	O
to	O
understand	B-T038
proteolysis	B-T038
-	O
related	O
pathologies	B-T091
.	O

Areas	O
covered	O
:	O
Proteomics	B-T091
-	O
based	O
methods	B-T170
to	O
investigate	O
proteolysis	B-T038
activity	I-T038
,	I-T038
focusing	O
on	O
substrate	O
identification	O
,	O
protease	B-T103
specificity	O
and	O
their	O
applications	B-T058
in	O
systems	B-T091
biology	I-T091
are	O
reviewed	O
.	O

Their	O
quantification	O
strategies	O
,	O
challenges	B-T058
and	O
pitfalls	O
are	O
underlined	O
and	O
the	O
biological	O
implications	O
of	O
protease	B-T103
malfunction	O
are	O
highlighted	O
.	O

Expert	O
commentary	O
:	O
Dysregulated	B-T033
protease	B-T038
activity	I-T038
is	O
a	O
hallmark	O
for	O
some	O
disease	B-T038
pathologies	B-T091
such	O
as	O
cancer	B-T038
.	O

Current	O
biochemical	O
approaches	O
are	O
low	O
throughput	O
and	O
some	O
are	O
limited	O
by	O
the	O
amount	O
of	O
sample	O
required	O
to	O
obtain	O
reliable	O
results	B-T033
.	O

Mass	B-T058
spectrometry	I-T058
based	O
proteomics	B-T091
provides	O
a	O
suitable	O
platform	O
to	O
investigate	O
protease	B-T038
activity	I-T038
,	O
providing	O
information	O
about	O
substrate	O
specificity	O
and	O
mapping	B-T058
cleavage	B-T082
sites	I-T082
.	O

Diabetic	B-T038
nephropathy	I-T038
as	O
the	O
cause	O
of	O
end	B-T038
-	I-T038
stage	I-T038
kidney	I-T038
disease	I-T038
reported	O
on	O
the	O
medical	B-T170
evidence	I-T170
form	I-T170
CMS2728	B-T170
at	O
a	O
single	O
center	B-T092

Background	O
:	O
End	B-T038
-	I-T038
stage	I-T038
renal	I-T038
disease	I-T038
(	O
ESRD	B-T038
)	O
incidence	O
due	O
to	O
Type	B-T170
2	I-T170
diabetic	B-T038
nephropathy	I-T038
(	O
DN	B-T038
)	O
is	O
35	O
-	O
50	O
%	O
,	O
according	O
to	O
the	O
United	B-T170
States	I-T170
Renal	I-T170
Data	I-T170
System	I-T170
.	O

Methods	O
:	O
A	O
single	O
-	O
center	B-T092
,	O
retrospective	B-T062
cohort	I-T062
study	I-T062
to	O
determine	O
incidence	O
and	O
diagnostic	O
accuracy	O
for	O
Type	B-T170
2	I-T170
DN	B-T038
as	O
the	O
primary	O
cause	O
of	O
ESRD	B-T038
(	O
Code	O
250	O
.	O
40	O
)	O
on	O
the	O
Center	B-T092
for	I-T092
Medicare	I-T092
&	I-T092
Medicaid	I-T092
(	O
CMS	B-T092
)	O
Medical	B-T170
Evidence	I-T170
Report	I-T170
form	I-T170
(	O
CMS2728	B-T170
)	O
submitted	O
at	O
renal	B-T058
replacement	I-T058
therapy	I-T058
initiation	O
.	O

All	O
patients	O
≥18	O
years	O
of	O
age	O
with	O
a	O
CMS2728	B-T170
submitted	O
between	O
1	O
March	O
2006	O
and	O
31	O
March	O
2015	O
at	O
a	O
single	O
academic	B-T092
military	I-T092
medical	I-T092
center	I-T092
(	O
ESRD	B-T038
Network	O
5	O
)	O
were	O
included	O
.	O

Medical	B-T170
records	I-T170
of	O
those	O
with	O
a	O
Code	O
250	O
.	O
40	O
diagnosis	B-T033
were	O
reviewed	O
to	O
determine	O
whether	O
they	O
met	O
the	O
Kidney	B-T092
Disease	I-T092
Outcomes	I-T092
Quality	I-T092
Initiative	I-T092
(	O
KDOQI	B-T092
)	O
2007	O
criteria	B-T170
for	O
DN	B-T038
.	O

Results	O
:	O
ESRD	B-T038
incidence	O
secondary	O
to	O
Type	B-T170
2	I-T170
DN	B-T038
was	O
18	O
.	O
7	O
%	O
(	O
56	O
/	O
299	O
individual	B-T098
CMS2728	B-T170
submissions	O
over	O
9	O
.	O
09	O
years	O
)	O
.	O

In	O
all	O
,	O
12	O
/	O
56	O
(	O
21	O
.	O
4	O
%	O
)	O
did	O
not	O
meet	O
KDOQI	B-T170
criteria	I-T170
for	O
Type	B-T170
2	I-T170
DN	B-T038
.	O

Although	O
all	O
had	O
diabetes	B-T038
,	O
those	O
not	O
meeting	O
criteria	O
had	O
shorter	O
disease	O
duration	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
were	O
more	O
likely	O
to	O
have	O
active	O
urine	B-T031
sediment	I-T031
(	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
and	O
were	O
less	O
likely	O
to	O
have	O
macroalbuminuria	B-T033
(	O
P	O
=	O
0	O
.	O
037	O
)	O
or	O
retinopathy	B-T038
(	O
P	O
=	O
0	O
.	O
002	O
)	O
prior	O
to	O
ESRD	B-T038
.	O

On	O
exact	O
logistic	B-T062
regression	I-T062
,	O
retinopathy	B-T038
was	O
significantly	O
associated	O
with	O
KDOQI	B-T092
-	O
predicted	O
DN	B-T038
[	O
odds	O
ratio	O
=	O
19	O
.	O
16	O
(	O
confidence	O
interval	O
2	O
.	O
76	O
-	O
223	O
.	O
7	O
)	O
,	O
P	O
=	O
0	O
.	O
0009	O
]	O
.	O

Conclusions	O
:	O
In	O
this	O
single	O
-	O
center	B-T092
cohort	B-T062
,	O
21	O
.	O
4	O
%	O
identified	O
as	O
having	O
Type	B-T170
2	I-T170
DN	B-T038
as	O
the	O
primary	O
cause	O
of	O
ESRD	B-T038
were	O
incorrectly	O
assigned	O
per	O
KDOQI	B-T092
2007	O
clinical	O
criteria	B-T170
.	O

If	O
replicated	O
in	O
larger	O
populations	B-T098
,	O
this	O
could	O
have	O
substantial	O
implications	O
regarding	O
the	O
epidemiology	B-T091
of	O
ESRD	B-T038
in	O
the	O
USA	B-T082
.	O

Socioeconomic	O
Predictors	O
of	O
Adherence	B-T033
Behavior	I-T033
Among	O
HIV	B-T033
-	I-T033
Positive	I-T033
Patients	O
Receiving	O
Antiretroviral	B-T058
Therapy	I-T058
in	O
Selangor	B-T082
,	O
Malaysia	B-T082

Medication	B-T033
adherence	I-T033
remains	O
a	O
critical	O
link	O
between	O
the	O
prescribed	O
ART	B-T058
regimen	B-T058
and	O
treatment	O
outcome	O
.	O

Several	O
factors	O
may	O
influence	O
adherence	B-T033
behavior	I-T033
.	O

This	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
aimed	O
to	O
highlight	O
socioeconomic	O
predictors	O
of	O
adherence	B-T033
behavior	I-T033
among	O
a	O
cohort	B-T098
of	O
242	O
adult	O
Malaysian	B-T098
patients	O
receiving	O
antiretroviral	B-T058
therapy	I-T058
in	O
Hospital	B-T092
Sungai	I-T092
Buloh	I-T092
,	O
Malaysia	B-T082
,	O
where	O
they	O
were	O
enrolled	O
in	O
a	O
parent	O
study	O
(	O
single	B-T062
-	I-T062
blinded	I-T062
randomized	B-T062
controlled	I-T062
trial	I-T062
)	O
between	O
January	O
and	O
December	O
2014	O
.	O

Statistical	O
analysis	O
of	O
secondary	O
data	O
on	O
adherence	B-T033
behavior	I-T033
and	O
sociodemographic	O
characteristics	O
of	O
the	O
patients	O
revealed	O
mean	B-T033
age	I-T033
of	O
33	O
.	O
4	O
years	O
and	O
ranged	O
from	O
18	O
to	O
64	O
years	O
;	O
88	O
.	O
8	O
%	O
were	O
males	O
.	O

A	O
total	O
of	O
224	O
(	O
93	O
%	O
)	O
patients	O
who	O
completed	O
6	O
months	O
'	O
adherence	O
assessment	O
were	O
included	O
in	O
the	O
model	O
.	O

Of	O
these	O
,	O
135	O
(	O
60	O
.	O
3	O
%	O
)	O
achieved	B-T033
optimal	O
adherence	O
.	O

Multivariate	B-T170
binary	I-T170
logistic	I-T170
regression	I-T170
analysis	I-T170
revealed	O
that	O
patient	O
'	O
s	O
income	O
and	O
ethnicity	O
were	O
significant	O
predictors	O
of	O
adherence	B-T033
behavior	I-T033
.	O

This	O
may	O
be	O
valuable	O
for	O
targeted	O
programmatic	B-T058
interventions	I-T058
to	O
further	O
enhance	O
successful	B-T201
treatment	I-T201
outcomes	O
among	O
the	O
target	B-T098
population	I-T098
.	O

A	O
Tobramycin	B-T103
Vector	I-T103
Enhances	O
Synergy	B-T033
and	O
Efficacy	O
of	O
Efflux	B-T103
Pump	I-T103
Inhibitors	I-T103
against	O
Multidrug	O
-	O
Resistant	O
Gram	B-T007
-	I-T007
Negative	I-T007
Bacteria	I-T007

Drug	B-T038
efflux	I-T038
mechanisms	O
interact	B-T038
synergistically	O
with	O
the	O
outer	B-T017
membrane	I-T017
permeability	B-T038
barrier	B-T038
of	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
,	O
leading	O
to	O
intrinsic	B-T082
resistance	O
that	O
presents	O
a	O
major	O
challenge	B-T058
for	O
antibiotic	B-T103
drug	B-T062
development	I-T062
.	O

Efflux	B-T103
pump	I-T103
inhibitors	I-T103
(	O
EPIs	B-T103
)	O
which	O
block	O
the	O
efflux	B-T038
of	O
antibiotics	B-T103
synergize	O
antibiotics	B-T103
,	O
but	O
the	O
clinical	B-T062
development	I-T062
of	O
EPI	B-T103
/	O
antibiotic	B-T103
combination	B-T058
therapy	I-T058
to	O
treat	B-T058
multidrug	O
-	O
resistant	O
(	O
MDR	O
)	O
Gram	B-T038
-	I-T038
negative	I-T038
infections	I-T038
has	O
been	O
challenging	B-T058
.	O

This	O
is	O
in	O
part	O
caused	O
by	O
the	O
inefficiency	B-T033
of	O
current	O
EPIs	B-T103
to	O
penetrate	O
the	O
outer	B-T017
membrane	I-T017
and	O
resist	O
efflux	B-T038
.	O

We	O
demonstrate	O
that	O
conjugation	B-T038
of	O
a	O
tobramycin	B-T103
(	O
TOB	B-T103
)	O
vector	O
to	O
EPIs	B-T103
like	O
NMP	B-T103
,	O
paroxetine	B-T103
,	O
or	O
DBP	B-T201
enhances	O
synergy	B-T033
and	O
efficacy	O
of	O
EPIs	B-T103
in	O
combination	O
with	O
tetracycline	B-T103
antibiotics	I-T103
against	O
MDR	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
including	O
Pseudomonas	B-T007
aeruginosa	I-T007
.	O

Besides	O
potentiating	B-T038
tetracycline	B-T103
antibiotics	I-T103
,	O
TOB	B-T103
-	O
EPI	B-T103
conjugates	O
can	O
also	O
suppress	O
resistance	O
development	O
to	O
the	O
tetracycline	B-T103
antibiotic	I-T103
minocycline	B-T103
,	O
thereby	O
providing	O
a	O
strategy	O
to	O
develop	O
more	O
effective	O
adjuvants	B-T103
to	O
rescue	O
tetracycline	B-T103
antibiotics	I-T103
from	O
resistance	O
in	O
MDR	O
Gram	B-T007
-	I-T007
negative	I-T007
bacteria	I-T007
.	O

Detection	B-T058
of	O
AMA	B-T103
-	I-T103
M2	I-T103
in	O
human	B-T204
saliva	B-T031
:	O
Potentials	O
in	O
diagnosis	B-T033
and	O
monitoring	B-T058
of	O
primary	B-T038
biliary	I-T038
cholangitis	I-T038

Serum	B-T031
anti	B-T103
-	I-T103
mitochondrial	I-T103
antibody	I-T103
type	I-T103
2	I-T103
(	O
AMA	B-T103
-	I-T103
M2	I-T103
)	O
is	O
considered	O
as	O
a	O
pivotal	O
biomarker	B-T201
for	O
the	O
diagnosis	B-T033
of	O
primary	B-T038
biliary	I-T038
cholangitis	I-T038
(	O
PBC	B-T038
)	O
.	O

However	O
,	O
serological	B-T058
tests	I-T058
have	O
many	O
limitations	O
,	O
including	O
inconvenience	O
,	O
invasiveness	O
,	O
and	O
infection	B-T033
risks	I-T033
.	O

Thus	O
,	O
a	O
less	O
invasive	O
approach	B-T082
to	O
detect	B-T033
AMA	B-T058
-	I-T058
M2	I-T058
titer	I-T058
is	O
desirable	O
.	O

We	O
examined	O
salivary	B-T031
AMA	B-T103
-	I-T103
M2	I-T103
of	O
potential	O
PBC	B-T038
patients	O
and	O
found	O
that	O
AMA	B-T103
-	I-T103
M2	I-T103
could	O
be	O
detected	B-T033
only	O
in	O
saliva	B-T031
of	O
serum	B-T031
AMA	B-T033
-	I-T033
M2	I-T033
-	I-T033
positive	I-T033
PBC	B-T038
patients	O
,	O
but	O
not	O
in	O
saliva	B-T031
of	O
serum	B-T031
AMA	B-T033
-	I-T033
M2	I-T033
-	I-T033
negative	I-T033
PBC	B-T038
patients	O
,	O
oral	B-T038
lichen	I-T038
planus	I-T038
patients	O
(	O
OLP	B-T038
)	O
patients	O
,	O
or	O
healthy	O
controls	O
.	O

Furthermore	O
,	O
the	O
concentration	O
of	O
salivary	B-T031
AMA	B-T103
-	I-T103
M2	I-T103
was	O
positively	O
correlated	O
with	O
the	O
amount	O
of	O
serum	B-T031
AMA	B-T103
-	I-T103
M2	I-T103
in	O
patients	O
.	O

The	O
salivary	B-T031
inflammatory	B-T103
cytokines	I-T103
were	O
increased	O
in	O
the	O
PBC	B-T038
,	O
consistent	O
with	O
the	O
results	O
of	O
serum	B-T031
test	B-T058
.	O

These	O
findings	O
indicated	O
that	O
saliva	B-T031
might	O
be	O
a	O
less	O
invasive	O
and	O
cost	O
-	O
effective	O
medium	O
to	O
accurately	O
test	O
for	O
AMA	B-T058
-	I-T058
M2	I-T058
levels	I-T058
and	O
this	O
is	O
a	O
promising	O
development	O
for	O
the	O
diagnosis	B-T033
and	O
monitoring	B-T058
of	O
PBC	B-T038
.	O

Mental	B-T038
health	I-T038
and	O
associated	O
factors	O
among	O
young	O
offenders	B-T098
in	O
Chile	B-T082
:	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062

Few	O
studies	O
in	O
Latin	B-T082
America	I-T082
have	O
explored	O
mental	B-T038
disorder	I-T038
among	O
young	O
offenders	B-T098
,	O
or	O
variables	O
associated	O
with	O
it	O
.	O

Our	O
aim	O
was	O
to	O
test	O
for	O
associations	O
between	O
childhood	O
adversity	O
or	O
substance	O
misuse	O
and	O
psychiatric	B-T038
disorders	I-T038
among	O
young	O
offenders	B-T098
.	O

Sentenced	O
adolescent	O
offenders	B-T098
were	O
recruited	O
from	O
young	O
offenders	B-T098
'	I-T098
institutions	O
or	O
community	O
centres	O
provided	O
by	O
the	O
Chilean	O
National	O
Service	O
for	O
Minors	O
.	O

Psychiatric	B-T038
disorders	I-T038
were	O
assessed	O
using	O
the	O
Mini	B-T058
International	I-T058
Neuropsychiatric	I-T058
Interview	I-T058
,	O
conducted	O
by	O
trained	B-T097
psychologists	I-T097
.	O

A	O
trained	B-T097
sociologist	I-T097
used	O
an	O
ad	O
hoc	O
interview	O
to	O
collect	O
information	O
about	O
childhood	O
experiences	O
,	O
including	O
parenting	B-T033
,	O
trauma	B-T037
,	O
education	B-T170
and	O
substance	O
misuse	O
.	O

Multivariable	B-T062
logistic	I-T062
regressions	I-T062
were	O
used	O
to	O
analyse	O
data	O
.	O

The	O
most	O
prevalent	O
psychiatric	B-T038
disorders	I-T038
among	O
the	O
935	O
participants	B-T098
were	O
marijuana	B-T038
dependence	I-T038
disorder	I-T038
,	O
major	B-T038
depressive	I-T038
disorder	I-T038
,	O
and	O
anxiety	B-T038
disorders	I-T038
.	O

Substance	B-T038
use	I-T038
disorders	I-T038
were	O
less	O
frequent	O
among	O
young	O
offenders	B-T098
who	O
were	O
serving	O
their	O
sentence	B-T033
in	O
young	O
offenders	B-T098
'	I-T098
institutions	O
than	O
among	O
those	O
serving	O
in	O
community	O
centres	O
and	O
more	O
frequent	O
among	O
those	O
who	O
started	O
to	O
use	B-T038
marijuana	I-T038
at	O
an	O
earlier	O
age	O
.	O

Among	O
other	O
variables	O
,	O
childhood	B-T038
maltreatment	I-T038
was	O
related	O
to	O
major	B-T038
depressive	I-T038
disorder	I-T038
,	O
and	O
maternal	B-T038
death	I-T038
to	O
anxiety	B-T038
disorders	I-T038
.	O

Higher	O
educational	B-T033
status	I-T033
was	O
related	O
to	O
a	O
lower	O
frequency	O
of	O
depressive	B-T038
and	O
anxiety	B-T038
disorders	I-T038
.	O

Our	O
findings	B-T033
suggest	O
that	O
greater	O
efforts	O
must	O
be	O
made	O
to	O
identify	O
vulnerable	O
young	O
people	B-T098
much	O
earlier	O
.	O

Few	O
of	O
these	O
young	O
offenders	B-T098
with	O
mental	B-T038
health	I-T038
problems	B-T033
had	O
been	O
well	O
adjusted	O
in	O
health	O
,	O
education	B-T170
or	O
socially	O
before	O
this	O
period	O
of	O
detention	O
.	O

©	O
2017	O
The	O
Authors	O
.	O

Criminal	O
Behaviour	O
and	O
Mental	O
Health	O
Published	O
by	O
John	O
Wiley	O
&	O
Sons	O
Ltd	O
.	O

Effects	O
of	O
regular	O
water	O
-	O
and	O
land	O
-	O
based	O
exercise	O
on	O
physical	B-T033
function	I-T033
after	O
5	O
years	O
:	O
A	O
long	B-T062
-	I-T062
term	I-T062
study	I-T062
on	O
the	O
well	O
-	O
being	O
of	O
older	B-T098
Japanese	I-T098
adults	B-T098

To	O
investigate	O
the	O
effects	O
of	O
5	O
years	O
of	O
physical	O
exercise	O
on	O
functional	O
parameters	O
among	O
older	B-T098
Japanese	I-T098
adults	B-T098
who	O
carried	O
out	O
water	O
-	O
or	O
land	O
-	O
based	O
exercise	O
.	O

We	O
retrospectively	O
investigated	O
data	O
from	O
5707	O
medical	B-T058
examinations	I-T058
and	O
enrolled	B-T058
77	O
older	B-T098
adults	I-T098
into	O
the	O
study	B-T062
.	O

Eligible	O
participants	B-T098
had	O
to	O
be	O
aged	O
≥60	O
years	O
,	O
and	O
engaged	O
in	O
water	O
-	O
based	O
exercise	O
(	O
n	O
=	O
38	O
)	O
or	O
a	O
combination	O
of	O
water	O
-	O
and	O
land	O
-	O
based	O
exercise	O
(	O
n	O
=	O
39	O
)	O
for	O
at	O
least	O
80	O
%	O
of	O
their	O
total	O
exercise	O
time	O
for	O
over	O
5	O
years	O
at	O
our	O
fitness	B-T092
center	I-T092
.	O

In	O
statistical	O
analysis	O
,	O
a	O
two	O
-	O
way	O
repeated	O
-	O
measures	O
analysis	O
of	O
variance	O
was	O
carried	O
out	O
to	O
examine	B-T033
the	O
effects	O
over	O
time	O
and	O
by	O
exercise	B-T033
type	I-T033
,	O
and	O
the	O
changes	O
in	O
each	O
parameter	O
over	O
5	O
years	O
were	O
also	O
compared	O
between	O
the	O
two	O
groups	O
.	O

We	O
found	B-T033
significant	O
main	O
effects	O
and	O
an	O
interaction	O
between	O
time	O
and	O
exercise	B-T033
type	I-T033
for	O
gait	O
speed	O
,	O
with	O
an	O
early	O
decline	O
in	O
the	O
combined	O
exercise	O
group	O
,	O
as	O
well	O
as	O
significant	O
main	O
effects	O
of	O
time	O
,	O
showing	O
a	O
functional	B-T033
decline	I-T033
in	O
grip	O
strength	O
,	O
one	B-T082
-	I-T082
leg	I-T082
standing	I-T082
time	O
and	O
step	B-T033
/	I-T033
height	I-T033
ratio	O
in	O
both	O
exercise	B-T033
types	I-T033
at	O
the	O
5	O
-	O
year	O
follow	B-T058
up	I-T058
.	O

The	O
5	O
-	O
year	O
changes	O
in	O
each	O
parameter	O
did	O
not	O
differ	O
between	O
the	O
two	O
groups	O
despite	O
the	O
frequency	B-T033
of	I-T033
exercise	I-T033
,	O
even	O
though	O
we	O
found	B-T033
a	O
negative	B-T033
correlation	O
between	O
changes	O
in	O
one	B-T082
-	I-T082
leg	I-T082
standing	I-T082
time	O
and	O
total	O
amount	O
of	O
water	O
-	O
based	O
exercise	O
.	O

Contrary	O
to	O
expectations	O
,	O
these	O
results	O
suggest	O
that	O
regular	O
engagement	O
in	O
water	O
-	O
based	O
exercise	O
,	O
even	O
combined	O
with	O
land	O
-	O
based	O
exercise	O
,	O
might	O
have	O
poor	O
long	O
-	O
term	O
benefits	O
for	O
maintaining	O
physical	O
performance	O
in	O
older	B-T098
adults	I-T098
.	O

Geriatr	O
Gerontol	O
Int	O
2017	O
;	O
•	O
•	O
:	O
•	O
•	O
-	O
•	O
•	O
.	O

Combined	O
exposures	B-T037
of	O
whole	O
-	O
body	O
vibration	O
and	O
awkward	O
posture	O
:	O
a	O
cross	B-T062
sectional	I-T062
investigation	I-T062
among	O
occupational	O
drivers	B-T098
by	O
means	O
of	O
simultaneous	O
field	O
measurements	O

Multifactorial	B-T033
workloads	O
such	O
as	O
whole	O
-	O
body	O
vibration	O
(	O
WBV	O
)	O
,	O
awkward	O
posture	O
and	O
heavy	O
lifting	O
are	O
potential	O
predictors	B-T033
for	O
low	B-T033
back	I-T033
pain	I-T033
(	O
LBP	B-T033
)	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
investigate	O
the	O
association	O
between	O
LBP	B-T033
and	O
these	O
exposures	B-T037
among	O
102	O
professional	O
drivers	B-T098
.	O

The	O
combined	O
exposures	B-T037
of	O
WBV	O
and	O
posture	O
are	O
measured	O
at	O
different	O
workplaces	B-T082
.	O

Health	O
and	O
personal	O
data	O
as	O
well	O
as	O
information	O
about	O
lifting	O
tasks	O
are	O
collected	O
by	O
a	O
questionnaire	B-T170
.	O

The	O
daily	O
vibration	B-T037
exposure	I-T037
value	O
(	O
odds	O
ratio	O
1	O
.	O
69	O
)	O
and	O
an	O
index	O
for	O
awkward	O
posture	O
(	O
odds	O
ratio	O
1	O
.	O
63	O
)	O
show	O
significant	O
association	O
with	O
the	O
occurence	O
of	O
LBP	B-T033
.	O

Awkward	O
posture	O
and	O
heavy	O
lifting	O
appear	O
to	O
be	O
more	O
strongly	O
associated	O
with	O
sick	O
leave	O
than	O
WBV	O
exposure	B-T037
.	O

Furthermore	O
,	O
a	O
combination	O
of	O
the	O
measurement	O
results	O
of	O
WBV	O
and	O
awkward	O
posture	O
into	O
one	O
quantity	O
also	O
shows	O
significant	O
correlation	O
to	O
LBP	B-T033
.	O

The	O
combined	O
exposure	B-T037
of	O
WBV	O
and	O
awkward	O
posture	O
can	O
be	O
described	O
in	O
terms	O
of	O
the	O
daily	O
vibration	B-T037
exposure	I-T037
and	O
the	O
index	O
for	O
awkward	O
posture	O
.	O

This	O
facilitates	O
work	B-T082
place	I-T082
assessments	O
and	O
future	O
research	B-T062
in	O
this	O
area	B-T082
.	O

Practitioner	O
Summary	O
:	O
For	O
the	O
first	O
time	O
,	O
quantitative	O
measures	O
combining	O
whole	O
-	O
body	O
vibration	O
and	O
awkward	O
posture	O
exposures	B-T037
have	O
shown	O
to	O
correlate	O
with	O
the	O
occurrence	O
of	O
low	B-T033
back	I-T033
pain	I-T033
significantly	O
.	O

This	O
validates	O
the	O
proposed	O
quantities	O
and	O
measurement	O
methods	O
,	O
which	O
facilitate	O
workplace	B-T082
assessments	O
and	O
assist	O
in	O
the	O
design	O
of	O
further	O
studies	B-T062
which	O
are	O
necessary	O
to	O
establish	O
a	O
causal	B-T037
exposure	I-T037
-	O
response	O
relationship	O
.	O

Association	O
of	O
CKIP	B-T017
-	I-T017
1	I-T017
P21A	I-T017
polymorphism	B-T082
with	O
risk	O
of	O
chronic	B-T038
heart	I-T038
failure	I-T038
in	O
a	O
Chinese	B-T098
population	I-T098

Pathological	O
cardiac	B-T038
hypertrophy	I-T038
is	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
chronic	B-T038
heart	I-T038
failure	I-T038
.	O

Casein	B-T103
kinase	I-T103
-	I-T103
2	I-T103
interacting	I-T103
protein	I-T103
-	I-T103
1	I-T103
(	O
CKIP	B-T103
-	I-T103
1	I-T103
)	O
can	O
inhibit	O
pathological	O
cardiac	B-T038
hypertrophy	I-T038
.	O

Therefore	O
,	O
we	O
investigated	O
whether	O
CKIP	B-T017
-	I-T017
1	I-T017
nonsynonymous	B-T082
polymorphism	I-T082
rs2306235	I-T082
(	O
Pro21Ala	B-T038
)	O
contributes	O
to	O
risk	O
and	O
prognosis	B-T058
of	O
chronic	B-T038
heart	I-T038
failure	I-T038
in	O
a	O
Chinese	B-T098
population	I-T098
.	O

A	O
total	O
of	O
923	O
adult	O
patients	O
with	O
chronic	B-T038
heart	I-T038
failure	I-T038
and	O
1020	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
were	O
recruited	O
.	O

CKIP	B-T017
-	I-T017
1	I-T017
rs2306235	I-T017
polymorphism	B-T082
was	O
genotyped	B-T058
using	O
PCR	B-T062
-	O
restriction	B-T058
fragment	I-T058
length	I-T058
polymorphism	I-T058
.	O

Additional	O
follow	B-T058
-	I-T058
up	I-T058
data	O
for	O
140	O
chronic	B-T038
heart	I-T038
failure	I-T038
patients	O
was	O
evaluated	B-T058
.	O

The	O
rs2306235	B-T017
G	B-T017
allele	I-T017
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
chronic	B-T038
heart	I-T038
failure	I-T038
(	O
OR	O
=	O
1	O
.	O
38	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
09	O
-	O
1	O
.	O
75	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
,	O
especially	O
in	O
patients	O
with	O
hypertension	B-T038
(	O
OR	O
=	O
1	O
.	O
45	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
09	O
-	O
1	O
.	O
75	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
coronary	B-T038
heart	I-T038
disease	I-T038
(	O
OR	O
=	O
1	O
.	O
41	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
09	O
-	O
1	O
.	O
83	O
,	O
p	O
=	O
0	O
.	O
010	O
)	O
after	O
adjustment	O
for	O
multiple	O
cardiovascular	O
risk	B-T033
factors	I-T033
.	O

However	O
,	O
rs2306235	B-T017
polymorphism	B-T082
was	O
not	O
associated	O
with	O
cardiovascular	O
mortality	O
in	O
chronic	B-T038
heart	I-T038
failure	I-T038
(	O
p	O
=	O
0	O
.	O
875	O
)	O
.	O

CKIP	B-T017
-	I-T017
1	I-T017
rs2306235	I-T017
polymorphism	B-T082
may	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
chronic	B-T038
heart	I-T038
failure	I-T038
in	O
a	O
Chinese	O
Han	O
population	O
.	O

Linking	O
phenological	O
events	O
in	O
migratory	B-T204
passerines	I-T204
with	O
a	O
changing	O
climate	O
:	O
50	O
years	O
in	O
the	O
Laurel	B-T082
Highlands	I-T082
of	I-T082
Pennsylvania	I-T082

Advanced	O
timing	O
of	O
both	O
seasonal	O
migration	O
and	O
reproduction	B-T038
in	O
birds	B-T204
has	O
been	O
strongly	O
associated	O
with	O
a	O
warming	O
climate	O
for	O
many	O
bird	B-T204
species	B-T170
.	O

Phenological	O
responses	O
to	O
climate	O
linking	O
these	O
stages	O
may	O
ultimately	O
impact	O
fitness	O
.	O

We	O
analyzed	B-T062
five	O
decades	O
of	O
banding	O
data	O
from	O
17	O
migratory	B-T204
bird	I-T204
species	B-T170
to	O
investigate	O
1	O
)	O
how	O
spring	O
arrival	O
related	O
to	O
timing	O
of	O
breeding	B-T038
,	O
2	O
)	O
if	O
the	O
interval	O
between	O
arrival	O
and	O
breeding	B-T038
has	O
changed	O
with	O
increasing	O
spring	O
temperatures	O
,	O
and	O
3	O
)	O
whether	O
arrival	O
timing	O
or	O
breeding	B-T038
timing	O
best	O
predicted	O
local	B-T033
productivity	I-T033
.	O

Four	O
of	O
17	O
species	B-T170
,	O
all	O
mid	B-T204
-	I-T204
to	I-T204
long	I-T204
-	I-T204
distance	I-T204
migrants	I-T204
,	O
hatched	B-T038
young	O
earlier	O
in	O
years	O
when	O
migrants	B-T098
arrived	O
earlier	O
to	O
the	O
breeding	O
grounds	O
(	O
~	O
1	O
:	O
1	O
day	O
advancement	O
)	O
.	O

The	O
interval	O
between	O
arrival	O
on	O
breeding	O
grounds	O
and	O
appearance	O
of	O
juveniles	O
shortened	O
with	O
warmer	O
spring	O
temperatures	O
for	O
12	O
species	B-T170
(	O
1	O
-	O
6	O
days	O
for	O
every	O
1°C	O
increase	O
)	O
and	O
over	O
time	O
for	O
seven	O
species	B-T170
(	O
1	O
-	O
8	O
days	O
per	O
decade	O
)	O
,	O
suggesting	O
that	O
some	O
migratory	B-T204
passerines	I-T204
adapt	O
to	O
climate	O
change	O
by	O
laying	B-T038
more	O
quickly	O
after	O
arrival	B-T033
or	O
reducing	O
the	O
time	O
from	O
laying	B-T038
to	O
fledging	O
.	O

We	O
found	O
more	O
support	O
for	O
the	O
former	O
,	O
that	O
the	O
rate	O
of	O
reproductive	B-T038
advancement	I-T038
was	O
higher	O
than	O
that	O
for	O
arrival	B-T033
in	O
warm	O
years	O
.	O

Timing	O
of	O
spring	O
arrival	O
and	O
breeding	B-T038
were	O
both	O
poor	O
predictors	O
of	O
avian	B-T204
productivity	O
for	O
most	O
migrants	B-T204
analyzed	B-T062
.	O

Nevertheless	O
,	O
we	O
found	O
evidence	O
that	O
fitness	B-T038
benefits	O
may	O
occur	O
from	O
shifts	O
to	O
earlier	O
spring	O
arrival	O
for	O
the	O
multi	B-T204
-	I-T204
brooded	I-T204
Song	I-T204
Sparrow	I-T204
.	O

Our	O
results	O
uniquely	O
demonstrate	O
that	O
co	O
-	O
occurring	O
avian	B-T204
species	B-T170
are	O
phenologically	O
plastic	O
in	O
their	O
response	O
to	O
climate	O
change	O
on	O
their	O
breeding	O
grounds	O
.	O

If	O
migrants	B-T098
continue	O
to	O
show	O
a	O
weaker	O
response	O
to	O
temperatures	O
during	O
migration	O
than	O
breeding	B-T038
,	O
and	O
the	O
window	O
between	O
arrival	O
and	O
optimal	B-T038
breeding	I-T038
shortens	O
further	O
,	O
biological	O
constraints	O
to	O
plasticity	O
may	O
limit	O
the	O
ability	O
of	O
species	B-T170
to	O
adapt	O
successfully	O
to	O
future	O
warming	O
.	O

Mucosal	B-T017
IgM	B-T103
Antibody	I-T103
with	O
d	B-T103
-	I-T103
Mannose	I-T103
Affinity	O
in	O
Fugu	B-T204
Takifugu	I-T204
rubripes	I-T204
Is	O
Utilized	O
by	O
a	O
Monogenean	B-T204
Parasite	B-T204
Heterobothrium	B-T204
okamotoi	I-T204
for	O
Host	B-T038
Recognition	I-T038

How	O
parasites	B-T204
recognize	B-T038
their	O
definitive	O
hosts	O
is	O
a	O
mystery	O
;	O
however	O
,	O
parasitism	O
is	O
reportedly	O
initiated	O
by	O
recognition	B-T038
of	O
certain	O
molecules	O
on	O
host	B-T017
surfaces	I-T017
.	O

Fish	B-T204
ectoparasites	B-T204
make	O
initial	B-T033
contact	I-T033
with	O
their	O
hosts	O
at	O
body	O
surfaces	O
,	O
such	O
as	O
skin	B-T022
and	O
gills	B-T017
,	O
which	O
are	O
covered	O
with	O
mucosa	B-T017
that	O
are	O
similar	O
to	O
those	O
of	O
mammalian	B-T017
guts	I-T017
.	O

Fish	B-T204
are	O
among	O
the	O
most	O
primitive	B-T204
vertebrates	I-T204
with	O
immune	B-T022
systems	I-T022
that	O
are	O
equivalent	O
to	O
those	O
in	O
mammals	B-T204
,	O
and	O
they	O
produce	O
and	O
secrete	B-T038
IgM	B-T103
into	O
mucus	B-T031
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
the	O
monogenean	B-T204
parasite	B-T204
Heterobothrium	B-T204
okamotoi	I-T204
utilizes	O
IgM	B-T103
to	O
recognize	O
its	O
host	O
,	O
fugu	B-T204
Takifugu	I-T204
rubripes	I-T204
Oncomiracidia	I-T204
are	O
infective	B-T204
larvae	I-T204
of	O
H	B-T204
.	I-T204

okamotoi	I-T204
that	O
shed	O
their	O
cilia	B-T017
and	O
metamorphose	B-T038
into	O
juveniles	O
when	O
exposed	O
to	O
purified	O
d	B-T103
-	I-T103
mannose	I-T103
-	O
binding	O
fractions	O
from	O
fugu	B-T204
mucus	B-T031
.	O

Using	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
analysis	I-T058
,	O
proteins	B-T103
contained	O
in	O
the	O
fraction	O
were	O
identified	O
as	O
d	B-T103
-	I-T103
mannose	I-T103
-	O
specific	O
IgM	B-T103
with	O
two	O
d	B-T103
-	I-T103
mannose	I-T103
-	O
binding	O
lectins	B-T103
.	O

However	O
,	O
although	O
deciliation	B-T038
was	O
significantly	O
induced	O
by	O
IgM	B-T103
and	O
was	O
inhibited	O
by	O
d	B-T103
-	I-T103
mannose	I-T103
or	O
a	O
specific	O
Ab	B-T103
against	O
fugu	B-T204
IgM	B-T103
,	O
other	O
lectins	B-T103
had	O
no	O
effect	O
,	O
and	O
IgM	B-T103
without	O
d	B-T103
-	I-T103
mannose	I-T103
affinity	O
induced	O
deciliation	B-T038
to	O
a	O
limited	O
degree	O
.	O

Subsequent	O
immunofluorescent	B-T058
staining	I-T058
experiments	I-T058
showed	O
that	O
fugu	B-T204
d	B-T103
-	I-T103
mannose	I-T103
-	O
specific	O
IgM	B-T103
binds	O
ciliated	B-T017
epidermal	I-T017
cells	I-T017
of	O
oncomiracidium	B-T204
.	O

These	O
observations	O
suggest	O
that	O
deciliation	B-T038
is	O
triggered	O
by	O
binding	O
of	O
fugu	B-T204
IgM	B-T103
to	O
cell	B-T103
surface	I-T103
Ags	I-T103
via	O
Ag	B-T103
binding	I-T103
sites	I-T103
.	O

Moreover	O
,	O
concentrations	O
of	O
d	B-T103
-	I-T103
mannose	I-T103
-	O
binding	O
IgM	B-T103
in	O
gill	B-T031
mucus	I-T031
were	O
sufficient	O
to	O
induce	O
deciliation	B-T038
in	O
vitro	O
,	O
indicating	O
that	O
H	B-T204
.	I-T204

okamotoi	I-T204
parasites	I-T204
initially	O
use	O
host	O
Abs	B-T103
to	O
colonize	B-T033
host	O
gills	B-T017
.	O

BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
immunized	B-T058
with	O
a	O
combination	O
of	O
virus	B-T017
-	I-T017
like	I-T017
particles	I-T017
incorporating	O
Kaposi	B-T005
sarcoma	I-T005
-	I-T005
associated	I-T005
herpesvirus	I-T005
(	O
KSHV	B-T005
)	O
envelope	O
glycoproteins	B-T103
gpK8	I-T103
.	I-T103
1	I-T103
,	O
gB	B-T103
,	O
and	O
gH	B-T103
/	O
gL	B-T103
induced	O
comparable	O
serum	B-T031
neutralizing	B-T103
antibody	I-T103
activity	B-T038
to	O
UV	O
-	O
inactivated	O
KSHV	B-T005

Infection	O
with	O
Kaposi	B-T005
sarcoma	I-T005
-	I-T005
associated	I-T005
herpesvirus	I-T005
(	O
KSHV	B-T005
)	O
is	O
estimated	O
to	O
account	O
for	O
over	O
44	O
,	O
000	O
new	O
cases	O
of	O
Kaposi	B-T038
sarcoma	I-T038
annually	O
,	O
with	O
84	O
%	O
occurring	O
in	O
Africa	B-T082
,	O
where	O
the	O
virus	B-T005
is	O
endemic	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
prophylactic	B-T103
vaccine	I-T103
against	O
KSHV	B-T005
.	O

KSHV	B-T005
gpK8	B-T103
.	I-T103
1	I-T103
,	O
gB	B-T103
,	O
and	O
gH	B-T103
/	O
gL	B-T103
glycoproteins	I-T103
,	O
implicated	O
in	O
the	O
virus	B-T005
entry	O
into	O
host	B-T017
cells	I-T017
,	O
are	O
attractive	O
vaccine	B-T103
targets	O
for	O
eliciting	O
potent	O
neutralizing	B-T103
antibodies	I-T103
(	O
nAbs	B-T103
)	O
against	O
virus	B-T038
infection	I-T038
.	O

We	O
incorporated	O
gpK8	B-T103
.	I-T103
1	I-T103
,	O
gB	B-T103
,	O
or	O
gH	B-T103
/	O
gL	B-T103
on	O
the	O
surface	O
of	O
virus	B-T017
-	I-T017
like	I-T017
particles	I-T017
(	O
VLPs	B-T017
)	O
and	O
characterized	O
these	O
VLPs	B-T017
for	O
their	O
composition	O
,	O
size	O
,	O
and	O
functionality	O
.	O

To	O
determine	O
which	O
viral	B-T017
glycoprotein	I-T017
(	I-T017
s	I-T017
)	I-T017
elicit	O
the	O
most	O
effective	O
serum	B-T031
-	O
nAbs	B-T103
,	O
we	O
immunized	B-T058
BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
with	O
gpK8	B-T103
.	I-T103
1	I-T103
,	O
gB	B-T103
,	O
or	O
gH	B-T103
/	O
gL	B-T103
VLPs	B-T017
individually	O
or	O
in	O
combination	O
.	O

Neutralizing	B-T103
antibody	I-T103
assay	O
revealed	O
that	O
sera	O
from	O
mice	B-T204
immunized	B-T058
with	O
the	O
VLPs	B-T017
inhibited	O
KSHV	B-T005
infection	B-T038
of	O
HEK	B-T017
-	I-T017
293	I-T017
cells	I-T017
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

As	O
a	O
single	O
immunogen	B-T103
,	O
gpK8	B-T103
.	I-T103
1	I-T103
VLPs	B-T017
stimulated	O
comparable	O
nAb	B-T103
activity	O
to	O
that	O
of	O
UV	O
-	O
inactivated	O
KSHV	B-T005
(	O
UV	B-T005
-	I-T005
KSHV	I-T005
)	O
.	O

In	O
contrast	O
,	O
UV	B-T005
-	I-T005
KSHV	I-T005
stimulated	O
higher	O
titers	O
of	O
nAb	O
compared	O
to	O
gB	B-T103
(	O
p	O
=	O
0	O
.	O
0316	O
)	O
or	O
gH	B-T103
/	O
gL	B-T103
(	O
p	O
=	O
0	O
.	O
0486	O
)	O
.	O

Mice	B-T204
immunized	B-T058
with	O
the	O
combination	O
of	O
gB	B-T103
and	O
gH	B-T103
/	O
gL	B-T103
VLPs	B-T017
had	O
a	O
better	O
nAb	O
response	O
than	O
those	O
immunized	B-T058
with	O
either	O
gB	B-T103
(	O
p	O
=	O
0	O
.	O
0268	O
)	O
,	O
or	O
gH	B-T103
/	O
gL	O
(	O
p	O
=	O
0	O
.	O
0397	O
)	O
as	O
single	O
VLP	B-T017
immunogens	B-T103
.	O

Immunization	B-T058
with	O
any	O
VLP	B-T017
combination	O
stimulated	O
comparable	O
nAb	B-T103
activity	O
to	O
UV	B-T005
-	I-T005
KSHV	I-T005
serum	B-T031
.	O

Our	O
data	O
provide	O
the	O
first	O
evidence	O
that	O
KSHV	B-T005
gpK8	B-T103
.	I-T103
1	I-T103
,	O
gB	B-T103
,	O
and	O
gH	B-T103
/	O
gL	B-T103
glycoproteins	I-T103
can	O
be	O
incorporated	O
onto	O
the	O
surface	O
of	O
VLPs	B-T017
and	O
used	O
as	O
prophylactic	B-T103
vaccine	I-T103
candidates	O
,	O
with	O
potential	O
to	O
prevent	O
KSHV	B-T005
infection	B-T038
.	O

A	O
missense	B-T038
variant	O
,	O
rs373863828	B-T017
-	I-T017
A	I-T017
(	I-T017
p	I-T017
.	I-T017
Arg457Gln	I-T017
)	I-T017
,	I-T017
of	I-T017
CREBRF	I-T017
and	O
body	B-T201
mass	I-T201
index	I-T201
in	O
Oceanic	O
populations	O

It	O
has	O
been	O
suggested	O
that	O
a	O
'	O
thrifty	O
'	O
genotype	O
hypothesis	O
can	O
account	O
for	O
high	O
prevalence	O
of	O
obesity	B-T038
in	O
the	O
island	B-T082
populations	B-T098
of	O
Oceania	B-T082
.	O

A	O
recent	O
genome	B-T062
-	I-T062
wide	I-T062
association	I-T062
study	I-T062
revealed	O
that	O
a	O
missense	B-T038
variant	O
,	O
rs373863828	B-T017
-	I-T017
A	I-T017
(	I-T017
p	I-T017
.	I-T017
Arg457Gln	I-T017
)	I-T017
,	I-T017
of	I-T017
the	I-T017
CREBRF	I-T017
gene	I-T017
(	O
encoding	O
CREB3	B-T103
regulatory	I-T103
factor	I-T103
)	O
was	O
associated	O
with	O
an	O
excessive	O
increase	O
in	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
in	O
Samoans	B-T098
.	O

In	O
the	O
present	O
study	O
,	O
the	O
association	O
of	O
rs373863828	B-T017
-	I-T017
A	I-T017
with	O
an	O
increase	O
in	O
BMI	B-T201
was	O
examined	B-T033
in	O
four	O
Austronesian	O
(	O
AN	O
)	O
-	O
speaking	O
populations	B-T098
in	O
Oceania	B-T082
.	O

We	O
found	O
that	O
rs373863828	B-T017
-	I-T017
A	I-T017
was	O
frequently	O
observed	O
(	O
frequency	O
of	O
0	O
.	O
15	O
)	O
in	O
Tongans	B-T098
(	O
Polynesians	B-T098
)	O
,	O
and	O
was	O
strongly	O
associated	O
with	O
higher	O
BMI	B-T201
(	O
P	O
=	O
6	O
.	O
1	O
×	O
10	O
(	O
-	O
4	O
)	O
)	O
.	O

A	O
single	O
copy	O
of	O
the	O
rs373863828	B-T017
-	I-T017
A	I-T017
allele	B-T017
increased	O
BMI	B-T201
by	O
3	O
.	O
09	O
kg	O
m	O
(	O
-	O
2	O
)	O
after	O
adjustment	O
of	O
age	O
and	O
sex	O
.	O

No	B-T033
significant	I-T033
association	O
was	O
detected	B-T058
in	O
the	O
other	O
three	O
AN	O
-	O
speaking	O
populations	B-T098
(	O
Melanesians	B-T098
and	O
Micronesians	B-T098
)	O
living	O
in	O
Solomon	B-T082
Islands	I-T082
.	O

This	O
was	O
probably	O
due	O
to	O
the	O
low	O
allele	O
frequency	O
(	O
0	O
.	O
02	O
-	O
0	O
.	O
06	O
)	O
of	O
rs373863828	B-T017
-	I-T017
A	I-T017
as	O
well	O
as	O
small	O
sample	O
size	O
.	O

The	O
rs373863828	B-T017
-	I-T017
A	I-T017
allele	B-T017
was	O
not	O
found	O
in	O
both	O
AN	O
-	O
speaking	O
and	O
non	O
-	O
AN	O
-	O
speaking	O
Melanesians	B-T098
living	O
in	O
Papua	B-T082
New	I-T082
Guinea	I-T082
.	O

Our	O
results	O
suggest	O
that	O
rs373863828	B-T017
-	I-T017
A	I-T017
of	I-T017
CREBRF	I-T017
,	O
a	O
promising	O
thrifty	O
variant	O
,	O
arose	O
in	O
recent	O
ancestors	O
of	O
AN	O
-	O
speaking	O
Polynesians	B-T098
.	O
Journal	O
of	O
Human	O
Genetics	O
advance	O
online	O
publication	O
,	O
13	O
April	O
2017	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
jhg	O
.	O
2017	O
.	O
44	O
.	O

Vaccination	B-T058
of	O
piglets	B-T204
at	O
2	O
and	O
3	O
weeks	O
of	O
age	O
with	O
Ingelvac	B-T103
PRRSFLEX®	I-T103
EU	I-T103
provides	O
protection	O
against	O
heterologous	O
field	O
challenge	O
in	O
the	O
face	O
of	O
homologous	O
maternally	B-T103
derived	I-T103
antibodies	I-T103

Due	O
to	O
difficulties	O
in	O
eradicating	B-T058
porcine	B-T038
reproductive	I-T038
and	I-T038
respiratory	I-T038
syndrome	I-T038
(	O
PRRS	B-T038
)	O
linked	O
to	O
biosecurity	O
challenges	O
,	O
transmission	B-T038
of	I-T038
the	I-T038
virus	I-T038
and	O
the	O
lack	O
of	O
efficient	O
DIVA	B-T103
vaccines	I-T103
,	O
successful	O
control	O
of	O
PRRS	B-T038
requires	O
a	O
combination	O
of	O
strict	O
management	B-T058
measures	I-T058
and	O
vaccination	B-T058
of	O
both	O
sows	O
and	O
piglets	B-T204
.	O

The	O
present	O
study	B-T062
aimed	O
to	O
assess	O
the	O
efficacy	O
of	O
a	O
recently	O
developed	O
MLV	B-T103
vaccine	I-T103
(	O
Ingelvac	B-T103
PRRSFLEX®	I-T103
EU	I-T103
)	O
in	O
piglets	B-T204
at	O
2	O
and	O
3	O
-	O
weeks	O
of	O
age	O
in	O
the	O
presence	B-T033
of	O
homologous	O
maternally	B-T103
derived	I-T103
antibodies	I-T103
as	O
the	O
dams	O
were	O
vaccinated	B-T058
with	O
the	O
same	O
vaccine	B-T103
strain	I-T103
(	O
ReproCyc®	B-T103
PRRS	I-T103
EU	I-T103
)	O
.	O

The	O
study	B-T062
was	O
carried	O
out	O
on	O
a	O
Hungarian	B-T204
farrow	I-T204
to	O
finish	O
farm	B-T082
naturally	B-T033
infected	I-T033
with	O
PRRSv	B-T005
.	O

The	O
study	B-T062
was	O
designed	O
as	O
a	O
blind	B-T062
,	O
placebo	B-T062
controlled	I-T062
side	O
by	O
side	O
trial	O
.	O

ORF5	B-T103
sequence	O
similarity	O
of	O
the	O
vaccine	B-T103
strain	I-T103
and	O
the	O
resident	B-T098
field	I-T098
strain	I-T098
was	O
87	O
.	O
8	O
%	O
.	O

PRRS	B-T038
specific	O
real	B-T062
-	I-T062
time	I-T062
quantitative	I-T062
PCR	I-T062
was	O
performed	O
from	O
serum	B-T031
samples	I-T031
to	O
measure	O
both	O
the	O
viral	B-T058
load	I-T058
and	O
the	O
frequency	O
of	O
virus	B-T033
positive	I-T033
animals	B-T204
.	O

At	O
the	O
time	O
of	O
the	O
natural	B-T038
infection	I-T038
observed	O
in	O
the	O
control	O
group	O
at	O
10	O
-	O
12	O
weeks	O
of	O
age	O
,	O
the	O
number	O
of	O
viraemic	B-T033
animals	B-T204
did	O
not	O
increase	O
significantly	O
in	O
the	O
vaccinated	B-T058
group	O
.	O

To	O
understand	O
the	O
infection	B-T038
dynamics	O
,	O
positive	B-T033
PCR	B-T062
samples	O
with	O
low	O
Ct	O
values	O
were	O
sequenced	O
(	O
ORF5	B-T103
)	O
and	O
the	O
data	O
analysis	O
indicated	B-T033
the	O
circulation	B-T033
of	O
wild	O
type	O
virus	O
in	O
both	O
groups	O
,	O
however	O
wild	O
type	O
virus	B-T005
was	O
only	O
found	O
in	O
non	O
-	O
vaccinated	O
animals	O
.	O

Our	O
data	O
indicate	O
that	O
piglets	B-T204
vaccinated	B-T058
at	O
as	O
early	O
as	O
2	O
weeks	O
of	O
age	O
with	O
Ingelvac	B-T103
PRRSFLEX®	I-T103
EU	I-T103
were	O
protected	O
both	O
in	O
terms	O
of	O
proportion	O
of	O
viraemic	B-T033
animals	B-T204
and	O
viraemia	B-T038
levels	O
.	O

It	O
has	O
to	O
be	O
highlighted	O
that	O
these	O
results	O
were	O
achieved	O
in	O
piglets	B-T204
with	O
high	O
levels	O
of	O
homologous	O
maternally	B-T103
derived	I-T103
antibodies	I-T103
(	O
MDA	B-T103
)	O
at	O
the	O
time	O
of	O
vaccination	B-T058
.	O

Lung	B-T033
nodule	I-T033
in	O
French	B-T082
Guiana	I-T082
in	O
a	O
immunocompetent	B-T201
patient	O

We	O
report	O
the	O
case	O
of	O
an	O
immunocompetent	B-T201
French	B-T098
soldier	B-T097
stationed	O
in	O
French	B-T082
Guiana	I-T082
,	O
who	O
developed	O
symptomatic	O
pulmonary	B-T038
histoplasmosis	I-T038
.	O

Comparison	O
of	O
Occlusive	O
and	O
Open	B-T082
Application	O
in	O
a	O
Psoriasis	B-T062
Plaque	I-T062
Test	I-T062
Design	I-T062
,	O
Exemplarily	O
Using	O
Investigations	O
of	O
Mapracorat	B-T103
0	O
.	O
1	O
%	O
Ointment	B-T103
versus	O
Vehicle	B-T103
and	O
Reference	O
Drugs	B-T103

Psoriasis	B-T062
plaque	I-T062
tests	I-T062
(	O
PPTs	B-T062
)	O
are	O
important	O
tools	O
in	O
the	O
early	O
phases	O
of	O
antipsoriatic	B-T103
drug	B-T091
development	I-T091
.	O

Two	O
distinct	O
PPT	B-T062
design	I-T062
variants	O
(	O
open	O
vs	O
.	O

occluded	O
drug	O
application	O
)	O
are	O
commonly	O
used	O
,	O
but	O
no	O
previous	O
work	O
has	O
aimed	O
to	O
directly	O
compare	O
and	O
contrast	O
their	O
performance	O
.	O

We	O
compared	O
the	O
antipsoriatic	B-T103
efficacy	O
of	O
mapracorat	B-T103
0	O
.	O
1	O
%	O
ointment	B-T103
and	O
reference	O
drugs	B-T103
reported	O
in	O
2	O
separate	O
studies	B-T062
,	O
representing	O
open	B-T062
and	O
occluded	B-T062
PPT	I-T062
designs	I-T062
.	O

The	O
drug	O
effect	O
size	O
was	O
measured	O
by	O
sonography	B-T058
(	O
mean	O
change	O
in	O
echo	O
-	O
poor	O
band	O
thickness	O
)	O
,	O
chromametry	B-T058
,	O
and	O
standardized	O
clinical	O
assessment	O
.	O

Antipsoriatic	B-T103
effects	O
were	O
detectable	O
for	O
the	O
study	B-T062
drugs	B-T103
in	O
both	O
occluded	B-T062
and	O
open	B-T062
PPTs	I-T062
.	O

Differences	O
between	O
the	O
potency	O
of	O
antipsoriatic	B-T103
drugs	I-T103
and	O
vehicle	B-T103
were	O
observable	O
.	O

The	O
total	O
antipsoriatic	B-T103
effect	O
size	O
appeared	O
to	O
be	O
higher	O
in	O
the	O
occluded	B-T062
PPT	I-T062
than	O
the	O
open	B-T062
PPT	I-T062
,	O
despite	O
the	O
shorter	O
treatment	O
duration	O
(	O
2	O
vs	O
.	O

4	O
weeks	O
)	O
.	O

Effect	O
dynamics	O
over	O
time	O
revealed	O
greater	O
differences	O
between	O
some	O
study	B-T062
drugs	B-T103
in	O
the	O
open	B-T062
PPT	I-T062
compared	O
to	O
the	O
occluded	B-T062
PPT	I-T062
.	O

Taking	O
the	O
higher	O
technical	O
challenges	O
for	O
the	O
open	B-T062
PPT	I-T062
into	O
account	O
,	O
we	O
recommend	O
the	O
occluded	B-T062
PPT	I-T062
as	O
a	O
standard	O
screening	B-T062
setting	O
in	O
early	O
drug	B-T091
development	I-T091
.	O

In	O
special	O
cases	O
,	O
considering	O
certain	O
drug	B-T103
aspects	O
or	O
study	B-T062
objectives	O
that	O
would	O
require	O
procedural	O
adaptations	O
,	O
an	O
open	B-T062
PPT	I-T062
could	O
be	O
the	O
better	O
-	O
suited	O
design	O
.	O

Finally	O
,	O
both	O
PPT	B-T062
models	O
show	O
clear	O
advantages	O
:	O
classification	B-T170
as	O
phase	B-T062
I	I-T062
studies	I-T062
,	O
small	O
number	O
of	O
psoriatic	O
subjects	O
,	O
relatively	O
short	O
study	B-T062
duration	O
,	O
excellent	O
discrimination	O
between	O
compounds	B-T103
and	O
concentrations	O
,	O
parallel	O
measurement	O
of	O
treatment	B-T201
response	I-T201
,	O
and	O
go	O
/	O
no	O
go	O
decisions	O
very	O
early	O
in	O
clinical	B-T062
development	I-T062
.	O

Insurance	O
Coverage	O
and	O
Utilization	O
at	O
a	O
Sexually	B-T092
Transmitted	I-T092
Disease	I-T092
Clinic	I-T092
in	O
a	O
Medicaid	O
Expansion	O
State	B-T082

In	O
Rhode	B-T082
Island	I-T082
,	O
the	O
Patient	B-T170
Protection	I-T170
and	I-T170
Affordable	I-T170
Care	I-T170
Act	I-T170
has	O
led	O
to	O
over	O
95	O
%	O
of	O
the	O
state	B-T082
'	I-T082
s	I-T082
population	O
being	O
insured	O
.	O

We	O
evaluated	B-T058
insurance	O
coverage	O
and	O
barriers	B-T033
to	O
insurance	B-T058
use	O
among	O
patients	O
presenting	O
for	O
services	B-T058
at	O
the	O
Rhode	B-T082
Island	I-T082
sexually	B-T092
transmitted	I-T092
disease	I-T092
(	I-T092
STD	I-T092
)	I-T092
clinic	I-T092
.	O

We	O
analyzed	B-T062
factors	O
associated	O
with	O
insurance	O
coverage	O
and	O
utilization	O
among	O
patients	O
presenting	O
for	O
STD	B-T038
services	B-T058
between	O
July	O
and	O
December	O
2015	O
.	O

A	O
total	O
of	O
692	O
patients	O
had	O
insurance	O
information	O
available	O
;	O
of	O
those	O
,	O
40	O
%	O
were	O
uninsured	B-T098
.	O

Patients	O
without	B-T098
insurance	I-T098
were	O
more	O
likely	O
than	O
those	O
with	O
insurance	B-T058
to	O
be	O
nonwhite	O
(	O
50	O
%	O
among	O
uninsured	B-T098
,	O
compared	O
with	O
40	O
%	O
among	O
insured	O
;	O
P	O
=	O
0	O
.	O
014	O
)	O
and	O
Hispanic	B-T098
or	O
Latino	B-T098
/	I-T098
a	I-T098
(	O
25	O
%	O
,	O
compared	O
with	O
16	O
%	O
;	O
P	O
=	O
0	O
.	O
006	O
)	O
,	O
and	O
less	O
likely	O
to	O
be	O
men	B-T098
who	O
have	O
sex	B-T038
with	O
men	B-T098
(	O
27	O
%	O
,	O
compared	O
with	O
39	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Of	O
those	O
with	O
health	B-T058
insurance	I-T058
,	O
26	O
%	O
obtained	O
coverage	O
as	O
a	O
result	O
of	O
the	O
Affordable	B-T170
Care	I-T170
Act	I-T170
,	O
and	O
56	O
%	O
of	O
those	O
were	O
previously	O
uninsured	B-T098
.	O

Among	O
uninsured	B-T098
individuals	I-T098
,	O
barriers	B-T033
to	O
obtaining	O
health	B-T058
insurance	I-T058
included	O
cost	O
and	O
unemployment	B-T033
.	O

Among	O
those	O
with	O
insurance	O
,	O
43	O
%	O
reported	O
willingness	B-T033
to	O
use	O
insurance	B-T058
for	O
STD	B-T038
services	B-T058
.	O

Barriers	B-T033
to	O
insurance	B-T058
use	O
included	O
concerns	O
about	O
anonymity	O
and	O
out	O
-	O
of	O
-	O
pocket	O
costs	O
.	O

Despite	O
expanded	O
insurance	B-T058
access	O
,	O
many	O
individuals	B-T098
presenting	O
to	O
the	O
Rhode	B-T082
Island	I-T082
STD	B-T092
Clinic	I-T092
were	O
uninsured	B-T098
.	O

Among	O
those	O
who	O
were	O
insured	O
,	O
significant	O
barriers	B-T033
still	O
existed	O
to	O
using	O
insurance	B-T058
.	O

STD	B-T092
clinics	I-T092
continue	O
to	O
play	O
an	O
important	O
role	O
in	O
providing	O
safety	B-T058
-	I-T058
net	I-T058
STD	B-T038
services	B-T058
in	O
states	B-T082
with	O
low	O
uninsured	B-T098
rates	O
.	O

Both	O
public	B-T092
and	O
private	B-T092
insurers	B-T092
are	O
needed	O
to	O
address	O
financial	O
barriers	O
and	O
optimize	O
payment	O
structures	B-T082
for	O
services	B-T058
.	O

Molecular	B-T058
subtyping	I-T058
of	O
Treponema	B-T007
pallidum	I-T007
and	O
associated	O
factors	O
of	O
serofast	O
status	O
in	O
early	B-T038
syphilis	I-T038
patients	O
:	O
Identified	O
novel	O
genotype	O
and	O
cytokine	B-T103
marker	B-T201

Serofast	O
,	O
a	O
persistent	O
nontreponemal	O
serological	O
response	B-T201
observed	O
in	O
early	B-T038
syphilis	I-T038
patients	O
after	O
conventional	B-T058
treatment	I-T058
,	O
remains	O
a	O
concern	O
of	O
clinicians	B-T097
and	O
syphilis	B-T038
patients	O
.	O

No	O
consensus	O
has	O
been	O
established	O
,	O
however	O
,	O
that	O
defines	O
an	O
effective	O
treatment	B-T058
strategy	I-T058
and	O
clarifies	O
the	O
pathogenesis	B-T038
.	O

In	O
this	O
study	B-T062
,	O
517	O
patients	O
with	O
early	B-T038
syphilis	I-T038
were	O
enrolled	B-T058
and	O
treated	O
.	O

Twelve	O
months	O
after	O
treatment	B-T058
,	O
79	O
.	O
3	O
%	O
(	O
410	O
/	O
517	O
)	O
of	O
patients	O
achieved	O
serological	O
cure	O
,	O
20	O
.	O
1	O
%	O
(	O
104	O
/	O
517	O
)	O
were	O
serofast	O
,	O
and	O
0	O
.	O
6	O
%	O
(	O
3	O
/	O
517	O
)	O
were	O
serological	O
failures	O
.	O

Multivariate	O
analysis	O
demonstrated	O
that	O
older	B-T098
age	I-T098
(	O
>	O
40	O
years	O
)	O
and	O
lower	O
baseline	O
RPR	O
titer	O
(	O
≤	O
1	O
:	O
8	O
)	O
were	O
associated	O
with	O
serofast	O
status	O
.	O

We	O
also	O
identified	O
21	O
T	B-T007
.	I-T007

pallidum	I-T007
molecular	B-T170
subtypes	I-T170
among	O
early	B-T038
syphilis	I-T038
patients	O
and	O
detected	O
a	O
new	O
subtype	B-T170
,	I-T170
14i	I-T170
/	I-T170
a	I-T170
.	O

We	O
found	O
that	O
the	O
proportion	O
of	O
14i	B-T170
/	I-T170
a	I-T170
type	I-T170
in	O
serofast	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
patients	O
with	O
serological	O
cure	O
,	O
predicting	O
an	O
increasing	O
risk	O
of	O
serofast	O
status	O
.	O

Levels	O
of	O
chemerin	B-T103
were	O
higher	O
in	O
the	O
serum	B-T031
of	O
serofast	O
cases	O
than	O
serological	O
cure	O
cases	O
,	O
potentially	O
indicating	O
a	O
novel	O
cytokine	B-T103
marker	B-T201
for	O
serofast	O
in	O
early	B-T038
syphilis	I-T038
patients	O
after	O
therapy	B-T058
.	O

We	O
hope	O
that	O
these	O
results	O
contribute	O
to	O
improve	B-T033
guidelines	B-T170
for	O
the	O
management	B-T058
of	O
syphilis	B-T038
patients	O
who	O
experience	O
serofast	O
.	O

Total	O
Fluorescence	O
Fingerprinting	O
of	O
Pesticides	B-T103
:	O
A	O
Reliable	O
Approach	O
for	O
Continuous	O
Monitoring	O
of	O
Soils	O
and	O
Waters	O

The	O
present	O
work	O
relates	O
to	O
the	O
creation	O
/	O
extension	O
of	O
a	O
database	B-T170
of	O
Total	B-T058
Excitation	I-T058
-	I-T058
Emission	I-T058
and	I-T058
Total	I-T058
Synchronous	I-T058
Fluorescence	I-T058
Matrices	I-T058
(	O
TEEMs	B-T058
and	I-T058
TSFMs	I-T058
)	O
along	O
with	O
optimal	B-T058
Synchronous	I-T058
Fluorescence	I-T058
Spectra	I-T058
(	O
SFS	B-T058
)	O
to	O
fingerprint	O
pesticides	B-T103
widely	O
used	O
in	O
Morocco	B-T082
.	O

This	O
spectrometric	B-T058
multi	I-T058
-	I-T058
component	I-T058
fingerprinting	I-T058
may	O
permit	O
the	O
direct	O
detection	B-T058
of	I-T058
pesticides	I-T058
persisting	B-T103
in	I-T103
soil	I-T103
or	O
water	B-T103
.	O

The	O
objective	O
of	O
the	O
current	O
investigation	O
is	O
to	O
detect	B-T058
four	I-T058
pesticide	I-T058
remains	O
in	O
agricultural	B-T082
soils	I-T082
by	O
applying	O
the	O
spectrometric	B-T058
fingerprinting	I-T058
results	O
.	O

They	O
are	O
the	O
commercial	O
:	O
i	O
)	O
insecticide	B-T103
Axlera	I-T103
5G	I-T103
(	O
carbamate	B-T103
)	O
,	O
ii	O
)	O
fungicide	B-T103
Orsalis	I-T103
5	I-T103
%	I-T103
SC	I-T103
(	O
triazole	B-T103
)	O
,	O
iii	O
)	O
insecticide	B-T103
Force	I-T103
0	I-T103
,	I-T103
5	I-T103
G	I-T103
(	O
pyrethrinoid	B-T103
)	O
and	O
iv	O
)	O
insecticide	B-T103
Proclaim	I-T103
05	I-T103
SG	I-T103
(	O
non	O
-	O
assigned	O
)	O
.	O

The	O
agricultural	O
plantations	O
monitored	O
are	O
located	O
in	O
the	O
great	B-T082
agricultural	I-T082
Doukkala	I-T082
region	I-T082
at	O
the	O
western	B-T082
Atlantic	I-T082
side	I-T082
of	O
Morocco	B-T082
,	O
where	O
these	O
chemicals	B-T103
are	O
in	O
large	O
sale	O
and	O
use	O
.	O

Engagement	O
of	O
cellular	B-T103
prion	I-T103
protein	I-T103
with	O
the	O
co	B-T103
-	I-T103
chaperone	I-T103
Hsp70	B-T103
/	I-T103
90	B-T103
organizing	I-T103
protein	I-T103
regulates	O
the	O
proliferation	B-T038
of	O
glioblastoma	B-T017
stem	I-T017
-	I-T017
like	I-T017
cells	I-T017

Glioblastoma	B-T038
(	O
GBM	B-T038
)	O
,	O
a	O
highly	O
aggressive	O
brain	B-T038
tumor	I-T038
,	O
contains	O
a	O
subpopulation	O
of	O
glioblastoma	B-T017
stem	I-T017
-	I-T017
like	I-T017
cells	I-T017
(	O
GSCs	B-T017
)	O
that	O
play	O
roles	O
in	O
tumor	B-T038
maintenance	O
,	O
invasion	B-T038
,	O
and	O
therapeutic	B-T038
resistance	I-T038
.	O

GSCs	B-T017
are	O
therefore	O
a	O
promising	O
target	O
for	O
GBM	B-T038
treatment	O
.	O

Our	O
group	O
identified	O
the	O
cellular	B-T103
prion	I-T103
protein	I-T103
(	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
)	O
and	O
its	O
partner	O
,	O
the	O
co	B-T103
-	I-T103
chaperone	I-T103
Hsp70	B-T103
/	I-T103
90	B-T103
organizing	I-T103
protein	I-T103
(	O
HOP	B-T103
)	O
,	O
as	O
potential	O
target	O
candidates	O
due	O
to	O
their	O
role	O
in	O
GBM	B-T038
tumorigenesis	B-T038
and	O
in	O
neural	B-T017
stem	I-T017
cell	I-T017
maintenance	O
.	O

GSCs	B-T017
expressing	O
different	O
levels	O
of	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
were	O
cultured	B-T058
as	O
neurospheres	B-T017
with	O
growth	B-T103
factors	I-T103
,	O
and	O
characterized	O
with	O
stem	B-T017
cells	I-T017
markers	B-T082
and	O
adhesion	B-T082
molecules	I-T082
markers	I-T082
through	O
immunofluorescence	B-T058
and	O
flow	B-T058
cytometry	I-T058
.	O

We	O
than	O
evaluated	O
GSC	B-T017
self	B-T038
-	I-T038
renewal	I-T038
and	O
proliferation	B-T038
by	O
clonal	B-T058
density	I-T058
assays	I-T058
and	O
BrdU	B-T058
incorporation	I-T058
,	O
respectively	O
,	O
in	O
front	O
of	O
recombinant	O
HOP	B-T103
treatment	O
,	O
combined	O
or	O
not	O
with	O
a	O
HOP	B-T103
peptide	B-T103
which	O
mimics	O
the	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
binding	B-T103
site	I-T103
.	O

Stable	O
silencing	B-T038
of	O
HOP	B-T103
was	O
also	O
performed	O
in	O
parental	O
and	O
/	O
or	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
-	O
depleted	O
cell	B-T017
populations	I-T017
,	O
and	O
proliferation	B-T038
in	O
vitro	O
and	O
tumor	O
growth	O
in	B-T082
vivo	I-T082
were	O
evaluated	O
.	O

Migration	B-T058
assays	I-T058
were	O
performed	O
on	O
laminin	B-T103
-	I-T103
1	I-T103
pre	O
-	O
coated	O
glass	O
.	O

We	O
observed	O
that	O
,	O
when	O
GBM	B-T038
cells	B-T017
are	O
cultured	B-T058
as	O
neurospheres	B-T017
,	O
they	O
express	O
specific	O
stemness	B-T082
markers	I-T082
such	O
as	O
CD133	B-T103
,	O
CD15	B-T103
,	O
Oct4	B-T103
,	O
and	O
SOX2	B-T103
;	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
is	O
upregulated	O
compared	O
to	O
monolayer	B-T058
culture	I-T058
and	O
co	O
-	O
localizes	O
with	O
CD133	B-T103
.	O

PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
silencing	B-T038
downregulates	O
the	O
expression	B-T038
of	I-T038
molecules	I-T038
associated	O
with	O
cancer	B-T017
stem	I-T017
cells	I-T017
,	O
upregulates	O
markers	B-T082
of	O
cell	B-T038
differentiation	I-T038
and	O
affects	O
GSC	B-T017
self	B-T038
-	I-T038
renewal	I-T038
,	O
pointing	O
to	O
a	O
pivotal	O
role	O
for	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
in	O
the	O
maintenance	O
of	O
GSCs	B-T017
.	O

Exogenous	O
HOP	B-T103
treatment	O
increases	O
proliferation	B-T038
and	O
self	B-T038
-	I-T038
renewal	I-T038
of	O
GSCs	B-T017
in	O
a	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
-	O
dependent	O
manner	O
while	O
HOP	B-T103
knockdown	O
disturbs	O
the	O
proliferation	B-T038
process	I-T038
.	O

In	B-T082
vivo	I-T082
,	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
and	O
/	O
or	O
HOP	B-T103
knockdown	O
potently	O
inhibits	O
the	O
growth	B-T038
of	O
subcutaneously	O
implanted	O
glioblastoma	B-T038
cells	B-T017
.	O

In	O
addition	O
,	O
disruption	O
of	O
the	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
-	I-T103
HOP	B-T103
complex	I-T103
by	O
a	O
HOP	B-T103
peptide	B-T103
,	O
which	O
mimics	O
the	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
binding	B-T103
site	I-T103
,	O
affects	O
GSC	B-T017
self	B-T038
-	I-T038
renewal	I-T038
and	O
proliferation	B-T038
indicating	O
that	O
the	O
HOP	B-T103
-	I-T103
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
complex	I-T103
is	O
required	O
for	O
GSC	B-T017
stemness	O
.	O

Furthermore	O
,	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
-	O
depleted	O
GSCs	B-T017
downregulate	O
cell	B-T017
adhesion	B-T103
-	I-T103
related	I-T103
proteins	I-T103
and	O
impair	O
cell	B-T038
migration	I-T038
indicating	O
a	O
putative	O
role	O
for	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
in	O
the	O
cell	B-T033
surface	I-T033
stability	I-T033
of	O
cell	B-T103
adhesion	I-T103
molecules	I-T103
and	O
GBM	B-T038
cell	O
invasiveness	B-T038
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
show	O
that	O
the	O
modulation	O
of	O
HOP	B-T103
-	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
engagement	O
or	O
the	O
decrease	O
of	O
PrP	B-T103
(	I-T103
C	I-T103
)	I-T103
and	O
HOP	B-T103
expression	B-T038
may	O
represent	O
a	O
potential	O
therapeutic	B-T058
intervention	I-T058
in	O
GBM	B-T038
,	O
regulating	O
glioblastoma	B-T017
stem	I-T017
-	I-T017
like	I-T017
cell	I-T017
self	B-T038
-	I-T038
renewal	I-T038
,	O
proliferation	B-T038
,	O
and	O
migration	B-T038
.	O

Cyclic	B-T038
thrombocytopenia	I-T038
synchronizing	O
with	O
the	O
menstrual	B-T038
cycle	I-T038
showing	O
periodic	O
phases	O
of	O
thrombocytopenia	B-T038
and	O
rebound	O
thrombocytosis	B-T038

A	O
37	O
-	O
year	O
-	O
old	O
woman	B-T098
was	O
admitted	B-T058
to	O
our	O
hospital	B-T092
for	O
purpura	B-T038
involving	O
the	O
extremities	B-T017
and	O
thrombocytopenia	B-T038
.	O

Prednisolone	B-T103
(	O
PSL	B-T103
)	O
was	O
administered	O
based	O
on	O
a	O
diagnosis	B-T033
of	O
idiopathic	B-T038
thrombocytopenic	I-T038
purpura	I-T038
(	O
ITP	B-T038
)	O
,	O
but	O
was	O
not	O
effective	O
for	O
maintaining	O
her	O
platelet	B-T058
count	I-T058
within	O
the	O
normal	O
range	O
,	O
which	O
showed	O
cyclic	O
fluctuation	O
corresponding	O
to	O
the	O
menstrual	B-T038
cycle	I-T038
.	O

Therefore	O
,	O
we	O
discontinued	B-T033
PSL	B-T103
,	O
and	O
cyclic	B-T038
thrombocytopenia	I-T038
(	O
CTP	B-T038
)	O
was	O
diagnosed	B-T033
.	O

CTP	B-T038
is	O
a	O
rare	B-T038
disease	I-T038
which	O
is	O
usually	O
treated	O
as	O
ITP	B-T038
but	O
with	O
no	B-T033
response	I-T033
.	O

Although	O
the	O
exact	O
cause	O
of	O
CTP	B-T038
is	O
uncertain	B-T033
,	O
in	O
our	O
case	O
,	O
a	O
hormonal	O
mechanism	O
may	O
be	O
responsible	O
for	O
fluctuating	O
platelet	B-T058
count	I-T058
.	O

Comparative	B-T058
evaluation	I-T058
of	O
iodine	B-T103
-	I-T103
131	I-T103
metaiodobenzylguanidine	I-T103
and	O
18	B-T103
-	I-T103
fluorodeoxyglucose	I-T103
positron	B-T058
emission	I-T058
tomography	I-T058
in	O
assessing	O
neural	B-T038
crest	I-T038
tumors	I-T038
:	O
Will	O
they	O
play	O
a	O
complementary	O
role	O
?	O

18	B-T103
-	I-T103
Fluorodeoxyglucose	I-T103
positron	B-T058
emission	I-T058
tomography	I-T058
(	O
FDG	B-T058
-	I-T058
PET	I-T058
)	O
has	O
established	O
a	O
role	O
in	O
the	O
evaluation	O
of	O
several	O
malignancies	B-T038
.	O

However	O
,	O
its	O
precise	O
clinical	O
role	O
in	O
the	O
neural	B-T038
crest	I-T038
cell	I-T038
tumors	I-T038
continues	O
to	O
evolve	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
iodine	B-T103
-	I-T103
131	I-T103
metaiodobenzylguanidine	I-T103
(	O
(	B-T103
131	I-T103
)	I-T103
I	I-T103
-	I-T103
MIBG	I-T103
)	O
and	O
FDG	B-T058
-	I-T058
PET	I-T058
of	O
head	O
to	O
head	O
in	O
patients	O
with	O
neural	B-T038
crest	I-T038
tumors	I-T038
both	O
qualitatively	O
and	O
semiquantitatively	O
and	O
to	O
determine	O
their	O
clinical	B-T033
utility	I-T033
in	O
disease	B-T033
status	I-T033
evaluation	I-T033
and	O
further	B-T058
management	I-T058
.	O

A	O
total	O
of	O
32	O
patients	O
who	O
had	O
undergone	O
(	B-T103
131	I-T103
)	I-T103
I	I-T103
-	I-T103
MIBG	I-T103
and	O
FDG	B-T058
-	I-T058
PET	I-T058
prospectively	O
were	O
evaluated	O
and	O
clinicopathologically	O
grouped	O
into	O
three	O
categories	O
:	O
neuroblastoma	B-T038
,	O
pheochromocytoma	B-T038
,	O
and	O
medullary	B-T038
carcinoma	I-T038
thyroid	I-T038
.	O

In	O
18	O
patients	O
of	O
neuroblastoma	B-T038
,	O
FDG	B-T058
PET	I-T058
and	O
(	B-T103
131	I-T103
)	I-T103
I	I-T103
-	I-T103
MIBG	I-T103
showed	O
patient	B-T033
-	I-T033
specific	I-T033
sensitivity	I-T033
of	O
84	O
%	O
and	O
72	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
maximum	O
standardized	O
uptake	O
value	O
(	O
SUVmax	O
)	O
of	O
primary	B-T038
lesions	I-T038
in	O
patients	O
with	O
unfavorable	O
histology	O
was	O
found	O
to	O
be	O
relatively	O
higher	O
than	O
those	O
with	O
favorable	O
histology	O
(	O
5	O
.	O
18	O
±	O
2	O
.	O
38	O
vs	O
.	O

3	O
.	O
21	O
±	O
1	O
.	O
69	O
)	O
.	O

The	O
mean	O
SUVmax	O
of	O
two	O
common	O
sites	O
(	O
posterior	B-T017
superior	I-T017
iliac	I-T017
spine	I-T017
[	O
PSIS	B-T017
]	O
and	O
greater	B-T017
trochanter	I-T017
)	O
was	O
higher	O
in	O
patients	O
with	O
involved	O
marrow	B-T017
than	O
those	O
with	O
uninvolved	O
one	O
(	O
2	O
.	O
36	O
and	O
2	O
.	O
75	O
vs	O
.	O

1	O
.	O
26	O
and	O
1	O
.	O
34	O
,	O
respectively	O
)	O
.	O

The	O
ratio	O
of	O
SUVmax	O
of	O
the	O
involved	O
/	O
contralateral	B-T082
normal	I-T082
sites	I-T082
was	O
2	O
.	O
16	O
±	O
1	O
.	O
9	O
.	O

In	O
equivocal	O
bone	B-T033
marrow	I-T033
results	I-T033
,	O
the	O
uptake	O
pattern	O
with	O
SUV	O
estimation	O
can	O
depict	O
metastatic	O
involvement	O
and	O
help	O
in	O
redirecting	O
the	O
biopsy	B-T201
site	I-T201
.	O

Among	O
seven	O
patients	O
of	O
pheochromocytoma	B-T038
,	O
FDG	B-T058
-	I-T058
PET	I-T058
revealed	O
100	O
%	O
patient	B-T033
-	I-T033
specific	I-T033
sensitivity	I-T033
.	O

FDG	B-T058
-	I-T058
PET	I-T058
detected	O
more	O
metastatic	B-T082
foci	I-T082
than	O
(	B-T103
131	I-T103
)	I-T103
I	I-T103
-	I-T103
MIBG	I-T103
(	O
18	O
vs	O
.	O

13	O
sites	O
)	O
.	O

In	O
seven	O
patients	O
of	O
medullary	B-T038
carcinoma	I-T038
thyroid	I-T038
,	O
FDG	B-T058
-	I-T058
PET	I-T058
localized	O
residual	O
,	O
recurrent	B-T038
,	O
or	O
metastatic	B-T038
disease	I-T038
with	O
much	O
higher	O
sensitivity	O
(	O
32	O
metastatic	B-T082
foci	I-T082
with	O
72	O
%	O
patient	B-T033
specific	I-T033
sensitivity	I-T033
)	O
than	O
(	B-T103
131	I-T103
)	I-T103
I	I-T103
-	I-T103
MIBG	I-T103
,	O
trending	O
along	O
the	O
higher	B-T058
serum	I-T058
calcitonin	I-T058
levels	I-T058
.	O

FDG	B-T058
-	I-T058
PET	I-T058
is	O
not	O
only	O
a	O
good	O
complementary	O
modality	O
in	O
the	O
management	O
of	O
neural	B-T038
crest	I-T038
cell	I-T038
tumors	I-T038
but	O
also	O
it	O
can	O
even	O
be	O
superior	O
,	O
especially	O
in	O
cases	O
of	O
(	B-T103
131	I-T103
)	I-T103
I	I-T103
-	I-T103
MIBG	I-T103
nonavid	B-T038
tumors	I-T038
.	O

Progressive	O
Occlusion	O
and	O
Recanalization	B-T058
after	O
Endovascular	B-T058
Treatment	I-T058
for	O
287	O
Unruptured	B-T038
Small	I-T038
Aneurysms	I-T038
(	O
<	O
5mm	O
)	O
:	O
A	O
Single	B-T092
-	I-T092
Center	I-T092
6	O
-	O
Year	O
Experience	B-T038

We	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
coiling	B-T082
for	O
small	O
unruptured	B-T038
intracranial	I-T038
aneurysms	I-T038
(	O
UIAs	B-T038
)	O
﹤5mm	O
)	O
on	O
progressive	O
occlusio	O
n	O
and	O
recanalization	B-T058
,	O
and	O
the	O
dubious	O
factors	O
related	O
to	O
progressive	O
occlusion	O
and	O
recanalization	B-T058
among	O
UIAs	B-T038
without	O
complete	O
occlusion	O
.	O

A	O
total	O
of	O
264	O
patients	O
with	O
287	O
small	O
UIAs	B-T038
were	O
coiled	O
in	O
our	O
institute	B-T092
between	O
June	O
2009	O
and	O
December	O
2014	O
.	O

All	O
UIAs	B-T038
enrolled	O
were	O
divided	O
into	O
small	O
(	O
3	O
-	O
5mm	O
)	O
and	O
very	O
small	O
(	O
<	O
3mm	O
)	O
group	O
s	O
,	O
and	O
UIAs	B-T038
without	O
initial	O
complete	O
occlusion	O
were	O
divided	O
into	O
progressive	O
,	O
stable	O
and	O
recanalization	B-T058
groups	O
.	O

Baseline	O
characteristics	O
,	O
procedure	B-T058
-	O
related	O
complications	B-T038
,	O
angiographic	B-T058
follow	B-T058
-	I-T058
up	I-T058
results	I-T058
,	O
and	O
clinical	O
outcomes	O
were	O
statistically	O
analyzed	O
.	O

Among	O
287	O
aneurysms	B-T038
,	O
211	O
aneurysms	B-T038
(	O
73	O
.	O
5	O
%	O
)	O
were	O
completely	O
coiled	O
,	O
three	O
(	O
1	O
.	O
2	O
%	O
)	O
intraoperative	O
ruptures	B-T037
and	O
12	O
(	O
4	O
.	O
2	O
%	O
)	O
perioperative	O
thromboembolic	B-T038
events	I-T038
occurred	O
.	O

Angiographic	B-T058
follow	B-T058
-	I-T058
up	I-T058
was	O
available	O
for	O
174	O
patients	O
(	O
65	O
.	O
9	O
%	O
)	O
,	O
the	O
incidence	O
of	O
recanalization	B-T058
was	O
5	O
.	O
7	O
%	O
.	O

Among	O
56	O
aneurysms	B-T038
without	O
complete	O
occlusion	O
,	O
43	O
(	O
76	O
.	O
8	O
%	O
)	O
had	O
progressive	O
occlusion	O
and	O
6	O
(	O
10	O
.	O
7	O
%	O
)	O
had	O
recanalization	B-T058
.	O

Anatomic	B-T033
results	I-T033
of	O
initial	O
and	O
follow	B-T058
-	I-T058
up	I-T058
between	O
small	O
and	O
very	O
small	O
groups	O
were	O
similar	O
in	O
both	O
groups	O
.	O

On	O
logistic	O
regression	O
analysis	O
,	O
smaller	O
size	B-T082
(	O
<	O
3mm	O
)	O
without	O
complete	O
occlusion	O
related	O
to	O
recanalization	B-T058
(	O
OR	O
,	O
8	O
.	O
0	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
3	O
-	O
50	O
.	O
0	O
,	O
P	O
=	O
0	O
.	O
026	O
)	O
.	O

Our	O
study	B-T062
suggested	O
that	O
coil	B-T058
embolization	I-T058
of	O
small	O
UIAs	B-T038
can	O
achieve	O
a	O
high	O
rate	O
of	O
progressive	O
occlusion	O
and	O
low	O
rate	O
of	O
recanalization	B-T058
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Anatomic	B-T033
results	I-T033
of	O
initial	O
and	O
follow	B-T058
-	I-T058
up	I-T058
between	O
small	O
(	O
3	O
-	O
5mm	O
)	O
and	O
very	O
small	O
(	O
<	O
3mm	O
)	O
groups	O
were	O
similar	O
in	O
both	O
groups	O
.	O

What	O
'	O
s	O
more	O
,	O
smaller	O
size	O
(	O
<	O
3mm	O
)	O
without	O
complete	O
occlusion	O
may	O
relate	O
to	O
recanalization	B-T058
.	O

Selection	O
of	O
an	O
Artificial	O
Diet	B-T168
for	O
Laboratory	B-T092
Rearing	O
of	O
Opogona	B-T204
sacchari	I-T204
(	O
Lepidoptera	B-T204
:	O
Tineidae	B-T204
)	O
(	O
Bojer	O
,	O
1856	O
)	O

The	O
banana	B-T204
moth	I-T204
Opogona	I-T204
sacchari	I-T204
(	O
Bojer	B-T204
)	O
(	O
Lepidoptera	B-T204
:	O
Tineidae	B-T204
)	O
is	O
a	O
polyphagous	B-T204
pest	I-T204
that	O
can	O
cause	O
serious	O
damage	O
,	O
in	O
particular	O
to	O
banana	B-T168
crops	B-T204
in	O
southern	B-T082
Brazil	B-T082
.	O

The	O
insect	B-T204
is	O
a	O
quarantine	O
pest	B-T204
in	O
several	O
countries	B-T082
,	O
including	O
Argentina	B-T082
,	O
the	O
main	O
consumer	B-T098
market	B-T082
for	O
bananas	B-T168
from	O
southern	B-T082
Brazil	B-T082
.	O

Little	O
information	O
is	O
available	O
about	O
the	O
biology	B-T091
and	O
ecology	O
of	O
this	O
moth	B-T204
,	O
such	O
as	O
a	O
suitable	O
diet	B-T168
for	O
laboratory	B-T092
rearing	O
.	O

In	O
order	O
to	O
provide	O
support	O
for	O
integrated	O
pest	O
management	O
of	O
the	O
pest	B-T204
,	O
this	O
study	B-T062
furnished	O
data	O
for	O
selecting	O
two	O
diets	B-T168
suitable	O
for	O
continuous	O
laboratory	B-T092
rearing	O
of	O
O	B-T204
.	I-T204

sacchari	I-T204
,	O
one	O
based	O
on	O
dried	O
beans	B-T168
,	O
wheat	B-T168
germ	I-T168
,	O
soy	B-T168
bran	I-T168
,	O
brewer	B-T204
'	I-T204
s	I-T204
yeast	I-T204
,	O
and	O
casein	B-T103
and	O
another	O
diet	B-T168
with	O
wheat	B-T168
germ	I-T168
and	O
casein	B-T103
as	O
protein	B-T103
sources	B-T033
.	O

With	O
both	O
diets	B-T168
,	O
the	O
viability	O
of	O
the	O
egg	B-T017
-	O
adult	O
period	O
exceeded	O
68	O
%	O
,	O
with	O
fertility	B-T038
over	O
338	O
eggs	B-T017
per	O
female	B-T098
.	O

A	O
corrected	O
biotic	O
potential	O
analysis	B-T062
gave	O
similar	O
values	O
for	O
the	O
two	O
diets	B-T168
.	O

The	O
impact	O
on	O
productivity	O
of	O
a	O
hypothetical	O
tax	O
on	O
sugar	B-T168
-	I-T168
sweetened	I-T168
beverages	I-T168

To	O
quantify	O
the	O
potential	O
impact	O
of	O
an	O
additional	O
20	O
%	O
tax	O
on	O
sugar	B-T168
-	I-T168
sweetened	I-T168
beverages	I-T168
(	O
SSBs	B-T168
)	O
on	O
productivity	O
in	O
Australia	B-T082
.	O

We	O
used	O
a	O
multi	B-T170
-	I-T170
state	I-T170
lifetable	I-T170
Markov	I-T170
model	I-T170
to	O
examine	B-T033
the	O
potential	O
impact	O
of	O
an	O
additional	O
20	O
%	O
tax	O
on	O
SSBs	B-T168
on	O
total	O
lifetime	O
productivity	O
in	O
the	O
paid	O
and	O
unpaid	O
sectors	O
of	O
the	O
economy	O
.	O

The	O
study	B-T098
population	I-T098
consisted	O
of	O
Australians	B-T098
aged	O
20	O
years	O
or	O
older	B-T098
in	O
2010	O
,	O
whose	O
health	O
and	O
other	O
relevant	O
outcomes	O
were	O
modelled	B-T062
over	O
their	O
remaining	O
lifetime	O
.	O

The	O
SSBs	B-T168
tax	O
was	O
estimated	O
to	O
reduce	O
the	O
number	O
of	O
people	B-T098
with	O
obesity	B-T038
by	O
1	O
.	O
96	O
%	O
of	O
the	O
entire	O
population	B-T098
(	O
437	O
,	O
000	O
fewer	O
persons	B-T098
with	O
obesity	B-T038
)	O
,	O
and	O
reduce	O
the	O
number	O
of	O
employees	B-T097
with	O
obesity	B-T038
by	O
317	O
,	O
000	O
persons	B-T098
.	O

These	O
effects	O
translated	O
into	O
productivity	O
gains	O
in	O
the	O
paid	O
sector	O
of	O
AU	O
$	O
751	O
million	O
for	O
the	O
working	O
-	O
age	O
population	B-T098
(	O
95	O
%	O
confidence	O
interval	O
:	O
AU	O
$	O
565	O
million	O
to	O
AU	O
$	O
954	O
million	O
)	O
,	O
using	O
the	O
human	O
capital	O
approach	B-T082
.	O

In	O
the	O
unpaid	O
sector	O
,	O
the	O
potential	O
productivity	O
gains	O
amounted	O
to	O
AU	O
$	O
1172	O
million	O
(	O
AU	O
$	O
929	O
million	O
to	O
AU	O
$	O
1435	O
million	O
)	O
using	O
the	O
replacement	B-T170
cost	I-T170
method	I-T170
.	O

These	O
productivity	O
benefits	O
are	O
in	O
addition	O
to	O
the	O
health	O
benefits	O
of	O
35	O
,	O
000	O
life	O
years	O
gained	O
and	O
a	O
reduction	O
in	O
healthcare	O
costs	O
of	O
AU	O
$	O
425	O
million	O
.	O

An	O
additional	O
20	O
%	O
tax	O
on	O
SSBs	B-T168
not	O
only	O
improves	B-T033
health	O
outcomes	O
and	O
reduces	O
healthcare	O
costs	O
,	O
but	O
provides	O
productivity	O
gains	O
in	O
both	O
the	O
paid	O
and	O
unpaid	O
sectors	O
of	O
the	O
economy	O
.	O

Keeping	O
the	O
Spirits	O
Up	O
:	O
The	O
Effect	O
of	O
Teachers	B-T097
'	I-T097
and	O
Parents	O
'	O
Emotional	B-T058
Support	I-T058
on	O
Children	O
'	O
s	O
Working	B-T038
Memory	I-T038
Performance	B-T038

Working	B-T038
memory	I-T038
,	O
used	O
to	O
temporarily	B-T038
store	I-T038
and	O
mentally	O
manipulate	O
information	O
,	O
is	O
important	O
for	O
children	O
'	O
s	O
learning	B-T038
.	O

It	O
is	O
therefore	O
valuable	O
to	O
understand	O
which	O
(	O
contextual	O
)	O
factors	O
promote	O
or	O
hinder	O
working	B-T038
memory	I-T038
performance	B-T038
.	O

Recent	O
research	B-T062
shows	O
positive	B-T033
associations	O
between	O
positive	B-T033
parent	O
-	O
child	O
and	O
teacher	O
-	O
student	O
interactions	O
and	O
working	B-T038
memory	I-T038
performance	B-T038
and	O
development	O
.	O

However	O
,	O
no	O
study	B-T062
has	O
yet	O
experimentally	O
investigated	O
how	O
parents	O
and	O
teachers	B-T097
affect	O
working	B-T038
memory	I-T038
performance	B-T038
.	O

Based	O
on	O
attachment	O
theory	O
,	O
the	O
current	O
study	B-T062
investigated	O
the	O
role	O
of	O
parent	O
and	O
teacher	B-T097
emotional	B-T058
support	I-T058
in	O
promoting	O
working	B-T038
memory	I-T038
performance	B-T038
by	O
buffering	O
the	O
negative	B-T033
effect	O
of	O
social	B-T038
stress	I-T038
.	O

Questionnaires	B-T170
and	O
an	O
experimental	B-T062
session	I-T062
were	O
completed	O
by	O
170	O
children	O
from	O
grade	O
1	O
to	O
2	O
(	O
Mage	O
=	O
7	O
years	O
6	O
months	O
,	O
SD	O
=	O
7	O
months	O
)	O
.	O

Questionnaires	B-T170
were	O
used	O
to	O
assess	O
children	O
'	O
s	O
perceptions	B-T038
of	O
the	O
teacher	O
-	O
student	O
and	O
parent	O
-	O
child	O
relationship	O
.	O

During	O
an	O
experimental	B-T062
session	I-T062
,	O
working	B-T038
memory	I-T038
was	O
measured	O
with	O
the	O
Corsi	O
task	O
backward	O
(	O
Milner	O
,	O
1971	O
)	O
in	O
a	O
pre	O
-	O
and	O
post	O
-	O
test	O
design	O
.	O

In	O
-	O
between	O
the	O
tests	B-T170
stress	B-T033
was	O
induced	O
in	O
the	O
children	O
using	O
the	O
Cyberball	O
paradigm	O
(	O
Williams	O
et	O
al	O
.	O
,	O
2000	O
)	O
.	O

Emotional	B-T058
support	I-T058
was	O
manipulated	O
(	O
between	O
-	O
subjects	O
)	O
through	O
an	O
audio	B-T170
message	B-T170
(	O
either	O
a	O
weather	O
report	B-T170
,	O
a	O
supportive	B-T058
message	B-T170
of	O
a	O
stranger	B-T098
,	O
a	O
supportive	B-T058
message	B-T170
of	O
a	O
parent	O
,	O
or	O
a	O
supportive	B-T058
message	B-T170
of	O
a	O
teacher	B-T097
)	O
.	O

Results	O
of	O
repeated	O
measures	O
ANOVA	O
showed	O
no	O
clear	O
effect	O
of	O
the	O
stress	B-T033
induction	O
.	O

Nevertheless	O
,	O
an	O
effect	O
of	O
parent	O
and	O
teacher	B-T097
support	B-T058
was	O
found	O
and	O
depended	O
on	O
the	O
quality	O
of	O
the	O
parent	O
-	O
child	O
relationship	O
.	O

When	O
children	O
had	O
a	O
positive	B-T033
relationship	O
with	O
their	O
parent	O
,	O
support	B-T058
of	O
parents	O
and	O
teachers	B-T097
had	O
little	O
effect	O
on	O
working	B-T038
memory	I-T038
performance	B-T038
.	O

When	O
children	O
had	O
a	O
negative	B-T033
relationship	O
with	O
their	O
parent	O
,	O
a	O
supportive	B-T058
message	B-T170
of	O
that	O
parent	O
decreased	O
working	B-T038
memory	I-T038
performance	B-T038
,	O
while	O
a	O
supportive	B-T058
message	B-T170
from	O
the	O
teacher	B-T097
increased	O
performance	B-T038
.	O

In	O
sum	O
,	O
the	O
current	O
study	B-T062
suggests	O
that	O
parents	O
and	O
teachers	B-T097
can	O
support	B-T058
working	B-T038
memory	I-T038
performance	B-T038
by	O
being	O
supportive	B-T058
for	O
the	O
child	O
.	O

Teacher	B-T097
support	B-T058
is	O
most	O
effective	O
when	O
the	O
child	O
has	O
a	O
negative	B-T033
relationship	O
with	O
the	O
parent	O
.	O

These	O
insights	O
can	O
give	O
direction	O
to	O
specific	O
measures	O
aimed	O
at	O
preventing	O
and	O
resolving	B-T033
working	B-T038
memory	I-T038
problems	B-T033
and	O
related	O
issues	B-T033
.	O

Management	O
of	O
tachyarrhythmia	B-T033
during	O
pregnancy	B-T038

Maternal	B-T033
tachyarrhythmia	B-T033
is	O
a	O
common	O
complication	B-T038
during	O
pregnancy	B-T038
due	O
to	O
hormonal	B-T033
changes	I-T033
that	O
enhance	O
pre	O
-	O
existing	O
arrhythmias	B-T033
or	O
induce	O
new	O
arrhythmias	B-T033
in	O
the	O
presence	B-T033
of	O
congenital	B-T017
heart	I-T017
defects	I-T017
in	O
pregnant	B-T098
females	I-T098
.	O

Presence	B-T033
of	O
tachyarrhythmia	B-T033
during	O
pregnancy	B-T038
poses	O
risk	O
to	O
the	O
mother	O
and	O
fetus	B-T017
,	O
calling	B-T038
for	O
proper	B-T058
treatment	I-T058
with	O
medications	B-T103
.	O

Use	O
of	O
antiarrhythmic	B-T103
drugs	I-T103
in	O
cases	O
of	O
maternal	B-T033
tachyarrhythmia	B-T033
must	O
give	O
due	O
consideration	O
of	O
potential	O
teratogenic	B-T038
side	I-T038
effects	I-T038
.	O

Utilization	O
of	O
antiarrhythmic	B-T103
drugs	I-T103
during	O
pregnancy	B-T038
has	O
been	O
well	O
studied	B-T062
;	O
some	O
result	O
in	O
minimal	O
fetal	B-T017
harm	B-T037
or	O
none	O
at	O
all	O
.	O

New	O
techniques	O
,	O
such	O
as	O
cardiac	B-T058
ablation	I-T058
,	O
have	O
also	O
been	O
implemented	O
with	O
minimal	O
or	O
no	O
radiation	B-T037
exposure	I-T037
to	O
the	O
fetus	B-T017
or	O
mother	O
.	O

Pregnant	B-T098
women	I-T098
with	O
tachyarrhythmia	B-T033
have	O
been	O
successfully	O
treated	B-T033
with	O
little	O
to	O
no	O
impact	O
on	O
the	O
developing	O
fetus	O
as	O
result	O
of	O
increasing	O
experience	B-T038
with	O
antiarrhythmic	B-T103
drugs	I-T103
and	O
progress	O
of	O
new	O
procedural	O
techniques	O
.	O

Hif	B-T103
-	I-T103
1α	I-T103
Overexpression	B-T038
Improves	B-T033
Transplanted	B-T058
Bone	I-T058
Mesenchymal	I-T058
Stem	I-T058
Cells	I-T058
Survival	B-T038
in	O
Rat	B-T038
MCAO	I-T038
Stroke	I-T038
Model	I-T038

Bone	B-T017
mesenchymal	I-T017
stem	I-T017
cells	I-T017
(	O
BMSCs	B-T017
)	O
death	B-T038
after	O
transplantation	B-T058
is	O
a	O
serious	O
obstacle	O
impacting	O
on	O
the	O
outcome	O
of	O
cell	B-T058
therapy	I-T058
for	O
cerebral	B-T038
infarction	I-T038
.	O

This	O
study	B-T062
was	O
aimed	O
to	O
investigate	O
whether	O
modification	O
of	O
BMSCs	B-T017
with	O
hypoxia	B-T103
-	I-T103
inducible	I-T103
factor	I-T103
1α	I-T103
(	O
Hif	B-T103
-	I-T103
1α	I-T103
)	O
could	O
enhance	O
the	O
survival	B-T038
of	O
the	O
implanted	B-T058
BMSCs	I-T058
.	O

BMSCs	B-T017
were	O
isolated	B-T058
from	O
Wistar	B-T204
rats	I-T204
,	O
and	O
were	O
infected	B-T038
with	O
Hif	B-T103
-	I-T103
1α	I-T103
-	I-T103
GFP	I-T103
lentiviral	I-T103
vector	I-T103
or	O
Hif	B-T103
-	I-T103
1α	I-T103
siRNA	I-T103
.	O

The	O
modified	O
BMSCs	B-T017
were	O
exposed	O
to	O
oxygen	B-T038
-	I-T038
glucose	I-T038
deprivation	I-T038
(	I-T038
OGD	I-T038
)	I-T038
condition	I-T038
,	O
cellular	B-T038
viability	I-T038
and	O
apoptosis	B-T038
were	O
then	O
assessed	O
.	O

An	O
inhibitor	B-T103
of	O
AMPK	B-T103
(	O
compound	B-T103
C	I-T103
)	O
was	O
used	O
to	O
detect	B-T058
whether	O
AMPK	B-T103
and	O
mTOR	B-T103
were	O
implicated	O
in	O
the	O
functions	O
of	O
Hif	B-T103
-	I-T103
1α	I-T103
on	O
BMSCs	B-T038
survival	I-T038
.	O

Besides	O
,	O
ultrastructure	O
of	O
BMSCs	B-T017
was	O
observed	O
and	O
the	O
expression	B-T038
of	I-T038
autophagy	I-T038
markers	I-T038
was	O
measured	O
.	O

The	O
modified	O
BMSCs	B-T017
were	O
transplanted	B-T058
into	O
middle	B-T017
cerebral	I-T017
artery	I-T017
occlusion	I-T017
(	O
MCAO	B-T017
)	O
model	B-T038
of	I-T038
rats	I-T038
,	O
and	O
the	O
cerebral	B-T038
infarction	I-T038
volume	O
and	O
neurological	B-T038
function	I-T038
was	O
assessed	O
.	O

The	O
results	O
indicated	O
that	O
Hif	B-T038
-	I-T038
1α	I-T038
overexpression	I-T038
protected	O
OGD	B-T038
induced	O
injury	B-T037
by	O
promoting	O
cellular	B-T038
viability	I-T038
and	O
inhibiting	B-T038
apoptosis	B-T038
.	O

AMPK	B-T103
was	O
activated	O
while	O
mTOR	B-T103
was	O
inactivated	O
by	O
Hif	B-T038
-	I-T038
1α	I-T038
overexpression	I-T038
,	O
and	O
that	O
might	O
be	O
through	O
which	O
Hif	B-T103
-	I-T103
1α	I-T103
functioned	O
BMSCs	B-T038
survival	I-T038
.	O

Hif	B-T038
-	I-T038
1α	I-T038
overexpression	I-T038
promoted	O
autophagy	B-T038
;	O
more	O
important	O
,	O
compound	B-T103
C	I-T103
abolished	O
the	O
induction	B-T038
of	I-T038
Hif	I-T038
-	I-T038
1α	I-T038
on	O
autophagy	B-T038
.	O

Transplantation	B-T058
of	I-T058
the	I-T058
overexpressed	I-T058
Hif	I-T058
-	I-T058
1α	I-T058
of	I-T058
BMSCs	I-T058
into	O
the	O
MCAO	B-T038
rats	I-T038
reduced	O
brain	B-T038
infarct	I-T038
volume	O
and	O
improved	B-T033
neurobehavioral	O
outcome	O
;	O
besides	O
,	O
it	O
inhibited	O
pro	B-T103
-	I-T103
inflammatory	I-T103
cytokines	I-T103
generation	O
while	O
promoted	O
neurotrophin	B-T103
secretion	B-T038
.	O

In	O
conclusion	O
,	O
Hif	B-T103
-	I-T103
1α	I-T103
might	O
be	O
contributed	O
in	O
the	O
survival	B-T038
of	I-T038
BMSCs	I-T038
by	O
regulating	O
the	O
activation	B-T038
of	I-T038
AMPK	I-T038
and	I-T038
mTOR	I-T038
,	O
as	O
well	O
as	O
by	O
promoting	O
autophagy	B-T038
.	O

Associations	O
between	O
major	O
life	O
events	O
and	O
adherence	O
,	O
glycemic	B-T058
control	I-T058
,	I-T058
and	O
psychosocial	O
characteristics	O
in	O
teens	B-T098
with	O
type	B-T038
1	I-T038
diabetes	I-T038

This	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
assessed	O
the	O
type	O
of	O
major	O
life	O
events	O
occurring	O
in	O
a	O
contemporary	O
sample	O
of	O
teens	B-T098
with	O
type	B-T038
1	I-T038
diabetes	I-T038
and	O
the	O
association	O
between	O
event	O
frequency	O
and	O
demographic	O
,	O
diabetes	B-T058
management	I-T058
,	O
and	O
psychosocial	O
characteristics	O
.	O

Parents	O
of	O
178	O
teens	B-T098
completed	O
the	O
Life	O
Events	O
Checklist	B-T170
to	O
report	O
major	O
events	O
teens	B-T098
had	O
experienced	O
in	O
the	O
last	O
year	O
:	O
42	O
%	O
experienced	O
0	O
to	O
1	O
event	O
(	O
n	O
=	O
75	O
)	O
,	O
32	O
%	O
experienced	O
2	O
to	O
3	O
events	O
(	O
n	O
=	O
57	O
)	O
,	O
and	O
26	O
%	O
experienced	O
4	O
+	O
events	O
(	O
n	O
=	O
46	O
)	O
.	O

Teens	B-T098
and	O
parents	O
completed	O
validated	O
measures	O
of	O
treatment	O
adherence	O
,	O
diabetes	B-T038
-	O
specific	O
self	B-T038
-	I-T038
efficacy	I-T038
,	O
quality	O
of	O
life	O
,	O
and	O
diabetes	B-T038
-	O
specific	O
family	B-T033
conflict	I-T033
.	O

Parent	O
-	O
youth	O
interview	O
and	O
chart	B-T058
review	I-T058
provided	O
demographics	B-T062
and	O
diabetes	B-T058
management	I-T058
data	O
.	O

Mean	O
number	O
of	O
events	O
/	O
teen	B-T098
was	O
2	O
.	O
6	O
±	O
2	O
.	O
7	O
(	O
range	O
=	O
0	O
-	O
15	O
)	O
.	O

The	O
most	O
common	O
events	O
were	O
"	O
Hospitalization	B-T058
of	O
a	O
family	O
member	O
"	O
(	O
24	O
%	O
)	O
,	O
"	O
Getting	B-T033
a	I-T033
bad	I-T033
report	I-T033
card	I-T033
"	O
(	O
20	O
%	O
)	O
,	O
"	O
Serious	O
arguments	O
between	O
parents	O
"	O
(	O
19	O
%	O
)	O
,	O
and	O
"	O
Serious	B-T033
illness	I-T033
/	O
injury	B-T037
in	O
a	O
family	O
member	O
"	O
(	O
19	O
%	O
)	O
.	O

Compared	O
with	O
teens	B-T098
experiencing	O
0	O
to	O
1	O
event	O
,	O
teens	B-T098
experiencing	O
4	O
+	O
events	O
were	O
less	O
likely	O
to	O
have	O
married	O
parents	O
(	O
P	O
=	O
.	O
01	O
)	O
and	O
a	O
parent	O
with	O
a	O
college	B-T170
degree	I-T170
(	O
P	O
=	O
.	O
006	O
)	O
.	O

Teen	B-T098
s	O
with	O
4	O
+	O
events	O
had	O
significantly	O
poorer	O
adherence	O
(	O
P	O
=	O
.	O
002	O
teen	B-T098
,	O
P	O
=	O
.	O
02	O
parent	O
)	O
,	O
lower	O
self	B-T038
-	I-T038
efficacy	I-T038
(	O
P	O
=	O
.	O
03	O
teen	B-T098
,	O
P	O
<	O
.	O
0001	O
parent	O
)	O
,	O
poorer	O
quality	O
of	O
life	O
(	O
P	O
<	O
.	O
0001	O
teen	B-T098
,	O
P	O
<	O
.	O
0001	O
parent	O
)	O
,	O
and	O
more	O
conflict	B-T033
(	O
P	O
=	O
.	O
006	O
teen	B-T098
,	O
P	O
=	O
.	O
02	O
parent	O
)	O
than	O
teens	B-T098
with	O
fewer	O
events	O
.	O

In	O
a	O
multivariate	B-T170
model	I-T170
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
21	O
,	O
P	O
<	O
.	O
0001	O
)	O
controlling	O
for	O
demographic	O
and	O
diabetes	B-T058
management	I-T058
characteristics	O
,	O
fewer	O
events	O
was	O
associated	O
with	O
lower	O
A1c	B-T103
(	O
P	O
=	O
.	O
0009	O
)	O
.	O

Occurrence	O
of	O
more	O
major	O
life	O
events	O
was	O
associated	O
with	O
poorer	O
diabetes	B-T058
care	I-T058
and	O
A1c	B-T103
and	O
more	O
negative	O
psychosocial	O
qualities	O
in	O
teens	B-T098
with	O
type	B-T038
1	I-T038
diabetes	I-T038
.	O

Metabolomics	B-T091
,	O
Nutrition	B-T033
,	O
and	O
Potential	O
Biomarkers	B-T201
of	O
Food	O
Quality	O
,	O
Intake	O
,	O
and	O
Health	O
Status	O

Diet	B-T168
,	O
dietary	B-T062
patterns	I-T062
,	O
and	O
other	O
environmental	O
factors	O
such	O
as	O
exposure	O
to	O
toxins	B-T103
are	O
playing	O
an	O
important	O
role	O
in	O
the	O
prevention	O
/	O
development	O
of	O
many	O
diseases	B-T038
,	O
like	O
obesity	B-T038
,	O
type	B-T038
2	I-T038
diabetes	I-T038
,	O
and	O
consequently	O
on	O
the	O
health	O
status	O
of	O
individuals	B-T098
.	O

A	O
major	O
challenge	O
nowadays	O
is	O
to	O
identify	O
novel	O
biomarkers	B-T201
to	O
detect	B-T033
as	O
early	O
as	O
possible	O
metabolic	O
dysfunction	O
and	O
to	O
predict	O
evolution	O
of	O
health	O
status	O
in	O
order	O
to	O
refine	O
nutritional	O
advices	O
to	O
specific	O
population	B-T098
groups	I-T098
.	O

Omics	O
technologies	O
such	O
as	O
genomics	B-T091
,	O
transcriptomics	O
,	O
proteomics	B-T091
,	O
and	O
metabolomics	B-T091
coupled	O
with	O
statistical	B-T170
and	O
bioinformatics	B-T170
tools	I-T170
have	O
already	O
shown	O
great	O
potential	O
in	O
this	O
research	O
field	O
even	O
if	O
so	O
far	O
only	O
few	O
biomarkers	B-T201
have	O
been	O
validated	O
.	O

For	O
the	O
past	O
two	O
decades	O
,	O
important	O
analytical	B-T058
techniques	I-T058
have	O
been	O
developed	O
to	O
detect	B-T033
as	O
many	O
metabolites	B-T103
as	O
possible	O
in	O
human	B-T204
biofluids	B-T031
such	O
as	O
urine	B-T031
,	O
blood	B-T031
,	O
and	O
saliva	B-T031
.	O

In	O
the	O
field	O
of	O
food	O
science	O
and	O
nutrition	B-T091
,	O
many	O
studies	B-T062
have	O
been	O
carried	O
out	O
for	O
food	B-T168
authenticity	O
,	O
quality	O
,	O
and	O
safety	O
,	O
as	O
well	O
as	O
for	O
food	O
processing	O
.	O

Furthermore	O
,	O
metabolomic	B-T091
investigations	O
have	O
been	O
carried	O
out	O
to	O
discover	O
new	O
early	O
biomarkers	B-T201
of	O
metabolic	O
dysfunction	O
and	O
predictive	O
biomarkers	B-T201
of	O
developing	O
pathologies	B-T091
(	O
obesity	B-T038
,	O
metabolic	B-T038
syndrome	I-T038
,	O
type	B-T038
-	I-T038
2	I-T038
diabetes	I-T038
,	O
etc	O
.	O
)	O
.	O

Great	O
emphasis	O
is	O
also	O
placed	O
in	O
the	O
development	O
of	O
methodologies	B-T062
to	O
identify	O
and	O
validate	O
biomarkers	B-T201
of	O
nutrients	B-T168
exposure	O
.	O

Draft	B-T082
Genome	I-T082
Sequence	I-T082
of	O
Bacillus	B-T007
cereus	I-T007
LA2007	I-T007
,	O
a	O
Human	B-T103
-	I-T103
Pathogenic	I-T103
Isolate	I-T103
Harboring	O
Anthrax	B-T103
-	I-T103
Like	I-T103
Plasmids	I-T103

We	O
present	O
the	O
genome	B-T082
sequence	I-T082
of	O
Bacillus	B-T007
cereus	I-T007
LA2007	I-T007
,	O
a	O
strain	O
isolated	O
in	O
2007	O
from	O
a	O
fatal	B-T038
pneumonia	I-T038
case	B-T170
in	O
Louisiana	B-T082
.	O

Sequence	B-T058
-	I-T058
based	I-T058
genome	I-T058
analysis	I-T058
revealed	O
that	O
LA2007	B-T007
carries	B-T033
a	O
plasmid	B-T103
highly	O
similar	O
to	O
Bacillus	B-T007
anthracis	I-T007
pXO1	I-T007
,	O
including	O
the	O
genes	B-T017
responsible	O
for	O
the	O
production	B-T103
and	O
regulation	B-T038
of	O
anthrax	B-T103
toxin	I-T103
.	O

Developing	O
elite	O
Neurospora	B-T204
crassa	I-T204
strains	O
for	O
cellulosic	B-T103
ethanol	B-T038
production	I-T038
using	O
fungal	O
breeding	B-T038

The	O
demand	O
for	O
renewable	O
and	O
sustainable	O
energy	O
has	O
generated	O
considerable	O
interest	B-T038
in	O
the	O
conversion	O
of	O
cellulosic	B-T103
biomass	O
into	O
liquid	O
fuels	O
such	O
as	O
ethanol	B-T103
using	O
a	O
filamentous	B-T204
fungus	I-T204
.	O

While	O
attempts	O
have	O
been	O
made	O
to	O
study	B-T062
cellulose	B-T038
metabolism	I-T038
through	O
the	O
use	O
of	O
knock	B-T038
-	I-T038
out	I-T038
mutants	B-T038
,	O
there	O
have	O
been	O
no	O
systematic	O
effort	O
to	O
characterize	O
natural	O
variation	O
for	O
cellulose	B-T038
metabolism	I-T038
in	O
ecotypes	O
adapted	O
to	O
different	O
habitats	B-T082
.	O

Here	O
,	O
we	O
characterized	O
natural	O
variation	O
in	O
saccharification	O
of	O
cellulose	B-T103
and	O
fermentation	B-T038
in	O
73	O
ecotypes	O
and	O
89	O
laboratory	B-T092
strains	O
of	O
the	O
model	B-T170
fungus	B-T204
Neurospora	B-T204
crassa	I-T204
.	O

We	O
observed	O
significant	O
variation	O
in	O
both	O
traits	O
among	O
natural	O
and	O
laboratory	O
generated	O
populations	B-T204
,	O
with	O
some	O
elite	O
strains	O
performing	O
better	O
than	O
the	O
reference	O
strain	O
.	O

In	O
the	O
F1	O
population	O
N345	O
,	O
15	O
%	O
of	O
the	O
population	B-T204
outperformed	O
both	O
parents	B-T204
with	O
the	O
top	O
performing	O
strain	O
having	O
10	O
%	O
improvement	O
in	O
ethanol	B-T038
production	I-T038
.	O

These	O
results	O
suggest	O
that	O
natural	O
alleles	B-T017
can	O
be	O
exploited	O
through	O
fungal	O
breeding	B-T038
for	O
developing	O
elite	O
industrial	O
strains	O
for	O
bioethanol	B-T038
production	I-T038
.	O

The	O
role	O
of	O
the	O
hippocampus	B-T017
and	O
the	O
function	O
of	O
calcitonin	B-T103
gene	I-T103
-	I-T103
related	I-T103
peptide	I-T103
in	O
the	O
mechanism	O
of	O
traumatic	B-T037
brain	I-T037
injury	I-T037
accelerating	O
fracture	B-T038
-	I-T038
healing	I-T038

This	O
research	O
attempts	O
to	O
identify	O
the	O
part	O
the	O
hippocampus	B-T017
plays	O
in	O
accelerated	O
fracture	B-T038
-	I-T038
healing	I-T038
after	O
traumatic	B-T037
brain	I-T037
injury	I-T037
as	O
well	O
as	O
to	O
test	O
functions	O
of	O
calcitonin	B-T103
gene	I-T103
-	I-T103
related	I-T103
peptide	I-T103
(	O
CGRP	B-T103
)	O
during	O
this	O
process	O
.	O

Experiments	O
were	O
carried	O
out	O
on	O
Male	O
Sprague	B-T204
-	I-T204
Dawley	I-T204
rats	I-T204
that	O
were	O
split	O
into	O
four	O
groups	O
at	O
random	O
:	O
TBI	B-T037
-	O
fracture	B-T037
group	O
,	O
fracture	B-T037
-	O
only	O
group	O
,	O
TBI	B-T037
-	O
only	O
group	O
,	O
and	O
control	O
group	O
.	O

In	O
the	O
first	O
week	O
,	O
blood	B-T031
specimen	I-T031
would	O
be	O
drawn	O
from	O
rats	B-T204
among	O
the	O
groups	O
except	O
those	O
of	O
the	O
control	O
group	O
at	O
three	O
-	O
time	O
points	O
(	O
24	O
,	O
72	O
and	O
168	O
hours	O
)	O
post	O
-	O
damage	B-T037
.	O

These	O
rats	B-T204
would	O
be	O
assessed	O
from	O
the	O
neurological	O
perspective	O
based	O
on	O
their	O
grades	O
of	O
performance	O
in	O
a	O
sequence	O
of	O
tests	O
24	O
hours	O
before	O
and	O
12	O
hours	O
after	O
brain	B-T037
injury	I-T037
.	O

Blood	B-T058
samples	I-T058
were	O
also	O
taken	O
from	O
the	O
control	O
group	O
24	O
hours	O
before	O
the	O
injury	B-T037
,	O
and	O
whole	O
brain	B-T017
tissues	I-T017
in	O
the	O
injured	O
groups	O
were	O
harvested	B-T058
at	O
72	O
and	O
168	O
hours	O
post	O
-	O
injury	B-T037
.	O

We	O
compared	O
the	O
serum	B-T031
CGRP	B-T103
concentration	O
,	O
the	O
distribution	O
of	O
CGRP	B-T103
,	O
the	O
CGRP	B-T103
expression	B-T038
,	O
and	O
the	O
expression	B-T038
of	O
CGRP	B-T103
in	O
the	O
hippocampus	B-T017
,	O
the	O
expression	B-T038
of	O
CGRP	B-T103
in	O
the	O
hippocampus	B-T017
,	O
the	O
expression	B-T038
of	O
CGRP	B-T103
in	O
the	O
hippocampus	B-T017
,	O
and	O
the	O
expression	B-T038
of	O
CGRP	B-T103
in	O
the	O
brain	B-T017
by	O
immunohistochemistry	B-T058
,	O
Western	B-T058
blotting	I-T058
,	O
RT	B-T038
-	O
Of	O
CGRP	B-T017
RNA	B-T038
expression	I-T038
levels	O
.	O

Neurological	B-T058
examinations	I-T058
suggested	O
that	O
the	O
functions	O
of	O
the	O
cerebral	B-T017
cortex	I-T017
,	O
cerebellum	B-T017
,	O
and	O
brain	B-T017
stem	I-T017
showed	O
significant	O
differences	O
pre	O
-	O
and	O
post	O
-	O
injury	B-T037
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

ELISA	B-T058
analysis	I-T058
indicated	O
a	O
great	O
density	O
of	O
CGRP	B-T103
in	O
TBI	B-T037
-	O
fracture	B-T037
group	O
at	O
different	O
time	O
points	O
.	O

Furthermore	O
,	O
in	O
the	O
TBI	B-T037
-	O
fracture	B-T037
group	O
,	O
CGRP	B-T103
in	O
both	O
hippocampus	B-T017
and	O
the	O
whole	B-T017
brain	I-T017
showed	O
a	O
noticeable	O
augment	O
in	O
RT	B-T062
-	I-T062
PCR	I-T062
and	O
western	B-T058
blot	I-T058
analysis	I-T058
at	O
72	O
and	O
168	O
h	O
post	O
-	O
injury	B-T037
,	O
and	O
only	O
in	O
this	O
group	O
,	O
immunohistochemistry	B-T058
analysis	I-T058
indicated	O
that	O
CGRP	B-T103
was	O
present	O
in	O
the	O
hippocampus	B-T017
at	O
168	O
hours	O
post	O
-	O
injury	B-T037
.	O

We	O
observed	O
that	O
the	O
hippocampus	B-T017
and	O
CGRP	B-T103
were	O
responsible	O
for	O
quick	O
bone	O
-	O
healing	O
mechanisms	O
.	O

We	O
suggest	O
a	O
role	O
for	O
the	O
hippocampus	B-T017
in	O
accelerated	O
fracture	B-T038
healing	I-T038
.	O

CGRP	B-T103
expression	B-T038
,	O
as	O
determined	O
by	O
IHC	B-T058
,	O
cannot	O
be	O
observed	O
in	O
other	O
groups	O
,	O
indicating	O
that	O
the	O
hippocampus	B-T017
may	O
be	O
the	O
specific	O
component	O
of	O
the	O
brain	B-T017
that	O
responds	O
to	O
"	O
big	B-T038
stress	I-T038
"	O
.	O

Bone	B-T017
extracellular	B-T017
matrix	I-T017
hydrogel	B-T103
enhances	O
osteogenic	B-T038
differentiation	I-T038
of	O
C2C12	B-T017
myoblasts	I-T017
and	O
mouse	B-T204
primary	O
calvarial	B-T017
cells	B-T017

Hydrogel	B-T103
scaffolds	I-T103
derived	O
from	O
the	O
extracellular	B-T017
matrix	I-T017
(	O
ECM	B-T017
)	O
of	O
mammalian	B-T017
tissues	I-T017
have	O
been	O
successfully	O
used	O
to	O
promote	O
tissue	B-T038
repair	I-T038
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
osteogenic	B-T038
potential	I-T038
of	O
ECM	B-T017
hydrogels	B-T103
prepared	O
from	O
demineralized	B-T103
and	O
decellularized	B-T103
bovine	I-T103
bone	I-T103
in	O
the	O
presence	O
and	O
absence	O
of	O
osteogenic	B-T103
medium	I-T103
.	O

Culture	B-T058
of	O
C2C12	B-T017
and	O
mouse	B-T204
primary	O
calvarial	B-T017
cells	B-T017
(	O
mPCs	B-T017
)	O
on	O
decellularized	B-T103
bone	I-T103
ECM	I-T103
(	O
bECM	B-T103
)	O
and	O
demineralized	B-T103
bone	I-T103
matrix	I-T103
(	O
DBM	B-T103
)	O
gels	B-T103
resulted	O
in	O
increased	O
expression	B-T058
of	O
osteogenic	B-T038
gene	I-T038
markers	I-T038
,	O
including	O
a	O
3	O
.	O
6	O
-	O
and	O
13	O
.	O
4	O
-	O
fold	O
increase	O
in	O
osteopontin	B-T103
and	O
15	O
.	O
7	O
-	O
and	O
27	O
.	O
1	O
-	O
fold	O
increase	O
in	O
osteocalcin	B-T103
when	O
mPCs	B-T017
were	O
cultured	B-T058
upon	O
bECM	B-T103
with	O
basal	B-T103
and	O
osteogenic	B-T103
media	I-T103
,	O
respectively	O
.	O

bECM	B-T103
hydrogels	B-T103
stimulated	O
the	O
osteogenic	B-T038
differentiation	I-T038
of	O
C2C12	B-T017
and	O
mPCs	B-T017
even	O
in	O
the	O
absence	O
of	O
osteogenic	B-T103
medium	I-T103
.	O

These	O
results	O
suggest	O
that	O
bECM	B-T103
hydrogel	B-T103
scaffolds	I-T103
may	O
have	O
great	O
utility	O
in	O
future	O
clinical	O
applications	O
for	O
bone	B-T017
tissue	B-T058
engineering	I-T058
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

J	O
Biomed	O
Mater	O
Res	O
Part	O
B	O
:	O
Appl	O
Biomater	O
,	O
2017	O
.	O

Prostate	B-T103
-	I-T103
specific	I-T103
antigen	I-T103
increase	O
during	O
dutasteride	B-T103
to	O
indicate	O
the	O
need	O
for	O
prostate	B-T058
biopsy	I-T058
:	O
influence	O
of	O
prostatic	B-T038
inflammation	I-T038

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	B-T062
the	O
significance	O
of	O
an	O
increase	O
in	O
total	O
prostate	O
-	O
specific	O
antigen	O
(	O
PSA	O
)	O
serum	O
levels	O
despite	O
dutasteride	B-T103
treatment	B-T058
as	O
a	O
predictor	O
of	O
prostate	B-T038
cancer	I-T038
(	O
PC	B-T038
)	O
at	O
biopsy	B-T058
.	O

We	O
focused	O
our	O
attention	O
on	O
the	O
rate	O
of	O
the	O
first	O
PSA	B-T103
increase	O
and	O
on	O
the	O
influence	O
of	O
prostatic	B-T038
inflammation	I-T038
.	O

From	O
2011	O
to	O
2016	O
,	O
365	O
men	B-T098
with	O
a	O
previous	O
negative	O
prostate	B-T058
biopsy	I-T058
and	O
persistent	O
elevated	O
PSA	B-T103
levels	O
received	O
dutasteride	B-T103
treatment	B-T058
.	O

The	O
population	B-T098
was	O
followed	O
for	O
a	O
range	O
of	O
12	O
-	O
48	O
months	O
.	O

One	O
hundred	O
twelve	O
cases	O
with	O
a	O
confirmed	O
PSA	B-T103
increase	O
>	O
0	O
.	O
5	O
ng	O
/	O
ml	O
over	O
the	O
nadir	O
value	O
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
were	O
included	O
in	O
Group	O
A	O
and	O
underwent	O
a	O
new	O
prostate	B-T058
biopsy	I-T058
.	O

In	O
Group	O
A	O
,	O
the	O
PSA	B-T103
increase	O
was	O
associated	O
with	O
PC	B-T038
at	O
the	O
re	B-T058
-	I-T058
biopsy	I-T058
in	O
66	O
%	O
of	O
cases	O
.	O

The	O
percentage	O
of	O
PSA	B-T033
reduction	I-T033
after	O
6	O
months	O
of	O
treatment	B-T058
was	O
not	O
a	O
significant	O
indicator	B-T201
of	O
the	O
risk	O
for	O
PC	B-T038
.	O

The	O
distribution	O
of	O
inflammatory	B-T033
infiltrates	I-T033
significantly	O
(	O
p	O
<	O
00	O
.	O
01	O
)	O
varied	O
from	O
positive	O
to	O
negative	O
prostate	B-T058
biopsies	I-T058
.	O

The	O
relative	O
risk	O
for	O
PC	B-T038
at	O
biopsy	B-T058
significantly	O
increase	O
d	O
according	O
to	O
PSA	B-T103
level	O
during	O
dutasteride	B-T103
.	O

Treatment	B-T058
with	O
dutasteride	B-T103
can	O
help	O
to	O
analyze	B-T062
PSA	B-T103
kinetic	O
.	O

A	O
persistent	O
prostatic	B-T038
inflammation	I-T038
is	O
a	O
factor	O
able	O
to	O
reduce	O
the	O
performance	O
of	O
PSA	B-T103
kinetic	O
during	O
dutasteride	B-T103
treatment	B-T058
.	O

Neurological	B-T033
Decline	I-T033
in	O
an	O
Elderly	B-T098
with	O
Repaired	O
Myelomeningocele	B-T017
Complicated	O
with	O
Lumbar	B-T038
Canal	I-T038
Stenosis	I-T038
:	O
a	O
case	B-T170
report	I-T170

Tethered	B-T038
cord	I-T038
syndrome	I-T038
is	O
a	O
well	O
-	O
known	O
complication	B-T038
after	O
myelomeningocele	B-T017
(	O
MMC	B-T017
)	O
repair	B-T058
in	O
childhood	O
.	O

However	O
,	O
late	O
complications	B-T038
in	O
adults	O
with	O
a	O
repaired	O
MMC	B-T017
are	O
not	O
well	O
understood	O
.	O

In	O
particular	O
,	O
the	O
influence	O
of	O
a	O
degenerative	B-T017
spinal	I-T017
deformity	I-T017
on	O
a	O
sustained	O
tethered	B-T033
cord	I-T033
is	O
still	O
unclear	O
.	O

A	O
63	O
-	O
year	O
-	O
old	O
man	O
with	O
a	O
repaired	O
MMC	B-T017
presented	O
with	O
a	O
progressive	B-T033
gait	I-T033
disturbance	I-T033
and	O
numbness	B-T033
in	O
both	O
lower	B-T017
limbs	I-T017
.	O

Magnetic	B-T170
resonance	I-T170
images	I-T170
demonstrated	O
that	O
the	O
tethered	B-T033
spinal	I-T033
cord	I-T033
was	O
compressed	O
by	O
severe	O
canal	B-T038
stenosis	I-T038
along	O
the	O
entire	B-T082
lumbar	I-T082
spine	I-T082
.	O

After	O
a	O
multi	B-T058
-	I-T058
level	I-T058
lumbar	I-T058
decompression	I-T058
surgery	B-T058
,	O
the	O
patient	O
recovered	O
to	O
baseline	O
neurological	O
status	O
.	O

In	O
adults	O
with	O
a	O
repaired	O
MMC	B-T017
,	O
lumbar	B-T038
canal	I-T038
stenosis	I-T038
should	O
be	O
investigated	O
as	O
a	O
possible	O
cause	O
of	O
late	O
neurological	B-T033
decline	I-T033
.	O

Clinical	O
manifestations	O
may	O
be	O
complicated	O
by	O
the	O
coexistence	O
of	O
both	O
the	O
original	O
and	O
subsequent	O
neurological	B-T038
disorders	I-T038
.	O

Because	O
these	O
additional	O
disorders	B-T038
result	O
from	O
compressive	B-T038
myelopathy	I-T038
,	O
early	O
surgical	B-T058
decompression	I-T058
is	O
indicated	O
to	O
avoid	O
irreversible	O
spinal	B-T038
cord	I-T038
dysfunction	I-T038
.	O

Epidemiology	B-T091
of	O
polyomavirus	B-T005
BK	I-T005
(	O
BKV	B-T005
)	O
and	O
the	O
emergent	O
African	B-T082
variant	O
in	O
kidney	B-T017
and	O
bone	B-T017
marrow	I-T017
transplant	O
recipients	O
in	O
the	O
Fundacion	B-T092
Valle	I-T092
del	I-T092
Lili	I-T092
in	I-T092
Cali	I-T092
,	O
Colombia	B-T082

To	O
describe	O
the	O
epidemiology	B-T091
of	O
BKV	B-T005
and	O
to	O
assess	O
the	O
presence	B-T033
of	O
the	O
African	B-T082
variant	O
in	O
bone	B-T017
marrow	I-T017
and	O
kidney	B-T033
transplant	I-T033
patients	I-T033
who	O
have	O
suspected	O
BKV	B-T005
reactivation	O
.	O

A	O
descriptive	B-T062
study	I-T062
was	O
conducted	O
,	O
using	O
institutional	B-T170
records	I-T170
,	O
at	O
the	O
Fundación	B-T092
Valle	I-T092
del	I-T092
Lili	I-T092
,	I-T092
Cali	I-T092
-	O
Colombia	B-T082
.	O

The	O
overall	O
prevalence	O
of	O
BKV	B-T005
during	O
the	O
study	O
period	O
was	O
51	O
%	O
.	O

The	O
African	B-T082
variant	O
was	O
identified	O
in	O
49	O
.	O
4	O
%	O
of	O
samples	O
that	O
were	O
positive	B-T033
for	O
BKV	B-T005
.	O

50	O
.	O
6	O
%	O
of	O
the	O
samples	O
were	O
found	O
to	O
have	O
the	O
wild	B-T017
strain	O
of	O
BKV	B-T005
.	O

Among	O
BKV	B-T005
positive	B-T033
patients	O
,	O
57	O
%	O
were	O
kidney	B-T033
transplant	I-T033
recipients	I-T033
and	O
43	O
%	O
were	O
bone	B-T017
marrow	I-T017
transplant	O
recipients	O
.	O

This	O
is	O
the	O
first	O
epidemiological	B-T062
study	I-T062
describing	O
the	O
African	B-T082
variant	O
of	O
BKV	B-T005
in	O
Colombia	B-T082
.	O

Thaw	B-T058
-	O
and	O
-	O
use	O
target	B-T017
cells	I-T017
pre	O
-	O
labeled	O
with	O
calcein	B-T103
AM	I-T103
for	O
antibody	B-T058
-	I-T058
dependent	I-T058
cell	I-T058
-	I-T058
mediated	I-T058
cytotoxicity	I-T058
assays	I-T058

In	O
vitro	O
antibody	B-T058
-	I-T058
dependent	I-T058
cell	I-T058
-	I-T058
mediated	I-T058
cytotoxicity	I-T058
(	I-T058
ADCC	I-T058
)	I-T058
assays	I-T058
are	O
routinely	O
performed	O
to	O
support	O
the	O
research	O
and	O
development	O
of	O
therapeutic	B-T103
antibodies	I-T103
.	O

In	O
ADCC	B-T058
assays	I-T058
,	O
target	B-T017
cells	I-T017
bound	O
by	O
the	O
antibodies	B-T103
are	O
lysed	B-T038
by	O
activated	O
effector	B-T017
cells	I-T017
following	O
interactions	O
between	O
the	O
Fc	B-T103
region	I-T103
of	O
the	O
bound	O
antibody	B-T103
and	O
Fcγ	B-T103
receptors	I-T103
on	O
effector	B-T017
cells	I-T017
.	O

Target	B-T017
cell	I-T017
lysis	B-T038
is	O
typically	O
measured	O
by	O
quantification	O
of	O
released	O
endogenous	O
enzymes	B-T103
,	O
e	O
.	O
g	O
.	O
,	O
lactate	B-T103
dehydrogenase	I-T103
,	O
or	O
measurement	O
of	O
released	O
exogenous	O
labels	B-T103
,	O
e	O
.	O
g	O
.	O
,	O
(	B-T103
51	I-T103
)	I-T103
Cr	I-T103
,	O
europium	B-T103
or	O
calcein	B-T103
.	O

ADCC	B-T058
assays	I-T058
based	O
on	O
the	O
detection	O
of	O
exogenous	O
labels	B-T103
released	O
from	O
lysed	B-T038
target	B-T017
cells	I-T017
generally	O
show	O
higher	O
sensitivity	O
and	O
require	O
shorter	O
incubation	B-T033
times	I-T033
.	O

However	O
,	O
target	B-T017
cells	I-T017
are	O
usually	O
labeled	O
immediately	O
prior	O
to	O
assay	B-T058
,	O
which	O
inadvertently	O
introduces	O
additional	O
assay	B-T058
variations	O
due	O
to	O
differences	O
in	O
target	B-T017
cell	I-T017
conditions	O
and	O
labeling	B-T058
/	O
handling	B-T058
processes	I-T058
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
use	O
of	O
thaw	B-T058
-	O
and	O
-	O
use	O
pre	O
-	O
labeled	O
target	B-T017
cells	I-T017
for	O
ADCC	B-T058
assays	I-T058
.	O

Thaw	B-T058
-	O
and	O
-	O
use	O
target	B-T017
cells	I-T017
in	O
our	O
experiments	O
were	O
pre	O
-	O
labeled	O
with	O
the	O
fluorescent	B-T103
dye	I-T103
calcein	I-T103
AM	I-T103
,	O
cryopreserved	B-T058
in	O
single	O
-	O
use	O
aliquots	O
and	O
used	O
directly	O
in	O
assays	B-T058
after	O
thawing	O
.	O

Upon	O
thaw	B-T058
,	O
the	O
pre	O
-	O
labeled	O
cells	B-T017
displayed	O
viability	B-T038
and	O
label	B-T103
retention	O
comparable	O
to	O
freshly	O
labeled	O
cells	B-T017
,	O
responded	O
to	O
ADCC	B-T038
mediated	O
by	O
both	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
and	O
engineered	B-T017
natural	I-T017
killer	I-T017
cells	I-T017
,	O
performed	O
stably	O
for	O
at	O
least	O
3	O
years	O
and	O
provided	O
favorable	O
precision	O
and	O
accuracy	O
to	O
ADCC	B-T058
assays	I-T058
.	O

Implementation	O
of	O
thaw	B-T058
-	O
and	O
-	O
use	O
pre	O
-	O
labeled	O
target	B-T017
cells	I-T017
in	O
ADCC	B-T058
assays	I-T058
can	O
help	O
to	O
alleviate	O
both	O
cell	B-T058
culture	I-T058
and	O
dye	B-T058
labeling	I-T058
derived	O
variability	O
,	O
increase	O
the	O
flexibility	O
of	O
assay	B-T058
scheduling	O
and	O
improve	O
assay	O
consistency	O
and	O
robustness	O
.	O

Pathways	B-T038
and	O
Genes	B-T017
Associated	O
with	O
Immune	B-T022
Dysfunction	B-T038
in	O
Sheep	B-T204
Paratuberculosis	B-T038

Multibacillary	B-T033
and	O
paucibacillary	B-T033
paratuberculosis	B-T038
are	O
both	O
caused	O
by	O
Mycobacterium	B-T007
avium	I-T007
subspecies	I-T007
paratuberculosis	I-T007
.	O

Multibacillary	B-T033
lesions	B-T033
are	O
composed	O
largely	O
of	O
infected	B-T033
epithelioid	B-T017
macrophages	I-T017
and	O
paucibacillary	B-T033
lesions	B-T033
contain	O
T	B-T017
cells	I-T017
but	O
few	O
bacteria	B-T007
.	O

Multibacillary	B-T033
disease	B-T038
is	O
similar	O
to	O
human	O
lepromatous	B-T038
leprosy	I-T038
,	O
with	O
variable	O
/	O
high	O
levels	O
of	O
antibody	B-T103
and	O
a	O
dysfunctional	O
immune	B-T038
response	I-T038
.	O

Animals	B-T204
with	O
paucibacillary	B-T033
disease	B-T038
have	O
high	O
cell	B-T038
-	I-T038
mediated	I-T038
immunity	I-T038
and	O
variable	O
levels	O
of	O
antibody	B-T103
.	O

This	O
study	O
aims	O
to	O
characterize	O
the	O
immunological	B-T038
dysfunction	I-T038
using	O
TruSeq	B-T170
analysis	B-T062
of	O
the	O
ileocaecal	B-T082
lymph	B-T017
node	I-T017
that	O
drains	O
disease	B-T038
lesions	B-T033
.	O

Immune	B-T022
dysfunction	B-T038
is	O
highlighted	O
by	O
repression	B-T038
of	O
TCR	B-T017
/	O
CD3	B-T017
genes	I-T017
,	O
T	B-T103
cell	I-T103
co	I-T103
-	I-T103
receptors	I-T103
/	O
co	B-T103
-	I-T103
stimulators	I-T103
,	O
T	B-T038
cell	I-T038
activation	I-T038
and	O
signal	B-T038
-	I-T038
transduction	I-T038
genes	B-T017
.	O

Inflammation	B-T038
was	O
an	O
acute	B-T038
phase	I-T038
response	I-T038
and	O
chronic	B-T038
inflammation	I-T038
,	O
with	O
little	O
evidence	O
of	O
acute	B-T033
inflammation	I-T033
.	O

The	O
high	O
levels	O
of	O
immunoglobulin	B-T103
and	O
plasma	B-T017
cell	I-T017
transcripts	B-T103
is	O
consistent	O
with	O
the	O
anti	B-T038
-	I-T038
MAP	I-T038
antibody	I-T038
responses	I-T038
in	O
paratuberculosis	B-T038
sheep	B-T204
.	O

Also	O
notable	O
was	O
the	O
overwhelming	O
reduction	O
in	O
mast	B-T017
cell	I-T017
transcripts	B-T103
,	O
potentially	O
affecting	O
DC	B-T038
activation	I-T038
of	I-T038
the	I-T038
immune	I-T038
response	I-T038
.	O

This	O
study	O
also	O
shows	O
that	O
there	O
were	O
no	O
fundamental	O
differences	O
in	O
the	O
gene	B-T038
expression	I-T038
patterns	O
in	O
multibacillary	B-T033
and	O
paucibacillary	B-T033
disease	B-T038
,	O
no	O
shift	O
in	O
T	B-T017
cell	I-T017
genes	B-T017
from	O
Th1	B-T017
to	O
Th2	B-T017
pattern	O
but	O
rather	O
an	O
incremental	O
decline	O
into	O
immune	B-T022
dysfunction	B-T038
leading	O
to	O
multibacillary	B-T033
pathology	B-T038
.	O

Modified	O
frailty	B-T170
index	I-T170
predicts	O
postoperative	B-T033
outcomes	O
in	O
older	O
gastrointestinal	B-T038
cancer	I-T038
patients	O

Frailty	B-T033
disproportionately	O
impacts	O
older	O
patients	O
with	O
gastrointestinal	B-T038
cancer	I-T038
,	O
rendering	O
them	O
at	O
increased	B-T033
risk	I-T033
for	I-T033
poor	I-T033
outcomes	I-T033
.	O

A	O
frailty	B-T170
index	I-T170
may	O
aid	O
in	O
preoperative	O
risk	O
stratification	B-T062
.	O

We	O
hypothesized	O
that	O
high	O
modified	B-T033
frailty	I-T033
index	I-T033
(	I-T033
mFI	I-T033
)	I-T033
scores	I-T033
are	O
associated	O
with	O
adverse	B-T033
outcomes	I-T033
after	O
tumor	B-T038
resection	B-T058
in	O
older	O
,	O
gastrointestinal	B-T038
cancer	I-T038
patients	O
.	O

Patients	O
(	O
60	O
-	O
90	O
years	O
old	O
)	O
who	O
underwent	O
gastrointestinal	O
tumor	O
resection	O
were	O
identified	O
in	O
the	O
2005	O
-	O
2012	O
NSQIP	B-T033
Participant	B-T098
Use	O
File	O
.	O

mFI	B-T033
was	O
defined	O
by	O
11	O
previously	O
described	O
,	O
preoperative	O
variables	O
.	O

Frailty	B-T033
was	O
defined	O
by	O
an	O
mFI	B-T033
score	I-T033
>	O
0	O
.	O
27	O
.	O

The	O
postoperative	B-T058
course	I-T058
was	O
evaluated	B-T058
using	O
univariate	O
and	O
multivariate	O
analysis	O
.	O

41	O
455	O
patients	O
(	O
mean	O
age	O
72	O
.	O
4	O
years	O
,	O
47	O
.	O
4	O
%	O
female	O
)	O
were	O
identified	O
.	O

The	O
most	O
prevalent	B-T082
form	I-T082
of	O
cancer	B-T038
was	O
colorectal	B-T038
(	O
69	O
.	O
3	O
%	O
,	O
n	O
=	O
28	O
708	O
)	O
and	O
2	O
.	O
8	O
%	O
of	O
patients	O
were	O
frail	B-T033
(	O
n	O
=	O
1	O
,	O
164	O
)	O
.	O

Frail	B-T033
patients	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
increased	O
length	O
of	O
stay	O
(	O
11	O
.	O
7	O
vs	O
9	O
.	O
0	O
days	O
)	O
,	O
major	O
complications	B-T038
(	O
29	O
.	O
1	O
%	O
vs	O
17	O
.	O
9	O
%	O
)	O
,	O
and	O
30	O
-	O
day	O
mortality	O
(	O
5	O
.	O
6	O
%	O
vs	O
2	O
.	O
5	O
%	O
)	O
,	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Multivariate	O
analysis	O
identified	O
mFI	B-T033
as	O
an	O
independent	O
predictor	O
of	O
major	O
complications	B-T038
(	O
OR	O
1	O
.	O
52	O
,	O
95	O
%	O
CI	O
1	O
.	O
39	O
-	O
1	O
.	O
65	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
30	O
-	O
day	O
mortality	O
(	O
OR	O
1	O
.	O
48	O
,	O
95	O
%	O
CI	O
1	O
.	O
24	O
-	O
1	O
.	O
75	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

mFI	B-T033
was	O
associated	O
with	O
the	O
incidence	O
of	O
postoperative	B-T033
complications	B-T038
and	O
mortality	O
in	O
older	O
surgical	O
patients	O
with	O
gastrointestinal	B-T038
cancer	I-T038
.	O

Spermatocytic	B-T038
Tumor	I-T038
With	O
Sarcoma	B-T038
:	O
A	O
Rare	O
Testicular	B-T038
Neoplasm	I-T038

Spermatocytic	B-T038
tumor	I-T038
,	O
formerly	O
known	O
as	O
spermatocytic	B-T038
seminoma	I-T038
,	O
is	O
an	O
uncommon	O
testicular	B-T038
neoplasm	I-T038
which	O
is	O
a	O
distinct	O
clinicopathologic	O
entity	O
from	O
classic	O
seminoma	B-T038
.	O

These	O
tumors	B-T038
are	O
not	O
associated	O
with	O
germ	B-T038
cell	I-T038
neoplasia	I-T038
in	O
situ	O
,	O
other	O
germ	B-T038
cell	I-T038
tumors	I-T038
,	O
or	O
isochromosome	B-T038
12p	I-T038
.	O

Although	O
typically	O
,	O
these	O
tumors	B-T038
have	O
an	O
excellent	O
prognosis	B-T058
occasional	O
cases	O
are	O
associated	O
with	O
sarcoma	B-T038
and	O
have	O
a	O
very	B-T033
poor	I-T033
prognosis	I-T033
.	O

We	O
present	O
a	O
case	O
of	O
spermatocytic	B-T038
tumor	I-T038
with	O
sarcoma	B-T038
showing	O
a	O
chondrosarcomatous	B-T038
component	I-T038
,	O
discuss	O
the	O
pathologic	O
findings	O
and	O
differential	B-T058
diagnosis	I-T058
and	O
provide	O
follow	B-T058
-	I-T058
up	I-T058
information	O
.	O

Remote	B-T082
Ischemic	B-T058
Conditioning	I-T058
and	O
Renal	B-T017
Protection	O

Over	O
the	O
course	O
of	O
the	O
last	O
2	O
decades	O
,	O
the	O
concept	O
of	O
remote	B-T082
ischemic	B-T058
conditioning	I-T058
(	O
RIC	B-T058
)	O
has	O
attracted	O
considerable	O
research	B-T062
interest	B-T038
,	O
because	O
RIC	B-T058
,	O
in	O
most	O
of	O
its	O
embodiments	O
offers	O
an	O
inexpensive	O
way	O
of	O
protecting	O
tissues	B-T017
against	O
ischemic	O
damage	B-T037
inflicted	O
by	O
a	O
number	O
of	O
medical	O
conditions	O
or	O
procedures	B-T058
.	O

Acute	B-T037
kidney	I-T037
injury	I-T037
(	O
AKI	B-T037
)	O
is	O
a	O
common	O
side	O
effect	O
in	O
the	O
context	O
of	O
various	O
medical	B-T058
procedures	I-T058
,	O
and	O
RIC	B-T058
has	O
been	O
suggested	O
as	O
a	O
means	O
of	O
reducing	O
its	O
incidence	O
.	O

Outcomes	O
regarding	O
kidney	B-T038
function	I-T038
have	O
been	O
reported	O
in	O
numerous	O
studies	B-T062
that	O
evaluated	O
the	O
effects	O
of	O
RIC	B-T058
in	O
a	O
variety	O
of	O
settings	O
(	O
eg	O
,	O
cardiac	B-T058
surgery	I-T058
,	O
interventions	B-T058
requiring	O
intravenous	B-T082
administration	I-T082
of	O
contrast	B-T103
media	I-T103
)	O
.	O

Although	O
several	O
individual	O
studies	B-T062
have	O
implied	O
a	O
beneficial	O
effect	O
of	O
RIC	B-T058
in	O
preserving	O
kidney	B-T038
function	I-T038
,	O
3	O
recently	O
published	O
randomized	B-T062
controlled	I-T062
trials	I-T062
evaluating	O
more	O
than	O
1000	O
patients	O
each	O
(	O
Effect	O
of	O
Remote	B-T058
Ischemic	I-T058
Preconditioning	I-T058
in	O
the	O
Cardiac	B-T058
Surgery	I-T058
,	O
Remote	B-T058
Ischaemic	I-T058
Preconditioning	I-T058
for	O
Heart	B-T058
Surgery	I-T058
,	O
and	O
E	B-T058
RIC	B-T058
CA	I-T058
)	O
were	O
negative	B-T033
.	O

However	O
,	O
AKI	B-T037
or	O
any	O
other	O
index	O
of	O
renal	B-T038
function	I-T038
was	O
not	O
a	O
stand	O
-	O
alone	O
primary	O
end	O
point	O
in	O
any	O
of	O
these	O
trials	B-T062
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
range	O
of	O
meta	B-T062
-	I-T062
analyses	I-T062
(	O
each	O
including	O
thousands	O
of	O
participants	B-T098
)	O
have	O
reported	O
mixed	O
results	O
,	O
with	O
the	O
most	O
recent	O
among	O
them	O
showing	O
benefit	O
from	O
RIC	B-T058
,	O
pinpointing	O
at	O
the	O
same	O
time	O
a	O
number	O
of	O
shortcomings	O
in	O
published	B-T170
studies	B-T062
,	O
adversely	O
affecting	O
the	O
quality	O
of	O
available	B-T170
data	I-T170
.	O

The	O
present	O
review	B-T170
provides	O
a	O
critical	O
appraisal	O
of	O
the	O
current	O
state	O
of	O
this	O
field	O
of	O
research	B-T062
.	O

It	O
is	O
the	O
opinion	O
of	O
the	O
authors	B-T097
of	O
this	O
review	B-T170
that	O
there	O
is	O
a	O
clear	O
need	O
for	O
a	O
common	O
clinical	B-T062
trial	I-T062
framework	O
for	O
ischemic	B-T058
conditioning	I-T058
studies	B-T062
.	O

If	O
the	O
current	O
babel	O
of	O
definitions	B-T170
,	O
procedures	O
,	O
outcomes	O
,	O
and	O
goals	B-T170
persists	I-T170
,	O
it	O
is	O
most	O
likely	O
that	O
soon	O
ischemic	B-T058
conditioning	I-T058
will	O
be	O
"	O
yesterday	O
'	O
s	O
news	O
"	O
with	O
no	O
definitive	O
conclusions	O
having	O
been	O
reached	O
in	O
terms	O
of	O
its	O
real	O
clinical	B-T058
utility	I-T058
.	O

Temporal	O
and	O
Spatial	O
Variability	O
of	O
Fungal	B-T017
Structures	I-T017
and	O
Host	B-T038
Responses	I-T038
in	O
an	O
Incompatible	B-T038
Rust	I-T038
-	I-T038
Wheat	I-T038
Interaction	I-T038

Information	O
about	O
temporal	O
and	O
spatial	O
variability	O
of	O
fungal	B-T017
structures	I-T017
and	O
host	B-T038
responses	I-T038
is	O
scarce	O
in	O
comparison	O
to	O
the	O
vast	O
amount	O
of	O
genetic	O
,	O
biochemical	O
,	O
and	O
physiological	O
studies	B-T062
of	O
host	B-T038
-	I-T038
pathogen	I-T038
interactions	I-T038
.	O

In	O
this	O
study	B-T062
,	O
we	O
used	O
avirulent	O
wild	B-T017
type	I-T017
and	O
virulent	O
mutant	B-T017
isolates	B-T103
of	O
Puccinia	B-T204
striiformis	I-T204
to	O
characterize	O
the	O
interactions	O
in	O
wheat	B-T168
carrying	O
yellow	B-T204
rust	I-T204
Yr2	B-T204
resistance	B-T038
.	O

Both	O
conventional	O
and	O
advanced	O
microscopic	O
techniques	O
were	O
used	O
for	O
a	O
detailed	O
study	B-T062
of	O
morphology	O
and	O
growth	B-T038
of	O
fungal	O
colonies	B-T017
and	O
associated	O
host	B-T038
cell	I-T038
responses	I-T038
.	O

The	O
growth	B-T038
of	O
the	O
wild	B-T017
type	I-T017
isolates	B-T103
was	O
highly	O
restricted	O
due	O
to	O
hypersensitive	B-T038
response	I-T038
(	O
HR	B-T038
,	O
plant	B-T204
cell	B-T038
death	I-T038
)	O
indicated	B-T033
by	O
autofluorescence	B-T058
and	O
change	O
in	O
the	O
shape	B-T082
of	O
the	O
affected	O
plant	B-T017
cells	I-T017
.	O

The	O
host	B-T038
response	I-T038
appeared	O
post	O
-	O
haustorial	B-T017
,	O
but	O
large	O
variation	O
in	O
the	O
time	O
and	O
stage	O
of	O
arrest	B-T038
was	O
observed	O
for	O
individual	B-T098
fungal	O
colonies	B-T017
,	O
probably	O
due	O
to	O
a	O
delay	O
between	B-T082
detection	B-T058
and	O
response	O
.	O

Some	O
colonies	B-T017
were	O
stopped	O
right	O
after	O
the	O
formation	O
of	O
the	O
primary	B-T038
infection	I-T038
hyphae	B-T204
whereas	O
others	O
formed	O
highly	O
branched	B-T082
mycelia	B-T204
.	O

HR	B-T038
was	O
first	O
observed	O
in	O
host	B-T017
cells	I-T017
in	O
direct	O
contact	O
with	O
fungal	B-T017
structures	I-T017
,	O
after	O
which	O
the	O
defense	B-T038
responses	I-T038
spread	O
to	O
adjacent	B-T082
host	B-T017
cells	I-T017
,	O
and	O
eventually	O
led	O
to	O
encasement	O
of	O
the	O
fungal	O
colony	B-T017
.	O

Several	O
cells	B-T017
with	O
HR	B-T038
contained	O
haustoria	B-T017
,	O
which	O
were	O
small	O
and	O
underdeveloped	O
,	O
but	O
some	O
cells	B-T017
contained	O
normal	O
sized	B-T082
haustoria	B-T017
without	O
signs	B-T033
of	O
hypersensitivity	B-T038
.	O

The	O
growth	B-T038
of	O
the	O
virulent	O
mutants	B-T017
in	O
the	O
resistant	O
plants	B-T204
was	O
similar	O
to	O
the	O
growth	B-T038
in	O
plants	B-T204
without	O
Yr2	B-T204
resistance	B-T038
,	O
which	O
is	O
a	O
strong	O
indication	O
that	O
the	O
incompatible	O
phenotype	O
was	O
associated	O
with	O
Yr2	B-T204
.	O

The	O
interaction	O
between	B-T082
P	B-T204
.	I-T204

striiformis	I-T204
and	O
wheat	B-T168
with	O
Yr2	B-T204
resistance	B-T038
was	O
highly	O
variable	O
in	O
time	O
and	O
space	O
,	O
which	O
demonstrate	O
that	O
histological	B-T091
studies	B-T062
are	O
important	O
for	O
a	O
deeper	B-T038
understanding	I-T038
of	O
host	B-T038
-	I-T038
pathogen	I-T038
interactions	I-T038
and	O
plant	B-T204
defense	B-T038
mechanisms	O
in	O
general	B-T082
.	O

The	O
Effects	O
of	O
Messages	B-T170
about	O
the	O
Causes	O
of	O
Obesity	B-T038
on	O
Disciplinary	O
Action	O
Decisions	B-T038
for	O
Overweight	B-T038
Employees	B-T097

We	O
investigated	O
the	O
impact	O
of	O
messages	B-T170
about	O
the	O
causes	O
of	O
obesity	B-T038
(	O
controllable	B-T033
or	O
uncontrollable	O
)	O
on	O
the	O
disciplinary	O
action	O
consequences	O
selected	O
for	O
obese	B-T038
employees	B-T097
in	O
response	O
to	O
a	O
work	O
-	O
related	O
mistake	O
.	O

Participants	B-T098
read	O
about	O
either	O
the	O
controllable	B-T033
or	O
uncontrollable	O
causes	O
of	O
obesity	B-T038
before	O
reviewing	O
an	O
ostensible	O
employee	B-T097
file	O
that	O
included	O
a	O
description	O
of	O
an	O
employee	B-T097
mistake	O
.	O

Depending	O
on	O
condition	O
,	O
the	O
file	O
contained	O
a	O
photo	O
of	O
the	O
employee	B-T097
that	O
either	O
depicted	O
them	O
as	O
obese	B-T038
or	O
average	O
weight	O
.	O

Participants	B-T098
were	O
more	O
willing	O
to	O
withhold	O
a	O
raise	O
or	O
promotion	O
from	O
an	O
obese	B-T038
employee	B-T097
than	O
from	O
an	O
average	O
-	O
weight	O
employee	B-T097
.	O

Further	O
,	O
there	O
was	O
little	O
evidence	O
that	O
the	O
messages	B-T170
about	O
the	O
causes	O
of	O
obesity	B-T038
affected	O
participants	B-T098
'	O
perceived	B-T033
control	I-T033
and	O
self	B-T038
-	I-T038
efficacy	I-T038
for	O
healthy	O
behaviors	O
.	O

Experience	B-T038
is	O
Instrumental	O
in	O
Tuning	O
a	O
Link	O
Between	O
Language	O
and	O
Cognition	B-T038
:	O
Evidence	O
from	O
6	O
-	O
to	O
7	O
-	O
Month	O
-	O
Old	O
Infants	O
'	O
Object	O
Categorization	B-T170

At	O
birth	O
,	O
infants	O
not	O
only	O
prefer	O
listening	B-T038
to	O
human	B-T204
vocalizations	O
,	O
but	O
also	O
have	O
begun	O
to	O
link	O
these	O
vocalizations	O
to	O
cognition	B-T038
:	O
For	O
infants	O
as	O
young	O
as	O
three	O
months	O
of	O
age	O
,	O
listening	B-T038
to	O
human	B-T204
language	O
supports	O
object	O
categorization	B-T170
,	O
a	O
core	B-T082
cognitive	O
capacity	O
.	O

This	O
precocious	O
link	B-T082
is	O
initially	O
broad	B-T082
:	O
At	O
3	O
and	O
4	O
months	O
,	O
vocalizations	O
of	O
both	O
humans	B-T204
and	O
nonhuman	B-T204
primates	I-T204
support	O
categorization	B-T170
.	O

But	O
by	O
6	O
months	O
,	O
infants	O
have	O
narrowed	O
the	O
link	O
:	O
Only	O
human	B-T204
vocalizations	O
support	O
object	O
categorization	B-T170
.	O

Here	O
we	O
ask	O
what	O
guides	O
infants	O
as	O
they	O
tune	O
their	O
initially	O
broad	B-T082
link	O
to	O
a	O
more	O
precise	O
one	O
,	O
engaged	O
only	O
by	O
the	O
vocalizations	O
of	O
our	O
species	B-T170
.	O

Across	O
three	O
studies	B-T062
,	O
we	O
use	O
a	O
novel	O
exposure	O
paradigm	O
to	O
examine	O
the	O
effects	O
of	O
experience	B-T038
.	O

We	O
document	O
that	O
merely	O
exposing	O
infants	O
to	O
nonhuman	B-T204
primate	I-T204
vocalizations	O
enables	B-T038
infants	O
to	O
preserve	O
the	O
early	O
-	O
established	O
link	O
between	O
this	O
signal	O
and	O
categorization	B-T170
.	O

In	O
contrast	O
,	O
exposing	O
infants	O
to	O
backward	O
speech	B-T038
-	O
a	O
signal	O
that	O
fails	O
to	O
support	O
categorization	B-T170
at	O
any	O
age	O
-	O
offers	O
no	O
such	O
advantage	O
.	O

Our	O
findings	B-T033
reveal	O
the	O
power	O
of	O
early	O
experience	B-T038
as	O
infants	O
specify	O
which	O
signals	O
,	O
from	O
an	O
initially	O
broad	B-T082
set	O
,	O
they	O
will	O
continue	O
to	O
link	O
to	O
cognition	B-T038
.	O

Bone	O
Degeneration	O
and	O
Its	O
Recovery	O
in	O
SMP30	B-T017
/	I-T017
GNL	I-T017
-	O
Knockout	B-T204
Mice	I-T204

Senescence	B-T103
marker	I-T103
protein	I-T103
-	I-T103
30	I-T103
(	O
SMP30	B-T103
)	O
decreases	O
androgen	B-T103
-	O
independently	O
with	O
aging	B-T038
and	O
is	O
a	O
lactone	B-T103
-	O
hydrolyzing	B-T103
enzyme	I-T103
gluconolactonase	B-T103
(	O
GNL	B-T103
)	O
that	O
is	O
involved	O
in	O
vitamin	B-T103
C	I-T103
biosynthesis	O
.	O

In	O
the	O
present	O
study	B-T062
,	O
bone	B-T017
properties	O
of	O
SMP30	B-T017
/	I-T017
GNL	I-T017
knockout	B-T204
(	I-T204
KO	I-T204
)	I-T204
mice	I-T204
with	O
deficiency	O
in	O
vitamin	B-T103
C	I-T103
synthesis	O
were	O
investigated	O
to	O
reveal	O
the	O
effects	O
of	O
SMP30	B-T103
/	I-T103
GNL	I-T103
and	O
exogenous	O
vitamin	B-T103
C	I-T103
supplementation	B-T103
on	O
bone	B-T038
formation	I-T038
.	O

Mineral	O
content	O
(	O
BMC	O
)	O
and	O
mineral	B-T201
density	I-T201
(	O
BMD	B-T201
)	O
of	O
the	O
mandible	B-T017
and	O
femur	B-T017
of	O
SMP30	B-T017
/	I-T017
GNL	I-T017
KO	B-T204
and	O
wild	B-T204
-	I-T204
type	I-T204
mice	I-T204
at	O
2	O
and	O
3	O
months	O
of	O
age	O
with	O
or	O
without	O
vitamin	B-T103
C	I-T103
supplementation	B-T103
were	O
measured	O
by	O
dual	B-T058
-	I-T058
energy	I-T058
X	I-T058
-	I-T058
ray	I-T058
absorptiometry	I-T058
.	O

Body	O
and	O
bone	B-T017
weight	O
of	O
both	O
age	O
groups	O
decreased	O
and	O
became	O
significantly	O
lower	O
than	O
those	O
of	O
wild	B-T204
-	I-T204
type	I-T204
mice	I-T204
.	O

The	O
bones	B-T017
of	O
SMP30	B-T017
/	I-T017
GNL	I-T017
KO	B-T204
mice	I-T204
were	O
rough	O
and	O
porous	O
,	O
with	O
BMC	O
and	O
BMD	B-T201
significantly	O
below	O
wild	B-T204
-	I-T204
type	I-T204
.	O

Oral	B-T082
supplementation	B-T103
with	O
vitamin	B-T103
C	I-T103
eliminated	O
differences	O
in	O
body	O
weight	O
,	O
bone	B-T017
weight	O
,	O
BMC	O
,	O
and	O
BMD	B-T201
between	O
SMP30	B-T017
/	I-T017
GNL	I-T017
KO	B-T204
and	O
wild	B-T204
-	I-T204
type	I-T204
mice	I-T204
at	O
each	O
age	O
.	O

These	O
results	O
indicate	O
that	O
bone	O
degeneration	O
in	O
SMP30	B-T017
/	I-T017
GNL	I-T017
KO	B-T204
mice	I-T204
was	O
caused	O
by	O
lack	O
of	O
vitamin	B-T103
C	I-T103
,	O
and	O
that	O
this	O
mouse	B-T204
strain	I-T204
is	O
an	O
appropriate	O
model	B-T204
for	O
bone	O
metabolism	O
in	O
humans	B-T204
,	O
which	O
have	O
no	O
ability	O
to	O
synthesize	O
vitamin	B-T103
C	I-T103
.	O

Utility	O
of	O
Post	B-T058
-	I-T058
Mortem	I-T058
Genetic	B-T062
Testing	I-T062
in	O
Cases	O
of	O
Sudden	B-T038
Arrhythmic	I-T038
Death	I-T038
Syndrome	I-T038

Sudden	B-T038
arrhythmic	I-T038
death	I-T038
syndrome	I-T038
(	O
SADS	B-T038
)	O
describes	O
a	O
sudden	B-T038
death	I-T038
with	O
negative	O
autopsy	B-T058
and	O
toxicological	O
analysis	B-T062
.	O

Cardiac	B-T038
genetic	I-T038
disease	I-T038
is	O
a	O
likely	O
etiology	O
.	O

This	O
study	B-T062
investigated	O
the	O
clinical	O
utility	O
and	O
combined	O
yield	O
of	O
post	B-T058
-	I-T058
mortem	I-T058
genetic	B-T062
testing	I-T062
(	O
molecular	B-T058
autopsy	I-T058
)	O
in	O
cases	O
of	O
SADS	B-T038
and	O
comprehensive	O
clinical	B-T058
evaluation	I-T058
of	O
surviving	O
relatives	O
.	O

We	O
evaluated	B-T058
302	O
expertly	O
validated	O
SADS	B-T038
cases	O
with	O
suitable	O
DNA	B-T103
(	O
median	O
age	O
:	O
24	O
years	O
;	O
65	O
%	O
males	O
)	O
who	O
underwent	O
next	O
-	O
generation	O
sequencing	B-T058
using	O
an	O
extended	O
panel	O
of	O
77	O
primary	B-T017
electrical	I-T017
disorder	I-T017
and	O
cardiomyopathy	B-T017
genes	I-T017
.	O

Pathogenic	B-T033
and	O
likely	O
pathogenic	O
variants	O
were	O
classified	O
using	O
American	B-T092
College	I-T092
of	I-T092
Medical	I-T092
Genetics	I-T092
(	O
ACMG	B-T092
)	O
consensus	B-T170
guidelines	I-T170
.	O

The	O
yield	O
of	O
combined	O
molecular	B-T058
autopsy	I-T058
and	O
clinical	B-T058
evaluation	I-T058
in	O
82	O
surviving	O
families	O
was	O
evaluated	B-T058
.	O

A	O
gene	B-T062
-	I-T062
level	I-T062
rare	I-T062
variant	I-T062
association	I-T062
analysis	I-T062
was	O
conducted	O
in	O
SADS	B-T038
cases	O
versus	O
controls	O
.	O

A	O
clinically	O
actionable	O
pathogenic	B-T033
or	O
likely	O
pathogenic	O
variant	O
was	O
identified	O
in	O
40	O
of	O
302	O
cases	O
(	O
13	O
%	O
)	O
.	O

The	O
main	O
etiologies	O
established	O
were	O
catecholaminergic	B-T038
polymorphic	I-T038
ventricular	I-T038
tachycardia	I-T038
and	O
long	B-T038
QT	I-T038
syndrome	I-T038
(	O
17	O
[	O
6	O
%	O
]	O
and	O
11	O
[	O
4	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Gene	B-T062
-	I-T062
based	I-T062
rare	I-T062
variants	I-T062
association	I-T062
analysis	I-T062
showed	O
enrichment	O
of	O
rare	O
predicted	O
deleterious	O
variants	O
in	O
RYR2	B-T017
(	O
p	O
=	O
5	O
×	O
10	O
(	O
-	O
5	O
)	O
)	O
.	O

Combining	O
molecular	B-T058
autopsy	I-T058
with	O
clinical	B-T058
evaluation	I-T058
in	O
surviving	O
families	O
increased	O
diagnostic	O
yield	O
from	O
26	O
%	O
to	O
39	O
%	O
.	O

Molecular	B-T058
autopsy	I-T058
for	O
electrical	B-T017
disorder	I-T017
and	O
cardiomyopathy	B-T017
genes	I-T017
,	O
using	O
ACMG	B-T092
guidelines	B-T170
for	O
variant	B-T170
classification	I-T170
,	O
identified	O
a	O
modest	O
but	O
realistic	O
yield	O
in	O
SADS	B-T038
.	O

Our	O
data	O
highlighted	O
the	O
predominant	O
role	O
of	O
catecholaminergic	B-T038
polymorphic	I-T038
ventricular	I-T038
tachycardia	I-T038
and	O
long	B-T038
QT	I-T038
syndrome	I-T038
,	O
especially	O
the	O
RYR2	B-T017
gene	I-T017
,	O
as	O
well	O
as	O
the	O
minimal	O
yield	O
from	O
other	O
genes	B-T017
.	O

Furthermore	O
,	O
we	O
showed	O
the	O
enhanced	O
utility	O
of	O
combined	O
clinical	B-T058
and	O
genetic	O
evaluation	O
.	O

Binding	O
of	O
DEAD	B-T103
-	I-T103
box	I-T103
helicase	I-T103
Dhh1	B-T103
to	O
the	O
5	B-T103
'	I-T103
UTR	I-T103
of	O
ASH1	B-T017
mRNA	B-T103
represses	B-T038
localized	O
translation	B-T038
of	O
ASH1	B-T017
in	O
yeast	B-T204
cells	B-T017

Local	B-T038
translation	I-T038
of	O
specific	O
mRNAs	B-T103
is	O
regulated	B-T038
by	O
dynamic	O
changes	O
in	O
their	O
subcellular	B-T017
localization	O
,	O
and	O
these	O
changes	O
are	O
due	O
to	O
complex	O
mechanisms	O
controlling	O
cytoplasmic	B-T017
mRNA	B-T038
transport	I-T038
.	O

The	O
budding	B-T204
yeast	I-T204
Saccharomyces	B-T204
cerevisiae	I-T204
is	O
well	O
suited	O
to	O
studying	O
these	O
mechanisms	O
because	O
many	O
of	O
its	O
transcripts	B-T103
are	O
transported	B-T038
from	O
the	O
mother	B-T017
cell	I-T017
to	O
the	O
budding	B-T038
daughter	B-T017
cell	I-T017
.	O

Here	O
,	O
we	O
investigated	O
the	O
translational	B-T038
control	I-T038
of	O
ASH1	B-T017
mRNA	B-T103
after	O
transport	B-T038
and	O
localization	O
.	O

We	O
show	O
that	O
although	O
ASH1	B-T017
transcripts	B-T103
were	O
translated	B-T038
after	O
they	O
reached	O
the	O
bud	B-T017
-	I-T017
tip	I-T017
,	O
some	O
mRNAs	B-T103
were	O
bound	O
by	O
the	O
RNA	B-T103
-	I-T103
binding	I-T103
protein	I-T103
Puf6	B-T103
and	O
were	O
non	B-T033
-	I-T033
polysomal	I-T033
.	O

We	O
also	O
found	O
that	O
the	O
DEAD	B-T103
-	I-T103
box	I-T103
helicase	I-T103
Dhh1	B-T103
complexed	O
with	O
the	O
untranslated	B-T103
ASH1	B-T017
mRNA	B-T103
and	O
Puf6	B-T103
.	O

Loss	O
of	O
Dhh1	B-T103
affected	O
local	B-T038
translation	I-T038
of	O
ASH1	B-T017
mRNA	B-T103
and	O
resulted	O
in	O
delocalization	O
of	O
ASH1	B-T017
transcript	B-T103
in	O
the	O
bud	B-T204
.	O

Forcibly	O
shifting	O
the	O
non	B-T033
-	I-T033
polysomal	I-T033
ASH1	B-T017
mRNA	B-T103
into	O
polysomes	B-T017
was	O
associated	O
with	O
Dhh1	B-T103
dissociation	B-T038
.	O

We	O
further	O
demonstrated	O
that	O
Dhh1	B-T103
is	O
not	O
recruited	O
to	O
ASH1	B-T017
mRNA	B-T103
co	B-T038
-	I-T038
transcriptionally	I-T038
,	O
suggesting	O
that	O
it	O
could	O
bind	O
to	O
ASH1	B-T017
mRNA	B-T103
within	O
the	O
cytoplasm	B-T017
.	O

Of	O
note	O
,	O
Dhh1	B-T103
bound	O
to	O
the	O
5	B-T103
UTR	I-T103
of	O
ASH1	B-T017
mRNA	B-T103
and	O
inhibited	O
its	O
translation	B-T038
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
after	O
localization	O
to	O
the	O
bud	B-T017
tip	I-T017
,	I-T017
a	O
portion	B-T082
of	O
the	O
localized	B-T082
ASH1	B-T017
mRNA	B-T103
becomes	O
translationally	B-T038
inactive	O
,	O
because	O
of	O
binding	O
of	O
Dhh1	B-T103
and	O
Puf6	B-T103
to	O
the	O
5	B-T103
'	I-T103
and	I-T103
3	I-T103
'	I-T103
UTRs	I-T103
of	O
ASH1	B-T017
mRNA	B-T103
.	O

The	O
Abundance	O
of	O
Endofungal	B-T007
Bacterium	I-T007
Rhizobium	B-T007
radiobacter	I-T007
(	O
syn	O
.	O
Agrobacterium	B-T007
tumefaciens	I-T007
)	O
Increases	O
in	O
Its	O
Fungal	O
Host	O
Piriformospora	B-T204
indica	I-T204
during	O
the	O
Tripartite	O
Sebacinalean	B-T204
Symbiosis	O
with	O
Higher	B-T204
Plants	I-T204

Rhizobium	B-T007
radiobacter	I-T007
(	O
syn	O
.	O

Agrobacterium	B-T007
tumefaciens	I-T007
,	O
syn	O
.	O

"	O
Agrobacterium	B-T007
fabrum	I-T007
"	O
)	O
is	O
an	O
endofungal	B-T007
bacterium	I-T007
of	O
the	O
fungal	O
mutualist	O
Piriformospora	B-T204
(	O
syn	O
.	O

Serendipita	B-T204
)	O
indica	B-T204
(	O
Basidiomycota	B-T204
)	O
,	O
which	O
together	O
form	O
a	O
tripartite	O
Sebacinalean	B-T204
symbiosis	O
with	O
a	O
broad	O
range	O
of	O
plants	B-T204
.	O

R	B-T007
.	I-T007

radiobacter	I-T007
strain	O
F4	O
(	O
RrF4	O
)	O
,	O
isolated	O
from	O
P	B-T204
.	I-T204

indica	I-T204
DSM	I-T204
11827	I-T204
,	O
induces	O
growth	B-T038
promotion	O
and	O
systemic	B-T038
resistance	I-T038
in	O
cereal	B-T168
crops	B-T204
,	O
including	O
barley	B-T204
and	O
wheat	B-T204
,	O
suggesting	O
that	O
R	B-T007
.	I-T007

radiobacter	I-T007
contributes	O
to	O
a	O
successful	O
symbiosis	O
.	O

Here	O
,	O
we	O
studied	O
the	O
impact	O
of	O
endobacteria	B-T007
on	O
the	O
morphology	O
and	O
the	O
beneficial	O
activity	O
of	O
P	B-T204
.	I-T204

indica	I-T204
during	O
interactions	O
with	O
plants	B-T204
.	O

Low	O
numbers	O
of	O
endobacteria	B-T007
were	O
detected	B-T033
in	O
the	O
axenically	B-T058
grown	I-T058
P	B-T204
.	I-T204

indica	I-T204
(	O
long	O
term	O
lab	B-T058
-	I-T058
cultured	I-T058
,	O
lcPiri	B-T204
)	O
whereas	O
mycelia	B-T204
colonizing	B-T033
the	O
plant	B-T204
root	I-T204
contained	O
increased	O
numbers	O
of	O
bacteria	B-T007
.	O

Higher	O
numbers	O
of	O
endobacteria	B-T007
were	O
also	O
found	O
in	O
axenic	B-T058
cultures	I-T058
of	O
P	B-T204
.	I-T204

indica	I-T204
that	O
was	O
freshly	O
re	O
-	O
isolated	O
(	O
riPiri	B-T204
)	O
from	O
plant	B-T204
roots	I-T204
,	O
though	O
numbers	O
dropped	O
during	O
repeated	O
axenic	B-T058
re	I-T058
-	I-T058
cultivation	I-T058
.	O

Prolonged	O
treatments	B-T058
of	O
P	B-T204
.	I-T204

indica	I-T204
cultures	B-T058
with	O
various	O
antibiotics	B-T103
could	O
not	O
completely	O
eliminate	O
the	O
bacterium	B-T007
,	O
though	O
the	O
number	O
of	O
detectable	B-T201
endobacteria	B-T007
decreased	O
significantly	O
,	O
resulting	O
in	O
partial	B-T033
-	I-T033
cured	I-T033
P	B-T204
.	I-T204

indica	I-T204
(	O
pcPiri	B-T204
)	O
.	O

pcPiri	B-T204
showed	O
reduced	O
growth	B-T038
in	O
axenic	B-T058
cultures	I-T058
and	O
poor	O
sporulation	B-T038
.	O

Consistent	O
with	O
this	O
,	O
pcPiri	B-T204
also	O
showed	O
reduced	O
plant	B-T038
growth	I-T038
promotion	O
and	O
reduced	O
systemic	B-T038
resistanc	I-T038
e	O
against	O
powdery	B-T204
mildew	I-T204
infection	B-T038
as	O
compared	O
with	O
riPiri	B-T204
and	O
lcPiri	B-T204
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
assumption	O
that	O
the	O
endobacterium	B-T007
R	B-T007
.	I-T007

radiobacter	I-T007
improves	B-T033
P	B-T204
.	I-T204

indica	I-T204
'	I-T204
s	I-T204
fitness	O
and	O
thus	O
contributes	O
to	O
the	O
success	O
of	O
the	O
tripartite	O
Sebacinalean	B-T204
symbiosis	O
.	O

Stem	B-T017
cell	I-T017
registry	O
programme	O
for	O
patients	O
with	O
ischemic	B-T038
cardiomyopathy	I-T038
undergoing	O
coronary	B-T058
artery	I-T058
bypass	I-T058
grafting	I-T058
:	O
what	O
benefits	O
does	O
it	O
derive	O
?	O

Standardization	B-T062
of	O
stem	O
cell	O
therapy	O
requires	O
application	O
of	O
appropriate	O
methods	B-T062
to	O
evaluate	B-T058
safety	O
and	O
efficac	O
y	O
,	O
including	O
long	O
-	O
term	O
pharmacovigilance	B-T062
.	O

To	O
accomplish	O
this	O
objective	B-T170
,	O
a	O
long	O
-	O
term	O
registry	B-T170
programme	I-T170
was	O
installed	O
.	O

We	O
analysed	O
150	O
patients	O
with	O
ischemic	B-T038
cardiomyopathy	I-T038
,	O
who	O
received	O
intramyocardial	B-T017
CD133	B-T017
+	I-T017
bone	I-T017
marrow	I-T017
mononuclear	I-T017
stem	I-T017
cell	I-T017
treatment	B-T058
combined	O
with	O
coronary	B-T058
artery	I-T058
bypass	I-T058
grafting	I-T058
(	O
CABG	B-T058
)	O
or	O
CABG	B-T058
alone	O
.	O

The	O
mortality	O
rate	O
,	O
major	O
adverse	B-T033
cerebral	I-T033
and	O
cardiac	B-T033
events	I-T033
,	O
and	O
functional	O
outcome	O
parameters	O
were	O
evaluated	B-T058
for	O
the	O
time	O
period	O
up	O
to	O
14	O
years	O
follow	B-T058
-	I-T058
up	I-T058
.	O

As	O
a	O
result	O
,	O
we	O
have	O
stratified	O
the	O
patient	O
population	B-T098
(	O
96	O
patients	O
)	O
into	O
responders	B-T033
and	O
non	B-T033
-	I-T033
responders	I-T033
.	O

Furthermore	O
,	O
the	O
analysis	B-T062
of	O
relevant	O
predictors	O
of	O
good	B-T033
response	I-T033
to	O
CD133	B-T017
+	I-T017
bone	I-T017
marrow	I-T017
mononuclear	I-T017
stem	I-T017
cell	I-T017
treatment	B-T058
was	O
performed	O
.	O

Several	O
positive	O
tendencies	O
related	O
to	O
stem	B-T058
cells	I-T058
transplantation	I-T058
were	O
demonstrated	O
.	O

First	O
,	O
no	B-T033
significant	I-T033
difference	O
in	O
major	O
adverse	B-T033
cardiovascular	I-T033
and	O
cerebral	B-T033
events	I-T033
was	O
observed	O
between	O
stem	B-T017
cell	I-T017
and	O
control	O
group	O
up	O
to	O
14	O
years	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Second	O
,	O
an	O
improvement	O
of	O
left	B-T201
ventricle	I-T201
ejection	I-T201
fraction	I-T201
(	O
LVEF	B-T201
)	O
in	O
stem	B-T017
cell	I-T017
group	O
retained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
CABG	B-T058
-	O
only	O
group	O
,	O
where	O
no	O
significant	O
changes	O
in	O
LVEF	B-T201
after	O
2	O
years	O
were	O
observed	O
.	O

In	O
addition	O
,	O
LVEF	B-T201
under	O
30	O
%	O
and	O
left	B-T058
ventricle	I-T058
end	I-T058
diastolic	I-T058
diameter	I-T058
above	O
60	O
mm	O
were	O
independent	O
predictors	O
of	O
functional	O
response	O
to	O
CD133	B-T017
+	I-T017
cell	I-T017
therapy	B-T058
.	O

Participants	B-T098
with	O
overt	B-T038
heart	I-T038
failure	I-T038
benefit	O
most	O
from	O
CABG	B-T058
combined	O
with	O
intramyocardial	B-T017
injection	B-T058
of	O
CD133	B-T017
+	I-T017
bone	I-T017
marrow	I-T017
mononuclear	I-T017
cell	I-T017
within	O
the	O
group	O
.	O

An	O
improvement	O
LVEF	B-T201
in	O
stem	B-T017
cell	I-T017
group	O
remained	O
for	O
5	O
years	O
in	O
contrast	O
with	O
the	O
CABG	B-T058
-	O
only	O
group	O
.	O

The	O
patients	O
,	O
in	O
whom	O
the	O
improvement	O
of	O
both	O
LVEF	B-T201
and	O
LVED	B-T058
was	O
observed	O
,	O
have	O
benefited	O
by	O
increased	O
life	O
expectancy	O
.	O

Effects	O
of	O
Environmental	B-T082
Factors	O
and	O
Metallic	B-T103
Electrodes	B-T074
on	O
AC	O
Electrical	O
Conduction	O
Through	O
DNA	B-T103
Molecule	I-T103

Deoxyribonucleic	B-T103
acid	I-T103
(	I-T103
DNA	I-T103
)	I-T103
is	O
one	O
of	O
the	O
best	O
candidate	O
materials	O
for	O
various	O
device	O
applications	O
such	O
as	O
in	O
electrodes	B-T074
for	O
rechargeable	O
batteries	O
,	O
biosensors	O
,	O
molecular	B-T074
electronics	I-T074
,	O
medical	B-T074
-	O
and	O
biomedical	B-T074
-	O
applications	O
etc	O
.	O

Hence	O
,	O
it	O
is	O
worthwhile	O
to	O
examine	O
the	O
mechanism	O
of	O
charge	O
transport	O
in	O
the	O
DNA	B-T103
molecule	I-T103
,	O
however	O
,	O
still	O
a	O
question	O
without	O
a	O
clear	O
answer	O
is	O
DNA	B-T103
a	O
molecular	O
conducting	O
material	O
(	O
wire	O
)	O
,	O
semiconductor	O
,	O
or	O
insulator	O
?	O
The	O
answer	O
,	O
after	O
the	O
published	O
data	O
,	O
is	O
still	O
ambiguous	O
without	O
any	O
confirmed	O
and	O
clear	O
scientific	O
answer	O
.	O

DNA	B-T103
is	O
found	O
to	O
be	O
always	O
surrounded	O
with	O
different	O
electric	O
charges	O
,	O
ions	B-T103
,	O
and	O
dipoles	O
.	O

These	O
surrounding	O
charges	O
and	O
electric	O
barrier	O
(	O
s	O
)	O
due	O
to	O
metallic	B-T103
electrodes	B-T074
(	O
as	O
environmental	B-T082
factors	O
(	O
EFs	O
)	O
)	O
play	O
a	O
substantial	O
role	O
when	O
measuring	O
the	O
electrical	O
conductivity	O
through	O
λ	B-T103
-	I-T103
double	I-T103
helix	I-T103
(	I-T103
DNA	I-T103
)	I-T103
molecule	I-T103
suspended	O
between	O
metallic	B-T103
electrodes	B-T074
.	O

We	O
found	O
that	O
strong	O
frequency	O
dependence	O
of	O
AC	O
-	O
complex	O
conductivity	O
comes	O
from	O
the	O
electrical	O
conduction	O
of	O
EFs	O
.	O

This	O
leads	O
to	O
superimposing	O
serious	O
incorrect	O
experimental	B-T062
data	O
to	O
measured	O
ones	O
.	O

At	O
1	O
MHz	O
,	O
we	O
carried	O
out	O
a	O
first	O
control	O
experiment	B-T062
on	O
electrical	O
conductivity	O
with	O
and	O
without	O
the	O
presence	O
of	O
DNA	B-T103
molecule	I-T103
.	O

If	O
there	O
are	O
possible	O
electrical	O
conduction	O
due	O
to	O
stray	O
ions	B-T103
and	O
contribution	O
of	O
substrate	O
,	O
we	O
will	O
detected	O
them	O
.	O

This	O
control	O
experiment	B-T062
revealed	O
that	O
there	O
is	O
an	O
important	O
role	O
played	O
by	O
the	O
environmental	B-T082
-	O
charges	O
around	O
DNA	B-T103
molecule	I-T103
and	O
any	O
experiment	B-T062
should	O
consider	O
this	O
role	O
.	O

We	O
have	O
succeeded	O
to	O
measure	O
both	O
electrical	O
conductivity	O
due	O
to	O
EFs	O
(	O
σ	O
ENV	O
)	O
and	O
electrical	O
conductivity	O
due	O
to	O
DNA	B-T103
molecule	I-T103
(	O
σ	B-T103
DNA	I-T103
)	O
independently	O
by	O
carrying	O
the	O
measurements	O
at	O
different	O
DNA	B-T103
-	O
lengths	O
and	O
subtracting	O
the	O
data	O
.	O

We	O
carried	O
out	O
measurements	O
as	O
a	O
function	O
of	O
frequency	O
(	O
f	O
)	O
and	O
temperature	O
(	O
T	O
)	O
in	O
the	O
ranges	O
0	O
.	O
1	O
Hz	O
<	O
f	O
<	O
1	O
MHz	O
and	O
288	O
K	O
<	O
T	O
<	O
343	O
K	O
.	O

The	O
measured	O
conductivity	O
(	O
σ	O
MES	O
)	O
portrays	O
a	O
metal	B-T103
-	O
like	O
behavior	O
at	O
high	O
frequencies	O
near	O
1	O
MHz	O
.	O

However	O
,	O
we	O
found	O
that	O
σ	B-T103
DNA	I-T103
was	O
far	O
from	O
this	O
behavior	O
because	O
the	O
conduction	O
due	O
to	O
EFs	O
superimposes	O
σ	B-T103
DNA	I-T103
,	O
in	O
particular	O
at	O
low	O
frequencies	O
.	O

By	O
measuring	O
the	O
electrical	O
conductivity	O
at	O
different	O
lengths	O
:	O
40	O
,	O
60	O
,	O
80	O
,	O
and	O
100	O
nm	O
,	O
we	O
have	O
succeeded	O
not	O
only	O
to	O
separate	O
the	O
electrical	O
conduction	O
of	O
the	O
DNA	B-T103
molecule	I-T103
from	O
all	O
EFs	O
effects	O
that	O
surround	O
the	O
molecule	B-T103
,	O
but	O
also	O
to	O
present	O
accurate	O
values	O
of	O
σ	B-T103
DNA	I-T103
and	O
the	O
dielectric	O
constant	O
of	O
the	O
molecule	O
ε	B-T103
'	I-T103
DNA	I-T103
as	O
a	O
function	O
of	O
temperature	O
and	O
frequency	O
.	O

Furthermore	O
,	O
in	O
order	O
to	O
explain	O
these	O
data	O
,	O
we	O
present	O
a	O
model	O
describing	O
the	O
electrical	O
conduction	O
through	O
DNA	B-T103
molecule	I-T103
:	O
DNA	B-T103
is	O
a	O
classical	O
semiconductor	O
with	O
charges	O
,	O
dipoles	O
and	O
ions	B-T103
that	O
result	O
in	O
creation	O
of	O
localized	O
energy	O
-	O
states	O
(	O
LESs	O
)	O
in	O
the	O
extended	O
bands	O
and	O
in	O
the	O
energy	O
gap	O
of	O
the	O
DNA	B-T103
molecule	I-T103
.	O

This	O
model	O
explains	O
clearly	O
the	O
mechanism	O
of	O
charge	O
transfer	O
mechanism	O
in	O
the	O
DNA	B-T103
,	O
and	O
it	O
sheds	O
light	O
on	O
why	O
the	O
charge	O
transfer	O
through	O
the	O
DNA	B-T103
can	O
lead	O
to	O
insulating	O
,	O
semiconducting	O
,	O
or	O
metallic	B-T103
behavior	O
on	O
the	O
same	O
time	O
.	O

The	O
model	O
considers	O
charges	O
on	O
DNA	B-T103
,	O
in	O
the	O
extended	O
bands	O
,	O
either	O
could	O
be	O
free	O
to	O
move	O
under	O
electric	O
field	O
or	O
localized	O
in	O
potential	O
wells	O
/	O
hills	O
.	O

Localization	O
of	O
charges	O
in	O
DNA	B-T103
is	O
an	O
intrinsic	O
structural	B-T082
-	O
property	O
of	O
this	O
solitaire	O
molecule	O
.	O

At	O
all	O
temperatures	O
,	O
the	O
expected	O
increase	O
in	O
thermal	O
-	O
induced	O
charge	O
is	O
attributed	O
to	O
the	O
delocalization	O
of	O
holes	O
(	O
or	O
/	O
and	O
electrons	B-T103
)	O
in	O
potential	O
hills	O
(	O
or	O
/	O
and	O
potential	O
wells	O
)	O
which	O
accurately	O
accounts	O
for	O
the	O
total	O
electric	O
and	O
dielectric	O
behavior	O
through	O
DNA	B-T103
molecule	I-T103
.	O

We	O
succeeded	O
to	O
fit	O
the	O
experiment	B-T062
al	O
data	O
to	O
the	O
proposed	O
model	O
with	O
reasonable	O
magnitudes	O
of	O
potential	O
hills	O
/	O
wells	O
that	O
are	O
in	O
the	O
energy	O
range	O
from	O
0	O
.	O
068	O
eV	O
.	O

Next	B-T062
-	I-T062
Generation	I-T062
Sequencing	I-T062
Approaches	O
to	O
Define	O
the	O
Role	O
of	O
the	O
Autophagy	B-T038
Lysosomal	I-T038
Pathway	I-T038
in	O
Human	B-T204
Disease	B-T038
:	O
The	O
Example	O
of	O
LysoPlex	B-T170

Next	B-T062
-	I-T062
Generation	I-T062
Sequencing	I-T062
(	I-T062
NGS	I-T062
)	I-T062
technologies	I-T062
have	O
deeply	O
changed	O
the	O
throughput	O
of	O
genetic	B-T058
testing	I-T058
allowing	O
analyzing	O
millions	O
of	O
DNA	O
fragments	O
in	O
parallel	O
.	O

One	O
key	O
application	O
is	O
the	O
understanding	O
of	O
genetically	O
heterogeneous	B-T033
and	O
complex	B-T038
diseases	I-T038
where	O
50	O
-	O
100	O
different	O
genes	B-T017
may	O
converge	O
to	O
control	O
the	O
same	O
pathways	B-T038
.	O

These	O
disorders	B-T038
cannot	O
be	O
studied	O
using	O
traditional	O
approaches	O
,	O
based	O
on	O
gene	B-T062
-	I-T062
by	I-T062
-	I-T062
gene	I-T062
Sanger	I-T062
sequencing	I-T062
.	O

We	O
have	O
set	O
up	O
an	O
NGS	B-T062
protocol	B-T170
based	O
on	O
a	O
specific	O
selection	O
of	O
DNA	B-T103
regions	I-T103
belonging	O
to	O
about	O
900	O
genes	B-T017
of	O
the	O
autophagy	B-T038
-	I-T038
lysosomal	I-T038
(	I-T038
ALP	I-T038
)	I-T038
pathway	I-T038
.	O

We	O
here	O
specify	O
all	O
the	O
technical	O
steps	O
and	O
challenges	B-T058
of	O
our	O
protocol	B-T170
,	O
named	O
LysoPlex	B-T170
.	O

This	O
is	O
based	O
on	O
the	O
Haloplex	O
technology	O
and	O
together	O
with	O
high	O
-	O
coverage	O
sequencing	O
empowers	O
a	O
high	O
and	O
uniform	O
coverage	O
of	O
ALP	B-T017
genes	I-T017
.	O

LysoPlex	B-T170
outplays	O
other	O
NGS	B-T062
applications	O
in	O
sensitivity	O
and	O
specificity	O
,	O
providing	O
an	O
accurate	O
picture	O
of	O
all	O
variations	O
in	O
ALP	B-T017
genes	I-T017
.	O

Typical	O
Skin	B-T037
Injuries	I-T037
in	O
Children	O
With	O
Autism	B-T038
Spectrum	I-T038
Disorder	I-T038

Pediatric	O
skin	B-T037
injuries	I-T037
have	O
primarily	O
been	O
described	O
in	O
typically	O
developing	O
children	O
.	O

Our	O
objectives	B-T170
were	O
to	O
describe	O
the	O
prevalence	O
and	O
pattern	B-T082
of	O
skin	B-T037
injuries	I-T037
of	O
children	O
with	O
autism	B-T038
spectrum	I-T038
disorder	I-T038
(	O
ASD	B-T038
)	O
,	O
to	O
describe	O
how	O
this	O
compared	O
with	O
previously	O
demonstrated	O
skin	B-T037
injury	I-T037
locations	B-T033
in	O
typically	O
developing	O
children	O
,	O
and	O
to	O
identify	O
differences	O
in	O
skin	B-T037
injury	I-T037
frequency	O
and	O
locations	B-T033
between	O
autistic	O
children	O
with	O
and	O
without	O
self	O
-	O
injurious	O
behaviors	O
(	O
SIBs	O
)	O
.	O

Children	O
with	O
ASD	B-T038
were	O
recruited	O
between	O
September	O
of	O
2011	O
and	O
September	O
of	O
2014	O
.	O

Demographic	O
information	O
was	O
obtained	O
from	O
the	O
caregiver	B-T097
.	O

All	O
skin	B-T037
injuries	I-T037
and	O
their	O
locations	B-T033
were	O
documented	B-T058
.	O

Of	O
the	O
41	O
children	O
enrolled	O
,	O
half	O
were	O
reported	O
to	O
have	O
SIBs	O
.	O

The	O
most	O
identified	O
skin	B-T037
injury	I-T037
locations	B-T033
were	O
the	O
legs	B-T017
,	O
knees	B-T017
,	O
and	O
back	B-T082
.	O

Children	O
with	O
autism	B-T038
(	O
1	O
)	O
obtain	O
skin	B-T037
injuries	I-T037
frequently	O
and	O
in	O
similar	O
locations	B-T033
as	O
typically	O
developing	O
children	O
and	O
(	O
2	O
)	O
rarely	O
obtain	O
skin	B-T037
injuries	I-T037
to	O
locations	B-T033
that	O
are	O
considered	O
uncommon	O
for	O
accidental	B-T037
injuries	I-T037
despite	O
reports	O
of	O
SIBs	O
.	O

Is	O
Total	B-T058
Elbow	I-T058
Arthroplasty	I-T058
Safe	O
as	O
an	O
Outpatient	B-T058
Procedure	I-T058
?	O

Ambulatory	B-T092
surgery	I-T092
centers	I-T092
are	O
the	O
preferred	B-T092
setting	I-T092
for	O
many	O
procedures	O
formerly	O
performed	O
in	O
a	O
hospital	B-T092
setting	B-T092
.	O

This	O
study	B-T062
sought	O
to	O
determine	O
whether	O
outpatient	O
total	B-T058
elbow	I-T058
arthroplasty	I-T058
(	O
TEA	B-T058
)	O
is	O
as	O
safe	O
as	O
inpatient	O
TEA	B-T058
.	O

A	O
retrospective	B-T062
analysis	I-T062
was	O
performed	O
of	O
inpatient	O
(	O
IP	O
)	O
versus	O
outpatient	O
(	O
OP	O
)	O
TEA	B-T058
by	O
a	O
single	O
surgeon	B-T097
over	O
a	O
period	O
of	O
18	O
years	O
.	O

Demographic	B-T062
,	O
social	O
,	O
and	O
comorbidity	O
measures	O
as	O
well	O
as	O
complication	B-T038
rates	O
were	O
analyzed	B-T062
and	O
stratified	O
by	O
IP	O
or	O
OP	O
status	O
.	O

Bivariate	O
comparison	O
showed	O
increased	O
prevalence	O
of	O
coronary	B-T038
artery	I-T038
disease	I-T038
in	O
the	O
OP	O
group	B-T098
(	O
32	O
%	O
vs	O
.	O

7	O
%	O
)	O
and	O
increased	O
age	O
in	O
the	O
IP	O
group	B-T098
(	O
68	O
years	O
vs	O
.	O

58	O
years	O
)	O
.	O

All	O
other	O
demographic	B-T062
,	O
social	O
,	O
and	O
comorbidity	O
factors	O
were	O
comparable	O
between	O
the	O
IP	O
and	O
OP	O
groups	B-T098
,	O
although	O
more	O
infections	B-T038
were	O
seen	O
in	O
the	O
IP	O
group	B-T098
.	O

The	O
surgeons	B-T097
'	I-T097
initial	B-T038
learning	I-T038
curve	I-T038
occurred	O
mostly	O
within	O
the	O
IP	O
group	B-T098
.	O

Most	O
important	O
,	O
no	O
difference	O
in	O
complication	B-T038
rate	O
was	O
observed	O
between	O
the	O
IP	O
and	O
OP	O
groups	B-T098
.	O

Developmental	O
Hypoxia	B-T038
Has	O
Negligible	O
Effects	O
on	O
Long	O
-	O
Term	O
Hypoxia	B-T038
Tolerance	O
and	O
Aerobic	B-T038
Metabolism	I-T038
of	O
Atlantic	B-T204
Salmon	I-T204
(	O
Salmo	B-T204
salar	I-T204
)	O

Exposure	O
to	O
developmental	O
hypoxia	B-T038
can	O
have	O
long	O
-	O
term	O
impacts	O
on	O
the	O
physiological	B-T038
performance	O
of	O
fish	B-T204
because	O
of	O
irreversible	O
plasticity	O
.	O

Wild	B-T170
and	O
captive	B-T033
-	I-T033
reared	I-T033
Atlantic	B-T204
salmon	I-T204
(	O
Salmo	B-T204
salar	I-T204
)	O
can	O
be	O
exposed	O
to	O
hypoxic	B-T038
conditions	O
during	O
development	O
and	O
continue	O
to	O
experience	O
fluctuating	O
oxygen	B-T103
levels	O
as	O
juveniles	O
and	O
adults	O
.	O

Here	O
,	O
we	O
examine	B-T033
whether	O
developmental	O
hypoxia	B-T038
impacts	O
subsequent	O
hypoxia	B-T038
tolerance	O
and	O
aerobic	O
performance	O
of	O
Atlantic	B-T204
salmon	I-T204
.	O

Individuals	B-T204
at	O
8°C	O
were	O
exposed	O
to	O
50	O
%	O
(	O
hypoxia	B-T038
)	O
or	O
100	O
%	O
(	O
normoxia	O
)	O
dissolved	B-T038
oxygen	I-T038
(	I-T038
DO	I-T038
)	I-T038
saturation	I-T038
(	O
as	O
percent	O
of	O
air	O
saturation	O
)	O
from	O
fertilization	O
for	O
∼100	O
d	O
(	O
800	O
degree	O
days	O
)	O
and	O
then	O
raised	O
in	O
normoxic	O
conditions	O
for	O
a	O
further	O
15	O
mo	O
.	O

At	O
18	O
mo	O
after	O
fertilization	O
,	O
aerobic	O
scope	O
was	O
calculated	O
in	O
normoxia	O
(	O
100	O
%	O
DO	B-T103
)	O
and	O
acute	O
(	O
18	O
h	O
)	O
hypoxia	B-T038
(	O
50	O
%	O
DO	B-T103
)	O
from	O
the	O
difference	O
between	O
the	O
minimum	O
and	O
maximum	O
oxygen	B-T201
consumption	I-T201
rates	O
(	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
respectively	O
)	O
at	O
10°C	O
.	O

Hypoxia	B-T038
tolerance	O
was	O
determined	O
as	O
the	O
DO	B-T103
at	O
which	O
loss	B-T033
of	I-T033
equilibrium	I-T033
(	O
LOE	B-T033
)	O
occurred	O
in	O
a	O
constantly	O
decreasing	B-T033
DO	B-T103
environment	O
.	O

There	O
was	O
no	O
difference	O
in	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
or	O
aerobic	O
scope	O
between	O
fish	B-T204
raised	O
in	O
hypoxia	B-T038
or	O
normoxia	O
.	O

There	O
was	O
some	O
evidence	O
that	O
hypoxia	B-T038
tolerance	O
was	O
lower	O
(	O
higher	O
DO	B-T103
at	O
LOE	B-T033
)	O
in	O
hypoxia	B-T038
-	O
raised	O
fish	B-T204
compared	O
with	O
those	O
raised	O
in	O
normoxia	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
effect	O
was	O
small	O
(	O
12	O
.	O
52	O
%	O
DO	B-T103
vs	O
.	O

11	O
.	O
73	O
%	O
DO	B-T103
at	O
LOE	B-T033
)	O
.	O

Acute	O
hypoxia	B-T038
significantly	O
reduced	O
aerobic	O
scope	O
by	O
reducing	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
while	O
[	O
Formula	O
:	O
see	O
text	O
]	O
remained	O
unchanged	B-T033
.	O

Interestingly	O
,	O
acute	O
hypoxia	B-T038
uncovered	O
individual	B-T204
-	O
level	O
relationships	O
between	O
DO	B-T103
at	O
LOE	B-T033
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
[	O
Formula	O
:	O
see	O
text	O
]	O
,	O
and	O
aerobic	O
scope	O
.	O

We	O
discuss	O
our	O
findings	O
in	O
the	O
context	O
of	O
developmental	O
trajectories	O
and	O
the	O
role	O
of	O
aerobic	O
performance	O
in	O
hypoxia	B-T038
tolerance	O
.	O

LDL	B-T103
particle	O
number	O
and	O
size	O
and	O
cardiovascular	B-T082
risk	O
:	O
anything	O
new	O
under	O
the	O
sun	O
?	O

We	O
provide	O
here	O
an	O
up	O
-	O
to	O
-	O
date	O
perspective	O
on	O
the	O
potential	O
use	O
of	O
LDL	B-T103
particle	O
number	O
and	O
size	O
as	O
complementary	O
risk	B-T033
factors	I-T033
to	O
predict	O
and	O
manage	O
cardiovascular	B-T038
disease	I-T038
(	O
CVD	B-T038
)	O
risk	O
in	O
the	O
clinical	O
realm	O
.	O

Studies	B-T062
show	O
that	O
a	O
significant	O
proportion	O
of	O
the	O
population	B-T098
has	O
discordant	O
LDL	B-T103
particle	O
number	O
and	O
cholesterol	B-T103
indices	B-T170
[	O
non	B-T103
-	I-T103
HDL	I-T103
cholesterol	I-T103
(	O
HDL	B-T103
-	I-T103
C	I-T103
)	O
]	O
.	O

Data	O
also	O
show	O
that	O
risk	O
prediction	O
may	O
be	O
improved	O
when	O
using	O
information	O
on	O
LDL	B-T103
particle	O
number	O
in	O
patients	O
with	O
discordant	O
particle	O
number	O
and	O
cholesterol	B-T103
data	O
.	O

Yet	O
,	O
most	O
of	O
the	O
current	O
CVD	B-T038
guidelines	B-T170
conclude	O
that	O
LDL	B-T103
particle	O
number	O
is	O
not	O
superior	O
to	O
cholesterol	B-T103
indices	B-T170
,	O
including	O
non	B-T103
-	I-T103
HDL	I-T103
-	I-T103
C	I-T103
concentrations	O
,	O
in	O
predicting	O
CVD	B-T038
risk	O
.	O

LDL	B-T103
particle	O
size	O
,	O
on	O
the	O
other	O
hand	O
,	O
has	O
not	O
been	O
independently	O
associated	O
with	O
CVD	B-T038
risk	O
after	O
adjustment	O
for	O
other	O
risk	B-T033
factors	I-T033
such	O
as	O
LDL	B-T103
cholesterol	I-T103
,	O
triglycerides	B-T103
,	O
and	O
HDL	B-T103
-	I-T103
C	I-T103
and	O
that	O
routine	O
use	O
of	O
information	O
pertaining	O
to	O
particle	O
size	O
to	O
determine	O
and	O
manage	O
patients	O
'	O
risk	O
is	O
not	O
yet	O
justified	O
.	O

Additional	O
studies	B-T062
are	O
required	O
to	O
settle	O
the	O
debate	O
on	O
which	O
of	O
cholesterol	B-T103
indices	B-T170
and	O
LDL	B-T103
particle	O
number	O
is	O
the	O
best	O
predictor	O
of	O
CVD	B-T038
risk	O
,	O
and	O
if	O
such	O
measures	O
should	O
be	O
integrated	O
in	O
clinical	B-T058
practice	I-T058
.	O

The	O
emerging	O
contribution	O
of	O
social	B-T204
wasps	I-T204
to	O
grape	B-T038
rot	I-T038
disease	I-T038
ecology	O

Grape	B-T038
sour	I-T038
(	I-T038
bunch	I-T038
)	I-T038
rot	I-T038
is	O
a	O
polymicrobial	O
disease	O
of	O
vineyards	B-T082
that	O
causes	O
millions	O
of	O
dollars	O
in	O
lost	O
revenue	O
per	O
year	O
due	O
to	O
decreased	O
quality	O
of	O
grapes	B-T168
and	O
resultant	B-T168
wine	I-T168
.	O

The	O
disease	B-T038
is	O
associated	O
with	O
damaged	O
berries	B-T168
infected	B-T033
with	O
a	O
community	O
of	O
acetic	B-T007
acid	I-T007
bacteria	I-T007
,	O
yeasts	B-T204
,	O
and	O
filamentous	B-T204
fungi	I-T204
that	O
results	O
in	O
rotting	O
berries	B-T168
with	O
high	O
amounts	O
of	O
undesirable	O
volatile	O
acidity	B-T103
.	O

Many	O
insect	B-T204
species	B-T170
cause	O
the	O
initial	O
grape	B-T168
berry	B-T168
damage	O
that	O
can	O
lead	O
to	O
this	O
disease	B-T038
,	O
but	O
most	O
studies	B-T062
have	O
focused	O
on	O
the	O
role	O
of	O
fruit	B-T204
flies	I-T204
in	O
facilitating	O
symptoms	B-T033
and	O
vectoring	B-T204
the	O
microorganisms	O
of	O
this	O
disease	B-T038
complex	O
.	O

Like	O
fruit	B-T204
flies	I-T204
,	O
social	B-T204
wasps	I-T204
are	O
abundant	O
in	O
vineyards	B-T082
where	O
they	O
feed	O
on	O
ripe	B-T168
berries	I-T168
and	O
cause	O
significant	O
damage	O
,	O
while	O
also	O
dispersing	B-T082
yeasts	B-T204
involved	O
in	O
wine	B-T168
fermentation	B-T038
.	O

Despite	O
this	O
,	O
their	O
possible	O
role	O
in	O
disease	B-T038
facilitation	O
and	O
dispersal	B-T038
of	I-T038
grape	I-T038
rots	I-T038
has	O
not	O
been	O
explored	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
the	O
paper	B-T204
wasp	I-T204
Polistes	O
dominulus	O
could	O
facilitate	O
grape	B-T038
sour	I-T038
rot	I-T038
in	O
the	O
absence	O
of	O
other	O
insect	B-T204
vectors	I-T204
.	O

Using	O
marker	B-T058
gene	I-T058
sequencing	I-T058
we	O
characterized	O
the	O
bacterial	B-T007
and	O
fungal	B-T204
community	O
of	O
wild	O
-	O
caught	O
adults	O
.	O

We	O
used	O
a	O
sterilized	O
foraging	B-T082
arena	I-T082
to	O
determine	O
if	O
these	O
wasps	B-T204
transfer	O
viable	O
microorganisms	O
when	O
foraging	O
.	O

We	O
then	O
tested	O
if	O
wasps	B-T204
harboring	O
their	O
native	B-T098
microbial	O
community	O
,	O
or	O
those	O
inoculated	B-T058
with	O
sour	B-T038
rot	I-T038
,	O
had	O
an	O
effect	O
on	O
grape	B-T038
sour	I-T038
rot	I-T038
incidence	O
and	O
severity	O
using	O
a	O
laboratory	B-T082
foraging	I-T082
arena	I-T082
.	O

We	O
found	O
that	O
all	O
wasps	B-T204
harbor	O
some	O
portion	O
of	O
the	O
sour	B-T038
rot	I-T038
microbial	O
community	O
and	O
that	O
they	O
have	O
the	O
ability	O
to	O
transfer	O
viable	O
microorganisms	O
when	O
foraging	O
.	O

Foraging	O
by	O
inoculated	B-T058
and	O
uninoculated	B-T204
wasps	I-T204
led	O
to	O
an	O
increase	O
in	O
berry	B-T038
rot	I-T038
disease	I-T038
symptom	B-T033
severity	O
and	O
incidence	O
.	O

Our	O
results	B-T033
indicate	O
that	O
paper	B-T204
wasps	I-T204
can	O
facilitate	O
sour	B-T038
rot	I-T038
diseases	I-T038
in	O
the	O
absence	O
of	O
other	B-T204
vectors	I-T204
and	O
that	O
the	O
mechanism	O
of	O
this	O
facilitation	O
may	O
include	O
both	O
increasing	O
host	O
susceptibility	B-T201
and	O
transmitting	O
these	O
microbial	O
communities	O
to	O
the	O
grapes	B-T168
.	O

Social	B-T204
wasps	I-T204
are	O
understudied	O
but	O
relevant	O
players	O
in	O
the	O
sour	B-T038
rot	I-T038
ecology	O
of	O
vineyards	B-T082
.	O

Low	O
-	O
intensity	O
pulsed	O
ultrasound	O
reduces	O
periodontal	B-T038
atrophy	I-T038
in	O
occlusal	B-T038
hypofunctional	O
teeth	B-T017

To	O
clarify	O
whether	O
low	O
-	O
intensity	O
pulsed	O
ultrasound	O
(	O
LIPUS	O
)	O
exposure	O
has	O
recovery	O
effects	O
on	O
the	O
hypofunctional	O
periodontal	B-T017
ligament	I-T017
(	O
PDL	B-T017
)	O
and	O
interradicular	B-T017
alveolar	I-T017
bone	I-T017
(	O
IRAB	B-T017
)	O
.	O

Twelve	O
-	O
week	O
-	O
old	O
male	O
Sprague	B-T204
-	I-T204
Dawley	I-T204
rats	I-T204
were	O
divided	O
into	O
three	O
groups	B-T098
(	O
n	O
=	O
5	O
each	O
)	O
:	O
a	O
normal	B-T038
occlusion	I-T038
(	O
C	O
)	O
group	B-T098
,	O
an	O
occlusal	B-T038
hypofunction	O
(	O
H	O
)	O
group	B-T098
,	O
and	O
an	O
occlusal	B-T098
hypofunction	I-T098
group	I-T098
subjected	O
to	O
LIPUS	O
(	O
HL	O
)	O
treatment	B-T058
.	O

Hypofunctional	O
occlusion	B-T038
of	O
the	O
maxillary	B-T017
first	I-T017
molar	I-T017
(	O
M1	B-T017
)	O
of	O
the	O
H	B-T098
and	O
HL	B-T098
groups	I-T098
was	O
induced	O
by	O
the	O
bite	B-T058
-	I-T058
raising	I-T058
technique	I-T058
.	O

Only	O
the	O
HL	B-T098
group	I-T098
was	O
irradiated	O
with	O
LIPUS	O
for	O
5	O
days	O
.	O

The	O
IRAB	B-T017
and	O
PDL	B-T017
of	O
M1	B-T017
were	O
examined	O
by	O
microcomputed	B-T058
tomography	I-T058
(	O
micro	B-T058
-	I-T058
CT	I-T058
)	O
analysis	B-T062
.	O

To	O
quantify	O
mRNA	B-T103
expression	B-T038
of	O
cytokines	B-T103
involved	O
in	O
PDL	B-T017
proliferation	O
and	O
development	O
,	O
real	B-T062
-	I-T062
time	I-T062
reverse	I-T062
transcription	I-T062
quantitative	I-T062
PCR	I-T062
(	O
qRT	B-T062
-	I-T062
PCR	I-T062
)	O
was	O
performed	O
for	O
twist	B-T017
family	I-T017
bHLH	I-T017
transcription	I-T017
factor	I-T017
1	I-T017
(	O
Twist1	B-T017
)	O
,	O
periostin	B-T017
,	O
and	O
connective	B-T017
tissue	I-T017
growth	I-T017
factor	I-T017
(	O
CTGF	B-T017
)	O
in	O
the	O
PDL	B-T017
samples	O
.	O

Micro	B-T058
-	I-T058
CT	I-T058
analysis	B-T062
showed	O
that	O
the	O
PDL	B-T017
volume	O
was	O
decreased	O
in	O
the	O
H	B-T098
group	I-T098
compared	O
with	O
that	O
of	O
the	O
C	B-T098
and	O
HL	B-T098
groups	I-T098
.	O

Both	O
bone	O
volume	O
per	O
tissue	O
volume	O
(	O
BV	O
/	O
TV	O
)	O
of	O
IRAB	B-T017
was	O
decreased	O
in	O
the	O
H	B-T098
group	I-T098
compared	O
with	O
that	O
in	O
the	O
C	B-T098
group	I-T098
.	O

LIPUS	O
exposure	O
restored	O
BV	O
/	O
TV	O
in	O
the	O
IRAB	B-T017
of	O
the	O
HL	B-T098
group	I-T098
.	O

qRT	B-T062
-	I-T062
PCR	I-T062
analysis	B-T062
showed	O
that	O
Twist1	B-T017
,	O
periostin	B-T017
,	O
and	O
CTGF	B-T017
mRNA	B-T103
levels	O
were	O
decreased	O
in	O
the	O
H	B-T098
group	I-T098
and	O
increased	O
in	O
the	O
HL	B-T098
group	I-T098
.	O

LIPUS	O
exposure	O
reduced	O
the	O
atrophic	B-T038
changes	O
of	O
alveolar	B-T017
bone	I-T017
by	O
inducing	O
the	O
upregulation	B-T038
of	O
periostin	B-T017
and	O
CTGF	B-T017
expression	B-T038
to	O
promote	O
PDL	B-T017
healing	B-T038
after	O
induction	B-T058
of	O
occlusal	B-T038
hypofunction	O
.	O

Radiologic	B-T058
assessment	I-T058
of	O
quality	O
of	O
root	B-T058
canal	I-T058
fillings	I-T058
and	O
periapical	B-T082
status	I-T082
in	O
an	O
Austrian	B-T098
subpopulation	B-T098
-	O
An	O
observational	B-T062
study	I-T062

Progress	O
in	O
endodontic	B-T058
techniques	I-T058
and	O
methodological	O
advances	O
have	O
altered	O
root	B-T058
canal	I-T058
therapy	I-T058
over	O
the	O
last	O
decades	O
.	O

These	O
techniques	O
and	O
methods	O
need	O
periodical	B-T170
documentation	B-T170
.	O

This	O
observational	B-T062
study	I-T062
determined	O
the	O
current	O
prevalence	O
of	O
endodontic	B-T058
treatments	I-T058
,	I-T058
and	O
investigated	O
the	O
relationship	O
of	O
various	O
factors	O
with	O
the	O
periapical	B-T082
status	I-T082
in	O
a	O
Lower	O
Austrian	B-T098
subpopulation	B-T098
.	O

One	O
thousand	O
orthopantomograms	B-T058
of	O
first	O
-	O
time	O
university	B-T092
adult	O
patients	O
radiographed	B-T058
at	O
an	O
outpatient	B-T092
clinic	I-T092
were	O
evaluated	B-T058
.	O

For	O
each	O
tooth	B-T017
,	O
the	O
presence	B-T033
of	O
periradicular	B-T038
pathosis	I-T038
and	O
/	O
or	O
endodontic	B-T058
treatment	I-T058
was	O
recorded	O
,	O
as	O
was	O
the	O
quality	O
of	O
(	O
post	O
-	O
)	O
endodontic	B-T058
treatment	I-T058
(	O
homogeneity	O
and	O
length	O
of	O
root	B-T058
canal	I-T058
fillings	I-T058
;	O
preparation	B-T033
failures	I-T033
;	O
posts	B-T074
/	O
screws	B-T074
;	O
apicoectomies	B-T058
;	O
coronal	B-T058
restorations	I-T058
)	O
.	O

Two	O
evaluators	B-T097
,	O
blinded	B-T062
to	O
each	O
other	O
,	O
scored	O
all	O
teeth	B-T017
.	O

In	O
cases	O
of	O
disagreement	O
,	O
they	O
joined	O
for	O
a	O
consensus	O
score	O
.	O

In	O
all	O
,	O
22	O
,	O
586	O
teeth	O
were	O
counted	O
.	O

Of	O
these	O
,	O
2	O
,	O
907	O
teeth	B-T017
(	O
12	O
.	O
9	O
%	O
)	O
had	O
periapical	B-T038
pathosis	I-T038
,	O
while	O
2	O
,	O
504	O
teeth	B-T017
had	O
undergone	O
root	B-T058
canal	I-T058
treatment	I-T058
.	O

Of	O
the	O
endodontically	B-T038
treated	I-T038
teeth	I-T038
,	O
52	O
%	O
showed	O
no	O
radiographic	O
signs	O
of	O
apical	B-T038
periodontitis	I-T038
,	O
while	O
44	O
.	O
9	O
%	O
had	O
overt	O
apical	O
lesions	O
,	O
and	O
3	O
,	O
1	O
%	O
revealed	O
widened	B-T038
periodontal	I-T038
ligament	I-T038
space	I-T038
.	O

The	O
majority	O
of	O
the	O
root	B-T058
canal	I-T058
fillings	I-T058
was	O
inhomogeneous	O
(	O
70	O
.	O
4	O
%	O
)	O
;	O
75	O
.	O
4	O
%	O
were	O
rated	O
too	O
short	O
,	O
and	O
3	O
.	O
8	O
%	O
too	O
long	O
.	O

The	O
presence	B-T033
of	O
apical	B-T017
pathosis	B-T038
was	O
significantly	O
correlated	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
2	O
.	O
556	O
[	O
confidence	O
interval	O
(	O
CI	O
)	O
2	O
.	O
076	O
-	O
3	O
.	O
146	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
with	O
poor	O
root	B-T058
canal	I-T058
fillings	I-T058
(	O
length	O
and	O
homogeneity	O
)	O
.	O

Posts	B-T074
or	O
screws	B-T074
positively	O
affected	O
periapical	B-T082
status	I-T082
(	O
OR	O
1	O
.	O
853	O
[	O
CI	O
1	O
.	O
219	O
-	O
2	O
.	O
819	O
]	O
;	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
but	O
endodontically	B-T038
treated	I-T038
posterior	I-T038
teeth	I-T038
were	O
infrequently	O
restored	B-T058
(	O
posts	B-T074
,	O
7	O
.	O
5	O
%	O
;	O
screws	B-T074
,	O
2	O
.	O
7	O
%	O
)	O
.	O

Best	O
results	O
were	O
found	O
for	O
teeth	B-T017
with	O
both	O
appropriate	O
endodontic	B-T058
treatment	I-T058
and	O
adequate	O
coronal	B-T058
restoration	I-T058
.	O

A	O
high	O
prevalence	O
of	O
periradicular	B-T033
radiolucencies	I-T033
was	O
observed	O
with	O
root	B-T017
canal	I-T017
filled	I-T017
teeth	I-T017
,	O
along	O
with	O
high	O
numbers	O
of	O
unmet	O
treatment	B-T058
needs	O
.	O

Periapical	B-T082
health	O
was	O
associated	O
with	O
adequate	O
root	B-T058
canal	I-T058
obturation	I-T058
and	O
high	O
-	O
grade	O
postendodontic	O
restorations	O
,	O
and	O
quality	O
regarding	O
these	O
latter	O
aspects	O
is	O
considered	O
mandatory	O
to	O
promote	O
periapical	B-T082
health	O
.	O

Chemical	O
composition	O
and	O
amino	B-T103
acid	I-T103
digestibility	O
of	O
soybean	B-T168
meal	I-T168
produced	O
in	O
the	O
United	B-T082
States	I-T082
,	O
China	B-T082
,	O
Argentina	B-T082
,	O
Brazil	B-T082
,	O
or	O
India	B-T082

An	O
experiment	O
was	O
conducted	O
to	O
compare	O
nutritional	O
composition	O
of	O
soybean	B-T168
meal	I-T168
(	O
SBM	B-T168
)	O
produced	O
in	O
China	B-T082
,	O
Argentina	B-T082
,	O
Brazil	B-T082
,	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O
,	O
or	O
India	B-T082
and	O
the	O
apparent	O
ileal	O
digestibility	O
(	O
AID	O
)	O
and	O
the	O
standardized	O
ileal	O
digestibility	O
(	O
SID	O
)	O
of	O
CP	B-T103
and	O
AA	B-T103
in	O
these	O
SBM	B-T168
when	O
fed	O
to	O
growing	O
pigs	B-T204
.	O

Five	O
sources	O
of	O
SBM	B-T168
from	O
China	B-T082
,	O
Argentina	B-T082
,	O
Brazil	B-T082
,	O
and	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O
,	O
and	O
4	O
sources	O
from	O
India	B-T082
were	O
collected	O
for	O
a	O
total	O
of	O
24	O
sources	O
of	O
SBM	B-T168
.	O

All	O
samples	O
were	O
analyzed	O
for	O
energy	O
,	O
DM	O
,	O
and	O
nutrients	B-T168
,	O
and	O
each	O
source	O
was	O
included	O
in	O
a	O
cornstarch	B-T103
based	I-T103
diet	I-T103
in	O
which	O
SBM	B-T168
was	O
the	O
only	O
AA	B-T103
contributing	O
ingredient	B-T103
.	O

An	O
N	B-T168
-	I-T168
free	I-T168
diet	I-T168
was	O
also	O
formulated	O
.	O

Twenty	O
-	O
five	O
barrows	O
(	O
initial	O
BW	O
:	O
30	O
.	O
53	O
±	O
1	O
.	O
73	O
kg	O
)	O
were	O
equipped	O
with	O
a	O
T	O
-	O
cannula	O
in	O
the	O
distal	B-T082
ileum	I-T082
and	O
randomly	O
allotted	O
to	O
a	O
25	O
×	O
8	O
Youden	B-T062
square	I-T062
design	I-T062
with	O
25	O
diets	B-T168
and	O
8	O
periods	O
.	O

Results	O
indicate	O
that	O
the	O
concentration	O
of	O
CP	B-T103
was	O
greater	O
(	O
<	O
0	O
.	O
05	O
)	O
in	O
SBM	B-T168
from	O
Brazil	B-T082
and	O
India	B-T082
(	O
49	O
.	O
3	O
and	O
49	O
.	O
5	O
%	O
,	O
respectively	O
)	O
than	O
in	O
SBM	B-T168
from	O
China	B-T082
,	O
Argentina	B-T082
,	O
or	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O

(	O
45	O
.	O
1	O
,	O
46	O
.	O
7	O
,	O
and	O
47	O
.	O
3	O
%	O
,	O
respectively	O
,	O
as	O
-	O
fed	O
basis	O
)	O
.	O

The	O
concentration	O
of	O
most	O
indispensable	O
AA	B-T103
followed	O
the	O
same	O
pattern	O
as	O
CP	B-T103
with	O
the	O
exception	O
that	O
SBM	B-T168
from	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O

contained	O
more	O
(	O
<	O
0	O
.	O
05	O
)	O
indispensable	O
AA	B-T103
than	O
SBM	B-T168
from	O
China	B-T082
or	O
Argentina	B-T082
.	O

However	O
,	O
SBM	B-T168
from	O
India	B-T082
contained	O
more	O
(	O
<	O
0	O
.	O
05	O
)	O
trypsin	B-T103
inhibitors	I-T103
than	O
SBM	B-T168
from	O
the	O
other	O
countries	B-T082
.	O

A	O
greater	O
(	O
<	O
0	O
.	O
05	O
)	O
AID	O
and	O
SID	O
of	O
CP	B-T103
and	O
most	O
AA	B-T103
was	O
observed	O
in	O
SBM	B-T168
from	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O

compared	O
with	O
SBM	B-T168
from	O
Brazil	B-T082
,	O
Argentina	B-T082
,	O
and	O
India	B-T082
,	O
but	O
there	O
were	O
no	O
differences	O
between	O
SBM	B-T168
from	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O

and	O
SBM	B-T168
from	O
China	B-T082
.	O

However	O
,	O
because	O
of	O
the	O
lower	O
concentration	O
of	O
AA	B-T103
in	O
SBM	B-T168
from	O
China	B-T082
,	O
the	O
concentration	O
of	O
standardized	O
ileal	O
digestible	O
AA	B-T103
in	O
SBM	B-T168
from	O
China	B-T082
was	O
less	O
(	O
<	O
0	O
.	O
05	O
)	O
than	O
in	O
SBM	B-T168
from	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O

Soybean	O
meal	O
from	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	O

or	O
Brazil	B-T082
had	O
less	O
(	O
<	O
0	O
.	O
05	O
)	O
variability	O
in	O
SID	O
values	O
than	O
SBM	B-T168
from	O
Argentina	B-T082
,	O
China	B-T082
,	O
or	O
India	B-T082
.	O

In	O
conclusion	O
,	O
the	O
SID	O
of	O
CP	B-T103
and	O
AA	B-T103
is	O
dependent	O
on	O
the	O
country	B-T082
where	O
the	O
SBM	B-T168
is	O
produced	O
.	O

This	O
difference	O
and	O
the	O
variability	O
within	O
each	O
country	B-T082
should	O
be	O
evaluated	O
when	O
formulating	B-T058
diets	I-T058
for	O
pigs	B-T204
.	O

Developing	O
understanding	B-T038
of	O
object	O
fall	B-T033
:	O
Going	O
beyond	O
inhibitory	O
processes	O

A	O
study	B-T062
is	O
reported	B-T170
where	O
118	O
participants	B-T098
aged	O
between	O
10	O
years	O
and	O
early	O
20s	O
drew	O
the	O
trajectories	O
they	O
expected	B-T170
objects	O
to	O
follow	O
as	O
they	O
fell	B-T033
.	O

The	O
younger	O
participants	B-T098
typically	O
anticipated	O
backward	B-T082
trajectories	O
during	O
fall	B-T033
from	O
moving	B-T038
carriers	O
while	O
forward	B-T082
but	O
non	O
-	O
parabolic	O
trajectories	O
were	O
relatively	O
more	O
frequent	O
amongst	O
the	O
older	B-T098
participants	I-T098
.	O

Both	O
patterns	B-T082
suggest	O
strong	O
sociocultural	O
influences	O
,	O
with	O
implications	O
for	O
models	B-T170
that	O
regard	O
development	O
in	O
this	O
area	O
as	O
purely	O
the	O
inhibition	O
of	O
principles	O
established	O
in	O
infancy	O
.	O

Statement	O
of	O
contribution	O
What	O
is	O
already	O
known	O
on	O
this	O
subject	O
?	O
Research	B-T062
with	O
infants	O
demonstrates	O
an	O
early	O
-	O
established	O
belief	O
that	O
dropped	O
objects	O
fall	B-T033
straight	B-T082
down	B-T082
.	O

The	O
erroneous	O
expectations	O
that	O
pre	O
-	O
schoolers	O
hold	O
about	O
object	O
fall	B-T033
are	O
consistent	O
with	O
failure	O
to	O
inhibit	O
the	O
presumption	O
of	O
straight	B-T082
-	O
down	B-T082
fall	B-T033
,	O
in	O
contexts	O
where	O
it	O
is	O
inappropriate	O
.	O

What	O
does	O
this	O
study	B-T062
add	O
?	O
The	O
research	B-T062
replicates	O
and	O
extends	O
research	B-T062
with	O
older	B-T098
participants	I-T098
,	O
which	O
indicates	O
errors	O
that	O
cannot	O
be	O
explained	B-T058
via	O
failed	O
inhibition	O
of	O
straight	B-T082
-	O
down	B-T082
fall	B-T033
.	O

It	O
is	O
the	O
first	O
study	B-T062
to	O
trace	O
patterns	B-T082
of	O
errors	O
across	O
late	O
childhood	O
,	O
adolescence	O
and	O
early	O
adulthood	O
.	O

A	O
consequence	O
of	O
the	O
findings	B-T033
is	O
that	O
adequate	O
modelling	O
in	O
developmental	B-T091
psychology	I-T091
must	O
consider	O
multilayered	O
interactions	O
between	O
prior	O
representations	O
and	O
sociocultural	O
experiences	B-T038
.	O

Attenuation	O
of	O
High	B-T103
Glucose	I-T103
-	O
Induced	O
Rat	B-T204
Cardiomyocyte	B-T017
Apoptosis	B-T038
by	O
Exendin	B-T103
-	I-T103
4	I-T103
via	O
Intervention	B-T058
of	O
HO	B-T103
-	I-T103
1	I-T103
/	O
Nrf	B-T103
-	I-T103
2	I-T103
and	O
the	O
PI3K	O
/	O
AKT	O
Signaling	O
Pathway	O

Exendin	B-T103
-	I-T103
4	I-T103
,	O
a	O
glucagon	B-T103
-	I-T103
like	I-T103
peptide	I-T103
-	I-T103
1	I-T103
receptor	I-T103
agonist	I-T103
,	O
demonstrated	O
cytoprotective	B-T038
actions	I-T038
beyond	O
glycemic	B-T033
control	I-T033
in	O
recent	O
studies	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	B-T062
were	O
to	O
investigate	O
the	O
effects	O
of	O
exendin	B-T103
-	I-T103
4	I-T103
on	O
high	B-T103
glucose	I-T103
(	O
HG	B-T103
)	O
-	O
induced	O
cardiomyocyte	B-T017
apoptosis	B-T038
and	O
the	O
possible	O
mechanisms	O
.	O

Rat	B-T204
cardiomyocytes	B-T017
were	O
divided	O
into	O
3	O
groups	O
:	O
normal	B-T103
glucose	I-T103
group	O
(	O
NG	B-T103
group	O
)	O
,	O
HG	B-T103
group	O
and	O
HG	B-T103
+	O
exendin	B-T103
-	I-T103
4	I-T103
group	O
(	O
HG	B-T103
+	O
Ex	B-T103
Group	O
)	O
.	O

Cardiomyocyte	B-T017
apoptosis	B-T038
was	O
evaluated	O
by	O
double	B-T058
-	I-T058
staining	I-T058
with	O
annexin	B-T103
V	I-T103
-	I-T103
fluorescein	I-T103
isothiocyanate	I-T103
(	O
FITC	B-T103
)	O
/	O
propidium	B-T103
iodide	I-T103
(	O
PI	B-T103
)	O
and	O
flow	B-T058
cytometry	I-T058
.	O

Intracellular	B-T082
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
production	O
was	O
detected	B-T033
by	O
2	B-T103
’	I-T103
,	I-T103
7	I-T103
’	I-T103
-	I-T103
dichlorodihydrofluorescein	I-T103
diacetate	I-T103
(	O
DCHF	B-T103
-	I-T103
DA	I-T103
)	O
incubation	B-T058
and	O
fluorescence	B-T058
microscopy	I-T058
.	O

LY294002	B-T103
(	O
LY	B-T103
)	O
,	O
a	O
phosphoinositide	B-T103
3	I-T103
-	I-T103
kinase	I-T103
(	O
PI3K	B-T103
)	O
pathway	B-T038
inhibitor	O
,	O
was	O
added	O
to	O
the	O
medium	B-T103
of	O
the	O
HG	B-T103
+	O
Ex	B-T103
+	O
LY	B-T103
Group	O
for	O
further	O
western	B-T058
blot	I-T058
analysis	I-T058
.	O

The	O
proteins	B-T103
analyzed	B-T062
involved	O
oxidative	B-T038
stress	I-T038
-	O
associated	B-T103
proteins	I-T103
,	O
heme	B-T103
oxygenase	I-T103
-	I-T103
1	I-T103
(	O
HO	B-T103
-	I-T103
1	I-T103
)	O
and	O
nuclear	B-T103
factor	I-T103
E2	I-T103
-	I-T103
related	I-T103
factor	I-T103
2	I-T103
(	O
Nrf	B-T103
-	I-T103
2	I-T103
)	O
,	O
and	O
apoptosis	B-T038
-	O
associated	B-T103
proteins	I-T103
,	O
caspase	B-T103
-	I-T103
3	I-T103
,	O
Bax	B-T103
/	I-T103
B	I-T103
-	I-T103
cell	I-T103
lymphoma	I-T103
2	I-T103
(	O
Bcl	B-T103
-	I-T103
2	I-T103
)	O
and	O
p	B-T103
-	I-T103
AKT	I-T103
/	O
AKT	B-T103
.	O

HG	B-T103
treatment	O
induced	O
cardiomyocyte	B-T017
apoptosis	B-T038
(	O
P	O
=	O
0	O
.	O
00	O
)	O
and	O
clearly	O
upregulated	B-T038
ROS	B-T103
production	O
(	O
P	O
=	O
0	O
.	O
00	O
)	O
;	O
exendin	B-T103
-	I-T103
4	I-T103
co	B-T058
-	I-T058
incubation	I-T058
also	O
ameliorated	O
cardiomyocyte	B-T017
apoptosis	B-T038
(	O
P	O
=	O
0	O
.	O
004	O
)	O
and	O
decreased	O
ROS	B-T103
(	O
P	O
=	O
0	O
.	O
00	O
)	O
level	O
significantly	O
.	O

HO	B-T103
-	I-T103
1	I-T103
and	O
Nrf	B-T103
-	I-T103
2	I-T103
protein	B-T038
expression	I-T038
levels	O
decreased	O
significantly	O
in	O
the	O
HG	B-T103
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
the	O
levels	O
were	O
elevated	O
by	O
exendin	B-T103
-	I-T103
4	I-T103
intervention	B-T058
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
exendin	B-T103
-	I-T103
4	I-T103
attenuated	O
HG	B-T103
-	O
induced	O
higher	O
protein	B-T038
expression	I-T038
,	O
including	O
cleaved	O
caspase	B-T103
-	I-T103
3	I-T103
and	O
Bax	B-T103
,	O
increased	O
the	O
expression	B-T038
of	O
Bcl	B-T103
-	I-T103
2	I-T103
protein	I-T103
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
these	O
impacts	O
of	O
exendin	B-T103
-	I-T103
4	I-T103
were	O
counteracted	O
significantly	O
by	O
co	B-T058
-	I-T058
incubation	I-T058
with	O
LY294002	B-T103
.	O

In	O
addition	O
,	O
exendin	B-T103
-	I-T103
4	I-T103
ameliorated	O
HG	B-T103
-	O
induced	O
p	B-T103
-	I-T103
AKT	I-T103
/	O
AKT	B-T103
lower	B-T038
expression	I-T038
,	O
and	O
this	O
impact	O
was	O
also	O
suppressed	O
by	O
LY294002	B-T103
.	O

Exendin	B-T103
-	I-T103
4	I-T103
ameliorates	O
HG	B-T103
-	O
induced	O
cardiomyocyte	B-T017
apoptosis	B-T038
,	O
and	O
the	O
mechanisms	O
may	O
involve	O
anti	B-T038
-	I-T038
oxidative	I-T038
stress	I-T038
via	O
the	O
HO	B-T103
-	I-T103
1	I-T103
/	O
Nrf	B-T103
-	I-T103
2	I-T103
system	O
,	O
as	O
well	O
as	O
intervention	B-T058
of	O
the	O
PI3K	O
/	O
AKT	O
signaling	O
pathway	O
.	O

KMAP	O
-	O
O	O
framework	O
for	O
care	B-T058
management	I-T058
research	B-T062
of	O
patients	O
with	O
type	B-T038
2	I-T038
diabetes	I-T038

To	O
review	O
impacts	O
of	O
interventions	B-T058
involving	O
self	B-T058
-	I-T058
management	I-T058
education	I-T058
,	O
health	O
coaching	O
,	O
and	O
motivational	B-T058
interviewing	I-T058
for	O
type	B-T038
2	I-T038
diabetes	I-T038
.	O

A	O
thorough	O
review	O
of	O
the	O
scientific	B-T170
literature	I-T170
on	O
diabetes	B-T038
care	B-T058
and	I-T058
management	I-T058
was	O
executed	O
by	O
a	O
research	B-T062
team	O
.	O

This	O
article	B-T170
summarizes	O
important	O
findings	O
in	O
regard	O
to	O
the	O
validity	O
of	O
developing	O
a	O
comprehensive	O
behavioral	O
system	O
as	O
a	O
framework	O
for	O
empirical	O
investigation	B-T058
.	O

The	O
behavioral	O
system	O
framework	O
consists	O
of	O
patients	O
'	O
knowledge	O
(	O
K	O
)	O
,	O
motivation	B-T038
(	O
M	B-T038
)	O
,	O
attitude	B-T038
(	O
A	B-T038
)	O
,	O
and	O
practice	B-T038
(	O
P	B-T038
)	O
as	O
predictor	O
variables	O
for	O
diabetes	B-T038
care	B-T170
outcomes	I-T170
(	O
O	B-T170
)	O
.	O

Care	B-T058
management	I-T058
strategies	O
or	O
health	O
education	O
programs	O
serve	O
as	O
the	O
intervention	B-T058
variable	O
that	O
directly	O
influences	O
K	O
,	O
M	B-T038
,	O
A	B-T038
,	O
and	O
P	B-T038
and	O
then	O
indirectly	O
affects	O
the	O
variability	O
in	O
patient	O
care	B-T170
outcomes	I-T170
of	O
patients	O
with	O
type	B-T038
2	I-T038
diabetes	I-T038
.	O

This	O
review	B-T170
contributes	O
to	O
the	O
understanding	O
of	O
the	O
KMAP	O
-	O
O	O
framework	O
and	O
how	O
it	O
can	O
guide	O
the	O
care	B-T058
management	I-T058
of	O
patients	O
with	O
type	B-T038
2	I-T038
diabetes	I-T038
.	O

It	O
will	O
allow	O
the	O
tailoring	O
of	O
interventions	B-T058
to	O
be	O
more	O
effective	O
through	O
knowledge	O
enhancement	O
,	O
increased	B-T038
motivation	I-T038
,	O
attitudinal	B-T038
changes	O
,	O
and	O
improved	B-T033
preventive	B-T058
practice	I-T058
to	O
reduce	O
the	O
progression	B-T038
of	O
type	B-T038
2	I-T038
diabetes	I-T038
and	O
comorbidities	O
.	O

Furthermore	O
,	O
the	O
use	O
of	O
health	O
information	O
technology	O
for	O
enhancing	O
changes	O
in	O
KMAP	O
and	O
communications	O
is	O
advocated	O
in	O
health	B-T058
promotion	I-T058
and	O
development	O
.	O

Bayesian	O
and	O
Phylogenic	B-T062
Approaches	I-T062
for	O
Studying	O
Relationships	O
among	O
Table	B-T204
Olive	I-T204
Cultivars	I-T204

To	O
enhance	O
table	B-T204
olive	I-T204
tree	I-T204
authentication	O
,	O
relationship	O
,	O
and	O
productivity	O
,	O
we	O
consider	O
the	O
analysis	B-T062
of	O
18	O
worldwide	O
table	B-T204
olive	I-T204
cultivars	I-T204
(	O
Olea	B-T204
europaea	I-T204
L	I-T204
.	I-T204
)	O
based	O
on	O
morphological	O
,	O
biological	O
,	O
and	O
physicochemical	B-T038
markers	I-T038
analyzed	O
by	O
bioinformatic	B-T170
and	O
biostatistic	B-T170
tools	I-T170
.	O

Accordingly	O
,	O
we	O
assess	O
the	O
relationships	O
between	O
the	O
studied	O
varieties	O
,	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
potential	O
productivity	O
-	O
quantitative	O
parameter	O
links	O
on	O
the	O
other	O
hand	O
.	O

The	O
bioinformatic	B-T170
analysis	B-T062
based	O
on	O
the	O
graphical	O
representation	O
of	O
the	O
matrix	B-T062
of	I-T062
Euclidean	I-T062
distances	I-T062
,	O
the	O
principal	O
components	O
analysis	O
,	O
unweighted	B-T062
pair	I-T062
group	I-T062
method	I-T062
with	O
arithmetic	O
mean	O
,	O
and	O
principal	B-T062
coordinate	I-T062
analysis	I-T062
(	O
PCoA	B-T062
)	O
revealed	O
three	O
major	O
clusters	O
which	O
were	O
not	O
correlated	O
with	O
the	O
geographic	B-T082
origin	B-T033
.	O

The	O
statistical	O
analysis	O
based	O
on	O
Kendall	O
'	O
s	O
and	O
Spearman	O
correlation	O
coefficients	O
suggests	O
two	O
highly	O
significant	O
associations	O
with	O
both	O
fruit	B-T168
color	O
and	O
pollinization	B-T038
and	O
the	O
productivity	O
character	O
.	O

These	O
results	O
are	O
confirmed	O
by	O
the	O
multiple	O
linear	O
regression	O
prediction	O
models	O
.	O

In	O
fact	O
,	O
based	O
on	O
the	O
coefficient	O
of	O
determination	O
(	O
R	O
(	O
2	O
)	O
)	O
value	O
,	O
the	O
best	O
model	B-T170
demonstrated	O
the	O
power	O
of	O
the	O
pollinization	B-T038
on	O
the	O
tree	O
productivity	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
846	O
)	O
.	O

Moreover	O
,	O
the	O
derived	O
directed	B-T170
acyclic	I-T170
graph	I-T170
showed	O
that	O
only	O
two	O
direct	O
influences	O
are	O
detected	B-T033
:	O
effect	O
of	O
tolerance	O
on	O
fruit	B-T168
and	O
stone	O
symmetry	O
on	O
side	O
and	O
effect	O
of	O
tolerance	O
on	O
stone	O
form	O
and	O
oil	B-T103
content	O
on	O
the	O
other	O
side	O
.	O

This	O
work	O
provides	O
better	O
understanding	O
of	O
the	O
diversity	O
available	O
in	O
worldwide	O
table	B-T204
olive	I-T204
cultivars	I-T204
and	O
supplies	O
an	O
important	O
contribution	O
for	O
olive	B-T204
breeding	B-T038
and	O
authenticity	O
.	O

Wiedemann	B-T038
-	I-T038
Rautenstrauch	I-T038
Syndrome	I-T038
With	O
Bilateral	B-T082
Tarsal	B-T017
Kink	I-T017
:	O
Three	O
Sutures	B-T058
for	O
Correction	O

The	O
authors	O
describe	O
a	O
5	O
-	O
month	O
-	O
old	O
male	O
infant	O
with	O
Wiedemann	B-T038
-	I-T038
Rautenstrauch	I-T038
syndrome	I-T038
,	O
which	O
is	O
an	O
extremely	O
rare	O
condition	B-T038
.	O

He	O
had	O
tarsal	B-T017
kink	I-T017
in	O
upper	B-T017
eyelids	I-T017
in	O
both	B-T017
eyes	I-T017
.	O

The	O
authors	O
treated	O
bilateral	B-T082
tarsal	B-T017
kink	I-T017
with	O
an	O
everting	B-T058
suture	B-T058
via	O
a	O
transconjunctival	B-T082
approach	I-T082
under	O
local	B-T058
anesthesia	I-T058
.	O

The	O
Indications	O
for	O
Laparoscopic	B-T058
Pancreatectomy	I-T058

Laparoscopic	B-T058
pancreatectomy	I-T058
is	O
not	O
yet	O
established	O
as	O
a	O
routine	B-T058
procedure	I-T058
everywhere	O
in	O
Germany	B-T082
or	O
in	O
other	O
countries	B-T082
.	O

Few	O
data	O
are	O
available	O
on	O
its	O
short	O
-	O
and	O
long	O
-	O
term	O
outcomes	O
.	O

From	O
2008	O
onward	O
,	O
a	O
working	B-T098
group	I-T098
initiated	O
by	O
10	O
centers	B-T092
and	O
currently	O
comprising	O
34	O
centers	B-T092
has	O
gathered	O
data	O
on	O
all	O
cases	O
of	O
laparoscopic	B-T058
pancreatectomy	I-T058
.	O

Procedures	B-T058
in	O
which	O
laparoscopy	B-T058
was	O
converted	O
to	O
open	B-T058
surgery	I-T058
are	O
also	O
included	O
.	O

The	O
registry	B-T170
now	O
contains	O
550	O
data	O
sets	O
representing	O
267	O
cases	O
of	O
benign	B-T038
disease	I-T038
,	O
244	O
malignancies	B-T038
,	O
and	O
39	O
borderline	B-T038
tumors	I-T038
.	O

The	O
most	O
common	O
procedure	B-T058
was	O
laparoscopic	B-T058
left	I-T058
pancreatectomy	I-T058
,	O
followed	O
by	O
resection	B-T058
of	O
the	O
head	B-T017
of	I-T017
the	I-T017
pancreas	I-T017
and	O
tumor	B-T038
enucleation	B-T058
.	O

The	O
most	O
common	O
intraoperative	B-T038
complication	I-T038
was	O
hemorrhage	B-T038
,	O
with	O
a	O
frequency	O
of	O
3	O
%	O
.	O

The	O
rate	O
of	O
conversion	O
to	O
open	B-T058
surgery	I-T058
was	O
35	O
%	O
;	O
if	O
minilaparotomies	B-T058
are	O
excluded	O
,	O
the	O
conversion	O
rate	O
was	O
only	O
16	O
%	O
.	O

39	O
%	O
of	O
patients	O
developed	O
a	O
pancreatic	B-T038
fistula	I-T038
after	O
surgery	B-T058
(	O
usually	O
grade	O
A	O
or	O
B	O
,	O
with	O
1	O
.	O
5	O
%	O
grade	O
C	O
)	O
and	O
3	O
%	O
underwent	O
reoperation	B-T058
because	O
of	O
postoperative	B-T038
hemorrhage	I-T038
.	O

The	O
procedure	B-T033
-	I-T033
related	I-T033
mortality	I-T033
was	O
1	O
.	O
3	O
%	O
.	O

91	O
%	O
of	O
the	O
patients	O
reported	O
only	O
very	O
mild	O
postoperative	B-T033
pain	I-T033
.	O

6	O
.	O
7	O
%	O
newly	O
developed	O
diabetes	B-T038
mellitus	I-T038
after	O
the	O
procedure	B-T058
.	O

The	O
patient	O
cohort	B-T098
in	O
the	O
registry	B-T170
consists	O
of	O
persons	B-T098
who	O
were	O
selected	O
to	O
undergo	O
laparoscopic	B-T058
pancreatectomy	I-T058
by	O
the	O
participating	O
hospital	B-T092
teams	O
,	O
and	O
the	O
data	O
are	O
thus	O
inherently	O
affected	O
by	O
selection	O
bias	O
.	O

The	O
operative	B-T058
procedures	I-T058
that	O
they	O
underwent	O
reflect	O
the	O
current	O
practice	O
of	O
laparoscopic	B-T058
pancreatectomy	I-T058
in	O
Germany	B-T082
.	O

The	O
complication	B-T038
rates	O
are	O
similar	O
to	O
those	O
of	O
open	B-T058
surgery	I-T058
.	O

Selection	O
bias	O
can	O
be	O
avoided	O
only	O
by	O
a	O
randomized	B-T062
trial	I-T062
.	O

Associations	O
of	O
NEUROD2	B-T017
polymorphisms	O
and	O
change	O
of	O
cognitive	B-T038
dysfunctions	I-T038
in	O
schizophrenia	B-T038
and	O
schizoaffective	B-T038
disorder	I-T038
after	O
eight	O
weeks	O
of	O
antipsychotic	B-T103
treatment	B-T058

NEUROD2	B-T017
is	O
a	O
neurospecific	B-T082
helix	I-T082
-	I-T082
loop	I-T082
-	I-T082
helix	I-T082
transcription	B-T103
factor	I-T103
which	O
has	O
an	O
impact	O
on	O
the	O
regulation	B-T038
of	O
glutamatergic	B-T103
and	O
GABAergic	B-T103
genes	B-T017
.	O

We	O
investigated	O
an	O
association	O
of	O
NEUROD2	B-T017
with	O
neurocognitive	B-T038
dysfunctions	I-T038
in	O
schizophrenia	B-T038
and	O
schizoaffective	B-T038
disorder	I-T038
patients	O
before	O
and	O
during	O
treatment	B-T058
with	O
different	O
second	B-T103
-	I-T103
generation	I-T103
antipsychotics	I-T103
.	O

Patients	O
were	O
genotyped	O
for	O
four	O
different	O
polymorphisms	O
of	O
the	O
NEUROD2	B-T017
gene	B-T017
(	O
(	O
rs9889354	O
(	O
A	O
/	O
G	O
)	O
,	O
rs1877032	O
(	O
C	O
/	O
T	O
)	O
,	O
rs12453682	O
(	O
C	O
/	O
T	O
)	O
and	O
rs11078918	O
(	O
C	O
/	O
G	O
)	O
)	O
.	O

Cognitive	B-T038
function	I-T038
was	O
assessed	O
at	O
baseline	O
and	O
week	O
8	O
.	O

Results	O
of	O
individual	O
neuropsychological	B-T058
tests	I-T058
were	O
assigned	O
to	O
six	O
cognitive	B-T170
domains	I-T170
(	O
reaction	O
time	O
and	O
quality	O
;	O
executive	B-T038
function	I-T038
;	O
working	O
,	O
verbal	B-T038
and	O
visual	B-T038
memory	I-T038
)	O
and	O
a	O
general	O
cognitive	O
index	B-T170
.	O

167	O
patients	O
were	O
included	O
in	O
the	O
study	B-T062
.	O

The	O
NEUROD2	B-T017
exonic	O
polymorphism	O
rs11078918	O
showed	O
significant	O
associations	O
with	O
verbal	B-T038
memory	I-T038
and	O
executive	B-T038
functions	I-T038
,	O
whereas	O
the	O
NEUROD2	B-T017
polymorphism	O
rs12453682	O
was	O
significantly	O
associated	O
with	O
working	O
and	O
verbal	B-T038
memory	I-T038
,	O
executive	B-T038
functions	I-T038
and	O
with	O
a	O
cognitive	O
index	B-T170
.	O

Significant	O
associations	O
were	O
found	O
at	O
baseline	O
and	O
after	O
eight	O
weeks	O
.	O

Moreover	O
,	O
significant	O
associations	O
between	O
the	O
change	O
in	O
neuropsychological	B-T058
test	I-T058
results	O
during	O
antipsychotic	B-T103
treatment	B-T058
and	O
the	O
NEUROD2	B-T017
polymorphisms	O
rs11078918	O
and	O
rs12453682	O
were	O
observed	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
NEUROD2	B-T017
gene	I-T017
could	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
of	O
neurocognitive	B-T038
dysfunctions	I-T038
as	O
well	O
as	O
in	O
the	O
change	O
of	O
cognitive	B-T033
symptoms	I-T033
under	O
antipsychotic	B-T103
treatment	B-T058
in	O
schizophrenia	B-T038
and	O
schizoaffective	B-T038
disorder	I-T038
.	O

New	O
Diterpenoids	B-T103
from	O
Clerodendranthus	B-T204
spicatus	I-T204

Two	O
new	O
diterpenoids	B-T103
,	O
neoorthosiphonones	B-T103
B	I-T103
and	O
C	B-T103
(	O
1	B-T103
and	O
2	B-T103
)	O
,	O
and	O
one	O
known	O
diterpenoid	B-T103
,	O
were	O
isolated	O
from	O
the	O
aerial	B-T204
parts	I-T204
of	O
Clerodendranthus	B-T204
spicatus	I-T204
.	O

Their	O
structures	B-T082
including	O
absolute	O
configurations	B-T082
were	O
determined	O
by	O
comprehensive	O
spectroscopic	B-T058
analyses	I-T058
and	O
X	B-T058
-	I-T058
ray	I-T058
crystallographic	I-T058
methods	I-T058
.	O

No	O
compound	O
was	O
found	O
to	O
inhibit	O
fibronectin	B-T103
production	O
at	O
the	O
concentration	O
of	O
20	O
μM	O
.	O

Stalk	B-T017
versus	O
base	B-T017
invasion	B-T033
in	O
pT1	B-T033
papillary	B-T038
cancers	I-T038
of	I-T038
the	I-T038
bladder	I-T038
:	O
improved	O
substaging	O
system	O
predicting	O
risk	O
of	O
progression	B-T038

Pathologic	B-T033
stage	I-T033
T1	I-T033
(	O
pT1	B-T033
)	O
bladder	B-T038
cancers	I-T038
are	O
a	O
clinically	O
heterogeneous	O
group	O
.	O

However	O
,	O
current	O
staging	B-T170
guidelines	O
for	O
superficially	B-T082
invasive	B-T038
cancers	I-T038
do	O
not	O
acknowledge	O
the	O
variability	O
in	O
type	O
and	O
extent	O
of	O
lamina	B-T033
propria	I-T033
invasion	I-T033
in	O
papillary	B-T038
urothelial	I-T038
carcinomas	I-T038
(	O
PUC	B-T038
)	O
,	O
and	O
historically	O
proposed	O
substaging	O
systems	O
showed	O
either	O
high	O
inter	O
-	O
observer	O
variation	O
or	O
limited	O
value	O
in	O
predicting	O
patient	B-T058
outcomes	I-T058
.	O

Herein	O
we	O
reappraise	O
pT1	B-T033
PUC	B-T038
substaging	O
,	O
aiming	O
to	O
identify	O
a	O
novel	O
scheme	B-T170
which	O
is	O
reproducible	O
and	O
prognostically	B-T170
meaningful	O
.	O

Stage	B-T033
pT1	I-T033
PUC	B-T038
diagnosed	B-T033
during	O
years	O
1999	O
-	O
2015	O
were	O
retrospectively	B-T062
reviewed	I-T062
and	O
characterized	O
as	O
focal	B-T082
invasion	B-T038
confined	O
to	O
papillary	B-T017
stalk	I-T017
,	O
focal	B-T082
invasion	B-T033
of	O
tumor	B-T038
base	B-T017
,	O
or	O
extensive	O
invasion	B-T033
of	O
tumor	B-T038
base	B-T017
.	O

Cases	O
with	O
concurrent	O
flat	B-T033
carcinoma	I-T033
in	I-T033
-	I-T033
situ	I-T033
,	O
angiolymphatic	B-T033
invasion	I-T033
,	O
absent	O
muscularis	B-T017
propria	I-T017
,	O
or	O
clinically	O
advanced	O
disease	O
were	O
excluded	O
.	O

We	O
calculated	O
cumulative	O
incidence	O
of	O
recurrence	B-T033
,	O
progression	B-T038
,	O
and	O
death	B-T038
by	O
tumor	B-T170
subtype	I-T170
and	O
evaluated	B-T058
differential	B-T033
risks	I-T033
using	O
log	B-T170
-	I-T170
rank	I-T170
tests	I-T170
and	O
Kaplan	O
-	O
Meier	O
curves	O
stratified	O
by	O
type	O
and	O
extent	B-T201
of	I-T201
invasion	I-T201
.	O

Among	O
62	O
patients	O
satisfying	O
inclusion	O
criteria	O
,	O
22	O
of	O
29	O
patients	O
with	O
base	B-T017
extensive	O
invasion	B-T033
progressed	O
while	O
4	O
of	O
13	O
with	O
base	B-T017
focal	B-T082
and	O
0	O
of	O
20	O
with	O
stalk	B-T017
only	O
invasion	B-T033
progressed	O
.	O

There	O
was	O
strong	O
evidence	O
that	O
base	B-T017
extensive	O
patients	O
had	O
higher	O
risk	O
of	O
progression	B-T038
and	O
death	B-T038
due	O
to	O
bladder	B-T038
cancer	I-T038
than	O
base	B-T017
focal	B-T082
or	O
stalk	B-T017
only	O
counterparts	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

However	O
,	O
tumor	B-T170
subtype	I-T170
was	O
not	O
significantly	O
associated	O
with	O
risk	O
of	O
recurrence	B-T033
(	O
P	O
=	O
0	O
.	O
21	O
)	O
.	O

We	O
propose	O
an	O
innovative	O
substaging	O
approach	O
for	O
reporting	O
site	O
and	O
extent	O
of	O
lamina	B-T033
propria	I-T033
invasion	I-T033
in	O
patients	O
with	O
pT1	B-T033
PUC	B-T038
allowing	O
patient	O
stratification	O
for	O
risk	O
of	O
progression	B-T038
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Basic	B-T062
science	I-T062
and	O
pathogenesis	B-T038
of	O
ageing	B-T038
with	O
HIV	B-T038
:	O
potential	O
mechanisms	O
and	O
biomarkers	B-T201

:	O
The	O
increased	O
prevalence	O
of	O
age	O
-	O
related	O
comorbidities	O
and	O
mortality	O
is	O
worrisome	B-T033
in	O
ageing	B-T038
HIV	B-T038
-	I-T038
infected	I-T038
patients	O
.	O

Here	O
,	O
we	O
aim	O
to	O
analyse	B-T062
the	O
different	O
ageing	B-T038
mechanisms	O
with	O
regard	O
to	O
HIV	B-T038
infection	I-T038
.	O

Ageing	B-T038
results	O
from	O
the	O
time	O
-	O
dependent	O
accumulation	B-T033
of	O
random	O
cellular	O
damage	O
.	O

Epigenetic	B-T038
modifications	I-T038
and	O
mitochondrial	B-T103
DNA	I-T103
haplogroups	O
modulate	B-T082
ageing	B-T038
.	O

In	O
antiretroviral	B-T058
treatment	I-T058
-	O
controlled	O
patients	O
,	O
epigenetic	B-T038
clock	I-T038
appears	O
to	O
be	O
advanced	O
,	O
and	O
some	O
haplogroups	O
are	O
associated	O
with	O
HIV	B-T038
infection	I-T038
severity	O
.	O

Telomere	B-T038
shortening	I-T038
is	O
enhanced	O
in	O
HIV	B-T038
-	I-T038
infected	I-T038
patients	O
because	O
of	O
HIV	B-T005
and	O
some	O
nucleoside	B-T103
analogue	I-T103
reverse	B-T103
transcriptase	I-T103
inhibitors	I-T103
.	O

Mitochondria	B-T017
-	O
related	O
oxidative	B-T038
stress	I-T038
and	O
mitochondrial	B-T103
DNA	I-T103
mutations	B-T038
are	O
increased	O
during	O
ageing	B-T038
and	O
also	O
by	O
some	O
nucleoside	B-T103
analogue	I-T103
reverse	B-T103
transcriptase	I-T103
inhibitors	I-T103
.	O

Overall	O
,	O
increased	O
inflammation	B-T038
or	O
'	O
inflammageing	B-T038
'	O
is	O
a	O
major	O
driver	O
of	O
ageing	B-T038
and	O
could	O
result	O
from	O
cell	B-T038
senescence	I-T038
with	O
secreted	O
proinflammatory	B-T103
mediators	I-T103
,	O
altered	O
gut	O
microbiota	O
,	O
and	O
coinfections	B-T038
.	O

In	O
HIV	B-T038
-	I-T038
infected	I-T038
patients	O
,	O
the	O
level	O
of	O
inflammation	B-T038
and	O
innate	O
immunity	O
activation	O
is	O
enhanced	O
and	O
related	O
to	O
most	O
comorbidities	O
and	O
to	O
mortality	O
.	O

This	O
status	O
could	O
result	O
,	O
in	O
addition	O
to	O
age	O
,	O
from	O
the	O
virus	B-T005
itself	O
or	O
viral	B-T103
protein	I-T103
released	O
from	O
reservoirs	O
,	O
from	O
HIV	B-T005
-	O
enhanced	O
gut	B-T017
permeability	O
and	O
dysbiosis	B-T038
,	O
from	O
antiretroviral	B-T058
treatment	I-T058
,	O
from	O
frequent	O
cytomegalovirus	B-T005
and	O
hepatitis	B-T005
C	I-T005
virus	I-T005
coinfections	B-T038
,	O
and	O
also	O
from	O
personal	O
and	O
environmental	O
factors	O
,	O
as	O
central	O
fat	B-T033
accumulation	I-T033
or	O
smoking	O
.	O

Adaptive	B-T038
immune	I-T038
activation	O
and	O
immunosenescence	B-T038
are	O
associated	O
with	O
comorbidities	O
and	O
mortality	O
in	O
the	O
general	B-T098
population	I-T098
but	O
are	O
less	O
predictive	O
in	O
HIV	B-T038
-	I-T038
infected	I-T038
patients	O
.	O

Biomarkers	B-T201
to	O
evaluate	B-T058
ageing	B-T038
in	O
HIV	B-T038
-	I-T038
infected	I-T038
patients	O
are	O
required	O
.	O

Numerous	O
systemic	O
or	O
cellular	B-T017
inflammatory	I-T017
,	O
immune	O
activation	O
,	O
oxidative	B-T038
stress	I-T038
,	O
or	O
senescence	O
markers	B-T201
can	O
be	O
tested	O
in	O
serum	B-T031
or	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
.	O

The	O
novel	O
European	B-T082
Study	B-T062
to	O
Establish	O
Biomarkers	B-T201
of	O
Human	B-T170
Ageing	I-T170
MARK	I-T170
-	I-T170
AGE	I-T170
algorithm	I-T170
,	O
evaluating	B-T058
the	O
biological	O
age	O
,	O
is	O
currently	O
assessed	O
in	O
HIV	B-T038
-	I-T038
infected	I-T038
patients	O
and	O
reveals	O
an	O
advanced	O
biological	O
age	O
.	O

Some	O
enhanced	O
inflammatory	O
or	O
innate	O
immune	O
activation	O
markers	B-T201
are	O
interesting	O
but	O
still	O
not	O
validated	O
for	O
the	O
patient	O
'	O
s	O
follow	B-T058
-	I-T058
up	I-T058
.	O

To	O
be	O
able	O
to	O
assess	O
patients	O
'	O
biological	O
age	O
is	O
an	O
important	O
objective	O
to	O
improve	O
their	O
healthspan	O
.	O

MESOTHELIAL	B-T017
CELL	I-T017
ADHERENCE	O
TO	O
VASCULAR	B-T074
PROSTHESES	I-T074
AND	O
THEIR	O
SUBSEQUENT	O
GROWTH	B-T038
IN	O
VITRO	O

Cell	B-T017
seeding	B-T058
may	O
decrease	O
the	O
thrombogenicity	B-T038
of	O
implanted	B-T074
vascular	O
grafts	O
,	O
but	O
its	O
application	O
is	O
hampered	O
by	O
the	O
limited	O
availability	O
of	O
autologous	O
endothelial	B-T017
cells	I-T017
.	O

Human	B-T204
peritoneal	B-T082
mesothelial	B-T017
cells	I-T017
have	O
blood	B-T038
flow	I-T038
supporting	O
qualities	O
and	O
are	O
readily	O
available	O
.	O

This	O
study	O
investigated	O
the	O
adherence	O
of	O
mesothelial	B-T017
cells	I-T017
to	O
vascular	B-T074
prostheses	I-T074
and	O
their	O
subsequent	O
growth	B-T038
in	O
vitro	O
.	O

Circular	B-T082
pieces	O
of	O
various	O
vascular	O
prosthetic	B-T103
materials	I-T103
were	O
seeded	B-T058
with	O
51Chromium	B-T103
-	I-T103
labeled	I-T103
mesothelial	B-T017
and	O
endothelial	B-T017
cells	I-T017
and	O
left	O
for	O
either	O
5	O
,	O
15	O
,	O
30	O
,	O
60	O
,	O
and	O
120	O
minutes	O
.	O

The	O
unattached	O
cells	B-T017
were	O
removed	O
and	O
the	O
degree	O
of	O
cell	B-T017
attachment	O
was	O
measured	O
.	O

The	O
number	O
of	O
mesothelial	B-T017
cells	I-T017
to	O
Dacron	B-T103
increased	O
during	O
the	O
first	O
60	O
min	O
up	O
to	O
35	O
.	O
2	O
%	O
of	O
the	O
seeded	B-T058
inoculum	O
where	O
after	O
a	O
plateau	O
was	O
reached	B-T033
.	O

Scanning	B-T058
electron	I-T058
microscopy	I-T058
showed	O
spreaded	O
mesothelial	B-T017
cells	I-T017
adherent	O
to	O
the	O
Dacron	B-T103
fibers	I-T103
.	O

A	O
significant	O
increase	O
in	O
adherence	O
was	O
observed	O
after	O
preincubation	B-T058
of	O
Dacron	B-T103
with	O
10	O
μg	O
/	O
mL	O
fibronectin	B-T103
,	O
but	O
no	O
improvement	O
was	O
found	B-T033
after	O
preincubation	B-T058
with	O
human	B-T204
serum	B-T103
albumin	I-T103
or	O
gelatin	B-T103
.	O

Mesothelial	B-T017
cells	I-T017
adhered	O
better	O
to	O
Gelcoated	O
than	O
to	O
Gelsealed	O
or	O
plain	B-T103
Dacron	I-T103
.	O

The	O
adherence	O
of	O
mesothelial	B-T017
cells	I-T017
to	O
ePTFE	B-T103
(	O
Teflon	B-T103
)	O
was	O
significantly	O
poorer	O
.	O

No	B-T033
significant	I-T033
differences	O
in	O
adherence	O
were	O
found	B-T033
between	O
mesothelial	B-T017
and	O
endothelial	B-T017
cells	I-T017
.	O

Mesothelial	B-T017
cell	I-T017
growth	B-T038
on	O
Dacron	B-T103
resulted	O
in	O
a	O
modest	O
increase	O
in	O
the	O
number	O
of	O
viable	O
cells	O
during	O
27	O
days	O
,	O
which	O
implies	O
biocompatibility	O
of	O
Dacron	B-T103
and	O
mesothelial	B-T017
cells	I-T017
in	O
vitro	O
.	O

Anterolateral	B-T082
entorhinal	B-T017
cortex	I-T017
volume	O
predicted	O
by	O
altered	O
intra	B-T170
-	I-T170
item	I-T170
configural	I-T170
processing	I-T170

Recent	O
functional	O
imaging	B-T058
studies	I-T058
have	O
proposed	O
that	O
the	O
human	B-T204
entorhinal	B-T017
cortex	I-T017
is	O
subdivided	O
into	O
functionally	O
distinct	O
anterolateral	B-T082
(	O
alERC	B-T017
)	O
and	O
posteromedial	O
(	O
pmERC	B-T017
)	O
subregions	B-T082
.	O

The	O
alERC	B-T017
overlaps	O
with	O
regions	O
that	O
are	O
affected	O
earliest	O
by	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
pathology	B-T038
,	O
yet	O
its	O
cognitive	B-T038
function	I-T038
remains	O
poorly	O
understood	O
.	O

Previous	O
human	B-T204
fMRI	B-T058
studies	I-T058
have	O
focused	O
on	O
its	O
role	O
in	O
object	O
memory	B-T038
,	O
but	O
rodent	B-T204
studies	B-T204
on	O
the	O
putatively	O
homologous	O
lateral	O
entorhinal	B-T017
cortex	I-T017
suggest	O
that	O
it	O
also	O
plays	O
an	O
important	O
role	O
in	O
representing	O
spatial	B-T082
properties	I-T082
of	O
objects	O
.	O

In	O
order	O
to	O
investigate	O
the	O
cognitive	O
effects	O
of	O
human	B-T204
alERC	B-T017
volume	O
differences	O
,	O
we	O
developed	O
an	O
eyetracking	O
-	O
based	O
task	O
to	O
evaluate	B-T058
intra	B-T170
-	I-T170
item	I-T170
configural	I-T170
processing	I-T170
(	O
i	O
.	O
e	O
.	O
,	O
processing	O
the	O
arrangement	B-T082
of	O
an	O
object	O
'	O
s	O
features	O
)	O
,	O
and	O
used	O
manual	B-T058
segmentation	I-T058
based	O
on	O
a	O
recently	O
-	O
developed	B-T170
protocol	I-T170
to	O
delineate	O
the	O
alERC	B-T017
/	O
pmERC	B-T017
as	O
well	O
as	O
other	O
medial	B-T017
temporal	I-T017
lobe	I-T017
(	O
MTL	B-T017
)	O
subregions	B-T082
.	O

In	O
a	O
group	O
of	O
older	O
adult	O
men	B-T098
and	O
women	B-T098
at	O
varying	O
stages	O
of	O
brain	B-T038
atrophy	I-T038
and	O
cognitive	B-T038
decline	I-T038
,	O
we	O
found	O
that	O
intra	B-T170
-	I-T170
item	I-T170
configural	I-T170
processing	I-T170
-	O
regardless	O
of	O
an	O
object	O
'	O
s	O
novelty	O
-	O
was	O
strongly	O
predicted	O
by	O
alERC	B-T017
volume	O
,	O
but	O
not	O
by	O
the	O
volume	O
of	O
any	O
other	O
MTL	B-T017
subregion	I-T017
.	O

These	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
human	B-T204
alERC	B-T017
plays	O
a	O
role	O
in	O
supporting	O
a	O
distinct	O
aspect	O
of	O
object	O
processing	O
,	O
namely	O
attending	O
to	O
the	O
arrangement	B-T082
of	O
an	O
object	O
'	O
s	O
component	O
features	O
.	O
SIGNIFICANCE	O
STATEMENT	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
pathology	B-T038
appears	O
earliest	O
in	O
brain	B-T082
regions	I-T082
that	O
overlap	O
with	O
the	O
anterolateral	B-T082
entorhinal	B-T017
cortex	I-T017
(	O
alERC	B-T017
)	O
.	O

However	O
,	O
the	O
cognitive	B-T038
role	I-T038
of	O
the	O
alERC	B-T017
is	O
poorly	O
understood	O
.	O

Previous	O
human	B-T062
studies	I-T062
treat	B-T058
the	O
alERC	B-T017
as	O
an	O
extension	O
of	O
the	O
neighboring	O
perirhinal	B-T082
cortex	I-T082
,	O
supporting	O
object	O
memory	B-T038
.	O

Animal	B-T204
studies	I-T204
suggest	O
that	O
the	O
alERC	B-T017
may	O
support	O
the	O
spatial	B-T082
properties	I-T082
of	O
objects	O
.	O

In	O
a	O
group	O
of	O
older	O
adult	O
humans	B-T204
at	O
the	O
earliest	O
stages	O
of	O
cognitive	B-T038
decline	I-T038
,	O
we	O
show	O
that	O
alERC	B-T017
volume	O
selectively	O
predicted	O
configural	B-T170
processing	I-T170
(	O
attention	B-T038
to	O
the	O
spatial	B-T082
arrangement	I-T082
of	O
an	O
object	O
'	O
s	O
parts	O
)	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
cognitive	B-T038
role	I-T038
related	O
to	O
alERC	B-T017
volume	O
in	O
humans	B-T204
.	O

This	O
task	O
can	O
be	O
adapted	O
to	O
serve	O
as	O
an	O
early	B-T170
detection	I-T170
method	I-T170
for	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
pathology	B-T038
.	O

Alcohol	B-T058
brief	I-T058
intervention	I-T058
in	O
primary	B-T058
care	I-T058
:	O
Blood	B-T038
pressure	I-T038
outcomes	O
in	O
hypertensive	B-T038
patients	O

In	O
clinical	B-T062
trials	I-T062
alcohol	B-T058
brief	I-T058
intervention	I-T058
(	O
BI	B-T058
)	O
in	O
adult	O
primary	B-T058
care	I-T058
has	O
been	O
efficacious	O
in	O
reducing	O
alcohol	O
consumption	O
,	O
but	O
we	O
know	O
little	O
about	O
its	O
impact	O
on	O
health	O
outcomes	O
.	O

Hypertension	B-T038
is	O
a	O
prevalent	O
and	O
costly	O
chronic	B-T033
condition	I-T033
in	O
the	O
U	B-T082
.	I-T082
S	I-T082
.	I-T082

and	O
worldwide	O
,	O
and	O
alcohol	O
use	O
is	O
a	O
modifiable	O
hypertension	B-T038
risk	B-T033
factor	I-T033
.	O

To	O
evaluate	O
the	O
effect	O
of	O
receiving	O
BI	B-T058
for	O
unhealthy	O
drinking	O
on	O
blood	B-T038
pressure	I-T038
(	I-T038
BP	I-T038
)	I-T038
control	I-T038
among	O
adult	O
hypertensive	B-T038
patients	O
by	O
analyzing	O
secondary	O
data	O
from	O
a	O
clustered	B-T062
,	O
randomized	B-T062
controlled	I-T062
trial	I-T062
on	O
alcohol	B-T058
screening	I-T058
,	O
brief	O
intervention	O
and	O
referral	O
to	O
treatment	O
(	O
SBIRT	O
)	O
implementation	O
by	O
primary	B-T097
care	I-T097
physicians	I-T097
(	O
PCP	B-T097
intervention	I-T097
arm	I-T097
)	O
and	O
non	B-T097
-	I-T097
physician	I-T097
providers	I-T097
and	O
medical	B-T097
assistants	I-T097
(	O
NPP	B-T097
&	O
MA	B-T097
intervention	I-T097
arm	I-T097
)	O
in	O
a	O
large	O
,	O
integrated	B-T092
health	I-T092
care	I-T092
delivery	I-T092
system	I-T092
.	O

Observational	B-T062
,	O
prospective	B-T062
cohort	I-T062
study	I-T062
.	O

3811	O
adult	O
hypertensive	B-T038
primary	O
care	O
patients	O
screening	B-T058
positive	O
for	O
past	O
-	O
year	O
heavy	O
drinking	O
at	O
baseline	O
,	O
of	O
which	O
1422	O
(	O
37	O
%	O
)	O
had	O
an	O
electronic	B-T170
health	I-T170
record	I-T170
BP	B-T038
measure	O
at	O
baseline	O
and	O
18	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Change	B-T033
in	I-T033
BP	I-T033
and	O
controlled	B-T038
BP	I-T038
(	O
systolic	O
/	O
diastolic	O
BP	O
<	O
140	O
/	O
90	O
mmHg	O
)	O
.	O

Overall	O
no	O
significant	O
associations	O
were	O
found	O
between	O
alcohol	B-T058
BI	I-T058
and	O
BP	B-T033
change	I-T033
at	O
18	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
when	O
analyzing	O
the	O
combined	O
sample	O
of	O
subjects	B-T098
in	O
both	O
intervention	B-T097
arms	I-T097
.	O

However	O
,	O
moderation	O
analyses	O
found	O
that	O
receiving	O
BI	B-T058
for	O
positive	O
past	O
-	O
year	O
unhealthy	O
drinking	O
was	O
positively	O
associated	O
with	O
better	O
BP	B-T038
control	I-T038
at	O
18months	O
in	O
the	O
PCP	B-T097
intervention	I-T097
arm	I-T097
,	O
and	O
for	O
those	O
with	O
lower	O
heavy	O
drinking	O
frequency	O
and	O
poor	O
BP	B-T038
control	I-T038
at	O
the	O
index	B-T058
screening	I-T058
.	O

Our	O
findings	O
suggest	O
that	O
hypertensive	B-T038
patients	O
may	O
benefit	O
from	O
receiving	O
physician	B-T097
brief	O
intervention	O
for	O
unhealthy	O
alcohol	O
use	O
in	O
primary	B-T058
care	I-T058
.	O

Findings	O
also	O
highlight	O
potential	O
population	O
-	O
level	O
benefits	O
of	O
alcohol	B-T058
BI	I-T058
if	O
widely	O
applied	O
,	O
suggesting	O
a	O
need	O
for	O
the	O
development	O
of	O
innovative	O
strategies	O
to	O
facilitate	O
SBIRT	O
delivery	O
in	O
primary	B-T058
care	I-T058
settings	O
.	O

Unusual	O
asymptomatic	B-T038
presentation	I-T038
of	O
bladder	B-T038
cancer	I-T038
metastatic	B-T038
to	I-T038
the	I-T038
penis	I-T038

Penile	B-T038
metastasis	I-T038
is	O
an	O
extremely	B-T038
rare	I-T038
event	I-T038
and	O
mainly	O
originate	O
from	O
primary	O
pelvic	B-T017
tumor	B-T082
sites	I-T082
such	O
us	O
urinary	B-T017
bladder	I-T017
,	O
gastro	B-T022
-	I-T022
intestinal	I-T022
tract	I-T022
and	O
prostate	B-T017
and	O
more	O
rarely	O
from	O
respiratory	B-T022
system	I-T022
,	O
bone	B-T038
tumors	I-T038
and	O
melanoma	B-T038
.	O

Here	O
we	O
describe	O
the	O
unusual	O
presentation	O
of	O
two	O
bladder	B-T038
urothelial	I-T038
cancer	I-T038
metastatic	O
to	O
the	O
penis	B-T017
with	O
no	B-T033
relevant	I-T033
clinical	I-T033
symptoms	I-T033
.	O

Namely	O
,	O
a	O
69	O
years	O
-	O
old	O
man	O
with	O
a	O
warthy	O
lesions	B-T033
of	O
the	O
foreskin	O
and	O
the	O
glans	O
misunderstood	O
for	O
a	O
condylomata	B-T038
that	O
at	O
histological	B-T058
and	O
immunohistochemical	O
analysis	O
showed	O
a	O
bladder	B-T038
urothelial	I-T038
carcinoma	I-T038
;	O
and	O
a	O
71	O
years	O
-	O
old	O
man	O
with	O
reddish	O
skin	O
lesion	O
of	O
the	O
glans	O
,	O
a	O
previous	O
history	B-T033
of	I-T033
bladder	I-T033
and	O
urethral	B-T038
carcinoma	I-T038
and	O
histological	B-T033
pagetoid	I-T033
spread	I-T033
of	O
urothelial	B-T038
cancer	I-T038
to	B-T017
the	I-T017
glans	I-T017
.	O

Recurrent	B-T038
bladder	I-T038
urothelial	I-T038
carcinoma	I-T038
is	O
usually	O
a	O
visceral	B-T017
disease	B-T038
that	O
rarely	O
presents	O
as	O
a	O
superficial	O
asymptomatic	B-T033
skin	B-T038
lesion	I-T038
.	O

The	O
two	O
reported	O
cases	B-T033
were	I-T033
asymptomatic	I-T033
superficial	B-T038
penis	I-T038
metastases	I-T038
with	O
a	O
relatively	O
slow	O
growth	O
and	O
a	O
fairy	B-T033
good	I-T033
prognosis	I-T033
after	O
conservative	O
surgical	O
approach	O
.	O

Accurate	O
clinical	O
examination	O
of	O
the	O
penis	O
is	O
mandatory	O
for	O
males	O
with	O
history	B-T033
of	I-T033
bladder	I-T033
cancer	I-T033
.	O

The	O
bachelorette	O
:	O
Female	O
Siamese	B-T204
fighting	I-T204
fish	I-T204
avoid	O
males	O
exposed	O
to	O
an	O
estrogen	B-T103
mimic	O

Due	O
to	O
improper	O
disposal	O
and	O
a	O
lack	O
of	O
removal	O
during	O
the	O
wastewater	O
treatment	O
process	O
,	O
endocrine	O
disrupting	O
chemicals	B-T103
enter	O
aquatic	O
ecosystems	O
where	O
they	O
exert	O
detrimental	O
effects	O
on	O
fish	B-T204
behavior	O
and	O
physiology	B-T038
.	O

Perhaps	O
the	O
most	O
well	O
-	O
studied	O
and	O
prevalent	O
EDC	B-T103
is	O
17α	B-T103
-	I-T103
ethinylestradiol	I-T103
(	O
EE2	B-T103
)	O
,	O
an	O
active	O
ingredient	B-T103
in	O
oral	B-T103
contraceptives	I-T103
,	O
which	O
is	O
known	O
to	O
cause	O
dramatic	O
reductions	O
in	O
male	O
-	O
typical	O
behaviors	O
.	O

While	O
it	O
is	O
likely	O
that	O
alterations	O
in	O
male	O
courtship	O
behavior	O
decrease	O
reproductive	B-T038
fitness	I-T038
,	O
this	O
is	O
rarely	O
explicitly	O
examined	O
.	O

To	O
this	O
end	O
,	O
whether	O
EE2	B-T103
exposure	O
reduces	O
male	O
attractiveness	O
to	O
female	O
Siamese	B-T204
fighting	I-T204
fish	I-T204
,	O
Betta	B-T204
splendens	I-T204
,	O
was	O
investigated	O
by	O
showing	O
females	O
video	B-T170
images	B-T170
of	O
exposed	B-T098
and	O
unexposed	B-T098
males	O
.	O

Females	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
two	O
exposure	O
conditions	O
(	O
exposed	O
to	O
EE2	B-T103
,	O
control	O
)	O
and	O
each	O
subject	O
then	O
viewed	O
four	O
different	O
video	B-T170
combinations	O
of	O
male	O
conspecifics	O
(	O
courting	O
exposed	B-T098
+	O
exposed	B-T098
;	O
courting	O
unexposed	B-T098
+	O
unexposed	B-T098
;	O
courting	O
unexposed	B-T098
+	O
exposed	B-T098
;	O
swimming	O
unexposed	B-T098
+	O
exposed	B-T098
)	O
.	O

Females	O
,	O
regardless	O
of	O
whether	O
or	O
not	O
they	O
were	O
exposed	O
to	O
EE2	B-T103
,	O
directed	O
markedly	O
less	O
behavior	O
towards	O
exposed	B-T098
males	O
,	O
especially	O
when	O
they	O
viewed	O
an	O
exposed	B-T098
male	O
and	O
an	O
unexposed	B-T098
male	O
simultaneously	O
.	O

These	O
findings	O
demonstrate	O
that	O
EE2	B-T103
can	O
have	O
significant	O
individual	O
-	O
and	O
population	B-T098
-	I-T098
level	I-T098
consequences	O
on	O
fitness	O
by	O
disrupting	O
sexual	O
selection	O
and	O
,	O
ultimately	O
,	O
the	O
success	O
of	O
exposed	B-T098
males	O
.	O

Targeting	O
accuracy	O
of	O
single	B-T082
-	I-T082
isocenter	I-T082
intensity	B-T058
-	I-T058
modulated	I-T058
radiosurgery	B-T058
for	O
multiple	O
lesions	B-T033

To	O
investigate	O
the	O
targeting	O
accuracy	O
of	O
intensity	B-T058
-	I-T058
modulated	I-T058
SRS	B-T058
(	O
IMRS	B-T058
)	O
plans	B-T170
designed	O
to	O
simultaneously	O
treat	O
multiple	O
brain	B-T017
metastases	B-T038
with	O
a	O
single	B-T082
isocenter	I-T082
.	O

A	O
home	B-T103
-	I-T103
made	I-T103
acrylic	I-T103
phantom	O
able	O
to	O
support	O
a	O
film	O
(	O
EBT3	O
)	O
in	O
its	O
coronal	B-T082
plane	I-T082
was	O
used	O
.	O

The	O
phantom	O
was	O
CT	B-T058
scanned	I-T058
and	O
three	O
coplanar	O
small	O
targets	O
(	O
a	O
central	B-T082
and	O
two	O
peripheral	B-T082
)	O
were	O
outlined	O
in	O
the	O
Eclipse	B-T058
system	I-T058
.	O

Peripheral	B-T082
targets	O
were	O
6	O
cm	O
apart	O
from	O
the	O
central	B-T082
one	O
.	O

A	O
reference	O
IMRS	B-T058
plan	B-T170
was	O
designed	O
to	O
simultaneously	O
treat	O
the	O
three	O
targets	O
,	O
but	O
only	O
a	O
single	B-T082
isocenter	I-T082
located	O
at	O
the	O
center	O
of	O
the	O
central	B-T082
target	O
was	O
used	O
.	O

After	O
positioning	B-T082
the	O
phantom	O
on	O
the	O
linac	B-T074
using	O
the	O
room	B-T082
lasers	O
,	O
a	O
CBCT	B-T058
scan	I-T058
was	O
acquired	O
and	O
the	O
reference	O
plan	B-T170
were	O
mapped	O
on	O
it	O
,	O
by	O
placing	O
the	O
planned	O
isocenter	B-T082
at	O
the	O
intersection	O
of	O
the	O
landmarks	O
used	O
in	O
the	O
film	O
showing	O
the	O
linac	B-T074
isocenter	B-T082
.	O

The	O
mapped	O
plan	B-T170
was	O
then	O
recalculated	O
and	O
delivered	O
.	O

The	O
film	O
dose	B-T058
distribution	I-T058
was	O
derived	O
using	O
a	O
cloud	B-T170
computing	I-T170
application	I-T170
(	O
www	B-T170
.	I-T170
radiochromic	I-T170
.	I-T170
com	I-T170
)	O
that	O
uses	O
a	O
triple	O
-	O
channel	O
dosimetry	B-T058
algorithm	B-T170
.	O

Comparison	O
of	O
dose	B-T058
distributions	I-T058
using	O
the	O
gamma	O
index	O
(	O
5	O
%	O
/	O
1	O
mm	O
)	O
were	O
performed	O
over	O
a	O
5	O
×	O
5	O
cm	O
(	O
2	O
)	O
region	O
centered	O
over	O
each	O
target	O
.	O

2D	O
shifts	O
required	O
to	O
get	O
the	O
best	O
gamma	O
passing	O
rates	O
on	O
the	O
peripheral	B-T082
target	O
regions	O
were	O
compared	O
with	O
the	O
reported	O
ones	O
for	O
the	O
central	B-T082
target	O
.	O

The	O
experiment	B-T062
was	O
repeated	O
ten	O
times	O
in	O
different	O
sessions	B-T058
.	O

Average	O
2D	O
shifts	O
required	O
to	O
achieve	O
optimal	O
gamma	O
passing	O
rates	O
(	O
99	O
%	O
,	O
97	O
%	O
,	O
99	O
%	O
)	O
were	O
0	O
.	O
7	O
mm	O
(	O
SD	O
:	O
0	O
.	O
3	O
mm	O
)	O
,	O
0	O
.	O
8	O
mm	O
(	O
SD	O
:	O
0	O
.	O
4	O
mm	O
)	O
and	O
0	O
.	O
8	O
mm	O
(	O
SD	O
:	O
0	O
.	O
3	O
mm	O
)	O
,	O
for	O
the	O
central	B-T082
and	O
the	O
two	O
peripheral	B-T082
targets	O
,	O
respectively	O
.	O

No	O
statistical	O
differences	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
were	O
found	O
for	O
targeting	O
accuracy	O
between	O
the	O
central	B-T082
and	O
the	O
two	O
peripheral	B-T082
targets	O
.	O

The	O
study	B-T062
revealed	O
a	O
targeting	O
accuracy	O
within	O
1	O
mm	O
for	O
off	O
-	O
isocenter	B-T082
targets	O
within	O
6	O
cm	O
of	O
the	O
linac	B-T074
isocenter	B-T082
,	O
when	O
a	O
single	B-T082
-	I-T082
isocenter	I-T082
IMRS	B-T058
plan	B-T170
is	O
designed	O
.	O

Physical	O
activity	O
limits	O
the	O
effects	O
of	O
age	O
and	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
on	O
postural	O
control	O

The	O
aim	O
was	O
to	O
study	O
the	O
possible	O
influence	O
of	O
physical	O
activity	O
on	O
the	O
postural	O
performance	O
of	O
subjects	B-T098
with	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
.	O

The	O
postural	O
performance	O
(	O
i	O
.	O
e	O
.	O

surface	O
area	O
of	O
the	O
center	B-T082
of	I-T082
foot	I-T082
pressure	I-T082
displacement	I-T082
)	O
of	O
3	O
groups	O
was	O
compared	O
:	O
Alzheimer	O
active	O
group	O
(	O
AA	O
)	O
,	O
Alzheimer	O
non	O
-	O
active	O
group	O
(	O
ANA	O
)	O
and	O
healthy	O
non	O
-	O
active	O
group	O
(	O
HNA	O
)	O
.	O

The	O
AA	B-T098
group	I-T098
'	I-T098
s	I-T098
postural	O
performance	O
was	O
superior	B-T082
to	O
that	O
of	O
the	O
ANA	O
and	O
HNA	O
groups	O
.	O

AD	B-T038
disturbed	O
postural	O
performance	O
but	O
participation	O
in	O
regular	O
physical	O
activity	O
made	O
it	O
possible	O
to	O
limit	O
the	O
disturbing	O
effects	O
of	O
AD	B-T038
to	O
a	O
surprising	O
extent	O
,	O
since	O
the	O
postural	O
performance	O
of	O
active	B-T098
AD	I-T098
subjects	I-T098
was	O
also	O
superior	B-T082
to	O
that	O
of	O
healthy	B-T098
subjects	I-T098
.	O

LAMP	B-T103
-	I-T103
2	I-T103
mediates	O
oxidative	B-T038
stress	I-T038
-	O
dependent	O
cell	B-T038
death	I-T038
in	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
treated	B-T058
lung	B-T017
epithelium	B-T017
cells	I-T017

Zinc	B-T103
is	O
an	O
essential	O
element	B-T103
for	O
the	O
biological	B-T022
system	I-T022
.	O

However	O
,	O
excessive	O
exogenous	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
would	O
disrupt	O
cellular	B-T038
Zn	I-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
homeostasis	I-T038
and	O
cause	B-T037
toxicity	I-T037
.	O

In	O
particular	O
,	O
Zinc	B-T103
salts	I-T103
or	O
ZnO	B-T103
nanoparticles	O
exposure	O
could	O
induce	O
respiratory	B-T037
injury	I-T037
.	O

Although	O
previous	O
studies	O
have	O
indicated	O
that	O
organelle	B-T017
damage	O
(	O
including	O
mitochondria	B-T017
or	O
lysosomes	B-T017
)	O
and	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
production	O
are	O
involved	O
in	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
induced	O
toxicity	B-T037
,	O
the	O
interplay	O
between	O
mitochondria	B-T017
/	O
lysosomes	B-T017
damage	O
and	O
ROS	B-T103
production	O
is	O
obscure	O
.	O

Herein	O
,	O
we	O
demonstrated	O
that	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
could	O
induce	O
deglycosylation	B-T038
of	O
lysosome	B-T103
-	I-T103
associated	I-T103
membrane	I-T103
protein	I-T103
1	I-T103
and	O
2	B-T103
(	O
LAMP	B-T103
-	I-T103
1	I-T103
and	O
LAMP	B-T103
-	I-T103
2	I-T103
)	O
,	O
which	O
primarily	O
locate	O
in	O
late	O
endosomes	B-T017
/	O
lysosomes	B-T017
,	O
in	O
A549	B-T017
lung	I-T017
epithelium	I-T017
cells	I-T017
.	O

Intriguingly	O
,	O
LAMP	B-T017
-	I-T017
2	I-T017
knockdown	B-T062
further	O
aggravated	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
mediated	O
ROS	B-T103
production	O
and	O
cell	B-T038
death	I-T038
,	O
indicating	O
LAMP	B-T103
-	I-T103
2	I-T103
(	O
not	O
LAMP	B-T103
-	I-T103
1	I-T103
)	O
was	O
involved	O
in	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
induced	O
toxicity	B-T037
.	O

Our	O
results	O
provide	O
a	O
new	O
insight	O
that	O
LAMP	B-T103
-	I-T103
2	I-T103
contributes	O
to	O
the	O
ROS	B-T103
clearance	O
and	O
cell	B-T038
death	I-T038
induced	O
by	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
treatment	B-T058
,	O
which	O
would	O
help	O
us	O
to	O
get	O
a	O
better	O
understanding	O
of	O
Zn	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
induced	O
toxicity	B-T037
in	O
respiratory	B-T022
system	I-T022
.	O

Fluorescence	B-T058
hyperspectral	I-T058
imaging	I-T058
(	O
fHSI	B-T058
)	O
using	O
a	O
spectrally	O
resolved	B-T033
detector	B-T074
array	I-T074

The	O
ability	O
to	O
resolve	O
multiple	O
fluorescent	O
emissions	O
from	O
different	O
biological	O
targets	O
in	O
video	O
rate	O
applications	O
,	O
such	O
as	O
endoscopy	B-T058
and	O
intraoperative	B-T058
imaging	I-T058
,	O
has	O
traditionally	O
been	O
limited	O
by	O
the	O
use	O
of	O
filter	O
-	O
based	O
imaging	B-T074
systems	I-T074
.	I-T074

Hyperspectral	B-T058
imaging	I-T058
(	O
HSI	B-T058
)	O
facilitates	O
the	O
detection	B-T058
of	O
both	O
spatial	B-T082
and	O
spectral	O
information	O
in	O
a	O
single	O
data	O
acquisition	O
,	O
however	O
,	O
instrumentation	O
for	O
HSI	B-T058
is	O
typically	O
complex	O
,	O
bulky	O
and	O
expensive	O
.	O

We	O
sought	O
to	O
overcome	O
these	O
limitations	O
using	O
a	O
novel	O
robust	O
and	O
low	O
cost	O
HSI	B-T058
camera	B-T074
based	O
on	O
a	O
spectrally	B-T074
resolved	I-T074
detector	I-T074
array	I-T074
(	O
SRDA	B-T074
)	O
.	O

We	O
integrated	O
this	O
HSI	B-T058
camera	B-T074
into	O
a	O
wide	B-T033
-	I-T033
field	I-T033
reflectance	B-T058
-	I-T058
based	I-T058
imaging	O
system	O
operating	O
in	O
the	O
near	O
-	O
infrared	O
range	O
to	O
assess	O
the	O
suitability	O
for	O
in	B-T058
vivo	I-T058
imaging	I-T058
of	O
exogenous	O
fluorescent	B-T103
contrast	I-T103
agents	I-T103
.	O

Using	O
this	O
fluorescence	B-T058
HSI	I-T058
(	O
fHSI	B-T058
)	O
system	O
,	O
we	O
were	O
able	O
to	O
accurately	O
resolve	O
the	O
presence	O
and	O
concentration	O
of	O
at	O
least	O
7	O
fluorescent	B-T103
dyes	I-T103
in	O
solution	O
.	O

We	O
also	O
demonstrate	O
high	O
spectral	O
unmixing	O
precision	O
,	O
signal	O
linearity	O
with	O
dye	B-T103
concentration	O
and	O
at	O
depth	B-T082
in	O
tissue	B-T017
mimicking	O
phantoms	O
,	O
and	O
delineate	B-T033
4	O
fluorescent	B-T103
dyes	I-T103
in	B-T082
vivo	I-T082
.	O

Our	O
approach	O
,	O
including	O
statistical	O
background	O
removal	O
,	O
could	O
be	O
directly	O
generalised	B-T082
to	O
broader	O
spectral	O
ranges	O
,	O
for	O
example	O
,	O
to	O
resolve	O
tissue	B-T017
reflectance	B-T058
or	O
autofluorescence	B-T058
and	O
in	O
future	O
be	O
tailored	O
to	O
video	O
rate	O
applications	O
requiring	O
snapshot	O
HSI	B-T058
data	O
acquisition	O
.	O

Biochemical	O
studies	B-T062
of	O
amylase	B-T103
,	O
lipase	B-T103
and	O
protease	B-T103
in	O
Callosobruchus	B-T204
maculatus	I-T204
(	O
Coleoptera	B-T204
:	O
Chrysomelidae	B-T204
)	O
populations	B-T098
fed	O
with	O
Vigna	B-T204
unguiculata	I-T204
grain	B-T168
cultivated	B-T062
with	O
diazotrophic	B-T007
bacteria	I-T007
strains	I-T007

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
enzymatic	B-T038
activity	I-T038
of	O
homogenates	O
of	O
insects	B-T204
fed	O
on	O
grain	B-T168
of	O
cowpea	B-T204
,	O
Vigna	B-T204
unguiculata	I-T204
(	I-T204
L	I-T204
.	I-T204
)	I-T204
,	O
cultivars	B-T204
grown	O
with	O
different	O
nitrogen	B-T103
sources	O
.	O

For	O
the	O
experiment	O
we	O
used	O
aliquots	O
of	O
the	O
homogenate	O
of	O
100	O
unsexed	O
adult	O
insects	B-T204
,	O
emerged	O
from	O
10	O
g	O
of	O
grain	B-T168
obtained	O
from	O
four	O
cowpea	B-T204
cultivars	B-T204
:	O
'	O
BRS	B-T204
Acauã	I-T204
'	O
,	O
'	O
BRS	B-T204
Carijó	I-T204
'	O
,	O
'	O
BRS	B-T204
Pujante	I-T204
'	O
,	O
and	O
'	O
BRS	B-T204
Tapaihum	I-T204
'	O
grown	O
under	O
different	O
regimes	O
of	O
nitrogen	B-T103
sources	O
:	O
mineral	B-T103
fertilizer	B-T103
,	O
inoculation	B-T058
with	O
strains	B-T007
of	I-T007
diazotrophs	I-T007
(	O
BR	B-T007
3267	I-T007
,	O
BR	B-T007
3262	I-T007
,	O
BR	B-T007
3299	I-T007
;	O
INPA	B-T007
03	I-T007
-	I-T007
11B	I-T007
,	O
03	B-T007
-	I-T007
84	I-T007
UFLA	I-T007
,	O
as	O
well	O
as	O
the	O
control	O
(	O
with	O
soil	O
nitrogen	B-T103
)	O
.	O

The	O
parameters	O
evaluated	O
were	O
enzymatic	B-T038
activities	I-T038
of	O
insect	B-T204
protease	B-T103
,	O
amylase	B-T103
and	O
lipase	B-T103
and	O
the	O
starch	B-T103
content	O
of	O
the	O
grains	B-T168
.	O

There	O
were	O
differences	O
in	O
the	O
enzymatic	B-T038
activity	I-T038
of	O
amylase	B-T103
,	O
lipase	B-T103
and	O
protease	B-T103
of	O
insect	B-T204
homogenate	O
according	O
to	O
the	O
food	B-T168
source	O
.	O

A	O
lower	O
activity	B-T038
of	I-T038
the	I-T038
enzyme	I-T038
amylase	B-T103
from	O
C	B-T204
.	I-T204

maculatus	I-T204
homogenate	O
was	O
observed	O
when	O
insects	B-T204
were	O
fed	O
grain	B-T168
of	O
the	O
cultivar	B-T204
BRS	I-T204
Carijó	I-T204
.	O

A	O
lower	O
activity	B-T038
of	I-T038
lipase	I-T038
enzyme	I-T038
from	O
C	B-T204
.	I-T204

maculatus	I-T204
homogenate	O
was	O
observed	O
when	O
the	O
insects	B-T204
fed	O
on	O
grain	B-T168
from	O
the	O
interaction	O
of	O
the	O
cultivar	B-T204
Tapaihum	I-T204
inoculated	O
with	O
BR	B-T007
3262	I-T007
diazotrophs	I-T007
.	O

The	O
lowest	O
proteolytic	B-T038
activity	I-T038
was	O
observed	O
in	O
homogenate	O
of	O
insects	B-T204
fed	O
on	O
interaction	O
of	O
'	O
BRS	B-T204
Carijó	I-T204
'	O
inoculated	O
with	O
BR	B-T007
3262	I-T007
diazotroph	I-T007
s	O
.	O

Starch	B-T103
content	O
correlated	O
positively	O
with	O
the	O
amylase	B-T038
activity	I-T038
of	O
C	B-T204
.	I-T204

maculatus	I-T204
homogenate	O
.	O

The	O
cultivar	B-T204
BRS	I-T204
Carijó	I-T204
had	O
a	O
different	O
behavior	O
from	O
the	O
other	O
cultivars	B-T204
,	O
according	O
to	O
the	O
cluster	B-T062
analysis	I-T062
.	O

The	O
correlation	O
of	O
the	O
results	O
of	O
the	O
survey	B-T170
SNOT	I-T170
-	I-T170
20	I-T170
of	O
objective	O
studies	O
of	O
nasal	B-T033
obstruction	I-T033
and	O
the	O
geometry	O
of	O
the	O
nasal	B-T082
cavities	I-T082

In	O
this	O
paper	O
were	O
verified	O
the	O
correlation	O
between	O
the	O
results	O
of	O
the	O
survey	B-T170
SNOT	I-T170
-	I-T170
20	I-T170
and	O
the	O
results	B-T033
of	I-T033
the	I-T033
objective	I-T033
tests	I-T033
of	O
nasal	B-T033
obstruction	I-T033
which	O
are	O
rhinomanometry	B-T058
and	O
acoustic	B-T058
rhinometry	I-T058
before	O
and	O
after	O
surgical	B-T058
treatment	I-T058
,	O
such	O
as	O
septoplasty	B-T058
,	O
septoconchoplasty	B-T058
,	O
ethmoidectomy	B-T058
and	O
septoethmoidectomy	B-T058
.	O

The	O
material	O
used	O
in	O
this	O
study	O
was	O
233	O
patients	O
diagnosed	B-T033
routinely	O
in	O
the	O
Rhinomanometry	B-T058
Laboratory	B-T092
of	O
the	O
Department	B-T092
of	I-T092
Otolaryngology	I-T092
at	O
the	O
Medical	B-T092
University	I-T092
of	O
Warsaw	O
,	O
reporting	O
rhinological	B-T038
problems	I-T038
.	O

Data	O
were	O
obtained	O
from	O
70	O
women	B-T098
(	O
31	O
,	O
4	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
18	O
to	O
81	O
years	O
of	O
age	O
and	O
153	O
men	B-T098
(	O
68	O
,	O
6	O
%	O
)	O
ranging	O
in	O
ages	O
from	O
16	O
to	O
81	O
years	O
of	O
age	O
.	O

The	O
researches	O
presented	O
in	O
the	O
study	O
were	O
made	O
using	O
the	O
device	O
RhinoMetrics	B-T074
SRE	I-T074
2100	I-T074
which	O
combines	O
the	O
Rhinomanometer	O
(	O
RhinoStream	O
)	O
and	O
Acoustic	B-T074
Rhinometer	I-T074
(	O
RhinoScan	B-T074
)	O
Interacoustics	B-T074
AS	I-T074
(	O
Denmark	B-T082
)	O
.	O

Survey	B-T170
SNOT	I-T170
-	I-T170
20	I-T170
(	O
Sino	B-T170
-	I-T170
Nasal	I-T170
Outcome	I-T170
Test	I-T170
-	I-T170
20	I-T170
)	O
in	O
Polish	O
was	O
completed	O
by	O
patients	O
before	O
surgery	O
and	O
during	O
the	O
postoperative	O
control	O
visits	O
.	O

The	O
calculated	O
correlations	O
between	O
the	O
objective	B-T033
parameter	I-T033
,	O
which	O
was	O
the	O
resistance	O
to	O
the	O
flow	B-T033
of	I-T033
air	I-T033
through	I-T033
the	I-T033
nasal	I-T033
cavity	I-T033
,	O
and	O
the	O
subjective	B-T033
feelings	I-T033
of	I-T033
respondents	I-T033
expressed	O
in	O
the	O
survey	B-T170
SNOT	I-T170
-	I-T170
20	I-T170
were	O
generally	O
weak	O
,	O
and	O
statistical	O
significance	O
was	O
achieved	O
with	O
respect	O
to	O
the	O
first	B-T062
question	I-T062
survey	I-T062
(	O
the	O
severity	B-T033
of	I-T033
the	I-T033
nose	I-T033
obstruction	I-T033
)	O
for	O
all	O
components	O
of	O
resistance	O
flow	O
.	O

The	O
feeling	O
of	O
nasal	B-T033
obstruction	I-T033
is	O
the	O
most	O
reproducible	O
and	O
reliable	O
complaint	O
reported	O
by	O
the	O
patient	O
with	O
rhinological	B-T038
problems	I-T038
.	O

Emergency	B-T092
department	I-T092
use	O
and	O
barriers	O
to	O
wellness	O
:	O
a	O
survey	B-T170
of	O
emergency	B-T092
department	I-T092
frequent	O
users	B-T098

There	O
is	O
no	O
common	O
understanding	O
of	O
how	O
needs	O
of	O
emergency	B-T092
department	I-T092
(	O
ED	B-T092
)	O
frequent	O
users	B-T098
differ	O
from	O
other	O
patients	O
.	O

This	O
study	B-T062
sought	O
to	O
examine	O
how	O
to	O
best	O
serve	O
this	O
population	B-T098
.	O

Examinations	B-T058
of	O
why	O
ED	B-T092
frequent	O
users	B-T098
present	B-T033
to	O
the	O
ED	B-T092
,	O
what	O
barriers	O
to	O
care	B-T058
exist	O
,	O
and	O
what	O
service	O
offerings	O
may	O
help	O
these	O
patients	O
achieve	O
an	O
optimal	O
level	O
of	O
health	O
were	O
conducted	O
.	O

We	O
performed	O
a	O
prospective	B-T062
study	I-T062
of	O
frequent	O
ED	B-T092
users	B-T098
in	O
an	O
adult	O
only	O
,	O
level	B-T092
1	I-T092
trauma	I-T092
center	I-T092
with	O
approximately	O
90	O
,	O
000	O
visits	B-T058
per	O
year	O
.	O

Frequent	O
ED	B-T092
users	B-T098
were	O
defined	O
as	O
those	O
who	O
make	O
four	O
or	O
more	O
ED	B-T058
visits	I-T058
in	O
a	O
12	O
month	O
period	O
.	O

Participants	B-T098
were	O
administered	O
a	O
piloted	O
structured	O
interview	O
by	O
a	O
trained	B-T097
researcher	I-T097
querying	B-T170
demographics	O
,	O
ED	B-T092
usage	O
,	O
perceived	O
barriers	O
to	O
care	B-T058
,	O
and	O
potential	O
aids	O
to	O
maintaining	O
health	O
.	O

Of	O
1	O
,	O
523	O
screened	B-T058
patients	O
,	O
297	O
were	O
identified	O
as	O
frequent	O
ED	B-T092
users	B-T098
.	O

One	O
hundred	O
frequent	O
ED	B-T092
users	B-T098
were	O
enrolled	O
.	O

The	O
mean	O
age	O
was	O
48	O
years	O
(	O
95	O
%	O
CI	O
45	O
-	O
51	O
)	O
.	O

The	O
majority	O
of	O
subjects	B-T098
were	O
female	B-T098
(	O
64	O
%	O
,	O
64	O
/	O
100	O
,	O
95	O
%	O
CI	O
55	O
-	O
73	O
%	O
)	O
,	O
white	B-T098
(	O
61	O
%	O
,	O
60	O
/	O
98	O
,	O
95	O
%	O
CI	O
52	O
-	O
71	O
%	O
)	O
and	O
insured	O
by	O
Medicaid	O
(	O
55	O
%	O
,	O
47	O
/	O
86	O
,	O
95	O
%	O
CI	O
44	O
-	O
65	O
%	O
)	O
or	O
Medicare	O
(	O
23	O
%	O
,	O
20	O
/	O
86	O
,	O
95	O
%	O
CI	O
14	O
-	O
32	O
%	O
)	O
.	O

Subjects	B-T098
had	O
a	O
median	O
of	O
6	O
ED	B-T058
visits	I-T058
,	O
and	O
2	O
inpatient	O
admissions	O
in	O
the	O
past	O
12	O
months	O
at	O
this	O
hospital	B-T092
.	O

Most	O
frequent	O
ED	B-T092
users	B-T098
(	O
61	O
%	O
,	O
59	O
/	O
96	O
,	O
95	O
%	O
CI	O
52	O
-	O
71	O
%	O
)	O
stated	O
the	O
primary	O
reason	O
for	O
their	O
visit	B-T058
was	O
that	O
they	O
felt	O
that	O
their	O
health	O
problem	O
could	O
only	O
be	O
treated	O
in	O
an	O
ED	B-T092
.	O

Transportation	O
presented	O
as	O
a	O
major	O
barrier	O
to	O
few	O
patients	O
(	O
7	O
%	O
,	O
7	O
/	O
95	O
,	O
95	O
%	O
CI	O
3	O
-	O
14	O
%	O
)	O
.	O

Subjects	B-T098
stated	O
that	O
"	O
after	B-T058
-	I-T058
hours	I-T058
options	I-T058
,	O
besides	O
the	O
ED	B-T092
for	O
minor	O
health	O
issues	O
"	O
(	O
63	O
%	O
,	O
60	O
/	O
95	O
,	O
95	O
%	O
CI	O
53	O
-	O
73	O
%	O
)	O
and	O
having	O
"	O
a	O
nurse	B-T097
to	O
work	O
with	O
you	O
one	B-T058
-	I-T058
on	I-T058
-	I-T058
one	I-T058
to	O
help	O
manage	O
health	B-T058
care	I-T058
needs	O
"	O
(	O
53	O
%	O
,	O
50	O
/	O
95	O
,	O
95	O
%	O
CI	O
43	O
-	O
63	O
%	O
)	O
would	O
be	O
most	O
helpful	O
in	O
achieving	O
optimal	O
health	O
.	O

This	O
study	B-T062
characterized	O
ED	B-T092
frequent	O
users	B-T098
and	O
identified	O
several	O
opportunities	O
to	O
better	O
serve	O
this	O
population	B-T098
.	O

By	O
understanding	O
barriers	O
to	O
care	B-T058
from	O
the	O
patient	O
perspective	O
,	O
health	O
systems	O
can	O
potentially	O
address	O
unmet	O
needs	O
that	O
prevent	O
wellness	O
in	O
this	O
population	B-T098
.	O

Contralateral	B-T082
Superior	B-T038
Cerebellar	I-T038
Artery	I-T038
Syndrome	I-T038
:	O
A	O
Consequence	O
of	O
Brain	B-T017
Herniation	I-T017

Vascular	B-T017
compromise	O
is	O
a	O
well	O
-	O
known	O
consequence	O
of	O
brain	B-T017
herniation	I-T017
syndromes	B-T038
.	O

Transtentorial	B-T082
brain	B-T017
herniation	I-T017
most	O
often	O
involves	O
posterior	B-T017
cerebral	I-T017
arteries	I-T017
.	O

However	O
,	O
isolated	O
involvement	O
of	O
contralateral	B-T082
superior	B-T017
cerebellar	I-T017
artery	I-T017
(	O
SCA	B-T017
)	O
during	O
unilateral	B-T082
impending	O
brain	B-T017
herniation	I-T017
is	O
reported	B-T058
only	O
once	O
and	O
we	O
present	O
another	O
case	O
of	O
this	O
exceedingly	O
rare	O
entity	O
.	O

A	O
24	O
-	O
year	O
-	O
old	O
man	B-T098
was	O
referred	O
to	O
us	O
with	O
impending	O
herniation	B-T017
due	O
to	O
a	O
multiloculated	B-T082
hydrocephalus	B-T038
,	O
and	O
during	O
the	O
course	B-T038
of	I-T038
illness	I-T038
,	O
he	O
developed	O
an	O
isolated	O
SCA	B-T017
ischemia	B-T038
in	O
the	O
opposite	O
side	O
of	O
the	O
most	O
dilated	B-T033
entrapped	O
horn	B-T017
.	O

In	O
the	O
current	O
article	B-T170
we	O
discuss	O
the	O
probable	O
pathophysiologic	O
mechanisms	O
of	O
this	O
phenomenon	O
,	O
as	O
well	O
as	O
recommending	O
more	O
inclusive	O
brain	B-T017
studies	O
in	O
cases	O
suspected	O
of	O
Kernohan	B-T038
-	I-T038
Woltman	I-T038
notch	I-T038
phenomenon	I-T038
in	O
unilateral	B-T082
brain	B-T017
herniation	I-T017
.	O

The	O
rationale	O
for	O
this	O
commentary	B-T170
is	O
that	O
contralateral	B-T082
SCA	B-T017
transient	B-T038
ischemia	I-T038
or	O
infarct	B-T038
might	O
be	O
the	O
underdiagnosed	B-T033
underlying	O
pathomechanism	B-T038
of	O
ipsilateral	B-T082
hemiparesis	B-T033
occurring	O
in	O
many	O
cases	O
of	O
this	O
somehow	O
vague	O
phenomenon	O
.	O

The	O
effects	O
of	O
clinical	O
supervision	O
on	O
supervisees	B-T098
and	O
patients	O
in	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
therapy	I-T058
:	O
a	O
study	B-T170
protocol	I-T170
for	O
a	O
systematic	B-T170
review	I-T170

Clinical	O
supervision	O
by	O
a	O
senior	O
therapist	O
is	O
a	O
very	O
common	O
practice	B-T038
in	O
psychotherapist	B-T097
training	O
and	O
psychiatric	O
care	O
settings	O
.	O

Though	O
clinical	O
supervision	O
is	O
advocated	O
by	O
most	O
educational	O
and	O
governing	O
institutions	O
,	O
the	O
effects	O
of	O
clinical	O
supervision	O
on	O
the	O
supervisees	B-T098
'	O
competence	O
,	O
e	O
.	O
g	O
.	O
,	O
attitudes	B-T038
,	O
behaviors	O
,	O
and	O
skills	O
,	O
as	O
well	O
as	O
on	O
treatment	O
outcomes	O
and	O
other	O
patient	O
variables	O
are	O
debated	O
and	O
largely	O
unknown	O
.	O

Evidence	O
-	O
based	O
practice	O
is	O
advocated	O
in	O
clinical	O
settings	O
but	O
has	O
not	O
yet	O
been	O
fully	O
implemented	O
in	O
educational	O
or	O
clinical	O
training	O
settings	O
.	O

The	O
aim	O
of	O
this	O
systematic	B-T170
review	I-T170
is	O
to	O
synthesize	O
and	O
present	O
the	O
empirical	B-T170
literature	I-T170
regarding	O
effects	O
of	O
clinical	O
supervision	O
in	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
therapy	I-T058
.	O

This	O
study	O
will	O
include	O
a	O
systematic	B-T170
review	I-T170
of	O
the	O
literature	B-T170
to	O
identify	O
studies	O
that	O
have	O
empirically	O
investigated	O
the	O
effects	O
of	O
supervision	O
on	O
supervised	B-T097
psychotherapists	I-T097
and	O
/	O
or	O
the	O
supervisees	O
'	O
patients	O
.	O

A	O
comprehensive	O
search	O
strategy	O
will	O
be	O
conducted	O
to	O
identify	O
published	O
controlled	O
studies	O
indexed	B-T170
in	O
the	O
MEDLINE	B-T170
,	O
EMBASE	B-T170
,	O
PsycINFO	O
,	O
and	O
Cochrane	B-T170
Library	I-T170
databases	I-T170
.	O

Data	O
on	O
supervision	O
outcomes	O
in	O
both	O
psychotherapists	B-T097
and	O
their	O
patients	O
will	O
be	O
extracted	O
,	O
synthesized	O
,	O
and	O
reported	B-T170
.	O

Risk	O
of	O
bias	O
and	O
quality	O
of	O
the	O
included	O
studies	O
will	O
be	O
assessed	O
systematically	O
.	O

This	O
systematic	B-T170
review	I-T170
will	O
rigorously	O
follow	O
established	O
guidelines	B-T170
for	O
systematic	B-T170
reviews	I-T170
in	O
order	O
to	O
summarize	O
and	O
present	O
the	O
evidence	O
base	O
for	O
clinical	O
supervision	O
in	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
therapy	I-T058
and	O
may	O
aid	O
further	O
research	B-T062
and	O
discussion	O
in	O
this	O
area	O
.	O

PROSPERO	O
CRD42016046834	O
.	O

Higher	B-T033
risk	I-T033
of	I-T033
revision	O
for	O
infection	B-T038
using	O
systemic	O
clindamycin	B-T103
prophylaxis	B-T058
than	O
with	O
cloxacillin	B-T103

Background	O
and	O
purpose	O
-	O
Clindamycin	B-T103
has	O
not	O
been	O
compared	O
with	O
other	O
antibiotics	B-T103
for	O
prophylaxis	B-T058
in	O
arthroplasty	B-T058
.	O

Since	O
2009	O
,	O
the	O
Swedish	B-T170
Knee	B-T058
Arthroplasty	I-T058
Register	I-T170
(	O
SKAR	B-T170
)	O
has	O
been	O
collecting	O
information	O
on	O
the	O
prophylactic	B-T058
antibiotic	I-T058
regime	I-T058
used	O
at	O
every	O
individual	B-T098
operation	O
.	O

In	O
Sweden	B-T082
,	O
when	O
there	O
is	O
allergy	B-T038
to	O
penicillin	B-T103
,	O
clindamycin	B-T103
has	O
been	O
the	O
recommended	O
alternative	O
.	O

We	O
examined	O
whether	O
there	O
were	O
differences	O
in	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	B-T038
depending	O
on	O
which	O
antibiotic	B-T103
was	O
used	O
as	O
systemic	O
prophylaxis	B-T058
.	O

Patients	O
and	O
methods	O
-	O
Patients	O
who	O
had	O
a	O
total	B-T058
knee	I-T058
arthroplasty	I-T058
(	O
TKA	B-T058
)	O
performed	O
due	O
to	O
osteoarthritis	B-T038
(	O
OA	B-T038
)	O
during	O
the	O
years	O
2009	O
-	O
2015	O
were	O
included	O
in	O
the	O
study	O
.	O

Information	O
on	O
which	O
antibiotic	B-T103
was	O
used	O
was	O
available	O
for	O
80	O
,	O
018	O
operations	O
(	O
55	O
,	O
530	O
patients	O
)	O
.	O

Survival	B-T170
statistics	I-T170
were	O
used	O
to	O
calculate	O
the	O
rate	O
of	O
revision	O
due	O
to	O
infection	B-T038
until	O
the	O
end	O
of	O
2015	O
,	O
comparing	O
the	O
group	O
of	O
patients	O
who	O
received	O
cloxacillin	B-T103
with	O
those	O
who	O
received	O
clindamycin	B-T103
as	O
systemic	O
prophylaxis	B-T058
.	O

Results	O
-	O
Cloxacillin	B-T103
was	O
used	O
in	O
90	O
%	O
of	O
the	O
cases	O
,	O
clindamycin	B-T103
in	O
7	O
%	O
,	O
and	O
cephalosporins	B-T103
in	O
2	O
%	O
.	O

The	O
risk	O
of	O
being	O
revised	O
due	O
to	O
infection	B-T038
was	O
higher	O
when	O
clindamycin	B-T103
was	O
used	O
than	O
when	O
cloxacillin	B-T103
was	O
used	O
(	O
RR	O
=	O
1	O
.	O
5	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
2	O
-	O
2	O
.	O
0	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
revision	O
rate	O
for	O
other	O
causes	O
(	O
p	O
=	O
0	O
.	O
2	O
)	O
.	O

Interpretation	B-T170
-	O
We	O
advise	O
that	O
patients	O
reporting	O
allergic	B-T038
reaction	I-T038
to	O
penicillin	B-T103
should	O
have	O
their	O
allergic	O
history	O
explored	O
.	O

In	O
the	O
absence	O
of	O
a	O
clear	O
history	O
of	O
type	B-T038
-	I-T038
I	I-T038
allergic	I-T038
reaction	I-T038
(	O
e	O
.	O
g	O
.	O

urticaria	B-T038
,	O
anaphylaxis	B-T038
,	O
or	O
bronchospasm	B-T038
)	O
,	O
we	O
suggest	O
the	O
use	O
of	O
a	O
third	B-T103
-	I-T103
generation	I-T103
cephalosporin	I-T103
instead	O
of	O
clindamycin	B-T103
as	O
perioperative	O
prophylaxis	B-T058
when	O
undergoing	O
a	O
TKR	B-T058
.	O

No	O
recommendation	O
can	O
be	O
given	O
regarding	O
patients	O
with	O
type	B-T038
-	I-T038
1	I-T038
allergy	I-T038
.	O

PCVMZM	B-T062
:	O
Using	O
the	O
Probabilistic	B-T062
Classification	I-T062
Vector	I-T062
Machines	I-T062
Model	I-T062
Combined	I-T062
with	I-T062
a	I-T062
Zernike	I-T062
Moments	I-T062
Descriptor	O
to	O
Predict	O
Protein	B-T038
-	I-T038
Protein	I-T038
Interactions	I-T038
from	O
Protein	B-T082
Sequences	I-T082

Protein	B-T038
-	I-T038
protein	I-T038
interactions	I-T038
(	O
PPIs	B-T038
)	O
are	O
essential	O
for	O
most	O
living	O
organisms	O
'	O
process	O
.	O

Thus	O
,	O
detecting	O
PPIs	B-T038
is	O
extremely	O
important	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
biological	O
systems	O
.	O

Although	O
many	O
PPIs	B-T038
data	O
have	O
been	O
generated	O
by	O
high	O
-	O
throughput	O
technologies	O
for	O
a	O
variety	O
of	O
organisms	O
,	O
the	O
whole	O
interatom	O
is	O
still	O
far	O
from	O
complete	O
.	O

In	O
addition	O
,	O
the	O
high	O
-	O
throughput	O
technologies	O
for	O
detecting	O
PPIs	B-T038
has	O
some	O
unavoidable	O
defects	O
,	O
including	O
time	O
consumption	O
,	O
high	O
cost	O
,	O
and	O
high	O
error	O
rate	O
.	O

In	O
recent	O
years	O
,	O
with	O
the	O
development	O
of	O
machine	O
learning	O
,	O
computational	B-T062
methods	I-T062
have	O
been	O
broadly	O
used	O
to	O
predict	O
PPIs	B-T038
,	O
and	O
can	O
achieve	O
good	O
prediction	O
rate	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
here	O
PCVMZM	B-T062
,	O
a	O
computational	B-T062
method	I-T062
based	O
on	O
a	O
Probabilistic	O
Classification	O
Vector	O
Machines	O
(	O
PCVM	O
)	O
model	O
and	O
Zernike	B-T170
moments	I-T170
(	I-T170
ZM	I-T170
)	I-T170
descriptor	I-T170
for	O
predicting	O
the	O
PPIs	B-T038
from	O
protein	B-T103
amino	B-T082
acids	I-T082
sequences	I-T082
.	O

Specifically	O
,	O
a	O
Zernike	B-T170
moments	I-T170
(	I-T170
ZM	I-T170
)	I-T170
descriptor	I-T170
is	O
used	O
to	O
extract	O
protein	B-T103
evolutionary	O
information	O
from	O
Position	O
-	O
Specific	O
Scoring	O
Matrix	O
(	O
PSSM	O
)	O
generated	O
by	O
Position	B-T170
-	I-T170
Specific	I-T170
Iterated	I-T170
Basic	I-T170
Local	I-T170
Alignment	I-T170
Search	I-T170
Tool	I-T170
(	I-T170
PSI	I-T170
-	I-T170
BLAST	I-T170
)	I-T170
.	O

Then	O
,	O
PCVM	O
classifier	O
is	O
used	O
to	O
infer	O
the	O
interactions	B-T038
among	O
protein	B-T103
.	O

When	O
performed	O
on	O
PPIs	B-T038
datasets	O
of	O
Yeast	B-T204
and	O
H	B-T007
.	I-T007

Pylori	I-T007
,	O
the	O
proposed	O
method	O
can	O
achieve	O
the	O
average	O
prediction	O
accuracy	O
of	O
94	O
.	O
48	O
%	O
and	O
91	O
.	O
25	O
%	O
,	O
respectively	O
.	O

In	O
order	O
to	O
further	O
evaluate	O
the	O
performance	O
of	O
the	O
proposed	O
method	O
,	O
the	O
state	B-T170
-	I-T170
of	I-T170
-	I-T170
the	I-T170
-	I-T170
art	I-T170
support	O
vector	O
machines	O
(	O
SVM	O
)	O
classifier	O
is	O
used	O
and	O
compares	O
with	O
the	O
PCVM	O
model	O
.	O

Experimental	B-T033
results	I-T033
on	O
the	O
Yeast	B-T204
dataset	O
show	O
that	O
the	O
performance	O
of	O
PCVM	O
classifier	O
is	O
better	O
than	O
that	O
of	O
SVM	O
classifier	O
.	O

The	O
experimental	B-T033
results	I-T033
indicate	O
that	O
our	O
proposed	O
method	O
is	O
robust	O
,	O
powerful	O
and	O
feasible	O
,	O
which	O
can	O
be	O
used	O
as	O
a	O
helpful	O
tool	O
for	O
proteomics	B-T062
research	I-T062
.	O

Conditional	O
Knockdown	B-T062
of	O
Endogenous	O
MicroRNAs	B-T103
in	O
CHO	B-T017
Cells	I-T017
Using	O
TET	B-T103
-	I-T103
ON	I-T103
-	I-T103
SanDI	I-T103
Sponge	I-T103
Vectors	I-T103

MicroRNAs	B-T103
(	O
miRNAs	B-T103
)	O
are	O
small	O
,	O
noncoding	B-T103
RNAs	I-T103
of	O
about	O
22	O
nucleotides	B-T103
in	O
length	O
and	O
have	O
proven	O
to	O
be	O
useful	O
targets	O
for	O
genetic	B-T062
modifications	I-T062
for	O
desirable	O
phenotype	O
in	O
the	O
biotech	B-T091
industry	O
.	O

The	O
use	O
of	O
constitutively	O
expressed	O
"	O
miRNA	B-T103
sponge	I-T103
"	I-T103
vectors	I-T103
in	O
which	O
multiple	O
,	O
tandem	B-T103
miRNA	I-T103
binding	B-T103
sites	I-T103
containing	O
transcripts	B-T103
are	O
transcriptionally	B-T038
regulated	I-T038
by	O
a	O
constitutive	O
promoter	B-T103
for	O
down	B-T038
regulating	I-T038
the	O
levels	O
of	O
endogenous	O
microRNAs	B-T103
in	O
Chinese	B-T017
hamster	I-T017
ovary	I-T017
(	I-T017
CHO	I-T017
)	I-T017
cells	I-T017
has	O
shown	O
to	O
be	O
more	O
advantageous	O
than	O
using	O
synthetic	O
antisense	B-T103
oligonucleotides	I-T103
.	O

The	O
application	O
of	O
miRNA	O
sponges	O
in	O
biotechnological	B-T091
processes	O
,	O
however	O
,	O
could	O
be	O
more	O
effective	O
,	O
if	O
expression	B-T038
of	O
miRNA	O
sponges	O
could	O
be	O
tuned	O
.	O

In	O
this	O
chapter	O
,	O
we	O
present	O
a	O
method	O
for	O
the	O
generation	O
of	O
stable	O
CHO	B-T017
cell	I-T017
lines	I-T017
expressing	B-T038
a	O
TET	O
-	O
ON	O
-	O
SanDI	O
-	O
miRNA	O
-	O
sponge	O
that	O
is	O
in	O
theory	O
expressed	O
only	O
in	O
the	O
presence	O
of	O
an	O
inducer	O
.	O

Forest	O
protected	B-T082
areas	I-T082
governance	O
in	O
Zimbabwe	B-T082
:	O
Shift	O
needed	O
away	O
from	O
a	O
long	B-T033
history	I-T033
of	O
local	B-T082
community	O
exclusion	O

In	O
this	O
literature	O
review	O
based	O
paper	O
we	O
explored	O
the	O
concept	O
of	O
exclusion	O
of	O
local	B-T082
communities	O
from	O
accessing	O
resources	O
in	O
forest	O
protected	B-T082
areas	I-T082
(	O
FPAs	B-T082
)	O
in	O
Zimbabwe	B-T082
.	O

We	O
discussed	O
the	O
colonial	B-T170
and	O
post	O
-	O
colonial	B-T170
forms	I-T170
,	O
causes	O
and	O
mechanisms	O
of	O
exclusion	O
and	O
their	O
social	O
,	O
economic	O
and	O
ecological	O
outcomes	O
.	O

We	O
examined	B-T033
the	O
range	O
of	O
powers	O
embodied	O
in	O
and	O
exercised	O
through	O
various	O
mechanisms	O
,	O
processes	O
and	O
social	O
relations	O
and	O
their	O
impact	O
on	O
local	B-T082
communities	O
'	O
access	O
to	O
FPA	B-T082
resources	O
and	O
associated	O
benefits	O
along	O
the	O
historical	O
trajectory	O
of	O
forest	O
governance	O
in	O
Zimbabwe	B-T082
.	O

Results	O
showed	O
that	O
the	O
forms	O
and	O
extent	B-T082
of	O
exclusion	O
changed	O
over	O
time	O
in	O
tandem	O
with	O
the	O
shifting	O
political	O
and	O
economic	O
landscape	O
.	O

During	O
the	O
colonial	O
period	O
,	O
it	O
was	O
total	O
exclusion	O
whereby	O
people	B-T098
were	O
evicted	O
from	O
forest	O
land	O
as	O
well	O
as	O
being	O
denied	O
access	O
to	O
basic	O
resources	O
for	O
their	O
livelihoods	O
.	O

Local	B-T082
communities	O
'	O
access	O
to	O
low	O
value	O
FPA	B-T082
resources	O
improved	B-T033
during	O
the	O
post	O
-	O
colonial	O
period	O
but	O
access	O
to	O
high	O
value	O
resources	O
like	O
commercial	O
timber	O
as	O
well	O
as	O
sharing	O
income	O
benefits	O
derived	O
from	O
FPA	B-T082
commercial	O
activities	O
remained	O
a	O
pipe	O
dream	O
.	O

Regulation	O
,	O
legitimation	O
,	O
force	O
and	O
markets	O
constituted	O
the	O
mixture	O
of	O
the	O
power	O
elements	O
that	O
FPA	B-T082
governing	O
authorities	O
used	O
to	O
exclude	O
local	B-T082
communities	O
.	O

These	O
powers	O
remained	O
intact	O
despite	O
attempts	O
at	O
collaborative	O
governance	O
in	O
the	O
1990s	O
.	O

However	O
,	O
from	O
the	O
year	O
2000	O
,	O
local	B-T082
communities	O
expressed	O
their	O
dissatisfaction	B-T038
with	O
the	O
centralised	O
exclusionary	O
governance	O
system	O
by	O
invading	O
the	O
FPAs	B-T082
rendering	O
them	O
ungovernable	B-T033
.	O

There	O
is	O
therefore	O
a	O
need	O
for	O
policy	B-T170
reform	O
within	O
the	O
FPA	B-T082
sector	B-T082
to	O
improve	B-T033
the	O
current	O
dire	O
situation	O
.	O

Renal	B-T038
arterial	I-T038
mycotic	I-T038
aneurysm	I-T038
after	O
kidney	B-T058
transplantation	I-T058

Mycotic	B-T038
aneurysm	I-T038
is	O
a	O
rare	O
condition	O
mostly	O
attributable	O
to	O
Candida	B-T204
or	O
Aspergillus	B-T204
species	I-T204
.	O

About	O
20	O
cases	O
of	O
Candida	B-T204
-	O
related	O
arteritis	B-T038
have	O
been	O
reported	O
in	O
kidney	B-T058
transplant	I-T058
patients	O
.	O

Herein	O
,	O
we	O
report	B-T170
the	O
case	O
of	O
a	O
40	O
-	O
year	O
-	O
old	O
man	O
who	O
received	O
a	O
kidney	B-T017
from	O
a	O
deceased	O
donor	B-T098
in	O
whom	O
an	O
accidental	O
digestive	O
wound	O
was	O
made	O
during	O
organ	B-T058
retrieval	I-T058
.	O

He	O
presented	O
with	O
sudden	O
anuria	B-T038
47	O
days	O
after	O
renal	B-T058
transplantation	I-T058
revealing	O
a	O
large	O
mycotic	B-T038
aneurysm	I-T038
of	O
the	O
kidney	B-T017
graft	I-T017
renal	B-T017
artery	I-T017
.	O

Organs	B-T017
derived	O
from	O
donors	B-T098
in	O
whom	O
a	O
digestive	O
breach	O
is	O
noticed	O
should	O
be	O
used	O
with	O
caution	O
.	O

Risk	O
of	O
cancer	O
in	O
patients	O
with	O
heart	B-T038
failure	I-T038
who	O
use	O
digoxin	B-T103
:	O
a	O
10	O
-	O
year	O
follow	B-T062
-	I-T062
up	I-T062
study	I-T062
and	O
cell	B-T017
-	O
based	O
verification	O

Heart	B-T038
failure	I-T038
(	O
HF	B-T038
)	O
is	O
the	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
in	O
the	O
world	B-T098
and	O
digoxin	B-T103
remains	O
one	O
of	O
the	O
oldest	O
therapies	B-T058
for	O
HF	B-T038
.	O

However	O
,	O
its	O
safety	O
and	O
efficacy	O
have	O
been	O
controversial	O
since	O
its	O
initial	O
use	O
and	O
there	O
is	O
uncertainty	B-T033
about	O
its	O
long	O
-	O
term	O
efficacy	O
and	O
safety	O
.	O

Recently	O
,	O
the	O
repositioning	B-T058
of	O
cardiac	B-T103
glycosides	I-T103
is	O
to	O
function	O
in	O
anti	B-T058
-	I-T058
tumor	I-T058
activity	I-T058
via	O
multiple	O
working	O
pathways	O
.	O

It	O
is	O
interesting	O
to	O
compare	O
the	O
potential	O
effects	O
of	O
digoxin	B-T103
in	O
clinical	O
patients	O
and	O
cell	B-T017
lines	I-T017
.	O

First	O
,	O
we	O
analyze	O
patient	B-T170
information	I-T170
retrieved	O
from	O
the	O
National	B-T170
Health	I-T170
Insurance	I-T170
Research	I-T170
database	I-T170
of	O
Taiwan	B-T082
between	O
January	O
1	O
,	O
2000	O
and	O
December	O
31	O
,	O
2000	O
.	O

This	O
retrospective	B-T062
study	I-T062
included	O
a	O
study	O
cohort	B-T098
(	O
1	O
,	O
219	O
patients	O
)	O
and	O
a	O
comparison	O
cohort	B-T098
.	O

Our	O
analytical	O
data	O
suggested	O
that	O
patients	O
taking	O
digoxin	B-T103
are	O
at	O
an	O
increased	O
risk	O
of	O
cancers	O
,	O
including	O
breast	B-T038
,	O
liver	B-T038
,	O
and	O
lung	B-T038
cancers	I-T038
,	O
during	O
the	O
10	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
period	I-T058
.	O

In	O
contrast	O
to	O
the	O
anti	B-T058
-	I-T058
tumor	I-T058
function	I-T058
of	O
digoxin	B-T103
,	O
we	O
further	O
examined	O
the	O
potential	O
pathway	O
of	O
digoxin	B-T103
via	O
the	O
cell	B-T017
-	O
based	O
strategy	O
using	O
several	O
breast	B-T038
cancer	I-T038
cell	B-T017
lines	I-T017
,	O
including	O
MCF	B-T017
-	I-T017
7	I-T017
,	O
BT	B-T017
-	I-T017
474	I-T017
,	O
MAD	B-T017
-	I-T017
MB	I-T017
-	I-T017
231	I-T017
,	O
and	O
ZR	B-T017
-	I-T017
75	I-T017
-	I-T017
1	I-T017
.	O

Digoxin	B-T103
consistently	O
exerted	O
its	O
cytotoxicity	B-T038
to	O
these	O
four	O
cell	B-T017
lines	I-T017
with	O
various	O
range	O
of	O
concentration	O
.	O

However	O
,	O
the	O
proliferation	O
of	O
ZR	B-T017
-	I-T017
75	I-T017
-	I-T017
1	I-T017
cells	I-T017
was	O
the	O
only	O
cell	B-T017
lines	I-T017
induced	O
by	O
digoxin	B-T103
and	O
the	O
others	O
were	O
dramatically	O
suppressed	O
by	O
digoxin	B-T103
.	O

The	O
responsiveness	O
of	O
SRSF3	B-T017
to	O
digoxin	B-T103
might	O
be	O
involved	O
with	O
cell	B-T170
-	I-T170
type	I-T170
differences	O
.	O

In	O
summary	O
,	O
we	O
combined	O
a	O
cohort	O
study	O
for	O
digoxin	B-T103
treatment	B-T058
for	O
HF	B-T038
patients	O
with	O
a	O
cell	B-T017
-	O
based	O
strategy	O
that	O
addresses	O
the	O
translation	O
issue	O
,	O
which	O
revealed	O
the	O
complexity	O
of	O
personalized	B-T058
medicine	I-T058
.	O

Comparison	O
and	O
Outcome	O
Analysis	O
of	O
Patients	O
with	O
Takotsubo	B-T038
Cardiomyopathy	I-T038
Triggered	O
by	O
Emotional	B-T038
Stress	I-T038
or	O
Physical	B-T038
Stress	I-T038

Background	O
:	O
Previous	O
studies	O
revealed	O
that	O
takotsubo	B-T038
cardiomyopathy	I-T038
(	O
TTC	B-T038
)	O
is	O
triggered	O
by	O
physical	B-T038
and	O
emotional	B-T038
stresses	I-T038
.	O

This	O
study	O
was	O
performed	O
to	O
determine	O
the	O
short	O
-	O
and	O
long	O
-	O
term	O
prognostic	O
impact	O
of	O
emotional	B-T038
-	I-T038
and	O
physical	B-T038
stress	I-T038
associated	O
with	O
TTC	B-T038
.	O

Methods	O
and	O
results	O
:	O
Our	O
institutional	B-T170
database	I-T170
constituted	O
a	O
collective	O
of	O
84	O
patients	O
diagnosed	B-T033
with	O
TTC	B-T038
between	O
2003	O
and	O
2015	O
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
as	O
per	O
the	O
presence	O
of	O
emotional	B-T038
stress	I-T038
(	O
n	O
=	O
24	O
,	O
21	O
%	O
)	O
or	O
physical	B-T038
stress	I-T038
(	O
n	O
=	O
60	O
,	O
52	O
.	O
6	O
%	O
)	O
.	O

The	O
endpoint	O
was	O
a	O
composite	O
of	O
in	B-T033
-	I-T033
hospital	I-T033
events	I-T033
(	O
thromboembolic	B-T038
events	I-T038
and	O
life	B-T033
-	I-T033
threatening	I-T033
arrhythmias	B-T033
)	O
,	O
myocardial	B-T038
infarction	I-T038
,	O
all	O
-	O
cause	O
of	O
mortality	O
,	O
re	O
-	O
hospitalization	O
due	O
to	O
heart	B-T038
failure	I-T038
,	O
stroke	B-T038
,	O
and	O
recurrence	O
of	O
TTC	B-T038
.	O

A	O
Kaplan	O
-	O
Meier	O
analysis	O
indicated	O
a	O
significantly	O
lower	O
event	O
-	O
free	O
survival	O
rate	O
over	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
5	O
years	O
in	O
the	O
emotional	B-T038
group	O
than	O
the	O
physical	B-T038
stress	I-T038
group	O
(	O
log	O
-	O
rank	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Multivariate	B-T170
Cox	I-T170
regression	I-T170
analysis	I-T170
revealed	O
only	O
emotional	B-T038
stress	I-T038
(	O
HR	O
0	O
.	O
4	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
2	O
-	O
0	O
.	O
9	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
as	O
a	O
negative	B-T033
independent	I-T033
predictor	I-T033
of	O
the	O
primary	O
endpoint	O
.	O

Conclusion	O
:	O
Rates	O
of	O
in	B-T033
-	I-T033
hospital	I-T033
events	I-T033
and	O
short	O
-	O
as	O
well	O
as	O
long	O
-	O
term	O
events	O
were	O
significantly	O
lower	O
in	O
TTC	B-T038
patients	O
suffering	B-T038
from	O
emotional	B-T038
stress	I-T038
as	O
compared	O
to	O
patients	O
with	O
physical	B-T038
stress	I-T038
.	O

Surviving	O
moment	O
to	O
moment	O
:	O
The	O
experience	B-T038
of	O
living	O
in	O
a	O
state	B-T033
of	O
ambivalence	B-T038
for	O
those	O
with	O
recurrent	O
suicide	B-T033
attempts	I-T033

This	O
qualitative	B-T062
study	I-T062
aimed	O
to	O
capture	O
the	O
experience	B-T038
of	O
living	O
in	O
the	O
ambivalent	B-T038
space	I-T038
between	O
life	O
and	O
death	O
for	O
adults	O
with	O
recurrent	O
suicide	B-T033
attempts	I-T033
(	O
RSA	B-T033
)	O
.	O

It	O
sought	O
to	O
expand	B-T082
upon	O
an	O
earlier	O
study	B-T062
that	O
explored	O
the	O
processes	B-T038
involved	O
in	O
transitioning	O
away	O
from	O
RSA	B-T033
among	O
adults	O
,	O
which	O
revealed	O
that	O
occupying	O
this	O
ambivalent	B-T038
space	I-T038
is	O
a	O
crucial	O
part	O
of	O
this	O
process	O
.	O

Interpretive	B-T062
phenomenological	I-T062
analysis	I-T062
(	O
IPA	B-T062
)	O
was	O
used	O
.	O

This	O
methodology	O
was	O
designed	O
to	O
explore	O
the	O
lived	B-T038
experiences	I-T038
and	O
meaning	B-T038
making	I-T038
and	O
enabled	O
interpretation	O
of	O
the	O
multidimensional	B-T082
subjective	O
experiences	B-T038
of	O
RSA	B-T033
participants	B-T098
.	O

In	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
were	O
conducted	O
with	O
eight	O
adult	B-T098
women	I-T098
with	O
a	O
history	O
of	O
RSA	B-T033
who	O
had	O
participated	O
in	O
a	O
therapeutic	B-T058
intervention	I-T058
at	O
the	O
research	B-T062
site	B-T082
(	O
Skills	O
for	O
Safer	O
Living	O
:	O
A	O
Psychosocial	O
/	O
Psychoeducational	O
Intervention	O
for	O
People	B-T098
with	O
Recurrent	O
Suicide	B-T033
Attempts	I-T033
[	O
SfSL	O
/	O
PISA	B-T033
]	O
)	O
.	O

The	O
six	O
stages	O
of	O
IPA	B-T062
were	O
followed	O
to	O
analyse	B-T062
the	O
interview	O
data	O
.	O

Analysis	B-T062
revealed	O
the	O
superordinate	O
theme	O
,	O
'	O
surviving	O
moment	O
to	O
moment	O
'	O
,	O
which	O
refers	O
to	O
a	O
precarious	B-T033
state	I-T033
of	O
making	B-T038
decisions	I-T038
about	O
one	O
'	O
s	O
life	O
and	O
destiny	O
on	O
a	O
moment	O
-	O
to	O
-	O
moment	O
basis	O
without	O
clear	O
commitment	O
to	O
either	O
life	O
or	O
death	O
.	O

Two	O
subordinate	O
themes	O
were	O
identified	O
:	O
'	O
deciding	O
not	O
to	O
die	O
in	O
the	O
moment	O
'	O
when	O
the	O
participants	B-T098
were	O
more	O
invested	O
in	O
dying	O
than	O
living	O
and	O
'	O
deciding	O
to	O
live	O
in	O
the	O
moment	O
'	O
when	O
they	O
were	O
more	O
invested	O
in	O
living	O
than	O
dying	O
.	O

The	O
study	B-T062
illuminated	O
the	O
complex	O
process	O
of	O
making	B-T038
decisions	I-T038
about	O
ones	O
'	O
destiny	O
on	O
a	O
moment	O
-	O
to	O
-	O
moment	O
basis	O
.	O

It	O
revealed	O
the	O
torment	O
experienced	B-T038
when	O
occupying	O
this	O
state	B-T033
,	O
while	O
paradoxically	O
,	O
also	O
revealing	O
how	O
indecision	B-T033
about	O
life	O
and	O
death	O
provided	O
a	O
lifeline	O
opportunity	O
for	O
those	O
with	O
RSA	B-T033
.	O

Clinicians	B-T097
who	O
recognize	O
the	O
subtle	O
distinctions	O
associated	O
with	O
this	O
in	O
-	O
between	O
state	B-T033
can	O
tailor	O
their	O
interventions	B-T058
accordingly	O
.	O

Surviving	O
moment	O
to	O
moment	O
is	O
characterized	O
by	O
a	O
state	B-T033
of	O
emotional	B-T033
flux	I-T033
and	O
uncertainty	B-T033
about	O
one	O
'	O
s	O
destiny	O
,	O
where	O
the	O
person	B-T098
has	O
not	O
fully	O
committed	O
to	O
either	O
life	O
or	O
death	O
.	O

Within	O
this	O
state	B-T033
,	O
there	O
are	O
two	O
interlinked	B-T038
subprocesses	I-T038
,	O
whereby	O
the	O
person	B-T098
is	O
leaning	O
more	O
towards	O
death	O
or	O
life	O
.	O

A	O
critical	O
feature	O
in	O
working	O
with	O
this	O
client	O
group	O
is	O
to	O
recognize	O
their	O
ambiguity	O
and	O
the	O
fragility	B-T033
and	O
temporality	B-T038
of	O
their	O
decisions	B-T038
about	O
their	O
destiny	O
.	O

The	O
practitioner	B-T097
has	O
an	O
opportunity	O
to	O
be	O
a	O
catalyst	O
in	O
the	O
momentum	O
towards	O
life	O
by	O
demonstrating	O
understanding	B-T038
of	O
this	O
survival	O
struggle	B-T033
and	O
tailoring	B-T058
intervention	I-T058
to	O
fit	O
with	O
the	O
nuanced	B-T038
processes	I-T038
within	O
this	O
state	B-T033
.	O

Does	O
a	O
policy	B-T170
of	O
earlier	O
induction	O
affect	O
labour	B-T038
outcomes	O
in	O
women	B-T098
induced	O
for	O
postmaturity	B-T038
?	O
A	O
retrospective	O
analysis	B-T062
in	O
a	O
tertiary	B-T092
hospital	I-T092
in	O
the	O
North	B-T082
of	O
England	B-T082

to	O
investigate	O
whether	O
a	O
change	O
in	O
the	O
management	O
of	O
postmature	B-T038
pregnancy	I-T038
to	O
earlier	O
induction	O
affects	O
the	O
length	B-T201
of	I-T201
labour	I-T201
and	O
the	O
induction	B-T058
process	I-T058
.	O

Secondly	O
,	O
to	O
assess	O
the	O
feasibility	B-T062
of	O
the	O
research	B-T062
process	I-T062
to	O
inform	O
a	O
future	O
larger	B-T062
study	I-T062
.	O

a	O
change	O
in	O
management	O
of	O
postmature	B-T038
pregnancy	I-T038
in	O
an	O
NHS	B-T058
hospital	B-T092
in	O
October	O
2013	O
,	O
from	O
induction	B-T058
at	O
42	O
weeks	O
gestation	B-T038
to	O
induction	B-T058
between	O
41	O
-	O
42	O
weeks	O
,	O
provided	O
an	O
opportunity	O
to	O
conduct	O
a	O
retrospective	O
analysis	B-T062
.	O

Pre	O
-	O
existing	O
data	O
from	O
the	O
maternity	O
database	B-T170
and	O
casenotes	O
were	O
collected	O
and	O
primary	B-T062
outcomes	I-T062
analysed	B-T062
using	O
the	O
Mann	B-T170
-	I-T170
Whitney	I-T170
test	I-T170
and	O
the	O
Hodges	O
-	O
Lehman	O
confidence	O
interval	O
for	O
differences	O
in	O
medians	O
.	O

a	O
large	B-T082
city	I-T082
based	O
tertiary	B-T092
referral	I-T092
hospital	I-T092
in	O
the	O
North	B-T082
of	O
England	B-T082
.	O

125	O
women	B-T098
induced	O
before	O
the	O
change	O
in	O
policy	B-T170
were	O
compared	O
with	O
309	O
women	B-T098
induced	O
after	O
the	O
change	O
.	O

primary	B-T062
outcomes	I-T062
were	O
length	O
of	O
1st	O
and	O
2nd	O
stage	O
of	O
labour	O
,	O
overall	O
length	B-T201
of	I-T201
labour	I-T201
,	O
length	O
of	O
induction	B-T058
to	O
established	O
labour	B-T038
and	O
length	O
of	O
induction	B-T058
to	O
birth	B-T038
.	O

the	O
median	O
overall	O
length	B-T201
of	I-T201
labour	I-T201
for	O
women	B-T098
induced	O
at	O
42	O
weeks	O
was	O
6	O
.	O
5	O
hours	O
,	O
while	O
for	O
women	B-T098
induced	O
at	O
41	O
-	O
42	O
weeks	O
this	O
was	O
5	O
.	O
2	O
hours	O
.	O

The	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
15	O
,	O
95	O
%	O
CI	O
for	O
median	O
difference	O
-	O
0	O
.	O
27	O
to	O
1	O
.	O
93	O
hours	O
)	O
with	O
a	O
small	O
effect	O
size	O
(	O
Pearson	O
'	O
s	O
r	O
=	O
-	O
0	O
.	O
08	O
)	O
.	O

The	O
median	O
length	O
of	O
induction	B-T058
to	O
birth	B-T038
was	O
13	O
.	O
6	O
hours	O
for	O
women	B-T098
induced	O
at	O
42	O
weeks	O
and	O
16	O
.	O
5	O
hours	O
for	O
women	B-T098
induced	O
at	O
41	O
-	O
42	O
weeks	O
.	O

This	O
difference	O
was	O
also	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
14	O
,	O
95	O
%	O
CI	O
for	O
median	O
difference	O
-	O
7	O
.	O
25	O
to	O
1	O
.	O
20	O
hours	O
)	O
with	O
a	O
small	O
effect	O
size	O
(	O
Pearson	O
'	O
s	O
r	O
=	O
-	O
0	O
.	O
13	O
)	O
.	O

This	O
study	B-T062
demonstrated	O
no	O
statistically	O
significant	O
difference	O
s	O
in	O
length	B-T201
of	I-T201
labour	I-T201
and	O
induction	B-T058
following	O
a	O
change	O
in	O
the	O
management	O
of	O
postmature	B-T038
pregnancy	I-T038
to	O
earlier	O
induction	O
.	O

A	O
large	B-T062
study	I-T062
is	O
needed	O
to	O
establish	O
definitively	O
the	O
effects	O
of	O
earlier	O
induction	O
on	O
labour	B-T038
outcomes	O
.	O

Liquid	B-T058
chromatography	I-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
-	O
based	O
quantitative	B-T058
proteomics	B-T091
analysis	I-T058
reveals	O
chondroprotective	B-T033
effects	I-T033
of	O
astragaloside	B-T103
IV	I-T103
in	O
interleukin	B-T103
-	I-T103
1β	I-T103
-	O
induced	O
SW1353	B-T017
chondrocyte	I-T017
-	I-T017
like	I-T017
cells	I-T017

Chondrocyte	B-T017
apoptosis	B-T038
played	O
a	O
key	O
role	O
on	O
the	O
progression	B-T038
of	O
Osteoarthritis	B-T038
(	O
OA	B-T038
)	O
.	O

Safe	O
and	O
effective	O
drugs	B-T058
are	O
urgently	O
needed	O
for	O
the	O
treatment	O
of	O
OA	B-T038
.	O

Previous	O
study	O
reported	O
that	O
Astragaloside	B-T103
IV	I-T103
(	O
ASG	B-T103
-	I-T103
IV	I-T103
)	O
had	O
exerted	O
a	O
protective	O
effect	O
against	O
articular	O
cartilage	O
degeneration	O
by	O
promoting	O
rapid	O
proliferation	O
of	O
chondrocyte	B-T017
.	O

Therefore	O
,	O
the	O
aim	O
of	O
our	O
study	O
is	O
to	O
explore	O
the	O
effects	O
and	O
mechanisms	O
of	O
ASG	B-T103
-	I-T103
IV	I-T103
in	O
chondrocyte	B-T017
apoptosis	B-T038
.	O

Isobaric	B-T058
Tags	I-T058
For	I-T058
Relative	I-T058
And	I-T058
Absolute	I-T058
Quantitation	I-T058
(	I-T058
iTRAQ	I-T058
)	I-T058
-	I-T058
based	I-T058
quantitative	I-T058
proteomics	B-T091
was	O
used	O
to	O
quantitatively	O
detect	B-T033
and	O
map	O
proteins	B-T103
in	O
SW1353	B-T017
chondrocyte	I-T017
-	I-T017
like	I-T017
cells	I-T017
pre	O
-	O
treated	O
with	O
ASG	B-T103
-	I-T103
IV	I-T103
or	O
interleukin	B-T103
-	I-T103
1β	I-T103
(	O
IL	B-T103
-	I-T103
1β	I-T103
)	O
or	O
ASG	B-T103
-	I-T103
IV	I-T103
+	O
IL	B-T103
-	I-T103
1β	I-T103
.	O

The	O
iTRAQ	B-T103
-	I-T103
labeled	I-T103
peptides	I-T103
were	O
fractionated	O
by	O
high	B-T058
-	I-T058
accuracy	I-T058
liquid	I-T058
chromatography	I-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
(	O
LC	B-T058
-	I-T058
MS	I-T058
)	O
.	O

Cell	B-T038
apoptosis	I-T038
and	O
differentially	B-T103
expressed	I-T103
proteins	I-T103
was	O
detected	B-T033
by	O
flow	B-T058
cytometry	I-T058
(	O
FCM	B-T058
)	O
,	O
quantitative	B-T062
real	I-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
qRT	B-T062
-	I-T062
PCR	I-T062
)	O
,	O
and	O
western	B-T058
blotting	I-T058
,	O
respectively	O
.	O

The	O
apoptosis	B-T038
of	O
the	O
IL	B-T103
-	I-T103
1β	I-T103
-	O
induced	O
SW1353	B-T017
cells	I-T017
treated	O
with	O
ASG	B-T103
-	I-T103
IV	I-T103
was	O
greatly	O
inhibited	O
.	O

Bioinformatics	B-T058
analysis	I-T058
revealed	O
that	O
gamma	B-T103
actin	I-T103
1	I-T103
(	O
ACTG1	B-T103
)	O
and	O
Yes	B-T103
Associated	I-T103
Protein	I-T103
1	I-T103
(	O
YAP1	B-T103
)	O
,	O
participating	O
in	O
the	O
Hippo	B-T038
signaling	I-T038
pathway	I-T038
and	O
Vitronectin	B-T103
(	O
VTN	B-T103
)	O
and	O
Collagen	B-T103
Type	I-T103
I	I-T103
Alpha	I-T103
1	I-T103
Chain	I-T103
(	O
COL1A1	B-T103
)	O
,	O
involving	O
in	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
-	O
receptor	O
interaction	O
signaling	O
pathway	O
,	O
were	O
all	O
significantly	O
up	B-T038
-	I-T038
regulated	I-T038
in	O
the	O
IL	B-T103
-	I-T103
1β	I-T103
-	O
induced	O
SW1353	B-T017
cells	I-T017
after	O
treatment	O
with	O
ASG	B-T103
-	I-T103
IV	I-T103
.	O

The	O
qRT	B-T062
-	I-T062
PCR	I-T062
and	O
Western	B-T058
blotting	I-T058
results	O
confirmed	O
the	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
these	O
four	O
genes	B-T017
.	O

ASG	B-T103
-	I-T103
IV	I-T103
played	O
a	O
positive	B-T033
role	I-T033
in	O
human	B-T204
osteoarthritic	B-T038
chondrocyte	B-T017
apoptosis	I-T038
,	O
possibly	O
through	O
modulation	O
of	O
the	O
Hippo	B-T038
signaling	I-T038
pathway	I-T038
by	O
up	B-T038
-	I-T038
regulating	I-T038
YAP1	B-T103
and	O
ACTG1	B-T103
expression	B-T038
,	O
and	O
also	O
by	O
up	B-T038
-	I-T038
regulating	I-T038
VTN	B-T103
and	O
COL1A1	B-T103
,	O
which	O
are	O
involved	O
in	O
the	O
ECM	O
-	O
receptor	O
interaction	O
pathway	O
.	O

Taken	O
together	O
,	O
all	O
the	O
results	O
suggested	O
that	O
ASG	B-T103
-	I-T103
IV	I-T103
had	O
a	O
novel	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
OA	B-T038
.	O

Open	B-T062
-	I-T062
label	I-T062
,	I-T062
multicentre	I-T062
safety	I-T062
study	I-T062
of	O
vemurafenib	B-T103
in	O
3219	O
patients	O
with	O
BRAF	B-T038
(	I-T038
V600	I-T038
)	I-T038
mutation	I-T038
-	O
positive	B-T033
metastatic	B-T038
melanoma	I-T038
:	O
2	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
data	O
and	O
long	O
-	O
term	O
responders	B-T062
'	I-T062
analysis	I-T062

The	O
orally	B-T082
available	O
BRAF	B-T103
kinase	I-T103
inhibitor	I-T103
vemurafenib	B-T103
is	O
an	O
effective	O
and	O
tolerable	O
treatment	B-T058
option	I-T058
for	O
patients	O
with	O
metastatic	B-T038
melanoma	I-T038
harbouring	O
BRAF	B-T038
(	I-T038
V600	I-T038
)	I-T038
mutations	I-T038
.	O

We	O
assessed	O
the	O
safety	O
of	O
vemurafenib	B-T103
in	O
a	O
large	O
population	B-T098
of	O
patients	O
with	O
few	O
alternative	O
treatment	B-T058
options	I-T058
;	O
we	O
report	O
updated	O
2	O
-	O
year	O
safety	O
.	O

This	O
was	O
an	O
open	B-T062
-	I-T062
label	I-T062
,	I-T062
multicentre	I-T062
study	I-T062
of	O
vemurafenib	B-T103
(	O
960	O
mg	O
bid	O
)	O
in	O
patients	O
with	O
previously	O
treated	O
or	O
untreated	B-T033
BRAF	B-T038
mutation	I-T038
-	O
positive	B-T033
metastatic	B-T038
melanoma	I-T038
(	O
cobas	B-T074
(	I-T074
®	I-T074
)	I-T074
4800	I-T074
BRAF	B-T058
V600	I-T058
Mutation	I-T058
Test	I-T058
)	O
.	O

The	O
primary	O
end	O
-	O
point	O
was	O
safety	O
;	O
efficacy	O
end	O
-	O
points	O
were	O
secondary	O
.	O

An	O
exploratory	B-T062
analysis	I-T062
was	O
performed	O
to	O
assess	O
safety	O
outcomes	O
in	O
patients	O
with	O
long	O
duration	O
of	O
response	O
(	O
DOR	O
)	O
(	O
≥12	O
or	O
≥24	O
months	O
)	O
.	O

After	O
a	O
median	B-T082
follow	B-T058
-	I-T058
up	I-T058
of	O
32	O
.	O
2	O
months	O
(	O
95	O
%	O
CI	O
,	O
31	O
.	O
1	O
-	O
33	O
.	O
2	O
months	O
)	O
,	O
3079	O
/	O
3219	O
patients	O
(	O
96	O
%	O
)	O
had	O
discontinued	B-T033
treatment	I-T033
.	O

Adverse	B-T038
events	I-T038
(	O
AEs	B-T038
)	O
were	O
largely	O
consistent	O
with	O
previous	O
reports	O
;	O
the	O
most	O
common	O
all	O
-	O
grade	O
treatment	O
-	O
related	O
AEs	B-T038
were	O
arthralgia	B-T033
(	O
37	O
%	O
)	O
,	O
alopecia	B-T038
(	O
25	O
%	O
)	O
and	O
hyperkeratosis	B-T038
(	O
23	O
%	O
)	O
;	O
the	O
most	O
common	O
grade	O
3	O
/	O
4	O
treatment	O
-	O
related	O
AEs	B-T038
were	O
squamous	B-T038
cell	I-T038
carcinoma	I-T038
of	I-T038
the	I-T038
skin	I-T038
(	O
8	O
%	O
)	O
and	O
keratoacanthoma	B-T038
(	O
8	O
%	O
)	O
.	O

In	O
the	O
exploratory	B-T062
analysis	I-T062
,	O
patients	O
with	O
DOR	O
≥12	O
months	O
(	O
n	O
=	O
287	O
)	O
or	O
≥24	O
months	O
(	O
n	O
=	O
133	O
)	O
were	O
more	O
likely	O
to	O
experience	O
grade	O
3	O
/	O
4	O
AEs	B-T038
than	O
the	O
overall	O
population	B-T098
.	O

No	O
new	O
specific	O
safety	O
signals	O
were	O
observed	O
with	O
longer	O
vemurafenib	B-T033
exposure	I-T033
.	O

After	O
2	O
years	O
'	O
follow	B-T058
-	I-T058
up	I-T058
,	O
safety	O
was	O
maintained	O
in	O
this	O
large	O
group	O
of	O
patients	O
with	O
BRAF	B-T038
(	I-T038
V600	I-T038
)	I-T038
mutation	I-T038
-	O
positive	B-T033
metastatic	B-T038
melanoma	I-T038
who	O
are	O
more	O
representative	O
of	O
routine	O
clinical	O
practice	O
than	O
typical	O
clinical	B-T062
trial	I-T062
populations	B-T098
.	O

These	O
data	O
suggest	O
that	O
long	O
-	O
term	O
vemurafenib	B-T103
treatment	O
is	O
effective	O
and	O
tolerable	O
without	O
the	O
development	O
of	O
new	O
safety	O
signals	O
.	O

Collecting	B-T062
and	O
Reporting	B-T062
Safety	I-T062
Data	I-T062
and	O
Monitoring	B-T062
Trial	I-T062
Conduct	I-T062
In	O
Pragmatic	B-T062
Trials	I-T062

Pragmatic	B-T062
trials	I-T062
offer	O
the	O
opportunity	O
to	O
obtain	O
real	O
-	O
life	O
data	O
on	O
the	O
relative	O
effectiveness	O
and	O
safety	O
of	O
a	O
treatment	B-T058
before	O
or	O
after	O
market	O
authorisation	O
.	O

This	O
is	O
the	O
penultimate	O
paper	O
in	O
a	O
series	O
of	O
eight	O
,	O
describing	O
the	O
impact	O
of	O
design	O
choices	O
on	O
the	O
practical	O
implementation	O
of	O
pragmatic	B-T062
trials	I-T062
.	O

This	O
paper	O
focuses	O
on	O
the	O
practical	O
challenges	O
of	O
collecting	B-T062
and	O
reporting	B-T062
safety	I-T062
data	I-T062
and	O
of	O
monitoring	B-T062
trial	I-T062
conduct	I-T062
while	O
maintaining	O
routine	O
clinical	O
care	O
practice	O
.	O

Current	O
ICH	B-T170
guidance	O
recommends	O
that	O
,	O
all	O
serious	B-T033
adverse	I-T033
events	I-T033
(	O
SAEs	B-T033
)	O
and	O
all	O
drug	B-T103
-	O
related	O
events	O
must	O
be	O
reported	O
in	O
an	O
interventional	B-T058
trial	B-T062
.	O

In	O
line	O
with	O
current	O
guidance	O
,	O
we	O
propose	O
a	O
risk	O
based	O
approach	B-T082
to	O
the	O
collection	B-T062
of	O
non	B-T033
-	O
drug	B-T103
related	O
non	B-T033
-	I-T033
serious	I-T033
AEs	I-T033
,	O
and	O
even	O
serious	O
events	O
not	O
related	O
to	O
treatment	B-T058
based	O
on	O
the	O
risk	O
profile	O
of	O
the	O
medicine	B-T103
/	O
class	O
in	O
the	O
patient	O
population	B-T098
of	O
interest	O
.	O

Different	O
options	O
available	O
to	O
support	O
the	O
collection	B-T062
and	O
reporting	B-T062
of	I-T062
safety	I-T062
data	I-T062
whilst	O
minimizing	O
study	B-T062
-	O
related	O
follow	B-T058
-	I-T058
up	I-T058
visits	I-T058
are	O
discussed	O
.	O

A	O
risk	O
-	O
based	O
approach	B-T082
to	O
monitoring	B-T062
trial	I-T062
conduct	I-T062
is	O
also	O
discussed	O
,	O
highlighting	O
the	O
difference	O
in	O
the	O
balance	O
of	O
risks	O
likely	O
to	O
occur	O
in	O
a	O
pragmatic	B-T062
trial	I-T062
compared	O
to	O
traditional	O
clinical	B-T062
trials	I-T062
,	O
and	O
the	O
careful	O
consideration	O
that	O
must	O
be	O
given	O
to	O
the	O
mitigation	O
and	O
management	B-T058
of	I-T058
these	I-T058
risks	I-T058
in	O
order	O
to	O
maintain	O
routine	O
care	O
.	O

A	O
pilot	B-T062
study	I-T062
of	O
intraocular	B-T058
lens	I-T058
explantation	I-T058
in	O
69	O
eyes	B-T017
in	O
Chinese	O
patients	O

To	O
study	O
the	O
effects	O
of	O
intraocular	B-T058
lens	I-T058
(	I-T058
IOL	I-T058
)	I-T058
explantation	I-T058
and	O
demographic	O
characteristics	O
.	O

Retrospective	O
non	B-T062
-	I-T062
comparative	I-T062
case	I-T062
series	I-T062
.	O

Clinical	B-T170
data	I-T170
recorded	O
from	O
patient	O
charts	O
included	O
the	O
following	O
:	O
demographic	O
,	O
preoperative	B-T058
and	O
postoperative	O
characteristics	O
;	O
complications	B-T038
;	O
surgical	O
methods	O
,	O
and	O
changes	O
in	O
visual	B-T058
acuity	I-T058
.	O

A	O
total	O
of	O
69	O
eyes	B-T017
in	O
67	O
Chinese	B-T098
patients	O
who	O
received	O
IOL	B-T058
explants	I-T058
were	O
studied	O
.	O

The	O
patients	O
'	O
mean	O
age	O
at	O
the	O
time	O
of	O
explantation	O
was	O
46	O
.	O
1	O
years	O
old	O
[	O
SD	O
22	O
.	O
5	O
(	O
6	O
-	O
85	O
)	O
]	O
,	O
and	O
37	O
patients	O
were	O
female	O
(	O
55	O
.	O
2	O
%	O
)	O
.	O

Regarding	O
employment	O
,	O
47	O
.	O
8	O
%	O
were	O
farmers	B-T097
,	O
23	O
.	O
9	O
%	O
were	O
retired	B-T097
,	O
16	O
.	O
4	O
%	O
were	O
students	B-T098
,	O
4	O
.	O
5	O
%	O
were	O
unemployed	B-T033
,	O
3	O
%	O
were	O
workers	B-T098
,	O
and	O
4	O
.	O
5	O
%	O
were	O
other	O
(	O
including	O
staff	O
members	O
,	O
teachers	B-T097
and	O
officers	O
)	O
.	O

The	O
main	O
reasons	O
for	O
explantation	B-T058
were	O
dislocation	B-T037
/	O
decentration	B-T033
in	O
41	O
cases	O
(	O
59	O
.	O
4	O
%	O
)	O
and	O
retinal	B-T038
detachment	I-T038
in	O
10	O
cases	O
(	O
14	O
.	O
5	O
%	O
)	O
.	O

The	O
third	O
most	O
prevalent	O
cause	O
was	O
incorrect	B-T033
lens	I-T033
power	I-T033
in	O
7	O
eyes	B-T017
(	O
10	O
.	O
1	O
%	O
)	O
.	O

The	O
remaining	O
reasons	O
were	O
endophthalmitis	B-T038
in	O
6	O
cases	O
(	O
8	O
.	O
7	O
%	O
)	O
,	O
posterior	B-T038
capsular	I-T038
opacity	I-T038
in	O
3	O
eyes	B-T017
(	O
4	O
.	O
3	O
%	O
)	O
,	O
and	O
impacting	O
retinal	B-T058
surgery	I-T058
operation	I-T058
in	O
2	O
cases	O
(	O
2	O
.	O
9	O
%	O
)	O
.	O

The	O
main	O
comorbidities	O
were	O
high	B-T038
myopia	I-T038
in	O
18	O
eyes	B-T017
(	O
26	O
.	O
1	O
%	O
)	O
,	O
trauma	B-T037
in	O
8	O
eyes	B-T017
(	O
11	O
.	O
6	O
%	O
)	O
,	O
retinal	B-T038
detachment	I-T038
in	O
6	O
eyes	B-T017
(	O
8	O
.	O
7	O
%	O
)	O
,	O
congenital	B-T017
cataracts	I-T017
in	O
8	O
eyes	B-T017
(	O
11	O
.	O
6	O
%	O
)	O
,	O
and	O
Marfan	B-T038
'	I-T038
s	I-T038
syndrome	I-T038
in	O
2	O
eyes	B-T017
(	O
2	O
.	O
9	O
%	O
)	O
.	O

The	O
mean	O
time	O
from	O
implantation	O
to	O
explantation	O
was	O
4	O
.	O
0y	O
[	O
SD	O
4	O
.	O
2	O
(	O
0	O
.	O
005	O
-	O
15	O
)	O
]	O
.	O

Treatment	B-T058
after	I-T058
explantation	I-T058
included	O
posterior	B-T058
chamber	I-T058
IOL	I-T058
implantation	I-T058
in	O
44	O
eyes	B-T017
(	O
63	O
.	O
8	O
%	O
)	O
and	O
aphakia	B-T017
in	O
25	O
eyes	B-T017
(	O
36	O
.	O
2	O
%	O
)	O
.	O

After	B-T033
surgery	I-T033
,	O
the	O
best	B-T033
corrected	I-T033
visual	I-T033
ability	I-T033
(	O
BCVA	B-T033
)	O
was	O
improved	O
in	O
50	O
cases	O
(	O
72	O
.	O
5	O
%	O
)	O
,	O
including	O
28	O
patients	O
(	O
40	O
.	O
6	O
%	O
)	O
in	O
whom	O
visual	B-T201
ability	I-T201
was	O
improved	O
by	O
more	O
than	O
two	O
lines	O
.	O

Dislocation	B-T037
/	O
decentration	B-T033
is	O
the	O
main	O
cause	O
for	O
explantation	B-T058
,	O
and	O
high	B-T038
myopia	I-T038
is	O
a	O
main	B-T033
risk	I-T033
factor	I-T033
.	O

Posterior	B-T058
chamber	I-T058
IOL	I-T058
implantation	I-T058
remains	O
the	O
most	O
elected	O
treatment	B-T058
after	I-T058
explantation	I-T058
.	O

Improvement	O
of	O
older	B-T098
-	O
person	B-T098
-	O
specific	O
QOL	O
after	O
hearing	B-T074
aid	I-T074
fitting	B-T058
and	O
its	O
relation	O
to	O
social	B-T033
interaction	I-T033

This	O
study	B-T062
aimed	O
to	O
investigate	O
whether	O
hearing	B-T074
aids	I-T074
use	O
is	O
associated	O
with	O
improvement	O
of	O
older	B-T098
-	O
person	B-T098
-	O
specific	O
QOL	O
and	O
whether	O
social	B-T033
interactions	I-T033
modify	O
the	O
association	O
.	O

The	O
WHOQOL	B-T170
-	I-T170
OLD	I-T170
questionnaire	I-T170
was	O
answered	B-T170
by	O
105	O
older	B-T098
adults	I-T098
aged	O
60	O
to	O
90	O
years	O
who	O
were	O
newly	O
fitted	B-T058
hearing	B-T074
aids	I-T074
on	O
the	O
day	O
of	O
fitting	B-T058
and	O
at	O
2	O
-	O
6	O
months	O
afterward	O
.	O

The	O
associations	O
between	O
the	O
daily	O
hours	O
of	O
hearing	B-T074
aid	I-T074
usage	O
and	O
social	O
relations	O
with	O
changes	O
in	O
the	O
WHOQOL	B-T170
-	I-T170
OLD	I-T170
total	O
score	O
after	O
hearing	B-T074
aids	I-T074
fitting	B-T058
were	O
estimated	O
adjusting	O
for	O
possible	B-T033
confounders	O
.	O

Older	B-T098
persons	B-T098
with	O
hearing	B-T033
loss	I-T033
experienced	O
significant	O
increases	O
in	O
WHOQOL	B-T170
-	I-T170
OLD	I-T170
total	O
score	O
after	O
hearing	B-T074
aid	I-T074
fitting	B-T058
.	O

Regular	O
use	O
of	O
hearing	B-T074
aid	I-T074
was	O
associated	O
with	O
a	O
greater	O
increase	O
in	O
the	O
total	O
score	O
.	O

The	O
combined	O
categorical	B-T170
variable	O
of	O
social	O
relations	O
and	O
hearing	B-T074
aid	I-T074
usage	O
revealed	O
no	O
separate	O
effects	O
of	O
these	O
two	O
variables	O
,	O
but	O
a	O
combined	O
effect	O
;	O
only	O
those	O
with	O
frequent	O
social	B-T033
interactions	I-T033
who	O
used	O
their	O
hearing	B-T074
aid	I-T074
regularly	O
had	O
a	O
significantly	O
greater	O
increase	O
in	O
WHOQOL	B-T170
-	I-T170
OLD	I-T170
total	O
score	O
.	O

This	O
study	B-T062
'	I-T062
s	I-T062
findings	O
indicate	O
that	O
hearing	B-T074
aid	I-T074
fitting	B-T058
may	O
be	O
associated	O
with	O
a	O
subsequent	O
improvement	O
in	O
older	B-T098
-	O
person	B-T098
-	O
specific	O
QOL	O
by	O
improvements	O
in	O
hearing	B-T038
due	O
to	O
the	O
hearing	B-T074
aid	I-T074
,	O
and	O
possibly	B-T033
enhanced	O
communication	O
opportunities	O
.	O

Enhancing	O
Comparative	B-T062
Effectiveness	I-T062
Research	I-T062
With	O
Automated	O
Pediatric	O
Pneumonia	B-T038
Detection	B-T058
in	O
a	O
Multi	B-T092
-	I-T092
Institutional	I-T092
Clinical	O
Repository	O
:	O
A	O
PHIS	B-T170
+	O
Pilot	B-T062
Study	I-T062

Community	B-T038
-	I-T038
acquired	I-T038
pneumonia	I-T038
is	O
a	O
leading	O
cause	O
of	O
pediatric	O
morbidity	O
.	O

Administrative	O
data	O
are	O
often	O
used	O
to	O
conduct	O
comparative	B-T062
effectiveness	I-T062
research	I-T062
(	O
CER	B-T062
)	O
with	O
sufficient	O
sample	O
sizes	O
to	O
enhance	O
detection	B-T033
of	O
important	O
outcomes	O
.	O

However	O
,	O
such	O
studies	O
are	O
prone	O
to	O
misclassification	O
errors	O
because	O
of	O
the	O
variable	O
accuracy	O
of	O
discharge	B-T033
diagnosis	I-T033
codes	B-T170
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
automated	O
,	O
scalable	O
,	O
and	O
accurate	O
method	B-T170
to	O
determine	O
the	O
presence	B-T033
or	O
absence	O
of	O
pneumonia	B-T038
in	O
children	O
using	O
chest	B-T058
imaging	I-T058
reports	B-T170
.	O

The	O
multi	B-T092
-	I-T092
institutional	I-T092
PHIS	B-T170
+	O
clinical	O
repository	O
was	O
developed	O
to	O
support	O
pediatric	O
CER	B-T062
by	O
expanding	O
an	O
administrative	O
database	B-T170
of	O
children	B-T092
'	I-T092
s	I-T092
hospitals	I-T092
with	O
detailed	O
clinical	O
data	O
.	O

To	O
develop	O
a	O
scalable	O
approach	O
to	O
find	B-T033
patients	O
with	O
bacterial	B-T038
pneumonia	I-T038
more	O
accurately	O
,	O
we	O
developed	O
a	O
Natural	O
Language	O
Processing	O
(	O
NLP	O
)	O
application	O
to	O
extract	O
relevant	O
information	O
from	O
chest	B-T058
diagnostic	I-T058
imaging	I-T058
reports	B-T170
.	O

Domain	O
experts	B-T097
established	O
a	O
reference	O
standard	O
by	O
manually	O
annotating	O
282	O
reports	B-T170
to	O
train	O
and	O
then	O
test	O
the	O
NLP	O
application	O
.	O

Findings	O
of	O
pleural	B-T038
effusion	I-T038
,	O
pulmonary	B-T033
infiltrate	I-T033
,	O
and	O
pneumonia	B-T038
were	O
automatically	O
extracted	O
from	O
the	O
reports	B-T170
and	O
then	O
used	O
to	O
automatically	O
classify	B-T170
whether	O
a	O
report	B-T170
was	O
consistent	O
with	O
bacterial	B-T038
pneumonia	I-T038
.	O

Compared	O
with	O
the	O
annotated	O
diagnostic	B-T058
imaging	I-T058
reports	B-T170
reference	O
standard	O
,	O
the	O
most	O
accurate	O
implementation	O
of	O
machine	O
learning	O
algorithms	B-T170
in	O
our	O
NLP	O
application	O
allowed	O
extracting	O
relevant	O
findings	O
with	O
a	O
sensitivity	O
of	O
.	O
939	O
and	O
a	O
positive	B-T033
predictive	O
value	O
of	O
.	O
925	O
.	O

It	O
allowed	O
classifying	B-T170
reports	B-T170
with	O
a	O
sensitivity	O
of	O
.	O
71	O
,	O
a	O
positive	B-T033
predictive	O
value	O
of	O
.	O
86	O
,	O
and	O
a	O
specificity	O
of	O
.	O
962	O
.	O

When	O
compared	O
with	O
each	O
of	O
the	O
domain	O
experts	B-T097
manually	O
annotating	O
these	O
reports	B-T170
,	O
the	O
NLP	O
application	O
allowed	O
for	O
significantly	O
higher	O
sensitivity	O
(	O
.	O
71	O
vs	O
.	O
527	O
)	O
and	O
similar	O
positive	B-T033
predictive	O
value	O
and	O
specificity	O
.	O

NLP	O
-	O
based	O
pneumonia	B-T038
information	O
extraction	O
of	O
pediatric	O
diagnostic	B-T058
imaging	I-T058
reports	B-T170
performed	O
better	O
than	O
domain	O
experts	B-T097
in	O
this	O
pilot	B-T062
study	I-T062
.	O

NLP	O
is	O
an	O
efficient	O
method	O
to	O
extract	O
information	O
from	O
a	O
large	O
collection	O
of	O
imaging	B-T170
reports	I-T170
to	O
facilitate	O
CER	B-T062
.	O

Determination	O
of	O
volatile	B-T103
organic	I-T103
compounds	I-T103
exhaled	B-T038
by	O
cell	B-T017
lines	I-T017
derived	O
from	O
hematological	B-T038
malignancies	I-T038

Background	O
:	O
The	O
gas	B-T103
human	B-T204
exhaled	B-T038
contains	O
many	O
volatile	B-T103
organic	I-T103
compounds	I-T103
(	O
VOCs	B-T103
)	O
,	O
which	O
is	O
related	O
to	O
the	O
health	O
status	O
of	O
body	B-T204
.	O

Analysis	B-T062
of	O
VOCs	B-T103
has	O
been	O
proposed	O
as	O
a	O
noninvasive	B-T170
diagnostic	B-T058
tool	I-T058
for	O
certain	O
cancers	B-T038
.	O

Detailed	O
research	O
on	O
the	O
VOCs	B-T103
in	O
gas	B-T103
exhaled	B-T038
by	O
cell	B-T017
can	O
characterize	O
cell	B-T170
type	I-T170
specific	O
metabolites	B-T103
and	O
may	O
be	O
helpful	O
to	O
detect	O
the	O
cancer	B-T103
markers	I-T103
in	O
clinical	O
practice	O
.	O

Methods	O
:	O
Solid	B-T058
phase	I-T058
microextraction	I-T058
-	O
gas	B-T058
chromatography	I-T058
-	O
mass	B-T058
spectrometry	I-T058
was	O
used	O
to	O
detect	O
VOCs	B-T103
in	O
the	O
headspace	O
of	O
tissue	O
culture	O
flask	O
in	O
non	B-T038
-	I-T038
Hodgkin	I-T038
'	I-T038
s	I-T038
lymphoma	I-T038
cell	B-T017
line	I-T017
JEKO	I-T017
and	O
acute	B-T038
mononuclear	I-T038
leukemia	I-T038
cell	B-T017
line	I-T017
SHI	I-T017
-	I-T017
1	I-T017
,	O
to	O
elaborate	O
the	O
characteristic	O
gaseous	B-T103
biomarkers	B-T103
of	O
hematological	B-T038
malignancies	I-T038
.	O

While	O
macrophage	B-T017
cells	I-T017
and	O
lymphocytic	B-T017
cells	I-T017
were	O
acted	O
as	O
control	O
.	O

The	O
blank	O
group	O
was	O
only	O
the	O
RPMI	B-T103
1640	I-T103
medium	I-T103
containing	O
10	O
%	O
fetal	B-T103
calf	I-T103
serum	I-T103
that	O
without	O
cells	B-T017
.	O

Results	O
:	O
Comparing	O
to	O
control	O
group	O
,	O
the	O
concentration	O
of	O
dimethyl	B-T103
sulphide	I-T103
,	O
2	B-T103
,	I-T103
4	I-T103
-	I-T103
dimethyl	I-T103
-	I-T103
heptane	I-T103
,	O
methylbenzene	B-T103
,	O
o	B-T103
-	I-T103
xylene	I-T103
,	O
dodecane	B-T103
and	O
1	B-T103
,	I-T103
3	I-T103
-	I-T103
ditert	I-T103
-	I-T103
butylbenzene	I-T103
in	O
JEKO	B-T017
cells	I-T017
were	O
relatively	O
higher	O
,	O
while	O
the	O
concentration	O
of	O
ethanol	B-T103
,	O
hexanal	B-T103
and	O
benzaldehyde	B-T103
was	O
lower	O
.	O

In	O
SHI	B-T017
-	I-T017
1	I-T017
cells	I-T017
,	O
the	O
levels	O
of	O
2	B-T103
,	I-T103
4	I-T103
-	I-T103
dimethyl	I-T103
-	I-T103
heptane	I-T103
,	O
benzene	B-T103
,	O
4	B-T103
-	I-T103
methyldecane	I-T103
,	O
chloroform	B-T103
,	O
3	B-T103
,	I-T103
7	I-T103
-	I-T103
dimethyl	I-T103
dodecane	I-T103
and	O
hexadecane	B-T103
were	O
significantly	O
elevated	O
,	O
but	O
the	O
levels	O
of	O
hexanol	B-T103
and	O
cyclohexanol	B-T103
were	O
distinctly	O
reduced	O
.	O

Conclusions	O
:	O
This	O
pilot	B-T062
study	I-T062
revealed	O
that	O
the	O
malignant	B-T038
hematological	I-T038
cells	B-T017
could	O
change	O
the	O
components	O
of	O
VOCs	B-T103
in	O
the	O
cell	B-T058
culture	I-T058
flask	I-T058
in	O
a	O
cell	B-T170
type	I-T170
specific	O
pattern	O
.	O

The	O
traits	O
of	O
VOCs	B-T103
in	O
our	O
setting	O
offered	O
new	O
strategy	O
for	O
hematological	B-T038
malignancies	I-T038
tracing	O
,	O
and	O
would	O
act	O
as	O
potential	O
biomarkers	B-T103
in	O
diagnosis	B-T033
of	O
malignant	O
hematological	B-T038
diseases	I-T038
.	O

Intratympanic	O
steroid	B-T103
delivery	O
by	O
an	O
indwelling	B-T074
catheter	I-T074
in	O
refractory	B-T038
severe	I-T038
sudden	I-T038
sensorineural	I-T038
hearing	I-T038
loss	I-T038

Many	O
studies	O
over	O
the	O
last	O
decade	O
showed	O
favorable	O
outcomes	O
with	O
intratympanic	O
(	O
IT	O
)	O
steroid	B-T058
treatment	I-T058
,	O
alone	O
as	O
salvage	B-T058
treatment	I-T058
or	O
in	O
combination	O
with	O
conventional	O
systemic	B-T058
therapy	I-T058
(	O
ST	B-T058
)	O
.	O

However	O
,	O
in	O
severe	O
to	O
profound	O
sensorineural	B-T038
hearing	I-T038
loss	I-T038
resistant	O
to	O
ST	B-T058
,	O
the	O
optimal	O
infusion	B-T058
mode	I-T058
,	O
the	O
type	O
and	O
concentration	O
of	O
the	O
solution	O
,	O
the	O
preferable	O
drug	B-T103
,	O
its	O
total	O
amount	O
,	O
and	O
the	O
duration	O
and	O
fractionation	B-T058
of	O
the	O
treatment	B-T058
are	O
still	O
debated	O
.	O

Aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
feasibility	O
and	O
the	O
outcomes	O
of	O
a	O
direct	O
and	O
constant	O
IT	O
delivery	O
of	O
dexamethasone	B-T103
(	O
DEX	B-T103
)	O
by	O
means	O
of	O
a	O
new	O
indwelling	B-T074
catheter	I-T074
.	O

A	O
prospective	B-T062
case	I-T062
-	I-T062
control	I-T062
study	I-T062
in	O
a	O
tertiary	B-T092
referral	I-T092
university	I-T092
hospital	I-T092
.	O

Ninety	O
-	O
nine	O
subjects	B-T098
treated	O
with	O
ST	B-T058
only	O
and	O
28	O
with	O
additional	O
IT	O
DEX	B-T103
have	O
been	O
included	O
in	O
the	O
study	O
.	O

A	O
4	B-T074
Fr	I-T074
catheter	I-T074
inserted	B-T058
in	O
a	O
sub	O
-	O
annular	O
fashion	O
with	O
a	O
minimal	O
postero	O
-	O
inferior	O
tympanotomy	B-T058
through	O
and	O
endocanalar	B-T082
approach	I-T082
under	O
local	B-T058
anesthesia	I-T058
.	O

DEX	B-T103
4mg	O
/	O
ml	O
delivered	O
daily	O
,	O
up	O
to	O
7	O
days	O
.	O

Daily	O
bone	B-T058
and	I-T058
air	I-T058
-	I-T058
conducted	I-T058
pure	I-T058
tone	I-T058
and	O
speech	B-T058
audiometry	I-T058
were	O
performed	O
with	O
a	O
follow	O
-	O
up	O
at	O
1	O
,	O
3	O
,	O
6	O
months	O
after	O
treatment	B-T058
.	O

Twenty	O
-	O
one	O
out	O
of	O
28	O
patients	O
(	O
75	O
%	O
)	O
refractory	O
to	O
ST	B-T058
gained	O
on	O
average	O
24	O
.	O
0dB±20	O
.	O
5dB	O
HL	B-T033
after	O
IT	O
-	O
DEX	B-T103
,	O
compared	O
to	O
35	O
.	O
4	O
%	O
(	O
average	O
6	O
.	O
7dB±16	O
.	O
6dB	O
HL	B-T033
)	O
of	O
those	O
receiving	O
only	O
medical	O
ST	B-T058
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

No	O
significant	O
side	B-T038
effects	I-T038
were	O
noted	O
.	O

In	O
severe	O
to	O
profound	O
sudden	B-T033
deafness	I-T033
refractory	O
to	O
conventional	O
ST	B-T058
,	O
the	O
daily	O
perfusion	B-T058
of	O
4mg	O
/	O
ml	O
DEX	B-T103
through	O
an	O
intratympanic	O
catheter	B-T074
is	O
an	O
easy	O
,	O
well	O
accepted	O
procedure	O
that	O
enables	O
patients	O
to	O
receive	O
a	O
drug	B-T103
in	O
the	O
middle	B-T082
ear	I-T082
in	O
a	O
repeatable	B-T058
or	O
sustained	B-T103
form	I-T103
,	O
with	O
minimal	O
discomfort	B-T062
and	I-T062
a	I-T062
partial	I-T062
rescue	I-T062
(	O
67	O
.	O
86	O
%	O
)	O
and	O
a	O
speech	O
recognition	O
gain	O
of	O
39	O
%	O
.	O

Design	O
,	O
synthesis	O
and	O
anti	B-T038
-	I-T038
tumor	I-T038
activity	I-T038
study	B-T062
of	O
novel	O
histone	B-T103
deacetylase	I-T103
inhibitors	I-T103
containing	O
isatin	B-T103
-	O
based	O
caps	O
and	O
o	B-T103
-	I-T103
phenylenediamine	I-T103
-	O
based	O
zinc	O
binding	O
groups	O

As	O
a	O
hot	O
topic	O
of	O
epigenetic	B-T091
studies	I-T091
,	O
histone	B-T103
deacetylases	I-T103
(	O
HDACs	B-T103
)	O
are	O
related	O
to	O
lots	O
of	O
diseases	B-T038
,	O
especially	O
cancer	B-T038
.	O

Further	O
researches	B-T062
indicated	O
that	O
different	O
HDAC	B-T103
isoforms	I-T103
played	O
various	O
roles	O
in	O
a	O
wide	O
range	O
of	O
tumor	O
types	O
.	O

Herein	O
a	O
novel	O
series	O
of	O
HDAC	B-T103
inhibitors	I-T103
with	O
isatin	B-T103
-	O
based	O
caps	O
and	O
o	B-T103
-	I-T103
phenylenediamine	I-T103
-	O
based	O
zinc	O
binding	O
groups	O
have	O
been	O
designed	O
and	O
synthesized	O
through	O
scaffold	B-T058
hopping	I-T058
strategy	I-T058
.	O

Among	O
these	O
compounds	B-T103
,	O
the	O
most	O
potent	O
compound	B-T103
9n	I-T103
exhibited	O
similar	O
if	O
not	O
better	O
HDAC	B-T103
inhibition	B-T038
and	O
antiproliferative	B-T038
activities	I-T038
against	O
multiple	O
tumor	B-T017
cell	I-T017
lines	I-T017
compared	O
with	O
the	O
positive	O
control	O
entinostat	B-T103
(	O
MS	B-T103
-	I-T103
275	I-T103
)	O
.	O

Additionally	O
,	O
compared	O
with	O
MS	B-T103
-	I-T103
275	I-T103
(	O
IC50	O
values	O
for	O
HDAC1	B-T103
,	O
2	B-T103
and	O
3	B-T103
were	O
0	O
.	O
163	O
,	O
0	O
.	O
396	O
and	O
0	O
.	O
605µM	O
,	O
respectively	O
)	O
,	O
compound	B-T103
9n	I-T103
with	O
IC50	O
values	O
of	O
0	O
.	O
032	O
,	O
0	O
.	O
256	O
and	O
0	O
.	O
311µM	O
for	O
HDAC1	B-T103
,	O
2	B-T103
and	O
3	B-T103
respectively	O
,	O
showed	O
a	O
moderate	O
HDAC1	B-T103
selectivity	O
.	O

Efficacy	O
of	O
42	O
Pharmacologic	B-T103
Cotreatment	B-T058
Strategies	O
Added	O
to	O
Antipsychotic	B-T103
Monotherapy	B-T058
in	O
Schizophrenia	B-T038
:	O
Systematic	O
Overview	O
and	O
Quality	O
Appraisal	O
of	O
the	O
Meta	B-T062
-	I-T062
analytic	I-T062
Evidence	O

Limited	O
treatment	B-T058
responses	O
in	O
schizophrenia	B-T038
prompted	O
the	O
testing	O
of	O
combining	O
an	O
antipsychotic	B-T103
drug	I-T103
treatment	B-T058
with	O
a	O
second	O
psychotropic	B-T103
medication	B-T103
.	O

A	O
comprehensive	O
evaluation	B-T058
of	O
the	O
efficacy	O
of	O
multiple	O
medication	B-T103
combinations	B-T103
is	O
missing	O
.	O

To	O
summarize	O
and	O
compare	O
the	O
meta	B-T062
-	I-T062
analytically	I-T062
determined	O
efficacy	O
of	O
pharmacologic	B-T103
combination	B-T103
strategies	O
of	O
antipsychotic	B-T103
drugs	I-T103
in	O
adults	O
with	O
schizophrenia	B-T038
.	O

Systematic	O
search	O
of	O
PubMed	B-T170
and	O
PsycInfo	O
until	O
May	O
13	O
,	O
2016	O
.	O

Meta	B-T062
-	I-T062
analyses	I-T062
of	O
randomized	B-T062
clinical	I-T062
trials	I-T062
comparing	O
the	O
efficacy	O
of	O
antipsychotic	B-T103
drugs	I-T103
combined	O
with	O
other	O
antipsychotic	B-T103
or	O
nonantipsychotic	B-T103
medications	I-T103
vs	O
placebos	B-T103
or	O
antipsychotic	B-T103
monotherapy	B-T058
among	O
adults	O
with	O
schizophrenia	B-T038
.	O

Independent	O
reviewers	B-T098
extracted	O
the	O
data	O
and	O
assessed	O
the	O
quality	O
of	O
the	O
methods	B-T170
of	O
the	O
included	O
meta	B-T062
-	I-T062
analyses	I-T062
using	O
A	O
Measurement	B-T170
Tool	I-T170
to	I-T170
Assess	I-T170
Systematic	I-T170
Reviews	I-T170
(	O
AMSTAR	B-T170
)	O
,	O
adding	O
6	O
new	O
items	O
to	O
rate	O
their	O
quality	O
.	O

Effect	O
sizes	O
,	O
expressed	O
as	O
standardized	B-T201
mean	I-T201
difference	I-T201
/	O
Hedges	O
g	O
or	O
risk	O
ratio	O
,	O
were	O
compared	O
separately	O
for	O
combinations	B-T103
with	O
any	O
antipsychotic	B-T103
drug	I-T103
and	O
for	O
combinations	B-T103
with	O
clozapine	B-T103
.	O

The	O
primary	O
outcome	O
was	O
total	O
symptom	B-T033
reduction	O
.	O

Secondary	O
outcomes	O
included	O
positive	B-T033
and	O
negative	B-T033
symptoms	B-T033
,	O
treatment	B-T058
recommendations	I-T058
by	O
authors	O
,	O
study	O
-	O
defined	O
inefficacies	B-T033
,	O
cognitive	O
and	O
depressive	B-T033
symptoms	I-T033
,	O
discontinuation	B-T058
of	O
treatment	B-T058
because	O
of	O
any	O
cause	O
,	O
and	O
inefficacies	B-T033
or	O
intolerabilities	O
.	O

Of	O
3397	O
publications	O
,	O
29	O
meta	B-T062
-	I-T062
analyses	I-T062
testing	O
42	O
combination	B-T103
strategies	O
in	O
381	O
individual	B-T098
trials	O
and	O
among	O
19	O
833	O
participants	B-T098
were	O
included	O
.	O

For	O
total	O
symptom	B-T033
reductions	B-T058
,	O
32	O
strategies	O
that	O
augmented	O
any	O
antipsychotic	B-T103
drug	I-T103
and	O
5	O
strategies	O
that	O
augmented	O
clozapine	B-T103
were	O
examined	O
.	O

Fourteen	O
combination	B-T103
treatments	B-T058
outperformed	O
controls	O
(	O
standard	B-T201
mean	I-T201
difference	I-T201
/	O
Hedges	O
g	O
,	O
-	O
1	O
.	O
27	O
[	O
95	O
%	O
CI	O
,	O
-	O
2	O
.	O
35	O
to	O
-	O
0	O
.	O
19	O
]	O
to	O
-	O
0	O
.	O
23	O
[	O
95	O
%	O
CI	O
,	O
-	O
0	O
.	O
44	O
to	O
-	O
0	O
.	O
02	O
]	O
;	O
P	O
=	O
.	O
05	O
)	O
.	O

No	O
combination	B-T103
strategies	O
with	O
clozapine	B-T103
outperformed	O
controls	O
.	O

The	O
quality	O
of	O
the	O
methods	B-T170
of	O
the	O
meta	B-T062
-	I-T062
analyses	I-T062
was	O
generally	O
high	O
(	O
mean	O
score	O
,	O
9	O
of	O
a	O
maximum	O
score	O
of	O
11	O
)	O
but	O
the	O
quality	O
of	O
the	O
meta	B-T062
-	I-T062
analyzed	I-T062
studies	I-T062
was	O
low	O
(	O
mean	O
score	O
,	O
2	O
.	O
8	O
of	O
a	O
maximum	O
score	O
of	O
8	O
)	O
.	O

Treatment	B-T058
recommendations	I-T058
correlated	O
with	O
the	O
effect	O
size	O
(	O
correlation	O
coefficient	O
,	O
0	O
.	O
22	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
35	O
-	O
0	O
.	O
10	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
yet	O
effect	O
sizes	O
were	O
inversely	O
correlated	O
with	O
study	O
quality	O
(	O
correlation	O
coefficient	O
,	O
-	O
0	O
.	O
06	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
01	O
to	O
-	O
0	O
.	O
12	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

Meta	B-T062
-	I-T062
analyses	I-T062
of	O
21	O
interventions	O
fully	O
or	O
partially	O
recommended	O
their	O
use	O
,	O
with	O
recommendations	O
being	O
positively	B-T033
correlated	O
with	O
the	O
effect	O
sizes	O
of	O
the	O
pooled	O
intervention	O
.	O

However	O
,	O
the	O
effect	O
sizes	O
were	O
inversely	O
correlated	O
with	O
meta	B-T062
-	I-T062
analyzed	I-T062
study	I-T062
quality	O
,	O
reducing	O
confidence	B-T038
in	O
these	O
recommendations	O
.	O

Higher	O
-	O
quality	O
trials	O
and	O
patient	O
-	O
based	O
meta	B-T062
-	I-T062
analyses	I-T062
are	O
needed	O
to	O
determine	O
whether	O
subpopulations	B-T098
might	O
benefit	O
from	O
combination	B-T103
treatment	B-T058
,	O
as	O
no	O
single	O
strategy	O
can	O
be	O
recommended	O
for	O
patients	O
with	O
schizophrenia	B-T038
based	O
on	O
the	O
current	O
meta	B-T062
-	I-T062
analytic	I-T062
literature	B-T170
.	O

Involvement	O
Of	O
Vascular	B-T017
Aldosterone	B-T103
Synthase	I-T103
In	O
Phosphate	B-T103
-	O
Induced	O
Osteogenic	B-T033
Transformation	I-T033
Of	O
Vascular	B-T017
Smooth	B-T017
Muscle	I-T017
Cells	I-T017

Vascular	B-T038
calcification	I-T038
resulting	O
from	O
hyperphosphatemia	B-T038
is	O
a	O
major	O
determinant	O
of	O
mortality	O
in	O
chronic	B-T038
kidney	I-T038
disease	I-T038
(	O
CKD	B-T038
)	O
.	O

Vascular	B-T038
calcification	I-T038
is	O
driven	O
by	O
aldosterone	B-T103
-	O
sensitive	O
osteogenic	B-T033
transformation	I-T033
of	O
vascular	B-T017
smooth	B-T017
muscle	I-T017
cells	I-T017
(	O
VSMCs	B-T017
)	O
.	O

We	O
show	O
that	O
even	O
in	O
absence	O
of	O
exogenous	O
aldosterone	B-T103
,	O
silencing	B-T038
and	O
pharmacological	B-T038
inhibition	I-T038
(	O
spironolactone	B-T103
,	O
eplerenone	B-T103
)	O
of	O
the	O
mineralocorticoid	B-T103
receptor	I-T103
(	O
MR	B-T103
)	O
ameliorated	O
phosphate	B-T103
-	O
induced	O
osteo	B-T033
-	I-T033
/	O
chondrogenic	B-T033
transformation	I-T033
of	O
primary	O
human	B-T204
aortic	B-T017
smooth	B-T017
muscle	I-T017
cells	I-T017
(	O
HAoSMCs	B-T017
)	O
.	O

High	O
phosphate	B-T103
concentrations	O
up	B-T038
-	I-T038
regulated	I-T038
aldosterone	B-T103
synthase	I-T103
(	O
CYP11B2	B-T103
)	O
expression	B-T038
in	O
HAoSMCs	B-T017
.	O

Silencing	B-T038
and	O
deficiency	B-T038
of	O
CYP11B2	B-T103
in	O
VSMCs	B-T017
ameliorated	O
phosphate	B-T103
-	O
induced	O
osteogenic	O
reprogramming	O
and	O
calcification	B-T038
.	O

Phosphate	B-T103
treatment	O
was	O
followed	O
by	O
nuclear	B-T038
export	I-T038
of	O
APEX1	B-T103
,	O
a	O
CYP11B2	B-T017
transcriptional	B-T103
repressor	I-T103
.	O

APEX1	B-T103
silencing	B-T038
up	B-T038
-	I-T038
regulated	I-T038
CYP11B2	B-T017
expression	B-T038
and	O
stimulated	O
osteo	B-T033
-	I-T033
/	O
chondrogenic	B-T033
transformation	I-T033
.	O

APEX1	B-T103
overexpression	B-T038
blunted	O
the	O
phosphate	B-T103
-	O
induced	O
osteo	B-T033
-	I-T033
/	O
chondrogenic	B-T033
transformation	I-T033
and	O
calcification	B-T038
of	O
HAoSMCs	B-T017
.	O

Cyp11b2	B-T017
expression	B-T038
was	O
higher	O
in	O
aortic	B-T017
tissue	B-T017
of	O
hyperphosphatemic	B-T038
klotho	B-T204
-	I-T204
hypomorphic	I-T204
(	I-T204
kl	I-T204
/	I-T204
kl	I-T204
)	I-T204
mice	I-T204
than	O
in	O
wild	B-T017
-	I-T017
type	I-T017
mice	B-T204
.	O

In	O
adrenalectomized	B-T204
kl	I-T204
/	I-T204
kl	I-T204
mice	I-T204
,	O
spironolactone	B-T103
treatment	O
still	O
significantly	O
ameliorated	O
aortic	B-T017
osteoinductive	O
reprogramming	O
.	O

Our	O
findings	O
suggest	O
that	O
VSMCs	B-T017
express	O
aldosterone	B-T103
synthase	I-T103
,	O
which	O
is	O
up	B-T038
-	I-T038
regulated	I-T038
by	O
phosphate	B-T103
-	O
induced	O
disruption	O
of	O
APEX1	B-T103
-	O
dependent	O
gene	B-T038
suppression	I-T038
.	O

Vascular	B-T017
CYP11B2	B-T103
may	O
contribute	O
to	O
stimulation	O
of	O
VSMCs	B-T017
osteo	B-T033
-	I-T033
/	O
chondrogenic	B-T033
transformation	I-T033
during	O
hyperphosphatemia	B-T038
.	O

Fairness	O
:	O
the	O
hidden	O
challenge	B-T058
for	O
competency	O
-	O
based	O
postgraduate	O
medical	O
education	O
programs	O

Competency	O
-	O
based	O
medical	O
education	O
systems	O
allow	O
institutions	O
to	O
individualize	O
teaching	O
practices	O
to	O
meet	O
the	O
needs	O
of	O
diverse	B-T098
learners	I-T098
.	O

Yet	O
,	O
the	O
focus	O
on	O
continuous	O
improvement	O
and	O
individualization	O
of	O
curricula	B-T170
does	O
not	O
exempt	O
programs	O
from	O
treating	O
learners	B-T098
in	O
a	O
fair	B-T033
manner	I-T033
.	O

When	O
learners	B-T098
fail	O
to	O
meet	O
key	O
competencies	O
and	O
are	O
placed	O
on	O
probation	O
or	O
dismissed	O
from	O
training	O
programs	O
,	O
issues	B-T033
of	O
fairness	O
may	O
form	O
the	O
basis	O
of	O
their	O
legal	B-T170
claims	I-T170
.	O

In	O
a	O
literature	O
search	O
,	O
we	O
found	O
no	O
in	O
-	O
depth	O
examination	O
of	O
fairness	O
.	O

In	O
this	O
paper	O
,	O
we	O
utilize	O
a	O
systems	O
lens	O
to	O
examine	B-T033
fairness	O
within	O
postgraduate	O
medical	O
education	O
contexts	O
,	O
focusing	O
on	O
educational	B-T033
opportunities	I-T033
,	O
assessment	B-T058
practices	I-T058
,	O
decision	O
-	O
making	O
processes	O
,	O
fairness	O
from	O
a	O
legal	O
standpoint	O
,	O
and	O
fairness	O
in	O
the	O
context	O
of	O
the	O
learning	O
environment	O
.	O

While	O
we	O
provide	O
examples	O
of	O
fairness	O
issues	B-T033
within	O
US	B-T082
training	O
programs	O
,	O
concerns	O
regarding	O
fairness	O
are	O
relevant	O
in	O
any	O
medical	O
education	O
system	O
which	O
utilizes	O
a	O
competency	O
-	O
based	O
education	O
framework	O
.	O

Assessment	O
oversight	O
committees	B-T097
and	O
annual	O
programmatic	O
evaluations	O
,	O
while	O
recommended	O
,	O
will	O
not	O
guarantee	O
fairness	O
within	O
postgraduate	O
medical	O
education	O
programs	O
,	O
but	O
they	O
can	O
provide	O
a	O
window	O
into	O
'	O
hidden	O
'	O
threats	O
to	O
fairness	O
,	O
as	O
everything	O
from	O
training	O
experiences	O
to	O
assessment	B-T058
practices	I-T058
may	O
be	O
examined	B-T033
by	O
these	O
committees	B-T097
.	O

One	O
of	O
the	O
first	O
steps	O
programs	O
can	O
take	O
is	O
to	O
recognize	O
that	O
threats	O
to	O
fairness	O
may	O
exist	O
in	O
any	O
educational	O
program	O
,	O
including	O
their	O
own	O
,	O
and	O
begin	O
conversations	O
about	O
how	O
to	O
address	O
these	O
issues	B-T033
.	O

Us3	B-T103
and	O
Us9	B-T103
proteins	B-T103
contribute	O
to	O
the	O
stromal	B-T033
invasion	I-T033
of	O
bovine	B-T005
herpesvirus	I-T005
1	I-T005
in	O
the	O
respiratory	B-T017
mucosa	I-T017

Bovine	O
herpesvirus	O
1	O
(	O
BHV	O
-	O
1	O
)	O
infection	O
may	O
lead	O
to	O
conjunctivitis	B-T038
,	O
upper	B-T017
respiratory	I-T017
tract	I-T017
problems	B-T033
,	O
pneumonia	B-T038
,	O
genital	B-T038
disorders	I-T038
and	O
abortion	B-T033
.	O

BHV	B-T005
-	I-T005
1	I-T005
is	O
able	O
to	O
spread	O
quickly	O
in	O
a	O
plaque	B-T033
-	O
wise	O
manner	O
and	O
invade	O
by	O
breaching	B-T037
the	O
basement	B-T017
membrane	I-T017
(	B-T017
BM	I-T017
)	I-T017
barrier	O
in	O
the	O
respiratory	B-T017
mucosa	I-T017
.	O

BHV	B-T005
-	I-T005
1	I-T005
Us3	B-T103
,	O
a	O
serine	B-T103
/	I-T103
threonine	I-T103
kinase	I-T103
,	O
induces	O
a	O
dramatic	O
cytoskeletal	B-T038
reorganization	I-T038
and	O
BHV	B-T005
-	I-T005
1	I-T005
Us9	B-T103
,	O
a	O
tail	B-T103
-	I-T103
anchored	I-T103
membrane	I-T103
protein	I-T103
,	O
is	O
required	O
for	O
axonal	B-T038
transport	I-T038
of	O
viruses	B-T005
in	O
neurons	B-T017
.	O

In	O
this	O
study	B-T062
,	O
we	O
investigated	O
the	O
role	O
of	O
Us3	B-T103
and	O
Us9	B-T103
during	O
BHV	O
-	O
1	O
infection	O
in	O
the	O
respiratory	B-T017
mucosa	I-T017
.	O

First	O
,	O
we	O
constructed	O
and	O
characterized	O
BHV	B-T005
-	I-T005
1	I-T005
Us3	B-T017
null	B-T005
,	O
Us9	B-T017
null	B-T005
and	O
revertant	B-T005
viruses	I-T005
.	O

Then	O
,	O
we	O
analysed	B-T062
the	O
viral	B-T038
replication	I-T038
and	O
plaque	B-T033
size	B-T082
(	O
latitude	O
)	O
in	O
Madin	B-T017
-	I-T017
Darby	I-T017
bovine	I-T017
kidney	I-T017
(	O
MDBK	B-T017
)	O
cells	B-T017
and	O
the	O
respiratory	B-T017
mucosa	I-T017
as	O
well	O
as	O
viral	B-T038
penetration	I-T038
depth	O
underneath	O
the	O
BM	B-T017
of	O
the	O
respiratory	B-T017
mucosa	I-T017
when	O
inoculated	B-T058
with	O
these	O
recombinant	B-T005
viruses	I-T005
.	O

Knockout	B-T038
of	O
Us3	B-T017
resulted	O
in	O
a	O
1	O
log10	O
reduction	O
in	O
viral	O
titre	O
and	O
plaque	B-T033
size	B-T082
(	O
latitude	O
)	O
in	O
MDBK	B-T017
cells	I-T017
and	O
the	O
trachea	B-T017
mucosa	I-T017
.	O

There	O
were	O
no	B-T033
defects	O
in	O
the	O
cell	B-T038
-	I-T038
to	I-T038
-	I-T038
cell	I-T038
spread	I-T038
observed	O
for	O
BHV	B-T005
-	I-T005
1	I-T005
Us9	B-T017
null	B-T005
virus	I-T005
.	O

Both	O
BHV	B-T005
-	I-T005
1	I-T005
Us3	B-T017
null	B-T005
and	O
Us9	B-T017
null	B-T005
viruses	I-T005
showed	O
a	O
significant	O
reduction	O
of	O
plaque	B-T033
penetration	O
underneath	O
the	O
BM	B-T017
;	O
however	O
,	O
penetration	O
was	O
not	O
completely	O
inhibited	O
.	O

In	O
conclusion	O
,	O
the	O
current	O
findings	B-T062
demonstrated	O
that	O
Us3	B-T017
and	O
Us9	B-T017
play	O
an	O
important	O
role	O
in	O
the	O
invasion	B-T033
of	O
BHV	B-T005
-	I-T005
1	I-T005
through	O
the	O
BM	B-T017
of	O
the	O
respiratory	B-T017
mucosa	I-T017
,	O
which	O
shows	O
the	O
way	O
forward	O
for	O
research	B-T062
-	O
based	O
attenuation	O
of	O
viruses	B-T005
in	O
order	O
to	O
make	O
safer	O
and	O
better	O
-	O
performing	O
vaccines	B-T103
.	O

Traumatic	B-T037
Brain	I-T037
Injury	I-T037
and	O
Depression	B-T038
in	O
a	O
Community	O
-	O
Based	O
Sample	O
:	O
A	O
Cohort	O
Study	O
Across	O
the	O
Adult	O
Life	O
Span	O

To	O
determine	O
whether	O
self	O
-	O
reported	O
traumatic	B-T037
brain	I-T037
injuries	I-T037
(	O
TBIs	B-T037
)	O
are	O
associated	O
with	O
"	O
cases	O
"	O
of	O
clinically	B-T033
significant	I-T033
depression	B-T038
in	O
the	O
general	O
community	O
.	O

To	O
examine	O
interactions	O
between	O
variables	O
previously	O
linked	O
to	O
depression	B-T038
after	O
a	O
TBI	B-T037
.	O

Population	B-T098
-	O
based	O
community	O
study	B-T062
(	O
Canberra	B-T082
and	O
Queanbeyan	O
,	O
Australia	B-T082
)	O
.	O

Three	O
age	B-T098
cohorts	I-T098
:	O
young	O
,	O
middle	O
-	O
aged	O
,	O
and	O
older	B-T098
adults	O
(	O
aged	O
20	O
-	O
24	O
,	O
40	O
-	O
44	O
,	O
and	O
60	O
-	O
64	O
years	O
at	O
baseline	O
)	O
randomly	O
selected	O
from	O
the	O
electoral	O
roll	O
and	O
followed	O
across	O
3	O
waves	O
(	O
4	O
years	O
apart	O
)	O
.	O

A	O
total	O
of	O
7397	O
,	O
6621	O
,	O
and	O
6042	O
people	B-T098
provided	O
their	O
TBI	B-T037
history	O
in	O
waves	O
1	O
to	O
3	O
.	O

Lifetime	O
(	O
TBIlifetime	O
:	O
sustained	O
at	O
any	O
time	O
since	O
birth	B-T038
)	O
,	O
recent	O
(	O
TBIrecent	O
:	O
in	O
the	O
preceding	O
4	O
years	O
)	O
,	O
and	O
multiple	O
(	O
TBImultiple	O
:	O
more	O
than	O
1	O
)	O
TBIs	B-T037
,	O
current	O
depression	B-T038
,	O
and	O
known	O
risk	B-T033
factors	I-T033
for	O
depression	B-T038
(	O
age	O
,	O
sex	O
,	O
marital	O
/	O
employment	B-T033
status	I-T033
,	O
prior	O
history	O
of	O
depression	B-T038
,	O
medical	B-T033
conditions	I-T033
,	O
recent	O
life	O
events	O
,	O
alcohol	O
consumption	O
,	O
social	O
support	O
,	O
physical	O
activity	O
)	O
.	O

Generalized	O
estimating	O
equations	O
demonstrated	O
a	O
significant	O
association	O
between	O
sustaining	O
a	O
TBI	B-T037
and	O
experiencing	O
clinically	B-T033
significant	I-T033
depression	B-T038
(	O
cases	O
)	O
,	O
even	O
after	O
controlling	O
for	O
multiple	O
demographic	O
and	O
health	O
/	O
lifestyle	O
factors	O
.	O

There	O
is	O
an	O
enduring	O
association	O
between	O
depression	B-T038
and	O
TBI	B-T037
,	O
suggesting	O
that	O
,	O
following	O
a	O
TBI	B-T037
,	O
individuals	B-T098
should	O
be	O
monitored	B-T097
and	O
supported	O
to	O
optimize	O
their	O
long	O
-	O
term	O
psychological	B-T038
health	I-T038
.	O

CS	B-T103
-	O
PEG	B-T103
decorated	O
PLGA	B-T103
nano	I-T103
-	I-T103
prototype	I-T103
for	O
delivery	O
of	O
bioactive	B-T103
compounds	I-T103
:	O
A	O
novel	O
approach	B-T082
for	O
induction	O
of	O
apoptosis	B-T038
in	O
HepG2	B-T017
cell	I-T017
line	I-T017

Polymer	B-T103
-	O
based	O
nanoparticles	O
are	O
used	O
as	O
vectors	B-T082
for	O
cancer	B-T038
drug	O
delivery	O
.	O

The	O
bioactive	B-T103
compounds	I-T103
(	O
quercetin	B-T103
,	O
ellagic	B-T103
acid	I-T103
and	O
gallic	B-T103
acid	I-T103
)	O
are	O
well	O
known	O
to	O
be	O
not	O
only	O
antioxidants	B-T103
but	O
also	O
chemopreventive	B-T103
candidates	I-T103
against	O
various	O
types	O
of	O
cancers	B-T038
.	O

To	O
circumvent	O
the	O
low	O
bioavailability	O
and	O
the	O
short	O
half	O
-	O
life	O
time	O
obstacles	O
,	O
we	O
hypothesized	O
a	O
novel	O
PLGA	B-T103
nano	I-T103
-	I-T103
platform	I-T103
functionalized	O
with	O
CS	B-T103
and	O
PEG	B-T103
to	O
encapsulate	O
these	O
phytochemicals	B-T103
.	O

This	O
encapsulation	O
will	O
protect	O
the	O
compounds	B-T103
from	O
the	O
phagocytic	B-T038
uptake	I-T038
and	O
deliver	O
PLGA	B-T103
-	I-T103
CS	I-T103
-	I-T103
PEG	I-T103
nano	I-T103
-	I-T103
prototype	I-T103
with	O
high	O
biodegradability	O
and	O
biosafety	O
.	O

Three	O
consequent	O
types	O
of	O
PLGA	B-T103
-	I-T103
based	I-T103
nanocomposites	I-T103
were	O
prepared	O
and	O
characterized	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
newly	O
synthesized	O
nano	O
-	O
formulations	O
against	O
human	B-T204
hepatocellular	B-T038
carcinoma	I-T038
(	O
HepG2	B-T017
)	O
and	O
colorectal	B-T038
cancer	I-T038
(	O
HCT	B-T017
116	I-T017
)	O
cell	B-T017
lines	I-T017
using	O
cell	B-T038
growth	I-T038
inhibition	I-T038
assays	B-T058
,	O
followed	O
by	O
apoptosis	B-T038
and	O
necrosis	B-T038
assays	B-T058
using	O
flow	B-T058
cytometry	I-T058
to	O
detect	B-T058
the	O
underlying	O
mechanism	O
of	O
HepG2	B-T017
cell	B-T038
death	I-T038
.	O

Through	O
Malvern	O
Zeta	O
Sizer	O
,	O
we	O
recorded	O
that	O
the	O
average	O
diameters	O
of	O
the	O
nano	O
-	O
prototypes	O
ranged	O
from	O
150	O
to	O
300nm	O
.	O

The	O
cytotoxic	B-T058
activity	I-T058
of	O
quercetin	B-T103
,	O
ellagic	B-T103
acid	I-T103
,	O
and	O
gallic	B-T103
acid	I-T103
-	O
encapsulated	O
PLGA	B-T103
,	O
PLGA	B-T103
-	I-T103
CS	I-T103
,	O
and	O
PLGA	B-T103
-	I-T103
CS	I-T103
-	I-T103
PEG	I-T103
nano	I-T103
-	I-T103
prototypes	I-T103
it	O
has	O
been	O
found	B-T033
that	O
they	O
reduce	O
the	O
IC50s	O
of	O
the	O
HepG2	B-T017
cells	I-T017
values	O
by	O
2	O
.	O
2	O
,	O
2	O
.	O
9	O
,	O
2	O
.	O
8	O
-	O
folds	O
,	O
1	O
,	O
1	O
.	O
5	O
,	O
2	O
.	O
7	O
-	O
folds	O
,	O
and	O
0	O
.	O
9	O
,	O
0	O
.	O
7	O
,	O
1	O
.	O
5	O
-	O
folds	O
,	O
respectively	O
.	O

Mechanistically	O
,	O
the	O
nano	O
-	O
platforms	O
of	O
quercetin	B-T103
seem	O
to	O
be	O
dependent	O
on	O
both	O
apoptosis	B-T038
and	O
necrosis	B-T038
,	O
while	O
those	O
of	O
ellagic	B-T103
acid	I-T103
and	O
gallic	B-T103
acid	I-T103
are	O
mainly	O
dependent	O
on	O
apoptosis	B-T038
.	O

CS	B-T103
-	O
PEG	B-T103
-	O
blended	O
PLGA	B-T103
nano	O
-	O
delivery	O
system	O
of	O
quercetin	B-T103
,	O
ellagic	B-T103
acid	I-T103
and	O
gallic	B-T103
acid	I-T103
can	O
potentiate	O
apoptosis	B-T038
-	I-T038
mediated	I-T038
cell	B-T038
death	I-T038
in	O
HepG2	B-T017
cell	I-T017
line	I-T017
.	O

Fingerprint	O
-	O
based	O
background	B-T033
checks	I-T033
for	O
personal	B-T097
care	I-T097
workers	I-T097
:	O
Stakeholder	B-T098
views	O
of	O
policy	B-T170
criteria	O

Decision	B-T098
makers	I-T098
face	O
difficult	O
choices	O
when	O
tasked	O
with	O
identifying	O
and	O
implementing	O
appropriate	O
mechanisms	O
for	O
protecting	B-T033
the	O
elderly	B-T098
and	O
other	O
vulnerable	B-T033
adults	I-T033
from	O
abuse	O
.	O

A	O
pilot	B-T062
project	I-T062
involving	O
fingerprint	O
-	O
based	O
criminal	B-T098
history	O
background	B-T033
checks	I-T033
for	O
personal	B-T097
care	I-T097
workers	I-T097
in	O
Michigan	O
has	O
supplied	O
an	O
opportunity	O
to	O
examine	O
one	O
such	O
mechanism	O
.	O

In	O
conjunction	O
with	O
the	O
pilot	B-T062
project	I-T062
,	O
we	O
have	O
conducted	O
a	O
stakeholder	B-T097
analysis	B-T062
with	O
the	O
aim	O
of	O
informing	O
decision	B-T098
makers	I-T098
about	O
stakeholder	B-T098
perceptions	B-T038
of	O
standard	O
policy	B-T170
criteria	O
like	O
effectiveness	O
,	O
efficiency	O
,	O
and	O
equity	O
.	O

We	O
employed	O
focus	O
groups	O
and	O
a	O
web	B-T170
-	I-T170
based	I-T170
survey	I-T170
to	O
collect	B-T062
data	O
from	O
stakeholders	B-T098
.	O

While	O
stakeholders	B-T098
generally	O
see	O
fingerprint	O
-	O
based	O
background	B-T033
checks	I-T033
for	O
personal	B-T097
care	I-T097
workers	I-T097
as	O
potentially	O
effective	O
and	O
as	O
a	O
net	O
benefit	O
,	O
they	O
also	O
point	O
to	O
a	O
variety	O
of	O
contingencies	O
.	O

They	O
also	O
recognize	O
difficulties	B-T033
and	O
constraints	O
for	O
government	B-T092
involvement	O
.	O

This	O
preliminary	B-T062
analysis	I-T062
provides	O
solid	O
foundational	O
information	O
for	O
decision	B-T098
makers	I-T098
and	O
for	O
more	O
extensive	O
benefit	O
-	O
cost	O
analysis	O
.	O

Penetrating	O
Craniomaxillofacial	B-T037
Injury	I-T037
Caused	I-T037
by	I-T037
a	I-T037
Pneumatic	I-T037
Nail	I-T037
Gun	I-T037

Craniomaxillofacial	O
injuries	O
can	O
be	O
complex	O
,	O
requiring	O
a	O
multidisciplinary	O
approach	O
.	O

The	O
primary	O
survey	O
is	O
always	O
the	O
first	O
step	O
in	O
trauma	O
management	O
prior	O
to	O
proceeding	O
with	O
further	O
evaluation	O
and	O
treatment	O
.	O

A	O
26	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
a	O
penetrating	O
nail	O
gun	O
injury	O
through	O
the	O
oral	B-T082
and	O
nasal	B-T082
cavities	I-T082
.	O

He	O
did	O
not	O
present	O
in	O
extremis	O
but	O
required	O
elective	O
endotracheal	O
intubation	O
for	O
intraoperative	O
assessment	O
and	O
treatment	O
.	O

Airway	O
management	O
was	O
enhanced	O
by	O
the	O
use	O
of	O
lingual	B-T058
nerve	I-T058
and	O
inferior	B-T058
alveolar	I-T058
nerve	I-T058
blocks	I-T058
via	O
the	O
Vazirani	O
-	O
Akinosi	O
technique	O
to	O
maintain	O
spontaneous	B-T033
respiration	I-T033
while	O
the	O
tongue	B-T017
was	O
distracted	B-T033
from	O
the	O
palate	B-T017
.	O

The	O
nail	O
was	O
removed	O
and	O
rapid	O
sequence	O
induction	O
initiated	O
for	O
orotracheal	O
intubation	O
.	O

Local	O
nerve	O
blocks	O
can	O
be	O
an	O
effective	O
tool	O
in	O
the	O
armamentarium	O
of	O
the	O
craniomaxillofacial	O
trauma	O
surgeon	O
in	O
managing	O
blunt	O
and	O
penetrating	O
injuries	O
.	O

We	O
demonstrate	O
its	O
utility	O
in	O
airway	O
management	O
when	O
a	O
penetrating	O
foreign	O
body	O
in	O
the	O
upper	B-T017
airway	I-T017
precludes	O
orotracheal	O
or	O
nasotracheal	O
intubation	O
.	O

Design	O
of	O
a	O
candidate	O
vibrational	O
signal	O
for	O
mating	B-T038
disruption	O
against	O
the	O
glassy	B-T204
-	I-T204
winged	I-T204
sharpshooter	I-T204
,	O
Homalodisca	B-T204
vitripennis	I-T204

The	O
glassy	B-T204
-	I-T204
winged	I-T204
sharpshooter	I-T204
(	O
GWSS	B-T204
)	O
,	O
Homalodisca	B-T204
vitripennis	I-T204
,	O
is	O
an	O
important	O
pest	B-T204
of	O
grapevines	B-T204
due	O
to	O
its	O
ability	O
to	O
transmit	O
Xylella	B-T007
fastidiosa	I-T007
,	O
the	O
causal	O
agent	O
of	O
Pierce	B-T038
'	I-T038
s	I-T038
disease	I-T038
.	O

GWSS	B-T204
mating	B-T038
communication	O
is	O
based	O
on	O
vibrational	O
signals	O
;	O
therefore	O
,	O
vibrational	O
mating	B-T038
disruption	O
could	O
be	O
an	O
alternative	O
to	O
insecticides	B-T103
for	O
suppression	O
of	O
GWSS	B-T204
population	B-T098
.	O

Our	O
objectives	B-T170
were	O
to	O
identify	O
spectral	O
features	O
of	O
female	O
signal	O
that	O
elicit	O
male	O
signaling	B-T038
,	O
design	O
disruptive	O
signals	O
able	O
to	O
alter	O
male	O
perception	B-T038
and	O
acceptance	O
of	O
a	O
female	O
,	O
and	O
determine	O
the	O
signal	O
intensity	O
required	O
for	O
future	O
field	O
applications	O
.	O

Results	O
showed	O
that	O
male	O
responses	O
to	O
playback	O
of	O
modified	O
female	O
signals	O
were	O
significantly	O
reduced	O
by	O
60	O
-	O
75	O
%	O
when	O
part	O
of	O
the	O
female	O
signal	O
spectral	O
components	O
above	O
or	O
below	O
400	O
Hz	O
were	O
deleted	O
.	O

Playback	O
bioassays	B-T058
showed	O
that	O
transmission	O
of	O
an	O
80	O
Hz	O
pure	O
frequency	O
tone	O
to	O
plants	B-T204
completely	O
suppressed	O
male	O
signaling	B-T038
to	O
female	O
signal	O
playback	O
,	O
even	O
if	O
the	O
disruptive	O
signal	B-T082
amplitude	I-T082
was	O
10	O
dB	O
lower	O
than	O
the	O
female	O
signal	O
playback	O
.	O

Although	O
the	O
mechanism	O
underlying	O
cessation	O
of	O
male	O
signaling	B-T038
activity	O
in	O
the	O
presence	B-T033
of	O
disruption	O
is	O
not	O
yet	O
understood	O
,	O
results	O
suggest	O
that	O
an	O
80	O
Hz	O
vibrational	O
signal	O
should	O
be	O
tested	O
in	O
laboratory	B-T092
and	O
field	O
experiments	O
to	O
assess	O
its	O
efficacy	O
in	O
disrupting	O
mating	B-T038
of	O
GWSS	B-T204
.	O

Barriers	O
and	O
facilitators	O
to	O
smoking	O
cessation	O
in	O
a	O
cancer	B-T038
context	O
:	O
A	O
qualitative	B-T062
study	I-T062
of	O
patient	O
,	O
family	O
and	O
professional	B-T097
views	O

Continued	O
smoking	O
after	O
cancer	B-T038
adversely	B-T038
affects	I-T038
quality	B-T033
of	I-T033
life	I-T033
and	O
survival	O
,	O
but	O
one	O
fifth	O
of	O
cancer	B-T038
survivors	O
still	O
smoke	O
.	O

Despite	O
its	O
demands	O
,	O
cancer	B-T038
presents	O
an	O
opportunity	O
for	O
positive	B-T033
behaviour	O
change	O
.	O

Smoking	O
often	O
occurs	O
in	O
social	B-T098
groups	I-T098
,	O
therefore	O
interventions	B-T058
which	O
target	O
families	O
and	O
individuals	B-T098
may	O
be	O
more	O
successful	O
.	O

This	O
qualitative	B-T062
study	I-T062
explored	O
patients	O
,	O
family	O
members	O
and	O
health	B-T097
professionals	I-T097
'	O
views	O
and	O
experiences	B-T038
of	O
smoking	O
and	O
smoking	O
cessation	O
after	O
cancer	B-T038
,	O
in	O
order	O
to	O
inform	O
future	O
interventions	B-T058
.	O

In	O
-	O
depth	O
qualitative	O
interviews	O
(	O
n	O
=	O
67	O
)	O
with	O
29	O
patients	O
,	O
14	O
family	O
members	O
and	O
24	O
health	B-T097
professionals	I-T097
.	O

Data	O
were	O
analysed	O
using	O
the	O
'	O
Framework	O
'	O
method	O
.	O

Few	O
patient	O
s	O
and	O
family	O
members	O
had	O
used	O
National	B-T058
Health	I-T058
Service	I-T058
(	O
NHS	B-T058
)	O
smoking	O
cessation	O
services	B-T058
and	O
more	O
than	O
half	O
still	O
smoked	O
.	O

Most	O
recalled	O
little	O
'	O
smoking	O
-	O
related	O
'	O
discussion	B-T058
with	O
clinicians	B-T097
but	O
were	O
receptive	O
to	O
talking	O
openly	O
.	O

Clinicians	B-T097
revealed	O
several	O
barriers	O
to	O
discussion	B-T058
.	O

Participants	B-T098
'	O
continued	O
smoking	O
was	O
explained	O
by	O
the	O
stress	B-T033
of	O
diagnosis	B-T058
;	O
desire	O
to	O
maintain	O
personal	O
control	O
;	O
and	O
lack	O
of	O
connection	O
between	O
smoking	O
,	O
cancer	B-T038
and	O
health	O
.	O

A	O
range	O
of	O
barriers	O
to	O
smoking	O
cessation	O
exist	O
for	O
patients	O
and	O
family	O
members	O
.	O

These	O
are	O
insufficiently	O
assessed	O
and	O
considered	O
by	O
clinicians	B-T097
.	O

Interventions	B-T058
must	O
be	O
more	O
effectively	O
integrated	O
into	O
routine	O
practice	O
.	O

Improving	O
the	O
Sexual	O
Health	O
of	O
Young	O
People	O
With	O
Mobility	B-T033
Impairments	I-T033
:	O
Challenges	B-T058
and	O
Recommendations	O

This	O
mixed	B-T062
-	I-T062
method	I-T062
study	I-T062
(	O
a	O
)	O
describes	O
challenges	B-T058
to	O
providing	O
sexual	O
health	O
services	B-T058
to	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
from	O
the	O
perspective	B-T082
of	O
health	B-T097
care	I-T097
providers	I-T097
and	O
experts	B-T097
and	O
(	O
b	O
)	O
describes	O
and	O
compares	O
sexual	O
health	O
-	O
related	O
experiences	B-T038
of	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
.	O

Secondary	O
data	O
analysis	O
of	O
My	O
Path	O
,	O
a	O
study	B-T062
focused	O
on	O
the	O
transition	O
to	O
adulthood	O
for	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
.	O

Using	O
an	O
exploratory	B-T062
sequential	I-T062
design	I-T062
,	O
qualitative	O
data	O
(	O
n	O
=	O
10	O
)	O
were	O
analyzed	B-T062
using	O
systematic	O
content	O
analysis	O
followed	O
by	O
quantitative	O
analysis	O
of	O
survey	O
data	O
(	O
N	O
=	O
337	O
)	O
.	O

Challenges	B-T058
included	O
not	O
talking	O
about	O
sex	O
,	O
managing	O
sexual	B-T038
development	I-T038
,	O
adaptation	B-T038
and	O
instruction	B-T170
,	O
parent	O
roles	O
,	O
and	O
safety	O
.	O

Survey	B-T170
data	O
showed	O
that	O
youth	O
with	O
mobility	B-T033
impairments	I-T033
are	O
diverse	O
in	O
their	O
experiences	B-T038
with	O
sexual	O
behavior	O
and	O
sources	B-T033
of	O
sexual	O
health	O
information	O
.	O

Although	O
connected	O
with	O
primary	B-T097
care	I-T097
providers	I-T097
,	O
few	O
received	O
information	O
about	O
sexual	O
health	O
.	O

Interventions	B-T058
to	O
improve	B-T033
youths	O
'	O
well	O
-	O
being	O
should	O
include	O
comprehensive	B-T058
care	I-T058
and	O
education	O
that	O
promotes	O
and	O
supports	O
healthy	O
sexual	B-T038
development	I-T038
.	O

Understanding	B-T038
the	O
interrelationship	O
between	O
the	O
synthesis	B-T038
of	O
urea	B-T103
and	O
gluconeogenesis	B-T038
by	O
formulating	O
an	O
overall	O
balanced	O
equation	O

It	O
is	O
well	O
known	O
that	O
a	O
strong	O
metabolic	O
interrelationship	O
exists	O
between	O
ureagenesis	B-T038
and	O
gluconeogenesis	B-T038
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
a	O
detailed	O
,	O
overall	O
equation	O
,	O
describing	O
a	O
possible	O
metabolic	O
link	B-T082
between	O
ureagenesis	B-T038
and	O
gluconeogenesis	B-T038
.	O

We	O
adopted	O
a	O
guided	B-T082
approach	I-T082
in	O
which	O
we	O
strongly	O
suggest	O
that	O
students	B-T098
,	O
when	O
faced	O
with	O
the	O
problem	B-T033
of	O
obtaining	O
the	O
overall	O
equation	O
of	O
a	O
metabolic	O
pathway	O
,	O
carefully	O
account	O
for	O
all	O
atoms	B-T103
and	O
charges	O
of	O
the	O
single	O
reactions	O
,	O
as	O
well	O
as	O
the	O
cellular	B-T038
localizations	I-T038
of	O
the	O
substrates	O
,	O
and	O
the	O
related	O
transport	B-T038
systems	O
.	O

If	O
this	O
suggestion	O
is	O
always	O
taken	O
into	O
account	O
,	O
a	O
balanced	O
,	O
overall	O
equation	O
of	O
a	O
metabolic	O
pathway	O
will	O
be	O
obtained	O
,	O
which	O
strongly	O
facilitates	O
the	O
discussion	O
of	O
its	O
physiological	O
role	O
.	O

Unfortunately	O
,	O
textbooks	B-T170
often	O
report	B-T170
unbalanced	O
overall	O
equations	O
of	O
metabolic	O
pathways	O
,	O
including	O
ureagenesis	B-T038
and	O
gluconeogenesis	B-T038
.	O

Most	O
likely	O
the	O
reason	O
is	O
that	O
metabolism	B-T038
and	O
enzymology	O
have	O
been	O
neglected	O
for	O
about	O
three	O
decades	O
,	O
owing	O
to	O
the	O
remarkable	O
advances	O
of	O
molecular	B-T091
biology	I-T091
and	O
molecular	B-T091
genetics	I-T091
.	O

In	O
this	O
paper	B-T170
,	O
we	O
strongly	O
suggest	O
that	O
students	B-T098
,	O
when	O
faced	O
with	O
the	O
problem	O
of	O
obtaining	O
the	O
overall	O
reaction	O
of	O
a	O
metabolic	O
pathway	O
,	O
carefully	O
control	O
if	O
the	O
single	O
reactions	O
are	O
properly	O
balanced	O
for	O
atoms	B-T103
and	O
charges	O
.	O

Following	O
this	O
suggestion	O
,	O
we	O
were	O
able	O
to	O
obtain	O
an	O
overall	O
equation	O
describing	O
the	O
metabolic	O
interrelationship	O
between	O
ureagenesis	B-T038
and	O
gluconeogenesis	B-T038
,	O
in	O
which	O
urea	B-T103
and	O
glucose	B-T103
are	O
the	O
final	O
products	O
.	O

The	O
aim	O
is	O
to	O
better	O
rationalize	O
this	O
topic	O
and	O
to	O
convince	O
students	B-T098
and	O
teachers	B-T097
that	O
metabolism	B-T038
is	O
an	O
important	O
and	O
rewarding	O
chapter	O
of	O
human	O
physiology	O
.	O

Delineation	O
of	O
B	B-T017
-	I-T017
cell	I-T017
Epitopes	B-T103
of	O
Salmonella	B-T007
enterica	I-T007
serovar	I-T007
Typhi	I-T007
Hemolysin	B-T103
E	I-T103
:	O
Potential	O
antibody	B-T103
therapeutic	B-T058
target	O

Hemolysin	B-T103
E	I-T103
(	O
HlyE	B-T103
)	O
is	O
an	O
immunogenic	O
novel	O
pore	B-T017
-	O
forming	O
toxin	B-T103
involved	O
in	O
the	O
pathogenesis	B-T038
of	O
typhoid	B-T038
fever	I-T038
.	O

Thus	O
,	O
mapping	O
of	O
B	B-T017
-	I-T017
cell	I-T017
epitopes	B-T103
of	O
Salmonella	B-T007
enterica	I-T007
serovar	I-T007
Typhi	I-T007
(	O
S	B-T007
.	I-T007

Typhi	I-T007
)	O
is	O
critical	O
to	O
identify	O
key	O
immunogenic	O
regions	O
of	O
HlyE	B-T103
.	O

A	O
random	O
20	O
-	O
mer	O
peptide	B-T103
library	I-T103
was	O
used	O
for	O
biopanning	O
with	O
enriched	O
anti	B-T103
-	I-T103
HlyE	I-T103
polyclonal	I-T103
antibodies	I-T103
from	O
typhoid	B-T038
patient	O
sera	B-T031
.	O

Bioinformatic	B-T091
tools	B-T170
were	O
used	O
to	O
refine	O
,	O
analyze	B-T062
and	O
map	O
the	O
enriched	O
peptide	O
sequences	O
against	O
the	O
protein	B-T103
to	O
identify	O
the	O
epitopes	B-T103
.	O

The	O
analysis	B-T062
identified	O
both	O
linear	B-T082
and	O
conformational	O
epitopes	B-T103
on	O
the	O
HlyE	B-T103
protein	I-T103
.	O

The	O
predicted	O
linear	B-T082
GAAAGIVAG	B-T082
and	O
conformational	O
epitope	B-T103
PYSQESVLSADSQNQK	B-T082
were	O
further	O
validated	O
against	O
the	O
pooled	O
sera	B-T031
.	O

The	O
identified	O
epitopes	B-T103
were	O
then	O
used	O
to	O
isolate	B-T058
epitope	B-T103
specific	O
monoclonal	B-T103
antibodies	I-T103
by	O
antibody	B-T103
phage	B-T062
display	I-T062
.	O

Monoclonal	B-T103
scFv	I-T103
antibodies	B-T103
were	O
enriched	O
for	O
both	O
linear	B-T082
and	O
conformational	O
epitopes	B-T103
.	O

Molecular	B-T170
docking	I-T170
was	O
performed	O
to	O
elucidate	O
the	O
antigen	B-T038
-	I-T038
antibody	I-T038
interaction	I-T038
of	O
the	O
monoclonal	B-T103
antibodies	I-T103
against	O
the	O
epitopes	B-T103
on	O
the	O
HlyE	B-T103
monomer	B-T103
and	O
oligomer	O
structure	O
.	O

An	O
in	O
-	O
depth	O
view	O
of	O
the	O
mechanistic	O
and	O
positional	O
characteristics	O
of	O
the	O
antibodies	B-T103
and	O
epitope	B-T103
for	O
HlyE	B-T103
was	O
successfully	O
accomplished	O
by	O
a	O
combination	O
of	O
phage	B-T062
display	I-T062
and	O
bioinformatic	B-T091
analysis	B-T062
.	O

The	O
predicted	O
function	O
and	O
structure	B-T082
of	O
the	O
antibodies	B-T103
highlights	O
the	O
possibility	O
of	O
utilizing	O
the	O
antibodies	B-T103
as	O
neutralizing	B-T103
agents	I-T103
for	O
typhoid	B-T038
fever	I-T038
.	O

Comparison	O
of	O
electrospun	O
and	O
solvent	O
cast	O
polylactic	B-T103
acid	I-T103
(	O
PLA	B-T103
)	O
/	O
poly	B-T103
(	I-T103
vinyl	I-T103
alcohol	I-T103
)	I-T103
(	O
PVA	B-T103
)	O
inserts	B-T103
as	O
potential	O
ocular	B-T017
drug	B-T103
delivery	I-T103
vehicles	I-T103

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
develop	O
,	O
characterize	O
and	O
compare	O
electrospun	O
nanofiber	O
inserts	B-T103
(	O
ENIs	O
)	O
and	O
solvent	O
cast	O
polymeric	B-T103
inserts	B-T103
(	O
SCIs	B-T103
)	O
for	O
ocular	B-T017
drug	B-T074
delivery	I-T074
.	O

ENI	O
and	O
SCI	B-T103
of	O
1	O
%	O
,	O
5	O
%	O
and	O
10	O
%	O
w	O
/	O
w	O
dexamethasone	B-T103
were	O
fabricated	O
using	O
a	O
blend	O
of	O
poly	B-T103
-	I-T103
lactic	I-T103
acid	I-T103
(	O
PLA	B-T103
)	O
and	O
poly	B-T103
-	I-T103
vinyl	I-T103
alcohol	I-T103
(	O
PVA	B-T103
)	O
.	O

Inserts	B-T103
were	O
characterized	O
for	O
morphology	O
,	O
thickness	O
,	O
pH	O
,	O
drug	O
content	O
,	O
drug	O
crystallinity	O
,	O
in	O
vitro	O
drug	O
release	O
,	O
sterility	O
,	O
dimethylformamide	B-T103
(	O
DMF	B-T103
)	O
and	O
chloroform	B-T103
content	O
,	O
and	O
cytotoxicity	B-T038
.	O

The	O
thickness	O
of	O
1	O
%	O
,	O
5	O
%	O
,	O
and	O
10	O
%	O
dexamethasone	B-T103
-	O
loaded	O
ENIs	O
were	O
found	O
to	O
be	O
50μm	O
,	O
62	O
.	O
5μm	O
,	O
and	O
93	O
.	O
3μm	O
,	O
respectively	O
,	O
with	O
good	O
folding	B-T033
endurance	I-T033
.	O

SCIs	B-T103
were	O
brittle	B-T033
,	O
with	O
thickness	O
values	O
>	O
200μm	O
.	O

Drug	O
release	O
rates	O
from	O
1	O
%	O
,	O
5	O
%	O
and	O
10	O
%	O
ENIs	O
were	O
found	O
to	O
be	O
0	O
.	O
62μg	O
/	O
h	O
,	O
1	O
.	O
46μg	O
/	O
h	O
,	O
and	O
2	O
.	O
30μg	O
/	O
h	O
,	O
respectively	O
,	O
while	O
those	O
from	O
SCIs	B-T103
were	O
erratic	O
.	O

DMF	B-T103
content	O
in	O
ENIs	O
and	O
SCIs	B-T103
were	O
0	O
.	O
007	O
%	O
w	O
/	O
w	O
and	O
0	O
.	O
123	O
%	O
w	O
/	O
w	O
,	O
respectively	O
,	O
while	O
chloroform	B-T103
was	O
not	B-T033
detected	I-T033
.	O

No	B-T033
cytotoxicity	B-T038
was	O
observed	O
from	O
ENIs	O
in	O
cultured	B-T017
bovine	B-T204
corneal	B-T017
endothelial	I-T017
cells	I-T017
for	O
up	O
to	O
24h	O
.	O

We	O
conclude	O
that	O
ENIs	O
are	O
better	O
than	O
SCIs	B-T103
and	O
could	O
be	O
utilized	O
as	O
a	O
potential	O
delivery	B-T074
system	I-T074
for	O
treating	O
anterior	B-T082
segment	I-T082
ocular	B-T038
diseases	I-T038
.	O

Quantitative	O
regulation	B-T038
of	O
histone	B-T103
variant	I-T103
H2A	I-T103
.	I-T103
Z	I-T103
during	O
cell	B-T038
cycle	I-T038
by	O
ubiquitin	B-T038
proteasome	I-T038
system	I-T038
and	O
SUMO	B-T017
-	I-T017
targeted	I-T017
ubiquitin	I-T017
ligases	I-T017

Quantitative	O
control	O
of	O
histones	B-T103
and	O
histone	B-T103
variants	I-T103
during	O
cell	B-T038
cycle	I-T038
is	O
relevant	O
to	O
their	O
epigenetic	B-T038
functions	I-T038
.	O

We	O
found	O
that	O
the	O
level	O
of	O
yeast	B-T103
histone	I-T103
variant	I-T103
H2A	I-T103
.	I-T103
Z	I-T103
in	O
the	O
G2	B-T038
/	I-T038
M	I-T038
-	I-T038
phase	I-T038
is	O
actively	O
kept	O
low	O
by	O
the	O
ubiquitin	B-T038
proteasome	I-T038
system	I-T038
and	O
SUMO	B-T017
-	I-T017
targeted	I-T017
ubiquitin	I-T017
ligases	I-T017
.	O

Overexpression	B-T038
of	O
H2A	B-T103
.	I-T103
Z	I-T103
induced	B-T038
defects	I-T038
in	I-T038
mitotic	I-T038
progression	I-T038
,	O
suggesting	O
functional	O
importance	O
of	O
this	O
quantitative	O
control	O
.	O

Tyrphostin	B-T103
AG	I-T103
-	I-T103
related	I-T103
compounds	I-T103
attenuate	O
H2O2	B-T103
-	O
induced	O
TRPM2	B-T103
-	O
dependent	O
and	O
-	O
independent	O
cellular	B-T017
responses	O

TRPM2	B-T103
is	O
a	O
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	I-T103
permeable	I-T103
channel	I-T103
that	O
is	O
activated	O
by	O
H2O2	B-T103
.	O

TRPM2	B-T103
-	O
mediated	O
Ca	B-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
signaling	I-T038
has	O
been	O
implicated	O
in	O
the	O
aggravation	B-T033
of	O
inflammatory	B-T038
diseases	I-T038
.	O

Therefore	O
,	O
the	O
development	O
of	O
TRPM2	B-T103
inhibitors	B-T103
to	O
prevent	O
the	O
aggravation	B-T033
of	O
these	O
diseases	B-T038
is	O
expected	O
.	O

We	O
recently	O
reported	O
that	O
some	O
Tyrphostin	B-T103
AG	I-T103
-	I-T103
related	I-T103
compounds	I-T103
inhibited	O
the	O
H2O2	B-T103
-	O
induced	O
activation	O
of	O
TRPM2	B-T103
by	O
scavenging	B-T038
the	I-T038
intracellular	I-T038
hydroxyl	I-T038
radical	I-T038
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
on	O
H2O2	B-T103
-	O
induced	O
cellular	B-T017
responses	O
in	O
human	B-T204
monocytic	B-T017
U937	B-T017
cells	I-T017
,	O
which	O
functionally	O
express	B-T038
TRPM2	B-T103
.	O

The	O
effects	O
of	O
AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
on	O
H2O2	B-T103
-	O
induced	O
changes	O
in	O
intracellular	B-T082
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
concentrations	O
,	O
extracellular	B-T103
signal	I-T103
-	I-T103
regulated	I-T103
kinase	I-T103
(	O
ERK	B-T103
)	O
activation	O
,	O
and	O
CXCL8	B-T103
secretion	B-T038
were	O
assessed	O
using	O
U937	B-T017
cells	I-T017
.	O

Ca	B-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
influxes	I-T038
via	O
TRPM2	B-T103
in	O
response	O
to	O
H2O2	B-T103
were	O
blocked	B-T038
by	O
AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
.	O

AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
also	O
inhibited	O
the	O
H2O2	B-T103
-	O
induced	O
activation	O
of	O
ERK	B-T103
,	O
and	O
subsequent	O
secretion	B-T038
of	O
CXCL8	B-T103
mediated	O
by	O
TRPM2	B-T103
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
.	O

Our	O
results	O
show	O
that	O
AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
inhibit	O
H2O2	B-T103
-	O
induced	O
CXCL8	B-T103
secretion	B-T038
following	O
ERK	B-T103
activation	O
,	O
which	O
is	O
mediated	O
by	O
TRPM2	B-T103
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
in	O
U937	B-T017
cells	I-T017
.	O

We	O
previously	O
reported	O
that	O
AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
blocked	B-T038
H2O2	B-T103
-	O
induced	O
TRPM2	B-T103
activation	O
by	O
scavenging	B-T038
the	I-T038
hydroxyl	I-T038
radical	I-T038
.	O

The	O
inhibitory	O
effects	O
of	O
AG	B-T103
-	I-T103
related	I-T103
compounds	I-T103
on	O
TRPM2	B-T103
-	O
independent	O
responses	O
may	O
be	O
due	O
to	O
scavenging	B-T038
of	I-T038
the	I-T038
hydroxyl	I-T038
radical	I-T038
.	O

Shared	B-T038
decision	I-T038
making	I-T038
in	O
the	O
UK	B-T082
:	O
Moving	O
towards	O
wider	O
uptake	O

Shared	B-T038
decision	I-T038
making	I-T038
(	O
SDM	B-T038
)	O
is	O
firmly	O
on	O
the	O
policy	B-T170
agenda	O
in	O
the	O
UK	B-T082
and	O
a	O
recent	O
legal	O
ruling	O
has	O
confirmed	O
its	O
importance	O
.	O

Policymakers	B-T097
,	O
ethicists	B-T097
,	O
professional	B-T097
regulators	I-T097
and	O
societies	B-T092
,	O
patient	B-T092
organisations	I-T092
and	O
now	O
the	O
courts	O
are	O
committed	O
to	O
ensuring	O
that	O
SDM	B-T038
becomes	O
the	O
norm	O
throughout	O
the	O
NHS	B-T058
,	O
but	O
an	O
unfavourable	O
economic	O
climate	O
makes	O
this	O
especially	O
challenging	O
.	O

Considerable	O
progress	O
has	O
been	O
made	O
over	O
the	O
last	O
few	O
years	O
,	O
with	O
new	O
learning	B-T038
from	O
demonstration	O
sites	B-T082
,	O
various	O
initiatives	B-T038
in	O
capacity	B-T058
building	I-T058
and	O
training	O
,	O
wider	O
availability	O
of	O
patient	O
decision	B-T170
aids	I-T170
,	O
and	O
important	O
leadership	O
initiatives	B-T038
.	O

Enthusiasm	B-T038
for	O
this	O
way	O
of	O
working	O
is	O
growing	O
among	O
clinicians	B-T097
,	O
patients	O
and	O
managers	B-T097
,	O
but	O
it	O
could	O
be	O
undermined	O
if	O
SDM	B-T038
comes	O
to	O
be	O
seen	O
primarily	O
as	O
a	O
means	O
of	O
cost	O
control	O
.	O

Lactate	B-T103
induces	O
osteoblast	B-T038
differentiation	I-T038
by	O
stabilization	B-T038
of	O
HIF1α	B-T103

Aerobic	O
glycolysis	O
is	O
involved	O
in	O
osteoblast	B-T038
differentiation	I-T038
induced	O
by	O
Wnt	B-T038
signaling	I-T038
or	O
PTH	B-T103
treatment	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
whether	O
lactate	B-T103
,	O
the	O
end	O
product	O
of	O
aerobic	O
glycolysis	O
,	O
plays	O
any	O
role	O
in	O
osteoblast	B-T038
differentiation	I-T038
.	O

Herein	O
we	O
report	O
that	O
in	O
cultures	B-T058
of	O
osteoblast	B-T017
-	I-T017
lineage	I-T017
cells	I-T017
,	O
lactate	B-T103
promoted	O
alkaline	B-T103
phosphatase	I-T103
-	O
positive	O
cell	B-T038
formation	I-T038
,	O
increased	O
the	O
activity	B-T038
of	O
alkaline	B-T103
phosphatase	I-T103
,	O
and	O
induced	O
the	O
expression	B-T038
of	O
osteocalcin	B-T103
.	O

This	O
osteoblast	B-T038
differentiation	I-T038
-	O
inducing	O
effect	O
of	O
lactate	B-T103
can	O
be	O
inhibited	O
by	O
blocking	O
its	O
entry	O
into	O
cells	B-T017
with	O
MCT1	B-T103
siRNA	B-T103
or	O
inhibitors	B-T103
,	O
and	O
by	O
interfering	O
with	O
its	O
metabolism	B-T038
by	O
using	O
specific	O
siRNAs	B-T103
for	O
LDHB	B-T103
and	O
PDH	B-T103
.	O

Moreover	O
,	O
lactate	B-T103
stabilized	O
HIF1α	B-T103
expression	B-T038
and	O
inhibited	O
HIF1α	B-T103
activity	O
,	O
with	O
BAY87	B-T103
-	I-T103
2243	I-T103
lowering	O
the	O
osteoblast	B-T038
differentiation	I-T038
-	O
inducing	O
effect	O
of	O
lactate	B-T103
.	O

Thus	O
,	O
these	O
findings	B-T033
reveal	O
an	O
unrecognized	O
role	O
for	O
aerobic	O
glycolysis	O
in	O
osteoblast	B-T038
differentiation	I-T038
via	O
its	O
end	O
product	O
,	O
lactate	B-T103
.	O

Committee	O
Opinion	O
No	O
.	O
701	O
Summary	O
:	O
Choosing	O
The	O
Route	B-T082
Of	O
Hysterectomy	B-T058
For	O
Benign	O
Disease	B-T038

Hysterectomy	B-T058
is	O
one	O
of	O
the	O
most	O
frequently	O
performed	O
surgical	B-T058
procedures	I-T058
in	O
the	O
United	B-T082
States	I-T082
.	O

Selection	O
of	O
the	O
route	B-T082
of	O
hysterectomy	B-T058
for	O
benign	O
causes	O
can	O
be	O
influenced	O
by	O
the	O
size	B-T082
and	O
shape	B-T082
of	O
the	O
vagina	B-T017
and	O
uterus	B-T017
;	O
accessibility	O
to	O
the	O
uterus	B-T017
;	O
extent	O
of	O
extrauterine	B-T038
disease	I-T038
;	O
the	O
need	O
for	O
concurrent	O
procedures	O
;	O
surgeon	B-T097
training	O
and	O
experience	B-T038
;	O
average	O
case	O
volume	O
;	O
available	O
hospital	B-T092
technology	B-T058
,	O
devices	B-T074
,	O
and	O
support	O
;	O
whether	O
the	O
case	O
is	O
emergent	O
or	O
scheduled	O
;	O
and	O
preference	O
of	O
the	O
informed	O
patient	O
.	O

Vaginal	B-T058
and	O
laparoscopic	B-T058
procedures	I-T058
are	O
considered	O
"	O
minimally	O
invasive	O
"	O
surgical	O
approaches	O
because	O
they	O
do	O
not	O
require	O
a	O
large	O
abdominal	B-T058
incision	I-T058
and	O
,	O
thus	O
,	O
typically	O
are	O
associated	O
with	O
shortened	O
hospitalization	B-T058
and	O
postoperative	O
recovery	O
times	O
compared	O
with	O
open	O
abdominal	B-T058
hysterectomy	I-T058
.	O

Minimally	O
invasive	O
approaches	O
to	O
hysterectomy	B-T058
should	O
be	O
performed	O
,	O
whenever	O
feasible	O
,	O
based	O
on	O
their	O
well	O
-	O
documented	O
advantages	O
over	O
abdominal	B-T058
hysterectomy	I-T058
.	O

The	O
vaginal	B-T082
approach	I-T082
is	O
preferred	O
among	O
the	O
minimally	O
invasive	O
approaches	O
.	O

Laparoscopic	B-T058
hysterectomy	I-T058
is	O
a	O
preferable	O
alternative	O
to	O
open	O
abdominal	B-T058
hysterectomy	I-T058
for	O
those	O
patients	O
in	O
whom	O
a	O
vaginal	B-T058
hysterectomy	I-T058
is	O
not	O
indicated	O
or	O
feasible	O
.	O

Although	O
minimally	O
invasive	O
approaches	O
to	O
hysterectomy	B-T058
are	O
the	O
preferred	O
route	B-T082
,	O
open	B-T058
abdominal	B-T058
hysterectomy	I-T058
remains	O
an	O
important	O
surgical	O
option	O
for	O
some	O
patients	O
.	O

The	O
obstetrician	B-T097
-	O
gynecologist	B-T097
should	O
discuss	O
the	O
options	O
with	O
patients	O
and	O
make	O
clear	O
recommendations	O
on	O
which	O
route	B-T082
of	O
hysterectomy	B-T058
will	O
maximize	O
benefits	O
and	O
minimize	O
risks	O
given	O
the	O
specific	O
clinical	O
situation	O
.	O

The	O
relative	O
advantages	O
and	O
disadvantages	O
of	O
the	O
approaches	O
to	O
hysterectomy	B-T058
should	O
be	O
discussed	O
in	O
the	O
context	O
of	O
the	O
patient	O
'	O
s	O
values	O
and	O
preferences	O
,	O
and	O
the	O
patient	O
and	O
health	B-T097
care	I-T097
provider	I-T097
should	O
together	O
determine	O
the	O
best	O
course	O
of	O
action	O
after	O
this	O
discussion	O
.	O

Measuring	O
nonlinear	O
signal	O
combination	O
using	O
EEG	B-T058

Relatively	O
little	O
is	O
known	O
about	O
the	O
processes	O
,	O
both	O
linear	B-T082
and	O
nonlinear	O
,	O
by	O
which	O
signals	O
are	O
combined	O
beyond	O
V1	B-T082
.	O

By	O
presenting	O
two	O
stimulus	O
components	O
simultaneously	O
,	O
flickering	B-T033
at	O
different	O
temporal	O
frequencies	O
(	O
frequency	O
tagging	O
)	O
while	O
measuring	O
steady	O
-	O
state	O
visual	B-T038
evoked	I-T038
potentials	I-T038
,	O
we	O
can	O
assess	O
responses	O
to	O
the	O
individual	O
components	O
,	O
including	O
direct	O
measurements	O
of	O
suppression	B-T038
on	O
each	O
other	O
,	O
and	O
various	O
nonlinear	O
responses	O
to	O
their	O
combination	O
found	O
at	O
intermodulation	O
frequencies	O
.	O

The	O
result	B-T033
is	O
a	O
rather	O
rich	O
dataset	B-T170
of	O
frequencies	O
at	O
which	O
responses	O
can	O
be	O
found	O
.	O

We	O
presented	O
pairs	O
of	O
sinusoidal	O
gratings	O
at	O
different	O
temporal	O
frequencies	O
,	O
forming	O
plaid	B-T033
patterns	I-T033
that	O
were	O
"	O
coherent	O
"	O
(	O
looking	B-T082
like	I-T082
a	I-T082
checkerboar	I-T082
d	O
)	O
and	O
"	O
noncoherent	B-T033
"	O
(	O
looking	O
like	O
a	O
pair	O
of	O
transparently	O
overlaid	B-T082
gratings	I-T082
)	O
,	O
and	O
found	O
clear	O
intermodulation	O
responses	O
to	O
compound	O
stimuli	O
,	O
indicating	O
nonlinear	O
summation	B-T038
.	O

This	O
might	O
have	O
been	O
attributed	O
to	O
cross	B-T082
-	I-T082
orientation	I-T082
suppression	B-T038
except	O
that	O
the	O
pattern	B-T082
of	O
intermodulation	O
responses	O
differed	O
for	O
coherent	O
and	O
noncoherent	B-T033
patterns	B-T082
,	O
whereas	O
the	O
effects	O
of	O
suppression	B-T038
(	O
measured	O
at	O
the	O
component	O
frequencies	O
)	O
did	O
not	O
.	O

A	O
two	B-T170
-	I-T170
stage	I-T170
model	I-T170
of	O
nonlinear	O
summation	B-T038
involving	O
conjunction	O
detection	B-T058
with	O
a	O
logical	O
AND	B-T170
gate	I-T170
described	O
the	O
data	O
well	O
,	O
capturing	O
the	O
difference	O
between	O
coherent	O
and	O
noncoherent	B-T033
plaids	O
over	O
a	O
wide	O
array	B-T082
of	O
possible	B-T033
response	O
frequencies	O
.	O

Multistimulus	O
frequency	O
-	O
tagged	O
EEG	B-T058
in	O
combination	O
with	O
computational	O
modeling	O
may	O
be	O
a	O
very	O
valuable	O
tool	O
in	O
studying	O
the	O
conjunction	O
of	O
these	O
signals	O
.	O

In	O
the	O
current	O
study	B-T062
the	O
results	B-T033
suggest	O
a	O
second	O
-	O
order	O
mechanism	O
responding	O
selectively	O
to	O
coherent	O
plaid	B-T033
patterns	I-T033
.	O

Sleep	B-T033
Loss	I-T033
Promotes	O
Astrocytic	O
Phagocytosis	B-T038
and	O
Microglial	B-T038
Activation	I-T038
in	O
Mouse	B-T017
Cerebral	I-T017
Cortex	I-T017

We	O
previously	O
found	O
that	O
Mertk	B-T103
and	O
its	O
ligand	B-T103
Gas6	I-T103
,	O
astrocytic	O
genes	B-T017
involved	O
in	O
phagocytosis	B-T038
,	O
are	O
upregulated	B-T038
after	O
acute	O
sleep	B-T033
deprivation	I-T033
.	O

These	O
results	O
suggested	O
that	O
astrocytes	B-T017
may	O
engage	O
in	O
phagocytic	B-T038
activity	I-T038
during	O
extended	B-T082
wake	B-T038
,	O
but	O
direct	O
evidence	O
was	O
lacking	O
.	O

Studies	B-T062
in	O
humans	B-T204
and	O
rodents	B-T204
also	O
found	B-T033
that	O
sleep	B-T033
loss	I-T033
increases	O
peripheral	B-T082
markers	B-T201
of	O
inflammation	B-T038
,	O
but	O
whether	O
these	O
changes	O
are	O
associated	O
with	O
neuroinflammation	O
and	O
/	O
or	O
activation	B-T038
of	O
microglia	B-T017
,	O
the	O
brain	B-T017
'	I-T017
s	I-T017
resident	O
innate	B-T017
immune	I-T017
cells	I-T017
,	O
was	O
unknown	O
.	O

Here	O
we	O
used	O
serial	B-T058
block	I-T058
-	I-T058
face	I-T058
scanning	I-T058
electron	I-T058
microscopy	I-T058
to	O
obtain	O
3D	O
volume	O
measurements	O
of	O
synapses	B-T082
and	O
surrounding	B-T082
astrocytic	O
processes	B-T038
in	O
mouse	B-T204
frontal	B-T017
cortex	I-T017
after	O
6	O
-	O
8	O
h	O
of	O
sleep	B-T038
,	O
spontaneous	O
wake	B-T038
,	O
or	O
sleep	B-T033
deprivation	I-T033
(	O
SD	B-T033
)	O
and	O
after	O
chronic	O
(	O
∼5	O
d	O
)	O
sleep	O
restriction	O
(	O
CSR	O
)	O
.	O

Astrocytic	O
phagocytosis	B-T038
,	O
mainly	O
of	O
presynaptic	B-T017
components	I-T017
of	I-T017
large	I-T017
synapses	I-T017
,	O
increased	O
after	O
both	O
acute	O
and	O
chronic	O
sleep	B-T033
loss	I-T033
relative	O
to	O
sleep	B-T038
and	O
wake	B-T038
.	O

MERTK	B-T103
expression	B-T038
and	O
lipid	B-T038
peroxidation	I-T038
in	O
synaptoneurosomes	B-T017
also	O
increased	O
to	O
a	O
similar	O
extent	B-T082
after	O
short	O
and	O
long	O
sleep	B-T033
loss	I-T033
,	O
suggesting	O
that	O
astrocytic	O
phagocytosis	B-T038
may	O
represent	O
the	O
brain	B-T017
'	I-T017
s	I-T017
response	O
to	O
the	O
increase	O
in	O
synaptic	B-T038
activity	I-T038
associated	O
with	O
prolonged	O
wake	B-T038
,	O
clearing	O
worn	O
components	O
of	O
heavily	O
used	O
synapses	B-T082
.	O

Using	O
confocal	B-T058
microscopy	I-T058
,	O
we	O
then	O
found	B-T033
that	O
CSR	O
but	O
not	O
SD	B-T033
mice	B-T204
show	O
morphological	B-T082
signs	B-T033
of	O
microglial	B-T038
activation	I-T038
and	O
enhanced	O
microglial	O
phagocytosis	B-T038
of	O
synaptic	B-T017
elements	I-T017
,	O
without	O
obvious	O
signs	B-T033
of	O
neuroinflammation	O
in	O
the	O
CSF	B-T031
.	O

Because	O
low	O
-	O
level	O
sustained	O
microglia	B-T038
activation	I-T038
can	O
lead	O
to	O
abnormal	B-T033
responses	O
to	O
a	O
secondary	O
insult	O
,	O
these	O
results	O
suggest	O
that	O
chronic	O
sleep	B-T033
loss	I-T033
,	O
through	O
microglia	B-T017
priming	B-T038
,	O
may	O
predispose	O
the	O
brain	B-T017
to	O
further	B-T082
damage	O
.	O
SIGNIFICANCE	O
STATEMENT	O
We	O
find	B-T033
that	O
astrocytic	O
phagocytosis	B-T038
of	O
synaptic	B-T017
elements	I-T017
,	O
mostly	O
of	O
presynaptic	B-T017
origin	I-T017
and	O
in	O
large	O
synapses	B-T082
,	O
is	O
upregulated	B-T038
already	O
after	O
a	O
few	O
hours	O
of	O
sleep	B-T033
deprivation	I-T033
and	O
shows	O
a	O
further	B-T082
significant	O
increase	O
after	O
prolonged	O
and	O
severe	O
sleep	B-T033
loss	I-T033
,	O
suggesting	O
that	O
it	O
may	O
promote	O
the	O
housekeeping	O
of	O
heavily	O
used	O
and	O
strong	O
synapses	B-T082
in	O
response	O
to	O
the	O
increased	O
neuronal	B-T017
activity	B-T038
of	O
extended	B-T082
wake	B-T038
.	O

By	O
contrast	O
,	O
chronic	O
sleep	O
restriction	O
but	O
not	O
acute	O
sleep	B-T033
loss	I-T033
activates	B-T038
microglia	B-T017
,	O
promotes	O
their	O
phagocytic	B-T038
activity	I-T038
,	O
and	O
does	O
so	O
in	O
the	O
absence	O
of	O
overt	O
signs	B-T033
of	O
neuroinflammation	O
,	O
suggesting	O
that	O
like	O
many	O
other	O
stressors	O
,	O
extended	B-T082
sleep	O
disruption	O
may	O
lead	O
to	O
a	O
state	O
of	O
sustained	O
microglia	B-T038
activation	I-T038
,	O
perhaps	O
increasing	O
the	O
brain	B-T017
'	I-T017
s	I-T017
susceptibility	O
to	O
other	O
forms	O
of	O
damage	O
.	O

Reflections	B-T062
on	O
Hip	O
Fracture	O
Recovery	O
From	O
Older	B-T098
Adults	I-T098
Enrolled	O
in	O
a	O
Clinical	B-T062
Trial	I-T062

This	O
study	B-T062
describes	O
patients	O
'	O
perspectives	O
on	O
recovery	O
during	O
participation	O
in	O
a	O
randomized	B-T062
controlled	I-T062
trial	I-T062
that	O
tested	B-T170
a	O
postoperative	O
hip	B-T037
fracture	I-T037
management	O
program	O
(	O
B4	B-T092
Clinic	I-T092
)	O
,	O
compared	O
with	O
usual	O
care	O
,	O
on	O
mobility	O
.	O

Semistructured	B-T082
qualitative	O
interviews	O
were	O
conducted	O
with	O
50	O
older	B-T098
adults	I-T098
with	O
hip	B-T037
fracture	I-T037
(	O
from	O
both	O
groups	B-T098
)	O
twice	O
over	O
12	O
months	O
.	O

A	O
total	O
of	O
32	O
women	B-T098
(	O
64	O
%	O
)	O
and	O
18	O
men	B-T098
(	O
36	O
%	O
)	O
participated	O
in	O
the	O
study	B-T062
with	O
a	O
mean	O
age	O
at	O
baseline	O
of	O
82	O
(	O
range	O
=	O
65	O
-	O
98	O
)	O
years	O
.	O

A	O
total	O
of	O
40	O
participants	B-T098
reported	B-T058
recovery	O
goals	B-T170
at	O
some	O
point	O
during	O
their	O
recovery	O
from	O
hip	B-T037
fracture	I-T037
but	O
only	O
18	O
participants	B-T098
realized	O
their	O
goals	B-T170
within	O
12	O
months	O
.	O

Recovering	B-T038
mobility	O
,	O
returning	O
to	O
prefracture	O
activities	O
,	O
and	O
obtaining	O
stable	O
health	O
were	O
the	O
most	O
commonly	O
reported	B-T058
goals	B-T170
.	O

Participants	B-T098
described	O
good	O
social	B-T058
support	I-T058
,	O
access	B-T082
to	O
physiotherapy	B-T058
,	O
and	O
positive	B-T033
perspective	O
as	O
most	O
important	O
to	O
recovery	O
.	O

These	O
factors	O
were	O
influenced	O
by	O
participants	B-T098
'	O
knowledge	B-T170
,	O
resources	O
,	O
and	O
monthly	O
contact	O
with	O
study	B-T062
staff	B-T097
(	O
perceived	B-T038
as	O
a	O
form	O
of	O
social	B-T058
support	I-T058
)	O
.	O

The	O
most	O
frequently	O
reported	B-T058
barriers	O
to	O
participants	B-T098
'	O
recovery	O
were	O
the	O
onset	O
of	O
complications	B-T038
,	O
pain	B-T033
,	O
and	O
limited	O
access	O
to	O
physiotherapy	B-T058
.	O

Potential	O
implications	O
of	O
these	O
findings	B-T033
include	O
design	O
and	O
modification	B-T033
of	O
new	O
or	O
preexisting	O
fracture	B-T037
programs	O
,	O
prioritizing	O
patient	B-T058
engagement	I-T058
and	O
enhanced	O
knowledge	B-T170
for	O
future	O
clinical	B-T062
research	I-T062
in	O
hip	O
fracture	O
recovery	O
.	O

It	O
takes	O
biking	O
to	O
learn	B-T038
:	O
Physical	O
activity	O
improves	B-T033
learning	B-T038
a	O
second	B-T033
language	I-T033

Recent	O
studies	B-T062
have	O
shown	O
that	O
concurrent	O
physical	O
activity	O
enhances	O
learning	B-T038
a	O
completely	O
unfamiliar	O
L2	B-T033
vocabulary	B-T170
as	O
compared	O
to	O
learning	B-T038
it	O
in	O
a	O
static	O
condition	O
.	O

In	O
this	O
paper	O
we	O
report	O
a	O
study	B-T062
whose	O
aim	O
is	O
twofold	O
:	O
to	O
test	O
for	O
possible	B-T033
positive	B-T033
effects	O
of	O
physical	O
activity	O
when	O
L2	B-T033
learning	B-T038
has	O
already	O
reached	O
some	O
level	O
of	O
proficiency	O
,	O
and	O
to	O
test	O
whether	O
the	O
assumed	O
better	O
performance	O
when	O
engaged	O
in	O
physical	O
activity	O
is	O
limited	O
to	O
the	O
linguistic	O
level	O
probed	O
at	O
training	O
(	O
i	O
.	O
e	O
.	O

L2	B-T033
vocabulary	B-T170
tested	O
by	O
means	O
of	O
a	O
Word	B-T062
-	I-T062
Picture	I-T062
Verification	I-T062
task	I-T062
)	O
,	O
or	O
whether	O
it	O
extends	O
also	O
to	O
the	O
sentence	B-T170
level	O
(	O
which	O
was	O
tested	O
by	O
means	O
of	O
a	O
Sentence	B-T062
Semantic	I-T062
Judgment	I-T062
Task	I-T062
)	O
.	O

The	O
results	O
show	O
that	O
Chinese	B-T098
speakers	I-T098
with	O
basic	O
knowledge	O
of	O
English	O
benefited	O
from	O
physical	O
activity	O
while	O
learning	B-T038
a	O
set	O
of	O
new	O
words	B-T170
.	O

Furthermore	O
,	O
their	O
better	O
performance	O
emerged	O
also	O
at	O
the	O
sentential	B-T170
level	O
,	O
as	O
shown	O
by	O
their	O
performance	O
in	O
a	O
Semantic	B-T062
Judgment	I-T062
task	I-T062
.	O

Finally	O
,	O
an	O
interesting	O
temporal	O
asymmetry	O
between	O
the	O
lexical	O
and	O
the	O
sentential	B-T170
level	O
emerges	O
,	O
with	O
the	O
difference	O
between	O
the	O
experimental	O
and	O
control	O
group	O
emerging	O
from	O
the	O
1st	O
testing	O
session	O
at	O
the	O
lexical	O
level	O
but	O
after	O
several	O
weeks	O
at	O
the	O
sentential	B-T170
level	O
.	O

The	O
added	O
value	O
of	O
cardiac	B-T033
index	I-T033
and	O
pulse	B-T038
pressure	I-T038
variation	O
monitoring	B-T058
to	O
mean	B-T033
arterial	I-T033
pressure	I-T033
-	O
guided	B-T058
volume	I-T058
therapy	I-T058
in	O
moderate	O
-	O
risk	O
abdominal	O
surgery	O
(	O
COGUIDE	B-T058
)	O
:	O
a	O
pragmatic	B-T062
multicentre	B-T062
randomised	B-T062
controlled	I-T062
trial	I-T062

There	O
is	O
disagreement	O
regarding	O
the	O
benefits	O
of	O
goal	B-T058
-	I-T058
directed	I-T058
therapy	I-T058
in	O
moderate	O
-	O
risk	O
abdominal	O
surgery	O
.	O

Therefore	O
,	O
we	O
tested	B-T170
the	O
hypothesis	O
that	O
the	O
addition	O
of	O
non	O
-	O
invasive	O
cardiac	B-T033
index	I-T033
and	O
pulse	B-T038
pressure	I-T038
variation	O
monitoring	B-T058
to	O
mean	B-T033
arterial	I-T033
pressure	I-T033
-	O
based	O
goal	B-T058
-	I-T058
directed	I-T058
therapy	I-T058
would	O
reduce	O
the	O
incidence	O
of	O
postoperative	B-T038
complications	I-T038
in	O
patients	O
having	O
moderate	O
-	O
risk	O
abdominal	O
surgery	O
.	O

In	O
this	O
pragmatic	B-T062
multicentre	B-T062
randomised	B-T062
controlled	I-T062
trial	I-T062
,	O
we	O
randomly	B-T062
allocated	I-T062
244	O
patients	O
by	O
envelope	B-T170
drawing	I-T170
in	O
a	O
1	O
:	O
1	O
fashion	O
,	O
stratified	O
per	O
centre	O
.	O

All	O
patients	O
had	O
mean	B-T033
arterial	I-T033
pressure	I-T033
,	O
cardiac	B-T033
index	I-T033
and	O
pulse	B-T038
pressure	I-T038
variation	O
measured	O
continuously	O
.	O

In	O
one	O
group	O
,	O
healthcare	B-T097
professionals	I-T097
were	O
blinded	B-T062
to	O
cardiac	B-T033
index	I-T033
and	O
pulse	B-T038
pressure	I-T038
variation	O
values	O
and	O
were	O
asked	O
to	O
guide	O
haemodynamic	B-T058
therapy	I-T058
only	O
based	O
on	O
mean	B-T033
arterial	I-T033
pressure	I-T033
(	O
control	O
group	O
)	O
.	O

In	O
the	O
second	O
group	O
,	O
cardiac	B-T033
index	I-T033
and	O
pulse	B-T038
pressure	I-T038
variation	O
values	O
were	O
displayed	O
and	O
kept	O
within	O
target	O
ranges	O
following	O
a	O
pre	B-T170
-	I-T170
defined	I-T170
algorithm	I-T170
(	O
CI	O
-	O
PPV	O
group	O
)	O
.	O

The	O
primary	B-T103
endpoint	I-T103
was	O
the	O
incidence	O
of	O
postoperative	B-T038
complications	I-T038
within	O
30	O
days	O
.	O

One	O
hundred	O
and	O
seventy	O
-	O
five	O
patients	O
were	O
eligible	O
for	O
final	O
analysis	B-T062
.	O

Overall	O
complication	B-T038
rates	I-T038
were	O
similar	O
(	O
42	O
/	O
94	O
(	O
44	O
.	O
7	O
%	O
)	O
vs	O
.	O

38	O
/	O
81	O
(	O
46	O
.	O
9	O
%	O
)	O
in	O
the	O
control	O
and	O
CI	O
-	O
PPV	O
groups	O
,	O
respectively	O
;	O
p	O
=	O
0	O
.	O
95	O
)	O
.	O

The	O
CI	O
-	O
PPV	O
group	O
had	O
lower	O
mean	O
(	O
SD	O
)	O
pulse	B-T038
pressure	I-T038
variation	O
values	O
(	O
9	O
.	O
5	O
(	O
2	O
.	O
0	O
)	O
%	O
vs	O
.	O

11	O
.	O
9	O
(	O
4	O
.	O
6	O
)	O
%	O
;	O
p	O
=	O
0	O
.	O
003	O
)	O
and	O
higher	O
mean	O
(	O
SD	O
)	O
cardiac	B-T033
indices	I-T033
(	O
2	O
.	O
76	O
(	O
0	O
.	O
62	O
)	O
l	O
min	O
(	O
-	O
1	O
)	O
.	O
m	O
(	O
-	O
2	O
)	O
vs	O
.	O

2	O
.	O
53	O
(	O
0	O
.	O
66	O
)	O
l	O
min	O
(	O
-	O
1	O
)	O
.	O
m	O
(	O
-	O
2	O
)	O
;	O
p	O
=	O
0	O
.	O
004	O
)	O
than	O
the	O
control	O
group	O
.	O

In	O
moderate	O
-	O
risk	O
abdominal	O
surgery	O
,	O
we	O
observed	O
no	O
additional	B-T170
value	I-T170
of	O
cardiac	B-T033
index	I-T033
and	O
pulse	B-T038
pressure	I-T038
variation	O
-	O
guided	B-T058
haemodynamic	I-T058
therapy	I-T058
to	O
mean	B-T033
arterial	I-T033
pressure	I-T033
-	O
guided	B-T058
volume	I-T058
therapy	I-T058
with	O
regard	O
to	O
postoperative	B-T038
complications	I-T038
.	O

Anterior	B-T074
single	I-T074
implants	I-T074
with	O
different	O
neck	O
designs	O
:	O
5	O
Year	O
results	O
of	O
a	O
randomized	B-T062
clinical	I-T062
trial	I-T062

The	O
design	O
of	O
the	O
implant	B-T074
neck	I-T074
might	O
be	O
significant	O
for	O
preservation	B-T058
of	O
marginal	B-T082
bone	B-T017
.	O

To	O
compare	O
the	O
5	O
-	O
year	O
radiographic	O
and	O
clinical	O
outcome	O
of	O
single	B-T074
anterior	I-T074
implants	I-T074
provided	O
with	O
a	O
smooth	O
neck	O
,	O
a	O
rough	O
neck	O
or	O
a	O
scalloped	O
rough	O
neck	O
.	O

93	O
Patients	O
with	O
a	O
missing	O
anterior	B-T082
tooth	B-T017
in	O
the	O
maxilla	B-T017
were	O
included	O
.	O

At	O
random	O
,	O
patients	O
received	O
an	O
implant	B-T074
with	O
a	O
1	O
.	O
5	O
mm	O
smooth	O
neck	O
(	O
"	O
smooth	O
group	O
"	O
)	O
,	O
a	O
rough	O
neck	O
with	O
grooves	O
(	O
"	O
rough	O
group	O
"	O
)	O
or	O
a	O
scalloped	O
rough	O
neck	O
with	O
grooves	O
(	O
"	O
scalloped	O
group	O
"	O
)	O
.	O

Implants	B-T074
were	O
installed	O
in	O
healed	B-T082
sites	I-T082
.	O

Follow	B-T058
-	I-T058
up	I-T058
visits	I-T058
were	O
conducted	O
after	O
final	O
crown	O
delivery	O
and	O
1	O
year	O
and	O
5	O
years	O
later	O
.	O

Scalloped	O
implants	B-T074
showed	O
significantly	O
more	O
initial	O
marginal	B-T082
bone	B-T038
resorption	I-T038
.	O

The	O
total	O
amount	O
of	O
bone	B-T038
loss	I-T038
was	O
1	O
.	O
26	O
±	O
0	O
.	O
90	O
mm	O
in	O
the	O
smooth	O
group	O
,	O
1	O
.	O
20	O
±	O
1	O
.	O
1	O
mm	O
in	O
the	O
rough	O
group	O
and	O
2	O
.	O
28	O
±	O
0	O
.	O
97	O
mm	O
in	O
the	O
scalloped	O
group	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Survival	O
rates	O
were	O
96	O
.	O
2	O
%	O
for	O
the	O
smooth	O
and	O
scalloped	O
group	O
and	O
100	O
%	O
for	O
the	O
rough	O
group	O
.	O

Scalloped	O
implants	B-T074
showed	O
deeper	B-T082
pocket	I-T082
depths	I-T082
,	O
more	O
bleeding	B-T038
and	O
more	O
technical	O
complications	O
.	O

There	O
were	O
no	O
differences	O
in	O
esthetic	O
outcome	O
nor	O
in	O
patient	O
satisfaction	O
.	O

For	O
anterior	B-T082
single	O
tooth	B-T038
replacements	I-T038
,	O
scalloped	O
implants	B-T074
show	O
less	O
favorable	O
radiographic	O
and	O
clinical	O
outcome	O
compared	O
to	O
regular	O
implants	B-T074
with	O
a	O
smooth	O
neck	O
or	O
rough	O
neck	O
.	O

Recessive	B-T038
mutations	I-T038
in	O
MSTO1	B-T103
cause	O
mitochondrial	B-T038
dynamics	I-T038
impairment	O
,	O
leading	O
to	O
myopathy	B-T038
and	O
ataxia	B-T033

We	O
report	O
here	O
the	O
first	O
families	O
carrying	O
recessive	O
variants	O
in	O
the	O
MSTO1	B-T017
gene	I-T017
:	O
compound	O
heterozygous	O
mutations	B-T038
were	O
identified	O
in	O
two	O
sisters	O
and	O
in	O
an	O
unrelated	B-T033
singleton	O
case	O
,	O
who	O
presented	O
a	O
multisystem	O
complex	O
phenotype	O
mainly	O
characterized	O
by	O
myopathy	B-T038
and	O
cerebellar	B-T033
ataxia	I-T033
.	O

Human	B-T103
MSTO1	I-T103
is	O
a	O
poorly	O
studied	O
protein	O
,	O
suggested	O
to	O
have	O
mitochondrial	B-T038
localization	I-T038
and	O
to	O
regulate	B-T038
morphology	O
and	O
distribution	B-T038
of	I-T038
mitochondria	I-T038
.	O

As	O
for	O
other	O
mutations	B-T038
affecting	O
genes	B-T017
involved	O
in	O
mitochondrial	B-T038
dynamics	I-T038
,	O
no	O
biochemical	O
defects	O
typical	O
of	O
mitochondrial	B-T038
disorders	I-T038
were	O
reported	B-T058
.	O

Studies	O
in	O
patients	O
'	O
fibroblasts	B-T017
revealed	O
that	O
MSTO1	B-T103
protein	I-T103
levels	O
were	O
strongly	O
reduced	O
,	O
the	O
mitochondrial	B-T033
network	I-T033
was	I-T033
fragmented	I-T033
and	O
the	O
fusion	O
events	O
among	O
mitochondria	B-T017
were	O
decreased	O
,	O
confirming	O
the	O
deleterious	B-T038
effect	I-T038
of	O
the	O
identified	O
variants	O
and	O
the	O
role	O
of	O
MSTO1	B-T103
in	O
modulating	B-T082
mitochondrial	B-T038
dynamics	I-T038
.	O

We	O
also	O
found	O
that	O
MSTO1	O
is	O
mainly	O
a	O
cytosolic	B-T103
protein	I-T103
.	O

These	O
findings	O
indicate	O
recessive	B-T038
mutations	I-T038
in	O
MSTO1	B-T103
as	O
a	O
new	O
cause	O
for	O
inherited	O
neuromuscular	B-T038
disorders	I-T038
with	O
multisystem	O
features	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
miniature	O
bird	B-T204
-	O
borne	O
passive	O
air	O
sampler	O
for	O
monitoring	B-T058
halogenated	B-T103
flame	I-T103
retardants	I-T103

Birds	B-T204
have	O
been	O
used	O
intensively	O
as	O
biomonitors	B-T074
of	O
halogenated	B-T103
flame	I-T103
retardants	I-T103
(	O
HFRs	B-T103
)	O
,	O
and	O
several	O
studies	B-T062
have	O
reported	O
elevated	O
tissue	B-T017
concentrations	O
and	O
inter	O
-	O
individual	B-T098
variability	O
for	O
these	O
contaminants	O
.	O

While	O
diet	B-T168
is	O
known	O
to	O
be	O
an	O
important	O
exposure	O
pathway	O
for	O
HFRs	B-T103
in	O
birds	B-T204
,	O
it	O
has	O
been	O
suggested	O
that	O
exposure	O
through	O
air	O
may	O
represent	O
an	O
underestimated	O
source	B-T033
of	O
HFRs	B-T103
for	O
certain	O
species	B-T170
.	O

However	O
,	O
a	O
method	B-T170
was	O
not	O
available	O
for	O
measuring	O
the	O
atmospheric	O
exposure	O
of	O
individual	B-T098
birds	B-T204
to	O
HFRs	B-T103
or	O
other	O
semi	O
-	O
volatile	O
contaminants	O
.	O

The	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
develop	O
a	O
bird	B-T204
-	O
borne	O
passive	O
air	O
sampler	O
(	O
PAS	O
)	O
enabling	O
the	O
determination	B-T058
of	O
individual	B-T098
atmospheric	O
exposure	O
to	O
gas	B-T103
-	O
and	O
particle	B-T103
-	I-T103
phase	I-T103
HFRs	B-T103
using	O
the	O
ring	B-T204
-	I-T204
billed	I-T204
gull	I-T204
(	O
Larus	B-T204
delawarensis	I-T204
)	O
nesting	O
in	O
the	O
Montreal	O
area	O
(	O
QC	B-T082
,	O
Canada	B-T082
)	O
.	O

The	O
new	O
miniaturized	O
elliptical	B-T082
-	I-T082
shaped	I-T082
PAS	O
(	O
mean	O
weight	O
:	O
2	O
.	O
72g	O
)	O
was	O
tested	O
using	O
two	B-T058
sorbent	I-T058
types	I-T058
during	O
three	O
exposure	O
periods	O
(	O
one	O
,	O
two	O
and	O
three	O
weeks	O
)	O
.	O

Results	O
showed	O
that	O
PAS	O
using	O
polyurethane	B-T103
foam	I-T103
(	O
PUF	B-T103
)	O
combined	O
with	O
a	O
glass	B-T103
fiber	I-T103
filter	O
collected	O
all	O
major	O
polybrominated	B-T103
diphenyl	I-T103
ethers	I-T103
(	O
PBDEs	B-T103
)	O
and	O
exhibited	O
better	O
performance	O
for	O
collecting	O
highly	O
hydrophobic	O
DecaBDE	B-T103
mixture	O
congeners	O
compared	O
to	O
the	O
PAS	O
using	O
polydimethylsiloxane	B-T103
(	O
PDMS	B-T103
)	O
.	O

Emerging	O
HFRs	B-T103
including	O
hexabromobenzene	B-T103
,	O
Dechlorane	B-T103
604	I-T103
Component	I-T103
B	I-T103
,	O
and	O
Dechlorane	B-T103
plus	I-T103
(	O
DP	B-T103
)	O
isomers	O
also	O
were	O
sampled	B-T058
by	O
the	O
PUF	B-T103
-	O
based	O
PAS	O
.	O

Sampling	B-T058
rates	O
for	O
most	O
HFRs	B-T103
were	O
comparable	O
between	O
the	O
three	O
exposure	O
periods	O
.	O

This	O
novel	O
bird	B-T204
-	O
borne	O
PAS	O
provides	O
valuable	O
information	O
on	O
the	O
non	O
-	O
dietary	O
exposure	O
of	O
free	O
-	O
ranging	O
birds	B-T204
to	O
HFRs	B-T103
.	O

Post	O
endodontic	B-T033
pain	I-T033
following	O
single	O
-	O
visit	O
root	B-T058
canal	I-T058
preparation	I-T058
with	O
rotary	B-T074
vs	O
reciprocating	B-T074
instruments	I-T074
:	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
randomized	B-T062
clinical	I-T062
trials	I-T062

In	O
endodontic	B-T058
therapy	I-T058
,	O
continuous	O
rotary	O
instrumentation	O
reduced	O
debris	O
compared	O
to	O
reciprocal	O
instrumentation	O
,	O
which	O
might	O
affect	O
the	O
incidence	O
of	O
post	B-T033
-	I-T033
endodontic	I-T033
pain	I-T033
(	O
PP	B-T033
)	O
.	O

The	O
aim	O
of	O
our	O
study	B-T062
was	O
to	O
assess	O
whether	O
PP	B-T033
incidence	O
and	O
levels	O
were	O
influenced	O
by	O
the	O
choice	O
of	O
rotary	B-T074
or	O
reciprocal	B-T074
instruments	I-T074
.	O

In	O
this	O
meta	B-T062
-	I-T062
analysis	I-T062
the	O
Pubmed	B-T170
and	O
EM	B-T170
databases	I-T170
were	O
searched	O
for	O
prospective	O
clinical	B-T062
randomized	I-T062
trials	I-T062
published	O
before	O
April	O
20	O
,	O
2016	O
,	O
using	O
combinations	O
of	O
the	O
keywords	O
:	O
root	B-T058
canal	I-T058
preparation	I-T058
/	O
instrumentation	O
/	O
treatment	B-T058
/	O
therapy	B-T058
;	O
post	O
-	O
operative	O
/	O
endodontic	B-T033
pain	I-T033
;	O
reciprocal	B-T074
and	O
rotary	B-T074
instruments	I-T074
.	O

Three	O
studies	B-T062
were	O
included	O
,	O
involving	O
a	O
total	O
of	O
1	O
,	O
317	O
patients	O
,	O
659	O
treated	O
with	O
reciprocating	B-T074
instruments	I-T074
and	O
658	O
treated	O
with	O
rotary	B-T074
instruments	I-T074
.	O

PP	B-T033
was	O
reported	O
in	O
139	O
patients	O
in	O
the	O
reciprocating	B-T098
group	I-T098
and	O
172	O
in	O
the	O
rotary	B-T098
group	I-T098
.	O

The	O
PP	B-T033
incidence	O
odds	O
ratio	O
was	O
1	O
.	O
27	O
with	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
(	O
0	O
.	O
25	O
,	O
6	O
.	O
52	O
)	O
favoring	O
rotary	B-T074
instruments	I-T074
.	O

The	O
mild	O
,	O
moderate	O
and	O
severe	O
PP	B-T033
levels	O
odds	O
ratios	O
were	O
0	O
.	O
31	O
(	O
0	O
.	O
11	O
,	O
0	O
.	O
84	O
)	O
,	O
2	O
.	O
24	O
(	O
0	O
.	O
66	O
,	O
7	O
.	O
59	O
)	O
and	O
11	O
.	O
71	O
(	O
0	O
.	O
63	O
,	O
218	O
.	O
15	O
)	O
,	O
respectively	O
.	O

No	O
evidence	O
of	O
publication	O
bias	O
was	O
found	O
.	O

Rotary	B-T074
instrument	I-T074
choice	O
in	O
endodontic	B-T058
therapy	I-T058
is	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
PP	B-T033
than	O
reciprocating	B-T074
instruments	I-T074
,	O
while	O
reciprocating	B-T074
instruments	I-T074
are	O
associated	O
with	O
less	O
mild	O
PP	B-T033
incidence	O
.	O

High	O
throughput	O
resistance	B-T038
profiling	O
of	O
Plasmodium	B-T038
falciparum	I-T038
infections	I-T038
based	O
on	O
custom	B-T062
dual	I-T062
indexing	I-T062
and	O
Illumina	B-T062
next	I-T062
generation	I-T062
sequencing	I-T062
-	I-T062
technology	I-T062

Genetic	B-T038
polymorphisms	I-T038
in	O
P	B-T204
.	I-T204

falciparum	I-T204
can	O
be	O
used	O
to	O
indicate	O
the	O
parasite	B-T204
'	I-T204
s	I-T204
susceptibility	B-T033
to	O
antimalarial	B-T103
drugs	I-T103
as	O
well	O
as	O
its	O
geographical	B-T082
origin	I-T082
.	O

Both	O
of	O
these	O
factors	O
are	O
key	O
to	O
monitoring	B-T058
development	O
and	O
spread	O
of	O
antimalarial	B-T038
drug	I-T038
resistance	I-T038
.	O

In	O
this	O
study	O
,	O
we	O
combine	O
multiplex	B-T058
PCR	I-T058
,	O
custom	B-T062
designed	I-T062
dual	I-T062
indexing	I-T062
and	O
Miseq	B-T170
sequencing	B-T058
for	O
high	O
throughput	O
SNP	B-T082
-	O
profiling	O
of	O
457	O
malaria	B-T038
infections	B-T038
from	O
Guinea	B-T082
-	I-T082
Bissau	I-T082
,	O
at	O
the	O
cost	O
of	O
10	O
USD	O
per	O
sample	O
.	O

By	O
amplifying	B-T038
and	O
sequencing	B-T058
15	O
genetic	O
fragments	O
,	O
we	O
cover	O
20	O
resistance	B-T038
-	O
conferring	O
SNPs	B-T082
occurring	O
in	O
pfcrt	B-T017
,	O
pfmdr1	B-T017
,	O
pfdhfr	B-T017
,	O
pfdhps	B-T017
,	O
as	O
well	O
as	O
the	O
entire	O
length	O
of	O
pfK13	B-T017
,	O
and	O
the	O
mitochondrial	B-T017
barcode	B-T170
for	O
parasite	B-T204
origin	B-T033
.	O

SNPs	B-T082
of	O
interest	O
were	O
sequenced	O
with	O
an	O
average	O
depth	O
of	O
2	O
,	O
043	O
reads	O
,	O
and	O
bases	O
were	O
called	O
for	O
the	O
various	O
SNP	B-T082
-	O
positions	B-T082
with	O
a	O
p	O
-	O
value	O
below	O
0	O
.	O
05	O
,	O
for	O
89	O
.	O
8	O
-	O
100	O
%	O
of	O
samples	O
.	O

The	O
SNP	B-T082
data	O
indicates	O
that	O
artemisinin	B-T038
resistance	I-T038
-	O
conferring	O
SNPs	B-T082
in	O
pfK13	B-T017
are	O
absent	O
from	O
the	O
studied	O
area	O
of	O
Guinea	B-T082
-	I-T082
Bissau	I-T082
,	O
while	O
the	O
pfmdr1	B-T017
86	O
N	O
allele	O
is	O
found	O
at	O
a	O
high	O
prevalence	O
.	O

The	O
mitochondrial	B-T017
barcodes	B-T170
are	O
unanimous	O
and	O
accommodate	O
a	O
West	B-T033
African	I-T033
origin	I-T033
of	O
the	O
parasites	B-T204
.	O

With	O
this	O
method	B-T170
,	O
very	O
reliable	O
high	O
throughput	O
surveillance	B-T058
of	O
antimalarial	B-T038
drug	I-T038
resistance	I-T038
becomes	O
more	O
affordable	O
than	O
ever	O
before	O
.	O

A	O
systematic	B-T170
review	I-T170
investigating	O
psychosocial	O
aspects	O
of	O
egg	O
sharing	O
in	O
the	O
United	B-T082
Kingdom	I-T082
and	O
their	O
potential	O
effects	O
on	O
egg	O
donation	O
numbers	O

This	O
review	B-T170
aims	O
to	O
provide	O
an	O
up	O
-	O
to	O
-	O
date	O
knowledge	B-T170
of	O
the	O
psychosocial	O
aspects	O
of	O
egg	O
donation	O
from	O
the	O
perspectives	O
of	O
the	O
egg	B-T098
share	I-T098
donor	I-T098
and	O
their	O
recipient	B-T098
.	O

It	O
explores	O
the	O
motives	O
,	O
experiences	B-T038
and	O
attitudes	B-T038
of	O
egg	B-T098
sharers	I-T098
and	O
their	O
views	O
towards	O
donor	B-T098
anonymity	O
and	O
disclosure	O
.	O

Conclusions	O
are	O
made	O
on	O
how	O
these	O
findings	B-T033
can	O
guide	B-T170
clinical	I-T170
practice	I-T170
and	O
improve	O
egg	O
sharing	O
numbers	O
.	O

A	O
systematic	O
search	O
of	O
peer	B-T170
-	I-T170
reviewed	I-T170
journals	I-T170
of	O
four	O
computerized	O
databases	O
was	O
undertaken	O
.	O

Eleven	O
studies	B-T062
were	O
included	O
in	O
the	O
review	B-T170
.	O

Psychosocial	O
aspects	O
towards	O
donation	O
were	O
positive	B-T033
from	O
the	O
egg	B-T098
share	I-T098
donor	I-T098
and	O
recipient	B-T098
.	O

Concerns	O
raised	O
were	O
whether	O
participating	O
in	O
the	O
egg	O
sharing	O
scheme	B-T170
would	O
impact	O
on	O
their	O
success	O
rates	O
,	O
as	O
well	O
as	O
frustration	B-T038
expressed	O
by	O
a	O
minority	B-T098
regarding	O
the	O
lack	B-T033
of	I-T033
knowledge	I-T033
of	O
egg	O
sharing	O
outside	O
of	O
fertility	B-T038
clinics	B-T092
.	O

The	O
2005	O
legislative	O
changes	O
in	O
the	O
UK	B-T082
have	O
not	O
caused	O
the	O
anticipated	O
dramatic	O
decrease	O
in	O
egg	O
donation	O
;	O
however	O
,	O
oocyte	B-T058
donation	I-T058
still	O
falls	O
short	O
of	O
demand	B-T058
.	O

Egg	O
sharing	O
provides	O
a	O
practical	O
option	O
for	O
more	O
patients	O
to	O
access	O
IVF	B-T058
,	O
whilst	O
also	O
providing	O
more	O
donor	B-T098
oocytes	I-T098
.	O

Improved	O
information	O
provision	O
will	O
result	O
in	O
greater	O
awareness	B-T038
of	O
egg	O
sharing	O
,	O
with	O
the	O
potential	O
to	O
recruit	O
more	O
donors	O
and	O
meet	O
the	O
needs	O
of	O
recipients	B-T098
currently	O
on	O
long	O
waiting	B-T170
lists	I-T170
.	O

Medication	O
regimen	O
complexity	O
and	O
prevalence	O
of	O
potentially	O
inappropriate	O
medicines	O
in	O
older	B-T098
patients	O
after	O
hospitalisation	B-T058

Background	O
There	O
is	O
a	O
relative	O
paucity	O
of	O
information	O
to	O
characterise	O
potential	O
changes	O
in	O
medication	O
regimen	O
complexity	O
and	O
prevalence	O
of	O
prescribing	B-T058
of	O
potentially	O
inappropriate	O
medications	O
after	O
hospitalisation	B-T058
,	O
both	O
in	O
Australia	B-T082
and	O
elsewhere	O
.	O

Objective	B-T170
To	O
evaluate	B-T058
medication	O
regimen	O
complexity	O
and	O
the	O
prevalence	O
of	O
potentially	O
inappropriate	O
medications	O
before	O
and	O
after	O
admission	B-T058
to	I-T058
hospital	I-T058
.	O

Setting	O
General	B-T092
medical	I-T092
units	I-T092
of	O
a	O
tertiary	B-T092
care	I-T092
hospital	I-T092
in	O
Australia	B-T082
.	O

Methods	O
Retrospective	B-T062
cohort	I-T062
study	I-T062
of	O
patients	O
aged	O
65	O
years	O
and	O
above	O
.	O

Medication	B-T058
complexity	O
was	O
measured	O
by	O
using	O
the	O
Medication	B-T170
Regimen	I-T170
Complexity	I-T170
Index	I-T170
(	O
MRCI	B-T170
)	O
.	O

Main	O
outcome	O
measure	O
The	O
primary	O
outcome	O
was	O
the	O
change	O
in	O
the	O
Medication	B-T170
Regimen	I-T170
Complexity	I-T170
Index	I-T170
for	O
all	O
prescribed	B-T103
medications	I-T103
after	O
hospitalization	B-T058
.	O

Results	B-T033
A	O
convenience	B-T062
sample	I-T062
of	O
100	O
patients	O
was	O
included	O
in	O
the	O
study	B-T062
.	O

There	O
was	O
a	O
significant	O
change	O
in	O
the	O
mean	O
medication	B-T058
complexity	O
score	O
(	O
as	O
measured	O
using	O
the	O
MRCI	B-T170
)	O
,	O
increasing	O
from	O
29	O
at	O
the	O
time	O
of	O
admission	O
to	O
32	O
at	O
the	O
time	O
of	O
discharge	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Factors	O
such	O
as	O
baseline	O
medication	O
regimen	O
complexity	O
(	O
pre	O
-	O
admission	O
MRCI	B-T170
)	O
and	O
length	O
of	O
stay	O
in	O
the	O
hospitals	O
appear	O
to	O
influence	O
the	O
change	O
in	O
medication	B-T058
complexity	O
.	O

However	O
,	O
the	O
proportion	O
of	O
patients	O
prescribed	O
at	O
least	O
one	O
potentially	O
inappropriate	O
medicine	O
(	O
PIM	O
)	O
decreased	O
significantly	O
,	O
from	O
52	O
%	O
pre	B-T058
-	I-T058
hospitalization	I-T058
to	O
42	O
%	O
at	O
discharge	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O

Conclusions	O
Relative	O
to	O
the	O
time	O
of	O
admission	O
,	O
overall	O
medication	B-T058
complexity	O
increased	O
and	O
the	O
proportion	O
of	O
patients	O
who	O
were	O
prescribed	O
PIMs	O
decreased	O
after	O
hospitalisation	B-T058
.	O

